<SEC-DOCUMENT>0001651308-25-000031.txt : 20250227
<SEC-HEADER>0001651308-25-000031.hdr.sgml : 20250227
<ACCEPTANCE-DATETIME>20250227061234
ACCESSION NUMBER:		0001651308-25-000031
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		154
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250227
DATE AS OF CHANGE:		20250227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BeiGene, Ltd.
		CENTRAL INDEX KEY:			0001651308
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				981209416
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37686
		FILM NUMBER:		25672628

	BUSINESS ADDRESS:	
		STREET 1:		C/O MOURANT GOVERNANCE SERVICES (CAYMAN)
		STREET 2:		94 SOLARIS AVENUE, CAMANA BAY
		CITY:			GRAND CAYMAN
		STATE:			E9
		ZIP:			KY1-1108
		BUSINESS PHONE:		13459494123

	MAIL ADDRESS:	
		STREET 1:		C/O MOURANT GOVERNANCE SERVICES (CAYMAN)
		STREET 2:		94 SOLARIS AVENUE, CAMANA BAY
		CITY:			GRAND CAYMAN
		STATE:			E9
		ZIP:			KY1-1108
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>bgne-20241231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:c70194b9-233f-4b06-bc07-707c5a5abbc8,g:477d344e-a417-40e8-b704-01a6f7f40ad7,d:c94bd2152a214042a118e81881a5a1e5-->
<html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:bgne="http://www.beigene.com/20241231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>bgne-20241231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-33">0001651308</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-34">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-35">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-36">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-87" name="us-gaap:GovernmentAssistanceLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration" id="f-486">http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-88" name="us-gaap:GovernmentAssistanceLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration" id="f-487">http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-89" name="us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-490">http://fasb.org/us-gaap/2024#DepreciationDepletionAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="c-90" name="us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-491">http://fasb.org/us-gaap/2024#DepreciationDepletionAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="c-91" name="us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-492">http://fasb.org/us-gaap/2024#DepreciationDepletionAndAmortization</ix:nonNumeric><ix:nonNumeric contextRef="c-151" name="bgne:CommercializationTerm" id="f-567">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList" id="f-660">http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense</ix:nonNumeric><ix:nonNumeric contextRef="c-362" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-1346">P3Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="bgne-20241231.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="employee"><xbrli:measure>bgne:employee</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>bgne:segment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="product"><xbrli:measure>bgne:product</xbrli:measure></xbrli:unit><xbrli:unit id="cny"><xbrli:measure>iso4217:CNY</xbrli:measure></xbrli:unit><xbrli:unit id="investment"><xbrli:measure>bgne:investment</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-02-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bgne:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bgne:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bgne:GuangzhouMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bgne:BeijingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bgne:SuzhouMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bgne:ShanghaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">bgne:GovernmentAssistanceManufacturingFacilityBuildOutMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">bgne:GovernmentAssistanceManufacturingFacilityBuildOutMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">bgne:GovernmentAssistanceManufacturingFacilityBuildOutMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bgne:DepreciationExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">bgne:GovernmentAssistanceManufacturingFacilityBuildOutMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bgne:DepreciationExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">bgne:GovernmentAssistanceManufacturingFacilityBuildOutMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bgne:DepreciationExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">bgne:GovernmentAssistanceManufacturingFacilityBuildOutMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">bgne:GovernmentAssistanceManufacturingFacilityBuildOutMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">bgne:GovernmentAssistanceManufacturingFacilityBuildOutMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">bgne:GovernmentAssistanceResearchAndDevelopmentProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">bgne:GovernmentAssistanceResearchAndDevelopmentProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">bgne:GovernmentAssistanceResearchAndDevelopmentProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">bgne:GovernmentAssistanceResearchAndDevelopmentProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">bgne:GovernmentAssistanceResearchAndDevelopmentProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bgne:ASDSpecialtyHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bgne:McKessonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bgne:ShanghaiPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bgne:ThreeLargestCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bgne:SinopharmMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bgne:ShanghaiPharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bgne:ASDSpecialtyHealthcareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bgne:ChinaResourcesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bgne:FourLargestCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationResearchAndDevelopmentServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationResearchAndDevelopmentServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationResearchAndDevelopmentServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:RightToAccessIntellectualPropertyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:RightToAccessIntellectualPropertyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:RightToAccessIntellectualPropertyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:MaterialRightsRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:MaterialRightsRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:MaterialRightsRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:TislelizumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationResearchAndDevelopmentServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:TislelizumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationResearchAndDevelopmentServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:TislelizumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationResearchAndDevelopmentServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:TislelizumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:TislelizumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:TislelizumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:TislelizumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:TislelizumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:TislelizumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:OciperlimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationResearchAndDevelopmentServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:OciperlimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationResearchAndDevelopmentServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:OciperlimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationResearchAndDevelopmentServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:OciperlimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:RightToAccessIntellectualPropertyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:OciperlimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:RightToAccessIntellectualPropertyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:OciperlimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:RightToAccessIntellectualPropertyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:OciperlimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:MaterialRightsRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:OciperlimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:MaterialRightsRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:OciperlimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:MaterialRightsRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:OciperlimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:OciperlimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:OciperlimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:OciperlimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:OciperlimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:OciperlimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:AmgenIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:AmgenIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:AmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:AmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bgne:AmgenIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:AmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-20</xbrli:startDate><xbrli:endDate>2022-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:AmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">bgne:BeigeneLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bgne:AmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-20</xbrli:startDate><xbrli:endDate>2022-04-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:AmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:AmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:AmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:AmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:AmgenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:AmgenIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:AmgenIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:AmgenIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:AmgenIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:AmgenIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bgne:ResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bgne:CollaborativeArrangementCompensationTypeAxis">bgne:UpfrontPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bgne:ResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bgne:CollaborativeArrangementCompensationTypeAxis">bgne:UpfrontPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bgne:ResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bgne:CollaborativeArrangementCompensationTypeAxis">bgne:UpfrontPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bgne:ResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bgne:CollaborativeArrangementCompensationTypeAxis">bgne:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bgne:ResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bgne:CollaborativeArrangementCompensationTypeAxis">bgne:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bgne:ResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="bgne:CollaborativeArrangementCompensationTypeAxis">bgne:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bgne:CollaborativeArrangementCompensationTypeAxis">bgne:RegulatoryAndCommercialMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOfFinancialPositionLocationActivityAccrualAxis">bgne:IntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bgne:CollaborativeArrangementCompensationTypeAxis">bgne:RegulatoryAndCommercialMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOfFinancialPositionLocationActivityAccrualAxis">bgne:IntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bgne:CollaborativeArrangementCompensationTypeAxis">bgne:RegulatoryAndCommercialMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementOfFinancialPositionLocationActivityAccrualAxis">bgne:IntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:STARMarketMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bgne:LeapTherapeuticIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bgne:LeapTherapeuticIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bgne:LeapTherapeuticIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bgne:LeapTherapeuticIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bgne:PiHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bgne:PiHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bgne:OtherEquityMethodInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bgne:OtherEquityMethodInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bgne:PiHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bgne:PiHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bgne:PiHealthIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bgne:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bgne:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">bgne:HopewellFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">bgne:HopewellFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bgne:ShanghaiChinaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bgne:ShanghaiChinaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bgne:ShanghaiChinaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-01</xbrli:startDate><xbrli:endDate>2024-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bgne:AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bgne:AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bgne:AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:StateAdministrationOfTaxationChinaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:SwissFederalTaxAdministrationFTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaConstructionBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedApril42018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaConstructionBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedApril42018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaConstructionBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedApril42018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedJanuary222020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedJanuary222020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedJanuary222020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedNovember92020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedNovember92020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedNovember92020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaCITICBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:LongTermBankLoanDatedJuly292022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaCITICBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:LongTermBankLoanDatedJuly292022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaCITICBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:LongTermBankLoanDatedJuly292022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedJuly282023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedJuly282023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedJuly282023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMinshengBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedDecember202023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMinshengBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedDecember202023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMinshengBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedDecember202023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaIndustrialBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedMarch212024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaIndustrialBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedMarch212024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaIndustrialBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedMarch212024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedJune52023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedJune52023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedJune52023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:HSBCBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedMay42023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:HSBCBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedMay42023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:HSBCBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedMay42023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaIndustrialBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedMay302023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaIndustrialBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedMay302023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaIndustrialBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedMay302023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ShanghaiPudongDevelopmentBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedNovember142023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ShanghaiPudongDevelopmentBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedNovember142023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ShanghaiPudongDevelopmentBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedNovember142023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedMay252023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ShanghaiPudongDevelopmentBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedMay252023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedMay252023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedMay252023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaConstructionBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:LongTermBankLoanApril42018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaConstructionBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:LongTermBankLoanApril42018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaConstructionBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:LongTermBankLoanApril42018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:LongTermBankLoanDatedJanuary222020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:LongTermBankLoanDatedJanuary222020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:LongTermBankLoanDatedJanuary222020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:LongTermBankLoanDatedNovember92020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:LongTermBankLoanDatedNovember92020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:LongTermBankLoanDatedNovember92020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaCITICBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:LongTermBankLoanDatedJuly292022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaCITICBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:LongTermBankLoanDatedJuly292022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaConstructionBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedJanuary222020Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:LongTermBankLoanDatedJuly292022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMinshengBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanMaturingJanuary272025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaIndustrialBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:BRUKINSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:BRUKINSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:BRUKINSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:TislelizumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:TislelizumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:TislelizumabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:XGEVAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:XGEVAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:XGEVAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:BLINCYTOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:BLINCYTOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:BLINCYTOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:KYPROLISMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:KYPROLISMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:KYPROLISMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:POBEVCYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:POBEVCYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:POBEVCYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:REVLIMIDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:REVLIMIDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:REVLIMIDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:RebatesReturnsAndOtherDeductionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:ContraARAccrualsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:RebatesReturnsAndOtherDeductionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:ContraARAccrualsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:RebatesReturnsAndOtherDeductionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:ContraARAccrualsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:RebatesReturnsAndOtherDeductionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:ContraARAccrualsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:RebatesReturnsAndOtherDeductionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:ContraARAccrualsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:ShareOptionAndIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:ShareIncentivePlan2011Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:ShareOptionAndIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:ShareOptionAndIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:ShareOptionAndIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:ShareOptionAndIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:ShareOptionAndIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:ShareOptionAndIncentivePlan2016Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:ThirdAmendedAndRestated2016PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:InducementEquityPlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-31</xbrli:startDate><xbrli:endDate>2024-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-29</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-31</xbrli:startDate><xbrli:endDate>2023-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-28</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-31</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-28</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-395"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-15</xbrli:startDate><xbrli:endDate>2023-08-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">bgne:MinimumPurchaseCommitmentsForSupplyPurchasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">us-gaap:CapitalAdditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bgne:InvestmentsFundingCommitmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-432"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-434"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bgne:AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bgne:AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-436"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bgne:AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-437"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bgne:AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-438"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bgne:AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bgne:AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-440"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-441"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-442"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-443"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-444"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-447"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001651308</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bgne:InvestmentsFundingCommitmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ic94bd2152a214042a118e81881a5a1e5_1"></div><div style="min-height:33.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:29.239%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:29.239%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.197%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(Mark One)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-3">December 31</ix:nonNumeric>, 2024</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.197%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-37686</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:3pt;text-align:center"><img src="bgne-20241231_g1.jpg" alt="BGNE New Logo 2.jpg" style="height:36px;margin-bottom:5pt;vertical-align:text-bottom;width:190px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">BEIGENE,&#160;LTD.</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="f-8">Cayman Islands</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">98-1209416</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">c/o Mourant Governance Services (Cayman) Limited</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-11">94 Solaris Avenue, Camana Bay</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-12">Grand Cayman</ix:nonNumeric></span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="f-13">Cayman Islands</ix:nonNumeric>  <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-14">KY1-1108</ix:nonNumeric></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(Address of principal executive offices, including zip code)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">+1 (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-15">345</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-16">949 4123</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:39.106%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:39.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">American Depositary Shares, each representing 13 Ordinary Shares, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">ONC</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Ordinary Shares, par value $0.0001 per share*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">06160</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">The Stock Exchange of Hong Kong Limited</span></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*Included in connection with the registration of the American Depositary Shares (&#8220;ADSs&#8221;) with the U.S. Securities and Exchange Commission. The ordinary shares are not listed for trading in the United States but are listed for trading on The Stock Exchange of Hong Kong Limited (&#8220;HKEx&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(g)&#160;of the Act: The RMB shares are ordinary shares of the registrant issued to permitted investors in the People&#8217;s Republic of China and listed and traded on the STAR Market in Renminbi. The RMB shares are not listed for trading in the United States or on the HKEx and are not fungible with the ordinary shares listed on the HKEx or the ADSs representing the ordinary shares listed on Nasdaq, and in no event will any RMB shares be able to be converted into the ordinary shares listed on the HKEx or the ADSs listed on Nasdaq, or vice versa.</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well&#8209;known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-20">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> &#160;No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Exchange Act.&#160;Yes&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> &#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-21">No</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-22">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> &#160;No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S&#8209;T (&#167; 232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-23">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> &#160;No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non&#8209;accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b&#8209;2 of the Exchange Act. :</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:24.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.595%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-24">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-25">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-26">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. &#160;<ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-27">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-28">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b&#8209;2 of the Exchange Act).&#160;Yes&#160;&#9744; &#160;No <ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-29">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">As of June&#160;28, 2024, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the ordinary shares, including in the form of ADSs, each representing 13 ordinary shares, held by non&#8209;affiliates of the registrant was approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-8" name="dei:EntityPublicFloat" scale="9" id="f-30">8.7</ix:nonFraction> billion, based upon the closing price of the registrant&#8217;s ADSs on the Nasdaq Global Select Market on June&#160;28, 2024.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:33.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">As of February&#160;14, 2025, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-31">1,387,367,704</ix:nonFraction> ordinary shares, par value $0.0001 per share, were outstanding, of which 870,983,672 ordinary shares were held in the form of 66,998,744 ADSs, and 115,055,260 were RMB shares.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-32" escape="true"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The registrant intends to file&#160;a definitive proxy statement pursuant to Regulation&#160;14A within 120&#160;days of the end of the fiscal&#160;year ended December&#160;31, 2024. Portions of such definitive proxy statement are incorporated by reference into Part&#160;III of this Annual Report on Form&#160;10&#8209;K.</span></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BeiGene,&#160;Ltd.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Annual Report on Form&#160;10&#8209;K</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:7.099%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.586%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_13">PART&#160;I&#160;</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_16">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_16">3</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_70">Item&#160;1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_70">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_70">53</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_100">Item&#160;1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_100">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_100">109</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_103">Item 1C</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_103">Cybersecurity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_103">109</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_106">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_106">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_106">111</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_109">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_109">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_109">111</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_112">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_112">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_112">112</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_115">PART&#160;II</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_118">Item&#160;5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_118">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_118">113</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_121">Item&#160;6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_121">Reserved</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_121">116</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_124">Item&#160;7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_124">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_124">117</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_127">Item&#160;7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_127">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_127">128</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Item&#160;8.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_175">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_175">130</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_133">Item&#160;9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_133">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_133">177</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_136">Item&#160;9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_136">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_136">177</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_139">Item&#160;9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_139">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_139">178</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_145">Item 9C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_145">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_145">178</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_148">PART&#160;III</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_151">Item&#160;10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_151">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_151">179</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_154">Item&#160;11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_154">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_154">179</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_157">Item&#160;12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_157">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_157">179</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_160">Item&#160;13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_160">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_160">179</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_163">Item&#160;14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_163">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_163">179</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_166">PART&#160;IV</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_169">Item&#160;15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_169">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_169">180</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_172">Item&#160;16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_172">Form&#160;10&#8209;K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_172">186</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_265">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward&#8209;Looking Statements and Market Data</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This Annual Report on Form 10&#8209;K (the &#8220;Annual Report&#8221;) contains forward&#8209;looking statements that involve substantial risks and uncertainties. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These forward-looking statements are based on management&#8217;s current expectations and projections about future events and trends that may affect the business, financial condition, and operating results.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> All statements other than statements of historical facts contained in this Annual Report, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected growth, are forward&#8209;looking statements. Forward-looking statements often include words such as, but not limited to, &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;ongoing,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of these terms or similar expressions. These forward&#8209;looking statements include, among other things, statements about:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully commercialize our approved medicines and to obtain approvals in additional indications and territories for our medicines;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ability to successfully develop and commercialize our in-licensed medicines and drug candidates and any other medicines and drug candidates we may in-license</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ability to further develop sales and marketing capabilities and launch and commercialize new medicines, if approved</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ability to maintain and expand regulatory approvals for our medicines and drug candidates, if approved</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the pricing and reimbursement of our medicines and drug candidates, if approved;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, timing, progress and results of our preclinical studies and clinical trials and our research and development programs;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to advance our drug candidates into, and successfully complete, clinical trials and obtain regulatory approvals;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reliance on the success of our clinical stage drug candidates;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans, expected milestones and the timing or likelihood of regulatory filings and approvals;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the implementation of our business model, strategic plans for our business, medicines, drug candidates and technology;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope of protection we (or our licensors) are able to establish and maintain for intellectual property rights covering our medicines, drug candidates and technology;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to operate our business without infringing, misappropriating or otherwise violating the intellectual property rights and proprietary technology of third parties;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs associated with enforcing or defending against intellectual property infringement, misappropriation or violation, product liability and other claims;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the regulatory environment and regulatory developments in the United States, China, the United Kingdom, Switzerland, the European Union and other jurisdictions in which we operate;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the accuracy of our estimates regarding expenses, revenues, including collaboration revenue, capital requirements and our need for additional financing;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential benefits of strategic collaboration and licensing agreements and our ability to enter into and maintain strategic arrangements;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our construction and operation of independent production facilities for small molecule medicines and large molecule biologics, as well as clinical R&amp;D facilities, to support the global demand for both commercial and clinical supply;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reliance on third parties to conduct drug development, manufacturing and other services;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manufacture and supply, or have manufactured and supplied, drug candidates for clinical development and medicines for commercial sale;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market access and acceptance of our medicines and drug candidates, if approved;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments relating to our competitors and our industry, including competing therapies;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size of the potential markets for our medicines and drug candidates and our ability to serve those markets;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to effectively manage our growth;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract and retain qualified employees and key personnel;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">statements regarding future revenue, key milestones, expenses, capital expenditures, capital requirements and share performance;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the future trading price of our American Depositary Shares (&#8220;ADSs&#8221;) listed on Nasdaq, our ordinary shares listed on HKEx, and our ordinary shares issued to permitted investors in China and listed and traded on the STAR in Renminbi (&#8220;RMB Shares&#8221;), as well as the impact of securities analysts&#8217; reports on these prices;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">anticipated timing and effects of the redomiciliation to Switzerland, including its tax treatment;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our expectations for our qualifying capital contribution reserves upon redomiciling to Switzerland; and</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our anticipated name change, including the potential benefits and risks.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These statements involve risks and uncertainties, including those that are described in &#8220;Item 1A. Risk Factors&#8221; of this Annual Report, that may cause actual future events or results to differ materially from those expected. Given these uncertainties, you should not place undue reliance on these forward-looking statements.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not assume any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe these industry publications and third-party research, surveys and studies are reliable, you are cautioned not to give undue weight to this information.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;I</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unless the context requires otherwise, references in this report to &#8220;BeiGene,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to BeiGene,&#160;Ltd. and its subsidiaries, on a consolidated basis.</span></div><div id="ic94bd2152a214042a118e81881a5a1e5_16"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Business</span></div><div id="ic94bd2152a214042a118e81881a5a1e5_19"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a leading global oncology company discovering and developing innovative treatments that are more accessible and affordable to cancer patients worldwide. In 2024, we generated total global revenue of approximately $3.8 billion, increasing revenue by approximately $1.4 billion from the prior year, while reducing our operating loss from the prior year by approximately $0.6 billion.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are serial innovators in hematology and have built a differentiated, wholly-owned, franchise. This includes a proven best-in-class Bruton&#8217;s Tyrosine Kinase inhibitor (&#8220;BTKi&#8221;), BRUKINSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and two late-stage assets, sonrotoclax (&#8220;BCL2i&#8221;) and our first-in-class BTK-CDAC, both of which have the potential to be best-in-class medicines.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BRUKINSA was designed for complete sustainable inhibition of BTK with the belief that this would improve patient outcomes. This hypothesis was supported in the ALPINE trial, where BRUKINSA demonstrated sustained superior efficacy and lower cardiac toxicity in an all-comers relapsed/refractory (&#8220;R/R&#8221;) chronic lymphocytic leukemia (&#8220;CLL&#8221;) population against ibrutinib. BRUKINSA is the only BTKi to prove superior efficacy to ibrutinib. BRUKINSA has the broadest label in the class, with U.S. approvals in CLL, mantle cell lymphoma (&#8220;MCL&#8221;), Waldenstr&#246;m&#8217;s macroglobulinemia (&#8220;WM&#8221;), marginal zone lymphoma (&#8220;MZL&#8221;) and follicular lymphoma (&#8220;FL&#8221;). In less than two years from its first approval in CLL, and despite being the third entrant to the market, BRUKINSA has become the leader in new patients starts in the U.S., in both frontline and R/R CLL, as well as all other approved indications. BRUKINSA generated $2.6 billion in sales in 2024, is approved in over 70 markets and remains in the early stage of its launch in many key markets, including Europe, Japan, Korea and Brazil.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sonrotoclax, our BCL2 inhibitor, is a selective BCL2i designed to have greater potency and selectivity, and potential for better tolerability than venetoclax. Our clinical program for sonrotoclax has enrolled over 1,800 patients to date. It is being tested in late-stage clinical trials with BRUKINSA, including as a fixed duration therapy in the Phase 3 CELESTIAL trial of BRUKINSA + sonrotoclax in 1L CLL, which is fully enrolled.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our BTK-CDAC, which is designed to promote the degradation, of both wildtype and mutant forms of BTK, including those that commonly result in resistance to BTK inhibitors in patients who experience progressive disease, has enrolled over 500 patients and is the most advanced BTK degrader in the clinic. Data presented at the American Society of Hematology (&#8220;ASH&#8221;) meeting in 2024 showed significant early efficacy signals and safety data in a heavily pretreated population. We plan to initiate a Phase 3 head-to-head trial in 2025 against pirtobrutinib, consistent with our strategy to develop medicines that have potential to meaningfully improve upon the current practice of care. With these three differentiated and synergistic assets, we believe we are uniquely positioned to provide the best solution for all CLL patients along their treatment journey and build a sustainable franchise in the $12 billion global CLL market.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a company built to address the long-lived challenges to return on investment in the pharmaceutical industry. Clinical trials represent more than 75% of the total cost of bringing an oncology medicine to patients, yet the industry continues to outsource this function to contract research organizations (&#8220;CROs&#8221;) at an ever-increasing cost per patient. Regulatory policies such as Project Optimus, while well intended, lead to meaningful program delays and increasing Phase 1 trial costs due to increased patient requirements and time. Increased competition exists for nearly every validated target, and pricing reform, such as the Inflation Reduction Act (&#8220;IRA&#8221;) in the U.S., is placing direct and indirect pressure on innovators. Since inception, we have focused on building unique and hard to replicate competitive advantages that address these industry-wide challenges. Most importantly, our internal clinical team of approximately 3,700 colleagues across the globe allows us to break from the traditional CRO model and develop medicines with greater speed and at a lower cost than many of our industry peers while maintaining quality. This capability paired with our internal research and manufacturing capabilities enables a &#8220;fast to proof-of-concept&#8221; (&#8220;PoC&#8221;) approach that can reduce time in early-stage development. We are innovating with intentionality and building best in class combinations to win in the increasingly competitive commercial landscape.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a deep and innovative solid tumor pipeline. In 2024 alone, we advanced 13 differentiated new molecular entities (&#8220;NMEs&#8221;) into the clinic, each of which have the potential to be first-in-class or best-in-class. Our intention is to build depth in the most prevalent cancers, including breast/gynecologic, lung and gastrointestinal. We have main PoC catalysts in the next six to eighteen months for key programs, including, our next-generation CDK4 inhibitor and potentially first-in-class B7H4 antibody-drug conjugate (&#8220;ADC&#8221;) in breast/gynecologic cancers, potential best-in-class pan-KRAS inhibitor in gastrointestinal (&#8220;GI&#8221;) cancer, differentiated mechanism of action (&#8220;MoA&#8221;) and first-in-class EGFR-CDAC in lung cancer, as well as our synergistic and potentially best-in-class PRMT5 and MAT2A inhibitors combination in lung cancer. We also have several exciting early stage assets, including CDK2i, B7H3 ADC, CEA-ADC, FGFR2b ADC, EGFRxMET TsAb, and IRAK4 CDAC.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in 2010, we have become a fully integrated global organization with more than 11,000 employees worldwide.</span></div><div id="ic94bd2152a214042a118e81881a5a1e5_22"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Holding Company Structure</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are a holding company currently incorporated in the Cayman Islands with operations primarily conducted through our subsidiaries in the U.S., China, the UK, Switzerland, and Australia. The following diagram depicts a summary of our corporate structure. Our corporate structure contains no variable interest entities. In 2024, we announced plans to redomicile our holding company to Switzerland in 2025.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><img src="bgne-20241231_g2.jpg" alt="2024 10-K Holding Company Chart.jpg" style="height:378px;margin-bottom:5pt;vertical-align:text-bottom;width:672px"/></div><div id="ic94bd2152a214042a118e81881a5a1e5_25"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Strategy</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We were founded with the vision to create an integrated biopharmaceutical company to address challenges in the pharmaceutical industry, creating impactful medicines that will be affordable and accessible to far more patients around the world. We are uniquely built to address an increasingly challenged industry and improve R&amp;D returns.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">We have built a substantial global clinical team of approximately 3,700 people on six continents, allowing us to run clinical trials predominantly without reliance on CROs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> We believe independence from traditional CRO models allows us to execute more cost-efficient development and achieve faster time to clinical proof-of-concept. It also allows us to expand the reach of our clinical sites, which supports diverse participation and the collection of robust data across all patient demographics. Our demonstrated ability to complete large-scale, multi-regional clinical trials is an important strategic competitive advantage and addresses an immense challenge in the pharmaceutical industry.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We have built a highly productive and cost-effective oncology research teams with 1,100+ scientists, allowing us to drive serial innovation to enable sustained market leadership</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our efforts have been validated by commercial approvals, clinical data, and collaborations that have secured $1.5 billion in collaboration payments to our company. We design each research program with a differentiated biological hypothesis MoA, which has resulted in multiple commercially approved medicines and a pipeline of wholly-owned assets with potential for combinations and depth in key tumor types. We have invested in diverse technology platforms to pursue innovation, including CDAC protein degraders, bispecific antibodies, tri-specific antibodies, and ADCs allowing us access to diverse modalities and to advance science with urgency and agility. Our CDAC platform, in particular, offers a differentiated approach from small molecules with its catalytic activity, higher barrier to resistance, and scaffold function disruption, and we believe it has the potential to emerge as a best-in-class approach. Our research and innovation capabilities are primed for discovering high-quality and impactful medicines for patients in a highly productive and cost-effective way.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We have built a strong commercial portfolio, with BRUKINSA and TEVIMBRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> driving global revenue.</span></div><div style="padding-left:72pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Solidifying our Sustainable Hematology Franchise</span></div><div style="padding-left:72pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our hematology franchise is led by BRUKINSA, which is supported by a broad clinical program with over 7,100 patients enrolled in more than 30 countries and regions across more than 35 trials. We continue to solidify our leadership in hematology, utilizing BRUKINSA as our cornerstone asset. We are focused on lifecycle management to build a sustainable hematology franchise maximizing value for our company, shareholders and patients globally. BRUKINSA has allowed us to build a strong franchise in hematology-oncology and we plan to solidify our leadership in CLL with our wholly-owned, emerging best-in-class hematology pipeline consisting of sonrotoclax and our BTK-CDAC, while amplifying our impact in other B-cell malignancies. We believe our BTK-CDAC combinations with BRUKINSA and sonrotoclax show promise to meaningfully outperform fixed duration regimens in CLL, and our three differentiated molecules offer potential best-in-disease combinations to cover the entire CLL patient spectrum and insulate BeiGene from end-of-lifecycle pricing pressure. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Expanding Access to Our PD-1 Inhibitor for Patients Worldwide and Building Global Commercial Capabilities to Support Prolific Pipeline</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our solid tumor franchise is led by our anti-PD-1 monoclonal antibody, TEVIMBRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is currently approved in the U.S., EU, China and other countries. We intend to expand TEVIMBRA&#8217;s global footprint through ongoing submissions and approvals. We are also developing a high-concentration subcutaneous formulation of TEVIMBRA which we believe will be competitive in global markets. With TEVIMBRA and the potentially best-in-class solid tumor pipeline assets, we are well-positioned to build our solid tumor business and deliver innovative therapies and combinations to patients.</span></div><div style="padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">We have a global commercial organization to deliver medicines to patients around the globe</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have established commercial capabilities in key large commercial markets of the U.S., E.U and China, and continue our rapid expansion of capabilities into Asia Pacific, Latin America, and Middle East regions, driving the delivery of highly effective and differentiated medicines to patients around the globe. This has enabled a geographically diversified revenue mix and a truly global business. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our business model is sustainable and results in strong global financial profile.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe we are financially well-positioned with cash and cash equivalents of $2.6 billion as of December&#160;31, 2024. Our product revenue has grown 73% since 2023 from our current portfolio and cornerstone assets, which we expect to grow significantly in 2025 and beyond. We significantly reduced our GAAP operating losses and achieved non-GAAP operating income for the first time for fiscal year 2024. We generated positive cash flows from operations for the first time in both the third and fourth quarters of 2024 after years of using cash in our operations. We will continue to be thoughtful and strategic in how we deploy our capital, and consistent with previous collaborations, we will actively explore partnerships that strengthen our business. We are committed to generating long-term value for our shareholders.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Commercial and Registration Stage Products</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the status of our commercial products as of February&#160;27, 2025:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.315%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:22.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.060%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ccccff;border-left:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PRODUCT</span></td><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ccccff;border-left:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">MECHANISM OF ACTION</span></td><td colspan="3" style="background-color:#ccccff;border-left:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">REGULATORY STATUS</span></td><td colspan="3" style="background-color:#ccccff;border-left:1pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">BEIGENE COMMERCIAL RIGHTS</span></td><td colspan="3" style="background-color:#ccccff;border-left:1pt solid #000000;border-right:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PARTNER&#160;</span></td></tr><tr><td colspan="3" style="border-left:2pt solid #000;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BRUKINSA</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #000;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BTK inhibitor</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Approved in 73 markets, incl. U.S., China, EU, Japan, and other markets</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Global</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:2pt solid #000;border-top:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-left:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TEVIMBRA</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Anti-PD-1 antibody</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Approved in 45 markets, incl. U.S., EU, China, and other markets</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Global</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-left:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PARTRUVIX</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PARP inhibitor</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Approved in China</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Global</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td></tr><tr><td colspan="3" style="border-left:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XGEVA</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Anti-RANK ligand antibody</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Approved in China</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mainland China</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amgen</span></td></tr><tr><td colspan="3" style="border-left:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BLINCYTO</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Anti-CD19 x anti-CD3 bispecific T-cell engager (BiTE) </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Approved in China</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mainland China</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amgen</span></td></tr><tr><td colspan="3" style="border-left:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">KYPROLIS</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proteasome inhibitor</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Approved in China</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mainland China</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amgen</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-left:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SYLVANT</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IL-6 antagonist</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Approved in China</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Greater China</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EUSA Pharma</span></td></tr><tr><td colspan="3" style="border-left:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">QARZIBA</span></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Anti-GD2 antibody</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Approved in China</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mainland China</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EUSA Pharma</span></td></tr><tr><td colspan="3" style="border-left:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">POBEVCY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (Avastin biosimilar)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Anti-VEGF antibody</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Approved in China</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Greater China</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bio-Thera</span></td></tr><tr><td colspan="3" style="border-left:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BAITUOWEI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(goserelin microspheres for injection)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gonadotropin-releasing hormone (GnRH) agonist </span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Approved in China</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mainland China</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Luye Pharma</span></td></tr><tr><td colspan="3" style="border-left:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TAFINLAR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (dabrafenib)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BRAF inhibitor</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Approved in China</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China Broad Markets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Novartis</span></td></tr><tr><td colspan="3" style="border-left:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MEKINIST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (trametinib)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MEK inhibitor</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Approved in China</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China Broad Markets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Novartis</span></td></tr><tr><td colspan="3" style="border-left:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VOTRIENT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (pazopanib)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">VEGFR inhibitor</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Approved in China</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China Broad Markets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Novartis</span></td></tr><tr><td colspan="3" style="border-left:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AFINITOR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (everolimus)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">mTOR inhibitor</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Approved in China</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China Broad Markets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Novartis</span></td></tr><tr><td colspan="3" style="border-bottom:2pt solid #000;border-left:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ZYKADIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> (ceritinib)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:2pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ALK inhibitor</span></td><td colspan="3" style="border-bottom:2pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Approved in China</span></td><td colspan="3" style="border-bottom:2pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China Broad Markets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="border-bottom:2pt solid #000;border-left:1pt solid #000;border-right:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Novartis</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1. Rights to promote and market in China&#8217;s broad markets pursuant to a Market Development Agreement with an affiliate of Novartis Pharma AG.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Abbreviations: ALK = anaplastic lymphoma kinase; BRAF = B-rapidly accelerated fibrosarcoma; MEK = mitogen-activated protein kinase (MAPK) / Extracellular-signal regulated kinase (ERK); mTOR = Mammalian target of rapamycin; VEGFR = vascular endothelial growth factor receptor</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see the section of this Annual Report titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; for revenue by product.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commercialize the following internally developed cancer medicines:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BRUKINSA</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Market Opportunity</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lymphomas are blood-borne cancers involving lymphatic cells of the immune system. They can be broadly categorized into non-Hodgkin&#8217;s lymphoma and Hodgkin&#8217;s lymphoma. In 2024, global revenues for BTK inhibitors were over $10 billion according to company reported financials. Global revenues are projected to be more than $15 billion in 2028, according to published reports. Please see the section of this Annual Report titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; for BRUKINSA net revenue generated in 2023 and 2024.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BRUKINSA</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BRUKINSA is a next-generation, oral, small molecule inhibitor of BTK designed to deliver complete and sustained inhibition of the BTK protein by optimizing bioavailability, half-life, and selectivity. With differentiated pharmacokinetics compared with other approved BTK inhibitors, BRUKINSA has been demonstrated to inhibit the proliferation of malignant B cells within a number of disease-relevant tissues. BRUKINSA has the broadest label globally of any BTK inhibitor and is the only BTK inhibitor to provide the flexibility of once or twice daily dosing.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are marketing BRUKINSA in the U.S., Europe, China, the UK, Canada, Australia, Japan, Brazil, and other markets.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BRUKINSA has approvals in five indications, including CLL/SLL, WM, R/R MCL, R/R MZL, R/R FL and is approved in more than 70 countries.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., BRUKINSA received accelerated approval from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for MCL in adult patients who have received at least one prior therapy in November 2019. It was then approved for patients with WM based on a head-to-head study vs ibrutinib, followed by an accelerated approval in R/R MZL patients who have received at least one anti-CD20-based regimen. In January 2023, BRUKINSA was approved for the treatment of adult patients with CLL or SLL in both the treatment naive and relapsed setting based on two Phase 3 studies. BRUKINSA is the only BTKi to demonstrate progression-free survival (&#8220;PFS&#8221;)</span><span style="color:#283349;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">superiority to ibrutinib in R/R CLL/SLL in all patient segments, including high-risk (17p/TP53). In March 2024, BRUKINSA received accelerated approval from the FDA for R/R FL in combination with obinutuzumab.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, BRUKINSA received approval from the European Commission (&#8220;EC&#8221;) for the treatment of adult patients with WM who have received at least one prior therapy or for the first-line treatment of patients unsuitable for chemo-immunotherapy, as well as for the treatment of patients with R/R MZL and for the treatment of patients with CLL. In November 2023, the EC approved BRUKINSA in combination with obinutuzumab for the treatment of adult patients with R/R FL who have received at least two prior lines of systemic therapy. BRUKINSA is now approved to treat more patient populations in Europe than any other BTK inhibitor.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In China, BRUKINSA has received approval from the China National Medical Products Administration (&#8220;NMPA&#8221;) for treatment-na&#239;ve adults with CLL or SLL, treatment-na&#239;ve adults with WM, R/R CLL/SLL, TN &amp; R/R WM, and conditional approval for adult patients with MCL who have received at least one prior therapy. Currently, all approved indications for BRUKINSA are included in the updated National Reimbursement Drug List (&#8220;NRDL&#8221;) by the China National Healthcare Security Administration (&#8220;NHSA&#8221;).</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BRUKINSA received approval in Japan for WM and CLL/SLL in December 2024.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">TEVIMBRA (tislelizumab)</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Market Opportunity</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Globally, the top four PD-1/PD-L1 antibody medicines had revenues of approximately $45 billion in 2024 based on public reports. The 2024 China PD-1/L1 market (net revenue) was approximately $3.4 billion.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global revenues are projected to be approximately $50 billion in 2025 and will increase through 2028, according to published reports, driven by multiple factors including indication expansion, approvals and adoptions in earlier lines of therapies, further market penetration, and extension of duration of therapy.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">TEVIMBRA</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">TEVIMBRA is a humanized IgG4 monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1 (&#8220;PD-1&#8221;) that we specifically designed to minimize binding to Fc receptor gamma (&#8220;Fc&#947;R&#8221;), which is believed to play an essential role in activating phagocytosis in macrophages, to minimize its negative impact on T effector cells.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tislelizumab is approved in China in fourteen indications:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">for neoadjuvant treatment in combination with platinum-based chemotherapy and for adjuvant treatment as monotherapy after surgery in patients with resectable stage II or III non-small cell lung cancer (&#8220;NSCLC&#8221;)&#8217; for first-line treatment for patients with extensive-stage small cell lung cancer in combination with etoposide and platinum chemotherapy;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">for the first-line treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high PD-L1 expression in combination with fluoropyrimidine and platinum chemotherapy;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">for first-line treatment of patients with unresectable, locally advanced or metastatic squamous NSCLC in combination with chemotherapy;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">for first-line treatment of patients with unresectable, locally advanced or metastatic non-squamous NSCLC, with epidermal growth factor receptor (&#8220;EGFR&#8221;) genomic tumor aberrations negative and anaplastic lymphoma kinase (&#8220;ALK&#8221;) genomic tumor negative in combination with pemetrexed and platinum chemotherapy;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">for second- or third-line treatment of patients with locally advanced or metastatic NSCLC who progressed on prior platinum-based chemotherapy;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">for the treatment of patients with locally advanced or metastatic esophageal squamous cell carcinoma (&#8220;ESCC&#8221;) who have disease progression following or are intolerant to first-line standard chemotherapy;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">for first-line treatment of patients with locally advanced or metastatic ESCC in combination with chemotherapy;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">for first-line treatment of patients with recurrent or metastatic nasopharyngeal cancer (&#8220;NPC&#8221;);</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">for first-line treatment of patients with unresectable or metastatic hepatocellular carcinoma (&#8220;HCC&#8221;);</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">for the treatment of patients with advanced hepatocellular carcinoma who have received Sorafenib, Lenvatinib or systemic chemotherapy containing Oxaliplatin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conditional approval for the treatment of patients with classical Hodgkin&#8217;s lymphoma (&#8220;cHL&#8221;) who received at least two prior lines of systemic chemotherapy regimens;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conditional approval for the treatment of patients with locally advanced or metastatic urothelial carcinoma (&#8220;UC&#8221;) with PD-L1 high expression whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy; and</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conditional approval for patients with previously treated, locally advanced unresectable or metastatic microsatellite instability-high (&#8220;MSI-H&#8221;) or mismatch repair-deficient (&#8220;dMMR&#8221;) solid tumors.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Full approval for those indications listed as having conditional approval is contingent upon results from ongoing confirmatory clinical trials.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tislelizumab was included in the NRDL in 2020 for cHL and UC, in 2021 for non-squamous NSCLC, squamous NSCLC and HCC, in 2022 for locally advanced or metastatic NSCLC, MSI-H solid tumors, locally advanced or metastatic ESCC following progression or intolerance to prior first-line chemotherapy, and first-line recurrent or metastatic NPC, and in 2023 for first-line locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high PD-L1 expression and first-line unresectable locally advanced, recurrent or metastatic ESCC.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, the EC has approved TEVIMBRA in six indications:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">for first-line treatment of adult patients with unresectable, locally advanced or metastatic ESCC whose tumors express PD-L1 with a tumor area positivity (&#8220;TAP&#8221;) score </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&gt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 5%, in combination with platinum-based chemotherapy;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">as monotherapy is indicated for the treatment of adult patients with unresectable, recurrent, locally advanced or metastatic ESCC after prior chemotherapy; </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">for the first-line treatment of adult patients with non-squamous NSCLC, whose tumors have PDL1 expression on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&gt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 50% of tumor cells with no EGFR or ALK positive mutations and who have locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or metastatic NSCLC, in combination with pemetrexed and platinum-containing chemotherapy;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">for the first-line treatment of adult patients with squamous non-small cell lung cancer who have: locally advanced NSCLC and are not candidates for surgical resection or platinum-based chemoradiation, or metastatic NSCLC in combination with carboplatin and either paclitaxel or nab-paclitaxel;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer after prior platinum-based therapy; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">for the first-line treatment of adult patients with HER-2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction (&#8220;G/GEJ&#8221;) adenocarcinoma whose tumors express PD L1 with a TAP score </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&gt;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 5%, in combination with platinum and fluoropyrimidine-based chemotherapy.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the FDA has approved TEVIMBRA as a treatment for adult patients with unresectable or metastatic ESCC after prior systemic therapy that did not include a PD-(L)1 inhibitor and as the first-line treatment of unresectable or metastatic HER2-negative G/GEJ in adults whose tumors express PD-L1 (&#8805;1) in combination with platinum and fluoropyrimidine-based chemotherapy. Additionally, one Biologics License Application (&#8220;BLAs&#8221;) for TEVIMBRA is under review for first-line treatment of patients with unresectable, locally advanced, or metastatic ESCC.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Japan, one Japanese New Drug Application (&#8220;J-NDA&#8221;) is under review by the Pharmaceuticals and Medical Devices Agency (&#8220;PMDA&#8221;) for first- and second-line treatment of ESCC.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received regulatory approvals for TEVIMBRA marketing applications in multiple geographies, including the EU (comprising 27 countries plus Iceland and Norway) and 16 countries across North America, Europe, APAC, and other markets.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">In-Licensed Products from Amgen</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently commercializing the following cancer medicines in China under an exclusive license from Amgen:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XGEVA (denosumab) is an antibody-based RANK ligand (&#8220;RANKL&#8221;) inhibitor that was approved globally for the prevention of skeletal-related events (&#8220;SREs&#8221;) in patients with bone metastases from solid tumors and in patients with multiple myeloma (&#8220;MM&#8221;), and for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone (&#8220;GCTB&#8221;). XGEVA is approved in over 70 countries worldwide. In China, XGEVA received conditional approval in the GCTB indication in May 2019 (converted to regular approval) and received conditional approval for the SRE indications in November 2020. We began marketing XGEVA in China in July 2020. In December 2020, we announced the inclusion of XGEVA in the NRDL for the treatment of GCTB, which was successfully renewed for inclusion in 2023. Beginning in January 2024, the SRE indication was also included in the NRDL.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BLINCYTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BLINCYTO (blinatumomab), a bispecific CD-19 directed CD3 T-cell engager, is the first and only approved bi-specific T-cell engager (&#8220;BiTE&#8221;) immunotherapy. It has been approved in 60 countries for use in patients with acute lymphoblastic leukemia (&#8220;ALL&#8221;). In China, BLINCYTO received conditional approval as a treatment for adult patients with R/R ALL in December 2020 (converted to regular approval) and was conditionally approved in April 2022 for pediatric patients with R/R B-cell precursor ALL. We began commercializing BLINCYTO in August 2021. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KYPROLIS (carfilzomib), a proteasome inhibitor, has been approved in over 60 countries for use in patients with R/R MM. It was approved in China as a treatment for patients with R/R MM in July 2021 and we began commercializing KYPROLIS in January 2022. KYPROLIS was included on the NRDL beginning in March 2023 for its approved indication in China.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-Licensed Products from BMS</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our settlement agreement with BMS, our commercialization of the following cancer medicines licensed from BMS terminates as of February 2025:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">REVLIMID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (lenalidomide), an oral immunomodulatory medicine</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">VIDAZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (azacitidine for injection), a pyrimidine nucleoside analog that has been shown to reverse the effects of DNA hypermethylation and promote subsequent gene re-expression.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other In-Licensed Products</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commercialize the following medicines in China under an exclusive license from EUSA Pharma:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SYLVANT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SYLVANT (siltuximab), an interleukin-6 (&#8220;IL-6&#8221;) antagonist, was approved as a treatment for patients with idiopathic multicentric Castleman disease (&#8220;iMCD&#8221;) who are human immunodeficiency virus (&#8220;HIV&#8221;) negative and human herpesvirus-8 (&#8220;HHV-8&#8221;) negative. SYLVANT was approved in China in December 2021 for the treatment of adult patients with multicentric Castleman disease (&#8220;MCD&#8221;) who are HIV negative and HHV-8 negative, also known as iMCD. Beginning in January 2024, Sylvant was included in the NRDL.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">QARZIBA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#9660;</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">QARZIBA (dinutuximab beta), a mouse-human chimeric monoclonal GD2 antibody, was granted conditional approval by the NMPA for the treatment of high-risk neuroblastoma in patients aged 12 months and above who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with a history of R/R neuroblastoma with or without residual disease. We began commercializing QARZIBA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in December 2021.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commercialize the following product in China under an exclusive license from Bio-Thera:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">POBEVCY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> (BAT1706)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">POBEVCY is a biosimilar to Avastin (bevacizumab) developed by Bio-Thera Solutions, Ltd., a commercial-stage biopharmaceutical company located in Guangzhou, China. In China, Avastin is approved for the treatment of patients with metastatic colorectal cancer, NSCLC, glioblastoma, ovarian, fallopian tube or primary peritoneal, and cervical cancers. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">POBEVCY was approved by the NMPA in China in November 2021 and launched in late 2021 for the treatment of patients with advanced, metastatic or recurrent NSCLC, metastatic colorectal cancer, recurrent glioblastoma, epithelial ovarian, fallopian tube, or primary peritoneal cancer and cervical cancer.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have acquired the right to develop, manufacture and commercialize POBEVCY in China, including Hong Kong, Macau, and Taiwan.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commercialize the following product in China under an exclusive license from Luye Pharma:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BAITUOWEI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(goserelin microspheres for injection)</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Baituowei (Goserelin Microspheres for Injection), developed by Luye Pharma, is the world&#8217;s first and only approved microsphere formulation of Goserelin. With its innovative microsphere formulation, Baituowei is able to ensure efficacy and safety while significantly improving patient experience. Baituowei was approved by the NMPA in China in June 2023 for the treatment of patients with prostate cancer requiring androgen deprivation therapy and included in the NRDL in 2023 and was  approved by the NMPA in China in September 2023 for treating breast cancer in premenopausal and perimenopausal women that can be treated with hormones and included in the NRDL in 2024.</span></div><div id="ic94bd2152a214042a118e81881a5a1e5_2081"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reimbursement and Market Access</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales are largely dependent on the availability and extent of coverage and reimbursement by third party payors. In many markets these third parties are government health systems and in some markets, such as the U.S., there are also private payors such as private health insurers and health systems. As of December&#160;31, 2024, we have commercialized our products in over 60 markets.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., most health insurance coverage is provided by private insurers, often accessed via employer-sponsored plans, and the two main public insurance programs, Medicare and Medicaid. All three types of programs usually have some type of coverage for pharmaceutical products. There is no central list of covered pharmaceuticals in the U.S., as there is no single payer system. As such, the prices paid for pharmaceuticals in the U.S. can vary.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer patient assistance programs in the U.S. under our myBeiGene program. This program seeks to enhance access to BRUKINSA and TEVIMBRA by assisting with obtaining reimbursement, co-pay assistance when allowed, temporary supply of free product for insurance delays, and free product assistance for some uninsured and underinsured patients. The programs also seek to support patients and caregivers by providing education and information about BRUKINSA and TEVIMBRA and their approved indications, nurse advocates, and connecting patients to sources of support such as support groups and transportation/lodging assistance.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In China, there is one main payor, the government&#8217;s national health care coverage system, which provides Basic Medical Insurance to the majority (greater than 95%) of China&#8217;s approximately 1.4 billion people. There are three types of coverage plans in China at the national level that depend on if a resident lives in an urban or rural setting and if they are employed. The different plans have different characteristics in terms of how the plan is paid for and what it covers. Coverage and reimbursement of pharmaceuticals in China comes under the purview of the NHSA, which oversees the NRDL. The NRDL is composed of three lists. The &#8216;A&#8217; and &#8216;B&#8217; list are commonly referred to as the &#8216;regular&#8217; lists. The A list generally includes older, off-patent medicines, while the B list generally includes newer medicines, some with remaining patent protection, which are reimbursed at a lower rate compared to the A list. In 2017, a third list was added to the system, often referred to as the &#8216;C&#8217; list or the &#8216;negotiation&#8217; list. This list generally includes newer innovative medicines which are accepted on the list after successful negotiation between the NHSA and the company. Typically, inclusion on the C list is accompanied by a discount to the prevailing list price in China for the medicine at the time of inclusion. The NRDL price for a medicine is its prevailing price in China, but the actual reimbursement rate that is used can be modified at the provincial level. Innovatively, in the 2022 NRDL, a price bidding process for non-exclusive drugs was undertaken on the C list to set the national reimbursement price benchmark. As additional indications are included in the NRDL, the price of the medicine is reduced to reflect increased patient demand as a result of NRDL inclusion.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several of our medicines are listed on the NRDL. In the latest NRDL list announced in November 2024, the following medicines and indications have been included in the NRDL, effective January 1, 2025:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Tislelizumab in thirteen of its eligible approved indications:</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">As a first-line treatment for patients with unresectable or metastatic HCC (approved in December 2023 and included in the NRDL at the end of 2024);</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">In combination with etoposide and platinum chemotherapy as the first-line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC) (approved in June 2024 and included in the NRDL at the end of 2024);</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">In combination with fluoropyrimidine and platinum chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (approved in April 2024 and included in the NRDL at the end of 2024)</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">In combination with paclitaxel plus platinum- or fluoropyrimidine- and platinum-based chemotherapy, for the first-line treatment of patients with unresectable locally advanced, recurrent or metastatic ESCC (approved in May 2023 and included in the NRDL at the end of 2023);</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">For the treatment of adult patients with locally advanced or metastatic non-squamous NSCLC with EGFR genomic tumor aberrations negative and ALK genomic tumor negative and have progressed after or did nottolerate prior platinum-based chemotherapy; and of adult patients with locally advanced or metastatic squamous NSCLC, with EGFR and ALK negative or unknown, that have progressed after or did not tolerate of prior platinum-based chemotherapy (approved in December 2021 and included in the NRDL at the beginning of 2023);</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">For the treatment of adult patients with advanced unresectable or metastatic MSI-H or dMMR solid tumors: patients with advanced colorectal cancer (CRC) who had been treated fluoropyrimidines, oxaliplatin and irinotecan; patients with other advanced solid tumors who develop disease progression after prior treatment and have no satisfactory alternative treatment options (approved in March 2022 and included in the NRDL at the beginning of 2023);</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">For the treatment of patients with locally advanced or metastatic ESCC who have disease progression following or are intolerant to first-line standard chemotherapy (approved in April 2022 and included in the NRDL at the beginning of 2023);</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">In combination with Gemcitabine and cisplatin, as first-line treatment in patients with recurrent or metastatic NPC (approved in June 2022 and included in the NRDL at the beginning of 2023);</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">For use in combination with pemetrexed and platinum chemotherapy as a first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous NSCLC, with EGFR genomic tumor aberrations negative and ALK genomic tumor negative (approved in June 2021 and included in the NRDL in 2021);</span></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:150pt"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> The indication is an expansion of the previous indication &#8220;In combination with fluoropyrimidine- and platinum-based chemotherapy, for the first-line treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high PD-L1 expression&#8221;, which was approved in February 2023 and included in the NRDL at the end of 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">For the treatment of patients with HCC who have been previously received Sorafenib, Lenvatinib or systemic chemotherapy containing Oxaliplatin (conditionally approved in June 2021 and included in the NRDL in 2021);</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">For use in combination with paclitaxel and carboplatin as a first-line treatment in patients with unresectable, locally advanced or metastatic squamous NSCLC (approved in January 2021 and included in the NRDL in 2021);</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">For the treatment of patients with locally advanced or metastatic UC with PD-L1 high expression whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy (conditionally approved in April 2020 and included in the NRDL in 2020); and</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">For the treatment of patients with cHL who have received at least two prior therapies (conditionally approved in December 2019 and included in the NRDL in 2020).</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">BRUKINSA in all four of its approved indications:</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">In combination with obinutuzumab, for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior lines of systemic therapy (approved in May 2024 and included in the NRDL at the end of 2024);</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">For the treatment of patients with CLL or SLL (approved in April 2023 and included in the NRDL at the end of 2023)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">For the treatment of patients with WM (approved in April 2023 and included in the NRDL at the end of 2023)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; and</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">For the treatment of adult patients with MCL who have received at least one prior therapy (conditionally approved in June 2020 and included in the NRDL in 2020).</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">BAITUOWEI in both of its eligible approved indication:</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">For the treatment of patients with breast cancer in premenopausal and perimenopausal women that can be treated with hormone therapy (approved in September, 2023 and included in the NRDL at the end of 2024);</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">For the treatment of patients with prostate cancer requiring androgen deprivation therapy (approved in June 2023 and included in the NRDL at the end of 2023).</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">KYPROLIS successfully renewed its approved indication in October 2024:</span></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">In combination with dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received at least two lines of therapy, including proteasome inhibitor and immunomodulator (approved in July 2021 and included in the NRDL at the beginning of 2023).</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, China started a new program to centrally purchase non-exclusive medicines for the nation&#8217;s health care system called &#8220;volume-based procurement,&#8221; or &#8220;group purchasing organization&#8221; or &#8220;4+7&#8221; when the program was first piloted in 11 major cities. After the 2018 pilot program, it was implemented nationally in 2019. It is a tender-based system that provides guaranteed volume for lowered pricing. Participation in the program requires a product to have passed a generic quality consistency evaluation, which in turn requires passing a bioequivalence comparison to the reference listed drug (&#8220;RLD&#8221;). The system offers a major portion of a market&#8217;s volume to winning bidders. More than one company can win a given tender, and more guaranteed volume is awarded as more bidders win. The system is still evolving and, as such, the exact terms of how many bidders win and what amount of volume is won and at what price are also evolving. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is common in China for pharmaceutical companies to employ patient assistance programs to help patients afford their innovative medicines. These programs have typically been offered to patients who are self-paying. A typical program provides a certain number of free doses to patients after a certain number of doses have been paid for. Usually, these programs end when a medicine is included in the NRDL. We offer these types of patient assistance programs to our patients. </span></div><div style="border-bottom:1pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:150pt"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The indication included &#8220;both treatment-na&#239;ve patients and adult patients with CLL/SLL who have received at least one prior therapy&#8221;. &#8220;For the treatment of adult patients with CLL/SLL who have received at least one prior therapy&#8221; was conditionally approved in June 2020 and included in the NRDL in 2020.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">The indication included &#8220;both treatment-na&#239;ve patients and adult patients with WM who have received at least one prior therapy&#8221;. &#8220;For the treatment of adult patients with WM who have received at least one prior therapy&#8221; was conditionally approved in June 2021 and included in the NRDL in 2021; converted to regular approval in 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_31"></div><hr style="page-break-after:always"/><div style="min-height:51.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Pipeline Products</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our pipeline as of February&#160;27, 2025:</span></div><div style="margin-top:9pt"><img src="bgne-20241231_g3.jpg" alt="Q42024_pipeline slide.jpg" style="height:426px;margin-bottom:5pt;vertical-align:text-bottom;width:758px"/></div><div style="height:15.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:51.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the status of our in-licensed drug candidates as of February&#160;27, 2025:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.490%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.794%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#b6b6b6;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Partner</span></td><td colspan="3" style="background-color:#b6b6b6;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Molecule / Asset</span></td><td colspan="3" style="background-color:#b6b6b6;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indications</span></td><td colspan="3" style="background-color:#b6b6b6;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Phase</span></td><td colspan="3" style="background-color:#b6b6b6;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commercial Rights</span></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amgen</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tarlatamab &#x5E;</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SCLC</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 3</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xaluritamig</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prostate cancer</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</span></td></tr><tr style="height:21pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Zymeworks</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Zanidatamab &#8224; + chemo + Tislelizumab</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GEA</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 3</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia, Australia, New Zealand</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Zanidatamab &#8224; (monotherapy)</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BTC</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 2</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia, Australia, New Zealand</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SpringWorks</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BGB-3245</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solid tumors</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ex-Asia plus Japan</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pfizer</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SEA-CD70</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MDS, AML</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia, Australia, New Zealand</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DualityBio</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BG-C9074/DB1312</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BC, EC, OC, CCA, sqNSCLC</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1a</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Global</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ensem</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CDK2i</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Breast cancer and other solid tumors</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Global</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CSPC</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MAT2Ai</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Solid tumors</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Global</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#x5E; Half-life extended BiTE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">; &#8224; ZW25; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> By MapKure, a JV with SpringWorks</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Abbreviations: AML = acute myelogenous leukemia; BC = breast cancer; BTC = biliary tract cancers; GEA = gastroesophageal adenocarcinoma; MDS = myelodysplastic syndromes; NSCLC = non-small cell lung cancer; SCLC = small cell lung cancer; EC = endometrial cancer; OC = ovarian cancer; CCA = cholangiocarcinoma</span></div><div style="height:15.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Commercial- and Clinical-Stage Drug Candidates</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A description of our commercial- and clinical-stage drug candidates and clinical data from selected clinical trials is set forth below. Historically, we have made available, and we intend to continue to make available, clinical data and/or topline results from clinical trials of our drug candidates in our press releases and/or filings with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), the Stock Exchange of Hong Kong Limited (&#8220;HKEx&#8221;), and the Shanghai Stock Exchange (&#8220;SSE&#8221;), copies of which are available on the Investors section of our website.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Hematology</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BRUKINSA (zanubrutinib), a BTK Inhibitor</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently evaluating zanubrutinib in a broad pivotal clinical program globally to treat a number of B-cell malignancies. Zanubrutinib has demonstrated sustained 24-hour BTK occupancy in both the peripheral blood, bone marrow and lymph node compartments in patients. Zanubrutinib is the only BTK inhibitor to demonstrate superior progression-free survival in R/R CLL versus IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ibrutinib), an approved BTK inhibitor.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Development Updates and Regulatory Status</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global BRUKINSA clinical development program includes over 7,100 patients enrolled in more than 30 countries and regions across more than 35 trials. BRUKINSA is approved in more than 70 markets, and more than 180,000 patients have been treated globally.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Five-year follow-up results from cohort 1 of the Phase 3 SEQUOIA study showed sustained PFS benefit (54-month PFS rate of 80%) with BRUKINSA in an all-comer population of patients with treatment-na&#239;ve (&#8220;TN&#8221;) CLL or SLL, with no new safety signals observed; detailed data were presented at the annual ASH 2024 conference.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Five-year follow-up data of BOVen (zanubrutinib, obinutuzumab, venetoclax) study in TN CLL demonstrated frequent unmeasurable minimal residual disease (&#8220;uMRD&#8221;) in peripheral blood (96%) and bone marrow (92%), and uMRD was durable with a median MRD-free survival of 34 months; detailed data were presented at the ASH 2024 conference.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the clinical data to date, we believe that BRUKINSA has a best-in-class profile, we have initiated broad global pivotal programs in multiple indications, which led to regulatory approvals of five indications globally. Current ongoing Phase 3 studies include:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">MANGROVE: A Randomized Global Study Comparing Zanubrutinib Plus Rituximab vs. Bendamustine Plus Rituximab in subjects With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation (MCL) (NCT04002297).</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">MAHOGANY: Zanubrutinib Plus Obinutuzumab vs Lenalidomide plus Rituximab in Relapsed/ Refractory Follicular Lymphoma (FL) (NCT05100862).</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also investigating zanubrutinib in several combination studies in MCL, MZL and CLL/SLL, including a Phase 3 trial in combination with sonrotoclax in front-line CLL/SLL. We continue to examine opportunities for zanubrutinib combinations with both sonrotoclax and our BTK-CDAC (BGB-16673).</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to pursue regulatory approvals for BRUKINSA globally, including regulatory approval of a new tablet formulation, providing patients with more convenience and flexibility.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sonrotoclax (BGB-11417), a Small Molecule Bcl-2 Inhibitor</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our differentiated BCL2 inhibitor, sonrotoclax, was intentionally designed to have higher potency and selectivity compared to venetoclax, with a shorter half-life and no accumulation. We believe that efficacy signals and safety data from more than 1,800 patients enrolled by December 2024 in different indications and in different combinations continue to support the pre-clinical best-in-class promise. </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple trials with registration potential have completed enrollment or are nearing complete enrollment. Single-arm Phase 2 trials of sonrotoclax monotherapy in R/R MCL (NCT05471843) and R/R CLL/SLL (NCT05479994) have completed enrollment. Enrollment for Phase 2 trial in R/R WM (NCT05952037) is ongoing. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our first Phase 3 randomized study in TN-CLL, CELESTIAL-TN CLL (NCT06073821), investigating sonrotoclax + BRUKINSA vs. venetoclax + obinutuzumab completed enrollment in Q1 2025. A Phase 2 study (NCT06637501) investigating sonrotoclax + BRUKINSA vs. BRUKINSA to support TN-CLL registration for contribution of components has also started enrollment.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical data of a Phase 1 trial investigating TN-CLL/SLL (NCT04277637) was presented at ASH 2024. Sonrotoclax in combination with BRUKINSA continued to show very promising efficacy signals and a generally favorable safety profile in patients with TN CLL/SLL, especially deep and durable levels of undetectable MRD, and no laboratory or clinical tumor lysis syndrome (&#8220;TLS&#8221;), which is a key differentiator for our combination.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With these encouraging results, our BCL2 inhibitor sonrotoclax program is steadily progressing at the pivotal stage. Additional pivotal development activities in R/R MCL and R/R CLL are under way.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BGB-16673, a BTK-targeted CDAC</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BGB&#8209;16673 is an orally available, brain-penetrating BTK targeting chimeric degradation activation compound (&#8220;CDAC&#8221;) designed to promote the degradation, or breakdown, of both wildtype and mutant forms of BTK, including those that commonly result in resistance to BTK inhibitors in patients who experience progressive disease. BGB-16673 is the most advanced BTK degrader in the clinic, with more than 500 patients treated to date across the global clinical development program. The FDA granted Fast Track Designation to BGB-16673 for the treatment of adult patients with R/R CLL/SLL who have been previously treated with at least two prior lines of therapy, including BTKi and BCL2 inhibitor, and adult patients with R/R MCL.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data from the Phase 1/2 CaDAnCe-101 CLL study (NCT05006716) was presented at ASH 2024 and demonstrated that treatment with BGB-16673 was generally well tolerated in this heavily pretreated population of patients. Promising antitumor activity was observed in patients with high-risk features, including in patients with BTK inhibitor-resistant mutations and those previously exposed to covalent BTK inhibitors, noncovalent BTK inhibitors, and BCL2 inhibitors. No atrial fibrillation was observed in either the CLL/SLL or WM cohorts.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">From the cohort of CLL/SLL patients, BGB-16673 demonstrated an ORR of 94% at the 200mg dose. Furthermore, amongst all doses delivered, 2 patients achieved a complete remission/complete remission with incomplete count recovery (CR/CRi). Grade &#8805;3 TEAEs were reported in 57% of patients. The most common grade &#8805;3 TEAEs (&#8805;10%) were neutropenia/neutrophil count decreased (20%) and pneumonia (10%). (Abstract 885)</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">From the cohort of Waldenstr&#246;m&#8217;s macroglobulinemia patients, BGB-16673 demonstrated a 93% disease control rate (DCR) and 26% very good partial response (VGPR). Grade &#8805;3 TEAEs were reported in 45% of patients. The most common grade &#8805;3 TEAE (&#8805;20%) was neutropenia/neutrophil count decreased. (Abstract 860)</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 2 expansion in R/R CLL with pivotal intent has commenced and a confirmatory Phase 3 study is planned for early 2025. In addition, we have announced intent to conduct a study comparing BGB-16673 to pirtobrutinib (ncBTKi with accelerated approval in R/R MCL and R/R CLL/SLL) and will work with health authorities to initiate this Phase 3 study.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Solid Tumors</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TEVIMBRA (tislelizumab), an anti-PD-1 Antibody</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tislelizumab is a humanized monoclonal antibody against the immune checkpoint receptor PD-1 that has been evaluated in pivotal clinical trials globally and for which we plan to commence additional pivotal trials in combination with standard of care to treat various solid and hematological cancers.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Development Updates and Regulatory Status</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed more than fourteen registration-enabling clinical trials in lung, liver, lymphoma, urothelial carcinoma, and nasopharyngeal cancer globally, including ten Phase 3 randomized trials and four Phase 2 trials supporting regulatory submissions globally. We have three active studies in lymphoma, urothelial carcinoma, and solid tumors:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A Phase 3 confirmatory trial in China comparing tislelizumab to salvage chemotherapy in patients with relapsed or refractory classical Hodgkin Lymphoma (cHL; NCT04486391).</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A Phase 3 confirmatory trial in China in patients with locally advanced or metastatic urothelial carcinoma (NCT03967977).</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A Phase 2 trial in China in patients with MSI-H/dMMR solid tumors (NCT03736889).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2024, we had enrolled over 14,000</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> subjects in clinical trials of tislelizumab monotherapy or in combination in more than 35 countries, including 4,700+ subjects outside of China. These studies include eight multi-regional registrational trials that are designed for global regulatory approvals. Data from our trials thus far have suggested that tislelizumab was generally well-tolerated and exhibited anti-tumor activity in a variety of tumor types. In 2024, we terminated a Phase 3 trial in China of tislelizumab versus placebo in combination with chemoradiotherapy in patients with localized ESCC (NCT03957590).</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lung Cancer</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ociperlimab (BGB-A1217), an anti-TIGIT Antibody</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ociperlimab (BGB-A1217) is an investigational humanized IgG1-variant monoclonal antibody directed against TIGIT. An immune checkpoint molecule, ociperlimab is currently being investigated in a global Phase 3 trial, AdvanTIG-302 (NCT04746924), in combination with tislelizumab in NSCLC. As of December 2024, more than 2,000 patients have been enrolled across the ociperlimab development program.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have completed patient enrollment in AdvanTIG-302 and will evaluate data when available to inform future development opportunities for ociperlimab.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BG-60366, an EGFR-targeted CDAC</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BG-60366 is an investigational EGFR&#8209;targeting CDAC being evaluated in a Phase 1 clinical trial (NCT06685718) as monotherapy in patients with EGFR-mutant Non-Small Cell Lung Cancer.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BG-89894 (SYH2039), a MAT2A Inhibitor</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BG-89894 (SYH2039) is an investigational MAT2A inhibitor being evaluated in a Phase 1 clinical trial (NCT06568614) as monotherapy in patients with advanced or metastatic solid tumors. We licensed this asset from CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd in December 2024.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BGB-58067, an MTA-Cooperative PRMT5 Inhibitor</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BGB-58067 is an investigational MTA-Cooperative PRMT5 inhibitor being evaluated in a Phase 1 clinical trial (NCT06568614) as monotherapy in patients with MTAP deficiency advanced or metastatic solid tumors.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BG-T187, an anti-EGFRxMET trispecific antibody</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BG-T187 is an investigational anti-EGFRxMET trispecific antibody being evaluated in a Phase 1 clinical trial (NCT06598800) as monotherapy or in combination with other therapeutic agents in patients with advanced solid tumors.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BGB-26808, a HPK-1 Inhibitor</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">BGB-26808 is a second-generation HPK-1 inhibitor with a different scaffold from BGB-15025 being evaluated in a Phase 1 clinical trial (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">NCT05981703</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">) as monotherapy or in combination with tislelizumab in patients with advanced solid tumors.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BGB-C354, an anti-B7H3 ADC</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BGB-C354 is an investigational antibody drug conjugate targeting B7H3 being evaluated in a Phase 1 clinical trial (NCT06422520) as monotherapy or in combination with tislelizumab in patients with advanced solid tumors.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gastro-Intestinal Cancer</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zanidatamab, a bispecific HER2-targeted antibody</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zanidatamab, a novel investigational ZIIHERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bispecific antibody targeting HER2, is currently in late-stage clinical development with Zymeworks Inc./Jazz Pharmaceuticals plc. We have development and commercial rights to zanidatamab in Asia (excluding Japan), Australia, and New Zealand. We are participating in one ongoing clinical study with zanidatamab, a global Phase 3 clinical trial (NCT05152147) examining zanidatamab in combination with chemotherapy with and without tislelizumab in HER2-positive gastroesophageal cancer.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Phase 2b study in patients with advanced or metastatic HER2-amplified biliary tract cancers (&#8220;BTC&#8221;) in which zanidatamab is being used as monotherapy have been completed. We are also participating with Jazz in a confirmatory study (NCT06282575) for 2L+ BTC. A BLA for the BTC indication is under review by China NMPA as of May 2024 and Orphan Drug Designation (&#8220;ODD&#8221;) was issued by Ministry of Food and Drug Safety in South Korea in December 2024. On November 20, 2024, the FDA granted accelerated approval of ZIIHERA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to Jazz for previously treated unresectable or metastatic HER2-positive biliary tract cancer. In July 2024, Jazz announced that the Marketing Authorisation Application or zanidatamab in 2L BTC was validated by the European Medicines Agency.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BG-C137, an anti-FGFR2b ADC</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BG-C137 is an investigational antibody drug conjugate targeting FGFR2b being evaluated in a Phase 1 clinical trial (NCT06625593) as monotherapy in patients with advanced solid tumors.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BGB-53038, a Pan-KRAS Inhibitor</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BGB-53038 is an investigational Pan-KRAS inhibitor being evaluated in a Phase 1 clinical trial (NCT06585488) as monotherapy and in combinations in patients with advanced or metastatic solid tumors with KRAS mutations or amplifications.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BGB-B2033, an anti-GPC3x4-1BB bispecific antibody</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BGB-B2033 is an investigational anti-GPC3x4-1BB bispecific antibody being evaluated in a Phase 1 clinical trial (NCT06427941) as monotherapy or in combination with tislelizumab in patients with selected advanced or metastatic solid tumors.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BGB-B3227, an anti-MUC1xCD16A bispecific antibody</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BGB-B3227 is an investigational anti-MUC1xCD16A bispecific antibody being evaluated in a Phase 1 clinical trial (NCT06540066) as monotherapy or in combination with tislelizumab in patients with advanced or metastatic solid tumors.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BG-C477, an anti-CEA ADC</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BG-C477 is an investigational antibody drug conjugate targeting CEA being evaluated in a Phase 1 clinical trial (NCT06596473) as monotherapy in patients with selected advanced solid tumors.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Breast/Gynecologic Cancer</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BGB-43395, a CDK4 Inhibitor</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BGB-43395 is an investigational CDK4 inhibitor being evaluated in a Phase 1 clinical trial (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NCT06120283</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) as monotherapy or in combination with either fulvestrant or letrozole in patients with hormone receptor positive (&#8220;HR+&#8221;) and human epidermal growth factor 2 negative (&#8220;HER2-&#8221;) breast cancer (&#8220;BC&#8221;) and other advanced solid tumors.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BG-68501, a CDK2 Inhibitor</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BG-68501 is an investigational CDK2 inhibitor being evaluated in a Phase 1 clinical trial (NCT06257264) as monotherapy or in combination with fulvestrant with or without BGB-43395 (CDK4i) in patients with HR+ and HER2- BC and other advanced solid tumors. BG-68501 is licensed from Ensem Therapeutics, Inc. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BG-C9074, an anti-B7H4 ADC</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">BG-C9074 is an investigational antibody drug conjugate targeting B7H4 being evaluated in a Phase 1 clinical trial (NCT06233942) as monotherapy or in combination with tislelizumab in patients with advanced solid tumors. BG-C9074 is licensed from Duality Biologics (Suzhou) Co., Ltd. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BGB-21447, a Bcl-2 Inhibitor</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BGB-21447 is an investigational Bcl-2 inhibitor being evaluated in a Phase 1 clinical trial (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NCT05828589</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) as monotherapy in BC and other solid tumors. In preclinical studies, BGB-21447 shows additional potency and selectivity, with a longer half-life than sonrotoclax. We believe the differentiated profiles of sonrotoclax and BGB-21447 may lead to unique development options for these programs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">I&amp;I</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BGB-45035, an IRAK4-targeted CDAC</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BGB-45035 is an investigational IRAK4&#8209;targeting chimeric degradation activation compound (&#8220;CDAC&#8221;) being evaluated in a Phase 1 clinical trial (NCT06342713) as monotherapy in healthy participants.</span></div><div id="ic94bd2152a214042a118e81881a5a1e5_37"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Preclinical Programs</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a proprietary biology research platform that has allowed us to research and develop both small molecules and biologic molecules. In the last decade, this platform has generated more than 30 clinical stage assets, including three internally-developed molecules that have been approved by regulatory bodies in the U.S., EU, China, and other markets, with other filings pending globally and planned to be submitted. The platform is a full-process technology system spanning from early discovery to commercialization of oncology medicines based on multiple drug technology platforms that can be applied to oncology and other fields. We have core technology platforms for the development of small molecule and antibody medicines and the manufacturing of our own and potentially other medicines. Currently, we have over 70 preclinical programs and we believe the majority have best-in-class or first-in-class potential.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate advancing many of our preclinical drug candidates into the clinic in the next 12 months. We believe that we have the opportunity to combine tislelizumab with our preclinical/clinical candidates to target multiple points in the cancer immunity cycle. We also may seek to develop companion diagnostics that will help identify patients who are most likely to benefit from the use of our medicines and drug candidates.</span></div><div id="ic94bd2152a214042a118e81881a5a1e5_40"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Supply</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture our medicines and drug candidates internally and in some cases with the help CMOs. The manufacturing of our medicines and drug candidates is subject to extensive regulations that impose various procedural and documentation requirements governing recordkeeping, manufacturing processes and controls, personnel, quality control, and quality assurance, among others. Our manufacturing facilities and the facilities of the CMOs we use to manufacture our medicines and drug candidates operate under current good manufacturing practice (&#8220;cGMP&#8221;) regulations conditions. cGMP regulations are requirements for the production of pharmaceuticals that will be used in humans.</span></div><div style="margin-top:9pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Manufacturing Facilities</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have manufacturing facilities for small molecule drugs and large molecule biologics in Suzhou and Guangzhou, China, respectively, to support the commercialization and potential future demand of our internally developed or in-licensed products. In July 2024, we opened our flagship U.S. campus for clinical R&amp;D and biologics manufacturing in New Jersey.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our U.S. flagship manufacturing and clinical R&amp;D facility is located on a 42-acre site at the Princeton West Innovation Park in Hopewell, New Jersey. The Hopewell facility is positioned strategically in the Interstate 95 corridor of New Jersey, with a deep and rich talent pool, and has more than one million square feet of developable real estate for potential future expansion to cover our existing medicines and pipeline. This site has 8,000 liters of large molecule biologics manufacturing capacity.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our manufacturing facility in Suzhou is 52,000 square meters and consists of a manufacturing base for small molecule drug products with an annual production capacity of about 600 million tablets and capsules. The facility meets or exceeds design criteria of the U.S., E.U., and China regulatory requirements, and has been in operation for clinical product supply since the beginning of 2024, with commercial supply expected to be put into operation in mid-2025. The biologics manufacturing business at the former site in Suzhou will conclude at the end of February 2025, with some quality control testing continuing until Q3 2025.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our state-of-the-art commercial-scale manufacturing facility of large molecule biologics in Guangzhou is approximately 158,000 square meters. Phases 1 and 2 of the facility were completed in September 2019 and December 2020, respectively, with 24,000 liters of single use disposable capacity. Additionally, total committed capacity has been increased to 64,000 liters, with 8 x 5,000L bioreactors in Phase 3 qualified in 2024. Phase 1 and 2 are currently approved for the end-to-end commercial production of tislelizumab for the China market. In April 2024, we opened a new campus equipped with a state-of-the-art ADC production facility and 2 x 500 liters biologics clinical capacity while reserving additional land for the next phase of expansion to support our growing pipeline of large molecule medicines and drug candidates. With the 2 x 500 liters biologics clinical capacity expansion, our Guangzhou manufacturing facility now has a total biologics capacity of 65,000 liters.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Manufacturing Organizations</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely on, and expect to continue to rely on, a limited number of third-party CMOs and CROs for the production of some drug products and drug substances and the supply of raw materials to meet the commercial, clinical, and preclinical needs of our medicines and drug candidates. We have adopted procedures to ensure that the production qualifications, facilities, and processes of the third-party suppliers engaged by us comply with relevant regulatory requirements and our internal quality and operational guidelines. We select our third-party suppliers carefully by considering a number of factors, including their qualifications, relevant expertise, production capacity, geographic proximity, reputation, track record, product quality, reliability in meeting delivery schedules, and business terms.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With our internal manufacturing capabilities and continued partnership with global contract manufacturers, we continue to diversify our global supply network and do not anticipate any disruption to supply on account of our established strategy to maintain sufficient safety stock of our products. We have commercial supply and related agreements with our manufacturing service providers. The FDA has approved an ex-China active pharmaceutical ingredients (&#8220;API&#8221;) source in January 2025, with EMA approval pending. For our commercial and clinical stage products in-licensed from Amgen, BMS and others, we rely on the licensors and their manufacturing facilities or their CMOs for the supply of those medicines and drug candidates.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our agreements with the outsourced suppliers engaged by us generally set out terms, including product quality or service details, technical standards or methods, delivery terms, agreed price and payment, and product inspection and acceptance criteria. Our outsourced suppliers procure raw materials themselves. Either party may terminate the agreements by serving notice to the other party under certain circumstances.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally obtain raw materials for our manufacturing activities from various suppliers who we believe have sufficient capacity to meet our demands. Raw materials and starting materials used at our facilities in Beijing and Suzhou include APIs custom-made by our third-party CROs and excipients, which are commercially available from well-known vendors that meet the requirements of the relevant regulatory agencies. The core raw materials used in manufacturing at our Guangzhou facility are genetically modified cell lines that we have co-developed and licensed from Boehringer Ingelheim and other third parties.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We typically order raw materials on a purchase order basis and do not enter into long-term, dedicated capacity or minimum supply arrangements. Our suppliers are generally not responsible for any defects in our finished products.</span></div><div id="ic94bd2152a214042a118e81881a5a1e5_43"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amgen Collaboration</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Agreement</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 31, 2019, our wholly-owned subsidiary, BeiGene Switzerland GmbH (&#8220;BeiGene Switzerland&#8221;), entered into a Collaboration Agreement with Amgen, which became effective on January 2, 2020 (as amended, the &#8220;Amgen Collaboration Agreement&#8221;). Pursuant to the terms of the Amgen Collaboration Agreement, we are responsible for commercializing Amgen&#8217;s oncology products XGEVA, BLINCYTO and KYPROLIS in China (excluding Hong Kong, Macao and Taiwan) for a period of five or seven years following each product&#8217;s regulatory approval in China, as specified in the Amgen Collaboration Agreement, with the commercialization period for XGEVA commencing following the transition of operational responsibilities for the product. In addition, as specified in the agreement, we have the option to retain one of the three products to commercialize for as long as the product is sold in China. The parties have agreed to equally share profits and losses for the products in China during each product&#8217;s commercialization period. After expiration of the commercialization period for each product, the products not retained will be transitioned back to Amgen and we will be eligible to receive tiered mid-single to low-double digit royalties on net sales in China of each product for an additional five years.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, pursuant to the terms of the Amgen Collaboration Agreement, we and Amgen have agreed to collaborate on the global clinical development and commercialization of a portfolio of Amgen clinical- and late-preclinical-stage oncology pipeline products. Starting from the commencement of the Amgen Collaboration Agreement, we and Amgen will co-fund global development costs, with BeiGene contributing up to $1.25 billion worth of development services and cash over the term of the collaboration. We will be eligible to receive tiered mid-single digit royalties on net sales of each product globally outside of China on a product-by-product and country-by-country basis, until the latest of the expiration of the last valid patent claim, the expiration of regulatory exclusivity, or the earlier of eight years after the first commercial sale of such product in the country of sale and 20 years from the date of first commercial sale of such product anywhere in the world.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each pipeline product that is approved in China, we will have the right to commercialize the product for seven years, with the parties sharing profits and losses for the product in China equally. In addition, we will have the right to retain approximately one of every three approved products, up to a total of six, other than AMG 510, to commercialize for as long as each such product is sold in China. After the expiration of the seven-year commercialization period, each product will be transitioned back to Amgen and we will be eligible to received tiered mid-single to low-double digit royalties on net sales in China for an additional five years. The parties are subject to specified exclusivity requirements in China and the rest of the world.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our ongoing assessment of the Amgen Collaboration Agreement cost-share contributions, we determined that our further investment in the development of AMG 510 was no longer commercially viable for us. As a result, in February 2023, we entered into an amendment to the Amgen Collaboration Agreement to (i) stop sharing costs with Amgen for the further development of AMG 510 during the period starting January 1, 2023 and ending August 31, 2023; and (ii) cooperate in good faith to prepare a transition plan with the termination of AMG 510 from the Amgen Collaboration Agreement.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BeiGene, Ltd. has guaranteed certain obligations of BeiGene Switzerland under the Amgen Collaboration Agreement pursuant to the terms of a separate Guarantee Agreement.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amgen Collaboration Agreement contains customary representations, warranties and covenants by the parties. The agreement will continue in effect on a product-by-product basis unless terminated by either party pursuant to its terms. The agreement may be terminated by mutual written consent of the parties, or by either party upon the other party&#8217;s uncured material breach, insolvency, failure to comply with specified compliance provisions, or subject to a specified negotiation mechanism, certain adverse economic impacts or the failure to meet commercial objectives. In addition, Amgen may terminate the agreement with respect to a pipeline product in the event it suspends development of such pipeline product on specified terms, subject to the parties determining whether to continue development of the pipeline product in China.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Purchase Agreement</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Amgen Collaboration Agreement, pursuant to a share purchase agreement dated October 31, 2019, as amended, by and between BeiGene, Ltd. and Amgen (as amended, the &#8220;Share Purchase Agreement&#8221;), we issued to Amgen 206,635,013 ordinary shares in the form of 15,895,001 ADSs of the Company on January 2, 2020, representing approximately 20.5% of our then outstanding shares, for an aggregate purchase price of $2.78 billion, or $13.45 per ordinary share, or $174.85 per ADS.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Share Purchase Agreement, Amgen agreed to (i) a lock-up on sales of its shares until the earliest of (a) the fourth anniversary of the closing, (b) the expiration or termination of the Collaboration Agreement and (c) a change of control of BeiGene, Ltd., (ii) a standstill until the date on which it holds less than 5% of our then outstanding shares, and (iii) a voting agreement to vote its shares on certain matters presented for shareholder approval until the later of (a) the fifth anniversary of the closing and (b) the expiration of the standstill period, all under specified circumstances and as set forth in the agreement. Following the later of (i) the expiration of the lock-up period and (ii) the expiration of the standstill period, Amgen has agreed not to sell shares representing more than 5% of our then outstanding shares in any rolling 12-month period. The lock-up has since expired and under the terms of the Share Purchase Agreement, Amgen now has specified registration rights. Additionally, we have agreed to use reasonable best efforts to provide Amgen with an opportunity to participate in subsequent new securities offerings upon the same terms and conditions as other purchasers in the offering in an amount needed to allow Amgen to hold up to 20.6% of our shares, subject to applicable law and HKEx rules and other specified conditions.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2020, BeiGene, Ltd. and Amgen entered into an Amendment No. 2 (the &#8220;Second Amendment&#8221;) to the Share Purchase Agreement in order to account for periodic dilution from the issuance of shares by us, which agreement was restated in its entirety on September 24, 2020 (the &#8220;Restated Second Amendment&#8221;). Pursuant to the Restated Second Amendment, Amgen had an option (the &#8220;Direct Purchase Option&#8221;) to subscribe for additional ADSs in an amount necessary to enable it to increase (and subsequently maintain) its ownership at approximately 20.6% of our outstanding shares. The Direct Purchase Option was exercisable on a monthly basis, but only if Amgen&#8217;s interest in our outstanding shares at the monthly reference date was less than 20.4%. The Direct Purchase Option (i) was exercisable by Amgen solely as a result of dilution arising from issuance of new shares by us under our equity incentive plans from time to time, and (ii) was subject to annual approval by our independent shareholders each year during the term of the Restated Second Amendment. The exercise period of the Direct Purchase Option commenced on December 1, 2020 and terminated on December 1, 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 30, 2023, BeiGene, Ltd. and Amgen entered into an Amendment No. 3 to the Share Purchase Agreement, pursuant to which Amgen elected to relinquish its right to appoint a designated director to the Company&#8217;s board of directors on account of the Company&#8217;s global growth. The Company has retained Anthony C. Hooper, who was Amgen&#8217;s director designee on the Company&#8217;s board of directors until Amgen relinquished its right to appoint a designated director. Mr. Hooper was most recently re-elected by shareholders in 2022 to serve a three-year term ending 2025.</span></div><div id="ic94bd2152a214042a118e81881a5a1e5_52"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proprietary nature of, and protection for, our medicines, drug candidates, and their methods of use are an important part of our strategy to develop and commercialize novel medicines, as described in more detail below. We have filed patent applications and obtained patents in the U.S. and other countries and regions, such as Europe and China, relating to our medicines and certain of our drug candidates, and are pursuing additional patent protection for them and for our other drug candidates and technologies. We sometimes rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection, including our manufacturing processes. We also rely on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen, and support our development programs. Additionally, in various markets, a period of regulatory exclusivity may be provided for drugs upon approval. The scope and term of such regulatory exclusivity will vary but, in general, the period will run concurrently with the term of any existing patent rights associated with the drug at the time of approval. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 14, 2025, we owned 63 issued U.S. patents, 15 issued European patents, 28 issued Japanese patents, 70 issued China patents, a number of pending patent applications in the U.S., Europe, Japan and China, and corresponding issued patents and pending patent applications internationally.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key patents for our medicines and late-stage clinical drug candidates as of February 14, 2025, are summarized below:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#acacac;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Molecule </span></td><td colspan="3" style="background-color:#acacac;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Territory</span></td><td colspan="3" style="background-color:#acacac;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General Subject Matter</span></td><td colspan="3" style="background-color:#acacac;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Expiration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:174%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td></tr><tr style="height:15pt"><td colspan="3" rowspan="20" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BRUKINSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(zanubrutinib)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of matter</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2034</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical composition</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2034</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method of treatment</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2034</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Crystalline forms</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Crystalline forms</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Crystalline forms</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method of treatment </span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method of treatment</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combination use</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2039</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method of treatment</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2043</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method of treatment</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2043</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method of treatment</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2043</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of matter</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2034</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combination use</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">3</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of matter</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2034</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Crystalline forms</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Crystalline forms</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of matter</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2034</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Crystalline forms</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combination use</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="13" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TEVIMBRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(tislelizumab)</span></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of matter </span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">4</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of matter</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of matter </span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Polynucleotide</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method of treatment</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of matter for antibodies</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">5</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of matter</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of matter </span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of matter</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of matter</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of matter for antibodies</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Polynucleotide</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Method of treatment</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PARTRUVIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(pamiparib)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of matter</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ociperlimab</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of matter</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2038</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of matter</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2038</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of matter</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2038</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sonrotoclax</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of matter</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2039</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of matter</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2039</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Composition of matter</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2039</span></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.62pt">Unless otherwise indicated, the expected expiration does not include any potential additional term for patent term extension (&#8220;PTE&#8221;), supplemental protection certificate (&#8220;SPC&#8221;) or pediatric exclusivity.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.62pt">SPCs have been filed in various European countries and have been granted at least in France, Germany, Italy, Spain and the United Kingdom, extending the original patent term in those countries to 2036.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.62pt">This patent is the subject of a pending opposition proceeding at the European Patent Office (EPO).</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.62pt">An application for PTE has been filed and if granted, will extend the original patent term to 2038.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:13.62pt">SPCs have been pending or have been granted in various European countries, extending the original patent term in those countries, where granted, to 2038.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our collaboration with Amgen, we have the right to commercialize three medicines in China. The key patents for them in China as of February 14, 2025 are summarized below:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#acacac;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="background-color:#acacac;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Territory</span></td><td colspan="3" style="background-color:#acacac;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General Subject Matter</span></td><td colspan="3" style="background-color:#acacac;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BLINCYTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (blinatumomab)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Use for the treatment of pediatric acute lymphoblastic leukemia</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(carfilzomib)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compound and Composition</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have one in-licensed medicine in China from Shandong Luye Pharmaceutical Co., Ltd (&#8220;Luye&#8221;). The key patent for it in China as of February 14, 2025 is summarized below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#acacac;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="background-color:#acacac;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Territory</span></td><td colspan="3" style="background-color:#acacac;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General Subject Matter</span></td><td colspan="3" style="background-color:#acacac;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BAITUOWEI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (goserelin microsphere)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Formulation</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2034</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our license agreement with Amgen, they retain the responsibility, but are not obligated, to prosecute, defend and enforce the patents for the corresponding in-licensed products. Under our license agreement with Luye, Luye retains the responsibility, but is not obligated, to prosecute the in-licensed patents for the corresponding in-licensed product, and we retain the responsibility, but is not obligated, to defend and enforce the patents for the corresponding in-licensed product.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain foreign jurisdictions similar extensions as compensation for regulatory delays are also available. The actual protection afforded by a patent varies on a claim by claim and country by country basis and depends upon many factors, including the type of patent, the scope of its coverage, the availability of any patent term extensions or adjustments, the availability of legal remedies in a particular country and the validity and enforceability of the patent.</span></div><div id="ic94bd2152a214042a118e81881a5a1e5_55"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a highly competitive global landscape, with our marketed products facing strong competition in regulated markets worldwide. Our primary competitors include a diverse array of entities, from leading global research-based biopharmaceutical companies to agile regional and local firms. These competitors are actively engaged in the development, production, and marketing of therapeutic products aimed at treating diseases similar to those in our current portfolio or pipeline. This global competition underscores the breadth and depth of our industry, requiring us to maintain a robust and agile approach to R&amp;D and excel in the commercialization of our innovative medicines across international markets.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table lists our key competitors for our principal products by competitor, product and territory, though it is not exhaustive.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:13.434%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.574%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:36.404%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Product</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Competitor</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Competitor-marketed product</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Territory</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="4" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">BRUKINSA </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">AbbVie &amp; Janssen</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">IMBRUVICA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">U.S., Europe, Asia Pacific &amp; China</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">AstraZeneca</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">CALQUENCE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">U.S., Europe, Asia Pacific &amp; China</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Eli Lilly</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">JAYPIRCA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">U.S., China &amp; Japan</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Innocare</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">YINUOKAI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">China</span></td></tr><tr style="height:14pt"><td colspan="3" rowspan="10" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">TEVIMBRA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Merck</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">KEYTRUDA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">U.S., Europe, Asia Pacific &amp; China</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Bristol Meyers Squibb</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">OPDIVO</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">U.S., Europe, Asia Pacific &amp; China</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">AstraZeneca</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">IMFINZI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">U.S., Europe, Asia Pacific &amp; China</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Roche</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">TECENTRIQ</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">U.S., Europe, Asia Pacific &amp; China</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Merck KGaA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">BAVENCIO</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">U.S., Europe, Asia Pacific &amp; China</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Regeneron &amp; Sanofi</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LIBTAYO</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">U.S., Europe, Asia Pacific &amp; China</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">GSK</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">JEMPERLI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">U.S., Europe, Asia Pacific &amp; China</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Junshi</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LOQTORZI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">U.S., Europe &amp; China</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Henlius</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">HANSIZHUANG</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">U.S., China &amp; South Asia</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various Chinese companies</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10+ products including PD-1/L1, PD-1xCTLA-4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">China</span></td></tr></table></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have several promising candidates in the pivotal development stage, including sonrotoclax, a BCL-2 inhibitor, and BGB-16673, a BTK-targeted degrader compound (&#8220;CDAC&#8221;). These products are in various stages of clinical trials conducted globally and show potential in addressing unmet medical needs.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table lists our key competitors for our late-stage pipeline products by competitor, asset, latest development stage, and clinical trial territory, although it is not exhaustive.</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.291%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.327%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Asset</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Competitor</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Competitor-asset  </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Latest development stage </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Territory</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sonrotoclax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">AbbVie &amp; Roche</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">VENCLEXTA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Approved</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Global</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ascentage Pharma</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Lisaftoclax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Phase 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Global</span></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">BGB-16673</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Eli Lilly (Loxo Oncology)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">JAYPIRCA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Approved</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Global</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Nurix Therapeutics</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">NX-5948</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">U.S.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">AbbVie</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ABBV-101</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Phase 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Global</span></td></tr></table></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we are advancing several promising candidates through pivotal programs, including novel antibody-drug conjugates (&#8220;ADCs&#8221;), multispecific antibodies, and targeted therapies for lung, breast, and gastrointestinal cancers. To our knowledge, Roche, AstraZeneca, Pfizer, and Merck are also developing new therapeutic options with similar mechanisms. Our candidates are well-positioned in the market to offer first-in-class and/or best-in-class profiles, particularly in addressing the limitations of existing treatments and offering new alternatives to patients.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the larger companies we compete with are well-capitalized and dedicate a significant number of financial resources to support their research and development, while using business development to supplement their internal pipelines as well as investing heavily in commercialization capabilities. As a result, we must continuously invest and gain experience in the development, acquisition, and marketing of innovative and branded medicines and drug candidates to compete effectively in both current and future markets. This requires us to devote substantial funds and resources to develop and generate evidence that prevents the erosion of existing products and delivers revenue from the next waves of innovation. </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The main forms of competition include efficacy, safety, and cost. The long-term success of our products depends on our ability to effectively demonstrate the value to physicians, patients, and third-party payers. This requires a much greater use of a direct sales force and promotion to realize significant revenues. We also have, and will continue to enter into, co-promotion, contract sales force or other such arrangements with third parties, for example, where our own direct sales force is not large enough or sufficiently well-aligned to achieve maximum market penetration. Furthermore, robust compliance approaches, science-based promotion model, and integrated management will also be competitive advantages in the industry in the long run, in which we invest significant effort to establish and grow.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the U.S., Europe, China and other jurisdictions extensively regulate the research and clinical development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing, and export and import of drugs like those we are developing and commercializing. Some jurisdictions also regulate drug pricing. Generally, for a new drug to be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific to each regulatory authority, submitted for review and approved by the regulatory authority.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Regulation</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Government Regulation and Product Approval</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;), and its implementing regulations, and biologics under the FDCA, its implementing regulations, and the Public Health Service Act (&#8220;PHSA&#8221;), and its implementing regulations.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Drug and Biologics Product Development</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process required by the FDA before a drug or biologic may be marketed in the U.S. generally involves the following:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completion of preclinical laboratory tests and animal studies according to Good Laboratory Practices (&#8220;GLP&#8221;) guidance;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completion of extensive chemistry, manufacturing, and control (&#8220;CMC&#8221;) studies;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission to the FDA of an IND application, which must become effective before human clinical trials may begin;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">performance of adequate and well-controlled human clinical trials according to Good Clinical Practice (&#8220;GCP&#8221;), to establish the safety and efficacy of the proposed drug or safety, purity and potency of the proposed biologic, for the intended use;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preparation and submission to the FDA of an NDA for a small molecule drug or a BLA for a biologic;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a determination by the FDA within 60 days of its receipt of an NDA or BLA to file the application for review;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product, or components thereof, are produced to assess compliance with cGMP;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">review of the product candidate by an FDA advisory committee, where appropriate and if applicable;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">payment of user fees for FDA review of the NDA or BLA (unless a fee waiver applies);</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA audits of some clinical trial sites to ensure compliance with GCPs; and</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA review and approval of the NDA or licensing of the BLA.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preclinical Studies and Clinical Trials</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a product candidate is identified for development, it enters the preclinical testing stage. Preclinical tests include laboratory evaluations of product chemistry, toxicity, formulation and stability, as well as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and animal studies. The conduct of the preclinical tests must comply with federal regulations and requirements, including GLP. The results of preclinical testing, along with other information, including information about product chemistry, manufacturing and controls and a proposed clinical trial protocol are reviewed by the FDA as part of an IND. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions related to the proposed clinical trial and places the trial on a full clinical hold. The FDA may also impose full or partial clinical holds at any time before or during clinical trials due to safety concerns or noncompliance and may be imposed on all products within a certain class of products. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with GCP regulations. Further, an institutional review board (&#8220;IRB&#8221;) must review and approve the plan for any clinical trial before it commences at any institution, and the IRB must conduct continuing review and reapprove the study at least annually. An IRB considers, among other things, whether the risks to individuals participating in the clinical trial are minimized and are reasonable in relation to anticipated benefits. Some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data safety monitoring board or committee. This group provides authorization as to whether or not a trial may move forward at designated check points based on access that only the group maintains to available data from the trial and may recommend halting the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each new clinical protocol and any amendments to the protocol must be filed with the FDA as an IND amendment and submitted to the IRBs for approval.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sponsor who wishes to conduct a clinical trial outside of the U.S. may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of an NDA or BLA. The FDA will accept a well-designed and well-conducted foreign clinical study not conducted under an IND if the study was conducted in accordance with GCP requirements, and the FDA is able to validate the data through an onsite inspection if deemed necessary.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Phase&#160;1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The product is initially introduced into a small number of healthy human subjects or patients and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion and, if possible, to gain early evidence on effectiveness. In the case of some products for severe or life-threatening diseases, especially when the product is suspected or known to be unavoidably toxic, the initial human testing may be conducted in patients with the target disease or condition.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Phase&#160;2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Involves clinical trials in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage and schedule.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Phase&#160;3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population. These clinical trials are intended to evaluate the overall risk/benefit relationship of the product and provide an adequate basis for product labeling.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication and are commonly intended to generate additional safety data regarding use of the product in a clinical setting. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA or BLA.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and safety reports must be submitted to the FDA and the investigators for serious and unexpected suspected AEs, any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator&#8217;s brochure, or any findings from other studies or animal or in vitro testing that suggest a significant risk in humans exposed to the product. The FDA, IRB, or the sponsor may suspend or terminate, or a data safety monitoring board may recommend the suspension or termination of, a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Expanded Access</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expanded access, sometimes called &#8220;compassionate use,&#8221; is the use of investigational products outside of clinical trials to treat patients with serious or immediately life-threatening diseases or conditions when there are no comparable or satisfactory alternative treatment options. There is no requirement for a company to provide expanded access to its investigational products. However, if a company decides to make one of its investigational products available for expanded access, the FDA reviews each request for expanded access and determines if treatment may proceed. We make available on our website our contact information for requesting access to our investigational drugs and expected timeline for us to acknowledge receiving such requests.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Review and Approval Processes</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of product development, preclinical studies and clinical trials, along with descriptions of the CMC, analytical tests conducted on the product, proposed labeling and other relevant information, are submitted to the FDA as part of an NDA for a new small molecule drug or a BLA for a biologic, requesting approval to market the product. The submission of an NDA or BLA is subject to the payment of a substantial user fee, although a waiver of such fee may be obtained under certain limited circumstances. The sponsor of an approved NDA or BLA is also subject to an annual prescription drug product program fee.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may request additional information rather than accept an NDA or BLA for filing. In this event, the NDA or BLA must be re-submitted with the additional information and the re-submitted application is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use, and a BLA to determine whether the biologic is safe, pure, and potent for its intended use. The FDA also evaluates whether the product&#8217;s manufacturing is cGMP-compliant to assure the product&#8217;s identity, strength, quality and purity. Before approving an NDA or BLA, the FDA typically will inspect the facility or facilities where the product is or will be manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities comply with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA or BLA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP and other requirements and the integrity of the clinical data submitted to the FDA.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The approval process can be lengthy and difficult, and the FDA may refuse to approve an NDA or BLA if the applicable regulatory criteria are not satisfied or may require additional data and information. Even if such data and information are submitted, the FDA may ultimately decide that the NDA or BLA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive, and the FDA may interpret data differently than we interpret the same data. The FDA will issue a complete response letter if the agency decides not to approve the NDA or BLA in its present form. The complete response letter describes the specific deficiencies identified in the NDA or BLA that must be satisfactorily addressed before it can be approved. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally, the complete response letter may include recommended actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the applicant may either resubmit the NDA or BLA, addressing all of the deficiencies identified in the letter, withdraw the application or request an opportunity for a hearing.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling, require post-approval studies, including Phase 4 clinical trials, to further assess a product&#8217;s safety and effectiveness, or may require testing and surveillance programs to monitor the safety of approved products. The FDA may also approve an NDA or BLA with a Risk Evaluation and Mitigation Strategy program to mitigate risks, which could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulation of Combination Products in the U.S.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain products may be comprised of components that would normally be regulated under different types of regulatory authorities in certain jurisdictions, and in the U.S. by different centers at the FDA. These products are known as combination products. Under the FDCA, the FDA is charged with assigning a center with primary jurisdiction, or a lead center, for review of a combination product. That determination is based on the &#8220;primary mode of action&#8221; of the combination product. We are developing combination products using our own drug candidates and third-party drugs.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulation of Companion Diagnostics in the U.S.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If safe and effective use of a therapeutic depends on an </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> diagnostic, then the FDA generally will require approval or clearance of that diagnostic, known as a companion diagnostic, at the same time that the FDA approves the therapeutic product. For novel drugs, a companion diagnostic device and its corresponding therapeutic should be approved or cleared contemporaneously by the FDA for the use indicated in the therapeutic product&#8217;s labeling. Once cleared or approved, the companion diagnostic must adhere to post-marketing requirements including the requirements of FDA&#8217;s quality system regulation, medical device reporting, recalls and corrections along with product marketing requirements and limitations. Companion diagnostic manufacturers are subject to unannounced FDA inspections at any time during which the FDA will conduct an audit of the product(s) and the company&#8217;s facilities for compliance with its authorities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expedited Programs</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may employ one of several tools to expedite the development and review of a medicine, including fast track designation, breakthrough therapy designation, priority review designation and accelerated approval. Fast track designation is designed to facilitate the development and review of a medicine that treats a serious or life-threatening disease or condition and fills an unmet medical need. Breakthrough therapy designation is intended to expedite the development and review of a medicine that treats a serious or life-threatening disease or condition and preliminary clinical evidence indicates substantial improvement over existing therapies. Priority review designation means the FDA&#8217;s goal is to take action on an application within six months of filing. The FDA may grant priority review designation to a medicine that would provide significant improvement in the safety or effectiveness of a treatment, diagnosis or prevention of a serious condition.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A product may also be eligible for accelerated approval if it treats a serious or life-threatening condition and generally provides a meaningful therapeutic benefit over available therapies. In addition, such product must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality (&#8220;IMM&#8221;) that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. A product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of post-approval clinical trials to confirm the effect on IMM or other clinical benefit. If the FDA concludes that a drug or biologic shown to be effective can be safely used only if distribution or use is restricted, it will require such post-marketing restrictions, as it deems necessary to assure safe use of the product. Under the Food and Drug Omnibus Reform Act of 2022 (&#8220;FDORA&#8221;), the FDA is now permitted to require, as appropriate, that such trials be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. Additionally, under FDORA, the FDA has increased authority for expedited procedures to withdraw its accelerated approval for such drug or biologic if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product. </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or that the time period for FDA review or approval may not be shortened. Furthermore, fast track designation, priority review, accelerated approval, and breakthrough therapy designation do not change the standards for approval.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pediatric Information</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pediatric Research Equity Act of 2003, all marketing applications for new active ingredients, indications, dosage forms, dosing regimens or routes of administration must contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred or inapplicable.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Best Pharmaceuticals for Children Act, a product may be eligible for pediatric exclusivity, which adds six months to existing exclusivity periods and patent terms. This exclusivity may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued written request for such a study.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-Approval Requirements</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any products for which we receive FDA approval are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information, product sampling and distribution requirements, complying with certain electronic records and signature requirements and complying with FDA promotion and advertising requirements. The FDA strictly regulates labeling, advertising, promotion and other types of information on products that are placed on the market. Products may be promoted only for the approved indications and in accordance with the provisions of the approved label. Further, manufacturers must continue to comply with cGMP requirements, which are extensive and require considerable time, resources and ongoing investment to ensure compliance. In addition, changes to the manufacturing process generally require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers and other entities involved in the manufacturing and distribution of approved products are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. The cGMP requirements apply to all stages of the manufacturing process, including the production, processing, sterilization, packaging, labeling, storage and shipment of the product. Manufacturers must establish validated systems to ensure that products meet specifications and regulatory requirements and test each product batch or lot prior to its release. Additionally, manufacturers and other parties involved in the drug supply chain for prescription drug products must also comply with product tracking and tracing requirements and notify the FDA of counterfeit, diverted, stolen and intentionally adulterated products or products that are otherwise unfit for distribution in the U.S.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may withdraw a product approval, revoke a biologics license or implement restrictions on such product if compliance with regulatory requirements is not maintained or if problems occur after the product reaches the market. Further, the failure to maintain compliance with regulatory requirements may result in administrative or judicial actions, such as fines, untitled or warning letters, holds on clinical trials, product seizures, product detention or refusal to permit the import or export of products, refusal to approve pending applications or supplements, restrictions on marketing or manufacturing, injunctions or civil or criminal penalties. We may undertake or be required to undertake a product recall.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patent Term Restoration and Regulatory Exclusivity</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain circumstances, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to five years as compensation for patent term lost during product development and FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of an NDA or BLA, plus the time between the submission date of an NDA or BLA and the approval of that application. Only one patent applicable to an approved product is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, if available, we intend to apply for restorations of patent term for some of our patents beyond their current expiration dates, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant NDA or BLA; however, there can be no assurance that any such extension will be granted to us.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data exclusivity provisions under the FDCA can also delay the submission or the approval of certain applications. The FDCA provides a five-year period of non-patent data exclusivity within the U.S. to the first applicant to gain approval of an NDA for a new chemical entity. During the exclusivity period, the FDA may not accept for review an abbreviated NDA (&#8220;ANDA&#8221;) or a 505(b)(2) NDA submitted by another company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required for approval. However, such an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement. The FDCA also provides three years of data exclusivity for an NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed to be essential to the approval of the application, for example, for new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory exclusivity in the U.S. can also include pediatric exclusivity and orphan drug exclusivity. Pediatric exclusivity, if granted, provides an additional six months of exclusivity for all formulations, dosage forms, and indications of the active moiety and, for drugs, patent terms. This exclusivity may be granted based on the voluntary completion of a pediatric trial, provided that at the time pediatric exclusivity is granted there is not less than nine months of term remaining. Orphan drug exclusivity is described below under &#8220;Orphan Drugs.&#8221;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biosimilars and Exclusivity</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PHSA includes an abbreviated approval pathway for biological products shown to be similar to, or interchangeable with, an FDA-licensed reference biological product. Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity and potency, can be shown through analytical studies, animal studies, and a clinical trial or trials. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product and, for products administered multiple times, the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reference biologic is granted 12 years of exclusivity from the time of first licensure of the product. The FDA may approve multiple &#8220;first&#8221; interchangeable products so long as they are all approved on the same first day of marketing. This exclusivity period, which may be shared amongst multiple first interchangeable products, lasts for the lesser of (i) one year after the first commercial marketing, (ii) 18 months after approval if there is no legal challenge, (iii) 18 months after the resolution in the applicant&#8217;s favor of a lawsuit challenging the biologic&#8217;s patents if an application has been submitted, or (iv) 42 months after the application has been approved if a lawsuit is ongoing within the 42-month period.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Orphan Drugs</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orphan drugs are defined by the FDA as products intended to treat a rare disease or condition that affects less than 200,000 persons in the U.S. or that affects more than 200,000 individuals in the U.S. and for which there is no reasonable expectation that costs of research and development of the product for the indication can be recovered by sales of the product in the U.S. A company must request orphan drug designation prior to filing and, if granted, the FDA will not approve another sponsor&#8217;s marketing application for the same drug for the same indication for seven years. Orphan drug exclusivity will not bar approval of another medicine for the same indication if it is shown to be clinically superior.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure of Clinical Trial Information</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sponsors of clinical trials of FDA-regulated products, including drugs and biologics, are required to register and disclose certain clinical trial information, which is publicly available at www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, study sites and investigators, and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to disclose the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed until the new product or new indication being studied has been approved. Competitors may use this publicly available information to gain knowledge regarding the progress of development programs.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmaceutical Coverage, Pricing, and Reimbursement</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. and in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend in part on the availability of coverage and reimbursement from third-party payors, including government authorities, managed care providers, private health insurers and other organizations. Patients generally rely on third-party payors to reimburse all or part of the associated healthcare costs and no uniform policy of coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the process for determining whether a payor will provide coverage for a product may be separate from the process for setting the reimbursement rate that the payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list which might not include all of the FDA-approved products for a particular indication. Moreover, a payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of any products, in addition to the costs required to obtain regulatory approvals. If third-party payors do not consider a product to be cost-effective or medically-necessary compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, products launched in the EU do not follow price structures of the U.S. and generally prices tend to be significantly lower.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Healthcare Reform</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. government and state legislatures have implemented cost containment programs to limit the growth of government-paid health care costs, including price controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. Such adoption of government controls and tightening of restrictive policies could limit payments for pharmaceuticals. For example, the Affordable Care Act (the &#8220;ACA&#8221;) contains provisions that may reduce the profitability of drug products, including increased rebates for drugs reimbursed by Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. Some of the provisions of the ACA have yet to be fully implemented, while certain provisions have been subject to judicial, Congressional, and Executive challenges. As a result, it is unclear how such efforts to challenge, repeal or replace the ACA, will impact our business.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted in the U.S. since the ACA was enacted. For example, the Bipartisan Budget Act of 2018 amended the ACA by increasing the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D from 50% to 70% and closing the coverage gap in most Medicare drug plans. In addition, the Budget Control Act of 2011 and the Bipartisan Budget Act of 2015 led to aggregate reductions of Medicare payments to providers of up to 2% per fiscal year that will remain in effect through 2031 unless additional Congressional action is taken. Further, the American Taxpayer Relief Act reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. The American Rescue Plan Act of 2021 eliminated the statutory Medicaid drug rebate cap, set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. These laws and regulations may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) was enacted containing provisions that reduce the out-of-pocket spending cap for Medicare Part D beneficiaries from $7,050 to $2,000 starting in 2025, thereby effectively eliminating the coverage gap; impose new manufacturer financial liability on certain drugs under Medicare Part D; allow the U.S. government to negotiate Medicare Part B and Part D price caps for certain high-cost drugs and biologics without generic or biosimilar competition; require companies to pay rebates to Medicare for certain drug prices that increase faster than inflation; and delay until January 1, 2032 the implementation of the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) rebate rule that would have limited the fees that pharmacy benefit managers can charge. Further, under the IRA, orphan drugs are exempted from the Medicare drug price negotiation program, but only if they have one orphan designation and for which the only approved indication is for that disease or condition. The implementation of the IRA is currently subject to ongoing litigation challenging the constitutionality of the IRA&#8217;s Medicare drug price negotiation program. The effects of the IRA on our business and the healthcare industry in general is not yet known.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, former President Biden issued multiple executive orders seeking to reduce prescription drug costs. President Trump reversed some of President Biden&#8217;s executive orders including rescinding Executive Order 14087 entitled &#8220;Lowering Prescription Drug Costs for Americans.&#8221; President Trump may issue new executive orders designed to impact drug pricing. Congress and the Trump administration have indicated that they will continue to seek new legislative measures to control drug costs.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) published a final rule that gives states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces. CMS also published a final rule to allow Medicare Advantage Plans the option of using step therapy for Part B drugs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has also been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed bills designed to bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The HHS implemented a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers ("PBMs"), unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between PBMs and manufacturers. Pursuant to court order, the removal and addition of the aforementioned safe harbors were delayed and recent legislation imposed a moratorium on implementation until January 1, 2032. Implementation of this change and new safe harbors for point-of-sale reductions in price for prescription pharmaceutical products and PBM service fees are currently under review by the Biden administration and may be amended or repealed.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there have been several changes to the 340B drug pricing program, which imposes ceilings on prices that drug manufacturers can charge for medications sold to certain health care facilities. In 2023, the U.S. District Court of South Carolina issued an opinion in Genesis Healthcare Inc. v. Becerra et al. that may lead to an expansion of the scope of patients eligible to access prescriptions at 340B pricing. The outcome of this judicial proceeding is currently uncertain.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. While much of the focus of state pricing policies is limited to Medicaid, we cannot assess the impact that these and other measures such as state transparency policies will have on our business.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other U.S. Healthcare Laws and Compliance Requirements</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various federal and state laws targeting fraud and abuse in the healthcare industry. These laws may impact, among other things, our sales, marketing and education programs. In addition, we may be subject to patient privacy, cybersecurity, trade, and national security regulation by both the federal government and the states in which we conduct our business prior to and after receiving regulatory approval of our product candidates. Some of the laws that may affect our ability to operate are detailed below:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal healthcare Anti-Kickback Statute (&#8220;AKS&#8221;), which prohibits, among other things, knowingly and willfully soliciting, receiving, providing, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation or arrangement of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Although there are several statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution, they are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. A person or entity can be found guilty of violating the AKS without actual knowledge of the statute or specific intent to violate it. Violations of the AKS carry potentially significant civil fines and criminal penalties, including imprisonment, fines, administrative federal civil monetary penalties, and exclusion from participation in federal healthcare programs. This law applies to our marketing practices, educational programs, pricing policies and relationships with healthcare providers. We continue to evaluate what effect, if any, these rules will have on our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal civil and criminal false claims and civil monetary penalty laws, such as the federal False Claims Act (&#8220;FCA&#8221;), which impose criminal and civil penalties and authorize civil whistleblower or qui tam actions, against individuals or entities for, among other things: knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false, fictitious or fraudulent; knowingly making or causing a false statement or record material to a false or fraudulent claim or obligation to pay or transmit money or property to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the federal AKS constitutes a false of fraudulent claim for purposes of the FCA. The government may deem manufacturers to have &#8220;caused&#8221; the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers or promoting a product off-label. Companies that submit claims directly to payors may also be liable under the FCA for the direct submission of such claims. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. When an entity is determined to have violated the FCA, the government may impose civil fines and penalties for each false claim, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs. Our marketing and activities relating to the reporting of wholesaler or estimated retail prices for our products, the reporting of prices used to calculate Medicaid rebate information and other information affecting federal, state and third-party reimbursement for our products, and the sale and marketing of our products and any future product candidates are subject to scrutiny under this law.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which prohibits, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal AKS, a person or entity can be found guilty of violating HIPAA without actual knowledge of the statute or specific intent to violate it.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As further amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;), HIPAA and their respective implementing regulations impose requirements on certain covered healthcare providers, health plans and healthcare clearinghouses as well as their respective business associates who perform services for them that involve the creation, maintenance, receipt, use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, made civil and criminal penalties directly applicable to business associates, and gave state attorneys authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA laws and seek attorneys&#8217; fees and costs. In addition, there may be other federal, state and non-U.S. laws which govern the privacy and security of health and other personal information and which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal transparency requirements under the ACA, including the provision commonly referred to as the Physician Payments Sunshine Act requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to Centers for Medicare &amp; Medicaid Services information related to payments or other transfers of value made to physicians, certain other licensed health care practitioners and teaching hospitals. Manufacturers are also required to disclose ownership and investment interest held by physicians and their immediate family members.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Federal price reporting laws, which require manufacturers to calculate and report complex pricing metrics in an accurate and timely manner to government programs.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Foreign Corrupt Practices Act, which prohibits companies and their intermediaries from making, or offering or promising to make, improper payments to non-U.S. officials for the purpose of obtaining or retaining business or otherwise seeking favorable treatment.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Executive Order 14117 on Preventing Access to Americans&#8217; Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern prohibits transactions involving certain sensitive personal data categories, including health data, genetic data, and biospecimens, to countries of concern, including China. The regulations also restrict investment agreements, employment agreements and vendor agreements involving such data and countries of concern. Actual or alleged violations of these regulations may be punishable by criminal and/or civil sanctions, and may result in exclusion from participation in federal and state programs.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, state privacy laws may be broader and require greater protections than HIPAA. These data privacy and security laws may differ from each other and often are not pre-empted by HIPAA, which may complicate compliance efforts. For example, certain states have passed privacy laws that grant consumers rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. Several states have passed laws specifically regulating consumer health data, which impose detailed consent requirements for uses and disclosures of such data. These laws provide for civil penalties for violations, and key concepts in such laws have not yet been tested, leading to significant uncertainty concerning the application of such laws to our practices. In addition, several of these laws allow for private claims, which could lead to litigation risks even where we believe we are in compliance.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we are subject to state equivalents of each of the healthcare laws described above, some of which may be broader in scope and may apply to healthcare services reimbursed by any third-party payor, not just governmental payors, but also private insurers. These laws are enforced by various state agencies and through private actions. Some states have passed laws that require pharmaceutical companies to comply with the April&#160;2003 Office of Inspector General Compliance Program Guidance for Pharmaceutical Manufacturers and/or other voluntary industry codes of conduct that restrict the payments made to healthcare providers and other potential referral sources. Several states and local laws also impose other marketing restrictions or require pharmaceutical companies to make marketing or price disclosures to the state, require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers, and require the registration of pharmaceutical sales representatives.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., to help patients afford our approved product, we may utilize programs to assist them, including patient assistance programs and co-pay coupon programs for eligible patients. Government enforcement agencies have shown increased interest in pharmaceutical companies&#8217; product and patient assistance programs, including reimbursement support services, and investigations into these programs have resulted in significant civil and criminal settlements. In addition, at least one insurer has directed its network pharmacies to no longer accept co-pay coupons for certain specialty drugs the insurer identified. Our co-pay coupon programs could become the target of similar insurer actions. In addition, the CMS issued guidance to the issuers of qualified health plans sold through the ACA&#8217;s marketplaces encouraging such plans to reject patient cost-sharing support from third parties and indicating that the CMS intends to monitor the provision of such support and may take regulatory action to limit it in the future. The CMS also requires individual market qualified health plans to accept third-party premium and cost-sharing payments from certain government-related entities. Furthermore, the Office of Inspector General (&#8220;OIG&#8221;) of the HHS has warned manufacturers that they may be subject to sanctions under the federal AKS and/or civil monetary penalty laws if they do not take appropriate steps to exclude Part D beneficiaries from using co-pay coupons. It is possible that changes in insurer policies regarding co-pay coupons and/or the introduction and enactment of new legislation or regulatory action could restrict or otherwise negatively affect these patient support programs, which could result in fewer patients using affected products, and therefore could have a material adverse effect on our sales, business, and financial condition.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party patient assistance programs that receive financial support from companies have become the subject of enhanced government and regulatory scrutiny. The OIG has established guidelines that suggest that it is lawful for pharmaceutical manufacturers to make donations to charitable organizations who provide co-pay assistance to Medicare patients, provided that such organizations, among other things, are bona fide charities, are entirely independent of and not controlled by the manufacturer, provide aid to applicants on a first-come basis according to consistent financial criteria and do not link aid to use of a donor&#8217;s product. However, donations to patient assistance programs have received some negative publicity and been the subject of multiple government enforcement actions, related to allegations regarding their use to promote branded pharmaceutical products over other less costly alternatives. Specifically, in recent years, there have been multiple settlements resulting out of government claims challenging the legality of their patient assistance programs under a variety of federal and state laws.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The scope and enforcement of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Federal and state enforcement has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">EU and UK Data Protection Laws</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, the General Data Protection Regulation (&#8220;GDPR&#8221;) governs the processing of personal data. The GDPR imposes a broad range of strict requirements on companies subject to the GDPR, such as including requirements relating to having legal basis for processing personal data relating to identifiable individuals and transferring such information outside the European Economic Area (&#8220;EEA&#8221;), including to the U.S., providing details to those individuals regarding the processing of their personal data, implementing safeguards to keep personal data secure, having data processing agreements with third parties who process personal data in countries not deemed adequate by the EU and the UK, responding to individuals&#8217; requests to exercise their rights in respect of their personal data, obtaining consent of the individuals to whom the personal data relates if there is no legal basis for processing, reporting security and privacy breaches involving personal data to the competent national data protection authority and affected individuals, appointing data protection officers, conducting data protection impact assessments, and record-keeping. The GDPR substantially increases the penalties to which we could be subject in the event of any non-compliance, including fines of up to &#8364;20,000,000 or 4% of total annual global revenue, whichever is greater. In addition, the UK&#8217;s European Union (Withdrawal) Act 2018 incorporated the GDPR (subject to certain UK specific amendments) into UK law, referred to as the UK GDPR. The UK GDPR and the UK Data Protection Act 2018 set out the UK&#8217;s data protection regime, which is independent from but aligned to the EU&#8217;s data protection regime. Non-compliance with the UK GDPR may result in monetary penalties of up to &#163;17.5 million or 4% of worldwide revenue, whichever is higher. Like the EU GDPR, the UK GDPR restricts personal data transfers outside the UK to countries not regarded by the UK as providing adequate protection. The UK government has confirmed that personal data transfers from the UK to the EEA remain free flowing. We are required to implement certain safeguards detailed in these regulations when conducting restricted data transfers under the EU and UK GDPR and regulators retain authority to further restrict or prohibit transfers to certain countries where applicable laws would undermine the privacy safeguards provided by the GDPR.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PRC Regulation</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the PRC, we operate in an increasingly complex legal and regulatory environment. We are subject to a variety of PRC laws, rules and regulations affecting many aspects of our business. This section summarizes the principal PRC laws, rules and regulations that we believe are relevant to our business and operations.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PRC Drug Regulation</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Introduction</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">China heavily regulates the development, approval, manufacturing and distribution of drugs, including biologics. The legal framework for the administration of pharmaceutical products in China was established by the Drug Administration Law of the PRC (the &#8220;DAL&#8221;). The DAL provides a framework for regulating pharmaceutical manufacturers, pharmaceutical trading companies, medical institutions, and the research, development, manufacturing, distribution, packaging, pricing, and advertisement activities related to pharmaceutical products. The Implementing Measures of the Drug Administration Law provides detailed implementation regulations for the DAL.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">The DAL</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The DAL embodies a regulatory trend to strengthen the life-cycle management of drugs, to balance the development of innovative drugs and generic drugs, and to enhance drug review and enforcement. It established the Marketing Authorization Holder (the &#8220;MAH&#8221;) system, and subject to approval by the NMPA, MAHs will be allowed to transfer their marketing authorizations. However, to date, it remains uncertain whether the transferability of MAH will offer more flexibility in structuring cross-border transactions. In addition, the implementation of the MAH system was accompanied by a range of new requirements for the MAHs. For example, a MAH must establish a quality assurance system and be responsible for the whole process and all aspects of preclinical research, clinical trials, manufacturing and distribution, post-marketing research, adverse drug reaction monitoring and reporting. A foreign MAH is required to engage a local agent to fulfill the MAH&#8217;s obligations and the foreign MAH is subject to joint and several liability in the event of any wrongdoing. On November 13, 2024, the NMPA issued the Interim Provisions for the Management of Domestic Responsible Persons Designated by Foreign Drug Marketing Authorization Holders (the &#8220;Interim Provisions&#8221;), which will come into effect on July 1, 2025. The Interim Provisions explicitly require foreign MAHs to designate local delegates and authorize them to undertake important post-marketing responsibilities together with the drug MAHs, including post-marketing change management, pharmacovigilance, and product quality complaint handling. As of July 1, 2025, the name, address and contact information of the domestic responsible person shall be listed in the package insert and detailed requirements of implementation shall be subject to further practical guidance and interpretation rules from the relevant government authorities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The DAL requires drug manufacturers and drug distributors to comply with current GMP and GSP requirements. Pursuant to the DAL, NMPA and its local counterparts are directed to strengthen their surveillance of drug manufacturers and distributors, including through regular site inspections and unannounced checks, to ensure their compliance. The NMPA has also been strengthening its regulation of clinical trial institutions by collaborating with the National Health Commission (the &#8220;NHC&#8221;), the chief healthcare regulator in China. The Measures for the Administration of Drug Clinical Trial Institutions jointly issued by the NMPA and the NHC provides detailed requirements on how drug clinical trial institutions should comply with GCP, including, among others, that all drug clinical trial institutions are required to be registered on an online system and disclose their key information essential for compliance with GCP.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The DAL also requires MAHs, manufacturers, distributors, and medical institutions to establish and implement drug track and trace systems. The Measures for the Quality Supervision of Drug Commercialization and Use established the requirements and standards for the drug track and trace system. A drug pharmacovigilance system will also be established to monitor, identify, evaluate and control adverse drug reactions and other possible drug-related problems. The Good Pharmacovigilance Practices provides detailed requirements on MAH&#8217;s pharmacovigilance obligations.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The DAL creates an expanded access pathway for investigational drugs under which a company sponsor of a clinical trial in China can apply to establish an expanded access treatment program for patients with life-threatening disease who otherwise do not satisfy the inclusion criteria of a clinical trial. To quality for expanded access: (1) the drug must be used for life-threatening diseases that lack effective treatment; (2) the drug must have demonstrated its potential efficacy based on medical observations; (3) such use is in line with ethical principles; (4) such expanded use has been reviewed and approved (although the approval pathway not clear), and has obtained patients&#8217; informed consent; and (5) the drug must be used within the clinical trial institution and used on patients with similar conditions.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The DAL provides heavy penalties for violations. Depending on various types of violations, the DAL imposes different penalties, including warnings, confiscation of illegal gains, fines of up to RMB5 million (about $725,000) or up to 30 times of illegal gains, revocation of required business and operating licenses, certificates or approval documents for drugs, suspension of business, temporary (10 years) or permanent debarment of companies, institutions and responsible persons, and criminal liabilities in the case of serious violations.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interpretation and implementation of the DAL have been evolving overtime. We plan to closely monitor the implementation of the DAL and its impact on our operations in China.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Regulatory Authorities and Government Reorganization</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In China, the NMPA is the primary regulator for pharmaceutical products and businesses. It is a sub-agency of the State Administration for Market Regulation (the &#8220;SAMR&#8221;), which is responsible for, in addition to drug regulation, consumer protection, advertising, anticorruption, antitrust, fair competition and intellectual property.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NMPA regulates almost all of the key stages of the life cycle of pharmaceutical products, including nonclinical studies, clinical trials, marketing approvals, manufacturing, advertising and promotion, distribution, and pharmacovigilance (i.e., post-marketing safety reporting obligations). The CDE, which remains under the NMPA, conducts the technical evaluation of each drug and biologic application for safety and efficacy.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NHC is China&#8217;s chief healthcare regulator. It is primarily responsible for overseeing the operation of medical institutions (including clinical trial sites) and regulating the licensure of hospitals and other medical personnel.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NHSA is the primary regulator overseeing national medical insurance and related drug reimbursement schemes, including, among others, the National Drug Reimbursement Price Negotiations, which have significant impact on innovative drugs&#8217; prices in China.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NHSA and its local counterparts at or below the provincial level of local government also oversee and organize public medical institutions&#8217; centralized bidding and procurement programs for pharmaceutical products. This is the primary way that public hospitals and their internal pharmacies procure drugs.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Preclinical and Clinical Development</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NMPA requires preclinical data to support registration applications for new drugs. Preclinical work, including safety assessment studies, must meet the GLP&#8217;s standards. The DAL requires the NMPA to accredit GLP labs, and that nonclinical studies of chemical drug substances and preparations and biologics that are not yet marketed in China be conducted in GLP-certified labs. There are no approvals required from the NMPA to conduct preclinical studies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Certificate for Use of Laboratory Animals is required for performing experimentation on animals under the Regulations for the Administration of Affairs Concerning Experimental Animals, the Administrative Measures on Good Practice of Experimental Animals, and the Administrative Measures on the Certificate for Experimental Animals (Trial). Applicants for this certificate must satisfy a number of conditions, including (1) the environment and facilities for lab animals&#8217; living and propagating must satisfy national requirements; (2) lab animals must be qualified and sourced from institutions with Certificates for Production of Lab Animals; and (3) the animals&#8217; feeding and experimentation must be conducted by professionals, specialized and skilled workers, or other trained personnel.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Registration Categories</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to engaging with the NMPA on research and development and approval, an applicant will need to determine the registration category for its drug candidate (which will ultimately need to be confirmed with the NMPA), which will determine the requirements for its clinical trial and marketing application. There are five categories for small molecule drugs: Category 1 (innovative drugs) refers to drugs that have a new chemical entity that has not been marketed anywhere in the world, Category 2 (improved new drugs) refers to drugs with a new indication, dosage form, route of administration, combination, or certain formulation changes not approved in the world, Categories 3 and 4 are for generics that reference an innovator drug (or certain well-known generic drugs) marketed either abroad or in China, respectively, and Category 5 refers to innovative or generic drugs that have already been marketed abroad but are not yet approved in China (i.e., imported drugs).</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Expedited Programs</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Priority Evaluation and Approval Programs to Encourage Innovation</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NMPA has adopted several expedited review and approval mechanisms that are intended to encourage innovation. Applications for these expedited programs can be submitted after the clinical trial application is admitted for review by the CDE. The NMPA&#8217;s Drug Registration Rules (&#8220;DRR&#8221;) provide certain categories of drugs that may be eligible for priority status, among which, the following may be particularly relevant for us: (1) drugs that are clinically and urgently needed but insufficient in supply; (2) innovative drugs and improved new drugs for prevention and treatment of major contagious diseases and rare diseases; (3) new pediatric drugs, (4) drugs designated as breakthrough therapies, and (5) drugs that satisfy the conditional approval criteria. If admitted to one of these expedited programs, an applicant will be entitled to more frequent and timely communication with reviewers at the CDE, expedited review and approval, and more agency resources throughout the approval process. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Conditional Approval</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NMPA also permits conditional approval of certain medicines based on early phase data. The agency has done this for medicines that meet unmet medical needs for life-threatening illnesses and also for medicines that treat orphan indications. Under the DRR, drugs that meet one of the three criteria might be eligible for conditional approval: (1) drugs that treat life threatening illnesses for which there are no effective treatment or preventive methods, but their clinical trials already have the data to prove efficacy and their clinical value is predictable, (2) drugs that are urgently needed for public health reasons, and their clinical trials already have the data to prove efficacy and their clinical value is predictable; or (3) vaccines that are urgently needed for major public health emergencies or otherwise deemed by the NHC to be urgently needed, and it is concluded upon evaluation that their benefits outweigh their risks. Following approval, the MAH is required to take risk mitigation measures and complete a post-market study as required by the NMPA within a prescribed timeline.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Breakthrough Therapy Designation</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Breakthrough therapy designation (&#8220;BTD&#8221;) is a process designed to expedite the development and review of clinical stage, innovative or improved new drugs that meet the following criteria: (1) they are intended to treat life threatening conditions or conditions that have serious negative impact on the quality of life, and (2) there are no effective treatment or preventive methods available, or there is preliminary clinical evidence indicating that they may demonstrate substantial improvement over available therapies. Applicants of drugs designated as breakthrough therapies will be entitled to direct communications with CDE at key states during the clinical trials and may seek CDE&#8217;s opinion on study progress.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Policies on Expediting Approval of Imported Oncology Drugs</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PRC government continues to establish measures and incentives to promote the development and swifter approval of marketing for oncology and other innovative drugs. Beginning in May 2018, the PRC eliminated tariffs on a significant number of imported innovative drugs, including oncology drugs, making the importation process more efficient. The PRC government has also stated that it will explore ways to expand access to reimbursement under the state health plans for innovative drugs (particularly for urgently needed oncology drugs).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Clinical Trials and Marketing Approval</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon completion of preclinical studies and preliminary CMC studies, a sponsor typically needs to conduct clinical trials in China for registering a new drug. The materials required for this application and the data requirements are determined by the registration category. The NMPA has taken a number of steps to increase efficiency for approving clinical trial applications, and it has also significantly increased monitoring and enforcement of GCP to ensure data integrity.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Trial Approval</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All clinical trials conducted in China for the purpose of seeking marketing approvals must be approved by the NMPA and conducted at hospitals satisfying GCP requirements. In addition to a standalone China trial to support development, imported drug applicants may include Chinese clinical sites as part of an international multicenter trial (&#8220;IMCT&#8221;). Domestically manufactured drugs are not subject to foreign approval requirements and the NMPA permits those drugs to conduct development via an IMCT as well.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The DAL has now also adopted an implied approval system for clinical trials of new drugs. Trials can proceed if after 60 business days, the applicant has not received any objections from the CDE, as opposed to the lengthier previous clinical trial pre-approval process in which the applicant had to wait for affirmative approval. The DAL also expands the number of trial sites by abolishing the GCP accreditation system and requiring trial sites to follow a more simplified notification procedure.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Trial Register </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials conducted in China must be registered and published through the Drug Clinical Trial Information Platform (http://www.chinadrugtrials.org.cn). Applicants are required to pre-register the trial information within one month after obtaining the clinical trial approval to obtain the trial&#8217;s unique registration number and to complete registration of certain follow-up information before the first subject&#8217;s enrollment in the trial. If the foregoing pre-registration and registration is not obtained within three years, the clinical trial approval automatically expires.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Human Genetic Resources Regulation</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Regulation on the Administration of Human Genetic Resources (&#8220;HGR Regulation&#8221;) applies to all human genetic resources (&#8220;HGR&#8221;)-related activities for R&amp;D purposes, including sampling, biobanking, use of HGR materials and associated data in China, and the provision or sharing of such materials or data with non-PRC parties. As BeiGene, Ltd. is a Cayman Islands company, we and our activities in China are subject to the HGR Regulation. Such non-PRC parties seeking access to China&#8217;s HGRs for scientific research, including clinical trials intended to support marketing approval of drugs and medical devices in China, must do so only through collaborations with Chinese parties, such as Chinese hospitals. The HGR Regulation prohibits non-PRC parties from independently sampling or biobanking any China HGR in China and requires approval for the sampling of certain HGR and biobanking of all HGR by Chinese parties. Any cross-border transfer of the HGR materials, either under an international collaboration or as a direct export, must be on an as-needed basis and requires approval. In addition, providing HGR data to non-PRC parties requires a record filing.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The HGR Regulation provides a record-filing procedure for international collaborations on clinical trials intended to support marketing approval of drugs in China that do not transfer HGR materials abroad, while the advance approval requirement still applies if such trials involve export of HGR materials or the collection, testing, analysis or disposal of HGR samples during the trials are not solely conducted at the clinical trial sites. Companies conducting global clinical trials may benefit little from this record filing procedure because those trials would often require cross-border transfer of HGR materials and the advance approval requirement would still apply.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The HGR Regulation requires parties to jointly apply for and own the patent rights arising from the results generated from international collaborations that utilize China HGR. Subject to approval, the parties may contractually agree on how to dispose of their patent rights and non-patent proprietary rights arising from the collaboration. As the joint ownership requirement is rather broad, it is unclear how this requirement will be implemented in practice.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The HGR Regulation also imposes severe penalties for various violations, including warnings, disgorgement of illegal gains, confiscation of illegal HGR, fines up to RMB10 million ($1,450,000) or 5-10 times of illegal gains in the event such illegal gains exceed RMB1 million ($145,000), and temporary (1-5 years) or permanent debarment of companies, institutions and responsible persons from future HGR projects regulated by the HGR Regulation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Implementing Rules for the HGR Regulation (the &#8220;HGR Implementing Rules&#8221;) provide several critical clarifications. HGR data is narrowed down to cover only the data derived from HGR materials and gene-irrelevant clinical data, image data, protein data, and metabolic data are expressly excluded. The use of the term non-PRC parties is also further clarified by elaborating that (1) &#8220;actual control&#8221; by non-PRC entities/individuals is interpreted to include not only being controlled through equity interests but also investment or contractual arrangements, which may cover variable interest entities (&#8220;VIEs&#8221;), and (2) companies incorporated in Hong Kong Special Administration Region (&#8220;SAR&#8221;) and Macau SAR but essentially controlled by Chinese domestic entities are not viewed as non-PRC parties. The industry guidance provides more clarifications from practice perspective. Notably, among others, (1) the non-PRC entity operating the electronic data capture system for an in-China trial is no longer regarded as a non-PRC party, (2) for gene-related scientific studies, if non-PRC entities do not substantively participate in such studies, nor obtain any study data, then such studies are no longer subject to the HGR regulation; and (3) human urine, feces, blood plasma, and blood serum are expressly excluded from the scope of HGR materials.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trial Exemptions and Acceptance of Foreign Data</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NMPA may be flexible on the requirements of trials and data generated in China, depending on the drug and the existing data. The NMPA has granted waivers for all or part of trials and stated that it will accept data generated abroad (even if not part of a global study), including early phase data, that meets its requirements. The NMPA issued the Technical Guidance Principles on Accepting Foreign Drug Clinical Trial Data (the &#8220;Guidance Principles&#8221;), as one of the implementing rules for the Opinions on Deepening the Reform of the Evaluation and Approval Systems and Encouraging Innovation on Drugs and Medical Devices (the &#8220;Innovation Opinion&#8221;). According to the Guidance Principles, data from foreign clinical trials must meet authenticity, completeness and accuracy requirements and such data must be obtained in compliance with the relevant requirements under the GCP of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Sponsors must be attentive to potentially meaningful ethnic differences in the subject population.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NMPA permits drugs approved outside of China to be approved in China on a conditional basis without the need for pre-approval clinical trials in China. Specifically, in 2018, the NMPA established a program permitting drugs that have been approved within the last ten years in the U.S., EU or Japan to be approved in China without local clinical trials if they (1) prevent or treat orphan diseases, (2) prevent or treat serious life-threatening illnesses for which there is either no effective therapy in China, or for which the foreign-approved drug would have clear clinical advantages. Applicants for such conditional approvals will be required to establish a risk mitigation plan and may be required to complete trials in China after the drug is approved. The CDE has developed a list of drugs that meet these criteria.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Trial Process and Good Clinical Practices</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As in other parts of the world, clinical trials in China typically have three phases. Phase 1 refers to the initial clinical pharmacology and human safety evaluation studies. Phase 2 refers to the preliminary evaluation of a drug candidate&#8217;s therapeutic efficacy and safety for target indication(s) in patients. Phase 3 (often the pivotal study) refers to clinical trials to further verify the drug candidate&#8217;s therapeutic efficacy and safety on patients with target indication(s) and ultimately provide sufficient evidence for the review of a drug registration application. The NMPA requires that the different phases of clinical trials in China receive ethics committee approval (with exemptions for certain specific circumstances, such as studies utilizing public information or anonymized data) and comply with GCP. The NMPA conducts inspections on clinical trials conducted in China to assess GCP compliance and may refuse to approve the drug if it finds substantial issues in the trials. In addition, upon granting the drug registration certificate, NMPA may, at its sole discretion, require a Phase 4 trial to be conducted by MAH within a specified period of time so as to further monitor and obtain safety and efficacy data of the drug.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generic small molecule drugs are required to conduct a bioequivalence trial, in vitro studies or in some cases a clinical trial to demonstrate therapeutic equivalence to an innovator drug marketed either in China or abroad or an internationally accepted generic drug. The NMPA has released catalogues of reference products, and it released first installment of a Marketed Drug List (China&#8217;s &#8220;Orange Book&#8221;) with information about drugs that may serve as reference products.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to GCP, sponsors of clinical trials are responsible for proper packaging and labeling of drugs used for clinical trials, and in double-blinded clinical trials, the investigational drugs shall be consistent with the control drug or placebo in appearance, odor, packaging, labeling, and certain other features. Pharmaceutical packaging must comply with national and professional standards. If there is no national or professional standard available, companies may formulate and implement their own standards after obtaining the approval of the provincial administration for medical products or bureau of standards. Changes in such approved packaging standards need to be re-approved. Drugs of which the packaging standards are not approved shall not be released or marketed in China, except for those specifically supplied to the military.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Drug Application (&#8220;NDA&#8221;) and Approval</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon completion of clinical trials, a sponsor may submit clinical trial data to support marketing approval for the drug. For domestically manufactured drugs, NDA sponsors must submit data derived from the submitted drugs in support of their approval. Under the DAL, upon approval of the registration application, the NMPA will issue a drug registration certificate to the applicant which is in fact the marketing approval of the drug, and the applicant is no longer required to be equipped with relevant manufacturing capability.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Manufacturing and Distribution</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All facilities that manufacture drugs in China must receive a Drug Manufacturing License (&#8220;DML&#8221;) with an appropriate &#8220;scope of manufacturing&#8221; from the local drug regulatory authority. This license must be renewed every five years, and the manufacturing facility is also required to comply with GMP. MAHs holding a Type B DML are allowed to contract manufacturing and must undertake the quality management obligations. NMPA has been increasing its regulatory oversight and control over contract manufacturing activities in China by way of imposing more specific and higher regulatory compliance requirements in terms of personnel, quality management system, and oversight of CMOs on MAHs. For instance, NMPA released a Guidance on Onsite Inspection of Contract Manufacturing Activities by Drug MAHs in October 2023, in which over 60 inspection items are set for issuing and maintaining Type B DML.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Similarly, to conduct sales, importation, shipping and storage, a company must obtain a Drug Distribution License (&#8220;DDL&#8221;) from the local drug regulatory authority, subject to renewal every five years. As with GMPs, companies are required to comply with GSP. One exception is that the DAL and relevant implementation rules allow the MAH to conduct wholesales of its drugs directly without holding a separate DDL for wholesale, however, a retail DDL would still be required if the MHA intends to conduct direct retail to patients.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">China has developed a &#8220;Two-Invoice System&#8221; to control distribution of prescription drugs. This system generally requires that no more than two invoices may be issued throughout the distribution chain, with one from the manufacturer to a distributor and another from the distributor to the end-user hospital. This excludes the sale of products invoiced from the manufacturer to its wholly-owned or controlled distributors, or for imported drugs, to their exclusive distributor, or from a distributor to its wholly-owned or controlled subsidiary (or between the wholly-owned or controlled subsidiaries). However, the system still significantly limits the options for companies to use multiple distributors to reach a larger geographic area in China. Compliance with the Two-Invoice System is a prerequisite for pharmaceutical companies to participate in procurement processes with public hospitals, which currently provide most of China&#8217;s healthcare. Manufacturers and distributors that fail to implement this system may lose their qualifications to participate in the bidding process or be blacklisted from engaging in drug sales to public hospitals in a locality.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-Marketing Surveillance</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the DAL, the MAH of a drug is ultimately responsible for pharmacovigilance, including quality assurance, adverse reaction reporting and monitoring, and product recalls. Distributors and user entities (e.g., hospitals) are also required to report, in their respective roles, adverse reactions of the products they sell or use, and assist the MAH with any product recalls. A MAH for a drug that is currently under the new drug monitoring period has to report all adverse drug reactions (as opposed to just serious adverse reactions) for that period.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Advertising and Promotion of Pharmaceutical Products</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">China has a strict regime for the advertising of approved medicines. No unapproved medicines may be advertised. The definition of an advertisement is very broad and does not expressly exclude scientific exchange. It can be any media that directly or indirectly introduces the product to end users. There is no clear line between advertising and any other type of promotion. An enterprise seeking to advertise a prescription drug may do so only in medical journals jointly approved by NMPA and the NHC, and each advertisement requires approval from a local drug regulatory authority. The content of an approved advertisement may not be altered without filing a new application for approval.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prescription drug advertisements are subject to strict content restrictions, which prohibit recommendations by doctors and hospitals and guarantees of effectiveness. Advertising that includes content that is outside of the drug&#8217;s approval documentation (off-label content) is prohibited. False advertising can result in civil suits from end users and administrative liability, including fines. In addition to advertisements, non-promotional websites that convey information about a drug must go through a separate approval process by a local drug regulatory authority.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Intellectual Property Protections</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendments to the PRC Patent Law (the &#8220;Amended PRC Patent Law&#8221;) provides a cause of action to allow a patent holder to initiate a declarative action during the regulatory review process of a generic drug application to determine whether the drug falls within the patent scope, which may be comparable to the patent linkage system in the U.S. The system requires that the NMPA continue to review the potentially infringing generic application during any lawsuit by the innovator. However, the NMPA may not approve the generic application pending resolution of the patent litigation in favor of the generic filer or for a specified period of time, whichever is shorter. The Amended PRC Patent Law also provides patent term extension (&#8220;PTE&#8221;) for the patent term lost during the regulatory review process of a new drug upon the patent holder&#8217;s request. The extended term shall not exceed five years, and the total patent term after approval of the drug shall not exceed 14 years.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 21, 2023, the final versions of Rules for Implementation of the Patent Law was published, and the China National Intellectual Property Administration (&#8220;CNIPA&#8221;) published new version of Patent Examination Guidelines accordingly. The Implementation Rules and Patent Examination Guidelines introduced detailed rules and examination guidelines on PTE, and took effect on January 20, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reimbursement and Pricing</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">China regulates drug prices mainly by establishing a consolidated procurement mechanism, restructuring medical insurance reimbursement standards and strengthening regulation of medical and pricing practices, as discussed below.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">National Reimbursement Drug List</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">China&#8217;s national medical insurance program currently consists of two fundamental sub-programs: (1) the basic medical insurance program for urban employees, under which urban employers are required to enroll their employees in the program and the insurance premium is jointly contributed by the employers and employees; and (2) the basic medical insurance program for urban and rural residents, which allows urban and rural residents who do not have employers to voluntarily participate in the basic medical insurance program and the insurance premium is jointly contributed by the participants and the government. Participants of the national medical insurance program and their employers, if any, are required to contribute to the payment of insurance premiums on a monthly basis. Program participants are eligible for full or partial reimbursement of the cost of medicines included in the NRDL. A pharmaceutical product listed in the NRDL must be clinically needed, safe, effective, reasonably priced, easy to use, and available in sufficient quantity.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that affect the inclusion of a pharmaceutical product in the NRDL include whether the product is used in large volumes and commonly prescribed for clinical use in the PRC and whether it is considered to be important in meeting the basic healthcare needs of the general public. Historically, special consideration has been given to, among others, innovative drugs with high clinical value and drugs for serious diseases. In addition, the government has also been negotiating with manufacturers of exclusive drugs with high clinical demands and proven effectiveness for price cuts in exchange for inclusion into the NRDL. The version of the NRDL released in 2024 (effective from January 1, 2025) covers approximately 3,159 drugs in total, including 91 new drugs listed for which the prices were determined through negotiations between the drug companies and government. China has been pursuing a policy of expediting the addition of innovative oncology drugs to this list. REVLIMID has been included in the NRDL since 2017. VIDAZA has been included in the NRDL since 2018. BRUKINSA (zanubrutinib), tislelizumab, and XGEVA (120-mg denosumab) have been included in the NRDL since 2020. PARP inhibitor PARTRUVIX (pamiparib) has been included in the NRDL since 2021. KYPROLIS has been included in the NRDL since 2022. SYLVANT and BAITUOWEI have been included in the NRDL since 2024.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Centralized Procurement and Tenders</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under current regulations, public medical institutions owned by the government or owned by state-owned or controlled enterprises are required to purchase pharmaceutical products through centralized online procurement processes. There are exceptions for drugs on the National List of Essential Drugs, which must comply with their own procurement rules, and for certain drugs subject to the central government&#8217;s special control, such as toxic, radioactive and narcotic drugs, and traditional Chinese medicines.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The centralized procurement process takes the form of public tenders that are typically conducted once every year by provincial or municipal-level government agencies. The bids are assessed by a committee randomly selected from a database of experts. The committee members assess the bids based on a number of factors, including bid price, product quality, clinical effectiveness, product safety, level of technology, the manufacturer&#8217;s qualifications and reputation, after-sale services and innovation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2018, the government implemented a &#8220;zero markup&#8221; policy on all drugs among all public healthcare institutions nationwide. In addition, some local governments have begun to allow medical institutions to collectively negotiate with manufacturers for a second price to further lower the already agreed bid price. The Two-Invoice System, described above, is also designed to reduce price mark-ups brought about by multi-tier distribution chains.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2019, the government adopted a volume-based, centralized drug procurement program to optimize the pricing of drugs. Drugs are selected from generic brands for volume-based, centralized drug procurement. The selected drugs must pass the bio-equivalence evaluation on quality and efficacy. All approved enterprises that produce drugs on the procurement list in China may participate. Clinical effects, adverse reactions, and batch stability of the drugs will be considered, and their consistency will be the main criteria for evaluation, while production capacity and stability of the supplier will also be considered.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, China has gradually improved its mechanism for centralized medicine procurement. On November 18, 2024, the NHSA together with the NHC jointly issued Notice on Improving Working Mechanism of Centralized Drug Procurement and Implementation. The new notice sets forth ten improvements to strengthen the management of the whole process of centralized drug procurement based upon existing policies.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other PRC National and Provincial Laws and Regulations</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical companies operating in China are subject to changing regulations under many other laws and regulations administered by governmental authorities at the national, provincial and municipal levels, some of which are or may become applicable to our business. For example, regulations controlling the confidentiality of patient medical information and the circumstances under which patient medical information may be released for inclusion in our information systems or released by us to third parties. The privacy of human subjects in clinical trials is also protected by privacy laws such as the Personal Information Protection Law. These laws and regulations governing both the disclosure and the use of confidential patient medical information may become more restrictive in the future, including restrictions on transfer of healthcare data. The Cybersecurity Law designates healthcare as a priority area that is part of critical information infrastructure, and China&#8217;s cyberspace administration has been working to finalize the regulatory regime on cross-border transfer of personal information.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PRC Regulation of Foreign Investment</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Foreign Investment Law of the PRC (the &#8220;Foreign Investment Law&#8221;) and its implementing rules (the &#8220;Implementing Rules&#8221;) establish a basic framework for access to, and the promotion and administration of foreign investments in China. The Foreign Investment Law establishes a pre-entry national treatment and negative list system for the administration of foreign investments. &#8220;Pre-entry national treatment&#8221; means that the treatment afforded to foreign investors at the market access stage shall be no less favorable than that afforded to domestic investors. &#8220;Negative list&#8221; refers to the special administrative measures for foreign investors&#8217; access to specific fields or industries. Foreign investments outside of the negative list will be granted national treatment. Foreign investors shall not invest in the prohibited fields as specified in the negative list, and foreign investors who invest in the restricted fields shall comply with certain special requirements including the shareholding percentage and citizenship of senior executives. The current industry entry clearance requirements governing foreign investment activities in the PRC are set out in two categories, namely the Special Entry Management Measures for the Access of Foreign Investment (Negative List) (2024 version), and the Encouraged Industry Catalogue for Foreign Investment (2022 version) (the &#8220;2022 Encouraged Industry Catalogue&#8221;). Industries not listed in these two categories are generally deemed &#8220;permitted&#8221; for foreign investments unless specifically restricted by other applicable PRC laws or regulations. Pursuant to the 2022 Encouraged Industry Catalogue, the research, development and manufacture of innovative oncology drugs, cell therapies, and certain other types of pharmaceutical products belongs to the encouraged industries for foreign investment. In September 2024, the Ministry of Commerce, the National Health Commission and the National Medical Products Administration jointly issued the Notice on Carrying out a Pilot Program for Expanding Opening-up in the Medical-related Field, which further allows foreign invested enterprises to engage in the technology development and application of human stem cell, gene diagnosis and treatment in four designated pilot free trade zones of China for the registration, marketing and production of products, and allow the establishment of wholly foreign-owned hospitals in selected cities and regions, which will further optimize foreign investment environment and attract foreign investment to propel the high-quality development of healthcare sector in China.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PRC Antitrust Regulation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">China&#8217;s anti-trust regulatory regime is founded on the Anti-Monopoly Law (the &#8220;AML&#8221;) (last amended in 2022) and supplemented by several implementation rules. The AML in general restricts monopolistic practices including concentration of undertakings, horizontal and vertical monopolistic agreements, and certain activities of market dominance abuse.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The AML provides heavy penalties for violations, including warnings, confiscation of illegal gains, a fine ranging up to 50% of the preceding year&#8217;s turnover, revocation of required business and operating licenses, suspension of business, and even criminal liabilities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SAMR is the chief regulator of anti-trust law in China, and the pharmaceutical sector has been one of its focused enforcement area for years. For example, in 2021, a local drug company was found to have engaged in resale price maintenance (&#8220;RPM&#8221;) practices and fined up to RMB 764 million, and in 2023, SAMR announced seven administrative penalty decisions on monopoly agreement reached and/or abuse of market dominance in pharmaceutical industry, among which, a local drug company was fined RMB 12.64 million for RPM.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulations Relating to Product Liability</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under current law, a defective product which causes property damage or physical injury to any person may subject the manufacturer or vendor of such product to civil liability for such damage or injury. Additionally, China&#8217;s Product Quality Law provides that manufacturers are liable for the quality of products produced by them, and sellers are required take measures to ensure the quality of the products sold by them. A manufacturer is liable for compensating for any bodily injury or property damage resulting from product defects unless the manufacturer is able to prove that: (1) the product was not distributed; (2) the defects causing injury or damage did not exist at the time that the product was distributed; or (3) science and technology at the time that the product was distributed was at a level incapable of detecting the defects. A seller is liable for compensating for any bodily injury or property damage of others caused by the defects in the product if such defects are attributable to the seller. A seller is required to pay compensation if it fails to indicate either the manufacturer or the supplier of the defective product. A person who is injured or whose property is damaged by the defects in the product may claim compensation from the manufacturer or the seller.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulations Relating to Technology Export Control</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Import and export of technologies for civilian use are regulated under the PRC Administrative Regulations on Technology Import and Export (the &#8220;TIER&#8221;). Technology export is broadly defined under Chinese law to encompass any cross-border transfer of technologies from a Chinese entity to overseas &#8211; whether by way of patent assignments, patent licenses, software licenses, transfers of technical know-how, or the provision of technical services, or by any other means. TIER divides technology export into the categories of (1) &#8220;prohibited&#8221; technologies, which cannot be exported outside China (2) &#8220;restricted&#8221; technologies, which requires approvals from the relevant Chinese authority, and (3) &#8220;unrestricted&#8221; technologies, which requires filing of proper transaction documents with the authority. The &#8220;prohibited&#8221; and &#8220;restricted&#8221; technologies are defined by the Catalogue of Technologies Prohibited or Restricted from Export (the &#8220;Catalogue&#8221;). The latest Catalogue, which was issued on December 21, 2023, included &#8220;cell cloning and gene editing technologies used in humans&#8221; into the prohibited list. It still remains unclear how the Chinese government would eventually enforce such prohibition on technology control. We plan to closely monitor China&#8217;s legislative and regulatory evolvement in this area and its potential impact on our operations in China. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulations Relating to Commercial Bribery</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical companies involved in a criminal investigation or administrative proceeding related to bribery are listed in the Adverse Records of Commercial Briberies by the provincial health commissions. If a pharmaceutical company or its agent is listed, public medical institutions located in the local provincial level region are prohibited from making any purchase from the company for two years. Where a pharmaceutical company or its agent is listed in the adverse records on two or more occasions within five years, all public medical institutions in China are not permitted to purchase any products from that company for two years.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulations Relating to Foreign Exchange</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Foreign Exchange Administration Regulations govern foreign currency exchange in China. Under these regulations, payments of current account items, such as profit distributions and trade and service-related foreign exchange transactions, may be made in foreign currencies without prior approval from the State Administration of Foreign Exchange (&#8220;SAFE&#8221;) by complying with certain procedural requirements. In contrast, approval from or registration with appropriate government authorities or designated banks is required when RMB is to be converted into a foreign currency and remitted out of China to pay capital expenses such as the repayment of foreign currency-denominated loans.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under current regulations, the capital of a foreign-invested enterprise and capital in RMB obtained by the foreign-invested enterprise from foreign exchange settlement must not be used for the following purposes: directly or indirectly for payment beyond the business scope of the enterprises or the payment prohibited by relevant laws and regulations; directly or indirectly for investment in securities or certain other financial products, unless otherwise provided by relevant laws and regulations; extending loans to non-related parties, unless permitted by the scope of business and located in the designated area; or paying expenses related to the purchase of residential real estate that is not for self-use, except for real estate enterprises. Regulations have relaxed the restrictions on foreign exchange inflow to further enhance trade and investment facilitation and enhance genuineness and compliance verification of cross-border transactions and cross-border capital flows. Furthermore, in 2019, SAFE issued the Circular of the State Administration of Foreign Exchange on Further Promoting the Facilitation of Cross-border Trade and Investment (&#8220;Circular 28&#8221;) which allows non-investment foreign-invested enterprises to use their capital funds to make equity investments in China, provided that such investments do not violate the effective Special Entry Management Measures for the Access of Foreign Investment (Negative List) and the target investment projects are genuine and in compliance with laws. The interpretation and implementation of Circular 28 in practice are subject to substantial uncertainty.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulations Relating to Dividend Distributions</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign-invested companies may pay dividends only out of their accumulated profit, if any, as determined in accordance with PRC accounting standards and regulations. Both PRC domestic companies and foreign invested PRC companies are required to allocate at least 10% of their respective accumulated after-tax profits each year, if any, to fund certain capital reserve funds until the aggregate amount of these reserve funds have reached 50% of the registered capital of the companies. A PRC company is not permitted to distribute any profits until any losses from prior fiscal years have been offset. Profits retained from prior fiscal years may be distributed together with distributable profits from the current fiscal year.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Labor Laws and Social Insurance</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Chinese law, employers must execute written labor contracts with their full-time employees and must comply with local minimum wage standards. Employers must establish a comprehensive management system to protect the rights of their employees, including a system governing occupational health and safety, and to truthfully inform prospective employees of the job description, working conditions, location, occupational hazards and status of safe production as well as remuneration and other conditions. Violations of these requirements may result in the imposition of fines and other administrative and criminal liability in the case of serious violations. In addition, employers must provide employees with welfare schemes covering pension insurance, unemployment insurance, maternity insurance, work-related injury insurance, medical insurance and housing funds. These payments are made to local administrative authorities, and any employer who fails to contribute may be fined and ordered to pay the deficit amount within a stipulated time limit.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulations Relating to Overseas Listing</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, the China Securities Regulatory Commission (the &#8220;CSRC&#8221;) released the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic (the &#8220;Overseas Listing Trial Measures&#8221;), and related guidelines requiring Chinese domestic companies&#8217; overseas offerings and listings of equity securities be filed with the CSRC.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Overseas Listing Trial Measures clarify the scope of overseas offerings and listings by Chinese domestic companies which are subject to the filing and reporting requirements thereunder, and provide that Chinese domestic companies that have already directly or indirectly offered and listed securities in overseas markets shall fulfil their filing obligations and report relevant information to the CSRC within three working days after conducting a follow-on offering of equity securities on the same overseas market, and follow the relevant reporting requirements within three working days upon the occurrence of any specified circumstances provided thereunder. According to the Overseas Listing Trial Measures, if we were deemed as an indirect overseas listed Chinese domestic company but fail to complete the filing procedures with the CSRC for any of our follow-on offerings or follow any other reporting requirements required thereunder, we may be subject to penalties, sanctions and fines imposed by the CSRC and relevant departments of the State Council.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rest of World Regulation</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For other countries outside of the U.S. and the PRC, the requirements governing the conduct of preclinical studies, clinical trials, drug licensing, manufacturing, pricing and reimbursement, and other matters impacting our business vary from country to country. In all cases, clinical trials must be conducted in accordance with GCP requirements, applicable regulatory requirements, and the ethical principles having their origin in the Declaration of Helsinki.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Status under Holding Foreign Companies Accountable Act</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Holding Foreign Companies Accountable Act (as amended, the &#8220;HFCAA&#8221;) includes requirements for the SEC to identify issuers who file annual reports with audit reports issued by independent registered public accounting firms located in foreign jurisdictions that the Public Company Accounting Oversight Board (&#8220;PCAOB&#8221;) is unable to inspect or investigate completely because of a position taken by a non-U.S. authority in the accounting firm&#8217;s jurisdiction (&#8220;Commission-Identified Issuers&#8221;). The HFCAA also requires that, to the extent that the PCAOB has been unable to inspect an issuer&#8217;s independent registered public accounting firm for two consecutive years since 2021, the SEC shall prohibit the issuer&#8217;s securities registered in the U.S. from being traded on any national securities exchange or over-the-counter markets in the U.S. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the HFCAA, each Commission-Identified Issuer is required to submit documentation to the SEC annually on or before its annual report due date that establishes that it is not owned or controlled by a government entity in its public accounting firm&#8217;s foreign jurisdiction and require additional specified disclosures by &#8220;foreign issuers&#8221; as defined in Rule 3b-4 promulgated under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). The SEC identifies an issuer as a Commission-Identified Issuer after the issuer files its annual report and on a rolling basis. To end an initial or subsequent trading prohibition, a Commission-Identified Issuer must certify that it has retained a registered public accounting firm that the PCAOB has determined it is able to inspect or investigate by filing financial statements that include an audit report signed by such a registered public accounting firm. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 30, 2022, the SEC added BeiGene, Ltd. to its conclusive list of issuers identified under the HFCAA. Ernst &amp; Young Hua Ming LLP, located in the PRC, served as our independent registered public accounting firm from 2014 to 2021, including for our annual report on Form 10-K for the year ended December 31, 2021. However, as our global business has expanded, we have built substantial organizational capabilities outside of the PRC and have evaluated, designed and implemented business processes and control changes. Therefore, on March 23, 2022, following a review process carried out by our audit committee, Ernst &amp; Young Hua Ming LLP resigned as our independent registered public accounting firm for the audits of our financial statements and internal control over financial reporting to be filed with the SEC. On the same day, our audit committee approved the engagement of Ernst &amp; Young LLP (U.S.) as the Company&#8217;s independent registered public accounting firm for the audits of our financial statements and internal control over financial reporting for the fiscal year ending December 31, 2022. Ernst &amp; Young LLP (U.S.) has continued to serve as our independent registered public accounting firm for the fiscal year ending December 31, 2023 and those thereafter. No changes were made to the accounting firms who audit our financial statements filed with the Shanghai Stock Exchange and the Hong Kong Stock Exchange, which remain Ernst &amp; Young Hua Ming LLP, located in Beijing, PRC, and Ernst &amp; Young, located in Hong Kong, PRC, respectively. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the PCAOB announced that it has secured complete access to inspect and investigate registered public accounting firms headquartered in mainland China and Hong Kong and confirmed that until such time as the PCAOB issues any new determination, there are no Commission-Identified Issuers at risk of having their securities subject to a trading prohibition under the HFCAA.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given that Ernst &amp; Young LLP (U.S.) has served as the principal accountant to audit our consolidated financial statements to be filed with the SEC since 2022, we believe this should preclude the delisting of our American Depositary Shares from Nasdaq under HFCAA. For a detailed description of risks related to our doing business in China and status under the HFCAA, see &#8220;Item 1A. Risk Factors&#8212;Risks Related to Our Doing Business in the PRC.&#8221;</span></div><div id="ic94bd2152a214042a118e81881a5a1e5_2099"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Doing Business in the PRC</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our operations in the PRC, the PRC government may exert influence over our operations at any time, which could result in a material change in our operations and/or the value of our ADSs, ordinary shares, or RMB Shares. For example, the PRC government has recently published policies that significantly affected certain industries such as the education and internet industries, and we cannot rule out the possibility that it will in the future release regulations or policies regarding any industry that could adversely affect the business, financial condition and results of operations of our company.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the PRC government has also indicated an intent to exert more oversight and control over securities offerings and other capital markets activities that are conducted outside of China and over foreign investment in China-based companies. Any such action, once taken by the PRC government, could significantly limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline or in extreme cases, become worthless. The PRC government initiated a series of regulatory actions and statements to regulate business operations in China, including enforcement actions against illegal activities in the securities market, enhancing supervision over China-based companies listed outside of China using the variable interest entity structure, adopting new measures to extend the scope of cybersecurity reviews, and expanding the efforts in anti-monopoly enforcement. For example, in July 2021, the relevant PRC government authorities made public the Opinions on Intensifying Crack-Down on Illegal Securities Activities (the &#8220;Securities Opinions&#8221;) which emphasized the need to strengthen the administration over illegal securities activities and the supervision on overseas listings by China-based companies and proposed to take measures, such as promoting the construction of relevant regulatory systems to deal with the risks and incidents faced by China-based overseas-listed companies. In September 2024, the State Council released the Administrative Regulations on Cyber Data Security, which require, among others, a prior cybersecurity review for cyber data processing activities which affect or may affect national security. In March 2023, the Overseas Listing Trial Measures, and five relevant guidelines issued by the CSRC took effect, requiring the Chinese domestic companies&#8217; overseas offerings and listings of equity securities be filed with the CSRC.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Chinese government may further promulgate relevant laws, rules and regulations that may impose additional and significant obligations and liabilities on overseas listed PRC companies regarding data security, cross-border data flow, anti-monopoly and unfair competition, and compliance with China&#8217;s securities laws. It is uncertain whether or how these new laws, rules and regulations and the interpretation and implementation thereof may affect us, but among other things, our ability to obtain external financing through the issuance of equity securities in the U.S., Hong Kong or other markets could be negatively affected, and as a result, the trading prices of our ADSs, ordinary shares and RMB Shares could significantly decline or become worthless. For a detailed description of risks related to our doing business in China, please see the section of this Annual Report titled &#8220;Item 1A. Risk Factors&#8212;Risks Related to Our Doing Business in the PRC.&#8221;</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Flow of Funds with our Operations including the PRC</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a holding company incorporated in the Cayman Islands with operations primarily conducted through direct and indirect subsidiaries in the U.S., China, the UK, Switzerland and Australia. The intercompany flow of funds within the organization is effected through capital contributions, intercompany loans, intercompany transfers of products and intellectual property, and cost reimbursements. Since formation in 2010, BeiGene, Ltd. has raised over $10.8 billion in various public and private stock offerings and from various borrowings. Of this amount, (1) $2.1 billion and RMB18.9 billion have been transferred as capital contributions to its operating subsidiaries and (2) $1.5 billion and RMB1.9 billion are outstanding intercompany loans due from its operating subsidiaries as of December 31, 2024. All biopharmaceutical patents previously owned by BeiGene, Ltd. have been transferred to operating subsidiaries for further development and commercialization. As of December 31, 2024, BeiGene, Ltd. held $400 million in cash and cash equivalents which are available for future investment in its programs and operating subsidiaries, of which $216 million is to be used in China pursuant to the obligations under the Company&#8217;s offering on the STAR Market. The Company&#8217;s subsidiaries outside of China have cash and cash equivalents of $1.1 billion that may be permanently transferred to BeiGene, Ltd. in the form of dividends and distributions or temporarily in the form of intercompany loans or advances without consent of a third-party; however, to date, BeiGene, Ltd. has not received any dividends or distributions from its operating subsidiaries. As of December 31, 2024, the Company has established a deferred tax liability of $24 million associated with potential withholding taxes in the U.S. and Canada on unremitted earnings that are no longer indefinitely reinvested. The amount of actual cash taxes associated with potential future distributions will depend on the timing of cash outflows at the parent and availability and use of cash in other jurisdictions that are not subject to withholding taxes. Please see the section of this Annual Report titled &#8220;Liquidity and Capital Resources&#8221; for further discussion.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, our board of directors has adopted a dividend policy which provides that we currently intend to retain all available funds and earnings, if any, to fund the development and expansion of our business, and we do not anticipate paying any cash dividends in the foreseeable future. Subject to applicable law and our amended and restated articles of association, any future determination to pay dividends will be made at the discretion of our board of directors and may be based on a number of factors, including our future operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions and other factors that our board of directors may deem relevant. This dividend policy reflects our board of directors&#8217; current views on our financial and cash flow position. We intend to continue to review our dividend policy from time to time, and there can be no assurance that dividends will be paid in any particular amount, if at all, for any given period.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any dividends on our ordinary shares or any other securities. If we pay dividends in the future, in order for us to distribute dividends to our shareholders and holders of ADSs, we may rely to some extent on dividends distributed by our PRC subsidiaries. PRC regulations may restrict the ability of our PRC subsidiaries to pay dividends to us, and such distributions will be subject to PRC withholding tax. In addition, PRC regulations currently permit payment of dividends of a PRC company only out of accumulated distributable after-tax profits, as determined in accordance with our articles of association and the accounting standards and regulations in the PRC.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may rely on dividends and other distributions on equity paid by our PRC subsidiaries or as noted above on dividends and distributions from our U.S, Canadian and other subsidiaries for our cash and financing requirements, including the funds necessary to pay dividends and other cash distributions to our shareholders or to service any debt we may incur. If any of our PRC subsidiaries incur debt on their own behalf in the future, the instruments governing the debt may restrict their ability to pay dividends or make other distributions to us from those subsidiaries in the PRC but not from our subsidiaries in the U.S., Canada and others. Under PRC laws and regulations, our PRC subsidiaries may pay dividends only out of their respective accumulated profits as determined in accordance with PRC accounting standards and regulations. In addition, a wholly foreign-owned enterprise is required to set aside at least 10% of its accumulated after-tax profits each year, if any, to fund a certain statutory reserve fund, until the aggregate amount of such fund reaches 50% of its registered capital. Such reserve funds cannot be distributed to us as dividends. At its discretion, a wholly foreign-owned enterprise may allocate a portion of its after-tax profits based on PRC accounting standards to an enterprise expansion fund, or a staff welfare and bonus fund. In addition, registered share capital and capital reserve accounts are also restricted from withdrawal in the PRC, up to the amount of net assets held in each operating subsidiary. As of December 31, 2024, these restricted assets totaled $1.7 billion.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our PRC subsidiaries generate primarily all of their revenue in RMB, which is not freely convertible into other currencies. As a result, any restriction on currency exchange may limit the ability of our PRC subsidiaries to use their RMB revenues to pay dividends to us. However, conversion of RMB to other currencies are permitted for the purpose of dividends according to the PRC&#8217;s regulations on foreign exchange control. The PRC government may, in accordance with applicable laws and regulations, impose limitations on access to foreign currencies for current account transactions and if this occurs in the future, we may not be able to pay dividends in foreign currencies to our shareholders. Any limitation on the ability of our PRC subsidiaries to pay dividends or make other kinds of payments to us could materially and adversely limit our ability to grow, make investments or acquisitions that could be beneficial to our business, pay dividends, or otherwise fund and conduct our business. As a result, and principally due to the restriction in China, our subsidiaries&#8217; restricted net assets (as defined in Rule 5-04 of Regulation S-X) exceeds 25% of our consolidated net assets and thus we have provided the stand-alone financial statements of BeiGene, Ltd. in Item 15 as Schedule 1.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PRC Enterprise Income Tax Law and its implementation rules provide that China-sourced income of foreign enterprises, such as dividends paid by a PRC subsidiary to its equity holders that are non-PRC resident enterprises, will normally be subject to PRC withholding tax at a rate of 10%, unless any such foreign investor&#8217;s jurisdiction of incorporation has a tax treaty with China that provides for a reduced withholding rate arrangement and such non-PRC resident enterprises constitute the beneficiary of such income.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to an arrangement between Mainland China and the Hong Kong Special Administrative Region and relevant tax regulations of the PRC, subject to certain conditions, a reduced withholding tax rate of 5% will be available for dividends from PRC entities provided that the recipient can demonstrate it is a Hong Kong tax resident and it is the beneficial owner of the dividends. The government adopted regulations in 2018 which stipulate that in determining whether a non-resident enterprise has the status as a beneficial owner, comprehensive analysis shall be conducted based on the factors listed therein and the actual circumstances of the specific case shall be taken into consideration. Specifically, it expressly excludes an agent or a designated payee from being considered as a &#8220;beneficial owner.&#8221; We own the PRC subsidiaries through BeiGene (Hong Kong) Co., Limited (&#8220;BeiGene HK&#8221;). BeiGene HK currently does not hold a Hong Kong tax resident certificate from the Inland Revenue Department of Hong Kong, and there is no assurance that the reduced withholding tax rate will be available.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Permissions Required from the PRC Authorities for Our Operations and Securities Offerings</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct our business in the PRC through our PRC subsidiaries. Our operations in the PRC are governed by PRC laws and regulations. As of the date of this annual report, our PRC subsidiaries have obtained all requisite licenses and permits from the PRC government authorities that are material for their business operations in the PRC, including, among others, business licenses issued by local counterparts of the SAMR, drug manufacturing licenses, drug trade license, clinical trial applications, drug registration certificates, licenses for use of experimental animals, pollutant discharge licenses and permits for urban sewage discharge into drainage pipe network. No material permissions have been denied to us by relevant government authorities in China. As of the date of this Annual Report, we do not operate our businesses in China or elsewhere through variable interest entities, or VIEs, and therefore are not subject to risks associated with contractual arrangements with VIEs. As of the date of this annual report, we have not received any inquiry, notice, warning, or sanctions regarding our business operations and corporate structure from the CSRC, the Cyberspace Administration of China (the &#8220;CAC&#8221;), or any other PRC governmental agency that would have a material impact on our business, results of operations or financial condition. However, given the uncertainties of interpretation and implementation of relevant laws and regulations and the enforcement practice by government authorities, we cannot assure you that we have obtained all permits or licenses required for conducting our business in the PRC. If (i) we have inadvertently concluded that such permissions, approvals, licenses or permits have been acquired or are not required, or (ii) applicable laws, regulations, or interpretations change and we are required to obtain such permissions, approvals, licenses or permits in the future, then we may have to expend time and costs to procure them. If we are unable to do so on commercially reasonable terms or in a timely manner, it could cause significant disruption to our business operations and damage our reputation, which would in turn have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our previous issuance of securities to foreign investors in stock markets outside the PRC, under current PRC laws, regulations and regulatory rules, as of the date of this Annual Report, we and our PRC subsidiaries, (i) are not required to obtain permissions from the CSRC, (ii) are not required to go through cybersecurity review by the Cyberspace Administration of China, or the CAC, and (iii) have not received or were denied such requisite permissions by any PRC authority. In 2023, the CSRC released the Overseas Listing Trial Measures and five relevant guidelines. The Overseas Listing Trial Measures require the Chinese domestic companies&#8217; overseas offerings and listings of equity shares, depositary receipts, convertible bonds, preferred shares or other equity securities be filed with the CSRC. See &#8220;Item 1. Business&#8212;Government Regulation&#8212;PRC Regulation&#8212;Regulations Relating to Overseas Listing&#8221;. If we were deemed as an indirect overseas listed Chinese domestic company subject to the filing requirements under the Overseas Listing Trial Measures, our offering of equity securities on Nasdaq or Hong Kong Stock Exchange in the future would be required to be filed with the CSRC within three working days after the offering is completed.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Annual Report, we have not received any inquiry, notice, warning or sanction regarding obtaining approval, completing filing or other procedures in connection with offering our equity securities in overseas stock markets from the CSRC or any other PRC governmental or regulatory authorities that have jurisdiction over our operations. However, there remains significant uncertainty as to the interpretation and implementation of regulatory requirements related to overseas securities offerings and other capital markets activities, including the Overseas Listing Trial Measures. Although we intend to fully comply with the then effective relevant laws and regulations applicable to any securities offerings we may conduct, there are uncertainties with respect to whether we will be able to fully comply with requirements to obtain any permissions and approvals from, or complete any reporting or filing procedures with, PRC authorities that may be in effect in the future. If we, for any reason, are unable to complete, or experience significant delays in completing the requisite filing or other procedure(s), we may face sanctions by the CSRC or other Chinese regulatory authorities as applicable. These regulatory authorities may impose fines and penalties on our operations in the PRC, limit our ability to pay dividends outside of China, limit our operations in the PRC, delay or restrict the repatriation of funds into the PRC or take other actions that could have a material adverse effect on our business, financial condition, results of operations and prospects, as well as the trading price of our ADSs, ordinary shares and RMB Shares.</span></div><div id="ic94bd2152a214042a118e81881a5a1e5_67"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Management Policies and Procedures </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The frequency and amount of intercompany transfers of funds is determined based on the working capital needs of our subsidiaries and intercompany transactions, and is subject to internal approval processes and funding arrangements. Our management reviews and monitors our cash and working capital needs and external debt repayment and borrowing needs, of our subsidiaries on a regular basis. In addition, capital contributions and intercompany loan arrangements are subject to local jurisdiction and banking regulations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BeiGene, Ltd. and its subsidiaries hold cash in demand deposits, time deposits and money market funds for the operating needs of each entity, including from intercompany transactions. As needed, cash to fund both short-term operating needs (such as investments in inventory or sales and marketing capabilities) and long-term investment needs (such as for property, plant and equipment) can be transferred from BeiGene, Ltd. or between subsidiaries to supply additional liquidity using capital contributions, intercompany advances or loans, as follows:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cash may be transferred between BeiGene HK and its operating subsidiaries in mainland China through intercompany loans and capital contributions. Cash generated from BeiGene HK is used to fund operations of its subsidiaries, and no funds were transferred from BeiGene HK&#8217;s subsidiaries in mainland China to fund operations of other BeiGene subsidiaries outside of mainland China for the years ended December 31, 2024 and 2023. For the years ended December 31, 2024 and 2023, the amount of cash transferred between BeiGene HK and its subsidiaries in mainland China was $106 million and $295 million, respectively.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cash may be transferred between BeiGene UK, Ltd. (&#8220;BeiGene UK&#8221;) and/or BeiGene Switzerland and their respective operating subsidiaries through intercompany fund advances and capital contributions. There are currently no restrictions on transferring funds between BeiGene UK or BeiGene Switzerland and their respective operating subsidiaries. Cash generated from BeiGene UK and BeiGene Switzerland may be used to fund operations of their respective subsidiaries, and no funds were transferred from BeiGene UK&#8217;s subsidiaries or from BeiGene Switzerland&#8217;s subsidiaries to fund operations of other BeiGene subsidiaries (such as BeiGene HK and its subsidiaries in mainland China) for the years ended December 31, 2024 and 2023. For the years ended December 31, 2024 and 2023, the amount of cash transferred between BeiGene UK to its respective subsidiaries was $142 million and $270 million, respectively. For the years ended December 31, 2024 and 2023, the amount of cash transferred between BeiGene Switzerland to its respective subsidiaries was nil.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Resources</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to attracting and retaining exceptional, passionate people to work with a clear purpose: creating impactful, affordable and accessible medicines to help more patients around the world live better. To this end, we provide opportunities for employees to grow and develop in their careers, supported by competitive compensation, benefits, health and wellness programs, and by programs that build connections among our employees worldwide.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the success of our business is fundamentally connected to the well-being of our employees. Hence, we take a holistic view of well-being &#8211; one that considers financial, physical, and social-emotional health &#8211; we are working to cultivate a community and culture where our colleagues can find balance both professionally and personally. Accordingly, we offer our employees and their families innovative, flexible and convenient health and wellness programs, that are tailored to the region of the world where they work.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitive compensation and benefits programs help meet the needs of our employees. In addition to base salaries, these programs include potential annual discretionary bonuses, equity awards, a 401(k) plan in the U.S. and pension plans in other jurisdictions, healthcare and insurance benefits, health savings, life and disability insurances, and flexible spending accounts, paid time off, family leave, and flexible work schedules, among others. In addition to our broad-based equity award programs, we have used equity-based grants with vesting conditions to facilitate retention of key personnel. In addition to compensation and benefits, we provide our employees opportunities for growth through challenging job assignments, performance management and training opportunities. We seek to remain competitive in our compensation and benefits by routinely benchmarking against industry peers.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our worldwide teams are united by a common mission. We are committed to encouraging a culture of open communication where employees can ask questions, raise concerns, and contribute creative solutions. Our management team routinely makes themselves available to all employees, including in regular town hall events that encourage open dialogue. Fostering a culture of accountability and compliance is also important, and all of our employees complete trainings on applicable corporate policies including our Global Code of Conduct which covers conflicts of interest; Harassment, Discrimination, and Retaliation Policy; Insider Trading Policy; and Anti-Corruption Policy.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At BeiGene, empowering our people begins with our culture and values: Bold Ingenuity, Collaborative Spirit, Driving Excellence, and most importantly, Patients First. As a global entity with many remote workers, we have been able to build a team of talented professionals with a wide range of experiences, regardless of their location. We are an equal opportunity employer. We do not discriminate on the basis of race, religion, color, sex, gender identity, sexual orientation, age, physical or mental disability, national origin, veteran status or any other basis covered by applicable law. All employment is decided on the basis of qualifications, merit, and business need. Further, we have policies in place that prohibit harassment and retaliation and a 24/7 ethics hotline where concerns can be raised on an anonymous basis. We maintain a culture where all voices are welcomed, heard, and respected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;14, 2025, we had over 11,000 full-time employees worldwide, across six continents, with approximately 1,700 employees in the U.S. and the balance outside of the U.S. We have also engaged and may continue to engage contingent workers to assist us with our operations. None of our employees are represented by a labor union or covered by a collective bargaining agreement, except as required by local laws such as in some European countries and Brazil. We also track voluntary and involuntary turnover rates and we consider our relations with our employees to be good.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Responsible Business &amp; Sustainability</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a global organization focused on providing innovative medicines to more patients around the world, our Responsible Business &amp; Sustainability (&#8220;RB&amp;S&#8221;) efforts are aligned with our corporate strategy. We believe: broad patient access and sustainable profitability are achievable through cost and speed efficiencies in drug discovery and development; the discovery of novel solutions is enabled by engaged colleagues with varied experiences and perspectives and an inclusive culture; and operational resilience is supported by our efforts to identify and mitigate risk in our operations and in our value chain. As such, our RB&amp;S strategy is focused on the following key areas:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">Advancing Global Health</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - We are focused on developing impactful medicines that will be accessible to far more patients around the world.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">Empowering Our Colleagues</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - We are committed to fostering a culture of innovation and building a global workforce that enables our colleagues to thrive.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">Innovating Sustainably</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - We aim to assess and mitigate our impact on the environment and ensure business continuity.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.5pt">Operating Responsibly</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - We operate with integrity, transparency, and discipline to ensure we are meeting the expectations of our stakeholders.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within each focus area, we have identified key strategic priorities against which we have set targets. Our targets are aspirational and may change; statements regarding these priorities and targets are not guarantees or promises that they will be met. We report our progress in late April of each year, and our reports can be found on our corporate website.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Information</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial information required under this Item&#160;1 is incorporated herein by reference from the section of this Annual Report titled &#8220;Part&#160;II-Item&#160;8-Financial Statements and Supplementary Data.&#8221; For financial information regarding our business, please see the section of this Annual Report titled &#8220;Part&#160;II-Item&#160;7-Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of this Annual Report and our consolidated audited financial statements and related notes included elsewhere in this Annual Report.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an exempted company incorporated on October 28, 2010 in the Cayman Islands with limited liability. Any company that is registered in the Cayman Islands but conducts business mainly outside of the Cayman Islands may apply to be registered as an exempted company. Our current registered office in the Cayman Islands is located at the offices of Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman KY1-1108, Cayman Islands. Our website address is www.beigene.com. We do not incorporate the information on or accessible through our website into this Annual Report, and you should not consider any information on, or that can be accessed through, our website as part of this Annual Report.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own various registered trademarks, trademark applications and unregistered trademarks and service marks, including the name &#8220;BeiGene&#8221; and our corporate logo. All other trade names, trademarks and service marks of other companies appearing in this Annual Report are the property of their respective holders. Solely for convenience, some of the trademarks and trade names in this document are referred to without the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and &#8482; symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend our use or display of other companies&#8217; trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make available on or through the Investor section of our website certain reports and amendments to those reports that we file with or furnish to the SEC, in accordance with the Exchange Act. These include our annual reports on Form 10-K, our quarterly reports on Form 10-Q, and our current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. We also make available, free of charge on our website, the reports filed with the SEC by our executive officers, directors and 10% shareholders pursuant to Section 16 under the Exchange Act. Additionally, we make available on our website our securities filings with the HKEx and the Shanghai Stock Exchange. We make this information available on or through our website free of charge as soon as reasonably practicable after we electronically file the information with, or furnish it to, the SEC, the HKEx, and the SSE. </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may use the Investors section of our website </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">at www.beigene.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our X (formerly known as Twitter) account at </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x.com/BeiGeneGlobal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our LinkedIn account at </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">linkedin.com/company/BeiGene,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> our Facebook account at </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">facebook.com/BeiGeneGlobal, and our Instagram account at instagram.com/BeiGeneGlobal</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to disclose material information and to comply with our disclosure obligations under Regulation FD. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors are encouraged to review the Investors section of our website because we may post material information on that site that is not otherwise disseminated by us. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information that is contained in and can be accessed through our website, our X posts, our LinkedIn posts and our Instagram posts are not incorporated into, and does not form a part of, this Annual Report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following section includes material factors that we believe may adversely affect our business and operations. You should carefully consider the risks and uncertainties described below and all information contained in this Annual Report, including our financial statements and the related notes and &#8220;Part II-Item 7-Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before deciding to invest in our ADSs, ordinary shares, or RMB Shares. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations, and growth prospects. In such an event, the market price of our ADSs, ordinary shares, and RMB Shares could decline, and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. Please refer to the explanation of the qualifications and limitation on forward-looking statements set forth on page 1 hereof.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Risk Factors</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Below is a summary of the material factors that make an investment in our ADSs listed on Nasdaq, our ordinary shares listed on the Stock Exchange of Hong Kong Limited, and our ordinary shares issued to permitted investors in China and listed and traded on the Science and Technology Innovation Board of the Shanghai Stock Exchange in Renminbi (&#8220;RMB Shares&#8221;) speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, are set forth herein and should be carefully considered, together with other information in this Annual Report and our other filings with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), before making an investment decision regarding our ADSs, ordinary shares or RMB shares.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our medicines may fail to achieve and maintain the degree of market acceptance by physicians, patients, third-party payors, and others in the medical community necessary for commercial success.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have limited experience in launching and marketing our internally developed and in-licensed medicines. If we are unable to further develop marketing and sales capabilities or enter into agreements with third parties to market and sell our medicines, we may not be able to generate substantial product sales revenue.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face substantial competition, which may result in others discovering, developing, or commercializing competing medicines before or more successfully than we do.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The market opportunities for our future medicines may be limited to those patients who are ineligible for or have failed prior treatments and may be small.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we or any third parties with which we may collaborate to market and sell our medicines are unable to achieve and maintain coverage and adequate levels of reimbursement or are subject to unfavorable pricing regulations, our commercial success and business operations could be adversely affected.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If clinical trials of our drug candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our drug candidates.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">All material aspects of the research, development, manufacturing and commercialization of pharmaceutical products are heavily regulated, and we may face difficulties in complying with or be unable to comply with such regulations, which could have a material adverse effect on our business.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The approval processes of regulatory authorities in the U.S., China, Europe and other comparable regulatory authorities are lengthy, time consuming, costly, and inherently unpredictable. If we experience delays or are ultimately unable to obtain regulatory approval for our drug candidates, our business will be substantially harmed.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our medicines and any future approved drug candidates will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our medicines and drug candidates.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have historically incurred significant net losses and may incur net losses in the future.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may need to obtain additional financing to fund our operations, and if we are unable to obtain such financing, we may be unable to complete the development of our drug candidates or achieve profitability.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to obtain and maintain patent protection for our medicines and drug candidates, we may lose market exclusivities in our medicines.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third parties to manufacture some of our commercial and clinical drug supplies. Our business could be harmed if those third parties fail to comply with manufacturing regulations, provide us with insufficient quantities of product or provide product at unacceptable quality levels or prices.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have entered into licensing and collaboration arrangements and may enter into additional collaborations, licensing arrangements, or strategic alliances in the future, and we may not realize the benefits of such arrangements.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we fail to maintain an effective distribution channel for our medicines, our business and sales could be adversely affected.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are not able to successfully develop and/or commercialize Amgen&#8217;s oncology products, the expected benefits of the collaboration will not materialize.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have significantly increased and expect to continue to increase our research, development, manufacturing, and commercial capabilities, and we may experience difficulties in managing our growth.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business is subject to complex and evolving industry-specific laws and regulations regarding the collection and transfer of personal data. These laws and regulations can be stringent and many are subject to change and uncertain interpretation, which could result in claims, changes to our data and other business practices, significant penalties, increased cost of operations, or otherwise adversely impact our business.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We manufacture some of our medicines and intend to manufacture some of our drug candidates, if approved. Failure to comply with regulatory requirements could result in sanctions being imposed against us and delays in receiving regulatory approvals for our manufacturing facilities, or damage to, destruction of or interruption of production at such facilities, could delay our development plans or commercialization efforts.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in the political and economic policies of the PRC government or in relations between China and the U.S. or other governments and the significant oversight and discretion the PRC government has over the conduct of the business operations of our PRC subsidiaries may materially and adversely affect our business, financial condition, and results of operations and may result in our inability to sustain our growth and expansion strategies.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The PRC government</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may intervene or influence our operations at any time, and has the ability to exert significant oversight and control over any offering of securities conducted overseas and/or foreign investment in China-based issuers,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which could result in a material change in our operations and limit or completely hinder our ability to offer or continue to offer securities to investors, and may cause the value of such securities to significantly decline or be worthless.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">There are uncertainties regarding the interpretation and enforcement of Chinese laws, rules and regulations, and rules and regulations in China can change quickly with little advance notice. </span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Filing or other procedures with the China Securities Regulatory Commission (&#8220;CSRC&#8221;) or other Chinese regulatory authorities may be required in connection with issuing our equity securities to foreign investors under Chinese law, and, if required, we cannot predict whether we will be able, or how long it will take us, to complete such filing or other procedures. If we fail to complete a filing with the CSRC, our future offering application may be impacted and we may be subject to penalties, sanctions and fines imposed by the CSRC and relevant departments of the State Council.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The trading prices of our ordinary shares, ADSs, and/or RMB Shares can be volatile, which could result in substantial losses to you.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Your rights as a shareholder will change as a result of the Continuation.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">As a result of increased shareholder voting requirements upon completion of the Continuation, we will have less flexibility with respect to certain aspects of capital management than previously.</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The Continuation will result in additional direct and indirect costs whether or not completed.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Clinical Development and Commercialization of Our Medicines and Drug Candidates</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our medicines may fail to achieve and maintain the degree of market acceptance by physicians, patients, third-party payors, and others in the medical community necessary for commercial success.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our medicines may fail to achieve and maintain sufficient market acceptance by physicians, patients, third-party payors, and others in the medical community. For example, current cancer treatments like chemotherapy and radiation therapy are well established in the medical community, and doctors may continue to rely on these treatments to the exclusion of our medicines. If our medicines do not achieve and maintain an adequate level of market acceptance, the sales of our medicines may be limited and we may not become profitable. The degree of market acceptance of our medicines will depend on a number of factors, including: the clinical indications for which our medicines are approved; physicians, hospitals, cancer treatment centers, and patients considering our medicines safe and effective; government agencies, professional societies, practice management groups, insurance carriers, physicians&#8217; groups, private health and science foundations recommending our medicines; the perceived advantages and relative cost of alternative treatments; the prevalence and severity of any side effects; product labeling, including limitations or warnings, or product insert requirements of regulatory authorities; the timing of market introduction of our medicines as well as competitive medicines; the availability of adequate coverage, reimbursement and pricing by third-party payors and government authorities; and the effectiveness of our sales and marketing efforts.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if our medicines achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received, are more cost effective or render our medicines obsolete.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited experience in launching and marketing our internally developed and in-licensed medicines. If we are unable to further develop marketing and sales capabilities or enter into agreements with third parties to market and sell our medicines, we may not be able to generate substantial product sales revenue.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We became a commercial-stage company in 2017, when we entered into a license and supply agreement with Celgene Logistics S&#224;rl, now a Bristol-Myers Squibb Company (&#8220;BMS&#8221;), to commercialize three of BMS&#8217;s approved cancer therapies, in the People&#8217;s Republic of China (&#8220;PRC&#8221; or &#8220;China&#8221;). In October 2019, we entered into a collaboration with Amgen for its commercial-stage oncology products and a portfolio of clinical- and late-preclinical-stage oncology pipeline products. We received the first approvals for our internally developed drug candidates in late 2019 in the United States (&#8220;U.S.&#8221;), in 2020 in China, and in 2021 in Europe. Given this, we have limited experience in commercializing our internally developed and in-licensed medicines, including building and managing a commercial team, conducting a comprehensive market analysis, obtaining state licenses and reimbursement, and managing distributors and a sales force for our medicines. As a result, our ability to successfully commercialize our medicines may involve more inherent risk, take longer, and cost more than it would if we were a company with substantial experience in launching medicines.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to, or decide not to, further develop internal sales, marketing, and commercial distribution capabilities for any or all of our medicines, we will likely pursue collaborative arrangements regarding the sales and marketing of our medicines. However, there can be no assurance that we will be able to establish or maintain such collaborative arrangements, or whether they will have effective sales forces. We would have little or no control over the marketing and sales efforts of such third parties, and our revenue from product sales may be lower than if we had commercialized our medicines ourselves. There can be no assurance that we will be able to further develop and successfully maintain internal sales and commercial distribution capabilities or establish or maintain relationships with third-party collaborators to successfully commercialize any medicine, and as a result, we may not be able to generate substantial product sales revenue.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing, or commercializing competing medicines before or more successfully than we do.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of new medicines is highly competitive. We face competition from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are a number of large pharmaceutical and biotechnology companies that currently market and sell medicines or are pursuing the development of medicines for the treatment of cancer for which we are commercializing our medicines or developing our drug candidates. For example, BRUKINSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, tislelizumab, and pamiparib face substantial competition, and some of our products face or are expected to face competition from generic therapies. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing, and commercialization.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize medicines that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than our medicines. Our competitors also may obtain approval from regulatory authorities for their medicines more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market and/or slow our regulatory approval.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved medicines than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific, management and marketing personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market opportunities for our future medicines may be limited to those patients who are ineligible for or have failed prior treatments and may be small.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In markets with approved therapies, we have and expect to initially seek approval of our drug candidates as a later stage therapy for patients who have failed other approved treatments. Subsequently, for those medicines that prove to be sufficiently beneficial, if any, we would expect to seek approval as a second-line therapy and potentially as a first-line therapy, but there is no guarantee that our medicines and drug candidates, even if approved, would be approved for second-line or first-line therapy.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our projections of both the number of people who have the diseases we are targeting, as well as the subset of people with these diseases in a position to receive later stage therapy and who have the potential to benefit from treatment with our medicines and drug candidates, may prove to be inaccurate and new studies may change the estimated incidence or prevalence of these cancers. Additionally, the potentially addressable patient population for our medicines and drug candidates may be limited or may not be amenable to treatment with our medicines and drug candidates. Even if we obtain significant market share for our medicines and drug candidates, because the potential target populations are small, we may never achieve profitability without obtaining regulatory approval for additional indications, including use as a first- or second-line therapy.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or any third parties with which we may collaborate to market and sell our medicines are unable to achieve and maintain coverage and adequate levels of reimbursement or are subject to unfavorable pricing regulations, our commercial success and business operations could be adversely affected.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability or the ability of any third parties with which we collaborate to commercialize our medicines successfully will depend in part on the extent to which reimbursement for these medicines is available from government health administration authorities, private health insurers and other organizations. In the U.S. and other countries, patients generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Sales of our medicines will depend substantially, on the extent to which the costs of our medicines will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or reimbursed by government health administration authorities, private health coverage insurers and other third-party payors. Without third-party payor reimbursement, patients may not be able to obtain or afford prescribed medications. Third-party payors also are seeking to encourage the use of generic or biosimilar products or entering into sole source contracts with healthcare providers, which could effectively limit the coverage and level of reimbursement for our medicines and have an adverse impact on the market access or acceptance of our medicines. In addition, reimbursement guidelines and incentives provided to prescribing physicians by third-party payors may have a significant impact on the prescribing physicians&#8217; willingness and ability to prescribe our products. For additional information, please see the section of this Annual Report titled &#8220;Part I&#8212;Item 1&#8212;Business&#8212;Government Regulation&#8212;Pharmaceutical Coverage, Pricing, and Reimbursement.&#8221;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., no uniform policy of coverage and reimbursement for drugs exists among third-party payors. As a result, obtaining coverage and reimbursement approval of a drug from a government or other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost- effectiveness data for the use of our medicines on a payor-by-payor basis, with no assurance that coverage and adequate reimbursement will be obtained. Coverage may be more limited than the purposes for which the medicine is approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or comparable regulatory authorities in other countries. Even if we obtain coverage for a given medicine, the resulting reimbursement rates might not be adequate for us to achieve or sustain profitability or may require co-payments that patients find unacceptably high. Additionally, third-party payors may not cover, or provide adequate reimbursement for, long-term follow-up evaluations required following the use of our medicines. Because some of our medicines and drug candidates have a higher cost of goods than conventional therapies and may require long-term follow-up evaluations, the risk that coverage and reimbursement rates may be inadequate for us to achieve profitability may be greater.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In China, drug prices are typically lower than in the U.S. and Europe, and until recently, the market has been dominated by generic drugs. Government authorities regularly review the inclusion or removal of medicines from China&#8217;s National Reimbursement Drug List (the &#8220;NRDL&#8221;), or provincial or local medical insurance catalogues for the National Medical Insurance Program, and the tier under which a medicine will be classified, both of which affect the amounts reimbursable to program participants for their purchases of those medicines. Products included in the NRDL have typically been generic and essential drugs. BRUKINSA, tislelizumab, PARTRUVIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have been included in the NRDL. While the demand for these medicines has generally increased after inclusion in the NRDL, there can be no assurance that demand will continue to increase and such increases will be sufficient to offset the reduction in the prices and our margins, which could have a material adverse effect on our business, financial condition and results of operations. We prepare for the NRDL negotiations in China for our eligible medicines/indications annually. If any of these medicines/indications are not included in the NRDL or included at a significantly lower price, the revenues for such medicines could be limited, which could have a material adverse effect on our business, financial condition and results of operations in China.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The government in China also has a program for volume-based, centralized drug procurement with minimum quantity commitments to negotiate lower prices from drug manufacturers and reduce the price of drugs. The Chinese government awards contracts to the bidders who can satisfy the quality and quantity requirements, with price being a significant factor in the procurement decisions. The successful bidders are guaranteed a sale volume for at least a year, which gives an opportunity to gain or increase market share. Many types of drugs are covered under the program, including drugs made by international pharmaceutical companies and generics made by domestic Chinese manufacturers. For example, in 2020, ABRAXANE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its generic forms were included in the program. We won the bid and became one of the three companies who were awarded a government contract, with a price for sales of ABRAXANE under the government contract that would have been significantly lower than the price that we had been charging. Also in 2020, VIDAZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and its generic forms were included for bidding in the program. We did not win the bid for VIDAZA, which resulted in the drug being restricted from use in public hospitals, which account for a large portion of the market, and a decline in sales revenue. Moreover, the program may change how generic drugs are priced and procured in China and is likely to accelerate the replacement of originator drugs with generics. This program may negatively impact our existing commercial operations in China as well as our strategies on how to commercialize our drugs in China, which could have a material adverse effect on our business, financial condition and results of operations in China.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Countries in Europe provide options to restrict the range of medicinal products for which their national health insurance systems provide reimbursement. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. Countries may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. Furthermore, some countries require approval of the sale price of a medicine before it can be marketed. In many countries, the pricing review period begins after marketing or licensing approval is granted. In some non-U.S. markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain regulatory approval for a medicine in a particular country, but then be subject to price regulations that delay our commercial launch of the medicine and negatively impact our revenues and results of operations.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increasingly, third-party payors are requiring that companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any medicine that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Reimbursement may impact the demand for, or the price of, any medicine which we commercialize. Obtaining or maintaining reimbursement for our medicines may be particularly difficult because of the higher prices often associated with medicines administered under the supervision of a physician. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any medicine and drug candidate that we in-license or successfully develop.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be significant delays in obtaining reimbursement for approved medicines. Moreover, eligibility for reimbursement does not imply that any medicine will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim payments for new medicines, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Payment rates may vary according to the use of the medicine and the clinical setting in which it is used, may be based on payments allowed for lower cost medicines that are already reimbursed, and may be incorporated into existing payments for other services. Net prices for medicines may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future weakening of laws that presently restrict imports of medicines from countries where they may be sold at lower prices than in the U.S. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for our medicines and any new medicines that we develop could have a material adverse effect on our business, our operating results, and our overall financial condition.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have operations in the U.S., China, Europe, and other markets and plan to expand in these and new markets on our own or with collaborators, which exposes us to risks of conducting business in international markets.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently developing and commercializing or plan to commercialize our medicines in international markets, including China, Europe and other markets outside of the U.S., either on our own or with third-party collaborators or distributors. Our international business relationships subject us to additional risks that may materially adversely affect our ability to attain or sustain profitable operations, including:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty of effective enforcement of contractual provisions in local jurisdictions;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential third-party patent rights or potentially reduced protection for intellectual property rights;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected changes in tariffs, including tariffs that have been or may in the future be imposed by the U.S. or other countries, trade barriers and regulatory requirements, including the loss of normal trade status between China and the U.S. or actions taken by U.S. or China governmental authorities on companies with significant operations in the U.S. and China, such as us, and protectionist or retaliatory measures taken by the U.S.or China;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic weakness;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with tax, employment, immigration and labor laws for employees traveling internationally;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effects of applicable non-U.S. tax structures and potentially adverse tax consequences;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">currency fluctuations, which could result in increased operating expenses and reduced revenue;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">workforce uncertainty and labor unrest;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of our employees and contracted third parties to comply with Office of Foreign Asset Control rules and regulations and the Foreign Corrupt Practices Act and other anti-bribery and corruption laws;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business interruptions resulting from geo-political actions, including trade disputes, war and terrorism, public health crises or natural disasters, including earthquakes, volcanoes, typhoons, floods, hurricanes and fires; </span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic and political instability; and</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">international military conflicts and related sanctions.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, on February 1, 2025, the U.S. imposed a 25% tariff on imports from Canada and Mexico, which were subsequently suspended for a period of one month, and a 10% additional tariff on imports from China. Historically, tariffs have led to increased trade and political tensions, between not only the U.S. and China, but also between the U.S. and other countries in the international community. Political tensions as a result of trade policies could reduce trade volume, investment, technological exchange and other economic activities between major international economies, resulting in a material adverse effect on global economic conditions and the stability of global financial markets. These and other risks, including the risks described in &#8220;Risks Related to Our Doing Business in the PRC&#8221;, may materially adversely affect our ability to attain or sustain revenue in international markets.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The illegal distribution and sale by third parties of counterfeit versions of our medicines or stolen products could have a negative impact on our reputation and business.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties might illegally distribute and sell counterfeit or unfit versions of our medicines, which do not meet our or our collaborators&#8217; rigorous manufacturing and testing standards. A patient who receives a counterfeit or unfit medicine may be at risk for a number of dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit or unfit medicines sold under our or our collaborators&#8217; brand name(s). In addition, thefts of inventory at warehouses, plants or while in transit, which are not properly stored and which are sold through unauthorized channels, could adversely impact patient safety, our reputation and our business.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical development is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our drug candidates may not be predictive of the results of later-stage clinical trials, and initial or interim results of a trial may not be predictive of the final results. Drug candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. In some instances, there can be significant variability in safety and/or efficacy results between different trials of the same drug candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, patient adherence to the dosing regimen and the rate of dropout among clinical trial participants. In the case of any trials we conduct, results may differ from earlier trials due to the larger number of clinical trial sites and additional countries involved in such trials. A number of companies in our industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Our future clinical trial results may not be favorable.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If clinical trials of our drug candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our drug candidates.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining regulatory approval for the sale of our drug candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of our drug candidates in humans. We may experience numerous unexpected events during clinical trials that could delay or prevent our ability to receive regulatory approval or commercialize our drug candidates, including but not limited to: regulators, institutional review boards, or ethics committees may not authorize us to conduct a clinical trial or may require us or our investigators to suspend or terminate clinical research or not rely on the results of our clinical research for various reasons, including noncompliance with regulatory requirements; our inability to reach agreements on acceptable terms with contract research organizations (&#8220;CROs&#8221;) and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly; manufacturing issues, including problems with supply quality, compliance with good manufacturing practice (&#8220;GMP&#8221;), or obtaining sufficient quantities of a drug candidate for use in a clinical trial; clinical trials of our drug candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon drug development programs; the number of patients required for clinical trials may be larger than we anticipate, enrollment may be insufficient or slower than we anticipate or patients may drop out at a higher rate than we anticipate; our third-party contractors, including clinical investigators, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; we might have to suspend or terminate clinical trials for various reasons, including a finding of a lack of clinical response or other unexpected characteristics or a finding that participants are being exposed to unacceptable health risks; the cost of clinical trials of our drug candidates may be greater than we anticipate; and the supply or quality of our medicines and drug candidates or other materials necessary to conduct clinical trials may be insufficient or inadequate.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are required to conduct additional clinical trials or other testing of our drug candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our drug candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if they raise safety concerns, we may be delayed in obtaining regulatory approval for our drug candidates, or not obtain regulatory approval at all; obtain approval for indications that are not as broad as intended; have the drug removed from the market after obtaining regulatory approval; be subject to additional post-marketing testing requirements; be subject to warning labels or restrictions on how the drug is distributed or used; or be unable to obtain reimbursement or obtain reimbursement at a commercially viable level for use of the drug.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant clinical trial delays may also increase our development costs and could shorten any periods during which we have the exclusive right to commercialize our drug candidates or allow our competitors to bring drugs to market before we do. This could impair our ability to commercialize our drug candidates and may harm our business and results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until its conclusion. We have and may continue to experience difficulties in patient enrollment in our clinical trials for a variety of reasons, including the size and nature of the patient population and the patient eligibility criteria defined in the protocol, competition from competing companies, and natural disasters or public health crises.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trials will likely compete with other clinical trials for drug candidates that are in the same therapeutic areas as our drug candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead enroll in a trial being conducted by a competitor. Because the number of qualified clinical investigators and clinical trial sites is limited, we expect to conduct some of our clinical trials at the same sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such sites. Even if we are able to enroll a sufficient number of patients in our clinical trials, delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could delay or prevent completion of these trials and adversely affect our ability to advance the development of our drug candidates.</span></div><div id="ic94bd2152a214042a118e81881a5a1e5_79"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Regulatory Approval and Extensive Government Regulation</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">All material aspects of the research, development, manufacturing and commercialization of pharmaceutical products are heavily regulated, and we may face difficulties in complying with or be unable to comply with such regulations, which could have a material adverse effect on our business.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently focusing our pharmaceutical-industry activities in the major markets of the U.S., China, Europe, and other select countries and regions. These areas all strictly regulate the pharmaceutical industry, and in doing so they employ broadly similar regulatory strategies, including regulation of product development and approval, manufacturing, and marketing, sales and distribution of products. However, there are differences in the regulatory regimes that make for a more complex and costly regulatory compliance burden. Additionally, the China National Medical Products Administration&#8217;s (&#8220;NMPA&#8221;) reform of the medicine and approval system may face implementation challenges. The timing and full impact of such reforms is uncertain and could prevent us from commercializing our medicines and drug candidates in a timely manner. In addition, the U.S. Supreme Court&#8217;s July 2024 decision to overturn established case law giving deference to regulatory agencies&#8217; interpretations of ambiguous statutory language has introduced uncertainty regarding the extent to which the FDA&#8217;s regulations, policies and decisions may become subject to increasing legal challenges, delays, and/or changes. From time to time, laws may be passed that significantly change the statutory provisions governing the approval, manufacturing, and marketing of products regulated by the FDA. In addition to new legislation, FDA regulations, guidance, and policies are often revised or reinterpreted by the agency in ways that may significantly affect the manner in which pharmaceutical products are regulated and marketed.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of obtaining regulatory approvals and compliance with laws and regulations require the expenditure of substantial time and financial resources. Failure to comply with requirements at any time during the product development process, approval process, or after approval, may subject us to administrative or judicial sanctions. These sanctions could include a regulator&#8217;s refusal to approve pending applications, withdrawal of an approval, license revocation, a clinical hold, voluntary or mandatory product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties. The failure to comply with these regulations could have a material adverse effect on our business. For example, in 2020, the NMPA suspended the importation, sales and use of ABRAXANE in China previously supplied to us by BMS, and the drug was subsequently recalled by BMS. This suspension was based on inspection findings at BMS&#8217;s contract manufacturing facility in the U.S. In any event, the receipt of regulatory approval does not assure the success of our commercialization efforts for our medicines.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to anti-kickback, false claims laws, physician payment transparency laws, fraud and abuse laws or similar healthcare and security laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished sales.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians and others play a primary role in the recommendation and prescription of our approved products. Our operations are subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal False Claims Act (&#8220;FCA&#8221;), and physician payment sunshine laws and regulations. These laws may impact, among other things, our proposed sales, marketing and education programs. In addition, we are subject to patient privacy regulation by both the federal government and the states in which we conduct our business. For additional information, please see the section of this Annual Report, titled &#8220;Part I&#8212;Item 1&#8212;Business&#8212;Government Regulation&#8212;Other U.S. Healthcare Laws and Compliance Requirements.&#8221;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the approval and commercialization for our medicines and drug candidates outside the U.S. subjects us to non-U.S. equivalents of the healthcare laws mentioned above, among other non-U.S. laws. Some of these non-U.S. laws may be broader in scope and subject to the discretion of non-U.S. law enforcement authorities, including Chinese authorities who recently increased anti-bribery efforts to reduce improper payments and other benefits received by physicians, staff and hospital administrators in relation to sales, marketing and purchase of pharmaceuticals. There are ambiguities as to what is required to comply with these state requirements, and if we fail to comply with an applicable state law requirement, we could be subject to penalties.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, we have made grants to independent charitable foundations that help financially needy patients with their premium, co-pay, and co-insurance obligations and we expect to make such grants in the future. If we choose to do so, and if we or our vendors or donation recipients are deemed to fail to comply with relevant laws or regulations in the operation of these programs, we could be subject to damages, fines, penalties, or other criminal, civil, or administrative sanctions or enforcement actions. We cannot ensure that our compliance controls and procedures will be sufficient to protect against acts of our employees, business partners, or vendors that may violate the laws or regulations of the jurisdictions in which we operate. Furthermore, there has been increased scrutiny of company-sponsored patient assistance programs, including co-pay assistance programs, and donations to third-party charities that provide such assistance. There has also been enhanced scrutiny by governments of reimbursement support offerings, clinical education programs and promotional speaker programs. Regardless of whether we have complied with the law, a government investigation could impact our business practices, harm our reputation, divert the attention of management, increase our expenses, and reduce the availability of foundation support for our patients who need assistance.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of fraud and abuse laws may be punishable by criminal and/or civil sanctions, including penalties, fines and/or exclusion or suspension from federal and state healthcare programs such as Medicare and Medicaid and debarment from contracting with the U.S. government. In addition, private individuals have the ability to bring actions on behalf of the U.S. government under the federal FCA as well as under the false claims laws of several states. Neither the U.S. government nor the U.S. courts have provided definitive guidance on the applicability of fraud and abuse laws to our business. Law enforcement authorities are increasingly focused on enforcing these laws, and it is possible that some of our practices may be challenged under these laws. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, individual imprisonment, reputational harm, diminished profits and future earnings, and curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. Furthermore, if any of the physicians or other providers or entities with whom we do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs, which may adversely affect our business.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in the Medicaid Drug Rebate Program, the 340B program, the U.S. Department of Veterans Affairs, Federal Supply Schedule (&#8220;FSS&#8221;) pricing program, and the Tricare Retail Pharmacy program, which require us to disclose average manufacturer pricing, and, in the future may require us to report the average sales price for certain of our drugs to the Medicare program. Pricing and rebate calculations vary across products and programs, are complex, and are often subject to interpretation by us, governmental or regulatory agencies and the courts. Furthermore, regulatory and legislative changes, and judicial rulings relating to these programs and policies (including coverage expansion), have increased and will continue to increase our costs and the complexity of compliance, have been and will continue to be time-consuming to implement, and could have a material adverse effect on our results of operations, particularly if CMS or another agency challenges the approach we take in our implementation. For example, in the case of our Medicaid pricing data, if we become aware that our reporting for a prior quarter was incorrect or has changed as a result of recalculation of the pricing data, we are generally obligated to resubmit the corrected data for up to three years after those data originally were due. Such restatements increase our costs and could result in an overage or underage in our rebate liability for past quarters. Price recalculations also may affect the ceiling price at which we are required to offer our products under the 340B program and give rise to an obligation to refund entities participating in the 340B program for overcharges during past quarters impacted by a price recalculation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Civil monetary penalties can be applied if we are found to have knowingly submitted any false price or product information to the government, if we are found to have made a misrepresentation in the reporting of our average sales price, if we fail to submit the required price data on a timely basis, or if we are found to have charged 340B covered entities more than the statutorily mandated ceiling price. Additionally, our agreement to participate in the 340B program or our Medicaid drug rebate agreement could be terminated, in which case federal payments may not be available under Medicaid or Medicare Part D for our covered outpatient drugs. Additionally, if we overcharge the government in connection with our arrangements with FSS or Tricare Retail Pharmacy, we are required to refund the difference to the government. Failure to make necessary disclosures and/or to identify contract overcharges can result in allegations against us under the FCA and other laws and regulations. Unexpected refunds to the government, and responding to a government investigation or enforcement action, would be expensive and time-consuming, and could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, legislation may be introduced that, if passed, would, among other things, further expand the 340B program to additional covered entities or would require participating manufacturers to agree to provide 340B discounted pricing on drugs used in an inpatient setting, and any additional future changes to the definition of average manufacturer price or the Medicaid rebate amount could affect our 340B ceiling price calculations and negatively impact our results of operations. Additionally, certain pharmaceutical manufacturers are involved in ongoing litigation regarding contract pharmacy arrangements under the 340B program. The outcome of those judicial proceedings and the potential impact on the way in which manufacturers extend discounts to covered entities through contract pharmacies remain uncertain.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The approval processes of regulatory authorities in the United States, China, Europe and other comparable regulatory authorities are lengthy, time consuming, costly, and inherently unpredictable. If we experience delays or are ultimately unable to obtain regulatory approval for our drug candidates, our business will be substantially harmed.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining regulatory approvals for the commercial sale of any drug candidate for a target indication, we must demonstrate in preclinical studies and well-controlled clinical trials, and, with respect to approval in the U.S., to the satisfaction of the FDA, that the drug candidate is safe and effective, or the biologic drug candidate is safe, pure, and potent, for use for that target indication and that the manufacturing facilities, processes and controls are adequate. In addition to preclinical and clinical data, the new drug application (&#8220;NDA&#8221;) or biologics license application (&#8220;BLA&#8221;) must include comprehensive information regarding the chemistry, manufacturing and controls (&#8220;CMC&#8221;) for the drug candidate. If we submit an NDA or BLA to the FDA, we cannot be certain that a submission will be accepted for filing and review by the FDA.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities outside of the U.S., such as the NMPA and European Medicines Agency (&#8220;EMA&#8221;), also have requirements for approval of medicines for commercial sale with which we must comply prior to marketing in those areas. Regulatory requirements, approval processes and review periods can vary from country to country and could delay or prevent the introduction of our drug candidates. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and obtaining regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Seeking regulatory approvals outside of the U.S. could require additional nonclinical studies or clinical trials, which could be costly and time consuming. For all of these reasons, we may not obtain regulatory approvals on a timely basis, if at all.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The processes required to obtain approval by the FDA, the NMPA, the EMA, and other comparable regulatory authorities are complex, costly, unpredictable and typically take many years following the commencement of preclinical studies and clinical trials and depend on numerous factors, including the substantial discretion of the regulatory authorities. Regulatory approval is never guaranteed. Furthermore, we have limited experience in obtaining regulatory approvals for our drug candidates, including preparing the required materials for regulatory submission and navigating the regulatory approval process. As a result, our ability to successfully obtain regulatory approval for our drug candidates may involve more inherent risk, take longer, and cost more than it would if we were a company with substantial experience in obtaining regulatory approvals.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our drug candidates could be delayed or fail to receive regulatory approval for many reasons, including:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to begin or complete clinical trials due to disagreements with regulatory authorities;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to demonstrate that a drug candidate is safe and effective or that a biologic candidate is safe, pure, and potent for its proposed indication;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of clinical trial results to meet the level of statistical significance required for approval;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reporting or data integrity issues related to our clinical trials;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disagreement with our interpretation of data from preclinical studies or clinical trials;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in approval policies or regulations that render our preclinical and clinical data insufficient for approval or require us to amend our clinical trial protocols;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory requests for additional analyses, reports, data, nonclinical studies and clinical trials, or questions regarding interpretations of data and results and the emergence of new information regarding our drug candidates or other products;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to satisfy regulatory conditions regarding endpoints, patient population, available therapies and other requirements for our clinical trials in order to support marketing approval on an accelerated basis or at all;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a delay in or the inability of health authorities to complete regulatory inspections of our development activities, regulatory filings or manufacturing operations, whether as a result of a public health crisis, government shutdown, resource shortages or other reasons, or our failure to satisfactorily complete such inspections;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure to conduct a clinical trial in accordance with regulatory requirements or our clinical trial protocols; and</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical sites, investigators or other participants in our clinical trials deviating from a trial protocol, failing to conduct the trial in accordance with regulatory requirements, or dropping out of a trial.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in 2022, the FDA extended the Prescription Drug User Fee Act goal date for the supplemental new drug application (&#8220;sNDA&#8221;) for BRUKINSA as a treatment for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma by three months, to allow time to review additional clinical data submitted by us, which was deemed a major amendment to the sNDA. In 2022, the FDA deferred action on the BLA for TEVIMBRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a second-line treatment for patients with unresectable or metastatic ESCC, citing only the inability to complete inspections due to COVID-19 related restrictions on travel. In 2024, the FDA deferred approval for tislelizumab in first-line unresectable, recurrent, locally advanced, or metastatic ESCC on account of a delay in scheduling clinical site inspections.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our development activities, regulatory filings and manufacturing operations also could be harmed or delayed by a shutdown of the U.S. government, including the FDA, or governments and regulatory authorities in other jurisdictions. If the FDA or other health authorities are delayed or unable to complete required regulatory inspections of our development activities, regulatory filings or manufacturing operations due to government shutdowns, public health crises, or other reasons, or we do not satisfactorily complete such inspections, our business could be materially harmed. Currently, federal agencies in the U.S. are operating under a continuing resolution that is set to expire on March 14, 2025. Without appropriation of additional funding to federal agencies, our business operations related to our product development activities for the U.S. market could be impacted.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delays in the completion of a clinical trial of any of our drug candidates will increase our costs, slow down our drug development and approval process, and jeopardize our ability to commence product sales and generate revenues for that candidate. Any of these occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our drug candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently conducting and may in the future conduct clinical trials for our drug candidates outside the U.S., and the FDA and comparable foreign regulatory authorities may not accept data from such trials.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently conducting and may in the future conduct clinical trials for our drug candidates outside the U.S., including in China. The acceptance of data from clinical trials conducted outside the U.S. or another jurisdiction by the FDA or comparable foreign regulatory authority may be subject to certain conditions or may not be accepted at all. The FDA will generally not consider the data from a foreign clinical trial not conducted under an IND unless (i) the trial was well-designed and well-conducted in accordance with good clinical practice (&#8220;GCP&#8221;) requirements, including requirements for the design, conduct, performance, monitoring, auditing, recording, analysis, and reporting of clinical trials in a way that provides assurance that the data and reported results are credible and accurate and that the rights, safety, and well-being of trial subjects are protected, and (ii) the FDA is able to validate the data from the trial through an on-site inspection, if necessary. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the U.S., the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering must be met. Many foreign regulatory authorities have similar approval requirements. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the U.S. or the applicable jurisdiction. If the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which could be costly and time-consuming, and which may result in drug candidates that we may develop not receiving approval for commercialization in the applicable jurisdictions.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our medicines and any future approved drug candidates will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our medicines and drug candidates.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our medicines and any additional drug candidates that are approved will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy, and other post-marketing information, including both federal and state requirements in the U.S. and requirements of comparable regulatory authorities in China, Europe and other regions. As such, we and our collaborators will be subject to ongoing review and periodic inspections to assess compliance with applicable post-approval regulations. Additionally, to the extent we want to make certain changes to the approved medicines, product labeling, or manufacturing processes, we will need to submit new applications or supplements to regulatory authorities for approval.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers and manufacturers&#8217; facilities are required to comply with extensive FDA, NMPA, EMA and comparable regulatory authority requirements, including, in the U.S., ensuring that quality control and manufacturing procedures conform to GMP regulations. As such, we and our contract manufacturers are and will be subject to continual review and inspections to assess compliance with GMP and adherence to commitments made in any NDA, BLA or other marketing application, and previous responses to any inspection observations. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. The failure to comply with these requirements could have a material adverse effect on our business. For example, in 2020, the NMPA suspended the importation, sales and use of ABRAXANE in China previously supplied to us by BMS, and the drug was subsequently recalled by BMS. This suspension was based on inspection findings at BMS&#8217;s contract manufacturing facility in the U.S.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory approvals for our medicines and any approvals that we receive for our drug candidates are and may be subject to limitations on the approved indicated uses for which the medicine may be marketed or to the conditions of approval, which could adversely affect the medicine&#8217;s commercial potential or contain requirements for potentially costly post-marketing testing and surveillance to monitor the safety and efficacy of the medicine or drug candidate. Failure to exhibit due diligence when conducting post-marketing requirements could result in withdrawal of approval for products. The FDA, NMPA, EMA or comparable regulatory authorities may also require a Risk Evaluation Mitigation Strategy (&#8220;REMS&#8221;) program or comparable program as a condition of approval of our drug candidates or following approval. In addition, if the FDA, NMPA, EMA or a comparable regulatory authority approves our drug candidates, we will have to comply with requirements including, for example, submissions of safety and other post-marketing information and reports, establishment registration, as well as continued compliance with GMP and GCP for any clinical trials that we conduct post-approval.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA, NMPA, EMA or comparable regulatory authorities may seek to impose a consent decree or withdraw marketing approval if compliance with regulatory requirements is not maintained or if problems occur after the drug reaches the market. Later discovery of previously unknown problems with our medicines or drug candidates or with our drug&#8217;s manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of our medicines, withdrawal of the product from the market, or voluntary or mandatory product recalls;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, untitled or warning letters, or holds on clinical trials;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal by the FDA, NMPA, EMA or comparable regulatory authorities to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals or withdrawal of approvals;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of our medicines and drug candidates; and</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA, NMPA, EMA and other regulatory authorities strictly regulate the marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for their approved indications and for use in accordance with the provisions of the approved label. The FDA, NMPA, EMA and other regulatory authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. The policies of the FDA, NMPA, EMA and of other regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our drug candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the U.S. or abroad, particularly in China, where the regulatory environment is constantly evolving. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any regulatory approval that we may have obtained and we may not achieve or sustain profitability.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if we obtain accelerated approval or conditional approval of any of our drug candidates, as we have done with the accelerated approval of BRUKINSA in the U.S. and China and certain approvals of tislelizumab, PARTRUVIX, XGEVA, BLINCYTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, KYPROLIS and QARZIBA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in China, we will be required to conduct a confirmatory study to verify the predicted clinical benefit and may also be required to conduct post-marketing safety studies. If we fail to conduct such studies in a timely manner or such studies fail to verify clinical benefit, such approval may be withdrawn. While operating under accelerated approval, we will be subject to certain restrictions that we would not be subject to upon receiving regular approval. For example, the FDA generally requires that all advertising and promotional materials be submitted to the FDA for review prior to dissemination or publication for products receiving accelerated approval, which could adversely impact the timing of the commercial launch of the product.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Undesirable adverse events caused by our medicines and drug candidates could interrupt, delay or halt clinical trials, delay or prevent regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following any regulatory approval.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undesirable adverse events (&#8220;AEs&#8221;) caused by our medicines and drug candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval, or could result in limitations or withdrawal following approvals. If the conduct or results of our trials or patient experience following approval reveal a high and unacceptable severity or prevalence of AEs, our trials could be suspended or terminated and regulatory authorities could order us to cease further development of, or deny approval of, our drug candidates or require us to cease commercialization following approval.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is typical in the development of pharmaceutical products, drug-related AEs and serious AEs (&#8220;SAEs&#8221;) have been reported in our clinical trials. Some of these events have led to patient deaths. Drug-related AEs or SAEs could affect patient recruitment or the ability of enrolled subjects to complete the trial and could result in product liability claims. Any of these occurrences may harm our reputation, business, financial condition and prospects significantly. In our periodic and current reports filed with the SEC and our press releases and scientific and medical presentations released from time to time, we disclose clinical results for our drug candidates, including the occurrence of AEs and SAEs. Each such disclosure speaks only as of the date of the data cutoff used in such report, and we undertake no duty to update such information unless required by applicable law. Also, a number of immune-related adverse events (&#8220;IRAEs&#8221;) have been associated with treatment with checkpoint inhibitors such as tislelizumab, including immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies, nephritis and renal dysfunction, skin adverse reactions, and encephalitis. These IRAEs may be more common in certain patient populations (potentially including elderly patients) and may be exacerbated when checkpoint inhibitors are combined with other therapies.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, undesirable side effects caused by our medicines and drug candidates, or caused by our medicines and drug candidates when used in combination with other drugs, could potentially cause significant negative consequences, including:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities could delay or halt pending clinical trials;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may suspend, delay or alter development of the drug candidate or marketing of the medicine;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw approvals or revoke licenses of the medicine, or we may determine to do so even if not required;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require additional warnings on the label;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to implement a REMS for the drug, as is the case with REVLIMID, or, if a REMS is already in place, to incorporate additional requirements under the REMS, or to develop a similar strategy as required by a regulatory authority;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to conduct post-marketing studies; and</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to subjects or patients.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of the particular drug or drug candidate, and could significantly harm our business, results of operations, financial condition, and prospects.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If safety, efficacy, or other issues arise with any medical product that is used in combination with our medicines, we may be unable to market such medicine or may experience significant regulatory delays or supply shortages, and our business could be materially harmed.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to develop certain of our medicines and drug candidates for use as a combination therapy. If a regulatory authority revokes its approval of the other therapeutic that we use in combination with our medicines or drug candidates, we will not be able to market our medicines or drug candidates in combination with such revoked therapeutic. If safety or efficacy issues arise with these or other therapeutics that we seek to combine with our medicines and drug candidates in the future, we may experience significant regulatory delays, and we may be required to redesign or terminate the applicable clinical trials. In addition, if manufacturing or other issues result in a supply shortage of any component of our combination medicines or drug candidates, we may not be able to complete clinical development of our drug candidates on our current timeline or at all, or we may experience disruptions in the commercialization of our approved medicines. For example, we have in-licensed drug candidates from third parties to conduct clinical trials in combination with our drug candidates. We may rely on those third parties to manufacture the in-licensed drug candidates and may not have control over their manufacturing process. If these third parties encounter any manufacturing difficulties, disruptions or delays and are not able to supply sufficient quantities of drug candidates, our drug combination study program may be delayed. For additional information, please see the section of this Annual Report titled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Risks Related to Our Reliance on Third Parties&#8212;We rely on third parties to manufacture some of our commercial and clinical drug supplies. Our business could be harmed if those third parties fail to comply with manufacturing regulations, provide us with insufficient quantities of product or provide product at unacceptable quality levels or prices.&#8221;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently enacted and future legislation and regulations may increase the difficulty and cost for us to obtain regulatory approval of and commercialize our medicines and drug candidates and affect the prices we may obtain.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., China, Europe and some other jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding healthcare that could prevent or delay regulatory approval of our drug candidates, restrict or regulate post-approval activities and affect our ability to profitably sell our medicines and any drug candidates for which we obtain regulatory approval. For example, the Creating and Restoring Equal Access to Equivalent Samples Act (CREATES Act), requires sponsors of approved new drug applications and biologics license applications to provide sufficient quantities of product samples on commercially reasonable, market-based terms to entities developing generic drugs and biosimilar biological products. The law establishes a private right of action allowing developers to sue application holders that refuse to sell them product samples needed to support their applications. If we are required to provide product samples or allocate additional resources to respond to such requests or any legal challenges under this law, our business could be adversely impacted. </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, proponents of drug reimportation may attempt to pass legislation that would directly allow reimportation under certain circumstances. For example, by Executive Order, the FDA works with states and Indian Tribes that propose to develop importation programs in accordance with the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. In January 2024, the FDA issued to Florida the first approval for a state importation plan and several states have pending applications with the FDA. If successfully implemented, importation of drugs from Canada may materially and adversely affect the price we receive for any of our product candidates. Legislation or regulations allowing the reimportation of drugs, if enacted, could decrease the price we receive for any products that we may develop and adversely affect our future revenues and prospects for profitability. We expect that healthcare reform measures may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved medicine. For additional information, please see the section of this Annual Report titled &#8220;Part I&#8212;Item 1&#8212;Business&#8212;Government Regulation&#8212;Healthcare Reform.&#8221;</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, changes to U.S. policy implemented by the U.S. Congress, the Trump administration or any new administration have impacted and may in the future impact, among other things, the U.S. and global economy, international trade relations, unemployment, immigration, healthcare, taxation, the U.S. regulatory environment, inflation and other areas. We cannot predict the initiatives or changes that may be adopted in the future or the impact, if any, they may have on our business. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect the demand for our product candidates, if we obtain regulatory approval; our ability to set a price that we believe is fair for our approved products; our ability to generate revenue and achieve or maintain profitability; the level of taxes that we are required to pay; and the availability of capital.</span></div><div id="ic94bd2152a214042a118e81881a5a1e5_82"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need for Additional Capital</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have historically incurred significant net losses and may incur net losses in the future.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment in pharmaceutical drug development is highly capital-intensive and speculative. It entails substantial upfront capital expenditures and significant risk that a drug candidate will fail to gain regulatory approval or become commercially viable. We continue to incur significant expenses related to our ongoing operations. As a result, we have incurred losses in most periods since our inception, other than periods when we were profitable due to revenue recognized from up-front license fees from collaboration agreements or the settlement of legal proceedings. As of December&#160;31, 2024, we had an accumulated deficit of $8.6 billion. Substantially all of our operating losses have resulted from costs incurred in connection with our research and development programs and from selling, general and administrative expenses associated with our operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we expect to achieve positive GAAP operating income for full year 2025 as product sales growth exceeds expense growth, we may incur losses in the future. We expect expenses to continue to increase as we continue to expand our development of, and seek regulatory approvals for, our drug candidates, and our manufacturing facilities, commercialize our medicines and launch new medicines, if approved, maintain and expand regulatory approvals, contribute up to $1.25 billion to the global development of a portfolio of Amgen pipeline assets under our collaboration agreement, and commercialize the medicines that we have in-licensed. In addition, we will continue to incur costs associated with operating as a public company. The size of any future net losses will depend, in part, on the number and scope of our drug development programs and the associated costs of those programs, the cost of our manufacturing activities, the cost of commercializing our approved products, our ability to generate revenues and the timing and amount of milestones and other payments we make or receive with arrangements with third parties. If we fail to achieve market acceptance for our medicines or if promising drug candidates fail in clinical trials or do not gain regulatory approval, or if approved, fail to achieve market acceptance, we may never become profitable. To the extent we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research, development, manufacturing and commercialization efforts, expand our business or continue our operations.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to obtain additional financing to fund our operations, and if we are unable to obtain such financing, we may be unable to complete the development of our drug candidates or achieve profitability.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of drug candidates will require the completion of clinical development, regulatory review, scale up and availability of manufacturing resources, significant marketing efforts and substantial investment before they can provide us with product sales revenue. Additionally, we are investing in the manufacturing and commercialization of our approved medicines. Our operations have consumed substantial amounts of cash since inception. Our operating activities used $0.1 billion, $1.2 billion and $1.5 billion of net cash during the years ended December&#160;31, 2024, 2023 and 2022, respectively. We recorded negative net cash flows from operating activities in 2024, 2023 and 2022 primarily due to our net losses of $0.6 billion, $0.9 billion and $2.0 billion, respectively. We cannot assure you that we will be able to generate positive cash flows from operating activities in the future.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since September 2017, we have generated revenues from the sale of medicines in China licensed from BMS, and since the fourth quarter of 2019, we have generated revenues from our internally developed medicines. These revenues are not yet sufficient to support our operations. Although it is difficult to predict our liquidity requirements, based upon our current operating plan, we believe that we have sufficient cash and cash equivalents to meet our projected operating requirements for at least the next 12 months. However, our existing cash and cash equivalents and potential future short-term investments may not be sufficient to enable us to complete all global development or launch all of our current medicines and drug candidates for the currently anticipated indications and to invest in additional programs. Accordingly, we may require further funding through public or private offerings, debt financing, collaboration and licensing arrangements or other sources.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our debt is primarily short-term in nature. As a result, we do not have many long-term commitments for funding. Our current debt also contains numerous financial and non-financial covenants, some of which include cross-default provisions that could require acceleration of repayment of loans in the event of default. Any acceleration may impact the Company&#8217;s ability to refinance debt obligations if an event of default occurs.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our liquidity and financial condition may be materially and adversely affected by negative net cash flows and our current debt structure, and we cannot assure you that we will have sufficient cash from other sources to fund our operations. If we resort to other financing activities to generate additional cash, we will incur financing costs and we cannot guarantee that we will be able to obtain the financing on terms acceptable to us, or at all, and if we raise financing by issuing further equity securities, your interest in our company may be diluted. If we are unable to raise capital when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or commercialization efforts. Our inability to obtain additional funding when we need it could seriously harm our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our shareholders, restrict our operations or require us to relinquish rights to our technologies or drug candidates.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek additional funding through a combination of equity offerings, debt financings, collaborations and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a holder of our shares. The incurrence of additional indebtedness or the issuance of certain equity securities could result in increased fixed payment obligations and could also result in certain additional restrictive covenants, such as limitations on our ability to incur additional debt or issue additional equity, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. In addition, issuance of additional equity securities, or the possibility of such issuance, may cause the market price of our shares to decline. In the event that we enter into collaborations or licensing arrangements in order to raise capital, we may be required to accept unfavorable terms, including relinquishing or licensing to a third party on unfavorable terms our rights to technologies or drug candidates that we otherwise would seek to develop or commercialize ourselves or potentially reserve for future potential arrangements when we might be able to achieve more favorable terms.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fluctuations in exchange rates could result in foreign currency exchange losses and could materially reduce the value of your investment.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur portions of our expenses, and derive revenues, in currencies other than the U.S. dollar or Hong Kong dollar, in particular, the RMB, the Euro, and Australian dollar. As a result, we are exposed to foreign currency exchange risk as our results of operations and cash flows are subject to fluctuations in foreign currency exchange rates. Fluctuations in currencies may be affected by, among other things, changes in political and economic conditions and the foreign exchange policies proposed or adopted by certain governments. We do not regularly engage in hedging transactions to protect against uncertainty in future exchange rates between particular foreign currencies and the U.S. dollar. Fluctuations in the value of the U.S. dollar against currencies in countries in which we operate could have a negative impact on our results of operations. We cannot predict the impact of foreign currency fluctuations, and foreign currency fluctuations in the future may adversely affect our financial condition, results of operations, and cash flows.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The value of the RMB against the U.S. dollar and other currencies may fluctuate and is affected by, among other things, changes in political and economic conditions and the foreign exchange policy proposed or adopted by the PRC, Australia and other governments. It is difficult to predict how market forces or PRC, Australia, other governments outside the U.S. and U.S. government policies may impact the exchange rate of the RMB and the U.S. dollar or any other currencies in the future. There remains significant international pressure on China to adopt a more flexible currency policy, including from the U.S. government, which has threatened to label China as a &#8220;currency manipulator,&#8221; which could result in greater fluctuation of the RMB against the U.S. dollar.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our revenues are denominated in U.S. dollars and RMB, our costs are denominated in U.S. dollars, Australian dollars and RMB, and a large portion of our financial assets and a significant portion of our debt is denominated in U.S. dollars and RMB. To the extent that we need to convert U.S. dollars into RMB for our operations, appreciation of the RMB against the U.S. dollar would have an adverse effect on the RMB amount we would receive. Conversely, if we decide to convert RMB into U.S. dollars for the purpose of making payments for dividends or for other business purposes, appreciation of the U.S. dollar against the RMB would have a negative effect on the U.S. dollar amount we would receive.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are limited instruments available for us to reduce our foreign currency risk exposure at reasonable costs. Furthermore, we are also currently required to obtain approval from or registration with appropriate government authorities or designated banks before converting significant sums of foreign currencies into RMB. All of these factors could materially and adversely affect our business, financial condition, results of operations, and prospects, and could reduce the value of, and any dividends payable on, our shares in foreign currency terms.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business, profitability and liquidity may be adversely affected by deterioration in the credit quality of, or defaults by, our distributors and customers or by actual events or concerns involving the liquidity, default, or non-performance of financial institutions, including the U.S. government, and an impairment in the carrying value of any short-term investments could negatively affect our consolidated results of operations.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our distributors and customers may default on their obligations to us as a result of bankruptcy, lack of liquidity, operational failure or other reasons. As we continue to expand our business, the amount and duration of our credit exposure will be expected to increase, as will the breadth of the entities to which we have credit exposure. Although we regularly review our credit exposure to specific distributors and customers that we believe may present credit concerns, default risks may arise from events or circumstances that are difficult to detect or foresee.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, actual events involving reduced liquidity, defaults, non-performance or other adverse developments that affect financial institutions, or concerns or rumors about any such events, have in the past and may in the future lead to market-wide liquidity problems. For example, in March 2023, Silvergate Bank, La Jolla, California, announced its decision to voluntarily liquidate its assets and wind down operations, Silicon Valley Bank, Santa Clara, California (&#8220;SVB&#8221;), was closed by the California Department of Financial Protection and Innovation, and Signature Bank, New York, New York, was closed by the New York State Department of Financial Services, and, in each case the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) was appointed as receiver. Since then, additional financial institutions have experienced similar failures and have been placed into receivership. These events lead to volatility and declines in the market for bank stock and questions regarding confidence in depository institutions. There is no guarantee that the federal government will guarantee depositors in the event of a future bank closure. Investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could adversely impact our ability to meet our operating expenses or result in breaches of our financial or contractual obligations which could have material adverse impact on our liquidity and our projected business operations, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of uncertain political, credit and financial market conditions, including the potential of the U.S. government to default on the payment of its obligations for a period of time due to federal debt ceiling limitations or other unresolved political issues, investments in financial instruments issued or guaranteed by the U.S. government pose credit default and liquidity risks. A payment default or delay by the U.S. government, or continued uncertainty surrounding the U.S. debt ceiling, could result in a variety of adverse effects for financial markets, market participants and U.S. and global economic conditions. In addition, U.S. debt ceiling and budget deficit concerns have increased the possibility a downgrade in the credit rating of the U.S. government and could result in economic slowdowns or a recession in the U.S. No assurance can be made that losses or significant deterioration in the fair value of our U.S. government issued or guaranteed investments will not occur. At December&#160;31, 2024, we had approximately $1.0&#160;billion invested in government money market funds. Downgrades to the U.S. credit rating could affect the stability of securities issued or guaranteed by the U.S. government and the valuation or liquidity of our portfolio of such investment securities. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and cash equivalents, restricted cash and short-term investments represent the maximum amount of loss due to credit risk. We had no short-term investments, cash and cash equivalents of $2.6 billion and restricted cash of $11.3 million as of December&#160;31, 2024, most of which are deposited in financial institutions outside of China. As required by the PRC securities laws, the net proceeds from our offering on the STAR Market of the Shanghai Stock Exchange (the &#8220;STAR Offering&#8221;) must be used in strict compliance with the planned uses as disclosed in the PRC prospectus for the STAR Offering as well as our proceeds management policy for the STAR Offering approved by our board of directors. Although our cash and cash equivalents in China are deposited with various major reputable financial institutions, the deposits placed with these financial institutions are not protected by statutory or commercial insurance. In the event of bankruptcy of one of these financial institutions, we may be unlikely to claim our deposits back in full.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we held no short-term investments. To the extent we invest in U.S. Treasury securities as short-term investments in the future, although we believe that such securities are of high credit quality and continually monitor the credit worthiness of these institutions, concerns about, or a default by, one institution in the U.S. market, could lead to significant liquidity problems, losses or defaults by other institutions, which in turn could adversely affect us.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to meet responsible business and sustainability expectations or standards or achieve our corporate strategy goals could adversely affect our business, results of operations, financial condition or stock price.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been focus from global regulators and stakeholders on responsible business and sustainability matters, including greenhouse gas emissions and climate-related risks; human capital management; responsible sourcing and supply chain; human rights and social responsibility; and corporate governance and oversight. As part of our long-term strategy and in-line with safeguarding sustainable value growth, we actively manage these issues. We have identified key strategic priorities and set goals that reflect our current plans and aspirations and cannot guarantee that we will be able to achieve them. Evolving stakeholder expectations and our efforts and ability to manage these issues and goals present numerous operational, regulatory, reputational, financial, legal, and other risks, any of which may be outside of our control or could have a material adverse impact on our business, including on our stock price. Further, there is uncertainty around the accounting standards and climate-related disclosures associated with emerging sustainability laws and reporting requirements and the related costs to comply with the emerging regulations. Our failure or perceived failure to achieve our sustainability goals or comply with sustainability-related regulations could expose us to increased scrutiny from the investment community and enforcement authorities. Our reputation also may be harmed by the perceptions that our stakeholders have about our action or inaction on these sustainability issues.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain patent protection for our medicines and drug candidates, we may lose market exclusivities in our medicines.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in large part on our ability to protect our valuable innovations including medicines, drug candidates and proprietary technologies by obtaining, maintaining and enforcing our intellectual property rights, including patent rights. We seek to protect our innovations that we consider commercially important by filing patent applications in the U.S., the PRC, Europe and other territories, or relying on trade secrets or regulatory exclusivities.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, filing, prosecuting and maintaining patents/patent applications in all countries worldwide could be prohibitively expensive. As the patent laws of different countries vary, our patent applications may not be granted in all countries and the issued patents may have various scope and enforceabilities. In addition, different countries may provide varying regulatory exclusivities to pharmaceutical drugs, and some countries provide no regulatory exclusivities. Consequently, we may not have the same patent protection or exclusivities to our medicines or drug candidates in all countries worldwide. Further, given the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting such drug candidates might expire before or shortly after such drug candidates are commercialized. As a result, our patents and patent applications may not provide us with sufficient length of exclusivities to our medicines or drug candidates. The issued patents and pending patent applications, if issued, for our medicines and drug candidates are expected to expire on various dates as described in &#8220;Part I&#8212;Item 1&#8212;Business&#8212;Intellectual Property&#8221; of this Annual Report. Upon expiration, we may no longer have exclusivities on the corresponding medicines or drug candidates.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, issued patents may be invalidated for a number of reasons, including but not limited to known or unknown prior art, deficiencies in the patent applications or the lack of novelty or inventive step of the underlying invention or technology. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have been and may further become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming and unsuccessful. Our patent rights relating to our medicines and drug candidates could be found invalid, unenforceable or not infringed by a court or government patent authorities.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may infringe, misappropriate or otherwise violate our intellectual property rights. Litigation may be necessary to enforce or defend our intellectual property rights or to protect our trade secrets. This can be expensive and time consuming. The third parties may also challenge the validity or enforceability of our patents.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When a generic drug company files an Abbreviated New Drug Application (&#8220;ANDA&#8221;) with the FDA seeking approval to market a generic version of any of our products before the expiration of Orange Book listed patents (&#8220;OB Patents&#8221;) covering such products, this will most likely trigger ANDA litigation. For example, on March 8, 2024, our subsidiaries, BeiGene USA, Inc. and BeiGene Switzerland GmbH, filed patent infringement suits against Sandoz Inc. (&#8220;Sandoz&#8221;), and MSN Pharmaceuticals, Inc. and MSN Laboratories Private Ltd. (collectively &#8220;MSN&#8221;), in the U.S. District Court for the District of New Jersey, in response to Sandoz&#8217;s and MSN&#8217;s notices informing their filings of ANDAs with the FDA regarding BRUKINSA. For additional information on this litigation, please see the section of this Annual Report titled &#8220;Legal Proceedings&#8221;. The success of ANDA litigation depends on the strength of the OB Patents and our ability to prove infringement. The outcome of ANDA litigation is inherently uncertain and may result in potential loss of market exclusivity for our products which may have a significant financial impact on product revenue. </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The scope, validity or enforceability of our or our collaborators&#8217; patents may be challenged in court or other authorities, and we or they may not be successful in enforcing or defending those intellectual property rights and, as a result, may not be able to develop or market the relevant product exclusively, which would have a material adverse effect on any potential sales of that product. As such, any issued patents may not protect us from generic or biosimilar competition for these medicines. Specifically, in patent litigation, defendants often challenge the validity and/or enforceability of the asserted patents, and there are numerous potential grounds upon which a patent can be found invalid and/or unenforceable. The validity of a patent can also be challenged before administrative bodies in the U.S. or abroad, even outside the context of litigation. Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover and protect our medicines or drug candidates. The outcome of such proceedings is inherently uncertain and may result in losing the patent protection on our medicines or drug candidates. Such a loss of patent protection could have a material adverse impact on our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lawsuits alleging infringing of intellectual property rights of third parties could be costly and time consuming and could prevent or delay us from developing or commercializing our medicines or drug candidates.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We respect third parties&#8217; valid intellectual property rights and diligently manage any freedom to operate risks associated with our medicines and drug candidates. Nevertheless, we bear the risk that we may be sued by third parties for patent infringement. We are aware of numerous issued patents and pending patent applications belonging to third parties that exist in fields of our medicines and drug candidates. There may also be third-party patents or patent applications of which we are currently unaware, and given the dynamic area in which we operate, additional patents are likely to be issued that relate to aspects of our business. There is a substantial amount of litigation and other claims and proceedings involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries generally. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our medicines and drug candidates may give rise to claims of infringement of the patent rights of others.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, on June 13, 2023, Pharmacyclics LLC (&#8220;Pharmacyclics&#8221;) filed a complaint in the U.S. District Court for the District of Delaware against us and one of our subsidiaries, alleging that BRUKINSA infringes a Pharmacyclics&#8217; patent issued on June 13, 2023. For additional information on this litigation, please see the section of this Annual Report titled &#8220;Legal Proceedings&#8221;. Defense of these claims, regardless of their merit, could involve substantial litigation expense and divert our technical personnel, management personnel, or both from their normal responsibilities.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If third parties bring successful claims against us for infringement of their intellectual property rights, we may be subject to injunctive or other equitable relief, which could prevent us from developing and commercializing one or more of our medicines and drug candidates. In the event of a successful claim against us of infringement or misappropriation, or a settlement by us of any such claims, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees in the case of willful infringement, pay royalties or redesign our infringing medicines and drug candidates, which may be impossible or require substantial time and cost.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even in the absence of litigation, we may seek to obtain licenses from third parties to mitigate freedom to operate risks and as a result, could impose costly royalty and other fees and expenses on us.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. We may also be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of others.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our issued patent and pending patent applications, we rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position and to protect our medicines and drug candidates. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties that have access to them, such as our employees, corporate collaborators, outside scientific collaborators, sponsored researchers, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. However, any of these parties may breach such agreements and disclose our proprietary information, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive and time- consuming, and the outcome is unpredictable. If any of our trade secrets were lawfully obtained or independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete with us and our competitive position would be harmed.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, many of our employees, including our senior management, were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these employees executed proprietary rights, non-disclosure and in some cases non-competition agreements in connection with their previous employment. Our employees may also have access to trade secrets of our collaboration partners. Although we try our best to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these employees have misappropriated trade secrets or other proprietary information, of any such employees&#8217; former employers. For example, in September 2024, AbbVie filed a lawsuit alleging misappropriation of certain trade secrets concerning our Bruton&#8217;s tyrosine kinase degrader program, including lead compound BGB-16673. Defending against such claims, regardless of their merit, could result in substantial costs and be a distraction to management. If we fail in defending any such claims, we may need to pay monetary damages and lose valuable intellectual property rights.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Reliance on Third Parties</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to manufacture some of our commercial and clinical drug supplies. Our business could be harmed if those third parties fail to comply with manufacturing regulations, provide us with insufficient quantities of product or provide product at unacceptable quality levels or prices.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we manufacture commercial supply of tislelizumab, zanubrutinib, and pamiparib at our manufacturing facilities in China, and recently opened our commercial-stage biologics manufacturing and clinical R&amp;D center in New Jersey and a new small molecule manufacturing campus in Suzhou, China, we continue to rely on outside vendors to manufacture supplies and process some of our medicines and drug candidates. For example, we have entered into a commercial supply agreement for tislelizumab with Boehringer Ingelheim Biopharmaceuticals (China) Ltd. (&#8220;Boehringer Ingelheim&#8221;) and entered into a commercial supply agreement for BRUKINSA with Catalent Pharma Solutions, LLC (&#8220;Catalent&#8221;). In addition, we generally rely on our collaboration partners and their third-party manufacturers for supply of in-licensed medicines in China. We have limited experience in manufacturing or processing our medicines and drug candidates on a commercial scale. Additionally, we have limited experience in managing the manufacturing process, and our process may be more difficult or expensive than the approaches currently in use.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on a limited number of third-party manufacturers exposes us to the following risks:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and regulatory authorities must evaluate and/or approve any manufacturers as part of their regulatory oversight of our medicines and drug candidates;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our manufacturers may have little or no experience with manufacturing our medicines and drug candidates, and therefore may require a significant amount of support from us to implement and maintain the infrastructure and processes required to manufacture our medicines and drug candidates;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our third-party manufacturers might be unable to timely manufacture our medicines and drug candidates or produce the quantity and quality required to meet our clinical and commercial needs, if any;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturers are subject to initial and ongoing periodic unannounced inspection by the FDA and corresponding state agencies in the U.S. to ensure strict compliance with GMP requirements, chain of distribution requirements and other government regulations and by other comparable regulatory authorities for corresponding non-U.S. requirements. Manufacturers may be unable to comply with these GMPs which may result in fines and civil penalties, suspension of production, suspension, delay or withdrawal of product approval, product liability claims, product seizure or recall and enforcement actions, including injunctions and criminal or civil prosecution;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not own, or may have to share, the intellectual property rights to some of the technology used and improvements made by our third-party manufacturers in the manufacturing process for our medicines and drug candidates;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">raw materials and components used in the manufacturing process, particularly those for which we have no other source or supplier, may not be available or may not be suitable or acceptable for use due to material or component defects;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our contract manufacturers and drug component suppliers may be subject to disruptions in their business, including unexpected demand for or shortage of raw materials or components, cyber-attacks on supplier systems, labor disputes or shortage and inclement weather, as well as natural or man-made disasters or pandemics; and</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing partners may require us to fund capital improvements to support scale-up of manufacturing and related activities to the extent our drug candidates or medicines become approved for commercial sale.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in March 2020, the NMPA suspended the importation, sales and use of ABRAXANE in China previously supplied to us by BMS, and the drug was subsequently recalled by BMS. This suspension was based on inspection findings at BMS&#8217;s contract manufacturing facility in the U.S. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these risks could delay or prevent the completion of our clinical trials or the approval of any of our drug candidates, result in higher costs or adversely impact development of our drug candidates or commercialization of our medicines. In addition, we will rely on third parties to perform certain specification tests on our medicines and drug candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable, patients could be put at risk of serious harm and regulatory authorities could place significant restrictions on our company until deficiencies are remedied.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, the raw materials for our manufacturing activities are supplied by multiple source suppliers, although portions of our supply chain may rely on sole source suppliers. We have agreements for the supply of drug materials with manufacturers or suppliers that we believe have sufficient capacity to meet our demands. In addition, we believe that adequate alternative sources for such supplies exist. However, there is a risk that, if supplies are interrupted, it would materially harm our business.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers of drug and biological products often encounter difficulties in production, particularly in scaling up or out, validating the production process, and assuring high reliability of the manufacturing process (including the absence of contamination). These problems include logistics and shipping, difficulties with production costs and yields, quality control, including stability of the product, product testing, operator error, availability of qualified personnel, as well as compliance with strictly enforced federal, state and non-U.S. regulations. Furthermore, if contaminants are discovered in the supply of our medicines and drug candidates or in the manufacturing facilities, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We cannot assure you that any stability failures or other issues relating to the manufacture of our medicines and drug candidates will not occur in the future. Additionally, our manufacturers may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable political environments. If our manufacturers were to encounter any of these difficulties, or otherwise fail to comply with their contractual obligations, our ability to provide our medicines for commercial sale and our drug candidates to patients in clinical trials would be jeopardized. Any delay or interruption in the supply of clinical trial supplies could delay the completion of clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to begin new clinical trials at additional expense or terminate clinical trials completely.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have entered into licensing and collaboration arrangements and may enter into additional collaborations, licensing arrangements, or strategic alliances in the future, and we may not realize the benefits of such arrangements.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into licensing and collaboration agreements and may enter into additional collaboration, licensing arrangements, or strategic alliances with third parties that we believe will complement or augment our research, development and commercialization efforts. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing shareholders, or disrupt our management and business.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in 2019, we entered into a strategic collaboration with Amgen with respect to its commercial-stage oncology products XGEVA, BLINCYTO and KYPROLIS and a portfolio of clinical- and late-preclinical-stage oncology pipeline products. In 2021, we entered into a collaboration and license agreement with Novartis Pharma AG (&#8220;Novartis&#8221;), granting Novartis rights to develop, manufacture and commercialize our anti-PD-1 antibody tislelizumab in certain territories, but that agreement was terminated in September 2023 and we regained full, global rights to develop, manufacture and commercialize tislelizumab. In December 2021, we entered into an option, collaboration and license agreement with Novartis to develop, manufacture and commercialize our investigational TIGIT inhibitor, ociperlimab, in North America, Europe, and Japan, terminated that agreement in July 2023 and regained full, global rights to develop, manufacture and commercialize ociperlimab. In December 2024, we entered into a global licensing agreement with CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. for a methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategic collaborations involve numerous risks. We may not achieve the revenue and cost synergies expected from our collaborations, and our management&#8217;s attention may be diverted from our drug discovery and development business. These synergies are inherently uncertain, and are subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and are beyond our control. If we achieve the expected benefits, they may not be achieved within the anticipated time frame. Additionally, strategic collaborations can be terminated for various reasons, including future acquisitions.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face significant competition in seeking appropriate strategic partners, and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic collaboration for our medicines and drug candidates because they may be deemed to be at too early of a stage of development for collaborative effort. If and when we collaborate with a third-party for development and commercialization of a medicine or drug candidate, we can expect to relinquish some or all of the control over the future success of that medicine or drug candidate to the third-party. For any medicines or drug candidates that we may seek to in-license from third parties, we may face significant competition from other pharmaceutical or biotechnology companies with greater resources or capabilities than us, and any agreement that we do enter may not result in the anticipated benefits.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaborations involving our medicines and drug candidates are subject to numerous risks, which may include the following:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators have significant discretion in determining the efforts and resources that they will apply to a collaboration;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not pursue development and commercialization of our drug candidates and medicines or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in their strategic focus due to the acquisition of competitive drugs, availability of funding, or other external factors, such as a business combination that diverts resources or creates competing priorities;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial, stop a clinical trial, abandon a drug candidate, repeat or conduct new clinical trials, or require a new formulation of a drug candidate for clinical testing;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators could independently develop, or develop with third parties, drugs that compete directly or indirectly with our medicines or drug candidates;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a collaborator with marketing and distribution rights to one or more medicines may not commit sufficient resources to their marketing and distribution or may set prices that reduce the profitability of the medicines;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disputes may arise between us and a collaborator that cause the delay or termination of the research, development or commercialization of our medicines and drug candidates, or that result in costly litigation or arbitration that diverts management attention and resources; and</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">collaborators may own or co-own intellectual property covering our medicines and drug candidates that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual property.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As a result, we may not be able to realize the benefit of current or future collaborations, licensing arrangements or strategic alliances if we are unable to successfully integrate products with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction or license, we will be able to fulfill all of our contractual obligations in a timely manner or achieve the revenue, specific net income or other goals that justify such transaction. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a drug candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain an effective distribution channel for our medicines, our business and sales could be adversely affected.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party distributors to distribute our approved medicines. For example, we rely on sole third-party distributors to distribute some of our in-licensed approved medicines in China and multiple third-party distributors for the distribution of our internally developed medicines. We also expect to rely on third-party distributors to distribute our other internally developed and in-licensed medicines, if approved. Our ability to maintain and grow our business will depend on our ability to maintain an effective distribution channel that ensures the timely delivery of our medicines. However, we have relatively limited control over our distributors, who may fail to distribute our medicines in the manner we contemplate. If price controls or other factors substantially reduce the margins our distributors can obtain through the resale of our medicines to hospitals, medical institutions and sub-distributors, they may terminate their relationship with us. While we believe alternative distributors are readily available, there is a risk that, if the distribution of our medicines is interrupted, our sales volumes and business prospects could be adversely affected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to successfully develop and/or commercialize Amgen&#8217;s oncology products, the expected benefits of the collaboration will not materialize.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Amgen pursuant to which we and Amgen have agreed to collaborate on the commercialization of Amgen&#8217;s oncology products XGEVA, BLINCYTO and KYPROLIS in China, and the global development and commercialization in China of a portfolio of Amgen&#8217;s clinical- and late-preclinical-stage pipeline products. Amgen has paused or stopped development of some of the pipeline assets due to portfolio prioritization, and the parties expect that the development plan for the pipeline assets will continue to evolve over time. In connection with our ongoing assessment of the collaboration agreement cost-share contributions, we determined that our further investment in the development of LUMAKRAS (sotorasib) (&#8220;AMG 510&#8221;), a first-in-class KRAS G12C inhibitor, was no longer commercially viable for BeiGene. As a result, in February 2023, we entered into an amendment to the collaboration agreement to (i) stop sharing costs with Amgen for the further development of AMG 510 during the period starting January 1, 2023 and ending August 31, 2023; and (ii) cooperate in good faith to prepare a transition plan with the termination of AMG 510 from the Amgen Collaboration Agreement. Additionally, for the period between 2020 and 2022, we were advised by Amgen that its applications to the Human Genetic Resources Administration of China (&#8220;HGRAC&#8221;) to obtain approval to conduct clinical studies in China for the pipeline assets were delayed. Approval from the HGRAC is required for the initiation of clinical trials involving the collection of human genetic materials in China. We do not expect the previous HGRAC delay to affect the conduct of the clinical trials in China for our drug candidates. The Amgen collaboration involves numerous risks, including unanticipated costs and diversion of our management&#8217;s attention from our other drug discovery and development business. There can be no assurance that we will be able to successfully develop and commercialize Amgen&#8217;s oncology products in China, which could disrupt our business and harm our financial results.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may rely on third parties to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our medicines and drug candidates and our business could be substantially harmed.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relied upon and plan to continue to rely to some extent upon third-party CROs to monitor and manage data and provide other services for our ongoing preclinical and clinical programs. We may rely on these parties for execution of our preclinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities. We, our CROs for our clinical programs and our clinical investigators are required to comply with GCPs, which are regulations and guidelines enforced by regulatory authorities for all of our drug candidates in clinical development. If we or any of our CROs or clinical investigators fail to comply with applicable GCPs and other regulatory requirements, the clinical data generated in our clinical trials may be deemed unreliable and regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. In addition, our pivotal clinical trials must be conducted with drug product produced under GMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. We could also be subject to government investigations and enforcement actions.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. In addition, our CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our ongoing clinical and nonclinical programs. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they or our clinical investigators obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our drug candidates. As a result, our results of operations and the commercial prospects for our drug candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Switching or adding additional CROs involves additional cost and delays, which can materially influence our ability to meet our desired clinical development timelines. There can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse effect on our business, financial condition and prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Industry, Business and Operations</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have significantly increased and expect to continue to increase our research, development, manufacturing, and commercial capabilities, and we may experience difficulties in managing our growth.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the beginning of 2024, we had approximately 10,500 employees, and we ended the year with over 11,000 employees, an increase of approximately 5%. As of the date of this Annual Report, we had over 11,000 employees. As our research, development, manufacturing and commercialization plans and strategies evolve, we must add a significant number of additional managerial, operational, drug development, clinical, regulatory affairs, manufacturing, sales, marketing, financial and other personnel in the U.S., China, Europe and other regions. Our recent growth and any anticipated future growth will impose significant added responsibilities on members of management, including: identifying, recruiting, integrating, maintaining, and motivating additional employees; managing the growth in our research, clinical operations, commercial, and supporting functions; and improving our operational, financial and management controls, reporting systems and procedures. Our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely, and for the foreseeable future will continue to rely, on certain independent organizations, advisors and consultants to provide certain services. There can be no assurance that the services of these independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, if at all. If we are not able to effectively manage our growth and further expand our organization by hiring new employees and expanding our groups of consultants and contractors as needed, we may not be able to successfully implement the tasks necessary to further develop, manufacture and commercialize our medicines and drug candidates and, accordingly, may not achieve our research, development, manufacturing and commercialization goals.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we have invested, and are investing significant time, resources and capital into the expansion of our facilities, including the creation of additional capacity at our Guangzhou and Suzhou manufacturing facilities and the construction of our Hopewell facility. If actual demand for our medicines does not meet our future projections, we will likely incur increased costs related to idle capacity including, but not limited to, acceleration of the timing of depreciation or impairment charges, which may adversely affect our financial condition and results of operations.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Xiaodong Wang, Ph.D., our Co-Founder, Chairman of our scientific advisory board, and director; John V. Oyler, our Co-Founder, Chief Executive Officer and Chairman of the board of directors; Xiaobin Wu, Ph.D., our President and Chief Operating Officer; Aaron Rosenberg, our Chief Financial Officer; and the other principal members of our management and scientific teams play a critical role in the Company&#8217;s operations and development. Although we have employment agreements or offer letters with each of our executive officers, these agreements do not prevent our executives from terminating their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided share option, restricted share unit and restricted share grants that vest over time or based on performance conditions. The value to employees of these equity grants that may be significantly affected by movements in our share price that are beyond our control and may be insufficient to counteract more lucrative offers from other companies. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating and executing our discovery, clinical development, manufacturing and commercialization strategy. The loss of the services of our executive officers or other key employees and consultants could impede the achievement of our research, development, manufacturing and commercialization objectives and seriously harm our ability to successfully implement our business strategy.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, replacing executives, key employees or consultants may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel or consultants on acceptable terms, given the competition among numerous pharmaceutical and biotechnology companies for similar personnel.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is subject to complex and evolving industry-specific laws and regulations regarding the collection and transfer of personal data. These laws and regulations can be stringent and many are subject to change and uncertain interpretation, which could result in claims, changes to our data and other business practices, significant penalties, increased cost of operations, or otherwise adversely impact our business.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities around the world have implemented industry-specific laws and regulations that affect the collection and transfer of personal data. For example, in China, the Regulation on the Administration of Human Genetic Resources (&#8220;HGR&#8221; and, such regulation, the &#8220;HGR Regulation&#8221;) applies to activities that involve sampling, biobanking, use of HGR materials and associated data, in China, and provision of such materials to non-PRC parties. The HGR Regulation prohibits both onshore or offshore entities established or actually controlled by non-PRC entities and individuals from sampling or biobanking any China HGR in China and require approval for the sampling of certain HGR and biobanking of all HGR by Chinese parties. Approval for any export or cross-border transfer of HGR material is required, and transfer of China HGR data by Chinese parties to non-PRC parties or entities established or actually controlled by them also requires the Chinese parties to file, before the transfer, a copy of the data to the HGR administration for record. The HGR Regulation also requires that non-PRC parties ensure the full participation of Chinese parties in international collaborations and all records and data must be shared with the Chinese parties. The Implementing Rules for the HGR Regulation and additional issued guidance has clarified many areas of the HGR Regulation. For information about applications under the HGR Regulation for clinical studies in China that may affect the Amgen collaboration, see the risk factor titled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;If we are not able to successfully develop and/or commercialize Amgen&#8217;s oncology products, the expected benefits of the collaboration will not materialize.&#8221;</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Cyberspace Administration of China (&#8220;CAC&#8221;) released the final Measures of Cross-Border Data Transfer Security Assessment, effective as of September 2022, under which any transfer of certain &#8220;important data&#8221; out of China triggers a security assessment to be conducted by the Chinese government. The term &#8220;important data&#8221; is a broadly defined term under the Cybersecurity Law and Data Security Law, and further clarifications need to be put in place by the Chinese government. However, under the latest draft Information Security Technology &#8211; Guideline for Identification of Critical Data, HGR data is classified as &#8220;important data,&#8221; and if the guidance is finalized as is, it can be expected that this new cross-border data transfer rule may create considerable additional regulatory burdens on international companies&#8217; human gene-involved R&amp;D activities in China.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Chinese parties fail to comply with data protection laws, regulations and practice standards, and our research data is obtained by unauthorized persons, used or disclosed inappropriately or destroyed, it could result in a loss of our confidential information and subject us to litigation and government enforcement actions. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our or our collaborators&#8217; practices, potentially resulting in suspension of relevant ongoing clinical trials or the initiation of new trials, confiscation of HGR samples and associated data and administrative fines, disgorgement of illegal gains, or temporary or permanent debarment of our or our collaborators&#8217; entities and responsible persons from further HGR projects and, consequently, a de-facto ban from initiating new clinical trials in China. So far, the HGR administration has disclosed a number of HGR violation cases.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To further enhance the administration of China HGR, in 2021, the Chinese government adopted amendments to the Criminal Code, which criminalize the illegal collection of China HGR, the illegal transfer of China HGR materials outside of China, and the transfer of China HGR data to non-PRC parties or entities established or actually controlled by them without going through security review and assessment. Also in 2021, the PRC Biosecurity Law became effective. The PRC Biosecurity Law establishes an integrated system to regulate biosecurity-related activities in China, including the security regulation of HGR and biological resources. The PRC Biosecurity Law for the first time expressly declared that China has sovereignty over its HGR and further endorsed the HGR Regulation by recognizing the fundamental regulatory principles and systems established by it over the utilization of Chinese HGR by foreign entities in China. Although the Biosecurity Law does not provide any specific new regulatory requirements on HGR, as it is a law adopted by China&#8217;s highest legislative authority, it gives the National Health Commission, China&#8217;s major regulatory authority of HGR, significantly more power and discretion to regulate HGR and it is expected that the overall regulatory landscape for Chinese HGR will continue to evolve and become even more rigorous. In addition, the interpretation and application of data protection laws in China are often uncertain and in flux.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that these areas will receive greater and continued attention and scrutiny from regulators and the public going forward, which could increase our compliance costs and subject us to heightened risks and challenges associated with data security and protection. If we are unable to manage these risks, we could become subject to significant penalties, including fines, suspension of business and revocation of required licenses, and our reputation and results of operations could be materially and adversely affected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We manufacture some of our medicines and intend to manufacture some of our drug candidates, if approved. Failure to comply with regulatory requirements could result in sanctions being imposed against us and delays in receiving regulatory approvals for our manufacturing facilities, or damage to, destruction of or interruption of production at such facilities, could delay our development plans or commercialization efforts.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have multiple manufacturing facilities in China. We recently opened our commercial-stage biologics manufacturing and clinical R&amp;D center in New Jersey and a new small molecule manufacturing campus in Suzhou, China. These facilities may encounter unanticipated delays and expenses in startup operations due to a number of factors, including regulatory requirements. If expansion, regulatory evaluation and/or approval of our facilities are delayed, we may not be able to manufacture sufficient quantities of our medicines and drug candidates, which would limit our development and commercialization activities and our opportunities for growth. Cost overruns associated with constructing or maintaining our facilities could require us to raise additional funds from other sources.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the similar manufacturing risks described in &#8220;Risks Related to Our Reliance on Third Parties,&#8221; our manufacturing facilities are subject to inspection in connection with clinical development and new drug approvals and ongoing, periodic inspection by the FDA, NMPA, EMA or other comparable regulatory agencies to ensure compliance with GMP and other regulatory requirements. Historically, some manufacturing facilities in China have had difficulty meeting the FDA&#8217;s, NMPA&#8217;s or EMA&#8217;s standards. Our failure to follow and document our adherence to such GMP regulations or other regulatory requirements may lead to significant delays in the availability of products for clinical or commercial use, may result in the termination of or a hold on a clinical trial, or may delay or prevent filing or approval of marketing applications for our drug candidates or the commercialization of our medicines. We also may encounter problems with achieving adequate or clinical-grade materials that meet FDA, NMPA, EMA or other comparable regulatory agency standards or specifications with consistent and acceptable production yield and costs, as well as shortages of qualified personnel, raw materials or key contractors.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with applicable regulations could also result in sanctions being imposed on us, including fines, injunctions, civil penalties, a requirement to suspend or put on hold one or more of our clinical trials, failure of regulatory authorities to grant marketing approval of our drug candidates, delays, suspension or withdrawal of approvals, supply disruptions, license revocation, seizures or recalls of drug candidates or medicines, operating restrictions and criminal prosecutions, any of which could harm our business.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To supply commercial quantities for our marketed products, produce our medicines in the quantities that we believe will be required to meet anticipated market demand, and to supply clinical drug material to support the continued growth of our clinical programs, we will need to increase, or &#8220;scale up,&#8221; the production process by a significant factor over the initial level of production, which will require substantial additional expenditures and various regulatory approvals and permits. If we are unable to do so, are delayed, or if the cost of this scale up is not economically feasible for us or we cannot find a third-party supplier, we may not be able to produce our medicines in a sufficient quantity to meet future demand. Furthermore, developing advanced manufacturing techniques and process controls is required to fully utilize our facilities. Advances in manufacturing techniques may render our facilities and equipment inadequate or obsolete.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our manufacturing facilities or the equipment in them is damaged or destroyed, we may not be able to quickly or inexpensively restore our manufacturing capacity or restore it at all. In the event of a temporary or protracted loss of the facilities or equipment, we might not be able to transfer manufacturing to a third party. Even if we could transfer manufacturing to a third party, the shift would likely be expensive and time-consuming, particularly since the new facility would need to comply with the necessary regulatory requirements and we would need regulatory agency approval before selling any medicines manufactured at that facility. Any interruption in manufacturing operations at our manufacturing facilities could result in our inability to satisfy the demands of our clinical trials or commercialization. Any disruption that impedes our ability to manufacture our drug candidates or medicines in a timely manner could materially harm our business, financial condition and operating results.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, we maintain insurance coverage against damage to our property, plant and equipment in amounts we believe are reasonable. However, our insurance coverage may not reimburse us, or may not be sufficient to reimburse us, for any expenses or losses we may suffer. We may be unable to meet our requirements for our drug candidates and medicines if there were a catastrophic event or interruption or failure of our manufacturing facilities or processes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to compliance requirements, including establishing and maintaining internal controls over financial reporting. We may be exposed to potential risks if we are unable to comply with these requirements.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company listed in the U.S., Hong Kong and Shanghai, we are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and the listing rules of the Nasdaq Global Select Market (&#8220;Nasdaq&#8221;), The Stock Exchange of Hong Kong Limited (the &#8220;HKEx&#8221;) and the STAR Market of the Shanghai Stock Exchange (the &#8220;SSE&#8221;), and incur significant legal, accounting and other expenses to comply with applicable requirements. These rules impose various requirements on public companies, including requiring certain corporate governance practices. Our management and other personnel devote a substantial amount of time to these requirements. Moreover, these rules and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costly.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the Sarbanes-Oxley Act of 2002 (the &#8220;Sarbanes-Oxley Act&#8221;) requires, among other things, that we maintain effective internal controls for financial reporting and disclosure controls and procedures. In particular, we must perform system and process evaluations and testing of our internal controls over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act. Such compliance may require that we incur substantial accounting expenses and expend significant management efforts. Our testing may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses. In the event we identify significant deficiencies or material weaknesses in our internal controls that we cannot remediate in a timely manner, the market price of our shares could decline if investors and others lose confidence in the reliability of our financial statements, we could be subject to sanctions or investigations by the SEC, HKEx, CSRC, SSE or other applicable regulatory authorities, and our business could be harmed.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we engage in acquisitions or strategic collaborations, this may increase our capital requirements, dilute our shareholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may evaluate various acquisitions and strategic collaborations, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any completed, in-process or potential acquisition or strategic collaboration may entail numerous risks, including:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased operating expenses and cash requirements;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the assumption of additional indebtedness or contingent or unforeseen liabilities;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issuance of our equity securities;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the diversion of our management&#8217;s attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing drugs or drug candidates and regulatory approvals, including applicable antitrust and trade regulation laws in the relevant U.S. and foreign jurisdictions in which we or the operations or assets we seek to acquire carry on business; and</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if we undertake acquisitions or strategic collaborations, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. For example, in connection with our transaction with Amgen, we issued to Amgen a total of 206,635,013 ordinary shares in the form of ADSs in 2020, representing 20.5% of the then issued share capital of the Company after giving effect to the share issuance, which resulted in Amgen becoming our largest shareholder and the ownership of our existing shareholders being diluted.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PRC regulations and rules concerning mergers and acquisitions, including the Regulations on Mergers and Acquisitions of Domestic Companies by Foreign Investors (the &#8220;M&amp;A Rules&#8221;), have established additional procedures and requirements that could make merger and acquisition activities by foreign investors more time consuming and complex. For example, the M&amp;A Rules require that the Ministry of Commerce of the PRC (the &#8220;MOFCOM&#8221;) be notified in advance of any change-of-control transaction in which a foreign investor takes control of a PRC domestic enterprise, if (i) any important industry is concerned, (ii) such transaction involves factors that have or may have impact on the national economic security, or (iii) such transaction will lead to a change in control of a domestic enterprise which holds a famous trademark or PRC time-honored brand. Moreover, under the Anti-Monopoly Law of the PRC and the Provisions on Thresholds for Prior Notification of Concentrations of Undertakings issued by the State Council, a transaction by way of merger, acquisition or contractual arrangement that allow one market player to take control of or to exert decisive impact on another market player requires advanced notice to the State Administration for Market Regulation (the &#8220;SAMR&#8221;) when such threshold is crossed and shall not be implemented without the clearance of prior notification. In addition, the Measures for Security Review of Foreign Investment and the Regulations on Implementation of Security Review System for the Merger and Acquisition of Domestic Enterprise by Foreign Investors (the &#8220;Security Review Rules&#8221;) specify that mergers and acquisitions by foreign investors that raise &#8220;national defense and security&#8221; concerns and mergers and acquisitions through which foreign investors may acquire the de facto control over domestic enterprises that raise &#8220;national security&#8221; concerns are subject to strict review by the MOFCOM, and prohibit any activities attempting to bypass a security review by structuring the transaction through, among other things, trusts, entrustment or contractual control arrangements. Furthermore, according to the Overseas Listing Trial Measures, if a Chinese overseas listed company issues overseas listed securities to acquire assets, such issuance would be subject to filing requirements with the CSRC. We may also be subject to similar review and regulations in other jurisdictions, such as the laws and regulations on foreign investment in the U.S. under the jurisdiction of the Committee on Foreign Investment in the United States (&#8220;CFIUS&#8221;) and other agencies, including the Foreign Investment Risk Review Modernization Act.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we may grow our business by acquiring complementary businesses. Complying with the requirements of the above-mentioned regulations and other relevant rules to complete such transactions could be time consuming, and any required approval or filing processes, including obtaining approval from or filing with CFIUS, the SAMR, the MOFCOM, the CSRC or other agencies may delay or inhibit our ability to complete such transactions. It is unclear whether those complementary businesses we may acquire in the future would be deemed to be in an industry that raises &#8220;national defense and security&#8221; or &#8220;national security&#8221; concerns. Furthermore, CFIUS, SAMR, MOFCOM, CSRC or other government agencies may make further determinations that increase the scrutiny of our future acquisitions in the U.S. or the PRC or prohibits such acquisitions. Our ability to expand our business or maintain or expand our market share through future acquisitions would as such be materially and adversely affected.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with the U.S. Foreign Corrupt Practices Act or other anti-bribery and corruption laws, our reputation may be harmed and we could be subject to penalties and significant expenses that have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the U.S. Foreign Corrupt Practices Act (the &#8220;FCPA&#8221;). The FCPA generally prohibits us from making improper payments to non-U.S. officials for the purpose of obtaining or retaining business. We are also subject to the anti-bribery and corruption laws of other jurisdictions, particularly China. The anti-bribery laws in China generally prohibit companies and their intermediaries from making payments to government officials for the purpose of obtaining or retaining business or securing any other improper advantage. As our business has expanded, the applicability of the FCPA and other anti-bribery and corruption laws to our operations has increased.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not fully control the interactions our employees, distributors and third-party promoters have with hospitals, medical institutions and doctors, and they may try to increase sales volumes of our products through means that constitute violations of U.S., PRC or other countries&#8217; anti-corruption and related laws. Although we have policies and procedures designed to ensure that we, our employees and our agents comply with anti-bribery laws, there is no assurance that such policies or procedures will prevent our agents, employees and intermediaries from engaging in bribery activities. If we, due to either our own deliberate or inadvertent acts or those of others, fail to comply with applicable anti-bribery and corruption laws, our reputation could be harmed and we could incur criminal or civil penalties, including but not limited to imprisonment, criminal and civil fines, suspension of our ability to do business with the government, denial of government reimbursement for our products and/or exclusion from participation in government healthcare programs, other sanctions and/or significant expenses, which could have a material adverse effect on our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our CROs or contract manufacturing organizations (&#8220;CMOs&#8221;) fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and third parties, such as our CROs or CMOs, are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and waste. In addition, our construction projects can only be put into operation after certain regulatory procedures with the relevant administrative authorities in charge of environmental protection, health and safety have been completed. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and waste. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and such liability could exceed our insurance coverage. We also could incur significant costs associated with civil or criminal fines and penalties.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses that we may incur due to injuries to our employees resulting from the use of or exposure to hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage, use or disposal of biological or hazardous materials.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may be required to incur substantial costs to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development, manufacturing or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our information technology systems, or those used by our contractors or collaborators, may fail or suffer security breaches, which could result in a material disruption of our product development and commercialization efforts.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our information technology systems and those of our contractors and collaborators, are vulnerable to damage from internal or external events, such as cyberattacks, computer viruses, unauthorized access to systems and data, malicious internet-based activity, online and offline fraud, wrongful conduct by insider employees and vendors, denial-of-service attacks, ransomware attacks, business email compromises, social engineering (including phishing attacks), computer malware, malicious codes, wrongful intrusions, and other similar activities, as well as natural disasters, terrorism, war, and telecommunication and electrical failures, which can compromise the confidentiality, integrity and availability of the systems. Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources. Although, to our knowledge, we have not experienced any material cyber incidents or data breaches to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our research, development, manufacturing, regulatory and commercialization efforts and our business operations.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we collect and store sensitive data, including, among other things, legally protected patient health information, personally identifiable information about our employees, banking information of our vendors, intellectual property, and proprietary business information. We manage and maintain our applications and data utilizing on-site systems and outsourced vendors. Because information systems, networks and other technologies are critical to many of our operating activities, shutdowns or service disruptions at our company or vendors that provide information systems, networks, or other services to us pose increasing risks. Such disruptions may be caused by events such as computer hacking, phishing attacks, ransomware, business email compromises, social engineering (including phishing attacks), dissemination of computer viruses, worms and other destructive or disruptive software, denial-of-service attacks and other malicious activity, as well as power outages, natural disasters (including extreme weather), terrorist attacks or other similar events. Such events could cause loss of data, damage to systems and data and leave us unable to utilize key business systems or access important data needed to operate our business. Like other companies in our industry, we, and our contractors and collaborators, have experienced and will continue to experience cybersecurity threats and incidents relating to our information technology systems and infrastructure, including malicious codes and viruses, phishing, email compromise attacks, ransomware, or other cyber-attacks. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such threats could adversely affect our security, leave us without access to important systems, products, raw materials, components, services or information and expose our confidential data. For example, one of our third-party vendors experienced a business email compromise which resulted in us sending payment to a fraudulent bank account. Funds were successfully recovered in this case, but it is possible that to the extent a similar future event occurs, funds will not be recoverable. In addition, system redundancy may be ineffective or inadequate, and our disaster recovery planning may not be sufficient to cover all eventualities. Significant events could result in a disruption of our operations, damage to our reputation or a loss of revenues.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could be subject to risks caused by misappropriation, misuse, leakage, falsification or intentional or accidental release or loss of information maintained in the information systems and networks of our company and our vendors, including personal information of our employees and patients, and company and vendor confidential data. In addition, outside parties may attempt to penetrate our systems or those of our vendors or fraudulently induce our personnel or the personnel of our vendors to disclose sensitive information in order to gain access to our data and/or systems. The number and complexity of these threats continue to increase over time. If a material breach of our information technology systems or those of our vendors occurs, we could be required to provide legal notifications and disclosures, as well as expend significant amounts of money and other resources to respond to these threats or breaches and to repair or replace information systems or networks and could suffer financial loss or the loss of valuable confidential information.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we could be subject to regulatory actions and/or claims made by individuals and groups in private litigation involving privacy issues related to data collection and use practices and other data privacy laws and regulations, including claims for misuse or inappropriate disclosure of data, as well as unfair or deceptive practices. Although we develop and maintain systems and controls designed to prevent these events from occurring, and we have processes to identify and mitigate threats, the development and maintenance of these systems, controls and processes is costly and requires ongoing monitoring and updating as technologies change and efforts to overcome security measures become increasingly sophisticated. Moreover, despite our efforts, the possibility of these events occurring cannot be eliminated entirely. It is possible that the risk of cyber-attacks or other privacy or data security incidents may be heightened as a result of our remote working environment, which may be less secure and more susceptible to hacking attacks. As we outsource more of our information systems to vendors, engage in more electronic transactions with payors and patients, and rely more on cloud-based information systems, the related security risks will increase and we will need to expend additional resources to protect our technology and information systems. In addition, there can be no assurance that our internal information technology systems or those of our contractors and collaborators, as well as our and their efforts to implement adequate security and control measures, will be sufficient to protect us against breakdowns, service disruptions, data deterioration or loss in the event of a system malfunction, or prevent data from being stolen or corrupted in the event of a cyberattack, data breach, ransomware, industrial espionage attack or insider threat attack that could adversely affect our business and operations and/or result in the loss or exposure of critical, proprietary, private, confidential or otherwise sensitive data, which could result in financial, legal, business or reputational harm to us. Further, our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our privacy and data security obligations. Further, although we maintain cyber liability insurance, this insurance may not provide adequate coverage against potential liabilities related to any experienced cybersecurity incident or breach.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The increasing use of artificial intelligence-based software (including machine learning) and social media platforms may result in reputation harm or liability or could otherwise adversely affect our business.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of artificial intelligence-based software is increasingly being used in the biopharmaceutical and global healthcare industries. As with many developing technologies, artificial intelligence-based software presents risks and challenges that could affect its further development, adoption, and use, and therefore our business. For example, algorithms may be flawed; data sets may be insufficient, of poor quality, or contain biased information; and inappropriate or controversial data practices by data scientists, engineers, and end-users could impair results. If the analyses that artificial intelligence applications assist in producing are deficient or inaccurate, we could be subjected to competitive harm, potential legal liability, and brand or reputational harm. Furthermore, use of artificial intelligence-based software may lead to the inadvertent release of confidential information which may impact our ability to realize the benefit of our intellectual property.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A growing number of laws and regulations are being adopted focused on enforcement efforts surrounding artificial intelligence and the use of such technologies in compliance with ethical standards and societal expectations. For example, the EU&#8217;s Artificial Intelligence Act imposes significant obligations on providers and deployers of artificial intelligence systems, and encourages ethical principles in the development and use of these systems. Likewise, in the U.S., several states passed laws to regulate various uses of artificial intelligence. In addition, various federal regulators have issued guidance and focused enforcement efforts on the use of artificial intelligence in regulated sectors. The FDA, for example, issued guidance on the use of artificial intelligence in medical devices, requiring detailed risk management and review processes to obtain approvals. We currently use systems that incorporate artificial intelligence, and if we develop or continue to use artificial intelligence systems governed by these laws or regulations, we will need to apply significant resources to design, develop, test and maintain such systems in accordance with applicable law and regulation, with the potential for significant enforcement or litigation in the event of any perceived non-compliance. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our vendors may incorporate artificial intelligence tools into their offerings, and the providers of these artificial intelligence tools may not meet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory standards, including with respect to privacy and data security. Further, bad actors around the world use increasingly sophisticated methods, including artificial intelligence, to engage in illegal activities involving the theft and misuse of personal information, confidential information and intellectual property. Any of these effects could damage our reputation, result in the loss of valuable property and information, cause us to breach applicable laws and regulations, and adversely impact our business.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Relatedly, social media platforms are increasingly being used to communicate about our products and the diseases our medicines and drug candidates are designed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear and create uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media channels to comment on the effectiveness of a product or to report an alleged adverse event. When such disclosures occur, there is a risk that we may fail to monitor and comply with applicable adverse event reporting obligations. There is also a risk of negative or inaccurate posts about us on social media, including criticism regarding our medicines or drug candidates. The immediacy of social media precludes us from having real-time control over postings made regarding our company, medicines or drug candidates. Our reputation could be damaged by negative publicity posted on social media platforms which we may not be able to timely reverse. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face restrictive regulatory actions or incur other harm to our business.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our failure to comply with privacy and data protection laws and regulations could lead to government enforcement actions and significant penalties against us, and adversely impact our operating results.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., Europe, China, and many other jurisdictions where we operate, we are subject to laws and regulations that address privacy, personal information protection, use of artificial intelligence-based software and data security. Numerous laws and regulations, including, without limitation, privacy laws (such as the European Union&#8217;s General Data Protection Regulation (&#8220;GDPR&#8221;) or similar laws), security breach notification laws (such as Australia&#8217;s amendment to the Privacy Act), health information privacy laws (such as the United States&#8217; Health Insurance Portability and Accountability Act (&#8220;HIPAA&#8221;) and the Human Genetic Resources Administration of China&#8217;s rules), and consumer protection laws (such as the United States&#8217; Federal Trade Commission&#8217;s unfair or deceptive practices rules, or California&#8217;s Consumer Privacy Act), govern the collection, use, disclosure and protection of health-related and other personal information. A subset of these laws also have strict requirements governing the cross-border transfer of, or access to, personal information (see the risk factor titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compliance with the Data Security Law of the People&#8217;s Republic of China (the &#8220;Data Security Law&#8221;), Cybersecurity Review Measures, Personal Information Protection Law of the People&#8217;s Republic of China (the &#8220;PIPL&#8221;), regulations and guidelines relating to the multi-level protection scheme (the &#8220;MLPS&#8221;) and any other future laws and regulations may entail significant expenses and could materially affect our business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The legal and regulatory landscape around data privacy is rapidly changing with countries, states and other localities passing new laws and regulations every year. For example, the U.S. Department of Justice issued regulations implementing Executive Order (&#8220;EO&#8221;) 14117, &#8220;Preventing Access to Americans&#8217; Bulk Sensitive Personal Data and United Stated Government-Related Data by Countries of Concern,&#8221; which are expected to become effective in April 2025 and prohibit transactions involving access to bulk sensitive data by countries of concern, such as China (including Hong Kong and Macau), Cuba, Iran, North Korea, Russia, and Venezuela. For example, the regulations prohibit transactions involving human genomic data and biospecimens of more than 100 U.S. individuals, except where necessary for specified exempt activities, such as for regulatory approvals, clinical investigations in support of FDA applications, and post-marketing surveillance. Tracking and complying with these laws and regulations requires significant time and expenses and could materially affect our business. By way of example and without limitation, these laws may require updating of contracts, informed consent forms, clinical trial protocols and privacy notices; changes to company procedures and corporate structures; limiting what personal information we collect, who has access to it and how/where we use it; performing internal assessments; changes to the security and hosting solution of our systems; changes to vendors and other third parties that we work with; specific reporting and remediation efforts in the event of a data breach; and even opening our business up for external assessments by government bodies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the variability and evolving state of these laws, we face uncertainty as to the exact interpretation of the new requirements, and we may face challenges in implementing all measures required by regulators or courts in their interpretation. Additionally, we may experience a reportable data breach (see the risk factor titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our information technology systems, or those used by our contractors or collaborators, may fail or suffer security breaches, which could result in a material disruption of our product development and commercialization efforts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;). Any failure or perceived failure by us to comply with applicable laws and regulations could subject us to significant administrative, civil or criminal fines or other penalties and negatively impact our reputation and our ability to participate in certain government-supported programs. For severe violations, in some countries these laws even allow courts and government agencies to delay or halt transfer of personal information, require deletion of personal information, or even order we stop collection, use or other processing of personal information in that country. All of these could materially harm our business, prospects, and financial condition or even disrupt our operations.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These laws apply not just to us, but also to those vendors working on our behalf, as well as our business partners. Any actual or perceived failure of them to comply with these laws and regulations could impact the services they provide to us, our collaborations with them and our reputation; additionally, there is a risk of liability flowing to us under certain contractual and/or legal conditions.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance with the Data Security Law of the People&#8217;s Republic of China (the &#8220;Data Security Law&#8221;), Cybersecurity Review Measures, Personal Information Protection Law of the People&#8217;s Republic of China (the &#8220;PIPL&#8221;), regulations and guidelines relating to the multi-level protection scheme (the &#8220;MLPS&#8221;) and any other future laws and regulations may entail significant expenses and could materially affect our business.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">China has implemented extensive data protection, privacy and information security rules and is considering a number of additional proposals relating to these subject areas. We face significant uncertainties and risks related to these laws, regulations and policies, some of which were only recently enacted, and the interpretation of these legal requirements by government regulators as applied to biotechnology companies like us. For example, we collect and maintain de-identified or pseudonymized health data for clinical trials in compliance that could be deemed &#8220;personal data&#8221; or &#8220;important data&#8221; by government regulators. With China&#8217;s growing emphasis of its sovereignty over data derived from China, the outbound transmission of de-identified or pseudonymized health data for clinical trials may be subject to the new national security legal regime, including the Data Security Law, the Cyber Security Law of the People&#8217;s Republic of China (the &#8220;Cyber Security Law&#8221;), the PIPL, and various implementing regulations and standards.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">China&#8217;s Data Security Law provides that the data processing activities must be conducted based on &#8220;data classification and hierarchical protection system&#8221; for the purpose of data protection and prohibits entities in China from transferring data stored in China to foreign law enforcement agencies or judicial authorities without prior approval by the relevant PRC authority. The classification of data is based on its importance in economic and social development, as well as the degree of harm expected to be caused to national security, public interests, or the legitimate rights and interests of individuals or organizations if such data is tampered with, destroyed, leaked, or illegally acquired or used.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cyber Security Law requires companies to take certain measures to ensure the security of their networks and data stored on their networks. Specifically, the Cyber Security Law provides that companies adopt an MLPS, under which network operators are required to perform obligations of security protection to ensure that the network is free from interference, disruption or unauthorized access, and prevent network data from being disclosed, stolen or tampered. Under the MLPS, entities operating information systems must have a thorough assessment of the risks and the conditions of their information and network systems to determine the level to which the entity&#8217;s information and network systems belong, from the lowest Level 1 to the highest Level 5 pursuant to a series of national standards on the grading and implementation of the classified protection of cybersecurity. The grading result will determine the set of security protection obligations that entities must comply with and when relevant government authority examination and approval is required.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Cyber Security Law and Data Security Law, we are required to establish and maintain a comprehensive data and network security management system that will enable us to monitor and respond appropriately to data security and network security risks. We are obligated to notify affected individuals and appropriate Chinese regulators of and respond to any data security and network security incidents. Chinese authorities have issued guidance, regulations, and amendments that continue to evolve the required standard of security and potential liabilities for violations. For example, the Network Data Security Management Regulations issued in September 2024 impose detailed and prescriptive requirements for protecting network security. Establishing and maintaining such systems takes substantial time, effort and cost, and we may not be able to establish and maintain such systems as fully as needed to ensure compliance with our legal obligations. Despite our investment, such systems may not adequately protect us or enable us to appropriately respond to or mitigate all data security and network security risks or incidents we may face.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, under the Data Security Law, data categorized as &#8220;important data,&#8221; which will be determined by governmental authorities in the form of catalogs, is to be processed and handled with a higher level of protection. The notion of important data is not clearly defined by the Cyber Security Law or the Data Security Law. In order to comply with the statutory requirements, we will need to determine whether we possess important data, monitor the important data catalogs that are expected to be published by local governments and departments, perform risk assessments and ensure we are complying with reporting obligations to applicable regulators. We may also be required to disclose to regulators business sensitive or network security-sensitive details regarding our processing of important data and may need to pass the government security review or obtain government approval in order to share important data with offshore recipients, which can include foreign licensors, or share data stored in mainland China with judicial and law enforcement authorities outside of mainland China. If judicial and law enforcement authorities outside mainland China require us to provide data stored in mainland China, and we are not able to pass any required government security review or obtain any required government approval to do so, we may not be able to meet the non-PRC authorities&#8217; requirements and may be unable to share information outside of China which may disrupt the operation of our business. The potential conflicts in legal obligations could have adverse impacts on our operations in and outside of mainland China. PRC regulatory authorities have also enhanced the supervision and regulation of cross-border data transmission. The Data Security Law prohibits entities and individuals in China from providing any foreign judicial or law enforcement authority with any data stored in China without approval from competent PRC authority and sets forth the legal liabilities of entities and individuals found to be in violation of their data protection obligations, including rectification order, warning, fines, suspension of relevant business, and revocation of business permits or licenses. Moreover, the CAC promulgated the Measures for the Security Assessment of Cross-border Data Transmission (effective September 2022) and the Provisions on Promoting and Standardizing Cross-Border Data Flows (effective March 2024), which provide certain clarification and relaxation to the compliance mechanisms for cross-border transfer of personal information, and provide several exemptions from undergoing security assessment, obtaining personal information protection certification, or entering into prescribed agreement for cross-border transfer of personal information for businesses. The provisions also explicitly state that data processors are not required to conduct data security assessment for cross-border important data transfers if the concerning data has not been notified or published as important data by relevant departments or regions. According to these measures, personal data processors are subject to security assessment prior to any cross-border transfer of data if the transfer involves (i) important data; (ii) personal information transferred overseas by operators of critical information infrastructure; (iii) non-sensitive personal data of more than 1 million persons or sensitive personal data of more than 10,000 persons transferred overseas since January 1 of the current year; or (iv) other circumstances as requested by the CAC. Though these measures have already taken effect, substantial uncertainties still exist with respect to the interpretation and implementation of these measures in practice and how they will affect our business operation.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CAC has taken action against several Chinese internet companies listed on U.S. securities exchanges for alleged national security risks and improper collection and use of the personal information of Chinese data subjects. According to the official announcement, the action was initiated based on the National Security Law of the People&#8217;s Republic of China (the &#8220;National Security Law&#8221;), the Cyber Security Law and the Cybersecurity Review Measures. Effective as of February 2022, the CAC, together with 12 other PRC governmental authorities, promulgated the Revised Cybersecurity Review Measures, pursuant to which critical information infrastructure operators procuring network products and services and online platform operators carrying out data processing activities, which affect or may affect national security, shall conduct a cybersecurity review. In addition, online platform operators possessing personal information of more than one million users seeking to be listed on foreign stock markets must apply for a cybersecurity review. The relevant competent governmental authorities may also initiate a cybersecurity review against the relevant operators if the authorities believe that the network product or service or data processing activities of such operators affect or may affect national security. There are still uncertainties as to the exact scope of network product or service or data processing activities that will or may affect national security, and the PRC government authorities may have discretion in the interpretation and enforcement of these measures.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the State Council published the Administrative Regulations on Cyber Data Security (&#8220;Cyber Data Security Regulations&#8221;, effective January 1, 2025), pursuant to which data processors are required to identify and report important data. Important data processors shall further adopt specific measures to secure the important data, such as designing the personnel and management institution responsible for the network data security, conducting risk assessment for the sharing, entrusted processing and joint processing of important data, and submit the annual risk assessment reports to competent authorities. Furthermore, data processors shall be subject to national security review if their cyber data processing activities affect or may affect national security. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There remain uncertainties as to how widespread the cybersecurity or national security review requirement and the enforcement action will be and what effect they will have on the life sciences sector generally and the Company in particular. China&#8217;s regulators may impose penalties for non-compliance ranging from fines or suspension of operations, and the imposition of any such penalties on our business could cause a material adverse effect on our business, financial condition, results of operations, prospects and the trading price of our ordinary shares, ADSs and RMB Shares, and could lead to our delisting from Nasdaq. As of the date of this Annual Report, we have not received any notice from any Chinese regulatory authority identifying us as a &#8220;critical information infrastructure operator,&#8221; &#8220;online platform operator&#8221; or &#8220;data processor&#8221; requiring us to go through the cybersecurity review procedures pursuant to the Revised Cybersecurity Review Measures or national security review under the Cyber Data Security Regulations. However, there remains uncertainty as to how the regulations if enacted as currently proposed, will be interpreted or implemented and whether the Chinese regulatory authorities will adopt additional regulations. We intend to closely monitor the evolving laws and regulations in this area and take all reasonable measures to mitigate compliance risks, we cannot guarantee that our business and operations will not be adversely affected by the potential impact of the Revised Cybersecurity Review Measures, the Cyber Data Security Regulations or other laws and regulations related to privacy, data protection and information security.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Standing Committee of the National People&#8217;s Congress of the PRC promulgated the PIPL, which expands data protection compliance obligations to cover the processing of personal information of persons by organizations and individuals in China, and the processing of personal information of persons in China outside of China if such processing is for purposes of providing products and services to, or analyzing and evaluating the behavior of, persons in China. The PIPL also provides that critical information infrastructure operators and personal information processing entities that process personal information meeting a volume threshold are also required to store in China personal information generated or collected in China, and to pass a security assessment for any export of such personal information. Lastly, the PIPL contains proposals for significant fines for serious violations of up to RMB50 million, or 5% of annual revenues from the prior year, and penalties, including that companies found to have violated the PIPL may be ordered to suspend any related activity.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interpretation, application and enforcement of these laws, rules and regulations evolve from time to time and their scope may continually change, through new legislation, amendments to existing legislation or changes in enforcement. Compliance with the Cyber Security Law, the Data Security Law and the PIPL could significantly increase the cost to us of providing our service offerings, require significant changes to our operations or even prevent us from providing certain service offerings in jurisdictions in which we currently operate or in which we may operate in the future. Despite our efforts to comply with applicable laws, regulations and other obligations relating to privacy, data protection and information security, it is possible that our practices, offerings or platform could fail to meet all of the requirements imposed by the Cyber Security Law, the Data Security Law and/or related implementing regulations. Any failure on our part to comply with such law or regulation, or any compromise of security that results in unauthorized access, use or release of personally identifiable information or other data, or the perception or allegation that any of the foregoing types of failure or compromise has occurred, could damage our reputation, discourage new and existing counterparties from contracting with us or result in investigations, fines, suspension or other penalties by Chinese government authorities and private claims or litigation, any of which could materially adversely affect our business, financial condition and results of operations. Even if our practices are not subject to legal challenge, the perception of privacy concerns, whether or not valid, may harm our reputation and adversely affect our business, financial condition and results of operations. Moreover, the legal uncertainty created by the Data Security Law and the actions taken by the Chinese government could materially adversely affect our ability, on favorable terms, to raise capital in the U.S. and other markets in the future.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or parties on whom we rely fail to maintain the necessary licenses for the development, manufacture, sale and distribution of our products, our ability to conduct our business could be materially impaired.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to obtain, maintain and renew various permits, licenses and certificates to develop, manufacture, promote and sell our products. Third parties, such as distributors, third-party promoters and third-party manufacturers, on whom we may rely to develop, manufacture, promote, sell and distribute our products may be subject to similar requirements. We and third parties on whom we rely may be also subject to regular inspections, examinations, inquiries or audits by the regulatory authorities, and an adverse outcome of such inspections, examinations, inquiries or audits may result in the loss or non-renewal of the relevant permits, licenses and certificates. Moreover, the criteria used in reviewing applications for, or renewals of permits, licenses and certificates may change from time to time, and there can be no assurance that we or the parties on whom we rely will be able to meet new criteria that may be imposed to obtain or renew the necessary permits, licenses and certificates. Many of such permits, licenses and certificates are material to the operation of our business, and if we or parties on whom we rely fail to maintain or renew material permits, licenses and certificates, our ability to conduct our business could be materially impaired. Furthermore, if the interpretation or implementation of existing laws and regulations change, or new regulations come into effect, requiring us or parties on whom we rely to obtain any additional permits, licenses or certificates that were previously not required to operate our business, there can be no assurance that we or parties on whom we rely will successfully obtain such permits, licenses or certificates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our financial and operating performance may be adversely affected by government shutdowns, public health crises, natural catastrophes, or other business interruptions outside of our control.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our global operations and those of our third-party contractors and collaborators expose us to natural or man-made disasters, such as earthquakes, hurricanes, floods, fires, explosions, public health crises, such as epidemics or pandemics, terrorist activity, wars, political uncertainty, or other business interruptions outside of our control. Furthermore, we do not maintain any insurance other than property insurance for some of our buildings, vehicles and equipment. Accordingly, unexpected business interruptions resulting from disasters could disrupt our operations and thereby result in substantial costs and diversion of resources. For example, our Guangzhou manufacturing facility was hit by a typhoon in 2019 and although the typhoon did not cause material damage to the facility, the boundary area and the adjacent land were flooded, causing a power outage for a few days. Afterwards, we fortified the facility to help prevent future interruptions. A significant disruption at our manufacturing facilities, even on a short-term basis, could impair our ability to timely produce products, which could have a material adverse effect on our business, financial position and results of operations.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our production process requires a continuous supply of electricity. We have encountered power shortages historically in China due to restricted power supply to industrial users during summers when the usage of electricity is high and supply is limited or as a result of damage to the electricity supply network. Because the duration of those power shortages was brief, they had no material impact on our operations. Longer interruptions of electricity supply could result in lengthy production shutdowns, increased costs associated with restarting production and the loss of production in progress. Any major suspension or termination of electricity or other unexpected business interruptions could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely in part on third-party manufacturers to produce and process our medicines and drug candidates. Our ability to obtain supplies of our medicines and drug candidates could be disrupted if the operations of these suppliers are affected by man-made or natural disasters, public health crises or other business interruptions which could cause us to delay or cease development or commercialization of some or all of our medicines and drug candidates. In addition, we partially rely on our third-party research institution collaborators for conducting research and development of our drug candidates, and they may be affected by such business interruptions, government shutdowns or withdrawn funding. For example, the ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. Currently, federal agencies in the U.S. are operating under a continuing resolution that is set to expire on March 14, 2025. Without appropriation of additional funding to federal agencies, our business operations related to our product development activities for the U.S. market could be impacted.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, the COVID-19 pandemic negatively impacted our business and our financial performance, and future global pandemics or other public health crises could have similar negative impacts, including delays or other disruptions to required regulatory inspections of our development activities, regulatory filings, manufacturing operations, or clinical trial recruitment and progress. Additionally, the commercial or clinical supply of our medicines and drug candidates could be negatively impacted due to reduced operations or a shutdown of our or our third-party manufacturing facilities, distribution channels and transportation systems, or shortages of raw materials and drug product. Additionally, as seen in connection with the COVID-19 pandemic, public health crises may result in significant governmental measures being implemented to control the spread of a virus, including quarantines, travel restrictions, social distancing and business shutdowns. These measures may negatively affect our business by inducing absenteeism or employee turnover, disrupting our operations, increasing the risk of a cybersecurity incident, or other business disruptions outside of our control.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Climate change manifesting as physical or transition risks, included related environmental regulation, could have a material adverse impact on our business operations, clients and customers.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The long-term effects of climate change are difficult to assess and predict. Our business and the activities of our clients and customers could be impacted by climate change. Climate change could manifest as a financial risk either through changes in the physical climate or from the process of transitioning to a low-carbon economy, including related environmental regulation of companies with respect to risks posed by climate change.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The physical impacts of climate change may include physical risks (such as rising sea levels or frequency and severity of extreme weather conditions), social and human effects (such as population dislocations or harm to health and well-being), compliance costs and transition risks (such as regulatory or technology changes) and other adverse effects. The effects could impair, for example, the availability and cost of certain products, commodities and energy (including utilities), which in turn may impact our ability to procure goods or services required for the operation of our business at the quantities and levels we require. Furthermore, related environmental regulation as a response to climate change could result in additional costs in the form of taxes and investments of capital to maintain complacent with such laws. We bear losses incurred as a result of, for example, physical damage to or destruction of our facilities, loss or spoilage of inventory, and business interruption due to weather events that may be attributable to climate change and could materially adversely affect our business operations, financial position or results of operation.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product liability claims or lawsuits could cause us to incur substantial liabilities.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability as a result of the commercialization of our medicines in the U.S., China, Europe and other markets, and for the clinical testing and any future commercialization of our drug candidates globally. For example, we may be sued if our medicines or drug candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the medicine, negligence, strict liability or a breach of warranties. Claims could also be asserted under applicable consumer protection acts. If we cannot successfully defend ourselves against or obtain indemnification from our collaborators for product liability claims, we may incur substantial liabilities or be required to limit commercialization of our medicines and drug candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: decreased demand for our medicines; injury to our reputation; withdrawal of clinical trial participants and inability to continue clinical trials; initiation of investigations by regulators; costs to defend the related litigation; a diversion of our management&#8217;s time and resources; substantial monetary awards to trial participants or patients; product recalls, withdrawals or labeling, marketing or promotional restrictions; loss of revenue; exhaustion of any available insurance and our capital resources; the inability to commercialize any medicine or drug candidate; and a decline in our share price.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of our medicines and drug candidates. Although we currently hold product liability coverage which we believe to be sufficient in light of our current products and clinical programs, the amount of such insurance coverage may not be adequate, and we may be unable to maintain such insurance at a reasonable cost or in an amount adequate to satisfy any liability that may arise, or we may not be able to obtain additional or replacement insurance at a reasonable cost, if at all. Our insurance policies may also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to the risks and challenges of doing business globally, which may adversely affect our business operations.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to risks and challenges associated with doing business globally. Accordingly, our business and financial results could be adversely affected due to a variety of factors, including: changes in a specific country&#8217;s or region&#8217;s political and cultural climate or economic condition; unexpected changes in laws and regulatory requirements in local jurisdictions; challenges in replicating or adapting our company policies and procedures to operating environments different from that of the U.S.; difficulty of effective enforcement of contractual provisions in local jurisdictions; inadequate intellectual property protection in certain countries; enforcement of anti-corruption and anti-bribery laws, such as the FCPA; trade-protection measures or disputes, import or export licensing requirements, and fines, penalties or suspension or revocation of export privileges; laws and regulations on foreign investment in the U.S. under the jurisdiction of the CFIUS and other agencies; the effects of applicable local tax regimes and potentially adverse tax consequences; the impact of public health crises on employees, our operations and the global economy; restrictions on international travel and commerce; and significant adverse changes in local currency exchange rates. In addition, in 2017 the United Kingdom Financial Conduct Authority (&#8220;UKFCA&#8221;), which regulates the London Interbank Offered Rate (&#8220;LIBOR&#8221;), announced that it would no longer require banks to submit rates for the calculation of LIBOR to the LIBOR administrator. Following June 30, 2023, the UKFCA ceased to publish one month, three month and six month USD LIBOR settings. In the U.S., the Alternative Reference Rate Committee (&#8220;ARRC&#8221;), a steering committee assembled by the Federal Reserve Board and the Federal Reserve Bank of New York, was tasked with identifying alternative reference rates to replace LIBOR. The AARC selected, and the Federal Reserve Bank of New York has recommended, the Secured Overnight Finance Rate (&#8220;SOFR&#8221;) as an alternative to LIBOR. SOFR is a broad measure of the cost of borrowing cash in the overnight U.S. treasury market. LIBOR and SOFR have significant differences: LIBOR was an unsecured lending rate and SOFR is a secured lending rate, and SOFR is an overnight rate while LIBOR is a forward-looking rate that reflected term rates at different maturities. At this time, it is not possible to predict how markets will respond to SOFR or other alternative reference rates, and as such, the replacement of LIBOR could have an adverse effect on the market for, or value of, LIBOR-linked financial instruments. Failure to manage these risks and challenges could negatively affect our ability to expand our businesses and operations as well as materially and adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future operating results could be negatively affected by changes in tax rates, the adoption of new tax legislation in the jurisdictions in which we operate, or exposure to additional tax liabilities.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The nature of our international operations subjects us to local, state, regional and national tax laws in jurisdictions around the world. Our future tax expense could be affected by changes in the mix of earnings in countries with differing statutory tax rates, changes in the valuation of deferred tax assets and liabilities or changes in tax laws or their interpretation. Additionally, tax rules governing cross-border activities are continually subject to modification intended to address concerns over base erosion and profit shifting (&#8220;BEPS&#8221;) and other perceived international tax avoidance techniques as a result of both coordinated actions by governments, such as the OECD/G20 Inclusive Framework on BEPS, and unilateral measures designed by individual countries. For example, the Cayman Islands has enacted the International Tax Co-operation (Economic Substance) Law (2020 Revision) (the &#8220;Economic Substance Law&#8221;), which originally took effect on January 1, 2019, and which is accompanied by Guidance on Economic Substance for Geographically Mobile Activities (Version 2.0; April 30, 2019) published by the Cayman Islands Tax Information Authority. The Economic Substance Law embraces a global initiative to combat BEPS and demonstrates the continued commitment of the Cayman Islands to international best practice. The Economic Substance Law provides that relevant entities that existed before January 1, 2019 and that had been conducting relevant activities by that date must comply with the economic substance requirements from July 1, 2019, and relevant entities that are established from January 1, 2019 onwards must comply with the requirements from the date they commence the relevant activity. Although we believe that we currently are not obliged to meet the economic substance requirements under the Economic Substance Law, we cannot predict any changes to the legislation or its interpretation in the future. If we are obliged to meet certain economic substance requirements in the future, our business and results of operations could be negatively impacted if we are required to make changes to our business in order to gain compliance or if we fail to comply.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received tax rulings from various governments that have jurisdictional authority over our operations. If we are unable to meet the requirements of such agreements, or if they expire or are renewed on less favorable terms, the result could negatively impact our future earnings. Additionally, the European Commission has opened formal investigations into specific tax rulings granted by several countries to specific taxpayers. While we believe that our rulings are consistent with accepted tax ruling practices, the ultimate resolution of such activities cannot be predicted and could also have an adverse impact on future operating results.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Doing Business in the PRC</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in the political and economic policies of the PRC government or in relations between China and the United States or other governments and the significant oversight and discretion the PRC government has over the conduct of the business operations of our PRC subsidiaries may materially and adversely affect our business, financial condition, and results of operations and may result in our inability to sustain our growth and expansion strategies.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to our operations in China, our business, results of operations, financial condition and prospects may be influenced to a significant degree by economic, political, legal and social conditions in the PRC or changes in government relations between China and the U.S. or other governments. There is significant uncertainty about the future relationship between the U.S. and China with respect to trade policies, data sharing, treaties, government regulations and tariffs. China&#8217;s economy differs from the economies of other countries in many respects, including with respect to the level of development, growth rate, amount of government involvement, regulation of foreign exchange and allocation of resources. While China&#8217;s economy has experienced significant growth over the past four decades, growth has been uneven across different regions and among various economic sectors. The Chinese government has implemented various measures to encourage economic development and guide the allocation of resources. Some of these measures may benefit the overall Chinese economy, but may have a negative effect on us. For example, our financial condition and results of operations may be adversely affected by government regulation over </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capital investments or changes in tax regulations that are currently applicable to us. In addition, in the past the Chinese government implemented certain measures, including interest rate increases, to manage the pace of economic growth and prevent the economy from overheating. These measures may cause decreased economic activity in China, which may adversely affect our business and results of operations.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The PRC government may intervene or influence our operations at any time, and has the ability to exert significant oversight and control over any offering of securities conducted overseas and/or foreign investment in China-based issuers, which could result in a material change in our operations and limit or completely hinder our ability to offer or continue to offer securities to investors, and may cause the value of such securities to significantly decline or be worthless.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Chinese government may intervene or influence our operations at any time, or may exert control over operations of our business, which could result in a material change in our operations and/or the value of our securities. Any actions by the Chinese government to exert more oversight and control over offerings that are conducted overseas and/or foreign investment in China-based issuers could significantly limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline or be worthless.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the PRC government has indicated its intent to exert more oversight and control over securities offerings and other capital markets activities that are conducted overseas and foreign investment in China-based companies. If the PRC authorities attempt to exercise such control or influence through regulation over our PRC subsidiaries, we could be required to restructure our operations to comply with such regulations or potentially cease operations in the PRC entirely, which could adversely affect our business, results of operations and financial condition. Any such action, once taken by the PRC government, could result in a material change in our operations, and could also significantly limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline or in extreme cases, become worthless.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the PRC government initiated a series of regulatory actions and statements to regulate business operations in China, including cracking down on illegal activities in the securities market, enhancing supervision over China-based companies listed overseas using the variable interest entity (&#8220;VIE&#8221;) structure, adopting new measures to extend the scope of cybersecurity reviews, and expanding the efforts in anti-monopoly enforcement. For example, in July 2021, the relevant PRC government authorities made public the Securities Opinions, which emphasized the need to strengthen the administration over illegal securities activities and the supervision on overseas listings by China-based companies and proposed to take effective measures, such as promoting the construction of relevant regulatory systems to deal with the risks and incidents faced by China-based overseas listed companies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, in July 2021, the PRC government provided guidance on China-based companies raising capital outside of China, including through VIE structures. In light of such developments, the SEC has imposed enhanced disclosure requirements on China-based companies seeking to register securities with the SEC. In February 2023, the CSRC released the Overseas Listing Trial Measures and five relevant guidelines which became effective as of March 31, 2023. According to the Overseas Listing Trial Measures, where Chinese companies that have directly or indirectly listed securities in overseas markets conduct follow-on offering of equity securities in such overseas markets, they shall fulfill the filing procedures with and report relevant information to the CSRC. As the Overseas Listing Trial Measures are subject to changes and may continue to evolve, we cannot assure you that we would not be deemed as an indirect overseas listed Chinese company under the Overseas Listing Trial Measures. If we are deemed as an indirect overseas listed Chinese company but fail to complete the filing procedures with the CSRC for any of our follow-on offerings or follow relevant reporting requirements thereunder, we may be subject to penalties, sanctions and fines imposed by the CSRC and relevant departments of the State Council. See also the section of this Annual Report titled &#8220;Part I&#8212;Item 1&#8212;Business&#8212;Government Regulation&#8212;PRC Regulation&#8212;Regulations Relating to Overseas Listing&#8221;. We are currently evaluating the implications and potential impact of the Overseas Listing Trial Measures and will continue to closely monitor the interpretation and implementation of the Overseas Listing Trial Measures. Due to our operations in China and stock listings in and outside of China, the Overseas Listing Trial Measures and any future PRC, U.S. or other rules and regulations that place restrictions on capital raising could adversely affect our business and results of operations and could significantly limit or completely hinder our ability to offer or continue to offer our ADSs or ordinary shares to investors, and could cause the value of our ADSs or ordinary shares to significantly decline or become worthless.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, the CSRC and other PRC governmental authorities jointly issued the revised Provisions on Strengthening Confidentiality and Archives Administration of Overseas Securities Offering and Listing by Domestic Companies (the &#8220;Revised Confidentiality Provisions&#8221;), which became effective as of March 31, 2023. According to the Revised Confidentiality Provisions, Chinese companies that directly or indirectly conduct overseas offerings and listings, shall strictly abide by the laws and regulations on confidentiality when providing or publicly disclosing, either directly or through their overseas listed entities, materials to securities services providers. In the event such materials contain state secrets or working secrets of government agencies, the Chinese companies shall first obtain approval from authorities, and file with the secrecy administrative department at the same level with the approving authority; in the event that such materials, if divulged, will jeopardize national security or public interest, the Chinese companies shall comply with procedures stipulated by national regulations. The Chinese companies shall also provide a written statement of the specific sensitive information provided when providing materials to securities service providers, and such written statements shall be retained for inspection. The interpretation and implementation of the Revised Confidentiality Provisions may continue to evolve.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, these statements and regulatory actions have had no impact on our daily business operations or our ability to accept foreign investments and list our securities on a U.S. or other foreign exchange. However, it is highly uncertain how the legislative or administrative agencies will further interpret, modify or implement such laws and regulations, or if they will promulgate any new laws or regulations, and their potential impact on our daily business operations, the ability to accept foreign investments and list our securities on a U.S., Hong Kong, or other stock exchanges. There are still substantial uncertainties as to how PRC governmental authorities will regulate overseas listing in practice and whether we are required to obtain any specific regulatory approvals from PRC governmental authorities for our offshore offerings. If PRC regulatory agencies later promulgate new rules or explanations requiring that we obtain their approvals for our future offshore offerings, we may be unable to obtain such approvals in a timely manner, or at all, and such approvals may be rescinded even if obtained. Any such circumstance could significantly limit or completely hinder our ability to continue to offer securities to investors and cause the value of such securities to significantly decline or be worthless. In addition, implementation of industry-wide regulations directly targeting our operations could cause the value of our securities to significantly decline. Therefore, investors of our company face potential uncertainty from actions taken by the government authorities affecting our business. Any intervention by the PRC government in our operations could undermine our business plan and cause the value of an investment in the Company to significantly decline or become worthless.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Historically, there has been legislation implemented which put our ADSs at risk of potential delisting. The delisting of our ADSs, or the threat of their being delisted, may materially and adversely affect the value of your investment.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Holding Foreign Companies Accountable Act (as amended, the &#8220;HFCAA&#8221;) provides that if the SEC determines an issuer has filed audit reports issued by a registered public accounting firm that has not been subject to inspection by the PCAOB for two consecutive years beginning in 2021, the SEC shall prohibit that issuer&#8217;s securities from being traded on a national securities exchange or in the over-the-counter trading market in the U.S. Following the filing of our annual report on Form 10-K for fiscal year ended December 31, 2021, which was audited by Ernst &amp; Young Hua Ming LLP, the SEC added us to its list of Commission-Identified Issuers identified under HFCAA. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, as our global business expanded, we built substantial organizational capabilities outside of the PRC and we evaluated, designed and implemented business processes and control changes which enabled us to engage Ernst &amp; Young LLP, located in Boston, Massachusetts, U.S., as our independent registered public accounting firm for the audits of our financial statements and internal control over financial reporting commencing for the fiscal years ended December 31, 2022 and those thereafter. We believe that this satisfies the PCAOB inspection requirements for the audit of our consolidated financial statements prior to the two-year deadline of the HFCAA. Given that Ernst and Young LLP (U.S.) has served as the principal accountant to audit our consolidated financial statements since 2022, we believe this should preclude the delisting of our ADSs from Nasdaq under HFCAA.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to enforcement under similar legislation that may be enacted into law or executive orders that may be adopted in the future. Although we are committed to complying with the rules and regulations applicable to listed companies in the U.S., we are currently unable to predict the potential impact on our listing status by any rules that may be adopted by the SEC in the future. If we failed to comply with those rules, it is possible that our ADSs would be delisted. The risk and uncertainty associated with a potential delisting would have a negative impact on the price of our ADSs, ordinary shares and RMB Shares.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There are uncertainties regarding the interpretation and enforcement of Chinese laws, rules and regulations, and rules and regulations in China can change quickly with little advance notice.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A large portion of our operations are conducted in China through our Chinese subsidiaries. Our Chinese subsidiaries are subject to laws, rules and regulations applicable to foreign investment in China. The Chinese legal system is a civil law system based on written statutes. Unlike the common law system, prior court decisions may be cited for reference but have limited precedential value.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, China&#8217;s legal system is still developing. The laws, rules and regulations are subject to interpretation and enforcement by PRC regulatory agencies and courts. In particular, on account of the relatively new implementation of certain laws, rules and regulations, the non-precedential nature of court decisions, and the discretion such laws, rules and regulations give to the relevant regulator in enforcement, the interpretation and enforcement of these laws, rules and regulations involve uncertainties and can be inconsistent. In addition, the legal system is based in part on government policies and rules which may quickly be amended from time to time with little advance notice. As a result, we may not be aware of our violation of these policies and rules until after the occurrence of the violation.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">China&#8217;s Foreign Investment Law and its implementing rule came into force in January 2020. The Foreign Investment Law and its implementing rules embody an expected regulatory trend to rationalize China&#8217;s foreign investment regulatory regime in line with prevailing international practice and the legislative efforts to unify the legal requirements for both foreign and domestic investments. There are still uncertainties with respect to the interpretation and implementation of the Foreign Investment Law and its implementing rules. For example, the Foreign Investment Law and its implementing rules provide that foreign invested entities established according to the previous laws regulating foreign investment prior to its implementation may maintain their structure and corporate governance for a five-year transition period. It is uncertain whether governmental authorities may require us to adjust the structure and corporate governance of certain of our Chinese subsidiaries in such transition period. Failure to take timely and appropriate measures to meet any of these or similar regulatory requirements could materially affect our current corporate governance practices and business operations and our compliance costs may increase significantly. In addition, the Security Review Rules embody China&#8217;s continued efforts to provide a legal regime for national security review comparable to similar procedures in other jurisdictions, such as CFIUS review in the U.S. There are still uncertainties with respect to the interpretation, implementation and enforcement of the Security Review Rules. For example, national security remains undefined and there is no clear guidance on whether the biotechnology industry requires security review and what factors the regulatory authority may consider in determining whether there are security concerns. It is difficult to evaluate the impact of the Security Review Rules on our existing investments or potential investments in China.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It may be difficult for overseas regulators to conduct investigations or collect evidence within China. In China, there are significant legal and other obstacles to providing information needed for regulatory investigations or litigations initiated outside China. According to Article 177 of the PRC Securities Law, no overseas securities regulator is allowed to directly conduct investigation or evidence collection activities within the PRC territory, which may increase the difficulties you face in protecting your interests. According to the Revised Confidentiality and Archives Administration Provisions, where overseas securities regulators or relevant competent authorities request to inspect, investigate or collect evidence from Chinese domestic companies concerning their overseas offering and listing or their securities firms and securities service providers that undertake securities business for such Chinese domestic companies, such inspection, investigation and evidence collection must be conducted under the cross-border regulatory cooperation mechanism, and the CSRC or competent authorities of the Chinese government will provide necessary assistance pursuant to bilateral and multilateral cooperation mechanism. Although the authorities in China may establish a regulatory cooperation mechanism with the securities regulatory authorities of another country or region to implement cross-border supervision and administration, such cooperation with the securities regulatory authorities in the Unities States may not be efficient in the absence of a mutual and practical cooperation mechanism. For risks associated with investing in us as a Cayman Islands company, see the risk factor titled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Because we are a Cayman Islands company, our shareholders may have fewer shareholder rights than they would have under Hong Kong law, Chinese law or U.S. law and may face difficulties in protecting their interests.&#8221;</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any administrative and court proceedings in the jurisdictions in which we operate, including China may be protracted, resulting in substantial costs and diversion of resources and management attention. Since administrative and court authorities have significant discretion in interpreting and implementing statutory and contractual terms, it may be difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection. These uncertainties may impede our ability to enforce the contracts we have entered and could materially and adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the PRC government has announced its plans to enhance its regulatory oversight of China-based companies listed overseas and cross-border law enforcement cooperation. The Securities Opinions called for:</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">tightening oversight of data security, cross-border data flow and administration of classified information, as well as amendments to relevant regulation to specify responsibilities of overseas listed China-based companies with respect to data security and information security;</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enhanced oversight of overseas listed companies as well as overseas equity fundraising and listing by China-based companies; and</span></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">extraterritorial application of China&#8217;s securities laws.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are uncertainties with respect to the interpretation and implementation of the Securities Opinions and the Overseas Listing Trial Measures. The PRC government may promulgate relevant laws, rules and regulations to impose additional and significant obligations and liabilities on overseas listed China-based companies regarding data security, cross-border data flow, and compliance with China&#8217;s securities laws. As a company with operations in China and stock listings in and outside of China, it is uncertain whether or how these laws, rules and regulations and their interpretation and implementation may affect us. However, among other things, our ability to obtain external financing through the issuance of equity securities overseas could be adversely affected if restrictions on overseas fundraising are imposed on companies like us.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Filing or other procedures with the CSRC or other Chinese regulatory authorities may be required in connection with issuing our equity securities to foreign investors under Chinese law, and, if required, we cannot predict whether we will be able, or how long it will take us, to complete such filing or other procedures. If we fail to complete a filing with the CSRC, our future offering application may be impacted and we may be subject to penalties, sanctions and fines imposed by the CSRC and relevant departments of the State Council.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous regulations, guidelines and other measures have been or are expected to be adopted in China under the umbrella of or in addition to the Cyber Security Law and Data Security Law. As there are still uncertainties regarding the interpretation and implementation of such regulatory guidance, we cannot assure investors that we will be able to comply with new regulatory requirements relating to our future overseas capital-raising activities outside of China and we may become subject to more stringent requirements with respect to matters including data privacy and cross-border investigation and enforcement of legal claims.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, the CSRC released the Overseas Listing Trial Measures and five relevant guidelines, requiring Chinese companies that have already directly or indirectly offered and listed securities in overseas markets to fulfill their filing obligations and report relevant information to the CSRC within three working days after conducting a follow-on offering of equity securities on the same overseas market. The Overseas Listing Trial Measures, the relevant guidelines and their implementation may continue to evolve. We may have to go through this filing process for any follow-on offerings we conduct on Nasdaq or Hong Kong Stock Exchange. If we fail to complete a filing with the CSRC for any of our follow-on offerings, we may be subject to penalties, sanctions and fines imposed by the CSRC and relevant departments of the State Council.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Annual Report, we have not received any inquiry, notice, warning or sanction regarding completing filing or other procedures in connection with offering our equity securities on Nasdaq or Hong Kong Stock Exchange from the CSRC or any other Chinese regulatory authorities that have jurisdiction over our operations. However, there remains uncertainty as to the interpretation and implementation of regulatory requirements related to securities offerings and other capital markets activities outside of China. If it is determined in the future that the filing or other procedure with the CSRC or any other regulatory authority is required for issuing our equity securities on Nasdaq or Hong Kong Stock Exchange, it is uncertain whether we will be able to and how long it would take for us to complete the filing or other procedure, despite our best efforts. If we, for any reason, are unable to complete, or experience significant delays in completing, the requisite relevant filing or other procedure(s), we may face sanctions by the CSRC or other Chinese regulatory authorities. These regulatory authorities may impose fines and penalties on our operations in China, limit our ability to pay dividends outside of China, limit our operations in China, delay or restrict the repatriation of funds into China or take other actions that could have a material adverse effect on our business, financial condition, results of operations and prospects, as well as the trading price of our ADSs, ordinary shares, and RMB Shares. In addition, if the CSRC or other regulatory authorities later promulgate new rules requiring that we obtain their approvals or complete filing or other procedures for any future public offerings on Nasdaq or Hong Kong Stock Exchange, we may be unable to obtain a waiver of such requirements, if and when procedures are established to obtain such a waiver. Any uncertainties and/or negative publicity regarding such a requirement could have a material adverse effect on the trading price of our ADSs, ordinary shares, and RMB Shares.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PRC regulations establish complex procedures for some acquisitions conducted by foreign investors, which could make it more difficult for us to pursue growth through acquisitions in China.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PRC regulations and rules concerning mergers and acquisitions set forth additional procedures and requirements that could make merger and acquisition activities of PRC-based companies by foreign investors more time-consuming and complex. See the risk factor titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we engage in acquisitions or strategic collaborations, this may increase our capital requirements, dilute our shareholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221; These rules, among others, specify that mergers and acquisitions by foreign investors that raise &#8220;national defense and security&#8221; concerns and mergers and acquisitions through which foreign investors may acquire the de facto control over domestic enterprises that raise &#8220;national security&#8221; concerns are subject to strict review by the MOFCOM, and the rules prohibit any activities attempting to bypass a security review by structuring the transaction through, among other things, trusts, entrustment or contractual control arrangements. Although we believe that our business is not in an industry related to national security, we cannot preclude the possibility that the competent PRC government authorities may publish explanations contrary to our understanding or broaden the scope of such security reviews in the future, in which case our future acquisitions and investment in the PRC, including those by way of entering into contractual control arrangements with target entities, may be closely scrutinized or prohibited. Moreover, according to the Anti-Monopoly Law, the SAMR shall be notified in advance of any concentration of undertaking if certain filing thresholds are triggered. We may grow our business in part by acquiring complementary businesses in China. Complying with the requirements of the laws and regulations mentioned above and other PRC regulations to complete such transactions could be time-consuming, and any required approval processes, including obtaining approval from the SAMR, may delay or inhibit our ability to complete such transactions, which could affect our ability to expand our business or maintain or expand our market share. Our ability to expand our business or maintain or expand our market share through future acquisitions would as such be materially and adversely affected.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Foreign Investment Security Review Measures promulgated by the NDRC and the MOFCOM came into effect. Pursuant to these measures investments in military, national defense-related areas or in locations in proximity to military facilities, or investments that would result in acquiring the actual control of assets in certain key sectors, such as critical agricultural products, energy and resources, equipment manufacturing, infrastructure, transport, cultural products and services, IT, Internet products and services, financial services and technology sectors, are required to be approved by designated governmental authorities in advance. Official guidance for these measures has not been issued by the designated office in charge of such security review yet, therefore there are great uncertainties with respect to the interpretation and implementation of the Foreign Investment Security Review Measures, including the scope of key sectors. If any of our business operations were to fall under the foregoing categories, we would need to take further actions in order to comply with these laws, regulations and rules, which may materially and adversely affect our current corporate structure, business, financial condition and results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may rely on dividends and other distributions on equity paid by our PRC subsidiaries to fund any cash and financing requirements we may have, and any limitation on the ability of our PRC subsidiaries to make payments to us could have a material and adverse effect on our ability to conduct our business.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a holding company incorporated in the Cayman Islands, and we may rely on dividends and other distributions on equity paid by our PRC subsidiaries for our cash and financing requirements, including the funds necessary to pay dividends and other cash distributions to our shareholders or to service any debt we may incur. If any of our PRC subsidiaries incur debt on their own behalf in the future, the instruments governing the debt may restrict their ability to pay dividends or make other distributions to us. Under PRC laws and regulations, our PRC subsidiaries may pay dividends only out of their respective accumulated profits as determined in accordance with PRC accounting standards and regulations. In addition, a wholly foreign- owned enterprise is required to set aside at least 10% of its accumulated after-tax profits each year, if any, to fund a certain statutory reserve fund, until the aggregate amount of such fund reaches 50% of its registered capital. Such reserve funds cannot be distributed to us as dividends until the liquidation of the enterprise. At its discretion, a wholly foreign-owned enterprise may allocate a portion of its after-tax profits based on PRC accounting standards to an enterprise expansion fund, or a staff welfare and bonus fund. In addition, registered share capital and capital reserve accounts are also restricted from withdrawal in the PRC, up to the amount of net assets held in each operating subsidiary. As of December&#160;31, 2024, these restricted assets totaled $1.7 billion.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our PRC subsidiaries generate primarily all of their revenue in RMB, which is not freely convertible into other currencies. As a result, any restriction on currency exchange may limit the ability of our PRC subsidiaries to use their RMB revenues to pay dividends to us.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the persistent capital outflow in the PRC and RMB&#8217;s depreciation against the U.S. dollar, the People&#8217;s Bank of China (&#8220;PBOC&#8221;) and China&#8217;s State Administration of Foreign Exchange (&#8220;SAFE&#8221;) promulgated a series of measures relating to oversight of capital flow in 2016, including stricter vetting procedures for domestic companies to remit foreign currency for overseas investments, dividends payments and shareholder loan repayments. The PRC government may continue to strengthen its oversight of capital flow, and more regulations and substantial vetting process may be put forward by the SAFE for cross-border transactions. Any limitation on the ability of our PRC subsidiaries to pay dividends or make other kinds of payments to us could materially and adversely limit our ability to grow, make investments or acquisitions that could be beneficial to our business, pay dividends, or otherwise fund and conduct our business.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PRC Enterprise Income Tax Law (the &#8220;EIT Law&#8221;) and its implementation rules provide that China-sourced income of foreign enterprises, such as dividends paid by a PRC subsidiary to its equity holders that are non-PRC resident enterprises, will normally be subject to PRC withholding tax at a rate of 10%, unless any such foreign investor&#8217;s jurisdiction of tax residency has a tax treaty with China that provides for a reduced withholding rate arrangement and such non-PRC resident enterprises constitute the beneficiary of such income.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to an arrangement between mainland China and the Hong Kong Special Administrative Region (the &#8220;Hong Kong Tax Treaty&#8221;) and relevant tax regulations of the PRC, subject to certain conditions, a reduced withholding tax rate of 5% will be available for dividends from PRC entities provided that the recipient holds at least 25% shares of the PRC entities and can demonstrate it is a Hong Kong tax resident and it is the beneficial owner of the dividends. The China government has adopted multiple regulations which stipulate that in determining whether a non-resident enterprise has the status as a beneficial owner, comprehensive analysis shall be conducted based on the factors listed therein and the actual circumstances of the specific case shall be taken into consideration. Specifically, it expressly excludes an agent or a designated payee from being considered as a &#8220;beneficial owner.&#8221; We own the PRC subsidiaries through BeiGene (Hong Kong) Co., Limited (&#8220;BeiGene HK&#8221;), a company incorporated under the laws of Hong Kong on November 22, 2010 and a wholly owned subsidiary of the Company. BeiGene HK currently does not hold a Hong Kong tax resident certificate from the Inland Revenue Department of Hong Kong, and there is no assurance that the reduced withholding tax rate will be available.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be treated as a resident enterprise for PRC tax purposes under the EIT Law and we may therefore be subject to PRC income tax on our worldwide taxable income. Dividends payable to foreign investors and gains on the sale of our ADSs or ordinary shares by our foreign investors may become subject to PRC tax.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the EIT Law, an enterprise established outside the PRC with &#8220;de facto management bodies&#8221; within the PRC is considered a &#8220;resident enterprise,&#8221; meaning that it is treated in a manner similar to a Chinese enterprise for PRC enterprise income tax purposes. The implementing rules of the EIT Law define &#8220;de facto management bodies&#8221; as &#8220;management bodies that exercise substantial and overall management and control over the production and operations, personnel, accounting, and properties&#8221; of the enterprise. In addition, PRC regulations specify that certain Chinese-controlled offshore incorporated enterprises, defined as enterprises incorporated under the laws of foreign countries or territories and that have PRC enterprises or enterprise groups as their primary controlling shareholders, will be classified as resident enterprises if all of the following are located or resident in China: (i) senior management personnel and departments that are responsible for daily production, operation and management; (ii) financial and personnel decision-making bodies; (iii) key properties, accounting books, company seal, and minutes of board meetings and shareholders&#8217; meetings; and (iv) half or more of senior management or directors having voting rights.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although BeiGene, Ltd. does not have a PRC enterprise or enterprise group as its primary controlling shareholder and is therefore not a Chinese-controlled offshore incorporated enterprise within the meaning of these regulations, in the absence of guidance specifically applicable to us, we have applied the guidance set forth in the regulations to evaluate the tax residence status of BeiGene, Ltd. and its subsidiaries organized outside of the PRC.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not aware of any offshore holding company with a corporate structure similar to ours that has been deemed a PRC &#8220;resident enterprise&#8221; by the PRC tax authorities. Accordingly, we do not believe that our company or any of our overseas subsidiaries should be treated as a PRC resident enterprise. However, the tax resident status of an enterprise is subject to determination by the PRC tax authorities and uncertainties remain with respect to the interpretation of the term &#8220;de facto management body.&#8221; If the PRC tax authorities determine that our Cayman Islands holding company is a resident enterprise for PRC enterprise income tax purposes, a number of unfavorable PRC tax consequences could follow and we may be subject to enterprise income tax at a rate of 25% on our worldwide taxable income, as well as to PRC enterprise income tax reporting obligations. If we are deemed a PRC resident enterprise, dividends paid on our shares and any gain realized from the transfer of our ordinary shares may be treated as income derived from sources within the PRC. As a result, dividends paid to non-PRC resident enterprise ADS holders or shareholders may be subject to PRC withholding tax at a rate of 10% (or 20% in the case of non-PRC individual ADS holders or shareholders) and gains realized by non-PRC resident enterprises ADS holders or shareholders from the transfer of our ordinary shares or ADSs may be subject to PRC tax at a rate of 10% (or 20% in the case of non-PRC individual ADS holders or shareholders), which may be reduced or exempted according to relevant tax treaties between PRC and the non-PRC resident enterprise/individual ADS holders&#8217; or shareholders&#8217; tax resident jurisdictions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our shareholders face uncertainties with respect to indirect transfers of equity interests in PRC resident enterprises or other assets attributed to a PRC establishment of a non-PRC company, or other assets attributable to a PRC establishment of a non-PRC company.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Chinese regulations, an &#8220;indirect transfer&#8221; of &#8220;PRC taxable assets,&#8221; including equity interests in a PRC resident enterprise, by non-PRC resident enterprises may be recharacterized and treated as a direct transfer of PRC taxable assets, if such arrangement does not have a reasonable commercial purpose and was established for the purpose of avoiding payment of PRC enterprise income tax. As a result, gains derived from such indirect transfer may be subject to PRC enterprise income tax. When determining whether there is a &#8220;reasonable commercial purpose&#8221; of the transaction arrangement, factors to be taken into consideration include: whether the main value of the equity interest of the relevant offshore enterprise derives from PRC taxable assets; whether the assets of the relevant offshore enterprise mainly consists of direct or indirect investment in the PRC or if its income mainly derives from the PRC; whether the offshore enterprise and its subsidiaries directly or indirectly holding PRC taxable assets have real commercial nature which is evidenced by their actual function and risk exposure; the duration of existence of the business model and organizational structure; the replicability of the transaction by direct transfer of PRC taxable assets; and the tax situation of such indirect transfer and applicable tax treaties or similar arrangements. In respect of an indirect offshore transfer of assets of a PRC establishment, the resulting gain is to be reported on with the enterprise income tax filing of the PRC establishment or place of business being transferred and would consequently be subject to PRC enterprise income tax at a rate of 25%. Where the underlying transfer relates to equity investments in a PRC resident enterprise, which is not related to a PRC establishment or place of business of a non-resident enterprise, a PRC enterprise income tax at the rate of 10% would apply, subject to available preferential tax treatment under applicable tax treaties or similar arrangements. Late payment of applicable tax will subject the transferor to default interest. Gains derived from the sale of shares by investors through a public stock exchange are not subject to the PRC enterprise income tax where such shares were acquired in a transaction through a public stock exchange. As such, the sale of the ADSs or ordinary shares on a public stock exchange will not be subject to PRC enterprise income tax. However, the sale of our ordinary shares or ADSs originally purchased from a stock exchange by a non-PRC resident enterprise outside a public stock exchange may be subject to PRC enterprise income tax under these regulations.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are uncertainties as to the application of these regulations, which may be determined by the tax authorities to be applicable to sale of the shares of our offshore subsidiaries or investments where PRC taxable assets are involved. The transferors and transferees may be subject to the tax filing and withholding or tax payment obligation, while our PRC subsidiaries may be requested to assist in the filing. Furthermore, we, our non-resident enterprises and PRC subsidiaries may be required to spend valuable resources to comply with these regulations or to establish that we and our non-resident enterprises should not be taxed under these regulations, for our previous and future restructuring or disposal of shares of our offshore subsidiaries, which may have a material adverse effect on our financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PRC tax authorities have the discretion to make adjustments to the taxable capital gains based on the difference between the fair value of the taxable assets transferred and the cost of investment. If the PRC tax authorities make adjustments to the taxable income of the transactions under these regulations, our income tax costs associated with such potential acquisitions or disposals will increase, which may have an adverse effect on our financial condition and results of operations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulations on currency exchange may limit our ability to utilize our revenue effectively.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PRC government exerts oversight on the conversion of RMB into foreign currencies and, in certain cases, the remittance of currency out of the PRC. A portion of our revenue is denominated in RMB. Shortages in availability of foreign currency may restrict the ability of our PRC subsidiaries to remit sufficient foreign currency to our offshore entities for our offshore entities to pay dividends or make other payments or otherwise to satisfy our foreign currency denominated obligations. The RMB is currently convertible under the &#8220;current account,&#8221; which includes dividends, trade and service-related foreign exchange transactions, but not under the &#8220;capital account,&#8221; which includes foreign direct investment and loans, including loans we may secure from our onshore subsidiaries. Currently, our PRC subsidiaries may purchase foreign currency for settlement of &#8220;current account transactions,&#8221; including payment of dividends to us, without the approval of SAFE by complying with certain procedural requirements. Since a portion of our revenue is denominated in RMB, any existing and future regulations on currency exchange may limit our ability to utilize revenue generated in RMB to fund our business activities outside of the PRC or pay dividends in foreign currencies to holders of our ordinary shares and the ADSs. Foreign exchange transactions under the capital account remain subject to limitations and require approvals from, or registration with, SAFE and other relevant PRC governmental authorities or designated banks. This could affect our ability to obtain foreign currency through debt or equity financing for our subsidiaries.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business benefits from certain financial incentives and discretionary policies granted by local governments. Expiration of, or changes to, these incentives or policies would have an adverse effect on our results of operations.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Local governments in the PRC have granted certain financial incentives from time to time to our PRC subsidiaries as part of their efforts to encourage the development of local businesses. The timing, amount and criteria of government financial incentives are determined within the discretion of the local government authorities and cannot be predicted with certainty before we actually receive any financial incentive. We generally do not have the ability to influence local governments in making these decisions. Local governments may decide to reduce or eliminate incentives at any time. In addition, some of the government financial incentives are granted on a project basis and subject to the satisfaction of certain conditions, including compliance with the applicable financial incentive agreements and completion of the specific project therein. We cannot guarantee that we will satisfy all relevant conditions, and if we do so we may be deprived of the relevant incentives. We cannot assure you of the continued availability of the government incentives currently enjoyed by us. Any reduction or elimination of incentives would have an adverse effect on our results of operations.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any failure to comply with PRC regulations regarding our employee equity plans and investments in offshore companies by PRC residents may subject the PRC plan participants and PRC-resident beneficial owners or us to fines and other legal or administrative sanctions.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our directors, executive officers and other employees who are PRC residents have participated in our employee equity plans. We are an overseas listed company, and therefore, we and our directors, executive officers and other employees who are PRC citizens or who have resided in the PRC for a continuous period of not less than one year and who have been granted restricted share units, restricted shares, options or other forms of equity incentives or rights to acquire equity are subject to the PRC regulations, according to which, employees, directors, supervisors and other management members participating in any share incentive plan of an overseas publicly listed company who are PRC citizens or who are non-PRC citizens residing in the PRC for a continuous period of not less than one year, subject to limited exceptions, are required to register with the SAFE through a domestic qualified agent, which could be a PRC subsidiary of such overseas listed company, and complete certain other procedures. We also face regulatory uncertainties that could restrict our ability to adopt additional equity incentive plans for our directors and employees under PRC law. Moreover, failure to comply with the various foreign exchange registration requirements could result in liability under PRC law for circumventing applicable foreign exchange restrictions.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The pharmaceutical industry in China is highly regulated, and such regulations are subject to change, which may affect approval and commercialization of our medicines and drug candidates.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A large portion of our business is conducted in China. The pharmaceutical industry in China is subject to comprehensive government regulation and supervision, encompassing the approval, registration, manufacturing, packaging, licensing and marketing of new medicines. In recent years, the regulatory framework in China for pharmaceutical companies has undergone significant changes, which we expect will continue. While we believe our strategies regarding research, development, manufacturing and commercialization in China are aligned with the Chinese government&#8217;s policies, they may in the future diverge, requiring a change in our strategies. Any such change may result in increased compliance costs on our business or cause delays in or prevent the successful research, development, manufacturing or commercialization of our drug candidates or medicines in China and reduce the current benefits we believe are available to us from developing and manufacturing medicines in China.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chinese authorities have become increasingly active in enforcing laws affecting the pharmaceutical industry. Specifically, the Chinese authorities have recently increased anti-bribery efforts to address improper payments and other benefits received by physicians, staff and hospital administrators in connection with the sales, marketing and purchase of pharmaceuticals products. Any failure by us or our partners to maintain compliance with applicable laws and regulations or obtain and maintain required licenses and permits may result in the suspension or termination of our business activities in China. Reports of what have come to be viewed as significant quality-control failures by Chinese vaccine manufacturers have led to enforcement actions against officials responsible for implementing national reforms favorable to innovative drugs (such as ours).This macro-industry event could cause state or private resources to be diverted away from fostering innovation and be redirected toward regulatory enforcement, which could adversely affect our research, development, manufacturing and commercialization activities and increase our compliance costs.</span></div><div id="ic94bd2152a214042a118e81881a5a1e5_97"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Ordinary Shares, ADSs, and RMB Shares</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The trading prices of our ordinary shares, ADSs, and/or RMB Shares can be volatile, which could result in substantial losses to you.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our ordinary shares, ADSs, and/or RMB Shares can be volatile and fluctuate widely in response to a variety of factors, many of which are beyond our control, including: announcements of regulatory approval or a complete response letter, or specific label indications or patient populations for its use, or changes or delays in the regulatory review process; announcements of therapeutic innovations, new products, acquisitions, strategic relationships, joint ventures or capital commitments by us or our competitors; adverse actions taken by regulatory agencies with respect to our clinical trials, manufacturing supply chain or sales and marketing activities; any adverse changes to our relationship with manufacturers or suppliers; the results of our testing and clinical trials; the results of our efforts to acquire or license additional medicines or drug candidates; variations in the level of expenses related to our existing medicines and drug candidates or preclinical, clinical development and commercialization programs; any intellectual property infringement actions in which we may become involved; announcements concerning our competitors or the pharmaceutical industry in general; the performance and fluctuation of the market prices of other companies with significant business operations in China that have listed their securities in Hong Kong, Shanghai or the U.S.; fluctuations in product revenue, sales and marketing expenses and profitability; manufacture, supply or distribution shortages; variations in our results of operations; announcements about our results of operations that are not in line with analyst expectations, the risk of which is enhanced because it is our policy not to give guidance on results of operations; publication of operating or industry metrics by third parties, including government statistical agencies, that differ from expectations of industry or financial analysts; changes in financial estimates by securities research analysts; media reports, whether or not true, about our business, our competitors or our industry; additions to or departures of our management; fluctuations of exchange rates between the RMB, the U.S. dollar and Hong Kong dollar; release or expiry of lock-up or other transfer restrictions on our outstanding ordinary shares, ADSs or RMB Shares; sales or perceived potential sales of additional ordinary shares, ADSs or RMB Shares by us, our executive officers and directors or our shareholders; general economic and market conditions and overall fluctuations in the U.S., Hong Kong or Shanghai equity markets; changes in accounting principles; trade disputes or U.S.-China government relations; and changes or developments in the U.S., PRC, the EU or global regulatory environment.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock market, in general, and pharmaceutical and biotechnology companies, in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our ordinary shares, ADSs, and/or RMB Shares, regardless of our actual operating performance.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The characteristics of capital markets in the United States, Hong Kong and Shanghai are different, which may cause volatility in the market price of our ordinary shares, ADSs, and RMB Shares.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ordinary shares are listed on the HKEx in Hong Kong under the stock code &#8220;06160&#8221;, our ADSs are listed on Nasdaq in the U.S. under the symbol &#8220;ONC&#8221;, and our RMB Shares are listed on the STAR Market in the PRC under the stock code &#8220;688235&#8221;. Under current PRC laws and regulations, our ADSs and ordinary shares listed on Nasdaq and the HKEx are not interchangeable or fungible with the RMB Shares listed on the STAR Market, and there is no trading or settlement between either Nasdaq or the HKEx on the one hand, and the STAR Market on the other hand. The three markets have different trading hours, trading characteristics (including trading volume and liquidity), trading and listing rules, and investor bases (including different levels of retail and institutional participation). As a result of these major differences, the trading prices of our ordinary shares, ADSs, and RMB Shares might not be the same, even allowing for currency differences. Fluctuations in the price of our ADSs due to circumstances peculiar to its home capital market could materially and adversely affect the price of the ordinary shares and/or RMB Shares, and vice versa. Because of the different characteristics of the U.S., Hong Kong and Shanghai equity markets, the historic market prices of our ordinary shares, ADSs, and RMB Shares may not be indicative of the performance of our securities going forward.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to securities litigation, which is expensive and could divert management attention.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies that have experienced volatility in the volume and market price of their shares have been subject to an increased incidence of securities class action litigation, particularly in our industry in recent years. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and/or reputational harm and divert our management&#8217;s attention from other business concerns, and, if adversely determined, could have a material adverse effect on our business, financial condition, and results of operations.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales of our ordinary shares, ADSs, and/or RMB Shares in the public market could cause the ordinary share, ADS, and/or RMB Share price to fall.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The price of our ordinary shares, ADSs, and/or RMB Shares could decline as a result of sales of a large number of the ordinary shares, ADSs, and/or RMB Shares or the perception that these sales could occur. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of February&#160;14, 2025, 1,387,367,704 ordinary shares, par value $0.0001 per share, were outstanding, of which 870,983,672 ordinary shares were held in the form of 66,998,744 ADSs, each representing 13 ordinary shares, and 115,055,260 were RMB Shares.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We filed a registration statement on Form S-3 with the SEC on behalf of certain shareholders on May 9, 2023, registering 298,738,765 ordinary shares, including 222,835,028 ordinary shares in the form of 17,141,156 ADSs to be resold by the selling shareholders identified therein and in any related prospectus supplement from time to time. Amgen also has specified registration rights pursuant to its share purchase agreement. Furthermore, we have registered or plan to register the offer and sale of all securities that we have issued and may issue in the future under our equity compensation plans, including upon the exercise of share options and vesting of restricted share units and under our employee share purchase plan. If these additional securities are sold, or if it is perceived that they will be sold, in the public market, the trading price of our ordinary shares, ADSs and/or RMB Shares could decline.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in the future, we may issue additional ordinary shares, ADSs, RMB Shares, or other equity or debt securities convertible into ordinary shares, ADSs, or RMB Shares in connection with a financing, acquisition, license, litigation settlement, employee arrangements or otherwise. Any such issuance could result in substantial dilution to our existing shareholders and could cause the ordinary share, ADS, and/or RMB Share price to decline.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The triple listing of our ADSs, ordinary shares and RMB Shares may adversely affect the liquidity and value of our ADSs, ordinary shares and/or RMB Shares and lead to increased compliance obligations and costs.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ADSs are traded on Nasdaq, our existing ordinary shares maintained on our Cayman register in Cayman Islands and Hong Kong register in Hong Kong, are traded on the HKEx, and our RMB Shares are traded on the STAR Market. The triple listing of our ADSs, ordinary shares and RMB Shares may dilute the liquidity of these securities in one or all three markets and may adversely affect the maintenance of an active trading market for ADSs in the U.S., the ordinary shares in Hong Kong, and/or the RMB Shares in the PRC. The price of our ADSs, ordinary shares and/or RMB Shares could also be adversely affected by trading of our securities on other markets. We may decide at some point in the future to delist our securities from one or more of the stock exchanges where they are currently traded, subject to our shareholders&#8217; approval if required. We cannot predict the effect such delisting of our securities from one or more of the stock exchanges would have on the market price of our securities on the other stock exchanges. Additionally, </span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the listing and trading of our equity securities in multiple jurisdictions and multiple markets has resulted in increased compliance obligations and costs for us, and we may face the risk of significant intervention by regulatory authorities in these jurisdictions and markets, such as inquiries, investigations, enforcement actions and other regulatory proceedings by regulatory authorities. In addition, we may be subject to securities litigation filed with the courts in China by the investors with respect to the RMB Shares traded on the STAR Market.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we do not expect to pay dividends in the foreseeable future, you must rely on price appreciation of the ordinary shares, ADSs and/or RMB Shares for return on your investment.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to retain most, if not all, of our available funds and earnings to fund the development and growth of our business. As a result, we do not expect to pay any cash dividends in the foreseeable future. Therefore, you should not rely on an investment in the ordinary shares, ADSs and/or RMB Shares as a source for any future dividend income.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors has significant discretion as to whether to distribute dividends. Even if our board of directors decides to declare and pay dividends, the timing, amount and form of future dividends, if any, will depend on, among other things, our future results of operations and cash flow, our capital requirements and surplus, the amount of distributions, if any, received by us from our subsidiaries, our financial condition, contractual and regulatory restrictions and other factors deemed relevant by our board of directors. Accordingly, the return on your investment in the ordinary shares, ADSs and/or RMB Shares will likely depend entirely upon any future price appreciation of the ordinary shares, ADSs and/or RMB Shares. There is no guarantee that the ordinary shares, ADSs and/or RMB Shares will appreciate in value or even maintain the price at which you purchased the ordinary shares, ADSs and/or RMB Shares. You may not realize a return on your investment in the ordinary shares, ADSs and/or RMB Shares and you may even lose your entire investment in the ordinary shares, ADSs and/or RMB Shares.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not continue to publish research or publish inaccurate or unfavorable research about our business, the market price for the ordinary shares, ADSs and/or RMB Shares and trading volume could decline.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for the ordinary shares, ADSs and RMB Shares relies in part on the research and reports that equity research analysts publish about us or our business. We do not control these analysts. If research analysts do not maintain adequate research coverage or if one or more of the analysts who covers us downgrades the ordinary shares, ADSs and/or RMB Shares or publishes inaccurate or unfavorable research about our business, the market price for the ordinary shares, ADSs and/or RMB Shares would likely decline. Historically, we are aware of instances in which analysts have published inaccurate research about our business. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which, in turn, could cause the market price or trading volume for the ordinary shares, ADSs and/or RMB Shares to decline significantly.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we are a Cayman Islands company, our shareholders may have fewer shareholder rights than they would have under Hong Kong law, Chinese law or U.S. law and may face difficulties in protecting their interests.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an exempted company with limited liability incorporated in the Cayman Islands. Our corporate affairs are governed by our amended and restated memorandum and articles of association (as may be further amended from time to time), the Companies Law (as amended) of the Cayman Islands, and the common law of the Cayman Islands. The rights of our shareholders and the fiduciary responsibilities of our directors under Cayman Islands law are not as clearly established as they would be under statutes or judicial precedent in some jurisdictions in Hong Kong, mainland China and the U.S. In particular, the Cayman Islands has a less developed body of securities law than Hong Kong, mainland China or the U.S. and less judicially interpreted body of corporate law than in Delaware.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a Cayman Islands exempted company, our shareholders have no general rights under Cayman Islands law to inspect corporate records and accounts or to obtain copies of lists of shareholders. Our directors have to determine whether or not, and under what conditions, our corporate records may be inspected by our shareholders, but are not obliged to make them available to our shareholders. This may make it more difficult for shareholders to obtain the information needed to establish facts necessary for a shareholder action or to solicit proxies from other shareholders in connection with a proxy contest. As a Cayman Islands company, we may not have standing to initiate a derivative action in a Hong Kong, mainland China or U.S. federal court. As a result, shareholders may be limited in their ability to protect their interests if they are harmed in a manner that would otherwise enable them to sue in a U.S. federal court. In addition, shareholders of Cayman Islands companies may not have standing to initiate a shareholder derivative action in Hong Kong, mainland China or U.S. federal courts.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our directors and executive officers reside outside of Hong Kong and the U.S. and a substantial portion of their assets are located outside of Hong Kong and the U.S. As a result, it may be difficult or impossible for shareholders to bring an action against us or against these individuals in Hong Kong or in the U.S. in the event that shareholders believe that their rights have been infringed under the securities laws of Hong Kong, the U.S. or otherwise. In addition, some of our directors and executive officers reside outside of China. To the extent our directors and executive officers reside outside of China or their assets are located outside of China, it may not be possible for investors to effect service of process upon us or our management inside China. Even if shareholders are successful in bringing an action, the laws of the Cayman Islands and China may render them unable to enforce a judgment against our assets or the assets of our directors and officers. There is no statutory recognition in the Cayman Islands of judgments obtained in the U.S., Hong Kong or China, although the courts of the Cayman Islands will generally recognize and enforce a non-penal judgment of a foreign court of competent jurisdiction without retrial on the merits.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the above, shareholders may have more difficulty protecting their interests in the face of actions taken by management, members of the board of directors or controlling shareholders than they would as shareholders of a Hong Kong company, a Chinese company or a U.S. company.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voting rights of our ADS holders are limited by the terms of the deposit agreement. The depositary for the ADSs will give us a discretionary proxy to vote the ordinary shares underlying our ADS holders&#8217; ADSs if they do not vote at shareholders&#8217; meetings, except in limited circumstances, which could adversely affect their interests.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of our ADSs may exercise their voting rights with respect to the ordinary shares underlying their ADSs only in accordance with the provisions of the deposit agreement. Upon receipt of voting instructions from ADS holders in the manner set forth in the deposit agreement, the depositary for the ADSs will endeavor to vote the holder&#8217;s underlying ordinary shares in accordance with these instructions. Under our articles of association, the minimum notice period required for convening an annual general meeting is 21 calendar days and the minimum notice period required for convening an extraordinary general meeting is 14 calendar days. When a general meeting is convened, ADS holders may not receive sufficient notice of a shareholders&#8217; meeting to permit them to withdraw their ordinary shares to allow them to cast their vote with respect to any specific matter at the meeting. In addition, the depositary and its agents may not be able to send voting instructions to ADS holders or carry out their voting instructions in a timely manner. We will make reasonable efforts to cause the depositary to extend voting rights to our ADS holders in a timely manner, but our ADS holders may not receive the voting materials in time to ensure that they can vote or instruct their agent to vote their shares.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the depositary and its agents will not be responsible for any failure to carry out any instructions to vote, for the manner in which any vote is cast or for the effect of any such vote. As a result, ADS holders may not be able to exercise their right to vote and they may lack recourse if the ordinary shares underlying their ADSs are not voted as they requested.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the deposit agreement for the ADSs, the depositary will give us a discretionary proxy to vote the ordinary shares underlying ADS holders&#8217; ADSs at shareholders&#8217; meetings if such holders do not give voting instructions to the depositary, unless we have failed to timely provide the depositary with our notice of meeting and related voting materials, we have instructed the depositary that we do not wish a discretionary proxy to be given, we have informed the depositary that there is substantial opposition as to a matter to be voted on at the meeting, or a matter to be voted on at the meeting would have a material adverse impact on shareholders.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effect of this discretionary proxy is that, if ADS holders fail to give voting instructions to the depositary, they cannot prevent the ordinary shares underlying their ADSs from being voted, absent the situations described above, and it may make it more difficult for such ADS holders to influence our management. Holders of our ordinary shares are not subject to this discretionary proxy.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our constitutional documents may discourage our acquisition by a third party, which could limit our shareholders&#8217; opportunity to sell their shares at a premium.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated memorandum and articles of association include provisions that could limit the ability of others to acquire control of our company, could modify our structure or could cause us to engage in change-of-control transactions. These provisions could have the effect of depriving our shareholders of an opportunity to sell their shares, at a premium over prevailing market prices by discouraging third parties from seeking to obtain control in a tender offer or similar transaction.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, our board of directors has the authority, without further action by our shareholders, to issue preferred shares in one or more series and to fix the powers and rights of these shares, including dividend rights, conversion rights, voting rights, terms of redemption and liquidation preferences, any or all of which may be greater than the rights associated with our ordinary shares. Preferred shares could thus be issued quickly with terms calculated to delay or prevent a change in control or make removal of management more difficult. In addition, if our board of directors authorizes the issuance of preferred shares, the market price of the ordinary shares and/or ADSs may fall and the voting and other rights of the holders of our ordinary shares and/or ADSs may be materially and adversely affected.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our directors are divided into three classes with staggered terms of three years each, shareholders can only elect or remove a limited number of our directors in any given year. The length of these terms could present an obstacle to certain actions, such as a merger or other change of control, which could be in the interest of our shareholders.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated memorandum and articles of association designate specific courts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our shareholders, which could limit our shareholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or other employees.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated memorandum and articles of association provide that, unless we consent in writing to the selection of an alternative forum, the courts of Cayman Islands will be the sole and exclusive forum for any derivative action or proceeding brought on behalf of us, any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of us to us or our shareholders, any action asserting a claim arising pursuant to any provision of the Companies Law of the Cayman Islands as amended from time to time, or the amended and restated memorandum and articles of association, or any action asserting a claim governed by the internal affairs doctrine (as such concept is recognized under the U.S. laws). Our amended and restated memorandum and articles of association further state that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the U.S. shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) and provide that any person or entity purchasing or otherwise acquiring any interest in any of our securities is deemed to have notice of and consented to these provisions; provided, however, that shareholders cannot and will not be deemed to have waived our compliance with U.S. federal securities laws and rules and regulations thereunder.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions may limit a shareholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated memorandum and articles of association provide that any shareholder bringing an unsuccessful action against us may be obligated to reimburse us for any costs we have incurred in connection with such unsuccessful action.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated memorandum and articles of association provide that under certain circumstances parties who bring actions or proceedings against us may be obligated to reimburse us for all fees, costs, and expenses, including but not limited to all reasonable attorneys&#8217; fees and other litigation expenses, that we incur in connection with such claim, to the extent the claimant is unsuccessful in obtaining a judgment on the merits in which the claiming party prevails. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The case law and potential legislative action on such fee-shifting articles are evolving and there exists considerable uncertainty regarding the validity of, and potential judicial and legislative responses to, such articles. Consistent with our directors&#8217; fiduciary duties to act in the best interests of the Company, the directors may in their sole discretion from time to time decide whether or not to enforce this article. In addition, given the unsettled state of the law related to fee-shifting articles, we may incur significant additional costs associated with resolving disputes with respect to such articles, which could adversely affect our business and financial condition.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a shareholder that brings any such claim or proceeding is unable to obtain the judgment sought, the attorneys&#8217; fees and other litigation expenses that might be shifted to a claiming party may be significant. This fee-shifting article, therefore, may dissuade or discourage current or former shareholders (and their attorneys) from initiating lawsuits or claims against us. In addition, it may impact the fees, contingency or otherwise, required by potential plaintiffs&#8217; attorneys to represent our shareholders or otherwise discourage plaintiffs&#8217; attorneys from representing our shareholders at all. As a result, this article may limit the ability of shareholders to affect the management and direction of our company, particularly through litigation or the threat of litigation.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Holders of ADSs may be subject to limitations on transfer of their ADSs.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADSs are transferable only on the books of the depositary. However, the depositary may close its books at any time it deems expedient in connection with the performance of its duties. The depositary may refuse to deliver, transfer or register transfers of ADSs when our books or the books of the depositary are closed, or at any time if we or the depositary think it is advisable to do so because of any requirement of law, under any provision of the deposit agreement or for any other reason, subject to ADS holders&#8217; right to cancel their ADSs and withdraw the underlying ordinary shares. Temporary delays in the cancellation of ADSs and withdrawal of the underlying ordinary shares may arise because the depositary has closed its books or we have closed our books, the transfer of ordinary shares is blocked to permit voting at a shareholders&#8217; meeting or we are paying a dividend on our ordinary shares.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, holders of ADSs may not be able to cancel their ADSs and withdraw the underlying ordinary shares when they owe money for fees, taxes and similar charges and when it is necessary to prohibit withdrawals in order to comply with any laws or governmental regulations that apply to ADSs or to the withdrawal of ordinary shares or other deposited securities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The depositary for the ADSs is entitled to charge holders fees for various services, including annual service fees.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depositary for the ADSs is entitled to charge holders fees for various services, including for the issuance of ADSs upon deposit of ordinary shares, cancellation of ADSs, distributions of cash dividends or other cash distributions, distributions of ADSs pursuant to share dividends or other free share distributions, distributions of securities other than ADSs, and annual service fees. In the case of ADSs issued by the depositary into The Depository Trust Company (&#8220;DTC&#8221;), the fees will be charged by the DTC participant to the account of the applicable beneficial owner in accordance with the procedures and practices of the DTC participant as in effect at the time.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dealings in ordinary shares registered in our Hong Kong register of members will be subject to Hong Kong stamp duty. There is uncertainty as to whether Hong Kong stamp duty will apply to the trading or conversion of the ADSs.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our Hong Kong public offering in 2018, we established a branch register of members in Hong Kong (the &#8220;Hong Kong share register&#8221;). Our ordinary shares that are traded on the HKEx, including those that may be converted from ADSs, are registered on the Hong Kong share register, and the trading of these ordinary shares on the HKEx are subject to Hong Kong stamp duty. To facilitate ADS to ordinary share conversion and trading between Nasdaq and the HKEx, we moved a portion of our issued ordinary shares from our Cayman share register to our Hong Kong share register.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Hong Kong Stamp Duty Ordinance, any person who effects a sale or purchase of Hong Kong stock, defined as stock the transfer of which is required to be registered in Hong Kong, is required to pay Hong Kong stamp duty. The stamp duty is currently set at a total rate of 0.2% of the greater of the consideration for, or the value of, shares transferred, with 0.1% payable by each of the buyer and the seller.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the best of our knowledge, Hong Kong stamp duty has not been levied in practice on the trading or conversion of ADSs of companies that are listed in both the U.S. and Hong Kong and that have maintained all or a portion of their ordinary shares, including ordinary shares underlying ADSs, in their Hong Kong share registers. However, it is unclear whether, as a matter of Hong Kong law, the trading or conversion of ADSs of these dual-listed companies constitutes a sale or purchase of the underlying Hong Kong registered ordinary shares that is subject to Hong Kong stamp duty. We advise investors to consult their own tax advisors on this matter. If Hong Kong stamp duty is determined by the competent authority to apply to the trading or conversion of the ADSs, the trading price and the value of your investment in our ADSs or ordinary shares may be affected.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Holders of ADSs may not receive distributions on our ordinary shares or any value for them if it is illegal or impractical to make them available.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depositary of the ADSs has agreed to distribute to ADS holders the cash dividends or other distributions it or the custodian for the ADSs receives on our ordinary shares or other deposited securities after deducting its fees and expenses. ADS holders will receive these distributions in proportion to the number of our ordinary shares that their ADSs represent. However, the depositary is not responsible for making such distributions if it is unlawful or impractical. For example, it would be unlawful to make a distribution to a holder of ADSs if it consists of securities that require registration under the Securities Act, but that are not registered or distributed pursuant to an exemption from registration. The depositary is not responsible for making a distribution available to holders of ADSs if any government approval or registration required for such distribution cannot be obtained after reasonable efforts made by the depositary. We have no obligation to take any other action to permit the distribution of the ADSs, ordinary shares, rights or anything else to holders of the ADSs. This means that holders of ADSs may not receive the distributions we make on our ordinary shares or any value for them if it is illegal or impractical for us to make them. These restrictions may materially reduce the value of our ADSs.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Holders of ADSs may not be able to participate in rights offerings and may experience dilution of their holdings.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may distribute rights to our shareholders, including rights to acquire securities. Under the deposit agreement, the depositary will not distribute rights to holders of ADSs unless the distribution and sale of rights and the securities to which these rights relate are either exempt from registration under the Securities Act with respect to all holders of ADSs or are registered under the Securities Act. The depositary may, but is not required to, attempt to sell these undistributed rights to third parties and may allow the rights to lapse. We may be unable to establish an exemption from registration under the Securities Act, and we are under no obligation to file a registration statement with respect to these rights or underlying securities or to try to have a registration statement declared effective. Accordingly, holders of ADSs may be unable to participate in our rights offerings and may experience dilution of their holdings as a result.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our corporate actions are substantially controlled by our directors, executive officers and other principal shareholders, who can exert significant influence over important corporate matters, which may reduce the price of our ordinary shares, ADSs, and/or RMB Shares and deprive shareholders of an opportunity to receive a premium for their ordinary shares, ADSs, and/or RMB Shares.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our directors, executive officers and principal shareholders beneficially owned approximately 49% of our outstanding ordinary shares as of February&#160;14, 2025. These shareholders, if acting together, could exert substantial influence over matters such as electing directors and approving material mergers, acquisitions or other business combination transactions. This concentration of ownership may also discourage, delay or prevent a change in control of our company, which could have the dual effect of depriving our shareholders of an opportunity to receive a premium for their shares as part of a sale of our company and reducing the price of our ordinary shares, ADSs, and/or RMB Shares. These actions may be taken even if they are opposed by our other shareholders. In addition, these persons could divert business opportunities away from us to themselves or others.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be a passive foreign investment company in future taxable years, which may have adverse U.S. federal income tax consequences for U.S. shareholders.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A non-U.S. corporation will be classified as a &#8220;passive foreign investment company&#8221; (&#8220;PFIC&#8221;) for any taxable year if either (1) 75% or more of its gross income consists of certain types of passive income or (2) 50% or more of the average quarterly value of its assets during such year produce or are held for the production of passive income. Based upon the composition of our income and assets, we believe that we were not a PFIC for the taxable year ended December 31, 2024. Nevertheless, because our PFIC status must be determined annually with respect to each taxable year and will depend on the composition and character of our assets and income, including our use of proceeds from any equity offerings, and the value of our assets (which may be determined, in part, by reference to the market value of our ADSs and ordinary shares, which may be volatile) over the course of such taxable year, we may be a PFIC in any taxable year. The determination of whether we will be or become a PFIC may also depend, in part, on how, and how quickly, we use our liquid assets and the cash raised in equity offerings. If we determine not to deploy significant amounts of cash for active purposes, our risk of being a PFIC may substantially increase. Because there are uncertainties in the application of the relevant rules and PFIC status is a factual determination made annually after the close of each taxable year, there can be no assurance that we will not be a PFIC for the current taxable year or any future taxable year. In addition, it is possible that the Internal Revenue Service may challenge our classification of certain income and assets as non-passive, which may result in our being or becoming a PFIC in the current or subsequent years.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are a PFIC for any taxable year during a U.S. shareholder&#8217;s holding period of the ordinary shares or ADSs, then such U.S. shareholder may incur significantly increased U.S. income tax on gain recognized on the sale or other disposition of the ordinary shares or ADSs and on the receipt of distributions on the ordinary shares or ADSs to the extent such distribution is treated as an &#8220;excess distribution&#8221; under the U.S. federal income tax rules. In addition, such holders may be subject to burdensome reporting requirements.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, if we are classified as a PFIC for any year during which a U.S. shareholder holds our ordinary shares or ADSs, we generally will continue to be treated as a PFIC for all succeeding years during which such U.S. shareholder holds such ordinary shares or ADSs. Each U.S. shareholder should consult its tax advisor regarding the PFIC rules and the U.S. federal income tax consequences of the acquisition, ownership and disposition of the ordinary shares and ADSs.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If you are a &#8220;Ten Percent Shareholder,&#8221; you may be subject to adverse U.S. federal income tax consequences if we are classified as a Controlled Foreign Corporation.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each &#8220;Ten Percent Shareholder&#8221; (as defined below) in a non-U.S. corporation that is classified as a &#8220;controlled foreign corporation&#8221; (&#8220;CFC&#8221;), for U.S. federal income tax purposes is generally required to include in income for U.S. federal tax purposes such Ten Percent Shareholder&#8217;s pro rata share of the CFC&#8217;s &#8220;Subpart F income&#8221; and investment of earnings in U.S. property, even if the CFC has made no distributions to its shareholders. Each Ten Percent Shareholder is also required to include in gross income its &#8220;global intangible low-taxed income,&#8221; which is determined by reference to the income of CFCs of which such Ten Percent Shareholder is a Ten Percent Shareholder. Ten Percent Shareholders that are corporations may be entitled to a deduction equal to the foreign portion of any dividend when a dividend is paid. A non-U.S. corporation will generally be classified as a CFC for U.S. federal income tax purposes if Ten Percent Shareholders own in the aggregate, directly or indirectly, more than 50% of either the total combined voting power of all classes of stock of such corporation entitled to vote or of the total value of the stock of such corporation. A &#8220;Ten Percent Shareholder&#8221; is a U.S. person (as defined by the Internal Revenue Code of 1986, as amended), who owns or is considered to own 10% or more of the total combined voting power of all classes of stock entitled to vote of such corporation or 10% of the value of all classes of stock of such corporation. The determination of CFC status is complex and includes attribution rules, the application of which is not entirely certain.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe we are not a CFC now, we may become one or own interests in one in the future. Holders are urged to consult their own tax advisors with respect to our potential CFC status and the consequences thereof.</span></div><div id="ic94bd2152a214042a118e81881a5a1e5_2256"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Continuation to Switzerland</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Your rights as a shareholder will change as a result of the Continuation.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As announced in August 2024, we are proposing to change our jurisdiction of incorporation from the Cayman Islands to Switzerland through a transaction known as a continuation under Section 206 of the Companies Act (as amended) of the Cayman Islands and Article 161 of the Swiss Federal Code on Private International Law (such transaction, the &#8220;Continuation&#8221;). Because of differences in Swiss law and Cayman law and certain changes that will be made to our governing documents in connection with the Continuation, your rights as a shareholder will change if the Continuation is completed. For a description of these differences, see &#8220;Proposal No. 1: Approval of the Continuation&#8201;&#8212;&#8201;Comparison of Shareholder Rights&#8221; in the Registration Statement on Form S-4, as amended, filed with the SEC on January 21, 2025.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As a result of increased shareholder voting requirements upon completion of the Continuation, we will have less flexibility with respect to certain aspects of capital management than previously.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Cayman law, our directors may issue, without shareholder approval, any ordinary shares authorized in our amended and restated articles of association that are not issued or reserved. In addition, our board of directors has the right, subject to statutory limitations, to declare and pay dividends on our ordinary shares without a shareholder vote. Swiss law allows our shareholders to authorize our board of directors to issue new registered shares from the redomiciled Swiss public company for general corporate purposes based on a capital band included in the proposed Swiss articles, and for convertible instruments and for long term incentive plan purposes based on a conditional capital included in the proposed Swiss articles, in each case without additional shareholder approval. However, the shareholder authorization for general corporate purposes must be renewed by the shareholders at least every five years, and both the authorizations under the capital band and the conditional capital are limited to 50% of a company&#8217;s stated capital. Swiss law also reserves for approval by shareholders many corporate actions over which our board of directors currently has authority. For example, dividends must be approved by shareholders. While we do not believe that the differences between Cayman law and Swiss law relating to our capital management will have an adverse effect on our company, we cannot assure you that situations will not arise where such flexibility would have provided substantial benefits to our shareholders.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Continuation will result in additional direct and indirect costs whether or not completed.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Continuation will result in additional direct costs. Following the Continuation, we may hold a large portion of meetings of our board of directors and management strategy meetings as well as our annual general meetings, beginning in 2025, in Basel. We also plan to continue expanding our physical presence in Switzerland. With that, we will further strengthen our presence in Switzerland. We will incur additional costs and expenses, primarily Swiss tax and professional fees, to comply with Swiss corporate and tax laws. In addition, we will incur attorneys&#8217; fees, accountants&#8217; fees, filing fees, mailing expenses and financial printing expenses in connection with the Continuation, whether or not it is approved. The Continuation may also result in certain indirect costs by diverting attention of our management and employees from our business with resulting increased administrative costs and expenses.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If you fail to make a required tax filing, the Continuation could result in adverse tax consequences for you.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on your circumstances, you may be required to make a filing with the U.S. Internal Revenue Service or your respective tax authority, as a result of the change of our place of incorporation. Failure to make this filing on a timely basis could result in your owing taxes because of the change, even though you will not have realized any income or liquidity as a result of the change. For a more detailed description of the tax consequences associated with this transaction, please read &#8220;Proposal No. 1: Approval of the Continuation&#8201;&#8212;&#8201;Material Tax Considerations&#8201;&#8212;&#8201;United States Tax Considerations&#8221; in the Registration Statement on Form S-4, as amended, filed with the SEC on January 21, 2025.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">You may be subject to Swiss withholding taxes on the payment of dividends.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under current Swiss law, distributions made out of capital contribution reserves recognized by the Swiss Federal Tax Administration or made in the form of a par value reduction are not subject to Swiss withholding tax. We currently expect to have qualifying capital contribution reserves in the amount of approximately US$10.6 billion available for distribution not subject to Swiss withholding tax as of the effective date of the Continuation. However, there can be no assurances that the Swiss withholding rules will not be changed in the future or that shareholders will approve a distribution out of qualifying capital contribution reserves recognized by the Swiss Federal Tax Administration. Further, over the long term, the amount of qualifying contribution reserves available may be limited. If we are unable to make a distribution out of qualifying capital contribution reserves, then any dividends paid will generally be subject to a Swiss withholding tax at a rate of 35%. The withholding tax must be withheld from the gross distribution and paid to the Swiss Federal Tax Administration. Currently, dividends, if any, paid on our shares are not subject to withholding tax in the Cayman Islands. A U.S. holder that qualifies for benefits under the Convention between the United States of America and the Swiss Confederation for the Avoidance of Double Taxation with Respect to Taxes on Income, (the &#8220;U.S.-Swiss Treaty&#8221;), may apply for a refund of the tax withheld in excess of the 15% treaty rate (or for a full refund in case of qualified pension funds). A China Holder that qualifies for benefits under the Agreement between the Government of the People&#8217;s Republic of China and the Swiss Federal Council for the Avoidance of Double Taxation with Respect to Taxes on Income and on Capital (&#8220;PRC-Swiss Treaty&#8221;) may apply for a refund of the tax withheld in excess of the 10% or 5% treaty rate (as applicable). A Hong Kong shareholder that qualifies for benefits under the Agreement between the Government of the Hong Kong Special Administrative Region of the People&#8217;s Republic of China and the Swiss Federal Council for the Avoidance of Double Taxation with respect to Taxes on Income (&#8220;Hong Kong-Swiss Treaty&#8221;) may apply for a refund of the tax withheld in excess of the 10% treaty rate (or a full refund in case of specific qualified persons, including, a pension fund, or a corporate shareholder that directly holds at least 10% our capital). Subject to applicable laws and regulations, this may also apply to other shareholders that are entitled to a dividend withholding tax rate lower than the Swiss withholding tax rate under the tax treaties between the shareholders&#8217; own tax residency jurisdictions and Switzerland. Switzerland currently has concluded more than 100 tax treaties with the same treatment regarding the refund of Swiss withholding taxes.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under current Swiss law, repurchases of shares for the purposes of capital reduction are treated as a partial liquidation subject to 35% Swiss withholding tax, irrespective of the tax residency of the shareholder. The repurchase of shares for purposes other than capital reduction, such as to retain as treasury shares for use in connection with equity incentive plans, convertible debt, similar instruments or acquisitions, will not be subject to the 35% Swiss withholding tax, irrespective of the tax residency of the shareholder. Any portion of the repurchase price attributable to par value or qualifying capital contribution reserves recognized by the Swiss Federal Tax Administration will not be subject to the 35% Swiss withholding tax. See &#8220;Proposal No. 1: Approval of the Continuation&#8201;&#8212;&#8201;Material Tax Considerations&#8201;&#8212;&#8201;Taxation of Shareholders Subsequent to the Continuation&#8201;&#8212;&#8201;Swiss Taxation&#8221; in the Registration Statement on Form S-4, as amended, filed with the SEC on January 21, 2025.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will be subject to various Swiss taxation as a result of the Continuation.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be subject to corporate income tax at federal, cantonal and communal levels on our worldwide income. However, qualifying net dividend income and net capital gains on the sale of qualifying investments in subsidiaries are effectively exempt from federal, cantonal and communal corporate income tax under the Swiss participation relief rules. Consequently, we expect dividends from our subsidiaries and capital gains from sales of investments in our subsidiaries to be exempt from Swiss corporate income tax. In addition, we will be subject to an annual cantonal capital tax on our year-end taxable equity. We will also be subject to a Swiss issuance stamp tax levied on any future issuance of shares or any other increase in our equity unless the equity is increased in the context of a merger or other qualifying restructuring transaction. In addition, we will be subject to some other Swiss taxes (e.g., VAT and Swiss securities transfer stamp tax). We are currently not subject to income, capital, stamp or issuance taxes in the Cayman Islands.</span></div><div id="ic94bd2152a214042a118e81881a5a1e5_100"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1B. Unresolved Staff Comments</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ic94bd2152a214042a118e81881a5a1e5_103"></div><div style="margin-bottom:9pt;margin-top:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1C. Cybersecurity</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="f-39" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="f-37" continuedAt="f-37-1" escape="true"><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true" id="f-38">We recognize the importance of safeguarding the security of our computer systems, software, networks, and other technology assets. Our cybersecurity efforts are aimed at preserving the confidentiality, integrity, and continued availability of information under our ownership or care with the aim to continually improve security features in order to keep pace with the evolving cyber threat landscape.</ix:nonNumeric></span></div></ix:nonNumeric></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><ix:continuation id="f-37-1"><div style="margin-bottom:9pt;margin-top:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview of Cybersecurity Risk Management and Strategy</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-right:4.5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity risk identification, assessment and management process is a critical part of our overall enterprise risk management (&#8220;ERM&#8221;) system. Within our ERM system, we adhere to our Information Security Management Policy (&#8220;ISM Policy&#8221;) which is aimed at providing guidelines to monitor, review and continually improve our Information Security Management System (&#8220;ISMS&#8221;). Our ISMS is informed by ISO/IEC 27001:2022 standards and is operated based on an action model that identifies information security missions and objectives, including improvement measures to achieve continuous optimization. Our Cybersecurity Incident Response Plan (&#8220;CIRP&#8221;) is a critical component of our cybersecurity incident identification and management process, which, along with our incident response team, is designed to guide our response to potential cybersecurity incidents effectively and efficiently. Our ISM Policy, ISMS and CIRP are all internal processes we use to assess, identify and manage material risks from cybersecurity threats.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true" id="f-40">We also utilize external partnerships to help protect the Company from cybersecurity threats.</ix:nonNumeric> This combination of people, processes and technology assist us to proactively manage and mitigate threats to our information technology environment. We have controls in place to defend against risks associated with cyber-attacks impacting our operations, compliance and financial reporting objectives. We are externally audited and certified under the ISO 27001 and assessed yearly according to National Institute of Standards and Technology (&#8220;NIST&#8221;) guidelines. Our external partners also evaluate our cybersecurity maturity and coverage as part of their services and keep us informed of emerging global threats. </span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-right:4.5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct a Testing, Training &amp; Exercise program to test, sustain and refine our ability to respond to cybersecurity incidents in accordance with the best practices. We also maintain an information security training program for our employees.  </span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-right:4.5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true" id="f-41">Our Third-Party Security Management Standard provides a framework for managing third-party information security risks and defines controls to minimize risks to the Company. It applies to third parties who have access to or process Company information. This framework includes processes for conducting, as appropriate, due diligence, risk assessment and planning, contract management, access control, ongoing monitoring, and possible service termination of, or changes to the third-party as part of the selection and management process.</ix:nonNumeric></span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-right:4.5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have implemented a Threat Intelligence function that informs of external cyber threats which allows us to proactively protect the Company and to allow us to improve the speed of our vulnerability management capabilities.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false" id="f-42">Cybersecurity threats have to date not materially affected us, our business strategy, results of operations or financial condition. Similar to other companies, we and our third-party vendors have and will continue to experience threats to our systems and data.</ix:nonNumeric></span></div></ix:continuation><div style="margin-bottom:9pt;margin-top:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board Oversight of Risks from Cybersecurity Threats</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="f-43" escape="true">The Board of Directors (&#8220;Board&#8221;) oversees risk management related to the operation of the business and corporate functions as well as the implementation of business strategy. Our Board has delegated to the Audit Committee oversight of risk management, which includes risks from cybersecurity threats. We routinely review critical elements of our cybersecurity policies and program with the Audit Committee.</ix:nonNumeric> </span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="f-46" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-45" continuedAt="f-45-1" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-44" escape="true"><div style="margin-bottom:9pt;margin-top:9pt;padding-right:4.5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The management team &#8211; including our <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true" id="f-47">Chief Information Security Officer (&#8220;CISO&#8221;)</ix:nonNumeric> &#8211; provides periodic reports to the Audit Committee which cover cybersecurity and other information technology risks affecting the Company. Such reports are typically provided at an <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true" id="f-48">Audit Committee</ix:nonNumeric> meeting and enable Audit Committee members to ask questions of management and engage in additional discussions in an open forum. The Audit Committee also periodically evaluates our overall cybersecurity strategy.</span></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Role in Assessing and Managing Material Risks from Cybersecurity Threats</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="f-49" continuedAt="f-49-1" escape="true"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Information Security Steering Committee (&#8220;ISSC&#8221;) is responsible for oversight of matters related to information security and currently consists of professionals in legal operations and risk management, information governance, human resources operations, internal audit, computerized systems, global security and technical operations, and research technology, all whose input bring significant value when assessing and managing cybersecurity risk. Our ISSC meets periodically and is presented with an update on cybersecurity matters from our CISO. Our CISO is responsible for facilitating the implementation of the plans and decisions made by the ISSC and directly provides updates to the Audit Committee as detailed above.</span></div></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><ix:continuation id="f-49-1"><ix:continuation id="f-45-1"><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="f-50" escape="true">Our Vice President of Global Technology Solutions head our Global Technology Solutions Team along with our CISO are responsible for leading the individuals tasked with maintaining our enterprise-wide cyber resilience strategy, policy, standards, architecture, and processes.</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="f-51" escape="true">Our CISO has over eighteen years of information technology and cybersecurity experience in multiple industries, including building and leading governance, risk, and compliance functions that cover ISO 27001 certified compliance, NIST Cybersecurity Framework assessments, Sarbanes-Oxley (&#8220;SOX&#8221;) information technology compliance, regional compliances, policy management, information technology risk management, vendor risk management, and security awareness. Our Vice President of Global Technology Solutions has over twenty years of experience leading technology organization and managing information security across multiple industries, including SOX 404 compliance, GxP audit and compliance, NIST Cybersecurity Framework assessments, managing incident response and communication with executives and board of directors</ix:nonNumeric>.</span></div></ix:continuation></ix:continuation><div id="ic94bd2152a214042a118e81881a5a1e5_106"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Properties</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease all of our facilities, other than the following facilities that we own: our offices and laboratories in Changping, Beijing, our manufacturing facility in Guangzhou, China, and our manufacturing facility and clinical R&amp;D center at the Princeton Innovation Park in Hopewell, New Jersey. We lease an aggregate of approximately 134,000 square meters of office space at approximately 46 other locations across the U.S., Europe, China, MENA, and South America, in cities such as Cambridge, Massachusetts; Ridgefield Park, New Jersey; and Emeryville, San Mateo and San Carlos, California in the U.S.; Beijing, Shanghai, Suzhou, and Guangzhou in China; and Basel, Switzerland, primarily for our offices and for our manufacturing facility in Suzhou, China, pursuant to leases with various expiration dates, with the latest expiring in 2031. We believe that our facilities are currently suitable and sufficient to meet our needs. We intend to add new facilities or expand existing facilities as we add employees and enter new locations, and we believe that suitable additional or substitute space will be available as needed to accommodate any such expansion of our operations.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to &#8220;Note 7: Leases&#8221; in the notes to our consolidated financial statements in this Annual Report for further information on our real property leases.</span></div><div id="ic94bd2152a214042a118e81881a5a1e5_109"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. Legal Proceedings</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may become involved in legal proceedings or be subject to claims of a nature considered ordinary course in our business, including the intellectual property litigation described herein. Most of the issues raised by such claims are highly complex and subject to substantial uncertainties. For a description of risks relating to these legal proceedings, see &#8220;Part I&#8212;Item 1A&#8212;Risk Factors&#8221; of this Annual Report, including the discussion under the headings entitled &#8220;Risks Related to Our Intellectual Property.&#8221; The outcome of any such proceedings, regardless of the merits, is inherently uncertain; therefore, assessing the likelihood of loss and any estimated damages is difficult and subject to considerable judgment. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacyclics Litigation</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 13, 2023, Pharmacyclics LLC (&#8220;Pharmacyclics&#8221;) filed a complaint in the U.S. District Court for the District of Delaware (the &#8220;Court&#8221;) against the Company and its subsidiary, BeiGene USA, Inc., alleging that BRUKINSA infringes Pharmacyclics&#8217; U.S Patent No. 11,672,803 issued on June 13, 2023 (the &#8220;&#8216;803 patent&#8221;). Pharmacyclics seeks a declaration of infringement, unspecified monetary damages and other relief. The Company intends to vigorously defend against the claims.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 12, 2023, the Court entered a joint stipulation filed by the parties to stay the infringement suit pending resolution of a petition for post-grant review (&#8220;PGR&#8221;) of the &#8216;803 Patent with the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) that was later filed by BeiGene on November 1, 2023. On May 1, 2024, the USPTO granted BeiGene&#8217;s PGR petition and is expected to issue a final decision on the validity of the &#8216;803 patent within 12 months.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ANDA Litigation</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 8, 2024, the Company&#8217;s two wholly-owned subsidiaries, BeiGene USA, Inc. and BeiGene Switzerland GmbH filed patent infringement suits under Hatch-Waxman Act against Sandoz Inc. (&#8220;Sandoz&#8221;) and separately against MSN Pharmaceuticals, Inc. and MSN Laboratories Private Ltd. (collectively &#8220;MSN&#8221;) in the U.S. District Court for the District of New Jersey. The patent infringement suits are in response to Sandoz&#8217;s and MSN&#8217;s notices to the Company concerning the filings of Abbreviated New Drug Applications (&#8220;ANDAs&#8221;) with the U.S. Food and Drug Administration (&#8220;FDA&#8221;), seeking FDA approval to market a generic version of BRUKINSA along with &#8220;Paragraph IV certifications&#8221; challenging certain BRUKINSA Orange Book patents for invalidity, unenforceability and/or non-infringement. According to the notices, neither Sandoz nor MSN have challenged BRUKINSA&#8217;s composition of matter patent, which remains intact in protecting BRUKINSA from generic competition until its expiration in 2034. On August 15, 2024, the court entered a joint stipulation and order dismissing the suit against Sandoz. On November 14, 2024, BeiGene entered into a settlement agreement with MSN wherein BeiGene granted MSN the right to sell a generic version of BRUKINSA in the U.S. no earlier than June 15, 2037, subject to potential acceleration or extension under circumstances customary for settlement of this type. On November 19, 2024, the court entered a joint stipulation and order dismissing the suit against MSN.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AbbVie Litigation</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 6, 2024, AbbVie Inc. filed a complaint in the U.S. District Court for the Northern District of Illinois against the Company, one of its wholly-owned subsidiaries and an individual scientist, alleging misappropriation of trade secrets concerning the Company&#8217;s Bruton&#8217;s tyrosine kinase (&#8220;BTK&#8221;) degrader program, including the lead compound, BGB-16673. The complaint seeks an unspecified amount of monetary damages, declaratory judgment, restitution and other equitable remedies. The Company is vigorously defending against the claims and filed a motion to dismiss the complaint in its entirety on December 19, 2024.</span></div><div id="ic94bd2152a214042a118e81881a5a1e5_112"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4. Mine Safety Disclosures</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II</span></div><div id="ic94bd2152a214042a118e81881a5a1e5_118"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our American Depositary Shares (&#8220;ADSs&#8221;) have been publicly traded on the Nasdaq Global Select Market under the symbol &#8220;BGNE&#8221; from February 3, 2016 to January 1, 2025, and under the symbol &#8220;ONC&#8221; since January 2, 2025. Our ordinary shares have been publicly traded on the Stock Exchange of Hong Kong Limited under the stock code &#8220;06160&#8221; since August 8, 2018. Our ordinary shares traded in Renminbi (the &#8220;RMB Shares&#8221;) have been publicly traded on the Science and Technology Innovation Board of the Shanghai Stock Exchange in China under the stock code &#8220;688235&#8221; since December 15, 2021.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholders</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 31, 2025, we had approximately 29,773 holders of record of our ordinary shares, 29,620 of which are holders of record of our RMB Shares, and 8 holders of record of our ADSs. These numbers do not include beneficial owners whose ordinary shares or ADSs are held by nominees in street name. Because many ordinary shares and ADSs are held by broker nominees, we are unable to estimate the total number of beneficial holders represented by these record holders.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any dividends on our ordinary shares or any other securities. We currently intend to retain all available funds and earnings, if any, to fund the development and expansion of our business, and we do not anticipate paying any cash dividends in the foreseeable future. If we pay dividends in the future, in order for us to distribute dividends to our shareholders and holders of ADSs, we may rely to some extent on dividends distributed by our PRC subsidiaries. PRC regulations may restrict the ability of our PRC subsidiaries to pay dividends to us, and such distributions will be subject to PRC withholding tax. In addition, PRC regulations currently permit payment of dividends of a PRC company only out of accumulated distributable after-tax profits, as determined in accordance with our PRC subsidiaries&#8217; formation and organizational documents and the accounting standards and regulations in the PRC. Subject to applicable law and our amended and restated articles of association, any future determination to pay dividends will be made at the discretion of our board of directors and may be based on a number of factors, including our future operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions and other factors that our board of directors may deem relevant.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Comparison Graph</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This graph is not &#8220;soliciting material,&#8221; is not deemed &#8220;filed&#8221; with the SEC and is not to be incorporated by reference into any of our filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph shows the total shareholder return of an investment of $100 in cash at market close on December 31, 2019 through December&#160;31, 2024 for our ADSs, the Nasdaq Composite Index (U.S.), and the Nasdaq Biotechnology Index.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to applicable SEC rules, all values assume reinvestment of the full amount of any dividends, although no dividends have been declared or paid to date. The shareholder return shown on the graph below is not necessarily indicative of future performance, and we do not make or endorse any predictions as to future shareholder returns.</span></div><div style="margin-bottom:9pt"><img src="bgne-20241231_g4.jpg" alt="5 year return.jpg" style="height:567px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-bottom:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.849%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/19</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/20</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/22</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/23</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12/31/24</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BeiGene, Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.00</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">155.88</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">163.45</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">132.69</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">108.81</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">111.43</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nasdaq Composite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.00</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">144.92</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">177.06</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">119.45</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">172.77</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">223.87</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nasdaq Biotechnology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.00</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">126.42</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">126.45</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">113.65</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">118.87</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">118.20</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:4pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Compensation Plan Information</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our equity compensation plan information required by this item is incorporated by reference to the information in &#8220;Part III&#8212;Item 12&#8212;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#8221; of this Annual Report.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Taxation</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cayman Islands Taxation</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cayman Islands currently levies no taxes on individuals or corporations based upon profits, income, gains or appreciation, and there is no taxation in the nature of inheritance tax or estate duty or withholding tax applicable to us or to any holder of the ADSs, ordinary shares and RMB Shares. There are no other taxes likely to be material to us levied by the Government of the Cayman Islands except for stamp duties which may be applicable on instruments executed in, or after execution brought within, the jurisdiction of the Cayman Islands. No stamp duty is payable in the Cayman Islands on the issue of shares by, or any transfers of shares of, Cayman Islands companies (except those which hold interests in land in the Cayman Islands). The Cayman Islands is not party to any double tax treaties that are applicable to any payments made to or by our company. There are no exchange control regulations or currency restrictions in the Cayman Islands.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments of dividends and capital in respect of the ADSs, ordinary shares and RMB Shares will not be subject to taxation in the Cayman Islands and no withholding will be required on the payment of a dividend or capital to any holder of the ADSs, ordinary shares or RMB Shares, as the case may be, nor will gains derived from the disposal of the ADSs, ordinary shares or RMB Shares be subject to Cayman Islands income or corporation tax.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PRC Taxation</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Enterprise Income Tax Law (&#8220;EIT Law&#8221;), an enterprise established outside the PRC with a &#8220;de facto management body&#8221; within the PRC is considered a &#8220;resident enterprise,&#8221; which means that it is treated in a manner similar to a Chinese enterprise for PRC enterprise income tax purposes. The implementation rules&#160;of the EIT Law define &#8220;de facto management body&#8221; as a managing body that exercises substantial and overall management and control over the production and operations, personnel, accounting and properties of an enterprise. In addition, the Notice Regarding the Determination of Chinese&#8209;Controlled Offshore Incorporated Enterprise as PRC Tax Resident Enterprises on the Basis of De Facto Management Bodies (&#8220;Circular 82)&#8221;, issued by the State Taxation Administration, which provides guidance on the determination of the tax residence status of a Chinese&#8209;controlled offshore incorporated enterprise, defines Chinese-controlled offshore incorporated enterprise as an enterprise that is incorporated under the laws of a foreign country or territory and that has a PRC enterprise or enterprise group as its primary controlling shareholder. Although BeiGene,&#160;Ltd. does not have a PRC enterprise or enterprise group as our primary controlling shareholder and is therefore not a Chinese&#8209;controlled offshore incorporated enterprise within the meaning of Circular 82, in the absence of guidance specifically applicable to us, we have applied the guidance set forth in Circular 82 to evaluate the tax residence status of BeiGene,&#160;Ltd. and its subsidiaries organized outside the PRC.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to Circular 82, a Chinese&#8209;controlled offshore incorporated enterprise will be regarded as a PRC tax resident by virtue of having a &#8220;de facto management body&#8221; in China and will be subject to PRC enterprise income tax on its worldwide income only if all of the following criteria are met:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the primary location of the enterprise&#8217;s senior executives of the day&#8209;to&#8209;day operational management and senior management departments performing their duties is in the PRC;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decisions relating to the enterprise&#8217;s financial and human resource matters are made or are subject to approval by organizations or personnel in the PRC;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the enterprise&#8217;s primary assets, accounting books and records, company seals, and board and shareholder meeting minutes are located or maintained in the PRC; and</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">50% or more of voting board members or senior executives habitually reside in the PRC.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, some of the members of our management team are located in China. However, we do not believe that we meet all of the conditions outlined in the immediately preceding paragraph. BeiGene,&#160;Ltd. and its offshore subsidiaries are incorporated outside the PRC. As a holding company, our key assets and records, including the resolutions and meeting minutes of our board of directors and the resolutions and meeting minutes of our shareholders, are located and maintained outside the PRC. We are not aware of any offshore holding companies with a corporate structure similar to ours that has been deemed a PRC &#8220;resident enterprise&#8221; by the PRC tax authorities. Accordingly, we believe that BeiGene,&#160;Ltd. and its offshore subsidiaries should not be treated as a &#8220;resident enterprise&#8221; for PRC tax purposes if the criteria for &#8220;de facto management body&#8221; as set forth in Circular 82 were deemed applicable to us. However, as the tax residency status of an enterprise is subject to determination by the PRC tax authorities and uncertainties remain with respect to the interpretation of the term &#8220;de facto management body&#8221; as applicable to our offshore entities, we will continue to monitor our tax status.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The implementation rules&#160;of the EIT Law provide that, (1)&#160;if the enterprise that distributes dividends is domiciled in the PRC or (2)&#160;if gains are realized from transferring equity interests of enterprises domiciled in the PRC, then such dividends or capital gains are treated as China&#8209;sourced income. It is not clear how &#8220;domicile&#8221; may be interpreted under the EIT Law, and it may be interpreted as the jurisdiction where the enterprise is a tax resident. Therefore, if we are considered as a PRC tax resident enterprise for PRC tax purposes, any dividends we pay to our overseas shareholders or ADS holders as well as gains realized by such shareholders or ADS holders from the transfer of our shares or ADSs may be regarded as China&#8209;sourced income. As a result, dividends paid to non&#8209;PRC resident enterprise ADS holders or shareholders may be subject to PRC withholding tax at a rate of up to 10% (or 20% in the case of non&#8209;PRC individual ADS holders or shareholders) and gains realized by non&#8209;PRC resident enterprise ADS holders or shareholders from the transfer of our ordinary shares or ADSs may be subject to PRC tax at a rate of 10% (or 20% in the case of non&#8209;PRC individual ADS holders or shareholders). It is also unclear whether, if we are considered a PRC resident enterprise, holders of our shares or ADSs would be able to claim the benefit of income tax treaties or agreements entered into between China and other countries or areas.</span></div><div id="ic94bd2152a214042a118e81881a5a1e5_121"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6. Reserved</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes appearing elsewhere in this Annual Report. In addition to historical information, this discussion and analysis contains forward&#8209;looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward&#8209;looking statements as a result of certain factors. We discuss factors that we believe could cause or contribute to these differences below and elsewhere in this report, including those set forth under &#8220;Part&#160;I&#8212;Item&#160;1A&#8212;Risk Factors&#8221; and under &#8220;Forward&#8209;Looking Statements and Market Data&#8221; in this Annual Report.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-GAAP Financial Measures</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We provide certain financial measures that are not defined under accounting principals generally accepted in the United States of America (&#8220;GAAP&#8221;), commonly referred to as non-GAAP financial measures, including Adjusted Operating Expenses and Adjusted Income (Loss) from Operations and certain other non-GAAP measures, each of which include adjustments to GAAP figures. These non-GAAP measures are intended to provide additional information on our operating performance. Adjustments to our GAAP figures exclude, as applicable, non-cash items such as share-based compensation, depreciation and amortization. Certain other special items or substantive events may also be included in the non-GAAP adjustments periodically when their magnitude is significant within the periods incurred. We maintain an established non-GAAP policy that guides the determination of what items may be excluded in non-GAAP financial measures. We believe that these non-GAAP measures, when considered together with the GAAP figures, can enhance an overall understanding of our operating performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of our historical and expected financial results and trends and to facilitate comparisons between periods and with respect to projected information. In addition, these non-GAAP financial measures are among the indicators BeiGene&#8217;s management uses for planning and forecasting purposes and measuring our performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, GAAP financial measures. The non-GAAP financial measures used by BeiGene may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fourth quarter and full year results demonstrate our tremendous growth as a global oncology powerhouse, reinforced by the continued success of BRUKINSA and the development of one of the most prolific solid tumor pipelines in oncology with multiple data readouts expected in 2025. BRUKINSA is now the unequivocal leader in new CLL patient starts in the U.S., holds the broadest label of any BTK inhibitor and serves as the cornerstone of our hematology franchise, showing immense promise as a backbone alongside our late stage BCL2 inhibitor, sonrotoclax, and our potential first-in-class BTK CDAC. We are also building future solid tumor franchises in breast, lung, and gastrointestinal cancers by leveraging our platforms in multi-specific antibodies, protein degraders and antibody-drug conjugates. 2025 marks an inflection point as we anticipate achieving positive GAAP operating income and operating cash flow alongside our intention to change our name to BeOne with our new NASDAQ ticker, ONC.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key highlights for the full year 2024 are as follows:</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Total global revenues of $1.1 billion and $3.8 billion, respectively, in the fourth quarter and full year, increases of 77.8% and 55.0%, respectively, compared to the prior year periods;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Narrowed GAAP operating loss and achieved full-year positive non-GAAP operating income</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Global BRUKINSA revenues of $828.0 million and $2.6 billion for the fourth quarter and full year 2024, increases of 100.5% and 104.9%, respectively, compared to the prior year periods; </span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Progressed pivotal-stage programs for BCL2 inhibitor sonrotoclax and BTK CDAC BGB-16673;</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Advanced six and thirteen NMEs into the clinic in the fourth quarter and full year, respectively; and </span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Anticipate multiple data readouts for innovative solid tumor programs in 1H 2025.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Business Developments</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 13, 2025 we participated in the 43</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">rd</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Annual J.P. Morgan Healthcare Conference and announced that we expect to achieve positive operating income for full year 2025 pursuant to generally accepted accounting principles. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 27, 2024, we announced that the U.S. Food and Drug Administration (&#8220;FDA&#8221;) approved TEVIMBRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(tislelizumab-jsgr), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma in adults whose tumors express PD-L1 (&#8805;1).</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 23, 2024, we announced that our American Depository Shares will begin trading on the Nasdaq Global Select Market under our new ticker symbols &#8220;ONC&#8221; as of January 2, 2025. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 12, 2024, we announced entering into a global licensing agreement with CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2024, we announced that the European Commission approved TEVIMBRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma and gastric or gastroesophageal junction adenocarcinoma.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 19, 2024, we announced entering into a settlement agreement with MSN Pharmaceuticals, Inc. and MSN Laboratories Private Ltd. resolving patent litigation related to MSN&#8217;s Abbreviated New Drug Application seeking approval to market a generic version of BRUKINSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (zanubrutinib) in the U.S.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 14, 2024, we announced our intention to change the Company&#8217;s name to &#8220;BeOne Medicines Ltd.&#8221; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">confirming our commitment to develop innovative medicines to eliminate cancer by partnering with the global community to serve as many patients as possible. Implementation of our new name is subject to shareholder approval to be sought at a future shareholder meeting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the&#160;Years Ended December&#160;31, 2024 and 2023</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the&#160;years ended December&#160;31, 2024 and 2023:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.116%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.161%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in&#160;thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,779,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,189,852&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,589,694&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,695&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268,927&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238,232)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,810,241&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,458,779&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,351,462&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales - product</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,216,152&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,078,859&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,137,293&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,953,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,778,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,831,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,508,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,784,351&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,286,595&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497,756&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(568,199)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,207,736)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">639,537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,009&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,638)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320,529)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income tax expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(533,001)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(825,836)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292,835&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,913&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(644,786)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(881,708)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236,922&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue increased by $1.4 billion to $3.8 billion for the year ended December&#160;31, 2024, from $2.5 billion for the year ended December&#160;31, 2023, primarily due to increased sales of BRUKINSA, as well as increased sales of in-licensed products from Amgen and tislelizumab. Collaboration revenue decreased year over year due to the recognition of the remaining deferred revenue associated with the Novartis collaborations upon termination of the agreements in 2023. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue by geographic area is presented as follows (amounts in thousands of U.S. dollars)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.577%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">United States total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,957,498</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,128,219</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,950,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">China total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,411,307</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,101,951</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,390,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,093,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Europe total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">362,626</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">202,014</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ROW total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">78,810</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,595</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,810&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,387)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,810,241</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,458,779</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:107%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%">Net product revenues by geographic area are based upon the location of the customer, and net collaboration revenue is recorded in the jurisdiction in which the related income is expected to be sourced from.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenue consisted of the following:</span></div><div style="margin-bottom:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.116%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.161%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Changes</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BRUKINSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,644,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,290,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,353,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tislelizumab</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620,836&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536,620&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,216&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BLINCYTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,331&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,342&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,989&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">POBEVCY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,509&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,547&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,038)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REVLIMID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,990)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,042&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,302&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,740&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total product revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,779,546&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,189,852&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,589,694&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenue was $3.8 billion for the year ended December&#160;31, 2024, compared to $2.2 billion in the prior year, primarily due to increased sales of BRUKINSA globally, driven by significant growth in the U.S. and Europe. In addition, product revenues in 2024 were positively impacted by growth from in-licensed products from Amgen and tislelizumab.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global sales of BRUKINSA totaled $2.6 billion for the year ended December&#160;31, 2024, representing a 104.9% increase compared to the prior year. U.S. sales of BRUKINSA totaled $2.0 billion for the year ended December&#160;31, 2024 compared to $945.6 million in the prior year, representing growth of 106.3%. U.S. volume growth continued to accelerate in the period due primarily to demand growth coming from expanded use in CLL as BRUKINSA continued to gain share in new patient starts in CLL and all other approved indications. In addition, U.S. sales were also positively impacted in the fourth quarter of 2024 by seasonality and the timing of customer order patterns of approximately $30.0 million. BRUKINSA sales in the EU totaled $358.8&#160;million for the year ended December&#160;31, 2024, representing growth of 193.6% compared to the prior-year period, driven by continued gains in market share across all major markets.  BRUKINSA sales in China totaled $258.1&#160;million for the year ended December&#160;31, 2024, representing growth of 33.2% compared to the prior year.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of tislelizumab totaled $620.8 million for the year ended December&#160;31, 2024, representing a 15.7% increase compared to the prior year. Certain additional tislelizumab indications have been included in the 2025 NRDL. There were no price reductions resulting from inclusion.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue totaled $30.7 million for the year ended December&#160;31, 2024, primarily related to revenue generated under the Novartis broad markets marketing and promotion agreement and royalty revenue under the Amgen collaboration. Collaboration revenue totaled $268.9 million for the year ended December&#160;31, 2023, primarily related to the recognition of the remaining deferred revenue associated with the former Novartis tislelizumab and ociperlimab collaborations which were terminated in the prior year.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gross Margin</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin on global product sales increased to $3.2 billion, or 84.3% as a percentage of sales, for the year ended December&#160;31, 2024, compared to $1.8 billion, or 82.7% as a percentage of sales, for the year ended December&#160;31, 2023, primarily due to proportionately higher sales mix of BRUKINSA compared to other products in our portfolio, partially offset by the impact of accelerated depreciation expense of $32.7 million resulting from the move to more efficient, larger scale production lines for tislelizumab. On an adjusted basis, which does not include the accelerated depreciation, gross margin as a percentage of product sales increased to 85.5% for the year ended December&#160;31, 2024, from 83.2% in the comparable period of the prior year.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expense</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense increased by $174.7 million, or 9.8%, to $2.0 billion for the year ended December&#160;31, 2024, from $1.8 billion for the year ended December&#160;31, 2023. The following table summarizes the external cost of development programs, upfront license and development milestone fees, and internal research and development expense for the years ended December&#160;31, 2024 and 2023:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.116%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.161%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Changes</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in&#160;thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External research and development expense:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of development programs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539,446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,971)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront license and development milestone fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amgen co-development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total external research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728,660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Internal research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,224,635&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,127,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,573&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,953,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,778,594&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174,701&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted research and development expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,668,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,558,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Our co-funding obligation for the development of the pipeline assets under the Amgen collaboration for the year ended December 31, 2024 totaled $148.4 million, of which $75.2 million was recorded as R&amp;D expense. The remaining $73.2 million was recorded as a reduction for the R&amp;D cost share liability.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">2. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjusted research and development expense is intended to provide investors and others with information about our performance without the effect of items that, by their nature, tend to obscure core operating results due to potential variability across periods based on the timing, frequency and magnitude of such items. Refer to Non-GAAP Financial Measures and Non-GAAP Reconciliation in this MD&amp;A for more information about, and a detailed reconciliation of, these items.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in external research and development expenses for the year ended December 31, 2024 was primarily attributable to higher upfront license and development milestone fees and increases in Amgen co-development expense, partially offset by lower external clinical trial costs.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal research and development expense increased $97.6 million, or 8.7%, to $1.2 billion for the year ended December 31, 2024 from $1.1 billion in the prior year, and was primarily attributable to the expansion of our global development organization and our clinical and preclinical drug candidates, as well as our continued efforts to internalize research and clinical trial activities. Included within internal research and development expenses for the year ended December 31, 2024 is $27.1 million of accelerated depreciation expense related to the move of clinical production to larger, more efficient production lines.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expense</span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.116%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.161%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Changes</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in&#160;thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Selling, general and administrative expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,831,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,508,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted selling, general and administrative expense</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,549,864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,284,689&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjusted selling, general and administrative expense is intended to provide investors and others with information about our performance without the effect of items that, by their nature, tend to obscure core operating results due to potential variability across periods based on the timing, frequency and magnitude of such items. Refer to Non-GAAP Financial Measures and Non-GAAP Reconciliation in this MD&amp;A for more information about, and a detailed reconciliation of, these items.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expense increased by $323.1 million, or 21.4%, to $1.8 billion for the year ended December&#160;31, 2024, from $1.5 billion for the year ended December&#160;31, 2023. The increase was due to continued investment in the global commercial launch of BRUKINSA primarily in the U.S. and Europe. Selling, general and administrative expenses as a percentage of product sales were 48.4% for the year ended December&#160;31, 2024 compared to 68.9% in the prior-year period. We expect continued investment growth in selling and marketing expenses as our product sales increase.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income, Net</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income, net decreased by $26.2 million, or 35.4%, to $47.8 million for the year ended December&#160;31, 2024, compared to $74.0 million for the year ended December&#160;31, 2023. The decrease in interest income was primarily attributable to lower interest rates earned on our cash and cash equivalents and lower cash balances in interest-bearing investments. Interest expense increased resulting from a higher debt balance, partially offset by an increase in interest capitalization related to Hopewell construction.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (Expense) Income, Net</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other expense, net for the year ended December 31, 2024 was $12.6 million, due to foreign exchange losses, primarily from holding net monetary assets denominated in the RMB at certain U.S. dollar functional entities, including BeiGene, Ltd. (the &#8220;Parent Company&#8221;), and unrealized losses on equity investments, partially offset by government subsidy income.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net for the year ended December&#160;31, 2023 was $307.9 million, primarily due to the noncash gain of $362.9 million recorded for the receipt of our ordinary shares as consideration for our settlement with BMS and government subsidy income, partially offset by foreign exchange losses resulting from the strengthening of the U.S. dollar compared to the RMB and the revaluation impact of RMB-denominated deposits held in U.S. dollar functional currency subsidiaries and unrealized losses on equity investments.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Tax Expense</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense was $111.8 million for the year ended December&#160;31, 2024 compared with $55.9 million for the year ended December&#160;31, 2023. The income tax expense for the year ended December&#160;31, 2024 was primarily attributable to higher pre-tax income resulting in current U.S. tax expense determined after other special tax deductions and research and development tax credits, including tax expense of $12.1 million due to the impact of tax reserves on uncertain tax positions related to research and development tax credits, lower taxable income in  China, higher tax expense in certain EU and ROW jurisdictions and the deferred impact of the Company&#8217;s unremitted earnings in the U.S. The Company&#8217;s tax expense for 2024 reflects the historic allocation of pre-tax earnings and losses among our significant jurisdictions. This allocation and resulting tax expense depends on various factors including the level of income and unremitted earnings generated in the U.S., and amount of research and development costs incurred in China and therefore may vary from the historic allocation. </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Organization for Economic Cooperation and Development (&#8220;OECD&#8221;) enacted model rules for a new global minimum tax framework (&#8220;BEPS Pillar Two&#8221;), and various governments around the world have enacted, or are in the process of enacting legislation on this. While we do not anticipate that this will have a material impact on our tax provision or effective tax rate, we will continue to monitor and assess pending legislation, guidance, and implementation by individual countries and evaluate the potential impact on our business in future periods.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      This section of this Form 10-K generally discusses 2024 and 2023 items and year-to-year comparisons between 2024 and 2023. Discussions of 2022 items and year-to-year comparisons between 2023 and 2022 can be found in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in Part II, Item 7 of the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2023.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP Reconciliation</span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.645%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">( in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reconciliation of GAAP to adjusted cost of sales - products:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP cost of sales - products</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amortization of intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted cost of sales - products</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">546,653&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,603&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reconciliation of GAAP to adjusted research and development:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,953,295&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,778,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Share-based compensation expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted research and development</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,668,368&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,558,960&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reconciliation of GAAP to adjusted selling, general and administrative:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP selling, general and administrative</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,831,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,508,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Share-based compensation expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amortization of intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted selling, general and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,549,864&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,284,689&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reconciliation of GAAP to adjusted operating expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP operating expenses </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,784,351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,286,595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Share-based compensation expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441,793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Depreciation </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,858&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amortization of intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,218,232&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,843,649&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reconciliation of GAAP to adjusted loss from operations:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP loss from operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(568,199)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,207,736)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: Share-based compensation expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441,793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: Amortization of intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted income (loss) from operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,356&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(752,473)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents our cash and debt balances as of December&#160;31, 2024 and 2023:</span></div><div style="margin-bottom:4pt;margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,638,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,185,984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">885,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred annual net losses and negative cash flows from operations since inception, resulting from the cost of funding our research and development programs and selling, general and administrative expenses associated with our operations, as well as supporting the commercialization of our products globally. We incurred net losses of $0.6 billion and $0.9 billion for the years ended December&#160;31, 2024 and 2023, respectively. As of December&#160;31, 2024, we had an accumulated deficit of $8.6 billion.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have financed our existing operations and investments in long-term assets principally through proceeds from public and private offerings of our securities, proceeds from debt and our collaborations, and since the third quarter of 2024 cash flow from operations. Based on our current operating plan, we expect that our existing cash and cash equivalents as of December&#160;31, 2024 will enable us to fund our operating expenses and planned long-term investments for at least the next 12 months after the date that the financial statements included in this report are issued. We have also financed our operations and investments with proceeds from debt incurred primarily from various banks both through our subsidiaries and the Parent Company of $1.0 billion at December&#160;31, 2024. The majority of those debt obligations, or approximately $762.1&#160;million, owed by BeiGene, Ltd., have due dates within the next 12 months. As of December 31, 2024, BeiGene, Ltd. will require loans or distributions from subsidiaries in fiscal year 2025 to fund its operations (see Note 10 in the Notes to the Financial Statements for further discussion of deferred taxes on the U.S. unremitted earnings expected to be distributed to the Parent Company). We believe we will have sufficient cash and cash equivalents and other sources of capital to be able to repay and/or refinance those debt obligations on a consolidated basis. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 15, 2021, we completed our initial public offering on the STAR Market of the Shanghai Stock Exchange (the &#8220;STAR Offering&#8221;). As required by the PRC securities laws, the net proceeds from the STAR Offering must be used in compliance with the planned uses as disclosed in the PRC prospectus as well as our proceeds management policy for the STAR Offering approved by our board of directors. As of December&#160;31, 2024, the Company had cash remaining related to the STAR Offering proceeds of $0.6 billion.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding our cash flows for the years ended December&#160;31, 2024 and 2023:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in&#160;thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,185,984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,875,037&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140,631)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,157,453)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(548,350)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193,449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net effect of foreign exchange rate changes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,705)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,082)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(547,237)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(689,053)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,638,747&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,185,984&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in operating activities improved versus the prior year due to our significantly improved revenue and $1.1 billion increase in gross margin in the current year and a decrease in cash used to fund working capital, offset by continued funding of our development pipeline, and commercial operations to support our global expansion.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing activities used $548.4 million of cash for the year ended December&#160;31, 2024, compared to $60.0 million of cash provided in the prior year due primarily to a decrease in proceeds from sales and maturities of investment securities, partially offset by a decrease in capital expenditures.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing activities provided $193.4 million of cash for the year ended December&#160;31, 2024, compared to $416.5 million of cash provided in the prior year period due primarily to a net reduction in short-term debt borrowings.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our borrowing and repayment cycle is dictated by the short-term maturities of our debt and the ability to increase our borrowings is dependent on interest rates, credit spreads, bank lending capacity and other factors. We expect to repay approximately $851.5 million of loans in 2025 and expect to be able to re-finance those on a consistent basis with our historical experience, with the cost of those borrowings depending on prevailing interest rates and credit spreads.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effects of Exchange Rates on Cash</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, we hold RMB denominated cash in our Parent Company (largely arising from the STAR Offering) and incur foreign currency gains or losses when remeasuring such cash to the U.S. dollar. In the year ended December&#160;31, 2024, we incurred realized losses on cash of $16.5 million that is included in the reconciling items between net loss and net cash used in operating activities on the consolidated statements of cash flows primarily related to the remeasurement of RMB denominated cash to USD. The RMB denominated cash in our Parent Company, however, is required to be used to fund RMB denominated expenditures and thus foreign currency gains or losses on such cash does not affect our ability to fund those expenditures. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have substantial operations in China, where the functional currency is the RMB and as such the net cash flows are translated to the U.S. dollar for financial reporting. This process generates translation gains and losses on RMB-denominated cash held in China that are included in the effects of foreign exchange rate changes on the consolidated statements of cash flows, as such translation gains and losses are excluded from cash flows from operating, investing and financing activities.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Liquidity and Material Cash Requirements</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our material cash requirements in the short- and long-term consist of the following operational, capital, and manufacturing expenditures, a portion of which contain contractual or other obligations. We plan to fund our material cash requirements with cash on hand.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual and Other Obligations</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our significant contractual obligations as of December&#160;31, 2024:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments&#160;Due&#160;by&#160;Period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Long-term</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Contractual obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease commitments</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase commitments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,944&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,521&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851,529&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166,484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-development funding commitment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funding commitment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,483&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital commitments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,681,138&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300,990&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,148&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Lease Commitments</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease office facilities in California, Massachusetts, Maryland, and New Jersey in the U.S.; Basel, Switzerland; and office or manufacturing facilities in Beijing, Shanghai, Suzhou and Guangzhou in China; under non-cancelable operating leases expiring on various dates. Payments under operating leases are expensed on a straight-line basis over the respective lease terms. The aggregate future minimum payments under these non-cancelable operating leases are summarized in the table above.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Purchase Commitments</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, purchase commitments amounted to $131.9 million, of which $32.5 million related to minimum purchase requirements for supply purchased from CMOs and $99.4&#160;million related to binding purchase order obligations of inventory from Amgen. We do not have any minimum purchase requirements for inventory from Amgen.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Obligations and Interest</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total debt obligations coming due in the next twelve months are $851.5 million. Total long-term debt obligations are $166.5 million. We have numerous financial and non-financial covenants on our debt obligations with various banks and other lenders. Some of these covenants include default and/or cross-default provisions that could require acceleration of repayment of our loans in the event of default. However, our debt is primarily short-term in nature. Any acceleration would be a matter of months but may impact our ability to refinance our debt obligations if an event of default occurs. As of December&#160;31, 2024, we are in compliance with all covenants of our material debt agreements. See above regarding Liquidity and Capital Resources and Note 12 in the Notes to the Financial Statements for further detail of our debt obligations. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on bank loans is paid quarterly until the respective loans are fully settled. For the purpose of contractual obligations calculation, current interest rates on floating rate obligations were used for the remainder contractual life of the outstanding borrowings.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Co-Development Funding Commitments</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our collaboration with Amgen, we are responsible for co-funding global clinical development costs for the licensed oncology pipeline assets, up to a total cap of $1.25 billion. We are funding our portion of the co-development costs by contributing cash and/or development services. As of December&#160;31, 2024, our remaining co-development funding commitment was $335.3 million.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Funding Commitment</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Funding commitment represents our committed capital related to two of our equity method investments. As of December&#160;31, 2024, our remaining capital commitment was $7.4 million and is expected to be paid from time to time over the investment period.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pension Plan</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a defined benefit pension plan in Switzerland that is collectively financed by employer and employee contributions. As of December 31, 2024, the plan was unfunded $16.4 million, with $3.9 million of employer contributions expected in 2025. The timing and amount of future long-term funding requirements will vary as a result of future changes in staffing and compensation levels, various actuarial assumptions and actual investment returns on plan assets. In the event of an underfunding, Switzerland pension foundations can levy additional contributions on the employer.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capital Commitments</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had capital commitments amounting to $48.3 million for the acquisition of property, plant and equipment as of December&#160;31, 2024, related to various facilities across the globe.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities, revenues, costs and expenses. We evaluate our estimates and judgments on an ongoing basis, and our actual results may differ from these estimates. We base our estimates on historical experience, known trends and events, contractual milestones and other various factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of these estimates are considered critical as they involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our consolidated financial statements. Our critical accounting estimates are summarized below. See Note 2 to our consolidated financial statements included in this Annual Report for a description of our significant accounting policies.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue when we transfer control of goods or services to our customers. Revenue is measured as the amount of consideration we expect to receive in exchange for goods and services. We generate revenue from product sales and revenue transactions with our collaboration partners.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenue</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine the appropriate transaction price for our product sales at the time we recognize a sale to a direct customer, we estimate any rebates, chargebacks or discounts that ultimately will be due to the direct customer and other customers in the distribution chain under the terms of our contracts. Significant judgments are required in making these estimates. We include variable consideration in the transaction price to the extent it is probable that a significant reversal will not occur and estimate variable consideration from rebates, chargebacks, trade discounts and allowances, sales returns allowances, and other incentives using the expected value method. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates for variable consideration for which reserves are established at the time of sale include government and commercial rebates, provisions for acceptance of NRDL pricing, chargebacks, trade discounts and allowances, sales returns allowances and other incentives that are offered within contracts between the Company and our customers, health care providers and other indirect customers. Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as our historical experience, current contractual and statutory requirements, channel inventory levels, specific known market events and trends, industry data and forecasted customer buying and payment patterns. We base our sales returns allowance on estimated distributor inventories, customer demand as reported by third-party sources, and actual returns history, as well as other factors, as appropriate. To date, sales returns have not been significant.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actual amounts of consideration ultimately received may differ from our estimates.&#160;We will reassess estimates for variable consideration periodically. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaborative arrangements may contain more than one unit of account, or performance obligation, including grants of licenses to intellectual property rights, agreements to provide research and development services and other deliverables. As part of the accounting for these arrangements, we must develop assumptions that require significant judgments to determine the standalone selling price for each performance obligation identified in the contract.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Standalone selling prices for licenses of intellectual property and the right to access and use intellectual property during an option period performance obligations are determined based on the probability-weighted present value of forecasted cash flows associated with the intellectual property. Stand-alone selling prices for research and development services performance obligations are based on the present value of estimated clinical trial costs plus a reasonable margin.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimates of standalone selling prices involve management&#8217;s key assumptions such as revenue growth rate, estimated clinical trial costs, mark-up rate, probability of technical and regulatory success, and discount rates. These significant assumptions are forward looking and could be affected by future economic, regulatory and market conditions. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2024, our existing deferred revenue balance was less than $1.0 million, and collaboration revenue is not expected to be a significant driver of our financial results until if and when additional agreements are entered into. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Measurement of Accrued Research and Development Expenses </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial costs are a significant component of our research and development expenses and are recognized as the related services are incurred and measured at the cost expected to be paid for those services. As such, certain of our research and development expenses in any one period are an estimate by us as to the amount incurred for that period but not yet invoiced to us by the service provider. We have a history of contracting with third parties that perform various clinical trial activities on behalf of us in the ongoing development of our product candidates. Expenses related to clinical trials not yet invoiced are accrued based on our estimates of the actual services performed by the third parties for the respective period. If the contracted amounts are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), we will modify the related accruals accordingly on a prospective basis. Revisions in the scope of a contract are charged to expense in the period in which the facts that give rise to the revision become probable.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting expenses that differ from amounts ultimately paid in any one period. To date, we have not made any material adjustments to our prior estimates of research and development expenses.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Measurement of Deferred Tax Assets</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Deferred tax assets represent amounts available to reduce income taxes payable on taxable income in future years. Such assets arise because of temporary differences between the financial reporting and tax basis of assets and liabilities, as well as from net operating losses and tax credit carryforwards. We evaluate the recoverability of these future tax deductions and credits by assessing the adequacy of future expected taxable income from all sources, including reversal of temporary differences, forecasted operating earnings and available tax planning strategies. These sources of income rely heavily on estimates that are based on a number of factors, including historical experience and short-range and long-range business forecasts. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Currently, we are in a three-year cumulative book loss position and as required by ASC 740, we provided a valuation allowance on all of our deferred tax assets. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Subsequent Measurement of Long-Lived Assets</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We test long-lived assets, which include property, plant and equipment and intangible assets with finite useful lives, for impairment at least annually and whenever events or circumstances change that indicate impairment may have occurred. A significant amount of judgment is involved in determining if an indicator of impairment has occurred. Such indicators may include, among others and without limitation: a significant decline in our expected future cash flows; a sustained, significant decline in the trading prices of our ADSs, our ordinary shares, and/or our RMB Shares and market capitalization; a significant adverse change in legal factors or in the business climate; unanticipated competition; and slower growth rates. For the years ended December&#160;31, 2024, 2023 and 2022, we determined there was no impairment of the value of our long-lived assets.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;2 to our consolidated financial statements included in this Annual Report for information regarding recent accounting pronouncements.</span></div><div id="ic94bd2152a214042a118e81881a5a1e5_127"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7A. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Risk</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to risk related to changes in interest rates on our outstanding borrowings. We had $720.1&#160;million of outstanding floating rate debt as of December&#160;31, 2024. A 100-basis point increase in interest rates as of December&#160;31, 2024 would increase our annual pre-tax interest expense by approximately $7.2&#160;million.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Exchange Rate Risk</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">China Exchange Rate Regime</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RMB is not freely convertible into foreign currencies for capital account transactions. The State Administration of Foreign Exchange, under the authority of the People&#8217;s Bank of China, controls the conversion of RMB into foreign currencies. The value of RMB against the U.S. dollar and other currencies is affected by, among other things, changes in China&#8217;s political and economic conditions and China&#8217;s foreign exchange prices. Since 2005, the RMB has been permitted to fluctuate within a narrow and managed band against a basket of certain foreign currencies. The RMB compared to the U.S. dollar depreciated approximately 2.8% for both the&#160;years ended December&#160;31, 2024 and 2023, and depreciated approximately 8.2% for the year ended December 31, 2022, respectively. It is difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate between the RMB and the U.S.&#160;dollar in the future.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transactional Risk</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to foreign exchange risk arising from various currency exposures when we enter into transactions  denominated in foreign currencies. Our reporting currency is the U.S.&#160;dollar, and our most significant functional currencies are the U.S. dollar and the RMB. A portion of our operating transactions and monetary assets and liabilities are in currencies other than the U.S. dollar and RMB, primarily the U.S. dollar against the RMB, Euro, and Australian dollar. During the years ended December&#160;31, 2024, 2023 and 2022, we recognized foreign exchange losses of $16.0 million, $64.8 million and $233.8 million, respectively, resulting from the strengthening of the U.S. dollar compared to the RMB and the revaluation impact of RMB-denominated deposits held in U.S. dollar functional currency entities, including the Parent Company. As of December&#160;31, 2024, the Parent Company held RMB-denominated deposits of $220.4 million. A hypothetical 10% appreciation in the U.S. dollar exchange rate compared with the RMB as of December&#160;31, 2024 would have resulted in an increase in foreign exchange loss of approximately $20.0 million. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Translational Risk</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also face foreign currency exposure that arises from translating the results of our global operations to the U.S. dollar at exchange rates that have fluctuated from the beginning of the period, primarily the RMB against the U.S. dollar. A significant depreciation of the RMB against the U.S. dollar may significantly reduce the U.S. dollar equivalent of our foreign cash balances and trade receivables. Further, volatility in exchange rate fluctuations may have a significant impact on the foreign currency translation adjustments recorded in other comprehensive income (loss). </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not used derivative financial instruments to reduce the effect of fluctuating currency exchange rates.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effects of Inflation</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation has had a material effect on our results of operations during the year ended December&#160;31, 2024.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_175"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;8. Financial Statements and Supplementary Data</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE,&#160;LTD.</span></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:92.301%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.499%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_178">Reports of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_178">131</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_181">Consolidated statements of operations for the years ended December 31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_181">4</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_181">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_181">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_181"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_181">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_181">134</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_184">Consolidated balance sheets as of December&#160;31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_184">4</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_184"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_184">3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_184">136</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_187">Consolidated statements of comprehensive loss for the&#160;years ended December&#160;31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_187">4</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_187">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_187">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_187"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_187">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_187">135</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_190">Consolidated statements of cash flows for the&#160;years ended December&#160;31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_190">4</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_190">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_190">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_190"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_190">2</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_190">&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_190">137</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_193">Consolidated statements of shareholders&#8217; equity for the&#160;years ended December&#160;31, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_193">4</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_193">, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_193">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_193"> and 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_193">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_193">138</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_196">Notes&#160;to consolidated financial statements&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_196">139</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_178"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and the Board of Directors of BeiGene, Ltd. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:19.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of BeiGene, Ltd. (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations, comprehensive loss, shareholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2024, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:19.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February 27, 2025 expressed an unqualified opinion thereon.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:19.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:19.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div style="text-align:justify;text-indent:19.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenue, Net</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:13.015%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.557%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2024, the Company recorded $286.3 million of accrued sales chargebacks, rebates, returns and other deductions. As discussed in Note 2 to the consolidated financial statements under the caption &#8220;Revenue Recognition&#8221;, the Company recognizes revenue when the transfer of control of goods or services to the customer is completed. To determine the appropriate transaction price at the time revenue is recognized, the Company estimates variable consideration related to rebates, chargebacks, trade discounts and allowances, and other incentives that will ultimately be due to the customer and others in the distribution channel under the terms of their contracts. Where appropriate, these estimates take into consideration, among other items, the Company&#8217;s historical experience, current contractual and statutory requirements, channel inventory levels, and forecasted customer buying and payment patterns. The Company recognizes revenue related to variable consideration to the extent it is probable that a significant revenue reversal will not occur and estimates variable consideration from rebates, chargebacks, trade discounts and allowances, and other incentives using the expected value method. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing the Company&#8217;s accrued revenue rebates in the United States is challenging due to the extent of effort required to audit the significant number of United States-based rebate programs, as the terms vary by program and by customer. Additionally, due to the volume of rebates and third-party processes and the timing of invoicing received from vendors, the actual amounts incurred for all programs are not known at the time the financial statements are filed.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluated and tested the design and operating effectiveness of internal controls over the Company&#8217;s process used in determining the measurement and completeness of accrued revenue rebates in the United States. This included testing controls over management&#8217;s review of contractual rebates and other inputs used in the estimation of accrued revenue rebates in the United States, including but not limited to the Company&#8217;s historical results, current contractual and statutory requirements, channel inventory levels, and forecasted customer buying and payment patterns. We tested controls over management&#8217;s review of contractual terms, and total invoicing to date, as well as controls to ensure that the data used to evaluate and support the significant assumptions were complete, accurate, and, where applicable, verified to external data sources.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To test the accrued revenue rebates in the United States, our audit procedures included, among others, testing the accuracy and completeness of the underlying data used in determining the accrued revenue rebates and evaluating the assumptions and inputs used by management. To evaluate the measurement and completeness of the accrual, we performed analytical procedures in combination with confirmations of a sample of the inventory remaining in the distribution channel at period end. We assessed the historical accuracy of management&#8217;s accrued revenue rebates estimates by comparing prior period accrued revenue rebates to the amount of actual payments made in subsequent periods. We examined terms and conditions for a sample of contracts with the Company&#8217;s customers and others in the distribution channel, tested a sample of credits issued and payments made throughout the year, and agreed rates to underlying contract terms. We performed independent calculations of the revenue rebate accruals using actual rebate invoicing and executed third-party contracts and assessed forecasted customer buying and payment patterns based on historical trends. Finally, we assessed subsequent events and subsequent period invoicing to determine whether there was any new information that would require adjustment to the accruals.</span></div><div><span><br/></span></div></td></tr></table></div><div style="margin-bottom:9pt;margin-top:4pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:4pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-52">Ernst&#160;&amp; Young LLP</ix:nonNumeric></span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2022.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-53">Boston, Massachusetts</ix:nonNumeric></span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;27, 2025</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and the Board of Directors of BeiGene, Ltd. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:0.7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:20.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited BeiGene, Ltd.&#8217;s internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, BeiGene, Ltd. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on the COSO criteria.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:20.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2024 and 2023, the related consolidated statements of operations, comprehensive loss, shareholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2024, and the related notes and our report dated February 27, 2025 expressed an unqualified opinion thereon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:0.7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:20.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:20.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:20.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:0.7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:20.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:20.3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:9pt"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst&#160;&amp; Young&#160;LLP</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston, Massachusetts</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;27, 2025</span></div><div style="margin-bottom:30pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133</span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_181"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE,&#160;LTD.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollars (&#8220;$&#8221;), except for number of shares and per share data)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:53.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-54">3,779,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-55">2,189,852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-56">1,254,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-57">30,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-58">268,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-59">161,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-60">3,810,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-61">2,458,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-62">1,415,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales - product</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-63">594,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-64">379,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-65">286,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-66">3,216,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-67">2,078,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-68">1,129,446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-69">1,953,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-70">1,778,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-71">1,640,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-72">1,831,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-73">1,508,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-74">1,278,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-75">3,784,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-76">3,286,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-77">2,919,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-78">568,199</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-79">1,207,736</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-80">1,789,665</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-81">47,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-82">74,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-83">52,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-84">12,638</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-85">307,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-86">223,852</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-87">533,001</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-88">825,836</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-89">1,961,037</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-90">111,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-91">55,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-92">42,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-93">644,786</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-94">881,708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-95">2,003,815</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-96"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-97">0.47</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-98"><ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-99">0.65</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-100"><ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-101">1.49</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding&#8212;basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-102"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-103">1,368,746,793</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-104"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-105">1,357,034,547</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-106"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-107">1,340,729,572</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per American Depositary Share (&#8220;ADS&#8221;)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="bgne:EarningsPerAmericanDepositoryShareBasic" scale="0" id="f-108"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="bgne:EarningsPerAmericanDepositoryShareDiluted" scale="0" id="f-109">6.12</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="2" sign="-" name="bgne:EarningsPerAmericanDepositoryShareBasic" scale="0" id="f-110"><ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="2" sign="-" name="bgne:EarningsPerAmericanDepositoryShareDiluted" scale="0" id="f-111">8.45</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" sign="-" name="bgne:EarningsPerAmericanDepositoryShareDiluted" scale="0" id="f-112"><ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" sign="-" name="bgne:EarningsPerAmericanDepositoryShareBasic" scale="0" id="f-113">19.43</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average ADSs outstanding&#8212;basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="bgne:WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted" format="ixt:num-dot-decimal" scale="0" id="f-114"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="bgne:WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-115">105,288,215</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="0" name="bgne:WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-116"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="0" name="bgne:WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted" format="ixt:num-dot-decimal" scale="0" id="f-117">104,387,273</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="0" name="bgne:WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-118"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="0" name="bgne:WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted" format="ixt:num-dot-decimal" scale="0" id="f-119">103,133,044</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134</span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_187"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE,&#160;LTD.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollars (&#8220;$&#8221;), except for number of shares and per share data)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.578%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-120">644,786</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-121">881,708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-122">2,003,815</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax of nil:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-123">47,565</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-124">25,464</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-125">90,421</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension liability adjustments, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-126">1,942</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-127">5,611</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-128">365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized holding (loss) gain, net</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-129">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-130">9,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-131">5,311</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-132">694,328</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-133">903,737</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-134">2,099,182</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135</span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_184"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE,&#160;LTD.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollars (&#8220;$&#8221;), except for number of shares and per share data)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:67.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-135">2,627,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-136">3,171,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-137">676,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-138">358,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-139">494,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-140">416,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-141">192,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-142">257,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-143">3,991,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-144">4,203,414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-145">1,578,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-146">1,324,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-147">139,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-148">95,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-149">51,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-150">57,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-151">160,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-152">125,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-153">1,929,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-154">1,601,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-155">5,920,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-156">5,805,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-157">404,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-158">315,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other payables</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-159">803,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-160">693,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax payable</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-161">25,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-162">22,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities, current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-163">17,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-164">21,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development cost share liability, current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="bgne:ResearchAndDevelopmentCostShareLiabilityCurrentPortion" format="ixt:num-dot-decimal" scale="3" id="f-165">111,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="bgne:ResearchAndDevelopmentCostShareLiabilityCurrentPortion" format="ixt:num-dot-decimal" scale="3" id="f-166">68,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-167">851,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-168">688,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-169">2,214,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-170">1,810,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-171">166,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-172">197,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-173">44,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-174">22,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-175">42,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-176">16,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development cost share liability, non-current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="bgne:ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion" format="ixt:num-dot-decimal" scale="3" id="f-177">54,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="bgne:ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion" format="ixt:num-dot-decimal" scale="3" id="f-178">170,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-179">66,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-180">50,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-181">373,789</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-182">457,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-183">2,588,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-184">2,267,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-12" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-185"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-13" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-186"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ordinary shares, <ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-187"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-188">0.0001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-189"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-190">9,500,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-191"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-192">1,387,367,704</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-193"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-194">1,359,513,224</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31,&#160;2024 and 2023, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-195">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-196">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-197">12,087,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-198">11,598,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-199">148,988</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-200">99,446</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-201">8,606,836</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-202">7,962,050</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-203">3,332,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-204">3,537,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-205">5,920,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-206">5,805,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136</span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_190"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE,&#160;LTD.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amounts in thousands of U.S. Dollars (&#8220;$&#8221;), except for number of shares and per share data)</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:53.592%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Note</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-207">644,786</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-208">881,708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-209">2,003,815</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-210">171,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-211">87,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-212">66,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-213">441,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-214">367,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-215">303,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="bgne:AcquiredInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-216">60,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="bgne:AcquiredInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-217">46,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="bgne:AcquiredInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-218">68,665</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amortization of research and development cost share liability</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="bgne:AmortizationOfResearchAndDevelopmentFinancingLiability" format="ixt:num-dot-decimal" scale="3" id="f-219">73,226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="bgne:AmortizationOfResearchAndDevelopmentFinancingLiability" format="ixt:num-dot-decimal" scale="3" id="f-220">55,294</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="bgne:AmortizationOfResearchAndDevelopmentFinancingLiability" format="ixt:num-dot-decimal" scale="3" id="f-221">96,402</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Unrealized losses on long-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-222">24,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-223">16,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-224">21,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Deferred income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="3" id="f-225">25,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="f-226">689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="3" id="f-227">2,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Gain on BMS termination settlement</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:fixed-zero" scale="3" id="f-228">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="3" id="f-229">362,917</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:fixed-zero" scale="3" id="f-230">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other items, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" format="ixt:num-dot-decimal" scale="3" id="f-231">11,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" format="ixt:num-dot-decimal" scale="3" id="f-232">5,998</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" format="ixt:num-dot-decimal" scale="3" id="f-233">9,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-234">329,443</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-235">188,306</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-236">304,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-237">91,496</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-238">140,948</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-239">56,689</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="f-240">45,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="f-241">12,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="f-242">3,282</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-243">121,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-244">21,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-245">4,352</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Accrued expenses and other payables</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-246">111,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-247">180,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-248">45,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="f-249">633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-250">255,587</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-251">151,816</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-252">14,838</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="f-253">587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-254">1,209</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-255">140,631</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-256">1,157,453</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-257">1,496,619</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-258">492,663</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-259">561,896</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-260">325,434</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Proceeds from sale or maturity of short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-261">2,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-262">673,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-263">1,563,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Purchase of in-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="bgne:PaymentsToPurchaseInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-264">31,800</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="bgne:PaymentsToPurchaseInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-265">15,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="bgne:PaymentsToPurchaseInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-266">143,665</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Purchase of intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-267">4,674</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-268">19,365</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:fixed-zero" scale="3" id="f-269">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Purchase of long-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireLongtermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-270">19,006</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:PaymentsToAcquireLongtermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-271">14,900</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:PaymentsToAcquireLongtermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-272">15,911</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-273">2,862</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-274">2,075</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-275">1,485</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-276">548,350</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-277">60,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-278">1,077,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Proceeds from long-term loan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="f-279">9,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="f-280">22,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="f-281">37,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Repayment of long-term loan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-282">28,031</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-283">13,690</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-284">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Proceeds from short-term loans</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-285">868,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-286">661,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-287">313,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Repayment of short-term loans</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-288">704,216</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-289">309,576</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-290">417,081</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Proceeds from option exercises and employee share purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="f-291">45,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="f-292">55,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="f-293">46,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Other financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-294">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-295">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-296">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-297">193,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-298">416,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-299">18,971</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Effect of foreign exchange rate changes, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-300">51,705</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-301">8,082</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-302">69,383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents, and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-303">547,237</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-304">689,053</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-305">507,850</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-306">3,185,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-307">3,875,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-308">4,382,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Cash, cash equivalents, and restricted cash, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-309">2,638,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-310">3,185,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-311">3,875,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Supplemental cash flow disclosures:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-312">2,627,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-313">3,171,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-314">3,869,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Short-term restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-315">9,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-316">11,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="f-317">196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-318">2,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-319">2,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-320">5,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Income taxes paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-321">69,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-322">56,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-323">29,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest paid</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="bgne:InterestPaidIncludingCapitalizedInterest" format="ixt:num-dot-decimal" scale="3" id="f-324">51,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="bgne:InterestPaidIncludingCapitalizedInterest" format="ixt:num-dot-decimal" scale="3" id="f-325">19,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="bgne:InterestPaidIncludingCapitalizedInterest" format="ixt:num-dot-decimal" scale="3" id="f-326">25,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Supplemental non-cash activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Accruals for capital expenditures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-327">70,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-328">91,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-329">95,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Purchase of in-process research and development included in accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="bgne:AcquiredInProcessResearchAndDevelopmentButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-330">60,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="bgne:AcquiredInProcessResearchAndDevelopmentButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-331">31,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="bgne:AcquiredInProcessResearchAndDevelopmentButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-332">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137</span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_193"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF SHAREHOLDERS&#8217; EQUITY </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollars (&#8220;$&#8221;), except for number of shares and per share data)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.715%"><tr><td style="width:1.0%"/><td style="width:36.185%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.185%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.757%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.514%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.475%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:23pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ordinary&#160;Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income/(Loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December&#160;31,&#160;2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-333">1,334,804,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-334">133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-335">11,191,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-336">17,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-337">5,076,527</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-338">6,132,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost from issuance of ordinary shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="f-339">152</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="f-340">152</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of shares reserved for share option exercises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-341">1,375,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of options, ESPP and release of RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-342">19,960,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-343">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-344">46,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-345">46,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-346">303,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-347">303,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-348">95,367</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-349">95,367</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-350">2,003,815</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-351">2,003,815</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-352">1,356,140,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-353">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-354">11,540,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-355">77,417</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-356">7,080,342</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-357">4,383,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of shares reserved for share option exercises</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-358">84,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of options, ESPP and release of RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-359">26,561,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-360">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-361">53,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-362">53,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cancellation of ordinary shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-28" decimals="INF" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="f-363">23,273,108</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="3" id="f-364">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="f-365">362,915</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="f-366">362,917</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-367">367,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-368">367,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-369">22,029</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-370">22,029</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-371">881,708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-372">881,708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-373">1,359,513,224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-374">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-375">11,598,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-376">99,446</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-377">7,962,050</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-378">3,537,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Use of shares reserved for share option exercises</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-36" decimals="INF" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-379">2,258,161</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of options, ESPP and release of RSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-36" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-380">30,112,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-381">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-382">45,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-383">45,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deconsolidation of a subsidiary</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="bgne:AdjustmentsToAdditionalPaidInCapitalDeconsolidationOfSubsidiary" format="ixt:num-dot-decimal" scale="3" id="f-384">2,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="bgne:AdjustmentsToAdditionalPaidInCapitalDeconsolidationOfSubsidiary" format="ixt:num-dot-decimal" scale="3" id="f-385">2,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-386">441,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-387">441,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-388">49,542</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-389">49,542</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-390">644,786</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-391">644,786</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-392">1,387,367,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-393">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-394">12,087,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-395">148,988</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-396">8,606,836</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-397">3,332,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138</span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_196"></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><div style="text-align:center"><span><br/></span></div><div id="ic94bd2152a214042a118e81881a5a1e5_199"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="f-398" continuedAt="f-398-1" escape="true">Description of Business</ix:nonNumeric></span></div><ix:continuation id="f-398-1"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BeiGene, Ltd. (the &#8220;Company&#8221;, &#8220;BeiGene&#8221;, &#8220;it&#8221;, &#8220;its&#8221;) is a leading global oncology company discovering and developing innovative treatments that are more accessible and affordable to cancer patients worldwide. In 2024, the Company generated total global revenue of approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="9" id="f-399">3.8</ix:nonFraction> billion, increasing revenue by approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-8" name="bgne:RevenueFromContractWithCustomerExcludingAssessedTaxPeriodIncreaseDecrease" scale="9" id="f-400">1.4</ix:nonFraction> billion from the prior year, while reducing its operating loss from the prior year by approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-8" sign="-" name="bgne:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestPeriodIncreaseDecrease" scale="9" id="f-401">0.6</ix:nonFraction> billion.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception in 2010, the Company has become a fully integrated global organization with more than <ix:nonFraction unitRef="employee" contextRef="c-12" decimals="-3" name="dei:EntityNumberOfEmployees" format="ixt:num-dot-decimal" scale="0" id="f-402">11,000</ix:nonFraction> employees worldwide.</span></div></ix:continuation><div id="ic94bd2152a214042a118e81881a5a1e5_202"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-403" continuedAt="f-403-1" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-403-1" continuedAt="f-403-2"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-404" continuedAt="f-404-1" escape="true">Basis of Presentation</ix:nonNumeric> and <ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-405" continuedAt="f-405-1" escape="true">Principles of Consolidation</ix:nonNumeric></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-404-1">The consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;).</ix:continuation> <ix:continuation id="f-405-1">The consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany transactions and balances between the Company and its wholly-owned subsidiaries are eliminated upon consolidation.</ix:continuation></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-406" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Areas where management uses subjective judgment include, but are not limited to, estimating the useful lives of long-lived assets, estimating variable consideration in product sales and collaboration revenue arrangements, identifying separate accounting units and the standalone selling price of each performance obligation in the Company&#8217;s revenue arrangements, assessing the impairment of long-lived assets, valuation and recognition of share-based compensation expenses, estimating uncertain tax positions, valuation of inventory, estimating the allowance for credit losses, determining defined benefit pension plan obligations, measurement of right-of-use assets and lease liabilities and the fair value of financial instruments. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from these estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-407" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Functional Currency and Foreign Currency Translation</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Functional currency and foreign currency gains and losses</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the U.S. dollar (&#8220;$&#8221; or U.S. dollar) as its reporting currency. Transactions in subsidiaries are recorded in the functional currency of the respective subsidiary and such transactions denominated in currencies other than the functional currency give rise to foreign exchange remeasurement (monetary assets and liabilities) and related gains and losses that are classified in other (expense) income, net in the consolidated statement of operations. The determination of functional currency is based on the criteria of Accounting Standard Codification (&#8220;ASC&#8221;) 830, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Matters</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For those periods presented, the Company has not entered into any foreign currency derivative instruments to hedge its foreign currency positions.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency translation</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For subsidiaries whose functional currencies are not the U.S. dollar, the Company uses the average exchange rate for the period and the exchange rate at the balance sheet date to translate the operating results and financial position to the U.S. dollar, which is the Company's reporting currency. Translation differences are recorded in accumulated other comprehensive loss, a component of shareholders&#8217; equity.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><ix:continuation id="f-403-2" continuedAt="f-403-3"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" id="f-408" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash on hand and bank deposits, which are unrestricted as to withdrawal and use. The Company considers all highly liquid investments with an original maturity date of three months or less at the date of purchase to be cash equivalents. Cash equivalents which consist primarily of money market funds are stated at fair value.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="f-409" continuedAt="f-409-1" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted cash</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash primarily consists of&#160;RMB-denominated cash deposits pledged in designated bank accounts as collateral for bank loans and letters of credit. The Company classifies restricted cash as current or non-current based on the term of the restriction.</span></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-409-1">In addition to the restricted cash balances above, the Company is required by the PRC securities law to use the proceeds from the STAR offering in strict compliance with the planned uses as disclosed in the PRC offering prospectus as well as those disclosed in the Company&#8217;s proceeds management policy approved by its board of directors.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="f-411" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:CreditLossFinancialInstrumentPolicyTextBlock" id="f-410" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Credit Losses</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are recorded at their invoiced amounts, net of trade discounts and allowances as well as an allowance for credit losses. The allowance for credit losses reflects the Company&#8217;s current estimate of credit losses expected to be incurred over the life of the receivables. The Company considers various factors in establishing, monitoring, and adjusting its allowance for credit losses including the aging of receivables and aging trends, customer creditworthiness and specific exposures related to particular customers. The Company also monitors other risk factors and forward-looking information, such as country specific risks and economic factors that may affect a customer&#8217;s ability to pay in establishing and adjusting its allowance for credit losses. Accounts receivable are written off after all collection efforts have ceased.</span></div></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryPolicyTextBlock" id="f-412" continuedAt="f-412-1" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Prior to the regulatory approval of product candidates, the Company may incur costs for the manufacture of drug product to support the commercial launch of those products. Until the date at which regulatory approval has been received or is otherwise considered probable, all such costs are recorded as research and development expenses as incurred. </span></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-412-1">Inventories are stated at the lower of cost and net realizable value, with cost determined in a manner that approximates weighted average cost. The Company periodically analyzes its inventory levels, and writes down inventory that has become obsolete, inventory that has a cost basis in excess of its estimated realizable value and inventory in excess of expected sales requirements as cost of product sales. The determination of whether inventory costs will be realizable requires estimates of future prices by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required, which would be recorded in the consolidated statements of operations.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentPolicyTextBlock" id="f-413" continuedAt="f-413-1" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consist of available-for-sale debt securities, convertible note instruments, public equity securities with readily determinable fair values, private equity securities without readily determinable fair values, and equity-method investments. The classification of an investment is determined based on the nature of the investment, the Company&#8217;s ability and intent to hold the investment, and the degree to which the Company may exercise influence over the investee.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Available-for-sale debt securities are stated at fair value, with the unrealized gains and losses, net of tax, reported in other comprehensive loss. The net carrying value of debt securities classified as available-for-sale is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization is computed using the effective interest method and included in interest income. Interest and dividends are included in interest income. Available-for-sale debt securities with original maturities greater than three months at the date of purchase and less than one year from the date of the balance sheet are classified as short-term. Available-for-sale debt securities with maturities beyond one year may be classified as short-term marketable securities due to their highly liquid nature and because they represent the Company&#8217;s investments that are available for current operations.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><ix:continuation id="f-403-3" continuedAt="f-403-4"><ix:continuation id="f-413-1" continuedAt="f-413-2"><div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Convertible note instruments are recorded using the fair value option method of accounting. Accordingly, convertible note instruments are remeasured at fair value on a recurring basis, with any changes in the fair value option recorded in other (expense) income, net.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Public equity securities with readily determinable fair values are recorded at fair value. Subsequent changes in fair value are recorded in other (expense) income, net. Derivative financial instruments to purchase public equity securities are recorded at fair value. The estimated fair value of derivative financial instruments is determined based on the Black-Scholes valuation model. Changes in fair value of derivative instruments are recorded in other (expense) income, net.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Private equity securities without readily determinable fair values and where the Company does not have significant influence are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Adjustments to private equity securities are recorded in other (expense) income, net. </span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Equity investments in common stock or in-substance common stock where the Company has significant influence over the financial and operating policies of the investee are accounted for as equity-method investments. Equity-method investments are initially recorded at cost and subsequently adjusted based on the Company&#8217;s percentage ownership in the investee&#8217;s income and expenses, as well as dividends, if any. The Company records its share of the investee&#8217;s results of operations in other (expense) income, net. The Company records impairment losses on our equity method investments if it deems the impairment to be other-than-temporary. The Company deems an impairment to be other-than-temporary based on various factors, including but not limited to, the length of time the fair value is below the carrying value and ability to retain the investment to allow for a recovery in fair value.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains or losses on sales of investments are determined based on the specific identification method.</span></div></ix:continuation><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-413-2">The Company regularly evaluates its investments in debt and equity for impairment. The Company recognizes an allowance on available-for-sale debt securities when a portion of the unrealized loss is attributable to a credit loss and a corresponding credit loss in net income. No allowance for credit losses were recorded for any periods presented.</ix:continuation> The Company recognized an impairment loss of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:num-dot-decimal" scale="3" id="f-414">7,635</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:num-dot-decimal" scale="3" id="f-415">7,529</ix:nonFraction> related to its investments in equity during the years ended December&#160;31, 2024 and 2023, respectively. No impairment losses on equity investments were recorded for the year ended December&#160;31, 2022.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-416" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-417" continuedAt="f-417-1" escape="true">Property, plant and equipment, other than land and construction in progress, are depreciated using the straight-line method over the estimated useful lives of the respective assets as follows:</ix:nonNumeric></span></div><ix:continuation id="f-417-1" continuedAt="f-417-2"><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.806%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful&#160;Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-44" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-418">20</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-45" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-419">3</ix:nonNumeric> to <ix:nonNumeric contextRef="c-46" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-420">10</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-47" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-421">3</ix:nonNumeric> to <ix:nonNumeric contextRef="c-48" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-422">5</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software, Electronic and Office Equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-49" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-423">3</ix:nonNumeric> to <ix:nonNumeric contextRef="c-50" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-424">5</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold Improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of useful life or lease term</span></td></tr></table></div></ix:continuation></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically evaluates whether events and circumstances have occurred that indicate the estimated useful lives of its long-lived assets may require reassessment. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><ix:continuation id="f-403-4" continuedAt="f-403-5"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-425" continuedAt="f-425-1" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies ASC, Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 842&#8221;) to account for its leases. The Company determines if an arrangement is a lease at inception. The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease component based on the Company&#8217;s policy election to combine lease and non-lease components for its leases. Leases are classified as operating or finance leases in accordance with the recognition criteria in ASC 842-20-25. The Company&#8217;s lease portfolio consists entirely of operating leases as of December&#160;31, 2024. The Company&#8217;s leases do not contain any material residual value guarantees or material restrictive covenants.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the commencement date of a lease, the Company determines the classification of the lease based on the relevant factors present and records a right-of-use (&#8220;ROU&#8221;) asset and lease liability. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and lease liabilities are calculated as the present value of the lease payments not yet paid. Variable lease payments not dependent on an index or rate are excluded from the ROU asset and lease liability calculations and are recognized in expense in the period which the obligation for those payments is incurred. As the rate implicit in the Company&#8217;s leases is not typically readily available, the Company uses an incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. This incremental borrowing rate reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. ROU assets include any lease prepayments and are reduced by lease incentives. Operating lease expense for lease payments is recognized on a straight-line basis over the lease term. Lease terms are based on the non-cancelable term of the lease and may contain options to extend the lease when it is reasonably certain that the Company will exercise that option. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases are included in operating lease right-of-use assets and operating lease liabilities on the consolidated balance sheet. Lease liabilities that become due within one year of the balance sheet date are classified as current liabilities.</span></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-425-1">Leases with an initial lease term of 12 months or less are not recorded on the consolidated balance sheet. Lease expense for these leases is recognized on a straight-line basis over the lease term.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="bgne:LandUseRightsPolicyPolicyTextBlock" id="f-426" continuedAt="f-426-1" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Land Use Right, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-426-1">All land in the PRC is owned by the PRC government. The PRC government may sell land use rights for a specified period of time. Land use rights represent operating leases in accordance with ASC 842. The purchase price of land use rights represents lease prepayments to the PRC government and is recorded as an operating lease ROU asset on the balance sheet. The ROU asset is amortized over the remaining lease term.</ix:continuation> <ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-427" continuedAt="f-427-1" escape="true">As of December&#160;31, 2024, the Company held land use rights in the following regions:</ix:nonNumeric></span></div><ix:continuation id="f-427-1" continuedAt="f-427-2"><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.806%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Terms</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Guangzhou</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-51" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-428">50</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beijing</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-52" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-429">36</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Suzhou</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-53" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-430">30</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shanghai</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-54" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-431">47</ix:nonNumeric> years</span></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="f-432" continuedAt="f-432-1" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired through business combinations are recognized as assets separate from goodwill and are measured at fair value upon acquisition. Intangible assets acquired in transactions that are not business combinations are recorded at the allocated portion of total consideration transferred based on their relative fair value in relation to net assets acquired. Intangible assets associated with milestone payments made to third parties subsequent to regulatory approval are recorded at cost. Identifiable intangible assets consist of post-approval milestone payments under license and commercialization agreements, that are amortized over the remainder of the product patent or the term of the commercialization agreements; and trading licenses that are amortized over the initial license term.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><ix:continuation id="f-403-5" continuedAt="f-403-6"><ix:continuation id="f-432-1"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite useful lives are tested for impairment when events or circumstances occur that could indicate that the carrying amount of an asset may not be recoverable. When these events occur, the Company evaluates the recoverability of the intangible assets by comparing the carrying amount of the assets to the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected undiscounted cash flows is less than the carrying amount of the assets, the Company recognizes an impairment loss based on the excess of the carrying amount of the assets over their fair value. Fair value is generally determined by discounting the cash flows expected to be generated by the assets, when the market prices are not readily available. For the years ended December&#160;31, 2024, 2023 and 2022, the Company determined that there were <ix:nonFraction unitRef="usd" contextRef="c-11" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="f-433"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="f-434"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="0" id="f-435">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> indicators of impairment of its other intangible assets.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-436" continuedAt="f-436-1" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-436-1">Long-lived assets are reviewed for impairment in accordance with authoritative guidance for impairment or disposal of long-lived assets. Long-lived assets are reviewed for events or changes in circumstances, which indicate that their carrying value may not be recoverable. Long-lived assets are reported at the lower of carrying amount or fair value less cost to sell.</ix:continuation> For the years ended December&#160;31, 2024, 2023 and 2022, there was <ix:nonFraction unitRef="usd" contextRef="c-10" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="3" id="f-437"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="3" id="f-438"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="3" id="f-439">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment of the value of the Company&#8217;s long-lived assets.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-440" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value of financial instruments</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies ASC topic 820 (&#8220;ASC 820&#8221;), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in measuring fair value. ASC 820 defines fair value, establishes a framework for measuring fair value and requires disclosures to be provided on fair value measurement. ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Include other inputs that are directly or indirectly observable in the marketplace.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Unobservable inputs which are supported by little or no market activity.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 820 describes three main approaches to measuring the fair value of assets and liabilities: (1) market approach; (2) income approach; and (3) cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><ix:continuation id="f-403-6" continuedAt="f-403-7"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial instruments measured at fair value on a recurring basis</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="f-441" escape="true"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth assets measured at fair value on a recurring basis as of December&#160;31, 2024 and 2023:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.186%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Price<br/>in&#160;Active<br/>Market&#160;for<br/>Identical<br/>Assets<br/>(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-442">950,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-443">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-444">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt instrument</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="bgne:InvestmentInDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="f-445">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="bgne:InvestmentInDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="f-446">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="bgne:InvestmentInDebtSecuritiesCurrent" scale="3" id="f-447">618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-448">2,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="f-449">168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="f-450">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt instrument</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="bgne:InvestmentInDebtSecuritiesNonCurrent" format="ixt:fixed-zero" scale="3" id="f-451">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="bgne:InvestmentInDebtSecuritiesNonCurrent" format="ixt:fixed-zero" scale="3" id="f-452">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="bgne:InvestmentInDebtSecuritiesNonCurrent" format="ixt:num-dot-decimal" scale="3" id="f-453">4,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-454">952,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="f-455">168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-456">5,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.186%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Price<br/>in&#160;Active<br/>Market&#160;for<br/>Identical<br/>Assets<br/>(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-457">1,052,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-458">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-459">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-460">2,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="f-461">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="f-462">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt instrument</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="bgne:InvestmentInDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="f-463">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="bgne:InvestmentInDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="f-464">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="bgne:InvestmentInDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-465">4,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-466">3,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="f-467">542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="f-468">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt instrument</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="bgne:InvestmentInDebtSecuritiesNonCurrent" format="ixt:fixed-zero" scale="3" id="f-469">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="bgne:InvestmentInDebtSecuritiesNonCurrent" format="ixt:fixed-zero" scale="3" id="f-470">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="bgne:InvestmentInDebtSecuritiesNonCurrent" format="ixt:num-dot-decimal" scale="3" id="f-471">4,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-472">1,057,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="f-473">542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-474">8,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash equivalents are highly liquid investments with original maturities of 3 months or less. The Company&#8217;s investments in U.S. Treasury securities are classified as available-for-sale debt securities. The Company determines the fair value of cash equivalents and available-for-sale debt securities using a market approach based on quoted prices in active markets. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s equity securities carried at fair value consist of holdings in common stock and warrants to purchase additional shares of common stock of Leap Therapeutics, Inc. (&#8220;Leap&#8221;), a publicly-traded biotechnology company. The common stock investment is measured and carried at fair value and classified as a Level 1 investment. The warrants to purchase additional shares of common stock are measured using the Black-Scholes option-pricing valuation model and classified as a Level 2 investment. Refer to Note 5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for details of the determination of the carrying amount of private equity investments without readily determinable fair values and equity method investments.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds convertible notes issued by private biotech companies. The Company has elected the fair value option method of accounting for the convertible notes. Accordingly, the convertible notes are remeasured at fair value on a recurring basis using Level 3 inputs, with any changes in the fair value option recorded in other (expense) income, net. The Company recorded losses on fair value adjustments of $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" sign="-" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" format="ixt:num-dot-decimal" scale="3" id="f-475">4,842</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" sign="-" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" format="ixt:num-dot-decimal" scale="3" id="f-476">1,492</ix:nonFraction> for the years ended December&#160;31, 2024 and 2023, respectively. There was <ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" format="ixt:fixed-zero" scale="0" id="f-477">no</ix:nonFraction> fair value adjustment during the year ended December&#160;31, 2022.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">144</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><ix:continuation id="f-403-7" continuedAt="f-403-8"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers of instruments between levels of valuation categories during the years ended December&#160;31, 2024 and 2023.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, the Company held time deposits of <ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-478">nil</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-479">42,852</ix:nonFraction>, respectively, that were classified as cash equivalents. As of December&#160;31, 2024 and 2023, the fair values of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and short-term debt approximated their carrying values due to their short-term nature. Long-term debt approximates its fair value due to the fact that the related interest rates approximate the rates currently offered by financial institutions for similar debt instrument of comparable maturities.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-480" continuedAt="f-480-1" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies ASC, Topic 606,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(&#8220;ASC 606&#8221;) to account for its revenue transactions. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Company recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenue</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. and EU, the Company generates product revenues from the sale of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BRUKINSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and TEVIMBRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In China, the Company generates product revenues from the sale of its internally developed drugs TEVIMBRA, BRUKINSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and PARTRUVIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and the sale of in-licensed products through its agreements with Amgen, BMS, Bio-Thera, EUSA Pharma and Luye Pharmaceutical.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the commercial profit share arrangement with Amgen, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company is the principal for in-licensed product sales to customers in China during the commercialization period and recognizes 100% of net product revenue on these sales. Amounts due to Amgen for its portion of net product sales are recorded as cost of sales. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the Company distributes its products through specialty pharmacies and specialty distributors. The specialty pharmacies and specialty distributors subsequently resell the product to health care providers and patients. In the EU, the Company distributes its products through distributors or directly to hospitals. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In China, the Company sells its internally developed products to multiple distributors, who in turn sell the product to hospitals or pharmacies within their authorized territories to be sold ultimately to patients. In-licensed products are sold to a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">first tier distributor who subsequently resells the products to second tier distributors who ultimately sell the products to health care providers and patients.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is the principal under the product sales as the Company controls the products with the ability to direct the use of, and obtain substantially all the remaining benefits from the products before they are sold to the customer. For product sales transactions, the Company has a single performance obligation which is to sell the products to its customer. The Company includes variable consideration in the transaction price to the extent it is probable that a significant reversal will not occur and estimates variable consideration from rebates, chargebacks, trade discounts and allowances, sales returns allowances and other incentives using the expected value method. Revenues for product sales are recognized at a point in time when the single performance obligation is satisfied upon delivery to the customer. The Company&#8217;s payment terms are approximately 30-90 days. Actual amounts of consideration ultimately received may differ from the Company&#8217;s estimates.&#160;The Company will reassess estimates for variable consideration periodically. If actual results in the future vary from the Company&#8217;s estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><ix:continuation id="f-480-1" continuedAt="f-480-2"><ix:continuation id="f-403-8" continuedAt="f-403-9"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates for variable consideration for which reserves are established at the time of sale include government and commercial rebates, provisions for acceptance of National Reimbursement Drug List (&#8220;NRDL&#8221;) pricing in the PRC, chargebacks, trade discounts and allowances, sales returns allowances and other incentives that are offered within contracts between the Company and its customers, health care providers and other indirect customers. Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as the Company's historical experience, current contractual and statutory requirements, channel inventory levels, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The Company bases its sales returns allowance on estimated distributor inventories, customer demand as reported by third-party sources, and actual returns history, as well as other factors, as appropriate. To date, sales returns have not been significant.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(&#8220;ASC 808&#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities.&#160;For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and therefore within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the five-step model under ASC 606 noted above. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s collaborative arrangements may contain more than one unit of account, or performance obligation, including grants of licenses to intellectual property rights, agreement to provide research and development services and other deliverables. The collaborative arrangements do not include a right of return for any deliverable. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.&#160;In developing the stand-alone selling price for a performance obligation, the Company considers competitor pricing for a similar or identical product, market awareness of and perception of the product, expected product life and current market trends. In general, the consideration allocated to each performance obligation is recognized when the respective obligation is satisfied either by delivering a good or providing a service, limited to the consideration that is not constrained. Non-refundable payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as advances from customers.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Upfront non-refundable payments for licensing the Company&#8217;s intellectual property are evaluated to determine if the license is distinct from the other performance obligations identified in the arrangement. For licenses determined to be distinct, the Company recognizes revenues from non-refundable up-front fees allocated to the license at a point in time, when the license is transferred to the licensee and the licensee is able to use and benefit from the license.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Options to License Intellectual Property:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Upfront non-refundable payments for options to license the Company&#8217;s intellectual property are evaluated to determine if the option represents a material right and is distinct from the other performance obligations identified in the arrangement. For options determined to be a material right and distinct, the Company defers the non-refundable up-front fees allocated to the option and recognizes revenues at a point in time, at the earlier of when the option is exercised or the option period expires.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Right to Access Intellectual Property during the Option Period:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The portion of a transaction price allocated to the other parties right to access the Company&#8217;s intellectual property to generate their own data during an option period is deferred and recognized as collaboration revenue over the option period on a straight-line basis as the right to use the intellectual property is provided and the data generated. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Services:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The portion of a transaction price allocated to research and development services performance obligations is deferred and recognized as collaboration revenue over time as delivery or performance of such services occurs.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><ix:continuation id="f-403-9" continuedAt="f-403-10"><ix:continuation id="f-480-2"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.&#160;If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.&#160;Milestones related to the Company&#8217;s development-based activities may include initiation of various phases of clinical trials. Due to the uncertainty involved in meeting these development-based targets, they are generally fully constrained at contract inception. The Company will assess whether the variable consideration is fully constrained each reporting period based on the facts and circumstances surrounding the clinical trials. Upon changes to constraint associated with the developmental milestones, variable consideration will be included in the transaction price when a significant reversal of revenue recognized is not expected to occur and allocated to the separate performance obligations. Regulatory milestones are fully constrained until the period in which those regulatory approvals are achieved due to the inherent uncertainty with the approval process. Regulatory milestones are included in the transaction price in the period regulatory approval is obtained. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-481" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of the costs associated with our research and development activities, conducting preclinical studies and clinical trials, and activities related to regulatory filings, which primarily include (i) payroll and related costs (including share-based compensation) associated with research and development personnel, (ii) costs related to clinical trials and preclinical testing of the Company&#8217;s technologies under development, (iii) costs to develop the product candidates, including raw materials and supplies, product testing, depreciation, and facility related expenses, (iv) expenses for research services provided by universities and contract laboratories, including sponsored research funding, and (v) other research and development expenses. Research and development expenses are charged to expense as incurred when these expenditures relate to the Company&#8217;s research and development services and have no alternative future uses.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial costs are a significant component of the Company&#8217;s research and development expenses. The Company has a history of contracting with third parties that perform various clinical trial activities on behalf of the Company in the ongoing development of the Company&#8217;s product candidates. Expenses related to clinical trials are accrued based on the Company&#8217;s estimates of the actual services performed by the third parties for the respective period. If the contracted amounts are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), the Company will modify the related accruals accordingly on a prospective basis. Revisions in the scope of a contract are charged to expense in the period in which the facts that give rise to the revision become probable. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquired In-Process Research and Development Expense</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has acquired rights to develop and commercialize product candidates. Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments (prior to government approval), are immediately expensed as acquired in-process research and development in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#8220;business&#8221; as defined under GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. Milestone payments made to third parties subsequent to regulatory approval are capitalized as intangible assets and amortized over the estimated remaining useful life of the related product. Royalties owed on sales of the products licensed pursuant to the agreements are expensed in the period the related revenues are recognized.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="bgne:GovernmentGrantsPolicyPolicyTextBlock" id="f-482" continuedAt="f-482-1" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Grants</span></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-482-1" continuedAt="f-482-2">Government financial incentives that involve no conditions or continuing performance obligations of the Company are recognized as other income upon receipt.</ix:continuation> During the years ended December&#160;31, 2024, 2023 and 2022, the Company recognized other income of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GovernmentAssistanceAmount" format="ixt:num-dot-decimal" scale="3" id="f-483">22,326</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:GovernmentAssistanceAmount" format="ixt:num-dot-decimal" scale="3" id="f-484">23,989</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:GovernmentAssistanceAmount" format="ixt:num-dot-decimal" scale="3" id="f-485">32,540</ix:nonFraction>, respectively, for government grants received after the related expenses have been incurred.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">147</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><ix:continuation id="f-403-10" continuedAt="f-403-11"><ix:continuation id="f-482-2"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event government grants or incentives involve continuing performance obligations, the Company will capitalize the payment as a liability and recognize the same financial statement caption as the performance obligation relates over the performance period. The Company received government assistance in the form of cash primarily to support the Guangzhou manufacturing facility build-out and research and development programs.</span></div></ix:continuation><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government assistance received to support the Guangzhou manufacturing facility build-out is recognized as other long-term liabilities and amortized over the same useful lives of the related assets as depreciation expense. As of December&#160;31, 2024 and 2023, <span style="-sec-ix-hidden:f-486"><span style="-sec-ix-hidden:f-487">other long-term liabilities</span></span> related to the Guangzhou manufacturing facility build-out totaled $<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:GovernmentAssistanceLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-488">30,235</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:GovernmentAssistanceLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-489">34,084</ix:nonFraction>, respectively. For the years ended December&#160;31, 2024, 2023 and 2022, <span style="-sec-ix-hidden:f-490"><span style="-sec-ix-hidden:f-491"><span style="-sec-ix-hidden:f-492">depreciation expense</span></span></span> is presented net of amortization of government assistance of $<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:GovernmentAssistanceAmount" format="ixt:num-dot-decimal" scale="3" id="f-493">3,053</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:GovernmentAssistanceAmount" format="ixt:num-dot-decimal" scale="3" id="f-494">2,938</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:GovernmentAssistanceAmount" format="ixt:num-dot-decimal" scale="3" id="f-495">3,169</ix:nonFraction>, respectively.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government assistance received to support research and development programs is recorded as other long-term liabilities upon receipt and recognized as other income when the associated research and development programs are completed. As of December&#160;31, 2024 and 2023, other long-term liabilities related to research and development programs totaled $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:GovernmentAssistanceLiabilityNoncurrent" scale="3" id="f-496">89</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:GovernmentAssistanceLiabilityNoncurrent" scale="3" id="f-497">120</ix:nonFraction>, respectively. For the years ended December&#160;31, 2022, the Company recognized other income of $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:GovernmentAssistanceAmount" format="ixt:num-dot-decimal" scale="3" id="f-498">1,664</ix:nonFraction> upon the completion of a designated research and development program. <ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:GovernmentAssistanceAmount" format="ixt:fixed-zero" scale="0" id="f-499"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:GovernmentAssistanceAmount" format="ixt:fixed-zero" scale="0" id="f-500">No</ix:nonFraction></ix:nonFraction> income was recognized during the years ended December&#160;31, 2024 and 2023 related to grants received for research and development programs.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-501" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as the changes in equity of the Company during a period from transactions and other events and circumstances excluding transactions resulting from investments by owners and distributions to owners. Among other disclosures, ASC 220, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, requires that all items that are required to be recognized under current accounting standards as components of comprehensive loss be reported in a financial statement that is displayed with the same prominence as other financial statements. For each of the periods presented, the Company&#8217;s comprehensive loss includes net loss, foreign currency translation adjustments, pension liability adjustments and unrealized holding gains/losses associated with the available-for-sale debt securities, and is presented in the consolidated statements of comprehensive loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-502" continuedAt="f-502-1" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Awards granted to employees</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies ASC 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 718&#8221;), to account for its employee share-based payments. In accordance with ASC 718, the Company determines whether an award should be classified and accounted for as a liability award or equity award. All the Company&#8217;s grants of share-based awards to employees were classified as equity awards and are recognized in the financial statements based on their grant date fair values. Specifically, the grant date fair value of share options is calculated using an option pricing model. The fair value of restricted shares and restricted share units are based on the closing market price of our ADSs on the Nasdaq Global Select Market on the date of grant. The Company has elected to recognize compensation expense using the straight-line method for all employee equity awards granted with graded vesting based on service conditions provided that the amount of compensation cost recognized at any date is at least equal to the portion of the grant-date value of the options that are vested at that date. The Company uses the accelerated method for all awards granted with graded vesting based on performance conditions. To the extent the required vesting conditions are not met resulting in the forfeiture of the share-based awards, previously recognized compensation expense relating to those awards are reversed. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in the subsequent period if actual forfeitures differ from initial estimates. Forfeiture rates are estimated based on historical and future expectations of employee turnover rates and are adjusted to reflect future changes in circumstances and facts, if any. Share-based compensation expense is recorded net of estimated forfeitures such that expense is recorded only for those share-based awards that are expected to vest. To the extent the Company revises these estimates in the future, the share-based payments could be materially impacted in the period of revision, as well as in following periods. The Company, with the assistance of an independent third-party valuation firm, determined the estimated fair value of the stock options granted to employees using the binomial option pricing model.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">148</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><ix:continuation id="f-403-11" continuedAt="f-403-12"><ix:continuation id="f-502-1"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Awards granted to non-employees</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounted for equity instruments issued to non-employees in accordance with the provisions of ASC 718 and ASC 505, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All transactions in which goods or services are received in exchange for equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The grant date is the measurement date of the fair value of the equity instrument issued. The expense is recognized in the same manner as if the Company had paid cash for the services provided by the non-employees in accordance with ASC 505-50, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity-based payments to non-employees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company estimated the fair value of share options granted to non-employees using the same method as employees.&#160;</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Modification of awards</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in any of the terms or conditions of the awards is accounted for as a modification of the award. Incremental compensation cost is measured as the excess, if any, of the fair value of the modified award over the fair value of the original award immediately before its terms are modified, measured based on the fair value of the awards and other pertinent factors at the modification date. For vested awards, the Company recognizes incremental compensation cost in the period the modification occurs. For unvested awards, the Company recognizes over the remaining requisite service period, the sum of the incremental compensation cost and the remaining unrecognized compensation cost for the original award on the modification date. If the fair value of the modified award is lower than the fair value of the original award immediately before modification, the minimum compensation cost the Company recognizes is the cost of the original award.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-503" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using enacted tax rates that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its uncertain tax positions using the provisions of ASC 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Company recognizes in the financial statements the benefit of a tax position which is &#8220;more likely than not&#8221; to be sustained under examination based solely on the technical merits of the position assuming a review by tax authorities having all relevant information. Tax positions that meet the recognition threshold are measured using a cumulative probability approach, at the largest amount of tax benefit that has a greater than fifty percent likelihood of being realized upon settlement. It is the Company&#8217;s policy to recognize interest and penalties related to unrecognized tax benefits, if any, as a component of income tax expense.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-504" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Per Share</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share is calculated in accordance with ASC 260, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Basic loss per ordinary share is computed by dividing net loss attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period using the two-class method. Under the two-class method, net income is allocated between ordinary shares and participating securities based on dividends declared (or accumulated) and participating rights in undistributed earnings as if all the earnings for the reporting period had been distributed.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted loss per share, when required, is calculated by dividing net loss attributable to ordinary shareholders as adjusted for the effect of dilutive ordinary equivalent shares, if any, by the weighted average number of ordinary and dilutive ordinary equivalent shares outstanding during the period. Ordinary equivalent shares consist of the ordinary shares issuable upon the conversion of the Company&#8217;s convertible preferred shares, if any, using the if-converted method, and ordinary shares issuable upon the conversion of the share options, and unvested restricted shares units and performance-based restricted shares units (&#8220;PSUs&#8221;), using the treasury stock method. The dilutive effects of PSUs are included in the weighted average common share calculation based on the cumulative achievement against the performance targets only when the performance targets have been achieved as of the end of the reporting period.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ordinary share equivalents are excluded from the computation of diluted loss per share if their effects would be anti-dilutive. Basic and diluted loss per ordinary share is presented in the Company&#8217;s consolidated statements of operations.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">149</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><ix:continuation id="f-403-12" continuedAt="f-403-13"><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-505" continuedAt="f-505-1" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><ix:continuation id="f-505-1" continuedAt="f-505-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 280, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-505-2">, the Company&#8217;s chief operating decision maker, the Chief Executive Officer, reviews the consolidated results when making decisions about allocating resources and assessing performance of the Company as a whole and hence, the Company has only <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-506">one</ix:nonFraction> reportable segment: pharmaceutical products.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-507" continuedAt="f-507-1" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of cash and credit risk</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that are potentially subject to credit risk consist of cash and cash equivalents and accounts receivable.</span></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-508">2,627,410</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-509">3,171,800</ix:nonFraction> were deposited with various major reputable financial institutions located in the U.S., PRC and other international financial institutions. <ix:continuation id="f-507-1" continuedAt="f-507-2">The deposits placed with financial institutions are not protected by statutory or commercial insurance. In the event of bankruptcy of one of these financial institutions, the Company may be unable to claim its deposits back in full. Management believes that these financial institutions are of high credit quality and continually monitors the credit worthiness of these financial institutions.</ix:continuation></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, the Company had accounts receivable, net of $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-510">676,278</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-511">358,027</ix:nonFraction>, respectively. Accounts receivable, net represent amounts arising from product sales. <ix:continuation id="f-507-2">The Company monitors economic conditions to identify facts or circumstances that may indicate receivables are at risk of collection.</ix:continuation></span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer concentration risk</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024, sales to the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s three largest product distributors, ASD Specialty Healthcare, McKesson and Shanghai Pharmaceutical represented approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-100" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-512">18.0</ix:nonFraction>%,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-101" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-513">16.9</ix:nonFraction>%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-102" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-514">11.1</ix:nonFraction>% </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of product revenue, respectively, and collectively, represented approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-103" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-515">51.0</ix:nonFraction>%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of trade accounts receivable as of December&#160;31, 2024.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023, sales to the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s four largest product distributors, Sinopharm, Shanghai Pharmaceutical, ASD Specialty Healthcare and China Resources represented approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-104" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-516">16.0</ix:nonFraction>%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-105" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-517">14.2</ix:nonFraction>%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-106" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-518">12.4</ix:nonFraction>%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-107" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-519">11.4</ix:nonFraction>%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of product revenue, respectively, and collectively, represented approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-108" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-520">53.2</ix:nonFraction>%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of trade accounts receivable as of December&#160;31, 2023. For the year ended December&#160;31, 2023, the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s collaboration revenue consisted entirely of revenue recognized under its out-licensing collaboration agreements with Novartis. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-521" continuedAt="f-521-1" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">New accounting standards which have been adopted</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 280): Improvements to Reportable Segment Disclosures. This update requires disclosure of incremental segment information on an annual and interim basis. This update is effective for annual periods beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024. Early adoption is permitted. This guidance should be applied retrospectively to all prior periods presented in the financial statements. The Company operates in one segment. Its chief operating decision maker is the Chief Executive Officer, who makes operating decisions, assesses performance, and allocates resources on a consolidated basis. The Company adopted ASU 2023-07 effective December 31, 2024. Refer to Footnote 21 for segment related disclosures.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><ix:continuation id="f-521-1"><ix:continuation id="f-403-13"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">New accounting standards which have not yet been adopted</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Subtopic 220-40): Disaggregation of Income Statement Expenses. This update requires that at each interim and annual reporting period public entities disclose (1) the amounts of purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions; (2) certain amounts that are already required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirements; (3) a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively; and (4) the total amount of selling expenses and, in annual reporting periods, the definition of selling expenses. In January 2025, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Subtopic 220-40): Clarifying the Effective Date. This update clarifies that ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact on its financial statements of adopting this guidance.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 740): Improvements to Income Tax Disclosures. This update requires that public entities on an annual basis, (1) in the rate reconciliation, disclose specific categories and provide additional information for reconciling items that meet a quantitative threshold; (2) about income taxes paid, disclose the amount of income taxes paid (net of refunds received) disaggregated by federal, state, and foreign taxes and by individual jurisdiction in which income taxes paid (net of refunds received) is equal to or greater than 5 percent of total income taxes paid (net of refunds received); and (3) disclose income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign and income tax expense (or benefit) disaggregated by federal, state, and foreign. This update is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. This guidance should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating the impact on its financial statements of adopting this guidance.</span></div></ix:continuation></ix:continuation><div id="ic94bd2152a214042a118e81881a5a1e5_205"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-522" continuedAt="f-522-1" escape="true">Collaborative and Licensing Arrangements</ix:nonNumeric></span></div><ix:continuation id="f-522-1" continuedAt="f-522-2"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative arrangements for the research and development, manufacture and/or commercialization of drug products and drug candidates. To date, these collaborative arrangements have included out-licenses of and options to out-license internally developed products and drug candidates to other parties, in-licenses of products and drug candidates from other parties, and profit- and cost-sharing arrangements. These arrangements may include non-refundable upfront payments, contingent obligations for potential development, regulatory and commercial performance milestone payments, cost-sharing and reimbursement arrangements, royalty payments, and profit sharing. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Out-Licensing Arrangements</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three years ended December&#160;31, 2024, the Company&#8217;s collaboration revenue related to its out-licensing collaborative agreements has consisted of research and development services revenue and right to access intellectual property revenue from its former collaboration agreements with Novartis for tislelizumab and ociperlimab. Other collaboration revenue consists primarily of revenue under the Novartis broad markets agreement and, beginning in 2024, royalty revenue under the Amgen collaboration agreement. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">151</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><ix:continuation id="f-522-2" continuedAt="f-522-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-523" continuedAt="f-523-1" escape="true"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total collaboration revenue recognized for the years ended December&#160;31, 2024, 2023 and 2022:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.429%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue from Collaborators</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development service revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-524">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-525">79,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-526">46,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right to access intellectual property revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-527">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-528">104,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-529">104,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Material rights revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-530">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-531">71,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-532">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-533">30,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-534">13,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-535">9,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-536">30,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-537">268,927</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-538">161,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Novartis</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tislelizumab Collaboration and License </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into a collaboration and license agreement with Novartis, granting Novartis rights to develop, manufacture and commercialize tislelizumab in North America, Europe, and Japan (the &#8220;Novartis Territory&#8221;). The Company and Novartis agreed to jointly develop tislelizumab in these licensed countries, with Novartis responsible for regulatory submissions after a transition period and for commercialization upon regulatory approvals. In addition, both companies had the ability to conduct clinical trials globally to explore combinations of tislelizumab with other cancer treatments, and the Company has an option to co-detail the product in North America, funded in part by Novartis.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement the Company received an upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-539">650,000</ix:nonFraction> from Novartis. A portion of the transaction price was allocated to the R&amp;D services to be performed under the agreement and deferred and was being recognized as collaboration revenue as the R&amp;D services were performed using a percentage-of-completion method. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, the Company and Novartis agreed to mutually terminate the collaboration and license agreement, effective immediately. Pursuant to the termination agreement, the Company regained full, global rights to develop, manufacture and commercialize tislelizumab with no royalty payments due to Novartis. Novartis may continue its ongoing clinical trials and has the ability to conduct future combination trials with tislelizumab subject to BeiGene&#8217;s approval. BeiGene agreed to provide Novartis with ongoing clinical supply of tislelizumab to support its clinical trials. Pursuant to the termination agreement, Novartis agreed to provide transition services to the Company to enable key aspects of the tislelizumab development and commercialization plan to proceed without disruption, including manufacturing, regulatory, safety and clinical support. Upon termination of the agreement in September 2023, there were no further performance obligations, and the remaining deferred revenue balance associated with the tislelizumab R&amp;D services was recognized in full.</span></div><ix:continuation id="f-523-1" continuedAt="f-523-2"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes collaboration revenue recognized in connection with the tislelizumab collaboration and license agreement for the years ended December&#160;31, 2024, 2023 and 2022:</span></div><div style="margin-bottom:3pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.429%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development service revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-540">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-541">72,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-542">39,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-543">2,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-544">5,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-545">9,493</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-546">2,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-547">77,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-548">49,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Represents revenue recognized on sale of tislelizumab clinical supply to Novartis in conjunction with the collaboration.</span></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">152</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><ix:continuation id="f-522-3" continuedAt="f-522-4"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ociperlimab Option, Collaboration and License Agreement and China Broad Market Development Agreement</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company expanded its collaboration with Novartis by entering into an option, collaboration and license agreement with Novartis to develop, manufacture and commercialize the Company&#8217;s investigational TIGIT inhibitor ociperlimab in the Novartis Territory. In addition, the Company and Novartis entered into an agreement granting the Company rights to market, promote and detail <ix:nonFraction unitRef="product" contextRef="c-134" decimals="INF" name="bgne:NumberOfProductsInitiatedMarketingAndPromotion" format="ixt-sec:numwordsen" scale="0" id="f-549">five</ix:nonFraction> approved Novartis oncology products, TAFINLAR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (dabrafenib), MEKINIST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (trametinib), VOTRIENT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pazopanib), AFINITOR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (everolimus), and ZYKADIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ceritinib), across designated regions of China referred to as &#8220;broad markets.&#8221; In the first quarter of 2022, the Company initiated marketing and promotion of these <ix:nonFraction unitRef="product" contextRef="c-134" decimals="INF" name="bgne:NumberOfProductsInitiatedMarketingAndPromotion" format="ixt-sec:numwordsen" scale="0" id="f-550">five</ix:nonFraction> products.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the option, collaboration and license agreement, the Company received an upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-551">300,000</ix:nonFraction>. At inception, a portion of the upfront cash payment was deferred related to performance obligations to be satisfied at a later point in time or over time. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, the Company and Novartis mutually agreed to terminate the ociperlimab option, collaboration and license agreement, effective immediately. Pursuant to the termination agreement, the Company regained full, global rights to develop, manufacture and commercialize ociperlimab. Upon termination the Company had no further performance obligations under the collaboration, and all remaining deferred revenue balances were recognized in full. The China broad markets agreement remains in place.</span></div><ix:continuation id="f-523-2" continuedAt="f-523-3"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes collaboration revenue recognized in connection with the ociperlimab option, collaboration and license agreement for the years ended December&#160;31, 2024, 2023 and 2022:</span></div><div style="margin-bottom:3pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.429%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development service revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-552">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-553">7,153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-554">7,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right to access intellectual property revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-555">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-556">104,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-557">104,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Material rights revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-558">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-559">71,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-560">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-561">18,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-562">8,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-563">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-564">18,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-565">192,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-566">112,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Represents revenue generated under the broad markets marketing and promotion agreement in conjunction with the collaboration.</span></div></ix:continuation><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In-Licensing Arrangements - Commercial</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the Company entered into a global strategic oncology collaboration with Amgen (&#8220;Amgen Collaboration Agreement&#8221;) for the commercialization and development in China, excluding Hong Kong, Taiwan and Macau, of Amgen&#8217;s XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and BLINCYTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and the joint global development of a portfolio of oncology assets in Amgen&#8217;s pipeline, with BeiGene responsible for development and commercialization in China. The agreement became effective on January 2, 2020, following approval by the Company&#8217;s shareholders and satisfaction of other closing conditions.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, the Company is responsible for the commercialization of XGEVA, KYPROLIS and BLINCYTO in China for <span style="-sec-ix-hidden:f-567">five</span> or <ix:nonNumeric contextRef="c-152" name="bgne:CommercializationTerm" format="ixt-sec:durwordsen" id="f-568">seven years</ix:nonNumeric>. Amgen is responsible for manufacturing the products globally and supplying the products to the Company at an agreed upon price. The Company and Amgen share equally in the China commercial profits and losses during the commercialization period. Following the commercialization period, the Company has the right to retain <ix:nonFraction unitRef="product" contextRef="c-153" decimals="INF" name="bgne:CollaborativeArrangementsNumberOfProductsCompanyHasTheRightToRetain" format="ixt-sec:numwordsen" scale="0" id="f-569">one</ix:nonFraction> product and is entitled to receive royalties on sales in China for an additional <ix:nonNumeric contextRef="c-154" name="bgne:CollaborativeArrangementsProductRetentionPeriod" format="ixt-sec:durwordsen" id="f-570">five years</ix:nonNumeric> on the products not retained. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">153</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><ix:continuation id="f-522-4" continuedAt="f-522-5"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen and the Company are also jointly developing a portfolio of Amgen oncology pipeline assets under the collaboration. The Company is responsible for conducting clinical development activities in China and co-funding global development costs by contributing cash and development services up to a total cap of $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="bgne:MaximumCashAndServicesDevelopmentCommitment" format="ixt:num-dot-decimal" scale="3" id="f-571">1,250,000</ix:nonFraction>. Amgen is responsible for all development, regulatory and commercial activities outside of China. For each pipeline asset that is approved in China, the Company will receive commercial rights for <ix:nonNumeric contextRef="c-152" name="bgne:CommercializationTerm" format="ixt-sec:durwordsen" id="f-572">seven years</ix:nonNumeric> from approval. The Company has the right to retain approximately one out of every three approved pipeline assets, other than LUMAKRAS (sotorasib) (&#8220;AMG 510&#8221;), Amgen&#8217;s KRAS G12C inhibitor, for commercialization in China. The Company and Amgen will share equally in the China commercial profits and losses during the commercialization period. The Company is entitled to receive royalties from sales in China for pipeline assets returned to Amgen for <ix:nonNumeric contextRef="c-152" name="bgne:RoyaltiesReceivingPeriod" format="ixt-sec:durwordsen" id="f-573">five years</ix:nonNumeric> after the <ix:nonNumeric contextRef="c-152" name="bgne:CommercializationTerm" format="ixt-sec:durwordsen" id="f-574">seven-year</ix:nonNumeric> commercialization period. The Company is also entitled to receive royalties from global sales of each product outside of China (with the exception of AMG 510).</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2022, the parties entered into the First Amendment to Amgen Collaboration Agreement, which amends certain terms and conditions relating to the financial responsibilities of the parties in connections with the development and commercialization of certain Amgen proprietary products for the treatment of oncology-related diseases and conditions. In connection with the Company&#8217;s ongoing assessment of the Amgen Collaboration Agreement cost-share contributions, the Company determined that further investment in the development of LUMAKRAS was no longer commercially viable for BeiGene. As a result, in February 2023, the Company and Amgen entered into the Second Amendment to the Amgen Collaboration Agreement to (i) stop sharing costs with Amgen for the further development of LUMAKRAS during the period starting January 1, 2023 and ending August 31, 2023; and (ii) cooperate in good faith to prepare a transition plan with the termination of LUMAKRAS from the Amgen Collaboration Agreement.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amgen Collaboration Agreement is within the scope of ASC 808, as both parties are active participants and are exposed to the risks and rewards dependent on the commercial success of the activities performed under the agreement. The Company is the principal for product sales to customers in China during the commercialization period and will recognize <ix:nonFraction unitRef="number" contextRef="c-155" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-575">100</ix:nonFraction>% of net product revenue on these sales. Amounts due to Amgen for its portion of net product sales will be recorded as cost of sales. Cost reimbursements due to or from Amgen under the profit share will be recognized as incurred and recorded to cost of sales; selling, general and administrative expense; or research and development expense, based on the underlying nature of the related activity subject to reimbursement. Costs incurred for the Company&#8217;s portion of the global co-development funding are recorded to research and development expense as incurred.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Amgen Collaboration Agreement, a Share Purchase Agreement (&#8220;SPA&#8221;) was entered into by the parties on October 31, 2019. On January 2, 2020, the closing date of the transaction, Amgen purchased <ix:nonFraction unitRef="shares" contextRef="c-156" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-576">15,895,001</ix:nonFraction> of the Company&#8217;s ADSs for $<ix:nonFraction unitRef="usdPerShare" contextRef="c-157" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-577">174.85</ix:nonFraction> per ADS, representing a <ix:nonFraction unitRef="number" contextRef="c-158" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="f-578">20.5</ix:nonFraction>% ownership stake in the Company. Per the SPA, the cash proceeds shall be used as necessary to fund the Company&#8217;s development obligations under the Amgen Collaboration Agreement. Pursuant to the SPA, Amgen also received the right to designate one member of the Company&#8217;s board of directors, and Anthony Hooper joined the Company&#8217;s board of directors as the Amgen designee in January 2020. Amgen relinquished its right to appoint a designated director to the Company&#8217;s board of directors in January 2023.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the fair value of the common stock at closing, the Company considered the closing price of the common stock on the closing date of the transaction and included a lack of marketability discount because the shares are subject to certain restrictions. The fair value of the shares on the closing date was determined to be $<ix:nonFraction unitRef="usdPerShare" contextRef="c-159" decimals="INF" name="bgne:SharePriceAmericanDepositoryShares" scale="0" id="f-579">132.74</ix:nonFraction> per ADS, or $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="bgne:ProceedsFromIssuanceOfAssetDepositoryShares" format="ixt:num-dot-decimal" scale="3" id="f-580">2,109,902</ix:nonFraction> in the aggregate. The Company determined that the premium paid by Amgen on the share purchase represents a cost share liability due to the Company&#8217;s co-development obligations. The fair value of the cost share liability on the closing date was determined to be $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="bgne:FairValueOfLiabilityAcquired" format="ixt:num-dot-decimal" scale="3" id="f-581">601,857</ix:nonFraction> based on the Company&#8217;s discounted estimated future cash flows related to the pipeline assets. The estimation of future cash flows involved management assumptions of revenue growth rates and probability of technical and regulatory success of the pipeline assets. The total cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-582">2,779,241</ix:nonFraction> were allocated based on the relative fair value method, with $<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="bgne:FairValueOfEquityInvestmentsIssued" format="ixt:num-dot-decimal" scale="3" id="f-583">2,162,407</ix:nonFraction> recorded to equity and $<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="bgne:FairValueOfFinancingCommitment" format="ixt:num-dot-decimal" scale="3" id="f-584">616,834</ix:nonFraction> recorded as a research and development cost share liability. The cost share liability is being amortized proportionately as the Company contributes cash and development services to its total co-development funding cap.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">154</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><ix:continuation id="f-522-5" continuedAt="f-522-6"><ix:nonNumeric contextRef="c-1" name="bgne:CollaborationAgreementsTableTextBlock" id="f-585" escape="true"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recorded related to the Company&#8217;s portion of the co-development funding on the pipeline assets for the years ended December&#160;31, 2024, 2023 and 2022 were as follows:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.309%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.377%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene&#8217;s portion of the development funding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="bgne:FinancingCommitmentExpenses" format="ixt:num-dot-decimal" scale="3" id="f-586">148,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="bgne:FinancingCommitmentExpenses" format="ixt:num-dot-decimal" scale="3" id="f-587">108,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="bgne:FinancingCommitmentExpenses" format="ixt:num-dot-decimal" scale="3" id="f-588">195,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amortization of research and development cost share liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="bgne:AmortizationOfFinancingCommitment" format="ixt:num-dot-decimal" scale="3" id="f-589">73,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="bgne:AmortizationOfFinancingCommitment" format="ixt:num-dot-decimal" scale="3" id="f-590">55,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="bgne:AmortizationOfFinancingCommitment" format="ixt:num-dot-decimal" scale="3" id="f-591">96,402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-592">75,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-593">53,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-594">98,955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining portion of development funding cap </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="us-gaap:OtherCommitment" format="ixt:num-dot-decimal" scale="3" id="f-595">335,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, the research and development cost share liability recorded in the Company&#8217;s balance sheet was as follows:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development cost share liability, current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="bgne:FinancingCommitmentCarryingValueCurrent" format="ixt:num-dot-decimal" scale="3" id="f-596">111,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="bgne:FinancingCommitmentCarryingValueCurrent" format="ixt:num-dot-decimal" scale="3" id="f-597">68,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development cost share liability, non-current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="bgne:FinancingCommitmentCarryingValueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-598">54,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="bgne:FinancingCommitmentCarryingValueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-599">170,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development cost share liability</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="bgne:FinancingCommitmentCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-600">165,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="bgne:FinancingCommitmentCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-601">238,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="bgne:ScheduleOfAmountsAndClassificationOfReimbursementExpenseTableTextBlock" id="f-602" escape="true"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net reimbursement paid under the commercial profit-sharing agreement for in-line product sales is classified in the consolidated statements of operations for the three years ended December&#160;31, 2024 as follows:</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:54.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.437%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.437%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.440%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales - product</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" sign="-" name="bgne:ReimbursementExpense" format="ixt:num-dot-decimal" scale="3" id="f-603">37,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" sign="-" name="bgne:ReimbursementExpense" format="ixt:num-dot-decimal" scale="3" id="f-604">8,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" sign="-" name="bgne:ReimbursementExpense" format="ixt:num-dot-decimal" scale="3" id="f-605">5,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="bgne:ReimbursementExpense" format="ixt:num-dot-decimal" scale="3" id="f-606">83,674</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="bgne:ReimbursementExpense" format="ixt:num-dot-decimal" scale="3" id="f-607">60,917</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="bgne:ReimbursementExpense" format="ixt:num-dot-decimal" scale="3" id="f-608">54,865</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-3" name="bgne:ReimbursementExpense" format="ixt:num-dot-decimal" scale="3" id="f-609">2,438</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" sign="-" name="bgne:ReimbursementExpense" format="ixt:num-dot-decimal" scale="3" id="f-610">1,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-3" name="bgne:ReimbursementExpense" format="ixt:num-dot-decimal" scale="3" id="f-611">1,216</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="bgne:ReimbursementExpense" format="ixt:num-dot-decimal" scale="3" id="f-612">48,962</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="bgne:ReimbursementExpense" format="ixt:num-dot-decimal" scale="3" id="f-613">50,871</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="bgne:ReimbursementExpense" format="ixt:num-dot-decimal" scale="3" id="f-614">50,183</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company purchases commercial inventory from Amgen to distribute in China. Total inventory purchases amounted to $<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" format="ixt:num-dot-decimal" scale="3" id="f-615">247,655</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-3" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" format="ixt:num-dot-decimal" scale="3" id="f-616">108,691</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" format="ixt:num-dot-decimal" scale="3" id="f-617">71,720</ix:nonFraction>, respectively, during the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024, 2023 and 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Net amounts payable to Amgen as of December&#160;31, 2024 and 2023 were $<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-618">116,563</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-619">55,474</ix:nonFraction>, respectively.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In-Licensing Arrangements - Development </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has in-licensed the rights to develop, manufacture and, if approved, commercialize multiple development stage drug candidates globally or in specific territories. These arrangements typically include non-refundable upfront payments, contingent obligations for potential development, regulatory and commercial performance milestone payments, cost-sharing arrangements, royalty payments, and profit sharing. </span></div><ix:nonNumeric contextRef="c-1" name="bgne:PaymentsDueToCollaborationPartnersTableTextBlock" id="f-620" continuedAt="f-620-1" escape="true"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront and milestone payments made under these arrangements for the years ended December&#160;31, 2024, 2023 and 2022 are set forth below. All upfront and development milestones were expensed to research and development expense. All regulatory and commercial milestones were capitalized as intangible assets and are being amortized over the remainder of the respective product patent or the term of the commercialization agreements.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">155</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><ix:continuation id="f-522-6"><ix:continuation id="f-620-1"><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:26.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.576%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments due to collaboration partners</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront payments</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-3" name="bgne:UpfrontAndMilestonePayments" format="ixt:num-dot-decimal" scale="3" id="f-621">60,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-3" name="bgne:UpfrontAndMilestonePayments" format="ixt:num-dot-decimal" scale="3" id="f-622">46,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-3" name="bgne:UpfrontAndMilestonePayments" format="ixt:num-dot-decimal" scale="3" id="f-623">68,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development milestone payments</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-3" name="bgne:UpfrontAndMilestonePayments" format="ixt:num-dot-decimal" scale="3" id="f-624">54,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-3" name="bgne:UpfrontAndMilestonePayments" format="ixt:fixed-zero" scale="3" id="f-625">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-3" name="bgne:UpfrontAndMilestonePayments" format="ixt:num-dot-decimal" scale="3" id="f-626">5,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regulatory and commercial milestone payments</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="bgne:UpfrontAndMilestonePayments" format="ixt:fixed-zero" scale="3" id="f-627">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="bgne:UpfrontAndMilestonePayments" format="ixt:num-dot-decimal" scale="3" id="f-628">24,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="bgne:UpfrontAndMilestonePayments" format="ixt:fixed-zero" scale="3" id="f-629">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="bgne:UpfrontAndMilestonePayments" format="ixt:num-dot-decimal" scale="3" id="f-630">114,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="bgne:UpfrontAndMilestonePayments" format="ixt:num-dot-decimal" scale="3" id="f-631">71,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="bgne:UpfrontAndMilestonePayments" format="ixt:num-dot-decimal" scale="3" id="f-632">74,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into a number of in-licensing collaborative arrangements during the years ended December&#160;31, 2024, 2023 and 2022. A summary of amounts incurred under these arrangements is included above. The Company may be required to pay additional amounts upon the achievement of various development and commercial milestones under these agreements. The Company may also incur significant research and development costs if the related product candidate were to advance to late-stage clinical trials. In addition, if any products related to these collaborations are approved for sale, the Company may be required to pay significant milestones upon approval and milestones and/or royalties on future sales. The payment of these amounts, however, is contingent upon the occurrence of various future events, which have a high degree of uncertainty of occurrence.</span></div></ix:continuation><div id="ic94bd2152a214042a118e81881a5a1e5_208"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" id="f-633" continuedAt="f-633-1" escape="true">Restricted Cash</ix:nonNumeric></span></div><ix:continuation id="f-633-1"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s restricted cash primarily consist of&#160;RMB-denominated cash deposits held in designated bank accounts for collateral for letters of credit. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="f-634" continuedAt="f-634-1" escape="true">The Company classifies restricted cash as current or non-current based on term of restriction. Restricted cash as of December&#160;31, 2024 and 2023 was as follows:</ix:nonNumeric></span></div><ix:continuation id="f-634-1"><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.499%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="f-635">9,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="f-636">11,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-637">2,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-638">2,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="f-639">11,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="f-640">14,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the restricted cash balances above, the Company is required by the PRC securities law to use the proceeds from the STAR Offering in strict compliance with the planned uses as disclosed in the PRC offering prospectus as well as those disclosed in the Company&#8217;s proceeds management policy approved by the board of directors. As of December&#160;31, 2024, the Company had cash remaining related to the STAR Offering proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="f-641">588,235</ix:nonFraction>.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">156</span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_211"></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="f-642" continuedAt="f-642-1" escape="true">Investments</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EquityMethodInvestmentsTextBlock" id="f-643" escape="true"><ix:continuation id="f-642-1"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s investments in equity securities:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.100%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.228%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Leap common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-644">2,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-645">3,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Leap warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="f-646">168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="f-647">542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities without readily determinable fair values</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pi Health, Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="3" id="f-648">40,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:fixed-zero" scale="3" id="f-649">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="3" id="f-650">48,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="3" id="f-651">55,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-method investments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-652">33,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-653">25,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" format="ixt:num-dot-decimal" scale="3" id="f-654">124,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" format="ixt:num-dot-decimal" scale="3" id="f-655">85,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Represents common stock and warrants to purchase additional shares of common stock of Leap. The Company measures the investment in the common stock and warrants at fair value, with changes in fair value recorded to other (expense) income, net.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the first quarter of 2024, the Company divested the net assets comprising substantially all of its Pi Health business with a carrying value of $<ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-3" name="bgne:DisposalGroupNotDiscontinuedOperationNetAssets" format="ixt:num-dot-decimal" scale="3" id="f-656">38,063</ix:nonFraction>. The consideration received for the divestiture consisted of preferred stock in a newly formed entity, Pi Health, Inc., with a fair value of $<ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" format="ixt:num-dot-decimal" scale="3" id="f-657">40,798</ix:nonFraction> and cash consideration of $<ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-3" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="3" id="f-658">1,000</ix:nonFraction>. The transaction resulted in a pre-tax gain of $<ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" format="ixt:num-dot-decimal" scale="3" id="f-659">3,735</ix:nonFraction> recorded within <span style="-sec-ix-hidden:f-660">other (expense) income, net</span> during year ended December&#160;31, 2024. The Company will account for its investment prospectively as a private equity security without a readily determinable fair value and the divestiture is not treated as a discontinued operation in the Statement of Operations and therefore the historical results of operations of the Pi Health business will remain in the Company&#8217;s continuing operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes unrealized (losses) gains related to investments in equity securities recorded in other (expense) income, net:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-661">1,307</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="3" id="f-662">425</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-663">30,102</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities without readily determinable fair values</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="bgne:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmountNet" format="ixt:num-dot-decimal" scale="3" id="f-664">7,596</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="bgne:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmountNet" format="ixt:num-dot-decimal" scale="3" id="f-665">6,448</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" sign="-" name="bgne:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmountNet" format="ixt:num-dot-decimal" scale="3" id="f-666">5,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-method investments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-667">10,275</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-668">7,856</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-669">3,682</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="ic94bd2152a214042a118e81881a5a1e5_214"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryDisclosureTextBlock" id="f-670" continuedAt="f-670-1" escape="true">Inventories, Net</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-671" escape="true"><ix:continuation id="f-670-1"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s inventories, net consisted of the following:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.499%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-672">170,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-673">148,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-674">60,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-675">39,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-676">264,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-677">228,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-678">494,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-679">416,122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">157</span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_217"></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-680" continuedAt="f-680-1" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="f-680-1" continuedAt="f-680-2"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for office and manufacturing facilities in the U.S., Switzerland, and China. The leases have remaining lease terms of up to <ix:nonNumeric contextRef="c-44" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="f-681">six years</ix:nonNumeric>, some of which include options to extend the leases that have not been included in the calculation of the Company&#8217;s lease liabilities and ROU assets. The Company has land use rights, which represent land acquired for the biologics manufacturing facility in Guangzhou, the land acquired for the Company&#8217;s research, development and office facility in Changping, Beijing, the land acquired for the Company&#8217;s research, development and manufacturing facility in Suzhou, and the land acquired for the Company&#8217;s research and development facility in Shanghai. The Company also has certain leases with terms of 12 months or less for certain equipment, office and lab space, which are expensed and not recorded on the balance sheet.</span></div><ix:continuation id="f-427-2" continuedAt="f-427-3"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.377%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-682">26,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-683">25,978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-684">25,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-685">4,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-686">6,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-687">6,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShortTermLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-688">2,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ShortTermLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-689">1,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ShortTermLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-690">1,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost </span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-691">34,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-692">33,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-693">34,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="bgne:AssetsAndLiabilitiesLesseeTableTextBlock" id="f-694" escape="true"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-695">60,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-696">43,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land use rights, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-697">78,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-698">51,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-699">139,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-700">95,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-701">17,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-702">21,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-703">44,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-704">22,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-705">61,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-706">44,201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-707" escape="true"><div style="margin-bottom:4pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities are as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.375%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December&#160;31,&#160;2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-708">19,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December&#160;31,&#160;2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-709">13,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December&#160;31,&#160;2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-710">12,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31, 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-711">11,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31, 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="f-712">7,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-713">3,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-714">68,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-715">6,681</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-716">61,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">158</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><ix:continuation id="f-680-2"><ix:continuation id="f-427-3"><div style="margin-bottom:4pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other supplemental information related to leases is summarized below:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.163%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.377%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used in operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-717">56,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-718">27,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-719">28,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for new operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-720">47,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-721">11,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-722">22,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-12" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-723">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-13" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-724">3</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-725">5.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-726">7.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation></ix:continuation><div id="ic94bd2152a214042a118e81881a5a1e5_220"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-727" continuedAt="f-727-1" escape="true">Property, Plant and Equipment, Net</ix:nonNumeric></span></div><ix:continuation id="f-727-1" continuedAt="f-727-2"><ix:continuation id="f-417-2" continuedAt="f-417-3"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net are recorded at cost less accumulated depreciation and consisted of the following:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-728">65,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-729">65,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-730">607,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-731">231,656</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-732">244,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-733">186,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-734">240,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-735">205,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software, electronics and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-736">100,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-737">83,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-738">64,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-739">60,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, at cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-740">1,323,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-741">832,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-742">399,105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-743">249,212</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="f-744">654,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="f-745">740,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-746">1,578,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-747">1,324,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has made a significant investment in its newly opened manufacturing and R&amp;D center in Hopewell, New Jersey. In the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-215" decimals="3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-748">272,670</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of assets were placed into service. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company had construction in progress of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="f-749">500,900</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to the Hopewell facility, the majority of which will be put into service in 2025.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, the Company acquired a land use right and the facility currently being constructed on the land for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-750">73,054</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company plans to complete the construction of the facility and build a research and development center on the land. Based on the relative fair values of the land use right and construction in progress, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-751">29,431</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the total purchase price was allocated to the land use right and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-752">43,623</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was allocated to the construction in progress. In May 2024, the Company acquired additional construction in progress in connection with the properties for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-753">22,538</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">159</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><ix:continuation id="f-727-2"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress (&#8220;CIP&#8221;) a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s of December&#160;31, 2024 and 2023 primarily related to the Hopewell facility, the new research and development facility acquired in 2024, a new building for Beijing Innerway Bio-tech Co., Ltd., and additional capacity at the Guangzhou and Suzhou manufacturing facilities. <ix:continuation id="f-417-3" continuedAt="f-417-4">CIP by fixed asset class are summarized as follows:</ix:continuation></span></div><ix:continuation id="f-417-4"><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:69.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.397%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="f-754">528,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="f-755">579,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="f-756">89,897</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="f-757">119,380</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="f-758">9,805</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="f-759">16,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="f-760">25,687</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="f-761">25,451</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="f-762">654,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="f-763">740,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the years ended December&#160;31, 2024, 2023 and 2022 were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-764">166,938</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-765">80,436</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-766">62,302</ix:nonFraction>, respectively. Included within depreciation expense for the year ended December&#160;31, 2024 is $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RestructuringReserveAcceleratedDepreciation" format="ixt:num-dot-decimal" scale="3" id="f-767">59,792</ix:nonFraction> of accelerated depreciation expense resulting from the move of production to more efficient, larger scale equipment for tislelizumab.</span></div></ix:continuation><div id="ic94bd2152a214042a118e81881a5a1e5_223"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="f-768" continuedAt="f-768-1" escape="true">Intangible Assets</ix:nonNumeric></span></div><ix:continuation id="f-768-1" continuedAt="f-768-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="f-769" continuedAt="f-769-1" escape="true"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets as of December&#160;31, 2024 and 2023 are summarized as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.581%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intangible<br/>assets, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intangible<br/>assets, net</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-770">62,889</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-771">12,370</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-772">50,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-773">64,274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-774">7,807</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-775">56,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-776">8,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-777">8,411</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="f-778">576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-779">8,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-780">8,316</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="f-781">671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-782">71,876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-783">20,781</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-784">51,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-785">73,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-786">16,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-787">57,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:7pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developed products represent post-approval milestone payments under license and commercialization agreements. The Company is amortizing the developed products over the remainder of the respective product patent or the term of the commercialization agreements.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for developed products is included in cost of sales-product in the accompanying consolidated statements of operations. Amortization expense for other intangible assets is included in selling, general and administrative expense in the accompanying consolidated statements of operations. The weighted-average life for each finite-lived intangible assets is approximately <ix:nonNumeric contextRef="c-227" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-788"><ix:nonNumeric contextRef="c-228" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-789">11</ix:nonNumeric></ix:nonNumeric> years. <ix:continuation id="f-769-1" continuedAt="f-769-2">Amortization expense is as follows:</ix:continuation></span></div><ix:continuation id="f-769-2"><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.139%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.525%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense - Cost of sales - product</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-790">4,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-791">3,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-792">3,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense - Selling, general and administrative</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="f-793">95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-794">3,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="f-795">751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-796">4,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-797">7,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-798">3,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">160</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="f-799" escape="true"><ix:continuation id="f-768-2"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense for each of the five succeeding years and thereafter, as of December&#160;31, 2024 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.701%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost of Sales - Product</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Selling, General and Administrative Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-800">4,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" id="f-801">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-802">4,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-803">4,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" id="f-804">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-805">4,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="f-806">4,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" id="f-807">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="f-808">4,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="f-809">4,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="f-810">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="f-811">4,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="3" id="f-812">4,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="3" id="f-813">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="3" id="f-814">4,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-815">27,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" scale="3" id="f-816">241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-817">27,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-818">50,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="f-819">576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-820">51,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="ic94bd2152a214042a118e81881a5a1e5_226"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-821" continuedAt="f-821-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="f-821-1" continuedAt="f-821-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="f-822" escape="true"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">loss) before income taxes are as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.322%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.606%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-823">201,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-824">117,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-825">67,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PRC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-826">263,159</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-827">315,852</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-828">583,610</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-829">471,358</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-830">627,430</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-831">1,445,171</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-832">533,001</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-833">825,836</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-834">1,961,037</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-835" escape="true"><div style="margin-bottom:4pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current and deferred components of the income tax expense (benefit) from continuing operations are as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.322%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.606%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current tax expense (benefit)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-836">57,222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-837">25,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-838">4,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PRC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-839">12,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-840">24,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-841">27,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-842">16,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-843">5,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-844">6,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-845">85,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-846">55,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-847">39,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax expense (benefit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-848">23,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-849">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-850">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PRC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="f-851">180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="f-852">687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-853">3,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-854">2,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-855">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="f-856">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-857">26,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="f-858">687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-859">3,482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-860">111,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-861">55,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-862">42,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">161</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-863" escape="true"><ix:continuation id="f-821-2" continuedAt="f-821-3"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the statutory tax rate to our effective income tax rate is as follow:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.576%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-864">533,001</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-865">825,836</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-866">1,961,037</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. statutory tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-867">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-10" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-868">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-11" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-869">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected taxation at U.S. statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-870">111,930</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-871">173,426</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-872">411,818</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign and preferential tax rate differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:num-dot-decimal" scale="3" id="f-873">93,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:num-dot-decimal" scale="3" id="f-874">144,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:num-dot-decimal" scale="3" id="f-875">209,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" format="ixt:num-dot-decimal" scale="3" id="f-876">1,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" format="ixt:num-dot-decimal" scale="3" id="f-877">19,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" format="ixt:num-dot-decimal" scale="3" id="f-878">29,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-879">53,446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-880">32,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-881">33,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-882">7,988</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-883">5,872</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-884">1,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-885">157,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-886">845,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-887">229,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax relief credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCredits" format="ixt:fixed-zero" scale="3" id="f-888">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCredits" format="ixt:num-dot-decimal" scale="3" id="f-889">704,928</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCredits" format="ixt:fixed-zero" scale="3" id="f-890">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research tax credits and incentives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="f-891">43,602</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="f-892">64,343</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" format="ixt:num-dot-decimal" scale="3" id="f-893">42,844</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deductible research expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="bgne:EffectiveIncomeTaxRateReconciliationDeductionResearchExpensesAmount" format="ixt:num-dot-decimal" scale="3" id="f-894">13,644</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="bgne:EffectiveIncomeTaxRateReconciliationDeductionResearchExpensesAmount" format="ixt:fixed-zero" scale="3" id="f-895">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="bgne:EffectiveIncomeTaxRateReconciliationDeductionResearchExpensesAmount" format="ixt:fixed-zero" scale="3" id="f-896">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax on unremitted earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion" format="ixt:num-dot-decimal" scale="3" id="f-897">23,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion" format="ixt:fixed-zero" scale="3" id="f-898">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion" format="ixt:fixed-zero" scale="3" id="f-899">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EffectiveIncomeTaxRateReconciliationFdiiAmount" format="ixt:num-dot-decimal" scale="3" id="f-900">40,397</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:EffectiveIncomeTaxRateReconciliationFdiiAmount" format="ixt:num-dot-decimal" scale="3" id="f-901">37,395</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:EffectiveIncomeTaxRateReconciliationFdiiAmount" format="ixt:num-dot-decimal" scale="3" id="f-902">6,272</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxation for the year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-903">111,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-904">55,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-905">42,778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-906">21.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-10" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-907">6.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-11" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-908">2.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">162</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><ix:continuation id="f-821-3" continuedAt="f-821-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-909" escape="true"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of deferred tax assets (liabilities) are as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.420%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.576%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals and reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" format="ixt:num-dot-decimal" scale="3" id="f-910">121,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" format="ixt:num-dot-decimal" scale="3" id="f-911">106,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" format="ixt:num-dot-decimal" scale="3" id="f-912">97,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses carryforward</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="3" id="f-913">1,137,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="3" id="f-914">996,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="3" id="f-915">862,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-916">38,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-917">26,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-918">19,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-919">34,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-920">68,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-921">86,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax relief credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign" format="ixt:num-dot-decimal" scale="3" id="f-922">704,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign" format="ixt:num-dot-decimal" scale="3" id="f-923">704,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign" format="ixt:fixed-zero" scale="3" id="f-924">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-925">1,081,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-926">699,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-927">813,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="bgne:DeferredTaxAssetsPropertyLeaseLiabilityObligation" format="ixt:num-dot-decimal" scale="3" id="f-928">11,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="bgne:DeferredTaxAssetsPropertyLeaseLiabilityObligation" format="ixt:num-dot-decimal" scale="3" id="f-929">7,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="bgne:DeferredTaxAssetsPropertyLeaseLiabilityObligation" format="ixt:num-dot-decimal" scale="3" id="f-930">10,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D and other capitalized costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-931">277,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-932">164,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-933">63,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-934">3,407,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-935">2,775,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-936">1,952,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-937">3,403,505</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-938">2,771,470</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-939">1,943,775</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-940">4,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-941">3,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-942">8,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-943">10,795</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-944">12,374</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-945">14,480</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax on unremitted earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" format="ixt:num-dot-decimal" scale="3" id="f-946">23,735</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" format="ixt:fixed-zero" scale="3" id="f-947">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" format="ixt:fixed-zero" scale="3" id="f-948">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-949">11,682</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-950">7,735</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-951">10,098</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-952">46,212</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-953">20,109</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-954">24,578</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets/(liabilities)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-955">42,007</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-956">16,494</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-957">15,996</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowances have been provided on deferred tax assets where, based on all available evidence, it was considered more likely than not that some portion or all of the recorded deferred tax assets will not be realized in future periods. After&#160;consideration&#160;of&#160;all&#160;positive&#160;and&#160;negative&#160;evidence, the Company&#160;believes&#160;that&#160;as of December&#160;31, 2024, it&#160;is&#160;more&#160;likely&#160;than not&#160;that net deferred tax assets will not be realized. Adjustments may be required in the future if the Company estimates that the amount of deferred tax assets to be realized is more or less than the net amount recorded.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="f-958" escape="true"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation allowances for the years ended December&#160;31, 2024, 2023 and 2022 were as follows:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.322%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.606%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance, as of January 1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-959">2,771,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-960">1,943,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-961">1,758,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions/(subtractions) charged to income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="bgne:DeferredTaxAssetValuationAllowanceChangesIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-962">157,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="bgne:DeferredTaxAssetValuationAllowanceChangesIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-963">845,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="bgne:DeferredTaxAssetValuationAllowanceChangesIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-964">229,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions/(subtractions) charged to equity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="bgne:DeferredTaxAssetValuationAllowanceGainLossIncludedInOtherComprehensiveIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-965">497,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="bgne:DeferredTaxAssetValuationAllowanceGainLossIncludedInOtherComprehensiveIncomeLoss" format="ixt:fixed-zero" scale="3" id="f-966">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="bgne:DeferredTaxAssetValuationAllowanceGainLossIncludedInOtherComprehensiveIncomeLoss" format="ixt:fixed-zero" scale="3" id="f-967">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="bgne:DeferredTaxAssetValuationAllowanceCurrencyTranslationAndOther" format="ixt:num-dot-decimal" scale="3" id="f-968">23,074</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="bgne:DeferredTaxAssetValuationAllowanceCurrencyTranslationAndOther" format="ixt:num-dot-decimal" scale="3" id="f-969">18,116</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="bgne:DeferredTaxAssetValuationAllowanceCurrencyTranslationAndOther" format="ixt:num-dot-decimal" scale="3" id="f-970">44,184</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance, as of December 31</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-971">3,403,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-972">2,771,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-973">1,943,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, the Company had net operating losses of approximately $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-974">6,720,659</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-975">5,945,753</ix:nonFraction>, respectively. As of December&#160;31, 2024, net operating losses were primarily comprised of: $<ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-976">2,185,546</ix:nonFraction> from entities in the PRC which expire in years 2025 through 2034; and $<ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-977">4,526,020</ix:nonFraction> derived from Switzerland which expires in years 2025 through 2031. The Company has approximately $<ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="3" id="f-978">43,677</ix:nonFraction> of U.S. research tax credits which will expire between 2036 and 2044 and approximately $<ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign" format="ixt:num-dot-decimal" scale="3" id="f-979">704,928</ix:nonFraction> of Switzerland tax relief credits which will expire in 2028, if not utilized.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">163</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><ix:continuation id="f-821-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-980" escape="true"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross unrecognized tax benefits for the years ended December&#160;31, 2024, 2023 and 2022 were as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.322%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.606%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance, as of January 1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-981">14,264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-982">11,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-983">9,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to prior tax years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-984">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-985">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-986">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions based on tax positions related to prior tax years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-987">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-988">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-989">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current tax year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-990">2,975</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-991">2,709</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-992">1,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions based on lapse of statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:fixed-zero" scale="3" id="f-993">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:fixed-zero" scale="3" id="f-994">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:fixed-zero" scale="3" id="f-995">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance, as of December 31</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-996">17,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-997">14,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-998">11,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current and prior year additions include assessment of U.S. federal and state tax credits and incentives. As of December&#160;31, 2024, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-999">17,239</ix:nonFraction> of unrecognized tax benefits substantially all of which, if recognized, would reduce the effective tax rate. The Company does not anticipate that the amount of existing unrecognized tax benefits will significantly change within the next 12 months.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to record interest and penalties related to income taxes as a component of income tax expense. For the years ended December&#160;31, 2024, 2023 and 2022, the Company&#8217;s accrued interest and penalties, where applicable, related to uncertain tax positions were not material.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducts business in a number of tax jurisdictions and, as such, is required to file income tax returns in multiple jurisdictions globally. As of December&#160;31, 2024, Australia tax matters are open to examination for the years 2013 through 2024, China tax matters are open to examination for the years 2014 through 2024, Switzerland tax matters are open to examination for the years 2021 through 2024, and U.S. federal tax matters are open to examination for years 2015 through 2024. Various U.S. states and other non-US tax jurisdictions in which the Company files tax returns remain open to examination for 2014 through 2024.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company qualifies for the Technology Advanced Service Enterprises and High and New Technology Enterprise status for certain subsidiaries in China, which begin to expire at the end of 2025. The income tax benefits attributable to this status for the year ended December&#160;31, 2024 is approximately $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="bgne:TaxBenefitFromForeignTaxStatus" format="ixt:num-dot-decimal" scale="3" id="f-1000">4,631</ix:nonFraction>, or less than $<ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="bgne:TaxBenefitFromForeignTaxStatusPerShare" scale="0" id="f-1001">0.01</ix:nonFraction> per share outstanding.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2024, the Company concluded that a portion of earnings from certain subsidiaries, primarily in the U.S. and Canada, are no longer indefinitely reinvested. As a result, the Company recognized a deferred tax liability of $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" format="ixt:num-dot-decimal" scale="3" id="f-1002">23,735</ix:nonFraction>. The Company continues to assert that earnings in other jurisdictions remain permanently reinvested.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">164</span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_229"></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="f-1003" continuedAt="f-1003-1" escape="true">Supplemental Balance Sheet Information</ix:nonNumeric></span></div><ix:continuation id="f-1003-1" continuedAt="f-1003-2"><ix:nonNumeric contextRef="c-1" name="bgne:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" id="f-1004" escape="true"><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid research and development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="bgne:PrepaidResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="3" id="f-1005">64,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="bgne:PrepaidResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="3" id="f-1006">60,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PrepaidTaxes" format="ixt:num-dot-decimal" scale="3" id="f-1007">23,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PrepaidTaxes" format="ixt:num-dot-decimal" scale="3" id="f-1008">37,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1009">32,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1010">37,859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="bgne:PrepaidGeneralAndAdministrativeExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1011">21,253</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="bgne:PrepaidGeneralAndAdministrativeExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1012">14,619</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid manufacturing cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="bgne:PrepaidManufacturingCosts" format="ixt:num-dot-decimal" scale="3" id="f-1013">19,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="bgne:PrepaidManufacturingCosts" format="ixt:num-dot-decimal" scale="3" id="f-1014">42,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-1015">9,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-1016">11,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PrepaidInsurance" format="ixt:num-dot-decimal" scale="3" id="f-1017">6,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PrepaidInsurance" format="ixt:num-dot-decimal" scale="3" id="f-1018">8,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1019">15,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1020">44,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1021">192,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1022">257,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock" id="f-1023" escape="true"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current assets consist of the following:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-1024">128,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:LongTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-1025">89,644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid supply cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="bgne:PrepaidSupplyCost" format="ixt:num-dot-decimal" scale="3" id="f-1026">12,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="bgne:PrepaidSupplyCost" format="ixt:num-dot-decimal" scale="3" id="f-1027">18,122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental deposits and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="bgne:RentalDepositsAndOther" format="ixt:num-dot-decimal" scale="3" id="f-1028">8,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="bgne:RentalDepositsAndOther" format="ixt:num-dot-decimal" scale="3" id="f-1029">8,195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepayment of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="bgne:PrepaymentOfLongTermAsset" format="ixt:num-dot-decimal" scale="3" id="f-1030">5,927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="bgne:PrepaymentOfLongTermAsset" format="ixt:num-dot-decimal" scale="3" id="f-1031">4,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid VAT</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ValueAddedTaxReceivableNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1032">2,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ValueAddedTaxReceivableNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1033">2,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1034">2,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1035">2,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1036">160,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1037">125,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="bgne:AccruedLiabilitiesAccountsPayableOtherAndOtherLiabilitiesCurrentTableTextBlock" id="f-1038" escape="true"><div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other payables consisted of the following:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1039">248,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1040">217,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales rebates and returns related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="bgne:AccruedSalesRebatesAndReturnsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1041">235,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="bgne:AccruedSalesRebatesAndReturnsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1042">139,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External research and development activities related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="bgne:AccruedLiabilitiesExternalResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-1043">154,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="bgne:AccruedLiabilitiesExternalResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-1044">162,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="bgne:AccruedExpensesCommercialActivities" format="ixt:num-dot-decimal" scale="3" id="f-1045">77,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="bgne:AccruedExpensesCommercialActivities" format="ixt:num-dot-decimal" scale="3" id="f-1046">87,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="bgne:AccruedGeneralAndAdministrativeExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1047">31,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="bgne:AccruedGeneralAndAdministrativeExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1048">36,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual income tax and other taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AccruedPayrollTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1049">34,904</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AccruedPayrollTaxesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1050">30,083</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="bgne:AccruedProfessionalFeesAndOtherCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1051">21,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="bgne:AccruedProfessionalFeesAndOtherCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1052">19,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1053">803,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1054">693,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">165</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:OtherNoncurrentLiabilitiesTableTextBlock" id="f-1055" escape="true"><ix:continuation id="f-1003-2"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities consist of the following:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred government grant income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:GovernmentAssistanceLiability" format="ixt:num-dot-decimal" scale="3" id="f-1056">30,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:GovernmentAssistanceLiability" format="ixt:num-dot-decimal" scale="3" id="f-1057">34,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1058">16,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1059">14,995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset retirement obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AssetRetirementObligationsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1060">3,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AssetRetirementObligationsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1061">1,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OtherSundryLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1062">16,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OtherSundryLiabilitiesNoncurrent" scale="3" id="f-1063">484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1064">66,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1065">50,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="ic94bd2152a214042a118e81881a5a1e5_232"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-1066" continuedAt="f-1066-1" escape="true">Debt</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtTableTextBlock" id="f-1067" continuedAt="f-1067-1" escape="true"><ix:continuation id="f-1066-1" continuedAt="f-1066-2"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s short-term and long-term debt obligations as of December&#160;31, 2024 and 2023: </span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.186%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.807%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lender</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Borrower</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Line of Credit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:12pt"><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RMB</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RMB</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Construction Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene Guangzhou Biologics Manufacturing Co., Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;RMB<ix:nonFraction unitRef="cny" contextRef="c-243" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" id="f-1068">580,000</ix:nonFraction> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-244" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:duryear" id="f-1069">9</ix:nonNumeric>-year </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 11, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1070">16,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="c-243" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1071">120,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1072">14,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="c-245" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1073">100,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Merchants Bank</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene Guangzhou Biologics Manufacturing Co., Ltd.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RMB<ix:nonFraction unitRef="cny" contextRef="c-246" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="f-1074">350,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-247" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:duryear" id="f-1075">9</ix:nonNumeric>-year</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 20, 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1076">8,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="c-246" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1077">62,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1078">8,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="c-248" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1079">62,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Merchants Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene Guangzhou Biologics Manufacturing Co., Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RMB<ix:nonFraction unitRef="cny" contextRef="c-249" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" id="f-1080">378,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-250" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:duryear" id="f-1081">9</ix:nonNumeric>-year </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 8, 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1082">8,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="c-249" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1083">59,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1084">5,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="c-251" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1085">40,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China CITIC Bank</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene (Suzhou) Co., Ltd.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RMB<ix:nonFraction unitRef="cny" contextRef="c-252" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" id="f-1086">480,000</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-253" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:duryear" id="f-1087">10</ix:nonNumeric>-year </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 28, 2032</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1088">1,384</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="c-252" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1089">10,100</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="f-1090">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="c-254" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="f-1091">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Merchants Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene, Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-255" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="f-1092">380,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-256" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:duryear" id="f-1093">1</ix:nonNumeric>-year </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1094">380,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="c-255" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1095">2,773,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1096">300,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="c-257" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1097">2,129,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Minsheng Bank</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene, Ltd.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-258" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="f-1098">150,000</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-259" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:duryear" id="f-1099">1</ix:nonNumeric>-year </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 16, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-259" decimals="3" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-1100">6.8</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1101">150,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="c-258" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1102">1,094,891</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1103">150,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="c-260" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1104">1,064,660</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Industrial Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene, Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RMB<ix:nonFraction unitRef="cny" contextRef="c-261" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" id="f-1105">675,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-262" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durday" id="f-1106">364</ix:nonNumeric>-days</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 27, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1107">92,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="c-261" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1108">675,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="f-1109">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="c-263" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="f-1110">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Merchants Bank</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene Guangzhou Biologics Manufacturing Co., Ltd.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RMB<ix:nonFraction unitRef="cny" contextRef="c-264" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" id="f-1111">400,000</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-265" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:duryear" id="f-1112">1</ix:nonNumeric>-year </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 5, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-265" decimals="3" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-1113">3.0</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1114">54,800</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="c-264" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1115">400,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1116">56,356</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="c-266" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1117">400,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HSBC Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene, Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RMB<ix:nonFraction unitRef="cny" contextRef="c-267" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" id="f-1118">340,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-268" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:duryear" id="f-1119">1</ix:nonNumeric>-year</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 5, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1120">46,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="c-267" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1121">340,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1122">47,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="c-269" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1123">340,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Industrial Bank</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene (Suzhou) Co., Ltd.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RMB<ix:nonFraction unitRef="cny" contextRef="c-270" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" id="f-1124">200,000</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-271" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:duryear" id="f-1125">1</ix:nonNumeric>-year</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 29, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-271" decimals="3" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-1126">2.8</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="f-1127">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="c-270" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="f-1128">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1129">28,177</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="c-272" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1130">200,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shanghai Pudong Development Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene, Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RMB<ix:nonFraction unitRef="cny" contextRef="c-273" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" id="f-1131">700,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-274" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:duryear" id="f-1132">1</ix:nonNumeric>-year</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 24, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-274" decimals="3" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-1133">2.9</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1134">93,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="c-273" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1135">679,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1136">49,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="c-275" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1137">350,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Merchants Bank</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene (Suzhou) Co., Ltd.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RMB<ix:nonFraction unitRef="cny" contextRef="c-276" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="0" id="f-1138">200,000</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-277" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:duryear" id="f-1139">1</ix:nonNumeric>-year</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 24, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-278" decimals="3" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-1140">3.2</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="f-1141">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="c-276" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:fixed-zero" scale="3" id="f-1142">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1143">28,037</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="c-279" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1144">199,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="33" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total short-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1145">851,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="c-12" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1146">6,215,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1147">688,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="c-13" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1148">4,885,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Construction Bank</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene Guangzhou Biologics Manufacturing Co., Ltd.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;RMB<ix:nonFraction unitRef="cny" contextRef="c-280" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" id="f-1149">580,000</ix:nonFraction> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-281" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:duryear" id="f-1150">9</ix:nonNumeric>-year</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 11, 2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1151">41,100</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="c-280" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1152">300,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1153">59,174</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="c-282" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1154">420,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Merchants Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene Guangzhou Biologics Manufacturing Co., Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RMB<ix:nonFraction unitRef="cny" contextRef="c-283" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="f-1155">350,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;<ix:nonNumeric contextRef="c-284" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:duryear" id="f-1156">9</ix:nonNumeric>-year</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 20, 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1157">27,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="c-283" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1158">204,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1159">37,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="c-285" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1160">267,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Merchants Bank</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene Guangzhou Biologics Manufacturing Co., Ltd.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;RMB<ix:nonFraction unitRef="cny" contextRef="c-286" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" id="f-1161">378,000</ix:nonFraction> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-287" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:duryear" id="f-1162">9</ix:nonNumeric>-year </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 8, 2029</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1163">33,020</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="c-286" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1164">241,025</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1165">42,337</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="c-288" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1166">300,500</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China CITIC Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene (Suzhou) Co., Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RMB<ix:nonFraction unitRef="cny" contextRef="c-289" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" id="f-1167">480,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-253" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:duryear" id="f-1168">10</ix:nonNumeric>-year </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 28, 2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1169">64,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="c-289" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1170">469,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1171">58,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="c-290" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1172">415,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1173">166,484</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="c-12" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1174">1,215,211</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1175">197,618</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cny" contextRef="c-13" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1176">1,402,643</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">166</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><ix:continuation id="f-1066-2"><ix:continuation id="f-1067-1"><div style="margin-bottom:9pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt">The outstanding borrowings bear floating interest rates benchmarking RMB loan interest rates of financial institutions in the PRC. The loan interest rate was <ix:nonFraction unitRef="number" contextRef="c-281" decimals="3" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-1177">4.2</ix:nonFraction>% as of December&#160;31, 2024. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Company repaid </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1178">13,739</ix:nonFraction> (or RMB<ix:nonFraction unitRef="cny" contextRef="c-281" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1179">100,000</ix:nonFraction>) during the year ended December&#160;31, 2024. The loan is secured by BeiGene Guangzhou Biologics Manufacturing Co., Ltd.&#8217;s property ownership certificate and fixed assets. </span></div><div style="margin-bottom:9pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt">The outstanding borrowings bear floating interest rates benchmarking RMB loan interest rates of financial institutions in the PRC. The loan interest rate was <ix:nonFraction unitRef="number" contextRef="c-247" decimals="3" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-1180">3.7</ix:nonFraction>% as of December&#160;31, 2024. The Company repaid $<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1181">8,730</ix:nonFraction> (RMB<ix:nonFraction unitRef="cny" contextRef="c-291" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1182">62,857</ix:nonFraction>) during the year ended December&#160;31, 2024. The loan is secured by Guangzhou Factory&#8217;s second land use right and certain fixed assets.</span></div><div style="margin-bottom:9pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt">The outstanding borrowings bear floating interest rates benchmarking RMB loan interest rates of financial institutions in the PRC. The loan interest rate was <ix:nonFraction unitRef="number" contextRef="c-249" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1183">3.8</ix:nonFraction>% as of December&#160;31, 2024. The Company repaid $<ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1184">5,562</ix:nonFraction> (RMB<ix:nonFraction unitRef="cny" contextRef="c-250" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1185">40,000</ix:nonFraction>) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">during the year ended December&#160;31, 2024. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The loan is secured by fixed assets that will be placed into service upon completion of the third phase of the Guangzhou manufacturing facility&#8217;s build out. </span></div><div style="margin-bottom:9pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt">The outstanding borrowings bear a floating interest rate benchmarked against prevailing interest rates of certain PRC financial institutions. The loan interest rate was <ix:nonFraction unitRef="number" contextRef="c-292" decimals="3" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1186">3.7</ix:nonFraction>% as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The Company drew down $<ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="f-1187">9,053</ix:nonFraction> (RMB<ix:nonFraction unitRef="cny" contextRef="c-253" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="f-1188">65,000</ix:nonFraction>) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">during the year ended December&#160;31, 2024. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The loan is secured by BeiGene (Suzhou) Co., Ltd.&#8217;s property ownership certificate of the small molecule manufacturing campus in Suzhou, China. </span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:12pt">The outstanding borrowings bear floating interest rates benchmarking the secured overnight financing rate. The loan interest rate was <ix:nonFraction unitRef="number" contextRef="c-256" decimals="3" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-1189">6.2</ix:nonFraction>% as of December&#160;31, 2024. $<ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1190">80,000</ix:nonFraction> of the borrowing matures on January 27, 2025, and $<ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1191">300,000</ix:nonFraction> matures on December 17, 2025.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt">The outstanding borrowings bear floating interest rates benchmarking RMB loan interest rates of financial institutions in the PRC. The loan interest rate was <ix:nonFraction unitRef="number" contextRef="c-294" decimals="3" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-1192">2.6</ix:nonFraction>% as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt">The outstanding borrowings bear floating interest rates benchmarking Hong Kong interbank market rate for RMB. The loan interest rate was <ix:nonFraction unitRef="number" contextRef="c-268" decimals="3" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="f-1193">4.4</ix:nonFraction>% as of December&#160;31, 2024.</span></div></ix:continuation><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has numerous financial and non-financial covenants on its debt obligations with various banks and other lenders. Some of these covenants include default and/or cross-default provisions that could require acceleration of repayment of loans in the event of default. However, the Company&#8217;s debt is primarily short-term in nature. Any acceleration would be a matter of months but may impact the Company&#8217;s ability to refinance debt obligations if an event of default occurs. As of December&#160;31, 2024, the Company is in compliance with all covenants of our material debt agreements.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contractual Maturities of Debt Obligations</span></div><ix:nonNumeric contextRef="c-1" name="srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock" id="f-1194" escape="true"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate contractual maturities of all borrowings due subsequent to December&#160;31, 2024 are as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:83.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.960%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity dates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December&#160;31,&#160;2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ContractualObligationDueInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-1195">851,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December&#160;31,&#160;2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ContractualObligationDueInSecondYear" format="ixt:num-dot-decimal" scale="3" id="f-1196">46,207</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ContractualObligationDueInThirdYear" format="ixt:num-dot-decimal" scale="3" id="f-1197">46,207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31, 2028</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ContractualObligationDueInFourthYear" format="ixt:num-dot-decimal" scale="3" id="f-1198">25,657</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31, 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ContractualObligationDueInFifthYear" format="ixt:num-dot-decimal" scale="3" id="f-1199">19,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ContractualObligationDueAfterFifthYear" format="ixt:num-dot-decimal" scale="3" id="f-1200">28,756</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ContractualObligation" format="ixt:num-dot-decimal" scale="3" id="f-1201">1,018,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on bank loans is paid quarterly until the respective loans are fully settled. Interest expense recognized for the years ended December&#160;31, 2024, 2023 and 2022 amounted to $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-1202">46,894</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-1203">20,800</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-1204">21,699</ix:nonFraction>, respectively, among which, $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="3" id="f-1205">32,158</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="0" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="3" id="f-1206">16,571</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="3" id="f-1207">2,594</ix:nonFraction> was capitalized, respectively. Interest paid for the years ended December&#160;31, 2024, 2023 and 2022, net of amounts capitalized, amounted to $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-1208">19,723</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="0" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="0" id="f-1209">3,484</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="0" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="0" id="f-1210">22,489</ix:nonFraction>, respectively.</span></div></ix:continuation><div id="ic94bd2152a214042a118e81881a5a1e5_235"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-1211" continuedAt="f-1211-1" escape="true">Product Revenue</ix:nonNumeric></span></div><ix:continuation id="f-1211-1" continuedAt="f-1211-2"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s product revenue is primarily derived from the sale of its internally developed products BRUKINSA and TEVIMBRA in the U.S., China, and other regions; XGEVA, BLINCYTO and KYPROLIS in China under a license from Amgen; REVLIMID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and VIDAZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in China under a license from BMS; and POBEVCY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in China under a license from Bio-Thera.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">167</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><ix:continuation id="f-1211-2"><ix:continuation id="f-523-3"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the Company&#8217;s net product sales for the years ended December&#160;31, 2024, 2023 and 2022.</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue - gross</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="bgne:RevenueFromContractWithCustomerExcludingAssessedTaxBeforeReductions" format="ixt:num-dot-decimal" scale="3" id="f-1212">4,786,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="bgne:RevenueFromContractWithCustomerExcludingAssessedTaxBeforeReductions" format="ixt:num-dot-decimal" scale="3" id="f-1213">2,718,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="bgne:RevenueFromContractWithCustomerExcludingAssessedTaxBeforeReductions" format="ixt:num-dot-decimal" scale="3" id="f-1214">1,438,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Rebates and sales returns</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="bgne:RevenueRecognitionRevenueReduction" format="ixt:num-dot-decimal" scale="3" id="f-1215">1,007,198</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="bgne:RevenueRecognitionRevenueReduction" format="ixt:num-dot-decimal" scale="3" id="f-1216">529,117</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="bgne:RevenueRecognitionRevenueReduction" format="ixt:num-dot-decimal" scale="3" id="f-1217">183,828</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue - net</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1218">3,779,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1219">2,189,852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1220">1,254,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table disaggregates net product revenue by product for the years ended December&#160;31, 2024, 2023 and 2022.</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BRUKINSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1221">2,644,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1222">1,290,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1223">564,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tislelizumab</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1224">620,836</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1225">536,620</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1226">422,885</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1227">224,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1228">92,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1229">63,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BLINCYTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1230">74,331</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1231">54,342</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1232">36,107</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1233">66,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1234">39,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1235">13,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">POBEVCY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1236">53,509</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1237">56,547</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-312" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1238">38,124</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REVLIMID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-313" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1239">36,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1240">76,018</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1241">79,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1242">60,042</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-317" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1243">43,302</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-318" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1244">36,702</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenue - net</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1245">3,779,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1246">2,189,852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1247">1,254,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="bgne:ScheduleOfAccruedSalesRebatesAndReturnsCurrentTableTextBlock" id="f-1248" escape="true"><div style="margin-bottom:4pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the roll-forward of accrued sales chargebacks, rebates, returns and other deductions for the years ended December&#160;31, 2024 and 2023.</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates, Returns and Other Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contra AR Accruals</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-319" decimals="-3" name="bgne:RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions" format="ixt:num-dot-decimal" scale="3" id="f-1249">41,817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-320" decimals="-3" name="bgne:AccountsReceivableAllowanceForChargebacksAndCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-1250">8,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-321" decimals="-3" name="bgne:RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions" format="ixt:num-dot-decimal" scale="3" id="f-1251">50,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts charged against product revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-322" decimals="-3" name="bgne:RevenueRecognitionRevenueReduction" format="ixt:num-dot-decimal" scale="3" id="f-1252">275,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-323" decimals="-3" name="bgne:RevenueRecognitionRevenueReduction" format="ixt:num-dot-decimal" scale="3" id="f-1253">254,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="bgne:RevenueRecognitionRevenueReduction" format="ixt:num-dot-decimal" scale="3" id="f-1254">529,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-322" decimals="-3" name="bgne:RevenueRecognitionRevenueReductionsPaymentsAndCredits" format="ixt:num-dot-decimal" scale="3" id="f-1255">176,912</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-323" decimals="-3" name="bgne:RevenueRecognitionRevenueReductionsPaymentsAndCredits" format="ixt:num-dot-decimal" scale="3" id="f-1256">232,231</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="bgne:RevenueRecognitionRevenueReductionsPaymentsAndCredits" format="ixt:num-dot-decimal" scale="3" id="f-1257">409,143</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-3" name="bgne:RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions" format="ixt:num-dot-decimal" scale="3" id="f-1258">139,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-3" name="bgne:AccountsReceivableAllowanceForChargebacksAndCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-1259">30,435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" name="bgne:RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions" format="ixt:num-dot-decimal" scale="3" id="f-1260">170,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts charged against product revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-3" name="bgne:RevenueRecognitionRevenueReduction" format="ixt:num-dot-decimal" scale="3" id="f-1261">491,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-3" name="bgne:RevenueRecognitionRevenueReduction" format="ixt:num-dot-decimal" scale="3" id="f-1262">515,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="bgne:RevenueRecognitionRevenueReduction" format="ixt:num-dot-decimal" scale="3" id="f-1263">1,007,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-3" name="bgne:RevenueRecognitionRevenueReductionsPaymentsAndCredits" format="ixt:num-dot-decimal" scale="3" id="f-1264">396,092</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-3" name="bgne:RevenueRecognitionRevenueReductionsPaymentsAndCredits" format="ixt:num-dot-decimal" scale="3" id="f-1265">495,178</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="bgne:RevenueRecognitionRevenueReductionsPaymentsAndCredits" format="ixt:num-dot-decimal" scale="3" id="f-1266">891,270</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-3" name="bgne:RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions" format="ixt:num-dot-decimal" scale="3" id="f-1267">235,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-330" decimals="-3" name="bgne:AccountsReceivableAllowanceForChargebacksAndCreditLoss" format="ixt:num-dot-decimal" scale="3" id="f-1268">50,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-331" decimals="-3" name="bgne:RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions" format="ixt:num-dot-decimal" scale="3" id="f-1269">286,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168</span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_238"></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-1270" continuedAt="f-1270-1" escape="true">Loss Per Share</ix:nonNumeric></span></div><ix:continuation id="f-1270-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-1271" escape="true"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss per share was calculated as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1272">644,786</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1273">881,708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1274">2,003,815</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding for computing basic and diluted loss per share</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-1275"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1276">1,368,746,793</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-1277"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1278">1,357,034,547</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1279"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-1280">1,340,729,572</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1281"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1282">0.47</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1283"><ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1284">0.65</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1285"><ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1286">1.49</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2024, 2023 and 2022, the computation of basic loss per share using the two-class method was not applicable, as the Company was in a net loss position.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of all share options and restricted share units were excluded from the calculation of diluted loss per share as their effect would have been anti-dilutive during the years ended December&#160;31, 2024, 2023 and 2022.</span></div></ix:continuation><div id="ic94bd2152a214042a118e81881a5a1e5_241"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-1287" continuedAt="f-1287-1" escape="true">Share-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="f-1287-1" continuedAt="f-1287-2"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2016 Share Option and Incentive Plan</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2016, in connection with its U.S. IPO, the board of directors and shareholders of the Company approved the 2016 Share Option and Incentive Plan (the &#8220;2016 Plan&#8221;), which became effective in February 2016. The Company initially reserved <ix:nonFraction unitRef="shares" contextRef="c-332" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1288">65,029,595</ix:nonFraction> ordinary shares for the issuance of awards under the 2016 Plan, plus any shares available under the 2011 Option Plan (the &#8220;2011 Plan&#8221;), and not subject to any outstanding options as of the effective date of the 2016 Plan, along with underlying share awards under the 2011 Plan that are cancelled or forfeited without issuance of ordinary shares. As of December&#160;31, 2024, ordinary shares cancelled or forfeited under the 2011 Plan that were carried over to the 2016 Plan totaled <ix:nonFraction unitRef="shares" contextRef="c-333" decimals="INF" name="bgne:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1289">5,166,900</ix:nonFraction>. The 2016 Plan provided for an annual increase in the shares available for issuance, to be added on the first day of each fiscal year, beginning on January 1, 2017, equal to the lesser of (i) five percent (<ix:nonFraction unitRef="number" contextRef="c-334" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="f-1290">5</ix:nonFraction>%)% of the outstanding shares of the Company&#8217;s ordinary shares on the last day of the immediately preceding fiscal year or (ii) such number of shares determined by the Company&#8217;s board of directors or the compensation committee. On January 1, 2018, <ix:nonFraction unitRef="shares" contextRef="c-335" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1291">29,603,616</ix:nonFraction> ordinary shares were added to the 2016 Plan under this provision. However, in August 2018, in connection with the Hong Kong IPO, the board of directors of the Company approved an amended and restated 2016 Plan to remove this &#8220;evergreen&#8221; provision and implement other changes required by the Hong Kong Stock Exchange (&#8220;HKEx&#8221;) rules. In December 2018, the shareholders of the Company approved a second amended and restated 2016 Plan to increase the number of shares authorized for issuance by <ix:nonFraction unitRef="shares" contextRef="c-336" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1292">38,553,159</ix:nonFraction> ordinary shares, as well as amend the cap on annual compensation to independent directors and make other changes. In June 2020, the shareholders approved an Amendment No. 1 to the 2016 Plan to increase the number of shares authorized for issuance by <ix:nonFraction unitRef="shares" contextRef="c-337" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1293">57,200,000</ix:nonFraction> ordinary shares and to extend the term of the plan through April 13, 2030. The number of shares available for issuance under the 2016 Plan is subject to adjustment in the event of a share split, share dividend or other change in the Company&#8217;s capitalization.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, share-based awards to acquire <ix:nonFraction unitRef="shares" contextRef="c-338" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-1294">83,064,175</ix:nonFraction> ordinary shares were available for future grant under the 2016 Plan.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to provide incentive opportunities under the 2016 Plan, the Board of Directors and shareholders of the Company approved an amendment to the 2016 Plan (the &#8220;Amendment No. 2&#8221;), which became effective as of June 22, 2022, to increase the number of authorized shares available for issuance under the 2016 Plan by <ix:nonFraction unitRef="shares" contextRef="c-339" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1295">66,300,000</ix:nonFraction> ordinary shares, or <ix:nonFraction unitRef="number" contextRef="c-339" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="f-1296">5</ix:nonFraction>%, of the Company&#8217;s outstanding shares as of March 31, 2022. In June 2024, the shareholders approved a third amended and restated 2016 Plan to increase the number of shares authorized for issuance by <ix:nonFraction unitRef="shares" contextRef="c-340" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1297">92,820,000</ix:nonFraction>. </span></div></ix:continuation><div style="margin-bottom:9pt;margin-top:9pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">169</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><ix:continuation id="f-1287-2" continuedAt="f-1287-3"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Inducement Equity Plan</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the board of directors of the Company approved the 2018 Inducement Equity Plan (the &#8220;2018 Plan&#8221;) and reserved&#160;<ix:nonFraction unitRef="shares" contextRef="c-341" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1298">12,000,000</ix:nonFraction>&#160;ordinary shares to be used exclusively for grants of awards to individuals who were not previously employees of the Company or its subsidiaries, as a material inducement to the individual&#8217;s entry into employment with the Company or its subsidiaries, within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. The 2018 Plan was approved by the board of directors upon recommendation of the compensation committee, without shareholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The terms and conditions of the 2018 Plan, and the forms of award agreements to be used thereunder, are substantially similar to the 2016 Plan and the forms of award agreements thereunder. In August 2018, in connection with the listing of the Company&#8217;s ordinary shares on the HKEx, the board of directors of the Company approved an amended and restated 2018 Plan to implement changes required by the HKEx rules.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the effectiveness of Amendment No. 2 to the 2016 Plan, on June 22, 2022, the 2018 Plan was terminated to the effect that no new equity awards shall be granted under the plan but the outstanding equity awards under the plan shall continue to vest and/or be exercisable in accordance with their terms.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Employee Share Purchase Plan</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the shareholders of the Company approved the 2018 Employee Share Purchase Plan (the &#8220;ESPP&#8221;).&#160;Initially,&#160;<ix:nonFraction unitRef="shares" contextRef="c-342" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1299">3,500,000</ix:nonFraction>&#160;ordinary shares of the Company were reserved for issuance under the ESPP. In August 2018, in connection with the Hong Kong IPO, the board of directors of the Company approved an amended and restated ESPP to remove an &#8220;evergreen&#8221; share replenishment provision originally included in the plan and implement other changes required by the HKEx rules. In December 2018, the shareholders of the Company approved a second amended and restated ESPP to increase the number of shares authorized for issuance by <ix:nonFraction unitRef="shares" contextRef="c-343" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1300">3,855,315</ix:nonFraction> ordinary shares to <ix:nonFraction unitRef="shares" contextRef="c-344" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1301">7,355,315</ix:nonFraction> ordinary shares. In June 2024, the shareholders of the Company approved a fourth amended and restated ESPP to increase the number of shares authorized for issuance by <ix:nonFraction unitRef="shares" contextRef="c-345" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1302">5,070,000</ix:nonFraction> ordinary shares to <ix:nonFraction unitRef="shares" contextRef="c-346" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1303">12,425,315</ix:nonFraction> ordinary shares. The ESPP allows eligible employees to purchase the Company&#8217;s ordinary shares (including in the form of ADSs) at the end of each offering period, which will generally be <ix:nonNumeric contextRef="c-347" name="bgne:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" format="ixt-sec:durwordsen" id="f-1304">six months</ix:nonNumeric>, at a&#160;<ix:nonFraction unitRef="number" contextRef="c-342" decimals="INF" name="bgne:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountOnPurchasePriceOfCommonStockPercent" scale="-2" id="f-1305">15</ix:nonFraction>%&#160;discount to the market price of the Company&#8217;s ADSs at the beginning or the end of each offering period, whichever is lower, using funds deducted from their payroll during the offering period. Eligible employees are able to authorize payroll deductions of up to&#160;<ix:nonFraction unitRef="number" contextRef="c-347" decimals="INF" name="bgne:MaximumPercentageOfEligibleEarningsSetSideToPurchaseOrdinaryShares" scale="-2" id="f-1306">10</ix:nonFraction>%&#160;of their eligible earnings, subject to applicable limitations.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" id="f-1307" escape="true"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarizes the shares issued under the ESPP:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Market Price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchase Price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">2</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Ordinary Shares Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ADS</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ordinary</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ADS</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ordinary</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Proceeds</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-348" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-1308">1,035,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-349" decimals="2" name="bgne:SharePriceAmericanDepositoryShares" scale="0" id="f-1309">165.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-349" decimals="2" name="us-gaap:SharePrice" id="f-1310">12.69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-349" decimals="2" name="bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice" id="f-1311">140.27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-349" decimals="2" name="bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice" id="f-1312">10.78</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" format="ixt:num-dot-decimal" scale="3" id="f-1313">11,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 29, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-350" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-1314">1,021,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-351" decimals="2" name="bgne:SharePriceAmericanDepositoryShares" scale="0" id="f-1315">165.65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-351" decimals="2" name="us-gaap:SharePrice" id="f-1316">12.74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-351" decimals="2" name="bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice" id="f-1317">140.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-351" decimals="2" name="bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice" id="f-1318">10.83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" format="ixt:num-dot-decimal" scale="3" id="f-1319">11,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-352" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-1320">794,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-353" decimals="2" name="bgne:SharePriceAmericanDepositoryShares" scale="0" id="f-1321">207.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-353" decimals="2" name="us-gaap:SharePrice" id="f-1322">15.97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-353" decimals="2" name="bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice" id="f-1323">176.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-353" decimals="2" name="bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice" id="f-1324">13.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-352" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" format="ixt:num-dot-decimal" scale="3" id="f-1325">10,777</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-354" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-1326">930,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-355" decimals="2" name="bgne:SharePriceAmericanDepositoryShares" scale="0" id="f-1327">171.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-355" decimals="2" name="us-gaap:SharePrice" id="f-1328">13.16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-355" decimals="2" name="bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice" id="f-1329">145.44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-355" decimals="2" name="bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice" id="f-1330">11.19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-354" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" format="ixt:num-dot-decimal" scale="3" id="f-1331">10,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-356" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-1332">861,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-357" decimals="2" name="bgne:SharePriceAmericanDepositoryShares" scale="0" id="f-1333">171.66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-357" decimals="2" name="us-gaap:SharePrice" id="f-1334">13.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-357" decimals="2" name="bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice" id="f-1335">145.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-357" decimals="2" name="bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice" id="f-1336">11.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-356" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" format="ixt:num-dot-decimal" scale="3" id="f-1337">9,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-358" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-1338">667,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-359" decimals="2" name="bgne:SharePriceAmericanDepositoryShares" scale="0" id="f-1339">210.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-359" decimals="2" name="us-gaap:SharePrice" id="f-1340">16.19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-359" decimals="2" name="bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice" id="f-1341">178.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-359" decimals="2" name="bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice" id="f-1342">13.76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-358" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" format="ixt:num-dot-decimal" scale="3" id="f-1343">9,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The market price is the lower of the closing price on Nasdaq on the issuance date or the offering date, in accordance with the terms of the ESPP.</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The purchase price is the price which was discounted from the applicable market price, in accordance with the terms of the ESPP.</span></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, <ix:nonFraction unitRef="shares" contextRef="c-360" decimals="INF" name="bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberOfAvailableSharesAvailableForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-1344">4,953,682</ix:nonFraction> ordinary shares were available for future issuance under the ESPP.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">170</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><ix:continuation id="f-1287-3" continuedAt="f-1287-4"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share options</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, share options have a contractual term of <ix:nonNumeric contextRef="c-361" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1345">10</ix:nonNumeric> years and vest over a <span style="-sec-ix-hidden:f-1346">three</span>- to <ix:nonNumeric contextRef="c-363" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1347">five-year</ix:nonNumeric> period, with the first tranche vesting one calendar year after the grant date or the service relationship start date and the remainder of the awards vesting on a monthly basis thereafter. Restricted shares and restricted share units generally vest over a <ix:nonNumeric contextRef="c-364" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1348"><ix:nonNumeric contextRef="c-365" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1349">four-year</ix:nonNumeric></ix:nonNumeric> period, with the first tranche vesting one calendar year after the grant date or the service relationship start date and the remainder of the awards vesting on a yearly basis thereafter, or sometimes vest upon the achievement of pre-specified performance conditions.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-1350" escape="true"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s share option activities under the 2011, 2016 and 2018 Plans:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.604%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant<br/>Date&#160;Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic&#160;Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1351">72,204,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1352">7.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-1353">12,516,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1354">12.34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1355">6.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-1356">5,898,217</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-1357">4.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1358">52,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1359">2,296,634</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-1360">16.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1361">76,526,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1362">7.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-1363">9,817,925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1364">16.37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1365">8.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-1366">6,974,331</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-1367">4.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1368">92,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1369">1,225,334</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-1370">17.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1371">78,145,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1372">9.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-1373">9,180,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1374">12.53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1375">6.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-1376">6,812,624</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-1377">3.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1378">69,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1379">2,530,134</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-1380">15.87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1381">77,982,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1382">9.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1383">4.83</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1384">429,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-1385">60,173,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-1386">8.42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1387">3.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-1388">406,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1389">75,311,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="f-1390">9.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1391">4.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1392">426,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the unrecognized compensation cost related to <ix:nonFraction unitRef="shares" contextRef="c-366" decimals="INF" name="bgne:ShareBasedPaymentArrangementNonvestedAwardOptionNumberOfShares" format="ixt:num-dot-decimal" scale="0" id="f-1393">15,137,970</ix:nonFraction> unvested share options expected to vest was $<ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="3" id="f-1394">82,424</ix:nonFraction>. This unrecognized compensation will be recognized over an estimated weighted-average amortization period of <ix:nonNumeric contextRef="c-361" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1395">2.4</ix:nonNumeric> years.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of employee share option awards vested during the years ended December&#160;31, 2024, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="3" id="f-1396">68,420</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="3" id="f-1397">61,121</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="3" id="f-1398">62,548</ix:nonFraction>, respectively.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair value of options</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the binomial option-pricing model in determining the estimated fair value of the options granted. The model requires the input of highly subjective assumptions including the estimated expected stock price volatility and, the exercise multiple for which employees are likely to exercise share options. For expected volatilities, the trading history and observation period of the Company&#8217;s own share price is used in conjunction with historical price volatilities of ordinary shares of several comparable companies in the same industry as the Company. For the exercise multiple, the Company was not able to develop an exercise pattern as reference, thus the exercise multiple is based on management&#8217;s estimation, which the Company believes is representative of the future exercise pattern of the options. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury Bills yield curve in effect at the time of grant.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">171</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><ix:continuation id="f-1287-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-1399" escape="true"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the range of fair values and the assumptions used to estimate those fair values of the share options granted in the years presented:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.508%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of ordinary share</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-367" decimals="INF" name="us-gaap:SharePrice" scale="0" id="f-1400">5.72</ix:nonFraction> ~ $<ix:nonFraction unitRef="usdPerShare" contextRef="c-368" decimals="INF" name="us-gaap:SharePrice" scale="0" id="f-1401">9.19</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-369" decimals="INF" name="us-gaap:SharePrice" scale="0" id="f-1402">7.26</ix:nonFraction> ~ $<ix:nonFraction unitRef="usdPerShare" contextRef="c-370" decimals="INF" name="us-gaap:SharePrice" scale="0" id="f-1403">10.72</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-371" decimals="INF" name="us-gaap:SharePrice" scale="0" id="f-1404">5.51</ix:nonFraction> ~ $<ix:nonFraction unitRef="usdPerShare" contextRef="c-372" decimals="INF" name="us-gaap:SharePrice" scale="0" id="f-1405">9.04</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-361" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-1406">3.8</ix:nonFraction>% ~ <ix:nonFraction unitRef="number" contextRef="c-361" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-1407">4.6</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-373" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-1408">3.4</ix:nonFraction>% ~ <ix:nonFraction unitRef="number" contextRef="c-373" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-1409">4.6</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-374" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-1410">1.8</ix:nonFraction>% ~ <ix:nonFraction unitRef="number" contextRef="c-374" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-1411">3.9</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected exercise multiple</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-361" decimals="1" name="bgne:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum" scale="0" id="f-1412">2.8</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-10" decimals="1" name="bgne:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum" scale="0" id="f-1413">2.8</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-11" decimals="1" name="bgne:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum" scale="0" id="f-1414">2.8</ix:nonFraction></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-361" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-1415">57</ix:nonFraction>% ~ <ix:nonFraction unitRef="number" contextRef="c-361" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-1416">58</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-373" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-1417">58</ix:nonFraction>% ~ <ix:nonFraction unitRef="number" contextRef="c-373" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-1418">60</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-374" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-1419">51</ix:nonFraction>% ~ <ix:nonFraction unitRef="number" contextRef="c-374" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-1420">60</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-361" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-1421">0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-373" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-1422">0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-374" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-1423">0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-361" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1424">10</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-373" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1425">10</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-374" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1426">10</ix:nonNumeric> years</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted share units</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="f-1427" escape="true"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s restricted share unit activities under the 2016 and 2018 Plans:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Numbers<br/>of&#160;Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant&#160;Date&#160;Fair&#160;Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-375" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-1428">36,082,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-375" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1429">18.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-376" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1430">38,707,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-376" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1431">12.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-376" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1432">12,533,586</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-376" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1433">16.37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-376" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1434">6,859,892</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-376" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-1435">16.72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-377" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-1436">55,397,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-377" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1437">14.87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-378" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1438">34,573,994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-378" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1439">15.57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-378" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1440">17,862,598</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-378" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1441">14.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-378" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1442">5,707,546</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-378" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-1443">15.47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-379" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-1444">66,401,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-379" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1445">15.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-364" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1446">49,693,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-364" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1447">12.53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-364" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1448">21,251,477</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-364" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1449">15.53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-364" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1450">9,012,471</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-364" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-1451">14.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-380" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-1452">85,830,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-380" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1453">13.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest at December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-380" decimals="INF" name="bgne:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1454">72,956,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-380" decimals="2" name="bgne:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue" scale="0" id="f-1455">13.67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the unrecognized compensation cost related to unvested restricted share units expected to vest was $<ix:nonFraction unitRef="usd" contextRef="c-380" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="3" id="f-1456">801,403</ix:nonFraction>. This unrecognized compensation will be recognized over an estimated weighted-average amortization period of <ix:nonNumeric contextRef="c-364" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1457">2.7</ix:nonNumeric> years.&#160;</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based compensation expense</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-1458" escape="true"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total share-based compensation cost recognized for the years ended December&#160;31, 2024, 2023 and 2022:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.322%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.606%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1459">186,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1460">163,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1461">139,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1462">255,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1463">204,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1464">163,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1465">441,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1466">367,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1467">303,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">172</span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_244"></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="f-1468" continuedAt="f-1468-1" escape="true">Accumulated Other Comprehensive (Loss) Income</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="f-1469" escape="true"><ix:continuation id="f-1468-1"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The movement of accumulated other comprehensive (loss) income was as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign&#160;Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains/Losses&#160;on<br/>Available-for-Sale<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension Liability Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-381" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1470">62,523</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-382" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1471">9,011</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-383" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1472">5,883</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1473">77,417</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-384" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1474">25,464</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-385" decimals="-3" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1475">9,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1476">6,422</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1477">22,840</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-384" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-1478">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-385" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-1479">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="3" id="f-1480">811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="3" id="f-1481">811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net-current period other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-384" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1482">25,464</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-385" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1483">9,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1484">5,611</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1485">22,029</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-387" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1486">87,987</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-388" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-1487">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-389" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1488">11,494</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1489">99,446</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-390" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1490">47,565</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-391" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="3" id="f-1491">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-392" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1492">2,753</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1493">50,353</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-390" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-1494">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-391" decimals="-3" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-1495">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-392" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="3" id="f-1496">811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="3" id="f-1497">811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net-current period other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-390" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1498">47,565</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-391" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-1499">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-392" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1500">1,942</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1501">49,542</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-393" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1502">135,552</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-394" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-1503">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-395" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1504">13,436</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1505">148,988</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The amounts reclassified from accumulated other comprehensive (loss) income were included in other (expense) income, net in the consolidated statements of operations.</span></div></ix:continuation></ix:nonNumeric><div id="ic94bd2152a214042a118e81881a5a1e5_247"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-1506" continuedAt="f-1506-1" escape="true">Shareholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="f-1506-1"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2024, 2023 and 2022, the Company completed the following equity transactions:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BMS Settlement</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2023, the Company entered into a Settlement and Termination Agreement (the &#8220;Settlement Agreement&#8221;) with BMS-Celgene and certain of its affiliates relating to the termination of the parties&#8217; ongoing contractual relationships, the previously-disclosed ongoing arbitration proceeding concerning ABRAXANE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;Arbitration&#8221;), the License and Supply Agreement (&#8220;LSA&#8221;), the Amended and Restated Quality Agreement (the &#8220;QA&#8221;), and the Share Subscription Agreement (the &#8220;SSA&#8221;), entered into by the parties in 2017 and 2018. Pursuant to the Settlement Agreement, the parties agreed to mutually dismiss the Arbitration and BMS-Celgene and its affiliates agreed to transfer <ix:nonFraction unitRef="shares" contextRef="c-396" decimals="INF" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="f-1507">23,273,108</ix:nonFraction> ordinary shares of the Company originally purchased in 2017, in each case subject to and in accordance with the terms and conditions of the Settlement Agreement. In consideration for the shares being returned, the Company agreed to drop its claims pursuant to the Settlement Agreement. Furthermore, the parties agreed to terminate the LSA and QA on December 31, 2023, subject to the Company&#8217;s right to continue selling all inventory of REVLIMID and VIDAZA until sold out or February 2025, whichever is earlier. The Settlement Agreement provides for a settlement and release by each party of claims arising from or relating to the Arbitration, the LSA, the QA and the SSA, as well as other disputes and potential disputes between the parties, in each case subject to and in accordance with the terms and conditions of the Agreement. The receipt of the shares occurred on August 15, 2023. The Company recorded a noncash gain upon receipt of $<ix:nonFraction unitRef="usd" contextRef="c-397" decimals="-3" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" format="ixt:num-dot-decimal" scale="3" id="f-1508">362,917</ix:nonFraction>, which represents the fair value on the day the shares were received. The gain was recorded within other (expense) income, net in the consolidated statements of operations. The shares were constructively retired during the year ended December 31, 2023. The Company recorded the amount of the cancelled shares in excess of par to additional paid-in capital.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">173</span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_250"></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18. <ix:nonNumeric contextRef="c-1" name="us-gaap:RestrictedAssetsDisclosureTextBlock" id="f-1509" continuedAt="f-1509-1" escape="true">Restricted Net Assets</ix:nonNumeric></span></div><ix:continuation id="f-1509-1"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to pay dividends may depend on the Company receiving distributions of funds from its PRC subsidiaries. Relevant PRC laws and regulations permit payments of dividends by the Company&#8217;s PRC subsidiaries only out of its retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. The results of operations reflected in the consolidated financial statements prepared in accordance with GAAP differ from those reflected in the statutory financial statements of the Company&#8217;s PRC subsidiaries.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the company law of the PRC, a domestic enterprise is required to provide statutory reserves of at least <ix:nonFraction unitRef="number" contextRef="c-12" decimals="INF" name="bgne:RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage" scale="-2" id="f-1510">10</ix:nonFraction>% of its annual after-tax profit until such reserve has reached <ix:nonFraction unitRef="number" contextRef="c-12" decimals="INF" name="bgne:RestrictedNetAssetsRequiredStatutoryReserveAsPercentageOfRegisteredCapital" scale="-2" id="f-1511">50</ix:nonFraction>% of its respective registered capital based on the enterprise&#8217;s PRC statutory accounts. A domestic enterprise is also required to provide discretionary surplus reserve, at the discretion of the Board of Directors, from the profits determined in accordance with the enterprise&#8217;s PRC statutory accounts. The aforementioned reserves can only be used for specific purposes and are not distributable as cash dividends. The Company&#8217;s PRC subsidiaries were established as domestic invested enterprises and therefore were subject to the above-mentioned restrictions on distributable profits.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2024, 2023 and 2022, <ix:nonFraction unitRef="usd" contextRef="c-12" decimals="INF" name="bgne:RestrictedNetAssetsAppropriatedToStatutoryReserves" format="ixt:fixed-zero" scale="0" id="f-1512"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="INF" name="bgne:RestrictedNetAssetsAppropriatedToStatutoryReserves" format="ixt:fixed-zero" scale="0" id="f-1513"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="INF" name="bgne:RestrictedNetAssetsAppropriatedToStatutoryReserves" format="ixt:fixed-zero" scale="0" id="f-1514">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> appropriation to statutory reserves was made, because the PRC subsidiaries had an accumulated deficit as of the end of such periods.&#160;</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these PRC laws and regulations, including the requirement to make annual appropriations of at least <ix:nonFraction unitRef="number" contextRef="c-12" decimals="INF" name="bgne:RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage" scale="-2" id="f-1515">10</ix:nonFraction>% of after-tax income and set aside as general reserve fund prior to payment of dividends, the Company&#8217;s PRC subsidiaries are restricted in their ability to transfer a portion of their net assets to the Company.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange and other regulations in the PRC may further restrict the Company&#8217;s PRC subsidiaries from transferring funds to the Company in the form of dividends, loans, and advances. As of December&#160;31, 2024 and 2023, amounts restricted were the net assets of the Company&#8217;s PRC subsidiaries, which, after intercompany eliminations, amounted to $<ix:nonFraction unitRef="usd" contextRef="c-398" decimals="-3" name="bgne:RestrictedNetAssetsAmount" format="ixt:num-dot-decimal" scale="3" id="f-1516">1,709,961</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-399" decimals="-3" name="bgne:RestrictedNetAssetsAmount" format="ixt:num-dot-decimal" scale="3" id="f-1517">2,114,277</ix:nonFraction>, respectively.</span></div></ix:continuation><div id="ic94bd2152a214042a118e81881a5a1e5_253"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19. <ix:nonNumeric contextRef="c-1" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="f-1518" continuedAt="f-1518-1" escape="true">Employee Benefit Plans</ix:nonNumeric></span></div><ix:continuation id="f-1518-1" continuedAt="f-1518-2"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Defined Contribution Plans</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Full-time employees of the Company in the PRC participate in a government mandated defined contribution plan, pursuant to which certain pension benefits, medical care, employee housing fund and other welfare benefits are provided to employees. Chinese labor regulations require that the Company&#8217;s PRC subsidiaries make contributions to the government for these benefits based on certain percentages of the employees&#8217; salaries. The Company has no legal obligation for the benefits beyond the contributions made. The total amounts for such employee benefits, which were expensed as incurred, were $<ix:nonFraction unitRef="usd" contextRef="c-400" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="3" id="f-1519">101,779</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-401" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="3" id="f-1520">94,358</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-402" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="3" id="f-1521">83,860</ix:nonFraction> for the years ended December&#160;31, 2024, 2023 and 2022, respectively.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a defined contribution 401(k) savings plan (the &#8220;401(k) Plan&#8221;) for U.S. employees. The 401(k) Plan covers all U.S. employees, and allows participants to defer a portion of their annual compensation on a pretax or Roth basis. In addition, the Company has a matching contribution to the 401(k) Plan, which, in the 2024 plan year, matched dollar for dollar of eligible contributions up to <ix:nonFraction unitRef="number" contextRef="c-403" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="f-1522">6</ix:nonFraction>%. Company contributions to the 401(k) Plan totaled $<ix:nonFraction unitRef="usd" contextRef="c-403" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="3" id="f-1523">20,839</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-404" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="3" id="f-1524">15,316</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-405" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="3" id="f-1525">10,298</ix:nonFraction> in the years ended December&#160;31, 2024, 2023 and 2022, respectively. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a government mandated&#160;program to cover its employees in Switzerland for pension, death, or disability. The program is considered a defined contribution plan.&#160;Employer and employee contributions are made based on various percentages of salaries and wages that vary based on employee age and other factors.&#160;Company contributions into the program amounted to $<ix:nonFraction unitRef="usd" contextRef="c-406" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="3" id="f-1526">3,825</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-407" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="3" id="f-1527">2,710</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-408" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="3" id="f-1528">3,887</ix:nonFraction> in the years ended December&#160;31, 2024, 2023 and 2022, respectively.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company contributions into defined contribution plans for the remaining subsidiaries were immaterial.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">174</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><ix:continuation id="f-1518-2"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Defined Benefit Plan</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a defined benefit pension plan covering its employees in Switzerland (the &#8220;Swiss Plan&#8221;). This plan is a government mandated fund that provides benefits to employees upon retirement, death, or disability. Contributions are made based on various percentages of participants&#8217; salaries and wages determined based on participants&#8217; age and other factors. As of December&#160;31, 2024 and 2023, the projected benefit obligations under the Swiss Plan were approximately $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="3" id="f-1529">80,199</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="3" id="f-1530">70,600</ix:nonFraction>, respectively, and plan assets were approximately $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="3" id="f-1531">63,794</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="3" id="f-1532">55,605</ix:nonFraction>, respectively. The funded status of the Swiss Plan is included in other long-term liabilities in the accompanying consolidated balance sheets.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s annual contribution to the Swiss Plan is estimated to be approximately $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" format="ixt:num-dot-decimal" scale="3" id="f-1533">3,922</ix:nonFraction> in 2025 and is expected to evolve thereafter proportionally with changes in staffing and compensation levels, actuarial assumptions and actual investment returns on plan assets.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock" id="f-1534" escape="true"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the total expected benefit payments to Swiss Plan participants in the following 10 years and have been estimated based on the same assumptions used to measure the Company&#8217;s benefit obligations as of December&#160;31, 2024:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.993%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.223%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December&#160;31,&#160;2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="3" id="f-1535">692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December&#160;31,&#160;2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="3" id="f-1536">604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="3" id="f-1537">994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31, 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="3" id="f-1538">593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31, 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" format="ixt:num-dot-decimal" scale="3" id="f-1539">1,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" format="ixt:num-dot-decimal" scale="3" id="f-1540">8,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="bgne:DefinedBenefitPlanExpectedFutureBenefitPaymentTotal" format="ixt:num-dot-decimal" scale="3" id="f-1541">13,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="ic94bd2152a214042a118e81881a5a1e5_256"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-1542" continuedAt="f-1542-1" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="f-1542-1" continuedAt="f-1542-2"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company had purchase commitments amounting to $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" format="ixt:num-dot-decimal" scale="3" id="f-1543">131,944</ix:nonFraction>, of which $<ix:nonFraction unitRef="usd" contextRef="c-409" decimals="-3" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" format="ixt:num-dot-decimal" scale="3" id="f-1544">32,538</ix:nonFraction> related to minimum purchase requirements for supply purchased from contract manufacturing organizations and $<ix:nonFraction unitRef="usd" contextRef="c-410" decimals="-3" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" format="ixt:num-dot-decimal" scale="3" id="f-1545">99,406</ix:nonFraction> related to binding purchase order obligations of inventory from Amgen. The Company does not have any minimum purchase requirements for inventory from Amgen.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capital Commitments</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had capital commitments amounting to $<ix:nonFraction unitRef="usd" contextRef="c-411" decimals="-3" name="us-gaap:OtherCommitment" format="ixt:num-dot-decimal" scale="3" id="f-1546">48,347</ix:nonFraction> for the acquisition of property, plant and equipment as of December&#160;31, 2024 related to various facilities across the globe.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Co-Development Funding Commitment</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Amgen Collaboration Agreement, the Company is responsible for co-funding global clinical development costs for the Amgen oncology pipeline assets up to a total cap of $<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="bgne:MaximumCashAndServicesDevelopmentCommitment" format="ixt:num-dot-decimal" scale="3" id="f-1547">1,250,000</ix:nonFraction>. The Company is funding its portion of the co-development costs by contributing cash and/or development services. As of December&#160;31, 2024, the Company&#8217;s remaining co-development funding commitment was $<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="us-gaap:OtherCommitment" format="ixt:num-dot-decimal" scale="3" id="f-1548">335,261</ix:nonFraction>.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Commitment</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had committed capital related to <ix:nonFraction unitRef="investment" contextRef="c-412" decimals="INF" name="bgne:LongTermFundingCommitmentNumberOfEquityInvestments" format="ixt-sec:numwordsen" scale="0" id="f-1549">two</ix:nonFraction> equity method investments in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-412" decimals="-3" name="bgne:LongTermFundingCommitmentMaximumAmount" format="ixt:num-dot-decimal" scale="3" id="f-1550">15,053</ix:nonFraction>. As of December&#160;31, 2024, the remaining capital commitment was $<ix:nonFraction unitRef="usd" contextRef="c-412" decimals="-3" name="us-gaap:OtherCommitment" format="ixt:num-dot-decimal" scale="3" id="f-1551">7,404</ix:nonFraction> and is expected to be paid from time to time over the investment period.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">175</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:103.5pt;width:100%"><div style="margin-bottom:3pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BEIGENE, LTD.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEARS ENDED DECEMBER 31, 2024, 2023 AND 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollar (&#8220;$&#8221;) and Renminbi (&#8220;RMB&#8221;),</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">except for number of shares and per share data)</span></div></div><ix:continuation id="f-1542-2"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Business Agreements</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements in the ordinary course of business with contract research organizations (&#8220;CROs&#8221;) to provide research and development services. These contracts are generally cancellable at any time by the Company with prior written notice.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also enters into collaboration agreements with institutions and companies to license intellectual property. The Company may be obligated to make future development, regulatory and commercial milestone payments and royalty payments on future sales of specified products associated with its collaboration agreements. Payments under these agreements generally become due and payable upon achievement of such milestones or sales. These commitments are not recorded on the consolidated balance sheet because the achievement and timing of these milestones are not fixed and determinable. When the achievement of these milestones or sales have occurred, the corresponding amounts are recognized in the consolidated financial statements.</span></div></ix:continuation><div id="ic94bd2152a214042a118e81881a5a1e5_259"></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">21. <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-1552" continuedAt="f-1552-1" escape="true">Segment and Geographic Information</ix:nonNumeric></span></div><ix:continuation id="f-1552-1"><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise for which separate financial information is available and evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company operates in <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-1553">one</ix:nonFraction> segment: pharmaceutical products. Its chief operating decision maker is the Chief Executive Officer, who makes operating decisions, assesses performance, and allocates resources on a consolidated basis. </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary measure of segment profitability for the Company&#8217;s operating segment is considered to be consolidated net loss. Significant segment expenses reviewed by the CODM on a regular basis included within net loss include cost of product sales, research and development expenses and selling, general and administrative expenses which are separately presented on the Company&#8217;s Consolidated Statements of Operations. Other segment items within net loss include interest income, net, other (expense) income, net and income tax expense. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s long-lived assets are primarily located in the U.S. and China.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by geographic area are based upon the location of the customer, and net collaboration revenue is recorded in the jurisdiction in which the related income is expected to be sourced from. <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="f-1554" continuedAt="f-1554-1" escape="true">Total net revenues by geographic area are presented as follows:</ix:nonNumeric></span></div><ix:continuation id="f-1554-1"><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. - total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1555">1,957,498</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1556">1,128,219</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1557">502,626</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-413" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1558">1,950,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-414" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1559">945,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-415" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1560">389,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-416" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1561">6,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-417" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1562">182,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-418" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1563">112,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">China- total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1564">1,411,307</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1565">1,101,951</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1566">840,032</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-419" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1567">1,390,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-420" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1568">1,093,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-421" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1569">840,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-422" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1570">20,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-423" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1571">8,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-424" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1572">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Europe- total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-425" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1573">362,626</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-426" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1574">202,014</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-427" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1575">63,257</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-428" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1576">359,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-429" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1577">122,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-430" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1578">14,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-431" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1579">3,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-432" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1580">79,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-433" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1581">48,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rest of world- total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1582">78,810</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1583">26,595</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1584">10,006</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-434" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1585">78,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-435" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1586">28,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-436" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1587">10,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-437" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1588">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-438" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1589">2,387</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-439" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1590">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1591">3,810,241</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1592">2,458,779</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1593">1,415,921</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">176</span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ic94bd2152a214042a118e81881a5a1e5_136"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9A. Controls and Procedures</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on their evaluation, required by paragraph (b) of Rules 13a-15 or 15d-15, promulgated under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act are effective, at a reasonable assurance level, as of December&#160;31, 2024, to ensure that information required to be disclosed in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in U.S. Securities and Exchange Commission rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurances of achieving the desired control objectives, and management necessarily was required to apply its judgment in designing and evaluating the controls and procedures.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act). Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our assessment and those criteria, management concluded that we maintained effective internal control over financial reporting as of December&#160;31, 2024.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of our internal control over financial reporting as of December&#160;31, 2024, has been tested by Ernst &amp; Young LLP, our independent registered public accounting firm, as stated in their report which is included in &#8220;Item 8&#8212;Financial Statements and Other Supplementary Data&#8221; in this Annual Report.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule&#160;13a&#8209;15(d)&#160;and 15d&#8209;15(d)&#160;of the Exchange Act that occurred during the three&#160;months ended December&#160;31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">177</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span><br/></span></div><div id="ic94bd2152a214042a118e81881a5a1e5_139"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9B. Other Information</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There were <ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1594"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1595"><ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1596"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1597">no trading arrangements</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric> for the purchase or sale of our securities entered into, modified or terminated by our directors or officers during the fourth quarter of 2024.</span></div><div id="ic94bd2152a214042a118e81881a5a1e5_145"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 30, 2022, the SEC added us to its conclusive list of issuers identified under the HFCAA following the filing of our annual report on Form 10-K with the SEC on February 28, 2022, which annual report was audited by Ernst &amp; Young Hua Ming LLP, a registered public accounting firm in mainland China that the PCAOB previously was unable to inspect or investigate completely, because of a position taken by an authority in the foreign jurisdiction. However, as our global business has expanded, we have evaluated, designed and implemented business processes and control changes and built substantial organizational capabilities outside of China. Therefore, on March 23, 2022, following a review process carried out by our audit committee, Ernst &amp; Young Hua Ming LLP resigned as our independent registered public accounting firm for the audit of our financial statements and internal control over financial reporting to be filed with the SEC. On the same day, our audit committee approved the engagement of Ernst &amp; Young LLP, located in Boston, Massachusetts, U.S., as the Company&#8217;s independent registered public accounting firm for the audit of our financial statements and internal control over financial reporting commencing for the fiscal year ending December 31, 2022. Given that Ernst &amp; Young LLP (U.S.) now serves as the principal accountant to audit our consolidated financial statements, we are able to comply with the HFCAA and certify that we have retained a registered public accounting firm that the PCAOB has determined it is able to inspect or investigate which would preclude a further finding by the SEC that we are a Commission-Identified Issuer.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, the PCAOB announced that it has secured complete access to inspect and investigate registered public accounting firms headquartered in mainland China and Hong Kong and confirmed that until such time as the PCAOB issues any new determination, there are no Commission-Identified Issuers at risk of having their securities subject to a trading prohibition under the HFCAA.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent known by the Company, the Company is not aware of and has no reason to believe that any governmental entity in the foreign jurisdiction in which the Company is incorporated or otherwise organized owns shares of any capital stock of record of the Company. Furthermore, to the extent known by the Company, the Company is not aware of and has no reason to believe that that any government entity in the foreign jurisdiction where its consolidated foreign operating entities are incorporated or otherwise organized owns shares of any capital stock of record of its consolidated foreign operating entities. The Company has determined that no governmental entity in China has a controlling financial interest in the Company or its consolidated foreign operating entities. To the extent known by the Company, the Company is not aware of and has no reason to believe that any official of the Chinese Communist Party is a board member of the Company or its consolidated foreign operating entities. The articles of incorporation of the Company, as amended, and those of its consolidated foreign operating entities, do not contain any wording received from any charter of the Chinese Communist Party.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">178</span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_148"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;III</span></div><div id="ic94bd2152a214042a118e81881a5a1e5_151"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;10. Directors, Executive Officers and Corporate Governance</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required under this item is incorporated herein by reference to our definitive proxy statement pursuant to Regulation 14A, which proxy statement will be filed with the U.S. Securities and Exchange Commission not later than 120 days after the close of our fiscal year ended December&#160;31, 2024.</span></div><div id="ic94bd2152a214042a118e81881a5a1e5_154"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;11. Executive Compensation</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required under this item is incorporated herein by reference to our definitive proxy statement pursuant to Regulation&#160;14A, which proxy statement will be filed with the U.S. Securities and Exchange Commission not later than 120&#160;days after the close of our fiscal&#160;year ended December&#160;31, 2024.</span></div><div id="ic94bd2152a214042a118e81881a5a1e5_157"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required under this item is incorporated herein by reference to our definitive proxy statement pursuant to Regulation&#160;14A, which proxy statement will be filed with the U.S. Securities and Exchange Commission not later than 120&#160;days after the close of our fiscal&#160;year ended December&#160;31, 2024.</span></div><div id="ic94bd2152a214042a118e81881a5a1e5_160"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;13. Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required under this item is incorporated herein by reference to our definitive proxy statement pursuant to Regulation&#160;14A, which proxy statement will be filed with the U.S. Securities and Exchange Commission not later than 120&#160;days after the close of our fiscal&#160;year ended December&#160;31, 2024.</span></div><div id="ic94bd2152a214042a118e81881a5a1e5_163"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;14. Principal Accountant Fees and Services</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our independent public accounting firm is Ernst &amp; Young LLP (PCAOB ID: 00<ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-1598">42</ix:nonNumeric>), located in Boston, Massachusetts, U.S. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required under this item is incorporated herein by reference to our definitive proxy statement pursuant to Regulation&#160;14A, which proxy statement will be filed with the U.S. Securities and Exchange Commission not later than 120&#160;days after the close of our fiscal&#160;year ended December&#160;31, 2024.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">179</span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_166"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;IV</span></div><div id="ic94bd2152a214042a118e81881a5a1e5_169"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;15. Exhibits and Financial Statement Schedules</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial statements listed in the Index to Consolidated Financial Statements beginning on page </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_175">130</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are filed as part of this Annual Report.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have included Additional Financial Information of Parent Company - Financial Statements Schedule I for the years ended December&#160;31, 2024, 2023 and 2022 on page </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_2110">181</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. No other financial statement schedules have been filed as part of this report because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits filed as part of this Annual Report are set forth on the Exhibit Index immediately following our consolidated financial statements. The Exhibit Index is incorporated herein by reference.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">180</span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_2110"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" id="f-1599" continuedAt="f-1599-1" escape="true"><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Schedule I - Condensed Financial Information of Registrant</span></div><div style="text-align:center"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="srt:ScheduleOfCondensedIncomeStatementTableTextBlock" id="f-1600" escape="true"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BeiGene, Ltd.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Information of Parent Company</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Operations</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollars (&#8220;$&#8221;))</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1601">353,903</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1602">326,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-1603">637,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1604">357,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1605">304,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1606">228,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1607">711,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1608">631,103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1609">865,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1610">711,006</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1611">631,103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1612">865,953</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-1613">3,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-1614">48,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-1615">39,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1616">63,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1617">297,856</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1618">1,173,306</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1619">644,383</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1620">879,977</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1621">1,999,674</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-1622">403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1623">1,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1624">4,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1625">644,786</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1626">881,708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1627">2,003,815</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">181</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="srt:CondensedStatementOfComprehensiveIncomeTableTextBlock" id="f-1628" escape="true"><ix:continuation id="f-1599-1" continuedAt="f-1599-2"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BeiGene, Ltd.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Information of Parent Company</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Comprehensive Loss</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollars (&#8220;$&#8221;))</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:58.458%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1629">644,786</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1630">881,708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1631">2,003,815</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax of nil:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1632">47,565</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1633">25,464</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1634">90,421</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension liability adjustments, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-3" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1635">1,942</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-1636">5,611</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-1637">365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized holding gain (loss), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-1638">35</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1639">9,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1640">5,311</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1641">694,328</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1642">903,737</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1643">2,099,182</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">182</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="srt:ScheduleOfCondensedBalanceSheetTableTextBlock" id="f-1644" escape="true"><ix:continuation id="f-1599-2" continuedAt="f-1599-3"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BeiGene, Ltd.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Information of Parent Company</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Balance Sheets</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollars (&#8220;$&#8221;))</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:71.640%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.792%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-1645">400,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-1646">723,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1647">249,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1648">785,471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1649">649,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1650">1,509,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loans to subsidiaries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1651">1,731,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1652">2,030,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment in wholly owned subsidiaries</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="f-1653">2,081,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-3" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="3" id="f-1654">1,207,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1655">114,728</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1656">69,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1657">4,576,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-1658">4,816,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other payables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1659">424,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1660">197,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indebtedness to subsidiaries</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-3" name="us-gaap:LoansPayableCurrent" format="ixt:fixed-zero" scale="3" id="f-1661">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-3" name="us-gaap:LoansPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1662">362,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1663">762,146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1664">547,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1665">1,186,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1666">1,107,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1667">58,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1668">171,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-1669">1,244,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-1670">1,279,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1671">3,332,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1672">3,537,327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1673">4,576,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-1674">4,816,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">183</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="srt:ScheduleOfCondensedCashFlowStatementTableTextBlock" id="f-1675" escape="true"><ix:continuation id="f-1599-3" continuedAt="f-1599-4"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BeiGene, Ltd.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Information of Parent Company</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Cash Flows</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollars (&#8220;$&#8221;))</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:58.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.540%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.793%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1676">644,786</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1677">881,708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1678">2,003,815</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-3" name="bgne:AcquiredInProcessResearchAndDevelopment" format="ixt:fixed-zero" scale="3" id="f-1679">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" name="bgne:AcquiredInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-1680">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" name="bgne:AcquiredInProcessResearchAndDevelopment" format="ixt:fixed-zero" scale="3" id="f-1681">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of research and development cost share liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-3" sign="-" name="bgne:AmortizationOfResearchAndDevelopmentFinancingLiability" format="ixt:num-dot-decimal" scale="3" id="f-1682">73,226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" sign="-" name="bgne:AmortizationOfResearchAndDevelopmentFinancingLiability" format="ixt:num-dot-decimal" scale="3" id="f-1683">55,294</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" sign="-" name="bgne:AmortizationOfResearchAndDevelopmentFinancingLiability" format="ixt:num-dot-decimal" scale="3" id="f-1684">96,402</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized (gains) losses in subsidiaries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-3" name="bgne:UnrealizedGainLossInSubsidiaries" format="ixt:num-dot-decimal" scale="3" id="f-1685">85,471</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" sign="-" name="bgne:UnrealizedGainLossInSubsidiaries" format="ixt:num-dot-decimal" scale="3" id="f-1686">237,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" sign="-" name="bgne:UnrealizedGainLossInSubsidiaries" format="ixt:num-dot-decimal" scale="3" id="f-1687">932,071</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other items, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" format="ixt:num-dot-decimal" scale="3" id="f-1688">31,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" sign="-" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" format="ixt:num-dot-decimal" scale="3" id="f-1689">374,370</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" sign="-" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" format="ixt:num-dot-decimal" scale="3" id="f-1690">596,496</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-1691">1,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-1692">30,519</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-1693">6,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other payables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1694">627,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1695">140,126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1696">875,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1697">143,472</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1698">1,168,628</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1699">882,145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-3" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:fixed-zero" scale="3" id="f-1700">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-1701">2,075</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-1702">1,485</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale or maturity of short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-1703">2,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-1704">552,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-1705">1,487,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of in-process research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-3" name="bgne:PaymentsToPurchaseInProcessResearchAndDevelopment" format="ixt:fixed-zero" scale="3" id="f-1706">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" name="bgne:PaymentsToPurchaseInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-1707">15,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" name="bgne:PaymentsToPurchaseInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-1708">75,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment in subsidiaries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-3" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" format="ixt:num-dot-decimal" scale="3" id="f-1709">406,624</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" format="ixt:num-dot-decimal" scale="3" id="f-1710">883,328</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" name="us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates" format="ixt:num-dot-decimal" scale="3" id="f-1711">2,675,908</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-3" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1712">37,120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1713">188,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1714">79,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1715">441,116</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1716">159,747</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1717">1,186,361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from short-term loans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-3" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1718">813,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1719">547,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1720">296,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of short-term loans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-3" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1721">593,898</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1722">293,002</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1723">247,460</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from option exercises and employee share purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="f-1724">45,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="f-1725">55,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="f-1726">46,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1727">264,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1728">310,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-1729">95,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of foreign exchange rate changes, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1730">4,356</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-1731">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-1732">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents, and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-1733">324,413</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-1734">1,017,823</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-1735">1,972,813</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash, beginning of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1736">724,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-445" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1737">1,742,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-446" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1738">3,715,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash, cash equivalents, and restricted cash, end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1739">400,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1740">724,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-445" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-1741">1,742,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">184</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-1599-4"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes</span></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Schedule I has been provided pursuant to the requirements of Rules 12-04(a) and 5-04(c) of Regulation S-X (the &#8220;Rules&#8221;), which require condensed financial information as to the financial position, changes in financial position and results of operations of a parent company as of the same dates and for the same periods for which audited consolidated financial statements have been presented when the restricted net assets of consolidated subsidiaries exceed 25 percent of consolidated net assets as of the end of the most recently completed fiscal year.</span></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The condensed financial information has been prepared using the same accounting policies as set out in the consolidated financial statements. For purposes of this condensed financial information, BeiGene, Ltd. (the &#8220;Parent Company&#8221;)&#8217;s investments in its wholly owned and majority owned subsidiaries are recorded under the equity method of accounting in accordance with ASC 323.</span></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted as allowed under the Rules. These footnote disclosures provide certain supplemental information relating to the operations of the Company and, as such, these statements should be read in conjunction with the notes to the consolidated financial statements.</span></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">As of December&#160;31, 2024, the Parent Company had a remaining capital commitment of $<ix:nonFraction unitRef="usd" contextRef="c-447" decimals="-3" name="us-gaap:OtherCommitment" format="ixt:num-dot-decimal" scale="3" id="f-1742">7,350</ix:nonFraction> on an equity investment which is expected to be paid from time to time over the investment period. The Parent Company has unconditionally guaranteed the payment and performance of the obligations of BeiGene Switzerland GmbH in accordance with the terms of the global strategic oncology collaboration with Amgen Inc. No amounts have been recognized related to this guarantee. The Parent Company has no other material contingencies, long-term obligations or guarantees not already disclosed in its consolidated financial statements.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">185</span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_172"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;16. Form&#160;10&#8209;K Summary</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">186</span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_262"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;Index</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.576%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed/&#160;Furnished<br/>Herewith</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated&#160;by&#160;Reference<br/>Herein&#160;from&#160;Form&#160;or&#160;Schedule</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SEC File/<br/>Reg.&#160;Number</span></td></tr><tr><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000165130823000085/a20230608formx7thamendedan.htm">Seventh Amended and Restated Memorandum and Articles of Association of the Registrant, as currently in effect</a></span></div></td><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K<br/>(Exhibit 3.1)</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/15/2023</span></td><td colspan="3" style="border-top:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000104746916010119/a2227322zex-4_1.htm">Deposit Agreement dated February&#160;5, 2016 by and among the Company, the Depositary and holders of the American Depositary Receipts</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K<br/>(Exhibit 4.1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/11/2016</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000110465916110814/a16-8198_1ex4d1.htm">Amendment No.&#160;1 to Deposit Agreement, dated April&#160;11, 2016, by and among the Registrant, Citibank, N.A. and holders of the American Depositary Receipts</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K<br/>(Exhibit 4.1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/11/2016</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000110465916138661/a16-11478_1ex4d7.htm">Letter Agreement, dated as of July&#160;11, 2016, between the Registrant and Citibank, N.A.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit 4.7)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/10/2016</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000110465917031586/a17-8817_1ex4d9.htm">Form of Letter Agreement between the Registrant and Citibank, N.A.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit 4.9)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/10/2017</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;of American Depositary Receipt (included in Exhibit&#160;4.1.1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000104746915009132/a2226351zex-4_3.htm">Specimen Certificate for Ordinary Shares</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1<br/>(Exhibit 4.3)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/9/2015</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-207459</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000104746916016775/a2230329zex-4_1.htm">Registration Rights Agreement, dated as of November&#160;16, 2016, by and among the Registrant and the investors named therein</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K<br/>(Exhibit 4.1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/17/2016</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000110465920131624/tm2037225d2_ex10-1.htm">Amendment No. 1 to Registration Rights Agreement, dated December 1, 2020, between the Company and the Investors</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K<br/>(Exhibit 10.1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/2/2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000165130823000068/exhibit103-amendmentno2tor.htm">Amendment No. 2 to Registration Rights Agreement, dated May 3, 2023, between the Company and the Investors</a></span></div><div><span><br/></span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit 10.3)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/4/2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit45-descriptionofsec.htm">Description of the Registrant&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Collaboration, License and Commercial Agreements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000110465917043714/a17-16972_1ex10d1.htm">Share Subscription Agreement, dated July 5, 2017, by and between Celgene Switzerland LLC and the Registrant</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K<br/>(Exhibit 10.1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/6/2017</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2##</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000165130819000079/exhibit101.htm">Letter Agreement, dated June 14, 2019, by and among the Registrant, BeiGene Switzerland GmbH, Celgene Corporation and Celgene Switzerland LLC, to terminate the Amended and Restated Exclusive License and Collaboration Agreement, dated August 31, 2017</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit 10.1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/8/2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.1##</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000165130820000020/exhibit109-sharepurcha.htm">Share Purchase Agreement, dated October 31, 2019, by and between the Registrant and Amgen Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K<br/>(Exhibit 10.9)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/2/2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000165130820000020/exhibit1010-sharepurch.htm">Amendment No. 1 to Share Purchase Agreement, dated December 6, 2019, by and between the Registrant and Amgen Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K<br/>(Exhibit 10.10)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/2/2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000165130820000174/ex101-restatedamendmen.htm">Restated Amendment No. 2 to Share Purchase Agreement, dated September 24, 2020, by and between the Registrant and Amgen Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K<br/>(Exhibit 10.1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/24/2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.576%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed/&#160;Furnished<br/>Herewith</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated&#160;by&#160;Reference<br/>Herein&#160;from&#160;Form&#160;or&#160;Schedule</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SEC File/<br/>Reg.&#160;Number</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000165130823000036/exhibit1044-amendmentno3to.htm">Amendment No. 3 to Share Purchase Agreement, dated January 30, 2023, by and between the Registrant and Amgen Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K<br/>(Exhibit 10.4.4)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/27/2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.1##</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000165130820000020/exhibit1011-collaborat.htm">Collaboration Agreement, dated October 31, 2019, by and among the Registrant, BeiGene Switzerland GmbH and Amgen Inc. </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K<br/>(Exhibit 10.11)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/2/2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.2##</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000165130822000139/a101-firstamendmenttocolla.htm">First Amendment to Collaboration Agreement, dated April 20, 2022, by and among the Registrant, BeiGene Switzerland GmbH and Amgen Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit 10.1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/8/2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.3##</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000165130823000068/exhibit101-secondamendment.htm">Second Amendment to Collaboration Agreement, dated February 26, 2023, by and among the Registrant, BeiGene Switzerland GmbH and Amgen Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit 10.1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/4/2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000165130820000020/exhibit1012-beigenegua.htm">Guarantee, dated October 31, 2019, by and between the Registrant and Amgen Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K<br/>(Exhibit 10.12)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/2/2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Equity and Other Compensation Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000104746915007900/a2226129zex-10_1.htm">2011 Option Plan, as amended and form of option agreements thereunder</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1<br/>(Exhibit 10.1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/16/2015</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-207459</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.1&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000165130824000055/a2024605formx2024agmxex101.htm">Third </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000165130824000055/a2024605formx2024agmxex101.htm">Amended and Restated 2016 Share Option and Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K<br/>(Exhibit 10.1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/5/2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.2&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000165130824000098/exhibit105-psuawardagreeme.htm">Form of Global Performance Share Unit Award Agreement for Employees under the Third Amended and Restated 2016 Share Option and Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit 10.5)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/7/2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.3&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000165130823000127/exhibit105beigene-rsuaward.htm">Form of Global Restricted Share Unit Award Agreement for Non-Employee Directors under the Third Amended and Restated 2016 Share Option and Incentive Plan </a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q <br/>(Exhibit 10.5)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/2/2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.4&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000165130824000098/exhibit106-rsuawardagreeme.htm">Form of Global Restricted Share Unit Award Agreement for Employees under the Third Amended and Restated 2016 Share Option and Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q <br/>(Exhibit 10.6)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/7/2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.5&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000165130824000098/exhibit107-rsuawardagreeme.htm">Form of Global Restricted Share Unit Award Agreement for Consultants under the Third Amended and Restated 2016 Share Option and Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q <br/>(Exhibit 10.7)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/7/2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.6&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000165130824000098/exhibit108-nqshareoptionag.htm">Form of Global Non-Qualified Share Option Agreement for Employees under the Third Amended and Restated 2016 Share Option and Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q <br/>(Exhibit 10.8)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/7/2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.7&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000165130823000127/exhibit109beigene-formofno.htm">Form of Global Non-Qualified Share Option Agreement for Non-Employee Directors under the Third Amended and Restated 2016 Share Option and Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q <br/>(Exhibit 10.9)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/2/2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.8&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000165130824000098/exhibit109-nqshareoptionag.htm">Form of Global Non-Qualified Share Option Agreement for Non-Employee Consultants under the Third Amended and Restated 2016 Share Option and Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q <br/>(Exhibit 10.9)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/7/2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000165130824000055/a2024605formx2024agmxex102.htm">Fourth Amended and Restated 2018 Employee Share Purchase Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K<br/>(Exhibit 10.2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/5/2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000104746916009740/a2227116zex-10_19.htm">Senior Executive Cash Incentive Bonus Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1<br/>(Exhibit 10.19)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/19/2016</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-207459</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000165130824000032/a202403ormxpaoanddirectorc.htm">Independent Director Compensation Policy, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K<br/>(Exhibit 10.1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/20/2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.576%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed/&#160;Furnished<br/>Herewith</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated&#160;by&#160;Reference<br/>Herein&#160;from&#160;Form&#160;or&#160;Schedule</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SEC File/<br/>Reg.&#160;Number</span></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Agreements with Executive Officers and Directors</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000104746916009740/a2227116zex-10_3.htm">Form&#160;of Indemnification Agreement, entered into between the Registrant and its directors and officers</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1<br/>(Exhibit 10.3)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/19/2016</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-207459</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000110465917026347/a17-11751_1ex10d1.htm">Employment Agreement, dated April 25, 2017, by and between the Registrant and John V. Oyler</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K<br/>(Exhibit 10.1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/26/2017</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.1&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000155837018006821/bgne-20180630ex1012a92b2.htm">Executive Employment Agreement, dated April 28, 2018, by and between BeiGene (Beijing) Co., Ltd. and Xiaobin Wu</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit 10.1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/9/2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.2&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000165130823000127/exhibit104aremploymentappo.htm">Amended and Restated Employment Apportionment Agreement, dated June 16, 2023, by and between BeiGene (Beijing) Co., Limited, BeiGene Guangzhou Biologics Manufacturing Co., Ltd., BeiGene Pharmaceutical (Shanghai) Co., Ltd. and Xiaobin Wu</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit 10.4)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/2/2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000165130824000098/exhibit104-juliawangsepara.htm">Separation and Transition Agreement, dated July 17, 2024, by and between the Registrant and Julia Wang</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit 10.4)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/7/2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000165130824000014/exhibit1016-consultingagre.htm">Consulting Agreement, dated December 7, 2023, by and between the Registrant and Xiaodong Wang</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K<br/>(Exhibit 10.16)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/26/2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000165130822000032/exhibit1020-employmentagre.htm">Employment Agreement, dated December 30, 2021, by and between BeiGene (Shanghai) Co., Ltd. and Lai Wang</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K<br/>(Exhibit 10.20)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/28/2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000165130823000127/exhibit103chanlee-offerlet.htm">Offer Letter, dated June 10, 2022, by and between the Registrant and Chan Lee</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit 10.3)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/2/2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000165130824000051/exhibit102-2024consultinga.htm">Consulting Agreement, dated January 23, 2024, by and between the Registrant and Thomas Malley</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit 10.2)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/8/2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000165130824000098/exhibit103-offerletterbyan.htm">Offer Letter, effective July 22, 2024, by and between the Registrant and Aaron Rosenberg</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit 10.3)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/7/2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.576%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed/&#160;Furnished<br/>Herewith</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated&#160;by&#160;Reference<br/>Herein&#160;from&#160;Form&#160;or&#160;Schedule</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SEC File/<br/>Reg.&#160;Number</span></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Agreements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000165130824000164/a20241210formxcmbloanxex10.htm">Facility Agreement, dated as of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000165130824000164/a20241210formxcmbloanxex10.htm">December 9, 2024, by and between the Registrant and China Merchants Bank Co., Ltd.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K<br/>(Exhibit 10.1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/10/2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21##</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000165130823000165/exhibit101.htm">Settlement and Termination Agreement, dated as of August 1, 2023, by and between the Registrant, BeiGene Switzerland GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Celgene Switzerland LLC, Celgene Kappa Holdings LLC, Celgene Holdings East Corporation and Celgene Logistics S&#224;rl</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q<br/>(Exhibit 10.1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/9/2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22##</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000165130824000014/exhibit1021bmssettlementag.htm">First Amendment to the Settlement and Termination Agreement, dated as of January 10, 2024, by and between the Registrant, BeiGene Switzerland GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Celgene Switzerland LLC, Celgene Kappa Holdings LLC, Celgene Holdings East Corporation and Celgene Logistics S&#224;rl</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K<br/>(Exhibit 10.21)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/26/2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1023beigenebms-sett.htm">Second Amendment to the Settlement and Termination Agreement, dated as of December 4, 2024, by and between the Registrant, BeiGene Switzerland GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Celgene Switzerland LLC, Celgene Kappa Holdings LLC, Celgene Holdings East Corporation and Celgene Logistics S&#224;rl</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000165130824000014/exhibit191-insidertradingp.htm"><ix:nonNumeric contextRef="c-1" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true" id="f-1743">Insider Trading Policy</ix:nonNumeric></a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K<br/>(Exhibit 19.1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/26/2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit192-beigenespecialt.htm">Special Trading Procedures for Insiders</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit21-2024q4beigeneltd.htm">List of Subsidiaries of the Registrant</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit231-2024q4.htm">Consent of Ernst&#160;&amp; Young LLP</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit311-2024q4.htm">Certification of Principal Executive Officer pursuant to Rule&#160;13a&#8209;14(a)&#160;and Rule&#160;15d&#8209;14(a)&#160;of the Securities Exchange Act of 1934, as adopted pursuant to Section&#160;302 of the Sarbanes&#8209;Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit312-2024q4.htm">Certification of Principal Financial Officer pursuant to Rule&#160;13a&#8209;14(a)&#160;and Rule&#160;15d&#8209;14(a)&#160;of the Securities Exchange Act of 1934, as adopted pursuant to Section&#160;302 of the Sarbanes&#8209;Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit321-2024q4.htm">Certification of Principal Executive Officer and Principle Financial Officer pursuant to 18&#160;U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes&#8209;Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1651308/000165130824000014/exhibit97-compensationreco.htm">Compensation Recovery Policy</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K<br/>(Exhibit 97)</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/26/2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-37686</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit991-disclosureforei.htm">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document - the instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.576%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed/&#160;Furnished<br/>Herewith</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated&#160;by&#160;Reference<br/>Herein&#160;from&#160;Form&#160;or&#160;Schedule</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td><td colspan="3" style="border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SEC File/<br/>Reg.&#160;Number</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.*)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;     Indicates a management contract or any compensatory plan, contract or arrangement.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">##&#160;&#160;&#160;&#160;Certain portions of the exhibit have been omitted by means of redacting a portion of the text and replacing it with &#8220;[*]&#8221;, because they are both (i) not material and (ii) the type of information that the Registrant treats as private or confidential.</span></div><div style="margin-bottom:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13pt">Furnished herewith.</span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="margin-bottom:10pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ic94bd2152a214042a118e81881a5a1e5_265"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934, the Registrant has duly caused this Form&#160;10&#8209;K to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:38.138%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:55.563%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">BEIGENE,&#160;LTD.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 27, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ JOHN V. OYLER</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John V. Oyler</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer and Chairman</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr></table></div><div style="text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic94bd2152a214042a118e81881a5a1e5_7">Table of Contents</a></span></div></div><div style="margin-bottom:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each person whose individual signature appears below hereby authorizes and appoints John V. Oyler, Aaron Rosenberg, and Chan Lee, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney&#8209;in&#8209;fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this Annual Report on Form&#160;10&#8209;K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys&#8209;in&#8209;fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys&#8209;in&#8209;fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.</span></div><div style="margin-bottom:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form&#160;10&#8209;K has been signed by the following persons in the capacities indicated below and on the dates indicated:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.920%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.253%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:30pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ JOHN V. OYLER</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Chairman</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2025</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John V. Oyler</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ AARON ROSENBERG</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aaron Rosenberg</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ OLIVIER BRANDICOURT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Olivier Brandicourt</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ MARGARET DUGAN</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Margaret Dugan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ MICHAEL GOLLER</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael Goller</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ ANTHONY C. HOOPER</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthony C. Hooper</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ RANJEEV KRISHANA</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ranjeev Krishana</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ ALESSANDRO RIVA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alessandro Riva</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ CORAZON (CORSEE) D. SANDERS</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corazon (Corsee) D. Sanders</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ SHALINI SHARP </span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shalini Sharp </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ XIAODONG WANG</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Xiaodong Wang</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ QINGQING YI</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Qingqing Yi</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.5
<SEQUENCE>2
<FILENAME>exhibit45-descriptionofsec.htm
<DESCRIPTION>EX-4.5
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ia34ad2d0171b45e6972a2dd7be734222_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 4.5</font></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="margin-bottom:8pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following description of our share capital is a summary and does not purport to be complete. It is subject to and qualified in its entirety by reference to our seventh amended and restated memorandum and articles of association (as amended or amended and restated, &#8220;our articles&#8221;), which is incorporated by reference as an exhibit to the Annual Report on Form 10-K. The terms &#8220;we,&#8221; &#8220;our,&#8221; and &#8220;us&#8221; refer solely to BeiGene, Ltd. and not its subsidiaries.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ordinary Shares</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an exempted company incorporated in the Cayman Islands with limited liability and our affairs are governed by our articles, the Companies Act (as amended) of the Cayman Islands (the &#8220;Cayman Companies Act&#8221;) and the common law of the Cayman Islands.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February 24, 2025, our authorized share capital was $1,000,000 divided into (i) 9,500,000,000 ordinary shares of a par value of $0.0001 each and (ii) 500,000,000 shares of a par value of $0.0001 each of such class or classes (howsoever designated) as the board of directors may determine.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our articles were adopted by special resolution passed on June 16, 2021 with effect from the listing of our ordinary shares traded in Renminbi (the &#8220;RMB Shares&#8221;) on the Science and Technology Innovation Board (the &#8220;STAR Market&#8221;) of the Shanghai Stock Exchange (the &#8220;SSE&#8221;) on December 15, 2021. The following are summaries of material provisions of our articles and the Cayman Companies Act insofar as they relate to the material terms of our ordinary shares. Under our articles, our name is BeiGene, Ltd.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion primarily concerns ordinary shares and the rights of holders of ordinary shares. The holders of American Depositary Shares (&#8220;ADSs&#8221;) are not treated as our shareholders and will be required to surrender their ADSs for cancellation and withdrawal from the depositary facility in which the ordinary shares are held in accordance with the provisions of the deposit agreement, as amended, in order to exercise directly shareholders&#8217; rights in respect of the ordinary shares. The depositary has agreed, so far as it is practical, to vote or cause to be voted the amount of ordinary shares represented by ADSs in accordance with the written instructions of the holders of such ADSs. See &#8220;Description of American Depositary Shares&#8212;Voting Rights.&#8221;</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ordinary shares are listed on The Stock Exchange of Hong Kong Limited (the &#8220;HKEx&#8221;) under the stock code &#8220;06160&#8221;. Our ADSs representing our ordinary shares are listed on the NASDAQ Global Select Market (the &#8220;NASDAQ&#8221;) under the symbol &#8220;ONC&#8221;. Our RMB Shares are listed on the STAR Market of the SSE under the stock code &#8220;688235&#8221;.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General</font></div><div style="margin-bottom:8pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our issued and outstanding ordinary shares are fully paid and non-assessable. Our ordinary shares are issued in registered form and are issued when registered in our registers of members. Each holder of our ordinary shares will be entitled to receive a certificate in respect of such ordinary shares if our directors resolve that share certificates shall be issued. Our shareholders who are non-residents of the Cayman Islands may freely hold and vote their ordinary shares. We may not issue shares to bearer.</font></div><div style="margin-bottom:8pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our registers of members holding ordinary shares (other than the RMB Shares) are maintained by our principal share registrar, Mourant Governance Services (Cayman) Limited, in the Cayman Islands, and by our Hong Kong share registrar, Computershare Hong Kong Investor Services Limited, in Hong Kong, respectively. Our register of members holding RMB Shares are maintained by China Securities Depository and Clearing Corporation Limited in China.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:134%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the RMB Shares are of the same class and have the same rights as our ordinary shares listed on the HKEx, the RMB Shares are not fungible with our ordinary shares listed on the HKEx or our ADSs representing our ordinary shares listed on the NASDAQ, and in no event will any RMB Shares be able to be converted into our ordinary shares listed on the HKEx or our ADSs listed on NASDAQ, or vice versa.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of our ordinary shares are entitled to such dividends as may be declared by our board of directors. In addition, our shareholders may by ordinary resolution declare a dividend, but no dividend may exceed the amount recommended by our directors. Under the Cayman Companies Act, a Cayman Islands company may pay a dividend out of either profit or share premium account, provided that in no circumstances may a dividend be paid if this would result in the company being unable to pay its debts as they fall due in the ordinary course of business.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voting Rights</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each ordinary share is entitled to one vote on all matters upon which the ordinary shares are entitled to vote.</font></div><div style="margin-bottom:8pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Voting at any meeting of shareholders is by poll.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An ordinary resolution to be passed by the shareholders requires the affirmative vote of a simple majority of the votes cast by the shareholders entitled to vote who are present in person or by proxy at a general meeting, while a special resolution requires the affirmative vote of at least two-thirds of the votes cast by the shareholders entitled to vote who are present in person or by proxy at a general meeting (except for certain types of winding up of the company, in which case the required majority to pass a special resolution shall be 100%). Both ordinary resolutions and special resolutions may also be passed by a unanimous written resolution signed by all the shareholders of our company, as permitted by the Cayman Companies Act and our articles. A special resolution is required for important matters such as a change of name and amendments to our articles. Our shareholders may effect certain changes by ordinary resolution, including increasing the amount of our authorized share capital, consolidating and dividing all or any of our share capital into shares of larger amounts than our existing shares and cancelling any authorized but unissued shares.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transfer of Ordinary Shares</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the restrictions contained in our articles, any of our shareholders may transfer all or any of his or her ordinary shares by an instrument of transfer in any usual or common form or any other form approved by our board of directors, executed by or on behalf of the transferor (and, if in respect of a nil or partly paid-up share, or if so required by our directors, by or on behalf of the transferee). Notwithstanding the foregoing, transfer of any ordinary shares through electronic transfer as recognized by the Designated Stock Exchanges (as defined in our articles) shall be deemed to satisfy the requirement for form of instrument of transfer.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors may, in its absolute discretion, decline to register any transfer of any ordinary share that has not been fully paid up or is subject to a company lien. Our board of directors may also decline to register any transfer of any ordinary share unless&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the instrument of transfer is lodged with us, accompanied by the certificate (if any) for the ordinary shares to which it relates and such other evidence as our board of directors may reasonably require to show the right of the transferor to make the transfer&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the instrument of transfer is in respect of only one class of shares&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the instrument of transfer is properly stamped, if required&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ordinary share transferred is fully paid and free of any lien in favor of us&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any fee related to the transfer has been paid to us&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the transfer is not to more than four joint holders&#59; and</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any applicable fee of such maximum sum as the Designated Stock Exchanges may determine to be payable, or such lesser sum as our board may from time to time require, related to the transfer is paid to us.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our directors refuse to register a transfer, they are required, within three months after the date on which the instrument of transfer was lodged, to send to each of the transferor and the transferee notice of such refusal.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:134%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidation</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a winding up of our company, if the assets available for distribution among the holders of our ordinary shares shall be more than sufficient to repay the whole of the share capital at the commencement of the winding up, the surplus will be distributed among the holders of our ordinary shares on a pro rata basis in proportion to the par value of the ordinary shares held by them. If our assets available for distribution are insufficient to repay all of the paid-up capital, the assets will be distributed so that the losses are borne by the holders of our ordinary shares in proportion to the par value of the ordinary shares held by them.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The liquidator may, with the sanction of a special resolution of our shareholders and any other sanction required by the Cayman Companies Act, divide amongst the shareholders in specie or in kind the whole or any part of the assets of our company, and may for that purpose value any assets and determine how the division shall be carried out as between our shareholders or different classes of shareholders.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we are a &#8220;limited liability&#8221; company registered under the Cayman Companies Act, the liability of our shareholders is limited to the amount, if any, unpaid on the shares respectively held by them. Our articles contain a declaration that the liability of our shareholders is so limited.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Calls on Ordinary Shares and Forfeiture of Ordinary Shares</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors may from time to time make calls upon shareholders for any amounts unpaid on their ordinary shares. The ordinary shares that have been called upon and remain unpaid are subject to forfeiture by the company. In addition, the holders of partly paid ordinary shares will have no right pursuant to the Cayman Companies Act to dividends nor will they be able to redeem their shares.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redemption, Repurchase and Surrender of Ordinary Shares</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may issue shares on terms that such shares are subject to redemption, at our option or at the option of the holders thereof, on such terms and in such manner as may be determined by our board of directors. We may also repurchase any of our shares provided that the manner and terms of such purchase have been approved by our board of directors or by ordinary resolution of our shareholders (but no repurchase may be made contrary to the terms or manner recommended by our directors), or as otherwise authorized by our articles. Under the Cayman Companies Act, the redemption or repurchase of any share may be paid out of our company&#8217;s profits or out of the proceeds of a new issue of shares made for the purpose of such redemption or repurchase, or out of capital (including share premium account and capital redemption reserve) if our company can, immediately following such payment, pay its debts as they fall due in the ordinary course of business. In addition, under the Cayman Companies Act no such share may be redeemed or repurchased (1) unless it is fully paid up, (2) if such redemption or repurchase would result in there being no shares outstanding or (3) if the company has commenced liquidation. In addition, our company may accept the surrender of any fully paid share for no consideration.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variations of Rights of Shares</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If at any time our share capital is divided into different classes of shares, all or any of the rights attached to any class of shares may be varied with the consent in writing of the holders of two-thirds of the issued shares of that class or with the sanction of a special resolution passed at a general meeting of the holders of the shares of that class. The rights conferred upon the holders of the shares of any class issued with preferred or other rights will not, unless otherwise expressly provided by the terms of issue of the shares of that class, be deemed to be varied by the creation or issue of further shares ranking&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pari passu</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;with such existing class of shares.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding the foregoing, our board of directors may issue preferred shares, without further action by the shareholders. See &#8220;&#8212; Differences in Corporate Law&#8212;Directors&#8217; Power to Issue Shares&#8221;.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:134%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General Meetings of Shareholders</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shareholders&#8217; meetings may be convened by a majority of our board of directors or our chairman. As a Cayman Islands exempted company, we are not obligated by the Cayman Companies Act to call shareholders&#8217; annual general meetings&#59; however, our corporate governance guidelines provide that we will hold an annual general meeting of shareholders every year to the extent required by the applicable listing rules. The annual general meeting shall be held at such time and place as may be determined by our board of directors.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our articles also permit our board of directors to hold any general meetings as (a) a physical meeting at a location (the &#8220;principal meeting place&#8221;) in any part of the world&#59; (b) a hybrid meeting at which shareholders and&#47;or their proxies attend by (i) physical attendance at the principal meeting place and (ii) means of electronic facilities&#59; or (c) an electronic meeting at which the shareholders and&#47;or their proxies attend solely by means of electronic facilities. If our board of directors determines to hold a general meeting as a hybrid or electronic meeting, participation in any such general meeting by electronic facilities shall be deemed to constitute presence in person at the meeting. To the extent required by the Designated Stock Exchange Rules (as defined in our articles) as applicable from time to time the Company shall facilitate holders of RMB Shares to attend a general meeting through an online voting platform, and such attendance by such holders shall be deemed to constitute a presence in person at the meeting.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cayman Companies Act provides shareholders with only limited rights to requisition a general meeting, and does not provide shareholders with any right to put any proposal before a general meeting. However, these rights may be provided in a company&#8217;s articles of association. Our articles provide that upon the requisition of shareholders representing not less than one-tenth of the voting rights entitled to vote at general meetings, our board will convene an extraordinary general meeting and put the resolutions so requisitioned to a vote at such meeting. However, shareholders may propose only ordinary resolutions to be put to a vote at such meeting. Our articles provide no other right for our shareholders to put any proposals before annual general meetings or extraordinary general meetings.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advance notice of at least 21 calendar days is required for the convening of any annual general meeting of our shareholders and advance notice of at least 14 calendar days is required for the convening of any other general meeting of our shareholders (including any extraordinary general meeting). All general meetings of shareholders shall occur at such time and place as determined by our directors and set forth in the notice for such meeting.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quorum required for a general meeting of shareholders at which an ordinary resolution has been proposed consists of such shareholders present in person or by proxy who together hold shares which carry the right to at least a simple majority of all votes capable of being exercised on a poll. The quorum required for a general meeting at which a special resolution has been proposed consists of such shareholders present in person or by proxy who together hold shares which carry the right to at least two-thirds of all votes capable of being exercised on a poll.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nomination, Election and Removal of Directors</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our articles provide that persons standing for election as directors at a duly constituted general meeting with requisite quorum shall be elected by an ordinary resolution of our shareholders, which requires the affirmative vote of a simple majority of the votes cast on the resolution by the shareholders entitled to vote who are present in person or by proxy at the meeting. Our articles further provide that our board of directors will be divided into three groups designated as Class I, Class II and Class III with as nearly equal a number of directors in each group as possible, with each director serving a three-year term and until his or her successor is duly elected and qualified, subject to his or her earlier resignation or removal.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the expiration of the term of each class, each director in that class, if nominated by the board of directors, shall be eligible for re-election at the annual general meeting to hold office for another three-year term and until such director&#8217;s successor has been duly elected. Our articles provide that, unless otherwise determined by shareholders in a general meeting, our board of directors will consist of not less than three directors. We have no provisions relating to retirement of directors upon reaching any age limit.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:134%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of a vacancy arising from the resignation of a director or as an addition to the existing board of directors, our board may, by the affirmative vote of a simple majority of the remaining directors present and voting at a board meeting, appoint any person to be a director, unless the board resolves to follow any available exceptions or exemptions.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For so long as our ordinary shares or ADSs are listed on the Designated Stock Exchanges, our directors are required to comply with the director nomination procedures required under the Designated Stock Exchange Rules, and our board of directors is required to include at least such number of independent directors as required by the Designated Stock Exchange Rules.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board shall have a chairman who has been elected and appointed by a majority of the directors then in office. The period for which our chairman holds office shall also be determined by a majority of all of our directors then in office. Our chairman shall preside as chairman at every meeting of our board. To the extent that our chairman is not present at a meeting of our board within 15 minutes after the time appointed for holding the same, the remaining attending directors may choose one of their number to be the chairman of that meeting.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our directors shall be elected by an ordinary resolution of the holders of ordinary shares at each annual general meeting of the company to fill the seats of those directors whose terms expire at such annual general meeting.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of our directors shall hold office until his or her successor is duly elected or appointed or his or her earlier resignation or removal, notwithstanding any agreement between the company and the director. Our directors may be removed at any time by an affirmative vote of a simple majority of the issued shares as of the applicable record date, with or without cause.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors may, from time to time, and except as required by applicable law or applicable listing rules, adopt, institute, amend, modify or revoke any of our corporate governance policies or initiatives of the company, which shall be intended to set forth the guiding principles and policies of the company and our board on various corporate governance related matters as the board shall determine by resolution from time to time.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proceedings of Board of Directors</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our articles provide that our business is to be managed and conducted by our board of directors. The quorum necessary for a board meeting may be fixed by the board and, unless so fixed at another number, will be a majority of the directors.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our articles provide that the board may from time to time at its discretion exercise all powers of our company to raise capital or borrow money, to mortgage or charge all or any part of the undertaking, property and assets (present and future) and uncalled capital of our company and, subject to the Cayman Companies Act, issue debentures, bonds and other securities of our company, whether outright or as collateral security for any debt, liability or obligation of our company or of any third party.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inspection of Books and Records</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of our ordinary shares will have no general right under the Cayman Companies Act to inspect or obtain copies of our list of shareholders or our corporate records provided that they are entitled to a copy of our articles.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Capital</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our shareholders may from time to time by ordinary resolution&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increase the share capital by such sum, to be divided into shares of such classes and amount, as the resolution shall prescribe&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">consolidate and divide all or any of our share capital into shares of a larger amount than our existing shares&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sub-divide our existing shares, or any of them into shares of a smaller amount, provided that in the subdivision the proportion between the amount paid and the amount, if any, unpaid on each reduced share shall be the same as it was in case of the share from which the reduced share is derived&#59; or</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cancel any shares which, at the date of the passing of the resolution, have not been taken or agreed to be taken by any person and diminish the amount of our share capital by the amount of the shares so cancelled.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:134%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our shareholders may by special resolution, subject to any confirmation or consent required by the Cayman Companies Act, reduce our share capital or any capital redemption reserve in any manner permitted by law.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restrictive Provisions</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our articles, in connection with any change of control, merger or sale of our company, the holders of our ordinary shares shall receive the same consideration with respect to their ordinary shares in connection with any such transaction.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Claims Against the Company</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our articles provide that, unless otherwise determined by a simple majority of our board of directors in its sole discretion, consistent with the directors&#8217; fiduciary duties to act in the best interests of the company, in the event that (1) any shareholder (the claiming party) initiates or asserts any claim or counterclaim or joins, offers substantial assistance to or has a direct financial interest in any claim against our company and (2) the claiming party (or the third party that received substantial assistance from the claiming party or in whose claim the claiming party had a direct financial interest) does not obtain a judgment on the merits in which the claiming party prevails, then each claiming party shall, to the fullest extent permissible by law, be obligated jointly and severally to reimburse us for all fees, costs and expenses (including, but not limited to, all reasonable attorneys&#8217; fees and other litigation expenses) that we may incur in connection with such claim.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exclusive Forum</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our articles provide that, subject to limited exceptions, the courts of Cayman Islands will be the sole and exclusive forum for (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our shareholders, (3) any action asserting a claim against us arising pursuant to any provision of the Cayman Companies Act or our articles, or (4) any other action asserting a claim against us that is governed by the internal affairs doctrine (as such concept is recognized under the laws of the United States). Any person or entity purchasing or otherwise acquiring any interest in our share capital shall be deemed to have notice of and to have consented to the provisions of our articles described above. Although we believe these provisions benefit us by providing increased consistency in the application of Cayman Islands law for the specified types of actions and proceedings, the provisions may have the effect of discouraging lawsuits against our directors and officers. It is possible that, in connection with one or more actions or proceedings described above, a court could find the choice of forum provisions contained in our articles to be inapplicable or unenforceable.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our articles further provide that, unless the Company consents in writing to the selection of an alternative forum, the federal district courts of the United States shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;).</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the initial public offering of our RMB Shares to permitted investors in the People&#8217;s Republic of China (the &#8220;PRC&#8221;) and the listing of our RMB Shares on the STAR Market of the SSE (the &#8220;STAR Offering&#8221;), we and each of our directors and executive officers signed letters of undertaking to (i) confirm and acknowledge that any legal suits, actions or proceedings against us and&#47;or our directors and officers arising from the STAR Offering and the listing of the RMB Shares on the STAR Market during the period when our RMB Shares are listed on the STAR Market (collectively, the &#8220;RMB Share Disputes&#8221;) shall be governed by the laws of the PRC and subject to the jurisdiction of competent courts in the PRC if such RMB Share Disputes are instituted in competent courts in the PRC, and (ii) undertake that we and our directors and officers waive any objections that we may have to the jurisdiction of such courts over the RMB Share Disputes or the application of PRC laws by such courts to the RMB Share Disputes.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:134%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exempted Company</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an exempted company with limited liability incorporated under the Cayman Companies Act. The Cayman Companies Act distinguishes between ordinary resident companies and exempted companies. Any company that is registered in the Cayman Islands but conducts business mainly outside of the Cayman Islands may apply to be registered as an exempted company. The requirements for an exempted company are essentially the same as for an ordinary company except for the exemptions and privileges listed below&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an exempted company does not have to file an annual return of its shareholders with the Registrar of Companies&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an exempted company&#8217;s register of members is not open to inspection&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an exempted company does not have to hold an annual general meeting&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an exempted company may issue no par value, negotiable or bearer shares&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an exempted company may obtain an undertaking against the imposition of any future taxation (such undertakings are usually given for 20 years in the first instance)&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an exempted company may register by way of continuation in another jurisdiction and be deregistered in the Cayman Islands&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an exempted company may register as a limited duration company&#59; and</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an exempted company may register as a segregated portfolio company.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Limited liability&#8221; means that the liability of each shareholder is limited to the amount unpaid by the shareholder on the shares of the company.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to reporting and other informational requirements of the Securities Exchange Act of 1934, as amended, as applicable to U.S. domestic issuers. The applicable listing rules require that every company listed on the applicable stock exchange hold an annual general meeting of shareholders. In addition, our articles allow directors to call an extraordinary general meeting of shareholders pursuant to the procedures set forth in our articles.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Register of Members</font></div><div style="margin-bottom:8pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Cayman Companies Act, we must keep a register of members and there should be entered therein&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the names and addresses of our members and a statement of the shares held by each member that distinguishes each share by its number (if applicable), confirms the amount paid or agreed to be considered as paid on the shares of each member, confirms the number and category of shares held by each member and confirms whether each relevant category of shares held by a member carries voting rights under the articles and, if so, whether such voting rights are conditional&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the date on which the name of any person was entered on the register as a member&#59; and</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the date on which any person ceased to be a member.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Cayman Companies Act, the register of members of our company is prima facie evidence of the matters set out in the register (that is, the register of members will raise a presumption of fact on the matters referred to above unless rebutted) and a member registered in the register of members is deemed as a matter of Cayman Companies Act to have legal title to the shares as set against its name in the register of members. Once our register of members has been updated, the shareholders recorded in the register of members will be deemed to have legal title to the shares set against their names.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the name of any person is incorrectly entered or omitted from our register of members, or if there is any default or unnecessary delay in entering on the register the fact of any person having ceased to be a member of our company, the person or member aggrieved (or any member of our company or our company itself) may apply to the Grand Court of the Cayman Islands for an order that the register be rectified, and the Court may either refuse such application or it may, if satisfied of the justice of the case, make an order for the rectification of the register.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:134%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Differences in Corporate Law</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cayman Companies Act is derived, to a large extent, from the older Companies Acts of England and Wales but does not follow recent United Kingdom statutory enactments, and accordingly there are significant differences between the Cayman Companies Act and the current Companies Act 2006 of United Kingdom. In addition, the Cayman Companies Act differs from laws applicable to United States corporations and their shareholders. Set forth below is a summary of certain significant differences between the provisions of the Cayman Companies Act applicable to us and the comparable laws applicable to companies incorporated in the State of Delaware in the United States.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mergers and Similar Arrangements</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cayman Companies Act permits mergers and consolidations between Cayman Islands companies and between Cayman Islands companies and non-Cayman Islands companies. For these purposes, (1) &#8220;merger&#8221; means the merging of two or more constituent companies and the vesting of their undertaking, property and liabilities in one of such companies as the surviving company, and (2) a &#8220;consolidation&#8221; means the combination of two or more constituent companies into a consolidated company and the vesting of the undertaking, property and liabilities of such companies to the consolidated company. In order to effect such a merger or consolidation, the directors of each constituent company must approve a written plan of merger or consolidation, which must then be authorized by (1) a special resolution of the shareholders of each constituent company, and (2) such other authorization, if any, as may be specified in such constituent company&#8217;s articles of association.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The plan must be filed with the Registrar of Companies together with a declaration as to the solvency of the consolidated or surviving company, a list of the assets and liabilities of each constituent company and an undertaking that a copy of the certificate of merger or consolidation will be given to the members and creditors of each constituent company and that notification of the merger or consolidation will be published in the Cayman Islands Gazette. Court approval is not required for a merger or consolidation effected in compliance with these statutory procedures.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A merger between a Cayman parent company and its Cayman subsidiary or subsidiaries does not require authorization by a resolution of shareholders. For this purpose a subsidiary is a company of which at least 90% of the issued shares entitled to vote are owned by the parent company.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consent of each holder of a fixed or floating security interest of a constituent company is required unless this requirement is waived by a court in the Cayman Islands.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except in certain limited circumstances, a dissenting shareholder of a Cayman Islands constituent company is entitled to payment of the fair value of his or her shares upon dissenting from a merger or consolidation. The exercise of such dissenter rights will preclude the exercise by the dissenting shareholder of any other rights to which he or she might otherwise be entitled by virtue of holding shares, except for the right to seek relief on the grounds that the merger or consolidation is void or unlawful.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are statutory provisions that facilitate the reconstruction and amalgamation of companies, provided that the arrangement is approved by a majority in number of each class of shareholders and creditors with whom the arrangement is to be made, and who must, in addition, represent three-fourths in value of each such class of shareholders or creditors, as the case may be, that are present and voting either in person or by proxy at a meeting, or meetings, convened for that purpose. The convening of the meetings and subsequently the arrangement must be sanctioned by the Grand Court of the Cayman Islands. While a dissenting shareholder has the right to express to the court the view that the transaction ought not to be approved, the court can be expected to approve the arrangement if it determines that&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the statutory provisions as to the required majority vote have been met&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the shareholders have been fairly represented at the meeting in question and the statutory majority are acting bona fide without coercion of the minority to promote interests adverse to those of the class&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the arrangement is such that may be reasonably approved by an intelligent and honest man or woman of that class acting in respect of his or her interest&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:134%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the arrangement is not one that would more properly be sanctioned under some other provision of the Cayman Companies Act.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When a takeover offer is made and accepted by holders of 90% of the shares affected within four months the offeror may, within a two-month period commencing on the expiration of such four-month period, require the holders of the remaining shares to transfer such shares on the terms of the offer. An objection can be made to the Grand Court of the Cayman Islands but this is unlikely to succeed in the case of an offer which has been so approved unless there is evidence of fraud, bad faith or collusion.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an arrangement and reconstruction is thus approved, or if a takeover offer is made and accepted, a dissenting shareholder would have no rights comparable to appraisal rights, which would otherwise ordinarily be available to dissenting shareholders of Delaware corporations, providing rights to receive payment in cash for the judicially determined value of the shares.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholders&#8217; Suits</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In principle, we will normally be the proper plaintiff to sue for a wrong done to us as a company, and as a general rule, a derivative action may not be brought by a minority shareholder. However, based on English law authorities, which would in all likelihood be of persuasive authority in the Cayman Islands, the Cayman Islands courts can be expected to follow and apply the common law principles (namely the rule in&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foss v. Harbottle</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;and the exceptions thereto) so that a non-controlling shareholder may be permitted to commence a class action against or derivative actions in the name of the company to challenge&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an act that is illegal or ultra vires with respect to the company and is therefore incapable of ratification by the shareholders&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an act that, although not ultra vires, requires authorization by a qualified (or special) majority (that is, more than a simple majority) that has not been obtained&#59; and</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an act that constitutes a &#8220;fraud on the minority&#8221; where the wrongdoers are themselves in control of the company.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indemnification of Directors and Executive Officers and Limitation of Liability</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cayman Companies Act does not limit the extent to which a company&#8217;s articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against civil fraud or the consequences of committing a crime. Our articles provide that we shall indemnify our officers and directors against all actions, proceedings, costs, charges, expenses, losses, damages or liabilities incurred or sustained by such directors or officer, other than by reason of such person&#8217;s dishonesty, willful default or fraud, in or about the conduct of our company&#8217;s business or affairs (including as a result of any mistake of judgment) or in the execution or discharge of his or her duties, powers, authorities or discretions, including without prejudice to the generality of the foregoing, any costs, expenses, losses or liabilities incurred by such director or officer in defending (whether successfully or otherwise) any civil proceedings concerning our company or its affairs in any court whether in the Cayman Islands or elsewhere. This standard of conduct is generally the same as permitted under the Delaware General Corporation Law for a Delaware corporation. In addition, we intend to enter into indemnification agreements with our directors and executive officers that will provide such persons with additional indemnification beyond that provided in our articles.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers or persons controlling us under the foregoing provisions, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Anti-Takeover Provisions in Our Articles</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some provisions of our articles may discourage, delay or prevent a change in control of our company or management that shareholders may consider favorable, including limitations on shareholder rights to nominate or remove directors, as well as provisions that authorize our board of directors to issue preferred shares in one or more </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:134%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">series and to designate the price, rights, preferences, privileges and restrictions of such preferred shares without any further vote or action by our shareholders.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Cayman Companies Act, our directors may only exercise the rights and powers granted to them under our articles, as amended and restated from time to time, for what they believe in good faith to be in the best interests of our company and for a proper purpose.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Directors&#8217; Fiduciary Duties</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Delaware corporate law, a director of a Delaware corporation has a fiduciary duty to the corporation and its shareholders. This duty has two components&#58; the duty of care and the duty of loyalty. The duty of care requires that a director act in good faith, with the care that an ordinarily prudent person would exercise under similar circumstances. Under this duty, a director must inform himself or herself of, and disclose to shareholders, all material information reasonably available regarding a significant transaction. The duty of loyalty requires that a director act in a manner he or she reasonably believes to be in the best interests of the corporation. He or she must not use his or her corporate position for personal gain or advantage. This duty prohibits self-dealing by a director and mandates that the best interests of the corporation and its shareholders take precedence over any interest possessed by a director, officer or controlling shareholder and not shared by the shareholders generally. In general, actions of a director are presumed to have been made on an informed basis, in good faith and in the honest belief that the action taken was in the best interests of the corporation. However, this presumption may be rebutted by evidence of a breach of one of the fiduciary duties. Should such evidence be presented concerning a transaction by a director, a director must prove the transaction was procedurally fair and provided fair value to the corporation.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a matter of Cayman law, a director of a Cayman Islands company is in the position of a fiduciary with respect to the company and therefore owes the following duties to the company&#8212;a duty to act bona fide in the best interests of the company, a duty not to make a profit based on his or her position as director (unless the company permits him or her to do so), a duty not to put himself or herself in a position where the interests of the company conflict with his or her personal interest or his or her duty to a third party, and a duty to exercise powers for the purpose for which such powers were intended. A director of a Cayman Islands company owes to the company a duty to act with skill and care. It was previously considered that a director need not exhibit in the performance of his or her duties a greater degree of skill than may reasonably be expected from a person of his or her knowledge and experience. However, English and Commonwealth courts have moved towards an objective standard with regard to the required skill and care, and these authorities are likely to be followed in the Cayman Islands.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Shareholder Proposals</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Delaware General Corporation Law, a shareholder has the right to put any proposal before the annual meeting of shareholders, provided it complies with the notice provisions in the governing documents. The Delaware General Corporation Law does not provide shareholders an express right to put any proposal before the annual meeting of shareholders, but in keeping with common law, Delaware corporations generally afford shareholders an opportunity to make proposals and nominations provided that they comply with the notice provisions in the certificate of incorporation or bylaws. A special meeting may be called by the board of directors or any other person authorized to do so in the governing documents, but shareholders may be precluded from calling special meetings.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cayman Companies Act provides shareholders with only limited rights to requisition a general meeting, and does not provide shareholders with any right to put any proposal before a general meeting. However, these rights may be provided in a company&#8217;s articles of association. Our articles allow our shareholders holding not less than one-tenth of the voting rights entitled to vote at general meetings to requisition an extraordinary general meeting of our shareholders, in which case our board is obliged to convene an extraordinary general meeting and to put the resolutions so requisitioned to a vote at such meeting. However, our shareholders may propose only ordinary resolutions to be put to a vote at such meetings. Our articles provide no other right to put any proposals before annual general meetings or extraordinary general meetings. As a Cayman Islands exempted company, we are not obligated by law to call shareholders&#8217; annual general meetings.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, our corporate governance guidelines require us to call such meetings every year to the extent required by the applicable listing rules.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:134%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cumulative Voting</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Delaware General Corporation Law, cumulative voting for elections of directors is not permitted unless the corporation&#8217;s certificate of incorporation specifically provides for it. Cumulative voting potentially facilitates the representation of minority shareholders on a board of directors since it permits the minority shareholder to cast all the votes to which the shareholder is entitled on a single director, which increases the shareholder&#8217;s voting power with respect to electing such director. As permitted under the Cayman Companies Act, our articles do not provide for cumulative voting. As a result, our shareholders are not afforded any less protections or rights on this issue than shareholders of a Delaware corporation.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Removal of Directors</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Delaware General Corporation Law, a director of a corporation with a classified board may be removed only for cause with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise. Under our articles, any director may be removed by an affirmative vote of a simple majority of the issued shares as of the applicable record date, with or without cause.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transactions with Interested Shareholders</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Delaware General Corporation Law contains a business combination statute applicable to Delaware public corporations whereby, unless the corporation has specifically elected not to be governed by such statute by amendment to its certificate of incorporation or bylaws that is approved by its shareholders, it is prohibited from engaging in certain business combinations with an &#8220;interested shareholder&#8221; for three years following the date that such person becomes an interested shareholder. An interested shareholder generally is a person or a group who or which owns or owned 15% or more of the target&#8217;s outstanding voting stock or who or which is an affiliate or associate of the corporation and owned 15% or more of the corporation&#8217;s outstanding voting stock within the past three years. This has the effect of limiting the ability of a potential acquirer to make a two-tiered bid for the target in which all shareholders would not be treated equally. The statute does not apply if, among other things, prior to the date on which such shareholder becomes an interested shareholder, the board of directors approves either the business combination or the transaction which resulted in the person becoming an interested shareholder. This encourages any potential acquirer of a Delaware corporation to negotiate the terms of any acquisition transaction with the target&#8217;s board of directors.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Cayman Companies Act has no comparable statute. As a result, we cannot avail ourselves of the types of protections afforded by the Delaware business combination statute. However, although the Cayman Companies Act does not regulate transactions between a company and its significant shareholders, it does provide that such transactions must be entered into bona fide in the best interests of the company and for a proper corporate purpose and not with the effect of constituting a fraud on the minority shareholders.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dissolution&#59; Winding Up</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Delaware General Corporation Law, unless the board of directors approves the proposal to dissolve, dissolution must be approved by shareholders holding 100% of the total voting power of the corporation. Only if the dissolution is initiated by the board of directors may it be approved by a simple majority of the corporation&#8217;s outstanding shares. Delaware law allows a Delaware corporation to include in its certificate of incorporation a supermajority voting requirement in connection with dissolutions initiated by the board of directors.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Cayman Companies Act and our articles, our company may be wound up only upon resolution of shareholders holding 100% of the total voting rights entitled to vote or if the winding up is initiated by our board of directors, by either a special resolution of our members or, if our company is unable to pay its debts as they fall due, by an ordinary resolution of our members. In addition, a company may be wound up by an order of the courts of the Cayman Islands. The court has authority to order winding up in a number of specified circumstances including where it is, in the opinion of the court, just and equitable to do so.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:134%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Variation of Rights of Shares</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Delaware General Corporation Law, a corporation may vary the rights of a class of shares with the approval of a majority of the outstanding shares of such class, unless the certificate of incorporation provides otherwise. Under the Cayman Companies Act and our articles, if our share capital is divided into more than one class of shares, we may materially and adversely vary the rights attached to any class only with the consent in writing of the holders of two-thirds of the shares of that class or with the sanction of a special resolution passed at a general meeting of the holders of the shares of that class.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amendment of Governing Documents</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Delaware General Corporation Law, a corporation&#8217;s certificate of incorporation may be amended only if adopted and declared advisable by the board of directors and approved by a majority of the outstanding shares entitled to vote, and the bylaws may be amended with the approval of a majority of the outstanding shares entitled to vote and may, if so provided in the certificate of incorporation, also be amended by the board of directors. Under the Cayman Companies Act and our articles, our articles may only be amended by special resolution of our shareholders.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rights of Non-Resident or Foreign Shareholders</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no limitations imposed by our articles on the rights of non-resident or foreign shareholders to hold or exercise voting rights on our shares. In addition, there are no provisions in our articles governing the ownership threshold above which shareholder ownership must be disclosed.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Directors&#8217; Power to Issue Shares</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our articles, our board of directors is empowered to issue or allot shares or grant options, restricted shares, restricted share units, share appreciation rights, dividend equivalent rights, warrants and analogous equity-based rights with or without preferred, deferred, qualified or other special rights or restrictions. In particular, pursuant to our articles, our board of directors has the authority, without further action by the shareholders, to issue all or any part of our capital and to fix the designations, powers, preferences, privileges, and relative participating, optional or special rights and the qualifications, limitations or restrictions therefrom, including dividend rights, conversion rights, voting rights, terms of redemption and liquidation preferences, any or all of which may be greater than the rights of our ordinary shares. Our board of directors, without shareholder approval, may issue preferred shares with voting, conversion or other rights that could adversely affect the voting power and other rights of holders of our ordinary shares. Subject to the directors&#8217; duty of acting in the best interest of our company, preferred shares can be issued quickly with terms calculated to delay or prevent a change in control of us or make removal of management more difficult. Additionally, the issuance of preferred shares may have the effect of decreasing the market price of the ordinary shares, and may adversely affect the voting and other rights of the holders of ordinary shares.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Registration Rights</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 16, 2016, we entered into a registration rights agreement with 667, L.P., Baker Brothers Life Sciences, L.P. and 14159, L.P., Hillhouse BGN Holdings Limited, HHLR Fund, L.P. (formerly known as Gaoling Fund, L.P.) and YHG Investment, L.P., (each an &#8220;Investor&#8221; and collectively, the &#8220;Investors&#8221;), all of which were existing shareholders. The registration rights agreement provides that, subject to certain limitations, if at any time and from time to time, the Investors demand that we register our ordinary shares and any other securities held by the Investors at the time any such demand is made on a Registration Statement on Form S-3 for resale under the Securities Act, we would be obligated to effect such registration. Our registration obligations under the registration rights agreement include our obligation to facilitate certain underwritten public offerings of our ordinary shares or ADSs by the Investors in the future. The registration rights agreement also requires us to pay expenses relating to such registrations and indemnify the Investors against certain liabilities. Our initial registration obligations under the registration rights agreement expired on November 16, 2020, but we and the Investors have entered into two separate amendments to the registration rights agreement, which have extended our registration obligations to December 31, 2026.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:134%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Share Purchase Agreement (as amended, the &#8220;Share Purchase Agreement&#8221;) dated October 31, 2019, by and between us and Amgen Inc. (&#8220;Amgen&#8221;), Amgen has specified registration rights. Following demand by Amgen, we shall, subject to certain limits as specified under the Share Purchase Agreement, file with the SEC a Registration Statement on Form S-3 (except if we are not then eligible to register for resale the registrable shares on Form S-3, in which case such registration shall be on another appropriate form in accordance with the Securities Act) covering the resale of the registrable shares of Amgen. In addition, where we propose to register any of our ordinary shares or ADSs under the Securities Act for sale to the public (other than a registration effected solely to implement an employee benefit plan or a transaction to which Rule 145 of the Securities Act is applicable, or a registration statement in a form not available for registering registrable shares for sale to the public), we will give notice to Amgen of our intention to do so and, upon the request of Amgen, use our reasonable best efforts to cause all the registrable shares of Amgen to be registered under the Securities Act in connection therewith, under specified circumstances and as set forth in the Share Purchase Agreement.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of American Depositary Shares</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">American Depositary Shares are frequently referred to as &#8220;ADSs&#8221; and represent ownership interests in securities that are on deposit with the depositary bank. Citibank, N.A. (&#8220;Citibank&#8221;) acts as the depositary bank for the ADSs. ADSs may be represented by certificates that are commonly known as &#8220;American Depositary Receipts&#8221; or &#8220;ADRs&#8221; that are issued by the depositary bank.&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The depositary bank typically appoints a custodian to safekeep the securities on deposit. In this case, the custodian is Citibank, N.A. Hong Kong, presently located at 9&#47;F, Citi Tower, One Bay East, 83 Hoi Bun Road, Kwun Tong, Kowloon, Hong Kong.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We have appointed Citibank as depositary bank pursuant to a deposit agreement. A copy of the deposit agreement, as amended, is on file with the SEC under cover of a Registration Statement on Form F-6. You may obtain a copy of the deposit agreement from the SEC&#8217;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549 and from the SEC&#8217;s website (www.sec.gov). Please refer to Registration Number 333-209044 when retrieving such copy.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are providing you with a summary description of the material terms of the ADSs and of your material rights as an owner of ADSs. Please remember that summaries by their nature lack the precision of the information summarized and that the rights and obligations of an owner of ADSs will be determined by reference to the terms of the deposit agreement and not by this summary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. We urge you to review the deposit agreement in its entirety. The portions of this summary description that are italicized describe matters that may be relevant to the ownership of ADSs but that may not be contained in the deposit agreement.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each ADS represents the right to receive, and to exercise the beneficial ownership interests in, 13 ordinary shares that are on deposit with the depositary bank and&#47;or custodian. An ADS also represents the right to receive, and to exercise the beneficial interests in, any other property received by the depositary bank or the custodian on behalf of the owner of the ADS but that has not been distributed to the owners of ADSs because of legal restrictions or practical considerations. We and the depositary bank may agree to change the ADS-to-ordinary share ratio by amending the deposit agreement. This amendment may give rise to, or change, the depositary fees payable by ADS owners. The custodian, the depositary bank and their respective nominees will hold all deposited property for the benefit of the holders and beneficial owners of ADSs. The deposited property does not constitute the proprietary assets of the depositary bank, the custodian or their nominees. Beneficial ownership in the deposited property will under the terms of the deposit agreement be vested in the beneficial owners of the ADSs.&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The depositary bank, the custodian and their respective nominees will be the record holders of the deposited property represented by the ADSs for the benefit of the holders and beneficial owners of the corresponding ADSs. A beneficial owner of ADSs may or may not be the holder of ADSs. Beneficial owners of ADSs will be able to receive, and to exercise beneficial ownership interests in, the deposited property only through the registered holders of the ADSs, the registered holders of the ADSs (on behalf of the applicable ADS owners) only through the depositary bank, and the depositary bank (on behalf of the owners of the corresponding ADSs) directly, or indirectly, through the custodian or their respective nominees, in each case upon the terms of the deposit agreement.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:134%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If you become an owner of ADSs, you will become a party to the deposit agreement and therefore will be bound to its terms and to the terms of any ADR that represents your ADSs. The deposit agreement and the ADR specify our rights and obligations as well as your rights and obligations as an owner of ADSs and those of the depositary bank. As an ADS holder you appoint the depositary bank to act on your behalf in certain circumstances. The deposit agreement and the ADRs are governed by New York law. However, our obligations to the holders of the ordinary shares will continue to be governed by the laws of the Cayman Islands, which may be different from the laws in the United States.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, applicable laws and regulations may require you to satisfy reporting requirements and obtain regulatory approvals in certain circumstances. You are solely responsible for complying with such reporting requirements and obtaining such approvals. Neither the depositary bank, the custodian, us or any of their or our respective agents or affiliates shall be required to take any actions whatsoever on your behalf to satisfy such reporting requirements or obtain such regulatory approvals under applicable laws and regulations.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The manner in which you own ADSs (e.g., in a brokerage account vs. as registered holder, or as holder of certificated vs. uncertificated ADSs) may affect your rights and obligations, and the manner in which, and extent to which, the depositary bank&#8217;s services are made available to you. As an owner of ADSs, we will not treat you as one of our shareholders and you will not have direct shareholder rights. The depositary bank will hold on your behalf the shareholder rights attached to the ordinary shares underlying your ADSs. As an owner of ADSs you will be able to exercise the shareholders rights for the ordinary shares represented by your ADSs through the depositary bank only to the extent contemplated in the deposit agreement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;To exercise any shareholder rights not contemplated in the deposit agreement you will, as an ADS owner, need to arrange for the cancellation of your ADSs and become a direct shareholder.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">As an owner of ADSs, you may hold your ADSs either by means of an ADR registered in your name, through a brokerage or safekeeping account, or through an account established by the depositary bank in your name reflecting the registration of uncertificated ADSs directly on the books of the depositary bank (commonly referred to as the &#8220;direct registration system&#8221; or &#8220;DRS&#8221;). The direct registration system reflects the uncertificated (book-entry) registration of ownership of ADSs by the depositary bank. Under the direct registration system, ownership of ADSs is evidenced by periodic statements issued by the depositary bank to the holders of the ADSs. The direct registration system includes automated transfers between the depositary bank and The Depository Trust Company (&#8220;DTC&#8221;), the central book-entry clearing and settlement system for equity securities in the United States. If you decide to hold your ADSs through your brokerage or safekeeping account, you must rely on the procedures of your broker or bank to assert your rights as ADS owner. Banks and brokers typically hold securities such as the ADSs through clearing and settlement systems such as DTC. The procedures of such clearing and settlement systems may limit your ability to exercise your rights as an owner of ADSs. Please consult with your broker or bank if you have any questions concerning these limitations and procedures. All ADSs held through DTC will be registered in the name of a nominee of DTC. This summary description assumes you have opted to own the ADSs directly by means of an ADS registered in your name and, as such, we will refer to you as the &#8220;holder.&#8221; When we refer to &#8220;you,&#8221; we assume the reader owns ADSs and will own ADSs at the relevant time.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The registration of the ordinary shares in the name of the depositary bank or the custodian shall, to the maximum extent permitted by applicable law, vest in the depositary bank or the custodian the record ownership in the applicable ordinary shares with the beneficial ownership rights and interests in such ordinary shares being at all times vested with the beneficial owners of the ADSs representing the ordinary shares. The depositary bank or the custodian shall at all times be entitled to exercise the beneficial ownership rights in all deposited property, in each case only on behalf of the holders and beneficial owners of the ADSs representing the deposited property.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends and Distributions</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a holder of ADSs, you generally have the right to receive the distributions we make on the securities deposited with the custodian. Your receipt of these distributions may be limited, however, by practical considerations and legal limitations. Holders of ADSs will receive such distributions under the terms of the deposit agreement in proportion to the number of ADSs held as of the specified record date, after deduction of the applicable fees, taxes and expenses.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:134%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distributions of Cash</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whenever we make a cash distribution for the securities on deposit with the custodian, we will deposit the funds with the custodian. Upon receipt of confirmation of the deposit of the requisite funds, the depositary bank will arrange for the funds received in a currency other than U.S. dollars to be converted into U.S. dollars and for the distribution of the U.S. dollars to the holders, subject to the applicable laws and regulations.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conversion into U.S. dollars will take place only if practicable and if the U.S. dollars are transferable to the United States. The depositary bank will apply the same method for distributing the proceeds of the sale of any property (such as undistributed rights) held by the custodian in respect of securities on deposit.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The distribution of cash will be made net of the fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit agreement. The depositary bank will hold any cash amounts it is unable to distribute in a non-interest bearing account for the benefit of the applicable holders and beneficial owners of ADSs until the distribution can be effected or the funds that the depositary bank holds must be escheated as unclaimed property in accordance with the laws of the relevant states of the United States.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distributions of Shares</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whenever we make a free distribution of the ordinary shares for the securities on deposit with the custodian, we will deposit the applicable number of the ordinary shares with the custodian. Upon receipt of confirmation of such deposit, the depositary bank will either distribute to holders new ADSs representing the ordinary shares deposited or modify the ADS-to-ordinary share ratio, in which case each ADS you hold will represent rights and interests in the additional ordinary shares so deposited. Only whole new ADSs will be distributed. Fractional entitlements will be sold and the proceeds of such sale will be distributed as in the case of a cash distribution.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The distribution of new ADSs or the modification of the ADS-to-ordinary share ratio upon a distribution of the ordinary shares will be made net of the fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit agreement. In order to pay such taxes or governmental charges, the depositary bank may sell all or a portion of the new ordinary shares so distributed.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No such distribution of new ADSs will be made if it would violate a law (e.g., the U.S. securities laws) or if it is not operationally practicable. If the depositary bank does not distribute new ADSs as described above, it may sell the ordinary shares received upon the terms described in the deposit agreement and will distribute the proceeds of the sale as in the case of a distribution of cash.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Distributions of Rights</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whenever we intend to distribute rights to subscribe for additional ordinary shares, we will give prior notice to the depositary bank and we will assist the depositary bank in determining whether it is lawful and reasonably practicable to distribute rights to subscribe for additional ADSs to holders.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depositary bank will establish procedures to distribute rights to subscribe for additional ADSs to holders and to enable such holders to exercise such rights if it is lawful and reasonably practicable to make the rights available to holders of ADSs, and if we provide all of the documentation contemplated in the deposit agreement (such as opinions to address the lawfulness of the transaction). You may have to pay fees, expenses, taxes and other governmental charges to subscribe for the new ADSs upon the exercise of your rights. The depositary bank is not obligated to establish procedures to facilitate the distribution and exercise by holders of rights to subscribe for new ordinary shares other than in the form of ADSs.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depositary bank will&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">not</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;distribute the rights to you if&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We do not timely request that the rights be distributed to you or we request that the rights not be distributed to you&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We fail to deliver satisfactory documents to the depositary bank&#59; or</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">It is not reasonably practicable to distribute the rights.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:134%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depositary bank will sell the rights that are not exercised or not distributed if such sale is lawful and reasonably practicable. The proceeds of such sale will be distributed to holders as in the case of a cash distribution. If the depositary bank is unable to sell the rights, it will allow the rights to lapse.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Elective Distributions</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whenever we intend to distribute a dividend payable at the election of shareholders either in cash or in additional shares, we will give prior notice thereof to the depositary bank and will indicate whether we wish the elective distribution to be made available to you. In such case, we will assist the depositary bank in determining whether such distribution is lawful and reasonably practicable.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depositary bank will make the election available to you only if it is reasonably practicable and if we have provided all of the documentation contemplated in the deposit agreement. In such case, the depositary bank will establish procedures to enable you to elect to receive either cash or additional ADSs, in each case as described in the deposit agreement.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the election is not made available to you, you will receive either cash or additional ADSs, depending on what a shareholder in the Cayman Islands would receive upon failing to make an election, as more fully described in the deposit agreement.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Distributions</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whenever we intend to distribute property other than cash, ordinary shares or rights to subscribe for additional ordinary shares, we will notify the depositary bank in advance and will indicate whether we wish such distribution to be made to you. If so, we will assist the depositary bank in determining whether such distribution to holders is lawful and reasonably practicable.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If it is reasonably practicable to distribute such property to you and if we provide all of the documentation contemplated in the deposit agreement to the depositary bank, the depositary bank will distribute the property to the holders in a manner it deems practicable.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The distribution will be made net of fees, expenses, taxes and governmental charges payable by holders under the terms of the deposit agreement. In order to pay such taxes and governmental charges, the depositary bank may sell all or a portion of the property received.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depositary bank will not distribute the property to you and will sell the property if&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We do not request that the property be distributed to you or if we request that the property not be distributed to you&#59; or</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We do not deliver satisfactory documents to the depositary bank&#59; or</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The depositary bank determines that all or a portion of the distribution to you is not reasonably practicable.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds of such a sale will be distributed to holders as in the case of a cash distribution.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redemption</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whenever we decide to redeem any of the securities on deposit with the custodian, we will notify the depositary bank in advance. If it is practicable and if we provide all of the documentation contemplated in the deposit agreement, the depositary bank will provide notice of the redemption to the holders.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The custodian will be instructed to surrender the shares being redeemed against payment of the applicable redemption price. The depositary bank will convert into U.S. dollars the redemption funds received in a currency other than U.S. dollars upon the terms of the deposit agreement and will establish procedures to enable holders to receive the net proceeds from the redemption upon surrender of their ADSs to the depositary bank. You may have to pay fees, expenses, taxes and other governmental charges upon the redemption of your ADSs. If less than all ADSs are being redeemed, the ADSs to be retired will be selected by lot or on a pro rata basis, as the depositary bank may determine.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:134%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes Affecting Ordinary Shares</font></div><div style="margin-bottom:8pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ordinary shares held on deposit for your ADSs may change from time to time. For example, there may be a change in nominal or par value, split-up, cancellation, consolidation or any other reclassification of such ordinary shares or a recapitalization, reorganization, merger, consolidation or sale of assets of the company.</font></div><div style="margin-bottom:8pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any such change were to occur, your ADSs would, to the extent permitted by law and the deposit agreement, represent the right to receive the property received or exchanged in respect of the ordinary shares held on deposit. The depositary bank may in such circumstances deliver new ADSs to you, amend the deposit agreement, the ADRs and the applicable Registration Statement(s) on Form F-6, call for the exchange of your existing ADSs for new ADSs and take any other actions that are appropriate to reflect as to the ADSs the change affecting the ordinary shares. If the depositary bank may not lawfully distribute such property to you, the depositary bank may sell such property and distribute the net proceeds to you as in the case of a cash distribution.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuance of ADSs Upon Deposit of Ordinary Shares</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depositary bank may create ADSs on behalf of investors who deposit ordinary shares with the custodian. The depositary bank will deliver these ADSs to the person you indicate only after you pay any applicable issuance fees and any charges and taxes payable for the transfer of the ordinary shares to the custodian. Your ability to deposit ordinary shares and receive ADSs may be limited by U.S. and Cayman Islands legal considerations applicable at the time of deposit.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of ADSs may be delayed until the depositary bank or the custodian receives confirmation that all required approvals have been given and that the ordinary shares have been duly transferred to the custodian. The depositary bank will only issue ADSs in whole numbers.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When you make a deposit of the ordinary shares, you will be responsible for transferring good and valid title to the depositary bank. As such, you will be deemed to represent and warrant that&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The ordinary shares are duly authorized, validly issued, fully paid, non-assessable and legally obtained.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">All preemptive (and similar) rights, if any, with respect to such ordinary shares have been validly waived or exercised.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">You are duly authorized to deposit the ordinary shares.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The ordinary shares presented for deposit are free and clear of any lien, encumbrance, security interest, charge, mortgage or adverse claim, and are not, and the ADSs issuable upon such deposit will not be, &#8220;restricted securities&#8221; (as defined in the deposit agreement).</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The ordinary shares presented for deposit have not been stripped of any rights or entitlements.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of the representations or warranties are incorrect in any way, we and the depositary bank may, at your cost and expense, take any and all actions necessary to correct the consequences of the misrepresentations.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transfer, Combination and Split Up of ADRs</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an ADR holder, you will be entitled to transfer, combine or split up your ADRs and the ADSs evidenced thereby. For transfers of ADRs, you will have to surrender the ADRs to be transferred to the depositary bank and also must&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ensure that the surrendered ADR is properly endorsed or otherwise in proper form for transfer&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide such proof of identity and genuineness of signatures as the depositary bank deems appropriate&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide any transfer stamps required by the State of New York or the United States&#59; and</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pay all applicable fees, charges, expenses, taxes and other government charges payable by ADR holders pursuant to the terms of the deposit agreement, upon the transfer of ADRs.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To have your ADRs either combined or split up, you must surrender the ADRs in question to the depositary bank with your request to have them combined or split up, and you must pay all applicable fees, charges and expenses payable by ADR holders, pursuant to the terms of the deposit agreement, upon a combination or split up of ADRs.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:134%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Withdrawal of Ordinary Shares Upon Cancellation of ADSs</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a holder, you will be entitled to present your ADSs to the depositary bank for cancellation and then receive the corresponding number of underlying ordinary shares at the custodian&#8217;s offices. Your ability to withdraw the ordinary shares held in respect of the ADSs may be limited by U.S. and Cayman Islands legal considerations applicable at the time of withdrawal. In order to withdraw the ordinary shares represented by your ADSs, you will be required to pay to the depositary bank the fees for cancellation of ADSs and any charges and taxes payable upon the transfer of the ordinary shares. You assume the risk for delivery of all funds and securities upon withdrawal. Once canceled, the ADSs will not have any rights under the deposit agreement.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If you hold ADSs registered in your name, the depositary bank may ask you to provide proof of identity and genuineness of any signature and such other documents as the depositary bank may deem appropriate before it will cancel your ADSs. The withdrawal of the ordinary shares represented by your ADSs may be delayed until the depositary bank receives satisfactory evidence of compliance with all applicable laws and regulations. Please keep in mind that the depositary bank will only accept ADSs for cancellation that represent a whole number of securities on deposit.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You will have the right to withdraw the securities represented by your ADSs at any time except for&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">temporary delays that may arise because (i) the transfer books for the ordinary shares or ADSs are closed, or (ii) the ordinary shares are immobilized on account of a shareholders&#8217; meeting or a payment of dividends&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obligations to pay fees, taxes and similar charges&#59; or</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions imposed because of laws or regulations applicable to ADSs or the withdrawal of securities on deposit.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deposit agreement may not be modified to impair your right to withdraw the securities represented by your ADSs except to comply with mandatory provisions of law.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voting Rights</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a holder, you generally have the right under the deposit agreement to instruct the depositary bank to exercise the voting rights for the ordinary shares represented by your ADSs. The voting rights of holders of ordinary shares are described in &#8220;&#8212; Ordinary Shares&#8221;.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At our request, the depositary bank will distribute to you any notice of shareholders&#8217; meeting received from us together with information explaining how to instruct the depositary bank to exercise the voting rights of the securities represented by ADSs.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the depositary bank timely receives voting instructions from a holder of ADSs, it will endeavor to vote the securities (in person or by proxy) represented by the holder&#8217;s ADSs in accordance with the voting instructions received from the holders of ADSs.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our articles provide that voting of shareholders at any meeting is by poll. Holders of ADSs in respect of which no timely voting instructions have been received, or timely voting instructions have been received however such instructions fail to specify the manner in which the depositary is to vote, shall be deemed to have instructed the depositary to give a discretionary proxy to a person designated by us to vote the ordinary shares represented by such holders&#8217; ADSs&#59; provided, that no such instruction shall be deemed given and no such discretionary proxy shall be given with respect to any matter as to which we inform the depositary that we do not wish such proxy to be given&#59; provided, further, that no such discretionary proxy shall be given with respect to any matter as to which we inform the depositary that (i) there exists substantial opposition, or (ii) the rights of shareholders of our company will be materially adversely affected.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please note that the ability of the depositary bank to carry out voting instructions may be limited by practical and legal limitations and the terms of the securities on deposit. We cannot assure you that you will receive voting materials in time to enable you to return voting instructions to the depositary bank in a timely manner.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:134%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fees and Charges</font></div><div style="margin-bottom:8pt;margin-top:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an ADS holder, you will be required to pay the following fees under the terms of the deposit agreement&#58;</font></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.701%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="border-bottom:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:134%">Service</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:134%">Fees</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:15.22pt;padding-right:-1.63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Issuance of ADSs upon deposit of ordinary shares (excluding issuances as a result of distributions of ADSs pursuant to (i) stock dividends or other free stock distributions, or (ii) exercise of rights to purchase additional ADSs)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.25pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:134%">Up to U.S. $5.00 per 100 ADSs (or fraction thereof) issued</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:15.22pt;padding-right:-1.63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Delivery of deposited property against surrender of ADSs</font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:5pt;padding-right:-1.63pt;text-indent:-18pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:134%">Up to U.S. $5.00 per 100 ADSs (or fraction thereof) canceled</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:15.22pt;padding-right:-1.63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Distribution of cash dividends or other cash distributions (i.e., sale of rights and other entitlements)</font></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:5pt;padding-right:-1.63pt;text-indent:-18pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:134%">Up to U.S. $5.00 per 100 ADSs (or fraction thereof) held</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:15.22pt;padding-right:-1.63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Distribution of ADSs pursuant to (i) stock dividends or other free stock distributions, or (ii) exercise of rights to purchase additional ADSs</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:134%">Up to U.S. $5.00 per 100 ADSs (or fraction thereof) held</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:15.22pt;padding-right:-1.63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Distribution of securities other than ADSs or rights to purchase additional ADSs (i.e., spin-off shares)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:134%">Up to U.S. $5.00 per 100 ADSs (or fraction thereof) held</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;padding-left:15.22pt;padding-right:-1.63pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ADS Services</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:134%">Up to U.S. $5.00 per 100 ADSs (or fraction thereof) held on the applicable record date(s) established by the depositary bank</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:8pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an ADS holder you will also be responsible to pay certain charges such as&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">taxes (including applicable interest and penalties) and other governmental charges&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the registration fees as may from time to time be in effect for the registration of the ordinary shares on the share register and applicable to transfers of the ordinary shares to or from the name of the custodian, the depositary bank or any nominees upon the making of deposits and withdrawals, respectively&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such cable, telex and facsimile transmission and delivery expenses as are expressly provided in the deposit agreement to be at the expense of the person depositing ordinary shares or withdrawing deposited securities or of the holders and beneficial owners of ADSs&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expenses and charges incurred by the depositary bank in the conversion of foreign currency&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the fees and expenses incurred by the depositary bank in connection with compliance with exchange control regulations and other regulatory requirements applicable to the ordinary shares, deposited securities, ADSs and ADRs&#59; and</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the fees and expenses incurred by the depositary bank, the custodian or any nominee in connection with the servicing or delivery of deposited property.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:134%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADS fees and charges payable upon (i) deposit of the ordinary shares against issuance of ADSs and (ii) surrender of ADSs for cancellation and withdrawal of the ordinary shares are charged to the person to whom the ADSs are delivered (in the case of ADS issuances) and to the person who delivers the ADSs for cancellation (in the case of ADS cancellations). In the case of ADSs issued by the depositary bank into DTC or presented to the depositary bank via DTC,&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the ADS issuance and cancellation fees and charges will be payable by the DTC participant(s) receiving the ADSs from the depositary bank or the DTC participant(s) surrendering the ADSs to the depositary bank for cancellation, as the case may be, on behalf of the beneficial owner(s) and will be charged by the DTC participant(s) to the account(s) of the applicable beneficial owner(s) in accordance with the procedures and practices of the DTC participant(s) as in effect at the time</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADS fees and charges in respect of distributions and the ADS service fee are payable by holders as of the applicable ADS record date established by the depositary bank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the case of distributions of cash, the amount of the applicable ADS fees and charges is deducted from the funds being distributed. In the case of (i) distributions other than cash and (ii) the ADS service fee, holders as of the ADS record date will be invoiced for the amount of the ADS fees and charges and such ADS fees and charges may be deducted from distributions made to holders of ADSs. For ADSs held through DTC, the ADS fees and charges for distributions other than cash and the ADS service fee may be deducted from distributions made through DTC, and may be charged to the DTC participants in accordance with the procedures and practices prescribed by DTC and the DTC participants in turn charge the amount of such ADS fees and charges to the beneficial owners for whom they hold ADSs.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In the event of refusal to pay the depositary bank fees, the depositary bank may, under the terms of the deposit agreement, refuse the requested service until payment is received or may set off the amount of the depositary bank fees from any distribution to be made to the ADS holder. Certain of the depositary fees and charges (such as the ADS services fee) may become payable shortly after the closing of the ADS offering. Note that the fees and charges you may be required to pay may vary over time and may be changed by us and by the depositary bank. You will receive prior notice of such changes. The depositary bank may reimburse us for certain expenses incurred by us in respect of the ADR program, by making available a portion of the ADS fees charged in respect of the ADR program or otherwise, upon such terms and conditions as we and the depositary bank agree from time to time.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendments and Termination</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may agree with the depositary bank to modify the deposit agreement at any time without your consent. We undertake to give holders 30 days&#8217; prior notice of any modifications that would materially prejudice any of their substantial rights under the deposit agreement. We will not consider to be materially prejudicial to your substantial rights any modifications or supplements that are reasonably necessary for the ADSs to be registered under the Securities Act or to be eligible for book-entry settlement, in each case without imposing or increasing the fees and charges you are required to pay. In addition, we may not be able to provide you with prior notice of any modifications or supplements that are required to accommodate compliance with applicable provisions of law.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You will be bound by the modifications to the deposit agreement if you continue to hold your ADSs after the modifications to the deposit agreement become effective. The deposit agreement cannot be amended to prevent you from withdrawing the ordinary shares represented by your ADSs (except as permitted by law).</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have the right to direct the depositary bank to terminate the deposit agreement. Similarly, the depositary bank may in certain circumstances on its own initiative terminate the deposit agreement. In either case, the depositary bank must give notice to the holders at least 30 days before termination. Until termination, your rights under the deposit agreement will be unaffected.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After termination, the depositary bank will continue to collect distributions received (but will not distribute any such property until you request the cancellation of your ADSs) and sell the securities held on deposit. After the sale, the depositary bank will hold the proceeds from such sale and any other funds then held for the holders of ADSs in a non-interest bearing account. At that point, the depositary bank will have no further obligations to holders other than to account for the funds then held for the holders of ADSs still outstanding (after deduction of applicable fees, taxes and expenses).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:134%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Books of Depositary</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depositary bank will maintain ADS holder records at its depositary office. You may inspect such records at such office during regular business hours but solely for the purpose of communicating with other holders in the interest of business matters relating to the ADSs and the deposit agreement.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depositary bank will maintain in New York facilities to record and process the issuance, cancellation, combination, split-up and transfer of ADSs. These facilities may be closed from time to time, to the extent not prohibited by law.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limitations on Obligations and Liabilities</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deposit agreement limits our obligations and the depositary bank&#8217;s obligations to you. Please note the following&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and the depositary bank are obligated only to take the actions specifically stated in the deposit agreement without negligence or bad faith.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The depositary bank disclaims any liability for any failure to carry out voting instructions, for any manner in which a vote is cast or for the effect of any vote, provided it acts in good faith and in accordance with the terms of the deposit agreement.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The depositary bank disclaims any liability for any failure to determine the lawfulness or practicality of any action, for the content of any document forwarded to you on our behalf or for the accuracy of any translation of such a document, for the investment risks associated with investing in the ordinary shares, for the validity or worth of the ordinary shares, for any tax consequences that result from the ownership of ADSs, for the credit-worthiness of any third party, for allowing any rights to lapse under the terms of the deposit agreement, for the timeliness of any of our notices or for our failure to give notice.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and the depositary bank will not be obligated to perform any act that is inconsistent with the terms of the deposit agreement.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and the depositary bank disclaim any liability if we or the depositary bank are prevented or forbidden from or subject to any civil or criminal penalty or restraint on account of, or delayed in, doing or performing any act or thing required by the terms of the deposit agreement, by reason of any provision, present or future of any law or regulation, or by reason of present or future provision of any provision of our articles, or any provision of or governing the securities on deposit, or by reason of any act of God or war or other circumstances beyond our control.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and the depositary bank disclaim any liability by reason of any exercise of, or failure to exercise, any discretion provided for in the deposit agreement or in our articles or in any provisions of or governing the securities on deposit.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and the depositary bank further disclaim any liability for any action or inaction in reliance on the advice or information received from legal counsel, accountants, any person presenting ordinary shares for deposit, any holder of ADSs or authorized representatives thereof, or any other person believed by either of us in good faith to be competent to give such advice or information.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and the depositary bank also disclaim liability for the inability by a holder to benefit from any distribution, offering, right or other benefit that is made available to holders of ordinary shares but is not, under the terms of the deposit agreement, made available to you.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and the depositary bank may rely without any liability upon any written notice, request or other document believed to be genuine and to have been signed or presented by the proper parties.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and the depositary bank also disclaim liability for any consequential or punitive damages for any breach of the terms of the deposit agreement.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">No disclaimer of any Securities Act liability is intended by any provision of the deposit agreement.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Nothing in the deposit agreement gives rise to a partnership or joint venture, or establishes a fiduciary relationship among us, the depositary bank and you as ADS holder.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:134%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Nothing in the deposit agreement precludes Citibank (or its affiliates) from engaging in transactions in which parties adverse to us or the ADS owners have interests, and nothing in the deposit agreement obligates Citibank to disclose those transactions, or any information obtained in the course of those transactions, to us or to the ADS owners, or to account for any payment received as part of those transactions.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">As the above limitations relate to our obligations and the depositary bank&#8217;s obligations to you under the deposit agreement, we believe that, as a matter of construction of the clause, such limitations would likely to continue to apply to ADS holders who withdraw the ordinary shares from the ADS facility with respect to obligations or liabilities incurred under the deposit agreement before the cancellation of the ADSs and the withdrawal of the ordinary shares, and such limitations would most likely not apply to ADS holders who withdraw the ordinary shares from the ADS facility with respect to obligations or liabilities incurred after the cancellation of the ADSs and the withdrawal of the ordinary shares and not under the deposit agreement.</font></div><div style="margin-bottom:8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In any event, you will not be deemed, by agreeing to the terms of the deposit agreement, to have waived our or the depositary bank&#8217;s compliance with U.S. federal securities laws and the rules and regulations promulgated thereunder. In fact, you cannot waive our or the depositary bank&#8217;s compliance with U.S. federal securities laws and the rules and regulations promulgated thereunder.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pre-Release Transactions</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depositary bank has informed us that it no longer engages in pre-release transactions and has no intention to do so in the future.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Taxes</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You will be responsible for the taxes and other governmental charges payable on the ADSs and the securities represented by the ADSs. We, the depositary bank and the custodian may deduct from any distribution the taxes and governmental charges payable by holders and may sell any and all property on deposit to pay the taxes and governmental charges payable by holders. You will be liable for any deficiency if the sale proceeds do not cover the taxes that are due.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depositary bank may refuse to issue ADSs, to deliver, transfer, split and combine ADRs or to release securities on deposit until all taxes and charges are paid by the applicable holder. The depositary bank and the custodian may take reasonable administrative actions to obtain tax refunds and reduced tax withholding for any distributions on your behalf. However, you may be required to provide to the depositary bank and to the custodian proof of taxpayer status and residence and such other information as the depositary bank and the custodian may require to fulfill legal obligations. You are required to indemnify us, the depositary bank and the custodian for any claims with respect to taxes based on any tax benefit obtained for you.</font></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Conversion</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depositary bank will arrange for the conversion of all foreign currency received into U.S. dollars if such conversion is practical, and it will distribute the U.S. dollars in accordance with the terms of the deposit agreement. You may have to pay fees and expenses incurred in converting foreign currency, such as fees and expenses incurred in complying with currency exchange controls and other governmental requirements.</font></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the conversion of foreign currency is not practical or lawful, or if any required approvals are denied or not obtainable at a reasonable cost or within a reasonable period, the depositary bank may take the following actions in its reasonable discretion&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">convert the foreign currency to the extent practical and lawful and distribute the U.S. dollars to the holders for whom the conversion and distribution is lawful and practical&#59;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">distribute the foreign currency to holders for whom the distribution is lawful and practical&#59; and</font></div><div style="margin-bottom:8pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hold the foreign currency (without liability for interest) for the applicable holders.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:134%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governing Law&#47;Waiver of Jury Trial</font></div><div style="margin-bottom:8pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deposit agreement and the ADRs will be interpreted in accordance with the laws of the State of New York. The rights of holders of ordinary shares (including the ordinary shares represented by ADSs) is governed by the laws of the Cayman Islands.</font></div><div style="margin-bottom:8pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AS A PARTY TO THE DEPOSIT AGREEMENT, YOU&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IRREVOCABLY WAIVE, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, YOUR RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF THE DEPOSIT AGREEMENT OR THE ADRs AGAINST US AND&#47;OR THE DEPOSITARY BANK.</font></div><div style="margin-bottom:8pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The deposit agreement provides that, to the extent permitted by law, ADS holders waive the right to a jury trial of any claim they may have against us or the depositary bank arising out of or relating to our ordinary shares, the ADSs or the deposit agreement, including any claim under U.S. federal securities laws. If we or the depositary bank opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable in the facts and circumstances of that case in accordance with applicable case law. However, you will not be deemed, by agreeing to the terms of the deposit agreement, to have waived our or the depositary bank&#8217;s compliance with U.S. federal securities laws and the rules and regulations promulgated thereunder.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:134%">23</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.23
<SEQUENCE>3
<FILENAME>exhibit1023beigenebms-sett.htm
<DESCRIPTION>EX-10.23
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i4baed455201d45878e230ff9d59fb167_1"></div><div style="min-height:61.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:0.2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 10.23</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:4.55pt;padding-left:83.87pt;padding-right:83.87pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Second Amendment to the Settlement and Termination Agreement</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:5.05pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This Second Amendment to the Settlement and Termination Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Second Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) is entered into as of December 4, 2024 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Second Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) by and among Bristol- Myers Squibb Company, a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">BMS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), Celgene Corporation, a Delaware corporation (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Celgene Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), Celgene Switzerland LLC, a Delaware limited liability company (&#8220;C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">elgene </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Switzerland</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), Celgene Holdings East Corporation, a New Jersey corporation (&#8220;C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">elgene East&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">), Celgene Kappa Holdings LLC, a Delaware limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Celgene Kappa</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;) and Celgene Logistics S&#224;rl (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Celgene Logistics</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;), a corporation incorporated under the laws of Switzerland, on the one hand (collectively, with BMS, Celgene Corporation, Celgene Switzerland, Celgene East, Celgene Kappa and Celgene Logistics, &#8220;Celgene&#8221;), and BeiGene, Ltd., an exempted company incorporated under the laws of the Cayman Islands, and BeiGene Switzerland GmbH, a company incorporated in Switzerland (&#8220;BeiGene Switzerland&#8221;, and together with BeiGene, Ltd., &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">BeiGene</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221;). BMS, Celgene Corporation, Celgene Switzerland, Celgene East, Celgene Kappa, Celgene Logistics, BeiGene Switzerland, and BeiGene, Ltd., are sometimes referred to herein individual as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.&#8221;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHERAS, Celgene and BeiGene entered into that certain Settlement and Termination Agreement as of August 1, 2023, and as amended on January 1, 2024 (the &#8220;Agreement&#8221;).</font></div><div style="margin-top:0.35pt;text-align:justify"><font><br></font></div><div style="padding-left:5pt;padding-right:5.75pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">WHEREAS, in an effort to ensure an appropriate process and timing for BeiGene to wind down its sales and marketing of the Products and for the smooth transition of the Products the Parties wish to amend the Agreement to clarify certain transition activities and processes.</font></div><div style="margin-top:0.5pt;text-align:justify"><font><br></font></div><div style="padding-left:23pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NOW, THEREFORE, the Parties, intending to be legally bound, hereby agree as follows&#58;</font></div><div style="margin-top:0.55pt;text-align:justify"><font><br></font></div><div style="padding-left:41pt;padding-right:6.55pt;text-align:justify;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.09pt;text-decoration:underline">Definition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Capitalized terms not defined herein shall have the meanings ascribed to such terms in the Settlement Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:40.9pt;text-align:justify;text-indent:-28.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">II.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.03pt;text-decoration:underline">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:0.35pt;text-align:justify"><font><br></font></div><div style="padding-left:77pt;padding-right:5.75pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.37pt">Notwithstanding anything to the contrary contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3 Pending Product Orders&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> Continued Right to Sell, the Parties mutually agree that BeiGene and the distributors and the hospitals shall be entitled to sell the Fall 2023 Supply of Revlimid and Vidaza until the earlier of (y) exhaustion of such Fall 2023 Supply Product inventory or (z) February 28, 2025.</font></div><div style="margin-top:0.25pt;text-align:justify"><font><br></font></div><div style="padding-left:77pt;padding-right:5.75pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.75pt">Notwithstanding anything to the contrary contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 3 Pending Product Orders&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Continued Right to Sell, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">the Parties mutually agree that Celgene may engage in pre-launch reintroduction activities for the Product in the Territory (including but not limited to promotional activities) as of the Second Amendment Effective Date&#59; provided, however that Celgene shall not sell itself or to any third-party any Product until the earlier of (y) exhaustion of such Fall 2023 Supply Product inventory or (z) January 1, 2025.</font></div><div style="margin-top:0.1pt;text-align:justify"><font><br></font></div><div style="padding-left:77pt;padding-right:5.75pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:10.37pt">Notwithstanding anything to the contrary contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2 Termination of the LSA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">and QA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Parties mutually agree to clarify that the PVA shall remain in full force and effect for the inventory of and sale of Product by BeiGene in accordance with Section II.a. above.</font></div><div style="margin-top:0.1pt;text-align:justify"><font><br></font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:61.2pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:0.2pt;padding-left:77pt;padding-right:5.75pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:9.75pt">Notwithstanding anything to the contrary contained in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">Section 2 Termination of the LSA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;text-decoration:underline">and QA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, the Parties mutually agree to clarify that the QA shall remain in full force and effect for the inventory of and sale of those Products by BeiGene in accordance with Section II.a. above and BeiGene shall continue to provide necessary support for such inventory and sales of Products in accordance with such QA.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:41pt;padding-right:5.75pt;text-align:justify;text-indent:-31.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">III.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:17.97pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. This Second Amendment shall be deemed incorporated into and made a part of the Agreement. The provisions of this Second Amendment shall constitute an amendment to the Agreement, and, to the extent that any term or provision of this Second Amendment may be deemed expressly inconsistent with any term or provision in the Agreement, the First Amendment, this Second Amendment shall govern and control. Except as expressly modified by the terms of this Second Amendment, all of the terms, conditions, and provisions of the Agreement are hereby ratified, and the Agreement remains in full force and effect.</font></div><div style="margin-top:0.05pt;text-align:justify"><font><br></font></div><div style="padding-left:41pt;padding-right:6.45pt;text-align:justify;text-indent:-32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">IV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.05pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. This Agreement shall be governed by, and construed in accordance with, the internal laws of the state of New York, without giving effect to the principles of conflicts of law.</font></div><div style="margin-top:0.05pt;text-align:justify"><font><br></font></div><div style="padding-left:41pt;padding-right:5.75pt;text-align:justify;text-indent:-28.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">V.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:18.11pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. This Second Amendment may be executed in one or more counterparts, each of which shall be deemed an original and all of which together shall constitute one and the same agreement and shall become effective when each Party has signed and delivered a copy to the other Party. Any manual signature on this Agreement that is faxed, scanned, photocopied, emailed or otherwise electronically transmitted in any generally accepted format, and any electronic signature valid under the Electronic Signatures in Global and National Commerce Act, 15 U.S.C. &#167; 7001, et. seq. shall for all purposes have the same validity, legal effect and admissibility in evidence as an original manual &#8220;wet ink&#8221; signature, and the Parties hereby waive any objection to the contrary.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:38.05pt;padding-right:38.05pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;Remainder of Page Intentionally Left Blank&#93;</font></div><div id="i4baed455201d45878e230ff9d59fb167_4"></div><div><font><br></font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:80%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:61.2pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:0.05pt;margin-top:0.1pt"><font><br></font></div><div><font><br></font></div><div style="margin-top:4.5pt;padding-left:18.85pt;padding-right:22.95pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the undersigned Parties, by their respective authorized counsel, to hereby execute this Second Amendment Agreement as of the Second Amendment Effective Date.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.306%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.612%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.432%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">BEIGENE, LTD.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">BEIGENE SWITZERLAND GMBH</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47;Chan Lee</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47;Michael Schoen</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Printed Name&#58; Chan Lee</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Printed Name&#58; Michael Schoen</font></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; SVP and General Counsel</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; Managing Director</font></div></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CELGENE SWITZERLAND LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CELGENE HOLDINGS EST CORPORATION</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47;Amy Fallone</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47;Amy Fallone</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Printed Name&#58; Amy Fallone</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Printed Name&#58; Amy Fallone</font></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; Manager</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Vice President and Secretary</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CELGENE LOGISTICS S&#192;RL</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CELGENE LOGISTICS S&#192;RL</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47;Shean Teo Burgat</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47;Graeme Lowe</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Printed Name&#58; Shean Teo Burgat</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Printed Name&#58; Graeme Lowe</font></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; Director</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Director</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CELGENE CORPORATION</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BRISTOL-MYERS SQUIBB COMPANY</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47;Amy Fallone</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47;Amy Fallone</font></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Printed Name&#58; Amy Fallone</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Printed Name&#58; Amy Fallone</font></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; Vice President and Secretary</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">Title&#58; Corporate Secretary</font></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">CELGENE KAPPA HOLDINGS LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#47;s&#47;Amy Fallone</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Printed Name&#58; Amy Fallone</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.2pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Title&#58; Vice President and Secretary</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:0.2pt"><font><br></font></div><div id="i4baed455201d45878e230ff9d59fb167_7"></div><div style="margin-top:4.5pt;padding-left:19.22pt;padding-right:19.22pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#91;Signature Page to Second Amendment of the Settlement and Termination Agreement&#93;</font></div><div style="height:59.76pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.2
<SEQUENCE>4
<FILENAME>exhibit192-beigenespecialt.htm
<DESCRIPTION>EX-19.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i5d07713e488f4108918cc696d73ec64d_1"></div><div style="min-height:56.88pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 19.2</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BEIGENE, LTD.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SPECIAL TRADING PROCEDURES FOR INSIDERS</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To comply with federal and state securities laws of the United States, the Hong Kong Model Code for Securities Dealings by Directors of Listed Issuers (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Model Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) set out in Appendix 10 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and certain provisions of the Securities and Futures Ordinance (Cap. 571) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SFO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (together, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Hong Kong Securities Trading Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and relevant provisions of the Securities Law of the People&#8217;s Republic of China, the Rules Governing the Listing of Stocks on Science and Technology Innovation Board of the Shanghai Stock Exchange and other relevant laws and regulations on A-shares (commonly known as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">A-Share Listing Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) governing insider trading, BeiGene, Ltd. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">BeiGene</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and its subsidiaries (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) has adopted these Special Trading Procedures for Insiders (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Trading Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  These Trading Procedures are in addition to and supplement the Company&#8217;s Insider Trading Policy (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Insider Trading Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), which is distributed to all directors, officers, employees and consultants of the Company.  </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">A. &#160;&#160;&#160;&#160;PERSONS COVERED BY THESE SPECIAL TRADING PROCEDURES </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">These Trading Procedures regulate securities trades by (a) all members of the Company&#8217;s board of directors (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and each member, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), (b) supervisors of the Company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Supervisors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; (c) executive officers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of the Company, (d) employees of the Company at the level of vice president or above, (e) members of the Company&#8217;s accounting and finance or investor relations teams, (f) employees who have access to the Company&#8217;s product revenue reports, (g) employees or consultants of the Company who are designated by the Insider Trading Compliance Officer (as defined below) and who perform specific functions within the Company that may provide them access to material, nonpublic information (as described in the Insider Trading Policy) concerning the Company, including, without limitation, members of the Company&#8217;s clinical and regulatory teams, business development team, or commercial sales team, and (h) such other individuals or teams as the Insider Trading Compliance Officer may designate from time to time (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Insiders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  The Company shall maintain a list of Insiders, and any persons who are designated as Insiders and thus bound by these Trading Procedures shall be notified of their status by the Company&#8217;s Insider Trading Compliance Officer or such officers designee.  From time to time, the Insider Trading Compliance Officer may designate all employees of the Company as Insiders.  These Trading Procedures also apply to the following persons (collectively, these persons and entities are referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#58; </font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">an Insider&#8217;s spouse or domestic partner, child, parent, significant other, other family member or other person, in each case, living in the Insider&#8217;s household&#59;</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">all trusts, family partnerships and other types of entities formed for the benefit of the Insider or the Insider&#8217;s family members over which the Insider has the ability to influence or direct investment decisions concerning the Company&#8217;s securities&#59;</font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">all persons who execute trades on behalf of the Insider&#59; and</font></div><div style="border-bottom:0.54pt solid #000000;margin-bottom:5pt;margin-top:10pt;opacity:1;width:144pt"></div><div style="margin-bottom:6pt;padding-left:21.6pt;text-indent:-21.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:12.00pt;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:12.00pt;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:12.00pt">The term &#8220;executive officers&#8221; refers to those officers subject to Section 16 of the Securities Exchange Act of 1934, as amended. </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:31.8pt">all investment funds, trusts, retirement plans, partnerships, corporations and other types of entities over which the Insider has the ability to influence or direct investment decisions concerning the Company&#8217;s securities&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that these Trading Procedures shall not apply to any such entity that engages in the investment of securities in the ordinary course of its business (e.g., an investment fund or partnership) if such entity has established its own insider trading controls and procedures in compliance with applicable securities laws and the Insider has included such entity on the Insider&#8217;s signed acknowledgment in the attached form. </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Insiders are responsible for ensuring compliance with these Trading Procedures and the Insider Trading Policy by all of their Affiliates. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Unless the context otherwise requires, references to &#8220;Insiders&#8221; in these Trading Procedures refer collectively to Insiders and their Affiliates. </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">These Trading Procedures apply to any and all transactions in the Company&#8217;s securities, including its ordinary shares, any other type of securities that the Company may issue (such as preferred shares, convertible debentures, warrants, exchange-traded options or other derivative securities), and any derivative securities that provide the economic equivalent of ownership of any of the Company&#8217;s securities or an opportunity, direct or indirect, to profit from any change in the value of the Company&#8217;s securities.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">B. &#160;&#160;&#160;&#160;SPECIAL TRADING RESTRICTIONS APPLICABLE TO INSIDERS </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Please see the Insider Trading Policy for a description of prohibited activities applicable to all Directors, Supervisors, officers and employees of the Company, including Insiders and for a discussion of what constitutes &#8220;insider trading&#8221; as well as &#8220;material&#8221; and &#8220;nonpublic&#8221; information.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">In particular, no Insider may trade in any type of securities of the Company or any derivatives relating to the securities of the Company if such Insider is in possession of material, nonpublic information about the Company, unless the trade has been effected under a pre-approved Rule 10b5-1 Plan (as defined below).  This prohibition applies even if such Insider receives pre-clearance and the trade would occur during a trading window in accordance with these Trading Procedures. </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any Insiders who are unsure whether the information that they possess is material or nonpublic should consult the Insider Trading Compliance Officer for guidance.  </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition to the restrictions on trading in Company securities set forth in the Insider Trading Policy, Insiders are subject to the following special trading restrictions&#58;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div><font><br></font></div></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">No Trading During Quarterly Blackout Windows for Restricted Insiders. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any (a) Director, (b) executive officer of the Company, (c) employee of the Company at the level of vice president or above, (d) member of the Company&#8217;s accounting and finance or investors relations teams, or (d) employee who has access to the Company&#8217;s product revenue reports (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Restricted Insiders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) may not trade in Company securities during four quarterly blackout periods.  Unless otherwise advised by the Insider Trading Compliance Officer, the four quarterly blackout periods consist of the periods that begin after market close on the fifteenth day of the month in which the fiscal quarter ends (i.e. March 15, June 15, September 15, and December 15) and end after market close on the first full trading day following the Company&#8217;s issuance of a press release (or other method of broad public dissemination) announcing its quarterly or annual results of operations.  Restricted Insiders may be allowed to trade during a quarterly blackout period only (a) pursuant to a pre-approved Rule 10b5-1 Plan as described in Section D of these Trading Procedures or (b) in accordance with the procedure for waivers described in Section E of these Trading Procedures.  Restricted Insiders may give Company shares during a quarterly blackout period if the gift has been approved by the Insider Trading Compliance Officer in accordance with Section B.8 below.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt">No Trading During Hong Kong Blackout Periods for Directors.</font></div><div style="padding-left:54pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No Director may trade the Company's securities during the Hong Kong blackout periods (as defined below).  The Company will notify The Stock Exchange of Hong Kong Limited (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">HKEx</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Securities and Futures Commission and the public (as applicable) when such blackout periods are in effect.  The Hong Kong blackout periods are in effect (i) during the 60 day period beginning immediately prior to the publication of the Company&#8217;s annual financial results or, if shorter, the period beginning at the end of the relevant financial year and continuing until the publication date of those results&#59; and (ii) during the 30 day period beginning immediately prior to the publication of the Company&#8217;s quarterly results and interim results or, if shorter, the period beginning at the end of the relevant quarterly or interim period and continuing until the publication date of those results.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3. No Trading During A-Share Blackout Periods for Directors and Senior Officers.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No Director or senior officer of BeiGene may trade the Company&#8217;s A-shares and derivative securities within the following periods&#58; (i) during the 30 day period beginning immediately prior to the publication of the Company&#8217;s annual report and semi-annual report prepared in accordance with the A-Share Listing Rules on the Shanghai Stock Exchange (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">SSE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) or during the 30 day period beginning immediately prior to the scheduled publication date for the Company&#8217;s annual report and semi-annual report and continuing until one day before the actual publication date in the event that the publication is delayed&#59; (ii) during the 10 day period beginning immediately prior to the publication of the Company&#8217;s quarterly reports and performance forecast prepared in accordance with the A-Share Listing Rules on the SSE&#59; and (iii) during the period beginning upon the occurrence of major events that may have a significant impact on the trading price of the Company&#8217;s A-shares and derivative securities or from the beginning of the Company&#8217;s decision-making process relating to such major events, to the date when the legally required disclosure is made.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4. Trades by Restricted Insiders Must be Pre-Cleared by the Insider Trading</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Compliance Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No Restricted Insider may trade in Company securities at any time unless the trade has been approved by the Insider Trading Compliance Officer or such officer&#8217;s designee in accordance with the procedures set forth below.  The Company has designated the General Counsel or highest legal officer, as its insider trading compliance officer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Insider Trading Compliance Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> The Insider Trading Compliance Officer or such officer&#8217;s designee will review and either approve or prohibit all proposed trades by Restricted Insiders in accordance with the procedures set forth in Section C below&#59; provided that proposed trades by any current member of the Company&#8217;s Executive Committee must be reviewed by the Insider Trading Compliance Officer.  The Insider Trading Compliance Officer may consult with the Company&#8217;s other officers and&#47;or legal counsel and will receive approval for his own trades from the Chief Financial Officer.  If a Restricted Insider is unable to contact the Insider Trading Compliance Officer or does not feel comfortable discussing the matter with the Insider Trading Compliance Officer, the Restricted Insider may contact the Chief Financial Officer, who will be the alternate Insider Trading Compliance Officer (the Insider Trading Compliance Officer and the alternate Insider Trading Compliance Officer are collectively referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Insider Trading Compliance Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; in these Trading Procedures).</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5. &#160;&#160;&#160;&#160;No Trading During Special Blackout Windows</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Insiders will not always be aware of material, non-public developments involving the Company.  If an Insider engages in a trade before a material, non-public development is disclosed to the public or resolved, the Insider and the Company might be exposed to a charge of insider trading that could be costly and difficult to refute even if the Insider was unaware of the development.  In addition, a trade by an Insider during such a period could result in adverse publicity for the Company.  </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Therefore, no Insider may trade in Company securities if the Insider is notified by the Insider Trading Compliance Officer or such officer&#8217;s designee that the trading window is closed because of the existence of a material, nonpublic development.  The Insider Trading Compliance Officer or such officer&#8217;s designee will subsequently notify Insiders once the material, nonpublic development is disclosed to the public or resolved and the trading window is open.  While the Insider Trading Compliance Officer will undertake reasonable efforts to notify Insiders of material, nonpublic developments that have occurred, or are soon likely to occur, each Insider has a duty not to trade in Company securities when material, nonpublic information exists, regardless of whether the Insider is notified by the Insider Trading Compliance Officer or such officer&#8217;s designee. </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6. &#160;&#160;&#160;&#160;No Short Sales or Margin Calls</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No Insider may at any time sell any securities of the Company that are not owned by such Insider at the time of the sale (a &#8220;short sale&#8221;) or use the Company&#8217;s shares as collateral in a margin account.  </font></div><div style="text-indent:36pt"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div><font><br></font></div></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7. &#160;&#160;&#160;&#160;No Purchases or Sales of Derivative Securities, Hedging Transactions or Pledges Without Pre-Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No Insider may buy or sell puts, calls, other derivative securities of the Company or any derivative securities that provide the economic equivalent of ownership of any of the Company&#8217;s securities or an opportunity, direct or indirect, to profit from any change in the value of the Company&#8217;s securities, engage in any other hedging transaction with respect to the Company&#8217;s securities or pledge Company securities as collateral for a loan (or modify an existing pledge), at any time unless such transaction has been approved by the Insider Trading Compliance Officer or the Audit Committee of the Board (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Audit Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any request for approval of such a transaction by an Insider must be submitted to the Insider Trading Compliance Officer or the Audit Committee in writing at least two weeks prior to the proposed execution of documents evidencing the transaction.  Any such request submitted by an Insider will be considered by the Insider Trading Compliance Officer or the Audit Committee on a case-by-case basis and, if permitted, will be subject to all of the other restrictions on trading in the Company&#8217;s securities set forth in these Trading Procedures.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8. &#160;&#160;&#160;&#160;Gifts Subject to Same Restrictions as All Other Securities Trades</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">   </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No Insider may give or make any other transfer of Company securities without consideration (e.g., a gift) during a period when the Insider is not permitted to trade unless the Insider submits a Share Transaction Request for Gifts form attached to these Trading Procedures and, if requested by the Insider Trading Compliance Officer, written acknowledgement from the donee agreeing not to sell the securities until such time as the Insider could sell.  As used in these Trading Procedures, the term &#8220;trades&#8221; and similar terms also include gifts.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">C.  &#160;&#160;&#160;&#160;PRE-CLEARANCE PROCEDURES </font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No Restricted Insider may trade in Company securities until&#58;</font></div><div style="padding-left:72pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">The Restricted Insider has notified the Insider Trading Compliance Officer or such officer&#8217;s designee of the amount and nature of the proposed trade(s) using the relevant Share Transaction Request form attached to these Trading Procedures and emailing that form to TradingApproval&#64;beigene.com&#59;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">The Restricted Insider has certified in writing prior to the proposed trade(s), by signing in the designated space in the relevant Share Transaction Request, that the Restricted Insider does not possess material, nonpublic information concerning the Company&#59;</font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">For executive officers and Directors, the Restricted Insider has informed the Insider Trading Compliance Officer whether, to the Restricted Insider&#8217;s best knowledge, (a) the Restricted Insider has (or is deemed to have) engaged in any opposite way transactions within the previous six months that were not exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and (b) the transaction will meet all of the applicable conditions of Rule 144 under the Securities Act of 1933, as amended&#59; and </font></div><div style="padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">The Insider Trading Compliance Officer or his designee has approved the trade(s) and has certified and dated his approval in writing or by electronic mail. </font></div><div style="padding-left:36pt"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">An electronic version of the Share Transfer Request form is also available via electronic platform for submission.  The written and electronic records of the above notification and approval shall be preserved and maintained to comply with the Hong Kong Securities Trading Requirements.  The Insider Trading Compliance Officer and such officer&#8217;s designee does not assume responsibility for, and approval by the Insider Trading Compliance Officer or such officer&#8217;s designee does not protect the Restricted Insider from, the consequences of prohibited insider trading, short-swing transactions under Section 16(b) of the Exchange Act or a violation of the registration requirements of the Securities Act of 1933, as amended.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Additional Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Restricted Insiders shall provide to the Insider Trading Compliance Officer any documentation reasonably requested by him in furtherance of the foregoing procedures.  Failure to provide the documentation will be grounds for denial of approval by the Insider Trading Compliance Officer.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">No Obligation to Approve Trades</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Insider Trading Compliance Officer has no obligation to approve a trade requested by a Restricted Insider and may reject a trading request in his sole reasonable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">discretion.  From time to time, an event may occur that is material to the Company and is known by only a few Directors or executives.  So long as the event remains material and nonpublic, the Insider Trading Compliance Officer may decide not to approve any trades in the Company&#8217;s securities without disclosing the reason. </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Completion of Trades</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">After receiving written clearance to engage in a trade signed by the Insider Trading Compliance Officer or such officer&#8217;s designee, a Restricted Insider must complete the trade within five business days (or the shorter period of time set forth on such clearance) or make a new trading request.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Post-Trade Reporting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Directors and executive officers must provide the Insider Trading Compliance Officer with sufficient information to report trades in the Company&#8217;s securities (including trades effected pursuant to a Rule 10b5-1 Plan) pursuant to Section 16 of the Exchange Act on the same day in which a trade occurs.  Compliance with this provision is imperative given the requirement of Section 16 of the Exchange Act that these persons report changes in ownership of Company securities within two business days.  The consequences of noncompliance with this reporting deadline include disclosure in the Company&#8217;s proxy statement for the next annual meeting of shareholders, as well as possible civil or criminal sanctions.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each report made by a Director and executive officer to the Insider Trading Compliance Officer must include the date of the trade, quantity of shares and, for purchases and sales, price and broker-dealer through which the trade was effected.  This reporting requirement may be satisfied by sending (or having the Restricted Insider&#8217;s broker send) duplicate confirmations of trades to the Insider Trading Compliance Officer so long as the information is received by the Insider Trading Compliance Officer on or before the required date.  This requirement is in addition to any required notification that the Company receives from the broker who completes the trade and may be satisfied via electronic mail.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Each Director shall disclose his or her interest in the securities of the Company or the associated corporation of the Company (as defined in Part XV of the SFO) and any change in that interest.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Where a change takes place in the interest of the securities of the Company held by a Director (including but not limited to purchase, sale, transfer, or any other change of nature of </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">interest (e.g. pledge), he or she shall within three business days of the change disclose the change to the Company, which, if required, shall then make an announcement on the website of the HKEx and make any required disclosure filings with the Securities and Futures Commission.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In relation to transactions by Directors in Company securities, the Company shall disclose in its interim reports (and summary interim reports, if any) and the Corporate Governance Report contained in its annual reports (and summary financial reports, if any)&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a) whether it has adopted a code of conduct regarding transactions by Directors in Company securities on terms no less exacting than those in the Model Code&#59;</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b) having made specific enquiry of all Directors, whether its Directors have or have not complied with the standard set out in the Model Code and its code of conduct regarding transactions by Directors in Company securities&#59; and</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c) in the event of any non-compliance with the standard set out in the Model Code, details of such non-compliance and an explanation of the remedial steps taken by the Company to address such non-compliance.</font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">D. &#160;&#160;&#160;&#160;EXEMPTIONS </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Pre-Approved Rule 10b5-1 Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Trades effected pursuant to a pre-approved Rule 10b5-1 plan (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Rule 10b5-1 Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) are not subject to the Company&#8217;s blackout periods or pre-clearance procedures and do not require submission by Insiders of a Share Transaction Request form.  Rule 10b5-1 of the Exchange Act provides an affirmative defense from insider trading liability under the federal securities laws for trading plans that meet its requirements.  A trading plan, arrangement or instruction that meets the requirements of Rule 10b5-1 enables Insiders to establish arrangements to trade in Company securities outside of the Company&#8217;s trading windows, even when in possession of material, nonpublic information.  If an Insider intends to trade pursuant to a Rule 10b5-1 Plan, the plan must satisfy the requirements set forth in the Requirements for 10b5-1 Trading Plans appended to these Trading Procedures.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Insider Trading Compliance Officer may refuse to approve a Rule 10b5-1 Plan in his sole discretion.  In determining whether to approve a Rule 10b5-1 Plan, the Insider Trading Compliance Officer may, in furtherance of the objectives expressed in the Insider Trading Policy, impose conditions in addition to those in Rule 10b5-1.  The Insider Trading Compliance Officer may consult with the Company&#8217;s legal counsel before approving a Rule 10b5-1 Plan.  Until such time as the Insider Trading Compliance Officer approves an Insider&#8217;s Rule 10b5-1 Plan, the Insider must comply with the pre-clearance procedures and trading windows set forth above.  </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any modification of an Insider&#8217;s Rule 10b5-1 Plan requires pre-approval by the Insider Trading Compliance Officer.  A modification must occur during a trading window and while the Insider is not aware of material, nonpublic information.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Employee Benefit Plans.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1. &#160;&#160;&#160;&#160;Exercise of Share Options and Warrants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The trading prohibitions and restrictions set forth in these Trading Procedures do not apply to the exercise of an option or warrant to purchase securities of the Company when payment of the exercise price is made in cash.  However, the exercise of an option or warrant to purchase securities of the Company is subject to the current reporting requirements of Section 16 of the Exchange Act by Directors and executive officers, and, therefore, such persons must comply with the post-trade reporting requirement described in Section C above for any such transaction.  In addition, the securities acquired upon the exercise of an option or warrant to purchase Company securities are subject to all of the requirements of these Trading Procedures and the Insider Trading Policy.  Moreover, these Trading Procedures apply to the use of outstanding Company securities to constitute part or all of the exercise price of an option or warrant, any net option or warrant exercise, any exercise of a share appreciation right, share withholding, any sale of shares as part of a broker-assisted cashless exercise of an option or warrant, or any other market sale for the purpose of generating the cash needed to pay the exercise price of an option or warrant.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.   &#160;&#160;&#160;&#160;Tax Withholding on Restricted Shares&#47;Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The trading prohibitions and restrictions set forth in these Trading Procedures do not apply to the withholding by the Company of shares upon vesting of restricted shares or upon settlement of restricted share units to satisfy applicable tax withholding requirements if (a) such withholding is required by the applicable plan or award agreement or (b) the election to exercise such tax withholding right was made by the Insider in compliance with these Trading Procedures.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.   &#160;&#160;&#160;&#160;Employee Stock Purchase Plan.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The trading prohibitions and restrictions set forth in these Trading Procedures do not apply to purchases of the Company&#8217;s securities with periodic wage withholding contributions pursuant to employees&#8217; advance instructions under the Company&#8217;s Employee Stock Purchase Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  However, without complying with these Trading Procedures, no Insider may&#58; (a) elect to participate in the Plan or alter the Insider&#8217;s instructions regarding the level of withholding or purchase by the Insider of Company securities under the Plan or (b) make cash contributions to the Plan (other than through periodic wage withholding).  Any sale of securities acquired under the Plan is subject to the prohibitions and restrictions of these Trading Procedures.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font></div><div style="text-indent:36pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">E. &#160;&#160;&#160;&#160;WAIVERS </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Insider Trading Compliance Officer or the Audit Committee may waive in writing any provision of these Trading Procedures in a specific instance. Any such waiver for a Director or executive officer by the Insider Trading Compliance Officer shall be reported to the Audit Committee.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">F. &#160;&#160;&#160;&#160;ACKNOWLEDGMENT </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition to the Company&#8217;s Insider Trading Policy, these Trading Procedures will be delivered to all current Insiders and to all new Insiders at the start of their employment or relationship with the Company.  Upon first receiving a copy of these Trading Procedures, each Insider must acknowledge that he or she has received a copy and agrees to comply with the terms of these Trading Procedures and the Insider Trading Policy.  The Insider shall return the acknowledgment attached hereto within ten (10) days of receipt to Human Resources as part of their new hire paperwork (for new employees) or to TradingApproval&#64;beigene.com (for existing employees).</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This acknowledgment will constitute consent for the Company to impose sanctions for violation of the Insider Trading Policy or these Trading Procedures and to issue any necessary stop- transfer orders to the Company&#8217;s transfer agent to ensure compliance.</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Insiders will be required upon the Company&#8217;s request or as part of annual compliance training to re-acknowledge and agree to comply with these Trading Procedures and the Insider Trading Policy (including any amendments or modifications).  For such purpose, an Insider will be deemed to have acknowledged and agreed to comply with these Trading Procedures and the Insider Trading Policy when copies have been delivered to the Insider by regular or electronic mail or through the Company&#8217;s online compliance training platform (or other delivery option used by the Company) by the Insider Trading Compliance Officer or such officer&#8217;s designee. ____________________</font></div><div style="text-align:center"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Failure to observe these Trading Procedures and the Insider Trading Policy could lead to significant legal problems and have other serious consequences, including termination of employment or service relationship.  Questions regarding these Trading Procedures or the Insider Trading Policy are encouraged and should be directed to the Insider Trading Compliance Officer.</font></div><div><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ACKNOWLEDGMENT</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I hereby acknowledge that I have read, that I understand, and that I agree to comply with, the Insider Trading Policy (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Insider Trading Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and the Special Trading Procedures for Insiders (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Trading Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) of BeiGene, Ltd. and its subsidiaries (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  I further acknowledge and agree that I am responsible for ensuring compliance with the Insider Trading Policy and the Trading Procedures by all of my &#8220;Affiliates&#8221; (including any such persons listed below). </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I also understand and agree that I will be subject to sanctions, including termination of my employment or service relationship, that may be imposed by the Company, in its sole discretion, for violation of the Insider Trading Policy or the Trading Procedures and that the Company may give stop-transfer and other instructions to the Company&#8217;s transfer agent against the transfer of any Company securities in a transaction that the Company considers to be in violation of the Insider Trading Policy or the Trading Procedures.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I hereby designate the following investment funds and partnerships as entities for which the Trading Procedures shall not apply&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> </font></div><div style="padding-left:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:13.35pt"> </font></div><div style="padding-left:15.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.848%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td></tr><tr style="height:30pt"><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td></tr></table></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I hereby represent to the Company that such entities&#58;  (a) engage in the investment of securities in the ordinary course of their respective businesses&#59; (b) have established insider trading controls and procedures designed to ensure compliance with applicable securities laws&#59; and (c) are aware such securities laws prohibit any person or entity who has material, nonpublic information concerning the Company from purchasing or selling securities of the Company or from communicating that information to any other person.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.681%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:2.77pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Signature&#58;</font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt;text-align:justify"><font><br></font></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.77pt;text-align:right"><font><br></font></div><div style="margin-top:0.05pt;padding-right:2.77pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:12.70pt">Name&#58;</font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td></tr><tr><td colspan="6" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-right:2.77pt;text-align:right"><font><br></font></div><div style="padding-right:2.77pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:12.70pt">Title&#58;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td></tr></table></div><div style="padding-left:216pt"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SHARE TRANSACTION REQUEST FOR TRADES </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Pursuant to BeiGene, Ltd.&#8217;s Special Trading Procedures for Insiders (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;text-decoration:underline">Trading Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8221;), I hereby notify BeiGene, Ltd. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8221;) of my intent to trade the securities of the Company as indicated below&#58;</font></div><div style="margin-top:0.05pt"><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.495%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:9.00pt;text-decoration:underline">REQUESTER INFORMATION</font></div><div style="padding-left:74.77pt;padding-right:2.77pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:9.00pt">Insider&#8217;s Name&#58;&#160;&#160;&#160;&#160; _________________________________________</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.651%"><tr><td style="width:1.0%"></td><td style="width:24.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:63.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:9.00pt;text-decoration:underline">INTENT TO PURCHASE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:9.00pt"> </font></div><div style="padding-left:117.97pt;padding-right:2.77pt;text-indent:-115.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:9.00pt">Number of shares or ADSs&#58; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;__________________________</font></div><div style="padding-left:117.97pt;padding-right:2.77pt;text-indent:-115.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:9.00pt">Intended trade date&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;__________________________</font></div></td></tr><tr style="height:32pt"><td colspan="3" rowspan="2" style="border-left:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:9.00pt">Means of acquiring shares or ADSs&#58;</font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:9.00pt"></font></div></td><td colspan="3" rowspan="2" style="border-right:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:9.00pt">Acquisition through employee benefit plan (please specify)&#58;  _____________________________</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:9.00pt">Purchase through a broker on the open market</font></div></td></tr><tr style="height:33pt"><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:9.00pt"></font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:9.00pt"></font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:9.00pt">Other (please specify)&#58; ___________________________________________________________</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.651%"><tr><td style="width:1.0%"></td><td style="width:33.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:9.00pt;text-decoration:underline">INTENT TO SELL </font></div><div style="padding-left:117.97pt;padding-right:2.77pt;text-indent:-115.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:9.00pt">Number of shares or ADSs&#58;&#160;&#160;&#160;&#160;__________________________</font></div><div style="padding-left:117.97pt;padding-right:2.77pt;text-indent:-115.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:9.00pt">Intended trade date&#58; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;__________________________</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:9.00pt">Means of selling shares or ADSs&#58;</font></div><div style="padding-left:8.27pt;padding-right:2.77pt"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:9.00pt"></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="border-right:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:9.00pt">Sale through a broker on the open market&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:9.00pt"></font></div></td><td colspan="3" style="padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="border-right:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:9.00pt">Other (please specify)&#58; __________________________________________________________</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.651%"><tr><td style="width:0.1%"></td><td style="width:2.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.301%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%;text-decoration:underline">CERTIFICATION </font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:122%">I hereby certify that (1) I am not in possession of any material, nonpublic information concerning the Company, as defined in the Company&#8217;s Insider Trading Policy and (2) if I am an executive officer or director of the Company, (a) to the best of my knowledge, the proposed trade(s) listed above will not constitute a short-swing transaction for purposes of Section 16(b) of the Securities Exchange Act of 1934, as amended, and will satisfy the requirements of Rule 144 under the Securities Act of 1933, as amended, and (b) I will report any future transactions in the Company&#8217;s securities (including transactions effected pursuant to a Rule 10b5-1 Plan) on the same day in which a transaction occurs, as required by the Trading Procedures.  I understand that, if I trade while possessing material, nonpublic information concerning the Company, I may be subject to severe civil and&#47;or criminal penalties and may be subject to sanctions by the Company including termination.</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Insider&#8217;s Signature </font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Date </font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.651%"><tr><td style="width:0.1%"></td><td style="width:2.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.301%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:9.00pt;text-decoration:underline">AUTHORIZED APPROVAL. This approval is valid for five (5) trading days from the date of approval.</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:9.00pt">Signature of Insider Trading Compliance Officer (or designee)</font></div><div style="padding-left:20.02pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.19pt;font-weight:400;line-height:8.20pt">&#160;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:9.00pt">Date </font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:700;line-height:120%">* NOTE&#58; Multiple lots must be listed on separate forms or broken out herein. </font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SHARE TRANSACTION REQUEST FOR GIFTS </font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Pursuant to BeiGene, Ltd.&#8217;s Special Trading Procedures for Insiders (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;text-decoration:underline">Trading Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8221;), I hereby notify BeiGene, Ltd. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">&#8221;) of my intent to gift securities of the Company as indicated below&#58; </font></div><div style="margin-top:0.15pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.495%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2.9pt;margin-top:3pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:80%;text-decoration:underline">REQUESTER INFORMATION</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:74.77pt;padding-right:2.77pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:87%">Insider&#8217;s Name&#58;&#160;&#160;&#160;&#160; _________________________________________</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.495%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:9.00pt;text-decoration:underline">INTENT TO GIFT</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:9.00pt">Number of shares or ADSs&#58; ________________________________</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:9.00pt">Intended gift date&#58; _______________________________</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:9.00pt">Means of gifting shares&#58;                                        </font><font style="font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:9.00pt"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:9.00pt">Through a broker</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:9.00pt">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:'Wingdings',sans-serif;font-size:7.5pt;font-weight:400;line-height:9.00pt"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:9.00pt">        Other (please specify)&#58; _______________________________ </font></div></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.651%"><tr><td style="width:0.1%"></td><td style="width:2.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.301%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%;text-decoration:underline">CERTIFICATION </font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:122%">I hereby certify that (a) (i) I am not in possession of any material, nonpublic information concerning the Company, as defined in the Company&#8217;s Insider Trading Policy, or (ii) if I am in possession of any material, nonpublic information concerning the Company at the time of making the gift, I understand that the Insider Trading Compliance Officer, prior to granting his approval, may request written acknowledgement from the donee agreeing not to trade in the securities until such time as I could trade in the securities, pursuant to the Trading Procedures, and (b) this is a bona fide gift for which no consideration is being received by me.</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Insider&#8217;s Signature </font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Date </font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.651%"><tr><td style="width:0.1%"></td><td style="width:2.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.301%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:9.00pt;text-decoration:underline">AUTHORIZED APPROVAL. This approval is valid for five (5) trading days from the date of approval. </font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:9.00pt">Signature of Insider Trading Compliance Officer (or designee)</font></div><div style="padding-left:20.02pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:8.20pt">&#160;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:9.00pt">Date </font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font><br></font></div></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:700;line-height:120%">*NOTE&#58; Multiple lots must be listed on separate forms or broken out herein. </font></div><div><font><br></font></div><div><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div><font><br></font></div></div><div style="text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">REQUIREMENTS FOR 10b5-1 TRADING PLANS </font></div><div style="text-align:center;text-indent:18pt"><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For transactions under a trading plan to be exempt from (i) the prohibitions in the Company&#8217;s Insider Trading Policy on transactions made while an Insider is aware of material, nonpublic information concerning the Company and (ii) the pre-clearance procedures and blackout periods established under the Trading Procedures, the trading plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> must comply with the requirements of Securities Exchange Act Rule 10b5-1 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Rule 10b5-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and meet the requirements set forth below.  As indicated below, any change to a plan that affects the amount, price or timing of a purchase or sale of the securities subject to the plan will be considered a modification of the plan without regard to materiality.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </font></div><div style="text-indent:18pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The adoption or modification of a trading plan must be approved in writing by the Insider Trading Compliance Officer. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The trading plan must be in writing and signed by the Insider adopting the trading plan.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The trading plan must be adopted or modified at a time when no quarterly, special or other trading blackout period is in effect with respect to the Insider adopting or modifying the plan.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The trading plan must include a written representation from the Insider that, at the time of adoption or modification&#58;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">the Insider is not aware of any material, nonpublic information concerning the Company and</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">the Insider is adopting or modifying the trading plan in good faith and not as part of a plan or scheme to evade the prohibitions of Section 10(b) of the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and Rule 10b5-1.  The Insider must act in good faith with respect to the trading plan throughout its duration.  </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">The Insider adopting or modifying the trading plan may not have entered into or altered a corresponding or hedging transaction or position with respect to the type of security subject to the trading plan and must agree not to enter into any such transaction while the trading plan is in effect.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline">  </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Each trading plan used by an Insider must be subject to a &#8220;cooling off&#8221; period prior to the first trade, as follows&#58;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">For Insiders other than Directors and executive officers, the first trade</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> under the trading plan may not occur until after the later of (i) the termination of the current quarterly blackout period, if then in effect, following adoption or modification of the trading plan and (ii) 30 calendar days after adoption or modification of the trading plan.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">For Insiders that are Directors or executive officers, the first trade</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> under the trading plan may not occur until after the later of (i) 90 calendar days after adoption or modification of the trading plan and (ii) two business days following the filing of a Form 10-Q or Form 10-K for the fiscal quarter in which the plan was adopted or modified (but not to exceed 120 days after adoption or modification of the trading plan).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Each trading plan used by an Insider must provide that the Insider may not communicate any material nonpublic information about the Company to the broker or other third party administering the plan or attempt to influence how the broker or such party executes (or exercises its discretion in executing) orders or other transactions under the trading plan in any way.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Unless otherwise approved in writing by the Insider Trading Compliance Officer, the trading plan must have a minimum term of one year (starting from when trades may first occur in accordance with these requirements).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:56.88pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt">Trading plans may be terminated only with the written approval of the Insider Trading Compliance Officer or such officer&#8217;s designee.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:3pt">During any 12-month period, an Insider may enter into only one trading plan that is designed to effect the purchase or sale or other transfer of the total amount of the Company&#8217;s securities covered by the trading plan in a single transaction&#59; provided the Insider Trading Compliance Officer may approve an additional non-concurrent single-trade trading plan if that plan is in place solely to satisfy withholding tax requirements and the Insider does not control the timing of such sales.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:3pt">Unless otherwise approved by the Insider Trading Compliance Officer and permitted by Rule 10b5-1, an Insider may have only one trading plan in effect at any time&#59; however, an Insider may adopt a new trading plan to replace an existing trading plan before the scheduled termination date of the existing trading plan so long as the new trading plan does not become effective before the completion or expiration of transactions under the existing trading plan, in all cases consistent with Rule 10b5-1 and other requirements of these Trading Procedures.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:3pt">The Insider Trading Compliance Officer or such officer&#8217;s designee must be promptly notified of any modification or termination of the trading plan, including any suspension of trading under the plan.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:3pt">If the trading plan grants discretion to a stockbroker or other person to execute trades under the plan&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">trades made under the plan must be executed by someone other than the stockbroker or other person who executes trades in other securities for the Insider who adopted the plan&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">the Insider who adopted the plan may not confer with the person administering the plan regarding the Company or its securities.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:3pt">Each trading plan used by an Insider must provide for suspension of trades under the plan if legal, regulatory or contractual restrictions are imposed on the Insider, or other events occur, that would prohibit trades under the plan.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:3pt">Each trading plan must contain an explicit acknowledgement by the Insider that all filings required by the Exchange Act, as a result of or in connection with transactions under the plan, are the sole obligation of the Insider and not the Company.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:3pt">All transactions under the trading plan must comply with applicable law.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:3pt">The trading plan (including any modified trading plan) must meet such other requirements as the Insider Trading Compliance Officer may determine.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </font></div><div style="padding-left:36pt"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>5
<FILENAME>exhibit21-2024q4beigeneltd.htm
<DESCRIPTION>EX-21
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i2a799794a9074541aca0ec5ca6ee1744_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsidiaries</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.225%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.230%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name&#160;of&#160;Subsidiary</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Incorporation or Organization</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage&#160;of Ownership&#160;by the&#160;Registrant</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene 101</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene Argentina S.R.L.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Argentina</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene AUS Pty Ltd</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australia</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene Austria GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Austria</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene (Beijing) Co., Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">People&#8217;s Republic of China</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene Belgium SRL</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Belgium</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene Biologics Co., Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">People&#8217;s Republic of China</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene Brasil Ltda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brazil</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene (Canada) ULC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene Chile Limitada</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chile</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene Colombia S.A.S.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colombia</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene ESP, S.L.U. Unipersonal</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Spain</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene France Sarl</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">France</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene Germany GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene Guangzhou Biologics Manufacturing Co., Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">People&#8217;s Republic of China</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene (Guangzhou) Innovation Technology Co., Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">People&#8217;s Republic of China</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene (Hong Kong) Co., Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene Hopewell Urban Renewal, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Jersey, United States</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene International GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene Ireland Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Republic of Ireland</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene (Italy) S.r.l.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Italy</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene Japan, GK</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene Korea Y.H.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Korea</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene Malaysia Sdn. Bhd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Malaysia</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene Mexico S. de R.L. de C.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mexico</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene Netherlands B.V.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Netherlands</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene NZ Unlimited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Zealand</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene Peru (Sociedad Comercial de Responsabilidad Limitada &#8211; S.R.L)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peru</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene Pharmaceuticals GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene Pharmaceuticals (Guangzhou) Co., Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">People&#8217;s Republic of China</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene Pharmaceuticals Israel Ltd. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Israel</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene Pharmaceutical (Shanghai) Co., Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">People&#8217;s Republic of China</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene Poland sp. z o.o.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene Portugal, Unipessoal Lda.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Portugal</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene Shanghai</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene Shanghai 101</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene (Shanghai) Co., Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">People&#8217;s Republic of China</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene (Shanghai) Development Co., Ltd. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">People&#8217;s Republic of China</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene (Shanghai) Management Consulting Co., Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">People&#8217;s Republic of China</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene (Shanghai) Research &#38; Development Co., Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">People&#8217;s Republic of China</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene Shanghai Asset Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hong Kong</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene Singapore Pte. Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Singapore</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene South Africa Pty Ltd. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Africa</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21</font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.225%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.230%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene (Suzhou) Co., Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">People&#8217;s Republic of China</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene Sweden AB</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sweden</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene Switzerland GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene (Taiwan) Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taiwan</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene (Thailand) Ltd. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thailand</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene Turkey Medical Products Trade Limited Company</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Turkey</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene UK, Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene United Kingdom, Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United Kingdom</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene USA, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware, United States</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene US Holdings, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware, United States</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene US Manufacturing Co., Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware, United States</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beijing Innerway Bio-tech Co., Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">People&#8217;s Republic of China</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeOne Medicines Global Business Services Sp. Z o.o.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Poland</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeOne Medicines GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Switzerland</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BG NC 1, Ltd. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BG NC 2, Ltd. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Newco 101</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cayman Islands</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SuGene Pharmaceuticals (Suzhou) Co., Ltd. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">People&#8217;s Republic of China</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>exhibit231-2024q4.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i212e5f10979d42ce9653ecdb28d099ee_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM AND REPORT ON SCHEDULE</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consent</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-209410) pertaining to the 2011 Option Plan, 2016 Share Option and Incentive Plan, and Non-Plan Share Options of BeiGene, Ltd.,</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-214064) pertaining to the 2011 Option Plan of BeiGene, Ltd.,</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-216885) pertaining to the 2016 Share Option and Incentive Plan of BeiGene, Ltd.,</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-223319) pertaining to the 2016 Share Option and Incentive Plan, as amended, of BeiGene, Ltd.,</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-225543) pertaining to the 2018 Employee Share Purchase Plan and the 2018 Inducement Equity Plan of BeiGene, Ltd.,</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-228786) pertaining to the Second Amended and Restated 2016 Share Option and Incentive Plan and the Second Amended and Restated 2018 Employee Share Purchase Plan of BeiGene, Ltd.,</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-241697) pertaining to the Second Amended and Restated 2016 Share Option and Incentive Plan, as amended, of BeiGene, Ltd.,</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-8 No. 333-266639) pertaining to the Second Amended and Restated 2016 Share Option and Incentive Plan, as amended, of BeiGene, Ltd., </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Registration Statement (Form S-3 No. 333- 271762) of BeiGene, Ltd. and the related prospectus, </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Registration Statement (Form S-3 No. 333-271765) of BeiGene, Ltd. and the related prospectus&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Registration Statement (From S-8 No. 333-279980) pertaining to the Third Amended and Restated 2016 Share Option and Incentive Plan and the Fourth Amended and Restated 2018 Employee Share Purchase Plan of BeiGene, Ltd., and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Registration Statement (Form S-4 No. 333-281324) of BeiGene, Ltd. and the related prospectus&#59;</font></div><div style="margin-bottom:6pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our reports dated February&#160;27, 2025, with respect to the consolidated financial statements of BeiGene, Ltd. and the effectiveness of internal control over financial reporting of BeiGene, Ltd. included in this Annual Report (Form 10-K) of BeiGene, Ltd. for the year ended December&#160;31, 2024.</font></div><div style="margin-bottom:6pt;margin-top:9pt"><font><br></font></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Report on Schedule</font></div><div style="margin-bottom:6pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Shareholders and the Board of Directors of BeiGene, Ltd.  </font></div><div style="margin-bottom:6pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the consolidated financial statements of BeiGene, Ltd. (the Company) as of December 31, 2024 and 2023, and for each of the three years in the period ended December 31, 2024, and have issued our report thereon dated February 27, 2025 included elsewhere in this Form 10-K. Our audits of the consolidated financial statements included the financial statement schedule listed in Item 15 of this Form 10-K (the &#8220;schedule&#8221;). This schedule is the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s schedule, based on our audits.</font></div><div style="margin-bottom:6pt;margin-top:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In our opinion, the schedule presents fairly, in all material respects, the information set forth therein when considered in conjunction with the consolidated financial statements.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:45.029%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Ernst &#38; Young LLP</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Boston, Massachusetts</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 27, 2025</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>exhibit311-2024q4.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i228d995c9e7e459988e2ba63939dd666_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS UNDER SECTION 302</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, John V. Oyler, certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this annual report on Form 10-K of BeiGene, Ltd.&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9pt;margin-top:15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;27, 2025</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:45.029%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; JOHN V. OYLER</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John V. Oyler</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer and Chairman </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>exhibit312-2024q4.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i4ae951f575cb463aaec1746a9ad99897_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS UNDER SECTION 302</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Aaron Rosenberg, certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this annual report on Form 10-K of BeiGene, Ltd.&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9pt;margin-top:15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;27, 2025</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:45.029%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Aaron Rosenberg</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aaron Rosenberg</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>exhibit321-2024q4.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ibdb71aad460443ad89e6abcdcad8ac7f_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS UNDER SECTION 906 </font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font><br></font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of BeiGene, Ltd., an exempted company incorporated in the Cayman Islands with limited liability (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that&#58; </font></div><div style="margin-bottom:12pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Annual Report on Form 10-K for the year ended December&#160;31, 2024 (the &#8220;Form 10-K&#8221;) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Company. </font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.058%"><tr><td style="width:1.0%"></td><td style="width:47.601%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; February 27, 2025</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#47;s&#47; JOHN V. OYLER</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John V. Oyler</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer and Chairman</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; February 27, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#47;s&#47; AARON ROSENBERG</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aaron Rosenberg</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="margin-bottom:12pt"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>10
<FILENAME>exhibit991-disclosureforei.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i78b01c3d53c646e9b68be7169df19893_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Exhibit 99.1</font></div></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS </font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) added BeiGene, Ltd. (the &#8220;Company&#8221;) to its conclusive list of issuers identified under the Holdings Foreign Companies Accountable Act (&#8220;HFCAA&#8221;) following the filing of our annual report on Form 10-K with the SEC, which annual report was audited by Ernst &#38; Young Hua Ming LLP, a registered public accounting firm in mainland China that the Public Company Accounting Oversight Board (&#8220;PCAOB&#8221;) previously was unable to inspect or investigate completely, because of a position taken by an authority in the foreign jurisdiction. On March 23, 2022, Ernst &#38; Young Hua Ming LLP resigned as our independent registered public accounting firm for the audit of our financial statements and internal control over financial reporting to be filed with the SEC and since that time, the Company has engaged Ernst &#38; Young LLP, located in Boston, Massachusetts, United States, as the Company&#8217;s independent registered public accounting firm for the audit of our financial statements and internal control over financial reporting for the fiscal years ending December 31, 2022, December 31, 2023 and December 31, 2024.</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that no governmental entity in China has a controlling financial interest in the Company or its consolidated foreign operating entities. To the extent known by the Company, the Company is not aware of and has no reason to believe that any official of the Chinese Communist Party is a board member of the Company or its consolidated foreign operating entities. The articles of incorporation of the Company, as amended, and those of its consolidated foreign operating entities, do not contain any wording received from any charter of the Chinese Communist Party.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>bgne-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:c70194b9-233f-4b06-bc07-707c5a5abbc8,g:477d344e-a417-40e8-b704-01a6f7f40ad7-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:bgne="http://www.beigene.com/20241231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.beigene.com/20241231">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af-sub/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bgne-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bgne-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bgne-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="bgne-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.beigene.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.beigene.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>9952151 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>9952152 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>9952153 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>9952154 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>9952155 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" roleURI="http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY">
        <link:definition>9952156 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://www.beigene.com/role/DescriptionofBusiness">
        <link:definition>9952157 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.beigene.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952158 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandLicensingArrangements" roleURI="http://www.beigene.com/role/CollaborativeandLicensingArrangements">
        <link:definition>9952159 - Disclosure - Collaborative and Licensing Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestrictedCash" roleURI="http://www.beigene.com/role/RestrictedCash">
        <link:definition>9952160 - Disclosure - Restricted Cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.beigene.com/role/Investments">
        <link:definition>9952161 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesNet" roleURI="http://www.beigene.com/role/InventoriesNet">
        <link:definition>9952162 - Disclosure - Inventories, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.beigene.com/role/Leases">
        <link:definition>9952163 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNet" roleURI="http://www.beigene.com/role/PropertyPlantandEquipmentNet">
        <link:definition>9952164 - Disclosure - Property, Plant and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssets" roleURI="http://www.beigene.com/role/IntangibleAssets">
        <link:definition>9952165 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.beigene.com/role/IncomeTaxes">
        <link:definition>9952166 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformation" roleURI="http://www.beigene.com/role/SupplementalBalanceSheetInformation">
        <link:definition>9952167 - Disclosure - Supplemental Balance Sheet Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.beigene.com/role/Debt">
        <link:definition>9952168 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenue" roleURI="http://www.beigene.com/role/ProductRevenue">
        <link:definition>9952169 - Disclosure - Product Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerShare" roleURI="http://www.beigene.com/role/LossPerShare">
        <link:definition>9952170 - Disclosure - Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.beigene.com/role/ShareBasedCompensation">
        <link:definition>9952171 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossIncome" roleURI="http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncome">
        <link:definition>9952172 - Disclosure - Accumulated Other Comprehensive (Loss) Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquity" roleURI="http://www.beigene.com/role/ShareholdersEquity">
        <link:definition>9952173 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestrictedNetAssets" roleURI="http://www.beigene.com/role/RestrictedNetAssets">
        <link:definition>9952174 - Disclosure - Restricted Net Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://www.beigene.com/role/EmployeeBenefitPlans">
        <link:definition>9952175 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.beigene.com/role/CommitmentsandContingencies">
        <link:definition>9952176 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandGeographicInformation" roleURI="http://www.beigene.com/role/SegmentandGeographicInformation">
        <link:definition>9952177 - Disclosure - Segment and Geographic Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleICondensedFinancialInformationofRegistrant" roleURI="http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrant">
        <link:definition>9952178 - Disclosure - Schedule I - Condensed Financial Information of Registrant</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandLicensingArrangementsTables" roleURI="http://www.beigene.com/role/CollaborativeandLicensingArrangementsTables">
        <link:definition>9955513 - Disclosure - Collaborative and Licensing Arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestrictedCashTables" roleURI="http://www.beigene.com/role/RestrictedCashTables">
        <link:definition>9955514 - Disclosure - Restricted Cash (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.beigene.com/role/InvestmentsTables">
        <link:definition>9955515 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesNetTables" roleURI="http://www.beigene.com/role/InventoriesNetTables">
        <link:definition>9955516 - Disclosure - Inventories, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.beigene.com/role/LeasesTables">
        <link:definition>9955517 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNetTables" roleURI="http://www.beigene.com/role/PropertyPlantandEquipmentNetTables">
        <link:definition>9955518 - Disclosure - Property, Plant and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsTables" roleURI="http://www.beigene.com/role/IntangibleAssetsTables">
        <link:definition>9955519 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.beigene.com/role/IncomeTaxesTables">
        <link:definition>9955520 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformationTables" roleURI="http://www.beigene.com/role/SupplementalBalanceSheetInformationTables">
        <link:definition>9955521 - Disclosure - Supplemental Balance Sheet Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.beigene.com/role/DebtTables">
        <link:definition>9955522 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueTables" roleURI="http://www.beigene.com/role/ProductRevenueTables">
        <link:definition>9955523 - Disclosure - Product Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerShareTables" roleURI="http://www.beigene.com/role/LossPerShareTables">
        <link:definition>9955524 - Disclosure - Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.beigene.com/role/ShareBasedCompensationTables">
        <link:definition>9955525 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossIncomeTables" roleURI="http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncomeTables">
        <link:definition>9955526 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansTables" roleURI="http://www.beigene.com/role/EmployeeBenefitPlansTables">
        <link:definition>9955527 - Disclosure - Employee Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandGeographicInformationTables" roleURI="http://www.beigene.com/role/SegmentandGeographicInformationTables">
        <link:definition>9955528 - Disclosure - Segment and Geographic Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SECScheduleArticle1204CondensedFinancialInformationofRegistrantTables" roleURI="http://www.beigene.com/role/SECScheduleArticle1204CondensedFinancialInformationofRegistrantTables">
        <link:definition>9955529 - Disclosure - SEC Schedule, Article 12-04, Condensed Financial Information of Registrant (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessDetails" roleURI="http://www.beigene.com/role/DescriptionofBusinessDetails">
        <link:definition>9955530 - Disclosure - Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesInvestmentsDetails" roleURI="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails">
        <link:definition>9955531 - Disclosure - Summary of Significant Accounting Policies - Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" roleURI="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails">
        <link:definition>9955532 - Disclosure - Summary of Significant Accounting Policies - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesLandUseRightNetDetails" roleURI="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesLandUseRightNetDetails">
        <link:definition>9955533 - Disclosure - Summary of Significant Accounting Policies - Land Use Right, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesGoodwillandOtherIntangibleAssetsDetails" roleURI="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesGoodwillandOtherIntangibleAssetsDetails">
        <link:definition>9955534 - Disclosure - Summary of Significant Accounting Policies - Goodwill and Other Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails" roleURI="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails">
        <link:definition>9955535 - Disclosure - Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>9955536 - Disclosure - Summary of Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesGovernmentGrantsDetails" roleURI="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesGovernmentGrantsDetails">
        <link:definition>9955537 - Disclosure - Summary of Significant Accounting Policies -Government Grants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSegmentInformationDetails" roleURI="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails">
        <link:definition>9955538 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesConcentrationofRisksDetails" roleURI="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesConcentrationofRisksDetails">
        <link:definition>9955539 - Disclosure - Summary of Significant Accounting Policies - Concentration of Risks (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandLicensingArrangementsRecognizedRevenueDetails" roleURI="http://www.beigene.com/role/CollaborativeandLicensingArrangementsRecognizedRevenueDetails">
        <link:definition>9955540 - Disclosure - Collaborative and Licensing Arrangements - Recognized Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandLicensingArrangementsNovartisDetails" roleURI="http://www.beigene.com/role/CollaborativeandLicensingArrangementsNovartisDetails">
        <link:definition>9955541 - Disclosure - Collaborative and Licensing Arrangements - Novartis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandLicensingArrangementsOciperlimabOptionCollaborationandLicenseAgreementandChinaBroadMarketDevelopmentAgreementDetails" roleURI="http://www.beigene.com/role/CollaborativeandLicensingArrangementsOciperlimabOptionCollaborationandLicenseAgreementandChinaBroadMarketDevelopmentAgreementDetails">
        <link:definition>9955542 - Disclosure - Collaborative and Licensing Arrangements - Ociperlimab Option, Collaboration and License Agreement and China Broad Market Development Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandLicensingArrangementsAmgenDetails" roleURI="http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails">
        <link:definition>9955543 - Disclosure - Collaborative and Licensing Arrangements - Amgen (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandLicensingArrangementsFundingExpensesDetails" roleURI="http://www.beigene.com/role/CollaborativeandLicensingArrangementsFundingExpensesDetails">
        <link:definition>9955544 - Disclosure - Collaborative and Licensing Arrangements - Funding Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandLicensingArrangementsFinancingLiabilityDetails" roleURI="http://www.beigene.com/role/CollaborativeandLicensingArrangementsFinancingLiabilityDetails">
        <link:definition>9955545 - Disclosure - Collaborative and Licensing Arrangements - Financing Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandLicensingArrangementsAmountsandClassificationofPaymentsIncomeExpenseDetails" roleURI="http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmountsandClassificationofPaymentsIncomeExpenseDetails">
        <link:definition>9955546 - Disclosure - Collaborative and Licensing Arrangements - Amounts and Classification of Payments (Income/(Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandLicensingArrangementsPaymentClassificationDetails" roleURI="http://www.beigene.com/role/CollaborativeandLicensingArrangementsPaymentClassificationDetails">
        <link:definition>9955547 - Disclosure - Collaborative and Licensing Arrangements - Payment Classification (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestrictedCashandInvestmentsRestrictionsonCashandCashEquivalentsDetails" roleURI="http://www.beigene.com/role/RestrictedCashandInvestmentsRestrictionsonCashandCashEquivalentsDetails">
        <link:definition>9955548 - Disclosure - Restricted Cash and Investments - Restrictions on Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestrictedCashNarrativeDetails" roleURI="http://www.beigene.com/role/RestrictedCashNarrativeDetails">
        <link:definition>9955549 - Disclosure - Restricted Cash - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsInvestmentsInEquitySecuritiesDetails" roleURI="http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails">
        <link:definition>9955550 - Disclosure - Investments - Investments In Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsEquityMethodInvestmentsDetails" roleURI="http://www.beigene.com/role/InvestmentsEquityMethodInvestmentsDetails">
        <link:definition>9955551 - Disclosure - Investments - Equity Method Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesNetDetails" roleURI="http://www.beigene.com/role/InventoriesNetDetails">
        <link:definition>9955552 - Disclosure - Inventories, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativesDetails" roleURI="http://www.beigene.com/role/LeasesNarrativesDetails">
        <link:definition>9955553 - Disclosure - Leases - Narratives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseExpenseDetails" roleURI="http://www.beigene.com/role/LeasesComponentsofLeaseExpenseDetails">
        <link:definition>9955554 - Disclosure - Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalBalanceSheetDetails" roleURI="http://www.beigene.com/role/LeasesSupplementalBalanceSheetDetails">
        <link:definition>9955555 - Disclosure - Leases - Supplemental Balance Sheet (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" roleURI="http://www.beigene.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails">
        <link:definition>9955556 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" roleURI="http://www.beigene.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1">
        <link:definition>9955556 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesOtherSupplementalInformationDetails" roleURI="http://www.beigene.com/role/LeasesOtherSupplementalInformationDetails">
        <link:definition>9955557 - Disclosure - Leases - Other Supplemental Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNetPropertyPlantandEquipmentNetDetails" roleURI="http://www.beigene.com/role/PropertyPlantandEquipmentNetPropertyPlantandEquipmentNetDetails">
        <link:definition>9955558 - Disclosure - Property, Plant and Equipment, Net- Property, Plant and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNetNarrativesDetails" roleURI="http://www.beigene.com/role/PropertyPlantandEquipmentNetNarrativesDetails">
        <link:definition>9955559 - Disclosure - Property, Plant and Equipment, Net - Narratives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNetConstructioninProgressDetails" roleURI="http://www.beigene.com/role/PropertyPlantandEquipmentNetConstructioninProgressDetails">
        <link:definition>9955560 - Disclosure - Property, Plant and Equipment, Net - Construction in Progress (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsIntangibleAssetsOutstandingDetails" roleURI="http://www.beigene.com/role/IntangibleAssetsIntangibleAssetsOutstandingDetails">
        <link:definition>9955561 - Disclosure - Intangible Assets - Intangible Assets Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsUsefulLifeDetails" roleURI="http://www.beigene.com/role/IntangibleAssetsUsefulLifeDetails">
        <link:definition>9955562 - Disclosure - Intangible Assets - Useful Life (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsAmortizationExpenseDetails" roleURI="http://www.beigene.com/role/IntangibleAssetsAmortizationExpenseDetails">
        <link:definition>9955563 - Disclosure - Intangible Assets - Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsExpectedAmortizationExpenseDetails" roleURI="http://www.beigene.com/role/IntangibleAssetsExpectedAmortizationExpenseDetails">
        <link:definition>9955564 - Disclosure - Intangible Assets - Expected Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeLossBeforeIncomeTaxesDetails" roleURI="http://www.beigene.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails">
        <link:definition>9955565 - Disclosure - Income Taxes - Income/(Loss) Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesCurrentandDeferredComponentsIncomeTaxesDetails" roleURI="http://www.beigene.com/role/IncomeTaxesCurrentandDeferredComponentsIncomeTaxesDetails">
        <link:definition>9955566 - Disclosure - Income Taxes - Current and Deferred Components Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationoftheStatutoryRateDetails" roleURI="http://www.beigene.com/role/IncomeTaxesReconciliationoftheStatutoryRateDetails">
        <link:definition>9955567 - Disclosure - Income Taxes - Reconciliation of the Statutory Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails" roleURI="http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails">
        <link:definition>9955568 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets (Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesScheduleofValuationAllowancesDetails" roleURI="http://www.beigene.com/role/IncometaxesScheduleofValuationAllowancesDetails">
        <link:definition>9955569 - Disclosure - Income taxes - Schedule of Valuation Allowances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativesDetails" roleURI="http://www.beigene.com/role/IncomeTaxesNarrativesDetails">
        <link:definition>9955570 - Disclosure - Income Taxes - Narratives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesGrossUnrecognizedTaxBenefitsDetails" roleURI="http://www.beigene.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails">
        <link:definition>9955571 - Disclosure - Income Taxes - Gross Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails">
        <link:definition>9955572 - Disclosure - Supplemental Balance Sheet Information - Schedule of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails" roleURI="http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails">
        <link:definition>9955573 - Disclosure - Supplemental Balance Sheet Information - Schedule of Other Non-current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformationScheduleofAccruedExpensesandOtherPayablesDetails" roleURI="http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofAccruedExpensesandOtherPayablesDetails">
        <link:definition>9955574 - Disclosure - Supplemental Balance Sheet Information - Schedule of Accrued Expenses and Other Payables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementalBalanceSheetInformationScheduleofOtherLongtermLiabilitiesDetails" roleURI="http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherLongtermLiabilitiesDetails">
        <link:definition>9955575 - Disclosure - Supplemental Balance Sheet Information - Schedule of Other Long-term Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtShorttermandLongtermDebtObligationsDetails" roleURI="http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails">
        <link:definition>9955576 - Disclosure - Debt - Short-term and Long-term Debt Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtContractualmaturitiesofdebtobligationsDetails" roleURI="http://www.beigene.com/role/DebtContractualmaturitiesofdebtobligationsDetails">
        <link:definition>9955577 - Disclosure - Debt - Contractual maturities of debt obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://www.beigene.com/role/DebtNarrativeDetails">
        <link:definition>9955578 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueProductSalesDetails" roleURI="http://www.beigene.com/role/ProductRevenueProductSalesDetails">
        <link:definition>9955579 - Disclosure - Product Revenue - Product Sales (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueAccruedSalesRebatesandReturnsDetails" roleURI="http://www.beigene.com/role/ProductRevenueAccruedSalesRebatesandReturnsDetails">
        <link:definition>9955580 - Disclosure - Product Revenue - Accrued Sales Rebates and Returns (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LossPerShareDetails" roleURI="http://www.beigene.com/role/LossPerShareDetails">
        <link:definition>9955581 - Disclosure - Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation2016ShareOptionandIncentivePlanDetails" roleURI="http://www.beigene.com/role/ShareBasedCompensation2016ShareOptionandIncentivePlanDetails">
        <link:definition>9955582 - Disclosure - Share-Based Compensation - 2016 Share Option and Incentive Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation2018InducementEquityPlanDetails" roleURI="http://www.beigene.com/role/ShareBasedCompensation2018InducementEquityPlanDetails">
        <link:definition>9955583 - Disclosure - Share-Based Compensation - 2018 Inducement Equity Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation2018EmployeeSharePurchasePlanDetails" roleURI="http://www.beigene.com/role/ShareBasedCompensation2018EmployeeSharePurchasePlanDetails">
        <link:definition>9955584 - Disclosure - Share-Based Compensation - 2018 Employee Share Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationSharesIssuedUnderEmployeeSharePurchasePlanDetails" roleURI="http://www.beigene.com/role/ShareBasedCompensationSharesIssuedUnderEmployeeSharePurchasePlanDetails">
        <link:definition>9955585 - Disclosure - Share-Based Compensation - Shares Issued Under Employee Share Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationOptionsandRestrictedSharesandRestrictedStockUnitsVestingPeriodsDetails" roleURI="http://www.beigene.com/role/ShareBasedCompensationOptionsandRestrictedSharesandRestrictedStockUnitsVestingPeriodsDetails">
        <link:definition>9955586 - Disclosure - Share-Based Compensation - Options and Restricted Shares and Restricted Stock Units Vesting Periods (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationShareOptionRollforwardDetails" roleURI="http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails">
        <link:definition>9955587 - Disclosure - Share-Based Compensation - Share Option Rollforward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationFairValueAssumptionsDetails" roleURI="http://www.beigene.com/role/ShareBasedCompensationFairValueAssumptionsDetails">
        <link:definition>9955588 - Disclosure - Share-Based Compensation - Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationRestrictedShareUnitsDetails" roleURI="http://www.beigene.com/role/ShareBasedCompensationRestrictedShareUnitsDetails">
        <link:definition>9955589 - Disclosure - Share-Based Compensation - Restricted Share Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationSharebasedCompensationExpenseDetails" roleURI="http://www.beigene.com/role/ShareBasedCompensationSharebasedCompensationExpenseDetails">
        <link:definition>9955590 - Disclosure - Share-Based Compensation - Share-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossIncomeDetails" roleURI="http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncomeDetails">
        <link:definition>9955591 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareholdersEquityDetails" roleURI="http://www.beigene.com/role/ShareholdersEquityDetails">
        <link:definition>9955592 - Disclosure - Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestrictedNetAssetsDetails" roleURI="http://www.beigene.com/role/RestrictedNetAssetsDetails">
        <link:definition>9955593 - Disclosure - Restricted Net Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansAdditionalInformationDetails" roleURI="http://www.beigene.com/role/EmployeeBenefitPlansAdditionalInformationDetails">
        <link:definition>9955594 - Disclosure - Employee Benefit Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansTotalExpectedBenefitPaymentsDetails" roleURI="http://www.beigene.com/role/EmployeeBenefitPlansTotalExpectedBenefitPaymentsDetails">
        <link:definition>9955595 - Disclosure - Employee Benefit Plans - Total Expected Benefit Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.beigene.com/role/CommitmentsandContingenciesDetails">
        <link:definition>9955596 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandGeographicInformationNarrativesDetails" roleURI="http://www.beigene.com/role/SegmentandGeographicInformationNarrativesDetails">
        <link:definition>9955597 - Disclosure - Segment and Geographic Information - Narratives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentandGeographicInformationScheduleofRevenuebyGeographicAreaDetails" roleURI="http://www.beigene.com/role/SegmentandGeographicInformationScheduleofRevenuebyGeographicAreaDetails">
        <link:definition>9955598 - Disclosure - Segment and Geographic Information - Schedule of Revenue by Geographic Area (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails" roleURI="http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails">
        <link:definition>9955599 - Disclosure - Schedule I - Condensed Financial Information of Registrant (Condensed Statements of Operations) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveLossDetails" roleURI="http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveLossDetails">
        <link:definition>9955600 - Disclosure - Schedule I - Condensed Financial Information of Registrant (Condensed Statements of Comprehensive Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails" roleURI="http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails">
        <link:definition>9955601 - Disclosure - Schedule I - Condensed Financial Information of Registrant (Condensed Balance Sheets) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails" roleURI="http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails">
        <link:definition>9955602 - Disclosure - Schedule I - Condensed Financial Information of Registrant (Condensed Statements of Cash Flows) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleICondensedFinancialInformationNotestoCondensedFinancialStatementsDetails" roleURI="http://www.beigene.com/role/ScheduleICondensedFinancialInformationNotestoCondensedFinancialStatementsDetails">
        <link:definition>9955603 - Disclosure - Schedule I - Condensed Financial Information (Notes to Condensed Financial Statements) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="bgne_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bgne_CollaborationMember" abstract="true" name="CollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_EarningsPerAmericanDepositoryShareBasic" abstract="false" name="EarningsPerAmericanDepositoryShareBasic" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="bgne_EarningsPerAmericanDepositoryShareDiluted" abstract="false" name="EarningsPerAmericanDepositoryShareDiluted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic" abstract="false" name="WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted" abstract="false" name="WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bgne_ResearchAndDevelopmentCostShareLiabilityCurrentPortion" abstract="false" name="ResearchAndDevelopmentCostShareLiabilityCurrentPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion" abstract="false" name="ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_AcquiredInProcessResearchAndDevelopment" abstract="false" name="AcquiredInProcessResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_AmortizationOfResearchAndDevelopmentFinancingLiability" abstract="false" name="AmortizationOfResearchAndDevelopmentFinancingLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_PaymentsToPurchaseInProcessResearchAndDevelopment" abstract="false" name="PaymentsToPurchaseInProcessResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_InterestPaidIncludingCapitalizedInterest" abstract="false" name="InterestPaidIncludingCapitalizedInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_AcquiredInProcessResearchAndDevelopmentButNotYetPaid" abstract="false" name="AcquiredInProcessResearchAndDevelopmentButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_AdjustmentsToAdditionalPaidInCapitalDeconsolidationOfSubsidiary" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalDeconsolidationOfSubsidiary" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_RestrictedNetAssetsDisclosureAbstract" abstract="true" name="RestrictedNetAssetsDisclosureAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bgne_LandUseRightsPolicyPolicyTextBlock" abstract="false" name="LandUseRightsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bgne_GovernmentGrantsPolicyPolicyTextBlock" abstract="false" name="GovernmentGrantsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bgne_CollaborationAgreementsTableTextBlock" abstract="false" name="CollaborationAgreementsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bgne_ScheduleOfAmountsAndClassificationOfReimbursementExpenseTableTextBlock" abstract="false" name="ScheduleOfAmountsAndClassificationOfReimbursementExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bgne_PaymentsDueToCollaborationPartnersTableTextBlock" abstract="false" name="PaymentsDueToCollaborationPartnersTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bgne_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bgne_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" abstract="false" name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bgne_AccruedLiabilitiesAccountsPayableOtherAndOtherLiabilitiesCurrentTableTextBlock" abstract="false" name="AccruedLiabilitiesAccountsPayableOtherAndOtherLiabilitiesCurrentTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bgne_ScheduleOfAccruedSalesRebatesAndReturnsCurrentTableTextBlock" abstract="false" name="ScheduleOfAccruedSalesRebatesAndReturnsCurrentTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="bgne_RevenueFromContractWithCustomerExcludingAssessedTaxPeriodIncreaseDecrease" abstract="false" name="RevenueFromContractWithCustomerExcludingAssessedTaxPeriodIncreaseDecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestPeriodIncreaseDecrease" abstract="false" name="NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestPeriodIncreaseDecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_GuangzhouMember" abstract="true" name="GuangzhouMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_BeijingMember" abstract="true" name="BeijingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bgne_SuzhouMember" abstract="true" name="SuzhouMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bgne_ShanghaiMember" abstract="true" name="ShanghaiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bgne_InvestmentInDebtSecuritiesCurrent" abstract="false" name="InvestmentInDebtSecuritiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_InvestmentInDebtSecuritiesNonCurrent" abstract="false" name="InvestmentInDebtSecuritiesNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_GovernmentAssistanceManufacturingFacilityBuildOutMember" abstract="true" name="GovernmentAssistanceManufacturingFacilityBuildOutMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bgne_GovernmentAssistanceResearchAndDevelopmentProgramsMember" abstract="true" name="GovernmentAssistanceResearchAndDevelopmentProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bgne_DepreciationExpenseMember" abstract="true" name="DepreciationExpenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bgne_ASDSpecialtyHealthcareMember" abstract="true" name="ASDSpecialtyHealthcareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_McKessonMember" abstract="true" name="McKessonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bgne_ShanghaiPharmaceuticalMember" abstract="true" name="ShanghaiPharmaceuticalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_ThreeLargestCustomersMember" abstract="true" name="ThreeLargestCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_SinopharmMember" abstract="true" name="SinopharmMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_ChinaResourcesMember" abstract="true" name="ChinaResourcesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_FourLargestCustomersMember" abstract="true" name="FourLargestCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_CollaborationResearchAndDevelopmentServiceMember" abstract="true" name="CollaborationResearchAndDevelopmentServiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_RightToAccessIntellectualPropertyRevenueMember" abstract="true" name="RightToAccessIntellectualPropertyRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_MaterialRightsRevenueMember" abstract="true" name="MaterialRightsRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bgne_CollaborationOtherMember" abstract="true" name="CollaborationOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_NovartisMember" abstract="true" name="NovartisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_TislelizumabMember" abstract="true" name="TislelizumabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_OciperlimabMember" abstract="true" name="OciperlimabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bgne_NumberOfProductsInitiatedMarketingAndPromotion" abstract="false" name="NumberOfProductsInitiatedMarketingAndPromotion" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bgne_AmgenIncMember" abstract="true" name="AmgenIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_BeigeneLtdMember" abstract="true" name="BeigeneLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_CommercializationTerm" abstract="false" name="CommercializationTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bgne_CollaborativeArrangementsNumberOfProductsCompanyHasTheRightToRetain" abstract="false" name="CollaborativeArrangementsNumberOfProductsCompanyHasTheRightToRetain" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bgne_CollaborativeArrangementsProductRetentionPeriod" abstract="false" name="CollaborativeArrangementsProductRetentionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bgne_MaximumCashAndServicesDevelopmentCommitment" abstract="false" name="MaximumCashAndServicesDevelopmentCommitment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_SharePriceAmericanDepositoryShares" abstract="false" name="SharePriceAmericanDepositoryShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="bgne_ProceedsFromIssuanceOfAssetDepositoryShares" abstract="false" name="ProceedsFromIssuanceOfAssetDepositoryShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_FairValueOfLiabilityAcquired" abstract="false" name="FairValueOfLiabilityAcquired" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_FairValueOfEquityInvestmentsIssued" abstract="false" name="FairValueOfEquityInvestmentsIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_FairValueOfFinancingCommitment" abstract="false" name="FairValueOfFinancingCommitment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_RoyaltiesReceivingPeriod" abstract="false" name="RoyaltiesReceivingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bgne_FinancingCommitmentExpenses" abstract="false" name="FinancingCommitmentExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_AmortizationOfFinancingCommitment" abstract="false" name="AmortizationOfFinancingCommitment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_FinancingCommitmentCarryingValueCurrent" abstract="false" name="FinancingCommitmentCarryingValueCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_FinancingCommitmentCarryingValueNoncurrent" abstract="false" name="FinancingCommitmentCarryingValueNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_FinancingCommitmentCarryingValue" abstract="false" name="FinancingCommitmentCarryingValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_ReimbursementExpense" abstract="false" name="ReimbursementExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_CollaborativeArrangementCompensationTypeAxis" abstract="true" name="CollaborativeArrangementCompensationTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="bgne_CollaborativeArrangementCompensationTypeDomain" abstract="true" name="CollaborativeArrangementCompensationTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_UpfrontPaymentsMember" abstract="true" name="UpfrontPaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_DevelopmentMilestonePaymentsMember" abstract="true" name="DevelopmentMilestonePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_RegulatoryAndCommercialMilestonePaymentsMember" abstract="true" name="RegulatoryAndCommercialMilestonePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_ResearchAndDevelopmentMember" abstract="true" name="ResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_IntangibleAssetsMember" abstract="true" name="IntangibleAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_UpfrontAndMilestonePayments" abstract="false" name="UpfrontAndMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_STARMarketMember" abstract="true" name="STARMarketMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_LeapTherapeuticIncMember" abstract="true" name="LeapTherapeuticIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_PiHealthIncMember" abstract="true" name="PiHealthIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bgne_OtherEquityMethodInvestmentsMember" abstract="true" name="OtherEquityMethodInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bgne_DisposalGroupNotDiscontinuedOperationNetAssets" abstract="false" name="DisposalGroupNotDiscontinuedOperationNetAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmountNet" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmountNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_HopewellFacilityMember" abstract="true" name="HopewellFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_ShanghaiChinaMember" abstract="true" name="ShanghaiChinaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember" abstract="true" name="AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_EffectiveIncomeTaxRateReconciliationDeductionResearchExpensesAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationDeductionResearchExpensesAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_DeferredTaxAssetsPropertyLeaseLiabilityObligation" abstract="false" name="DeferredTaxAssetsPropertyLeaseLiabilityObligation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_DeferredTaxAssetsActivityRollForward" abstract="true" name="DeferredTaxAssetsActivityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bgne_DeferredTaxAssetValuationAllowanceChangesIncludedInEarnings" abstract="false" name="DeferredTaxAssetValuationAllowanceChangesIncludedInEarnings" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_DeferredTaxAssetValuationAllowanceGainLossIncludedInOtherComprehensiveIncomeLoss" abstract="false" name="DeferredTaxAssetValuationAllowanceGainLossIncludedInOtherComprehensiveIncomeLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_DeferredTaxAssetValuationAllowanceCurrencyTranslationAndOther" abstract="false" name="DeferredTaxAssetValuationAllowanceCurrencyTranslationAndOther" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_TaxBenefitFromForeignTaxStatus" abstract="false" name="TaxBenefitFromForeignTaxStatus" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_TaxBenefitFromForeignTaxStatusPerShare" abstract="false" name="TaxBenefitFromForeignTaxStatusPerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="bgne_PrepaidResearchAndDevelopmentCosts" abstract="false" name="PrepaidResearchAndDevelopmentCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_PrepaidGeneralAndAdministrativeExpensesCurrent" abstract="false" name="PrepaidGeneralAndAdministrativeExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_PrepaidManufacturingCosts" abstract="false" name="PrepaidManufacturingCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_PrepaidSupplyCost" abstract="false" name="PrepaidSupplyCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_RentalDepositsAndOther" abstract="false" name="RentalDepositsAndOther" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_PrepaymentOfLongTermAsset" abstract="false" name="PrepaymentOfLongTermAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_AccruedSalesRebatesAndReturnsCurrent" abstract="false" name="AccruedSalesRebatesAndReturnsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_AccruedLiabilitiesExternalResearchAndDevelopment" abstract="false" name="AccruedLiabilitiesExternalResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_AccruedExpensesCommercialActivities" abstract="false" name="AccruedExpensesCommercialActivities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_AccruedGeneralAndAdministrativeExpensesCurrent" abstract="false" name="AccruedGeneralAndAdministrativeExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_AccruedProfessionalFeesAndOtherCurrent" abstract="false" name="AccruedProfessionalFeesAndOtherCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_ShortTermBankLoanDatedApril42018Member" abstract="true" name="ShortTermBankLoanDatedApril42018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bgne_ShortTermBankLoanDatedJanuary222020Member" abstract="true" name="ShortTermBankLoanDatedJanuary222020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_ShortTermBankLoanDatedNovember92020Member" abstract="true" name="ShortTermBankLoanDatedNovember92020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_LongTermBankLoanDatedJuly292022Member" abstract="true" name="LongTermBankLoanDatedJuly292022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_ShortTermBankLoanDatedJuly282023Member" abstract="true" name="ShortTermBankLoanDatedJuly282023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bgne_ShortTermBankLoanDatedDecember202023Member" abstract="true" name="ShortTermBankLoanDatedDecember202023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bgne_ShortTermBankLoanDatedMarch212024Member" abstract="true" name="ShortTermBankLoanDatedMarch212024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bgne_ShortTermBankLoanDatedJune52023Member" abstract="true" name="ShortTermBankLoanDatedJune52023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bgne_ShortTermBankLoanDatedMay42023Member" abstract="true" name="ShortTermBankLoanDatedMay42023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bgne_ShortTermBankLoanDatedMay302023Member" abstract="true" name="ShortTermBankLoanDatedMay302023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bgne_ShortTermBankLoanDatedNovember142023Member" abstract="true" name="ShortTermBankLoanDatedNovember142023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bgne_ShortTermBankLoanDatedMay252023Member" abstract="true" name="ShortTermBankLoanDatedMay252023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bgne_LongTermBankLoanApril42018Member" abstract="true" name="LongTermBankLoanApril42018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_LongTermBankLoanDatedJanuary222020Member" abstract="true" name="LongTermBankLoanDatedJanuary222020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_LongTermBankLoanDatedNovember92020Member" abstract="true" name="LongTermBankLoanDatedNovember92020Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_ShortTermBankLoanMaturingJanuary272025Member" abstract="true" name="ShortTermBankLoanMaturingJanuary272025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bgne_ChinaConstructionBankMember" abstract="true" name="ChinaConstructionBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_ChinaMerchantsBankMember" abstract="true" name="ChinaMerchantsBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_ChinaCITICBankMember" abstract="true" name="ChinaCITICBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_ChinaMinshengBankMember" abstract="true" name="ChinaMinshengBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_ChinaIndustrialBankMember" abstract="true" name="ChinaIndustrialBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_HSBCBankMember" abstract="true" name="HSBCBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bgne_ShanghaiPudongDevelopmentBankMember" abstract="true" name="ShanghaiPudongDevelopmentBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_ProductNameAxis" abstract="true" name="ProductNameAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="bgne_ProductNameDomain" abstract="true" name="ProductNameDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_BRUKINSAMember" abstract="true" name="BRUKINSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_XGEVAMember" abstract="true" name="XGEVAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_BLINCYTOMember" abstract="true" name="BLINCYTOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_KYPROLISMember" abstract="true" name="KYPROLISMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_POBEVCYMember" abstract="true" name="POBEVCYMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_REVLIMIDMember" abstract="true" name="REVLIMIDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_OtherMember" abstract="true" name="OtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeReductions" abstract="false" name="RevenueFromContractWithCustomerExcludingAssessedTaxBeforeReductions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_RevenueRecognitionRevenueReduction" abstract="false" name="RevenueRecognitionRevenueReduction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_RebatesReturnsAndOtherDeductionsMember" abstract="true" name="RebatesReturnsAndOtherDeductionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bgne_ContraARAccrualsMember" abstract="true" name="ContraARAccrualsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bgne_AccruedSalesRebatesAndReturnsRollForward" abstract="true" name="AccruedSalesRebatesAndReturnsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bgne_RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions" abstract="false" name="RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_AccountsReceivableAllowanceForChargebacksAndCreditLoss" abstract="false" name="AccountsReceivableAllowanceForChargebacksAndCreditLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions" abstract="false" name="RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_RevenueRecognitionRevenueReductionsPaymentsAndCredits" abstract="false" name="RevenueRecognitionRevenueReductionsPaymentsAndCredits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_ShareOptionAndIncentivePlan2016Member" abstract="true" name="ShareOptionAndIncentivePlan2016Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_ShareIncentivePlan2011Member" abstract="true" name="ShareIncentivePlan2011Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_ThirdAmendedAndRestated2016PlanMember" abstract="true" name="ThirdAmendedAndRestated2016PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bgne_InducementEquityPlan2018Member" abstract="true" name="InducementEquityPlan2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_EmployeeSharePurchasePlan2018Member" abstract="true" name="EmployeeSharePurchasePlan2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountOnPurchasePriceOfCommonStockPercent" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountOnPurchasePriceOfCommonStockPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="bgne_MaximumPercentageOfEligibleEarningsSetSideToPurchaseOrdinaryShares" abstract="false" name="MaximumPercentageOfEligibleEarningsSetSideToPurchaseOrdinaryShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberOfAvailableSharesAvailableForFutureIssuance" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardNumberOfAvailableSharesAvailableForFutureIssuance" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="bgne_ShareBasedPaymentArrangementNonvestedAwardOptionNumberOfShares" abstract="false" name="ShareBasedPaymentArrangementNonvestedAwardOptionNumberOfShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestOutstandingNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestOutstandingNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="bgne_RestrictedNetAssetsAbstract" abstract="true" name="RestrictedNetAssetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="bgne_RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage" abstract="false" name="RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="bgne_RestrictedNetAssetsRequiredStatutoryReserveAsPercentageOfRegisteredCapital" abstract="false" name="RestrictedNetAssetsRequiredStatutoryReserveAsPercentageOfRegisteredCapital" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="bgne_RestrictedNetAssetsAppropriatedToStatutoryReserves" abstract="false" name="RestrictedNetAssetsAppropriatedToStatutoryReserves" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_RestrictedNetAssetsAmount" abstract="false" name="RestrictedNetAssetsAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_DefinedBenefitPlanExpectedFutureBenefitPaymentTotal" abstract="false" name="DefinedBenefitPlanExpectedFutureBenefitPaymentTotal" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_MinimumPurchaseCommitmentsForSupplyPurchasedMember" abstract="true" name="MinimumPurchaseCommitmentsForSupplyPurchasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_InvestmentsFundingCommitmentMember" abstract="true" name="InvestmentsFundingCommitmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="bgne_LongTermFundingCommitmentNumberOfEquityInvestments" abstract="false" name="LongTermFundingCommitmentNumberOfEquityInvestments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="bgne_LongTermFundingCommitmentMaximumAmount" abstract="false" name="LongTermFundingCommitmentMaximumAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="bgne_UnrealizedGainLossInSubsidiaries" abstract="false" name="UnrealizedGainLossInSubsidiaries" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>bgne-20241231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:c70194b9-233f-4b06-bc07-707c5a5abbc8,g:477d344e-a417-40e8-b704-01a6f7f40ad7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="bgne-20241231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c96777c6-18e2-4d67-b270-8062e27d2a21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_f3f2d51e-661a-434e-b6b6-cc2d325730e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c96777c6-18e2-4d67-b270-8062e27d2a21" xlink:to="loc_us-gaap_GrossProfit_f3f2d51e-661a-434e-b6b6-cc2d325730e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_6df56da7-e3a4-4197-8366-0c61dd75afab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_c96777c6-18e2-4d67-b270-8062e27d2a21" xlink:to="loc_us-gaap_CostsAndExpenses_6df56da7-e3a4-4197-8366-0c61dd75afab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_0790068d-617f-468d-8588-ca916fd14cae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_949adcaf-71c2-405a-8ead-1d739466d94e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_0790068d-617f-468d-8588-ca916fd14cae" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_949adcaf-71c2-405a-8ead-1d739466d94e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_72b6e517-4458-4930-b9be-32e1f770ee99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_0790068d-617f-468d-8588-ca916fd14cae" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_72b6e517-4458-4930-b9be-32e1f770ee99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_501d7b9c-0e08-44ba-807f-ef0318d07dff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_13bebed4-feb7-42a8-9460-2ddb65677229" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_501d7b9c-0e08-44ba-807f-ef0318d07dff" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_13bebed4-feb7-42a8-9460-2ddb65677229" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_30bdc0b3-5613-43ec-99d7-01ee77b1a489" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_501d7b9c-0e08-44ba-807f-ef0318d07dff" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_30bdc0b3-5613-43ec-99d7-01ee77b1a489" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9e46316c-6e15-4a0c-bf61-ef353f825302" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_694bcc25-9b6e-4911-a30d-c018447b3dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9e46316c-6e15-4a0c-bf61-ef353f825302" xlink:to="loc_us-gaap_OperatingIncomeLoss_694bcc25-9b6e-4911-a30d-c018447b3dd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_bda39708-4ddc-4780-b4b4-6c3f1b9146a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9e46316c-6e15-4a0c-bf61-ef353f825302" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_bda39708-4ddc-4780-b4b4-6c3f1b9146a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_cf7caff0-6624-4b85-a7fd-bd36b2bb0b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9e46316c-6e15-4a0c-bf61-ef353f825302" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_cf7caff0-6624-4b85-a7fd-bd36b2bb0b3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_36bbad52-833b-4c93-b564-099369aa9225" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_30d71e4b-3e51-4929-b629-e73aa378077b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_36bbad52-833b-4c93-b564-099369aa9225" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_30d71e4b-3e51-4929-b629-e73aa378077b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_982d7db0-81c5-4818-97c9-0df4d8f2337c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_36bbad52-833b-4c93-b564-099369aa9225" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_982d7db0-81c5-4818-97c9-0df4d8f2337c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="bgne-20241231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_add9d465-f16d-4f9f-953d-ea8224fbbc2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6373b6e4-b1eb-4b63-b49e-393dbd0c74a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_add9d465-f16d-4f9f-953d-ea8224fbbc2a" xlink:to="loc_us-gaap_NetIncomeLoss_6373b6e4-b1eb-4b63-b49e-393dbd0c74a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_02b456f8-371a-4df8-86c2-7fbd0e52ad25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_add9d465-f16d-4f9f-953d-ea8224fbbc2a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_02b456f8-371a-4df8-86c2-7fbd0e52ad25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_09785051-e01f-4a05-b52b-344970bfa376" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_add9d465-f16d-4f9f-953d-ea8224fbbc2a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_09785051-e01f-4a05-b52b-344970bfa376" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1189e7b9-b672-42bc-b3f4-7fcb13bb6b52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_add9d465-f16d-4f9f-953d-ea8224fbbc2a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1189e7b9-b672-42bc-b3f4-7fcb13bb6b52" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bgne-20241231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4e0bdb88-6f03-4db7-bb95-d4112b498c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_bc7b5b85-039a-46fe-ac4c-a9916091a775" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4e0bdb88-6f03-4db7-bb95-d4112b498c9e" xlink:to="loc_us-gaap_CommonStockValue_bc7b5b85-039a-46fe-ac4c-a9916091a775" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_faf81478-65be-4544-8515-d83e851b5150" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4e0bdb88-6f03-4db7-bb95-d4112b498c9e" xlink:to="loc_us-gaap_AdditionalPaidInCapital_faf81478-65be-4544-8515-d83e851b5150" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_795acbc3-f2c4-43d4-b6da-b3be9f66f0c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4e0bdb88-6f03-4db7-bb95-d4112b498c9e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_795acbc3-f2c4-43d4-b6da-b3be9f66f0c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e9be89a5-fcf4-433e-b1e8-596fe418e433" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4e0bdb88-6f03-4db7-bb95-d4112b498c9e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e9be89a5-fcf4-433e-b1e8-596fe418e433" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6cd8bc35-8536-44f4-b456-54d0f1d72951" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_694c5448-688b-4374-b644-51faf8b6629d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6cd8bc35-8536-44f4-b456-54d0f1d72951" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_694c5448-688b-4374-b644-51faf8b6629d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1bbab9a0-e325-4ebc-841b-1ff456fcdb46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6cd8bc35-8536-44f4-b456-54d0f1d72951" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1bbab9a0-e325-4ebc-841b-1ff456fcdb46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_32606d64-ddf7-4e80-a21a-a8b8905d36bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6cd8bc35-8536-44f4-b456-54d0f1d72951" xlink:to="loc_us-gaap_InventoryNet_32606d64-ddf7-4e80-a21a-a8b8905d36bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6e1ce327-5e51-4c99-ada2-fb7449946851" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6cd8bc35-8536-44f4-b456-54d0f1d72951" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6e1ce327-5e51-4c99-ada2-fb7449946851" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e45750fa-5f43-45e8-8df2-6dda597179e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_cdf1366c-029f-4db1-996b-c3034d6bc019" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e45750fa-5f43-45e8-8df2-6dda597179e5" xlink:to="loc_us-gaap_LiabilitiesCurrent_cdf1366c-029f-4db1-996b-c3034d6bc019" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_4038b68a-0675-47e0-a968-1cf4c8463927" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e45750fa-5f43-45e8-8df2-6dda597179e5" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_4038b68a-0675-47e0-a968-1cf4c8463927" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_afc7c912-37d7-448c-832d-1329a20272b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e474a334-93a1-4496-a663-18f8a873450e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_afc7c912-37d7-448c-832d-1329a20272b8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e474a334-93a1-4496-a663-18f8a873450e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_fe48c89d-516e-42a4-a3bf-694a21d76458" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_afc7c912-37d7-448c-832d-1329a20272b8" xlink:to="loc_us-gaap_LongTermDebtCurrent_fe48c89d-516e-42a4-a3bf-694a21d76458" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_509468b9-b190-4508-b5d2-0acf7e0801e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_afc7c912-37d7-448c-832d-1329a20272b8" xlink:to="loc_us-gaap_TaxesPayableCurrent_509468b9-b190-4508-b5d2-0acf7e0801e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_16a28d72-0fee-4040-a9dc-15098ba4d284" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_afc7c912-37d7-448c-832d-1329a20272b8" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_16a28d72-0fee-4040-a9dc-15098ba4d284" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ResearchAndDevelopmentCostShareLiabilityCurrentPortion_357879bd-1c70-4f41-b310-ea221ea3245d" xlink:href="bgne-20241231.xsd#bgne_ResearchAndDevelopmentCostShareLiabilityCurrentPortion"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_afc7c912-37d7-448c-832d-1329a20272b8" xlink:to="loc_bgne_ResearchAndDevelopmentCostShareLiabilityCurrentPortion_357879bd-1c70-4f41-b310-ea221ea3245d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_eea1389a-5014-43b8-b3ff-647419ccb712" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_afc7c912-37d7-448c-832d-1329a20272b8" xlink:to="loc_us-gaap_AccountsPayableCurrent_eea1389a-5014-43b8-b3ff-647419ccb712" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_3a7b0b9a-21f0-4105-bd02-639111f37be6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_58cd6fe8-c31c-4eee-938e-be4d39f17fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_3a7b0b9a-21f0-4105-bd02-639111f37be6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_58cd6fe8-c31c-4eee-938e-be4d39f17fe5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_55b95be4-4ddc-44ef-9894-3ec4ced6b8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_3a7b0b9a-21f0-4105-bd02-639111f37be6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_55b95be4-4ddc-44ef-9894-3ec4ced6b8ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4b8804e3-67fc-463c-bfd4-de71fd0d0163" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_3a7b0b9a-21f0-4105-bd02-639111f37be6" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4b8804e3-67fc-463c-bfd4-de71fd0d0163" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d4f8e537-3110-4a81-9680-58e67991ba7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_3a7b0b9a-21f0-4105-bd02-639111f37be6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d4f8e537-3110-4a81-9680-58e67991ba7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_08ae6ac4-b278-485f-83a4-371ac0c8642f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6ed76fcc-c1e1-43ee-8d67-876fb25c55a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_08ae6ac4-b278-485f-83a4-371ac0c8642f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6ed76fcc-c1e1-43ee-8d67-876fb25c55a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion_58aeee06-1b51-47ad-91bc-4a687bc92d11" xlink:href="bgne-20241231.xsd#bgne_ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_08ae6ac4-b278-485f-83a4-371ac0c8642f" xlink:to="loc_bgne_ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion_58aeee06-1b51-47ad-91bc-4a687bc92d11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f15c8854-3b86-4f64-ba8a-be82cb98432a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_08ae6ac4-b278-485f-83a4-371ac0c8642f" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f15c8854-3b86-4f64-ba8a-be82cb98432a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_de32f096-3895-4fcc-83ce-998825bb6315" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_08ae6ac4-b278-485f-83a4-371ac0c8642f" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_de32f096-3895-4fcc-83ce-998825bb6315" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_3c2d12b8-009a-4b8a-a361-9f5a606344e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_08ae6ac4-b278-485f-83a4-371ac0c8642f" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_3c2d12b8-009a-4b8a-a361-9f5a606344e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6ea97394-66a0-4e06-8013-fd363d197fde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d0ec515c-e0b6-4967-a8bb-8a98ea2a986a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6ea97394-66a0-4e06-8013-fd363d197fde" xlink:to="loc_us-gaap_AssetsCurrent_d0ec515c-e0b6-4967-a8bb-8a98ea2a986a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_65fcb5ff-d000-48c3-9a8f-dd4eaa22dc45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_6ea97394-66a0-4e06-8013-fd363d197fde" xlink:to="loc_us-gaap_AssetsNoncurrent_65fcb5ff-d000-48c3-9a8f-dd4eaa22dc45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_cbdf8146-f3c7-4a55-8fa6-0c83819f0173" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_126896bf-02f4-4319-87f5-1a97ebdb011b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cbdf8146-f3c7-4a55-8fa6-0c83819f0173" xlink:to="loc_us-gaap_Liabilities_126896bf-02f4-4319-87f5-1a97ebdb011b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_77c92f60-5a94-4056-ae59-5cdfffd94ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cbdf8146-f3c7-4a55-8fa6-0c83819f0173" xlink:to="loc_us-gaap_StockholdersEquity_77c92f60-5a94-4056-ae59-5cdfffd94ed7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_014024fe-de78-4163-8eba-987f65a34ead" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cbdf8146-f3c7-4a55-8fa6-0c83819f0173" xlink:to="loc_us-gaap_CommitmentsAndContingencies_014024fe-de78-4163-8eba-987f65a34ead" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="bgne-20241231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a0ab5af7-893f-4991-8481-f8d8fab23be7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments_ca841069-bab4-4ccc-99ba-ea5223987a57" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a0ab5af7-893f-4991-8481-f8d8fab23be7" xlink:to="loc_us-gaap_PaymentsToAcquireLongtermInvestments_ca841069-bab4-4ccc-99ba-ea5223987a57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ef9b74d1-8044-423b-a590-1b8de7fdcfe9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a0ab5af7-893f-4991-8481-f8d8fab23be7" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_ef9b74d1-8044-423b-a590-1b8de7fdcfe9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_049497fb-4b51-4e9e-9787-07705bdb7976" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a0ab5af7-893f-4991-8481-f8d8fab23be7" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_049497fb-4b51-4e9e-9787-07705bdb7976" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_7fb257cd-a811-4e9e-acce-ee91bcb22772" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a0ab5af7-893f-4991-8481-f8d8fab23be7" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_7fb257cd-a811-4e9e-acce-ee91bcb22772" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_PaymentsToPurchaseInProcessResearchAndDevelopment_eef5eb45-6a62-4aeb-b47e-1cec82b19092" xlink:href="bgne-20241231.xsd#bgne_PaymentsToPurchaseInProcessResearchAndDevelopment"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a0ab5af7-893f-4991-8481-f8d8fab23be7" xlink:to="loc_bgne_PaymentsToPurchaseInProcessResearchAndDevelopment_eef5eb45-6a62-4aeb-b47e-1cec82b19092" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_a2c9ca5e-a233-440c-bf18-54b7874a40dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a0ab5af7-893f-4991-8481-f8d8fab23be7" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_a2c9ca5e-a233-440c-bf18-54b7874a40dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c39b3e72-1df6-4e83-8d8a-55859a904205" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0b82ed91-1757-4d26-b13d-d07a40048116" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c39b3e72-1df6-4e83-8d8a-55859a904205" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0b82ed91-1757-4d26-b13d-d07a40048116" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e78afd89-ded2-48f4-b3e4-da428577643a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c39b3e72-1df6-4e83-8d8a-55859a904205" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e78afd89-ded2-48f4-b3e4-da428577643a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_26bb3da0-0a9c-47bf-98bd-450730644e93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c39b3e72-1df6-4e83-8d8a-55859a904205" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_26bb3da0-0a9c-47bf-98bd-450730644e93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_43c4359b-4984-4b2e-b2cf-47b80e8c201d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c39b3e72-1df6-4e83-8d8a-55859a904205" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_43c4359b-4984-4b2e-b2cf-47b80e8c201d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b66a6cc-20b9-4fd3-a2d8-2160b0c52e95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_efa57b2e-492a-40d1-8b21-30a5d006733c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b66a6cc-20b9-4fd3-a2d8-2160b0c52e95" xlink:to="loc_us-gaap_NetIncomeLoss_efa57b2e-492a-40d1-8b21-30a5d006733c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7135cbee-d5a4-45ec-b3fe-b2da3e8cdb46" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b66a6cc-20b9-4fd3-a2d8-2160b0c52e95" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7135cbee-d5a4-45ec-b3fe-b2da3e8cdb46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_c4f42b5c-4a4a-4e3b-b10c-a62f43567dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b66a6cc-20b9-4fd3-a2d8-2160b0c52e95" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_c4f42b5c-4a4a-4e3b-b10c-a62f43567dcf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_09739781-70a2-458e-ab19-52c0747a9ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b66a6cc-20b9-4fd3-a2d8-2160b0c52e95" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_09739781-70a2-458e-ab19-52c0747a9ee5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_60fc9fc9-7702-498f-abeb-85877f7f9321" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b66a6cc-20b9-4fd3-a2d8-2160b0c52e95" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_60fc9fc9-7702-498f-abeb-85877f7f9321" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AmortizationOfResearchAndDevelopmentFinancingLiability_4ff42309-012c-4d37-bc67-bf21d0397393" xlink:href="bgne-20241231.xsd#bgne_AmortizationOfResearchAndDevelopmentFinancingLiability"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b66a6cc-20b9-4fd3-a2d8-2160b0c52e95" xlink:to="loc_bgne_AmortizationOfResearchAndDevelopmentFinancingLiability_4ff42309-012c-4d37-bc67-bf21d0397393" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_ef5b918b-c32f-4269-992f-192298331fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b66a6cc-20b9-4fd3-a2d8-2160b0c52e95" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_ef5b918b-c32f-4269-992f-192298331fd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5e9b9f54-0a66-4cf0-868a-f165609d020f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b66a6cc-20b9-4fd3-a2d8-2160b0c52e95" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5e9b9f54-0a66-4cf0-868a-f165609d020f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AcquiredInProcessResearchAndDevelopment_e00626ab-c110-47c5-ab72-f37ce66813b6" xlink:href="bgne-20241231.xsd#bgne_AcquiredInProcessResearchAndDevelopment"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b66a6cc-20b9-4fd3-a2d8-2160b0c52e95" xlink:to="loc_bgne_AcquiredInProcessResearchAndDevelopment_e00626ab-c110-47c5-ab72-f37ce66813b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_f6c4cd02-f48d-4ee5-b795-c031866e4388" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b66a6cc-20b9-4fd3-a2d8-2160b0c52e95" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_f6c4cd02-f48d-4ee5-b795-c031866e4388" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_505d59c9-c3ad-4e8c-8008-5ef4cb7136eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b66a6cc-20b9-4fd3-a2d8-2160b0c52e95" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_505d59c9-c3ad-4e8c-8008-5ef4cb7136eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_683576a9-8ad8-4697-915f-4e0dcb54474c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b66a6cc-20b9-4fd3-a2d8-2160b0c52e95" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_683576a9-8ad8-4697-915f-4e0dcb54474c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_58f0726d-ecd9-42f0-b328-e22c6857aa52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b66a6cc-20b9-4fd3-a2d8-2160b0c52e95" xlink:to="loc_us-gaap_ShareBasedCompensation_58f0726d-ecd9-42f0-b328-e22c6857aa52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_acd6d28c-5cf5-4cc3-9db8-de05e0527ade" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b66a6cc-20b9-4fd3-a2d8-2160b0c52e95" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_acd6d28c-5cf5-4cc3-9db8-de05e0527ade" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_183f4de9-1be3-4f42-9f51-54b38a528348" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b66a6cc-20b9-4fd3-a2d8-2160b0c52e95" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_183f4de9-1be3-4f42-9f51-54b38a528348" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_b57f7b70-a819-4514-9af6-92d1701613d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8b66a6cc-20b9-4fd3-a2d8-2160b0c52e95" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_b57f7b70-a819-4514-9af6-92d1701613d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_69c18836-6141-4bea-8645-087bbe0f4d31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_5113e7a6-9865-4ff3-ae52-1a6595007f98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_69c18836-6141-4bea-8645-087bbe0f4d31" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_5113e7a6-9865-4ff3-ae52-1a6595007f98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_deaa26c3-4aad-4160-8b2a-caa0bcaaeeaa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_69c18836-6141-4bea-8645-087bbe0f4d31" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_deaa26c3-4aad-4160-8b2a-caa0bcaaeeaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_12608286-4c0a-44b7-9a8d-6a4c13b5e027" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_69c18836-6141-4bea-8645-087bbe0f4d31" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_12608286-4c0a-44b7-9a8d-6a4c13b5e027" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_f168d00b-995f-4c2d-b142-7d7350511a32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_69c18836-6141-4bea-8645-087bbe0f4d31" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_f168d00b-995f-4c2d-b142-7d7350511a32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_bc97b2b9-953e-423f-aaa5-11248877b1ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_69c18836-6141-4bea-8645-087bbe0f4d31" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_bc97b2b9-953e-423f-aaa5-11248877b1ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_c84cf417-048d-4239-960d-83a99fa98304" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_69c18836-6141-4bea-8645-087bbe0f4d31" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_c84cf417-048d-4239-960d-83a99fa98304" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_1bfc4ab4-7140-4ce9-b3ae-3b537d2ea475" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d6c7c369-689f-4c7e-807a-969fdcfc99cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_1bfc4ab4-7140-4ce9-b3ae-3b537d2ea475" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d6c7c369-689f-4c7e-807a-969fdcfc99cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b880ca26-5119-4c3a-9818-d32458734478" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_1bfc4ab4-7140-4ce9-b3ae-3b537d2ea475" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b880ca26-5119-4c3a-9818-d32458734478" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_InvestmentInDebtSecuritiesCurrent_a0f2fcd4-fae3-41af-87dd-c21e1cc8e3b5" xlink:href="bgne-20241231.xsd#bgne_InvestmentInDebtSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_1bfc4ab4-7140-4ce9-b3ae-3b537d2ea475" xlink:to="loc_bgne_InvestmentInDebtSecuritiesCurrent_a0f2fcd4-fae3-41af-87dd-c21e1cc8e3b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_c5b59835-a6fb-4ef8-8ba1-6992368785aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_1bfc4ab4-7140-4ce9-b3ae-3b537d2ea475" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_c5b59835-a6fb-4ef8-8ba1-6992368785aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_InvestmentInDebtSecuritiesNonCurrent_45753a45-fc09-482f-90d9-9d584e11d75c" xlink:href="bgne-20241231.xsd#bgne_InvestmentInDebtSecuritiesNonCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_1bfc4ab4-7140-4ce9-b3ae-3b537d2ea475" xlink:to="loc_bgne_InvestmentInDebtSecuritiesNonCurrent_45753a45-fc09-482f-90d9-9d584e11d75c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/CollaborativeandLicensingArrangementsFundingExpensesDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#CollaborativeandLicensingArrangementsFundingExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.beigene.com/role/CollaborativeandLicensingArrangementsFundingExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bgne_FinancingCommitmentExpenses_60e08b5a-4e38-452c-952f-0a145eb4d8a0" xlink:href="bgne-20241231.xsd#bgne_FinancingCommitmentExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_baae05f2-51bd-4dbb-9473-552cd911ddae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bgne_FinancingCommitmentExpenses_60e08b5a-4e38-452c-952f-0a145eb4d8a0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_baae05f2-51bd-4dbb-9473-552cd911ddae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AmortizationOfFinancingCommitment_79faa318-8806-4160-8ffe-31c765bf2e6c" xlink:href="bgne-20241231.xsd#bgne_AmortizationOfFinancingCommitment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bgne_FinancingCommitmentExpenses_60e08b5a-4e38-452c-952f-0a145eb4d8a0" xlink:to="loc_bgne_AmortizationOfFinancingCommitment_79faa318-8806-4160-8ffe-31c765bf2e6c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/CollaborativeandLicensingArrangementsFinancingLiabilityDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#CollaborativeandLicensingArrangementsFinancingLiabilityDetails"/>
  <link:calculationLink xlink:role="http://www.beigene.com/role/CollaborativeandLicensingArrangementsFinancingLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bgne_FinancingCommitmentCarryingValue_fb6c47d4-dc50-4ec8-b1b7-7e7182326ce4" xlink:href="bgne-20241231.xsd#bgne_FinancingCommitmentCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_FinancingCommitmentCarryingValueNoncurrent_192135a2-a4d3-4d13-b21e-592a83052508" xlink:href="bgne-20241231.xsd#bgne_FinancingCommitmentCarryingValueNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bgne_FinancingCommitmentCarryingValue_fb6c47d4-dc50-4ec8-b1b7-7e7182326ce4" xlink:to="loc_bgne_FinancingCommitmentCarryingValueNoncurrent_192135a2-a4d3-4d13-b21e-592a83052508" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_FinancingCommitmentCarryingValueCurrent_afb01883-e352-4987-87a0-8a5808b03fa2" xlink:href="bgne-20241231.xsd#bgne_FinancingCommitmentCarryingValueCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bgne_FinancingCommitmentCarryingValue_fb6c47d4-dc50-4ec8-b1b7-7e7182326ce4" xlink:to="loc_bgne_FinancingCommitmentCarryingValueCurrent_afb01883-e352-4987-87a0-8a5808b03fa2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/RestrictedCashandInvestmentsRestrictionsonCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#RestrictedCashandInvestmentsRestrictionsonCashandCashEquivalentsDetails"/>
  <link:calculationLink xlink:role="http://www.beigene.com/role/RestrictedCashandInvestmentsRestrictionsonCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_09caba23-02e4-4086-85ae-b45f77be3424" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_6330ead4-01ca-4016-a2af-a37812447160" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCash_09caba23-02e4-4086-85ae-b45f77be3424" xlink:to="loc_us-gaap_RestrictedCashCurrent_6330ead4-01ca-4016-a2af-a37812447160" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_9c04ec8e-0bba-44e5-9657-ea3b2c5ac3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestrictedCash_09caba23-02e4-4086-85ae-b45f77be3424" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_9c04ec8e-0bba-44e5-9657-ea3b2c5ac3b9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#InvestmentsInvestmentsInEquitySecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_ea6a1165-2dea-4cd1-b039-0acb896bde03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_bd795255-7430-47e3-bf1d-751426ad4fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_ea6a1165-2dea-4cd1-b039-0acb896bde03" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_bd795255-7430-47e3-bf1d-751426ad4fdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_9e9e4c45-a267-463f-a5f5-8238f822ff2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_ea6a1165-2dea-4cd1-b039-0acb896bde03" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_9e9e4c45-a267-463f-a5f5-8238f822ff2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_2c11c1c0-43e5-4616-bce3-241757656add" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_ea6a1165-2dea-4cd1-b039-0acb896bde03" xlink:to="loc_us-gaap_EquityMethodInvestments_2c11c1c0-43e5-4616-bce3-241757656add" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/InventoriesNetDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#InventoriesNetDetails"/>
  <link:calculationLink xlink:role="http://www.beigene.com/role/InventoriesNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e85e00f6-52bf-4199-ad7b-c4282b47ce3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_1fb4eee1-f4c8-4339-ac19-868e694b93a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_e85e00f6-52bf-4199-ad7b-c4282b47ce3b" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_1fb4eee1-f4c8-4339-ac19-868e694b93a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_b3fb2a5a-c8c0-4132-960c-46cedd78f725" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_e85e00f6-52bf-4199-ad7b-c4282b47ce3b" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_b3fb2a5a-c8c0-4132-960c-46cedd78f725" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_4191d22d-a01a-4861-a29a-1edce982e254" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_e85e00f6-52bf-4199-ad7b-c4282b47ce3b" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_4191d22d-a01a-4861-a29a-1edce982e254" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.beigene.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_3544b708-1940-41d8-b5e0-72b3c6cc7677" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_767de947-a48c-4e82-bd1e-2975a359c00f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_3544b708-1940-41d8-b5e0-72b3c6cc7677" xlink:to="loc_us-gaap_OperatingLeaseCost_767de947-a48c-4e82-bd1e-2975a359c00f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_139cdcb5-306b-4a8e-bd46-2666c3392bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_3544b708-1940-41d8-b5e0-72b3c6cc7677" xlink:to="loc_us-gaap_VariableLeaseCost_139cdcb5-306b-4a8e-bd46-2666c3392bc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_a17e47b9-4749-468a-8937-b3d1e20e7b07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_3544b708-1940-41d8-b5e0-72b3c6cc7677" xlink:to="loc_us-gaap_ShortTermLeaseCost_a17e47b9-4749-468a-8937-b3d1e20e7b07" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/LeasesSupplementalBalanceSheetDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#LeasesSupplementalBalanceSheetDetails"/>
  <link:calculationLink xlink:role="http://www.beigene.com/role/LeasesSupplementalBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_41741508-df46-4ac7-862c-9da271f1dd06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6c158b3e-ce50-47b4-8e9e-92fa39345010" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_41741508-df46-4ac7-862c-9da271f1dd06" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6c158b3e-ce50-47b4-8e9e-92fa39345010" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_68d7a0ee-01dd-4b13-a7e6-a56365b56f36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_41741508-df46-4ac7-862c-9da271f1dd06" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_68d7a0ee-01dd-4b13-a7e6-a56365b56f36" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.beigene.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b7b4708c-72ba-497f-8de8-bb1f59a566ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_73ec5cb9-6397-4fa4-9780-be0fb4fd4442" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b7b4708c-72ba-497f-8de8-bb1f59a566ea" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_73ec5cb9-6397-4fa4-9780-be0fb4fd4442" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8469da1b-e16c-4f02-b20f-e9d373874909" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b7b4708c-72ba-497f-8de8-bb1f59a566ea" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8469da1b-e16c-4f02-b20f-e9d373874909" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c19ebeaf-1f81-4c1b-b9f5-e8709321d58e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b7b4708c-72ba-497f-8de8-bb1f59a566ea" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c19ebeaf-1f81-4c1b-b9f5-e8709321d58e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8a26b29c-5c59-47de-a536-44c074d7fe73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b7b4708c-72ba-497f-8de8-bb1f59a566ea" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8a26b29c-5c59-47de-a536-44c074d7fe73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_6829a9a8-b4ed-4a6f-b310-6507a44fbd84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b7b4708c-72ba-497f-8de8-bb1f59a566ea" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_6829a9a8-b4ed-4a6f-b310-6507a44fbd84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a7577fb7-62d6-43b1-9b3b-790207a2c94d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b7b4708c-72ba-497f-8de8-bb1f59a566ea" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a7577fb7-62d6-43b1-9b3b-790207a2c94d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="bgne-20241231.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.beigene.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_04ed5dd7-f697-4934-ada1-9b91a16b1f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_540dfefd-2dc5-4b83-b5a0-eddf45040919" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_04ed5dd7-f697-4934-ada1-9b91a16b1f2d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_540dfefd-2dc5-4b83-b5a0-eddf45040919" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_71309f9c-8728-482f-8b5d-9c7ff6045993" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_04ed5dd7-f697-4934-ada1-9b91a16b1f2d" xlink:to="loc_us-gaap_OperatingLeaseLiability_71309f9c-8728-482f-8b5d-9c7ff6045993" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/PropertyPlantandEquipmentNetPropertyPlantandEquipmentNetDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#PropertyPlantandEquipmentNetPropertyPlantandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.beigene.com/role/PropertyPlantandEquipmentNetPropertyPlantandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1dc4233e-7902-4c74-8cb2-7dd636d264a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_f4a2ab68-d4ef-4f18-b138-eb5270369c30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1dc4233e-7902-4c74-8cb2-7dd636d264a7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_f4a2ab68-d4ef-4f18-b138-eb5270369c30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d2174369-5254-4141-bfa0-9333a4453be7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1dc4233e-7902-4c74-8cb2-7dd636d264a7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d2174369-5254-4141-bfa0-9333a4453be7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_078887f8-be9c-4979-9869-1cae6bc7daac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1dc4233e-7902-4c74-8cb2-7dd636d264a7" xlink:to="loc_us-gaap_ConstructionInProgressGross_078887f8-be9c-4979-9869-1cae6bc7daac" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/IntangibleAssetsIntangibleAssetsOutstandingDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#IntangibleAssetsIntangibleAssetsOutstandingDetails"/>
  <link:calculationLink xlink:role="http://www.beigene.com/role/IntangibleAssetsIntangibleAssetsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f89f57db-b170-4ba7-b409-799a1125cbd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_90f666dc-19ff-4a35-8310-ce80b566c190" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f89f57db-b170-4ba7-b409-799a1125cbd8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_90f666dc-19ff-4a35-8310-ce80b566c190" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_574f83da-2fdf-4087-9410-4c09dddac58a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f89f57db-b170-4ba7-b409-799a1125cbd8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_574f83da-2fdf-4087-9410-4c09dddac58a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/IntangibleAssetsExpectedAmortizationExpenseDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#IntangibleAssetsExpectedAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.beigene.com/role/IntangibleAssetsExpectedAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d8e166d7-4f5b-45c2-a4c2-3578f372dbbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_ef8c3a69-ea4a-42b9-858a-4b6e225b714f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d8e166d7-4f5b-45c2-a4c2-3578f372dbbc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_ef8c3a69-ea4a-42b9-858a-4b6e225b714f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_8211a633-f1e2-4bfe-bea6-6edad16d7318" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d8e166d7-4f5b-45c2-a4c2-3578f372dbbc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_8211a633-f1e2-4bfe-bea6-6edad16d7318" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_5b47bfe6-5f33-4ec8-ac84-0c762736956a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d8e166d7-4f5b-45c2-a4c2-3578f372dbbc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_5b47bfe6-5f33-4ec8-ac84-0c762736956a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_3d457ee6-9d08-496a-9179-c7aca3e33fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d8e166d7-4f5b-45c2-a4c2-3578f372dbbc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_3d457ee6-9d08-496a-9179-c7aca3e33fc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_eba0b03d-16ea-4b25-88d9-b9cb2812e0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d8e166d7-4f5b-45c2-a4c2-3578f372dbbc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_eba0b03d-16ea-4b25-88d9-b9cb2812e0e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_7bb23418-cb8b-4b70-b9d8-69df7810f165" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d8e166d7-4f5b-45c2-a4c2-3578f372dbbc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_7bb23418-cb8b-4b70-b9d8-69df7810f165" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#IncomeTaxesIncomeLossBeforeIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.beigene.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_85572e50-7f03-4f21-ab7b-37585ae7fedd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_702c3e81-bb2e-4408-8cdc-7690d94c7f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_85572e50-7f03-4f21-ab7b-37585ae7fedd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_702c3e81-bb2e-4408-8cdc-7690d94c7f8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_e854a9ff-ea28-44fc-89fb-8372cd787772" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_85572e50-7f03-4f21-ab7b-37585ae7fedd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_e854a9ff-ea28-44fc-89fb-8372cd787772" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/IncomeTaxesCurrentandDeferredComponentsIncomeTaxesDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#IncomeTaxesCurrentandDeferredComponentsIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.beigene.com/role/IncomeTaxesCurrentandDeferredComponentsIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_82d84630-85a3-4b56-a30c-6097fe99eb29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_f0752dce-68e8-4349-a486-24e5e0b004c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_82d84630-85a3-4b56-a30c-6097fe99eb29" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_f0752dce-68e8-4349-a486-24e5e0b004c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d619b873-b9d9-40ff-a0bc-de7a414364e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_82d84630-85a3-4b56-a30c-6097fe99eb29" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d619b873-b9d9-40ff-a0bc-de7a414364e7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/IncomeTaxesReconciliationoftheStatutoryRateDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#IncomeTaxesReconciliationoftheStatutoryRateDetails"/>
  <link:calculationLink xlink:role="http://www.beigene.com/role/IncomeTaxesReconciliationoftheStatutoryRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_03aef5b7-91f3-45fe-970a-0c35f2d74269" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_51800cd6-97cf-472a-9554-5ab301f06602" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_03aef5b7-91f3-45fe-970a-0c35f2d74269" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_51800cd6-97cf-472a-9554-5ab301f06602" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_aee6a455-9999-4527-a4f3-cb7b5d560efd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_03aef5b7-91f3-45fe-970a-0c35f2d74269" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_aee6a455-9999-4527-a4f3-cb7b5d560efd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_c5bd2899-0e2c-4d37-9f81-0d62d32ce7ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_03aef5b7-91f3-45fe-970a-0c35f2d74269" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_c5bd2899-0e2c-4d37-9f81-0d62d32ce7ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion_52965e77-bb15-488a-b1f9-95fb351044af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_03aef5b7-91f3-45fe-970a-0c35f2d74269" xlink:to="loc_us-gaap_IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion_52965e77-bb15-488a-b1f9-95fb351044af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_a807833c-68bb-49ad-9cdd-caabaea586ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_03aef5b7-91f3-45fe-970a-0c35f2d74269" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_a807833c-68bb-49ad-9cdd-caabaea586ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_EffectiveIncomeTaxRateReconciliationDeductionResearchExpensesAmount_5771da26-0442-4242-830e-a7b601a82165" xlink:href="bgne-20241231.xsd#bgne_EffectiveIncomeTaxRateReconciliationDeductionResearchExpensesAmount"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_03aef5b7-91f3-45fe-970a-0c35f2d74269" xlink:to="loc_bgne_EffectiveIncomeTaxRateReconciliationDeductionResearchExpensesAmount_5771da26-0442-4242-830e-a7b601a82165" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_d91b5f57-a9b1-49d5-b2f9-319b472f6aac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_03aef5b7-91f3-45fe-970a-0c35f2d74269" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_d91b5f57-a9b1-49d5-b2f9-319b472f6aac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_27a0924d-a60c-46d1-9d59-4af0517020e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_03aef5b7-91f3-45fe-970a-0c35f2d74269" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_27a0924d-a60c-46d1-9d59-4af0517020e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_dd06977f-4c99-41be-8b22-2c949bebafba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_03aef5b7-91f3-45fe-970a-0c35f2d74269" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_dd06977f-4c99-41be-8b22-2c949bebafba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_10c286c9-e5b3-47d3-b3d3-8e35e5f4383e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_03aef5b7-91f3-45fe-970a-0c35f2d74269" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_10c286c9-e5b3-47d3-b3d3-8e35e5f4383e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount_7f53873d-c92d-4784-be48-6de10c2eed1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_03aef5b7-91f3-45fe-970a-0c35f2d74269" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount_7f53873d-c92d-4784-be48-6de10c2eed1c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_e0c7eafd-1a90-4f36-958c-c320f67aff6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_db822fb0-f9d9-4c4d-9130-1e5a187590ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e0c7eafd-1a90-4f36-958c-c320f67aff6b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_db822fb0-f9d9-4c4d-9130-1e5a187590ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_03951b9a-2c33-4820-8131-ea5ea024d87e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e0c7eafd-1a90-4f36-958c-c320f67aff6b" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_03951b9a-2c33-4820-8131-ea5ea024d87e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_227f0147-c73a-485d-b386-d5a671834e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e0c7eafd-1a90-4f36-958c-c320f67aff6b" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_227f0147-c73a-485d-b386-d5a671834e0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_aef263b5-5585-4587-a169-68bf4404ae45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e0c7eafd-1a90-4f36-958c-c320f67aff6b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_aef263b5-5585-4587-a169-68bf4404ae45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_DeferredTaxAssetsPropertyLeaseLiabilityObligation_b9850606-2017-4517-b745-2a0b26d3f831" xlink:href="bgne-20241231.xsd#bgne_DeferredTaxAssetsPropertyLeaseLiabilityObligation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e0c7eafd-1a90-4f36-958c-c320f67aff6b" xlink:to="loc_bgne_DeferredTaxAssetsPropertyLeaseLiabilityObligation_b9850606-2017-4517-b745-2a0b26d3f831" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_33a25ab3-49bf-4628-84ef-2a26f41954bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e0c7eafd-1a90-4f36-958c-c320f67aff6b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_33a25ab3-49bf-4628-84ef-2a26f41954bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_d49074bd-d508-4112-bb50-0e120c101d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e0c7eafd-1a90-4f36-958c-c320f67aff6b" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_d49074bd-d508-4112-bb50-0e120c101d6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign_6dbc1885-ee1f-4896-97b5-d2424100296e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e0c7eafd-1a90-4f36-958c-c320f67aff6b" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign_6dbc1885-ee1f-4896-97b5-d2424100296e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_d353d8ec-98b1-4e46-9431-b462a67b91f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_2d1f7ade-051d-4ec9-a436-18f889270a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_d353d8ec-98b1-4e46-9431-b462a67b91f4" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_2d1f7ade-051d-4ec9-a436-18f889270a7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_3333a200-93aa-4c45-bb70-da48e5329710" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_d353d8ec-98b1-4e46-9431-b462a67b91f4" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_3333a200-93aa-4c45-bb70-da48e5329710" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_5a56ebce-f3b0-4a3a-b591-b275b6f4c525" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_989879e3-ff6d-4fe3-b1d7-0353a7372842" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5a56ebce-f3b0-4a3a-b591-b275b6f4c525" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_989879e3-ff6d-4fe3-b1d7-0353a7372842" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_c2aa6326-d5cd-4794-b887-75961b14d9a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5a56ebce-f3b0-4a3a-b591-b275b6f4c525" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_c2aa6326-d5cd-4794-b887-75961b14d9a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_293b0774-dcac-48a1-a7bf-56ad22d16757" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5a56ebce-f3b0-4a3a-b591-b275b6f4c525" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_293b0774-dcac-48a1-a7bf-56ad22d16757" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0c5f013c-34ce-4966-b48f-cc9d18ff0119" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_f657f945-0b98-422d-8144-45563aa61e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0c5f013c-34ce-4966-b48f-cc9d18ff0119" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_f657f945-0b98-422d-8144-45563aa61e1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a8672284-8f1f-4e37-8d3e-9c00a31de3cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_0c5f013c-34ce-4966-b48f-cc9d18ff0119" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_a8672284-8f1f-4e37-8d3e-9c00a31de3cb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a435f2d8-7c78-464b-b950-a2c255fd0a23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_PrepaidManufacturingCosts_d73636e5-0100-4c2d-a474-449607f5fbb2" xlink:href="bgne-20241231.xsd#bgne_PrepaidManufacturingCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a435f2d8-7c78-464b-b950-a2c255fd0a23" xlink:to="loc_bgne_PrepaidManufacturingCosts_d73636e5-0100-4c2d-a474-449607f5fbb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_feb68aa7-f8f8-434f-9c6e-184d2d9e4902" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a435f2d8-7c78-464b-b950-a2c255fd0a23" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_feb68aa7-f8f8-434f-9c6e-184d2d9e4902" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_PrepaidResearchAndDevelopmentCosts_5640df00-0461-4551-a4c1-cb82456da815" xlink:href="bgne-20241231.xsd#bgne_PrepaidResearchAndDevelopmentCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a435f2d8-7c78-464b-b950-a2c255fd0a23" xlink:to="loc_bgne_PrepaidResearchAndDevelopmentCosts_5640df00-0461-4551-a4c1-cb82456da815" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_PrepaidGeneralAndAdministrativeExpensesCurrent_3b1edf31-a5cd-4bbf-b3ef-db771b552d98" xlink:href="bgne-20241231.xsd#bgne_PrepaidGeneralAndAdministrativeExpensesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a435f2d8-7c78-464b-b950-a2c255fd0a23" xlink:to="loc_bgne_PrepaidGeneralAndAdministrativeExpensesCurrent_3b1edf31-a5cd-4bbf-b3ef-db771b552d98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_8d875a45-fff0-4c4d-8b47-5cd01b01e2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a435f2d8-7c78-464b-b950-a2c255fd0a23" xlink:to="loc_us-gaap_PrepaidInsurance_8d875a45-fff0-4c4d-8b47-5cd01b01e2d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_f20384ff-0ab4-42c2-a799-d12a15eb9b74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a435f2d8-7c78-464b-b950-a2c255fd0a23" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_f20384ff-0ab4-42c2-a799-d12a15eb9b74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_3f479b8a-1038-4245-ba05-443b4e693dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidTaxes"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a435f2d8-7c78-464b-b950-a2c255fd0a23" xlink:to="loc_us-gaap_PrepaidTaxes_3f479b8a-1038-4245-ba05-443b4e693dfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_88035ec6-5010-430d-a416-fe4d9e744c98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a435f2d8-7c78-464b-b950-a2c255fd0a23" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_88035ec6-5010-430d-a416-fe4d9e744c98" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_fa1da20e-7c03-4dbd-b4ab-d0a58c3ef1da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableNoncurrent_2b5aa21f-1229-4e8d-b24d-90ef4f652075" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValueAddedTaxReceivableNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_fa1da20e-7c03-4dbd-b4ab-d0a58c3ef1da" xlink:to="loc_us-gaap_ValueAddedTaxReceivableNoncurrent_2b5aa21f-1229-4e8d-b24d-90ef4f652075" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_PrepaymentOfLongTermAsset_f6c72186-fbf7-4d94-849a-668d685cb231" xlink:href="bgne-20241231.xsd#bgne_PrepaymentOfLongTermAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_fa1da20e-7c03-4dbd-b4ab-d0a58c3ef1da" xlink:to="loc_bgne_PrepaymentOfLongTermAsset_f6c72186-fbf7-4d94-849a-668d685cb231" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RentalDepositsAndOther_efd66690-679b-46b0-8d25-c86d31c1bc6e" xlink:href="bgne-20241231.xsd#bgne_RentalDepositsAndOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_fa1da20e-7c03-4dbd-b4ab-d0a58c3ef1da" xlink:to="loc_bgne_RentalDepositsAndOther_efd66690-679b-46b0-8d25-c86d31c1bc6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_3be8d548-2bb6-4b22-84b8-98f6f6aaaa96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_fa1da20e-7c03-4dbd-b4ab-d0a58c3ef1da" xlink:to="loc_us-gaap_LongTermInvestments_3be8d548-2bb6-4b22-84b8-98f6f6aaaa96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_e421e634-b6fe-4b54-9e67-08a9c796a28c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_fa1da20e-7c03-4dbd-b4ab-d0a58c3ef1da" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_e421e634-b6fe-4b54-9e67-08a9c796a28c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_PrepaidSupplyCost_b69532d0-cc9e-42c4-8a5a-079c373843c8" xlink:href="bgne-20241231.xsd#bgne_PrepaidSupplyCost"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_fa1da20e-7c03-4dbd-b4ab-d0a58c3ef1da" xlink:to="loc_bgne_PrepaidSupplyCost_b69532d0-cc9e-42c4-8a5a-079c373843c8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofAccruedExpensesandOtherPayablesDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#SupplementalBalanceSheetInformationScheduleofAccruedExpensesandOtherPayablesDetails"/>
  <link:calculationLink xlink:role="http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofAccruedExpensesandOtherPayablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4ac33964-f825-4562-a53c-b86964b72ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AccruedSalesRebatesAndReturnsCurrent_d953386c-e91f-4067-994c-93cf4e07f739" xlink:href="bgne-20241231.xsd#bgne_AccruedSalesRebatesAndReturnsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4ac33964-f825-4562-a53c-b86964b72ec0" xlink:to="loc_bgne_AccruedSalesRebatesAndReturnsCurrent_d953386c-e91f-4067-994c-93cf4e07f739" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AccruedExpensesCommercialActivities_752d4a0f-f938-4410-8469-01de540e52a3" xlink:href="bgne-20241231.xsd#bgne_AccruedExpensesCommercialActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4ac33964-f825-4562-a53c-b86964b72ec0" xlink:to="loc_bgne_AccruedExpensesCommercialActivities_752d4a0f-f938-4410-8469-01de540e52a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedPayrollTaxesCurrent_173c7540-0a2c-4f84-a651-f17743702db0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4ac33964-f825-4562-a53c-b86964b72ec0" xlink:to="loc_us-gaap_AccruedPayrollTaxesCurrent_173c7540-0a2c-4f84-a651-f17743702db0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_889160d6-dec0-4a5f-99ab-75df20b4e03c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4ac33964-f825-4562-a53c-b86964b72ec0" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_889160d6-dec0-4a5f-99ab-75df20b4e03c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AccruedLiabilitiesExternalResearchAndDevelopment_449ccf13-d66c-4349-9a08-c75edb41716d" xlink:href="bgne-20241231.xsd#bgne_AccruedLiabilitiesExternalResearchAndDevelopment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4ac33964-f825-4562-a53c-b86964b72ec0" xlink:to="loc_bgne_AccruedLiabilitiesExternalResearchAndDevelopment_449ccf13-d66c-4349-9a08-c75edb41716d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AccruedProfessionalFeesAndOtherCurrent_fb2f1455-5383-4662-9047-cd4f5cccd256" xlink:href="bgne-20241231.xsd#bgne_AccruedProfessionalFeesAndOtherCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4ac33964-f825-4562-a53c-b86964b72ec0" xlink:to="loc_bgne_AccruedProfessionalFeesAndOtherCurrent_fb2f1455-5383-4662-9047-cd4f5cccd256" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AccruedGeneralAndAdministrativeExpensesCurrent_848243a7-c9b2-4270-97b2-359104e62c51" xlink:href="bgne-20241231.xsd#bgne_AccruedGeneralAndAdministrativeExpensesCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_4ac33964-f825-4562-a53c-b86964b72ec0" xlink:to="loc_bgne_AccruedGeneralAndAdministrativeExpensesCurrent_848243a7-c9b2-4270-97b2-359104e62c51" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherLongtermLiabilitiesDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#SupplementalBalanceSheetInformationScheduleofOtherLongtermLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherLongtermLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_568b0f21-6afb-43e2-9662-4651552f7688" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_ca2ef74e-296b-4a34-be84-bebe8e02853c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_568b0f21-6afb-43e2-9662-4651552f7688" xlink:to="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_ca2ef74e-296b-4a34-be84-bebe8e02853c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_7ebc68ec-2bde-433d-a8cc-06abfebdbe79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_568b0f21-6afb-43e2-9662-4651552f7688" xlink:to="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_7ebc68ec-2bde-433d-a8cc-06abfebdbe79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceLiability_d97d89a0-fd69-4c67-9309-22750fa58c62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_568b0f21-6afb-43e2-9662-4651552f7688" xlink:to="loc_us-gaap_GovernmentAssistanceLiability_d97d89a0-fd69-4c67-9309-22750fa58c62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetRetirementObligationsNoncurrent_223e3ca1-5fa7-45a1-a920-e5fcea340bda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetRetirementObligationsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_568b0f21-6afb-43e2-9662-4651552f7688" xlink:to="loc_us-gaap_AssetRetirementObligationsNoncurrent_223e3ca1-5fa7-45a1-a920-e5fcea340bda" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/DebtContractualmaturitiesofdebtobligationsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#DebtContractualmaturitiesofdebtobligationsDetails"/>
  <link:calculationLink xlink:role="http://www.beigene.com/role/DebtContractualmaturitiesofdebtobligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_34bbdcff-1584-4883-b1c4-0fbf65e55cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear_6c4d9bdc-9ca2-49ef-b2a5-f58f55ff939d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInThirdYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_34bbdcff-1584-4883-b1c4-0fbf65e55cb0" xlink:to="loc_us-gaap_ContractualObligationDueInThirdYear_6c4d9bdc-9ca2-49ef-b2a5-f58f55ff939d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInFifthYear_5e4136c9-9258-4657-a11a-fa5a83388154" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInFifthYear"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_34bbdcff-1584-4883-b1c4-0fbf65e55cb0" xlink:to="loc_us-gaap_ContractualObligationDueInFifthYear_5e4136c9-9258-4657-a11a-fa5a83388154" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_b241c157-74e3-4048-aaea-b490879323d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_34bbdcff-1584-4883-b1c4-0fbf65e55cb0" xlink:to="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_b241c157-74e3-4048-aaea-b490879323d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueAfterFifthYear_1a56f02f-be95-4c91-a99b-ed37d611658f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueAfterFifthYear"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_34bbdcff-1584-4883-b1c4-0fbf65e55cb0" xlink:to="loc_us-gaap_ContractualObligationDueAfterFifthYear_1a56f02f-be95-4c91-a99b-ed37d611658f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInFourthYear_68a7def1-41e3-4c5d-b117-349e5793d4dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInFourthYear"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_34bbdcff-1584-4883-b1c4-0fbf65e55cb0" xlink:to="loc_us-gaap_ContractualObligationDueInFourthYear_68a7def1-41e3-4c5d-b117-349e5793d4dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear_a69b63c6-4e8c-4805-af4f-e75acb604f85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInSecondYear"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractualObligation_34bbdcff-1584-4883-b1c4-0fbf65e55cb0" xlink:to="loc_us-gaap_ContractualObligationDueInSecondYear_a69b63c6-4e8c-4805-af4f-e75acb604f85" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ProductRevenueProductSalesDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ProductRevenueProductSalesDetails"/>
  <link:calculationLink xlink:role="http://www.beigene.com/role/ProductRevenueProductSalesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f77583d3-dbbe-454a-8efa-08d0972e9486" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RevenueRecognitionRevenueReduction_fc440a7d-712a-4640-8327-255ac28bebb9" xlink:href="bgne-20241231.xsd#bgne_RevenueRecognitionRevenueReduction"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f77583d3-dbbe-454a-8efa-08d0972e9486" xlink:to="loc_bgne_RevenueRecognitionRevenueReduction_fc440a7d-712a-4640-8327-255ac28bebb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeReductions_0b63ebdf-90f6-4593-bee1-dc060186c8bf" xlink:href="bgne-20241231.xsd#bgne_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeReductions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f77583d3-dbbe-454a-8efa-08d0972e9486" xlink:to="loc_bgne_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeReductions_0b63ebdf-90f6-4593-bee1-dc060186c8bf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#AccumulatedOtherComprehensiveLossIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0b723d6a-75ba-4204-a7bb-538b5a184d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_2244e852-503d-4210-b320-9e8862e8fcbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0b723d6a-75ba-4204-a7bb-538b5a184d6d" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_2244e852-503d-4210-b320-9e8862e8fcbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_97bedd62-0876-407d-bc9e-a638f3f252bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_0b723d6a-75ba-4204-a7bb-538b5a184d6d" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_97bedd62-0876-407d-bc9e-a638f3f252bc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/EmployeeBenefitPlansTotalExpectedBenefitPaymentsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#EmployeeBenefitPlansTotalExpectedBenefitPaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.beigene.com/role/EmployeeBenefitPlansTotalExpectedBenefitPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bgne_DefinedBenefitPlanExpectedFutureBenefitPaymentTotal_0273d15e-db91-4424-8db1-41131f4346cc" xlink:href="bgne-20241231.xsd#bgne_DefinedBenefitPlanExpectedFutureBenefitPaymentTotal"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_b7d89279-45aa-4d8c-a4f1-2284b9f70913" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bgne_DefinedBenefitPlanExpectedFutureBenefitPaymentTotal_0273d15e-db91-4424-8db1-41131f4346cc" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_b7d89279-45aa-4d8c-a4f1-2284b9f70913" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_425fb11b-ddaa-4336-b278-3dabe872f2b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bgne_DefinedBenefitPlanExpectedFutureBenefitPaymentTotal_0273d15e-db91-4424-8db1-41131f4346cc" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_425fb11b-ddaa-4336-b278-3dabe872f2b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_65088e7b-d54e-4777-8918-5ff7c8d52dca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bgne_DefinedBenefitPlanExpectedFutureBenefitPaymentTotal_0273d15e-db91-4424-8db1-41131f4346cc" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_65088e7b-d54e-4777-8918-5ff7c8d52dca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_e361133e-9666-4824-bc73-d3e0db13bcd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bgne_DefinedBenefitPlanExpectedFutureBenefitPaymentTotal_0273d15e-db91-4424-8db1-41131f4346cc" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_e361133e-9666-4824-bc73-d3e0db13bcd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_da99429c-b04b-44a1-ab95-83d3f1887859" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bgne_DefinedBenefitPlanExpectedFutureBenefitPaymentTotal_0273d15e-db91-4424-8db1-41131f4346cc" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_da99429c-b04b-44a1-ab95-83d3f1887859" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_a5da938d-b01a-4191-b991-d8b7da34f4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_bgne_DefinedBenefitPlanExpectedFutureBenefitPaymentTotal_0273d15e-db91-4424-8db1-41131f4346cc" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_a5da938d-b01a-4191-b991-d8b7da34f4b8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails"/>
  <link:calculationLink xlink:role="http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ba76973f-cc42-495b-8adb-417559066f88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableCurrent_bf4c2792-75d0-4df8-9221-1461c42f5c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ba76973f-cc42-495b-8adb-417559066f88" xlink:to="loc_us-gaap_LoansPayableCurrent_bf4c2792-75d0-4df8-9221-1461c42f5c0d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_1f318779-e048-4723-aba0-d8f8ed05aa9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ba76973f-cc42-495b-8adb-417559066f88" xlink:to="loc_us-gaap_LongTermDebtCurrent_1f318779-e048-4723-aba0-d8f8ed05aa9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5cd17afa-f2b3-4f71-8003-aed9be03751e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_ba76973f-cc42-495b-8adb-417559066f88" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_5cd17afa-f2b3-4f71-8003-aed9be03751e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e5f0a9cd-18dc-4dff-8b9f-9c7978fecf04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_8c1354de-1e4a-466f-97e9-958be2dd8266" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e5f0a9cd-18dc-4dff-8b9f-9c7978fecf04" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_8c1354de-1e4a-466f-97e9-958be2dd8266" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_65173415-a742-409f-a854-3146f84fccca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e5f0a9cd-18dc-4dff-8b9f-9c7978fecf04" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_65173415-a742-409f-a854-3146f84fccca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_dd1e6363-960f-4429-9dad-80a376e361d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e5f0a9cd-18dc-4dff-8b9f-9c7978fecf04" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_dd1e6363-960f-4429-9dad-80a376e361d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d5931136-ea0f-4400-96fa-e9711768b757" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e5f0a9cd-18dc-4dff-8b9f-9c7978fecf04" xlink:to="loc_us-gaap_AssetsCurrent_d5931136-ea0f-4400-96fa-e9711768b757" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"/>
  <link:calculationLink xlink:role="http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4baec107-2418-4511-9b97-92da48ed6480" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_24b77331-0193-4685-aa5c-eb7f6576c553" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4baec107-2418-4511-9b97-92da48ed6480" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_24b77331-0193-4685-aa5c-eb7f6576c553" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_55517d15-2db8-442a-b85c-6b38eb2b81ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4baec107-2418-4511-9b97-92da48ed6480" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_55517d15-2db8-442a-b85c-6b38eb2b81ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_5670b204-cb2a-4d2a-b592-e17d97a82b26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4baec107-2418-4511-9b97-92da48ed6480" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_5670b204-cb2a-4d2a-b592-e17d97a82b26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_0d4f5c95-9a0f-4d10-b9ee-7786ac652bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4baec107-2418-4511-9b97-92da48ed6480" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_0d4f5c95-9a0f-4d10-b9ee-7786ac652bf3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_PaymentsToPurchaseInProcessResearchAndDevelopment_9087d5f8-a342-4f1b-81b9-77a40e2b59a4" xlink:href="bgne-20241231.xsd#bgne_PaymentsToPurchaseInProcessResearchAndDevelopment"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4baec107-2418-4511-9b97-92da48ed6480" xlink:to="loc_bgne_PaymentsToPurchaseInProcessResearchAndDevelopment_9087d5f8-a342-4f1b-81b9-77a40e2b59a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e462bbc-9bb3-4248-aa42-6c40ce37230d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AcquiredInProcessResearchAndDevelopment_c8978e37-cdbe-4694-a331-51d88963f768" xlink:href="bgne-20241231.xsd#bgne_AcquiredInProcessResearchAndDevelopment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e462bbc-9bb3-4248-aa42-6c40ce37230d" xlink:to="loc_bgne_AcquiredInProcessResearchAndDevelopment_c8978e37-cdbe-4694-a331-51d88963f768" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_ee670a97-e95d-4bbd-bb14-05ffd7cace05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e462bbc-9bb3-4248-aa42-6c40ce37230d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_ee670a97-e95d-4bbd-bb14-05ffd7cace05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AmortizationOfResearchAndDevelopmentFinancingLiability_30d61d4c-3af5-465c-aa3e-e79306f696dc" xlink:href="bgne-20241231.xsd#bgne_AmortizationOfResearchAndDevelopmentFinancingLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e462bbc-9bb3-4248-aa42-6c40ce37230d" xlink:to="loc_bgne_AmortizationOfResearchAndDevelopmentFinancingLiability_30d61d4c-3af5-465c-aa3e-e79306f696dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_UnrealizedGainLossInSubsidiaries_4a4057b2-084c-40c7-9d3e-0e09c6dd67cd" xlink:href="bgne-20241231.xsd#bgne_UnrealizedGainLossInSubsidiaries"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e462bbc-9bb3-4248-aa42-6c40ce37230d" xlink:to="loc_bgne_UnrealizedGainLossInSubsidiaries_4a4057b2-084c-40c7-9d3e-0e09c6dd67cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_569fe0ba-ec94-47be-bc44-2d87ad55b0a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e462bbc-9bb3-4248-aa42-6c40ce37230d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_569fe0ba-ec94-47be-bc44-2d87ad55b0a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_12c0c2f6-9fcd-4a3e-9279-ab8e54a4a667" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e462bbc-9bb3-4248-aa42-6c40ce37230d" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_12c0c2f6-9fcd-4a3e-9279-ab8e54a4a667" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_34ba9059-b2c6-43ff-8d30-b2e76a65e271" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7e462bbc-9bb3-4248-aa42-6c40ce37230d" xlink:to="loc_us-gaap_NetIncomeLoss_34ba9059-b2c6-43ff-8d30-b2e76a65e271" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>bgne-20241231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:c70194b9-233f-4b06-bc07-707c5a5abbc8,g:477d344e-a417-40e8-b704-01a6f7f40ad7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="bgne-20241231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a0abca92-a84a-4edc-847c-14f71c7a04c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_us-gaap_StatementTable_a0abca92-a84a-4edc-847c-14f71c7a04c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c7499391-8ac1-4570-bba8-6e810463d7d9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a0abca92-a84a-4edc-847c-14f71c7a04c9" xlink:to="loc_srt_ProductOrServiceAxis_c7499391-8ac1-4570-bba8-6e810463d7d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c7499391-8ac1-4570-bba8-6e810463d7d9_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c7499391-8ac1-4570-bba8-6e810463d7d9" xlink:to="loc_srt_ProductsAndServicesDomain_c7499391-8ac1-4570-bba8-6e810463d7d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d9d410af-752e-41a0-9604-b29e8c50e710" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c7499391-8ac1-4570-bba8-6e810463d7d9" xlink:to="loc_srt_ProductsAndServicesDomain_d9d410af-752e-41a0-9604-b29e8c50e710" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_decba163-c03e-45d8-bfb3-c7287dd266b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d9d410af-752e-41a0-9604-b29e8c50e710" xlink:to="loc_us-gaap_ProductMember_decba163-c03e-45d8-bfb3-c7287dd266b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_CollaborationMember_89033f71-0915-4f08-807f-5682057dc3b0" xlink:href="bgne-20241231.xsd#bgne_CollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d9d410af-752e-41a0-9604-b29e8c50e710" xlink:to="loc_bgne_CollaborationMember_89033f71-0915-4f08-807f-5682057dc3b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_565c8888-3909-44b7-b9e4-d6b1af6661bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_us-gaap_RevenuesAbstract_565c8888-3909-44b7-b9e4-d6b1af6661bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a387db92-a7ca-4162-b390-b99ce1e3e23a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_565c8888-3909-44b7-b9e4-d6b1af6661bf" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a387db92-a7ca-4162-b390-b99ce1e3e23a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_a36666ce-15b6-444d-a695-19c6c037a103" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_a36666ce-15b6-444d-a695-19c6c037a103" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_88c12e60-d39b-43c7-add5-9de85e5c2f98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_us-gaap_GrossProfit_88c12e60-d39b-43c7-add5-9de85e5c2f98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_3b84d2f2-0a39-4e38-a2df-53fec8bc0a87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_3b84d2f2-0a39-4e38-a2df-53fec8bc0a87" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d6fddc95-edab-49ad-8116-d400b767f320" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3b84d2f2-0a39-4e38-a2df-53fec8bc0a87" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d6fddc95-edab-49ad-8116-d400b767f320" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_674d6484-5414-4cb9-985b-1b7ff1e0902f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3b84d2f2-0a39-4e38-a2df-53fec8bc0a87" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_674d6484-5414-4cb9-985b-1b7ff1e0902f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_e3c1ea6c-4a39-42f3-89fc-b8d6b5f816d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3b84d2f2-0a39-4e38-a2df-53fec8bc0a87" xlink:to="loc_us-gaap_CostsAndExpenses_e3c1ea6c-4a39-42f3-89fc-b8d6b5f816d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b1afc452-8f0a-496e-a098-63587b58ce96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_us-gaap_OperatingIncomeLoss_b1afc452-8f0a-496e-a098-63587b58ce96" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_31d8b8ed-c767-44c8-a7a1-fddb4cd24d56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_31d8b8ed-c767-44c8-a7a1-fddb4cd24d56" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_ffd0375d-b365-4b07-a0ec-3b92f94db5bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_ffd0375d-b365-4b07-a0ec-3b92f94db5bd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9cb4e265-a8af-4c21-afea-4a02a87ed684" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9cb4e265-a8af-4c21-afea-4a02a87ed684" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_890aa676-d35e-4385-8366-9ebfef2ed1c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_890aa676-d35e-4385-8366-9ebfef2ed1c6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7e41921a-66db-46c8-89ed-c68604c63bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_us-gaap_NetIncomeLoss_7e41921a-66db-46c8-89ed-c68604c63bf9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6d7f559c-287f-4903-a0c7-e8ba93c1ad5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_us-gaap_EarningsPerShareBasic_6d7f559c-287f-4903-a0c7-e8ba93c1ad5e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_e58a73b0-e0c8-4d1f-922e-d0d1e62a4647" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_us-gaap_EarningsPerShareDiluted_e58a73b0-e0c8-4d1f-922e-d0d1e62a4647" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d30579c7-4bb9-410a-8588-08f740ef70da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d30579c7-4bb9-410a-8588-08f740ef70da" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6ca66255-f6e7-4d07-be55-df268b0e2d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6ca66255-f6e7-4d07-be55-df268b0e2d5a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_EarningsPerAmericanDepositoryShareBasic_63b724fd-2804-483d-9dfb-dfb54e128a79" xlink:href="bgne-20241231.xsd#bgne_EarningsPerAmericanDepositoryShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_bgne_EarningsPerAmericanDepositoryShareBasic_63b724fd-2804-483d-9dfb-dfb54e128a79" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_EarningsPerAmericanDepositoryShareDiluted_35b582fc-f1f9-4ee4-84c9-8d6c9afd4495" xlink:href="bgne-20241231.xsd#bgne_EarningsPerAmericanDepositoryShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_bgne_EarningsPerAmericanDepositoryShareDiluted_35b582fc-f1f9-4ee4-84c9-8d6c9afd4495" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic_081adea9-cff0-414a-b560-689ca61cbcf6" xlink:href="bgne-20241231.xsd#bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic_081adea9-cff0-414a-b560-689ca61cbcf6" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted_75f9e4ea-252b-409b-86ba-8c0cf9787abd" xlink:href="bgne-20241231.xsd#bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted_75f9e4ea-252b-409b-86ba-8c0cf9787abd" xlink:type="arc" order="17"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" xlink:type="simple" xlink:href="bgne-20241231.xsd#CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c8c1ce8c-03e7-4d1d-9249-51e62016093f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_98030edb-c311-4c0f-8aa6-980942661211" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c8c1ce8c-03e7-4d1d-9249-51e62016093f" xlink:to="loc_us-gaap_StatementTable_98030edb-c311-4c0f-8aa6-980942661211" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_512fd803-1169-4ee1-a591-68af8ffe3995" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_98030edb-c311-4c0f-8aa6-980942661211" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_512fd803-1169-4ee1-a591-68af8ffe3995" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_512fd803-1169-4ee1-a591-68af8ffe3995_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_512fd803-1169-4ee1-a591-68af8ffe3995" xlink:to="loc_us-gaap_EquityComponentDomain_512fd803-1169-4ee1-a591-68af8ffe3995_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_219d80cf-67cb-4407-a913-33ba0c0b3d69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_512fd803-1169-4ee1-a591-68af8ffe3995" xlink:to="loc_us-gaap_EquityComponentDomain_219d80cf-67cb-4407-a913-33ba0c0b3d69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_abadd8e7-377d-4a00-8009-7b116bd3fbad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_219d80cf-67cb-4407-a913-33ba0c0b3d69" xlink:to="loc_us-gaap_CommonStockMember_abadd8e7-377d-4a00-8009-7b116bd3fbad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3fd415ea-58b1-4adc-a89d-40f1eaa17e78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_219d80cf-67cb-4407-a913-33ba0c0b3d69" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3fd415ea-58b1-4adc-a89d-40f1eaa17e78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_146c107c-6521-48df-b5c8-25e142a44389" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_219d80cf-67cb-4407-a913-33ba0c0b3d69" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_146c107c-6521-48df-b5c8-25e142a44389" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_7184e7bd-e95a-4720-9245-1cffab4fc098" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_219d80cf-67cb-4407-a913-33ba0c0b3d69" xlink:to="loc_us-gaap_RetainedEarningsMember_7184e7bd-e95a-4720-9245-1cffab4fc098" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c052df07-b978-4af5-b545-2a09f15a4010" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c8c1ce8c-03e7-4d1d-9249-51e62016093f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c052df07-b978-4af5-b545-2a09f15a4010" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_91361636-22d3-440e-8676-e3f09056c0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c052df07-b978-4af5-b545-2a09f15a4010" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_91361636-22d3-440e-8676-e3f09056c0cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5b749ea4-1ead-42e5-9221-062b5c69ab8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c052df07-b978-4af5-b545-2a09f15a4010" xlink:to="loc_us-gaap_StockholdersEquity_5b749ea4-1ead-42e5-9221-062b5c69ab8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_d38f8c42-80ee-454a-ad41-1c47c074283f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c052df07-b978-4af5-b545-2a09f15a4010" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_d38f8c42-80ee-454a-ad41-1c47c074283f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7e8f54b7-41a1-4eab-bcbc-7ce09bd5e7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c052df07-b978-4af5-b545-2a09f15a4010" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7e8f54b7-41a1-4eab-bcbc-7ce09bd5e7cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f0675abc-52dd-439a-9993-2d16864cc1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c052df07-b978-4af5-b545-2a09f15a4010" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f0675abc-52dd-439a-9993-2d16864cc1d0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_33869640-d4fb-4520-98d0-a694f9a366bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c052df07-b978-4af5-b545-2a09f15a4010" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_33869640-d4fb-4520-98d0-a694f9a366bd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AdjustmentsToAdditionalPaidInCapitalDeconsolidationOfSubsidiary_9d0601d4-a57a-4c6c-9f42-02725c31952b" xlink:href="bgne-20241231.xsd#bgne_AdjustmentsToAdditionalPaidInCapitalDeconsolidationOfSubsidiary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c052df07-b978-4af5-b545-2a09f15a4010" xlink:to="loc_bgne_AdjustmentsToAdditionalPaidInCapitalDeconsolidationOfSubsidiary_9d0601d4-a57a-4c6c-9f42-02725c31952b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5afea0ba-651d-4753-bda7-16044dd9ae4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c052df07-b978-4af5-b545-2a09f15a4010" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5afea0ba-651d-4753-bda7-16044dd9ae4c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_78693e74-969f-4514-9c84-3b7c6649702d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c052df07-b978-4af5-b545-2a09f15a4010" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_78693e74-969f-4514-9c84-3b7c6649702d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_4815c696-935e-4bf5-8f98-7f5207067763" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c052df07-b978-4af5-b545-2a09f15a4010" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_4815c696-935e-4bf5-8f98-7f5207067763" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8f72bf80-e2e9-4cba-885d-eb8d6a66ea05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c052df07-b978-4af5-b545-2a09f15a4010" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8f72bf80-e2e9-4cba-885d-eb8d6a66ea05" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_db5d67d1-b841-44af-b029-c33be6011569" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c052df07-b978-4af5-b545-2a09f15a4010" xlink:to="loc_us-gaap_NetIncomeLoss_db5d67d1-b841-44af-b029-c33be6011569" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d43ae119-a4a2-4f98-8aed-d55a7491b315" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_352def9d-a6e3-4413-a3e4-1ead7ee76813" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_12b7501c-e0c7-49ad-b9a2-1f377b26ea42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1ab586b9-67b0-4caa-a8ba-55c553542f23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_12b7501c-e0c7-49ad-b9a2-1f377b26ea42" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1ab586b9-67b0-4caa-a8ba-55c553542f23" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7a2d14a3-9c41-41ad-bb43-8eef6e8f0302" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1ab586b9-67b0-4caa-a8ba-55c553542f23" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7a2d14a3-9c41-41ad-bb43-8eef6e8f0302" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7a2d14a3-9c41-41ad-bb43-8eef6e8f0302_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7a2d14a3-9c41-41ad-bb43-8eef6e8f0302" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7a2d14a3-9c41-41ad-bb43-8eef6e8f0302_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ac9fdab-13aa-4437-b51d-b413ea9b2b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7a2d14a3-9c41-41ad-bb43-8eef6e8f0302" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ac9fdab-13aa-4437-b51d-b413ea9b2b3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_fb1fbf59-def5-4937-a39d-bc16b63ec9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ac9fdab-13aa-4437-b51d-b413ea9b2b3a" xlink:to="loc_us-gaap_BuildingMember_fb1fbf59-def5-4937-a39d-bc16b63ec9d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_d3581217-e2c8-4e23-8be0-32aa06c0d5a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ac9fdab-13aa-4437-b51d-b413ea9b2b3a" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_d3581217-e2c8-4e23-8be0-32aa06c0d5a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_LaboratoryEquipmentMember_623a201f-50f0-46c3-bfc8-035771b82c46" xlink:href="bgne-20241231.xsd#bgne_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ac9fdab-13aa-4437-b51d-b413ea9b2b3a" xlink:to="loc_bgne_LaboratoryEquipmentMember_623a201f-50f0-46c3-bfc8-035771b82c46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_d522026b-a743-4598-a74e-b52dd517c134" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ac9fdab-13aa-4437-b51d-b413ea9b2b3a" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_d522026b-a743-4598-a74e-b52dd517c134" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_afe15e42-0384-47bb-9846-2ed13295a575" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1ab586b9-67b0-4caa-a8ba-55c553542f23" xlink:to="loc_srt_RangeAxis_afe15e42-0384-47bb-9846-2ed13295a575" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_afe15e42-0384-47bb-9846-2ed13295a575_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_afe15e42-0384-47bb-9846-2ed13295a575" xlink:to="loc_srt_RangeMember_afe15e42-0384-47bb-9846-2ed13295a575_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b988b256-721b-4ec7-9dd7-acd97e669fed" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_afe15e42-0384-47bb-9846-2ed13295a575" xlink:to="loc_srt_RangeMember_b988b256-721b-4ec7-9dd7-acd97e669fed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6740703c-8e95-4f41-bc4d-c03356acf45c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b988b256-721b-4ec7-9dd7-acd97e669fed" xlink:to="loc_srt_MinimumMember_6740703c-8e95-4f41-bc4d-c03356acf45c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9b05cec3-e85d-4bc2-bb1b-0bae86ec4ba0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b988b256-721b-4ec7-9dd7-acd97e669fed" xlink:to="loc_srt_MaximumMember_9b05cec3-e85d-4bc2-bb1b-0bae86ec4ba0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_3ecf8bd5-c00b-4724-9dc8-3bd32c1861bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_12b7501c-e0c7-49ad-b9a2-1f377b26ea42" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_3ecf8bd5-c00b-4724-9dc8-3bd32c1861bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4b85f627-e6d5-4fb6-b3ce-45b13354412f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_3ecf8bd5-c00b-4724-9dc8-3bd32c1861bb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4b85f627-e6d5-4fb6-b3ce-45b13354412f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesLandUseRightNetDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#SummaryofSignificantAccountingPoliciesLandUseRightNetDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesLandUseRightNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_248214a8-7263-4c0b-a6fd-ab7a4cd5bcdb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_baf68af2-2623-490d-aeb2-9febcadbbdc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_248214a8-7263-4c0b-a6fd-ab7a4cd5bcdb" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_baf68af2-2623-490d-aeb2-9febcadbbdc0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5e13f1b1-6e84-48b1-aca0-7e075305ecde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_baf68af2-2623-490d-aeb2-9febcadbbdc0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5e13f1b1-6e84-48b1-aca0-7e075305ecde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5e13f1b1-6e84-48b1-aca0-7e075305ecde_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5e13f1b1-6e84-48b1-aca0-7e075305ecde" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5e13f1b1-6e84-48b1-aca0-7e075305ecde_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8158b4b7-773b-4b82-9e59-d7fe4521e0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5e13f1b1-6e84-48b1-aca0-7e075305ecde" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8158b4b7-773b-4b82-9e59-d7fe4521e0d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_3154e877-0890-42ba-a541-3adf0a62c19f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8158b4b7-773b-4b82-9e59-d7fe4521e0d8" xlink:to="loc_us-gaap_LandMember_3154e877-0890-42ba-a541-3adf0a62c19f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a4917e68-11b5-429e-9ed3-a472f75f76a2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_baf68af2-2623-490d-aeb2-9febcadbbdc0" xlink:to="loc_srt_StatementGeographicalAxis_a4917e68-11b5-429e-9ed3-a472f75f76a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a4917e68-11b5-429e-9ed3-a472f75f76a2_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_a4917e68-11b5-429e-9ed3-a472f75f76a2" xlink:to="loc_srt_SegmentGeographicalDomain_a4917e68-11b5-429e-9ed3-a472f75f76a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a91ddaf9-5197-4e0d-99cb-90e914ad0376" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_a4917e68-11b5-429e-9ed3-a472f75f76a2" xlink:to="loc_srt_SegmentGeographicalDomain_a91ddaf9-5197-4e0d-99cb-90e914ad0376" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_GuangzhouMember_f36ee151-fcff-4689-86f2-e5cc8b982e46" xlink:href="bgne-20241231.xsd#bgne_GuangzhouMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a91ddaf9-5197-4e0d-99cb-90e914ad0376" xlink:to="loc_bgne_GuangzhouMember_f36ee151-fcff-4689-86f2-e5cc8b982e46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_BeijingMember_675dd22e-12e3-418b-b075-489f7d31d13e" xlink:href="bgne-20241231.xsd#bgne_BeijingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a91ddaf9-5197-4e0d-99cb-90e914ad0376" xlink:to="loc_bgne_BeijingMember_675dd22e-12e3-418b-b075-489f7d31d13e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_SuzhouMember_54f89f1f-225f-4c87-b49d-1a38f9f6a014" xlink:href="bgne-20241231.xsd#bgne_SuzhouMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a91ddaf9-5197-4e0d-99cb-90e914ad0376" xlink:to="loc_bgne_SuzhouMember_54f89f1f-225f-4c87-b49d-1a38f9f6a014" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShanghaiMember_6310626b-3f51-4097-8639-fad14555fd1e" xlink:href="bgne-20241231.xsd#bgne_ShanghaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_a91ddaf9-5197-4e0d-99cb-90e914ad0376" xlink:to="loc_bgne_ShanghaiMember_6310626b-3f51-4097-8639-fad14555fd1e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9c6bd573-2a00-4b62-82aa-7ef4adab1eee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_248214a8-7263-4c0b-a6fd-ab7a4cd5bcdb" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9c6bd573-2a00-4b62-82aa-7ef4adab1eee" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_75609d95-da85-4ae9-9c6d-e752327562e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d9c94054-eb82-483c-a829-8f5499cf0684" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_75609d95-da85-4ae9-9c6d-e752327562e7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d9c94054-eb82-483c-a829-8f5499cf0684" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_abe39a97-c30f-4f27-ad12-e17731807410" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d9c94054-eb82-483c-a829-8f5499cf0684" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_abe39a97-c30f-4f27-ad12-e17731807410" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_abe39a97-c30f-4f27-ad12-e17731807410_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_abe39a97-c30f-4f27-ad12-e17731807410" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_abe39a97-c30f-4f27-ad12-e17731807410_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0790754b-9c1a-426f-877d-d44552a1302b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_abe39a97-c30f-4f27-ad12-e17731807410" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0790754b-9c1a-426f-877d-d44552a1302b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_675ab2fd-a278-4cfe-a1fd-6fc74cf2e011" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0790754b-9c1a-426f-877d-d44552a1302b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_675ab2fd-a278-4cfe-a1fd-6fc74cf2e011" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4a1bcf56-d91e-437e-8232-0c6709e49457" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d9c94054-eb82-483c-a829-8f5499cf0684" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4a1bcf56-d91e-437e-8232-0c6709e49457" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a1bcf56-d91e-437e-8232-0c6709e49457_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4a1bcf56-d91e-437e-8232-0c6709e49457" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a1bcf56-d91e-437e-8232-0c6709e49457_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_58789ed9-e7f6-4535-8f5c-ec4ed6feba11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4a1bcf56-d91e-437e-8232-0c6709e49457" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_58789ed9-e7f6-4535-8f5c-ec4ed6feba11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_dfb0485e-c030-4e5d-b624-410d83d31139" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_58789ed9-e7f6-4535-8f5c-ec4ed6feba11" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_dfb0485e-c030-4e5d-b624-410d83d31139" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b2ab1e22-43af-4932-807a-879b8f75779e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_58789ed9-e7f6-4535-8f5c-ec4ed6feba11" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b2ab1e22-43af-4932-807a-879b8f75779e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8edbd466-b202-4759-a010-c51eb66024ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_58789ed9-e7f6-4535-8f5c-ec4ed6feba11" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8edbd466-b202-4759-a010-c51eb66024ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_582857cb-6d8d-4e5c-85ac-2ed11a78a3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d9c94054-eb82-483c-a829-8f5499cf0684" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_582857cb-6d8d-4e5c-85ac-2ed11a78a3bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_582857cb-6d8d-4e5c-85ac-2ed11a78a3bc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_582857cb-6d8d-4e5c-85ac-2ed11a78a3bc" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_582857cb-6d8d-4e5c-85ac-2ed11a78a3bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e76410bc-1047-47c5-a913-8483cbff404a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_582857cb-6d8d-4e5c-85ac-2ed11a78a3bc" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e76410bc-1047-47c5-a913-8483cbff404a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_893b6bd4-2497-4cf7-a3e8-17efc61fdb52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e76410bc-1047-47c5-a913-8483cbff404a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_893b6bd4-2497-4cf7-a3e8-17efc61fdb52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_90cdf4ff-70fd-4a2c-acf7-ff7af0e56c75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e76410bc-1047-47c5-a913-8483cbff404a" xlink:to="loc_us-gaap_BankTimeDepositsMember_90cdf4ff-70fd-4a2c-acf7-ff7af0e56c75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b9093b89-5a3e-4733-a6c8-7ee11039f8ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d9c94054-eb82-483c-a829-8f5499cf0684" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b9093b89-5a3e-4733-a6c8-7ee11039f8ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b9093b89-5a3e-4733-a6c8-7ee11039f8ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b9093b89-5a3e-4733-a6c8-7ee11039f8ef" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b9093b89-5a3e-4733-a6c8-7ee11039f8ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4e8d195d-4eaf-4ab1-ac38-56bb8e5141d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b9093b89-5a3e-4733-a6c8-7ee11039f8ef" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4e8d195d-4eaf-4ab1-ac38-56bb8e5141d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_39ab17b3-3f39-4b5a-a5b1-9eb26f63f5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4e8d195d-4eaf-4ab1-ac38-56bb8e5141d1" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_39ab17b3-3f39-4b5a-a5b1-9eb26f63f5b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_059c7013-f17b-4733-a234-e26145eb611a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4e8d195d-4eaf-4ab1-ac38-56bb8e5141d1" xlink:to="loc_us-gaap_ConvertibleDebtMember_059c7013-f17b-4733-a234-e26145eb611a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_ebed343f-9391-4e1a-ae35-08250b82f7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4e8d195d-4eaf-4ab1-ac38-56bb8e5141d1" xlink:to="loc_us-gaap_EquitySecuritiesMember_ebed343f-9391-4e1a-ae35-08250b82f7a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiabilityAbstract_79056f2e-a969-4746-acaf-09186f6685a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetAssetLiabilityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_75609d95-da85-4ae9-9c6d-e752327562e7" xlink:to="loc_us-gaap_FairValueNetAssetLiabilityAbstract_79056f2e-a969-4746-acaf-09186f6685a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e8cbee91-449d-4516-9459-04316d7720dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetAssetLiabilityAbstract_79056f2e-a969-4746-acaf-09186f6685a7" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e8cbee91-449d-4516-9459-04316d7720dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_93edf438-48ab-44e4-9ffe-95726fcd40d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetAssetLiabilityAbstract_79056f2e-a969-4746-acaf-09186f6685a7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_93edf438-48ab-44e4-9ffe-95726fcd40d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_84bb167b-b98b-4c68-9456-4ce7db58fd64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_93edf438-48ab-44e4-9ffe-95726fcd40d3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_84bb167b-b98b-4c68-9456-4ce7db58fd64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_InvestmentInDebtSecuritiesCurrent_f143720d-2dfe-475b-b81c-c3e69cce471a" xlink:href="bgne-20241231.xsd#bgne_InvestmentInDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_93edf438-48ab-44e4-9ffe-95726fcd40d3" xlink:to="loc_bgne_InvestmentInDebtSecuritiesCurrent_f143720d-2dfe-475b-b81c-c3e69cce471a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_ce122174-6f7e-44d9-8b6b-db0ec5c3b193" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetAssetLiabilityAbstract_79056f2e-a969-4746-acaf-09186f6685a7" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_ce122174-6f7e-44d9-8b6b-db0ec5c3b193" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_a6e762be-ee8b-4ab5-ad72-18b2b64f9bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_ce122174-6f7e-44d9-8b6b-db0ec5c3b193" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_a6e762be-ee8b-4ab5-ad72-18b2b64f9bb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_InvestmentInDebtSecuritiesNonCurrent_77d77c86-86bb-4615-be9a-648847b977aa" xlink:href="bgne-20241231.xsd#bgne_InvestmentInDebtSecuritiesNonCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_ce122174-6f7e-44d9-8b6b-db0ec5c3b193" xlink:to="loc_bgne_InvestmentInDebtSecuritiesNonCurrent_77d77c86-86bb-4615-be9a-648847b977aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_0b935a67-2c47-4da1-87cc-effafe627938" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetAssetLiabilityAbstract_79056f2e-a969-4746-acaf-09186f6685a7" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_0b935a67-2c47-4da1-87cc-effafe627938" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_3792f0ad-7db2-44c9-ae78-bac4292a7557" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_75609d95-da85-4ae9-9c6d-e752327562e7" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_3792f0ad-7db2-44c9-ae78-bac4292a7557" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesGovernmentGrantsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#SummaryofSignificantAccountingPoliciesGovernmentGrantsDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesGovernmentGrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a7ee1d71-fd7c-4801-b5bd-41a18f5cb67d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0f64a8da-7eb5-485b-8d3e-74a495e25a88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a7ee1d71-fd7c-4801-b5bd-41a18f5cb67d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0f64a8da-7eb5-485b-8d3e-74a495e25a88" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceTypeAxis_3961f4db-5a42-42f5-95bc-7d77963a0b36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0f64a8da-7eb5-485b-8d3e-74a495e25a88" xlink:to="loc_us-gaap_GovernmentAssistanceTypeAxis_3961f4db-5a42-42f5-95bc-7d77963a0b36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceTypeDomain_3961f4db-5a42-42f5-95bc-7d77963a0b36_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GovernmentAssistanceTypeAxis_3961f4db-5a42-42f5-95bc-7d77963a0b36" xlink:to="loc_us-gaap_GovernmentAssistanceTypeDomain_3961f4db-5a42-42f5-95bc-7d77963a0b36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceTypeDomain_892730ba-9301-4451-a323-0fbeabbd5c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GovernmentAssistanceTypeAxis_3961f4db-5a42-42f5-95bc-7d77963a0b36" xlink:to="loc_us-gaap_GovernmentAssistanceTypeDomain_892730ba-9301-4451-a323-0fbeabbd5c7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_GovernmentAssistanceManufacturingFacilityBuildOutMember_694d7939-74c3-4661-a980-bd90b1a563c7" xlink:href="bgne-20241231.xsd#bgne_GovernmentAssistanceManufacturingFacilityBuildOutMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GovernmentAssistanceTypeDomain_892730ba-9301-4451-a323-0fbeabbd5c7e" xlink:to="loc_bgne_GovernmentAssistanceManufacturingFacilityBuildOutMember_694d7939-74c3-4661-a980-bd90b1a563c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_GovernmentAssistanceResearchAndDevelopmentProgramsMember_7d7be0d7-ac84-43d2-9022-d1ce0ffe1111" xlink:href="bgne-20241231.xsd#bgne_GovernmentAssistanceResearchAndDevelopmentProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GovernmentAssistanceTypeDomain_892730ba-9301-4451-a323-0fbeabbd5c7e" xlink:to="loc_bgne_GovernmentAssistanceResearchAndDevelopmentProgramsMember_7d7be0d7-ac84-43d2-9022-d1ce0ffe1111" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a6b01b91-a808-4dab-893d-ebc760fe232e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0f64a8da-7eb5-485b-8d3e-74a495e25a88" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a6b01b91-a808-4dab-893d-ebc760fe232e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a6b01b91-a808-4dab-893d-ebc760fe232e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a6b01b91-a808-4dab-893d-ebc760fe232e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a6b01b91-a808-4dab-893d-ebc760fe232e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_68fde5de-5490-4b13-9f19-2606ee895f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a6b01b91-a808-4dab-893d-ebc760fe232e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_68fde5de-5490-4b13-9f19-2606ee895f1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_DepreciationExpenseMember_396eb4a1-d368-4216-b0fe-32dc58330463" xlink:href="bgne-20241231.xsd#bgne_DepreciationExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_68fde5de-5490-4b13-9f19-2606ee895f1d" xlink:to="loc_bgne_DepreciationExpenseMember_396eb4a1-d368-4216-b0fe-32dc58330463" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceAmount_3eaca663-7258-41a9-aa2a-c9a855037f56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a7ee1d71-fd7c-4801-b5bd-41a18f5cb67d" xlink:to="loc_us-gaap_GovernmentAssistanceAmount_3eaca663-7258-41a9-aa2a-c9a855037f56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration_e9225b09-c126-48d1-88dd-f1b1a235b2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a7ee1d71-fd7c-4801-b5bd-41a18f5cb67d" xlink:to="loc_us-gaap_GovernmentAssistanceLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration_e9225b09-c126-48d1-88dd-f1b1a235b2ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceLiabilityNoncurrent_6c816c43-b7ff-49ef-b0e3-f3e6b5cfca37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a7ee1d71-fd7c-4801-b5bd-41a18f5cb67d" xlink:to="loc_us-gaap_GovernmentAssistanceLiabilityNoncurrent_6c816c43-b7ff-49ef-b0e3-f3e6b5cfca37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_5531c0c2-340a-41fe-92b3-a471693df68e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a7ee1d71-fd7c-4801-b5bd-41a18f5cb67d" xlink:to="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_5531c0c2-340a-41fe-92b3-a471693df68e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_53b82d10-bce3-453d-a4dd-0f63faa925dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a7ee1d71-fd7c-4801-b5bd-41a18f5cb67d" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_53b82d10-bce3-453d-a4dd-0f63faa925dc" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesConcentrationofRisksDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#SummaryofSignificantAccountingPoliciesConcentrationofRisksDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesConcentrationofRisksDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_9fdbe1e2-1f96-4430-8369-f9ae545e7091" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_d44e19da-32c2-49f1-bf54-51e3731ac6df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9fdbe1e2-1f96-4430-8369-f9ae545e7091" xlink:to="loc_us-gaap_ConcentrationRiskTable_d44e19da-32c2-49f1-bf54-51e3731ac6df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a8c9e545-3cc8-42bc-9c3f-c8ca54eac26b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_d44e19da-32c2-49f1-bf54-51e3731ac6df" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a8c9e545-3cc8-42bc-9c3f-c8ca54eac26b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a8c9e545-3cc8-42bc-9c3f-c8ca54eac26b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a8c9e545-3cc8-42bc-9c3f-c8ca54eac26b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a8c9e545-3cc8-42bc-9c3f-c8ca54eac26b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_aad82212-5d3d-47d2-9a66-b60363b42849" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a8c9e545-3cc8-42bc-9c3f-c8ca54eac26b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_aad82212-5d3d-47d2-9a66-b60363b42849" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_2255b19d-8e77-4847-9083-95c820bcdc21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_aad82212-5d3d-47d2-9a66-b60363b42849" xlink:to="loc_us-gaap_SalesRevenueNetMember_2255b19d-8e77-4847-9083-95c820bcdc21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_07fe1e7b-f28d-49ac-b44a-11a572c53392" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_aad82212-5d3d-47d2-9a66-b60363b42849" xlink:to="loc_us-gaap_AccountsReceivableMember_07fe1e7b-f28d-49ac-b44a-11a572c53392" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_d4ae5364-9039-40da-98d7-0c264bda40cc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_d44e19da-32c2-49f1-bf54-51e3731ac6df" xlink:to="loc_srt_MajorCustomersAxis_d4ae5364-9039-40da-98d7-0c264bda40cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_d4ae5364-9039-40da-98d7-0c264bda40cc_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_d4ae5364-9039-40da-98d7-0c264bda40cc" xlink:to="loc_srt_NameOfMajorCustomerDomain_d4ae5364-9039-40da-98d7-0c264bda40cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_3ab37dc3-565d-4fb8-a425-a06430507fe4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_d4ae5364-9039-40da-98d7-0c264bda40cc" xlink:to="loc_srt_NameOfMajorCustomerDomain_3ab37dc3-565d-4fb8-a425-a06430507fe4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ASDSpecialtyHealthcareMember_9e1f4d03-314c-444e-b833-e911d3c880ba" xlink:href="bgne-20241231.xsd#bgne_ASDSpecialtyHealthcareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_3ab37dc3-565d-4fb8-a425-a06430507fe4" xlink:to="loc_bgne_ASDSpecialtyHealthcareMember_9e1f4d03-314c-444e-b833-e911d3c880ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_McKessonMember_61e7e1a1-39af-4164-adcb-3f9ad8422336" xlink:href="bgne-20241231.xsd#bgne_McKessonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_3ab37dc3-565d-4fb8-a425-a06430507fe4" xlink:to="loc_bgne_McKessonMember_61e7e1a1-39af-4164-adcb-3f9ad8422336" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShanghaiPharmaceuticalMember_90734010-eb85-4cac-8a51-c574e1db9891" xlink:href="bgne-20241231.xsd#bgne_ShanghaiPharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_3ab37dc3-565d-4fb8-a425-a06430507fe4" xlink:to="loc_bgne_ShanghaiPharmaceuticalMember_90734010-eb85-4cac-8a51-c574e1db9891" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ThreeLargestCustomersMember_d3c7eb89-200b-4139-9ce9-b24c740b38fe" xlink:href="bgne-20241231.xsd#bgne_ThreeLargestCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_3ab37dc3-565d-4fb8-a425-a06430507fe4" xlink:to="loc_bgne_ThreeLargestCustomersMember_d3c7eb89-200b-4139-9ce9-b24c740b38fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_SinopharmMember_adc64ec9-aabe-4ed6-affa-9a1020daadda" xlink:href="bgne-20241231.xsd#bgne_SinopharmMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_3ab37dc3-565d-4fb8-a425-a06430507fe4" xlink:to="loc_bgne_SinopharmMember_adc64ec9-aabe-4ed6-affa-9a1020daadda" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ChinaResourcesMember_706ef4ad-ebef-478f-994e-e3a8c7c94446" xlink:href="bgne-20241231.xsd#bgne_ChinaResourcesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_3ab37dc3-565d-4fb8-a425-a06430507fe4" xlink:to="loc_bgne_ChinaResourcesMember_706ef4ad-ebef-478f-994e-e3a8c7c94446" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_FourLargestCustomersMember_2bf749b6-866b-4975-a36e-97afd87ef429" xlink:href="bgne-20241231.xsd#bgne_FourLargestCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_3ab37dc3-565d-4fb8-a425-a06430507fe4" xlink:to="loc_bgne_FourLargestCustomersMember_2bf749b6-866b-4975-a36e-97afd87ef429" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_357210c8-e91c-49e0-a34e-25cb6b62bb29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_d44e19da-32c2-49f1-bf54-51e3731ac6df" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_357210c8-e91c-49e0-a34e-25cb6b62bb29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_357210c8-e91c-49e0-a34e-25cb6b62bb29_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_357210c8-e91c-49e0-a34e-25cb6b62bb29" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_357210c8-e91c-49e0-a34e-25cb6b62bb29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_36342f2b-aa18-47b6-8ae9-c01dab9b9231" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_357210c8-e91c-49e0-a34e-25cb6b62bb29" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_36342f2b-aa18-47b6-8ae9-c01dab9b9231" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_467755ad-dda8-4156-a3c4-b1fa3271a860" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_36342f2b-aa18-47b6-8ae9-c01dab9b9231" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_467755ad-dda8-4156-a3c4-b1fa3271a860" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_297b0a62-35a3-443b-a782-3b9fdc6872db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9fdbe1e2-1f96-4430-8369-f9ae545e7091" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_297b0a62-35a3-443b-a782-3b9fdc6872db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_eb7f4115-400b-4b70-bf9f-712bd9f95ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9fdbe1e2-1f96-4430-8369-f9ae545e7091" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_eb7f4115-400b-4b70-bf9f-712bd9f95ae2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_3867c463-563a-43a3-a1de-ebf93323f4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9fdbe1e2-1f96-4430-8369-f9ae545e7091" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_3867c463-563a-43a3-a1de-ebf93323f4e7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/CollaborativeandLicensingArrangementsRecognizedRevenueDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#CollaborativeandLicensingArrangementsRecognizedRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/CollaborativeandLicensingArrangementsRecognizedRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_aded5866-e472-4d93-b5aa-1e083be904f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_c9d47afd-cdb7-4a23-b824-52fdee6c807c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_aded5866-e472-4d93-b5aa-1e083be904f5" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_c9d47afd-cdb7-4a23-b824-52fdee6c807c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8f2ed051-ccb1-4f1c-a666-2582b5f237ad" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_c9d47afd-cdb7-4a23-b824-52fdee6c807c" xlink:to="loc_srt_ProductOrServiceAxis_8f2ed051-ccb1-4f1c-a666-2582b5f237ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8f2ed051-ccb1-4f1c-a666-2582b5f237ad_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8f2ed051-ccb1-4f1c-a666-2582b5f237ad" xlink:to="loc_srt_ProductsAndServicesDomain_8f2ed051-ccb1-4f1c-a666-2582b5f237ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f65662d5-6f69-4954-8756-8904284ca426" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8f2ed051-ccb1-4f1c-a666-2582b5f237ad" xlink:to="loc_srt_ProductsAndServicesDomain_f65662d5-6f69-4954-8756-8904284ca426" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_CollaborationMember_136b44d3-c109-4485-a155-c3f0e363acb6" xlink:href="bgne-20241231.xsd#bgne_CollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f65662d5-6f69-4954-8756-8904284ca426" xlink:to="loc_bgne_CollaborationMember_136b44d3-c109-4485-a155-c3f0e363acb6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_CollaborationResearchAndDevelopmentServiceMember_1069249f-f851-40e9-9cd4-636d42601de9" xlink:href="bgne-20241231.xsd#bgne_CollaborationResearchAndDevelopmentServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bgne_CollaborationMember_136b44d3-c109-4485-a155-c3f0e363acb6" xlink:to="loc_bgne_CollaborationResearchAndDevelopmentServiceMember_1069249f-f851-40e9-9cd4-636d42601de9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RightToAccessIntellectualPropertyRevenueMember_7e671c1e-27d8-443d-a025-4a2d88e37d11" xlink:href="bgne-20241231.xsd#bgne_RightToAccessIntellectualPropertyRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bgne_CollaborationMember_136b44d3-c109-4485-a155-c3f0e363acb6" xlink:to="loc_bgne_RightToAccessIntellectualPropertyRevenueMember_7e671c1e-27d8-443d-a025-4a2d88e37d11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_MaterialRightsRevenueMember_3b7b893f-e8dc-433b-a927-27db1d6347db" xlink:href="bgne-20241231.xsd#bgne_MaterialRightsRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bgne_CollaborationMember_136b44d3-c109-4485-a155-c3f0e363acb6" xlink:to="loc_bgne_MaterialRightsRevenueMember_3b7b893f-e8dc-433b-a927-27db1d6347db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_CollaborationOtherMember_6e543a41-08ac-4173-aa1b-b3dddbe73760" xlink:href="bgne-20241231.xsd#bgne_CollaborationOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bgne_CollaborationMember_136b44d3-c109-4485-a155-c3f0e363acb6" xlink:to="loc_bgne_CollaborationOtherMember_6e543a41-08ac-4173-aa1b-b3dddbe73760" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d2ce94a8-a0ea-4e18-917a-5220191186d8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_c9d47afd-cdb7-4a23-b824-52fdee6c807c" xlink:to="loc_srt_CounterpartyNameAxis_d2ce94a8-a0ea-4e18-917a-5220191186d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d2ce94a8-a0ea-4e18-917a-5220191186d8_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d2ce94a8-a0ea-4e18-917a-5220191186d8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d2ce94a8-a0ea-4e18-917a-5220191186d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf3bd66b-6955-46bf-8d24-eaf571ef435d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d2ce94a8-a0ea-4e18-917a-5220191186d8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf3bd66b-6955-46bf-8d24-eaf571ef435d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_NovartisMember_febd7b35-0b64-4dde-9d86-97a0d5c3c01e" xlink:href="bgne-20241231.xsd#bgne_NovartisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf3bd66b-6955-46bf-8d24-eaf571ef435d" xlink:to="loc_bgne_NovartisMember_febd7b35-0b64-4dde-9d86-97a0d5c3c01e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_TislelizumabMember_8c921694-f1b5-442a-b9b7-8c2fd8011b11" xlink:href="bgne-20241231.xsd#bgne_TislelizumabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf3bd66b-6955-46bf-8d24-eaf571ef435d" xlink:to="loc_bgne_TislelizumabMember_8c921694-f1b5-442a-b9b7-8c2fd8011b11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_OciperlimabMember_48bc0891-abce-42d2-a1be-70d4704f59f4" xlink:href="bgne-20241231.xsd#bgne_OciperlimabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf3bd66b-6955-46bf-8d24-eaf571ef435d" xlink:to="loc_bgne_OciperlimabMember_48bc0891-abce-42d2-a1be-70d4704f59f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_e9554c45-c65f-42a3-9c6c-778f55eb1558" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_aded5866-e472-4d93-b5aa-1e083be904f5" xlink:to="loc_us-gaap_RevenuesAbstract_e9554c45-c65f-42a3-9c6c-778f55eb1558" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_db982ce1-63e2-4412-88b4-ad2a489b0f73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_e9554c45-c65f-42a3-9c6c-778f55eb1558" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_db982ce1-63e2-4412-88b4-ad2a489b0f73" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/CollaborativeandLicensingArrangementsNovartisDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#CollaborativeandLicensingArrangementsNovartisDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/CollaborativeandLicensingArrangementsNovartisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_260f31a0-f0ff-43e9-9863-d161df00c971" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_76c2cda2-3dd2-4dc3-8162-5a3fb9be74c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_260f31a0-f0ff-43e9-9863-d161df00c971" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_76c2cda2-3dd2-4dc3-8162-5a3fb9be74c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d8a203bf-efba-4717-99f4-1b2fc448df79" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_76c2cda2-3dd2-4dc3-8162-5a3fb9be74c3" xlink:to="loc_srt_CounterpartyNameAxis_d8a203bf-efba-4717-99f4-1b2fc448df79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d8a203bf-efba-4717-99f4-1b2fc448df79_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d8a203bf-efba-4717-99f4-1b2fc448df79" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d8a203bf-efba-4717-99f4-1b2fc448df79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_85e392e4-e863-42b1-a7b7-802b457ca62d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d8a203bf-efba-4717-99f4-1b2fc448df79" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_85e392e4-e863-42b1-a7b7-802b457ca62d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_NovartisMember_2a466124-f063-409b-b5d6-a2d7787fc5b5" xlink:href="bgne-20241231.xsd#bgne_NovartisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_85e392e4-e863-42b1-a7b7-802b457ca62d" xlink:to="loc_bgne_NovartisMember_2a466124-f063-409b-b5d6-a2d7787fc5b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_10c78c8a-20b0-4f0f-89bf-05778b8e6834" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_76c2cda2-3dd2-4dc3-8162-5a3fb9be74c3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_10c78c8a-20b0-4f0f-89bf-05778b8e6834" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_10c78c8a-20b0-4f0f-89bf-05778b8e6834_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_10c78c8a-20b0-4f0f-89bf-05778b8e6834" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_10c78c8a-20b0-4f0f-89bf-05778b8e6834_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd9062f1-9da6-40ca-91fa-3137d7e832dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_10c78c8a-20b0-4f0f-89bf-05778b8e6834" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd9062f1-9da6-40ca-91fa-3137d7e832dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_4e1918cd-9f55-474e-b58b-38d23c7f7f79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd9062f1-9da6-40ca-91fa-3137d7e832dd" xlink:to="loc_us-gaap_CollaborativeArrangementMember_4e1918cd-9f55-474e-b58b-38d23c7f7f79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_f6612db8-4979-4517-a325-5436a995fcb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_260f31a0-f0ff-43e9-9863-d161df00c971" xlink:to="loc_us-gaap_ContractWithCustomerLiability_f6612db8-4979-4517-a325-5436a995fcb0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/CollaborativeandLicensingArrangementsOciperlimabOptionCollaborationandLicenseAgreementandChinaBroadMarketDevelopmentAgreementDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#CollaborativeandLicensingArrangementsOciperlimabOptionCollaborationandLicenseAgreementandChinaBroadMarketDevelopmentAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/CollaborativeandLicensingArrangementsOciperlimabOptionCollaborationandLicenseAgreementandChinaBroadMarketDevelopmentAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_37424d5b-f570-4670-81f2-6b64ecbbf1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1dc658ce-2466-463b-8f58-27e352b13f20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_37424d5b-f570-4670-81f2-6b64ecbbf1a4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1dc658ce-2466-463b-8f58-27e352b13f20" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9b1f4d5e-ac7f-4019-8f26-398e365936d2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1dc658ce-2466-463b-8f58-27e352b13f20" xlink:to="loc_srt_CounterpartyNameAxis_9b1f4d5e-ac7f-4019-8f26-398e365936d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9b1f4d5e-ac7f-4019-8f26-398e365936d2_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_9b1f4d5e-ac7f-4019-8f26-398e365936d2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9b1f4d5e-ac7f-4019-8f26-398e365936d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8fdb8d47-b7ff-47de-9c43-3cd3664afe21" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_9b1f4d5e-ac7f-4019-8f26-398e365936d2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8fdb8d47-b7ff-47de-9c43-3cd3664afe21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_NovartisMember_9e828236-5cb3-40e6-a556-cd3a40d565ba" xlink:href="bgne-20241231.xsd#bgne_NovartisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8fdb8d47-b7ff-47de-9c43-3cd3664afe21" xlink:to="loc_bgne_NovartisMember_9e828236-5cb3-40e6-a556-cd3a40d565ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4f88a485-30be-4cd0-b2cd-ecc5155e66f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1dc658ce-2466-463b-8f58-27e352b13f20" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4f88a485-30be-4cd0-b2cd-ecc5155e66f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4f88a485-30be-4cd0-b2cd-ecc5155e66f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4f88a485-30be-4cd0-b2cd-ecc5155e66f9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4f88a485-30be-4cd0-b2cd-ecc5155e66f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0ef94151-fbd7-498c-a786-0be258aba3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4f88a485-30be-4cd0-b2cd-ecc5155e66f9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0ef94151-fbd7-498c-a786-0be258aba3d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_9f03600f-5d16-4046-97d6-70fd113c4269" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0ef94151-fbd7-498c-a786-0be258aba3d3" xlink:to="loc_us-gaap_CollaborativeArrangementMember_9f03600f-5d16-4046-97d6-70fd113c4269" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_NumberOfProductsInitiatedMarketingAndPromotion_7b1b4eb3-8355-4a79-9237-7d00eea99ddc" xlink:href="bgne-20241231.xsd#bgne_NumberOfProductsInitiatedMarketingAndPromotion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_37424d5b-f570-4670-81f2-6b64ecbbf1a4" xlink:to="loc_bgne_NumberOfProductsInitiatedMarketingAndPromotion_7b1b4eb3-8355-4a79-9237-7d00eea99ddc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_5bd5ffca-1015-45a6-ac85-f461008a3ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_37424d5b-f570-4670-81f2-6b64ecbbf1a4" xlink:to="loc_us-gaap_ContractWithCustomerLiability_5bd5ffca-1015-45a6-ac85-f461008a3ca6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#CollaborativeandLicensingArrangementsAmgenDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6565941d-159b-49ae-81a1-0439e612a83c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5e22669c-f51a-4868-9af9-1433f4460c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6565941d-159b-49ae-81a1-0439e612a83c" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5e22669c-f51a-4868-9af9-1433f4460c2f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_091fb1cf-e082-4fb7-8fb6-c1d8fd26ab0f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5e22669c-f51a-4868-9af9-1433f4460c2f" xlink:to="loc_srt_CounterpartyNameAxis_091fb1cf-e082-4fb7-8fb6-c1d8fd26ab0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_091fb1cf-e082-4fb7-8fb6-c1d8fd26ab0f_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_091fb1cf-e082-4fb7-8fb6-c1d8fd26ab0f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_091fb1cf-e082-4fb7-8fb6-c1d8fd26ab0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f8356671-b5b7-48a6-9888-243481cd5cb3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_091fb1cf-e082-4fb7-8fb6-c1d8fd26ab0f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f8356671-b5b7-48a6-9888-243481cd5cb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AmgenIncMember_5eb6c569-0cc4-4a26-932d-d8c2b3bac286" xlink:href="bgne-20241231.xsd#bgne_AmgenIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f8356671-b5b7-48a6-9888-243481cd5cb3" xlink:to="loc_bgne_AmgenIncMember_5eb6c569-0cc4-4a26-932d-d8c2b3bac286" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_90e61995-431d-41e3-89a7-4f0084c1088a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5e22669c-f51a-4868-9af9-1433f4460c2f" xlink:to="loc_srt_RangeAxis_90e61995-431d-41e3-89a7-4f0084c1088a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_90e61995-431d-41e3-89a7-4f0084c1088a_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_90e61995-431d-41e3-89a7-4f0084c1088a" xlink:to="loc_srt_RangeMember_90e61995-431d-41e3-89a7-4f0084c1088a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1918b3c3-6e71-40ec-aafa-3dcef973e2c6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_90e61995-431d-41e3-89a7-4f0084c1088a" xlink:to="loc_srt_RangeMember_1918b3c3-6e71-40ec-aafa-3dcef973e2c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8464a8e7-4a7a-4fde-841e-f9da0eb782c3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1918b3c3-6e71-40ec-aafa-3dcef973e2c6" xlink:to="loc_srt_MinimumMember_8464a8e7-4a7a-4fde-841e-f9da0eb782c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e9408f77-f006-48a8-8710-624492b6ec6c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1918b3c3-6e71-40ec-aafa-3dcef973e2c6" xlink:to="loc_srt_MaximumMember_e9408f77-f006-48a8-8710-624492b6ec6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d2c90f62-5031-43a1-a265-705ab841e223" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5e22669c-f51a-4868-9af9-1433f4460c2f" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d2c90f62-5031-43a1-a265-705ab841e223" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d2c90f62-5031-43a1-a265-705ab841e223_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d2c90f62-5031-43a1-a265-705ab841e223" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d2c90f62-5031-43a1-a265-705ab841e223_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ccfb263c-a754-4ca0-8830-3864250b883c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d2c90f62-5031-43a1-a265-705ab841e223" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ccfb263c-a754-4ca0-8830-3864250b883c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_4070e956-3330-4643-8961-efdeaecb7e97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ccfb263c-a754-4ca0-8830-3864250b883c" xlink:to="loc_us-gaap_SalesRevenueNetMember_4070e956-3330-4643-8961-efdeaecb7e97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_075d7afb-5e40-44b2-a6b5-6b51f9d0f1eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5e22669c-f51a-4868-9af9-1433f4460c2f" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_075d7afb-5e40-44b2-a6b5-6b51f9d0f1eb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_075d7afb-5e40-44b2-a6b5-6b51f9d0f1eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_075d7afb-5e40-44b2-a6b5-6b51f9d0f1eb" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_075d7afb-5e40-44b2-a6b5-6b51f9d0f1eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_9e075823-511f-4f1e-a73d-62fe01b187e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_075d7afb-5e40-44b2-a6b5-6b51f9d0f1eb" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_9e075823-511f-4f1e-a73d-62fe01b187e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_fc4cf879-44bb-429d-9c4f-0d464cd5f6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_9e075823-511f-4f1e-a73d-62fe01b187e6" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_fc4cf879-44bb-429d-9c4f-0d464cd5f6b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_154c4429-fb96-422d-9561-161dc398a1f2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5e22669c-f51a-4868-9af9-1433f4460c2f" xlink:to="loc_dei_LegalEntityAxis_154c4429-fb96-422d-9561-161dc398a1f2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_154c4429-fb96-422d-9561-161dc398a1f2_default" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_154c4429-fb96-422d-9561-161dc398a1f2" xlink:to="loc_dei_EntityDomain_154c4429-fb96-422d-9561-161dc398a1f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e0f5cfc6-c3cb-432d-adec-e056847cd39e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_154c4429-fb96-422d-9561-161dc398a1f2" xlink:to="loc_dei_EntityDomain_e0f5cfc6-c3cb-432d-adec-e056847cd39e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AmgenIncMember_4d9a1c29-7fdb-4dfe-a627-77fc7e0682a8" xlink:href="bgne-20241231.xsd#bgne_AmgenIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e0f5cfc6-c3cb-432d-adec-e056847cd39e" xlink:to="loc_bgne_AmgenIncMember_4d9a1c29-7fdb-4dfe-a627-77fc7e0682a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_c8a4f01a-fae8-444e-8a55-3f8625ad791c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5e22669c-f51a-4868-9af9-1433f4460c2f" xlink:to="loc_srt_OwnershipAxis_c8a4f01a-fae8-444e-8a55-3f8625ad791c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_c8a4f01a-fae8-444e-8a55-3f8625ad791c_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_c8a4f01a-fae8-444e-8a55-3f8625ad791c" xlink:to="loc_srt_OwnershipDomain_c8a4f01a-fae8-444e-8a55-3f8625ad791c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_fb048b27-6b1f-4c8e-897f-af805fcc26d2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_c8a4f01a-fae8-444e-8a55-3f8625ad791c" xlink:to="loc_srt_OwnershipDomain_fb048b27-6b1f-4c8e-897f-af805fcc26d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_BeigeneLtdMember_b7c94638-f260-4b0a-9946-d5dc9f62e0c4" xlink:href="bgne-20241231.xsd#bgne_BeigeneLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_fb048b27-6b1f-4c8e-897f-af805fcc26d2" xlink:to="loc_bgne_BeigeneLtdMember_b7c94638-f260-4b0a-9946-d5dc9f62e0c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_185c3e4e-6cd2-45d9-aad0-16179a2e52f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5e22669c-f51a-4868-9af9-1433f4460c2f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_185c3e4e-6cd2-45d9-aad0-16179a2e52f8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_185c3e4e-6cd2-45d9-aad0-16179a2e52f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_185c3e4e-6cd2-45d9-aad0-16179a2e52f8" xlink:to="loc_us-gaap_ClassOfStockDomain_185c3e4e-6cd2-45d9-aad0-16179a2e52f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_81717194-b698-42d1-a2b1-4ab18cb1b8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_185c3e4e-6cd2-45d9-aad0-16179a2e52f8" xlink:to="loc_us-gaap_ClassOfStockDomain_81717194-b698-42d1-a2b1-4ab18cb1b8d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2a8cd247-0159-4ef2-a3b1-aed1e8224c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_81717194-b698-42d1-a2b1-4ab18cb1b8d2" xlink:to="loc_us-gaap_CommonStockMember_2a8cd247-0159-4ef2-a3b1-aed1e8224c0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_CommercializationTerm_a8bf37eb-14ad-4560-99be-cd2546c67a50" xlink:href="bgne-20241231.xsd#bgne_CommercializationTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6565941d-159b-49ae-81a1-0439e612a83c" xlink:to="loc_bgne_CommercializationTerm_a8bf37eb-14ad-4560-99be-cd2546c67a50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_CollaborativeArrangementsNumberOfProductsCompanyHasTheRightToRetain_b2052de4-baaa-4d82-8fc7-e05638afe353" xlink:href="bgne-20241231.xsd#bgne_CollaborativeArrangementsNumberOfProductsCompanyHasTheRightToRetain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6565941d-159b-49ae-81a1-0439e612a83c" xlink:to="loc_bgne_CollaborativeArrangementsNumberOfProductsCompanyHasTheRightToRetain_b2052de4-baaa-4d82-8fc7-e05638afe353" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_CollaborativeArrangementsProductRetentionPeriod_0536e4b3-71fe-4d7b-aba8-821add233e35" xlink:href="bgne-20241231.xsd#bgne_CollaborativeArrangementsProductRetentionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6565941d-159b-49ae-81a1-0439e612a83c" xlink:to="loc_bgne_CollaborativeArrangementsProductRetentionPeriod_0536e4b3-71fe-4d7b-aba8-821add233e35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_MaximumCashAndServicesDevelopmentCommitment_dd4152d0-7073-45d7-9e3e-4ebac13b220d" xlink:href="bgne-20241231.xsd#bgne_MaximumCashAndServicesDevelopmentCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6565941d-159b-49ae-81a1-0439e612a83c" xlink:to="loc_bgne_MaximumCashAndServicesDevelopmentCommitment_dd4152d0-7073-45d7-9e3e-4ebac13b220d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_e2a424a3-1a04-4d62-ad91-372dc0f76fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6565941d-159b-49ae-81a1-0439e612a83c" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_e2a424a3-1a04-4d62-ad91-372dc0f76fcb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f5d871a1-365e-47d5-98b3-c7f0e229390b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6565941d-159b-49ae-81a1-0439e612a83c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f5d871a1-365e-47d5-98b3-c7f0e229390b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_f2363b5e-2c0f-44d5-b0e1-12de5a18626e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6565941d-159b-49ae-81a1-0439e612a83c" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_f2363b5e-2c0f-44d5-b0e1-12de5a18626e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_cce7a6e8-545e-4024-bb89-4ef407103072" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6565941d-159b-49ae-81a1-0439e612a83c" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_cce7a6e8-545e-4024-bb89-4ef407103072" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_SharePriceAmericanDepositoryShares_55a790ce-ac89-48dc-8706-cb0d78a8e86e" xlink:href="bgne-20241231.xsd#bgne_SharePriceAmericanDepositoryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6565941d-159b-49ae-81a1-0439e612a83c" xlink:to="loc_bgne_SharePriceAmericanDepositoryShares_55a790ce-ac89-48dc-8706-cb0d78a8e86e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ProceedsFromIssuanceOfAssetDepositoryShares_8e930cd0-f34c-46a5-a5b2-012df6e0fb9d" xlink:href="bgne-20241231.xsd#bgne_ProceedsFromIssuanceOfAssetDepositoryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6565941d-159b-49ae-81a1-0439e612a83c" xlink:to="loc_bgne_ProceedsFromIssuanceOfAssetDepositoryShares_8e930cd0-f34c-46a5-a5b2-012df6e0fb9d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_FairValueOfLiabilityAcquired_2ef5ad8a-063e-451f-9ec3-ec972e47dd60" xlink:href="bgne-20241231.xsd#bgne_FairValueOfLiabilityAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6565941d-159b-49ae-81a1-0439e612a83c" xlink:to="loc_bgne_FairValueOfLiabilityAcquired_2ef5ad8a-063e-451f-9ec3-ec972e47dd60" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5dbce81a-2aa2-4c8b-8db4-02c1d9e4b768" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6565941d-159b-49ae-81a1-0439e612a83c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5dbce81a-2aa2-4c8b-8db4-02c1d9e4b768" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_FairValueOfEquityInvestmentsIssued_28500e33-46fa-4acd-8f92-01bdd353e48d" xlink:href="bgne-20241231.xsd#bgne_FairValueOfEquityInvestmentsIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6565941d-159b-49ae-81a1-0439e612a83c" xlink:to="loc_bgne_FairValueOfEquityInvestmentsIssued_28500e33-46fa-4acd-8f92-01bdd353e48d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_FairValueOfFinancingCommitment_7b8b7ff1-0ec6-411b-a13f-dce7844dc5cf" xlink:href="bgne-20241231.xsd#bgne_FairValueOfFinancingCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6565941d-159b-49ae-81a1-0439e612a83c" xlink:to="loc_bgne_FairValueOfFinancingCommitment_7b8b7ff1-0ec6-411b-a13f-dce7844dc5cf" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RoyaltiesReceivingPeriod_41b2273e-b8b8-49ff-9566-884520567938" xlink:href="bgne-20241231.xsd#bgne_RoyaltiesReceivingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6565941d-159b-49ae-81a1-0439e612a83c" xlink:to="loc_bgne_RoyaltiesReceivingPeriod_41b2273e-b8b8-49ff-9566-884520567938" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/CollaborativeandLicensingArrangementsFundingExpensesDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#CollaborativeandLicensingArrangementsFundingExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/CollaborativeandLicensingArrangementsFundingExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d6a6b9ae-e4f0-4e25-9242-a9f57cd7bcef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_01774a39-fad0-4af8-84f0-9308254fcb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d6a6b9ae-e4f0-4e25-9242-a9f57cd7bcef" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_01774a39-fad0-4af8-84f0-9308254fcb2d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_98e4cde7-6145-414b-8143-ec4e6cbc9697" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_01774a39-fad0-4af8-84f0-9308254fcb2d" xlink:to="loc_srt_CounterpartyNameAxis_98e4cde7-6145-414b-8143-ec4e6cbc9697" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98e4cde7-6145-414b-8143-ec4e6cbc9697_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_98e4cde7-6145-414b-8143-ec4e6cbc9697" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98e4cde7-6145-414b-8143-ec4e6cbc9697_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9dba0c5f-f515-4da0-84fb-8aa2c0893b17" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_98e4cde7-6145-414b-8143-ec4e6cbc9697" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9dba0c5f-f515-4da0-84fb-8aa2c0893b17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AmgenIncMember_0401b145-db7e-46f7-9cfe-47728e437061" xlink:href="bgne-20241231.xsd#bgne_AmgenIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9dba0c5f-f515-4da0-84fb-8aa2c0893b17" xlink:to="loc_bgne_AmgenIncMember_0401b145-db7e-46f7-9cfe-47728e437061" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_FinancingCommitmentExpenses_07de0488-5f67-429f-bcbc-d6aeec33cc54" xlink:href="bgne-20241231.xsd#bgne_FinancingCommitmentExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d6a6b9ae-e4f0-4e25-9242-a9f57cd7bcef" xlink:to="loc_bgne_FinancingCommitmentExpenses_07de0488-5f67-429f-bcbc-d6aeec33cc54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AmortizationOfFinancingCommitment_369f2a0c-1d90-4b66-9b8c-fbf7e0e50e17" xlink:href="bgne-20241231.xsd#bgne_AmortizationOfFinancingCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d6a6b9ae-e4f0-4e25-9242-a9f57cd7bcef" xlink:to="loc_bgne_AmortizationOfFinancingCommitment_369f2a0c-1d90-4b66-9b8c-fbf7e0e50e17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_454d47de-c237-4533-984f-805f7ed6c366" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d6a6b9ae-e4f0-4e25-9242-a9f57cd7bcef" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_454d47de-c237-4533-984f-805f7ed6c366" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_974d60c6-11eb-44ca-a395-67efdf4cb961" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d6a6b9ae-e4f0-4e25-9242-a9f57cd7bcef" xlink:to="loc_us-gaap_OtherCommitment_974d60c6-11eb-44ca-a395-67efdf4cb961" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/CollaborativeandLicensingArrangementsFinancingLiabilityDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#CollaborativeandLicensingArrangementsFinancingLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/CollaborativeandLicensingArrangementsFinancingLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_bd815e25-e4be-449f-b45b-2be8d06826ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_19eb7c92-d943-4786-8893-fed615b72945" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_bd815e25-e4be-449f-b45b-2be8d06826ea" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_19eb7c92-d943-4786-8893-fed615b72945" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_13739990-4142-499e-806d-37f9c3004921" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_19eb7c92-d943-4786-8893-fed615b72945" xlink:to="loc_srt_CounterpartyNameAxis_13739990-4142-499e-806d-37f9c3004921" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_13739990-4142-499e-806d-37f9c3004921_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_13739990-4142-499e-806d-37f9c3004921" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_13739990-4142-499e-806d-37f9c3004921_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fcc0db2c-32b6-4318-b961-10b5037b5d66" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_13739990-4142-499e-806d-37f9c3004921" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fcc0db2c-32b6-4318-b961-10b5037b5d66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AmgenIncMember_7518f282-a78d-473e-af3f-d6de50374d76" xlink:href="bgne-20241231.xsd#bgne_AmgenIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fcc0db2c-32b6-4318-b961-10b5037b5d66" xlink:to="loc_bgne_AmgenIncMember_7518f282-a78d-473e-af3f-d6de50374d76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_FinancingCommitmentCarryingValueCurrent_4e8dfd43-3687-43c4-b0e5-e0693a8c66fb" xlink:href="bgne-20241231.xsd#bgne_FinancingCommitmentCarryingValueCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_bd815e25-e4be-449f-b45b-2be8d06826ea" xlink:to="loc_bgne_FinancingCommitmentCarryingValueCurrent_4e8dfd43-3687-43c4-b0e5-e0693a8c66fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_FinancingCommitmentCarryingValueNoncurrent_c0381042-ef2c-4ef0-8696-b67816370d8d" xlink:href="bgne-20241231.xsd#bgne_FinancingCommitmentCarryingValueNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_bd815e25-e4be-449f-b45b-2be8d06826ea" xlink:to="loc_bgne_FinancingCommitmentCarryingValueNoncurrent_c0381042-ef2c-4ef0-8696-b67816370d8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_FinancingCommitmentCarryingValue_ac64d3d5-2dac-4991-a307-2b1004592d94" xlink:href="bgne-20241231.xsd#bgne_FinancingCommitmentCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_bd815e25-e4be-449f-b45b-2be8d06826ea" xlink:to="loc_bgne_FinancingCommitmentCarryingValue_ac64d3d5-2dac-4991-a307-2b1004592d94" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmountsandClassificationofPaymentsIncomeExpenseDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#CollaborativeandLicensingArrangementsAmountsandClassificationofPaymentsIncomeExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmountsandClassificationofPaymentsIncomeExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39509f78-1700-4508-ae90-03d1be407221" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_aa293f40-f8a7-4c31-b5f6-7f35864d74ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39509f78-1700-4508-ae90-03d1be407221" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_aa293f40-f8a7-4c31-b5f6-7f35864d74ca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6b869935-a4ed-43fa-b2f2-3cc03febfa5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_aa293f40-f8a7-4c31-b5f6-7f35864d74ca" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6b869935-a4ed-43fa-b2f2-3cc03febfa5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6b869935-a4ed-43fa-b2f2-3cc03febfa5e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6b869935-a4ed-43fa-b2f2-3cc03febfa5e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6b869935-a4ed-43fa-b2f2-3cc03febfa5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_415cce6f-22ee-4afe-9813-ed223bfa2135" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6b869935-a4ed-43fa-b2f2-3cc03febfa5e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_415cce6f-22ee-4afe-9813-ed223bfa2135" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_5ba57ea4-abf4-4946-b566-41e9e167b534" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_415cce6f-22ee-4afe-9813-ed223bfa2135" xlink:to="loc_us-gaap_CostOfSalesMember_5ba57ea4-abf4-4946-b566-41e9e167b534" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1aa7e853-e79b-433c-8027-320eb62ded3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_415cce6f-22ee-4afe-9813-ed223bfa2135" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1aa7e853-e79b-433c-8027-320eb62ded3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_22eb9387-02cf-45f6-92a9-1ba0b7011695" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_415cce6f-22ee-4afe-9813-ed223bfa2135" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_22eb9387-02cf-45f6-92a9-1ba0b7011695" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b32a47e7-76a8-4664-a76d-019dd9a53095" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_aa293f40-f8a7-4c31-b5f6-7f35864d74ca" xlink:to="loc_srt_CounterpartyNameAxis_b32a47e7-76a8-4664-a76d-019dd9a53095" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b32a47e7-76a8-4664-a76d-019dd9a53095_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_b32a47e7-76a8-4664-a76d-019dd9a53095" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b32a47e7-76a8-4664-a76d-019dd9a53095_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_27daefe3-9eba-4ced-8ca2-13bcfd753846" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_b32a47e7-76a8-4664-a76d-019dd9a53095" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_27daefe3-9eba-4ced-8ca2-13bcfd753846" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AmgenIncMember_2071ccd7-68f6-459a-8d01-fced2ce23e67" xlink:href="bgne-20241231.xsd#bgne_AmgenIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_27daefe3-9eba-4ced-8ca2-13bcfd753846" xlink:to="loc_bgne_AmgenIncMember_2071ccd7-68f6-459a-8d01-fced2ce23e67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_190be5da-4349-4980-b994-b3363d224c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_aa293f40-f8a7-4c31-b5f6-7f35864d74ca" xlink:to="loc_us-gaap_TypeOfArrangementAxis_190be5da-4349-4980-b994-b3363d224c5e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_190be5da-4349-4980-b994-b3363d224c5e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_190be5da-4349-4980-b994-b3363d224c5e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_190be5da-4349-4980-b994-b3363d224c5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c46bd19e-1777-4f35-b715-2d0b3473383a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_190be5da-4349-4980-b994-b3363d224c5e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c46bd19e-1777-4f35-b715-2d0b3473383a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_081fc47b-2627-4445-8f48-62e29c70fda0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c46bd19e-1777-4f35-b715-2d0b3473383a" xlink:to="loc_us-gaap_CollaborativeArrangementMember_081fc47b-2627-4445-8f48-62e29c70fda0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6af0c21e-9dad-4317-906f-187d55391f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_aa293f40-f8a7-4c31-b5f6-7f35864d74ca" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6af0c21e-9dad-4317-906f-187d55391f6e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_6af0c21e-9dad-4317-906f-187d55391f6e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6af0c21e-9dad-4317-906f-187d55391f6e" xlink:to="loc_us-gaap_RelatedPartyDomain_6af0c21e-9dad-4317-906f-187d55391f6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_cfe3fe4a-2038-40b2-97a0-08421ba19d95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6af0c21e-9dad-4317-906f-187d55391f6e" xlink:to="loc_us-gaap_RelatedPartyDomain_cfe3fe4a-2038-40b2-97a0-08421ba19d95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_d587e337-de9c-49a1-b15b-cb5bcdbd542e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_cfe3fe4a-2038-40b2-97a0-08421ba19d95" xlink:to="loc_us-gaap_RelatedPartyMember_d587e337-de9c-49a1-b15b-cb5bcdbd542e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ReimbursementExpense_e24325ab-c2e6-4960-89cf-b43e52432d1a" xlink:href="bgne-20241231.xsd#bgne_ReimbursementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39509f78-1700-4508-ae90-03d1be407221" xlink:to="loc_bgne_ReimbursementExpense_e24325ab-c2e6-4960-89cf-b43e52432d1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_f3e4e4f2-8eb6-4f88-9b18-17a568e4d8da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39509f78-1700-4508-ae90-03d1be407221" xlink:to="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_f3e4e4f2-8eb6-4f88-9b18-17a568e4d8da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_e3e901aa-3207-4dc3-949a-c9cceffb957d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39509f78-1700-4508-ae90-03d1be407221" xlink:to="loc_us-gaap_AccountsPayableCurrent_e3e901aa-3207-4dc3-949a-c9cceffb957d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/CollaborativeandLicensingArrangementsPaymentClassificationDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#CollaborativeandLicensingArrangementsPaymentClassificationDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/CollaborativeandLicensingArrangementsPaymentClassificationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31c21562-b2ff-4ba0-8659-ade17721dc04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b4abbf83-dd44-4624-8390-8424bd79de6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31c21562-b2ff-4ba0-8659-ade17721dc04" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b4abbf83-dd44-4624-8390-8424bd79de6d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_CollaborativeArrangementCompensationTypeAxis_ee31630e-185e-4441-bfdd-3fc132d7b2c4" xlink:href="bgne-20241231.xsd#bgne_CollaborativeArrangementCompensationTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b4abbf83-dd44-4624-8390-8424bd79de6d" xlink:to="loc_bgne_CollaborativeArrangementCompensationTypeAxis_ee31630e-185e-4441-bfdd-3fc132d7b2c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_CollaborativeArrangementCompensationTypeDomain_ee31630e-185e-4441-bfdd-3fc132d7b2c4_default" xlink:href="bgne-20241231.xsd#bgne_CollaborativeArrangementCompensationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bgne_CollaborativeArrangementCompensationTypeAxis_ee31630e-185e-4441-bfdd-3fc132d7b2c4" xlink:to="loc_bgne_CollaborativeArrangementCompensationTypeDomain_ee31630e-185e-4441-bfdd-3fc132d7b2c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_CollaborativeArrangementCompensationTypeDomain_50829dd7-7972-40bf-9e41-2e5061faab9a" xlink:href="bgne-20241231.xsd#bgne_CollaborativeArrangementCompensationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bgne_CollaborativeArrangementCompensationTypeAxis_ee31630e-185e-4441-bfdd-3fc132d7b2c4" xlink:to="loc_bgne_CollaborativeArrangementCompensationTypeDomain_50829dd7-7972-40bf-9e41-2e5061faab9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_UpfrontPaymentsMember_37c7dd0a-f775-4006-9dab-178b1c6068d8" xlink:href="bgne-20241231.xsd#bgne_UpfrontPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bgne_CollaborativeArrangementCompensationTypeDomain_50829dd7-7972-40bf-9e41-2e5061faab9a" xlink:to="loc_bgne_UpfrontPaymentsMember_37c7dd0a-f775-4006-9dab-178b1c6068d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_DevelopmentMilestonePaymentsMember_7b573aa2-8a55-4493-91ec-90726c34dde9" xlink:href="bgne-20241231.xsd#bgne_DevelopmentMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bgne_CollaborativeArrangementCompensationTypeDomain_50829dd7-7972-40bf-9e41-2e5061faab9a" xlink:to="loc_bgne_DevelopmentMilestonePaymentsMember_7b573aa2-8a55-4493-91ec-90726c34dde9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RegulatoryAndCommercialMilestonePaymentsMember_02b4c580-15c3-44e3-965c-561afd2238d5" xlink:href="bgne-20241231.xsd#bgne_RegulatoryAndCommercialMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bgne_CollaborativeArrangementCompensationTypeDomain_50829dd7-7972-40bf-9e41-2e5061faab9a" xlink:to="loc_bgne_RegulatoryAndCommercialMilestonePaymentsMember_02b4c580-15c3-44e3-965c-561afd2238d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d78c9938-c8a2-44c3-9d8a-db4f7c68d933" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b4abbf83-dd44-4624-8390-8424bd79de6d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d78c9938-c8a2-44c3-9d8a-db4f7c68d933" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d78c9938-c8a2-44c3-9d8a-db4f7c68d933_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d78c9938-c8a2-44c3-9d8a-db4f7c68d933" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d78c9938-c8a2-44c3-9d8a-db4f7c68d933_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6e465880-1473-4ece-9881-ddde2e0564b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d78c9938-c8a2-44c3-9d8a-db4f7c68d933" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6e465880-1473-4ece-9881-ddde2e0564b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ResearchAndDevelopmentMember_77ae5933-80b2-4e38-9f5b-518ccd8890b1" xlink:href="bgne-20241231.xsd#bgne_ResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6e465880-1473-4ece-9881-ddde2e0564b0" xlink:to="loc_bgne_ResearchAndDevelopmentMember_77ae5933-80b2-4e38-9f5b-518ccd8890b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_a54b5af7-1e47-424a-ab29-e0c0ae3a97dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b4abbf83-dd44-4624-8390-8424bd79de6d" xlink:to="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_a54b5af7-1e47-424a-ab29-e0c0ae3a97dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_a54b5af7-1e47-424a-ab29-e0c0ae3a97dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_a54b5af7-1e47-424a-ab29-e0c0ae3a97dd" xlink:to="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_a54b5af7-1e47-424a-ab29-e0c0ae3a97dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_8b9b2dfe-bef4-4394-8ec1-d790a7dcc604" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_a54b5af7-1e47-424a-ab29-e0c0ae3a97dd" xlink:to="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_8b9b2dfe-bef4-4394-8ec1-d790a7dcc604" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_IntangibleAssetsMember_67cd143b-72e4-4ade-a076-6979e253a52c" xlink:href="bgne-20241231.xsd#bgne_IntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_8b9b2dfe-bef4-4394-8ec1-d790a7dcc604" xlink:to="loc_bgne_IntangibleAssetsMember_67cd143b-72e4-4ade-a076-6979e253a52c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_UpfrontAndMilestonePayments_ab6080d4-c7f2-47dd-a36d-47035590c20a" xlink:href="bgne-20241231.xsd#bgne_UpfrontAndMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31c21562-b2ff-4ba0-8659-ade17721dc04" xlink:to="loc_bgne_UpfrontAndMilestonePayments_ab6080d4-c7f2-47dd-a36d-47035590c20a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/RestrictedCashNarrativeDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#RestrictedCashNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/RestrictedCashNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_3832d9b6-6c58-4f12-b10a-8a13a8cdb11f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_0298ff43-b9d3-48c5-88d6-033d045988c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_3832d9b6-6c58-4f12-b10a-8a13a8cdb11f" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_0298ff43-b9d3-48c5-88d6-033d045988c8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8ae360a7-7886-4250-9d81-dbae17fc3ea6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_0298ff43-b9d3-48c5-88d6-033d045988c8" xlink:to="loc_srt_CounterpartyNameAxis_8ae360a7-7886-4250-9d81-dbae17fc3ea6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8ae360a7-7886-4250-9d81-dbae17fc3ea6_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_8ae360a7-7886-4250-9d81-dbae17fc3ea6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8ae360a7-7886-4250-9d81-dbae17fc3ea6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ba383ce8-7b8e-4e0c-aaf6-f7d843ff2014" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_8ae360a7-7886-4250-9d81-dbae17fc3ea6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ba383ce8-7b8e-4e0c-aaf6-f7d843ff2014" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_STARMarketMember_4db61da5-f296-4be2-89b5-8912fe6cb7c8" xlink:href="bgne-20241231.xsd#bgne_STARMarketMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ba383ce8-7b8e-4e0c-aaf6-f7d843ff2014" xlink:to="loc_bgne_STARMarketMember_4db61da5-f296-4be2-89b5-8912fe6cb7c8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_49b87b6a-7d3f-4efa-92e7-7853a8d4ff1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_0298ff43-b9d3-48c5-88d6-033d045988c8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_49b87b6a-7d3f-4efa-92e7-7853a8d4ff1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_49b87b6a-7d3f-4efa-92e7-7853a8d4ff1a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_49b87b6a-7d3f-4efa-92e7-7853a8d4ff1a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_49b87b6a-7d3f-4efa-92e7-7853a8d4ff1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70b942dc-d109-4c4d-bb1d-54e5636c908e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_49b87b6a-7d3f-4efa-92e7-7853a8d4ff1a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70b942dc-d109-4c4d-bb1d-54e5636c908e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_55ff05fb-020d-440f-a55d-47262926e3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70b942dc-d109-4c4d-bb1d-54e5636c908e" xlink:to="loc_us-gaap_IPOMember_55ff05fb-020d-440f-a55d-47262926e3d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_3597e1ce-b325-46aa-97ad-e9fb8c2881db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_3832d9b6-6c58-4f12-b10a-8a13a8cdb11f" xlink:to="loc_us-gaap_RestrictedCash_3597e1ce-b325-46aa-97ad-e9fb8c2881db" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#InvestmentsInvestmentsInEquitySecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_b169939d-838b-4490-8c8c-39cea72f710b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_b44b84d4-1350-4baa-a604-9a33791dd097" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b169939d-838b-4490-8c8c-39cea72f710b" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_b44b84d4-1350-4baa-a604-9a33791dd097" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b123ad23-caa0-4fdc-a015-cece17108ded" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_b44b84d4-1350-4baa-a604-9a33791dd097" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b123ad23-caa0-4fdc-a015-cece17108ded" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_b123ad23-caa0-4fdc-a015-cece17108ded_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b123ad23-caa0-4fdc-a015-cece17108ded" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_b123ad23-caa0-4fdc-a015-cece17108ded_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_4cf89fa0-2847-4ed4-9ea4-bc7e9618fbb8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b123ad23-caa0-4fdc-a015-cece17108ded" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_4cf89fa0-2847-4ed4-9ea4-bc7e9618fbb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_LeapTherapeuticIncMember_b5b3025a-1742-426e-8aed-442442dd2979" xlink:href="bgne-20241231.xsd#bgne_LeapTherapeuticIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_4cf89fa0-2847-4ed4-9ea4-bc7e9618fbb8" xlink:to="loc_bgne_LeapTherapeuticIncMember_b5b3025a-1742-426e-8aed-442442dd2979" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_PiHealthIncMember_fbc2b5f8-c0b7-4acb-9cb0-194e658478de" xlink:href="bgne-20241231.xsd#bgne_PiHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_4cf89fa0-2847-4ed4-9ea4-bc7e9618fbb8" xlink:to="loc_bgne_PiHealthIncMember_fbc2b5f8-c0b7-4acb-9cb0-194e658478de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_OtherEquityMethodInvestmentsMember_2e312f88-1760-4d0c-b054-507f327ce3b6" xlink:href="bgne-20241231.xsd#bgne_OtherEquityMethodInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_4cf89fa0-2847-4ed4-9ea4-bc7e9618fbb8" xlink:to="loc_bgne_OtherEquityMethodInvestmentsMember_2e312f88-1760-4d0c-b054-507f327ce3b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a3f0dd5e-0a31-4246-9df0-81d91a96b629" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_b44b84d4-1350-4baa-a604-9a33791dd097" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a3f0dd5e-0a31-4246-9df0-81d91a96b629" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a3f0dd5e-0a31-4246-9df0-81d91a96b629_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a3f0dd5e-0a31-4246-9df0-81d91a96b629" xlink:to="loc_us-gaap_ClassOfStockDomain_a3f0dd5e-0a31-4246-9df0-81d91a96b629_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1da493b6-a272-48bd-a0d8-5d84a63160a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a3f0dd5e-0a31-4246-9df0-81d91a96b629" xlink:to="loc_us-gaap_ClassOfStockDomain_1da493b6-a272-48bd-a0d8-5d84a63160a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8be0c021-5aa1-4b29-8de4-4240adbb9a40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1da493b6-a272-48bd-a0d8-5d84a63160a3" xlink:to="loc_us-gaap_CommonStockMember_8be0c021-5aa1-4b29-8de4-4240adbb9a40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_88a788f7-89d7-41ac-95cb-366ae90b30c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1da493b6-a272-48bd-a0d8-5d84a63160a3" xlink:to="loc_us-gaap_WarrantMember_88a788f7-89d7-41ac-95cb-366ae90b30c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_bd8f7402-0f30-4135-891a-6d5524ff6a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_b44b84d4-1350-4baa-a604-9a33791dd097" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_bd8f7402-0f30-4135-891a-6d5524ff6a7e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_bd8f7402-0f30-4135-891a-6d5524ff6a7e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_bd8f7402-0f30-4135-891a-6d5524ff6a7e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_bd8f7402-0f30-4135-891a-6d5524ff6a7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_76651578-d1db-482d-91c8-90568005798d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_bd8f7402-0f30-4135-891a-6d5524ff6a7e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_76651578-d1db-482d-91c8-90568005798d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_5b662038-bf17-4439-89ec-c3d257480d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_76651578-d1db-482d-91c8-90568005798d" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_5b662038-bf17-4439-89ec-c3d257480d9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_90f9ff9f-772a-42f1-b652-00462de81dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_b44b84d4-1350-4baa-a604-9a33791dd097" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_90f9ff9f-772a-42f1-b652-00462de81dd9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_90f9ff9f-772a-42f1-b652-00462de81dd9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_90f9ff9f-772a-42f1-b652-00462de81dd9" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_90f9ff9f-772a-42f1-b652-00462de81dd9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_29f3ff9a-79dd-4d25-b815-0213bb3e38ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_90f9ff9f-772a-42f1-b652-00462de81dd9" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_29f3ff9a-79dd-4d25-b815-0213bb3e38ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_PiHealthIncMember_3109e6bc-8f6d-4bb8-a256-959d8004b6a0" xlink:href="bgne-20241231.xsd#bgne_PiHealthIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_29f3ff9a-79dd-4d25-b815-0213bb3e38ae" xlink:to="loc_bgne_PiHealthIncMember_3109e6bc-8f6d-4bb8-a256-959d8004b6a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_f22d5c4d-40e9-4cfe-9d82-d782d7e872d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b169939d-838b-4490-8c8c-39cea72f710b" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_f22d5c4d-40e9-4cfe-9d82-d782d7e872d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_5176ad8f-0502-4fb8-92a9-eef7880b7eac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b169939d-838b-4490-8c8c-39cea72f710b" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_5176ad8f-0502-4fb8-92a9-eef7880b7eac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_9e285bcb-3046-48b8-b331-0d84de7c7f23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b169939d-838b-4490-8c8c-39cea72f710b" xlink:to="loc_us-gaap_EquityMethodInvestments_9e285bcb-3046-48b8-b331-0d84de7c7f23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_bed5d13e-6e00-4c8a-9a17-ab27e8e18763" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b169939d-838b-4490-8c8c-39cea72f710b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_bed5d13e-6e00-4c8a-9a17-ab27e8e18763" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_DisposalGroupNotDiscontinuedOperationNetAssets_92ecddb2-bd4a-4bd9-8879-172c3cb57c2f" xlink:href="bgne-20241231.xsd#bgne_DisposalGroupNotDiscontinuedOperationNetAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b169939d-838b-4490-8c8c-39cea72f710b" xlink:to="loc_bgne_DisposalGroupNotDiscontinuedOperationNetAssets_92ecddb2-bd4a-4bd9-8879-172c3cb57c2f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_096e6017-7594-4b5a-abc3-bd33963df46c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b169939d-838b-4490-8c8c-39cea72f710b" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_096e6017-7594-4b5a-abc3-bd33963df46c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_d79a14b6-4d72-400a-99a7-603ab342de12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b169939d-838b-4490-8c8c-39cea72f710b" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_d79a14b6-4d72-400a-99a7-603ab342de12" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList_23dcc068-e981-4ced-bdf1-1af3343ecbaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b169939d-838b-4490-8c8c-39cea72f710b" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList_23dcc068-e981-4ced-bdf1-1af3343ecbaf" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/InvestmentsEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#InvestmentsEquityMethodInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/InvestmentsEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_44452974-4d66-4c97-9d53-6770130fac23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_75d0dee0-cf48-4ee9-b17a-b2bf333f6d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_44452974-4d66-4c97-9d53-6770130fac23" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_75d0dee0-cf48-4ee9-b17a-b2bf333f6d6a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5df1a0e2-8878-4cd2-958c-0d4cacc7cce4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_75d0dee0-cf48-4ee9-b17a-b2bf333f6d6a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5df1a0e2-8878-4cd2-958c-0d4cacc7cce4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5df1a0e2-8878-4cd2-958c-0d4cacc7cce4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5df1a0e2-8878-4cd2-958c-0d4cacc7cce4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5df1a0e2-8878-4cd2-958c-0d4cacc7cce4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1d4df840-bfe2-40fe-98f5-3adeb6842432" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5df1a0e2-8878-4cd2-958c-0d4cacc7cce4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1d4df840-bfe2-40fe-98f5-3adeb6842432" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_b466c399-a2f9-4db5-82c6-4e02b733d064" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1d4df840-bfe2-40fe-98f5-3adeb6842432" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_b466c399-a2f9-4db5-82c6-4e02b733d064" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_7246d964-a9da-4cdd-82e6-11bdf691dc45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_44452974-4d66-4c97-9d53-6770130fac23" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_7246d964-a9da-4cdd-82e6-11bdf691dc45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmountNet_fcd47f6c-de6c-4e97-a495-3ba1404c3a95" xlink:href="bgne-20241231.xsd#bgne_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmountNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_44452974-4d66-4c97-9d53-6770130fac23" xlink:to="loc_bgne_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmountNet_fcd47f6c-de6c-4e97-a495-3ba1404c3a95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d64fa669-99d1-40c5-94fa-8c0fa11dc0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_44452974-4d66-4c97-9d53-6770130fac23" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d64fa669-99d1-40c5-94fa-8c0fa11dc0f5" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/LeasesNarrativesDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#LeasesNarrativesDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/LeasesNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_7291826a-3faf-49b2-a8c4-cd306f3e8e33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_5f9f80f9-e4ba-49b3-ac3b-4a2cc46abe36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_7291826a-3faf-49b2-a8c4-cd306f3e8e33" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_5f9f80f9-e4ba-49b3-ac3b-4a2cc46abe36" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_17c2f27c-3837-4276-a9a3-55179219d8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5f9f80f9-e4ba-49b3-ac3b-4a2cc46abe36" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_17c2f27c-3837-4276-a9a3-55179219d8ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_17c2f27c-3837-4276-a9a3-55179219d8ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_17c2f27c-3837-4276-a9a3-55179219d8ff" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_17c2f27c-3837-4276-a9a3-55179219d8ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f842d19d-b10a-43ae-b03e-1dcfff53f4ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_17c2f27c-3837-4276-a9a3-55179219d8ff" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f842d19d-b10a-43ae-b03e-1dcfff53f4ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_07123bb7-8d03-492b-b87d-1ed396f9702d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f842d19d-b10a-43ae-b03e-1dcfff53f4ef" xlink:to="loc_us-gaap_BuildingMember_07123bb7-8d03-492b-b87d-1ed396f9702d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_00c0c590-22fb-4ec0-bd63-40695d0e1d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_7291826a-3faf-49b2-a8c4-cd306f3e8e33" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_00c0c590-22fb-4ec0-bd63-40695d0e1d1d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/LeasesSupplementalBalanceSheetDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#LeasesSupplementalBalanceSheetDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/LeasesSupplementalBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_3ce77701-401a-4bb5-9907-1995dd2c5554" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_795c3f3c-f928-476a-85b2-181c6df6b0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3ce77701-401a-4bb5-9907-1995dd2c5554" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_795c3f3c-f928-476a-85b2-181c6df6b0b0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b0ba005d-ac57-4b0b-8adf-7ea26b29ca63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_795c3f3c-f928-476a-85b2-181c6df6b0b0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b0ba005d-ac57-4b0b-8adf-7ea26b29ca63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b0ba005d-ac57-4b0b-8adf-7ea26b29ca63_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b0ba005d-ac57-4b0b-8adf-7ea26b29ca63" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b0ba005d-ac57-4b0b-8adf-7ea26b29ca63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_372e8ecd-bad0-4d1b-91f3-7f6dfeea4400" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b0ba005d-ac57-4b0b-8adf-7ea26b29ca63" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_372e8ecd-bad0-4d1b-91f3-7f6dfeea4400" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_9dbaa027-e50c-4c97-a303-b0af2c3bd382" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_372e8ecd-bad0-4d1b-91f3-7f6dfeea4400" xlink:to="loc_us-gaap_BuildingMember_9dbaa027-e50c-4c97-a303-b0af2c3bd382" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_91bee69e-347e-4083-a02d-1994d3eb32b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_372e8ecd-bad0-4d1b-91f3-7f6dfeea4400" xlink:to="loc_us-gaap_LandMember_91bee69e-347e-4083-a02d-1994d3eb32b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0058a509-6503-4130-8bb7-201ca636e379" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3ce77701-401a-4bb5-9907-1995dd2c5554" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0058a509-6503-4130-8bb7-201ca636e379" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ce6516db-6a79-43f5-ab7c-050bf6a00d42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3ce77701-401a-4bb5-9907-1995dd2c5554" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ce6516db-6a79-43f5-ab7c-050bf6a00d42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_001d839e-b9ac-468a-8120-3f25da020754" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3ce77701-401a-4bb5-9907-1995dd2c5554" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_001d839e-b9ac-468a-8120-3f25da020754" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_9dcf0273-991f-4fdf-aad6-ba27b8e81d37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3ce77701-401a-4bb5-9907-1995dd2c5554" xlink:to="loc_us-gaap_OperatingLeaseLiability_9dcf0273-991f-4fdf-aad6-ba27b8e81d37" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/PropertyPlantandEquipmentNetPropertyPlantandEquipmentNetDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#PropertyPlantandEquipmentNetPropertyPlantandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/PropertyPlantandEquipmentNetPropertyPlantandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_61933011-607f-43d1-a193-9b053878a996" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_32acd11b-9993-4cfb-bd67-97f7dd71c00f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_61933011-607f-43d1-a193-9b053878a996" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_32acd11b-9993-4cfb-bd67-97f7dd71c00f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bc258995-a170-4325-bbe9-64f632c31b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_32acd11b-9993-4cfb-bd67-97f7dd71c00f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bc258995-a170-4325-bbe9-64f632c31b9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bc258995-a170-4325-bbe9-64f632c31b9d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bc258995-a170-4325-bbe9-64f632c31b9d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_bc258995-a170-4325-bbe9-64f632c31b9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fbe52e4a-0aa6-4d48-8405-b29f8669c60c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bc258995-a170-4325-bbe9-64f632c31b9d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fbe52e4a-0aa6-4d48-8405-b29f8669c60c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_0f8cf275-3c2c-4cb5-9406-dbccfac19f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fbe52e4a-0aa6-4d48-8405-b29f8669c60c" xlink:to="loc_us-gaap_LandMember_0f8cf275-3c2c-4cb5-9406-dbccfac19f0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_75abae9d-7d4b-4a86-91ef-3c86516224ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fbe52e4a-0aa6-4d48-8405-b29f8669c60c" xlink:to="loc_us-gaap_BuildingMember_75abae9d-7d4b-4a86-91ef-3c86516224ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_7566c77a-0442-4946-9beb-23634e073f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fbe52e4a-0aa6-4d48-8405-b29f8669c60c" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_7566c77a-0442-4946-9beb-23634e073f1f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_LaboratoryEquipmentMember_7ec64954-7b54-44bb-aa3c-ba93a04c58a0" xlink:href="bgne-20241231.xsd#bgne_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fbe52e4a-0aa6-4d48-8405-b29f8669c60c" xlink:to="loc_bgne_LaboratoryEquipmentMember_7ec64954-7b54-44bb-aa3c-ba93a04c58a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_e3241373-3b61-44a5-a642-a37650d14330" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fbe52e4a-0aa6-4d48-8405-b29f8669c60c" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_e3241373-3b61-44a5-a642-a37650d14330" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_08786001-87c4-45dc-b990-e3a400761ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fbe52e4a-0aa6-4d48-8405-b29f8669c60c" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_08786001-87c4-45dc-b990-e3a400761ef1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_69b429cc-9ce0-4d9b-ac2a-25559f0efc6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_61933011-607f-43d1-a193-9b053878a996" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_69b429cc-9ce0-4d9b-ac2a-25559f0efc6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_20d6ac25-5b39-4aae-886b-26ed6b9e1d42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_69b429cc-9ce0-4d9b-ac2a-25559f0efc6a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_20d6ac25-5b39-4aae-886b-26ed6b9e1d42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_277c8dc5-74d0-431d-a9d1-aef16c4aabeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_69b429cc-9ce0-4d9b-ac2a-25559f0efc6a" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_277c8dc5-74d0-431d-a9d1-aef16c4aabeb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_c9b9d3e2-a06d-4d3c-b323-1aa65ba8e79d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_69b429cc-9ce0-4d9b-ac2a-25559f0efc6a" xlink:to="loc_us-gaap_ConstructionInProgressGross_c9b9d3e2-a06d-4d3c-b323-1aa65ba8e79d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b5cbee6f-efd3-47a0-97c1-ce2328d1c300" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_69b429cc-9ce0-4d9b-ac2a-25559f0efc6a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b5cbee6f-efd3-47a0-97c1-ce2328d1c300" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/PropertyPlantandEquipmentNetNarrativesDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#PropertyPlantandEquipmentNetNarrativesDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/PropertyPlantandEquipmentNetNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4f10c6ad-540e-4e13-aba6-daffc4f27acd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b54ad027-0c58-4f14-9ee9-a6fc084c98db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4f10c6ad-540e-4e13-aba6-daffc4f27acd" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b54ad027-0c58-4f14-9ee9-a6fc084c98db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_e2aa449f-8e0e-47a2-85e3-21d210f7431d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b54ad027-0c58-4f14-9ee9-a6fc084c98db" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_e2aa449f-8e0e-47a2-85e3-21d210f7431d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_e2aa449f-8e0e-47a2-85e3-21d210f7431d_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_e2aa449f-8e0e-47a2-85e3-21d210f7431d" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_e2aa449f-8e0e-47a2-85e3-21d210f7431d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_8123dfbc-8e76-42a9-baa3-c834f05d2d12" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_e2aa449f-8e0e-47a2-85e3-21d210f7431d" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_8123dfbc-8e76-42a9-baa3-c834f05d2d12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_HopewellFacilityMember_531811b4-18b0-4251-afb1-17a421e2daba" xlink:href="bgne-20241231.xsd#bgne_HopewellFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_8123dfbc-8e76-42a9-baa3-c834f05d2d12" xlink:to="loc_bgne_HopewellFacilityMember_531811b4-18b0-4251-afb1-17a421e2daba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_00caf128-a858-4f07-b76f-882425437d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b54ad027-0c58-4f14-9ee9-a6fc084c98db" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_00caf128-a858-4f07-b76f-882425437d7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_00caf128-a858-4f07-b76f-882425437d7d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_00caf128-a858-4f07-b76f-882425437d7d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_00caf128-a858-4f07-b76f-882425437d7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d1242d84-85a8-4c8e-8f86-604ff7990dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_00caf128-a858-4f07-b76f-882425437d7d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d1242d84-85a8-4c8e-8f86-604ff7990dd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_33dcbd2e-81c9-4a27-ae1a-eace76e92baf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d1242d84-85a8-4c8e-8f86-604ff7990dd4" xlink:to="loc_us-gaap_LandMember_33dcbd2e-81c9-4a27-ae1a-eace76e92baf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_4702ebe7-2ed6-4c13-ae6d-d95e273a2c31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d1242d84-85a8-4c8e-8f86-604ff7990dd4" xlink:to="loc_us-gaap_ConstructionInProgressMember_4702ebe7-2ed6-4c13-ae6d-d95e273a2c31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_33d62e31-47d9-4795-962c-64c3a1ba5407" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b54ad027-0c58-4f14-9ee9-a6fc084c98db" xlink:to="loc_srt_StatementGeographicalAxis_33d62e31-47d9-4795-962c-64c3a1ba5407" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_33d62e31-47d9-4795-962c-64c3a1ba5407_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_33d62e31-47d9-4795-962c-64c3a1ba5407" xlink:to="loc_srt_SegmentGeographicalDomain_33d62e31-47d9-4795-962c-64c3a1ba5407_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8c35e416-e478-4499-85b9-d4b871e2c6e2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_33d62e31-47d9-4795-962c-64c3a1ba5407" xlink:to="loc_srt_SegmentGeographicalDomain_8c35e416-e478-4499-85b9-d4b871e2c6e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShanghaiChinaMember_cc97cd5f-7787-4c5d-823b-c1e227abb53f" xlink:href="bgne-20241231.xsd#bgne_ShanghaiChinaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8c35e416-e478-4499-85b9-d4b871e2c6e2" xlink:to="loc_bgne_ShanghaiChinaMember_cc97cd5f-7787-4c5d-823b-c1e227abb53f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_fe526792-fe49-4a15-a957-6ba9c29cba28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4f10c6ad-540e-4e13-aba6-daffc4f27acd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_fe526792-fe49-4a15-a957-6ba9c29cba28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_a555820e-33a6-4a1b-9da6-b1af90507906" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4f10c6ad-540e-4e13-aba6-daffc4f27acd" xlink:to="loc_us-gaap_ConstructionInProgressGross_a555820e-33a6-4a1b-9da6-b1af90507906" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_68170017-e5aa-4718-8c59-e9f8491c9908" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4f10c6ad-540e-4e13-aba6-daffc4f27acd" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_68170017-e5aa-4718-8c59-e9f8491c9908" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_b0316198-55bc-492c-be35-475ee14acbee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4f10c6ad-540e-4e13-aba6-daffc4f27acd" xlink:to="loc_us-gaap_Depreciation_b0316198-55bc-492c-be35-475ee14acbee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_8502c440-8740-4b0c-9c13-7f437ebec37e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4f10c6ad-540e-4e13-aba6-daffc4f27acd" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_8502c440-8740-4b0c-9c13-7f437ebec37e" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/PropertyPlantandEquipmentNetConstructioninProgressDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#PropertyPlantandEquipmentNetConstructioninProgressDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/PropertyPlantandEquipmentNetConstructioninProgressDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a8e84deb-f6e2-4229-bf0f-55973041e54a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0e195824-02aa-4d7a-a5f2-027b3d9818aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a8e84deb-f6e2-4229-bf0f-55973041e54a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0e195824-02aa-4d7a-a5f2-027b3d9818aa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_604733a8-cea0-43d8-9c6c-4bec091ddad6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0e195824-02aa-4d7a-a5f2-027b3d9818aa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_604733a8-cea0-43d8-9c6c-4bec091ddad6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_604733a8-cea0-43d8-9c6c-4bec091ddad6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_604733a8-cea0-43d8-9c6c-4bec091ddad6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_604733a8-cea0-43d8-9c6c-4bec091ddad6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2fe9acbb-e18e-4d1a-b6d3-15d0010a287a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_604733a8-cea0-43d8-9c6c-4bec091ddad6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2fe9acbb-e18e-4d1a-b6d3-15d0010a287a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_5cc76a93-4249-439e-8a95-a7c86c59247e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2fe9acbb-e18e-4d1a-b6d3-15d0010a287a" xlink:to="loc_us-gaap_BuildingMember_5cc76a93-4249-439e-8a95-a7c86c59247e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_bcfc94ef-89a0-447b-a0c8-3b87abb9fb7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2fe9acbb-e18e-4d1a-b6d3-15d0010a287a" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_bcfc94ef-89a0-447b-a0c8-3b87abb9fb7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_LaboratoryEquipmentMember_ab0346a9-9472-4721-b06c-c6ce549bfbdc" xlink:href="bgne-20241231.xsd#bgne_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2fe9acbb-e18e-4d1a-b6d3-15d0010a287a" xlink:to="loc_bgne_LaboratoryEquipmentMember_ab0346a9-9472-4721-b06c-c6ce549bfbdc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_925ded01-2c41-4c05-8e7b-9bb4a1e88629" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2fe9acbb-e18e-4d1a-b6d3-15d0010a287a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_925ded01-2c41-4c05-8e7b-9bb4a1e88629" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_aebfffcb-14fd-4425-a78b-f5926130d1b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGrossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a8e84deb-f6e2-4229-bf0f-55973041e54a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_aebfffcb-14fd-4425-a78b-f5926130d1b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_e8f05d32-93af-4f34-a9bd-d874aa19ffd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_aebfffcb-14fd-4425-a78b-f5926130d1b3" xlink:to="loc_us-gaap_ConstructionInProgressGross_e8f05d32-93af-4f34-a9bd-d874aa19ffd2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/IntangibleAssetsIntangibleAssetsOutstandingDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#IntangibleAssetsIntangibleAssetsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/IntangibleAssetsIntangibleAssetsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_52c9aef8-4738-41ad-abe8-5afd93138a39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3de15181-b4bb-4a80-8801-e71a4e9cbe7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_52c9aef8-4738-41ad-abe8-5afd93138a39" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3de15181-b4bb-4a80-8801-e71a4e9cbe7e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1f11fbad-7d24-4d78-9949-e2ee2e0e4ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3de15181-b4bb-4a80-8801-e71a4e9cbe7e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1f11fbad-7d24-4d78-9949-e2ee2e0e4ebd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1f11fbad-7d24-4d78-9949-e2ee2e0e4ebd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1f11fbad-7d24-4d78-9949-e2ee2e0e4ebd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1f11fbad-7d24-4d78-9949-e2ee2e0e4ebd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2bb12ef0-c37f-4056-9cea-39b41a341a72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1f11fbad-7d24-4d78-9949-e2ee2e0e4ebd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2bb12ef0-c37f-4056-9cea-39b41a341a72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_b0026140-4c20-46ba-81b1-fdcf4361f417" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2bb12ef0-c37f-4056-9cea-39b41a341a72" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_b0026140-4c20-46ba-81b1-fdcf4361f417" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_a670eb77-eaea-45cf-997a-df59edb75436" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2bb12ef0-c37f-4056-9cea-39b41a341a72" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_a670eb77-eaea-45cf-997a-df59edb75436" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_79aa49b1-fdec-4b3b-87d9-a5bd36436d78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_52c9aef8-4738-41ad-abe8-5afd93138a39" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_79aa49b1-fdec-4b3b-87d9-a5bd36436d78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f7df9ad5-95a0-4cea-8bed-c20d97ae97fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_79aa49b1-fdec-4b3b-87d9-a5bd36436d78" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f7df9ad5-95a0-4cea-8bed-c20d97ae97fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bee6bcf2-58b0-48bf-b07f-f615f6983030" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_79aa49b1-fdec-4b3b-87d9-a5bd36436d78" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bee6bcf2-58b0-48bf-b07f-f615f6983030" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9b216407-5699-49da-a3e5-a66f9c3ef55c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_79aa49b1-fdec-4b3b-87d9-a5bd36436d78" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9b216407-5699-49da-a3e5-a66f9c3ef55c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/IntangibleAssetsUsefulLifeDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#IntangibleAssetsUsefulLifeDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/IntangibleAssetsUsefulLifeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_973354cc-37cb-49c4-bc70-8cee9ee69855" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_71531f3c-5ca8-4aae-b7a4-996e1a4b40eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_973354cc-37cb-49c4-bc70-8cee9ee69855" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_71531f3c-5ca8-4aae-b7a4-996e1a4b40eb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_95c3646c-c22d-4a24-a685-55fc573757e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_71531f3c-5ca8-4aae-b7a4-996e1a4b40eb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_95c3646c-c22d-4a24-a685-55fc573757e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_95c3646c-c22d-4a24-a685-55fc573757e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_95c3646c-c22d-4a24-a685-55fc573757e7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_95c3646c-c22d-4a24-a685-55fc573757e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cf96abfc-b062-4313-979f-fcb7527142ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_95c3646c-c22d-4a24-a685-55fc573757e7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cf96abfc-b062-4313-979f-fcb7527142ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_2af593e7-f44d-400d-8a8c-03df705b4931" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cf96abfc-b062-4313-979f-fcb7527142ac" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_2af593e7-f44d-400d-8a8c-03df705b4931" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_a116da14-ae2e-4926-881c-02a231432f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cf96abfc-b062-4313-979f-fcb7527142ac" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_a116da14-ae2e-4926-881c-02a231432f7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4f876d9f-cedf-435b-b93d-ce4245406ddf" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_71531f3c-5ca8-4aae-b7a4-996e1a4b40eb" xlink:to="loc_srt_RangeAxis_4f876d9f-cedf-435b-b93d-ce4245406ddf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4f876d9f-cedf-435b-b93d-ce4245406ddf_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4f876d9f-cedf-435b-b93d-ce4245406ddf" xlink:to="loc_srt_RangeMember_4f876d9f-cedf-435b-b93d-ce4245406ddf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fb3d7621-8cd1-4b3b-aa20-05947903c42a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4f876d9f-cedf-435b-b93d-ce4245406ddf" xlink:to="loc_srt_RangeMember_fb3d7621-8cd1-4b3b-aa20-05947903c42a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_39d94c92-17b7-4f4f-ade7-b7435e693291" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fb3d7621-8cd1-4b3b-aa20-05947903c42a" xlink:to="loc_srt_WeightedAverageMember_39d94c92-17b7-4f4f-ade7-b7435e693291" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2a8a294d-3332-4b93-b77e-57240464f5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_973354cc-37cb-49c4-bc70-8cee9ee69855" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2a8a294d-3332-4b93-b77e-57240464f5bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1c52f3d4-bd62-456a-be7b-2c62f2430e41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2a8a294d-3332-4b93-b77e-57240464f5bc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1c52f3d4-bd62-456a-be7b-2c62f2430e41" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/IntangibleAssetsAmortizationExpenseDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#IntangibleAssetsAmortizationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/IntangibleAssetsAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d6e28348-5d12-4d98-b8d2-fa28083d83a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f5f9f94e-8e1c-4bfe-ad25-b370551b758f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d6e28348-5d12-4d98-b8d2-fa28083d83a8" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f5f9f94e-8e1c-4bfe-ad25-b370551b758f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4316b2fb-3d8a-4551-b526-10a43dde02fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f5f9f94e-8e1c-4bfe-ad25-b370551b758f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4316b2fb-3d8a-4551-b526-10a43dde02fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_4316b2fb-3d8a-4551-b526-10a43dde02fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4316b2fb-3d8a-4551-b526-10a43dde02fd" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_4316b2fb-3d8a-4551-b526-10a43dde02fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_97d65824-1503-4f7c-85c1-8e2157e93769" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4316b2fb-3d8a-4551-b526-10a43dde02fd" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_97d65824-1503-4f7c-85c1-8e2157e93769" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_2ceecaac-a436-42f2-b685-c075b1502d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_97d65824-1503-4f7c-85c1-8e2157e93769" xlink:to="loc_us-gaap_CostOfSalesMember_2ceecaac-a436-42f2-b685-c075b1502d4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d8284f7e-4371-498e-930b-35dead082692" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_97d65824-1503-4f7c-85c1-8e2157e93769" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d8284f7e-4371-498e-930b-35dead082692" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_f3ab317b-0285-4eb8-b7be-cb88c258e31c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d6e28348-5d12-4d98-b8d2-fa28083d83a8" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_f3ab317b-0285-4eb8-b7be-cb88c258e31c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/IntangibleAssetsExpectedAmortizationExpenseDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#IntangibleAssetsExpectedAmortizationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/IntangibleAssetsExpectedAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_163e1adf-7b9b-45d3-a8d4-25d31232ce5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_1dccdb44-e8cd-467d-bc32-b7e56bc5b367" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_163e1adf-7b9b-45d3-a8d4-25d31232ce5f" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_1dccdb44-e8cd-467d-bc32-b7e56bc5b367" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a589b6a5-fe33-42c3-b6e0-e6c1ce9db4fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_1dccdb44-e8cd-467d-bc32-b7e56bc5b367" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a589b6a5-fe33-42c3-b6e0-e6c1ce9db4fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a589b6a5-fe33-42c3-b6e0-e6c1ce9db4fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a589b6a5-fe33-42c3-b6e0-e6c1ce9db4fd" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a589b6a5-fe33-42c3-b6e0-e6c1ce9db4fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a7510647-bd36-4ba0-b336-1dbdd4406d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a589b6a5-fe33-42c3-b6e0-e6c1ce9db4fd" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a7510647-bd36-4ba0-b336-1dbdd4406d5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_a85cb096-0498-46c9-8808-56153b715eb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a7510647-bd36-4ba0-b336-1dbdd4406d5e" xlink:to="loc_us-gaap_CostOfSalesMember_a85cb096-0498-46c9-8808-56153b715eb6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8ecf67f7-51d6-4f60-93aa-a70c5764b5be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a7510647-bd36-4ba0-b336-1dbdd4406d5e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8ecf67f7-51d6-4f60-93aa-a70c5764b5be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_56aff900-097b-409f-a3cb-7355202779df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_163e1adf-7b9b-45d3-a8d4-25d31232ce5f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_56aff900-097b-409f-a3cb-7355202779df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e3bc026c-acd8-47ee-acf7-f59d505169c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_56aff900-097b-409f-a3cb-7355202779df" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e3bc026c-acd8-47ee-acf7-f59d505169c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b7014720-0539-463c-93b9-1d67fc1ae5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_56aff900-097b-409f-a3cb-7355202779df" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b7014720-0539-463c-93b9-1d67fc1ae5d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_53b01f46-d27c-4a81-b0ef-4d07c8aa24ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_56aff900-097b-409f-a3cb-7355202779df" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_53b01f46-d27c-4a81-b0ef-4d07c8aa24ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_fc2e5f0b-454c-49f8-809e-ffcca50e3b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_56aff900-097b-409f-a3cb-7355202779df" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_fc2e5f0b-454c-49f8-809e-ffcca50e3b3e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_415d2750-5538-49e8-a964-b0f21c8030f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_56aff900-097b-409f-a3cb-7355202779df" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_415d2750-5538-49e8-a964-b0f21c8030f1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_29d2d2ff-7ed3-48d1-812d-a10877d40cca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_56aff900-097b-409f-a3cb-7355202779df" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_29d2d2ff-7ed3-48d1-812d-a10877d40cca" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_211a0f8b-2bac-442c-9580-edb722a5321e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_56aff900-097b-409f-a3cb-7355202779df" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_211a0f8b-2bac-442c-9580-edb722a5321e" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#IncomeTaxesIncomeLossBeforeIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_3f023c76-2374-43e7-bd7d-e70d2bb74eba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_c408c49f-7101-42b5-8141-93a2bdb41010" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_3f023c76-2374-43e7-bd7d-e70d2bb74eba" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_c408c49f-7101-42b5-8141-93a2bdb41010" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_600663e0-bbdd-4043-9c63-7f793fae55cb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c408c49f-7101-42b5-8141-93a2bdb41010" xlink:to="loc_srt_StatementGeographicalAxis_600663e0-bbdd-4043-9c63-7f793fae55cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_600663e0-bbdd-4043-9c63-7f793fae55cb_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_600663e0-bbdd-4043-9c63-7f793fae55cb" xlink:to="loc_srt_SegmentGeographicalDomain_600663e0-bbdd-4043-9c63-7f793fae55cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1a297e07-92c1-435f-a406-1d76edeceed7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_600663e0-bbdd-4043-9c63-7f793fae55cb" xlink:to="loc_srt_SegmentGeographicalDomain_1a297e07-92c1-435f-a406-1d76edeceed7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_fb2ad12f-c9b1-471c-882b-cdf2080f00c9" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1a297e07-92c1-435f-a406-1d76edeceed7" xlink:to="loc_country_US_fb2ad12f-c9b1-471c-882b-cdf2080f00c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_ac5bcdcf-e561-4f83-ad95-3de748e3dda0" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1a297e07-92c1-435f-a406-1d76edeceed7" xlink:to="loc_country_CN_ac5bcdcf-e561-4f83-ad95-3de748e3dda0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember_e01141de-6fc1-45d0-a496-4c363eb06d40" xlink:href="bgne-20241231.xsd#bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1a297e07-92c1-435f-a406-1d76edeceed7" xlink:to="loc_bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember_e01141de-6fc1-45d0-a496-4c363eb06d40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_a6ee2500-540e-4efd-8600-efa08549e753" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_3f023c76-2374-43e7-bd7d-e70d2bb74eba" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_a6ee2500-540e-4efd-8600-efa08549e753" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_27af7034-9581-42f2-ace2-2df80e803793" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_a6ee2500-540e-4efd-8600-efa08549e753" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_27af7034-9581-42f2-ace2-2df80e803793" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_fc7b09a5-fd81-48b0-8d55-49fa255294df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_a6ee2500-540e-4efd-8600-efa08549e753" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_fc7b09a5-fd81-48b0-8d55-49fa255294df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3922ce98-1745-479a-b029-cf4a4ee9d708" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_a6ee2500-540e-4efd-8600-efa08549e753" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3922ce98-1745-479a-b029-cf4a4ee9d708" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/IncomeTaxesCurrentandDeferredComponentsIncomeTaxesDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#IncomeTaxesCurrentandDeferredComponentsIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/IncomeTaxesCurrentandDeferredComponentsIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_7374516f-9eb4-4f7a-b2b2-b8a62ef7820c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_d59bd74b-18ad-4ac6-ad20-14977052b2de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_7374516f-9eb4-4f7a-b2b2-b8a62ef7820c" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_d59bd74b-18ad-4ac6-ad20-14977052b2de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_2bd581e7-282f-4582-bc57-fcf93d81d93e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_d59bd74b-18ad-4ac6-ad20-14977052b2de" xlink:to="loc_srt_StatementGeographicalAxis_2bd581e7-282f-4582-bc57-fcf93d81d93e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2bd581e7-282f-4582-bc57-fcf93d81d93e_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_2bd581e7-282f-4582-bc57-fcf93d81d93e" xlink:to="loc_srt_SegmentGeographicalDomain_2bd581e7-282f-4582-bc57-fcf93d81d93e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9e143ce1-ee99-4367-a7c4-254014e430d5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_2bd581e7-282f-4582-bc57-fcf93d81d93e" xlink:to="loc_srt_SegmentGeographicalDomain_9e143ce1-ee99-4367-a7c4-254014e430d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_d75f2e5e-b4eb-40d1-9ec1-30cdb495b149" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9e143ce1-ee99-4367-a7c4-254014e430d5" xlink:to="loc_country_US_d75f2e5e-b4eb-40d1-9ec1-30cdb495b149" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_790934c1-b618-48bc-886c-bfc6424dd0e1" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9e143ce1-ee99-4367-a7c4-254014e430d5" xlink:to="loc_country_CN_790934c1-b618-48bc-886c-bfc6424dd0e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember_1116a023-65ce-46f3-9499-795bf757d0b6" xlink:href="bgne-20241231.xsd#bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9e143ce1-ee99-4367-a7c4-254014e430d5" xlink:to="loc_bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember_1116a023-65ce-46f3-9499-795bf757d0b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_dc0f3337-77b2-4b79-bee4-6a194eb2b862" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_7374516f-9eb4-4f7a-b2b2-b8a62ef7820c" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_dc0f3337-77b2-4b79-bee4-6a194eb2b862" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_92462934-b182-428d-9e0f-656776b73cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_7374516f-9eb4-4f7a-b2b2-b8a62ef7820c" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_92462934-b182-428d-9e0f-656776b73cdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_98756bad-3723-4834-b375-c3597e6dc3df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_7374516f-9eb4-4f7a-b2b2-b8a62ef7820c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_98756bad-3723-4834-b375-c3597e6dc3df" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/IncomeTaxesNarrativesDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#IncomeTaxesNarrativesDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/IncomeTaxesNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_ab1b607b-618c-4bfe-accf-cf6eb54ec1be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_b281ab18-5e14-4d3f-83c2-43c902693a32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_ab1b607b-618c-4bfe-accf-cf6eb54ec1be" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_b281ab18-5e14-4d3f-83c2-43c902693a32" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_387abc0e-bae9-4259-8d04-0c20ac6bbc28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_b281ab18-5e14-4d3f-83c2-43c902693a32" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_387abc0e-bae9-4259-8d04-0c20ac6bbc28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_387abc0e-bae9-4259-8d04-0c20ac6bbc28_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_387abc0e-bae9-4259-8d04-0c20ac6bbc28" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_387abc0e-bae9-4259-8d04-0c20ac6bbc28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_9ff41a4c-432c-4580-af21-91ad8076142b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_387abc0e-bae9-4259-8d04-0c20ac6bbc28" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_9ff41a4c-432c-4580-af21-91ad8076142b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAdministrationOfTaxationChinaMember_aca2a436-b0da-4073-9058-e11f0a072e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAdministrationOfTaxationChinaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_9ff41a4c-432c-4580-af21-91ad8076142b" xlink:to="loc_us-gaap_StateAdministrationOfTaxationChinaMember_aca2a436-b0da-4073-9058-e11f0a072e0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SwissFederalTaxAdministrationFTAMember_5e46196f-ac28-4d59-9083-94d8c616fd50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SwissFederalTaxAdministrationFTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_9ff41a4c-432c-4580-af21-91ad8076142b" xlink:to="loc_us-gaap_SwissFederalTaxAdministrationFTAMember_5e46196f-ac28-4d59-9083-94d8c616fd50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_eae343d8-4417-43b3-b5b2-e526f32bd4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_9ff41a4c-432c-4580-af21-91ad8076142b" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_eae343d8-4417-43b3-b5b2-e526f32bd4c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_590b6f70-d4a4-426d-9e24-394c429c89aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_ab1b607b-618c-4bfe-accf-cf6eb54ec1be" xlink:to="loc_us-gaap_OperatingLossCarryforwards_590b6f70-d4a4-426d-9e24-394c429c89aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_35398a52-1895-4252-818b-f9c47b247642" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_ab1b607b-618c-4bfe-accf-cf6eb54ec1be" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_35398a52-1895-4252-818b-f9c47b247642" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign_1a713fcd-f06b-45c7-a244-7b44956ee48a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_ab1b607b-618c-4bfe-accf-cf6eb54ec1be" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign_1a713fcd-f06b-45c7-a244-7b44956ee48a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_50ef90d6-3077-47a2-bacf-5c9f90b9aca1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_ab1b607b-618c-4bfe-accf-cf6eb54ec1be" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_50ef90d6-3077-47a2-bacf-5c9f90b9aca1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_TaxBenefitFromForeignTaxStatus_183fc263-a5e7-4dc1-accd-3e48d84e1535" xlink:href="bgne-20241231.xsd#bgne_TaxBenefitFromForeignTaxStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_ab1b607b-618c-4bfe-accf-cf6eb54ec1be" xlink:to="loc_bgne_TaxBenefitFromForeignTaxStatus_183fc263-a5e7-4dc1-accd-3e48d84e1535" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_TaxBenefitFromForeignTaxStatusPerShare_39abdd65-d9fe-47b5-be6c-59329b1d990c" xlink:href="bgne-20241231.xsd#bgne_TaxBenefitFromForeignTaxStatusPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_ab1b607b-618c-4bfe-accf-cf6eb54ec1be" xlink:to="loc_bgne_TaxBenefitFromForeignTaxStatusPerShare_39abdd65-d9fe-47b5-be6c-59329b1d990c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_59a095cc-de8f-4bac-9d32-8b36a6a23834" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_ab1b607b-618c-4bfe-accf-cf6eb54ec1be" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_59a095cc-de8f-4bac-9d32-8b36a6a23834" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#DebtShorttermandLongtermDebtObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_405e5c7b-f91c-4453-9ba2-5a689cf5ca90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0d18d7bc-5e76-4a6c-8ab6-45a558e55a87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_405e5c7b-f91c-4453-9ba2-5a689cf5ca90" xlink:to="loc_us-gaap_DebtInstrumentTable_0d18d7bc-5e76-4a6c-8ab6-45a558e55a87" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_420e0698-1a53-4292-b7b4-6b02ffa06e44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0d18d7bc-5e76-4a6c-8ab6-45a558e55a87" xlink:to="loc_us-gaap_DebtInstrumentAxis_420e0698-1a53-4292-b7b4-6b02ffa06e44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_420e0698-1a53-4292-b7b4-6b02ffa06e44_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_420e0698-1a53-4292-b7b4-6b02ffa06e44" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_420e0698-1a53-4292-b7b4-6b02ffa06e44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_837c7087-6bf9-4ac1-a5ec-aea58ec28392" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_420e0698-1a53-4292-b7b4-6b02ffa06e44" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_837c7087-6bf9-4ac1-a5ec-aea58ec28392" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShortTermBankLoanDatedApril42018Member_3203ff7e-b496-417f-8413-647a2d9fa2e9" xlink:href="bgne-20241231.xsd#bgne_ShortTermBankLoanDatedApril42018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_837c7087-6bf9-4ac1-a5ec-aea58ec28392" xlink:to="loc_bgne_ShortTermBankLoanDatedApril42018Member_3203ff7e-b496-417f-8413-647a2d9fa2e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShortTermBankLoanDatedJanuary222020Member_62f3b53d-5ad1-41ec-8912-58c22e03dd60" xlink:href="bgne-20241231.xsd#bgne_ShortTermBankLoanDatedJanuary222020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_837c7087-6bf9-4ac1-a5ec-aea58ec28392" xlink:to="loc_bgne_ShortTermBankLoanDatedJanuary222020Member_62f3b53d-5ad1-41ec-8912-58c22e03dd60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShortTermBankLoanDatedNovember92020Member_2489a641-29c6-4eec-874a-5e2ae13ba121" xlink:href="bgne-20241231.xsd#bgne_ShortTermBankLoanDatedNovember92020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_837c7087-6bf9-4ac1-a5ec-aea58ec28392" xlink:to="loc_bgne_ShortTermBankLoanDatedNovember92020Member_2489a641-29c6-4eec-874a-5e2ae13ba121" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_LongTermBankLoanDatedJuly292022Member_db44b231-1888-40e3-8026-6296d9792906" xlink:href="bgne-20241231.xsd#bgne_LongTermBankLoanDatedJuly292022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_837c7087-6bf9-4ac1-a5ec-aea58ec28392" xlink:to="loc_bgne_LongTermBankLoanDatedJuly292022Member_db44b231-1888-40e3-8026-6296d9792906" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShortTermBankLoanDatedJuly282023Member_588a4ba5-e9b1-4ecb-93e8-750c674635a6" xlink:href="bgne-20241231.xsd#bgne_ShortTermBankLoanDatedJuly282023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_837c7087-6bf9-4ac1-a5ec-aea58ec28392" xlink:to="loc_bgne_ShortTermBankLoanDatedJuly282023Member_588a4ba5-e9b1-4ecb-93e8-750c674635a6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShortTermBankLoanDatedDecember202023Member_d2cdb8d2-2b90-45c6-9d67-14d7e2a99590" xlink:href="bgne-20241231.xsd#bgne_ShortTermBankLoanDatedDecember202023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_837c7087-6bf9-4ac1-a5ec-aea58ec28392" xlink:to="loc_bgne_ShortTermBankLoanDatedDecember202023Member_d2cdb8d2-2b90-45c6-9d67-14d7e2a99590" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShortTermBankLoanDatedMarch212024Member_62d3d740-baf8-48e4-a87c-3ad73b771b8f" xlink:href="bgne-20241231.xsd#bgne_ShortTermBankLoanDatedMarch212024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_837c7087-6bf9-4ac1-a5ec-aea58ec28392" xlink:to="loc_bgne_ShortTermBankLoanDatedMarch212024Member_62d3d740-baf8-48e4-a87c-3ad73b771b8f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShortTermBankLoanDatedJune52023Member_04c9b26f-f54e-4274-8366-8a883c2425ce" xlink:href="bgne-20241231.xsd#bgne_ShortTermBankLoanDatedJune52023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_837c7087-6bf9-4ac1-a5ec-aea58ec28392" xlink:to="loc_bgne_ShortTermBankLoanDatedJune52023Member_04c9b26f-f54e-4274-8366-8a883c2425ce" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShortTermBankLoanDatedMay42023Member_1d0a806d-0a6d-426b-a719-d728a2136e87" xlink:href="bgne-20241231.xsd#bgne_ShortTermBankLoanDatedMay42023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_837c7087-6bf9-4ac1-a5ec-aea58ec28392" xlink:to="loc_bgne_ShortTermBankLoanDatedMay42023Member_1d0a806d-0a6d-426b-a719-d728a2136e87" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShortTermBankLoanDatedMay302023Member_505c1226-1030-42eb-8faf-5a94a6030803" xlink:href="bgne-20241231.xsd#bgne_ShortTermBankLoanDatedMay302023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_837c7087-6bf9-4ac1-a5ec-aea58ec28392" xlink:to="loc_bgne_ShortTermBankLoanDatedMay302023Member_505c1226-1030-42eb-8faf-5a94a6030803" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShortTermBankLoanDatedNovember142023Member_6224745c-6837-424b-b747-6e310f6996e1" xlink:href="bgne-20241231.xsd#bgne_ShortTermBankLoanDatedNovember142023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_837c7087-6bf9-4ac1-a5ec-aea58ec28392" xlink:to="loc_bgne_ShortTermBankLoanDatedNovember142023Member_6224745c-6837-424b-b747-6e310f6996e1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShortTermBankLoanDatedMay252023Member_f1213215-fb75-4862-a468-dcf44b32427e" xlink:href="bgne-20241231.xsd#bgne_ShortTermBankLoanDatedMay252023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_837c7087-6bf9-4ac1-a5ec-aea58ec28392" xlink:to="loc_bgne_ShortTermBankLoanDatedMay252023Member_f1213215-fb75-4862-a468-dcf44b32427e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_LongTermBankLoanApril42018Member_726db4db-f8d2-4cdc-960d-823499531134" xlink:href="bgne-20241231.xsd#bgne_LongTermBankLoanApril42018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_837c7087-6bf9-4ac1-a5ec-aea58ec28392" xlink:to="loc_bgne_LongTermBankLoanApril42018Member_726db4db-f8d2-4cdc-960d-823499531134" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_LongTermBankLoanDatedJanuary222020Member_4db133f3-74b4-4224-b740-8cf54da78c49" xlink:href="bgne-20241231.xsd#bgne_LongTermBankLoanDatedJanuary222020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_837c7087-6bf9-4ac1-a5ec-aea58ec28392" xlink:to="loc_bgne_LongTermBankLoanDatedJanuary222020Member_4db133f3-74b4-4224-b740-8cf54da78c49" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_LongTermBankLoanDatedNovember92020Member_30c48985-dedd-4c6e-9802-9c7e7aa01901" xlink:href="bgne-20241231.xsd#bgne_LongTermBankLoanDatedNovember92020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_837c7087-6bf9-4ac1-a5ec-aea58ec28392" xlink:to="loc_bgne_LongTermBankLoanDatedNovember92020Member_30c48985-dedd-4c6e-9802-9c7e7aa01901" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShortTermBankLoanMaturingJanuary272025Member_ee227e04-e844-4c70-921e-74892cde0447" xlink:href="bgne-20241231.xsd#bgne_ShortTermBankLoanMaturingJanuary272025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_837c7087-6bf9-4ac1-a5ec-aea58ec28392" xlink:to="loc_bgne_ShortTermBankLoanMaturingJanuary272025Member_ee227e04-e844-4c70-921e-74892cde0447" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_eb7052d2-be4f-49b3-9a13-409bd4187ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0d18d7bc-5e76-4a6c-8ab6-45a558e55a87" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_eb7052d2-be4f-49b3-9a13-409bd4187ef7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_eb7052d2-be4f-49b3-9a13-409bd4187ef7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_eb7052d2-be4f-49b3-9a13-409bd4187ef7" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_eb7052d2-be4f-49b3-9a13-409bd4187ef7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_7a6306bd-a393-4cba-846a-a0bdc0a12f86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_eb7052d2-be4f-49b3-9a13-409bd4187ef7" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_7a6306bd-a393-4cba-846a-a0bdc0a12f86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ChinaConstructionBankMember_de7ab032-d630-49ca-8f87-6f0f581c9857" xlink:href="bgne-20241231.xsd#bgne_ChinaConstructionBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_7a6306bd-a393-4cba-846a-a0bdc0a12f86" xlink:to="loc_bgne_ChinaConstructionBankMember_de7ab032-d630-49ca-8f87-6f0f581c9857" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ChinaMerchantsBankMember_6b2fe2ed-ad06-40f5-825a-28634223d2fa" xlink:href="bgne-20241231.xsd#bgne_ChinaMerchantsBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_7a6306bd-a393-4cba-846a-a0bdc0a12f86" xlink:to="loc_bgne_ChinaMerchantsBankMember_6b2fe2ed-ad06-40f5-825a-28634223d2fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ChinaCITICBankMember_d0800933-d0b1-4c6b-8cc6-c02c6c16c23e" xlink:href="bgne-20241231.xsd#bgne_ChinaCITICBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_7a6306bd-a393-4cba-846a-a0bdc0a12f86" xlink:to="loc_bgne_ChinaCITICBankMember_d0800933-d0b1-4c6b-8cc6-c02c6c16c23e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ChinaMinshengBankMember_29de4b1e-fea5-4cba-be99-96f3540af74f" xlink:href="bgne-20241231.xsd#bgne_ChinaMinshengBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_7a6306bd-a393-4cba-846a-a0bdc0a12f86" xlink:to="loc_bgne_ChinaMinshengBankMember_29de4b1e-fea5-4cba-be99-96f3540af74f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ChinaIndustrialBankMember_dfa50afe-c134-47fd-a9e6-63a043775b4f" xlink:href="bgne-20241231.xsd#bgne_ChinaIndustrialBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_7a6306bd-a393-4cba-846a-a0bdc0a12f86" xlink:to="loc_bgne_ChinaIndustrialBankMember_dfa50afe-c134-47fd-a9e6-63a043775b4f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_HSBCBankMember_48c6f65c-ab15-470f-a872-69d06d1eedbf" xlink:href="bgne-20241231.xsd#bgne_HSBCBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_7a6306bd-a393-4cba-846a-a0bdc0a12f86" xlink:to="loc_bgne_HSBCBankMember_48c6f65c-ab15-470f-a872-69d06d1eedbf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShanghaiPudongDevelopmentBankMember_49699034-4bb1-4399-b83e-075728f1e6b1" xlink:href="bgne-20241231.xsd#bgne_ShanghaiPudongDevelopmentBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_7a6306bd-a393-4cba-846a-a0bdc0a12f86" xlink:to="loc_bgne_ShanghaiPudongDevelopmentBankMember_49699034-4bb1-4399-b83e-075728f1e6b1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_41c1576f-248f-4175-b20b-181973a8e1aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0d18d7bc-5e76-4a6c-8ab6-45a558e55a87" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_41c1576f-248f-4175-b20b-181973a8e1aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_41c1576f-248f-4175-b20b-181973a8e1aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_41c1576f-248f-4175-b20b-181973a8e1aa" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_41c1576f-248f-4175-b20b-181973a8e1aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_f13ee427-7c78-409f-bfb2-068121511c14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_41c1576f-248f-4175-b20b-181973a8e1aa" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_f13ee427-7c78-409f-bfb2-068121511c14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_7d8cf257-08b6-4e63-9832-02dfb0d6d14c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_f13ee427-7c78-409f-bfb2-068121511c14" xlink:to="loc_us-gaap_LoansPayableMember_7d8cf257-08b6-4e63-9832-02dfb0d6d14c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_35dea4dd-8fc5-493b-8176-4a2e481d2dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0d18d7bc-5e76-4a6c-8ab6-45a558e55a87" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_35dea4dd-8fc5-493b-8176-4a2e481d2dc0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_35dea4dd-8fc5-493b-8176-4a2e481d2dc0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_35dea4dd-8fc5-493b-8176-4a2e481d2dc0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_35dea4dd-8fc5-493b-8176-4a2e481d2dc0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_598f6fae-de04-4688-acde-7e4eb0fde978" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_35dea4dd-8fc5-493b-8176-4a2e481d2dc0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_598f6fae-de04-4688-acde-7e4eb0fde978" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_f3941e58-92a5-498b-9419-3778afec879e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_598f6fae-de04-4688-acde-7e4eb0fde978" xlink:to="loc_us-gaap_LoansPayableMember_f3941e58-92a5-498b-9419-3778afec879e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ff9b6b20-322a-4615-9de3-a085833aa44f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_405e5c7b-f91c-4453-9ba2-5a689cf5ca90" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ff9b6b20-322a-4615-9de3-a085833aa44f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_c1a271a7-1411-4e44-9d5c-4efc3f929054" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_405e5c7b-f91c-4453-9ba2-5a689cf5ca90" xlink:to="loc_us-gaap_DebtInstrumentTerm_c1a271a7-1411-4e44-9d5c-4efc3f929054" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_d2771440-0af9-48c7-b7ee-93c7d6c34a73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_405e5c7b-f91c-4453-9ba2-5a689cf5ca90" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_d2771440-0af9-48c7-b7ee-93c7d6c34a73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_29907080-a494-4d03-b501-ac19599e452e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_405e5c7b-f91c-4453-9ba2-5a689cf5ca90" xlink:to="loc_us-gaap_LongTermDebtCurrent_29907080-a494-4d03-b501-ac19599e452e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_c2cb7d77-3621-44fa-964f-bf2b410cb4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_405e5c7b-f91c-4453-9ba2-5a689cf5ca90" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_c2cb7d77-3621-44fa-964f-bf2b410cb4e3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_7af19167-942c-4468-a923-fcd7c917ea75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_405e5c7b-f91c-4453-9ba2-5a689cf5ca90" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_7af19167-942c-4468-a923-fcd7c917ea75" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f88ad50d-59d0-4906-bad2-7ec3f8ffa09c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_405e5c7b-f91c-4453-9ba2-5a689cf5ca90" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f88ad50d-59d0-4906-bad2-7ec3f8ffa09c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_a1ba8319-2f36-4a58-92d1-c92979ab7977" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_405e5c7b-f91c-4453-9ba2-5a689cf5ca90" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_a1ba8319-2f36-4a58-92d1-c92979ab7977" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_9eee4daf-bd25-44a9-8732-89fd91f9ca4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_405e5c7b-f91c-4453-9ba2-5a689cf5ca90" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_9eee4daf-bd25-44a9-8732-89fd91f9ca4f" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ProductRevenueProductSalesDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ProductRevenueProductSalesDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/ProductRevenueProductSalesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_136f3974-221e-4659-adf7-434ba070df98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_8b7dcc9f-ad9c-4bc9-b21c-93169bafa2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_136f3974-221e-4659-adf7-434ba070df98" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_8b7dcc9f-ad9c-4bc9-b21c-93169bafa2e4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b6f6a10b-abb6-40ee-95aa-606d3af83eef" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8b7dcc9f-ad9c-4bc9-b21c-93169bafa2e4" xlink:to="loc_srt_ProductOrServiceAxis_b6f6a10b-abb6-40ee-95aa-606d3af83eef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b6f6a10b-abb6-40ee-95aa-606d3af83eef_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b6f6a10b-abb6-40ee-95aa-606d3af83eef" xlink:to="loc_srt_ProductsAndServicesDomain_b6f6a10b-abb6-40ee-95aa-606d3af83eef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_af7a050d-314a-46e9-afad-c162173030cd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b6f6a10b-abb6-40ee-95aa-606d3af83eef" xlink:to="loc_srt_ProductsAndServicesDomain_af7a050d-314a-46e9-afad-c162173030cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_5315e949-0afb-461e-bd64-6fb874c11fab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_af7a050d-314a-46e9-afad-c162173030cd" xlink:to="loc_us-gaap_ProductMember_5315e949-0afb-461e-bd64-6fb874c11fab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ProductNameAxis_15b3c760-5342-42cd-80f8-bfb2cfd67a58" xlink:href="bgne-20241231.xsd#bgne_ProductNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8b7dcc9f-ad9c-4bc9-b21c-93169bafa2e4" xlink:to="loc_bgne_ProductNameAxis_15b3c760-5342-42cd-80f8-bfb2cfd67a58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ProductNameDomain_15b3c760-5342-42cd-80f8-bfb2cfd67a58_default" xlink:href="bgne-20241231.xsd#bgne_ProductNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_bgne_ProductNameAxis_15b3c760-5342-42cd-80f8-bfb2cfd67a58" xlink:to="loc_bgne_ProductNameDomain_15b3c760-5342-42cd-80f8-bfb2cfd67a58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ProductNameDomain_8d3e7114-e03d-4a43-bdcc-6437c61b31f2" xlink:href="bgne-20241231.xsd#bgne_ProductNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_bgne_ProductNameAxis_15b3c760-5342-42cd-80f8-bfb2cfd67a58" xlink:to="loc_bgne_ProductNameDomain_8d3e7114-e03d-4a43-bdcc-6437c61b31f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_BRUKINSAMember_ffb6c2d5-b98c-496e-b103-0165d3c74a28" xlink:href="bgne-20241231.xsd#bgne_BRUKINSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bgne_ProductNameDomain_8d3e7114-e03d-4a43-bdcc-6437c61b31f2" xlink:to="loc_bgne_BRUKINSAMember_ffb6c2d5-b98c-496e-b103-0165d3c74a28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_TislelizumabMember_a96f00c7-6d59-4567-bce5-e3de585b5d4d" xlink:href="bgne-20241231.xsd#bgne_TislelizumabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bgne_ProductNameDomain_8d3e7114-e03d-4a43-bdcc-6437c61b31f2" xlink:to="loc_bgne_TislelizumabMember_a96f00c7-6d59-4567-bce5-e3de585b5d4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_XGEVAMember_2f18d773-f828-4aec-96ab-6f906743c07f" xlink:href="bgne-20241231.xsd#bgne_XGEVAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bgne_ProductNameDomain_8d3e7114-e03d-4a43-bdcc-6437c61b31f2" xlink:to="loc_bgne_XGEVAMember_2f18d773-f828-4aec-96ab-6f906743c07f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_BLINCYTOMember_ea6f95d4-306e-4da0-97fc-01cf2db57807" xlink:href="bgne-20241231.xsd#bgne_BLINCYTOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bgne_ProductNameDomain_8d3e7114-e03d-4a43-bdcc-6437c61b31f2" xlink:to="loc_bgne_BLINCYTOMember_ea6f95d4-306e-4da0-97fc-01cf2db57807" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_KYPROLISMember_94f6df57-e696-4ab1-8d4e-36d256ccd56e" xlink:href="bgne-20241231.xsd#bgne_KYPROLISMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bgne_ProductNameDomain_8d3e7114-e03d-4a43-bdcc-6437c61b31f2" xlink:to="loc_bgne_KYPROLISMember_94f6df57-e696-4ab1-8d4e-36d256ccd56e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_POBEVCYMember_7d657f8c-1bc7-4cb4-877c-50cf3f7a2ee6" xlink:href="bgne-20241231.xsd#bgne_POBEVCYMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bgne_ProductNameDomain_8d3e7114-e03d-4a43-bdcc-6437c61b31f2" xlink:to="loc_bgne_POBEVCYMember_7d657f8c-1bc7-4cb4-877c-50cf3f7a2ee6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_REVLIMIDMember_58c8f8a5-3ac0-4bee-81e0-e385bb2d19fa" xlink:href="bgne-20241231.xsd#bgne_REVLIMIDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bgne_ProductNameDomain_8d3e7114-e03d-4a43-bdcc-6437c61b31f2" xlink:to="loc_bgne_REVLIMIDMember_58c8f8a5-3ac0-4bee-81e0-e385bb2d19fa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_OtherMember_7df1abba-3011-4bfc-b835-44e021468e34" xlink:href="bgne-20241231.xsd#bgne_OtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bgne_ProductNameDomain_8d3e7114-e03d-4a43-bdcc-6437c61b31f2" xlink:to="loc_bgne_OtherMember_7df1abba-3011-4bfc-b835-44e021468e34" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_83eaa942-59c7-4008-8d38-aadc1a2c4878" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_136f3974-221e-4659-adf7-434ba070df98" xlink:to="loc_us-gaap_RevenuesAbstract_83eaa942-59c7-4008-8d38-aadc1a2c4878" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeReductions_8385708d-c50c-4fc2-b64d-c9e2210603b5" xlink:href="bgne-20241231.xsd#bgne_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeReductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_83eaa942-59c7-4008-8d38-aadc1a2c4878" xlink:to="loc_bgne_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeReductions_8385708d-c50c-4fc2-b64d-c9e2210603b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RevenueRecognitionRevenueReduction_25c35dbc-c4a8-4712-833d-aaeddc8c4ede" xlink:href="bgne-20241231.xsd#bgne_RevenueRecognitionRevenueReduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_83eaa942-59c7-4008-8d38-aadc1a2c4878" xlink:to="loc_bgne_RevenueRecognitionRevenueReduction_25c35dbc-c4a8-4712-833d-aaeddc8c4ede" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_60282b98-e187-4376-936b-f4dd1915ed5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_83eaa942-59c7-4008-8d38-aadc1a2c4878" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_60282b98-e187-4376-936b-f4dd1915ed5b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ProductRevenueAccruedSalesRebatesandReturnsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ProductRevenueAccruedSalesRebatesandReturnsDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/ProductRevenueAccruedSalesRebatesandReturnsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_ceed2f3a-1f09-4c95-a9a3-2db474faa73f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_3525ec93-6029-4dda-adce-366a5d332983" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ceed2f3a-1f09-4c95-a9a3-2db474faa73f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_3525ec93-6029-4dda-adce-366a5d332983" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7f14cec3-0160-4bef-b18e-b479ea2957a6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3525ec93-6029-4dda-adce-366a5d332983" xlink:to="loc_srt_ProductOrServiceAxis_7f14cec3-0160-4bef-b18e-b479ea2957a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7f14cec3-0160-4bef-b18e-b479ea2957a6_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7f14cec3-0160-4bef-b18e-b479ea2957a6" xlink:to="loc_srt_ProductsAndServicesDomain_7f14cec3-0160-4bef-b18e-b479ea2957a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ff080f2c-45b8-4d90-9491-4a67173039be" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7f14cec3-0160-4bef-b18e-b479ea2957a6" xlink:to="loc_srt_ProductsAndServicesDomain_ff080f2c-45b8-4d90-9491-4a67173039be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_45bd84b7-7878-4455-abba-b15ba3fb0075" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ff080f2c-45b8-4d90-9491-4a67173039be" xlink:to="loc_us-gaap_ProductMember_45bd84b7-7878-4455-abba-b15ba3fb0075" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RebatesReturnsAndOtherDeductionsMember_2127fc84-6dc0-4c42-a97d-adc6eb0ed84e" xlink:href="bgne-20241231.xsd#bgne_RebatesReturnsAndOtherDeductionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_45bd84b7-7878-4455-abba-b15ba3fb0075" xlink:to="loc_bgne_RebatesReturnsAndOtherDeductionsMember_2127fc84-6dc0-4c42-a97d-adc6eb0ed84e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ContraARAccrualsMember_32c87981-1ed1-4a70-8b4f-2006a5bd1b87" xlink:href="bgne-20241231.xsd#bgne_ContraARAccrualsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_45bd84b7-7878-4455-abba-b15ba3fb0075" xlink:to="loc_bgne_ContraARAccrualsMember_32c87981-1ed1-4a70-8b4f-2006a5bd1b87" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AccruedSalesRebatesAndReturnsRollForward_5b6b1354-5bc5-4791-bf93-743927df65c1" xlink:href="bgne-20241231.xsd#bgne_AccruedSalesRebatesAndReturnsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ceed2f3a-1f09-4c95-a9a3-2db474faa73f" xlink:to="loc_bgne_AccruedSalesRebatesAndReturnsRollForward_5b6b1354-5bc5-4791-bf93-743927df65c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions_1f976779-d82c-4516-a7e1-a09eef51bb7d" xlink:href="bgne-20241231.xsd#bgne_RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bgne_AccruedSalesRebatesAndReturnsRollForward_5b6b1354-5bc5-4791-bf93-743927df65c1" xlink:to="loc_bgne_RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions_1f976779-d82c-4516-a7e1-a09eef51bb7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AccountsReceivableAllowanceForChargebacksAndCreditLoss_0825a4a7-6ffa-4741-bae5-8859df128a8c" xlink:href="bgne-20241231.xsd#bgne_AccountsReceivableAllowanceForChargebacksAndCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bgne_AccruedSalesRebatesAndReturnsRollForward_5b6b1354-5bc5-4791-bf93-743927df65c1" xlink:to="loc_bgne_AccountsReceivableAllowanceForChargebacksAndCreditLoss_0825a4a7-6ffa-4741-bae5-8859df128a8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions_9d946214-0abe-4b34-a4e3-1ebec022d6b8" xlink:href="bgne-20241231.xsd#bgne_RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bgne_AccruedSalesRebatesAndReturnsRollForward_5b6b1354-5bc5-4791-bf93-743927df65c1" xlink:to="loc_bgne_RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions_9d946214-0abe-4b34-a4e3-1ebec022d6b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RevenueRecognitionRevenueReduction_085b557c-d6d2-453b-aa32-73ae9532e217" xlink:href="bgne-20241231.xsd#bgne_RevenueRecognitionRevenueReduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bgne_AccruedSalesRebatesAndReturnsRollForward_5b6b1354-5bc5-4791-bf93-743927df65c1" xlink:to="loc_bgne_RevenueRecognitionRevenueReduction_085b557c-d6d2-453b-aa32-73ae9532e217" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RevenueRecognitionRevenueReductionsPaymentsAndCredits_4f3a959c-9924-4cab-a9fe-bd06fd831b1e" xlink:href="bgne-20241231.xsd#bgne_RevenueRecognitionRevenueReductionsPaymentsAndCredits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bgne_AccruedSalesRebatesAndReturnsRollForward_5b6b1354-5bc5-4791-bf93-743927df65c1" xlink:to="loc_bgne_RevenueRecognitionRevenueReductionsPaymentsAndCredits_4f3a959c-9924-4cab-a9fe-bd06fd831b1e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions_0d94d7ed-362d-44ca-9c31-ae0440e80d32" xlink:href="bgne-20241231.xsd#bgne_RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AccountsReceivableAllowanceForChargebacksAndCreditLoss_e836b772-fdaf-4670-b531-2f109494c42a" xlink:href="bgne-20241231.xsd#bgne_AccountsReceivableAllowanceForChargebacksAndCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions_bec436fa-c157-4d69-b46a-d765a713ea47" xlink:href="bgne-20241231.xsd#bgne_RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ShareBasedCompensation2016ShareOptionandIncentivePlanDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ShareBasedCompensation2016ShareOptionandIncentivePlanDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/ShareBasedCompensation2016ShareOptionandIncentivePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ad4261d-2210-45f9-ac0e-7e0aaf83e3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_99efa4da-cb31-4642-b998-2f43a1d2d250" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ad4261d-2210-45f9-ac0e-7e0aaf83e3a9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_99efa4da-cb31-4642-b998-2f43a1d2d250" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e31f101c-b5a7-460f-a3a7-f0e8460fb61f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_99efa4da-cb31-4642-b998-2f43a1d2d250" xlink:to="loc_us-gaap_PlanNameAxis_e31f101c-b5a7-460f-a3a7-f0e8460fb61f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e31f101c-b5a7-460f-a3a7-f0e8460fb61f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_e31f101c-b5a7-460f-a3a7-f0e8460fb61f" xlink:to="loc_us-gaap_PlanNameDomain_e31f101c-b5a7-460f-a3a7-f0e8460fb61f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d7754f2f-d53f-4dc4-a3ac-f383f1bd23f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_e31f101c-b5a7-460f-a3a7-f0e8460fb61f" xlink:to="loc_us-gaap_PlanNameDomain_d7754f2f-d53f-4dc4-a3ac-f383f1bd23f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShareOptionAndIncentivePlan2016Member_90011731-9330-44a0-bde0-fa6359a9b3d3" xlink:href="bgne-20241231.xsd#bgne_ShareOptionAndIncentivePlan2016Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d7754f2f-d53f-4dc4-a3ac-f383f1bd23f3" xlink:to="loc_bgne_ShareOptionAndIncentivePlan2016Member_90011731-9330-44a0-bde0-fa6359a9b3d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShareIncentivePlan2011Member_f6e800ff-fbc3-4163-81e9-0221e5487cc3" xlink:href="bgne-20241231.xsd#bgne_ShareIncentivePlan2011Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d7754f2f-d53f-4dc4-a3ac-f383f1bd23f3" xlink:to="loc_bgne_ShareIncentivePlan2011Member_f6e800ff-fbc3-4163-81e9-0221e5487cc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ThirdAmendedAndRestated2016PlanMember_e18be0c2-41d3-4c80-940d-57c86eebb6b5" xlink:href="bgne-20241231.xsd#bgne_ThirdAmendedAndRestated2016PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d7754f2f-d53f-4dc4-a3ac-f383f1bd23f3" xlink:to="loc_bgne_ThirdAmendedAndRestated2016PlanMember_e18be0c2-41d3-4c80-940d-57c86eebb6b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_30a465aa-ff40-4aef-95a4-69404e6e705c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_99efa4da-cb31-4642-b998-2f43a1d2d250" xlink:to="loc_us-gaap_AwardTypeAxis_30a465aa-ff40-4aef-95a4-69404e6e705c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30a465aa-ff40-4aef-95a4-69404e6e705c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_30a465aa-ff40-4aef-95a4-69404e6e705c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_30a465aa-ff40-4aef-95a4-69404e6e705c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d78a06c-aaeb-4162-ab79-3288899a9cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_30a465aa-ff40-4aef-95a4-69404e6e705c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d78a06c-aaeb-4162-ab79-3288899a9cbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_60800ce3-e998-4b9c-bfa3-b44a2126e9e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d78a06c-aaeb-4162-ab79-3288899a9cbb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_60800ce3-e998-4b9c-bfa3-b44a2126e9e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_3bc198ca-d616-4acf-acfb-80a07ecc4934" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ad4261d-2210-45f9-ac0e-7e0aaf83e3a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_3bc198ca-d616-4acf-acfb-80a07ecc4934" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7fa397a7-8a9f-4be4-ab14-61ca3b10bc58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_3bc198ca-d616-4acf-acfb-80a07ecc4934" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7fa397a7-8a9f-4be4-ab14-61ca3b10bc58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriod_dd603e24-31d6-42a6-b805-28b8a421aba7" xlink:href="bgne-20241231.xsd#bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_3bc198ca-d616-4acf-acfb-80a07ecc4934" xlink:to="loc_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriod_dd603e24-31d6-42a6-b805-28b8a421aba7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_415f84cf-38c8-4065-8492-c28b260751f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_3bc198ca-d616-4acf-acfb-80a07ecc4934" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_415f84cf-38c8-4065-8492-c28b260751f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_ef3e5dea-05d2-41f4-9f4a-4acc3b017325" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_3bc198ca-d616-4acf-acfb-80a07ecc4934" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_ef3e5dea-05d2-41f4-9f4a-4acc3b017325" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f78040a7-e954-42b3-8ef5-6d83b282894b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_3bc198ca-d616-4acf-acfb-80a07ecc4934" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f78040a7-e954-42b3-8ef5-6d83b282894b" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ShareBasedCompensation2018InducementEquityPlanDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ShareBasedCompensation2018InducementEquityPlanDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/ShareBasedCompensation2018InducementEquityPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8707993-7ed7-4ee1-a3f5-047ba507f844" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4809eca-3cdb-4aef-bd8a-2d5e90b9696f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8707993-7ed7-4ee1-a3f5-047ba507f844" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4809eca-3cdb-4aef-bd8a-2d5e90b9696f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_be1dacc9-f1fe-44d0-bc73-48ca3a3bf456" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4809eca-3cdb-4aef-bd8a-2d5e90b9696f" xlink:to="loc_us-gaap_PlanNameAxis_be1dacc9-f1fe-44d0-bc73-48ca3a3bf456" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_be1dacc9-f1fe-44d0-bc73-48ca3a3bf456_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_be1dacc9-f1fe-44d0-bc73-48ca3a3bf456" xlink:to="loc_us-gaap_PlanNameDomain_be1dacc9-f1fe-44d0-bc73-48ca3a3bf456_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b9ffb85d-1d66-4205-8702-00697d69f429" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_be1dacc9-f1fe-44d0-bc73-48ca3a3bf456" xlink:to="loc_us-gaap_PlanNameDomain_b9ffb85d-1d66-4205-8702-00697d69f429" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_InducementEquityPlan2018Member_e1d185cc-b4d7-4d8b-8316-17b1540c84e6" xlink:href="bgne-20241231.xsd#bgne_InducementEquityPlan2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_b9ffb85d-1d66-4205-8702-00697d69f429" xlink:to="loc_bgne_InducementEquityPlan2018Member_e1d185cc-b4d7-4d8b-8316-17b1540c84e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ba89ee7b-1f5a-4636-be24-643bcbacd155" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8707993-7ed7-4ee1-a3f5-047ba507f844" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ba89ee7b-1f5a-4636-be24-643bcbacd155" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ShareBasedCompensation2018EmployeeSharePurchasePlanDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ShareBasedCompensation2018EmployeeSharePurchasePlanDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/ShareBasedCompensation2018EmployeeSharePurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e120cd7-8a03-4be3-a8f6-7fc3257143b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e31f6a33-a0f9-4c05-b573-29b6f9c2af34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e120cd7-8a03-4be3-a8f6-7fc3257143b6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e31f6a33-a0f9-4c05-b573-29b6f9c2af34" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f8d23593-d99a-4350-a850-4f32877f42ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e31f6a33-a0f9-4c05-b573-29b6f9c2af34" xlink:to="loc_us-gaap_PlanNameAxis_f8d23593-d99a-4350-a850-4f32877f42ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f8d23593-d99a-4350-a850-4f32877f42ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_f8d23593-d99a-4350-a850-4f32877f42ac" xlink:to="loc_us-gaap_PlanNameDomain_f8d23593-d99a-4350-a850-4f32877f42ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_52c47a57-6899-4841-84c3-263eecb8f598" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_f8d23593-d99a-4350-a850-4f32877f42ac" xlink:to="loc_us-gaap_PlanNameDomain_52c47a57-6899-4841-84c3-263eecb8f598" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_EmployeeSharePurchasePlan2018Member_5e98f909-7eb2-4763-a9ff-9032cd794a14" xlink:href="bgne-20241231.xsd#bgne_EmployeeSharePurchasePlan2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_52c47a57-6899-4841-84c3-263eecb8f598" xlink:to="loc_bgne_EmployeeSharePurchasePlan2018Member_5e98f909-7eb2-4763-a9ff-9032cd794a14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c1227679-90e6-43e7-9d5d-ad0e970d355e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e120cd7-8a03-4be3-a8f6-7fc3257143b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c1227679-90e6-43e7-9d5d-ad0e970d355e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_9c3ac6cb-374e-4d3c-b31c-d7c50976ded8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e120cd7-8a03-4be3-a8f6-7fc3257143b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_9c3ac6cb-374e-4d3c-b31c-d7c50976ded8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_ed45fc50-14b8-48be-be61-228137e7cc66" xlink:href="bgne-20241231.xsd#bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e120cd7-8a03-4be3-a8f6-7fc3257143b6" xlink:to="loc_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_ed45fc50-14b8-48be-be61-228137e7cc66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountOnPurchasePriceOfCommonStockPercent_12380a31-f2ee-4340-a55c-11a8e8841ecc" xlink:href="bgne-20241231.xsd#bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountOnPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e120cd7-8a03-4be3-a8f6-7fc3257143b6" xlink:to="loc_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountOnPurchasePriceOfCommonStockPercent_12380a31-f2ee-4340-a55c-11a8e8841ecc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_MaximumPercentageOfEligibleEarningsSetSideToPurchaseOrdinaryShares_ad77c31f-7a31-4f2a-bb22-64fe27282a2c" xlink:href="bgne-20241231.xsd#bgne_MaximumPercentageOfEligibleEarningsSetSideToPurchaseOrdinaryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e120cd7-8a03-4be3-a8f6-7fc3257143b6" xlink:to="loc_bgne_MaximumPercentageOfEligibleEarningsSetSideToPurchaseOrdinaryShares_ad77c31f-7a31-4f2a-bb22-64fe27282a2c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberOfAvailableSharesAvailableForFutureIssuance_519207ca-31fe-4fd1-9084-d56ff69180e8" xlink:href="bgne-20241231.xsd#bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberOfAvailableSharesAvailableForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e120cd7-8a03-4be3-a8f6-7fc3257143b6" xlink:to="loc_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberOfAvailableSharesAvailableForFutureIssuance_519207ca-31fe-4fd1-9084-d56ff69180e8" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ShareBasedCompensationSharesIssuedUnderEmployeeSharePurchasePlanDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ShareBasedCompensationSharesIssuedUnderEmployeeSharePurchasePlanDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/ShareBasedCompensationSharesIssuedUnderEmployeeSharePurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d53b6d61-c332-4383-86c8-35deea33fec5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32b0e9f1-a3ff-4e07-ad06-8d6a6826c8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d53b6d61-c332-4383-86c8-35deea33fec5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32b0e9f1-a3ff-4e07-ad06-8d6a6826c8f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_c4a133a2-6b49-4db8-ad1d-3422f1189cef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32b0e9f1-a3ff-4e07-ad06-8d6a6826c8f7" xlink:to="loc_us-gaap_PlanNameAxis_c4a133a2-6b49-4db8-ad1d-3422f1189cef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c4a133a2-6b49-4db8-ad1d-3422f1189cef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_c4a133a2-6b49-4db8-ad1d-3422f1189cef" xlink:to="loc_us-gaap_PlanNameDomain_c4a133a2-6b49-4db8-ad1d-3422f1189cef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_78d3cc78-8587-4ed6-be32-9296b49d5f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_c4a133a2-6b49-4db8-ad1d-3422f1189cef" xlink:to="loc_us-gaap_PlanNameDomain_78d3cc78-8587-4ed6-be32-9296b49d5f6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_EmployeeSharePurchasePlan2018Member_1ab9496f-b418-4b00-ba2a-da743718ec75" xlink:href="bgne-20241231.xsd#bgne_EmployeeSharePurchasePlan2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_78d3cc78-8587-4ed6-be32-9296b49d5f6d" xlink:to="loc_bgne_EmployeeSharePurchasePlan2018Member_1ab9496f-b418-4b00-ba2a-da743718ec75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_302ea9b8-fd63-46ab-9b00-13192ee57c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d53b6d61-c332-4383-86c8-35deea33fec5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_302ea9b8-fd63-46ab-9b00-13192ee57c7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_SharePriceAmericanDepositoryShares_ef12e6a0-0b9b-4264-afab-491549ca79f4" xlink:href="bgne-20241231.xsd#bgne_SharePriceAmericanDepositoryShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d53b6d61-c332-4383-86c8-35deea33fec5" xlink:to="loc_bgne_SharePriceAmericanDepositoryShares_ef12e6a0-0b9b-4264-afab-491549ca79f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_d1182f1f-959b-4540-8e49-364686b47585" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d53b6d61-c332-4383-86c8-35deea33fec5" xlink:to="loc_us-gaap_SharePrice_d1182f1f-959b-4540-8e49-364686b47585" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice_5c0d951a-b07a-4a96-bc4a-a80ab2693617" xlink:href="bgne-20241231.xsd#bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d53b6d61-c332-4383-86c8-35deea33fec5" xlink:to="loc_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice_5c0d951a-b07a-4a96-bc4a-a80ab2693617" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice_048aae94-04c4-44d2-b571-2108550be5fb" xlink:href="bgne-20241231.xsd#bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d53b6d61-c332-4383-86c8-35deea33fec5" xlink:to="loc_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice_048aae94-04c4-44d2-b571-2108550be5fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_2de0f653-c4fe-4f10-94ac-42879a2434cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d53b6d61-c332-4383-86c8-35deea33fec5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_2de0f653-c4fe-4f10-94ac-42879a2434cf" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ShareBasedCompensationOptionsandRestrictedSharesandRestrictedStockUnitsVestingPeriodsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ShareBasedCompensationOptionsandRestrictedSharesandRestrictedStockUnitsVestingPeriodsDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/ShareBasedCompensationOptionsandRestrictedSharesandRestrictedStockUnitsVestingPeriodsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8fa55366-1498-4ad1-ba23-0fb0ec016bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d220c7b5-699f-414c-8d99-d82cffce47d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8fa55366-1498-4ad1-ba23-0fb0ec016bc5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d220c7b5-699f-414c-8d99-d82cffce47d0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_50afd271-b213-46e0-9318-f1ee37c07b86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d220c7b5-699f-414c-8d99-d82cffce47d0" xlink:to="loc_us-gaap_AwardTypeAxis_50afd271-b213-46e0-9318-f1ee37c07b86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50afd271-b213-46e0-9318-f1ee37c07b86_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_50afd271-b213-46e0-9318-f1ee37c07b86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_50afd271-b213-46e0-9318-f1ee37c07b86_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a74a4bdd-ec98-4752-812d-a10a55d74ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_50afd271-b213-46e0-9318-f1ee37c07b86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a74a4bdd-ec98-4752-812d-a10a55d74ee0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_149a9e26-fb6a-41c0-ba8d-40454f7b73b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a74a4bdd-ec98-4752-812d-a10a55d74ee0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_149a9e26-fb6a-41c0-ba8d-40454f7b73b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_653c9d22-8a35-4dac-82f6-d460c719d627" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a74a4bdd-ec98-4752-812d-a10a55d74ee0" xlink:to="loc_us-gaap_RestrictedStockMember_653c9d22-8a35-4dac-82f6-d460c719d627" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_59029a31-761b-4c60-bb6a-ab5ee2a5582c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a74a4bdd-ec98-4752-812d-a10a55d74ee0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_59029a31-761b-4c60-bb6a-ab5ee2a5582c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6a7755f8-6ba7-441c-92ea-8e3f38b3b4ba" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d220c7b5-699f-414c-8d99-d82cffce47d0" xlink:to="loc_srt_RangeAxis_6a7755f8-6ba7-441c-92ea-8e3f38b3b4ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6a7755f8-6ba7-441c-92ea-8e3f38b3b4ba_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6a7755f8-6ba7-441c-92ea-8e3f38b3b4ba" xlink:to="loc_srt_RangeMember_6a7755f8-6ba7-441c-92ea-8e3f38b3b4ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_08d285bd-ea3b-4cc6-9ee6-222557572959" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6a7755f8-6ba7-441c-92ea-8e3f38b3b4ba" xlink:to="loc_srt_RangeMember_08d285bd-ea3b-4cc6-9ee6-222557572959" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b185dc19-fab4-40d1-b0cf-7442de509fa1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_08d285bd-ea3b-4cc6-9ee6-222557572959" xlink:to="loc_srt_MinimumMember_b185dc19-fab4-40d1-b0cf-7442de509fa1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0598bf0b-e8ad-4edb-b39d-6f781fda1063" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_08d285bd-ea3b-4cc6-9ee6-222557572959" xlink:to="loc_srt_MaximumMember_0598bf0b-e8ad-4edb-b39d-6f781fda1063" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ef3d7b33-c42f-4b6f-b5c9-f303d1d5f36c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8fa55366-1498-4ad1-ba23-0fb0ec016bc5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ef3d7b33-c42f-4b6f-b5c9-f303d1d5f36c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8df2eeeb-2684-46a5-bf71-dd269215c70f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8fa55366-1498-4ad1-ba23-0fb0ec016bc5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8df2eeeb-2684-46a5-bf71-dd269215c70f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ShareBasedCompensationShareOptionRollforwardDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_912144c9-2b36-4426-a327-ab4da7e039a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d64fcc59-7701-4f00-a44e-33438bc79fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_912144c9-2b36-4426-a327-ab4da7e039a1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d64fcc59-7701-4f00-a44e-33438bc79fb3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_86ef4d52-f16f-4046-9f7c-ffcdee1f085e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d64fcc59-7701-4f00-a44e-33438bc79fb3" xlink:to="loc_us-gaap_AwardTypeAxis_86ef4d52-f16f-4046-9f7c-ffcdee1f085e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_86ef4d52-f16f-4046-9f7c-ffcdee1f085e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_86ef4d52-f16f-4046-9f7c-ffcdee1f085e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_86ef4d52-f16f-4046-9f7c-ffcdee1f085e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c368421-abf1-47a3-ab5a-c5916811a1b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_86ef4d52-f16f-4046-9f7c-ffcdee1f085e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c368421-abf1-47a3-ab5a-c5916811a1b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c78f3b83-a1a1-41ee-9789-0ab92710ddcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c368421-abf1-47a3-ab5a-c5916811a1b3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c78f3b83-a1a1-41ee-9789-0ab92710ddcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_788f6f10-5a7f-4019-ba9f-111994a88139" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_912144c9-2b36-4426-a327-ab4da7e039a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_788f6f10-5a7f-4019-ba9f-111994a88139" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_68945fce-7090-45e1-a9f8-974a08e40047" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_788f6f10-5a7f-4019-ba9f-111994a88139" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_68945fce-7090-45e1-a9f8-974a08e40047" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3b273f8b-91ff-49ff-9776-207392a73275" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_788f6f10-5a7f-4019-ba9f-111994a88139" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3b273f8b-91ff-49ff-9776-207392a73275" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0844c46c-e3dd-4c21-8128-9241e72e9633" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_788f6f10-5a7f-4019-ba9f-111994a88139" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0844c46c-e3dd-4c21-8128-9241e72e9633" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_64c879ee-ca5a-4f14-a70f-3df965823d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_788f6f10-5a7f-4019-ba9f-111994a88139" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_64c879ee-ca5a-4f14-a70f-3df965823d1a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4b15edf1-f960-4306-a6c4-09014f1fb865" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_453a1807-2694-47c0-a25f-ef6f938167c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_912144c9-2b36-4426-a327-ab4da7e039a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_453a1807-2694-47c0-a25f-ef6f938167c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f0233263-5ec4-4f89-8d68-678c9f380ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_912144c9-2b36-4426-a327-ab4da7e039a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f0233263-5ec4-4f89-8d68-678c9f380ba9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7fca11e3-a650-46bd-bcee-603e31244282" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_912144c9-2b36-4426-a327-ab4da7e039a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7fca11e3-a650-46bd-bcee-603e31244282" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3f678de2-8dae-4a91-aca1-ee5a98f4d54c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7fca11e3-a650-46bd-bcee-603e31244282" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3f678de2-8dae-4a91-aca1-ee5a98f4d54c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_375cdbd1-b5be-4426-9a55-167366347b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7fca11e3-a650-46bd-bcee-603e31244282" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_375cdbd1-b5be-4426-9a55-167366347b6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f5a28ec6-36da-460b-a8c3-4e9d5c74ef5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7fca11e3-a650-46bd-bcee-603e31244282" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f5a28ec6-36da-460b-a8c3-4e9d5c74ef5d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_420bfbe3-698c-4b74-b53b-f20014311db0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7fca11e3-a650-46bd-bcee-603e31244282" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_420bfbe3-698c-4b74-b53b-f20014311db0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_34587230-c50f-43ef-a69e-24bdaa97a5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0b86fcc2-1f12-4808-a4e8-e4c803740fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_912144c9-2b36-4426-a327-ab4da7e039a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0b86fcc2-1f12-4808-a4e8-e4c803740fc6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_358234b1-b86f-469b-be03-3af8e3fb960b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_912144c9-2b36-4426-a327-ab4da7e039a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_358234b1-b86f-469b-be03-3af8e3fb960b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_c3264cb3-bbeb-4764-bbc6-2dba0ed35b25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_912144c9-2b36-4426-a327-ab4da7e039a1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_c3264cb3-bbeb-4764-bbc6-2dba0ed35b25" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_825b6817-c51b-4cda-bc87-d602b901a0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_c3264cb3-bbeb-4764-bbc6-2dba0ed35b25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_825b6817-c51b-4cda-bc87-d602b901a0ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_81ba04a0-2a18-45ac-b518-924d3cbc8587" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_912144c9-2b36-4426-a327-ab4da7e039a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_81ba04a0-2a18-45ac-b518-924d3cbc8587" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0ad77356-5a97-4463-b1a7-06aa4fc30c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_81ba04a0-2a18-45ac-b518-924d3cbc8587" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0ad77356-5a97-4463-b1a7-06aa4fc30c2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_65a7e1ca-3c9e-4a70-aa7e-7f3281884d30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_81ba04a0-2a18-45ac-b518-924d3cbc8587" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_65a7e1ca-3c9e-4a70-aa7e-7f3281884d30" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_db6a89a1-c9f8-4720-be63-cd5eee9551a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_81ba04a0-2a18-45ac-b518-924d3cbc8587" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_db6a89a1-c9f8-4720-be63-cd5eee9551a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_cb449fca-0165-4502-8a2b-96233c2e1d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_912144c9-2b36-4426-a327-ab4da7e039a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_cb449fca-0165-4502-8a2b-96233c2e1d1a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f6dd14fe-92c9-44c3-b2a2-6933183e7a02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_cb449fca-0165-4502-8a2b-96233c2e1d1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f6dd14fe-92c9-44c3-b2a2-6933183e7a02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_89f7bb35-95e3-4d69-984e-e6b4ea7a3ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_cb449fca-0165-4502-8a2b-96233c2e1d1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_89f7bb35-95e3-4d69-984e-e6b4ea7a3ef5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_cbe24967-756e-4ef0-a641-cfa27481f2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_cb449fca-0165-4502-8a2b-96233c2e1d1a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_cbe24967-756e-4ef0-a641-cfa27481f2f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8ca92b7a-4be1-4df8-8ac2-aee1b2168a94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_cb449fca-0165-4502-8a2b-96233c2e1d1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8ca92b7a-4be1-4df8-8ac2-aee1b2168a94" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShareBasedPaymentArrangementNonvestedAwardOptionNumberOfShares_6e08a13f-f52d-4b5d-9a2c-438132c7bdf8" xlink:href="bgne-20241231.xsd#bgne_ShareBasedPaymentArrangementNonvestedAwardOptionNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_912144c9-2b36-4426-a327-ab4da7e039a1" xlink:to="loc_bgne_ShareBasedPaymentArrangementNonvestedAwardOptionNumberOfShares_6e08a13f-f52d-4b5d-9a2c-438132c7bdf8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_10283972-be45-459b-88a1-c44cffc9d077" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_912144c9-2b36-4426-a327-ab4da7e039a1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_10283972-be45-459b-88a1-c44cffc9d077" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c9355cf4-c8f9-4e07-ab97-5aec14dceb14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_912144c9-2b36-4426-a327-ab4da7e039a1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c9355cf4-c8f9-4e07-ab97-5aec14dceb14" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_3abe3ff5-4a02-461b-92ae-cb8f184dd75c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_912144c9-2b36-4426-a327-ab4da7e039a1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_3abe3ff5-4a02-461b-92ae-cb8f184dd75c" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ShareBasedCompensationFairValueAssumptionsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ShareBasedCompensationFairValueAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/ShareBasedCompensationFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_215441e9-1885-4159-ad16-35d60abfdc6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72c5e984-9fed-498d-830b-d326618a0947" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_215441e9-1885-4159-ad16-35d60abfdc6a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72c5e984-9fed-498d-830b-d326618a0947" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2054f0ff-3c75-4491-b53e-2d3da89d3dff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72c5e984-9fed-498d-830b-d326618a0947" xlink:to="loc_us-gaap_AwardTypeAxis_2054f0ff-3c75-4491-b53e-2d3da89d3dff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2054f0ff-3c75-4491-b53e-2d3da89d3dff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2054f0ff-3c75-4491-b53e-2d3da89d3dff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2054f0ff-3c75-4491-b53e-2d3da89d3dff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b1b3e45b-32ee-44fe-b051-d8ab62ef3ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2054f0ff-3c75-4491-b53e-2d3da89d3dff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b1b3e45b-32ee-44fe-b051-d8ab62ef3ce6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c6afdd3e-bb50-4333-9887-ffe62729cc66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b1b3e45b-32ee-44fe-b051-d8ab62ef3ce6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c6afdd3e-bb50-4333-9887-ffe62729cc66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_44740395-d6a8-4446-b54e-76c939efba06" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72c5e984-9fed-498d-830b-d326618a0947" xlink:to="loc_srt_RangeAxis_44740395-d6a8-4446-b54e-76c939efba06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_44740395-d6a8-4446-b54e-76c939efba06_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_44740395-d6a8-4446-b54e-76c939efba06" xlink:to="loc_srt_RangeMember_44740395-d6a8-4446-b54e-76c939efba06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_16f4e979-4c7b-4e13-b749-7e4248c69fa3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_44740395-d6a8-4446-b54e-76c939efba06" xlink:to="loc_srt_RangeMember_16f4e979-4c7b-4e13-b749-7e4248c69fa3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1d483379-0392-4814-8686-a52d1a5427df" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_16f4e979-4c7b-4e13-b749-7e4248c69fa3" xlink:to="loc_srt_MinimumMember_1d483379-0392-4814-8686-a52d1a5427df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_601d2875-d028-4838-90e2-ea693d4e5da9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_16f4e979-4c7b-4e13-b749-7e4248c69fa3" xlink:to="loc_srt_MaximumMember_601d2875-d028-4838-90e2-ea693d4e5da9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_59e387e4-68e9-4081-880c-80f7a419622c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_215441e9-1885-4159-ad16-35d60abfdc6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_59e387e4-68e9-4081-880c-80f7a419622c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_48ff6230-2447-449d-bdea-353f0636164e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_59e387e4-68e9-4081-880c-80f7a419622c" xlink:to="loc_us-gaap_SharePrice_48ff6230-2447-449d-bdea-353f0636164e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1041840a-318d-4df7-9396-84582c2cbe4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_59e387e4-68e9-4081-880c-80f7a419622c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1041840a-318d-4df7-9396-84582c2cbe4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2c9086d1-a866-4444-a5f3-5f539a0e5492" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_59e387e4-68e9-4081-880c-80f7a419622c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2c9086d1-a866-4444-a5f3-5f539a0e5492" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum_da75a87c-6daf-4f8c-ab6c-a660a6f01360" xlink:href="bgne-20241231.xsd#bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_59e387e4-68e9-4081-880c-80f7a419622c" xlink:to="loc_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum_da75a87c-6daf-4f8c-ab6c-a660a6f01360" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_c4ba8a7c-bef2-4246-a19c-0a5aee49eb42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_59e387e4-68e9-4081-880c-80f7a419622c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_c4ba8a7c-bef2-4246-a19c-0a5aee49eb42" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_59ab6d2e-f91b-4d49-92b2-90fa6d78e30d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_59e387e4-68e9-4081-880c-80f7a419622c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_59ab6d2e-f91b-4d49-92b2-90fa6d78e30d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d6dd8d61-5632-47c7-a61e-78f330dde5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_59e387e4-68e9-4081-880c-80f7a419622c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d6dd8d61-5632-47c7-a61e-78f330dde5b4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8987a95b-a47c-43b4-b563-0f1b2eaa729e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_59e387e4-68e9-4081-880c-80f7a419622c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8987a95b-a47c-43b4-b563-0f1b2eaa729e" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ShareBasedCompensationRestrictedShareUnitsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ShareBasedCompensationRestrictedShareUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/ShareBasedCompensationRestrictedShareUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a64c00-6ca5-4f2a-b7e9-c69f8fe229e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deda8de9-bfd9-4b10-b9f2-5d985b4ef6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a64c00-6ca5-4f2a-b7e9-c69f8fe229e6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deda8de9-bfd9-4b10-b9f2-5d985b4ef6c3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9542f629-33f0-4f48-89cb-766dfdbfe52f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deda8de9-bfd9-4b10-b9f2-5d985b4ef6c3" xlink:to="loc_us-gaap_AwardTypeAxis_9542f629-33f0-4f48-89cb-766dfdbfe52f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9542f629-33f0-4f48-89cb-766dfdbfe52f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9542f629-33f0-4f48-89cb-766dfdbfe52f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9542f629-33f0-4f48-89cb-766dfdbfe52f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a5c35ec-2f9d-4255-8f80-96cbf394181c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9542f629-33f0-4f48-89cb-766dfdbfe52f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a5c35ec-2f9d-4255-8f80-96cbf394181c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2191502f-6d22-40a4-ae74-9fac062a0876" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a5c35ec-2f9d-4255-8f80-96cbf394181c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2191502f-6d22-40a4-ae74-9fac062a0876" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_735ca510-df58-433f-9bd6-14059ec521eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a64c00-6ca5-4f2a-b7e9-c69f8fe229e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_735ca510-df58-433f-9bd6-14059ec521eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_368c676c-f014-43d3-8471-e4b4d1ffce99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_735ca510-df58-433f-9bd6-14059ec521eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_368c676c-f014-43d3-8471-e4b4d1ffce99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4e28c6be-da1f-49dd-8945-432463b67a93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_735ca510-df58-433f-9bd6-14059ec521eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4e28c6be-da1f-49dd-8945-432463b67a93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_25da48a7-69f6-49fa-a293-7e7a14f13ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_735ca510-df58-433f-9bd6-14059ec521eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_25da48a7-69f6-49fa-a293-7e7a14f13ef1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9ba54d6d-5731-4643-99b8-0970dc9a2764" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_735ca510-df58-433f-9bd6-14059ec521eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9ba54d6d-5731-4643-99b8-0970dc9a2764" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b5da67ff-f654-4ff4-9313-b14cf15f327e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestOutstandingNumber_07005d69-fbee-4b31-aca4-b95f49845323" xlink:href="bgne-20241231.xsd#bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a64c00-6ca5-4f2a-b7e9-c69f8fe229e6" xlink:to="loc_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestOutstandingNumber_07005d69-fbee-4b31-aca4-b95f49845323" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_98c18fb8-e7f9-4d40-9b7e-4b5d91b7242e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a64c00-6ca5-4f2a-b7e9-c69f8fe229e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_98c18fb8-e7f9-4d40-9b7e-4b5d91b7242e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0b0c3666-545c-438f-b8b2-bd4b9c0b81e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_98c18fb8-e7f9-4d40-9b7e-4b5d91b7242e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0b0c3666-545c-438f-b8b2-bd4b9c0b81e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e91e3fad-a03a-428d-ba59-59a37f5f2812" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_98c18fb8-e7f9-4d40-9b7e-4b5d91b7242e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e91e3fad-a03a-428d-ba59-59a37f5f2812" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5e47641c-88b7-44f7-a498-bfbe34543fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_98c18fb8-e7f9-4d40-9b7e-4b5d91b7242e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5e47641c-88b7-44f7-a498-bfbe34543fbf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_569ecdf3-6ff5-4c34-be92-92dde8f1a3e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_98c18fb8-e7f9-4d40-9b7e-4b5d91b7242e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_569ecdf3-6ff5-4c34-be92-92dde8f1a3e2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d390192d-f570-41c1-a53f-85356673e027" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue_58e6df25-9736-4e15-91bc-1d2dd79cdbaf" xlink:href="bgne-20241231.xsd#bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a64c00-6ca5-4f2a-b7e9-c69f8fe229e6" xlink:to="loc_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue_58e6df25-9736-4e15-91bc-1d2dd79cdbaf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_67faf673-c988-43b0-a3be-5cff17f8888e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a64c00-6ca5-4f2a-b7e9-c69f8fe229e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_67faf673-c988-43b0-a3be-5cff17f8888e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c21545b9-c908-4020-9ea8-9dff6b202ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_67faf673-c988-43b0-a3be-5cff17f8888e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c21545b9-c908-4020-9ea8-9dff6b202ca6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d2b08fb5-66f8-426a-abe6-51c4784025fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_67faf673-c988-43b0-a3be-5cff17f8888e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d2b08fb5-66f8-426a-abe6-51c4784025fe" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ShareBasedCompensationSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ShareBasedCompensationSharebasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/ShareBasedCompensationSharebasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3e644949-a0ad-4cf2-9cca-046ba6027ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bda29dd6-68a9-4096-9715-9309f2619a66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3e644949-a0ad-4cf2-9cca-046ba6027ab7" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bda29dd6-68a9-4096-9715-9309f2619a66" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_bc09f224-0ea7-45c8-8d98-7942e274d705" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bda29dd6-68a9-4096-9715-9309f2619a66" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_bc09f224-0ea7-45c8-8d98-7942e274d705" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_bc09f224-0ea7-45c8-8d98-7942e274d705_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bc09f224-0ea7-45c8-8d98-7942e274d705" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_bc09f224-0ea7-45c8-8d98-7942e274d705_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_514ecdfd-05ce-476f-a489-873fef714361" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bc09f224-0ea7-45c8-8d98-7942e274d705" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_514ecdfd-05ce-476f-a489-873fef714361" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ca5cdc58-657a-4edb-a6c7-e40977870286" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_514ecdfd-05ce-476f-a489-873fef714361" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ca5cdc58-657a-4edb-a6c7-e40977870286" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_94dea62d-cf56-45e4-9a2e-d9cb44b3ab27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_514ecdfd-05ce-476f-a489-873fef714361" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_94dea62d-cf56-45e4-9a2e-d9cb44b3ab27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_726edf2a-6a38-486a-9b77-64a3575dcd16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3e644949-a0ad-4cf2-9cca-046ba6027ab7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_726edf2a-6a38-486a-9b77-64a3575dcd16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d9a0b6a7-d800-4cab-b186-98ba4f4a53d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_726edf2a-6a38-486a-9b77-64a3575dcd16" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d9a0b6a7-d800-4cab-b186-98ba4f4a53d3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#AccumulatedOtherComprehensiveLossIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_076a65b2-ae9f-4984-8d5b-0a35ebfb57b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_5c59be1f-fe7d-4701-bec6-a2baa8f710a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_076a65b2-ae9f-4984-8d5b-0a35ebfb57b6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_5c59be1f-fe7d-4701-bec6-a2baa8f710a7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1844aed4-62ae-4bd3-9ef2-388def6f488f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_5c59be1f-fe7d-4701-bec6-a2baa8f710a7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1844aed4-62ae-4bd3-9ef2-388def6f488f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1844aed4-62ae-4bd3-9ef2-388def6f488f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1844aed4-62ae-4bd3-9ef2-388def6f488f" xlink:to="loc_us-gaap_EquityComponentDomain_1844aed4-62ae-4bd3-9ef2-388def6f488f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1527ecc2-515f-4146-8e53-7e995f2053ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1844aed4-62ae-4bd3-9ef2-388def6f488f" xlink:to="loc_us-gaap_EquityComponentDomain_1527ecc2-515f-4146-8e53-7e995f2053ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_66904ca5-55e7-41de-a628-526cbd89521c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1527ecc2-515f-4146-8e53-7e995f2053ff" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_66904ca5-55e7-41de-a628-526cbd89521c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_af945e0b-4cc1-43a6-b1e8-250206df823c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_66904ca5-55e7-41de-a628-526cbd89521c" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_af945e0b-4cc1-43a6-b1e8-250206df823c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_4128ad1c-914b-4ea1-8e44-2c71b5e63fec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_66904ca5-55e7-41de-a628-526cbd89521c" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_4128ad1c-914b-4ea1-8e44-2c71b5e63fec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_a9263f72-99f0-459e-b192-48fec70fb094" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_66904ca5-55e7-41de-a628-526cbd89521c" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_a9263f72-99f0-459e-b192-48fec70fb094" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_9dfdbd31-da00-41f6-85f9-b63e95912101" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_076a65b2-ae9f-4984-8d5b-0a35ebfb57b6" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_9dfdbd31-da00-41f6-85f9-b63e95912101" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_229f2911-0070-4c59-9666-c6484a6da003" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_9dfdbd31-da00-41f6-85f9-b63e95912101" xlink:to="loc_us-gaap_StockholdersEquity_229f2911-0070-4c59-9666-c6484a6da003" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_6fd9ce49-9623-4ae0-8ea6-deed439728ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_9dfdbd31-da00-41f6-85f9-b63e95912101" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_6fd9ce49-9623-4ae0-8ea6-deed439728ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_0b8be900-9717-4655-bb09-1fec3f37aea5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_9dfdbd31-da00-41f6-85f9-b63e95912101" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_0b8be900-9717-4655-bb09-1fec3f37aea5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e27d6f79-e5aa-4448-b3d9-ce1addbd787f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_9dfdbd31-da00-41f6-85f9-b63e95912101" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e27d6f79-e5aa-4448-b3d9-ce1addbd787f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c279dbf3-9d97-449e-a813-9de07f36dcbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ShareholdersEquityDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ShareholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/ShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_e886818a-0d09-4bfc-a641-cd98b2764131" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_23b51665-377e-4000-abd6-716cc24eb670" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e886818a-0d09-4bfc-a641-cd98b2764131" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_23b51665-377e-4000-abd6-716cc24eb670" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1e10f03c-9ffb-412c-be16-db267ed61121" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_23b51665-377e-4000-abd6-716cc24eb670" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1e10f03c-9ffb-412c-be16-db267ed61121" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1e10f03c-9ffb-412c-be16-db267ed61121_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1e10f03c-9ffb-412c-be16-db267ed61121" xlink:to="loc_us-gaap_EquityComponentDomain_1e10f03c-9ffb-412c-be16-db267ed61121_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_03648c5a-935c-4a25-96ef-3bcf2ba6238b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1e10f03c-9ffb-412c-be16-db267ed61121" xlink:to="loc_us-gaap_EquityComponentDomain_03648c5a-935c-4a25-96ef-3bcf2ba6238b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0d937521-34a1-4afd-8642-5e891dbf30f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_03648c5a-935c-4a25-96ef-3bcf2ba6238b" xlink:to="loc_us-gaap_CommonStockMember_0d937521-34a1-4afd-8642-5e891dbf30f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_77cd8a81-803f-4a2e-b5ad-f31af1d412b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e886818a-0d09-4bfc-a641-cd98b2764131" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_77cd8a81-803f-4a2e-b5ad-f31af1d412b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_febe996f-7d68-4189-a098-01d9e32d93b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e886818a-0d09-4bfc-a641-cd98b2764131" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_febe996f-7d68-4189-a098-01d9e32d93b4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/RestrictedNetAssetsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#RestrictedNetAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/RestrictedNetAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_0d4dc035-c76d-494e-8d3e-b068213dac6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9e265c4d-e0ae-41f2-ae8c-4eb146fe8503" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0d4dc035-c76d-494e-8d3e-b068213dac6a" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9e265c4d-e0ae-41f2-ae8c-4eb146fe8503" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_1f55a4fb-0cff-4fe1-b7e1-8678904386c0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9e265c4d-e0ae-41f2-ae8c-4eb146fe8503" xlink:to="loc_srt_StatementGeographicalAxis_1f55a4fb-0cff-4fe1-b7e1-8678904386c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1f55a4fb-0cff-4fe1-b7e1-8678904386c0_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_1f55a4fb-0cff-4fe1-b7e1-8678904386c0" xlink:to="loc_srt_SegmentGeographicalDomain_1f55a4fb-0cff-4fe1-b7e1-8678904386c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_66ffe7f0-585a-40a5-b3d2-fe30fedb3d5a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_1f55a4fb-0cff-4fe1-b7e1-8678904386c0" xlink:to="loc_srt_SegmentGeographicalDomain_66ffe7f0-585a-40a5-b3d2-fe30fedb3d5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_f31f0289-cfd3-42cc-a5e9-bb11c15866ea" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_66ffe7f0-585a-40a5-b3d2-fe30fedb3d5a" xlink:to="loc_country_CN_f31f0289-cfd3-42cc-a5e9-bb11c15866ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RestrictedNetAssetsAbstract_1b2e10bc-2760-4d89-8362-c08788f0ac38" xlink:href="bgne-20241231.xsd#bgne_RestrictedNetAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0d4dc035-c76d-494e-8d3e-b068213dac6a" xlink:to="loc_bgne_RestrictedNetAssetsAbstract_1b2e10bc-2760-4d89-8362-c08788f0ac38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage_f5159140-5b86-4cc5-a97d-712df8cca201" xlink:href="bgne-20241231.xsd#bgne_RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bgne_RestrictedNetAssetsAbstract_1b2e10bc-2760-4d89-8362-c08788f0ac38" xlink:to="loc_bgne_RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage_f5159140-5b86-4cc5-a97d-712df8cca201" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RestrictedNetAssetsRequiredStatutoryReserveAsPercentageOfRegisteredCapital_865ce712-805f-432c-b559-76a14a1c53fc" xlink:href="bgne-20241231.xsd#bgne_RestrictedNetAssetsRequiredStatutoryReserveAsPercentageOfRegisteredCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bgne_RestrictedNetAssetsAbstract_1b2e10bc-2760-4d89-8362-c08788f0ac38" xlink:to="loc_bgne_RestrictedNetAssetsRequiredStatutoryReserveAsPercentageOfRegisteredCapital_865ce712-805f-432c-b559-76a14a1c53fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RestrictedNetAssetsAppropriatedToStatutoryReserves_04d1f8db-302d-42d6-8067-97cf8ec8327e" xlink:href="bgne-20241231.xsd#bgne_RestrictedNetAssetsAppropriatedToStatutoryReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bgne_RestrictedNetAssetsAbstract_1b2e10bc-2760-4d89-8362-c08788f0ac38" xlink:to="loc_bgne_RestrictedNetAssetsAppropriatedToStatutoryReserves_04d1f8db-302d-42d6-8067-97cf8ec8327e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RestrictedNetAssetsAmount_42540244-66e5-4ce8-8960-3276cb07626e" xlink:href="bgne-20241231.xsd#bgne_RestrictedNetAssetsAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_bgne_RestrictedNetAssetsAbstract_1b2e10bc-2760-4d89-8362-c08788f0ac38" xlink:to="loc_bgne_RestrictedNetAssetsAmount_42540244-66e5-4ce8-8960-3276cb07626e" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/EmployeeBenefitPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#EmployeeBenefitPlansAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/EmployeeBenefitPlansAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_2cb76e12-4e00-4fc6-8e08-099984c31e37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTable_abd97c9f-884a-4967-9642-723b17aadc07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_2cb76e12-4e00-4fc6-8e08-099984c31e37" xlink:to="loc_us-gaap_DefinedContributionPlanTable_abd97c9f-884a-4967-9642-723b17aadc07" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_040cb408-fbd4-4b9c-aa85-6aeaaa85b615" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedContributionPlanTable_abd97c9f-884a-4967-9642-723b17aadc07" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_040cb408-fbd4-4b9c-aa85-6aeaaa85b615" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_040cb408-fbd4-4b9c-aa85-6aeaaa85b615_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_040cb408-fbd4-4b9c-aa85-6aeaaa85b615" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_040cb408-fbd4-4b9c-aa85-6aeaaa85b615_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_bdfcc0ba-ac99-4fa9-810a-e591bca13a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_040cb408-fbd4-4b9c-aa85-6aeaaa85b615" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_bdfcc0ba-ac99-4fa9-810a-e591bca13a1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_743b312b-83e4-4268-b077-989120cce77e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_bdfcc0ba-ac99-4fa9-810a-e591bca13a1f" xlink:to="loc_us-gaap_DomesticPlanMember_743b312b-83e4-4268-b077-989120cce77e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_bf8c8aee-d52b-49a9-99eb-e735f0ab2fcb" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_743b312b-83e4-4268-b077-989120cce77e" xlink:to="loc_country_US_bf8c8aee-d52b-49a9-99eb-e735f0ab2fcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_4b314629-bee8-4e15-9a01-40d3d5af44df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_bdfcc0ba-ac99-4fa9-810a-e591bca13a1f" xlink:to="loc_us-gaap_ForeignPlanMember_4b314629-bee8-4e15-9a01-40d3d5af44df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_2173e6f1-a406-41e3-929d-56a027363bcc" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ForeignPlanMember_4b314629-bee8-4e15-9a01-40d3d5af44df" xlink:to="loc_country_CN_2173e6f1-a406-41e3-929d-56a027363bcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CH_1e263a46-e406-42f2-b688-418a7f353ed4" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CH"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ForeignPlanMember_4b314629-bee8-4e15-9a01-40d3d5af44df" xlink:to="loc_country_CH_1e263a46-e406-42f2-b688-418a7f353ed4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_edde486b-e513-460f-84b6-de0193e2b189" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_2cb76e12-4e00-4fc6-8e08-099984c31e37" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_edde486b-e513-460f-84b6-de0193e2b189" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_7d06042a-ffbf-45aa-a371-8ce572784b73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_2cb76e12-4e00-4fc6-8e08-099984c31e37" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_7d06042a-ffbf-45aa-a371-8ce572784b73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_77e13b5f-20fe-44c0-b5ad-e07ff9b0475f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_2cb76e12-4e00-4fc6-8e08-099984c31e37" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_77e13b5f-20fe-44c0-b5ad-e07ff9b0475f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_5615bf5b-70da-4af9-b7e9-fc7add72c98e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_2cb76e12-4e00-4fc6-8e08-099984c31e37" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_5615bf5b-70da-4af9-b7e9-fc7add72c98e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_f5ab0d60-36e1-416d-9c7b-f8067c82df6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_2cb76e12-4e00-4fc6-8e08-099984c31e37" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_f5ab0d60-36e1-416d-9c7b-f8067c82df6f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_ae2e7692-dc31-42b5-88d5-1c62bbbc61ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_a2a552cf-8a3f-40cb-934a-212d1d8e8ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_ae2e7692-dc31-42b5-88d5-1c62bbbc61ed" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_a2a552cf-8a3f-40cb-934a-212d1d8e8ae3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_b26d105d-861b-42bc-9586-4d7f8574f58a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_a2a552cf-8a3f-40cb-934a-212d1d8e8ae3" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_b26d105d-861b-42bc-9586-4d7f8574f58a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_b26d105d-861b-42bc-9586-4d7f8574f58a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_b26d105d-861b-42bc-9586-4d7f8574f58a" xlink:to="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_b26d105d-861b-42bc-9586-4d7f8574f58a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_4007fca1-46e9-4ffd-843c-4bc6e6b3daf8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_b26d105d-861b-42bc-9586-4d7f8574f58a" xlink:to="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_4007fca1-46e9-4ffd-843c-4bc6e6b3daf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_MinimumPurchaseCommitmentsForSupplyPurchasedMember_cb7495c9-1704-4b55-a67a-014817fe4e75" xlink:href="bgne-20241231.xsd#bgne_MinimumPurchaseCommitmentsForSupplyPurchasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_4007fca1-46e9-4ffd-843c-4bc6e6b3daf8" xlink:to="loc_bgne_MinimumPurchaseCommitmentsForSupplyPurchasedMember_cb7495c9-1704-4b55-a67a-014817fe4e75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_3bf69013-5c2b-4ca4-8051-56134fc24440" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_4007fca1-46e9-4ffd-843c-4bc6e6b3daf8" xlink:to="loc_us-gaap_InventoriesMember_3bf69013-5c2b-4ca4-8051-56134fc24440" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalAdditionsMember_c42dcfed-4458-4ddb-a2e4-3578a2390f52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalAdditionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_4007fca1-46e9-4ffd-843c-4bc6e6b3daf8" xlink:to="loc_us-gaap_CapitalAdditionsMember_c42dcfed-4458-4ddb-a2e4-3578a2390f52" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_12e7f000-7af9-46e5-b077-1cc7bf56b88f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_a2a552cf-8a3f-40cb-934a-212d1d8e8ae3" xlink:to="loc_srt_CounterpartyNameAxis_12e7f000-7af9-46e5-b077-1cc7bf56b88f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_12e7f000-7af9-46e5-b077-1cc7bf56b88f_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_12e7f000-7af9-46e5-b077-1cc7bf56b88f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_12e7f000-7af9-46e5-b077-1cc7bf56b88f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_19fdcc9e-0dc7-48f9-a287-6745bb5aa9d8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_12e7f000-7af9-46e5-b077-1cc7bf56b88f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_19fdcc9e-0dc7-48f9-a287-6745bb5aa9d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AmgenIncMember_88a45ec4-2db3-4418-992d-8be28686c7e3" xlink:href="bgne-20241231.xsd#bgne_AmgenIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_19fdcc9e-0dc7-48f9-a287-6745bb5aa9d8" xlink:to="loc_bgne_AmgenIncMember_88a45ec4-2db3-4418-992d-8be28686c7e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_e95e54f2-caca-462d-b7b3-030be0cb5cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_a2a552cf-8a3f-40cb-934a-212d1d8e8ae3" xlink:to="loc_us-gaap_OtherCommitmentsAxis_e95e54f2-caca-462d-b7b3-030be0cb5cbe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_e95e54f2-caca-462d-b7b3-030be0cb5cbe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_e95e54f2-caca-462d-b7b3-030be0cb5cbe" xlink:to="loc_us-gaap_OtherCommitmentsDomain_e95e54f2-caca-462d-b7b3-030be0cb5cbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_bcbfc0bb-95f3-4873-9b03-bd8502d4065d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_e95e54f2-caca-462d-b7b3-030be0cb5cbe" xlink:to="loc_us-gaap_OtherCommitmentsDomain_bcbfc0bb-95f3-4873-9b03-bd8502d4065d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_InvestmentsFundingCommitmentMember_732258b1-42d9-417a-a9c2-24ded2930406" xlink:href="bgne-20241231.xsd#bgne_InvestmentsFundingCommitmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_bcbfc0bb-95f3-4873-9b03-bd8502d4065d" xlink:to="loc_bgne_InvestmentsFundingCommitmentMember_732258b1-42d9-417a-a9c2-24ded2930406" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract_1bda52c1-e7ed-45da-a655-86199438508b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_ae2e7692-dc31-42b5-88d5-1c62bbbc61ed" xlink:to="loc_us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract_1bda52c1-e7ed-45da-a655-86199438508b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_534b196e-3232-40ed-a50d-f22ea4e76dae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract_1bda52c1-e7ed-45da-a655-86199438508b" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_534b196e-3232-40ed-a50d-f22ea4e76dae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_dae98251-1690-49bb-81bd-31e5e7e8e5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract_1bda52c1-e7ed-45da-a655-86199438508b" xlink:to="loc_us-gaap_OtherCommitment_dae98251-1690-49bb-81bd-31e5e7e8e5ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_MaximumCashAndServicesDevelopmentCommitment_208fdf3e-75ee-4f87-ac68-01a7e8f0572c" xlink:href="bgne-20241231.xsd#bgne_MaximumCashAndServicesDevelopmentCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract_1bda52c1-e7ed-45da-a655-86199438508b" xlink:to="loc_bgne_MaximumCashAndServicesDevelopmentCommitment_208fdf3e-75ee-4f87-ac68-01a7e8f0572c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_LongTermFundingCommitmentNumberOfEquityInvestments_af8c3174-e0e8-4369-87ae-df7a63165e9d" xlink:href="bgne-20241231.xsd#bgne_LongTermFundingCommitmentNumberOfEquityInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract_1bda52c1-e7ed-45da-a655-86199438508b" xlink:to="loc_bgne_LongTermFundingCommitmentNumberOfEquityInvestments_af8c3174-e0e8-4369-87ae-df7a63165e9d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_LongTermFundingCommitmentMaximumAmount_e38442a9-e15f-4fb4-8e50-b60f7a4b8b72" xlink:href="bgne-20241231.xsd#bgne_LongTermFundingCommitmentMaximumAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract_1bda52c1-e7ed-45da-a655-86199438508b" xlink:to="loc_bgne_LongTermFundingCommitmentMaximumAmount_e38442a9-e15f-4fb4-8e50-b60f7a4b8b72" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/SegmentandGeographicInformationScheduleofRevenuebyGeographicAreaDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#SegmentandGeographicInformationScheduleofRevenuebyGeographicAreaDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/SegmentandGeographicInformationScheduleofRevenuebyGeographicAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_81de1f84-3420-4fe4-af38-44b2099f2cae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_6f414b55-ad71-4bcc-99b0-6f26497d2ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_81de1f84-3420-4fe4-af38-44b2099f2cae" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_6f414b55-ad71-4bcc-99b0-6f26497d2ae9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ae2d12ee-c0f5-4a77-a4fb-ab72d86613d7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_6f414b55-ad71-4bcc-99b0-6f26497d2ae9" xlink:to="loc_srt_StatementGeographicalAxis_ae2d12ee-c0f5-4a77-a4fb-ab72d86613d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ae2d12ee-c0f5-4a77-a4fb-ab72d86613d7_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_ae2d12ee-c0f5-4a77-a4fb-ab72d86613d7" xlink:to="loc_srt_SegmentGeographicalDomain_ae2d12ee-c0f5-4a77-a4fb-ab72d86613d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ce9d18ef-03ec-4472-93b5-a1a221eee4fa" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_ae2d12ee-c0f5-4a77-a4fb-ab72d86613d7" xlink:to="loc_srt_SegmentGeographicalDomain_ce9d18ef-03ec-4472-93b5-a1a221eee4fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_66a37587-f39f-4664-b23d-706a3315b6c9" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ce9d18ef-03ec-4472-93b5-a1a221eee4fa" xlink:to="loc_country_US_66a37587-f39f-4664-b23d-706a3315b6c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_8989ebea-e2c3-42c6-80a7-5ce6b1ad8a15" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ce9d18ef-03ec-4472-93b5-a1a221eee4fa" xlink:to="loc_country_CN_8989ebea-e2c3-42c6-80a7-5ce6b1ad8a15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_d699e86a-49cb-4d11-b76a-0f42b07f0e2c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ce9d18ef-03ec-4472-93b5-a1a221eee4fa" xlink:to="loc_srt_EuropeMember_d699e86a-49cb-4d11-b76a-0f42b07f0e2c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember_ea62ba23-27b7-4eaa-8538-e1d93f0ff795" xlink:href="bgne-20241231.xsd#bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ce9d18ef-03ec-4472-93b5-a1a221eee4fa" xlink:to="loc_bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember_ea62ba23-27b7-4eaa-8538-e1d93f0ff795" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_20a3a776-4272-41c7-9c03-4ccf15c67d9c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_6f414b55-ad71-4bcc-99b0-6f26497d2ae9" xlink:to="loc_srt_ProductOrServiceAxis_20a3a776-4272-41c7-9c03-4ccf15c67d9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_20a3a776-4272-41c7-9c03-4ccf15c67d9c_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_20a3a776-4272-41c7-9c03-4ccf15c67d9c" xlink:to="loc_srt_ProductsAndServicesDomain_20a3a776-4272-41c7-9c03-4ccf15c67d9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2aee94bd-bfb7-4faf-801c-93e278477b7f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_20a3a776-4272-41c7-9c03-4ccf15c67d9c" xlink:to="loc_srt_ProductsAndServicesDomain_2aee94bd-bfb7-4faf-801c-93e278477b7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_3ca94270-ecbb-423d-9fed-55e0918f3bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2aee94bd-bfb7-4faf-801c-93e278477b7f" xlink:to="loc_us-gaap_ProductMember_3ca94270-ecbb-423d-9fed-55e0918f3bbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_CollaborationMember_c3c65d0e-a33f-49cb-8c4d-4cb583a39425" xlink:href="bgne-20241231.xsd#bgne_CollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2aee94bd-bfb7-4faf-801c-93e278477b7f" xlink:to="loc_bgne_CollaborationMember_c3c65d0e-a33f-49cb-8c4d-4cb583a39425" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_696fe433-cbfa-480b-811e-5bc5faae5ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_81de1f84-3420-4fe4-af38-44b2099f2cae" xlink:to="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_696fe433-cbfa-480b-811e-5bc5faae5ddc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8d0b20ea-4640-4730-a34a-b664746edf39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_696fe433-cbfa-480b-811e-5bc5faae5ddc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8d0b20ea-4640-4730-a34a-b664746edf39" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedStatementOfIncomeCaptionsLineItems_e5955ff4-9411-4efd-b425-a1a9658ba59a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedStatementOfIncomeCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedStatementOfComprehensiveIncomeTable_0fedf38b-056c-410f-bf5b-bff3e95f7558" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedStatementOfComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedStatementOfIncomeCaptionsLineItems_e5955ff4-9411-4efd-b425-a1a9658ba59a" xlink:to="loc_srt_CondensedStatementOfComprehensiveIncomeTable_0fedf38b-056c-410f-bf5b-bff3e95f7558" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_624eba0d-2b79-4f68-9726-982b945a8901" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_CondensedStatementOfComprehensiveIncomeTable_0fedf38b-056c-410f-bf5b-bff3e95f7558" xlink:to="loc_srt_ConsolidatedEntitiesAxis_624eba0d-2b79-4f68-9726-982b945a8901" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_624eba0d-2b79-4f68-9726-982b945a8901_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_624eba0d-2b79-4f68-9726-982b945a8901" xlink:to="loc_srt_ConsolidatedEntitiesDomain_624eba0d-2b79-4f68-9726-982b945a8901_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_ca318714-6cbf-4940-8c13-9e1c9b8e126e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_624eba0d-2b79-4f68-9726-982b945a8901" xlink:to="loc_srt_ConsolidatedEntitiesDomain_ca318714-6cbf-4940-8c13-9e1c9b8e126e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_5f99990f-09f9-4448-9774-fc34f6a2b284" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_ca318714-6cbf-4940-8c13-9e1c9b8e126e" xlink:to="loc_srt_ParentCompanyMember_5f99990f-09f9-4448-9774-fc34f6a2b284" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_b5ff7b21-9aa0-4bfd-8dc6-392e44131b67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedStatementOfIncomeCaptionsLineItems_e5955ff4-9411-4efd-b425-a1a9658ba59a" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_b5ff7b21-9aa0-4bfd-8dc6-392e44131b67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_accf8368-b271-44a6-bc55-f03ccfb283a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b5ff7b21-9aa0-4bfd-8dc6-392e44131b67" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_accf8368-b271-44a6-bc55-f03ccfb283a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3d8773a1-fea7-4dff-b323-7fe47a87daa2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b5ff7b21-9aa0-4bfd-8dc6-392e44131b67" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3d8773a1-fea7-4dff-b323-7fe47a87daa2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_1fd2482e-1e7d-4830-9d02-924f310076f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b5ff7b21-9aa0-4bfd-8dc6-392e44131b67" xlink:to="loc_us-gaap_CostsAndExpenses_1fd2482e-1e7d-4830-9d02-924f310076f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_aa01433b-ef58-4e30-8d56-703be7800a48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedStatementOfIncomeCaptionsLineItems_e5955ff4-9411-4efd-b425-a1a9658ba59a" xlink:to="loc_us-gaap_OperatingIncomeLoss_aa01433b-ef58-4e30-8d56-703be7800a48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_de06ac3b-df17-4eae-9253-e282059fc688" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedStatementOfIncomeCaptionsLineItems_e5955ff4-9411-4efd-b425-a1a9658ba59a" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_de06ac3b-df17-4eae-9253-e282059fc688" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_dc701eaf-c9fd-4bcb-a5e4-d970eb451679" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedStatementOfIncomeCaptionsLineItems_e5955ff4-9411-4efd-b425-a1a9658ba59a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_dc701eaf-c9fd-4bcb-a5e4-d970eb451679" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7fa93018-aa8c-4385-abf5-6ce7707d75a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedStatementOfIncomeCaptionsLineItems_e5955ff4-9411-4efd-b425-a1a9658ba59a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7fa93018-aa8c-4385-abf5-6ce7707d75a3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c0ebd0fd-cac2-4af0-8489-788621ecba48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedStatementOfIncomeCaptionsLineItems_e5955ff4-9411-4efd-b425-a1a9658ba59a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c0ebd0fd-cac2-4af0-8489-788621ecba48" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b6c4dee9-c194-4e69-acbc-39d6382cc4ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedStatementOfIncomeCaptionsLineItems_e5955ff4-9411-4efd-b425-a1a9658ba59a" xlink:to="loc_us-gaap_NetIncomeLoss_b6c4dee9-c194-4e69-acbc-39d6382cc4ca" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveLossDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedStatementOfIncomeCaptionsLineItems_2ac13703-aa7b-4736-a50e-c995cab8762c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedStatementOfIncomeCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedStatementOfComprehensiveIncomeTable_1046e37f-44c4-4a27-a0d2-27e86e275fe0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedStatementOfComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedStatementOfIncomeCaptionsLineItems_2ac13703-aa7b-4736-a50e-c995cab8762c" xlink:to="loc_srt_CondensedStatementOfComprehensiveIncomeTable_1046e37f-44c4-4a27-a0d2-27e86e275fe0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_534226a3-674d-408b-af9a-b4cbfd8b61f6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_CondensedStatementOfComprehensiveIncomeTable_1046e37f-44c4-4a27-a0d2-27e86e275fe0" xlink:to="loc_srt_ConsolidatedEntitiesAxis_534226a3-674d-408b-af9a-b4cbfd8b61f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_534226a3-674d-408b-af9a-b4cbfd8b61f6_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_534226a3-674d-408b-af9a-b4cbfd8b61f6" xlink:to="loc_srt_ConsolidatedEntitiesDomain_534226a3-674d-408b-af9a-b4cbfd8b61f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_fb8d91ca-35bf-4752-9e8b-13b6512ab8ba" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_534226a3-674d-408b-af9a-b4cbfd8b61f6" xlink:to="loc_srt_ConsolidatedEntitiesDomain_fb8d91ca-35bf-4752-9e8b-13b6512ab8ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_d2150be1-724d-42b9-a813-5738d1b70e6d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_fb8d91ca-35bf-4752-9e8b-13b6512ab8ba" xlink:to="loc_srt_ParentCompanyMember_d2150be1-724d-42b9-a813-5738d1b70e6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_699126b7-7c32-4dda-963c-8856516963f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedStatementOfIncomeCaptionsLineItems_2ac13703-aa7b-4736-a50e-c995cab8762c" xlink:to="loc_us-gaap_NetIncomeLossAbstract_699126b7-7c32-4dda-963c-8856516963f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ebd6d390-1327-4028-982a-5da078f37ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_699126b7-7c32-4dda-963c-8856516963f8" xlink:to="loc_us-gaap_NetIncomeLoss_ebd6d390-1327-4028-982a-5da078f37ed6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_6f9f7585-23e5-4796-b44f-fddf362bc96f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedStatementOfIncomeCaptionsLineItems_2ac13703-aa7b-4736-a50e-c995cab8762c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_6f9f7585-23e5-4796-b44f-fddf362bc96f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_ca4ba2ef-4d6b-4c99-a31e-e6b2ed72dde4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_6f9f7585-23e5-4796-b44f-fddf362bc96f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_ca4ba2ef-4d6b-4c99-a31e-e6b2ed72dde4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_34ce0955-8950-47f6-bb16-242a7bec3da5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_6f9f7585-23e5-4796-b44f-fddf362bc96f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_34ce0955-8950-47f6-bb16-242a7bec3da5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_c18d1f7f-5402-4858-814e-0979cc430836" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_6f9f7585-23e5-4796-b44f-fddf362bc96f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_c18d1f7f-5402-4858-814e-0979cc430836" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0868937e-fc53-4762-b654-9aa5e014f0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedStatementOfIncomeCaptionsLineItems_2ac13703-aa7b-4736-a50e-c995cab8762c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_0868937e-fc53-4762-b654-9aa5e014f0b1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_23026e97-efc2-43bf-8807-0d4deed6268c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_288cbd45-4c17-44f8-af81-be20379a8531" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_23026e97-efc2-43bf-8807-0d4deed6268c" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_288cbd45-4c17-44f8-af81-be20379a8531" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_8b5451cb-7509-45de-9cfb-40b856d0df9d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_288cbd45-4c17-44f8-af81-be20379a8531" xlink:to="loc_srt_ConsolidatedEntitiesAxis_8b5451cb-7509-45de-9cfb-40b856d0df9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_8b5451cb-7509-45de-9cfb-40b856d0df9d_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_8b5451cb-7509-45de-9cfb-40b856d0df9d" xlink:to="loc_srt_ConsolidatedEntitiesDomain_8b5451cb-7509-45de-9cfb-40b856d0df9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_21273b64-6a42-4d11-934f-110d924c00ff" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_8b5451cb-7509-45de-9cfb-40b856d0df9d" xlink:to="loc_srt_ConsolidatedEntitiesDomain_21273b64-6a42-4d11-934f-110d924c00ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_99cf494b-94da-4f9b-b876-9a37021dc7ae" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_21273b64-6a42-4d11-934f-110d924c00ff" xlink:to="loc_srt_ParentCompanyMember_99cf494b-94da-4f9b-b876-9a37021dc7ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_1752a212-fd6b-487e-b0cf-c51e22b5bf47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_23026e97-efc2-43bf-8807-0d4deed6268c" xlink:to="loc_us-gaap_AssetsAbstract_1752a212-fd6b-487e-b0cf-c51e22b5bf47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_7cfcb840-2a54-4176-a568-8fa06aafdd33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_1752a212-fd6b-487e-b0cf-c51e22b5bf47" xlink:to="loc_us-gaap_AssetsCurrentAbstract_7cfcb840-2a54-4176-a568-8fa06aafdd33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7516961d-c9e9-4b0c-9429-69f4ab5fc972" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7cfcb840-2a54-4176-a568-8fa06aafdd33" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7516961d-c9e9-4b0c-9429-69f4ab5fc972" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8e529e0a-7e3d-4e6e-aa5a-9ba170bd4ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7cfcb840-2a54-4176-a568-8fa06aafdd33" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8e529e0a-7e3d-4e6e-aa5a-9ba170bd4ed8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_32a34bbc-09fb-40ce-8668-fc210d810e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7cfcb840-2a54-4176-a568-8fa06aafdd33" xlink:to="loc_us-gaap_AssetsCurrent_32a34bbc-09fb-40ce-8668-fc210d810e3b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_ae5f2fee-560e-4a3b-bc9d-e3fe0123de2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7cfcb840-2a54-4176-a568-8fa06aafdd33" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_ae5f2fee-560e-4a3b-bc9d-e3fe0123de2b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_fbbbaa78-b47d-4862-90f4-5a26964e0fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_1752a212-fd6b-487e-b0cf-c51e22b5bf47" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_fbbbaa78-b47d-4862-90f4-5a26964e0fa6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0ae2c372-632c-4889-bfae-0515aa72a1df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_1752a212-fd6b-487e-b0cf-c51e22b5bf47" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_0ae2c372-632c-4889-bfae-0515aa72a1df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2156f4a1-dc40-40e8-bb37-3be520b04be1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_1752a212-fd6b-487e-b0cf-c51e22b5bf47" xlink:to="loc_us-gaap_Assets_2156f4a1-dc40-40e8-bb37-3be520b04be1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_01759c9d-748d-44a0-94b7-9e92ff6f3725" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_23026e97-efc2-43bf-8807-0d4deed6268c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_01759c9d-748d-44a0-94b7-9e92ff6f3725" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_4593e0ca-06a4-41b2-853f-576962a4b95f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_01759c9d-748d-44a0-94b7-9e92ff6f3725" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_4593e0ca-06a4-41b2-853f-576962a4b95f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_db081d88-ad76-4bad-90ea-0b1422761d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4593e0ca-06a4-41b2-853f-576962a4b95f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_db081d88-ad76-4bad-90ea-0b1422761d2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableCurrent_d758c61e-f3a8-4946-8b29-7a38263f4e97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4593e0ca-06a4-41b2-853f-576962a4b95f" xlink:to="loc_us-gaap_LoansPayableCurrent_d758c61e-f3a8-4946-8b29-7a38263f4e97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_c26abdd3-840a-4c79-812e-5b161ecfb4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4593e0ca-06a4-41b2-853f-576962a4b95f" xlink:to="loc_us-gaap_LongTermDebtCurrent_c26abdd3-840a-4c79-812e-5b161ecfb4e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_af56dac0-f610-4809-a9c0-c4e4a6b997d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_01759c9d-748d-44a0-94b7-9e92ff6f3725" xlink:to="loc_us-gaap_LiabilitiesCurrent_af56dac0-f610-4809-a9c0-c4e4a6b997d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_07469846-2666-4cb5-bc1f-3b451d471b72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_01759c9d-748d-44a0-94b7-9e92ff6f3725" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_07469846-2666-4cb5-bc1f-3b451d471b72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_4fcce210-7408-401d-8eb1-eca9cc029bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_07469846-2666-4cb5-bc1f-3b451d471b72" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_4fcce210-7408-401d-8eb1-eca9cc029bf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_99ceaf2a-a328-4175-ba0e-f410c18b8592" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_01759c9d-748d-44a0-94b7-9e92ff6f3725" xlink:to="loc_us-gaap_Liabilities_99ceaf2a-a328-4175-ba0e-f410c18b8592" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2876bdb2-acc0-4c68-bdc6-31a76f369718" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_01759c9d-748d-44a0-94b7-9e92ff6f3725" xlink:to="loc_us-gaap_StockholdersEquity_2876bdb2-acc0-4c68-bdc6-31a76f369718" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6b3317ae-86a6-4d12-84c0-834b5ded7332" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_01759c9d-748d-44a0-94b7-9e92ff6f3725" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_6b3317ae-86a6-4d12-84c0-834b5ded7332" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_cc67e6f5-5273-4233-8d6a-551e61c8a5be" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedCashFlowStatementsCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedCashFlowStatementTable_b9a0a392-4e3f-4821-be0e-c7deec249f65" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedCashFlowStatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_cc67e6f5-5273-4233-8d6a-551e61c8a5be" xlink:to="loc_srt_CondensedCashFlowStatementTable_b9a0a392-4e3f-4821-be0e-c7deec249f65" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_9e914609-f3ef-4251-8ab9-98b65044ad0b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_CondensedCashFlowStatementTable_b9a0a392-4e3f-4821-be0e-c7deec249f65" xlink:to="loc_srt_ConsolidatedEntitiesAxis_9e914609-f3ef-4251-8ab9-98b65044ad0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_9e914609-f3ef-4251-8ab9-98b65044ad0b_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_9e914609-f3ef-4251-8ab9-98b65044ad0b" xlink:to="loc_srt_ConsolidatedEntitiesDomain_9e914609-f3ef-4251-8ab9-98b65044ad0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_dc6279a5-c1ff-4e19-9af9-fa93019544f5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_9e914609-f3ef-4251-8ab9-98b65044ad0b" xlink:to="loc_srt_ConsolidatedEntitiesDomain_dc6279a5-c1ff-4e19-9af9-fa93019544f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_d5d56fb0-bd65-408f-b301-aec18c05ab81" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_dc6279a5-c1ff-4e19-9af9-fa93019544f5" xlink:to="loc_srt_ParentCompanyMember_d5d56fb0-bd65-408f-b301-aec18c05ab81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_40712f61-735d-47aa-8914-9407e9e38f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_cc67e6f5-5273-4233-8d6a-551e61c8a5be" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_40712f61-735d-47aa-8914-9407e9e38f1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4180ea68-3f99-4244-b0b2-28f73ef629a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_40712f61-735d-47aa-8914-9407e9e38f1a" xlink:to="loc_us-gaap_NetIncomeLoss_4180ea68-3f99-4244-b0b2-28f73ef629a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b15f26d5-682d-4d25-9ee7-4bc6fb391b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_40712f61-735d-47aa-8914-9407e9e38f1a" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b15f26d5-682d-4d25-9ee7-4bc6fb391b9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AcquiredInProcessResearchAndDevelopment_ec0895cc-036d-441b-8139-0a47ae31bdb9" xlink:href="bgne-20241231.xsd#bgne_AcquiredInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b15f26d5-682d-4d25-9ee7-4bc6fb391b9a" xlink:to="loc_bgne_AcquiredInProcessResearchAndDevelopment_ec0895cc-036d-441b-8139-0a47ae31bdb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AmortizationOfResearchAndDevelopmentFinancingLiability_87b7b667-fc0f-43b5-b0d0-a3adac07d3ed" xlink:href="bgne-20241231.xsd#bgne_AmortizationOfResearchAndDevelopmentFinancingLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b15f26d5-682d-4d25-9ee7-4bc6fb391b9a" xlink:to="loc_bgne_AmortizationOfResearchAndDevelopmentFinancingLiability_87b7b667-fc0f-43b5-b0d0-a3adac07d3ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_UnrealizedGainLossInSubsidiaries_4c745294-f3bc-44d7-a15e-ba3f6e5729fb" xlink:href="bgne-20241231.xsd#bgne_UnrealizedGainLossInSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b15f26d5-682d-4d25-9ee7-4bc6fb391b9a" xlink:to="loc_bgne_UnrealizedGainLossInSubsidiaries_4c745294-f3bc-44d7-a15e-ba3f6e5729fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_3ffebf7c-d7a5-495c-aae8-439d6be1f4c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b15f26d5-682d-4d25-9ee7-4bc6fb391b9a" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_3ffebf7c-d7a5-495c-aae8-439d6be1f4c4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae08183d-042d-4283-9540-66b02f059e17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_40712f61-735d-47aa-8914-9407e9e38f1a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae08183d-042d-4283-9540-66b02f059e17" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d3ca87af-84fa-4855-a7ab-1e3168d02a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae08183d-042d-4283-9540-66b02f059e17" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d3ca87af-84fa-4855-a7ab-1e3168d02a7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_87892b47-82ad-4a9f-a93c-a19de4d4727f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae08183d-042d-4283-9540-66b02f059e17" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_87892b47-82ad-4a9f-a93c-a19de4d4727f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c1094223-d1e4-4b89-876e-07ea6dc4d0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_40712f61-735d-47aa-8914-9407e9e38f1a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c1094223-d1e4-4b89-876e-07ea6dc4d0bf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5e0af889-1e36-4ff1-9796-4b4f2742f8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_cc67e6f5-5273-4233-8d6a-551e61c8a5be" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5e0af889-1e36-4ff1-9796-4b4f2742f8fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_0c039ffd-a607-425f-84e7-e3be2045a090" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5e0af889-1e36-4ff1-9796-4b4f2742f8fe" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_0c039ffd-a607-425f-84e7-e3be2045a090" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_48c4783b-665d-45e5-91f3-69131ede454e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5e0af889-1e36-4ff1-9796-4b4f2742f8fe" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_48c4783b-665d-45e5-91f3-69131ede454e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_PaymentsToPurchaseInProcessResearchAndDevelopment_9e2fb10c-7c8f-4db9-bffa-8c8d83d41578" xlink:href="bgne-20241231.xsd#bgne_PaymentsToPurchaseInProcessResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5e0af889-1e36-4ff1-9796-4b4f2742f8fe" xlink:to="loc_bgne_PaymentsToPurchaseInProcessResearchAndDevelopment_9e2fb10c-7c8f-4db9-bffa-8c8d83d41578" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_99e789a2-5850-4ea2-907b-72f7262bd04a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5e0af889-1e36-4ff1-9796-4b4f2742f8fe" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_99e789a2-5850-4ea2-907b-72f7262bd04a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_f2586bab-c397-4fb5-ae4e-9f69c5d043d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5e0af889-1e36-4ff1-9796-4b4f2742f8fe" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_f2586bab-c397-4fb5-ae4e-9f69c5d043d8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7570fb15-3987-4821-9d8f-6f283e46eceb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5e0af889-1e36-4ff1-9796-4b4f2742f8fe" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7570fb15-3987-4821-9d8f-6f283e46eceb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6b7809c3-5384-43f2-8c71-dd07a9ef825c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_cc67e6f5-5273-4233-8d6a-551e61c8a5be" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6b7809c3-5384-43f2-8c71-dd07a9ef825c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_f7e0696b-34b6-447b-b2bc-68add09b52d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6b7809c3-5384-43f2-8c71-dd07a9ef825c" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_f7e0696b-34b6-447b-b2bc-68add09b52d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_64093b5f-825c-4f86-a3f7-9b890c0553fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6b7809c3-5384-43f2-8c71-dd07a9ef825c" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_64093b5f-825c-4f86-a3f7-9b890c0553fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_5d125f9a-3af1-4d5e-8809-55b44a351037" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6b7809c3-5384-43f2-8c71-dd07a9ef825c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_5d125f9a-3af1-4d5e-8809-55b44a351037" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7b52218c-b6c5-49b2-bf20-1ba72842bb5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6b7809c3-5384-43f2-8c71-dd07a9ef825c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7b52218c-b6c5-49b2-bf20-1ba72842bb5b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b8f5241a-81a5-4045-93eb-f5d3e3e0ce22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_cc67e6f5-5273-4233-8d6a-551e61c8a5be" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b8f5241a-81a5-4045-93eb-f5d3e3e0ce22" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_39901ca6-9f28-4056-9cea-10e2cde4f558" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_cc67e6f5-5273-4233-8d6a-551e61c8a5be" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_39901ca6-9f28-4056-9cea-10e2cde4f558" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b028ae59-3340-4f0d-86ca-26568ec58115" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_cc67e6f5-5273-4233-8d6a-551e61c8a5be" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b028ae59-3340-4f0d-86ca-26568ec58115" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_44e0ab03-73da-42fb-a610-79e0210fe4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ScheduleICondensedFinancialInformationNotestoCondensedFinancialStatementsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ScheduleICondensedFinancialInformationNotestoCondensedFinancialStatementsDetails"/>
  <link:definitionLink xlink:role="http://www.beigene.com/role/ScheduleICondensedFinancialInformationNotestoCondensedFinancialStatementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_76762c23-cc51-47ac-b587-c960abd8b2b5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_22a21884-369b-45ca-9ce5-89c6a3a7a5f7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_76762c23-cc51-47ac-b587-c960abd8b2b5" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_22a21884-369b-45ca-9ce5-89c6a3a7a5f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_35bb3e8b-44d8-449c-abb9-73253ea58a68" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_22a21884-369b-45ca-9ce5-89c6a3a7a5f7" xlink:to="loc_srt_ConsolidatedEntitiesAxis_35bb3e8b-44d8-449c-abb9-73253ea58a68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_35bb3e8b-44d8-449c-abb9-73253ea58a68_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_35bb3e8b-44d8-449c-abb9-73253ea58a68" xlink:to="loc_srt_ConsolidatedEntitiesDomain_35bb3e8b-44d8-449c-abb9-73253ea58a68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_09abf9c1-5854-42f1-ab8a-b1ddc1a35c50" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_35bb3e8b-44d8-449c-abb9-73253ea58a68" xlink:to="loc_srt_ConsolidatedEntitiesDomain_09abf9c1-5854-42f1-ab8a-b1ddc1a35c50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_0cb7de0b-2d08-48a0-9a3e-ee3cbc2721e6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_09abf9c1-5854-42f1-ab8a-b1ddc1a35c50" xlink:to="loc_srt_ParentCompanyMember_0cb7de0b-2d08-48a0-9a3e-ee3cbc2721e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_4c8c1167-e0cc-4fa8-a267-abdf2be469ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_22a21884-369b-45ca-9ce5-89c6a3a7a5f7" xlink:to="loc_us-gaap_OtherCommitmentsAxis_4c8c1167-e0cc-4fa8-a267-abdf2be469ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_4c8c1167-e0cc-4fa8-a267-abdf2be469ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_4c8c1167-e0cc-4fa8-a267-abdf2be469ab" xlink:to="loc_us-gaap_OtherCommitmentsDomain_4c8c1167-e0cc-4fa8-a267-abdf2be469ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_9b5d0800-0d02-4844-9ce9-d65a97078c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_4c8c1167-e0cc-4fa8-a267-abdf2be469ab" xlink:to="loc_us-gaap_OtherCommitmentsDomain_9b5d0800-0d02-4844-9ce9-d65a97078c5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_InvestmentsFundingCommitmentMember_5f0c2f1d-06d3-47f4-bd83-0c4df6419120" xlink:href="bgne-20241231.xsd#bgne_InvestmentsFundingCommitmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_9b5d0800-0d02-4844-9ce9-d65a97078c5f" xlink:to="loc_bgne_InvestmentsFundingCommitmentMember_5f0c2f1d-06d3-47f4-bd83-0c4df6419120" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_f5abc413-3da7-4884-882e-5d7da96a5689" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_76762c23-cc51-47ac-b587-c960abd8b2b5" xlink:to="loc_us-gaap_OtherCommitment_f5abc413-3da7-4884-882e-5d7da96a5689" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="691"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>bgne-20241231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:c70194b9-233f-4b06-bc07-707c5a5abbc8,g:477d344e-a417-40e8-b704-01a6f7f40ad7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_f0b242f0-ebdd-4594-99a7-c9d3c5544c3c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts and Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted_f23c7302-7ab6-4f4c-9abb-278f07087da5_terseLabel_en-US" xlink:label="lab_bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average ADSs outstanding, diluted (in shares)</link:label>
    <link:label id="lab_bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted_label_en-US" xlink:label="lab_bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Of American Depository Shares Outstanding, Diluted</link:label>
    <link:label id="lab_bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted_documentation_en-US" xlink:label="lab_bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Number Of American Depository Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted" xlink:href="bgne-20241231.xsd#bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted" xlink:to="lab_bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_d2717c20-e0d3-4f74-b758-6682aef38079_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease Liabilities, Payments Due</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_FairValueOfEquityInvestmentsIssued_060f2c55-9d7e-4b75-8ee8-66039c640572_verboseLabel_en-US" xlink:label="lab_bgne_FairValueOfEquityInvestmentsIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value of equity investments issued</link:label>
    <link:label id="lab_bgne_FairValueOfEquityInvestmentsIssued_label_en-US" xlink:label="lab_bgne_FairValueOfEquityInvestmentsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Equity Investments Issued</link:label>
    <link:label id="lab_bgne_FairValueOfEquityInvestmentsIssued_documentation_en-US" xlink:label="lab_bgne_FairValueOfEquityInvestmentsIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value of Equity Investments Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_FairValueOfEquityInvestmentsIssued" xlink:href="bgne-20241231.xsd#bgne_FairValueOfEquityInvestmentsIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_FairValueOfEquityInvestmentsIssued" xlink:to="lab_bgne_FairValueOfEquityInvestmentsIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_GovernmentGrantsPolicyPolicyTextBlock_3727230a-dba7-49d8-8bf0-56c22a17d447_terseLabel_en-US" xlink:label="lab_bgne_GovernmentGrantsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Grants</link:label>
    <link:label id="lab_bgne_GovernmentGrantsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_bgne_GovernmentGrantsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Grants, Policy [Policy Text Block]</link:label>
    <link:label id="lab_bgne_GovernmentGrantsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_bgne_GovernmentGrantsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for government grants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_GovernmentGrantsPolicyPolicyTextBlock" xlink:href="bgne-20241231.xsd#bgne_GovernmentGrantsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_GovernmentGrantsPolicyPolicyTextBlock" xlink:to="lab_bgne_GovernmentGrantsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_549c8057-9f3f-478d-b491-c234c44f6093_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_050efdc1-f588-4657-b517-4997168e8f4a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year ending December&#160;31,&#160;2026</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_9bb3a065-a5e8-4d47-ad5d-0a07b427c26b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidTaxes_3548f02a-36bf-49f3-abd1-6381668cd70c_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid taxes</link:label>
    <link:label id="lab_us-gaap_PrepaidTaxes_label_en-US" xlink:label="lab_us-gaap_PrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidTaxes" xlink:to="lab_us-gaap_PrepaidTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_AccruedExpensesCommercialActivities_427e6a03-924b-4a31-8b6f-7b5b421c257f_terseLabel_en-US" xlink:label="lab_bgne_AccruedExpensesCommercialActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial activities</link:label>
    <link:label id="lab_bgne_AccruedExpensesCommercialActivities_label_en-US" xlink:label="lab_bgne_AccruedExpensesCommercialActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Expenses, Commercial Activities</link:label>
    <link:label id="lab_bgne_AccruedExpensesCommercialActivities_documentation_en-US" xlink:label="lab_bgne_AccruedExpensesCommercialActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Expenses, Commercial Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AccruedExpensesCommercialActivities" xlink:href="bgne-20241231.xsd#bgne_AccruedExpensesCommercialActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_AccruedExpensesCommercialActivities" xlink:to="lab_bgne_AccruedExpensesCommercialActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_df7c7c32-4df9-4bed-9622-3206eca0ba5d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayment of long-term loan</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_a8797ed6-5103-4bac-abaf-7afc5dea7340_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_b4ccf5df-f5e9-4b16-a05e-68b156ce2a1b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year Ending December 31,</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_CommercializationTerm_a0be09e5-63da-4429-a87b-09a21ce713ff_terseLabel_en-US" xlink:label="lab_bgne_CommercializationTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercialization term (years)</link:label>
    <link:label id="lab_bgne_CommercializationTerm_label_en-US" xlink:label="lab_bgne_CommercializationTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercialization Term</link:label>
    <link:label id="lab_bgne_CommercializationTerm_documentation_en-US" xlink:label="lab_bgne_CommercializationTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercialization Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_CommercializationTerm" xlink:href="bgne-20241231.xsd#bgne_CommercializationTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_CommercializationTerm" xlink:to="lab_bgne_CommercializationTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_cc07ff41-84ec-4a9e-8b2f-334a7351796a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected taxation at U.S. statutory tax rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_984267cd-cab8-41a8-abe3-320dbca55f8c_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b1d59683-2c00-495a-889e-96afb2d0b12f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9c07d939-69ec-4c65-97be-15f6659177e9_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ed1fc9ec-2159-4638-b7b5-eb94eb1c25e9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_7c81a8c6-b1d7-40f3-9c36-dd9e06c03317_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentAssistanceAmount_6cf16767-a9ce-4f9f-ab35-a3e6904cd2f5_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government assistance amount</link:label>
    <link:label id="lab_us-gaap_GovernmentAssistanceAmount_label_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Assistance, Income, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceAmount" xlink:to="lab_us-gaap_GovernmentAssistanceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_ef35237b-4c01-44a3-a83b-3dc38188cf60_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol(s)</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberOfAvailableSharesAvailableForFutureIssuance_3746d0bb-b894-458d-a964-1422f8250f63_terseLabel_en-US" xlink:label="lab_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberOfAvailableSharesAvailableForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for future issuance (in shares)</link:label>
    <link:label id="lab_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberOfAvailableSharesAvailableForFutureIssuance_label_en-US" xlink:label="lab_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberOfAvailableSharesAvailableForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number Of Available Shares Available For Future Issuance</link:label>
    <link:label id="lab_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberOfAvailableSharesAvailableForFutureIssuance_documentation_en-US" xlink:label="lab_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberOfAvailableSharesAvailableForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number Of Available Shares Available For Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberOfAvailableSharesAvailableForFutureIssuance" xlink:href="bgne-20241231.xsd#bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberOfAvailableSharesAvailableForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberOfAvailableSharesAvailableForFutureIssuance" xlink:to="lab_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberOfAvailableSharesAvailableForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_4d246fc6-f3fc-43a0-b7d0-5d8bea12e984_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year ending December 31, 2027</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8fe9a963-16d0-4a1d-aa3b-b7eaaa52f465_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentChargesAbstract_38e2e59e-7f89-4a89-92a5-21978a3dc192_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentChargesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentChargesAbstract_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentChargesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentChargesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentChargesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentChargesAbstract" xlink:to="lab_us-gaap_AssetImpairmentChargesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_153bfa5e-dd63-4172-a74e-764ee6964108_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems" xlink:to="lab_us-gaap_IncomeTaxExaminationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_2d7cb4a0-a4eb-4092-91c8-0c194e448178_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_PrepaidSupplyCost_0e30aabd-f123-428d-beeb-6657ce76fc06_terseLabel_en-US" xlink:label="lab_bgne_PrepaidSupplyCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid supply cost</link:label>
    <link:label id="lab_bgne_PrepaidSupplyCost_label_en-US" xlink:label="lab_bgne_PrepaidSupplyCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Supply Cost</link:label>
    <link:label id="lab_bgne_PrepaidSupplyCost_documentation_en-US" xlink:label="lab_bgne_PrepaidSupplyCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid Supply Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_PrepaidSupplyCost" xlink:href="bgne-20241231.xsd#bgne_PrepaidSupplyCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_PrepaidSupplyCost" xlink:to="lab_bgne_PrepaidSupplyCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_86f7fccf-2cb9-4cb8-b55d-3cacdd466611_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities with readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_e8e4df5d-1148-4d21-b0b4-397ba8a37904_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_b9ec77cd-15a8-4706-9e80-b9ddce9a2fde_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_e8cc7d54-01f7-40f1-82e3-ac42e799588f_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation [Line Items]</link:label>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_label_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_fd11bedb-cc51-4d63-8301-3c9d7fdc64fe_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_d0b9d8de-f5db-476f-aa00-35a7bcdbf537_verboseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Land use rights, net</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_9b357f86-0210-490a-87fd-5a26210702e2_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_AccruedGeneralAndAdministrativeExpensesCurrent_e50942ee-7044-42b0-85bc-e4ed6de0c544_terseLabel_en-US" xlink:label="lab_bgne_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued general and administrative expenses</link:label>
    <link:label id="lab_bgne_AccruedGeneralAndAdministrativeExpensesCurrent_label_en-US" xlink:label="lab_bgne_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued General And Administrative Expenses, Current</link:label>
    <link:label id="lab_bgne_AccruedGeneralAndAdministrativeExpensesCurrent_documentation_en-US" xlink:label="lab_bgne_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued General And Administrative Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:href="bgne-20241231.xsd#bgne_AccruedGeneralAndAdministrativeExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:to="lab_bgne_AccruedGeneralAndAdministrativeExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f8461d58-51f7-4b29-8535-37cfbce089a4_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development collaborative arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_16d36129-d669-4107-aae2-413856f43f53_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_1e9069fa-9d96-45e8-9f7c-fbc0e6e43583_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_385f45d4-f3c7-4b43-b7f5-354ad4a0ad28_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_e90869a0-5c94-4ebb-98d8-39dc6a7add0b_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_2fea48d2-9c9e-467d-8fe8-f86eed998d7c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Per share acquisition price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_41c808d6-55f8-4001-b8b9-bb4a5cf921de_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_9c5e5176-8f9e-4c68-a8c0-d7d5466a6703_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">U.S. - total revenue</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_248a4f7f-c542-4da9-b4fc-59bb51e9c80b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net, by Type [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_c43ba0da-8084-4afc-b367-fbafd816f937_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_317219fe-1846-4ac5-9d27-88f65d682ceb_totalLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_f4e719bb-faf8-44fe-9b17-05911ecee693_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_EarningsPerAmericanDepositoryShareDiluted_627f96b7-c68d-4964-9175-27f414007ef5_terseLabel_en-US" xlink:label="lab_bgne_EarningsPerAmericanDepositoryShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per American Depositary Share (ADS), diluted (in dollars per share)</link:label>
    <link:label id="lab_bgne_EarningsPerAmericanDepositoryShareDiluted_label_en-US" xlink:label="lab_bgne_EarningsPerAmericanDepositoryShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per American Depository Share, Diluted</link:label>
    <link:label id="lab_bgne_EarningsPerAmericanDepositoryShareDiluted_documentation_en-US" xlink:label="lab_bgne_EarningsPerAmericanDepositoryShareDiluted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Earnings Per American Depository Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_EarningsPerAmericanDepositoryShareDiluted" xlink:href="bgne-20241231.xsd#bgne_EarningsPerAmericanDepositoryShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_EarningsPerAmericanDepositoryShareDiluted" xlink:to="lab_bgne_EarningsPerAmericanDepositoryShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_835b7647-aba6-4df1-b554-6339ceee0631_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross carrying amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_04acc08b-eb8f-45a9-a7b3-d918501e94e5_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]</link:label>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_label_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount_ab14c16b-024a-4f86-99a6-40f313bab5a0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Foreign-derived intangible income</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, FDII, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_5dc8c401-ad72-4ca9-bae0-7f7a3566751d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d84fb5ac-7cac-4d47-9699-745e4f4a2923_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_354cab27-513b-400b-b702-32b737348463_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_2802b970-7563-43f7-8060-adea00c6e530_terseLabel_en-US" xlink:label="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Contractual Maturities of Debt Obligations</link:label>
    <link:label id="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_label_en-US" xlink:label="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:to="lab_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_RestrictedNetAssetsRequiredStatutoryReserveAsPercentageOfRegisteredCapital_77064776-7858-4342-9f60-9cb397291c8a_terseLabel_en-US" xlink:label="lab_bgne_RestrictedNetAssetsRequiredStatutoryReserveAsPercentageOfRegisteredCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Required statutory reserve as a percentage of registered capital (as a percent)</link:label>
    <link:label id="lab_bgne_RestrictedNetAssetsRequiredStatutoryReserveAsPercentageOfRegisteredCapital_label_en-US" xlink:label="lab_bgne_RestrictedNetAssetsRequiredStatutoryReserveAsPercentageOfRegisteredCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Net Assets, Required Statutory Reserve as Percentage of Registered Capital</link:label>
    <link:label id="lab_bgne_RestrictedNetAssetsRequiredStatutoryReserveAsPercentageOfRegisteredCapital_documentation_en-US" xlink:label="lab_bgne_RestrictedNetAssetsRequiredStatutoryReserveAsPercentageOfRegisteredCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Required statutory reserve as a percentage of registered capital.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RestrictedNetAssetsRequiredStatutoryReserveAsPercentageOfRegisteredCapital" xlink:href="bgne-20241231.xsd#bgne_RestrictedNetAssetsRequiredStatutoryReserveAsPercentageOfRegisteredCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_RestrictedNetAssetsRequiredStatutoryReserveAsPercentageOfRegisteredCapital" xlink:to="lab_bgne_RestrictedNetAssetsRequiredStatutoryReserveAsPercentageOfRegisteredCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_693cc0dc-506b-4e12-bacd-3e918749b3c5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ShortTermBankLoanMaturingJanuary272025Member_54635eca-51df-4685-927e-503995546795_terseLabel_en-US" xlink:label="lab_bgne_ShortTermBankLoanMaturingJanuary272025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short Term Bank Loan Maturing January 27, 2025</link:label>
    <link:label id="lab_bgne_ShortTermBankLoanMaturingJanuary272025Member_label_en-US" xlink:label="lab_bgne_ShortTermBankLoanMaturingJanuary272025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short Term Bank Loan Maturing January 27, 2025 [Member]</link:label>
    <link:label id="lab_bgne_ShortTermBankLoanMaturingJanuary272025Member_documentation_en-US" xlink:label="lab_bgne_ShortTermBankLoanMaturingJanuary272025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short Term Bank Loan Maturing January 27, 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShortTermBankLoanMaturingJanuary272025Member" xlink:href="bgne-20241231.xsd#bgne_ShortTermBankLoanMaturingJanuary272025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ShortTermBankLoanMaturingJanuary272025Member" xlink:to="lab_bgne_ShortTermBankLoanMaturingJanuary272025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_bac31eb3-fd1e-4f3e-a120-074d0eb26252_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price - Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_cee9d20f-bc43-4ce1-95a9-e85d2744bd61_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_UpfrontPaymentsMember_12c701db-7031-45d2-80fd-47e9bf7ac6c2_terseLabel_en-US" xlink:label="lab_bgne_UpfrontPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payments</link:label>
    <link:label id="lab_bgne_UpfrontPaymentsMember_label_en-US" xlink:label="lab_bgne_UpfrontPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Payments [Member]</link:label>
    <link:label id="lab_bgne_UpfrontPaymentsMember_documentation_en-US" xlink:label="lab_bgne_UpfrontPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_UpfrontPaymentsMember" xlink:href="bgne-20241231.xsd#bgne_UpfrontPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_UpfrontPaymentsMember" xlink:to="lab_bgne_UpfrontPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_dcf1944c-a1fb-4c21-9187-a411d3c61a0b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_f225bfdd-e747-4f9c-84b8-a5b9310c1c9d_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_2305a40d-9943-4e7a-b89d-45dde8884b62_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets:</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_01709e0b-1926-4f86-accb-fb5d51a73e1b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from divestiture of businesses</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_99273700-fb45-4cf4-aace-e59dd1527006_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_5cc5276b-e652-42c2-9d80-0650d186ff41_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_63ee8585-7dfa-4de2-a5c4-d6a5f212a251_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_94f519d0-9ee2-4fa9-86f6-8f6851c22a67_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs (Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d050fb93-e2b4-4284-8861-136016e69647_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_RestrictedNetAssetsAmount_68bbf42c-1305-4a76-855a-af7625a44444_terseLabel_en-US" xlink:label="lab_bgne_RestrictedNetAssetsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted net assets</link:label>
    <link:label id="lab_bgne_RestrictedNetAssetsAmount_label_en-US" xlink:label="lab_bgne_RestrictedNetAssetsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Net Assets, Amount</link:label>
    <link:label id="lab_bgne_RestrictedNetAssetsAmount_documentation_en-US" xlink:label="lab_bgne_RestrictedNetAssetsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted net assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RestrictedNetAssetsAmount" xlink:href="bgne-20241231.xsd#bgne_RestrictedNetAssetsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_RestrictedNetAssetsAmount" xlink:to="lab_bgne_RestrictedNetAssetsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_04442d59-be0e-4c03-9bf2-363455b49a69_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation expenses</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_ee7f2c38-c4e4-4348-a8d2-84d1f475cc75_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other Non-Current Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Assets, Noncurrent [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_8a7a57d5-1854-4a27-b1cb-0a1d04b63b78_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other payables</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_466e09a9-b794-471d-9ba5-7cac009a7bf8_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_BeijingMember_f4aba18d-7ae5-43ec-9d45-a5fc7d41fd13_terseLabel_en-US" xlink:label="lab_bgne_BeijingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Beijing</link:label>
    <link:label id="lab_bgne_BeijingMember_label_en-US" xlink:label="lab_bgne_BeijingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Beijing [Member]</link:label>
    <link:label id="lab_bgne_BeijingMember_documentation_en-US" xlink:label="lab_bgne_BeijingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Beijing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_BeijingMember" xlink:href="bgne-20241231.xsd#bgne_BeijingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_BeijingMember" xlink:to="lab_bgne_BeijingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_858d5dbd-dd70-474f-a022-0e6947a8e3e5_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_POBEVCYMember_1278e0bf-c17e-42b2-8983-ec36c5f90676_terseLabel_en-US" xlink:label="lab_bgne_POBEVCYMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">POBEVCY&#174;</link:label>
    <link:label id="lab_bgne_POBEVCYMember_label_en-US" xlink:label="lab_bgne_POBEVCYMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">POBEVCY [Member]</link:label>
    <link:label id="lab_bgne_POBEVCYMember_documentation_en-US" xlink:label="lab_bgne_POBEVCYMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">POBEVCY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_POBEVCYMember" xlink:href="bgne-20241231.xsd#bgne_POBEVCYMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_POBEVCYMember" xlink:to="lab_bgne_POBEVCYMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_03808e60-6c29-4e7a-971b-9c5efaf2ee28_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories, Net</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_PrepaymentOfLongTermAsset_b58fe4c9-ceeb-4c03-b887-a47d856c01ee_terseLabel_en-US" xlink:label="lab_bgne_PrepaymentOfLongTermAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment of property and equipment</link:label>
    <link:label id="lab_bgne_PrepaymentOfLongTermAsset_label_en-US" xlink:label="lab_bgne_PrepaymentOfLongTermAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepayment of Long Term Asset</link:label>
    <link:label id="lab_bgne_PrepaymentOfLongTermAsset_documentation_en-US" xlink:label="lab_bgne_PrepaymentOfLongTermAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of prepayment of long term asset.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_PrepaymentOfLongTermAsset" xlink:href="bgne-20241231.xsd#bgne_PrepaymentOfLongTermAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_PrepaymentOfLongTermAsset" xlink:to="lab_bgne_PrepaymentOfLongTermAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList_68bbadb7-fbc4-439e-a68d-f4250740f264_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_9629aff4-382a-47e8-895c-22cbebcb043e_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_fe05d3c9-2082-421d-91c4-75b27c8f582f_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_10351cba-7124-47f7-a4e6-530f39a7e147_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year ending December&#160;31,&#160;2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_0125d550-b4b3-426a-9691-4e3cebf715ec_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financing activities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_NumberOfProductsInitiatedMarketingAndPromotion_2b31d148-9915-44d5-b2ef-0b79a32cb0ea_terseLabel_en-US" xlink:label="lab_bgne_NumberOfProductsInitiatedMarketingAndPromotion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of products</link:label>
    <link:label id="lab_bgne_NumberOfProductsInitiatedMarketingAndPromotion_label_en-US" xlink:label="lab_bgne_NumberOfProductsInitiatedMarketingAndPromotion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Products Initiated Marketing And Promotion</link:label>
    <link:label id="lab_bgne_NumberOfProductsInitiatedMarketingAndPromotion_documentation_en-US" xlink:label="lab_bgne_NumberOfProductsInitiatedMarketingAndPromotion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Products Initiated Marketing And Promotion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_NumberOfProductsInitiatedMarketingAndPromotion" xlink:href="bgne-20241231.xsd#bgne_NumberOfProductsInitiatedMarketingAndPromotion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_NumberOfProductsInitiatedMarketingAndPromotion" xlink:to="lab_bgne_NumberOfProductsInitiatedMarketingAndPromotion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_14224401-d2ef-4d08-bd59-2ae2e46d49d5_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss attributable to BeiGene, Ltd.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_AmortizationOfResearchAndDevelopmentFinancingLiability_85ee01eb-3a2a-4529-9d9d-c1c139e180ae_terseLabel_en-US" xlink:label="lab_bgne_AmortizationOfResearchAndDevelopmentFinancingLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of research and development cost share liability</link:label>
    <link:label id="lab_bgne_AmortizationOfResearchAndDevelopmentFinancingLiability_label_en-US" xlink:label="lab_bgne_AmortizationOfResearchAndDevelopmentFinancingLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Research And Development Financing Liability</link:label>
    <link:label id="lab_bgne_AmortizationOfResearchAndDevelopmentFinancingLiability_documentation_en-US" xlink:label="lab_bgne_AmortizationOfResearchAndDevelopmentFinancingLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortization of Research And Development Financing Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AmortizationOfResearchAndDevelopmentFinancingLiability" xlink:href="bgne-20241231.xsd#bgne_AmortizationOfResearchAndDevelopmentFinancingLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_AmortizationOfResearchAndDevelopmentFinancingLiability" xlink:to="lab_bgne_AmortizationOfResearchAndDevelopmentFinancingLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_e16abd8c-9a53-4af1-8128-14adaf8d2609_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_4d0fbcfa-6efe-484b-8946-b0531962c915_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets/(liabilities)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedPayrollTaxesCurrent_a98c421e-d9ac-4a0f-ae8b-2f47dd584279_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedPayrollTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual income tax and other taxes</link:label>
    <link:label id="lab_us-gaap_AccruedPayrollTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedPayrollTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Payroll Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedPayrollTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedPayrollTaxesCurrent" xlink:to="lab_us-gaap_AccruedPayrollTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_3a12019f-227a-403d-b621-88127d2026e6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_TaxBenefitFromForeignTaxStatusPerShare_5879e7f6-82d9-4753-a7f3-167788c9d0bd_terseLabel_en-US" xlink:label="lab_bgne_TaxBenefitFromForeignTaxStatusPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit from foreign tax status (per share)</link:label>
    <link:label id="lab_bgne_TaxBenefitFromForeignTaxStatusPerShare_label_en-US" xlink:label="lab_bgne_TaxBenefitFromForeignTaxStatusPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Benefit From Foreign Tax Status, Per Share</link:label>
    <link:label id="lab_bgne_TaxBenefitFromForeignTaxStatusPerShare_documentation_en-US" xlink:label="lab_bgne_TaxBenefitFromForeignTaxStatusPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Benefit From Foreign Tax Status, Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_TaxBenefitFromForeignTaxStatusPerShare" xlink:href="bgne-20241231.xsd#bgne_TaxBenefitFromForeignTaxStatusPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_TaxBenefitFromForeignTaxStatusPerShare" xlink:to="lab_bgne_TaxBenefitFromForeignTaxStatusPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_e55abb10-e9a2-4e4c-aced-ffbe690f2fc5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_7c8660e0-e051-49a0-a9d0-56754505b427_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in wholly owned subsidiaries</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_b818782a-2575-4bc6-a33a-21b6e9e13883_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_6ba613e1-9d0a-46f6-ad14-1ad8b1784f47_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_a42723dc-46a1-44c1-990f-72228dde63ae_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_35b3d5bb-d120-4724-82a2-3c3931a0f55b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price - Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_00601fb4-aa94-4d4d-b498-0b9adba85de8_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible debt instrument</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_34245253-10e6-461a-a24a-cfc13798f4a7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_7df4fcd1-7c1a-4d47-bb7f-9140f5c4319a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_51c6d42b-cff1-459a-894b-2db910e56d0a_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Functional Currency and Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71a6cd00-5570-4a7f-b1f4-48c147c2836a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_0852901f-8443-43b9-93fd-38a77067bafd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_ae17b08e-a894-43b7-893e-29d63b03938a_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_RevenueFromContractWithCustomerExcludingAssessedTaxPeriodIncreaseDecrease_277ba3a3-d3e5-430d-bbc4-c432bd43834d_terseLabel_en-US" xlink:label="lab_bgne_RevenueFromContractWithCustomerExcludingAssessedTaxPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, period increase</link:label>
    <link:label id="lab_bgne_RevenueFromContractWithCustomerExcludingAssessedTaxPeriodIncreaseDecrease_label_en-US" xlink:label="lab_bgne_RevenueFromContractWithCustomerExcludingAssessedTaxPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue From Contract With Customer, Excluding Assessed Tax, Period Increase (Decrease)</link:label>
    <link:label id="lab_bgne_RevenueFromContractWithCustomerExcludingAssessedTaxPeriodIncreaseDecrease_documentation_en-US" xlink:label="lab_bgne_RevenueFromContractWithCustomerExcludingAssessedTaxPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue From Contract With Customer, Excluding Assessed Tax, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RevenueFromContractWithCustomerExcludingAssessedTaxPeriodIncreaseDecrease" xlink:href="bgne-20241231.xsd#bgne_RevenueFromContractWithCustomerExcludingAssessedTaxPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_RevenueFromContractWithCustomerExcludingAssessedTaxPeriodIncreaseDecrease" xlink:to="lab_bgne_RevenueFromContractWithCustomerExcludingAssessedTaxPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ShanghaiChinaMember_b47d59f5-ad0c-47a5-a1ed-e06f84ccfbef_terseLabel_en-US" xlink:label="lab_bgne_ShanghaiChinaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shanghai, China</link:label>
    <link:label id="lab_bgne_ShanghaiChinaMember_label_en-US" xlink:label="lab_bgne_ShanghaiChinaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shanghai, China [Member]</link:label>
    <link:label id="lab_bgne_ShanghaiChinaMember_documentation_en-US" xlink:label="lab_bgne_ShanghaiChinaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shanghai, China</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShanghaiChinaMember" xlink:href="bgne-20241231.xsd#bgne_ShanghaiChinaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ShanghaiChinaMember" xlink:to="lab_bgne_ShanghaiChinaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_OciperlimabMember_6e4ada54-0032-4e35-a221-322aca25daf8_terseLabel_en-US" xlink:label="lab_bgne_OciperlimabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ociperlimab</link:label>
    <link:label id="lab_bgne_OciperlimabMember_label_en-US" xlink:label="lab_bgne_OciperlimabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ociperlimab [Member]</link:label>
    <link:label id="lab_bgne_OciperlimabMember_documentation_en-US" xlink:label="lab_bgne_OciperlimabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ociperlimab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_OciperlimabMember" xlink:href="bgne-20241231.xsd#bgne_OciperlimabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_OciperlimabMember" xlink:to="lab_bgne_OciperlimabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_2222c37a-2d29-4c70-951a-723374f7dba7_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_82adf7b2-87aa-4c6c-9acf-7d998ee1549a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, at cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_26fa8ec7-8154-4130-97c4-528132de12f0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of shares reserved for share option exercises (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d67f1174-5933-4736-8567-8f52bedaa4fa_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_d0be6132-ab19-42b4-8011-6feedeb4f3b2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_62f1992f-7ff0-4ed4-ae13-be5e3be50ecb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_ccd7deef-c64b-434d-95ea-e51aa923be1a_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestPeriodIncreaseDecrease_9d31861f-c47e-469b-a406-4d03cd555fd6_negatedTerseLabel_en-US" xlink:label="lab_bgne_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net loss period decrease</link:label>
    <link:label id="lab_bgne_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestPeriodIncreaseDecrease_label_en-US" xlink:label="lab_bgne_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable To Noncontrolling Interest, Period Increase (Decrease)</link:label>
    <link:label id="lab_bgne_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestPeriodIncreaseDecrease_documentation_en-US" xlink:label="lab_bgne_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable To Noncontrolling Interest, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestPeriodIncreaseDecrease" xlink:href="bgne-20241231.xsd#bgne_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestPeriodIncreaseDecrease" xlink:to="lab_bgne_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_862b71a9-6e91-4eda-a440-f3f1d37cef9a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reductions based on lapse of statute of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_d6e78887-2a4a-4336-ab5a-5c7df267fe75_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7e2f2fc3-dd89-48b0-adfc-badd8fcc43db_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized holding (loss) gain, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_912cfa0a-fdc1-49b0-917c-6e49c465827a_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares outstanding&#8212; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bbf7425a-2f1e-4a36-b14a-02d9a6dec855_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding for computing diluted loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CondensedFinancialStatementsCaptionsLineItems_4018818d-7261-425f-bef1-c06865a2fb3a_terseLabel_en-US" xlink:label="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Condensed Financial Statements, Captions [Line Items]</link:label>
    <link:label id="lab_srt_CondensedFinancialStatementsCaptionsLineItems_label_en-US" xlink:label="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Condensed Financial Statements, Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_cdd42f82-ad7b-44d1-8949-24a98d0abf58_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Movement in accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_c631d6d6-4e27-4d62-9177-c017b20a25e6_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_faf73f79-cef0-439d-a90c-53edc45f8753_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_225efd3a-5785-4edf-a8bd-5dc929d2b583_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at the beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_cd414514-aaa6-4889-8d87-2d364347c189_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at the ending of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_db2a4131-7435-494b-9449-eeb3e25be560_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_6f5ef5e0-4cde-4297-bac4-3d404caf87b4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_b829eb3c-1bdd-4f42-bff7-2f45313319c0_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative and Licensing Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_8a4cafe9-0643-4033-bbeb-f91961a74de9_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_CollaborationResearchAndDevelopmentServiceMember_f496f898-5d0f-45a3-ab7d-d64d49c713b8_terseLabel_en-US" xlink:label="lab_bgne_CollaborationResearchAndDevelopmentServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development service revenue</link:label>
    <link:label id="lab_bgne_CollaborationResearchAndDevelopmentServiceMember_label_en-US" xlink:label="lab_bgne_CollaborationResearchAndDevelopmentServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Research And Development Service [Member]</link:label>
    <link:label id="lab_bgne_CollaborationResearchAndDevelopmentServiceMember_documentation_en-US" xlink:label="lab_bgne_CollaborationResearchAndDevelopmentServiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration, Research and Development Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_CollaborationResearchAndDevelopmentServiceMember" xlink:href="bgne-20241231.xsd#bgne_CollaborationResearchAndDevelopmentServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_CollaborationResearchAndDevelopmentServiceMember" xlink:to="lab_bgne_CollaborationResearchAndDevelopmentServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_d41fde8b-253d-4944-94c6-96fdb27879d6_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software, Electronic and Office Equipment</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_c56e55d3-d1cb-4398-b8eb-4977b35610f3_verboseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Software, electronics and office equipment</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_14417475-3f7b-429a-8689-43e0a6949bf6_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ShanghaiPharmaceuticalMember_08df6614-254d-49eb-9024-8720536b72f9_terseLabel_en-US" xlink:label="lab_bgne_ShanghaiPharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shanghai Pharmaceutical</link:label>
    <link:label id="lab_bgne_ShanghaiPharmaceuticalMember_label_en-US" xlink:label="lab_bgne_ShanghaiPharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shanghai Pharmaceutical [Member]</link:label>
    <link:label id="lab_bgne_ShanghaiPharmaceuticalMember_documentation_en-US" xlink:label="lab_bgne_ShanghaiPharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shanghai Pharmaceutical</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShanghaiPharmaceuticalMember" xlink:href="bgne-20241231.xsd#bgne_ShanghaiPharmaceuticalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ShanghaiPharmaceuticalMember" xlink:to="lab_bgne_ShanghaiPharmaceuticalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_441f2546-fbce-469e-a1ae-9e5083c42f4a_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_e332fd23-6e8a-479c-8a0d-457a41088c1e_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_0b270354-341b-426a-8512-e25ba9fe1b8f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employer contribution to retirement plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_DisposalGroupNotDiscontinuedOperationNetAssets_e23673cc-a50f-4a4a-b61a-50c0d923506d_terseLabel_en-US" xlink:label="lab_bgne_DisposalGroupNotDiscontinuedOperationNetAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net assets disposed of</link:label>
    <link:label id="lab_bgne_DisposalGroupNotDiscontinuedOperationNetAssets_label_en-US" xlink:label="lab_bgne_DisposalGroupNotDiscontinuedOperationNetAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Net Assets</link:label>
    <link:label id="lab_bgne_DisposalGroupNotDiscontinuedOperationNetAssets_documentation_en-US" xlink:label="lab_bgne_DisposalGroupNotDiscontinuedOperationNetAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net assets attributable to disposal group not classified as discontinued operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_DisposalGroupNotDiscontinuedOperationNetAssets" xlink:href="bgne-20241231.xsd#bgne_DisposalGroupNotDiscontinuedOperationNetAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_DisposalGroupNotDiscontinuedOperationNetAssets" xlink:to="lab_bgne_DisposalGroupNotDiscontinuedOperationNetAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_6ef65082-4cc6-4b56-8504-89c658e43645_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales - product</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_f7e1726e-9257-4b7f-91af-2de2cf326b98_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost of Sales - Product</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_bbd555b7-9ad2-4a90-8cfa-22350001a23a_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product revenue, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ChinaConstructionBankMember_b13ef9f6-0a90-4998-b4ad-133c5e2f4271_terseLabel_en-US" xlink:label="lab_bgne_ChinaConstructionBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">China Construction Bank</link:label>
    <link:label id="lab_bgne_ChinaConstructionBankMember_label_en-US" xlink:label="lab_bgne_ChinaConstructionBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">China Construction Bank [Member]</link:label>
    <link:label id="lab_bgne_ChinaConstructionBankMember_documentation_en-US" xlink:label="lab_bgne_ChinaConstructionBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">China Construction Bank [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ChinaConstructionBankMember" xlink:href="bgne-20241231.xsd#bgne_ChinaConstructionBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ChinaConstructionBankMember" xlink:to="lab_bgne_ChinaConstructionBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_20ec27ee-67a0-4c1f-888a-8a268a40401d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares reserved and available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_b44a679b-41fe-4ad1-836c-ca41f6258987_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_9b6abcd6-0369-4b6f-bc0e-acb754bc8d9e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_0b967507-ec43-46e8-af49-d394655fadbb_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_7ca12917-e83f-4307-85b0-99cd4a08a5fa_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities with readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_bf01ad39-8cf6-406b-8988-d2f74cd5d65f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gains/Losses&#160;on Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_2114b7cc-dd99-4557-b528-2360b29f5aa7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ff4c73ec-25c7-4a03-9d8e-3b3bbb19434a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_be50ad72-cd71-48f1-a341-83d426f1f963_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5ed0102c-0c83-4e49-8009-f8dbed9a683e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_16d287a9-ae85-474d-979f-c6102fdf0796_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net-current period other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f3231533-d1d2-4478-a39c-fb9ee20c80b2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield (as percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_4df93480-d188-498d-bce3-596e996d9a86_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_FinancingCommitmentExpenses_3283ce15-a5fc-456c-af92-5df442cc23b8_totalLabel_en-US" xlink:label="lab_bgne_FinancingCommitmentExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">BeiGene&#8217;s portion of the development funding</link:label>
    <link:label id="lab_bgne_FinancingCommitmentExpenses_label_en-US" xlink:label="lab_bgne_FinancingCommitmentExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Commitment Expenses</link:label>
    <link:label id="lab_bgne_FinancingCommitmentExpenses_documentation_en-US" xlink:label="lab_bgne_FinancingCommitmentExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financing Commitment Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_FinancingCommitmentExpenses" xlink:href="bgne-20241231.xsd#bgne_FinancingCommitmentExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_FinancingCommitmentExpenses" xlink:to="lab_bgne_FinancingCommitmentExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_DepreciationExpenseMember_482c6199-1f7f-497d-972c-213528fd060d_terseLabel_en-US" xlink:label="lab_bgne_DepreciationExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation Expense</link:label>
    <link:label id="lab_bgne_DepreciationExpenseMember_label_en-US" xlink:label="lab_bgne_DepreciationExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation Expense [Member]</link:label>
    <link:label id="lab_bgne_DepreciationExpenseMember_documentation_en-US" xlink:label="lab_bgne_DepreciationExpenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Depreciation Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_DepreciationExpenseMember" xlink:href="bgne-20241231.xsd#bgne_DepreciationExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_DepreciationExpenseMember" xlink:to="lab_bgne_DepreciationExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_ef4d69fd-fbfb-47a0-9b7b-f9f9a7805656_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_BLINCYTOMember_e65696c8-2f3e-48f0-984c-3ef7d27e32b1_terseLabel_en-US" xlink:label="lab_bgne_BLINCYTOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BLINCYTO&#174;</link:label>
    <link:label id="lab_bgne_BLINCYTOMember_label_en-US" xlink:label="lab_bgne_BLINCYTOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BLINCYTO [Member]</link:label>
    <link:label id="lab_bgne_BLINCYTOMember_documentation_en-US" xlink:label="lab_bgne_BLINCYTOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BLINCYTO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_BLINCYTOMember" xlink:href="bgne-20241231.xsd#bgne_BLINCYTOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_BLINCYTOMember" xlink:to="lab_bgne_BLINCYTOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedAssetsDisclosureTextBlock_6e43907b-d3ac-4654-93fd-86161b177104_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Net Assets</link:label>
    <link:label id="lab_us-gaap_RestrictedAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_RevenueRecognitionRevenueReductionsPaymentsAndCredits_8831f0f8-4eb2-42f0-8bd3-532d188d8d32_negatedTerseLabel_en-US" xlink:label="lab_bgne_RevenueRecognitionRevenueReductionsPaymentsAndCredits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments and credits</link:label>
    <link:label id="lab_bgne_RevenueRecognitionRevenueReductionsPaymentsAndCredits_label_en-US" xlink:label="lab_bgne_RevenueRecognitionRevenueReductionsPaymentsAndCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition Revenue Reductions Payments And Credits</link:label>
    <link:label id="lab_bgne_RevenueRecognitionRevenueReductionsPaymentsAndCredits_documentation_en-US" xlink:label="lab_bgne_RevenueRecognitionRevenueReductionsPaymentsAndCredits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition Revenue Reductions Payments And Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RevenueRecognitionRevenueReductionsPaymentsAndCredits" xlink:href="bgne-20241231.xsd#bgne_RevenueRecognitionRevenueReductionsPaymentsAndCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_RevenueRecognitionRevenueReductionsPaymentsAndCredits" xlink:to="lab_bgne_RevenueRecognitionRevenueReductionsPaymentsAndCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ParentCompanyMember_808665f6-636c-486c-97c4-07974331d957_terseLabel_en-US" xlink:label="lab_srt_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Parent Company</link:label>
    <link:label id="lab_srt_ParentCompanyMember_label_en-US" xlink:label="lab_srt_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent Company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ParentCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ParentCompanyMember" xlink:to="lab_srt_ParentCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_7547055e-df25-4563-9ee3-28a96d867274_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock_6ffdd190-dcf7-48e2-a4a7-b8c89adef704_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Condensed Statements of Cash Flows</link:label>
    <link:label id="lab_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock_label_en-US" xlink:label="lab_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Condensed Cash Flow Statement [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedCashFlowStatementTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:to="lab_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_41bb6c49-37ba-4074-9742-8a0e9d94a832_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_f5c7e02e-50b4-4a8a-bff7-6d08892b2bda_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_95c28e04-87c6-438e-b55d-d594bf7a1467_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_c362de76-f883-4ba5-a992-c0c3fae73cd9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage_54644358-5470-4f0b-b435-9a84914292be_terseLabel_en-US" xlink:label="lab_bgne_RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum required statutory reserve of annual after-tax profit (as a percent)</link:label>
    <link:label id="lab_bgne_RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage_label_en-US" xlink:label="lab_bgne_RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Net Assets, Minimum Required Statutory Reserve of Annual After-tax Profit, Percentage</link:label>
    <link:label id="lab_bgne_RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage_documentation_en-US" xlink:label="lab_bgne_RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum required statutory reserve of annual after-tax profit as a percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage" xlink:href="bgne-20241231.xsd#bgne_RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage" xlink:to="lab_bgne_RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_LongTermFundingCommitmentMaximumAmount_230a2956-8965-4452-bea1-df2a68758e0b_terseLabel_en-US" xlink:label="lab_bgne_LongTermFundingCommitmentMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum commitment</link:label>
    <link:label id="lab_bgne_LongTermFundingCommitmentMaximumAmount_label_en-US" xlink:label="lab_bgne_LongTermFundingCommitmentMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Funding Commitment, Maximum Amount</link:label>
    <link:label id="lab_bgne_LongTermFundingCommitmentMaximumAmount_documentation_en-US" xlink:label="lab_bgne_LongTermFundingCommitmentMaximumAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-term Funding Commitment, Maximum Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_LongTermFundingCommitmentMaximumAmount" xlink:href="bgne-20241231.xsd#bgne_LongTermFundingCommitmentMaximumAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_LongTermFundingCommitmentMaximumAmount" xlink:to="lab_bgne_LongTermFundingCommitmentMaximumAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_dcc7b4c8-9115-45aa-80b8-399231b2f4a0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on BMS termination settlement</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) from Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ResearchAndDevelopmentCostShareLiabilityCurrentPortion_87984f5c-1f1b-4a12-bfab-8e994d72b7bf_terseLabel_en-US" xlink:label="lab_bgne_ResearchAndDevelopmentCostShareLiabilityCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development cost share liability, current portion</link:label>
    <link:label id="lab_bgne_ResearchAndDevelopmentCostShareLiabilityCurrentPortion_label_en-US" xlink:label="lab_bgne_ResearchAndDevelopmentCostShareLiabilityCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Cost Share Liability, Current Portion</link:label>
    <link:label id="lab_bgne_ResearchAndDevelopmentCostShareLiabilityCurrentPortion_documentation_en-US" xlink:label="lab_bgne_ResearchAndDevelopmentCostShareLiabilityCurrentPortion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Cost Share Liability, Current Portion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ResearchAndDevelopmentCostShareLiabilityCurrentPortion" xlink:href="bgne-20241231.xsd#bgne_ResearchAndDevelopmentCostShareLiabilityCurrentPortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ResearchAndDevelopmentCostShareLiabilityCurrentPortion" xlink:to="lab_bgne_ResearchAndDevelopmentCostShareLiabilityCurrentPortion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0b6353b7-11a1-4414-a228-eb68f6a530bb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of the Range of Fair Values and the Assumptions Used to Estimate the Fair Values of the Share Options Granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_d9648d54-90a8-40dd-8497-7713f3ca52f1_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_0eb0d3f3-74c5-4a3d-9509-0468842b9523_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_ff8fe850-d873-4a07-97d5-3fb5912c251f_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ff24a03b-e530-4ce3-91a3-84905e97bf1c_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_b2f445a8-5c36-4f5a-a9cc-ac313b11a1f0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_913e7329-517c-4a5f-b79a-98b3517696ad_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive (loss) income, net of tax of nil:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_0164c5ab-ba7d-4957-9259-e2b70db9cf3a_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_SummaryOfValuationAllowanceTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="lab_us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_2e8869e6-b727-43e4-a774-201043d2afa7_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_17a49377-c595-406e-bce8-f7f237d5eeca_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_CollaborativeArrangementsNumberOfProductsCompanyHasTheRightToRetain_403fa126-eca1-4f67-b62a-52948a293a03_terseLabel_en-US" xlink:label="lab_bgne_CollaborativeArrangementsNumberOfProductsCompanyHasTheRightToRetain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of products company has the right to retain</link:label>
    <link:label id="lab_bgne_CollaborativeArrangementsNumberOfProductsCompanyHasTheRightToRetain_label_en-US" xlink:label="lab_bgne_CollaborativeArrangementsNumberOfProductsCompanyHasTheRightToRetain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements, Number Of Products Company Has The Right To Retain</link:label>
    <link:label id="lab_bgne_CollaborativeArrangementsNumberOfProductsCompanyHasTheRightToRetain_documentation_en-US" xlink:label="lab_bgne_CollaborativeArrangementsNumberOfProductsCompanyHasTheRightToRetain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements, Number Of Products Company Has The Right To Retain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_CollaborativeArrangementsNumberOfProductsCompanyHasTheRightToRetain" xlink:href="bgne-20241231.xsd#bgne_CollaborativeArrangementsNumberOfProductsCompanyHasTheRightToRetain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_CollaborativeArrangementsNumberOfProductsCompanyHasTheRightToRetain" xlink:to="lab_bgne_CollaborativeArrangementsNumberOfProductsCompanyHasTheRightToRetain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_5ac6ce55-c9d5-4778-8066-ebd7bb24e93c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax relief credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_91a5afc8-defc-4343-9c87-689b2861d0d6_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_1ad723bf-0dcb-4a20-b55a-e77be53c8d62_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_499d5761-2916-417b-9684-26dbbeb9eab8_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_CollaborativeArrangementsProductRetentionPeriod_a3615581-ef53-473d-98ae-bd29e22b0ce9_terseLabel_en-US" xlink:label="lab_bgne_CollaborativeArrangementsProductRetentionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product retention period</link:label>
    <link:label id="lab_bgne_CollaborativeArrangementsProductRetentionPeriod_label_en-US" xlink:label="lab_bgne_CollaborativeArrangementsProductRetentionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements, Product Retention Period</link:label>
    <link:label id="lab_bgne_CollaborativeArrangementsProductRetentionPeriod_documentation_en-US" xlink:label="lab_bgne_CollaborativeArrangementsProductRetentionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements, Product Retention Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_CollaborativeArrangementsProductRetentionPeriod" xlink:href="bgne-20241231.xsd#bgne_CollaborativeArrangementsProductRetentionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_CollaborativeArrangementsProductRetentionPeriod" xlink:to="lab_bgne_CollaborativeArrangementsProductRetentionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_8bbec433-e2f0-467a-807a-d9936327caba_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_cc28f785-8f67-495e-a391-cbfefd14bfea_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss per share diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_149e6753-9ca9-4150-9263-aa344c45fbde_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_97c032db-a176-48dc-a543-7a799922c099_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_5cf2b653-64df-4bb8-b865-eb219f065718_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_fc610708-ceaf-4cfb-a3a4-e5dd0cc9b83a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets Amortization Expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_3e6c1347-4d89-48fb-8e63-941aa72b7ca3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PRC</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_c9b9948b-8ce4-49a0-ba3c-f036b0837fb2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_5448cc77-d6e0-4817-b480-b5d2b5ec8429_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_InvestmentInDebtSecuritiesCurrent_c34da13f-86e8-4c6f-98e2-5681ed3d8193_terseLabel_en-US" xlink:label="lab_bgne_InvestmentInDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible debt instrument</link:label>
    <link:label id="lab_bgne_InvestmentInDebtSecuritiesCurrent_label_en-US" xlink:label="lab_bgne_InvestmentInDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment In Debt Securities, Current</link:label>
    <link:label id="lab_bgne_InvestmentInDebtSecuritiesCurrent_documentation_en-US" xlink:label="lab_bgne_InvestmentInDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment In Debt Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_InvestmentInDebtSecuritiesCurrent" xlink:href="bgne-20241231.xsd#bgne_InvestmentInDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_InvestmentInDebtSecuritiesCurrent" xlink:to="lab_bgne_InvestmentInDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_FairValueOfLiabilityAcquired_2b68ce89-0144-44c2-9136-b6443ada4f32_terseLabel_en-US" xlink:label="lab_bgne_FairValueOfLiabilityAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of cost share liability</link:label>
    <link:label id="lab_bgne_FairValueOfLiabilityAcquired_label_en-US" xlink:label="lab_bgne_FairValueOfLiabilityAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Liability Acquired</link:label>
    <link:label id="lab_bgne_FairValueOfLiabilityAcquired_documentation_en-US" xlink:label="lab_bgne_FairValueOfLiabilityAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Of Liability Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_FairValueOfLiabilityAcquired" xlink:href="bgne-20241231.xsd#bgne_FairValueOfLiabilityAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_FairValueOfLiabilityAcquired" xlink:to="lab_bgne_FairValueOfLiabilityAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_fa229beb-e727-4dd4-b71d-56c24ee0c3f6_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_MaterialRightsRevenueMember_60c19dba-6b84-49fd-8e9e-e0d9f7dfa096_terseLabel_en-US" xlink:label="lab_bgne_MaterialRightsRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material rights revenue</link:label>
    <link:label id="lab_bgne_MaterialRightsRevenueMember_label_en-US" xlink:label="lab_bgne_MaterialRightsRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Rights Revenue [Member]</link:label>
    <link:label id="lab_bgne_MaterialRightsRevenueMember_documentation_en-US" xlink:label="lab_bgne_MaterialRightsRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Material Rights Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_MaterialRightsRevenueMember" xlink:href="bgne-20241231.xsd#bgne_MaterialRightsRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_MaterialRightsRevenueMember" xlink:to="lab_bgne_MaterialRightsRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentAssistanceLiabilityNoncurrent_5fec0950-baab-4679-976a-91587217c505_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government assistance, liability, noncurrent</link:label>
    <link:label id="lab_us-gaap_GovernmentAssistanceLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Assistance, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceLiabilityNoncurrent" xlink:to="lab_us-gaap_GovernmentAssistanceLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_e4b2dbdd-259d-4417-a640-bd73893ffd16_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_48953203-4d55-4b34-8324-8b8a5c7e52f1_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Participant's contributions matched (as a percent)</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_c3108869-9e6a-444a-9573-77e1e0071424_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_ee69ac45-c126-4cf5-8462-77fdb948edc8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CondensedStatementOfComprehensiveIncomeTableTextBlock_5c5c125a-73b9-40d5-a22d-2b6af398d375_terseLabel_en-US" xlink:label="lab_srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Condensed Statements of Comprehensive Loss</link:label>
    <link:label id="lab_srt_CondensedStatementOfComprehensiveIncomeTableTextBlock_label_en-US" xlink:label="lab_srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Condensed Statement of Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedStatementOfComprehensiveIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:to="lab_srt_CondensedStatementOfComprehensiveIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_DeferredTaxAssetsPropertyLeaseLiabilityObligation_e5d33dab-9a46-42e6-aedd-7a7330f98208_terseLabel_en-US" xlink:label="lab_bgne_DeferredTaxAssetsPropertyLeaseLiabilityObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liability obligation</link:label>
    <link:label id="lab_bgne_DeferredTaxAssetsPropertyLeaseLiabilityObligation_label_en-US" xlink:label="lab_bgne_DeferredTaxAssetsPropertyLeaseLiabilityObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Property, Lease Liability Obligation</link:label>
    <link:label id="lab_bgne_DeferredTaxAssetsPropertyLeaseLiabilityObligation_documentation_en-US" xlink:label="lab_bgne_DeferredTaxAssetsPropertyLeaseLiabilityObligation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Property, Lease Liability Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_DeferredTaxAssetsPropertyLeaseLiabilityObligation" xlink:href="bgne-20241231.xsd#bgne_DeferredTaxAssetsPropertyLeaseLiabilityObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_DeferredTaxAssetsPropertyLeaseLiabilityObligation" xlink:to="lab_bgne_DeferredTaxAssetsPropertyLeaseLiabilityObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_EmployeeSharePurchasePlan2018Member_90015461-b887-4b55-aa10-8ea3fd5fe749_terseLabel_en-US" xlink:label="lab_bgne_EmployeeSharePurchasePlan2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Share Purchase Plan 2018</link:label>
    <link:label id="lab_bgne_EmployeeSharePurchasePlan2018Member_label_en-US" xlink:label="lab_bgne_EmployeeSharePurchasePlan2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Share Purchase Plan2018 [Member]</link:label>
    <link:label id="lab_bgne_EmployeeSharePurchasePlan2018Member_documentation_en-US" xlink:label="lab_bgne_EmployeeSharePurchasePlan2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The 2018 Employee Share Purchase Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_EmployeeSharePurchasePlan2018Member" xlink:href="bgne-20241231.xsd#bgne_EmployeeSharePurchasePlan2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_EmployeeSharePurchasePlan2018Member" xlink:to="lab_bgne_EmployeeSharePurchasePlan2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_674db296-f37a-4238-98e0-f4690addbf05_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Research tax credits and incentives</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_70995b26-a400-47ea-8e67-5ce31344d9c3_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-tax gain</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_a5d46702-7d76-488c-ad30-8adaf901e2b0_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_5026a4da-d09b-49c2-8410-cbffa2472bd3_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_74955bb8-6d7f-4af9-aaf3-1d3a11a1d9d7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_a823cf18-9920-49d4-b516-46d5cd3e2c62_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of income / (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8066d897-391a-4e85-99d1-cc03a29c24b2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a1fe9fba-af46-4c56-92f2-27c2e882a4ee_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of unrecognized share-based compensation cost over average amortization (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b018edff-5e5a-4fe2-ae73-9524b4481bb8_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_69ce0fcb-c294-49e5-8e96-234b64f60cff_totalLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Product revenue - net</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c96338ef-a36c-46c8-9646-dc07ae4d5571_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue from contract with customer</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_9e6b725f-6857-4f51-8c24-9ee37a8dddd1_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_afd2c000-8fbe-4729-a253-682177152485_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_e8e8a058-70e0-4555-8198-b81f35e4ebcb_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_ea7208fb-eacc-4a59-aa51-e0d42e1ffa7d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in ordinary shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_cda35642-7274-4e7d-9343-1b5de4181e2a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other items, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_5d6f8c64-7f82-4e3e-8ef9-e1568ed43d85_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation related</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_ddd9d146-a81d-487b-a8a0-913a086231e8_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7c2f2a11-9142-4abf-b5ae-3bb22bb32141_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_f3062c94-ac24-4cdb-b4fa-e26708849175_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_b41117af-078c-4f76-ba96-0b4134d44532_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b554d603-30c7-45a9-98e2-d887e22ee6ba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_ca8e0469-6683-44fa-bda8-73120240fc23_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c7bb9594-344d-4dca-99cd-b982721e65a9_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ShortTermBankLoanDatedApril42018Member_88a8b18f-ba92-4858-8ad6-f8f68f7b4788_terseLabel_en-US" xlink:label="lab_bgne_ShortTermBankLoanDatedApril42018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short Term Bank Loan Dated April 4 2018</link:label>
    <link:label id="lab_bgne_ShortTermBankLoanDatedApril42018Member_label_en-US" xlink:label="lab_bgne_ShortTermBankLoanDatedApril42018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short Term Bank Loan Dated April 4 2018 [Member]</link:label>
    <link:label id="lab_bgne_ShortTermBankLoanDatedApril42018Member_documentation_en-US" xlink:label="lab_bgne_ShortTermBankLoanDatedApril42018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short Term Bank Loan Dated April 4 2018</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShortTermBankLoanDatedApril42018Member" xlink:href="bgne-20241231.xsd#bgne_ShortTermBankLoanDatedApril42018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ShortTermBankLoanDatedApril42018Member" xlink:to="lab_bgne_ShortTermBankLoanDatedApril42018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_df55577c-5cb8-43da-9cbd-2b7baef5d0a0_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_8eeabd71-2cb0-4c1a-b62a-c7cfb37395b9_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income (Expense), Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_4eacb681-2e06-4810-9fb1-a553c3a0cf58_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_SinopharmMember_34ffaf2a-a2d1-4c1b-8be8-56622da58f95_terseLabel_en-US" xlink:label="lab_bgne_SinopharmMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sinopharm</link:label>
    <link:label id="lab_bgne_SinopharmMember_label_en-US" xlink:label="lab_bgne_SinopharmMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sinopharm [Member]</link:label>
    <link:label id="lab_bgne_SinopharmMember_documentation_en-US" xlink:label="lab_bgne_SinopharmMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sinopharm</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_SinopharmMember" xlink:href="bgne-20241231.xsd#bgne_SinopharmMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_SinopharmMember" xlink:to="lab_bgne_SinopharmMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_c2a984d5-6048-4461-98a5-ddd1bbf2de91_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee defined contribution plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfCondensedIncomeStatementTableTextBlock_0e119d64-5abb-4880-af44-4e82b6af2999_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Condensed Statements of Operations</link:label>
    <link:label id="lab_srt_ScheduleOfCondensedIncomeStatementTableTextBlock_label_en-US" xlink:label="lab_srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Condensed Income Statement [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:to="lab_srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_be948785-04a1-4272-8ee5-f300d318efd2_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_d39a1fb3-e953-4bc3-90b9-a5fcdb06424a_totalLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_df8f00d9-b540-4061-af25-3585f8c2a9bd_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_6329c90d-d154-4c36-ae51-c053bbf3e374_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Shares Issued Under Employee Share Purchase Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_0dcad62d-e1e9-4008-8652-34b9fa87bcc1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant unobservable inputs used in the fair value measurement</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_fe167855-e74f-458d-99c7-dffa3cc6f449_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a278b45-bad4-4ec4-9f3a-4cb49b8541e5_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b495a9e8-096a-431a-94a6-cbc33ae66190_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at the beginning of the year (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5e982fee-f5fe-4936-ae16-f2bd8f2a05d1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at the end of the year (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3d7652cd-b719-4150-960f-dd49fb1ba698_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions_38910c2f-0b14-4901-82b6-e57e0d781931_terseLabel_en-US" xlink:label="lab_bgne_RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_bgne_RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions_e771dcc6-c0f9-4cfa-b3c0-16d3899b2bd2_periodEndLabel_en-US" xlink:label="lab_bgne_RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_bgne_RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions_label_en-US" xlink:label="lab_bgne_RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Allowance For Chargebacks And Credit Loss And Reserves For Sales Returns, Rebates And Other Deductions</link:label>
    <link:label id="lab_bgne_RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions_documentation_en-US" xlink:label="lab_bgne_RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Allowance For Chargebacks And Credit Loss And Reserves For Sales Returns, Rebates And Other Deductions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions" xlink:href="bgne-20241231.xsd#bgne_RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions" xlink:to="lab_bgne_RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_db03f438-cfe4-4696-8fe9-282f63674e23_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Options - Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_280757ba-ebad-4fb8-885c-ed11854a019a_terseLabel_en-US" xlink:label="lab_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule I - Condensed Financial Information of Registrant</link:label>
    <link:label id="lab_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Condensed Financial Information of Parent Company Only Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:to="lab_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_2a4f5845-2689-47f5-a56a-56288499e418_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation [Table]</link:label>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_label_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_dbb6ac20-55da-44d3-a26f-70e077aeb80c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ReimbursementExpense_9d57d4f2-0c07-44b1-9c71-48e62997257b_negatedTerseLabel_en-US" xlink:label="lab_bgne_ReimbursementExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_bgne_ReimbursementExpense_label_en-US" xlink:label="lab_bgne_ReimbursementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reimbursement Expense</link:label>
    <link:label id="lab_bgne_ReimbursementExpense_documentation_en-US" xlink:label="lab_bgne_ReimbursementExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reimbursement Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ReimbursementExpense" xlink:href="bgne-20241231.xsd#bgne_ReimbursementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ReimbursementExpense" xlink:to="lab_bgne_ReimbursementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d05159e0-d1fd-43a8-8ca9-316f10712fd2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at the beginning of the year (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f2b17d2d-216f-4bb3-8b3e-8c2a26b3519c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at the end of the year (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_9eb21e76-b5eb-44da-a0f6-4639b3d7a6bd_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_20e25031-023f-471e-a36b-7d89a5eb5dde_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_4d447265-fec7-41d5-be4f-72accd509adc_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_62ade153-2321-4a13-9599-91b9a5b4176f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at the beginning of the year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4eb8e3e3-e03a-41b0-b327-84d707879b0d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at the end of the year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_label_en-US" xlink:label="lab_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Condensed Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="lab_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_67ae7fe9-c9fc-4501-abd5-86a779a16704_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_8745a5d1-5c06-4a5e-aa43-6b3023fd5708_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ThirdAmendedAndRestated2016PlanMember_fd748f5b-fa2c-4e67-a4d0-82cd97b15452_terseLabel_en-US" xlink:label="lab_bgne_ThirdAmendedAndRestated2016PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Third Amended and Restated 2016 Plan</link:label>
    <link:label id="lab_bgne_ThirdAmendedAndRestated2016PlanMember_label_en-US" xlink:label="lab_bgne_ThirdAmendedAndRestated2016PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Third Amended And Restated 2016 Plan [Member]</link:label>
    <link:label id="lab_bgne_ThirdAmendedAndRestated2016PlanMember_documentation_en-US" xlink:label="lab_bgne_ThirdAmendedAndRestated2016PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Third Amended And Restated 2016 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ThirdAmendedAndRestated2016PlanMember" xlink:href="bgne-20241231.xsd#bgne_ThirdAmendedAndRestated2016PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ThirdAmendedAndRestated2016PlanMember" xlink:to="lab_bgne_ThirdAmendedAndRestated2016PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_fc4c7f1a-0628-4a75-b43a-8eb213f4fd91_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_be56f91b-8dc6-483b-a323-c421a9ab467a_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_LongTermBankLoanApril42018Member_151c91d1-2414-48fe-ad85-8fece588614d_terseLabel_en-US" xlink:label="lab_bgne_LongTermBankLoanApril42018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term bank April 4, 2018</link:label>
    <link:label id="lab_bgne_LongTermBankLoanApril42018Member_label_en-US" xlink:label="lab_bgne_LongTermBankLoanApril42018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long Term Bank Loan April42018 [Member]</link:label>
    <link:label id="lab_bgne_LongTermBankLoanApril42018Member_documentation_en-US" xlink:label="lab_bgne_LongTermBankLoanApril42018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long Term Bank Loan dated April 4, 2018.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_LongTermBankLoanApril42018Member" xlink:href="bgne-20241231.xsd#bgne_LongTermBankLoanApril42018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_LongTermBankLoanApril42018Member" xlink:to="lab_bgne_LongTermBankLoanApril42018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2ca6fd37-d2b2-4907-9e56-8a54a8bdf839_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_bfdac4c1-26b1-438f-8317-aff187cd23e7_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_819a11fa-e36c-4840-b75d-99230d178736_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_50eafa3e-49b8-4cf5-ac13-3a25a6781f77_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_UnrealizedGainLossInSubsidiaries_7a6945f2-0ae6-4908-aa38-217c2204f357_negatedTerseLabel_en-US" xlink:label="lab_bgne_UnrealizedGainLossInSubsidiaries" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized losses on long-term investments</link:label>
    <link:label id="lab_bgne_UnrealizedGainLossInSubsidiaries_label_en-US" xlink:label="lab_bgne_UnrealizedGainLossInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) In Subsidiaries</link:label>
    <link:label id="lab_bgne_UnrealizedGainLossInSubsidiaries_documentation_en-US" xlink:label="lab_bgne_UnrealizedGainLossInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) In Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_UnrealizedGainLossInSubsidiaries" xlink:href="bgne-20241231.xsd#bgne_UnrealizedGainLossInSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_UnrealizedGainLossInSubsidiaries" xlink:to="lab_bgne_UnrealizedGainLossInSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_144cf385-e678-4a64-82d0-a450b93c7efb_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1_4b4401f9-e299-42d5-8029-ab500931464f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss on fair value</link:label>
    <link:label id="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1_label_en-US" xlink:label="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Option, Changes in Fair Value, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:to="lab_us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_AccruedSalesRebatesAndReturnsCurrent_1e6c89df-cea2-4485-8c45-8e06edc1a651_terseLabel_en-US" xlink:label="lab_bgne_AccruedSalesRebatesAndReturnsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales rebates and returns related</link:label>
    <link:label id="lab_bgne_AccruedSalesRebatesAndReturnsCurrent_label_en-US" xlink:label="lab_bgne_AccruedSalesRebatesAndReturnsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Sales Rebates and Returns, Current</link:label>
    <link:label id="lab_bgne_AccruedSalesRebatesAndReturnsCurrent_documentation_en-US" xlink:label="lab_bgne_AccruedSalesRebatesAndReturnsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Sales Rebates and Returns, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AccruedSalesRebatesAndReturnsCurrent" xlink:href="bgne-20241231.xsd#bgne_AccruedSalesRebatesAndReturnsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_AccruedSalesRebatesAndReturnsCurrent" xlink:to="lab_bgne_AccruedSalesRebatesAndReturnsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_a35271f5-42c6-4729-9e26-78bb27b259b8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date&#160;Fair Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_335fc530-8369-4a54-90d9-7c79988a8b65_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentAssistanceLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration_47afa65c-6ecd-465d-b39d-7fde7b03c915_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Assistance, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_GovernmentAssistanceLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Assistance, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:to="lab_us-gaap_GovernmentAssistanceLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_d5a1af4d-d88a-497e-8a7f-6187ee1afbed_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_33c3f2af-3ea1-4487-9f4e-fdbe2160ad55_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_adb23fd6-ccf9-41a3-bd6c-3b21037c7555_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_5ec32618-dba1-4676-a4fe-db31edb3469f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Projected benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_7da100e3-3cfe-485a-b9db-8795baaf1bea_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Loss before tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_STARMarketMember_f78d89d0-9739-4490-8ea1-f8c8e5d10726_terseLabel_en-US" xlink:label="lab_bgne_STARMarketMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STAR Market</link:label>
    <link:label id="lab_bgne_STARMarketMember_label_en-US" xlink:label="lab_bgne_STARMarketMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">STAR Market [Member]</link:label>
    <link:label id="lab_bgne_STARMarketMember_documentation_en-US" xlink:label="lab_bgne_STARMarketMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">STAR Market</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_STARMarketMember" xlink:href="bgne-20241231.xsd#bgne_STARMarketMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_STARMarketMember" xlink:to="lab_bgne_STARMarketMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_f68730b9-f92c-458a-a074-3eabe968ee82_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_d22704be-cb46-47a3-b7de-37ec65195eec_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_61fe2ff3-21d0-4c76-a592-b1ed0e701beb_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net product revenues by geographic area</link:label>
    <link:label id="lab_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_label_en-US" xlink:label="lab_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographic Areas, Revenues from External Customers [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract" xlink:to="lab_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_XGEVAMember_aee6af19-20a0-439a-b1fd-0ef0583855f4_terseLabel_en-US" xlink:label="lab_bgne_XGEVAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">XGEVA&#174;</link:label>
    <link:label id="lab_bgne_XGEVAMember_label_en-US" xlink:label="lab_bgne_XGEVAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">XGEVA [Member]</link:label>
    <link:label id="lab_bgne_XGEVAMember_documentation_en-US" xlink:label="lab_bgne_XGEVAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">XGEVA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_XGEVAMember" xlink:href="bgne-20241231.xsd#bgne_XGEVAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_XGEVAMember" xlink:to="lab_bgne_XGEVAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_026fd8e6-2611-44df-baf2-b3ae22a4b0ff_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_09c44831-5af9-4709-ab7a-5725d1fc9885_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_97950dce-96b9-473d-8713-06917bef32dc_periodStartLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, as of January 1</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_d2d85a6a-8e99-4fa9-bfed-29b2e746bb8a_periodEndLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, as of December 31</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_ae4009fd-abf3-4ce6-9dde-706a3456dae0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of long-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Interest in Subsidiaries and Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:to="lab_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_d5bbdfe9-ed6c-4849-b800-c20ae31de194_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a0e4c2f6-be25-488a-b3e2-aa8d621a4758_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_eb45b245-f351-4426-98d1-b7a8a2676f61_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_CollaborationOtherMember_823fdc8b-f420-469b-9b9c-8d5bc7ab772d_terseLabel_en-US" xlink:label="lab_bgne_CollaborationOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_bgne_CollaborationOtherMember_label_en-US" xlink:label="lab_bgne_CollaborationOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Other [Member]</link:label>
    <link:label id="lab_bgne_CollaborationOtherMember_documentation_en-US" xlink:label="lab_bgne_CollaborationOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_CollaborationOtherMember" xlink:href="bgne-20241231.xsd#bgne_CollaborationOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_CollaborationOtherMember" xlink:to="lab_bgne_CollaborationOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember_7cef6b51-3d08-46f3-8a46-ca3eda404191_terseLabel_en-US" xlink:label="lab_bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember_33dccc66-24a1-483e-ae0c-b8645e1da01a_verboseLabel_en-US" xlink:label="lab_bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Rest of world- total revenue</link:label>
    <link:label id="lab_bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember_label_en-US" xlink:label="lab_bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Other Countries Except China And United States Of America [Member]</link:label>
    <link:label id="lab_bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember_documentation_en-US" xlink:label="lab_bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">All Other Countries Except China and The United States of America [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember" xlink:href="bgne-20241231.xsd#bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember" xlink:to="lab_bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_7d20efea-ceff-438d-9d4a-bf75c88b4fee_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_a56c7808-a4bb-4115-84f7-325d664b7426_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_UpfrontAndMilestonePayments_6aad621d-3f67-40c9-8d9e-c7b1a6b0399a_terseLabel_en-US" xlink:label="lab_bgne_UpfrontAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_bgne_UpfrontAndMilestonePayments_label_en-US" xlink:label="lab_bgne_UpfrontAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront And Milestone Payments</link:label>
    <link:label id="lab_bgne_UpfrontAndMilestonePayments_documentation_en-US" xlink:label="lab_bgne_UpfrontAndMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront And Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_UpfrontAndMilestonePayments" xlink:href="bgne-20241231.xsd#bgne_UpfrontAndMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_UpfrontAndMilestonePayments" xlink:to="lab_bgne_UpfrontAndMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_3a274068-ef5e-483c-a334-0233a0f18b2b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_6151581b-e4a9-4c24-bf72-a334dc58820b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary&#160;Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfCondensedFinancialStatementsTable_b81226e1-0658-45d4-b167-a2989d115e48_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Condensed Financial Statements [Table]</link:label>
    <link:label id="lab_srt_ScheduleOfCondensedFinancialStatementsTable_label_en-US" xlink:label="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Condensed Financial Statements [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligationDueInThirdYear_f2a18c06-d5c8-404b-92d2-19ba8dd204cf_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year ending December 31, 2027</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInThirdYear_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInThirdYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInThirdYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInThirdYear" xlink:to="lab_us-gaap_ContractualObligationDueInThirdYear" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_PrepaidManufacturingCosts_e5b33e3a-f515-4520-b0b9-afa174977df5_terseLabel_en-US" xlink:label="lab_bgne_PrepaidManufacturingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid manufacturing cost</link:label>
    <link:label id="lab_bgne_PrepaidManufacturingCosts_label_en-US" xlink:label="lab_bgne_PrepaidManufacturingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Manufacturing Costs</link:label>
    <link:label id="lab_bgne_PrepaidManufacturingCosts_documentation_en-US" xlink:label="lab_bgne_PrepaidManufacturingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid Manufacturing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_PrepaidManufacturingCosts" xlink:href="bgne-20241231.xsd#bgne_PrepaidManufacturingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_PrepaidManufacturingCosts" xlink:to="lab_bgne_PrepaidManufacturingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion_858da4ef-f59e-47b7-9c79-48f5234e2d4d_terseLabel_en-US" xlink:label="lab_bgne_ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development cost share liability, non-current portion</link:label>
    <link:label id="lab_bgne_ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion_label_en-US" xlink:label="lab_bgne_ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Cost Share Liability, Non-current Portion</link:label>
    <link:label id="lab_bgne_ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion_documentation_en-US" xlink:label="lab_bgne_ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Cost Share Liability, Non-current Portion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion" xlink:href="bgne-20241231.xsd#bgne_ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion" xlink:to="lab_bgne_ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice_98734a67-ef5b-4870-9ab1-f15763ede7b5_terseLabel_en-US" xlink:label="lab_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price, ADS (in dollars per share)</link:label>
    <link:label id="lab_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice_label_en-US" xlink:label="lab_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued In Period American Depository Shares Exercise Price</link:label>
    <link:label id="lab_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice_documentation_en-US" xlink:label="lab_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period American Depository Shares Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice" xlink:href="bgne-20241231.xsd#bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice" xlink:to="lab_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_PaymentsDueToCollaborationPartnersTableTextBlock_5f60442a-a9c7-4fa9-815d-c3a061f39cc0_terseLabel_en-US" xlink:label="lab_bgne_PaymentsDueToCollaborationPartnersTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Payments Due to Collaboration Partners</link:label>
    <link:label id="lab_bgne_PaymentsDueToCollaborationPartnersTableTextBlock_label_en-US" xlink:label="lab_bgne_PaymentsDueToCollaborationPartnersTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Due To Collaboration Partners [Table Text Block]</link:label>
    <link:label id="lab_bgne_PaymentsDueToCollaborationPartnersTableTextBlock_documentation_en-US" xlink:label="lab_bgne_PaymentsDueToCollaborationPartnersTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments Due To Collaboration Partners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_PaymentsDueToCollaborationPartnersTableTextBlock" xlink:href="bgne-20241231.xsd#bgne_PaymentsDueToCollaborationPartnersTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_PaymentsDueToCollaborationPartnersTableTextBlock" xlink:to="lab_bgne_PaymentsDueToCollaborationPartnersTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_a9113a46-7590-42bc-a441-c00974fdabcb_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_a16adc33-550e-4d56-b473-ff1f9deb3f95_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost from issuance of ordinary shares</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_fe3f9cc3-28d3-4758-b6f4-2d607a8dcb77_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_9a6b1438-5320-4fb5-aa0b-04880b4950b4_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_c1b14767-d6e3-4616-83e3-9f23fb090cc7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_cbfa331b-d0d7-40d5-992e-1938bd3d3d55_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign&#160;Currency Translation Adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ShareOptionAndIncentivePlan2016Member_c3bc2671-416c-4eee-a3b7-1aa0f5e05f10_terseLabel_en-US" xlink:label="lab_bgne_ShareOptionAndIncentivePlan2016Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Plan</link:label>
    <link:label id="lab_bgne_ShareOptionAndIncentivePlan2016Member_label_en-US" xlink:label="lab_bgne_ShareOptionAndIncentivePlan2016Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Option And Incentive Plan2016 [Member]</link:label>
    <link:label id="lab_bgne_ShareOptionAndIncentivePlan2016Member_documentation_en-US" xlink:label="lab_bgne_ShareOptionAndIncentivePlan2016Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The 2016 Share Option and Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShareOptionAndIncentivePlan2016Member" xlink:href="bgne-20241231.xsd#bgne_ShareOptionAndIncentivePlan2016Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ShareOptionAndIncentivePlan2016Member" xlink:to="lab_bgne_ShareOptionAndIncentivePlan2016Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_HopewellFacilityMember_0e4c98a2-1247-4f15-ad78-b23f29806b3a_terseLabel_en-US" xlink:label="lab_bgne_HopewellFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hopewell Facility</link:label>
    <link:label id="lab_bgne_HopewellFacilityMember_label_en-US" xlink:label="lab_bgne_HopewellFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hopewell Facility [Member]</link:label>
    <link:label id="lab_bgne_HopewellFacilityMember_documentation_en-US" xlink:label="lab_bgne_HopewellFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hopewell Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_HopewellFacilityMember" xlink:href="bgne-20241231.xsd#bgne_HopewellFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_HopewellFacilityMember" xlink:to="lab_bgne_HopewellFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4fae6b27-a8e3-4ce9-9420-4f964720d5b6_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_4939c640-d4cf-4828-bd3e-4ddf01bb49e6_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_94ffd9e3-6c44-4daf-b1e7-fe3c3a8cd025_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment and Geographic Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_8ec80763-cce3-4042-ae53-fe38bfc6056a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_6cbe7d00-e823-4aa3-a151-24ddec480cd0_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_f1da139e-3c82-48cd-9ded-91bb70649c94_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Shares</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_ee910860-6548-4791-8d10-65093b4ffddb_terseLabel_en-US" xlink:label="lab_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain]</link:label>
    <link:label id="lab_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_label_en-US" xlink:label="lab_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:to="lab_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_RestrictedNetAssetsDisclosureAbstract_e8d1ec20-1b7b-4937-8ad4-612f82498df3_terseLabel_en-US" xlink:label="lab_bgne_RestrictedNetAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Net Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_bgne_RestrictedNetAssetsDisclosureAbstract_label_en-US" xlink:label="lab_bgne_RestrictedNetAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Net Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_bgne_RestrictedNetAssetsDisclosureAbstract_documentation_en-US" xlink:label="lab_bgne_RestrictedNetAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Net Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RestrictedNetAssetsDisclosureAbstract" xlink:href="bgne-20241231.xsd#bgne_RestrictedNetAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_RestrictedNetAssetsDisclosureAbstract" xlink:to="lab_bgne_RestrictedNetAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_5d53cc45-4463-45b8-9b62-2763afa20358_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanTable_905e4471-29d5-4611-ba43-2fe220b8cb72_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan [Table]</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanTable_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanTable" xlink:to="lab_us-gaap_DefinedContributionPlanTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_f0dea4b7-a82a-4941-9976-b3d8be7c1835_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Income&#160;(Loss) Before Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_1b8484f8-c425-423b-b004-62cdef70e618_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_92db4a0f-46e2-4508-adad-af8be5a8db5e_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, as of January 1</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_043e62c8-5df4-4a39-b87e-5d6f04d324bd_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, as of December 31</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_7c745de6-e4ad-4cc4-8c61-890f572b96b2_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BeiGene USA</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_473987bf-a595-4b82-9bac-3cb4823d23fc_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_6b1a9816-e2f1-48d7-a664-b631127b3306_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_a021ca10-45f3-45c1-9e95-eb76410699ea_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic_02661ff4-8b3a-44b7-a7f7-d82585df2488_terseLabel_en-US" xlink:label="lab_bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average ADSs outstanding, basic (in shares)</link:label>
    <link:label id="lab_bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic_label_en-US" xlink:label="lab_bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Of American Depository Shares Outstanding, Basic</link:label>
    <link:label id="lab_bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic_documentation_en-US" xlink:label="lab_bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted Average Number of American Depository Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic" xlink:href="bgne-20241231.xsd#bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic" xlink:to="lab_bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_AmgenIncMember_9bda5b58-5b18-4cad-9270-8e7ecc0b711c_terseLabel_en-US" xlink:label="lab_bgne_AmgenIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amgen, Inc</link:label>
    <link:label id="lab_bgne_AmgenIncMember_label_en-US" xlink:label="lab_bgne_AmgenIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amgen, Inc [Member]</link:label>
    <link:label id="lab_bgne_AmgenIncMember_documentation_en-US" xlink:label="lab_bgne_AmgenIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amgen, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AmgenIncMember" xlink:href="bgne-20241231.xsd#bgne_AmgenIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_AmgenIncMember" xlink:to="lab_bgne_AmgenIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ShortTermBankLoanDatedDecember202023Member_d61bd24a-29dd-41ae-90de-5b61fe6d6d74_terseLabel_en-US" xlink:label="lab_bgne_ShortTermBankLoanDatedDecember202023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short Term Bank Loan Dated December 20, 2023</link:label>
    <link:label id="lab_bgne_ShortTermBankLoanDatedDecember202023Member_label_en-US" xlink:label="lab_bgne_ShortTermBankLoanDatedDecember202023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short Term Bank Loan Dated December 20, 2023 [Member]</link:label>
    <link:label id="lab_bgne_ShortTermBankLoanDatedDecember202023Member_documentation_en-US" xlink:label="lab_bgne_ShortTermBankLoanDatedDecember202023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short Term Bank Loan Dated December 20, 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShortTermBankLoanDatedDecember202023Member" xlink:href="bgne-20241231.xsd#bgne_ShortTermBankLoanDatedDecember202023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ShortTermBankLoanDatedDecember202023Member" xlink:to="lab_bgne_ShortTermBankLoanDatedDecember202023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_37f9143e-06c0-4a1f-a9cc-ce4e3ef6fc14_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_26f63bb0-53a7-4c30-8907-00a42505da6b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_5e9b8967-47d3-4a78-b4b1-87802690dc6d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax on unremitted earnings</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_56ffe0d8-2050-4aca-965b-53f6912029e5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax on unremitted earnings</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Undistributed Foreign Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_854c782e-a82d-460c-b93c-976ae641af60_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9bd3d4f0-a128-4c40-92e8-db2fb415aa54_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e0f3614b-84aa-49cc-8cb2-64109493cb9d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Grant&#160;Date&#160;Fair&#160;Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_AcquiredInProcessResearchAndDevelopment_834cd67c-5cda-470d-aae5-a5612cfae897_terseLabel_en-US" xlink:label="lab_bgne_AcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_bgne_AcquiredInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_bgne_AcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired In Process Research And Development</link:label>
    <link:label id="lab_bgne_AcquiredInProcessResearchAndDevelopment_documentation_en-US" xlink:label="lab_bgne_AcquiredInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acquired In Process Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AcquiredInProcessResearchAndDevelopment" xlink:href="bgne-20241231.xsd#bgne_AcquiredInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_AcquiredInProcessResearchAndDevelopment" xlink:to="lab_bgne_AcquiredInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_f26b22c6-6257-402c-bd4b-0fbc601a1595_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_676ce902-4f24-4ad5-a9dc-22091d13bd12_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_488544bd-1b4d-485b-9296-8bcc3cfea7da_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_c0fc0ee5-7cf8-4a09-8a97-907904f55216_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_3f6bd7ce-7fda-40cf-9a37-3a5b8abac7b4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cancellation of ordinary shares (in share)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_85c6d988-cb4e-4e82-b63d-0f2dddbbfbd2_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cancellation of ordinary shares (in share)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_247e9eaa-d550-4cb8-8988-2ab498e6c11f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_d9661cd8-15ac-4f2c-b911-ebad506f4523_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_NovartisMember_abdb39d6-6c4f-4a00-accc-f1a5ffeebbc6_terseLabel_en-US" xlink:label="lab_bgne_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novartis</link:label>
    <link:label id="lab_bgne_NovartisMember_label_en-US" xlink:label="lab_bgne_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis [Member]</link:label>
    <link:label id="lab_bgne_NovartisMember_documentation_en-US" xlink:label="lab_bgne_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Novartis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_NovartisMember" xlink:href="bgne-20241231.xsd#bgne_NovartisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_NovartisMember" xlink:to="lab_bgne_NovartisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_58470e93-1495-4b57-a467-5c7c54a207d1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Short-Term and Long-Term Debt Obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_a568907c-c8e4-4de7-9091-cff1de4008a1_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_21047114-18b8-4c28-b88b-56d06cefb8b3_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_f99d1658-a4fc-4fd8-be37-8175116280a5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f5ed11a6-a004-4d8b-8b13-c21892a1cc82_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_a20ddb53-39e2-4a5b-96c6-f793a169020f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restrictions on Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_43c354a8-4b7c-4dbd-8320-1b28a90f3c88_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_9a25caf1-f34a-42eb-a132-f25dc7953f03_verboseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_b63e5719-52d0-4a6a-939d-393d85c35e49_netLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Manufacturing equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_InterestPaidIncludingCapitalizedInterest_62fdfbe1-4843-448c-9d31-4ad7a5d034a0_terseLabel_en-US" xlink:label="lab_bgne_InterestPaidIncludingCapitalizedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_bgne_InterestPaidIncludingCapitalizedInterest_label_en-US" xlink:label="lab_bgne_InterestPaidIncludingCapitalizedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Including Capitalized Interest</link:label>
    <link:label id="lab_bgne_InterestPaidIncludingCapitalizedInterest_documentation_en-US" xlink:label="lab_bgne_InterestPaidIncludingCapitalizedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Paid, Including Capitalized Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_InterestPaidIncludingCapitalizedInterest" xlink:href="bgne-20241231.xsd#bgne_InterestPaidIncludingCapitalizedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_InterestPaidIncludingCapitalizedInterest" xlink:to="lab_bgne_InterestPaidIncludingCapitalizedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_InvestmentInDebtSecuritiesNonCurrent_50f2e0c5-9c35-4fcb-bdb8-96f0f06c0665_terseLabel_en-US" xlink:label="lab_bgne_InvestmentInDebtSecuritiesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible debt instrument</link:label>
    <link:label id="lab_bgne_InvestmentInDebtSecuritiesNonCurrent_label_en-US" xlink:label="lab_bgne_InvestmentInDebtSecuritiesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment In Debt Securities, Non Current</link:label>
    <link:label id="lab_bgne_InvestmentInDebtSecuritiesNonCurrent_documentation_en-US" xlink:label="lab_bgne_InvestmentInDebtSecuritiesNonCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment In Debt Securities, Non Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_InvestmentInDebtSecuritiesNonCurrent" xlink:href="bgne-20241231.xsd#bgne_InvestmentInDebtSecuritiesNonCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_InvestmentInDebtSecuritiesNonCurrent" xlink:to="lab_bgne_InvestmentInDebtSecuritiesNonCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_fd7e0bee-395d-421e-a35f-8c0e205d707b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cf0806c3-8991-4fb0-b7f8-c723c5b17f9f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CondensedCashFlowStatementsCaptionsLineItems_535118d1-ba25-4764-8390-68eafec18bdb_terseLabel_en-US" xlink:label="lab_srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Condensed Cash Flow Statements, Captions [Line Items]</link:label>
    <link:label id="lab_srt_CondensedCashFlowStatementsCaptionsLineItems_label_en-US" xlink:label="lab_srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Condensed Cash Flow Statements, Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedCashFlowStatementsCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:to="lab_srt_CondensedCashFlowStatementsCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_4eddf3d5-36cb-4f52-b19c-96d490c2d944_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from short-term loans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_f16c8b4e-b2ce-4b17-afbb-eb7a0af4ed5b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_87d2482c-b897-458b-87f3-0db6935633b5_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_TislelizumabMember_4b6e5c19-6c0c-4f19-9189-3af016486c27_terseLabel_en-US" xlink:label="lab_bgne_TislelizumabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tislelizumab</link:label>
    <link:label id="lab_bgne_TislelizumabMember_label_en-US" xlink:label="lab_bgne_TislelizumabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tislelizumab [Member]</link:label>
    <link:label id="lab_bgne_TislelizumabMember_documentation_en-US" xlink:label="lab_bgne_TislelizumabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tislelizumab [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_TislelizumabMember" xlink:href="bgne-20241231.xsd#bgne_TislelizumabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_TislelizumabMember" xlink:to="lab_bgne_TislelizumabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion_45bb81da-bf77-4628-9c47-dcbb5a5e8c09_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax on unremitted earnings</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deduction, Extraterritorial Income Exclusion, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion" xlink:to="lab_us-gaap_IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeReductions_29076671-8bf7-4997-8881-f62bde450847_terseLabel_en-US" xlink:label="lab_bgne_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeReductions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product revenue - gross</link:label>
    <link:label id="lab_bgne_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeReductions_label_en-US" xlink:label="lab_bgne_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeReductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax, Before Reductions</link:label>
    <link:label id="lab_bgne_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeReductions_documentation_en-US" xlink:label="lab_bgne_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeReductions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax, Before Reductions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeReductions" xlink:href="bgne-20241231.xsd#bgne_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeReductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeReductions" xlink:to="lab_bgne_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeReductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_349d1b71-0942-48e8-8d8e-f6ef4ebcc781_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_9b5c1ac4-db29-47b9-a8ad-955a92887750_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_OtherMember_730387b7-ddc6-43fe-872d-4c28ef3a25c2_terseLabel_en-US" xlink:label="lab_bgne_OtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_bgne_OtherMember_label_en-US" xlink:label="lab_bgne_OtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other [Member]</link:label>
    <link:label id="lab_bgne_OtherMember_documentation_en-US" xlink:label="lab_bgne_OtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_OtherMember" xlink:href="bgne-20241231.xsd#bgne_OtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_OtherMember" xlink:to="lab_bgne_OtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_b53407d8-6d59-4659-a627-11cab7584dc1_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other investing activities</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_c8fc18e3-4bf4-41d8-ac1e-f7f088294aa8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other investing activities</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_LandUseRightsPolicyPolicyTextBlock_5586734e-573a-4e67-9968-b642895fce91_terseLabel_en-US" xlink:label="lab_bgne_LandUseRightsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land Use Right, Net</link:label>
    <link:label id="lab_bgne_LandUseRightsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_bgne_LandUseRightsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land Use Rights, Policy [Policy Text Block]</link:label>
    <link:label id="lab_bgne_LandUseRightsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_bgne_LandUseRightsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for land use rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_LandUseRightsPolicyPolicyTextBlock" xlink:href="bgne-20241231.xsd#bgne_LandUseRightsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_LandUseRightsPolicyPolicyTextBlock" xlink:to="lab_bgne_LandUseRightsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_899ae6a4-22c6-484f-b6a6-eb537b74acae_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_aa64abe9-623a-42b3-a131-decef350e92d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_RebatesReturnsAndOtherDeductionsMember_a5238258-c49f-4265-a440-1cc89cfec73e_terseLabel_en-US" xlink:label="lab_bgne_RebatesReturnsAndOtherDeductionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rebates, Returns and Other Deductions</link:label>
    <link:label id="lab_bgne_RebatesReturnsAndOtherDeductionsMember_label_en-US" xlink:label="lab_bgne_RebatesReturnsAndOtherDeductionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rebates, Returns and Other Deductions [Member]</link:label>
    <link:label id="lab_bgne_RebatesReturnsAndOtherDeductionsMember_documentation_en-US" xlink:label="lab_bgne_RebatesReturnsAndOtherDeductionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rebates, Returns and Other Deductions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RebatesReturnsAndOtherDeductionsMember" xlink:href="bgne-20241231.xsd#bgne_RebatesReturnsAndOtherDeductionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_RebatesReturnsAndOtherDeductionsMember" xlink:to="lab_bgne_RebatesReturnsAndOtherDeductionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_536da1ea-4294-4913-9e1a-b842188d150d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful&#160;lives (in years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_516badee-50e8-49d6-8441-8f63fc0dfb20_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number&#160;of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_3b84acde-215d-4f84-b1a5-662028c0a874_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_581da423-1543-4d24-b2ed-875a6e537b85_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_InvestmentsFundingCommitmentMember_03027d27-7680-45fa-b6bc-7029d98b7f1d_terseLabel_en-US" xlink:label="lab_bgne_InvestmentsFundingCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments Funding Commitment</link:label>
    <link:label id="lab_bgne_InvestmentsFundingCommitmentMember_label_en-US" xlink:label="lab_bgne_InvestmentsFundingCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Funding Commitment [Member]</link:label>
    <link:label id="lab_bgne_InvestmentsFundingCommitmentMember_documentation_en-US" xlink:label="lab_bgne_InvestmentsFundingCommitmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments Funding Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_InvestmentsFundingCommitmentMember" xlink:href="bgne-20241231.xsd#bgne_InvestmentsFundingCommitmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_InvestmentsFundingCommitmentMember" xlink:to="lab_bgne_InvestmentsFundingCommitmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SwissFederalTaxAdministrationFTAMember_d461dd3d-30c1-415d-8d1c-69dd59592d49_terseLabel_en-US" xlink:label="lab_us-gaap_SwissFederalTaxAdministrationFTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Swiss Federal Tax Administration (FTA)</link:label>
    <link:label id="lab_us-gaap_SwissFederalTaxAdministrationFTAMember_label_en-US" xlink:label="lab_us-gaap_SwissFederalTaxAdministrationFTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Swiss Federal Tax Administration (FTA) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SwissFederalTaxAdministrationFTAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SwissFederalTaxAdministrationFTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SwissFederalTaxAdministrationFTAMember" xlink:to="lab_us-gaap_SwissFederalTaxAdministrationFTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligationDueInNextTwelveMonths_ea2e6684-8cfc-4975-a018-0be5c88a18e5_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year ending December&#160;31,&#160;2025</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:to="lab_us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAdministrationOfTaxationChinaMember_66f0b030-043d-45a7-9213-09c1ada8dd01_terseLabel_en-US" xlink:label="lab_us-gaap_StateAdministrationOfTaxationChinaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State Administration of Taxation, China</link:label>
    <link:label id="lab_us-gaap_StateAdministrationOfTaxationChinaMember_label_en-US" xlink:label="lab_us-gaap_StateAdministrationOfTaxationChinaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State Administration of Taxation, China [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAdministrationOfTaxationChinaMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAdministrationOfTaxationChinaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAdministrationOfTaxationChinaMember" xlink:to="lab_us-gaap_StateAdministrationOfTaxationChinaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_dc660c11-7dff-46b7-a3cf-7169cda1e149_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_9f403e69-a083-472a-9511-a86108170832_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales - product</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_c413c577-da87-4ac8-86dd-98f8d3d5189f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_108ebdec-e2e1-49dd-ad64-cabfa5a7d092_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5abe6201-7f58-4221-849b-0d86ba5d2c5b_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_000905b8-5ed6-4835-9d13-d3c89bfb9360_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_a3c0078f-ef0c-465b-8cfe-0113e76eb9c6_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_951ec2ad-a810-4c56-9386-3b61378aa133_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding number of shares (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_04b6207a-4126-407e-a355-0da0436fdd25_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_a08e1547-b23b-4865-a9f0-719e76c0b4de_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_a3d9e3d6-45ea-4737-9e30-8d3a4d5d8b5b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of the Statutory Tax Rate to Effective Income Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_61297031-9809-45c3-b2ec-6ff0b54383e2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_dbce3444-da91-4efa-b6ae-8c70c99cb4da_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_aca1691d-934e-4702-a1fb-09e75bb85243_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year ending December&#160;31,&#160;2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligationDueAfterFifthYear_43056fb3-2f51-4ec7-ade6-1545952a1c92_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueAfterFifthYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueAfterFifthYear_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueAfterFifthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueAfterFifthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueAfterFifthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueAfterFifthYear" xlink:to="lab_us-gaap_ContractualObligationDueAfterFifthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue_d8f9bc99-fc2d-4d62-a4f1-e0752706658c_terseLabel_en-US" xlink:label="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair value- Expected to vest (in dollars per share)</link:label>
    <link:label id="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expected To Vest Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents, as of the balance sheet date, the weighted average grant date fair value of non-vested equity-based payment instruments, excluding stock (or unit) options that are expected to vest.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue" xlink:href="bgne-20241231.xsd#bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue" xlink:to="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_KYPROLISMember_604e0bb2-6d95-43dd-98d4-7fc0f3c45f44_terseLabel_en-US" xlink:label="lab_bgne_KYPROLISMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">KYPROLIS&#174;</link:label>
    <link:label id="lab_bgne_KYPROLISMember_label_en-US" xlink:label="lab_bgne_KYPROLISMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">KYPROLIS [Member]</link:label>
    <link:label id="lab_bgne_KYPROLISMember_documentation_en-US" xlink:label="lab_bgne_KYPROLISMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">KYPROLIS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_KYPROLISMember" xlink:href="bgne-20241231.xsd#bgne_KYPROLISMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_KYPROLISMember" xlink:to="lab_bgne_KYPROLISMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_57c5e563-b643-419f-9fbe-343a4443d804_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Net Product Revenues by Geographic Area</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_CollaborativeArrangementCompensationTypeDomain_b883d3c1-4b27-4d01-a5a3-bb287d9e83f6_terseLabel_en-US" xlink:label="lab_bgne_CollaborativeArrangementCompensationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Compensation Type [Domain]</link:label>
    <link:label id="lab_bgne_CollaborativeArrangementCompensationTypeDomain_label_en-US" xlink:label="lab_bgne_CollaborativeArrangementCompensationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Compensation Type [Domain]</link:label>
    <link:label id="lab_bgne_CollaborativeArrangementCompensationTypeDomain_documentation_en-US" xlink:label="lab_bgne_CollaborativeArrangementCompensationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Compensation Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_CollaborativeArrangementCompensationTypeDomain" xlink:href="bgne-20241231.xsd#bgne_CollaborativeArrangementCompensationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_CollaborativeArrangementCompensationTypeDomain" xlink:to="lab_bgne_CollaborativeArrangementCompensationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_2f6e5eda-e12a-401b-b9c3-899d8cfefdda_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_b9b042f0-4063-4973-8430-9d4a63de5eed_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_fc22ea3d-b543-4699-822b-4d38450b49fb_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_e6037b4b-c29e-4e5c-87fe-a30cc2ac1cdc_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriod_2fa1e005-f024-4ed6-96d8-d582e03dbeb2_terseLabel_en-US" xlink:label="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares cancelled or forfeited (in shares)</link:label>
    <link:label id="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriod_label_en-US" xlink:label="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Cancelled or Forfeited in Period</link:label>
    <link:label id="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriod_documentation_en-US" xlink:label="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of shares under options granted in a plan that were canceled after the initial public offering date, as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriod" xlink:href="bgne-20241231.xsd#bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriod" xlink:to="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_AmortizationOfFinancingCommitment_632ed21e-059d-4c79-9486-daa4ae812f42_terseLabel_en-US" xlink:label="lab_bgne_AmortizationOfFinancingCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Amortization of research and development cost share liability</link:label>
    <link:label id="lab_bgne_AmortizationOfFinancingCommitment_label_en-US" xlink:label="lab_bgne_AmortizationOfFinancingCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Financing Commitment</link:label>
    <link:label id="lab_bgne_AmortizationOfFinancingCommitment_documentation_en-US" xlink:label="lab_bgne_AmortizationOfFinancingCommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortization of Financing Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AmortizationOfFinancingCommitment" xlink:href="bgne-20241231.xsd#bgne_AmortizationOfFinancingCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_AmortizationOfFinancingCommitment" xlink:to="lab_bgne_AmortizationOfFinancingCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_c7d94187-ef04-4ded-834c-1770eed1eff6_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_163d7cd7-4c00-4d43-ae2f-7e8fa3864ed2_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_50785bcc-198a-4731-82c4-f9ab219dc88c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_39e98726-0d55-4d63-b64b-dd6710c2b902_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Street Address</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_efd328e5-6532-40dc-93f8-053564aabed3_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_2144f390-3a70-4ddb-9f34-cf2039181afa_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Street Address Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_DeferredTaxAssetValuationAllowanceChangesIncludedInEarnings_310d161f-e33b-45de-8526-42c05af284f5_terseLabel_en-US" xlink:label="lab_bgne_DeferredTaxAssetValuationAllowanceChangesIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions/(subtractions) charged to income tax provision</link:label>
    <link:label id="lab_bgne_DeferredTaxAssetValuationAllowanceChangesIncludedInEarnings_label_en-US" xlink:label="lab_bgne_DeferredTaxAssetValuationAllowanceChangesIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, Valuation Allowance, Changes Included In Earnings</link:label>
    <link:label id="lab_bgne_DeferredTaxAssetValuationAllowanceChangesIncludedInEarnings_documentation_en-US" xlink:label="lab_bgne_DeferredTaxAssetValuationAllowanceChangesIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, Valuation Allowance, Changes Included In Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_DeferredTaxAssetValuationAllowanceChangesIncludedInEarnings" xlink:href="bgne-20241231.xsd#bgne_DeferredTaxAssetValuationAllowanceChangesIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_DeferredTaxAssetValuationAllowanceChangesIncludedInEarnings" xlink:to="lab_bgne_DeferredTaxAssetValuationAllowanceChangesIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_decededd-f543-4ca9-b156-3a433b5a2865_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of foreign exchange rate changes, net</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestOutstandingNumber_4fa70d94-6ce6-4df6-98bf-57fb373532fd_terseLabel_en-US" xlink:label="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Shares - Expected to vest (in shares)</link:label>
    <link:label id="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expected To Vest Outstanding Number</link:label>
    <link:label id="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestOutstandingNumber_documentation_en-US" xlink:label="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents, as of the balance sheet date, the number of non-vested equity-based payment instruments, excluding stock (or unit) options that are expected to vest.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestOutstandingNumber" xlink:href="bgne-20241231.xsd#bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestOutstandingNumber" xlink:to="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_715b7bcd-a6cd-487c-b62d-b2115c27bc24_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Terms</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_51e6ff60-8d53-49a8-b6c9-5f109fb00ffb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract term (years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_fd36676a-3ef7-4d59-8837-9eeed126485b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at the end of the period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_867f1601-4e10-4a27-a46a-cc5dc2be5256_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent_80806087-37d0-45ef-bec7-ffde7338c4a8_terseLabel_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loans to subsidiaries</link:label>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:to="lab_us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_4d630f4e-a1fd-4dbe-91d0-145226480f35_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_fa9feace-e6be-4492-a954-be8a6f9bcd0e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Expected Benefit Payments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Expected Benefit Payments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum_474ca0c6-de57-498f-be6c-5d4d104722da_terseLabel_en-US" xlink:label="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected exercise multiple, maximum</link:label>
    <link:label id="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum_label_en-US" xlink:label="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share Based Payment Award, Fair Value Assumptions Expected, Exercise Multiple, Maximum</link:label>
    <link:label id="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum_documentation_en-US" xlink:label="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the expected maximum exercise multiple that is used as an assumption in estimating the fair value of share-based compensation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum" xlink:href="bgne-20241231.xsd#bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum" xlink:to="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_7bc38649-e6c2-435b-aae1-7cc48476bd02_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_1c823add-6c94-4459-a391-357fd7a66b8c_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Reductions based on tax positions related to prior tax years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_d0df0232-04b7-4eb1-b1c6-b6d682c91928_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_41c0ccea-b261-4635-870d-064e50b7f9e6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_91a69b5e-a93f-44ca-bce0-f0a34ede5b9d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_b8eaf8b5-80b0-4f5d-b0af-fa09e54060f0_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_972d48e0-a16c-4b06-82a1-a9ef5258571b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:to="lab_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_00257a85-53f5-487c-bd6a-91547920d326_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Pension liability adjustments, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f14dc366-dea6-4702-aefd-c9014aa2a7f8_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ProductNameAxis_02668e1e-f8ad-4498-8b93-b00b4124d739_terseLabel_en-US" xlink:label="lab_bgne_ProductNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Name [Axis]</link:label>
    <link:label id="lab_bgne_ProductNameAxis_label_en-US" xlink:label="lab_bgne_ProductNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Name [Axis]</link:label>
    <link:label id="lab_bgne_ProductNameAxis_documentation_en-US" xlink:label="lab_bgne_ProductNameAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ProductNameAxis" xlink:href="bgne-20241231.xsd#bgne_ProductNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ProductNameAxis" xlink:to="lab_bgne_ProductNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_86a436bc-dca8-44de-8154-198d54528199_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Other Types [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ShortTermBankLoanDatedJune52023Member_54593640-b8bd-4504-9065-9b3683f398d8_terseLabel_en-US" xlink:label="lab_bgne_ShortTermBankLoanDatedJune52023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short Term Bank Loan Dated June 5 2023</link:label>
    <link:label id="lab_bgne_ShortTermBankLoanDatedJune52023Member_label_en-US" xlink:label="lab_bgne_ShortTermBankLoanDatedJune52023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short Term Bank Loan Dated June 5 2023 [Member]</link:label>
    <link:label id="lab_bgne_ShortTermBankLoanDatedJune52023Member_documentation_en-US" xlink:label="lab_bgne_ShortTermBankLoanDatedJune52023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short Term Bank Loan Dated June 5 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShortTermBankLoanDatedJune52023Member" xlink:href="bgne-20241231.xsd#bgne_ShortTermBankLoanDatedJune52023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ShortTermBankLoanDatedJune52023Member" xlink:to="lab_bgne_ShortTermBankLoanDatedJune52023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0d675a26-d1b4-4428-975c-dd78fb3a826c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_51e421f1-3cae-455b-9485-a9a7f0ab5b33_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares outstanding&#8212;basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b8edc509-a864-4a10-960c-5fb6d5898403_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding for computing basic loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_CollaborativeArrangementCompensationTypeAxis_a6a05480-2ee7-4307-9d47-9a90bc35d478_terseLabel_en-US" xlink:label="lab_bgne_CollaborativeArrangementCompensationTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Compensation Type [Axis]</link:label>
    <link:label id="lab_bgne_CollaborativeArrangementCompensationTypeAxis_label_en-US" xlink:label="lab_bgne_CollaborativeArrangementCompensationTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Compensation Type [Axis]</link:label>
    <link:label id="lab_bgne_CollaborativeArrangementCompensationTypeAxis_documentation_en-US" xlink:label="lab_bgne_CollaborativeArrangementCompensationTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Compensation Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_CollaborativeArrangementCompensationTypeAxis" xlink:href="bgne-20241231.xsd#bgne_CollaborativeArrangementCompensationTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_CollaborativeArrangementCompensationTypeAxis" xlink:to="lab_bgne_CollaborativeArrangementCompensationTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_cb576fb3-0278-4f96-8ade-4a5bc9fba936_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_AcquiredInProcessResearchAndDevelopmentButNotYetPaid_f7a82021-c4b4-46c3-982b-ad66c32b9146_terseLabel_en-US" xlink:label="lab_bgne_AcquiredInProcessResearchAndDevelopmentButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase of in-process research and development included in accounts payable</link:label>
    <link:label id="lab_bgne_AcquiredInProcessResearchAndDevelopmentButNotYetPaid_label_en-US" xlink:label="lab_bgne_AcquiredInProcessResearchAndDevelopmentButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired In Process Research And Development But Not Yet Paid</link:label>
    <link:label id="lab_bgne_AcquiredInProcessResearchAndDevelopmentButNotYetPaid_documentation_en-US" xlink:label="lab_bgne_AcquiredInProcessResearchAndDevelopmentButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acquired In Process Research And Development But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AcquiredInProcessResearchAndDevelopmentButNotYetPaid" xlink:href="bgne-20241231.xsd#bgne_AcquiredInProcessResearchAndDevelopmentButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_AcquiredInProcessResearchAndDevelopmentButNotYetPaid" xlink:to="lab_bgne_AcquiredInProcessResearchAndDevelopmentButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_b31da131-0897-4c6a-8761-2411bdce62c2_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in Progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_ed408a1f-f3eb-4227-b807-8d05e3ee4d05_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e5b59ca2-dcc1-4796-968e-b06d48e912ae_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_8636efb7-2bbd-410b-b69d-ea39cb0b3e70_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ShortTermBankLoanDatedNovember142023Member_23c1bbcc-e8f0-473b-9640-a7556bd6652e_terseLabel_en-US" xlink:label="lab_bgne_ShortTermBankLoanDatedNovember142023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short Term Bank Loan Dated November 14, 2023</link:label>
    <link:label id="lab_bgne_ShortTermBankLoanDatedNovember142023Member_label_en-US" xlink:label="lab_bgne_ShortTermBankLoanDatedNovember142023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short Term Bank Loan Dated November 14, 2023 [Member]</link:label>
    <link:label id="lab_bgne_ShortTermBankLoanDatedNovember142023Member_documentation_en-US" xlink:label="lab_bgne_ShortTermBankLoanDatedNovember142023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short Term Bank Loan Dated November 14, 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShortTermBankLoanDatedNovember142023Member" xlink:href="bgne-20241231.xsd#bgne_ShortTermBankLoanDatedNovember142023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ShortTermBankLoanDatedNovember142023Member" xlink:to="lab_bgne_ShortTermBankLoanDatedNovember142023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ASDSpecialtyHealthcareMember_1f2438cf-ce3b-4258-9921-d9c21f4cf4bf_terseLabel_en-US" xlink:label="lab_bgne_ASDSpecialtyHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASD Specialty Healthcare</link:label>
    <link:label id="lab_bgne_ASDSpecialtyHealthcareMember_label_en-US" xlink:label="lab_bgne_ASDSpecialtyHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ASD Specialty Healthcare [Member]</link:label>
    <link:label id="lab_bgne_ASDSpecialtyHealthcareMember_documentation_en-US" xlink:label="lab_bgne_ASDSpecialtyHealthcareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ASD Specialty Healthcare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ASDSpecialtyHealthcareMember" xlink:href="bgne-20241231.xsd#bgne_ASDSpecialtyHealthcareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ASDSpecialtyHealthcareMember" xlink:to="lab_bgne_ASDSpecialtyHealthcareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_FourLargestCustomersMember_d7265c2c-17e2-4866-8cd3-3f4d6a22cd29_terseLabel_en-US" xlink:label="lab_bgne_FourLargestCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Four Largest Customers</link:label>
    <link:label id="lab_bgne_FourLargestCustomersMember_label_en-US" xlink:label="lab_bgne_FourLargestCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Four Largest Customers [Member]</link:label>
    <link:label id="lab_bgne_FourLargestCustomersMember_documentation_en-US" xlink:label="lab_bgne_FourLargestCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Four Largest Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_FourLargestCustomersMember" xlink:href="bgne-20241231.xsd#bgne_FourLargestCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_FourLargestCustomersMember" xlink:to="lab_bgne_FourLargestCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_4cff8e27-ed01-450f-823d-aa05e58061ef_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from long-term loan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Long-Term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_6a08b6f7-59dc-4ff6-b96a-3bfbe8bde60e_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_49a3fc8a-095a-40fb-82e9-208d4b587139_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Component of Lease Expense</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e0a5c4f9-f189-497d-afc0-259763a56e24_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additonal disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_7dc9cb6c-2ddc-42cb-89f9-8575f6b17e2f_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice_d8905ac2-bb4f-4729-8165-40b1cbbe3000_terseLabel_en-US" xlink:label="lab_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Price, Ordinary (in dollars per share)</link:label>
    <link:label id="lab_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice_label_en-US" xlink:label="lab_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued In Period Exercise Price</link:label>
    <link:label id="lab_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice_documentation_en-US" xlink:label="lab_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice" xlink:href="bgne-20241231.xsd#bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice" xlink:to="lab_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_RevenueRecognitionRevenueReduction_f4db35e6-2628-4f1b-b6ff-9bc23fb60096_negatedLabel_en-US" xlink:label="lab_bgne_RevenueRecognitionRevenueReduction" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Rebates and sales returns</link:label>
    <link:label id="lab_bgne_RevenueRecognitionRevenueReduction_2e5c716f-15b7-4787-ac21-b3e0544412de_terseLabel_en-US" xlink:label="lab_bgne_RevenueRecognitionRevenueReduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts charged against product revenue</link:label>
    <link:label id="lab_bgne_RevenueRecognitionRevenueReduction_label_en-US" xlink:label="lab_bgne_RevenueRecognitionRevenueReduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Revenue Reduction</link:label>
    <link:label id="lab_bgne_RevenueRecognitionRevenueReduction_documentation_en-US" xlink:label="lab_bgne_RevenueRecognitionRevenueReduction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Revenue Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RevenueRecognitionRevenueReduction" xlink:href="bgne-20241231.xsd#bgne_RevenueRecognitionRevenueReduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_RevenueRecognitionRevenueReduction" xlink:to="lab_bgne_RevenueRecognitionRevenueReduction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0b498e7e-5d34-4544-aca8-1c151bb6d5e1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of the Computations of Basic and Diluted Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8fbc3a73-893b-4edb-b548-00d3efaba793_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period of award (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_b6de26ad-2543-4855-b6f8-d1e8570dc34c_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_0cc45447-1a96-4ae9-b842-e3e6e1adb491_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_72975504-6462-4d6e-a4c0-350ef0eb5815_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ShortTermBankLoanDatedJuly282023Member_3834d773-76ed-4d84-b2b2-262d68a89742_terseLabel_en-US" xlink:label="lab_bgne_ShortTermBankLoanDatedJuly282023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short Term Bank Loan Dated July 28, 2023</link:label>
    <link:label id="lab_bgne_ShortTermBankLoanDatedJuly282023Member_label_en-US" xlink:label="lab_bgne_ShortTermBankLoanDatedJuly282023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short Term Bank Loan Dated July 28, 2023 [Member]</link:label>
    <link:label id="lab_bgne_ShortTermBankLoanDatedJuly282023Member_documentation_en-US" xlink:label="lab_bgne_ShortTermBankLoanDatedJuly282023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short Term Bank Loan Dated July 28, 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShortTermBankLoanDatedJuly282023Member" xlink:href="bgne-20241231.xsd#bgne_ShortTermBankLoanDatedJuly282023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ShortTermBankLoanDatedJuly282023Member" xlink:to="lab_bgne_ShortTermBankLoanDatedJuly282023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_MinimumPurchaseCommitmentsForSupplyPurchasedMember_51666219-04c3-4390-9885-e6b686b425ab_terseLabel_en-US" xlink:label="lab_bgne_MinimumPurchaseCommitmentsForSupplyPurchasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum Purchase Commitments For Supply Purchased</link:label>
    <link:label id="lab_bgne_MinimumPurchaseCommitmentsForSupplyPurchasedMember_label_en-US" xlink:label="lab_bgne_MinimumPurchaseCommitmentsForSupplyPurchasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum Purchase Commitments For Supply Purchased [Member]</link:label>
    <link:label id="lab_bgne_MinimumPurchaseCommitmentsForSupplyPurchasedMember_documentation_en-US" xlink:label="lab_bgne_MinimumPurchaseCommitmentsForSupplyPurchasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minimum Purchase Commitments For Supply Purchased [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_MinimumPurchaseCommitmentsForSupplyPurchasedMember" xlink:href="bgne-20241231.xsd#bgne_MinimumPurchaseCommitmentsForSupplyPurchasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_MinimumPurchaseCommitmentsForSupplyPurchasedMember" xlink:to="lab_bgne_MinimumPurchaseCommitmentsForSupplyPurchasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_a2d6e4fd-189c-4a59-beae-733f0700546f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_EarningsPerAmericanDepositoryShareBasic_b1027616-8813-4d21-9c2b-f28321bdf11b_terseLabel_en-US" xlink:label="lab_bgne_EarningsPerAmericanDepositoryShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per American Depositary Share (ADS), basic (in dollars per share)</link:label>
    <link:label id="lab_bgne_EarningsPerAmericanDepositoryShareBasic_label_en-US" xlink:label="lab_bgne_EarningsPerAmericanDepositoryShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per American Depository Share, Basic</link:label>
    <link:label id="lab_bgne_EarningsPerAmericanDepositoryShareBasic_documentation_en-US" xlink:label="lab_bgne_EarningsPerAmericanDepositoryShareBasic" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Earnings per American Depository Share, basic and diluted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_EarningsPerAmericanDepositoryShareBasic" xlink:href="bgne-20241231.xsd#bgne_EarningsPerAmericanDepositoryShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_EarningsPerAmericanDepositoryShareBasic" xlink:to="lab_bgne_EarningsPerAmericanDepositoryShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1316fa1e-fd20-4c12-94b9-58f2618b296d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_HSBCBankMember_c2378d18-9d9f-47a1-b06a-29a4788ceec3_terseLabel_en-US" xlink:label="lab_bgne_HSBCBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">HSBC Bank</link:label>
    <link:label id="lab_bgne_HSBCBankMember_label_en-US" xlink:label="lab_bgne_HSBCBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">HSBC Bank [Member]</link:label>
    <link:label id="lab_bgne_HSBCBankMember_documentation_en-US" xlink:label="lab_bgne_HSBCBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">HSBC Bank</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_HSBCBankMember" xlink:href="bgne-20241231.xsd#bgne_HSBCBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_HSBCBankMember" xlink:to="lab_bgne_HSBCBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_e4904e36-f35d-4c5f-8fa1-e53de0b15bd0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_18f7c880-2506-41eb-9733-1b9ded8d31d3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_691689f8-09fd-4374-9aba-5b8d6a85e69d_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at the beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1e66f9d8-3d73-41ca-ba61-8480847f5bcb_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at the ending of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_29ded62b-4bf3-4167-b208-294cadd0da88_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_5415d729-384c-4a22-b28d-d4c4344a28e1_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_9439ea5c-7d63-4e0d-b6fe-0c2d72ae6799_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_208eb54f-4bcd-46c7-b19d-98a375dba746_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_da17445b-0580-4011-94f2-04b73cfbb5f8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, non-current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_6a70f16f-226c-4f66-be6e-23d65e1a0f95_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, non-current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_e2ede7d5-6527-46ab-9eb8-4945773cf180_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_a97b03fb-c039-44bc-bb95-8099b1f505d9_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loans Payable</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_4fbf8eb0-fcf8-445c-8140-255d57812b8e_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_82f3a02d-9e4f-4c01-83f2-d604fe3acd34_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Other-than-Temporary Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:to="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_dd69fb2a-3557-4c1e-a600-86ba9b3c1811_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_65842ccd-e1f7-4f86-880e-ce5a3cd12ddd_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions based on tax positions related to prior tax years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_f2063db1-a7d1-49b3-9bb1-f71feb1e7f30_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_da8be95d-52a2-4fa2-85d7-098d8234e9a2_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_SuzhouMember_86c9710e-2829-42f3-9f8b-8197767ad58f_terseLabel_en-US" xlink:label="lab_bgne_SuzhouMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Suzhou</link:label>
    <link:label id="lab_bgne_SuzhouMember_label_en-US" xlink:label="lab_bgne_SuzhouMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Suzhou [Member]</link:label>
    <link:label id="lab_bgne_SuzhouMember_documentation_en-US" xlink:label="lab_bgne_SuzhouMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Suzhou</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_SuzhouMember" xlink:href="bgne-20241231.xsd#bgne_SuzhouMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_SuzhouMember" xlink:to="lab_bgne_SuzhouMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligationDueInFourthYear_e5415df2-7098-4df1-80ce-d6bf7ffb62f0_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInFourthYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year ending December 31, 2028</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInFourthYear_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInFourthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInFourthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInFourthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInFourthYear" xlink:to="lab_us-gaap_ContractualObligationDueInFourthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_b9fa6d83-03c9-4c05-ad69-9ea997a68ab0_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Assistance, Income, Increase (Decrease), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Assistance, Income, Increase (Decrease), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_EffectiveIncomeTaxRateReconciliationDeductionResearchExpensesAmount_bab7bd9a-141c-4e6b-badc-31c65e85c19c_negatedLabel_en-US" xlink:label="lab_bgne_EffectiveIncomeTaxRateReconciliationDeductionResearchExpensesAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deductible research expenses</link:label>
    <link:label id="lab_bgne_EffectiveIncomeTaxRateReconciliationDeductionResearchExpensesAmount_label_en-US" xlink:label="lab_bgne_EffectiveIncomeTaxRateReconciliationDeductionResearchExpensesAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deduction, Research Expenses, Amount</link:label>
    <link:label id="lab_bgne_EffectiveIncomeTaxRateReconciliationDeductionResearchExpensesAmount_documentation_en-US" xlink:label="lab_bgne_EffectiveIncomeTaxRateReconciliationDeductionResearchExpensesAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deduction, Research Expenses, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_EffectiveIncomeTaxRateReconciliationDeductionResearchExpensesAmount" xlink:href="bgne-20241231.xsd#bgne_EffectiveIncomeTaxRateReconciliationDeductionResearchExpensesAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_EffectiveIncomeTaxRateReconciliationDeductionResearchExpensesAmount" xlink:to="lab_bgne_EffectiveIncomeTaxRateReconciliationDeductionResearchExpensesAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_0b7a50a8-b65b-4160-87dd-36be20141d38_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_64647a20-6141-44c9-bd66-0583e6552fe7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_dd349168-89b7-4979-8bb7-dd19656b0177_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetRetirementObligationsNoncurrent_bb8373ee-f452-4037-9254-76355a37dd5e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetRetirementObligationsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset retirement obligation</link:label>
    <link:label id="lab_us-gaap_AssetRetirementObligationsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetRetirementObligationsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Retirement Obligations, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetRetirementObligationsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetRetirementObligationsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetRetirementObligationsNoncurrent" xlink:to="lab_us-gaap_AssetRetirementObligationsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_405c7036-cf8d-4a74-95f0-bdadc1fdd948_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_LongTermBankLoanDatedNovember92020Member_13fc7864-4167-4381-8925-7541dbcc4f98_terseLabel_en-US" xlink:label="lab_bgne_LongTermBankLoanDatedNovember92020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term bank November 9, 2020</link:label>
    <link:label id="lab_bgne_LongTermBankLoanDatedNovember92020Member_label_en-US" xlink:label="lab_bgne_LongTermBankLoanDatedNovember92020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long Term Bank Loan Dated November 9 2020 [Member]</link:label>
    <link:label id="lab_bgne_LongTermBankLoanDatedNovember92020Member_documentation_en-US" xlink:label="lab_bgne_LongTermBankLoanDatedNovember92020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long Term Bank Loan Dated November 9 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_LongTermBankLoanDatedNovember92020Member" xlink:href="bgne-20241231.xsd#bgne_LongTermBankLoanDatedNovember92020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_LongTermBankLoanDatedNovember92020Member" xlink:to="lab_bgne_LongTermBankLoanDatedNovember92020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_45c1ed92-ae30-427a-8d92-306eff67e354_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ProceedsFromIssuanceOfAssetDepositoryShares_eb2f1a90-95d2-4a22-8438-9e80a8fc5a01_terseLabel_en-US" xlink:label="lab_bgne_ProceedsFromIssuanceOfAssetDepositoryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from ADS shares</link:label>
    <link:label id="lab_bgne_ProceedsFromIssuanceOfAssetDepositoryShares_label_en-US" xlink:label="lab_bgne_ProceedsFromIssuanceOfAssetDepositoryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance Of Asset Depository Shares</link:label>
    <link:label id="lab_bgne_ProceedsFromIssuanceOfAssetDepositoryShares_documentation_en-US" xlink:label="lab_bgne_ProceedsFromIssuanceOfAssetDepositoryShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance Of Asset Depository Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ProceedsFromIssuanceOfAssetDepositoryShares" xlink:href="bgne-20241231.xsd#bgne_ProceedsFromIssuanceOfAssetDepositoryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ProceedsFromIssuanceOfAssetDepositoryShares" xlink:to="lab_bgne_ProceedsFromIssuanceOfAssetDepositoryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_96e718c2-338f-45b8-b068-6caec81b7e6b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_47687756-776c-4e77-8663-8129349ba1c0_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable and Allowance for Credit Losses</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_1d87a5c1-b757-473e-a282-b3d686042be9_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_905977ee-cda1-4f03-84a2-1def8c0b56ba_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_BeigeneLtdMember_71396c83-01af-42e5-9ee4-30de13ecebbf_terseLabel_en-US" xlink:label="lab_bgne_BeigeneLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Beigene Ltd</link:label>
    <link:label id="lab_bgne_BeigeneLtdMember_label_en-US" xlink:label="lab_bgne_BeigeneLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Beigene Ltd [Member]</link:label>
    <link:label id="lab_bgne_BeigeneLtdMember_documentation_en-US" xlink:label="lab_bgne_BeigeneLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Beigene Ltd [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_BeigeneLtdMember" xlink:href="bgne-20241231.xsd#bgne_BeigeneLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_BeigeneLtdMember" xlink:to="lab_bgne_BeigeneLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_6a39e873-4adb-4d3a-8e6a-66cf11e364fd_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed products</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_f6e25dfb-62af-4fed-bbc3-573387201a3e_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_FinancingCommitmentCarryingValueNoncurrent_fc5ebdd2-1a02-4258-8071-e952b187bcd3_terseLabel_en-US" xlink:label="lab_bgne_FinancingCommitmentCarryingValueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development cost share liability, non-current portion</link:label>
    <link:label id="lab_bgne_FinancingCommitmentCarryingValueNoncurrent_label_en-US" xlink:label="lab_bgne_FinancingCommitmentCarryingValueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Commitment, Carrying Value, Non-current</link:label>
    <link:label id="lab_bgne_FinancingCommitmentCarryingValueNoncurrent_documentation_en-US" xlink:label="lab_bgne_FinancingCommitmentCarryingValueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financing Commitment, Carrying Value, Non-current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_FinancingCommitmentCarryingValueNoncurrent" xlink:href="bgne-20241231.xsd#bgne_FinancingCommitmentCarryingValueNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_FinancingCommitmentCarryingValueNoncurrent" xlink:to="lab_bgne_FinancingCommitmentCarryingValueNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_dea9b8e1-4e53-417b-937d-7e825e14cc6d_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_d15cd69c-3864-471f-a69a-d4e97231c71b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year ending December 31, 2029</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_a5b6cd1a-ff43-488e-bbcd-8bfd68a0fcca_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_294c0cad-fc3d-412f-a632-6e6a82bf6dc3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0fe2befa-1737-48e5-8fe7-4772f7339dbb_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise of options, ESPP and release of RSUs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_dead3edc-79fd-4a25-b74a-f4416aacc220_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Ordinary Shares Issued ( in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_RoyaltiesReceivingPeriod_8b0d6d72-66ae-4028-98c0-0c89e9b5ac23_terseLabel_en-US" xlink:label="lab_bgne_RoyaltiesReceivingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties receiving period</link:label>
    <link:label id="lab_bgne_RoyaltiesReceivingPeriod_label_en-US" xlink:label="lab_bgne_RoyaltiesReceivingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalties Receiving Period</link:label>
    <link:label id="lab_bgne_RoyaltiesReceivingPeriod_documentation_en-US" xlink:label="lab_bgne_RoyaltiesReceivingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalties Receiving Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RoyaltiesReceivingPeriod" xlink:href="bgne-20241231.xsd#bgne_RoyaltiesReceivingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_RoyaltiesReceivingPeriod" xlink:to="lab_bgne_RoyaltiesReceivingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_FairValueOfFinancingCommitment_bd56b54a-b9ae-4ed4-8ef9-8a0b7851a740_verboseLabel_en-US" xlink:label="lab_bgne_FairValueOfFinancingCommitment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value of financing commitment</link:label>
    <link:label id="lab_bgne_FairValueOfFinancingCommitment_label_en-US" xlink:label="lab_bgne_FairValueOfFinancingCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Of Financing Commitment</link:label>
    <link:label id="lab_bgne_FairValueOfFinancingCommitment_documentation_en-US" xlink:label="lab_bgne_FairValueOfFinancingCommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Of Financing Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_FairValueOfFinancingCommitment" xlink:href="bgne-20241231.xsd#bgne_FairValueOfFinancingCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_FairValueOfFinancingCommitment" xlink:to="lab_bgne_FairValueOfFinancingCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ShortTermBankLoanDatedJanuary222020Member_6375fd14-53a8-49ae-9acc-6854bbf23565_terseLabel_en-US" xlink:label="lab_bgne_ShortTermBankLoanDatedJanuary222020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short Term Bank Loan Dated January 22, 2020</link:label>
    <link:label id="lab_bgne_ShortTermBankLoanDatedJanuary222020Member_label_en-US" xlink:label="lab_bgne_ShortTermBankLoanDatedJanuary222020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short Term Bank Loan Dated January 22, 2020 [Member]</link:label>
    <link:label id="lab_bgne_ShortTermBankLoanDatedJanuary222020Member_documentation_en-US" xlink:label="lab_bgne_ShortTermBankLoanDatedJanuary222020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short Term Bank Loan Dated January 22, 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShortTermBankLoanDatedJanuary222020Member" xlink:href="bgne-20241231.xsd#bgne_ShortTermBankLoanDatedJanuary222020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ShortTermBankLoanDatedJanuary222020Member" xlink:to="lab_bgne_ShortTermBankLoanDatedJanuary222020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8b3d251f-1ad3-4142-b214-28742ccd96fd_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash, beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3e6d37c1-0f3b-4ba7-8892-e8de4df93e03_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash, end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligationFiscalYearMaturityAbstract_6381b34e-fe66-4918-8798-6200e32265ed_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual Maturities of Debt Obligations</link:label>
    <link:label id="lab_us-gaap_ContractualObligationFiscalYearMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationFiscalYearMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:to="lab_us-gaap_ContractualObligationFiscalYearMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_762fe6b6-4e97-4de6-8a81-7fdf4091b1f8_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities with readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_8afd4e89-c6c4-4b7d-899e-6974dd995b09_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_73f8c9e1-0955-4971-bcea-7009b7f77975_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_11bb6e52-bde6-40fb-b0dc-27b286e7e0e9_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c7f256e5-0877-429f-8fc6-e02f400c6ca3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ScheduleOfAmountsAndClassificationOfReimbursementExpenseTableTextBlock_94dbaa86-5fab-4fdd-a40a-967e592de908_terseLabel_en-US" xlink:label="lab_bgne_ScheduleOfAmountsAndClassificationOfReimbursementExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Amounts and Classification of Reimbursement Expense</link:label>
    <link:label id="lab_bgne_ScheduleOfAmountsAndClassificationOfReimbursementExpenseTableTextBlock_label_en-US" xlink:label="lab_bgne_ScheduleOfAmountsAndClassificationOfReimbursementExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Amounts And Classification Of Reimbursement Expense [Table Text Block]</link:label>
    <link:label id="lab_bgne_ScheduleOfAmountsAndClassificationOfReimbursementExpenseTableTextBlock_documentation_en-US" xlink:label="lab_bgne_ScheduleOfAmountsAndClassificationOfReimbursementExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Amounts And Classification Of Reimbursement Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ScheduleOfAmountsAndClassificationOfReimbursementExpenseTableTextBlock" xlink:href="bgne-20241231.xsd#bgne_ScheduleOfAmountsAndClassificationOfReimbursementExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ScheduleOfAmountsAndClassificationOfReimbursementExpenseTableTextBlock" xlink:to="lab_bgne_ScheduleOfAmountsAndClassificationOfReimbursementExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_FinancingCommitmentCarryingValueCurrent_fd6972a9-c917-4e3a-98be-b37e67e2f3db_terseLabel_en-US" xlink:label="lab_bgne_FinancingCommitmentCarryingValueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development cost share liability, current portion</link:label>
    <link:label id="lab_bgne_FinancingCommitmentCarryingValueCurrent_label_en-US" xlink:label="lab_bgne_FinancingCommitmentCarryingValueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Commitment, Carrying Value, Current</link:label>
    <link:label id="lab_bgne_FinancingCommitmentCarryingValueCurrent_documentation_en-US" xlink:label="lab_bgne_FinancingCommitmentCarryingValueCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financing Commitment, Carrying Value, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_FinancingCommitmentCarryingValueCurrent" xlink:href="bgne-20241231.xsd#bgne_FinancingCommitmentCarryingValueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_FinancingCommitmentCarryingValueCurrent" xlink:to="lab_bgne_FinancingCommitmentCarryingValueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_83e6919f-e824-40d4-8e49-6496d8c6a21d_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_ba3e02f6-4f84-4ea3-92e3-50dece362903_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of each exchange on which registered</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_LaboratoryEquipmentMember_6c6f31ea-8830-4307-860a-7d35432f6b7a_terseLabel_en-US" xlink:label="lab_bgne_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:label id="lab_bgne_LaboratoryEquipmentMember_1e24aedf-267c-436b-8656-368f21c16f3e_verboseLabel_en-US" xlink:label="lab_bgne_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_bgne_LaboratoryEquipmentMember_a6da6ea3-4e1c-4565-ab10-8472aa91ac1d_netLabel_en-US" xlink:label="lab_bgne_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_bgne_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_bgne_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_bgne_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_bgne_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to laboratory equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_LaboratoryEquipmentMember" xlink:href="bgne-20241231.xsd#bgne_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_LaboratoryEquipmentMember" xlink:to="lab_bgne_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_AccruedSalesRebatesAndReturnsRollForward_c8db0231-154f-4cff-a95f-9cb210f07275_terseLabel_en-US" xlink:label="lab_bgne_AccruedSalesRebatesAndReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued sales rebates and returns</link:label>
    <link:label id="lab_bgne_AccruedSalesRebatesAndReturnsRollForward_label_en-US" xlink:label="lab_bgne_AccruedSalesRebatesAndReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Sales Rebates and Returns [Roll Forward]</link:label>
    <link:label id="lab_bgne_AccruedSalesRebatesAndReturnsRollForward_documentation_en-US" xlink:label="lab_bgne_AccruedSalesRebatesAndReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Sales Rebates and Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AccruedSalesRebatesAndReturnsRollForward" xlink:href="bgne-20241231.xsd#bgne_AccruedSalesRebatesAndReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_AccruedSalesRebatesAndReturnsRollForward" xlink:to="lab_bgne_AccruedSalesRebatesAndReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireLongtermInvestments_d2d9f7ae-a1e8-41e7-8087-ad017787239c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of long-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireLongtermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireLongtermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_CollaborationMember_c220a568-7d85-473e-b1ff-f4e57481f926_terseLabel_en-US" xlink:label="lab_bgne_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_bgne_CollaborationMember_label_en-US" xlink:label="lab_bgne_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:label id="lab_bgne_CollaborationMember_documentation_en-US" xlink:label="lab_bgne_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_CollaborationMember" xlink:href="bgne-20241231.xsd#bgne_CollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_CollaborationMember" xlink:to="lab_bgne_CollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_743c5e0c-3272-42ac-b42e-3d86c0527f2e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_df29ea69-8f5c-436f-aed6-9c41f36bff98_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numbers of&#160;Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_DeferredTaxAssetValuationAllowanceCurrencyTranslationAndOther_e7eb39fb-1a7e-4c28-afde-feca5209ea35_terseLabel_en-US" xlink:label="lab_bgne_DeferredTaxAssetValuationAllowanceCurrencyTranslationAndOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation and other</link:label>
    <link:label id="lab_bgne_DeferredTaxAssetValuationAllowanceCurrencyTranslationAndOther_label_en-US" xlink:label="lab_bgne_DeferredTaxAssetValuationAllowanceCurrencyTranslationAndOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, Valuation Allowance, Currency Translation And Other</link:label>
    <link:label id="lab_bgne_DeferredTaxAssetValuationAllowanceCurrencyTranslationAndOther_documentation_en-US" xlink:label="lab_bgne_DeferredTaxAssetValuationAllowanceCurrencyTranslationAndOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, Valuation Allowance, Currency Translation And Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_DeferredTaxAssetValuationAllowanceCurrencyTranslationAndOther" xlink:href="bgne-20241231.xsd#bgne_DeferredTaxAssetValuationAllowanceCurrencyTranslationAndOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_DeferredTaxAssetValuationAllowanceCurrencyTranslationAndOther" xlink:to="lab_bgne_DeferredTaxAssetValuationAllowanceCurrencyTranslationAndOther" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitment_0e0b3b1d-4361-4d0b-a8cd-e89e67998a59_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Remaining portion of development funding cap</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_6f1abc52-75ff-4975-8580-06209449052c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other commitments</link:label>
    <link:label id="lab_us-gaap_OtherCommitment_label_en-US" xlink:label="lab_us-gaap_OtherCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitment" xlink:to="lab_us-gaap_OtherCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_2e501445-5f54-40c4-b21f-89c55a78c277_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_5faebe10-250c-4542-9e06-2825c9fd0d64_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_DeferredTaxAssetsActivityRollForward_2e6bd24a-9ec1-4609-9bfc-334020e777aa_terseLabel_en-US" xlink:label="lab_bgne_DeferredTaxAssetsActivityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Activity [Roll Forward]</link:label>
    <link:label id="lab_bgne_DeferredTaxAssetsActivityRollForward_label_en-US" xlink:label="lab_bgne_DeferredTaxAssetsActivityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Activity [Roll Forward]</link:label>
    <link:label id="lab_bgne_DeferredTaxAssetsActivityRollForward_documentation_en-US" xlink:label="lab_bgne_DeferredTaxAssetsActivityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_DeferredTaxAssetsActivityRollForward" xlink:href="bgne-20241231.xsd#bgne_DeferredTaxAssetsActivityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_DeferredTaxAssetsActivityRollForward" xlink:to="lab_bgne_DeferredTaxAssetsActivityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b07a7bda-c2fd-420c-b585-8d93d4b577be_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_beefc167-4ea7-40be-8795-217d9926a7b1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_f787a1fc-3bcd-47fd-b7c2-2f534975a08f_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_f29ef7a0-4262-460a-9b4e-b2d6662bce80_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_f7438bd2-7da0-4c8c-b842-fa0c50716501_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign_a511c6e8-8bdc-4196-bbef-80fc5fb6bc1e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax relief credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ac7ad541-1d7f-4133-96f3-e8a61ff40bec_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_LeapTherapeuticIncMember_60a77536-4359-4fee-a8f4-45b65075db25_terseLabel_en-US" xlink:label="lab_bgne_LeapTherapeuticIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leap Therapeutic, Inc</link:label>
    <link:label id="lab_bgne_LeapTherapeuticIncMember_label_en-US" xlink:label="lab_bgne_LeapTherapeuticIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leap Therapeutic, Inc [Member]</link:label>
    <link:label id="lab_bgne_LeapTherapeuticIncMember_documentation_en-US" xlink:label="lab_bgne_LeapTherapeuticIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Leap Therapeutic, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_LeapTherapeuticIncMember" xlink:href="bgne-20241231.xsd#bgne_LeapTherapeuticIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_LeapTherapeuticIncMember" xlink:to="lab_bgne_LeapTherapeuticIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_91fb7d42-f01d-4597-bf06-720083672b55_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Europe- total revenue</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_e5595416-8d13-44a4-9d43-4302a790d0b7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ContraARAccrualsMember_fe9ed5fb-66a6-4a00-a3b3-bc2447124926_terseLabel_en-US" xlink:label="lab_bgne_ContraARAccrualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contra AR Accruals</link:label>
    <link:label id="lab_bgne_ContraARAccrualsMember_label_en-US" xlink:label="lab_bgne_ContraARAccrualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contra AR Accruals [Member]</link:label>
    <link:label id="lab_bgne_ContraARAccrualsMember_documentation_en-US" xlink:label="lab_bgne_ContraARAccrualsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contra AR Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ContraARAccrualsMember" xlink:href="bgne-20241231.xsd#bgne_ContraARAccrualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ContraARAccrualsMember" xlink:to="lab_bgne_ContraARAccrualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ShareBasedPaymentArrangementNonvestedAwardOptionNumberOfShares_547390e8-fd9d-4638-83a4-bd54b4976bab_terseLabel_en-US" xlink:label="lab_bgne_ShareBasedPaymentArrangementNonvestedAwardOptionNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee service share based compensation nonvested stock options</link:label>
    <link:label id="lab_bgne_ShareBasedPaymentArrangementNonvestedAwardOptionNumberOfShares_label_en-US" xlink:label="lab_bgne_ShareBasedPaymentArrangementNonvestedAwardOptionNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Number of Shares</link:label>
    <link:label id="lab_bgne_ShareBasedPaymentArrangementNonvestedAwardOptionNumberOfShares_documentation_en-US" xlink:label="lab_bgne_ShareBasedPaymentArrangementNonvestedAwardOptionNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Service Share Based Compensation Nonvested Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShareBasedPaymentArrangementNonvestedAwardOptionNumberOfShares" xlink:href="bgne-20241231.xsd#bgne_ShareBasedPaymentArrangementNonvestedAwardOptionNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ShareBasedPaymentArrangementNonvestedAwardOptionNumberOfShares" xlink:to="lab_bgne_ShareBasedPaymentArrangementNonvestedAwardOptionNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_RestrictedNetAssetsAbstract_5088f9b6-fa2d-41c2-bbc4-de2fffa4f4fb_terseLabel_en-US" xlink:label="lab_bgne_RestrictedNetAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted net assets</link:label>
    <link:label id="lab_bgne_RestrictedNetAssetsAbstract_label_en-US" xlink:label="lab_bgne_RestrictedNetAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Net Assets [Abstract]</link:label>
    <link:label id="lab_bgne_RestrictedNetAssetsAbstract_documentation_en-US" xlink:label="lab_bgne_RestrictedNetAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Net Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RestrictedNetAssetsAbstract" xlink:href="bgne-20241231.xsd#bgne_RestrictedNetAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_RestrictedNetAssetsAbstract" xlink:to="lab_bgne_RestrictedNetAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_8ef0e6e9-16a7-4186-8a97-f98d69057d6a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset amortization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_df109777-5385-4de6-afbc-ece53676e856_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Activity, Accrual [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Activity, Accrual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis" xlink:to="lab_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_ca36097d-11bd-49cf-8907-a3b6057e1182_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_24d1a5a2-3aef-4559-81f2-55a347d28406_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_44c966a2-80b3-4092-964d-79fa215293b6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other payables</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_8c667a2b-3d72-4c63-98fe-43c3128ac3a8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_c386b4a9-f2d9-4ff6-b38e-2aea910eeba8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_AccruedLiabilitiesAccountsPayableOtherAndOtherLiabilitiesCurrentTableTextBlock_c8a78489-a78f-4d21-93fb-330f5a3d9b2d_verboseLabel_en-US" xlink:label="lab_bgne_AccruedLiabilitiesAccountsPayableOtherAndOtherLiabilitiesCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses and Other Payables</link:label>
    <link:label id="lab_bgne_AccruedLiabilitiesAccountsPayableOtherAndOtherLiabilitiesCurrentTableTextBlock_label_en-US" xlink:label="lab_bgne_AccruedLiabilitiesAccountsPayableOtherAndOtherLiabilitiesCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Accounts Payable, Other, and Other Liabilities, Current [Table Text Block]</link:label>
    <link:label id="lab_bgne_AccruedLiabilitiesAccountsPayableOtherAndOtherLiabilitiesCurrentTableTextBlock_documentation_en-US" xlink:label="lab_bgne_AccruedLiabilitiesAccountsPayableOtherAndOtherLiabilitiesCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of accrued liabilities, other accounts payable, and other liabilities, current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AccruedLiabilitiesAccountsPayableOtherAndOtherLiabilitiesCurrentTableTextBlock" xlink:href="bgne-20241231.xsd#bgne_AccruedLiabilitiesAccountsPayableOtherAndOtherLiabilitiesCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_AccruedLiabilitiesAccountsPayableOtherAndOtherLiabilitiesCurrentTableTextBlock" xlink:to="lab_bgne_AccruedLiabilitiesAccountsPayableOtherAndOtherLiabilitiesCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_c84f5a7b-e2c8-4e41-b5b1-553491154262_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions_334df66a-f122-4fd7-9cf9-7c05cf5a4705_periodStartLabel_en-US" xlink:label="lab_bgne_RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_bgne_RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions_d375450f-a141-43c2-8d86-fc07932174ca_periodEndLabel_en-US" xlink:label="lab_bgne_RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_bgne_RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions_label_en-US" xlink:label="lab_bgne_RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition Reserve For Sales Returns, Rebates And Other Deductions</link:label>
    <link:label id="lab_bgne_RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions_documentation_en-US" xlink:label="lab_bgne_RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition Reserve For Sales Returns, Rebates And Other Deductions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions" xlink:href="bgne-20241231.xsd#bgne_RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions" xlink:to="lab_bgne_RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_2c7f719d-af73-4464-ba49-60d3f21c10c4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_9e2860ae-6a96-4756-9383-728527a16b7f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_17fbc08e-684b-4c5e-9214-c5e36903c5d6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a006b97b-59c3-4393-92b0-e210321e7d5f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_701b9b35-acb1-4d20-abc7-c64141f082f3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_e24e5f12-c56e-47c8-b638-93cee3a06b39_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_69644523-6ae9-427f-a3aa-b771b4c88449_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined benefit plan, plan asset</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_3653ceea-8112-4ffb-b9c6-126c4c22a7bd_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension liability</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability, Defined Benefit Pension Plan, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_60bb532f-cc8f-4b57-8394-ce95d4befba1_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_GuangzhouMember_3886c107-54da-4bd1-b41b-1a76510d5b4c_terseLabel_en-US" xlink:label="lab_bgne_GuangzhouMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Guangzhou</link:label>
    <link:label id="lab_bgne_GuangzhouMember_label_en-US" xlink:label="lab_bgne_GuangzhouMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guangzhou [Member]</link:label>
    <link:label id="lab_bgne_GuangzhouMember_documentation_en-US" xlink:label="lab_bgne_GuangzhouMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Guangzhou</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_GuangzhouMember" xlink:href="bgne-20241231.xsd#bgne_GuangzhouMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_GuangzhouMember" xlink:to="lab_bgne_GuangzhouMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_RightToAccessIntellectualPropertyRevenueMember_93cb7803-b222-4e81-92f0-737d037c0d39_terseLabel_en-US" xlink:label="lab_bgne_RightToAccessIntellectualPropertyRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right to access intellectual property revenue</link:label>
    <link:label id="lab_bgne_RightToAccessIntellectualPropertyRevenueMember_label_en-US" xlink:label="lab_bgne_RightToAccessIntellectualPropertyRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right To Access Intellectual Property Revenue [Member]</link:label>
    <link:label id="lab_bgne_RightToAccessIntellectualPropertyRevenueMember_documentation_en-US" xlink:label="lab_bgne_RightToAccessIntellectualPropertyRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Right To Access Intellectual Property Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RightToAccessIntellectualPropertyRevenueMember" xlink:href="bgne-20241231.xsd#bgne_RightToAccessIntellectualPropertyRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_RightToAccessIntellectualPropertyRevenueMember" xlink:to="lab_bgne_RightToAccessIntellectualPropertyRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_ed2b06cf-a290-425c-9ed5-3fe8cb37c26a_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in wholly owned subsidiaries</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_a04dbaae-d9c5-4c76-a245-c6d8cf333d62_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4e2bade9-64f6-4638-815d-c5f692fcfe3b_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ShortTermBankLoanDatedNovember92020Member_a1dbae94-03e6-4011-8a40-16e575d26b21_terseLabel_en-US" xlink:label="lab_bgne_ShortTermBankLoanDatedNovember92020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short Term Bank Loan Dated November 9, 2020</link:label>
    <link:label id="lab_bgne_ShortTermBankLoanDatedNovember92020Member_label_en-US" xlink:label="lab_bgne_ShortTermBankLoanDatedNovember92020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short Term Bank Loan Dated November 9, 2020 [Member]</link:label>
    <link:label id="lab_bgne_ShortTermBankLoanDatedNovember92020Member_documentation_en-US" xlink:label="lab_bgne_ShortTermBankLoanDatedNovember92020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short Term Bank Loan Dated November 9, 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShortTermBankLoanDatedNovember92020Member" xlink:href="bgne-20241231.xsd#bgne_ShortTermBankLoanDatedNovember92020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ShortTermBankLoanDatedNovember92020Member" xlink:to="lab_bgne_ShortTermBankLoanDatedNovember92020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfCondensedBalanceSheetTableTextBlock_dba12e08-37d2-4049-9d0e-c5dbe7fce4de_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Condensed Balance Sheets</link:label>
    <link:label id="lab_srt_ScheduleOfCondensedBalanceSheetTableTextBlock_label_en-US" xlink:label="lab_srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Condensed Balance Sheet [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="lab_srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_f3aad28e-3f74-4908-befc-502f9f7d90d6_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_c574306a-6e06-4bb5-93d7-a8201b3d5aab_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront cash payment received</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_832c2826-eaef-4120-921a-791a73fb3030_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_97e36f42-9c43-414a-8ab4-d6cdce981db1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_6a2056ad-4c8e-40ad-93b6-13188e737134_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_b299e7d1-adda-4881-aa27-18100af5fe52_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_6588f8e7-a1ea-4b38-831c-c51beb961610_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_250191a4-0f73-4db0-b1c3-eec56927d1eb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4ed03479-98fa-4d79-b0ef-1c51c21d631a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1865ce80-7e3b-474b-93d4-09e1e1289e23_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e4a5755f-dc98-42e7-a49e-edb08e07ef89_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_f4e3404e-d836-43b9-ae37-7c08b27b3f49_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Additional Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_97b9899c-96a7-40ea-a1e9-4211cc8fcdb7_terseLabel_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss) before reclassifications</link:label>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, before Reclassifications, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:to="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_e72f1cd8-c442-4df6-9f8c-1977e0518a80_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ShareIncentivePlan2011Member_ece070d8-b05d-49f3-a33f-f42d3f714616_terseLabel_en-US" xlink:label="lab_bgne_ShareIncentivePlan2011Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2011 Plan</link:label>
    <link:label id="lab_bgne_ShareIncentivePlan2011Member_label_en-US" xlink:label="lab_bgne_ShareIncentivePlan2011Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Incentive Plan2011 [Member]</link:label>
    <link:label id="lab_bgne_ShareIncentivePlan2011Member_documentation_en-US" xlink:label="lab_bgne_ShareIncentivePlan2011Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2011 Share Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShareIncentivePlan2011Member" xlink:href="bgne-20241231.xsd#bgne_ShareIncentivePlan2011Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ShareIncentivePlan2011Member" xlink:to="lab_bgne_ShareIncentivePlan2011Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_LongTermBankLoanDatedJuly292022Member_2aae7181-7da4-4c3e-9483-d366f12951ba_terseLabel_en-US" xlink:label="lab_bgne_LongTermBankLoanDatedJuly292022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long Term Bank Loan Dated July 29, 2022</link:label>
    <link:label id="lab_bgne_LongTermBankLoanDatedJuly292022Member_label_en-US" xlink:label="lab_bgne_LongTermBankLoanDatedJuly292022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long Term Bank Loan Dated July 29, 2022 [Member]</link:label>
    <link:label id="lab_bgne_LongTermBankLoanDatedJuly292022Member_documentation_en-US" xlink:label="lab_bgne_LongTermBankLoanDatedJuly292022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long Term Bank Loan Dated July 29, 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_LongTermBankLoanDatedJuly292022Member" xlink:href="bgne-20241231.xsd#bgne_LongTermBankLoanDatedJuly292022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_LongTermBankLoanDatedJuly292022Member" xlink:to="lab_bgne_LongTermBankLoanDatedJuly292022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_OtherEquityMethodInvestmentsMember_c69f31e1-7e98-4112-ba02-07d46cbbfdb5_terseLabel_en-US" xlink:label="lab_bgne_OtherEquityMethodInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_bgne_OtherEquityMethodInvestmentsMember_label_en-US" xlink:label="lab_bgne_OtherEquityMethodInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Equity Method Investments [Member]</link:label>
    <link:label id="lab_bgne_OtherEquityMethodInvestmentsMember_documentation_en-US" xlink:label="lab_bgne_OtherEquityMethodInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_OtherEquityMethodInvestmentsMember" xlink:href="bgne-20241231.xsd#bgne_OtherEquityMethodInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_OtherEquityMethodInvestmentsMember" xlink:to="lab_bgne_OtherEquityMethodInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_4ed6bb86-2975-4a3b-b26e-5f84cc9a74c9_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_48414e26-3be8-4aa6-a507-84e0055978b9_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f131fb02-322c-49be-93fb-8ee609dccffd_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_a304b220-53c9-49f1-abe7-8387af0da374_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_d4ebc726-6446-485b-ba2f-1baef61dfc5c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7ad86346-bff6-47a1-ab00-6aa7d19c860e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_a15841a3-05fb-42a4-8e82-1a57a98d8d7e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_ec2d7726-a562-499f-8dd5-69c3a6b3de94_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract_abe45c80-7963-461c-b1da-f89070b236f6_terseLabel_en-US" xlink:label="lab_us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase and Capital commitments</link:label>
    <link:label id="lab_us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract_label_en-US" xlink:label="lab_us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unconditional Purchase Obligations (Excluding Capital Stock Redemptions) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract" xlink:to="lab_us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ChinaMinshengBankMember_7a98f1ec-5310-4515-9010-7c053e3b1ab7_terseLabel_en-US" xlink:label="lab_bgne_ChinaMinshengBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">China Minsheng Bank</link:label>
    <link:label id="lab_bgne_ChinaMinshengBankMember_label_en-US" xlink:label="lab_bgne_ChinaMinshengBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">China Minsheng Bank [Member]</link:label>
    <link:label id="lab_bgne_ChinaMinshengBankMember_documentation_en-US" xlink:label="lab_bgne_ChinaMinshengBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">China Minsheng Bank</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ChinaMinshengBankMember" xlink:href="bgne-20241231.xsd#bgne_ChinaMinshengBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ChinaMinshengBankMember" xlink:to="lab_bgne_ChinaMinshengBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_052e628c-71eb-4d83-9edf-9aeebc778a60_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale or maturity of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_07ba488a-b411-4a94-8294-51349634072d_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentAssistanceTypeAxis_8c55fed0-93f5-4f91-89e0-b79ded4e0b3a_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Assistance, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_GovernmentAssistanceTypeAxis_label_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Assistance, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceTypeAxis" xlink:to="lab_us-gaap_GovernmentAssistanceTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CH_c318fcf6-5b16-47f0-b0a0-467ff424b400_terseLabel_en-US" xlink:label="lab_country_CH" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SWITZERLAND</link:label>
    <link:label id="lab_country_CH_label_en-US" xlink:label="lab_country_CH" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SWITZERLAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CH" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CH"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CH" xlink:to="lab_country_CH" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_56511252-e9bd-48cf-946d-9c98f7e0171d_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_bc9069ee-1568-427c-88f1-1c91587b3220_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other payables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_25585532-646c-4c8c-be6b-0d64142e3931_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PRC</link:label>
    <link:label id="lab_country_CN_cdfc54be-2e90-4c13-86b6-c94a0082d4a1_verboseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">China- total revenue</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_CollaborationAgreementsTableTextBlock_9213b14f-9a4c-4aed-b76c-a751232ee795_terseLabel_en-US" xlink:label="lab_bgne_CollaborationAgreementsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaboration Agreements</link:label>
    <link:label id="lab_bgne_CollaborationAgreementsTableTextBlock_label_en-US" xlink:label="lab_bgne_CollaborationAgreementsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreements [Table Text Block]</link:label>
    <link:label id="lab_bgne_CollaborationAgreementsTableTextBlock_documentation_en-US" xlink:label="lab_bgne_CollaborationAgreementsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_CollaborationAgreementsTableTextBlock" xlink:href="bgne-20241231.xsd#bgne_CollaborationAgreementsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_CollaborationAgreementsTableTextBlock" xlink:to="lab_bgne_CollaborationAgreementsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_8b1c27ec-8511-4bc9-b0bb-a27f138d3d7d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ChinaCITICBankMember_abc82c71-2f6a-467a-b1bd-e3f9371d7188_terseLabel_en-US" xlink:label="lab_bgne_ChinaCITICBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">China CITIC Bank</link:label>
    <link:label id="lab_bgne_ChinaCITICBankMember_label_en-US" xlink:label="lab_bgne_ChinaCITICBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">China CITIC Bank [Member]</link:label>
    <link:label id="lab_bgne_ChinaCITICBankMember_documentation_en-US" xlink:label="lab_bgne_ChinaCITICBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">China CITIC Bank</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ChinaCITICBankMember" xlink:href="bgne-20241231.xsd#bgne_ChinaCITICBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ChinaCITICBankMember" xlink:to="lab_bgne_ChinaCITICBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityNumberOfEmployees_7bccbdc7-d971-44f0-87ba-19ac845b848d_terseLabel_en-US" xlink:label="lab_dei_EntityNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of employees</link:label>
    <link:label id="lab_dei_EntityNumberOfEmployees_label_en-US" xlink:label="lab_dei_EntityNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Number of Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityNumberOfEmployees" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityNumberOfEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityNumberOfEmployees" xlink:to="lab_dei_EntityNumberOfEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_8ed28150-8d4d-4bb8-a06f-9e2d86cec540_totalLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI and without Readily Determinable Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:to="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_af499a54-f08c-4970-87a5-56f1d22312cd_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Liability Adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ShanghaiPudongDevelopmentBankMember_6c306b0d-ea31-4def-bec6-baafdbe90045_terseLabel_en-US" xlink:label="lab_bgne_ShanghaiPudongDevelopmentBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shanghai Pudong Development Bank</link:label>
    <link:label id="lab_bgne_ShanghaiPudongDevelopmentBankMember_label_en-US" xlink:label="lab_bgne_ShanghaiPudongDevelopmentBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shanghai Pudong Development Bank [Member]</link:label>
    <link:label id="lab_bgne_ShanghaiPudongDevelopmentBankMember_documentation_en-US" xlink:label="lab_bgne_ShanghaiPudongDevelopmentBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shanghai Pudong Development Bank</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShanghaiPudongDevelopmentBankMember" xlink:href="bgne-20241231.xsd#bgne_ShanghaiPudongDevelopmentBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ShanghaiPudongDevelopmentBankMember" xlink:to="lab_bgne_ShanghaiPudongDevelopmentBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_8d03ecb1-481b-473b-9ec0-6fe2dd1e775b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed annual interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_2ff163ff-a99b-4207-a1e2-cee0c455209b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_92c51a9c-42f8-4579-865a-ae2e21abf053_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental cash flow disclosures:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_GovernmentAssistanceResearchAndDevelopmentProgramsMember_f4bb0bad-2f61-466d-aa2c-822b3816c5d1_terseLabel_en-US" xlink:label="lab_bgne_GovernmentAssistanceResearchAndDevelopmentProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Assistance, Research And Development Programs</link:label>
    <link:label id="lab_bgne_GovernmentAssistanceResearchAndDevelopmentProgramsMember_label_en-US" xlink:label="lab_bgne_GovernmentAssistanceResearchAndDevelopmentProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Assistance, Research And Development Programs [Member]</link:label>
    <link:label id="lab_bgne_GovernmentAssistanceResearchAndDevelopmentProgramsMember_documentation_en-US" xlink:label="lab_bgne_GovernmentAssistanceResearchAndDevelopmentProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government Assistance, Research And Development Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_GovernmentAssistanceResearchAndDevelopmentProgramsMember" xlink:href="bgne-20241231.xsd#bgne_GovernmentAssistanceResearchAndDevelopmentProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_GovernmentAssistanceResearchAndDevelopmentProgramsMember" xlink:to="lab_bgne_GovernmentAssistanceResearchAndDevelopmentProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_7af4509c-9a20-43cc-9425-e79579aff371_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">R&amp;D and other capitalized costs</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, In-Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_8c8def22-9b94-4935-9dc0-08d97bcd709c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest capitalized</link:label>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_label_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Costs Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestCostsCapitalized" xlink:to="lab_us-gaap_InterestCostsCapitalized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_6c62e96b-eb3c-42af-9a9b-1d9eb965d2e7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_03478b02-9d9a-4a4a-b9e3-90c0a6099e98_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic&#160;Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_f474e3b0-38bb-4c7e-b3c9-287085944323_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3361d819-4df0-409b-ba46-ac31c7c5c48f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_53224e58-e8b1-4723-8288-9ae8e14531bb_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoriesMember_1ed990ba-2d3d-49f5-bbc8-15beab45703d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_label_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember" xlink:to="lab_us-gaap_InventoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_AssetsAndLiabilitiesLesseeTableTextBlock_d3328c4b-aa6e-4be9-bad5-03f9b78da809_terseLabel_en-US" xlink:label="lab_bgne_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Supplemental Balance Sheet Information</link:label>
    <link:label id="lab_bgne_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_bgne_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_bgne_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_bgne_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="bgne-20241231.xsd#bgne_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_bgne_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ShortTermBankLoanDatedMay302023Member_649ca771-ff58-4fff-aa63-0aabc2d1c6f6_terseLabel_en-US" xlink:label="lab_bgne_ShortTermBankLoanDatedMay302023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short Term Bank Loan Dated May 30 2023</link:label>
    <link:label id="lab_bgne_ShortTermBankLoanDatedMay302023Member_label_en-US" xlink:label="lab_bgne_ShortTermBankLoanDatedMay302023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short Term Bank Loan Dated May 30 2023 [Member]</link:label>
    <link:label id="lab_bgne_ShortTermBankLoanDatedMay302023Member_documentation_en-US" xlink:label="lab_bgne_ShortTermBankLoanDatedMay302023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short Term Bank Loan Dated May 30 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShortTermBankLoanDatedMay302023Member" xlink:href="bgne-20241231.xsd#bgne_ShortTermBankLoanDatedMay302023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ShortTermBankLoanDatedMay302023Member" xlink:to="lab_bgne_ShortTermBankLoanDatedMay302023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_d32f45eb-3861-4437-a45b-1c012bca442b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_a0d917d3-f2e3-4506-97ba-400b1e42a229_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_565b9b20-a534-4616-b47e-31dd9427e9fd_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_a1d06e00-da81-4f1d-bad2-213d4912802e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e7b670bb-7f3e-4b67-891f-14f59726ac53_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_c10a86d4-673b-4aeb-81bf-8e5dd62512dc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Restricted Shares Activities and Restricted Share Units Activities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetAssetLiabilityAbstract_b150d892-6a91-4a8d-8704-15b09a226622_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetAssetLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueNetAssetLiabilityAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueNetAssetLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Net Asset (Liability) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiabilityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetAssetLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetAssetLiabilityAbstract" xlink:to="lab_us-gaap_FairValueNetAssetLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_898719c9-414e-42c5-8a1d-bad596ab50fb_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ROU assets obtained in exchange for new operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d31a556d-7ede-4218-a41e-3e73c505ac13_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income/(Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_26421c55-55b7-4a08-b9a8-7a4892c71b91_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1bc195db-bed4-4e13-82c5-a5cf0ba68fb9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_b7859724-6dab-499c-b163-42d9e0d6d63d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_30f5a7d0-e7b1-43cd-b36e-292b5b115c9a_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_f4a3f071-0250-4e78-9adc-b74e2e6022c1_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_7721827c-95e6-45d6-ba1a-6d58ef606bb3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_2ff6fcb0-f3b0-4416-a775-99f4a7718d5c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligationDueInSecondYear_57549d78-268d-415e-b1c7-b53b5c6413bd_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year ending December&#160;31,&#160;2026</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInSecondYear_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInSecondYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInSecondYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInSecondYear" xlink:to="lab_us-gaap_ContractualObligationDueInSecondYear" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_AdjustmentsToAdditionalPaidInCapitalDeconsolidationOfSubsidiary_95a79a72-b374-49d7-a4d3-f44594c0b023_terseLabel_en-US" xlink:label="lab_bgne_AdjustmentsToAdditionalPaidInCapitalDeconsolidationOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deconsolidation of a subsidiary</link:label>
    <link:label id="lab_bgne_AdjustmentsToAdditionalPaidInCapitalDeconsolidationOfSubsidiary_label_en-US" xlink:label="lab_bgne_AdjustmentsToAdditionalPaidInCapitalDeconsolidationOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Deconsolidation Of Subsidiary</link:label>
    <link:label id="lab_bgne_AdjustmentsToAdditionalPaidInCapitalDeconsolidationOfSubsidiary_documentation_en-US" xlink:label="lab_bgne_AdjustmentsToAdditionalPaidInCapitalDeconsolidationOfSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Deconsolidation Of Subsidiary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AdjustmentsToAdditionalPaidInCapitalDeconsolidationOfSubsidiary" xlink:href="bgne-20241231.xsd#bgne_AdjustmentsToAdditionalPaidInCapitalDeconsolidationOfSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_AdjustmentsToAdditionalPaidInCapitalDeconsolidationOfSubsidiary" xlink:to="lab_bgne_AdjustmentsToAdditionalPaidInCapitalDeconsolidationOfSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ShanghaiMember_1b1e1f57-6d5c-4383-b6a3-a768f8fa7fc6_terseLabel_en-US" xlink:label="lab_bgne_ShanghaiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shanghai</link:label>
    <link:label id="lab_bgne_ShanghaiMember_label_en-US" xlink:label="lab_bgne_ShanghaiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shanghai [Member]</link:label>
    <link:label id="lab_bgne_ShanghaiMember_documentation_en-US" xlink:label="lab_bgne_ShanghaiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shanghai</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShanghaiMember" xlink:href="bgne-20241231.xsd#bgne_ShanghaiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ShanghaiMember" xlink:to="lab_bgne_ShanghaiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_RestrictedNetAssetsAppropriatedToStatutoryReserves_45577b66-f584-4eea-a7df-0e66c2f7b826_terseLabel_en-US" xlink:label="lab_bgne_RestrictedNetAssetsAppropriatedToStatutoryReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Appropriation to statutory reserves</link:label>
    <link:label id="lab_bgne_RestrictedNetAssetsAppropriatedToStatutoryReserves_label_en-US" xlink:label="lab_bgne_RestrictedNetAssetsAppropriatedToStatutoryReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Net, Assets Appropriated to Statutory Reserves</link:label>
    <link:label id="lab_bgne_RestrictedNetAssetsAppropriatedToStatutoryReserves_documentation_en-US" xlink:label="lab_bgne_RestrictedNetAssetsAppropriatedToStatutoryReserves" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount appropriated to statutory reserves.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RestrictedNetAssetsAppropriatedToStatutoryReserves" xlink:href="bgne-20241231.xsd#bgne_RestrictedNetAssetsAppropriatedToStatutoryReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_RestrictedNetAssetsAppropriatedToStatutoryReserves" xlink:to="lab_bgne_RestrictedNetAssetsAppropriatedToStatutoryReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_6cd9a058-2e29-47a1-bee0-def3ebd955bc_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment Useful Life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_5842f541-80cc-42a9-95c4-963c24dbafcb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_c2b70207-b635-4180-a5ec-f244dcdb6b04_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_DevelopmentMilestonePaymentsMember_c17658d7-594e-48f7-9bfd-05846beadfb0_terseLabel_en-US" xlink:label="lab_bgne_DevelopmentMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development milestone payments</link:label>
    <link:label id="lab_bgne_DevelopmentMilestonePaymentsMember_label_en-US" xlink:label="lab_bgne_DevelopmentMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development Milestone Payments [Member]</link:label>
    <link:label id="lab_bgne_DevelopmentMilestonePaymentsMember_documentation_en-US" xlink:label="lab_bgne_DevelopmentMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_DevelopmentMilestonePaymentsMember" xlink:href="bgne-20241231.xsd#bgne_DevelopmentMilestonePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_DevelopmentMilestonePaymentsMember" xlink:to="lab_bgne_DevelopmentMilestonePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrentAbstract_9200b270-82ae-4025-8038-8dd0963a2a14_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrentAbstract" xlink:to="lab_us-gaap_OtherAssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligationDueInFifthYear_4468cb60-f86f-43df-a9f0-2553fa2124da_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInFifthYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year ending December 31, 2029</link:label>
    <link:label id="lab_us-gaap_ContractualObligationDueInFifthYear_label_en-US" xlink:label="lab_us-gaap_ContractualObligationDueInFifthYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInFifthYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInFifthYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligationDueInFifthYear" xlink:to="lab_us-gaap_ContractualObligationDueInFifthYear" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_LongTermBankLoanDatedJanuary222020Member_fc4094a3-8e3b-4f36-8445-5757fbcf9820_terseLabel_en-US" xlink:label="lab_bgne_LongTermBankLoanDatedJanuary222020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long Term Bank Loan Dated January 22, 2020</link:label>
    <link:label id="lab_bgne_LongTermBankLoanDatedJanuary222020Member_label_en-US" xlink:label="lab_bgne_LongTermBankLoanDatedJanuary222020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long Term Bank Loan Dated January 22 2020 [Member]</link:label>
    <link:label id="lab_bgne_LongTermBankLoanDatedJanuary222020Member_documentation_en-US" xlink:label="lab_bgne_LongTermBankLoanDatedJanuary222020Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long Term Bank Loan Dated January 22 2020</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_LongTermBankLoanDatedJanuary222020Member" xlink:href="bgne-20241231.xsd#bgne_LongTermBankLoanDatedJanuary222020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_LongTermBankLoanDatedJanuary222020Member" xlink:to="lab_bgne_LongTermBankLoanDatedJanuary222020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_542458e5-4fbb-4d0b-884d-3bc6ceea0155_terseLabel_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable and Allowance for Credit Losses</link:label>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Loss, Financial Instrument [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:to="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CondensedCashFlowStatementTable_31574cd9-116b-4f49-b31a-e6d5170cc2d2_terseLabel_en-US" xlink:label="lab_srt_CondensedCashFlowStatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Condensed Cash Flow Statement [Table]</link:label>
    <link:label id="lab_srt_CondensedCashFlowStatementTable_label_en-US" xlink:label="lab_srt_CondensedCashFlowStatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Condensed Cash Flow Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedCashFlowStatementTable" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedCashFlowStatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedCashFlowStatementTable" xlink:to="lab_srt_CondensedCashFlowStatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ThreeLargestCustomersMember_5c547b06-b780-49b2-908f-c48207581d6d_terseLabel_en-US" xlink:label="lab_bgne_ThreeLargestCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Three Largest Customers</link:label>
    <link:label id="lab_bgne_ThreeLargestCustomersMember_label_en-US" xlink:label="lab_bgne_ThreeLargestCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Three Largest Customers [Member]</link:label>
    <link:label id="lab_bgne_ThreeLargestCustomersMember_documentation_en-US" xlink:label="lab_bgne_ThreeLargestCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Three Largest Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ThreeLargestCustomersMember" xlink:href="bgne-20241231.xsd#bgne_ThreeLargestCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ThreeLargestCustomersMember" xlink:to="lab_bgne_ThreeLargestCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_237471f0-5a18-4a25-931d-cd1f33f00232_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_f6af261a-ac6a-46e1-9de7-0a7afe03dc30_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseMember_09fac167-085d-461e-9824-e85adc0e3edb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Operating Income (Expense)</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_RegulatoryAndCommercialMilestonePaymentsMember_507bf207-4bb3-42b2-a6d3-1696c528543f_terseLabel_en-US" xlink:label="lab_bgne_RegulatoryAndCommercialMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Regulatory and commercial milestone payments</link:label>
    <link:label id="lab_bgne_RegulatoryAndCommercialMilestonePaymentsMember_label_en-US" xlink:label="lab_bgne_RegulatoryAndCommercialMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regulatory And Commercial Milestone Payments [Member]</link:label>
    <link:label id="lab_bgne_RegulatoryAndCommercialMilestonePaymentsMember_documentation_en-US" xlink:label="lab_bgne_RegulatoryAndCommercialMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Regulatory And Commercial Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RegulatoryAndCommercialMilestonePaymentsMember" xlink:href="bgne-20241231.xsd#bgne_RegulatoryAndCommercialMilestonePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_RegulatoryAndCommercialMilestonePaymentsMember" xlink:to="lab_bgne_RegulatoryAndCommercialMilestonePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_MaximumPercentageOfEligibleEarningsSetSideToPurchaseOrdinaryShares_d14d4384-ae5f-4ed0-8006-2e9b0496325b_terseLabel_en-US" xlink:label="lab_bgne_MaximumPercentageOfEligibleEarningsSetSideToPurchaseOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum percentage of eligible earnings as after-tax withholdings to purchase ordinary shares (as a percent)</link:label>
    <link:label id="lab_bgne_MaximumPercentageOfEligibleEarningsSetSideToPurchaseOrdinaryShares_label_en-US" xlink:label="lab_bgne_MaximumPercentageOfEligibleEarningsSetSideToPurchaseOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Percentage of Eligible Earnings Set a Side to Purchase Ordinary Shares</link:label>
    <link:label id="lab_bgne_MaximumPercentageOfEligibleEarningsSetSideToPurchaseOrdinaryShares_documentation_en-US" xlink:label="lab_bgne_MaximumPercentageOfEligibleEarningsSetSideToPurchaseOrdinaryShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum Percentage of Eligible Earnings Set a Side to Purchase Ordinary Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_MaximumPercentageOfEligibleEarningsSetSideToPurchaseOrdinaryShares" xlink:href="bgne-20241231.xsd#bgne_MaximumPercentageOfEligibleEarningsSetSideToPurchaseOrdinaryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_MaximumPercentageOfEligibleEarningsSetSideToPurchaseOrdinaryShares" xlink:to="lab_bgne_MaximumPercentageOfEligibleEarningsSetSideToPurchaseOrdinaryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_a494db55-1b50-4465-97e5-217040b0fd01_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">U.S. statutory tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CondensedStatementOfComprehensiveIncomeTable_ab8eb7ba-13c2-4683-a859-41d7f26f5b68_terseLabel_en-US" xlink:label="lab_srt_CondensedStatementOfComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Condensed Statement of Comprehensive Income [Table]</link:label>
    <link:label id="lab_srt_CondensedStatementOfComprehensiveIncomeTable_label_en-US" xlink:label="lab_srt_CondensedStatementOfComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Condensed Statement of Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedStatementOfComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedStatementOfComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedStatementOfComprehensiveIncomeTable" xlink:to="lab_srt_CondensedStatementOfComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_9218c9ca-37bd-4c52-9551-41b9f83a208a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Deferred Tax Assets (Liabilities)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_cfeae558-9d1b-4618-96dd-ed23e8b5c1c9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_76b60164-e71e-46d0-ae3a-972fbffcb176_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_3f1dfb8b-e478-4b94-90b7-0eb2c6ce2418_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountOnPurchasePriceOfCommonStockPercent_3a0ec417-21b5-41eb-959a-aa78419539eb_terseLabel_en-US" xlink:label="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountOnPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount on purchase price of common stock (as a percent)</link:label>
    <link:label id="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountOnPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountOnPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Discount on Purchase Price of Common Stock, Percent</link:label>
    <link:label id="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountOnPurchasePriceOfCommonStockPercent_documentation_en-US" xlink:label="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountOnPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Discount on Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountOnPurchasePriceOfCommonStockPercent" xlink:href="bgne-20241231.xsd#bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountOnPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountOnPurchasePriceOfCommonStockPercent" xlink:to="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountOnPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_4472ec99-bce0-4269-ab48-643f4bb04a6a_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_c0507283-360b-434c-9704-a13fe4280e82_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentAssistanceLiability_7d1b6dd7-f6bf-4af4-afa0-3a3a394f3ad0_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred government grant income</link:label>
    <link:label id="lab_us-gaap_GovernmentAssistanceLiability_label_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Assistance, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceLiability" xlink:to="lab_us-gaap_GovernmentAssistanceLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CondensedStatementOfIncomeCaptionsLineItems_2323ab3f-f9b6-4a3f-8696-3f20d2de8f2f_terseLabel_en-US" xlink:label="lab_srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Condensed Statement of Income Captions [Line Items]</link:label>
    <link:label id="lab_srt_CondensedStatementOfIncomeCaptionsLineItems_label_en-US" xlink:label="lab_srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Condensed Statement of Income Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedStatementOfIncomeCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:to="lab_srt_CondensedStatementOfIncomeCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableNoncurrent_412cc17a-51ea-4413-9b58-c106fb8e6d4a_terseLabel_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid VAT</link:label>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableNoncurrent_label_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value Added Tax Receivable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValueAddedTaxReceivableNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValueAddedTaxReceivableNoncurrent" xlink:to="lab_us-gaap_ValueAddedTaxReceivableNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_20088b0a-65a1-429a-85cd-67cfd621440d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_717d5e67-8266-49e1-a7a4-c6160a8f570e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_6ba44306-9ec4-4d75-b53f-e459e99ac1f0_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_d3ee0b69-0daf-4347-ab1f-09aac2bdd21d_verboseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_BuildingMember_943d252e-c5de-4f9c-bd29-d7b0a3e41e3a_netLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_90ef4c8e-c96d-4af3-99d4-6b55b5b7f929_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ScheduleOfAccruedSalesRebatesAndReturnsCurrentTableTextBlock_53678c5f-902c-4363-b9db-a1f6ecd025a3_terseLabel_en-US" xlink:label="lab_bgne_ScheduleOfAccruedSalesRebatesAndReturnsCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Sales Rebates and Returns</link:label>
    <link:label id="lab_bgne_ScheduleOfAccruedSalesRebatesAndReturnsCurrentTableTextBlock_label_en-US" xlink:label="lab_bgne_ScheduleOfAccruedSalesRebatesAndReturnsCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Sales Rebates and Returns Current [Table Text Block]</link:label>
    <link:label id="lab_bgne_ScheduleOfAccruedSalesRebatesAndReturnsCurrentTableTextBlock_documentation_en-US" xlink:label="lab_bgne_ScheduleOfAccruedSalesRebatesAndReturnsCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Sales Rebates and Returns Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ScheduleOfAccruedSalesRebatesAndReturnsCurrentTableTextBlock" xlink:href="bgne-20241231.xsd#bgne_ScheduleOfAccruedSalesRebatesAndReturnsCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ScheduleOfAccruedSalesRebatesAndReturnsCurrentTableTextBlock" xlink:to="lab_bgne_ScheduleOfAccruedSalesRebatesAndReturnsCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_cfc44545-80be-4ad3-8641-fb7606429ffb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_3d17b7a5-6e5d-4620-ab9e-171a91259702_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_1f1f1209-2b55-41a1-bf67-30907ed50d16_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from option exercises and employee share purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_1c91a61e-2572-4cba-bee4-0c730f26e088_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_83f0fb11-8c4f-4213-a7e8-724010f11b83_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_042bf732-4ed8-4ff8-8671-49e6cd0aa006_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_c4a5c8aa-3daa-47ff-8043-8f9d7f6d7cc2_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_c5f7ea34-6488-451e-b714-d90cce226ca9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_08d43ce2-ccd5-4783-aa76-892c85661d62_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_7b9b3dee-b491-46ac-82da-9b83d950af38_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized losses on long-term investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_ff716951-9c85-4f70-9ffd-cfd399bde779_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, maximum (as percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_882c5b00-f17a-4e35-803b-d091f4db1033_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_dab70db1-1553-449e-924c-2726d3228675_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_FinancingCommitmentCarryingValue_3d3f04e4-6d62-4052-965c-0fcd99b88f4a_totalLabel_en-US" xlink:label="lab_bgne_FinancingCommitmentCarryingValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total research and development cost share liability</link:label>
    <link:label id="lab_bgne_FinancingCommitmentCarryingValue_label_en-US" xlink:label="lab_bgne_FinancingCommitmentCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Commitment, Carrying Value</link:label>
    <link:label id="lab_bgne_FinancingCommitmentCarryingValue_documentation_en-US" xlink:label="lab_bgne_FinancingCommitmentCarryingValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financing Commitment, Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_FinancingCommitmentCarryingValue" xlink:href="bgne-20241231.xsd#bgne_FinancingCommitmentCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_FinancingCommitmentCarryingValue" xlink:to="lab_bgne_FinancingCommitmentCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_8701f816-3be3-4c95-927e-0d1ca96c8ccb_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_DefinedBenefitPlanExpectedFutureBenefitPaymentTotal_56545b8a-6d13-4918-aed9-9e5fe5809560_totalLabel_en-US" xlink:label="lab_bgne_DefinedBenefitPlanExpectedFutureBenefitPaymentTotal" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_bgne_DefinedBenefitPlanExpectedFutureBenefitPaymentTotal_label_en-US" xlink:label="lab_bgne_DefinedBenefitPlanExpectedFutureBenefitPaymentTotal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Total</link:label>
    <link:label id="lab_bgne_DefinedBenefitPlanExpectedFutureBenefitPaymentTotal_documentation_en-US" xlink:label="lab_bgne_DefinedBenefitPlanExpectedFutureBenefitPaymentTotal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_DefinedBenefitPlanExpectedFutureBenefitPaymentTotal" xlink:href="bgne-20241231.xsd#bgne_DefinedBenefitPlanExpectedFutureBenefitPaymentTotal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_DefinedBenefitPlanExpectedFutureBenefitPaymentTotal" xlink:to="lab_bgne_DefinedBenefitPlanExpectedFutureBenefitPaymentTotal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_6a3d5400-d497-49fd-95b9-d4fc8a46e0f8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2030 and thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_45fab2a4-5f4c-46ab-a170-033099fede5d_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c43628ce-b4c8-41ca-acb8-adbaf87dd26a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of options, ESPP and release of RSUs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_a33d301f-3246-4e31-9441-61966a4a5c28_verboseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additions based on tax positions related to the current tax year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_d4fe40a2-3f12-447a-8b2b-b58e6805aeed_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_9d190127-14f7-46c3-9e32-32fab9bcfae6_netLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Market price, Ordinary (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_84802c61-1fdd-419b-aa31-aadc45cccf5f_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of ordinary share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_86b61dbf-6970-4c62-89a7-1622e71fd14e_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_d04b92e5-f2c0-4c9e-b24d-a22832ba7366_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year ending December&#160;31,&#160;2025</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ProductNameDomain_2f6de35d-08c7-40e2-a34a-70a2b874f079_terseLabel_en-US" xlink:label="lab_bgne_ProductNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Name [Domain]</link:label>
    <link:label id="lab_bgne_ProductNameDomain_label_en-US" xlink:label="lab_bgne_ProductNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Name [Domain]</link:label>
    <link:label id="lab_bgne_ProductNameDomain_documentation_en-US" xlink:label="lab_bgne_ProductNameDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ProductNameDomain" xlink:href="bgne-20241231.xsd#bgne_ProductNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ProductNameDomain" xlink:to="lab_bgne_ProductNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_cfa668c6-d0a1-4af2-b093-a09e85938688_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_963f1089-182f-42cd-b446-d202e8490ea2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax, Examination [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Examination [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationTable" xlink:to="lab_us-gaap_IncomeTaxExaminationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_LongTermFundingCommitmentNumberOfEquityInvestments_ce991e92-e500-4149-a46b-d51f686b33b3_terseLabel_en-US" xlink:label="lab_bgne_LongTermFundingCommitmentNumberOfEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of equity investments</link:label>
    <link:label id="lab_bgne_LongTermFundingCommitmentNumberOfEquityInvestments_label_en-US" xlink:label="lab_bgne_LongTermFundingCommitmentNumberOfEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Funding Commitment, Number of Equity Investments</link:label>
    <link:label id="lab_bgne_LongTermFundingCommitmentNumberOfEquityInvestments_documentation_en-US" xlink:label="lab_bgne_LongTermFundingCommitmentNumberOfEquityInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-Term Funding Commitment, Number of Equity Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_LongTermFundingCommitmentNumberOfEquityInvestments" xlink:href="bgne-20241231.xsd#bgne_LongTermFundingCommitmentNumberOfEquityInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_LongTermFundingCommitmentNumberOfEquityInvestments" xlink:to="lab_bgne_LongTermFundingCommitmentNumberOfEquityInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_958b576e-94f5-48ee-8157-cf6785840605_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Activity, Accrual [Domain]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Activity, Accrual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain" xlink:to="lab_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_e3f7ddd5-1534-47b8-9914-71120e437a80_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_177b2827-ed2b-42bc-9444-f7b3cf6f0c25_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_a26467d2-a24a-41e1-b27b-4b3dedcec2b9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility, minimum (as percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_TaxBenefitFromForeignTaxStatus_e946dd13-d313-400d-bb9c-331ddc65855f_terseLabel_en-US" xlink:label="lab_bgne_TaxBenefitFromForeignTaxStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit from foreign tax status</link:label>
    <link:label id="lab_bgne_TaxBenefitFromForeignTaxStatus_label_en-US" xlink:label="lab_bgne_TaxBenefitFromForeignTaxStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Benefit From Foreign Tax Status</link:label>
    <link:label id="lab_bgne_TaxBenefitFromForeignTaxStatus_documentation_en-US" xlink:label="lab_bgne_TaxBenefitFromForeignTaxStatus" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Benefit From Foreign Tax Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_TaxBenefitFromForeignTaxStatus" xlink:href="bgne-20241231.xsd#bgne_TaxBenefitFromForeignTaxStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_TaxBenefitFromForeignTaxStatus" xlink:to="lab_bgne_TaxBenefitFromForeignTaxStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_67e6569a-57c1-4083-abe5-214c53168257_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a632601a-a7c1-463a-ab28-f0216d042358_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_9740d671-d151-48d1-8683-ddcdd6675ffd_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_84651dfd-edc7-4133-901e-355e1bb21133_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_efcbe6d9-3665-43f3-8014-2fd3f224817b_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_69efd53c-9537-403f-a9f8-d05d7d7a92af_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year ending December 31, 2028</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_076f5001-cf90-47af-9e39-297ab08a9f89_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_REVLIMIDMember_16c31951-0fdb-413f-ab36-34e27e63a0b3_terseLabel_en-US" xlink:label="lab_bgne_REVLIMIDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">REVLIMID&#174;</link:label>
    <link:label id="lab_bgne_REVLIMIDMember_label_en-US" xlink:label="lab_bgne_REVLIMIDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">REVLIMID [Member]</link:label>
    <link:label id="lab_bgne_REVLIMIDMember_documentation_en-US" xlink:label="lab_bgne_REVLIMIDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revlimid [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_REVLIMIDMember" xlink:href="bgne-20241231.xsd#bgne_REVLIMIDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_REVLIMIDMember" xlink:to="lab_bgne_REVLIMIDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_01d42ce9-29a7-4135-bab6-02b8dbaae554_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_7bffe33d-7566-41c8-8322-648a1da265b8_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_54fe30d8-94b3-446f-b6d7-432c73d964b6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_83049047-a36d-4cb1-9b3c-28a627f0118b_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_4184ef37-97c6-44dc-aef0-b09368059deb_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_42c78a1a-feec-4ee9-be9d-086cb6777baf_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_16fc8a46-890b-4a0e-997a-033ae0b5640d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quoted&#160;Price in&#160;Active Market&#160;for Identical Assets (Level&#160;1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_1847d765-12a3-4bae-86e1-282bd924f7c3_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_44ecbf3d-d22f-449b-97e2-44faa045b92a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_1f779684-8c5d-4350-a9eb-b9e70b13d2ba_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental non-cash activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ShortTermBankLoanDatedMay42023Member_0e94f038-bf88-44af-b3ee-83da59ece301_terseLabel_en-US" xlink:label="lab_bgne_ShortTermBankLoanDatedMay42023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short Term Bank Loan Dated May 4 2023</link:label>
    <link:label id="lab_bgne_ShortTermBankLoanDatedMay42023Member_label_en-US" xlink:label="lab_bgne_ShortTermBankLoanDatedMay42023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short Term Bank Loan Dated May 4 2023 [Member]</link:label>
    <link:label id="lab_bgne_ShortTermBankLoanDatedMay42023Member_documentation_en-US" xlink:label="lab_bgne_ShortTermBankLoanDatedMay42023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short Term Bank Loan Dated May 4 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShortTermBankLoanDatedMay42023Member" xlink:href="bgne-20241231.xsd#bgne_ShortTermBankLoanDatedMay42023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ShortTermBankLoanDatedMay42023Member" xlink:to="lab_bgne_ShortTermBankLoanDatedMay42023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b1e6af40-f5e9-4c56-8b38-946b86b9c5cc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Options - Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_955d60fb-0936-415c-8993-20599d0ad228_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_IntangibleAssetsMember_9a11e781-4b3a-4f78-9812-bf5c22e86af7_terseLabel_en-US" xlink:label="lab_bgne_IntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset</link:label>
    <link:label id="lab_bgne_IntangibleAssetsMember_label_en-US" xlink:label="lab_bgne_IntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets [Member]</link:label>
    <link:label id="lab_bgne_IntangibleAssetsMember_documentation_en-US" xlink:label="lab_bgne_IntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_IntangibleAssetsMember" xlink:href="bgne-20241231.xsd#bgne_IntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_IntangibleAssetsMember" xlink:to="lab_bgne_IntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7df390ef-167b-4561-adec-ac8a2936c944_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_cc520048-ba67-4947-9a1d-14aff718a105_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_ff29de7f-7f2b-47b1-ae26-b5c0e681fd9f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_deb60de5-b3db-4e14-b558-c3d300386dc4_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities without readily determinable fair values</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_f93fb477-bcfc-40b3-8f1c-151600ec8bbd_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase commitments</link:label>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_label_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_28a6342c-4121-4c4a-8f66-b4cb9133ba18_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_a0033aa2-a5b5-43bf-b9f6-6f8f2749c4fa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_d259418e-dd47-439a-b93f-fa86a7e21519_terseLabel_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bank Time Deposits [Member]</link:label>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_label_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bank Time Deposits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BankTimeDepositsMember" xlink:to="lab_us-gaap_BankTimeDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_ddce17bd-2de7-405f-b92b-d12fac68cddf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_8a83badd-f046-46e6-b4c4-3667e02b8797_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cancellation of ordinary shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_57146fc3-4208-4591-93b2-0cfefc75c4fa_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cancellation of ordinary shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased and Retired During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6dbb3b4e-f52f-4011-88dd-62e6b466fed9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year ending December 31, 2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_19b4ba18-4fc7-4d5d-8d88-f97e24a209e5_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-deductible expenses</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_0874cd09-b207-4333-a53a-c5427fce330a_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalAdditionsMember_a6456f62-04e8-4dce-ad55-1658fbeb4ca0_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalAdditionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital Addition Purchase Commitments</link:label>
    <link:label id="lab_us-gaap_CapitalAdditionsMember_label_en-US" xlink:label="lab_us-gaap_CapitalAdditionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Addition Purchase Commitments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalAdditionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalAdditionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalAdditionsMember" xlink:to="lab_us-gaap_CapitalAdditionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_PrepaidResearchAndDevelopmentCosts_66aeed64-6652-441b-a4ff-0739c775978d_terseLabel_en-US" xlink:label="lab_bgne_PrepaidResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid research and development costs</link:label>
    <link:label id="lab_bgne_PrepaidResearchAndDevelopmentCosts_label_en-US" xlink:label="lab_bgne_PrepaidResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Research and Development Costs</link:label>
    <link:label id="lab_bgne_PrepaidResearchAndDevelopmentCosts_documentation_en-US" xlink:label="lab_bgne_PrepaidResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of consideration paid in advance for research and development that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_PrepaidResearchAndDevelopmentCosts" xlink:href="bgne-20241231.xsd#bgne_PrepaidResearchAndDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_PrepaidResearchAndDevelopmentCosts" xlink:to="lab_bgne_PrepaidResearchAndDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableCurrent_0584e919-8863-413d-90e5-175e56e86a61_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development cost share liability, current portion</link:label>
    <link:label id="lab_us-gaap_LoansPayableCurrent_label_en-US" xlink:label="lab_us-gaap_LoansPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loans Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableCurrent" xlink:to="lab_us-gaap_LoansPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_AccountsReceivableAllowanceForChargebacksAndCreditLoss_a9b4b7bf-0a40-4695-a79e-a303a9df6ac9_periodStartLabel_en-US" xlink:label="lab_bgne_AccountsReceivableAllowanceForChargebacksAndCreditLoss" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_bgne_AccountsReceivableAllowanceForChargebacksAndCreditLoss_54ce1695-49c9-4921-b04e-c267bbb906fa_periodEndLabel_en-US" xlink:label="lab_bgne_AccountsReceivableAllowanceForChargebacksAndCreditLoss" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_bgne_AccountsReceivableAllowanceForChargebacksAndCreditLoss_label_en-US" xlink:label="lab_bgne_AccountsReceivableAllowanceForChargebacksAndCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance For Chargebacks And Credit Loss</link:label>
    <link:label id="lab_bgne_AccountsReceivableAllowanceForChargebacksAndCreditLoss_documentation_en-US" xlink:label="lab_bgne_AccountsReceivableAllowanceForChargebacksAndCreditLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance For Chargebacks And Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AccountsReceivableAllowanceForChargebacksAndCreditLoss" xlink:href="bgne-20241231.xsd#bgne_AccountsReceivableAllowanceForChargebacksAndCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_AccountsReceivableAllowanceForChargebacksAndCreditLoss" xlink:to="lab_bgne_AccountsReceivableAllowanceForChargebacksAndCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticPlanMember_cfe66702-6f42-4a64-bec3-661fdea50073_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember" xlink:to="lab_us-gaap_DomesticPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_b3991fa0-472a-4b57-b718-898ac7d3f3e1_terseLabel_en-US" xlink:label="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering period</link:label>
    <link:label id="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_label_en-US" xlink:label="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Offering Period</link:label>
    <link:label id="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_documentation_en-US" xlink:label="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:href="bgne-20241231.xsd#bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:to="lab_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_SharePriceAmericanDepositoryShares_03a58843-5217-44de-8028-9ebd147d0e2e_verboseLabel_en-US" xlink:label="lab_bgne_SharePriceAmericanDepositoryShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share price, ADS (in dollars per share)</link:label>
    <link:label id="lab_bgne_SharePriceAmericanDepositoryShares_9821a883-bb69-4cba-a693-c747a1e4bd98_terseLabel_en-US" xlink:label="lab_bgne_SharePriceAmericanDepositoryShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market price, ADS (in dollars per share)</link:label>
    <link:label id="lab_bgne_SharePriceAmericanDepositoryShares_label_en-US" xlink:label="lab_bgne_SharePriceAmericanDepositoryShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price, American Depository Shares</link:label>
    <link:label id="lab_bgne_SharePriceAmericanDepositoryShares_documentation_en-US" xlink:label="lab_bgne_SharePriceAmericanDepositoryShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Price of each American Depository Share. Each American Depositary Share represents 13 ordinary shares of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_SharePriceAmericanDepositoryShares" xlink:href="bgne-20241231.xsd#bgne_SharePriceAmericanDepositoryShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_SharePriceAmericanDepositoryShares" xlink:to="lab_bgne_SharePriceAmericanDepositoryShares" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_RentalDepositsAndOther_f8ac63bf-c622-4218-a1d2-1183202d8c32_terseLabel_en-US" xlink:label="lab_bgne_RentalDepositsAndOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rental deposits and other</link:label>
    <link:label id="lab_bgne_RentalDepositsAndOther_label_en-US" xlink:label="lab_bgne_RentalDepositsAndOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rental Deposits and Other</link:label>
    <link:label id="lab_bgne_RentalDepositsAndOther_documentation_en-US" xlink:label="lab_bgne_RentalDepositsAndOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of rental deposits and other.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RentalDepositsAndOther" xlink:href="bgne-20241231.xsd#bgne_RentalDepositsAndOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_RentalDepositsAndOther" xlink:to="lab_bgne_RentalDepositsAndOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b2a901cb-f3c0-4b54-bf15-ef018700170d_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a0dbf7be-5c52-4118-85b5-7d1dd89334f2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_a5ed81ee-fffa-475b-9b7c-2db29e832f37_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_6b4999d2-e7ab-4bbd-8b77-6788e9d7b860_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accruals and reserves</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ShortTermBankLoanDatedMarch212024Member_b2590d3d-f8b2-4742-8e97-5f3c88ddc92f_terseLabel_en-US" xlink:label="lab_bgne_ShortTermBankLoanDatedMarch212024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short Term Bank Loan Dated March 21, 2024</link:label>
    <link:label id="lab_bgne_ShortTermBankLoanDatedMarch212024Member_label_en-US" xlink:label="lab_bgne_ShortTermBankLoanDatedMarch212024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short Term Bank Loan Dated March 21, 2024 [Member]</link:label>
    <link:label id="lab_bgne_ShortTermBankLoanDatedMarch212024Member_documentation_en-US" xlink:label="lab_bgne_ShortTermBankLoanDatedMarch212024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short Term Bank Loan Dated March 21, 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShortTermBankLoanDatedMarch212024Member" xlink:href="bgne-20241231.xsd#bgne_ShortTermBankLoanDatedMarch212024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ShortTermBankLoanDatedMarch212024Member" xlink:to="lab_bgne_ShortTermBankLoanDatedMarch212024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_a818bfe7-7811-4e6e-8ed2-8ead03845c23_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_McKessonMember_b513fbd1-8737-4230-aa5d-5d47c7dc64b5_terseLabel_en-US" xlink:label="lab_bgne_McKessonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">McKesson</link:label>
    <link:label id="lab_bgne_McKessonMember_label_en-US" xlink:label="lab_bgne_McKessonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">McKesson [Member]</link:label>
    <link:label id="lab_bgne_McKessonMember_documentation_en-US" xlink:label="lab_bgne_McKessonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">McKesson</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_McKessonMember" xlink:href="bgne-20241231.xsd#bgne_McKessonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_McKessonMember" xlink:to="lab_bgne_McKessonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_AuditInformationAbstract_label_en-US" xlink:label="lab_bgne_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_bgne_AuditInformationAbstract_documentation_en-US" xlink:label="lab_bgne_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AuditInformationAbstract" xlink:href="bgne-20241231.xsd#bgne_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_AuditInformationAbstract" xlink:to="lab_bgne_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_a315ba17-c895-4309-9fa3-80f76d6afa88_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accelerated depreciation expense</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Accelerated Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:to="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ChinaIndustrialBankMember_48dbb05a-8d48-413d-9dcb-364de0ffcca6_terseLabel_en-US" xlink:label="lab_bgne_ChinaIndustrialBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">China Industrial Bank</link:label>
    <link:label id="lab_bgne_ChinaIndustrialBankMember_label_en-US" xlink:label="lab_bgne_ChinaIndustrialBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">China Industrial Bank [Member]</link:label>
    <link:label id="lab_bgne_ChinaIndustrialBankMember_documentation_en-US" xlink:label="lab_bgne_ChinaIndustrialBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">China Industrial Bank [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ChinaIndustrialBankMember" xlink:href="bgne-20241231.xsd#bgne_ChinaIndustrialBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ChinaIndustrialBankMember" xlink:to="lab_bgne_ChinaIndustrialBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_a37a2bd7-1f95-4f34-8c35-01f5eef773aa_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_c2aba9f2-34aa-4c33-a961-2f35a7abab60_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_60ddfb1f-575e-40f8-bfe4-13b8e71b081c_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_450f3683-d369-4e41-8fc9-8d253d5762f4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_InducementEquityPlan2018Member_c99ab5f8-cd4d-497a-8ad2-dd2095696c63_terseLabel_en-US" xlink:label="lab_bgne_InducementEquityPlan2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inducement Equity Plan2018</link:label>
    <link:label id="lab_bgne_InducementEquityPlan2018Member_label_en-US" xlink:label="lab_bgne_InducementEquityPlan2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inducement Equity Plan2018 [Member]</link:label>
    <link:label id="lab_bgne_InducementEquityPlan2018Member_documentation_en-US" xlink:label="lab_bgne_InducementEquityPlan2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The 2018 Inducement Equity Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_InducementEquityPlan2018Member" xlink:href="bgne-20241231.xsd#bgne_InducementEquityPlan2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_InducementEquityPlan2018Member" xlink:to="lab_bgne_InducementEquityPlan2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ResearchAndDevelopmentMember_f9d26ebf-cc4b-4bed-9c1a-c28f11cc0193_terseLabel_en-US" xlink:label="lab_bgne_ResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_bgne_ResearchAndDevelopmentMember_label_en-US" xlink:label="lab_bgne_ResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development [Member]</link:label>
    <link:label id="lab_bgne_ResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_bgne_ResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ResearchAndDevelopmentMember" xlink:href="bgne-20241231.xsd#bgne_ResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ResearchAndDevelopmentMember" xlink:to="lab_bgne_ResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_c89e3ff3-1caa-4c43-9bc8-58f5c28dbd3e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign and preferential tax rate differential</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_c454a9d9-dc7b-4e52-be27-fe4063a7928a_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_PrepaidGeneralAndAdministrativeExpensesCurrent_0c9fc945-8c56-4e67-9816-92ec6e710f1c_terseLabel_en-US" xlink:label="lab_bgne_PrepaidGeneralAndAdministrativeExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid general and administrative expenses</link:label>
    <link:label id="lab_bgne_PrepaidGeneralAndAdministrativeExpensesCurrent_label_en-US" xlink:label="lab_bgne_PrepaidGeneralAndAdministrativeExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid General and Administrative Expenses, Current</link:label>
    <link:label id="lab_bgne_PrepaidGeneralAndAdministrativeExpensesCurrent_documentation_en-US" xlink:label="lab_bgne_PrepaidGeneralAndAdministrativeExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepaid General and Administrative Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_PrepaidGeneralAndAdministrativeExpensesCurrent" xlink:href="bgne-20241231.xsd#bgne_PrepaidGeneralAndAdministrativeExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_PrepaidGeneralAndAdministrativeExpensesCurrent" xlink:to="lab_bgne_PrepaidGeneralAndAdministrativeExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_e0a58990-9e9f-4f9e-a26a-9042b6b3498b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_9c054823-b1ed-4214-b914-338f4468c243_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level&#160;2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_699b95f2-2ea8-4eeb-a3d2-36eea32d5a0d_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_edbccb9e-fc37-4c17-bf14-3b8055ac8ba4_verboseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Net Product Sales</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_6b1752fc-a5a2-4d61-8fba-b09b56822bbc_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Net Product Sales</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_DeferredTaxAssetValuationAllowanceGainLossIncludedInOtherComprehensiveIncomeLoss_70a4d9ad-06cd-42fe-985d-c0819f2d11fb_negatedTerseLabel_en-US" xlink:label="lab_bgne_DeferredTaxAssetValuationAllowanceGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Additions/(subtractions) charged to equity</link:label>
    <link:label id="lab_bgne_DeferredTaxAssetValuationAllowanceGainLossIncludedInOtherComprehensiveIncomeLoss_label_en-US" xlink:label="lab_bgne_DeferredTaxAssetValuationAllowanceGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, Valuation Allowance, Gain (Loss) Included In Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_bgne_DeferredTaxAssetValuationAllowanceGainLossIncludedInOtherComprehensiveIncomeLoss_documentation_en-US" xlink:label="lab_bgne_DeferredTaxAssetValuationAllowanceGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, Valuation Allowance, Gain (Loss) Included In Other Comprehensive Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_DeferredTaxAssetValuationAllowanceGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:href="bgne-20241231.xsd#bgne_DeferredTaxAssetValuationAllowanceGainLossIncludedInOtherComprehensiveIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_DeferredTaxAssetValuationAllowanceGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:to="lab_bgne_DeferredTaxAssetValuationAllowanceGainLossIncludedInOtherComprehensiveIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_8ec4d565-ab89-4e24-83d1-61e86eef8aac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Total Compensation Cost Recognized</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_2a9bde86-f194-401c-aa66-44385729409e_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d0c54bd8-df87-4139-9287-ed181c176b9f_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_af6e2aa4-9d97-4af2-81b6-dff382dc393d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of each class</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract_045b55e1-ddc0-47ec-9aed-af30c59b2e2d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_6f3301ae-2f19-4bb6-b95f-d4c13b758466_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_d28b228e-480e-465c-9153-0a6425673fab_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, 0.0001 par value per share; 9,500,000,000 shares authorized; 1,387,367,704 and 1,359,513,224 shares issued and outstanding as of December&#160;31,&#160;2024 and 2023, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_1af619e2-8794-4af6-b63d-274b7aa9edf6_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_5b49527f-25d0-4620-ab3e-14b57f6f7e1d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected employer contributions, 2025</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_542866f8-fbb1-465d-91d6-28fea1d8ee9c_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_838fb454-20d6-4d0d-b018-595f1826f91b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_PaymentsToPurchaseInProcessResearchAndDevelopment_52e3de67-c179-4ad6-b9f8-6adbd8cb8de9_negatedTerseLabel_en-US" xlink:label="lab_bgne_PaymentsToPurchaseInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of in-process research and development</link:label>
    <link:label id="lab_bgne_PaymentsToPurchaseInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_bgne_PaymentsToPurchaseInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Purchase In-process Research and Development</link:label>
    <link:label id="lab_bgne_PaymentsToPurchaseInProcessResearchAndDevelopment_documentation_en-US" xlink:label="lab_bgne_PaymentsToPurchaseInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash outflows from the purchase of in-process research and development acquired in an exclusive license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_PaymentsToPurchaseInProcessResearchAndDevelopment" xlink:href="bgne-20241231.xsd#bgne_PaymentsToPurchaseInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_PaymentsToPurchaseInProcessResearchAndDevelopment" xlink:to="lab_bgne_PaymentsToPurchaseInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_99ed1b11-d147-4f4f-826d-1c54143e7584_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_b15b423b-1f83-48f0-a209-86419e0814ba_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_4ff965ce-9702-46f7-b3f9-a356d5365160_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a333a2e4-7e8e-4bcd-980d-c2c57f8b2935_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_e7574c87-4014-4fc8-809f-cab52e46b1e4_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year ending December 31, 2029</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_3fdc91ac-36e1-4a11-a8bd-fbbacbde6d18_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_61128930-4920-45c6-8da2-f6e4d9bec7ca_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_3deaa00f-a596-41b9-9a87-d50b6aa5fe42_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_e666c0bf-9fe7-452b-acc5-b563d19d2076_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total gross deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_198cbe87-8da1-4ccc-aa40-dc3c1e004ddc_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_7720b71a-07d7-47f1-b244-afc51003a635_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss per share basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ChinaMerchantsBankMember_86dfa5f9-a6e0-450a-94d7-8097506e1b6d_terseLabel_en-US" xlink:label="lab_bgne_ChinaMerchantsBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">China Merchants Bank</link:label>
    <link:label id="lab_bgne_ChinaMerchantsBankMember_label_en-US" xlink:label="lab_bgne_ChinaMerchantsBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">China Merchants Bank [Member]</link:label>
    <link:label id="lab_bgne_ChinaMerchantsBankMember_documentation_en-US" xlink:label="lab_bgne_ChinaMerchantsBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">China Merchants Bank</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ChinaMerchantsBankMember" xlink:href="bgne-20241231.xsd#bgne_ChinaMerchantsBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ChinaMerchantsBankMember" xlink:to="lab_bgne_ChinaMerchantsBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_3a6a21db-55eb-4cdf-b70e-4e03948d9d4f_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Payments to acquire equity interest</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_19c24255-cdb0-4e01-b8b0-fa192d061600_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating cash flows used in operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligation_6e10faa0-4df1-4f4c-a6f7-8124d736a456_totalLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_label_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_6f0f700d-9831-462b-bcb9-7b98a714017a_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_d0afba18-c4ed-4b86-9cb2-8a8881096913_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accruals for capital expenditures</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ShortTermBankLoanDatedMay252023Member_9595a609-b62c-4a3f-9248-738ca121f39d_terseLabel_en-US" xlink:label="lab_bgne_ShortTermBankLoanDatedMay252023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short Term Bank Loan Dated, May 25, 2023</link:label>
    <link:label id="lab_bgne_ShortTermBankLoanDatedMay252023Member_label_en-US" xlink:label="lab_bgne_ShortTermBankLoanDatedMay252023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short Term Bank Loan Dated, May 25, 2023 [Member]</link:label>
    <link:label id="lab_bgne_ShortTermBankLoanDatedMay252023Member_documentation_en-US" xlink:label="lab_bgne_ShortTermBankLoanDatedMay252023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short Term Bank Loan Dated, May 25, 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShortTermBankLoanDatedMay252023Member" xlink:href="bgne-20241231.xsd#bgne_ShortTermBankLoanDatedMay252023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ShortTermBankLoanDatedMay252023Member" xlink:to="lab_bgne_ShortTermBankLoanDatedMay252023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0e1e4b98-4561-478a-9c33-b9027726535e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_0a6054cd-31b7-4413-b12f-59d5fe6d533d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_d8ff240e-3ea6-49b1-93e5-81f0f48608d1_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_92241031-bc8e-411b-b8c1-ab89118a7134_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_deab5646-7b77-4e92-ae6e-a98b0e176b63_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized share-based compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_22eb46b1-65e1-4c9a-b497-ff2f06d27124_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Risks</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e21ecc2f-8c3e-4d1e-84c7-d13d7b17a6d6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_26b49f56-de4b-4d5b-b52d-8c15960eca95_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_64749d95-b927-412c-8fc7-f9b3f9b02703_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, minimum (as percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesNoncurrent_ba93a364-829a-44b5-987d-4fa8ad14c75b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Sundry Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_MaximumCashAndServicesDevelopmentCommitment_cd4f7cff-b88c-4188-b708-f789dba5fa25_terseLabel_en-US" xlink:label="lab_bgne_MaximumCashAndServicesDevelopmentCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum cash and development services commitment</link:label>
    <link:label id="lab_bgne_MaximumCashAndServicesDevelopmentCommitment_label_en-US" xlink:label="lab_bgne_MaximumCashAndServicesDevelopmentCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Cash And Services Development Commitment</link:label>
    <link:label id="lab_bgne_MaximumCashAndServicesDevelopmentCommitment_documentation_en-US" xlink:label="lab_bgne_MaximumCashAndServicesDevelopmentCommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum Cash And Services Development Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_MaximumCashAndServicesDevelopmentCommitment" xlink:href="bgne-20241231.xsd#bgne_MaximumCashAndServicesDevelopmentCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_MaximumCashAndServicesDevelopmentCommitment" xlink:to="lab_bgne_MaximumCashAndServicesDevelopmentCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_1d1ed922-8d8b-4613-ae13-ba648c475cf4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility, maximum (as percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_140d5485-a2d1-4ba0-a89b-1e2bb4a4213c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayment of short-term loans</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_4e2c95cc-11e5-4267-a95a-4b7d5788c6c1_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayment of short-term loans</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c5f7cee7-b0ff-465b-a327-fb04474d3be5_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_5889accc-4791-42b3-9102-f217417eea32_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_1ffc8592-4c25-432a-8553-010ab9bd69fb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b2cb05cd-d903-4021-816a-5d4bea92cb58_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share Option Activities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c750a77f-8760-4f23-95e4-046f72046d38_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_19ef876b-3322-47f9-969b-c9d724fc3679_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7c3d621b-48e4-4643-827e-da1c7fcc9712_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8a577b8e-c037-403f-96d6-9ee6fcba2d67_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_6bea2cfa-f8b4-419c-8dfe-512abea88cea_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4c2be063-4161-42fc-b338-90d01b012a49_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_a822803f-941d-4708-9ef7-618d580c45af_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_a79f8d0a-859f-4474-9102-54431e9e9981_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_17a3b210-2833-4380-bfa9-33dae9f8d973_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_3d15917e-3dc3-4ba0-b690-8bc20437b574_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Right of use asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_9339e5f2-172f-4dd8-bb26-06131c4ef92e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_79c9b69f-314a-485c-91cd-4e748bb4dc50_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_743cd7e3-d26b-4fce-a094-52f637c58e27_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_GovernmentAssistanceManufacturingFacilityBuildOutMember_15b806a7-5181-415a-84a0-682f445838d5_terseLabel_en-US" xlink:label="lab_bgne_GovernmentAssistanceManufacturingFacilityBuildOutMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Assistance, Manufacturing Facility Build-Out</link:label>
    <link:label id="lab_bgne_GovernmentAssistanceManufacturingFacilityBuildOutMember_label_en-US" xlink:label="lab_bgne_GovernmentAssistanceManufacturingFacilityBuildOutMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Assistance, Manufacturing Facility Build-Out [Member]</link:label>
    <link:label id="lab_bgne_GovernmentAssistanceManufacturingFacilityBuildOutMember_documentation_en-US" xlink:label="lab_bgne_GovernmentAssistanceManufacturingFacilityBuildOutMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government Assistance, Manufacturing Facility Build-Out</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_GovernmentAssistanceManufacturingFacilityBuildOutMember" xlink:href="bgne-20241231.xsd#bgne_GovernmentAssistanceManufacturingFacilityBuildOutMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_GovernmentAssistanceManufacturingFacilityBuildOutMember" xlink:to="lab_bgne_GovernmentAssistanceManufacturingFacilityBuildOutMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentAssistanceTypeDomain_33b51651-e2a0-480b-a555-d67360581bf4_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Assistance, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_GovernmentAssistanceTypeDomain_label_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Assistance, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceTypeDomain" xlink:to="lab_us-gaap_GovernmentAssistanceTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_28a83009-1b28-4800-905f-6048108078e5_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_3267c5ef-eeb5-44e1-bebc-4387577b99c6_terseLabel_en-US" xlink:label="lab_bgne_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_bgne_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_bgne_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets [Table Text Block]</link:label>
    <link:label id="lab_bgne_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_documentation_en-US" xlink:label="lab_bgne_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of prepaid expenses and other current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:href="bgne-20241231.xsd#bgne_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="lab_bgne_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_61aebe33-8ca5-4236-abfa-4d526be4356a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGrossAbstract_df68d98e-4f97-4483-af5d-9de87f1a61db_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGrossAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_76b18a58-a8e9-4758-bbb6-a60bc18cbdf7_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_7936c4e5-2555-403d-b47b-804e52743bd1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_30614dde-d931-4415-b1ba-fec7738d7015_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_947b354d-9373-4106-bbbe-c98b04737381_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_49362553-9d7b-4b39-bc44-dd03acfbeebe_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_46ab0bd1-cd25-4d9b-a12f-bf599c28ca42_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_PiHealthIncMember_abcd13a9-b1ac-4b6b-a398-6fdfd06bb88b_terseLabel_en-US" xlink:label="lab_bgne_PiHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pi Health, Inc</link:label>
    <link:label id="lab_bgne_PiHealthIncMember_label_en-US" xlink:label="lab_bgne_PiHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pi Health, Inc [Member]</link:label>
    <link:label id="lab_bgne_PiHealthIncMember_documentation_en-US" xlink:label="lab_bgne_PiHealthIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pi Health, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_PiHealthIncMember" xlink:href="bgne-20241231.xsd#bgne_PiHealthIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_PiHealthIncMember" xlink:to="lab_bgne_PiHealthIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d8ab7ad2-ef9b-4a21-8431-625a1bb5213b_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c1fd1785-58f5-49b0-8d77-f1c3a7c8a87f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at the beginning of the year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_42ced3db-0c12-488c-9b2a-adf5dac0c7c5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at the end of the year (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_4f60526c-5ab3-4775-ba42-caefb68e776e_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_378c933b-06d8-4978-8849-56a5f91d09c9_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Information</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1f15e252-2ecb-4494-95f9-3a23bd9d0823_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year ending December&#160;31,&#160;2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_f30cee0f-8c7a-48b9-9f49-ed9ff8e2f9cf_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement, inventory purchases</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Purchases from Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7883b782-c485-4d9c-b27a-80951bfe323c_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_572fbddb-e299-46ee-81ef-cceefb566955_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_e4e7901b-aa17-49e0-bc35-d960fa545f60_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmountNet_81981bc0-78b2-4e1e-92a2-03b8489053bf_negatedLabel_en-US" xlink:label="lab_bgne_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmountNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Equity securities without readily determinable fair values</link:label>
    <link:label id="lab_bgne_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmountNet_label_en-US" xlink:label="lab_bgne_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmountNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount, Net</link:label>
    <link:label id="lab_bgne_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmountNet_documentation_en-US" xlink:label="lab_bgne_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmountNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmountNet" xlink:href="bgne-20241231.xsd#bgne_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmountNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmountNet" xlink:to="lab_bgne_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmountNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_247878a7-2c6a-4221-94b8-e964baf19040_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Gross Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_AccruedLiabilitiesExternalResearchAndDevelopment_2cc568bd-aff4-438c-baf5-f6dc11eccad7_terseLabel_en-US" xlink:label="lab_bgne_AccruedLiabilitiesExternalResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">External research and development activities related</link:label>
    <link:label id="lab_bgne_AccruedLiabilitiesExternalResearchAndDevelopment_label_en-US" xlink:label="lab_bgne_AccruedLiabilitiesExternalResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, External Research And Development</link:label>
    <link:label id="lab_bgne_AccruedLiabilitiesExternalResearchAndDevelopment_documentation_en-US" xlink:label="lab_bgne_AccruedLiabilitiesExternalResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date related to external research and development activities related</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AccruedLiabilitiesExternalResearchAndDevelopment" xlink:href="bgne-20241231.xsd#bgne_AccruedLiabilitiesExternalResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_AccruedLiabilitiesExternalResearchAndDevelopment" xlink:to="lab_bgne_AccruedLiabilitiesExternalResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_795cb36d-8429-4668-b11a-1fd75240ddd9_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_32921ff0-a99e-4073-a014-c9cc1698c36a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_5f367693-3717-4d33-803b-bf187e4018f0_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_f0ac19e3-1e1d-4f50-b99b-016d56efe003_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_3c7348fd-141e-4f2f-8da3-257c173fc04c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other Long-Term Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_ea4566a6-a126-44a7-ba9f-2a607b21a35e_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minority interest in investment (as a percent)</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Ownership Percentage, Noncontrolling Owner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_f3adc007-fcec-4cee-b011-497b741ef902_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_ChinaResourcesMember_f82aeb79-5a2e-40ea-91e0-ab2db609455a_terseLabel_en-US" xlink:label="lab_bgne_ChinaResourcesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">China Resources</link:label>
    <link:label id="lab_bgne_ChinaResourcesMember_label_en-US" xlink:label="lab_bgne_ChinaResourcesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">China Resources [Member]</link:label>
    <link:label id="lab_bgne_ChinaResourcesMember_documentation_en-US" xlink:label="lab_bgne_ChinaResourcesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">China Resources</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ChinaResourcesMember" xlink:href="bgne-20241231.xsd#bgne_ChinaResourcesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_ChinaResourcesMember" xlink:to="lab_bgne_ChinaResourcesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_c1b179f6-cbba-47b2-9853-3ff841e918a3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_7d626f47-6b68-4206-ae60-4475fd510baa_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Share Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_AccruedProfessionalFeesAndOtherCurrent_7234e1aa-1575-4cd6-9d63-88fce98824eb_terseLabel_en-US" xlink:label="lab_bgne_AccruedProfessionalFeesAndOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_bgne_AccruedProfessionalFeesAndOtherCurrent_label_en-US" xlink:label="lab_bgne_AccruedProfessionalFeesAndOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees and Other, Current</link:label>
    <link:label id="lab_bgne_AccruedProfessionalFeesAndOtherCurrent_documentation_en-US" xlink:label="lab_bgne_AccruedProfessionalFeesAndOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received and amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AccruedProfessionalFeesAndOtherCurrent" xlink:href="bgne-20241231.xsd#bgne_AccruedProfessionalFeesAndOtherCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_AccruedProfessionalFeesAndOtherCurrent" xlink:to="lab_bgne_AccruedProfessionalFeesAndOtherCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ba3c2e28-10cd-43a8-b92b-01e3aa1ca918_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_bgne_BRUKINSAMember_4055c5ee-3add-4fcf-ad43-99458fef1c6d_terseLabel_en-US" xlink:label="lab_bgne_BRUKINSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BRUKINSA&#174;</link:label>
    <link:label id="lab_bgne_BRUKINSAMember_label_en-US" xlink:label="lab_bgne_BRUKINSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BRUKINSA [Member]</link:label>
    <link:label id="lab_bgne_BRUKINSAMember_documentation_en-US" xlink:label="lab_bgne_BRUKINSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Brukinsa [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_BRUKINSAMember" xlink:href="bgne-20241231.xsd#bgne_BRUKINSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_bgne_BRUKINSAMember" xlink:to="lab_bgne_BRUKINSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_f0e28640-6d74-4b8b-86f3-80badba0baa8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Current and Deferred Components of the Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_52527e1e-bb88-48a5-a99e-2394f67e1044_negatedLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_ecac4cde-9441-414f-8b8e-23bb9ce57186_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total fair value of the employee share option awards vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_cc0d008d-e874-4871-a474-f80e17fe894e_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net operating losses carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_78a51ede-2e22-47db-b5d4-f5687888c55b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>bgne-20241231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:c70194b9-233f-4b06-bc07-707c5a5abbc8,g:477d344e-a417-40e8-b704-01a6f7f40ad7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.beigene.com/role/Cover" xlink:type="simple" xlink:href="bgne-20241231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_f6f48eab-a9ec-475a-bae1-efada95779d4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:to="loc_dei_DocumentType_f6f48eab-a9ec-475a-bae1-efada95779d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_7a6fdda1-1ed2-4d4a-bf9d-2f589faff85d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:to="loc_dei_DocumentAnnualReport_7a6fdda1-1ed2-4d4a-bf9d-2f589faff85d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_7af1acf5-950a-40ed-af0a-0695e62c38fa" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:to="loc_dei_DocumentPeriodEndDate_7af1acf5-950a-40ed-af0a-0695e62c38fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_b0cd4f39-be05-4492-8855-8f859e028a9b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:to="loc_dei_CurrentFiscalYearEndDate_b0cd4f39-be05-4492-8855-8f859e028a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_6025d40d-d9be-4025-bb6e-23ada895060a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:to="loc_dei_DocumentTransitionReport_6025d40d-d9be-4025-bb6e-23ada895060a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_d18cdb84-66dc-40a4-afc2-c1724ad76244" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:to="loc_dei_EntityFileNumber_d18cdb84-66dc-40a4-afc2-c1724ad76244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_7ecf99a1-4c3b-48ca-8475-966ef6008064" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:to="loc_dei_EntityRegistrantName_7ecf99a1-4c3b-48ca-8475-966ef6008064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_de7df9a7-b864-40b5-84af-0b4b466e542f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:to="loc_dei_EntityIncorporationStateCountryCode_de7df9a7-b864-40b5-84af-0b4b466e542f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_726aa953-2df9-4802-92a2-19ce45973141" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:to="loc_dei_EntityTaxIdentificationNumber_726aa953-2df9-4802-92a2-19ce45973141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_fe99791d-a873-45ff-8140-56dc192e38d8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:to="loc_dei_EntityAddressAddressLine1_fe99791d-a873-45ff-8140-56dc192e38d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_09f2f52d-8e93-481d-b7c1-13ee8e775b25" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:to="loc_dei_EntityAddressAddressLine2_09f2f52d-8e93-481d-b7c1-13ee8e775b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_d77b6149-5cca-4d49-ad06-3e3a0968d9c5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:to="loc_dei_EntityAddressCityOrTown_d77b6149-5cca-4d49-ad06-3e3a0968d9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_d0fe7c18-e0cc-407c-b181-9e946de78fd0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:to="loc_dei_EntityAddressCountry_d0fe7c18-e0cc-407c-b181-9e946de78fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f76c52ab-8072-4078-9276-e0c791a841d9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:to="loc_dei_EntityAddressPostalZipCode_f76c52ab-8072-4078-9276-e0c791a841d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_dc3d4399-52b1-4cd2-aa47-83eb2ab278cd" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:to="loc_dei_CityAreaCode_dc3d4399-52b1-4cd2-aa47-83eb2ab278cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_731915ff-bb97-4e88-879e-7942d84a09ad" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:to="loc_dei_LocalPhoneNumber_731915ff-bb97-4e88-879e-7942d84a09ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ae34f217-217c-4435-88f1-c9b08d7558cb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:to="loc_dei_Security12bTitle_ae34f217-217c-4435-88f1-c9b08d7558cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_03ddcffd-73e8-48e5-a5dc-a53e4a24021e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:to="loc_dei_TradingSymbol_03ddcffd-73e8-48e5-a5dc-a53e4a24021e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_1291dc53-9a3a-4c9d-ad7a-51d5604de011" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:to="loc_dei_SecurityExchangeName_1291dc53-9a3a-4c9d-ad7a-51d5604de011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_36ed9ad9-0c2f-4da4-b472-d6f5bcf5ffea" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_36ed9ad9-0c2f-4da4-b472-d6f5bcf5ffea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_f4dcbe67-dd1f-4c83-a714-c03a833cce58" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:to="loc_dei_EntityVoluntaryFilers_f4dcbe67-dd1f-4c83-a714-c03a833cce58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_403a727b-1696-4460-9a77-2bcfb6ca6430" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:to="loc_dei_EntityCurrentReportingStatus_403a727b-1696-4460-9a77-2bcfb6ca6430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_8f496155-1095-4b02-8dd1-b7fcdc991dc2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:to="loc_dei_EntityInteractiveDataCurrent_8f496155-1095-4b02-8dd1-b7fcdc991dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_47f1c5e3-7b15-44c1-aefe-855a6450b27a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:to="loc_dei_EntityFilerCategory_47f1c5e3-7b15-44c1-aefe-855a6450b27a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_8123715b-0afd-467a-8cc4-1182430b17bc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:to="loc_dei_EntitySmallBusiness_8123715b-0afd-467a-8cc4-1182430b17bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_bf38cea3-80b3-4108-8a68-41ba2cb01606" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:to="loc_dei_EntityEmergingGrowthCompany_bf38cea3-80b3-4108-8a68-41ba2cb01606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_8d36eb6f-aa3d-40cd-b575-49e0919f8636" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:to="loc_dei_IcfrAuditorAttestationFlag_8d36eb6f-aa3d-40cd-b575-49e0919f8636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_9cd0f964-51c8-4603-8727-7ee0df2e6bdb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_9cd0f964-51c8-4603-8727-7ee0df2e6bdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_d36d6945-2434-4860-8f1d-3c4020189265" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:to="loc_dei_EntityShellCompany_d36d6945-2434-4860-8f1d-3c4020189265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_509cfc9f-3b65-4b2a-af6c-3adfa5f70891" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:to="loc_dei_EntityPublicFloat_509cfc9f-3b65-4b2a-af6c-3adfa5f70891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_ad66e475-d4fb-4d4a-97ce-6615cfd7385e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_ad66e475-d4fb-4d4a-97ce-6615cfd7385e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_1f05ce81-0f48-4480-a61c-9c5cb37a3b4b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_1f05ce81-0f48-4480-a61c-9c5cb37a3b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_e253286b-646a-4201-9fe4-674594a556c5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:to="loc_dei_EntityCentralIndexKey_e253286b-646a-4201-9fe4-674594a556c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_fcd2b3bd-77ed-4ea3-8c79-7139d2ae2646" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:to="loc_dei_AmendmentFlag_fcd2b3bd-77ed-4ea3-8c79-7139d2ae2646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_77467a12-99e0-4e93-a6ce-299daf71bba7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:to="loc_dei_DocumentFiscalYearFocus_77467a12-99e0-4e93-a6ce-299daf71bba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_399c290d-715d-47da-a1ac-7f6c0714e7c4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_176eb0e6-fe18-4745-a036-aab5881294ea" xlink:to="loc_dei_DocumentFiscalPeriodFocus_399c290d-715d-47da-a1ac-7f6c0714e7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/AuditInformation" xlink:type="simple" xlink:href="bgne-20241231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AuditInformationAbstract_3859ecda-8023-4084-81e8-0e39414d07c5" xlink:href="bgne-20241231.xsd#bgne_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_effca270-0abe-4706-9a49-33db226cf182" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_AuditInformationAbstract_3859ecda-8023-4084-81e8-0e39414d07c5" xlink:to="loc_dei_AuditorName_effca270-0abe-4706-9a49-33db226cf182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_d4c42732-55d9-488b-b285-c7655ba884e9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_AuditInformationAbstract_3859ecda-8023-4084-81e8-0e39414d07c5" xlink:to="loc_dei_AuditorFirmId_d4c42732-55d9-488b-b285-c7655ba884e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_e4d83ba8-f57a-4fe9-8efa-285d26c2f757" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_AuditInformationAbstract_3859ecda-8023-4084-81e8-0e39414d07c5" xlink:to="loc_dei_AuditorLocation_e4d83ba8-f57a-4fe9-8efa-285d26c2f757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="bgne-20241231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_bf5477bc-3820-4a09-8790-a05c26dfa30e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a0abca92-a84a-4edc-847c-14f71c7a04c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_bf5477bc-3820-4a09-8790-a05c26dfa30e" xlink:to="loc_us-gaap_StatementTable_a0abca92-a84a-4edc-847c-14f71c7a04c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c7499391-8ac1-4570-bba8-6e810463d7d9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a0abca92-a84a-4edc-847c-14f71c7a04c9" xlink:to="loc_srt_ProductOrServiceAxis_c7499391-8ac1-4570-bba8-6e810463d7d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d9d410af-752e-41a0-9604-b29e8c50e710" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c7499391-8ac1-4570-bba8-6e810463d7d9" xlink:to="loc_srt_ProductsAndServicesDomain_d9d410af-752e-41a0-9604-b29e8c50e710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_decba163-c03e-45d8-bfb3-c7287dd266b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d9d410af-752e-41a0-9604-b29e8c50e710" xlink:to="loc_us-gaap_ProductMember_decba163-c03e-45d8-bfb3-c7287dd266b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_CollaborationMember_89033f71-0915-4f08-807f-5682057dc3b0" xlink:href="bgne-20241231.xsd#bgne_CollaborationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d9d410af-752e-41a0-9604-b29e8c50e710" xlink:to="loc_bgne_CollaborationMember_89033f71-0915-4f08-807f-5682057dc3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a0abca92-a84a-4edc-847c-14f71c7a04c9" xlink:to="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_565c8888-3909-44b7-b9e4-d6b1af6661bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_us-gaap_RevenuesAbstract_565c8888-3909-44b7-b9e4-d6b1af6661bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a387db92-a7ca-4162-b390-b99ce1e3e23a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_565c8888-3909-44b7-b9e4-d6b1af6661bf" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a387db92-a7ca-4162-b390-b99ce1e3e23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_a36666ce-15b6-444d-a695-19c6c037a103" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_a36666ce-15b6-444d-a695-19c6c037a103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_88c12e60-d39b-43c7-add5-9de85e5c2f98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_us-gaap_GrossProfit_88c12e60-d39b-43c7-add5-9de85e5c2f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_3b84d2f2-0a39-4e38-a2df-53fec8bc0a87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_3b84d2f2-0a39-4e38-a2df-53fec8bc0a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_d6fddc95-edab-49ad-8116-d400b767f320" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3b84d2f2-0a39-4e38-a2df-53fec8bc0a87" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_d6fddc95-edab-49ad-8116-d400b767f320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_674d6484-5414-4cb9-985b-1b7ff1e0902f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3b84d2f2-0a39-4e38-a2df-53fec8bc0a87" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_674d6484-5414-4cb9-985b-1b7ff1e0902f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_e3c1ea6c-4a39-42f3-89fc-b8d6b5f816d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_3b84d2f2-0a39-4e38-a2df-53fec8bc0a87" xlink:to="loc_us-gaap_CostsAndExpenses_e3c1ea6c-4a39-42f3-89fc-b8d6b5f816d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b1afc452-8f0a-496e-a098-63587b58ce96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_us-gaap_OperatingIncomeLoss_b1afc452-8f0a-496e-a098-63587b58ce96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_31d8b8ed-c767-44c8-a7a1-fddb4cd24d56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_31d8b8ed-c767-44c8-a7a1-fddb4cd24d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_ffd0375d-b365-4b07-a0ec-3b92f94db5bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_ffd0375d-b365-4b07-a0ec-3b92f94db5bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9cb4e265-a8af-4c21-afea-4a02a87ed684" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9cb4e265-a8af-4c21-afea-4a02a87ed684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_890aa676-d35e-4385-8366-9ebfef2ed1c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_890aa676-d35e-4385-8366-9ebfef2ed1c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7e41921a-66db-46c8-89ed-c68604c63bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_us-gaap_NetIncomeLoss_7e41921a-66db-46c8-89ed-c68604c63bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_6d7f559c-287f-4903-a0c7-e8ba93c1ad5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_us-gaap_EarningsPerShareBasic_6d7f559c-287f-4903-a0c7-e8ba93c1ad5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_e58a73b0-e0c8-4d1f-922e-d0d1e62a4647" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_us-gaap_EarningsPerShareDiluted_e58a73b0-e0c8-4d1f-922e-d0d1e62a4647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d30579c7-4bb9-410a-8588-08f740ef70da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d30579c7-4bb9-410a-8588-08f740ef70da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6ca66255-f6e7-4d07-be55-df268b0e2d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6ca66255-f6e7-4d07-be55-df268b0e2d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_EarningsPerAmericanDepositoryShareBasic_63b724fd-2804-483d-9dfb-dfb54e128a79" xlink:href="bgne-20241231.xsd#bgne_EarningsPerAmericanDepositoryShareBasic"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_bgne_EarningsPerAmericanDepositoryShareBasic_63b724fd-2804-483d-9dfb-dfb54e128a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_EarningsPerAmericanDepositoryShareDiluted_35b582fc-f1f9-4ee4-84c9-8d6c9afd4495" xlink:href="bgne-20241231.xsd#bgne_EarningsPerAmericanDepositoryShareDiluted"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_bgne_EarningsPerAmericanDepositoryShareDiluted_35b582fc-f1f9-4ee4-84c9-8d6c9afd4495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic_081adea9-cff0-414a-b560-689ca61cbcf6" xlink:href="bgne-20241231.xsd#bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic_081adea9-cff0-414a-b560-689ca61cbcf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted_75f9e4ea-252b-409b-86ba-8c0cf9787abd" xlink:href="bgne-20241231.xsd#bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_cde63ae9-31c1-41f3-ac77-d803b89a7f61" xlink:to="loc_bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted_75f9e4ea-252b-409b-86ba-8c0cf9787abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="bgne-20241231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_19282f6a-8231-4a9d-802e-22449ac9c23d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_6c5002ed-6b17-448a-9db9-d02928a5bcc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_19282f6a-8231-4a9d-802e-22449ac9c23d" xlink:to="loc_us-gaap_NetIncomeLossAbstract_6c5002ed-6b17-448a-9db9-d02928a5bcc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0ceb63be-9eb9-46ac-a696-6cf71e20f127" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_6c5002ed-6b17-448a-9db9-d02928a5bcc0" xlink:to="loc_us-gaap_NetIncomeLoss_0ceb63be-9eb9-46ac-a696-6cf71e20f127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_f9faf1db-7850-4329-8ac1-335ebcd9d6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_6c5002ed-6b17-448a-9db9-d02928a5bcc0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_f9faf1db-7850-4329-8ac1-335ebcd9d6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_8ec998ae-43b8-483f-8a0d-fb144be4d205" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_f9faf1db-7850-4329-8ac1-335ebcd9d6f7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_8ec998ae-43b8-483f-8a0d-fb144be4d205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_42ddd2e5-0901-4133-8a51-8970ca122a69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_f9faf1db-7850-4329-8ac1-335ebcd9d6f7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_42ddd2e5-0901-4133-8a51-8970ca122a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a09728e2-ba7d-4601-8884-402500afeae5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_f9faf1db-7850-4329-8ac1-335ebcd9d6f7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a09728e2-ba7d-4601-8884-402500afeae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b4979759-4c2d-4042-978b-cb8c6b08c1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_6c5002ed-6b17-448a-9db9-d02928a5bcc0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_b4979759-4c2d-4042-978b-cb8c6b08c1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="bgne-20241231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3a5a6484-c2b2-49d8-b2a7-6e9d5eaa7350" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_3cfa74e0-d812-49c8-a481-81ca86dfb01c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3a5a6484-c2b2-49d8-b2a7-6e9d5eaa7350" xlink:to="loc_us-gaap_AssetsAbstract_3cfa74e0-d812-49c8-a481-81ca86dfb01c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_50ca1f00-0a87-4cd5-a799-a86490b7ee02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3cfa74e0-d812-49c8-a481-81ca86dfb01c" xlink:to="loc_us-gaap_AssetsCurrentAbstract_50ca1f00-0a87-4cd5-a799-a86490b7ee02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32df1a81-e220-4ac8-98e4-c8cb7a39cef2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_50ca1f00-0a87-4cd5-a799-a86490b7ee02" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32df1a81-e220-4ac8-98e4-c8cb7a39cef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9a4eeb5a-3e0e-422b-8551-e859011e2f03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_50ca1f00-0a87-4cd5-a799-a86490b7ee02" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9a4eeb5a-3e0e-422b-8551-e859011e2f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_cb6b6a45-dbc8-4a80-8b45-3cad8ad393fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_50ca1f00-0a87-4cd5-a799-a86490b7ee02" xlink:to="loc_us-gaap_InventoryNet_cb6b6a45-dbc8-4a80-8b45-3cad8ad393fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fc1c196c-e967-4533-a433-4289ba6b87ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_50ca1f00-0a87-4cd5-a799-a86490b7ee02" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fc1c196c-e967-4533-a433-4289ba6b87ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_aee80647-cbbf-4e73-b15b-4f4276cf0f44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_50ca1f00-0a87-4cd5-a799-a86490b7ee02" xlink:to="loc_us-gaap_AssetsCurrent_aee80647-cbbf-4e73-b15b-4f4276cf0f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6898e6d7-2fa1-4a0c-9768-905733e57b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3cfa74e0-d812-49c8-a481-81ca86dfb01c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6898e6d7-2fa1-4a0c-9768-905733e57b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_afeec0f2-4234-48a6-a084-3841422213e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3cfa74e0-d812-49c8-a481-81ca86dfb01c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_afeec0f2-4234-48a6-a084-3841422213e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5bdf6b82-1edc-4213-972e-7554a672e290" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3cfa74e0-d812-49c8-a481-81ca86dfb01c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5bdf6b82-1edc-4213-972e-7554a672e290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_13ee87b3-0275-44d7-baff-72adae577d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3cfa74e0-d812-49c8-a481-81ca86dfb01c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_13ee87b3-0275-44d7-baff-72adae577d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_940d82f5-67bb-4362-afad-9fb659442b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3cfa74e0-d812-49c8-a481-81ca86dfb01c" xlink:to="loc_us-gaap_AssetsNoncurrent_940d82f5-67bb-4362-afad-9fb659442b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_7645d583-e797-400b-82fe-ea0ecaa96e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_3cfa74e0-d812-49c8-a481-81ca86dfb01c" xlink:to="loc_us-gaap_Assets_7645d583-e797-400b-82fe-ea0ecaa96e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52f32f11-1e7f-4bea-8426-4f1a79459a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3a5a6484-c2b2-49d8-b2a7-6e9d5eaa7350" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52f32f11-1e7f-4bea-8426-4f1a79459a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_558a926f-9c5d-4e5e-a994-509f6ec072ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52f32f11-1e7f-4bea-8426-4f1a79459a7f" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_558a926f-9c5d-4e5e-a994-509f6ec072ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_03d4d04f-ce65-4687-81d2-e6cd859bca98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_558a926f-9c5d-4e5e-a994-509f6ec072ec" xlink:to="loc_us-gaap_AccountsPayableCurrent_03d4d04f-ce65-4687-81d2-e6cd859bca98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_ea642555-5890-423d-b820-9cd84cae8f11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_558a926f-9c5d-4e5e-a994-509f6ec072ec" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_ea642555-5890-423d-b820-9cd84cae8f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_d016f4d0-345b-4f52-9b6c-dd9a1412550c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_558a926f-9c5d-4e5e-a994-509f6ec072ec" xlink:to="loc_us-gaap_TaxesPayableCurrent_d016f4d0-345b-4f52-9b6c-dd9a1412550c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_90823fad-c47e-4378-b368-a97ea8d900b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_558a926f-9c5d-4e5e-a994-509f6ec072ec" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_90823fad-c47e-4378-b368-a97ea8d900b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ResearchAndDevelopmentCostShareLiabilityCurrentPortion_960fb2ce-a5fa-458c-88ac-69357b6c645f" xlink:href="bgne-20241231.xsd#bgne_ResearchAndDevelopmentCostShareLiabilityCurrentPortion"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_558a926f-9c5d-4e5e-a994-509f6ec072ec" xlink:to="loc_bgne_ResearchAndDevelopmentCostShareLiabilityCurrentPortion_960fb2ce-a5fa-458c-88ac-69357b6c645f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_81c9a69b-e899-4c10-a91e-eb34fa0ae9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_558a926f-9c5d-4e5e-a994-509f6ec072ec" xlink:to="loc_us-gaap_LongTermDebtCurrent_81c9a69b-e899-4c10-a91e-eb34fa0ae9c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_003da2df-2368-4a07-a8b8-97b027c8b8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_558a926f-9c5d-4e5e-a994-509f6ec072ec" xlink:to="loc_us-gaap_LiabilitiesCurrent_003da2df-2368-4a07-a8b8-97b027c8b8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_e0ddfe56-cd1f-42b1-9b4d-7412d69754f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52f32f11-1e7f-4bea-8426-4f1a79459a7f" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_e0ddfe56-cd1f-42b1-9b4d-7412d69754f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_30b4cfa6-caf7-4457-b145-6f12394fd67c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_e0ddfe56-cd1f-42b1-9b4d-7412d69754f3" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_30b4cfa6-caf7-4457-b145-6f12394fd67c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_26346438-5dd8-4ca9-9d4a-41b4aa48b7fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_e0ddfe56-cd1f-42b1-9b4d-7412d69754f3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_26346438-5dd8-4ca9-9d4a-41b4aa48b7fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_ebbf9c11-0af2-40a6-a29d-f5a7a5d7f761" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_e0ddfe56-cd1f-42b1-9b4d-7412d69754f3" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_ebbf9c11-0af2-40a6-a29d-f5a7a5d7f761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion_87a6c648-f74e-4cbb-9930-52ff732eb11a" xlink:href="bgne-20241231.xsd#bgne_ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_e0ddfe56-cd1f-42b1-9b4d-7412d69754f3" xlink:to="loc_bgne_ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion_87a6c648-f74e-4cbb-9930-52ff732eb11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_5f4b97e0-75f4-4177-aacd-eeef0cf8cc5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_e0ddfe56-cd1f-42b1-9b4d-7412d69754f3" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_5f4b97e0-75f4-4177-aacd-eeef0cf8cc5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_1599c903-e2f6-45ca-ba8d-a5b29aba2111" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_e0ddfe56-cd1f-42b1-9b4d-7412d69754f3" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_1599c903-e2f6-45ca-ba8d-a5b29aba2111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_38fae4da-92cf-4bb0-90ce-e6d14473a46c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52f32f11-1e7f-4bea-8426-4f1a79459a7f" xlink:to="loc_us-gaap_Liabilities_38fae4da-92cf-4bb0-90ce-e6d14473a46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_0e9c4220-893b-4560-beff-2340412e94ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52f32f11-1e7f-4bea-8426-4f1a79459a7f" xlink:to="loc_us-gaap_CommitmentsAndContingencies_0e9c4220-893b-4560-beff-2340412e94ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_f71e0d23-7a87-48ff-a98c-b39eeedacd0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52f32f11-1e7f-4bea-8426-4f1a79459a7f" xlink:to="loc_us-gaap_StockholdersEquityAbstract_f71e0d23-7a87-48ff-a98c-b39eeedacd0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_c5a5aecc-328f-4970-afd9-5a3eccc743c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f71e0d23-7a87-48ff-a98c-b39eeedacd0b" xlink:to="loc_us-gaap_CommonStockValue_c5a5aecc-328f-4970-afd9-5a3eccc743c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_6a7bba85-140c-409b-b815-49b8658638ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f71e0d23-7a87-48ff-a98c-b39eeedacd0b" xlink:to="loc_us-gaap_AdditionalPaidInCapital_6a7bba85-140c-409b-b815-49b8658638ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3d17b1f8-0928-453b-877e-5b6cc587298f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f71e0d23-7a87-48ff-a98c-b39eeedacd0b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3d17b1f8-0928-453b-877e-5b6cc587298f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_60c026e7-09d9-4b3f-9de4-14db1b50859b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f71e0d23-7a87-48ff-a98c-b39eeedacd0b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_60c026e7-09d9-4b3f-9de4-14db1b50859b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f73bfe26-dcba-4794-983f-aeb17388ec3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_f71e0d23-7a87-48ff-a98c-b39eeedacd0b" xlink:to="loc_us-gaap_StockholdersEquity_f73bfe26-dcba-4794-983f-aeb17388ec3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_386a0caa-56d6-4ce5-a65c-de993ee4bdc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_52f32f11-1e7f-4bea-8426-4f1a79459a7f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_386a0caa-56d6-4ce5-a65c-de993ee4bdc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="bgne-20241231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d6762e80-bfcb-424f-8750-5bd80cb78e04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_cd0847a7-7ae8-4d6b-813d-641c432d6138" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d6762e80-bfcb-424f-8750-5bd80cb78e04" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_cd0847a7-7ae8-4d6b-813d-641c432d6138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b81861df-3c7c-4c11-a429-1ba98385428c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_cd0847a7-7ae8-4d6b-813d-641c432d6138" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b81861df-3c7c-4c11-a429-1ba98385428c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a9daf289-5208-4abc-9587-29a31e03572e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_cd0847a7-7ae8-4d6b-813d-641c432d6138" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a9daf289-5208-4abc-9587-29a31e03572e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b8467a39-6d08-43c2-a5d8-9016140ea1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_cd0847a7-7ae8-4d6b-813d-641c432d6138" xlink:to="loc_us-gaap_CommonStockSharesIssued_b8467a39-6d08-43c2-a5d8-9016140ea1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1b04f979-5c22-417b-9056-6d22c4d08a23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_cd0847a7-7ae8-4d6b-813d-641c432d6138" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1b04f979-5c22-417b-9056-6d22c4d08a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="bgne-20241231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_2eec1466-33c0-422b-a2ee-5b354173c9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e215a0ca-2877-41f9-bdbb-e9f24f303e53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2eec1466-33c0-422b-a2ee-5b354173c9bb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e215a0ca-2877-41f9-bdbb-e9f24f303e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_044124da-bc1d-4b83-b893-6fac36c998e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e215a0ca-2877-41f9-bdbb-e9f24f303e53" xlink:to="loc_us-gaap_NetIncomeLoss_044124da-bc1d-4b83-b893-6fac36c998e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad5425b6-6461-4b2d-a5ed-d798dd4fb2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e215a0ca-2877-41f9-bdbb-e9f24f303e53" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad5425b6-6461-4b2d-a5ed-d798dd4fb2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4c0d75f1-1231-4381-a2ef-2bc3a706ee9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad5425b6-6461-4b2d-a5ed-d798dd4fb2e5" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4c0d75f1-1231-4381-a2ef-2bc3a706ee9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_0bd703cd-9819-4cf8-96dc-7b02a554ffc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad5425b6-6461-4b2d-a5ed-d798dd4fb2e5" xlink:to="loc_us-gaap_ShareBasedCompensation_0bd703cd-9819-4cf8-96dc-7b02a554ffc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AcquiredInProcessResearchAndDevelopment_b3ba2732-b9d3-4ff8-928b-54961f4b9629" xlink:href="bgne-20241231.xsd#bgne_AcquiredInProcessResearchAndDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad5425b6-6461-4b2d-a5ed-d798dd4fb2e5" xlink:to="loc_bgne_AcquiredInProcessResearchAndDevelopment_b3ba2732-b9d3-4ff8-928b-54961f4b9629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AmortizationOfResearchAndDevelopmentFinancingLiability_6bb6eb2e-f30a-4ff5-927d-88ef1d682c98" xlink:href="bgne-20241231.xsd#bgne_AmortizationOfResearchAndDevelopmentFinancingLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad5425b6-6461-4b2d-a5ed-d798dd4fb2e5" xlink:to="loc_bgne_AmortizationOfResearchAndDevelopmentFinancingLiability_6bb6eb2e-f30a-4ff5-927d-88ef1d682c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_9419c39b-258a-46f2-bd79-88a99e6fe095" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad5425b6-6461-4b2d-a5ed-d798dd4fb2e5" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_9419c39b-258a-46f2-bd79-88a99e6fe095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_8899dd9e-a942-4514-acb6-d662b3de7fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad5425b6-6461-4b2d-a5ed-d798dd4fb2e5" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_8899dd9e-a942-4514-acb6-d662b3de7fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_7dab8f5a-d9fa-4fea-8fdb-e50072dd1158" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad5425b6-6461-4b2d-a5ed-d798dd4fb2e5" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_7dab8f5a-d9fa-4fea-8fdb-e50072dd1158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_709a01b3-94d3-4115-9fd2-2cf1c3a9acf0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ad5425b6-6461-4b2d-a5ed-d798dd4fb2e5" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_709a01b3-94d3-4115-9fd2-2cf1c3a9acf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c106318c-3861-436a-9920-2f988312134f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e215a0ca-2877-41f9-bdbb-e9f24f303e53" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c106318c-3861-436a-9920-2f988312134f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_de636b9c-1925-4999-bea2-a5e62fba02f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c106318c-3861-436a-9920-2f988312134f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_de636b9c-1925-4999-bea2-a5e62fba02f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_de769b7c-18de-4427-bc86-35a8aea5eab8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c106318c-3861-436a-9920-2f988312134f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_de769b7c-18de-4427-bc86-35a8aea5eab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_b365d2e5-95f9-413e-835e-a3a5eb13cbaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c106318c-3861-436a-9920-2f988312134f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_b365d2e5-95f9-413e-835e-a3a5eb13cbaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_71445285-e01d-4bdc-98af-114b8a9c6f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c106318c-3861-436a-9920-2f988312134f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_71445285-e01d-4bdc-98af-114b8a9c6f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_7ddd6270-f354-413f-a231-44bf7817682f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c106318c-3861-436a-9920-2f988312134f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_7ddd6270-f354-413f-a231-44bf7817682f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9ab8dfbf-da11-4746-99d6-f4d8e4c9fdb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c106318c-3861-436a-9920-2f988312134f" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9ab8dfbf-da11-4746-99d6-f4d8e4c9fdb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_1865a70b-6045-4be6-93e2-a7440b60b77d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_c106318c-3861-436a-9920-2f988312134f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_1865a70b-6045-4be6-93e2-a7440b60b77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f8189382-78b4-47d8-9d6b-eca6c1d9c577" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e215a0ca-2877-41f9-bdbb-e9f24f303e53" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f8189382-78b4-47d8-9d6b-eca6c1d9c577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a3dcfea1-f0fe-44a5-89fc-7513ed8899ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2eec1466-33c0-422b-a2ee-5b354173c9bb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a3dcfea1-f0fe-44a5-89fc-7513ed8899ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7a9cb534-a35d-4e16-b79e-66966c0e5a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a3dcfea1-f0fe-44a5-89fc-7513ed8899ab" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7a9cb534-a35d-4e16-b79e-66966c0e5a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_d831ba79-f523-4d91-9aba-de6ce7021682" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a3dcfea1-f0fe-44a5-89fc-7513ed8899ab" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_d831ba79-f523-4d91-9aba-de6ce7021682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_PaymentsToPurchaseInProcessResearchAndDevelopment_dc113487-8aa9-42c8-99f7-07f4b4531042" xlink:href="bgne-20241231.xsd#bgne_PaymentsToPurchaseInProcessResearchAndDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a3dcfea1-f0fe-44a5-89fc-7513ed8899ab" xlink:to="loc_bgne_PaymentsToPurchaseInProcessResearchAndDevelopment_dc113487-8aa9-42c8-99f7-07f4b4531042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_689f2651-3257-4259-b38a-88f8f162e083" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a3dcfea1-f0fe-44a5-89fc-7513ed8899ab" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_689f2651-3257-4259-b38a-88f8f162e083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireLongtermInvestments_ff345662-adf5-45f9-bce8-b0b038b18e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireLongtermInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a3dcfea1-f0fe-44a5-89fc-7513ed8899ab" xlink:to="loc_us-gaap_PaymentsToAcquireLongtermInvestments_ff345662-adf5-45f9-bce8-b0b038b18e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_4c3a7ec0-6a23-4b25-985f-1d6ca57fc3c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a3dcfea1-f0fe-44a5-89fc-7513ed8899ab" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_4c3a7ec0-6a23-4b25-985f-1d6ca57fc3c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c7e42002-ef86-410f-8408-315eaa751fda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a3dcfea1-f0fe-44a5-89fc-7513ed8899ab" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c7e42002-ef86-410f-8408-315eaa751fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8d4e72cc-04ad-4871-8300-b4121983d3a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2eec1466-33c0-422b-a2ee-5b354173c9bb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8d4e72cc-04ad-4871-8300-b4121983d3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_b341c080-afe8-46f8-91af-50ad757955b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8d4e72cc-04ad-4871-8300-b4121983d3a2" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_b341c080-afe8-46f8-91af-50ad757955b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_38f81495-79d2-4703-a642-8e6f04920980" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8d4e72cc-04ad-4871-8300-b4121983d3a2" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_38f81495-79d2-4703-a642-8e6f04920980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_b1abead8-a6eb-4377-8eb9-a1e331ccc63a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8d4e72cc-04ad-4871-8300-b4121983d3a2" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_b1abead8-a6eb-4377-8eb9-a1e331ccc63a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_b20fdd9d-28df-48eb-beaf-990f66bef0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8d4e72cc-04ad-4871-8300-b4121983d3a2" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_b20fdd9d-28df-48eb-beaf-990f66bef0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_f5237a5d-4ab2-428a-9681-4bc8fbc38f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8d4e72cc-04ad-4871-8300-b4121983d3a2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_f5237a5d-4ab2-428a-9681-4bc8fbc38f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_8ef39dfc-2a1d-4fec-a03b-1642c7871037" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8d4e72cc-04ad-4871-8300-b4121983d3a2" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_8ef39dfc-2a1d-4fec-a03b-1642c7871037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_63935417-2f49-4cf5-a510-3f89b79b8be5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8d4e72cc-04ad-4871-8300-b4121983d3a2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_63935417-2f49-4cf5-a510-3f89b79b8be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ee264191-c372-4915-a957-0c5c7c9c8612" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2eec1466-33c0-422b-a2ee-5b354173c9bb" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ee264191-c372-4915-a957-0c5c7c9c8612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_87e0b40e-1c2c-41e7-85e6-f30ddaf79c63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2eec1466-33c0-422b-a2ee-5b354173c9bb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_87e0b40e-1c2c-41e7-85e6-f30ddaf79c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8a2e194a-22d2-498f-b2f0-c819f4d1762f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2eec1466-33c0-422b-a2ee-5b354173c9bb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8a2e194a-22d2-498f-b2f0-c819f4d1762f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b2a0f109-9959-4c87-b7ac-ac2149428e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2eec1466-33c0-422b-a2ee-5b354173c9bb" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b2a0f109-9959-4c87-b7ac-ac2149428e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_69547cfe-2696-48f4-9b54-00cd9e1eae55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2eec1466-33c0-422b-a2ee-5b354173c9bb" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_69547cfe-2696-48f4-9b54-00cd9e1eae55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_069d20a2-1441-4717-a09b-eaaaa68605f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_69547cfe-2696-48f4-9b54-00cd9e1eae55" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_069d20a2-1441-4717-a09b-eaaaa68605f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_e3e2e99e-82e6-47e8-937b-3a56012ccbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_69547cfe-2696-48f4-9b54-00cd9e1eae55" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_e3e2e99e-82e6-47e8-937b-3a56012ccbcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_0e28d62c-85a4-431e-a379-6657950acf2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_69547cfe-2696-48f4-9b54-00cd9e1eae55" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_0e28d62c-85a4-431e-a379-6657950acf2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_23a6c84d-af4b-4b4d-9b4b-86cc7f18eef6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_69547cfe-2696-48f4-9b54-00cd9e1eae55" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_23a6c84d-af4b-4b4d-9b4b-86cc7f18eef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_InterestPaidIncludingCapitalizedInterest_d7086799-eb96-4dca-a1a6-f741e7763040" xlink:href="bgne-20241231.xsd#bgne_InterestPaidIncludingCapitalizedInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_69547cfe-2696-48f4-9b54-00cd9e1eae55" xlink:to="loc_bgne_InterestPaidIncludingCapitalizedInterest_d7086799-eb96-4dca-a1a6-f741e7763040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_94d77c29-4592-406c-8b9b-00b82e6fc10f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2eec1466-33c0-422b-a2ee-5b354173c9bb" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_94d77c29-4592-406c-8b9b-00b82e6fc10f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_b829b5f8-7f16-4cae-91a6-fe3019b2d720" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_94d77c29-4592-406c-8b9b-00b82e6fc10f" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_b829b5f8-7f16-4cae-91a6-fe3019b2d720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AcquiredInProcessResearchAndDevelopmentButNotYetPaid_f7455a47-84df-4a43-b08d-a4bf56c68aa6" xlink:href="bgne-20241231.xsd#bgne_AcquiredInProcessResearchAndDevelopmentButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_94d77c29-4592-406c-8b9b-00b82e6fc10f" xlink:to="loc_bgne_AcquiredInProcessResearchAndDevelopmentButNotYetPaid_f7455a47-84df-4a43-b08d-a4bf56c68aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" xlink:type="simple" xlink:href="bgne-20241231.xsd#CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_5110156c-784f-498a-be7f-12870e5e38ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_98030edb-c311-4c0f-8aa6-980942661211" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_5110156c-784f-498a-be7f-12870e5e38ad" xlink:to="loc_us-gaap_StatementTable_98030edb-c311-4c0f-8aa6-980942661211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_512fd803-1169-4ee1-a591-68af8ffe3995" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_98030edb-c311-4c0f-8aa6-980942661211" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_512fd803-1169-4ee1-a591-68af8ffe3995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_219d80cf-67cb-4407-a913-33ba0c0b3d69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_512fd803-1169-4ee1-a591-68af8ffe3995" xlink:to="loc_us-gaap_EquityComponentDomain_219d80cf-67cb-4407-a913-33ba0c0b3d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_abadd8e7-377d-4a00-8009-7b116bd3fbad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_219d80cf-67cb-4407-a913-33ba0c0b3d69" xlink:to="loc_us-gaap_CommonStockMember_abadd8e7-377d-4a00-8009-7b116bd3fbad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3fd415ea-58b1-4adc-a89d-40f1eaa17e78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_219d80cf-67cb-4407-a913-33ba0c0b3d69" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3fd415ea-58b1-4adc-a89d-40f1eaa17e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_146c107c-6521-48df-b5c8-25e142a44389" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_219d80cf-67cb-4407-a913-33ba0c0b3d69" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_146c107c-6521-48df-b5c8-25e142a44389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_7184e7bd-e95a-4720-9245-1cffab4fc098" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_219d80cf-67cb-4407-a913-33ba0c0b3d69" xlink:to="loc_us-gaap_RetainedEarningsMember_7184e7bd-e95a-4720-9245-1cffab4fc098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c8c1ce8c-03e7-4d1d-9249-51e62016093f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_98030edb-c311-4c0f-8aa6-980942661211" xlink:to="loc_us-gaap_StatementLineItems_c8c1ce8c-03e7-4d1d-9249-51e62016093f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c052df07-b978-4af5-b545-2a09f15a4010" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c8c1ce8c-03e7-4d1d-9249-51e62016093f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c052df07-b978-4af5-b545-2a09f15a4010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_91361636-22d3-440e-8676-e3f09056c0cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c052df07-b978-4af5-b545-2a09f15a4010" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_91361636-22d3-440e-8676-e3f09056c0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5b749ea4-1ead-42e5-9221-062b5c69ab8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c052df07-b978-4af5-b545-2a09f15a4010" xlink:to="loc_us-gaap_StockholdersEquity_5b749ea4-1ead-42e5-9221-062b5c69ab8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_d38f8c42-80ee-454a-ad41-1c47c074283f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c052df07-b978-4af5-b545-2a09f15a4010" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_d38f8c42-80ee-454a-ad41-1c47c074283f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7e8f54b7-41a1-4eab-bcbc-7ce09bd5e7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c052df07-b978-4af5-b545-2a09f15a4010" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7e8f54b7-41a1-4eab-bcbc-7ce09bd5e7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f0675abc-52dd-439a-9993-2d16864cc1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c052df07-b978-4af5-b545-2a09f15a4010" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f0675abc-52dd-439a-9993-2d16864cc1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_33869640-d4fb-4520-98d0-a694f9a366bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c052df07-b978-4af5-b545-2a09f15a4010" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_33869640-d4fb-4520-98d0-a694f9a366bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AdjustmentsToAdditionalPaidInCapitalDeconsolidationOfSubsidiary_9d0601d4-a57a-4c6c-9f42-02725c31952b" xlink:href="bgne-20241231.xsd#bgne_AdjustmentsToAdditionalPaidInCapitalDeconsolidationOfSubsidiary"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c052df07-b978-4af5-b545-2a09f15a4010" xlink:to="loc_bgne_AdjustmentsToAdditionalPaidInCapitalDeconsolidationOfSubsidiary_9d0601d4-a57a-4c6c-9f42-02725c31952b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5afea0ba-651d-4753-bda7-16044dd9ae4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c052df07-b978-4af5-b545-2a09f15a4010" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5afea0ba-651d-4753-bda7-16044dd9ae4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_78693e74-969f-4514-9c84-3b7c6649702d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c052df07-b978-4af5-b545-2a09f15a4010" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_78693e74-969f-4514-9c84-3b7c6649702d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_4815c696-935e-4bf5-8f98-7f5207067763" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c052df07-b978-4af5-b545-2a09f15a4010" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_4815c696-935e-4bf5-8f98-7f5207067763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8f72bf80-e2e9-4cba-885d-eb8d6a66ea05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c052df07-b978-4af5-b545-2a09f15a4010" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_8f72bf80-e2e9-4cba-885d-eb8d6a66ea05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_db5d67d1-b841-44af-b029-c33be6011569" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c052df07-b978-4af5-b545-2a09f15a4010" xlink:to="loc_us-gaap_NetIncomeLoss_db5d67d1-b841-44af-b029-c33be6011569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d43ae119-a4a2-4f98-8aed-d55a7491b315" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c052df07-b978-4af5-b545-2a09f15a4010" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d43ae119-a4a2-4f98-8aed-d55a7491b315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_352def9d-a6e3-4413-a3e4-1ead7ee76813" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_c052df07-b978-4af5-b545-2a09f15a4010" xlink:to="loc_us-gaap_StockholdersEquity_352def9d-a6e3-4413-a3e4-1ead7ee76813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="bgne-20241231.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ee3ab185-bd77-4478-9511-db4a5c0d72dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_a188e62d-68f0-49e8-9642-90e93ce7885c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ee3ab185-bd77-4478-9511-db4a5c0d72dc" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_a188e62d-68f0-49e8-9642-90e93ce7885c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="bgne-20241231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b5311746-40be-467d-b067-2b688a574a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_e8fddb0e-b2d7-467d-9ec9-08d54df4a5df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b5311746-40be-467d-b067-2b688a574a7c" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_e8fddb0e-b2d7-467d-9ec9-08d54df4a5df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/CollaborativeandLicensingArrangements" xlink:type="simple" xlink:href="bgne-20241231.xsd#CollaborativeandLicensingArrangements"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/CollaborativeandLicensingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_6415d363-e163-4427-9e28-97c4ae900238" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_c1a4b151-d1c2-48dd-86f5-d99a5cd814c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_6415d363-e163-4427-9e28-97c4ae900238" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_c1a4b151-d1c2-48dd-86f5-d99a5cd814c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/RestrictedCash" xlink:type="simple" xlink:href="bgne-20241231.xsd#RestrictedCash"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/RestrictedCash" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_f4114456-cbcd-4d70-9149-1f955cf78649" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_f0c500c6-a8b0-4e03-942f-583445d53353" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_f4114456-cbcd-4d70-9149-1f955cf78649" xlink:to="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_f0c500c6-a8b0-4e03-942f-583445d53353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/Investments" xlink:type="simple" xlink:href="bgne-20241231.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f21db2d7-f63c-49f8-bea0-07e7cf7e909f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_09ba2024-864a-4662-a3b3-bbd16250f89e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_f21db2d7-f63c-49f8-bea0-07e7cf7e909f" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_09ba2024-864a-4662-a3b3-bbd16250f89e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/InventoriesNet" xlink:type="simple" xlink:href="bgne-20241231.xsd#InventoriesNet"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/InventoriesNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_ac4b0743-1987-45ac-874e-455f1f07bb1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_4d81b76f-5bad-4203-a02d-90a3d48e666e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_ac4b0743-1987-45ac-874e-455f1f07bb1b" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_4d81b76f-5bad-4203-a02d-90a3d48e666e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/Leases" xlink:type="simple" xlink:href="bgne-20241231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8b655eb0-a1e9-4327-9ac2-92eb5a307ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_b7777aa5-ce4f-4d6c-9a4d-beac27b9b68a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8b655eb0-a1e9-4327-9ac2-92eb5a307ebc" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_b7777aa5-ce4f-4d6c-9a4d-beac27b9b68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/PropertyPlantandEquipmentNet" xlink:type="simple" xlink:href="bgne-20241231.xsd#PropertyPlantandEquipmentNet"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/PropertyPlantandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_89b1bb5a-8269-4d08-86fc-2d31c4173a91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_74d017d7-d40d-4298-9926-fd7413e5bd52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_89b1bb5a-8269-4d08-86fc-2d31c4173a91" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_74d017d7-d40d-4298-9926-fd7413e5bd52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/IntangibleAssets" xlink:type="simple" xlink:href="bgne-20241231.xsd#IntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/IntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1763dc2e-4c55-468f-aa68-ce23907f3bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_f1947552-d729-4b04-addf-977683c0b63c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1763dc2e-4c55-468f-aa68-ce23907f3bf4" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_f1947552-d729-4b04-addf-977683c0b63c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/IncomeTaxes" xlink:type="simple" xlink:href="bgne-20241231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d61fbf8b-bd20-4309-a32d-a00ffff5af92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_f25ba9ff-044e-4d22-9248-5b367b4b8da7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d61fbf8b-bd20-4309-a32d-a00ffff5af92" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_f25ba9ff-044e-4d22-9248-5b367b4b8da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/SupplementalBalanceSheetInformation" xlink:type="simple" xlink:href="bgne-20241231.xsd#SupplementalBalanceSheetInformation"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/SupplementalBalanceSheetInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_52706975-6be8-4d15-b75c-1e4b97549668" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_34aa947b-a80e-456f-8a03-7d912158b0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_52706975-6be8-4d15-b75c-1e4b97549668" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_34aa947b-a80e-456f-8a03-7d912158b0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/Debt" xlink:type="simple" xlink:href="bgne-20241231.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_174a8d18-89f3-4278-8b2b-d26a40446635" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_619d981b-c65a-4c5f-adf8-b295ff6374b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_174a8d18-89f3-4278-8b2b-d26a40446635" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_619d981b-c65a-4c5f-adf8-b295ff6374b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ProductRevenue" xlink:type="simple" xlink:href="bgne-20241231.xsd#ProductRevenue"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/ProductRevenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d9c1bbd0-7d6e-4176-9fa5-46099c826885" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_3bf163b4-059f-4448-a80e-184706d84360" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_d9c1bbd0-7d6e-4176-9fa5-46099c826885" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_3bf163b4-059f-4448-a80e-184706d84360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/LossPerShare" xlink:type="simple" xlink:href="bgne-20241231.xsd#LossPerShare"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/LossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e5864e50-9b38-487e-8851-6514fd0dabc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_94140868-4e80-4147-9c51-28ab523ee114" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e5864e50-9b38-487e-8851-6514fd0dabc9" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_94140868-4e80-4147-9c51-28ab523ee114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="bgne-20241231.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a8da6654-bf90-42f1-9189-68d6519618cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_43bbb741-4663-4598-9258-7959b49e7d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a8da6654-bf90-42f1-9189-68d6519618cd" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_43bbb741-4663-4598-9258-7959b49e7d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncome" xlink:type="simple" xlink:href="bgne-20241231.xsd#AccumulatedOtherComprehensiveLossIncome"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2a95871b-8d38-4b94-a1af-64862fd13d83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_0d35541f-858c-4239-8a03-569b17e850dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2a95871b-8d38-4b94-a1af-64862fd13d83" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_0d35541f-858c-4239-8a03-569b17e850dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ShareholdersEquity" xlink:type="simple" xlink:href="bgne-20241231.xsd#ShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/ShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a1e5f4ac-9136-4e49-baef-485e2cfd35c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c656c6a8-e83c-47e6-a89e-02fad75c6b28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a1e5f4ac-9136-4e49-baef-485e2cfd35c4" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c656c6a8-e83c-47e6-a89e-02fad75c6b28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/RestrictedNetAssets" xlink:type="simple" xlink:href="bgne-20241231.xsd#RestrictedNetAssets"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/RestrictedNetAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RestrictedNetAssetsDisclosureAbstract_ed7a7cc7-abca-4fab-807b-4c9c7f0746d9" xlink:href="bgne-20241231.xsd#bgne_RestrictedNetAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedAssetsDisclosureTextBlock_79d82d55-20ad-4a21-91ab-e2dd6e9fc535" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_RestrictedNetAssetsDisclosureAbstract_ed7a7cc7-abca-4fab-807b-4c9c7f0746d9" xlink:to="loc_us-gaap_RestrictedAssetsDisclosureTextBlock_79d82d55-20ad-4a21-91ab-e2dd6e9fc535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="bgne-20241231.xsd#EmployeeBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b7b97a13-316a-4e63-9ab0-77188e3d393c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_389b4a67-8359-42b9-b468-bf72b4dcc625" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b7b97a13-316a-4e63-9ab0-77188e3d393c" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_389b4a67-8359-42b9-b468-bf72b4dcc625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="bgne-20241231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9a8ee104-f567-4c41-b071-9f5f3abcb296" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9f9c1d28-ac62-47b0-a5c3-3886b2568956" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9a8ee104-f567-4c41-b071-9f5f3abcb296" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9f9c1d28-ac62-47b0-a5c3-3886b2568956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/SegmentandGeographicInformation" xlink:type="simple" xlink:href="bgne-20241231.xsd#SegmentandGeographicInformation"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/SegmentandGeographicInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_b233d121-d828-4f2f-b213-9daac8338891" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_05ce13a5-f374-4101-8315-f12ba4b75423" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b233d121-d828-4f2f-b213-9daac8338891" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_05ce13a5-f374-4101-8315-f12ba4b75423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrant" xlink:type="simple" xlink:href="bgne-20241231.xsd#ScheduleICondensedFinancialInformationofRegistrant"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrant" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_1be97b71-15eb-497e-9a12-3f513f865757" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_e6360b29-88a7-462a-8797-8f90acce102d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_1be97b71-15eb-497e-9a12-3f513f865757" xlink:to="loc_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_e6360b29-88a7-462a-8797-8f90acce102d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="bgne-20241231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_41672e44-9885-4cb7-8582-38f868d63560" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_b0be7e66-f400-4657-9928-422c64ed813e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_41672e44-9885-4cb7-8582-38f868d63560" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_b0be7e66-f400-4657-9928-422c64ed813e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_05247323-e5e0-493a-bec0-98cc434f4e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_41672e44-9885-4cb7-8582-38f868d63560" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_05247323-e5e0-493a-bec0-98cc434f4e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_c9c398e5-d1c4-433d-8513-937885e40144" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_41672e44-9885-4cb7-8582-38f868d63560" xlink:to="loc_us-gaap_UseOfEstimates_c9c398e5-d1c4-433d-8513-937885e40144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_b1fa7b66-fba2-4e2f-98b0-397caf6efa60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_41672e44-9885-4cb7-8582-38f868d63560" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_b1fa7b66-fba2-4e2f-98b0-397caf6efa60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_fd8b26a8-a832-4190-807b-524a5c8a3d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_41672e44-9885-4cb7-8582-38f868d63560" xlink:to="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_fd8b26a8-a832-4190-807b-524a5c8a3d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_09f9b257-411b-4275-9489-68a00b23072a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_41672e44-9885-4cb7-8582-38f868d63560" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_09f9b257-411b-4275-9489-68a00b23072a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_092e9ae9-0b0e-4289-9e69-76e0688369cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_41672e44-9885-4cb7-8582-38f868d63560" xlink:to="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_092e9ae9-0b0e-4289-9e69-76e0688369cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_a11d9c1c-e08b-4925-9c60-4f2b3c58bbb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_41672e44-9885-4cb7-8582-38f868d63560" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_a11d9c1c-e08b-4925-9c60-4f2b3c58bbb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_ee5a6375-89a7-41f9-960c-d75a101a9761" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_41672e44-9885-4cb7-8582-38f868d63560" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_ee5a6375-89a7-41f9-960c-d75a101a9761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_fa036fc7-b0dd-4e3f-a93e-3ad2a8651580" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_41672e44-9885-4cb7-8582-38f868d63560" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_fa036fc7-b0dd-4e3f-a93e-3ad2a8651580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_b14cb9d6-c638-430f-bb4d-63260c8de69c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_41672e44-9885-4cb7-8582-38f868d63560" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_b14cb9d6-c638-430f-bb4d-63260c8de69c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_e9349ef8-8cc8-4092-ae71-739eb6feac11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_41672e44-9885-4cb7-8582-38f868d63560" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_e9349ef8-8cc8-4092-ae71-739eb6feac11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_LandUseRightsPolicyPolicyTextBlock_41dc1022-1f3b-46d7-a588-b922347bfc92" xlink:href="bgne-20241231.xsd#bgne_LandUseRightsPolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_41672e44-9885-4cb7-8582-38f868d63560" xlink:to="loc_bgne_LandUseRightsPolicyPolicyTextBlock_41dc1022-1f3b-46d7-a588-b922347bfc92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_c11674b3-b9d9-4bc2-b8d1-ce37bb0871e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_41672e44-9885-4cb7-8582-38f868d63560" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_c11674b3-b9d9-4bc2-b8d1-ce37bb0871e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_a2aa8ea7-ae60-4d37-bac9-976d66d1e498" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_41672e44-9885-4cb7-8582-38f868d63560" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_a2aa8ea7-ae60-4d37-bac9-976d66d1e498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_20660f40-4345-4866-a624-b8ff04fcc389" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_41672e44-9885-4cb7-8582-38f868d63560" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_20660f40-4345-4866-a624-b8ff04fcc389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_6488da21-8583-4adc-828b-688304e01a99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_41672e44-9885-4cb7-8582-38f868d63560" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_6488da21-8583-4adc-828b-688304e01a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_fea1365c-6e37-4cd8-b6fc-8fe9cdbb360a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_41672e44-9885-4cb7-8582-38f868d63560" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_fea1365c-6e37-4cd8-b6fc-8fe9cdbb360a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_GovernmentGrantsPolicyPolicyTextBlock_f0bdae9f-15fb-4f64-ae09-55b35262216a" xlink:href="bgne-20241231.xsd#bgne_GovernmentGrantsPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_41672e44-9885-4cb7-8582-38f868d63560" xlink:to="loc_bgne_GovernmentGrantsPolicyPolicyTextBlock_f0bdae9f-15fb-4f64-ae09-55b35262216a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_ba0c2c81-4b12-4a7a-9cbc-b532f06830d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_41672e44-9885-4cb7-8582-38f868d63560" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_ba0c2c81-4b12-4a7a-9cbc-b532f06830d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_252efaf7-c0af-48b5-a6ff-b428bbc6376e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_41672e44-9885-4cb7-8582-38f868d63560" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_252efaf7-c0af-48b5-a6ff-b428bbc6376e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_9819cf81-9fa1-4daa-a3de-23bf43609a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_41672e44-9885-4cb7-8582-38f868d63560" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_9819cf81-9fa1-4daa-a3de-23bf43609a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_a91c243a-ce5a-494e-821a-7664eeada262" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_41672e44-9885-4cb7-8582-38f868d63560" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_a91c243a-ce5a-494e-821a-7664eeada262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_3ed17c76-adb0-470f-91b3-2cc7ce4e3edc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_41672e44-9885-4cb7-8582-38f868d63560" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_3ed17c76-adb0-470f-91b3-2cc7ce4e3edc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_88c9b6dd-60e8-471d-af92-2ae28cdc4053" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_41672e44-9885-4cb7-8582-38f868d63560" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_88c9b6dd-60e8-471d-af92-2ae28cdc4053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f1bc7fad-d966-4db5-88f5-de60dc420189" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_41672e44-9885-4cb7-8582-38f868d63560" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f1bc7fad-d966-4db5-88f5-de60dc420189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="bgne-20241231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_06fd15e6-2a3a-4ad1-93ee-64881651cd19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_a4e3a930-1651-4139-a255-2d3cc578a6af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_06fd15e6-2a3a-4ad1-93ee-64881651cd19" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_a4e3a930-1651-4139-a255-2d3cc578a6af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_7010adf8-880a-4eaa-9ae7-26c3783a542d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_06fd15e6-2a3a-4ad1-93ee-64881651cd19" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_7010adf8-880a-4eaa-9ae7-26c3783a542d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_bdab9576-5f82-49a0-8ea0-eedd02f565c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_06fd15e6-2a3a-4ad1-93ee-64881651cd19" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_bdab9576-5f82-49a0-8ea0-eedd02f565c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/CollaborativeandLicensingArrangementsTables" xlink:type="simple" xlink:href="bgne-20241231.xsd#CollaborativeandLicensingArrangementsTables"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/CollaborativeandLicensingArrangementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_edfbc7d8-0cce-4c38-8ec7-cfe45471e82e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_1a9dde4f-7ea6-4170-9c17-bd4b5a3c0f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_edfbc7d8-0cce-4c38-8ec7-cfe45471e82e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_1a9dde4f-7ea6-4170-9c17-bd4b5a3c0f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_CollaborationAgreementsTableTextBlock_a2ff6cab-2f48-4d4c-b8ca-8fb1a5dc1ed1" xlink:href="bgne-20241231.xsd#bgne_CollaborationAgreementsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_edfbc7d8-0cce-4c38-8ec7-cfe45471e82e" xlink:to="loc_bgne_CollaborationAgreementsTableTextBlock_a2ff6cab-2f48-4d4c-b8ca-8fb1a5dc1ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ScheduleOfAmountsAndClassificationOfReimbursementExpenseTableTextBlock_dd23476b-73f6-4d91-bdcd-d5fc1da4870e" xlink:href="bgne-20241231.xsd#bgne_ScheduleOfAmountsAndClassificationOfReimbursementExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_edfbc7d8-0cce-4c38-8ec7-cfe45471e82e" xlink:to="loc_bgne_ScheduleOfAmountsAndClassificationOfReimbursementExpenseTableTextBlock_dd23476b-73f6-4d91-bdcd-d5fc1da4870e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_PaymentsDueToCollaborationPartnersTableTextBlock_f5decbea-22a5-42f9-b143-ae40a328731a" xlink:href="bgne-20241231.xsd#bgne_PaymentsDueToCollaborationPartnersTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_edfbc7d8-0cce-4c38-8ec7-cfe45471e82e" xlink:to="loc_bgne_PaymentsDueToCollaborationPartnersTableTextBlock_f5decbea-22a5-42f9-b143-ae40a328731a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/RestrictedCashTables" xlink:type="simple" xlink:href="bgne-20241231.xsd#RestrictedCashTables"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/RestrictedCashTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_23d499ec-f7f7-4e39-9d40-e59f0122d0d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_4ad7f518-0f52-45ae-be63-d8f7697cae32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_23d499ec-f7f7-4e39-9d40-e59f0122d0d6" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_4ad7f518-0f52-45ae-be63-d8f7697cae32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/InvestmentsTables" xlink:type="simple" xlink:href="bgne-20241231.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a0a6cb2f-7643-46dc-bdaf-99ca309d6e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_722004fa-cf6c-4582-b1e2-d53c4000d3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a0a6cb2f-7643-46dc-bdaf-99ca309d6e9e" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_722004fa-cf6c-4582-b1e2-d53c4000d3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/InventoriesNetTables" xlink:type="simple" xlink:href="bgne-20241231.xsd#InventoriesNetTables"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/InventoriesNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_b8a59939-34f8-43e0-9a42-ffa93382c16a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_c98e2e0f-4bd1-4045-b795-d57cb66b4e10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_b8a59939-34f8-43e0-9a42-ffa93382c16a" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_c98e2e0f-4bd1-4045-b795-d57cb66b4e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/LeasesTables" xlink:type="simple" xlink:href="bgne-20241231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e4900c12-ce44-414e-946b-12e14d587e14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_e4c296fc-e806-48dc-82f4-f1028dd1799e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e4900c12-ce44-414e-946b-12e14d587e14" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_e4c296fc-e806-48dc-82f4-f1028dd1799e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AssetsAndLiabilitiesLesseeTableTextBlock_55e56782-2cd4-41b3-8f57-fd100369ee15" xlink:href="bgne-20241231.xsd#bgne_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e4900c12-ce44-414e-946b-12e14d587e14" xlink:to="loc_bgne_AssetsAndLiabilitiesLesseeTableTextBlock_55e56782-2cd4-41b3-8f57-fd100369ee15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_95c3bd27-63b9-4cb1-83c1-98e61b808611" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e4900c12-ce44-414e-946b-12e14d587e14" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_95c3bd27-63b9-4cb1-83c1-98e61b808611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/PropertyPlantandEquipmentNetTables" xlink:type="simple" xlink:href="bgne-20241231.xsd#PropertyPlantandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/PropertyPlantandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_956565a2-3526-40b9-9e01-0ac12ea75b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_478fde5c-715b-4d30-9eb4-f906f8c64fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_956565a2-3526-40b9-9e01-0ac12ea75b6c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_478fde5c-715b-4d30-9eb4-f906f8c64fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/IntangibleAssetsTables" xlink:type="simple" xlink:href="bgne-20241231.xsd#IntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/IntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a01e4a74-883f-48d5-95c6-cbfdc5b47727" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_03429927-fc2d-42f8-9893-8af264353b62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a01e4a74-883f-48d5-95c6-cbfdc5b47727" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_03429927-fc2d-42f8-9893-8af264353b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_6f02e553-3f48-4c63-be08-876e42ce8aee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a01e4a74-883f-48d5-95c6-cbfdc5b47727" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_6f02e553-3f48-4c63-be08-876e42ce8aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="bgne-20241231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7d1441a0-c640-49bd-b6cb-099da240554d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_3f5c8dcd-a1d2-4fa5-a040-2c34a88344ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7d1441a0-c640-49bd-b6cb-099da240554d" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_3f5c8dcd-a1d2-4fa5-a040-2c34a88344ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_9097c9a4-cf55-4498-b855-91ee2a087aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7d1441a0-c640-49bd-b6cb-099da240554d" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_9097c9a4-cf55-4498-b855-91ee2a087aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_97cd6f75-78e5-4836-b8b0-fe21dc8fd81e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7d1441a0-c640-49bd-b6cb-099da240554d" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_97cd6f75-78e5-4836-b8b0-fe21dc8fd81e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_f2109e65-6609-47af-812a-f1390b148100" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7d1441a0-c640-49bd-b6cb-099da240554d" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_f2109e65-6609-47af-812a-f1390b148100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_8099b03b-426b-45b7-8355-a3a1e07ac46e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7d1441a0-c640-49bd-b6cb-099da240554d" xlink:to="loc_us-gaap_SummaryOfValuationAllowanceTextBlock_8099b03b-426b-45b7-8355-a3a1e07ac46e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_425960a9-902d-4f6d-9f9c-5cc95361a41c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7d1441a0-c640-49bd-b6cb-099da240554d" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_425960a9-902d-4f6d-9f9c-5cc95361a41c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/SupplementalBalanceSheetInformationTables" xlink:type="simple" xlink:href="bgne-20241231.xsd#SupplementalBalanceSheetInformationTables"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/SupplementalBalanceSheetInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_f6e13f6b-c41f-4ae9-af64-637a8bd8026b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_8bc4f4d8-a9ec-4a1e-aaba-504d214103c4" xlink:href="bgne-20241231.xsd#bgne_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_f6e13f6b-c41f-4ae9-af64-637a8bd8026b" xlink:to="loc_bgne_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_8bc4f4d8-a9ec-4a1e-aaba-504d214103c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_94697dea-e23e-4c9c-af00-c1a2b3d35371" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_f6e13f6b-c41f-4ae9-af64-637a8bd8026b" xlink:to="loc_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_94697dea-e23e-4c9c-af00-c1a2b3d35371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AccruedLiabilitiesAccountsPayableOtherAndOtherLiabilitiesCurrentTableTextBlock_ee047d53-4a61-4117-a668-7c7818f01de1" xlink:href="bgne-20241231.xsd#bgne_AccruedLiabilitiesAccountsPayableOtherAndOtherLiabilitiesCurrentTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_f6e13f6b-c41f-4ae9-af64-637a8bd8026b" xlink:to="loc_bgne_AccruedLiabilitiesAccountsPayableOtherAndOtherLiabilitiesCurrentTableTextBlock_ee047d53-4a61-4117-a668-7c7818f01de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_b2961d20-ed39-4eed-9648-a48d2dc30cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_f6e13f6b-c41f-4ae9-af64-637a8bd8026b" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_b2961d20-ed39-4eed-9648-a48d2dc30cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/DebtTables" xlink:type="simple" xlink:href="bgne-20241231.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_85f0db0e-4613-4c1f-b715-4cbed5fb9186" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_6f526bf2-3e15-43fc-a5bd-c1e3153fd183" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_85f0db0e-4613-4c1f-b715-4cbed5fb9186" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_6f526bf2-3e15-43fc-a5bd-c1e3153fd183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_b3301d17-0e41-4c0d-baa5-b6a894d8b92e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_85f0db0e-4613-4c1f-b715-4cbed5fb9186" xlink:to="loc_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock_b3301d17-0e41-4c0d-baa5-b6a894d8b92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ProductRevenueTables" xlink:type="simple" xlink:href="bgne-20241231.xsd#ProductRevenueTables"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/ProductRevenueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f716c5b0-f460-417f-b69e-3f3dd610992c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_443c1e8d-8005-41e4-aa49-f8885d75072f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f716c5b0-f460-417f-b69e-3f3dd610992c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_443c1e8d-8005-41e4-aa49-f8885d75072f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ScheduleOfAccruedSalesRebatesAndReturnsCurrentTableTextBlock_70f0fa75-9ec3-486a-bfc9-6437b09132d6" xlink:href="bgne-20241231.xsd#bgne_ScheduleOfAccruedSalesRebatesAndReturnsCurrentTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f716c5b0-f460-417f-b69e-3f3dd610992c" xlink:to="loc_bgne_ScheduleOfAccruedSalesRebatesAndReturnsCurrentTableTextBlock_70f0fa75-9ec3-486a-bfc9-6437b09132d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/LossPerShareTables" xlink:type="simple" xlink:href="bgne-20241231.xsd#LossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/LossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_dcbb0132-6ba7-46d3-b557-bcc03fb8031e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3d10dade-a35b-4a14-997a-a22742f4cd99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dcbb0132-6ba7-46d3-b557-bcc03fb8031e" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3d10dade-a35b-4a14-997a-a22742f4cd99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="bgne-20241231.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d7c4a564-d0f0-4f96-97f0-604342b47c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_af1e72ad-f41a-403d-8bce-8471f027614e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d7c4a564-d0f0-4f96-97f0-604342b47c0f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_af1e72ad-f41a-403d-8bce-8471f027614e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_61c8d2e5-33a9-4408-b6d1-26d9b83bea99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d7c4a564-d0f0-4f96-97f0-604342b47c0f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_61c8d2e5-33a9-4408-b6d1-26d9b83bea99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2a9f54b0-2b50-4215-91c3-f24f88ee0e41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d7c4a564-d0f0-4f96-97f0-604342b47c0f" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2a9f54b0-2b50-4215-91c3-f24f88ee0e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_78a347d9-86aa-4fa8-a219-10db006a5b77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d7c4a564-d0f0-4f96-97f0-604342b47c0f" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_78a347d9-86aa-4fa8-a219-10db006a5b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_539ea8a9-c208-4cde-b387-26cae932e435" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d7c4a564-d0f0-4f96-97f0-604342b47c0f" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_539ea8a9-c208-4cde-b387-26cae932e435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncomeTables" xlink:type="simple" xlink:href="bgne-20241231.xsd#AccumulatedOtherComprehensiveLossIncomeTables"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncomeTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2d39b5e4-90a9-4a47-a62e-4c842767cac2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_137c4c36-a610-4f31-b40c-5cf1b6bdc315" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2d39b5e4-90a9-4a47-a62e-4c842767cac2" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_137c4c36-a610-4f31-b40c-5cf1b6bdc315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/EmployeeBenefitPlansTables" xlink:type="simple" xlink:href="bgne-20241231.xsd#EmployeeBenefitPlansTables"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/EmployeeBenefitPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_99448c9f-f80a-4698-aee9-15aa721cd9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_bca91ce9-f5b1-4e91-b030-5eef665c04a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_99448c9f-f80a-4698-aee9-15aa721cd9d9" xlink:to="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_bca91ce9-f5b1-4e91-b030-5eef665c04a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/SegmentandGeographicInformationTables" xlink:type="simple" xlink:href="bgne-20241231.xsd#SegmentandGeographicInformationTables"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/SegmentandGeographicInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_5cc65f45-988b-43e7-83f3-618f26c00264" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_9aac9ad3-eb22-492a-8ae6-1ed9955c8d14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5cc65f45-988b-43e7-83f3-618f26c00264" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_9aac9ad3-eb22-492a-8ae6-1ed9955c8d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/SECScheduleArticle1204CondensedFinancialInformationofRegistrantTables" xlink:type="simple" xlink:href="bgne-20241231.xsd#SECScheduleArticle1204CondensedFinancialInformationofRegistrantTables"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/SECScheduleArticle1204CondensedFinancialInformationofRegistrantTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_585975dd-410a-4325-8808-394fc6365f05" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedIncomeStatementTableTextBlock_3c8e5cff-1be3-4003-b10f-3e0b6f361fc3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_585975dd-410a-4325-8808-394fc6365f05" xlink:to="loc_srt_ScheduleOfCondensedIncomeStatementTableTextBlock_3c8e5cff-1be3-4003-b10f-3e0b6f361fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedStatementOfComprehensiveIncomeTableTextBlock_2677a8be-7e8b-4880-be98-a4816822ebff" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedStatementOfComprehensiveIncomeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_585975dd-410a-4325-8808-394fc6365f05" xlink:to="loc_srt_CondensedStatementOfComprehensiveIncomeTableTextBlock_2677a8be-7e8b-4880-be98-a4816822ebff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedBalanceSheetTableTextBlock_f7907ccd-c826-4e0b-bc53-0aca625f06c8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_585975dd-410a-4325-8808-394fc6365f05" xlink:to="loc_srt_ScheduleOfCondensedBalanceSheetTableTextBlock_f7907ccd-c826-4e0b-bc53-0aca625f06c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock_6f74024c-c7ff-42f0-88de-8e1d171a26b8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedCashFlowStatementTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_585975dd-410a-4325-8808-394fc6365f05" xlink:to="loc_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock_6f74024c-c7ff-42f0-88de-8e1d171a26b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#DescriptionofBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/DescriptionofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_922573d7-68ca-4715-b9ae-bb898a883684" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6f35e72f-a60c-473f-960b-301084a9ac6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_922573d7-68ca-4715-b9ae-bb898a883684" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6f35e72f-a60c-473f-960b-301084a9ac6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RevenueFromContractWithCustomerExcludingAssessedTaxPeriodIncreaseDecrease_e079f061-dec3-4702-9501-e05a95f4b772" xlink:href="bgne-20241231.xsd#bgne_RevenueFromContractWithCustomerExcludingAssessedTaxPeriodIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_922573d7-68ca-4715-b9ae-bb898a883684" xlink:to="loc_bgne_RevenueFromContractWithCustomerExcludingAssessedTaxPeriodIncreaseDecrease_e079f061-dec3-4702-9501-e05a95f4b772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestPeriodIncreaseDecrease_ee836825-22c5-4e22-8904-a35b52b5bc1d" xlink:href="bgne-20241231.xsd#bgne_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestPeriodIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_922573d7-68ca-4715-b9ae-bb898a883684" xlink:to="loc_bgne_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestPeriodIncreaseDecrease_ee836825-22c5-4e22-8904-a35b52b5bc1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityNumberOfEmployees_4c7718b0-7701-4c6b-8b07-9c6a675011b5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityNumberOfEmployees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_922573d7-68ca-4715-b9ae-bb898a883684" xlink:to="loc_dei_EntityNumberOfEmployees_4c7718b0-7701-4c6b-8b07-9c6a675011b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#SummaryofSignificantAccountingPoliciesInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5f093da4-a73f-472d-be7a-828b4d0a4112" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_15928bf0-2fec-437b-b471-9dad492af5ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5f093da4-a73f-472d-be7a-828b4d0a4112" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_15928bf0-2fec-437b-b471-9dad492af5ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b9795fff-35a6-40d8-b8cc-6f7a9ecaf6b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1ab586b9-67b0-4caa-a8ba-55c553542f23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b9795fff-35a6-40d8-b8cc-6f7a9ecaf6b6" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1ab586b9-67b0-4caa-a8ba-55c553542f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7a2d14a3-9c41-41ad-bb43-8eef6e8f0302" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1ab586b9-67b0-4caa-a8ba-55c553542f23" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7a2d14a3-9c41-41ad-bb43-8eef6e8f0302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ac9fdab-13aa-4437-b51d-b413ea9b2b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7a2d14a3-9c41-41ad-bb43-8eef6e8f0302" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ac9fdab-13aa-4437-b51d-b413ea9b2b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_fb1fbf59-def5-4937-a39d-bc16b63ec9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ac9fdab-13aa-4437-b51d-b413ea9b2b3a" xlink:to="loc_us-gaap_BuildingMember_fb1fbf59-def5-4937-a39d-bc16b63ec9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_d3581217-e2c8-4e23-8be0-32aa06c0d5a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ac9fdab-13aa-4437-b51d-b413ea9b2b3a" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_d3581217-e2c8-4e23-8be0-32aa06c0d5a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_LaboratoryEquipmentMember_623a201f-50f0-46c3-bfc8-035771b82c46" xlink:href="bgne-20241231.xsd#bgne_LaboratoryEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ac9fdab-13aa-4437-b51d-b413ea9b2b3a" xlink:to="loc_bgne_LaboratoryEquipmentMember_623a201f-50f0-46c3-bfc8-035771b82c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_d522026b-a743-4598-a74e-b52dd517c134" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3ac9fdab-13aa-4437-b51d-b413ea9b2b3a" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_d522026b-a743-4598-a74e-b52dd517c134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_afe15e42-0384-47bb-9846-2ed13295a575" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1ab586b9-67b0-4caa-a8ba-55c553542f23" xlink:to="loc_srt_RangeAxis_afe15e42-0384-47bb-9846-2ed13295a575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b988b256-721b-4ec7-9dd7-acd97e669fed" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_afe15e42-0384-47bb-9846-2ed13295a575" xlink:to="loc_srt_RangeMember_b988b256-721b-4ec7-9dd7-acd97e669fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6740703c-8e95-4f41-bc4d-c03356acf45c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b988b256-721b-4ec7-9dd7-acd97e669fed" xlink:to="loc_srt_MinimumMember_6740703c-8e95-4f41-bc4d-c03356acf45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9b05cec3-e85d-4bc2-bb1b-0bae86ec4ba0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b988b256-721b-4ec7-9dd7-acd97e669fed" xlink:to="loc_srt_MaximumMember_9b05cec3-e85d-4bc2-bb1b-0bae86ec4ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_12b7501c-e0c7-49ad-b9a2-1f377b26ea42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1ab586b9-67b0-4caa-a8ba-55c553542f23" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_12b7501c-e0c7-49ad-b9a2-1f377b26ea42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_3ecf8bd5-c00b-4724-9dc8-3bd32c1861bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_12b7501c-e0c7-49ad-b9a2-1f377b26ea42" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_3ecf8bd5-c00b-4724-9dc8-3bd32c1861bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4b85f627-e6d5-4fb6-b3ce-45b13354412f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_3ecf8bd5-c00b-4724-9dc8-3bd32c1861bb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_4b85f627-e6d5-4fb6-b3ce-45b13354412f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesLandUseRightNetDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#SummaryofSignificantAccountingPoliciesLandUseRightNetDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesLandUseRightNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_688b832b-3343-43a7-affa-86b920aafd14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_baf68af2-2623-490d-aeb2-9febcadbbdc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_688b832b-3343-43a7-affa-86b920aafd14" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_baf68af2-2623-490d-aeb2-9febcadbbdc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5e13f1b1-6e84-48b1-aca0-7e075305ecde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_baf68af2-2623-490d-aeb2-9febcadbbdc0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5e13f1b1-6e84-48b1-aca0-7e075305ecde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8158b4b7-773b-4b82-9e59-d7fe4521e0d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5e13f1b1-6e84-48b1-aca0-7e075305ecde" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8158b4b7-773b-4b82-9e59-d7fe4521e0d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_3154e877-0890-42ba-a541-3adf0a62c19f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8158b4b7-773b-4b82-9e59-d7fe4521e0d8" xlink:to="loc_us-gaap_LandMember_3154e877-0890-42ba-a541-3adf0a62c19f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a4917e68-11b5-429e-9ed3-a472f75f76a2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_baf68af2-2623-490d-aeb2-9febcadbbdc0" xlink:to="loc_srt_StatementGeographicalAxis_a4917e68-11b5-429e-9ed3-a472f75f76a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a91ddaf9-5197-4e0d-99cb-90e914ad0376" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_a4917e68-11b5-429e-9ed3-a472f75f76a2" xlink:to="loc_srt_SegmentGeographicalDomain_a91ddaf9-5197-4e0d-99cb-90e914ad0376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_GuangzhouMember_f36ee151-fcff-4689-86f2-e5cc8b982e46" xlink:href="bgne-20241231.xsd#bgne_GuangzhouMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a91ddaf9-5197-4e0d-99cb-90e914ad0376" xlink:to="loc_bgne_GuangzhouMember_f36ee151-fcff-4689-86f2-e5cc8b982e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_BeijingMember_675dd22e-12e3-418b-b075-489f7d31d13e" xlink:href="bgne-20241231.xsd#bgne_BeijingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a91ddaf9-5197-4e0d-99cb-90e914ad0376" xlink:to="loc_bgne_BeijingMember_675dd22e-12e3-418b-b075-489f7d31d13e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_SuzhouMember_54f89f1f-225f-4c87-b49d-1a38f9f6a014" xlink:href="bgne-20241231.xsd#bgne_SuzhouMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a91ddaf9-5197-4e0d-99cb-90e914ad0376" xlink:to="loc_bgne_SuzhouMember_54f89f1f-225f-4c87-b49d-1a38f9f6a014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShanghaiMember_6310626b-3f51-4097-8639-fad14555fd1e" xlink:href="bgne-20241231.xsd#bgne_ShanghaiMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_a91ddaf9-5197-4e0d-99cb-90e914ad0376" xlink:to="loc_bgne_ShanghaiMember_6310626b-3f51-4097-8639-fad14555fd1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_248214a8-7263-4c0b-a6fd-ab7a4cd5bcdb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_baf68af2-2623-490d-aeb2-9febcadbbdc0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_248214a8-7263-4c0b-a6fd-ab7a4cd5bcdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9c6bd573-2a00-4b62-82aa-7ef4adab1eee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_248214a8-7263-4c0b-a6fd-ab7a4cd5bcdb" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9c6bd573-2a00-4b62-82aa-7ef4adab1eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesGoodwillandOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#SummaryofSignificantAccountingPoliciesGoodwillandOtherIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesGoodwillandOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ffd8213c-2831-4b32-9303-44873d6f2ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_8255d2e1-02c4-4acd-bb90-61e5071c2a35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ffd8213c-2831-4b32-9303-44873d6f2ce1" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_8255d2e1-02c4-4acd-bb90-61e5071c2a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d3f9e658-6605-4926-ba21-2885abe248a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentChargesAbstract_f4421ee5-2a38-42b2-afae-48439bf65c89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentChargesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d3f9e658-6605-4926-ba21-2885abe248a9" xlink:to="loc_us-gaap_AssetImpairmentChargesAbstract_f4421ee5-2a38-42b2-afae-48439bf65c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_955bef36-6d73-48d0-8e79-713650d14744" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetImpairmentChargesAbstract_f4421ee5-2a38-42b2-afae-48439bf65c89" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_955bef36-6d73-48d0-8e79-713650d14744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5a34618e-7722-4ebc-9784-fc83027b2058" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d9c94054-eb82-483c-a829-8f5499cf0684" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5a34618e-7722-4ebc-9784-fc83027b2058" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d9c94054-eb82-483c-a829-8f5499cf0684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_abe39a97-c30f-4f27-ad12-e17731807410" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d9c94054-eb82-483c-a829-8f5499cf0684" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_abe39a97-c30f-4f27-ad12-e17731807410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0790754b-9c1a-426f-877d-d44552a1302b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_abe39a97-c30f-4f27-ad12-e17731807410" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0790754b-9c1a-426f-877d-d44552a1302b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_675ab2fd-a278-4cfe-a1fd-6fc74cf2e011" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0790754b-9c1a-426f-877d-d44552a1302b" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_675ab2fd-a278-4cfe-a1fd-6fc74cf2e011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4a1bcf56-d91e-437e-8232-0c6709e49457" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d9c94054-eb82-483c-a829-8f5499cf0684" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4a1bcf56-d91e-437e-8232-0c6709e49457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_58789ed9-e7f6-4535-8f5c-ec4ed6feba11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4a1bcf56-d91e-437e-8232-0c6709e49457" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_58789ed9-e7f6-4535-8f5c-ec4ed6feba11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_dfb0485e-c030-4e5d-b624-410d83d31139" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_58789ed9-e7f6-4535-8f5c-ec4ed6feba11" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_dfb0485e-c030-4e5d-b624-410d83d31139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b2ab1e22-43af-4932-807a-879b8f75779e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_58789ed9-e7f6-4535-8f5c-ec4ed6feba11" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b2ab1e22-43af-4932-807a-879b8f75779e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8edbd466-b202-4759-a010-c51eb66024ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_58789ed9-e7f6-4535-8f5c-ec4ed6feba11" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8edbd466-b202-4759-a010-c51eb66024ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_582857cb-6d8d-4e5c-85ac-2ed11a78a3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d9c94054-eb82-483c-a829-8f5499cf0684" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_582857cb-6d8d-4e5c-85ac-2ed11a78a3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e76410bc-1047-47c5-a913-8483cbff404a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_582857cb-6d8d-4e5c-85ac-2ed11a78a3bc" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e76410bc-1047-47c5-a913-8483cbff404a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_893b6bd4-2497-4cf7-a3e8-17efc61fdb52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e76410bc-1047-47c5-a913-8483cbff404a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_893b6bd4-2497-4cf7-a3e8-17efc61fdb52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_90cdf4ff-70fd-4a2c-acf7-ff7af0e56c75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_e76410bc-1047-47c5-a913-8483cbff404a" xlink:to="loc_us-gaap_BankTimeDepositsMember_90cdf4ff-70fd-4a2c-acf7-ff7af0e56c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_b9093b89-5a3e-4733-a6c8-7ee11039f8ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d9c94054-eb82-483c-a829-8f5499cf0684" xlink:to="loc_us-gaap_FinancialInstrumentAxis_b9093b89-5a3e-4733-a6c8-7ee11039f8ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4e8d195d-4eaf-4ab1-ac38-56bb8e5141d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_b9093b89-5a3e-4733-a6c8-7ee11039f8ef" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4e8d195d-4eaf-4ab1-ac38-56bb8e5141d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_39ab17b3-3f39-4b5a-a5b1-9eb26f63f5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4e8d195d-4eaf-4ab1-ac38-56bb8e5141d1" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_39ab17b3-3f39-4b5a-a5b1-9eb26f63f5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_059c7013-f17b-4733-a234-e26145eb611a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4e8d195d-4eaf-4ab1-ac38-56bb8e5141d1" xlink:to="loc_us-gaap_ConvertibleDebtMember_059c7013-f17b-4733-a234-e26145eb611a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_ebed343f-9391-4e1a-ae35-08250b82f7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4e8d195d-4eaf-4ab1-ac38-56bb8e5141d1" xlink:to="loc_us-gaap_EquitySecuritiesMember_ebed343f-9391-4e1a-ae35-08250b82f7a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_75609d95-da85-4ae9-9c6d-e752327562e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_d9c94054-eb82-483c-a829-8f5499cf0684" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_75609d95-da85-4ae9-9c6d-e752327562e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetAssetLiabilityAbstract_79056f2e-a969-4746-acaf-09186f6685a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueNetAssetLiabilityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_75609d95-da85-4ae9-9c6d-e752327562e7" xlink:to="loc_us-gaap_FairValueNetAssetLiabilityAbstract_79056f2e-a969-4746-acaf-09186f6685a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e8cbee91-449d-4516-9459-04316d7720dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetAssetLiabilityAbstract_79056f2e-a969-4746-acaf-09186f6685a7" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e8cbee91-449d-4516-9459-04316d7720dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_93edf438-48ab-44e4-9ffe-95726fcd40d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetAssetLiabilityAbstract_79056f2e-a969-4746-acaf-09186f6685a7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_93edf438-48ab-44e4-9ffe-95726fcd40d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_84bb167b-b98b-4c68-9456-4ce7db58fd64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_93edf438-48ab-44e4-9ffe-95726fcd40d3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_84bb167b-b98b-4c68-9456-4ce7db58fd64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_InvestmentInDebtSecuritiesCurrent_f143720d-2dfe-475b-b81c-c3e69cce471a" xlink:href="bgne-20241231.xsd#bgne_InvestmentInDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_93edf438-48ab-44e4-9ffe-95726fcd40d3" xlink:to="loc_bgne_InvestmentInDebtSecuritiesCurrent_f143720d-2dfe-475b-b81c-c3e69cce471a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_ce122174-6f7e-44d9-8b6b-db0ec5c3b193" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetAssetLiabilityAbstract_79056f2e-a969-4746-acaf-09186f6685a7" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_ce122174-6f7e-44d9-8b6b-db0ec5c3b193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_a6e762be-ee8b-4ab5-ad72-18b2b64f9bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_ce122174-6f7e-44d9-8b6b-db0ec5c3b193" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_a6e762be-ee8b-4ab5-ad72-18b2b64f9bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_InvestmentInDebtSecuritiesNonCurrent_77d77c86-86bb-4615-be9a-648847b977aa" xlink:href="bgne-20241231.xsd#bgne_InvestmentInDebtSecuritiesNonCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_ce122174-6f7e-44d9-8b6b-db0ec5c3b193" xlink:to="loc_bgne_InvestmentInDebtSecuritiesNonCurrent_77d77c86-86bb-4615-be9a-648847b977aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_0b935a67-2c47-4da1-87cc-effafe627938" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetAssetLiabilityAbstract_79056f2e-a969-4746-acaf-09186f6685a7" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_0b935a67-2c47-4da1-87cc-effafe627938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_3792f0ad-7db2-44c9-ae78-bac4292a7557" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_75609d95-da85-4ae9-9c6d-e752327562e7" xlink:to="loc_us-gaap_FairValueOptionChangesInFairValueGainLoss1_3792f0ad-7db2-44c9-ae78-bac4292a7557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesGovernmentGrantsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#SummaryofSignificantAccountingPoliciesGovernmentGrantsDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesGovernmentGrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d43205ff-1130-4308-a6f6-2c987b5df1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0f64a8da-7eb5-485b-8d3e-74a495e25a88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d43205ff-1130-4308-a6f6-2c987b5df1c2" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0f64a8da-7eb5-485b-8d3e-74a495e25a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceTypeAxis_3961f4db-5a42-42f5-95bc-7d77963a0b36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0f64a8da-7eb5-485b-8d3e-74a495e25a88" xlink:to="loc_us-gaap_GovernmentAssistanceTypeAxis_3961f4db-5a42-42f5-95bc-7d77963a0b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceTypeDomain_892730ba-9301-4451-a323-0fbeabbd5c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GovernmentAssistanceTypeAxis_3961f4db-5a42-42f5-95bc-7d77963a0b36" xlink:to="loc_us-gaap_GovernmentAssistanceTypeDomain_892730ba-9301-4451-a323-0fbeabbd5c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_GovernmentAssistanceManufacturingFacilityBuildOutMember_694d7939-74c3-4661-a980-bd90b1a563c7" xlink:href="bgne-20241231.xsd#bgne_GovernmentAssistanceManufacturingFacilityBuildOutMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GovernmentAssistanceTypeDomain_892730ba-9301-4451-a323-0fbeabbd5c7e" xlink:to="loc_bgne_GovernmentAssistanceManufacturingFacilityBuildOutMember_694d7939-74c3-4661-a980-bd90b1a563c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_GovernmentAssistanceResearchAndDevelopmentProgramsMember_7d7be0d7-ac84-43d2-9022-d1ce0ffe1111" xlink:href="bgne-20241231.xsd#bgne_GovernmentAssistanceResearchAndDevelopmentProgramsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GovernmentAssistanceTypeDomain_892730ba-9301-4451-a323-0fbeabbd5c7e" xlink:to="loc_bgne_GovernmentAssistanceResearchAndDevelopmentProgramsMember_7d7be0d7-ac84-43d2-9022-d1ce0ffe1111" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a6b01b91-a808-4dab-893d-ebc760fe232e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0f64a8da-7eb5-485b-8d3e-74a495e25a88" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a6b01b91-a808-4dab-893d-ebc760fe232e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_68fde5de-5490-4b13-9f19-2606ee895f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a6b01b91-a808-4dab-893d-ebc760fe232e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_68fde5de-5490-4b13-9f19-2606ee895f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_DepreciationExpenseMember_396eb4a1-d368-4216-b0fe-32dc58330463" xlink:href="bgne-20241231.xsd#bgne_DepreciationExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_68fde5de-5490-4b13-9f19-2606ee895f1d" xlink:to="loc_bgne_DepreciationExpenseMember_396eb4a1-d368-4216-b0fe-32dc58330463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a7ee1d71-fd7c-4801-b5bd-41a18f5cb67d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0f64a8da-7eb5-485b-8d3e-74a495e25a88" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a7ee1d71-fd7c-4801-b5bd-41a18f5cb67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceAmount_3eaca663-7258-41a9-aa2a-c9a855037f56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a7ee1d71-fd7c-4801-b5bd-41a18f5cb67d" xlink:to="loc_us-gaap_GovernmentAssistanceAmount_3eaca663-7258-41a9-aa2a-c9a855037f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration_e9225b09-c126-48d1-88dd-f1b1a235b2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a7ee1d71-fd7c-4801-b5bd-41a18f5cb67d" xlink:to="loc_us-gaap_GovernmentAssistanceLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration_e9225b09-c126-48d1-88dd-f1b1a235b2ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceLiabilityNoncurrent_6c816c43-b7ff-49ef-b0e3-f3e6b5cfca37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a7ee1d71-fd7c-4801-b5bd-41a18f5cb67d" xlink:to="loc_us-gaap_GovernmentAssistanceLiabilityNoncurrent_6c816c43-b7ff-49ef-b0e3-f3e6b5cfca37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_5531c0c2-340a-41fe-92b3-a471693df68e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a7ee1d71-fd7c-4801-b5bd-41a18f5cb67d" xlink:to="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_5531c0c2-340a-41fe-92b3-a471693df68e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_53b82d10-bce3-453d-a4dd-0f63faa925dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a7ee1d71-fd7c-4801-b5bd-41a18f5cb67d" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_53b82d10-bce3-453d-a4dd-0f63faa925dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#SummaryofSignificantAccountingPoliciesSegmentInformationDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fdb9c54d-6dbb-471e-b458-1904a7d708f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_0f2dcbba-973a-4f64-9754-0059d36ac567" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fdb9c54d-6dbb-471e-b458-1904a7d708f9" xlink:to="loc_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_0f2dcbba-973a-4f64-9754-0059d36ac567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_b34eaf96-fa12-4051-9f5c-9b840e42c7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract_0f2dcbba-973a-4f64-9754-0059d36ac567" xlink:to="loc_us-gaap_NumberOfReportableSegments_b34eaf96-fa12-4051-9f5c-9b840e42c7a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesConcentrationofRisksDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#SummaryofSignificantAccountingPoliciesConcentrationofRisksDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesConcentrationofRisksDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_aacb9036-78c3-44ea-ad16-7d43f04236b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_d44e19da-32c2-49f1-bf54-51e3731ac6df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aacb9036-78c3-44ea-ad16-7d43f04236b1" xlink:to="loc_us-gaap_ConcentrationRiskTable_d44e19da-32c2-49f1-bf54-51e3731ac6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a8c9e545-3cc8-42bc-9c3f-c8ca54eac26b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_d44e19da-32c2-49f1-bf54-51e3731ac6df" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a8c9e545-3cc8-42bc-9c3f-c8ca54eac26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_aad82212-5d3d-47d2-9a66-b60363b42849" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a8c9e545-3cc8-42bc-9c3f-c8ca54eac26b" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_aad82212-5d3d-47d2-9a66-b60363b42849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_2255b19d-8e77-4847-9083-95c820bcdc21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_aad82212-5d3d-47d2-9a66-b60363b42849" xlink:to="loc_us-gaap_SalesRevenueNetMember_2255b19d-8e77-4847-9083-95c820bcdc21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_07fe1e7b-f28d-49ac-b44a-11a572c53392" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_aad82212-5d3d-47d2-9a66-b60363b42849" xlink:to="loc_us-gaap_AccountsReceivableMember_07fe1e7b-f28d-49ac-b44a-11a572c53392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_d4ae5364-9039-40da-98d7-0c264bda40cc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_d44e19da-32c2-49f1-bf54-51e3731ac6df" xlink:to="loc_srt_MajorCustomersAxis_d4ae5364-9039-40da-98d7-0c264bda40cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_3ab37dc3-565d-4fb8-a425-a06430507fe4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_d4ae5364-9039-40da-98d7-0c264bda40cc" xlink:to="loc_srt_NameOfMajorCustomerDomain_3ab37dc3-565d-4fb8-a425-a06430507fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ASDSpecialtyHealthcareMember_9e1f4d03-314c-444e-b833-e911d3c880ba" xlink:href="bgne-20241231.xsd#bgne_ASDSpecialtyHealthcareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_3ab37dc3-565d-4fb8-a425-a06430507fe4" xlink:to="loc_bgne_ASDSpecialtyHealthcareMember_9e1f4d03-314c-444e-b833-e911d3c880ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_McKessonMember_61e7e1a1-39af-4164-adcb-3f9ad8422336" xlink:href="bgne-20241231.xsd#bgne_McKessonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_3ab37dc3-565d-4fb8-a425-a06430507fe4" xlink:to="loc_bgne_McKessonMember_61e7e1a1-39af-4164-adcb-3f9ad8422336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShanghaiPharmaceuticalMember_90734010-eb85-4cac-8a51-c574e1db9891" xlink:href="bgne-20241231.xsd#bgne_ShanghaiPharmaceuticalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_3ab37dc3-565d-4fb8-a425-a06430507fe4" xlink:to="loc_bgne_ShanghaiPharmaceuticalMember_90734010-eb85-4cac-8a51-c574e1db9891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ThreeLargestCustomersMember_d3c7eb89-200b-4139-9ce9-b24c740b38fe" xlink:href="bgne-20241231.xsd#bgne_ThreeLargestCustomersMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_3ab37dc3-565d-4fb8-a425-a06430507fe4" xlink:to="loc_bgne_ThreeLargestCustomersMember_d3c7eb89-200b-4139-9ce9-b24c740b38fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_SinopharmMember_adc64ec9-aabe-4ed6-affa-9a1020daadda" xlink:href="bgne-20241231.xsd#bgne_SinopharmMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_3ab37dc3-565d-4fb8-a425-a06430507fe4" xlink:to="loc_bgne_SinopharmMember_adc64ec9-aabe-4ed6-affa-9a1020daadda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ChinaResourcesMember_706ef4ad-ebef-478f-994e-e3a8c7c94446" xlink:href="bgne-20241231.xsd#bgne_ChinaResourcesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_3ab37dc3-565d-4fb8-a425-a06430507fe4" xlink:to="loc_bgne_ChinaResourcesMember_706ef4ad-ebef-478f-994e-e3a8c7c94446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_FourLargestCustomersMember_2bf749b6-866b-4975-a36e-97afd87ef429" xlink:href="bgne-20241231.xsd#bgne_FourLargestCustomersMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_3ab37dc3-565d-4fb8-a425-a06430507fe4" xlink:to="loc_bgne_FourLargestCustomersMember_2bf749b6-866b-4975-a36e-97afd87ef429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_357210c8-e91c-49e0-a34e-25cb6b62bb29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_d44e19da-32c2-49f1-bf54-51e3731ac6df" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_357210c8-e91c-49e0-a34e-25cb6b62bb29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_36342f2b-aa18-47b6-8ae9-c01dab9b9231" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_357210c8-e91c-49e0-a34e-25cb6b62bb29" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_36342f2b-aa18-47b6-8ae9-c01dab9b9231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_467755ad-dda8-4156-a3c4-b1fa3271a860" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_36342f2b-aa18-47b6-8ae9-c01dab9b9231" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_467755ad-dda8-4156-a3c4-b1fa3271a860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_9fdbe1e2-1f96-4430-8369-f9ae545e7091" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_d44e19da-32c2-49f1-bf54-51e3731ac6df" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_9fdbe1e2-1f96-4430-8369-f9ae545e7091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_297b0a62-35a3-443b-a782-3b9fdc6872db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9fdbe1e2-1f96-4430-8369-f9ae545e7091" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_297b0a62-35a3-443b-a782-3b9fdc6872db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_eb7f4115-400b-4b70-bf9f-712bd9f95ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9fdbe1e2-1f96-4430-8369-f9ae545e7091" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_eb7f4115-400b-4b70-bf9f-712bd9f95ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_3867c463-563a-43a3-a1de-ebf93323f4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9fdbe1e2-1f96-4430-8369-f9ae545e7091" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_3867c463-563a-43a3-a1de-ebf93323f4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/CollaborativeandLicensingArrangementsRecognizedRevenueDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#CollaborativeandLicensingArrangementsRecognizedRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/CollaborativeandLicensingArrangementsRecognizedRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_87c1c5f4-2790-4bfa-9cea-11fdd2747e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_c9d47afd-cdb7-4a23-b824-52fdee6c807c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_87c1c5f4-2790-4bfa-9cea-11fdd2747e4e" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_c9d47afd-cdb7-4a23-b824-52fdee6c807c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_8f2ed051-ccb1-4f1c-a666-2582b5f237ad" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_c9d47afd-cdb7-4a23-b824-52fdee6c807c" xlink:to="loc_srt_ProductOrServiceAxis_8f2ed051-ccb1-4f1c-a666-2582b5f237ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f65662d5-6f69-4954-8756-8904284ca426" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8f2ed051-ccb1-4f1c-a666-2582b5f237ad" xlink:to="loc_srt_ProductsAndServicesDomain_f65662d5-6f69-4954-8756-8904284ca426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_CollaborationMember_136b44d3-c109-4485-a155-c3f0e363acb6" xlink:href="bgne-20241231.xsd#bgne_CollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f65662d5-6f69-4954-8756-8904284ca426" xlink:to="loc_bgne_CollaborationMember_136b44d3-c109-4485-a155-c3f0e363acb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_CollaborationResearchAndDevelopmentServiceMember_1069249f-f851-40e9-9cd4-636d42601de9" xlink:href="bgne-20241231.xsd#bgne_CollaborationResearchAndDevelopmentServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_CollaborationMember_136b44d3-c109-4485-a155-c3f0e363acb6" xlink:to="loc_bgne_CollaborationResearchAndDevelopmentServiceMember_1069249f-f851-40e9-9cd4-636d42601de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RightToAccessIntellectualPropertyRevenueMember_7e671c1e-27d8-443d-a025-4a2d88e37d11" xlink:href="bgne-20241231.xsd#bgne_RightToAccessIntellectualPropertyRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_CollaborationMember_136b44d3-c109-4485-a155-c3f0e363acb6" xlink:to="loc_bgne_RightToAccessIntellectualPropertyRevenueMember_7e671c1e-27d8-443d-a025-4a2d88e37d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_MaterialRightsRevenueMember_3b7b893f-e8dc-433b-a927-27db1d6347db" xlink:href="bgne-20241231.xsd#bgne_MaterialRightsRevenueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_CollaborationMember_136b44d3-c109-4485-a155-c3f0e363acb6" xlink:to="loc_bgne_MaterialRightsRevenueMember_3b7b893f-e8dc-433b-a927-27db1d6347db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_CollaborationOtherMember_6e543a41-08ac-4173-aa1b-b3dddbe73760" xlink:href="bgne-20241231.xsd#bgne_CollaborationOtherMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_CollaborationMember_136b44d3-c109-4485-a155-c3f0e363acb6" xlink:to="loc_bgne_CollaborationOtherMember_6e543a41-08ac-4173-aa1b-b3dddbe73760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d2ce94a8-a0ea-4e18-917a-5220191186d8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_c9d47afd-cdb7-4a23-b824-52fdee6c807c" xlink:to="loc_srt_CounterpartyNameAxis_d2ce94a8-a0ea-4e18-917a-5220191186d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf3bd66b-6955-46bf-8d24-eaf571ef435d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d2ce94a8-a0ea-4e18-917a-5220191186d8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf3bd66b-6955-46bf-8d24-eaf571ef435d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_NovartisMember_febd7b35-0b64-4dde-9d86-97a0d5c3c01e" xlink:href="bgne-20241231.xsd#bgne_NovartisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf3bd66b-6955-46bf-8d24-eaf571ef435d" xlink:to="loc_bgne_NovartisMember_febd7b35-0b64-4dde-9d86-97a0d5c3c01e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_TislelizumabMember_8c921694-f1b5-442a-b9b7-8c2fd8011b11" xlink:href="bgne-20241231.xsd#bgne_TislelizumabMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf3bd66b-6955-46bf-8d24-eaf571ef435d" xlink:to="loc_bgne_TislelizumabMember_8c921694-f1b5-442a-b9b7-8c2fd8011b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_OciperlimabMember_48bc0891-abce-42d2-a1be-70d4704f59f4" xlink:href="bgne-20241231.xsd#bgne_OciperlimabMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_cf3bd66b-6955-46bf-8d24-eaf571ef435d" xlink:to="loc_bgne_OciperlimabMember_48bc0891-abce-42d2-a1be-70d4704f59f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_aded5866-e472-4d93-b5aa-1e083be904f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_c9d47afd-cdb7-4a23-b824-52fdee6c807c" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_aded5866-e472-4d93-b5aa-1e083be904f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_e9554c45-c65f-42a3-9c6c-778f55eb1558" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_aded5866-e472-4d93-b5aa-1e083be904f5" xlink:to="loc_us-gaap_RevenuesAbstract_e9554c45-c65f-42a3-9c6c-778f55eb1558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_db982ce1-63e2-4412-88b4-ad2a489b0f73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_e9554c45-c65f-42a3-9c6c-778f55eb1558" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_db982ce1-63e2-4412-88b4-ad2a489b0f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/CollaborativeandLicensingArrangementsNovartisDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#CollaborativeandLicensingArrangementsNovartisDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/CollaborativeandLicensingArrangementsNovartisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_dd9bb58a-8038-4164-90fa-a2f807db28bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_76c2cda2-3dd2-4dc3-8162-5a3fb9be74c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_dd9bb58a-8038-4164-90fa-a2f807db28bc" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_76c2cda2-3dd2-4dc3-8162-5a3fb9be74c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d8a203bf-efba-4717-99f4-1b2fc448df79" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_76c2cda2-3dd2-4dc3-8162-5a3fb9be74c3" xlink:to="loc_srt_CounterpartyNameAxis_d8a203bf-efba-4717-99f4-1b2fc448df79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_85e392e4-e863-42b1-a7b7-802b457ca62d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d8a203bf-efba-4717-99f4-1b2fc448df79" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_85e392e4-e863-42b1-a7b7-802b457ca62d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_NovartisMember_2a466124-f063-409b-b5d6-a2d7787fc5b5" xlink:href="bgne-20241231.xsd#bgne_NovartisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_85e392e4-e863-42b1-a7b7-802b457ca62d" xlink:to="loc_bgne_NovartisMember_2a466124-f063-409b-b5d6-a2d7787fc5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_10c78c8a-20b0-4f0f-89bf-05778b8e6834" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_76c2cda2-3dd2-4dc3-8162-5a3fb9be74c3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_10c78c8a-20b0-4f0f-89bf-05778b8e6834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd9062f1-9da6-40ca-91fa-3137d7e832dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_10c78c8a-20b0-4f0f-89bf-05778b8e6834" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd9062f1-9da6-40ca-91fa-3137d7e832dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_4e1918cd-9f55-474e-b58b-38d23c7f7f79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd9062f1-9da6-40ca-91fa-3137d7e832dd" xlink:to="loc_us-gaap_CollaborativeArrangementMember_4e1918cd-9f55-474e-b58b-38d23c7f7f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_260f31a0-f0ff-43e9-9863-d161df00c971" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_76c2cda2-3dd2-4dc3-8162-5a3fb9be74c3" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_260f31a0-f0ff-43e9-9863-d161df00c971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_f6612db8-4979-4517-a325-5436a995fcb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_260f31a0-f0ff-43e9-9863-d161df00c971" xlink:to="loc_us-gaap_ContractWithCustomerLiability_f6612db8-4979-4517-a325-5436a995fcb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/CollaborativeandLicensingArrangementsOciperlimabOptionCollaborationandLicenseAgreementandChinaBroadMarketDevelopmentAgreementDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#CollaborativeandLicensingArrangementsOciperlimabOptionCollaborationandLicenseAgreementandChinaBroadMarketDevelopmentAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/CollaborativeandLicensingArrangementsOciperlimabOptionCollaborationandLicenseAgreementandChinaBroadMarketDevelopmentAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_bc1af24b-a192-4d07-b295-11e891d6a3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1dc658ce-2466-463b-8f58-27e352b13f20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_bc1af24b-a192-4d07-b295-11e891d6a3ab" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1dc658ce-2466-463b-8f58-27e352b13f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9b1f4d5e-ac7f-4019-8f26-398e365936d2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1dc658ce-2466-463b-8f58-27e352b13f20" xlink:to="loc_srt_CounterpartyNameAxis_9b1f4d5e-ac7f-4019-8f26-398e365936d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8fdb8d47-b7ff-47de-9c43-3cd3664afe21" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_9b1f4d5e-ac7f-4019-8f26-398e365936d2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8fdb8d47-b7ff-47de-9c43-3cd3664afe21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_NovartisMember_9e828236-5cb3-40e6-a556-cd3a40d565ba" xlink:href="bgne-20241231.xsd#bgne_NovartisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8fdb8d47-b7ff-47de-9c43-3cd3664afe21" xlink:to="loc_bgne_NovartisMember_9e828236-5cb3-40e6-a556-cd3a40d565ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4f88a485-30be-4cd0-b2cd-ecc5155e66f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1dc658ce-2466-463b-8f58-27e352b13f20" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4f88a485-30be-4cd0-b2cd-ecc5155e66f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0ef94151-fbd7-498c-a786-0be258aba3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4f88a485-30be-4cd0-b2cd-ecc5155e66f9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0ef94151-fbd7-498c-a786-0be258aba3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_9f03600f-5d16-4046-97d6-70fd113c4269" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0ef94151-fbd7-498c-a786-0be258aba3d3" xlink:to="loc_us-gaap_CollaborativeArrangementMember_9f03600f-5d16-4046-97d6-70fd113c4269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_37424d5b-f570-4670-81f2-6b64ecbbf1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1dc658ce-2466-463b-8f58-27e352b13f20" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_37424d5b-f570-4670-81f2-6b64ecbbf1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_NumberOfProductsInitiatedMarketingAndPromotion_7b1b4eb3-8355-4a79-9237-7d00eea99ddc" xlink:href="bgne-20241231.xsd#bgne_NumberOfProductsInitiatedMarketingAndPromotion"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_37424d5b-f570-4670-81f2-6b64ecbbf1a4" xlink:to="loc_bgne_NumberOfProductsInitiatedMarketingAndPromotion_7b1b4eb3-8355-4a79-9237-7d00eea99ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_5bd5ffca-1015-45a6-ac85-f461008a3ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_37424d5b-f570-4670-81f2-6b64ecbbf1a4" xlink:to="loc_us-gaap_ContractWithCustomerLiability_5bd5ffca-1015-45a6-ac85-f461008a3ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#CollaborativeandLicensingArrangementsAmgenDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_d3a025d2-4e58-41d8-8541-82c6952601db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5e22669c-f51a-4868-9af9-1433f4460c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_d3a025d2-4e58-41d8-8541-82c6952601db" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5e22669c-f51a-4868-9af9-1433f4460c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_091fb1cf-e082-4fb7-8fb6-c1d8fd26ab0f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5e22669c-f51a-4868-9af9-1433f4460c2f" xlink:to="loc_srt_CounterpartyNameAxis_091fb1cf-e082-4fb7-8fb6-c1d8fd26ab0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f8356671-b5b7-48a6-9888-243481cd5cb3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_091fb1cf-e082-4fb7-8fb6-c1d8fd26ab0f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f8356671-b5b7-48a6-9888-243481cd5cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AmgenIncMember_5eb6c569-0cc4-4a26-932d-d8c2b3bac286" xlink:href="bgne-20241231.xsd#bgne_AmgenIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f8356671-b5b7-48a6-9888-243481cd5cb3" xlink:to="loc_bgne_AmgenIncMember_5eb6c569-0cc4-4a26-932d-d8c2b3bac286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_90e61995-431d-41e3-89a7-4f0084c1088a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5e22669c-f51a-4868-9af9-1433f4460c2f" xlink:to="loc_srt_RangeAxis_90e61995-431d-41e3-89a7-4f0084c1088a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1918b3c3-6e71-40ec-aafa-3dcef973e2c6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_90e61995-431d-41e3-89a7-4f0084c1088a" xlink:to="loc_srt_RangeMember_1918b3c3-6e71-40ec-aafa-3dcef973e2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8464a8e7-4a7a-4fde-841e-f9da0eb782c3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1918b3c3-6e71-40ec-aafa-3dcef973e2c6" xlink:to="loc_srt_MinimumMember_8464a8e7-4a7a-4fde-841e-f9da0eb782c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e9408f77-f006-48a8-8710-624492b6ec6c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1918b3c3-6e71-40ec-aafa-3dcef973e2c6" xlink:to="loc_srt_MaximumMember_e9408f77-f006-48a8-8710-624492b6ec6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d2c90f62-5031-43a1-a265-705ab841e223" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5e22669c-f51a-4868-9af9-1433f4460c2f" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d2c90f62-5031-43a1-a265-705ab841e223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ccfb263c-a754-4ca0-8830-3864250b883c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d2c90f62-5031-43a1-a265-705ab841e223" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ccfb263c-a754-4ca0-8830-3864250b883c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_4070e956-3330-4643-8961-efdeaecb7e97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ccfb263c-a754-4ca0-8830-3864250b883c" xlink:to="loc_us-gaap_SalesRevenueNetMember_4070e956-3330-4643-8961-efdeaecb7e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_075d7afb-5e40-44b2-a6b5-6b51f9d0f1eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5e22669c-f51a-4868-9af9-1433f4460c2f" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_075d7afb-5e40-44b2-a6b5-6b51f9d0f1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_9e075823-511f-4f1e-a73d-62fe01b187e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_075d7afb-5e40-44b2-a6b5-6b51f9d0f1eb" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_9e075823-511f-4f1e-a73d-62fe01b187e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_fc4cf879-44bb-429d-9c4f-0d464cd5f6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_9e075823-511f-4f1e-a73d-62fe01b187e6" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_fc4cf879-44bb-429d-9c4f-0d464cd5f6b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_154c4429-fb96-422d-9561-161dc398a1f2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5e22669c-f51a-4868-9af9-1433f4460c2f" xlink:to="loc_dei_LegalEntityAxis_154c4429-fb96-422d-9561-161dc398a1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e0f5cfc6-c3cb-432d-adec-e056847cd39e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_154c4429-fb96-422d-9561-161dc398a1f2" xlink:to="loc_dei_EntityDomain_e0f5cfc6-c3cb-432d-adec-e056847cd39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AmgenIncMember_4d9a1c29-7fdb-4dfe-a627-77fc7e0682a8" xlink:href="bgne-20241231.xsd#bgne_AmgenIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e0f5cfc6-c3cb-432d-adec-e056847cd39e" xlink:to="loc_bgne_AmgenIncMember_4d9a1c29-7fdb-4dfe-a627-77fc7e0682a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_c8a4f01a-fae8-444e-8a55-3f8625ad791c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5e22669c-f51a-4868-9af9-1433f4460c2f" xlink:to="loc_srt_OwnershipAxis_c8a4f01a-fae8-444e-8a55-3f8625ad791c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_fb048b27-6b1f-4c8e-897f-af805fcc26d2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_c8a4f01a-fae8-444e-8a55-3f8625ad791c" xlink:to="loc_srt_OwnershipDomain_fb048b27-6b1f-4c8e-897f-af805fcc26d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_BeigeneLtdMember_b7c94638-f260-4b0a-9946-d5dc9f62e0c4" xlink:href="bgne-20241231.xsd#bgne_BeigeneLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_fb048b27-6b1f-4c8e-897f-af805fcc26d2" xlink:to="loc_bgne_BeigeneLtdMember_b7c94638-f260-4b0a-9946-d5dc9f62e0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_185c3e4e-6cd2-45d9-aad0-16179a2e52f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5e22669c-f51a-4868-9af9-1433f4460c2f" xlink:to="loc_us-gaap_StatementClassOfStockAxis_185c3e4e-6cd2-45d9-aad0-16179a2e52f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_81717194-b698-42d1-a2b1-4ab18cb1b8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_185c3e4e-6cd2-45d9-aad0-16179a2e52f8" xlink:to="loc_us-gaap_ClassOfStockDomain_81717194-b698-42d1-a2b1-4ab18cb1b8d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2a8cd247-0159-4ef2-a3b1-aed1e8224c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_81717194-b698-42d1-a2b1-4ab18cb1b8d2" xlink:to="loc_us-gaap_CommonStockMember_2a8cd247-0159-4ef2-a3b1-aed1e8224c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6565941d-159b-49ae-81a1-0439e612a83c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_5e22669c-f51a-4868-9af9-1433f4460c2f" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6565941d-159b-49ae-81a1-0439e612a83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_CommercializationTerm_a8bf37eb-14ad-4560-99be-cd2546c67a50" xlink:href="bgne-20241231.xsd#bgne_CommercializationTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6565941d-159b-49ae-81a1-0439e612a83c" xlink:to="loc_bgne_CommercializationTerm_a8bf37eb-14ad-4560-99be-cd2546c67a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_CollaborativeArrangementsNumberOfProductsCompanyHasTheRightToRetain_b2052de4-baaa-4d82-8fc7-e05638afe353" xlink:href="bgne-20241231.xsd#bgne_CollaborativeArrangementsNumberOfProductsCompanyHasTheRightToRetain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6565941d-159b-49ae-81a1-0439e612a83c" xlink:to="loc_bgne_CollaborativeArrangementsNumberOfProductsCompanyHasTheRightToRetain_b2052de4-baaa-4d82-8fc7-e05638afe353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_CollaborativeArrangementsProductRetentionPeriod_0536e4b3-71fe-4d7b-aba8-821add233e35" xlink:href="bgne-20241231.xsd#bgne_CollaborativeArrangementsProductRetentionPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6565941d-159b-49ae-81a1-0439e612a83c" xlink:to="loc_bgne_CollaborativeArrangementsProductRetentionPeriod_0536e4b3-71fe-4d7b-aba8-821add233e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_MaximumCashAndServicesDevelopmentCommitment_dd4152d0-7073-45d7-9e3e-4ebac13b220d" xlink:href="bgne-20241231.xsd#bgne_MaximumCashAndServicesDevelopmentCommitment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6565941d-159b-49ae-81a1-0439e612a83c" xlink:to="loc_bgne_MaximumCashAndServicesDevelopmentCommitment_dd4152d0-7073-45d7-9e3e-4ebac13b220d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_e2a424a3-1a04-4d62-ad91-372dc0f76fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6565941d-159b-49ae-81a1-0439e612a83c" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_e2a424a3-1a04-4d62-ad91-372dc0f76fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f5d871a1-365e-47d5-98b3-c7f0e229390b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6565941d-159b-49ae-81a1-0439e612a83c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_f5d871a1-365e-47d5-98b3-c7f0e229390b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_f2363b5e-2c0f-44d5-b0e1-12de5a18626e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6565941d-159b-49ae-81a1-0439e612a83c" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_f2363b5e-2c0f-44d5-b0e1-12de5a18626e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_cce7a6e8-545e-4024-bb89-4ef407103072" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6565941d-159b-49ae-81a1-0439e612a83c" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_cce7a6e8-545e-4024-bb89-4ef407103072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_SharePriceAmericanDepositoryShares_55a790ce-ac89-48dc-8706-cb0d78a8e86e" xlink:href="bgne-20241231.xsd#bgne_SharePriceAmericanDepositoryShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6565941d-159b-49ae-81a1-0439e612a83c" xlink:to="loc_bgne_SharePriceAmericanDepositoryShares_55a790ce-ac89-48dc-8706-cb0d78a8e86e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ProceedsFromIssuanceOfAssetDepositoryShares_8e930cd0-f34c-46a5-a5b2-012df6e0fb9d" xlink:href="bgne-20241231.xsd#bgne_ProceedsFromIssuanceOfAssetDepositoryShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6565941d-159b-49ae-81a1-0439e612a83c" xlink:to="loc_bgne_ProceedsFromIssuanceOfAssetDepositoryShares_8e930cd0-f34c-46a5-a5b2-012df6e0fb9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_FairValueOfLiabilityAcquired_2ef5ad8a-063e-451f-9ec3-ec972e47dd60" xlink:href="bgne-20241231.xsd#bgne_FairValueOfLiabilityAcquired"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6565941d-159b-49ae-81a1-0439e612a83c" xlink:to="loc_bgne_FairValueOfLiabilityAcquired_2ef5ad8a-063e-451f-9ec3-ec972e47dd60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5dbce81a-2aa2-4c8b-8db4-02c1d9e4b768" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6565941d-159b-49ae-81a1-0439e612a83c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5dbce81a-2aa2-4c8b-8db4-02c1d9e4b768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_FairValueOfEquityInvestmentsIssued_28500e33-46fa-4acd-8f92-01bdd353e48d" xlink:href="bgne-20241231.xsd#bgne_FairValueOfEquityInvestmentsIssued"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6565941d-159b-49ae-81a1-0439e612a83c" xlink:to="loc_bgne_FairValueOfEquityInvestmentsIssued_28500e33-46fa-4acd-8f92-01bdd353e48d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_FairValueOfFinancingCommitment_7b8b7ff1-0ec6-411b-a13f-dce7844dc5cf" xlink:href="bgne-20241231.xsd#bgne_FairValueOfFinancingCommitment"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6565941d-159b-49ae-81a1-0439e612a83c" xlink:to="loc_bgne_FairValueOfFinancingCommitment_7b8b7ff1-0ec6-411b-a13f-dce7844dc5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RoyaltiesReceivingPeriod_41b2273e-b8b8-49ff-9566-884520567938" xlink:href="bgne-20241231.xsd#bgne_RoyaltiesReceivingPeriod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_6565941d-159b-49ae-81a1-0439e612a83c" xlink:to="loc_bgne_RoyaltiesReceivingPeriod_41b2273e-b8b8-49ff-9566-884520567938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/CollaborativeandLicensingArrangementsFundingExpensesDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#CollaborativeandLicensingArrangementsFundingExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/CollaborativeandLicensingArrangementsFundingExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_1f2ec3b2-4f82-4224-b6fd-c638794eaa50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_01774a39-fad0-4af8-84f0-9308254fcb2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_1f2ec3b2-4f82-4224-b6fd-c638794eaa50" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_01774a39-fad0-4af8-84f0-9308254fcb2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_98e4cde7-6145-414b-8143-ec4e6cbc9697" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_01774a39-fad0-4af8-84f0-9308254fcb2d" xlink:to="loc_srt_CounterpartyNameAxis_98e4cde7-6145-414b-8143-ec4e6cbc9697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9dba0c5f-f515-4da0-84fb-8aa2c0893b17" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_98e4cde7-6145-414b-8143-ec4e6cbc9697" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9dba0c5f-f515-4da0-84fb-8aa2c0893b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AmgenIncMember_0401b145-db7e-46f7-9cfe-47728e437061" xlink:href="bgne-20241231.xsd#bgne_AmgenIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9dba0c5f-f515-4da0-84fb-8aa2c0893b17" xlink:to="loc_bgne_AmgenIncMember_0401b145-db7e-46f7-9cfe-47728e437061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d6a6b9ae-e4f0-4e25-9242-a9f57cd7bcef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_01774a39-fad0-4af8-84f0-9308254fcb2d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d6a6b9ae-e4f0-4e25-9242-a9f57cd7bcef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_FinancingCommitmentExpenses_07de0488-5f67-429f-bcbc-d6aeec33cc54" xlink:href="bgne-20241231.xsd#bgne_FinancingCommitmentExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d6a6b9ae-e4f0-4e25-9242-a9f57cd7bcef" xlink:to="loc_bgne_FinancingCommitmentExpenses_07de0488-5f67-429f-bcbc-d6aeec33cc54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AmortizationOfFinancingCommitment_369f2a0c-1d90-4b66-9b8c-fbf7e0e50e17" xlink:href="bgne-20241231.xsd#bgne_AmortizationOfFinancingCommitment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d6a6b9ae-e4f0-4e25-9242-a9f57cd7bcef" xlink:to="loc_bgne_AmortizationOfFinancingCommitment_369f2a0c-1d90-4b66-9b8c-fbf7e0e50e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_454d47de-c237-4533-984f-805f7ed6c366" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d6a6b9ae-e4f0-4e25-9242-a9f57cd7bcef" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_454d47de-c237-4533-984f-805f7ed6c366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_974d60c6-11eb-44ca-a395-67efdf4cb961" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_d6a6b9ae-e4f0-4e25-9242-a9f57cd7bcef" xlink:to="loc_us-gaap_OtherCommitment_974d60c6-11eb-44ca-a395-67efdf4cb961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/CollaborativeandLicensingArrangementsFinancingLiabilityDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#CollaborativeandLicensingArrangementsFinancingLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/CollaborativeandLicensingArrangementsFinancingLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_396ccd5e-198c-496b-afae-c2a28288fa26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_19eb7c92-d943-4786-8893-fed615b72945" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_396ccd5e-198c-496b-afae-c2a28288fa26" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_19eb7c92-d943-4786-8893-fed615b72945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_13739990-4142-499e-806d-37f9c3004921" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_19eb7c92-d943-4786-8893-fed615b72945" xlink:to="loc_srt_CounterpartyNameAxis_13739990-4142-499e-806d-37f9c3004921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fcc0db2c-32b6-4318-b961-10b5037b5d66" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_13739990-4142-499e-806d-37f9c3004921" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fcc0db2c-32b6-4318-b961-10b5037b5d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AmgenIncMember_7518f282-a78d-473e-af3f-d6de50374d76" xlink:href="bgne-20241231.xsd#bgne_AmgenIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fcc0db2c-32b6-4318-b961-10b5037b5d66" xlink:to="loc_bgne_AmgenIncMember_7518f282-a78d-473e-af3f-d6de50374d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_bd815e25-e4be-449f-b45b-2be8d06826ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_19eb7c92-d943-4786-8893-fed615b72945" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_bd815e25-e4be-449f-b45b-2be8d06826ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_FinancingCommitmentCarryingValueCurrent_4e8dfd43-3687-43c4-b0e5-e0693a8c66fb" xlink:href="bgne-20241231.xsd#bgne_FinancingCommitmentCarryingValueCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_bd815e25-e4be-449f-b45b-2be8d06826ea" xlink:to="loc_bgne_FinancingCommitmentCarryingValueCurrent_4e8dfd43-3687-43c4-b0e5-e0693a8c66fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_FinancingCommitmentCarryingValueNoncurrent_c0381042-ef2c-4ef0-8696-b67816370d8d" xlink:href="bgne-20241231.xsd#bgne_FinancingCommitmentCarryingValueNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_bd815e25-e4be-449f-b45b-2be8d06826ea" xlink:to="loc_bgne_FinancingCommitmentCarryingValueNoncurrent_c0381042-ef2c-4ef0-8696-b67816370d8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_FinancingCommitmentCarryingValue_ac64d3d5-2dac-4991-a307-2b1004592d94" xlink:href="bgne-20241231.xsd#bgne_FinancingCommitmentCarryingValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_bd815e25-e4be-449f-b45b-2be8d06826ea" xlink:to="loc_bgne_FinancingCommitmentCarryingValue_ac64d3d5-2dac-4991-a307-2b1004592d94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmountsandClassificationofPaymentsIncomeExpenseDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#CollaborativeandLicensingArrangementsAmountsandClassificationofPaymentsIncomeExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmountsandClassificationofPaymentsIncomeExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_dbbe2a46-7e62-4ba0-88dd-85b48beacf5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_aa293f40-f8a7-4c31-b5f6-7f35864d74ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_dbbe2a46-7e62-4ba0-88dd-85b48beacf5c" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_aa293f40-f8a7-4c31-b5f6-7f35864d74ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6b869935-a4ed-43fa-b2f2-3cc03febfa5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_aa293f40-f8a7-4c31-b5f6-7f35864d74ca" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6b869935-a4ed-43fa-b2f2-3cc03febfa5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_415cce6f-22ee-4afe-9813-ed223bfa2135" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6b869935-a4ed-43fa-b2f2-3cc03febfa5e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_415cce6f-22ee-4afe-9813-ed223bfa2135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_5ba57ea4-abf4-4946-b566-41e9e167b534" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_415cce6f-22ee-4afe-9813-ed223bfa2135" xlink:to="loc_us-gaap_CostOfSalesMember_5ba57ea4-abf4-4946-b566-41e9e167b534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1aa7e853-e79b-433c-8027-320eb62ded3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_415cce6f-22ee-4afe-9813-ed223bfa2135" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1aa7e853-e79b-433c-8027-320eb62ded3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_22eb9387-02cf-45f6-92a9-1ba0b7011695" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_415cce6f-22ee-4afe-9813-ed223bfa2135" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_22eb9387-02cf-45f6-92a9-1ba0b7011695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b32a47e7-76a8-4664-a76d-019dd9a53095" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_aa293f40-f8a7-4c31-b5f6-7f35864d74ca" xlink:to="loc_srt_CounterpartyNameAxis_b32a47e7-76a8-4664-a76d-019dd9a53095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_27daefe3-9eba-4ced-8ca2-13bcfd753846" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_b32a47e7-76a8-4664-a76d-019dd9a53095" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_27daefe3-9eba-4ced-8ca2-13bcfd753846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AmgenIncMember_2071ccd7-68f6-459a-8d01-fced2ce23e67" xlink:href="bgne-20241231.xsd#bgne_AmgenIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_27daefe3-9eba-4ced-8ca2-13bcfd753846" xlink:to="loc_bgne_AmgenIncMember_2071ccd7-68f6-459a-8d01-fced2ce23e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_190be5da-4349-4980-b994-b3363d224c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_aa293f40-f8a7-4c31-b5f6-7f35864d74ca" xlink:to="loc_us-gaap_TypeOfArrangementAxis_190be5da-4349-4980-b994-b3363d224c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c46bd19e-1777-4f35-b715-2d0b3473383a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_190be5da-4349-4980-b994-b3363d224c5e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c46bd19e-1777-4f35-b715-2d0b3473383a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_081fc47b-2627-4445-8f48-62e29c70fda0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c46bd19e-1777-4f35-b715-2d0b3473383a" xlink:to="loc_us-gaap_CollaborativeArrangementMember_081fc47b-2627-4445-8f48-62e29c70fda0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6af0c21e-9dad-4317-906f-187d55391f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_aa293f40-f8a7-4c31-b5f6-7f35864d74ca" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6af0c21e-9dad-4317-906f-187d55391f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_cfe3fe4a-2038-40b2-97a0-08421ba19d95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6af0c21e-9dad-4317-906f-187d55391f6e" xlink:to="loc_us-gaap_RelatedPartyDomain_cfe3fe4a-2038-40b2-97a0-08421ba19d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_d587e337-de9c-49a1-b15b-cb5bcdbd542e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_cfe3fe4a-2038-40b2-97a0-08421ba19d95" xlink:to="loc_us-gaap_RelatedPartyMember_d587e337-de9c-49a1-b15b-cb5bcdbd542e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39509f78-1700-4508-ae90-03d1be407221" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_aa293f40-f8a7-4c31-b5f6-7f35864d74ca" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39509f78-1700-4508-ae90-03d1be407221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ReimbursementExpense_e24325ab-c2e6-4960-89cf-b43e52432d1a" xlink:href="bgne-20241231.xsd#bgne_ReimbursementExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39509f78-1700-4508-ae90-03d1be407221" xlink:to="loc_bgne_ReimbursementExpense_e24325ab-c2e6-4960-89cf-b43e52432d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_f3e4e4f2-8eb6-4f88-9b18-17a568e4d8da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39509f78-1700-4508-ae90-03d1be407221" xlink:to="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_f3e4e4f2-8eb6-4f88-9b18-17a568e4d8da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_e3e901aa-3207-4dc3-949a-c9cceffb957d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39509f78-1700-4508-ae90-03d1be407221" xlink:to="loc_us-gaap_AccountsPayableCurrent_e3e901aa-3207-4dc3-949a-c9cceffb957d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/CollaborativeandLicensingArrangementsPaymentClassificationDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#CollaborativeandLicensingArrangementsPaymentClassificationDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/CollaborativeandLicensingArrangementsPaymentClassificationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentAbstract_a63cb1d1-9497-4a9b-8c0d-1e0c3e32d9ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b4abbf83-dd44-4624-8390-8424bd79de6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentAbstract_a63cb1d1-9497-4a9b-8c0d-1e0c3e32d9ba" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b4abbf83-dd44-4624-8390-8424bd79de6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_CollaborativeArrangementCompensationTypeAxis_ee31630e-185e-4441-bfdd-3fc132d7b2c4" xlink:href="bgne-20241231.xsd#bgne_CollaborativeArrangementCompensationTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b4abbf83-dd44-4624-8390-8424bd79de6d" xlink:to="loc_bgne_CollaborativeArrangementCompensationTypeAxis_ee31630e-185e-4441-bfdd-3fc132d7b2c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_CollaborativeArrangementCompensationTypeDomain_50829dd7-7972-40bf-9e41-2e5061faab9a" xlink:href="bgne-20241231.xsd#bgne_CollaborativeArrangementCompensationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_CollaborativeArrangementCompensationTypeAxis_ee31630e-185e-4441-bfdd-3fc132d7b2c4" xlink:to="loc_bgne_CollaborativeArrangementCompensationTypeDomain_50829dd7-7972-40bf-9e41-2e5061faab9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_UpfrontPaymentsMember_37c7dd0a-f775-4006-9dab-178b1c6068d8" xlink:href="bgne-20241231.xsd#bgne_UpfrontPaymentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_CollaborativeArrangementCompensationTypeDomain_50829dd7-7972-40bf-9e41-2e5061faab9a" xlink:to="loc_bgne_UpfrontPaymentsMember_37c7dd0a-f775-4006-9dab-178b1c6068d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_DevelopmentMilestonePaymentsMember_7b573aa2-8a55-4493-91ec-90726c34dde9" xlink:href="bgne-20241231.xsd#bgne_DevelopmentMilestonePaymentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_CollaborativeArrangementCompensationTypeDomain_50829dd7-7972-40bf-9e41-2e5061faab9a" xlink:to="loc_bgne_DevelopmentMilestonePaymentsMember_7b573aa2-8a55-4493-91ec-90726c34dde9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RegulatoryAndCommercialMilestonePaymentsMember_02b4c580-15c3-44e3-965c-561afd2238d5" xlink:href="bgne-20241231.xsd#bgne_RegulatoryAndCommercialMilestonePaymentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_CollaborativeArrangementCompensationTypeDomain_50829dd7-7972-40bf-9e41-2e5061faab9a" xlink:to="loc_bgne_RegulatoryAndCommercialMilestonePaymentsMember_02b4c580-15c3-44e3-965c-561afd2238d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d78c9938-c8a2-44c3-9d8a-db4f7c68d933" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b4abbf83-dd44-4624-8390-8424bd79de6d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d78c9938-c8a2-44c3-9d8a-db4f7c68d933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6e465880-1473-4ece-9881-ddde2e0564b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d78c9938-c8a2-44c3-9d8a-db4f7c68d933" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6e465880-1473-4ece-9881-ddde2e0564b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ResearchAndDevelopmentMember_77ae5933-80b2-4e38-9f5b-518ccd8890b1" xlink:href="bgne-20241231.xsd#bgne_ResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6e465880-1473-4ece-9881-ddde2e0564b0" xlink:to="loc_bgne_ResearchAndDevelopmentMember_77ae5933-80b2-4e38-9f5b-518ccd8890b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_a54b5af7-1e47-424a-ab29-e0c0ae3a97dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b4abbf83-dd44-4624-8390-8424bd79de6d" xlink:to="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_a54b5af7-1e47-424a-ab29-e0c0ae3a97dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_8b9b2dfe-bef4-4394-8ec1-d790a7dcc604" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis_a54b5af7-1e47-424a-ab29-e0c0ae3a97dd" xlink:to="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_8b9b2dfe-bef4-4394-8ec1-d790a7dcc604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_IntangibleAssetsMember_67cd143b-72e4-4ade-a076-6979e253a52c" xlink:href="bgne-20241231.xsd#bgne_IntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain_8b9b2dfe-bef4-4394-8ec1-d790a7dcc604" xlink:to="loc_bgne_IntangibleAssetsMember_67cd143b-72e4-4ade-a076-6979e253a52c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31c21562-b2ff-4ba0-8659-ade17721dc04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b4abbf83-dd44-4624-8390-8424bd79de6d" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31c21562-b2ff-4ba0-8659-ade17721dc04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_UpfrontAndMilestonePayments_ab6080d4-c7f2-47dd-a36d-47035590c20a" xlink:href="bgne-20241231.xsd#bgne_UpfrontAndMilestonePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_31c21562-b2ff-4ba0-8659-ade17721dc04" xlink:to="loc_bgne_UpfrontAndMilestonePayments_ab6080d4-c7f2-47dd-a36d-47035590c20a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/RestrictedCashandInvestmentsRestrictionsonCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#RestrictedCashandInvestmentsRestrictionsonCashandCashEquivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/RestrictedCashandInvestmentsRestrictionsonCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_a0bd75b0-92b9-4cc9-852d-0415285c756a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_70483486-e749-4cd9-8c41-7014f2154b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_a0bd75b0-92b9-4cc9-852d-0415285c756a" xlink:to="loc_us-gaap_RestrictedCashCurrent_70483486-e749-4cd9-8c41-7014f2154b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_27d842ea-49db-4efc-8312-ccacd37311d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_a0bd75b0-92b9-4cc9-852d-0415285c756a" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_27d842ea-49db-4efc-8312-ccacd37311d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_b397b82e-d50b-459e-964e-53646c17649d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_a0bd75b0-92b9-4cc9-852d-0415285c756a" xlink:to="loc_us-gaap_RestrictedCash_b397b82e-d50b-459e-964e-53646c17649d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/RestrictedCashNarrativeDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#RestrictedCashNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/RestrictedCashNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_ecb73d52-278d-43be-bb04-ffa9be6b2afa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_0298ff43-b9d3-48c5-88d6-033d045988c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_ecb73d52-278d-43be-bb04-ffa9be6b2afa" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_0298ff43-b9d3-48c5-88d6-033d045988c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8ae360a7-7886-4250-9d81-dbae17fc3ea6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_0298ff43-b9d3-48c5-88d6-033d045988c8" xlink:to="loc_srt_CounterpartyNameAxis_8ae360a7-7886-4250-9d81-dbae17fc3ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ba383ce8-7b8e-4e0c-aaf6-f7d843ff2014" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_8ae360a7-7886-4250-9d81-dbae17fc3ea6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ba383ce8-7b8e-4e0c-aaf6-f7d843ff2014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_STARMarketMember_4db61da5-f296-4be2-89b5-8912fe6cb7c8" xlink:href="bgne-20241231.xsd#bgne_STARMarketMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ba383ce8-7b8e-4e0c-aaf6-f7d843ff2014" xlink:to="loc_bgne_STARMarketMember_4db61da5-f296-4be2-89b5-8912fe6cb7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_49b87b6a-7d3f-4efa-92e7-7853a8d4ff1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_0298ff43-b9d3-48c5-88d6-033d045988c8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_49b87b6a-7d3f-4efa-92e7-7853a8d4ff1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70b942dc-d109-4c4d-bb1d-54e5636c908e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_49b87b6a-7d3f-4efa-92e7-7853a8d4ff1a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70b942dc-d109-4c4d-bb1d-54e5636c908e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_55ff05fb-020d-440f-a55d-47262926e3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_70b942dc-d109-4c4d-bb1d-54e5636c908e" xlink:to="loc_us-gaap_IPOMember_55ff05fb-020d-440f-a55d-47262926e3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_3832d9b6-6c58-4f12-b10a-8a13a8cdb11f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_0298ff43-b9d3-48c5-88d6-033d045988c8" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_3832d9b6-6c58-4f12-b10a-8a13a8cdb11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_3597e1ce-b325-46aa-97ad-e9fb8c2881db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_3832d9b6-6c58-4f12-b10a-8a13a8cdb11f" xlink:to="loc_us-gaap_RestrictedCash_3597e1ce-b325-46aa-97ad-e9fb8c2881db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#InvestmentsInvestmentsInEquitySecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5817b9c1-aed0-41fb-9632-e16ceb528c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_b44b84d4-1350-4baa-a604-9a33791dd097" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_5817b9c1-aed0-41fb-9632-e16ceb528c1c" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_b44b84d4-1350-4baa-a604-9a33791dd097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b123ad23-caa0-4fdc-a015-cece17108ded" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_b44b84d4-1350-4baa-a604-9a33791dd097" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b123ad23-caa0-4fdc-a015-cece17108ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_4cf89fa0-2847-4ed4-9ea4-bc7e9618fbb8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_b123ad23-caa0-4fdc-a015-cece17108ded" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_4cf89fa0-2847-4ed4-9ea4-bc7e9618fbb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_LeapTherapeuticIncMember_b5b3025a-1742-426e-8aed-442442dd2979" xlink:href="bgne-20241231.xsd#bgne_LeapTherapeuticIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_4cf89fa0-2847-4ed4-9ea4-bc7e9618fbb8" xlink:to="loc_bgne_LeapTherapeuticIncMember_b5b3025a-1742-426e-8aed-442442dd2979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_PiHealthIncMember_fbc2b5f8-c0b7-4acb-9cb0-194e658478de" xlink:href="bgne-20241231.xsd#bgne_PiHealthIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_4cf89fa0-2847-4ed4-9ea4-bc7e9618fbb8" xlink:to="loc_bgne_PiHealthIncMember_fbc2b5f8-c0b7-4acb-9cb0-194e658478de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_OtherEquityMethodInvestmentsMember_2e312f88-1760-4d0c-b054-507f327ce3b6" xlink:href="bgne-20241231.xsd#bgne_OtherEquityMethodInvestmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_4cf89fa0-2847-4ed4-9ea4-bc7e9618fbb8" xlink:to="loc_bgne_OtherEquityMethodInvestmentsMember_2e312f88-1760-4d0c-b054-507f327ce3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a3f0dd5e-0a31-4246-9df0-81d91a96b629" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_b44b84d4-1350-4baa-a604-9a33791dd097" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a3f0dd5e-0a31-4246-9df0-81d91a96b629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1da493b6-a272-48bd-a0d8-5d84a63160a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a3f0dd5e-0a31-4246-9df0-81d91a96b629" xlink:to="loc_us-gaap_ClassOfStockDomain_1da493b6-a272-48bd-a0d8-5d84a63160a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8be0c021-5aa1-4b29-8de4-4240adbb9a40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1da493b6-a272-48bd-a0d8-5d84a63160a3" xlink:to="loc_us-gaap_CommonStockMember_8be0c021-5aa1-4b29-8de4-4240adbb9a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_88a788f7-89d7-41ac-95cb-366ae90b30c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1da493b6-a272-48bd-a0d8-5d84a63160a3" xlink:to="loc_us-gaap_WarrantMember_88a788f7-89d7-41ac-95cb-366ae90b30c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_bd8f7402-0f30-4135-891a-6d5524ff6a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_b44b84d4-1350-4baa-a604-9a33791dd097" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_bd8f7402-0f30-4135-891a-6d5524ff6a7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_76651578-d1db-482d-91c8-90568005798d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_bd8f7402-0f30-4135-891a-6d5524ff6a7e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_76651578-d1db-482d-91c8-90568005798d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_5b662038-bf17-4439-89ec-c3d257480d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_76651578-d1db-482d-91c8-90568005798d" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_5b662038-bf17-4439-89ec-c3d257480d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_90f9ff9f-772a-42f1-b652-00462de81dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_b44b84d4-1350-4baa-a604-9a33791dd097" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_90f9ff9f-772a-42f1-b652-00462de81dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_29f3ff9a-79dd-4d25-b815-0213bb3e38ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_90f9ff9f-772a-42f1-b652-00462de81dd9" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_29f3ff9a-79dd-4d25-b815-0213bb3e38ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_PiHealthIncMember_3109e6bc-8f6d-4bb8-a256-959d8004b6a0" xlink:href="bgne-20241231.xsd#bgne_PiHealthIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_29f3ff9a-79dd-4d25-b815-0213bb3e38ae" xlink:to="loc_bgne_PiHealthIncMember_3109e6bc-8f6d-4bb8-a256-959d8004b6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_b169939d-838b-4490-8c8c-39cea72f710b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_b44b84d4-1350-4baa-a604-9a33791dd097" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_b169939d-838b-4490-8c8c-39cea72f710b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_f22d5c4d-40e9-4cfe-9d82-d782d7e872d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b169939d-838b-4490-8c8c-39cea72f710b" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_f22d5c4d-40e9-4cfe-9d82-d782d7e872d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_5176ad8f-0502-4fb8-92a9-eef7880b7eac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b169939d-838b-4490-8c8c-39cea72f710b" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_5176ad8f-0502-4fb8-92a9-eef7880b7eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_9e285bcb-3046-48b8-b331-0d84de7c7f23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b169939d-838b-4490-8c8c-39cea72f710b" xlink:to="loc_us-gaap_EquityMethodInvestments_9e285bcb-3046-48b8-b331-0d84de7c7f23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_bed5d13e-6e00-4c8a-9a17-ab27e8e18763" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b169939d-838b-4490-8c8c-39cea72f710b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_bed5d13e-6e00-4c8a-9a17-ab27e8e18763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_DisposalGroupNotDiscontinuedOperationNetAssets_92ecddb2-bd4a-4bd9-8879-172c3cb57c2f" xlink:href="bgne-20241231.xsd#bgne_DisposalGroupNotDiscontinuedOperationNetAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b169939d-838b-4490-8c8c-39cea72f710b" xlink:to="loc_bgne_DisposalGroupNotDiscontinuedOperationNetAssets_92ecddb2-bd4a-4bd9-8879-172c3cb57c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_096e6017-7594-4b5a-abc3-bd33963df46c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b169939d-838b-4490-8c8c-39cea72f710b" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_096e6017-7594-4b5a-abc3-bd33963df46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_d79a14b6-4d72-400a-99a7-603ab342de12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b169939d-838b-4490-8c8c-39cea72f710b" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_d79a14b6-4d72-400a-99a7-603ab342de12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList_23dcc068-e981-4ced-bdf1-1af3343ecbaf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_b169939d-838b-4490-8c8c-39cea72f710b" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList_23dcc068-e981-4ced-bdf1-1af3343ecbaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/InvestmentsEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#InvestmentsEquityMethodInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/InvestmentsEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d764ded8-935c-476f-b3a7-3af3df31b68f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_75d0dee0-cf48-4ee9-b17a-b2bf333f6d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d764ded8-935c-476f-b3a7-3af3df31b68f" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_75d0dee0-cf48-4ee9-b17a-b2bf333f6d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_5df1a0e2-8878-4cd2-958c-0d4cacc7cce4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_75d0dee0-cf48-4ee9-b17a-b2bf333f6d6a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_5df1a0e2-8878-4cd2-958c-0d4cacc7cce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1d4df840-bfe2-40fe-98f5-3adeb6842432" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_5df1a0e2-8878-4cd2-958c-0d4cacc7cce4" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1d4df840-bfe2-40fe-98f5-3adeb6842432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseMember_b466c399-a2f9-4db5-82c6-4e02b733d064" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingIncomeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1d4df840-bfe2-40fe-98f5-3adeb6842432" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseMember_b466c399-a2f9-4db5-82c6-4e02b733d064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_44452974-4d66-4c97-9d53-6770130fac23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_75d0dee0-cf48-4ee9-b17a-b2bf333f6d6a" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_44452974-4d66-4c97-9d53-6770130fac23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_7246d964-a9da-4cdd-82e6-11bdf691dc45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_44452974-4d66-4c97-9d53-6770130fac23" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_7246d964-a9da-4cdd-82e6-11bdf691dc45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmountNet_fcd47f6c-de6c-4e97-a495-3ba1404c3a95" xlink:href="bgne-20241231.xsd#bgne_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmountNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_44452974-4d66-4c97-9d53-6770130fac23" xlink:to="loc_bgne_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmountNet_fcd47f6c-de6c-4e97-a495-3ba1404c3a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d64fa669-99d1-40c5-94fa-8c0fa11dc0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_44452974-4d66-4c97-9d53-6770130fac23" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d64fa669-99d1-40c5-94fa-8c0fa11dc0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/InventoriesNetDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#InventoriesNetDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/InventoriesNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_aa2f2a7b-114f-4e17-9351-57284f91e83c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_cb459e3b-5166-4506-98ae-28767edcca60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_aa2f2a7b-114f-4e17-9351-57284f91e83c" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_cb459e3b-5166-4506-98ae-28767edcca60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_77892301-7c17-40f5-ac63-b327d2b6f4c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_aa2f2a7b-114f-4e17-9351-57284f91e83c" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_77892301-7c17-40f5-ac63-b327d2b6f4c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_fdeb1223-28c2-4e94-ad8e-843130f9cadb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_aa2f2a7b-114f-4e17-9351-57284f91e83c" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_fdeb1223-28c2-4e94-ad8e-843130f9cadb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_91f7de88-06d7-4aac-befd-de303d85b68c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_aa2f2a7b-114f-4e17-9351-57284f91e83c" xlink:to="loc_us-gaap_InventoryNet_91f7de88-06d7-4aac-befd-de303d85b68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/LeasesNarrativesDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#LeasesNarrativesDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/LeasesNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8f813a17-b7f0-48aa-978e-1478ec170f02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_5f9f80f9-e4ba-49b3-ac3b-4a2cc46abe36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8f813a17-b7f0-48aa-978e-1478ec170f02" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_5f9f80f9-e4ba-49b3-ac3b-4a2cc46abe36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_17c2f27c-3837-4276-a9a3-55179219d8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5f9f80f9-e4ba-49b3-ac3b-4a2cc46abe36" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_17c2f27c-3837-4276-a9a3-55179219d8ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f842d19d-b10a-43ae-b03e-1dcfff53f4ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_17c2f27c-3837-4276-a9a3-55179219d8ff" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f842d19d-b10a-43ae-b03e-1dcfff53f4ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_07123bb7-8d03-492b-b87d-1ed396f9702d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f842d19d-b10a-43ae-b03e-1dcfff53f4ef" xlink:to="loc_us-gaap_BuildingMember_07123bb7-8d03-492b-b87d-1ed396f9702d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_7291826a-3faf-49b2-a8c4-cd306f3e8e33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_5f9f80f9-e4ba-49b3-ac3b-4a2cc46abe36" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_7291826a-3faf-49b2-a8c4-cd306f3e8e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_00c0c590-22fb-4ec0-bd63-40695d0e1d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_7291826a-3faf-49b2-a8c4-cd306f3e8e33" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_00c0c590-22fb-4ec0-bd63-40695d0e1d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_feefb9a8-35da-44a0-9811-d8626b677ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_8891e864-7418-44c7-b970-8ab3940e08a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_feefb9a8-35da-44a0-9811-d8626b677ec6" xlink:to="loc_us-gaap_OperatingLeaseCost_8891e864-7418-44c7-b970-8ab3940e08a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_e591419c-62fb-4587-8972-764a6d265519" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_feefb9a8-35da-44a0-9811-d8626b677ec6" xlink:to="loc_us-gaap_VariableLeaseCost_e591419c-62fb-4587-8972-764a6d265519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_8b994681-2f3f-4158-a640-764cad2eb00e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_feefb9a8-35da-44a0-9811-d8626b677ec6" xlink:to="loc_us-gaap_ShortTermLeaseCost_8b994681-2f3f-4158-a640-764cad2eb00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_bb742e6a-30ac-4ad2-9bda-45f5547aeba7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_feefb9a8-35da-44a0-9811-d8626b677ec6" xlink:to="loc_us-gaap_LeaseCost_bb742e6a-30ac-4ad2-9bda-45f5547aeba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/LeasesSupplementalBalanceSheetDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#LeasesSupplementalBalanceSheetDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/LeasesSupplementalBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_e30d68ad-7273-4874-bbb1-7351cfceeab9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_795c3f3c-f928-476a-85b2-181c6df6b0b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_e30d68ad-7273-4874-bbb1-7351cfceeab9" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_795c3f3c-f928-476a-85b2-181c6df6b0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b0ba005d-ac57-4b0b-8adf-7ea26b29ca63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_795c3f3c-f928-476a-85b2-181c6df6b0b0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b0ba005d-ac57-4b0b-8adf-7ea26b29ca63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_372e8ecd-bad0-4d1b-91f3-7f6dfeea4400" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b0ba005d-ac57-4b0b-8adf-7ea26b29ca63" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_372e8ecd-bad0-4d1b-91f3-7f6dfeea4400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_9dbaa027-e50c-4c97-a303-b0af2c3bd382" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_372e8ecd-bad0-4d1b-91f3-7f6dfeea4400" xlink:to="loc_us-gaap_BuildingMember_9dbaa027-e50c-4c97-a303-b0af2c3bd382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_91bee69e-347e-4083-a02d-1994d3eb32b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_372e8ecd-bad0-4d1b-91f3-7f6dfeea4400" xlink:to="loc_us-gaap_LandMember_91bee69e-347e-4083-a02d-1994d3eb32b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_3ce77701-401a-4bb5-9907-1995dd2c5554" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_795c3f3c-f928-476a-85b2-181c6df6b0b0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_3ce77701-401a-4bb5-9907-1995dd2c5554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_0058a509-6503-4130-8bb7-201ca636e379" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3ce77701-401a-4bb5-9907-1995dd2c5554" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_0058a509-6503-4130-8bb7-201ca636e379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ce6516db-6a79-43f5-ab7c-050bf6a00d42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3ce77701-401a-4bb5-9907-1995dd2c5554" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ce6516db-6a79-43f5-ab7c-050bf6a00d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_001d839e-b9ac-468a-8120-3f25da020754" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3ce77701-401a-4bb5-9907-1995dd2c5554" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_001d839e-b9ac-468a-8120-3f25da020754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_9dcf0273-991f-4fdf-aad6-ba27b8e81d37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3ce77701-401a-4bb5-9907-1995dd2c5554" xlink:to="loc_us-gaap_OperatingLeaseLiability_9dcf0273-991f-4fdf-aad6-ba27b8e81d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c86f0c7d-99f9-43c5-8ca9-abf5628a92c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_43ca3db3-cfc3-426c-87e6-1cb954ab057d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c86f0c7d-99f9-43c5-8ca9-abf5628a92c2" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_43ca3db3-cfc3-426c-87e6-1cb954ab057d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8dd27907-8e88-40f0-8bfb-4ee7a2f68173" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_43ca3db3-cfc3-426c-87e6-1cb954ab057d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8dd27907-8e88-40f0-8bfb-4ee7a2f68173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0425d8b2-321f-46c1-b2b3-ef5d3693729b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_43ca3db3-cfc3-426c-87e6-1cb954ab057d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0425d8b2-321f-46c1-b2b3-ef5d3693729b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_02b4792c-3fec-4e91-8851-b27f38702a39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_43ca3db3-cfc3-426c-87e6-1cb954ab057d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_02b4792c-3fec-4e91-8851-b27f38702a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c38b10d4-6038-4797-9c36-7243face9f56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_43ca3db3-cfc3-426c-87e6-1cb954ab057d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c38b10d4-6038-4797-9c36-7243face9f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0097eeec-1280-4f9d-b5ad-5878e3cadf5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_43ca3db3-cfc3-426c-87e6-1cb954ab057d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_0097eeec-1280-4f9d-b5ad-5878e3cadf5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_39d77d75-f93f-4179-9cfc-2fbc57b63687" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_43ca3db3-cfc3-426c-87e6-1cb954ab057d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_39d77d75-f93f-4179-9cfc-2fbc57b63687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9c10c809-c1b0-410d-957b-e59b450a2c22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_43ca3db3-cfc3-426c-87e6-1cb954ab057d" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9c10c809-c1b0-410d-957b-e59b450a2c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_44367dd6-82c8-41ba-a360-f5964764a8c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c86f0c7d-99f9-43c5-8ca9-abf5628a92c2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_44367dd6-82c8-41ba-a360-f5964764a8c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_822bde71-4505-4a17-be72-500e6d754574" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c86f0c7d-99f9-43c5-8ca9-abf5628a92c2" xlink:to="loc_us-gaap_OperatingLeaseLiability_822bde71-4505-4a17-be72-500e6d754574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/LeasesOtherSupplementalInformationDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#LeasesOtherSupplementalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/LeasesOtherSupplementalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_68c0c599-79a5-4edf-8a86-a91f365e1cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_fd2dcd28-1175-4ffa-9ba2-8068ccca9a61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_68c0c599-79a5-4edf-8a86-a91f365e1cf3" xlink:to="loc_us-gaap_OperatingLeasePayments_fd2dcd28-1175-4ffa-9ba2-8068ccca9a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a8d0a3a6-2c4e-4447-92d7-8ed6e090de49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_68c0c599-79a5-4edf-8a86-a91f365e1cf3" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_a8d0a3a6-2c4e-4447-92d7-8ed6e090de49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_65425eea-aca7-41c0-a97a-e023970484ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_68c0c599-79a5-4edf-8a86-a91f365e1cf3" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_65425eea-aca7-41c0-a97a-e023970484ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5630be2d-3190-4029-89e1-337d839518a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_68c0c599-79a5-4edf-8a86-a91f365e1cf3" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5630be2d-3190-4029-89e1-337d839518a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/PropertyPlantandEquipmentNetPropertyPlantandEquipmentNetDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#PropertyPlantandEquipmentNetPropertyPlantandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/PropertyPlantandEquipmentNetPropertyPlantandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a6b0b8aa-469f-4121-8a1d-ef08a441cf30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_32acd11b-9993-4cfb-bd67-97f7dd71c00f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a6b0b8aa-469f-4121-8a1d-ef08a441cf30" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_32acd11b-9993-4cfb-bd67-97f7dd71c00f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bc258995-a170-4325-bbe9-64f632c31b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_32acd11b-9993-4cfb-bd67-97f7dd71c00f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bc258995-a170-4325-bbe9-64f632c31b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fbe52e4a-0aa6-4d48-8405-b29f8669c60c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_bc258995-a170-4325-bbe9-64f632c31b9d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fbe52e4a-0aa6-4d48-8405-b29f8669c60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_0f8cf275-3c2c-4cb5-9406-dbccfac19f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fbe52e4a-0aa6-4d48-8405-b29f8669c60c" xlink:to="loc_us-gaap_LandMember_0f8cf275-3c2c-4cb5-9406-dbccfac19f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_75abae9d-7d4b-4a86-91ef-3c86516224ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fbe52e4a-0aa6-4d48-8405-b29f8669c60c" xlink:to="loc_us-gaap_BuildingMember_75abae9d-7d4b-4a86-91ef-3c86516224ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_7566c77a-0442-4946-9beb-23634e073f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fbe52e4a-0aa6-4d48-8405-b29f8669c60c" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_7566c77a-0442-4946-9beb-23634e073f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_LaboratoryEquipmentMember_7ec64954-7b54-44bb-aa3c-ba93a04c58a0" xlink:href="bgne-20241231.xsd#bgne_LaboratoryEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fbe52e4a-0aa6-4d48-8405-b29f8669c60c" xlink:to="loc_bgne_LaboratoryEquipmentMember_7ec64954-7b54-44bb-aa3c-ba93a04c58a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_e3241373-3b61-44a5-a642-a37650d14330" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fbe52e4a-0aa6-4d48-8405-b29f8669c60c" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_e3241373-3b61-44a5-a642-a37650d14330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_08786001-87c4-45dc-b990-e3a400761ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_fbe52e4a-0aa6-4d48-8405-b29f8669c60c" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_08786001-87c4-45dc-b990-e3a400761ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_61933011-607f-43d1-a193-9b053878a996" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_32acd11b-9993-4cfb-bd67-97f7dd71c00f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_61933011-607f-43d1-a193-9b053878a996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_69b429cc-9ce0-4d9b-ac2a-25559f0efc6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_61933011-607f-43d1-a193-9b053878a996" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_69b429cc-9ce0-4d9b-ac2a-25559f0efc6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_20d6ac25-5b39-4aae-886b-26ed6b9e1d42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_69b429cc-9ce0-4d9b-ac2a-25559f0efc6a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_20d6ac25-5b39-4aae-886b-26ed6b9e1d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_277c8dc5-74d0-431d-a9d1-aef16c4aabeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_69b429cc-9ce0-4d9b-ac2a-25559f0efc6a" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_277c8dc5-74d0-431d-a9d1-aef16c4aabeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_c9b9d3e2-a06d-4d3c-b323-1aa65ba8e79d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_69b429cc-9ce0-4d9b-ac2a-25559f0efc6a" xlink:to="loc_us-gaap_ConstructionInProgressGross_c9b9d3e2-a06d-4d3c-b323-1aa65ba8e79d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b5cbee6f-efd3-47a0-97c1-ce2328d1c300" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_69b429cc-9ce0-4d9b-ac2a-25559f0efc6a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b5cbee6f-efd3-47a0-97c1-ce2328d1c300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/PropertyPlantandEquipmentNetNarrativesDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#PropertyPlantandEquipmentNetNarrativesDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/PropertyPlantandEquipmentNetNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0e2459a5-dfba-4b87-a74f-432d1c41fc79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b54ad027-0c58-4f14-9ee9-a6fc084c98db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0e2459a5-dfba-4b87-a74f-432d1c41fc79" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b54ad027-0c58-4f14-9ee9-a6fc084c98db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_e2aa449f-8e0e-47a2-85e3-21d210f7431d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b54ad027-0c58-4f14-9ee9-a6fc084c98db" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_e2aa449f-8e0e-47a2-85e3-21d210f7431d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_8123dfbc-8e76-42a9-baa3-c834f05d2d12" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_e2aa449f-8e0e-47a2-85e3-21d210f7431d" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_8123dfbc-8e76-42a9-baa3-c834f05d2d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_HopewellFacilityMember_531811b4-18b0-4251-afb1-17a421e2daba" xlink:href="bgne-20241231.xsd#bgne_HopewellFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_8123dfbc-8e76-42a9-baa3-c834f05d2d12" xlink:to="loc_bgne_HopewellFacilityMember_531811b4-18b0-4251-afb1-17a421e2daba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_00caf128-a858-4f07-b76f-882425437d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b54ad027-0c58-4f14-9ee9-a6fc084c98db" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_00caf128-a858-4f07-b76f-882425437d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d1242d84-85a8-4c8e-8f86-604ff7990dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_00caf128-a858-4f07-b76f-882425437d7d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d1242d84-85a8-4c8e-8f86-604ff7990dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_33dcbd2e-81c9-4a27-ae1a-eace76e92baf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d1242d84-85a8-4c8e-8f86-604ff7990dd4" xlink:to="loc_us-gaap_LandMember_33dcbd2e-81c9-4a27-ae1a-eace76e92baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_4702ebe7-2ed6-4c13-ae6d-d95e273a2c31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d1242d84-85a8-4c8e-8f86-604ff7990dd4" xlink:to="loc_us-gaap_ConstructionInProgressMember_4702ebe7-2ed6-4c13-ae6d-d95e273a2c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_33d62e31-47d9-4795-962c-64c3a1ba5407" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b54ad027-0c58-4f14-9ee9-a6fc084c98db" xlink:to="loc_srt_StatementGeographicalAxis_33d62e31-47d9-4795-962c-64c3a1ba5407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8c35e416-e478-4499-85b9-d4b871e2c6e2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_33d62e31-47d9-4795-962c-64c3a1ba5407" xlink:to="loc_srt_SegmentGeographicalDomain_8c35e416-e478-4499-85b9-d4b871e2c6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShanghaiChinaMember_cc97cd5f-7787-4c5d-823b-c1e227abb53f" xlink:href="bgne-20241231.xsd#bgne_ShanghaiChinaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8c35e416-e478-4499-85b9-d4b871e2c6e2" xlink:to="loc_bgne_ShanghaiChinaMember_cc97cd5f-7787-4c5d-823b-c1e227abb53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4f10c6ad-540e-4e13-aba6-daffc4f27acd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b54ad027-0c58-4f14-9ee9-a6fc084c98db" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4f10c6ad-540e-4e13-aba6-daffc4f27acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_fe526792-fe49-4a15-a957-6ba9c29cba28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4f10c6ad-540e-4e13-aba6-daffc4f27acd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_fe526792-fe49-4a15-a957-6ba9c29cba28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_a555820e-33a6-4a1b-9da6-b1af90507906" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4f10c6ad-540e-4e13-aba6-daffc4f27acd" xlink:to="loc_us-gaap_ConstructionInProgressGross_a555820e-33a6-4a1b-9da6-b1af90507906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_68170017-e5aa-4718-8c59-e9f8491c9908" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4f10c6ad-540e-4e13-aba6-daffc4f27acd" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_68170017-e5aa-4718-8c59-e9f8491c9908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_b0316198-55bc-492c-be35-475ee14acbee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4f10c6ad-540e-4e13-aba6-daffc4f27acd" xlink:to="loc_us-gaap_Depreciation_b0316198-55bc-492c-be35-475ee14acbee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_8502c440-8740-4b0c-9c13-7f437ebec37e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4f10c6ad-540e-4e13-aba6-daffc4f27acd" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_8502c440-8740-4b0c-9c13-7f437ebec37e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/PropertyPlantandEquipmentNetConstructioninProgressDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#PropertyPlantandEquipmentNetConstructioninProgressDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/PropertyPlantandEquipmentNetConstructioninProgressDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7a2c0579-13f4-4cba-9073-52f41c078f99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0e195824-02aa-4d7a-a5f2-027b3d9818aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7a2c0579-13f4-4cba-9073-52f41c078f99" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0e195824-02aa-4d7a-a5f2-027b3d9818aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_604733a8-cea0-43d8-9c6c-4bec091ddad6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0e195824-02aa-4d7a-a5f2-027b3d9818aa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_604733a8-cea0-43d8-9c6c-4bec091ddad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2fe9acbb-e18e-4d1a-b6d3-15d0010a287a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_604733a8-cea0-43d8-9c6c-4bec091ddad6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2fe9acbb-e18e-4d1a-b6d3-15d0010a287a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_5cc76a93-4249-439e-8a95-a7c86c59247e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2fe9acbb-e18e-4d1a-b6d3-15d0010a287a" xlink:to="loc_us-gaap_BuildingMember_5cc76a93-4249-439e-8a95-a7c86c59247e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_bcfc94ef-89a0-447b-a0c8-3b87abb9fb7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2fe9acbb-e18e-4d1a-b6d3-15d0010a287a" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_bcfc94ef-89a0-447b-a0c8-3b87abb9fb7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_LaboratoryEquipmentMember_ab0346a9-9472-4721-b06c-c6ce549bfbdc" xlink:href="bgne-20241231.xsd#bgne_LaboratoryEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2fe9acbb-e18e-4d1a-b6d3-15d0010a287a" xlink:to="loc_bgne_LaboratoryEquipmentMember_ab0346a9-9472-4721-b06c-c6ce549bfbdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_925ded01-2c41-4c05-8e7b-9bb4a1e88629" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2fe9acbb-e18e-4d1a-b6d3-15d0010a287a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_925ded01-2c41-4c05-8e7b-9bb4a1e88629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a8e84deb-f6e2-4229-bf0f-55973041e54a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0e195824-02aa-4d7a-a5f2-027b3d9818aa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a8e84deb-f6e2-4229-bf0f-55973041e54a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_aebfffcb-14fd-4425-a78b-f5926130d1b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a8e84deb-f6e2-4229-bf0f-55973041e54a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_aebfffcb-14fd-4425-a78b-f5926130d1b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_e8f05d32-93af-4f34-a9bd-d874aa19ffd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGrossAbstract_aebfffcb-14fd-4425-a78b-f5926130d1b3" xlink:to="loc_us-gaap_ConstructionInProgressGross_e8f05d32-93af-4f34-a9bd-d874aa19ffd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/IntangibleAssetsIntangibleAssetsOutstandingDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#IntangibleAssetsIntangibleAssetsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/IntangibleAssetsIntangibleAssetsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2353c434-3702-4a77-a706-d6e235e28ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3de15181-b4bb-4a80-8801-e71a4e9cbe7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2353c434-3702-4a77-a706-d6e235e28ce8" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3de15181-b4bb-4a80-8801-e71a4e9cbe7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1f11fbad-7d24-4d78-9949-e2ee2e0e4ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3de15181-b4bb-4a80-8801-e71a4e9cbe7e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1f11fbad-7d24-4d78-9949-e2ee2e0e4ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2bb12ef0-c37f-4056-9cea-39b41a341a72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1f11fbad-7d24-4d78-9949-e2ee2e0e4ebd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2bb12ef0-c37f-4056-9cea-39b41a341a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_b0026140-4c20-46ba-81b1-fdcf4361f417" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2bb12ef0-c37f-4056-9cea-39b41a341a72" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_b0026140-4c20-46ba-81b1-fdcf4361f417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_a670eb77-eaea-45cf-997a-df59edb75436" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2bb12ef0-c37f-4056-9cea-39b41a341a72" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_a670eb77-eaea-45cf-997a-df59edb75436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_52c9aef8-4738-41ad-abe8-5afd93138a39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3de15181-b4bb-4a80-8801-e71a4e9cbe7e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_52c9aef8-4738-41ad-abe8-5afd93138a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_79aa49b1-fdec-4b3b-87d9-a5bd36436d78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_52c9aef8-4738-41ad-abe8-5afd93138a39" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_79aa49b1-fdec-4b3b-87d9-a5bd36436d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f7df9ad5-95a0-4cea-8bed-c20d97ae97fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_79aa49b1-fdec-4b3b-87d9-a5bd36436d78" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f7df9ad5-95a0-4cea-8bed-c20d97ae97fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bee6bcf2-58b0-48bf-b07f-f615f6983030" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_79aa49b1-fdec-4b3b-87d9-a5bd36436d78" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bee6bcf2-58b0-48bf-b07f-f615f6983030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9b216407-5699-49da-a3e5-a66f9c3ef55c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_79aa49b1-fdec-4b3b-87d9-a5bd36436d78" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9b216407-5699-49da-a3e5-a66f9c3ef55c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/IntangibleAssetsUsefulLifeDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#IntangibleAssetsUsefulLifeDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/IntangibleAssetsUsefulLifeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a71635a4-3f54-4719-a3b8-7873e985292b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_71531f3c-5ca8-4aae-b7a4-996e1a4b40eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a71635a4-3f54-4719-a3b8-7873e985292b" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_71531f3c-5ca8-4aae-b7a4-996e1a4b40eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_95c3646c-c22d-4a24-a685-55fc573757e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_71531f3c-5ca8-4aae-b7a4-996e1a4b40eb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_95c3646c-c22d-4a24-a685-55fc573757e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cf96abfc-b062-4313-979f-fcb7527142ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_95c3646c-c22d-4a24-a685-55fc573757e7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cf96abfc-b062-4313-979f-fcb7527142ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_2af593e7-f44d-400d-8a8c-03df705b4931" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cf96abfc-b062-4313-979f-fcb7527142ac" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_2af593e7-f44d-400d-8a8c-03df705b4931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_a116da14-ae2e-4926-881c-02a231432f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cf96abfc-b062-4313-979f-fcb7527142ac" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_a116da14-ae2e-4926-881c-02a231432f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4f876d9f-cedf-435b-b93d-ce4245406ddf" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_71531f3c-5ca8-4aae-b7a4-996e1a4b40eb" xlink:to="loc_srt_RangeAxis_4f876d9f-cedf-435b-b93d-ce4245406ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fb3d7621-8cd1-4b3b-aa20-05947903c42a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4f876d9f-cedf-435b-b93d-ce4245406ddf" xlink:to="loc_srt_RangeMember_fb3d7621-8cd1-4b3b-aa20-05947903c42a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_39d94c92-17b7-4f4f-ade7-b7435e693291" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fb3d7621-8cd1-4b3b-aa20-05947903c42a" xlink:to="loc_srt_WeightedAverageMember_39d94c92-17b7-4f4f-ade7-b7435e693291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_973354cc-37cb-49c4-bc70-8cee9ee69855" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_71531f3c-5ca8-4aae-b7a4-996e1a4b40eb" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_973354cc-37cb-49c4-bc70-8cee9ee69855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2a8a294d-3332-4b93-b77e-57240464f5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_973354cc-37cb-49c4-bc70-8cee9ee69855" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2a8a294d-3332-4b93-b77e-57240464f5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1c52f3d4-bd62-456a-be7b-2c62f2430e41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_2a8a294d-3332-4b93-b77e-57240464f5bc" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1c52f3d4-bd62-456a-be7b-2c62f2430e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/IntangibleAssetsAmortizationExpenseDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#IntangibleAssetsAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/IntangibleAssetsAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_76d78afe-6fa9-4a8e-bb31-64b195f8809b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f5f9f94e-8e1c-4bfe-ad25-b370551b758f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_76d78afe-6fa9-4a8e-bb31-64b195f8809b" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f5f9f94e-8e1c-4bfe-ad25-b370551b758f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_4316b2fb-3d8a-4551-b526-10a43dde02fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f5f9f94e-8e1c-4bfe-ad25-b370551b758f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_4316b2fb-3d8a-4551-b526-10a43dde02fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_97d65824-1503-4f7c-85c1-8e2157e93769" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_4316b2fb-3d8a-4551-b526-10a43dde02fd" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_97d65824-1503-4f7c-85c1-8e2157e93769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_2ceecaac-a436-42f2-b685-c075b1502d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_97d65824-1503-4f7c-85c1-8e2157e93769" xlink:to="loc_us-gaap_CostOfSalesMember_2ceecaac-a436-42f2-b685-c075b1502d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d8284f7e-4371-498e-930b-35dead082692" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_97d65824-1503-4f7c-85c1-8e2157e93769" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_d8284f7e-4371-498e-930b-35dead082692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d6e28348-5d12-4d98-b8d2-fa28083d83a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f5f9f94e-8e1c-4bfe-ad25-b370551b758f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d6e28348-5d12-4d98-b8d2-fa28083d83a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_f3ab317b-0285-4eb8-b7be-cb88c258e31c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d6e28348-5d12-4d98-b8d2-fa28083d83a8" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_f3ab317b-0285-4eb8-b7be-cb88c258e31c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/IntangibleAssetsExpectedAmortizationExpenseDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#IntangibleAssetsExpectedAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/IntangibleAssetsExpectedAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2217cdc8-31dc-453c-a974-c58b29e6c5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_1dccdb44-e8cd-467d-bc32-b7e56bc5b367" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2217cdc8-31dc-453c-a974-c58b29e6c5bf" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_1dccdb44-e8cd-467d-bc32-b7e56bc5b367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a589b6a5-fe33-42c3-b6e0-e6c1ce9db4fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_1dccdb44-e8cd-467d-bc32-b7e56bc5b367" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a589b6a5-fe33-42c3-b6e0-e6c1ce9db4fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a7510647-bd36-4ba0-b336-1dbdd4406d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a589b6a5-fe33-42c3-b6e0-e6c1ce9db4fd" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a7510647-bd36-4ba0-b336-1dbdd4406d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_a85cb096-0498-46c9-8808-56153b715eb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a7510647-bd36-4ba0-b336-1dbdd4406d5e" xlink:to="loc_us-gaap_CostOfSalesMember_a85cb096-0498-46c9-8808-56153b715eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8ecf67f7-51d6-4f60-93aa-a70c5764b5be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a7510647-bd36-4ba0-b336-1dbdd4406d5e" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_8ecf67f7-51d6-4f60-93aa-a70c5764b5be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_163e1adf-7b9b-45d3-a8d4-25d31232ce5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_1dccdb44-e8cd-467d-bc32-b7e56bc5b367" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_163e1adf-7b9b-45d3-a8d4-25d31232ce5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_56aff900-097b-409f-a3cb-7355202779df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_163e1adf-7b9b-45d3-a8d4-25d31232ce5f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_56aff900-097b-409f-a3cb-7355202779df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e3bc026c-acd8-47ee-acf7-f59d505169c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_56aff900-097b-409f-a3cb-7355202779df" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_e3bc026c-acd8-47ee-acf7-f59d505169c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b7014720-0539-463c-93b9-1d67fc1ae5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_56aff900-097b-409f-a3cb-7355202779df" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_b7014720-0539-463c-93b9-1d67fc1ae5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_53b01f46-d27c-4a81-b0ef-4d07c8aa24ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_56aff900-097b-409f-a3cb-7355202779df" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_53b01f46-d27c-4a81-b0ef-4d07c8aa24ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_fc2e5f0b-454c-49f8-809e-ffcca50e3b3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_56aff900-097b-409f-a3cb-7355202779df" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_fc2e5f0b-454c-49f8-809e-ffcca50e3b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_415d2750-5538-49e8-a964-b0f21c8030f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_56aff900-097b-409f-a3cb-7355202779df" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_415d2750-5538-49e8-a964-b0f21c8030f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_29d2d2ff-7ed3-48d1-812d-a10877d40cca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_56aff900-097b-409f-a3cb-7355202779df" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_29d2d2ff-7ed3-48d1-812d-a10877d40cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_211a0f8b-2bac-442c-9580-edb722a5321e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_56aff900-097b-409f-a3cb-7355202779df" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_211a0f8b-2bac-442c-9580-edb722a5321e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#IncomeTaxesIncomeLossBeforeIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_77b27659-248d-4325-951a-773e88d2e8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_c408c49f-7101-42b5-8141-93a2bdb41010" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_77b27659-248d-4325-951a-773e88d2e8f0" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_c408c49f-7101-42b5-8141-93a2bdb41010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_600663e0-bbdd-4043-9c63-7f793fae55cb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c408c49f-7101-42b5-8141-93a2bdb41010" xlink:to="loc_srt_StatementGeographicalAxis_600663e0-bbdd-4043-9c63-7f793fae55cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1a297e07-92c1-435f-a406-1d76edeceed7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_600663e0-bbdd-4043-9c63-7f793fae55cb" xlink:to="loc_srt_SegmentGeographicalDomain_1a297e07-92c1-435f-a406-1d76edeceed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_fb2ad12f-c9b1-471c-882b-cdf2080f00c9" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1a297e07-92c1-435f-a406-1d76edeceed7" xlink:to="loc_country_US_fb2ad12f-c9b1-471c-882b-cdf2080f00c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_ac5bcdcf-e561-4f83-ad95-3de748e3dda0" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1a297e07-92c1-435f-a406-1d76edeceed7" xlink:to="loc_country_CN_ac5bcdcf-e561-4f83-ad95-3de748e3dda0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember_e01141de-6fc1-45d0-a496-4c363eb06d40" xlink:href="bgne-20241231.xsd#bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1a297e07-92c1-435f-a406-1d76edeceed7" xlink:to="loc_bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember_e01141de-6fc1-45d0-a496-4c363eb06d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_3f023c76-2374-43e7-bd7d-e70d2bb74eba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_c408c49f-7101-42b5-8141-93a2bdb41010" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_3f023c76-2374-43e7-bd7d-e70d2bb74eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_a6ee2500-540e-4efd-8600-efa08549e753" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_3f023c76-2374-43e7-bd7d-e70d2bb74eba" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_a6ee2500-540e-4efd-8600-efa08549e753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_27af7034-9581-42f2-ace2-2df80e803793" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_a6ee2500-540e-4efd-8600-efa08549e753" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_27af7034-9581-42f2-ace2-2df80e803793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_fc7b09a5-fd81-48b0-8d55-49fa255294df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_a6ee2500-540e-4efd-8600-efa08549e753" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_fc7b09a5-fd81-48b0-8d55-49fa255294df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3922ce98-1745-479a-b029-cf4a4ee9d708" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_a6ee2500-540e-4efd-8600-efa08549e753" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3922ce98-1745-479a-b029-cf4a4ee9d708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/IncomeTaxesCurrentandDeferredComponentsIncomeTaxesDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#IncomeTaxesCurrentandDeferredComponentsIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/IncomeTaxesCurrentandDeferredComponentsIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a32cef72-523e-45ca-8f31-d27a5c710fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_d59bd74b-18ad-4ac6-ad20-14977052b2de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a32cef72-523e-45ca-8f31-d27a5c710fd0" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_d59bd74b-18ad-4ac6-ad20-14977052b2de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_2bd581e7-282f-4582-bc57-fcf93d81d93e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_d59bd74b-18ad-4ac6-ad20-14977052b2de" xlink:to="loc_srt_StatementGeographicalAxis_2bd581e7-282f-4582-bc57-fcf93d81d93e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9e143ce1-ee99-4367-a7c4-254014e430d5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_2bd581e7-282f-4582-bc57-fcf93d81d93e" xlink:to="loc_srt_SegmentGeographicalDomain_9e143ce1-ee99-4367-a7c4-254014e430d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_d75f2e5e-b4eb-40d1-9ec1-30cdb495b149" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9e143ce1-ee99-4367-a7c4-254014e430d5" xlink:to="loc_country_US_d75f2e5e-b4eb-40d1-9ec1-30cdb495b149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_790934c1-b618-48bc-886c-bfc6424dd0e1" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9e143ce1-ee99-4367-a7c4-254014e430d5" xlink:to="loc_country_CN_790934c1-b618-48bc-886c-bfc6424dd0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember_1116a023-65ce-46f3-9499-795bf757d0b6" xlink:href="bgne-20241231.xsd#bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9e143ce1-ee99-4367-a7c4-254014e430d5" xlink:to="loc_bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember_1116a023-65ce-46f3-9499-795bf757d0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_7374516f-9eb4-4f7a-b2b2-b8a62ef7820c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_d59bd74b-18ad-4ac6-ad20-14977052b2de" xlink:to="loc_us-gaap_IncomeTaxExaminationLineItems_7374516f-9eb4-4f7a-b2b2-b8a62ef7820c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_dc0f3337-77b2-4b79-bee4-6a194eb2b862" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_7374516f-9eb4-4f7a-b2b2-b8a62ef7820c" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_dc0f3337-77b2-4b79-bee4-6a194eb2b862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_92462934-b182-428d-9e0f-656776b73cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_7374516f-9eb4-4f7a-b2b2-b8a62ef7820c" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_92462934-b182-428d-9e0f-656776b73cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_98756bad-3723-4834-b375-c3597e6dc3df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_7374516f-9eb4-4f7a-b2b2-b8a62ef7820c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_98756bad-3723-4834-b375-c3597e6dc3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/IncomeTaxesReconciliationoftheStatutoryRateDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#IncomeTaxesReconciliationoftheStatutoryRateDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/IncomeTaxesReconciliationoftheStatutoryRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5be05d71-8e30-401d-baa8-c4e9355e1e32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_345e9066-c32b-485c-bf7f-f844da3878c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5be05d71-8e30-401d-baa8-c4e9355e1e32" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_345e9066-c32b-485c-bf7f-f844da3878c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_88279c26-b30c-4ee5-b262-f6f4c2591ba1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5be05d71-8e30-401d-baa8-c4e9355e1e32" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_88279c26-b30c-4ee5-b262-f6f4c2591ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_67a652ff-c85a-4e0e-ba32-2b46f0753765" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5be05d71-8e30-401d-baa8-c4e9355e1e32" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_67a652ff-c85a-4e0e-ba32-2b46f0753765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_e3a7e316-000d-4818-a616-b2a7dfdccdcb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5be05d71-8e30-401d-baa8-c4e9355e1e32" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_e3a7e316-000d-4818-a616-b2a7dfdccdcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_876a14b3-66c9-4764-bc07-433ee8d1c8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5be05d71-8e30-401d-baa8-c4e9355e1e32" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_876a14b3-66c9-4764-bc07-433ee8d1c8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_6b351f18-2941-45c3-9d13-8f944ba3da60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5be05d71-8e30-401d-baa8-c4e9355e1e32" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_6b351f18-2941-45c3-9d13-8f944ba3da60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_5969cc91-7371-48cf-8932-a2944e923094" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5be05d71-8e30-401d-baa8-c4e9355e1e32" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_5969cc91-7371-48cf-8932-a2944e923094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_2ac445f8-f4fd-4276-b137-1ad6530bed74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5be05d71-8e30-401d-baa8-c4e9355e1e32" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_2ac445f8-f4fd-4276-b137-1ad6530bed74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_24f700bc-5580-4769-b123-a183ac0860ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5be05d71-8e30-401d-baa8-c4e9355e1e32" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_24f700bc-5580-4769-b123-a183ac0860ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_759d65e1-2c81-465b-945e-4973c51d49d5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5be05d71-8e30-401d-baa8-c4e9355e1e32" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_759d65e1-2c81-465b-945e-4973c51d49d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_EffectiveIncomeTaxRateReconciliationDeductionResearchExpensesAmount_6ca27394-8ea2-4baf-bb4d-cd746ed16095" xlink:href="bgne-20241231.xsd#bgne_EffectiveIncomeTaxRateReconciliationDeductionResearchExpensesAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5be05d71-8e30-401d-baa8-c4e9355e1e32" xlink:to="loc_bgne_EffectiveIncomeTaxRateReconciliationDeductionResearchExpensesAmount_6ca27394-8ea2-4baf-bb4d-cd746ed16095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion_cc581313-6983-4fc4-af41-3b455d94f70c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5be05d71-8e30-401d-baa8-c4e9355e1e32" xlink:to="loc_us-gaap_IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion_cc581313-6983-4fc4-af41-3b455d94f70c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount_6729ba5d-d416-4bb6-9a2f-5b5c3d6bdde6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5be05d71-8e30-401d-baa8-c4e9355e1e32" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount_6729ba5d-d416-4bb6-9a2f-5b5c3d6bdde6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e202fca5-47bc-48a3-aba5-8fb13f6dc97c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5be05d71-8e30-401d-baa8-c4e9355e1e32" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e202fca5-47bc-48a3-aba5-8fb13f6dc97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_02979900-8acd-43b3-8068-c48ae45f6f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5be05d71-8e30-401d-baa8-c4e9355e1e32" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_02979900-8acd-43b3-8068-c48ae45f6f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_84e25537-0cbb-47f3-8818-d758aacd03de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_bee6e3f8-09d2-4da7-a72e-3774c032c961" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_84e25537-0cbb-47f3-8818-d758aacd03de" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_bee6e3f8-09d2-4da7-a72e-3774c032c961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_d467de12-034c-4437-bd32-5d6c3d0e0d02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_bee6e3f8-09d2-4da7-a72e-3774c032c961" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_d467de12-034c-4437-bd32-5d6c3d0e0d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_721b7a13-ac30-48e9-9bde-c4b82ebb1321" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_bee6e3f8-09d2-4da7-a72e-3774c032c961" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_721b7a13-ac30-48e9-9bde-c4b82ebb1321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_a358f6f3-36b9-4b74-85b9-dba33da2356c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_bee6e3f8-09d2-4da7-a72e-3774c032c961" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_a358f6f3-36b9-4b74-85b9-dba33da2356c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_b9f1697d-68ad-44e0-aab1-ffb584eb0208" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_bee6e3f8-09d2-4da7-a72e-3774c032c961" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_b9f1697d-68ad-44e0-aab1-ffb584eb0208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign_f551819a-f2da-40da-b4ea-7ea5dfc68bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_bee6e3f8-09d2-4da7-a72e-3774c032c961" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign_f551819a-f2da-40da-b4ea-7ea5dfc68bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_6f5b0160-1fe3-4037-84af-93e01433e121" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_bee6e3f8-09d2-4da7-a72e-3774c032c961" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_6f5b0160-1fe3-4037-84af-93e01433e121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_DeferredTaxAssetsPropertyLeaseLiabilityObligation_c9c9c0a1-2ebd-4ffb-b811-cd3adecf7196" xlink:href="bgne-20241231.xsd#bgne_DeferredTaxAssetsPropertyLeaseLiabilityObligation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_bee6e3f8-09d2-4da7-a72e-3774c032c961" xlink:to="loc_bgne_DeferredTaxAssetsPropertyLeaseLiabilityObligation_c9c9c0a1-2ebd-4ffb-b811-cd3adecf7196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_7828cf84-683c-4340-a0bc-f9f5a5e17f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_bee6e3f8-09d2-4da7-a72e-3774c032c961" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_7828cf84-683c-4340-a0bc-f9f5a5e17f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1d1a90b9-255b-4d3d-a2ed-6f26244ff1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_bee6e3f8-09d2-4da7-a72e-3774c032c961" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_1d1a90b9-255b-4d3d-a2ed-6f26244ff1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_31e8cd8c-20ec-4f01-b626-46192f88eb87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_bee6e3f8-09d2-4da7-a72e-3774c032c961" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_31e8cd8c-20ec-4f01-b626-46192f88eb87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b12df6d9-b471-4a51-b43c-a10230784db4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_bee6e3f8-09d2-4da7-a72e-3774c032c961" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b12df6d9-b471-4a51-b43c-a10230784db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_10dbc807-15f2-4849-af2e-5671e29623e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_bee6e3f8-09d2-4da7-a72e-3774c032c961" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_10dbc807-15f2-4849-af2e-5671e29623e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_78f9807f-7ea2-4194-961c-be678f2b2778" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_bee6e3f8-09d2-4da7-a72e-3774c032c961" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_78f9807f-7ea2-4194-961c-be678f2b2778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_30027bc8-722d-4235-8afe-4b20ba9caeb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_bee6e3f8-09d2-4da7-a72e-3774c032c961" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_30027bc8-722d-4235-8afe-4b20ba9caeb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_dd9a44ba-7358-4ed3-bfc1-d3764e9804ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_bee6e3f8-09d2-4da7-a72e-3774c032c961" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_dd9a44ba-7358-4ed3-bfc1-d3764e9804ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_49d4482c-f14f-423f-a030-e59b359c5cde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_bee6e3f8-09d2-4da7-a72e-3774c032c961" xlink:to="loc_us-gaap_DeferredTaxLiabilities_49d4482c-f14f-423f-a030-e59b359c5cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/IncometaxesScheduleofValuationAllowancesDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#IncometaxesScheduleofValuationAllowancesDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/IncometaxesScheduleofValuationAllowancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2be79c31-3ca8-478b-80e0-f6d4cbbb174b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_DeferredTaxAssetsActivityRollForward_e540dfa1-c74f-48c6-93af-37131e3b6f61" xlink:href="bgne-20241231.xsd#bgne_DeferredTaxAssetsActivityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2be79c31-3ca8-478b-80e0-f6d4cbbb174b" xlink:to="loc_bgne_DeferredTaxAssetsActivityRollForward_e540dfa1-c74f-48c6-93af-37131e3b6f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_27e14600-d553-413b-9f38-d1cac2513ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_DeferredTaxAssetsActivityRollForward_e540dfa1-c74f-48c6-93af-37131e3b6f61" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_27e14600-d553-413b-9f38-d1cac2513ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_DeferredTaxAssetValuationAllowanceChangesIncludedInEarnings_2ccf25d4-3e6a-454b-ad8e-6420e065d7ef" xlink:href="bgne-20241231.xsd#bgne_DeferredTaxAssetValuationAllowanceChangesIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_DeferredTaxAssetsActivityRollForward_e540dfa1-c74f-48c6-93af-37131e3b6f61" xlink:to="loc_bgne_DeferredTaxAssetValuationAllowanceChangesIncludedInEarnings_2ccf25d4-3e6a-454b-ad8e-6420e065d7ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_DeferredTaxAssetValuationAllowanceGainLossIncludedInOtherComprehensiveIncomeLoss_cb604812-4602-46f6-b8a2-cf60b8822d21" xlink:href="bgne-20241231.xsd#bgne_DeferredTaxAssetValuationAllowanceGainLossIncludedInOtherComprehensiveIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_DeferredTaxAssetsActivityRollForward_e540dfa1-c74f-48c6-93af-37131e3b6f61" xlink:to="loc_bgne_DeferredTaxAssetValuationAllowanceGainLossIncludedInOtherComprehensiveIncomeLoss_cb604812-4602-46f6-b8a2-cf60b8822d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_DeferredTaxAssetValuationAllowanceCurrencyTranslationAndOther_b8886539-8f95-4d51-a306-40c352afe929" xlink:href="bgne-20241231.xsd#bgne_DeferredTaxAssetValuationAllowanceCurrencyTranslationAndOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_DeferredTaxAssetsActivityRollForward_e540dfa1-c74f-48c6-93af-37131e3b6f61" xlink:to="loc_bgne_DeferredTaxAssetValuationAllowanceCurrencyTranslationAndOther_b8886539-8f95-4d51-a306-40c352afe929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6b27ab53-dcf9-42a0-ad70-ad9ed7cf6268" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_DeferredTaxAssetsActivityRollForward_e540dfa1-c74f-48c6-93af-37131e3b6f61" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_6b27ab53-dcf9-42a0-ad70-ad9ed7cf6268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/IncomeTaxesNarrativesDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#IncomeTaxesNarrativesDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/IncomeTaxesNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_984bac9c-5972-4fe5-992d-d21be3d87393" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_b281ab18-5e14-4d3f-83c2-43c902693a32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_984bac9c-5972-4fe5-992d-d21be3d87393" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_b281ab18-5e14-4d3f-83c2-43c902693a32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_387abc0e-bae9-4259-8d04-0c20ac6bbc28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_b281ab18-5e14-4d3f-83c2-43c902693a32" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_387abc0e-bae9-4259-8d04-0c20ac6bbc28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_9ff41a4c-432c-4580-af21-91ad8076142b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_387abc0e-bae9-4259-8d04-0c20ac6bbc28" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_9ff41a4c-432c-4580-af21-91ad8076142b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAdministrationOfTaxationChinaMember_aca2a436-b0da-4073-9058-e11f0a072e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAdministrationOfTaxationChinaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_9ff41a4c-432c-4580-af21-91ad8076142b" xlink:to="loc_us-gaap_StateAdministrationOfTaxationChinaMember_aca2a436-b0da-4073-9058-e11f0a072e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SwissFederalTaxAdministrationFTAMember_5e46196f-ac28-4d59-9083-94d8c616fd50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SwissFederalTaxAdministrationFTAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_9ff41a4c-432c-4580-af21-91ad8076142b" xlink:to="loc_us-gaap_SwissFederalTaxAdministrationFTAMember_5e46196f-ac28-4d59-9083-94d8c616fd50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_eae343d8-4417-43b3-b5b2-e526f32bd4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_9ff41a4c-432c-4580-af21-91ad8076142b" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_eae343d8-4417-43b3-b5b2-e526f32bd4c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_ab1b607b-618c-4bfe-accf-cf6eb54ec1be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_b281ab18-5e14-4d3f-83c2-43c902693a32" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_ab1b607b-618c-4bfe-accf-cf6eb54ec1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_590b6f70-d4a4-426d-9e24-394c429c89aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_ab1b607b-618c-4bfe-accf-cf6eb54ec1be" xlink:to="loc_us-gaap_OperatingLossCarryforwards_590b6f70-d4a4-426d-9e24-394c429c89aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_35398a52-1895-4252-818b-f9c47b247642" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_ab1b607b-618c-4bfe-accf-cf6eb54ec1be" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_35398a52-1895-4252-818b-f9c47b247642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign_1a713fcd-f06b-45c7-a244-7b44956ee48a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_ab1b607b-618c-4bfe-accf-cf6eb54ec1be" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign_1a713fcd-f06b-45c7-a244-7b44956ee48a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_50ef90d6-3077-47a2-bacf-5c9f90b9aca1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_ab1b607b-618c-4bfe-accf-cf6eb54ec1be" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_50ef90d6-3077-47a2-bacf-5c9f90b9aca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_TaxBenefitFromForeignTaxStatus_183fc263-a5e7-4dc1-accd-3e48d84e1535" xlink:href="bgne-20241231.xsd#bgne_TaxBenefitFromForeignTaxStatus"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_ab1b607b-618c-4bfe-accf-cf6eb54ec1be" xlink:to="loc_bgne_TaxBenefitFromForeignTaxStatus_183fc263-a5e7-4dc1-accd-3e48d84e1535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_TaxBenefitFromForeignTaxStatusPerShare_39abdd65-d9fe-47b5-be6c-59329b1d990c" xlink:href="bgne-20241231.xsd#bgne_TaxBenefitFromForeignTaxStatusPerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_ab1b607b-618c-4bfe-accf-cf6eb54ec1be" xlink:to="loc_bgne_TaxBenefitFromForeignTaxStatusPerShare_39abdd65-d9fe-47b5-be6c-59329b1d990c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_59a095cc-de8f-4bac-9d32-8b36a6a23834" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_ab1b607b-618c-4bfe-accf-cf6eb54ec1be" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_59a095cc-de8f-4bac-9d32-8b36a6a23834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#IncomeTaxesGrossUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4e28f519-2476-429a-b542-0a71f5c605aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e06b35a6-c564-4f02-a2c8-fb0013d39ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4e28f519-2476-429a-b542-0a71f5c605aa" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e06b35a6-c564-4f02-a2c8-fb0013d39ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_c5c6272e-15f6-4d24-b5e3-fd421c907bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e06b35a6-c564-4f02-a2c8-fb0013d39ea0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_c5c6272e-15f6-4d24-b5e3-fd421c907bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_505ec28b-d528-4451-a101-ee44527386de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e06b35a6-c564-4f02-a2c8-fb0013d39ea0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_505ec28b-d528-4451-a101-ee44527386de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_f21b9ab6-4732-4de5-9704-e4e8da8958e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e06b35a6-c564-4f02-a2c8-fb0013d39ea0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_f21b9ab6-4732-4de5-9704-e4e8da8958e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_9ee1cb6d-44a9-409e-addb-4cc22f078f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e06b35a6-c564-4f02-a2c8-fb0013d39ea0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_9ee1cb6d-44a9-409e-addb-4cc22f078f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_27e1cd55-b6db-4325-b09f-247ec27f766b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e06b35a6-c564-4f02-a2c8-fb0013d39ea0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_27e1cd55-b6db-4325-b09f-247ec27f766b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_e3633fb7-67fb-48a2-bf91-46271979f2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e06b35a6-c564-4f02-a2c8-fb0013d39ea0" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_e3633fb7-67fb-48a2-bf91-46271979f2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_3f19cabf-9e8a-4130-a8a3-6123e278a9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_3fd10fcc-a5ff-4102-b19c-2d302dbff95d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_3f19cabf-9e8a-4130-a8a3-6123e278a9ee" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_3fd10fcc-a5ff-4102-b19c-2d302dbff95d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_PrepaidResearchAndDevelopmentCosts_22ca995c-b8a7-4108-8942-be847e04811c" xlink:href="bgne-20241231.xsd#bgne_PrepaidResearchAndDevelopmentCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_3fd10fcc-a5ff-4102-b19c-2d302dbff95d" xlink:to="loc_bgne_PrepaidResearchAndDevelopmentCosts_22ca995c-b8a7-4108-8942-be847e04811c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidTaxes_f3006db4-084b-4d56-80c3-8f80347f72e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_3fd10fcc-a5ff-4102-b19c-2d302dbff95d" xlink:to="loc_us-gaap_PrepaidTaxes_f3006db4-084b-4d56-80c3-8f80347f72e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_2001fe2f-94c3-469a-a816-0941105a10ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_3fd10fcc-a5ff-4102-b19c-2d302dbff95d" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_2001fe2f-94c3-469a-a816-0941105a10ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_PrepaidGeneralAndAdministrativeExpensesCurrent_c43c575b-a0bc-468d-96a5-d423cac02345" xlink:href="bgne-20241231.xsd#bgne_PrepaidGeneralAndAdministrativeExpensesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_3fd10fcc-a5ff-4102-b19c-2d302dbff95d" xlink:to="loc_bgne_PrepaidGeneralAndAdministrativeExpensesCurrent_c43c575b-a0bc-468d-96a5-d423cac02345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_PrepaidManufacturingCosts_a45033b2-1282-42e0-93b9-dab6541f3ce8" xlink:href="bgne-20241231.xsd#bgne_PrepaidManufacturingCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_3fd10fcc-a5ff-4102-b19c-2d302dbff95d" xlink:to="loc_bgne_PrepaidManufacturingCosts_a45033b2-1282-42e0-93b9-dab6541f3ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_96c53ef2-d320-47b5-a4fb-bb2b938c459a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_3fd10fcc-a5ff-4102-b19c-2d302dbff95d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_96c53ef2-d320-47b5-a4fb-bb2b938c459a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_2e986fc4-f2f9-4763-bd57-d9b996c79a35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_3fd10fcc-a5ff-4102-b19c-2d302dbff95d" xlink:to="loc_us-gaap_PrepaidInsurance_2e986fc4-f2f9-4763-bd57-d9b996c79a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_4b9dca8e-5589-4192-9bbf-d08323714bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_3fd10fcc-a5ff-4102-b19c-2d302dbff95d" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_4b9dca8e-5589-4192-9bbf-d08323714bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ff406b7c-08ef-496b-8c52-745ddd078488" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_3fd10fcc-a5ff-4102-b19c-2d302dbff95d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ff406b7c-08ef-496b-8c52-745ddd078488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_a7d379fd-e9d5-40a9-bd5c-76bf5292d751" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrentAbstract_3c751c53-84c2-473f-b4a4-6ac161013f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_a7d379fd-e9d5-40a9-bd5c-76bf5292d751" xlink:to="loc_us-gaap_OtherAssetsNoncurrentAbstract_3c751c53-84c2-473f-b4a4-6ac161013f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_5d6c9188-10a2-40fe-bb48-62d210659664" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsNoncurrentAbstract_3c751c53-84c2-473f-b4a4-6ac161013f5f" xlink:to="loc_us-gaap_LongTermInvestments_5d6c9188-10a2-40fe-bb48-62d210659664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_PrepaidSupplyCost_fa916a35-32c6-4dd2-9249-a2d45b32e437" xlink:href="bgne-20241231.xsd#bgne_PrepaidSupplyCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsNoncurrentAbstract_3c751c53-84c2-473f-b4a4-6ac161013f5f" xlink:to="loc_bgne_PrepaidSupplyCost_fa916a35-32c6-4dd2-9249-a2d45b32e437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RentalDepositsAndOther_0cfe239e-44f1-4bc7-9be0-7b71704b2b75" xlink:href="bgne-20241231.xsd#bgne_RentalDepositsAndOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsNoncurrentAbstract_3c751c53-84c2-473f-b4a4-6ac161013f5f" xlink:to="loc_bgne_RentalDepositsAndOther_0cfe239e-44f1-4bc7-9be0-7b71704b2b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_PrepaymentOfLongTermAsset_6a437737-ec72-49ab-8fbb-c705578e235e" xlink:href="bgne-20241231.xsd#bgne_PrepaymentOfLongTermAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsNoncurrentAbstract_3c751c53-84c2-473f-b4a4-6ac161013f5f" xlink:to="loc_bgne_PrepaymentOfLongTermAsset_6a437737-ec72-49ab-8fbb-c705578e235e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableNoncurrent_6e0b682a-eb79-4b32-8aae-db958f8b8f26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValueAddedTaxReceivableNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsNoncurrentAbstract_3c751c53-84c2-473f-b4a4-6ac161013f5f" xlink:to="loc_us-gaap_ValueAddedTaxReceivableNoncurrent_6e0b682a-eb79-4b32-8aae-db958f8b8f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_95dbd4a0-dfd0-483e-b150-59c4f343c72c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsNoncurrentAbstract_3c751c53-84c2-473f-b4a4-6ac161013f5f" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_95dbd4a0-dfd0-483e-b150-59c4f343c72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ac43af36-2b98-446c-9e39-37eb15dd8cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherAssetsNoncurrentAbstract_3c751c53-84c2-473f-b4a4-6ac161013f5f" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ac43af36-2b98-446c-9e39-37eb15dd8cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofAccruedExpensesandOtherPayablesDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#SupplementalBalanceSheetInformationScheduleofAccruedExpensesandOtherPayablesDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofAccruedExpensesandOtherPayablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_4c3505e9-d1ad-4ed9-9b9e-dc8c1c650bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_d27c3ac0-4a19-4771-9b81-a0f7c124dcb1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_4c3505e9-d1ad-4ed9-9b9e-dc8c1c650bb0" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_d27c3ac0-4a19-4771-9b81-a0f7c124dcb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_49fe70fd-57c5-4055-b668-4a5135358d04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_d27c3ac0-4a19-4771-9b81-a0f7c124dcb1" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_49fe70fd-57c5-4055-b668-4a5135358d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AccruedSalesRebatesAndReturnsCurrent_ec0a7005-7599-4d9e-8ad8-2f7112ccffa8" xlink:href="bgne-20241231.xsd#bgne_AccruedSalesRebatesAndReturnsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_d27c3ac0-4a19-4771-9b81-a0f7c124dcb1" xlink:to="loc_bgne_AccruedSalesRebatesAndReturnsCurrent_ec0a7005-7599-4d9e-8ad8-2f7112ccffa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AccruedLiabilitiesExternalResearchAndDevelopment_536deda6-e9e4-49c7-80af-f3c1ed4cf571" xlink:href="bgne-20241231.xsd#bgne_AccruedLiabilitiesExternalResearchAndDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_d27c3ac0-4a19-4771-9b81-a0f7c124dcb1" xlink:to="loc_bgne_AccruedLiabilitiesExternalResearchAndDevelopment_536deda6-e9e4-49c7-80af-f3c1ed4cf571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AccruedExpensesCommercialActivities_03800b5e-0c6c-48ce-9641-f5a76d0bf4c2" xlink:href="bgne-20241231.xsd#bgne_AccruedExpensesCommercialActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_d27c3ac0-4a19-4771-9b81-a0f7c124dcb1" xlink:to="loc_bgne_AccruedExpensesCommercialActivities_03800b5e-0c6c-48ce-9641-f5a76d0bf4c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AccruedGeneralAndAdministrativeExpensesCurrent_4e6c7706-ccc1-4cf3-9cc7-bcc4f7421dc7" xlink:href="bgne-20241231.xsd#bgne_AccruedGeneralAndAdministrativeExpensesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_d27c3ac0-4a19-4771-9b81-a0f7c124dcb1" xlink:to="loc_bgne_AccruedGeneralAndAdministrativeExpensesCurrent_4e6c7706-ccc1-4cf3-9cc7-bcc4f7421dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedPayrollTaxesCurrent_3d1ae1b8-6642-4d95-8f77-868dea4f18a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedPayrollTaxesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_d27c3ac0-4a19-4771-9b81-a0f7c124dcb1" xlink:to="loc_us-gaap_AccruedPayrollTaxesCurrent_3d1ae1b8-6642-4d95-8f77-868dea4f18a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AccruedProfessionalFeesAndOtherCurrent_533aa9c1-0b56-4a1d-9e54-0471ac54afef" xlink:href="bgne-20241231.xsd#bgne_AccruedProfessionalFeesAndOtherCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_d27c3ac0-4a19-4771-9b81-a0f7c124dcb1" xlink:to="loc_bgne_AccruedProfessionalFeesAndOtherCurrent_533aa9c1-0b56-4a1d-9e54-0471ac54afef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c3b687f7-fd73-4335-9094-a0580a29df97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_d27c3ac0-4a19-4771-9b81-a0f7c124dcb1" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c3b687f7-fd73-4335-9094-a0580a29df97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherLongtermLiabilitiesDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#SupplementalBalanceSheetInformationScheduleofOtherLongtermLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherLongtermLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_b36754da-742d-4104-afea-1d85ed6b94a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_7165f4d8-6772-42ab-bc75-7b147323d61f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_b36754da-742d-4104-afea-1d85ed6b94a6" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_7165f4d8-6772-42ab-bc75-7b147323d61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceLiability_7e17a7b3-58b8-465d-b456-b6fd416a2a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GovernmentAssistanceLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_7165f4d8-6772-42ab-bc75-7b147323d61f" xlink:to="loc_us-gaap_GovernmentAssistanceLiability_7e17a7b3-58b8-465d-b456-b6fd416a2a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_c987460c-264c-4f06-a3d1-e69ee781ab39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_7165f4d8-6772-42ab-bc75-7b147323d61f" xlink:to="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_c987460c-264c-4f06-a3d1-e69ee781ab39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetRetirementObligationsNoncurrent_eabd04ca-dc41-420b-97d5-408ff3c882c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetRetirementObligationsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_7165f4d8-6772-42ab-bc75-7b147323d61f" xlink:to="loc_us-gaap_AssetRetirementObligationsNoncurrent_eabd04ca-dc41-420b-97d5-408ff3c882c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_38228530-7f5c-49ac-9d82-77a2bc472151" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_7165f4d8-6772-42ab-bc75-7b147323d61f" xlink:to="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_38228530-7f5c-49ac-9d82-77a2bc472151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_89b4e20e-bf7f-4fe3-986b-73dfa851a672" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrentAbstract_7165f4d8-6772-42ab-bc75-7b147323d61f" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_89b4e20e-bf7f-4fe3-986b-73dfa851a672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#DebtShorttermandLongtermDebtObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ffdb8261-905a-4b37-aadd-f36b6bd7e984" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0d18d7bc-5e76-4a6c-8ab6-45a558e55a87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ffdb8261-905a-4b37-aadd-f36b6bd7e984" xlink:to="loc_us-gaap_DebtInstrumentTable_0d18d7bc-5e76-4a6c-8ab6-45a558e55a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_420e0698-1a53-4292-b7b4-6b02ffa06e44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0d18d7bc-5e76-4a6c-8ab6-45a558e55a87" xlink:to="loc_us-gaap_DebtInstrumentAxis_420e0698-1a53-4292-b7b4-6b02ffa06e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_837c7087-6bf9-4ac1-a5ec-aea58ec28392" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_420e0698-1a53-4292-b7b4-6b02ffa06e44" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_837c7087-6bf9-4ac1-a5ec-aea58ec28392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShortTermBankLoanDatedApril42018Member_3203ff7e-b496-417f-8413-647a2d9fa2e9" xlink:href="bgne-20241231.xsd#bgne_ShortTermBankLoanDatedApril42018Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_837c7087-6bf9-4ac1-a5ec-aea58ec28392" xlink:to="loc_bgne_ShortTermBankLoanDatedApril42018Member_3203ff7e-b496-417f-8413-647a2d9fa2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShortTermBankLoanDatedJanuary222020Member_62f3b53d-5ad1-41ec-8912-58c22e03dd60" xlink:href="bgne-20241231.xsd#bgne_ShortTermBankLoanDatedJanuary222020Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_837c7087-6bf9-4ac1-a5ec-aea58ec28392" xlink:to="loc_bgne_ShortTermBankLoanDatedJanuary222020Member_62f3b53d-5ad1-41ec-8912-58c22e03dd60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShortTermBankLoanDatedNovember92020Member_2489a641-29c6-4eec-874a-5e2ae13ba121" xlink:href="bgne-20241231.xsd#bgne_ShortTermBankLoanDatedNovember92020Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_837c7087-6bf9-4ac1-a5ec-aea58ec28392" xlink:to="loc_bgne_ShortTermBankLoanDatedNovember92020Member_2489a641-29c6-4eec-874a-5e2ae13ba121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_LongTermBankLoanDatedJuly292022Member_db44b231-1888-40e3-8026-6296d9792906" xlink:href="bgne-20241231.xsd#bgne_LongTermBankLoanDatedJuly292022Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_837c7087-6bf9-4ac1-a5ec-aea58ec28392" xlink:to="loc_bgne_LongTermBankLoanDatedJuly292022Member_db44b231-1888-40e3-8026-6296d9792906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShortTermBankLoanDatedJuly282023Member_588a4ba5-e9b1-4ecb-93e8-750c674635a6" xlink:href="bgne-20241231.xsd#bgne_ShortTermBankLoanDatedJuly282023Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_837c7087-6bf9-4ac1-a5ec-aea58ec28392" xlink:to="loc_bgne_ShortTermBankLoanDatedJuly282023Member_588a4ba5-e9b1-4ecb-93e8-750c674635a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShortTermBankLoanDatedDecember202023Member_d2cdb8d2-2b90-45c6-9d67-14d7e2a99590" xlink:href="bgne-20241231.xsd#bgne_ShortTermBankLoanDatedDecember202023Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_837c7087-6bf9-4ac1-a5ec-aea58ec28392" xlink:to="loc_bgne_ShortTermBankLoanDatedDecember202023Member_d2cdb8d2-2b90-45c6-9d67-14d7e2a99590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShortTermBankLoanDatedMarch212024Member_62d3d740-baf8-48e4-a87c-3ad73b771b8f" xlink:href="bgne-20241231.xsd#bgne_ShortTermBankLoanDatedMarch212024Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_837c7087-6bf9-4ac1-a5ec-aea58ec28392" xlink:to="loc_bgne_ShortTermBankLoanDatedMarch212024Member_62d3d740-baf8-48e4-a87c-3ad73b771b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShortTermBankLoanDatedJune52023Member_04c9b26f-f54e-4274-8366-8a883c2425ce" xlink:href="bgne-20241231.xsd#bgne_ShortTermBankLoanDatedJune52023Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_837c7087-6bf9-4ac1-a5ec-aea58ec28392" xlink:to="loc_bgne_ShortTermBankLoanDatedJune52023Member_04c9b26f-f54e-4274-8366-8a883c2425ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShortTermBankLoanDatedMay42023Member_1d0a806d-0a6d-426b-a719-d728a2136e87" xlink:href="bgne-20241231.xsd#bgne_ShortTermBankLoanDatedMay42023Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_837c7087-6bf9-4ac1-a5ec-aea58ec28392" xlink:to="loc_bgne_ShortTermBankLoanDatedMay42023Member_1d0a806d-0a6d-426b-a719-d728a2136e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShortTermBankLoanDatedMay302023Member_505c1226-1030-42eb-8faf-5a94a6030803" xlink:href="bgne-20241231.xsd#bgne_ShortTermBankLoanDatedMay302023Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_837c7087-6bf9-4ac1-a5ec-aea58ec28392" xlink:to="loc_bgne_ShortTermBankLoanDatedMay302023Member_505c1226-1030-42eb-8faf-5a94a6030803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShortTermBankLoanDatedNovember142023Member_6224745c-6837-424b-b747-6e310f6996e1" xlink:href="bgne-20241231.xsd#bgne_ShortTermBankLoanDatedNovember142023Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_837c7087-6bf9-4ac1-a5ec-aea58ec28392" xlink:to="loc_bgne_ShortTermBankLoanDatedNovember142023Member_6224745c-6837-424b-b747-6e310f6996e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShortTermBankLoanDatedMay252023Member_f1213215-fb75-4862-a468-dcf44b32427e" xlink:href="bgne-20241231.xsd#bgne_ShortTermBankLoanDatedMay252023Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_837c7087-6bf9-4ac1-a5ec-aea58ec28392" xlink:to="loc_bgne_ShortTermBankLoanDatedMay252023Member_f1213215-fb75-4862-a468-dcf44b32427e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_LongTermBankLoanApril42018Member_726db4db-f8d2-4cdc-960d-823499531134" xlink:href="bgne-20241231.xsd#bgne_LongTermBankLoanApril42018Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_837c7087-6bf9-4ac1-a5ec-aea58ec28392" xlink:to="loc_bgne_LongTermBankLoanApril42018Member_726db4db-f8d2-4cdc-960d-823499531134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_LongTermBankLoanDatedJanuary222020Member_4db133f3-74b4-4224-b740-8cf54da78c49" xlink:href="bgne-20241231.xsd#bgne_LongTermBankLoanDatedJanuary222020Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_837c7087-6bf9-4ac1-a5ec-aea58ec28392" xlink:to="loc_bgne_LongTermBankLoanDatedJanuary222020Member_4db133f3-74b4-4224-b740-8cf54da78c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_LongTermBankLoanDatedNovember92020Member_30c48985-dedd-4c6e-9802-9c7e7aa01901" xlink:href="bgne-20241231.xsd#bgne_LongTermBankLoanDatedNovember92020Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_837c7087-6bf9-4ac1-a5ec-aea58ec28392" xlink:to="loc_bgne_LongTermBankLoanDatedNovember92020Member_30c48985-dedd-4c6e-9802-9c7e7aa01901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShortTermBankLoanMaturingJanuary272025Member_ee227e04-e844-4c70-921e-74892cde0447" xlink:href="bgne-20241231.xsd#bgne_ShortTermBankLoanMaturingJanuary272025Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_837c7087-6bf9-4ac1-a5ec-aea58ec28392" xlink:to="loc_bgne_ShortTermBankLoanMaturingJanuary272025Member_ee227e04-e844-4c70-921e-74892cde0447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_eb7052d2-be4f-49b3-9a13-409bd4187ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0d18d7bc-5e76-4a6c-8ab6-45a558e55a87" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_eb7052d2-be4f-49b3-9a13-409bd4187ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_7a6306bd-a393-4cba-846a-a0bdc0a12f86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_eb7052d2-be4f-49b3-9a13-409bd4187ef7" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_7a6306bd-a393-4cba-846a-a0bdc0a12f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ChinaConstructionBankMember_de7ab032-d630-49ca-8f87-6f0f581c9857" xlink:href="bgne-20241231.xsd#bgne_ChinaConstructionBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_7a6306bd-a393-4cba-846a-a0bdc0a12f86" xlink:to="loc_bgne_ChinaConstructionBankMember_de7ab032-d630-49ca-8f87-6f0f581c9857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ChinaMerchantsBankMember_6b2fe2ed-ad06-40f5-825a-28634223d2fa" xlink:href="bgne-20241231.xsd#bgne_ChinaMerchantsBankMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_7a6306bd-a393-4cba-846a-a0bdc0a12f86" xlink:to="loc_bgne_ChinaMerchantsBankMember_6b2fe2ed-ad06-40f5-825a-28634223d2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ChinaCITICBankMember_d0800933-d0b1-4c6b-8cc6-c02c6c16c23e" xlink:href="bgne-20241231.xsd#bgne_ChinaCITICBankMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_7a6306bd-a393-4cba-846a-a0bdc0a12f86" xlink:to="loc_bgne_ChinaCITICBankMember_d0800933-d0b1-4c6b-8cc6-c02c6c16c23e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ChinaMinshengBankMember_29de4b1e-fea5-4cba-be99-96f3540af74f" xlink:href="bgne-20241231.xsd#bgne_ChinaMinshengBankMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_7a6306bd-a393-4cba-846a-a0bdc0a12f86" xlink:to="loc_bgne_ChinaMinshengBankMember_29de4b1e-fea5-4cba-be99-96f3540af74f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ChinaIndustrialBankMember_dfa50afe-c134-47fd-a9e6-63a043775b4f" xlink:href="bgne-20241231.xsd#bgne_ChinaIndustrialBankMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_7a6306bd-a393-4cba-846a-a0bdc0a12f86" xlink:to="loc_bgne_ChinaIndustrialBankMember_dfa50afe-c134-47fd-a9e6-63a043775b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_HSBCBankMember_48c6f65c-ab15-470f-a872-69d06d1eedbf" xlink:href="bgne-20241231.xsd#bgne_HSBCBankMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_7a6306bd-a393-4cba-846a-a0bdc0a12f86" xlink:to="loc_bgne_HSBCBankMember_48c6f65c-ab15-470f-a872-69d06d1eedbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShanghaiPudongDevelopmentBankMember_49699034-4bb1-4399-b83e-075728f1e6b1" xlink:href="bgne-20241231.xsd#bgne_ShanghaiPudongDevelopmentBankMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_7a6306bd-a393-4cba-846a-a0bdc0a12f86" xlink:to="loc_bgne_ShanghaiPudongDevelopmentBankMember_49699034-4bb1-4399-b83e-075728f1e6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_41c1576f-248f-4175-b20b-181973a8e1aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0d18d7bc-5e76-4a6c-8ab6-45a558e55a87" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_41c1576f-248f-4175-b20b-181973a8e1aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_f13ee427-7c78-409f-bfb2-068121511c14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_41c1576f-248f-4175-b20b-181973a8e1aa" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_f13ee427-7c78-409f-bfb2-068121511c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_7d8cf257-08b6-4e63-9832-02dfb0d6d14c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_f13ee427-7c78-409f-bfb2-068121511c14" xlink:to="loc_us-gaap_LoansPayableMember_7d8cf257-08b6-4e63-9832-02dfb0d6d14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_35dea4dd-8fc5-493b-8176-4a2e481d2dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0d18d7bc-5e76-4a6c-8ab6-45a558e55a87" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_35dea4dd-8fc5-493b-8176-4a2e481d2dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_598f6fae-de04-4688-acde-7e4eb0fde978" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_35dea4dd-8fc5-493b-8176-4a2e481d2dc0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_598f6fae-de04-4688-acde-7e4eb0fde978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_f3941e58-92a5-498b-9419-3778afec879e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_598f6fae-de04-4688-acde-7e4eb0fde978" xlink:to="loc_us-gaap_LoansPayableMember_f3941e58-92a5-498b-9419-3778afec879e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_405e5c7b-f91c-4453-9ba2-5a689cf5ca90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0d18d7bc-5e76-4a6c-8ab6-45a558e55a87" xlink:to="loc_us-gaap_DebtInstrumentLineItems_405e5c7b-f91c-4453-9ba2-5a689cf5ca90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ff9b6b20-322a-4615-9de3-a085833aa44f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_405e5c7b-f91c-4453-9ba2-5a689cf5ca90" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ff9b6b20-322a-4615-9de3-a085833aa44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_c1a271a7-1411-4e44-9d5c-4efc3f929054" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_405e5c7b-f91c-4453-9ba2-5a689cf5ca90" xlink:to="loc_us-gaap_DebtInstrumentTerm_c1a271a7-1411-4e44-9d5c-4efc3f929054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_d2771440-0af9-48c7-b7ee-93c7d6c34a73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_405e5c7b-f91c-4453-9ba2-5a689cf5ca90" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_d2771440-0af9-48c7-b7ee-93c7d6c34a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_29907080-a494-4d03-b501-ac19599e452e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_405e5c7b-f91c-4453-9ba2-5a689cf5ca90" xlink:to="loc_us-gaap_LongTermDebtCurrent_29907080-a494-4d03-b501-ac19599e452e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_c2cb7d77-3621-44fa-964f-bf2b410cb4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_405e5c7b-f91c-4453-9ba2-5a689cf5ca90" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_c2cb7d77-3621-44fa-964f-bf2b410cb4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_7af19167-942c-4468-a923-fcd7c917ea75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_405e5c7b-f91c-4453-9ba2-5a689cf5ca90" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_7af19167-942c-4468-a923-fcd7c917ea75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f88ad50d-59d0-4906-bad2-7ec3f8ffa09c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_405e5c7b-f91c-4453-9ba2-5a689cf5ca90" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f88ad50d-59d0-4906-bad2-7ec3f8ffa09c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_a1ba8319-2f36-4a58-92d1-c92979ab7977" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_405e5c7b-f91c-4453-9ba2-5a689cf5ca90" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_a1ba8319-2f36-4a58-92d1-c92979ab7977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_9eee4daf-bd25-44a9-8732-89fd91f9ca4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_405e5c7b-f91c-4453-9ba2-5a689cf5ca90" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_9eee4daf-bd25-44a9-8732-89fd91f9ca4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/DebtContractualmaturitiesofdebtobligationsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#DebtContractualmaturitiesofdebtobligationsDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/DebtContractualmaturitiesofdebtobligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_694707e2-d9c0-4856-b6b0-e293c0bcadb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract_44180d2c-2c67-45e1-bc9b-d8bb39e4c7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationFiscalYearMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_694707e2-d9c0-4856-b6b0-e293c0bcadb5" xlink:to="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract_44180d2c-2c67-45e1-bc9b-d8bb39e4c7d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_14d4c5ac-98ac-4c92-8b23-4b4614c907cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract_44180d2c-2c67-45e1-bc9b-d8bb39e4c7d0" xlink:to="loc_us-gaap_ContractualObligationDueInNextTwelveMonths_14d4c5ac-98ac-4c92-8b23-4b4614c907cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInSecondYear_301f292d-f98c-459a-9df0-de1c2ee9b269" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInSecondYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract_44180d2c-2c67-45e1-bc9b-d8bb39e4c7d0" xlink:to="loc_us-gaap_ContractualObligationDueInSecondYear_301f292d-f98c-459a-9df0-de1c2ee9b269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInThirdYear_026ee98b-a2c8-4f2b-9af2-c57354d8c176" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInThirdYear"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract_44180d2c-2c67-45e1-bc9b-d8bb39e4c7d0" xlink:to="loc_us-gaap_ContractualObligationDueInThirdYear_026ee98b-a2c8-4f2b-9af2-c57354d8c176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInFourthYear_cdc4b59f-ead8-4e58-9e30-56f7365999b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInFourthYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract_44180d2c-2c67-45e1-bc9b-d8bb39e4c7d0" xlink:to="loc_us-gaap_ContractualObligationDueInFourthYear_cdc4b59f-ead8-4e58-9e30-56f7365999b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueInFifthYear_48689054-83c3-4fd2-8099-65a8b01fdb6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueInFifthYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract_44180d2c-2c67-45e1-bc9b-d8bb39e4c7d0" xlink:to="loc_us-gaap_ContractualObligationDueInFifthYear_48689054-83c3-4fd2-8099-65a8b01fdb6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligationDueAfterFifthYear_12bf9059-17e1-4ff4-a128-81c8ca1dc36e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligationDueAfterFifthYear"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract_44180d2c-2c67-45e1-bc9b-d8bb39e4c7d0" xlink:to="loc_us-gaap_ContractualObligationDueAfterFifthYear_12bf9059-17e1-4ff4-a128-81c8ca1dc36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_d942a836-078a-4a79-b01a-1041787967a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractualObligationFiscalYearMaturityAbstract_44180d2c-2c67-45e1-bc9b-d8bb39e4c7d0" xlink:to="loc_us-gaap_ContractualObligation_d942a836-078a-4a79-b01a-1041787967a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0d9c48b9-c35a-4690-bba2-b7adeac5b328" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_edd97d9e-5a1e-4235-a354-a7392be3a412" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0d9c48b9-c35a-4690-bba2-b7adeac5b328" xlink:to="loc_us-gaap_InterestExpenseDebt_edd97d9e-5a1e-4235-a354-a7392be3a412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized_4b2e8eb5-9108-4fc9-9792-94be49e34266" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0d9c48b9-c35a-4690-bba2-b7adeac5b328" xlink:to="loc_us-gaap_InterestCostsCapitalized_4b2e8eb5-9108-4fc9-9792-94be49e34266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_95220c08-7208-46bb-8569-90c2f17b3684" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0d9c48b9-c35a-4690-bba2-b7adeac5b328" xlink:to="loc_us-gaap_InterestPaidNet_95220c08-7208-46bb-8569-90c2f17b3684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ProductRevenueProductSalesDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ProductRevenueProductSalesDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/ProductRevenueProductSalesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0a9462f2-b455-46d2-9966-bc732c7bc0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_8b7dcc9f-ad9c-4bc9-b21c-93169bafa2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0a9462f2-b455-46d2-9966-bc732c7bc0f2" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_8b7dcc9f-ad9c-4bc9-b21c-93169bafa2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b6f6a10b-abb6-40ee-95aa-606d3af83eef" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8b7dcc9f-ad9c-4bc9-b21c-93169bafa2e4" xlink:to="loc_srt_ProductOrServiceAxis_b6f6a10b-abb6-40ee-95aa-606d3af83eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_af7a050d-314a-46e9-afad-c162173030cd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b6f6a10b-abb6-40ee-95aa-606d3af83eef" xlink:to="loc_srt_ProductsAndServicesDomain_af7a050d-314a-46e9-afad-c162173030cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_5315e949-0afb-461e-bd64-6fb874c11fab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_af7a050d-314a-46e9-afad-c162173030cd" xlink:to="loc_us-gaap_ProductMember_5315e949-0afb-461e-bd64-6fb874c11fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ProductNameAxis_15b3c760-5342-42cd-80f8-bfb2cfd67a58" xlink:href="bgne-20241231.xsd#bgne_ProductNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8b7dcc9f-ad9c-4bc9-b21c-93169bafa2e4" xlink:to="loc_bgne_ProductNameAxis_15b3c760-5342-42cd-80f8-bfb2cfd67a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ProductNameDomain_8d3e7114-e03d-4a43-bdcc-6437c61b31f2" xlink:href="bgne-20241231.xsd#bgne_ProductNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_ProductNameAxis_15b3c760-5342-42cd-80f8-bfb2cfd67a58" xlink:to="loc_bgne_ProductNameDomain_8d3e7114-e03d-4a43-bdcc-6437c61b31f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_BRUKINSAMember_ffb6c2d5-b98c-496e-b103-0165d3c74a28" xlink:href="bgne-20241231.xsd#bgne_BRUKINSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_ProductNameDomain_8d3e7114-e03d-4a43-bdcc-6437c61b31f2" xlink:to="loc_bgne_BRUKINSAMember_ffb6c2d5-b98c-496e-b103-0165d3c74a28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_TislelizumabMember_a96f00c7-6d59-4567-bce5-e3de585b5d4d" xlink:href="bgne-20241231.xsd#bgne_TislelizumabMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_ProductNameDomain_8d3e7114-e03d-4a43-bdcc-6437c61b31f2" xlink:to="loc_bgne_TislelizumabMember_a96f00c7-6d59-4567-bce5-e3de585b5d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_XGEVAMember_2f18d773-f828-4aec-96ab-6f906743c07f" xlink:href="bgne-20241231.xsd#bgne_XGEVAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_ProductNameDomain_8d3e7114-e03d-4a43-bdcc-6437c61b31f2" xlink:to="loc_bgne_XGEVAMember_2f18d773-f828-4aec-96ab-6f906743c07f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_BLINCYTOMember_ea6f95d4-306e-4da0-97fc-01cf2db57807" xlink:href="bgne-20241231.xsd#bgne_BLINCYTOMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_ProductNameDomain_8d3e7114-e03d-4a43-bdcc-6437c61b31f2" xlink:to="loc_bgne_BLINCYTOMember_ea6f95d4-306e-4da0-97fc-01cf2db57807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_KYPROLISMember_94f6df57-e696-4ab1-8d4e-36d256ccd56e" xlink:href="bgne-20241231.xsd#bgne_KYPROLISMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_ProductNameDomain_8d3e7114-e03d-4a43-bdcc-6437c61b31f2" xlink:to="loc_bgne_KYPROLISMember_94f6df57-e696-4ab1-8d4e-36d256ccd56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_POBEVCYMember_7d657f8c-1bc7-4cb4-877c-50cf3f7a2ee6" xlink:href="bgne-20241231.xsd#bgne_POBEVCYMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_ProductNameDomain_8d3e7114-e03d-4a43-bdcc-6437c61b31f2" xlink:to="loc_bgne_POBEVCYMember_7d657f8c-1bc7-4cb4-877c-50cf3f7a2ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_REVLIMIDMember_58c8f8a5-3ac0-4bee-81e0-e385bb2d19fa" xlink:href="bgne-20241231.xsd#bgne_REVLIMIDMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_ProductNameDomain_8d3e7114-e03d-4a43-bdcc-6437c61b31f2" xlink:to="loc_bgne_REVLIMIDMember_58c8f8a5-3ac0-4bee-81e0-e385bb2d19fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_OtherMember_7df1abba-3011-4bfc-b835-44e021468e34" xlink:href="bgne-20241231.xsd#bgne_OtherMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_ProductNameDomain_8d3e7114-e03d-4a43-bdcc-6437c61b31f2" xlink:to="loc_bgne_OtherMember_7df1abba-3011-4bfc-b835-44e021468e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_136f3974-221e-4659-adf7-434ba070df98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8b7dcc9f-ad9c-4bc9-b21c-93169bafa2e4" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_136f3974-221e-4659-adf7-434ba070df98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_83eaa942-59c7-4008-8d38-aadc1a2c4878" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_136f3974-221e-4659-adf7-434ba070df98" xlink:to="loc_us-gaap_RevenuesAbstract_83eaa942-59c7-4008-8d38-aadc1a2c4878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeReductions_8385708d-c50c-4fc2-b64d-c9e2210603b5" xlink:href="bgne-20241231.xsd#bgne_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeReductions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_83eaa942-59c7-4008-8d38-aadc1a2c4878" xlink:to="loc_bgne_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeReductions_8385708d-c50c-4fc2-b64d-c9e2210603b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RevenueRecognitionRevenueReduction_25c35dbc-c4a8-4712-833d-aaeddc8c4ede" xlink:href="bgne-20241231.xsd#bgne_RevenueRecognitionRevenueReduction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_83eaa942-59c7-4008-8d38-aadc1a2c4878" xlink:to="loc_bgne_RevenueRecognitionRevenueReduction_25c35dbc-c4a8-4712-833d-aaeddc8c4ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_60282b98-e187-4376-936b-f4dd1915ed5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_83eaa942-59c7-4008-8d38-aadc1a2c4878" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_60282b98-e187-4376-936b-f4dd1915ed5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ProductRevenueAccruedSalesRebatesandReturnsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ProductRevenueAccruedSalesRebatesandReturnsDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/ProductRevenueAccruedSalesRebatesandReturnsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_efc446f4-c812-48da-a575-cec6c7de8872" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_3525ec93-6029-4dda-adce-366a5d332983" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_efc446f4-c812-48da-a575-cec6c7de8872" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_3525ec93-6029-4dda-adce-366a5d332983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7f14cec3-0160-4bef-b18e-b479ea2957a6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3525ec93-6029-4dda-adce-366a5d332983" xlink:to="loc_srt_ProductOrServiceAxis_7f14cec3-0160-4bef-b18e-b479ea2957a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ff080f2c-45b8-4d90-9491-4a67173039be" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7f14cec3-0160-4bef-b18e-b479ea2957a6" xlink:to="loc_srt_ProductsAndServicesDomain_ff080f2c-45b8-4d90-9491-4a67173039be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_45bd84b7-7878-4455-abba-b15ba3fb0075" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ff080f2c-45b8-4d90-9491-4a67173039be" xlink:to="loc_us-gaap_ProductMember_45bd84b7-7878-4455-abba-b15ba3fb0075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RebatesReturnsAndOtherDeductionsMember_2127fc84-6dc0-4c42-a97d-adc6eb0ed84e" xlink:href="bgne-20241231.xsd#bgne_RebatesReturnsAndOtherDeductionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_45bd84b7-7878-4455-abba-b15ba3fb0075" xlink:to="loc_bgne_RebatesReturnsAndOtherDeductionsMember_2127fc84-6dc0-4c42-a97d-adc6eb0ed84e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ContraARAccrualsMember_32c87981-1ed1-4a70-8b4f-2006a5bd1b87" xlink:href="bgne-20241231.xsd#bgne_ContraARAccrualsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_45bd84b7-7878-4455-abba-b15ba3fb0075" xlink:to="loc_bgne_ContraARAccrualsMember_32c87981-1ed1-4a70-8b4f-2006a5bd1b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_ceed2f3a-1f09-4c95-a9a3-2db474faa73f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3525ec93-6029-4dda-adce-366a5d332983" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_ceed2f3a-1f09-4c95-a9a3-2db474faa73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AccruedSalesRebatesAndReturnsRollForward_5b6b1354-5bc5-4791-bf93-743927df65c1" xlink:href="bgne-20241231.xsd#bgne_AccruedSalesRebatesAndReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ceed2f3a-1f09-4c95-a9a3-2db474faa73f" xlink:to="loc_bgne_AccruedSalesRebatesAndReturnsRollForward_5b6b1354-5bc5-4791-bf93-743927df65c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions_1f976779-d82c-4516-a7e1-a09eef51bb7d" xlink:href="bgne-20241231.xsd#bgne_RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_AccruedSalesRebatesAndReturnsRollForward_5b6b1354-5bc5-4791-bf93-743927df65c1" xlink:to="loc_bgne_RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions_1f976779-d82c-4516-a7e1-a09eef51bb7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AccountsReceivableAllowanceForChargebacksAndCreditLoss_0825a4a7-6ffa-4741-bae5-8859df128a8c" xlink:href="bgne-20241231.xsd#bgne_AccountsReceivableAllowanceForChargebacksAndCreditLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_AccruedSalesRebatesAndReturnsRollForward_5b6b1354-5bc5-4791-bf93-743927df65c1" xlink:to="loc_bgne_AccountsReceivableAllowanceForChargebacksAndCreditLoss_0825a4a7-6ffa-4741-bae5-8859df128a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions_9d946214-0abe-4b34-a4e3-1ebec022d6b8" xlink:href="bgne-20241231.xsd#bgne_RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_AccruedSalesRebatesAndReturnsRollForward_5b6b1354-5bc5-4791-bf93-743927df65c1" xlink:to="loc_bgne_RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions_9d946214-0abe-4b34-a4e3-1ebec022d6b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RevenueRecognitionRevenueReduction_085b557c-d6d2-453b-aa32-73ae9532e217" xlink:href="bgne-20241231.xsd#bgne_RevenueRecognitionRevenueReduction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_AccruedSalesRebatesAndReturnsRollForward_5b6b1354-5bc5-4791-bf93-743927df65c1" xlink:to="loc_bgne_RevenueRecognitionRevenueReduction_085b557c-d6d2-453b-aa32-73ae9532e217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RevenueRecognitionRevenueReductionsPaymentsAndCredits_4f3a959c-9924-4cab-a9fe-bd06fd831b1e" xlink:href="bgne-20241231.xsd#bgne_RevenueRecognitionRevenueReductionsPaymentsAndCredits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_AccruedSalesRebatesAndReturnsRollForward_5b6b1354-5bc5-4791-bf93-743927df65c1" xlink:to="loc_bgne_RevenueRecognitionRevenueReductionsPaymentsAndCredits_4f3a959c-9924-4cab-a9fe-bd06fd831b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions_0d94d7ed-362d-44ca-9c31-ae0440e80d32" xlink:href="bgne-20241231.xsd#bgne_RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_AccruedSalesRebatesAndReturnsRollForward_5b6b1354-5bc5-4791-bf93-743927df65c1" xlink:to="loc_bgne_RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions_0d94d7ed-362d-44ca-9c31-ae0440e80d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AccountsReceivableAllowanceForChargebacksAndCreditLoss_e836b772-fdaf-4670-b531-2f109494c42a" xlink:href="bgne-20241231.xsd#bgne_AccountsReceivableAllowanceForChargebacksAndCreditLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_AccruedSalesRebatesAndReturnsRollForward_5b6b1354-5bc5-4791-bf93-743927df65c1" xlink:to="loc_bgne_AccountsReceivableAllowanceForChargebacksAndCreditLoss_e836b772-fdaf-4670-b531-2f109494c42a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions_bec436fa-c157-4d69-b46a-d765a713ea47" xlink:href="bgne-20241231.xsd#bgne_RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_AccruedSalesRebatesAndReturnsRollForward_5b6b1354-5bc5-4791-bf93-743927df65c1" xlink:to="loc_bgne_RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions_bec436fa-c157-4d69-b46a-d765a713ea47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/LossPerShareDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#LossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/LossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ea8b77ce-5edb-4c78-a87a-32a171afb5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_ac5f0e37-6849-4fe7-91bc-8252d7832bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ea8b77ce-5edb-4c78-a87a-32a171afb5bb" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_ac5f0e37-6849-4fe7-91bc-8252d7832bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3ad04967-5ad3-4ab8-9de0-cc313326ef61" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_ac5f0e37-6849-4fe7-91bc-8252d7832bf9" xlink:to="loc_us-gaap_NetIncomeLoss_3ad04967-5ad3-4ab8-9de0-cc313326ef61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_fcda6fe4-ad15-46b0-aa42-13e756479f10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ea8b77ce-5edb-4c78-a87a-32a171afb5bb" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_fcda6fe4-ad15-46b0-aa42-13e756479f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6a29f98e-9da0-42d9-b23c-73f48e5c9b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_fcda6fe4-ad15-46b0-aa42-13e756479f10" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6a29f98e-9da0-42d9-b23c-73f48e5c9b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_da2a7937-5d1c-447c-91b7-22c7465c44c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_fcda6fe4-ad15-46b0-aa42-13e756479f10" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_da2a7937-5d1c-447c-91b7-22c7465c44c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_2c8819a7-9279-4bb6-92bb-5cdf2940d167" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_fcda6fe4-ad15-46b0-aa42-13e756479f10" xlink:to="loc_us-gaap_EarningsPerShareBasic_2c8819a7-9279-4bb6-92bb-5cdf2940d167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_a8f31f6a-e7b1-41bb-8f21-ee8ff0864081" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_fcda6fe4-ad15-46b0-aa42-13e756479f10" xlink:to="loc_us-gaap_EarningsPerShareDiluted_a8f31f6a-e7b1-41bb-8f21-ee8ff0864081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ShareBasedCompensation2016ShareOptionandIncentivePlanDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ShareBasedCompensation2016ShareOptionandIncentivePlanDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/ShareBasedCompensation2016ShareOptionandIncentivePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_36cc92be-cdad-417c-bb98-54da2c6ec6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_99efa4da-cb31-4642-b998-2f43a1d2d250" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_36cc92be-cdad-417c-bb98-54da2c6ec6c3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_99efa4da-cb31-4642-b998-2f43a1d2d250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e31f101c-b5a7-460f-a3a7-f0e8460fb61f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_99efa4da-cb31-4642-b998-2f43a1d2d250" xlink:to="loc_us-gaap_PlanNameAxis_e31f101c-b5a7-460f-a3a7-f0e8460fb61f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d7754f2f-d53f-4dc4-a3ac-f383f1bd23f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_e31f101c-b5a7-460f-a3a7-f0e8460fb61f" xlink:to="loc_us-gaap_PlanNameDomain_d7754f2f-d53f-4dc4-a3ac-f383f1bd23f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShareOptionAndIncentivePlan2016Member_90011731-9330-44a0-bde0-fa6359a9b3d3" xlink:href="bgne-20241231.xsd#bgne_ShareOptionAndIncentivePlan2016Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d7754f2f-d53f-4dc4-a3ac-f383f1bd23f3" xlink:to="loc_bgne_ShareOptionAndIncentivePlan2016Member_90011731-9330-44a0-bde0-fa6359a9b3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShareIncentivePlan2011Member_f6e800ff-fbc3-4163-81e9-0221e5487cc3" xlink:href="bgne-20241231.xsd#bgne_ShareIncentivePlan2011Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d7754f2f-d53f-4dc4-a3ac-f383f1bd23f3" xlink:to="loc_bgne_ShareIncentivePlan2011Member_f6e800ff-fbc3-4163-81e9-0221e5487cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ThirdAmendedAndRestated2016PlanMember_e18be0c2-41d3-4c80-940d-57c86eebb6b5" xlink:href="bgne-20241231.xsd#bgne_ThirdAmendedAndRestated2016PlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d7754f2f-d53f-4dc4-a3ac-f383f1bd23f3" xlink:to="loc_bgne_ThirdAmendedAndRestated2016PlanMember_e18be0c2-41d3-4c80-940d-57c86eebb6b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_30a465aa-ff40-4aef-95a4-69404e6e705c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_99efa4da-cb31-4642-b998-2f43a1d2d250" xlink:to="loc_us-gaap_AwardTypeAxis_30a465aa-ff40-4aef-95a4-69404e6e705c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d78a06c-aaeb-4162-ab79-3288899a9cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_30a465aa-ff40-4aef-95a4-69404e6e705c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d78a06c-aaeb-4162-ab79-3288899a9cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_60800ce3-e998-4b9c-bfa3-b44a2126e9e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1d78a06c-aaeb-4162-ab79-3288899a9cbb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_60800ce3-e998-4b9c-bfa3-b44a2126e9e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ad4261d-2210-45f9-ac0e-7e0aaf83e3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_99efa4da-cb31-4642-b998-2f43a1d2d250" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ad4261d-2210-45f9-ac0e-7e0aaf83e3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_3bc198ca-d616-4acf-acfb-80a07ecc4934" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2ad4261d-2210-45f9-ac0e-7e0aaf83e3a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_3bc198ca-d616-4acf-acfb-80a07ecc4934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7fa397a7-8a9f-4be4-ab14-61ca3b10bc58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_3bc198ca-d616-4acf-acfb-80a07ecc4934" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_7fa397a7-8a9f-4be4-ab14-61ca3b10bc58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriod_dd603e24-31d6-42a6-b805-28b8a421aba7" xlink:href="bgne-20241231.xsd#bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_3bc198ca-d616-4acf-acfb-80a07ecc4934" xlink:to="loc_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriod_dd603e24-31d6-42a6-b805-28b8a421aba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_415f84cf-38c8-4065-8492-c28b260751f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_3bc198ca-d616-4acf-acfb-80a07ecc4934" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_415f84cf-38c8-4065-8492-c28b260751f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_ef3e5dea-05d2-41f4-9f4a-4acc3b017325" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_3bc198ca-d616-4acf-acfb-80a07ecc4934" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_ef3e5dea-05d2-41f4-9f4a-4acc3b017325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f78040a7-e954-42b3-8ef5-6d83b282894b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_3bc198ca-d616-4acf-acfb-80a07ecc4934" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f78040a7-e954-42b3-8ef5-6d83b282894b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ShareBasedCompensation2018InducementEquityPlanDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ShareBasedCompensation2018InducementEquityPlanDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/ShareBasedCompensation2018InducementEquityPlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_34b1155e-0f57-4152-8230-d95e4ba17dcd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4809eca-3cdb-4aef-bd8a-2d5e90b9696f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_34b1155e-0f57-4152-8230-d95e4ba17dcd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4809eca-3cdb-4aef-bd8a-2d5e90b9696f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_be1dacc9-f1fe-44d0-bc73-48ca3a3bf456" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4809eca-3cdb-4aef-bd8a-2d5e90b9696f" xlink:to="loc_us-gaap_PlanNameAxis_be1dacc9-f1fe-44d0-bc73-48ca3a3bf456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b9ffb85d-1d66-4205-8702-00697d69f429" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_be1dacc9-f1fe-44d0-bc73-48ca3a3bf456" xlink:to="loc_us-gaap_PlanNameDomain_b9ffb85d-1d66-4205-8702-00697d69f429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_InducementEquityPlan2018Member_e1d185cc-b4d7-4d8b-8316-17b1540c84e6" xlink:href="bgne-20241231.xsd#bgne_InducementEquityPlan2018Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_b9ffb85d-1d66-4205-8702-00697d69f429" xlink:to="loc_bgne_InducementEquityPlan2018Member_e1d185cc-b4d7-4d8b-8316-17b1540c84e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8707993-7ed7-4ee1-a3f5-047ba507f844" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4809eca-3cdb-4aef-bd8a-2d5e90b9696f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8707993-7ed7-4ee1-a3f5-047ba507f844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ba89ee7b-1f5a-4636-be24-643bcbacd155" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a8707993-7ed7-4ee1-a3f5-047ba507f844" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_ba89ee7b-1f5a-4636-be24-643bcbacd155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ShareBasedCompensation2018EmployeeSharePurchasePlanDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ShareBasedCompensation2018EmployeeSharePurchasePlanDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/ShareBasedCompensation2018EmployeeSharePurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f218f7b2-fda3-4934-84c0-8a1a02b6e8ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e31f6a33-a0f9-4c05-b573-29b6f9c2af34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f218f7b2-fda3-4934-84c0-8a1a02b6e8ea" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e31f6a33-a0f9-4c05-b573-29b6f9c2af34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_f8d23593-d99a-4350-a850-4f32877f42ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e31f6a33-a0f9-4c05-b573-29b6f9c2af34" xlink:to="loc_us-gaap_PlanNameAxis_f8d23593-d99a-4350-a850-4f32877f42ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_52c47a57-6899-4841-84c3-263eecb8f598" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_f8d23593-d99a-4350-a850-4f32877f42ac" xlink:to="loc_us-gaap_PlanNameDomain_52c47a57-6899-4841-84c3-263eecb8f598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_EmployeeSharePurchasePlan2018Member_5e98f909-7eb2-4763-a9ff-9032cd794a14" xlink:href="bgne-20241231.xsd#bgne_EmployeeSharePurchasePlan2018Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_52c47a57-6899-4841-84c3-263eecb8f598" xlink:to="loc_bgne_EmployeeSharePurchasePlan2018Member_5e98f909-7eb2-4763-a9ff-9032cd794a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e120cd7-8a03-4be3-a8f6-7fc3257143b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e31f6a33-a0f9-4c05-b573-29b6f9c2af34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e120cd7-8a03-4be3-a8f6-7fc3257143b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c1227679-90e6-43e7-9d5d-ad0e970d355e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e120cd7-8a03-4be3-a8f6-7fc3257143b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c1227679-90e6-43e7-9d5d-ad0e970d355e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_9c3ac6cb-374e-4d3c-b31c-d7c50976ded8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e120cd7-8a03-4be3-a8f6-7fc3257143b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_9c3ac6cb-374e-4d3c-b31c-d7c50976ded8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_ed45fc50-14b8-48be-be61-228137e7cc66" xlink:href="bgne-20241231.xsd#bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e120cd7-8a03-4be3-a8f6-7fc3257143b6" xlink:to="loc_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_ed45fc50-14b8-48be-be61-228137e7cc66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountOnPurchasePriceOfCommonStockPercent_12380a31-f2ee-4340-a55c-11a8e8841ecc" xlink:href="bgne-20241231.xsd#bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountOnPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e120cd7-8a03-4be3-a8f6-7fc3257143b6" xlink:to="loc_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountOnPurchasePriceOfCommonStockPercent_12380a31-f2ee-4340-a55c-11a8e8841ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_MaximumPercentageOfEligibleEarningsSetSideToPurchaseOrdinaryShares_ad77c31f-7a31-4f2a-bb22-64fe27282a2c" xlink:href="bgne-20241231.xsd#bgne_MaximumPercentageOfEligibleEarningsSetSideToPurchaseOrdinaryShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e120cd7-8a03-4be3-a8f6-7fc3257143b6" xlink:to="loc_bgne_MaximumPercentageOfEligibleEarningsSetSideToPurchaseOrdinaryShares_ad77c31f-7a31-4f2a-bb22-64fe27282a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberOfAvailableSharesAvailableForFutureIssuance_519207ca-31fe-4fd1-9084-d56ff69180e8" xlink:href="bgne-20241231.xsd#bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberOfAvailableSharesAvailableForFutureIssuance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5e120cd7-8a03-4be3-a8f6-7fc3257143b6" xlink:to="loc_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberOfAvailableSharesAvailableForFutureIssuance_519207ca-31fe-4fd1-9084-d56ff69180e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ShareBasedCompensationSharesIssuedUnderEmployeeSharePurchasePlanDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ShareBasedCompensationSharesIssuedUnderEmployeeSharePurchasePlanDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/ShareBasedCompensationSharesIssuedUnderEmployeeSharePurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f0faa07c-7e2d-489d-9487-9fe526bb96c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32b0e9f1-a3ff-4e07-ad06-8d6a6826c8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f0faa07c-7e2d-489d-9487-9fe526bb96c6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32b0e9f1-a3ff-4e07-ad06-8d6a6826c8f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_c4a133a2-6b49-4db8-ad1d-3422f1189cef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32b0e9f1-a3ff-4e07-ad06-8d6a6826c8f7" xlink:to="loc_us-gaap_PlanNameAxis_c4a133a2-6b49-4db8-ad1d-3422f1189cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_78d3cc78-8587-4ed6-be32-9296b49d5f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_c4a133a2-6b49-4db8-ad1d-3422f1189cef" xlink:to="loc_us-gaap_PlanNameDomain_78d3cc78-8587-4ed6-be32-9296b49d5f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_EmployeeSharePurchasePlan2018Member_1ab9496f-b418-4b00-ba2a-da743718ec75" xlink:href="bgne-20241231.xsd#bgne_EmployeeSharePurchasePlan2018Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_78d3cc78-8587-4ed6-be32-9296b49d5f6d" xlink:to="loc_bgne_EmployeeSharePurchasePlan2018Member_1ab9496f-b418-4b00-ba2a-da743718ec75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d53b6d61-c332-4383-86c8-35deea33fec5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32b0e9f1-a3ff-4e07-ad06-8d6a6826c8f7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d53b6d61-c332-4383-86c8-35deea33fec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_302ea9b8-fd63-46ab-9b00-13192ee57c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d53b6d61-c332-4383-86c8-35deea33fec5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_302ea9b8-fd63-46ab-9b00-13192ee57c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_SharePriceAmericanDepositoryShares_ef12e6a0-0b9b-4264-afab-491549ca79f4" xlink:href="bgne-20241231.xsd#bgne_SharePriceAmericanDepositoryShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d53b6d61-c332-4383-86c8-35deea33fec5" xlink:to="loc_bgne_SharePriceAmericanDepositoryShares_ef12e6a0-0b9b-4264-afab-491549ca79f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_d1182f1f-959b-4540-8e49-364686b47585" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d53b6d61-c332-4383-86c8-35deea33fec5" xlink:to="loc_us-gaap_SharePrice_d1182f1f-959b-4540-8e49-364686b47585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice_5c0d951a-b07a-4a96-bc4a-a80ab2693617" xlink:href="bgne-20241231.xsd#bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d53b6d61-c332-4383-86c8-35deea33fec5" xlink:to="loc_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice_5c0d951a-b07a-4a96-bc4a-a80ab2693617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice_048aae94-04c4-44d2-b571-2108550be5fb" xlink:href="bgne-20241231.xsd#bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d53b6d61-c332-4383-86c8-35deea33fec5" xlink:to="loc_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice_048aae94-04c4-44d2-b571-2108550be5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_2de0f653-c4fe-4f10-94ac-42879a2434cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d53b6d61-c332-4383-86c8-35deea33fec5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_2de0f653-c4fe-4f10-94ac-42879a2434cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ShareBasedCompensationOptionsandRestrictedSharesandRestrictedStockUnitsVestingPeriodsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ShareBasedCompensationOptionsandRestrictedSharesandRestrictedStockUnitsVestingPeriodsDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/ShareBasedCompensationOptionsandRestrictedSharesandRestrictedStockUnitsVestingPeriodsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_60cf87d1-8c8f-48d8-be6c-ab91f28aa484" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d220c7b5-699f-414c-8d99-d82cffce47d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_60cf87d1-8c8f-48d8-be6c-ab91f28aa484" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d220c7b5-699f-414c-8d99-d82cffce47d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_50afd271-b213-46e0-9318-f1ee37c07b86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d220c7b5-699f-414c-8d99-d82cffce47d0" xlink:to="loc_us-gaap_AwardTypeAxis_50afd271-b213-46e0-9318-f1ee37c07b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a74a4bdd-ec98-4752-812d-a10a55d74ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_50afd271-b213-46e0-9318-f1ee37c07b86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a74a4bdd-ec98-4752-812d-a10a55d74ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_149a9e26-fb6a-41c0-ba8d-40454f7b73b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a74a4bdd-ec98-4752-812d-a10a55d74ee0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_149a9e26-fb6a-41c0-ba8d-40454f7b73b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_653c9d22-8a35-4dac-82f6-d460c719d627" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a74a4bdd-ec98-4752-812d-a10a55d74ee0" xlink:to="loc_us-gaap_RestrictedStockMember_653c9d22-8a35-4dac-82f6-d460c719d627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_59029a31-761b-4c60-bb6a-ab5ee2a5582c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a74a4bdd-ec98-4752-812d-a10a55d74ee0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_59029a31-761b-4c60-bb6a-ab5ee2a5582c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6a7755f8-6ba7-441c-92ea-8e3f38b3b4ba" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d220c7b5-699f-414c-8d99-d82cffce47d0" xlink:to="loc_srt_RangeAxis_6a7755f8-6ba7-441c-92ea-8e3f38b3b4ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_08d285bd-ea3b-4cc6-9ee6-222557572959" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6a7755f8-6ba7-441c-92ea-8e3f38b3b4ba" xlink:to="loc_srt_RangeMember_08d285bd-ea3b-4cc6-9ee6-222557572959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b185dc19-fab4-40d1-b0cf-7442de509fa1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_08d285bd-ea3b-4cc6-9ee6-222557572959" xlink:to="loc_srt_MinimumMember_b185dc19-fab4-40d1-b0cf-7442de509fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_0598bf0b-e8ad-4edb-b39d-6f781fda1063" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_08d285bd-ea3b-4cc6-9ee6-222557572959" xlink:to="loc_srt_MaximumMember_0598bf0b-e8ad-4edb-b39d-6f781fda1063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8fa55366-1498-4ad1-ba23-0fb0ec016bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d220c7b5-699f-414c-8d99-d82cffce47d0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8fa55366-1498-4ad1-ba23-0fb0ec016bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ef3d7b33-c42f-4b6f-b5c9-f303d1d5f36c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8fa55366-1498-4ad1-ba23-0fb0ec016bc5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ef3d7b33-c42f-4b6f-b5c9-f303d1d5f36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8df2eeeb-2684-46a5-bf71-dd269215c70f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8fa55366-1498-4ad1-ba23-0fb0ec016bc5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_8df2eeeb-2684-46a5-bf71-dd269215c70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ShareBasedCompensationShareOptionRollforwardDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a15c5d88-ac37-45d0-9425-ec7f9baabbbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d64fcc59-7701-4f00-a44e-33438bc79fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a15c5d88-ac37-45d0-9425-ec7f9baabbbb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d64fcc59-7701-4f00-a44e-33438bc79fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_86ef4d52-f16f-4046-9f7c-ffcdee1f085e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d64fcc59-7701-4f00-a44e-33438bc79fb3" xlink:to="loc_us-gaap_AwardTypeAxis_86ef4d52-f16f-4046-9f7c-ffcdee1f085e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c368421-abf1-47a3-ab5a-c5916811a1b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_86ef4d52-f16f-4046-9f7c-ffcdee1f085e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c368421-abf1-47a3-ab5a-c5916811a1b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c78f3b83-a1a1-41ee-9789-0ab92710ddcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6c368421-abf1-47a3-ab5a-c5916811a1b3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c78f3b83-a1a1-41ee-9789-0ab92710ddcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_912144c9-2b36-4426-a327-ab4da7e039a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d64fcc59-7701-4f00-a44e-33438bc79fb3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_912144c9-2b36-4426-a327-ab4da7e039a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_788f6f10-5a7f-4019-ba9f-111994a88139" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_912144c9-2b36-4426-a327-ab4da7e039a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_788f6f10-5a7f-4019-ba9f-111994a88139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_68945fce-7090-45e1-a9f8-974a08e40047" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_788f6f10-5a7f-4019-ba9f-111994a88139" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_68945fce-7090-45e1-a9f8-974a08e40047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3b273f8b-91ff-49ff-9776-207392a73275" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_788f6f10-5a7f-4019-ba9f-111994a88139" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3b273f8b-91ff-49ff-9776-207392a73275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0844c46c-e3dd-4c21-8128-9241e72e9633" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_788f6f10-5a7f-4019-ba9f-111994a88139" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0844c46c-e3dd-4c21-8128-9241e72e9633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_64c879ee-ca5a-4f14-a70f-3df965823d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_788f6f10-5a7f-4019-ba9f-111994a88139" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_64c879ee-ca5a-4f14-a70f-3df965823d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4b15edf1-f960-4306-a6c4-09014f1fb865" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_788f6f10-5a7f-4019-ba9f-111994a88139" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4b15edf1-f960-4306-a6c4-09014f1fb865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_453a1807-2694-47c0-a25f-ef6f938167c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_912144c9-2b36-4426-a327-ab4da7e039a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_453a1807-2694-47c0-a25f-ef6f938167c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f0233263-5ec4-4f89-8d68-678c9f380ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_912144c9-2b36-4426-a327-ab4da7e039a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f0233263-5ec4-4f89-8d68-678c9f380ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7fca11e3-a650-46bd-bcee-603e31244282" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_912144c9-2b36-4426-a327-ab4da7e039a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7fca11e3-a650-46bd-bcee-603e31244282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3f678de2-8dae-4a91-aca1-ee5a98f4d54c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7fca11e3-a650-46bd-bcee-603e31244282" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3f678de2-8dae-4a91-aca1-ee5a98f4d54c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_375cdbd1-b5be-4426-9a55-167366347b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7fca11e3-a650-46bd-bcee-603e31244282" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_375cdbd1-b5be-4426-9a55-167366347b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f5a28ec6-36da-460b-a8c3-4e9d5c74ef5d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7fca11e3-a650-46bd-bcee-603e31244282" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f5a28ec6-36da-460b-a8c3-4e9d5c74ef5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_420bfbe3-698c-4b74-b53b-f20014311db0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7fca11e3-a650-46bd-bcee-603e31244282" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_420bfbe3-698c-4b74-b53b-f20014311db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_34587230-c50f-43ef-a69e-24bdaa97a5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_7fca11e3-a650-46bd-bcee-603e31244282" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_34587230-c50f-43ef-a69e-24bdaa97a5a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0b86fcc2-1f12-4808-a4e8-e4c803740fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_912144c9-2b36-4426-a327-ab4da7e039a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0b86fcc2-1f12-4808-a4e8-e4c803740fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_358234b1-b86f-469b-be03-3af8e3fb960b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_912144c9-2b36-4426-a327-ab4da7e039a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_358234b1-b86f-469b-be03-3af8e3fb960b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_c3264cb3-bbeb-4764-bbc6-2dba0ed35b25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_912144c9-2b36-4426-a327-ab4da7e039a1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_c3264cb3-bbeb-4764-bbc6-2dba0ed35b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_825b6817-c51b-4cda-bc87-d602b901a0ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_c3264cb3-bbeb-4764-bbc6-2dba0ed35b25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_825b6817-c51b-4cda-bc87-d602b901a0ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_81ba04a0-2a18-45ac-b518-924d3cbc8587" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_912144c9-2b36-4426-a327-ab4da7e039a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_81ba04a0-2a18-45ac-b518-924d3cbc8587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0ad77356-5a97-4463-b1a7-06aa4fc30c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_81ba04a0-2a18-45ac-b518-924d3cbc8587" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0ad77356-5a97-4463-b1a7-06aa4fc30c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_65a7e1ca-3c9e-4a70-aa7e-7f3281884d30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_81ba04a0-2a18-45ac-b518-924d3cbc8587" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_65a7e1ca-3c9e-4a70-aa7e-7f3281884d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_db6a89a1-c9f8-4720-be63-cd5eee9551a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_81ba04a0-2a18-45ac-b518-924d3cbc8587" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_db6a89a1-c9f8-4720-be63-cd5eee9551a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_cb449fca-0165-4502-8a2b-96233c2e1d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_912144c9-2b36-4426-a327-ab4da7e039a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_cb449fca-0165-4502-8a2b-96233c2e1d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f6dd14fe-92c9-44c3-b2a2-6933183e7a02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_cb449fca-0165-4502-8a2b-96233c2e1d1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f6dd14fe-92c9-44c3-b2a2-6933183e7a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_89f7bb35-95e3-4d69-984e-e6b4ea7a3ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_cb449fca-0165-4502-8a2b-96233c2e1d1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_89f7bb35-95e3-4d69-984e-e6b4ea7a3ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_cbe24967-756e-4ef0-a641-cfa27481f2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_cb449fca-0165-4502-8a2b-96233c2e1d1a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_cbe24967-756e-4ef0-a641-cfa27481f2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8ca92b7a-4be1-4df8-8ac2-aee1b2168a94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_cb449fca-0165-4502-8a2b-96233c2e1d1a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_8ca92b7a-4be1-4df8-8ac2-aee1b2168a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShareBasedPaymentArrangementNonvestedAwardOptionNumberOfShares_6e08a13f-f52d-4b5d-9a2c-438132c7bdf8" xlink:href="bgne-20241231.xsd#bgne_ShareBasedPaymentArrangementNonvestedAwardOptionNumberOfShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_912144c9-2b36-4426-a327-ab4da7e039a1" xlink:to="loc_bgne_ShareBasedPaymentArrangementNonvestedAwardOptionNumberOfShares_6e08a13f-f52d-4b5d-9a2c-438132c7bdf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_10283972-be45-459b-88a1-c44cffc9d077" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_912144c9-2b36-4426-a327-ab4da7e039a1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_10283972-be45-459b-88a1-c44cffc9d077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c9355cf4-c8f9-4e07-ab97-5aec14dceb14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_912144c9-2b36-4426-a327-ab4da7e039a1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c9355cf4-c8f9-4e07-ab97-5aec14dceb14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_3abe3ff5-4a02-461b-92ae-cb8f184dd75c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_912144c9-2b36-4426-a327-ab4da7e039a1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_3abe3ff5-4a02-461b-92ae-cb8f184dd75c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ShareBasedCompensationFairValueAssumptionsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ShareBasedCompensationFairValueAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/ShareBasedCompensationFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_31c559e7-4f6a-4e95-a44f-c7d5cbc99cff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72c5e984-9fed-498d-830b-d326618a0947" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_31c559e7-4f6a-4e95-a44f-c7d5cbc99cff" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72c5e984-9fed-498d-830b-d326618a0947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2054f0ff-3c75-4491-b53e-2d3da89d3dff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72c5e984-9fed-498d-830b-d326618a0947" xlink:to="loc_us-gaap_AwardTypeAxis_2054f0ff-3c75-4491-b53e-2d3da89d3dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b1b3e45b-32ee-44fe-b051-d8ab62ef3ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2054f0ff-3c75-4491-b53e-2d3da89d3dff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b1b3e45b-32ee-44fe-b051-d8ab62ef3ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_c6afdd3e-bb50-4333-9887-ffe62729cc66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b1b3e45b-32ee-44fe-b051-d8ab62ef3ce6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_c6afdd3e-bb50-4333-9887-ffe62729cc66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_44740395-d6a8-4446-b54e-76c939efba06" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72c5e984-9fed-498d-830b-d326618a0947" xlink:to="loc_srt_RangeAxis_44740395-d6a8-4446-b54e-76c939efba06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_16f4e979-4c7b-4e13-b749-7e4248c69fa3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_44740395-d6a8-4446-b54e-76c939efba06" xlink:to="loc_srt_RangeMember_16f4e979-4c7b-4e13-b749-7e4248c69fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1d483379-0392-4814-8686-a52d1a5427df" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_16f4e979-4c7b-4e13-b749-7e4248c69fa3" xlink:to="loc_srt_MinimumMember_1d483379-0392-4814-8686-a52d1a5427df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_601d2875-d028-4838-90e2-ea693d4e5da9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_16f4e979-4c7b-4e13-b749-7e4248c69fa3" xlink:to="loc_srt_MaximumMember_601d2875-d028-4838-90e2-ea693d4e5da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_215441e9-1885-4159-ad16-35d60abfdc6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_72c5e984-9fed-498d-830b-d326618a0947" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_215441e9-1885-4159-ad16-35d60abfdc6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_59e387e4-68e9-4081-880c-80f7a419622c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_215441e9-1885-4159-ad16-35d60abfdc6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_59e387e4-68e9-4081-880c-80f7a419622c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_48ff6230-2447-449d-bdea-353f0636164e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_59e387e4-68e9-4081-880c-80f7a419622c" xlink:to="loc_us-gaap_SharePrice_48ff6230-2447-449d-bdea-353f0636164e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1041840a-318d-4df7-9396-84582c2cbe4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_59e387e4-68e9-4081-880c-80f7a419622c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1041840a-318d-4df7-9396-84582c2cbe4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2c9086d1-a866-4444-a5f3-5f539a0e5492" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_59e387e4-68e9-4081-880c-80f7a419622c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2c9086d1-a866-4444-a5f3-5f539a0e5492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum_da75a87c-6daf-4f8c-ab6c-a660a6f01360" xlink:href="bgne-20241231.xsd#bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_59e387e4-68e9-4081-880c-80f7a419622c" xlink:to="loc_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum_da75a87c-6daf-4f8c-ab6c-a660a6f01360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_c4ba8a7c-bef2-4246-a19c-0a5aee49eb42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_59e387e4-68e9-4081-880c-80f7a419622c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_c4ba8a7c-bef2-4246-a19c-0a5aee49eb42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_59ab6d2e-f91b-4d49-92b2-90fa6d78e30d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_59e387e4-68e9-4081-880c-80f7a419622c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_59ab6d2e-f91b-4d49-92b2-90fa6d78e30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d6dd8d61-5632-47c7-a61e-78f330dde5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_59e387e4-68e9-4081-880c-80f7a419622c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d6dd8d61-5632-47c7-a61e-78f330dde5b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8987a95b-a47c-43b4-b563-0f1b2eaa729e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_59e387e4-68e9-4081-880c-80f7a419622c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8987a95b-a47c-43b4-b563-0f1b2eaa729e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ShareBasedCompensationRestrictedShareUnitsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ShareBasedCompensationRestrictedShareUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/ShareBasedCompensationRestrictedShareUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_15aded83-c201-4e84-8779-b11e3ed177db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deda8de9-bfd9-4b10-b9f2-5d985b4ef6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_15aded83-c201-4e84-8779-b11e3ed177db" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deda8de9-bfd9-4b10-b9f2-5d985b4ef6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9542f629-33f0-4f48-89cb-766dfdbfe52f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deda8de9-bfd9-4b10-b9f2-5d985b4ef6c3" xlink:to="loc_us-gaap_AwardTypeAxis_9542f629-33f0-4f48-89cb-766dfdbfe52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a5c35ec-2f9d-4255-8f80-96cbf394181c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9542f629-33f0-4f48-89cb-766dfdbfe52f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a5c35ec-2f9d-4255-8f80-96cbf394181c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2191502f-6d22-40a4-ae74-9fac062a0876" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3a5c35ec-2f9d-4255-8f80-96cbf394181c" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2191502f-6d22-40a4-ae74-9fac062a0876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a64c00-6ca5-4f2a-b7e9-c69f8fe229e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_deda8de9-bfd9-4b10-b9f2-5d985b4ef6c3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a64c00-6ca5-4f2a-b7e9-c69f8fe229e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_735ca510-df58-433f-9bd6-14059ec521eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a64c00-6ca5-4f2a-b7e9-c69f8fe229e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_735ca510-df58-433f-9bd6-14059ec521eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_368c676c-f014-43d3-8471-e4b4d1ffce99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_735ca510-df58-433f-9bd6-14059ec521eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_368c676c-f014-43d3-8471-e4b4d1ffce99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4e28c6be-da1f-49dd-8945-432463b67a93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_735ca510-df58-433f-9bd6-14059ec521eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_4e28c6be-da1f-49dd-8945-432463b67a93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_25da48a7-69f6-49fa-a293-7e7a14f13ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_735ca510-df58-433f-9bd6-14059ec521eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_25da48a7-69f6-49fa-a293-7e7a14f13ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9ba54d6d-5731-4643-99b8-0970dc9a2764" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_735ca510-df58-433f-9bd6-14059ec521eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9ba54d6d-5731-4643-99b8-0970dc9a2764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b5da67ff-f654-4ff4-9313-b14cf15f327e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_735ca510-df58-433f-9bd6-14059ec521eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b5da67ff-f654-4ff4-9313-b14cf15f327e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestOutstandingNumber_07005d69-fbee-4b31-aca4-b95f49845323" xlink:href="bgne-20241231.xsd#bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a64c00-6ca5-4f2a-b7e9-c69f8fe229e6" xlink:to="loc_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestOutstandingNumber_07005d69-fbee-4b31-aca4-b95f49845323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_98c18fb8-e7f9-4d40-9b7e-4b5d91b7242e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a64c00-6ca5-4f2a-b7e9-c69f8fe229e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_98c18fb8-e7f9-4d40-9b7e-4b5d91b7242e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0b0c3666-545c-438f-b8b2-bd4b9c0b81e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_98c18fb8-e7f9-4d40-9b7e-4b5d91b7242e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0b0c3666-545c-438f-b8b2-bd4b9c0b81e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e91e3fad-a03a-428d-ba59-59a37f5f2812" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_98c18fb8-e7f9-4d40-9b7e-4b5d91b7242e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_e91e3fad-a03a-428d-ba59-59a37f5f2812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5e47641c-88b7-44f7-a498-bfbe34543fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_98c18fb8-e7f9-4d40-9b7e-4b5d91b7242e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_5e47641c-88b7-44f7-a498-bfbe34543fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_569ecdf3-6ff5-4c34-be92-92dde8f1a3e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_98c18fb8-e7f9-4d40-9b7e-4b5d91b7242e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_569ecdf3-6ff5-4c34-be92-92dde8f1a3e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d390192d-f570-41c1-a53f-85356673e027" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_98c18fb8-e7f9-4d40-9b7e-4b5d91b7242e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d390192d-f570-41c1-a53f-85356673e027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue_58e6df25-9736-4e15-91bc-1d2dd79cdbaf" xlink:href="bgne-20241231.xsd#bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a64c00-6ca5-4f2a-b7e9-c69f8fe229e6" xlink:to="loc_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue_58e6df25-9736-4e15-91bc-1d2dd79cdbaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_67faf673-c988-43b0-a3be-5cff17f8888e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_17a64c00-6ca5-4f2a-b7e9-c69f8fe229e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_67faf673-c988-43b0-a3be-5cff17f8888e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c21545b9-c908-4020-9ea8-9dff6b202ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_67faf673-c988-43b0-a3be-5cff17f8888e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_c21545b9-c908-4020-9ea8-9dff6b202ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d2b08fb5-66f8-426a-abe6-51c4784025fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_67faf673-c988-43b0-a3be-5cff17f8888e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d2b08fb5-66f8-426a-abe6-51c4784025fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ShareBasedCompensationSharebasedCompensationExpenseDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ShareBasedCompensationSharebasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/ShareBasedCompensationSharebasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82152214-435b-4ba1-9bae-5c6efd8194e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bda29dd6-68a9-4096-9715-9309f2619a66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_82152214-435b-4ba1-9bae-5c6efd8194e8" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bda29dd6-68a9-4096-9715-9309f2619a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_bc09f224-0ea7-45c8-8d98-7942e274d705" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bda29dd6-68a9-4096-9715-9309f2619a66" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_bc09f224-0ea7-45c8-8d98-7942e274d705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_514ecdfd-05ce-476f-a489-873fef714361" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_bc09f224-0ea7-45c8-8d98-7942e274d705" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_514ecdfd-05ce-476f-a489-873fef714361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ca5cdc58-657a-4edb-a6c7-e40977870286" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_514ecdfd-05ce-476f-a489-873fef714361" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_ca5cdc58-657a-4edb-a6c7-e40977870286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_94dea62d-cf56-45e4-9a2e-d9cb44b3ab27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_514ecdfd-05ce-476f-a489-873fef714361" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_94dea62d-cf56-45e4-9a2e-d9cb44b3ab27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3e644949-a0ad-4cf2-9cca-046ba6027ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bda29dd6-68a9-4096-9715-9309f2619a66" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3e644949-a0ad-4cf2-9cca-046ba6027ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_726edf2a-6a38-486a-9b77-64a3575dcd16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3e644949-a0ad-4cf2-9cca-046ba6027ab7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_726edf2a-6a38-486a-9b77-64a3575dcd16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d9a0b6a7-d800-4cab-b186-98ba4f4a53d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_726edf2a-6a38-486a-9b77-64a3575dcd16" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d9a0b6a7-d800-4cab-b186-98ba4f4a53d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#AccumulatedOtherComprehensiveLossIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_332aa647-cf25-4a59-8bab-64b0e0a070cd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_5c59be1f-fe7d-4701-bec6-a2baa8f710a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_332aa647-cf25-4a59-8bab-64b0e0a070cd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_5c59be1f-fe7d-4701-bec6-a2baa8f710a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1844aed4-62ae-4bd3-9ef2-388def6f488f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_5c59be1f-fe7d-4701-bec6-a2baa8f710a7" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1844aed4-62ae-4bd3-9ef2-388def6f488f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1527ecc2-515f-4146-8e53-7e995f2053ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1844aed4-62ae-4bd3-9ef2-388def6f488f" xlink:to="loc_us-gaap_EquityComponentDomain_1527ecc2-515f-4146-8e53-7e995f2053ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_66904ca5-55e7-41de-a628-526cbd89521c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_1527ecc2-515f-4146-8e53-7e995f2053ff" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_66904ca5-55e7-41de-a628-526cbd89521c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_af945e0b-4cc1-43a6-b1e8-250206df823c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_66904ca5-55e7-41de-a628-526cbd89521c" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_af945e0b-4cc1-43a6-b1e8-250206df823c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_4128ad1c-914b-4ea1-8e44-2c71b5e63fec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_66904ca5-55e7-41de-a628-526cbd89521c" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_4128ad1c-914b-4ea1-8e44-2c71b5e63fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_a9263f72-99f0-459e-b192-48fec70fb094" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_66904ca5-55e7-41de-a628-526cbd89521c" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_a9263f72-99f0-459e-b192-48fec70fb094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_076a65b2-ae9f-4984-8d5b-0a35ebfb57b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_5c59be1f-fe7d-4701-bec6-a2baa8f710a7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_076a65b2-ae9f-4984-8d5b-0a35ebfb57b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_9dfdbd31-da00-41f6-85f9-b63e95912101" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_076a65b2-ae9f-4984-8d5b-0a35ebfb57b6" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_9dfdbd31-da00-41f6-85f9-b63e95912101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_229f2911-0070-4c59-9666-c6484a6da003" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_9dfdbd31-da00-41f6-85f9-b63e95912101" xlink:to="loc_us-gaap_StockholdersEquity_229f2911-0070-4c59-9666-c6484a6da003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_6fd9ce49-9623-4ae0-8ea6-deed439728ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_9dfdbd31-da00-41f6-85f9-b63e95912101" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_6fd9ce49-9623-4ae0-8ea6-deed439728ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_0b8be900-9717-4655-bb09-1fec3f37aea5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_9dfdbd31-da00-41f6-85f9-b63e95912101" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_0b8be900-9717-4655-bb09-1fec3f37aea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e27d6f79-e5aa-4448-b3d9-ce1addbd787f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_9dfdbd31-da00-41f6-85f9-b63e95912101" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_e27d6f79-e5aa-4448-b3d9-ce1addbd787f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c279dbf3-9d97-449e-a813-9de07f36dcbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_9dfdbd31-da00-41f6-85f9-b63e95912101" xlink:to="loc_us-gaap_StockholdersEquity_c279dbf3-9d97-449e-a813-9de07f36dcbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ShareholdersEquityDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ShareholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/ShareholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_44d81cb6-4875-4be7-974e-aa539d6b9c26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_23b51665-377e-4000-abd6-716cc24eb670" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_44d81cb6-4875-4be7-974e-aa539d6b9c26" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_23b51665-377e-4000-abd6-716cc24eb670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1e10f03c-9ffb-412c-be16-db267ed61121" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_23b51665-377e-4000-abd6-716cc24eb670" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1e10f03c-9ffb-412c-be16-db267ed61121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_03648c5a-935c-4a25-96ef-3bcf2ba6238b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1e10f03c-9ffb-412c-be16-db267ed61121" xlink:to="loc_us-gaap_EquityComponentDomain_03648c5a-935c-4a25-96ef-3bcf2ba6238b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0d937521-34a1-4afd-8642-5e891dbf30f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_03648c5a-935c-4a25-96ef-3bcf2ba6238b" xlink:to="loc_us-gaap_CommonStockMember_0d937521-34a1-4afd-8642-5e891dbf30f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_e886818a-0d09-4bfc-a641-cd98b2764131" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_23b51665-377e-4000-abd6-716cc24eb670" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_e886818a-0d09-4bfc-a641-cd98b2764131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_77cd8a81-803f-4a2e-b5ad-f31af1d412b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e886818a-0d09-4bfc-a641-cd98b2764131" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_77cd8a81-803f-4a2e-b5ad-f31af1d412b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_febe996f-7d68-4189-a098-01d9e32d93b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_e886818a-0d09-4bfc-a641-cd98b2764131" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue_febe996f-7d68-4189-a098-01d9e32d93b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/RestrictedNetAssetsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#RestrictedNetAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/RestrictedNetAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RestrictedNetAssetsDisclosureAbstract_f45f94e6-6ab3-4b29-b08e-c93215eb8a48" xlink:href="bgne-20241231.xsd#bgne_RestrictedNetAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9e265c4d-e0ae-41f2-ae8c-4eb146fe8503" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_RestrictedNetAssetsDisclosureAbstract_f45f94e6-6ab3-4b29-b08e-c93215eb8a48" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9e265c4d-e0ae-41f2-ae8c-4eb146fe8503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_1f55a4fb-0cff-4fe1-b7e1-8678904386c0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9e265c4d-e0ae-41f2-ae8c-4eb146fe8503" xlink:to="loc_srt_StatementGeographicalAxis_1f55a4fb-0cff-4fe1-b7e1-8678904386c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_66ffe7f0-585a-40a5-b3d2-fe30fedb3d5a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_1f55a4fb-0cff-4fe1-b7e1-8678904386c0" xlink:to="loc_srt_SegmentGeographicalDomain_66ffe7f0-585a-40a5-b3d2-fe30fedb3d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_f31f0289-cfd3-42cc-a5e9-bb11c15866ea" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_66ffe7f0-585a-40a5-b3d2-fe30fedb3d5a" xlink:to="loc_country_CN_f31f0289-cfd3-42cc-a5e9-bb11c15866ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_0d4dc035-c76d-494e-8d3e-b068213dac6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9e265c4d-e0ae-41f2-ae8c-4eb146fe8503" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_0d4dc035-c76d-494e-8d3e-b068213dac6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RestrictedNetAssetsAbstract_1b2e10bc-2760-4d89-8362-c08788f0ac38" xlink:href="bgne-20241231.xsd#bgne_RestrictedNetAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_0d4dc035-c76d-494e-8d3e-b068213dac6a" xlink:to="loc_bgne_RestrictedNetAssetsAbstract_1b2e10bc-2760-4d89-8362-c08788f0ac38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage_f5159140-5b86-4cc5-a97d-712df8cca201" xlink:href="bgne-20241231.xsd#bgne_RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_RestrictedNetAssetsAbstract_1b2e10bc-2760-4d89-8362-c08788f0ac38" xlink:to="loc_bgne_RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage_f5159140-5b86-4cc5-a97d-712df8cca201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RestrictedNetAssetsRequiredStatutoryReserveAsPercentageOfRegisteredCapital_865ce712-805f-432c-b559-76a14a1c53fc" xlink:href="bgne-20241231.xsd#bgne_RestrictedNetAssetsRequiredStatutoryReserveAsPercentageOfRegisteredCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_RestrictedNetAssetsAbstract_1b2e10bc-2760-4d89-8362-c08788f0ac38" xlink:to="loc_bgne_RestrictedNetAssetsRequiredStatutoryReserveAsPercentageOfRegisteredCapital_865ce712-805f-432c-b559-76a14a1c53fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RestrictedNetAssetsAppropriatedToStatutoryReserves_04d1f8db-302d-42d6-8067-97cf8ec8327e" xlink:href="bgne-20241231.xsd#bgne_RestrictedNetAssetsAppropriatedToStatutoryReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_RestrictedNetAssetsAbstract_1b2e10bc-2760-4d89-8362-c08788f0ac38" xlink:to="loc_bgne_RestrictedNetAssetsAppropriatedToStatutoryReserves_04d1f8db-302d-42d6-8067-97cf8ec8327e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_RestrictedNetAssetsAmount_42540244-66e5-4ce8-8960-3276cb07626e" xlink:href="bgne-20241231.xsd#bgne_RestrictedNetAssetsAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_bgne_RestrictedNetAssetsAbstract_1b2e10bc-2760-4d89-8362-c08788f0ac38" xlink:to="loc_bgne_RestrictedNetAssetsAmount_42540244-66e5-4ce8-8960-3276cb07626e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/EmployeeBenefitPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#EmployeeBenefitPlansAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/EmployeeBenefitPlansAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_34f4888e-c458-40cf-8341-1ba49a9c7085" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTable_abd97c9f-884a-4967-9642-723b17aadc07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_34f4888e-c458-40cf-8341-1ba49a9c7085" xlink:to="loc_us-gaap_DefinedContributionPlanTable_abd97c9f-884a-4967-9642-723b17aadc07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_040cb408-fbd4-4b9c-aa85-6aeaaa85b615" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_abd97c9f-884a-4967-9642-723b17aadc07" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_040cb408-fbd4-4b9c-aa85-6aeaaa85b615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_bdfcc0ba-ac99-4fa9-810a-e591bca13a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_040cb408-fbd4-4b9c-aa85-6aeaaa85b615" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_bdfcc0ba-ac99-4fa9-810a-e591bca13a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_743b312b-83e4-4268-b077-989120cce77e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_bdfcc0ba-ac99-4fa9-810a-e591bca13a1f" xlink:to="loc_us-gaap_DomesticPlanMember_743b312b-83e4-4268-b077-989120cce77e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_bf8c8aee-d52b-49a9-99eb-e735f0ab2fcb" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_743b312b-83e4-4268-b077-989120cce77e" xlink:to="loc_country_US_bf8c8aee-d52b-49a9-99eb-e735f0ab2fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_4b314629-bee8-4e15-9a01-40d3d5af44df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_bdfcc0ba-ac99-4fa9-810a-e591bca13a1f" xlink:to="loc_us-gaap_ForeignPlanMember_4b314629-bee8-4e15-9a01-40d3d5af44df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_2173e6f1-a406-41e3-929d-56a027363bcc" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignPlanMember_4b314629-bee8-4e15-9a01-40d3d5af44df" xlink:to="loc_country_CN_2173e6f1-a406-41e3-929d-56a027363bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CH_1e263a46-e406-42f2-b688-418a7f353ed4" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CH"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignPlanMember_4b314629-bee8-4e15-9a01-40d3d5af44df" xlink:to="loc_country_CH_1e263a46-e406-42f2-b688-418a7f353ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_2cb76e12-4e00-4fc6-8e08-099984c31e37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_abd97c9f-884a-4967-9642-723b17aadc07" xlink:to="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_2cb76e12-4e00-4fc6-8e08-099984c31e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_edde486b-e513-460f-84b6-de0193e2b189" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_2cb76e12-4e00-4fc6-8e08-099984c31e37" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_edde486b-e513-460f-84b6-de0193e2b189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_7d06042a-ffbf-45aa-a371-8ce572784b73" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_2cb76e12-4e00-4fc6-8e08-099984c31e37" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_7d06042a-ffbf-45aa-a371-8ce572784b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_77e13b5f-20fe-44c0-b5ad-e07ff9b0475f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_2cb76e12-4e00-4fc6-8e08-099984c31e37" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_77e13b5f-20fe-44c0-b5ad-e07ff9b0475f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_5615bf5b-70da-4af9-b7e9-fc7add72c98e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_2cb76e12-4e00-4fc6-8e08-099984c31e37" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_5615bf5b-70da-4af9-b7e9-fc7add72c98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_f5ab0d60-36e1-416d-9c7b-f8067c82df6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_2cb76e12-4e00-4fc6-8e08-099984c31e37" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_f5ab0d60-36e1-416d-9c7b-f8067c82df6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/EmployeeBenefitPlansTotalExpectedBenefitPaymentsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#EmployeeBenefitPlansTotalExpectedBenefitPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/EmployeeBenefitPlansTotalExpectedBenefitPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_77fe6cf4-894e-4842-bee8-92a0207ffe5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_5533d0b3-55dd-468f-91d6-7ff14f952d30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_77fe6cf4-894e-4842-bee8-92a0207ffe5c" xlink:to="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_5533d0b3-55dd-468f-91d6-7ff14f952d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_8478b092-3cbf-4c83-96e5-0c7c86960f66" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_5533d0b3-55dd-468f-91d6-7ff14f952d30" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_8478b092-3cbf-4c83-96e5-0c7c86960f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_adaee3c9-32c2-4fd8-a9f0-03ad469afe96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_5533d0b3-55dd-468f-91d6-7ff14f952d30" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_adaee3c9-32c2-4fd8-a9f0-03ad469afe96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_5784a9c7-1e93-4dbf-bddd-0e858c46cc95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_5533d0b3-55dd-468f-91d6-7ff14f952d30" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_5784a9c7-1e93-4dbf-bddd-0e858c46cc95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_fddf8783-cac8-43bd-b2d4-027a334258bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_5533d0b3-55dd-468f-91d6-7ff14f952d30" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_fddf8783-cac8-43bd-b2d4-027a334258bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_fffce1d5-3aac-4056-bb33-1b770f2b952f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_5533d0b3-55dd-468f-91d6-7ff14f952d30" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_fffce1d5-3aac-4056-bb33-1b770f2b952f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_561560d2-6e6b-428f-b332-9d596464eb34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_5533d0b3-55dd-468f-91d6-7ff14f952d30" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_561560d2-6e6b-428f-b332-9d596464eb34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_DefinedBenefitPlanExpectedFutureBenefitPaymentTotal_a7911e76-757f-4318-a267-f6c21ed974c4" xlink:href="bgne-20241231.xsd#bgne_DefinedBenefitPlanExpectedFutureBenefitPaymentTotal"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract_5533d0b3-55dd-468f-91d6-7ff14f952d30" xlink:to="loc_bgne_DefinedBenefitPlanExpectedFutureBenefitPaymentTotal_a7911e76-757f-4318-a267-f6c21ed974c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7ff077ca-02ca-4338-9e4c-4f173d08f792" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_a2a552cf-8a3f-40cb-934a-212d1d8e8ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7ff077ca-02ca-4338-9e4c-4f173d08f792" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_a2a552cf-8a3f-40cb-934a-212d1d8e8ae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_b26d105d-861b-42bc-9586-4d7f8574f58a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_a2a552cf-8a3f-40cb-934a-212d1d8e8ae3" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_b26d105d-861b-42bc-9586-4d7f8574f58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_4007fca1-46e9-4ffd-843c-4bc6e6b3daf8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis_b26d105d-861b-42bc-9586-4d7f8574f58a" xlink:to="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_4007fca1-46e9-4ffd-843c-4bc6e6b3daf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_MinimumPurchaseCommitmentsForSupplyPurchasedMember_cb7495c9-1704-4b55-a67a-014817fe4e75" xlink:href="bgne-20241231.xsd#bgne_MinimumPurchaseCommitmentsForSupplyPurchasedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_4007fca1-46e9-4ffd-843c-4bc6e6b3daf8" xlink:to="loc_bgne_MinimumPurchaseCommitmentsForSupplyPurchasedMember_cb7495c9-1704-4b55-a67a-014817fe4e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_3bf69013-5c2b-4ca4-8051-56134fc24440" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoriesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_4007fca1-46e9-4ffd-843c-4bc6e6b3daf8" xlink:to="loc_us-gaap_InventoriesMember_3bf69013-5c2b-4ca4-8051-56134fc24440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalAdditionsMember_c42dcfed-4458-4ddb-a2e4-3578a2390f52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalAdditionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain_4007fca1-46e9-4ffd-843c-4bc6e6b3daf8" xlink:to="loc_us-gaap_CapitalAdditionsMember_c42dcfed-4458-4ddb-a2e4-3578a2390f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_12e7f000-7af9-46e5-b077-1cc7bf56b88f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_a2a552cf-8a3f-40cb-934a-212d1d8e8ae3" xlink:to="loc_srt_CounterpartyNameAxis_12e7f000-7af9-46e5-b077-1cc7bf56b88f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_19fdcc9e-0dc7-48f9-a287-6745bb5aa9d8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_12e7f000-7af9-46e5-b077-1cc7bf56b88f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_19fdcc9e-0dc7-48f9-a287-6745bb5aa9d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AmgenIncMember_88a45ec4-2db3-4418-992d-8be28686c7e3" xlink:href="bgne-20241231.xsd#bgne_AmgenIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_19fdcc9e-0dc7-48f9-a287-6745bb5aa9d8" xlink:to="loc_bgne_AmgenIncMember_88a45ec4-2db3-4418-992d-8be28686c7e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_e95e54f2-caca-462d-b7b3-030be0cb5cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_a2a552cf-8a3f-40cb-934a-212d1d8e8ae3" xlink:to="loc_us-gaap_OtherCommitmentsAxis_e95e54f2-caca-462d-b7b3-030be0cb5cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_bcbfc0bb-95f3-4873-9b03-bd8502d4065d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_e95e54f2-caca-462d-b7b3-030be0cb5cbe" xlink:to="loc_us-gaap_OtherCommitmentsDomain_bcbfc0bb-95f3-4873-9b03-bd8502d4065d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_InvestmentsFundingCommitmentMember_732258b1-42d9-417a-a9c2-24ded2930406" xlink:href="bgne-20241231.xsd#bgne_InvestmentsFundingCommitmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_bcbfc0bb-95f3-4873-9b03-bd8502d4065d" xlink:to="loc_bgne_InvestmentsFundingCommitmentMember_732258b1-42d9-417a-a9c2-24ded2930406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_ae2e7692-dc31-42b5-88d5-1c62bbbc61ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationTable_a2a552cf-8a3f-40cb-934a-212d1d8e8ae3" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_ae2e7692-dc31-42b5-88d5-1c62bbbc61ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract_1bda52c1-e7ed-45da-a655-86199438508b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems_ae2e7692-dc31-42b5-88d5-1c62bbbc61ed" xlink:to="loc_us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract_1bda52c1-e7ed-45da-a655-86199438508b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_534b196e-3232-40ed-a50d-f22ea4e76dae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract_1bda52c1-e7ed-45da-a655-86199438508b" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_534b196e-3232-40ed-a50d-f22ea4e76dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_dae98251-1690-49bb-81bd-31e5e7e8e5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract_1bda52c1-e7ed-45da-a655-86199438508b" xlink:to="loc_us-gaap_OtherCommitment_dae98251-1690-49bb-81bd-31e5e7e8e5ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_MaximumCashAndServicesDevelopmentCommitment_208fdf3e-75ee-4f87-ac68-01a7e8f0572c" xlink:href="bgne-20241231.xsd#bgne_MaximumCashAndServicesDevelopmentCommitment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract_1bda52c1-e7ed-45da-a655-86199438508b" xlink:to="loc_bgne_MaximumCashAndServicesDevelopmentCommitment_208fdf3e-75ee-4f87-ac68-01a7e8f0572c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_LongTermFundingCommitmentNumberOfEquityInvestments_af8c3174-e0e8-4369-87ae-df7a63165e9d" xlink:href="bgne-20241231.xsd#bgne_LongTermFundingCommitmentNumberOfEquityInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract_1bda52c1-e7ed-45da-a655-86199438508b" xlink:to="loc_bgne_LongTermFundingCommitmentNumberOfEquityInvestments_af8c3174-e0e8-4369-87ae-df7a63165e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_LongTermFundingCommitmentMaximumAmount_e38442a9-e15f-4fb4-8e50-b60f7a4b8b72" xlink:href="bgne-20241231.xsd#bgne_LongTermFundingCommitmentMaximumAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract_1bda52c1-e7ed-45da-a655-86199438508b" xlink:to="loc_bgne_LongTermFundingCommitmentMaximumAmount_e38442a9-e15f-4fb4-8e50-b60f7a4b8b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/SegmentandGeographicInformationNarrativesDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#SegmentandGeographicInformationNarrativesDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/SegmentandGeographicInformationNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_1eed1cbf-0eab-4886-851f-f68265f228e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_32c2d87d-f7d6-415d-8589-c2629c2ea4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1eed1cbf-0eab-4886-851f-f68265f228e2" xlink:to="loc_us-gaap_NumberOfOperatingSegments_32c2d87d-f7d6-415d-8589-c2629c2ea4c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/SegmentandGeographicInformationScheduleofRevenuebyGeographicAreaDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#SegmentandGeographicInformationScheduleofRevenuebyGeographicAreaDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/SegmentandGeographicInformationScheduleofRevenuebyGeographicAreaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f008a266-1f6c-4cbb-a04c-7945bb7131c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_6f414b55-ad71-4bcc-99b0-6f26497d2ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f008a266-1f6c-4cbb-a04c-7945bb7131c8" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_6f414b55-ad71-4bcc-99b0-6f26497d2ae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ae2d12ee-c0f5-4a77-a4fb-ab72d86613d7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_6f414b55-ad71-4bcc-99b0-6f26497d2ae9" xlink:to="loc_srt_StatementGeographicalAxis_ae2d12ee-c0f5-4a77-a4fb-ab72d86613d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ce9d18ef-03ec-4472-93b5-a1a221eee4fa" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_ae2d12ee-c0f5-4a77-a4fb-ab72d86613d7" xlink:to="loc_srt_SegmentGeographicalDomain_ce9d18ef-03ec-4472-93b5-a1a221eee4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_66a37587-f39f-4664-b23d-706a3315b6c9" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ce9d18ef-03ec-4472-93b5-a1a221eee4fa" xlink:to="loc_country_US_66a37587-f39f-4664-b23d-706a3315b6c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_8989ebea-e2c3-42c6-80a7-5ce6b1ad8a15" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ce9d18ef-03ec-4472-93b5-a1a221eee4fa" xlink:to="loc_country_CN_8989ebea-e2c3-42c6-80a7-5ce6b1ad8a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_d699e86a-49cb-4d11-b76a-0f42b07f0e2c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ce9d18ef-03ec-4472-93b5-a1a221eee4fa" xlink:to="loc_srt_EuropeMember_d699e86a-49cb-4d11-b76a-0f42b07f0e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember_ea62ba23-27b7-4eaa-8538-e1d93f0ff795" xlink:href="bgne-20241231.xsd#bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ce9d18ef-03ec-4472-93b5-a1a221eee4fa" xlink:to="loc_bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember_ea62ba23-27b7-4eaa-8538-e1d93f0ff795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_20a3a776-4272-41c7-9c03-4ccf15c67d9c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_6f414b55-ad71-4bcc-99b0-6f26497d2ae9" xlink:to="loc_srt_ProductOrServiceAxis_20a3a776-4272-41c7-9c03-4ccf15c67d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2aee94bd-bfb7-4faf-801c-93e278477b7f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_20a3a776-4272-41c7-9c03-4ccf15c67d9c" xlink:to="loc_srt_ProductsAndServicesDomain_2aee94bd-bfb7-4faf-801c-93e278477b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_3ca94270-ecbb-423d-9fed-55e0918f3bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2aee94bd-bfb7-4faf-801c-93e278477b7f" xlink:to="loc_us-gaap_ProductMember_3ca94270-ecbb-423d-9fed-55e0918f3bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_CollaborationMember_c3c65d0e-a33f-49cb-8c4d-4cb583a39425" xlink:href="bgne-20241231.xsd#bgne_CollaborationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2aee94bd-bfb7-4faf-801c-93e278477b7f" xlink:to="loc_bgne_CollaborationMember_c3c65d0e-a33f-49cb-8c4d-4cb583a39425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_81de1f84-3420-4fe4-af38-44b2099f2cae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_6f414b55-ad71-4bcc-99b0-6f26497d2ae9" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_81de1f84-3420-4fe4-af38-44b2099f2cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_696fe433-cbfa-480b-811e-5bc5faae5ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_81de1f84-3420-4fe4-af38-44b2099f2cae" xlink:to="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_696fe433-cbfa-480b-811e-5bc5faae5ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8d0b20ea-4640-4730-a34a-b664746edf39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract_696fe433-cbfa-480b-811e-5bc5faae5ddc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8d0b20ea-4640-4730-a34a-b664746edf39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_d6183366-7575-433a-9740-9a4e8c8076b5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedStatementOfComprehensiveIncomeTable_0fedf38b-056c-410f-bf5b-bff3e95f7558" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedStatementOfComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_d6183366-7575-433a-9740-9a4e8c8076b5" xlink:to="loc_srt_CondensedStatementOfComprehensiveIncomeTable_0fedf38b-056c-410f-bf5b-bff3e95f7558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_624eba0d-2b79-4f68-9726-982b945a8901" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedStatementOfComprehensiveIncomeTable_0fedf38b-056c-410f-bf5b-bff3e95f7558" xlink:to="loc_srt_ConsolidatedEntitiesAxis_624eba0d-2b79-4f68-9726-982b945a8901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_ca318714-6cbf-4940-8c13-9e1c9b8e126e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_624eba0d-2b79-4f68-9726-982b945a8901" xlink:to="loc_srt_ConsolidatedEntitiesDomain_ca318714-6cbf-4940-8c13-9e1c9b8e126e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_5f99990f-09f9-4448-9774-fc34f6a2b284" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_ca318714-6cbf-4940-8c13-9e1c9b8e126e" xlink:to="loc_srt_ParentCompanyMember_5f99990f-09f9-4448-9774-fc34f6a2b284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedStatementOfIncomeCaptionsLineItems_e5955ff4-9411-4efd-b425-a1a9658ba59a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedStatementOfIncomeCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedStatementOfComprehensiveIncomeTable_0fedf38b-056c-410f-bf5b-bff3e95f7558" xlink:to="loc_srt_CondensedStatementOfIncomeCaptionsLineItems_e5955ff4-9411-4efd-b425-a1a9658ba59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_b5ff7b21-9aa0-4bfd-8dc6-392e44131b67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedStatementOfIncomeCaptionsLineItems_e5955ff4-9411-4efd-b425-a1a9658ba59a" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_b5ff7b21-9aa0-4bfd-8dc6-392e44131b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_accf8368-b271-44a6-bc55-f03ccfb283a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b5ff7b21-9aa0-4bfd-8dc6-392e44131b67" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_accf8368-b271-44a6-bc55-f03ccfb283a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3d8773a1-fea7-4dff-b323-7fe47a87daa2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b5ff7b21-9aa0-4bfd-8dc6-392e44131b67" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3d8773a1-fea7-4dff-b323-7fe47a87daa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_1fd2482e-1e7d-4830-9d02-924f310076f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_b5ff7b21-9aa0-4bfd-8dc6-392e44131b67" xlink:to="loc_us-gaap_CostsAndExpenses_1fd2482e-1e7d-4830-9d02-924f310076f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_aa01433b-ef58-4e30-8d56-703be7800a48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedStatementOfIncomeCaptionsLineItems_e5955ff4-9411-4efd-b425-a1a9658ba59a" xlink:to="loc_us-gaap_OperatingIncomeLoss_aa01433b-ef58-4e30-8d56-703be7800a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_de06ac3b-df17-4eae-9253-e282059fc688" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedStatementOfIncomeCaptionsLineItems_e5955ff4-9411-4efd-b425-a1a9658ba59a" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_de06ac3b-df17-4eae-9253-e282059fc688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_dc701eaf-c9fd-4bcb-a5e4-d970eb451679" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedStatementOfIncomeCaptionsLineItems_e5955ff4-9411-4efd-b425-a1a9658ba59a" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_dc701eaf-c9fd-4bcb-a5e4-d970eb451679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7fa93018-aa8c-4385-abf5-6ce7707d75a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedStatementOfIncomeCaptionsLineItems_e5955ff4-9411-4efd-b425-a1a9658ba59a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7fa93018-aa8c-4385-abf5-6ce7707d75a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c0ebd0fd-cac2-4af0-8489-788621ecba48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedStatementOfIncomeCaptionsLineItems_e5955ff4-9411-4efd-b425-a1a9658ba59a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c0ebd0fd-cac2-4af0-8489-788621ecba48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b6c4dee9-c194-4e69-acbc-39d6382cc4ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedStatementOfIncomeCaptionsLineItems_e5955ff4-9411-4efd-b425-a1a9658ba59a" xlink:to="loc_us-gaap_NetIncomeLoss_b6c4dee9-c194-4e69-acbc-39d6382cc4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveLossDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_87252ced-53ad-45eb-80c6-d42df7807c0c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedStatementOfComprehensiveIncomeTable_1046e37f-44c4-4a27-a0d2-27e86e275fe0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedStatementOfComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_87252ced-53ad-45eb-80c6-d42df7807c0c" xlink:to="loc_srt_CondensedStatementOfComprehensiveIncomeTable_1046e37f-44c4-4a27-a0d2-27e86e275fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_534226a3-674d-408b-af9a-b4cbfd8b61f6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedStatementOfComprehensiveIncomeTable_1046e37f-44c4-4a27-a0d2-27e86e275fe0" xlink:to="loc_srt_ConsolidatedEntitiesAxis_534226a3-674d-408b-af9a-b4cbfd8b61f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_fb8d91ca-35bf-4752-9e8b-13b6512ab8ba" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_534226a3-674d-408b-af9a-b4cbfd8b61f6" xlink:to="loc_srt_ConsolidatedEntitiesDomain_fb8d91ca-35bf-4752-9e8b-13b6512ab8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_d2150be1-724d-42b9-a813-5738d1b70e6d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_fb8d91ca-35bf-4752-9e8b-13b6512ab8ba" xlink:to="loc_srt_ParentCompanyMember_d2150be1-724d-42b9-a813-5738d1b70e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedStatementOfIncomeCaptionsLineItems_2ac13703-aa7b-4736-a50e-c995cab8762c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedStatementOfIncomeCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedStatementOfComprehensiveIncomeTable_1046e37f-44c4-4a27-a0d2-27e86e275fe0" xlink:to="loc_srt_CondensedStatementOfIncomeCaptionsLineItems_2ac13703-aa7b-4736-a50e-c995cab8762c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_699126b7-7c32-4dda-963c-8856516963f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedStatementOfIncomeCaptionsLineItems_2ac13703-aa7b-4736-a50e-c995cab8762c" xlink:to="loc_us-gaap_NetIncomeLossAbstract_699126b7-7c32-4dda-963c-8856516963f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ebd6d390-1327-4028-982a-5da078f37ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_699126b7-7c32-4dda-963c-8856516963f8" xlink:to="loc_us-gaap_NetIncomeLoss_ebd6d390-1327-4028-982a-5da078f37ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_6f9f7585-23e5-4796-b44f-fddf362bc96f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedStatementOfIncomeCaptionsLineItems_2ac13703-aa7b-4736-a50e-c995cab8762c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_6f9f7585-23e5-4796-b44f-fddf362bc96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_ca4ba2ef-4d6b-4c99-a31e-e6b2ed72dde4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_6f9f7585-23e5-4796-b44f-fddf362bc96f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_ca4ba2ef-4d6b-4c99-a31e-e6b2ed72dde4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_34ce0955-8950-47f6-bb16-242a7bec3da5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_6f9f7585-23e5-4796-b44f-fddf362bc96f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent_34ce0955-8950-47f6-bb16-242a7bec3da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_c18d1f7f-5402-4858-814e-0979cc430836" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract_6f9f7585-23e5-4796-b44f-fddf362bc96f" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_c18d1f7f-5402-4858-814e-0979cc430836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0868937e-fc53-4762-b654-9aa5e014f0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedStatementOfIncomeCaptionsLineItems_2ac13703-aa7b-4736-a50e-c995cab8762c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_0868937e-fc53-4762-b654-9aa5e014f0b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_88d60f00-ca86-498f-ad31-14b4095a6d5f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_288cbd45-4c17-44f8-af81-be20379a8531" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_88d60f00-ca86-498f-ad31-14b4095a6d5f" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_288cbd45-4c17-44f8-af81-be20379a8531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_8b5451cb-7509-45de-9cfb-40b856d0df9d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_288cbd45-4c17-44f8-af81-be20379a8531" xlink:to="loc_srt_ConsolidatedEntitiesAxis_8b5451cb-7509-45de-9cfb-40b856d0df9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_21273b64-6a42-4d11-934f-110d924c00ff" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_8b5451cb-7509-45de-9cfb-40b856d0df9d" xlink:to="loc_srt_ConsolidatedEntitiesDomain_21273b64-6a42-4d11-934f-110d924c00ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_99cf494b-94da-4f9b-b876-9a37021dc7ae" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_21273b64-6a42-4d11-934f-110d924c00ff" xlink:to="loc_srt_ParentCompanyMember_99cf494b-94da-4f9b-b876-9a37021dc7ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_23026e97-efc2-43bf-8807-0d4deed6268c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_288cbd45-4c17-44f8-af81-be20379a8531" xlink:to="loc_srt_CondensedFinancialStatementsCaptionsLineItems_23026e97-efc2-43bf-8807-0d4deed6268c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_1752a212-fd6b-487e-b0cf-c51e22b5bf47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_23026e97-efc2-43bf-8807-0d4deed6268c" xlink:to="loc_us-gaap_AssetsAbstract_1752a212-fd6b-487e-b0cf-c51e22b5bf47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_7cfcb840-2a54-4176-a568-8fa06aafdd33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1752a212-fd6b-487e-b0cf-c51e22b5bf47" xlink:to="loc_us-gaap_AssetsCurrentAbstract_7cfcb840-2a54-4176-a568-8fa06aafdd33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7516961d-c9e9-4b0c-9429-69f4ab5fc972" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7cfcb840-2a54-4176-a568-8fa06aafdd33" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7516961d-c9e9-4b0c-9429-69f4ab5fc972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8e529e0a-7e3d-4e6e-aa5a-9ba170bd4ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7cfcb840-2a54-4176-a568-8fa06aafdd33" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8e529e0a-7e3d-4e6e-aa5a-9ba170bd4ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_32a34bbc-09fb-40ce-8668-fc210d810e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7cfcb840-2a54-4176-a568-8fa06aafdd33" xlink:to="loc_us-gaap_AssetsCurrent_32a34bbc-09fb-40ce-8668-fc210d810e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_ae5f2fee-560e-4a3b-bc9d-e3fe0123de2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7cfcb840-2a54-4176-a568-8fa06aafdd33" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetNoncurrent_ae5f2fee-560e-4a3b-bc9d-e3fe0123de2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_fbbbaa78-b47d-4862-90f4-5a26964e0fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1752a212-fd6b-487e-b0cf-c51e22b5bf47" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_fbbbaa78-b47d-4862-90f4-5a26964e0fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0ae2c372-632c-4889-bfae-0515aa72a1df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1752a212-fd6b-487e-b0cf-c51e22b5bf47" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_0ae2c372-632c-4889-bfae-0515aa72a1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_2156f4a1-dc40-40e8-bb37-3be520b04be1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1752a212-fd6b-487e-b0cf-c51e22b5bf47" xlink:to="loc_us-gaap_Assets_2156f4a1-dc40-40e8-bb37-3be520b04be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_01759c9d-748d-44a0-94b7-9e92ff6f3725" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_23026e97-efc2-43bf-8807-0d4deed6268c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_01759c9d-748d-44a0-94b7-9e92ff6f3725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_4593e0ca-06a4-41b2-853f-576962a4b95f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_01759c9d-748d-44a0-94b7-9e92ff6f3725" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_4593e0ca-06a4-41b2-853f-576962a4b95f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_db081d88-ad76-4bad-90ea-0b1422761d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4593e0ca-06a4-41b2-853f-576962a4b95f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_db081d88-ad76-4bad-90ea-0b1422761d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableCurrent_d758c61e-f3a8-4946-8b29-7a38263f4e97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LoansPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4593e0ca-06a4-41b2-853f-576962a4b95f" xlink:to="loc_us-gaap_LoansPayableCurrent_d758c61e-f3a8-4946-8b29-7a38263f4e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_c26abdd3-840a-4c79-812e-5b161ecfb4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_4593e0ca-06a4-41b2-853f-576962a4b95f" xlink:to="loc_us-gaap_LongTermDebtCurrent_c26abdd3-840a-4c79-812e-5b161ecfb4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_af56dac0-f610-4809-a9c0-c4e4a6b997d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_01759c9d-748d-44a0-94b7-9e92ff6f3725" xlink:to="loc_us-gaap_LiabilitiesCurrent_af56dac0-f610-4809-a9c0-c4e4a6b997d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_07469846-2666-4cb5-bc1f-3b451d471b72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_01759c9d-748d-44a0-94b7-9e92ff6f3725" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_07469846-2666-4cb5-bc1f-3b451d471b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_4fcce210-7408-401d-8eb1-eca9cc029bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_07469846-2666-4cb5-bc1f-3b451d471b72" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_4fcce210-7408-401d-8eb1-eca9cc029bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_99ceaf2a-a328-4175-ba0e-f410c18b8592" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_01759c9d-748d-44a0-94b7-9e92ff6f3725" xlink:to="loc_us-gaap_Liabilities_99ceaf2a-a328-4175-ba0e-f410c18b8592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2876bdb2-acc0-4c68-bdc6-31a76f369718" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_01759c9d-748d-44a0-94b7-9e92ff6f3725" xlink:to="loc_us-gaap_StockholdersEquity_2876bdb2-acc0-4c68-bdc6-31a76f369718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6b3317ae-86a6-4d12-84c0-834b5ded7332" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_01759c9d-748d-44a0-94b7-9e92ff6f3725" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_6b3317ae-86a6-4d12-84c0-834b5ded7332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_3453a499-137b-4317-8b80-592c61b9b2c7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedCashFlowStatementTable_b9a0a392-4e3f-4821-be0e-c7deec249f65" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedCashFlowStatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_3453a499-137b-4317-8b80-592c61b9b2c7" xlink:to="loc_srt_CondensedCashFlowStatementTable_b9a0a392-4e3f-4821-be0e-c7deec249f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_9e914609-f3ef-4251-8ab9-98b65044ad0b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementTable_b9a0a392-4e3f-4821-be0e-c7deec249f65" xlink:to="loc_srt_ConsolidatedEntitiesAxis_9e914609-f3ef-4251-8ab9-98b65044ad0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_dc6279a5-c1ff-4e19-9af9-fa93019544f5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_9e914609-f3ef-4251-8ab9-98b65044ad0b" xlink:to="loc_srt_ConsolidatedEntitiesDomain_dc6279a5-c1ff-4e19-9af9-fa93019544f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_d5d56fb0-bd65-408f-b301-aec18c05ab81" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_dc6279a5-c1ff-4e19-9af9-fa93019544f5" xlink:to="loc_srt_ParentCompanyMember_d5d56fb0-bd65-408f-b301-aec18c05ab81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_cc67e6f5-5273-4233-8d6a-551e61c8a5be" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedCashFlowStatementsCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementTable_b9a0a392-4e3f-4821-be0e-c7deec249f65" xlink:to="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_cc67e6f5-5273-4233-8d6a-551e61c8a5be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_40712f61-735d-47aa-8914-9407e9e38f1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_cc67e6f5-5273-4233-8d6a-551e61c8a5be" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_40712f61-735d-47aa-8914-9407e9e38f1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4180ea68-3f99-4244-b0b2-28f73ef629a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_40712f61-735d-47aa-8914-9407e9e38f1a" xlink:to="loc_us-gaap_NetIncomeLoss_4180ea68-3f99-4244-b0b2-28f73ef629a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b15f26d5-682d-4d25-9ee7-4bc6fb391b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_40712f61-735d-47aa-8914-9407e9e38f1a" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b15f26d5-682d-4d25-9ee7-4bc6fb391b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AcquiredInProcessResearchAndDevelopment_ec0895cc-036d-441b-8139-0a47ae31bdb9" xlink:href="bgne-20241231.xsd#bgne_AcquiredInProcessResearchAndDevelopment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b15f26d5-682d-4d25-9ee7-4bc6fb391b9a" xlink:to="loc_bgne_AcquiredInProcessResearchAndDevelopment_ec0895cc-036d-441b-8139-0a47ae31bdb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_AmortizationOfResearchAndDevelopmentFinancingLiability_87b7b667-fc0f-43b5-b0d0-a3adac07d3ed" xlink:href="bgne-20241231.xsd#bgne_AmortizationOfResearchAndDevelopmentFinancingLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b15f26d5-682d-4d25-9ee7-4bc6fb391b9a" xlink:to="loc_bgne_AmortizationOfResearchAndDevelopmentFinancingLiability_87b7b667-fc0f-43b5-b0d0-a3adac07d3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_UnrealizedGainLossInSubsidiaries_4c745294-f3bc-44d7-a15e-ba3f6e5729fb" xlink:href="bgne-20241231.xsd#bgne_UnrealizedGainLossInSubsidiaries"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b15f26d5-682d-4d25-9ee7-4bc6fb391b9a" xlink:to="loc_bgne_UnrealizedGainLossInSubsidiaries_4c745294-f3bc-44d7-a15e-ba3f6e5729fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_3ffebf7c-d7a5-495c-aae8-439d6be1f4c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b15f26d5-682d-4d25-9ee7-4bc6fb391b9a" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_3ffebf7c-d7a5-495c-aae8-439d6be1f4c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae08183d-042d-4283-9540-66b02f059e17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_40712f61-735d-47aa-8914-9407e9e38f1a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae08183d-042d-4283-9540-66b02f059e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d3ca87af-84fa-4855-a7ab-1e3168d02a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae08183d-042d-4283-9540-66b02f059e17" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d3ca87af-84fa-4855-a7ab-1e3168d02a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_87892b47-82ad-4a9f-a93c-a19de4d4727f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ae08183d-042d-4283-9540-66b02f059e17" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_87892b47-82ad-4a9f-a93c-a19de4d4727f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c1094223-d1e4-4b89-876e-07ea6dc4d0bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_40712f61-735d-47aa-8914-9407e9e38f1a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c1094223-d1e4-4b89-876e-07ea6dc4d0bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5e0af889-1e36-4ff1-9796-4b4f2742f8fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_cc67e6f5-5273-4233-8d6a-551e61c8a5be" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5e0af889-1e36-4ff1-9796-4b4f2742f8fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_0c039ffd-a607-425f-84e7-e3be2045a090" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5e0af889-1e36-4ff1-9796-4b4f2742f8fe" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_0c039ffd-a607-425f-84e7-e3be2045a090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_48c4783b-665d-45e5-91f3-69131ede454e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5e0af889-1e36-4ff1-9796-4b4f2742f8fe" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_48c4783b-665d-45e5-91f3-69131ede454e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_PaymentsToPurchaseInProcessResearchAndDevelopment_9e2fb10c-7c8f-4db9-bffa-8c8d83d41578" xlink:href="bgne-20241231.xsd#bgne_PaymentsToPurchaseInProcessResearchAndDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5e0af889-1e36-4ff1-9796-4b4f2742f8fe" xlink:to="loc_bgne_PaymentsToPurchaseInProcessResearchAndDevelopment_9e2fb10c-7c8f-4db9-bffa-8c8d83d41578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_99e789a2-5850-4ea2-907b-72f7262bd04a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5e0af889-1e36-4ff1-9796-4b4f2742f8fe" xlink:to="loc_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates_99e789a2-5850-4ea2-907b-72f7262bd04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_f2586bab-c397-4fb5-ae4e-9f69c5d043d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5e0af889-1e36-4ff1-9796-4b4f2742f8fe" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_f2586bab-c397-4fb5-ae4e-9f69c5d043d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7570fb15-3987-4821-9d8f-6f283e46eceb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_5e0af889-1e36-4ff1-9796-4b4f2742f8fe" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7570fb15-3987-4821-9d8f-6f283e46eceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6b7809c3-5384-43f2-8c71-dd07a9ef825c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_cc67e6f5-5273-4233-8d6a-551e61c8a5be" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6b7809c3-5384-43f2-8c71-dd07a9ef825c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_f7e0696b-34b6-447b-b2bc-68add09b52d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6b7809c3-5384-43f2-8c71-dd07a9ef825c" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_f7e0696b-34b6-447b-b2bc-68add09b52d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_64093b5f-825c-4f86-a3f7-9b890c0553fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6b7809c3-5384-43f2-8c71-dd07a9ef825c" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_64093b5f-825c-4f86-a3f7-9b890c0553fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_5d125f9a-3af1-4d5e-8809-55b44a351037" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6b7809c3-5384-43f2-8c71-dd07a9ef825c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_5d125f9a-3af1-4d5e-8809-55b44a351037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7b52218c-b6c5-49b2-bf20-1ba72842bb5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6b7809c3-5384-43f2-8c71-dd07a9ef825c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7b52218c-b6c5-49b2-bf20-1ba72842bb5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b8f5241a-81a5-4045-93eb-f5d3e3e0ce22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_cc67e6f5-5273-4233-8d6a-551e61c8a5be" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b8f5241a-81a5-4045-93eb-f5d3e3e0ce22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_39901ca6-9f28-4056-9cea-10e2cde4f558" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_cc67e6f5-5273-4233-8d6a-551e61c8a5be" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_39901ca6-9f28-4056-9cea-10e2cde4f558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b028ae59-3340-4f0d-86ca-26568ec58115" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_cc67e6f5-5273-4233-8d6a-551e61c8a5be" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b028ae59-3340-4f0d-86ca-26568ec58115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_44e0ab03-73da-42fb-a610-79e0210fe4f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedCashFlowStatementsCaptionsLineItems_cc67e6f5-5273-4233-8d6a-551e61c8a5be" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_44e0ab03-73da-42fb-a610-79e0210fe4f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.beigene.com/role/ScheduleICondensedFinancialInformationNotestoCondensedFinancialStatementsDetails" xlink:type="simple" xlink:href="bgne-20241231.xsd#ScheduleICondensedFinancialInformationNotestoCondensedFinancialStatementsDetails"/>
  <link:presentationLink xlink:role="http://www.beigene.com/role/ScheduleICondensedFinancialInformationNotestoCondensedFinancialStatementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_926f74da-9b51-4df0-85fd-7aaec6c64a8c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_22a21884-369b-45ca-9ce5-89c6a3a7a5f7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_926f74da-9b51-4df0-85fd-7aaec6c64a8c" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_22a21884-369b-45ca-9ce5-89c6a3a7a5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_35bb3e8b-44d8-449c-abb9-73253ea58a68" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_22a21884-369b-45ca-9ce5-89c6a3a7a5f7" xlink:to="loc_srt_ConsolidatedEntitiesAxis_35bb3e8b-44d8-449c-abb9-73253ea58a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_09abf9c1-5854-42f1-ab8a-b1ddc1a35c50" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_35bb3e8b-44d8-449c-abb9-73253ea58a68" xlink:to="loc_srt_ConsolidatedEntitiesDomain_09abf9c1-5854-42f1-ab8a-b1ddc1a35c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_0cb7de0b-2d08-48a0-9a3e-ee3cbc2721e6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_09abf9c1-5854-42f1-ab8a-b1ddc1a35c50" xlink:to="loc_srt_ParentCompanyMember_0cb7de0b-2d08-48a0-9a3e-ee3cbc2721e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_4c8c1167-e0cc-4fa8-a267-abdf2be469ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_22a21884-369b-45ca-9ce5-89c6a3a7a5f7" xlink:to="loc_us-gaap_OtherCommitmentsAxis_4c8c1167-e0cc-4fa8-a267-abdf2be469ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_9b5d0800-0d02-4844-9ce9-d65a97078c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_4c8c1167-e0cc-4fa8-a267-abdf2be469ab" xlink:to="loc_us-gaap_OtherCommitmentsDomain_9b5d0800-0d02-4844-9ce9-d65a97078c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_bgne_InvestmentsFundingCommitmentMember_5f0c2f1d-06d3-47f4-bd83-0c4df6419120" xlink:href="bgne-20241231.xsd#bgne_InvestmentsFundingCommitmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_9b5d0800-0d02-4844-9ce9-d65a97078c5f" xlink:to="loc_bgne_InvestmentsFundingCommitmentMember_5f0c2f1d-06d3-47f4-bd83-0c4df6419120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_76762c23-cc51-47ac-b587-c960abd8b2b5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_22a21884-369b-45ca-9ce5-89c6a3a7a5f7" xlink:to="loc_srt_CondensedFinancialStatementsCaptionsLineItems_76762c23-cc51-47ac-b587-c960abd8b2b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitment_f5abc413-3da7-4884-882e-5d7da96a5689" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCommitment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_76762c23-cc51-47ac-b587-c960abd8b2b5" xlink:to="loc_us-gaap_OtherCommitment_f5abc413-3da7-4884-882e-5d7da96a5689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>bgne-20241231_g1.jpg
<TEXT>
begin 644 bgne-20241231_g1.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MMY4(9'4_9_O*RJ?^ U^]7_#0?@?_ *'#PW_X,H/_ (JC_AH/P/\ ]#AX:_\
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M/-L'[O>P;:&^]L:@GF/Y0Y)$DC96;Y66O[ /^"3NO7'B7_@F3\ [V\9FN)/
M>CABWWFVV<2K_P".@5\FV_\ P<O?L87=Q'#!!XLGFFD$44<?@>5I)'9MJJHV
M\L6K]*M(\L:7;^3 UI#Y2E(63RS$,#Y=O;'I02?Q\_\ !3/_ )20?'W_ +*#
MK?\ Z6RU]F_\&F.EPWG_  4[UVXD53)9^ M0>(X^ZS7EBI_\=KXR_P""F?\
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M3E'7^)9K\$GZ-$U% X%%?7G\RGYQ_P#!U#_RB0US_L9]%_\ 2I:_F;K^M/\
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MEN:O%8:&(Y5'F5['CM%>Q_\ "(:3_P! O3O_  &3_"C_ (1#2?\ H%Z=_P"
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M9K148%%%?IA_"LI-[A11102%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %&*** "BBB@ Q1UHHH .M%%% !1110 4444 %%%% !1110 44
944 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>bgne-20241231_g2.jpg
<TEXT>
begin 644 bgne-20241231_g2.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" C*#Z # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P 9O?\ 5P'_ )7*/^,WO^K@/_*Y0!^_U%?@#_QF]_U<!_Y7*/\ C-[_ *N
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M_P 9O?\ 5P'_ )7*/^,WO^K@/_*Y0!^_U%?@#_QF]_U<!_Y7*/\ C-[_ *N
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]G+PYX?NK6.'Q+?I_:FMR*OS&ZE /EL>_EILC]/D)[U]"T44 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %?''_!4C]G)/CA^SC?:]I]NK^)_!2R:O:,H^>2U"YNH?Q11(!U+0J.]
M?8]175K#>VTMO<1+-!,ACDCD&5=2,$$=P10!^3?_  1;^/DECXA\4_"'4I\V
MM]&VN:2';[LR!4N(U'^TFQ\#IY3GO7ZTU_/=$DW[$O[?"1QRO#8^$?%(4NQ(
M9]-D;D$^K6LO/^]WK^A!6#J&4AE(R".AH 6BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /Q*_P""RW@F/P[^U+IFN01;4\0>'[>XF?\
MO3Q220G\HTAK]8?V5?%C>.OV:?A=KDDAFN+OPW8&>0G),RP(LG_CZM7YZ?\
M!<C2Q'JGP=U$)\TT.JV[/C^XUHR@_P#?QOUK[!_X)GWYU+]AWX7RDYVV][#_
M -\7]PG_ ++0!]/4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\ ?\ !:O_
M )-9\+?]CG:_^D-]2?\ !%3_ )-9\5'O_P )G=?^D-C2_P#!:O\ Y-9\+?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X _X+5_\ )K/A
M;_L<[7_TAOJ/^"*G_)K/BG_L<[K_ -(;&C_@M7_R:SX6_P"QSM?_ $AOJ/\
M@BI_R:SXI_['.Z_](;&@#[_HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUWXB_$#08/$\CZD^F:;87I8V\*1I&SRE 0&9FDV_-D )QUH YO\ X*D_M'>
MOVEOA/\ "?Q#X#UD:E;P:AJ,5W:S(8KFSD,=N0LL9Y7(!P1E3@X)P:^U_P#@
ME7_R8YX!_P"NVI?^E]Q7Y^?\%4/V0?!_[./BCPKXD\"0?V1H?B;[1%-H@9W2
MVN(=A+Q%B2$<2CY/X2IQP<+^@?\ P2K_ .3'/ /_ %VU+_TON* /K6BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH _*O_ (+G?\T3_P"XW_[85]5?\$N/^3$_AE_W
M$_\ TZ7=?*O_  7._P":)_\ <;_]L*^JO^"7'_)B?PR_[B?_ *=+N@#ZJHHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#X _X+5_\FL^%O\ L<[7_P!(;ZC_
M ((J?\FL^*?^QSNO_2&QH_X+5_\ )K/A;_L<[7_TAOJ/^"*G_)K/BG_L<[K_
M -(;&@#[_HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH \J_:Q_Y-9^,G_8F:S_ .D,U?BI
M_P $W_CSX-_9U_:$N/%7CG4)M-T5]$N;)9H;:2X;S7DA91M0$]$;G':OW@^(
M7@FQ^)7@'Q+X1U.6X@TWQ!IESI5U+:,JS)%/$T3LA96 8*YP2",XR#TKX@_X
M<J?!#_H:?B!_X,;'_P"0Z (?V@O^"L7P6G^$GB?3/!MSJ7B?Q#JFG7%A:V[:
M;)!!&\D;())6E"Y0;LD*"3C'&<CXR_X)%^"=:\1?M?:7KEA%)_97A_3KRYU*
M<#"!98'@C0GU9Y%('4B-C_":^W=,_P"",'P+L+Z*>?7/'&I1(<M:W6I6JQO[
M$QVJM^3"OKOX/_ _P-\!/"H\/> _#MIX>TPMYDJP M).^,;Y9&)>1L#&6)XX
MZ4 ?BM_P4\^&NH_"K]LS7-?NK%;C1_$3V^MV#31YAN $19HV['$B,"O]UE)^
M\*_0'P;?_L)>,? 5MXJ&F_"O2;>2W6:>QU..TM[RV8KDQ/ V'+@A@ H.[!VY
MKZ=^.7[/O@3]HSP@?#GCS0XM7LD;S+>8$QW%K)_?AE7YD/ SC@C@@CBOBN__
M .")?PRFU+S+/Q[XKMK'<2;>5;:23&> '\L#IZJ: /+/V<_VGOA5\3OVIO"_
MA+P/^S+X0L1+K;-I_B*V4)=6UO"S2+=^6(/D=43?C=P>,UZ%_P %O/\ DEGP
MT_[#-Q_Z(%?6?[-'[%GPP_93M[F3P;IEQ<:U=Q^3<Z[JTPGO98\YV!@JJBY
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MR^(=.D_9H\'>(1X3L?AQI,^EMJ@T&R'^CV$#L\V5^5>&5O,/RCES7SC\&_\
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MN9W\UY(F4;0>F$;FOTS_ .'O/[//_01\0?\ @G?_ !KE?^'*GP0_Z&GX@?\
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
M'_!:O_DUGPM_V.=K_P"D-]1_P14_Y-9\4_\ 8YW7_I#8T?\ !:O_ )-9\+?]
MCG:_^D-]1_P14_Y-9\4_]CG=?^D-C0!]_P!%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 07
MMG!J5G/:742SVUQ&T4L3C*NC##*?8@FN4^%WP=\$_!3P\-#\#>&=.\,Z;D%X
M[&$*TS 8#2R'+R-CC<Y)]Z[*B@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH _*O_ (+G?\T3_P"XW_[85]5?\$N/^3$_AE_W
M$_\ TZ7=?*O_  7._P":)_\ <;_]L*^JO^"7'_)B?PR_[B?_ *=+N@#ZJHHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#X _X+5_\FL^%O\ L<[7_P!(;ZC_
M ((J?\FL^*?^QSNO_2&QH_X+5_\ )K/A;_L<[7_TAOJ/^"*G_)K/BG_L<[K_
M -(;&@#[_HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** /RK_X+G?\T3_[C?\ [85]5?\
M!+C_ ),3^&7_ '$__3I=U\J_\%SO^:)_]QO_ -L*^JO^"7'_ "8G\,O^XG_Z
M=+N@#ZJHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXY#X(LM3^)]U?S0Q:=9^<EA;VRHACF<EF>1V9G&Q2.$))7C=R7P__P""UGQ
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(D:*7+#<QW'' ;:<>2_\$C_V-_$/AWQ)+\9_&6F7&CPK:/:^'K.\C:.:;S5
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MH5J]V9P0PE,QCW[P0#NSG(ZUW]% #)H4N(GBE19(G4JR.,A@>"".XKA?"?P
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MKLAM;6)8XHU]%50 !["OQ<_:RFN_VZ/^"C%E\/\ P].\VCZ;/'X=%U"<K#!
MS27UP.H^5C/@_P 6Q!W K]K:XOPE\$_AWX!UR;6O#'@+PQX<UF9&BEU'2=&M
MK6X=&(9E:2- Q!(!()Y(% '4:-I-IX?T>QTNPA6WL;*".VMX5Z)&BA54?0 "
MKE%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!^5?\ P7._YHG_ -QO_P!L*^JO^"7'_)B?PR_[B?\ Z=+N
MOE7_ (+G?\T3_P"XW_[85]5?\$N/^3$_AE_W$_\ TZ7= 'U51110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% 'P!_P6K_Y-9\+?]CG:_\ I#?4?\$5/^36?%/_
M &.=U_Z0V-'_  6K_P"36?"W_8YVO_I#?4?\$5/^36?%/_8YW7_I#8T ??\
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 ?E7_P7._YHG_W&_P#VPKZJ_P""7'_)B?PR
M_P"XG_Z=+NOE7_@N=_S1/_N-_P#MA7U5_P $N/\ DQ/X9?\ <3_].EW0!]54
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7T#]JKX26/C/1(_L%SO-KJ>DO())+&Z4 M&3@;E(*LK8&58< Y ]BH ****
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MKG"JX 8,1NW;LJ ?JK1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^5?\ P7._YHG_ -QO
M_P!L*^JO^"7'_)B?PR_[B?\ Z=+NOE7_ (+G?\T3_P"XW_[85]5?\$N/^3$_
MAE_W$_\ TZ7= 'U51110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'P!_P6K_Y
M-9\+?]CG:_\ I#?4?\$5/^36?%/_ &.=U_Z0V-'_  6K_P"36?"W_8YVO_I#
M?4?\$5/^36?%/_8YW7_I#8T ??\ 1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'XP?\%L/^3DO!
MO_8I0_\ I9=5\^_%CX*^+?V3KGX/?$WP]>W4-AXCT/2_$FD:Q'UMKYK:*6>!
MNWRNY(!&&C<#G#5]!?\ !;#_ ).2\&_]BE#_ .EEU7WOHW[/^A?M,_\ !/CX
M:^!M=58OM7@G1IK"^V[GLKM;"+RIU^A)!'\2LR]Z $\%?M+Z/^U1^PYXV\86
M'E6VJIX8U*TUG34;)L[Q;.3>HSSL;(=#W5AGD$#\]/\ @C#_ ,G7ZW_V*5Y_
MZ56E>)_#CXF^-_V)?B1\2/ NO6<T<.J:;>^'->TC=\KEX72&YCSP2I<.K?Q(
M[ 8WYKVS_@C#_P G7ZW_ -BE>?\ I5:4 ?KY\</BA9_!?X0^+O'%_M:#0]-F
MO%C8X$LH7$4?U>0HH]VK\>O^"67P@'[07[3'BCQ9XLA_M?3]+TZ[NK]YQN6X
MN[X/" _^\CW+_5!7T]_P6D^-'_"._"KPM\-+*?;=^([PZC?HIY^R6Y&Q6'H\
MS*P]X#7PK^R;^WOXG_9!\*ZWHWACPIX?U9]7O5O+F^U03&8[4")&-DBC:OSD
M<9S(W- '8?L>^([S]CG_ (*##PGJ\[16#:K<>$-0DD^42122A8)3V"F1;>3/
M]W-?NS7\T_[1'Q\U+]HKXN7_ ,0]0TC3_#VLWT< GCT@R+&TD2!%D^9B0VU4
M'7^$5^^/[.7Q]LOBO^R]X8^)U]-D-HS7&K&%"S)<6ZLMUA ,_?CD( &2",=:
M /P_^,'PM^(7["O[1\5T+6;3[K1]4.H>']8DAW6M]"DFZ-U)^5@5(#IG*Y*F
MOO/X/?\ !:KPQK4,-A\4?!%WHD[@1RZEH+"[M6R.6:"0AT7V#2&OHOPC^VA^
MSA^UEXDLOAE#<V_BZ[U<2&'2M;T*4P2F.-I&_P!='M#!48COQQS7GWQF_P""
M0/P:\?6UW<>#GU'X>:PX)B^QS-=V6_U>&4EL>R2(!^E 'J_[._@O]E[XB-9^
M-?A%X<\%7=[ISK(EYI5@D-Y8NP(&]"JR1,1N^\!GFODC_@N5_P @KX-_]=M6
M_P#0;.OB+]FOQ1XH_9I_;(\.V=I=M#J.G>)E\/:K#;N?+NH3<BWN(B/XE/)&
M1PP5NH%?;O\ P7*_Y!7P;_Z[:M_Z#9T >Z_\$AO^3-M._P"PU?\ _H:U].?&
M[X0Z#\=_A?X@\$>(K6.YL-4MFC5Y$W&WFQF.9/1D;# CTQT)KYC_ ."0W_)F
MVG?]AJ__ /0UKZ>^-7Q:T3X&_"_Q%XV\07,5O8:3:/,JR-M,\N#Y<*^K.^U0
M/4T ?A9_P3K\9:C\,_VU? 444WE"_OI-#O8_X94F5H]I^D@C8>Z"OW2^.'Q0
ML_@O\(?%WCB_VM!H>FS7BQL<"64+B*/ZO(44>[5^%O\ P3K\&ZA\3/VUO 4L
M47FKI]])KE[)CY8DA5I-Q^LAC4>[BONO_@M)\:/^$=^%7A;X:64^V[\1WAU&
M_13S]DMR-BL/1YF5A[P&@#YA_P""67P@'[07[3'BCQ9XLA_M?3]+TZ[NK]YQ
MN6XN[X/" _\ O(]R_P!4%8?['OB.\_8Y_P""@P\)ZO.T5@VJW'A#4))/E$D4
MDH6"4]@ID6WDS_=S7'_LF_M[^)_V0?"NMZ-X8\*>']6?5[U;RYOM4$QF.U B
M1C9(HVK\Y'&<R-S7F'[1'Q\U+]HKXN7_ ,0]0TC3_#VLWT< GCT@R+&TD2!%
MD^9B0VU4'7^$4 ?TK22+'&SN0J*,ECT K^=+X0:9_P -4_MH:#'XD)N(?%_B
MHWNI+DC?"\S32QCTR@91Z<>E?NK^RO\ &"+]H#]G?P3XT=TFNM3TY8]048P+
MN/,5P,=AYB.1[$>M?A5\(-4_X96_;0T&3Q(IMX?"'BHV6I-@G9"DS0RR#UPA
M9AZ\>M ']%5M;0V=O%;V\2001((XXHU"JB@8"@#@ #M7RM_P4Z^%6G?$S]D'
MQA=7%NKZGX:1-;T^XQ\T31L!*,^C0M(".F=I["OJFVN8;RWBN+>5)X)4$D<L
M;!E=2,A@1P01WKY6_P""G7Q5T[X9_L@^,+6XN%34_$J)HFGV^?FE:1@93CT6
M%9"3TSM'<4 ?$7_!$SQU=Z?\:/'?@\RXT[5-"74S&W3SK>>.-<>A*7,F?7:/
M2NZ_X*Q?M+?&;X2?%WPWH'A/7]4\'^$9M*2\AO-+_=&]N?-D64-,!D[ (QY>
M>-P)!W"N%_X(F>!;O4/C1X[\8&+.G:7H2Z89&Z>=<3QNN/4A+:3/IN'K7Z_:
MIHNGZY D.I6%KJ$*.)%CNH5E56'1@&!Y'K0!XK^P[\0/&OQ2_9=\#^)OB!&X
M\37MO*99Y81$]U$LSK#.R   O&$;(&&SN'!KW>D50J@ 8 X %+0!_/)^U[K5
M_P#&[]N?QU:2W \VZ\5'P];2=52.&86D>!Z8C!]R2>]?T >"?!ND_#OP?HWA
MC0;1;'1M(M([*TMU_AC10HSZGC)/4DDGK7\__P"U[HM_\$?VY_'5U+;CS;7Q
M4?$-M'T5XYIA=QX/IB0#V(([5_0!X)\9:3\1/!^C>)]!NUOM&U>TCO;2X7^*
M-U##/H><$=000>E ' _M6_"K3OC1^SOX\\*ZC;K.;C2IYK1F&3#=1(9()!Z$
M2*O3J,CH37X\?\$F?'5WX1_;+\/:7%+LL_$EA>Z9=*>A"P-<)^.^W0 _[1]:
M_8?]JWXJZ=\%_P!G?QYXJU&X6 V^E3PVBL<&:ZE0QP1CU)D9>G09/0&OQX_X
M),^!;OQ=^V7X>U2*+?9^&["]U.Z8] &@:W3\=]PA _V3Z4 >@_\ !;#_ ).2
M\&_]BE#_ .EEU7S[\6/@KXM_9.N?@]\3?#U[=0V'B/0]+\2:1K$?6VOFMHI9
MX&[?*[D@$8:-P.<-7T%_P6P_Y.2\&_\ 8I0_^EEU7WOHW[/^A?M,_P#!/CX:
M^!M=58OM7@G1IK"^V[GLKM;"+RIU^A)!'\2LR]Z $\%?M+Z/^U1^PYXV\86'
ME6VJIX8U*TUG34;)L[Q;.3>HSSL;(=#W5AGD$#\]/^",/_)U^M_]BE>?^E5I
M7B?PX^)OC?\ 8E^)'Q(\"Z]9S1PZIIM[X<U[2-WRN7A=(;F//!*EPZM_$CL!
MC?FO;/\ @C#_ ,G7ZW_V*5Y_Z56E 'T'_P %N_'EYIOP^^&G@^";99ZOJ-WJ
M-RB]6-M'&D8/MFZ<X]5![5U7_!&7X5Z;X=_9_P!:\<M;1MK?B+5I;?[5MRZV
MD 54C![#S#*QQU^7/W17*_\ !;OP'>:G\/OAIXP@AWV>D:C=Z=<NO53<QQO&
M3[9MG&?5@.]=5_P1E^*FF^(OV?\ 6O S7,:ZWX=U:6X^RYP[6DX5DD [CS!*
MIQT^7/WA0!^@]?"OB;_@D7\,M>^)VH^-;/Q7XFT.[NM5?5X[*Q-L(+:5I?-V
MQ@Q$A0W09X&!7W57YQ>,O^"Q%MH_QDU3P+X;^%T?BF"WUEM'LM7C\2B)+UA+
MY0D51:/A6;IAFR,'/- 'K?\ P5$^+WQ'^#/[.]KJ_P .KBYTN:YU:*TU/6+.
M,/+9VS1R$$'!\O=($7S.V0 06%>>?\$C_CQ\5/C1X6\=Q>/=3OO$FC:7/:KI
MFLZB-TOFN)#-!YN,R!0(FY)*[_1@!^@-Q;Q7D$D$\230R*5>.10RL#U!!ZBH
M=-TNST>SCL["T@L;2,82WMHUCC0>@4  4 6J*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _*O\
MX+G?\T3_ .XW_P"V%?57_!+C_DQ/X9?]Q/\ ].EW7RK_ ,%SO^:)_P#<;_\
M;"OJK_@EQ_R8G\,O^XG_ .G2[H ^JJ*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ^ /^"U?_)K/A;_L<[7_ -(;ZC_@BI_R:SXI_P"QSNO_ $AL:/\ @M7_
M ,FL^%O^QSM?_2&^H_X(J?\ )K/BG_L<[K_TAL: /O\ HHHH **** "BBB@
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MIDM&JR .QDPS;<;2&+#V#_@LA\*?&WQ0TWX4+X-\'Z_XM:RFU0W2Z'ID]Z8
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M'?V,])_8_P#AY<V37<6M>,-89)M8U:./:A*CY((L\^4F6P3RQ8L0.%7Z4HH
M_)3_ (*]?!/XB?$O]H#PGJ/A#P%XG\5:?#X8BMY;O1-'N+R*.07=RQ1GC1@&
MPRG!.<,#WK](/V9=)OM!_9M^%&F:G97&G:E9>$M)MKJSNXFBF@E2SB5XW1@"
MK*P(*D9!!!KTNB@#\_O^"J'[%-U\:_"MO\2O VD3:AXZT6-8+W3K"$R3ZI9Y
MXV(H)>6(G( &60L.2J"O O\ @DK\#OB/\-_VFM7U3Q;\/_%/A;3)/#%U;I>Z
MUHMS9PM(;BU(0/(BJ6(5CC.<*?2OU^HH X[XO_"?P]\</AOKO@GQ3:?:]&U:
MW,,F,;XFZI+&3T=&"LI]5'4<5^+_ ,1OV%_VC/V.?B.WB7X<0ZWKUE:NWV'Q
M)X1C:2=HCR5GMDW.HQC<K*T9QU(K]T:* /PF\4?M*?MK_&'2;CPC=#QM<0SC
M[-=6^D>%Q9SR;LC:\D%NCJ",@@$ @'(ZU]%_\$\_^"9?B7P;X\TKXG?%NRCT
MJ327%SH_AMI%DG^T#[D]QMRJ!.&5 2VX MMVX;]3J* /CC_@J=X?^)_B+]F^
M&W^&D>K7.W5(WUNTT,.;J:R\N3C:GS-&)/++*N>Q/ ->%?\ !%'XC^*O$NF_
M$WPYJNJWFJ:#I1L+FSCNYFD%K+,9Q(J%B2 XB4[1QE2>I.?KO]M#PK\:O'7P
MVL?#GP6U/3]'U'5KPV6L7][((GMK%XGW2)(02OS!5.Q6?YP5Q@FI?V,?V3=)
M_9%^%'_"-VMX-7UW4)OMNL:J(]@GFVA0B#J(T PH/)RS<%B  >^4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!^5?\ P7._YHG_ -QO_P!L*^JO^"7'_)B?PR_[B?\ Z=+NOE7_
M (+G?\T3_P"XW_[85]5?\$N/^3$_AE_W$_\ TZ7= 'U51110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% 'P!_P6K_Y-9\+?]CG:_\ I#?4?\$5/^36?%/_ &.=
MU_Z0V-'_  6K_P"36?"W_8YVO_I#?4?\$5/^36?%/_8YW7_I#8T ??\ 1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 ?E7_P7._YHG_W&_P#VPKZJ_P""7'_)B?PR_P"X
MG_Z=+NOE7_@N=_S1/_N-_P#MA7U5_P $N/\ DQ/X9?\ <3_].EW0!]54444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,J(H+,S'  '4DUS>A_$_P=XFU1]-T?Q9H>JZBG#6=CJ4,TR\$\HK$C@'MVH
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M0'Z9-4_^$LT/_H,Z?_X%1_XT :U%4;/7=-U*;RK34+6ZEQN\N&=7;'K@&KU
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^5?_!<
M[_FB?_<;_P#;"OJK_@EQ_P F)_#+_N)_^G2[KY5_X+G?\T3_ .XW_P"V%?57
M_!+C_DQ/X9?]Q/\ ].EW0!]54444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
M\ ?\%J_^36?"W_8YVO\ Z0WU'_!%3_DUGQ3_ -CG=?\ I#8T?\%J_P#DUGPM
M_P!CG:_^D-]1_P $5/\ DUGQ3_V.=U_Z0V- 'W_1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5_/7\5O^4B_B/_LIDG_IRK^A2OYR
M?VGO$%UX3_;3^)FMV0C-YIOCB^O8!*I9/,CO7==PR,C*C/- ']&U?!7_  6>
M_P"34-$_[&VS_P#26[KXU_X?)?'O_GS\'_\ @KE_^/UY7^T=_P % OB?^U'X
M#MO"/C*WT&+2K>_CU)&TNRDAE\U$D1<LTC#;B5N,>E 'WI_P1'_Y(O\ $/\
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MK?$K7;-(I+O2_'-]>PI."8V>.]9U# $$C*C."#CO0!]P_P##C'_JMG_EJ?\
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M#GX"WVN^'_%VF^,M8\27,<NK7.EEQ'9F-#Y5J5=5<,@D=B7523)P, $^$_\
M!9KX/^$)KSP]\0_^$OTW2/&?V,6#^';HNT^IVZR,4EA5 VTH78$N%0C'S J
MP!YYK/\ P1M\6:/\$+CQ<WCNS?Q9;:8VI2^&_P"SF$7RQ^8T N?,R7 !&3&
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MC=.M:?P]_P"",7Q1\3:Y#=?$#QEH>A:>Y4W#6,LNH7K# RH#*B _PY+G&.A
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /A[_@L1I9U#]D#SPN[[#XAL;@G'3*RQY_\ (GZUP7_!$?55F^"?Q!TT
M."]OXA2X*9Y DMHU!_'RC^5?1_\ P46\'2>-_P!B_P"*%E#$99K73TU-<#E1
M;3QW#G_OB-_PS7PI_P $0_'$6G_$;XE>$))=LNJ:7:ZG"C=_LTKQMCWQ=+QZ
M#VH _7JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH _)S_@N1JJ3:Y\']-##S+>VU2X9>
MX$C6J@_^0F_*OLG_ ()JZ<=+_8A^%T)7:6M;N?&,?ZR]N),_^/5^;7_!8SQQ
M%XF_:PM]&@EWKX=T&ULID!X6:1I+@_CLFB_*OUU_9I\'2?#_ /9Y^&OAV:(P
M76G>';""XC;J)A AE_\ 'RU 'I5%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 4-?T.S\3:#J6CZC$)]/U"VDM+B(]'CD4HZ_B":_ 3]F7Q+>_L>?MU:/:Z\
MWD1Z-KL_AW5F;Y4,$C-;O*?]D;EE'J%'6OZ"J_&?_@LA^S^_@WXO:3\4=.MV
M&D^+(EM;]E7Y8[^! HR>WF0JI [F*0T ?LQ17S%_P3Q_:23]I#]G/1KN^NEG
M\6: %TC6D9LR-(BCRYR.N)8]K9Z;Q(!]VOIV@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JKJFI6
MNBZ;=ZA?3I:V5I"\\\\APL<:J69B?0 $_A5JOAS_ (*R?M'+\(_V?W\%:5>K
M%XF\;%K$HC?O(M/ _P!)?V#Y6+GJ)'Q]V@#\TO EK=?MK?M[6=Q+;-):>*?%
M#:A<P2#/E:=&YE=#_NV\>SW('K7]"%?E;_P1=_9[FA_X2;XQZI;[(I4;0M%W
MK]X;E>YF'ME8XP1_TU%?JE0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MPWEG<1K-#<6[AXY4895E8<$$$$$<'-6* "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MFOW^HH _ '_AUQ^T[_T3/_ROZ7_\DT?\.N/VG?\ HF?_ )7]+_\ DFOW^HH
M_ '_ (=<?M._]$S_ /*_I?\ \DT?\.N/VG?^B9_^5_2__DFOW^HH _ '_AUQ
M^T[_ -$S_P#*_I?_ ,DT?\.N/VG?^B9_^5_2_P#Y)K]_J* /P!_X=<?M._\
M1,__ "OZ7_\ )-'_  ZX_:=_Z)G_ .5_2_\ Y)K]_J* /P!_X=<?M._]$S_\
MK^E__)-'_#KC]IW_ *)G_P"5_2__ ))K]_J* /P!_P"'7'[3O_1,_P#ROZ7_
M /)-'_#KC]IW_HF?_E?TO_Y)K]_J* /P!_X=<?M._P#1,_\ ROZ7_P#)-'_#
MKC]IW_HF?_E?TO\ ^2:_?ZB@#\ ?^'7'[3O_ $3/_P K^E__ "31_P .N/VG
M?^B9_P#E?TO_ .2:_?ZB@#\ ?^'7'[3O_1,__*_I?_R31_PZX_:=_P"B9_\
ME?TO_P"2:_?ZB@#\ ?\ AUQ^T[_T3/\ \K^E_P#R37E7QT_9;^)_[-?]B?\
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M_E?TO_Y)K]_J* /P!_X=<?M._P#1,_\ ROZ7_P#)-'_#KC]IW_HF?_E?TO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ K\J_\ @N=_S1/_ +C?_MA7ZJ5^5?\ P7._YHG_
M -QO_P!L* /HK_@DG_R9;X?_ .PGJ'_H\U]E5\:_\$D_^3+?#_\ V$]0_P#1
MYK[*H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ K\J_P#@N=_S1/\ [C?_ +85^JE?E7_P7._YHG_W&_\ VPH ^BO^
M"2?_ "9;X?\ ^PGJ'_H\U]E5\:_\$D_^3+?#_P#V$]0_]'FOLJ@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "ORK_X
M+G?\T3_[C?\ [85^JE?E7_P7._YHG_W&_P#VPH ^BO\ @DG_ ,F6^'_^PGJ'
M_H\U]E5\:_\ !)/_ ),M\/\ _83U#_T>:^RJ "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_*O_@N=_P T3_[C?_MA
M7ZJ5^5?_  7._P":)_\ <;_]L* /HK_@DG_R9;X?_P"PGJ'_ */-?95?&O\
MP23_ .3+?#__ &$]0_\ 1YK[*H **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8/V;?^AOU#_P27?_ ,;H_P"'L'[-O_0WZA_X)+O_ .-UX!_PXYT/_HK>H?\
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M /C] 'O_ /P]@_9M_P"AOU#_ ,$EW_\ &Z/^'L'[-O\ T-^H?^"2[_\ C=>
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M/_HK>H?^"./_ ./T >__ /#V#]FW_H;]0_\ !)=__&Z/^'L'[-O_ $-^H?\
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M]'_#CG0_^BMZA_X(X_\ X_0![_\ \/8/V;?^AOU#_P $EW_\;H_X>P?LV_\
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M-O\ T-^H?^"2[_\ C=> ?\..=#_Z*WJ'_@CC_P#C]'_#CG0_^BMZA_X(X_\
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M8/V;?^AOU#_P27?_ ,;H_P"'L'[-O_0WZA_X)+O_ .-UX!_PXYT/_HK>H?\
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M /C] 'O_ /P]@_9M_P"AOU#_ ,$EW_\ &Z/^'L'[-O\ T-^H?^"2[_\ C=>
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M/_HK>H?^"./_ ./T >__ /#V#]FW_H;]0_\ !)=__&Z/^'L'[-O_ $-^H?\
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M]'_#CG0_^BMZA_X(X_\ X_0![_\ \/8/V;?^AOU#_P $EW_\;H_X>P?LV_\
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M]FG2/!_C3Q#=Z=KUO?7<\D$.F7$ZA))2RG>B$<@^M?2/_#V#]FW_ *&_4/\
MP27?_P ;KY[M_P#@AQI*Q 3_ !?O)9.[1^'T0?D;@_SJ7_AQSH?_ $5O4/\
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MX<<Z'_T5O4/_  1Q_P#Q^@#W_P#X>P?LV_\ 0WZA_P""2[_^-T?\/8/V;?\
MH;]0_P#!)=__ !NO /\ AQSH?_16]0_\$<?_ ,?H_P"''.A_]%;U#_P1Q_\
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M /C='_#V#]FW_H;]0_\ !)=__&Z\ _X<<Z'_ -%;U#_P1Q__ !^C_AQSH?\
MT5O4/_!''_\ 'Z /?_\ A[!^S;_T-^H?^"2[_P#C='_#V#]FW_H;]0_\$EW_
M /&Z\ _X<<Z'_P!%;U#_ ,$<?_Q^C_AQSH?_ $5O4/\ P1Q__'Z /?\ _A[!
M^S;_ -#?J'_@DN__ (W1_P /8/V;?^AOU#_P27?_ ,;KP#_AQSH?_16]0_\
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M%;U#_P $<?\ \?H ]_\ ^'L'[-O_ $-^H?\ @DN__C='_#V#]FW_ *&_4/\
MP27?_P ;KP#_ (<<Z'_T5O4/_!''_P#'Z/\ AQSH?_16]0_\$<?_ ,?H ]__
M .'L'[-O_0WZA_X)+O\ ^-T?\/8/V;?^AOU#_P $EW_\;KP#_AQSH?\ T5O4
M/_!''_\ 'Z/^''.A_P#16]0_\$<?_P ?H ]__P"'L'[-O_0WZA_X)+O_ .-T
M?\/8/V;?^AOU#_P27?\ \;KP#_AQSH?_ $5O4/\ P1Q__'Z/^''.A_\ 16]0
M_P#!''_\?H ]_P#^'L'[-O\ T-^H?^"2[_\ C='_  ]@_9M_Z&_4/_!)=_\
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MU#_P27?_ ,;KP#_AQSH?_16]0_\ !''_ /'Z/^''.A_]%;U#_P $<?\ \?H
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M''_\?H_X<<Z'_P!%;U#_ ,$<?_Q^@#W_ /X>P?LV_P#0WZA_X)+O_P"-T?\
M#V#]FW_H;]0_\$EW_P#&Z\ _X<<Z'_T5O4/_  1Q_P#Q^C_AQSH?_16]0_\
M!''_ /'Z /?_ /A[!^S;_P!#?J'_ ()+O_XW1_P]@_9M_P"AOU#_ ,$EW_\
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M6]0_\$<?_P ?H_X<<Z'_ -%;U#_P1Q__ !^@#W__ (>P?LV_]#?J'_@DN_\
MXW1_P]@_9M_Z&_4/_!)=_P#QNO /^''.A_\ 16]0_P#!''_\?H_X<<Z'_P!%
M;U#_ ,$<?_Q^@#W_ /X>P?LV_P#0WZA_X)+O_P"-T?\ #V#]FW_H;]0_\$EW
M_P#&Z\ _X<<Z'_T5O4/_  1Q_P#Q^C_AQSH?_16]0_\ !''_ /'Z /?_ /A[
M!^S;_P!#?J'_ ()+O_XW1_P]@_9M_P"AOU#_ ,$EW_\ &Z\ _P"''.A_]%;U
M#_P1Q_\ Q^C_ (<<Z'_T5O4/_!''_P#'Z /?_P#A[!^S;_T-^H?^"2[_ /C=
M'_#V#]FW_H;]0_\ !)=__&Z\ _X<<Z'_ -%;U#_P1Q__ !^C_AQSH?\ T5O4
M/_!''_\ 'Z /?_\ A[!^S;_T-^H?^"2[_P#C='_#V#]FW_H;]0_\$EW_ /&Z
M\ _X<<Z'_P!%;U#_ ,$<?_Q^C_AQSH?_ $5O4/\ P1Q__'Z /?\ _A[!^S;_
M -#?J'_@DN__ (W1_P /8/V;?^AOU#_P27?_ ,;KP#_AQSH?_16]0_\ !''_
M /'Z/^''.A_]%;U#_P $<?\ \?H ]_\ ^'L'[-O_ $-^H?\ @DN__C=>K_ '
M]L#X7_M-ZEJ]C\/]:N=5N=)BCGNUGL)K8(CL54@R*,\J>E?G!^TA_P $E=)^
M _P/\6^/H/B3>ZQ-H=J+E;&32$B6;,BI@N)3C[V>AZ5J?\$/O^1^^*?_ &#+
M+_T;)0!^NE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'X _\ !4?_ )/L^)O_ '#/_37:5^_U?@#_ ,%1_P#D^SXF_P#<
M,_\ 37:5^_U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!\Z_P#!0[_DRWXJ_P#8,7_T?%7PK_P0^_Y'[XI_]@RR_P#1
MLE?=7_!0[_DRWXJ_]@Q?_1\5?"O_  0^_P"1^^*?_8,LO_1LE 'ZZ4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?@#_P5
M'_Y/L^)O_<,_]-=I7[_5^ /_  5'_P"3[/B;_P!PS_TUVE?O]0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?.O_  4.
M_P"3+?BK_P!@Q?\ T?%7PK_P0^_Y'[XI_P#8,LO_ $;)7W5_P4._Y,M^*O\
MV#%_]'Q5\*_\$/O^1^^*?_8,LO\ T;)0!^NE%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% 'X _\%1_^3[/B;_W#/\ TUVE
M?O\ 5^ /_!4?_D^SXF_]PS_TUVE?O]0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 ?.O_!0[_DRWXJ_]@Q?_ $?%7PK_
M ,$/O^1^^*?_ &#++_T;)7W5_P %#O\ DRWXJ_\ 8,7_ -'Q5\*_\$/O^1^^
M*?\ V#++_P!&R4 ?KI1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!^ /\ P5'_ .3[/B;_ -PS_P!-=I7[_5^ /_!4?_D^
MSXF_]PS_ --=I7[_ % !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!\Z_\%#O^3+?BK_V#%_]'Q5\*_\ !#[_ )'[XI_]
M@RR_]&R5]U?\%#O^3+?BK_V#%_\ 1\5?"O\ P0^_Y'[XI_\ 8,LO_1LE 'ZZ
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ?9:UK'D>?!I<<D=NOE01P+L5W=AE8E)RQY)Z#@?8'_#ZOXW_P#0K?#_ /\
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M0!^U-%?BM_P^K^-__0K?#_\ \%U]_P#)E'_#ZOXW_P#0K?#_ /\ !=??_)E
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !17AGQ^_;6^$/[-LAM/&/BF+^V]NY=#TQ#
M=7V,9&Z->(P1T,A4'L:^(O'G_!<"&/4)(O!?PODGLA]R[U[4A'(W/>&)&"\?
M]-#U]N0#]4**_%_4/^"U_P 8Y+DM8^#O UM;]H[BUO)GZG^(7*#ICM5;_A]7
M\;_^A6^'_P#X+K[_ .3* /VIHK\5O^'U?QO_ .A6^'__ (+K[_Y,H_X?5_&_
M_H5OA_\ ^"Z^_P#DR@#]J:*_%;_A]7\;_P#H5OA__P""Z^_^3*/^'U?QO_Z%
M;X?_ /@NOO\ Y,H _:FBOQ6_X?5_&_\ Z%;X?_\ @NOO_DRC_A]7\;_^A6^'
M_P#X+K[_ .3* /VIHK\5O^'U?QO_ .A6^'__ (+K[_Y,H_X?5_&__H5OA_\
M^"Z^_P#DR@#]J:*_%;_A]7\;_P#H5OA__P""Z^_^3*/^'U?QO_Z%;X?_ /@N
MOO\ Y,H _:FBOQ6_X?5_&_\ Z%;X?_\ @NOO_DRC_A]7\;_^A6^'_P#X+K[_
M .3* /VIHK\5O^'U?QO_ .A6^'__ (+K[_Y,H_X?5_&__H5OA_\ ^"Z^_P#D
MR@#]J:*_%;_A]7\;_P#H5OA__P""Z^_^3*/^'U?QO_Z%;X?_ /@NOO\ Y,H
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M_P#H5OA__P""Z^_^3*/^'U?QO_Z%;X?_ /@NOO\ Y,H _:FBOQ6_X?5_&_\
MZ%;X?_\ @NOO_DRC_A]7\;_^A6^'_P#X+K[_ .3* /VIHK\5O^'U?QO_ .A6
M^'__ (+K[_Y,H_X?5_&__H5OA_\ ^"Z^_P#DR@#]J:*_%;_A]7\;_P#H5OA_
M_P""Z^_^3*/^'U?QO_Z%;X?_ /@NOO\ Y,H _:FBOQ6_X?5_&_\ Z%;X?_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#PE['_ .-4?\,G?!#_ *(W\/\ _P )>Q_^-5ZK10!Y5_PR=\$/^B-_#_\
M\)>Q_P#C5'_#)WP0_P"B-_#_ /\ "7L?_C5>JT4 >5?\,G?!#_HC?P__ /"7
ML?\ XU1_PR=\$/\ HC?P_P#_  E['_XU7JM% 'E7_#)WP0_Z(W\/_P#PE['_
M .-4?\,G?!#_ *(W\/\ _P )>Q_^-5ZK10!Y5_PR=\$/^B-_#_\ \)>Q_P#C
M5'_#)WP0_P"B-_#_ /\ "7L?_C5>JT4 >5?\,G?!#_HC?P__ /"7L?\ XU1_
MPR=\$/\ HC?P_P#_  E['_XU7JM% 'E7_#)WP0_Z(W\/_P#PE['_ .-4?\,G
M?!#_ *(W\/\ _P )>Q_^-5ZK10!Y5_PR=\$/^B-_#_\ \)>Q_P#C5'_#)WP0
M_P"B-_#_ /\ "7L?_C5>JT4 >5?\,G?!#_HC?P__ /"7L?\ XU1_PR=\$/\
MHC?P_P#_  E['_XU7JM% 'E7_#)WP0_Z(W\/_P#PE['_ .-4?\,G?!#_ *(W
M\/\ _P )>Q_^-5ZK10!Y5_PR=\$/^B-_#_\ \)>Q_P#C5'_#)WP0_P"B-_#_
M /\ "7L?_C5>JT4 >5?\,G?!#_HC?P__ /"7L?\ XU1_PR=\$/\ HC?P_P#_
M  E['_XU7JM% 'E7_#)WP0_Z(W\/_P#PE['_ .-4?\,G?!#_ *(W\/\ _P )
M>Q_^-5ZK10!Y5_PR=\$/^B-_#_\ \)>Q_P#C5'_#)WP0_P"B-_#_ /\ "7L?
M_C5>JT4 >5?\,G?!#_HC?P__ /"7L?\ XU1_PR=\$/\ HC?P_P#_  E['_XU
M7JM% 'E7_#)WP0_Z(W\/_P#PE['_ .-4?\,G?!#_ *(W\/\ _P )>Q_^-5ZK
M10!Y5_PR=\$/^B-_#_\ \)>Q_P#C5'_#)WP0_P"B-_#_ /\ "7L?_C5>JT4
M>5?\,G?!#_HC?P__ /"7L?\ XU1_PR=\$/\ HC?P_P#_  E['_XU7JM% 'E7
M_#)WP0_Z(W\/_P#PE['_ .-4?\,G?!#_ *(W\/\ _P )>Q_^-5ZK10!Y5_PR
M=\$/^B-_#_\ \)>Q_P#C5'_#)WP0_P"B-_#_ /\ "7L?_C5>JT4 >5?\,G?!
M#_HC?P__ /"7L?\ XU1_PR=\$/\ HC?P_P#_  E['_XU7JM% 'E7_#)WP0_Z
M(W\/_P#PE['_ .-4?\,G?!#_ *(W\/\ _P )>Q_^-5ZK10!Y5_PR=\$/^B-_
M#_\ \)>Q_P#C5'_#)WP0_P"B-_#_ /\ "7L?_C5>JT4 >5?\,G?!#_HC?P__
M /"7L?\ XU1_PR=\$/\ HC?P_P#_  E['_XU7JM% 'E7_#)WP0_Z(W\/_P#P
ME['_ .-4?\,G?!#_ *(W\/\ _P )>Q_^-5ZK10!Y5_PR=\$/^B-_#_\ \)>Q
M_P#C5'_#)WP0_P"B-_#_ /\ "7L?_C5>JT4 >5?\,G?!#_HC?P__ /"7L?\
MXU1_PR=\$/\ HC?P_P#_  E['_XU7JM% 'E7_#)WP0_Z(W\/_P#PE['_ .-4
M?\,G?!#_ *(W\/\ _P )>Q_^-5ZK10!Y5_PR=\$/^B-_#_\ \)>Q_P#C5'_#
M)WP0_P"B-_#_ /\ "7L?_C5>JT4 >5?\,G?!#_HC?P__ /"7L?\ XU1_PR=\
M$/\ HC?P_P#_  E['_XU7JM% 'E7_#)WP0_Z(W\/_P#PE['_ .-4?\,G?!#_
M *(W\/\ _P )>Q_^-5ZK10!Y5_PR=\$/^B-_#_\ \)>Q_P#C5'_#)WP0_P"B
M-_#_ /\ "7L?_C5>JT4 >5?\,G?!#_HC?P__ /"7L?\ XU1_PR=\$/\ HC?P
M_P#_  E['_XU7JM% 'E7_#)WP0_Z(W\/_P#PE['_ .-4?\,G?!#_ *(W\/\
M_P )>Q_^-5ZK10!Y5_PR=\$/^B-_#_\ \)>Q_P#C5'_#)WP0_P"B-_#_ /\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW$$'P>\$2( !FZT&VN&X&/O2(Q_6KG_#)WP0_P"B-_#_ /\ "7L?_C5>JT4
M>5?\,G?!#_HC?P__ /"7L?\ XU1_PR=\$/\ HC?P_P#_  E['_XU7JM% 'E7
M_#)WP0_Z(W\/_P#PE['_ .-4?\,G?!#_ *(W\/\ _P )>Q_^-5ZK10!Y5_PR
M=\$/^B-_#_\ \)>Q_P#C5'_#)WP0_P"B-_#_ /\ "7L?_C5>JT4 >5?\,G?!
M#_HC?P__ /"7L?\ XU1_PR=\$/\ HC?P_P#_  E['_XU7JM% 'E7_#)WP0_Z
M(W\/_P#PE['_ .-4?\,G?!#_ *(W\/\ _P )>Q_^-5ZK10!Y5_PR=\$/^B-_
M#_\ \)>Q_P#C5'_#)WP0_P"B-_#_ /\ "7L?_C5>JT4 >5?\,G?!#_HC?P__
M /"7L?\ XU1_PR=\$/\ HC?P_P#_  E['_XU7JM% 'E7_#)WP0_Z(W\/_P#P
ME['_ .-4?\,G?!#_ *(W\/\ _P )>Q_^-5ZK10!Y5_PR=\$/^B-_#_\ \)>Q
M_P#C5'_#)WP0_P"B-_#_ /\ "7L?_C5>JT4 >5?\,G?!#_HC?P__ /"7L?\
MXU1_PR=\$/\ HC?P_P#_  E['_XU7JM% 'E7_#)WP0_Z(W\/_P#PE['_ .-4
M?\,G?!#_ *(W\/\ _P )>Q_^-5ZK10!Y5_PR=\$/^B-_#_\ \)>Q_P#C5'_#
M)WP0_P"B-_#_ /\ "7L?_C5>JT4 >5?\,G?!#_HC?P__ /"7L?\ XU1_PR=\
M$/\ HC?P_P#_  E['_XU7JM% 'E7_#)WP0_Z(W\/_P#PE['_ .-4?\,G?!#_
M *(W\/\ _P )>Q_^-5ZK10!Y5_PR=\$/^B-_#_\ \)>Q_P#C5'_#)WP0_P"B
M-_#_ /\ "7L?_C5>JT4 >5?\,G?!#_HC?P__ /"7L?\ XU1_PR=\$/\ HC?P
M_P#_  E['_XU7JM% 'E7_#)WP0_Z(W\/_P#PE['_ .-4?\,G?!#_ *(W\/\
M_P )>Q_^-5ZK10!Y5_PR=\$/^B-_#_\ \)>Q_P#C5'_#)WP0_P"B-_#_ /\
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M_P#PE['_ .-4?\,G?!#_ *(W\/\ _P )>Q_^-5ZK10!Y5_PR=\$/^B-_#_\
M\)>Q_P#C5'_#)WP0_P"B-_#_ /\ "7L?_C5>JT4 >5?\,G?!#_HC?P__ /"7
ML?\ XU1_PR=\$/\ HC?P_P#_  E['_XU7JM% 'E7_#)WP0_Z(W\/_P#PE['_
M .-4?\,G?!#_ *(W\/\ _P )>Q_^-5ZK10!Y5_PR=\$/^B-_#_\ \)>Q_P#C
M5'_#)WP0_P"B-_#_ /\ "7L?_C5>JT4 >5?\,G?!#_HC?P__ /"7L?\ XU1_
MPR=\$/\ HC?P_P#_  E['_XU7JM% 'E7_#)WP0_Z(W\/_P#PE['_ .-4?\,G
M?!#_ *(W\/\ _P )>Q_^-5ZK10!Y5_PR=\$/^B-_#_\ \)>Q_P#C5'_#)WP0
M_P"B-_#_ /\ "7L?_C5>JT4 >5?\,G?!#_HC?P__ /"7L?\ XU1_PR=\$/\
MHC?P_P#_  E['_XU7JM% 'E7_#)WP0_Z(W\/_P#PE['_ .-4?\,G?!#_ *(W
M\/\ _P )>Q_^-5ZK10!Y5_PR=\$/^B-_#_\ \)>Q_P#C5'_#)WP0_P"B-_#_
M /\ "7L?_C5>JT4 >5?\,G?!#_HC?P__ /"7L?\ XU1_PR=\$/\ HC?P_P#_
M  E['_XU7JM% 'E7_#)WP0_Z(W\/_P#PE['_ .-4?\,G?!#_ *(W\/\ _P )
M>Q_^-5ZK10!Y5_PR=\$/^B-_#_\ \)>Q_P#C5'_#)WP0_P"B-_#_ /\ "7L?
M_C5>JT4 >5?\,G?!#_HC?P__ /"7L?\ XU1_PR=\$/\ HC?P_P#_  E['_XU
M7JM% 'E7_#)WP0_Z(W\/_P#PE['_ .-4?\,G?!#_ *(W\/\ _P )>Q_^-5ZK
M10!Y5_PR=\$/^B-_#_\ \)>Q_P#C5'_#)WP0_P"B-_#_ /\ "7L?_C5>JT4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]I-LHLXM-\?S:(D:_*$5KJ2UV?DV* /Z Z*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^2?_  6G^!%I
MH^O^$?BSIEJ(7U<G1=8=%PKSQIOMI#ZN8UE0D]H4]*_6ROC[_@K!H*:Q^Q/X
MMNF16;2[W3[Q">JDW4<)(]\3$?B: +7_  2W^+C?%;]D3PY;W5P;C5/"\TN@
M7)=LMMBPT'7L()(E_P" 'Z#ZWK\P/^"'.LF?PM\7-)R=MK>Z;= =OWJ7"_\
MM&OT_H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *_%;_ (+5G_C*;PJ.W_"&6O\ Z77U
M?M37XK?\%J_^3IO"W_8F6O\ Z77U 'ZI_LFJ%_97^#84 #_A#='/'O90UZM7
ME7[)W_)K/P;_ .Q,T;_TAAKU6@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_ '.?\ @J=S
M_P!%F_\ <Y7[_5^ /_.4W_NLW_N<H _?ZBBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2P@E9-V'M\9P>:^JO^"8&K%OV&O!-_J5X2L;ZG)-=74O"JM]<99F8\  =3T
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *\J_:Q_Y-9^,G_8F:S_ .D,U>JUY5^U
MC_R:S\9/^Q,UG_TAFH _*O\ X(J?\G3>*?\ L3+K_P!+K&OVIK\5O^"*G_)T
MWBG_ +$RZ_\ 2ZQK]J: "BBB@ HHHH *J:M_R"KW_KB__H)JW535O^05>_\
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M&-/OM.^".H>#-+\)WU^SM8ZQI?F :C=*A++=>:S-YK*IVL&VY 0*HVBO,?\
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M>(=0FT5[>\"B6XM)=PMQ,%)4.KB%OE/!4@'!.?LK_@MY_P DL^&G_89N/_1
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M\1K?[-KTUC'>QI]M2[_<,[JIWJS ?-&_&?YT ?OC^Q3_ ,FC_"'_ +%FQ_\
M12U@_M-?MX_"K]EFX73/$VHW.J^)GC\Q= T6-9KI%(RK2[F5(@<C&Y@2#D B
MK?[*.NQ^%_V(?AQK,R[XM.\&V]XZYQE8[;>1GMTK\<_V3? I_;0_;2TZ/Q_-
M/J=MK%W=:UK6)&!F2-&D\K<#E49@D?!!53@8P* /O?P]_P %K_A=?ZLL&K^"
MO%&DV+/M%Y%]GN-HY^9D#J<=.F3UZ]_NCX7_ !4\*?&;P;9>*O!FMVVO:%>#
M]W<VY/RL,91U.&1QD95@",\BOFC]JW]@CX.^)OV?_%H\/> =%\,>(=(TFXOM
M+U#1+-+:;SH8VD5)"@'F*Y7:=^[ALCD U\3?\$8?BMJ6@_';7_ 3W,C:'K^E
M27BVK.=J7<#(5D4= 3&T@..3A<_=% 'V[^TS_P %+/ W[+WQ2G\#:_X7\0ZK
MJ$-K#=FXTT0>45D!('SR*<C'I5#X\?\ !53X1?!/6O["MX=3\9:['&K74&B^
M48+1RN?*DF9P/,' *H&VG()!!%?GQ_P5X_Y/)U+_ + UA_Z U?HA\ _^";?P
M+\,?"#2+/6O"%KXQU74K&.>^UC5MQG=Y$#'RL-^Y49P-F#@<DG)(!TO[+/\
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ML%?HK7YU?\$2_P#D@7CK_L9C_P"DL%?HK0!\F?\ !1/XG?"#X=_#GP[#\8O
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M206BB8\NS$+N? ^Z%'&2W=_MW?L?6W[7WPLMM+M;R'2O%VBRO=:-?W(8PAF
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M U^DW@'X8^-/VE?V&T\&?'8W5IXVU^TO(=3FGM(89K>5+V5K27RH@J914MV
M &X#GDDT ?-O_!$"ZL6^''Q/MHRG]IIJUI),H(W>2T+B,GVW++C\:ZS_ (+6
MS0K^S%X2B9XQ<MXPMV2,D;RHLKP,0.N 67/U'J*^+O"_P!_:X_8C^*EY/X$\
M+:Y>3S?Z(U]X?T\ZKI^H0EB5+J%8*,C/[P(R9_ASSV7QV_9+_:R_:%^'MK\2
M?B,FH:[XG6^BLM-\&V\42RVUF\;M+<&*,K'#\R1+MP7;.7QM&0#ZN_X(P_\
M)J&M_P#8VWG_ *2VE?=DVI6EM<16\UU#%<3?ZN)Y &?Z G)_"OD'_@E=\)?&
M'P9_9QU;0O&WA^\\-ZO+XDN;M+2]4!VA:WME5^">"48?@:^'OVXOV1?VA/'7
M[7OB36])\,:YXILM3O8I=$UBP;=!;P8411F3($'ED8.XK@J6Z'<0#]J**PO
M>G:MH_@?P[8:_>+J.NVNG6\&H7BDD3W"Q*LL@)Y.YPQY]:W: "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
M\ ?^<IO_ '6;_P!SE?O]7X _\Y3?^ZS?^YR@#]_J*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK'PK^-U]\3](LI'\'^+)Q<R75NAVV.H;1YJ2$?=,C RJQQDLX'W:^F/V:O\
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M_P 28:.88^\H&,Y%?O+\-? &F?"OP!X?\'Z*UP^DZ'916%JUTX>4QQJ%7<P
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M^"@/[6US<V>G-'K'BS44:5+<&2/3;) D>]V./DBA1<L<;BO RP%?IK_P5=^
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MY_$4W@B;697UY;=+O^UKI)@!"9"FS;&N/]:V>O:O>: "BBB@ HHHH *^5?\
M@J/_ ,F)_$W_ +AG_ITM*^JJ^5?^"H__ "8G\3?^X9_Z=+2@#Y5_X(8_\UL_
M[@G_ +?U^JE?E7_P0Q_YK9_W!/\ V_K]5* "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MOQ6_X+5_\G3>%O\ L3+7_P!+KZOVIK\5O^"U?_)TWA;_ +$RU_\ 2Z^H _53
M]D[_ )-9^#?_ &)FC?\ I##7JM>5?LG?\FL_!O\ [$S1O_2&&O5: "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ K)\6V^K77A768-!NH['79+*9+"ZE0.D-P8V$3
MLI!! ?:2",'%:U% 'QA^Q]^POKWPV^(FI_&+XR^(XO&_Q<U#<(KB-VDAT]63
M8Q5BJ[I"A\OA0J+E5R#FOL^BB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *_ '_G*;_P!UF_\ <Y7[_5^ /_.4W_NLW_N<H _?ZBBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "J.N:'IWB;1K[2-7L;?4M+OH6M[JSNHQ)%-&PPR,IX(()&#5ZB@#X;\<?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\5O^"U?_
M "=-X6_[$RU_]+KZOVIK\5O^"U?_ "=-X6_[$RU_]+KZ@#]5/V3O^36?@W_V
M)FC?^D,->JUY5^R=_P FL_!O_L3-&_\ 2&&O5: "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M K\ ?^<IO_=9O_<Y7[_5^ /_ #E-_P"ZS?\ N<H _?ZBBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "OE7_@J/_P F)_$W_N&?^G2TKZJKY5_X*C_\
MF)_$W_N&?^G2TH ^5?\ @AC_ ,UL_P"X)_[?U^JE?E7_ ,$,?^:V?]P3_P!O
MZ_52@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?B)X@N=4ATBWX8VB?:Y0]XZ^B9PH/WGQP0KX /4/^"@W_!3#6/@G\0+?X?\
MPIFT^XUO33OUW4;J 7$<,A'RVJ#.-X!W.>QVKU# ?5W['VH?%_Q%\);3Q'\9
M;JS3Q#K&VZM=)M+);8V%L1\BR@<F5L[B#]T;1@,&K\\O^"7G[$]S\5/$Z?&_
MXC6TMYHEK=M<:-;7^7;5+P.2UU)NY:-'SC/WY!G.$(;]@* "BOSI_;._X*NQ
M_!OQMJ/@/X7Z-8^(_$&FR-;:CK&I%GL[><<-#''&RM*ZG(8E@%88PW./ ;C_
M (*;?M7?#3[%KGC3P);P:!=N/*_MGPU=6,$RG/$4VY<G&<'+=.AYH _92BO
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MM)K7PQ\<?#^ZD9GT+4(]3M-QZ0W*E71?99(2WUEK])Z "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KY5_X*C_\ )B?Q-_[AG_ITM*^JJ^5?^"H__)B?Q-_[AG_ITM*
M/E7_ ((8_P#-;/\ N"?^W]?JI7Y5_P#!#'_FMG_<$_\ ;^OU4H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *_%;_ (+5_P#)TWA;_L3+7_TNOJ_:FOQ6_P""U?\ R=-X
M6_[$RU_]+KZ@#]5/V3O^36?@W_V)FC?^D,->JUY5^R=_R:S\&_\ L3-&_P#2
M&&O5: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M261@3C>TI9=W]U4'KGZMD_X(L>&-/^',<FE?$#7H/B9;0">#4=T2:=]K4!E
MC6/S43<,!Q(6'WL'&VOAW]I!I/@W_P %#?%FK:M$XCTWQTNONA7>6@>Y2\4@
M'KF-UP/?%?O3J?Q*\*Z/X#D\;7FOZ?!X2CL_MYU@SJ;<P%=P<,/O C&,9)R
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M[1XVTFV%WX=TRZ4>5*_/G7 )/SRQC:57L&9QDKE?VNK\&?VT/V;_ !'^P?\
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M3]O;X>Z-XT^*GQ.U1/"6CQC1=!T^WVS3B* "-C\PV1CY5&XJSOMRW0$^Q?\
M!;S_ ))9\-/^PS<?^B!7L'_!)/\ Y,M\/_\ 83U#_P!'F@#\J?VNO@!>_L4?
MM%0:%H'B&ZNOLT%KKFCZM@17,0+MM+;> Z21/R.N <#.*_??X4^+)?'OPO\
M!_B:956;6M&L]2=5& &F@20@#MRU?CI_P6>_Y.OT3_L4K/\ ]*KNOUI_9E_Y
M-M^%'_8I:3_Z1Q4 ?COXZD7X._\ !65KBQD:SA7X@6MS*RG&(KR6-YQ]"MQ(
M,>AK]TZ_"7]H15\??\%5;BSB;S5NO'.DZ<2G.-CVT##\-AS]*_=J@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *_ '_ )RF_P#=9O\ W.5^_P!7X _\Y3?^ZS?^YR@#]_J*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "O*OVL?\ DUGXR?\ 8F:S_P"D,U>JUY5^UC_R:S\9/^Q,
MUG_TAFH _*O_ ((J?\G3>*?^Q,NO_2ZQK]J:_%;_ ((J?\G3>*?^Q,NO_2ZQ
MK]J: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KP+]O;4)=+_8Y^+,T()=M$D@.!_#(
MRQM^C&O?:\N_:C\%W7Q%_9Q^)?ANPA^T:AJ/A^]BM8?[\_DL8U_%PHH _/G_
M ((:V,;3?&:\)4RJND0J.-P4F\)_ [1^1]*]8_X+5_\ )K/A;_L<[7_TAOJ^
M>_\ @B-XRBT_XL?$;PL[;9=5T:WU"//?[-,4(^N+K/X&OH3_ (+5_P#)K/A;
M_L<[7_TAOJ /BS]A?_@GEI_[87P]U_Q+>>-KKPP^EZI_9PMX-.6Y$@\F.3?N
M,BX^_C&.U?2?_#CG0_\ HK>H?^"./_X_75?\$2_^2!>.O^QF/_I+!7Z*T ?S
MB>&? Z?#']M;2?!T5VVH1>'OB##I"W;Q^69Q!J0B#E<G:6V9QDXSUK]??^"K
M?B*^\/\ [%OBJ.QE>'^T;RRL9WCZ^4TZLPSV!V!3Z@D=Z_*GQ9_RDDUG_LK,
MW_IX:OV[_:J^!L7[1OP#\7> 3-':W>I6P>QN9<[8KJ)UEA9L<A=Z*&Q_"6ZT
M ? W_!#_ ,'Z9)#\4_%$D,,NL1/8Z=#(R@R00L)9) #V#L$SZ^4*]@_X+)>#
M],UG]ENPUVXAA&JZ-KMO]EN&4>9LE5TDB4^C?(Q'_3,'M7P1^R_^T=XV_P""
M;OQ>\5:#XP\%W4T&HI%!JVB7$GV>96B9_)N(9-K*PP\F",JX;AN :W_VS?V]
M->_;D@\-_#SP;X*O=-TI;];I+%'-Y?:C=A&2,!8U&%4._P HW9)!)& * /J_
M_@B9XDOK_P""OCS19Y)'L=.UV.>W#=$,T"[U4_6(''JV>]? OP'\)Z/XY_;\
MT30M?TZ#5M'O/&5PMS97*[HIE$TC;77^)<@9!X(X.0<5^N__  3O_9EO_P!F
M']GRUTC7D1/%6M73:OJL2$-]G=T14@W#@E$1<XXW,^"1@G\GOV6_^4CGAG_L
M<[K_ -&2T ?M'^U=X>T[6/V6/BKIMW9PRV*>%=1=("@VHT5L[Q,HQ@%'1&'H
M5'I7Y;?\$4[B1?VGO%L <B)_!UR[)V++>V0!_ ,WYU^K7[37_)MOQ7_[%+5O
M_2.6ORA_X(J?\G3>*?\ L3+K_P!+K&@#5_X+-_"/Q%I?QLT3XAFVFN?"VJZ7
M#IRWBJ2EM<Q-(3"Q_AW*P=<_>^?'W37TAX@_X*K? _4/V;;M8KJ\?QA=:$UE
M_P (E_9TX*7#0F/89BGD^4&.=P<G;_#GY:\:_P""P6I?$#P_\7/!-[K FU?X
M/-' \6ABY>&SN[J.0O/#<"-@^YD"X?C"L=A!#5XGH_[8W[.5OJD%Y=_LA:*L
MJ*-S1^)9)HBPQ_RP>WV$$COGCKF@#UG_ ((I_"GQ#)\3O%_Q'>UFMO#$&COH
MD=RZE5NKF2>&4JA_B"+#EL="Z>M?KY7Q7^R;_P %*/@]\9-7T;X?:=H4_P -
MM6E'V?3-*GBA6PD;'RP021X"L><*43)P!DD"OM2@#\J_^"YW_-$_^XW_ .V%
M?,>J?L?7GC']@_P=\;/"\4UUJ&CO?VVOV*EGW6:7DVRY0=O+R0X'&T[N-K$_
M3G_!<[_FB?\ W&__ &PKZ0_X)46T-Y^PYX5M[B))X);K4HY(I%#*ZF[E!4@\
M$$=J /&_^"3?[:<?C+P[:_!3Q?=JFO:3 ?\ A';J0@?;+1!DVQ]9(@"5]8Q_
ML$G]#O&VK3Z!X,U_4[49N;+3[BYB&,Y=(V8<=^0*_#W]O3]E?6?V+?CEIWC'
MP/)<Z=X1U*]_M#0+^V)W:7=(P<VQ;L5/S)G[R<<E6K]4/V*OVK-&_; ^#*ZA
M.EO#XHL4%CXBTE?NI*5(\Q5//E2@$KZ'<N25)H _)7_@F7X;L_B%^VYX/FU_
M9J)MS>ZL5N_G,]PD$C(QSU99"),^J9K]KOVDO!^F>/?@!\0]"U>&&6QNM"O,
MF=05C=869)?8HZJX/8J#7XL_$GX9^/O^":G[5VF>*['2WO-#L-0EGT+4IE8V
MNHV;JR/;LX^[)Y4C(PZ@_, 1M)]O_:&_X+#-\4O@[K?A#PGX$N/#NIZ]926%
M[J-]?K.MM#(A241*J*68JS*'.W;G.">@!YS_ ,$>?$E]H_[7']FV\D@L]6T*
M\@N8UY4A-DJL?HR8!_VB.]4/^"O'_)Y.I?\ 8&L/_0&KZ;_X)#_LB^(O =UJ
MWQ=\8:9/HTFH6)T[0["\C*3-"[(\ER5/*JVQ53/)!<]"I/S)_P %>/\ D\G4
MO^P-8?\ H#4 ?LA^SSX-T/P%\$?!.D>'M+MM(TV/2;:46]JFU2[Q*SNW=F9B
M26.2222:_$73],MO"7_!4*RT[2(EL+&U^+,5M!!"H5(XCJP78H' 4*=H'I7[
MI_";_DE?@W_L"V7_ *(2OPVU/_E*LG_98(?_ $[K0!^A7_!7[X1^(OB1^SCI
MFK^'[:;4%\+ZI_:.H6D"EG^S-$Z-, .3Y9*D^BECT4UXQ_P3K_X*"_!_X+_L
MXVO@;Q]JUQX:UC1KJZDB9=.N+E+^.65I05:%'VN"Q0A]HP%()R<?0?\ P5:D
M^)5K^S,][X U"ZL-.MKT/XC.GS>5<&Q*,,[@0?+#[=ZKR01GY0U?F5\.?VGO
M@=X9\#Z#HWB;]E_1_%.KZ=$B3ZTOB6XM7O' &Z62/RGY8Y)7=MYP !Q0!U7P
MEAU']L'_ (*36OC+P9I-U9Z/_P )7!XDGD=,&TLK:9'\R4C(5W$8&,GYY ,G
MK7[)?M)0PW'[.OQ3BN,>0_A755DW=-IM)0?TKX._9Q_X*G? +P68?#4'PKF^
M$^CW$J@W6D10W%ONX DN"BI(< G+;7;BOK?]MSXB6/AW]B[XF^(K.\@N;+4/
M#TEI:W4,@>.5;P+;QNC X(/G@@CV- 'YY?\ !$F\N$^.7C^U5<VLGAQ99&]'
M6YB"C\G?\J_8ZORD_P""('@>[^W?%#QC(FVQ$=II$#X^_)EY9 #_ +(\K_OL
M5^K= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5\J_\%1_^3$_B;_W#/_3I:5]55\J_
M\%1_^3$_B;_W#/\ TZ6E 'RK_P $,?\ FMG_ '!/_;^OU4K\J_\ @AC_ ,UL
M_P"X)_[?U^JE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_<Y0!^_U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD3ZSHFG:L\((C:^M(YB@/4#<#C.!TK3M[>*U@C@@C2&&-0B1QJ%55 P  .@
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MZYX?TOQ1ILNG:SIMGJVGR\26E] DT3_5&!!_*O-X_P!DOX(17PNT^#_@5)U
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MW@CPX=<^T_;/[3.DV_VGSPV_S?-V;M^[YMV<YYS77T4 ?FK_ ,%JO"OCK6O
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7X _\Y3?^ZS?^
MYROW^K\ O!1_X3?_ (*?65W:CY+GXJOJ"[?[BZFTQ_\ '5H _?VBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KSG]I'29->_9W^*6F19\V]\*ZI;+CKE[251_.O1J
MK:EI\.K:==6-PNZWN8FAD4=U8$$?D: /Q-_X(TZRFE_M:ZA;, 3J/A>\M5SZ
MB>VE_E$:_;NOY]?V<=<N?V/_ -O+1[/6YQ!!H7B*?P_J<\GRH;>1GMFF/^R
MXE'LHK^@J@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *^3?^"I]]#9_L-_$**4X:ZDTV&,>
MK#4+=_Y(?RKZRK\W?^"U7Q:AT7X4^#_AW;S(;_7-1.IW4:D%EMK=2JY'8-)*
M"#W\EO0T <K_ ,$-;&6/3_C->$?N9I=(A4_[2"\)_21:_4RO@_\ X(Y_#.;P
M?^S#>^)KI667Q7K$UU #Q_H\($"G_OXDWX8K[PH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M \W_ &COB]9_ CX'^,O'-W+'$VDZ=)):K)TENF&RWC]]TK(OXU^.W_!)WX97
M'Q/_ &O+7Q)?>9<6OA>SN-9N)I"3YEPX\F($]=VZ4R>_EFNG_P""J?[9EI\<
M/&-M\,_!UW]K\(^&[MI+R]@;,>HWX!3Y,?>CB!=0W1F9B,@*3]X?\$S_ -E]
M_P!G3X P7VM6;6OC3Q84U+4TE7$EO%@_9[<]P51BQ!Y#RN.PH ^NJ*** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@.H530!]*_#CP#I'PK\!Z!X0T&$V^CZ+9QV5LC'+;$4#<Q[L3DD]R372444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFPLF@>()4M+H.>T>YMLP]XV;CJ!TKZ,K\8_C)_P1E^)GA:XNKKX>:[I?C;3
M2T5G=R"PO\=0N'_=,>V[S%S_ '1V\8M?@K^V+\*(4M=(T/XK:-! -J1>'9[U
MT4?=PHMF(QQV[8[4 ?T!T5^ +-^V^S$_\7_Y]!K8H_XS>_ZN _\ *Y0!^_U%
M?@#_ ,9O?]7 ?^5RC_C-[_JX#_RN4 ?O]17X _\ &;W_ %<!_P"5RC_C-[_J
MX#_RN4 ?O]17X _\9O?]7 ?^5RC_ (S>_P"K@/\ RN4 ?O\ 45^ /_&;W_5P
M'_E<H_XS>_ZN _\ *Y0!^_U%?@#_ ,9O?]7 ?^5RC_C-[_JX#_RN4 ?O]17X
M _\ &;W_ %<!_P"5RC_C-[_JX#_RN4 ?O]17X _\9O?]7 ?^5RC_ (S>_P"K
M@/\ RN4 ?O\ 45^ /_&;W_5P'_E<H_XS>_ZN _\ *Y0!^_U%?@#_ ,9O?]7
M?^5RC_C-[_JX#_RN4 ?O]17X _\ &;W_ %<!_P"5RC_C-[_JX#_RN4 ?O]17
MX _\9O?]7 ?^5RC_ (S>_P"K@/\ RN4 ?O\ 45^ /_&;W_5P'_E<H_XS>_ZN
M _\ *Y0!^_U%?@#_ ,9O?]7 ?^5RC_C-[_JX#_RN4 ?O]17X _\ &;W_ %<!
M_P"5RC_C-[_JX#_RN4 ?O]17X _\9O?]7 ?^5RC_ (S>_P"K@/\ RN4 ?O\
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M_JX#_P KE'_&;W_5P'_E<H _?ZBOP!_XS>_ZN _\KE'_ !F]_P!7 ?\ E<H
M_?ZBOP!_XS>_ZN _\KE'_&;W_5P'_E<H _?ZBOP!_P",WO\ JX#_ ,KE'_&;
MW_5P'_E<H _?ZBOP!_XS>_ZN _\ *Y1_QF]_U<!_Y7* /W^HK\ ?^,WO^K@/
M_*Y1_P 9O?\ 5P'_ )7* /W^HK\ ?^,WO^K@/_*Y1_QF]_U<!_Y7* /W^HK\
M ?\ C-[_ *N _P#*Y1_QF]_U<!_Y7* /W^HK\ ?^,WO^K@/_ "N4?\9O?]7
M?^5R@#]_J*_ '_C-[_JX#_RN4?\ &;W_ %<!_P"5R@#]_J*_ '_C-[_JX#_R
MN4?\9O?]7 ?^5R@#]_J*_ '_ (S>_P"K@/\ RN4?\9O?]7 ?^5R@#]_J*_ '
M_C-[_JX#_P KE'_&;W_5P'_E<H _?ZBOP!_XS>_ZN _\KE'_ !F]_P!7 ?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_E<K]_J* /P!_P",WO\ JX#_ ,KE'_&;W_5P'_E<K]_J* /P!_XS>_ZN _\
M*Y1_QF]_U<!_Y7*_?ZB@#\ ?^,WO^K@/_*Y1_P 9O?\ 5P'_ )7*_?ZB@#\
M?^,WO^K@/_*Y1_QF]_U<!_Y7*_?ZB@#\ ?\ C-[_ *N _P#*Y1_QF]_U<!_Y
M7*_?ZB@#\ ?^,WO^K@/_ "N4?\9O?]7 ?^5ROW^HH _ '_C-[_JX#_RN4?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% '\]?_!2'_D]KXI?]?MO_ .DD%?T*5_/7_P %
M(?\ D]KXI?\ 7[;_ /I)!7]"E !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!Y5^UC_R:S\9/^Q,UG_TAFK\J_P#@BI_R
M=-XI_P"Q,NO_ $NL:_53]K'_ )-9^,G_ &)FL_\ I#-7Y5_\$5/^3IO%/_8F
M77_I=8T ?M31110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!_/7_ ,%(?^3VOBE_U^V__I)!7]"E?SU_\%(?^3VOBE_U^V__
M *205_0I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 >5?M8_P#)K/QD_P"Q,UG_ -(9J_*O_@BI_P G3>*?^Q,NO_2Z
MQK]5/VL?^36?C)_V)FL_^D,U?E7_ ,$5/^3IO%/_ &)EU_Z76- '[4T444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?SU_\
M%(?^3VOBE_U^V_\ Z205_0I7\]?_  4A_P"3VOBE_P!?MO\ ^DD%?T*4 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'E
M7[6/_)K/QD_[$S6?_2&:ORK_ ."*G_)TWBG_ +$RZ_\ 2ZQK]5/VL?\ DUGX
MR?\ 8F:S_P"D,U?E7_P14_Y.F\4_]B9=?^EUC0!^U-%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '\]?\ P4A_Y/:^*7_7
M[;_^DD%?T*5_/7_P4A_Y/:^*7_7[;_\ I)!7]"E !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y5^UC_ ,FL_&3_ +$S
M6?\ TAFK\J_^"*G_ "=-XI_[$RZ_]+K&OU4_:Q_Y-9^,G_8F:S_Z0S5^5?\
MP14_Y.F\4_\ 8F77_I=8T ?M31110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%>*
M?\-K? 3_ **]X/\ _!M%_C0![717BG_#:WP$_P"BO>#_ /P;1?XT?\-K? 3_
M **]X/\ _!M%_C0![717BG_#:WP$_P"BO>#_ /P;1?XT?\-K? 3_ **]X/\
M_!M%_C0![717BG_#:WP$_P"BO>#_ /P;1?XT?\-K? 3_ **]X/\ _!M%_C0!
M[717BG_#:WP$_P"BO>#_ /P;1?XT?\-K? 3_ **]X/\ _!M%_C0![717BG_#
M:WP$_P"BO>#_ /P;1?XT?\-K? 3_ **]X/\ _!M%_C0![717BG_#:WP$_P"B
MO>#_ /P;1?XT?\-K? 3_ **]X/\ _!M%_C0![717BG_#:WP$_P"BO>#_ /P;
M1?XT?\-K? 3_ **]X/\ _!M%_C0![717BG_#:WP$_P"BO>#_ /P;1?XT?\-K
M? 3_ **]X/\ _!M%_C0![717BG_#:WP$_P"BO>#_ /P;1?XT?\-K? 3_ **]
MX/\ _!M%_C0![717BG_#:WP$_P"BO>#_ /P;1?XT?\-K? 3_ **]X/\ _!M%
M_C0![717BG_#:WP$_P"BO>#_ /P;1?XT?\-K? 3_ **]X/\ _!M%_C0![717
MBG_#:WP$_P"BO>#_ /P;1?XT?\-K? 3_ **]X/\ _!M%_C0![717BG_#:WP$
M_P"BO>#_ /P;1?XT?\-K? 3_ **]X/\ _!M%_C0![717BG_#:WP$_P"BO>#_
M /P;1?XT?\-K? 3_ **]X/\ _!M%_C0![717BG_#:WP$_P"BO>#_ /P;1?XT
M?\-K? 3_ **]X/\ _!M%_C0![717BG_#:WP$_P"BO>#_ /P;1?XT?\-K? 3_
M **]X/\ _!M%_C0![717BG_#:WP$_P"BO>#_ /P;1?XT?\-K? 3_ **]X/\
M_!M%_C0![717BG_#:WP$_P"BO>#_ /P;1?XT?\-K? 3_ **]X/\ _!M%_C0!
M[717BG_#:WP$_P"BO>#_ /P;1?XT?\-K? 3_ **]X/\ _!M%_C0![717BG_#
M:WP$_P"BO>#_ /P;1?XT?\-K? 3_ **]X/\ _!M%_C0![717BG_#:WP$_P"B
MO>#_ /P;1?XT?\-K? 3_ **]X/\ _!M%_C0![717BG_#:WP$_P"BO>#_ /P;
M1?XT?\-K? 3_ **]X/\ _!M%_C0![717BG_#:WP$_P"BO>#_ /P;1?XT?\-K
M? 3_ **]X/\ _!M%_C0![717BG_#:WP$_P"BO>#_ /P;1?XT?\-K? 3_ **]
MX/\ _!M%_C0![717BG_#:WP$_P"BO>#_ /P;1?XT?\-K? 3_ **]X/\ _!M%
M_C0![717BG_#:WP$_P"BO>#_ /P;1?XT?\-K? 3_ **]X/\ _!M%_C0![717
MBG_#:WP$_P"BO>#_ /P;1?XT?\-K? 3_ **]X/\ _!M%_C0![717BG_#:WP$
M_P"BO>#_ /P;1?XT?\-K? 3_ **]X/\ _!M%_C0![717BG_#:WP$_P"BO>#_
M /P;1?XT?\-K? 3_ **]X/\ _!M%_C0![717BG_#:WP$_P"BO>#_ /P;1?XT
M?\-K? 3_ **]X/\ _!M%_C0![717BG_#:WP$_P"BO>#_ /P;1?XT?\-K? 3_
M **]X/\ _!M%_C0![717BG_#:WP$_P"BO>#_ /P;1?XT?\-K? 3_ **]X/\
M_!M%_C0![717BG_#:WP$_P"BO>#_ /P;1?XT?\-K? 3_ **]X/\ _!M%_C0!
M[717BG_#:WP$_P"BO>#_ /P;1?XT?\-K? 3_ **]X/\ _!M%_C0![717BG_#
M:WP$_P"BO>#_ /P;1?XT?\-K? 3_ **]X/\ _!M%_C0![717BG_#:WP$_P"B
MO>#_ /P;1?XT?\-K? 3_ **]X/\ _!M%_C0![717BG_#:WP$_P"BO>#_ /P;
M1?XT?\-K? 3_ **]X/\ _!M%_C0![717BG_#:WP$_P"BO>#_ /P;1?XT?\-K
M? 3_ **]X/\ _!M%_C0![717BG_#:WP$_P"BO>#_ /P;1?XT?\-K? 3_ **]
MX/\ _!M%_C0![717BG_#:WP$_P"BO>#_ /P;1?XT?\-K? 3_ **]X/\ _!M%
M_C0![717BG_#:WP$_P"BO>#_ /P;1?XT?\-K? 3_ **]X/\ _!M%_C0![717
MBG_#:WP$_P"BO>#_ /P;1?XT?\-K? 3_ **]X/\ _!M%_C0![717BG_#:WP$
M_P"BO>#_ /P;1?XT?\-K? 3_ **]X/\ _!M%_C0![717BG_#:WP$_P"BO>#_
M /P;1?XT?\-K? 3_ **]X/\ _!M%_C0![717BG_#:WP$_P"BO>#_ /P;1?XT
M?\-K? 3_ **]X/\ _!M%_C0![717BG_#:WP$_P"BO>#_ /P;1?XT?\-K? 3_
M **]X/\ _!M%_C0![717BG_#:WP$_P"BO>#_ /P;1?XT?\-K? 3_ **]X/\
M_!M%_C0![717BG_#:WP$_P"BO>#_ /P;1?XT?\-K? 3_ **]X/\ _!M%_C0!
M[717BG_#:WP$_P"BO>#_ /P;1?XT?\-K? 3_ **]X/\ _!M%_C0![717BG_#
M:WP$_P"BO>#_ /P;1?XT?\-K? 3_ **]X/\ _!M%_C0![717BG_#:WP$_P"B
MO>#_ /P;1?XT?\-K? 3_ **]X/\ _!M%_C0![717BG_#:WP$_P"BO>#_ /P;
M1?XT?\-K? 3_ **]X/\ _!M%_C0![717BG_#:WP$_P"BO>#_ /P;1?XT?\-K
M? 3_ **]X/\ _!M%_C0![717BG_#:WP$_P"BO>#_ /P;1?XT?\-K? 3_ **]
MX/\ _!M%_C0![717BG_#:WP$_P"BO>#_ /P;1?XT?\-K? 3_ **]X/\ _!M%
M_C0![717BG_#:WP$_P"BO>#_ /P;1?XT?\-K? 3_ **]X/\ _!M%_C0![717
MBG_#:WP$_P"BO>#_ /P;1?XT?\-K? 3_ **]X/\ _!M%_C0![717BG_#:WP$
M_P"BO>#_ /P;1?XT?\-K? 3_ **]X/\ _!M%_C0![717BG_#:WP$_P"BO>#_
M /P;1?XT?\-K? 3_ **]X/\ _!M%_C0![717BG_#:WP$_P"BO>#_ /P;1?XT
M?\-K? 3_ **]X/\ _!M%_C0![717BG_#:WP$_P"BO>#_ /P;1?XT?\-K? 3_
M **]X/\ _!M%_C0!^*W_  4A_P"3VOBE_P!?MO\ ^DD%?T*5_.I^WIXOT3Q[
M^UQ\1M?\.:K:ZWHM[=P/;7]C*)89E%M"I*L.#@J1^%?N!_PVM\!/^BO>#_\
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MUT5XI_PVM\!/^BO>#_\ P;1?XT?\-K? 3_HKW@__ ,&T7^- 'M=%>*?\-K?
M3_HKW@__ ,&T7^-'_#:WP$_Z*]X/_P#!M%_C0![717BG_#:WP$_Z*]X/_P#!
MM%_C1_PVM\!/^BO>#_\ P;1?XT >UT5XI_PVM\!/^BO>#_\ P;1?XT?\-K?
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M#_\ P;1?XT >UT5XI_PVM\!/^BO>#_\ P;1?XT?\-K? 3_HKW@__ ,&T7^-
M'M=%>*?\-K? 3_HKW@__ ,&T7^-'_#:WP$_Z*]X/_P#!M%_C0![717BG_#:W
MP$_Z*]X/_P#!M%_C1_PVM\!/^BO>#_\ P;1?XT >UT5XI_PVM\!/^BO>#_\
MP;1?XT?\-K? 3_HKW@__ ,&T7^- 'M=%>*?\-K? 3_HKW@__ ,&T7^-'_#:W
MP$_Z*]X/_P#!M%_C0![717BG_#:WP$_Z*]X/_P#!M%_C1_PVM\!/^BO>#_\
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MUT5XI_PVM\!/^BO>#_\ P;1?XT?\-K? 3_HKW@__ ,&T7^- 'M=%>*?\-K?
M3_HKW@__ ,&T7^-'_#:WP$_Z*]X/_P#!M%_C0![717BG_#:WP$_Z*]X/_P#!
MM%_C1_PVM\!/^BO>#_\ P;1?XT >UT5XI_PVM\!/^BO>#_\ P;1?XT?\-K?
M3_HKW@__ ,&T7^- 'M=%8_A+Q?HGCWP[9:_X<U6UUO1;U2]M?V,HEAF4,5)5
MAP<%2/PK8H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#OJZ_^,T?\.2_BG_T/7@__ +ZNO_C-?LI10!^-?_#DOXI_]#UX/_[ZNO\
MXS1_PY+^*?\ T/7@_P#[ZNO_ (S7[*44 ?C7_P .2_BG_P!#UX/_ .^KK_XS
M1_PY+^*?_0]>#_\ OJZ_^,U^RE% 'XU_\.2_BG_T/7@__OJZ_P#C-'_#DOXI
M_P#0]>#_ /OJZ_\ C-?LI10!^-?_  Y+^*?_ $/7@_\ [ZNO_C-'_#DOXI_]
M#UX/_P"^KK_XS7[*44 ?C7_PY+^*?_0]>#_^^KK_ .,T?\.2_BG_ -#UX/\
M^^KK_P",U^RE% 'XU_\ #DOXI_\ 0]>#_P#OJZ_^,T?\.2_BG_T/7@__ +ZN
MO_C-?LI10!^-?_#DOXI_]#UX/_[ZNO\ XS1_PY+^*?\ T/7@_P#[ZNO_ (S7
M[*44 ?C7_P .2_BG_P!#UX/_ .^KK_XS1_PY+^*?_0]>#_\ OJZ_^,U^RE%
M'XU_\.2_BG_T/7@__OJZ_P#C-'_#DOXI_P#0]>#_ /OJZ_\ C-?LI10!^-?_
M  Y+^*?_ $/7@_\ [ZNO_C-'_#DOXI_]#UX/_P"^KK_XS7[*44 ?C7_PY+^*
M?_0]>#_^^KK_ .,T?\.2_BG_ -#UX/\ ^^KK_P",U^RE% 'XU_\ #DOXI_\
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MC7_PY+^*?_0]>#_^^KK_ .,T?\.2_BG_ -#UX/\ ^^KK_P",U^RE% 'XU_\
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M_P#[ZNO_ (S7[*44 ?C7_P .2_BG_P!#UX/_ .^KK_XS1_PY+^*?_0]>#_\
MOJZ_^,U^RE% 'XU_\.2_BG_T/7@__OJZ_P#C-'_#DOXI_P#0]>#_ /OJZ_\
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M_OJZ_P#C-'_#DOXI_P#0]>#_ /OJZ_\ C-?LI10!^-?_  Y+^*?_ $/7@_\
M[ZNO_C-'_#DOXI_]#UX/_P"^KK_XS7[*44 ?S.?M"_!+5?V<_C!K_P /-;O[
M/4]3T?[/YUU8;_)?SK>.==N\!N%E .1U!K[/_P"')?Q3_P"AZ\'_ /?5U_\
M&:\5_P""H_\ R?9\3?\ N&?^FNTK]_J /QK_ .')?Q3_ .AZ\'_]]77_ ,9H
M_P"')?Q3_P"AZ\'_ /?5U_\ &:_92B@#\:_^')?Q3_Z'KP?_ -]77_QFC_AR
M7\4_^AZ\'_\ ?5U_\9K]E** /QK_ .')?Q3_ .AZ\'_]]77_ ,9H_P"')?Q3
M_P"AZ\'_ /?5U_\ &:_92B@#\:_^')?Q3_Z'KP?_ -]77_QFC_AR7\4_^AZ\
M'_\ ?5U_\9K]E** /QK_ .')?Q3_ .AZ\'_]]77_ ,9H_P"')?Q3_P"AZ\'_
M /?5U_\ &:_92B@#\:_^')?Q3_Z'KP?_ -]77_QFC_AR7\4_^AZ\'_\ ?5U_
M\9K]E** /QK_ .')?Q3_ .AZ\'_]]77_ ,9H_P"')?Q3_P"AZ\'_ /?5U_\
M&:_92B@#\:_^')?Q3_Z'KP?_ -]77_QFC_AR7\4_^AZ\'_\ ?5U_\9K]E**
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MZ\'_ /?5U_\ &:_92B@#\:_^')?Q3_Z'KP?_ -]77_QFC_AR7\4_^AZ\'_\
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M\9K]E** /QK_ .')?Q3_ .AZ\'_]]77_ ,9H_P"')?Q3_P"AZ\'_ /?5U_\
M&:_92B@#\:_^')?Q3_Z'KP?_ -]77_QFC_AR7\4_^AZ\'_\ ?5U_\9K]E**
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MZ\'_ /?5U_\ &:_92B@#\:_^')?Q3_Z'KP?_ -]77_QFC_AR7\4_^AZ\'_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'E7[6/_)K/
MQD_[$S6?_2&:ORK_ ."*G_)TWBG_ +$RZ_\ 2ZQK]5/VL?\ DUGXR?\ 8F:S
M_P"D,U?E7_P14_Y.F\4_]B9=?^EUC0!^U-%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5^ /_!+C_D^SX9?]Q/\ ]-=W7[_5^ /_  2X_P"3[/AE_P!Q/_TUW= '
M[_4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 ?@#_P5'_Y/L^)O_<,_P#37:5^_P!7X _\
M%1_^3[/B;_W#/_37:5^_U !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7Y*_\%QO^1J^$G_7E
MJ7_HRWK]:J_)7_@N-_R-7PD_Z\M2_P#1EO0!]J_\$WO^3)?A;_UY7'_I7/7T
MK7S5_P $WO\ DR7X6_\ 7E<?^E<]?2M !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 >5?M8_P#)K/QD_P"Q,UG_ -(9J_*O_@BI_P G3>*?^Q,NO_2ZQK]5/VL?
M^36?C)_V)FL_^D,U?E7_ ,$5/^3IO%/_ &)EU_Z76- '[4T444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7X _P#!+C_D^SX9?]Q/_P!-=W7[_5^ /_!+C_D^SX9?
M]Q/_ --=W0!^_P!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!^ /_  5'_P"3[/B;_P!P
MS_TUVE?O]7X _P#!4?\ Y/L^)O\ W#/_ $UVE?O]0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5^2O\ P7&_Y&KX2?\ 7EJ7_HRWK]:J_)7_ (+C?\C5\)/^O+4O_1EO0!]J
M_P#!-[_DR7X6_P#7E<?^E<]?2M?-7_!-[_DR7X6_]>5Q_P"E<]?2M !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 >5?M8_\FL_&3_L3-9_](9J_*O\ X(J?\G3>
M*?\ L3+K_P!+K&OU4_:Q_P"36?C)_P!B9K/_ *0S5^5?_!%3_DZ;Q3_V)EU_
MZ76- '[4T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7X _\$N/^3[/AE_W$_P#T
MUW=?O]7X _\ !+C_ )/L^&7_ '$__37=T ?O]1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!^ /_!4?_D^SXF_]PS_ --=I7[_ %?@#_P5'_Y/L^)O_<,_]-=I7[_4 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %?DK_P7&_Y&KX2?]>6I?^C+>OUJK\E?^"XW_(U?"3_K
MRU+_ -&6] 'VK_P3>_Y,E^%O_7E<?^E<]?2M?-7_  3>_P"3)?A;_P!>5Q_Z
M5SU]*T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!Y5^UC_ ,FL_&3_ +$S6?\
MTAFK\J_^"*G_ "=-XI_[$RZ_]+K&OU4_:Q_Y-9^,G_8F:S_Z0S5^5?\ P14_
MY.F\4_\ 8F77_I=8T ?M31110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?@#_ ,$N
M/^3[/AE_W$__ $UW=?O]7X _\$N/^3[/AE_W$_\ TUW= '[_ %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% 'X _\ !4?_ )/L^)O_ '#/_37:5^_U?@#_ ,%1_P#D^SXF
M_P#<,_\ 37:5^_U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7Y*_P#!<;_D:OA)_P!>6I?^
MC+>OUJK\E?\ @N-_R-7PD_Z\M2_]&6] 'VK_ ,$WO^3)?A;_ ->5Q_Z5SU]*
MU\U?\$WO^3)?A;_UY7'_ *5SU]*T %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5?\ P_._ZHG_ .77_P#<5'_#\[_JB?\ Y=?_ -Q4 ?JI17Y5_P##\[_JB?\
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M5?\ P_._ZHG_ .77_P#<5'_#\[_JB?\ Y=?_ -Q4 ?JI17Y5_P##\[_JB?\
MY=?_ -Q4?\/SO^J)_P#EU_\ W%0!^JE%?E7_ ,/SO^J)_P#EU_\ W%1_P_._
MZHG_ .77_P#<5 'ZJ45^5?\ P_._ZHG_ .77_P#<5'_#\[_JB?\ Y=?_ -Q4
M ?JI17Y5_P##\[_JB?\ Y=?_ -Q4?\/SO^J)_P#EU_\ W%0!^JE%?E7_ ,/S
MO^J)_P#EU_\ W%1_P_._ZHG_ .77_P#<5 'ZJ45^5?\ P_._ZHG_ .77_P#<
M5'_#\[_JB?\ Y=?_ -Q4 ?JI17Y5_P##\[_JB?\ Y=?_ -Q4?\/SO^J)_P#E
MU_\ W%0!^JE%?E7_ ,/SO^J)_P#EU_\ W%1_P_._ZHG_ .77_P#<5 'ZJ45^
M5?\ P_._ZHG_ .77_P#<5'_#\[_JB?\ Y=?_ -Q4 ??_ .UC_P FL_&3_L3-
M9_\ 2&:ORK_X(J?\G3>*?^Q,NO\ TNL:ZKXL?\%E/^%H?"OQEX-_X5!_9G_"
M1:->:1]M_P"$F\W[/]H@>+S-GV-=VW?G;N&<8R.M?*O[%/[5W_#'OQ4U7QE_
MPBW_  EOV[1I=(^Q?VA]BV;YX)?,W^5)G'D8V[1][.>,$ _HIHK\J_\ A^=_
MU1/_ ,NO_P"XJ/\ A^=_U1/_ ,NO_P"XJ /U4HK\J_\ A^=_U1/_ ,NO_P"X
MJ/\ A^=_U1/_ ,NO_P"XJ /U4HK\J_\ A^=_U1/_ ,NO_P"XJ/\ A^=_U1/_
M ,NO_P"XJ /U4HK\J_\ A^=_U1/_ ,NO_P"XJ/\ A^=_U1/_ ,NO_P"XJ /U
M4HK\J_\ A^=_U1/_ ,NO_P"XJ/\ A^=_U1/_ ,NO_P"XJ /U4HK\J_\ A^=_
MU1/_ ,NO_P"XJ/\ A^=_U1/_ ,NO_P"XJ /U4HK\J_\ A^=_U1/_ ,NO_P"X
MJ/\ A^=_U1/_ ,NO_P"XJ /U4HK\J_\ A^=_U1/_ ,NO_P"XJ/\ A^=_U1/_
M ,NO_P"XJ /U4HK\J_\ A^=_U1/_ ,NO_P"XJ/\ A^=_U1/_ ,NO_P"XJ /U
M4HK\J_\ A^=_U1/_ ,NO_P"XJ/\ A^=_U1/_ ,NO_P"XJ /U4HK\J_\ A^=_
MU1/_ ,NO_P"XJ/\ A^=_U1/_ ,NO_P"XJ /U4HK\J_\ A^=_U1/_ ,NO_P"X
MJ/\ A^=_U1/_ ,NO_P"XJ /U4HK\J_\ A^=_U1/_ ,NO_P"XJ/\ A^=_U1/_
M ,NO_P"XJ /U4HK\J_\ A^=_U1/_ ,NO_P"XJ/\ A^=_U1/_ ,NO_P"XJ /U
M4HK\J_\ A^=_U1/_ ,NO_P"XJ/\ A^=_U1/_ ,NO_P"XJ /U4HK\J_\ A^=_
MU1/_ ,NO_P"XJ/\ A^=_U1/_ ,NO_P"XJ /U4HK\J_\ A^=_U1/_ ,NO_P"X
MJ/\ A^=_U1/_ ,NO_P"XJ /U4HK\J_\ A^=_U1/_ ,NO_P"XJ/\ A^=_U1/_
M ,NO_P"XJ /U4HK\J_\ A^=_U1/_ ,NO_P"XJ/\ A^=_U1/_ ,NO_P"XJ /U
M4HK\J_\ A^=_U1/_ ,NO_P"XJ/\ A^=_U1/_ ,NO_P"XJ /U4HK\J_\ A^=_
MU1/_ ,NO_P"XJ/\ A^=_U1/_ ,NO_P"XJ /U4HK\J_\ A^=_U1/_ ,NO_P"X
MJ/\ A^=_U1/_ ,NO_P"XJ /U4HK\J_\ A^=_U1/_ ,NO_P"XJ/\ A^=_U1/_
M ,NO_P"XJ /U4HK\J_\ A^=_U1/_ ,NO_P"XJ/\ A^=_U1/_ ,NO_P"XJ /U
M4HK\J_\ A^=_U1/_ ,NO_P"XJZ+2/^"X'A*:Y"ZI\+M:L[?',EGJ<-P__?+(
M@_6@#],J*^2/A?\ \%2OV?/B9<0VLOBBY\'7LQPD'BBT-JO_  *9"\*_\"D%
M?5FEZM9:YI\%_IMY;ZA8W"[X;JUE66*1?564D$>XH MT444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%?+'[5'
M_!13X8?LP_:-)>Y/B_QK&"/^$?TF5<P-Z7,W*P_[N&?D'9CFORZ^*_[?W[0O
M[5/B(:!X=N]2T:TNR8[;PUX(BE6:5?1WCS-*<8R,A>ORC)H _9_XH?M-?"KX
M+F1/&GC[0M!NHQEK&:[5[O'J($W2'\%KYC\7?\%CO@/X?DDCTNV\4^)V'"26
M&FI#$W7G,\D; <?W>XXZX^'OA+_P21^.7Q,5=1\2+IO@*SF/F%M;N#->.#U;
MR8MQ!]1(R&OJOP5_P1)^'FGPQ'Q7X_\ $FN3K@N-*A@L(F.>F'69L=N&!]Q0
M!DZA_P %P?"T;+]A^%FL7"\Y-QJL41'ITC:L#_A^=_U1/_RZ_P#[BKZ)TW_@
MDE^SG8P[)O#^L:@W'[RYUF<-T_V"H_2N@_X=;_LQ?]$SS_W']3_^2: /E;_A
M^=_U1/\ \NO_ .XJ/^'YW_5$_P#RZ_\ [BKZJ_X=<?LQ?]$S_P#*_JG_ ,DT
M?\.N/V8O^B9_^5_5/_DF@#Y5_P"'YW_5$_\ RZ__ +BH_P"'YW_5$_\ RZ__
M +BKZJ_X=<?LQ?\ 1,__ "OZI_\ )-'_  ZX_9B_Z)G_ .5_5/\ Y)H ^5?^
M'YW_ %1/_P NO_[BH_X?G?\ 5$__ "Z__N*OJK_AUQ^S%_T3/_ROZI_\DT?\
M.N/V8O\ HF?_ )7]4_\ DF@#Y5_X?G?]43_\NO\ ^XJ/^'YW_5$__+K_ /N*
MOJK_ (=<?LQ?]$S_ /*_JG_R31_PZX_9B_Z)G_Y7]4_^2: /E7_A^=_U1/\
M\NO_ .XJ/^'YW_5$_P#RZ_\ [BKZJ_X=<?LQ?]$S_P#*_JG_ ,DT?\.N/V8O
M^B9_^5_5/_DF@#Y5_P"'YW_5$_\ RZ__ +BH_P"'YW_5$_\ RZ__ +BKZJ_X
M=<?LQ?\ 1,__ "OZI_\ )-'_  ZX_9B_Z)G_ .5_5/\ Y)H ^5?^'YW_ %1/
M_P NO_[BH_X?G?\ 5$__ "Z__N*OJK_AUQ^S%_T3/_ROZI_\DT?\.N/V8O\
MHF?_ )7]4_\ DF@#Y5_X?G?]43_\NO\ ^XJ/^'YW_5$__+K_ /N*OJK_ (=<
M?LQ?]$S_ /*_JG_R31_PZX_9B_Z)G_Y7]4_^2: /E7_A^=_U1/\ \NO_ .XJ
M/^'YW_5$_P#RZ_\ [BKZJ_X=<?LQ?]$S_P#*_JG_ ,DT?\.N/V8O^B9_^5_5
M/_DF@#Y5_P"'YW_5$_\ RZ__ +BH_P"'YW_5$_\ RZ__ +BKZJ_X=<?LQ?\
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MI_\ )-'_  ZX_9B_Z)G_ .5_5/\ Y)H ^5?^'YW_ %1/_P NO_[BH_X?G?\
M5$__ "Z__N*OJK_AUQ^S%_T3/_ROZI_\DT?\.N/V8O\ HF?_ )7]4_\ DF@#
MY5_X?G?]43_\NO\ ^XJ/^'YW_5$__+K_ /N*OJK_ (=<?LQ?]$S_ /*_JG_R
M31_PZX_9B_Z)G_Y7]4_^2: /E7_A^=_U1/\ \NO_ .XJ/^'YW_5$_P#RZ_\
M[BKZJ_X=<?LQ?]$S_P#*_JG_ ,DT?\.N/V8O^B9_^5_5/_DF@#Y5_P"'YW_5
M$_\ RZ__ +BH_P"'YW_5$_\ RZ__ +BKZJ_X=<?LQ?\ 1,__ "OZI_\ )-'_
M  ZX_9B_Z)G_ .5_5/\ Y)H ^5?^'YW_ %1/_P NO_[BH_X?G?\ 5$__ "Z_
M_N*OJK_AUQ^S%_T3/_ROZI_\DT?\.N/V8O\ HF?_ )7]4_\ DF@#Y5_X?G?]
M43_\NO\ ^XJ/^'YW_5$__+K_ /N*OJK_ (=<?LQ?]$S_ /*_JG_R31_PZX_9
MB_Z)G_Y7]4_^2: /E7_A^=_U1/\ \NO_ .XJ^ /V6_CI_P ,U_';PS\1_P"Q
M/^$C_L7[5_Q+/M?V7SO.M98/];L?;CS=WW3G;CC.1^U/_#KC]F+_ *)G_P"5
M_5/_ ))H_P"'7'[,7_1,_P#ROZI_\DT ?*O_  _._P"J)_\ EU__ '%1_P /
MSO\ JB?_ )=?_P!Q5]5?\.N/V8O^B9_^5_5/_DFC_AUQ^S%_T3/_ ,K^J?\
MR30!\J_\/SO^J)_^77_]Q4?\/SO^J)_^77_]Q5]5?\.N/V8O^B9_^5_5/_DF
MC_AUQ^S%_P!$S_\ *_JG_P DT ?*O_#\[_JB?_EU_P#W%1_P_._ZHG_Y=?\
M]Q5]5?\ #KC]F+_HF?\ Y7]4_P#DFC_AUQ^S%_T3/_ROZI_\DT ?*O\ P_._
MZHG_ .77_P#<5'_#\[_JB?\ Y=?_ -Q5]5?\.N/V8O\ HF?_ )7]4_\ DFC_
M (=<?LQ?]$S_ /*_JG_R30!\J_\ #\[_ *HG_P"77_\ <5'_  _._P"J)_\
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M -Q5]5?\.N/V8O\ HF?_ )7]4_\ DFC_ (=<?LQ?]$S_ /*_JG_R30!\J_\
M#\[_ *HG_P"77_\ <5'_  _._P"J)_\ EU__ '%7U5_PZX_9B_Z)G_Y7]4_^
M2:/^'7'[,7_1,_\ ROZI_P#)- 'RK_P_._ZHG_Y=?_W%1_P_._ZHG_Y=?_W%
M7U5_PZX_9B_Z)G_Y7]4_^2:/^'7'[,7_ $3/_P K^J?_ "30!\J_\/SO^J)_
M^77_ /<5'_#\[_JB?_EU_P#W%7U5_P .N/V8O^B9_P#E?U3_ .2:/^'7'[,7
M_1,__*_JG_R30!\J_P##\[_JB?\ Y=?_ -Q4?\/SO^J)_P#EU_\ W%7U5_PZ
MX_9B_P"B9_\ E?U3_P"2:/\ AUQ^S%_T3/\ \K^J?_)- 'RK_P /SO\ JB?_
M )=?_P!Q4L?_  7.4R*'^"A5,_,5\59('L/L0S7U3_PZX_9B_P"B9_\ E?U3
M_P"2:9+_ ,$M?V8Y(W5?ALT;," ZZ]J>5]QFY(S]10!\^:7_ ,%P/"$S#^T?
MA?K=JNX FUU*&8[>YPR)S[?J*]2\&_\ !8+X ^)IH8M3D\2>%"Y :35=+$D:
MGUS;O*<>^/PJ_JW_  2-_9VU&/;;Z+K>EM@C?::S*Q^O[S>,CZ5Y%XY_X(B^
M"[RWE/@[XC:]I$_5$UNUAOD/'0F,0D9/?G'H: /N[X:?'SX<?&.(-X*\;Z'X
MDDV[S;V-ZC7"+ZO#G>O_  )17?5^$GQ5_P""6?Q_^#4XU;0+&#QI;6S>;'>>
M%;EC=Q$=#Y+!)-W_ %S#_6G?!/\ X*9?'7]G;6CH7BZ:Y\::9:2>5<Z-XL\Q
M;^#'55N&'FHW3B0.!_=H _=FBOGC]E_]NGX8?M46<=MH&I'1_%2ING\-:JRQ
MW8P/F:+G;,@YY0Y ^\%S7T/0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 445X%^UI^V9X'_9)\)B\UZ;^U/$MW&6
MTSPW:R 7%T>0'8\^5$".9".Q"ACQ0![U--';PR2RNL44:EGD<@*J@9))/05\
MU?%K_@HY\ OA!-/:7WCB#7]4AR#I_AN,W[Y'53(G[I2#QAI <_0X_);XP?M:
M_'G]NGQ7'X4L4OIM/O'_ -&\&^%X7$+*#]Z;&6EQP2TAVKC("BO?O@K_ ,$6
M?&'B*U@O_B7XNL_"4<BASI.DQB]NQ_LO(2(T/7[OF"@#U_Q!_P %NO %M(PT
M/X<^)-13/#:A<V]H3SZ(9?YUR4W_  7-C69Q%\%6>($[6?Q2%8CL2!9G!_$U
M[IX7_P""/O[/^A0*FH0>)/$<FW!DU#5?+R?4"!(\?YZUU]O_ ,$M/V9(841_
MAP\[*,&237M2#-[G%P!^0H ^6?\ A^=_U1/_ ,NO_P"XJ/\ A^=_U1/_ ,NO
M_P"XJ^JO^'7'[,7_ $3/_P K^J?_ "31_P .N/V8O^B9_P#E?U3_ .2: /E7
M_A^=_P!43_\ +K_^XJ/^'YW_ %1/_P NO_[BKZJ_X=<?LQ?]$S_\K^J?_)-'
M_#KC]F+_ *)G_P"5_5/_ ))H ^5?^'YW_5$__+K_ /N*C_A^=_U1/_RZ_P#[
MBKZJ_P"'7'[,7_1,_P#ROZI_\DT?\.N/V8O^B9_^5_5/_DF@#Y5_X?G?]43_
M /+K_P#N*C_A^=_U1/\ \NO_ .XJ^JO^'7'[,7_1,_\ ROZI_P#)-'_#KC]F
M+_HF?_E?U3_Y)H ^5?\ A^=_U1/_ ,NO_P"XJ/\ A^=_U1/_ ,NO_P"XJ^JO
M^'7'[,7_ $3/_P K^J?_ "31_P .N/V8O^B9_P#E?U3_ .2: /E7_A^=_P!4
M3_\ +K_^XJ/^'YW_ %1/_P NO_[BKZJ_X=<?LQ?]$S_\K^J?_)-'_#KC]F+_
M *)G_P"5_5/_ ))H ^5?^'YW_5$__+K_ /N*C_A^=_U1/_RZ_P#[BKZJ_P"'
M7'[,7_1,_P#ROZI_\DT?\.N/V8O^B9_^5_5/_DF@#Y5_X?G?]43_ /+K_P#N
M*C_A^=_U1/\ \NO_ .XJ^JO^'7'[,7_1,_\ ROZI_P#)-'_#KC]F+_HF?_E?
MU3_Y)H ^5?\ A^=_U1/_ ,NO_P"XJ/\ A^=_U1/_ ,NO_P"XJ^JO^'7'[,7_
M $3/_P K^J?_ "31_P .N/V8O^B9_P#E?U3_ .2: /E7_A^=_P!43_\ +K_^
MXJ/^'YW_ %1/_P NO_[BKZJ_X=<?LQ?]$S_\K^J?_)-'_#KC]F+_ *)G_P"5
M_5/_ ))H ^5?^'YW_5$__+K_ /N*C_A^=_U1/_RZ_P#[BKZJ_P"'7'[,7_1,
M_P#ROZI_\DT?\.N/V8O^B9_^5_5/_DF@#Y5_X?G?]43_ /+K_P#N*C_A^=_U
M1/\ \NO_ .XJ^JO^'7'[,7_1,_\ ROZI_P#)-'_#KC]F+_HF?_E?U3_Y)H ^
M5?\ A^=_U1/_ ,NO_P"XJ/\ A^=_U1/_ ,NO_P"XJ^JO^'7'[,7_ $3/_P K
M^J?_ "31_P .N/V8O^B9_P#E?U3_ .2: /E7_A^=_P!43_\ +K_^XJ/^'YW_
M %1/_P NO_[BKZJ_X=<?LQ?]$S_\K^J?_)-'_#KC]F+_ *)G_P"5_5/_ ))H
M ^5?^'YW_5$__+K_ /N*C_A^=_U1/_RZ_P#[BKZJ_P"'7'[,7_1,_P#ROZI_
M\DT?\.N/V8O^B9_^5_5/_DF@#Y5_X?G?]43_ /+K_P#N*C_A^=_U1/\ \NO_
M .XJ^JO^'7'[,7_1,_\ ROZI_P#)-'_#KC]F+_HF?_E?U3_Y)H ^5?\ A^=_
MU1/_ ,NO_P"XJ/\ A^=_U1/_ ,NO_P"XJ^JO^'7'[,7_ $3/_P K^J?_ "31
M_P .N/V8O^B9_P#E?U3_ .2: /E7_A^=_P!43_\ +K_^XJ/^'YW_ %1/_P N
MO_[BKZJ_X=<?LQ?]$S_\K^J?_)-'_#KC]F+_ *)G_P"5_5/_ ))H ^5?^'YW
M_5$__+K_ /N*C_A^=_U1/_RZ_P#[BKZJ_P"'7'[,7_1,_P#ROZI_\DT?\.N/
MV8O^B9_^5_5/_DF@#Y5_X?G?]43_ /+K_P#N*C_A^=_U1/\ \NO_ .XJ^JO^
M'7'[,7_1,_\ ROZI_P#)-'_#KC]F+_HF?_E?U3_Y)H ^5?\ A^=_U1/_ ,NO
M_P"XJ/\ A^=_U1/_ ,NO_P"XJ^JO^'7'[,7_ $3/_P K^J?_ "31_P .N/V8
MO^B9_P#E?U3_ .2: /E7_A^=_P!43_\ +K_^XJ/^'YW_ %1/_P NO_[BKZJ_
MX=<?LQ?]$S_\K^J?_)-'_#KC]F+_ *)G_P"5_5/_ ))H _%;]J3XZ?\ #2GQ
MV\3?$?\ L3_A'/[:^R_\2S[7]J\GR;6*#_6[$W9\K=]T8W8YQD_?_P#P_._Z
MHG_Y=?\ ]Q5]5?\ #KC]F+_HF?\ Y7]4_P#DFC_AUQ^S%_T3/_ROZI_\DT ?
M*O\ P_._ZHG_ .77_P#<5'_#\[_JB?\ Y=?_ -Q5]5?\.N/V8O\ HF?_ )7]
M4_\ DFC_ (=<?LQ?]$S_ /*_JG_R30!\J_\ #\[_ *HG_P"77_\ <5'_  _.
M_P"J)_\ EU__ '%7U5_PZX_9B_Z)G_Y7]4_^2:/^'7'[,7_1,_\ ROZI_P#)
M- 'RK_P_._ZHG_Y=?_W%1_P_._ZHG_Y=?_W%7U5_PZX_9B_Z)G_Y7]4_^2:/
M^'7'[,7_ $3/_P K^J?_ "30!\J_\/SO^J)_^77_ /<5'_#\[_JB?_EU_P#W
M%7U5_P .N/V8O^B9_P#E?U3_ .2:/^'7'[,7_1,__*_JG_R30!\J_P##\[_J
MB?\ Y=?_ -Q4?\/SO^J)_P#EU_\ W%7U5_PZX_9B_P"B9_\ E?U3_P"2:/\
MAUQ^S%_T3/\ \K^J?_)- 'RK_P /SO\ JB?_ )=?_P!Q4?\ #\[_ *HG_P"7
M7_\ <5?57_#KC]F+_HF?_E?U3_Y)H_X=<?LQ?]$S_P#*_JG_ ,DT ?*O_#\[
M_JB?_EU__<5'_#\[_JB?_EU__<5?57_#KC]F+_HF?_E?U3_Y)H_X=<?LQ?\
M1,__ "OZI_\ )- 'RK_P_._ZHG_Y=?\ ]Q4?\/SO^J)_^77_ /<5?57_  ZX
M_9B_Z)G_ .5_5/\ Y)H_X=<?LQ?]$S_\K^J?_)- 'RK_ ,/SO^J)_P#EU_\
MW%1_P_._ZHG_ .77_P#<5?57_#KC]F+_ *)G_P"5_5/_ ))H_P"'7'[,7_1,
M_P#ROZI_\DT ?*O_  _._P"J)_\ EU__ '%1_P /SO\ JB?_ )=?_P!Q5]5?
M\.N/V8O^B9_^5_5/_DFC_AUQ^S%_T3/_ ,K^J?\ R30!\J_\/SO^J)_^77_]
MQ4?\/SO^J)_^77_]Q5]5?\.N/V8O^B9_^5_5/_DFC_AUQ^S%_P!$S_\ *_JG
M_P DT ?*O_#\[_JB?_EU_P#W%1_P_._ZHG_Y=?\ ]Q5]5?\ #KC]F+_HF?\
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M/^'7'[,7_1,__*_JG_R30!\J_P##\[_JB?\ Y=?_ -Q4?\/SO^J)_P#EU_\
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M]F+_ *)G_P"5_5/_ ))H_P"'7'[,7_1,_P#ROZI_\DT ?*O_  _._P"J)_\
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MUQ^S%_T3/_ROZI_\DT?\.N/V8O\ HF?_ )7]4_\ DF@#Y5_X?G?]43_\NO\
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M ,DT?\.N/V8O^B9_^5_5/_DF@#Y5_P"'YW_5$_\ RZ__ +BH_P"'YW_5$_\
MRZ__ +BKZJ_X=<?LQ?\ 1,__ "OZI_\ )-'_  ZX_9B_Z)G_ .5_5/\ Y)H
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M^J)_^77_ /<5?57_  ZX_9B_Z)G_ .5_5/\ Y)H_X=<?LQ?]$S_\K^J?_)-
M'RK_ ,/SO^J)_P#EU_\ W%1_P_._ZHG_ .77_P#<5?57_#KC]F+_ *)G_P"5
M_5/_ ))H_P"'7'[,7_1,_P#ROZI_\DT ?*O_  _._P"J)_\ EU__ '%1_P /
MSO\ JB?_ )=?_P!Q5]5?\.N/V8O^B9_^5_5/_DFC_AUQ^S%_T3/_ ,K^J?\
MR30!\J_\/SO^J)_^77_]Q4?\/SO^J)_^77_]Q5]5?\.N/V8O^B9_^5_5/_DF
MC_AUQ^S%_P!$S_\ *_JG_P DT ?*O_#\[_JB?_EU_P#W%1_P_._ZHG_Y=?\
M]Q5]5?\ #KC]F+_HF?\ Y7]4_P#DFC_AUQ^S%_T3/_ROZI_\DT ?*O\ P_._
MZHG_ .77_P#<5'_#\[_JB?\ Y=?_ -Q5]5?\.N/V8O\ HF?_ )7]4_\ DFC_
M (=<?LQ?]$S_ /*_JG_R30!\J_\ #\[_ *HG_P"77_\ <5'_  _._P"J)_\
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M -Q5]5?\.N/V8O\ HF?_ )7]4_\ DFC_ (=<?LQ?]$S_ /*_JG_R30!\J_\
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M4T;#*NC X92"""* +=%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1_PZX_9B_P"B9_\ E?U3_P"2:^JJ* /E7_AUQ^S%_P!$S_\ *_JG_P DT?\
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MJB@#Y5_X=<?LQ?\ 1,__ "OZI_\ )-'_  ZX_9B_Z)G_ .5_5/\ Y)KZJHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MYF)]UH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M73_$7_")F6<:]#JVD+;:?:H(W\LP2>6%!W[-GEL=XY^89( /U$HHHH ****
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M#-$P9)$8 JRD=0000?>IZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YM_X*$?
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ML)['P=;*MD)!\OVZXW*K\]=D:RGV9T/85]!?\%M_$CV?P8^'V@JQ"W^O27C
M=_(MV7_VXKN?^".OA"+P_P#LER:L$'GZ]KUW=-)W*QA(%7Z Q,?^!&@#[FHH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1110 445C>*/&GA_P/8Q7OB/7=,\/V<LGDQW&J7D=M&[D$A SL 6P"<=< T
M;-%9'ACQAH/C;3VO_#NMZ=KUBLAA:ZTN[CN8@X )0LA(W ,#CKR/6M>@ HHH
MH **** "BBB@ HHK%\4^-O#O@>SBN_$FO:7X?M9I/*CGU2\CMD=\$[0SL 3@
M$X'H: -JBLGPSXNT+QIIQU#P]K6GZ[8"0Q&ZTRZCN(@X )7<A(R 1QGN*UJ
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MAF;3]6L%;<D%VBHSA">2C*Z.N>0&P<D$U^./PM_Y2::9_P!E,E_].#U]U?\
M!$MC_P *!\<KD[1XG) [?\>D'^%?"OPM_P"4FFF?]E,E_P#3@] '[_5A>//$
MZ>"? _B+Q%)&)4TC3KC4&C8X#"*)I",]L[:W:Y#XP>&9_&OPD\;^'K5/,N=6
MT.^L(D!QN>6W= ,_5A0!^!G[(/PZ_P"&IOVPO#.F>+'?4;?6-3N-8UIW/-RJ
M+)<RJW?$C+L..?G-?T-V-C;:996]G9V\5I:6\:PPV\"!(XT48554<     <
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M#[4II9, ;G;39"QP.!DD]*_([_@K9_R>EX@_[!FG_P#H@5^M/QN_Y,9\??\
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MAWS;W^EPZQ&A/W7@E$3$?47*9_W!7Z[T %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %?BS_P6LG=OVH/"<)/[M/!ULX7T)O;T$_\ CH_*
MOVFK\5O^"U?_ "=-X6_[$RU_]+KZ@#]4/V1X5M_V5?@XJ# /@[2'_%K.(G]2
M:]9KRK]D[_DUGX-_]B9HW_I##7JM !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^ 3-N_X*
MG9P!_P 7EQP/^HW7[^U^ /\ SE-_[K-_[G* /W^HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH _*[_ (+F3NL'P6A!_=NVM.5]2!8@
M'_QX_G7U'_P2TA6+]A?X<,HP9&U-V^O]I70_D!7RS_P7._YHG_W&_P#VPKZJ
M_P""7'_)B?PR_P"XG_Z=+N@#ZJHHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M';_:=&UK0=3M9U&-RY@.UU/9U8*RGL5!H _7_P#83_:>@_:E^ ^EZ[<RQ_\
M"5Z9C3M>MUP,7*J,3!1T65<..P)91]VOEK_@L)^U0?#?AFS^"OAV[QJFM(E[
MKSPGYHK0-F*WR.AD9=Q'7:@'1Z^1O@G\5?%7_!,K]JWQ1H?B&SGU/2X1)I^J
MV%NWEC4(=I>TN8L\ \HX)Y"R.O!)KT']@WX0ZW^V5^TMXL^-OC]/MVE:-=/J
MDY=3Y5QJ+ FWMU!_Y9PJ%;;G@)$IX:@#QS_@F7_R?'\,/^NU]_Z07-?T$U_/
MM_P3+_Y/C^&'_7:^_P#2"YK]C_VW?%?Q(\*?L]:XWPGT?4M7\:ZA)%86K:3
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MDGV6,C,<#%2%MP,_ZM5;;GGYMP !^LNFZI9ZQ9QW=A=P7UK(,I/;2+(C#U#
MD&OS_P#^"V'_ ";;X-_[&V'_ -([JOC7_@F/\7?%?P:_:VTGP%+=SQ:)K]U/
MI&K:1)*6A6X5'V2JH.T2+)&J[O[K,.]?97_!;#_DVWP;_P!C;#_Z1W5 &K_P
M1A_Y-0UO_L;;S_TEM*^]:^"O^",/_)J&M_\ 8VWG_I+:5Y;_ ,%2=+_:#^,'
MQ(M_!'@CP=XKU#X<:?9Q/*VCVDK6VHW3_,S2,HPX0%%"G(4ACU/ !^D,GQ.\
M'0ZE_9\GBS0TO\@?96U*$2\G ^3=GDD=JZ7.>1R*_)GQQ_P1BM_"OP6U/78/
MB)<7/C+3-,EU":U:P7[#-)'$7,"'=O4$@J)#GUV#I5?_ ((V?M"^++SXAZY\
M*=5U*YU7PTVDR:II\=U(9#8RQ21(R1DGY8W60DJ. R @#+9 /UDOM6LM+V&]
MO+>T#YV^?*J;L=<9//44V;6M/M]+?4I;^UCTY%+M>/,HA50<$E\X S[U^87_
M  7*_P"05\&_^NVK?^@V=>,?LV_L@_&O]M;X&^&;/4?&$/@[X2^'1/;Z%!/"
MTBWLQGD::40JR[\2/(GF.W!&U1PV #]G=#\5:+XF61M'U>PU58SAVL;E)@I]
M#M)QU'YUJ5_.QXZ\+_$+_@GM^TTMG8ZXJ^(-#>"\@OK!W2WO[9PKA'7()C<
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M@1%&/0** /PK_:4_X)V_%;]D'28/'EEK,&NZ%8S*7UO07DM[G3G+ 1O(APR
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MO[4&M:O>1+-/HGAR>>S+#)CFDFAB+CW\MY5_X'0!T_A__@B7\0;[P\ESJWQ
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MN\:?"G]JBP^%-UJ4]WX9UJ>[TZ\TN25I(;>YACE=9H03\C;HRIQC<K'()"X
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MTVSU&/!79=P)*,'J,,#5FSLK?3X1#:P16T(.1'"@11GV% 'QQ^W]X4G\"_\
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M5_!WQ$U7QW\)+,ZIJ_A+3'U+4M-PSB\L#)''+$T2D&1?F5BH(8;-R\J*]?\
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MJJ<AB6_O?-FOUT_X*-?\HZ?&?_7EHO\ Z<+.OL"B@#\J_P#@AC_S6S_N"?\
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M )-9^#?_ &)FC?\ I##7JM>5?LG?\FL_!O\ [$S1O_2&&O5: "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ K\ ?^<IO_ '6;_P!SE?O]7X _\Y3?^ZS?^YR@#]_J*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /RK_ ."YW_-$_P#N
M-_\ MA7U5_P2X_Y,3^&7_<3_ /3I=U\J_P#!<[_FB?\ W&__ &PKZJ_X)<?\
MF)_#+_N)_P#ITNZ /JJBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _%;_@M7_P G3>%O
M^Q,M?_2Z^K]5/V3O^36?@W_V)FC?^D,-?E7_ ,%J_P#DZ;PM_P!B9:_^EU]7
MZJ?LG?\ )K/P;_[$S1O_ $AAH ]5HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KY5_X*C_ /)B?Q-_[AG_ *=+2OJJOE7_ (*C_P#)B?Q-
M_P"X9_Z=+2@#Y5_X(8_\UL_[@G_M_7ZJ5^5?_!#'_FMG_<$_]OZ_52@ HHHH
M Y3XL_\ )*_&7_8%O?\ T0]?B9_P23_Y/2\/_P#8,U#_ -$&OW \>Z/<>(?
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M+682QCS;V>9,,.OR2+^.: /RK_X+"_\ )X#_ /8OV/\ .6OK3_@IUI-WJ/\
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M2A!VA2!N'/&*^@?^"C7[ ^I_M81Z%XI\':C9V7C/1K=K%K7479(+VU+EPH<
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M[ ?["5M^R%X>U+4]:U"WUOQ[K4:Q7MU9AOL]I IW""$L S MAF<A<D*,#;R
M?FC_ ,%8]%O=+_;8\5W-TDBP:E8Z==VA<8#1"UCA)7U'F0R#Z@U])>%/^",'
MA/QIX8TG7])^,=[=Z9JEI%>6TT>BQLKQR(&4@B?!X(KZK_;L_85TG]L#PWI]
MW9ZA%X?\=:.C1Z?J<T9:&:)CDV\^/FV;N0PR4)8@')!^&_#7[*_[>OP;T7_A
M#?!FK7J>&5D>.+^R_$EH+>%2V2T7GNLD2DDMA%4Y+'&3R 1^&?V./V??A;\?
M-"T>3]I21O&NA^(;6-='7PY+O:\CG0K!O5BH8N N03@FOIS_ (+/?\FH:)_V
M-MG_ .DMW7 _L4_\$M_$G@/XI:?\3OC%JEK=ZMIMU_:-CH]I<&Z=KS=N6XN9
MB,%E?YPJELL%8MP5/T7_ ,%'?V=_&'[3/P'TWPIX)ALY]7@U^WU!UO;@0)Y*
M07",=Q'7,B\?6@#RC_@BI_R:SXI_['.Z_P#2&QKW3]O;]I74/V6?V?+WQ7HM
MO!/X@O;V+2=,-R-T44\BNYD9?XMJ12$+W(&>,US7_!-G]G+QE^S#\#=<\+>.
M(+.#5KSQ'/J<2V5R)T\E[6UC!+ <'="_'T]:]$_; _9KL_VK/@CJ7@B>_P#[
M*OQ-'?Z;?,I=(+J,,$+J.J,KNAQR Y(R1B@#\T?V7_@K\=O^"B%CKOBWQ5\<
M==T3PS97QL'"S2RB:?8LCI%:I)%%&H61/F_VONG%>)?M]?LPV7[*OC_PUX;M
MO&E]XRN;W2_MUQ+?A4> F5D "!F*J0I(R?6O=?A?^QA^V]^SOJEYHOP[U"'2
MM)OY0]S=V&M6CV+.,+YABG^<-@#YA%NP .V*N?&K_@DO\9O$!T37;?Q1;^/O
M&NJ)+<>)=0U34/+1)_D$<<32#?(H7<-QQT&%4 "@#]&_V*?^31_A#_V+-C_Z
M*6OQL_X)B_\ $N_;P^&J7)$+))J43!CT<Z;=*%^NX@5^VO[-?@35?AA\ ?A]
MX2UQ(H]8T71;6QNU@D\Q!*D85@K=QD=:_-S]H3_@DK\2+'XO:EXO^#FNZ=_9
MEY?-J-I;37KV-]IDK.7*QN%VE5)^5PP8# QQN(!^D/[37_)MOQ7_ .Q2U;_T
MCEK\H?\ @BI_R=-XI_[$RZ_]+K&OO+X#_!'XQZ3^QG\0_ ?Q,UJX\1^/]:MM
M6MK*YU+6'OSLGM!%"AGD)*KOW<=!DGO7B/\ P39_83^*G[,/QRUSQ3XXM-+@
MTF\\.3Z9$UE?K._G/=6L@!4#@;87Y^GK0!S7_!<K_D%?!O\ Z[:M_P"@V=?4
M'_!+C_DQ/X9?]Q/_ -.EW7#?\%._V2?B#^U38_#J+P';6%P^AR7[7GVZ[%O@
M3"W";<CG_5-^E>W?L/\ PA\1? ?]EWP5X%\5QV\.OZ5]M^TI:S"6,>;>SS)A
MAU^21?QS0!^5?_!87_D\!_\ L7['^<M?H9^UIX<\ >*/V [>T^(>NIX:TQ-&
MTZ>PU/RC+)%?K"I@"1CF0M\RE1_ SG(QN'@/_!0S]@+XM?M(?M"-XO\ !EGI
M4^C'2;:SW7FH+"_F(7W?*1T^8<UZ9_P4FD\#>$_V)-!\+?$.2\36]MG#HL.E
M!7D_M&"#:7.[Y?*56=6/7#\<D4 ?&_[%_BC]K?X(_#VXNOA5\.W\5>!O$$[W
MEL-4L&E@,H C:>$++&XW!%')*G8.#BO4_P!GS_@G[\8OCE^T-#\8OV@HUTBW
M^WQZI/8W$D9N]0DBQY,/EQDB&%?+12&(;8H4#G</$_V5_P!D_P#:I^(WPMM/
M%/PT\:ZAX,\*W+RI8QCQ/=:>+D*Y61XXX2<+YBL,MMR5SR.:G^)7Q4_;'_8;
M\4:&/&?CC6)H]021[(ZIJ2ZS9WJQE?-3]Z7((\Q0?NL PP<8- '[DUY5^T]\
M=!^S;\%M<^(<F@R^([?27MQ-8PW @8K+.D.[<5;H9%/2K'[-/QD7]H+X%>#_
M (@BR73I-:M#)-:(Q98IDD:*55)&2N^-L9[8KL?&_@O1_B-X/UGPOX@LUU#1
M-7M9+.\MG)&^-U*D CD'G((Y! (Y% 'R[^Q[_P %#?#'[8GBG7O";>&#X5U"
MULQ<PVM]?I<_;XR2LJJOEK]T;21SD,>P-8O[<W[$GP0UGX(^.O&K>&M,\%>(
M=%TFYU"VU?1T%FLD\<;,D<L2#9)YCA5.5+G=P<U\B_%K_@CS\5? OBF34_A3
MX@LO$>F)-YEEY]W_ &?J=MSP"QQ&Q4<;U=2<$[5Z5RES_P $\_VQOBM]GTWQ
MC+?-81R#8?$WBZ.\@BP,!@J33$8Z<+F@#,_X)":QJ>G?MB6-I8R2+9:AHU]#
M?HI^5HE02*2/:1(_S]ZY+_@I4K:?^WG\1))U,:?:=.ESCJOV"V.1^%?J%^P?
M^P#IO[(-IJ6MZKJT7B3QWJL MI[VWB*6]I;Y#&&'=\S;F4%G;&=JC:N#GR[_
M (*,?\$Y_$'[1?C*U^(GPZN+$>)#:QV>IZ5?3&%;L)D1S1R'*API"E3@$*I!
MR#D ^_KC7=.L]%DUB>_MH-)CMS=/?2RJL*PA=QD+DX"[><YQBOP'_9-OK?5/
M^"AWA"]M)EN+6X\7SS0S1G*NC/*58'T((-?0?PO_ .":/[3/CJWL_"'Q&\>7
MWA3X:VS1B72V\0R7Z-&O18+5':($8 !<J%SD!L8K>^ /_!,OXJ?"']K?P[XP
M%EIB^!-&U^6Y@D;4UDN?L89Q$2N!E]I7/OF@#W#_ (+/?\FH:)_V-MG_ .DM
MW6#_ ,$3_$VE3_L_>,_#R7\+:Y:^)Y;^:PW?O4MY;2UCCEQ_=+0RKGU0^U>U
M_P#!1W]G?QA^TS\!]-\*>"8;.?5X-?M]0=;VX$">2D%PC'<1US(O'UKXE\$?
M\$M/CY\,? L7B[P9XN3PO\4[>\GBET_3]6,*7-B4C\ORYT  ?>)-R2?*PVG*
ME?F /4?^"WGB/3HOAU\-=!:2,ZM/JMQ?)'GYUACAV,?8%I4Z]<''0UZ-_P $
MCR/"'[%-WK>M7"V&D-K6HZB+JY.R..VC2-)'+'^$-#*2?8^E?)&B_P#!,?\
M:7^/OQ&CU3XOZM_9,+,J7>M:UK$>IW7DJ?NP)%(^>IVJS(HR>G0_K;X'^#_A
M?X?_  ET[X;Z9IX/A6STXZ7]EF.XS1,I$A<]V<LY8]RQH _.OXC?\$^?V?\
M]J?QCK>H? KXL:/I?B%T:_NM!T^6._L5RP!=41@\"%F&<%E!("J!@5\E?%CX
M&_'O_@G+XGTG5X?$KZ-!J,S"TUCPUJ+M:W3QX8QRQ,%+<$$I(A4\XS@U]%:]
M_P $S?V@/V;OBA-XL_9^\50W\&Z1+1EO([6^C@8AO)N$F'DRKPHZD,5!*+QB
MOXL_8G_;-_:XUO18OC-KMCI>F:>6,<NH75F4MPQ <I;V(*O(0!@G' P6% 'U
MU\/OC]J/[2W_  3A\:>-M:M8;37)?"NN6=^MJI6)YHK>9"Z ] RA6QV+$=J^
M&/\ @BI_R=-XI_[$RZ_]+K&OTUT_]FO3_AC^R)KWP>\#JTQD\.:CIUM->N%>
MYNKB&4&25@,#=))GT48 X KY._X)L_L)_%3]F'XY:YXI\<6FEP:3>>')],B:
MROUG?SGNK60 J!P-L+\_3UH \/\ ^"VFDW</Q^\"ZFX?[#<>&!;1$CY?,CNY
MV?'OB6//U%?H[^PCXBT[Q/\ L?\ PGN=,ECEA@T&WL9?+/W9H%\F4'WWHU8W
M[<O['>G_ +8'PRM=+CO8M'\6:-*]SHVIS*6C5G4"2&7 )\N3:F2HR"B'!P5;
M\[/AS^PK^VO\+KB^\,>$-5NO"F@WLG[^\T_Q5'#9,V0IE"))YJD@#YA&&P /
M:@#D?^"O'B;2O$7[7UQ%IE_!?OIFB6EA>>0VX0W"O*[1,>FX+(F1V)P>017Z
MD:M_RCQO?^R6/_Z:37YY?&'_ ((\_%&RUK2/^$*U*S\5K-IJ3:QJ>J7ZV[2:
MBTLIE$:,"WE[?*P6)))8GK@?IQJ'PSUNX_9%N?AXD</_  DDG@9M $9E'E?:
MC8&#&_\ N[_XO3F@#\M?^"*G_)TWBG_L3+K_ -+K&O3_ /@IY^WI\0_ /Q<N
M_A3\/=8E\*VNEVL#ZIJ5C@7D\TT:RJB28S$JH\?W<,23SCBNU_X)L_L)_%3]
MF'XY:YXI\<6FEP:3>>')],B:ROUG?SGNK60 J!P-L+\_3UJ[_P %$/\ @FWX
ME_:"^(0^)'PYO+%]<NK:.WU72-2F,(G,2A(Y8I,%=VP*I5MH^0$'DB@#GO"O
M_!*/QWXUT*RUKXJ?'OQ =7FB6XN;.%I;K[,2N64W$T_S$=SL X/7K7QI_P $
M_P"TBT_]OKX?VL%S]M@AU:]CCN=P;S56VN 'R.#D#/XU]5^ _P!DG]M/XN:7
M;^ _BA\0+[PC\.=HM[[S=4M[NZN+< CRU,#,T@8<8ED"X/(.,4S]EW_@FK\5
M?@?^USX;\97=MIK>"-&U2[>.X_M%)+EK8Q31Q,4"C+$,F1QU- &E_P %RO\
MD%?!O_KMJW_H-G7U!_P2X_Y,3^&7_<3_ /3I=UPW_!3O]DGX@_M4V/PZB\!V
MUA</H<E^UY]NNQ;X$PMPFW(Y_P!4WZ5[=^P_\(?$7P'_ &7?!7@7Q7';PZ_I
M7VW[2EK,)8QYM[/,F&'7Y)%_'- 'S_\ \%GO^34-$_[&VS_]);NJO_!%3_DU
MGQ3_ -CG=?\ I#8UZO\ \%'?V=_&'[3/P'TWPIX)ALY]7@U^WU!UO;@0)Y*0
M7",=Q'7,B\?6J_\ P39_9R\9?LP_ W7/"WCB"S@U:\\1SZG$ME<B=/)>UM8P
M2P'!W0OQ]/6@#\9/A3\&;7Q_^TSI_P ,O%VN2>%/MNLW&D76HR0K(\%RID5%
M*%E!+3*J=1][\*_0#6O^"*7A;P[H]]JNI?&2]M-.L8)+JYN)-#3;%$BEG8_O
M^@4$_A78_MT?\$M[WXS>.+[XC_"S4;'2_$E^WGZGHM\QAANIP/\ 70RJ#LD;
M W*P"LQ+;E.<^&>(/V9?V_?B'X?D\$^(]6U2Y\,RQB&9KWQ-9M%.G *RLDIF
MD'J'!S@]<\@'K'_!.WX(_!'P!^T!-JGPX^.K_$+7?[&N8I='70YK0?9R\6Z0
MR,<85@G'<D5[/^W!\.?V:OCUK%OX<^)'Q!T?P9\0M)18;6\3488;Z%) '2*2
M-^)(SO#!3@C<2I7<<V_^"?\ ^P-#^R+I^IZ]K^IV^M^/M8@%K<360;[-96^X
M.88BP#/N=59G(&=B *,$MQO_  4$_P"";]]^TYXIM_'W@75K'2O%Z6JVM]8Z
MD62WOUCSY;K(JL4D ^3D%2 O*[22 ?(OQJ_X)(_%;X,Z?J/BKP7XFT_Q=I^D
M1O>;K5GT_4D1!N9UC)*DJ 3\LNXXX!/%>Q_\$H?VTO'_ ,1/B!=?"GQQJ]QX
MHLO[-FOM,U34':6\@>-DW1/*3F1"K,07R05 !P<#G;KX/_\ !134O!\W@*ZU
M::7PU-:&SDN)=5THR/"PVE#<Y^TG*DY).<=Z^E/^"??_  3S/[*-QJ'B[Q9J
M=KK7CR_MC9(NGEFM+"W8JS*C,H9Y&*KEL  # ZDD ^VJ*** "O*OVL?^36?C
M)_V)FL_^D,U>JUY5^UC_ ,FL_&3_ +$S6?\ TAFH _*O_@BI_P G3>*?^Q,N
MO_2ZQK]J:_%;_@BI_P G3>*?^Q,NO_2ZQK]J: "BBB@ HHHH **** "BBB@
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M_:G_  VO\3?[8$OF?;(/)#Y_X]_LT7E;<]MFWIQUK]6_V:Y?V2_C!\.[#0O
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M?^"-O_)H]Y_V,U[_ .BK>ONJ@#FOB+\2/#/PE\(7_BCQ?K-KH.A6*;IKRZ;
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MYW_-$_\ N-_^V%?57_!+C_DQ/X9?]Q/_ -.EW0!]54444 ?GU^TU_P %8O\
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M*X_XK?\ !4W2_A=^T3J/PHE^'EYJ%Q9ZK!I9U1-52-&,GE_/Y?E$@#S.F>U
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M#\5O^"U?_)TWA;_L3+7_ -+KZOU4_9._Y-9^#?\ V)FC?^D,-?E7_P %J_\
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M[6/_ ":S\9/^Q,UG_P!(9J]5KRK]K'_DUGXR?]B9K/\ Z0S4 ?E7_P $5/\
MDZ;Q3_V)EU_Z76-?M37XK?\ !%3_ ).F\4_]B9=?^EUC7[4T %%%% !1110
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M^"B7@+]K+4I/#T%C=>$?&<<)G&C:A,DJ7* $N;>88\PJ.2I56QR 0&(^ _\
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ME/ELP8[&1<DYPH'0"@#]GOVY)DN/V.?BQ+$ZR1/X>N&5T.0P*@@@]Q7YW?\
M!$?_ )+1\0_^Q?C_ /2E*^N_&E]/J7_!)E+FYD:6>3X9V>^1B26(LXADD]2<
M5\B?\$1_^2T?$/\ [%^/_P!*4H ^L/\ @I-^TUX-^ ]OX&TGQG\'M(^+5EK1
MN[B&/5KJ.%;)X#",IOMY>6$N,C;PN.<U[[^R;\4]/^-/[//@WQCI/A>V\%Z;
MJ$$J6^@V<BR0V:13R0A$*QQC;B+( 0 9QVS7Y^?\%RO^0K\&_P#KCJW_ *%9
MU]?_ /!,O_DQSX8?]<;[_P!+[F@#%_:R_P""E'P^_9:\4GPD^FWWB_Q='&DM
MUI^GR)%%9JR[E$LK9PY4JP558X()QD9^;[7_ (+?&&^A;4_@K<6NEW# I/%X
M@W2>7T+*K6JJYS_M*.V>]9_[2GP]_90^#O[36H^.?'WQ$\1>*?&+:Y_;E[X.
MTZV@O858R^8+>;]V%5 -H\MY Q7&1@USO[8__!2SX1?M(? CQ!X#TOP+X@BU
M";R'TF_U2VM46SECE1MXV2N4^0.GRYR&QT)H _2[]GC]HGP=^TY\.[?QAX,N
MI7LVD:"YLKM52ZLIA@F*5 Q ;!!&"0000:].K\I_^"&M]/YWQDLS(QM]NDS"
M,DX#9O 2![C&?H/2OU8H **** /YW?VG+>*\_;O\>P3Q)/!+XWF22.10RNIN
ML$$'@@CM7["_M$?LQ_LW:+\&_%-[XG\ ^"?".FPV,SC5K'2[;3[B&0(Q0Q21
M*CL^X#" G<<#!SBOQK_:\TN37/VTOB?IL3K'+>>+KJW1WSM5GN"H)QVYKZ.U
MC_@BK\8K.S:73_%?@S49E!/V=KFZA9N. I,!&3[D#WH \U_X)3Z1K>I?MK>#
MKG28I&M+&VOI]2D524CMC:RQY?V,CQ*/]HK7[)?M5?'O_AF7X&Z_\1?["_X2
M3^RGMD_LW[7]E\WS;B.'/F>6^W'F;ONG.,<9S7Y*_L?_ +6'B/\ 8,^+5_\
M#7Q[X3TVSTAM26SUZ9;6--2M&W867[0G^OC0,6"MN!5B4(SS^B'_  52.?V&
M_'I'(\[3?_2^WH \F\&_\%D/!FJ?"_Q%XJ\2^#+C0=4L;R&RTWP_9:H+V?46
M=&9GWM#$(D3:-S'=]X8R2 ?H+]DS]L2R_:1^!GB'XGZUHUOX$TC1M0N;:X2;
M4/M21006\4SS/*8X^,2-QMX"]Z_.W_@D?^S+\/OCIKGCWQ!X[T./Q(?#OV&*
MQT^\^:TW3><6DDC_ .6A'DJ &RN&;()P1^F?QF^ _P -[C]G/QAX%8Z9\*_
MM]$)]1O-#@MM.AMU62-WD/RB,;A&%9B.0?I0!\A>//\ @M;X5L=:N=/\"_#;
M5O%<2N8[>\OKY;$3'^^L2QRMMSR =I(ZA3Q6A\'_ /@L]X+\8>+;71/'7@>]
M\!07,RVZZI'J*WUO Q."TX,431H#U(#X[C&37DWP&_:6_9+_ &%]7\22>";W
MQE\3=6U,1P_VL=+MU$*)OS'%)*865&)!8A3G:O7%?+7[>/[1W@K]J+XN:?XR
M\'>&KWPV?[,2TU$7T<2274ZR.1*?+9@QV,BY)SA0.@% '[Y^//&*>"_AWXB\
M5Q0+J46DZ5<ZHL"2[!<"*%I H?!P&VXW8.,YP:_,[_A^=_U1/_RZ_P#[BK[U
M_968>(_V3OA0NIHE^EWX/TR.X2X42+,IM(U8.&SNW#.<]<FOG/\ X* _$OX/
M?LH?#0VVE?#GP3<_$378GBT>S;0;1OLR]&NY%\O[B'[H/WWP.0'( /(-)_X+
M@?VIJME9?\*6\K[1,D.__A*L[=S 9Q]BYZU]4?\ !0SX]>'/@'\%],U#Q5\-
M].^*&CZOK$>FOHNJ3I%"K&&642Y>&4$CRL#Y01NR",5\#?\ !+_]A]_C-XJC
M^+GCRQ\SP=I=T9-,LKA,+JUXK9+D=X8V'(Z,XV\A7%?2/_!;#_DVWP;_ -C;
M#_Z1W5 'NW[ /QRT#X^? F36?#'P^T_X9Z-INK3Z7#H6F3I+"-D<4AD!2&(
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M ,%GO!?C#Q;:Z)XZ\#WO@*"YF6W75(]16^MX&)P6G!BB:- >I ?'<8R:\F^
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M_P#I=?4 ?JI^R=_R:S\&_P#L3-&_](8:]5KRK]D[_DUGX-_]B9HW_I##7JM
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M ."CGP%^!6L_%)/&_P 5_C+?^$]5N=/AM;3P_I]FMY<&&/=AEC4,ZJS,YW,
MN2>>M>8_\$GOVQ/ WPE\+R_";Q(-0@U[Q+XLB?2IK>V\V&62Z2WME1V!^3#Q
M*22,8?VKYM_;,NC_ ,-_>,G^(Z7LNBQ>)H1>1*6\TZ4&C*"/G(S;;=N,=>*
M/L?X@?\ !2[]F*^^#NI?#32OAWXAN] _LR33[&U&CV<=I"6C**Z[KC<K#.[<
M%W9YZ\UX!_P1OU*XLOVM[JWB?;#>>&[R*9>S*)(''_CR#]:^OOBW^V]^S!\*
M?@MJ.B_"^#1M<UC4=/>STO1/#6E&W(>6,QJ\DAB 0C=D@YD/]TDU\;_\$>O^
M3P$_[%^^_G%0!VO_  6T_P"2^^!?^Q9'_I5/7V)^PO\ L7_"#0_V;_!FO:AX
M)TCQ3KGBC1K;5-0O_$-E%>OF>)7,48D4K'&N[;A0,XRQ)YKX[_X+:?\ )??
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M)!;1%I+=HEVQW; <E#&%1C_#Y:$\,<4/V._^"MND_#;X:Z5X)^*^D:OJ+:-
MMII^O:0L<SR6Z#$<<\;NAW*HVAU)W +D @L0#C/$G[;W[;&DZEJK+I.N0Z=;
M2RD3/X*78L2L?F+&#& HSFO0_P#@G_\ M\?&OX^_M-Z#X.\8>(+34O#]S:7D
MUQ!#I=O V8X'9#O1 P^8+WJG^UU_P5TT?XB_#+6/!?PKT+5K&76H)+&_UK7(
MXXFBMG4JX@CCD?YF!(WL1M&<*205V/\ @C?^S#J^DZAK'QF\0Z?)965S9MIF
M@+<(5:=796FN5!_@PBHK=&W2>G(!YY_P6T_Y+[X%_P"Q9'_I5/7V+^PQ^Q?\
M(-%_9L\&:WJ'@G2/%.M>*-'MM4U"_P#$-C#>R;IXE<Q1AU(2-<X 4#.,DD\U
M\=?\%M/^2^^!?^Q9'_I5/7Z:?L=_\FH?![_L4M+_ /26.@#\-/VDOA'H7A']
MM'Q3\/\ 1XFT[P]_PDD=G!#">;>&=HSL3.>%$A SGH*_:>S_ &!O@3IGPQNO
M!5M\.=#:VN+,VS:I=6:3:B7VE1-]I8>8) 26!4@ G@ <5^1_[6W_ "DD\2?]
MC;8?^V]?OI0!^!G_  2KU.:P_;B\!01-A+V#4K>4>JBPN),?]]1K^5?6G_!<
M;_D5?A)_U^ZE_P"B[>OD#_@EQ_R?9\,O^XG_ .FN[KZ__P""XW_(J_"3_K]U
M+_T7;T =7_P2?_99^'__  H"Q^)NL:%8^(O$_B"XN46;5+5)UL889WA$<*L"
M 6*,S.,$[@O0<_,W_!7[X"^%OA'\6O"/B#PGH]IH%KXGL)S=V-A$(H#<0.@:
M54'RJ66:,$* "4SC))/HO_!.7_@H?X$^"?P@M?AM\4'N/#-GI\L]UI&MQ6,U
MQ#<PRRR.Z2+&K/N$ID 95*D<':5);Y]_X*,?M5Z3^UY\9- C\#VUY=>'=%M?
ML&GR30,DU]<2R9D=8_O '$:JI&X[22.<  _4S]DOQI??$#_@G_X3UC4I6N+W
M_A%[JR>5B2SBW\ZW5F)ZDK$,GN<FOPO^!_P;U_\ :!^*.B^ ?##V<>N:MY_V
M=K^4Q0CRH))GW,%8CY(FQP><5^^/P+^%MY\%OV+="\&ZDGE:IIOA>8WL60?+
MN)(Y)IDR.#MDD9<CKC-?C]_P2X_Y/L^&7_<3_P#37=T =_\ \.;?CW_S^>#_
M /P:2_\ QBO /VFOV2?''[)VK:%I_C:729;C6()+BV_LJY>90J,JMN+(N#EA
MZU_1]7Y%_P#!<'_D?OA9_P!@R]_]&QT ?97_  2X_P"3$_AE_P!Q/_TZ7=?5
M5?*O_!+C_DQ/X9?]Q/\ ].EW7U50 4444 %%%% !1110 4444 %%%% !1110
M 5^ /_.4W_NLW_N<K]_J_ '_ )RF_P#=9O\ W.4 ?O\ 4444 %%%% !1110
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MX3CX:^,/[4M=:N?$#26$MK:>=#*EP(D4$@Y4AU;.1C!4@GD"Q_P6J^".J?\
M"4>#_BO96TD^CM8C0=1DC7*VTJ222P,WH'$LBYZ9C ZL,@'-?LZ_\%(/@S\
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MW;*0!((ER>/GKY8^&/[9G[-?[6_@60_M$:'X0T3QM'-)$RW.GS*&MP!L>&[
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M71?!W[&OQ<T[0-(L-#T]?#=^XM--MDMX@QB;)V( ,GUQ7YU?\$2_^2^^.O\
ML63_ .E4%?<_Q@^.WA7]HS]@CXL^,O!LMU-HLN@ZG;*UY 89-\<1#?*>W-?#
M'_!$O_DOOCK_ +%D_P#I5!0!RG_!9+_D[BS_ .Q9LO\ T;<5^AG[)/[$_P &
M_"?P \)RW/@31?$VI:]H]KJ&HZCX@L(;V>5YH4D95,BG8@+8"K@84$Y/)_//
M_@LE_P G<6?_ &+-E_Z-N*_7_P#9[_Y(%\-/^Q9TS_TECH _#*Y\*V7P6_X*
M-66A>'$-OIFB?$6UBL82Q/EPB^0I'DG) 4[<GD@<U^CW_!933==OOV4].FTM
M)7TRT\1VLVJ^5GY83%,B,_\ L>:\0_WBGI7Y]?&7_E)]J'_91K7_ -+(J_4#
M_@IU\8O$OP9_9>O[SPYH]GJAUB]CT:^GU"U2Z@L[:6.3=(T3@JVXJL8W@KF3
MGG (!X[_ ,$@_B)\-/#_ .SIJNFOK>CZ-XNCU:>XU>.^N8X)Y(\+Y,F7(+1A
M.!C@,'Z9Y^*?%&H:3XY_X*<VM[\(C%/IMUXVL9M/FTP;8797B-S*A'!C+K.^
M1P5)/0U@_#+PS^R/JO@'1YO''C'XEZ-XPV_\3."PLK5[3?GD0?NV.WI@LV?]
MD=*^\?V*?&G[$7PH\1+'X!\5;/&-TOV=-8\:I+#=,K<>7'+)%'!&3G!";2W3
MD8H _1FJ]_86VJV-S97MO%=V=S&T,]O.@>.6-@0RLIX(()!!Z@U8KY]_;P\,
M^/?$G[,GBD_#35M9TCQ?IWE:C;-H-W-;74\<3@S1(T1#,3'OP@^\0H]* /E+
M]H'_ ((PZ#XFU*\UCX3^)U\+23,9!H&M(\UFC')Q'.N9(U]F60^_:OB#X@?L
MU?M&_L1W;>)VM]8\,V,4BJ?$GAG4"]J><*)'B;*J2<8E50<XP<UZA^Q-_P %
M+?$7P-\7ZW;?%K6/%?CWPYJR1+Y]]J<M]=:9+%O^:))WP5??AU#*?E4\[<'Z
M"_:R_P""J_PG^('P+\6^#/!^D:SKVJ>(M-ETX2:A:+;6UJ)5*F4DL69TX90%
MQD#YAB@#O?\ @F=^WUX@_:0O-2^'_P 0/(N?%VFV7V^TUB")8OM]NK*D@E10
M%$JET.5 #*3P"I+?!7[6W_*23Q)_V-MA_P"V]>N_\$8?A1K6L?''7O'YM9HO
M#FBZ5+8?:V#*DUU,R8B4]&VHKLP_ARF?O"O)O^"C.D:I\+OV\O%>LRVKJL]W
M8Z[I\DHPMPGE1'<OJHECD3ZH: /WPK\"_P#@GO\ \I#/!/\ V$]4_P#2.ZK[
MU\3?\%DOA3%X %[X9T37M8\:7$(6W\/SVHC2.X8 !9)@2"H)ZH&)XX&<CX!_
MX)QS7%Q^WU\/9;N$V]W)>ZBTT)4J4<V5T67!Y&#D8- 'W1_P6T_Y(%X%_P"Q
MF'_I+/7'_P#!(+]E_P !^)OAKK'Q1\1Z-:>(]?;5)=+LH]3MTF@L8XXXV+QH
MP(\QS(<N1D!0!C+9[#_@MI_R0+P+_P!C,/\ TEGKP?\ X)G_ +>O@[]G7P3J
M7@'XDI<:)H-U>R:IINOPVDMPF]E5)8Y$C#,1F-=K(IY+ XXH N?\%D/@!X1^
M'>L^!/&WA?1K/0;C7#=66I6^GP+##,\0C:.78N 'P[AB!SA<]*^L_P#@GYK.
ML?&'_@GII^C?;V@U>.PU+P[;7SDYBP9$@;//"(\8X[(*^ _^"G'[9OA?]J;Q
M1X4T7P(US>>&?#J3R'4;BW: WEQ-Y8.Q&PP15C !8*26;C !/Z.?LC_#?Q=^
MSC^P586=CHXO/'\.CWNN1Z/=HW[R\E$D\-LZJ0P;'E1D9SNSTH _(;X1^.O&
MG[ O[1!U'Q)X$@N-;TV.6SN='UV$IOC8C,D$N" 3L&V90P()QD-7U#XW_:"_
M90_;N\6Z!=?%&Q\4_![Q+ &MFU/27M&M+KS&7:+BX,#L=A!PS1H%#L2<=.Z^
M#G_!3CP3\>M>U3PG^TMX0\)Z/H(A_P!!FGTJ:\A6XWA7CE5_-,9QR& &"AR1
MQ7RU_P %!]'_ &<=/\2^&;CX!7T,TEU'<-K5KITDTEE%@Q^2R&7[K',N50E0
M%7A>X!^J_P >/ ^D_#7_ ()[>-?"V@ZG=:SH>D^";BUL+^\G2>6:W6W/EL71
M55AMQ@J , 8KX%_X(E_\E]\=?]BR?_2J"OI?X=Z-K^@_\$=]3L_$D5Q!J'_"
M':M+'%=9\Q;9Y)WMP<\@>4T9 [*5%?-'_!$O_DOOCK_L63_Z504 1?\ !:KQ
MU?:I\??"/A0S'^RM(T!;Q(<G'VBXGE$C?]\0PC\#ZU]U?L3_ +*/PW\)?LM^
M!EOO!NB:SJ?B'1;?5=5O-3T^*YEGDN8EE,;,X;Y$#*@4<?+G&22?C;_@MA\)
M]1M?B'X(^)$%O))H][IG]AW,RC*17$4LDL8;T+I*V/7R3^/K'[(O_!4+X0^$
M?V;_  KX=\?ZM>Z'XG\,Z;'I7V2/3I[@7L<"!(7B>-64$QA 0Y7Y@W;!(!\
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MEXQI]RX5L=?F1#]0*_0*3]N+]DC]GSX3V\WPYMM(U&ZCMD?3O#NBZ6T5W-*
M-@GE>/Y&!^\\C%^I <\'\^?^"8LC3?M\?#J1T,;M)JK,AZJ3IEWQ0!]'?\%Q
MO^1J^$G_ %Y:E_Z,MZ]>_P""<O[$?P>UG]G'PGX^\2^#['Q?XDU]9;F:77HQ
M=00A)WC6..%OW87$8))4L2QR<8 \A_X+C?\ (U?"3_KRU+_T9;U]J_\ !-[_
M ),E^%O_ %Y7'_I7/0!\[_\ !:/3[72/V<_AW8V-M#96-KXA2""VMXQ''%&M
MG,JHB@850   . !76?\ !'V\33OV.=4NY?\ 5P>(K^5L>BP0$_RKF_\ @MI_
MR0+P+_V,P_\ 26>NH_X(YPI<?L@W\4BAXY/$E\K*>A!AMP10!^4'@CXQ:)J'
M[2$?Q+^*NAS>-=-N-4GU;4M(5U(NY&WM'&=_!C60IE3P57;C!K[!_:(_X*1?
M!GX^?!W6_!=U\&KNVN);*2/2+[?; Z;<A2898RJAE"OC*J1N4LIX)KYZT.SF
M_8,_;6BM_&>@?VWI'A_4I89[6ZA21;_39D=$G16&UCY;B11_?3:2"#C]$?B_
M_P % OV7/"OPOU/5O!5IX;\4^+I+1O[*T<^&G5?M!7Y#<%HD"QJQ!8;PQ (7
MF@#Y]_X(E_$._L_BMX[\#M=R'2K_ $<:PEJQR@GAFBB+@=F*3X..H09S@8Y_
M_@L'\%?&>F_'P_$9].N[_P %ZII]K;Q:E"A>&REC78T$A _=DGYUW<-O."2&
M ^G_ /@FC^TMXW_:7\7>+-0U?X>>!_#'AO1[%8!JGAG1I;.:6[DD4K#YCS.&
M41J[,H&0?+)(R,Y?[87_  4:^(?[,?[0UYX&O_ FB7_@B1;:>WOKJ*<SWMG)
M&GGE?W@1F5_.3&,949H \(T?_@II\.?BI\&Q\+OC+\*C;Z1-8?V>^K>$A 6M
MVV!5N(+:9 L,BD*P(9L%?ND?+7V#_P $Z/@S\#/!>B^(/%_P1\=>(/%=CK*0
MVNHV>MW,)>UDC+L@>%((FC?YWP6R""2N1S7S_P#M0:]^PK\5O@_XH\1Z'=:)
MIOC0Z?--I1\/V4]A=R7NPF)7MPBHP9]H8NO0D[A]ZO.?^")^C:_)\=?&NJV\
M5P/#,7AYK:\FY\DW+7$+0*>Q?:DY'H-WK0!^R5%%% 'XK?\ !:O_ ).F\+?]
MB9:_^EU]7ZJ?LG?\FL_!O_L3-&_](8:_*O\ X+5_\G3>%O\ L3+7_P!+KZOU
M4_9._P"36?@W_P!B9HW_ *0PT >JT444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5\J_\%1_^3$_B;_W#/\ TZ6E?55?*O\ P5'_ .3$_B;_
M -PS_P!.EI0!\J_\$,?^:V?]P3_V_K]5*_*O_@AC_P UL_[@G_M_7ZJ4 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y5^UC_R:S\9/^Q,UG_T
MAFKU6O*OVL?^36?C)_V)FL_^D,U 'Y5_\$5/^3IO%/\ V)EU_P"EUC7[4U^*
MW_!%3_DZ;Q3_ -B9=?\ I=8U^U- !1110 4444 %%%% !1110 4444 %%%%
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M$C]@KX$_%SQ]J/C7Q9X&_M7Q-J#QR7-]_:]_#YC1HL:'9'.J#"HHX4=.><T
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M D:;F)9L*H&223CDF@#\%/CW_P I*-=_[*!!_P"E4=?8'_!<(:[_ ,(K\*#
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MUX;T7X9>"--T+1K1K#P_H5@EK:6J-).T5O"@54!8L[D*H')+'W- 'YK?"_\
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M<,/:OKBB@"OI^GVNDV-O96-M#9V5M&L,%O;QB..)%&%15'"J   !P *L444
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M%_ASP'?^$F.C^'1,NE7,=Y*MY:K+,TTBB;=N96=V.U]P&> *7X(_\$_?@C\
MO$D7B+PUX5:Y\00-NMM2U>Z>[DMCC&8@QV(W7Y@N[GK7T910!6U+3X-7TV[L
M;I2]M=1/!*H)!*,I4C(Z<$U\\?"/_@GO\$O@=\0M)\;>$/#EY8>(M+\W[+<2
MZI<3*GF0O"^4=RIRDCCD=\U](44 %>+?'[]C_P"%_P"TWJ6D7WQ T6YU6YTF
M*2"T:"_FM@B.P9@1&PSRHZU[310!Q_PC^$_AOX'?#W2?!/A"SDL/#NE^;]EM
MY9WF9/,F>9\NY+'+R.>3WQ78444 %%%% !1110 4444 %%%% !1110 4444
M%?@#_P Y3?\ NLW_ +G*_?ZOP!_YRF_]UF_]SE '[_4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 ?E7_P7._YHG_W&_\ VPKZJ_X)
M<?\ )B?PR_[B?_ITNZ^5?^"YW_-$_P#N-_\ MA7U5_P2X_Y,3^&7_<3_ /3I
M=T ?55%%% &9XD\,Z1XRT*]T77M,M-9TB]C,5S8WT*S0S(?X61@017RIXF_X
M)2?LY^(M1>\B\*W^BEV+-#IFJSI$2<=%=F"CV7 Y^E?7U% 'SK\(?^"??P)^
M">M6VM:!X(ANM;MG$D&HZQ/)>R1..C(LC%$8'D,J@@]^!7T5110!\W_$7_@G
MO\$OBI\2=0\>>(_#EY=^);^>.YGN8]4N(E9T554[%<*.$7@#M7TA110!\Y>
M?^"?OP4^&7Q/LOB#X?\ #MY:^*+.YENX;J35+B1!)(KJYV,Y4Y#MQCO73_M
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M$5Z)\'_^"?'P)^">N0:WH/@F&\UJW97@U#6IWOGA=3E7C60E$<'D,J@C P:
M.Q_9)TOQ'HG[,OPRL?%HG7Q#!H-JMU'=!A-'^[&Q) W(=4VJV><@YKUNBB@#
MYW^,?[ 'P+^.6KW&L>(?!,%KKEPVZ;4]'FDLI96SDLXC(1V/=G4M[UPGA_\
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M5_\ )TWA;_L3+7_TNOJ_53]D[_DUGX-_]B9HW_I##0!ZK1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7RK_P %1_\ DQ/XF_\ <,_].EI7
MU57RK_P5'_Y,3^)O_<,_].EI0!\J_P#!#'_FMG_<$_\ ;^OU4K\J_P#@AC_S
M6S_N"?\ M_7ZJ4 %%%% !1110 4444 %%%% !7S7XB_;^^&6@?M!Q_!J.WU_
M6/&37\&FXTRR26V6>0*<&0R# 0-\YQA=K>AKU?X]?$Z'X+_!?QIXXF$;'0]+
MGNX8Y?NR3!"(8S_O2%%_X%7Y<?\ !'SX>W?Q0_:"\=?%OQ$[:E>:/ VV\N.7
M?4+UW+S9_O>6LX/_ %VH _03]IK]MSX>?LG:MH6G^-H=:EN-8@DN+;^RK1)E
M"HP5MQ:1<'+#UKQJU_X+&? *XN%CDB\66R-G,LNE(57COME)_(=Z^</^"X/_
M "/WPL_[!E[_ .C8ZZC]B3_@G#\'/C[^RQX.\;^*;;6O^$AU=;X7$UEJ)B0>
M7>W$*%4VD A(UZYR10!]N?!/]M;X,_M!:D-+\&>-K2ZUIBP32KV.2SNI<#<3
M''*JF3 R3LW8 .>E>X5_.'^TY\+_ /AE+]J#Q'X5\*>(+N8^&[VWN=-U9) E
MU"6ABN(\LF,2(7"DC'*YP.E?T3>$=1N]8\*:+?W\'V6^NK*&>X@(_P!7(T:L
MR_@21^% &M17D'QW_:T^%?[-L<*^//%=OIE_<1^;;Z7!&]Q>2KG&X11@E5)!
M 9L+D'GBO(_!O_!53]G;QAJT>GR>*KSP_++((HIM9TV6&%B3@$R*&5%_VG*@
M=R* /KNOE77/^"E?P6\/_':3X5W=[JPUB+4?[(GU1+('3X;OS!&8FDW[^'^4
ML$*@@Y; S7U'97MOJ5G#=VD\5U:SH)(IX7#I(I&0RL."".XK\VO%>B?L4W7[
M9TL^J7>N#XEOXH2&?14@N?[-EU8SA=S8CP=TQ#'Y]A.<C!(H ^_?BU\5?#OP
M1^'6M^-_%=VUEH.D1++<21QEW)9U1$51U9G=5 ]6'(ZUYC^RY^VQ\.?VN/[;
MB\&_VM8ZCI 1[G3]:MDAF\MR0LB[)'5ER".&R.,@9&>H_:F3X>R? 'QBOQ52
M1_ )MD&IF%)&D13*@C=!&"VY9/+8$#@@'I7S[_P3FT?]FO39?&O_  H>^UC6
M=21;7^U[[7(Y5F6)C)Y,:%XT7;E)"=HR2!N)PN #M?CM_P %'/@_^SS\4_\
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M_?*FOP N=1^(?_!2#]JZVM9KHQ7^N7+);QR,\EKHM@@+$*.RH@).,;W/]YZ
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MM]N\ /&PW, O3)Y%97P=_P""C'P+^-WBZT\,:'XIEL-<O'\NTM=8M'M!<N2
M$1V^0N2<!=VYCP : /IFBBOF?XM?\%&O@+\&_$%SH6K^,O[2UFUD,5S9Z):R
M7GD,."K2*/+# Y!7=D$$$"@#Z8HKX ^,'_!7/P'#X&MA\'K*Z\;>/M0NUM+7
M1K_3[B)8<C_6.J@&7)PHCC;))Y(QSV_[/W[6WC3PQ^SMXD^)/[36D7G@5K77
MOL5M"V@W%JXMWCA$9$!!D(,K2#<?3VH ^R**^/\ _A[!^S;_ -#?J'_@DN__
M (W76_"G_@H=\$/C5\0-)\%^$_$EY?>(-4:1;6WETJYA5RD;R-EW0*/E1CR>
MU %C]I;]N[X;?LI^*]+\/>-(-<EO]1LOM\)TNS29/+\QDY+2+@Y0\8]*]M\!
M>,K#XC>!O#OBS2EF72]>TVVU2T6X0+((9XEE3> 2 VUQD9//>OR)_P""VG_)
M?? O_8LC_P!*IZ^T/!_[9OPF_9G_ &8?@E9>-_$HM]8N/!.BR1:38P/<W1C-
ME"-[(@PB]<%RN<'&<4 ?8E%> ? 7]NKX.?M':\V@^#_$Y_X2#89$TK4[=[6>
M90"6,0<8D("EB$)(') %>_T %%?-OQH_X*'? WX%^(;C0->\6'4->MG,=SI^
MBVSW;V[ <K(RC8K \%2VX'J!5/X1_P#!2/X"_&37K?1--\6MHNL7++';VNO6
MS6?G.W15D.8]V>-I8$D@#- 'T]117S?\(_\ @H1\$OCA\0M)\$^$/$=Y?^(M
M4\W[+;RZ7<0J_EPO,^7= HPD;GD]L4 ?2%%<]\0O'FC?"_P3K7BSQ#</::)H
M]LUW>3QQ-(R1KU(502?H!7F/P#_;,^%?[3&NZGH_@#6[G5+_ $ZV%W<QSZ?/
M;A8RP0$&10#R1P* /;Z*** "O-OC?^T9\._V<]!AU;Q_XEMM#AN"RVMN0TMS
M<D8R(H4!=L9&2!@9&2,UZ37\_7_!3#QIK'C#]LKQ[%JLTC0Z/-%IEC;N?E@M
MTB0@*.P9F=_JYH _12;_ (+-? B'4?LRZ3XUFAY_TQ-,MQ%W[&Y#_P#CO>OI
M#X"_M;_"O]I2*9? GBF#4=1MX_-N-)N4:WO(ER 6,3@%E!(!9-R@D#.:^>?A
M5_P3(_9=\7?"S2;_ $ZPN?&,>H62/'XECUNX#R,4&9%2*01*<Y^4H=IX(XKY
M+T;_ ()L?M#? O\ :$@\4?#?38M0TG0=:^TZ3J4VK6L,MS:J_"RH7'WX\HZD
M '+<8- 'ZE?M%?M%>%?V8? $?C#QA'J$NDR7L=@%TR!9I?,=79?E9E&,(W.?
M2H/V;?VEO"/[5'@:^\6>#(]2BTNSU*32Y%U2W6&3SDBBE. KL-NV9.<]<\5\
MV_\ !9+_ )-'L_\ L9K+_P!%7%>8_P#!+7XW^!_@'^Q;XL\2>//$-MX?TK_A
M-KJ.-Y@SR32?8;$[(XT!>1L<X4' Y.!S0!^G%%?)G@/_ (*C_L]>//$5IHL7
MBNYT2YNG$<,VM6,EM;ECG :4Y1!QU<J.1S7UEG/(Y% "T5XK\</VRO@]^SKJ
M4>F>.O&5OINLR1B5=+MH);NYVGHS)$K>6#V+[0<<9KR+P[_P5F_9VU[58[*;
MQ!JVC+(^Q;K4=)E6'M@DIO*CGJ0 ,'.* /L>BL[P[XBTOQ=H=CK6B:A;:MI-
M]"L]K>V<HDBFC89#*PX(->#77[?OP6LOC$OPNE\17B^,FUE- %G_ &7<%/MC
MRB%4\S9MQO8#=G'?- 'T517RW\5/^"E?P$^$?BRZ\-ZEXIGU75;-VCNTT6R>
MZCMY <%&D&$+ Y!"DX((.#Q7K?P-_:+^'O[1WAV?6? 'B*#6[>V<1W4&UHKB
MV8YVB6)P'4-M;!(PV#@G!H ])HK!\<>//#WPU\,WOB+Q5K-GH&B6:[I[Z^E$
M<:=@,GJQ/ 49))  )KY6OO\ @K1^SE9ZHUI'XDU6[A#;?ML&C7'D_7YE#X_X
M#0!]CU\Z?M+?MW?#;]E/Q7I?A[QI!KDM_J-E]OA.EV:3)Y?F,G):1<'*'C'I
M7R?\7O\ @II\4_B9X\U#0/V8_ D_B_0-/$:RZ^FAW=]-*S ?.(P%$$>25_>J
M2=I/R]*\@_X+4-))\<OA\TPVRMX50N,8PWVF;/ZT ?KYX"\96'Q&\#>'?%FE
M+,NEZ]IMMJEHMP@600SQ+*F\ D!MKC(R>>];U?'?@_\ ;-^$W[,_[,/P2LO&
M_B46^L7'@G19(M)L8'N;HQFRA&]D081>N"Y7.#C.*]%^ O[=7P<_:.UYM!\'
M^)S_ ,)!L,B:5J=N]K/,H!+&(.,2$!2Q"$D#D@"@#W^BBOE_XF_\%*OV??A;
MK-[H]]XU_M?5K-S'/:Z'93781P<%?-5?*)!SD!^,$'% 'U!69XH\2:;X-\-Z
MMK^LW2V.D:5:2WUY=."5BAB0O(Y YP%4GCTKYQ^%'_!2CX!_%[7[70]/\6R:
M-J]VZQ6UMKMH]H)G8@!%D.8]Q)  + D],U[]\2/[ _X5WXH_X2N%;GPO_9=U
M_:L+*S![3R6\Y2%^8Y3=P.?2@#PO]G+_ (*#?"C]I[QU?>$?";ZS9:W;PO<P
MQ:Q9K"MW$A 9HF5WZ;@=K;6QDXX-?2]?GM^P'HO[)%G\9]4?X*ZCKNL^-#I<
MTP.MQ3A;2T\R-9!$7C1<DO&,G<V,X."V?T)H **AN[N#3[6:ZNIH[:VA1I)9
MIF"I&@&2S$\   DDU\G>-O\ @JA^SIX-O9[2/Q?=>(KB%S&XT339IH\C/W96
M58W'NK$'/6@#ZWHKYZ^"'[?'P3_: UZ'0?"_BU8O$$Y(@TK5;>2TGGP"<1[Q
MM<X!.U6)P.E>M_%+XF^'_@WX!U?QEXINI++0-*C62[N(X6E9%9U08106/S,O
M0=Z .JHKY]^'O[>GP1^)7A/Q;XFTOQBMMH7A5;=M5O=3M)K58O/\SRE4.H,C
M,87 5 22 ,<BN TC_@J]^SIJVN1Z<?%&HV*22^4E]>:3.EN<M@,6VDJISG+*
M,#KB@#[!HJKI>J6>N:;::CIUW!?Z?=Q)/;W5M()(IHV 971@2&4@@@C@@UXM
M\?OVUOA%^S3>Q:=XT\3+%K<JK(NCZ?"UU=A#T=T48C![;RN>V: /4OB'XXT[
MX9> _$/B[6%G;2M"L)]2NUMD#RF*)"[[5) +84X&17B/[-?[>OPT_:J\9:CX
M9\%P:[%J5A8-J4IU2S2&/REDCC."LC9;=(O&.F:\P^('[='PA_:8_9H^,NB^
M#M?E3Q G@W5)_P"R-4MFMKAT%JY8IG*R8[A&) !)&.:^/O\ @B?_ ,G)>,O^
MQ2F_]++6@#]GZ*** "BBB@ HHHH **** "O*OVL?^36?C)_V)FL_^D,U>JUY
M5^UC_P FL_&3_L3-9_\ 2&:@#\J_^"*G_)TWBG_L3+K_ -+K&OVIK\5O^"*G
M_)TWBG_L3+K_ -+K&OVIH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH _ '_G*;_W6;_W.5^_U?@#_ ,Y3?^ZS?^YROW^H **** /(_CA^
MR=\*/VD+W2KSXB^$H_$-WI<<D5I.+VYM71'(+*3!(A894$!LXR<8R<^F>'M!
MLO"N@:;HNFQO#IVG6T=G;1R2O*RQ1J$0%W)9B !\S$D]22:T** "BBB@ HHH
MH *\H^-G[*_PJ_:(6%O'_@VQUR[@3RX=0!>WNXUY(43Q,K[023M)*Y)XYKU>
MOF_XI?\ !1#X _"34YM,U;Q_:ZCJD)99+/0X9+\HPSE6>)3&K9&-K,"">G7
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M\1% ^?+4[<>8G7KFNY^%OQ-\/_&3P#I'C+PM=27N@:K&TEI<20M$SJKLARC
M,/F5NH[4 =5117(_%?XL>%O@CX#U/QCXRU1=(T#3PIFN"C2,69@J(J*"S,S$
M  #OGH": .NHKR+]G?\ :J^'/[46DZI?> =7EOFTN1([ZSNK9X)[??N\LLK#
ME6V-@@D?*1U!%>NT %%%% !1110 445X;\>OVT?A3^S3XCT_0O'VN76EZE?V
MGVV".#3Y[@-%O9,[HU('S(W!]* /<JHVNAZ;8:E?:C;:?:V^H7Q4W=U%"JRW
M!50JF1P,MA0%&2<  5C?#/XD:%\7? FC^,/#%R]YH.K1&>TGDA:)G0,5R48
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MPB@L?F9>@[UYU\ _VS/A7^TQKNIZ/X UNYU2_P!.MA=W,<^GSVX6,L$!!D4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ K\ ?^<IO_ '6;_P!SE?O]7X _\Y3?
M^ZS?^YR@#]_J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** /RK_ ."YW_-$_P#N-_\ MA7U5_P2X_Y,3^&7_<3_ /3I=U\J_P#!<[_F
MB?\ W&__ &PKZJ_X)<?\F)_#+_N)_P#ITNZ /JJBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA/S5[S_P25\5ZYXH_8[TJ/699KB/2M4N].T^68EF-JNQU4$]55I)$'H$ '
MKY#TG]BCPO\ %[Q=ITOQ/_;.\,>-[2S0*D-MXDBO[WRMPS'&\]PWE \<[6&<
M?+7ZO_"[X?\ AOX6_#[0O"OA"SBLO#>FVRQ644+;P4/S%RW\;,26+?Q%B>]
M'4T5\8Z7_P %6O@WJOQNB^'D4.MB*;4AI47B1H(AI[S%]BMGS-XC+\;ROH2
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MC#7_ !/ISV-G:>';N.]$6_@R3.C%8U4=B=QXPO4CYA_X(C_\EH^(?_8OQ_\
MI2E 'U3_ ,%)/V3/&'[34?A>ZL_'?ASP?X.\.PS372^(;F2"(W$C*/-9@A7
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M/$NF_L$>)?&6BS30^([CPE!<_:+<D20F>.,32J1RK(DCL&'0KGM7Y]_\$?\
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M@UX]_P %F_BAX4@\/^$/AWJ/AG[=XEN\ZK9>()I&CCTN+?Y;[=JDR%]IW)T
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M^S+XSUVX_:)^)7P]\4W<,21:?H5MJ<DIMI-S>:\]N &+8"!0P(Y?C(!'UO\
M\%3OB=XC^%_[)>IW'AF[N-.O-6U*VTF>]M6VR0V\@=I"K=5W",)D<X<_6OAC
M_@F'^RY\%?CMI/BG7?B=>6^KZQI]\D%KX=N-3:T40[%?[2ZHZO(&8E1SM&QL
M@YH \=_;ZM?@'_PL30M2^ 5Y:OI%Y9/_ &I9V"W"P07"R?*RK, 5W*P^5?E&
MSH"3G]9? /B;4O&7_!-V#6-7NGO=3N?AS<&>YE)9Y66QD7>Q/)8[<D]R2:_*
M[_@H]9_!#0?BIHOAWX)VFF0V6DV+PZO-I#M-;O<E\A1,6;S&5>"02 3C.00/
MT]^#7_*,'3_^R<W7_I'+0!\ ?\$8?^3K];_[%*\_]*K2OVTK\2_^",/_ "=?
MK?\ V*5Y_P"E5I7[:4 >(_MD_!WQ9\?/@'KG@7P?KMCX>OM6DA2ZO-09UC-J
MKAY(\HK-\VU0>,$;@>#7P7^SY^SK^RW^S98:^GQV^(/P^\>>*Y+G9!#97\E[
M#96X094PH,B4N6SN4D!4QC+9]1_X+/?%#Q)X-^#_ (-\-:+>7&GZ9XDO[A=4
MEMVV&6.%$*P,PYVL9"Q'?R^>.#Y/_P $Y_V1?V>?B9\#?^$W^(EQI_B+Q&US
M<+=:??:NUK%I<4;%5WQI(A)9!YFYR1AA@#;F@#XY_:RD^&7A/]H:?5/@)JY7
MPHB6U_8S64DZ_8KM1EQ&TH$@PZAQDG!; .  /V$_;TU*;6?^"??CG4+C:;B[
MT6QGDVC W-<6[' ],FOQ\_;=N_A7<?M!:Q!\'+>S@\%6<$-I&VGAOL\LZ+B5
MXV8DNI;C?T;&1D$$_KS^V]_RCF\6_P#8OZ;_ .CK:@#\SO\ @G#^R!IO[6GC
M+Q);^)M:O++P=X>%K=W^EV,A234)I/.6$;N0JJ%ERV-V'(7&XL/2?^"G?[#O
MP]_9G\(^$/%7P^@O-,M]0U!]-O+"YNWN4+>49$D1G)93\C@C)!R.F.>^_P""
M&O\ R%?C)_UQTG_T*\KTK_@MI_R0+P+_ -C,/_26>@#L?^":7Q0N]-_X)_R:
M[JLDE]#X3.J>4LCY)@@!G$>3T #%1Z  =!7YH_LK_"N]_;D_:VCM/&NJ74\>
MJRW.MZ]>0MMFDC7YBB$@A=SM&@[*IXZ 5^AO_!,GPJ_CK_@GGXJ\-QE5DUBY
MUG3E+_=!FMUC&?;YJ^!?^"=GQ>TG]G/]K;3;OQI+_86F7$-UH6H7%V"@LG?&
MTR9^Z!+&BL3]T$D\ T ?;?[:W_!,OX6^%?@-XC\9?#'3IO!NO^&;";4)E_M"
MYN(;^VCC)FC<2NY5C&&P5P">&!#9'@G_  1/_P"3DO&7_8I3?^EEK7VI^WQ^
MV%\+?"?[-OC+0;/Q7I7B77_%&DSZ38:;HM]%<R?OXBGG2;&.R-5;=D_>P .M
M?%?_  1/_P"3DO&7_8I3?^EEK0!^S]%%% !1110 4444 %%%% !7E7[6/_)K
M/QD_[$S6?_2&:O5:\J_:Q_Y-9^,G_8F:S_Z0S4 ?E7_P14_Y.F\4_P#8F77_
M *76-?M37XK?\$5/^3IO%/\ V)EU_P"EUC7[4T %%%% !1110 4444 %%%%
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MT3_L4K/_ -*KNO>OV=?^"3'A/XB_"O1_&'Q6\5Z]K/B3Q#I]O>Q+I-VL<=G
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M]LS_ )2(>,/^QFL__08*^O\ _@AS_P BK\6_^OW3?_1=Q7R!^V9_RD0\8?\
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M7(!PG_!87_D\!_\ L7['^<M?LI\$?^2+^ ?^Q?T__P!)HZ_&O_@L+_R> _\
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MP(615Z<AL;B ?L!\._B=X3^+7AN/7_!OB'3_ !+H\C;/M>G3K*JN "4?'*.
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M_, /TI\9_%^[^/7_  2P\0>.M1$0U+5?"-R+SR1A&N(G:&5@.P+Q,<=LX[4
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M%% !1110 4444 %%%% !1110 445^:G_  4X_;>\<?"_XF>&/AC\)];FTGQ
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M ,G3>%O^Q,M?_2Z^K]5/V3O^36?@W_V)FC?^D,-?E7_P6K_Y.F\+?]B9:_\
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M++494@LSCIOCB4,_/8OM/0J17W/:6D&GVL-K:PQVUM"BQQ0PH%2- ,!5 X
M   J:B@#Y*_:G_X)K_#+]IW79_$SS7G@_P 8S*!/JNE*C1W9  #3PMP[ #&Y
M2C'C). *^=M#_P""'6A6^J>9K'Q:U&^TW?G[/8Z)';3;,GCS&FD&>G.SMTK]
M/J* //O@;\"?!O[.O@*U\(^"-+&G:7$QEEDD;?/=3'&Z6:3J[G &>@
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M^(YQ>>-_$]J=\%[K83R+:3L\4"C:&&.&<N0>00<5]@44 %?$'[3'_!*;X?\
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M'PS\(Z7X7\+Z7;Z-H.F0B"ULK9<*BCOZEB226.2Q)))))H _//\ X<A^"/\
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ML^9[8QWS63^V!_P3C\$?M9:_%XH?5[SPAXP2W6U?4K.%9X;E%SL\Z$E=S+G
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MGGLV,=Z_1CX"? +P?^S;\.[3P;X*L7M=-A<S37%PP>XNYV #33. -SD*HX
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M/BQ9>-?^%B_\(G]FTF'2_L/]A_;=WERS2>9O^T1XSYN-NW^'KSP ?37[/?\
MR0+X:?\ 8LZ9_P"DL=?B7X\_Y2E3_P#94[?_ -.25^ZGP]\*?\('X!\->&?M
M7V[^Q=,MM.^U>7Y?G>3$L>_;D[<[<XR<9ZFOB77O^"5?]M_M2O\ &3_A9_D[
MO%,?B;^Q?^$?W?=N5G\CSOM0Z[=N_9WSM[4 ?;7Q"_Y$'Q-_V#+G_P!%-7X@
M_P#!)/\ Y/2\/_\ 8,U#_P!$&OW.\1:3_;WA_4],\WR/MMK+;>;MW;-Z%=V,
MC.,],U\0?LD_\$NO^&6OC3I_C_\ X69_PD_V2UN+;^SO[ ^R;O-C*;O,^TR8
MQG.-O/M0!X?_ ,%RO^0K\&_^N.K?^A6=?07_  2U_:$\$>*?V8?#O@M-:M;'
MQ/X62:WOM-O9DBE9&G>1)HP3\\9$@7(Z,"#C@GK?VY?V$?\ AM"Z\&S?\)Q_
MPAW_  CJ7:;?[)^W?://,)S_ *^+;M\GWSN[8Y\-\?\ _!&#PMKW@;PO9^'?
M&C:)XKTNU^S:EJC:86MM6.XD2M!YV87 .,JS A1D9YH ^7_^"NOQG\.?%7]H
M71]-\,ZE;:Q:>&])%E=7EI(LD1NGE=WC5U)#;5\L'!X;<.U?5/[1?@V]^'__
M  1UTS0M2B:WO[?2-%>>%\[HWDO;>5D/H07P1ZBI/V<_^"._ACX9^,M/\3?$
M'Q2/'$NGRI<6VC6]D;>S,JX*F8L[-*H;G9A0<#=D$K7UU^U5\!?^&FO@;K_P
MZ_MW_A&_[5>V?^TOL?VKRO*N(YL>7YB;L^7M^\,9SSC% 'PW_P $.?\ D5?B
MW_U^Z;_Z+N*^>?\ @JS\:O%?CK]J;6_A[=:M-9>$/#AL[>TTXR,EN9)+>*9[
MB50<,V92 Q'"*,8R<_I+^P[^Q/\ \,8Z5XNLO^$S_P"$P_M^:VFW_P!E_8?(
M\I9!C'G2[L^9[8QWS7.?ME?\$V_"?[6/B.'Q9;:]<>#?&*P+;3WT=L+JWO(T
M&$\V(LAWJ/E#JPXX(; P </:_P#!-W]E/X)_"W_A*/B#-)K^EVMHLUSK^IZS
M/;PS$J#NB2VD3.[^!%WDY &X\U\ ?\$PC$?V]/AP81B'?JFP'^[_ &9=X_2O
ML_X-_P#!&72?#_B+3[SXD>/9?%^AV+F2/P]86KVL$ISG#R&0L%/=452?[WKW
M'[.O_!+"W_9[_:-T?XHVGQ'&J6NF3WLL6A+H/V<;)[>:%4\[[2V-@F!SLYVX
MP,\ 'T;^TQ^UI\/OV4/#^FZGXXN[PRZI(\=AINFP":ZN=@4R,JEE4*NY,EF
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M6<1L<F*5&XD3/(&002<$98'A_P!B/_@GI_PQOXT\1>(!X^_X2X:OIZV/V?\
ML;[%Y6)%??N^T2;ONXQ@=>M 'Y;_  K;4OV_/VQ-$LOBCXNN+.#7[J=WD$P
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M)_X1_P"T>7Y,,46WS?M29SY6<[!C=CG&2 ??5?@7^Q#_ ,I&?"7_ &,&I?\
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M ?@#_P $N/\ D^SX9?\ <3_]-=W7[_5^ /\ P2X_Y/L^&7_<3_\ 37=U^_U
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MK6^NH0D]Q(L]U/) K'8\Z0LJPKN(X,A&>-W(QY+_ ,%$?'7[07CMO %S\=?
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MJ5^7O@[Q)X^O/VLV\0>#]-_M[XB/XBN]0LK2XB$YEN_,DD)*L0&8'<P]U!H
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MC?%'^(%?GA^Q%X\_:6\"^$/$;? KP@FNZ5=WR#4KP:='<N)DC&R,LS @!7)
M_P!LT >ZZ?\ \%'/VD?V7?B%8:%^T%X1&J6$\8=T>SAL[IX\X,MO-!^XDP>J
MXP3QE.M?JQX+\9:/\0O".C^)M O8]1T75K6.\M+J/H\;J&!QV/."#R""#R*_
M&3]HSPA^V9^U-I>C6/CSX67=S'I$TDUI)9:9%!(A=0K@L'Y!VKQZJ*_13_@F
MWX)\9?#7]E/0?"WCC0[KP]JVEWUZD5G> "00O.TRM@$\%I'_ "H ^H:_-_\
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MLM0M[N[1</-'"]N8E8]]IEDQ_O'VH ^T/^"9?_)CGPP_ZXWW_I?<U]05\O\
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M/VLV\0>#]-_M[XB/XBN]0LK2XB$YEN_,DD)*L0&8'<P]U!H ^P_$7[1_[?\
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M;_W#/_3I:4 ?*O\ P0Q_YK9_W!/_ &_K]5*_*O\ X(8_\UL_[@G_ +?U^JE
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M%15'"J   !P,59HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *YSXC> ]*^*7@+Q!X0UU))-(URQFT^Z$+!9!'(A4LA(.&&<@X." :Z.
MB@#S7X%_LZ?#[]G#PS)H?@'P_#HUO.RO=7!=I;FZ<# :65R6;&3@9VC)P!FO
M2J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRW]H#]FOP-^TUH.B
MZ-X\L+C4--TK45U**&VN&@,CB-T*.Z_-L(<Y"E3E5YXKU*B@#%\&^#-"^'OA
MG3_#OAK2K71-#T^(0VMC9QA(XUZ\#N2222>22222:VJ** "BBB@ HHHH ***
M* "BBB@#\ ?^"7'_ "?9\,O^XG_Z:[NOW^K\ ?\ @EQ_R?9\,O\ N)_^FN[K
M]_J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OQ6_P""
MU?\ R=-X6_[$RU_]+KZOVIK\5O\ @M7_ ,G3>%O^Q,M?_2Z^H _53]D[_DUG
MX-_]B9HW_I##7JM>5?LG?\FL_!O_ +$S1O\ TAAKU6@ HHHH **** "BBB@
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MH+\5/VS-!M/A_#X<L]-TJYNHY3I.@037-U?2J<HK$EBP#<A44<XSG K]!_\
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MN_M%_P#!2[XH?M476@>$OA/H?B'P)*MUYP3PUJEQ+JFH2;"HCW6ZQD1C<QV
M-DA6)& !^C/[-7P[^(7PU_9!O;#XI>(-4\0>-[RQOK^^?5M1DOY;7?&0EOYK
MLV=J*N0#M#,V,]3] Z'X3T/PSYO]CZ-I^D^;_K/L-K'#OQZ[0,UJLH=2K ,I
M&"#T- 'X1?\ !)/_ )/2\/\ _8,U#_T0:_=ZJ%GH&EZ?,)K73;2VF P)(8%1
MAGW J_0!^ /QN\%^/_V'_P!L:\\7+HDGV?3_ !#+J^BW]S YLK^W>1G5-XP"
M2CE'4-E3N'H:^_?'WBKQC_P4(_X)K^(=;TK08K+Q/<71FBT73I&D%RMI=*S1
MKNY+,BL0O=@H'6OT Z\'D5#9V5OI\(AM8(K:$'(CA0(HS["@#\)/V$_VY(/V
M*3XVT?7?!%QK2ZO+"[F&86UU;S0AU\N0.IROSMZ%3G@YXH_MY?''XI_M+0>#
M?'_B_P '/X*\ 2/=VOA6QEY>3B%KB4NRJ\N[$/S[0GRX49#D_NQJ/@_0=8U&
M+4+_ $33;V_B(,=U<6D<DJ$="&(R,8J]?:79:HJ"\L[>["<J)XE?;GKC(XH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MK\ ?^<IO_=9O_<Y7[_5^ /\ SE-_[K-_[G* /W^HHHH **** "BBB@ HHHH
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M]XN\2V[PQ^4#]VVC(7S, D*D8$8QC*BOW:L=%T_3)&>SL+:T=AAF@A5"1Z'
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MDTS47MT+BQ?S3(DD@'W5?>5W= 4 )!9<_J;:V<%A L%M!';PKG;'$@51DY.
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M,?A5);3+,D>E>2Y4YVNDKJRGW!!% 'Y)_P#!53_D^/Q]_P!<=-_](+>OV/\
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M8?BG=:OJ%OIMO+X:U&UCDN9 @>:6VDCBC7/5F=E4 <DD5^4__!&'_DZ_6_\
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M8$^/@\,?$'QC?^.+2%HKJ[T_5-3DU&VU&T?C?!/.#+%T;! 7#*=RD9!_3_\
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M_P!LWX)?#74?B9J'QLU;4O[-B6]U/3]-\6:@\\$2G.2KA8Y%3)+*#@#. PH
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M ?\ @EQ_R?9\,O\ N)_^FN[K]_J "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "OQ6_P""U?\ R=-X6_[$RU_]+KZOVIK\5O\ @M7_ ,G3
M>%O^Q,M?_2Z^H _53]D[_DUGX-_]B9HW_I##7JM>5?LG?\FL_!O_ +$S1O\
MTAAKU6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\4_]B9=?^EUC7[4T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MYF/%=I0!_/5)&LO_  4@9'4.C?%C#*PR"/[8Z&O2O^"B'[).I?LC_&*Q\?\
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MB\LKL1L65H9X" Q'S$%6(PQR.F #H_V^OAS^T[X+^%?AV\^./Q$T;Q9H%UK
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M\,7GPNU+Q#HUW<_;)H]0L+B]A60*$,D%W;L5^8*@()8?*. 3SE:]\"_VB_\
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M)FQ@< G@"OF?_@M5<M<?!'X8/8E3H\NLR2 QC"D_9CY6!Z;2^*^??@S^Q/\
M'']LSXZQ_$#XSZ9J>B>'[JYBNM6O];MS9SW<* !;:VMR%9595"!MH55.[+'
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M% !1110 4444 %%%% 'X _\ .4W_ +K-_P"YROW^K\ ?^<IO_=9O_<Y7[_4
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% 'X _\$N/^3[/AE_W$_\
MTUW=?O\ 5^ /_!+C_D^SX9?]Q/\ ]-=W7[_4 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %?C]_P6\T![?XL?#;6RF([S1)[(-CJ89]Y'
MX?:!^=?L#7P)_P %D_A/)XR_9ST?QC:0&6Z\(ZJKS,!G9:7($4A_[^BV_ &@
M#WO]@+Q(GBK]C;X3WD;;A%HR6)YSS;NUN1^<5?0%?G!_P1;^,D.O?"?Q5\-K
MNX']H^'[[^TK.)FY:TN  P4>B2HQ/_79?6OT?H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1ZQIJ.V 9H<I.BCNS1LC?2%J /UTHHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<>9% K)Y:GL'+$@\A3P/TG^/WAO4_&7P)^(V@:*&;6-4\.:C96:IU::2VD1
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M ^[:*^ ?VRO^"J&G_ GQK>> OAYH-KXO\66+>3?WM[*_V*SGXQ"$CPTS@G#
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M0",5N4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_H)KYQ_;B_8_TG]K?X6MIZ^38^,])#W&A:I)P$D(&Z"0@9\J3:H/H0K#.,$
M]/\ @3\:O#O[07PMT/QQX9N5FL-2A5I8-P,EI. /,@D]'1L@^O!&003W]?@#
M^RG^U-XX_8#^,&M:)KVD7<VC-<_8_$7AB=MDD<B''G19^42J,X/W74@$XVLO
M[C_!WXS^#_CSX'LO%G@K6(=8TBY&"4.);>3 +12IU1QGE3Z@C(() .WHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)G_Y7]+_ /DF@#]_J*_ '_AUQ^T[_P!$S_\ *_I?_P DT?\ #KC]IW_HF?\
MY7]+_P#DF@#]_J*_ '_AUQ^T[_T3/_ROZ7_\DT?\.N/VG?\ HF?_ )7]+_\
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M^T[_ -$S_P#*_I?_ ,DT?\.N/VG?^B9_^5_2_P#Y)H _?ZBOP!_X=<?M._\
M1,__ "OZ7_\ )-'_  ZX_:=_Z)G_ .5_2_\ Y)H _?ZBOP!_X=<?M._]$S_\
MK^E__)-'_#KC]IW_ *)G_P"5_2__ ))H _?ZBOP!_P"'7'[3O_1,_P#ROZ7_
M /)-'_#KC]IW_HF?_E?TO_Y)H _?ZBOP!_X=<?M._P#1,_\ ROZ7_P#)-'_#
MKC]IW_HF?_E?TO\ ^2: /W^HK\ ?^'7'[3O_ $3/_P K^E__ "31_P .N/VG
M?^B9_P#E?TO_ .2: /W^HK\ ?^'7'[3O_1,__*_I?_R31_PZX_:=_P"B9_\
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M_E?TO_Y)H _?ZBOP!_X=<?M._P#1,_\ ROZ7_P#)-'_#KC]IW_HF?_E?TO\
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MP;-E)I^X>\QRB?\ 3'[Q_CVC*M^LMK:PV-M%;V\,=O;PH(XX8E"HB@8"@#@
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M>@KW'_@H9^S1??M)?LVWF@^'85D\2:'<1ZOI-MNVB=XT=&@!]6C=PN>-P3)
MYK\T_P!A?]O*[_8E_P"$I\"^-_"NJ7VA7%Z;MK.%5@OM/O@JQR!HY-N0RQQ@
MJQ!4QY Y- 'T%_P6X^'.CQZ+\._'4-O%#KKW4VCW$R\/<0;/-C#>H1A)@_\
M30^U>O?\$U_%U_XH_P""?-[;WTCRC1CJVFV[R=?)"&50#W \XJ/0#':O@C]L
M[]K;7OV__B-X2\->"/">I1:58%X],T<*)[V\NI<;Y7"9  5% 7)"@,Q;YB!^
MJG[.OP#D_9K_ &.$\$WCQRZS#I%Y=ZI)$VY#=2H[R*I[A<A >X0'O0!^1?\
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M?#I)=+\$2^&/A1H>J0F:[F<3O<:@R2B(-+M4 B,R?NTSC)+$_+C[*_X(J?\
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MM\J0R^W>LK_ARI\;_P#H:?A__P"#&^_^0Z /U4_X:Q^"'_19/A__ .%18_\
MQVC_ (:Q^"'_ $63X?\ _A46/_QVORK_ .'*GQO_ .AI^'__ (,;[_Y#H_X<
MJ?&__H:?A_\ ^#&^_P#D.@#]5/\ AK'X(?\ 19/A_P#^%18__':/^&L?@A_T
M63X?_P#A46/_ ,=K\J_^'*GQO_Z&GX?_ /@QOO\ Y#H_X<J?&_\ Z&GX?_\
M@QOO_D.@#]5/^&L?@A_T63X?_P#A46/_ ,=H_P"&L?@A_P!%D^'_ /X5%C_\
M=K\J_P#ARI\;_P#H:?A__P"#&^_^0Z/^'*GQO_Z&GX?_ /@QOO\ Y#H _53_
M (:Q^"'_ $63X?\ _A46/_QVC_AK'X(?]%D^'_\ X5%C_P#':_*O_ARI\;_^
MAI^'_P#X,;[_ .0Z/^'*GQO_ .AI^'__ (,;[_Y#H _53_AK'X(?]%D^'_\
MX5%C_P#':/\ AK'X(?\ 19/A_P#^%18__':_*O\ X<J?&_\ Z&GX?_\ @QOO
M_D.C_ARI\;_^AI^'_P#X,;[_ .0Z /U4_P"&L?@A_P!%D^'_ /X5%C_\=H_X
M:Q^"'_19/A__ .%18_\ QVORK_X<J?&__H:?A_\ ^#&^_P#D.C_ARI\;_P#H
M:?A__P"#&^_^0Z /U4_X:Q^"'_19/A__ .%18_\ QVC_ (:Q^"'_ $63X?\
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MGQO_ .AI^'__ (,;[_Y#H _53_AK'X(?]%D^'_\ X5%C_P#':/\ AK'X(?\
M19/A_P#^%18__':_*O\ X<J?&_\ Z&GX?_\ @QOO_D.C_ARI\;_^AI^'_P#X
M,;[_ .0Z /U4_P"&L?@A_P!%D^'_ /X5%C_\=H_X:Q^"'_19/A__ .%18_\
MQVORK_X<J?&__H:?A_\ ^#&^_P#D.C_ARI\;_P#H:?A__P"#&^_^0Z /U4_X
M:Q^"'_19/A__ .%18_\ QVC_ (:Q^"'_ $63X?\ _A46/_QVORK_ .'*GQO_
M .AI^'__ (,;[_Y#H_X<J?&__H:?A_\ ^#&^_P#D.@#]5/\ AK'X(?\ 19/A
M_P#^%18__':/^&L?@A_T63X?_P#A46/_ ,=K\J_^'*GQO_Z&GX?_ /@QOO\
MY#H_X<J?&_\ Z&GX?_\ @QOO_D.@#]5/^&L?@A_T63X?_P#A46/_ ,=H_P"&
ML?@A_P!%D^'_ /X5%C_\=K\J_P#ARI\;_P#H:?A__P"#&^_^0Z/^'*GQO_Z&
MGX?_ /@QOO\ Y#H _53_ (:Q^"'_ $63X?\ _A46/_QVC_AK'X(?]%D^'_\
MX5%C_P#':_*O_ARI\;_^AI^'_P#X,;[_ .0Z/^'*GQO_ .AI^'__ (,;[_Y#
MH _53_AK'X(?]%D^'_\ X5%C_P#':/\ AK'X(?\ 19/A_P#^%18__':_*O\
MX<J?&_\ Z&GX?_\ @QOO_D.C_ARI\;_^AI^'_P#X,;[_ .0Z /U4_P"&L?@A
M_P!%D^'_ /X5%C_\=H_X:Q^"'_19/A__ .%18_\ QVORK_X<J?&__H:?A_\
M^#&^_P#D.C_ARI\;_P#H:?A__P"#&^_^0Z /U4_X:Q^"'_19/A__ .%18_\
MQVC_ (:Q^"'_ $63X?\ _A46/_QVORK_ .'*GQO_ .AI^'__ (,;[_Y#H_X<
MJ?&__H:?A_\ ^#&^_P#D.@#]5/\ AK'X(?\ 19/A_P#^%18__':/^&L?@A_T
M63X?_P#A46/_ ,=K\J_^'*GQO_Z&GX?_ /@QOO\ Y#H_X<J?&_\ Z&GX?_\
M@QOO_D.@#]5/^&L?@A_T63X?_P#A46/_ ,=H_P"&L?@A_P!%D^'_ /X5%C_\
M=K\J_P#ARI\;_P#H:?A__P"#&^_^0Z/^'*GQO_Z&GX?_ /@QOO\ Y#H _53_
M (:Q^"'_ $63X?\ _A46/_QVC_AK'X(?]%D^'_\ X5%C_P#':_*O_ARI\;_^
MAI^'_P#X,;[_ .0Z/^'*GQO_ .AI^'__ (,;[_Y#H _53_AK'X(?]%D^'_\
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M\/\ _P *BQ_^.U^5?_#E3XW_ /0T_#__ ,&-]_\ (='_  Y4^-__ $-/P_\
M_!C??_(= 'ZJ?\-8_!#_ *+)\/\ _P *BQ_^.T?\-8_!#_HLGP__ /"HL?\
MX[7Y5_\ #E3XW_\ 0T_#_P#\&-]_\AT?\.5/C?\ ]#3\/_\ P8WW_P AT ?J
MI_PUC\$/^BR?#_\ \*BQ_P#CM'_#6/P0_P"BR?#_ /\ "HL?_CM?E7_PY4^-
M_P#T-/P__P#!C??_ "'1_P .5/C?_P!#3\/_ /P8WW_R'0!^JG_#6/P0_P"B
MR?#_ /\ "HL?_CM'_#6/P0_Z+)\/_P#PJ+'_ ..U^5?_  Y4^-__ $-/P_\
M_!C??_(='_#E3XW_ /0T_#__ ,&-]_\ (= 'ZJ?\-8_!#_HLGP__ /"HL?\
MX[1_PUC\$/\ HLGP_P#_  J+'_X[7Y5_\.5/C?\ ]#3\/_\ P8WW_P AT?\
M#E3XW_\ 0T_#_P#\&-]_\AT ?JI_PUC\$/\ HLGP_P#_  J+'_X[1_PUC\$/
M^BR?#_\ \*BQ_P#CM?E7_P .5/C?_P!#3\/_ /P8WW_R'1_PY4^-_P#T-/P_
M_P#!C??_ "'0!^JG_#6/P0_Z+)\/_P#PJ+'_ ..T?\-8_!#_ *+)\/\ _P *
MBQ_^.U^5?_#E3XW_ /0T_#__ ,&-]_\ (='_  Y4^-__ $-/P_\ _!C??_(=
M 'ZJ?\-8_!#_ *+)\/\ _P *BQ_^.T?\-8_!#_HLGP__ /"HL?\ X[7Y5_\
M#E3XW_\ 0T_#_P#\&-]_\AT?\.5/C?\ ]#3\/_\ P8WW_P AT ?JI_PUC\$/
M^BR?#_\ \*BQ_P#CM'_#6/P0_P"BR?#_ /\ "HL?_CM?E7_PY4^-_P#T-/P_
M_P#!C??_ "'1_P .5/C?_P!#3\/_ /P8WW_R'0!^JG_#6/P0_P"BR?#_ /\
M"HL?_CM'_#6/P0_Z+)\/_P#PJ+'_ ..U^5?_  Y4^-__ $-/P_\ _!C??_(=
M'_#E3XW_ /0T_#__ ,&-]_\ (= 'ZJ?\-8_!#_HLGP__ /"HL?\ X[1_PUC\
M$/\ HLGP_P#_  J+'_X[7Y5_\.5/C?\ ]#3\/_\ P8WW_P AT?\ #E3XW_\
M0T_#_P#\&-]_\AT ?JI_PUC\$/\ HLGP_P#_  J+'_X[1_PUC\$/^BR?#_\
M\*BQ_P#CM?E7_P .5/C?_P!#3\/_ /P8WW_R'1_PY4^-_P#T-/P__P#!C??_
M "'0!^JG_#6/P0_Z+)\/_P#PJ+'_ ..T?\-8_!#_ *+)\/\ _P *BQ_^.U^5
M?_#E3XW_ /0T_#__ ,&-]_\ (='_  Y4^-__ $-/P_\ _!C??_(= 'ZJ?\-8
M_!#_ *+)\/\ _P *BQ_^.T?\-8_!#_HLGP__ /"HL?\ X[7Y5_\ #E3XW_\
M0T_#_P#\&-]_\AT?\.5/C?\ ]#3\/_\ P8WW_P AT ?JI_PUC\$/^BR?#_\
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MK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_ /A46/\ \=K\J_\ ARI\;_\
MH:?A_P#^#&^_^0Z/^'*GQO\ ^AI^'_\ X,;[_P"0Z /U4_X:Q^"'_19/A_\
M^%18_P#QVC_AK'X(?]%D^'__ (5%C_\ ':_*O_ARI\;_ /H:?A__ .#&^_\
MD.C_ (<J?&__ *&GX?\ _@QOO_D.@#]5/^&L?@A_T63X?_\ A46/_P =H_X:
MQ^"'_19/A_\ ^%18_P#QVORK_P"'*GQO_P"AI^'_ /X,;[_Y#H_X<J?&_P#Z
M&GX?_P#@QOO_ )#H _53_AK'X(?]%D^'_P#X5%C_ /':/^&L?@A_T63X?_\
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M9/A__P"%18__ !VC_AK'X(?]%D^'_P#X5%C_ /':_*O_ (<J?&__ *&GX?\
M_@QOO_D.C_ARI\;_ /H:?A__ .#&^_\ D.@#]5/^&L?@A_T63X?_ /A46/\
M\=H_X:Q^"'_19/A__P"%18__ !VORK_X<J?&_P#Z&GX?_P#@QOO_ )#H_P"'
M*GQO_P"AI^'_ /X,;[_Y#H _53_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T6
M3X?_ /A46/\ \=K\J_\ ARI\;_\ H:?A_P#^#&^_^0Z/^'*GQO\ ^AI^'_\
MX,;[_P"0Z /U4_X:Q^"'_19/A_\ ^%18_P#QVC_AK'X(?]%D^'__ (5%C_\
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M?A__ .#&^_\ D.C_ (<J?&__ *&GX?\ _@QOO_D.@#]5/^&L?@A_T63X?_\
MA46/_P =H_X:Q^"'_19/A_\ ^%18_P#QVORK_P"'*GQO_P"AI^'_ /X,;[_Y
M#H_X<J?&_P#Z&GX?_P#@QOO_ )#H _53_AK'X(?]%D^'_P#X5%C_ /':/^&L
M?@A_T63X?_\ A46/_P =K\J_^'*GQO\ ^AI^'_\ X,;[_P"0Z/\ ARI\;_\
MH:?A_P#^#&^_^0Z /U4_X:Q^"'_19/A__P"%18__ !VC_AK'X(?]%D^'_P#X
M5%C_ /':_*O_ (<J?&__ *&GX?\ _@QOO_D.C_ARI\;_ /H:?A__ .#&^_\
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M_P =K\J_^'*GQO\ ^AI^'_\ X,;[_P"0Z/\ ARI\;_\ H:?A_P#^#&^_^0Z
M/U4_X:Q^"'_19/A__P"%18__ !VC_AK'X(?]%D^'_P#X5%C_ /':_*O_ (<J
M?&__ *&GX?\ _@QOO_D.C_ARI\;_ /H:?A__ .#&^_\ D.@#]5/^&L?@A_T6
M3X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VORK_X<J?&_P#Z&GX?_P#@
MQOO_ )#H_P"'*GQO_P"AI^'_ /X,;[_Y#H _53_AK'X(?]%D^'__ (5%C_\
M':/^&L?@A_T63X?_ /A46/\ \=K\J_\ ARI\;_\ H:?A_P#^#&^_^0Z/^'*G
MQO\ ^AI^'_\ X,;[_P"0Z /U4_X:Q^"'_19/A_\ ^%18_P#QVC_AK'X(?]%D
M^'__ (5%C_\ ':_*O_ARI\;_ /H:?A__ .#&^_\ D.C_ (<J?&__ *&GX?\
M_@QOO_D.@#]5/^&L?@A_T63X?_\ A46/_P =H_X:Q^"'_19/A_\ ^%18_P#Q
MVORK_P"'*GQO_P"AI^'_ /X,;[_Y#H_X<J?&_P#Z&GX?_P#@QOO_ )#H _53
M_AK'X(?]%D^'_P#X5%C_ /':/^&L?@A_T63X?_\ A46/_P =K\J_^'*GQO\
M^AI^'_\ X,;[_P"0Z/\ ARI\;_\ H:?A_P#^#&^_^0Z /U4_X:Q^"'_19/A_
M_P"%18__ !VC_AK'X(?]%D^'_P#X5%C_ /':_*O_ (<J?&__ *&GX?\ _@QO
MO_D.C_ARI\;_ /H:?A__ .#&^_\ D.@#]5/^&L?@A_T63X?_ /A46/\ \=H_
MX:Q^"'_19/A__P"%18__ !VORK_X<J?&_P#Z&GX?_P#@QOO_ )#H_P"'*GQO
M_P"AI^'_ /X,;[_Y#H _53_AK'X(?]%D^'__ (5%C_\ ':/^&L?@A_T63X?_
M /A46/\ \=K\J_\ ARI\;_\ H:?A_P#^#&^_^0Z/^'*GQO\ ^AI^'_\ X,;[
M_P"0Z /U4_X:Q^"'_19/A_\ ^%18_P#QVC_AK'X(?]%D^'__ (5%C_\ ':_*
MO_ARI\;_ /H:?A__ .#&^_\ D.C_ (<J?&__ *&GX?\ _@QOO_D.@#]5/^&L
M?@A_T63X?_\ A46/_P =H_X:Q^"'_19/A_\ ^%18_P#QVORK_P"'*GQO_P"A
MI^'_ /X,;[_Y#H_X<J?&_P#Z&GX?_P#@QOO_ )#H _53_AK'X(?]%D^'_P#X
M5%C_ /':/^&L?@A_T63X?_\ A46/_P =K\J_^'*GQO\ ^AI^'_\ X,;[_P"0
MZ/\ ARI\;_\ H:?A_P#^#&^_^0Z /U4_X:Q^"'_19/A__P"%18__ !VC_AK'
MX(?]%D^'_P#X5%C_ /':_*O_ (<J?&__ *&GX?\ _@QOO_D.C_ARI\;_ /H:
M?A__ .#&^_\ D.@#]5/^&L?@A_T63X?_ /A46/\ \=I9?VKO@G#;^>WQ@\!^
M4=V&'B6R.X@ D#$O)&1P/45^57_#E3XW_P#0T_#_ /\ !C??_(=*O_!%/XW;
MAN\5>  N>2-0OB?_ $CH ^__ (A?\%.OV=_A_;R$>.!XENUSML_#UI)=,^/2
M3"Q?FXSGTKX)_:4_X+!>.?B-:SZ+\,-.;X?:1("CZI+(LVIRK_LD#9!D?W=S
M#J'%=YX'_P""(&IR74<GC'XGVD%N.7M]#TYI7;V$DK*%^NP_2OLWX"_\$\?@
MG^S[=VNIZ1X:;7O$5L0T>M^(9!=SHPZ,B8$4; ]&1 WO0!^9G[+/_!-?XG?M
M+>(H/%?Q$_M+PIX0NI/M5UJFJDG4]3R<GRDDRV6S_K9!CG(W]*_9SX6_"GPI
M\%O!=CX4\&:+;Z'H=F/DMX!R['K)(Q^9W..68DFNMHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME)ID5E;QZ:D(MELTB40K$%VB,)C 7;QMQC'%6Z* .#\(_ /X8^ -:CUCPO\
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M22#T9U&XCV)KL[BWBO+>6">))X)5*21R*&5U(P00>"".U244 <'X1^ ?PQ\
M:U'K'A?X<^$O#>KQJR)J&D:':VLZJPPP$D<88 C@C/-=Y110!B>,/ _AWX@Z
M++I'B?0M-\1:5)]^RU2T2XB)]=K@C/O7F>F?L8_ G1]2%_:_"3P@MR&#J9-)
MAD56 P"%92H]>!UYZ\U[/10!';V\5G;Q001)!!$H2..-0JHH&  !P !VK\Z/
M^"F4GBSX\^--'^!/@GX1OXAU]H[;4V\97-LK+86\DC#$<VW]PC-$0[LRY"%0
MK9!K]&Z* /-?V;_@U;?L^_ WP?\ #ZVN!>?V+9^7-<J"%FN'=I9W4'D*TLCD
M#L"*]*HHH S]>\/:5XJTN?3-:TRSUC39QB6SO[=)X9!UPR."#^(KR.7]B7X!
MS7QNF^$/A$2D$;5TJ)8^3G[@&W]..@KVRB@#%\*>"_#W@/2ETSPSH.F>'=-4
M[A9Z39QVL(. ,[(U Z =NU;5%% 'E_CK]E[X1_$S5Y-6\4?#?PUK6JRD&2^N
M=-C,\F#D;I  S<^I/<=#73^ ?A9X.^%>FOI_@[PMH_A>SD;=)#I-E';B1O5M
M@&X^YS74T4 %>:>-OV9_A+\2-:DUCQ/\-_"^N:O+_K=0O-*A>XEX &^3;N?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!^ /_!4?_D^SXF_]PS_ --=I7[_ %?@#_P5
M'_Y/L^)O_<,_]-=I7[_4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1D$$=17D_P ;?VL/A/\ L[/!#X_\9V6B7UPGF1:>B27-VZ\X;R859PI((#,
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MV_\ /,3QIO./FVKDXR<<''I7Q;L_#.H?"OQA;^-/^10?2+O^V#M<[;/R6,S
M("V0FXC:"V1QSB@#S#X!_MQ?"+]I3Q5J'AOP1K\]UK5G$UP+6]LI;9IX58*9
M(]X 8 LO!PV#G'6O>Z_.W_@GS\/?V4/#?QGU:Y^#OQ UWQSXT_LV9XX=8L[B
M%;.S\R-9&0M:PJS9:-222<'@#YC7D/\ P4N_;OTOQ<W@JP^"/Q4U^PO]+N=0
MBUU-#EU#2CG]PL0=BL8EP4FQ@MCGIGD _7"BO@7_ ()^_MW?#[5/@S\./ /C
M7XC:AK'Q:OKJXLY8=4M[^\N)YI;Z8VZO=-&R']TT0!,F%& 2,8'WI>7EOIUG
M/=W<\=K:P1M++/,X1(T499F8\   DD],4 345\R>)/\ @I7^S;X7UB33+KXG
M6ES<1OL>33=/O+R <=1-#"T;#_=8]:]@^$_QT\ ?'32;C4O 7BO3O$UK;.$G
M^QR'S(6(R \; .F><;@,X..E '=T4V21(8VDD941069F.  .I)KYE\5?\%*O
MV<?"'B%]&O/B1;7-S%(8Y9M-L+J\MXR._G11,C#_ '"U ';?M ?M=_#+]F.\
MT6U^(.LW&E3:Q'+)9K!8S7.]8RH?)C4XP77KZUWGPM^)OA_XR> =(\9>%KJ2
M]T#58VDM+B2%HF=5=D.48!A\RMU':ORC_P""QWCGP_\ $EO@IXD\+ZO:Z[H5
M_I^I26U]9R!XY!YEN#SV((((/((((!%?>/\ P3>_Y,E^%O\ UY7'_I7/0!]*
MT444 %%%% 'X _\ !+C_ )/L^&7_ '$__37=U^_U?@#_ ,$N/^3[/AE_W$__
M $UW=?O]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'X _\%1_^3[/B;_W#/\ TUVE?O\ 5^ /_!4?_D^SXF_]
MPS_TUVE?O]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!^ /_ #E-_P"ZS?\ N<K]_J_
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M9S^&>L_M\?M;&V\7ZU<*^LRW&LZYJ,.#*L"#)2(-D+R8XE&"$!'!"X/Z#_\
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M "1?Q]_V+^H?^DTE=K7%?&[_ )(OX^_[%_4/_2:2@#\2_P#@D_\ \GM>$/\
MKRU'_P!)):_>FOP6_P""3_\ R>UX0_Z\M1_])):_>F@#\ ?"W_*4&U_[*RW_
M *=C7[I_%G_DE?C+_L"WO_HAZ_!KQ-KMM\)?^"CVIZYKS_9].T7XG2:A=RX)
MVVZZD9&? !)_=_-BOV&_:0_:W^$?@/X(>)-1NO'>B:D=0TNXM["STB_AN[B\
MDDC9$$:(Q)&2,MPJ]R* /RU_X)#_ /)Y.F_]@:__ /0%KZ*_X+E?\@KX-_\
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M4/PU"CP)'XPLTTC9)*ZF 7$8!#2DN02"06.2* /V1_X*:?\ )CGQ/_ZXV/\
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M@>!?AAX-\1?#/QWK]CX6:;4VU?2]2U2<0VLOF1(DL+2MA(RIA5AN(W>8PZ@
M@'Z5?M"?\D"^)?\ V+.I_P#I+)7XK?\ !)__ )/:\(?]>6H_^DDM?HS^W9^V
MY\+O"'[/'C70M \;:)XG\5^(-,GTBST_1+^.[>/ST\MY9#$6$82-V<;B-Q
MSFOAS_@C=\.[_P 2?M-ZAXJ2!O[*\-Z/,9K@J2HFGQ%''GLQ7S6^B&@#VG_@
MN5_R"O@W_P!=M6_]!LZXK]@__@G+HW[2OP?T;Q[\2_%.L7.@$W%GH.@Z7<B,
M6\,=S)YI=W5MH:8S-L0#KN+$M@=K_P %RO\ D%?!O_KMJW_H-G7TK_P2K_Y,
M<\ _]=M2_P#2^XH _)?]LGX&Q?L<_M-2Z#X/UJ_>WL4M-9TF^N&7[5;D_,N7
M4 %DD0X8 < <5^VGQ<\0/XL_8S\::W*NV34O %[>LH&,&33G<_\ H5?D_P#\
M%A?^3P'_ .Q?L?YRU^I/BS_DP76?^R9S?^FIJ /S+_X(P_\ )U^M_P#8I7G_
M *56E,_X*A_LA^!OV9;CP5JWA";5I;KQ1=ZE+?C4KE)E#(8&78%1=O,S]<]J
M?_P1A_Y.OUO_ +%*\_\ 2JTKW'_@N/9RR>'OA!=!"8(KK5(G?!P&9+8J,^X1
MORH O?\ !-_]A'X;>+/A'\+/C=?3ZX/&45[<7ZQQ7B+:>9;7\\4?[ORR<;8E
MR-W)STJK_P %I/COK.@Z;X/^%FDW<EE8:Q!)JVL>4Q4W,:OL@B)'\&Y96([E
M4]*]I_X)6_%3PE=?L@^!_"__  D>E1^(=-N;ZUGTN2\C6Y#R7T\T?[LD,=RR
MKC .?SKY<_X+=>![ZW^)'PZ\8^2S:9>:3+I!F4$A)89FEVMZ96<D>NQO2@#(
M_99^#?[%D/P=T>_^+7C;3]7\;ZI;_:+NVFU6ZM5TUFY6)%@*Y95QN+ELMG@#
MBOG[4/'FA?L=?M?1^(_@KXO_ .$K\(:?<1303K*6%U:2*#/:3$ ;L99<X[*P
MP0*^U_V*/V+_ -E_]I;X"^'M??1I[_Q5;6Z6NOV\>M7,<D-XHP[-&)!M5\;U
MP-N&P.A \F^.%K^P[\%?BAJ7@C_A7'BKQ=>:>8XYKS0==>6W\UE!,08W )92
M0I '!R.H- 'TQ_P6 ^.&H^!?V>="\,Z#>/;'QK>M#<W,+8,EC%&'DC!'.'9X
M0?5=RGAJ^=/^"=/_  3F\%?M!?"FZ^(?Q%FU&YM;N\EL]+TW3[GR$\N/"O-(
MX&XDON4*, ;,G=NP/3O^"SW@>;_A2GPEURTLY(-.T6^ETUXW;<T'GVZ&-6.3
MT^S$9]<<\UW?_!(GXX^%=2_9IC\#W.M65CXB\.ZA=;["ZG2.22WFD,R3("?F
M7=(ZDCH5YQD9 /@/_@H9^R4G[)7Q$T?2=$UB[U+P/K44U_I-O?3;Y;20%%N(
MV  4_P#++#@ LNT')3)_63_@F]_R9+\+?^O*X_\ 2N>OSJ_X+ ?';P=\6?BQ
MX2T#PGJL.N/X7M+F+4+VS=9+833-&?*2120S*(_FQP"V,Y# ?HK_ ,$WO^3)
M?A;_ ->5Q_Z5ST ?2M%%% !1110!^ /_  2X_P"3[/AE_P!Q/_TUW=?O]7X
M_P#!+C_D^SX9?]Q/_P!-=W7[_4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!^ /_!4?_D^SXF_]PS_ --=I7[_
M %?@#_P5'_Y/L^)O_<,_]-=I7[_4 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX U3_@E+_:7[4$OQA_X6CY>_Q:/%']B_\(]G&+L7'D>=]J]MN_9[[>U??]%
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M^1Y;LV[/GR;L[NF!C%>?_M5?\$J_^&FOCEK_ ,1?^%G_ /"-_P!JI;)_9O\
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M3C_A,?\ A(DM$V_V3]A^S^09CG_7R[MWG>V-O?/'0?MN?L>?\-D>"_#V@?\
M"7?\(A_9.H-??:/[-^V^;F-DV;?.CV_>SG)Z=*^D** /#_V/?V9_^&3_ (/C
MP+_PD?\ PE.-0GOOM_V'['_K HV>7YDG3;UW<YZ5\W?M4?\ !)/PU\;/'6I>
M,_!7B;_A"-6U25KG4-/FL_M-G/.V2\J8=6B9F.6^\"22 *_0&B@#\Y/A1_P1
MG\)>$_#_ (F_X2WQ:?%'B+4=+N;#3+A=.\NTTJ:6)D6Z\HRDSR(6#*"R $=,
MX8>H_L2_\$[?^&.?'VN^)O\ A8'_  EW]J:9_9WV7^Q?L7E?O4DW[OM$F?N8
MQ@=>M?95% 'YH_\ !9+X1^!=5\,Z-\0M1\8PZ)XXTZV73K'06"RR:O 9BV$3
M<&3RS)(QDP5P=IY*U[Q_P2U^'^K?#_\ 8Z\+KK,$EK<:Q<W&L0V\H(9()6'E
M$@C@,BK(/9Q7I?Q2_8Z^%?QI^+&C_$+QKX>_M_6M*LDL;>WN96^R%$E>1&DB
M&!(0TC<.2I!Y4U[3'&D,:QQJJ(H"JJC  '0 4 .K$\;^&_\ A,O!>OZ!]H^Q
M_P!JZ?<6/VC9O\KS8V3?MR-V-V<9&<=16W10!\%?LG_\$L_^&7_C;I'Q"_X6
M=_PDO]GPW$/]F_V!]D\SS86CSYGVE\8W9^Z<XQQ7WK110!\1?MB_\$O_  W^
MT]XXD\;Z)XFD\$^*+I%34";$7=M>[%"HY0.A23 4%@2"%'RYR:XOX!_\$<_!
MWP[UQ]9\>>)O^$\N8E<6>GBP^SV4<A&%DE0R,9MIY"DJOJ&K]$:* /A7]D/_
M ()@_P##*OQDMO'O_"RO^$H\FRGL_P"S_P"P?LF?-4#=YGVF3ICIMY]J]%_;
ME_8?_P"&T+7P;#_PFG_"'?\ ".O=ON_LK[=]H\\0C'^NBV[?)]\[NV.?J6B@
M#R3]E7X"_P##,OP-T#X=?V[_ ,))_93W+_VE]C^R^;YMQ)-CR_,?;CS-OWCG
M&>,XK _;/_99_P"&O/A/9>"O^$G_ .$3^S:M#JGV[^S_ +;N\N*:/R]GFQXS
MYN=V[^'ISQ[U10!\]?L3_LE_\,=_#;6?"?\ PE7_  EW]HZL^J?;/[.^Q>7N
MABB\O9YLF?\ 59W9'WL8XR?&/VK/^"5'AS]HCXJ3>.] \8'X?:A?+OU.WAT@
M7D=U< _\? Q/%Y;D?>Z[B-W!))^[** /,/#7P9FU#X%Q?#?XI:S!\3HY+(Z?
M?ZC<6)M&OHA]QI$\V0B4 +^\#Y+*&X/-? OQ$_X(B6=UK%Q<^!_B6^GZ:Y9H
MM/UO3O/>+GA?.C==PQQG9GCOFOU)HH _-[X(_P#!&#PEX-\36FL?$'QC-XVM
M[6194T6TL?L=M*000)F+NSH>ZKLSZD9!_1'4-2TOPKHLEW?W5GH^DV48+SW$
MB0001C &6)"JHX'I6A7G_P ?OA3_ ,+R^#?BSP%_:G]B?V]9&S_M#[/]H\C+
M [O+WKNZ=-PH _*O_@L5\3/A?\2/&7@)O!VOZ?XD\4Z?:7,&IW>CW,=S;I;%
MU,,3RH2N]7\\[0<@.=V,K7U+_P $?O@FWP[_ &<;OQE?6QAU7QI>FY1F7#?8
MH-T< (Z\N9W![K(IKS_X?_\ !$?PKHOB*UO/%WQ*U#Q1I4,BR/IMCI*Z<9@#
MG8TAGE(4]#M .,X(/(_2/1M'L?#ND6.E:9:0V&FV,"6UM:VZ!(X8D4*B*!T
M   ]J / _P!O3X2^"?C%^SIK&E^._%L'@;2[&>/4K?7KDJ8[:YC5PF4)'F[E
M=UV*=QW?+SBOBO\ X(F_#S4HO$'Q,\:A)1X>\F'1K:YD0H+F;>97P.1E%$>>
M>/-'6OT.^/\ ^SIX*_:8\)Z=X;\=6=Q>Z38ZC'J:16LY@9I$1TVEU^8*5D8'
M:0?<5UW@/P#X=^&'A33_  SX4T>UT+0K!/+M[&S3:B#.2?4L222Q))))))-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?@#_ ,%1_P#D
M^SXF_P#<,_\ 37:5^_U?@#_P5'_Y/L^)O_<,_P#37:5^_P!0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!^ /_.4W_NLW_N<K]_J_ 'QL/^$5_P""GM[<,=OD?%5+W)_V
MM467/_CU?O\ 4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5+[5['2]@
MO;VWM"^=OGRJF['7&3SU%6Z_*#_@N5_R%?@W_P!<=6_]"LZ /U9M+RWU" 36
ML\=S"W DA<,IQUY%-O=0M=-A$MW<PVL1.T/-($7/ID]^*^/_ /@E?J%KI/["
MOAF^OKB*SLK6XU.>>XG<)'%&MU*S.S'@  $DGH!7YY_M@?M$>*?^"@W[1&B^
M!?A];7%YX9MKPV/A_3UR@NY#D27TP_A!4$Y;_5QJ2<$OD _<FQU>QU3>+*]M
M[LIC=Y$JOMSTS@\=#44/B#2[C5IM*BU*SEU2%=\MDDZ&9%XY9,[@.1R1WKR3
M]DG]E_0/V4?A+9>%-*V7>K38N=8U;;A[ZZ(P6]0B_=1>P'J6)^+_ (.?\$O?
MBA\/?VOK#XC:CXYTNY\.Z?K<FKG4(9YFU*_5G9C%)&4"@R!BLAWD89L;NE '
MZ=T444 %%,CF28$QNKA6*DJ<X(."/J#3Z "BBO*?VA/VGOA]^S!X9M=9\>:P
MUBMX[1V5C;1&:ZNV4 L(XQV4,N6)"C<N3DC(!ZM17F?[._Q_\/?M,?#&S\=>
M%[/4[#2+J>:W2'5XHXYPT;E6)6.1UQD<?-^5>C75Y!8P^;<SQV\60-\KA5R>
M@R: &WNH6NFPB6[N8;6(G:'FD"+GTR>_%)8ZE::G&TEG=0W<:G:7@D#@'TR#
MUKX3_P""SW_)J&B?]C;9_P#I+=UE?\$3_P#DVWQE_P!C;-_Z1VM 'Z%445 M
M];27;VJW$37,:[GA#@NH/<KU Y% $]%%% !113(IDN(UDB=9(VY#*<@_C0 ^
MBF22I#&TDCK'&HRS,< #U)I] &)J/CCPYH^IKIU_K^EV6H-M"VEQ>QQRG=]W
M"%L\]N.:VZ_,7_@M)\#TN/#GA#XO:9$R:CITZZ)J4D7!,+[Y+>0GMLD#KG_I
MLOI7U_\ L-_'T_M'?LV^%O%-U)YFN6\9TO6"2"3>0@*[G_KHI27';S * />Z
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ***9-,MO#)*YPB*68^P&: /P$
M_P""7'_)]GPR_P"XG_Z:[NOW^K\!_P#@EK;M<_MU?#N1%VI"NIR%1DX!TZY7
M^;"OWXH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7_R=-X6_[$RU_P#2Z^K[B\4> ?"7Q)_X)>^$M&\:^(+;PIHO_"!Z'<#7+O\
MU=E/':V[PN1U;+A4VK\S!RJ\D4 ?"?[)O[(7BO\ X*+?\)/\0OB3\2M6%E8W
MQL(YI!]JGFN"BR2*@=@D,:J\?RJ,'=@!0O/COQB^%2?L;_M3:7X0\<+'\2/"
M&A7$%ZEG=^;%#=V,V&?$8D_=O][@,5+H,[EX/I/[$GQF_:&_9U\.ZY-\-_A?
MJGQ,\!ZQ>.5FM=$OKBV>YC!C,T$D:!@"%4,&7^$ A6!KO?!7[&OQU_;@_:+'
MQ'^-/AR;P5X:GGAEU".^A:SD>VC "V=M;L?-7*@+O?&,LQ+-\I /T9^+7BSP
M?^Q/^R_XC\0^%/#^GZ7H^B6IDT[2;5/+AENIG5(@<<D-(ZECUQN-?CG\'_@_
M\8?^"E'Q:UJ[U'Q0;N6QC%SJ.LZS*YM[)9&(CBAB087<5;;&@50$)XQS^G7_
M  5HT^XNOV*_$;VX;RK74=/EG"C@1_:%09]MSI^E>"_\$/-7L&\-_%?2P\:Z
MFMW87+)GYVA*3*"!W 8'_OH>HH ^8?VPO@3\:?V2_A?IGPX\3^(H_%OPLU+4
MX]1TR\@61H[2\BBD0Q /S 621CL!*MMR.0U?:W_!$_\ Y-M\9?\ 8VS?^D=K
M5K_@M)JUE;_LQ^&].ENX8]0NO%%O-!:LX$DB1VUR'=5ZE5+H">@WKZBJO_!$
M_P#Y-M\9?]C;-_Z1VM 'SG_P40_;8\>_%3XW:A\'?AMJ6H:=X?TV_&BR0Z-*
MR7.LW^[RW1F0AC&)"8UC!PQ4L<Y4+0\3?\$>?BUX.^'D_BNP\5:1J7B>PMC?
M/H>GB83ED4.4AFQ\\OW@!A02!@\UXO\ "^Z@\%?\%&-*D\3LMLEC\1'2[ENF
M$:Q2?;F42.3P '(8D]A7] ]Y>0:?:3W5U-';6T"-++-*P5(T499F)X  !))H
M _+/_@E?^W5XI\5>-HO@[\0]7N-?^V022:!JVH2F2ZCDC4N]M)(WS2*4#,I8
MDJ4V\@J%Y+_@MY_R53X:?]@6X_\ 1XKYV_8E4^)/V_O \^A1L+63Q%<7D2HI
M.VV"S2-GT'E@U]$_\%O/^2J?#3_L"W'_ */% '+_  G_ &8/VD_VW_@OX86X
M\36GA+X9:)IT>FZ'I^HS30P7RPKL$ODQJQDRRD&63W" @8KP+P+\2OBI_P $
M_P#]H/5-+M;KR]7T6[:TU/11</)I^HJ1\NY01N5E975L!AD=#D5^TG[ ?_)F
MWPG_ .P,G_H;U^0/_!1[_D_CXA_]?NG?^D-K0![SX\_X)^?M6?M2:-<_$'XA
M>*-,77+B$W=EX5U*\E22 8)$"1+&8;=B, +NZGYRIW&N7_X)+_M%>*?!_P"T
M-IWPOOM3NKKPGXCAN85TZZE9H[*ZBA:998U/W21"T9 P#O!/W17[6U^ /[!7
M_*03P-_V&K[_ -)[B@#]A_V[/!D/CS]C_P"+&FS $0:%/J:9&?GM0+I<>^80
M/QKX>_X(?^.KKSOBAX,EFW606TU>WA_N2$O%,P^H$ _X"*_0O]IZ\CT_]FOX
ML7,H5HX?"6K.RMT;%G+Q^/2OS _X(D6$TGQN^(%ZK,+>'PZL+KV+/<QE3]<1
MM^9H _8RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N!_: \5?\(-\"?B)
MXAWA&TOP]?W:$_WTMW91]2P _&N^KXN_X*U?%)?A_P#LDZCHL,XCU#Q9?V^E
M1JI^?RE;SIF ]-L00_\ 70>M 'P7_P $=_"[:[^UVVH;?DT7P_>WN[L"S10
M?E.?R-?N+7Y>_P#!$7X9FW\._$?X@SQ<W=S!H=G(1@@1KYT^/4$RP?\ ?%?J
M%0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% 'X _P#!4?\ Y/L^)O\ W#/_ $UVE?O]7X _\%1_^3[/B;_W#/\
MTUVE?O\ 4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 ?*?_!3+X'R?&S]E+Q$+"U-UKOA
MMUUZQ1%R[>2")T'<YA:4A1U95]J^+_\ @B_\?(/#OC?Q/\)]3N?*A\0*-5TE
M6.%-U$F)XQ_M/$%;Z6Y]J_7J2-)HVCD571@596&00>H(K\!?VO?@QK_[#/[6
M$6J>%B^FZ8;U?$'A:]1<HD8DW>0>Q\ILQE3U0J3P] '[^45Y;^S3\?=$_:6^
M#NA>.=$=$-W'Y5_9*^YK*[4 2P-WX)R">JLK=&KU*@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "OSX_X*L?LK_%']I+4/AI)\.?#'_"1)H\6HK?'^T+6U\DRF
MV,?^OE3=GRW^[G&.<9%?H/10!\W_ /!/?X1^+/@=^RWX<\(>-M)_L7Q%:75[
M)-9_:8;C8LEP[H=\3LARK \'OS7S+_P4D_X)RZ_\8/&%I\1?A'HL-_XBU!A!
MKNCK<P6HG8*=EVK2NB;L (XSEOD8#.\G]*J* /EG_@G]8_'#P;\*AX'^-/A2
M;2Y]!5(='UE]3M+O[3:XPL$@AF=@T6  Q !3:.J\_$WP%_8)^.W@O]M70O'N
ML^!OL?A.V\33ZA+J']KV$FV!GD*OY:SESD,. N>>E?K_ $4 ?#__  5._9P^
M(O[1W@'P/IOP[\._\)#>Z;J<UQ=1?;;:U\N-H@H.9Y$!Y[ DUZ!_P3D^#/C'
MX#?LTV7A3QUH_P#8>OQZG=W#6GVJ&XQ&[ J=\+NO..F<U]044 ?F!_P5 _8S
M^,7[1/Q]T#Q)\/?!_P#PD&BVOAFWT^:Y_M.SMMLZW5W(R;9ID8X66,Y Q\W7
M(./6/VJO#?A3P3_P31\+^#_BWJ%UX7OK+P_HVF11Z>B7=RNK6]M'B%$#A)<&
M*0-\X7:&(8<&ON>OF_\ ;N_9-D_:Z^#T/AW3]5BT;Q#I=Z-1TVXN@3;O($9&
MBEV@D*RN?F )! .",@@'Y5_LJ_"_]KOQY\-S=_![7/$>F^"8+EX8%3Q +&U,
MF29/)C>0#[Q.XJ,%B>2<X[#QQ^TE^VU^Q[K&D7'Q$U.]CMK\LT%OKBV>HVEU
MMV[D\V$L5(X^59%8 Y[UW?PA\._MU_L>>'9?!OAKP);^(/#2SO+:PR+;ZA#$
MSDEVB:.99%5B"2K\9). 6Y7XB?LP_ME?MR^(]'3XHV.E^"_#NFLS6ZW,L$5M
M;EMHD9887DF>0@#&_CL&7)H ^]OACXN\/?M[_LAQWFL::VG:;XNT^XL-0L8Y
M=SVDZ2-$S(V/X9(Q(A(Z;,CJ*_,4_L&_M7?LL_%*;4?A=#>:CC=!;>(/#MY
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MP3$^G$1_,)-0D8&YV@?W=L46/[T3>M?I_P#MO_M16/[*_P #]3\0)+"_BK4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /P!_X*C_\ )]GQ
M-_[AG_IKM*_?ZOP!_P""H_\ R?9\3?\ N&?^FNTK]_J "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ KY;_;&_8!\#_M8:?)J9"^&?'\,6RU\0VT>?- 'RQW*#'FI
MV#<,O&#C*GZDHH _GMUKPQ^T#_P3D^)J7:R7_A:>5]D6HV;>?I6K1KSM.1LE
M&.=C@.N<X4X-??O[.?\ P6-\$>-([;2OBOI;>!]7*A3J]BKW.FRMZE0#+#D]
MB' ZEA7W[XM\':%X^T"ZT/Q)H]CKVCW2[9K'4;=9X9/3*L",CL>U?GW\?/\
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M /!=??\ R90!^U-%?BM_P^K^-_\ T*WP_P#_  77W_R91_P^K^-__0K?#_\
M\%U]_P#)E '[4T5^*W_#ZOXW_P#0K?#_ /\ !=??_)E'_#ZOXW_]"M\/_P#P
M77W_ ,F4 ?M317XK?\/J_C?_ -"M\/\ _P %U]_\F4?\/J_C?_T*WP__ /!=
M??\ R90!^U-%?BM_P^K^-_\ T*WP_P#_  77W_R91_P^K^-__0K?#_\ \%U]
M_P#)E '[4T5^*W_#ZOXW_P#0K?#_ /\ !=??_)E'_#ZOXW_]"M\/_P#P77W_
M ,F4 ?M317XK?\/J_C?_ -"M\/\ _P %U]_\F4?\/J_C?_T*WP__ /!=??\
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M -"M\/\ _P %U]_\F4?\/J_C?_T*WP__ /!=??\ R90!^U-%?BM_P^K^-_\
MT*WP_P#_  77W_R91_P^K^-__0K?#_\ \%U]_P#)E '[4T5^*W_#ZOXW_P#0
MK?#_ /\ !=??_)E'_#ZOXW_]"M\/_P#P77W_ ,F4 ?M317XK?\/J_C?_ -"M
M\/\ _P %U]_\F4?\/J_C?_T*WP__ /!=??\ R90!^U-%?BM_P^K^-_\ T*WP
M_P#_  77W_R91_P^K^-__0K?#_\ \%U]_P#)E '[4T5^*W_#ZOXW_P#0K?#_
M /\ !=??_)E'_#ZOXW_]"M\/_P#P77W_ ,F4 ?M317XK?\/J_C?_ -"M\/\
M_P %U]_\F4?\/J_C?_T*WP__ /!=??\ R90!^U-%?BM_P^K^-_\ T*WP_P#_
M  77W_R91_P^K^-__0K?#_\ \%U]_P#)E '[4T5^*W_#ZOXW_P#0K?#_ /\
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MWI5KI>DV%KI>FVJ"*WL[*%8884'1410 H]@*NT %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'X _
M\%1_^3[/B;_W#/\ TUVE?O\ 5^ /_!4?_D^SXF_]PS_TUVE?O]0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P#C5>JT4 >5?\,G?!#_ *(W\/\ _P )>Q_^-4?\,G?!#_HC?P__ /"7L?\
MXU7JM% 'E7_#)WP0_P"B-_#_ /\ "7L?_C5'_#)WP0_Z(W\/_P#PE['_ .-5
MZK10!Y5_PR=\$/\ HC?P_P#_  E['_XU1_PR=\$/^B-_#_\ \)>Q_P#C5>JT
M4 >5?\,G?!#_ *(W\/\ _P )>Q_^-4?\,G?!#_HC?P__ /"7L?\ XU7JM% '
ME7_#)WP0_P"B-_#_ /\ "7L?_C5'_#)WP0_Z(W\/_P#PE['_ .-5ZK10!Y5_
MPR=\$/\ HC?P_P#_  E['_XU1_PR=\$/^B-_#_\ \)>Q_P#C5>JT4 >5?\,G
M?!#_ *(W\/\ _P )>Q_^-4?\,G?!#_HC?P__ /"7L?\ XU7JM% 'E7_#)WP0
M_P"B-_#_ /\ "7L?_C5'_#)WP0_Z(W\/_P#PE['_ .-5ZK10!Y5_PR=\$/\
MHC?P_P#_  E['_XU1_PR=\$/^B-_#_\ \)>Q_P#C5>JT4 >5?\,G?!#_ *(W
M\/\ _P )>Q_^-4?\,G?!#_HC?P__ /"7L?\ XU7JM% 'E7_#)WP0_P"B-_#_
M /\ "7L?_C5'_#)WP0_Z(W\/_P#PE['_ .-5ZK10!Y5_PR=\$/\ HC?P_P#_
M  E['_XU1_PR=\$/^B-_#_\ \)>Q_P#C5>JT4 >5?\,G?!#_ *(W\/\ _P )
M>Q_^-4?\,G?!#_HC?P__ /"7L?\ XU7JM% 'E7_#)WP0_P"B-_#_ /\ "7L?
M_C5'_#)WP0_Z(W\/_P#PE['_ .-5ZK10!Y5_PR=\$/\ HC?P_P#_  E['_XU
M1_PR=\$/^B-_#_\ \)>Q_P#C5>JT4 >5?\,G?!#_ *(W\/\ _P )>Q_^-4?\
M,G?!#_HC?P__ /"7L?\ XU7JM% 'E7_#)WP0_P"B-_#_ /\ "7L?_C5'_#)W
MP0_Z(W\/_P#PE['_ .-5ZK10!Y5_PR=\$/\ HC?P_P#_  E['_XU1_PR=\$/
M^B-_#_\ \)>Q_P#C5>JT4 >5?\,G?!#_ *(W\/\ _P )>Q_^-4?\,G?!#_HC
M?P__ /"7L?\ XU7JM% 'E7_#)WP0_P"B-_#_ /\ "7L?_C5'_#)WP0_Z(W\/
M_P#PE['_ .-5ZK10!Y5_PR=\$/\ HC?P_P#_  E['_XU1_PR=\$/^B-_#_\
M\)>Q_P#C5>JT4 >5?\,G?!#_ *(W\/\ _P )>Q_^-4?\,G?!#_HC?P__ /"7
ML?\ XU7JM% 'E7_#)WP0_P"B-_#_ /\ "7L?_C5'_#)WP0_Z(W\/_P#PE['_
M .-5ZK10!Y5_PR=\$/\ HC?P_P#_  E['_XU1_PR=\$/^B-_#_\ \)>Q_P#C
M5>JT4 >5?\,G?!#_ *(W\/\ _P )>Q_^-4?\,G?!#_HC?P__ /"7L?\ XU7J
MM% 'E7_#)WP0_P"B-_#_ /\ "7L?_C5'_#)WP0_Z(W\/_P#PE['_ .-5ZK10
M!Y5_PR=\$/\ HC?P_P#_  E['_XU1_PR=\$/^B-_#_\ \)>Q_P#C5>JT4 >5
M?\,G?!#_ *(W\/\ _P )>Q_^-4?\,G?!#_HC?P__ /"7L?\ XU7JM% 'E7_#
M)WP0_P"B-_#_ /\ "7L?_C5'_#)WP0_Z(W\/_P#PE['_ .-5ZK10!Y5_PR=\
M$/\ HC?P_P#_  E['_XU1_PR=\$/^B-_#_\ \)>Q_P#C5>JT4 >5?\,G?!#_
M *(W\/\ _P )>Q_^-4?\,G?!#_HC?P__ /"7L?\ XU7JM% 'E7_#)WP0_P"B
M-_#_ /\ "7L?_C5'_#)WP0_Z(W\/_P#PE['_ .-5ZK10!Y5_PR=\$/\ HC?P
M_P#_  E['_XU1_PR=\$/^B-_#_\ \)>Q_P#C5>JT4 >5?\,G?!#_ *(W\/\
M_P )>Q_^-4?\,G?!#_HC?P__ /"7L?\ XU7JM% 'E7_#)WP0_P"B-_#_ /\
M"7L?_C5'_#)WP0_Z(W\/_P#PE['_ .-5ZK10!Y5_PR=\$/\ HC?P_P#_  E[
M'_XU1_PR=\$/^B-_#_\ \)>Q_P#C5>JT4 >5?\,G?!#_ *(W\/\ _P )>Q_^
M-4?\,G?!#_HC?P__ /"7L?\ XU7JM% 'E7_#)WP0_P"B-_#_ /\ "7L?_C5'
M_#)WP0_Z(W\/_P#PE['_ .-5ZK10!YMIO[,_P@T>0R:?\*?!%BY():V\.V<9
M)'0Y$8Z5WVF:38Z+:+:Z=96]A:K]V&UB6-!P!PJ@#H!^56Z* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /P!_P""H_\ R?9\3?\ N&?^FNTK]_J_ '_@J/\ \GV?
M$W_N&?\ IKM*_?Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***R?%?BS1
M? OAV^U[Q#JEKHNC6,9FN;Z]E$<42CN6/Y8[D@"@#6KS/XR?M*?#+]G^Q6X\
M>^,=.T!Y$\R*SD<RW<R],I @:1AGC(7'O7YH?M=?\%>-9\3S7WA?X*+)H6C<
MQ2>*[F/%[<#D$V\;#]RI[,P+]"!&17B7P)_X)V?'#]JC4%\5:[Y_AS1=287$
MWB7Q5)))<W@;K)'$29921@AGVJPZ/0!]<?%'_@MIX5TN2>V^'_@#4M>8$JE_
MKETME%_O")!(S#V)0_3I7SKXD_X+*?'76)/^)=I_A+08@>!:Z=+*Q'/4RS,#
MU[ =![Y^U_A-_P $@_@CX%MH)/%*ZI\0=37#/)J%RUI;;O\ 9AA*D#V=WKZ9
M\)_LT_"7P+&BZ!\-/"FELH \Z#1[?S3CIF0IN/XF@#\5;[_@JG^TO>;/*\?6
M]EMSGR-"T\[OKO@;],=:J_\ #T;]IW_HIG_E TO_ .1J_?.QTBQTO>;*RM[0
MOC=Y$2INQTS@<]35N@#\ ?\ AZ-^T[_T4S_R@:7_ /(U'_#T;]IW_HIG_E T
MO_Y&K]_J* /P!_X>C?M._P#13/\ R@:7_P#(U'_#T;]IW_HIG_E TO\ ^1J_
M?ZB@#\ ?^'HW[3O_ $4S_P H&E__ "-1_P /1OVG?^BF?^4#2_\ Y&K]_J*
M/P!_X>C?M._]%,_\H&E__(U'_#T;]IW_ **9_P"4#2__ )&K]_J* /P!_P"'
MHW[3O_13/_*!I?\ \C4?\/1OVG?^BF?^4#2__D:OW^HH _ '_AZ-^T[_ -%,
M_P#*!I?_ ,C4?\/1OVG?^BF?^4#2_P#Y&K]_J* /P!_X>C?M._\ 13/_ "@:
M7_\ (U'_  ]&_:=_Z*9_Y0-+_P#D:OW^HH _ '_AZ-^T[_T4S_R@:7_\C4?\
M/1OVG?\ HIG_ )0-+_\ D:OW^HH _ '_ (>C?M._]%,_\H&E_P#R-1_P]&_:
M=_Z*9_Y0-+_^1J_?ZB@#\ ?^'HW[3O\ T4S_ ,H&E_\ R-1_P]&_:=_Z*9_Y
M0-+_ /D:OW^HH _ '_AZ-^T[_P!%,_\ *!I?_P C4?\ #T;]IW_HIG_E TO_
M .1J_?ZB@#\ ?^'HW[3O_13/_*!I?_R-1_P]&_:=_P"BF?\ E TO_P"1J_?Z
MB@#\ ?\ AZ-^T[_T4S_R@:7_ /(U'_#T;]IW_HIG_E TO_Y&K]_J* /P!_X>
MC?M._P#13/\ R@:7_P#(U'_#T;]IW_HIG_E TO\ ^1J_?ZB@#\ ?^'HW[3O_
M $4S_P H&E__ "-1_P /1OVG?^BF?^4#2_\ Y&K]_J* /P!_X>C?M._]%,_\
MH&E__(U'_#T;]IW_ **9_P"4#2__ )&K]_J* /P!_P"'HW[3O_13/_*!I?\
M\C4?\/1OVG?^BF?^4#2__D:OW^HH _ '_AZ-^T[_ -%,_P#*!I?_ ,C4?\/1
MOVG?^BF?^4#2_P#Y&K]_J* /P!_X>C?M._\ 13/_ "@:7_\ (U'_  ]&_:=_
MZ*9_Y0-+_P#D:OW^HH _ '_AZ-^T[_T4S_R@:7_\C4?\/1OVG?\ HIG_ )0-
M+_\ D:OW^HH _ '_ (>C?M._]%,_\H&E_P#R-1_P]&_:=_Z*9_Y0-+_^1J_?
MZB@#\ ?^'HW[3O\ T4S_ ,H&E_\ R-1_P]&_:=_Z*9_Y0-+_ /D:OW^HH _
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M:OW^HH _ '_AZ-^T[_T4S_R@:7_\C4?\/1OVG?\ HIG_ )0-+_\ D:OW^HH
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M\H&E_P#R-1_P]&_:=_Z*9_Y0-+_^1J_?ZB@#\ ?^'HW[3O\ T4S_ ,H&E_\
MR-1_P]&_:=_Z*9_Y0-+_ /D:OW^HH _ '_AZ-^T[_P!%,_\ *!I?_P C4?\
M#T;]IW_HIG_E TO_ .1J_?ZB@#\ ?^'HW[3O_13/_*!I?_R-1_P]&_:=_P"B
MF?\ E TO_P"1J_?ZB@#\ ?\ AZ-^T[_T4S_R@:7_ /(U'_#T;]IW_HIG_E T
MO_Y&K]_J* /P!_X>C?M._P#13/\ R@:7_P#(U'_#T;]IW_HIG_E TO\ ^1J_
M?ZB@#\ ?^'HW[3O_ $4S_P H&E__ "-1_P /1OVG?^BF?^4#2_\ Y&K]_J*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %?S[Z_"/V@_\ @H]=6MQ_IECKGQ#^
MRMN^;=9)>"/\A GZ5_017X _\$]6'BS]O[P#<D;_ +1J>H7W3^[:7,N>WI0!
M^_U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !7XM_\%HO!,6A_M&^&O$4$7EKKN@1B9L??F@ED0G_ +]M"/PK
M]I*_*C_@N9;(LWP7N 0)6768R.Y -D1V[;C^= 'WE^QKXN?QQ^RI\*=7EE,]
MQ)X>M()I6.2\D48A=C[EHR3[U[+7RW_P3#NGO/V&?AC(_P!Y8]0CZ]EU&Z4?
MH!7U)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!117XE:?^T%\4I/^"E;^%V^)/B]O#7_"U)=._L8Z[=&S^RC5600>3YFSR]GR
M[,;<<8Q0!^VM%%% !17Y.?MS?\%4O$MCXVU7P!\&;R'3++3)VM+WQ2B)<374
MR_*Z6P8%416W+YF"6(RI4 %O$]%_9Q_;F^)&DQ>*$?Q]*LB^;"VJ^*_LET01
MVAFN5D7@]"HXZ4 ?N?17X;_";_@H9^T!^RG\0O\ A&OB?)K/B?3K.8+J6@^*
M]QU"-6YWQ7$@,F<$%=Q9",8'.:_:/X;_ !$T+XL^!-$\7^&;U;_0]8MENK:9
M>NT]58?PNI!5EZAE(/2@#I:*^ /%/_!5K_A&OVFKKX1?\*N^T^3XF7PY_;'_
M  D.W.;@0^=Y/V4^N[9O]MW>OO\ H **_%/XB_'_ .*%C_P4H?PQ;?$CQ=;^
M&O\ A8=G9?V-%KMTMG]G:\B5H?)$FS85)!7&""1BOVLH **** "BBB@ HHHH
M **** "BOR<_;F_X*I>);'QMJO@#X,WD.F66F3M:7OBE$2XFNIE^5TM@P*HB
MMN7S,$L1E2H +>)Z+^SC^W-\2-)B\4(_CZ59%\V%M5\5_9+H@CM#-<K(O!Z%
M1QTH _<^BOPW^$W_  4,_: _93^(7_"-?$^36?$^G6<P74M!\5[CJ$:MSOBN
M) 9,X(*[BR$8P.<U^T?PW^(FA?%GP)HGB_PS>K?Z'K%LMU;3+UVGJK#^%U(*
MLO4,I!Z4 =+1110 4444 %%%% !1110 4444 %%%% !17P!\!?\ @JU_PN_]
MH+0OAA_PJ[^Q?[4O9[/^U?\ A(?/\ORXY'W>5]E7.?+QC<,9Z\5]_P! !17Y
M9_LX?!7]LG0?VQ;#6/&VK:])X7BU":76+ZZUL3:7=VI##;%!YA!#?+L0(#'\
MI(3;Q^IE !1110 4444 %%<M\1OBEX1^$/AQ]>\9^(M/\-:0K"/[5J$XC#N>
MB(.KL<'Y5!/!XXH^&?Q/\,?&+P;9>*_!VJIK?AZ\:1+>^CBDC60QR-&^ ZJW
M#(PZ=N* .IHKG?B-XYT[X8^ ?$?B[5M_]F:%I\^HW(C&7:.*,N0H[DA<#W(K
M\1-<_:P_::_;A^*[^'/ NK:QIHO&DDM/#GAF\^PPVUNISF:<%"P (R\C8)(
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MQIOP9O+NU\3?VC#)=QZ?>"TNKBR"R"2.*4LN&WF)B-PRJL.<X(!](T5\B?\
M!-GP+\;? OPEUNV^-%UJ;W-QJ(ETBTUJ^%W=P0[!O+/N8JK-T0MD$,<#=S]=
MT %%%% !1110 4444 %?E7_P7._YHG_W&_\ VPK]5*_*O_@N=_S1/_N-_P#M
MA0!]5?\ !+C_ ),3^&7_ '$__3I=U]55\J_\$N/^3$_AE_W$_P#TZ7=?55 !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7X _\$N/^3[/
MAE_W$_\ TUW=?O\ 5^ /_!+C_D^SX9?]Q/\ ]-=W0!^_U%%% 'Q__P %8/\
MDR7Q?_U^Z=_Z5Q5^=_\ P33_ &PO G[)=]\0I?&\.KRIKT=@EI_9-JDQ!A-P
M7W[G7'^M7'7O7Z(?\%8/^3)?%_\ U^Z=_P"E<5? ?_!+;]E7X<_M/7_Q(B^(
M.D7&JIHL6GM9""]EMMAE-P'SY;#=GRTZ],4 ?:7_  ^2^ G_ #Y^,/\ P5Q?
M_'Z^E?BKX];5/V6?&'C7PY<W6GM<>#+S6--N0?+G@+6+S1/P?E=<J>#P17BG
M_#I_]FW_ *%#4/\ P=W?_P <KV3XZ>';+PG^R7\0M"TN)H=.TSP1J%E:Q,Q<
MK%'82(@)/)(51R>30!^=?_!*']HKXG_%?]I35M&\9>/->\3:5'X9NKE+/5+Z
M2:)95N+95<*QQN =AG_:-?9W_!2GQYXC^&O[(_BC7_"NM7WA_6K>[L4BO]/F
M:&9%:YC5@&'(R"0?K7YV?\$8F"_M8:R"0"WA.\ ]_P#2;2OO7_@K!_R9+XO_
M .OW3O\ TKBH \R_X) _&3QU\8/#?Q-F\;>+-6\52V-W8):OJMT\YA5TG+!=
MQXSM7/T%?/'_  4T_:7^*WPS_:QUO0O"?Q"\1>'=&BT^RD2QT[4)(859H06(
M4'&2>37JO_!#G_D5?BW_ -?NF_\ HNXKY@_X*V?\GI>(/^P9I_\ Z(% 'N_A
M7XE_M?\ [6GQ@\+>,O#>F>)O#GPC36;26*WM+I-,MY=.2="[N[.C76Y%;=@N
MI)95&.*^E_\ @HQ^W;<?LHZ#I?ASPG!;W?Q UV%KB&2[3?%I]J"4\]D_C=F#
M*BGY<HQ;(&UOKCP;"EOX0T.*)%CB2Q@5408"@1J  .PK\/\ _@KI-=2?MF:P
MMP28H](L%M^<XC\K)^GSEZ .G^'_ (-_;K_:.\*K\1M \9^+#I=T6EL]OB8:
M6EYM8@F*W61$VY! RJJ<'&17<_L<_P#!2CXD>!?C!:?"_P".5W-JNGSZA_8\
MFH:E$L=_I%UO,8$K #S$\SY7+Y9?O;L+M/ZB_!6WL+7X.^!8=+55TU-"L1;!
M  /*^SIMQCVQ7X??\%3[>PL_VW_'7]GA8Y6AT^2Z5!M F-E"2>.Y782?4F@#
M]./^"I'Q&\4?"W]EUM;\(:_J'AO5_P"V[.#[;IL[0R^6PDW+N4YP<#CVKX"_
M9[_:V_:G^,G@F^^%?PYO=6\3^+KJ^EU*\\47UTLMQ961CAC$22S'9"N]7.XG
M=E\)@YS]A_\ !5>2\F_83TA]0!6_;4M+:X!ZB0Q/O_7-<S_P1)M;9?@AX_N5
MAB%Y)XB6.28*/,9%MHBBD]2H+.0.@+-ZF@#Y'^('Q8_:_P#V'OB+I4GC;QEX
M@N'O=UQ;1ZSJK:OIFH1JP\Q '=@N,@,%V.H92-N5-?L)^S1\=M-_:0^"?AOQ
M_IT/V(:E"RW5FS;C:W,;%)H\]P'4X/&5*G S7QY_P6SCL#^S_P"!GD"_VFOB
M=1 <?-Y)M)_-Q[;A#^E9O_!+^;4HO^">WQ4>W+"YCU+638G)&"--MRN/3Y]U
M 'DWQ\_;^^,G[3/QV/PO_9ZNKG2])>Y>RLI],V1W>IE,E[AIW_U$0"LPVE?E
M&6)S@9/Q*\*_MQ_L@>&1X^U?XBZIKVA6LR/>O_;;ZO%;;F"@317"G"$D+E00
M">HR#7R]^QIHOQ7\0?&B&S^#&KV^B^.&L+AHKBX>) 80%\Q5,B,N2.>F< U]
MN>-/V=?V_OB'X5U3PUXB\8Z7JFAZG UM>6<MY9!98SU4E801]00: /L7]A']
MKZV_:\^%,^JW=M;:9XPT:9;76M.M2?+5F!,4T88DB.0*V 22&1QDXR?CK_@H
M!^WY\4;'X_3?!WX17DFA-87%OI\]Y9Q(]YJ-[*$(B1G!\M09%3Y<$L&R<8%>
MK?\ !,O]CGXJ_LK^,O&]QXXM]-M](UJPMXXQ8WRSLT\4C%<@#@!9'Y]Z\A_:
M+_X*):KK7Q\NO OP-^&GAS5-?CU7^SX?$&H:4MU?WMZC[=\"_*$ =3AW+9"[
MOEH Y/XM?!']M_X!^ [SXE:M\7M4U*QL(5NK^SL/%-U<O9IN7)>"51$P4D;O
M+W# ;J,U]9?\$Q_VS_$?[4GA'Q+HGC<PW/BSPT8';4X8TA^WV\V\*S1J JNC
M1D$J "&7@'.?GKX]>#_VZKSX#^--6^(WCCP]8^#H]+FFU;1(X[(3M;A</$&@
MMCDD'M+CW%8'_!$/_DJGQ+_[ MO_ .CS0!V?_!73X^?$?X1_%CP/8^"O&VN>
M%K.ZT1YYX-+O7@2603NNY@IY. !FN \._&+]L[]K[X<Z)#\+;?5M+\,Z'IT&
MGW6MV^HPV=UJ][%$HFE:[F='=F<-\L9"KN <D\T[_@MQ_P EH^'G_8OR?^E+
MU^CG[$D*0_LB_")8T6-3X:LV(48&3&"3]223^- 'Y8?LR_MV?&SX#_M!:=X+
M^*&OZUKVCOJJ:/K>E>))FN;JS9G$9ECE<EPR$AL;BK@'U##]O*_ G_@H)&D/
M_!0OQNJ*$4ZKIC848Y-I:DG\22:_?:@"MJ6HP:1IMW?W3^7:VL3SRO\ W452
MS'\@:_&%?VOOVEOVZ/CO/X2^%/B&;P7IEQYLUI864XM$LK1"/WUS<JID)Y3.
MW/S-A5YQ7Z__ !/\=Z)\,?AWXB\5^)&(T+2+&6[O L?F%XU4DH%_B+?= [DU
M^47@?]M;X\_M)?$V]T7]G;X9^%/!C1PM(UQ::=;M<06VX<W%S*!%@D+A0@)(
MP V* .3^-.J?MC?L%ZIH>K>)?BIJ&O:=J,SQ6]TVL2ZQ92NJJS1.EVNY25Z?
M*.C;3G-?JC^R7\>A^TM\ ?"_CY[./3K[4(Y(;VSB8LD5Q%(T4FW/.UBF\ \A
M7 .:_*#_ (*!>$/VH= ^'GAB[^//C?1?$>BS:F8["QTR.!'BN!"Y+L(K:(8V
MEA]X]>G>ONK_ ()#?\F;:=_V&K__ -#6@#\Y_!_[?'QG^'?[0%Q?W'BSQ%XU
ML;/4+ZWM_#-YJ,TEM=2.LL4"-&"2RK(T;;1R=F 0<$=[\=)OV\=!\,W'Q2\8
MZOXK\-Z#&PGFBT;5XK6.QC8@)YEI;R;E7Y@/G4D8^<@\GSG]B6%)O^"B_A)9
M$611XBU!@&&1D17!!^H(!_"OV4_;(C2;]D[XP*ZAU'A34FPPSR+9R#^! - '
MS7_P2S_;.\5?M&:'XD\(>/;H:KXD\/1Q75MJWEJDEW:N2A$H7 +HP7Y@/F#C
M/();S_\ X*:?\%"O%7PI\;/\*?AEJ']B:I:P1RZWKD:*\\;2H'2WAW A#Y;*
MS/C=\ZA2N#GR'_@B7_R7WQU_V+)_]*H*\*_:BCBN_P#@H?XMBUT*UE)XTB2X
M#X*_9_.C'.>,>7CK0![Q\-_#'[>W@?PU9_%JUU;Q)X@TP1KJ+^']>ULWSW%K
M]\YLI)"5#+_"FV0 C: <5\X_!'QPWQ._X* >#O&+6@T]O$/Q%@U<VBR>8(#/
MJ EV;L#=MWXS@9QTK^A[IP.!7X#>'[6WL?\ @J5';VD,=O:P_%R2.&&%0J(@
MU9@JJ!P !@ "@#]^J\J_:K\>W?PP_9M^)/B?3Y?(U'3]"NGM)?\ GG.T92-O
MP=E/X5ZK7DO[6G@6[^)7[,_Q,\-Z?#]IU"^T*Z%K".LDR(7C4>Y95'XT ?CG
M_P $IOA7IOQ0_:ZTJ35K:.\L_#6G7&O"WF&4:6-HXHB1WVR3HX]T%?O-7X0?
M\$F_B=I_PX_:\TVVU*XCM;?Q-IEQH232G"B9WCFB7/JSP*@]W [U^[] 'YL?
M\%K/A5INH?"SP;\1(K:)-:TW51H\UPJX>6VFCDD56/<(\7 /3S6QU->2_L2:
ME\6_B=^PA\0? OPHU2ZL_&6B>)K6?3IK6_6SEBMIPKRH)&8 *3'*V,\EVKU[
M_@M9\4M.TWX2^#?A\DR/K6J:L-7DA'+1VL$<D88CMNDE&#W\M_0U?_X(I^"+
MO1O@7XS\37$/E0ZYK:PVS'K)';Q %A[;Y77ZJU 'Y:^)/#OQ#M/VA[C0]6O+
MB3XHKXA6UENVO \IU/SPH?S\X+>9@[\X[YK]G_\ @GW\._VAO /_  GO_"^=
M8U#5?M?V#^Q?MVLIJ'E[?M/VC;M=MF=T&<XS@>E?F!\4U*_\%-=3!&/^+F1'
M_P J"5^_U '\^?[3'C)?AW_P4,\6^*WM3?)H7C=-4:U5]AF$%PDNP-@XSMQG
M!QFO=_BIJ_[>7Q7\*WWQ4*>)/"7A!83J,&F>'M2CTYK>T"[]PMTE%Q(H49^<
M,Y!SC;T\>^-4*7'_  4XU.*5%DB?XB6JLCC(8&[B!!'<5^]&N0I<:+J$4B+)
M&]O(K*PR""I!!H _,_\ X)9?MT>.?BIX]O/A;\1-6E\2R26,E[I&K70!NE:,
M@R0RN.9 5)8,V6!0@D@C;[-_P4@_;NO/V5]$TSPMX.2"7X@:Y US'<7*"2/3
M;7<4$Y0\.[,K!%/R_(Q8' #?G=_P2?\ ^3VO"'_7EJ/_ *22UH_\%=)+N3]L
MS5UN"3"FD6"VV3TC\LD_^/EZ /3O OP9_;R^-'A2S^(MG\1M;TV'4(OMMC87
M7B62R>ZC<;E=;:/]TJL#\H?;Q@X P:]%_87_ ."A?Q C^,T7P4^.DGFZG-=R
M:7::K>Q+#>6]^K;5M9]N%<,P**V-VXJ"6#96CX5^%W_!06Y\,:1-HWC_ $U=
M'DLX7LA'=6(40% 8\?N.FW%>>VO_  3E_:DUCXW:7\2/$AT/4-?CUBUU6ZOS
MJ<2N[Q2(V_:B 9P@Z 9Q0!]L_P#!4CXC>*/A;^RZVM^$-?U#PWJ_]MV<'VW3
M9VAE\MA)N7<IS@X''M7YZ?!G]L#]J+XI?#>[^''P[NO$WBWQ?<ZG)?7_ (BR
M;JYM+)HH4B@2:3Y;=3(LK%R0<LH4CYL_='_!87_DS]_^Q@L?Y2UP_P#P1*A1
M?@/X\E"*)6\2[6?') M82 3Z#)_,T ?4'[$OAOXF>$_V>-"T_P"+LVI3^.EN
M+N2[?5=16_GV-.[1 RK(X(V%<+N^4<8&,5T7[5?CV[^&'[-OQ)\3Z?+Y&HZ?
MH5T]I+_SSG:,I&WX.RG\*]5KR7]K3P+=_$K]F?XF>&]/A^TZA?:%="UA'629
M$+QJ/<LJC\: /QS_ ."4WPKTWXH?M=:5)JUM'>6?AK3KC7A;S#*-+&T<41([
M[9)T<>Z"OWFK\(/^"3?Q.T_X<?M>:;;:E<1VMOXFTRXT))I3A1,[QS1+GU9X
M%0>[@=Z_=^@#\V/^"UGPJTW4/A9X-^(D5M$FM:;JHT>:X5</+;31R2*K'N$>
M+@'IYK8ZFMC_ ((K^.[O7/@+XO\ #%S-YL6@ZV);92>8XKB,,5^F^.1OJS5E
M_P#!:SXI:=IOPE\&_#Y)D?6M4U8:O)".6CM8(Y(PQ';=)*,'OY;^AJ__ ,$4
M_!%WHWP+\9^)KB'RH=<UM8;9CUDCMX@"P]M\KK]5:@#Y3_:,_;-^*_PG_;8\
M6);^.O$4WA70?%8D_P"$>CU)TMI;:*96:WV\J$905Q@C!Z5V_C;3_P!O7X_>
M';CXH65QX@\,:!-#]NT_0?#NL?V;(;4J64QV\<BRR_+R/,R[Y&T'(%>'?'*U
MMK[_ (*8:Q;WD45Q:3?$*WCFBG4-&Z&[C#*P/!!&00>,5^_/3@<"@#\K_P#@
MFC_P4-\8^-OB19_"CXGZJ_B ZHCC1=;NE'VF.=$+F"9P!YBLJMM=LL& !)##
M;];_ +>G[8<'[(?PMMK^QM8=2\8ZY(]KHUG<9\H% #)/)CDI&&3Y006+J,@9
M(_)#P.L$'_!2[2ET$!;!?BJ%MA'P/L_]JXXQV\O/X5]#?\%NY+L_%OX;QN3]
MA70YVB&>/,-P=_Z".@#)^%OA/]N+]KKP_P#\+"TCXD:MHNC7$K&SEDUQ])@N
MBC%6\J"W4 H&4KEE"D@\GFNE^ /[?GQB_9M^/2_"K]HBY>_TO[8EI>7VJ;#=
M:9O \N=9TXE@.Y6);=\IRI&-II_L_?#G]N+5_@OX/O/ASXWT^R\#S6"-I-O]
MILU,4.3A2&A+ @Y!R2<YKF_BI_P3D_:U^-WBH^)?&]QH>O:X8$MC>2ZE!&QC
M3.U2(T4'&3SC- 'W1_P5(^(WBCX6_LNMK?A#7]0\-ZO_ &W9P?;=-G:&7RV$
MFY=RG.#@<>U?GI\&?VP/VHOBE\-[OX<?#NZ\3>+?%]SJ<E]?^(LFZN;2R:*%
M(H$FD^6W4R+*Q<D'+*%(^;/V=_P50M=2LOV#=$M]9*G5X=1TJ.],;;E\\1.)
M,'N-V>:P?^")4*+\!_'DH11*WB7:SXY(%K"0"?09/YF@#W'X!^)/'_[.?[$]
M[XF^-W]J:AXN\/VVHZI?1:EJ:WMU,HED>&/S@[CYE**!GY<@8&,5^?/PU^-'
M[7'_  4"^(FO6'@KQY)X1T^TC^TSK8WCZ98Z=$Y81Q^9"C3,S88#[S':2< <
M?JO^T]\:/#7P!^"?B'QEXKT\:QIEK&L2:44#?;9G8+'#\P( +$9)!  )P<8K
M\V/@]^U#^U/^U'K^N)\"/!WA'P!I%NR+>7FFZ9;1Q0@[O+6::X#"5P"QPB>I
MV@&@#@?'WQJ_:T_8 ^)FD:=XT\=W7B>WNXOM44.I:B^K66H0+(0ZAYAYL9SP
M2-C %>V*^[/VG;KXS?M+?LZ_"[Q7^S[?7^A:CK AU:]CM-72RDCMY;;/E-(6
M4/MD.T@=US7YN_\ !0KPQ\??#?B+P:/CUXMTKQ3J5Q:W#Z9_9:1JMO&'02!A
M';PKECM['IV[_KA^P'_R9M\)_P#L#)_Z&] 'X0_!3P[\0_$/QRT;2/A_>7%I
M\1)KN9+&YM[P6\JS!)#(1,2 IVA^<\Y]Z_<[]@_P7\9? OPAU>P^.&I7FJ>+
M)-=FGM9KW4UOW%D;>W5%$BLP \Q9CMSW)[U^2/[!:E?^"@W@8$8(UJ^!!_Z]
M[BOW^H _%G]D/]I[XM>+OV[?#/AC6_B+XCU7P[/K=_!+I=UJ$DD#QI%<%5*$
MX(!5<#V%?47_  5Z^,/CCX0^"OAS<^"?%>K>%KB]U"[CN9-*NG@:95CC*ABI
MY )/YU\'_L0_\I&?"7_8P:E_Z)N:^P/^"X/_ "(/PL_["=[_ .BHZ /%/A!^
MT;^UW^TS\*M+\"_"LZK=3:+YW]O>,IKR-;JZDEFD>.,W4Y C"1LBA8SYAVYS
MMXKSW0_VPOVF?V/?C2-(^(6O^(-4GL9HSJOAOQ/?F_CN(&PQ\J4LX7*GY9(F
MP#CJ 5K]'_\ @DY"D?[$_A1D15:2^U%G*C!8_:I!D^IP /P%?!?_  6<C2/]
MK'2&50K/X4LV8@=3]INAD_@ /PH _4K]HS]IS2/@/^SE??%1+8ZI%):P/I5F
MQ*?:IK@#R58C.U<-N8_W5;'.*_./X%WO[7O_  4 F\0^*M(^+4O@?P]I]U]E
M#6=U+I]L)\+(((H[==S!59-S.Q.&&2V2*^O_ (\? V3]H#_@G+X<\/VM]:Z=
MJ5CX9TG5[.XOIEAM_,@M48K)(V%160R+N) 4L"3@&OS]_8/_ ."AL/['OA?Q
M)X,\0^&)_$>B7E^^I6\VF748EAN3&D3J<Y5XV$4>&!XP3\V[@ XOXM2>-;;]
MISP[\,_VG_%.O>)]&\/WZVD]Q9Z@&>.WN0C?:(99(SN4@QN=R[BJ%,J1Q^XW
MP5^#?AOX _#C3/ _A**XAT'3FF:!+N8S2 R2M*^6/7YG:OQLTCX>_$'_ (*<
M_M9S>.4\*7&@>";J[MUOM08,;:RL855/+68J!+.RH?E4?>?)"J"1^YE ' ?M
M ?#>;XP?!'QSX*MIDMKO7-'N;&WFDSL29XR(RV/X0^W/MFOP,^$OQ.^)'[!/
MQ]N=0;0QIWB;3XY=-U'1]8B81W$#,I9<J1E241E=20=JD;AU_H(^*'Q1\,_!
MCP+J7C'QCJ1TCPYIOE_:[T6TMQY7F2+$GR1(SG+NHX4XSD\9->&Z)\2_V8_V
M^KB_\,VW]D?$:[TVU^TR17VCW-O/;0E@I>*6:*-U^9@#Y;9&1ZT >$>!?^"M
M7P0^-&@S^&/BOX5O/"]KJ,?DWD-["-4TR521PS(HDQG!YBP/6OK/X$?#/X(:
M; GC7X1:!X3@BO[=K4:SX9AA EB+*S1%X_\ :1"5/(*C(R*^)OVIO^"0O@;3
MO OB/Q;\,-9U#P_?:593:A_8>I2_:K2=8D+F-)&Q)&Q .&=G&< X&2/G7_@D
M'\5M;\)?M36G@VWNI6T#Q7974=W9$DQ":"!YXYL=F C=,^DA'I0![+_P5L_:
M"^)?PE^/?A72_!?CG7?"^G7'AF*YEM=+OG@C>4W5RI<A3RVU5&?0"OT-_9:U
M[4?%/[-?PMUG6+V?4M5O_#.GW-U>7+EY9Y7MT9W9CR6)))/O7Y9?\%L/^3D?
M!I[?\(G#_P"EEU7Z>_L<L&_9/^#Q4@C_ (1/3!Q[6T= 'Y8_MG?M0_%SP7^V
MYXP\-Z%\1_$FD:!;:M9Q0Z;9ZC)'!&C00%E" X )9C^)K[0_X+"_\F?O_P!C
M!8_REK\X/V]?^4@GCG_L-6/_ *3V]?H__P %A?\ DS]_^Q@L?Y2T ?GS^QC\
M5?CI??#W7/@W\!M)>/7M6U)M9U'Q#'*B/:6PBBB"!Y,)%DH<N26.0$ /)T?B
M!\6/VOOV'?B-I4GC7QIX@N9+T&XMH]8U5M7TR_C5@)$ =F"XR P78ZAE(VY4
MU]<?\$2;6V7X(>/[E88A>2>(ECDF"CS&1;:(HI/4J"SD#H"S>IJ?_@MI#8-\
M _ LT@3^U%\3!("5&[R3:SF7!ZXW+#G\/04 ?7_[.?[0&D?M"? G0?B19Q&Q
MAO+9VO;,G<;6XB)6>//<!E)4]2I4X&<5^4>J?MF?M#_MR?'B'P1\,_%,G@"P
MU*2?^R]-LKW["8X8XG<O-<H/-=RB$D*<9^ZHZU]=?\$8XYIOV3=?CN5W0-XL
MO%B5N08S:6F?PW;Z^=_VB/\ @D7\0_!_C2^\3_!/4;?5M(^T&[LM*:\^Q:E8
M,3N$<4C$(X7^%MZMC P2,D Y3XM>*/VPO^"?NOZ!J?BGXEW/B?3=3E=8'NM5
MFUBQN"FTO$ZW*B1,@CD!3C.UNM?K!^S;\:+;]H;X'^$OB%:V9TY=:M6>6T+[
MQ#-'(\4R!L#($D;@' R *_'K3?VSOVM/V/\ Q%::5X[GUJYMVY73/'-JUPMT
MBD!C%<M^\8#.-R2$<C.:_7K]F']H+2?VGO@WHWCW2;.73%O#)!=:?,^]K6XC
M8J\>X !AT8-@95AD Y  /RO_ &0_VGOBUXN_;M\,^&-;^(OB/5?#L^MW\$NE
MW6H220/&D5P54H3@@%5P/85][_\ !1#]L:X_9+^%U@= AAN/&WB.22VTK[2N
M^*V2,*9KAE_BV[T"J>"S@G(!!_+K]B'_ )2,^$O^Q@U+_P!$W->W_P#!;IKG
M_A;_ ,.5;_CT&A3&/_?^T-O_ $"4 <+\$[7]MS]J&WO/'GA#QWXIDT^WG94N
M+C7S86=Q,N2T<5ON6)\$X/R;!T)&,#Q#]LSXO^/_ (M?$[2H_BCHG]A^//"V
MC1>'=43:$-Q)%//*)R@^52RSK]PE6QN7"L /VJ_X)]P6-O\ L9_"A=/"B Z0
M'?8 !YID<R]._F%\U^:G_!:2UM[?]JSP])##'')/X0M))VC4 R/]KO%#,1U.
MU4&3V4#H!0!^G'@'4+K2/V%?#E]93R6MY:_#BVG@GB8J\<BZ8K*RGL00"#[5
M^?O_  2L_:-^*/Q4_:;NM%\8>/M?\2Z2OA^[N!9:G?R31"198 K[6.,@,W/N
M:^^?"?\ R8+HW_9,X?\ TU+7Y@?\$;?^3N+S_L6;W_T;;T ?<7_!3;]M3Q#^
MR[X5\/:!X($-OXN\2":0:G/$LHL+>(J"RHP*M(S/@;@0 K<$XKY6^'_P/_;E
M^/7PYTSXE:=\6]2L+;4(Q=Z?IDWB>YL9[J(X*2"*)/)"L!D!V7(YQ@\_17_!
M1C]NK0_V>_$FG^#])\#Z%XS\</9BZDNO$-J)K;3H78[%VX#2,VUC@.H P3G.
M*\^^'8_X*#?%[PGINM:-K7ASX>>'[RV1["RNK"QM_P#1V4;-L?V>:2-0N,!M
MIQCCI0!SW_!.[]OCXG:M\=;+X/?%349?$,6H-/96M]J"HMY874*.YCDD !E#
M>6R?/E@Q7G&17U%_P5(^(WBCX6_LNMK?A#7]0\-ZO_;=G!]MTV=H9?+82;EW
M*<X.!Q[5^6?[),&K6O\ P4*\'0Z]=1W^NQ^+ITO[J+[DUP'E$KK\J\%]Q' Z
M]!TK]*?^"PO_ "9^_P#V,%C_ "EH ^%_@S^V!^U%\4OAO=_#CX=W7B;Q;XON
M=3DOK_Q%DW5S:6310I% DTGRVZF196+D@Y90I'S9^E/C=XB^.GP!_P"":NBW
M?B[Q+XAT+XHKXC"W>H/K'VF]\B2:=D0SI(^5V;/EW<  8&,5N?\ !$J%%^ _
MCR4(HE;Q+M9\<D"UA(!/H,G\S7<?\%A?^3/W_P"Q@L?Y2T 5?^"1_P 5_&7Q
M<^"OC'4?&GB;5/%%_;>(#;PW&J7+3O'']FA;8"QX&6)Q[FN0_P""D7_!0_Q#
M\$?%,?PM^%\L=MXM$4<VJZRT*SO9>8 T<$,;@J9&4JQ8@X#J ,G*O_X(E_\
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M@'X@/'J?B;2;'^T[76HHDB:ZMA(D3K*B +O5I(\,H&X-R,C+?H%7P)_P3O\
M^"C6J?M+>(I_A]X]TVUMO%\5I)>6>JZ<AC@OHT*[T>/)V2 '=E3M8 \*0-WW
MW0 5^5?_  7._P":)_\ <;_]L*_52ORK_P""YW_-$_\ N-_^V% 'U5_P2X_Y
M,3^&7_<3_P#3I=U]55\J_P#!+C_DQ/X9?]Q/_P!.EW7U50 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5^ /_  2X_P"3[/AE_P!Q/_TU
MW=?O]7X _P#!+C_D^SX9?]Q/_P!-=W0!^_U%%% 'RC_P4_\ #6K^+OV.?%>F
M:%I5]K6I27E@R6>GV[SS,%NHRQ"("3@ D\=J_)?X&ZU^T_\ LVRZS)\.?#/C
M#PZ^L+"M\?\ A$C=><(MYC_U]N^W'F/]W&<\YP*_H6HH _$#_AL+]O#^]XP_
M\(*V_P#D*OT\_90U'QG\:OV/]#;XLF^_X2S7K34K+5_MM@EC<;&NKB%,PK&B
MH?)$>/D&1@\YR?H.B@#^?^3X,_M#_L*?'9M2\.>'=:_M*PDDM[+6].TM[VPU
M*W?*@9"LC!UP3&WS*<<!@#7J?QP\+_M=?M8?!O6/''Q$TS4M,\,>'C!-IWA2
MWTJ2WFU&>6>.+?':*/-?8DK-YDF<*IV_><C]K:* /S>_X(R> ?$_@3PS\4X_
M$OAS5O#SW-YI[0+JMC+:F4*D^XJ)%&[&1G'J*^;O^"I7PB\=^,/VOM=U+0?!
M7B+6].?3K%5O-.TJ>XA9A" 0'1""0>O-?ME10!E^%XWA\,Z1'(K(ZV<*LK#!
M!"#((KXG_P""F7[">K_M,:;I7C;P*D,WCG1+8V<NG32+%_:5IN9U1'/ D1V<
MKN(!#L,@@9^[** /Q-^&'[7G[6W[,_@FU^&,?P\N[J+3E-KIYU_PU>2W=JA)
MVI$R,JNH+?+N#C&T#Y0!6S^R7^P'\4_V@OC=%\4/C1IE_HV@'4?[8OAKD1AO
M=8GW^8(U@8;DB+8W%@HV?*GJO[,T4 ?$'_!87_DS]_\ L8+'^4M?GE^QG)\?
M?A'X#\0?&+X,6J^(M,MK_P#L?7O#OV62[\U%C26.9H$(9U7S&&Z,ATY_A9L?
MI%_P5A\)ZWXR_91?3O#^C:AKNH?V[9R?9=-M7N)=H$F6V("<#(YQWKCO^".G
M@GQ%X'^!WC6T\2:#JGA^ZF\1F6.#5+.2V=T^S0C<%=02,@C(]#0!\)?%/5/V
MFO\ @H9\0M#M-4\$WY^P!HK2SL]*FLM,L!(1OEDDE)VYVKEG<G" #T/[%?LJ
M?L_VG[-7P'\.> (YX]0N;2)Y=1O%7Y;FZE8O*P!'W03M7(SM1<\UZ]10!^*O
MQZ_8E^,G[&WQW3XC_!O3-2USPY:WK7VE7>CP-=3V*-G=;7,"#<4VLR%@"K(>
M2"2 _P",7[;_ .TY^TO\/[SX<P_"R;3H=9C$%\="T"^>YN8\@M&N\N$4D<X&
M<<9 SG]IZ* /AG_@E[^QCXA_9I\(Z_XG\<0)8^+?$JPQ+I:NKM8VL99@KLI(
M\QV;)4$[0J#.=P'P;\4OV>OC3^Q5^U/)X[\->#]0\0:9IVL2ZEH^LP:?+>65
MQ#(S8CG,?,;E'9&4E6R"5.,-7[L44 ?DE\3/BU^U=^W)\)_%5E9^ S\._ .F
MZ;<7^HF.UN8[C6?*C9Q:1%QOF+LF-D:@9X9CD*=+_@C9\-?%_@7XF?$2?Q)X
M5UOP]!/I%ND4FJZ=-;+(PF)(4NHR<=A7ZMT4 ?DU_P %C_AGXP\<_%[P'<^&
M_"FN>(+>'0GCEFTO3IKE(V^T.=K%%(!QS@U^@G['NEWNA_LL_"K3]1L[C3[^
MV\.644]K=1-%+$XB4%65@"I![$5[#10!^'7[=_P>\>^(OV]/&.KZ5X(\1ZGI
M,NHZ:T=_9Z3<30.JVEL&(D5"I ((//!!K]Q:** /,OVF/A//\<O@+XX\"VMR
MEG>ZUIKP6TTN=BS@AXMV.=I=5!QV)ZU^-?[//BSX_P#_  3X^(_B 'X3ZG>'
M5(19WECJ&FW#0S^6Q*207$0*M@LPW*64AB.N"/WAHH _$W]K[P_^U/\ M+_#
MW1?B/X[\'WNE: NI+8:1X)TG3[@W$6^*1VO)+?#2 ?N@F^0@_,-JJIY^\?\
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M"HN+P?P@%Y8"[G(/+[CGC)Z5^YE% 'X6?#']AC]H?]LKXC#Q1\1(]9T*PO)
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MU/RFK5% 'XB?\$P/A!X\\(_MC>%-3UWP3XBT738[._5[S4-)G@A4M:R!07=
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %?E7_P %SO\ FB?_ '&__;"OU4K\J_\ @N=_S1/_ +C?_MA0!]5?
M\$N/^3$_AE_W$_\ TZ7=?55?*O\ P2X_Y,3^&7_<3_\ 3I=U]54 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %?@#_P $N/\ D^SX9?\
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M?\$N/^3$_AE_W$__ $Z7=?55?*O_  2X_P"3$_AE_P!Q/_TZ7=?55 !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7X _\$N/^3[/AE_W$
M_P#TUW=?O]7X _\ !+C_ )/L^&7_ '$__37=T ?O]1110 4444 %?B#K&I2?
M\%!O^"EEE97!:\\'0ZF;6*(G,8TBRW._T$Q5S_O3XK]=?VE/&%S\/_V>?B7X
MCLI?(O\ 3/#E_<VLG]V=;=_+/_?>VOR^_P"")/A&+4/C-\0/$K@,^EZ''91Y
M'0W$X8D>^+8C\30!^Q"*L:JJJ%51@*HP /2OQ-_X*F?$34?CY^V%I/PW\.YU
M : (-!LK:-LK+J-RZ-+CT.YH8C[Q&OV*^*GQ"T_X3_#7Q/XRU0@6&A:=/?R+
MG!?RT+!!_M,0%'NPK\9_^"8O@?4/V@/VV+GQYK^;PZ+]J\37TS@E9+R5RL0]
MCYDK2#_KD: .K_X(Z_%R?X>_'[Q+\,=79K6+Q+:L8K>;@I?VFYBF#T)B,^?4
MQJ*_9>OPE_;4T6__ &1_^"@]SXNT.+R8GU.V\7Z>@^595E??/'_NF5;A"/[I
MK]Q?"OB;3_&GA?2/$&DS"YTO5K.&^M)A_'#*@=&_%6% &+>_&+P%INN-HMYX
MW\.6NLK*(&TZ;5K=+@2$@!#&7W;B2.,9YKKZ_ O]HW_E)CK7_8\V7_HZ&OWT
MH X_0?C)X!\5:M!I>B>./#>L:G<;O)LK#5K>>:3:I9MJ(Y8X523@< $]J["O
MP!_X)<?\GV?#+_N)_P#IKNZ^[/\ @LQ\7/%W@+X6^"O#?AZ^N=+TCQ-=7<>K
MW%JQ1I$A2(I;EAR%?S') Z^7@\9! /L[6/VC/A/X?U1M-U7XG^#=-U%7\MK.
M\\06D4P;.-I1I <YXQBNXT?6=/\ $&FP:CI=];:EI]PN^&ZLYEEBD7U5U)!'
MT-?B-^QW^R+^SS^T+\,$E\4_&&Z\,_$B266(Z&UU:VJ0X<B,HDR;K@,FUCL<
M8)(.,<^_?L%_LQ?M,?LL_M!&SO="DD^$VH3SV^J7']K63031JK_9[Q(!.TB,
M6"' 7=M8@^P!ZG_P4R_;&UWX*>"_#H^$WQ"TFQ\3?VU+9:K;69LK^>)$C?*2
M12+)Y9#C!X!R,>U=;_P3]_:W7XK? 73M1^*'Q&T*Y\<7&J7%L(;RYL[&X= Z
MB)1 @3KG PN3[U\+?\%/?V,;+X%:O=_%"#Q3/K$_CCQ3?7,FFR62Q+:><TEP
M0'#DO@G;R!GK6S^P'_P3KT[X[>!?#/Q:G\<76CW%AKN\:7'IRRH_V:9&'[PR
M C=CTX]Z /UT\5?$CPEX%FMXO$OBG1?#TMPI:&/5=0AMFD4'!*B1AD#(Z>M-
MU;XF>#]!\,V_B/4_%>AZ=X>N%#0ZM=ZC#%:2*02"LK,$(P">#VK\L/\ @N#_
M ,C]\+/^P9>_^C8ZXOX#_P#!/CXL?MF?#?PCXK\5^.;7PMX-L[!=-\/6\L3W
MLJVL9VET@#HJ*S!CDN&8@D@#:: /N_\ X*"?L_>$_P!I_P"%?A9;_P")FC>!
M/L=V;W2]4U*XB-C?"2+E<F1<Y7:RLI/ /!!R.N_8-^!>@?L]_ G_ (1OP_XW
ML_B!#/J<]_<ZQITB-;>>ZQH8XPCN%"K&G!8G))XSBOE#_@L#X;_X0W]F/X.Z
M!]H^V?V5J$=C]HV;/-\JR*;]N3MSMSC)QGJ:];_X(]?\F?I_V,%]_**@#[6U
M'4K31[*6\O[J&RM(1NDN+B01QH.F2Q.!^-<&O[2'PEDU-M.7XH^"VU!>&M!X
M@M#*.G5/,SW';O7YS?\ !1KX/?M#_M)?M$?V#H/A/6KCX:Z7]EM--FC.+)Y'
M1&GNI!NY*N[)NP<+$,=3E_[0'_!(?P/\*_V?_$OB[1_'6N3>)/#NDSZG<?VD
M(/L=X88S(Z)&J*\98*P7+OR1UH _5F.198U=&#HPRK*<@CU%.K\J?^"*_P ;
M-?U35/&7PQU+4I[[1;.P76-,MYV+BT(E6*94)Y",9(SMZ @D %FS^JU !111
M0!^!?_!53_D^/Q]_UQTW_P!(+>O>Y/\ @BCK6I>"+36- ^*UE?:G=62745AJ
M&B/:Q%F0,$,RSR$<G&=GOBO!/^"JG_)\?C[_ *XZ;_Z06]=_=?\ !8WXOQ^"
MX=!T?P]X5T>:&T2TBU)+>>6:)53:'57EV;^ ?F4CVH X;_@GM\=O&GP%_:D\
M,^#/[0NHM"UW6H] U?0Y6+P>;++Y*R!,X61)"OSCG (.02*_>ZOPG_X)E6WP
MLOOVCM-\3?$OQF+'Q1;W;2Z)IE_ P@O;UQ\LLER3M#!F)5&P6<*=V<*WZB?\
M%!/VDK[]F/\ 9UU+Q!HCI'XGU2Y32-)DD4,(9I%=FFVD$$I''(PSQN"YR."
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M$ZAXY\->*H/&NBZ0#<WJQVAL;RTA7DS!?,<.$[E6! &[&,X_8[X1^%K+P/\
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MLVT]QDC('EHY;I[5TNN>(-+\+Z9+J.LZE9Z3I\/,EW?3I#$GU=B /Q-?@/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %?@#_P $N/\ D^SX9?\ <3_]-=W7[_5^ /\ P2X_Y/L^&7_<3_\
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M+CX4^%O&%YX0\-3>(F\/:;8V-T]K"RK,8C/<O'AY=VTR;#D#@*,\GUSXS?\
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MK_X:ZOK5[X]U'1/$.E:BUI=Z39PPR%(BBM%-ACNVOEU!Z9C;TKO?CE_P3O\
MV=/V;;C1[?XC?'77O#L^K)+)91_V&]TTBQE0Y(@C?: 77[V,\XS@XN:M_P $
ML?C]\"_'%SJWP1^(<36<X:&.ZAU*72[X0GG9,%&QP..0W) .U>QX=_X)2?'/
MXU>/H==^-WC^!;92L=Q=/J,NJ:E)$IR(XMPV(O) );Y2<[&Z4 ?<?P$\,^%/
M#/["L&D> O$5WXP\*QZ#JG]G:Q>VKVTMTKO<.<QNJLH#,RC('"@]\U^8G_!(
M&\@M?VQK2.658Y+C0[Z*%6."[ (Y4>IVHQ^BFOVQ\%^!]%^'_@G1_">B626N
MA:59QV%K:GY@(D4* V?O$@<D\DDD]:_*WXM?\$;/'>C^.KW6?A'XQTA-'-PT
M]E:ZI<SVE[9*QXC61$</M!QO)4D#IF@#V3_@LE:_#6[^#_AL^)]4N+#QY;W$
MTGAN&RMA.]PI""X27+*$A/[K+YR&"X5N17AWP=T+]O\ ^%?PET_P/X3\*F/0
M)X&;3+B[GTV2XL8I,MM21Y_W?+$A9!E2<#& *QO^"D$?AWX?_ _X*_##QDMY
MK'QI\/Z*LLNIV5YOM8;=WV/YSNFZ;>T+;0-I7:6)P=K5?AQ_P3+_ &HM2\#Z
M'K.E^/M+\+PSVJ75KI,WB*_AN+96&Y%*Q0M&C8(. _&><'- 'TG_ ,$^?^"<
M.O? GQTWQ0^*%[;7/C!(Y4T[3+6;[0+1I5*RSS2]'E*LZ@*2 &8[B2-N;_P6
MX_Y(O\//^Q@D_P#29Z^0IOVB/VE?V"?C@GASQ?XNU+Q!]A,<]SHFJ:K)J-A?
M6K\YC:0EH]W.&4*P8<@\@_HK_P %"OV9_%_[8WPF\#V?@.3389K:^&J2?VQ.
M]N/)> A0,(QW98<$"@#'_P""/7_)GZ?]C!??RBK\X/V:]3MO"?\ P4>T";5I
M5L8XO&EW:R-,P4)(\LT2@DG ^=@/QK]:_P#@G_\ L]^*/V9?@"O@SQ?)I\NK
MC5;F]W:;.TL7ER!-OS,JG/RGM7R7^V9_P2=\3_$3XL:WX]^%6IZ2D.N7#WU]
MH>IRO;O#=-\TCPR!65E=]SD-MVECC(Z 'VU^VMXPT3P;^RC\59M;U.VTR._\
M-:CIEH;APIGNI[66.&%!U9F9@ ![GH"1^8?_  14_P"3IO%/_8F77_I=8UZ1
M\/\ _@DA\2/%6GWM]\7O'4>IS6>GW":+H=OJ4]R/M)B(A\V=P!%&K[<K&&R!
MU%>E?\$Y_P!@3XF_LK_&[6_%GC.?09=+O/#T^EQKI=Z\TGG/<VTHR&C4;=L+
M\YZXXH \B_X+@_\ (_?"S_L&7O\ Z-CK[J_X)X_\F6_"K_L&-_Z/EKQ7_@I-
M^Q'\0_VL?%/@C4/!,VBQ6^CV5Q;W/]JW;PL6=T9=H6-LC"GTKZ9_9-^%NL_!
M7]G7P/X(\0-:OK.C636]RUE(9(2QE=OE8@$C##L* /Q<_P""H_\ R?9\3?\
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MZ;;0$_<:XC6X:7'H0LL.?7<OI7ZC4 ?EK_P7*_Y!7P;_ .NVK?\ H-G7N/\
MP2>T#3-0_8TT":ZTVTN9CJ=^#)- KM_KSW(I?^"EG['OCO\ :TL?A[%X(FTB
M)]!DOWN_[6NGA!$PMPFS:C9_U39Z=J]3_80^ _B3]F_]G72O!'BQ[&36;6]N
MKAVTZ9I8=LDI9<,54YP>>* /<[?PWI%I,DT&EV4,J'*R1VZ*RGU! XK\G?\
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M_!83X.7W@O\ :67QRD$K:-XPL8)/M.T^6EU;QK!)%GIGRXX7]]Y]*_;BO/\
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M_P"XW_[85]5?\$N/^3$_AE_W$_\ TZ7=<5_P4P_8V\>_M;?\*X_X0>;1XO\
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MR^,;3GV/P=_P3=_:R^ /B;4#\,_'&E6%MJ&(9K_2]7DMDFC#'89HGC^\H)/
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MTD;*[*>AY![8(!\2_LD_L7^+_P!O;PCJ'Q#^)WQ;\02:,=0DL8K1KA[RYG9
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<GP9T^V^('C_ ,4^+]%TVYF53-8ZW$;6"1_NI+;6TACCSCC*!<G'4XK]"?\
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M*7?ME^(/V4? GARP\'00KXK\4O<K;ZE<QK*EC% (O,<1L"&<F9 NX%1AB0<
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M%_&WPN\;7'Q6^(>E2^&Y5L9+/1]&NP%NR9=N^>5.L0"@H$;#$LQ(  W?0O\
MP4O_ &8_$/[3'P&M;3PA"MYXH\/ZBNIVUBSJAO(_+>.6)68A0^&5AD\[,=Z
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M6_\ !0']I#X$?#_2OA[JOP;N]8OM#@6QM;O5=+OHKGRE^6-95 ^<J,*&&W(
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M_P"5!*_;']I+XP>&O@1\%O$OC/Q99?VIH]C %.F[%?[9*[!(X<,"/F=E!)!
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4J+BY*A<(#R(T50JCV+'!8U[M10 4444 %%%% !1110 4444 %%%% !1110
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M*** "BBB@ HHHH *_*O_ (+G?\T3_P"XW_[85^JE?E7_ ,%SO^:)_P#<;_\
M;"@#ZJ_X)<?\F)_#+_N)_P#ITNZ^JJ^5?^"7'_)B?PR_[B?_ *=+NOJJ@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/[8O[;'A']C_ ,,V4VJVTFO>)]4#'3= M91&\JJ0&EED(/E1@G&[!)/ !PQ
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M'5U*RVNN:>NIVJ-T6YMVVNH'8M'*2?\ KB* /V$HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *_*O_@N=_P T3_[C?_MA7ZJ5^5?_  7._P":)_\ <;_]
ML* /JK_@EQ_R8G\,O^XG_P"G2[KZJKY5_P""7'_)B?PR_P"XG_Z=+NOJJ@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?I7LW_!)O]HRV^&/PF^.6DZI,/L_A[3G\8VL#-]\)$8YP!ZDI:J,=2U>T_\
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M0*_6?]I'X.7'Q]_9#\1>!K(*=3U'1()+$.VT&ZA\N>%2>P9XE4GT8T ? ?\
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MH \6_P""3?[1EM\,?A-\<M)U28?9_#VG/XQM8&;[X2(QS@#U)2U48ZEJQ/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!.@=)%(P593P01V-3T4 >$ZI^PK^S_J]]->7'PF\,K-*VYOL]GY*9]D0A1^
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M#+_N)_\ ITNZ^JJ^5?\ @EQ_R8G\,O\ N)_^G2[KZJH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV.!]H[0R'N_$9Y^YP#^D-O<17EO%/!*D\$JAXY(V#*ZD9!!'!!'>@"2BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0LH;KS7] U<K\1/A7X.^+6BG2?&?AC2_$^G\E8=3M4F\LG@LA(RC?[2D'WH
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M#_\ P?6O_P <H_X:$^%G_12_!_\ X/K7_P".5^0'_#FWX]_\_G@__P &DO\
M\8H_X<V_'O\ Y_/!_P#X-)?_ (Q0!^O_ /PT)\+/^BE^#_\ P?6O_P <H_X:
M$^%G_12_!_\ X/K7_P".5^0'_#FWX]_\_G@__P &DO\ \8H_X<V_'O\ Y_/!
M_P#X-)?_ (Q0!^O_ /PT)\+/^BE^#_\ P?6O_P <H_X:$^%G_12_!_\ X/K7
M_P".5^0'_#FWX]_\_G@__P &DO\ \8H_X<V_'O\ Y_/!_P#X-)?_ (Q0!^O_
M /PT)\+/^BE^#_\ P?6O_P <H_X:$^%G_12_!_\ X/K7_P".5^0'_#FWX]_\
M_G@__P &DO\ \8H_X<V_'O\ Y_/!_P#X-)?_ (Q0!^O_ /PT)\+/^BE^#_\
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MH_X:$^%G_12_!_\ X/K7_P".5^0'_#FWX]_\_G@__P &DO\ \8H_X<V_'O\
MY_/!_P#X-)?_ (Q0!^O_ /PT)\+/^BE^#_\ P?6O_P <H_X:$^%G_12_!_\
MX/K7_P".5^0'_#FWX]_\_G@__P &DO\ \8H_X<V_'O\ Y_/!_P#X-)?_ (Q0
M!^O_ /PT)\+/^BE^#_\ P?6O_P <H_X:$^%G_12_!_\ X/K7_P".5^0'_#FW
MX]_\_G@__P &DO\ \8H_X<V_'O\ Y_/!_P#X-)?_ (Q0!^O_ /PT)\+/^BE^
M#_\ P?6O_P <H_X:$^%G_12_!_\ X/K7_P".5^0'_#FWX]_\_G@__P &DO\
M\8H_X<V_'O\ Y_/!_P#X-)?_ (Q0!^O_ /PT)\+/^BE^#_\ P?6O_P <H_X:
M$^%G_12_!_\ X/K7_P".5^0'_#FWX]_\_G@__P &DO\ \8H_X<V_'O\ Y_/!
M_P#X-)?_ (Q0!^O_ /PT)\+/^BE^#_\ P?6O_P <H_X:$^%G_12_!_\ X/K7
M_P".5^0'_#FWX]_\_G@__P &DO\ \8H_X<V_'O\ Y_/!_P#X-)?_ (Q0!^O_
M /PT)\+/^BE^#_\ P?6O_P <H_X:$^%G_12_!_\ X/K7_P".5^0'_#FWX]_\
M_G@__P &DO\ \8H_X<V_'O\ Y_/!_P#X-)?_ (Q0!^O_ /PT)\+/^BE^#_\
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MH_X:$^%G_12_!_\ X/K7_P".5^0'_#FWX]_\_G@__P &DO\ \8H_X<V_'O\
MY_/!_P#X-)?_ (Q0!^O_ /PT)\+/^BE^#_\ P?6O_P <H_X:$^%G_12_!_\
MX/K7_P".5^0'_#FWX]_\_G@__P &DO\ \8H_X<V_'O\ Y_/!_P#X-)?_ (Q0
M!^O_ /PT)\+/^BE^#_\ P?6O_P <H_X:$^%G_12_!_\ X/K7_P".5^0'_#FW
MX]_\_G@__P &DO\ \8H_X<V_'O\ Y_/!_P#X-)?_ (Q0!^O_ /PT)\+/^BE^
M#_\ P?6O_P <H_X:$^%G_12_!_\ X/K7_P".5^0'_#FWX]_\_G@__P &DO\
M\8H_X<V_'O\ Y_/!_P#X-)?_ (Q0!^O_ /PT)\+/^BE^#_\ P?6O_P <H_X:
M$^%G_12_!_\ X/K7_P".5^0'_#FWX]_\_G@__P &DO\ \8H_X<V_'O\ Y_/!
M_P#X-)?_ (Q0!^O_ /PT)\+/^BE^#_\ P?6O_P <H_X:$^%G_12_!_\ X/K7
M_P".5^0'_#FWX]_\_G@__P &DO\ \8H_X<V_'O\ Y_/!_P#X-)?_ (Q0!^O_
M /PT)\+/^BE^#_\ P?6O_P <H_X:$^%G_12_!_\ X/K7_P".5^0'_#FWX]_\
M_G@__P &DO\ \8H_X<V_'O\ Y_/!_P#X-)?_ (Q0!^O_ /PT)\+/^BE^#_\
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MH_X:$^%G_12_!_\ X/K7_P".5^0'_#FWX]_\_G@__P &DO\ \8H_X<V_'O\
MY_/!_P#X-)?_ (Q0!^O_ /PT)\+/^BE^#_\ P?6O_P <H_X:$^%G_12_!_\
MX/K7_P".5^0'_#FWX]_\_G@__P &DO\ \8H_X<V_'O\ Y_/!_P#X-)?_ (Q0
M!^O_ /PT)\+/^BE^#_\ P?6O_P <H_X:$^%G_12_!_\ X/K7_P".5^0'_#FW
MX]_\_G@__P &DO\ \8H_X<V_'O\ Y_/!_P#X-)?_ (Q0!^O_ /PT)\+/^BE^
M#_\ P?6O_P <H_X:$^%G_12_!_\ X/K7_P".5^0'_#FWX]_\_G@__P &DO\
M\8H_X<V_'O\ Y_/!_P#X-)?_ (Q0!^O_ /PT)\+/^BE^#_\ P?6O_P <H_X:
M$^%G_12_!_\ X/K7_P".5^0'_#FWX]_\_G@__P &DO\ \8H_X<V_'O\ Y_/!
M_P#X-)?_ (Q0!^O_ /PT)\+/^BE^#_\ P?6O_P <H_X:$^%G_12_!_\ X/K7
M_P".5^0'_#FWX]_\_G@__P &DO\ \8H_X<V_'O\ Y_/!_P#X-)?_ (Q0!^O_
M /PT)\+/^BE^#_\ P?6O_P <H_X:$^%G_12_!_\ X/K7_P".5^0'_#FWX]_\
M_G@__P &DO\ \8H_X<V_'O\ Y_/!_P#X-)?_ (Q0!^O_ /PT)\+/^BE^#_\
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)%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>bgne-20241231_g3.jpg
<TEXT>
begin 644 bgne-20241231_g3.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" C*#Z # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'_\ <E'_  ]T_P"J4?\ EQ__ ')1]7J]@]I#N?HE17YV_P##W3_JE'_EQ_\
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M/=/^J4?^7'_]R4?\/=/^J4?^7'_]R4?5ZO8/:0[GZ)45^=O_  ]T_P"J4?\
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M_<E'U>KV#VD.Y^B5%?G;_P /=/\ JE'_ )<?_P!R4?\ #W3_ *I1_P"7'_\
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M5^=O_#W3_JE'_EQ__<E'_#W3_JE'_EQ__<E'U>KV#VD.Y^B5%?G;_P /=/\
MJE'_ )<?_P!R4?\ #W3_ *I1_P"7'_\ <E'U>KV#VD.Y^B5%?G;_ ,/=/^J4
M?^7'_P#<E'_#W3_JE'_EQ_\ W)1]7J]@]I#N?HE17YV_\/=/^J4?^7'_ /<E
M'_#W3_JE'_EQ_P#W)1]7J]@]I#N?HE17YV_\/=/^J4?^7'_]R4?\/=/^J4?^
M7'_]R4?5ZO8/:0[GZ)45^=O_  ]T_P"J4?\ EQ__ ')1_P /=/\ JE'_ )<?
M_P!R4?5ZO8/:0[GZ)45^=O\ P]T_ZI1_Y<?_ -R4?\/=/^J4?^7'_P#<E'U>
MKV#VD.Y^B5%?G;_P]T_ZI1_Y<?\ ]R4?\/=/^J4?^7'_ /<E'U>KV#VD.Y^B
M5%?G;_P]T_ZI1_Y<?_W)1_P]T_ZI1_Y<?_W)1]7J]@]I#N?HE17YV_\ #W3_
M *I1_P"7'_\ <E'_  ]T_P"J4?\ EQ__ ')1]7J]@]I#N?HE17YV_P##W3_J
ME'_EQ_\ W)1_P]T_ZI1_Y<?_ -R4?5ZO8/:0[GZ)45^=O_#W3_JE'_EQ_P#W
M)1_P]T_ZI1_Y<?\ ]R4?5ZO8/:0[GZ)45^=O_#W3_JE'_EQ__<E'_#W3_JE'
M_EQ__<E'U>KV#VD.Y^B5%?G;_P /=/\ JE'_ )<?_P!R4?\ #W3_ *I1_P"7
M'_\ <E'U>KV#VD.Y^B5%?G;_ ,/=/^J4?^7'_P#<E'_#W3_JE'_EQ_\ W)1]
M7J]@]I#N?HE17YV_\/=/^J4?^7'_ /<E'_#W3_JE'_EQ_P#W)1]7J]@]I#N?
MHE17YV_\/=/^J4?^7'_]R4?\/=/^J4?^7'_]R4?5ZO8/:0[GZ)45^=O_  ]T
M_P"J4?\ EQ__ ')1_P /=/\ JE'_ )<?_P!R4?5ZO8/:0[GZ)45^=O\ P]T_
MZI1_Y<?_ -R4?\/=/^J4?^7'_P#<E'U>KV#VD.Y^B5%?G;_P]T_ZI1_Y<?\
M]R4?\/=/^J4?^7'_ /<E'U>KV#VD.Y^B5%?G;_P]T_ZI1_Y<?_W)1_P]T_ZI
M1_Y<?_W)1]7J]@]I#N?HE17YV_\ #W3_ *I1_P"7'_\ <E'_  ]T_P"J4?\
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M.Y^B5%?G;_P]T_ZI1_Y<?_W)1_P]T_ZI1_Y<?_W)1]7J]@]I#N?HE17YV_\
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MSM_X>Z?]4H_\N/\ ^Y*/^'NG_5*/_+C_ /N2CZO5[![2'<_1*BOSM_X>Z?\
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M_5*/_+C_ /N2CZO5[![2'<_1*BOSM_X>Z?\ 5*/_ "X__N2C_A[I_P!4H_\
M+C_^Y*/J]7L'M(=S]$J*_.W_ (>Z?]4H_P#+C_\ N2C_ (>Z?]4H_P#+C_\
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M]4H_\N/_ .Y*/^'NG_5*/_+C_P#N2CZO5[![2'<_1*BOSM_X>Z?]4H_\N/\
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MSM_X>Z?]4H_\N/\ ^Y*/^'NG_5*/_+C_ /N2CZO5[![2'<_1*BOSM_X>Z?\
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M_5*/_+C_ /N2CZO5[![2'<_1*BOSM_X>Z?\ 5*/_ "X__N2C_A[I_P!4H_\
M+C_^Y*/J]7L'M(=S]$J*_.W_ (>Z?]4H_P#+C_\ N2C_ (>Z?]4H_P#+C_\
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M]4H_\N/_ .Y*/^'NG_5*/_+C_P#N2CZO5[![2'<_1*BOSM_X>Z?]4H_\N/\
M^Y*/^'NG_5*/_+C_ /N2CZO5[![2'<_1*BOSM_X>Z?\ 5*/_ "X__N2C_A[I
M_P!4H_\ +C_^Y*/J]7L'M(=S]$J*_.W_ (>Z?]4H_P#+C_\ N2C_ (>Z?]4H
M_P#+C_\ N2CZO5[![2'<_1*BOSM_X>Z?]4H_\N/_ .Y*/^'NG_5*/_+C_P#N
M2CZO5[![2'<_1*BOSM_X>Z?]4H_\N/\ ^Y*/^'NG_5*/_+C_ /N2CZO5[![2
M'<_1*BOSM_X>Z?\ 5*/_ "X__N2C_A[I_P!4H_\ +C_^Y*/J]7L'M(=S]$J*
M_.W_ (>Z?]4H_P#+C_\ N2C_ (>Z?]4H_P#+C_\ N2CZO5[![2'<_1*BOSM_
MX>Z?]4H_\N/_ .Y*?'_P5R0R()/A4RQY&YE\0[B!W('V49/XBCZO5[![2'<_
M0^BOA'0_^"LGA&XN-NL>!-:L(/[]E=0W+?\ ?+>7_.O?_A?^VA\(?BS<0VFD
M^++>PU24A5T_6%-G,S'HJE_D=O9&)J)4:D=T4IQ>S/;Z***Q+"BBB@ HHHH
M**** "BBB@ HHHH ***Y'XB?%SP;\)M-6^\7^)-/T"!@3&MW,!)+CKY<8R[G
MV4&FDWH@.NHKXU\8_P#!4KX7:',\.AZ5KWB5UZ3I EM W/K(V_\ -*X"\_X*
MX6B;/LOPOFFZ[O.UT1X],8MVSW]*V5"H^AG[2/<_0FBOSM_X>Z?]4H_\N/\
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M1_Y<?_W)1_P]T_ZI1_Y<?_W)1]7J]@]I#N?HE17YV_\ #W3_ *I1_P"7'_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,[8R4E<****R+"BBB@ HHHH ***^3?V]/VLG^!/A:+PMX;FV^-M<@9TN%/\
MR#[8DJ9O]]B&5/0AF_A -PBYRY43*2BKLI?M>?M[:5\%_M/A7P4UMKGC8?)/
M,WSVNF^N_'WY?]@'"_Q=-I_,+XA?$[Q5\5_$$FM>+=<O-<U%N!)=/E8U_NQH
M,*B_[*@"N:EE>>1Y)':21R69V.2Q/4D]S3:]FG2C36FYQ2FY!1116YF%%%%
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M^)W8DX]!S@#L !63117O'GA1113$%%%% !1110 4444 %%%% !1110 4444
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MMCY4'<_@,D@']I?@7\!- ^"?POT7PE!;6VHS6<9:ZOI;==US<,=TDG.2!DX
MSPH4=JR)(_A%^Q9\-Y[B.WLO"FCYR0F9+R_E X4$DO,_U.%!_A%>@_#7QQ;_
M !*\ Z!XJM+:6SM=8LX[V*"8@NBNNX!L<9P>U>16K2J+1:'9""CZGXJ?M40I
M;_M(?$F.)%CC77KL*B#  \P\ 5Y97JW[5G_)RGQ,_P"P_=_^C#7E->K#X4<D
MMV%%%%62%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% #HI7@D22-VCD0AE=3@J1T(/8U^W'['_ ,:9
M/CM\"="U^\=7UJVW:=J>#G-Q$ "Y]W0I)CMOQ7XBU^A'_!)GQE(NI>/_  I(
M^89(K?5(8_[K*S12'\0T7_?-<>*CS0OV-J3M*Q^C=%%%>0=H4444 %>._M:?
M&=O@3\"]?\26K*-8D5;#3 Q_Y>9<A6]]BAY,=_+Q7L5?G;_P5H\92?\ %O\
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MO)=7$S=$C12S,?H 37X0_&SXK:E\:_B?KWC#4RR2ZC.6AMRVX6\"_+%$/94
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MBM\$?[$U.;SM:\)R)I[R,VYY+4J3;NWN KQ_]LL]Z^JZ_*#_ ()=^,I-#_:
MOM#+XMM<TF9/+]98F65#^"B7_OJOU?KQ,1'EJ.QW4W>(4445SFH4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %?GQ_P %;S)_9/PQ SY7GZCN],[;;']:_0>OBW_@JAX/
MDUGX(:%K\,>]M%UA1,W]R&:-D)_[[6(?C6]!VJ(SJ?"S\KJ***]PX HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MIXO^*^JKJ/B_Q#?Z_=Q@K&UY*66($Y(1!\J#/90!7*UU4:/LEKN93GSG[S_
M/_DA7PY_[%O3?_26.OS[_;(_;D\?VOQ>USPCX(UI_#>AZ#<M9/-:(GGW5PG$
MK,Y!(4/N4*N/NY.2>/T$^ ?_ "0KX<_]BWIO_I+'7XG_ !SG>Z^-GQ!F?EY/
M$.H.WU-S(37)AXJ4Y-HVJ2:BK'Z5_P#!.W]I3Q7\=/#OBK2?&5XNJ:KH4EO)
M#J)C2.2:&82#8X10"4,7WL9.\9Z9/D?_  5J\,VL.J?#GQ!'"JWMQ#>V,\P'
M+)&T3Q*3[&67_OHU#_P23_Y&+XE?]>MC_P"AS5T?_!6S_D7?AM_U]7W_ *!#
M324<39?UH+>EJ>$_L:_MB>&?V9-$UK3]2\'7FJ7>K7233ZM9W:!_*1<)%Y3*
M!A29&SOY+GIBMC]HK_@HAXS^(/BZ"+X9ZGJ?A/PQ#&@CB:&)+RYF(^8R$%\
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M /!0K]C_ ,*^#_!,GQ+\%:=#H)M;B./5M-M5VVTB2N$26-!Q&P=E4JN%(;.
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MDED8Y9F8\DDGK7)2IRJ2]K,VG)17)$J4445Z)S!1110 4444 %%%% !1110
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MIOH75CM(\GHHHKO.<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLJ^JJX)_0&NO#Q@HW@8U'*]F?N7^S_\ "73_ ((?"/P_X5LH8XI;6V62^F4
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M5^//[4"-'^T=\3@PP?\ A([\_@9W(_2C#Q3J2NAU&^5'V7_P2/\ ^0=\4/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'7NPFJD>9'GRBXNS"BBBM"0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K]H_V!_\ DTGX?_\ 7*[_ /2R>OQ<KVGP
M#^V3\8?AAX1T_P ,>&?%_P#9FAV =;:U_LRSE\L,[.WS20LQRS,>2>M<U>FZ
MD;(UIR47=G8_\%&_^3L/$O\ UZV/_I-'7S+73_$?XE>)/BUXLN?$OBS4?[5U
MNY1$ENO(CAW*BA5&V-5484 <"N8K:$>6*3(D[ML****LD_>?X!_\D*^'/_8M
MZ;_Z2QU^)?QK_P"2R>//^P_?_P#I1)7H^@?MU?'#POH6FZ-IGC?[-ING6T=I
M:P_V38OY<4:A$7<T!)PH R22<<UXEK6L7GB+6;_5=0F^T7]]<275Q-M5=\CL
M6=L* !DDG  %<E&C*G)M]3:<U))(^\_^"2?_ ",7Q*_Z];'_ -#FKH_^"MG_
M "+OPV_Z^K[_ - AKX<^$GQ[\=_ NXU*?P/KO]B2ZDD:73?8X+CS%0L5'[V-
M\8W-TQUJS\6_VC/B'\=+?38/''B'^VXM->1[5?L5O;^6SA0Q_=1IG.U>N>E'
ML9>V]IT#G7)RGZ7_ /!-GQ]IGBC]FO3=!MIH_P"T_#ES<6UY;KPRB6:2:-R/
M1@Y&>Y1NX->?_M:?\$]?$7QH^+%]XV\'^(-)M6U5(OMUGK3RQB.2.-8PT;1Q
MOD%47Y2!@YY(.!^=_P ._B=XI^$_B*+7/"6MW6B:DG!DMV^61<YVNARKK_LL
M"*^@6_X*6_&UM+-J-1T=9_\ G^&F)YPXQT)V>_W?TXJ'1J1FYTWN4IQ<;2/O
M']DG]F31?V6=(N=-NM=M]6\8^( )KB08BW1PC[D$9.XHADRS=RPR!P*\7_X*
MS:+<7'@'P%JJ1L;6UU.XMI' X5I8E90?J(6_*OA:V_:.^)5K\3(OB"/%U]-X
MNA1XX]0N0DP1'4JR+$ZF,)ACA0N >0 >:U_B3^UQ\6/B]X5G\-^+O%*ZOHTT
MB2O;-IEG$=Z'*D/'"K @^A'<=#1&C-5%-NX.I'EY4CZ>_P"";.K_  J\4V-[
MX/\ %'A?P[<^.(;A[G3KS4K"*6:[MRH+(CNI^="&. <E6XX5J]=_:R_X)^P?
M&[Q%;^)_!NIV'AK6!;I;7-C<P%;2<)PC@Q@E&"_*?E(("],'/Y56=Y<:?=0W
M5K/);7,+B2*:%RCHP.0RL.00>XKZ'\&_\%!/C;X-T^WL1XHCUJW@&%_MBTCN
M)"..&EP)&^K,3SUZ54Z4^?GIL49QMRR1]9?LE_\ !/OQ)\#_ (I:?XW\3>*M
M/FFT^.9(M.T7S728R1M&?,DD5/E ;=M"\L!R,<[?_!2_XU:/X7^#5Q\/X[F.
M?Q%XC>%FM4(+V]K'*LIE8=@S1A!GKEL?=-?(WB;_ (*0_&WQ!:206^L:;H0D
M7:9-,TY ^.^&DWD'W'/IBOFW7=>U+Q1J]UJNL7]SJFIW3F2>\O)6EEE8]V9B
M234QHSE-3J/8'.*CRQ/L/_@FG^T'8?#?QQJ?@CQ!?QV.C^(RDEE-,<1QWR_*
M%)[>8IQD]T0=Z^S?VM_V1-+_ &G='TZ9-1_L+Q/I89+34#%YD<D;')BE4$$K
MD9!!^4D\')%?C!7O?PW_ &Y?C'\,=+ATNP\4G4]-A0)#;:Q MUY:CH%=AO
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M\#:]_8;ZF(UNS]CM[CS!'NV?ZV-\8WMTQG//:K?Q:_:4^(_QRTZPL?&_B/\
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M%%% !1110 4444 %%%% !1110 445Z_^S%^SGK/[2'Q$AT.R,EGHUKMGU;5
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ML1_TT8#_ &NE?/'PA_:^^*?P2TK^R?#GB-FT<'<FG:A$MS#%UXC#C* YR0I
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M7;$B@_,[')&>:XJKIQ<(*+%)\SN%%%%:$!1110 4444 %%%% !1110 4444
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MO_Y;G_W71]8I=P]G/L?G=17Z(_\ #HO_ *JO_P"6Y_\ =='_  Z+_P"JK_\
MEN?_ '71]8I=P]G/L?G=17Z(_P##HO\ ZJO_ .6Y_P#=='_#HO\ ZJO_ .6Y
M_P#=='UBEW#V<^Q^=U%?HC_PZ+_ZJO\ ^6Y_]UT?\.B_^JK_ /EN?_=='UBE
MW#V<^Q^=U%?HC_PZ+_ZJO_Y;G_W71_PZ+_ZJO_Y;G_W71]8I=P]G/L?G=17Z
M(_\ #HO_ *JO_P"6Y_\ =='_  Z+_P"JK_\ EN?_ '71]8I=P]G/L?G=17Z(
M_P##HO\ ZJO_ .6Y_P#=='_#HO\ ZJO_ .6Y_P#=='UBEW#V<^Q^=U%?HC_P
MZ+_ZJO\ ^6Y_]UT?\.B_^JK_ /EN?_=='UBEW#V<^Q^=U%?HC_PZ+_ZJO_Y;
MG_W71_PZ+_ZJO_Y;G_W71]8I=P]G/L?G=17Z(_\ #HO_ *JO_P"6Y_\ =='_
M  Z+_P"JK_\ EN?_ '71]8I=P]G/L?G=17Z(_P##HO\ ZJO_ .6Y_P#=='_#
MHO\ ZJO_ .6Y_P#=='UBEW#V<^Q^=U%?HC_PZ+_ZJO\ ^6Y_]UT?\.B_^JK_
M /EN?_=='UBEW#V<^Q^=U%?HC_PZ+_ZJO_Y;G_W71_PZ+_ZJO_Y;G_W71]8I
M=P]G/L?G=17Z(_\ #HO_ *JO_P"6Y_\ =='_  Z+_P"JK_\ EN?_ '71]8I=
MP]G/L?G=17Z(_P##HO\ ZJO_ .6Y_P#=='_#HO\ ZJO_ .6Y_P#=='UBEW#V
M<^Q^=U%?HC_PZ+_ZJO\ ^6Y_]UT?\.B_^JK_ /EN?_=='UBEW#V<^Q^=U%?H
MC_PZ+_ZJO_Y;G_W71_PZ+_ZJO_Y;G_W71]8I=P]G/L?G=17Z(_\ #HO_ *JO
M_P"6Y_\ =='_  Z+_P"JK_\ EN?_ '71]8I=P]G/L?G=17Z(_P##HO\ ZJO_
M .6Y_P#=='_#HO\ ZJO_ .6Y_P#=='UBEW#V<^Q^=U%?HC_PZ+_ZJO\ ^6Y_
M]UT?\.B_^JK_ /EN?_=='UBEW#V<^Q^=U%?HC_PZ+_ZJO_Y;G_W71_PZ+_ZJ
MO_Y;G_W71]8I=P]G/L?G=17Z(_\ #HO_ *JO_P"6Y_\ =='_  Z+_P"JK_\
MEN?_ '71]8I=P]G/L?G=17Z(_P##HO\ ZJO_ .6Y_P#=='_#HO\ ZJO_ .6Y
M_P#=='UBEW#V<^Q^=U%?HC_PZ+_ZJO\ ^6Y_]UT?\.B_^JK_ /EN?_=='UBE
MW#V<^Q^=U%?HC_PZ+_ZJO_Y;G_W71_PZ+_ZJO_Y;G_W71]8I=P]G/L?G=17Z
M(_\ #HO_ *JO_P"6Y_\ =='_  Z+_P"JK_\ EN?_ '71]8I=P]G/L?G=17Z(
M_P##HO\ ZJO_ .6Y_P#=='_#HO\ ZJO_ .6Y_P#=='UBEW#V<^Q^=U%?HC_P
MZ+_ZJO\ ^6Y_]UT?\.B_^JK_ /EN?_=='UBEW#V<^Q^=U%?HC_PZ+_ZJO_Y;
MG_W71_PZ+_ZJO_Y;G_W71]8I=P]G/L?G=17Z(_\ #HO_ *JO_P"6Y_\ =='_
M  Z+_P"JK_\ EN?_ '71]8I=P]G/L?G=17Z(_P##HO\ ZJO_ .6Y_P#=='_#
MHO\ ZJO_ .6Y_P#=='UBEW#V<^Q^=U%?HC_PZ+_ZJO\ ^6Y_]UT?\.B_^JK_
M /EN?_=='UBEW#V<^Q^=U%?HC_PZ+_ZJO_Y;G_W71_PZ+_ZJO_Y;G_W71]8I
M=P]G/L?G=17Z(_\ #HO_ *JO_P"6Y_\ =='_  Z+_P"JK_\ EN?_ '71]8I=
MP]G/L?G=17Z(_P##HO\ ZJO_ .6Y_P#=='_#HO\ ZJO_ .6Y_P#=='UBEW#V
M<^Q^=U%?HC_PZ+_ZJO\ ^6Y_]UT?\.B_^JK_ /EN?_=='UBEW#V<^Q^=U%?H
MC_PZ+_ZJO_Y;G_W71_PZ+_ZJO_Y;G_W71]8I=P]G/L?G=17Z(_\ #HO_ *JO
M_P"6Y_\ =='_  Z+_P"JK_\ EN?_ '71]8I=P]G/L?G=17Z(_P##HO\ ZJO_
M .6Y_P#=='_#HO\ ZJO_ .6Y_P#=='UBEW#V<^Q^=U%?HC_PZ+_ZJO\ ^6Y_
M]UT?\.B_^JK_ /EN?_=='UBEW#V<^Q^=U%?HC_PZ+_ZJO_Y;G_W71_PZ+_ZJ
MO_Y;G_W71]8I=P]G/L?G=17Z(_\ #HO_ *JO_P"6Y_\ =='_  Z+_P"JK_\
MEN?_ '71]8I=P]G/L?G=17Z(_P##HO\ ZJO_ .6Y_P#=='_#HO\ ZJO_ .6Y
M_P#=='UBEW#V<^Q^=U%?HC_PZ+_ZJO\ ^6Y_]UT?\.B_^JK_ /EN?_=='UBE
MW#V<^Q^=U%?HC_PZ+_ZJO_Y;G_W71_PZ+_ZJO_Y;G_W71]8I=P]G/L?G=17Z
M(_\ #HO_ *JO_P"6Y_\ =='_  Z+_P"JK_\ EN?_ '71]8I=P]G/L?G=17Z(
M_P##HO\ ZJO_ .6Y_P#=='_#HO\ ZJO_ .6Y_P#=='UBEW#V<^Q^=U%?HC_P
MZ+_ZJO\ ^6Y_]UT?\.B_^JK_ /EN?_=='UBEW#V<^Q^=U%?HC_PZ+_ZJO_Y;
MG_W71_PZ+_ZJO_Y;G_W71]8I=P]G/L?G=17Z(_\ #HO_ *JO_P"6Y_\ =='_
M  Z+_P"JK_\ EN?_ '71]8I=P]G/L?G=17Z(_P##HO\ ZJO_ .6Y_P#=='_#
MHO\ ZJO_ .6Y_P#=='UBEW#V<^Q^=U%?HC_PZ+_ZJO\ ^6Y_]UT?\.B_^JK_
M /EN?_=='UBEW#V<^Q^=U%?HC_PZ+_ZJO_Y;G_W71_PZ+_ZJO_Y;G_W71]8I
M=P]G/L?G=17Z(_\ #HO_ *JO_P"6Y_\ =='_  Z+_P"JK_\ EN?_ '71]8I=
MP]G/L?G=17Z(_P##HO\ ZJO_ .6Y_P#=='_#HO\ ZJO_ .6Y_P#=='UBEW#V
M<^Q^=U%?HC_PZ+_ZJO\ ^6Y_]UT?\.B_^JK_ /EN?_=='UBEW#V<^Q^=U%?H
MC_PZ+_ZJO_Y;G_W71_PZ+_ZJO_Y;G_W71]8I=P]G/L?G=17Z(_\ #HO_ *JO
M_P"6Y_\ =='_  Z+_P"JK_\ EN?_ '71]8I=P]G/L?G=17Z(_P##HO\ ZJO_
M .6Y_P#=='_#HO\ ZJO_ .6Y_P#=='UBEW#V<^Q^=U%?HC_PZ+_ZJO\ ^6Y_
M]UT?\.B_^JK_ /EN?_=='UBEW#V<^Q^=U%?HC_PZ+_ZJO_Y;G_W71_PZ+_ZJ
MO_Y;G_W71]8I=P]G/L?G=17Z(_\ #HO_ *JO_P"6Y_\ =='_  Z+_P"JK_\
MEN?_ '71]8I=P]G/L?G=17Z(_P##HO\ ZJO_ .6Y_P#=='_#HO\ ZJO_ .6Y
M_P#=='UBEW#V<^Q^=U%?HC_PZ+_ZJO\ ^6Y_]UT?\.B_^JK_ /EN?_=='UBE
MW#V<^Q^=U%?HC_PZ+_ZJO_Y;G_W71_PZ+_ZJO_Y;G_W71]8I=P]G/L?G=17Z
M(_\ #HO_ *JO_P"6Y_\ =='_  Z+_P"JK_\ EN?_ '71]8I=P]G/L?G=17Z(
M_P##HO\ ZJO_ .6Y_P#=='_#HO\ ZJO_ .6Y_P#=='UBEW#V<^Q^=U%?HC_P
MZ+_ZJO\ ^6Y_]UT?\.B_^JK_ /EN?_=='UBEW#V<^Q^=U%?HC_PZ+_ZJO_Y;
MG_W71_PZ+_ZJO_Y;G_W71]8I=P]G/L?G=17Z(_\ #HO_ *JO_P"6Y_\ =='_
M  Z+_P"JK_\ EN?_ '71]8I=P]G/L?G=17Z(_P##HO\ ZJO_ .6Y_P#=='_#
MHO\ ZJO_ .6Y_P#=='UBEW#V<^Q^=U%?HC_PZ+_ZJO\ ^6Y_]UT?\.B_^JK_
M /EN?_=='UBEW#V<^Q^=U%?HC_PZ+_ZJO_Y;G_W71_PZ+_ZJO_Y;G_W71]8I
M=P]G/L?G=17Z(_\ #HO_ *JO_P"6Y_\ =='_  Z+_P"JK_\ EN?_ '71]8I=
MP]G/L?G=17Z(_P##HO\ ZJO_ .6Y_P#=='_#HO\ ZJO_ .6Y_P#=='UBEW#V
M<^Q^=U%?HC_PZ+_ZJO\ ^6Y_]UT?\.B_^JK_ /EN?_=='UBEW#V<^Q^=U%?H
MC_PZ+_ZJO_Y;G_W773^%/^"3O@^PFC?Q'XWUC654Y:/3[:*R5O8[C*<?0Y]Q
M2^L4NX>REV/S,M+2>_NHK:UADN;F9Q''#"A9W8G 4 <DD]A7W!^RS_P3CUOQ
M5J%KXB^*EI-H>@)MEBT(OMN[SOB7',*>HX<\C"]:^[OA/^S+\-?@GME\)^%K
M2SU +M.I7&;B[.>O[UR64'N%P/:O4*Y:F*<M(:&T:-M9%+1]&L/#NE6FF:79
MP:?IUI&L-O:VT8CCB0# 55'  %7:**X#H"BBB@ HHHH **** *NJ:79:YIMU
MI^HVD-_874;0SVMS&)(Y488*LIX(([&OS2_:H_X)PZOX=U"Y\1_"BSDUC0Y,
MR3>'P^ZZM#U/DY.94]%Y<=/FZC]-Z*UIU)4W=$2BI;G\\5Y9W&FW<UK=P26M
MU"YCEAF0HZ,#@JRGD$'L:AK]UOBQ^S7\-OC8&D\6^%K.^ORNP:E"#!=J!T_>
MH0Q [!B1[5\Q^+/^"3_@W4)I'\.>-=9T56.5COK>*]5?8;3$<?4_C7HQQ4'\
M6AS.C);'YBT5^B/_  Z+_P"JK_\ EN?_ '71_P .B_\ JJ__ );G_P!UUI]8
MI=R?9S['YW45^B/_  Z+_P"JK_\ EN?_ '71_P .B_\ JJ__ );G_P!UT?6*
M7</9S['YW45^B/\ PZ+_ .JK_P#EN?\ W71_PZ+_ .JK_P#EN?\ W71]8I=P
M]G/L?G=17Z(_\.B_^JK_ /EN?_=='_#HO_JJ_P#Y;G_W71]8I=P]G/L?G=17
MZ(_\.B_^JK_^6Y_]UT?\.B_^JK_^6Y_]UT?6*7</9S['YW45^B/_  Z+_P"J
MK_\ EN?_ '71_P .B_\ JJ__ );G_P!UT?6*7</9S['YW45^B/\ PZ+_ .JK
M_P#EN?\ W71_PZ+_ .JK_P#EN?\ W71]8I=P]G/L?G=17Z(_\.B_^JK_ /EN
M?_=='_#HO_JJ_P#Y;G_W71]8I=P]G/L?G=17Z(_\.B_^JK_^6Y_]UT?\.B_^
MJK_^6Y_]UT?6*7</9S['YW45^B/_  Z+_P"JK_\ EN?_ '71_P .B_\ JJ__
M );G_P!UT?6*7</9S['YW45^B/\ PZ+_ .JK_P#EN?\ W71_PZ+_ .JK_P#E
MN?\ W71]8I=P]G/L?G=17Z(_\.B_^JK_ /EN?_=='_#HO_JJ_P#Y;G_W71]8
MI=P]G/L?G=17Z(_\.B_^JK_^6Y_]UT?\.B_^JK_^6Y_]UT?6*7</9S['YW45
M^B/_  Z+_P"JK_\ EN?_ '71_P .B_\ JJ__ );G_P!UT?6*7</9S['YW45^
MB/\ PZ+_ .JK_P#EN?\ W71_PZ+_ .JK_P#EN?\ W71]8I=P]G/L?G=17Z(_
M\.B_^JK_ /EN?_=='_#HO_JJ_P#Y;G_W71]8I=P]G/L?G=17Z(_\.B_^JK_^
M6Y_]UT?\.B_^JK_^6Y_]UT?6*7</9S['YW45^B/_  Z+_P"JK_\ EN?_ '71
M_P .B_\ JJ__ );G_P!UT?6*7</9S['YW45^B/\ PZ+_ .JK_P#EN?\ W71_
MPZ+_ .JK_P#EN?\ W71]8I=P]G/L?G=17Z(_\.B_^JK_ /EN?_=='_#HO_JJ
M_P#Y;G_W71]8I=P]G/L?G=17Z(_\.B_^JK_^6Y_]UT?\.B_^JK_^6Y_]UT?6
M*7</9S['YW45^B/_  Z+_P"JK_\ EN?_ '71_P .B_\ JJ__ );G_P!UT?6*
M7</9S['YW45^B/\ PZ+_ .JK_P#EN?\ W71_PZ+_ .JK_P#EN?\ W71]8I=P
M]G/L?G=17Z(_\.B_^JK_ /EN?_=='_#HO_JJ_P#Y;G_W71]8I=P]G/L?G=17
MZ(_\.B_^JK_^6Y_]UT?\.B_^JK_^6Y_]UT?6*7</9S['YW45^B/_  Z+_P"J
MK_\ EN?_ '71_P .B_\ JJ__ );G_P!UT?6*7</9S['YW45^B/\ PZ+_ .JK
M_P#EN?\ W71_PZ+_ .JK_P#EN?\ W71]8I=P]G/L?G=17Z(_\.B_^JK_ /EN
M?_=='_#HO_JJ_P#Y;G_W71]8I=P]G/L?G=17Z(_\.B_^JK_^6Y_]UT?\.B_^
MJK_^6Y_]UT?6*7</9S['YW45^B/_  Z+_P"JK_\ EN?_ '71_P .B_\ JJ__
M );G_P!UT?6*7</9S['YW45^B/\ PZ+_ .JK_P#EN?\ W71_PZ+_ .JK_P#E
MN?\ W71]8I=P]G/L?G=17Z(_\.B_^JK_ /EN?_=='_#HO_JJ_P#Y;G_W71]8
MI=P]G/L?G=17Z(_\.B_^JK_^6Y_]UT?\.B_^JK_^6Y_]UT?6*7</9S['YW45
M^B/_  Z+_P"JK_\ EN?_ '71_P .B_\ JJ__ );G_P!UT?6*7</9S['YW45^
MB/\ PZ+_ .JK_P#EN?\ W71_PZ+_ .JK_P#EN?\ W71]8I=P]G/L?G=17Z(_
M\.B_^JK_ /EN?_=='_#HO_JJ_P#Y;G_W71]8I=P]G/L?G=17Z(_\.B_^JK_^
M6Y_]UT?\.B_^JK_^6Y_]UT?6*7</9S['YW45^B/_  Z+_P"JK_\ EN?_ '71
M_P .B_\ JJ__ );G_P!UT?6*7</9S['YW45^B/\ PZ+_ .JK_P#EN?\ W773
M^%/^"3O@^PFC?Q'XWUC654Y:/3[:*R5O8[C*<?0Y]Q2^L4NX>REV/S,M+2>_
MNHK:UADN;F9Q''#"A9W8G 4 <DD]A7W!^RS_ ,$X];\5:A:^(OBI:3:'H";9
M8M"+[;N\[XEQS"GJ.'/(PO6ON[X3_LR_#7X)[9?"?A:TL]0"[3J5QFXNSGK^
M]<EE![A<#VKU"N6IBG+2&AM&C;612T?1K#P[I5IIFEV<&GZ=:1K#;VMM&(XX
MD P%51P !5VBBN Z HHHH **** "BBB@ HHHH ^+OVOO^"?VG_%:2[\7?#V*
MVT?Q>Y,MWIS$1VNHMW8'I'*?7[K'[V"2U?F9XW\ ^(_AMK\VB>*-&O-#U2'E
MK>\B*$CLRGHRGLRD@]C7] E<QX^^&/A3XI:2-,\6^'[#7[)22B7L(<QD]61O
MO(?=2#792Q,H:2U1C*DI:H_ .BOU7\;?\$M?ACKTSS>'M7UOPN[9Q LJW<"^
MF!(-_P";UYV__!(Q2S;?BL0N> WAW) ^OVJNU8FF^IA[*1^=E%?HC_PZ+_ZJ
MO_Y;G_W71_PZ+_ZJO_Y;G_W73^L4NXO9S['YW45^B/\ PZ+_ .JK_P#EN?\
MW71_PZ+_ .JK_P#EN?\ W71]8I=P]G/L?G=17Z(_\.B_^JK_ /EN?_=='_#H
MO_JJ_P#Y;G_W71]8I=P]G/L?G=17Z(_\.B_^JK_^6Y_]UT?\.B_^JK_^6Y_]
MUT?6*7</9S['YW45^B/_  Z+_P"JK_\ EN?_ '71_P .B_\ JJ__ );G_P!U
MT?6*7</9S['YW45^B/\ PZ+_ .JK_P#EN?\ W71_PZ+_ .JK_P#EN?\ W71]
M8I=P]G/L?G=17Z(_\.B_^JK_ /EN?_=='_#HO_JJ_P#Y;G_W71]8I=P]G/L?
MG=17Z(_\.B_^JK_^6Y_]UT?\.B_^JK_^6Y_]UT?6*7</9S['YW45^B/_  Z+
M_P"JK_\ EN?_ '71_P .B_\ JJ__ );G_P!UT?6*7</9S['YW45^B/\ PZ+_
M .JK_P#EN?\ W71_PZ+_ .JK_P#EN?\ W71]8I=P]G/L?G=17Z(_\.B_^JK_
M /EN?_=='_#HO_JJ_P#Y;G_W71]8I=P]G/L?G=17Z(_\.B_^JK_^6Y_]UT?\
M.B_^JK_^6Y_]UT?6*7</9S['YW45^B/_  Z+_P"JK_\ EN?_ '71_P .B_\
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M '71_P .B_\ JJ__ );G_P!UT?6*7</9S['YW45^B/\ PZ+_ .JK_P#EN?\
MW71_PZ+_ .JK_P#EN?\ W71]8I=P]G/L?G=17Z(_\.B_^JK_ /EN?_=='_#H
MO_JJ_P#Y;G_W71]8I=P]G/L?G=17Z(_\.B_^JK_^6Y_]UT?\.B_^JK_^6Y_]
MUT?6*7</9S['YW45^B/_  Z+_P"JK_\ EN?_ '71_P .B_\ JJ__ );G_P!U
MT?6*7</9S['YW45^B/\ PZ+_ .JK_P#EN?\ W71_PZ+_ .JK_P#EN?\ W71]
M8I=P]G/L?G=17Z(_\.B_^JK_ /EN?_=='_#HO_JJ_P#Y;G_W71]8I=P]G/L?
MG=17Z(_\.B_^JK_^6Y_]UT?\.B_^JK_^6Y_]UT?6*7</9S['YW45^B/_  Z+
M_P"JK_\ EN?_ '71_P .B_\ JJ__ );G_P!UT?6*7</9S['YW45^B/\ PZ+_
M .JK_P#EN?\ W71_PZ+_ .JK_P#EN?\ W71]8I=P]G/L?G=17Z(_\.B_^JK_
M /EN?_=='_#HO_JJ_P#Y;G_W71]8I=P]G/L?G=17Z(_\.B_^JK_^6Y_]UT?\
M.B_^JK_^6Y_]UT?6*7</9S['YW45^B/_  Z+_P"JK_\ EN?_ '71_P .B_\
MJJ__ );G_P!UT?6*7</9S['YW45^B/\ PZ+_ .JK_P#EN?\ W71_PZ+_ .JK
M_P#EN?\ W71]8I=P]G/L?G=17Z(_\.B_^JK_ /EN?_=='_#HO_JJ_P#Y;G_W
M71]8I=P]G/L?G=17Z(_\.B_^JK_^6Y_]UT?\.B_^JK_^6Y_]UT?6*7</9S['
MYW45^B/_  Z+_P"JK_\ EN?_ '71_P .B_\ JJ__ );G_P!UT?6*7</9S['Y
MW45^B/\ PZ+_ .JK_P#EN?\ W71_PZ+_ .JK_P#EN?\ W71]8I=P]G/L?G=1
M7Z2:'_P23T>WN,ZQ\2+Z^@_N6.DI;-_WTTL@_2O?_A?^PK\'?A7<0W=KX:_M
M[4H2"E]K\GVM@1T(C($0.><A :B6*IK;4:I2ZGYS_LY_L0>//CQ>66H7%G+X
M9\'2,&DUJ^CVF6/_ *=XS@R$]FX3WXP?UC^$?P=\+?!#P?;^'/">G+8V4?S2
MS-AIKF3&#+*^/F8_D!P   *[0 *  , 4M>?4K2J;['3&"B%%%%8&@4444 %%
M%% !1110 4V1%D1D=0Z,,%6&01Z&G44 ?GU^UK_P3E.KW=SXL^$EI##<2$R7
MGAC>L<;'J7MB2%7_ *YD@?W2.%K\\?$'AW5/"FL7.E:UIUUI6IVK;)K.\A:*
M6-O1E8 BOZ$ZX;XG?!#P)\9+);;QEX8L=;V*4BN)4*7$0/4),I#J/8,*[:>)
M<=):F$J2>J/P5HK]2/&/_!*GX?ZM,\OAWQ/KGA\MTAN!'>1+] 0C8^K&N(_X
M=%_]57_\MS_[KKL6)I/J8>RD?G=17Z(_\.B_^JK_ /EN?_=='_#HO_JJ_P#Y
M;G_W73^L4NX>SGV/SNHK]$?^'1?_ %5?_P MS_[KH_X=%_\ 55__ "W/_NNC
MZQ2[A[.?8_.ZBOT1_P"'1?\ U5?_ ,MS_P"ZZ/\ AT7_ -57_P#+<_\ NNCZ
MQ2[A[.?8_.ZBOT1_X=%_]57_ /+<_P#NNC_AT7_U5?\ \MS_ .ZZ/K%+N'LY
M]C\[J*_1'_AT7_U5?_RW/_NNC_AT7_U5?_RW/_NNCZQ2[A[.?8_.ZBOT1_X=
M%_\ 55__ "W/_NNC_AT7_P!57_\ +<_^ZZ/K%+N'LY]C\[J*_1'_ (=%_P#5
M5_\ RW/_ +KH_P"'1?\ U5?_ ,MS_P"ZZ/K%+N'LY]C\[J*_1'_AT7_U5?\
M\MS_ .ZZ/^'1?_55_P#RW/\ [KH^L4NX>SGV/SNHK]$?^'1?_55__+<_^ZZ/
M^'1?_55__+<_^ZZ/K%+N'LY]C\[J*_1'_AT7_P!57_\ +<_^ZZ/^'1?_ %5?
M_P MS_[KH^L4NX>SGV/SNHK]$?\ AT7_ -57_P#+<_\ NNC_ (=%_P#55_\
MRW/_ +KH^L4NX>SGV/SNHK]$?^'1?_55_P#RW/\ [KH_X=%_]57_ /+<_P#N
MNCZQ2[A[.?8_.ZBOT1_X=%_]57_\MS_[KH_X=%_]57_\MS_[KH^L4NX>SGV/
M,OV/?V]Y/@3H,?@WQ?IUUK/A..1GL[FR*FYL=Q+,@1B \98EL9!4ENN0!]J:
M;^WY\!->M]LOC-;8D;F@OM,NEQ@COY14G/H37SQ_PZ+_ .JK_P#EN?\ W71_
MPZ+_ .JK_P#EN?\ W77+/ZO-WN:Q]I%6L>Y^,/\ @HY\$O#-E-)8:[>^);M
M=MKIFGS*6/8;Y51,>X)K\W?VGOVE-;_:7\=)K.H6ZZ;I-BC0:9I:/O%O&3EB
MS8&YV(&3@=  ,"OJ_P#X=%_]57_\MS_[KH_X=%_]57_\MS_[KJJ<L/3=T]12
M526C1^=U%?HC_P .B_\ JJ__ );G_P!UT?\ #HO_ *JO_P"6Y_\ ==='UBEW
M,_9S['YW45^B/_#HO_JJ_P#Y;G_W71_PZ+_ZJO\ ^6Y_]UT?6*7</9S['YW4
M5^B/_#HO_JJ__EN?_=='_#HO_JJ__EN?_=='UBEW#V<^Q^=U%?HC_P .B_\
MJJ__ );G_P!UT?\ #HO_ *JO_P"6Y_\ =='UBEW#V<^Q^=U%?HC_ ,.B_P#J
MJ_\ Y;G_ -UT?\.B_P#JJ_\ Y;G_ -UT?6*7</9S['YW45^B/_#HO_JJ_P#Y
M;G_W71_PZ+_ZJO\ ^6Y_]UT?6*7</9S['YW45^B/_#HO_JJ__EN?_=='_#HO
M_JJ__EN?_=='UBEW#V<^Q^=U%?HC_P .B_\ JJ__ );G_P!UT?\ #HO_ *JO
M_P"6Y_\ =='UBEW#V<^Q^=U%?HC_ ,.B_P#JJ_\ Y;G_ -UT?\.B_P#JJ_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<=\8OB$GPI^%OBCQ<\
M'VHZ1827,<!.!)(!A%)[ L5!/H::5W9 ==+*D,;22.L<:C<S,<  =R:(9DN(
MUDB=9(V&5=#D$>H-?D%\,?A/\4_V_O%&OZWJOB^)+;39$,TVI2.T4+2;RD=O
M @PH 4_W1CN32_&/]GKXI?L-WFC^*M&\7DV%U<FWBU/1Y'A*3;2PCFB;Y2&5
M2<'<#L8'H,]?U=7Y>;4P]H[7MH?K_17DG[*_QHD^/?P3T+Q7=PQV^JOOM=0B
MB^X+B-MK,OH&&UP.V_'.,UZ?JNL6&A69N]2OK;3[53@SW4RQ(">VYB!7*XN+
MLS9.ZN7**S=#\2:1XFMC<:/JMEJMO_SUL;A)D_-215^::.WB:25UBC499W(
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **_%"Y\)^(_B_P#M4^(/!6DZ[)I]WJ?B+4889KFXD$,>
MV29^=N3C"$<"O=+[_@F?\8[&SEN+/QWH]W=1+OC@2]NHV=AR &*8!],\>XKL
M=",;<T[&*J-[(_3NBOS3_8(_:6\=Z7\:(_A-XRU&]UFRNVN+6%=2E::?3[F!
M)'*AV);81&RE22 =N,#.?M7]IOX]6/[.OPIO_%,\4=YJ+,+33+&1L"XN7!*@
MXYVJ S-CLI Y(K&=*49\G<N,U)7/59)%AC9W9411N9F.  .I)I(9DN(UDB=9
M(V&5=#D$>H-?D/X#^$_QK_;XUC4O$.H^( =&MIS$][JD[I9PR8#>3;P(#R%<
M'@ 8/+9/+?BA\!_C'^PS>:9XITGQ,W]ER3B)-3T:9Q$LI!(CGA<8(8 \,&4X
M]>*V^KJ_+S:F?M'O;0_7VBO%_P!DGX^-^T1\';'Q'=P1VNM6TK6&IPQ#">>@
M4ET'965E;'8DC)QFO@;X3^,=?N/^"AAT^76]2EL/^$PU*/[*]W(8M@DGPNS.
M,# XQVK*-%R<D^A;FE;S/UAHHIDLJ0QO)(RI&@+,S'  '4FL#0?17Y-7GCSX
MJ_M]?'/4/#WAWQ#+H'AV)9;F"R^TR0VMK9HRIYD@09DD;>O4'ER!M7IG>/--
M^,7_  3_ /B1H4R>+FU.QOXS/$L=Q))9WL:./-AEADZ,,CD<@."K YQV?5^G
M-KV,?:=;:'Z[45\^_'SPWJ7[3W[+^G_\(IJ5CH%SK\.GZK!/JET\,44;!92C
M2(C'.#C[O7TJ?]B_X.^(/@C\)[W0/$FM:;KU_+JTUXMUI5W)<Q"-HH5"EG13
MN!1CC&.1SS7/RKEO?7L:7UL>]T445F4%9/B;Q9H?@O2VU/Q#K.GZ#IJNL9O-
M3NH[:$,>B[W(&3V&:UJ^5/\ @I?_ ,FNWW_85L__ $(U<(\TE$F3LKGLW_#1
MWPF_Z*AX,_\ "@M/_CE:6@?&KX>^+-2CT_1/'GAG6+^0X2UT_6+>>5OHB.2?
MRK\S_P!C[]A_0_VEOAGJ?B?4_$VH:-/::O+IJV]I CJRK##)N);G.92/P%2?
MM9?L%6_[/'P]B\9:+XKGUBTBNH[:YM;VW6*1=^=KHZMSR -N,\YSQBNKV-/F
MY.;4RYY6O8_5^H;N\@L+66YN9H[>WB4O)-,X5$4=22> *^;_ /@GQ\4-?^*7
M[.]K<^([B2]OM)OYM*2]F.9+B*-(W1F/\1 DV9ZG9DY.37QQ^U5\<?&'[5GQ
MV'PM\&3S'P[%J/\ 9=G8PR%8KZ9'(>YF(ZH"K,,Y"HF[&2:RC1<IN+Z%N:23
M/T%OOVL/@YIU_P#8YOB3X=\_=M/EWR2(#G'+KE1^)KO_  KXRT#QUI8U+PYK
M>GZ]IY;;]JTVZ2XCW=U+(2 ?;K7P[X=_X)-Z$N@H->\=ZB^M-&"[:=;1K;QO
MW #Y9P/7*YQG Z#PO3?@O\:_V0_VB((_!>DZOXL$ CG^T:18326NHV;,04F5
M00AX8$,?E8 @_=-:>RIRTA+4GGDOB1^K/B;Q9H?@O2VU/Q#K.GZ#IJNL9O-3
MNH[:$,>B[W(&3V&:Y#_AH[X3?]%0\&?^%!:?_'*\3_X*27'VO]E.>?RI(?-U
M&Q?RY5VNF23AAV([U\F_L??L/Z'^TM\,]3\3ZGXFU#1I[35Y=-6WM($=6588
M9-Q+<YS*1^ J84HN'/)V'*3YN5(_3#0/C5\/?%FI1Z?HGCSPSK%_(<):Z?K%
MO/*WT1')/Y5V=?E!^UE^P5;_ +/'P]B\9:+XKGUBTBNH[:YM;VW6*1=^=KHZ
MMSR -N,\YSQBOLG_ ()\?%#7_BE^SO:W/B.XDO;[2;^;2DO9CF2XBC2-T9C_
M !$"39GJ=F3DY-*=**ASP=T$9._*T?2U%%<+\:OC#HGP)^'U_P"+_$$5W/I]
MJR1^38QAY9'=MJJ 2!R3U) KG2;=D:[&WXT\?>&_ASI*:GXHURQT#3WE$"7.
MH3K"C2$$A 6/)(5CCV-7_#_B#3?%6BVFKZ/?0:GIEVGF6]W:N'CE7U5AP17X
MS?M1_M'>,OVE;^TU_4=,FT?P7:3R6VE6<89H%DP"Y:4@"27;MSCH,8 SS^H7
M[&O_ ":[\./^P6O_ *$U=%2C[."D]S*,^:5D>Q75U#8VTMQ<S1V]O$I>265@
MJ(H&223P /6N-T7XY?#GQ)K"Z3I/CWPSJ>J,VQ+.TU>WEE=O155R6/L*^!/^
M"A7Q@\1?$OXV:9\%O#EU)#IT,]K:W%M&Y5;V^N"AC$A'54$D8 Z;BQY(&+'Q
M6_X);ZIX;\"6E_X"UN[\4^+(7C%SI]P(;6.;/#/"[NH3:<'#,<C/.< U&C&R
M<Y6N)S=WRK8_2JL#Q;X^\,> ;6.Y\3>(M*\/6\A(CEU2]CME<CJ%+L,GV%>6
M_!W7?&OPG_9GDU#XM1?\3WPQ8W,MQ(+E)WN;>%2\9+J2"Y4!,GDE<G)-?G[\
M#?A7XA_X*!?&;Q/K_C+Q#=6FGV*+/=2VX#M$LC,(+: -\L:@*YS@_<.02Q-1
M"DG=R>B*E.UDEJS]5?"/CWPSX^LWN_#/B'2_$-M&0'ETN\CN%0GH&*$X/L:3
MQ!X_\,>$;J.VUSQ)I&BW$B>8D.H7T4#LN2-P#L"1D$9]J_/WPS^Q7\7_ -G7
M]HK2];^&A?7O"MO)"\U]<7EO;&>W9@)[:6(R L=N<,%Q]UAAAQ[_ /M7_L1_
M\-/^,M(U[_A-/^$:_L^P^P_9_P"ROM?F?O'?=N\Y,??QC!Z=:'"FI+WM 4I6
MVU/;_P#A=7P\_P"A\\,_^#BW_P#BZT_#_P 0O"OBR\>ST/Q+H^LW:1F5H-/O
MXIY%0$ L51B0,LHS[CUK\Q?V@O\ @G]HW[/?PUO_ !9J_P 5/M;QD066GKH
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M?VP)M9\>^,O%-W9Z6]V\+WS+Y]Y?7  9MI;A44,!NYY^4#@XVOVG/^"?>H_
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MY]/U-8EA>ZV<R0R(H"[PN6! &0C9Y&3S2HM)R3O8T517LS[?HHHKG-0HHHH
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M0=*_/']F'_E(58_]A_6/_15U6<:<)\S3T1;E)6OU/UWKQ2?]M'X*P:O)I?\
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MN,QV\7EW4T?R*2<9V;C[DUDX_NU*W7<J_O6N>M4445@:!1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M++]BN=2E6&WN+=Y"X'FL0H=6=AM)'R[2,\XVOVU/VY](\(>%(- ^%OBVUO\
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MSWY4UU5>>]SI"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1&#K'$"0^2ZJ2Q &%P,[LC:5"<JC5MR%4BHGZ55^0_\ P30_Y.BL?^P7>?\
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M=#E3Q7-&2]BXWUN:M/G3/C#_ ()]L+;]LJ6*4[)&@U*,*>[#)(_('\J^E/\
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M<TU_.6R%D,DB 1D\M@G(&T  Y'Z#P_\ !5+X16\211>&_&,<2*%5$L+,!0.
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M4445R&P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !2,H=2K ,I&"",@TM>9?&C]
MH[P)^S__ &/_ ,)KJ<VG?VMYWV3R;26??Y7E[\[%.,>:G7KGVII.3LA-VW/"
M?BE_P3'^&_CC6I]4\/ZCJ'@N2<EI+.S59[4,><JCX9.?X0VWT KG?"/_  2C
M\%:7JB7'B'Q?J^O6B,&^QVT"68?!Y5VR[;3_ +.T^]>E_P##QOX%?]#->_\
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MDYKU[]H3]G?PY^T1X!C\,ZR7T\VTR3V-_:(OFVK+P0H/&UERI7IT/4#'G/\
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MJG\K#GCW/IJBOF7_ (>-_ K_ *&:]_\ !3<__$4?\/&_@5_T,U[_ ."FY_\
MB*/95/Y6'/'N?35%?,O_  \;^!7_ $,U[_X*;G_XBC_AXW\"O^AFO?\ P4W/
M_P 11[*I_*PYX]SZ:HKYE_X>-_ K_H9KW_P4W/\ \11_P\;^!7_0S7O_ (*;
MG_XBCV53^5ASQ[GTU17S+_P\;^!7_0S7O_@IN?\ XBC_ (>-_ K_ *&:]_\
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M*/\ AXW\"O\ H9KW_P %-S_\15R=>2LT_N$O9K5'E/\ PZ9\)_\ 0^:U_P"
MD-'_  Z9\)_]#YK7_@)#7JW_  \;^!7_ $,U[_X*;G_XBC_AXW\"O^AFO?\
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MK<?6O(?^'?/P!_Z$'_RLZA_\D5\[?\/=/^J4?^7'_P#<E'_#W3_JE'_EQ_\
MW)25*O'1?F-SIO<^D;#]@;X"Z;=QW,7P_A>2,Y"W&I7LR'ZH\Q4_B*]VTG2;
M'0=-MM.TRSM]/T^UC$4%K:QK'%$@X"JJ@  >@K\^/^'NG_5*/_+C_P#N2C_A
M[I_U2C_RX_\ [DI2HUY;Z_,%."V/T2HK\[?^'NG_ %2C_P N/_[DH_X>Z?\
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M:3NT/VD%L?5_Q>_9'^%OQNU+^U/$WAI#K&-K:E82O;3R#&!O*$"0@8P7!(
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MZI1_Y<?_ -R4?\/=/^J4?^7'_P#<E'U>KV#VD.Y^B5%?G;_P]T_ZI1_Y<?\
M]R4?\/=/^J4?^7'_ /<E'U>KV#VD.Y^B5%?G;_P]T_ZI1_Y<?_W)1_P]T_ZI
M1_Y<?_W)1]7J]@]I#N?HE17YV_\ #W3_ *I1_P"7'_\ <E'_  ]T_P"J4?\
MEQ__ ')1]7J]@]I#N?HE17YV_P##W3_JE'_EQ_\ W)1_P]T_ZI1_Y<?_ -R4
M?5ZO8/:0[GZ)45^=O_#W3_JE'_EQ_P#W)1_P]T_ZI1_Y<?\ ]R4?5ZO8/:0[
MGZ)45^=O_#W3_JE'_EQ__<E'_#W3_JE'_EQ__<E'U>KV#VD.Y^B5%?G;_P /
M=/\ JE'_ )<?_P!R4?\ #W3_ *I1_P"7'_\ <E'U>KV#VD.Y^B5%?G;_ ,/=
M/^J4?^7'_P#<E'_#W3_JE'_EQ_\ W)1]7J]@]I#N?HE17YV_\/=/^J4?^7'_
M /<E'_#W3_JE'_EQ_P#W)1]7J]@]I#N?HE17YV_\/=/^J4?^7'_]R4?\/=/^
MJ4?^7'_]R4?5ZO8/:0[GZ)45^=O_  ]T_P"J4?\ EQ__ ')1_P /=/\ JE'_
M )<?_P!R4?5ZO8/:0[GV]\5O@[X0^-WAVWT+QKI']M:5;W2WL5O]IF@VS*CH
M&W1.K'Y9'&"<<].!7E7_  [Y^ /_ $(/_E9U#_Y(KYV_X>Z?]4H_\N/_ .Y*
M/^'NG_5*/_+C_P#N2K5*O%67YB<Z;W/I72/V#O@/HE_%>6_P^MI)8SE5O+Z[
MN8SSGF.65E/X@U[O9V<&GVD%K:P1VUK BQ10PH$2-%&%55'     %?GG_P /
M=/\ JE'_ )<?_P!R4?\ #W3_ *I1_P"7'_\ <E*5&M+=7^8*<%L?>7C[P#H/
MQ0\(ZAX8\36/]IZ'?A%N;7SI(O,"NKK\T;*PPRJ>".E8/PE^!'@;X%V>HVG@
M?0_[$M]0D26Y3[7/<>8R@A3F5W(P">F*^*_^'NG_ %2C_P N/_[DH_X>Z?\
M5*/_ "X__N2E["M:UM/4?M(7N?H#XD\/Z?XN\.ZIH6K6_P!KTK4[66RN[?>R
M>9#(A1UW*0PRK$9!!&>#7!_"7]FOX<? W4;^^\$>'/[$NKZ)8+B3[=<W&] =
MP&)9' Y],5\=?\/=/^J4?^7'_P#<E'_#W3_JE'_EQ_\ W)1["LE9+\0]I#<_
M0ZXMXKRWE@GC6:"52DD<BAE92,$$'J"*\.\-_L0?!7PAXDL-?T;P<^G:O87"
MW5M=0:Q?@QR*<@@>?C'L1@C@C%?,7_#W3_JE'_EQ_P#W)1_P]T_ZI1_Y<?\
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MTBX-I%:?9[6"-TPA;!RW.3NJX*+?O.Q,KVT/;O\ A=7P\_Z'SPS_ .#BW_\
MBZ/^%U?#S_H?/#/_ (.+?_XNOD+_ (=,^$_^A\UK_P !(:/^'3/A/_H?-:_\
M!(:VY:/\WX$<T^Q]>_\ "ZOAY_T/GAG_ ,'%O_\ %T?\+J^'G_0^>&?_  <6
M_P#\77R%_P .F?"?_0^:U_X"0T?\.F?"?_0^:U_X"0T<M'^;\ YI]CZ]_P"%
MU?#S_H?/#/\ X.+?_P"+H_X75\//^A\\,_\ @XM__BZ^0O\ ATSX3_Z'S6O_
M  $AH_X=,^$_^A\UK_P$AHY:/\WX!S3['U[_ ,+J^'G_ $/GAG_P<6__ ,71
M_P +J^'G_0^>&?\ P<6__P 77R%_PZ9\)_\ 0^:U_P" D-'_  Z9\)_]#YK7
M_@)#1RT?YOP#FGV/KW_A=7P\_P"A\\,_^#BW_P#BZ/\ A=7P\_Z'SPS_ .#B
MW_\ BZ^0O^'3/A/_ *'S6O\ P$AH_P"'3/A/_H?-:_\  2&CEH_S?@'-/L?7
MO_"ZOAY_T/GAG_P<6_\ \71_PNKX>?\ 0^>&?_!Q;_\ Q=?(7_#IGPG_ -#Y
MK7_@)#1_PZ9\)_\ 0^:U_P" D-'+1_F_ .:?8^O?^%U?#S_H?/#/_@XM_P#X
MNC_A=7P\_P"A\\,_^#BW_P#BZ^0O^'3/A/\ Z'S6O_ 2&C_ATSX3_P"A\UK_
M ,!(:.6C_-^ <T^Q]>_\+J^'G_0^>&?_  <6_P#\71_PNKX>?]#YX9_\'%O_
M /%U\A?\.F?"?_0^:U_X"0T?\.F?"?\ T/FM?^ D-'+1_F_ .:?8^O?^%U?#
MS_H?/#/_ (.+?_XNC_A=7P\_Z'SPS_X.+?\ ^+KY"_X=,^$_^A\UK_P$AH_X
M=,^$_P#H?-:_\!(:.6C_ #?@'-/L?7O_  NKX>?]#YX9_P#!Q;__ !='_"ZO
MAY_T/GAG_P '%O\ _%U\A?\ #IGPG_T/FM?^ D-'_#IGPG_T/FM?^ D-'+1_
MF_ .:?8^O?\ A=7P\_Z'SPS_ .#BW_\ BZ/^%U?#S_H?/#/_ (.+?_XNOD+_
M (=,^$_^A\UK_P !(:/^'3/A/_H?-:_\!(:.6C_-^ <T^Q]>_P#"ZOAY_P!#
MYX9_\'%O_P#%T?\ "ZOAY_T/GAG_ ,'%O_\ %U\A?\.F?"?_ $/FM?\ @)#1
M_P .F?"?_0^:U_X"0T<M'^;\ YI]CZ]_X75\//\ H?/#/_@XM_\ XNC_ (75
M\//^A\\,_P#@XM__ (NOD+_ATSX3_P"A\UK_ ,!(:/\ ATSX3_Z'S6O_  $A
MHY:/\WX!S3['U[_PNKX>?]#YX9_\'%O_ /%T?\+J^'G_ $/GAG_P<6__ ,77
MR%_PZ9\)_P#0^:U_X"0T?\.F?"?_ $/FM?\ @)#1RT?YOP#FGV/KW_A=7P\_
MZ'SPS_X.+?\ ^+H_X75\//\ H?/#/_@XM_\ XNOD+_ATSX3_ .A\UK_P$AH_
MX=,^$_\ H?-:_P# 2&CEH_S?@'-/L?7O_"ZOAY_T/GAG_P '%O\ _%T?\+J^
M'G_0^>&?_!Q;_P#Q=?(7_#IGPG_T/FM?^ D-'_#IGPG_ -#YK7_@)#1RT?YO
MP#FGV/KW_A=7P\_Z'SPS_P"#BW_^+H_X75\//^A\\,_^#BW_ /BZ^0O^'3/A
M/_H?-:_\!(:/^'3/A/\ Z'S6O_ 2&CEH_P WX!S3['U[_P +J^'G_0^>&?\
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MYX9_\'%O_P#%U\A?\.F?"?\ T/FM?^ D-'_#IGPG_P!#YK7_ ("0T<M'^;\
MYI]CZ]_X75\//^A\\,_^#BW_ /BZ/^%U?#S_ *'SPS_X.+?_ .+KY"_X=,^$
M_P#H?-:_\!(:/^'3/A/_ *'S6O\ P$AHY:/\WX!S3['U[_PNKX>?]#YX9_\
M!Q;_ /Q='_"ZOAY_T/GAG_P<6_\ \77R%_PZ9\)_]#YK7_@)#1_PZ9\)_P#0
M^:U_X"0T<M'^;\ YI]CZ]_X75\//^A\\,_\ @XM__BZ/^%U?#S_H?/#/_@XM
M_P#XNOD+_ATSX3_Z'S6O_ 2&C_ATSX3_ .A\UK_P$AHY:/\ -^ <T^Q]>_\
M"ZOAY_T/GAG_ ,'%O_\ %T?\+J^'G_0^>&?_  <6_P#\77R%_P .F?"?_0^:
MU_X"0T?\.F?"?_0^:U_X"0T<M'^;\ YI]CZ]_P"%U?#S_H?/#/\ X.+?_P"+
MH_X75\//^A\\,_\ @XM__BZ^0O\ ATSX3_Z'S6O_  $AH_X=,^$_^A\UK_P$
MAHY:/\WX!S3['U[_ ,+J^'G_ $/GAG_P<6__ ,71_P +J^'G_0^>&?\ P<6_
M_P 77R%_PZ9\)_\ 0^:U_P" D-'_  Z9\)_]#YK7_@)#1RT?YOP#FGV/KW_A
M=7P\_P"A\\,_^#BW_P#BZ/\ A=7P\_Z'SPS_ .#BW_\ BZ^0O^'3/A/_ *'S
M6O\ P$AH_P"'3/A/_H?-:_\  2&CEH_S?@'-/L?7O_"ZOAY_T/GAG_P<6_\
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M_P"#BW_^+H_X75\//^A\\,_^#BW_ /BZ^0O^'3/A/_H?-:_\!(:/^'3/A/\
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M_A1_P]!^(G_1+[+_ +ZN/\*/J]3L'M(GZ1T5^;G_  ]!^(G_ $2^R_[ZN/\
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M$.%"\'.2=H Y-;_A?PMI/@GP_9:'H5C%IFDV2>7;VD (2-<DX'XD_G7YX_\
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M_+NU;_XS1_PQM^UG_P!%R_\ +NU;_P",T>RC_.@YWV/T2HK\[?\ AC;]K/\
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MYT'.^Q^B5%?G;_PQM^UG_P!%R_\ +NU;_P",T?\ #&W[6?\ T7+_ ,N[5O\
MXS1[*/\ .@YWV/T2HK\[?^&-OVL_^BY?^7=JW_QFC_AC;]K/_HN7_EW:M_\
M&:/91_G0<[['Z)45^=O_  QM^UG_ -%R_P#+NU;_ .,T?\,;?M9_]%R_\N[5
MO_C-'LH_SH.=]C]$J*_.W_AC;]K/_HN7_EW:M_\ &:/^&-OVL_\ HN7_ )=V
MK?\ QFCV4?YT'.^Q^B5%?G;_ ,,;?M9_]%R_\N[5O_C-'_#&W[6?_1<O_+NU
M;_XS1[*/\Z#G?8_1*BOSM_X8V_:S_P"BY?\ EW:M_P#&:/\ AC;]K/\ Z+E_
MY=VK?_&:/91_G0<[['Z)45^=O_#&W[6?_1<O_+NU;_XS1_PQM^UG_P!%R_\
M+NU;_P",T>RC_.@YWV/T2HK\[?\ AC;]K/\ Z+E_Y=VK?_&:/^&-OVL_^BY?
M^7=JW_QFCV4?YT'.^Q^B5%?G;_PQM^UG_P!%R_\ +NU;_P",T?\ #&W[6?\
MT7+_ ,N[5O\ XS1[*/\ .@YWV/T2HK\[?^&-OVL_^BY?^7=JW_QFC_AC;]K/
M_HN7_EW:M_\ &:/91_G0<[['Z)45^=O_  QM^UG_ -%R_P#+NU;_ .,T?\,;
M?M9_]%R_\N[5O_C-'LH_SH.=]C]$J*_.W_AC;]K/_HN7_EW:M_\ &:/^&-OV
ML_\ HN7_ )=VK?\ QFCV4?YT'.^Q^B5%?G;_ ,,;?M9_]%R_\N[5O_C-'_#&
MW[6?_1<O_+NU;_XS1[*/\Z#G?8_1*BOSM_X8V_:S_P"BY?\ EW:M_P#&:/\
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M  SC\)O^B7^#/_"?M/\ XW1_PSC\)O\ HE_@S_PG[3_XW7HM%'-+N%D>=?\
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M *)?X,_\)^T_^-UZ+11S2[A9'G7_  SC\)O^B7^#/_"?M/\ XW1_PSC\)O\
MHE_@S_PG[3_XW7HM%'-+N%D>=?\ #./PF_Z)?X,_\)^T_P#C='_#./PF_P"B
M7^#/_"?M/_C=>BT4<TNX61YU_P ,X_";_HE_@S_PG[3_ .-T?\,X_";_ *)?
MX,_\)^T_^-UZ+7GGQ:_: \!? M=+/CC7O[$&J&1;3_0[BX\TQ[=_^JC?&-Z]
M<=>*:<Y.R%HMQO\ PSC\)O\ HE_@S_PG[3_XW1_PSC\)O^B7^#/_  G[3_XW
M7H:.)$5E.589!IU+FEW'9'G7_#./PF_Z)?X,_P#"?M/_ (W1_P ,X_";_HE_
M@S_PG[3_ .-UZ+11S2[A9'G7_#./PF_Z)?X,_P#"?M/_ (W1_P ,X_";_HE_
M@S_PG[3_ .-UZ+11S2[A9'G7_#./PF_Z)?X,_P#"?M/_ (W1_P ,X_";_HE_
M@S_PG[3_ .-UZ+11S2[A9'G7_#./PF_Z)?X,_P#"?M/_ (W1_P ,X_";_HE_
M@S_PG[3_ .-UZ+11S2[A9'G7_#./PF_Z)?X,_P#"?M/_ (W1_P ,X_";_HE_
M@S_PG[3_ .-UZ+11S2[A9'G7_#./PF_Z)?X,_P#"?M/_ (W1_P ,X_";_HE_
M@S_PG[3_ .-UZ+11S2[A9'G7_#./PF_Z)?X,_P#"?M/_ (W1_P ,X_";_HE_
M@S_PG[3_ .-UZ+11S2[A9'G7_#./PF_Z)?X,_P#"?M/_ (W1_P ,X_";_HE_
M@S_PG[3_ .-UZ+11S2[A9'G7_#./PF_Z)?X,_P#"?M/_ (W1_P ,X_";_HE_
M@S_PG[3_ .-UZ+11S2[A9'G7_#./PF_Z)?X,_P#"?M/_ (W1_P ,X_";_HE_
M@S_PG[3_ .-UZ+11S2[A9'G7_#./PF_Z)?X,_P#"?M/_ (W1_P ,X_";_HE_
M@S_PG[3_ .-UZ+11S2[A9'G7_#./PF_Z)?X,_P#"?M/_ (W1_P ,X_";_HE_
M@S_PG[3_ .-UZ+11S2[A9'G7_#./PF_Z)?X,_P#"?M/_ (W1_P ,X_";_HE_
M@S_PG[3_ .-UZ+11S2[A9'G7_#./PF_Z)?X,_P#"?M/_ (W1_P ,X_";_HE_
M@S_PG[3_ .-UZ+11S2[A9'G7_#./PF_Z)?X,_P#"?M/_ (W1_P ,X_";_HE_
M@S_PG[3_ .-UZ+11S2[A9'G7_#./PF_Z)?X,_P#"?M/_ (W1_P ,X_";_HE_
M@S_PG[3_ .-UZ+11S2[A9'G7_#./PF_Z)?X,_P#"?M/_ (W1_P ,X_";_HE_
M@S_PG[3_ .-UZ+11S2[A9'G7_#./PF_Z)?X,_P#"?M/_ (W1_P ,X_";_HE_
M@S_PG[3_ .-UZ+11S2[A9'G7_#./PF_Z)?X,_P#"?M/_ (W1_P ,X_";_HE_
M@S_PG[3_ .-UZ+11S2[A9'G7_#./PF_Z)?X,_P#"?M/_ (W1_P ,X_";_HE_
M@S_PG[3_ .-UZ+11S2[A9'G7_#./PF_Z)?X,_P#"?M/_ (W1_P ,X_";_HE_
M@S_PG[3_ .-UZ+11S2[A9'G7_#./PF_Z)?X,_P#"?M/_ (W1_P ,X_";_HE_
M@S_PG[3_ .-UZ+11S2[A9'G:_LY_"=&#+\,/!JL#D$>'[0$?^0Z]$HHI-M[@
M%5+K2+"^D\RYLK>XDQC?+$K''IDBK=%(9G?\(WI/_0+LO_ =/\*/^$;TG_H%
MV7_@.G^%?/7[17[;OASX*ZG-X?TBS_X2?Q/%Q/"LOEV]H?21P"2_^PH^I4U\
MV1_\%*OB4+[S'T+PPUMT,"VUP#C/9O/ZXXSC''2O%Q&<X/#S]G*5VNVMC]/R
MGPVXCSG"K&4*"C"6L>9J+DNZ6]NS=D^A^C'_  C>D_\ 0+LO_ =/\*/^$;TG
M_H%V7_@.G^%>$?LY_MF^&OCI=IHEY;'PWXK*EDL99?,BN@ 2?)DP,D 9*$ X
MZ;L$CZ(KTJ&(IXF"J4971\1FV3X[(\4\'F-)TZBZ/JNZ:T:\T[&=_P (WI/_
M $"[+_P'3_"C_A&])_Z!=E_X#I_A6C172>.9W_"-Z3_T"[+_ ,!T_P */^$;
MTG_H%V7_ (#I_A6C10!G?\(WI/\ T"[+_P !T_PH_P"$;TG_ *!=E_X#I_A6
MC10!G?\ "-Z3_P! NR_\!T_PH_X1O2?^@79?^ Z?X5HT4 9W_"-Z3_T"[+_P
M'3_"C_A&])_Z!=E_X#I_A6C10!G?\(WI/_0+LO\ P'3_  H_X1O2?^@79?\
M@.G^%:-% &=_PC>D_P#0+LO_  '3_"C_ (1O2?\ H%V7_@.G^%:-% &=_P (
MWI/_ $"[+_P'3_"C_A&])_Z!=E_X#I_A6C10!G?\(WI/_0+LO_ =/\*/^$;T
MG_H%V7_@.G^%:-% &=_PC>D_] NR_P# =/\ "C_A&])_Z!=E_P" Z?X5HT4
M9W_"-Z3_ - NR_\  =/\*/\ A&])_P"@79?^ Z?X5HT4 9W_  C>D_\ 0+LO
M_ =/\*/^$;TG_H%V7_@.G^%:-% &=_PC>D_] NR_\!T_PH_X1O2?^@79?^ Z
M?X5HT4 9W_"-Z3_T"[+_ ,!T_P */^$;TG_H%V7_ (#I_A6C10!G?\(WI/\
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MHT4 9W_"-Z3_ - NR_\  =/\*/\ A&])_P"@79?^ Z?X5HT4 9W_  C>D_\
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MDV^5;#YTK7/M2BOGC]E3]KJ+]I^Z\81P>&/[ AT$P;)O[0-S]J64RX.#$FS
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MV]]J+.R#D#>ZR0Q-L!/+*&QZ4*E.2ND#E%.S/L:BD5@R@@Y!Y!%+6184444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 (S"-2S$*JC)). !7COB3]L#X/>%-2>QO_'%FURA(;[#!/=H"#@@O
M#&ZY]LU\J_M[?M*:EJ?B>[^&OA^\DM-'L0$U:6%BK7<Q )A)_P">:@@$=V)S
M]T5\75\9F&?NA5=+#Q3MNWW_  /Z6X0\(Z>;8"&89Q5E!5%>,863L]G)R4EK
MO:VV[OHOVD^'?QR\!_%C<OA3Q/8ZM.J[VM5+13A?[QBD"OCWQBNZK\+='UB^
M\/ZI:ZEIEY-8:A:R"6"YMW*21L.A5AR#7ZP?LB?'R7X\?#/[5J?EKXCTJ06>
MH^6-HE.W*3 #@;QG('&Y6Q@8KMRO.5CI>RJJT_+9GS7'GAM+A:@LPP-1U,/=
M)\UN:+>UVK)I[7LK.RMJ>Y4445],?AP45\U?M1?MQ>&OV;-6MM!72)_%'B::
M);B2QAN!;Q6\1.%,DI5L,V"0H4\#)QD9L_LN_ML>&/VEKR[T>/3+CPUXGMH3
M<G3;B83QS1 @%HI0J[MN5R"JGYN,@$C7V<^7GMH3S1O:Y]&45\V_M2?MO>&?
MV:]2M=#&E3>*/%$\0N&TZ"X$$=O$3@&64JVUFP2%"DX&3M!7+_V7?VW/#'[2
ME_=:*-,F\,>)X(C<#3;BX6=)X@0"T4H5=Q&1E2H.#D9&<'LY\O/;0.97L?1]
M%?/O[3_[9GA3]F?[+IUU9S^(?$]W%Y\.DVLHB"19(#RR$'8"0P&%8DCICFN<
M_9C_ &^/#7[0_B@^%[O0YO"7B.5'EM+>2Z%U#=*H+,JR;$(<*"VTKT!P>*/9
MSY>>V@<RO:Y]2T45\C_M.?M]?\,X_$YO"'_""?\ "0XLH;O[9_:_V;[^[Y=G
MD/TV]<]ZF,)3=H@Y**NSZXHK\[?^'NG_ %2C_P N/_[DKJ]3_P""G7]F_#30
M/%O_  K7S/[5U&]T_P"Q_P!NX\K[.ENV_?\ 9OFW>?C&!C;U.>-?J]3L3[2/
M<^YZ*X[X0_%'2/C-\.M%\7Z(W^A:E"',+,&>"0<21-C^)6!'OC/>O*O@+^UM
M_P +N^,7CCP)_P (I_8O_",M./[0_M'S_M/EW'D_ZOREV9^]]XXZ>]9<DM=-
MBN9:'T-117QK^T-_P43_ .%"_%K6O!'_  K_ /MS^SE@;[=_;7V?S/,A23_5
M_9WQC?C[QSC-$(2J.T0E)1U9]E45R_PU\>6GQ)^'7A[Q=:I]FM=7L(K[R6</
MY.] 60L.I4Y4GVKX]\/_ /!42V\3?$S3O"UE\.V:SO\ 5X]-@U)M;P3&\PC6
M8Q?9^#@AMN[VSWIQIRE>RV!R2W/NJBO(?VA/VHO!7[-VD6\_B2>>ZU2\5FLM
M(L5#W$X'!8Y(5$!/WF([X#$8KY?T?_@K9HT^L)%JOPWOK+2BQW75GJJ7$X'8
MB)HHU/\ WW51HSFKQ0G.,79L^_J*\[C^-V@:U\$]3^)?AF9/$&CVNEW.I1QJ
MYB,AAC9VA8D$QME2IR#CT-<W^RI^T=_PTWX!U'Q-_P (]_PC?V/4GT_[+]M^
MU;]L4;[]WEIC_68QCMUYJ.65F[;%<RO8]HHHHJ!A1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %4-=U[3O#&D76J:M>PZ=IUJGF37-PX
M1$7W)_+W)Q5^OSA_;A^-%]XU^)%UX1M9VC\/Z!)Y30JW$]UC]X[>NTDH >F&
M/\5<.,Q2PE+G:N^A]APMP[5XES!82,N6"7-)]EY>;;LOOZ'OGB7_ (*$?#[2
M;Z2WTS3=8UQ$./M4420Q-SU7>P;IGJH[5UWPM_;(^'GQ0U.'2TN;G0-5F;9#
M;ZLBQK,Q. J2*Q7)XP"03V!K\O:6OEXYQB5*[LUV/Z'K>%^1SH.G2<XS_FYK
MN_FMONM\C]M:*^:_V'?C/??$OP!>Z)K-PUUJ_A]HXA<2-EYK=P?++'NRE&4G
MT"YY-?2E?7T*T<1352.S/Y?S?+*V38ZK@,1\4';U6Z?S33"BJNJ:E;:+IEWJ
M%Y)Y-I:0O/-)M+;452S' &3@ ]*_+W]K3]O3Q#\3DM+3X9S:_P"%/"=G=%9-
M>MY9+2>^G"G";XR-B!26V%LMD$@8 KLITY5'9'BRDHK4_4RBL#2-8BT[P'9:
MKJ,["&#34NKF=]SMM6(,['&23@$]R:_-+]K3]O3Q#\3DM+3X9S:_X4\)V=T5
MDUZWEDM)[Z<*<)OC(V(%);86RV02!@"G3I2J.R"4U%79^IE%97A2:2X\+Z/+
M*[2RR6<+/(Y)9F* DDGJ:^-_^"BW[4&I?#_2[;X?^"]2O=/\27*)?ZGJ.FRO
M%+8VH8;%$B8*,[8R01A1C^.IA!SERH<I**NS[=HKQ#]BOQ#JOBK]F7P3JFM:
ME>:QJ=Q#.9KV_G>>:0BXE +.Y+'  ')Z 5[%KEK<WVBW]O9R_9[N:WDCAEW%
M=CE2%;(Y&#@Y'-3)<K:&G=7+M%?EQ\9/@?\ M.?!#X>:GXRUWXTWMWIFGF(2
MPZ?XJU-YCOD6,;0Z*O5AG+#C-7?@O\"OVFOB]X*T#QKI?QGO(=&U!C*EO?\
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MOM5E((+8!!R,BNW7XA>')? LOC*#5[>[\,16<FH-J5H3/'Y"*6=QL!+8"MD
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M@?LG?$[Q+^T5\?\ XD>/)=9U%/ >DA=)T32([F1+)R6)$S19"M)L3<2P)'G
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M\0>%M%O!X9^$VG:5]LO]2V!#?.(C(T.<[Y>1MVKM3KN)( KS'Q-XBTOX\?\
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MGAK7/$<B6.CWT-L;:ZNG"Q!'L6ME;<> !,&'L:2A&24K='^ W)IN-STGP_\
MM=?&SP+\2M \+_%WX316L6MM^XF\+I)<21QA@K2!(Y9Q)M++N4%6 (.#P#<_
MX*'?&+_A4\7@$_\ "$>#?&7]H27@QXNTG[=]GV>1S%\Z["V[YNN=J^E?1WC[
MXX> OA;JVE:;XL\4Z?H-YJ@9K6.\DVAU7 +,V,(N3C+$ \XZ&OBW_@K-(LUK
M\*W1@Z-)J#*RG(((ML$&HIVG4C[MBI7C%ZGTA^U%^U-:?LZ^&]$BL]);Q#XO
MUY_)TO1X20&(P"[;03M#,JA1RQ.!T)'C<G[9WQC^#.MZ'+\<_AC8:#X5U>80
MIJ>BN2UN3@Y<":8$@9/EG8Q )&<$5YG_ ,%&M'O$_:%^%.H3:Q-X:TRYL+>V
MBUV(G-C(ETQDG7#*0T8EC?AE/ Y'6NM\:_L+ZUXKT_2M.\7?M37^L65_()M/
MM-:1YX[F0*</"DE^0[;6/*@G#'UJHQIQBG+KZDN4FW8]L_:@_:UNO@[J7A'P
MSX+T"+Q?XO\ %05]/CDFVVXC9@L;'!!<NQP "HP"2W8^=V/[6WQX^&_CSP]H
MOQ:^$-NEEK<A2!O"JO<7 52H=E2.:<2%0P)3*D@\5%^U)\!_A5K_ (;^&_@[
MQC\3[7PSX^TG3[;2+#4I( [7D?RQAIK<-E$9U8ABX"DMEB*\5^(]W^T#^PE>
M:)J%S\3+7Q7H=].T-MIMY>RW:R(@!(:"8!HUY^]"W&0"P)&2$(2BDEKYW_ )
M2DG<_416W*".AYY&*6L_P_JAUS0=-U$Q-;F\MH[@Q-U3>@;:?IG%:%<)T!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7GO[0/Q G^
M%OP9\6>)[3 O;&SQ;,PR%FD98HV([@.ZG'M7H5>5?M2^"[SX@?L_^--%T^)I
M[V2T6XAA09:1H9$F"*.Y/EX'N:YL2YJA4=/XK.WK;0]O(X8>IFN%AB_X3J04
MK[<O,N:_RN?CW=74U]<RW%Q*\]Q,YDDED8LSL3DL2>I)[U%117XL?Z;I)*R+
M6EZI=Z'J5KJ-A<26E]:RK-!<0MM>-U.58'L017[3_"7QH?B-\,?#'B9T$<VI
MZ?#<2HHP%D*C>![!MV*_%!$:1U1%+,QP%49)/I7[0? ?P?<^ ?@WX.T"\3R[
MVRTV%;B,C[DI7<Z_@S$?A7V?#+G[2HE\-E]_3]3^9_&^GAOJ6"J.WM>:27?E
MM[WROR_>:'Q6^(EG\)?AWKWB_4+:>\L](MC<26]MM\R3D  ;B!U(K\LOBU\9
M_'WQR^.?PJ\2^*M$D\-^'+K4K:3P]IC,2OD&ZC#RY."Y8A?GVJ&"C:,"OUPU
M#3;35K-[2^M8;VUDQO@N(Q(C8((RI&#@@'ZBOS]_X*#<?M0?!$#@>9;_ /I:
MM?I6':YK6U/X_J7L?4_[77Q>O?@C\ _$GB72F5-9VQV=A(ZA@DTKA ^#P2JE
MG .1E1D$5^>7_#+OQ"@^ O\ PT2OCR\_X24J-5-OF3[88#(%\XW7F9+X^?;M
M^[WSQ7V%_P %,[*:Z_9AN98BWEVVK6DLNWIM)9!GVW.OZ5477K$_\$S3=K(@
M@_X0LV>8R"/-V>3CZ^9P??-53DX0375BDN:33['6_!_]J :G^R!#\5?$=O+?
MWFE6<B:E%9A5>>:)_+W $@ O\K'TW' Z"OA/XM?&?Q]\<OCG\*O$OBK1)/#?
MARZU*VD\/:8S$KY!NHP\N3@N6(7Y]JA@HVC K[!_X)M^'8KK]E6*+4[.&[LK
M[5[J=8;B,2(ZJR*"5(QP\9_(5Y9_P4&X_:@^"(' \RW_ /2U:NGRQJN*7<4K
MN"=S]"Z\V_:5_P"3>_B3_P!B]??^B'KTFO-OVE?^3>_B3_V+U]_Z(>N&/Q(W
MELS\U?V6_P!@_P#X:5^'-QXJ_P"$X_X1SR=0DL?LG]D_:L[$1M^_STZ[\8QV
MZUT?A/PKXK_8U_:^\%^!O#GC1_%ECJT]JE_96:-&C132%'2:WWN%=%!D#9R
M0> 37.?LM_L'_P##2OPYN/%7_"<?\(YY.H26/V3^R?M6=B(V_?YZ==^,8[=:
MU]1\#Z[_ ,$Y_C]X3OUN])\::;JZ%?-FL%BN!%O"2A,EFA?#\,KX;)!! (KU
M)2YI2CS7\K?J<B5DG;YGZN5@>.O'>@_#7PK?^(_$VI0Z3HUBF^:ZFS@9. H
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MD7^DP[67SS&I$HE'S2[EP-[@-\A!X )FI3C&-X_F.,FW9GT11117(;!1110
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M^$K_ .$E_MYK<[?[.^R>1Y1E/_/5]V?-]L;>^>'5DDYKO84(NT6?.DD:V?\
MP5JC$(\H2_,X4XW$Z02<_C7INL?M'>)?B9^TQK/@+X2>$_"B^(O#\$\%]XK\
M5QR%ECC=$FCB$0$@42%0!N(8KG '-=Y-^R/YW[6T?QN_X2O&P ?V%_9W7_0_
MLW^O\W_@7W/;WKC_ (J?\$_X/%GQ;O?B!X*^(FK?#G5]0D:>\_L^!G8RN,2-
M%(DL31[^2P);)8]!Q4<U.35WT*Y9*]NYX!X#M-;L/^"H&GV_B37K3Q)KL;R"
M[O[&T%K"7_LMSL6,$XV#"9)R=N3R:W=>TV'5/^"LEG%.BR(DL,X#+D;H]*#J
M?J&4$>A%>Q^"?^"?=C\-?C-X6\?^'?'%]Y^E9>^@U:T-W-J4K^8LTC3"5-A=
M)-H^0XV@G=DYZ^;]D?SOVMH_C=_PE>-@ _L+^SNO^A_9O]?YO_ ON>WO5.I"
M]T^EA<KM\SY[_P""LT2QR?"RY0;;@/J"B1>& 'V8C]:I^+)%3_@J=X:;7EWV
M12U%C]I *Y-@1$5S_P!-\X_VO>OI/]K7]DO_ (:D3PLO_"5?\(S_ &&]PW_(
M.^U^=YOE?]-8]N/+]\Y[8K0_:,_9&\+?M%6^EW5]>76@^)M*3R[+7-/ \Q5!
MR$=3]]0WS#D$$G!&3E1J148Q?G^(W%W;]#U+Q#_PB4.OZ+-KO]BIK>9$TJ34
M/)%SGY3(("_S=DR$]%SVKX9_X*U?ZGX6_P#774/Y6U>A>'_^"=,>J>+=-UOX
MH?%'Q!\3TTY@;>SU%71" V[RW:2:5C&3U52N?6O0/VL?V1U_:>A\*1)XH'A9
M-!-P55=-^U"42B(  >;'MV^5[YSVQ44W"G-/FN5+FE%JQ\O?\%#8]>F_:6^$
MD>F7L.G2-96BZ;>7ZAK6"[-VV9'!5@0I\DME6X X/2NF^*W[)/[4WQNT&VT;
MQK\1?!6MZ=;W NXHC&8"DH5E#!HK!6Z,PQG'/3@5]2_M"_LR^%?VCO"-II'B
M S6E]8$O8:M9X$UNQ ##!R&1L#*GK@8((!KQ+P[_ ,$]]:76M)N?%GQT\8>)
M-/TI@UE:6[RVKP8XVI(T\NP$ #Y IQT(JXU8\JULUY$N+NRG^TA^REJ_C3PS
M\*KVW\?:1X5^)WA_3[72(IKF_>WAOIU"8-O* )%D$FXJ0A+;AP#7D?BKXT_M
M%_LQZYH&J?%_P[I'C718+EH-/OK^&UDD4[<OY%S"/,B=E'6122%Z'%?6O[17
M[&_A/]H3^RK^XU#4/#_B72H5M[36;.0RR&-3E5E#G,FUB6#;@V2?FKS'3/\
M@G7/X@\1:9??%#XN^)/B9ING/O@TV^$L:Y)!92\D\I"-M 8)M) ^\*(5(<MI
MN_R_()1=]#Z^T75(M<T>QU*W#""\@CN(PPP=KJ&&??!J[4<$,=K#'#"BQ11J
M$1$& J@8  [#%25Q&X4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 ?BW\=X[F+XV^/UO ?M/\ ;]\7SGG-
MPY!'MC&/;%<+7W9^W=^RSJFH:Y<?$GPE8R7\<Z+_ &Q86ZEI491@7"J.64J
M& Y&-W()(^$Z_'LPPU3"XB4)K=W7FC_1_@_/,)GV34,1A9)M1C&2ZQDE9IK\
MNZU"ON+_ ()@QW/]L_$"10WV3[/9J_7!?=-M_'&[\Z^-/"?A'6?'6O6FBZ!I
MUQJNJ73;(K:W3<Q]SV"CJ6. !R2*_67]EKX#1_ +X:QZ5<21W&O7TGVO4[B/
M[OF%0!&I[J@& >Y+'C.*]3(<-4J8I5DO=C?7Y6L?!^+6=X3!9!4RV<DZU?E2
MCULI*3DUVTLO-Z;,]BHHHK]-/X</ ?B%\"_"_@7QYX@^/%AX?UCQ=XYL[)W@
MT6&3SDN9A&L:>6GE.Z.%4*"G0$G::^8_V.)+3X@?ME>,?&GBTVW@CQH5F-IX
M)>VEMY]SQJKNWF*H)$>25^^Q9GVJJ\]?\7OVO/B'^S7^U%=6'CJ&?5/AA=QM
M+IUOI]G LCQ,%PZ2$*7>-PR,C./O9/537G'P_P#%UY^U_P#MY:'X[\*:'>:1
MX=\/I#)=74X"R"&)7VF8H2H>1F*! QRHZX!QWQC+D;EM;?\ 0YVU=6[G0_"&
MS@\>?\%._'5_J<2W;:/]KDMA,,^6\*Q6Z,!SR 3CTZ]:/BU:P> /^"GO@>]T
MB);9]:^R27:Q?(':99;>0G'JJ@GU//O6/\6O$ES^Q[^WE??$'6-(N[_PIXCA
MDE62U4%Y$DC02B,L0I=)5!*DCY2O3<#3_A/XDE_;$_;QLOB!I.DWEGX3\-6\
M<I:^"[XUC1Q"'VDJ'>9BP4$\*3S@U>OQ].4GRZW///B%\8]$\$?MZ>,O&OB_
M3+CQ';Z'>316&G)M ::*,0P [LA57!;/)! .">*]X_9V_:$^"W[1'Q]M=9U7
MX=CPC\49COL-0^WO<17+1QD8RHC42["WWH_F"XW$A17G7Q[0_LK_ +=$7Q-U
M[PU-KOA/593?6SI@_O'A\N786&WS8W)<*2."O(SD4K/QI!^V#^W-X)\3^ O#
MFH:1IFDO:7&HWD\:1RE()&D:68QEE4L-L0&XDX4>PIQ4HW\M[_@*[3MYGZAT
M445Y9UGYY_L4_P#)\WQM_P![4O\ TX)3O^"MB[K?X7+ZR:B/TMJ;^Q3_ ,GS
M?&W_ 'M2_P#3@E/_ ."M7^I^%O\ UUU#^5M7HK^.O3]#F_Y=LSOV3_&&J_LD
M?M$ZQ\%?&-VR^'=:F632KR?Y8C,X_<2KV F4!" >'4#L:O?L&?\ )X7QP_W[
M[_TX5ZU^WQ^SO)\6OA3;>*] MF;QCX7C%S"UN#YMQ:@;I(@1R67_ %B]3E6
MY>OGK_@EGJEUK?QP\?:C?3M<WUYI+7$\[_>DD>Y1F8^Y))_&E=3IRFM^H:QD
MHGZ;U^5_[1'@6#XF?\%%-4\+7&WR]42&WRP!VL=,4JW/<, 0>Q&:_5"OSFUZ
M'SO^"LMF-F_$D+8QG&-*!S^&,UCAW9R?DS2IK;U(?@%\?I/!O[ ?Q'L)Y#'K
M/AF6;2;5?,PZ_;#B-@"<@J\DQQZ1U\\V7P_7X>?&;X"6QC\NYU*VT;5I\J Q
M>>\=QG'4A-@YYP .U7?C]\.]7T?]JSQ9\-=,EEBT_P 2^([:=;91\DGGMOB/
M<X3[0X_.O:_VR=(@T7]N'X06UM#Y-O'!HT48YQM2]=5 ^@&*[59/3[6IAK;7
MH1WGA^U^/O\ P4RU#2/%D4>HZ-I4\B+83?-&\5M!NCC()Y4R?.R\@Y;(P37Z
M"?$+X5^&?B?X%O/".O:7#/HMQ!Y*Q1QJIM^,*\1QA&7@J0.,5\&?M6^%?%?[
M+O[4]E\=/#NDOJGAV]E$UV%W"*.5H_)GAE8 [!(IW*QXW-T.W!W?BA_P5*T'
M6OA[?:=X'\.:]:>++^W-M'<7_E1Q6;.I!DC:.1F=E)^4;5YP3Z'FE"=3E<-K
M&BDHW4CZ%UCX'^%_@'^RS\2?#OA.&ZBL)-#U*YE:\N6F>24VC*7.>%R%7A0!
MQTKRW_@E3_R0+Q%_V,DW_I-;5L_#&P^)5O\ L.^.KSXH:K?7^MW^A:E<6MOJ
M0'VBUM?LC"-93@,78AG.\D@,H.""*^9_V*?VU/!'[-_PQU7PYXETKQ!?7UWJ
M\E^DFDV\$D8C:&) "9)D.[,;=L8(YH492A)+5W'=*2>Q^I]%?,'PE_X*%?#K
MXR?$+1_!VBZ+XHM=3U1W2&6_M;9(5*QLYW%;AF'"GHIYQ7T_7)*,H.TD;)J6
MP4445 PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M86GD8?-&S*?E8'@GK5W7L;>8M>>_D?-UP/V?-+^.7B\^%OAQXA^,_C"ZD?\
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M'\:]AL_A_K\/[(,?@E[#'B<>"O[(-CYT?_'U]B\KR]^[9]_C=NV]\XYKB/\
M@G]\&_&'P1^$.M:)XUTC^Q=3N-;EO(H/M,,^Z(P0*&W1.RCYD88)SQ64I\T)
M7?4M1M)61Z;^T]K,_A_]G?XC7UL[17$>A7:I(G!5FC*@CT^]7BG_  3!T>'3
M_P!FV6\CYFO]:N993C^ZL<8'Y)^M?1WQ8\''XA?##Q7X9!VOJVEW%FC9QAGC
M95.?J17RU_P2X\02M\(_%7A6]5X=1T+7'\RVE4J\2R(ORD'H=\<O%1'^#+U*
M?QHX#]DMOL__  41^,:2 H\@U?:K \_Z?"W\N:]V_P""C;JO[)_B8$@%KJQ
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M:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOOV0?VD_$'A6W\ :M\8M'?P!;F.)!&DAN_*C(*!OW"NP&!A&F(^4#/ Q[?\
M$7]CS1?B-^S_ *3\-M0\0:I=7ND@367B*_E:YN%N<$,[!FYC.YAY8( 7 !&
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MVYQV[5ZI14.HVK%<J/DOX#_L43^&?V;O%GPM^(MUI]^NMZF]]'<Z)-(_V?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"*XM8;N
M/RYXDF3.=LBAA^1J2EHH'=VL%%%% @HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7Z,V?_'I!_N+_*LI0Y8J7<I2NVB:BBBLBPHHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*K([CXS?M.?$KQU\?9O@U\$4T^SU.Q5O[2\0:A&)%A=0&? 96543(4DHQ+'
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MT3_T.UJ;+EBO,=]6_(V/ /[5>J^%OV'=/^+'C*;_ (2+Q%(;B%%\N.W%U/\
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M\*"T_P#CE=-X4^(/A;QY'+)X:\2Z1XBCAQYC:3?Q703/3)C8XZ=Z_*O]EO\
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M#!AGBN _83\?>!-2^!_B77/#7@^/X:^';'59WO+:;69M03*6\+O.TLP!4;,
MKT&S/<T<CY6WT#FU1]345\5:A_P4D>_N-4U#PA\(?$GBOP7ICE;KQ'&SQ1Q
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MAT\!^(7P+\+^!?'GB#X\6'A_6/%WCFSLG>#189/.2YF$:QIY:>4[HX50H*=
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M=L=>:*M.?-*5M A*-DKGT+1117,:A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P \?)_U7F>7_J_E^[[]>:R_B7^RK\*?B_XA77?%G@ZUU/6-JJUY'/-;/*%
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M)*R863Z'*_$/X5^$?BQHZZ7XO\/V.OV2$M&MW'EHF(P6C<89"1W4@UP?@/\
M8Y^#?PS\00:WX?\  UG;ZI;L'@N+JXGO#"P.0Z":1PK ]& !'K7LU%"E)*R8
M66X4445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M KS[X_\ P_F^*7P;\5^&+;!O+ZS)M@QP#-&RR1@GL"Z*/QKT&BLZE-582IRV
M:M]YV8/%5<#B:6+HNTZ<E)>L7=?BC\)KJUGL;J:VN89+>XA=HY895*NC X*D
M'D$$8Q45?J7^T3^Q)X;^-6HS:_I5W_PC'BB7F>XCB\RWNSZR1Y!#?[:GZAJ^
M;8_^":/Q&-V%?Q%X76VWX,BSW)?;GKM\@#/MN_&OS#$9)C*-1QA'F71H_NK*
M/%#AS,<)&MB*ZHU+>]&5]'Y.UFNUM>Z3T/E+2-)O->U2TTW3K:2\O[R58(+>
M(9:21B J@>I)K]I?A+X+/PZ^&7ACPR[K)-I>GPV\KKT:0*-Y'L6W5Y1^SG^Q
MMX9^!%TNM7-RWB/Q7M*KJ$T0CCM@1@B&/)P2#@L221TV@D'Z$KZS)<LG@8RJ
M5OBET[(_GOQ,XXPW%%6E@LNNZ%)M\S5N:3TND]4DMKV;N]-@K\]/^"@__)T7
MP1_ZZ6__ *6K7Z%U\]?M"?LE?\+W^*'@CQC_ ,)5_8?_  C31M]B_L[[1]IV
MSB7[_FILSC'W3Z^U?749*,KL_"IIM61S?_!2S1IM4_9>U"XB1G73]3M+F3;V
M4L8\GVS(*YD?$;19/^"9;7GV^W8#PO\ V*5$@!%UCR/+P3][/..I'/2OKCQ9
MX5TKQSX9U/P_KEFE_I&I0-;7-O)G#HPP>1R#W!'((!'(KX@'_!)?PW_PE#7!
M^(.J?\([YF1IXT^/[4$_N_:-^W/OY7X5=.4.51D[6=R9*5[H[W_@GO-:_#S]
MD$>(-?NH],TEKV]U*2YN/E2.%2$+$]^8CTZY&*\ZU*3QK_P4;\526FG3W'@_
MX%Z1>;9+HKBXU21,'A>A;I@'Y8]P)W, M?1WQQ_9C@^*/P0TWX8>&]='@?0K
M.2#(ALOM0D@B!VQ%?,3J^URQ))*\]<U\N_\ #HO_ *JO_P"6Y_\ ==7&4&W-
MNS?D2U*RBEH??/@WP?I'P_\ "NE^'-!LTL-(TV!;>VMTYVJ/4GDDG))/)))/
M)KC_ -I7_DWOXD_]B]??^B'K,_9@^ ?_  S?\,V\(_V[_P )%F^EO?MGV/[+
M]\(-NSS'Z;.N>_2NW^)7@W_A8GP]\2>%_MG]G_VSI\]A]J\KS?)\Q"F_9D;L
M9SC(SZUS:*=[W->A^;O[&/[$7@;]HKX47?B?Q)JOB&ROXM4ELECTNY@CBV*D
M; D/"YSESWQTXJA\5/"C_L"?M ^%F^&GC"ZU--2C0W^CWTD<DOE^8!Y4X10"
MK@G:=H8$,1ZUZ)_PZ+_ZJO\ ^6Y_]UUZ)\$_^"9GA7X8^,M.\1^(/$]SXPN-
M.F6YM;3[$MG;^:IRK2+OD+X.T@;@,CG(XKN=6%VW*Z[6.=0=K6-7]IH_M5-\
M3,_!\8\(&RAP/^)5_P ?'S>9_P ?/[S^[[>E?+W[9/\ PN'_ (4G\.?^%P>9
M_;?]M:CYN/LNS9Y=OY&?LW[O.//QWZYK]6JX?XR?!WPW\=/ MYX4\46SS6$S
M"6.:%@LUM,N=LL;8.&&3U!!!((()%<U.LHM72T^\UE"Z>I8N/^$-N/AKI\FL
M1Z./!XM;62,:FL7V)(QL,)^?Y  =FWWVX[5\4_\ !5J223PA\,6TYE;0C<7?
MS6Y!M]^R+RL8X^[YF,=LUT[?\$U]2O+&#P_J/QN\37O@2WD#0^'3"PCC4'("
M[IVB##)Y$74]*]^\1?LI_#WQ'\$;3X62Z8]OX<LE!M)H' N8)QD_: Y!S(2S
M$D@@[B",'%.,H4Y*2=Q-2DFK6/F7Q;^S?^U7\7OA[_PCVM_$WP/JWA:_AA<6
MJP+$K(I5XRK1Z>K+C:I&TC\JQ/VN?ASKWPC_ &"? 'A#Q)=V5[JVE:]'"\VG
MN[PE"MVT84NJL<(R@Y4<@UWFG_\ !.+6ECL=)U#XZ^*KKPC8R![71;>-XA!M
M.5\LM.\:,/41]>PKV/\ :"_99@^-WP;T/X?VWB>\T:#2KN&Y34M0C?4YY1''
M(F'9Y59F/F9W%NV,8Z:>TBI1UTOV)Y79Z'E?QH_Y1BV'_8L:)_Z':UW_ /P3
MW_Y-)\$_[U[_ .ED]=/XT_9U_P"$P_9BM_A!_P )!]D\K2['3?[9^Q;\_9VB
M._R?,'WO*Z;^-W4XYW_V>_A!_P *'^$>B>"/[6_MS^S3.?MWV;[/YGF3/+_J
M][XQOQ]XYQGVK&4E[-QZW-%%\U_(\L_X*-?\FG^)_P#KZL?_ $ICKD/A/I-K
M8?\ !,N]2&%0L_A?5;B3(!W.S3DD_I^0KWO]HWX+_P##0'PGU3P5_;']@_;9
M8)/MWV7[3L\N59,;-Z9SMQ]X8S6=X9_9_P#^$=_9G?X1_P!O?:-VD7.E?VQ]
MCV_Z[S/WGD^8>GF?=W\XZBB,TH*/F)Q?,WY'A7_!,:QMX_V:?$<RPJ);C6;H
M2MCEP+>$ 'V S^9KSS_@F#XALO!_@WXR:YJ#-'IVEK;WEPT:EB(XX[AVP!U.
M%/%?6'[,G[.O_#.?PQOO"'_"0?\ "0_:;V:\^V?8OLVW>B)MV>8^<;,YSWZ5
MR_[,_P"QO9? #0/&VC:CXB7QAI_BE$BN87T\V@6,+(K(?WK[@PE([8Q5RJ1?
M/KO82B_=/-O@U\8/B9^T9IGBK7OAYI?@?X5^"?MTD5[J=W9O=ZE),L2L\Q12
MD3MY;)DN/;+8K@_^"3O_ !]?%CYQ)QI_S@8!YNN<5W.B?\$SXO#NJZE::=\6
M_$UAX(U)_P#3/#]FAA>ZC&<)+*LFQ\9(R8>AZ5ZC^S3^R&G[-/B[QC?Z5XH_
MM+0M?P(])DT\QO:!'=HAYQF;S-JR,IRH)X/'0W*=/EE&+WL)1E=-GSW_ ,$G
M_P#D+?%K_?T__P!"NJ9^R/G_ (>&?&C'7;J^/_!A#7T5^R?^R3_PS!=^+9_^
M$K_X27^WFMSM_L[[)Y'E&4_\]7W9\WVQM[YX;\(OV1_^%5_M#>,_BC_PE?\
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M8@ NQ      4   =SDE5)PE'N_2WWCC&2?D>D4445QFP4444 %%%% !1110
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MAN#_ &74[2.YBW#H=K@C/X4GA?P;H'@G3S8>'=#TW0+$L7-KI=I';1;CU.U
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M&1*K;F!48'&/K7UYKWBC1O"MJMSK>K6.CVS':)K^Y2!"?0%R!FOS6_X)._\
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M?'6O>']'UO3/&.@JM]9PWL:W"SQO&70.HRJ-TR.:?_P5;_Y+KX7_ .Q;C_\
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M@UY1^U1^WIX:^"\.I^&O"[KX@\?1[H#"$/V;3Y.FZ9N-S#/"+GD?,5[^6?\
M!)'4YY=!^)>GL6^SV]S87" CY=TBSJV/?$2_I7TKX?\ V0/AYH_Q;UGXDWMC
M+KOBC4+Y[^-]18/!9NQX\J( #(XPS;B#R"*PE&%.HU+9&B<I15CX(_X)NZI>
M:Y^UA=:CJ-Q)=W]YIE]<7%Q,<O)(SHS,Q]223^-?K+7Y,?\ !-C_ ).LN/\
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MHNDMT81;34WU/UA\;?\ (FZ]_P!>%Q_Z+:OS3_X)1NL?QB\8,S!570"2S'
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME^R3^V+:_M23^)+4^&O^$7O='6&00G4!=^?'(7!8'RX\;2H!X/WAS67^U?\
MMPVG[,?BW1_#T?A0^*+V]LS>S?\ $Q^R"!"Y1!_J9-Q8J_IC ZYJ_9SYN2VI
M/,K<W0^H:*^4-=_;M_L7]F/P]\7O^$(\[^UM5;3/[&_M;;Y6TS#?YWD'=_J>
MFP?>Z\<^N?LW_M :1^T=\-X/%&FVW]FW*RM;7VF-.)7M)EYVE@!N!4JP; R#
MTR#2E3E%7:&I)NR/4Z*^>=%_:V_MC]J[4?@M_P (IY/V-7/]N?VCNW[;=9O]
M1Y0Q][;]_MGVKZ&J91<=QII[!1114C"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KR']KS_DV3XD_P#8%G_E7KU<S\3/
M =I\4/ &O>$[^XGM++6+5[26:VQYB*W4KD$9^HJHNTDV)ZH^"_\ @D?_ ,A'
MXH?]<M-_G<U]W_%C_DEGC+_L#7G_ *(>O-_V:?V2_#G[,4_B&70=8U353K2P
M+,-1,?R>49"NW8J]?,.<^@KV'Q)HD7B;P[JFCSR/%!J%K+:221XW*LB%21GN
M :UJS4JG,MB(1<8V9^:?_!*%BGQ0\<,%+D:*AVKU/[]>!78^+=0_9D_;"^+U
MQHTUOK_@[QG=1N#KSK%8Q7,T>%$3H[L&DP#U120N-V<"OHS]F_\ 8U\,?LS^
M(M6UC0M;U;5)]1M1:21Z@8MJJ'#9&Q%YR*Q?CE_P3]^&_P :O$5SXA#WWA;7
M;I_,NKC2BGE7#GJ[Q,"-QZDJ5R<DY)S6[JP=1RNT9J,E&Q\%_M3?LMQ?LJ7V
MA:EHOQ!AUFYN[AC;P0I]FOK78 PE^1VXS@;AMY(P/3[$\2>,M=^('_!,N\U[
MQ+))-K5UH>)YY?OS!+ORTD;U+HB,3WW9J'P-_P $L_ASX?U:"]\0:YK'BB&(
M[OL+[+6"3V?9\Y'T8?TKZ=^)7PITGXD?"W5/ 4K/I&C7UJEF/[/5$,$:E2JQ
M@@J -H&,8Q1.M%\JO>SW",&KGQW_ ,$EO^1,^(?_ &$+7_T6]?(?PM^%OA"T
M_:3NO /Q8O+K1-)AN[G3I;R.X6'RKA21$SR,I 1B,;L8^<'('-?J?^S;^S#H
M/[,NEZW8:#JNI:K'JLT<\K:B8\H44J NQ5X^;O6!^T-^Q'\/_P!H;5!K=_\
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M)84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M 'BOT(K\U/\ @H5K5WX;_; ^&&KV%C-J=]86-A=065NI:2XD2^F98U !)9B
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M  6Q_P"%%Z/9A:?<\9_X>A?!S_GV\3?^"^/_ ..T?\/0O@Y_S[>)O_!?'_\
M':]F_P"&4_@[_P!$S\,_^"V/_"C_ (93^#O_ $3/PS_X+8_\*+T>S"T^YXS_
M ,/0O@Y_S[>)O_!?'_\ ':/^'H7P<_Y]O$W_ (+X_P#X[7LW_#*?P=_Z)GX9
M_P#!;'_A1_PRG\'?^B9^&?\ P6Q_X47H]F%I]SQG_AZ%\'/^?;Q-_P""^/\
M^.T?\/0O@Y_S[>)O_!?'_P#':]F_X93^#O\ T3/PS_X+8_\ "C_AE/X._P#1
M,_#/_@MC_P *+T>S"T^YXS_P]"^#G_/MXF_\%\?_ ,=H_P"'H7P<_P"?;Q-_
MX+X__CM>S?\ #*?P=_Z)GX9_\%L?^%'_  RG\'?^B9^&?_!;'_A1>CV86GW/
M&?\ AZ%\'/\ GV\3?^"^/_X[1_P]"^#G_/MXF_\ !?'_ /':]F_X93^#O_1,
M_#/_ (+8_P#"C_AE/X._]$S\,_\ @MC_ ,*+T>S"T^YXS_P]"^#G_/MXF_\
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M-_X+X_\ X[1_P]"^#G_/MXF_\%\?_P =KV;_ (93^#O_ $3/PS_X+8_\*/\
MAE/X._\ 1,_#/_@MC_PHO1[,+3[GC/\ P]"^#G_/MXF_\%\?_P =H_X>A?!S
M_GV\3?\ @OC_ /CM>S?\,I_!W_HF?AG_ ,%L?^%'_#*?P=_Z)GX9_P#!;'_A
M1>CV86GW/&?^'H7P<_Y]O$W_ (+X_P#X[1_P]"^#G_/MXF_\%\?_ ,=KV;_A
ME/X._P#1,_#/_@MC_P */^&4_@[_ -$S\,_^"V/_  HO1[,+3[GC/_#T+X.?
M\^WB;_P7Q_\ QVC_ (>A?!S_ )]O$W_@OC_^.U[-_P ,I_!W_HF?AG_P6Q_X
M4?\ #*?P=_Z)GX9_\%L?^%%Z/9A:?<\9_P"'H7P<_P"?;Q-_X+X__CM'_#T+
MX.?\^WB;_P %\?\ \=KV;_AE/X._]$S\,_\ @MC_ ,*/^&4_@[_T3/PS_P""
MV/\ PHO1[,+3[GC/_#T+X.?\^WB;_P %\?\ \=H_X>A?!S_GV\3?^"^/_P".
MU[-_PRG\'?\ HF?AG_P6Q_X4?\,I_!W_ *)GX9_\%L?^%%Z/9A:?<\9_X>A?
M!S_GV\3?^"^/_P".T?\ #T+X.?\ /MXF_P#!?'_\=KV;_AE/X._]$S\,_P#@
MMC_PH_X93^#O_1,_#/\ X+8_\*+T>S"T^YXS_P /0O@Y_P ^WB;_ ,%\?_QV
MC_AZ%\'/^?;Q-_X+X_\ X[7LW_#*?P=_Z)GX9_\ !;'_ (4?\,I_!W_HF?AG
M_P %L?\ A1>CV86GW/&?^'H7P<_Y]O$W_@OC_P#CM'_#T+X.?\^WB;_P7Q__
M !VO9O\ AE/X._\ 1,_#/_@MC_PH_P"&4_@[_P!$S\,_^"V/_"B]'LPM/N>,
M_P##T+X.?\^WB;_P7Q__ !VC_AZ%\'/^?;Q-_P""^/\ ^.U[-_PRG\'?^B9^
M&?\ P6Q_X4?\,I_!W_HF?AG_ ,%L?^%%Z/9A:?<\9_X>A?!S_GV\3?\ @OC_
M /CM'_#T+X.?\^WB;_P7Q_\ QVO9O^&4_@[_ -$S\,_^"V/_  H_X93^#O\
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M"^#G_/MXF_\ !?'_ /':]F_X93^#O_1,_#/_ (+8_P#"C_AE/X._]$S\,_\
M@MC_ ,*+T>S"T^YXS_P]"^#G_/MXF_\ !?'_ /':/^'H7P<_Y]O$W_@OC_\
MCM>S?\,I_!W_ *)GX9_\%L?^%'_#*?P=_P"B9^&?_!;'_A1>CV86GW/&?^'H
M7P<_Y]O$W_@OC_\ CM'_  ]"^#G_ #[>)O\ P7Q__':]F_X93^#O_1,_#/\
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MK4L8+RSL4CEC+*5.U@,C*L1]":]"K&?+?W"XWZA1114%!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 8/C3P+H'Q$T232/$>E6^KZ>YSY5PN2C=-R,.4;D_,I!YK
MP.]_X)\_#*ZOC/%>>(;.+.?LL-Y$8^O3+Q,W_CU?35%<U7#T:SO4BF>[E^>Y
MIE<7#!8B4(OHGI]VU_,X#X7_  )\%?!Z%_\ A&M&CM[N1=LM_.QEN9!Z%VY
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M20Z6&KZQ:7,<<OWXR;>X#(WNK J<<9%>;V?[./[(4WA72M;N/C%K%LE^L?\
MHAU:S:YA=A]V2%;4R)@Y!+* .N<5UW[:7@GPS\._V'/ ^A>#=9F\0>&8-?CD
ML=2GN8[AIDD2[D)\R-54@%R!@# &*T7+SQLM;]K$ZV9WWQH_Y1BV'_8L:)_Z
M':UW_P#P3W_Y-)\$_P"]>_\ I9/7 ?&C_E&+8?\ 8L:)_P"AVM=__P $]_\
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MOZ?_ .A75>A?LY_M!>/_ !Y^V5\3? VNZ]]N\+:,-1^PV'V.WC\GRKR../\
M>)&';",1\S'.<G)KSW_@D_\ \A;XM?[^G_\ H5U3/V1QN_X*&?&@=,KJX_\
M*A#142<ZE^R%%NT3;US]I/XV_M%?'+7?!7P.NM.\-:'X?DDCN-8OX(Y%E"L4
M\R1I(Y-JLP.Q$3=C))QG;SOB#]J3X^^$OVCOA]\./%EU8Z',VHV-GJ?]F6T$
MMOJ\,MR%\]&DC+H&0E3M*\J>%/ ROV'_ !]H'[.?QV^*?@OQ_J<'AR\NKA88
M;[59!%$7@DEX:5CM7>L@<$D!L=>1G(_:%^+GAOXN_MY?"^X\+7\>JZ;I.H:3
MIS7]NVZ&:47QD8QM_$H\P#<."0<<8-4HKFY>72PKNU[ZGK_[:'[4'Q(^"G[0
MW@S0O"-[]HTB\L+>XFT+[- WVZ5KF5-GFM&SKN"JORD>V#S7+?&WXS?M5?LW
MR:'XR\8:OX9O_#^I77E-H>G6T;P6[E-_D2,8UE!(#X997&5.6Z9C_;6C6;]O
M#X*1N-R-_9*D>W]I25Z3_P %3_\ DW?1_P#L8[?_ -)[BHCR^XK+4IW]YWV/
M5OC-\8/'-O\  72O&'PI\(2>*-8UFVM[J*+ F^QP2QB0R&)6#3,,A0J9Y.3P
M,'Y<^*'Q8_:Q_9LT#0?&WC7Q)X?UK1M0N5@?1A9PDP2,A<1RF."-@<*PRDC<
MKR3WTOV@OC]XR^"O[(_P-L_!]TVD3:[H=M'<ZM'&&DA2.UA_=ID$*S;R=W4!
M#CU'CW[8%O\ "^Q^%OA@Z#\3=7^*?C:]N8YY-1U377OVMK;RGWH8P=L.7:/"
M,-XVD>M.E#:ZT;%*7F?5_P"UU^T;XJ\(_LO>"_B'X&U ^'=0UZYL9"3!#<[8
M9[664QXEC(."%^;:#QVSBO+]3^*?[6'BOX(0?%;2-4T'P[X;LM.%TUBL$,M_
M?PQJ/,NF$D+( V'?:K1_+T4\9J?M=,K_ /!/'X-E2&&-'&0<]-/E!KZ'TF-8
M?^"?\2H,#_A7);\3IQ)_4U"Y8Q6G4>LF]>AR'@/]N:.X_9%O?BGXCL()-?TV
MZ;27L+1C''=WGRF/;G)12KJS=<!7QV%><:/XS_;&\=?#U?BEHVI:'!HLT1O+
M7PI;Z?&]S<P \&-#"SL&'('G!F&,#D ^!^$?!FI^+O\ @G;XIN--@:X_L7QN
M-3N4C4LP@6SBC=@/1?-#'T )[5]F_ #]KKX7>'?V7_"]WJ_BW3;/4-!T:*SN
MM&:X07[201A-L<#,&<MM!!''S=1@XN45"[C&^HDW+=G?Z7\3/']Y^RYXB\6>
M*/#S^"/'-AHM]<" B-T$L4+M'.B$OM!(!V2<@@@@C!/EO[(_[46NZY^S+XV^
M(WQ-UEM9;0=1N%\V.U@@<Q);P,D2K&B*69W(!(ZL,G%>C:Y\:O#7QX_97^(O
MB7PLUZVG?V%J4#?;;1X&61;5RRC(VMC(Y0L,\9R*^0?V=/".H>./^"<_Q?TG
M2H6N+YM8DN4AC4LT@ACLYF50.22L9 'K6<8IQ?,K:HMMW5NQWG@[XD?M:?'W
MPO>?$CP7J/A[P]X9WR_8/#\D$3R7BQD@A&>%R3N!7+21@LIP *],^%O[< \9
M?LP^+_B'J&CQ1^)_"B&*_P!-A+)#-,V!"ZDY*HY;!!R05;KP3\@_LZ_ _P#9
MT^(OPM&L>/?B3J'A7Q1:22K?:>VJ6EJI4,3&T,<L#/)E-N0I8[L].!7U3\&?
M W[/?P>^"?Q#\0:!XKU'QOX#U2WAAUV*Z=;QHE&]54PPPI)&6\[DL!C .5P3
M6E2,%I;KV(BY=SS3P-\4/VJ_C-X%O/B%X1\<^$)[2!99F\(V$$$MZNPG]WY9
M@=@S#E5:4,05]1G[(_9]\8^./''PUL=2^(7A5O"/B7<R2VN0%F4 %953<S1Y
MS@H_S J>Q%?G1?\ P&^ /BKPC<^./A]\:6\"W-KY\\>B>)YH3>H\>XJD:HZR
M@' VE1*Q!'5LBOJG_@FW\3O&7Q*^$.LMXMU&[UE--U+[+8:A?'?*\?E*S1F0
M\R;2<[F)/SXS@ ":T5RMI;>5AP;O9GUO1117"= 4444 %%%% !1110 4444
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M[3GQZ_X9Q^&)\7_V'_PD.+V&S^Q_:_LOWPWS;]C]-O3'>OD?_A[I_P!4H_\
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M"O@3X=W7CJ-[D6EC>0ZF;=[V0G&8XO(<[2<X)/(Y(%>0?MY_MK'X@W5Y\.?
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MD.[+K"4V!OF;D#/S'UKH]-TVST73[:PT^T@L;"UC6&"UMHQ'%%&HPJ(J@!5
M   X %6:*+L#E].^%O@S1_$TOB2P\(Z#9>(IGDDDU>WTR&.[=GSO8RA=Y+9.
M23SDYKJ***+M[@%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1_CCPR?&G@W7- %_/I?]J64UD;RV \V$2(5++GC(!.*_.S]H'X;_  H_8_\
M@K<^ -1\/IXX\>>)HKBXL?$4MC%#)9@,JHQ<NSQ[,\*G#E6W;<UG1C"3M+<]
M&;:V/T7\(>+]&\?>&M/\0>']0AU31[^(36UU <JZ]._(((((."""" 17G7[0
MG[4/@O\ 9KTW3+GQ0;V\N=1E*6^GZ4D<ERR@9:4J[H @.!G/5A@'G'!_L9^
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MY8&,3.3ZML#?\"K%Q7(IHN_O6/8Z***R+"BBB@ HHHH **** "BBB@ HHHH
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M/E=F^P71[317BG[3W[4OAW]F?PI%?7L4>L^(+MU6QT&.Z$,LZ[OGD9MK%$4
M_-M.3A>_'>_"/Q]_PM3X9^&O%WV#^S/[9LH[S['YWG>3N&=N_:N['K@?2CE?
M+S= NKV.NHKQ3]I[]J7P[^S/X4BOKV*/6?$%VZK8Z#'="&6==WSR,VUBB* ?
MFVG)PO?CO?A'X^_X6I\,_#7B[[!_9G]LV4=Y]C\[SO)W#.W?M7=CUP/I1ROE
MYN@75['7445S'Q(^)'A_X3>#]0\3>)M0CT[2[-"Q9V&Z5L$K'&O\3MC 4=:2
MUT0SIZ*\-_91_:;'[4'A76]:7PV?#:Z;?"S$)OOM1DS&K[L^6FW[V,8/UKVJ
M_O[;2[&XO;R>.UM+>-IIIY6"I&B@EF8GH  3FG*+B^5[B335T6**^9_V;OVV
M+']I#XH>(_"VF>%Y-,T[3+:6[MM5EOO,:ZC698U)A\H>66#AL;VQTYZUUUA^
MTK;1_M*:A\']=T3^Q;UK-;W1]4^U^;'J:E-S+L\M?+8 /QE@?+;GIFG3DFTT
M+F3U/:J***S*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?V]K++%IGBKP[-/ UY;ACY(_UL8E&TC.9?D)(VUSG@'1K+]IW]J3X=:W\-_
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M-8:79)Y=G8V\=M G7;&BA5'Y 5=KSGY'4%%%%( HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2&A?L+_ KP[JD6H6GP]LY9XSE5OKNYNX?QBFE9#^*U[M'&L,:HBA$4;551@
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M3]U61<4TM3\^/ ^=!_X*J>)(;XNCZA#-]F+C&_=91R#'MM1A^%,_X*V8%O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6&H?X4>RC_.@YW_*?I'17YN?\,E?M>?]%:O?_"PU#_"C_ADK]KS_ **U>_\
MA8:A_A1[*/\ .@YW_*?I'17YN?\ #)7[7G_16KW_ ,+#4/\ "C_ADK]KS_HK
M5[_X6&H?X4>RC_.@YW_*?I'17YN?\,E?M>?]%:O?_"PU#_"C_ADK]KS_ **U
M>_\ A8:A_A1[*/\ .@YW_*?I'17YN?\ #)7[7G_16KW_ ,+#4/\ "C_ADK]K
MS_HK5[_X6&H?X4>RC_.@YW_*?I'17YN?\,E?M>?]%:O?_"PU#_"C_ADK]KS_
M **U>_\ A8:A_A1[*/\ .@YW_*?I'17YN?\ #)7[7G_16KW_ ,+#4/\ "C_A
MDK]KS_HK5[_X6&H?X4>RC_.@YW_*?I'17YN?\,E?M>?]%:O?_"PU#_"C_ADK
M]KS_ **U>_\ A8:A_A1[*/\ .@YW_*?I'17YN?\ #)7[7G_16KW_ ,+#4/\
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MM>?]%:O?_"PU#_"C_ADK]KS_ **U>_\ A8:A_A1[*/\ .@YW_*?I'17YN?\
M#)7[7G_16KW_ ,+#4/\ "C_ADK]KS_HK5[_X6&H?X4>RC_.@YW_*?I'17YN?
M\,E?M>?]%:O?_"PU#_"C_ADK]KS_ **U>_\ A8:A_A1[*/\ .@YW_*?I'17Y
MN?\ #)7[7G_16KW_ ,+#4/\ "C_ADK]KS_HK5[_X6&H?X4>RC_.@YW_*?I'1
M7YN?\,E?M>?]%:O?_"PU#_"C_ADK]KS_ **U>_\ A8:A_A1[*/\ .@YW_*?I
M'17YN?\ #)7[7G_16KW_ ,+#4/\ "C_ADK]KS_HK5[_X6&H?X4>RC_.@YW_*
M?I'17YN?\,E?M>?]%:O?_"PU#_"C_ADK]KS_ **U>_\ A8:A_A1[*/\ .@YW
M_*?I'17YN?\ #)7[7G_16KW_ ,+#4/\ "C_ADK]KS_HK5[_X6&H?X4>RC_.@
MYW_*?I'17YN?\,E?M>?]%:O?_"PU#_"C_ADK]KS_ **U>_\ A8:A_A1[*/\
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M6&H?X4>RC_.@YW_*?I'17YN?\,E?M>?]%:O?_"PU#_"C_ADK]KS_ **U>_\
MA8:A_A1[*/\ .@YW_*?I'17YN?\ #)7[7G_16KW_ ,+#4/\ "C_ADK]KS_HK
M5[_X6&H?X4>RC_.@YW_*?I'17YN?\,E?M>?]%:O?_"PU#_"C_ADK]KS_ **U
M>_\ A8:A_A1[*/\ .@YW_*?I'17YN?\ #)7[7G_16KW_ ,+#4/\ "C_ADK]K
MS_HK5[_X6&H?X4>RC_.@YW_*?I'17YN?\,E?M>?]%:O?_"PU#_"C_ADK]KS_
M **U>_\ A8:A_A1[*/\ .@YW_*?I'17YN?\ #)7[7G_16KW_ ,+#4/\ "C_A
MDK]KS_HK5[_X6&H?X4>RC_.@YW_*?I'17YN?\,E?M>?]%:O?_"PU#_"C_ADK
M]KS_ **U>_\ A8:A_A1[*/\ .@YW_*?I'17YN?\ #)7[7G_16KW_ ,+#4/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\02B75-3UI975 0D:["$C0$G"JH"CGH*F%&4XN3T0Y5%%V/V3HHKPO\ :_\
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MPC\-/"6A:M<K>:II>D6EE=W"N7$LT<*([AFY.64G)Y.:Z>N0W"BBBD 4444
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MBFAD^5@P.><@X/0@5]ZZ]K=W^U!^QM+J.EWFG^'-1\2Z2A\^]N6BM;6990)
M9 "P4.C@'!/2KE2Y;-.Z8E.]U;4^@J*^8OV%?@QKOP8\)^*++7?%.A^*9;V]
MCFCFT/4)+Q(E$>"KET7:2><"OIVLI)1=D[EIW5PHKYR_;J_:$U']G_X0)<:
MZQ>)=;N?L%E<, ?LR["TDX4@ABH  !XRX)SC!^+_ (:?L;_&']HSP'%\2+KQ
MR([R_,D^GIJUY<23S[2R[RXSY89@P'7CG !K6%+FCS2=D1*=G9*Y^KM%?G3_
M ,$\/VDO&4OQ)NOA-XSU"YU6$PS?8&OY?,GLYX,F2'><ED*AN"3M\L8X)KU;
M]O3]L.]^!-C:>$/!\L:>,M3@^T37KH'&GVQ+*K*#P9&*G&<@!22.5I.C)3Y$
M"FN7F/KF[OK:PC#W-Q%;H3M#3.%!/IDU*CK(JLK!E89#*<@CUK\G?AS^P7\7
M/VAM'@\;^)_$46FC5(UGMY]?GFNKVYC8;ED(Y*J<Y&Y@><XP03S7CKX>_&7]
M@3QAINHV6NM#IUY)F"]TV9WL;TK@F*>%@.<?PL/4J3C(U]A%OE4]2?:/=K0_
M8FBO/?@#\6X/CE\)/#WC*&W%E)J$)^T6H)(AF1BDB@GG&Y203U4@]Z]"KD::
M=F:[ZA1112&%%%% !1110 445A^./%]EX!\'ZQXBU$G['IML]Q(J_>?:.%'N
M3@#W(I2:BFWL:4J<ZTXTJ:O*322[M[$?C3Q_X=^'>D_VEXDUBUT>SSA7N7P7
M/HBCYF/LH)KR:/\ ;@^$,EX(/^$@N40X'VAM.G\OKC^YGWZ=Z_/'XI?%'7OB
MYXMNM?UZZ:6:1B(;=6/E6T>>(XP>BC\R>3DFN0KY*MG53G_=15O,_IC+/"G!
M+#)YE6DZKWY&DEY:IWMWT]#]G_"WB[1?&^CQ:KH&J6NK:?)PMQ:R!USW!QT(
M[@\BM>OR,^"/QJUOX(^,K?5],FDDL)&5+_3BW[NZBSR".@8#)5NQ]B0?UGT?
M5K77M(L=3LI/.LKV".Y@D'\4;J&4_B"*]O XU8R+TM);GY'Q?PE5X7Q$4I<]
M*=^6773=/S7?K]Z5RBBOES]K#]M"U^"UU=>"?"VEWFO?$:XM=\$4=N6@M RD
MB1N,R, -P101P=Q'0^M&+F[(_/FU%79]1T5\<?\ !,SQ]XF^('PU\7WGB?Q#
MJOB*ZAUA8XIM5O9+EXU,*':I=CM&23@<5Q?[3GQC^*7Q@_:23X(?"C6Y/#2V
M*#[9J%O<O;-)+Y8E=WG0&1(T4A=J<EB<[LJ!I[%\[A?8CG7+<^^Z*^!OV8?C
M-\4?A-^TA+\$/BOK4GB,W2'['J%Q</<LDOE>:C).X#R1NH(P_(;'3!!]6_:P
M_;0M?@M=77@GPMI=YKWQ&N+7?!%';EH+0,I(D;C,C #<$4$<'<1T(Z,N;E6H
M^=6NSZCHKXX_X)F>/O$WQ ^&OB^\\3^(=5\174.L+'%-JM[)<O&IA0[5+L=H
MR2<#BOL>LYQY).(XOF5PHK\\?V^O%WQ"3]ICP)X.\%^-=:\,'7-.M+:.*RU6
MXM+;SY;N:(22"(_[N6VDX'?&*I:I^R7^UIH>FW6HK\:)+TVD;3_9X?%FIEY-
MHSM DC"DG'\1 ]:V5%63<K7(Y]6DC]&Z*^0O^"=_[2/B?XY>$_$>D>+[AM3U
M;0)(#'JC1A6GAE#[5DV@ LIC/.,D$9R02;'A;QMXB^(7[?WBS3+;7]2B\(^#
M]$6-]+@O9%M)KED0;GB!V,P:9^HR#$.>,5#I-2<7T*YDTFNI]:T5^1OP#T']
MH3]I?4/$R>%?C!K.G#19(O/&K>)M0B#"4R;=GEA\X\MLYQU'6ND^*=O^TU^Q
MO_8GBC7?B=)XAL;R[%LL3:O<ZE 7"E_+DCN47 95;E.>.H.*U^KZ\O,KD>TT
MO;0_4ZBN;^&OC!?B%\/?#7BA+=K1=8TVWO\ R&ZQ^9&K[??&<9[UQ?[3OQYM
M/V=?A/J'BF6W6]U%G6TTVS<D+-<N#M#8YVJ S''.%(')%<RBV^5;FMU:YZQ1
M7YH>#_ O[6O[4&BKXY@^(,OA'2[TE[&W.JW&F)-'DX:.*V0_)Q@-)RPP<L#D
M^G?LD_'#XRZ/\9-1^$?Q4TW4-<-JK*NM?9C*;-@F]/-G1=KQ2+T=SNRPR><#
M:5&R=FFT9J?D?<-%?"5U\1O%B_\ !3Z#PJ/%&M#PN0,Z(-0F^Q'_ (E1D_U.
M[9]_YNG7GK7W;6<H<MO,N,N:X45\+_\ !3SXB^*_ ,7PW/ACQ/K/APW<E\+C
M^R=0EM?.V_9]N_RV&[&YL9Z9/K7W':L6M823DE%))^E$H<L5+N"E=M$M%%%9
ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6#I7ACQCH^O:D(VF-KI]VDT@0$ L0IX )'/N*[FAIK<84444@"BBB@ HHHH
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MFYU4C+J<[AQ7F'QH_8=^&'Q7\(G2],\.Z3X(U2.19+?5M#TV*%TP1N5T38)
M5R,,>"01TKCOVFOAG!\'?V _$7@^UU2^UFUTNWM8HKK4"IE*F^B8+\H "KG
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"? WAZ.+R7M=*@:=0/\ EO(OF3'\9'<_C7-_#HWZR-?BGZ'H]%%%<AL%%%%
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M_M@?MP>%?!/PVN]+^'GBZQUGQGJ6V.VNM$N([J.Q3<"\K2+N3.T%0N<Y8'&
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M%PKFW@6X-P;=Y 5DEEE/WY"I*@+E0">22-NDJ<%>3EZ$J4M%8\XO/^4MEO\
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MBOQ/)X@U+P!I\FIR2>;(T,LT$4CYR6:&-UC8D\G*G/?-*G*"5IHZI*70\/\
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M7H/_  3G\)WWA7]F#1WOX)+9]5O+C48DD&"8G(5&QCHP0,/4$'O72Z%^PO\
M KP[JD6H6GP]LY9XSE5OKNYNX?QBFE9#^*UZ_P"*_$FG> _".K:[J#K;:7I-
MG)=S,HX6.-"Q  ]AP!4RE'EY()C2=^:1\)?!&%M<_P""G'Q&OK97:WLHKSS7
MV\ A88CGT^;I7Z#5\;_\$[?AQ?/I/C'XNZ[:FWU3QO?RS6BMU6U\UG9AW >1
MCUZB-3T//V12K/WK+IH%/:X4445@:!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT>QJ?RASQ[GUY17R'_P]"^#G_/MXF_\ !?'_ /':/^'H7P<_Y]O$W_@OC_\
MCM'L:G\H<\>Y]>45\A_\/0O@Y_S[>)O_  7Q_P#QVC_AZ%\'/^?;Q-_X+X__
M ([1[&I_*'/'N?7E%?(?_#T+X.?\^WB;_P %\?\ \=H_X>A?!S_GV\3?^"^/
M_P".T>QJ?RASQ[GUY17R'_P]"^#G_/MXF_\ !?'_ /':/^'H7P<_Y]O$W_@O
MC_\ CM'L:G\H<\>Y]>45\A_\/0O@Y_S[>)O_  7Q_P#QVC_AZ%\'/^?;Q-_X
M+X__ ([1[&I_*'/'N?7E%?(?_#T+X.?\^WB;_P %\?\ \=H_X>A?!S_GV\3?
M^"^/_P".T>QJ?RASQ[GUY17R'_P]"^#G_/MXF_\ !?'_ /':/^'H7P<_Y]O$
MW_@OC_\ CM'L:G\H<\>Y]>45\A_\/0O@Y_S[>)O_  7Q_P#QVC_AZ%\'/^?;
MQ-_X+X__ ([1[&I_*'/'N?7E?(_Q,_X)N^"/BAX_U[Q9?^)_$%I>ZQ=/=RPV
MQ@\M&;J%S&3CZFH_^'H7P<_Y]O$W_@OC_P#CM'_#T+X.?\^WB;_P7Q__ !VK
MC"M#6*)<H2W9SO\ PZA^'G_0W^)OSM__ (U7KOP)_8?^&OP#UJ'7=+M[W6O$
M4*LL6J:M,)&A###>6BJJ*<<;L%L$C/)KA/\ AZ%\'/\ GV\3?^"^/_X[1_P]
M"^#G_/MXF_\ !?'_ /':M^WDK.XE[-;'UW7RA\9/^"<'PU^*&M7.M:3/>>"]
M4N6,DRZ:J/:2.>2_DL/E/LC*.O&3FJ?_  ]"^#G_ #[>)O\ P7Q__':/^'H7
MP<_Y]O$W_@OC_P#CM1&%:#O%,;E"6Y@^!_\ @E;X!T+5(+OQ'XCU;Q/!$=QL
M51;.*7V<J6?'^ZRGWK[.T?1['P_I5IIFF6D-CI]G$L%O:VZ!(XHU&%50.@ %
M?)__  ]"^#G_ #[>)O\ P7Q__':/^'H7P<_Y]O$W_@OC_P#CM.4:T_B3!.$=
MB?XI?\$X_!/Q6^(6N^+M1\3:_:7NKW!N98+4P>6C$ 87=&3CCN:Y;_AU#\//
M^AO\3?G;_P#QJNB_X>A?!S_GV\3?^"^/_P".T?\ #T+X.?\ /MXF_P#!?'_\
M=JE]82LKD_NSN?V=/V,_#7[->NZSJWA_7M7U"YU*S^QN-0\HK& P8,H5!SD=
M^*\GF_X)3^ +B:267QEXHDED8L[LUN2Q)R23Y76M_P#X>A?!S_GV\3?^"^/_
M ..T?\/0O@Y_S[>)O_!?'_\ ':/WZ=]1_N]CG?\ AU#\//\ H;_$WYV__P :
MKWVS_9FT*R_9Q;X-KJFHMH36\EM]O8Q_:=KSF8G[NW.YL=.E>2?\/0O@Y_S[
M>)O_  7Q_P#QVC_AZ%\'/^?;Q-_X+X__ ([2DJ\M[@O9K8]:_9N_9ET+]F?1
M-8TS0M4U'5(M3N$N9'U$Q[E95V@+L5>,>M>Q5\A_\/0O@Y_S[>)O_!?'_P#'
M:/\ AZ%\'/\ GV\3?^"^/_X[42IU9.[12E!*R9Z;^TI^RIH?[3@T!->UW5M*
M@T?SFAATTQA9&EV99]ZMD@1@#TR?6O$/^'4/P\_Z&_Q-^=O_ /&JZ+_AZ%\'
M/^?;Q-_X+X__ ([1_P /0O@Y_P ^WB;_ ,%\?_QVKBJ\597)?LV[LV?@A_P3
M^\'? OXE:7XTTGQ%KFH7^GK,L=O>F'RF\R)XSG:@/ <GKU%?1/C'P9H?Q \.
M7N@>(],M]8T>\39/:7*Y5AV([A@>0P(((!!!KY=_X>A?!S_GV\3?^"^/_P".
MT?\ #T+X.?\ /MXF_P#!?'_\=J90K2=VG<:E!*R.;\7?\$I_ FJZA+/X?\5Z
MSH$#G(M9XX[M(_4*3M;'U)/O6IX!_P""7'PT\-WT5WXBU?6/%AC(/V61EM;9
M\==RI\YY]''XUH?\/0O@Y_S[>)O_  7Q_P#QVC_AZ%\'/^?;Q-_X+X__ ([6
ME\1:VI/[L^JO#OAO2O".BVFCZ)IUMI6EVB>7!9V<0CBC7T"CCKS[DUI5\A_\
M/0O@Y_S[>)O_  7Q_P#QVM+PW_P4D^$WBKQ%I6BV5OXC%YJ5W%9P&6PC5/,D
M<(NX^:<#+"L/8U-VC3GCW/JJBBBL2PHHHH **** "BBB@"&\L[?4+62VNH([
MFWD&UX9D#HP]"#P:XV/X&?#F&^^V)X$\.+<=0PTN#@]<@;< \=1S7<45$H1E
M\2N=5'%8C#IJC4<4][-J_P!Q'##';0I%#&L42 *L:* J@=  .@J2BBK.;?5A
M1110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH ***\S_:)^-D'[/OPPO/&5QI,FM16T\,!M(IQ"S>8X7.XJ>F?2FDY.R$
MW;5F;\9OV4?AI\>+I+WQ1H"G5EP/[4L'-O<LH& KNOWP!C&X'&.,5Y/I?_!,
M/X,Z?>"><^(M3BW[OLUUJ*K'C ^7,<:-C_@6>>M>:_\ #VS2/^B;7O\ X-T_
M^-4?\/;-(_Z)M>_^#=/_ (U78J>(BK(Q<J;U9]Q^"? OA_X;^'+70?#.DVNB
MZ1;#]W:VJ;5R>K$]68]V))/<FN4^,G[//@+X]:?#;^,="COY[=2MM?Q.T-U;
MY[+(I!QGG:<KGD@U\C_\/;-(_P"B;7O_ (-T_P#C5'_#VS2/^B;7O_@W3_XU
M4*C63NEJ5SPM8]:\*?\ !-GX+^&=62^GL=6U_P N02);:M?;H01V*QJFX>S9
M!^E?3]C8VVEV<%G9V\5I:0((XK>! D<: 8"JHX  ["O@;_A[9I'_ $3:]_\
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MKU>P>TCW/T K'\8^%;#QUX3UCPYJJR/IFK6DME<K$^QS'(I5@#V.">:^%_\
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MY5_P]LTC_HFU[_X-T_\ C5'_  ]LTC_HFU[_ .#=/_C5*-*O'X1N5-[GJO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH K:CIMIK%C-97]K#>V<R[);>XC
M$D<B^C*1@CZUY3??LC?"+4+[[7+X*M$ER3M@N)XH_P#OA) OX8KU^BLITJ=3
MXXI^J/0PN8XW W^J5I4[[\LG&_W-&'X3\$>'_ >F_8/#NC66C6A.6CLX5CWG
MU8CEC[G)K<HHK1)15DM#CJ5)UINI4DY2>[>K?S"BBBF9A1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[]M_\51_PQI\$_\ HG&B_P#?MO\ XJO9Z*/:3[ARKL>,?\,:?!/_ *)QHO\
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M!/\ Z)QHO_?MO_BJ]GHH]I/N'*NQXQ_PQI\$_P#HG&B_]^V_^*H_X8T^"?\
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M[]M_\51_PQI\$_\ HG&B_P#?MO\ XJO9Z*/:3[ARKL>,?\,:?!/_ *)QHO\
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M!/\ Z)QHO_?MO_BJ]GHH]I/N'*NQXQ_PQI\$_P#HG&B_]^V_^*H_X8T^"?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=KKL$!"S+$&CEBSTWQ.%=0><$J,X.*/>M?H&E[&I_P *W\)?]"OHO_@OA_\
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MJL,,K#D=JZ(G:"3T%3=K1CT.=_X5OX2_Z%?1?_!?#_\ $T?\*W\)?]"OHO\
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M+_X+X?\ XFNCHHNPL<Y_PK?PE_T*^B_^"^'_ .)H_P"%;^$O^A7T7_P7P_\
MQ-='11=A8YS_ (5OX2_Z%?1?_!?#_P#$T?\ "M_"7_0KZ+_X+X?_ (FNCHHN
MPL<Y_P *W\)?]"OHO_@OA_\ B:/^%;^$O^A7T7_P7P__ !-='11=A8YS_A6_
MA+_H5]%_\%\/_P 31_PK?PE_T*^B_P#@OA_^)KHZ*+L+'.?\*W\)?]"OHO\
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M_P %\/\ \371T4786.<_X5OX2_Z%?1?_  7P_P#Q-'_"M_"7_0KZ+_X+X?\
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MOSP_:P_9!C^%/PC\3?$3Q-XBN?%/C75-:A"3-(_DVL,CL2@+'=*V !N;  &
MHQD_;_[)G_)L/PX_[ <'_H-;3A!4TXZZD1DW*S.8_9/_ &MO^&G[OQ;!_P (
MI_PC7]@M;C=_:/VOS_-,H_YY)MQY7OG=VQS]#5^>7_!)_P#Y"WQ:_P!_3_\
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M7O5>,>&_V1OAOX2^,5S\2]*TRXLO$,KM(D-O<&*T@=D*2,D2 #YP6)#9&6)
M%>SUC/EO[FQ<;VU/-/VAOCII'[/'PSOO%NJPF^D1UM[+3DD\M[RX;.V,-@[1
M@,Q;!PJDX)P#Y/\ '?\ ;4O_ (#^!OASKNI^ !=WWBVU>YETW^V/+-@56)MA
M?[.=YQ, ?E7!4]:\C_;FU"?XF?M6?!WX6NK2Z.)[>[NH,G;+YUQM?<.^V*%L
M'_;;I53_ (*T*%M_A8 , 2Z@ !]+:NBG3C>*EU,I2=FUT/T'AD\Z%'QC<H;'
MU%?/GP%_:V_X7=\8O''@3_A%/[%_X1EIQ_:']H^?]I\NX\G_ %?E+LS][[QQ
MT]Z^@+/_ (](/]Q?Y5^?/[!G_)X7QP_W[[_TX5C"*E&3?0N3::/6OVA_^"B'
MA#X'^++OPMI>B77C#7K%@EXL-RMM:P/WC,I5R7'&0$P,XW9! RO@?_P4M\(?
M%+Q;8>'-?\/77@V^U"58+6X:[6[M6D8X5'?8A0L2 #M(R>2.M>!_%3P]\3OV
M,?VDO%7Q-TCPM:^)?#NL7%Q<QZE<V3W%O#%-*)&1W0AH)5/RAB0&Y(##('1Z
M-^U3\!/VG/&VBO\ %WX=-X?\10LEM9:U#J,S6_+*5\V2$Q,HW]-ZNJ\G<,FN
MKV4.6ZC?SO\ H9\TKZNQ^D%%(N-HQR*6O/.@*\0_:O\ VEO^&8?!>D:__P (
MY_PDO]H:@+'[/]N^R>7^[=]^[RWS]S&,#KUKV^OB+_@J]_R1GPC_ -A\?^DT
MU:THJ4TF1-M1;1[%\=OVJ/\ A2?P-\+_ !%_X1C^V?[;>T3^S?[0\CR?/MWF
MSYGE-NV[=OW1G.>.E?-2?\%<U++N^%)"YY*^(LD#Z?9:V?V[?^3&_AA_UWTG
M_P!():H_#O\ X*1?#/P;\%_#7A.^\+^)-5U#2]$MM-GA:UM?LD\D<*HPW&8G
M82#R4SCMVKIA3CR7Y;ZF3D[VO8^G_P!FG]J;PO\ M->'[V[T:&?2]6T]E6^T
MF\96DBW#Y71APZ$@C=@'*G('&8_A'^TK;?$;XL>.?AQJVB?\(UXH\,SML@-W
M]H2_M@0!.A\M-O#(2I!XD4Y/./E#_@E_X1U74OB)X\\?1Z4=(\,7,#V=O&JD
M1&1YQ)Y<1P PC5<'TW+ZUM?M17G_  IG]OCX6^.++$2:Y'!:WX *AU+FVD8G
MN?*D3_OA:ETX\\H+L4I/E4F??]%%%<9L%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7'_%_X@1_"
MSX8^)/%<D:S'3+-I8HG.%DE.%C4GT+LH_&NPKQK]L/0;KQ)^S7XYL[-&>9+6
M.[VKUV0SQS/_ ..QM7-B92IT)SAND[>MCVLCP]#%9KA</B?X<ZD(R_PN23_
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M79E@O/)+&OTV\5>%=)\<>'[S0]=LH]1TF\4)<6LI(250P;!P1QD#COTK\_\
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MW[+_ (/U77=4O=:U2=KSS;[4+AYYY-MW,J[G<EC@  9/  %>7_&C_E&+8?\
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MY%>B^!_B)X;^)WAM=<\*:U::YI;DH+BSDW!7 !*,.JL 1E6 (R.*^&_ MC\
MEO?%>C_"SX.>(/C)/=RE&U&ZLHI=/M&*X\J.\N2#".K;R"QSG<0!B#_@DY-*
MH^*MH24AC:P<0YSM8_:0>>_  _"G*E%0<E?02F[I,Z3_ ()E_$;Q9X]U/XGK
MXF\3ZSXB6S>Q%LNK:A-="#<USNV>8QVYVKG'7:/2O0O@7J&FW'[5'Q @M_CC
MK7C2\07WF>![RQO8[72L748/ER2R&%O*/[L;%&0Q(P,UXW_P2?\ ^0M\6O\
M?T__ -"NJ9^R.VW_ (*&?&@]<+JY_P#*A#6E2/O3MV(B](GV#\5/VFOAC\%-
M1M]/\9>+;72=0G7>MFD,MS,%[,R0H[(#V+  X.,XJG)^UE\)EU;POIJ>,[6Z
MN_$QC72EM+>>=+AGE\I5+I&51M_RD.5([XKXN_8?\ Z!^T9\=OBGXT\?Z9!X
MCO+6X6:&QU6,2Q!YY)>6B8;6V+&$ ((7/3@8R/VA?A'X;^$7[>7POM_"UA'I
M6FZMJ&DZBUA;KMAAE-\8V$:_PJ?+!VC@$G'&!4^QAS<C;O8KGE;FZ'W_ .-?
MV@OA_P##OQUH_@[Q%XA73/$6K(DEG:26L[+(KNR*3(J&-!N5A\S#&,G YKF+
M/]M+X)W_ (J3P[!\0M-?4GE\E6V3"V9NP%R4\D@^N_!KY _X*$>&H?&?[87P
MOT"YW&VU2RT^REV'#;)+^9&P>QPQKI/^"D'P'\ _#WX*^&M7\+>%=+\.WUKJ
MT=AYVFVRPM-"\$I(E*\R',2G<^6Z\\G*C2@^5.]V-SEK;H?>'BGQ9HW@C0;K
M6O$&J6NC:3:J&FO+V41QIDX )/<D@ =22 .37D&@_MR? WQ'K46E6?Q!LUNY
M&V*;NUN;:$GI_K98EC'M\W->=?%.X^&'BC]C?X<WOQGU6^M;&?2M/N+>33YY
M!=2WAM!S&@R';!;EU*C))QUKY=_:XC\)ZE\%_#=]X-^!NJ?#[1[6^A@3Q+K%
MC;V%Q=AH9,1F-6:2<,%W^:Q(^7_:J:=*,M'<)3:V/TJ^*?Q@\(_!7P[#KWC/
M5_[&TJ:Y6TCN/LTT^Z5E9@NV)&;HC'.,<5POB;]M#X+>$9K&+5/'EG%->01W
M,<<%M<3NJ2*&3S!'&QB)5@=K[3@]*^8?VQKJ6\_X)]?!^>=S)-)_8[,YZD_V
M?+S75:!^S#\.X_V"9=2F\*:;+X@N/"<FNMK4MNK7JW!MS.I6;[RJ"%&T$+@8
M(.3D5."BG+O8.:5[(^S-!\4:/XH\/VVNZ1J=KJ.C7,7G0WUO*KPNG.6# XXP
M<^F#GI7C]_\ MP? W3=>.D3?$.P:[#;"\,%Q+;Y_Z[I&8L>^[%? ?AWXCZWX
M?_X)QZYIUG=O##?>,CHSLK$,ML]LD\B ^C,I!'<.P[FOK_X&_L@_"KQ=^RWX
M6LM1\+V-Q>Z[HT-Y<ZZL$?\ :*33()"T<Y4LNPG 7[N%P0<G+E2C3NYOJ"FY
M;'OOCC7M+UWX/^(M6L/$ZZ9I%QHMS/%XDTTM/]EC,+'[3'Y1W.4'S#8<DKP<
MUYC^Q3>6-]\,=5>P^*^J?&"$:O(#K6K6MU;R0-Y,7^CA;EV<J.&R#C,A[YK0
M\3?"/P]\$?V4_'WA;PQ'=1Z5#H&IRJMY=/.V]K=RQ!8X4$\[5 7))QDFOCO]
MF_QGJ?@'_@G7\7=9T>=K744UB2WBGC8J\?G1V<+,I'1@LA(/8@4HP4H.SZC<
MK-7/LSQ-^V=\%O!_B:70-4\>V,6IPOY<J003W$<;="K2QQM&"#U!;CO7K.E^
M(M*UK0X=:T_4K2]TB:+SX[^WF5X'CQG>'!QC@\Y[5^3_ ,!]6M]/^#?]F/\
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M7/?$2UFOOA_XGMK:&2XN)M+NHXX8E+.[&)@%4#DDGC KZR+:>A_.+U1\=_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M <*ZD!@&(SUY/K6AINFV>BZ?;6&GVD%C86L:PP6MM&(XHHU&%1%4 *H   '
M J'4?(HH?+[UQUC8VVF6<-I9V\5I:PJ$B@@0(B*.@51P!["O@']OB$^+/VK/
M@CX:M%\R],D#,JN,A9+Q0/IQ&QR:_06OD'X>?#'7_BI^VUXL^*'B30=0T?P]
MX6C&E: NJ6DENUW(%:/SHPP&^,9F<-T_>ICD'#HOE;D^B">JL?7U%%%8&@44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%^E?<=%<5?!T,2[U(ZGU>3\49OD4'3P-9QB_LM)KULT[?*Q\F?"O_@G[X?\
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MQ8XO;3')_P"O6M'PI_P3+^%_@_Q1I&O6>O>+I;S2[R&]A2>\M3&SQN'4,!;
MD949P0?>OKFBG[:IW#DCV"BBBL2PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HJE>:UI^G2".[OK:U<C(6:94/Y$U/:WEO?1"
M6VGCN(O[\3AA^8J%.+?*GJ*ZO8FHHHJQA1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y)\8_BA/H,O\
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MVQXN\+V7C;PMJWA_4_._L[5+62SN1!(8W,;J58!AR,@D5\/_ +3'AN/]E7X
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M1ED8KGL@8_G7U[^Q7>?!35?".LZC\'-,N-$CGEB75M-O+F>2>&0*WE[EEED
M&&;#(<'!YR, JTU&-U&WXA"3;W+_ .TA^V?X'_9QF32]06XUWQ/+&)4T?3\
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M5R0" ?E'.:^'_P!N;4)_B9^U9\'?A:ZM+HXGM[NZ@R=LOG7&U]P[[8H6P?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#CE'++L%T=YJ.GVNKZ?<V-[;QW=E=1-#/;S*&21&!#*P/4$$@BO@#XO?\
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MM/\ XY6495(RYEN4U%JQZ+7Q/^U!_P $[G^-7Q0N?&'AC7K'PZVH1*VH6MU
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M0Q)K'AN[NY%AMY-<M8XX9)&("KOCDD"Y)ZM@>]"ISDKI:!S).S9]0T5\&?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBM+6%0D4$"!$11T"J. /84W3=-L]%T^VL-/M(+&PM8UA@M;:,1Q11J,*B*H
M50   . !4TL@AC=R&(4%B%4L>/0#DFL)2<F:)6/S]^(,)\7?\%3/"UM9KYAT
MFWMWN"KCY?+MI)B3Z??48ZU^@M?(?[(/PM\0:Y\7_B3\:_&6A7V@:CKEY)9:
M1IVK6SV]U#:AE)=HV QE4B0'K\C]CS]>5K6>JBNB(AU?<****P- HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MEQ$2.H#H2,_C6GTY-'M*G\S'RQ['SO\ \.^?@#_T(/\ Y6=0_P#DBC_AWS\
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MECV/G;_AWS\ ?^A!_P#*SJ'_ ,D4?\.^?@#_ -"#_P"5G4/_ )(KU[Q)\6O
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M'?/P!_Z$'_RLZA_\D5]$T4>TG_,PY8]CYV_X=\_ '_H0?_*SJ'_R11_P[Y^
M/_0@_P#E9U#_ .2*^B:*/:3_ )F'+'L?.W_#OGX _P#0@_\ E9U#_P"2*/\
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MWS\ ?^A!_P#*SJ'_ ,D5]$T4>TG_ #,.6/8^=O\ AWS\ ?\ H0?_ "LZA_\
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M ,/]&\(:#&R:;ID/EJ\F#)*Y)9Y'(ZLS$L<<<\8&!69^T%_R0?XC?]BYJ/\
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MHI'>.5"L<@)RY!5DQQU.<5Q?CG]B'XO:EXT\-?$S0/B+I47Q2A@0:M?72-%
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M?\)9>Z'JEOX@^S+#'IDLLHVH9]XD$D2<$2CIGO\ CQO_  Q3\6?@OXNUJ_\
M@)\2-/\ #VB:O)OETO7(RXA )*J,PS*^W) 8JK!3@D\DZ3G&3E%/>Q,8N-G8
M]V\2?"7PA\#_ (<?$?Q+X"\,V.@>(I-'U"[^W6D1,QD\MY %8DE5W@$(N%&!
M@# KX(_8KU?XYZ'X)\0W7PH^''A?Q98WE\8=0U/6)(UN2PC0^0=UU$3& VX#
M:1EVY/0?9O[,/[*^O?"&[\1ZWXW\;7?B_7-?#_:K..:46"EVS(Y1B!*['^(J
MN!D <UY=%^Q7\8?@KXIUJ;X$?$O3]"\.ZL_F2:;KBEC#_=49@F5R.0),*V,
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MOW;^3-*5RY'F$.O5L$< #T3X2_\ #:?_  LSPU_PF_\ R*'VZ/\ M7_D"_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8?A[<65W<:_/%()[B%78%UB268N=R[\[48@8VE<5]'1Y+VDM3>=]T?0'P?\
MV@O#OQ<^#,7Q&B+:3ID,$TFHQ7#;C9/""9E8@?, !N!QRI!P,XKXWUK_ (*5
M?$S6]2U?7/!/PRAO/A_I<NVXO+NSNIY(TSPTT\3"*$L,':0VW/5NM;WA/6?!
MEG_P33\96_@"]O;[[/:2PZJ;Z(0W(NI702ET4LH4HPV[68; ,G<&KOOV$?#N
MGWO[$LEK+#'+#JO]J"\3:/GW,\9#>IV*HY[8K7EA#FDU?6Q%W*R3/7OA?^TQ
MX6^)'P+F^)Y9M*TJQ@FDU.WE;>]I)$N9(\\;CC!7'W@R\ G%?(.I_P#!2#XN
M>)I-5UWP/\+;>X\$:>Y$]Y=6%W>&%1R3-/$ZQQDK@X(.W/4]:T?^"8^@Z=\0
M?A!\3O"7B"T74?#]Q?6YFLW9E#[XV# E2#_RR3H>U>Y?&[XB?#?]BGX)77AW
M0;""RNK^*X72?#\,K2O+++NW2OO9F$0)Y).. H["CEA";ARW87<HIWL=S^S#
M^T=I7[2_P_?7[*QDTG4+.?[)?Z=)()/)DVA@5? W(P/!(!X(QQ7KEQ<1VL$D
MTTBQ0QJ7>1SA54#))/8 5\K?\$Z_@7K/P>^$%[J/B*WDL-7\2W"7GV"8%9+>
M!%VQ!Q_"YW,Q'4!E!P00/J34M/M]7T^ZL;N(36EU$T,T9) =&!##(YY!-<]1
M14VH[&L;\NI\ >*O^"C'Q%\8^+-6MO@Y\-U\1:#I9/FWEQI]W?2NF2!,RP,H
MA4X. Q/ SD<@>_?LB?M=6G[36AZK#=:4-#\4:.L;7EI'(7AE1L@2Q$_,!N4@
MJ<E<CDYK2U^Z^$G[#/PWU?5;#38= L[V;SDTVWG>6?4+D(%5(Q(['H!G&%4$
MDXR<^+_\$Z_A3KT=QXV^+OB"Q.DGQ<[G3K,J5W0O*9GE [(6*A/4*3T*D[OD
ME!M1MV,US*239W'[$?[5'BS]I.^\<0^)M/T:Q70VM1;'28)HR_F&8-O\R5\_
MZI<8QU-?5%?GE_P2?_Y"WQ:_W]/_ /0KJOT-K*M%1J-(JFVXW85\)_M$?MM_
M%CX=_M$:Q\-_ WA/1O$GV=8#:6YTV[NKV;=;),_RQ3#=C+'A> .>F:^[*_*W
M]HSQCXL\ _\ !1#5=>\#Z'_PD?BBT6#['IGV26Z\[=IJ(_[J(AVPC,W!XQD\
M U5"*E)W5]!5&TE8] _X;)_:S_Z(;_Y:.K?_ !ZOIWQI^TL?@]^S?HGQ"\=Z
M/);>(KVSMPV@PQ/;.U])'N,&V3<T0&&)+9*A3PQP#\Q?\-D_M9_]$-_\M'5O
M_CU?2O[57P%U+]IKX%VFC6]Q%I7B2WDAU2V2X#)"9Q&RM$_5E!$C#/)! SWK
M2:C>*DDEY$Q;L[,^83_P4"^/]U8R>)K/X/P'P6%:X%[_ &/J$D:P#G<;H.(\
M =6V@>U?7'[+_P"TIH_[3'@6;6[&R?2=3L9A;:CILDGF>2Y&597P-R,,X. <
MAACCGX<TO]H;]IS]EO1H="\8>#GU7PQID<=HKZQIAEMXX% 41I>6Y"-\HP"[
M/C/(/2OK/]BSXT_#;XO>'-9E\%>"M+\ :U:M%_:NDZ?:00A\@^7('B1?,3.\
M L 0<\<@DJP2C=1^:"$G>S9A_M1_MX:;\#_$W_"%^%]%/BWQJ0@EAWD6]JSC
M*(P7+22$%3L7'##YL\5XY#_P42^,/P[U.TG^*7PC_LO0KI_+1DTZ\TR4]R4:
MX9UD(&3MXSZBLC]@O3;?QU^V%\2_$VMA+[5[);RYMWE7)262Z"-(O'!"$J.1
M@.1]/T(\>_#_ ,/?%#PS<^'O%.EPZQHUPR/):S%@"RL&4@J0000.01Z=#2E[
M.DU!QN"YI:IG-7G[0'@JQ^"X^*<FJ?\ %)-:"[28+^]?)VB((3_K"_R;<_>[
M]Z^-+C_@HA\8OB%?WMU\+?A%_:>@6LGEM+)IMYJ<B]P9&MV14)'.WG'J>M:?
M_!3/1]/^'7P0\!^$_#.GVVA^'FU:60V%C$(X]R1D@X'7F1B<]2<FOKO]GKPM
MIO@WX'^!M+TF".&TCT>UE_=KCS)'B5WD/ R69F8G')-)*$(<]KW'[TGRW/&O
MV4_VY;'X^>()_!_B+1/^$5\:0HS);J[-!=[!^\"A@&C=>3Y;9X!.XX('U17#
M6OP/\!V?Q$NO'D7A;3QXON2&?5FCW2A@FS<N20C%>"5 )YSFNYKGFXMWBK&D
M;VU"BOE/]L3X'ZG\5/$'A^Z\0_%FR\#_  NAQ#J6F7-R++S&.27$CMY<KM\J
M@2 !!D@$DAOD?PMJ7A_]G_\ :_\ !.B_!OX@WWB3PGJ=]96NHAKE9(I&EF\J
M2)RB+'* I#!@O&X8.1FM8T5-73U)E/E>Q]=_M!?M5>+/A/\ M,_#OX=Z1I^C
M7&B>(C8B[N+V"9KE/.NWA?RV655&%4$94\^O2NC_ &K?VL!^SG<>%]*M-!_M
MG6?$4CI!)--Y=O;JK(K.X'S.<R+A1MR,_,._SM^VA_R?K\$OKI/_ *<I*X/_
M (*-?!71/"?QL\-ZU:76H277C6XEEU!)I$*1%&@C'D@("HPQ^\6YK:%.$G"_
M5&<I-7L?J717G_P-^">A_ #P'%X2\/76H7FFQW$ER)=3DCDFW.02,HB#'''%
M>#?\%'_CAKWPG^%NC:3X9U"32M5\1W;P/>6[E)X[>-07\MARI)9!N'(!/KFN
M6,.>7+$V<N579])?%'Q1=>"?AIXL\16,<,M[I.DW5_!'<*6C:2*%G4, 02N5
M&<$''<5Y)^Q3^T%XB_:0^&.J^(_$MEI=C?6FKR6"1Z3%)'&8UAB<$B21SNS(
MW?& .*^==<_8+N_A'\ /$/B_1?'FO6_CA=#GN=6@61!87D)A9KBW:,KN;Y&<
M!F8\C.T$\'[#_P 3E^#?[$OQ*\9&!;J32M9GDA@D;:LDS6]JD:D^A=ESCM6_
MLX\CY7=W,^9\ROH?H917YO\ P!_9/U#]LCP7-\2_BQX[\0W<^HW$T>EV]G,@
M$2HY5G_>*RJA<,!&BJ $SGG Z[]E7XE>,O@U^TQKO[/_ (MURX\3Z4OF-I%[
M>R%I8ML(FC"EB2$>'K'DA6'R]\PZ*U2=VAJ>UUN?>5%?C_<>(O!_Q3^-GC:'
M]H_Q;XRT*XM[Z2*QBTY ]O9;9&!B9#'(R #;M"1X/S$G)Y^ROV$_!=QX9C\1
MRZ+\8+'XA>!'D*:?I,1>6>R!;,;R;R# Y3<&B"88\@\<N='DC=L(SYGL>H?#
MGQ1\:]2^,OB?3?&/A#1M*^'%O]I_L?5[.96NKG;,H@\Q1<N1NB+,<QKR!TZ5
M[-7YX?LB_P#*0WXS_35__3A#7FWP]^'FK?%C]N/XJ^$['Q/J/A72[[4=4?5[
MG29!'<S6J763"CX^7<Y3)Y&,Y!'!ITDV];61*GH?JQ17YA_\(3=_L4_MM>!O
M#?A/Q#JMWX:\1R68GM[V52TT4\S6[)*$"HY5@75MH(X],GN?VPO$_BCX[?M0
M^'?@#HVNRZ'X?E2(ZE]G)(F=HVG=I%!&\)$%*H3C=R>Q$^QU5GI:Y7/IL?H'
M17Y;_MH?LO7/[-7PETR/POXQUK4_ ^H:E'%>Z+J\L<@CNPDCQS1;54*"!("
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ME(U'[M3Z\]:[NBBO<RW*L'E%'V&#I\JZ]V^[>[.'$8JMBY\]:5V%9GB?1?\
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M511*I.2LV-12V/G?]E']D?\ X9BN/%TO_"5_\)+_ ,) ;<X_L[[)Y'E&4_\
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M^KR[K[P]HC](Z*_-S_AK7]KS_HDM[_X1^H?XT?\ #6O[7G_1);W_ ,(_4/\
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M?P##<0^&/#>D>'(;E@\\>DV$5JLK 8!81J-Q )Z^M?GW_P -:_M>?]$EO?\
MPC]0_P :/^&M?VO/^B2WO_A'ZA_C1[&;W?XASQ['WMX:^$7@3P9JQU3P_P""
MO#NA:F4:,WFFZ5!;S;6^\N]$!P<#(SSBNMK\W/\ AK7]KS_HDM[_ .$?J'^-
M'_#6O[7G_1);W_PC]0_QI>PF]VOO'[2/8_2.BO,OV;O&'C+QY\'M%UOQ]H\F
M@^*KA[@75A)926C1A9W6/]U)\RY0*>>N<]Z]-KF:Y78T6JN%%%%(84444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5X1\</A_<0:C)XAL8FEM9@#=*@R8F QO_W2,?0_6O=Z1@&!!&0>
M"#7EYEE]/,L.Z%33JGV9SUZ,:\.1GQ54EO;RW<\<$$;332,%2- 2S$] !7U'
MJ7PE\*:I,TTNDQQ2,<DV[O&/^^5('Z5I:!X'T+PNY?3--AMI2,>;R[X]-S$G
M]:_/X<(XGVEIU(\O=7O]UOU/&66U+ZR5C%^$W@=_!?A]OM0 U&\823@'.P ?
M*F>^,G\2:[>BBOTO#8>GA*,:%)>[$]VG!4XJ$=D<E\6O#^N^*OAKXCTKPQJL
MFA^(;FRD73[^*0H8IP,H=PY ) !(Z FOSB\.?MO_ !<^#OA#6/AEXN\):CKG
MC:22>*TU+6KB9KJ(R9 #1E&,X!)*%7 Q@#( K]2J*[X5%%6DKCE%O5.Q\/\
M[)G[)>O:;^RIX]T#Q1 VBZSXY@?R;2Z4K):*(BL#2KU5MY+%<9 P#@Y ^=_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.3E0W52R!@#GA@#GFOCCX0_MT_'WXE+J7A+P_IUMXL\:Z@T;Z?<_98(8["%
M_G.P^1"23'AI#M&.A+ 5,:,I7\AN:5O,_4&BORW'[9W[0'[./Q530_BN5UF!
M&2:[TRXM[96>!_\ EI!- H'3..2H(*D @XW/B!^T-^U=XG\%W'Q3T/31X/\
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M9P5*36K#FES(_32BBOG;]M+Q'\5_A_\ #U?&7PSU:.&'20S:OITEC%<%H/\
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M'\,Z(+C4+$6L+>?<LBE3YA4R#!G3@,!^[Z<DF/9R3<7T'S*R9]-45^5WPO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9HC"4KN*!R2W/KVBBN>\?>/] ^&'A2^\2>)]2BTK1K)=TMQ+D]3@*JCEF)P
MH!))J=]$4=#17POKO_!6#P7::B8M(\%:WJ5FK[?M%S/%;L5[L$&_\ 2/?%>K
M? ?]O3X<?'/7K?P_";[PWXBN3MMK'547;<MC)6.5"5)ZX#;2>P-:NC4BKM$*
M<6[7/I*BN5^*7Q"LOA3\/==\7:C;3WEEI%N;F6"UV^8Z@@87<0,\]S7"?LV_
MM/:#^TUI>MW^@Z5J6EQZ5-'!*NHB/+EU+ KL9N/E[UGRMKFZ%75['LM%%%2,
M*IZQK%EX>TF]U34KF.RT^RA>XN+F8X2*-%+,Q/H ":N5\P?MS>!_BS\6O!ME
MX*^'>D1S:1>'S]8O9+^& R!6^2W =@2,C>QQ@X09^\*N$5*23=A2=E<^#?B=
MXL\5_MY?M+16'A^)EM9G:TTBWN"5BLK-,EII< [<\NQP3DA1G"BNJ_8I^.VI
M?LP_&C4? /C/?IN@ZE>_8-0AN#@:?>J=B3>@4G"L>A4JV<(*^Q/V%_V4)OV>
M?"5]JOB6"'_A.-88I<>6ZR+:6RM\D*N,@EB-[$<'Y1_#D\-^W;^Q/K'QF\0Z
M;XS\ 65O-XBD M=5M))D@%PBK^[G#,0-R@;#SDC9_=-=_M82?LOLG-R22Y^I
M]+?'[XV:3^S_ /#'4?&&JP27J0LL%M9PL%:YG<X1 QZ#@DGG 4G!Z'XX\ ?%
MS]JW]J[3[G5_!,N@>!_#)G:V^W>4B(S #(#2++*Q (RRJ!G@="!Z,/V>_B;\
M:/V1Y/AI\188-'\7:+-$^C:I)=QW$5TL0(C$IC+,"$9XR<9P5;YCN%>.?!7X
M:_MA?!G2+OP/X8T:QT[1YYVE6^U"XLYHK1GP&EC;>S8. =NUNYV@DUE",(Q>
MJOYER;;6]CR+X/Z%K/AG]OK0]*\1:O\ V_KMIXD:*^U+>S_:)@&W-EN>OKZ5
MZG_P5F_Y*)X#_P"P5/\ ^CJL^"_V&_B_\+/VD/#?BY$MO&.FV>IV]_?:M]MC
MADF+X-R=DC[BP+28)^]@'C.!Z=_P4 _9@^(7Q\\8>%+_ ,&:5!J%KI]A+!<-
M->10%7:3<  [#/'I6_/'VL7?H9\KY&K%?]LU2W_!/_P00,A8=%)]O]&Q_6NP
M_P""8DBO^S+A3DIK=VK>QVQG^1%>A_$3X W/Q5_93M/AM>S1Z9K4>C6,,<SG
M?'#=VZ1D E<Y4LA4D9X8D9XKXJ^$OP4_:\^!MQJ7ACP98_V5IM_/NFG:>QGM
M ^T#ST,A8J=H X&3@ @D#&,>6=-PO9W-'>,D[&)^U#<1S_\ !1R#RW#[-<T)
M&V]F$=KD5[%_P5L_Y%WX;?\ 7U??^@0UQMW^P'\5M#^.WA?Q&LZ>+8(]1LM5
MUC6Y[R*-I+CSQ)<%49@Y5<<$C+8S@9P/>O\ @H-^SWXW^/VC^"K?P7IL.HRZ
M9/=27(FNHX-H=8@N-Y&?NGI5\T5.%GL39\LM#T/]AW2XM)_95^'T44:QB2SD
MN&V]VDFD<D_]]5\@?\%9O^2B> _^P5/_ .CJ^ZOV;?!6K?#GX%^#/#6NP+;:
MOIM@L%S"DBR!7#,<!E)!Z]J^;/\ @H!^S!\0OCYXP\*7_@S2H-0M=/L)8+AI
MKR* J[2;@ '89X]*RI22K-M]RY)\EC0_:P_Y1UZ3_P!@O0OYP4?\$J/^3>?$
M/_8TW'_I):5ZI\4_@1JOQ._9'A^''F0V/B!-%L(4,SYB6ZMQ$VPL ?E+1E=P
MSP<U\I?LI_!']I[X.^-M)T7^RYM#\!-K,%[K5NU[8O'(F561E(=G),:C(0\[
M0#T%.-I4I1OU$[J2=CT?]HS]N?Q5I?Q?_P"%5?"7P_:ZOXB2Z6PFO+]/,W71
MQ^[A3>JC8?O.YP"#P NX^'_M;> _VAX/A&OB3XN^-=/N=(_M"&&+P_8NJXE8
M/M9EBB6,[0#CYG-=S^TE^QK\5/#_ .T!/\4_A+$NJO=7XU98XIX8[BRN<@OE
M92JR(S9/&20Q#+@9*_$[]G7]IW]IOP;+=^/KG2])ETD++I7A>W>%?M<S,JO(
M[(Y1"(RQ!9R0<J%7<36L.2/*XM>?<B7,[IW.N_9,_P"4=/CC_KPUW_TG>O-?
M^"3-K&_C[Q]<E?WT>F6\:MZ*TI)'YHOY5[Y^SC\#_'_@7]D?QU\.O$>BPV6O
M74&I1::D=Y%*DXN+;:@+*Q"GS"P.>Q!KG?\ @GY^S)\0/@'XD\87GC/2H-/@
MU&TMXK9H;R*?<RNQ8$(QQP1UJ)2CRU-=RDG>)\__ /!58 ?M#>'L#&?"UOG_
M ,"[NOO#XW:?#8_LA>,;.) L%OX.N(XUQ@ +:';^6!7SA^WM^R=\2?CM\8-'
MU_P=I%OJ&F6^A0V,DDU]# 1,MQ<.1M=@3\LB<].:^LOBQX/U3Q5\ O%7A?3H
M5FUF_P##UQI\$+2*JM,UN45=Q. -QZGBHE)<M-7V*2=Y'Q3_ ,$C_P#D(_%#
M_KEIO\[FO,OV*_\ D_)_^OK6/_0)J^G/^">_[-OCSX 7GCJ3QIID&G+JL=DM
MKY-W%/O,9GWYV,<8WKU]:XC]F?\ 9%^)OPU_:N;QQKVC6]KX=,^HO]H2^AD;
M$JR"/Y%8MR6';BMI3CS5-=T9J+M'0\1^*%Q!:?\ !23SO$/EBS3Q?I[2--C8
M(LP>66SQM"["<\8S7Z9?'^YTZS^!OQ EU9HUT\:#>K+YQ&#F!P!SW)( '<D5
M\N_MO_LG6'QS\7KK_@SQ%HMMX]M88[;4=$O+V.)[I NZ)NN4D"LH^8 ,NWD8
M^;S.3]EK]H7Q9X$U.T^+/C>ZL/ V@Z?->FP;4UNI;DPQ,\:_+D$ J/FD8[<<
M ]H?+447>UBE>+:L5_\ @DS_ ,E$\>?]@J#_ -'5^BGQ \%6/Q(\$:YX6U.6
MX@T_6+.2RGDM&5951U*DH65@#@\9!'M7YV_\$F8V/Q \>N%)0:7 "V. 3*<#
M]#^5?IE66(TJME4_@.'^"_PAT?X%_#W3_!V@W-]=Z99/*\<NHR(\Q,DC.V2B
M(O5CCY>E=Q117,VV[LVV"BBBD 4444 %%%% !1110 4444 %%%% '*_%+XB6
M7PF^'^M>+M2LKW4+#281//;Z<B/.4W!25#LJ\9W')' /7I7@/PS^)/P=_;ZM
M]<L]6\$13W6BB(!-86-;SR9-WS121-O50P(.UNI4GJ*^F=>T.P\4:'J&CZI;
M)>:9J%O):75O)G;+$ZE74X[$$BOS0\9_L"_&7X*^/I-?^#NJ2:G:;I#:S65^
MEG?01$Y\J42,JR#&!P2&QRHX%=-)0::;L^AE.ZZ71U7[6O\ P3[\!_#OX6Z_
MXY\'ZE?Z-+I,:SOIE[,)[>52ZKM1F&]6^;C+-D@# SFNC_X)0^.M6UGP5XV\
M+WDTD^EZ+<VMQ8[R2(OM F\R-?1<Q!L#NS'O7CGB/]G_ /:Z^/36^C>,OM[:
M6CJY_M;4K>&T1N@=HXF)<CU",1SZU]W?LK?LWZ?^S3\.3H<-TNIZS?3?:M3U
M%4VB63&%1!U"(. #W+'C=@;5)6I<LI79$5>=TK(\Z_X*7_\ )KM]_P!A6S_]
M"-<[_P $J/\ DWGQ#_V--Q_Z26E>I?MM?"?Q+\:/@7=>&O"EG'?:O)?V\ZPR
MSI"-B,2QW.0.]8W[!/P5\6? GX/ZQH'C&QBT_4[C79KZ..&X2<&%K>W0'<A(
M!W1OQUXK)27L&KZW+L_:7,#_ (*<?\FR/_V&;3^4E>0_\$^_V:_AI\7O@CJ.
MM^+_  I;ZWJD>N3VJ7$L\R$1+# P7".!P78].]?2'[<'PC\3?&SX'MX;\)6<
M=]JQU*WN?*EG2$;$#[CN<@=Q7Q=X+_93_:T^'.DOI?A>[O- TYYFN&M=/\0P
MQ1F0@ N0).I"J,^PK6FTZ7*I6=R)?'>US[:_X87^!7_1/;+_ ,"KG_X[4_[6
MGQ,M_@+^S?KU[IS"SNVM5T;245CE99%V(5)/5$#O_P!LZ^/?^%(_ML?]#-K/
M_A41?_'*V/C7^SC^T9\6_A/\-?"^IV']KWVBQ7EUJMY>ZS [SW4MU+Y0+%_F
MV0", _\ 30CM4\BYES3NO4?-H[1/E#]G?XS^*_@#XHN_%'A7PYI^M7]Q:M8B
M74[.>=(D+*S;/+D3#':HR2>,CO4W[1GQN\7?M!^(+#Q'XL\-Z?HU[96HLO/T
MRSG@66/>64/YDCY(+-C&/O=^*_7G]F_X4CX*_!/PKX2=$6^L[427S(00UU(3
M)-SW =B ?0"K_P =?AE!\8OA'XI\'SA=^IV3I;N_2.X7YX7/LLBH?H*T^L1Y
M[\OS)]F^6USS?]A/XO?\+<_9WT&2YF\W5]#']C7VXY8M$H\MSW.Z(QDGNV[T
MK\S/@W\(+/X[_M-/X*O]0GTNUU"]U!FNK=%=T\M)91@'CDH!^-?:/[!/[/OQ
M>_9[\<:Y!XJT2"V\*ZS:#S7BU""8Q7,9S$VU7)P5:13@=USTKE_V8?V/?BA\
M,_VJ+'QMK^BVUKX>BGU"1KB._AD8"6&94^16+<EU[<9HC*--S<7Z TY*-T='
M:_\ !)OP8EPAN?'&NRP _.D4$*,1[,0V/R-?6'P<^"?A+X#^$U\/^$=.^Q6K
M/YL\\K^9/<R8QOD<]3CL, =@*[NBN.56<U:3-E&,=D<I\6/^26>,O^P->?\
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MHGA?Q1:1V6LVL]U)+#',DJ@/.[K\RD@\$5A)J-'EOK<T5W.]CX ^!]G%??\
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MAH?,G@.X7X$_&K]F[QD,V&E>*/#5K8W[GA9&;="Y;V >W;)_NCL*YCXBR_\
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M/@_PY!87LR[)M0F9I[J1202IE<DA<@?*N%X!Q7SK_P %6_\ DA7A?_L9(_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5Y3^U9_R;7\3/^P!=_\ HLUZM7E/
M[5G_ ";7\3/^P!=_^BS5P^)"ELS\^O\ @G'X/^'GBW6O'2?$#3M!U"&"WM#9
MC7!$55BTN_9O[X"YQ[5[[^UO\-?V;M!^"7B"ZM+3PKI'B)+9VT<Z'-&ES+=
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MSL9VW;_/3KOZ8[=:N*BW:3L3*Z6B/J/_ (232?\ H*67_@0G^-'_  DFD_\
M04LO_ A/\:_/[_AT7_U5?_RW/_NNC_AT7_U5?_RW/_NNMN2E_/\ @1S3_E/T
M!_X232?^@I9?^!"?XT?\))I/_04LO_ A/\:_/[_AT7_U5?\ \MS_ .ZZ/^'1
M?_55_P#RW/\ [KHY*7\_X!S3_E/T!_X232?^@I9?^!"?XT?\))I/_04LO_ A
M/\:_/[_AT7_U5?\ \MS_ .ZZ/^'1?_55_P#RW/\ [KHY*7\_X!S3_E/T!_X2
M32?^@I9?^!"?XT?\))I/_04LO_ A/\:_/[_AT7_U5?\ \MS_ .ZZ/^'1?_55
M_P#RW/\ [KHY*7\_X!S3_E/T!_X232?^@I9?^!"?XT?\))I/_04LO_ A/\:_
M/[_AT7_U5?\ \MS_ .ZZ/^'1?_55_P#RW/\ [KHY*7\_X!S3_E/T!_X232?^
M@I9?^!"?XT?\))I/_04LO_ A/\:_/[_AT7_U5?\ \MS_ .ZZ/^'1?_55_P#R
MW/\ [KHY*7\_X!S3_E/T!_X232?^@I9?^!"?XT?\))I/_04LO_ A/\:_/[_A
MT7_U5?\ \MS_ .ZZ/^'1?_55_P#RW/\ [KHY*7\_X!S3_E/T!_X232?^@I9?
M^!"?XT?\))I/_04LO_ A/\:_/[_AT7_U5?\ \MS_ .ZZ/^'1?_55_P#RW/\
M[KHY*7\_X!S3_E/T!_X232?^@I9?^!"?XT?\))I/_04LO_ A/\:_/[_AT7_U
M5?\ \MS_ .ZZ/^'1?_55_P#RW/\ [KHY*7\_X!S3_E/T!_X232?^@I9?^!"?
MXT?\))I/_04LO_ A/\:_/[_AT7_U5?\ \MS_ .ZZ/^'1?_55_P#RW/\ [KHY
M*7\_X!S3_E/T!_X232?^@I9?^!"?XT?\))I/_04LO_ A/\:_/[_AT7_U5?\
M\MS_ .ZZ/^'1?_55_P#RW/\ [KHY*7\_X!S3_E.L_;4_8U'QR\7#QOX+\2:/
M!KLEND%]IVH78C2XV#:CHXSAMN%(88.T<COY/K'PG_:S\6^%SX.U;Q?92^')
M8EM)$EUVS"O"HP [I^]92!R#DGN#76?\.B_^JK_^6Y_]UT?\.B_^JK_^6Y_]
MUUT1J0BDN>]O(S<9-WM^)] _L??L\Z%^S#X/U*"Y\2Z=K'B/6)(Y;^[@E58E
M5 0D4>3DJI9SN(!);H, 5] ?\))I/_04LO\ P(3_ !K\_O\ AT7_ -57_P#+
M<_\ NNC_ (=%_P#55_\ RW/_ +KK&4:<G=S_  +3DE91/T!_X232?^@I9?\
M@0G^-'_"2:3_ -!2R_\  A/\:_/[_AT7_P!57_\ +<_^ZZ/^'1?_ %5?_P M
MS_[KJ>2E_/\ @/FG_*?H#_PDFD_]!2R_\"$_QH_X232?^@I9?^!"?XU^?W_#
MHO\ ZJO_ .6Y_P#=='_#HO\ ZJO_ .6Y_P#==')2_G_ .:?\I^@/_"2:3_T%
M++_P(3_&C_A)-)_Z"EE_X$)_C7Y_?\.B_P#JJ_\ Y;G_ -UT?\.B_P#JJ_\
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MFD_]!2R_\"$_QH_X232?^@I9?^!"?XU^?W_#HO\ ZJO_ .6Y_P#=='_#HO\
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MI_RGZ _\))I/_04LO_ A/\:/^$DTG_H*67_@0G^-?G]_PZ+_ .JK_P#EN?\
MW71_PZ+_ .JK_P#EN?\ W71R4OY_P#FG_*?H#_PDFD_]!2R_\"$_QH_X232?
M^@I9?^!"?XU^?W_#HO\ ZJO_ .6Y_P#=='_#HO\ ZJO_ .6Y_P#==')2_G_
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M@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCU:O /VSOV=M:_:4^'.C^'M#U*PTNZLM52_>74-^QD$,J;1L4G.9!^1KJ?\
MAJSX._\ 13/#/_@RC_QH_P"&K/@[_P!%,\,_^#*/_&E%3B[I ^5JS9\.VO\
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M_!W4_@-\%](\&ZO>VFH7UG-<2/<66[RF$DK.,;@#P&]*E_X:L^#O_13/#/\
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M]0M+: S/#,J>6[-$OS/%)'PVWE?G)(R".+\;?\%&/'GQF\*W?@3P?\.9-/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_>:_X.\>>%=0UUI)_M2V>K7KV]S;RE0I99&23?$P1>@QQN4\G-SX(_#7QO\
MMI?M+)\4/$NDOIOA6*]BO;FZ$;);LD 416L!/^L/R(&(Z#<202 ?U.N[&VOT
M"7-O%<HIR%F0, ?7FI8T6-%1%"(HP%48 'H*Z776KC&S9E[-[-Z'P)_P4;^"
MGCZZ\1:7\2/!LNJW^FV\"1:A86#R.;26)F9+D1@G*E3AB!\NP$_>X\A^(_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^%V )NS!-]M_X\#<??\ -V??X^YT]^:^J:SE%QM?J6FGL%%?+/[<7[4WBO\
M9GC\&-X8T_1K\ZT]TMQ_:T,LFWRO)V[/+E3'^L;.<]!TKZBMY#+!&YZLH)Q[
MBAQ:2D^HN9-M$E%%%04%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7!?&[X,Z+\>O %UX0\075_9Z;<313/+ILB),&C;
M<H!='&,CGBN]HIIM.Z%N?&7_  ZH^$W_ $,/C/\ \#;3_P"1:/\ AU1\)O\
MH8?&?_@;:?\ R+7UWKWB"Q\-:>UY?S"&(< =6<^BCN:\POOCU+YY%GI*B$=#
M/*=Q]\ <?K7HT:>*Q"O3V/-Q.,PF$=JLK/MN>)_\.J/A-_T,/C/_ ,#;3_Y%
MH_X=4?";_H8?&?\ X&VG_P BU] ^&_C=8ZC<);ZI;?V<S' G5]\>??C*_K7I
M:L'4,I#*PR".0:SK+$X=VJ71KAZ^'Q4>:B[GQG_PZH^$W_0P^,__  -M/_D6
MC_AU1\)O^AA\9_\ @;:?_(M?9M%8>VJ?S'7[./8^,O\ AU1\)O\ H8?&?_@;
M:?\ R+1_PZH^$W_0P^,__ VT_P#D6OLVBCVU3^8/9Q['QE_PZH^$W_0P^,__
M  -M/_D6C_AU1\)O^AA\9_\ @;:?_(M?9M%'MJG\P>SCV/C+_AU1\)O^AA\9
M_P#@;:?_ "+1_P .J/A-_P!##XS_ / VT_\ D6OLVBCVU3^8/9Q['QE_PZH^
M$W_0P^,__ VT_P#D6C_AU1\)O^AA\9_^!MI_\BU]FT4>VJ?S![./8^,O^'5'
MPF_Z&'QG_P"!MI_\BT?\.J/A-_T,/C/_ ,#;3_Y%K[-HH]M4_F#V<>Q\9?\
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M4?";_H8?&?\ X&VG_P BU]FT4>VJ?S![./8^,O\ AU1\)O\ H8?&?_@;:?\
MR+1_PZH^$W_0P^,__ VT_P#D6OLVBCVU3^8/9Q['QE_PZH^$W_0P^,__  -M
M/_D6C_AU1\)O^AA\9_\ @;:?_(M?9M%'MJG\P>SCV/C+_AU1\)O^AA\9_P#@
M;:?_ "+1_P .J/A-_P!##XS_ / VT_\ D6OLVBCVU3^8/9Q['QE_PZH^$W_0
MP^,__ VT_P#D6C_AU1\)O^AA\9_^!MI_\BU]FT4>VJ?S![./8^,O^'5'PF_Z
M&'QG_P"!MI_\BT?\.J/A-_T,/C/_ ,#;3_Y%K[-HH]M4_F#V<>Q\9?\ #JCX
M3?\ 0P^,_P#P-M/_ )%H_P"'5'PF_P"AA\9_^!MI_P#(M?9M%'MJG\P>SCV/
MC+_AU1\)O^AA\9_^!MI_\BT?\.J/A-_T,/C/_P #;3_Y%K[-HH]M4_F#V<>Q
M\9?\.J/A-_T,/C/_ ,#;3_Y%H_X=4?";_H8?&?\ X&VG_P BU]FT4>VJ?S![
M./8^,O\ AU1\)O\ H8?&?_@;:?\ R+1_PZH^$W_0P^,__ VT_P#D6OLVBCVU
M3^8/9Q['QE_PZH^$W_0P^,__  -M/_D6C_AU1\)O^AA\9_\ @;:?_(M?9M%'
MMJG\P>SCV/C+_AU1\)O^AA\9_P#@;:?_ "+1_P .J/A-_P!##XS_ / VT_\
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M_P"!MI_\BT?\.J/A-_T,/C/_ ,#;3_Y%K[-HH]M4_F#V<>Q\9?\ #JCX3?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@OX9_P"^+3_XW1_9?[</_07\,_\ ?%I_\;K[>HH]K_=7W!R>;/B'^R_VX?\
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MZ"_AG_OBT_\ C=']E_MP_P#07\,_]\6G_P ;K[>HH]K_ '5]P<GFSXA_LO\
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MW@EM[&_A1;B:2W9'D55C=P<QNVT9R2,8Z5\PK^W+I:_L<M\)CHFI+XJ_L_\
ML<7B>6+3[/OQN)W;]_E_+MVXSSFMDI37G?4AVB_D?0/['>D^(/BO^P;J/A72
M-7;1=4:ZN],L]1\UU,"&1)&(*?,.)'&!UZ<9KYU^.7[..B?LU_&CX*Z%I=Y<
M:I?7ES;7.H:E<?*;B;[8@RL>2$4#H,D^I/6ONW]B'X7W_P )_P!G'PWI>K6S
M6>K7ADU*ZMW7#QM*V55AV8($!'8C':OFW_@H/_R=%\$?^NEO_P"EJTH3?M6E
MMJ.4?<39]2?MB>#]&\;_ +.?C#3M=U^W\,:>L"7/]J72LT4,D<BN@95RS!F
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *\4_;,\077AK]FGQK<V;F.>:"&SW*<82:>.*3\T=A^->UUQ/QJ^':_%
MCX5>)?"9D2*34K4I#))]U)E(>)C[!T4GZ5RXJ,JE"I"&[3MZV/=R'$4,)FV$
MQ&*_APJ0<O\ "I)O\#\5Z*T/$&@:AX5UN^TC5K22QU*RE:"XMYAAHW4X(/\
MCT-9]?B[33LS_3.$XU(J<'=/5-=4%?LY^SWXANO%7P/\#ZI>LTEY/I-OYLC]
M794"EC]=N?QK\@O ?@?5_B1XMTSPYH5JUWJ=_*(HT4<*/XG8]E498GL :_:/
MP+X4M_ O@O0O#EHV^WTJRALT<C!<1H%W'W.,_C7VO#-.?/4J?9M;YG\R>-V*
MPWU;!X2Z=7FE+S4;6_%VMWL^QN5YA<?"?X8?#/Q=K7Q7N=,LM$UOR99-0UZY
MNI H1]N]F#/L!.T#(7/8=2#Z?7Y1?MQ_M13?$+XT3>#IX;BZ^'GAC4?(NM)M
M;K[,^IS1-B5GDVMM&X,B_*< ;L9/'Z)1A*H[(_D:<E%79Z=\-(;G]L;]MI/B
MCH^G7%CX \)&*./4+B/8;J2$$Q*/]MG?>1_"@&[!(!?\"E77/^"F_P 1;N^4
M?:+-+XP>:,L"OE0J5_[9D_@?QK2_9[_X*&:/K7BOP9\-= ^$MOX6TB\NHM.M
M_LVM;TM5=OO;/LR[CDDG+ DDDG)S7.?M'6OB[]D?]KB;XT:3X?DUWPIK2$W&
MTLD0=XUCE@DD"GRF+*)%)!!SQG# =5I7<&K:61EI9-=S0^.RKX>_X*<?#F\L
M56&>_33S<,!]\N98&)_[9J!^%?7UQ\)_AA\,_%VM?%>YTRRT36_)EDU#7KFZ
MD"A'V[V8,^P$[0,A<]AU(/QK^SE:^*_VM/VN8OC3JWAR7P_X6T>$&VWEWB=U
MC:.**.5E E8,S2,5  QVR,^=_MQ_M13?$+XT3>#IX;BZ^'GAC4?(NM)M;K[,
M^IS1-B5GDVMM&X,B_*< ;L9/"<'.2@GLM1\RBG(].^&D-S^V-^VTGQ1T?3KB
MQ\ >$C%''J%Q'L-U)""8E'^VSOO(_A0#=@D _H?7P+^SW_P4,T?6O%?@SX:Z
M!\);?PMI%Y=1:=;_ &;6MZ6JNWWMGV9=QR23E@2223DYK[ZKGK<R:35NQI3M
M;0_,_P#X**:QJOA[]K;X;:IH5C_:>MV.G6-S8V7E/+Y\Z7LS1Q[$(9MS #:I
M!.<"LSQA_P % OV@%NW\(:OX0\/^#]9U*/R(_P"T-,N+&>(2957'VJ?RU'^T
MXV^M=I^VA_R?K\$OKI/_ *<I*^D/VROV:;7]HKX8S16<,:^+](5[C1[D\%FP
M"\#'^[(% YZ,%/8YZ%*"4%-&5FW*S.4_8'_9AUK]GOP=K>I>*)+=/$'B!H6>
MSMY%E6UAC#;5,BDJS$R,3M)7A>37-_L-@_$+XJ?'3XI2MYZ:GK!TRQFP<>2A
M9L G_8^S\=L5Y7^S)^UU=>&_V<?B)X(\3SRQ>)_".D7)T?[8<2-%CREMR"0=
MT,C*,==A XV5]+_L$>"3X)_99\+^9&$N=66;59> "?-8^63Z_NQ'45.:/,Y;
MLJ-G9(_//]E_XU?%3X-WGC6?X:^"U\71W;0MJ;R:5=7JVJQF4QDF!UV [I/O
M==O'0UV5_P"/_C)_P48U33/"'V;PSIEAI-Q]KG%JXMA%D%/.=)97FD"@L,1@
MC+#<.A'K'_!)_P#Y"WQ:_P!_3_\ T*ZK%_;@^"^K?L[?%;2?CC\.PVG6TU\)
M;U8 =EK>L3EF _Y93@L&'3)8?Q@5T.4?:N-M>C,DGR)]#]"/ /A"V^'_ ('\
M/^&;20S6VCV$%C'*R[2XC0)N([$XS^-?''_!5_6+NU^%O@S3HI2EI=ZM))-&
M/XS'$=F?8;V_2OJ[X+?%C2?C;\-=%\8:.=D%_#F6W+!FMIAQ)$V.ZMD>XP>]
M<%^V3^S]-^T1\';G1M-,:>(M/F&H:892%5Y54AHBQZ!U9AGH#M)X%<--\M1.
M1T2]Z.AV7[/7A;3?!OP/\#:7I,$<-I'H]K+^[7'F2/$KO(>!DLS,Q..2:M6O
MP/\  =G\1+KQY%X6T\>+[DAGU9H]TH8)LW+DD(Q7@E0"><YK\_\ X>_MW?$/
M]F#PK:?#OQ]\.)K^^T>,6MC+>7+V$JP+PBL/*=9548"NN 5 Y/6N[_9%\+_%
MKXV?M!7WQJ\9'4/#'AYTS%8QM+;0ZA^[,<,21$Y:%%.XLV0S =<L1I*E*/-)
MO3\R5-.R2,Z\_P"4MEO_ +H_],YK]#Z_*W]HSXM_\*+_ ."B&J^-_P"RO[;_
M ++6 _8?M'V?S?,TU(O]9L?&-^?NGICWKT#_ (>Z?]4H_P#+C_\ N2KG2G44
M7%=$3&<8W3[EG_@K5_J?A;_UUU#^5M7Z!V?_ !Z0?[B_RK\TO^"C7CG_ (61
M\+_@3XM^Q?V=_;%I=W_V/S?-\G>EJVS?M7=C.,X'TK?A_P""N'DPHG_"J<[5
M"Y_X2/T'_7K0Z4YTXJ*VN',HS=S]%**\2_91_:4_X:>\$ZKX@_X1S_A&OL.H
M&Q^S_;OM>_$:/OW>6F/OXQ@].M>VUQRBXNS-T[JZ"BBBI&%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'SI\4O$4VO>++
MN(N?LUD[6\29X&#AC]20?P KCZW?'6GR:9XOU:&12N;AY%SW5CN4_D:PJ_0\
M/&,:45#:R/R+%RG/$3=3>["O<?@CXBEU+1KG39W+M8LIB9CD^6V<+^!!_,5X
M=7K_ ,!=/D5-6OF!$3%(5/J1DG\LK^=<69QB\-)RZ6L>EDLIQQL5'9WOZ6/7
M****^)/TL^$/VGOA+\6OVG/VC8O P;5/"OPPL[8/'JK6SR64SA SR,$(5Y"[
M;%5V7 0D8R<\M^Q#JGBOX3_M3>)/@Y;^)?\ A,/"%E!.9)H'+6UN\85A+&N6
M\H[G\IU!QN;!R5%?6_B[QY\-OC;?>*/@JWBN5-?N[2:VO[*P1X[B*,;1(%D>
M,QYPPXYR"<#@D?)?PMCF_8Q_;.M/A5X?NE\0>$O%0M_-^U6\1OX#(K",O,BJ
M2492=OW=CD[0QS7=&3E!P:Z;?J<[5I*1ZK^UQ^U3XP\-^*-2^%/PS\-7=[XM
M?33>76L@C;8VY0LTD8Z A?\ EHY4*<<,2*YO_@E Q?X4^-68EF.MJ23U/[A*
M^M?B1IMI:^ ?&MW#:PQ7=UI-SY\\<85Y=L#A=S 9; X&>@KY)_X)/?\ ))_&
MG_8;7_T0E0FG1=EV*UYU<X?]HVZ\6_M<?M<3?!;2O$$FA>$]%0BXVAGB+I&L
MDL\D89?-8,PC4$@#'&,L2_\ 9OOO%W[)O[6Z?!36/$$FO>%=6CQ:EPRQ!FB,
MD4T<98^42RM&R@D'WP#5[X%,NA_\%-_B+:WS#[1>)?"#S3AB6\J90O\ VS!_
M 4?'@?V]_P %./AO:6?[R:SCL/.7^[L,LS?^.$&M_P#IWTM<C^]UN?H97S?^
MU=^U!KGP=U30_!?@KPK<>)O'?B2%FT[C=##ABNXH/FD8$$X^50!DM@$5](56
M_LVT_M'^T/LL/V_RO(^U>6/-\O.=F[&=N><=,UY\6D[M7.AW:T/SS_X)@7FJ
MW_Q6^+=SKLTESK<J0O?33.&=YS/+YA)'!.[/3BIOVT/^3]?@E]=)_P#3E)4G
M_!-7_DM7QH_ZZ+_Z4S5'^VA_R?K\$OKI/_IRDKO_ .7[]/T.;_EV?H?1117G
M'4?&_P#P5/\ ^3=]'_[&.W_])[BOH#]FW_DWGX9_]BWI_P#Z3I7@G_!4JUEG
M_9STV2-"R0^(+9Y&'\*F&=<G\6 _&O<OV7-2MM5_9R^&LUK,D\2Z!9PEHV#
M/'$J.N0>H96!'8@@UT2_@KU,E\;/D3P3_P I7/$7^Y-_Z;DKS;XY_!O_ (7Y
M_P %"_$G@K^U_P"POM_EO]N^S?:-GEV$<F-F],YVX^\,9KT;X>2IJ7_!5;Q1
M-:NL\4*W"NRD8!6Q2-A]0W%><_'/X-_\+\_X*%^)/!7]K_V%]O\ +?[=]F^T
M;/+L(Y,;-Z9SMQ]X8S77%VE>]O=,7M\P^/'[!]Y^S#\/;GQ_IWQ5$VH:?-"L
M%NEBVG3R,SA?W,BW#DN,[L =%)R,5]K?L_?&S4;C]D'2?B-XZ,S75CI=Q<W<
M\B[9+I('D5)/=I%13GN6SWKXV^,O_!-?4O@Y\.]7\:Z;X]M-?;1(OMLMC>:0
M+97C0@M@F616./X67#=.]>W^'OB=JO[17_!/'QG<'2;6TU;3=/GTU[?3XA%!
M(MNL<@:.,<(/+Q\HXR#@ 8 BI:I%:WUWV*C[K>ECPWP'\/\ XK_\%&-<UWQ#
MK_C%O#?@NRN3!#;JK36\4A&X0PVZN@8JK)ND<ACN7EN@Z?2?V>OCY^Q_\4/#
MH^'5_?\ Q"\,7LA:YLK9&@M7 *^8EQ$\ACA8@_))OSP>1@@^L_\ !+7Q3INH
M_ ?5-#AGC&JZ;K$LMS;[OG\N5$,<F,]#M9<X'*'ZU[E\;OVH/ G[/FH:#9^+
M[RY@EU@R&+[)!YYA1,9DD4'<%). 0#D@\<&IG4DING%:=AJ*Y>9L]7C8O&C,
MAC8@$HQ!*^W'%.J.WG6Z@CFCW;)%#KN4J<$9&0>0?8U)7"= 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTF*_\9ZY&L@N+B$RB-9':.)(DR TC.I.6RH Y!W?+X=XC^.O[8GP!L8?%7Q
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M9V\C[XU/XO>!-%L--OM0\:^';"RU-/,L;FZU6"..[7^]$S. X]US5_Q%X_\
M#'A#2K?4]>\1Z3HFFW&!#>:C?16\,N1D;7=@#D<\&OSN^'_[)/@[Q+^P_JGQ
M&\0)?:CXQ;1[N_L;Z2]EVV<=OO6&%(PVTIMB&0P)&X@8P*=^Q7^R_P"%/C_\
M$M:\0>/9=3UR:QFFTG1H6U"98],B2-9"T2A@,EY6.TY7C.,DUHZ4$F[[.Q//
M+:Q^D6EZM9:YI]O?Z;>6^H6%PN^&ZM95EBD4]U9201[BLKQ9\0O"W@.*&7Q-
MXET?P[',<1/JU_%:B0^BF1AG\*^#?^";/Q!O/"'P<^,,]S,]UIGAM1JL-JY.
MU6$$S28]-WDIG'I65^QQ\ -'_:[O/&?Q2^+,EUXGGFU)K.*Q^URP1!]BR.Q,
M;!PJB2-416"J 1@\83HJ+ES/1#YVTK=3]%]"\0:7XHTN'4M&U*SU?3IAF*\L
M9TFAD'JKJ2#^!K'N_BEX+L->NM#N?%^@VVM6D;37&FS:G"MS#&J;V=XRVY5"
M?,21@#GI7P1::5+^Q/\ MP^'?"OA.^N/^$'\9?9$ETNXE:0*LTC0KD]VCE4L
MK'G:Q4DY)/,?%+X<V/Q;_P""EU_X2U669-(U*Y@^VQP2&,S0QV"3-$2.0&\L
M#CGG(P>::HIO?2UQ>T?;4_2?0OB!X7\4:+<:QHWB32-7TBW+":_L;^*>"+ R
M=TBL5&!R<FL_0?C#X"\5:H-,T3QOX<UC4B2!9V&K6\\V1U&Q')['MVKXR_;N
M^!*_"W]GW1-%^&7AZXL/!%OJ\FH:]9V$TTS,QC 265G9V*#:1EB0I">@KP.Q
MU+]EKXD6OA^R@L?$OP8UR&XCDNM66674[>0 8*!S*2AW882")0,<C'0C1C*/
M,FP<VG8_7BBLCP@;8^%-&^QZP_B&T^QP^3J\DR3->IL&V8N@"L7&&W* #G(K
M7KD-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH JZEI=GK%L;>]MHKJ$\[)5##ZCT
M-<VOPG\*K-YG]E_\!,\FW\MU==16T*U2FK0DUZ,YZF'HUG>I!-^:3*UAIUKI
M=LMO9V\=M O2.)0H_2K-%%9-MN[-TE%61B>*O!/AWQY81V/B70-+\0V4<@F2
MVU6SCNHU< @,%D4@-@D9Z\FN5_X9Q^$W_1+_  9_X3]I_P#&Z]%HI\S6S"R,
MCPOX/T'P1IG]G>'-$T[0-/\ ,,OV32[2.VBWG&6V( ,G YQV%9B_"GP2OB8^
M(QX.T >(6D\TZL-,@^UE_P"]YNW?GWS7544KL KG?$/PZ\*>+M4L=3UWPQHV
MM:E8D&TO-0T^*>:WPVX>6[J2N&YX(YYKHJ*-MAA7(-\'_ ;^(O[?;P3X<;7?
M,\[^U#I-N;KS/[_F[-V[WSFNOHHNUL 5RVM?"KP5XDUU-;U;P?H&J:S'MV:C
M>Z9!-<+M^[B1E+#';GBNIHHNUL G3@<"L'Q;X \+^/K>W@\3^&](\1P6[%X8
M]6L8KI8F(P2HD4X)'<5OT4;; ,AACMX4BBC6**-0J1H %50,  #H*H>(?#>D
M>+M)FTK7=*LM:TR;;YMEJ%ND\,F"&&Y'!4X(!&1U K2HI 9^@^']*\*Z3;Z7
MHNF6>CZ9;@B&RL($@AC!))"H@"C))/ ZDUC>)?A7X*\9ZE%J/B#P?H.NZA"
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MPB  ?E6E112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M 193)&DGE[EVAHY #E>#@$G]'J*;K-MMK1B]G9*SV/S=^$?PY^,%U^WEX?\
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M!,>3$I1AN55<L[%PI9C@* >#3/ASXLC_ ."FUYXI;PQK*^&&1@-:.GRBR/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MIZH[I#+?VMLD*E8V<[BMPS#A3T4\XI1A*2;2V&Y):,^GZ***@84444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !16-
MXN\8Z+X#T&YUK7]1ATO3+<9DN)CQST  Y9CV4 D]A7R]X@_X*,>%[+4'AT?P
MMJ>J6JDC[1<3I;;O=5PYQ]<'VKEK8JCA_P"+*Q]#E?#V:YTG+ 4'-+=Z)>EV
MTK^5[GUU17SK\+/VXO GQ#U*#2]1CN?"NI3L$B^WLK6\C$X"B4=#_O!1[U]%
M5=*M3KQYJ<KHY,RRG'915]CCZ3IR\^OH]G\F%%%%;GDA1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 R:9+>)Y9&"1HI9F8X  Y)->6?\
M#5GP=_Z*9X9_\&4?^->GWUHM_8W%LY*I-&T99>H!!''YU\4?\.H?AY_T-_B;
M\[?_ .-5K!0?QNQ$N;[)]$?\-6?!W_HIGAG_ ,&4?^-=?X'^)WA+XF6]U/X4
M\1:;XAAM65)Y-.N%F$3$$@,5/!(!K\:OVH_AI\/_ (2_$,^$? FM:KXCNK#,
M>J75X\31I/G'DQ[$&67G<>>3MZ@U^C7_  3]_9^UGX&_">ZNO$1:WUGQ'+'?
M2:<RX-G&JD1H_P#MD,2P[9 Z@UO4HPA#F3W(C.4I6L?45%>(_$+]M+X.?#'6
M[C1M:\9P-JMNQ2:UT^WFNS$P."K-$C*K CE2V1Z5L?"G]J;X7_&K4/[.\)>+
M+>^U3:7_ +/GBDMIV &3M255+X')VYQ7-R2M>VAIS+:YZM17$_$_XT^"O@S:
M6%UXSUZ'0H+YVCMGFBD?S&4 L!L5N@(ZUR?C?]KSX2_#W1-(U35_&%LL.K6Z
M7=E#;1233RPN,K)Y2J612.A<#.#WI*,GLAW2/8JXWQQ\9/ WPUO;>S\5^+-)
M\/75Q'YL,.H720M(F<;@">1D8K-^$W[07P^^.,-PW@OQ+;ZQ-;*'GM=CPW$2
MDXW&*15;;GC<!C/>OG3]NCX;_"+QMXV\.7'Q&^),_@C4(=.:.VM8;-IA-%YK
M$OD*<<Y'X5<(7ERR)E+2Z/LBQOK?4K*WO+29+BUN(UEBFC.5=&&58'N""#4]
M8'@N/3]*\!Z#'97HN=*MM-@6&]D^020K$NV0YZ94 ^V:\AU+]N_X&:7KQTF;
MQY;R3J[1O/;V=Q+;JP./]:L90@_W@2/>I47+X5<JZ6YZ+XA^./P^\)^)O^$=
MUKQEHVEZ[NC7^SKJ\1)\N 4&TG/S9&/K7<5^1W[8&K66N_MP6>HZ;=PW]A=3
M:-+!=6T@DCE0QPD,K#@@CN*_5SQ1XJT?P5H=UK.OZG:Z/I5JNZ:\O)1'&@)P
M,D]R2 !U)( K2I3Y%%KJ1&5V_(U:*^;YO^"AWP&BO1;_ /"92NN<&X32;PQC
M_P A9/X"O9?#OQ6\(^+O!-QXOT77[/4_#EO%)--?VKEUB6-=S[@!N5E')4C/
MM6;A*.Z*4D]F=-<74-JBO/+'"K.L8:1@H+,0JJ,]R2 !W)%2U^2OQ._:;_X3
MG]LSP]K-UXRFOOAKHGB.QN;$X=;6"W1XV>01!02W#Y8J6/3I@5^GG@_XM^#_
M ![X,F\6Z'K]K=^&H3)YNIR%H88_+^^6,@7:%[D\5I4I2II-]11FI7.NHKYT
MU;_@H+\"=(U![1O&;7;QL4>2TTVZEC!!QPXCPP]UR*]:^&?Q@\&?&/1Y=3\&
M>(;37K2)@LOD%EDA)&0'C8!TSSC<!G!]*S<)15VA\R>S.QHKS;6/VCOAOH/Q
M(3P#?^*;>V\7O<06JZ6T,I<RS*C1+N";?F$B'KWYKC/$G[=7P1\*^)9-#O?&
MT,EU$_ERS6=I/<V\;9Q@RQHRG'?:2!0H2>R#F7<]\HKS?QM^T=\-?A[X1T[Q
M/KGB_3H-&U)/,L)H'-PUVOK$D89G [D# SSBJGPB_:>^&OQRNI[/P?XFAO\
M484,CV$T,EO/M!Y8)(JEEY&2N0,C.*.65KVT'=;'J=%97BCQ5H_@K0[K6=?U
M.UT?2K5=TUY>2B.- 3@9)[DD #J20!7@DW_!0[X#17HM_P#A,I77.#<)I-X8
MQ_Y"R?P%$8REL@<DMV?2%<1X4^-W@#QUKSZ+X>\8:-K6KHK.UE97B22A5.&.
MT'. 2,UK^!OB!X<^)GA^+7/"VLVFN:5*Q07-I)N 8=58=589'RD \BORT_8$
MUK3_  W^U/KNJ:K>V^G:=::9J,MQ=74@CCB02)EF8\ 5I"GS*3?0B4K->9^M
M=1SSQVL,DTTBQ0QJ7>21@JJH&223T %>$Z+^W5\#M>\0+H]MX[MH[EW$<<UU
M:7$%N[$XQYKQA!SW) ]ZL_MK^)+GP[^RO\0+ZPDQ)-8I:^8A_P"6<\L<+X/N
MDC?G4<DN91:M<KF5FT<)K7_!2[X-:-XO?1%FUO4+:.41/K=E8J]D.<%@3()&
M4>JQG/5<BOJ#1]8LO$&DV6J:;=1WNG7L*7%M<PMN26-U#*RGN""#7Y:_"?X_
M^&?!W[,ECX2UGX'ZSXN\"R7)?Q'XB!>WMWNC.&7;(B$,RKY2C=*A^4#IU_1[
MX)7GA#4/A3X:N/ 2+%X0DM VGQ!G/EQY.4.XE@5;<""3@@BM:U-0V1$).6YW
M%%%%<QJ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ'-K/B+5;31=*A95DO+V41Q(6(506/')('XU\>6__!*;X>V\\<J^+O$Q*,&
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUY].7+439U25XV/C_P#;<^*DOQ>^#'P+\-Z;*LFI>-'MM2EBC8$A_+6(*?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>\_Y2V6_^Z/_ $SFM7%)V_NDIO\ $_0^BBBO..D**** "BBB@ HHHH ****
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M4^M=]^SCXX_9:^&OP+T[Q!KUCIFJ^.[>!WOK/4K-KJ\DN@QPL*.I15/RA67
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M$>DZ-(D>H:I9V+N0JK<W"1EB>@ )&:O0S1W$2R1.LL;#*NA!!'J#0 ^BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M') YX%?HI^PY\6O WQ'^#-IIG@K1V\-+X?VVMYHLDOG-"[Y82^9@&02'>=Y
M)8,,<5\S?M,_\%&O!WQ4^#VN^#_"GAS6TO=8C%M+<ZU%!%%!'O5F90DDA=B%
M('W<$@Y.,'K?^"57PQUKP_X9\6^,]1MY+33-<-O;:<).//6$R^9*!_=W.%![
MD-2J7E2O-6:'&RG:.IWUY_P4X^#]C>3VTEMXE\R&1HVVZ?&1D'!Q^]]JX?\
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M[@VT"61@HR >,=!6E\6O@5X&^.=A86?C?0EUNWL)6FMA]IF@:-F&&PT3J2"
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M<ZM9+T'&/+U"BBBLBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:V7_ (-W_P#C-'_#VS5O^B:V7_@W?_XS1[&N]_S%STS[4\1?LS_#+Q9\0/\
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M!^&_['7PA^$^O1ZWX>\'P1ZM"2T-W>7$UTT)]4$KL%(_O 9]Z^1/^'MFK?\
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M6_Z)K9?^#=__ (S1]6J]@]K'N?I'17YN?\/;-6_Z)K9?^#=__C-'_#VS5O\
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MT36R_P#!N_\ \9H_X>V:M_T36R_\&[__ !FE*A6EO^8*I!;'Z1T5\0?L]_\
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MRAQ&1MR6;KUQ7<?'']KSX^>-O!=]X=\5:4_A;1KM?)O?(T:6T:=&Q^[9Y<D
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M_)=?"_\ V+<?_I5<5]/_ /!-[XO?\+$^ <6@7<WF:KX3F_L]PQRQMFRUNWT
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M7V7_ 'U<?X4?5ZG8/:1/TCHK\W/^'H/Q$_Z)?9?]]7'^%'_#T'XB?]$OLO\
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M;N\GFNWA;)P4\YV"$9P"H!]Z^0?^'H/Q$_Z)?9?]]7'^%'_#T'XB?]$OLO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBO*OC!\4)O#;#1M)<)J#IN
MGN.IA4] /]HCG/88]>.'&XRE@*+KUGHOQ?9&56K&C'GD>G7-];6>/M%Q%!GI
MYCA<_G4D<J31AXW61&Z,IR#7QC=74U[.\UQ-)/,YRTDC%F)]R:TO#OBK5/"M
MXMSIMV\!SEH\Y23V9>AKXB'&$74M.C:/KK]UCR5F2OK'0^OZ*YWP)XRM_&V@
MQW\2^5,I\N>'/W' &1]#G(^M=%7W]&M"O3C5IN\7JCV8R4XJ4=F%%5-7U:ST
M'2;W4]1N([2PLX7N+BXE.%BC12S,3Z  G\*^%/%7_!63P_IWB*:UT#P#>ZUH
M\;[5U"ZU);220 X++%Y3\'J,L#Z@5U0IRJ?"@E)1W/O:BO./@O\ 'WPE\<_A
MZWC#0+I[?3X&>.]BOP(I+)T4,RR<E0 I#;@2,'KUQ\L^+/\ @J[X8TGQ=-8:
M'X)OM=T&&7R_[6DOUMGE ."\<)C;*GJ-SJ2#R%Z4XTIR;26PG**U;/NVBN+^
M&OQ>\,_%;X<VGC;0[X'0YHGED>XPCVQ3/F)*,G:RX.><=P2"#7R)XF_X*O\
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M>!7'_!6[[/<2Q?\ "J=VQBN?^$BQG!Q_SZTU1J-M);![2-KW/T.HKX*\&_\
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M4OVX?^&G/&^J>'O^$*_X1K[#IYOOM/\ :OVO?B1$V;?)3'W\YR>G2L/XW?\
M!2SP/\,/$-UH7AS2+GQOJ%G(T5S-#<BULT<'#*LI5RY!!R0FWT8T>QGS<MM0
MYXVO<^PJ*^0/@3_P4E\%?%CQ-9^'=?T6Y\%:K?2B&UDFNEN;.1R0%0R[4*LQ
M.!E-O^UR*^OZB4)0=I(:DI;!17+?%#XC:1\)? .M>+==E,>FZ7 9G5?OR-T2
M-?\ :9BJCW(K"^!_Q9N/BQ\(M+\=ZOHL?A*#4(I+I;66]\\1VZLP$KR%(P 0
MI;I@*0<TN5VYN@[J]CT:BOB#XF?\%4/!OA?7);#PCX7O/&,$+%'U"6[%A!(1
MWCS&[,/=E7\N:]#_ &<?V]_!7Q_UR'PY-87/A/Q1,I:"RO)5F@N2 24BF &Y
M@!G:RKGMGFM'1J)<S1//%NUSZ<HKY;_:B_;BA_9F^(ND>&;CP:^OP7UA'?R7
ML>I"!HE:62,J(S$VX@1Y^\,YQQUKZ(TGQAIWB+P;;>)M(G34-+NK(7UM+&W$
MD93<.>W'Y5#A))-K1CYDW8W**^??V4?VK9?VHM#\3WT/A1?#LVC211)"^I?:
M5G:1789;R4V %,=&Z^U;G[-O[2EE^T%I_B"&71V\,^)O#]\UEJ>B2W/VAH<$
MA7$FQ-RDJX^Z""A'H2W3E&]UL"DGL>S4445F4%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7E/[5G_)M?Q,_[ %W_P"B
MS7JU<Y\1O!-K\2O >O\ A6^GFM;/6+.6RFFM\>8BNI4E<@C//<5479IB>Q^9
M_P#P37^+_@SX2ZWX\F\8>(;/P_'?6]FELUVQ E*M*6 P#TW#\Z^O_BU^V1\#
M9OAKXDMY_%>E^)5GL)H5TF!'E:Z=D(6/&W R<?,< =<C%>:_\.H?AY_T-_B;
M\[?_ .-5>L?^"5/PK@\MKKQ#XNNG5LLJW5M&C#/0C[.3^1_*NR<J,Y<[;,(J
M<5:Q\Y?\$M]'U>Z_:!U'4+-)!I5IHTR7\HR$^=T\M">F2R[@/]ACVJI^W)\/
M=<^ /[4,/Q#TB+RK#5K^/7=-NMNY$O(V1YHW]_,&_'=9!Z&OTS^$_P &_"'P
M1\,G0O!VD)I5@TGG3'>TDD\F "[NQ+,< =\#H !6GX^^'OAWXH>&+KP]XITF
MWUK1[G_66UP#P1T96!#(P[,I!'8TOK'[SGMH/V?NV/#O!W[8GP/^.O@!K;Q)
MK>D:2MY#MU'0/$TB1 %<$KE_DD7(R""<\< \#XJ_;@\;_ ?5-,TK0/A+HNEQ
MZM:WOGWVJZ/8+#;M%Y;+Y0DP"YW,IX!7CKGBOH[Q'_P2H^'>HZA)/I'B?7]'
M@=MPM7,5PJ#T4E0V/J2?>NH^&_\ P33^$W@B]AO=7&I>,;J,AA%JLRK;9'?R
MHU7</9BP]J<94:;YDWZ":G+1HPOV4_A@WQ>_X)]Q>#&OVT;^V3>0B^-OYWEC
M[8S;MFY=WW<?>%>>?\.B_P#JJ_\ Y;G_ -UU^A=C8VVEV<%G9V\5I:0((XK>
M! D<: 8"JHX  ["IZQ]O--N+M<T]FFE<_-+_ (*4? &_\.Z-X#\8V"OJ%AI>
MDP>'=3NHX]H0Q?ZB5ER<!R[KUP"$&3D5[G^RG^W!\/?$OPIT+2?%OB2Q\+^)
MM(M([&ZCU.0017 C7:LL;GY3N502,@ALC&,$_5NM:+8>(])N]+U2S@U#3KN-
MH;BUN8P\<J$8*LIX(-?'OC3_ ()9_#77M6DO-"UK6O#,$C%C8QNES"GLA<;P
M/]YFJXU(3AR5.A+C*+O$\Q_;*_;XNF\4:%HWP;\3R(FFNT]]JUF@>&YE/RI"
MH=2LB*,DG!4EEQ]VOJM?C%XD^$?[+^F^/_B3IMQJ^NV]I#<ZK::7 D,D7G2!
M5!1F !02('YZACC'%<M\$_\ @GW\,O@WKUMKSK?>*M;M9%EM;C5W4Q6TBXPZ
M1( NX'D%MV.",$9KZ.UG1['Q%I-YI>IVD5]IUY"UO<6LZADEC8$,K ]0034S
ME3TC%:(<5+5L^(OAKXB_91_: AU?QKXA\+^'/"&M6ER[7%CJ^HBW:9=JMY_E
M*ZQR!F)'"L<CGDU\]? W3XOV@_V]X==T&Q$7ARSUAM9B$</EI;V=J1]FR@ V
M9*0*!V+ =J^DO$W_  2G\ ZGKDEUH_BG6M%TZ1]WV!DCN/+'/RI(V& Z?>W'
MW/6OHWX#_LX^"OV=M FTWPI92?:+H@WFIWCB2ZNB,[=[   #)PJ@ 9)QDDG5
MU813Y6W?\".63:NCX"_X*F>"[O0_C9H'BE(V%EJ^E)$LV#C[1 [!E]/N/$?Q
M->^_M7_M4^ _%G[(>HMHWB73;W6_$UG;P0Z5;W*/<Q,SQM,LD8)9-BAP=P'.
M!W%?3/Q?^#?A;XY>#I_#7BRP^V6+L)(I8VV36TH! DB?^%AD^H()!!!(KY<T
M7_@E/\.['6DN=1\3^(-3T])-XL<PP[U!SL>14R01P=H4^A%*-2$HQY]XC<9)
MOEZD?_!*GP3<Z-\)?%'B6XB,4>MZFL-N6'^LCMT(WCVWR2+]4-<Q_P %9/'<
MD.C^!?!L3$1W$TVK7(]?+411?^C)?R%?>?AOPWI?@_0;'1=%L8=,TJQB6"VM
M+==J1H.@ _KU)))YKPO]H[]B[PS^TMXLTW7M=U_6-,FL;(6,<&GF+RROF.Y8
M[T8Y)?'7^$5$:D75]I(IQ?)RH[G]F;P/%\.O@#X#T&.+R9(-)AFG7'_+>5?-
MF_\ (DCU\V_\% /V9?B3\?/&GA:[\':='J.F:=I\D4JS7\4*I,TF20KL.2H7
M)'H/2OMFTMDL[6&WC_U<2+&OT P*FK*-1QGSK<IQ37*?D;X^_9]_:B\%_#/5
MIO$>N:V/!NFV)%U8MXJ,UNMLB@;/)$Q!4  ;0,8'2J'[#'@/XK^)O'>E:KX(
MU+4+3PCIFOZ?)XA@M=7-K%-")0SB2'>/.'EJXQ@Y!([U^K?Q,\!VGQ0\ :]X
M3O[B>TLM8M7M)9K;'F(K=2N01GZBN _9M_9AT']F72];L-!U74M5CU6:.>5M
M1,>4**5 78J\?-WKI^L7@TUJ9>S]Y=CV6BBBN$Z HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*G!!!P>""*TJ "BJ]IJ%K?M<+;7,-PUO*89A#(&,4@ )1L=&PRG!YP1ZU8H
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M,3\0?AKX8\2.H275-.@NI47HLC("X'L&R*_$^W@DNIXX88VEFD8(D:#+,Q.
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M^'7BK5K?2]%\?>%]7U.X)$-E8:S;3S2D DA45RQP 3P.@-=K7,TUN:A1112
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M  U!X/UW6O\ A&_^$:_LV\^Q^1]O^U^9F,/NW>7'C[V,8/3K7YP?LK_M<?\
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M\=NUGJNF"Z;2%N&_B"LTL"'NK#]ZA[@L1U%5OVT/^3]?@E]=)_\ 3E)74?\
M!1SX%WRV^F?&?P<LEIX@T%D35);08D:$']U<<=3&?E/!RK#/"5HFG"-.75?B
M3JFY(RO^"2O_ "*OQ&_Z_;/_ -%RTS2+S_A3/_!3[4+"TQ%IGC.W/GQ %5WS
M0B7=[DSPGG_;:G_\$E?^15^(W_7[9_\ HN6JWQ!A/B[_ (*F>%K:S7S#I-O;
MO<%7'R^7;23$GT^^HQUI2_BS3[ O@B?H+1117GG2%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_@GM_P#XBC_A2OP\_P"A#\,_^">W_P#B*+TNS"T^YX/_ ,/+_@G_ ,_VM?\
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M7X>?]"'X9_\ !/;_ /Q%'_"E?AY_T(?AG_P3V_\ \11>EV86GW/!_P#AY?\
M!/\ Y_M:_P#!8W^-'_#R_P""?_/]K7_@L;_&O>/^%*_#S_H0_#/_ ()[?_XB
MC_A2OP\_Z$/PS_X)[?\ ^(HO2[,+3[G@_P#P\O\ @G_S_:U_X+&_QH_X>7_!
M/_G^UK_P6-_C7O'_  I7X>?]"'X9_P#!/;__ !%'_"E?AY_T(?AG_P $]O\
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MQKWC_A2OP\_Z$/PS_P"">W_^(H_X4K\//^A#\,_^">W_ /B*+TNS"T^YX/\
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M;_\ Q%%Z79A:?<\'_P"'E_P3_P"?[6O_  6-_C1_P\O^"?\ S_:U_P""QO\
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MW/!_^'E_P3_Y_M:_\%C?XT?\/+_@G_S_ &M?^"QO\:]X_P"%*_#S_H0_#/\
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MC?XT?\/+_@G_ ,_VM?\ @L;_ !KWC_A2OP\_Z$/PS_X)[?\ ^(H_X4K\//\
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M/^A#\,_^">W_ /B*/^%*_#S_ *$/PS_X)[?_ .(HO2[,+3[G@_\ P\O^"?\
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M2:3%+'&4\I'RPDD<YRYZ$=N*^BZB47%\K*3NKH****D84444 %%%% !1110
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MHK>H612 :W**0&+X6\$^'? UD]GX;T#2_#]I(V][?2[..VC9O4JB@$UM444
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M-Q )QU/-?,O[(/PM\0:Y\7_B3\:_&6A7V@:CKEY)9:1IVK6SV]U#:AE)=HV
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MY96< \A=P7U!%?6E%)59I63#EC>]CYZ_:U_9+_X:D3PLO_"5?\(S_8;W#?\
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M:S;GV)N8AG(!9F9B<=1DY^@:*MU9R5FR>2*=[!1116184444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\*:;X/\ &-C$DE_'9[F.HPC"B</(6D(#'!1F.TL"#\W'E?\ P5L_Y&+X:_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRO\ \%%?$7B#Q:LUCX:UZ&247L<+.!%<(K>8%498+-&RG )X)Y(K[O\ A/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'I'BW241KNW@8F&>-N!-%GE1N&"I)QD<G-.5&<%=B512=CZ/HHHK T"BBB@
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M+3[BPO8$8X$OE2L?,48/ "DX.">E?H=IVH6VKZ?:WUE.EU9W42SP3Q'*21L
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MI13INH[1"4E'5GZ*45^9,G[;O[4<,;R2?#M8XT!9F;PQ>  #J2=]>K_LK_\
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M]*X<=G^%RRWURO&%]K[_ ';F]# 5,3_!@V?"7_#I/5O^BE67_@H?_P"/4?\
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MJW_12K+_ ,%#_P#QZOTCHH^LU>X>RCV/S<_X=)ZM_P!%*LO_  4/_P#'J/\
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MH_X=)ZM_T4JR_P#!0_\ \>K](Z*/K-7N'LH]C\W/^'2>K?\ 12K+_P %#_\
MQZC_ (=)ZM_T4JR_\%#_ /QZOTCHH^LU>X>RCV/S<_X=)ZM_T4JR_P#!0_\
M\>H_X=)ZM_T4JR_\%#__ !ZOTCHH^LU>X>RCV/S<_P"'2>K?]%*LO_!0_P#\
M>H_X=)ZM_P!%*LO_  4/_P#'J_2.BCZS5[A[*/8_-S_ATGJW_12K+_P4/_\
M'J/^'2>K?]%*LO\ P4/_ /'J_2.BCZS5[A[*/8_-S_ATGJW_ $4JR_\ !0__
M ,>H_P"'2>K?]%*LO_!0_P#\>K](Z*/K-7N'LH]C\W/^'2>K?]%*LO\ P4/_
M /'J/^'2>K?]%*LO_!0__P >K](Z*/K-7N'LH]C\W/\ ATGJW_12K+_P4/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "OE3_@I?_R:[??]A6S_ /0C7U77RI_P4O\ ^37;[_L*
MV?\ Z$:UH_Q(D3^%GS/^P[^V5X!_9X^$^K>'/%,.L2:A=:W-J$9T^U26/RF@
MMXQDEUYS$W&/2E_;&_;@\)_M$?#ZW\#^$O#FJ-++J$-Q]OU9(HMC)N $2*[Y
M+;L98K@$C'-=5_P3S_9N^&WQA^"^M:SXQ\+6^N:G!X@FLX[B::9"L*VULX3"
M.!]Z1STSS79?MB?L7_"+P;\"?$GBSP_HR^%=8T>*.:&>&[F:.8F14$3H[,#N
MWX! !SMYQQ7:W2575.YA:?)Y'L7[%OP=O_V>OV?HK#Q!-"=1O+B;6KQ+>021
MP;XT 0.#AL)$I)'&2<$CD_GS^R7X<C_:2_:^@U+Q9"NH137-UX@O[=AE)'4E
MU0@]4\QD&WH5&.AKZ+_X)8^/-9\4^%/'/@?5)YKW0=,6":S$A+?9Q/YJR1@G
MHIV!@O0'>>YKYM_9@\2)^S%^U];V/BM_L5O9WESH.H7$AV)%O)C64D\>7O",
M3TV\TXIIU%U!M-1['Z[^)_&'AWP#I<=]XBUO2_#FFF18$N=4NX[6$N02$#.0
M,X4D#T!]*^7?B=\-?V4?B[\0)/&'B3QSX5FU&:)([B&U\5VUO#<%<@2.$D#%
M\8!(8<**]C_:+^ NE_M-?#NR\.7FLSZ99)?1:E'>6*I*7VQR* ,\%2)<Y]A7
MY9_MA?LYZ#^S;XPT;0M&\22^();NT:YNEN!&LEN=V%!53QD<C/6N>A%2>DK,
MTJ-KIH?=?_!1*>PNOV04FTJZCO=+DO-/>TNH9_/2:$\HZR9.\%<$-DYSG)S7
MSM^P[^V5X!_9X^$^K>'/%,.L2:A=:W-J$9T^U26/RF@MXQDEUYS$W&/2O4_V
MH?\ E&O\/?\ L%^'_P#TF2N7_P"">?[-WPV^,/P7UK6?&/A:WUS4X/$$UG'<
M333(5A6VMG"81P/O2.>F>:UCRJB^?:Y#NYZ'*_MC?MP>$_VB/A];^!_"7AS5
M&EEU"&X^WZLD46QDW ")%=\EMV,L5P"1CFOL3]B'X):G\"?@39Z/K4L+ZOJ5
MW)JUS';R"2.$R)&JQAQPV$C3)'&2<$CD^+_MB?L7_"+P;\"?$GBSP_HR^%=8
MT>*.:&>&[F:.8F14$3H[,#NWX! !SMYQQ69_P2F^(VNZWX?\9>$+ZXEN]&T8
MVUU8>82WV8S&421@GHI*!@O0'>>YI2Y94?W>R&KJ?O'WS7R9_P %./\ DV1_
M^PS:?RDKY6UCX3_MD2:M>M;7WCX6S3N8MGBE@NW<<8'VC@8KN/CEH?Q!\._\
M$^H;/XF2:I+XI'B=&=M8O3=S^42^S,A=N,9P,\5,:2A*+4D]1RES)JQC?L2_
MMG^ /V?/A'?>&O%$.L2:C-K$U\IT^U26/RVBA09)=><QMQCTJM^V-^VYX9_:
M.\#V7@;P?X=U,-+J4,YOM66*([EW*JQ(KM]XN/F8C R,<Y':_P#!/O\ 9K^&
MGQ>^".HZWXO\*6^MZI'KD]JEQ+/,A$2PP,%PC@<%V/3O71?MH?L;_"/P)\"=
M?\7>'=''A;6=*\EH)(+N9X[@M,B>4T;LP.0YP5P<@9. 16MZ7M=G>Y%I\GD>
MW?L@_ *\^$7[.L7A/Q#,DE_K#3WE\EG-E8?/14\M)%/)"*N67C<3@D8)V/@?
M^R-\/_V?/$FI:YX2AU!+V^M19R?;;D3*D>X,0OR@C)5<\GH*^>O^"5'Q&UKQ
M#X,\9>$]0N);K3-!FM9[!I&+>0L_F[X@3T7,08#U9ZR?V[/VT+^/5KOX3?#>
M>9M2=Q9ZMJED2TOF,<&T@V\[LG:S#G/RCG-8N%2524$_4T4HJ*D>3?\ !0KQ
M]IGQP_:"T#POX+0:WJ&F1#1VFM<-]HO))C^Y0_Q!20,YQN9AVS7K?_!2@W/@
MG]GGX5^"S<-*(YXTFDW',IMK41Y/J,R9^N*[;]B/]AV/X/I:^./'$$=QXVDC
MW6EAD,FE*P())'#3$'!(X7) SUKG_P#@K'H<MS\-? ^KJA,-GJTML[ '@RP[
MA_Z)-:*4?:0A'9$-/E<GU/8OV"_#]G:_LB^#(##')'?Q7<UR&48E+W,H(;U^
M7"_0"OA__@GC>OX3_:_;1H)6\BZM=0TY\MC>L8,@R._,(-?<7[!>O6EY^R/X
M*F$RHEE%=0W!9A^[*7,I.[T^7#?0BOAW_@GK9-XL_;";6;:-OL]K;:CJ+;AR
MJ2 Q#/H<S**(_P#+V_\ 6X/[!^CFH?LT_#74_B3;>/[CPM _B^WN5NTU,3S!
MC*HPK,@?8Q  QE3C QT%?G?^UU^U#9_M?:UX4\%>"M%EL[>WOF,=YK$\-NT\
MSC8HSO*1H!DY+\Y' QS^@DG[4GPNF^)B_#@^)5D\6RW3:>VFFSN !* V4,AC
M$?\ #C[W.1CK7S?_ ,%#OV??AMX3^ H\1Z'X9TCPOK6GWUO!;2:5:QVOVE9&
MVO&ZH '.W+Y.2-AYP3G.B[37/>_0N>J?*?2_PD^"-AX-_9]T'X:Z^(=<LX=.
M^RZ@N6\J=G8O*H/!*;G8#IQBN)\87GPJ_8$^'E_XATGPM=65CK.HQ6SVFF2M
M,\UQY<C)DSR_*@5'^Z>,\+R:X3]@OXT/I_[)%YKWCO4Y(-%\,ZE-81ZC<*\I
M6T"PL@.T,Q"M,R#CA5 Z#CVGPCXY^$G[6>AW3Z?#IGCO2='O%#Q:MI;-'',8
MSAQ%<1C^%F ;;_>Q6<E*,GS:J^I2LTK;GP3^R_X7U7]JG]L&]^*31V>B:3IV
MJC6;BU6Z5I@5QY,2IPSY(7<^T+PW0D"OU1K\A_VJM)L_V:?VP+>[^&(_LB>W
M6TU%+"S8B.&9R=\ 4=$< $ITQ(1C&!7Z[J=R@D;3Z'M5XC7EDMFB:?5"T445
MR&P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7@/[=GC:Z\"_LN
M^,[JQD\F[OHH],1\X(6>18Y,>_EF2O?J\$_;F\"W7C[]F#QG9V,9FO;.*/4H
MXU&2P@D620 >OEA\>^*TIVYU<F7PNQ\S?\$IOA;I=['XM\?7EHMQJ5K.FE6$
MLB@B %!),R^C$-&,]0,C^(U]S>,OBEX#\&W7]E>*_%WAW0[FX@\S[#K.IP6[
MRPL67=LD8$H2K#.,'!'8U\'?\$J_BUI6DW7BKP!J-U':7VH2QZEIPFD"BX8+
MLEC7/5\!& &20&/\-?1/[3'[$.A_M*>.K'Q1JGB;4-%FL]-CTX06L$;H5266
M3>2W?,I'X"NBLDZKYW9&4/@]TP/A+\'?V7O!/Q/L_$'A+QCH-WXJDO';3;>#
MQ7$YCDEW*(H88Y!N!#E A#9!QS7QW_P46=8_VMM19CM5;2P))[#RUKD/A[X1
MT[P#^VSX6\.:1J8UG3=,\8V=K!?JRMYZK<H-V5./RKK?^"C4(N/VLM3B)P'L
MK%21[Q 5U0CRU%K?0RD[QV/T8U7]L+X+:/:M//\ $C0I452VVUN/M#G'HL88
MY]L<U^8OA34D^,G[<FE:SX,TZ2UL]0\80ZG;1)&%:.!+A97F91D*=J-(P[$F
MOL"/_@E#\.@ZE_%OBADSR%:V!(]CY7%>_? C]E3X>_L[K/+X6TZ>75;B/R9]
M7U*;SKJ1,YVY "H,@$A%7.!G.!CFC.E23Y-6S5QE-JY\'?\ !5#QI<ZO\;-"
M\.;S]@T;2%E6//'G3NQ=OQ1(A_P&OT1^ OPZT_X4_!_PKX:TZV6W2UL(FGX
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M->?_ /!+CX(ZCH-KK?Q*O[BW6VU2U_LVPM89TE8IYBO))(%)V'*( I^;[Q(
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M2Y>Q)^UQ^W]X.^-7PEU3P+X4\/ZM))J<D'F7^JQQQ+"(Y4E!C57<LQ*;>=N
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M6TMW'V=O-*C8H*<A5Y'->N_L2_%CQ+\:/@7:^)?%=Y'?:O)?W$#310)"-B,
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MI5_"T,L4B@D9!&Y21\K#.0PY!YK\I?V'=4O/A7^V=:>&UG<V]Q<7^A7?.WS
MBR%21_UTA0U^MNK:M9Z#I=YJ6H7,=G86<+W%Q<3-A(HU!9F)[  $U^1W[&-G
M<?%']MRRU^VA?[*E]J&NW!(),<;+)MSC_;EC7\:*'P3OM8*GQ1/M7]MKX"_$
MC]H.[\'>'_!^JKI7AI1=-K;W%ZT5LQW0^3OB7+2D8D*C:0#U(R*_/_\ :2^!
M^E_L]_''0/"&EWMQJ216EC<7%Y< *TTSR-O8*.%7@87)P!U)YK]IZ_*'_@HK
M_P G>:;_ ->&G_\ HQZK#3;?)T%5BK7/TU^*D5[/\,/&$>F_\A%]'O%MN/\
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MR>:UI>S=U3W\R9\VCEL?HU^VE\5/$?P:^ VI^)_"MW'9:Q!=VT232PI,H5Y
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MP/\ BU\9/V>_VG-'^$7Q/\0R>+-/UIT1)[B[>]93*I$4T,\@$FW>NTJ_'WB
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MT(G+&< NBJN %C^8G=G=D <SJ7A3]KW]F/5M(UE->U/XHV$\^V?3["XN];3
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MRQXSL\_[A;_@'X5S'_!4?Q9=:Y\>]%\/>;MLM)TB+9&YP@FFD9G?/;*B(?\
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M6UZJC"B4+RK 8 < G  (.!CZ%_X61X2_Z&C1?_!A#_\ %4?\+(\)?]#1HO\
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M3E9VV&HQB?FM:_L;_M1?#NTU7P7X6U,MX2U-V%S+IVM1P6LH8!2S([+(I90
MP5>0,'(KZY_8P_9'C_9H\.ZA>:M>0ZGXOUA46[FMP?)MHUR1#&3RW)RS8&2%
MX^7)]P_X61X2_P"AHT7_ ,&$/_Q5'_"R/"7_ $-&B_\ @PA_^*ISJSFK-"C"
M,7<^2OVP/V$]6^)_C;_A8OPXU&'3O%+&.2[LIIF@\Z6/ 2>&4?ZN0!5X. =H
M.0<Y\<O?V._VG/COJFF:?\2]?-KHUC+A;C4]3BNA&N,&1(H6.]R!C+;2<\D<
MU^C'_"R/"7_0T:+_ .#"'_XJC_A9'A+_ *&C1?\ P80__%4XUJD5:P.$6[G,
M>"?V?_"7@GX*K\,(;0W7AV2RDL[SS#B2[,@(EE8CH[$DY'W> , "OA:]_8A^
M/_P!\7:E=_!WQ U_IMV-HEM+^.TG>/<=J31RD(S+DX8$]21@G%?HA_PLCPE_
MT-&B_P#@PA_^*H_X61X2_P"AHT7_ ,&$/_Q51&I.-^MQN,6?$?[/'_!/WQ7-
M\3(OB%\9]3BU&^@NA>KIGV@W<MW..5>XEZ;5;!V@MG;@X7@_?]<Y_P +(\)?
M]#1HO_@PA_\ BJ/^%D>$O^AHT7_P80__ !53.4ZCNQQ2CL='17.?\+(\)?\
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MKK-QHC@(ZWOBN.2"13U5AYQ9E&>A4CCCM7Z6?\+(\)?]#1HO_@PA_P#BJ/\
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M!['!'Y^#]B+]I7X*ZM>+\.];EN;.9^9]!UL6/GKT4RQ2N@R >F6QV)K]*O\
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MX/%PMM#%#?K+)96"L3A4 P96&23TW-_= Q]S?\+(\)?]#1HO_@PA_P#BJ/\
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M?#.'3/[/_M2+6[5;B]$+).2))4*X^Z9-_'3:V*^[O^%D>$O^AHT7_P &$/\
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M?;/":ZGI-PVH?VA:QXCA2 2GRVE#_*4;C;DXXSQ7WM_PDFD_]!2R_P# A/\
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MOASJSZIX7\.WV@:B\+6[76GZ_8Q2&,D$H2+CH2JG'L*_6O\ X232?^@I9?\
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M)4[VZA**D?GM\(?V(?B=\8/BM'X^^/5PRP12I-)8W$\<MQ?;/N1%8B4BAXY
MP<<!1G</T9K/_P"$DTG_ *"EE_X$)_C1_P ))I/_ $%++_P(3_&B<Y5'J$8J
M.QHU^8W[3W[(7QL\:?M*>*/&G@[PM)<6$UY!=:?J,6JV<#[HX8@'4/,K*0Z'
MJ!TK]*/^$DTG_H*67_@0G^-'_"2:3_T%++_P(3_&BG4E3=T@E%25F?FC:_!_
M]MZXEV2:MXBMEQGS)?%-L1]/EG)_2MGX,?\ !-_QMXD\?V_B;XQ:C;O8"X^T
MWEB;YKN]OV!R%DD&5"L0,G<6(R.#R/T5_P"$DTG_ *"EE_X$)_C1_P ))I/_
M $%++_P(3_&M?K$[:)(CV<>K/%?VVOA?XD^+G[/^I>&O"&F?VKK,MW:R1VHG
MB@RB2 L=TC*HP/>L;]@7X0^+?@K\%=0T'QGI/]C:M+K<]VEO]IAGS$T,"JVZ
M)V7JC#&<\5]!_P#"2:3_ -!2R_\  A/\:/\ A)-)_P"@I9?^!"?XUESRY.3H
M7RKFYCEOCMX:U+QE\%?'6@Z/;?;-6U/1+RTM+?>J>9*\+*B[F(49) R2!7R_
M_P $[?V<_B'\"]9\;S^./#W]B1:E;VB6K?;;>X\QD:4L/W4CXQN7KCK7V3_P
MDFD_]!2R_P# A/\ &C_A)-)_Z"EE_P"!"?XT*<E!PZ,'%-IFC7Y/^*OV.?VB
M=-^-'B/Q?X1\,W-A-)K%[=V&I6>MV4,HCEDDPRYG#+N1^AP<$@U^I_\ PDFD
M_P#04LO_  (3_&C_ (232?\ H*67_@0G^-.G4E3O9;A**EN?F7_PJ7]N'_G^
M\3?^%5:?_)->U_LB^ _VE_#OQ<%W\5KG6I?"OV"9"M]KMO>1^>2NS]VDSG/W
MN<<5]D_\))I/_04LO_ A/\:/^$DTG_H*67_@0G^-7*M*2MRHE02=[FC16=_P
MDFD_]!2R_P# A/\ &C_A)-)_Z"EE_P"!"?XUSFIHT5%;W4-Y"LL$J3Q-T>-@
MRG\14M( HHHH **** "BBB@#A/B%X%DUQO[1L%!O%7$D73S0.A'N/UKR>YM9
MK.8Q7$3PR+U212I_(U])TUXTDP'56_WAFOS#/N!,+F^(>+H5/93E\6ETWWM=
M6??77M<^EP.>5<)35*<>9+;6S1\^Z'X9U#Q!<+':6[,A.&F881?<G_)KV_PU
MX?@\-:3'9PG>1\TDF.78]3_GTK4'' X%+7J\.\)87A]NLI>TJO3F:M9=DM;>
M>K.7,,UJX]*%N6*Z?YA1117W1XA\,_M(?LE_%#1_CA)\7?@??K'K=[\UW8F>
M**5)BH1V3SOW3QN "RN>&R0#D;9/V;?V2/B7J/QK3XO?&[4TFU^U^:TT]9XY
M93+M**S^5^Z1$4_*B$Y)R<8^;[BHK?VTN7E,^17N?$G[5'[*/Q'D^-%K\8?@
MM>1Q^)V55N[+SHH91*J>5YL9E_=.K1@*R.>V?FW$++^RW^RO\24^-%U\8/C5
M>Q3^)UB9+.S$T4L@D*>69'\H>4BK'D*J'JQ/&.?M:BCVTN7E#D5[GYK?M(?
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M_>1)I7GC?']UM[@'U1O2OI?QQX+TCXC>$=6\,Z]:K>Z1J<#6]Q"W!*GH0>S
MX8'J" >U?F=XH_8Q^.O[,_CF?Q!\*+V\UJQ!9(+[29$%UY1Y\N>W;A_P#J2
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MD^@!/:O-_P#@E!XQM+KX:^,?"WG#^T+/5AJ7DGKY4T*1Y'J T!SZ9'K7T5\
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M[./8^#_^'3/A/_H?-:_\!(:/^'3/A/\ Z'S6O_ 2&OO"BCZQ4[A[./8^#_\
MATSX3_Z'S6O_  $AH_X=,^$_^A\UK_P$AK[PHH^L5.X>SCV/@_\ X=,^$_\
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MO_Y;G_W77Z)44?6*O</9P['YV_\ #HO_ *JO_P"6Y_\ =='_  Z+_P"JK_\
MEN?_ '77Z)44?6*O</9P['YV_P##HO\ ZJO_ .6Y_P#=='_#HO\ ZJO_ .6Y
M_P#==?HE11]8J]P]G#L?G;_PZ+_ZJO\ ^6Y_]UT?\.B_^JK_ /EN?_==?HE1
M1]8J]P]G#L?G;_PZ+_ZJO_Y;G_W71_PZ+_ZJO_Y;G_W77Z)44?6*O</9P['Y
MV_\ #HO_ *JO_P"6Y_\ =='_  Z+_P"JK_\ EN?_ '77Z)44?6*O</9P['YV
M_P##HO\ ZJO_ .6Y_P#=='_#HO\ ZJO_ .6Y_P#==?HE11]8J]P]G#L?G;_P
MZ+_ZJO\ ^6Y_]UT?\.B_^JK_ /EN?_==?HE11]8J]P]G#L?G;_PZ+_ZJO_Y;
MG_W71_PZ+_ZJO_Y;G_W77Z)44?6*O</9P['YV_\ #HO_ *JO_P"6Y_\ =='_
M  Z+_P"JK_\ EN?_ '77Z)44?6*O</9P['YV_P##HO\ ZJO_ .6Y_P#=='_#
MHO\ ZJO_ .6Y_P#==?HE11]8J]P]G#L?G;_PZ+_ZJO\ ^6Y_]UT?\.B_^JK_
M /EN?_==?HE11]8J]P]G#L?G;_PZ+_ZJO_Y;G_W71_PZ+_ZJO_Y;G_W77Z)4
M4?6*O</9P['YV_\ #HO_ *JO_P"6Y_\ =='_  Z+_P"JK_\ EN?_ '77Z)44
M?6*O</9P['YV_P##HO\ ZJO_ .6Y_P#=='_#HO\ ZJO_ .6Y_P#==?HE11]8
MJ]P]G#L?G;_PZ+_ZJO\ ^6Y_]UT?\.B_^JK_ /EN?_==?HE11]8J]P]G#L?G
M;_PZ+_ZJO_Y;G_W71_PZ+_ZJO_Y;G_W77Z)44?6*O</9P['YV_\ #HO_ *JO
M_P"6Y_\ =='_  Z+_P"JK_\ EN?_ '77Z)44?6*O</9P['YV_P##HO\ ZJO_
M .6Y_P#=='_#HO\ ZJO_ .6Y_P#==?HE11]8J]P]G#L?G;_PZ+_ZJO\ ^6Y_
M]UT?\.B_^JK_ /EN?_==?HE11]8J]P]G#L?G;_PZ+_ZJO_Y;G_W71_PZ+_ZJ
MO_Y;G_W77Z)44?6*O</9P['YV_\ #HO_ *JO_P"6Y_\ =='_  Z+_P"JK_\
MEN?_ '77Z)44?6*O</9P['YV_P##HO\ ZJO_ .6Y_P#=='_#HO\ ZJO_ .6Y
M_P#==?HE11]8J]P]G#L?G;_PZ+_ZJO\ ^6Y_]UT?\.B_^JK_ /EN?_==?HE1
M1]8J]P]G#L?G;_PZ+_ZJO_Y;G_W71_PZ+_ZJO_Y;G_W77Z)44?6*O</9P['Y
MV_\ #HO_ *JO_P"6Y_\ =='_  Z+_P"JK_\ EN?_ '77Z)44?6*O</9P['YV
M_P##HO\ ZJO_ .6Y_P#=='_#HO\ ZJO_ .6Y_P#==?HE11]8J]P]G#L?G;_P
MZ+_ZJO\ ^6Y_]UT?\.B_^JK_ /EN?_==?HE11]8J]P]G#L?G;_PZ+_ZJO_Y;
MG_W71_PZ+_ZJO_Y;G_W77Z)44?6*O</9P['YV_\ #HO_ *JO_P"6Y_\ =='_
M  Z+_P"JK_\ EN?_ '77Z)44?6*O</9P['FW[._P=_X4'\)-&\$?VO\ V[_9
MSSM]N^S?9_,\R9Y?]7O?&-^/O'.,^U>DT45SMN3NS3;0****0PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7WQ$_P"BH67_ 'S<?XT>SI_S_@'-+^4_2.BOS<_X=??$3_HJ%E_WS<?XT?\
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MK[XB?]%0LO\ OFX_QH]G3_G_  #FE_*?I'17YN?\.OOB)_T5"R_[YN/\:/\
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M'_#K[XB?]%0LO^^;C_&CV=/^?\ YI?RGZ1T5^;G_  Z^^(G_ $5"R_[YN/\
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M%_S/^%<ZSY>=VR/./3S4S^F:X,55=##U*J5W%-_<KDU)<D')=$?/GC;QM?\
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MU7X0Z=XEO?#'@'P^LL>I)82'-RL)"S.Z@@.S2,L:ALJH&[!.0<7XX_!_7/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4&70_P#@J9X.NKY@+>[2U\DS'"C?;20KC_MH./>K:7.I=;7%KRV\SC]"\/\
MB[_@G[^TKX+\/?\ "5R>(/!GB9HDN5\IH(9%>3RG)A,C!9(R58,&Y! [D5[?
M^V[X4^+7QB^(7@[X=>$[;5-+\#7Z@ZIK5O&YM3(S-D3E.=B(H(5L*S/Z@$<!
M_P %*Q_;7QJ^#&BVOSZ@\C8C_P"NMS"B?F4;\J^Q/%7QH\ P^-E^&6H>)EL/
M%NK1&"&QCBD\[]Y&Q!5]A13M!(W'&<#DD Y2D_=J6N_ZU+26L>A\&_!?1?%?
M[)_[9V@?"[0O&'_"8:+JC(NHV=LI2)5=&9FD@WN(I8P@DR#G;C)PQ%>C?\%1
MKY]>N/A3X'@F6&35=2EF9GZ(<QPHQ]OWK_E7"^,/",7_  3S_:*\$3^";Z3Q
M!HWB:,6]]8:O!!->B+S51PDJ(I4-O#+MVY:/#;@*]:_:]_9OL_VAOCUX0BNO
MB1X;T&U@MX[";1+B\5=3;+/*3!$?ONX*@ XP%W<XP;NO:1F]K;DV?*XG _!/
M_@G[X4C^(>B>(?#?QST;Q=)X=U.VOY[/2["*4_NI5?8S)=OLSMQD@XST-)^U
MEKGC#]H7]K?3O@-IWB.3PUX<6-%FV;C',QMOM,DDJ*1YN$PJH2!D=LDUYS^T
M9\$H?V%?BM\//$OP]\2ZI.;V21_LU\Z-<#RGCWHQC5 \<BR;=I7L>3GCZ%_;
M _9ATGXM?$S1?$7A/XA:-X,^*$B011:;J.HBWDNBN3%)'LS*LH (!56R$'3!
M).;WE)NZ:=M-@MHTD>,>%[7Q=_P3]_:6\*>$)/%;>)/!?B0P_:(?+:&(I+*8
MC)Y)9A'(C_-E6.X<$\D#].Z_'7XY? KQ9\.?C1\.]&\8>,YO''CC7);=[F3S
MIKHP(;@10HLDIWR9PYY"^@'>OV*K'$6]V6[9=/JC\]/^"MB[K?X7KTS)J(_2
MVKGO%'_!+'4?"_A+4=>TGXFQ75_8VCW<=O-I#6JMM0L1YHG<KP#SM-=#_P %
M; 6M_A> <'S-1Q^5M69>?L+_ +2_BS3?[-U[XQP7^BW*@3VMSXCU.Y1EQT,3
MQ!6^A-;PDXTX^]8SDKR>ESU3_@FK\;O$/Q(^&OB/1_%&HRZF_AN>(6^HWDI>
M4P2JYV.['+!#&V">S = *V_$W_!3#X-^'/$TNDQ/KFMPQ/L;5-,LHWM,C@X+
MRJS >JJ0>Q-<U\0/@+;?LE_L-?$73/#^HS:AK=_#&=2U;RO+:822QPNJJ"2L
M8C9P 2?O,<\UXG^S'=?M V_P%BTKP#\(_!GB?P5JS7 GO-4>+SK\F1D<3JUY
M&3MQL&4'RJ.O4Y\D)N4^E_0KFE&T3]&_ _Q(\-_$?P;:^*O#NKV^HZ#<1M(M
MXI**H7.X.&P4*X.0P!&.:^=]5_X*7?!G2_%S:*L^MWMJLGEMK=K8JUD/5AEQ
M*R@]UC.>V1S7@7@GX5_%;]GS]CWX[:=XKT!]$@O8;:6QC34()P1(_DW1 BD?
M;B/9G.,@=\5[U_P3C\%^'[7]F"PU"'3[2:^UJ>[&J2O$K-,%F>-8W)ZJ$4?+
MT^8\<G,.G"*<GJKV*YI2:6QXI^Q7K-CXB_;V^+6J:9=1WVG7L&J7%M<PMN26
M-[^%E93W!!!KU#]G/_A4_P#PV5\3?^$6_P"$S_X3O&H_VI_:_P!D_LS_ (_(
M_-\CR_WO^LV[=W\.<\UY/^PYHNG>&_VZOBKI6D*D>EV5OJEO:I&052-;^%54
M8XP  /PK4_9%X_X*&?&<GTU?_P!.$-:U%K+T1$>GJ>^?%[_@H!\*?@[XJNO#
MEY+JWB#5K.0PWD6AVR2K;2#JC/))&I8="%+8.0<$$#KO@S^UG\/OCMH.KZAX
M:N[I;K2;<W5YI-]"(KN., G<%W%6'&,JQ ) )&17AO@?XP>'==^,GC%_V??@
MM9>(-;3%OK'BF;4(]-LU)=\.J8;<KL')*!6?;D@@ UYA^PC#?V/[;WQ1M=1C
ML+:^2TU);JWT@M]C647T.X1;N=@.=N1G%9NG'E>EFBN9W1R5M^WI!=?M9KX^
MU:[\3W?PZLXY(].T%5B$D&ZW,>[R?-$>[>SDL6+;3C/8?:/Q(_;>^'OPH\6^
M'M!\16^M6S:UIL.JQWR6\36\$$N['FGS=^X;#D*K=L9-?.O@G_E*YXB_W)O_
M $W)61^VYX?MO%7[=GPLT>\MUN[*^BTN"X@?&V2)KV4.ISV*YK1QA*45;H2G
M))OS/8?'7[4'PK_:4_9S^)4U]IOC2T\(:0;.+4I[6VMHKF0O<(8_LY>1T)W*
MI8-@A3TR17J_['LG@^']G+PS)X);64\*+]K:V;Q&81> "YE\PR&+Y,;]^,?P
MXSSFL7]OB-8?V1_'2(H1%CLU55&  +N#  KP7PKK%_H?_!*&ZN=-D>&X:UNK
M=FCSGRI=3>.4?BCL/QK+E4H::79=[2U['J/C#_@I=\'/"GB"32X'USQ$L3F-
M[_1[.-[8$'!PTDJ%A_M*"".A->\_"7XQ>$_C=X43Q#X0U-=2T_S##(&0QRP2
M  E)$894X(/H0002.:\(_P""=_@_P[+^R?IK#3;6>36IKP:MYD8?[21,\863
M/4"-5&.G)]37O?PU^#W@OX.Z7-I_@WP[9Z#;S%3,;=29)BN=IDD8EWQDXW$X
MR?6LZBA&\4M45'F>K*/[07_)!_B-_P!BYJ/_ *325^8G[*G[#/\ PTWX!U'Q
M-_PFW_"-_8]2?3_LO]D_:M^V*-]^[STQ_K,8QVZ\U^G?[07_ "0?XC?]BYJ/
M_I-)7Y;_ +-_[$&H?M)?"O7/%>E>*H-*U&POI+"#2[FR+QW#K%'("TPDR@/F
M8^XV,9[\;T'RP;O8SJ*\EI<T/B=X#\4?\$__ (L>%3X6^(7]OW%V/M<UC;(U
MMO57"F*XMQ(X*2 D*2><-C!4&ON_]N[QT_@_]E?Q5-&QM[S5XX=,B0GG]\X$
MB\=_+$GY5\/?L-^ _AQ_PO0>&?B;I.I6OCO3[I_[.L[^5!8/<1D'RI(M@;S5
M*EERY1L$8SM#?3W[>"M\0OB7\$/A;&@ECUC7/[0O%(SB&,JA.,\C8TYQ_LU=
M36I%/IU%'X6T?/'[;W@<?#SX _L[>'=ABEMM.NC.I!!$TBVTDF1Z[W:NZ;_@
MDJ$LS<'XL+&!'YA,GA_:HXSR?M7 ]ZN_\%:T'V7X7(/E'F:B!@=.+:O$OVDO
MV!=>^ '@NV\6V6N_\)CH:.JZ@8;$VLUH&^ZY7?("F?E+9&"R\8.:N$FX1M*S
M=R9)<STN>T?\$V_B=XJA^*GC'X9W^N2>)_#NGVLT]K=?:#/#"\,Z1;H7)_U4
M@?( XX! Y-?HA7RE_P $]?#_ ,*8_A7/KOP]MKQ-7NI!;ZTVL3)-?0R+R(BR
MJJ^7SN4JHW C=\P('U;7%6:<W9&]/2)^57QS^#?_  OS_@H7XD\%?VO_ &%]
MO\M_MWV;[1L\NPCDQLWIG.W'WAC-'QX_8/O/V8?A[<^/].^*HFU#3YH5@MTL
M6TZ>1F<+^YD6X<EQG=@#HI.1BCXY_!O_ (7Y_P %"_$G@K^U_P"POM_EO]N^
MS?:-GEV$<F-F],YVX^\,9J[\9?\ @FOJ7P<^'>K^-=-\>VFOMHD7VV6QO-(%
MLKQH06P3+(K''\++ANG>N]2MRKFMHM+'/:]W8]C\?^.]?^)7_!,&[\0>)_,?
M6;BTMTEN)DVM<+'J,<:2GU+*JMGN23WKPS]GW_@G6?CQ\(M%\;K\0/[$.I>>
M!8'1O/\ +\N9XO\ 6?:%SG9G[HQG'->M>(/C-=?&W_@FGXKU2_TZUTV]TQ[;
M298["(16[>5<VVQHXQP@V,HVC@$'  P!Y)^S[^S/^T'\1/A#HNM^"/BF/#GA
M6\\];;2V\0ZA:B+;,Z2?NHHR@W.K'@\[LGDFLXWC&5GRZE.S:TOH=M^Q7XN\
M:?!C]J?6/@GK&N-KNC9N8"GG/)##-$AE66$-]S<H(91W/.2H-?I'7RC^R/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1#G&.C9^CM%?.O[.?[</@3]H6^3185G\->*64LNDZ@ZD3X&3Y,HXDP.<$*V
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M"G*I\*)E)1W/T)HK\[?^'NG_ %2C_P N/_[DKTG]G?\ X*(?\+\^+>C>"/\
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M!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(OP]\-V>D^./%T6BV8\37>AW-O+JK1AKCRE@8!%<\JN ,A< XR<FOG#]EO\
M97^)*?&BZ^,'QJO8I_$ZQ,EG9B:*602%/+,C^4/*15CR%5#U8GC'/USX[TVY
MUGP/XAT^SC\Z[N].N((8]P7<[1,JC)( R2.3Q6522O&*>Q<5HVSXW_X)/?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#:=/0_0KP3X-T#Q?\*? R:]H>FZVD&CVAB74;2.X$9,$>2N\'&<#IZ5\7?\
M!4?P+X;\(^$? <FA>'M*T62:^N5E?3K**W,@$:$!BBC('O7W3\)_^26>#?\
ML#6?_HA*^,O^"M/_ ")GP\_["%U_Z+2N:BW[5(TG\!ZC^P_\+O!GB#]EGP+J
M&J>$="U*_FBNC+=7FFPRROB[F W,RDG  '/8"OIO2-&T_P /Z=#I^EV-MIMA
M#D16MG"L429))VJH &22>.Y->%_L#_\ )I/P_P#^N5W_ .ED]?0%95&^=^I<
M?A05\+>(/^"E#^!_CAXI\)^(_#5O%X<T.^O[/[;92.]U,8?,6(!3\H+NJ DG
M W$]J^Z:_(KP[X<L_%?_  4DO=-U"VCO+-_&M_,\$H!1_+EED (/!&4''>M*
M$8RYN9;(FHVK6/6=<_X*=?$/PWK=K<ZK\*[?2O#]VQ>W@OC<0W$T0QG9,RA6
M/(Y"8YZ5VWCW_@I1-JL<$/PC\"7_ (MGCM([O4;J\MIFCLMRY,1CB&25Y!<L
M%R#C<.:T_P#@JU:0O\!/#-TT:FXC\30QI)CD*UK<E@/8E%_(5TG_  3/\-V.
MD?LS6>I6]O&EYJVHW4US,%&^39(8D!/H G [9/J:U_=^S53E(][FY;E3]D/]
MO*+]H3Q1+X1\1:+!H/B0PO<6<EG*S6]VJ<N@5OF1POS=6! ;IC!^J/$WB&Q\
M(^'=4US4Y1!IVFVLMY<RG^&.-"['\@:_*7]G.WCTO_@I +:U40PP^)-<AC51
M@*@CNU _+BOJG_@IM\6SX)^"=MX3LY_+U+Q5<^2X4X86D15Y3^+&)?<,U34I
M+VBC'J5&;Y6WT/B3X;_#77_VTOBU\2-=D:1+P6%]K>%Y!N#D6ML#Z9*J/]F,
MU[M_P2M^+ATOQ-XE^&]]-LAU!/[4T]'.,3Q@+,@'JR;&^D1KS;]CK]L'PI^S
M#X3URSO?"NHZQK6K7BS37EK/&B>2B8BCPW/!:4Y_V_:O)(?C+9^%_P!I(?$O
MPCI]QI=A'K1U2'3977<L;MF:#*\;2&D0?[+"NR4934H-:=#!-1L[ZG[,_&K_
M )(WX\_[ %__ .D\E?D]^QC^T5:?L[ZKXNO_ .Q;OQ%K>JV<-EI>EVN1YTWF
M$_,P!( 'H"22 !W'ZI_$W6K/Q)^S_P"+-7TZ9;G3[_PQ=W5O,O1XWM796'U!
M!K\]O^"57A_3M2^,GB;4[J%)K[3='S:%UR8S)*JNZ^AVC;GT<^M<E&RI3YD;
M3^)6.^T/_@I]XF\->,(=-^)/PW.B6$C!I%M5FANX(FZ/Y4W^L_-<\XK[\\/Z
M]8>*=#T_6=*NH[W3+^!+FVN(CE9(W4,K#Z@BOC'_ (*M>&=-N?@[X6U^2&,:
MM9ZXME#/CYC#+!,[I]-T*'_@/O7I'_!.K4KK4/V4?"Z7.XK:W%Y!"SG):,7$
MC#\ 6*_\!J*D8RIJI%6'%M2<6?2U%%%<IL%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M117,_$+XD>&OA3X;?7O%>JQZ-I"2I"UU*CN ['"C" GGZ4U=Z(#IJ*\'_P"&
MZ/@5_P!%"LO_  %N?_C5:?A_]L?X+>*-3BT^P^(>D_:I3M1;HO;*Q/0;Y55<
MGTS5^SGV9/,NY[+12*P=0RD,I&01R#69XD\4:1X-T6YU?7M3M-'TNV&9KR^F
M6*),G RS$#DX '<G%9E&I17SG??\%"/@/8W_ -E/C5IL-M>:#2[MXUY_O"+D
M>ZY%>K?#3XV>!?C%9R7/@WQ/8:ZL?,D,#E9XQZO$P#J/<J*MPE%7:)YD]F=M
M17,_$+XD>&OA3X;?7O%>JQZ-I"2I"UU*CN ['"C" GGZ5Y;_ ,-T? K_ **%
M9?\ @+<__&J%&4M4A\R6[/>**\:\/_MC_!;Q1J<6GV'Q#TG[5*=J+=%[96)Z
M#?*JKD^F:]D5@ZAE(92,@CD&DXN.Z!-/86BBN8^(GQ,\,_"?PZ==\6ZM'HVD
M^<L'VJ5'<;VSM7"*3S@]J2N]$,Z>BO!_^&Z/@5_T4*R_\!;G_P"-5J>'?VQ/
M@QXJU2+3]/\ B'I)NI3M1;IGME8]@&E55S[9J_9S[,GF7<]DHI 0P!!R#7G_
M ,3OC_\ #SX-O#'XR\5V&B7$R>9':R%I)V3GYA%&&?&01G&"1BH2;T16QZ#1
M7#?#;XX> _C MQ_PAWBG3]=DMU#306\A$T:GHS1L P';)&,\5V\DB0QM)(RI
M&H+,S'  '4DT--:,-QU%>+:U^V;\%/#^KMIEY\0]*^U*_EM]G$EQ&K<Y!DC1
MD'3UKU'PGXPT/QWH=OK/AW5K/6M*G_U=W93+)&?49'0CN#R.]-QDM6A73V-B
MBN?\;?$#PU\-]';5?%.N6.@Z>#M$]].L89O[J@\L?89->>^%?VP?@UXTUB+2
MM*\?Z7)?2R"*.*X$EL)&/15:55#$].#UXZT*,FKI!='L5%9'BSQ9H_@7P]>:
M[K]_#I>D6:A[B[G)"1@L%!./<@?C7E__  V7\$_^BCZ+_P!_&_\ B:%&4MD%
MTMSV>BO&/^&R_@G_ -%'T7_OXW_Q->ST.+CN@33V"BBBI&%%%% !1110 444
M4 %%%% !1110 4444 %%%% !117GOQ/^/_P_^#-W86OC/Q)!H4]\C26R30RO
MYBJ0&(V(W0D=::3;LA;;GH5%<%\+_CMX#^-#:DO@OQ';Z\VG>6;I88Y$,6_=
ML)#JN<[&Z>E:WQ$^)GACX3^'3KOBW5X=%TD2K!]IF5F!D;.U0%!))P>W8T^5
MWM;4+JUSIZ*\G\!_M5?"GXF^*+3P[X8\8VNK:U=!S#:1V\ZLX1"[<L@'"J3U
M[5-JG[4'POT7Q]_PA-[XNMK?Q3]KCL/[.:"8OY\A4(FX)MR2R]\<T^25[6#F
M7<]2HHKR_7OVG/AAX7\?'P5JGBVVM/% N(;7^SF@F+^;*%,:[@A7D.O?O4I.
M6R"Z6YZA117DGQ0_:N^%/P=U!]/\3^,+.VU2/A]/M4>ZG0^CI$K;#CGYL=O4
M4*+EHD#:6YZW17C7PY_;"^$/Q4U:VTKP_P",[635;@[8K*\AEM))&_NKYJ*&
M8]@I)->RTW%QT:!-/8**Y_QYX^T#X8^%;[Q+XGU*/2=$L0K3W4BL^W+!5 50
M68DD   DYK.^%?Q>\)?&KPY+KW@S5O[9TF*Y:T>X^S308E559EVRHK='4YQC
MFE9VO;0+]#L:***0PHHHH ***JZIJMEH>G7&H:E>6^GV%NADFNKJ58HHE'5F
M9B ![F@"U17SQJW_  4 ^!.CZH;&3QL+AE.'GM-/NIH5_P"!K&0WU7->L_#C
MXM^#OB[I4NH^#O$-EKUK$VR4VSG?$W8.C ,F>VX#-6X2BKM$J2>S.NHKSWXG
M_'_X?_!F[L+7QGXD@T*>^1I+9)H97\Q5(#$;$;H2.M<3_P -T? K_HH5E_X"
MW/\ \:H4)/5(.9=SWBBN)^'?QL\!_%E9/^$0\5Z9KLD:[Y+>VG'G(OJT1PX'
M/4BNVJ6FM&4%%<_X\\?:!\,?"M]XE\3ZE'I.B6(5I[J16?;E@J@*H+,22
M2<UG?"OXO>$OC5X<EU[P9JW]LZ3%<M:/<?9IH,2JJLR[945NCJ<XQS19VO;0
M5^AV-%4=<US3O#.DW.J:O?VVF:;:IYD]W>2K%%$OJS,0 *\BTO\ ;2^"6L:T
MNE6WQ#TO[6SB,&99882Q.!B5T$?4==V.GK3492V072W/:Z*;'(LT:NC*Z,-R
MLIR"#T(-8OC;QMH?PY\,7WB+Q)J,6DZ+9!3<7DP)5-S!%X ).691@#J:7D,W
M**\Y^&7[1'PZ^,FJ7>G>#?%%MKE]:P_:)H(HI498]P7=\ZKD9(''J*]&H:<=
M&*]]@HHKR?QY^U5\*?AEXHN_#OB?QC:Z3K5J$,UI);SLR!T#KRJ$<JP/7O0H
MN6B0-I;GK%%>#_\ #='P*_Z*%9?^ MS_ /&J]&^'?QD\$?%JUDG\'^)]-U\1
M#=+%:S#S8@>A>,X=1]0*IPDM6@YD]F=E1114#"BBH+V\@TVSGN[J58+:WC:6
M65SA411EF)]  : )Z*\C\$_M9?"3XB^)[+P[X=\:V>I:S>EEM[589HS(54L0
M"Z 9PI/7G%>N4W%QW0DT]@HKS#XC?M,?#+X1^(%T/Q=XKM]%U5H%N1;2P3.3
M&Q(5LHA')4]^U>GT--:M!<****0PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-U)<S-(Q459!1114%!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)ZRBFR/9]F?GO^PC^QCX]^'_ ,2+/XC^-%CT%+>"98-*F82W<[2HR%I,'$8
M8GDEB>"!UKF?^"G7P^\4^+?C5X;NM#\-:QK5K'X?CB>;3["6=%?[3<':612
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MDHR4KEN*:L?&'[*>N>*M:_8Q\9^$/$.@ZQ8:UH.EW]C:17UC+%)<V\D$C0A
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@W=\8[53_:"_9[^.W@?3[?Q3\3O[1\5:/9ND;ZA<ZP^H)"&8 (Q+EXU8D+G
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M:^J_@E\*=.^"?POT#P;IC>;%IL&V6X(P9YF):64CMN<L0.PP.U?._P#P4O\
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M1NVVKGW%^RG\-_&WPC^#NG^$_'.IV&K:AILKQV<^GSRS*MIA3'&S2(ARI+J
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MC),AW8 ; !&&7FO8OAE\1=(^+7@+1?%V@M(VE:K )X5G 61.2K(X!(#*P92
M2,@\FK<))<S6@N9-V.HHHKR_XV?M)^ ?V?[&*;Q=K(@O)U+6^F6J>==SCU6,
M=%X(W,57/&<U*3D[(&[;GJ%%?$\?_!5SX:&Z*OX5\5K;9/[Q8;8OCL=OGXST
M[_G7T9\%/VC/ ?[0&ERW7A#6!<W-NJM=:;<H8KJVSTWH>H[;E++GC-:2ISBK
MM"4HO9GIE%4=;US3_#6DW>J:M>P:;IMI&9;B[NI!''$@ZLS'@"OE>^_X*=_!
MFSUIK&,>(KRV#8_M*#3E$!]P&D63'_ *F,)3^% Y*.Y];45RWPW^)WACXN>%
M[?Q#X3U>WUC2YOE\R$X:-\ E)$/S(XR,JP!Y'K74U+TT904444@"BBB@ HHK
M*\5^)K#P7X8U;7]4E\G3=+M);RYD'41QH6;'J< X% &K17S%\(_^"A7PT^,?
MQ TKP?I>G>(M,U+4V=+>;5;:WC@+JC,$+).Y!;:0..20.]?3M5*,H.TD)-2V
M"BO#_P!HC]KSP=^S1J>C6/B?3=<OY=5ADF@;28(9%548 AO,E3!RPZ9KUGPC
MXFM?&GA/1?$-C'-%9:M907\$=P )%CEC5U# $@, PS@D9[FAQ:2;6@75[&O1
M114C"BBB@ HHHH **** "N"^-WASQOXJ\ 76G_#WQ%;^%_$SS1-%J5RFY$0-
MEUQL?J..E=[133L[B/C+_A1/[7'_ $7'1?\ P&'_ ,C4?\*)_:X_Z+CHO_@,
M/_D:OLN2188V=V5$4;F9C@ #J2:\5\4?MG?!WPG?26=SXR@N[F-MK+IUO-=*
M.Q_>1H4/X-75!U:CM"%_1')6K4,.KUIJ*\W8\>_X43^UQ_T7'1?_  &'_P C
M4?\ "B?VN/\ HN.B_P#@,/\ Y&KZ/^'/QZ^'_P 6I7A\*>*++5;I5+FU^:&?
M:.K>5(%<@>N,5WU3*<X/EE&S]#2G*G6CSTY<R[IW/C+_ (43^UQ_T7'1?_ 8
M?_(U'_"B?VN/^BXZ+_X##_Y&K[-HJ?:OLON->1'QE_PHG]KC_HN.B_\ @,/_
M )&H_P"%$_M<?]%QT7_P&'_R-7V;11[5]E]P<B/C+_A1/[7'_1<=%_\  8?_
M "-1_P *)_:X_P"BXZ+_ . P_P#D:OLVBCVK[+[@Y$?&7_"B?VN/^BXZ+_X#
M#_Y&H_X43^UQ_P!%QT7_ ,!A_P#(U?9M%'M7V7W!R(^,O^%$_M<?]%QT7_P&
M'_R-1_PHG]KC_HN.B_\ @,/_ )&K[-HH]J^R^X.1'QE_PHG]KC_HN.B_^ P_
M^1J/^%$_M<?]%QT7_P !A_\ (U?9M%'M7V7W!R(^,O\ A1/[7'_1<=%_\!A_
M\C4?\*)_:X_Z+CHO_@,/_D:OLVBCVK[+[@Y$?&7_  HG]KC_ *+CHO\ X##_
M .1J/^%$_M<?]%QT7_P&'_R-7V;11[5]E]P<B/C+_A1/[7'_ $7'1?\ P&'_
M ,C4?\*)_:X_Z+CHO_@,/_D:OLVBCVK[+[@Y$?&7_"B?VN/^BXZ+_P" P_\
MD:C_ (43^UQ_T7'1?_ 8?_(U?9M%'M7V7W!R(^,O^%$_M<?]%QT7_P !A_\
M(U'_  HG]KC_ *+CHO\ X##_ .1J^S:*/:OLON#D1\9?\*)_:X_Z+CHO_@,/
M_D:C_A1/[7'_ $7'1?\ P&'_ ,C5]FT4>U?9?<'(CXR_X43^UQ_T7'1?_ 8?
M_(U'_"B?VN/^BXZ+_P" P_\ D:OLVBCVK[+[@Y$?&7_"B?VN/^BXZ+_X##_Y
M&H_X43^UQ_T7'1?_  &'_P C5]FT4>U?9?<'(CXR_P"%$_M<?]%QT7_P&'_R
M-1_PHG]KC_HN.B_^ P_^1J^S:*/:OLON#D1\9?\ "B?VN/\ HN.B_P#@,/\
MY&H_X43^UQ_T7'1?_ 8?_(U?9M%'M7V7W!R(^,O^%$_M<?\ 1<=%_P# 8?\
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MPHG]KC_HN.B_^ P_^1J^S:*/:OLON#D1\9?\*)_:X_Z+CHO_ (##_P"1J/\
MA1/[7'_1<=%_\!A_\C5]FT4>U?9?<'(CYO\ @C\+?V@?"OC^UU#XA?$_3?%/
MAE(95ETVV@"N[E<(V?(3H>>M?2%%%92ES.Y25@HHHJ1A1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9
M_B#Q!IWA70[[6-7NX[#3+&%KBYNI3A(HU&68^P%:%>4_M6?\FU_$S_L 7?\
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M!(#OL!8 D*H;G.W/[!U-:G&F[)CA)R5V%%%%8&@4444 %%%% !1110 4444
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M<9H;@[W3/B7]I+_@H]H?Q6^$^M>#O#/A74K2;6(A;SWFJ/$%ACW*6VHA;<Q
M(Y*XSGG%>B?\$L_A)K7A7PEXG\:ZK;26=GX@^SPZ;')E3-%$9"TVW^Z6<!2>
MNUB.""?IZP_9A^$>F7<=S;?#;PND\9W(QTJ%MI]0"IYKTR.-(8UCC14C4!55
M1@ #H *4JL>3D@K7&HOFYI,^?+G]@'X"WEQ+/-X#WRRN7=O[8OQEB<D\3UY-
M^W;\+?#'P>_8['AWPAIG]D:,FOV\ZVWVB6?#OO+'=(S-S]:^WJP_&/@?P_\
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MB8/;:*QA4C3FY)%RBY1L=E!!':P1PPHL44:A$11@*H&  /3%2445SF@4444
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MR)IEG'!YA'=MH&X^YKHJSJ5%)*,59(J,;.[W/ES_ (*2_P#)J^M?]?\ 9?\
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M[ ?BK6;^-M-\0?$*]^QZ7"^5E%L\6PR$=5/EBX8'_:C/<5A?L;_L,:5^T1X
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MWVL>W4445QFX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MIEQJUM'<Q6QMK5U1R7) .6XXQ7S[K'_!4'X?Z;X%TO6(-$U"^UZ_,A_L*.5
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MF%60#D!B>N2I%>>:;\2OB%\+?VROBSJWPU\*_P#"7Z[+J.IVTMC_ &=<7NR
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M649PQ/)^F-)TXR=EH[$QDTKL_3FBBBN$Z HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$MOAIK6J?%C5/&X@DA\/:782V371X6:XD*8B'KA<L<=/DS]X5;_X**? #7_
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M)19?^"Z^_P#BZ_2.BCVL/Y Y9?S'YN?\/&/C?_T2BR_\%U]_\71_P\8^-_\
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M67_@NOO_ (NC_AXQ\;_^B467_@NOO_BZ_2.BCVL/Y Y9?S'YN?\ #QCXW_\
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MHH]K#^0.67\Q^;G_  \8^-__ $2BR_\ !=??_%T?\/&/C?\ ]$HLO_!=??\
MQ=?I'11[6'\@<LOYC\W/^'C'QO\ ^B467_@NOO\ XNC_ (>,?&__ *)19?\
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M6]K#%+X(:YE1%5YWU>^#2$#!8A9P 3UX '-?*W_!0+]D'PA\'?!/A_Q;\/\
M1&T>P2[:RU2$7<]P#YBYADS*[%0"CJ<'!+K7Z;U%<VL-Y"8KB&.>(]4D4,I_
M U$*TXR3;N.4(M6L?-G[!/Q4A^,7[-VG:;J3+=ZAH*MH=]%+SYD2J/))'<&(
MJN3U*-7Q=\8/@)\2/V)?B]_PG/@.*ZN/#,,LDMAJD,1N$@A88:WNUQP,';N;
MAAA@0PPOZPV>GVNGAA:VT-L&^]Y,83/UP*G(# @C(-.-;EDVEH^@.%TD]S\U
MF_X*T^(/[%$2_#S31J^.;HZC(;?./^>.S=_Y$KQ3PI\/_B_^VC\8AXPDTAIC
M<W,+76LR6_V73[>./:%56Q\VU5 VKN<]3GDU^M\GPQ\'2WOVQ_">AO>8Q]H;
M383)US][;GJ372(JQJJJH55& JC  ]*T5>,/@C9D^S<OB9\T?MZ?#OQ]XU^%
M-MJ/P\U76+;5=&G::YTS1[N:%[^W90& 2,CS'0A6"GMOQR<'Y6^%O_!2[6_A
MG\*+?PEK'A-];\2Z3"UG:ZE<WC("%R$\]"I8LG .&!8#^$\U^H58=]X&\-ZE
MJ2ZC>>']+N]04[ENY[*)Y0?4.5SV'?M6<*D5'EG&Y4HN]TS\\_\ @G3\!_%7
MB#XJ7/QC\2VDUE81I<26,UU$4:_N+@,KRQCCY KO\W0EP!G!Q^E%(JA%"J J
M@8  P!2U%2HZDN9CC'E5CY4_X*7_ /)KM]_V%;/_ -"-5_\ @F/_ ,FR)_V&
M;O\ E'7U;=6D%[%Y5Q#'/'G.R5 P_(T6MG!8Q>7;P1V\><[(D"C/K@4_:?N^
M2P<OO<Q^3_\ SDV_[G/_ -FKZJ_X*A_\FUVW_8?M?_1<U?6/]D6'VK[3]BM_
MM&[=YWE+OSZYQG-2W5G;WT?EW,$=Q'G.R5 PSZX-6ZUY1E;8E0T:[GP?^SQ\
M6%^"O_!.74/%"2"/4(IKZWT_U-U+,4B('?:S;B/1#7C'_!/?]F'PY\>M3\6Z
M[XZTM]9T#3TCM8(6N9H/,NI#O9]\3JQ*(O()Q^]![<?JD=)L6M1;&RMS; [A
M#Y2[ ?7&,9J2TL;:PC*6UO%;H3N*PH%!/K@4_;V4K*S8>SVOT/GW_AWS\ ?^
MA!_\K.H?_)%?GSX-OKG]C']M(VEW(\6E:7JC6-R\A_UNFSXVR-ZXC>.3']Y!
M7['U3N=&T^\E,MQ8VT\IX+R0JQ_,BE"LXW4M4PE33M;0_-__ (*S,'\8?#ME
M(93I]T01R#^\CJ?X<_MX^)/V:_A[I_P_\>^ KR\UG2;)$TJ[%R(8[BT*_P"C
MELJ=RA<*'3.0 , @U^C=UI5E?;/M%G;W&P87S8E;:/09'%5=:\*Z+XD@A@U;
M2+#5(83NBCO;9)EC/'*A@<'@=/2FJT>10E&]@Y'=R3/S*_8:^%_BOXZ?M&S_
M !@\0VLT>CVEY<:G+?M'MBNKU\A88L]0I<L<9"A #@D5^I-1V]O%:0I#!$D,
M*#:L<:A54>@ Z5)652I[1W*C'E5@HHHK(L**** "BBB@ HHHH ^$OV[?V5=4
MUC6I_B1X0L)+\S1K_;.GVR[I0R@*+A%'+ J & &1MW<Y8CX,(*D@C!K]X*X3
MQ-\"?AWXQOGOM9\%:'?WLC;GN9+&,2N<YRS  MSZFO?PN:NC!4ZBND?#9GPS
M'%UG7P\^5O=/:_<_'3P?X+USX@>(+;1/#VF7&JZG<-MCM[=<GK]YCT51W8X
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M5]&45,JSTY5:PU!==3\S_!_CO]K3]E_1AX$M_A_-XMTRSREC<G2;C4XX8LG
MBFMG'R\Y"R9*CC  P/1/V2OV8_B)KWQGG^-OQC\RVULAI+&PN @G>5H_+$DB
M+Q$B1G:L?#9P<+M^;[LHJG6;3LK-B5/NS\S_ -HK2OBQX#_;CU;XD>!OAWK7
MB7[&L'V2X&B7=U92[K!(7^:(#=C<PX;@CGIBM[_ALG]K/_HAO_EHZM_\>K]$
MJ*/;*R3C>P<COHSY0^/W[/NN?M>_L\>#]2U"VA\.?$FTM([];6XADMXDED1?
M/MG5]SQ@D#&[)!0 \$UX+I/QP_;"^&/A]/!$GPZO=8N;./[)!K4NA7%],B@;
M4(N(G,$FT ?,P;/5B:_2FBE&M96:NAN%W=,^.?V'?V5?%7PW\0Z]\3/B3(3X
MUUQ71+1Y%EDA61Q)++*RY'F.P'"GY0#GEL+]C445E.;F[LJ,5%61\)?LN?#G
MQ9X?_;L^+6OZIX7UK3="OAJGV75+S3YHK6???1,GERLH5MR@L,$Y )K[MHHI
MSGSNX1CRJQ\*_P#!4#X=^+/'UO\ #G_A%O"^L^)&M)+\SC2=/FNO)W"WV[_+
M4[<[6QGK@^E<DW[6G[7&I6IT^U^#3Z?-*GE1W:>%-15HCC 8&60Q@CK\P(]1
M7Z+T5I&LE%1<;V)<-6TSX[_8=_92\3_##7M?^(_Q(*GQKK0>..U,JRR0+(_F
M322,I*F21@O"YV@'G+$#YQFD^-WP,_:I^)GC7P5\+=:UW^TM1U"VBFO/#U]<
M6LL$ET)!)&8MF<[%PP8C!-?JE10JSNW)7N+V:LDC\[E_;(_:R+ 'X'<9_P"A
M2U;_ ./5^A.GS2W%C;2SIY<SQJSI@C:Q )&#TYJQ16<Y*6RL7%-;L^%O^"??
MPZ\6>"_B[\6[SQ!X8UG0K.^D4VMQJ6GRV\=Q_I$I_=LZ@-P0>,\$5]=^)_@_
MX#\;:I_:7B+P3X=U_4=@C^V:II-O<S;!T7>Z$X&3QGO77443J.4N848J*L?'
M/[?OP;=_V==*\/?#CP.S*GB*&[?2O"VD< >1.K2F*!/4J"V/3VKU"P\.:LG[
M$,6A-I=XNN#P#]C.F&W?[3Y_V#9Y7E8W;]WR[<9SQBO=J*?M'RI=@Y=;GPE^
MR+\.?%GAK]BGXMZ'J_A?6M*UN^.J?9=-O=/FAN;C?I\:)Y<;*&;<P*C .2,5
M)^QS\ ]=\0?L?_$3P#XKT?4_"E[K>I7*P+JUE);2*3;V_ER[)%!*B1.H'.TC
MK7W36%XY\'V'Q \':SX:U/S!8:K:R6DS0MM=5=2-RGLPZ@^H%6ZS=_-BY-CX
M(^ OC7]H7]F?1;SX6+\&;_Q;Y5S+_96J1^9'9PLY)):<(8WB+?, 7C(W$$C@
M#(_8'L=>L_VU/B7%XDFCN]?AL=134KBW):)KG[;#YA4D#@MNQP.*]+TK]F+]
MJ/X9?:])\"?&O3+KPZS9A.O[Y)T7& JK);S^6 .R. >N!7J_[*'[)\G[/UQX
MA\0Z]X@;Q3XT\0D-?7VPB-!N+LJ%OF8L[99CC.U?E&#G>4X\LGI=F:B[KR/&
M_P!ESX<^+/#_ .W9\6M?U3POK6FZ%?#5/LNJ7FGS16L^^^B9/+E90K;E!88)
MR 31^UM\.?%GB3]M;X/ZYI'A?6M4T2Q.F?:]2LM/FFMK?9J$COYDBJ57:I#'
M)& <U]VT5S^V?-S6Z6-.32P4445@:!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_D_-_P#&*/J]3L'M(GZ(T5^=W_#TCQ;_ -$A_P#)^;_XQ1_P](\6_P#1(?\
MR?F_^,4?5ZG8/:1/T1HK\[O^'I'BW_HD/_D_-_\ &*/^'I'BW_HD/_D_-_\
M&*/J]3L'M(GZ(T5^=W_#TCQ;_P!$A_\ )^;_ .,4?\/2/%O_ $2'_P GYO\
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MG$4D9/E2GTY^Z?;)S^E>G5\5QR-%(KHQ1U.0RG!!'>OKSP?J[Z]X7TO4)/\
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M;:/&8F/VIV1&PJGU*#_:I<GO\B'S>[S,]\M-0M;]KA;:YAN&MY3#,(9 QBD
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M#<?%70;>+Q?HXC@FMHX;DVZSK+*L>=Y1BI4L<@KD%2#@UY#\*_V\=:^,FO\
MARQ\,?!S7=1TZ]GCM=5UF*Y=K/2Y6.6!E$&U@B%6)8QGG !X)2IR:ND',D['
MUW17R'XN_P""@3MXUUGP[\-?A7XB^)YT:4P7MYIOF)&K!BI*B.&5BNY2 S!<
MX.,C!/H7[-?[7WAS]HR[U31XM+O?#'BO2U,EWHNH$,VP-L9D8 ;MK$*P95(+
M#CO3=*:5VA<T6['O5%%%9%A1110 4444 %%%% !1110 4444 %%%% !1110
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M7Z(T4>V7\J^X.3S9^=W_  F7[=7_ $ O_)33?_BJ/^$R_;J_Z 7_ )*:;_\
M%5^B-%'ME_*ON#D\V?G=_P )E^W5_P! +_R4TW_XJC_A,OVZO^@%_P"2FF__
M !5?HC11[9?RK[@Y/-GYW?\ "9?MU?\ 0"_\E--_^*H_X3+]NK_H!?\ DIIO
M_P 57Z(T4>V7\J^X.3S9^=W_  F7[=7_ $ O_)33?_BJ/^$R_;J_Z 7_ )*:
M;_\ %5^B-%'ME_*ON#D\V?G=_P )E^W5_P! +_R4TW_XJC_A,OVZO^@%_P"2
MFF__ !5?HC11[9?RK[@Y/-GYW?\ "9?MU?\ 0"_\E--_^*H_X3+]NK_H!?\
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M_)33?_BJ/^$R_;J_Z 7_ )*:;_\ %5^B-%'ME_*ON#D\V?G=_P )E^W5_P!
M+_R4TW_XJC_A,OVZO^@%_P"2FF__ !5?HC11[9?RK[@Y/-GYW?\ "9?MU?\
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ME^W5_P! +_R4TW_XJC_A,OVZO^@%_P"2FF__ !5?HC11[9?RK[@Y/-GYW?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA?[-&^5,[2-P[# "YZ853^D-%%14GSO:R148\H4445D4%%%% !1110 4444
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M%]0D.H6J11^4LD<9P0[<YE7C'K5*+:;2%=;'NU%0WETEC9SW,F?+A1I&VCG
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% &;XB\-:3XNTF?2];TVUU;3IQB2UO(EEC;W
MP1U]^U>'7_[!OP9OKYKD>&[BU#$L8+?49UCY] 7)'T!'7TKZ#HK:G6J4O@DT
M<E;"8?$M.M34K=TF<C\/?A+X/^%-@]IX3\/V>BQ28$CPJ6EDQTWR,2[?\")K
MKJ**SE)R=Y.[.B%.%.*A!62Z(*BNK6&^MIK:YACN+>9#')#*H9'4C!5@>"".
M,&I:*DLPO"?@/PUX"M)K7PSX=TGPY:SOYLL.DV,5JDCXQN98U )P ,GTJ?Q-
MX3T/QII9TWQ!HVGZ[IS,'-IJ=JEQ"6'0['!&1ZXK6HIW>X&7X;\*Z+X.TU=.
MT#1[#0]/4EEM--MDMX@3U(1 !G\*OW5K#?6TUM<PQW%O,ACDAE4,CJ1@JP/!
M!'&#4M%(#"\)^ _#7@*TFM?#/AW2?#EK._FRPZ38Q6J2/C&YEC4 G  R?2MV
MBB@"MJ.FVFL6,]E?VL-[9SJ4EM[B,21R*>H92,$>QKE-"^"GP\\+ZI'J6C>
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"VGX)_:0U*YT?3;>\T/Q%;Q&?^S=0"GSHQ@,T3J2&P2,@X/?! )',_L+?
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M3D#)%9QY87INVCZEN\K21]9_L^_%R+XY?"'P[XT2U%C+J,+">U5MPBF1VCD
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M:!875Y-)J$JL\SV\;2,0)0 2Q)P *\'_ ."LW_)1/ ?_ &"I_P#T=5#X>_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M6<$E\".)W9(0RQ_W0""QY^[C?[I\;/CIX3^ GA"?7O%&H)#\K?9-/C8&YO9
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M'?KQ7LE?&_\ P5/_ .3=]'_[&.W_ /2>XJ:45*:3";:BVCS7_A[I_P!4H_\
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MFVL=M:6\5K;1#:D,*!$0>@ X%0OHNGR7'VA[&V:?=N\UH5+9]<XSFM/K'O\
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M*XG429^HE%<U\-_B!I/Q4\"Z+XLT*5I=+U6W6XAWC#)U#(P[,K!E/NIKS_\
M:L_:&L?V<_A7>:VQCGU^\W6NCV4G/FW!'WV']Q!\S?@,@L*P46Y<JW-+JUSV
M6BO@C_@G7^T/\1/C+\0O%5AXS\33Z[9VFEK/!%+#$@20RJI8;$7L37??M&?
M#XD_M&?';2-%U.]O-$^"UI:YGFTR^B22>;:68M$226+%4!9&50I('S'.KI<L
M^63(4[JZ1]<T5^?7[..GZC^S_P#MM:I\(/"WB2^\0^!7LGGN+6\E$OV1Q )
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M ,%"?VCM9^!O@'0]/\*:F=,\4ZW=EDN8T1VAMH@#(0&!&69HU&1T+>E>5_\
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M/_!1"TT>X_93\4R:HL)N(9K1]/:3&];@W$:_)[E#(#C^$M7(_MB_L(M\=O$
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M;/AM_:0*W/\ 8=J &SGR]@\K_P <V5ZO4=O;Q6=O%!!&L,$2A(XXU"JJ@8
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MM:GY0_L#_P#)ZNH?]<M4_P#0C7W-^W1_R:?\0O\ KUA_]*8J\1_9<_8P\?\
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MA:R"6"[M-$MHI8G'1D=4!4CU!KN:PJ2C)WB:132U"OST_P"":O\ R6KXT?\
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MK-5&M&2O&*:'RWU3/B'_ (3S]N'_ *)QX9_\";3_ .3:/^$\_;A_Z)QX9_\
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M\,_^!-I_\FT?\)Y^W#_T3CPS_P"!-I_\FU]O44>U7\J#D\V?$/\ PGG[</\
MT3CPS_X$VG_R;1_PGG[</_1./#/_ ($VG_R;7V]11[5?RH.3S9\0_P#">?MP
M_P#1./#/_@3:?_)M'_">?MP_]$X\,_\ @3:?_)M?;U%'M5_*@Y/-GQ#_ ,)Y
M^W#_ -$X\,_^!-I_\FT?\)Y^W#_T3CPS_P"!-I_\FU]O44>U7\J#D\V?$/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\I_:L_Y-K^)G_8 N_\
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MM],^VI&S!6=?F4@/M*\]<-[UU7[1+?M#_%'1;36?B=X1U9=.T%)'6_?0Q:K
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MZ*AX,_\ "@M/_CE'_#1WPF_Z*AX,_P#"@M/_ (Y7S-_PZA^'G_0W^)OSM_\
MXU1_PZA^'G_0W^)OSM__ (U6W+1_F9%Y]CZ9_P"&COA-_P!%0\&?^%!:?_'*
M/^&COA-_T5#P9_X4%I_\<KYF_P"'4/P\_P"AO\3?G;__ !JC_AU#\//^AO\
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M .-4<M'^9A>?8^F?^&COA-_T5#P9_P"%!:?_ !RC_AH[X3?]%0\&?^%!:?\
MQROF;_AU#\//^AO\3?G;_P#QJC_AU#\//^AO\3?G;_\ QJCEH_S,+S['TS_P
MT=\)O^BH>#/_  H+3_XY1_PT=\)O^BH>#/\ PH+3_P".5\S?\.H?AY_T-_B;
M\[?_ .-4?\.H?AY_T-_B;\[?_P"-4<M'^9A>?8^F?^&COA-_T5#P9_X4%I_\
M<H_X:.^$W_14/!G_ (4%I_\ '*^9O^'4/P\_Z&_Q-^=O_P#&J/\ AU#\//\
MH;_$WYV__P :HY:/\S"\^Q],_P##1WPF_P"BH>#/_"@M/_CE'_#1WPF_Z*AX
M,_\ "@M/_CE?,W_#J'X>?]#?XF_.W_\ C5'_  ZA^'G_ $-_B;\[?_XU1RT?
MYF%Y]CZ9_P"&COA-_P!%0\&?^%!:?_'*/^&COA-_T5#P9_X4%I_\<KYF_P"'
M4/P\_P"AO\3?G;__ !JC_AU#\//^AO\ $WYV_P#\:HY:/\S"\^Q],_\ #1WP
MF_Z*AX,_\*"T_P#CE'_#1WPF_P"BH>#/_"@M/_CE?,W_  ZA^'G_ $-_B;\[
M?_XU1_PZA^'G_0W^)OSM_P#XU1RT?YF%Y]CZ9_X:.^$W_14/!G_A06G_ ,<H
M_P"&COA-_P!%0\&?^%!:?_'*^9O^'4/P\_Z&_P 3?G;_ /QJC_AU#\//^AO\
M3?G;_P#QJCEH_P S"\^Q],_\-'?";_HJ'@S_ ,*"T_\ CE'_  T=\)O^BH>#
M/_"@M/\ XY7S-_PZA^'G_0W^)OSM_P#XU1_PZA^'G_0W^)OSM_\ XU1RT?YF
M%Y]CZ9_X:.^$W_14/!G_ (4%I_\ '*/^&COA-_T5#P9_X4%I_P#'*^9O^'4/
MP\_Z&_Q-^=O_ /&J/^'4/P\_Z&_Q-^=O_P#&J.6C_,PO/L?3/_#1WPF_Z*AX
M,_\ "@M/_CE'_#1WPF_Z*AX,_P#"@M/_ (Y7S-_PZA^'G_0W^)OSM_\ XU1_
MPZA^'G_0W^)OSM__ (U1RT?YF%Y]CZ9_X:.^$W_14/!G_A06G_QRC_AH[X3?
M]%0\&?\ A06G_P <KYF_X=0_#S_H;_$WYV__ ,:H_P"'4/P\_P"AO\3?G;__
M !JCEH_S,+S['TS_ ,-'?";_ **AX,_\*"T_^.4?\-'?";_HJ'@S_P *"T_^
M.5\S?\.H?AY_T-_B;\[?_P"-4?\ #J'X>?\ 0W^)OSM__C5'+1_F87GV/IG_
M (:.^$W_ $5#P9_X4%I_\<H_X:.^$W_14/!G_A06G_QROF;_ (=0_#S_ *&_
MQ-^=O_\ &J/^'4/P\_Z&_P 3?G;_ /QJCEH_S,+S['TS_P -'?";_HJ'@S_P
MH+3_ ..4?\-'?";_ **AX,_\*"T_^.5\S?\ #J'X>?\ 0W^)OSM__C5'_#J'
MX>?]#?XF_.W_ /C5'+1_F87GV/IG_AH[X3?]%0\&?^%!:?\ QRC_ (:.^$W_
M $5#P9_X4%I_\<KYF_X=0_#S_H;_ !-^=O\ _&J/^'4/P\_Z&_Q-^=O_ /&J
M.6C_ #,+S['TS_PT=\)O^BH>#/\ PH+3_P".4?\ #1WPF_Z*AX,_\*"T_P#C
ME?,W_#J'X>?]#?XF_.W_ /C5'_#J'X>?]#?XF_.W_P#C5'+1_F87GV/IG_AH
M[X3?]%0\&?\ A06G_P <H_X:.^$W_14/!G_A06G_ ,<KYF_X=0_#S_H;_$WY
MV_\ \:H_X=0_#S_H;_$WYV__ ,:HY:/\S"\^Q],_\-'?";_HJ'@S_P *"T_^
M.4?\-'?";_HJ'@S_ ,*"T_\ CE?,W_#J'X>?]#?XF_.W_P#C5'_#J'X>?]#?
MXF_.W_\ C5'+1_F87GV/IG_AH[X3?]%0\&?^%!:?_'*/^&COA-_T5#P9_P"%
M!:?_ !ROF;_AU#\//^AO\3?G;_\ QJC_ (=0_#S_ *&_Q-^=O_\ &J.6C_,P
MO/L?3/\ PT=\)O\ HJ'@S_PH+3_XY1_PT=\)O^BH>#/_  H+3_XY7S-_PZA^
M'G_0W^)OSM__ (U1_P .H?AY_P!#?XF_.W_^-4<M'^9A>?8^F?\ AH[X3?\
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M-!=6WA;59(I8V&5=&68AE((((X(->M_LJ_MTZC\8/B'+\/?'?AF+POXMV2&
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2EU&\,0P3'#ORJ XY8G@G.UJ^Y?^&COA-_T5#P9_X4%I_P#'*/\ AH[X3?\
M14/!G_A06G_QRB-6K%62!Q@W<[#PKX7TSP3X;TS0-&M4LM*TVW2VMK=.B(HP
M![GU)Y)R34OB+3Y-6\/ZG8PLJRW5K+"C.2%#,A )QVR:XK_AH[X3?]%0\&?^
M%!:?_'*/^&COA-_T5#P9_P"%!:?_ !RL.66]C2Z/G[]B+]CGQI^S7XT\1:OX
MGU/0;ZVU'3UM(ETFXFD=7$BMEA)"@ P.Q-?8U>=?\-'?";_HJ'@S_P *"T_^
M.4?\-'?";_HJ'@S_ ,*"T_\ CE5/GF^9HF/+%61Z+17G7_#1WPF_Z*AX,_\
M"@M/_CE'_#1WPF_Z*AX,_P#"@M/_ (Y4<LNQ5T>BT5YU_P -'?";_HJ'@S_P
MH+3_ ..4?\-'?";_ **AX,_\*"T_^.4<LNP71Z+17G7_  T=\)O^BH>#/_"@
MM/\ XY1_PT=\)O\ HJ'@S_PH+3_XY1RR[!='HM%>=?\ #1WPF_Z*AX,_\*"T
M_P#CE'_#1WPF_P"BH>#/_"@M/_CE'++L%T>BT5YU_P -'?";_HJ'@S_PH+3_
M ..4?\-'?";_ **AX,_\*"T_^.4<LNP71Z+17G7_  T=\)O^BH>#/_"@M/\
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M **AX,_\*"T_^.4<LNP71Z+17G7_  T=\)O^BH>#/_"@M/\ XY1_PT=\)O\
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M63;Y7D[=GERIC_6-G.>@Z5W_ .T!XJ^-.@VWAR3X0^$=&\4O<>:=4&K2K&(
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3E3QU8#F_@C;>-OVR/VMM&^+VH^&G\-^$=!$3Q2-N:(B(,8H4E(7SG,C%F(
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MM.,;6\PY9---GB'PY^'.B?%K]D'P3X4\0VWVK2]1\+:?&X'#1L+>,I(A[,K
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "O&/VC/V4_"7[3G_"/?\)1J.M6']B?:/LW]D3PQ[_.\K?O\R)\X
M\E<8QU/7M[/151DXNZ$TGHSXR_X=4?";_H8?&?\ X&VG_P BT?\ #JCX3?\
M0P^,_P#P-M/_ )%KO_VG/VRM&^ \S:#I=JFO^,&C#M:LY6"S5AE6F(Y)/!"#
M!(Y)7(S\<7_[?OQEO+YIXM<L;&(DD6MOID)C&>P+JS<?[U>Q0PF+KQYT[+S/
MF<9GF P51TIWE);V5[?BCZ(_X=4?";_H8?&?_@;:?_(M'_#JCX3?]##XS_\
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M;3_Y%H_X=4?";_H8?&?_ (&VG_R+7V;11[:I_,'LX]CXR_X=4?";_H8?&?\
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M?_(M?9M%'MJG\P>SCV/C+_AU1\)O^AA\9_\ @;:?_(M'_#JCX3?]##XS_P#
MVT_^1:^S:*/;5/Y@]G'L?&7_  ZH^$W_ $,/C/\ \#;3_P"1:/\ AU1\)O\
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ML!7W/^R3\([SX)_ 7PUX9U-535U1[N^12"$FE<N4R.NT%5S_ +-?*W_!0?\
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M:[#]OOX(^,-:UWP/\5O >FRZSK/AAHQ<6-M$99ML<HFAD5!\SA7W!E'.&!Z
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M**XM?C1X#;QI_P (BOB_1V\4>;Y']DK>(;GS -Q39G.[':NTIV:W **S]?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK[X@WGAOX<?#37/B7!8LPN;[2Y&!*JVUI(HHX9"\?HS%,_0@UX=_P3[^V_\
M"O\ ]HS^S?\ D(_V3']F_P"NGE7NW]<5ZG_P2?\ [,_X55XS\KR_[8_ME?M.
M,;_)\A/*SWQN\[';.?>G4C&+E)J]K!&3:21Y5\-_B5IGQ=_X*8:)XJTB&ZMK
M.]5E-M?1&*>"1-*>.2-U[,KJRG&1Q7Z=U^;VG/IDG_!60G2FB:'[3*)3"<KY
MXTMA+^._=GWS7Z0UC7^S;LBZ?7U/RB_: ^.OC+5OVRO"NMW7@'7+>[\-W44>
MF>%9I9C)J&R>3$T*F$%?.P.51L[!RV*^LOC3^V_J/P4^'_P[\0:M\-;I-2\5
MQ3O/HU[J+6DVG-$8_D;=;DL3YG=5QCWKQ[]I#_E)5\*?]S3/_2B:I/\ @K4K
M?9?A?)M.Q9M0!;' .+? S^!_*NBT9N$6NAGK%2=S[#^/'Q=_X4G\'];\=?V3
M_;/]FI"_V#[3Y'F>9*D>/,V-C&_/W3G%>97'[8WV?]DNW^-G_"([O-F\K^P_
M[3QC_2S;Y\_R?;=]SV]Z9^WAJ]JO['/BB1I547L5BD&Y@"[&XA< <\G:I/&>
MAKYOU'_E$Q8?]??_ +EGK"G3BXIM=;%RDTVO(]*O_P#@I<LWA&V\0>'OA/K^
MOZ?!&AUJ^29X['39F )B^T"!@Y&<998P>,9!S6MJ7_!2#1M6\,P:AX!^'GB7
MQQ?PVPNM7M887ABTE<L")IECD'\)((7:0?O Y4,^$^DVMA_P3+O4AA4+/X7U
M6XDR =SLTY)/Z?D*J?\ !,:QMX_V:?$<RPJ);C6;H2MCEP+>$ 'V S^9JW&F
MDWR[.PDY72ON>Z_LT_M*:!^TQX+N-:TBTGTN]L9A;W^FW+!V@<KN4JP^^A&<
M-@'Y3P,5Y/\ $#_@H-ING^.[WP?\./ .N?%+6;"21+K^RRR1#8=KF,I'*[A6
MX+; OH2"#7A'_!/ :@OPA^/PT<$:H+!?L>S.?-\BZV8QS]['2O0?^"3O]C?\
M*V\;>3Y7_"0?VK']KQCS/LWDCR,]]N_S\>^:)4X0<G:Z0*3E9=SVG]G?]LKP
MU\>-<NO#%UI-]X-\;6B%Y=#U3!+[<[Q$^%+%>I5E5L'(! )'$_%;_@H%;?"K
MXW:Y\/)_ =YJ\MB(X[6YL+XO->W$D2/%$L'D\;FD"YWGID G"GR/]HS[/_P\
MF^&O_",;/[:WZ;_:GD]=WF/OWX[_ &;;G/\ #C/%1KID>J?\%9'$J)(D$OVC
M;)ZKI8*D>X;!_"FJ</B:TM<7-+;S/?+_ /;8_P"$'^#'_"<?$3X>:UX(U*YU
M!]/T[PW<.7NKQE0-YG[R.(QQ\G)9>W&[(SPY_P""CFH^%[RPF\?_  3\4^"O
M#U[)LAU6X:1M^1D%4D@B#<<X5R<9QFO1OVX/@+IOQN^'>FO<>*]/\':KHMRU
MQ8W^K3B&T9G4!HY&S\N2%(8 D;>AS7RWXY\2?M1?LVZ/:7_Q!M-(^(?@C2[F
M'9<:O';ZC")<[4D\PA;E7YP)'Z%NY."J<:<UMKZ_D.3E%GZ2Z'K5CXDT:PU;
M3+F.]TV^@2YMKF(Y66-U#*P]B"#5ZN0^$/Q"A^*_PQ\->+X+-M/CUBRCNC:,
M^_R6(^9-V!N 8$9P,XS@5U]<;T=C8****0PHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"G
MJVCV&O:?-8:G8V^HV,PQ);7<2RQN/1E8$'\:\Z3]EWX2QWWVL?#[0C+NW;6M
M%,?_ 'P?EQ[8KU&BM(U)PTBVC"I0I56G4@G;NDROI^GVNDV<-G8VT-G:0KMC
MM[>,1QH/15 P!]*L445F;;:(****!A1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7R9_P4X_Y-D?\ [#-I_*2OK.ODS_@I
MQ_R;(_\ V&;3^4E;4?XD2)_"SY?_ &.?V'_"G[1WPKO?%&MZ]K.F7D&JS6"P
MZ>8O+*)%$X8[T)SF0]^PJI^UY^P?8?L[^ 8?&&A>*+K5K(7T=I-9:A"BR*'#
M%75U(#8*@%=O?.>,5R7[.'AO]I75OA_=W/PAFU)/"RW\BS+9ZC:0+]I$<9?Y
M)9%8G:8^0,'BLS]H#PW^T)%I.GW_ ,8K;Q->>';6=2&N+E7MXV)QUCW(CD$J
M&89YQSTKTO>]I\:MV.73EV/T,_X)^?$S7OB?^SK877B*XEO;[3+V;2TO9SND
MN(HU1D9CW(#[,GD[,G)R:^*?VDOC%XQ_;#_: C^''A&YD_X1Q-0.GZ;8+*5@
MN'C+;[R;'485F!P=J#@9SG[5_9/^)G@OQM^S3-;?#C39-$_L&SFM9=(N9!)-
M!<%&<.T@ \SS&);> ,DMP,$#XA_X)CBU/[3D?VC_ %PT:[-M_P!=,QY_\<WU
MSP2C*<[;&DM5&-]SZ T+_@D[X4CT-%UGQOK,VLF,;I;&&*.W5\<X1E9F /\
MM GVKPC1/@9\;/V2_P!HR!?!6C:QXLAMS'(;S2[&4VFH6;MS'-P50G# AF^5
M@"#T-?>G[8/[0VH_LT_#/3/$^F:1:ZS/=ZO%IK07<C(JJT,TFX%><YB _$U\
M?_\ #V7Q;_T(>B_^!<U%.5::;W3"2A%VV/??^"F,WVC]EU9=CQ;]7LVV2##+
ME9#@CUKYC_8Y_8?\*?M'?"N]\4:WKVLZ9>0:K-8+#IYB\LHD43ACO0G.9#W[
M"O?OV\O$\OC;]B+PUXBG@2VFU>72M0>&,DK&TL)D*@GJ 6Q7R3^SAX;_ &E=
M6^']W<_"&;4D\++?R+,MGJ-I OVD1QE_DED5B=ICY P>*JE?V6CMJ*5N?:YU
MO[7G[!]A^SOX!A\8:%XHNM6LA?1VDUEJ$*+(H<,5=74@-@J 5V]\YXQ7V9_P
M3\^)FO?$_P#9UL+KQ%<2WM]IE[-I:7LYW27$4:HR,Q[D!]F3R=F3DY-?GG^T
M!X;_ &A(M)T^_P#C%;>)KSP[:SJ0UQ<J]O&Q..L>Y$<@E0S#/..>E?H_^Q+\
M2/ ?CSX(Z;9> ].ET.TT/_0[O2;F02303'+EV< >9YA+-OP,G=P,$":U_9*[
MOYCA;GTT/?Z*^5IO^"E7P5AF>-K[6=R,5/\ Q+&ZC\:]:\.?M$^$/%GP9U/X
MGZ9/<-X9L(+F=WN8O*D/D [E"GN2,#U)%<;ISCNC=23V9\&_\%)/B!>?%#X[
M>&_ACH6Z[.D^7 8(S_K;^Z*X7CKA#$!Z%W%5O^";/Q(N_AA\=]=^'&MEK1-;
M$EL;>4X\K4+8L0OL2OG*?4A!Z5R_[&-UIOQ*_:NOOB%X[UK3=,CLI+C6W?4[
MN.%);N1B(D3>1G:7+C'3RA53]M)M.^'/[5,7COP)KFFZA'?26^NPS:9=1SI!
M>(X\Q6V,>2Z"0@]?,KTN56]AY?B<M]><_7VO!_VQ/VD+;]G/X6S7MK)')XKU
M3=:Z/;-@_O,?-.R]TC!!]R57^*O0-%^,'AS5/@_9_$BXO(['PY-I:ZI+-(V?
M)0IN9#CJRG*X')88'-? 7PC\-ZM_P4 _:;U#Q[XHMI(_AYX?D58K"7F,QJ28
M+3T);F24CU(XW+CAIPU<I[(Z)2Z+=GAO['\FH3_M?>!)]5-P^HW&IO//)=9\
MUW>&1R[9Y);=G)ZYS7[3U^5'A]5C_P""H+JJA57Q1< *HP /*?BOL3]N/]II
M/V?_ (:-9:1<*OC374>#3E4Y:UCZ27)'^SG"YZL1U"M6]=.I.*75&=-\L7<^
M6O\ @HU^TI/X]\13?"SPK*]QHNBN9];FMLL)[E.?+./X(?XNV_K]P&O4?^"3
MO_)*_&O_ &&D_P#1"5Y_X4_9F?X3_L/_ !'\;^)+=CXS\2Z4DF)QF2SM&FC9
M8SGD.YP[]_N X*G/H'_!)W_DE?C7_L-)_P"B$JI\JHN,>@HWYTV>=?\ !6+Q
M2U]XZ\ ^%HB6:SL)[]HUY+&>41KQZ_Z.V/J:U+/_ ())M/#'YOQ56*XV*TL*
M^']WEL1G&?M7/?G'.*O?M>?L<_%GXY_M%3>(=$MM/7P[+':VEM?S7ZH;:-(U
M+NZ?>XD:0@(&/2O*OCY^Q5XW_9:\+Q?$K1?'LNKRVES&;ZZLXI+*YM9'<!9
MWF-O7>5!)(.6'!YQ49>Y&,9V8I+5MH_1+]G'X+_\,_\ PGTSP5_;']O?8I9Y
M?MWV7[-O\R5GQLWOC&['WN<5Z;7@'[$OQZOOV@/@G;ZKK15_$.EW+:9J$RJ%
M%PZJKK,%' W(ZYZ#<K8 &!7O]>?/F4GS;G1&UE8****@H**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** ,CQ?XHL? _A36?$6J.T>G:59S7UPRC+>7&
MA=L#N<#@=S7Y#V5OX^_X*%?M"7$;WOV*VP\Z^<6DMM'L58 *JCJW*CMO8Y)
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MD\-:MI/G?9_M]I-:^=MW;-Z%=V,C.,YQD5IT4I2E)\S>HTDE9'AG[)_[,?\
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MM.BBLBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[>7[=<P;(RQ;&(I%!Y)Y()KGOB1^Q;\(?BIK2:OK?A54U/"K)<V%S+;-.%
M\P(P#G QN(W>]+VE.4(PDGH'+)2<D?!7['FFZE\?_P!MJY\=FR\FPMK^\\0W
MHSE8/,+B&,'N=\B >R,>U?K+7)_#?X5>$OA#X?&B>#]#MM"TW=O:.#<S2-_>
M=V)=VQQEB3@8KK*RJU/:2NMBX1Y4%%%%8EA1110 4444 %%%8WC#Q?H_@'PU
M?^(-?O5TW1[%/,N;J1698UR!DA03U(Z"@#9HKP?_ (;H^!7_ $4*R_\  6Y_
M^-4?\-T? K_HH5E_X"W/_P :K3V<_P"5D\T>Y[Q17!_"[XZ>!?C3_:?_  A7
MB&'7O[-\K[7Y,4J>5YF_9G>JYSY;]/[M=Y4--.S*WV"BBBD 445YAXN_:8^&
M7@/QJ/".O>*[?3O$6Z)/L#P3,V9 #&,JA7D,._>FDY;(5[;GI]%%%(84455U
M/5+/1;&:]U"[@L+*$;I;BZD6.-!G&69B .3WH M4444 %%%% !1110 4444
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M9?\ @+<__&J/^&Z/@5_T4*R_\!;G_P"-4_9S_E8N:/<]XHKB/BA\9/"WP?\
M!8\3>(KUX[&5DBM(;>,RW%[,XS'##&.7=NP^I) !->11_M*_%ZZC_M:V_9L\
M0MX7(\T7$^NVD6I^5US]@(\S?_TSW9J5%L=T?2E%</\ "+XR>&OC9X;EUCPY
M/./L\[6E[I]]"8+NQN%^]#/$>4<?B#V)KN*35M&,****0!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7'_%7XL>&O@OX1D\2^*[R2QTB.9(&FB@>8[W.%&U 3VKL*^5/^"E__
M ":[??\ 85L__0C5TXJ4E%DR=DV:/_#QOX%?]#->_P#@IN?_ (BN@\/_ +=?
MP*\2ZE!86GQ M8;B8X4W]G<VD0/^U++$J+^+5\F?L$?LG?#;X[?!_6-?\8Z/
M<:AJ=OKLUC'+%?30 0K;V[@;48 _-(_/7FH_VY?V,OAS\$?A?!XL\)W%YI5]
M_:$=K_9UW>>='<(X;(0,-VY< _>(VALCH:Z_9T>?DUN8\T[<Q^EL,\=U#'-#
M(LL4BATD0@JRD9!!'4$5D>,O&V@_#W0+C6_$NKVFB:5!_K+J\E")D]%&>K'L
MHR3V%?./_!-?7]<U[]F>V&M2S3PV6J7%GILDY+$VJK&5 )ZJKM*H] N.U?%G
MQ>\:>)_VY?VI+;PKHU\1H7VZ2PTB,$FW@M8RQDNV7."S(K2$]2-J@\"LHT;S
M<6]$6ZEDGW/MJ\_X*2? ^UOGMTUK4[J-6V_:8=+E\L^XW -C\*]<^$O[0_P]
M^.$,C>#O$MKJEQ$"TMBP:&ZC4'&XQ. VW./F QSUKQ?P]_P31^#.EZ#'9ZE9
M:IK6H>6%DU*;4)(G+XY94C(4<] 0V/?K7S7K/["7Q?\ @S\>K/4_A(DNJ:59
M2)>V&LW-Y!;F($D-!."RES@%6VKAE8<#) ODHRNHNS\Q7FMT?HE\5?BQX:^"
M_A&3Q+XKO)+'2(YD@::*!YCO<X4;4!/:O%?^'C?P*_Z&:]_\%-S_ /$5D?\
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M?'?P%_9)UO0K[5X=?\4:!HVH-I=S9;VP%B=[>,;P"2APH&,8"CM7PY_P3Z^
MG@+]H+Q)XUF^("R:W=6$4$MOISWLL+3>:TGFSLT;*[%2J#[V,R<]14PIQM*4
MGHNPY2>B6[/TC^%GQ\^'_P :X;A_!7B>SUM[<9FMU#PSQK_>,4BJX7/&[;C/
M>NXOKZVTNRGO+RXBM+2W1I9KB=PD<:*,LS,>  !DDU^3=GX8M/@5_P %#M%\
M._#>ZGN--AUVSM##',92D,RQ_:H&;^((KR [LD;>>5)KWC_@JQ\3KW1O"/A+
MP193M##K$LM]?JAQOCAV"-#ZJ7=FQZQK5.BN>,8O1B]I[K;Z'NK?MY? I=:_
MLS_A/;?SL[?/%E<FWW>GF^7M_'./>O=M/U"UU:QM[VQN8;RSN$66&XMW#QR(
M1D,K#@@CN*_.NW_8'\'3?L;_ /"8XOO^$\;P]_PD2W7V@[,^3YXM_*^[@IA,
M]=W.>U=!_P $J/BE?ZIX=\7>!+R9I[?2VCU'3E=L^6DA994'HNX(P'J['O1.
ME#E<H/8(R=TI=3ZK^*O[3GPQ^"MXMEXO\66NFZBR;Q8Q1R7-QC&06CB5B@/8
MM@&D^%?[3WPP^-5\UAX0\6VNHZDJ>8;":.2VN",9)5)54OCN5R!7YJ?LF_#C
M1?VDOVG_ !!;?%>2>[NY(;O4)K":X>![N[$J*T192& 4,[;5(.(_0&G?M<?#
M70_V:_VEO#L'PIDGM+Q(;74(M/AN'N)+2[,K!8P22YW!4.UB2=_H0*T]A"_)
M?7\"?:2MS=#]>Z*;&S,BEEVL1RN<X]J=7 = 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5XK\3OVPOA?\(/&D
MGA3Q/K5S9:U&D<C0QV$TJXD *_,JD<@^M>U5^0__  44_P"3NK__ *];#_T6
MM=%&FJDK,SJ2<5='Z\5XO\6/VOOAA\$_%A\-^+=9N+'5O(2Y\F*PFF&Q\[3N
M12.QXKVBOR/_ ."G/_)S;?\ 8%M/YR4J--5)<K"I)Q5T?IW\4_C#X7^#/@]?
M%'BJ]DL=&::. 31V[S-O<$J-J@GL:\:_X>-_ K_H9KW_ ,%-S_\ $5SO_!2;
M_DU.#_L*6/\ Z"]>$_L-?L>_#KX]_!Z_\1^++;4)M3AUF:R1K6\,*>6L4+ 8
M ZYD;FM(4Z?L^>=R92ES<J/LGP+^V9\&?B-KD&CZ'XZLY-2N"J16][;SV?F,
M3@(K31HK,3P%!))Z5Z5X]\=:/\-/!^I^)]?N&M='TV/S;F:.-I"J[@N0J@D\
MD=*_+#]NW]DOPW^SC-X;U?PIJ-VVG:Q)-"VGWT@DD@>-4.Y' !93N.<\@XY.
M<#Z3N/'>I_$?_@E[?:UK-P]WJ9TB2TFN)"2\OD7GDJS$\LQ6-22>2<FG*C&T
M91>C8*;U3W1](?!?]HGP-\?X]7D\%:E-J*Z48ENO.M)(-ADW[,;U&<^6W3TK
MI_B'\1/#WPJ\)7WB7Q1J4>EZ/9J#)-("22>%15'+,3P% R:^ O\ @E_XNT?P
M%X(^,/B#7[^+3=(T_P#LZ:XNICA44"Y_,DX  Y)( Y->4?%CXG>._P#@H!\;
M+'PSX6LYH/#\$K?V=I\AQ%;1#A[RZ89 ;!YZXR$7)/S'L/WC71"]I[J?5GZ'
M?"O]K_X:_&CQ2GA[PAJ&H:KJ1C:9U&EW"1Q1KU=W9 JC.!DGDD <D5[57E7[
M.O[._AS]G+P+%H6BH+J_FVRZEJTB!9;R8#J?1!DA4SA0>Y))^5/VJ?VIOB7X
MV^)VM? WX6Z!/;Z@LGV.ZU"TD+W4ZLBEMAP%MXP'PSDDXYW+62@JDK0V\R^;
ME5Y'U)X&_:K^&OQ(^)%WX&\.ZX^H^(+8SAXTM91"?*.'*RE=K#/0@X/;-=U\
M0?'VB_"_P;J?BCQ#</::-IR+)<S1Q-(RAG5!A5!)Y8=!7Y8_\$X;&72_VLHK
M*< 3V^GWT,@4Y&Y0 <'ZBOT>_:@_X13_ (4/XN_X3C^T?^$5\B/[=_9.W[3M
M\Z/;LW<9W;>O;-54IQA445L*,G*+9>^#?Q\\&?'S3=1O_!FHS:C:Z?,L%PTU
MK) 5=EW  .!GCTKT2OEK]@G_ (53_P (CXI_X53_ ,)%_9_VZ+[;_P )#Y?F
M>;Y?R[-G;'K7U+652*C)I%Q=U=A1116904444 %%%% !7R/^TY^WU_PSC\3C
MX0_X07_A(<64-Y]L_M?[+]\M\NSR'Z;>N>_2OKBBKBXI^\KDN[6C/SM_X>Z?
M]4H_\N/_ .Y*/^'NG_5*/_+C_P#N2OT2HK;VE+^3\2.6?\Q^=O\ P]T_ZI1_
MY<?_ -R4?\/=/^J4?^7'_P#<E?HE11[2E_)^(<L_YC\[?^'NG_5*/_+C_P#N
M2C_A[I_U2C_RX_\ [DK]$J*/:4OY/Q#EG_,?G;_P]T_ZI1_Y<?\ ]R4?\/=/
M^J4?^7'_ /<E?HE11[2E_)^(<L_YC\[?^'NG_5*/_+C_ /N2C_A[I_U2C_RX
M_P#[DK]$J*/:4OY/Q#EG_,?G;_P]T_ZI1_Y<?_W)1_P]T_ZI1_Y<?_W)7Z)4
M4>TI?R?B'+/^8_.W_A[I_P!4H_\ +C_^Y*/^'NG_ %2C_P N/_[DK]$J*/:4
MOY/Q#EG_ #'YV_\ #W3_ *I1_P"7'_\ <E'_  ]T_P"J4?\ EQ__ ')7Z)44
M>TI?R?B'+/\ F/SM_P"'NG_5*/\ RX__ +DH_P"'NG_5*/\ RX__ +DK]$J*
M/:4OY/Q#EG_,?G;_ ,/=/^J4?^7'_P#<E'_#W3_JE'_EQ_\ W)7Z)44>TI?R
M?B'+/^8_.W_A[I_U2C_RX_\ [DH_X>Z?]4H_\N/_ .Y*_1*BCVE+^3\0Y9_S
M'YV_\/=/^J4?^7'_ /<E'_#W3_JE'_EQ_P#W)7Z)44>TI?R?B'+/^8_.W_A[
MI_U2C_RX_P#[DH_X>Z?]4H_\N/\ ^Y*_1*BCVE+^3\0Y9_S'YV_\/=/^J4?^
M7'_]R4?\/=/^J4?^7'_]R5^B5%'M*7\GXARS_F/SM_X>Z?\ 5*/_ "X__N2C
M_A[I_P!4H_\ +C_^Y*_1*BCVE+^3\0Y9_P Q^=O_  ]T_P"J4?\ EQ__ ')1
M_P /=/\ JE'_ )<?_P!R5^B5%'M*7\GXARS_ )C\[?\ A[I_U2C_ ,N/_P"Y
M*/\ A[I_U2C_ ,N/_P"Y*_1*BCVE+^3\0Y9_S'YV_P##W3_JE'_EQ_\ W)1_
MP]T_ZI1_Y<?_ -R5^B5%'M*7\GXARS_F/SM_X>Z?]4H_\N/_ .Y*/^'NG_5*
M/_+C_P#N2OT2HH]I2_D_$.6?\Q^=O_#W3_JE'_EQ_P#W)1_P]T_ZI1_Y<?\
M]R5^B5%'M*7\GXARS_F/SM_X>Z?]4H_\N/\ ^Y*/^'NG_5*/_+C_ /N2OT2H
MH]I2_D_$.6?\Q^=O_#W3_JE'_EQ__<E'_#W3_JE'_EQ__<E?HE11[2E_)^(<
ML_YC\[?^'NG_ %2C_P N/_[DH_X>Z?\ 5*/_ "X__N2OT2HH]I2_D_$.6?\
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M_P"J4?\ EQ__ ')1_P /=/\ JE'_ )<?_P!R5^B5%'M*7\GXARS_ )C\[?\
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MXCB<'!4R !20?[I.*]Q\6: ?%7A?5M&^WW>E?VA:R6IO;!E6>$.I4M&64@,
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MO9U_:ZT(6V/L[07X?;T\O[/(1^H6JA)U:<E/H*24)*QWO_!5[_DLGA#_ +
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M%O<:>M];S)<VCQ>='-"P=9$(R&4@X((Z&G*$H?$@4E+8LT5\9?\ #U?X3?\
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M/_&3X5#2-)T*U\*W_AE8[6YT>QR;=4;<8Y8BQ+%6*OG<2VX-DG()^5/VC/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5^07_!1Z-IOVL-5C0[7:RL5!]"8A7Z^U^0__  44_P"3
MNK__ *];#_T6M=F%^/Y&%;X3T3_AW?\ M#?]%)T7_P 'NH__ "/7R]^T3\)O
M%GP7^(A\.^,]8M]<UD6D5Q]JM;J:X3RV+;5WRHK9&#QC'-?NK7Y'_P#!3G_D
MYMO^P+:?SDK:A6E.=F14@HJZ/K3_ (*3?\FIP?\ 84L?_07KXP_9Q^(O[1?A
M7X?7=C\)M)U*\\-O?R223V>BQWBK<F.,,-[(W(41G'3IQS7V?_P4F_Y-3@_[
M"EC_ .@O5;_@EE_R;EJO_8R7/_I/;5$)<M&[5]1M7G8^6KS]G/\ :8_:H\96
M%UX[M-1MDB'E?VCKZ1VD%I&6^8I @7DXSA$R<#)Z&OL_]H'X;:7\'_V$?$_@
M[1R[:?I.D+"DDF-TC&=&>1L<99V9CCNU?3=>(?ML_P#)J_Q%_P"P>O\ Z.CK
M+VKJ2BME<TY%%-GY%?"+P3XT^+VMQ?#SPEYTZ:K<1W-S;[BMNOE!@)YB!PL8
MD?D_WL $D ^N_!_QMK_["7[3U_H_B)6?2TF&G:PD:G;<6C$-'<QCO@%9%[X+
M+QDU[W_P2/AC-K\3YC&IE#Z<@DVC<%(N21GTR!^5=S_P4I_9W_X3[P!'\1-&
MM=VO>&XB+Y8U^:XL,Y8^YB)+_P"ZTGH!79*JG4=*6QA&+Y>9;GV7I^H6VK:?
M;7UE/'=6=U$LT$\+!DDC8!E92.H(((/O573?#>DZ-?7][8:99V5YJ$GG7EQ;
MP*DER^,!I& RYP ,G/ KX3_X)G_M,?VMIK?";Q%=YO+-&GT&:9N9(1\TEMD]
MTY91_=W#@(*^_J\VI!TY.+.J,E)7/RA_8'_Y/5U#_KEJG_H1K[F_;H_Y-/\
MB%_UZP_^E,5?#/[ _P#R>KJ'_7+5/_0C7W-^W1_R:?\ $+_KUA_]*8JZZO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!XQ^V5_
MR:[\1_\ L%M_Z$M?*G_!(O\ YJO_ -PG_P!O*^_O$WAG2_&6@WNB:W91:EI5
M['Y5Q:S#*2KUP?RKG_AS\&?!/PC_ +0_X0[PY9>'_P"T/+^U?8U(\[R]VS.2
M>F]_^^C6\:B5-P[F;BW)2.-_;'N-?M?V9?'\OAEIX]66P!WVQ(D6#S4^T$$<
M_P"I\W\*_/?]AOQQ\!/!5MK]Q\6+*S?7UF633[K5-.>^MQ"%Y5$5'"R;LG)7
M/W<'M7ZVLH=2K ,I&"",@UXUJ'[&WP5U37FUBX^'>D&]9B[",/'"23DDPJPC
M/_?-53J1C!PEU["E%MIH_,/XA?%+1OB1^V)I?C32K!M'\,RZYIILTDC$0^S0
M/%%YFT8 #>4S8'3..H-?3/\ P5P_Y!WPO_ZZZE_*VK["\8?LX_#+Q]<6,^O^
M"=(U&2QM5LK7=!L$,"DE8U"X 4%FP.V36G\0/@SX)^*UOIL/B[PY9Z_%IV_[
M(MX&;RMP4-CGOL7\JT]M'FBTMB?9NS7<YK]DR$0_LT?#10<YT*V;\T!_K7YX
M_MJ?\GY)_P!?6C_^@0U^J_A_P_IWA70['1](M([#3+&%;>VM8AA(HU&%4>P%
M<7XH_9Z^''C3Q</%&N>$-.U+Q!NC;^T)U8R9C "'KV"C'TK.G54)N3ZE2BY1
M2/E3_@K#<:_'X \#QV;3KX;DO[@:B(R1&TX1#;A\<=!.1GN/:N._9Y^/_P"S
M7\'_ (&Z=J,NB6MS\1K2U/VFWN-+::]NKOD_N[AD9$C8],, HQD9X/Z&^)/#
M.D^,-%NM'US3;75]+NEV36=Y$LL3CW4C'7D'L:\U\(?LD_"#P)K\>M:+X"TN
MVU..02Q3R[Y_*<=&19&8(1VV@8//6G&K'V?)),'%\W,C\]/^":%X+7]J6>*[
M'V>ZN-(O(A$PVGS \;E<'G("-Q[5+_P4NM9]$_:CL]2:)TCGTFSN8I,<-L>1
M3CMP4Z5^D6G?L_\ PZTCQXWC2R\):?:^*FN);MM4B5EF,L@82/G.,MO;/'.X
MU:^)WP3\#?&:SM[;QIX;L]>2V+&"28,DL6>H21"'4' R <' ]*OVZ]ISVZ$^
MS?+RGQY^UM^TE8?M ?LIZ_?_  VEU0:=I^LV=MKIF@,+?99(Y" 0"<H9?*!S
MQVY%>;?L9_%;]G'X;?#*>[\=Z=:'QY;W$LKS:AI3WTDJ9_="V.QE3C /*G.2
M3CFOT*\"_ _P%\-=#U'1_#?A73M,TS40%O;98O,6Y ! $F\G>,,1@YZGUKD=
M/_8U^"NEZZ-7M_AWI O P<"0/)""#D$0LQC'/HM)58*+A9V'RROS'YO?L[^-
M8/%/[>NA^*)+0Z1;ZUX@NKN&TDX,2W"2F).V?]8@R.#GBNI_X*F_\G&Z5_V+
M=M_Z47-?HYK7[/?PY\0^-(_%VH>$-.N?$L<L,Z:F4*RK)"%$3 @CE0B8_P!T
M4OC[]GWX=?%+6H]7\6>$M/UW4XX%MDN;I6+B-2S!>". 68_C5?6(\ZE;H3[-
M\K1E_M&?\FP_$3_L5KW_ -)FKY#_ ."1?_-5_P#N$_\ MY7Z!:UX?T[Q%H-[
MHNI6D=YI5Y;M:W%K(/DDB9=K(?8@D5S?PY^#/@GX1_VA_P (=X<LO#_]H>7]
MJ^QJ1YWE[MF<D]-[_P#?1K"-1*G*'<T<?>3/S,_X*3_\G66__8+L?_0GKM/^
M"L5QK_\ PL'P5#*TX\+'2W>V7)\HW@E<3'TW",P>^#[U]W^./V>OAQ\2?$"Z
MYXG\(:=K.KK&L0N[E6+[5)*C@]LFNC\<?#_PW\2M#?1O%.B6>NZ8S!_L][$'
M"L.C*>JM[@@\UJJZ7)IL0Z;=_,^!M2^/W[.'@[]G&_TCX>Z!;3>-M8T:32H[
M0:2_V]9Y8C$SS7+)\VTN6^5SGHN.U#_@DK>0Q^+OB):,X%Q+8VDJ)W*I)(&/
MX%U_.OMKX=_LQ_"WX4ZM_:GA;P7IVF:D-VV\8//-'NZ['D9BOI\I'''2KW@3
M]G_X=_#'7I=:\*^$M/T+5)86MWN;-65FC9@S(><8)53CV%*56'+**OJ-0=TV
M?D_XV\8:E\._VW/%OBK2M/DU2YT3Q;?:@]K&I)DACGD:8$@':/+#Y;'RC)[5
M]1_M(_\ !1#P!XV^!6MZ!X034KC7_$%FUC)#>6IB6SCD&V4NV<,=A8 (2,D$
M\"OK_3?@'\/=(\<W'C*S\)Z?!XGN)9II=35"97>8,)2<G'S!V!X[FN8?]C?X
M*R>(6UIOAWHYOF?>5VOY&<YSY&[RO_':IUJ<FG);"4)*Z3/!/^"67PJU+PK\
M._$OC+4K=K:+Q)/!%8+(N&>"#S,RC_99Y"!Z^7GH17W#3(88[>%(HD6**-0J
M(@ 50!@  =!3ZYJDW4DY,UC'E5@HHHK,H**** "BBB@ HHHH **** "BBB@
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M^"B7PX^+?C_1?"&CZ)XIMM2U:8PP2WUI;)"K!2V6*W#$#"GH#7R]_P %7O\
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M5T9RB[\T3\Y_VO/VPKC]JJ\T#P?X+T34;71(;Q9H89U!O+^[(*1_)&6"A=[
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O*?VK/\ DVOXF?\
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MQ<TOQ'H?[$_BK3O%U[;ZEXEL_"D]O?7MH[O'/(D)7S SJK$L "20.2:^(O\
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M/7]L]L+>8O 'MY%AM%?R]N2Q!8YP6(!)" UE1ARKVEK]BZDKOE.Q_P""1_\
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M\>INC-[O\0YX]C[H\<?"OP=\3(8H_%?A?2?$(A!$3:A9I*\0/78Q&5_ BHO
MOPA\$?#'S#X3\)Z1X?EE01RS6%FD<LBCH'D W,._)-?#G_#9/[6?_1#?_+1U
M;_X]1_PV3^UG_P!$-_\ +1U;_P"/4>QG:U_Q#GCO8_1*BOSM_P"&R?VL_P#H
MAO\ Y:.K?_'J/^&R?VL_^B&_^6CJW_QZE["7=?>'M$?HE17YV_\ #9/[6?\
MT0W_ ,M'5O\ X]1_PV3^UG_T0W_RT=6_^/4>PEW7WA[1'Z)45^=O_#9/[6?_
M $0W_P M'5O_ (]1_P -D_M9_P#1#?\ RT=6_P#CU'L)=U]X>T1^B5%?G;_P
MV3^UG_T0W_RT=6_^/4?\-D_M9_\ 1#?_ "T=6_\ CU'L)=U]X>T1^B5%?G;_
M ,-D_M9_]$-_\M'5O_CU'_#9/[6?_1#?_+1U;_X]1["7=?>'M$?HE17YV_\
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M#?\ RT=6_P#CU'L)=U]X>T1^B5%?G;_PV3^UG_T0W_RT=6_^/4?\-D_M9_\
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M < XKN:522G-R0XKE5F?G'^W5$L_[;WP?C<;D:+2P1[?VC+7E?[<\.K?!O\
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M4KXI_!3P1\;-+M]/\:^';;7;>V<O TC/'+"3C=LEC974' R P!P,YP*XJ?\
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M'Q L?VHOBO;V,]CX9U'1-6AM_,&U7DGE\X(!W*(HSCIO'K7TQ_P3355_97U
MA0"VKWI) Z_NHJ^G;SX;>&+SP'<^"CHMK;^%;BU>RDTNS4VT7DL"&1?+*E<Y
M/*D'G-5/AI\(_"?P?\*R>&_".D_V3HLDSSM:_:9ILNX 8[I'9N0HXSCBB=92
MBU8(PY7<^+/^"3?_ !Y_$_\ Z^;'^4]5?V*SM_;D^-Q SSJ7'_<02OLSX3?
M/P'\#4U1/!&A?V(NILCW8^V3W'F%-VT_O9&QC<W3'6F^"?V?_ /P[\=:WXQ\
M/:#_ &?XCUKS#?WOVRXE\[S)!(_R/(47+@'Y5&.@XHE5BW)]Q*#27D?"?PJ^
M-R?M&?$CQM)\8OBWJOP[T73>;#PWI^KC2;::/>XDA=L RE J#:?G8L2. 157
M_@GI=:%<?MC>/I?#2M#X>ETW4#ID<KNS_9_MD!C!+DL3LQ]XD^M?:WBO]CWX
M.>-O&$OBC6? MC=:U-+Y\TRS311S29R7DB1Q&Y)Y)93NSSFMK0/V<OAUX5^(
MS>.M&\-1Z5XG:$6YN;.ZGBB\H1K&$\A7$6W:JC&S'R@]1FJ=:'*TEN)0E=-D
MOA']H+P#X\^(FM>!M"U[[=XIT;SOMUA]CN(_)\J01R?O'C"-AV ^5CG.1D5Z
M)7S#\&/@O<:7^UA\1?B';^$)O!^A26TVF1M=732R:S=27(EGO55F;RXSL4*!
M@$$$#J!]/5SS23]TUBVUJ?FI^TQXE/[._P#P4&T3XCZM87=SH=U!#<DP*,O'
M]F-K*(R>&9!\VW(ZCD9!KTW]IK]O+X2>*/@9XJT#POKEQK^M:U8R6$5K'I]Q
M (O,7:SNTJ(N%!/W223CC'-?7'C[X:^%OBEH9TCQ;H-EKVG[MZQ7D08QMC&Y
M&^\C8R-RD'!->6Z%^PO\"O#NJ1:A:?#VSEGC.56^N[F[A_&*:5D/XK6ZJ4VH
MN2=T9\LE>W4\C_95^">H^*OV ]5\+72-8W?BJ*]NK/SLKC?@0.>.%8QJW?*M
MGO7D7[$?[5FA?LVZ=XA^&?Q0BO/#;6NI2W$=VUJ\OD2[526"5(U+@Y0$, P.
MXYP ,_I?'&L,:HBA$4;551@ #H *\X^*7[./PU^-$\=QXR\(V.KWD8"K> O;
MW&T=%,L3*Y4?W2<5*JJ7,IK1CY&K<O0^3OBW^W]KGCCXH>$O"?[/X_MJ6><Q
MW$U]IY\F^=\;55'"R)&@#,SG9W/W5R?O:W$JP1B=D:;:-[1J54MCD@$G S[F
MO/OA;^SO\.?@JTTG@SPI9:-<S#:]WEY[@J>J^;*S.%_V0V/:O1:SJ2B[*"*B
MGNPHHHK(L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "N"^-WQ$UOX6^ +K7_  _X
M-O\ QYJ4,T4::+II<32*S89ALCD.%')^7\J[VBFM]1'QE_PW-\6?^C6/&?\
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M11SP_D_%ARR[GQE_PW-\6?\ HUCQG_WW=_\ R!1_PW-\6?\ HUCQG_WW=_\
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M?_R!1_PW-\6?^C6/&?\ WW=__(%?9M%'/#^3\6'++N?&7_#<WQ9_Z-8\9_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#!4SQUXHTB32_"_@_3]"U.Z!B2\\][R5,\ QIM4;_3(8>U?I;_ ,(WI/\
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MKP@?#]OJQ6&ZAL[E[^\O!D$1)MC3"DCD!22.,XR#]9_\$_\ ]F;4/@3X O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9P<.^ ?[57@']HV*[3PM=W4&IV:^9/I6IPB*Y2/(&_"LRLN2!E6."1G&1GY
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M.&+[")(HR\B;_,WDKM93\F-P/;FJ/[9'QZG^#/PXBT_0!)<>.O$\O]EZ';0
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M/$T]M=(T=K? R02W,Q=W>1",.%55"H<J W(X6OIWXY?L!_#7XNV^F'2-.L_
M%[:39EN- T^.);B'!W1M&NU-V<$/@D8(Y!KHE"E!\DKW[F:<Y+F1],T5D^$_
M#X\*>%])T47MUJ2Z?:QVHO+Y@T\P10H=R  6..2 *UJY#8**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "OF[]L;Q1\</#?_"(_P#"F=.FO_.^V?VKY-E#<;,>
M1Y&?,'RYS-TZX]J^D:*J,N5WM<35U8_-S_A:/[</_0NWO_@EM/\ "C_A:/[<
M/_0NWO\ X);3_"OT<O+V#3[=I[F9((EZNYP*YR3XF:%'(5$TK@?Q+$<'\ZW]
MO'^5$>S?=GP-_P +1_;A_P"A=O?_  2VG^%'_"T?VX?^A=O?_!+:?X5^B>DZ
M]8:Y&7LKE)]OWE'##Z@\UH4>V7\B%[-]V?FY_P +1_;A_P"A=O?_  2VG^%'
M_"T?VX?^A=O?_!+:?X5^D=%'ME_(@Y'W9^;G_"T?VX?^A=O?_!+:?X4?\+1_
M;A_Z%V]_\$MI_A7Z1T4>V7\B#D?=GYN?\+1_;A_Z%V]_\$MI_A1_PM']N'_H
M7;W_ ,$MI_A7Z1T4>V7\B#D?=GYN?\+1_;A_Z%V]_P#!+:?X4?\ "T?VX?\
MH7;W_P $MI_A7Z1T4>V7\B#D?=GYN?\ "T?VX?\ H7;W_P $MI_A1_PM']N'
M_H7;W_P2VG^%?I'11[9?R(.1]V?FY_PM']N'_H7;W_P2VG^%'_"T?VX?^A=O
M?_!+:?X5^D=%'ME_(@Y'W9^;G_"T?VX?^A=O?_!+:?X4?\+1_;A_Z%V]_P#!
M+:?X5^D=%'ME_(@Y'W9^;G_"T?VX?^A=O?\ P2VG^%'_  M']N'_ *%V]_\
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M_P#!+:?X4?\ "T?VX?\ H7;W_P $MI_A7Z1T4>V7\B#D?=GYN?\ "T?VX?\
MH7;W_P $MI_A1_PM']N'_H7;W_P2VG^%?I'11[9?R(.1]V?FY_PM']N'_H7;
MW_P2VG^%'_"T?VX?^A=O?_!+:?X5^D=%'ME_(@Y'W9^;G_"T?VX?^A=O?_!+
M:?X4?\+1_;A_Z%V]_P#!+:?X5^D=%'ME_(@Y'W9^;G_"T?VX?^A=O?\ P2VG
M^%'_  M']N'_ *%V]_\ !+:?X5^D=%'ME_(@Y'W9^;G_  M']N'_ *%V]_\
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M7;W_ ,$MI_A7Z1T4>V7\B#D?=GYN?\+1_;A_Z%V]_P#!+:?X4?\ "T?VX?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M ,T@4;@"<]*^[/BG\$? WQLTVWL?&OARUUV&V8M \A>*:'.,A)8V5U!P,@,
M<#.<"CX7?!+P-\%M/GLO!7ANST**X(,\D6Z2:;&=H>5RSL!DX!8@9..M'MHV
MO;WK6#D=_(^0?VX/VPWL_%A^$7A77E\,H\B0>(?%&V1S9HV"T48B!?(4Y8J,
M\[1CDUU_[)_Q,_9H^%<6F^"O /BLZIXFUJ:.":_N-*O4N-1G/"AF:$*B D[5
MR%&<G))8^G^)/V&?@CXN\0:EK>K>"C>:IJ-Q)=W5P=6OE,DKL6=L+. ,DG@
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MU[0?A!JMC-Y]A>+>W4$VTKOC=+5E;! (R"#@C-?1O_#OGX _]"#_ .5G4/\
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MR9^^49=C*"#][J0 ?TA\ _#7PM\+=#&C^$M"LM T[=O:&SB"^8V -[M]YVP
M-S$G@<TWX@?#+PK\5-%.D>+=!L=>L,[ECO(@QC;IN1OO(V/XE(-:.LG)W6CT
M)]F[:;GR5^T1_P %(O!>F^ 9[;X5:U-K'BR[*K!>'3I(X;(!@69Q<1KO)7(
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#Y@_:/\ V'-"^,FJ3^(_#]XGAKQ/,=UR6C+6MXW]YU'*/ZLN<]P2<U\TQ_\
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M)^T)^S7X7_:.\&6NA^(&FM+NQ;S;#5+0+YULY ##D$,C8&Y3UP.00"/G\?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@A%!!^E2T5G*?-%1[%*-FV%%%%9E!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M?)G_  4X_P"39'_[#-I_*2OK.ODS_@IQ_P FR/\ ]AFT_E)6U'^)$B?PLS?^
M"67_ ";EJO\ V,ES_P"D]M71?\%)?^35]:_Z_P"R_P#1PKG?^"67_)N6J_\
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M(ZUXC\(7^K#7= M#?3&_G62.[BC&Z7("C8P7<PV\?+@CG(ZO_@EQ\7M5\8^
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M_'=K);,[+-:SM$=C. K,N1D;HVZ\U7U=7<4]?P%[1[M:'T9_P5I_Y$SX>?\
M80NO_1:5M?\ .*__ +@'_MW6)_P5ED67P3\.G1@Z-?W15E.008DYK;_YQ7_]
MP#_V[IQ_AP]1/XI>AB_\$EO^1,^(?_80M?\ T6]?:'CCXH>$/AG:QW'BOQ+I
M?AZ.7_5?VA=)$TG^XI.6_ &OB_\ X)+?\B9\0_\ L(6O_HMZD^-'[$Q\9?'&
M]\>_%;XI:79^#+N>1F26X%C/!;J#Y-O&TI:,*N5W'//S'&6J:D8RK2YG8<6U
M!6/JOP?^TE\+?'NJ1:;H/CS0]0U&5MD5HMVJ2RMZ(K8+'V&:])K\7_VM/!OP
M6\%:MH0^#WBB;6I2)1J4 F:>*$J4\IXYM@!)R^0&;[H/'?\ 5C]F[Q-?>,/@
M'X UG4YWNM0N]%MFN+B0Y>601@,['N21DGU-9U:2A%274J,W)M,](K\=;-?$
MG[>O[3TVEZSXF_L2VN)+E[*.Z!D2RM8R2L,,65#/M SR,D,Q-?L57YM?M._\
M$[O%UMXYU'QC\*=FH6=W<->G2%N1!=V<I.YC"[$*Z[LD?,&&0 &ZU6'E&+=W
M9BJ)NQD_'C_@F?<?#7X=ZAXH\)>*+OQ%=:7&)Y],FL0DLJ _.T3(QY4<[2.0
M#SG /O7_  3^^)WC>;X:^(]&^)EKJVGP^&@ES::MK\$T3/:,KLZM)*!N$6S.
M<\*X'0"OD/3?VI/VE/V=;N*S\1SZT;96"BS\86#S)+CL)G D(Q_=DQ7W1^S=
M^TMHG[9/PX\2Z#J%H^@Z\MF]GJEE;2ALPS(T?GP,P/'+#!!VG&<@@G6JI\GO
MZKN1#EYM-#Y2^*G[6^K>,OVPO#E@?&MNGPMT?Q+821&QF$=E)"DD3M-,X/[S
M!R<L2HV\ 5^A<GQN\ 0^#8O%DGC#1D\,S3_98]6:\3[.TO/R!\XW?*>/8U^1
M/B;X$Z!HW[84/PI@N]2;PZ_B"TTHW4DL9N_*E,89MP0)N&\X.S'3@U]:?MJ_
M!G1?@+^Q9IGA#P_=7]YIMOXDBF274I$>8M(L[,"41!C)XXIU*<'R174(RDKL
M^WO!_C;0/B!HRZOX;UBSUS3&=HQ=V,PEC++]X;AQD5AZM\;O &A>,!X4U'QA
MHUEXE::*W&E37B+<&24*8TV$YRP=,#ON%>%_\$T/^37;'_L*WG_H0KY+_:*_
MY296W_8R>'O_ $395A&BI3E"^QHYM13/U<FFCMX7EE=8HHU+.[D!5 &223T%
M><Z9^TG\*M9\0)HEC\1/#=UJ<CK''#%J41\UV. J-NVNQ/&U237RA_P50^+F
MK:!H/A?P%IER]I::P);[4FB<JTT:$+'$<=4+%F(/4HOIS'\%/^":?@OQ/\%]
M'U7Q3J6K)XHUJQCOEFLIE2*R\Q \:!"IW$!EW9/)SC'6E&G%04YO<')\UHH\
M4T'_ )2;2_\ 8YW/_H3U]'?MY_!#PG\4_'/AJ]\0_%;0?A_<6NG-#%::L@+S
MJ96/F+F1>,G'X5\??L^:'JGA?]N+PYHNMW3WVKZ;XEELKJZD<N99(F=&;<>3
MDKG)KU[_ (*Q?\E3\$_]@9__ $>U=DD_:Q2?0Q3]QW/T?\!V$.E^!O#ME;W<
M>H6]MIUM#'=P_<G58E D7D\,!D?6N9\7?M#?#+P'J[:5X@\=Z#I>IHXCDLYK
MY/.B8C(\Q 24XP<MCK7C7[1'QDU+X)_L6:'JNBRFVUK4=,T_2K.Z5L- \MN"
MTB_[01'*^AP>U?(/[*?P'^"_Q'\%ZEXF^+7Q(T_3-8O+J2.WTV?7[>SGC48S
M/()#O9F8G&>,#)W9XY(TE).<GH:N=FDC]4O#?BG1O&6DQZGH&K6.MZ;(2$O-
M.N4GB8CJ Z$C(JCXT^(GA?X<V$=[XI\0Z;X>M96V1RZE=)")&]%W$;C]*_+O
M]G[QL/V9OVQXO!WAKQ?#XH\!ZMJ<.F/<6=TD]K=1W"IY,N4)3S(VD0,R]-KC
M@$BLK]K;7+>^_;8U=?BBFK7'A2QNH8!:Z<P686 C#1B'=@88MN..I9^<\U:P
M_O6OI:XO::7/TL\+_M._"?QGJ4>G:/\ $#0;N^E;;%;F\6-Y&]%#XW'V&:]/
MK\O-8^ O[,_QPATJ#X5_$>W\#:SYVVXL_$+S?OE(/RJLY7,@.W&QR",]Z_17
MX2^#=3^'OPYT+PWK'B*7Q7?:;!]G;5YX?*DN%!.S<N]^0NU<EB3MR>36-2$8
M[?B7&3>YUU%%%8&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7YV_\%=/^:4?]Q;_VSK]$J_.W_@KI_P TH_[BW_MG73A_
MXJ,JGP,^F_V5]?LO"O['O@O6M3F^SZ=IN@M>7,V,[(H][NV/8 U^=_B3Q=\2
M_P#@H/\ &Y=$TZ8VVF O-9Z;-,5L],M5(!FDQG<_S*"V"26 &!@#ZMU6\GL?
M^"6*26^[S&\.PQ':<'8]RJ/^&UFK@?\ @DA8VKWOQ.O&VF]CCTZ%..5C8W);
M!]"47_OD5O'W%.IUN9OWN6(FJ?\ !).YC\/R/I_Q(CN-;6,LL-SI)BMY'QPI
M<2LRC/\ %M;_ ':\\_92_:*\9?LR_&9?ACXYN9_^$:.H?V7=V-W)YBZ9,6VK
M-"W.(\D$@?*5;<.<&OU<K\B?^"F%E;67[4-W-;%1-<Z59S7&T8(D 9!GWV(G
MZ44:CK-PGJ$XJ'O1/UVHK*\)W<^H>%M'NKK/VF:SADESR=Y0$_J36K7GG2?F
M1^W9^TUXH^)'Q4E^#O@6[N(=+@NDTN[CL7V2:G?,P1H688.Q6;9LZ%@Q.0%Q
ML:#_ ,$F+^Y\,QS:Q\08;'7Y(MQM+733-;Q/C[AD,BEQ_M!1]#W\6_928>(/
MV\-#GU8_O9M;U*ZD,G)\X17$BY]]X'XU^Q%>A4FZ*4(:'-&*J7E(_)S]G?Q%
M\6/V4_VC#\/YK+5-:TB&^CM]8T?38I;R PR[2MU"JJ2IVLK@@ D#:WH/UB)"
M@DG % 4+D@8)Y/O7P9_P5 ^/&L>$=-T+X=:'>2Z>-8MWOM5FA8J\EON*1P@@
M_=9ED+#OM4="0<&WB)I)69I_#BSZDU7]J'X2:'K1TJ]^(OAV"^5BCQF_C*HP
MZAG!VJ?J17H6BZ[IOB72[?4M(U"UU73KA=T-Y93+-#(.F5=201]#7P/\&?\
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MHOA7\?OA]\;([EO!7BBTUN2VYFMU5X9T7CYC%*JOMR<;MN,]Z^>?%W["E_\
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M>'O"K367A?Q!#'$+%IGEVQ7",HC+,2S!9HPP+$D8'7K3]C&UK^]:XN=W\C]
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MMO"Y'WPT\[#'W69$1<]@H-<[^T1\,-!_8[_:B^%/B+P##-HND7TJ&:R^TRS
M;95CG 9V9RKQR@;23SGZ C1BTDWJU<'-W\C].*\YM?VAOA[??%:3X:VWB..?
MQK&6#Z;';3L%*Q^8P,H3R\A>HW9!&.O%8?[5'QZM_P!G_P"%-[K$16?Q%?'[
M#HMEMWM/=,/E.WJ53[Q^@'5A7P+^R?X/\0>!_P!O/1M,\5S//XD:WGO=1:4[
MG$\]BT[JYSRP,F"?4&HITN:+DQRG9I(_5RN"^'_QV\"?%+Q)K^@^%=?CUC5-
M!?R]0BAMYE2([V3B1D".-RL,H6''I7D?[5VD_&SX@>)=#\"_#.<:#X9U*T9]
M<\0X$9@4N5V"4G=RHSMB&\YY(4FOG[_@EKI7]A?$SXK:;YOG_8XH+?S=NW?L
MFE7=C)QG'3-"IKV;FWJ-R?,D?HU117A'[6%Y\8)]"T#0?@_ L>J:Q<R0W^J,
MJC[# %'S^8_RQYR><%^/D&16,5S.Q;=E<[K2OCMX$USXHW_PZL-?CN_&-A&T
MMSIT=O,1&JA2V9=GEY&]<J&R"<8R#4/Q:_: \!? M=+/CC7O[$&J&1;3_0[B
MX\TQ[=_^JC?&-Z]<=>*^!_V*/!-[\-_VZO$WAK4=3.LZAIUA>Q7.H$,#/+NB
M9W^8DG))Y)R>M=E_P5J_U/PM_P"NNH?RMJZ?8Q]HH7T9ESOE<C]!T<2(K*<J
MPR#3JAL_^/2#_<7^535R&QSWC_Q_H/PO\(W_ (G\3W_]F:'8A#<77DR2[-SJ
MB_+&K,<LRC@'K7B__#P;X _]#]_Y1M0_^1ZF_;\_Y-*\>?[EI_Z60U\5_L]_
M\,A_\*CT3_A:7_(\9G^W_P#(7_Y[/Y7_ ![_ +O_ %>S[OX\YKJITXRAS._R
M,92:E9'W]\+?VJOA;\:/$DF@^#?%']LZM';M=-;_ -GW4&(U*AFW2Q*O5EXS
MGFM3XI?M#?#GX+/%%XS\66.C74JATLR'FN2A) ?R8E9]N5(W;<9!YKR']E/0
M_P!FB\\7ZKJOP5@WZ[96GE7<V_4QLAD8<8NCM.6C'09&/>OB?Q[-X2\+_ME>
M/9?CWH6N:YH\][.UO'9S,C>6T@^S2'#HS1"$  (P(P!@XQ3C2C*36NGW@YM(
M_2SX8_M-?##XR7YL/"'C&QU74-I863K);7# =2L<JHS 8YP#BO3Z_.?PK^SW
M\!OC%\0_#^N_ OXHKX&U?2Y$N#HLT$\\\DJ,KAXUN98Y.!PVTNIXZ8.?T7^O
M6LJD8Q?N_B7%M[@S!%+,0JJ,DG@"O"]<_;C^!GAW6'TR[^(5C)<JP4M96UQ=
MPY/_ $UBC:,_]]<5/^VII_B#5/V8_'5OX92XDU)K1"\=IGS'MQ*AG4 <D>5O
MR!U&17YZ?LY:M^RM<>"X-,^*FAZQ;>*1YAGUF2:[:U;+'8(UMGR"%V\-&>>Y
M[:4Z2E%R=_D3*33LC]7/!?CKP]\1M!AUKPQK-GKFERG:MU92B10PZJ<?=89&
M5.".XJMX^^)GA7X6:+_:WBW7K'0+ G:DEY*%,C==J+]YVQSA037SS^Q5^SUH
M?PEOO$/B'P5\4H?'/@_6D$:6-O;J! ZOF-GD65@9%0LI^1"<YP.E?,OAWPK+
M^WC^V9XI7Q/J%W%X2T$3&.U@<*PM8I1%%"F?N%V;>S $_>Z$@A*G%R>NB!R=
MEIJS[<\&_MG?!;Q]K4>DZ/X^L&OY&"QQWT,]D)&)P%5IXT5F).  237I/C_Q
M_H/PO\(W_B?Q/?\ ]F:'8A#<77DR2[-SJB_+&K,<LRC@'K7RO\:/^":'P]\3
M>$3'\.K,>$/$D4BM%-<7US<6TRY 99!(TA'RY(*8Y SQ5_\ :1\$ZW\.?^"?
M>N^&O$.O_P#"3:IIMI:0/J7E&,R*+V'8IRS$[5PNXG)VYP*7+3DURO=CO))W
M1]+_  ]^(?A_XJ^$;'Q/X6U#^U-#O=XM[KR9(=^QV1OED56&&5AR.U='7SG_
M ,$]_P#DTGP3_O7O_I9/7OVNZM%H&AZAJ<X8P65O)<R!1R512QQ^ K*4>63B
MBHNZ3.6^)GQL\"_!NSBN?&?B:QT)9@3%#.Y::4#J4B0%V [D*<5SOPW_ &KO
MA+\6M672_"_C:QOM3<[8[.XCEM)ICC.(TG1#(< \*#TKX/\ V5_@[%^W!\7?
M&_Q ^)=U=7^FV<T;'3X9C&)GD+^7#N4[DBC1,87!.5^;@Y]P^-/_  3-\+ZW
M_8]Y\*K@>!M3MKE3<?:;NXN(FCZ^8A9G<2JP7&& //0X-=#ITXOED]?P,^:3
MU2T/MFBLGPGINHZ/X7TFPU?4AK.J6MK'#=:@(O*^TR*H#2;,G;N()QD]:UJY
M#8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHKYY_;M^)/B7X4_ &[U_PIJLFCZNFH6T*W
M42(Y",Q###@CGZ548\S44)NRN?0U%?D]\-/BQ^U]\8M!GUGP=K.JZYID%RUG
M)<11V"!9E5'*8=0?NR(>F.:M>*_V@/VN/V?[BQU;QK+?1:;-((U75;"UGM)F
MY/EM)$ORL0"<!U8@'' KI^KN]N97,O:+>Q^J]%>6?LT_'2S_ &B/A1I_BVVM
M?L%T9&M+^SSN$%R@&]5/=2&5AWPPSSFOGS]L[]O:7X/ZU/X'\!1VUYXIB5?M
MVJ3 2PV#'D1*G1Y<8)S\JY ()R%QC3E*7(EJ:.22N?:U%?E9I=G^VMXZL$\2
M6=QXK%M(HG3=>6]CO5N05MV9"0>P"=,=JWO@/_P4"^('P]^(4/@_XR+)=Z=]
MI^R7=U?6@M[_ $US@!G "AD!.6#+NP<@G&#J\/*WNM,S]HNJ/TUHKYY_;L^)
M7B3X5_ "Z\0>$]5DT?5EU"VB6ZB1'.QF.X88$<_2OB3X:?%C]K[XQ:#/K/@[
M6=5US3(+EK.2XBCL$"S*J.4PZ@_=D0],<U,*+G'FNDBI347:Q^L-%?E1XK_:
M _:X_9_N+'5O&LM]%ILT@C5=5L+6>TF;D^6TD2_*Q )P'5B <<"OT$_9I^.E
MG^T1\*-/\6VUK]@NC(UI?V>=P@N4 WJI[J0RL.^&&><TIT907->Z",U)V/4Z
M**\B_:A_:"LOV;_A=/XFGM!J.HSS+9:=8L^T37#*S L>H155F./0#@D5C%.3
MLBV[*[/7:*_+#3_C)^V'X_\ "=Y\3=$N+Y?"L FF$EG:V*PK&A^<QP2 R2JN
M"-VU_NMSP:^I_P!AO]KR\_:.T?5-&\26T%OXMT>-)9)K52L5Y QV^9M_A<-@
M,!Q\P(QT&\J,HJ][V(51-V/JBBOC']N3]M'6O@OK5GX#\!QQGQ9=0I<7.H21
M";[(KDB...,@AI&QGY@0 1P2WR^":C^TQ^U)^S;K6B:K\2H9[W1=3<R"PU2"
MU\NX4 ;D$D W0N <A21CJ5(!%.-"4E?N)U$G8_4FBN'\,_%_0/%'P?M_B1;R
MNGAZ32WU60D9>*-$+2J1_>0JZGW4U^?6G_M/?M)_M6>.-7MOA4/[$T>R E-I
M:+;(MO&2PC,UQ,,EVP?E4@'!(7 )J(4I2OTL5*:1^GM%?GK^SG^V9\4/#/QT
MMOA3\9XOM-Y>7::<MQ+;Q175I<N%$*DQ822-R5^;!/SA@Q'!^_=8UK3_  [I
M=SJ6JWUOINGVR&2>ZNY5BBB4=69F( 'UJ9TW3=F.,E)7+M%?EO\ M:_\% M=
M\3^.(-.^%'B"]T7PYIBNCZE;C8VHRDC+@,,B-0,+G!.6)ZC'Z5>"=2DO/ F@
MW][/OEETVWGGGD(&6,2LS$_F:J=*5-)OJ*,E)M(WJ*_-'QG^V-\:?VD/BA>^
M%O@7;36&EVRR-%]F2#[1<0J=IGEFF^6)22, %<;@,DFK?PG_ &UOBW\'_C);
M^ ?CA$;N":XBM9Y+B"&.YL?,P$E5X0$EC^8$GYB1R&XP;^KSMY]NI/M$?I'1
M117,:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !17@_[;OQ"\0_"_]G;7O$/A?4Y-(UFWN+1(KN-$=E#SHK##
M CD$CI7PG\,_B]^UW\9-)NM3\&ZWJFN6-K/]FFFACL4"2;0VW#JIZ,#^-;PH
MN<>:Z2,Y347:Q^LE%?E/??M:?M0?L]>(K0?$"&YN+.1\_8]=TV)8+@#AA'/$
MJG.!_"Y ZD'O^BOP%^-FB?M ?#>P\7:(K0),6ANK*1@TEI<+C?$Q'7&00>ZL
MIP,XI3HRIJ^Z'&:EH>AT5\R_MD?ME67[-NFV^CZ1;0:OXWU&(RP6TS'R;.+D
M":8#DY((5 1G:Q) '/QYX=\1_MB_'RS_ .$BT"\\1OIDQ+PS6D\&EV[J/^>8
M9HPZ]LC.<=2<U4:+DN9NR%*HD[+4_5VBORL\)_MM?'+]G?Q]'H/Q4MKO6+)7
M5KK3]8MUCNUB)YD@F4#=T."2R'! QU'Z;Z'XJL/&'@NR\1:+<?:-.U&Q6]M)
MP,;D=-RDCL<$9!Z'BIJ4I4[7'&:D;E%?G!^P7^TY\3_BS\>5T+Q;XLN-9TG^
MR[F?[++!"@WJ4VME$!XR>_>OIG]L#]K+2_V;?"/D69AU#QMJ49_LW3VY6)>0
M;B8=D!S@=6(P. Q#E1E&?)U$IIKF/H:BO@/]BG6_V@/CYK$?BGQ1X\U&T\ 6
M<Q# 6MNCZG(IYBC(BR(P?O./]U><E?=/VPK'XY7VF^&!\$VF6Z6:X_M3R9[.
M+Y-J>5G[00#SO^[^/:DZ?+/D;0U*ZO8^B**_(CQO^T)^U+\._&T/@_6_%=ZG
MB>;RPFEV(L+V;<_W$(@5\.>"%/S8(.,$5]H>)O\ A?FE?L:Z48);VY^,GFJ]
MTUHD$LPC:Z=@I 7R\K"44X'&#R>M5*BXVNUJ2JE[Z'U/17A_[']U\3;SX3RR
M?%A;U?%/]I3!1?Q1QR?9]D>SA !C._WKW"L9+E=C1.ZN%%%%2,**** "BBB@
M KYY_;X\#W_CK]E_Q3;Z9!)=7NGM!J2PQJ2S)%(#)@#TC+M_P&OH:DJHRY9*
M0FKJQ^8?_!/7]K;P;\&?#.N>#/&]])H]I=7YU*RU$PO+%N:-$>-]@++_ *I"
M#C'+9QWZ']OS]L+P#\3OA=;^"?!&JMK]Q=WL5U>7<<$D4,,<>2$RZJ68L5/
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M'O%=AKVK>(M,ETVTT^S?=.OGH8W:5,9B"HS'YP.1@<FO.O\ @D]X"OM/\/\
MCGQA=6[1V6HRV]A92MQYGE>8TQ [C,D8SZAAV->FW'_!,GX,3>(7U)8]>AM&
M.?[)CU$?9EYZ E#+_P"1*^GO#/AG2O!N@V6BZ'I]OI6DV48BM[2U0)'&H[ #
MWR2>I))/-92G"--PAU-%&3ES2/RI_P"";<:R?M72L1RFF7S+]=R#^1-?H-^V
M#X$O?B1^S7X[T+38O/OWLUNH8A]Z1H)4GVCW(B( [DBJ7PC_ &./AQ\$O&S>
M*O#%MJ,6KM#);EKF\:5-KD%OE(Z\"O<*56JI5%./0(1M'E9^/W[%OA/X$>/&
MUS1OBU+#IVKJZ3:;>7NJ/8V\D6,/'O#J@<, 0&Y.[C.*[_5+3]DN'XN6_@?1
M? WB+Q?]IN(;.WU/0=6DFBGGD( 1 \R;@"0"P..N,XKZJ^*G_!/7X1_%3Q#<
M:W+:ZGX:U"ZD,URV@W*0QS.<Y8QR1NJDDY.T+D\]SGI?@C^QC\,?@+JPUC0-
M,N=0UU5*1ZIJ\XGFB4C!V *J(2,Y8*#R1G!Q6\JT'>5WZ$*F]K(^=O\ @J_;
MQV?@/X;V\0VQ17MS&@SG $48%;W_ #BO_P"X!_[=U](?'']G;P=^T-I^E67B
M^&\F@TV5YK<6ER82&< ') YX JQ_PH3PG_PI7_A5GDW7_")_9?L?E_:#YWE[
M]_\ K,9SN[UBJD>2,>S*Y7S-GR;_ ,$EO^1,^(?_ &$+7_T6]?,W@#4M(_:3
M_:IGD^-_B.;3+"XDN!MGNA;QQNA/E6@D;B)!R.V2,9W-FOU#^!W[.W@[]GG3
M]5LO"$-Y#!J4J37 N[DS$L@(&"1QP37GWQ=_8$^%/QB\57'B.^M]3T+5;M_-
MNY-$N4B6YD)R7='1UW'N5 SU//-:*M'GD^Y/(^5+L?#'[=.F_!;PC-X4\+?"
M:VTQKJS$\^JWNFW)NU(8((HVG+MN8;7)7/RY'K7Z+_LA,K?LQ_#8J=P_L:$<
M>H!!'YUQ_P#P[\^"Z^"1X:7P]<+$;I+N34?M;?;9'574 R]DPY^10%S@XR,U
M['\+?AIH_P (/ ^G^$] :Z.D6&_[.MY,9G0.[.5W'MN8X].E9U*D9045T*C%
MJ5V;NO6=WJ&AZC:V%VVGWT]M)%!=J 3!(RD*X!!!VD@\CM7Y@_ ;]M3QS\'_
M (X:EI7QJUC6M0TP+)IM[;W/SMITZN")A&H^8<,#MY*L",X /ZFUXY\:OV2O
MAI\>KI;_ ,3:&8]84!?[6TZ3[/<LH& '8##@#&-X.,<8%13G&-U-:,J46]8G
ME_QX_;:^!NH?"?Q#IZ:W;>,I]0L9;>#2(;25O-=E95+%T"H V#DG(P" 3BOG
M+_@E'X1U.Y^+'BOQ,D3KH]GHS:?)-@A7FEFB=4!Z'"PL3Z?+ZU] Z;_P2Y^#
MUC??:)[[Q1J,6<_9;G4(1'UZ9CA5L?\  J^G? 7P]\.?"_PS;>'_  KI%OHN
MD6_*6]LIY8]69CEG8X&68DG')K1U(0@X0ZD\LI23D?E9\9-:L_!?_!1J75]9
MF%CIUCXKTZ[N9W'$4(\ARYQV"_-]*^I_V_/%6B?%K]D>[U[PEJD&NZ1I^NVQ
MEO+,EHP5+1-SCD!I4&1QS7J7QV_8G^&_[07B)=?UY-4TS7#&L4M]H]RL3S*H
MPH=71U) XSM!QQG@8ZKX:_LV^"OAC\*;WX=6=K<:OX9OFE>[AU>43-.9%56W
M%54#A1]T#!&1S3=6'NRZH2@]5W/EW_@GC^T1\/O!?P%N] \3>*]+\.ZEINHS
MSF'4KA83-$X5E:/<?GYW#:N3QTY%?,OC+XEZ9\8/V^-*\6:*7;2;[Q7I,=K)
M(I4R1PO;P"3!Y ;RMPSS@C(!XK[8A_X)A_!F+7_[08^(I;3?N_LI]17[-C/W
M<B,2X_[:9]Z[[4OV)_A7?^/-$\6QZ1<:=J&BM:M8V]A<&&VB^SD&(>6!@\J"
M?4DD]:M5:49.2OJ+EDTD^A\P_P#!6+P'?/=>!_&<-LTFGI'-I5S.O2.3=YD0
M/^\/-Y_V?I7M_P !_P!M7X5R? ?P_=:[XLL=%U71]+AM+_3;I]MR988PC&*/
M[T@;;D;<_> .#D5]'>,/!NB?$#PY>Z#XBTRWU?1[Q-D]I<KN5AU!]00>0PP0
M0""#7S-I_P#P3)^#-CXBBU-TUZ]M48-_95QJ"FU;!S@E8Q(1_P #K)3A*"C/
MH4XR4KQ/A[X%>,A\1/V[M#\4K"UM'K/BF:_2%SEHTD:1U4GN0"!^%>K_ /!6
M+_DJ?@G_ + S_P#H]J^R[+]C7X9Z;\5[7XAV>G75GKUK/'/!';W.RUB*1B-5
M6(# 4* ,#TJ]\;OV4/ /[0>M:=JGBZWOYKNPMS;0FTNS" A8MR .3DFM?;P]
MI&71(GV;Y6CQ#]LWP)>^-/V%_"]U81><^@6^F:M*B_>\E;8Q.1_NB;<?92>U
M?._['_@7]F[XA?#^[A^)EU:Z1XOL)Y&DDU'69+&.YMS\R-'EU5B/F4J.?ESC
MG-?J3I6@V>C^'[/188O,T^UM4LTBF^?=$J! &SUX'/K7S%XT_P"":/P<\7:U
M+J-LFN>&1*Q=[/1;R-;?).3A98I-H]E( SP.E13JI1<&VAR@[W1X'\(8_P!F
M+Q-^T%IGA7PCX \37VIV^IAM,UJUU&26U=H3YGGLKRJ1&-A;HV0.G.*[;X\?
MM ? [XG?&@?#KXH?#Z]L9=.O)-,E\3WTRVTEGC<4<-$Q8PL=A&X[0)-Q'7/T
MU\#_ -ESX>_L^+<2>$])==2N4\N?5+Z4S73IG.S<<!5Z<* #@9R14/QN_91^
M&_Q_FCO/%.C.-7B01)JVGS&"Y" Y"DC*N.3C>IQDXQ1[2#G=WL/EERGYV?M7
M?LU?"#X3^$8]>\!?$^'7+V:Y2*/0FO+>]D=&R6=7AP55?5E.<@9R>?M+_@G'
MK?B'7/V9=.?7Y9KB.WO[BVTV6X)+&T79M )ZA7,JCK@*!VP,SPW_ ,$Q_@WH
M.IQW=T?$&O1H^_[)J5^@B/L?*CC8C\:^J-'T>Q\/:3::9IEI#8:=9Q+!;VMN
M@2.*-1A551P !2JU5*'*G<(P:=RY1117(;!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %?G;_P5T_YI1_W%O_;.OT2KRGXZ
M?LS^"?VBO[$_X3&"]F_L?S_LOV.Y,./-\O?G Y_U2?K6U&2A-29$TY1LC@_@
M7X#@^*'["?A[PG<.(H]8\-O:"4C/ENV\(_\ P%MK?A7P!^SC\8]:_8G^.FL:
M?XKTFZ%FV=.UO38P/-7:V8YH\X#%<Y'.&5S@\@U^N/P_\#:7\-/!ND^%]$25
M-*TN$6]NLTF]PH)/+=SS7(?&3]FOX>?'F&+_ (2_0([R]A79#J5N[0742_W1
M(I!*\GY6RO).*TA5BG)26C(<'9-;H\ZUC_@HA\#=-\.OJ=OXIFU.X\LO'IMM
MIUP+AV ^Y\Z*JG/&68#WK\_M%T_Q%^W9^U=)?-8RPV&H7D<]Z$.Y=.TV,JNT
MM@#=Y8"C@;G;MFOM*U_X):_""WOA</J7BNYBW9^RRW\ C^F5@#8_X%7TC\+_
M (/^#_@SH)T?P=H5MHMFY#2F(%I9V P&DD8EG/7[Q.,\8JU4ITD_9[BY92^+
M8["-%C1410B*,!5& !Z"G445Q&Y^0W[0WA'7OV0_VO(_&5G9>=I4^K-KVE.1
MMBGB=RTUOD="N]XSW"E6[BON+1?^"B7P1U3PLNK7/B6?2[L1;Y=)N+"=KE'Q
M_JQM0HQSW#8]2.:]Q^(7PU\,?%;PW-H/BS1K;6]+D.[R;A3E&Q@.C##(PR?F
M4@\GFOF:[_X)<_!ZXU)KF.^\46L))/V.'4(3$.O&6A+_ /CW:NSVE.HE[3=&
M'+*+?*?-W@G]I#XN?M#_ +6RMX!U[6/#^B:G>1@Z<K">WLM/BVJ\TD3AHPY4
M%B<<NX4'D5UG_!5[X<ZC_P )-X/\=PV[RZ6]D='N)D4D0R)(\L88]MXEDQ_N
M&ON+X/\ P#\#? G2)+#P;H<.FF8#[3>.3+<W&.GF2-EB,DX7A1DX KKO$WAC
M2?&>@WFBZ[IUOJVDWB>7/9W<8>.1?<'N#@@]00".:7MDIJ45HA\C<6FSYO\
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M4T3QIAV?]V$B0CESU)XQ6,9)0DGU+E%MIGLE%%%8FA^>GP(_Y2<?$C_KG?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1163XF\7:%X+TTZCXAUK3]"T\,$-UJ=U';
MQ;CT&]R!G\: -:BLSP[XFT?Q=I<>IZ%JMCK6FR$A+S3KE)X6(ZX="0?SK3H
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MCJ)N[VXFC:5C'Y;* D8P&;)[LH]^U?!?[9&DZ;\&OVQ+&X^&T,.D:A"MC?\
MV/30(T@O68_($7A0ZB-BN,'S#Q@U^N595I.+C./;0J"O>+/Q[_;J^ ?A?]GG
M7O!'A[PS',RR:2T]Y>W+[I;J;S6!=NPX  50 ![Y)_5[X>PQW'PV\-12HLL4
MFDVRNC@%6!A4$$'J*_.G_@K%_P E3\$_]@9__1[5^AOA'5H-!^$>BZG<B0VU
MEH<-S*(D+OM2W5CM4<DX!P!UI56Y4X-A#231PGQ(_P"$!_9-^'_BKXDZ)X'T
MNQG@B@CN8-(@CLFN@\Z1JN57 ^:3/3M7YX^']3;]NS]K.RU;Q!?:3X/TYI+=
M5L9[L>;+!$?EMH=V/-F?GG  W$XX"G]!?@W^U5\-?VF=;U7PYH,=U=S6,"7C
MPZM:(B3(' W(I8D[6VYR!C<M?$O_  5 \+^&/"?Q8\+7?AZUM=+UR\L'GU&.
MQ41$E9,0RLJXPQPXW=3L'I5T;J3BU[W<4]KK8_4VBN0^#NJ:GKGPD\$ZCK;%
M]9O-$LKB]9NIF>!&D)]]Q-=?7"]'8Z HHHI %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!\R_\ !1K_ )-/\3?]?5C_
M .E,=>=_\$H?^2-^+_\ L/G_ -)X:]$_X*-?\FG^)O\ KZL?_2F.O._^"4/_
M "1OQ?\ ]A\_^D\-=B_W=^IC_P O#V_]M3P78>-OV9?'<-];K,^G:?)JMLY'
MS130 R!E/8X#*?9F'>OE/_@DKXDN%U/XB: S%K5X;2^123A'#2(Q'U#)G_=%
M?1_[>'Q9T7X=_L]>*=,NM0MUUO7K-M.L=/\ ,'G3"4[)'"9SM5"Y+=,@#J0*
M\"_X).> [RWL?'7C&>)H[*Y:WTRT<CB1DW238]ANB'XGTIQ_@2N)_P 16/ /
M'$(^/7[?][I6M,USI]WXN&E2QY*YL[>;R=@],QQ'\23UK]:_$WB;0OAKX2NM
M8UBYAT?0-+A4RS>6?+@C!"C"J"<#(& *_)O]I+3;[]G']M^X\3R6DDUG_;L/
MBBU_A%U$\HFE13_O^;'^%?IYJ4/@S]I_X/WEG::M_:GA77H!%)<Z9,HD4 JQ
M7)!V." "I&1T(IU]5!] I_:[GA/Q4^,_[)?QLN])N?&OB#3=<ETOS!:EX[Z+
M:'V[@?+5=P^4<-D#GBO?/A7K'@C6OA3:2_#I[5_"$4,T%E]CB>.)=K,' 5@#
M][=U'6OS;_;B_9K^%?[/>AZ+;^$=:O+CQ5<W@%UIM[?QS21VWEL1(8U12H+;
M0">N3BOL#_@GO_R9_H?_ %UU#_THDJ:D(JFI1;L.,GS6:/S@_9<^.-O^SU\0
M=0\726+:E=)I%Q:V=KG"R7#E F\]D&"3CG P.33? GB'3OCK^T=H^H_%W7+D
MZ=K6HJ-1O%.T<\1Q9S^ZBW;$)'W$SC&,U:_9"^"&G?M ?&O3O#&L7<MII,<$
ME]=" ?O)HX]N8E/\.XL!N[#/>OI[_@HW^RIIGAGP[H_Q!\%:1#IVG:;#%I>J
MV-G'M1(AA8)\#TXC8GDYC]":[I2@JG+U9SI-QOT1^A^BZ+8>&](L]*TNSAT_
M3;.)8+>UMT"1Q(HP%4#H *\!_;:_:9/[.OPS0:4RMXOUPO;:6& 80  >9<$'
MKL#+@'@LRYR :Y;_ ()[_M+_ /"XOAS_ ,(GKEWYGB[PW"L9:1LO>68PL<W/
M)9>$8_[A/+U\K_\ !1G4/[0_:UTNSUR1XM#M;"QC')(%NTC-*X'KEG'_  $5
MP4Z7[WEET.B4_<NCZA_8-_9KB\'^%8/BAXNCDU3X@>)D-ZMU?$R2VD$OS#!;
MGS) =S,><,%X^;/9?M[^--=\ _LXZMK'AS5KS1-4CO;1$O+&4Q2*K2@, PYP
M17O^EW=E?:;:W&FS07&GR1JUO+:LK1-'CY2A7@KCICBOF;_@I+_R:OK7_7_9
M?^CA41DYU4WW*:Y861)_P3O\>>(OB)\ KC5?$^M7NO:DNM7$(NK^9I9!&(XB
M%R>P)/YU]/U\A_\ !+S_ )-KN?\ L/W7_HN&OKRIK:5&.'PH****Q+"BBB@
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M\//^A#\,_P#@GM__ (BCFH_R_B'+/N?(7_#V;PG_ -"'K7_@7#1_P]F\)_\
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MH_X>S>$_^A#UK_P+AKZ]_P"%*_#S_H0_#/\ X)[?_P"(H_X4K\//^A#\,_\
M@GM__B*.:C_+^(<L^Y\A?\/9O"?_ $(>M?\ @7#1_P /9O"?_0AZU_X%PU]>
M_P#"E?AY_P!"'X9_\$]O_P#$4?\ "E?AY_T(?AG_ ,$]O_\ $4<U'^7\0Y9]
MSY"_X>S>$_\ H0]:_P# N&C_ (>S>$_^A#UK_P "X:^O?^%*_#S_ *$/PS_X
M)[?_ .(H_P"%*_#S_H0_#/\ X)[?_P"(HYJ/\OXARS[GR%_P]F\)_P#0AZU_
MX%PT?\/9O"?_ $(>M?\ @7#7U[_PI7X>?]"'X9_\$]O_ /$4?\*5^'G_ $(?
MAG_P3V__ ,11S4?Y?Q#EGW/D+_A[-X3_ .A#UK_P+AH_X>S>$_\ H0]:_P#
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MTWPWIT6GZ3I]KI=A%DQVME"L,29))PJ@ 9))^IJ]7.[7T-%MJ%%%%(84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[9K:SE;RP%VQ'&S,N&5< @!S@#-?H;45_C*I[!1117.:!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '"_&[XMZ
M5\#OAEK?C+5U::#3XQY5JC8>XF8A8X@>VYB,GG R>U?F-H?_  OS]O[Q;JLE
MKK)M-$M&!ECDNI+32K+=DI&$0,7? /.UFX^8@8KZ+_X*Q:Q/;_"_P3I:,1;W
M6L27$BCNT<)"_P#HUJ](_P"";NAVND_LJZ%=P)&)M3O;VZN&48)=9VA&[U.V
M)?PQ7;"U.E[1+5F$O>GR]#XH^)G[/?QS_8QL+3Q3I_BB7^Q(9E4WWAZ^F\JW
M=CA5GA=5&UCQR&4Y /) K[+^"_[2TW[0W[)OCG5KS;9^+-&TB]M=1%L=@,@M
MG:.= #\H<?DRMC@"OIOQ!X=TOQ7I%QI6M:;:ZOI=QM$UE?0K-#* P8!D8$,,
M@'!':N/^*6AZ;X=^!OCFRTK3[73+--!O]MO9PK%&O^C/T50!42J^T24EJ4H<
MKT>A^27[/?PZ^*/[27B;4M#\,^-9;&[L+3[;*^K:K=1QE-ZIA3&KG.6'4#OS
M7I/Q$_9K_:3_ &>='N/%T7BN\O['3QYUS>>'M<N)#!& "7='",R#G/RD  D\
M<UT'_!*'_DLGB_\ [ !_]*(J_3^\LX-1LY[2ZA2XMIXVBEAD&5=&&&4CN""1
M716K.G/EMH90@I1N?*/[!_[75[^T!HNH>&_%;Q-XST>)9_M$:",7]MD+YI4<
M!U8@-@ ?.I Y('RG_P % O&&OZ/^U=?6EAK>I65J+6Q(@M[N2-.8US\H..:P
M?V![B3PS^V?HVE6TA\B<ZE8/@YW1I;S2#_QZ)3^%/_X*-S"W_:RU24C(2RL6
MQ](@:N,%&LTNJ$Y-T]3],/C_ /'KP[^SSX N?$FO2>;,<Q6&FQL!->SXX1?0
M#JS=%'J< _F]\(="^+?[<WQDU+6KOQ)J>B: LROJ5]97$D5O9Q?P6UN@."^T
M8 Y[LQ)/S>-_'[XU>+?VB/%]YXRUV*:/2XY19V5O$&-K8H062%6QC>0I8D\L
M03C  'ZP_L9^)/!7B7]GWPU-X&L(=)T^"/R+S3T;=)!>*!YPD;JS$X;<>2K*
M>.@R<?J\+VU?X%7]I*W0\4_;B^/=]^R[\/\ PI\//AY-)I>I7UN['47D\Z>V
MM4(7(9\DR2,6_>'D;6/4@CY_F_90_:#'PM;XIR>.KK[8-/.K-8G6;O\ M$0;
M-Y.[IOV<[=V>W7BOU U[P3X=\5,&UO0-+UAE4(&O[..<A020/G4\9)/XU\V?
MMR?M4Z)\%/ .H>#-)DCNO&6LV+VL5K#C;I\$BE#-)CH=I.Q>YP>@YSIU'I&"
MUZE2BM6V8?\ P3O_ &HO$/QJT?7/"WC"Z.I:YHD<=Q;ZD^T27%NQV$2  99&
M ^?JP<9Y&3!^RW^R[\7/A3\<+OQ/XP\06^H^'I+:ZB2WCU6:X8,[*4.QU X
M/?BL?_@ES\%=0\)^#==^(&JPM;'Q"([;38I%(8VT98M+_NNY 'M'GH17A/\
MP3J_Y.\U+_KPU#_T8E:2BKU.38E/2-S]7J***\\Z0KQG]K3X(ZK^T%\'[CPC
MHU_9Z=>R7D%R)[[?Y85"21\H)SSZ5[-7#^,OCC\/OAWJXTKQ/XRT;0=2:)9A
M:W]XD4AC)(#8)Z$@\^U5&Z=X[B=K69^?MI_P2W^*-A&8[;QYH-M&3N*PS72@
MGUP(^O J5/\ @E?\1-4O(!J_C_13;*<&1?M%PZ ]=JLJ@_\ ?0K[?_X:L^#O
M_13/#/\ X,H_\:/^&K/@[_T4SPS_ .#*/_&NOVU;M^!CR0+/[/OP!\._LZ^
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M-\NO^,+^(17&H>5LBMX\Y,4(/(!.,L3EMJ\+TKN/^&K/@[_T4SPS_P"#*/\
MQH_X:L^#O_13/#/_ (,H_P#&MI5*LU9K\"%&$7='G'[7W[%.G?M*-::[I>HQ
MZ%XQLX1;+<3(6M[J$,2$E ^8%2S8<9ZD$'C;\[Z!_P $U?BAXS\0::/B9X_M
M;G0; ^2OV>_N+ZY$(Q\D(F0+&IP ,].NTXP?L_\ X:L^#O\ T4SPS_X,H_\
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M\-6?!W_HIGAG_P &4?\ C1_PU9\'?^BF>&?_  91_P"-')+L',NYZM17E/\
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M9X9_\&4?^-')+L',NYZM17E/_#5GP=_Z*9X9_P#!E'_C1_PU9\'?^BF>&?\
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M]_> ? >A_#'PAIGAGPY8II^CZ?%Y4$*\GU+,3RS,226/)))KB?\ AJSX._\
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MS3H_(@O_ "O-BEA+;C%*N02 2Q5@>-S<'-=M_P -6?!W_HIGAG_P91_XT?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBU]FT4>VJ?S![./8^,O^'5'PF_Z&'QG_ .!MI_\ (M'_  ZH^$W_ $,/C/\
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M_P#(M'_#JCX3?]##XS_\#;3_ .1:^S:*/;5/Y@]G'L?&7_#JCX3?]##XS_\
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MVG_R+7V;11[:I_,'LX]CXR_X=4?";_H8?&?_ (&VG_R+1_PZH^$W_0P^,_\
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M'[+?@OX5_#SQ%)\0/'?Q?\(>+_BQJS%Y+I_$-I*EFT@PR1?/\TA!VE^F/E0
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M]T_&?]G_ ,$?'S0X].\8:0MXT&XVM]"QBN;8GJ8Y!R >,J<J<#(.!7A&A?\
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MSM-W?3N9;FZ*YP7<]ADX50%&3@#)HDZ5FUJV"Y]$ST>BBBN8U"BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7/\ \=HO0[,/WGD<9_P\O^"?_/\ :U_X+&_QH_X>7_!/_G^UK_P6-_C79_\
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M1_P\O^"?_/\ :U_X+&_QKL_^&%_@5_T3VR_\"KG_ ..T?\,+_ K_ *)[9?\
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M ()_\_VM?^"QO\:/^'E_P3_Y_M:_\%C?XUV?_#"_P*_Z)[9?^!5S_P#':/\
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M"O\ HGME_P"!5S_\=HO0[,/WGD<9_P /+_@G_P _VM?^"QO\:/\ AY?\$_\
MG^UK_P %C?XUV?\ PPO\"O\ HGME_P"!5S_\=H_X87^!7_1/;+_P*N?_ ([1
M>AV8?O/(XS_AY?\ !/\ Y_M:_P#!8W^-'_#R_P""?_/]K7_@L;_&NS_X87^!
M7_1/;+_P*N?_ ([1_P ,+_ K_HGME_X%7/\ \=HO0[,/WGD<9_P\O^"?_/\
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M_#R_X)_\_P!K7_@L;_&C_AY?\$_^?[6O_!8W^-=G_P ,+_ K_HGME_X%7/\
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M5_T3VR_\"KG_ ..T?\,+_ K_ *)[9?\ @5<__':+T.S#]YY'&?\ #R_X)_\
M/]K7_@L;_&C_ (>7_!/_ )_M:_\ !8W^-=G_ ,,+_ K_ *)[9?\ @5<__':/
M^&%_@5_T3VR_\"KG_P".T7H=F'[SR.,_X>7_  3_ .?[6O\ P6-_C1_P\O\
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MT,LFWRO)V[/+E3'^L;.<]!TKO_V@/%7QIT&V\.2?"'PCHWBE[CS3J@U:58Q
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_5:Z=K'S.?9?2IP6(I*VMG_F==45U=0V-K-<W,J6]O"C222R,%5% R6)/
MSFI:^,?VNO"GQL^+WBOQ!X6T6\'AGX3:=I7VR_U+8$-\XB,C0YSOEY&W:NU.
MNXD@"OW6$>9V;L?$2=D?2WPI^-G@OXW:7?:CX)UH:W96,_V:XE%M- $DVAL8
ME12>"#D9%'Q3^-W@;X*:;;WWC7Q':Z%#<L5@20/)--C&2D4:L[ 9&2%(&1G&
M17RE_P $GO\ DD_C3_L-K_Z(2O/-8\'V'[4__!1;Q%X?\6F:^\,Z##)$+&.9
MT!BMT5?+#(05#32,QP0>2.":W]E'GDF]$9\[Y4^K/O'X7_&KP1\:-,FO_!?B
M.UUV" A9EB#1RQ9Z;XG"NH/."5&<'%=E=74-C:S7-S*EO;PHTDDLC!510,EB
M3P  ,YK\W=#\(V/[*G_!130/#WA5IK+POX@ACB%BTSR[8KA&41EF)9@LT88%
MB2,#KUKUG]KKPI\;/B]XK\0>%M%O!X9^$VG:5]LO]2V!#?.(C(T.<[Y>1MVK
MM3KN)( I.DN96>CU&I.VJU/I;X4_&SP7\;M+OM1\$ZT-;LK&?[-<2BVF@"2;
M0V,2HI/!!R,BNXKX:_X)/?\ ))_&G_8;7_T0E?<M9U(J$W%%Q?,KL\H^*G[4
MWPO^"GB&'0_&GB?^QM4FMUNTM_[/NI\Q,S*&W11,O5&XSGBN1MOV_O@'=3I"
MGC]%=S@&32KZ-?Q9H !^)KY1_;^_X1O_ (;*\!?\)C_R*G]G6/\ :G^M_P"/
M;[5-YG^J^?[N?N\^E5/BP_[$Z?#CQ#_PAZ73^*39R#3/L?\ :^\7&/W9/V@^
M5MW8W;NV<<XKHC1@XIM/7L9.;N]C]+]#U[3?$VD6FJZ1?V^IZ9=H);>\M)5D
MBE4]U93@BN7^)GQL\"_!NSBN?&?B:QT)9@3%#.Y::4#J4B0%V [D*<5X%_P3
M_P!!\2?"O]EV^O\ Q;;7%G;&ZNM6LK*X5EFCM!$I/RG[NYDD8#N&S_%7S5^R
MO\'8OVX/B[XW^('Q+NKJ_P!-LYHV.GPS&,3/(7\N'<IW)%&B8PN"<K\W!SFJ
M4;R;>B*YW966K/O#X;_M7?"7XM:LNE^%_&UC?:FYVQV=Q'+:33'&<1I.B&0X
M!X4'I7K-?$WQI_X)F^%];_L>\^%5P/ VIVURIN/M-W<7$31]?,0LSN)58+C#
M 'GH<&OL/PGINHZ/X7TFPU?4AK.J6MK'#=:@(O*^TR*H#2;,G;N()QD]:SFH
M:.#*BY?:-7IR:\.U7]MWX'Z+XA?1+KX@V/VY)/*9H;>XF@#9Q_KTC,>/?=@5
MZ-\6O#-[XT^%WBW0-.N_L-_J>E7-I!<%MHC=XF523V&3R?2OR)^&OC[P9X<^
M#OC;X<:Q\+H?$OQ+U*\:TTG4X;=)[B*1@(]H?EU:-URHBXD+8..2=*-)5$VR
M9R<6?LUI^HVNKV%O?6-S#>65S&LL-Q;N'CE1AE65AP000015BO%/V-_AOXB^
M%'[//A?P[XI_=ZQ")IWM=VXVRR2M(L1/3(#<XX!)'.,U[76$DDVD:+5'%_$S
MXS>"?@YIL5]XS\26.@PS9\E+ARTTV,;O+B4%WQN&=JG&1FN3^'_[77P@^*.M
M1:1X<\<6-UJ<S;(;6ZBFM'F;LJ"=$WGV7)KX,_;,_L[0OVVCJ7Q6TG6-9\ R
M6\#6UO82['EMA !MB8LHPLY<LH93DGD9!/1O\#_V7_VA+C1[3X4>._\ A6?B
M2.0,]GJ"7,SW&<[447,RYD! (,4AXSD'((ZU1ARIN^OW&/.[V1^F%%>2_&#X
MSZ;^S'\&[?7?%=[)KVH6L,-E$L8$,VJ7>P D D[,[6=N3M /4X!^;(_VO?VD
M;CPO_P +$B^#.E_\*XV&\^:23[8;4#)D!\X-MV_-YGD;=O/3FN>-.4E=&CDD
M?;OB#7K'PKH.I:UJD_V73-.MI+NZGV,_EQ1J6=MJ@DX )P 3Z5Q?@K]H+P#\
M1/ .M>-/#VO?VAX9T;SOMU]]CN(O)\J(2R?(\8=L(P/RJ<YP,GBO.?\ A?6@
M?M$?LB^/O$^A!K:0>']1@OM.F8-+9SBU<LA(^\,$%6P,@C@'('A7[!6K_P#"
M/_L4?%?5/L5GJ7V*ZU*Y^QZA%YMM/LT^%O+E3(W(V,%<\@D5:I^ZV]TQ<VJL
M?9?PI^,G@_XW:!<ZWX*U?^VM,M[EK.6?[--!ME"JQ7;*BL?E=3D#'-=I7R]^
MP/\ %:+XD?!G7]<G\+^%_!<-GK$T3VOA?3OL-J56WA<RNFYLOAL%L]%7TKS>
MQ_;@^+GQI\?:K8?!#X:Z?XA\.:6^)KO5G9'F3<0'\PS11Q%P#M0[FX)[$!.D
M^9I= YU9-GU*_P"T%X!C^+:_#%M>QXX;D:7]CN/^>/G?ZWR_+_U?S?>]NO%>
MB5^7WPM\>7GQ*_X*7:/KNI:#=>&-3D,EO>:3>',EM/%I;Q2+G R-R$@X&00:
M_4&E4I^SLO(<9<USGO$?Q"\->$=4TC3-8UNRL-3U>=;:PL991Y]U(S!0$C'S
M,,D9(&!G)(KH:_)KX]^(_B[-^VSX<OK_ ,+:3!XYM9X$\/Z9'*IM[R!9Y?LS
MRGSR 7YSETZ=%KZ9_:6_:V^*G[/?P_\ AC>7WAWP[;>*]?BN?[9L;J.6:&VD
MC,6%B,5QTQ(<Y=^W-6Z#]U)ZLGVF]^A]F45Y3^TM\5M6^#?P'\1>-M%M[*ZU
M73H[=XH;]'>!C)/'&VX*RL>'.,,.<5\Y^-?VXO'?AO\ 9-\ ?%"VTGPZ^O\
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M* ?"?Q4VN_#[XO>$-+DUFY\+F(7EK;Q-)*BQRB:*4JO)0-O#8^[D'IDCS_\
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M+):?_P %4O\ D9/A'_UUO/\ T.VK]":*4:UG%VV&X737<^*/V^_@CXPUK7?
M_P 5O >FRZSK/AAHQ<6-M$99ML<HFAD5!\SA7W!E'.&!Z D<A\3/V_)/C9\-
M=3^'W@CX?>)/^$_UVU;3KJS:%98[4.-DVPH=[_*67+(F,Y/3%?H-11&JK)25
M[ XZNSW/S^\>_ N^_9__ .";_B70=8:/^W;V[MM2U".(AEAE>Y@41AAPVU$0
M$CC.<9&*^@/V#$$?[)?@3RT4$PW+8Z DW4QY_&OH&BIE4<HV?>XU&SNC\Y_B
MQ^T)X7D\>>(-+_:.^ 'V2,;8=-U'2;;S+N0*2"/MC/"98R""K1L,8((YX@_8
M#^'5WJ'[1WB/X@>$?#>J^&/A;]DN+:R&JN6:99&39$K'_68*;S@L%P 6)P3^
MC]%7[;W7%+?S)Y-;MA1117,:A1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !117EG[47CV\^&OP%\7Z]I\C0ZA%:K;VTJ'#1R32)"''NOF;O^ U=.#J
M34%N]#&M5C0I2JRVBF_N/$OVDOV]K7X;ZY=^&/ UE:ZYK5JQBO-0NRS6MO(#
M@QJJD&1ASDY !&/FY ^;(?\ @H!\8X[I9FUG3Y8PVXP/IL.PC^[D -C\<^]?
M.3,68DG)/))HK[FEE^'IQY7%/S9^+XK/,=B*CFJCBNB3LE_G\S].OV9/VX--
M^,FIP>&?$]G!X?\ %4HQ;O Y^RWK8R53<24?T4DYQP<\5]35^$MG>3Z?>075
MK,]O<P2++%-&Q5D=3E6!'0@@'-?M5\'O&,OQ ^%?A/Q'/C[3J6FP7$^T<>:4
M'F8]MVZOG\RP<,.U.GLS[OAW-JN/C*C7UE'6_=>?H=A7.M\1O":^+AX5/BC1
MAXH/31#J$/VT_)YG^IW;_N?-TZ<]*Z*OSPO/^4MEO_NC_P!,YKR*<.>_DC["
M4N6Q^A]%%?&'_!23X_:[\.?"N@^"?"MW/8:QXD9WN;JT8K.ELA"B-".09';&
M1SA6'\53"#J244.4N57/IW6?C1\/O#NK-I>K>.O#6F:FK;&LKS5[>&8-TP49
MPV?PKKX9H[B%)8I%EB<!E=""K ]"".HKX-\%_P#!*?PO-X+M7\5^*];'BN:'
M?,=,:%;2"1AG9M>-F<*>"VY=V.BUWG[$OP)^+GP!USQ-H/B>^L[OP!ND_LY/
MM>^0RB3Y9HHQGRTD4L65F!SCC.36LH0LW&6Q*E*^J/KFJ.M:[IOAO3)]1U?4
M+72M/@&Z6[O9UABC'JSL0!^)J]7Q9^UI^S;\3?VDOCMX7T]RUE\*+)8UFNH+
MN+=$Y#--+Y+/N9R-L:G:<9!QC=6<(J3LW9%2;2T1]8^$_B-X3\?"X/ACQ/HW
MB,6^/..DZA%=>7GIN\MCC/O6KK.M:?X=TRXU+5K^UTS3K==\UW>3+#%$O3+.
MQ  ^IK\MOC1\$X?V,OVC/AC)\-_$&JWUWJ4T;_8[R1&N/]>L9C9HU0-'*&*[
M2O\ "W7MZ/\ MNS:I\=/VL/ /P634Y=/T#;#+.L?3SI=[22XZ,RPJ N<X+-_
M>-;>Q3:L]&9\[MJM3[R\*>//#7CRUEN?#7B+2?$5O"VV2;2;V*Z1#Z$QL0#5
M_6M=TWPWID^HZOJ%KI6GP#=+=WLZPQ1CU9V( _$U^9GC;X9K^P5^U1\.;WPG
MK>I7'AG6S'%<C49$,CQF41W$;E$564*Z.#MR#CT!KV[]K3]FWXF_M)?';POI
M[EK+X462QK-=07<6Z)R&::7R6?<SD;8U.TXR#C&ZDZ4;KWM&/G=MM3ZQ\)_$
M;PGX^%P?#'B?1O$8M\><=)U"*Z\O/3=Y;'&?>NBK\J?C1\$X?V,OVC/AC)\-
M_$&JWUWJ4T;_ &.\D1KC_7K&8V:-4#1RABNTK_"W7M^JU14@HV<7=,J,F[IG
M.^+OB-X3^'ZVI\4>)]&\-BZW"W.KZA%:^=MQNV>8PW8W+G'3(]:W;:YAO+>*
MXMY4G@E021RQL&5U(R&!'!!'>OSY_P""MP+6OPP ZF34?Y6U=O\ \$Y?CU<Z
MYX;OOA+XH\RU\4>%MRVD=U\LCVJMM:(@\[HF^7']TK_=-5[']VJB%S^]RGUE
MH/Q&\)^*M8OM(T7Q/HVL:K8[A=V-AJ$4\]OM;:WF(C%DPWRG(&#Q715^>?[!
MG_)X7QP_W[[_ -.%>S?%S]NNT\'_ !&N_ G@/P'K'Q1\2Z>6&H6^D,RI 5QN
M4%(I6<J2 WR@*>,Y! 4J3YN6.H*:M=GU-17A7[-_[6WAW]H:XU32$TR\\+^+
MM)!:]T'4B#(JAMK,C8!8*V%8%5*D@$<@GE_C=^W5H7PQ\>/X#\+^%M5^(OC:
M-@DFFZ5E41RNXQ[U5V:0+R55"!R"000(]G/FY;:E<RM<^G:*^8_@I^W/HOQ(
M\=1^!?%WA35?AKXSF)6#3M7),<K?PQAV2-ED89(5D ., DD Z_[2'[9&A_ '
MQ!IOA:ST#4/&?C348UE@T;3FV;59BJ!WVL=S$':JHQXR<9&7[.?-RVU#F5KG
MT+17R7\*_P!OR#Q5\4+#P#XY^'>M?#?7]1D2&SCOW:7+N/D$BO%$Z;C@ [6&
M2,D#FNV_:>_;#\-?LTK8V$^GW'B/Q3J">;;:/:RB/$>[:'ED(;8I.0N%8D@\
M<$T>RGS<MM1<T;7N>R^*O&GA[P+IR:AXDUW3/#U@\@A6ZU6\CMHFD()"!G8
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;F),1K;1QY!$>>G"D\FN$_X)J?9O^%X?%W^W=G_":?\ 33_6[?M,GVK&>?\
M6>3G\,U]+_L[?LGI\"M8U#7+_P >>(_&>NWX/VB6^NI(K5V.,R&#>V]SC&Z1
MFQVP>:YWXU?L(Z!\2?'3^.O"GB?5/ASXTDD\V34M)!:-Y,8:78K(RR$<%E<
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MTMJ#YKVZ0QF.<8_BB;J<?<)R<(!7)?LE_$R3XQ?M\6WC&>V^QW.J6$SSP@Y
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M&.,XR03E1<*4E*,K_(;YIJS5CIO!WQ1\+^.O MOXPTG6[*?P_+!]H>\,ZJD
M"Y82DGY&7^(-@C'->2_ O]LK0/CU\5?$O@S0]#OO)TD330ZVDB26MS DBQB3
MG:R;RP*KALCG(KP76?\ @DGI%QK$DNE?$B]L=*+92UN])2XF5<]#*LL8)]]@
M^E?5O[/_ .SCX0_9Q\,3Z3X8@FEN+MEDOM3O&#7%TR@A=Q  "KD[5  &3U))
M,R5**=G=C7.WKH>I4445SF@4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:Q8Z99>([R2\O9X[:%&TNX4,[L%49*8')'-?1U*491^)6!-/8****D84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 45Y'\9OVJOAI\!YA:>*O$"IJS)O72
M;&,W%UM(R"R+P@(Z%RH/:O+_  __ ,%,/@MK=YY%S=ZUHBEP@GU#3B8SGO\
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MU##]#659/25[IETVM5:Q<HHHKE-0HHHH **** "BBB@ HHHH **** "BBB@
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M@-Y>TXYYXYK[I_;8_9S\!WG[./B/4=+\+:3HFJ>'K87MC=:;9QV[(J,-\9V
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M4?7E%%?#W[9WAOXP_&WXQ>'OAMX8M=8T;X?31QB^UF""7[%)(X9I&G=  41
M $)P6]R,9PCSNU[%2=D?<-%?E3KW@'QG_P $^/CEX'CT3QG)X@TC7YD-Q:0P
MM;K=(LJI)%+;EW4G#_(^<Y)QC'/K?[=GCCQ;\3OCEX/^ WA759-)L]32*347
MB=D$SRLV!+M.6CCC3?LZ$MSG"XU]CJK/1]2/:::K4^^Z*_,/0O#_ (N_X)^_
MM*^"_#W_  E<GB#P9XF:)+E?*:"&17D\IR83(P62,E6#!N00.Y%?5G[5W[4&
MN?!W5-#\%^"O"MQXF\=^)(6;3N-T,.&*[B@^:1@03CY5 &2V 14RHNZ47>XU
M/34^D**_.K_@F!>:K?\ Q6^+=SKLTESK<J0O?33.&=YS/+YA)'!.[/3BOT5J
M*D/9RY1QES*X45XA^U1^TD?V<_"VDW%GX=N/$VO:Y<M8Z;90MM0S8!&_ +'D
MC"J,L>,CK7QQ^QCK/C#Q!^W;XCO_ !ZKQ>+9=-NS?028'DM^YVQ@ D*%7:H7
M/  !YJXTG*+F)S2=C]-J*_/;_@K5_J?A;_UUU#^5M7Z!V?\ QZ0?[B_RJ)0Y
M8QEW*4KMKL3445\^?M^?\FE>//\ <M/_ $LAJ8KFDD-NRN?0=%?.?_!/?_DT
MGP3_ +U[_P"ED]?/G[:'_)^OP2^ND_\ IRDK6-.\W"^Q+E:*9^A]%?EK_P %
M2IKBW_:$\)RVCR1W4>@0-"\)(=7%U<%2I'.<XQBOL?\ 9=_:"@_:$^ ,NI7$
MJGQ+IEJ]CK$(&#YPC.V4#^[(HW?7<.U$J+4%/N)3O)Q/H.BOS_\ ^"3LAA\&
M_$N15WLMW:,%'?$<O%>"^#=+U/\ ;H^)7B&7Q]\7;/P=+',&T[2M0/F(VXL/
M*M8&EC0! BYP2QSD@DDU?L/>DF]$+VFB=MS]>J*^#?@5^SO\>?V9?CEIFGZ/
M?R>,_A7<,D=_.;R*"%(F&"XMI)BR21D!OW>[< !DY(&S^WQ^TIXM\*^(O#OP
MH^'-S-9^)]=$;7-Y:.%N%$KF.&")C]QG;)+ @@!<$9-1[*\E&+N/GTNT?;-%
M?F]-_P $OO'4>C_\)&GQ.CD\=I']H%NMO*!YXYVB\\W?G/\ 'Y8Y_.OHG]B?
MQ+\6O^%<:I9_&#2=0L?[*(-CJ^L$+<7$(#;UE!.\E-H/F,/F#=3C-$J<4KQE
M<%)WLT?3%%?E\-6^)W_!1;XM^(-*TCQ)+X6^&^E/DQ!F\F*%F*Q%XD*^?,^U
MFPQPN& (& ;_ (B_8^^-G[)NKZ+K_P )O%.H>+Q/=+'<V>G6CP?-@D>?;^8Z
M21$ @LQ^4D=.#5^Q2T<K,7M'NEH?IE163X3U#4M5\+Z3>:SIIT?5[BUCDO-/
M,BR?9YBH+Q[E)!PV1D$]*UJY34**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ KD?BYXYD^&?PQ\4>+(K-;^31M/FOEM7DV"4HI;:6P<9QUP:ZZO*?VK/
M^3:_B9_V +O_ -%FJCK)(3V/C+_A[9JW_1-;+_P;O_\ &:MZ;_P5NN?MB#4/
MAI$;4G#FVU@AUYZ@-#@\9XX^HKSS_@G'\3O 7PUUKQU+XZUC3=(BN[>T6T;4
M5R'96E+!>#T!7\Q7OG[6_P"T-^SYXJ^"?B#2[6]T;Q-K]S;21Z3'I]GOEM[D
MC"RB3:!&%."3D9 (P>E>A*$%/DY#F4I6OS'TY\#?CMX6_:"\%IXC\+7$AB5S
M#<V5TH6XM)1SLD4$CD8(()!!X/7#?CA\>O"7[/WA$Z[XKO6B60LEI8P+ON+R
M0#.R-?RRQ(49&2,BOE'_ ()2_#[7=#\)^,_%5_#+:Z/K4EK!8+("/M'D^;OE
M /509 H(ZD,.U?/'[4&N:I^TI^VI)X/6\>WLH=9C\,6*L2Z6JK*(II-N>ID\
MQSWP .U8JC%U7&^B-.=\J?5GIWB'_@K-XBEU!SH7@+2[:Q#C:-0NY)I67ODH
M$ )_''O7HOP9_P""HWA[Q=KUKH_CKPZ?"INI%BCU6UN?.M48X&90P5HUS_$"
MV,\X )KZT^&7P=\(?!_PW;Z+X5T.UTRUB38\JQ@S3G'+2R'YG8]R3[=,"O O
MVC/^"?'A;XY>,+#Q!I&HP^![G8ZZF+'3ED6].04?:'15<?/EN=V1GI0I4):.
M-EW%:HM;GU='(LB*Z,'1AD,IR"/44ZN9^&?@MOAUX T#PN=3N-872+2.R2]N
ME59)$0;4W <<* /PKIJY#<YWX@?$#0/A?X2U#Q+XFU&/3-'L4W2SR<DD\*J@
M<LQ. %'))KX'\=?\%9+S^TIHO!O@:W%@K8CNM<N6,D@SU,4> G&>-[?7M63_
M ,%6OB5>7?C;PKX$AF9--LK'^UIXU) DGD=XTW>NU(VQ_P!=6KZ[_9%^ /AS
MX,_"/PX]KIELWB/4+&*\U+5&B!GDED0.4W'D(F[: ,# SC))/7&,*<%.:NV8
MMRE+EB>$?![_ (*F:!XFUR'2_'OAS_A%8IB$35[.X-Q;HQ_YZH5#(O\ M MU
MY  S7VOKOBG2?#/AF]\0ZE?PVNBV=LUY/>ELQK"J[BX(SD8Z8SGM7S5^T]^P
M3X>^/_B/2M;T>^M?!>IH734[JVL!+]M0XV$H'0;U((W$Y(/.=HKTB;]FO3]8
M_9SM/A!K/B35[S2H;:*T?5+8QPW3Q12B2-.590HVHN,'*KC/6LY^R=G'3N./
M.KIGRWXN_P""LUE::]+#X:\ 2:EI$;86ZU'4?L\LPSU\M8W"?BQZ]!TKZ*_9
MA_;$\*?M,0W5G96LV@^)K./SKC1[J029CR!YD4@ \Q02H/"D$CC!!//^&/"_
MP@_8!^'%U;:YK!,>M7$S&ZOK3SKN^ 0?N,1IRJKV.%RY)QDU\D?\$^?!.J^,
M_P!J:\\=Z#I<NE>"]-DOI9"4Q$JSI(L-JIZ%AYBM@=!'[C.SA3E"3BK6Z]R.
M:2:39]]?M.?'Z#]F[X8MXMFTC^W)&O(;*&P^U?9O,=]Q/S['QA48_=.<?C7R
M-_P]T_ZI1_Y<?_W)6C_P5H\6^3X=^'_AA),_:;JYU*6,'IY:+'&3]?.D_(UP
MOPC_ &FOV9O!O@3PKX>\1?"R+7-5M=.A34=;F\-V%P9+DJ#)EG;S'4,2-Q&>
M!QBG3IQ]FI.-V$I/FLG8^P_V3?VHO^&HO#NO:I_PC/\ PC/]EW26WE?;_M?F
M[DW;L^5'C'3&#7ND]Q':P2332+##&I=Y)&"JJ@9))/0 5PGP6/PWU#P?%K7P
MPL-!M- U(^:9-!LH[5)' QB1$52'7H0PR.E?+?\ P4._:)O;>&U^"W@II+OQ
M-KYCBU-;3F1(9"!':KC^.7(R/[F!T>N?D]I/EBK&G-RQNR;PS_P48?QY^T9I
MO@3P]X=L[CPM?ZJNG0:Q-,XFE3.#,$Q@ D$J#S@C//%?;M?C/\&?AW>?"?\
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ML]6LBP<VU];I-&6'0[6!&15PERR4B9*ZL?DO^RG^W1_PS'\/-1\+_P#"$_\
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MNX,"3E<5^EFB_#/P?X;U"._TCPIH>EWT8(2ZLM.AAE4$8(#*H(R"1^-3^*_
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MUQM:U3P+X;U'5V;<U]=:3!),S>K.R$D^YKL+>WBM+>.""-(88U")'&H544#
M  Z #M52K1::BK7W$H.ZN]C\[/VR/B9\:_V>OC]:>);77M5N_AY<74%Y8V8D
M(LWVJOG6DNT<9*O@'JK C)!QR_[4G_!0+3/CQ\)?^$&\)^&M4L+K6)(1J,E]
MY;8"2*XBA"%BY9U3YB%. 1MYX_335-)L=<T^:QU*RM]0L9AMEMKJ)98W'7#*
MP(/XURWASX*_#WP?JG]I:%X&\.:-J(.1=V&E00RKP!\K*@(''04HU867-'5
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M&VTNTCMHR?7:@ S6Q45*G/9)62*C'EU>X4445B6%%%% !1110 4444 %%%%
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M*^5)H\ML8?BI_P $^_C%X/T6_P#%,6L^#]9N1G3[:X=[:: R!)"87&89!O#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9W_0A7O_ (335^D=%;>VC_(B.1]S\W/^&@OVSO\ H0KW_P )IJ/^&@OVSO\
MH0KW_P )IJ_2.BCVT?Y$'(^Y^;G_  T%^V=_T(5[_P"$TU'_  T%^V=_T(5[
M_P"$TU?I'11[:/\ (@Y'W/S<_P"&@OVSO^A"O?\ PFFH_P"&@OVSO^A"O?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_&*/90_G0<\OY3](Z*_-S_AA/]IS_HKUE_X4VI__ !BC_AA/]IS_ **]9?\
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MYT'/+^4_2.BOS<_X83_:<_Z*]9?^%-J?_P 8H_X83_:<_P"BO67_ (4VI_\
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MX83_ &G/^BO67_A3:G_\8H]E#^=!SR_E/TCHK\W/^&$_VG/^BO67_A3:G_\
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M]IS_ **]9?\ A3:G_P#&*/90_G0<\OY3](Z*_-S_ (83_:<_Z*]9?^%-J?\
M\8H_X83_ &G/^BO67_A3:G_\8H]E#^=!SR_E/TCHK\W/^&$_VG/^BO67_A3:
MG_\ &*/^&$_VG/\ HKUE_P"%-J?_ ,8H]E#^=!SR_E/TCHK\W/\ AA/]IS_H
MKUE_X4VI_P#QBC_AA/\ :<_Z*]9?^%-J?_QBCV4/YT'/+^4_2.BOSAM?V%_V
MFHKF)W^+EFR*X++_ ,)+J9R >1_J*_1ZLYQ4=G<N,F]T%%%8?C;4)-,\*ZC<
M1$K((P@8=1N8+G]:\_%XB.#P]3$SVA%R?HE<WI4W6J1IK=M+[SDO&'Q0DM;F
M2ST?83&=KW3#<,^BCI^)_P#KUQP\>:^LF_\ M.;.<]!C\L8K!HK^3,PXGS7,
M*[KRKRBNBBVDO2WY[GZKA\MPN'IJ"@GYM7;/5?!GQ,;4;F.QU4(DSG;'<*,!
MCZ,.Q]Q7H=?,_3D5]">%[Y]2\.Z?<R'=))"N]O5@,$_F*_8^!.(L3FD:F"QD
MN:4%=2ZM;-/O;37K?4^0SS+Z>%<:U%63T:\_(U*X+XA_';P)\*=>T'1?%.OQ
MZ9JNNR>5I]J+>:9YF+J@SY:-L!9@ S8!YYX.+/QFUKQ/X=^%_B+4/!>GC5/%
M4-M_Q+K0PF422E@H^4$9QDGK@8R>,U^6OQ8^'/Q%\&_'WX6ZS\4];_M?QAXB
MO[2\G@W*XLD6Z15AW+\G'/RQC8O8GK7['2IJINSY"<G'8_7UF"*68A549)/
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M17Q+-^V3\8?B[XX\3:5\#?AOI6NZ1X?N/L]Q?:U< -+\S*' ,\*J&*,0H+'
MR<9P/4/V5_VF/$WQIU+Q#X>\9>!;SPKX@T-VCGNH(9382.K[7CWL"$D4D?)O
M;<,D'BG*E**NP4TW8^BJ***Q+"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&"]LKL_*,=Q/BZE5_57RP6VB;?K>Y^MGP,_;#\"_'&\32K62?0O$3 E-+U+
M,V!D^4X.U\>G#<$[<#->Z5^$ME>W&FWD%W:3R6UU!(LL4T+%7C=3E64CD$$
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MIY9D?RAY2*L>0JH>K$\8Y^N?'>FW.L^!_$.GV<?G7=WIUQ!#'N"[G:)E49)
M&21R>*RJ25XQ3V+BM&V?&_\ P2>_Y)/XT_[#:_\ HA*^Y:^4_P#@GM\$?&OP
M.^'OB?3/&VB_V+>WFJ+<P1?:H+C?'Y2KNS$[ <@\$YKZLJ*S3J-HJGI%7/EG
M]K#X"?#+]I?Q#8:%-XYTCPY\3["/R+6%;N&6ZDC(\WRI;4N)&7!+J1@C<3R#
M@_+NM?!?]J#]D#1Y-?T/Q4^J>%M)C:6:+3=1:YM((01DO:3JHQ@#)13M&?F
MYKZ(_; _8Y\1?$[QMIWQ,^&NKQZ3XXT^.,/;R2F'[0T1)CDCE'W9 ,+AOE(
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M:^'/"%M=/?1:/91VOVF1=IE8#YGVY.,DDXR<9QDUUM<+WT-UL%%%%(84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:E#FF^5KT)C4LE<_2?Q_XZT?X9^#-7\4:_="TTC2X&GGD[D#@*H[LS$*!W+
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MNI:3H=]?VK2+N42Q6[NA([C<HXKY:_8)_:J\>_M">+O%.G>+[BQFMM/L8KB
M6EH(2&:3:<D'GBO0K/Q9=>./^">^HZU?2&:]N/A]>K/*S;C)(EE)&SD^I*DG
MW-?+O_!)G_DHGCS_ +!4'_HZHC!>SG=:HIR?-&Q^FE<A\8O$U]X+^$?C?Q#I
MC(NI:3H=]?VK2+N42Q6[NA([C<HXKKZ\Z_:._P"3>?BA_P!BMJG_ *22US1^
M)&KV/G#]@G]JKQ[^T)XN\4Z=XON+&:VT^QBN(!:6@A(9I-IR0>>*^U*_,O\
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MP'H=Y\)].U#4M9FU+RKN/3]).H.L'E.<E C;1N"_-CV[U\?_ +!/PMU+XO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMHZ;:6"BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[J6FH\R1K(RN@,B[X\.&/&#D ^AKSCPG^S#JGCS]DJS^&?Q6OIKCQ$LD\_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#/\ X.+?_P"+KY"_X=,^$_\ H?-:_P# 2&C_ (=,^$_^A\UK_P !(:VY:/\
M-^!'-/L?7O\ PNKX>?\ 0^>&?_!Q;_\ Q='_  NKX>?]#YX9_P#!Q;__ !=?
M(7_#IGPG_P!#YK7_ ("0T?\ #IGPG_T/FM?^ D-'+1_F_ .:?8^O?^%U?#S_
M *'SPS_X.+?_ .+H_P"%U?#S_H?/#/\ X.+?_P"+KY"_X=,^$_\ H?-:_P#
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MF?"?_0^:U_X"0T?\.F?"?_0^:U_X"0T<M'^;\ YI]CZ]_P"%U?#S_H?/#/\
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M\\,_^#BW_P#BZ^0O^'3/A/\ Z'S6O_ 2&C_ATSX3_P"A\UK_ ,!(:.6C_-^
M<T^Q]>_\+J^'G_0^>&?_  <6_P#\71_PNKX>?]#YX9_\'%O_ /%U\A?\.F?"
M?_0^:U_X"0T?\.F?"?\ T/FM?^ D-'+1_F_ .:?8^O?^%U?#S_H?/#/_ (.+
M?_XNC_A=7P\_Z'SPS_X.+?\ ^+KY"_X=,^$_^A\UK_P$AH_X=,^$_P#H?-:_
M\!(:.6C_ #?@'-/L?7O_  NKX>?]#YX9_P#!Q;__ !='_"ZOAY_T/GAG_P '
M%O\ _%U\A?\ #IGPG_T/FM?^ D-'_#IGPG_T/FM?^ D-'+1_F_ .:?8^O?\
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M^:U_X"0T?\.F?"?_ $/FM?\ @)#1RT?YOP#FGV/KW_A=7P\_Z'SPS_X.+?\
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M_P"'3/A/_H?-:_\  2&C_ATSX3_Z'S6O_ 2&CEH_S?@'-/L?7O\ PNKX>?\
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M3/A/_H?-:_\  2&CEH_S?@'-/L?7O_"ZOAY_T/GAG_P<6_\ \71_PNKX>?\
M0^>&?_!Q;_\ Q=?(7_#IGPG_ -#YK7_@)#1_PZ9\)_\ 0^:U_P" D-'+1_F_
M .:?8^O?^%U?#S_H?/#/_@XM_P#XNC_A=7P\_P"A\\,_^#BW_P#BZ^0O^'3/
MA/\ Z'S6O_ 2&C_ATSX3_P"A\UK_ ,!(:.6C_-^ <T^Q]>_\+J^'G_0^>&?_
M  <6_P#\71_PNKX>?]#YX9_\'%O_ /%U\A?\.F?"?_0^:U_X"0T?\.F?"?\
MT/FM?^ D-'+1_F_ .:?8^O?^%U?#S_H?/#/_ (.+?_XNC_A=7P\_Z'SPS_X.
M+?\ ^+KY"_X=,^$_^A\UK_P$AH_X=,^$_P#H?-:_\!(:.6C_ #?@'-/L?7O_
M  NKX>?]#YX9_P#!Q;__ !='_"ZOAY_T/GAG_P '%O\ _%U\A?\ #IGPG_T/
MFM?^ D-'_#IGPG_T/FM?^ D-'+1_F_ .:?8^O?\ A=7P\_Z'SPS_ .#BW_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M 2<#@ FNRKY/^ __  3Y\/? CXH:3XUL/%FIZI=:>LRK:W%O&B/YD3Q')'/
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M4W+F:L?G+K'_  3&^+]]JU[<QW/AKRYIWD7=J$@."Q(S^Z]Z^M?@];/^PO\
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MT>,B>14S$P!7*!#SUSGO7I%%%>>W=W.A;!1112&%%%% !1110 4444 %%%%
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M"%(QT)Q7US^Q1X/^.?PRNM?\*?$ZWDO?"]NN[2-5FU*&[(=7VE$Q(91&RD,
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "O*?VK/^3:_B9_V +O\ ]%FO5J\I_:L_Y-K^)G_8
M N__ $6:N'Q(4MF?E%^R_P#\+N^W>(/^%+_;/M7EP_VG]D^SYV9?R\^=[[^E
M=G\;I/VK-4\$WL7Q#A\4OX7A.^\ @C6WV@CF7R  R @'YLKD U=_8%_:.\&_
ML\ZOXSN/&$]Y#'JD%K';?8[8S$F-I"V<'C[XKZD^(W_!2WX3S>!]:M]&@U;6
MM3N;62W@LYK'RXG9U*CS&9ON<\XR<=!7ISE-5-(7\SDBH\NK&?\ !-'Q]\.;
MSX>WWA/PS9W6F>+;?%]J\=_(LLEX2%3SHW4 >6I(4)@%=PSDL6/R9HF+S_@H
MT?[6X/\ PL*;K_>6];R@/;(3%=I_P2W\!ZSJGQHU/Q7%!)'H6EZ;+:SW1&$>
M:4ILB![G +GTVC/45)_P4*^">O?"GXU1?%?P]'-%I.JW,-Y]MMD/_$OU"/;]
MX]M[*)%)ZL7';F5:-64;[H>K@GV/T.^/7Q(N?A#\(?$_C&SLXM0N=)MA.EM.
MQ5)"75<$CD?>KX*_X>R^+?\ H0]%_P# N:O;?AK_ ,%+OA;XJ\)0#QS]I\-:
MTL6V[M3927=M*X'6-HU8X8] P&.F3C)^7OVWOVLO!7QXT?1_#G@K09[:ST^\
M^VR:K<PI 9CY;)L6-<G;\^<L0<C[O>LJ-+7EG#YESEI>+/O+X._M/6GC#]FU
M?BUXNMHM L8C.;N.S#SK&D<YB! P6.>.W>N;_P"'C?P*_P"AFO?_  4W/_Q%
M8?[)?P?7QY^PSI_@GQ5!J6CVFM"Z,GEJ(;CR7N6D1T\Q6 # *02I!!R.N:R/
M^'5'PF_Z&'QG_P"!MI_\BUGRTE)J7<J\[*Q\L_\ !2K7U\2_'S2+^WD:33Y_
M#5C-9LP(S$[2R X/3)8\5^J7P[AM[?X?^&8K0YM(],M5AXQ\@B4+^F*^&/\
M@I%^S7>?\(?X3\:>'()]0MO#.FQZ+J*X#S+:)S#.VT#(4EPY XW@X !QH_LM
M_P#!13P5I7PST?PU\1[F\T?5]&MELTU);9[B&[B08C)$:EE<*%4Y!!(W9Y(%
MSBZE*/)K8F+Y9NY][UYK^T-\;])_9^^%^J>*]3VS3QCR-/LBV&N[I@?+C'MP
M68]E5CVQ7YX_M=?MG:A\=_&OAG0_A5/K=A9:;<$VUU9M);W=_>2$(FQ4.X #
MA1PQ+MD#BOHWXT?LA_$3X[? GX8Z!JGBJUD\6:,LESJU[K4CLSRRJ"8PT:G=
ML^YGN%!Y)K/V*CRNH[7+Y^:ZB>6?L=_!+5OB<WC+X_?$ O?7]W#>-I N%XDF
M,;+)<@=E3F.,=!AL8VJ:P?\ @D[_ ,E3\;?]@9/_ $>M0ZE_P3-^*.AZ)=W!
M\>Z+]EM+=Y3#'/= ;54D@#R\=!7@?[,G[/7B;]HCQ)J^E>&-<M-"N=/M!=2R
MW<DJ!T+A=H\M2<Y.>:[/=G&7O:?D8:Q:T/V^K\M;Z;_AN;]NQ+)YFN?!&BR,
M%3G8UA;-\Y _Z;2D#/!Q*/[HK] _VCO&DWP]^ _COQ!;-Y=W9Z3/]G?.-LSK
MLC;\&93^%?'?_!)?P?&MC\0/%4D:M*TEMID$F.54!I)1^):'_OFN2E[L)5/D
M;3UDHGZ$11)!&D<:+'&@"JBC 4#H .PKR/\ :O\ C,/@5\#?$/B2&41ZM(GV
M'2P1G-W*"$..^T!I"/1#7K]?G7_P5F\:3>=X!\)1MMM]MQJLZY^\V1%$<>P\
M[_OJLJ,>>:3+F^6+9TW_  2]^#:V?A76OBGJJFXU76II+&PFFRS+ C_OI-QZ
MEY05)_Z9>YK[NK@?@'X/C\ _!/P/H$<:QM9:/;)*%& 9C&&E;\79C^-=]2J2
MYYMA%<J2"BBBLBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH ^=O^"@US/:_LC^.3 2N[[%&[*<$(;V '\^GXUX3_ ,$DX;=?
M#7Q(E4_Z6UW8K(,?P!)BGZL]?9?QH^'$/Q=^%7BCP?-*L']K63P1S.,K%+]Z
M-R.X5U4_A7Y:_LN_'+5/V*/C'XB\/^-](O(M,NRMEJUG&!YMO+&Q,5P@/#J
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MX&@A^QZ;8W]P\L,]P6!=X@^2%C"E3MP"S]RIQR^QDH.<M#7G5[(^^Z***P-
MKSOQY^T+\./A?KBZ/XK\7:=H>IM"MP+6Z9@YC8D!N >"5/Y5Z)7AWQE_8X^'
M'QX\7)XD\56VHRZFEJEH&M;QHD\M"Q'R@=<N>:N/+?WMB7>VA:_X;+^"?_11
M]%_[^-_\31_PV7\$_P#HH^B_]_&_^)KSO_AVA\$_^?'6O_!FW^%'_#M#X)_\
M^.M?^#-O\*VM1[LCWST3_ALOX)_]%'T7_OXW_P 31_PV7\$_^BCZ+_W\;_XF
MO._^':'P3_Y\=:_\&;?X4?\ #M#X)_\ /CK7_@S;_"BU'NP]\]$_X;+^"?\
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M)_\ /CK7_@S;_"BU'NP]\]$_X;+^"?\ T4?1?^_C?_$T?\-E_!/_ **/HO\
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M\]$_X;+^"?\ T4?1?^_C?_$T?\-E_!/_ **/HO\ W\;_ .)KSO\ X=H?!/\
MY\=:_P#!FW^%'_#M#X)_\^.M?^#-O\*+4>[#WST3_ALOX)_]%'T7_OXW_P 3
M1_PV7\$_^BCZ+_W\;_XFO._^':'P3_Y\=:_\&;?X4?\ #M#X)_\ /CK7_@S;
M_"BU'NP]\]$_X;+^"?\ T4?1?^_C?_$T?\-E_!/_ **/HO\ W\;_ .)KSO\
MX=H?!/\ Y\=:_P#!FW^%'_#M#X)_\^.M?^#-O\*+4>[#WST3_ALOX)_]%'T7
M_OXW_P 31_PV7\$_^BCZ+_W\;_XFO._^':'P3_Y\=:_\&;?X4?\ #M#X)_\
M/CK7_@S;_"BU'NP]\]$_X;+^"?\ T4?1?^_C?_$T?\-E_!/_ **/HO\ W\;_
M .)KSO\ X=H?!/\ Y\=:_P#!FW^%'_#M#X)_\^.M?^#-O\*+4>[#WST3_ALO
MX)_]%'T7_OXW_P 31_PV7\$_^BCZ+_W\;_XFO._^':'P3_Y\=:_\&;?X4?\
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MO._^':'P3_Y\=:_\&;?X4?\ #M#X)_\ /CK7_@S;_"BU'NP]\]$_X;+^"?\
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M)_\ /CK7_@S;_"BU'NP]\]$_X;+^"?\ T4?1?^_C?_$T?\-E_!/_ **/HO\
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MNTFMK^RL$>.XBC&T2!9'C,><,..<@G X)'SW\)?V5_VE?"?Q,\-:SXG^+_\
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M9KB,'/E&><*T2$]=H)Y."IY'WW8V-OIME;V=I!';6EO&L4,,2A4C11A54#@
M   >U93C"*2B[LN+D]T3T445B6%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5C^,/">F^//"NJ^'=9A:XTK5+9[2ZB1RA>-QA@&
M!R.#U%;%?.W[77[77_#*_P#PBG_%*?\ "3_V]]K_ .8C]D\CR/)_Z92;MWG>
MV-O?/%QC*3M'<3:2NS._X=R? K_H6;W_ ,&US_\ %U:L/^">/P'L9-[^#IKL
MY! N-6NR!CV$HS^.:^??^'NG_5*/_+C_ /N2C_A[I_U2C_RX_P#[DKJ]GB//
M[S'FI'WQX1\%Z#X!T.'1O#>CV6AZ7$2R6EA L4>X]6( Y8]R>3WJ]K&CV'B#
M2[K3=4LK?4=.NHS%/:742RQ2H>JLK @CV-?GS_P]T_ZI1_Y<?_W)1_P]T_ZI
M1_Y<?_W)6?U>KO8KVD.Y[OXF_P""<_P1\1W\EW'H-[HSR/O:/3+^1(\Y!("-
MN"CV7 &>,<8ZGX;_ +%/P=^%U]%?Z7X0@OM2B;<EYJ\C7CH>Q57)12.Q"@^]
M?+__  ]T_P"J4?\ EQ__ ')1_P /=/\ JE'_ )<?_P!R5I[/$-6_4GFIGZ)4
M5^=O_#W3_JE'_EQ__<E'_#W3_JE'_EQ__<E9_5ZO8KVD.Y^A\L23QO'(BR1N
M"K(PR&!Z@CN*^<O&W_!/GX*>-M4EU ^')M#N)FWR+HMT]O$QSGB+E%^BJ!S7
MS[_P]T_ZI1_Y<?\ ]R4?\/=/^J4?^7'_ /<E5&C6C\*_$3G![GUG\(_V3?A=
M\$K[^T/#/AB%-6QA=2OI&N;A.,'8SD^7GG.P#.:]?K\[?^'NG_5*/_+C_P#N
M2C_A[I_U2C_RX_\ [DI.A6D[M#52"V/T*O[*+4K&XL[A=T%Q&T4B@XRK @C/
MT->7?!O]EOX=_ 76+_4_!FDW&GWE] +:=YKV6<,@8-C#L0.0.E?(W_#W3_JE
M'_EQ_P#W)1_P]T_ZI1_Y<?\ ]R4>PK)62_$/:0W/N[XB_#W1?BIX,U+PKXBM
MY+K1M15%N(8IFB9@KJX&Y2"/F0=#[5C?!WX'^$/@/X?O-&\&Z?)I]A=W1O)D
MEN'G+2%%3.YR2!A%XZ5\5?\ #W3_ *I1_P"7'_\ <E'_  ]T_P"J4?\ EQ__
M ')1["M:UM ]I"]S]$J\A^,7[*?PY^/'B"TUKQEI-SJ%_:6HLX7BOIH%6,.S
MXVHP&<NW/7IZ5\E_\/=/^J4?^7'_ /<E'_#W3_JE'_EQ_P#W)0J%:+ND#J0>
MY^AT,*6\,<4:[8XU"JOH , 5)7YV_P##W3_JE'_EQ_\ W)1_P]T_ZI1_Y<?_
M -R4OJ]7L'M(=S]$J*_.W_A[I_U2C_RX_P#[DH_X>Z?]4H_\N/\ ^Y*/J]7L
M'M(=S]$J*_.W_A[I_P!4H_\ +C_^Y*/^'NG_ %2C_P N/_[DH^KU>P>TAW/T
M2HK\[?\ A[I_U2C_ ,N/_P"Y*/\ A[I_U2C_ ,N/_P"Y*/J]7L'M(=S]$J*_
M.W_A[I_U2C_RX_\ [DH_X>Z?]4H_\N/_ .Y*/J]7L'M(=S]$J*_.W_A[I_U2
MC_RX_P#[DH_X>Z?]4H_\N/\ ^Y*/J]7L'M(=S]$J*_.W_A[I_P!4H_\ +C_^
MY*/^'NG_ %2C_P N/_[DH^KU>P>TAW/T2HK\[?\ A[I_U2C_ ,N/_P"Y*/\
MA[I_U2C_ ,N/_P"Y*/J]7L'M(=S]$J*_.W_A[I_U2C_RX_\ [DH_X>Z?]4H_
M\N/_ .Y*/J]7L'M(=S]$J*_.W_A[I_U2C_RX_P#[DH_X>Z?]4H_\N/\ ^Y*/
MJ]7L'M(=S]$J*_.W_A[I_P!4H_\ +C_^Y*/^'NG_ %2C_P N/_[DH^KU>P>T
MAW/T2HK\[?\ A[I_U2C_ ,N/_P"Y*/\ A[I_U2C_ ,N/_P"Y*/J]7L'M(=S]
M$J*_.W_A[I_U2C_RX_\ [DH_X>Z?]4H_\N/_ .Y*/J]7L'M(=S]$J*_.W_A[
MI_U2C_RX_P#[DH_X>Z?]4H_\N/\ ^Y*/J]7L'M(=S]$J*_.W_A[I_P!4H_\
M+C_^Y*/^'NG_ %2C_P N/_[DH^KU>P>TAW/T2HK\[?\ A[I_U2C_ ,N/_P"Y
M*/\ A[I_U2C_ ,N/_P"Y*/J]7L'M(=S]$J*_.W_A[I_U2C_RX_\ [DH_X>Z?
M]4H_\N/_ .Y*/J]7L'M(=S]$J*_.W_A[I_U2C_RX_P#[DH_X>Z?]4H_\N/\
M^Y*/J]7L'M(=S]$J*_.W_A[I_P!4H_\ +C_^Y*/^'NG_ %2C_P N/_[DH^KU
M>P>TAW/T2HK\[?\ A[I_U2C_ ,N/_P"Y*/\ A[I_U2C_ ,N/_P"Y*/J]7L'M
M(=S]$J*_.W_A[I_U2C_RX_\ [DH_X>Z?]4H_\N/_ .Y*/J]7L'M(=S]$J*_.
MW_A[I_U2C_RX_P#[DH_X>Z?]4H_\N/\ ^Y*/J]7L'M(=S]$J*_.W_A[I_P!4
MH_\ +C_^Y*/^'NG_ %2C_P N/_[DH^KU>P>TAW/T2HK\[?\ A[I_U2C_ ,N/
M_P"Y*/\ A[I_U2C_ ,N/_P"Y*/J]7L'M(=S]$J\V^+G[.?P\^.4,8\8^&[?4
MKN)-D.H1EH;J->< 2H0Q4$D[22N3TKXV_P"'NG_5*/\ RX__ +DH_P"'NG_5
M*/\ RX__ +DIJA6B[I![2#W/=O#O_!.7X(Z!J27DFA7VKF-Q(L.HZA(\0QT!
M5=NX>S9SWKZ1TG2;'0=-MM.TRRM].L+9!'!:VL2Q11*.BJJ@ #V%?GQ_P]T_
MZI1_Y<?_ -R4?\/=/^J4?^7'_P#<E.5&O+XOS$ITUL?37Q"_8B^$GQ0\9:GX
MH\0Z#=7>LZBZR7,T>HSQJQ5%0857 '"CH*YW_AW)\"O^A9O?_!M<_P#Q=>#_
M /#W3_JE'_EQ_P#W)1_P]T_ZI1_Y<?\ ]R57L\0M%^8N:F?2O@;]AGX0?#GQ
M=I?B70M NK;5]-F$]M,^I3R!7 (R59R#U[U=\&_L9_"OP+\0;?QMIFB7)\1P
M3R727=UJ$T_[V0,&<JS$$_.QR1P>:^7?^'NG_5*/_+C_ /N2C_A[I_U2C_RX
M_P#[DI>SQ#_X<.:F?HE7!_&#X(^#_CMX?M=%\9:8VI6-K<B[A$<SPND@5ER&
M0@XPQR,X/'H*^*?^'NG_ %2C_P N/_[DH_X>Z?\ 5*/_ "X__N2I5"JG=(KV
MD'U/MOX1?!OPQ\#O#,OA_P (VMQ9:3)<M=F">ZDGVR,JJQ4N20#M' XSD]S6
MQX\\$Z5\2/".J>&=;CFETG4HO)N8X)FA9TR"5W*00#C!P>02*^#/^'NG_5*/
M_+C_ /N2C_A[I_U2C_RX_P#[DH]A6O>VH>TAL?8/P9_9I^'_ , ;C5)_!>CR
M:?/J2QI<R374D[%4+%0"[':,L<XZ\9Z"O4:_.W_A[I_U2C_RX_\ [DH_X>Z?
M]4H_\N/_ .Y*'0K2=V@52"V/K#XO?LE?#+XY>)H=?\7:'+>ZK%;+:">"\E@S
M&K,RA@C $@L>3SC ["D^(G[)?PW^*ND^&-.\3:7>:C;>'+/[#IW_ !,)D=(L
M(,,P8%SB->6R>*^4/^'NG_5*/_+C_P#N2C_A[I_U2C_RX_\ [DJO95U;R\Q<
M],]Y7_@G+\"58$^&+Q@#]TZM<X/_ (_7J/PP_9R^&OP9F>X\'^$+#2+Q@5-X
M=\]P%/51-*S. ?0'%?&O_#W3_JE'_EQ__<E'_#W3_JE'_EQ__<E#I5Y:/\Q<
MU-;'Z)5YM\7/V<_AY\<H8QXQ\-V^I7<2;(=0C+0W4:\X E0ABH))VDE<GI7Q
MM_P]T_ZI1_Y<?_W)1_P]T_ZI1_Y<?_W)4JA6B[I%>T@]SW;P[_P3E^".@:DE
MY)H5]JYC<2+#J.H2/$,= 57;N'LV<]Z^D=)TFQT'3;;3M,LK?3K"V01P6MK$
ML442CHJJH  ]A7Y\?\/=/^J4?^7'_P#<E'_#W3_JE'_EQ_\ W)3E1KR^+\Q*
M=-;'Z)45^>5M_P %;OM%Q%%_PJG;YCA<_P#"19QDX_Y]:_0VL)TY4_B1I&2E
ML%%%5=4U"/2=-N;R7F.%"Y ZG';\:YZE2-*$JDW9)7;\D:1BY-1CNR+5M<L=
M#@$U]<I;H?NAN6;Z <FN<'Q6T+S-N;@+G[_E<?SS^E>3ZUK-SKVH27=T^^1S
MPO9!V4>@JC7\^9AXC8V5=_4(1C36W,FV_-ZJWIT[GWV'X>HJ"]O)N7EL?1FE
MZQ9:U;^?97"7$?0E>H]B.H_&KE?//A_7KGP[J4=W;,>#AX\_*Z]P:^@+.[CO
M[."YB.8ID61?H1D5^F\*\3QXAHR4X\M6&Z6S3ZK_ "Z=SYK-,M>7S3B[Q>W^
M3)J*SO$7B+3/"6AWNL:S?P:9I=E&9KB[N7"1Q*.Y)K\^OBI_P4.U?QA\<O"'
MA_X6:F^G^$O[2M[2]OIK*)GU/S)D5MJRH6C0+D C:QW$G&!7W\*<JFQX,I*.
MY^BU%<+\;_BO8?!'X6Z_XSU"$W46FP!H[56VF>9F"1QY[9=E!.#@9.#BOSY7
M]K#]JJ/PK_PMU[*U;X<FYQY'V"V%IM\S9M S]IV;OEWEL9_BIPI2J*Z"4U$_
M4"BO-OAK\=O#OC[X)Z9\2[FZAT319K0W%X]W* EHZ$I*C-[.I [GCCG%?&7Q
M4_X*':OXP^.7A#P_\+-3?3_"7]I6]I>WTUE$SZGYDR*VU94+1H%R 1M8[B3C
M HC2E-M); YJ*N?HM116+XT\5V?@7P?K?B/4!(UCI-G-?3K$,N4C0N0H]<"L
M2S:HK\V-$_:,_:S_ &D9=0U[X6Z3;Z3X;M[AK=8K6*QVJ1\P5I;PYD<*RY*8
M'^R,XKUC]DO]KSQSXL^+&H?";XL:1'8^+;=)#!=1P"!S)&N]HY4!VG*9973
M('?(-=$J$HINZT,U439]GT50UO7M,\,Z;-J.KZC::5I\(S+=WTZPQ1CU9V(
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MD<'\JV-%U[3/$FG1:AI&HVFJV$O^KNK*=9HGQUPRD@_G19[C+]%%%( HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M (#I_A6C10!G?\(WI/\ T"[+_P !T_PH_P"$;TG_ *!=E_X#I_A6C10!G?\
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M!G?\(WI/_0+LO_ =/\*/^$;TG_H%V7_@.G^%:-% &=_PC>D_] NR_P# =/\
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M ,FD^"?]Z]_]+)ZT_P!MCX<^'?'?[/GBN^US3OMUUH&G76I:;)Y\D?D7"Q,
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M8V<C%[:;LZ9X&?[PZ$?XBN9K^>*U&IAZDJ556DMSXJ47"3C+=!7TA\!9Y)O
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MQ1K7B*ST6&VN8QJNH2W7D(!=,^SS&.W(09QUP/2N8^#,GQQ_;@\3>(?%]O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0@,"",BJ8T73
MUDWBPM@^<[O)7.?7I5VBLITJ=2W/%.W=%1E*/PNP4445J2%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %+5]%L=>LFM-0M8[N
MW;G9(,X/J#V/N.:X2;X!^&)9BZF^A7/^K2<%1^:D_K7I%%<.(P.%Q34J]-2?
MFC*=&G4UG&YA>&?!.C>$8V&F620R,,/,Q+2-[%CSCV'%;M%%=-.E3HQ4*<4D
MNBT+C%15HJR"HKJUAOK::VN88[BWF0QR0RJ&1U(P58'@@CC!J6BM2C"\)^ _
M#7@*TFM?#/AW2?#EK._FRPZ38Q6J2/C&YEC4 G  R?2I_$WA/0_&FEG3?$&C
M:?KNG,P<VFIVJ7$)8=#L<$9'KBM:BG=[@9?AOPKHO@[35T[0-'L-#T]266TT
MVV2WB!/4A$ &?PJ_=6L-];36US#'<6\R&.2&50R.I&"K \$$<8-2T4@,+PGX
M#\-> K2:U\,^'=)\.6L[^;+#I-C%:I(^,;F6-0"< #)]*W:** *VHZ;::Q8S
MV5_:PWMG.I26WN(Q)'(IZAE(P1[&N4T+X*?#SPOJD>I:-X"\,Z1J,9REY8Z/
M;PS+]'5 1^==I13NP"N2USX0^!/$^LC5]8\%>'=6U8$$7]]I4$TX(Z?O&0MQ
M]:ZVBB[6P#5C6.-4555%&T*!@ >F*Y_PG\.?"?@-KQO#/A?1O#K7FW[2=)T^
M&U,^W.W?Y:C=C<V,]-Q]:Z*B@#G?"?PY\)^ FNV\,^&-&\.M>;3<MI.GQ6IG
MVYV[_+4;L;FQGIN/K4?B?X8>#?&U];WOB+PEH>O7MN-L-QJFFPW,D0SG"LZD
MCGGBNFHHN[W$<[_PKGPG_P )-;^(_P#A&-&_X2&WC$4.K?V?%]KB0(4"K+MW
M@;25P#T)'2NBHHH&8/BSP#X8\>V\$'B;PYI/B."!B\46K6,5TL;'@E1(I /T
MJU%X6T6'P_\ V%'I%A'H?EF'^S%MD%MY9ZIY6-NWVQBM2BB[ Y'3?A!X#T;1
M]0TG3_!/AVQTK4!MO+&VTF"."Y Z"1%0*XX'4&K+?#/P>_A)?"K>%-#;PPIW
M#13IT/V('?OR(=NS._YNG7GK72T478K(Q[7P=H%EX9/ARWT/38/#QA:W.DQ6
MD:VGE-G<GE ;-IR<C&#DTWPSX*\/>"=+?3?#N@Z9H.G2.97L],LX[:%G( +%
M$4 D@ 9QV%;5%%V,Y[PG\//"O@%;H>&/#.C^'!=%6N!I-A%:^<5SM+^6HW8R
M<9Z9-+XL^'WA;QY%#%XF\-:/XBCA.8DU:PBNA&?51(IQ^%=!11=WN(S]"\/Z
M7X7TN'3=&TVSTC3H1B*SL8$AAC'HJ* !^ K-7X<^$X_%C>*5\,:,OB=N#K0T
M^(7I^39_KMN_[OR]>G'2NBHHNQD5U:PWUO);W,,=Q!(I5XI5#*P/4$'@BN2T
M3X+_  ^\,ZLFJZ/X$\,Z5JD;%DO;'1[>&92>I#J@8'\:[*BB[ ****0!1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5XQ\?/VL/!/[..I:19>*XM5DFU2
M*2:#^SK991M0@'=EUP<D5[/7GOQ/^ 'P_P#C-=V%UXS\-P:[/8HT=L\TTJ>6
MK$%@-CKU('6KCRW][83O;0\%_P"'H7P<_P"?;Q-_X+X__CM'_#T+X.?\^WB;
M_P %\?\ \=KY:_X*-?!;P5\&?%'@NV\&:##H4%]9W$ERD,LC^8RN@4G>S= 3
MTKZM^ G[&_P;\6?!'P%K>K>!K2]U34-#L[JZN&N;@&65X59F($@ R23P*[)0
MHQBIV>I@I3;<3T3X@?M@>!/AM\-?"'CC5HM7;1?%$:R6"VUJCS % XWJ7 7@
M]B:]'^%_Q&TGXN> ](\7:&MPFE:I&TD"W<827"NR'<H) Y4]Z^>/VQ6^#'PH
M^&?@?2/'G@6_\0^&K2=K32=/TN\EA^R[(@.6$R%AMP.2:])^"_Q"^'OAG]F7
M1O%VCVLG@[X>V=E-<16^H2M*]M$)G# DL[,Q?. "Q)8 <X%<\HKD329HF[V;
M/9Z*^%_$'_!5_P &66IO#I'@O6=4LEDV_:KBXBMRR_WE3YOP!(]\5[;^SG^V
M;X%_:.NY]+TH7>B^(H(S,VE:D%#2H#RT3*2' XR.",],<TI49Q5VAJ<6[)FC
M\>OVMO _[.>KZ5IOBN+5I+C4H&N(/[.MEE7:K;3N)=<'->L>&]>MO%7AW2M:
MLA(+/4K6*\@$JX?RY$#KN&3@X85^;O\ P5F_Y*)X#_[!4_\ Z.K[Z^$=];Z9
M\#O!=Y>3QVMI;^'+*6:>9@J1HMLA9F)X  !))]*J=-1IQDMV*,FY-'=45\6>
M._\ @J7\/?#>O3:?H&@ZMXHMH9/+;48V2VAD'=HPV68?[RKG'IS7M'[/7[7'
M@/\ :.CN+?0+BXT[7+93)-HNI*J7'E@X\Q-I*NN2,E3D9&0,C,.E.*YFAJ<6
M[)F?\7/VU/A]\%OB&O@SQ!#K+ZPR0R!K.T22+$OW?F,@/UXKT#XT?&70/@/X
M'E\5>)4O'TR.>.W86,0DDW.2%X++QQZU^:?_  4*_P"3Q(?^O73OYU][?MCZ
MYX#\/_!6YN_B/X=O/%'AD7UNKZ?8SM#(9"QV-N61#@'/\5;2IQ7)YDJ3][R.
MP^"'QO\ #OQ_\&/XG\,)>QZ:EW)9D7\*Q2>8BJ3P&;C#CO7H-?*'P/\ CA\+
M?AO^RIX@\?>!_!^K:'X-TK4F$^DR7!GN9)F:"-G5I)7X/F)P6'W3QZ\A_P /
M7OAY_P!"AXF_*W_^.UFZ4I-\BT'SI)79]O45\G?"?_@HOX*^+OQ$T/P?IOAK
M7[.^U:8P13W0@\I"%9LMMD)QA>PK?^,/[<WA/X,_%E? .J:!K-]J3?9_])M!
M#Y/[X#;]YP>,\\5/LIWY;:CYXVO<^DJ*QO&7B:#P5X/UWQ#=123VNDV$]_+%
M#C>Z11L[*N2!DA3C->1?LU_M=>&_VG+[7K;0=&U32GT>.&25M1$>'$A<#;L=
MNFP]?6H46TY+8JZO8]VHKY=NO^"A/P[T?XL:[X(UJSU/13HUQ>6UUJ]T(S;;
MK</G:%8NQ<IM50N26 Q7G_\ P]>\"?\ "0M;GP?K_P#8H;:M^KP^<1GKY.[
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M.F;JJ9X&!EB"!C!(P]G+FY+:FG,K<Q[]17Y7:1^U5^UO\7?,UCP=8W_]E%F
M.B>&XI;0%>JK)-'(21Z;R:V_AO\ \%'/B7\./&PT+XOZ-]MM%F6.],EA]AU"
MR!P"PC 56 ^]M*@GLPK;ZM/HT1[6)^FU%4M%UFR\1:/8:MIMPEYIU]!'=6UQ
M']V6)U#(P]B"#^-7:Y34**\X^/?QU\/?L]_#^Y\4>(&:8;A!9V$) EO)R"5C
M7/3@$ENP!// /Y]+^VC^TU\<M9NYOAQI$]GI]N^&M]"T5+U(01\JRS31N-Q
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M?V4+=R?MR]#Y/^ '[9'BK]E/2[SP5J7@2PO;(7#RW5K?0O8W^]N"LCE3D <
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M$_\ @HA#I.FJ+:QM-=UFQCAC&%$2Q72JN/0!1^0K[6_X)R_\FG^&?^OJ^_\
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MG$D<9#2IM9B"3&'QQG(%<Y_P2I^+WG67B?X;7L_SPG^V--5C_"=J3H/H?*8
M?WG-%3EJ4KP^R$;QG9]3YV^&?P_TKXH?MX3>&];B6XTFZ\4ZE+<0,<+,L+SS
M>6WLQC"D=P37WY^VW\%?"7B#]FOQ3<IH>GV-]H%G]NT^ZM;=(GM_+(8HI 'R
MLNY2O3D<9 K\Y[&Z\7Z/^UGXGUWP-ISZKXAT/7]2U2.SC4N98XIY#*NT$%@4
M+ JO)!..:]H_:._X**-\:?A5<^"?#WA.ZT.\U?9#J,]Q<+,50,"8H@J@MN(
M+'!QD8YR-IPG*<7'9$1E%1:9ZA_P29\37E]X-^(&@2RR/9Z=>VEW C<JC3I*
MKA?^_"DC_&OO:OE;_@GC\!M7^#'PBO;[Q':RZ?KWB.Y6[DL9UVR6\"*5B5QU
M#G<[$'H& (!!KZIKAK-.HVC>G=15PHHHK T"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ KRG]JS_ )-K^)G_ & +O_T6:]6K
MRG]JS_DVOXF?]@"[_P#19JX?$A2V9^:7[#?[4/A7]F?5?%USXHT_6+^/5X;:
M. :1#%(5,;2%M_F2IC[XQC/>O;OVA?\ @I)X(^(WPC\1^%/#7AC77OM:M'LF
MFUF*"&&!'&"XV2R%F Z# YP<\5P/_!-?X0>#/BUK?CR'QAX>L]?CL;>S>V6[
M4D1%FE#$8(Z[1^5?5_Q<_83^"$WP_P#$-W#X;B\+W-K9S72:K:7<R_9F1"VX
MJSE"O'(*],XP<&N^I*DJOO)W.:*GRZ'(?\$R?@CJWP]^'^M^,=8,<;>*OLYL
MK:.0.4MXO,(=B#@%S(?EZ@*,XS@?)OQ663]HC]O:]T/599'T^X\4+H1$+8*6
M<$ODML/8E(W;/JQ-=O\ \$M_B%K>F_&34?"$=U-+X?U+3IKN6S9B8XIXRFV8
M#H"1E"1URN>@QP_QPAF_9S_;NO-?O;:5[&#Q'%XC18A@SVTTHF<)GC^*2/TR
MIJXIJK+O83MR+L?K;)-H'P[\+*TTVG^'/#NEPJGF32);6MK$,*H+$A57H.:^
M=?C=H?[,O[06L:-J?B[X@^%)KO2T>)'L_%%I 9HV(/ER,'W,H()&",;F]:]A
M\?>&=#_:,^#.HZ/9:TK:%XDLU$6J6!64&,LK!E['[N.>G-?F9^V-^Q[X9_9E
M\+Z'?:;XNN=9U34KPPFPO%BC<0A&)E"J=Q 8*N<8^:N2C%2>KLS:;:6VA^HW
MPEL_!^F?#[2-/\!7UGJ'A2SC-O936-_]NB"JQRHFWONPV1]XXQCC&*Z^OAS]
MG/3?%6L?\$X9[/P0]['XJF^V+I[:=<_9[@2?;23LDW+M.W/.17SW_P *E_;.
M_P"?[X@?^%6W_P DT>Q4F[RV8<]DM#<_X*J>,KK4_C-X=\-^:W]GZ5HZW BS
M\OG32/O;'^Y'$/PK]!OV>?A[8?"_X*^#_#]A;K (-.ADN"% :2X= \KMCJ2[
M-^@[5^;O_!1GP+K6@^,/A[KVK1SM+J7A>UM+J:=M[&\@R)@SY.YL2(2<\Y-?
MH_\ LZ_$?3/BI\%_"6OZ9<K<"2PBAN5# M#<1H$EC8=B&!Z]00>A%75_@PML
M3#XW<R/CQ^RSX&_:,NM#N?%D-XL^D&012Z?*L+RH^,QR,5)*9&0 1@DX/)S;
M\3?"0^&/V=];\ ?#A9M)F72KBSTG-])OADD#$'SF8L/F8G.>.@P !7"?M8?M
ME:9^S'J7AO3QI*>)-2U(O-=6*7?DR6]L.!)G:W+-D $<[&Y'6O8/A)\1K?XN
M?#G0_&%IIM[I%KJT'GQ6FH!1,J[B QVL1AL;E.>58' Z5A[ZBF]C3W6VNI^:
MGQT_8;B_9_\ V=M3\7^)-:_MWQI-?VT(^R,PM;978[\%L-*QQ]Y@!S]W/-?4
M_P#P3'_Y-D3_ +#-W_*.K'_!2_\ Y-=OO^PK9_\ H1JO_P $Q_\ DV1/^PS=
M_P HZZ)3<Z-Y=S-149V1[5\1?V<?AO\ %GQ!:ZYXL\*VVL:M;+&D5V\LL;A4
M8LJG8ZY4$DX.0<G/6OB;]OG]KW2?'6GZW\'-!T:X^UVNKK:ZAJ=^\<<0>"3[
ML6&/!< %W*X /'.1]D_$3]JKX8?"OQA#X5\3>)1I^ORF(+9_8YWP)" K%U0H
M%YZENQ]*\[_;$_9\^&E]\"?'_B"7PMHVDZ[:VL^JQZU:6D<%T]UDO\\J@-)Y
MCG:0Q.=_K@C.D^62<T_(J6J?*;W[#OP7O/@?\!;#3-2NH+G4]5N7UBY%K,LT
M,32I&JHCJ=K82-,D$C<6P2,$^R^-?%VG> ?".L^)-6E\G3=*M)+RX;C.Q%+$
M#U8XP!W) KXA_P""3_C/6]4\+^.O#=W/+<:)I,UI<6(D.1 \WG>:BYZ*?*5M
MHX!W'JU;_P#P5.^)+^'?A'H'A"VG,<_B*_,MPJM]ZVMP&*D>AD>$\_W#^!*F
MY5N5@I)0NCR?]E#P;J7[9/[2&O\ Q<\<0>?HFC3I)!8N-\!F_P"7>V7/!2)1
MO;U.TD?.:_3&O"/V(/AO%\-?V:?!UL(U6\U6V&LW;@8+O< .N?=8S&G_  "O
M=ZBM+FE9;(<%9!1116!H%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?FY_
MP5L_Y&+X:_\ 7K??^APUU_P._P""B'PL^'?P>\&^&-5M_$#:EI.EP6=P;>QC
M:,R(@!VDRC(R/2N0_P""MG_(Q?#7_KUOO_0X:]:_9^_8A^"GC?X(>!O$&M^"
M_MNKZEI%O=75Q_:M['YDC("S;4F"C)[  5Z'N>QCSG-[W.^4]<^ O[77@;]H
MS7-2TGPI%JT=UI]L+J8ZA;)$NPL%X(=LG)K\_?\ @HAXBO\ Q]^UE+X967,6
ME066E6B?PAID29CCU+3X)_V0.U?I!\)_V9_AM\#=4O=2\$>&_P"Q+V]A%O/+
M]NN;C?&&# 8ED8#D#D#-?G#_ ,%&O"FH> _VIG\3QH5@UJVM-2M9@I"^9"BP
MLN?[P,*L?9U]:5#D]J^7L.I?DU/U&\$>#= ^$/@'3]!TJ.'3-"T>T">9(50!
M47+RR-P,G!9F/<DFO%?CE-^SE^T-I&FZ?XN^(GA*5=/N/M%O<6?B2SBG7((9
M-^\G8W&5[E5/:O4O"/C'0?VAO@Z-3T6]']F>(-->"0QLKR6CR1E9(W X$B%B
M"/4>AK\Z_P!JS]A7PK^SM\*YO$]KXTO-0U(W,5O;Z?>1Q1^?N8!RN#DE5YXK
M&E%.7O.S+D]-%H??/PET3X;>%_A)JFB_"W4].U+PY:+<;SINK?VBD<S)N8%_
M,?:3D-MR!SG'-?EC^Q7\;_#OP ^,,WB?Q.E[)IKZ7/9@6$*RR>8[QD<%EXPA
M[U]<_P#!,3_DWGXA_P#85F_])(Z^6/V#?A+X4^-'QOG\/^,M*_MC2%TBXNA;
M_:)8/WBO$%;=$ZMP&;C..:Z8)1]HI:HRDV^5H^VO^'H7P<_Y]O$W_@OC_P#C
MM>L?M':S;^(OV3_'>K6@<6M_X7GNHA(,-L>#<N1V."*YK_AWS\ ?^A!_\K.H
M?_)%=3^TMI=KH?[*_C_3;&+R+*S\-7%O!%N+;(TA*J,DDG  Y)S7*_9\RY+F
MWO6?,?GI_P $^?VA/!'P!UCQK<>--2FTZ+4X+6.V,-K)/N*-*6SL4X^\.M?2
M?QW_ ."A?PCUSX2>*M%T"YO=?U75M-N+""V;3Y(HE:6,H'D,@4;5W9P,DXQ[
MU\W?\$^/V?? _P ?=4\<6OC32I-2338+22U:*[E@:,NTH?[C#.=J]<].*Q?V
MH/V<KK]C[XJ:-KNDVEOXD\'74WG6"ZY:I=0EU^_:W*$;7X.0<#*G(P5)';*-
M.=5I[F"<E#R/7_\ @E+\-]:C\4>*_'4UM+;Z$VG_ -DV\T@(6YE:5)'V?WM@
MB )[%P/7'UGX9_8X^'/A'XP#XEZ?;ZE_PDWVJXO&:XO#+$\TZNLCE6!.?WC$
M<\$^U:?[+?QN\/?';X2Z=K.@V4&C/:?Z%>Z-;A56QF4#**  -A!#*<=#Z@@>
M3_MP?MG1_ ?36\)>%9([CQY?0;VF(#)I<3#B1AWD(Y53P/O-Q@-RR=2I4:6C
M9JN6,4V>0_\ !5+XM>'M4M/#?P^L9HKW7["\.I7S1D-]C4Q,B1,>S/OW%>H"
M*3]X5Z&O@G4?A]_P3#O-&U6*6#4!H$UW+!-PT7GW#3*A'\)"R $=CG/-><?L
M3_L3WGBK4K;XK?%2&6[6XD%_INEW[%Y+QV.\75SGDJ2=RJ>6/S-Q@-]8_ME?
M\FN_$?\ [!;?^A+5RE&+C2CK9B2;O-GYP_L>^./C -+\1^!/@YI\*ZSJDT5]
M>:U.8R+*"-2F!Y@V*6+=2&/]T9Y'=W7[3W[1/[)OQ,L],^)US)X@TZ<":2QO
M?*E2YA+8+P3H,JPP1@G /WEZ5WO_  23U"P6W^)-EN1=49[&;:3\S0@3#('H
M&//^\*=_P5MNK$V?PUMRRG4EDOY H8;EB(@!)'7!8#'^Z:V<E*LZ;B9I-0YD
MS[X\,>)-/\8>&]+UW29Q=:9J5M'>6TP&-\;J&4X[<$<=JTZ\=_8]AN8?V8?A
MNMT<RG2(F'^X<E/_ !TK7K.HZA;:1I]U?7DRVUG:Q-/--(<+&B@LS'V !->;
M)6DT=2>ES\Z?^"JWQ:-YJWA;X;6,I9+9?[7U!$.<R-F.!#[A?-;'_31:\E_:
MZ_9<;X#_  U^$^NVT#07-QIPL=:9>"NH9:?)/<X>1![0+7F/BCQ]XG^,W[0N
MK^/=&T&Z\1:B=3&J0::EI)=!+>*11"DB1\E%58D/(!_&O6_C+\=OV@_CMX%N
M/"GB?X:SMILTL<XDM?#5XDT4B-D,C$D XRIXZ,:]6,94U&*^9QMJ5VS]%?V6
M_BTOQL^!?A?Q-)*)=2>W%KJ/J+J+Y)"1VW$;Q[.*_.;_ (*<_P#)S;?]@6T_
MG)7H'_!*WXN'2/&'B+X<WLVVWU:/^T[!6/2XB&)5 ]6CPWTAKS__ (*<_P#)
MS;?]@6T_G)65.'LZ[1<I<U-,_6?3?^0=:_\ 7)?Y"OR]_P""IGP^TOPQ\6O#
MOB33[=;6Y\06,AO1&,"2:%E7S"/[Q5T!/?8/?/ZA:;_R#K7_ *Y+_(5^87_!
M5#QQI_B+XL>%_#EA/'=76B:?(;L1$-Y<LS@B,XZ,%C5L>CBL,-?VFAI5^$]-
M_:L^,&IZE_P3X\ WCW+-J'BI-.LK^7?\T@6%Y)6)_P!IX!G_ 'B#6]_P2Q^'
MNG:5\(=<\8&V!UC5M2>T^T, 2MO"J;47T!=Y"?7"^@K"_:N^#>J:7_P3\\!6
M+6KC4?":Z?>ZA#L^:(-"\<RX_P!F2<9/HI)K7_X)7_$C3=2^%>N^"GN576M+
MU%[Y+=B 7MI50!E'4[71PV.FY?45H_X+Y>Y*^-7/K/XL?"[0_C-X"U7PCXBB
MD?3-00*TD&T30L""LD996"NI&0<'\JYOX&?LV^"/V=['4(/!]I>0R:CY?VRX
MO+R29I_+W;"5)V*1O;E5'7Z5>^/_ ,9-/^ _PKUKQ??B*:6UCV6=G))L^U7+
M<1Q X)Y/)P#A58]JXS]E3]JJT_:@T;5[NV\+W_AZ726BCN&FE2:V=W#$+'(-
MK,0%R04& R^M<J4^1M;&ON\WF>[T445D6%%%?('[5GC7]I/P_P#$Z*U^$VDW
M%[X7.GQ.TD6G03C[06?>-SC/0)Q5PCSNUR9/E5SZUN],L]093=6D%R5X4S1J
M^/ID5/%$D,:QQHL<:C:JJ,  =@*_-_\ X6C^W#_T+M[_ ."6T_PH_P"%H_MP
M_P#0NWO_ ();3_"M_8/^9?>1[1=F?HW=Z?:Z@JK=6T-RJG($T8<#Z9J2"WBM
M85BAC2&)?NI&H51] *_.#_A:/[</_0NWO_@EM/\ "C_A:/[</_0NWO\ X);3
M_"CV#_F7WA[1=F?H)K7P_P#"WB2Z^TZOX:TC5;C(/G7MA%,^0, Y92>E:VGZ
M=::3:I:V-K#9VR?=AMXPB+] !@5^<O\ PM']N'_H7;W_ ,$MI_A1_P +1_;A
M_P"A=O?_  2VG^%'L)?S+[P]HNQ^C-WI=GJ#*UU:07+*, S1*Q'TR*L1HL:*
MB*$11@*HP /05^;W_"T?VX?^A=O?_!+:?X4?\+1_;A_Z%V]_\$MI_A1[!_S+
M[P]HNS/T%\0> ?#'BRX2?7/#FDZS/&-J2:A8Q3LH] 74X%:NGZ;::3:):V-K
M#96L>=D-O&(T7)R<*!@<U^<O_"T?VX?^A=O?_!+:?X4?\+1_;A_Z%V]_\$MI
M_A1["7\R^\/:+L?HQ<:187DWG3V5O-+_ ,])(E9N.G)%2W5I!>Q>5<0QSQYS
MLE0,/R-?G%_PM']N'_H7;W_P2VG^%'_"T?VX?^A=O?\ P2VG^%'L'_,OO#VB
M[,_1?^Q[#[+]F^Q6_P!GW;O)\I=F?7&,9J+_ (1O2?\ H%V7_@.G^%?G;_PM
M']N'_H7;W_P2VG^%'_"T?VX?^A=O?_!+:?X4>P?\R^\/:+L?HI'H&F0R+)'I
MMHDBD,K+ H((Z$'%3:CIMIK%E+9W]K#>VDHVR6]Q&)(W'H5(P:_.7_A:/[</
M_0NWO_@EM/\ "C_A:/[</_0NWO\ X);3_"CV#_F7WA[1=C]#=!\(Z%X7M9;;
M1=%T_2+>7F2&PM8X$?ZA0 :NV>FV>GEC:VD%L6^]Y,:IGZX%?G+_ ,+1_;A_
MZ%V]_P#!+:?X4?\ "T?VX?\ H7;W_P $MI_A1[!_S+[P]HNQ^C"Z18+=?:5L
MK<7&XMYPB7?D]3G&<U)=65O?QB.YMXKB,'<%E0, ?7!^IK\X_P#A:/[</_0N
MWO\ X);3_"C_ (6C^W#_ -"[>_\ @EM/\*/8/^9?>'M%V9^CUM:PV<(BMX8X
M(AT2-0JC\!4,>D6,-U]I2RMTN,EO.6)0^3U.<9[FOSG_ .%H_MP_]"[>_P#@
MEM/\*/\ A:/[</\ T+M[_P""6T_PH]@_YE]X>T79GZ):YX;TGQ/:"UUC2[+5
MK4'<(;ZW29,XQG:P(I;#P_I>EZ;_ &=9:;9V>G_\^MO B1?]\ 8_2OSL_P"%
MH_MP_P#0NWO_ ();3_"C_A:/[</_ $+M[_X);3_"CV$OYE]X>T78_1JWTVSM
M(I(H+2"&.3[Z1QJH;MR .:2WTJRLUD6WL[>!9!AQ'$JAAZ' YZFOSF_X6C^W
M#_T+M[_X);3_  H_X6C^W#_T+M[_ ."6T_PH]@_YE]X>T79GZ$:'X)\.^%YI
M)=&T#2])ED)+O8V<<+.3U)*J,UMU^;G_  M']N'_ *%V]_\ !+:?X4?\+1_;
MA_Z%V]_\$MI_A1[!_P R^\/:+L?I'17YN?\ "T?VX?\ H7;W_P $MI_A1_PM
M']N'_H7;W_P2VG^%+V#_ )E]X>T79GZ1T5^;G_"T?VX?^A=O?_!+:?X4?\+1
M_;A_Z%V]_P#!+:?X4>P?\R^\/:+LS](Z*_-S_A:/[</_ $+M[_X);3_"C_A:
M/[</_0NWO_@EM/\ "CV#_F7WA[1=F?I'17YN?\+1_;A_Z%V]_P#!+:?X4?\
M"T?VX?\ H7;W_P $MI_A1[!_S+[P]HNS/TCHK\W/^%H_MP_]"[>_^"6T_P *
M/^%H_MP_]"[>_P#@EM/\*/8/^9?>'M%V9^D=%?FY_P +1_;A_P"A=O?_  2V
MG^%'_"T?VX?^A=O?_!+:?X4>P?\ ,OO#VB[,_2.BOS<_X6C^W#_T+M[_ ."6
MT_PH_P"%H_MP_P#0NWO_ ();3_"CV#_F7WA[1=F?I'17YN?\+1_;A_Z%V]_\
M$MI_A1_PM']N'_H7;W_P2VG^%'L'_,OO#VB[,_2.BOS<_P"%H_MP_P#0NWO_
M ();3_"C_A:/[</_ $+M[_X);3_"CV#_ )E]X>T79GZ1T5^;G_"T?VX?^A=O
M?_!+:?X4?\+1_;A_Z%V]_P#!+:?X4>P?\R^\/:+LS](Z*_-S_A:/[</_ $+M
M[_X);3_"C_A:/[</_0NWO_@EM/\ "CV#_F7WA[1=F?I'17YN?\+1_;A_Z%V]
M_P#!+:?X4?\ "T?VX?\ H7;W_P $MI_A1[!_S+[P]HNS/TCHK\W/^%H_MP_]
M"[>_^"6T_P */^%H_MP_]"[>_P#@EM/\*/8/^9?>'M%V9^D=%?FY_P +1_;A
M_P"A=O?_  2VG^%'_"T?VX?^A=O?_!+:?X4>P?\ ,OO#VB[,_2.BOS<_X6C^
MW#_T+M[_ ."6T_PH_P"%H_MP_P#0NWO_ ();3_"CV#_F7WA[1=F?I'17YN?\
M+1_;A_Z%V]_\$MI_A1_PM']N'_H7;W_P2VG^%'L'_,OO#VB[,_2.BOS<_P"%
MH_MP_P#0NWO_ ();3_"C_A:/[</_ $+M[_X);3_"CV#_ )E]X>T79GZ1T5^;
MG_"T?VX?^A=O?_!+:?X4?\+1_;A_Z%V]_P#!+:?X4>P?\R^\/:+LS](Z*_-S
M_A:/[</_ $+M[_X);3_"C_A:/[</_0NWO_@EM/\ "CV#_F7WA[1=F?I'5>[T
M^UU!5%U;0W(7E1-&'Q],U^<G_"T?VX?^A=O?_!+:?X4?\+1_;A_Z%V]_\$MI
M_A1[!_S+[P]HNS/T?M[>*UA6*")(8E^ZD:A5'T J2OS<_P"%H_MP_P#0NWO_
M ();3_"C_A:/[</_ $+M[_X);3_"CV#_ )E]X>T79GZ/SP1W43131K+$W#)(
MH8'Z@U2_X1O2?^@79?\ @.G^%?G;_P +1_;A_P"A=O?_  2VG^%'_"T?VX?^
MA=O?_!+:?X4_8/\ F7WA[1=C]&K/3;33]_V6UAMMV-WDQA,XZ9P*LU^;G_"T
M?VX?^A=O?_!+:?X4?\+1_;A_Z%V]_P#!+:?X4O8/^9?>'M%V9^D=5/[(L/M7
MVG[%;_:-V[SO*7?GUSC.:_.?_A:/[</_ $+M[_X);3_"C_A:/[</_0NWO_@E
MM/\ "G[!_P R^\/:+LS](Z*_-S_A:/[</_0NWO\ X);3_"C_ (6C^W#_ -"[
M>_\ @EM/\*7L'_,OO#VB[,_1BYTBPO9O-N+*WGEQC?)$K-^9%3S0QW,3131K
M+&PPR.H(/U!K\X/^%H_MP_\ 0NWO_@EM/\*/^%H_MP_]"[>_^"6T_P *?L'_
M #+[P]HNS/T;L]/M=/#"UMH;8-][R8PF?K@4RXTBPNI_.FLK>:;C]Y)$K-QT
MY(K\Y_\ A:/[</\ T+M[_P""6T_PH_X6C^W#_P!"[>_^"6T_PH]@_P"9?>'M
M%V/T7N=&T^\E,MQ8VT\IX+R0JQ_,BK8 4  8 K\W?^%H_MP_]"[>_P#@EM/\
M*/\ A:/[</\ T+M[_P""6T_PH]@_YE]X>T79GZ1,H92",@\$&JEKH]A92^;;
MV-M!)C&^*%5/Y@5^='_"T?VX?^A=O?\ P2VG^%'_  M']N'_ *%V]_\ !+:?
MX4>P?\R^\/:+LS]&(=)L;>X-Q%9V\4YR3*D2ACGKSC-9T7@7PW!KCZS'X>TJ
M/6)&W/J"V40N&;U,FW<3^-?GQ_PM']N'_H7;W_P2VG^%'_"T?VX?^A=O?_!+
M:?X4>PE_,OO#VB['Z1T5^;G_  M']N'_ *%V]_\ !+:?X5N>!_B5^V7=>-O#
M\&NZ#>1Z')J%NE^[:1:J%MS(HE)(&1\N[D4O8/\ F7WA[1=F?H/1117,:A11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;X1_:].\$:U=R:8[$_\ %/>)/L<4F>-_ER/%AL=\9'8U>\(_\$UOBQ\1M?\
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MRN9>RB>1_!']G/0?V??A=?\ A3PY-<WLUZ))KJ]O'^:XN&C";MH^5%P% 4=
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M^.5Y?6G@CQ&NMW-C&);B/['<0%%)P#^]C7(R>U/E=KVT%=;'I=%%%2,****
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MZ_+U1O3E2K+F@?&7_#JCX3?]##XS_P# VT_^1:/^'5'PF_Z&'QG_ .!MI_\
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MH^$W_0P^,_\ P-M/_D6OLVBCVU3^8/9Q['QE_P .J/A-_P!##XS_ / VT_\
MD6C_ (=4?";_ *&'QG_X&VG_ ,BU]FT4>VJ?S![./8^,O^'5'PF_Z&'QG_X&
MVG_R+1_PZH^$W_0P^,__  -M/_D6OLVBCVU3^8/9Q['QE_PZH^$W_0P^,_\
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M<(VO<&WJ[['USX=UVT\4:!INLV#F2QU"VCNX&88)CD4,I(['!%:%>;_LV_\
M)O/PS_[%O3__ $G2O2*X7H[&ZV"BBBD,**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"@;_Y'E_\ BJ-0#_A9OAK_ *"7_D"7_P")H_X6;X:_Z"7_ ) E_P#B:/\
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MX6;X:_Z"7_D"7_XFC_A9OAK_ *"7_D"7_P")H_X5EX:_Z!O_ )'E_P#BJ/\
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MFC_A67AK_H&_^1Y?_BJ/^%9>&O\ H&_^1Y?_ (JC4 _X6;X:_P"@E_Y E_\
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M?_BJ/^%9>&O^@;_Y'E_^*HU /^%F^&O^@E_Y E_^)H_X6;X:_P"@E_Y E_\
MB:/^%9>&O^@;_P"1Y?\ XJC_ (5EX:_Z!O\ Y'E_^*HU /\ A9OAK_H)?^0)
M?_B:/^%F^&O^@E_Y E_^)H_X5EX:_P"@;_Y'E_\ BJ/^%9>&O^@;_P"1Y?\
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M"7_XFC_A67AK_H&_^1Y?_BJ/^%9>&O\ H&_^1Y?_ (JC4 _X6;X:_P"@E_Y
ME_\ B:/^%F^&O^@E_P"0)?\ XFC_ (5EX:_Z!O\ Y'E_^*H_X5EX:_Z!O_D>
M7_XJC4 _X6;X:_Z"7_D"7_XFC_A9OAK_ *"7_D"7_P")H_X5EX:_Z!O_ )'E
M_P#BJ/\ A67AK_H&_P#D>7_XJC4 _P"%F^&O^@E_Y E_^)H_X6;X:_Z"7_D"
M7_XFC_A67AK_ *!O_D>7_P"*H_X5EX:_Z!O_ )'E_P#BJ-0#_A9OAK_H)?\
MD"7_ .)H_P"%F^&O^@E_Y E_^)H_X5EX:_Z!O_D>7_XJC_A67AK_ *!O_D>7
M_P"*HU /^%F^&O\ H)?^0)?_ (FC_A9OAK_H)?\ D"7_ .)H_P"%9>&O^@;_
M .1Y?_BJ/^%9>&O^@;_Y'E_^*HU /^%F^&O^@E_Y E_^)H_X6;X:_P"@E_Y
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M!(!U('8CN/\ ([&F(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQCY6)YX&&KY>^*'[!?CW]FG1=1^(7@3XBK-%HT#75Q)$)--O$B!!(7:[K(,
M9!9<XZ'I753E[JBG9^FYE):M[GZ%?#/7O$=K\(](U7XE06_A_P 0VMB9-:WS
MQ&&)H\[Y2Z,4"E5WG!P,D<8KP3Q!_P %./@UH>NG3[;_ (2#6X%8*=2T^P3[
M/UP3^]D1R![)],UXI\7OV@O%'Q8_X)V6&M7DK'5;C6H]$UFZ@_=^>D>Y]Y
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M %%%% !1110 4444 %%%% !1110 4444 %%%% 'E7Q9_9W\/?%*8WY=M'UO
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MZ712YY::[!RHQ/!'A.S\ ^#=#\-:?)/-8:/90V$$ERP:5HXD"*7*@ MA1G
MSV%;=%%04%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"N#^,G_(L6O_ %^+_P"@/7>5P?QD_P"18M?^OQ?_ $!Z3V ZCPK_ ,BQH_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MK@_C)_R+%K_U^+_Z ]=Y7!_&3_D6+7_K\7_T!Z3V ZCPK_R+&C_]></_ * *
MU*R_"O\ R+&C_P#7G#_Z *U*8!1110!PGQQ^)2?"/X7:[XF*K)<VL6RUB?H\
M[D)&".X#$$^P-?DIX@\0:CXJUJ]U?5KN6_U*\E,T]Q,<L['^0[ #@  #BOT4
M_;^M+BX^ JR0 ^5;ZM;R3X'\!611G_@3)7YMU\;G-23K*GT2/ZI\*\#0IY54
MQL5>I.;3?5))67XW^[L%7M$UJ_\ #>KV>J:9=26.H6DJS07$+8:-P<@BJ-%?
M/IM:H_:I1C.+C)73/UU^ OQ.7XO?"O0_$C!4O)HS%>1IP$N$.U\#L"1N ]&%
M>@U\S?\ !/JTN+?X%W<DP;R[C6KB2#(_@$<*G'_ E>OIFOTC"U)5*$)RW:/X
M.XBP=++\WQ6%H?!&<DO)7V^6P5^-6N>--,^'/[?&N>)M9:1-+TOQK=W-RT*;
MW"+</G"]S7[*U^.&H>$=)\>?\% =7\/:[:?;M'U+QO=V]U;>8\?F1FX?(W(0
MP^H(->OAK>]?L?+5>A]R?\/+_@G_ ,_VM?\ @L;_ !KX5T/QIIGQ&_;XT/Q-
MHS2/I>J>-;2YMFF38Y1KA,97L:_0S_AWS\ ?^A!_\K.H?_)%?GSI_A'2? ?_
M  4!TCP]H5I]AT?3?&]I;VMMYCR>7&+A,#<Y+'ZDDUK1]G[W)?8B?-IS'Z#?
MMC?M96W[,OA:QCL+2'5?%NK;Q8V<[D10HOWIY0.2H) "@C<<\C!KY5;XZ?ME
MZ?X,_P"%D3Z>7\'&#[9M?3++8L!&[S3$N+@1[>=QXVG=G'-<C_P5)ENI/VCM
M-2?Y84\/6PM_]PS7!)_[ZW?E7N5U_P -H:AX?ETY]%\*MI4]J;=D62S"&%DV
MD ^9TVFE&,8PB[+7N-MN3W/>OV2?VHK#]ISP1=7WV)=)\0Z4Z0ZGIZ.70%@2
MDL9/.Q]KX!Y!4@YX)^-K'_@H)\6M%^,7B+0FCA\5QK>W>F:1HT5C&A>X\XQP
M;F10[ >@.6X&1G(]6_8!_9C^)OP%^(7B._\ %^EV^GZ+J.E"%&AO8IR\ZS(R
M<(Q(&TR<U\\_LHV<5Y_P4*B\U0ZQ:SK4JJ1QN$5U@_@<'\*48TTYVU20.4K1
MZ'6?$+]J;]J[X":]I>H>/X;:SL-3+2VVG7-C9O;2*I4M'O@^=2 1PS[AFNUU
M#]J_]HO]HBRO-6^"G@]M&\-:;&%N;LI;3W$DX0/(BF<[7QGA(T+8()Y8 ;O_
M  5F _X5[X"..?[4G_\ 10KV[]@?3XM/_9-\!B)%4S1W4[E1]YFNICD^^,#\
M*3E%4U4Y5<:3YG&YX[^P;^VEXK^,WBZ]\#>.V@U#5%M'O++5H8$@>38RAXI$
M0!<X;(*J/NL#GBI_VM?VXO$7@OXB1_#'X5:?%J7BKS(X+F^,7VEEN'QMMX8N
MC/RN2<@$[<9!(^=?V#_E_;:E X'_ !-!@?1ZXC19O'<W[;>NS>#8+.?QY_PD
MNK-:0Z@4$/G!KC>#O(7(7?C)Z@8YQ6GLH>T;MTN1SOE2/==8_:>_:H_9OOM)
MU7XK:)'JGAZ\GV&.X@LU5^"3&LUIQ')@$@.">#P0#7W_ /"WXD:1\7?A_HGB
M_0G9M-U2#SD608>-@2KQM_M*ZLIQQE>*^%?C!\.?VO/C9X,D\+>*]#\.S:7-
M/',!!<VD4@D0Y4JWF=>OX$U]'_L,_"GQA\&/@G)X9\:6D=EJ,6JW$UO#%<),
M! ZQD'<A(^_YG%855%POI?R-87O;H?0M%%%<9L%<WX]\1/X=T%Y83MNIF\J(
M_P!TGDM^ 'YXKI*\Y^,D;FSTQQ_JUD=3]2!C^1KY?B?%UL#D^(Q%!VDEH^UV
ME?Y7N>GEM*%?%TZ<]K_EJ>7.[2.SNQ9V.2S'))]:2BBOY WU9^M%O2M4N-%O
MXKRU?9-&<CT([@^QKZ#TO4(]5TVVO(N$FC#@>F1T_"OG&O=OA[&\?@W30_WM
MK-^!=B/T(K]F\-<96^M5\'?W''F]&FE^*?X'Q_$=&'LH5OM7M\MSHJ***_H$
M^"/Q1_8O^+WAWX'_ !OM?%'BB2XBTJ.QN+=FM83*^YU 7Y1]*^[O%7_!3'X-
M#P[J"V]OK.NS20M&NG-8"-9]PQM9G; 4YY//&>#TKX<_8<^%OACXP_'JT\.>
M+],_M?1I+"YG:V^T2P9=%!4[HV5N/K7Z":U_P3?^!NJ6]S':^'[_ $>25-J3
M6>JW#-"<8W*)6<$]_F!%>G7]ES^_>YRT^?E]T^:_^"8'P7U^X^(-]\2KFSEL
M/#5O936=G+(I O)G8!A'G[R(%;+?WL#J#CNOVUOVO/B'\"_CWIV@>'M5AM?#
MQTZUO+BW-C#,[%I9!)AG7.2J #FO /V5?&FN? 3]K]/ ^D:Q+J7A^Z\03:!>
M0HQ\B\42M"D^WH&4A7##G (S@FM'_@J'_P G*6O_ & +7_T9-3<>:M[VJ:%>
MT-#UOX<?M"?M._%[XN^%M2L=%O- ^'&M:F@19-#5[1;+.YF:=DWD^6#APZJS
M#CTKK/VL_P!N7Q'X/^(Z_#'X4Z?#J/B=98[>YOS%]I87#]+>&+&&<97).<$E
M<9!-?:.@Z5#H.AZ=IEO&L-O9VT=O'&O1510H ]@!7XV>&9/'LW[:FL2^#;>S
MN/'W_"1:L]M#J!00F;-P9,[R%R%WD9/4#'.*RI\M23=DK?UJ7*\5:^Y[QK'[
M4'[4_P"S=J&D:G\5M%BU3P_>S;?+N(+-%D&,F-9K3B-\ D!P3P>" :^X-+^/
M7A[6O@3_ ,+4L$N;O0_[->_%M%'NN"R9#0;1_&)%*>F1UQS7QK\7_AS^UY\;
M/!LGA;Q7H?AV;2YYXY@L%S:12>8ARI5O,Z]?PS7K_P"SO;ZW^QE^R;K]Y\3[
M+[-_8M_-=0VEG/'.TD4OE+&BLK;<M,S#D\9R:FI&,HIJU_(<6T_(\!\._M,?
MM7_M(:MJU_\ ##3X=-TBQE\I[:TMK(1Q$\JC37GWY ,9VD=<[1D5T/[//[;7
MQ5TGX\6/PQ^+L$5[<7E^-+DE>TB@NK2Y<XC_ -2!&Z%BHZ=&#!L#F7P/^T/^
MTY^U,=2O?AEI&@^$/#\-SY$NI-'&VV3:IVO)-O\ ,<*5R4CX!7ID5\[#P[XI
M\*_MW^%-+\:ZY'XC\4P>+=%-_J<+LZ3.TMLP"EE4X565?NC[O05NHQE>+26G
MS,^9JS39]>?M>?MF^,O _P 6+'X4_#"PMI/$TS6T4UY=1K*_VB?:8H8E8[ 2
MKH2SY'S]L9KS+QW\6/VS/@/I]KXD\7RVNHZ,TZP-$;*PGB#M]U9/LRK(H."
M00,\9R17HO[;'[$.K?%KQU%X]\$ZM8VOB"ZCCBNM-U"?[.;B2-52-X),??VA
M5(;'W00>U?/$WQ)_:Q_9;B$^O-X@_L6W81NVM(NJ6/7"H9\OM!. -LB^@J*:
M@XKEM?S*DVF[W/MG5?C3\1?B1^R?+XR\!^&=0T;XB,T,0TBXLMSK()XUF,:R
MJ \9C+,K>A]0:_,3X!:Y\3=%^+CWOPVLY+OQMY5P&ACMHYFV'_6_(XV_X5^K
M/[(W[2D?[3'PYGUF?3DTG6].N?L>H6D+EHMVT,LD9/(5@>AY!5ADXR?@K_@G
MK_R>)-_UZZC_ #HI/E4TUL$M7%W/U"^&=UKE]\./"ESXGC:'Q+-I-I)JD;($
M*W1A0S J.!ARW X%=(S!%+,0J@9)/ %+7E?[4WC@_#K]GGQ[KJ2>3/%I<MO!
M)G&V:;$,9'N'D4_A7 ES2MW.C9'R;^P&K_%C]IKXP?%252]NSR0VK./NBYG+
MH![K% %^C>]?H-7R;_P3-\#GPO\ LVQ:M+'MG\0ZE<7P8C#>4A$"#Z9B=A_O
MU]95K6=ZCMT(I_"?G/\ \%8O'UV+WP/X*BD*6/E2ZO<1AO\ 6/N\J(D?[($O
M_??M7TQ^Q!\'='^%?P \+75K91+K6O6,.JZA?&,>=*9E$B1ENNU%95"]."<9
M)KY;_P""LG@NYC\2>!?%J1[K.:TFTJ20#[CH_FH#_O"1\?[C5]:_L8_$K3_B
M7^SCX+GL[@27>E6$.D7T1(+Q30((_F'^TJJX]F%;3_@1L1'^([FC\=O"OPU^
M.7@>_P#!_BGQ!I4*M(&CN$O8!<V4R-]^,L3M;@J>.06!ZUS/P9^!'A+X,^ _
M&&C?"+Q9+=ZYJ5KYL=S>7\%]Y-RJ.L,AC50@&YAN^49 'H*^9OV@/^"<2:3I
MOQ&^),GQ'7;#'J&OC36T7:&/[R80>;]HZDX3=M[YV]JR/^"3/_)1/'G_ &"H
M/_1U'*O9MQE=(.9\RNCT#]B']L;QW\4/C)J?@?XBWT,]Q+9RM9(MG%;O'<PM
MF2,A%&24WGGIY=>D?M^?M-:]^S[X2\-6WA&\AL_$FL7COYDT"3!+6)/G^5@1
MDO)'@^S5\I_M4:/-^R[^VYI?CO3H6CTO4+R'Q BQCA]SE;R+ZL?,/TE%+^TC
MJ'_#6G[<6C>#]'N?M>BV\EOH\<\!R/)3,UW*/==TOU\M:U]G&4U.WNVN3S-)
MQZGT[K'QE^)_A+]@6?XF:MJT1\=7$5K?P3FQB5(8)[V&.-?+V[3F%]V2,Y?V
M%>&_#/\ ;0_:!^,WA%O"_@71$\0>.4FDN+W7#;6\45K;':L2*K%8@VX.=TF<
M] #@D?3O[?5G!IW[&OC:TMHE@MH(].BBB085%6_M@%'L !7EO_!)_3HHOA#X
MQOQ&HFGUWR&D ^8JEO&R@^P,C8^IK./+[-S<>I3OS*-SRCP#^W7\9OA/\9+;
MPG\8ECO;47<=KJ4%S8P07-HDF,2QM JJP 8-T8,O0C((_3BOR?\ ^"ET:1_M
M3:<RJ%+Z/9,Q ZGS91D_@!^5?K!45E&T9)6N.FW=I] HHHKD-@JCKNL0^']&
MO=2N/]1:PM,P'4X&<#W/3\:O5Q?QEAEG^&.OK#G>(58X'\(=2WZ UTX6G&M7
MITY;2:7WLY\34=*A.I'=)O[D?)_B?Q+?>+M:N-3U"4RW$S<#^%%[*H[ 5ET4
M5^_PA&G%0@K)'X9.<JDG.3NV+'(T;JZ,4=3D,IP0?45]<_!?QQ+XV\'))>/Y
MFHV;_9YV[O@ J_X@_F#7R+7T%^RS#*MGXBE.?):2!5]-P#D_HRU\KQ-0IU,
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M',JM2Z5TD5R\D;-GD?CO]H+]L#]GQ=+USQ^T0TBZF\F..]LM.E@F?:6V.UJ
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MM@;B-5!..?\ ES_Q-=;4/:JGRK4Q7-R<UP\5?M2_M)?&C1]6\9?"3PO)X?\
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M#FDP:#\(_!6G6R+'!:Z+9Q*JCCB!!FNPKBJ24G9*UC>*:W84445D6<O\3?\
MD1]2_P"V?_HU*/AE_P B/IO_ &T_]&O1\3?^1'U+_MG_ .C4H^&7_(CZ;_VT
M_P#1KTNH^AU%%%%,04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 445B>-O&&G?#_PCK'B35VD33-*M9+NY:%-[B-!E
ML+W.!TH VZ*^5/\ AY?\$_\ G^UK_P %C?XUIZ;_ ,%%_@7J$D$;^)KNR:5@
MI^TZ7< )D_Q%4( ]ZU]E4_E(YX]SZ8HK-\.>)-*\7Z)::QHFHVVK:5=IYD%Y
M9RB2*1>F0P]P0?0@BG:_X@TSPKHUWJVL7]OIFF6D9EN+NZD$<<:CNS'@5GY%
MFA17RKKW_!2WX*Z+J,EK;WNLZRB''VFPTX^4?IYC(3]<5WWPE_;(^%'QHU2/
M2M!\2+;ZS(=L6FZI$UK-,?2/=\KGK\JDGCI5NG-*[1/-'N>V4445F4%%?.GQ
M _;V^$_PT\9:MX7UN[U5-5TN8V]PL-@SH& !X;//6N?_ .'E_P $_P#G^UK_
M ,%C?XUK[*;UL1SQ[GU717S-X8_X*'?!_P 7>)-)T+3[S5VO]4NX;*W633F5
M3)(X1 3G@98<U],U$HRC\2*33V"BO&+_ /:Y^'.G_&:/X7G4+J?Q4]U'9;(+
M8O LSJ&"&3.,C.#Z'(ZBO9Z'%QW073V"BO#OBA^VG\(OA'K=QHNM^*%N-9MS
MMGL=,MY+IXF!P5=D&Q6'=2P([BND^$7[2?PX^.;7$7@WQ+!J5[;KOEL98WM[
MA5_O".159EY'S+D#(!.:?)*W-;07,KVN>FT5YA\6/VF/AM\#=4LM-\;^)/[$
MO;V$W$$7V&YN-\88J3F*-@.0>"<UPO\ P\&^ /\ T/W_ )1M0_\ D>A4YM72
M#F2W9]$T5Y/\*_VJ/A=\:O$<N@^#/$_]LZM%;-=O;_V?=08B5E5FW2Q*O5U&
M,YYKUBI<7%V:&FGL%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 445\J?\/+_ ()_\_VM?^"QO\:N,)2^%"<D
MMSZKHKY4_P"'E_P3_P"?[6O_  6-_C7J'P-_:A\#?M#76KV_@^>^FDTM(Y+G
M[9:F$ 2%@N,GG[AING.*NT)2B]$SUNBL7QAXTT+X?^'[K7/$>JVNC:3;#,MW
M>2!$'H!ZL>@49)/ %?-.I_\ !33X+:?J#V\,^NZC$IP+JUTW$;<]0)'5L?5:
M482E\*!R2W9]845Y)\'_ -JOX9?'*Z-EX6\212ZL 3_9=ZC6]R0!DE4<#> .
M24)QWQ79_$[XCZ-\(_ VJ>+?$#S1Z/IJHUPUO&9' >18UPHZ_,ZTG&2?*UJ.
MZM<ZBBOE3_AY?\$_^?[6O_!8W^-'_#R_X)_\_P!K7_@L;_&M/8U/Y2>>/<^J
MZ*\O^)7[1W@WX3_#;0O'6OS7D>@:T\$=H]O;&20F:%YDW+GCY$;/H:\D_P"'
ME_P3_P"?[6O_  6-_C4JG.6J0W**W9]5T5\Y:'_P4'^!>N7D-K_PF#V$DN K
M7VG7$48)[,^S:OU) ]Z^A;"_MM4L;>\LKB&\L[B-98;BW</'(C#*LK#@@@@@
MCK4RC*/Q(::>Q8HHHJ1A1110 445\_?%+]N3X7?![QWJ?A#Q%=:G'K.G>5YZ
MV]BTB#S(DE7# \_+(M5&+D[10FTMSZ!HKBOA#\8/#?QP\&1>*/"MQ-<:7)-)
M;_Z1$8Y%D0X8,IZ=0?H17,?'+]J3P'^SS>Z3:>+[N\BN=3CDE@CL[8S':A4$
MM@\9+<>N#Z4<LF^6VH75KGKE%>2? W]J'P-^T-=:O;^#Y[Z:32TCDN?MEJ80
M!(6"XR>?N&N$\6?\%"OA#X+\5:SX>U.\U9=2TF]FL+E8].9E$L4C(X!SR-RG
MFJ]G-NUM1<RM>Y]+45\J?\/+_@G_ ,_VM?\ @L;_ !KNO@U^V/\ #CX\>+G\
M-^%;G49=32U>[*W5FT2>6A4'YB>N7'%-TYI7:#FB^I[C17RM-_P4J^"L,SQM
M?:SN1BI_XEC=1^--_P"'E_P3_P"?[6O_  6-_C1[&I_*+GCW/JNBO!/A/^VU
M\,OC1XWL_"GAJZU*75[I))(UN;%HDPB%VRQ/H#7O=1*+B[-%)I[!17SI\0/V
M]OA/\-/&6K>%];N]535=+F-O<+#8,Z!@ >&SSUKG_P#AY?\ !/\ Y_M:_P#!
M8W^-7[*;UL3SQ[GU717S-X8_X*'?!_Q=XDTG0M/O-7:_U2[ALK=9-.95,DCA
M$!.>!EAS7TS42C*/Q(I-/8****D845C^,/%FF> _"NK>(M9G^S:5I=K)=W,N
M,D(BEC@=SQ@#N2!7D'PB_;5^&'QL\:0>%O#=_?'6)XI)H8[RS,*R!!N95)/+
M;<G'HI]*I1DU=(5TM#W>BBO$?'G[87PZ^&_Q1C^'^M7.H)XBDEMX0D-F7BW3
M!3'\^?\ ;&?2B,7+1(&TMSVZBBBI&%%%% !7RI_P4O\ ^37;[_L*V?\ Z$:^
MJZ^5/^"E_P#R:[??]A6S_P#0C6M'^)$B?PL^)_V7OVY+[]F?P!J'A>V\(V^O
MQW>IR:D;F6^: J7BBCV;0C9QY(.<_P 7M3_VD/V\/$7[1WA&#PB^@Z=X7T22
MXCGNG65[F61D)VY;:-J#.2 I8E1SU!^DO^"96J>%+/X!Z_#KUWHT%RWB6X(C
MU&6)7,9M;4<!SG;G=[=:Z7]N:'X*M\ -=<_\(N/$85/[&.EFW%X9]Z\)Y?S%
M,$[L\8Z\XKN<H>UMRZ]S"TN3<](_8Z\$>'_A'^S;8+H>NV?BJ&43ZI>:EIK%
MH9K@J-ZIQN&U45,$!OER0"<#X!_8#T=/B3^UO8:KKI6_NK=+O6W:;_EI<_PO
M[L'DWCW7/:O</^"3-UJEU8_$G3IB\GAY39R+&_W%G<2J^WW9%7=_NK7SUX%U
M*[_8F_;!"ZY:S'3M)OIK2<E26FT^8%5G3'WOD99 /5<<'.",6I5(WU!O2+Z'
MZK?&CXV^&/@)X3@\1^+);F'3)KM+)&M8#*_F,KL!@=L1MS7R_P")?VR?V6/&
MGB2+Q!X@\._VYK,4*VZ7>I>'UN&5%9F4#?D<%F.<9YKZ!\=:+\*?VH?AK:KJ
M^JV.O^$UFCU%)[743"J.$95+LK K@.P*MC!ZC(K\N_VRO"WPA\&>.M,TGX27
M<=Y;06SC5'M[R2ZB$^_Y561B5;"]=A('?FL:$(R=G>Y=236JV/MW]OSQ!IOB
MS]BVPUO1U*:1J4VF7EFIC\LB"1=\8V_P_*PX[5\@?LO?MR7W[,_@#4/"]MX1
MM]?CN]3DU(W,M\T!4O%%'LVA&SCR0<Y_B]J^D_VH?^4:_P /?^P7X?\ _29*
M=_P3*U3PI9_ /7X=>N]&@N6\2W!$>HRQ*YC-K:C@.<[<[O;K6D;1I.ZOJ2[N
M:L['S;^TA^WAXB_:.\(P>$7T'3O"^B27$<]TZRO<RR,A.W+;1M09R0%+$J.>
MH/Z$?L3_  [T'X:_L_Z+8Z#K]EXGCO99+^[U33WW02W#X#*F>0$"*GS 'Y,D
M G \N_;FA^"K? #77/\ PBX\1A4_L8Z6;<7AGWKPGE_,4P3NSQCKSBO//^"2
MNH:O):_$:R9I&T&-[.9%8_(EPPE#%?<HBY_W5J9VE1O%62'&ZGKJ??9\1:4I
M(.IV8(_Z>$_QKY7_ ."E]W!>_LOM+;S1SQ_VU:#?$P8=).XKYMU;_@EG\5[_
M %6]N8_$'@T1S3O(H:]N\@%B1G_1NO-=;\>_@GKGP _X)_P^$O$-UI]YJ4?B
M:.Y,NF2220[7+D#+HASQSQ4QIPC*+C*^HY2DT[H\>_9C_;JOOV:_A[=>%;;P
MA;Z]'/J,FH?:I;]H""\<:;=HC;IY><Y[U%^TC^W-XB_:5\-V7A2;1=.\*Z%]
MJCN+AEFDN'=UR%+/M&$&[)"H3D#GM7T[_P $U=4\)6O[/FJP:]=Z+#<OK]S^
M[U&2%7,9@MQT<YV]?;K6K^WE#\%F^ 6L.@\,#Q2#%_8S:28!>&7S4W!?+Y*;
M"VX'C!S][;6W-#VMN77N19\FY[)^QM\/?#_PU_9_\/Z?X>UVS\36]QOO;K5K
M!]T,]PY^?;GD!=H3! /R<@'(KX_^/7C+5OV[/VD-+^%O@ZZ8>!M#G9[G4(OF
MC?8=L]V>S  ^7'ZELYP_'+?L>3>.]0_9=^/NE>%(]1N9I([%-.AL5+2&>4NE
MR(@.=QA"9(Y "FN.^$OA?]J#X%KJ(\#^#O$6B-J)3[5)_P ([%</)LSM&Z6%
MR -QX! YI1I\LY2OJ#E=)6T-+P#X4TWP+_P44TSP]HT'V72M+\2FTMHLY*HB
M$#)[GCD]S7VS_P %&M=NM)_9=UJSM(9I9-6O;6R8PH6*H)/.8G'08AP2?[V.
M]?F3#X@^**_M '5XXK[_ (6O_:;2F/[!']H^V8.1Y&S9NZ_+MQ[5^F=C^T]J
MOP(_9J\$^+/C/I/B"]\2ZE<365XMKI\$,T<WF3-$)(RT2H#%&,8'.,X[T5HM
M2A+<(-6:/B3]G7Q%^TIX-^%5R_PJ\.WB>%VO9-1FOHM*AG>[?:B,J^:"9% C
M Q&,@[N<U]8?L5?MRWGQOUZ3P/XWM;6R\5B)YK*\ME,<=Z$Y>,QG[LBKEN#@
MA6X!7GZ*^"OQN\.?'3X<VWC'0Y6M[&0R)<6]TZ"6T=&(990"0IP W7[K ]Z_
M-'X$F/QO_P %$SJ?A+Y]);Q)J6H1SP+^[^R9F+/QT5E.!_O@5.E53YHV:'K"
MUF:'_!2:\U7Q=^U#::1::==WC6.G6FG6MO% [_:)7+380 ?,Q\X+\O/RX[5T
M?BO]JC]JWX)W%CKWC;0X[/P_=2*L5E=Z3"EJ,<^5OB^=&*@X#MGC@<&OJOQM
M^WAX"^'_ ,:#\-M9TS7+'4HKZ&RN-2N(H4LHO-5&24OYN[9AU))48&35?_@H
MAX@T73?V5?$EMJ$T)N=3EM8=.C8@M+,+B.3*?1$=B1V!'>E&;]R$H:#<=Y)G
MJ/[/WQPTC]H/X9:?XNTF,VIE9H+RQ=][VEPN-\1; SP58' RK*<#.!Z17Q)_
MP2GTC4;/X-^*;ZX5TTZ\UK_10PP&*0H)''J,E5SZH?2OMNN6I%1FXHVB[Q38
M4445D4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?D!^V
M-</\1/VY-2T>[DW6G]HZ=H\:L2 D92$,,]AN=S_P*OU_K\EO^"B7@?4OAK^T
M\/&$$+"RUQ+?4K2=@2GGPJD<B9]08T8CTD%=F%^-^AC5^$_6.SM(-/M(+6VB
M2"V@18HHHUVJBJ,!0.P &*Y#QE\%_ OQ$UZPUGQ1X4TOQ!J-C$8+>74K<3A$
M+;MNQLJ>>>0<9/K5'X/?'3PE\:/!%AXAT/5[-_-@5[NS,ZB6RDV@O'(IP05/
M&2,$8(R"#7R-^T[_ ,%$M3\ ?%RRT3X:2:1XCTJPA\O4FFC,\-S<,WW(I(V!
M^10!E3C<Q!!VUC"G.4K+<N4HI79ZW_P4-L;;3/V0]?M+.WBM+2">PCB@@0(D
M:BXC 55'  '85P7_  2A_P"2-^+_ /L/G_TGAKL/V\KS4]0_8KU&ZUJSCT_5
MYO[-DO+.%RZ03&>(O&&(&0K$C/?%>=?\$M_%6B:#\(?%D.IZQ8:=*^NEUCN[
MI(F9?L\0R Q&1FME_ ?J9_\ +Q'WG7P?_P %9O\ DGO@/_L*3_\ HD5]F_\
M"R/"7_0T:+_X,(?_ (JOB_\ X*O7$5W\-?A]/!(DT,FI3.DD;!E=3"""".H(
M[UG0O[1%5/A9[5_P3Y_Y-!\ _P#;_P#^G"YKD?\ @IQX;L=6_9N.ISPJU[I.
MJ6TMM-CYE\PF-USZ$,"1ZJOI6I^P3XV\.Z1^R;X%M+[7M,LKJ/[=O@N+R.-U
MS?W!&5+9&00?QKRC_@I=^T)X5U+X;V?P_P! UNSUG5[R_CNKY;&99DMH(U+!
M79<@.SE"%SG"DG&1G2,7[?3N)M>S+_\ P3AUV:__ &5_'VFROO73[Z\,0_NI
M):1MC_OH,?Q-?#'P2^!U_P#&[3_'$.C>9)K>A:/_ &M:VB#/VK9*BR1#_:*,
MQ7'5E [U^AW[!_PYO/ G[(.L7^H1/!<>(Q>:K'&_!$!@$<1Q_M",N/4.*^?O
M^"4/_)9/%_\ V #_ .E$5="ER^TE$S:ORIGHW_!,G]HXZGIL_P )M>NLW=FK
MW6A22GEX<EI;?GJ5)+J/[I?LHKRC_@F)_P G/:__ -@"\_\ 2FWI/VWO@WJG
M[,WQTTOXG>"PVGZ3JE[]OMI81\EGJ"G?)$0.-C\N%Z$&1<86H_\ @ES,;C]I
M3696 #/X=NF..G-Q;&AI.$IQZB5^91?0XS]J+QQ%I7[=&O>(]5M&U.ST;7;.
M22R#!?.BMEA_=@G(&X1XSC^(G%>W^)?VYOVAO!,5AXJ\5?"_3K'P5?RH8(;K
M3[B)2N=Z 3&0E9" "&9<'&0O:O(/VS-!B^'O[;5_J.L6V_1+R^L-8VLF1-;D
M1^;QW^>.5??%?>'[<'B[PW=?LB>*KV34+2\L=7MK==,DCD5UN9&EC>(QD9W<
M#?QV4GM2DXV@FKW&K^]J>I?!#XR:'\>/ASIOB_02T=M=;HYK64@R6LR\/$^.
MXX(]05/>NYFA2XA>*10\<BE65NA!&"*^(_\ @E%:W\7P=\73R[AITVN8MU(Q
M^\6"/S&'KP8Q_P !K[?KAJ14)N*.B+YHIL_*3]HC1?B!^Q7^T%I7B/1-;U:_
M\*3W)O=*6\O9987CS^]LI=S'. VW)Y*LK9W9P?'_ /:3\5_MA_%SPMX/^&+Z
MEINEL(X[6W29H));B1 TTLQ0\)&,KW ".P^]7LO_  5#^.&AVOA2Q^&%O;6V
MI:]=2QZC=32#<VFQJ3LVG^&23)'LF[(^<&OFC]D?XG2?LI_M!11^.-$;3+?4
M;9+"^DOH-MQI\<P22.<9&0OW"P[J3P2 *]"'O04VO>1RRTERWT/U7^#?PQM_
MA#\.])\,PWUSJLUM'NNM0O)&>6ZG;EY"6)(!/1<\  =J[:F0S)<1)+$ZR1.H
M970Y# \@@]Q3Z\MMMW9V'X]>%8T^+'_!0L?VLJW=O<^,KB1HY_NM%!*[1H0>
MHVQ*N#UQBOV%K\>/C197O[+_ .W!<:_/9R26,.O+X@MASBXM9I#(RH3UQNDC
MS_>4]:_5SPO\5?!_C/PK'XET;Q)IM[H;1><;Q;E52-<9/F9(*$<Y#8(P<UV8
MA746MK&%/JF4-<^!7P]\3>,)/%.L^#='U?7Y$2-KW4+19VP@PN X*@@=P,\#
MGBODG_@K(H7X=^ @!@#5)P /^N(K'\9?\%$?%=Y^T@/#'PVL=)\4^%[BZM])
MLXKJ-E-U.S!6ECE1LA2[8!(9=JAL<UK_ /!6+=_PKKP#NQN_M2;.WIGR113A
M*-2/,$I)Q=CVC_@GS_R:#X!_[?\ _P!.%S7(_P#!3CPW8ZM^S<=3GA5KW2=4
MMI;:;'S+YA,;KGT(8$CU5?2M3]@GQMX=TC]DWP+:7VO:9974?V[?!<7D<;KF
M_N",J6R,@@_C7E'_  4N_:$\*ZE\-[/X?Z!K=GK.KWE_'=7RV,RS);01J6"N
MRY =G*$+G.%).,C*C%^WT[C;7LSI_P#@E?K4FI_ ?Q%I4Y$L5CKL@C5AD".2
M"(E?IN#G\37L'[2OQ23]F/X:OXD\*^$;'4-7U/4X;(6EO!Y7G2,DC;W\M=SD
M+&WY]:\D_8AT^3]GO]C?5_'.MZ;?727<EQXA:SM%4SFU6-$0JK,HY6-I.3]U
ML^@KU;]FG]K[PM^TS<:Y:Z197&BW^F%'%GJ$L9FGB;/[Q54G@$8.,XROJ*FH
MO?E-*Z3"/PI=3X3_ &3?[._: _:V/C?XB>*;#3/$::@FHVFC>6\3WUTF/*CC
M)&U5CV)A2Q<[ ,'EA^LE?D7_ ,%!K[27_:R\WP5)&-9BMK07DFG$;O[2#M@Y
M7_EH%\@'OD<\@U^M]KYWV6'[1M\_8OF;>F['./;-5B-5&7<*?5'DW[7G_)LG
MQ)_[ L_\J_+;]E/]K"[_ &6[CQ-+:^&X?$/]MK;JPFNS!Y7E&0C&$;.?-]NE
M?J3^UY_R;)\2?^P+/_*OBK_@ECJ7A_3[_P"))UZZTVV5HM/\G^T9(T!P;G=M
MWGZ9Q[5=%I4975R9WYU8Y/XV?\%)O$_Q:^'NJ^$K+PGIWA^VU6%K:\NC<O=2
M&%L;E0%5"DC()(;@G&#S7T[_ ,$T?AOX?\'_  DU37--\1V'B'6-=GB;4%L&
M;%B(U;RH'# ,''F.QR /FP,@;CZ!\>H_@1=?"OQ*?$K^$1:-:2E9K?[.;D3%
M24,.SYS)NQC;R?IFOBG_ ()8ZAJL/Q\UJTM6D.ESZ%*][&,[,I+%Y;'_ &@6
M('LS>]-VG2?*K6%K&:N[F5\3OBMKW[2W[3&L>$_%7Q)/PU\'VNH75G:_:6=+
M2V6%F5/,3>BF1RN2SL "2 0,"N\G_8R^,/PI\0Z%K?P-^($GB[3KC)>]M+V.
MTB@VD$+(K3,DT;9Z#/0Y7N>C^*WP7_9\_:L^+]S!X%^(PT'X@ZGYL]Q:P:?+
M+9W<J EWPRH!(0&+;7YP6VDY)\%^+G[/?Q7_ &(9]-\36/BZ.WL[RZ%O!?Z#
M>RQ.9 K,$EB8#(*JW'SKV/7%:QDG:,7;R:)MU>OF?KEX2FUBX\+Z3+XAMH+/
M7FM8S?P6LF^))]H\P(W==V<>U?E?^UQXBO/VGOVRK/P1HTQDLK&\A\.6KKRJ
M,'_TF8C_ &7,F3W6(5]E^&_VH;^/]AV+XMZ^(X]>&F31K\@1;B]69[:)@HXP
M\BJQ & "V!@5^</[/OPM^,_C_7[WQC\+;&ZNM6TN8K-JL=[;021R3*P;#3NN
MYF4MG&<!N<9&<:$.5RD]+:%U)7LD>P?\%$O@^GP7^*_A/Q7X7A.F:;?64$5N
MT Q]GNK-4C7'8?NQ 1ZE6-?I!\$/B9;?&+X3^&/&%ML7^U+-9)XT.1%.,I,@
M_P!V177\*_,[XN? G]K3QKX2G?Q[IVHZUHFDA]19;C5K"8Q;(VW.JI*6)VEN
M%!)]"<5Z_P#\$J/B]YMKXG^&U[/\T1_MG358_P )VQSH/H?*8 ?WG/K3J1YJ
M2=[M"B[3VM<^<?C+J7B+2?VY?$ESX14-XH'BAH],!17_ -(=PD?#<'YF'7CU
MKUSXW?L4_%_X?^#;[XG3?$RX\2>(=-B:^U);>:XCG@0?-*\,Q?+!/O'A/E4D
M#C%><^./%FG^!?\ @H9?Z_JKB+3+#QBLUS*PR(XQ*H9_^ @[OPK]+?VE/'6B
M>&?V<_'&LWE];MI]WH=Q!:R+(&2YDGA9(50C[V\NN,=CGI5SG*+@DMQ1BI)W
M/(?^">O[2VL_'3P/K&B^*KEK_P 2>'7B!U!E :ZMI PC+XZNIC<$XY!4G)R:
M^M*_-S_@DMHMTWB+XAZOMD6RCM;2TW8.QY&>1L9[D!/PW#UK](ZXZ\5&HTC:
MFVXJX4445@:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7!_&3_D6+7_K\7_T!Z[R
MN#^,G_(L6O\ U^+_ .@/2>P'4>%?^18T?_KSA_\ 0!6I67X5_P"18T?_ *\X
M?_0!6I3 **** .?\?^"M/^(W@O6/#6J+FRU*W:%V R4/57'NK!6'NHK\G_BU
M\(_$/P;\53Z+KUJR ,3;7BJ?)NH\\.C?ED=1T-?L!67XD\+Z/XPTN33=<TNT
MU>PDY:WO(5E3/8X(X([$<BO*QV!CC$FG:2/T7A#C&OPO4E3E#GHSU<;V:?=>
M=MUUTV/Q=KLOA7\)_$/Q@\4P:)X?LVF=B#<73 ^3:QYP9)&[ >G4]!DU^CI_
M8Y^#QO/M/_"&1>9NW;?MUULS_N>;MQ[8Q7J/AGPGHO@O2TT[0=*L]'L5.X6]
MG"L29[D@#DGU/->/2R6?-^]DK>1^I9EXL87ZNUEM"7M'UG9)>=DW?TT*7PZ\
M"V'PT\$:/X9TP9M-.@$0D(P9&ZO(1ZLQ9C[FNCHHKZN,5%**V1_-U:M4Q%25
M:J[RDVV^[>K85^<ND?LE_%>U_;>D\?R^%=OA$^+I]4&H_P!HVA_T9IW97\OS
M?,Z$'&W/M7Z-45M"HX7MU.>45*UPK\Y=7_9+^*]U^V]'X_B\*[O"(\70:H=1
M_M&T'^C+.C,_E^;YG0$XVY]J_1JBG"HZ=[=0E%2W/F#]M[]D>;]I'P_INI^'
M[BWL_&&C*Z0"Z)6*\A8@F%F .T@C*GIDL#C=D?,C>&?VT)O )^&1TF[.B_9_
ML#3F6R\QK7&SRC<[_N[>,YW8XSCBOTZHJHUG%<MKDN";N?-_[%7[+NH?LX^#
M;\^(-474?$6JLK30V\K/;6<:YVQQYQEB3EF &3@<A<GP+]G7]E/XI^!/VR#X
MYUSPO]A\+?;]4G^W_P!H6LGR31SB(^6DI?DNO\/&><5^AM%'MI>\^X<BT\CY
M+_X*&? SQO\ '+P;X2L?!&B?VW=6-_+/<1_:X+?8ACV@YE= >?3->M?LH^!=
M<^&O[/?@WPUXDLO[.UO3[>5+FU\U)?+8SR,!N1F4_*P/!/6O6J*AU&X*'0KE
M7-S'YY?LE_LI_%/X9_M22>+_ !+X7_LWPZ?M^+S^T+67_6!MGR1RL_.1VX[U
MK_M:?L3>-M0^+'_"U?A%,IUF6=+VXT])UMYX;I,?OX6<A6#;<LK$'=G&X-@?
M>U%:>WES<Q/LU:Q^8OC;X4_M<?M0?V9X>\:6$>EZ):3B1I;MK:TMUE4%?.<1
M$O(<$XVJ0,G &2:_0'X*?"Z#X-?#/1/"4%_<:JUC$?.O[DDO<2L2SOR3@9.
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MX:X:H\/49)2YZD_BEMMLDNWY_<E\UF68SS":;5HK9!1117V1XY^0O@?]C?\
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M1;>]QN":2['(_"1?$\?PR\,1^-!CQ8EA$FJ'?&^ZX"X=LQ_*<D9^7CFO"/\
M@H=X3\:_$'X.:9X8\%:!?:[<7FJQS7JV:@[((D<@-DCK(8R/]TU]2T5G&7++
MF*<;JQR'P?\ !8^'/PJ\(^& H5])TNWM)=O\4BQJ)&_%MQ_&NOHHJ6[NY1Q?
MQ@^$N@?&[P!J7A+Q'"[Z?> ,LT) EMY5.4EC)!PP/X$$@Y!(K\Y=2_8I_:&_
M9Y\475_\,-4FU2SFS&+W0[Y;:62,'*K/!(RY/? W@>M?J=16M.K*GHMB)04M
M3\H-8_9\_:R_:"FALO%PU8Z;YGF?\3W48K>TC;.-QA1NH[80G'2OL[]C_P#8
M[MOV8[/4[^\UMM<\2ZM$D-R\*>7:PHIW!(P?F8Y/+MC.!A5YS](TC+N4C)7(
MQD=153K2DN79"C32=SXX_P""HG@+3]>^!-AXFEEB@U/0-1C$!D.&FCGPDD2^
MIR(W^D;5X_\ \$I_A5_:'B3Q3\0[R'=%I\0TFQ=AD>=)AYF'NJ!!])365X^_
M9A_:S^.5]::)XVOH[S1K2X\R"ZOM2M4M58@CS3'!ER0,CE"1N..IK[X_9_\
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M (DU*&PTVV>ZNI3A40=/4D]@/4U]A?#GP7%X#\*VVEHRRSY,MQ,HP'D/4_0
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M  !T %25SU)NI)R9I&/*K!1116904444 %%%% !1110 4444 %%%% !1110
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M )6'-'N?1-%?.W_#P;X _P#0_?\ E&U#_P"1Z/\ AX-\ ?\ H?O_ "C:A_\
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M^^$6J>"[?58]&EO98)1>20F95\N57QM##.=N.O>OB[_ATGJW_12K+_P4/_\
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MAEXE^#WPTLO"7B/Q-#XJ&FGRK&]2V:%X[? VQ,"S;MO(!S]W Q\M>GU\[?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7_@F%\!]?7QI>_$S4[2;3]$M[.2QT_SE*-=RR;=SJ".8U4$;NA9AC.UL:O\
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MM<__ !=?35%'M:G\S#DCV/F7_AW)\"O^A9O?_!M<_P#Q='_#N3X%?]"S>_\
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MN3X%?]"S>_\ @VN?_BZ/^'<GP*_Z%F]_\&US_P#%U]-44>UJ?S,.2/8^9?\
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MZ(T4>UC_ "(.1]S\[O\ AI;]L7_HE7_ENW/_ ,<H_P"&EOVQ?^B5?^6[<_\
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MG_XY7Z(T4>UC_(@Y'W/SN_X:6_;%_P"B5?\ ENW/_P <H_X:6_;%_P"B5?\
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MF?$NYNH=$T6:T-Q>/=R@):.A*2HS>SJ0.YXXYQ7QE\5/^"AVK^,/CEX0\/\
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MDC7>T<J [3E,LKI@$#OD&O'M0_9$_:._9KUR[N/A!XDN=9T"25IEBL;R.)B
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ)\,M>TS3?#^FWD5]I\^K7<HG4<%X&$<;;U^\G.-R'GO7?\ _!5K_DA/A?\
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M0,Y=F!R,DX'0 #%?GK+IJ?LT?\%![;2/"LTUMI=OXAL[801MO_T2[$3/!_M
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M7SI&X0D'( #-@@D $$^5>!?^"JW@G7=8@L_$OA74_#%M+)L^W13K>Q1+GAG
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M -&O1\3?^1'U+_MG_P"C4H^&7_(CZ;_VT_\ 1KTNH^AU%%%%,04444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4A.!D\
M"EK/\0+(^@ZDL6?--M*$QUW;#BHG+EBY=A-V5SYL^)GC^Y\::U*J2LNE0.5M
MX02 P'&\CU/Z#BN,HHK^>L1B*F*JRK57>3/BYSE4DY2W9I>'_$%]X9U2*_T^
M9H9XSS_=<=U8=P:^KO"OB&'Q5X?LM4@&U;A,LG]Q@<,OX$&OC^OH_P" BR+X
M#R_W6NI"G^[A?ZYK[/A/%5(XF6&O[K5_1JVIZF75)*;AT/1Z\R^.W[0G@_\
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M']C:V\=?"^PM-)MM2QIVD64-M' FGW$C/YF8E&P-&5E;: 06 /(.:\D^$O[
M[_'3X::7\0O'_P 0?$LOC77+==0LKB.=95M8V^:'>9 SR'&UOE9 -V!TR>?V
M:LY2=D:<W1:GZ$.VU&([#-?+'[$O[5/BW]I*\\<P^)=.T:Q&AFU%M_9,$L9?
MS#,&W^9*^?\ 5+C&.IKDOV#?CAXPU#Q1XU^#_CS4)-9UGPN9FMM1N)3),4CF
M\J6-G;YG 9E*L>0"1T"@<-_P2E_Y"/Q=_P!ZP_G=5I[/EC._2Q/-=QL?57[/
M?BCXU>(KCQ$/BYX0T;PM#"8?[*;29E<W )D\W?MN)L8 CQ]W[QZ]O9:_-O\
MX)G^(HO".D?'379P#!IEK;7KAC@%8UNW//\ P&LC]F_X#:E^W5JWB7XD_$KQ
MAK445K??9;*'2IE1XI<+*5B:176*- Z855R2<Y&.2=)<TFW9((ST5CZ2N/VJ
MO%D7[<D7P:&GZ,?"[ $W9@F^V_\ '@;C[_F[/O\ 'W.GOS7U37Y=_"GPGKG@
M7_@I;I&@>(-=N/$M]I[RPQZK>8,UQ;_V8Y@+G)RPC**2>2037ZB5%:*CRV[%
M0;=[GSS\6?VL!\/_ -H3P1\)[#0?M=_KTULUSJ=Q-MBMX992F$0<N^$?DE0O
M'#<BOH:OR:^/?[-?AC1_VV?#G@.&^U9M'\53P7E[-)-$;B-[F>7S!$PC"@#
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M\2:A<:EI'@]5O;;SY2[PP^5*SQ*S=$'DY Z#<?6N'^!_PGU__@H1JWBCQO\
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MH^%?&'Q2_:"\%^*O$&D_$CX+6WQD\*7;[=/M]%T_S+1 I/S@+%.V&!Y689!
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M?\C%\-?^O6^_]#AKW7QE\$KCX]_L#^!_#NGX.MV_AG2-1TU68*KW$=FF$)/
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MX8S"G4Y:45*/>Z7X-_YGSD\!6B[15T>/:+H]WX@U2WL+*(RW,[;54=!ZD^@
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M]5[ ?E_,TGA_P!IN@RK/AKNY7E9)L87Z#_\ 773548V)E*X44459!^4/A/\
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M *57%?I5X;_Y)WI?_8*B_P#1(K8N])L;^0/<V=O<.!M#31*Q ],D5:"A5"@
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M7_$NU^*WQ"LKNQTZSN3J5I'J2%;C4KPG>LQ5AN"*Q\S<<;F"XR,FOT5T_P
M^&-)OA>V/AO2;*\!#"XM[&*.3(& =P7.<5O5;K)1:IQM<GD=[R=S\U/^"M/_
M ".7P\_Z\+K_ -&)7WQ\%?\ DC?@/_L 6'_I/'74W>F6>H,INK2"Y*\*9HU?
M'TR*L1HL:*B*$11@*HP /05G*IS04+;%J-I-GY1_L#_\GJZA_P!<M4_]"-=;
M_P %"O@3XJ\#_&*+XS^&+:XNM-F>VN[JYMTW_P!FWEN$5'<#D(PC0ANFX,#C
M*Y_2:WTFQM9O.@LK>&;G]Y'$JMSUY JT0&!!&0:U^L/GYTB/9^[8_,/XF_\
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MMH_[L<:!%!]\ 45Y.--0>_4=-7DY+8U****\\Z HHHH **** "BBB@ HHHH
M**** .7^)O\ R(^I?]L__1J4?#+_ )$?3?\ MI_Z->CXF_\ (CZE_P!L_P#T
M:E'PR_Y$?3?^VG_HUZ74?0ZBBBBF(**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** /FGXJ?#:Y\)ZI->VD+2:-.
M^Y'09$)/\#>@]#_6O/Z^U&59%*LH96&"I&017/S_  ]\,W$_G2:'8E\Y.V$
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M?[6G[7,7QIU;PY+X?\+:/"#;;R[Q.ZQM'%%'*R@2L&9I&*@ 8[9&?O/XG?\
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MI_;.^'7Q)U72KZX\+V4%F[7%K%N\QH9I6DC4L0N\*P.TL.HK6_;UL]1_:(^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?_)7_P"SH_X4E_U&?_)7_P"SHU ]0HKR_P#X4E_U&?\ R5_^SH_X4E_U&?\
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M+_\ A27_ %&?_)7_ .SH_P"%)?\ 49_\E?\ [.C4#U"BO+_^%)?]1G_R5_\
MLZ/^%)?]1G_R5_\ LZ-0/4**\O\ ^%)?]1G_ ,E?_LZ/^%)?]1G_ ,E?_LZ-
M0/4**\O_ .%)?]1G_P E?_LZ/^%)?]1G_P E?_LZ-0/4**\O_P"%)?\ 49_\
ME?\ [.C_ (4E_P!1G_R5_P#LZ-0/4**\O_X4E_U&?_)7_P"SH_X4E_U&?_)7
M_P"SHU ]0HKR_P#X4E_U&?\ R5_^SH_X4E_U&?\ R5_^SHU ]0HKR_\ X4E_
MU&?_ "5_^SH_X4E_U&?_ "5_^SHU ]0HKR__ (4E_P!1G_R5_P#LZ/\ A27_
M %&?_)7_ .SHU ]0HKR__A27_49_\E?_ +.C_A27_49_\E?_ +.C4#U"BO+_
M /A27_49_P#)7_[.C_A27_49_P#)7_[.C4#U"BO+_P#A27_49_\ )7_[.C_A
M27_49_\ )7_[.C4#U"BO+_\ A27_ %&?_)7_ .SH_P"%)?\ 49_\E?\ [.C4
M#U"BO+_^%)?]1G_R5_\ LZ/^%)?]1G_R5_\ LZ-0/4**\O\ ^%)?]1G_ ,E?
M_LZ/^%)?]1G_ ,E?_LZ-0/4**\O_ .%)?]1G_P E?_LZ/^%)?]1G_P E?_LZ
M-0/4**\O_P"%)?\ 49_\E?\ [.C_ (4E_P!1G_R5_P#LZ-0/4**\O_X4E_U&
M?_)7_P"SH_X4E_U&?_)7_P"SHU ]0HKR_P#X4E_U&?\ R5_^SH_X4E_U&?\
MR5_^SHU ]0HKR_\ X4E_U&?_ "5_^SH_X4E_U&?_ "5_^SHU ]0HKR__ (4E
M_P!1G_R5_P#LZ/\ A27_ %&?_)7_ .SHU ].=UC4LS!5'4L<"N4\2?$C2M#A
M=()EO[S'RQPME0?]IAP/YUSJ_!,9&[625]!;8_\ 9ZZ+0_ACHVBR+*\;7TZ]
M&N,%0?4+C'YYHU Y_P %^&K[Q'K/_"1ZT#C<'@C88W'L<=E';U_GZ;110(**
M**8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%>.?M6ZYJ?A[X3R7>DZC=Z7=_;8$%Q9SM%)M)
M.1N4@XKFX_V;?'4D:M_PNSQ"-P!Z3_\ R34.3O9(M15KMGT/17SS\-]<\:?#
M?XRP?#[Q/K[>*M/U&R:[L[V;)EC*[CDEB6YV,"I+?PD$<U[OK&O:9X=M/M6J
MZC::9:YV^=>3K"F?3<Q IJ5Q-6+]%9^B^(-+\26INM)U*SU2V!VF:RG29,^F
MY21FDUKQ%I/AJU6YU?4[/2K=FVB:]N$A0GTRQ S5$FC161;>+]"O)K"*WUO3
MIY=05GLXX[N-FN57.XQ@'YP,'.,XQ6!8:=L^+.IWO_"8?:=^GHG_  B_G9^S
M<K^_V>8<9Z9V#[W6E<9VU%8.J>/O#&AW_P!AU+Q'I.GWO'^C75]%%)ST^5F!
MIWB[Q1:>%_"U]K$UY:6T<4#/#+=2A8G?:2BY)&=QP  <G/%%PL;E%>9_!'XJ
M6_COX>VFI:IK.G2:RD<MQ?PQ31J;9!(^"Z Y10H'+=ADD]:ZX^/O#"S64)\1
MZ2);U5:UC^W1;IPWW2@W?,#VQUHNFKA9IV-ZBLK7/%6B>%TC?6=8L-)20X1K
MZZ2$-]-Q&:FTW7],UC3S?Z?J-I?6(!)N;:=9(N!D_,"1TIB+]%>/_#7XV6WB
M_P"(GB_2;O7-(-G;W,5OHT4,\8-TN'+,AW$R$_+G;QP, 5U5AIVSXLZG>_\
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M]G)=W]W!96D8R\]Q((T4>I8G JCH7B_0O%'FC1M:T[5S%_K/L-W'-L^NTG%
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MDEYIM[;ZA:/]VXM95EC;Z,I(-<KX(T[['XM\7S?\)A_PD/VBY1O[+\[?_96
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M46TLEJ%];WT-34/V:/!UU\/TT&QTZVTW4(XE,.N1P!KM)A@^87R&;GJNX#G
MQQCDOVC-6U+0?#/@3P?>7>IZPFJ3K!JD^EP_Z7?Q1! Z(F[[TA;.,]N]:6I#
MXQ^(/";^#KGP[IMG-/#]CN/%*ZFK1-$1M9UA \P,5[^N>!VVO&GP)^W?#WPS
MI/AV^6PUOPNT<^F7DRX1Y5QN\P#. Y&3@'!]1D4WJM$).SU9YOXJ_P"$+UGP
MK<:;I_P4\9:5>K$?LE]:^'!%-%*!\C&57W'!QG.<U'\6+KQ!XF_9V\!#7([K
M3/$,NLV]M*UY&T,RN/.19&#8() 5L^^:] U+7OC+XBTB71(O!VG^'KZXC,+^
M(/[81X8LC#/'$N9%;'3DX-<[^TAX;NM#^#_@[1O[6NKZ^BUJUA.J7<C22O*4
MES(2Q)^\<@9X&!VJ7LREND=9XR_9]\%+\-=1L+;1[:WO;6T>:+5@BB[\Y%+"
M1Y?O-EAD@G')Z<8\I^(&IIX]_9<\)^(M6MH+O6ENH;0WTT2M,565XV^<\_-L
M!//)KT?6+CXP^)]"F\*R^'-+TJ6XB-K<^*%U)7A9",.\< &]6()QGH?3BK7Q
M(^#%S/\  NT\'^& EQ=Z6898%G81_:&1LMD] 6)8\D#)ZBFU>]D).UKLYK]H
MZXM?">B^$/!^D:9/8Z+K=^QOK'P[;*LT\*;-\4<:X!9]X^N.<UA^*O\ A"]9
M\*W&FZ?\%/&6E7JQ'[)?6OAP1312@?(QE5]QP<9SG->@^+O!'B?XN>#=.OKS
M38_!7C/1;W[5IJ/=I=1Y4+]]T&-K$>A(VCKSF+4M>^,OB+2)=$B\':?X>OKB
M,POX@_MA'ABR,,\<2YD5L=.3@T-:L$]#E?'OC;Q3'^S+H*ZHMYI7B'5[B+1[
MN2ZC:&=5+.I=@V""ZQC)/4,?6NX\4?L^^"H?AW>:=I^B6EC>6EHSVVJ11A;I
M)D4E9#*/F;YN2"<?I6IXL^$!\4?"6/PC<ZQ=7>H01H\6L7CM)*;E#N$C%B3@
MG(QG@' Z5R]Y=_&/Q!X<N/#%UX:TW3[F6!K:?Q,NH))%(NTAFCMQA@[#INP
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M7&5^0<\ C%>M^"-#O='^%VB:1=P^3J-MI,-M+#O5MLBQ!2N0<'GN#BO'M/\
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M]JUU<64QE5U:-BI1FV$X4D8(/.">*E*R6A5]7J<MX>OO@EH?A]O#ZV:^/]9
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M</<R.-S2)*S[@I)."".,'KS7??#KX9^(O^$!\2?#CQ?;R2:$A>'2]82>-S)
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MWMR#'')W52&;C_@1^M:]:F04444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_LW[89!]E\[S=FR1D^]M7.=N>G>EY#\SKJ***8@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH AO/^/.?_ *YM
M_*N%^ /_ "1SPK_UZ?\ LS5WLD8EC=#P&!4X]ZRO"'A>U\%^&M/T.QDFEM+*
M/RHWN&!D(R3R0 ,\]@*74?0V*\4\4?\ )UW@O_L"W/\ [4KVNO%/%'_)UW@O
M_L"W/_M2E(J/4]3\9:A/I7A'6[VUD\JYMK*::*3 .UUC)!P>#R.]>._""^^)
MWQ-\.Z%XGNO%UKI6G&55?3X],BD>]B1MLCO(0-C,5? 48 Q7K7Q"_P"1!\2?
M]@VY_P#135RG[-O_ "0_PG_U[O\ ^C7I/X@7PF7X*^(VMW7BGXK1WQGU>T\/
MSJ+"PM;=3+MV.?+38NYRQ4 9R:I:5I/QB\9Z&FNOXLM/!]S<*98?#_\ 8R2B
M-?X%EDDRZL>^ <>F>!RNC:]JGA?5?C_JNBP^?J=K<1R0KMW;2%?+X[[1EL>U
M9^B_\(%K7@VTUSQA\4M8\07EU"LMUHZZP5'FMUB2UC^<<G;@<=Q@5%R['HGP
MV^)6H?$WX,^(KS5[>*WU:Q2[L+KR00CND6=P!Z<,,CU'X#0_9A_Y(;X7_P"N
M<O\ Z.>O-_V96C7X)_$"%(&M&CO;W_19,[X0;= %.><C!'/I7I'[,/\ R0WP
MO_USE_\ 1STXZM"EI<WOC-XAU#PG\+_$6KZ5<?9=0M+;S(9MBOM;<!G# @]>
MXKSGQC\7-?L],^'&C6>J6&C:GXFLDGNO$&I1J8H,1J6VIPN]F;@'C) [Y':_
MM$?\D4\6_P#7G_[.M<#XDU[PS:^"OAMH_CGPY%>^%M2TV%/[:EE8"RG$*X4[
M5W+N&/F#CC/933D]0CML=5I=C\5/"?B/21<:S:?$#0+R39>S&S@L)[)3C$B!
M7 <<Y(Y)Q@#G->LU\B^*-.\/?#34=&F^$7C6XO-9O=02-?#MEJ"WMK,I/.Y5
MSM XY<DXZ8QFOKE<[1N&#CFG%]"9=SQ7QM_R=%\/O^P9=_\ H+TS2?BUK.GZ
MA\8;K4)#J=GX8D#6-F(TCVKL<[2RKDC(&2<D8I_C;_DZ+X??]@R[_P#07K%\
M"ZE<Z/XN^.E[::3_ &[/!=QN--W[?M "R;D!VMR1GC!ST[U/7^NQ73^NY/X2
MG^*/CSPC#XKTCXB:/-<S1>>N@6^EPO;HV,B!YBV]3V.>0>_>K?QM'BSQ!^SW
M=7NI.OA;48;<OJNF1QQW*W #;=BN&.P$X<$$D=#WKB8/#OP/\5:'!XFT[Q O
M@#5C$9I(K#5/)N+>7'S((FY.#D#RU&[MUK1TW6/$GBC]DOQ3<Z[--?R".86=
M[<+MEN;564K(P//9^3R0!UZTNEA];G2Z#XKU;X.? FVU[6]8/BAYK6U72[%;
M-+8Q%XU"0Y4DN!U+'G"FK\?AGXS3:<NKMXUTN'4BGG?\([_9,9M0V,^49\^9
M[9]>_>N*^(5K;_$_]FG1(O#MQ!KMUH<-C=7=C9RAY %A*NC*O(;!8XX/RFJ^
MG^&_V;KWPNNMNMA;KY/F/9RZM<BZ5L<IY7F[R<\< Y[9H\@\SNF_:(C7X*S>
M,#IP76HYCIS:9DE?MN=NW(Y*_P 7TXSFJ.N:7\7]%\(WWB"\\3Z;JTBVLDMU
MX:735CB6,J2ZQSJ=Y=5Z9&"?7OQNM>"4UC]G./4_#/@Z;PY%;ZJFN1Z2UU)=
M2W$2#89#Y@R,I\VT9&%!YS7IOB#]H+P5>?#VZU"PUFWO;V\M62WTJ%@]XTKH
M0L9A!W Y."<8]Z=^[%;LA/V4_P#DA/ASZW/_ *425Z'XP\36O@SPOJFN7H9K
M:PMVG=5ZM@<*/<G _&O//V4_^2$^'/K<_P#I1)73_&?PS=>,?A;XDTBQ7S+V
MXM288QU=U(<*/<[<?C5+X29?$<!X;A^+GQ%\/P>*(/%VG>%H[Y/M%EHL>F1W
M$9B/*>9,WS L,9V@\'. >!I>&?B]J?B;X6^-+FYACTKQ=X:ANH+M(0'C2>.-
MBLB Y!4E3P<\J>HIGPK^.7@^/X::4FKZY8Z-J.EVB6E[87D@AG22)0K!8S\S
M9VY&T'KCKD5QO@&UN]5^'?QE\936LEG9>(DO)K&.5-C/ L4FV3'H=_7N5-3?
MLR[=T:WP_NOBU\4OA_INNP>+K'PZS1$0I_9D=P]Z5)!>5B L8+ X"+P/>NZ^
M!7Q$U#XC>#I[C5X8H=8T^]ET^\\A2$:1,'< >F0P_'/TI_[/?_)%O"/_ %Y+
M_P"A&N6_99_Y GC?_L:+S_T&.FNA+UN>K>+/$=OX0\,ZIK=VK/;Z?;/<.B]6
MVJ3M'N>GXUXYHL_Q@\;>$U\967B'3M'^T1&[L?#2Z:DR318RBO,QWAF'IZCI
MG ])^+_AN[\7?#'Q)I%@N^]NK-Q"G]]Q\P7\2,?C7!_#GX]>$-+^$^GOJNKV
MVG:GI%DMK=Z7<.$NA+$H0JL1^9LD<8!Z\XP<-[Z@MKH?\1/$M_XN_9CUS5-4
MTBYT+49K BXL+J)HWC=9 IP& .TXR,]B*I:IXTUGPKX>^"=II=Y]EM]5DM+6
M\3RD?S8C%'\N6!*]3R,&CQ=XCU_Q=^RWX@UGQ'8P:;?7MH\L=K!&Z;(3(OE[
M@S$[B/F[<$<"L3QI_P @O]GW_K\L_P#T5'4,I'0_$CQYXUL?CEHGA+PQ<VJP
M:CI1E,=Y$IBB??)NF) WG:J<*& )Q[U%J'B;Q]\)_'7A>U\1^([7Q=H'B"\%
M@7&G):2VTK$!=H3@C)'4G(!X'6K.M?\ )W'A[_L6Y/\ T9)1^T?_ ,AOX6_]
MC1;?^A"GW8NJ1N>*/&FLZ=\>O!WARWO/+T;4+&XFN;;RD/F.JL5.XC<,8'0B
MN?L?%?CGXQ>)_$$'A36[;P?X<T6[:P%^UBEY/=SK]["N=H7H?7D=<\2^-O\
MDZ+X??\ 8,N__07K&^"GBW2_A5JWC#P9XLO[;0KZ/59;^UFOY!#%=028VNKL
M=O\ #TSGG'4'!?74.AV?@7QOXOM-+\56?B[0KJZU/0 6@O+"S<1ZLFTE?)&,
M%^ "%_O#@<UB:5I/QB\9Z&FNOXLM/!]S<*98?#_]C)*(U_@6623+JQ[X!QZ9
MX%>X^-7B/Q)H7Q%UKPQ8V]QH&C6_EZ5?"!S)<S ?O9!EMK(@RV-O/'N*XW1?
M^$"UKP;::YXP^*6L>(+RZA66ZT==8*CS6ZQ):Q_..3MP..XP*+A8]<^ ?Q*U
M#XF^"9;S5[>*WU:QO)+"Z\D$([H%.X ].&&1ZC\!X+9:?J=Y^S=X\EL=6_LZ
MWM];O)+N#[,LOVN/,8\O<>4YP=PYXQ7H?[&+1KX$\1PI UHT>MR_Z+)G?"#'
M& ISSD8(Y]*Y/PK"\W[,?Q05%W,-3O6P/0&,D_D#2W2*V;.PBOO%OP[_ &:[
MK6CXI_M&]73K6?3F_L^&+[%&1&/+QR).#C<PS72?#.#XB>)ET+Q3K7BFU@TF
M^A^T2>'K?3H^(V0F/]^?FW<J6X Z@5R?B[Q-I/B#]DV\CTS4K6_DM-'LXKB.
MWE5VA?\ =C:X!RIX/!YXKV;X?_\ (A^&_P#L&VW_ **6J6Y#V/+/A_\ %CQ-
M=?"GQ7K]S:W/BG6+'5;BTLK.TM07< H$7;$HRHW$DXS@'FC5M)^,=CX4N/$K
M^-["&_AMFO)/#R:/'Y"[5W&(3$ER<#\^,XYKSOPWXOUOP3^S[XOU/06,%W_P
MDTT4EV(Q(;:-F0-(%(Y[#VW9J[XHTOX<IX-N+B\^(6M?$'5;BV;[+IC:T]PT
MMP8SM @B^9!GG#=.A]*B^A=M3V#POXZD^)'P+D\0S0);3W>F7(EBC)VAT#HV
M,\X)4G\>IZUY1X;^)>H?#G]FWP$-+-I;WVK7;6"7VH9^SV@::0F5_H!].IYQ
M@]5\ Y4D_9:0*V2EGJ"M['?*<?D17,>&/$FE^'?V:?!7_"1>&UU_PO=3M;ZC
M,S$_85,S[9MH4DX.>05(. #DT[[/R%;=>9VQL/BWX;CL-6T[Q18?$BTED3S]
M.:QM[',1ZO%*K@$_4X]CTKV8<@<8]J^1O'N@_#SP#H<VO?#/QW/I>O.T8M=*
MTC4_M2W#$C"-%DO_ -]''8@]*^B-/^(5GI?_  BFC>)+A;'Q7K-JCK9+"[!I
M0@,@W!2JX.>I%5%]"9(P?BQX_P!=TWQ#X?\ !WA);4>(];,C_:KQ2T=G @RT
MA4=3P<9X^4\'->=?&+Q%\6/@WX5%Z?%MKXAM;J=(?[0_LJ*WGLWSD#8 R,C
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M-N$&=XR>6 ^3D^IZ= 1>H26AZGXR\56G@GPKJFNWH9K:P@:9D4@,^.BC/<G
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTV_A,-S;D]G0_0\@D5U]>%ZYY=G^UUX=-@=D]UH<HU!8P!N0;]A;'4Y5>O\
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MA^".AR6FTR3//)<L  S2^:P.[U. HY[ 5C>!?+L_VHOB';:>=MG+IT$UW'&
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MR2%CB )]^*X7P'\5/'/A&ZUC4[[X0>(-8\0:O<&:[U$Q3Q94<1Q(OV=MJ(N
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M691LPIR<_A3OBQ;6-U\,?%,>H!/L?]FSLY900N(R00#W! (]P*^<O%2RZO\
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M Y>0LP!;D!2QY"G ."?8?$6H>%8?C-X6M+[3+J;Q7+9SM87R,1##$ V]6&\
MDC/\!Z]17C_Q.\!Z-\!/&7@;6O! FTJ[OM16RN--6YDE6ZA)7=PY8D<@=QEE
M/4"NX\;?\G1?#['_ $#+O_T%ZE::%/74Z;Q9\=-!\,>()-!MK'5_$VM0KOGL
M?#]D;J2!?5^0!U'&<C(R.:UOA_\ %/0OB1%=C3&N+:_LVV7>FW\)AN;<GLZ'
MZ'D$BO.OV41'<:'XPO9SOUF?7[C[:[#]YD!2H)ZD9+'ZDT:YY=G^UUX=-@=D
M]UH<HU!8P!N0;]A;'4Y5>O\ =6JN]&3RK5%G0?\ D[+Q-_V+\/\ Z''6WJ_[
M0>A6>J7MAI.C>(O%LEBYBNY?#^FFYB@<=59R5&>O3(X-<Y8W4%E^U)XON+J3
MR;:+PU')+(21M0%"3D>@S5+X<^,M9/AT6_PP^&0@\*M+(UMJ.JZJ(O-?.&<H
MVZ0C/?<>F.,8I7'8]4^'_P 3-!^*&C3WVAW#N(&\JXMYT,<T#XZ.O;ZC(X//
M!KP7]GGXPZ7X-^',>CQZ7K7B+5Q>7$\MCH-B;F2&,O@._( !(]<^U;O[-;:A
M_P +(^+2ZG]C6_\ MD+7":<S-;B4F;?LW<]>N>^:U/V.[&SM_A;=7$ 7[5<:
MG.;AN,Y7 4'V"X/XGUH3;L.R29Z9X"^)6@_$C2Y[[1KEF^S/Y5S;W"&*:W?^
MZZGIWYY'!YX-<?<?M(Z#)<W0TC0/$_B6PM7,<VJ:-I9FM59?O?.6&0.N0,8Y
M&:Y_28[>V_:<\=PJZV^DW&@1RZFX<)&DF$ 9CG .PL<GU)]SF^#O#?Q.^&.@
M16_@:^\/>/O"'F,]E&\H2;878MMD#!#R3R6;G/ Z4^9D\J/;_!OC31_'V@PZ
MQH=XM[82DJ'"E65AU5E(R"/0^QZ&MJ21(8VDD94C4%F9C@ #J2:\R^!_CK2O
M%=MKEA:^%X_!^L:;=XU/2XXT4>:P/[S*JNXG8>2,_+W&#6E\>KB>U^#?B][;
M=YO]GR+\N<[3PW_CI-5?2Y-M;&!=?M-^%HY+F6TTWQ!JNC6KF.XUVPTUI+&$
MCKNDR#@>H!ZC&:]&C\5Z/+X;'B!=1M_[%,'VG[<7Q'Y>,[L]OY]JYSX2Z9IG
M_"F_#-G%%%)ILVDQ>8A VOOC!DW?4EL_4UXY\8KOPNG[-L=MX'DD3PHNJQV\
MK)YV OF%I,&7YF&_'/(STJ;M*[*LF[([S_AI[PWY/VX:'XG;0-^W^WQI+?8<
M9QNWYW8SQ]W/M6C\=-4M-;^ ?B2_L+B.[LKFP$L,\1RKJ64@@UW\-CIXT!+-
M8H?[*^S"(1;1Y7D[<8QTV[?PQ7R[X,F>3]C_ ,:1B1Y+*&XN8[-F_P">6]",
M>V2Q^I-#OLP26Z.A\:?\@O\ 9]_Z_+/_ -%1UZQXX^,.A^!]5ATA[?4=;UV:
M/S4TG1;0W-SY?]XJ" !]37D_C3_D%_L^_P#7Y9_^BHZW[CQE#:?%3Q,/ /@.
M;Q/XE41PZSJDVHBVACP %13(6'&.54+]WOBDG8=KG8>!_C=H'CC7IM!%KJ>A
M:]$GF?V9K=K]GG9<9) R0>.<9SCG'6O,/^%@:7\/_P!I+X@7&HK=7,]U:64%
MI8V,!FN+F3RD.R-!U./4@>]4YKSQ/=?M2> I_$]EI>F7DEE<".UTVX:5UA\N
M; E8X!.[=C''6NF\%V-G/^UEX^N90K7EOIML(-V,@-'$'(]^%'XGUI7;MZCL
ME]QW/@GXTZ%XUUR30_LNJ:!KR1^:-*URT-M<.G]Y1D@C'.,YQDXP#5_X@?%/
M0?AO%:#5))Y[Z\;9::;8Q&:YN&]$0?S) SQG->??'Y/L_P 1?A-=V8QJW]M>
M2I3[Y@.SS1UY7!Y^I]>8]-$=Y^U[JOV\[I;70$_L]9!D*"R;RN>A^9^GJU5S
M/8FRW.O\)_'30O$_B&/0;K3]9\,:S,N^WLO$%D;5[@#J4Y(/0\9!X.*F\=_&
MSP_\._$-MHVJQ7SWEU;?:8!:P"7SB7V+$H#;C(S= !CW%<7^UH(K?PCX:O8C
MLUBWURW-C(@'F;\,2 >H' /'=11XPLXKS]JWP(9D#&+2+B51V# 2X/ZT7>P6
M6YW&G_&+1Y/"&H^)-7LM5\*V%C-Y$J:Y:&"8MA2-J L6SN &.IKFY?VF_#]B
M8)M4\/>*M%TJ=PL>K:AI)CM6S]TAMQ)!'(XZ5?\ CUK7AG2]'T2/7]$N/$M[
M-J"'2M)MI&4S72@[2<, 5&<'<&'S=#7GWQM\1?$;7OA3X@_MCP?I/AK1Q"IN
M#>:H+J<@2+M$?E@+NW8QFAMH$DS5_:N\=2Z?X L;73HM4DAU&:&7^TM/0FU,
M6?\ 5O(&ZN",+R&Q6[X]\<>%M>^%D&K>,/"VO0Z0U_%"--O8#;70E!PCE1(O
MRY_VN?2N'^+#,_[*G@IF)9BFEDD\G[@KK/VLO^22P?\ 83M/_0C2UU8UT1W?
MC[XIZ!\-[>S&IR3S7MX=EGIMC$9KFX/HB#^9(&>,YK*\)_'30O$_B&/0;K3]
M9\,:S,N^WLO$%D;5[@#J4Y(/0\9!X.*X[21'>?M<ZG]O.Z6U\/Q_V>L@R%!*
M;RN>A^9^GJU/_:T$5OX1\-7L1V:Q;ZY;FQD0#S-^&) /4#@'CNHI\SU8N5:(
M[/QI\;O#?@'Q7!H&L?:XKJ>S^V1R11!T<%RBQJ V]I"1PH4_7K53PU\?-!U_
MQ1;^'KO3-<\-:K= FUAUVP-M]HQG[G)]#UQGIUKEO$=C#??M<>%6GC5V@\/R
M3(",@.'F /X9-3?M'(%\1?"N8#$J^)H$##J 67(_' HN]6.RT1[=1116AD>#
M_M%WA\4>)?"W@&35FT72-0$VH:Q=JX0+:Q*3@D\ $JW7C(4D'%<59^ O@SXL
MU:QL/A[XK_X1OQ;:3K);WJFXD,K*>@$S*KD]?D(^A'%;'Q^\+6'B+]H#X=6N
MNMLT34(7MI/WFP2LK%A$3D8W,T:_\"XYK1_:4^&'@OP_\++W6+#1[#0-5L'B
M:RNM/A6W<R&11M.P#=D9ZYQC/:L7NV;K9(]+^,'A&;Q9X!NX[64Q:UI^-0T^
MZC&&CN8AN4CTSROT:K_PN\;)\1/ .C>(%5$DNX 9HTZ)*I*NH]MP/X8K6\,W
M5Q?>&=*N;T;;N:SBDG&,8<H"WZDUY/\ LF?+\/M8C0DV\>N72PY& %^3I6G4
MS^R>J^*_">E>-]"N-&UNU^VZ;<;3)#YCQ[MK!A\R$$<@=#7A/Q8^$_P:^$OA
M.;5[_P +^?<,?+M+)=2N@]Q+V4?O> .I/8>IP#[KXM\5Z;X(\/7NM:O<"VL+
M1-[L>I/0*H[L3@ >IKQ/X7^#]2^,WBZ/XG>,8&BT^,_\4_HTG*Q1@_+,P/4]
MP?XC\W0**F5GI;4<;K7H1?L]_"N3X2>&=;\<ZY8S6^I7-K),ND6F6:VMA^\\
ML!FR7.T<,V0  3G->S^"_'>E^._!]KXDTYI(].N$9\7 "O'M)#!@"0""#W-=
M Z+(C(ZAE88*GH1Z5\C?\)%=?"_P'\3_ (>PN3?0ZFEKI$63O>&\. %^B M]
M6-'P!\9[Q8_&[1;[X7W?CU;#4X]%MRP\N2*,3R!7"%E DVD;B1RPZ&L6]_::
M\-V]BNH6NC^(]5TE45KC5+#33):VQ(!*R2E@N5R,[<C/<U2^+7A>+P7^R_J.
MA0X*6&G0PEA_$P=-S?BV3^-=3I.FVUG\!;>SBA06P\.@>65&#FWR<CODDY]<
MT:[!IN9VI?M%>&H8EET:PUOQ=%Y*SS2>']/:X6W5EW#S6)4(<=5/([@5U_@G
MX@:'\0/#*:[H]V)=/.X.THV-$R_>5P?ND?EC!Z5P7[)MO%!\#-">.-4::2XD
MD91@NWGNN3ZG"@?@*\HTV>YTWX$_&I=/S&4UZYB"K_#&SQJ^/^ $T<SW8^57
ML>O3_M): \T[:5H7B;Q#IL#E)=6TG2VFM%(/S?.6&0/4#'IFMK6/C=X9TSX>
MIXTMI+C6-",JQ/)I\89XBS;?G5V4K@D @\\CBN#^'-O\7;7P'X?CT%/A\FC_
M &&)K4/]MW["H(+8XW'.21W)JIX&^%^J:AH?Q5T75=6\-W4^M'>;'P_<-)'8
MW15\[XW ,>6"'!Y^4^E*\@LCU_QW\0M*^'O@V?Q+J(FFT^(1D+:JK22;V 7:
M&90>N>O0&G2_$#28OA\?&6Z5M'%A_:'RJ/,,>S=MQG&[MC/7O7SYH.N+\7/"
MOPE\&W:F4+/*^K0LP/[NS4H%<?[1*\&LV34KR^^%&G_"A9F75G\3OH,F#EOL
ML<GFM)] &3\!1S!R'T'J7Q@\.Z%X$T[Q7JTD^F6.H1I);6UQ&#<R%QE5"*3E
MB.>#@=R*Q='_ &AM!OM:LM,U31_$'A26^8):2^(-/-M%<,>BJVXC/(ZX'(KE
M_'MK;K^TA\+]-N@!I=K93M:0N,IYRJV.O<;4(/7(%=#^U+;V4_P0\0->;08O
M)>!F )67S5"[?0G)''8FG=ZOL*RT7<Z3XB_%K0?A;)I8UTW$4.H-*J3PQADC
MV+N.[D'G@#:"237E'QP^)$7C[X(^+XXM U[1/LAM&+:U8_9A*'G7:4^8DCY3
M^E,^)4<FM7GP$&I@RS37<$DXDY+/LA8Y_'K79?M6?\D+\0?[UO\ ^CTI2;:8
MTDFC8U3XG:/\-_!/AAM06ZO+V^@MX+/3=/C$MS<,44'8A(R!D9)(ZCN0*TO&
MGQ4T;P!I>G7&KQ7B7VH$):Z3;Q":\E? )140D$C(!.[&2!GD5X+\+9M1\$_&
M+1I_B&EO=7?B#2H8]$U/),=H0H MTSPI(.TXYR1R=Y)]/^,7@FY\3^,/#6H^
M&O%&GZ)XWTM)7LK.^96%Q$PPYV<M@ ,,A3P3TZTU)V%RI/4U/#?QXT/7/$%K
MHE_I>N>%=4O.+2W\06!M3<D=D.2,_4C)X'-5?VBKJ2X\#VOARV?9>>)-1M]+
M3!P0C.&D/_?*D?C7&ZY\2O%/@V\TN;XK> M)O=+AO$6WU[32LR6LA/$@1]S*
M>,[OD/''/%=;JS?\)=^T-HED#OLO#.ER:A(,';]HG/EIGW" D?C1>ZL%K.YZ
MC96<.GV<%K;H(K>"-8HT7HJJ, ?D*\:UK_D[CP]_V+<G_HR2O0=/^)6DZC\1
M-2\&1I<KJ]A;+=R-)&!$R'9]TYR3\X[>M>>:M*DW[76B(C!VB\.2"0+SMS)(
M1G\Q^=.704>IVOCCXPZ'X'U6'2'M]1UO79H_-32=%M#<W/E_WBH( 'U-5O _
MQNT#QQKTV@BUU/0M>B3S/[,UNU^SSLN,D@9(/'.,YQSCK7'W'C*&T^*GB8>
M? <WB?Q*HCAUG5)M1%M#'@ *BF0L.,<JH7[O?%<I->>)[K]J3P%/XGLM+TR\
MDLK@1VNFW#2NL/ES8$K' )W;L8XZTN9W*44>I:Y\;O[#UB\T_P#X0'QQJ'V:
M5H_M5CHWFP2X/WD;>-RGL:E^''QQTKXF>(-3T>RT77-,O-.CWW(U2U2(1G=M
MV'#L0W7@@?=/I69\:/B=?Z3<V7@OPB%N?&VM?)%S\ME$0=T[^A !(^A/8 ]1
M\*_AK8_"[PK%I5J[75U(WGWM])]^YG(^9S[>@[#U.27K<G2QS4_Q^\B:2/\
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M;_;XTEOL.,XW;\[L9X^[GVKSWXW-X0TWX2>)M,\&%K>T7Q!$FN+ )MB2ELN
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M6_\ Q[Q_[H_E5*]VF0[6NB2BBBJ)"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MDF&-AO<C*[F;@$\5U_Q$^$?_  F>J:-K>F:W<>&_$NDJR6VI6\2R@H>JO&Q
M8=>,]SG.:]#HHY4',SQ#Q=^S?J/Q"T.2#Q3X]U#6-64J;2Y^R1PVMMALEA;1
MD!F*Y7<6[UV7C'X7R^,;OP5<SZL(9O#MY'>.1;;A=,H4$??^3)7_ &L9[UWM
M%'*@YF<38?#?[#\6=3\;?VCO^VZ>EA]A\C&S:5._?NY^[TV]^M8]O\']2T?X
MF:AXIT/Q9-IECJD\4^I:0UBDRW!3C D)!0')Z#/)Y/0>G44<J#F9X#^T'X-T
M_P ??$SX<Z.K;]0DGE:\C3G_ $%=KOO] 2I"YXRQKWT *  ,"N5\+?"SPKX+
MUK4=7T;1XK/4M09FN+G>\CMN;<P&YCM!/.%P.!Z"NKH2W8-[(^=(?V5_$NFW
M%Z=(^*^K:-:W-Q)<FULK>6) S').%N ">@SCM71>!_V:X=#\4V?B/Q/XJU/Q
MIJ]B<VKWY8)$>QPSNQ(ZCYL9YQ7M-%+D0^9G$ZW\-_[8^*7A[QC_ &CY/]DV
MTUM]B\C=YN\,-V_<-N-W3:>E8.M_!.\M_%6H>(?!?BRZ\&W^I'=?Q+:1W=M.
MW7?Y3D /DGGW.,9.?5**?*A<S. ^'?PCM_!.K7^O:AJMUXD\4Z@@CN=6O $.
MS(.R-!PB\#C)Z#MQ7?T44TK";ON>;^-?@ZVN>*E\5>&_$%SX1\3>4+>:\MX$
MGBN8QT$L38#D #!)[#K@8L_#WX3KX/UK4?$&JZQ<>)O%&H((I]4N8UB"QC!\
MN.->$7(' /8=*[^BERJ]Q\SM8\KUOX)WEOXJU#Q#X+\677@V_P!2.Z_B6TCN
M[:=NN_RG( ?)//N<8R<ZOP[^$=OX)U:_U[4-5NO$GBG4$$=SJUX AV9!V1H.
M$7@<9/0=N*[^BCE6X<SV//="^$W]BZIX^O?[5\[_ (2IMVS[/M^R_(Z]=YW_
M '\_P]*PF_9WM9/AKX<\--KEQ#JF@3-<6.M6L(C>.0NS9V%CQR.-W\(YKU^B
MCE0<S/&M:^ >M>.-%NK#QE\0=0UY6C86T=O9164$<A'RR21QG]Z5." 6 JYX
MG^ __"6?"WPSX,O=<!CT>:!WNQ:'_2(XU9 FSS/ERK 9W'IT]/6:*.5!S,\:
MOO@+KFL6JZ)JGQ'U:^\'KA?[+:UB6X>,<A'NA\SCURO->CZKX&T36/!\GA:X
ML(_[#:W6V%K'E0B+C;M/8C (/J*WJ*.5!S,\67X#>)TTD>'E^*&JCPGM\G[!
M]AB^T^3T\O[3G=C''3&.,8KK-?\ A%IM]\)[CP'I$O\ 8VGO (8YO+\XI\X<
ML1N&XD@D\CDUWM%'*@YF9.F>'H;/PK::%<D7EO%9)92%EVB50@0\9.,CMGO7
MF&B_ GQ)X5M3H^A_$O4M-\+;FVZ>+"&2XC5B252X;E>O!"\=:]EHIV0<S1YG
M\,/@E;_"OQ5X@U+3M6FN=/U9(LV=TA>5)$SF1IBWSEBSD_*/O=>*;X#^#^I?
M#WQ5?W6G>+)F\,WEU->/H,MBAQ+(,9$V=P .,  #@9SUKTZBERH.9GFOA'X(
MZ=H?@;7O"VK7(UO3]8O)KN7]SY)7?M(4?,W*E00V>N.*P%^ WB=-)'AY?BAJ
MH\)[?)^P?88OM/D]/+^TYW8QQTQCC&*]IHHY4',SS[Q-\&]-U7X1S> =(F_L
M73VCCCCF\OSBFV59"Q&Y=Q8@Y.1RV:ZV'1?*\,II'G9VV8M/.V>B;=V,_CC-
M:E%.R%=G%?#CX>-\.?AK;>%UU4W36T<RB_6'RB"[N^[;N.,;O[W;M67^S_#J
ML/P]7^U=4OM;=KVX-OJ&H&3S;BW$A6.3#DL P&X#)X(KTFBBP[G-?$?PE<>.
M_!6J:!;:FVCR7\8A:\6+S2J;@6&W<N=R@KU[UXKIO[*_B[1;&*RT_P",6M6-
MG",1V]M#-'&@SG 5;D <D]*^CZ*3BGJP4FMCA_A3X!UCX?Z3>VFL^+;[Q?-/
M/YJ7-\'#1+M V#=(_&1GJ.M<K\/[=?'GQE\3^.!\^F:;&-!TV0])&0[IY%]M
MQ*@CKD^E>NW5NEY;2P2;O+E0HVQV1L$8.&4@@^X.1530- T_POH]II6E6J66
MGVJ>7##'DA1]3R23R222223S1;8+[FA7"?%;X-^'_B]IL-OJ\<D-W;Y-M?6Q
M"RQ9ZCD$%3@9!_#!YKNZ*;5]&).VQ\[_ /#*.L7Z+8ZQ\4M?U+0NC:=\Z@J.
M@RTK+_XY7L&E_#7PWI/@AO",&F1_V"\30RVS$DRAOO,S=2Q/.[.0<8Q@5U%%
M)12&Y-GST?V4=2T5WA\)_$W7_#>ELQ?[$A=@"?=)8Q^F:]!^%/P3T?X6->7D
M5S=:OKE\,7>J7S;I).<X']T$\]23QDG QZ)10HI Y-G$V'PW^P_%G4_&W]H[
M_MNGI8?8?(QLVE3OW[N?N]-O?K7;444]A7N5-6TJSUS3;G3[^WCN[*YC,4T,
M@RKJ1@@UX+-^R9<Z+=W!\&_$/7/"EC,V]K2(NXS_ +R21Y'U!/N:^A:*3BGN
M-2:V/,OA7\!=$^&-Y<:K]JNM=\0W((FU2_.7P>H0?PY[DDD^N.*]-HHII):(
M3;>YYOXU^#K:YXJ7Q5X;\07/A'Q-Y0MYKRW@2>*YC'02Q-@.0 ,$GL.N!BS\
M/?A.O@_6M1\0:KK%QXF\4:@@BGU2YC6(+&,'RXXUX1<@< ]ATKOZ*7*KW'S.
MUCRO6_@G>6_BK4/$/@OQ9=>#;_4CNOXEM([NVG;KO\IR 'R3S[G&,G.K\._A
M';^"=6O]>U#5;KQ)XIU!!'<ZM> (=F0=D:#A%X'&3T';BN_HHY5N',]CSW0O
MA-_8NJ>/KW^U?._X2IMVS[/M^R_(Z]=YW_?S_#TK";]G>UD^&OASPTVN7$.J
M:!,UQ8ZU:PB-XY"[-G86/'(XW?PCFO7Z*.5!S,\:UKX!ZUXXT6ZL/&7Q!U#7
ME:-A;1V]E%901R$?+))'&?WI4X(!8"MW5_A#+K/P3C^'\VM .EK#:C4Q:?PQ
MNK*?*W^B ?>]_:O2**.5!S,\87X!Z_9:2F@:;\2=4L/"I01R::+2.24(1ATC
MN"=Z*><+S@<<UW4/PM\.0_#W_A"A8 Z 8/):$M\S<[MY;^_N^;/K76T4<J#F
M9XLOP&\3II(\/+\4-5'A/;Y/V#[#%]I\GIY?VG.[&..F,<8Q76:_\(M-OOA/
M<> ](E_L;3W@$,<WE^<4^<.6(W#<202>1R:[VBCE0<S,G3/#T-GX5M-"N2+R
MWBLDLI"R[1*H0(>,G&1VSWKS#1?@3XD\*VIT?0_B7J6F^%MS;=/%A#)<1JQ)
M*I<-RO7@A>.M>RT4[(.9H\S^&'P2M_A7XJ\0:EIVK37.GZLD6;.Z0O*DB9S(
MTQ;YRQ9R?E'WNO%-\!_!_4OA[XJO[K3O%DS>&;RZFO'T&6Q0XED&,B;.X '&
M  !P,YZUZ=12Y4',SS7PC\$=.T/P-KWA;5KD:WI^L7DUW+^Y\DKOVD*/F;E2
MH(;/7'%8"_ ;Q.FDCP\OQ0U4>$]OD_8/L,7VGR>GE_:<[L8XZ8QQC%>TT4<J
M#F9R@^'6FV'PWNO!ND#^S=/DL9K*-\>84\Q6!<C(W'+%CR,GTJS\/?"/_"!^
M"](\/_:_MW]GP"'[1Y?E^9R3G;DXZ^IKHJ*=D*[.!^'?PP;X=Z'XDLEU<W+:
MM?W&H"X6#RC;F10,??.=NW.<C\*J?L_PZK#\/5_M75+[6W:]N#;ZAJ!D\VXM
MQ(5CDPY+ ,!N R>"*])HI6L.Y7O[&WU2QN+.[B6>UN(VBEB<95T8893[$$UX
M%-^R7<6<T]IH/Q#US1/#<[,9-'C+LI5OO+D2*I&./F4GUS7T+10XI[@I-;',
M_#OX>:/\,?#,.B:+$R6Z,9))9"#)-(<9=SCDG ]@  *X.>W7XC?M"6TR?O-)
M\$VS!W_A:^F'W!V.U "?0@"O8JRO#OAC3/"=E+:Z5:BVAEFDN927:1Y)7;<S
MN[$LQ)[DG@ = *+= OU-6O!/$7[-.O:AXRUW7M%^).H^&AJUQY\MM86\B?0,
MRSKNQSR1WKWNBFTGN)-K8^>O^&:O'7_1;?$/_?,__P DUZ-XD^%LGB3Q!X%U
M:76&67PR[.X> NUX65%)+;_E/R9_BZUW]%+E0^9G%_%[X<_\+5\%3^'_ .T?
M[+\V:.7[1Y'G8V-G&W<O7ZU#\1?A1:^/CI-[%J5UH>OZ2Q:QU6Q(WQY #*RG
MAE..1^N"0>ZHIV0KL\A/P-UGQ+?6#>.O'5WXLT^RF6XBTV/3XK&%Y!T,@0G>
M!Z'U^N=_XB?"&T\<:II^MV6IW7ASQ-IXV6VK6."VPYRCJ>'7D\<=3V)![^BE
MRH?,SR>Q^".I:MKVFZGXY\9W7C$:9*)[.R%E'96RRCH[I&3O([=/3D9%=%JG
MPW_M+XK:+XT_M'R_[-LI+/[#Y&?,W[OFW[N,;NFT].M=M11RH.9G"_$GX8_\
M+"U7PG>_VE_9_P#8.I)J&SR/,\_:5.S.X;?N]>>O2K/Q:^'G_"TO ]YX=_M#
M^S/M$D3_ &GR?-V['#8V[ESG&.M=C13LA79%:P_9K6&'=N\M F[&,X&,UR7Q
M*^&&G?$O3[..YN+C3=2L)OM%AJ=DVV>VDXY4^AP,CV'0@&NRHHM?0-CRG2/@
MGJ-WXFTS6O&OC&Y\8RZ2_F:?;-91VD$4G:1D0G>PP""?0=:V/B-\)+?QQJ>G
M:W8ZI=>'?$^F@K:ZM9@,0ISE'0\.G)XR.I[$@]]12Y4/F9Y5H_P1O;OQ/I^O
M>-O%MUXSO-,?S+"%K2.SMH'Z[S$A(9@0.>.@SG K?UOX;_VQ\4O#WC'^T?)_
MLFVFMOL7D;O-WAANW[AMQNZ;3TKMJ*.5!S,\TL_@A8FZ^(']I7S7]EXND5Y+
M=(?+:V #8PVX[B"00<#!'0UDZ7\$?%%GI\6AW/Q.U6;PO$@A2QM[**"Y\H=$
M-R"7QCC@#CCBO8:*.5!S,\J\%? F/P/X,\8^&+36#)INNM.;<-;'=9"2,QX)
MWGS,#;S\N=OOQC:#^S[XB\&:%!I/AGXDW^CV;)B[A.GQSH[_ ,3P[VW0YZD!
MCSS[5[=11RH.9G+_  \^'>E?#3P\-)TL2R*TC37%U<MOFN)6^\[MCD]!]!7#
M_P#"B=6\,W]^_@/QS=^$-.OI#--IK6$=["CGJ8@Y'E_AGMS@ #V"BCE0<S.+
M^&WPMT[X;V=\8+FYU/5=1D\Z_P!4O7W37+\X)] ,G ]^II/A+\-_^%7>&[G2
M?[1_M/SKV6\\[R/*QOQ\N-S=,=<_A7:T4[(5V>4:Q\%-4M_&&J>(O!OC.X\(
MW.K%6O[<V,5Y#*X_B"N0%/4YYZGIFJMI^ST;/Q]X?\8'Q5?W^MV,CM>SZA&)
M?M:LNW8@5E$*@%\  CYO:O8:*7*A\S/,?%WP?U'5/B$GB_P[XKF\,ZC):K9W
M:"R2Y2>(,"  Q&T\8SR>!C'?8L/AM]A^+&I^-3J/F?;=/2P^P^1C9M*G?OW<
MYV]-O?K7;44<J#F9X_\ \*)U;PS?W[^ _'-WX0TZ^D,TVFM81WL*.>IB#D>7
M^&>W.  .L^&_PMT[X;V=_P"1<W.IZKJ4GG7^J7K[IKE^<$^@&3@>_4UVE%'*
MD',SBOA%\-_^%5^#UT+^T?[4Q<2S_:/(\G[YSC;N;IZYI/!WPU_X1/QSXP\1
M?VC]J_X2&2&3[-Y&S[/Y:L,;MQW9W>@QBNVHIV0KL\O\&6>KP_&KQJSZU?ZI
MHOV>W*6\QD%O9SMDF&,%BI(0*Q*@8W@$5ZA110E8&[A7"_"7X8_\*MTK5[+^
MTO[3_M#4I=0W^1Y/E[PHV8W-G&WKQUZ5W5%'F%SR']H#=XNCT#X>V;'[7K]X
MDEUMS^YLX6#R.?Q"@9ZGBO6;:WCL[>*"%!'%$@1%7H% P!^59]OX7TRV\176
MO):YU:ZA2WDNG=F/E*20B@DA!DY(4#)Y.36K1;6X7TL<!'\*VE^,3^/+W5?M
M?EV7V*RT_P"S;1;#NV_<=Q.7_A'W_:N_HHHV"]SSWX<_"4?#?Q)XIO;+53+I
M6MW'VI-+,&T6LF220^\Y!SC[HX ]*N_"7X;_ /"KO#=SI/\ :/\ :?G7LMYY
MWD>5C?CY<;FZ8ZY_"NUHHLD%VSA? _PQ_P"$-\;>,?$']I?;/^$BGCF^S^1L
M^S[-_&[<=V=_H.E,O?AZ+3XHW/C]KQYUCT=K Z7';@L^&+[@Y?DGIMQ^-=[1
M19!=GSG\-_#"^+=$O=7^&WQ U#PAX;N[B1KO0[JR@G>T?)W!"7/D CYAC/!!
M[58_9>T.PM/%'Q*NM(FDO=#:^AL[>[FD\XW+1JYD<OT8L7#$CCYO2N_U[]GG
MX>>)M6DU+4/#%O)>2/O=X9980[$Y)94=5))ZY'-=QHVBZ?X=TV'3]+LH-/LH
M1B.WMXPB+] *A1U+<M#RQ?@1JOA?4+Z7P%XXN_"%A>RF:737L8KVW1SU,:N1
MLS@>O3'3 '4_#GX5V?P__M.\:_NM;U[5'#W^K7QS),0,!0!PJCG"_K@#';T5
M7*D3S,XKX1?#?_A5?@]="_M'^U,7$L_VCR/)^^<XV[FZ>N:3P=\-?^$3\<^,
M/$7]H_:O^$ADAD^S>1L^S^6K#&[<=V=WH,8KMJ*=D*["O*]<^"E[#XJU#Q#X
M+\67/@V_U,AK^)+2.[MIV'\?E.0 YR<M[GIDY]4HH:N";1PG@/X0Z7X-TC6+
M>ZGFUZ^ULLVJW]_@O=Y!!4@=%PS87W/-<I:_ ?Q'X;M9=*\*_$G4M#\-NS%=
M.DL8KF2$,<LL4S$,@Y.,=.O)YKV:BERH?,SC?"_PMTGP7X%O/#.D&2**ZCE$
MUW.?,EEED7:TK],GIP,#@5BVGP9^R_!%_AY_;&[=;O!_:7V7'WI"^?+W^^/O
M5Z911RH.9GE?B+X&?VI9^%+C3/$-QH?B7P[:)9VVKV\"N)$"!2'B8X(.#QG^
M(@YK$\7?LWZC\0M#D@\4^/=0UC5E*FTN?LD<-K;8;)86T9 9BN5W%N]>WT4<
MJ#F9Y?\ $KX(I\3YO";ZAK<UK_8@<R/:Q%))W94&]&W_ +I@R!A][GU[Y\OP
M'U;Q)=6D7C/QW?>*="LY5EBTHV45LLC*?E\YT),HQZ@$^M>P44<J#F9Q?Q(^
M%FF?$C3K&*>>XTO4-.D\_3]2L6V36K\<K[<#(]AC!&:Y)O@1J_BB\L_^$\\=
M7?B[2K.031:8EC'90NXZ&783Y@^N#UYY->PT4<J8<S1Q/CKX:CQIXD\(:J-0
M^Q#P_>F[\GR-_G_=^7.X;?N]<'KTJ]\2/A]IWQ.\*W&AZD\L,<C++'<0$"2&
M13E77/\ G!-=113LA79Y$/@GXBURR.E^+?B/J>O:'MV?8;6SBLFE &,2RH2\
M@QU!(R>M:/A3X*Q:'\(+OP!?ZL^I64RS1K=1P"%T61BPPI9AD,2<_I7IE%+E
M0^9GGO@?X;ZWX9\'ZAX>U;Q:WB"WDM!9V;M8) ;2,(4Q\K$OU').>.M4['X#
MZ3)\(;'P'K%U)J,%GEX[^%/(E23>S+(@RVTC<1R2#SZUZ=11RH.9GC-U\!_$
MGB&UBTCQ-\2M2UKPTA&[3H[&*WEF53\JR3@EG''.1SUX-=/\1/A+;>-O#.@Z
M'97:Z)::/>V]U"J0>:NR)2JQ@;EQP>N3TZ&N_HHY4',S \>^%?\ A./!NL:#
M]J^Q?VA;M!]H\OS/+SWVY&?ID5PGQ*\,WWAGX")H^F>(+W3K_2K.W@@O=/C=
M9[F2,*B1JJ/N!D;"\$XW=Z]:HIM7$G8HZ'%<0:+I\=VS/=I;QK,S-N)<*-Q)
M[G.>:@\4>&=.\9>'[W1=6MQ<Z?>1^7+'G!ZY!![$$ @^H%:M%,1\[#]D>Z*?
MV7)\1]>?PIG T;) V9SMSOV?^0_PKW/0]%TKP/X;M].L(H[#2=/APJYX1 "2
MQ)ZGJ23UY-:U9^O:'9>)M'N]*U&-IK&Z0Q31I*\9=3U&Y"& /?!Y'%2HI;%.
M3>YYC\"=/?7]4\5_$.>-D_X2.[VV*R AA9P_)&W/3=C./0 ]Z]>J&TM8;&UA
MMK:)(+>%!''%&H544#   Z "IJ:5D)N[/G2']E?Q+IMQ>G2/BOJVC6MS<27)
MM;*WEB0,QR3A;@ GH,X[5V_PM^$/B7P%X@GU#6/B+JOBVVDMFA6ROA*$1BRD
M2#=,XR I'3^(\UZI14\J17,V>5:U\#[JV\47_B#P5XKNO!E_J)W7T,=K'=6T
M[\_/Y3D -R>??C&3G3\!_"-?"WB"[\2:UK=UXI\4W47V=]1ND6)(HLYV11+P
M@)ZC)]L9.?0J*?*A<S/'K;X%ZWX7U346\&>/KOPSI&H7#74VFMIT-VJNWWO+
M9S\@_#L.N*M>#?@)#X(^) \66>OWMX\UDUK?1ZB#/-=2,03*9=PV_=3Y=I&%
MKU>BCE0<S/*M8^"=_:^*-0UWP3XNN?!ESJ;>9?VZV4=W;S/_ 'Q&Y 5CDDGG
MJ>E)\/\ X#IX#^(5SXK_ .$@NM6N;NP-K="\CW233,ZLTQ?=@#Y0 @7  '/K
MZM11RH.9GDMW\#]4T;7M3U+P-XUN_"":I,;F[L6LHKVW,IZNB.1L)[]?3H !
MO?#SX40^"=5U+7+_ %:Z\1^)=2 2YU2\54.P=$C1>$7IQST'88KO**.5!S,*
M^=(?V5_$NFW%Z=(^*^K:-:W-Q)<FULK>6) S').%N ">@SCM7T710XI[@I-;
M'BW@?]FN'0_%-GXC\3^*M3\::O8G-J]^6"1'L<,[L2.H^;&><5V>M_#?^V/B
MEX>\8_VCY/\ 9-M-;?8O(W>;O##=OW#;C=TVGI7;44<J#F9Y7K?P3O+?Q5J'
MB'P7XLNO!M_J1W7\2VD=W;3MUW^4Y #Y)Y]SC&3G5^'?PCM_!.K7^O:AJMUX
MD\4Z@@CN=6O $.S(.R-!PB\#C)Z#MQ7?T4<JW#F>QP:_"J&3XFZUXKN;T7%O
MJFEC3)--:# "\9;?NYR!C&T=>M<MHOP)\2>%;4Z/H?Q+U+3?"VYMNGBPADN(
MU8DE4N&Y7KP0O'6O9:*.5!S,\R^&7P1M_A;XH\0ZCIVK37.GZO'&#9W2%Y4D
M7.9&F+?.6+.3\H^]UXKE_"?[.&M_#_2WB\,?$2\T>]N)&:[D_LZ.:WF!/RD0
MNYV.!QN#<@#@5[K11RH.9G$?#OX4Z=\/[/42US/K6JZJ_F:EJ=]AI+EL8P1V
M3DX7GKU-<I8_ OQ!X1,UIX*^(=]X<T*25I1IEQI\5\L)8Y*QNY!5>O'XDD\U
M[%11RH.9G'?#7X8V'PWL;U8;JYU34]0F^T7^I7K!IKB3U/H!DX'N>3757UE!
MJ5G/:74*7%K/&T4L,@RKHPP5([@@U/13M;05^IXK'^SYK.E:?<:%H7Q$U32?
M",Y8-I)M(YI8T8Y9([@D,B\GH.YSG)KOHOA?X=B^'H\%?8=V@>1Y!A9CN/.[
M>6_O[OFSZUUE%+E2'S-GBR_ ;Q.FDCP\OQ0U4>$]OD_8/L,7VGR>GE_:<[L8
MXZ8QQC%=AK'PGTVX^%-UX$TA_P"R-/DMOL\<NSS2F6W%B,C<2<D\CDUW-%'*
M@YF>;ZU\'?[8M?A]#_:_D_\ ")S0R[OLV[[5Y:JN/O\ R9V_[76J&L?!35+?
MQAJGB+P;XSN/"-SJQ5K^W-C%>0RN/X@KD!3U.>>IZ9KU>BCE0<S/'K3]GHV?
MC[P_XP/BJ_O];L9':]GU",2_:U9=NQ K*(5 +X !'S>U.U[X SZI\2-8\:Z?
MXLN]$U>Z2);5[6W!^SE$5&#AF*RHP4$J0.0.>.?7Z*.5!S,\T\'_  ;FTWQ6
MGBGQ3XCN?&'B&",PVMQ-;I;PVR'KY<2D@,<GG/?IWJ[\1OA);^.-3T[6['5+
MKP[XGTT%;75K,!B%.<HZ'ATY/&1U/8D'OJ*?*K6#F=[GE6C_  1O;OQ/I^O>
M-O%MUXSO-,?S+"%K2.SMH'Z[S$A(9@0.>.@SG K?U3X;_P!I?%;1?&G]H^7_
M &;926?V'R,^9OW?-OW<8W=-IZ=:[:BERH.9G$_%#X7VOQ,T^P5K^XTC5--N
M!=6.HVN"\$@]CU'3C(Z#FN0UKX!ZUXXT6ZL/&7Q!U#7E:-A;1V]E%901R$?+
M))'&?WI4X(!8"O9:*'%,%)H\TUCX+Q^(/@[9>!;[5Y&DLX8HX=3A@"$-$?W;
M>66/8 $;N><$55\1_!S6O&7PY7PWKWC(ZE?+?1W8U1M-2,[$QB/RU<#U^;/>
MO5:*.5!S,X#XB?".W\;ZCINM6.JW7AWQ/IJ[+75K,!B%.<HZ'ATY/&1U/8D'
M)T?X(WMWXGT_7O&WBVZ\9WFF/YEA"UI'9VT#]=YB0D,P('/'09S@5ZK11RH.
M9G$WOPV^V?%S3_&_]H[/LFFMI_V'R,[\LS;_ #-W'WNFWMUH^)'PU_X6#?>%
MKC^T?L']AZI'J6WR/,\[80=F=PVY]>?I7;44[(5V>7_'BSU>YTWPZ=%UJ_TN
M_P#[7@C2UL#(&O0S ,CE&&$5 [DD$84_6O4***.MPOI8X[XH?"W1?BSX=_LK
M6%D0QOYMO=0D"2!\8R/4$=0>#]0"/-=#_97=M:L;KQ=XWU;QC86+B2VTZ\WK
M$K#INW2/D=.!MSCTXKWNBDXIZL:DUH<E\5/&,?@3P%JNJ<M<K%Y-I$@RTD[_
M "QJH').XCIV!JO\&O I^'/PXT?19<&\CC\VZ8<YF<[GY[X)QGT KH-8\+Z9
MK]]IEWJ%K]JFTV8W%J'=MD<N" ^P':Q )P6!QU&#6K3MK<5]+'FWQR^#K_&;
M0=/TP:TVC+:W/V@N+;SQ)\I4#&]<8R>>:X&/]F;QO#&J)\:O$"(H"JJI.  .
M@ ^TU]#T4G%-W&I-*QY-\,_@WXG\"^)O[3U;XDZMXJM/(>+[!>B7R]QQA_FF
M<9&#V[US/BSP;IWB_P#:I\/SVY\UM+T];[4U7E%='86X;_;W,#@]E%>]SPI=
M020RKOBD4HRGN",$5SG@;X9^&?AK;7,'AO28]-2Y8-,P=Y'<CIEW8M@9.!G
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
B*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>bgne-20241231_g4.jpg
<TEXT>
begin 644 bgne-20241231_g4.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" .8!%0# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOS8QDUY7_P %,[V[^,/PW_9+NK^X,%_XGM&>XN#%]R2XBL-S[/E[N3MX].*
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MY^_:1_;J^$W[+=Y'IOBW5[F]\0R1"9="T6 7%V$.,,X+*D><Y&]U)'(S7/\
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M-UR^F\8W3VE@VDP0R+$ZM$I,OF2I@9G3[N[H?;/RG_P6Q_Y(_P##C_L8G_\
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MPW_PC41T,Z)T%O\ 9LY^T<;O,W]3CWH ^_ <C(Y%+3(XTAC2.-%CC0!551@
M#H /2GT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\*/AUXD\%^"M6\8^+/'RRC1/"$-Q#;S[H0WVAIYF)2**-EVM(0?O+QR<=?\
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M,&DG3(KGQ)9>(8)EUR*VN(#BV@?8UN<1B1C*>B,JKEAC[0;Q%XF7Q1XBL?\
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MC;XO^*OB[X_\)Z5\.[^\\+MX:L/"NFZBE_<3 R"4SWER@$;L"H5 O16.<8Y
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MV^NQZK<ZS>30/;K(KQ*HB@5))&PV')*C!!.T S+S]NCQ=?:?JOC'PI\!M?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3]CWQX=)US^Q5MH(Y[Q?LB7'VRW#@-;_ #']WN)5MZ\C9CN: />/^%A>'_\
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M@QQY"*QRS!=Q.30!VU%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7S+X[_9+\::C\3O%?B7P#
M\;=8^'&C^,'AF\0:-::/;7CS2I"L'F6US(0]LQC1>5!(89SP /IJB@#YN^$?
M['9^%=E\';3_ (3%]7A^',VL/"TNG".2^CO@X56(E(1HP_+8._'1<UO^*OV4
M]&\>:Q\7IM?U2:YTWXA6NG0-;6T(AFTU[.-ECFBF+-N<.5D4[1M*#[U>Y44
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MQ\HQ^O&A7-Q>:'I]Q=Q>3=2V\<DL?]QRH+#\#F@"]17G_B[XS6'@C6)[75-
M\0I86[Q++K4>G[[% ^WYO,W9(!< X!.00 37H% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% 'G/QX^ OA7]HKP*?"_BN*Z6".X2]L
M[[3YS!=V-RF=D\,F#M<;CU!'/(->%_#S_@G=X6T7]G;5/A]KVO:\-=\36UE%
MXE\0:;J8EN;@6V/+MHI)H2%MEQM5/+!VX!KZZHH ^??@'^QOI?[/>JVL^D_$
MSXE>(M(M;)K"W\.>)->2ZTJ&,XP4MEA15*@8&. ">.:Q/"G_  3Q^%G@_P"(
M&G^(K2Z\37.D:7J+:OI?@R]U8S:#I]ZW/VB&V*Y#@\C+D>V  /IVB@#YH\7?
M\$_?ACXR^)UYXPO+OQ+;V>HZG'K.J>$K35#'H>IWR9*W%Q;;"6?)R<, 3GCE
ML_2P&!@# I:* /,/VE_^2)>(_P#MV_\ 2F*O3Z\P_:7_ .2)>(_^W;_TIBKT
M^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#S#]I?_DB7B/\ [=O_ $IBKT^O,/VE_P#DB7B/_MV_]*8J]/H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH \P_:7_Y(EXC_ .W;_P!*8J]/KS#]I?\ Y(EXC_[=O_2F*O3Z "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P 4[_HW_$^_M&+_ )ZQ-_J,;_O_ "=??I7NU !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!%>;+^W5\#7^*H^&Z>.4D\9G4_[&&FQZ7>L/M>_R_*\X0^5][C=OV^]>/_\
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MW:^=9/B+^T3^UW(\'A6Q?P=X0F)0W-N[6T!7H=]R1OE]"(ACU6O?_A!^PO\
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M/*GW))( XBD<<?,Z$_*ISP,>R444 >8?M+_\D2\1_P#;M_Z4Q5Z?7F'[2_\
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M7A&3QKX8@.TZE?1>:NSMB_M\@$_]-@S>W%>C>$_B;\2_V%_%47A7QM:3>(?
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M/!\C8:ZN8QZM;-C],UU1XIR.>V+A_P"!)?F82R3,H[X>7W'I%%<)!\</!4^
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M4EO)_>5_[/M?^?:'_OV*/[/M?^?:'_OV*L45I[.'\J)YY=RO_9]K_P ^T/\
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MA9K)>M.$OS#^U,ME_$P*^4Y(\3A_:=L6SYNA7"?[EPK?T%2?\-.:9_T!;O\
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M7F2X/AN\X[_ZV"3RQU'4=OK7;'A.G_S#3HR]&D_NLCF>-JOXY2_$_3D:=:*
M!:P@#H/+'^%310QP*1'&L8/.% %?F19_\%DM8T&;[)XN^#4EI= 9/DZL]NV?
M^N<D!/\ X]77Z7_P6=^'4S#^TO ?BBT7<,FU>VG..Y^9TY]N_M6CX7S.GJJ'
MW.+_ "9E]8C+>1^A=%?$>D_\%>O@7J&W[1:^+-+SG/VO3(FQCU\N9^M=-'_P
M5._9W>-6/BK4(R0"5;1KK(]CA,?E7-+),RCH\/+[F_R#VD.Y];45\K67_!3[
M]G"Z5C+X\FLR#@+-HE^2?<;(&_6K/_#S3]FO_HI'_E"U+_Y&K+^R,Q7_ ##S
M_P# 9?Y#]I#N?4%%?+LG_!3;]FQ49A\1BY R%70M2R?89MZS?^'I?[.W_0V7
M_P#X);O_ .-TUD^8O_F'G_X"_P#(7M(=SZTHKX]O/^"KG[/MM-LCUG6;M<9\
MR'2)0OT^;!_2N>O/^"P7P/M8=\>E>,KMLX\N'3;<-]?FN%'ZUK'(\SEMAY?<
M'M(=S[@DA29=LB+(O7##(J+^S[7_ )]H?^_8KX'U#_@LQ\*XV?[#X,\87 VY
M7[1%:Q9;T.)VP/?GZ5RVI_\ !:K08=W]G?"O4;H[<K]JUF.'+>AVPO@>_P"E
M;+AG-*CO]7^^WZL/K$8[2/T?DTJRF7;)9V[KUPT2D?RJ+^P-+_Z!MI_WX7_"
MOS1;_@KWXX\0 GP[\#FDWJ'CSJ$]WQQD_);ID?3&,]Z#_P %$/VJ->4MX>_9
M]:16 D0_\([JMW\A[_(RYSZ]*I\)8S>K3A'UE'_,I8MK:3_$_2N3PWI$R[9-
M*LG7KAK="/Y5'_PB.A?] 73_ /P%C_PK\V&_::_;O\1%C9?"9=+^;=@>'I(L
M YPH\^4\#\QQDT?VW_P4<UY@;;3TTQ5;#?N=#CZ^TI)('M^M9OA.GO5J4%ZR
M7^12QE5;.7XGZ3-X/T%E*MHFG$'@@VD?^%0?\(#X8_Z%S2?_  !B_P#B:_-\
M_"C_ (*#ZXO^E>,UL-C9 _M.RB+9_P"N*=/K2M^QO^V]KPD%W\<TT_:V\8\6
M:C%N)ST\F#H/0X'(K-\+9;_R]KT/DK_H6L=B%\,I?>S]'_\ A ?#'_0N:3_X
M Q?_ !-12_#GPM,P+>'=,!Z?+:HO\A7YS?\ #M_]I;4Y775/V@'>*;<9V_MK
M4YBQ/7(8#=D]<FF#_@DS\4-64KJ_QS+JA!C7RKJX&>_WI5QVZ9J'PSD.T\13
M_P#!=_T*6/QBVE+_ ,"9^D>F^!_#^C7B7=CHUE:W4>=DT4*AER,'![<$C\:W
M*^$?V8O^"95]\ ?C9X?^).H_$]O$=WI:W*OIRZ0T0G\VWD@&9FN&. ) V-G5
M0/>ONZO/KX' Y?+V67S4H/5M1Y%?T]$M2)5JM=\U9MOS=PHHHKF)"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** /.OCK\>/#/[/?@V+Q#XF%_=+=7<>G6&FZ3:FYO+^ZDSY<$,8
MQN=MIZD#CKG&>/\ V8_VNO"O[2W@?4=:M[.[\)ZIHT<4FLZ/K6(WLDDB\R.;
M><!H70,RR87(4D@5R'_!06X\#6OPS\)R^.;KQ+X?A3Q+:-I?BWPTD)?0;_#B
M*YG,CC$(!8-@,2.F#@UX]_P3R\87_P =/AKXJ^$'CN?2_B%X%T/2-'^S:A:P
M")-D\7F-I\YC;:[0E%4_Q'#!\YP #ZN^!?[3/@G]HNZ\8KX)N+G4++PQJ(TV
M?4G1!;7;E=V^W8,2\?!&XA<XR,@@GS_P?_P4#^&'C;XG6'A"QM?$D-GJFH2Z
M3I7BZZTOR]#U.\CP&@M[G?EGSP,H 3CGE<\%^Q)H5OIOCK]JO1]&M(-/MH?%
M\MK9VMJ@BBA40,J(BJ %4<  =,5\F?#OQ-I7B#]F_P#9;^&&E:C;GXF:3\4A
M)?Z-&0;ZQ$5Y<O)-+%]]%"NAW,!G:?[IP ?>'B[_ (*!_#'P;\3[SP?>6GB2
MXM-.U*/1M4\6VFE^9H>F7SY M[BYW@J^1@X4@'//#8^E@<C(Y%?CU\1/$VD:
M+^SA^T]\+]1O;=/B3J_Q7>33]!D8?;KQ9;JV:*2*,_.Z[8W.X#'(Y^89_7C0
MK:XL]#T^WNY/.NHK>..63^^X4!C^)S0!Y]^TO_R1+Q'_ -NW_I3%47QM_:6\
M#? 6Q!\1:BUQJ\J;K;0M-437UQUQB/("*2"-\A5<\9SQ7/\ [24?BZ7P=X@2
MX.ACP0S6HDVM<+J.TRQ9P1\@_>=QSM]ZY#PG^R?>/=2:EJ"V>DWMTYEN+B3_
M $J]D<]6DDR=Q/J7)KYO-<UQ>!G&E@\'*O.2ONHP7^*3_+33J>GA<##%0E.>
M(C22[W;^45:_WH^5_C)\;OCG^U!Y^FV=G=^ O \WR_V7ITQAGNH_^GBZ;:S
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /,/VE_^2)>(_P#MV_\ 2F*O
M3Z\P_:7_ .2)>(_^W;_TIBKT^@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#S#]I?_DB7B/\ [=O_ $IBKT^O
M,/VE_P#DB7B/_MV_]*8J]/H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH \P_:7_Y(EXC_ .W;_P!*8J]/KS#]
MI?\ Y(EXC_[=O_2F*O3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "N1^+'Q4\.?!/X?:QXT\67C6.A:5$))Y4C,CDLP1$11R69F
M50/4\X&3775X+^W))X-C_9C\8-X_TOQ!J?A0+ ;MO"Z1-?VI$R&.XC\UE4>6
MX1B23P#D$9H S_V;?VVO"W[1&J^(=%_L'7/!'B'1UGNCI7B*W\F6XLHYWA^T
M)_NLNV1/^6;DKEL;B? _]M?1OC[XDTRP\/\ PQ^)MEHVI+,]MXKU7P\L.BNL
M88[OM*S,,,4*KQRQ XKX^_9@^.WB.PC^*GP\A\<M\2? TGAWQ#X@CUW3--2X
MU337%[/'YD@611*\Z,;@([!B74 A>J_LM^*H?A[\6_V>/#WP@^,OB/XE>'O%
M&EW \3^%=9N(YH=%ABA5E86L9<6#!RWR;V)*_?=6R0#ZS\7?\% _ACX-^)]Y
MX/O+3Q)<6FG:E'HVJ>+;32_,T/3+Y\@6]Q<[P5?(P<*0#GGAL?2P.1D<BOQZ
M^(GB;2-%_9P_:>^%^HWMNGQ)U?XKO)I^@R,/MUXLMU;-%)%&?G==L;G<!CD<
M_,,_KQH5M<6>AZ?;W<GG745O''+)_?<* Q_$YH \^_:7_P"2)>(_^W;_ -*8
MJ]/KPG]I?P_XD_X0GQ'J?_"5_P#%._Z-_P 2'^SHO^>L2_Z_._[_ ,_3VZ5[
MM0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH \P_:7_Y(EXC_ .W;_P!*8J]/KS#]
MI?\ Y(EXC_[=O_2F*O3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** /,/VE_^2)>(_P#MV_\ 2F*O3Z\P_:7_
M .2)>(_^W;_TIBKT^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#S#]I?_DB7B/\ [=O_ $IBKT^O,/VE_P#D
MB7B/_MV_]*8J]/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** .?^(7CC3/AGX%\0>+=9:1=)T.QFU"Z\E0SF.)"[!02 6(&
M"1R17S1^S3^VGXR^-GQ&OM)\0_"+5?"WA>[59])UZWD-Y%;H;."Z2._9 5A:
M2*99$8[1\XCP64L?HGXO/.GPL\6FV\,+XUE_LJY'_"./-Y(U-3&P:WW[6P7&
M5'RGDU^7?[&/B2YNOVBH] ^#[>*M'\*:L]Q%XI\#ZPTUU9Z% -+A52TTJ B1
M+L30JV0[+"@( X(!]6>!O^"B<7C#QQX8%Q\-=4TCX7^+-<E\.>'O'4VHQ.+V
M]5BBJ]F%WQ([!@&+'ITX;;]C5^0'PUOI?%7PW_9]_9OM]-U:V^*'@SXAG4_$
M.FO92QG3K*&YGE:Y:0KLVE9UP0QSC_:7/Z_T >8?M+_\D2\1_P#;M_Z4Q5Z?
M7F'Q,^%7B3XB?VE8_P#";_V?X=O/+_XE7]DQ2[-FP_ZW<'.77=^..E'_  @/
MQ)_Z*K_Y;MM_\50!Z?17F'_" _$G_HJO_ENVW_Q5'_" _$G_ **K_P"6[;?_
M !5 'I]%>8?\(#\2?^BJ_P#ENVW_ ,51_P (#\2?^BJ_^6[;?_%4 >GT5YA_
MP@/Q)_Z*K_Y;MM_\51_P@/Q)_P"BJ_\ ENVW_P 50!Z?17F'_" _$G_HJO\
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M_P#+=MO_ (J@#T^BO,/^$!^)/_15?_+=MO\ XJC_ (0'XD_]%5_\MVV_^*H
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M$VF^&O[/_M*Y^S?VA>1V%M^[9O,GDSL3Y0<9P>3@>IK4KQS7?@WXW\2_V?\
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M .6[;?\ Q5'_  @/Q)_Z*K_Y;MM_\50!Z?17F'_" _$G_HJO_ENVW_Q5'_"
M_$G_ **K_P"6[;?_ !5 'I]%>8?\(#\2?^BJ_P#ENVW_ ,51_P (#\2?^BJ_
M^6[;?_%4 =WJ'B;3=+US2M(NKGRM1U3S?L</EL?-\I0TG(&!A2#R1GMFM2O-
M=#^%NO+XRTCQ!XF\9R>(WTA)Q9P)ID5H$:5 CEBA.X;>WJ <]0?2J "BBB@
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M 'A/3S-;SZ;K+(&F:VCBE_?%[B02.6C&.1\S,@H _5RBOS4U;X7:K^T)\?O
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MN92>55E.R)1MY#'Y@*_0"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8+>W"XA*AU7<F2<,RA.@X7X]?&7QUH7QB\<7OQ;\8_&?X8:-<W:?\(3JO@<
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MX?\ $/C72O"M]I^FR>%;W7-:NTM[:W>,J+5IG8C"NAA4D\G+=3Q0!]!>%_\
M@H!^S[XR\:0^%-)^)NFSZU-+Y$*2P7$$$LF0 J7$D:Q,22 ,.<D\9KIOCA^U
MG\*?V;]0TJQ^(OBK_A';K5(GFM(_[.N[KS40@,<P1.!@D=<5^;'B[X8Q_#GX
M':5X8^-/[,-M;>%=/6$/\7/A3<V<E\T*8VW3GRY&99!C<TS(IW9"J=H'T)\;
MM*\)?%;]L[]DNWNH+/QOX/U7P[J4\7]M6T=U%?PFS:2*26-UVL3A'Y48;G (
MH ^G_@O^UY\'_P!H74[G3? 'C>SUS4[=#(]B\$]I<%!C+K'.B,ZC(R5! R,U
MJ?$S]I3X;?!WQEX7\*^,/$\6C:_XFE6'2K-K:>7SV,BQC<\:,L8+N!ND*CKS
MP<?'O[9'P?\  ?P'^/'[-OC/X>^&=+\'^(KOQG;Z5/;:! EE%=VKLBN&AB !
M(#E=P'(E(;=\N/FC]KKXM?##XU?'#X^:KXF\7#2]9\-Z;;:#X"C6UN93+=6T
MWFSNKQQLJ;I4EC#.5&)L]!F@#]I<XY/ KYWUK_@H9^SMX?\ %K>&[SXI:4-3
M601,UO!<3VJMZ&YCC:$8[DO@=\5Y!\:?VB-4^)__  2QU7XB:'=L-;U'0[:S
MU*:U?:T,S7$=O>CCIUE],!@:L_#_ .!7[)?@+X"_#30_%^C^"=WC/2(S:ZUK
MB1+>:C,T"23.EXV'B.9!C:Z[2RJN#@4 ?:FDZO8Z]I=KJ6F7EOJ.G74:S6]W
M:RK)%-&PRK(RDA@1T(KP+XB?\%!?@%\*?&FJ^$O%/CW^R_$&ER^3>6?]CZA-
MY3E0V-\<#*>&'0GK7E7_  28U2:;X"^+M'M[U]1\,:'XOO['0KI\G?:8CD!!
M]"TC-TZN:^9?%'AGXG>(OVU/VA_^%<_!/P!\8C#J=E]N'CFRM;C^S\PGR_(\
M^XAQOP^[;NSY:YQQD _1_P"&G[57PI^,/@[7_%'@_P 8VNM:-H$+7&J/'!-'
M-:1JK-O>!T64 A'(^7YMIQG%=C\,_B9X;^,'@C3/%_A'4O[7\.ZDK/:7GD2P
M^8%=D;Y)%5QAE8<@=*_,_P#9=&J?#CXE_M*VWC+PQ'\*?BY<>"YM0L_#OA6V
MBL]'M;.*#_76S0RN/,WF,Y5N#O.XMN"[VD_M ?$J^_9%_9G\(Z3XRU.Q\7_%
M#6IM*OO&=[,]W>VUNEXR.RR2$DR$.@!+ X0A2.H /TYK$\-^-=!\83ZO#H>K
M6NJOI%XVGW_V202"WN517:)B.-X5UR.V<'G(KXJAC\8_LS_M6^!_A+)\4/&?
MCWP+\2])OH/,\3:B+O5=)NXHV/VB"Y"!@.@ P%&2>2HKYL_9MUK6/V;_ -D_
MX_\ Q<\/>*_$ESKNE>(;SPY8Z7>WHGTL2RRV:C49+<IA[I=Y_>,=I "E<&@#
M]@Z*_+'X+_$[XP^$?B9\,M3T/3OVC/%EMK%U#:^,[?XBZ%(^C&*;:&N;%E+_
M &98V9G /!4 %@ 0>R^$_ASXO_ML^&O'_P 3-,^-7B;P%KUAXFN-,\,Z'I5]
MY&C6UO T; 7<"*3,Q5R,MW )W X !]R^)OC3X-\'_$?POX"U?6?LGBSQ.LSZ
M3I_V69_M*Q*6D/F*A1, '[[+GMFNWK\[_P!K3PCXH\0?MD?LL^'G\83:1XGF
MTJ^M[SQ+H]K'%)O$/^D2P1R!UC9P) N=VPN".0*Y'5?'GC_X*ZA^UK\*8_B9
MXN\46/A?PI#K>AZWKNI/-JME(\<3-MNE*L/]>!Q@?(" N3N /T^HK\J/%FJ?
M%;X+_L^_ #XYK\:_&WB'7=<O]+L]0T34]0#Z5+:SQ.X0P;/GDVIM::0L[$EL
M@X->^?$[6?&/[2'[:VK?!6Q\?^)/AMX)\)>'X]7OY_"5V++4M2N93&4 N"I*
MQJ)5X 8?*P(RP*@'U+\6OC/X.^!?AF#Q!XXUC^Q-(FNX[&.X^RS7&9I,[$VQ
M([<[3SC'')KM58,H(Y!Y%?CC^TK\3/&,?PW^)7P8\8^([KQK)X!\>:-_9GB.
M_ -U/:SI.RQ3LO#.FU?F)W$LW8 #ZQ^)&L^,?VD/VT-2^"MCX_\ $GPV\$^$
MO#L6KW\_A*[%EJ6I7,OEE +@J2L:B5> &'RL",L"H!]O45^=&A?M1?$/X%_#
MW]J+P;K/B&Y\;:W\+1 = \3:C$);EX[OY(1<8!$C1,R,2V2?F!P!@><?M#>%
MOBW\&?V+?"OQ/L?C]X_U+6_$TFG76M6USK+^3$;E#*HLG3$D 4L$90^QP<X7
M:H !^KU%?G1H/[3'B#]FOP;^U'X0\8>)M2UGQ#X2F_M3PK>:W>R75S+;WZ*E
MI&KR,698I&B)&>-[>E?6_P"R/X1\3^"OV=?!-AXTUW5/$7BN:R%[J5]K%[+=
MW'FS$R^67D);$8=8\=/DH ]@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!_Q=\;_%#7[?5[:WT'P#?>%?[/?0;8%T9[R5-ZSF-"%#><517/RJ,[?W HH
M_,'XZ^"?!7[7O_!0KP#HGA%+[65\*(UI\0+A;26*TB2SG+I [,J[BSJT1894
M[DVD[21^GH&!@# I:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JG-K%A;ZI:Z
M9+?6T6I74<DUO9O*HFFCC*B1T0G+*ID3) P-ZYZBKE>#^-/V3]&\:?&JR^(<
MUSIT,EK-:RG2WT2":&\*$^<]TSDF:5@MOY4IP8#;)LR&8$ ]#U3XV> =%^(V
MG^ ;_P 8:-:>,]0B:6VT26\1;F0#;@;,\,V\%5.&<!BH(1B.IU36+#0[=+C4
M;ZVT^"2:.W26ZE6-6ED<1QQ@L0"S.RJHZDL .37YZ_$#3[/X<?$O5[KQ/X<T
MWXK_  JU1O%>MWVK^%-33^T[2+[5IDD[W*;H\RV<\$<2M!-Y@15PJM#M;VS]
ML3P/8>(?^%5>-FUK5KR.S\9^&TT[3!>%-.C:34(@USY2@&25HWV!I2P52=H4
MLQ(!]#^-OB1X2^&>GP7_ (O\4:+X4L;B7R(;G6]0ALXI),%MBM*R@M@$X'.
M:DUSX@>%O"_A5?$^L^)-(TGPVR1R+K%]?Q0V963'EL)F8)AMR[3GG(QUKQW3
M,:Q^W5X@6_59O[%\!V1TQ9"K>3]IO;C[2Z#&5+>1"I/<*!7@'P!5IOV@O _A
M.>$#PIX>\2^/)M"M&9#!&T-U#'"8TQQY2W-RJX^Z"V,"@#[N\.>)M(\8:+:Z
MSH.JV.MZ1=J7M]0TVX2XMYE!()21"589!'!Z@T^UU_3+[5K_ $JVU&TN-3L%
MC>[LHIU::W60$QF1 =R!@K%<@9P<=*\._9[1M+^._P"T3H]I'Y.AP^(-/OH8
MXR!$MU<:=#)=%5 X9GVNWJSD]22>*^.7QT\>>#[C]H!="UJ*VD\+6?AV71%G
MLXI([:2ZD*S[LKEPX !#$X'W=IYH ^M:*^1?BIXN^+OPW\7>*?#7A_QS=>*+
MZ'P:?&-F-5TNQ#K/:7J">RC\F",&&>%FC&\-(APPDSFLWXR?M>:]#=76O?#V
M]6X\+66AZ3$[?V>;Q7U/6;B 6;LD:-+)Y%L6F\J(@N9HUY) H ^S*CN+B*SM
MY9YY4@@B4O)+(P544#)))X  [U\G:/\ %3XHVNM:_H7@Z7QC\2C<^%[R]TS4
M?''@R;0?L>L0[1%;M*UG90O%,')"GYE:(Y?:WR\7XL^(-[XL^"OQ6\/:E\5O
M&D>O3> +S49?"OCCPC::1J\+1QR^:\$BVD4,UNX!BD$:SE<ADG0\D ^X[2[@
MU"UANK6:.YMID62*:%@R2(1D,I'!!!!!%35\3:1\6-?TO5O"OPU/C?QQI6G:
M-X,T[6+G7?#O@\:WJ=[/=;Q#"P@TV>"&")(B,F(/(=HWDHY;HO!7QH^)/Q7U
MCX>> ;V[U/X>:W>66KZCK.N+HBVE[>6]E<I;0/;6M_$X@%QYL<S>9"Q5054#
M.X 'U1I>OZ9KCWR:;J-IJ#V-PUG=K:SK*;>=0"T4FTG8X#*2IP1D<<U?KY\_
M9 TC4]!'Q?L=8U0:WJ47CR\\[41 L!N,VMH0[(ORJQ!&[;A<YP%& .C_ &A/
M'7B+P_<?#_PMX7OH]%U3QGKXTAM9:!)WL(%MIKB:2*-P4:4K 53>K("V65@,
M$ ]@HKXX^+7QJ^(GP=TOXN>%+;Q9_P )!K?A_2M(UW1/$>J65K]I2.[O3;R6
M]U%#%'"^#$Y#)&AV28^\NX^I>#=>\7^$OVDI/ 6L^+[OQCH^H^%6UY)-2LK2
M"6RN8[M862)K:*(&%ED'RR!W!0?.<F@#W-W6-69F"JHR68X 'K61<>-/#UGX
M3/BB?7=,A\,_9A>_VU)>1K9^00&$OG%MFP@@[LXP>M<;^T1\/;;XE?"?7M)O
M]6U?3M,6UFGN[?2+O[*;^-87_P!'FD4>9Y3'&Y49"P&TDJ64^4^ /!_@SQ)^
MQG\$-5\?ZI_9OA;PMHFB^(+@7$\<=G,T%FOEK=!U(>,,X<)QET3KC! /H3P;
MX\\-?$31SJWA3Q%I/B?2_,:'[=HU[%=P>8N"R;XV*[AD9&<\BLSQ+\8O /@O
M2[34O$'CCPWH6G7DTEO;7FI:M;V\,TL;%9(T=W 9E8$, <@@@U\_>"]5UK2U
M^-WQTLM";P[I_BFSLX/#.CWD?DW&IRP1R16U[/'C,;7,D\2*K#?L1-P' 'J-
MK\%T^'WA:PO_  AX?TG7O'NG^'8/#D%SXBU.>"W>W4AI S+%-MWOF1]L8,I"
MAF& 5 /7%N(F@$ZR(82N\2!AM*XSG/ICO5;3]:T[5M'M]6L;^UO-*N(%N8;Z
MWF62"6)EW+(K@[2I7D,#C'-?*'PQ\#Z-\3?V%+#PR-9\1:=I^BVE_8:M8VTR
M6$L\]LT\=Q92F)G9;82@@)%("8U12Q4LIV?!]Q<3_L)?"?P]9.4O_%/AW0_#
M\6QRCB.Y@B2X=2!PR6_GR _],Z /I"7Q1HT&DV>JR:M8QZ7>- MM>M<H(9S,
MRK"$?.UC(SH%P?F+*!G(K.\;?$KPA\,[.VN_&'BK1/"EI<R>3!/K>HPV<<KX
MSM5I64,<#.!S7SW^V3\-+&:7X6^)9-2U4IH_C3PY::?HD=UY>FV[-J,2M/Y*
M ;Y2C>6#(6"KG8%+,3L^-(YOA_\ M5W7C?Q#X:USQ%X:U3PE%HVF7NBZ//JQ
ML+A+F22X@DA@C=XQ.KPGS" A\HAF&!0!]&1RI-&DD;K)&X#*RG((/0@^E4[7
M7],OM6O]*MM1M+C4[!8WN[**=6FMUD!,9D0'<@8*Q7(&<''2O!_V"[C4V_9V
ML[34["32SI^M:Q86UA))')]E@BU"=(X T9*D1@>6-I(PG!QBN1^.7QT\>>#[
MC]H!="UJ*VD\+6?AV71%GLXI([:2ZD*S[LKEPX !#$X'W=IYH ^M:*\*\&Z]
MXO\ "7[24G@+6?%]WXQT?4?"K:\DFI65I!+97,=VL+)$UM%$#"RR#Y9 [@H/
MG.37-?M$>//&WA7XA7$=SK_C+P'\/H]!:XL_$_A#PQ!KL*7RM(9_[1C-O<31
MQH@A9-B1JP:7=*"!@ ^D/[4L_P"TAIWVN#^T##]H%IYB^;Y0;:7V9SMR0,XQ
MDXJU7PMXJ^(%[X0^-_C/XLZ7XUD\6VVF?"&WUZ&"PAM8]+U+;-=!8U_=O,D!
MD7S@!,9 S%3(R@(/4F\7>/\ X.^)/A5<>)O'$OC>S\;7+:9J>FW-C:6L=C<M
M:2W22V)AA23RE,+QE)WE8JR'>"#N /I>J&CZ_IGB*WFGTK4K34X(9Y+662SG
M698YHV*21L5)PZL"K*>000:^?_@'K'Q6^)GAGP)\3Y?%UM<:7XD>2[U/PA<V
MT$5E8Z?('\C['-';_:&N(\0[O.D9'W2X"?)CR/X!_$[5]3\<-\+=$UFX\%BZ
M\;^*M4N]<DLHW;45M]09FTZS\Z-HVD*S))))@[4!"9;>8@#[KHKA_CE\0YOA
M+\'/&OC2WM$OKC0=(N=0BMI20DCQQLRJQ'."0,XYQ7DMOXF^(/PG\6?"5O$G
MCF3QM:^.KPZ3J6G75C:6L=A=-:R7*2V)AA23RE,+QE)WE8JRG>"#N /I*J%K
MK^F7VK7^E6VHVEQJ=@L;W=E%.K36ZR F,R(#N0,%8KD#.#CI7AW[(^J>-_B%
MX%MO'7B_QU?ZN][<ZA:QZ''8V4%C%'%>2PQN2EN)FEVQ<GS=GS'Y.,UQ7QR^
M.GCSP?<?M +H6M16TGA:S\.RZ(L]G%)';274A6?=E<N'  (8G ^[M/- 'UK5
M"]U_3--U+3M.O-1M+74-19TLK2:=4ENF1=[B)"<N54%CM!P!DU\N_$?XT>,_
MV;_%7C>#5/$ES\0-/L_ -QXKMH=6L[6W>WO8;D0^4C6T46;=O-3*R!W&S[YR
M:I^)O#OC#P?\8_@+XA\5^/+OQLI&JSW-K/IUI L%S_94TC_93;QH?)(5@$E,
MK\+^\/.0#Z]HKX?^'O[27C[Q1X?\#^/+._\ &OB"^\0:C:R7_@F'P!>+HMMI
MMS*$)MM0%@I,D$;K(9GN7BDV284!EV^@>"_BAX[U+]I[4O@]?^*K22/P[)-X
MFN=21;3[7J.ES!1:6#1!!Y;1R2/YDBH&V16YW S$T ?4%4&U_3%UQ-%.HV@U
ME[<WBZ<9U^T& ,$,HCSNV!B%W8QD@9J_7SQ\:/BMXI\)_%3Q)H^E:I]ETZS^
M&>J>(8(?L\3[+^&95CFW,I)P"1M)VGN#0!]#T5\K^"_B%\0/#OB3X&WVO^-)
M_$UG\0=(N9]5TF;3[2"VLYDT]+M'LVBB25>0RE9I)00^1MP*V?@'K'Q6^)GA
MGP)\3Y?%UM<:7XD>2[U/PA<VT$5E8Z?('\C['-';_:&N(\0[O.D9'W2X"?)@
M ^@-'U_3/$5O-/I6I6FIP0SR6LLEG.LRQS1L4DC8J3AU8%64\@@@U?KXN_9_
M\<ZYH/C[PEX<L;WR-%U[QUX[_M*V\I&\_P BXDDB^8J67:Q)^4C/?-:\OQV\
M<ZQXHOO!-IKW]G:AK7Q.O?#%EK(M+=I-+TVWL5NY!$C)L>4A61&E60 R9(;:
M%(!].:EX]\,Z,=7&H>(M)L3HZ12ZE]IOHH_L229\MILL/+#X.TMC..*W0<C(
MY%?#?BK5/&?P/U+]I[6K?QA/K/B.QTCP]<6.N7EC;+<!&:= )8TC$#.!N&5B
M4$;?ESDGO?%GBSXC^)/'GQWM-+^(-YX6TSP1I=E?Z3#I^F6,S//)8/,Z3M/!
M)OA+H#M78_S'$@&  #ZHHKY;\#_%+QO^T/XLT[1M,\4S?#Z"P\%:1XBOYM&L
MK6XEO+[4%=DCQ=1S!;>,0ME54.Q<?O%V_-Z1^RCXV\2?$/X&:'KGBZ^@U+Q#
M-<W\-U<VL*11,8KV>)0BKP%"HH')) !))R2 >N45\Z_\))XU\2?M%?$W3#XW
MU'1/!W@VPTK4(-)TFQLGDNWEBEDECEDFMY6\MA#C";7RYPZX KRGX>_M)>/O
M%'A_P/X\L[_QKX@OO$&HVLE_X)A\ 7BZ+;:;<RA";;4!8*3)!&ZR&9[EXI-D
MF% 9=H!]HZ7K^F:X]\FFZC::@]C<-9W:VLZRFWG4 M%)M)V. RDJ<$9''-7Z
M^0/$'QL^(DXU.RTSQ)'8W3?&*/P?!<26$$@@TUX$)C"E/F8%BP=LMD#)(R#!
MXJ^+OQ&^$_B?QS;7'C.Y\3>'? .L:#J.I76J:?9K=W.CWT;QWD4C6\,2#R&
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M&/C#XX)I?CK4/!FF>#M(L-3TJQM=+L9)A/+I[SO%<FX@D+1[T&57:^2P$@&
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MF]A-9FSEDN&M8A' ;E)[:6*7;@/CRP-X#8X&)_VOO'NO?"_]FKQ_XJ\,7_\
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MFNZHH ^2?AQ\&-?OO&WP\FU;X>^(M%/AEGO-2U7Q9X]OM:LS<K;M"G]EV_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
%110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914413645792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 14, 2025</div></th>
<th class="th"><div>Jun. 28, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BEIGENE,&#160;LTD.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">E9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1209416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Street Address</a></td>
<td class="text">c/o Mourant Governance Services (Cayman) Limited<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Street Address Two</a></td>
<td class="text">94 Solaris Avenue, Camana Bay<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City</a></td>
<td class="text">Grand Cayman<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">KY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">KY1-1108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">949 4123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of each class</a></td>
<td class="text">American Depositary Shares, each representing 13 Ordinary Shares, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol(s)</a></td>
<td class="text">ONC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of each exchange on which registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,387,367,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The registrant intends to file&#160;a definitive proxy statement pursuant to Regulation&#160;14A within 120&#160;days of the end of the fiscal&#160;year ended December&#160;31, 2024. Portions of such definitive proxy statement are incorporated by reference into Part&#160;III of this Annual Report on Form&#160;10&#8209;K.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001651308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914413698720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst&#160;& Young LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914415384288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 3,810,241<span></span>
</td>
<td class="nump">$ 2,458,779<span></span>
</td>
<td class="nump">$ 1,415,921<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">3,216,152<span></span>
</td>
<td class="nump">2,078,859<span></span>
</td>
<td class="nump">1,129,446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,953,295<span></span>
</td>
<td class="nump">1,778,594<span></span>
</td>
<td class="nump">1,640,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">1,831,056<span></span>
</td>
<td class="nump">1,508,001<span></span>
</td>
<td class="nump">1,278,603<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">3,784,351<span></span>
</td>
<td class="nump">3,286,595<span></span>
</td>
<td class="nump">2,919,111<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(568,199)<span></span>
</td>
<td class="num">(1,207,736)<span></span>
</td>
<td class="num">(1,789,665)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income, net</a></td>
<td class="nump">47,836<span></span>
</td>
<td class="nump">74,009<span></span>
</td>
<td class="nump">52,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(12,638)<span></span>
</td>
<td class="nump">307,891<span></span>
</td>
<td class="num">(223,852)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(533,001)<span></span>
</td>
<td class="num">(825,836)<span></span>
</td>
<td class="num">(1,961,037)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">111,785<span></span>
</td>
<td class="nump">55,872<span></span>
</td>
<td class="nump">42,778<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (644,786)<span></span>
</td>
<td class="num">$ (881,708)<span></span>
</td>
<td class="num">$ (2,003,815)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.47)<span></span>
</td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (1.49)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.47)<span></span>
</td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (1.49)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding&#8212;basic (in shares)</a></td>
<td class="nump">1,368,746,793<span></span>
</td>
<td class="nump">1,357,034,547<span></span>
</td>
<td class="nump">1,340,729,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding&#8212; diluted (in shares)</a></td>
<td class="nump">1,368,746,793<span></span>
</td>
<td class="nump">1,357,034,547<span></span>
</td>
<td class="nump">1,340,729,572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_EarningsPerAmericanDepositoryShareBasic', window );">Net loss per American Depositary Share (ADS), basic (in dollars per share)</a></td>
<td class="num">$ (6.12)<span></span>
</td>
<td class="num">$ (8.45)<span></span>
</td>
<td class="num">$ (19.43)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_EarningsPerAmericanDepositoryShareDiluted', window );">Net loss per American Depositary Share (ADS), diluted (in dollars per share)</a></td>
<td class="num">$ (6.12)<span></span>
</td>
<td class="num">$ (8.45)<span></span>
</td>
<td class="num">$ (19.43)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic', window );">Weighted-average ADSs outstanding, basic (in shares)</a></td>
<td class="nump">105,288,215<span></span>
</td>
<td class="nump">104,387,273<span></span>
</td>
<td class="nump">103,133,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted', window );">Weighted-average ADSs outstanding, diluted (in shares)</a></td>
<td class="nump">105,288,215<span></span>
</td>
<td class="nump">104,387,273<span></span>
</td>
<td class="nump">103,133,044<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 3,779,546<span></span>
</td>
<td class="nump">$ 2,189,852<span></span>
</td>
<td class="nump">$ 1,254,612<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales - product</a></td>
<td class="nump">594,089<span></span>
</td>
<td class="nump">379,920<span></span>
</td>
<td class="nump">286,475<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bgne_CollaborationMember', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 30,695<span></span>
</td>
<td class="nump">$ 268,927<span></span>
</td>
<td class="nump">$ 161,309<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_EarningsPerAmericanDepositoryShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings per American Depository Share, basic and diluted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_EarningsPerAmericanDepositoryShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_EarningsPerAmericanDepositoryShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Per American Depository Share, Diluted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_EarningsPerAmericanDepositoryShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Number of American Depository Shares Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Number Of American Depository Shares Outstanding, Diluted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bgne_CollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bgne_CollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914413849184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (644,786)<span></span>
</td>
<td class="num">$ (881,708)<span></span>
</td>
<td class="num">$ (2,003,815)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Other comprehensive (loss) income, net of tax of nil:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="num">(47,565)<span></span>
</td>
<td class="num">(25,464)<span></span>
</td>
<td class="num">(90,421)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent', window );">Pension liability adjustments, net</a></td>
<td class="num">(1,942)<span></span>
</td>
<td class="num">(5,611)<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized holding (loss) gain, net</a></td>
<td class="num">(35)<span></span>
</td>
<td class="nump">9,046<span></span>
</td>
<td class="num">(5,311)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to BeiGene, Ltd.</a></td>
<td class="num">$ (694,328)<span></span>
</td>
<td class="num">$ (903,737)<span></span>
</td>
<td class="num">$ (2,099,182)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (k)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914414547136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS<br> &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,627,410<span></span>
</td>
<td class="nump">$ 3,171,800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">676,278<span></span>
</td>
<td class="nump">358,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">494,986<span></span>
</td>
<td class="nump">416,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">192,919<span></span>
</td>
<td class="nump">257,465<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">3,991,593<span></span>
</td>
<td class="nump">4,203,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Investment in wholly owned subsidiaries</a></td>
<td class="nump">1,578,423<span></span>
</td>
<td class="nump">1,324,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">139,309<span></span>
</td>
<td class="nump">95,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">51,095<span></span>
</td>
<td class="nump">57,138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">160,490<span></span>
</td>
<td class="nump">125,362<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">1,929,317<span></span>
</td>
<td class="nump">1,601,861<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">5,920,910<span></span>
</td>
<td class="nump">5,805,275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">404,997<span></span>
</td>
<td class="nump">315,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other payables</a></td>
<td class="nump">803,713<span></span>
</td>
<td class="nump">693,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Tax payable</a></td>
<td class="nump">25,930<span></span>
</td>
<td class="nump">22,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">17,576<span></span>
</td>
<td class="nump">21,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_ResearchAndDevelopmentCostShareLiabilityCurrentPortion', window );">Research and development cost share liability, current portion</a></td>
<td class="nump">111,154<span></span>
</td>
<td class="nump">68,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Short-term debt</a></td>
<td class="nump">851,529<span></span>
</td>
<td class="nump">688,366<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,214,899<span></span>
</td>
<td class="nump">1,810,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">166,484<span></span>
</td>
<td class="nump">197,618<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current portion</a></td>
<td class="nump">44,277<span></span>
</td>
<td class="nump">22,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">42,007<span></span>
</td>
<td class="nump">16,494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion', window );">Research and development cost share liability, non-current portion</a></td>
<td class="nump">54,286<span></span>
</td>
<td class="nump">170,662<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">66,735<span></span>
</td>
<td class="nump">50,810<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">373,789<span></span>
</td>
<td class="nump">457,835<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,588,688<span></span>
</td>
<td class="nump">2,267,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares, 0.0001 par value per share; 9,500,000,000 shares authorized; 1,387,367,704 and 1,359,513,224 shares issued and outstanding as of December&#160;31,&#160;2024 and 2023, respectively</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">12,087,908<span></span>
</td>
<td class="nump">11,598,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(148,988)<span></span>
</td>
<td class="num">(99,446)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(8,606,836)<span></span>
</td>
<td class="num">(7,962,050)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">3,332,222<span></span>
</td>
<td class="nump">3,537,327<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 5,920,910<span></span>
</td>
<td class="nump">$ 5,805,275<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_ResearchAndDevelopmentCostShareLiabilityCurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Cost Share Liability, Current Portion</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_ResearchAndDevelopmentCostShareLiabilityCurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Cost Share Liability, Non-current Portion</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914413866864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Ordinary shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized (in shares)</a></td>
<td class="nump">9,500,000,000<span></span>
</td>
<td class="nump">9,500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued (in shares)</a></td>
<td class="nump">1,387,367,704<span></span>
</td>
<td class="nump">1,359,513,224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding (in shares)</a></td>
<td class="nump">1,387,367,704<span></span>
</td>
<td class="nump">1,359,513,224<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914415145552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (644,786)<span></span>
</td>
<td class="num">$ (881,708)<span></span>
</td>
<td class="num">$ (2,003,815)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">171,762<span></span>
</td>
<td class="nump">87,675<span></span>
</td>
<td class="nump">66,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">441,618<span></span>
</td>
<td class="nump">367,618<span></span>
</td>
<td class="nump">303,162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">46,800<span></span>
</td>
<td class="nump">68,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_AmortizationOfResearchAndDevelopmentFinancingLiability', window );">Amortization of research and development cost share liability</a></td>
<td class="num">(73,226)<span></span>
</td>
<td class="num">(55,294)<span></span>
</td>
<td class="num">(96,402)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized losses on long-term investments</a></td>
<td class="nump">24,022<span></span>
</td>
<td class="nump">16,221<span></span>
</td>
<td class="nump">21,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income tax expense</a></td>
<td class="nump">25,983<span></span>
</td>
<td class="nump">689<span></span>
</td>
<td class="nump">2,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Gain on BMS termination settlement</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(362,917)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other items, net</a></td>
<td class="nump">11,163<span></span>
</td>
<td class="num">(5,998)<span></span>
</td>
<td class="nump">9,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(329,443)<span></span>
</td>
<td class="num">(188,306)<span></span>
</td>
<td class="nump">304,112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(91,496)<span></span>
</td>
<td class="num">(140,948)<span></span>
</td>
<td class="num">(56,689)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">45,126<span></span>
</td>
<td class="nump">12,120<span></span>
</td>
<td class="num">(3,282)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">121,497<span></span>
</td>
<td class="nump">21,484<span></span>
</td>
<td class="num">(4,352)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other payables</a></td>
<td class="nump">111,354<span></span>
</td>
<td class="nump">180,111<span></span>
</td>
<td class="nump">45,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">633<span></span>
</td>
<td class="num">(255,587)<span></span>
</td>
<td class="num">(151,816)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="num">(14,838)<span></span>
</td>
<td class="nump">587<span></span>
</td>
<td class="num">(1,209)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(140,631)<span></span>
</td>
<td class="num">(1,157,453)<span></span>
</td>
<td class="num">(1,496,619)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(492,663)<span></span>
</td>
<td class="num">(561,896)<span></span>
</td>
<td class="num">(325,434)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sale or maturity of short-term investments</a></td>
<td class="nump">2,655<span></span>
</td>
<td class="nump">673,240<span></span>
</td>
<td class="nump">1,563,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_PaymentsToPurchaseInProcessResearchAndDevelopment', window );">Purchase of in-process research and development</a></td>
<td class="num">(31,800)<span></span>
</td>
<td class="num">(15,000)<span></span>
</td>
<td class="num">(143,665)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of intangible assets</a></td>
<td class="num">(4,674)<span></span>
</td>
<td class="num">(19,365)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireLongtermInvestments', window );">Purchase of long-term investments</a></td>
<td class="num">(19,006)<span></span>
</td>
<td class="num">(14,900)<span></span>
</td>
<td class="num">(15,911)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other investing activities</a></td>
<td class="num">(2,862)<span></span>
</td>
<td class="num">(2,075)<span></span>
</td>
<td class="num">(1,485)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(548,350)<span></span>
</td>
<td class="nump">60,004<span></span>
</td>
<td class="nump">1,077,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from long-term loan</a></td>
<td class="nump">9,053<span></span>
</td>
<td class="nump">22,502<span></span>
</td>
<td class="nump">37,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term loan</a></td>
<td class="num">(28,031)<span></span>
</td>
<td class="num">(13,690)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short-term loans</a></td>
<td class="nump">868,270<span></span>
</td>
<td class="nump">661,530<span></span>
</td>
<td class="nump">313,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of short-term loans</a></td>
<td class="num">(704,216)<span></span>
</td>
<td class="num">(309,576)<span></span>
</td>
<td class="num">(417,081)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from option exercises and employee share purchase plan</a></td>
<td class="nump">45,373<span></span>
</td>
<td class="nump">55,712<span></span>
</td>
<td class="nump">46,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other financing activities</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">193,449<span></span>
</td>
<td class="nump">416,478<span></span>
</td>
<td class="num">(18,971)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of foreign exchange rate changes, net</a></td>
<td class="num">(51,705)<span></span>
</td>
<td class="num">(8,082)<span></span>
</td>
<td class="num">(69,383)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(547,237)<span></span>
</td>
<td class="num">(689,053)<span></span>
</td>
<td class="num">(507,850)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, beginning of year</a></td>
<td class="nump">3,185,984<span></span>
</td>
<td class="nump">3,875,037<span></span>
</td>
<td class="nump">4,382,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, end of year</a></td>
<td class="nump">2,638,747<span></span>
</td>
<td class="nump">3,185,984<span></span>
</td>
<td class="nump">3,875,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">2,627,410<span></span>
</td>
<td class="nump">3,171,800<span></span>
</td>
<td class="nump">3,869,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Short-term restricted cash</a></td>
<td class="nump">9,312<span></span>
</td>
<td class="nump">11,473<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Long-term restricted cash</a></td>
<td class="nump">2,025<span></span>
</td>
<td class="nump">2,711<span></span>
</td>
<td class="nump">5,277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="nump">69,430<span></span>
</td>
<td class="nump">56,003<span></span>
</td>
<td class="nump">29,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_InterestPaidIncludingCapitalizedInterest', window );">Interest paid</a></td>
<td class="nump">51,175<span></span>
</td>
<td class="nump">19,753<span></span>
</td>
<td class="nump">25,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Accruals for capital expenditures</a></td>
<td class="nump">70,314<span></span>
</td>
<td class="nump">91,804<span></span>
</td>
<td class="nump">95,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_AcquiredInProcessResearchAndDevelopmentButNotYetPaid', window );">Purchase of in-process research and development included in accounts payable</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 31,800<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired In Process Research And Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_AcquiredInProcessResearchAndDevelopmentButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired In Process Research And Development But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_AcquiredInProcessResearchAndDevelopmentButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_AmortizationOfResearchAndDevelopmentFinancingLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of Research And Development Financing Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_AmortizationOfResearchAndDevelopmentFinancingLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_InterestPaidIncludingCapitalizedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Paid, Including Capitalized Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_InterestPaidIncludingCapitalizedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_PaymentsToPurchaseInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of in-process research and development acquired in an exclusive license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_PaymentsToPurchaseInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914418167520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF SHAREHOLDERS&#8217; EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Ordinary&#160;Shares</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income/(Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at the beginning of period (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,334,804,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning of period at Dec. 31, 2021</a></td>
<td class="nump">$ 6,132,563<span></span>
</td>
<td class="nump">$ 133<span></span>
</td>
<td class="nump">$ 11,191,007<span></span>
</td>
<td class="nump">$ 17,950<span></span>
</td>
<td class="num">$ (5,076,527)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Cost from issuance of ordinary shares</a></td>
<td class="num">$ (152)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(152)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of shares reserved for share option exercises (in shares)</a></td>
<td class="nump">5,898,217<span></span>
</td>
<td class="nump">1,375,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Exercise of options, ESPP and release of RSUs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,960,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of options, ESPP and release of RSUs</a></td>
<td class="nump">$ 46,964<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">46,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">303,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(95,367)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(95,367)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(2,003,815)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,003,815)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at the ending of period (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,356,140,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the ending of period at Dec. 31, 2022</a></td>
<td class="nump">$ 4,383,355<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
<td class="nump">11,540,979<span></span>
</td>
<td class="num">(77,417)<span></span>
</td>
<td class="num">(7,080,342)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of shares reserved for share option exercises (in shares)</a></td>
<td class="nump">6,974,331<span></span>
</td>
<td class="nump">84,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Exercise of options, ESPP and release of RSUs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,561,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of options, ESPP and release of RSUs</a></td>
<td class="nump">$ 53,008<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">53,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">367,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">367,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Cancellation of ordinary shares (in share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,273,108)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Cancellation of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">(362,915)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(22,029)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,029)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (881,708)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(881,708)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at the ending of period (in shares) at Dec. 31, 2023</a></td>
<td class="nump">1,359,513,224<span></span>
</td>
<td class="nump">1,359,513,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the ending of period at Dec. 31, 2023</a></td>
<td class="nump">$ 3,537,327<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
<td class="nump">11,598,688<span></span>
</td>
<td class="num">(99,446)<span></span>
</td>
<td class="num">(7,962,050)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of shares reserved for share option exercises (in shares)</a></td>
<td class="nump">6,812,624<span></span>
</td>
<td class="num">(2,258,161)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Exercise of options, ESPP and release of RSUs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,112,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of options, ESPP and release of RSUs</a></td>
<td class="nump">$ 45,553<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">45,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_AdjustmentsToAdditionalPaidInCapitalDeconsolidationOfSubsidiary', window );">Deconsolidation of a subsidiary</a></td>
<td class="nump">2,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">441,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">441,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Cancellation of ordinary shares</a></td>
<td class="num">(362,917)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(49,542)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,542)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (644,786)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(644,786)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at the ending of period (in shares) at Dec. 31, 2024</a></td>
<td class="nump">1,387,367,704<span></span>
</td>
<td class="nump">1,387,367,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the ending of period at Dec. 31, 2024</a></td>
<td class="nump">$ 3,332,222<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
<td class="nump">$ 12,087,908<span></span>
</td>
<td class="num">$ (148,988)<span></span>
</td>
<td class="num">$ (8,606,836)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_AdjustmentsToAdditionalPaidInCapitalDeconsolidationOfSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Deconsolidation Of Subsidiary</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_AdjustmentsToAdditionalPaidInCapitalDeconsolidationOfSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914534395056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business</a></td>
<td class="text">Description of Business<div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BeiGene, Ltd. (the &#8220;Company&#8221;, &#8220;BeiGene&#8221;, &#8220;it&#8221;, &#8220;its&#8221;) is a leading global oncology company discovering and developing innovative treatments that are more accessible and affordable to cancer patients worldwide. In 2024, the Company generated total global revenue of approximately $3.8 billion, increasing revenue by approximately $1.4 billion from the prior year, while reducing its operating loss from the prior year by approximately $0.6 billion.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since its inception in 2010, the Company has become a fully integrated global organization with more than 11,000 employees worldwide.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914419159136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany transactions and balances between the Company and its wholly-owned subsidiaries are eliminated upon consolidation.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Areas where management uses subjective judgment include, but are not limited to, estimating the useful lives of long-lived assets, estimating variable consideration in product sales and collaboration revenue arrangements, identifying separate accounting units and the standalone selling price of each performance obligation in the Company&#8217;s revenue arrangements, assessing the impairment of long-lived assets, valuation and recognition of share-based compensation expenses, estimating uncertain tax positions, valuation of inventory, estimating the allowance for credit losses, determining defined benefit pension plan obligations, measurement of right-of-use assets and lease liabilities and the fair value of financial instruments. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from these estimates.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Functional Currency and Foreign Currency Translation</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Functional currency and foreign currency gains and losses</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the U.S. dollar (&#8220;$&#8221; or U.S. dollar) as its reporting currency. Transactions in subsidiaries are recorded in the functional currency of the respective subsidiary and such transactions denominated in currencies other than the functional currency give rise to foreign exchange remeasurement (monetary assets and liabilities) and related gains and losses that are classified in other (expense) income, net in the consolidated statement of operations. The determination of functional currency is based on the criteria of Accounting Standard Codification (&#8220;ASC&#8221;) 830, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Matters</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For those periods presented, the Company has not entered into any foreign currency derivative instruments to hedge its foreign currency positions.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency translation</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For subsidiaries whose functional currencies are not the U.S. dollar, the Company uses the average exchange rate for the period and the exchange rate at the balance sheet date to translate the operating results and financial position to the U.S. dollar, which is the Company's reporting currency. Translation differences are recorded in accumulated other comprehensive loss, a component of shareholders&#8217; equity.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash on hand and bank deposits, which are unrestricted as to withdrawal and use. The Company considers all highly liquid investments with an original maturity date of three months or less at the date of purchase to be cash equivalents. Cash equivalents which consist primarily of money market funds are stated at fair value.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted cash</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash primarily consists of&#160;RMB-denominated cash deposits pledged in designated bank accounts as collateral for bank loans and letters of credit. The Company classifies restricted cash as current or non-current based on the term of the restriction.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the restricted cash balances above, the Company is required by the PRC securities law to use the proceeds from the STAR offering in strict compliance with the planned uses as disclosed in the PRC offering prospectus as well as those disclosed in the Company&#8217;s proceeds management policy approved by its board of directors. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Credit Losses</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are recorded at their invoiced amounts, net of trade discounts and allowances as well as an allowance for credit losses. The allowance for credit losses reflects the Company&#8217;s current estimate of credit losses expected to be incurred over the life of the receivables. The Company considers various factors in establishing, monitoring, and adjusting its allowance for credit losses including the aging of receivables and aging trends, customer creditworthiness and specific exposures related to particular customers. The Company also monitors other risk factors and forward-looking information, such as country specific risks and economic factors that may affect a customer&#8217;s ability to pay in establishing and adjusting its allowance for credit losses. Accounts receivable are written off after all collection efforts have ceased.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Prior to the regulatory approval of product candidates, the Company may incur costs for the manufacture of drug product to support the commercial launch of those products. Until the date at which regulatory approval has been received or is otherwise considered probable, all such costs are recorded as research and development expenses as incurred. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost and net realizable value, with cost determined in a manner that approximates weighted average cost. The Company periodically analyzes its inventory levels, and writes down inventory that has become obsolete, inventory that has a cost basis in excess of its estimated realizable value and inventory in excess of expected sales requirements as cost of product sales. The determination of whether inventory costs will be realizable requires estimates of future prices by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required, which would be recorded in the consolidated statements of operations. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consist of available-for-sale debt securities, convertible note instruments, public equity securities with readily determinable fair values, private equity securities without readily determinable fair values, and equity-method investments. The classification of an investment is determined based on the nature of the investment, the Company&#8217;s ability and intent to hold the investment, and the degree to which the Company may exercise influence over the investee.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Available-for-sale debt securities are stated at fair value, with the unrealized gains and losses, net of tax, reported in other comprehensive loss. The net carrying value of debt securities classified as available-for-sale is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization is computed using the effective interest method and included in interest income. Interest and dividends are included in interest income. Available-for-sale debt securities with original maturities greater than three months at the date of purchase and less than one year from the date of the balance sheet are classified as short-term. Available-for-sale debt securities with maturities beyond one year may be classified as short-term marketable securities due to their highly liquid nature and because they represent the Company&#8217;s investments that are available for current operations.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Convertible note instruments are recorded using the fair value option method of accounting. Accordingly, convertible note instruments are remeasured at fair value on a recurring basis, with any changes in the fair value option recorded in other (expense) income, net.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Public equity securities with readily determinable fair values are recorded at fair value. Subsequent changes in fair value are recorded in other (expense) income, net. Derivative financial instruments to purchase public equity securities are recorded at fair value. The estimated fair value of derivative financial instruments is determined based on the Black-Scholes valuation model. Changes in fair value of derivative instruments are recorded in other (expense) income, net.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Private equity securities without readily determinable fair values and where the Company does not have significant influence are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Adjustments to private equity securities are recorded in other (expense) income, net. </span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Equity investments in common stock or in-substance common stock where the Company has significant influence over the financial and operating policies of the investee are accounted for as equity-method investments. Equity-method investments are initially recorded at cost and subsequently adjusted based on the Company&#8217;s percentage ownership in the investee&#8217;s income and expenses, as well as dividends, if any. The Company records its share of the investee&#8217;s results of operations in other (expense) income, net. The Company records impairment losses on our equity method investments if it deems the impairment to be other-than-temporary. The Company deems an impairment to be other-than-temporary based on various factors, including but not limited to, the length of time the fair value is below the carrying value and ability to retain the investment to allow for a recovery in fair value.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains or losses on sales of investments are determined based on the specific identification method.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly evaluates its investments in debt and equity for impairment. The Company recognizes an allowance on available-for-sale debt securities when a portion of the unrealized loss is attributable to a credit loss and a corresponding credit loss in net income. No allowance for credit losses were recorded for any periods presented. The Company recognized an impairment loss of $7,635 and $7,529 related to its investments in equity during the years ended December&#160;31, 2024 and 2023, respectively. No impairment losses on equity investments were recorded for the year ended December&#160;31, 2022.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Property, plant and equipment, other than land and construction in progress, are depreciated using the straight-line method over the estimated useful lives of the respective assets as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful&#160;Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 10 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software, Electronic and Office Equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold Improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of useful life or lease term</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically evaluates whether events and circumstances have occurred that indicate the estimated useful lives of its long-lived assets may require reassessment. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies ASC, Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 842&#8221;) to account for its leases. The Company determines if an arrangement is a lease at inception. The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease component based on the Company&#8217;s policy election to combine lease and non-lease components for its leases. Leases are classified as operating or finance leases in accordance with the recognition criteria in ASC 842-20-25. The Company&#8217;s lease portfolio consists entirely of operating leases as of December&#160;31, 2024. The Company&#8217;s leases do not contain any material residual value guarantees or material restrictive covenants.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the commencement date of a lease, the Company determines the classification of the lease based on the relevant factors present and records a right-of-use (&#8220;ROU&#8221;) asset and lease liability. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and lease liabilities are calculated as the present value of the lease payments not yet paid. Variable lease payments not dependent on an index or rate are excluded from the ROU asset and lease liability calculations and are recognized in expense in the period which the obligation for those payments is incurred. As the rate implicit in the Company&#8217;s leases is not typically readily available, the Company uses an incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. This incremental borrowing rate reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. ROU assets include any lease prepayments and are reduced by lease incentives. Operating lease expense for lease payments is recognized on a straight-line basis over the lease term. Lease terms are based on the non-cancelable term of the lease and may contain options to extend the lease when it is reasonably certain that the Company will exercise that option. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases are included in operating lease right-of-use assets and operating lease liabilities on the consolidated balance sheet. Lease liabilities that become due within one year of the balance sheet date are classified as current liabilities.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial lease term of 12 months or less are not recorded on the consolidated balance sheet. Lease expense for these leases is recognized on a straight-line basis over the lease term. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Land Use Right, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All land in the PRC is owned by the PRC government. The PRC government may sell land use rights for a specified period of time. Land use rights represent operating leases in accordance with ASC 842. The purchase price of land use rights represents lease prepayments to the PRC government and is recorded as an operating lease ROU asset on the balance sheet. The ROU asset is amortized over the remaining lease term. As of December&#160;31, 2024, the Company held land use rights in the following regions:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Terms</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Guangzhou</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beijing</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Suzhou</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shanghai</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 years</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired through business combinations are recognized as assets separate from goodwill and are measured at fair value upon acquisition. Intangible assets acquired in transactions that are not business combinations are recorded at the allocated portion of total consideration transferred based on their relative fair value in relation to net assets acquired. Intangible assets associated with milestone payments made to third parties subsequent to regulatory approval are recorded at cost. Identifiable intangible assets consist of post-approval milestone payments under license and commercialization agreements, that are amortized over the remainder of the product patent or the term of the commercialization agreements; and trading licenses that are amortized over the initial license term.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite useful lives are tested for impairment when events or circumstances occur that could indicate that the carrying amount of an asset may not be recoverable. When these events occur, the Company evaluates the recoverability of the intangible assets by comparing the carrying amount of the assets to the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected undiscounted cash flows is less than the carrying amount of the assets, the Company recognizes an impairment loss based on the excess of the carrying amount of the assets over their fair value. Fair value is generally determined by discounting the cash flows expected to be generated by the assets, when the market prices are not readily available. For the years ended December&#160;31, 2024, 2023 and 2022, the Company determined that there were no indicators of impairment of its other intangible assets.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets are reviewed for impairment in accordance with authoritative guidance for impairment or disposal of long-lived assets. Long-lived assets are reviewed for events or changes in circumstances, which indicate that their carrying value may not be recoverable. Long-lived assets are reported at the lower of carrying amount or fair value less cost to sell. For the years ended December&#160;31, 2024, 2023 and 2022, there was no impairment of the value of the Company&#8217;s long-lived assets.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value of financial instruments</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies ASC topic 820 (&#8220;ASC 820&#8221;), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in measuring fair value. ASC 820 defines fair value, establishes a framework for measuring fair value and requires disclosures to be provided on fair value measurement. ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Include other inputs that are directly or indirectly observable in the marketplace.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Unobservable inputs which are supported by little or no market activity.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 820 describes three main approaches to measuring the fair value of assets and liabilities: (1) market approach; (2) income approach; and (3) cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial instruments measured at fair value on a recurring basis</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth assets measured at fair value on a recurring basis as of December&#160;31, 2024 and 2023:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Price<br/>in&#160;Active<br/>Market&#160;for<br/>Identical<br/>Assets<br/>(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt instrument</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt instrument</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952,817&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,234&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Price<br/>in&#160;Active<br/>Market&#160;for<br/>Identical<br/>Assets<br/>(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,052,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt instrument</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt instrument</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,057,795&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,883&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash equivalents are highly liquid investments with original maturities of 3 months or less. The Company&#8217;s investments in U.S. Treasury securities are classified as available-for-sale debt securities. The Company determines the fair value of cash equivalents and available-for-sale debt securities using a market approach based on quoted prices in active markets. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s equity securities carried at fair value consist of holdings in common stock and warrants to purchase additional shares of common stock of Leap Therapeutics, Inc. (&#8220;Leap&#8221;), a publicly-traded biotechnology company. The common stock investment is measured and carried at fair value and classified as a Level 1 investment. The warrants to purchase additional shares of common stock are measured using the Black-Scholes option-pricing valuation model and classified as a Level 2 investment. Refer to Note 5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for details of the determination of the carrying amount of private equity investments without readily determinable fair values and equity method investments.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds convertible notes issued by private biotech companies. The Company has elected the fair value option method of accounting for the convertible notes. Accordingly, the convertible notes are remeasured at fair value on a recurring basis using Level 3 inputs, with any changes in the fair value option recorded in other (expense) income, net. The Company recorded losses on fair value adjustments of $4,842 and $1,492 for the years ended December&#160;31, 2024 and 2023, respectively. There was no fair value adjustment during the year ended December&#160;31, 2022.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers of instruments between levels of valuation categories during the years ended December&#160;31, 2024 and 2023.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, the Company held time deposits of nil and $42,852, respectively, that were classified as cash equivalents. As of December&#160;31, 2024 and 2023, the fair values of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and short-term debt approximated their carrying values due to their short-term nature. Long-term debt approximates its fair value due to the fact that the related interest rates approximate the rates currently offered by financial institutions for similar debt instrument of comparable maturities.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies ASC, Topic 606,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(&#8220;ASC 606&#8221;) to account for its revenue transactions. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Company recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenue</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. and EU, the Company generates product revenues from the sale of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BRUKINSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and TEVIMBRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In China, the Company generates product revenues from the sale of its internally developed drugs TEVIMBRA, BRUKINSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and PARTRUVIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and the sale of in-licensed products through its agreements with Amgen, BMS, Bio-Thera, EUSA Pharma and Luye Pharmaceutical.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the commercial profit share arrangement with Amgen, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company is the principal for in-licensed product sales to customers in China during the commercialization period and recognizes 100% of net product revenue on these sales. Amounts due to Amgen for its portion of net product sales are recorded as cost of sales. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the Company distributes its products through specialty pharmacies and specialty distributors. The specialty pharmacies and specialty distributors subsequently resell the product to health care providers and patients. In the EU, the Company distributes its products through distributors or directly to hospitals. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In China, the Company sells its internally developed products to multiple distributors, who in turn sell the product to hospitals or pharmacies within their authorized territories to be sold ultimately to patients. In-licensed products are sold to a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">first tier distributor who subsequently resells the products to second tier distributors who ultimately sell the products to health care providers and patients.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is the principal under the product sales as the Company controls the products with the ability to direct the use of, and obtain substantially all the remaining benefits from the products before they are sold to the customer. For product sales transactions, the Company has a single performance obligation which is to sell the products to its customer. The Company includes variable consideration in the transaction price to the extent it is probable that a significant reversal will not occur and estimates variable consideration from rebates, chargebacks, trade discounts and allowances, sales returns allowances and other incentives using the expected value method. Revenues for product sales are recognized at a point in time when the single performance obligation is satisfied upon delivery to the customer. The Company&#8217;s payment terms are approximately 30-90 days. Actual amounts of consideration ultimately received may differ from the Company&#8217;s estimates.&#160;The Company will reassess estimates for variable consideration periodically. If actual results in the future vary from the Company&#8217;s estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates for variable consideration for which reserves are established at the time of sale include government and commercial rebates, provisions for acceptance of National Reimbursement Drug List (&#8220;NRDL&#8221;) pricing in the PRC, chargebacks, trade discounts and allowances, sales returns allowances and other incentives that are offered within contracts between the Company and its customers, health care providers and other indirect customers. Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as the Company's historical experience, current contractual and statutory requirements, channel inventory levels, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The Company bases its sales returns allowance on estimated distributor inventories, customer demand as reported by third-party sources, and actual returns history, as well as other factors, as appropriate. To date, sales returns have not been significant.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(&#8220;ASC 808&#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities.&#160;For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and therefore within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the five-step model under ASC 606 noted above. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s collaborative arrangements may contain more than one unit of account, or performance obligation, including grants of licenses to intellectual property rights, agreement to provide research and development services and other deliverables. The collaborative arrangements do not include a right of return for any deliverable. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.&#160;In developing the stand-alone selling price for a performance obligation, the Company considers competitor pricing for a similar or identical product, market awareness of and perception of the product, expected product life and current market trends. In general, the consideration allocated to each performance obligation is recognized when the respective obligation is satisfied either by delivering a good or providing a service, limited to the consideration that is not constrained. Non-refundable payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as advances from customers.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Upfront non-refundable payments for licensing the Company&#8217;s intellectual property are evaluated to determine if the license is distinct from the other performance obligations identified in the arrangement. For licenses determined to be distinct, the Company recognizes revenues from non-refundable up-front fees allocated to the license at a point in time, when the license is transferred to the licensee and the licensee is able to use and benefit from the license.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Options to License Intellectual Property:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Upfront non-refundable payments for options to license the Company&#8217;s intellectual property are evaluated to determine if the option represents a material right and is distinct from the other performance obligations identified in the arrangement. For options determined to be a material right and distinct, the Company defers the non-refundable up-front fees allocated to the option and recognizes revenues at a point in time, at the earlier of when the option is exercised or the option period expires.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Right to Access Intellectual Property during the Option Period:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The portion of a transaction price allocated to the other parties right to access the Company&#8217;s intellectual property to generate their own data during an option period is deferred and recognized as collaboration revenue over the option period on a straight-line basis as the right to use the intellectual property is provided and the data generated. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Services:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The portion of a transaction price allocated to research and development services performance obligations is deferred and recognized as collaboration revenue over time as delivery or performance of such services occurs.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.&#160;If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.&#160;Milestones related to the Company&#8217;s development-based activities may include initiation of various phases of clinical trials. Due to the uncertainty involved in meeting these development-based targets, they are generally fully constrained at contract inception. The Company will assess whether the variable consideration is fully constrained each reporting period based on the facts and circumstances surrounding the clinical trials. Upon changes to constraint associated with the developmental milestones, variable consideration will be included in the transaction price when a significant reversal of revenue recognized is not expected to occur and allocated to the separate performance obligations. Regulatory milestones are fully constrained until the period in which those regulatory approvals are achieved due to the inherent uncertainty with the approval process. Regulatory milestones are included in the transaction price in the period regulatory approval is obtained. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of the costs associated with our research and development activities, conducting preclinical studies and clinical trials, and activities related to regulatory filings, which primarily include (i) payroll and related costs (including share-based compensation) associated with research and development personnel, (ii) costs related to clinical trials and preclinical testing of the Company&#8217;s technologies under development, (iii) costs to develop the product candidates, including raw materials and supplies, product testing, depreciation, and facility related expenses, (iv) expenses for research services provided by universities and contract laboratories, including sponsored research funding, and (v) other research and development expenses. Research and development expenses are charged to expense as incurred when these expenditures relate to the Company&#8217;s research and development services and have no alternative future uses.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial costs are a significant component of the Company&#8217;s research and development expenses. The Company has a history of contracting with third parties that perform various clinical trial activities on behalf of the Company in the ongoing development of the Company&#8217;s product candidates. Expenses related to clinical trials are accrued based on the Company&#8217;s estimates of the actual services performed by the third parties for the respective period. If the contracted amounts are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), the Company will modify the related accruals accordingly on a prospective basis. Revisions in the scope of a contract are charged to expense in the period in which the facts that give rise to the revision become probable. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquired In-Process Research and Development Expense</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has acquired rights to develop and commercialize product candidates. Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments (prior to government approval), are immediately expensed as acquired in-process research and development in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#8220;business&#8221; as defined under GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. Milestone payments made to third parties subsequent to regulatory approval are capitalized as intangible assets and amortized over the estimated remaining useful life of the related product. Royalties owed on sales of the products licensed pursuant to the agreements are expensed in the period the related revenues are recognized.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Grants</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government financial incentives that involve no conditions or continuing performance obligations of the Company are recognized as other income upon receipt. During the years ended December&#160;31, 2024, 2023 and 2022, the Company recognized other income of $22,326, $23,989, and $32,540, respectively, for government grants received after the related expenses have been incurred.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event government grants or incentives involve continuing performance obligations, the Company will capitalize the payment as a liability and recognize the same financial statement caption as the performance obligation relates over the performance period. The Company received government assistance in the form of cash primarily to support the Guangzhou manufacturing facility build-out and research and development programs.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government assistance received to support the Guangzhou manufacturing facility build-out is recognized as other long-term liabilities and amortized over the same useful lives of the related assets as depreciation expense. As of December&#160;31, 2024 and 2023, <span style="-sec-ix-hidden:f-486"><span style="-sec-ix-hidden:f-487">other long-term liabilities</span></span> related to the Guangzhou manufacturing facility build-out totaled $30,235 and $34,084, respectively. For the years ended December&#160;31, 2024, 2023 and 2022, <span style="-sec-ix-hidden:f-490"><span style="-sec-ix-hidden:f-491"><span style="-sec-ix-hidden:f-492">depreciation expense</span></span></span> is presented net of amortization of government assistance of $3,053, $2,938 and $3,169, respectively.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government assistance received to support research and development programs is recorded as other long-term liabilities upon receipt and recognized as other income when the associated research and development programs are completed. As of December&#160;31, 2024 and 2023, other long-term liabilities related to research and development programs totaled $89 and $120, respectively. For the years ended December&#160;31, 2022, the Company recognized other income of $1,664 upon the completion of a designated research and development program. No income was recognized during the years ended December&#160;31, 2024 and 2023 related to grants received for research and development programs.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as the changes in equity of the Company during a period from transactions and other events and circumstances excluding transactions resulting from investments by owners and distributions to owners. Among other disclosures, ASC 220, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, requires that all items that are required to be recognized under current accounting standards as components of comprehensive loss be reported in a financial statement that is displayed with the same prominence as other financial statements. For each of the periods presented, the Company&#8217;s comprehensive loss includes net loss, foreign currency translation adjustments, pension liability adjustments and unrealized holding gains/losses associated with the available-for-sale debt securities, and is presented in the consolidated statements of comprehensive loss.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Awards granted to employees</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies ASC 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 718&#8221;), to account for its employee share-based payments. In accordance with ASC 718, the Company determines whether an award should be classified and accounted for as a liability award or equity award. All the Company&#8217;s grants of share-based awards to employees were classified as equity awards and are recognized in the financial statements based on their grant date fair values. Specifically, the grant date fair value of share options is calculated using an option pricing model. The fair value of restricted shares and restricted share units are based on the closing market price of our ADSs on the Nasdaq Global Select Market on the date of grant. The Company has elected to recognize compensation expense using the straight-line method for all employee equity awards granted with graded vesting based on service conditions provided that the amount of compensation cost recognized at any date is at least equal to the portion of the grant-date value of the options that are vested at that date. The Company uses the accelerated method for all awards granted with graded vesting based on performance conditions. To the extent the required vesting conditions are not met resulting in the forfeiture of the share-based awards, previously recognized compensation expense relating to those awards are reversed. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in the subsequent period if actual forfeitures differ from initial estimates. Forfeiture rates are estimated based on historical and future expectations of employee turnover rates and are adjusted to reflect future changes in circumstances and facts, if any. Share-based compensation expense is recorded net of estimated forfeitures such that expense is recorded only for those share-based awards that are expected to vest. To the extent the Company revises these estimates in the future, the share-based payments could be materially impacted in the period of revision, as well as in following periods. The Company, with the assistance of an independent third-party valuation firm, determined the estimated fair value of the stock options granted to employees using the binomial option pricing model.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Awards granted to non-employees</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounted for equity instruments issued to non-employees in accordance with the provisions of ASC 718 and ASC 505, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All transactions in which goods or services are received in exchange for equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The grant date is the measurement date of the fair value of the equity instrument issued. The expense is recognized in the same manner as if the Company had paid cash for the services provided by the non-employees in accordance with ASC 505-50, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity-based payments to non-employees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company estimated the fair value of share options granted to non-employees using the same method as employees.&#160;</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Modification of awards</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in any of the terms or conditions of the awards is accounted for as a modification of the award. Incremental compensation cost is measured as the excess, if any, of the fair value of the modified award over the fair value of the original award immediately before its terms are modified, measured based on the fair value of the awards and other pertinent factors at the modification date. For vested awards, the Company recognizes incremental compensation cost in the period the modification occurs. For unvested awards, the Company recognizes over the remaining requisite service period, the sum of the incremental compensation cost and the remaining unrecognized compensation cost for the original award on the modification date. If the fair value of the modified award is lower than the fair value of the original award immediately before modification, the minimum compensation cost the Company recognizes is the cost of the original award.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using enacted tax rates that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its uncertain tax positions using the provisions of ASC 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Company recognizes in the financial statements the benefit of a tax position which is &#8220;more likely than not&#8221; to be sustained under examination based solely on the technical merits of the position assuming a review by tax authorities having all relevant information. Tax positions that meet the recognition threshold are measured using a cumulative probability approach, at the largest amount of tax benefit that has a greater than fifty percent likelihood of being realized upon settlement. It is the Company&#8217;s policy to recognize interest and penalties related to unrecognized tax benefits, if any, as a component of income tax expense.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Per Share</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share is calculated in accordance with ASC 260, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Basic loss per ordinary share is computed by dividing net loss attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period using the two-class method. Under the two-class method, net income is allocated between ordinary shares and participating securities based on dividends declared (or accumulated) and participating rights in undistributed earnings as if all the earnings for the reporting period had been distributed.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted loss per share, when required, is calculated by dividing net loss attributable to ordinary shareholders as adjusted for the effect of dilutive ordinary equivalent shares, if any, by the weighted average number of ordinary and dilutive ordinary equivalent shares outstanding during the period. Ordinary equivalent shares consist of the ordinary shares issuable upon the conversion of the Company&#8217;s convertible preferred shares, if any, using the if-converted method, and ordinary shares issuable upon the conversion of the share options, and unvested restricted shares units and performance-based restricted shares units (&#8220;PSUs&#8221;), using the treasury stock method. The dilutive effects of PSUs are included in the weighted average common share calculation based on the cumulative achievement against the performance targets only when the performance targets have been achieved as of the end of the reporting period.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ordinary share equivalents are excluded from the computation of diluted loss per share if their effects would be anti-dilutive. Basic and diluted loss per ordinary share is presented in the Company&#8217;s consolidated statements of operations.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 280, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company&#8217;s chief operating decision maker, the Chief Executive Officer, reviews the consolidated results when making decisions about allocating resources and assessing performance of the Company as a whole and hence, the Company has only one reportable segment: pharmaceutical products. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of cash and credit risk</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that are potentially subject to credit risk consist of cash and cash equivalents and accounts receivable.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, $2,627,410 and $3,171,800 were deposited with various major reputable financial institutions located in the U.S., PRC and other international financial institutions. The deposits placed with financial institutions are not protected by statutory or commercial insurance. In the event of bankruptcy of one of these financial institutions, the Company may be unable to claim its deposits back in full. Management believes that these financial institutions are of high credit quality and continually monitors the credit worthiness of these financial institutions.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, the Company had accounts receivable, net of $676,278 and $358,027, respectively. Accounts receivable, net represent amounts arising from product sales. The Company monitors economic conditions to identify facts or circumstances that may indicate receivables are at risk of collection.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Customer concentration risk</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2024, sales to the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s three largest product distributors, ASD Specialty Healthcare, McKesson and Shanghai Pharmaceutical represented approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.0%,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.9%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.1% </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of product revenue, respectively, and collectively, represented approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51.0%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of trade accounts receivable as of December&#160;31, 2024.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023, sales to the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s four largest product distributors, Sinopharm, Shanghai Pharmaceutical, ASD Specialty Healthcare and China Resources represented approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.0%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.2%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.4%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.4%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of product revenue, respectively, and collectively, represented approximately </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53.2%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of trade accounts receivable as of December&#160;31, 2023. For the year ended December&#160;31, 2023, the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s collaboration revenue consisted entirely of revenue recognized under its out-licensing collaboration agreements with Novartis. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">New accounting standards which have been adopted</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 280): Improvements to Reportable Segment Disclosures. This update requires disclosure of incremental segment information on an annual and interim basis. This update is effective for annual periods beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024. Early adoption is permitted. This guidance should be applied retrospectively to all prior periods presented in the financial statements. The Company operates in one segment. Its chief operating decision maker is the Chief Executive Officer, who makes operating decisions, assesses performance, and allocates resources on a consolidated basis. The Company adopted ASU 2023-07 effective December 31, 2024. Refer to Footnote 21 for segment related disclosures.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">New accounting standards which have not yet been adopted</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Subtopic 220-40): Disaggregation of Income Statement Expenses. This update requires that at each interim and annual reporting period public entities disclose (1) the amounts of purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions; (2) certain amounts that are already required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirements; (3) a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively; and (4) the total amount of selling expenses and, in annual reporting periods, the definition of selling expenses. In January 2025, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Subtopic 220-40): Clarifying the Effective Date. This update clarifies that ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact on its financial statements of adopting this guidance.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 740): Improvements to Income Tax Disclosures. This update requires that public entities on an annual basis, (1) in the rate reconciliation, disclose specific categories and provide additional information for reconciling items that meet a quantitative threshold; (2) about income taxes paid, disclose the amount of income taxes paid (net of refunds received) disaggregated by federal, state, and foreign taxes and by individual jurisdiction in which income taxes paid (net of refunds received) is equal to or greater than 5 percent of total income taxes paid (net of refunds received); and (3) disclose income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign and income tax expense (or benefit) disaggregated by federal, state, and foreign. This update is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. This guidance should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating the impact on its financial statements of adopting this guidance.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914413447072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Licensing Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative and Licensing Arrangements</a></td>
<td class="text">Collaborative and Licensing Arrangements<div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative arrangements for the research and development, manufacture and/or commercialization of drug products and drug candidates. To date, these collaborative arrangements have included out-licenses of and options to out-license internally developed products and drug candidates to other parties, in-licenses of products and drug candidates from other parties, and profit- and cost-sharing arrangements. These arrangements may include non-refundable upfront payments, contingent obligations for potential development, regulatory and commercial performance milestone payments, cost-sharing and reimbursement arrangements, royalty payments, and profit sharing. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Out-Licensing Arrangements</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three years ended December&#160;31, 2024, the Company&#8217;s collaboration revenue related to its out-licensing collaborative agreements has consisted of research and development services revenue and right to access intellectual property revenue from its former collaboration agreements with Novartis for tislelizumab and ociperlimab. Other collaboration revenue consists primarily of revenue under the Novartis broad markets agreement and, beginning in 2024, royalty revenue under the Amgen collaboration agreement. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total collaboration revenue recognized for the years ended December&#160;31, 2024, 2023 and 2022:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.429%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue from Collaborators</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development service revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right to access intellectual property revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Material rights revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,695&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268,927&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,309&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Novartis</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tislelizumab Collaboration and License </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company entered into a collaboration and license agreement with Novartis, granting Novartis rights to develop, manufacture and commercialize tislelizumab in North America, Europe, and Japan (the &#8220;Novartis Territory&#8221;). The Company and Novartis agreed to jointly develop tislelizumab in these licensed countries, with Novartis responsible for regulatory submissions after a transition period and for commercialization upon regulatory approvals. In addition, both companies had the ability to conduct clinical trials globally to explore combinations of tislelizumab with other cancer treatments, and the Company has an option to co-detail the product in North America, funded in part by Novartis.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement the Company received an upfront cash payment of $650,000 from Novartis. A portion of the transaction price was allocated to the R&amp;D services to be performed under the agreement and deferred and was being recognized as collaboration revenue as the R&amp;D services were performed using a percentage-of-completion method. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, the Company and Novartis agreed to mutually terminate the collaboration and license agreement, effective immediately. Pursuant to the termination agreement, the Company regained full, global rights to develop, manufacture and commercialize tislelizumab with no royalty payments due to Novartis. Novartis may continue its ongoing clinical trials and has the ability to conduct future combination trials with tislelizumab subject to BeiGene&#8217;s approval. BeiGene agreed to provide Novartis with ongoing clinical supply of tislelizumab to support its clinical trials. Pursuant to the termination agreement, Novartis agreed to provide transition services to the Company to enable key aspects of the tislelizumab development and commercialization plan to proceed without disruption, including manufacturing, regulatory, safety and clinical support. Upon termination of the agreement in September 2023, there were no further performance obligations, and the remaining deferred revenue balance associated with the tislelizumab R&amp;D services was recognized in full.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes collaboration revenue recognized in connection with the tislelizumab collaboration and license agreement for the years ended December&#160;31, 2024, 2023 and 2022:</span></div><div style="margin-bottom:3pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.429%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development service revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,345&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,148&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Represents revenue recognized on sale of tislelizumab clinical supply to Novartis in conjunction with the collaboration.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ociperlimab Option, Collaboration and License Agreement and China Broad Market Development Agreement</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, the Company expanded its collaboration with Novartis by entering into an option, collaboration and license agreement with Novartis to develop, manufacture and commercialize the Company&#8217;s investigational TIGIT inhibitor ociperlimab in the Novartis Territory. In addition, the Company and Novartis entered into an agreement granting the Company rights to market, promote and detail five approved Novartis oncology products, TAFINLAR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (dabrafenib), MEKINIST</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (trametinib), VOTRIENT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pazopanib), AFINITOR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (everolimus), and ZYKADIA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ceritinib), across designated regions of China referred to as &#8220;broad markets.&#8221; In the first quarter of 2022, the Company initiated marketing and promotion of these five products.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the option, collaboration and license agreement, the Company received an upfront cash payment of $300,000. At inception, a portion of the upfront cash payment was deferred related to performance obligations to be satisfied at a later point in time or over time. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, the Company and Novartis mutually agreed to terminate the ociperlimab option, collaboration and license agreement, effective immediately. Pursuant to the termination agreement, the Company regained full, global rights to develop, manufacture and commercialize ociperlimab. Upon termination the Company had no further performance obligations under the collaboration, and all remaining deferred revenue balances were recognized in full. The China broad markets agreement remains in place.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes collaboration revenue recognized in connection with the ociperlimab option, collaboration and license agreement for the years ended December&#160;31, 2024, 2023 and 2022:</span></div><div style="margin-bottom:3pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.429%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development service revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right to access intellectual property revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Material rights revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,259&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,469&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,161&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Represents revenue generated under the broad markets marketing and promotion agreement in conjunction with the collaboration.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In-Licensing Arrangements - Commercial</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the Company entered into a global strategic oncology collaboration with Amgen (&#8220;Amgen Collaboration Agreement&#8221;) for the commercialization and development in China, excluding Hong Kong, Taiwan and Macau, of Amgen&#8217;s XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and BLINCYTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and the joint global development of a portfolio of oncology assets in Amgen&#8217;s pipeline, with BeiGene responsible for development and commercialization in China. The agreement became effective on January 2, 2020, following approval by the Company&#8217;s shareholders and satisfaction of other closing conditions.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, the Company is responsible for the commercialization of XGEVA, KYPROLIS and BLINCYTO in China for <span style="-sec-ix-hidden:f-567">five</span> or seven years. Amgen is responsible for manufacturing the products globally and supplying the products to the Company at an agreed upon price. The Company and Amgen share equally in the China commercial profits and losses during the commercialization period. Following the commercialization period, the Company has the right to retain one product and is entitled to receive royalties on sales in China for an additional five years on the products not retained. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen and the Company are also jointly developing a portfolio of Amgen oncology pipeline assets under the collaboration. The Company is responsible for conducting clinical development activities in China and co-funding global development costs by contributing cash and development services up to a total cap of $1,250,000. Amgen is responsible for all development, regulatory and commercial activities outside of China. For each pipeline asset that is approved in China, the Company will receive commercial rights for seven years from approval. The Company has the right to retain approximately one out of every three approved pipeline assets, other than LUMAKRAS (sotorasib) (&#8220;AMG 510&#8221;), Amgen&#8217;s KRAS G12C inhibitor, for commercialization in China. The Company and Amgen will share equally in the China commercial profits and losses during the commercialization period. The Company is entitled to receive royalties from sales in China for pipeline assets returned to Amgen for five years after the seven-year commercialization period. The Company is also entitled to receive royalties from global sales of each product outside of China (with the exception of AMG 510).</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2022, the parties entered into the First Amendment to Amgen Collaboration Agreement, which amends certain terms and conditions relating to the financial responsibilities of the parties in connections with the development and commercialization of certain Amgen proprietary products for the treatment of oncology-related diseases and conditions. In connection with the Company&#8217;s ongoing assessment of the Amgen Collaboration Agreement cost-share contributions, the Company determined that further investment in the development of LUMAKRAS was no longer commercially viable for BeiGene. As a result, in February 2023, the Company and Amgen entered into the Second Amendment to the Amgen Collaboration Agreement to (i) stop sharing costs with Amgen for the further development of LUMAKRAS during the period starting January 1, 2023 and ending August 31, 2023; and (ii) cooperate in good faith to prepare a transition plan with the termination of LUMAKRAS from the Amgen Collaboration Agreement.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amgen Collaboration Agreement is within the scope of ASC 808, as both parties are active participants and are exposed to the risks and rewards dependent on the commercial success of the activities performed under the agreement. The Company is the principal for product sales to customers in China during the commercialization period and will recognize 100% of net product revenue on these sales. Amounts due to Amgen for its portion of net product sales will be recorded as cost of sales. Cost reimbursements due to or from Amgen under the profit share will be recognized as incurred and recorded to cost of sales; selling, general and administrative expense; or research and development expense, based on the underlying nature of the related activity subject to reimbursement. Costs incurred for the Company&#8217;s portion of the global co-development funding are recorded to research and development expense as incurred.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Amgen Collaboration Agreement, a Share Purchase Agreement (&#8220;SPA&#8221;) was entered into by the parties on October 31, 2019. On January 2, 2020, the closing date of the transaction, Amgen purchased 15,895,001 of the Company&#8217;s ADSs for $174.85 per ADS, representing a 20.5% ownership stake in the Company. Per the SPA, the cash proceeds shall be used as necessary to fund the Company&#8217;s development obligations under the Amgen Collaboration Agreement. Pursuant to the SPA, Amgen also received the right to designate one member of the Company&#8217;s board of directors, and Anthony Hooper joined the Company&#8217;s board of directors as the Amgen designee in January 2020. Amgen relinquished its right to appoint a designated director to the Company&#8217;s board of directors in January 2023.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the fair value of the common stock at closing, the Company considered the closing price of the common stock on the closing date of the transaction and included a lack of marketability discount because the shares are subject to certain restrictions. The fair value of the shares on the closing date was determined to be $132.74 per ADS, or $2,109,902 in the aggregate. The Company determined that the premium paid by Amgen on the share purchase represents a cost share liability due to the Company&#8217;s co-development obligations. The fair value of the cost share liability on the closing date was determined to be $601,857 based on the Company&#8217;s discounted estimated future cash flows related to the pipeline assets. The estimation of future cash flows involved management assumptions of revenue growth rates and probability of technical and regulatory success of the pipeline assets. The total cash proceeds of $2,779,241 were allocated based on the relative fair value method, with $2,162,407 recorded to equity and $616,834 recorded as a research and development cost share liability. The cost share liability is being amortized proportionately as the Company contributes cash and development services to its total co-development funding cap.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recorded related to the Company&#8217;s portion of the co-development funding on the pipeline assets for the years ended December&#160;31, 2024, 2023 and 2022 were as follows:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.377%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene&#8217;s portion of the development funding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amortization of research and development cost share liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,165&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,314&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,955&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining portion of development funding cap </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, the research and development cost share liability recorded in the Company&#8217;s balance sheet was as follows:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development cost share liability, current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development cost share liability, non-current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development cost share liability</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,440&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,666&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net reimbursement paid under the commercial profit-sharing agreement for in-line product sales is classified in the consolidated statements of operations for the three years ended December&#160;31, 2024 as follows:</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:54.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.437%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.437%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.440%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales - product</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,358&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83,674)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,917)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,865)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,438)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,216)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,962)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,871)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,183)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company purchases commercial inventory from Amgen to distribute in China. Total inventory purchases amounted to $247,655, $108,691 and $71,720, respectively, during the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024, 2023 and 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Net amounts payable to Amgen as of December&#160;31, 2024 and 2023 were $116,563 and $55,474, respectively.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In-Licensing Arrangements - Development </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has in-licensed the rights to develop, manufacture and, if approved, commercialize multiple development stage drug candidates globally or in specific territories. These arrangements typically include non-refundable upfront payments, contingent obligations for potential development, regulatory and commercial performance milestone payments, cost-sharing arrangements, royalty payments, and profit sharing. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront and milestone payments made under these arrangements for the years ended December&#160;31, 2024, 2023 and 2022 are set forth below. All upfront and development milestones were expensed to research and development expense. All regulatory and commercial milestones were capitalized as intangible assets and are being amortized over the remainder of the respective product patent or the term of the commercialization agreements.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments due to collaboration partners</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront payments</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development milestone payments</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regulatory and commercial milestone payments</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,027&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,165&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,165&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into a number of in-licensing collaborative arrangements during the years ended December&#160;31, 2024, 2023 and 2022. A summary of amounts incurred under these arrangements is included above. The Company may be required to pay additional amounts upon the achievement of various development and commercial milestones under these agreements. The Company may also incur significant research and development costs if the related product candidate were to advance to late-stage clinical trials. In addition, if any products related to these collaborations are approved for sale, the Company may be required to pay significant milestones upon approval and milestones and/or royalties on future sales. The payment of these amounts, however, is contingent upon the occurrence of various future events, which have a high degree of uncertainty of occurrence.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914413439824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restricted Cash<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Restricted Cash</a></td>
<td class="text">Restricted Cash<div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s restricted cash primarily consist of&#160;RMB-denominated cash deposits held in designated bank accounts for collateral for letters of credit. The Company classifies restricted cash as current or non-current based on term of restriction. Restricted cash as of December&#160;31, 2024 and 2023 was as follows:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,337&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,184&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the restricted cash balances above, the Company is required by the PRC securities law to use the proceeds from the STAR Offering in strict compliance with the planned uses as disclosed in the PRC offering prospectus as well as those disclosed in the Company&#8217;s proceeds management policy approved by the board of directors. As of December&#160;31, 2024, the Company had cash remaining related to the STAR Offering proceeds of $588,235.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914413497440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">Investments<div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s investments in equity securities:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.100%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Leap common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Leap warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities without readily determinable fair values</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pi Health, Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-method investments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,981&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,317&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,429&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Represents common stock and warrants to purchase additional shares of common stock of Leap. The Company measures the investment in the common stock and warrants at fair value, with changes in fair value recorded to other (expense) income, net.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the first quarter of 2024, the Company divested the net assets comprising substantially all of its Pi Health business with a carrying value of $38,063. The consideration received for the divestiture consisted of preferred stock in a newly formed entity, Pi Health, Inc., with a fair value of $40,798 and cash consideration of $1,000. The transaction resulted in a pre-tax gain of $3,735 recorded within <span style="-sec-ix-hidden:f-660">other (expense) income, net</span> during year ended December&#160;31, 2024. The Company will account for its investment prospectively as a private equity security without a readily determinable fair value and the divestiture is not treated as a discontinued operation in the Statement of Operations and therefore the historical results of operations of the Pi Health business will remain in the Company&#8217;s continuing operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes unrealized (losses) gains related to investments in equity securities recorded in other (expense) income, net:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,307)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(425)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities without readily determinable fair values</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,596)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,448)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-method investments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,275)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,856)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,682)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/940-320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph b<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914531579648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories, Net</a></td>
<td class="text">Inventories, Net<div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s inventories, net consisted of the following:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494,986&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416,122&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914413497440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for office and manufacturing facilities in the U.S., Switzerland, and China. The leases have remaining lease terms of up to six years, some of which include options to extend the leases that have not been included in the calculation of the Company&#8217;s lease liabilities and ROU assets. The Company has land use rights, which represent land acquired for the biologics manufacturing facility in Guangzhou, the land acquired for the Company&#8217;s research, development and office facility in Changping, Beijing, the land acquired for the Company&#8217;s research, development and manufacturing facility in Suzhou, and the land acquired for the Company&#8217;s research and development facility in Shanghai. The Company also has certain leases with terms of 12 months or less for certain equipment, office and lab space, which are expensed and not recorded on the balance sheet.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.377%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost </span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,052&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,762&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,071&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land use rights, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,309&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,853&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,201&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities are as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.375%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December&#160;31,&#160;2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December&#160;31,&#160;2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December&#160;31,&#160;2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31, 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31, 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,534&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,681)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,853&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other supplemental information related to leases is summarized below:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.377%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used in operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for new operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914419103840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment, Net</a></td>
<td class="text">Property, Plant and Equipment, Net<div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net are recorded at cost less accumulated depreciation and consisted of the following:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607,857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software, electronics and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, at cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,510&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832,751&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(399,105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(249,212)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,578,423&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,324,154&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has made a significant investment in its newly opened manufacturing and R&amp;D center in Hopewell, New Jersey. In the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$272,670</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of assets were placed into service. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company had construction in progress of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$500,900</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to the Hopewell facility, the majority of which will be put into service in 2025.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, the Company acquired a land use right and the facility currently being constructed on the land for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$73,054</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company plans to complete the construction of the facility and build a research and development center on the land. Based on the relative fair values of the land use right and construction in progress, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$29,431</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the total purchase price was allocated to the land use right and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$43,623</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was allocated to the construction in progress. In May 2024, the Company acquired additional construction in progress in connection with the properties for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$22,538</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress (&#8220;CIP&#8221;) a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s of December&#160;31, 2024 and 2023 primarily related to the Hopewell facility, the new research and development facility acquired in 2024, a new building for Beijing Innerway Bio-tech Co., Ltd., and additional capacity at the Guangzhou and Suzhou manufacturing facilities. CIP by fixed asset class are summarized as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,897&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,380&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,805&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,687&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,451&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654,018&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740,615&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the years ended December&#160;31, 2024, 2023 and 2022 were $166,938, $80,436 and $62,302, respectively. Included within depreciation expense for the year ended December&#160;31, 2024 is $59,792 of accelerated depreciation expense resulting from the move of production to more efficient, larger scale equipment for tislelizumab.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914413449840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text">Intangible Assets<div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets as of December&#160;31, 2024 and 2023 are summarized as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intangible<br/>assets, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intangible<br/>assets, net</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,370)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,807)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,411)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,316)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,876&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,781)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,095&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,261&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,123)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,138&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:7pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Developed products represent post-approval milestone payments under license and commercialization agreements. The Company is amortizing the developed products over the remainder of the respective product patent or the term of the commercialization agreements.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for developed products is included in cost of sales-product in the accompanying consolidated statements of operations. Amortization expense for other intangible assets is included in selling, general and administrative expense in the accompanying consolidated statements of operations. The weighted-average life for each finite-lived intangible assets is approximately 11 years. Amortization expense is as follows:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense - Cost of sales - product</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense - Selling, general and administrative</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,824&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,239&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,976&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense for each of the five succeeding years and thereafter, as of December&#160;31, 2024 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.701%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost of Sales - Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Selling, General and Administrative Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,519&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,095&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914413439824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">loss) before income taxes are as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PRC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263,159)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(315,852)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(583,610)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(471,358)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(627,430)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,445,171)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(533,001)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(825,836)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,961,037)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current and deferred components of the income tax expense (benefit) from continuing operations are as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current tax expense (benefit)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PRC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,778&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax expense (benefit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PRC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,007&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,482&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,785&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,872&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,778&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the statutory tax rate to our effective income tax rate is as follow:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(533,001)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(825,836)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,961,037)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. statutory tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected taxation at U.S. statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111,930)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173,426)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(411,818)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign and preferential tax rate differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,988)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,872)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax relief credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(704,928)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research tax credits and incentives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,602)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,343)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,844)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deductible research expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,644)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax on unremitted earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,397)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,395)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,272)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxation for the year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,778&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of deferred tax assets (liabilities) are as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals and reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses carryforward</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,137,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax relief credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704,928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704,928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081,442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D and other capitalized costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,407,710&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,775,085&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,952,357&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,403,505)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,771,470)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,943,775)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,205&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,582&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,795)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,374)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,480)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax on unremitted earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,735)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,682)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,735)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,098)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,212)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,109)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,578)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets/(liabilities)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,007)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,494)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,996)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowances have been provided on deferred tax assets where, based on all available evidence, it was considered more likely than not that some portion or all of the recorded deferred tax assets will not be realized in future periods. After&#160;consideration&#160;of&#160;all&#160;positive&#160;and&#160;negative&#160;evidence, the Company&#160;believes&#160;that&#160;as of December&#160;31, 2024, it&#160;is&#160;more&#160;likely&#160;than not&#160;that net deferred tax assets will not be realized. Adjustments may be required in the future if the Company estimates that the amount of deferred tax assets to be realized is more or less than the net amount recorded.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation allowances for the years ended December&#160;31, 2024, 2023 and 2022 were as follows:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance, as of January 1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,771,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,943,775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,758,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions/(subtractions) charged to income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions/(subtractions) charged to equity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497,823&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,074)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,116)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,184)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance, as of December 31</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,403,505&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,771,470&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,943,775&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, the Company had net operating losses of approximately $6,720,659 and $5,945,753, respectively. As of December&#160;31, 2024, net operating losses were primarily comprised of: $2,185,546 from entities in the PRC which expire in years 2025 through 2034; and $4,526,020 derived from Switzerland which expires in years 2025 through 2031. The Company has approximately $43,677 of U.S. research tax credits which will expire between 2036 and 2044 and approximately $704,928 of Switzerland tax relief credits which will expire in 2028, if not utilized.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross unrecognized tax benefits for the years ended December&#160;31, 2024, 2023 and 2022 were as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance, as of January 1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to prior tax years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions based on tax positions related to prior tax years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current tax year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions based on lapse of statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance, as of December 31</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,239&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,264&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,555&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current and prior year additions include assessment of U.S. federal and state tax credits and incentives. As of December&#160;31, 2024, the Company had $17,239 of unrecognized tax benefits substantially all of which, if recognized, would reduce the effective tax rate. The Company does not anticipate that the amount of existing unrecognized tax benefits will significantly change within the next 12 months.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to record interest and penalties related to income taxes as a component of income tax expense. For the years ended December&#160;31, 2024, 2023 and 2022, the Company&#8217;s accrued interest and penalties, where applicable, related to uncertain tax positions were not material.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducts business in a number of tax jurisdictions and, as such, is required to file income tax returns in multiple jurisdictions globally. As of December&#160;31, 2024, Australia tax matters are open to examination for the years 2013 through 2024, China tax matters are open to examination for the years 2014 through 2024, Switzerland tax matters are open to examination for the years 2021 through 2024, and U.S. federal tax matters are open to examination for years 2015 through 2024. Various U.S. states and other non-US tax jurisdictions in which the Company files tax returns remain open to examination for 2014 through 2024.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company qualifies for the Technology Advanced Service Enterprises and High and New Technology Enterprise status for certain subsidiaries in China, which begin to expire at the end of 2025. The income tax benefits attributable to this status for the year ended December&#160;31, 2024 is approximately $4,631, or less than $0.01 per share outstanding.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2024, the Company concluded that a portion of earnings from certain subsidiaries, primarily in the U.S. and Canada, are no longer indefinitely reinvested. As a result, the Company recognized a deferred tax liability of $23,735. The Company continues to assert that earnings in other jurisdictions remain permanently reinvested.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914413505472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Supplemental Balance Sheet Information</a></td>
<td class="text">Supplemental Balance Sheet Information<div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid research and development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid manufacturing cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,919&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,465&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current assets consist of the following:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid supply cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental deposits and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepayment of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid VAT</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,546&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,362&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other payables consisted of the following:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales rebates and returns related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External research and development activities related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual income tax and other taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,083&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803,713&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693,731&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities consist of the following:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred government grant income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset retirement obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,735&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,810&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914534838016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s short-term and long-term debt obligations as of December&#160;31, 2024 and 2023: </span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.807%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lender</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Borrower</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Line of Credit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:12pt"><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RMB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RMB</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Construction Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene Guangzhou Biologics Manufacturing Co., Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;RMB580,000 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9-year </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 11, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Merchants Bank</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene Guangzhou Biologics Manufacturing Co., Ltd.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RMB350,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9-year</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 20, 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Merchants Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene Guangzhou Biologics Manufacturing Co., Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RMB378,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9-year </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 8, 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China CITIC Bank</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene (Suzhou) Co., Ltd.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RMB480,000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-year </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 28, 2032</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,384&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Merchants Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene, Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$380,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-year </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,773,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,129,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Minsheng Bank</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene, Ltd.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$150,000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-year </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 16, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.8%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,094,891&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,064,660&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Industrial Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene, Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RMB675,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">364-days</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 27, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">675,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Merchants Bank</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene Guangzhou Biologics Manufacturing Co., Ltd.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RMB400,000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-year </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 5, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,800&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56,356&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HSBC Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene, Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RMB340,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-year</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 5, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,903&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Industrial Bank</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene (Suzhou) Co., Ltd.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RMB200,000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-year</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 29, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,177&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shanghai Pudong Development Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene, Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RMB700,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-year</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 24, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">679,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Merchants Bank</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene (Suzhou) Co., Ltd.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RMB200,000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-year</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 24, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,037&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="33" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total short-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">851,529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,215,538&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">688,366&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,885,838&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Construction Bank</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene Guangzhou Biologics Manufacturing Co., Ltd.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;RMB580,000 </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9-year</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 11, 2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,174&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">420,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Merchants Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene Guangzhou Biologics Manufacturing Co., Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RMB350,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;9-year</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 20, 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,638&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">267,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Merchants Bank</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene Guangzhou Biologics Manufacturing Co., Ltd.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;RMB378,000 </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9-year </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 8, 2029</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,020&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">241,025&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,337&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China CITIC Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene (Suzhou) Co., Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RMB480,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-year </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 28, 2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">469,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166,484&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,215,211&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197,618&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,402,643&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt">The outstanding borrowings bear floating interest rates benchmarking RMB loan interest rates of financial institutions in the PRC. The loan interest rate was 4.2% as of December&#160;31, 2024. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Company repaid </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$13,739 (or RMB100,000) during the year ended December&#160;31, 2024. The loan is secured by BeiGene Guangzhou Biologics Manufacturing Co., Ltd.&#8217;s property ownership certificate and fixed assets. </span></div><div style="margin-bottom:9pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt">The outstanding borrowings bear floating interest rates benchmarking RMB loan interest rates of financial institutions in the PRC. The loan interest rate was 3.7% as of December&#160;31, 2024. The Company repaid $8,730 (RMB62,857) during the year ended December&#160;31, 2024. The loan is secured by Guangzhou Factory&#8217;s second land use right and certain fixed assets.</span></div><div style="margin-bottom:9pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt">The outstanding borrowings bear floating interest rates benchmarking RMB loan interest rates of financial institutions in the PRC. The loan interest rate was 3.8% as of December&#160;31, 2024. The Company repaid $5,562 (RMB40,000) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">during the year ended December&#160;31, 2024. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The loan is secured by fixed assets that will be placed into service upon completion of the third phase of the Guangzhou manufacturing facility&#8217;s build out. </span></div><div style="margin-bottom:9pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt">The outstanding borrowings bear a floating interest rate benchmarked against prevailing interest rates of certain PRC financial institutions. The loan interest rate was 3.7% as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The Company drew down $9,053 (RMB65,000) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">during the year ended December&#160;31, 2024. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The loan is secured by BeiGene (Suzhou) Co., Ltd.&#8217;s property ownership certificate of the small molecule manufacturing campus in Suzhou, China. </span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:12pt">The outstanding borrowings bear floating interest rates benchmarking the secured overnight financing rate. The loan interest rate was 6.2% as of December&#160;31, 2024. $80,000 of the borrowing matures on January 27, 2025, and $300,000 matures on December 17, 2025.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt">The outstanding borrowings bear floating interest rates benchmarking RMB loan interest rates of financial institutions in the PRC. The loan interest rate was 2.6% as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt">The outstanding borrowings bear floating interest rates benchmarking Hong Kong interbank market rate for RMB. The loan interest rate was 4.4% as of December&#160;31, 2024.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has numerous financial and non-financial covenants on its debt obligations with various banks and other lenders. Some of these covenants include default and/or cross-default provisions that could require acceleration of repayment of loans in the event of default. However, the Company&#8217;s debt is primarily short-term in nature. Any acceleration would be a matter of months but may impact the Company&#8217;s ability to refinance debt obligations if an event of default occurs. As of December&#160;31, 2024, the Company is in compliance with all covenants of our material debt agreements.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contractual Maturities of Debt Obligations</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate contractual maturities of all borrowings due subsequent to December&#160;31, 2024 are as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity dates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December&#160;31,&#160;2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851,529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December&#160;31,&#160;2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,207&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31, 2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,657&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31, 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,756&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018,013&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:4pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on bank loans is paid quarterly until the respective loans are fully settled. Interest expense recognized for the years ended December&#160;31, 2024, 2023 and 2022 amounted to $46,894, $20,800 and $21,699, respectively, among which, $32,158, $16,571 and $2,594 was capitalized, respectively. Interest paid for the years ended December&#160;31, 2024, 2023 and 2022, net of amounts capitalized, amounted to $19,723, $3,484 and $22,489, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914413446048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Product Revenue</a></td>
<td class="text">Product Revenue<div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s product revenue is primarily derived from the sale of its internally developed products BRUKINSA and TEVIMBRA in the U.S., China, and other regions; XGEVA, BLINCYTO and KYPROLIS in China under a license from Amgen; REVLIMID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and VIDAZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in China under a license from BMS; and POBEVCY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in China under a license from Bio-Thera.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the Company&#8217;s net product sales for the years ended December&#160;31, 2024, 2023 and 2022.</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue - gross</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,786,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,718,969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,438,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Rebates and sales returns</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,007,198)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(529,117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183,828)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue - net</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,779,546&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,189,852&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254,612&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table disaggregates net product revenue by product for the years ended December&#160;31, 2024, 2023 and 2022.</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BRUKINSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,644,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,290,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tislelizumab</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620,836&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536,620&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422,885&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BLINCYTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,331&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,342&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,107&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">POBEVCY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,509&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,547&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,124&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REVLIMID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,042&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,302&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,702&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenue - net</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,779,546&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,189,852&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254,612&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the roll-forward of accrued sales chargebacks, rebates, returns and other deductions for the years ended December&#160;31, 2024 and 2023.</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates, Returns and Other Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contra AR Accruals</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,817&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts charged against product revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176,912)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232,231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(409,143)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,936&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,435&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,371&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts charged against product revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(396,092)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(495,178)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(891,270)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,699&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,299&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914413499216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss Per Share</a></td>
<td class="text">Loss Per Share<div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss per share was calculated as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(644,786)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(881,708)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,003,815)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding for computing basic and diluted loss per share</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,368,746,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,357,034,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340,729,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.47)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.65)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.49)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2024, 2023 and 2022, the computation of basic loss per share using the two-class method was not applicable, as the Company was in a net loss position.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of all share options and restricted share units were excluded from the calculation of diluted loss per share as their effect would have been anti-dilutive during the years ended December&#160;31, 2024, 2023 and 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914419157008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based Compensation<div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2016 Share Option and Incentive Plan</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2016, in connection with its U.S. IPO, the board of directors and shareholders of the Company approved the 2016 Share Option and Incentive Plan (the &#8220;2016 Plan&#8221;), which became effective in February 2016. The Company initially reserved 65,029,595 ordinary shares for the issuance of awards under the 2016 Plan, plus any shares available under the 2011 Option Plan (the &#8220;2011 Plan&#8221;), and not subject to any outstanding options as of the effective date of the 2016 Plan, along with underlying share awards under the 2011 Plan that are cancelled or forfeited without issuance of ordinary shares. As of December&#160;31, 2024, ordinary shares cancelled or forfeited under the 2011 Plan that were carried over to the 2016 Plan totaled 5,166,900. The 2016 Plan provided for an annual increase in the shares available for issuance, to be added on the first day of each fiscal year, beginning on January 1, 2017, equal to the lesser of (i) five percent (5%)% of the outstanding shares of the Company&#8217;s ordinary shares on the last day of the immediately preceding fiscal year or (ii) such number of shares determined by the Company&#8217;s board of directors or the compensation committee. On January 1, 2018, 29,603,616 ordinary shares were added to the 2016 Plan under this provision. However, in August 2018, in connection with the Hong Kong IPO, the board of directors of the Company approved an amended and restated 2016 Plan to remove this &#8220;evergreen&#8221; provision and implement other changes required by the Hong Kong Stock Exchange (&#8220;HKEx&#8221;) rules. In December 2018, the shareholders of the Company approved a second amended and restated 2016 Plan to increase the number of shares authorized for issuance by 38,553,159 ordinary shares, as well as amend the cap on annual compensation to independent directors and make other changes. In June 2020, the shareholders approved an Amendment No. 1 to the 2016 Plan to increase the number of shares authorized for issuance by 57,200,000 ordinary shares and to extend the term of the plan through April 13, 2030. The number of shares available for issuance under the 2016 Plan is subject to adjustment in the event of a share split, share dividend or other change in the Company&#8217;s capitalization.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, share-based awards to acquire 83,064,175 ordinary shares were available for future grant under the 2016 Plan.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to continue to provide incentive opportunities under the 2016 Plan, the Board of Directors and shareholders of the Company approved an amendment to the 2016 Plan (the &#8220;Amendment No. 2&#8221;), which became effective as of June 22, 2022, to increase the number of authorized shares available for issuance under the 2016 Plan by 66,300,000 ordinary shares, or 5%, of the Company&#8217;s outstanding shares as of March 31, 2022. In June 2024, the shareholders approved a third amended and restated 2016 Plan to increase the number of shares authorized for issuance by 92,820,000. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Inducement Equity Plan</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the board of directors of the Company approved the 2018 Inducement Equity Plan (the &#8220;2018 Plan&#8221;) and reserved&#160;12,000,000&#160;ordinary shares to be used exclusively for grants of awards to individuals who were not previously employees of the Company or its subsidiaries, as a material inducement to the individual&#8217;s entry into employment with the Company or its subsidiaries, within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. The 2018 Plan was approved by the board of directors upon recommendation of the compensation committee, without shareholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The terms and conditions of the 2018 Plan, and the forms of award agreements to be used thereunder, are substantially similar to the 2016 Plan and the forms of award agreements thereunder. In August 2018, in connection with the listing of the Company&#8217;s ordinary shares on the HKEx, the board of directors of the Company approved an amended and restated 2018 Plan to implement changes required by the HKEx rules.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the effectiveness of Amendment No. 2 to the 2016 Plan, on June 22, 2022, the 2018 Plan was terminated to the effect that no new equity awards shall be granted under the plan but the outstanding equity awards under the plan shall continue to vest and/or be exercisable in accordance with their terms.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Employee Share Purchase Plan</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the shareholders of the Company approved the 2018 Employee Share Purchase Plan (the &#8220;ESPP&#8221;).&#160;Initially,&#160;3,500,000&#160;ordinary shares of the Company were reserved for issuance under the ESPP. In August 2018, in connection with the Hong Kong IPO, the board of directors of the Company approved an amended and restated ESPP to remove an &#8220;evergreen&#8221; share replenishment provision originally included in the plan and implement other changes required by the HKEx rules. In December 2018, the shareholders of the Company approved a second amended and restated ESPP to increase the number of shares authorized for issuance by 3,855,315 ordinary shares to 7,355,315 ordinary shares. In June 2024, the shareholders of the Company approved a fourth amended and restated ESPP to increase the number of shares authorized for issuance by 5,070,000 ordinary shares to 12,425,315 ordinary shares. The ESPP allows eligible employees to purchase the Company&#8217;s ordinary shares (including in the form of ADSs) at the end of each offering period, which will generally be six months, at a&#160;15%&#160;discount to the market price of the Company&#8217;s ADSs at the beginning or the end of each offering period, whichever is lower, using funds deducted from their payroll during the offering period. Eligible employees are able to authorize payroll deductions of up to&#160;10%&#160;of their eligible earnings, subject to applicable limitations.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarizes the shares issued under the ESPP:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Market Price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchase Price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">2</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Ordinary Shares Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ADS</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ordinary</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ADS</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ordinary</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Proceeds</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.69&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,178&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 29, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,021,397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">930,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The market price is the lower of the closing price on Nasdaq on the issuance date or the offering date, in accordance with the terms of the ESPP.</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The purchase price is the price which was discounted from the applicable market price, in accordance with the terms of the ESPP.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, 4,953,682 ordinary shares were available for future issuance under the ESPP.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share options</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, share options have a contractual term of 10 years and vest over a <span style="-sec-ix-hidden:f-1346">three</span>- to five-year period, with the first tranche vesting one calendar year after the grant date or the service relationship start date and the remainder of the awards vesting on a monthly basis thereafter. Restricted shares and restricted share units generally vest over a four-year period, with the first tranche vesting one calendar year after the grant date or the service relationship start date and the remainder of the awards vesting on a yearly basis thereafter, or sometimes vest upon the achievement of pre-specified performance conditions.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s share option activities under the 2011, 2016 and 2018 Plans:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant<br/>Date&#160;Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic&#160;Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,204,888&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,516,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,898,217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,296,634)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,526,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,817,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,974,331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,051&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,225,334)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,145,113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,180,301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,812,624)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,530,134)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,982,656&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.83</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429,581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,173,280&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,311,250&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the unrecognized compensation cost related to 15,137,970 unvested share options expected to vest was $82,424. This unrecognized compensation will be recognized over an estimated weighted-average amortization period of 2.4 years.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of employee share option awards vested during the years ended December&#160;31, 2024, 2023 and 2022 was $68,420, $61,121 and $62,548, respectively.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair value of options</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the binomial option-pricing model in determining the estimated fair value of the options granted. The model requires the input of highly subjective assumptions including the estimated expected stock price volatility and, the exercise multiple for which employees are likely to exercise share options. For expected volatilities, the trading history and observation period of the Company&#8217;s own share price is used in conjunction with historical price volatilities of ordinary shares of several comparable companies in the same industry as the Company. For the exercise multiple, the Company was not able to develop an exercise pattern as reference, thus the exercise multiple is based on management&#8217;s estimation, which the Company believes is representative of the future exercise pattern of the options. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury Bills yield curve in effect at the time of grant.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the range of fair values and the assumptions used to estimate those fair values of the share options granted in the years presented:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of ordinary share</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.72 ~ $9.19</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7.26 ~ $10.72</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.51 ~ $9.04</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8% ~ 4.6%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4% ~ 4.6%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8% ~ 3.9%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected exercise multiple</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57% ~ 58%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58% ~ 60%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51% ~ 60%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted share units</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s restricted share unit activities under the 2016 and 2018 Plans:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Numbers<br/>of&#160;Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant&#160;Date&#160;Fair&#160;Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,082,982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,707,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,533,586)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,859,892)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,397,173&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,573,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,862,598)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,707,546)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,401,023&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,693,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,251,477)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,012,471)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,830,667&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest at December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,956,067&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the unrecognized compensation cost related to unvested restricted share units expected to vest was $801,403. This unrecognized compensation will be recognized over an estimated weighted-average amortization period of 2.7 years.&#160;</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based compensation expense</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total share-based compensation cost recognized for the years ended December&#160;31, 2024, 2023 and 2022:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441,793&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,588&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303,162&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914413458448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive (Loss) Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Accumulated Other Comprehensive (Loss) Income</a></td>
<td class="text">Accumulated Other Comprehensive (Loss) Income<div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The movement of accumulated other comprehensive (loss) income was as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign&#160;Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains/Losses&#160;on<br/>Available-for-Sale<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension Liability Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,523)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,011)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,883)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,417)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,464)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,422)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,840)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net-current period other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,464)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,046&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,611)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,029)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87,987)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,494)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,446)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,565)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,753)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,353)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net-current period other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,565)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,942)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,542)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,552)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,436)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148,988)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The amounts reclassified from accumulated other comprehensive (loss) income were included in other (expense) income, net in the consolidated statements of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/220/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914424053104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text">Shareholders&#8217; Equity<div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2024, 2023 and 2022, the Company completed the following equity transactions:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">BMS Settlement</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 1, 2023, the Company entered into a Settlement and Termination Agreement (the &#8220;Settlement Agreement&#8221;) with BMS-Celgene and certain of its affiliates relating to the termination of the parties&#8217; ongoing contractual relationships, the previously-disclosed ongoing arbitration proceeding concerning ABRAXANE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;Arbitration&#8221;), the License and Supply Agreement (&#8220;LSA&#8221;), the Amended and Restated Quality Agreement (the &#8220;QA&#8221;), and the Share Subscription Agreement (the &#8220;SSA&#8221;), entered into by the parties in 2017 and 2018. Pursuant to the Settlement Agreement, the parties agreed to mutually dismiss the Arbitration and BMS-Celgene and its affiliates agreed to transfer 23,273,108 ordinary shares of the Company originally purchased in 2017, in each case subject to and in accordance with the terms and conditions of the Settlement Agreement. In consideration for the shares being returned, the Company agreed to drop its claims pursuant to the Settlement Agreement. Furthermore, the parties agreed to terminate the LSA and QA on December 31, 2023, subject to the Company&#8217;s right to continue selling all inventory of REVLIMID and VIDAZA until sold out or February 2025, whichever is earlier. The Settlement Agreement provides for a settlement and release by each party of claims arising from or relating to the Arbitration, the LSA, the QA and the SSA, as well as other disputes and potential disputes between the parties, in each case subject to and in accordance with the terms and conditions of the Agreement. The receipt of the shares occurred on August 15, 2023. The Company recorded a noncash gain upon receipt of $362,917, which represents the fair value on the day the shares were received. The gain was recorded within other (expense) income, net in the consolidated statements of operations. The shares were constructively retired during the year ended December 31, 2023. The Company recorded the amount of the cancelled shares in excess of par to additional paid-in capital.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914413068160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restricted Net Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_RestrictedNetAssetsDisclosureAbstract', window );"><strong>Restricted Net Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedAssetsDisclosureTextBlock', window );">Restricted Net Assets</a></td>
<td class="text">Restricted Net Assets<div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s ability to pay dividends may depend on the Company receiving distributions of funds from its PRC subsidiaries. Relevant PRC laws and regulations permit payments of dividends by the Company&#8217;s PRC subsidiaries only out of its retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. The results of operations reflected in the consolidated financial statements prepared in accordance with GAAP differ from those reflected in the statutory financial statements of the Company&#8217;s PRC subsidiaries.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the company law of the PRC, a domestic enterprise is required to provide statutory reserves of at least 10% of its annual after-tax profit until such reserve has reached 50% of its respective registered capital based on the enterprise&#8217;s PRC statutory accounts. A domestic enterprise is also required to provide discretionary surplus reserve, at the discretion of the Board of Directors, from the profits determined in accordance with the enterprise&#8217;s PRC statutory accounts. The aforementioned reserves can only be used for specific purposes and are not distributable as cash dividends. The Company&#8217;s PRC subsidiaries were established as domestic invested enterprises and therefore were subject to the above-mentioned restrictions on distributable profits.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2024, 2023 and 2022, no appropriation to statutory reserves was made, because the PRC subsidiaries had an accumulated deficit as of the end of such periods.&#160;</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these PRC laws and regulations, including the requirement to make annual appropriations of at least 10% of after-tax income and set aside as general reserve fund prior to payment of dividends, the Company&#8217;s PRC subsidiaries are restricted in their ability to transfer a portion of their net assets to the Company.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange and other regulations in the PRC may further restrict the Company&#8217;s PRC subsidiaries from transferring funds to the Company in the form of dividends, loans, and advances. As of December&#160;31, 2024 and 2023, amounts restricted were the net assets of the Company&#8217;s PRC subsidiaries, which, after intercompany eliminations, amounted to $1,709,961 and $2,114,277, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_RestrictedNetAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted Net Assets Disclosure [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_RestrictedNetAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for assets that are restricted in their use, generally by contractual agreements or regulatory requirements. This would include, but not limited to, a description of the restricted assets and the terms of the restriction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914534395056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">Employee Benefit Plans<div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Defined Contribution Plans</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Full-time employees of the Company in the PRC participate in a government mandated defined contribution plan, pursuant to which certain pension benefits, medical care, employee housing fund and other welfare benefits are provided to employees. Chinese labor regulations require that the Company&#8217;s PRC subsidiaries make contributions to the government for these benefits based on certain percentages of the employees&#8217; salaries. The Company has no legal obligation for the benefits beyond the contributions made. The total amounts for such employee benefits, which were expensed as incurred, were $101,779, $94,358 and $83,860 for the years ended December&#160;31, 2024, 2023 and 2022, respectively.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a defined contribution 401(k) savings plan (the &#8220;401(k) Plan&#8221;) for U.S. employees. The 401(k) Plan covers all U.S. employees, and allows participants to defer a portion of their annual compensation on a pretax or Roth basis. In addition, the Company has a matching contribution to the 401(k) Plan, which, in the 2024 plan year, matched dollar for dollar of eligible contributions up to 6%. Company contributions to the 401(k) Plan totaled $20,839, $15,316 and $10,298 in the years ended December&#160;31, 2024, 2023 and 2022, respectively. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a government mandated&#160;program to cover its employees in Switzerland for pension, death, or disability. The program is considered a defined contribution plan.&#160;Employer and employee contributions are made based on various percentages of salaries and wages that vary based on employee age and other factors.&#160;Company contributions into the program amounted to $3,825, $2,710, and $3,887 in the years ended December&#160;31, 2024, 2023 and 2022, respectively.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company contributions into defined contribution plans for the remaining subsidiaries were immaterial.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Defined Benefit Plan</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a defined benefit pension plan covering its employees in Switzerland (the &#8220;Swiss Plan&#8221;). This plan is a government mandated fund that provides benefits to employees upon retirement, death, or disability. Contributions are made based on various percentages of participants&#8217; salaries and wages determined based on participants&#8217; age and other factors. As of December&#160;31, 2024 and 2023, the projected benefit obligations under the Swiss Plan were approximately $80,199 and $70,600, respectively, and plan assets were approximately $63,794 and $55,605, respectively. The funded status of the Swiss Plan is included in other long-term liabilities in the accompanying consolidated balance sheets.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s annual contribution to the Swiss Plan is estimated to be approximately $3,922 in 2025 and is expected to evolve thereafter proportionally with changes in staffing and compensation levels, actuarial assumptions and actual investment returns on plan assets.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the total expected benefit payments to Swiss Plan participants in the following 10 years and have been estimated based on the same assumptions used to measure the Company&#8217;s benefit obligations as of December&#160;31, 2024:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.993%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.223%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December&#160;31,&#160;2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December&#160;31,&#160;2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31, 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31, 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,462&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914531368528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company had purchase commitments amounting to $131,944, of which $32,538 related to minimum purchase requirements for supply purchased from contract manufacturing organizations and $99,406 related to binding purchase order obligations of inventory from Amgen. The Company does not have any minimum purchase requirements for inventory from Amgen.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capital Commitments</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had capital commitments amounting to $48,347 for the acquisition of property, plant and equipment as of December&#160;31, 2024 related to various facilities across the globe.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Co-Development Funding Commitment</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Amgen Collaboration Agreement, the Company is responsible for co-funding global clinical development costs for the Amgen oncology pipeline assets up to a total cap of $1,250,000. The Company is funding its portion of the co-development costs by contributing cash and/or development services. As of December&#160;31, 2024, the Company&#8217;s remaining co-development funding commitment was $335,261.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Commitment</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had committed capital related to two equity method investments in the amount of $15,053. As of December&#160;31, 2024, the remaining capital commitment was $7,404 and is expected to be paid from time to time over the investment period.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Business Agreements</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements in the ordinary course of business with contract research organizations (&#8220;CROs&#8221;) to provide research and development services. These contracts are generally cancellable at any time by the Company with prior written notice.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also enters into collaboration agreements with institutions and companies to license intellectual property. The Company may be obligated to make future development, regulatory and commercial milestone payments and royalty payments on future sales of specified products associated with its collaboration agreements. Payments under these agreements generally become due and payable upon achievement of such milestones or sales. These commitments are not recorded on the consolidated balance sheet because the achievement and timing of these milestones are not fixed and determinable. When the achievement of these milestones or sales have occurred, the corresponding amounts are recognized in the consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914419346832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment and Geographic Information</a></td>
<td class="text">Segment and Geographic Information<div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise for which separate financial information is available and evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company operates in one segment: pharmaceutical products. Its chief operating decision maker is the Chief Executive Officer, who makes operating decisions, assesses performance, and allocates resources on a consolidated basis. </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary measure of segment profitability for the Company&#8217;s operating segment is considered to be consolidated net loss. Significant segment expenses reviewed by the CODM on a regular basis included within net loss include cost of product sales, research and development expenses and selling, general and administrative expenses which are separately presented on the Company&#8217;s Consolidated Statements of Operations. Other segment items within net loss include interest income, net, other (expense) income, net and income tax expense. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s long-lived assets are primarily located in the U.S. and China.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by geographic area are based upon the location of the customer, and net collaboration revenue is recorded in the jurisdiction in which the related income is expected to be sourced from. Total net revenues by geographic area are presented as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. - total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,957,498</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,128,219</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">502,626</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,950,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">China- total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,411,307</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,101,951</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">840,032</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,390,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,093,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Europe- total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">362,626</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">202,014</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63,257</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rest of world- total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">78,810</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,595</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,006</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,810&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,387)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,810,241</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,458,779</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,415,921</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914413447888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule I - Condensed Financial Information of Registrant<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract', window );"><strong>Condensed Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock', window );">Schedule I - Condensed Financial Information of Registrant</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Schedule I - Condensed Financial Information of Registrant</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BeiGene, Ltd.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Information of Parent Company</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Operations</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollars (&#8220;$&#8221;))</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353,903&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,801&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">711,006&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631,103&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865,953&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(711,006)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(631,103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(865,953)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(297,856)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,173,306)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(644,383)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(879,977)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,999,674)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(644,786)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(881,708)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,003,815)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BeiGene, Ltd.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Information of Parent Company</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Comprehensive Loss</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollars (&#8220;$&#8221;))</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:58.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(644,786)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(881,708)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,003,815)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax of nil:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,565)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,464)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90,421)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension liability adjustments, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,942)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,611)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized holding gain (loss), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,311)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(694,328)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(903,737)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,099,182)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BeiGene, Ltd.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Information of Parent Company</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Balance Sheets</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollars (&#8220;$&#8221;))</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:71.640%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">723,964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">249,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">785,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">649,151&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,509,435&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loans to subsidiaries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,731,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,030,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment in wholly owned subsidiaries</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,081,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,207,352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114,728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,576,480&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,816,397&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other payables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">424,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indebtedness to subsidiaries</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">362,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">762,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">547,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,186,257&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,107,421&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171,649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,244,257&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,279,070&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,332,223&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,537,327&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,576,480&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,816,397&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BeiGene, Ltd.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Information of Parent Company</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Cash Flows</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollars (&#8220;$&#8221;))</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:58.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.793%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(644,786)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(881,708)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,003,815)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of research and development cost share liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73,226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(55,294)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(96,402)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized (gains) losses in subsidiaries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(85,471)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">932,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other items, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(374,370)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(596,496)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other payables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">627,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(140,126)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">875,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(143,472)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,168,628)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(882,145)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,075)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,485)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale or maturity of short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">552,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,487,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of in-process research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(75,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment in subsidiaries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(406,624)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(883,328)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,675,908)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37,120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188,656&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(441,116)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(159,747)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,186,361)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from short-term loans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">813,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">547,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of short-term loans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(593,898)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(293,002)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(247,460)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from option exercises and employee share purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264,531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310,552&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95,693&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of foreign exchange rate changes, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,356)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents, and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(324,413)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,017,823)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,972,813)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash, beginning of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">724,548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,742,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,715,184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash, cash equivalents, and restricted cash, end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400,135&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">724,548&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,742,371&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes</span></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Schedule I has been provided pursuant to the requirements of Rules 12-04(a) and 5-04(c) of Regulation S-X (the &#8220;Rules&#8221;), which require condensed financial information as to the financial position, changes in financial position and results of operations of a parent company as of the same dates and for the same periods for which audited consolidated financial statements have been presented when the restricted net assets of consolidated subsidiaries exceed 25 percent of consolidated net assets as of the end of the most recently completed fiscal year.</span></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The condensed financial information has been prepared using the same accounting policies as set out in the consolidated financial statements. For purposes of this condensed financial information, BeiGene, Ltd. (the &#8220;Parent Company&#8221;)&#8217;s investments in its wholly owned and majority owned subsidiaries are recorded under the equity method of accounting in accordance with ASC 323.</span></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted as allowed under the Rules. These footnote disclosures provide certain supplemental information relating to the operations of the Company and, as such, these statements should be read in conjunction with the notes to the consolidated financial statements.</span></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">As of December&#160;31, 2024, the Parent Company had a remaining capital commitment of $7,350 on an equity investment which is expected to be paid from time to time over the investment period. The Parent Company has unconditionally guaranteed the payment and performance of the obligations of BeiGene Switzerland GmbH in accordance with the terms of the global strategic oncology collaboration with Amgen Inc. No amounts have been recognized related to this guarantee. The Parent Company has no other material contingencies, long-term obligations or guarantees not already disclosed in its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914419163008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (644,786)<span></span>
</td>
<td class="num">$ (881,708)<span></span>
</td>
<td class="num">$ (2,003,815)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914421496320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914421308864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914415307968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the importance of safeguarding the security of our computer systems, software, networks, and other technology assets. Our cybersecurity efforts are aimed at preserving the confidentiality, integrity, and continued availability of information under our ownership or care with the aim to continually improve security features in order to keep pace with the evolving cyber threat landscape.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview of Cybersecurity Risk Management and Strategy</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-right:4.5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity risk identification, assessment and management process is a critical part of our overall enterprise risk management (&#8220;ERM&#8221;) system. Within our ERM system, we adhere to our Information Security Management Policy (&#8220;ISM Policy&#8221;) which is aimed at providing guidelines to monitor, review and continually improve our Information Security Management System (&#8220;ISMS&#8221;). Our ISMS is informed by ISO/IEC 27001:2022 standards and is operated based on an action model that identifies information security missions and objectives, including improvement measures to achieve continuous optimization. Our Cybersecurity Incident Response Plan (&#8220;CIRP&#8221;) is a critical component of our cybersecurity incident identification and management process, which, along with our incident response team, is designed to guide our response to potential cybersecurity incidents effectively and efficiently. Our ISM Policy, ISMS and CIRP are all internal processes we use to assess, identify and manage material risks from cybersecurity threats.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also utilize external partnerships to help protect the Company from cybersecurity threats. This combination of people, processes and technology assist us to proactively manage and mitigate threats to our information technology environment. We have controls in place to defend against risks associated with cyber-attacks impacting our operations, compliance and financial reporting objectives. We are externally audited and certified under the ISO 27001 and assessed yearly according to National Institute of Standards and Technology (&#8220;NIST&#8221;) guidelines. Our external partners also evaluate our cybersecurity maturity and coverage as part of their services and keep us informed of emerging global threats. </span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-right:4.5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct a Testing, Training &amp; Exercise program to test, sustain and refine our ability to respond to cybersecurity incidents in accordance with the best practices. We also maintain an information security training program for our employees.  </span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-right:4.5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Third-Party Security Management Standard provides a framework for managing third-party information security risks and defines controls to minimize risks to the Company. It applies to third parties who have access to or process Company information. This framework includes processes for conducting, as appropriate, due diligence, risk assessment and planning, contract management, access control, ongoing monitoring, and possible service termination of, or changes to the third-party as part of the selection and management process.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-right:4.5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have implemented a Threat Intelligence function that informs of external cyber threats which allows us to proactively protect the Company and to allow us to improve the speed of our vulnerability management capabilities.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cybersecurity threats have to date not materially affected us, our business strategy, results of operations or financial condition. Similar to other companies, we and our third-party vendors have and will continue to experience threats to our systems and data.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the importance of safeguarding the security of our computer systems, software, networks, and other technology assets. Our cybersecurity efforts are aimed at preserving the confidentiality, integrity, and continued availability of information under our ownership or care with the aim to continually improve security features in order to keep pace with the evolving cyber threat landscape.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text">The Board of Directors (&#8220;Board&#8221;) oversees risk management related to the operation of the business and corporate functions as well as the implementation of business strategy. Our Board has delegated to the Audit Committee oversight of risk management, which includes risks from cybersecurity threats. We routinely review critical elements of our cybersecurity policies and program with the Audit Committee.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;padding-right:4.5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The management team &#8211; including our Chief Information Security Officer (&#8220;CISO&#8221;) &#8211; provides periodic reports to the Audit Committee which cover cybersecurity and other information technology risks affecting the Company. Such reports are typically provided at an Audit Committee meeting and enable Audit Committee members to ask questions of management and engage in additional discussions in an open forum. The Audit Committee also periodically evaluates our overall cybersecurity strategy.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;padding-right:4.5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The management team &#8211; including our Chief Information Security Officer (&#8220;CISO&#8221;) &#8211; provides periodic reports to the Audit Committee which cover cybersecurity and other information technology risks affecting the Company. Such reports are typically provided at an Audit Committee meeting and enable Audit Committee members to ask questions of management and engage in additional discussions in an open forum. The Audit Committee also periodically evaluates our overall cybersecurity strategy.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Role in Assessing and Managing Material Risks from Cybersecurity Threats</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Information Security Steering Committee (&#8220;ISSC&#8221;) is responsible for oversight of matters related to information security and currently consists of professionals in legal operations and risk management, information governance, human resources operations, internal audit, computerized systems, global security and technical operations, and research technology, all whose input bring significant value when assessing and managing cybersecurity risk. Our ISSC meets periodically and is presented with an update on cybersecurity matters from our CISO. Our CISO is responsible for facilitating the implementation of the plans and decisions made by the ISSC and directly provides updates to the Audit Committee as detailed above.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Vice President of Global Technology Solutions head our Global Technology Solutions Team along with our CISO are responsible for leading the individuals tasked with maintaining our enterprise-wide cyber resilience strategy, policy, standards, architecture, and processes. Our CISO has over eighteen years of information technology and cybersecurity experience in multiple industries, including building and leading governance, risk, and compliance functions that cover ISO 27001 certified compliance, NIST Cybersecurity Framework assessments, Sarbanes-Oxley (&#8220;SOX&#8221;) information technology compliance, regional compliances, policy management, information technology risk management, vendor risk management, and security awareness. Our Vice President of Global Technology Solutions has over twenty years of experience leading technology organization and managing information security across multiple industries, including SOX 404 compliance, GxP audit and compliance, NIST Cybersecurity Framework assessments, managing incident response and communication with executives and board of directors.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Information Security Steering Committee (&#8220;ISSC&#8221;) is responsible for oversight of matters related to information security and currently consists of professionals in legal operations and risk management, information governance, human resources operations, internal audit, computerized systems, global security and technical operations, and research technology, all whose input bring significant value when assessing and managing cybersecurity risk. Our ISSC meets periodically and is presented with an update on cybersecurity matters from our CISO. Our CISO is responsible for facilitating the implementation of the plans and decisions made by the ISSC and directly provides updates to the Audit Committee as detailed above.</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Vice President of Global Technology Solutions head our Global Technology Solutions Team along with our CISO are responsible for leading the individuals tasked with maintaining our enterprise-wide cyber resilience strategy, policy, standards, architecture, and processes. Our CISO has over eighteen years of information technology and cybersecurity experience in multiple industries, including building and leading governance, risk, and compliance functions that cover ISO 27001 certified compliance, NIST Cybersecurity Framework assessments, Sarbanes-Oxley (&#8220;SOX&#8221;) information technology compliance, regional compliances, policy management, information technology risk management, vendor risk management, and security awareness. Our Vice President of Global Technology Solutions has over twenty years of experience leading technology organization and managing information security across multiple industries, including SOX 404 compliance, GxP audit and compliance, NIST Cybersecurity Framework assessments, managing incident response and communication with executives and board of directors.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;padding-right:4.5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The management team &#8211; including our Chief Information Security Officer (&#8220;CISO&#8221;) &#8211; provides periodic reports to the Audit Committee which cover cybersecurity and other information technology risks affecting the Company. Such reports are typically provided at an Audit Committee meeting and enable Audit Committee members to ask questions of management and engage in additional discussions in an open forum. The Audit Committee also periodically evaluates our overall cybersecurity strategy.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Role in Assessing and Managing Material Risks from Cybersecurity Threats</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Information Security Steering Committee (&#8220;ISSC&#8221;) is responsible for oversight of matters related to information security and currently consists of professionals in legal operations and risk management, information governance, human resources operations, internal audit, computerized systems, global security and technical operations, and research technology, all whose input bring significant value when assessing and managing cybersecurity risk. Our ISSC meets periodically and is presented with an update on cybersecurity matters from our CISO. Our CISO is responsible for facilitating the implementation of the plans and decisions made by the ISSC and directly provides updates to the Audit Committee as detailed above.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">Our CISO has over eighteen years of information technology and cybersecurity experience in multiple industries, including building and leading governance, risk, and compliance functions that cover ISO 27001 certified compliance, NIST Cybersecurity Framework assessments, Sarbanes-Oxley (&#8220;SOX&#8221;) information technology compliance, regional compliances, policy management, information technology risk management, vendor risk management, and security awareness. Our Vice President of Global Technology Solutions has over twenty years of experience leading technology organization and managing information security across multiple industries, including SOX 404 compliance, GxP audit and compliance, NIST Cybersecurity Framework assessments, managing incident response and communication with executives and board of directors<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">Our Vice President of Global Technology Solutions head our Global Technology Solutions Team along with our CISO are responsible for leading the individuals tasked with maintaining our enterprise-wide cyber resilience strategy, policy, standards, architecture, and processes.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914415041152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of PresentationThe consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">Principles of ConsolidationThe consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany transactions and balances between the Company and its wholly-owned subsidiaries are eliminated upon consolidation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Areas where management uses subjective judgment include, but are not limited to, estimating the useful lives of long-lived assets, estimating variable consideration in product sales and collaboration revenue arrangements, identifying separate accounting units and the standalone selling price of each performance obligation in the Company&#8217;s revenue arrangements, assessing the impairment of long-lived assets, valuation and recognition of share-based compensation expenses, estimating uncertain tax positions, valuation of inventory, estimating the allowance for credit losses, determining defined benefit pension plan obligations, measurement of right-of-use assets and lease liabilities and the fair value of financial instruments. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from these estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Functional Currency and Foreign Currency Translation</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Functional Currency and Foreign Currency Translation</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Functional currency and foreign currency gains and losses</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the U.S. dollar (&#8220;$&#8221; or U.S. dollar) as its reporting currency. Transactions in subsidiaries are recorded in the functional currency of the respective subsidiary and such transactions denominated in currencies other than the functional currency give rise to foreign exchange remeasurement (monetary assets and liabilities) and related gains and losses that are classified in other (expense) income, net in the consolidated statement of operations. The determination of functional currency is based on the criteria of Accounting Standard Codification (&#8220;ASC&#8221;) 830, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Matters</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For those periods presented, the Company has not entered into any foreign currency derivative instruments to hedge its foreign currency positions.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency translation</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For subsidiaries whose functional currencies are not the U.S. dollar, the Company uses the average exchange rate for the period and the exchange rate at the balance sheet date to translate the operating results and financial position to the U.S. dollar, which is the Company's reporting currency. Translation differences are recorded in accumulated other comprehensive loss, a component of shareholders&#8217; equity.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy', window );">Cash and cash equivalents</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash on hand and bank deposits, which are unrestricted as to withdrawal and use. The Company considers all highly liquid investments with an original maturity date of three months or less at the date of purchase to be cash equivalents. Cash equivalents which consist primarily of money market funds are stated at fair value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted cash</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted cash</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash primarily consists of&#160;RMB-denominated cash deposits pledged in designated bank accounts as collateral for bank loans and letters of credit. The Company classifies restricted cash as current or non-current based on the term of the restriction.</span></div>In addition to the restricted cash balances above, the Company is required by the PRC securities law to use the proceeds from the STAR offering in strict compliance with the planned uses as disclosed in the PRC offering prospectus as well as those disclosed in the Company&#8217;s proceeds management policy approved by its board of directors.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock', window );">Accounts Receivable and Allowance for Credit Losses</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Credit Losses</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are recorded at their invoiced amounts, net of trade discounts and allowances as well as an allowance for credit losses. The allowance for credit losses reflects the Company&#8217;s current estimate of credit losses expected to be incurred over the life of the receivables. The Company considers various factors in establishing, monitoring, and adjusting its allowance for credit losses including the aging of receivables and aging trends, customer creditworthiness and specific exposures related to particular customers. The Company also monitors other risk factors and forward-looking information, such as country specific risks and economic factors that may affect a customer&#8217;s ability to pay in establishing and adjusting its allowance for credit losses. Accounts receivable are written off after all collection efforts have ceased.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable and Allowance for Credit Losses</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Credit Losses</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade accounts receivable are recorded at their invoiced amounts, net of trade discounts and allowances as well as an allowance for credit losses. The allowance for credit losses reflects the Company&#8217;s current estimate of credit losses expected to be incurred over the life of the receivables. The Company considers various factors in establishing, monitoring, and adjusting its allowance for credit losses including the aging of receivables and aging trends, customer creditworthiness and specific exposures related to particular customers. The Company also monitors other risk factors and forward-looking information, such as country specific risks and economic factors that may affect a customer&#8217;s ability to pay in establishing and adjusting its allowance for credit losses. Accounts receivable are written off after all collection efforts have ceased.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Prior to the regulatory approval of product candidates, the Company may incur costs for the manufacture of drug product to support the commercial launch of those products. Until the date at which regulatory approval has been received or is otherwise considered probable, all such costs are recorded as research and development expenses as incurred. </span></div>Inventories are stated at the lower of cost and net realizable value, with cost determined in a manner that approximates weighted average cost. The Company periodically analyzes its inventory levels, and writes down inventory that has become obsolete, inventory that has a cost basis in excess of its estimated realizable value and inventory in excess of expected sales requirements as cost of product sales. The determination of whether inventory costs will be realizable requires estimates of future prices by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required, which would be recorded in the consolidated statements of operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consist of available-for-sale debt securities, convertible note instruments, public equity securities with readily determinable fair values, private equity securities without readily determinable fair values, and equity-method investments. The classification of an investment is determined based on the nature of the investment, the Company&#8217;s ability and intent to hold the investment, and the degree to which the Company may exercise influence over the investee.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Available-for-sale debt securities are stated at fair value, with the unrealized gains and losses, net of tax, reported in other comprehensive loss. The net carrying value of debt securities classified as available-for-sale is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization is computed using the effective interest method and included in interest income. Interest and dividends are included in interest income. Available-for-sale debt securities with original maturities greater than three months at the date of purchase and less than one year from the date of the balance sheet are classified as short-term. Available-for-sale debt securities with maturities beyond one year may be classified as short-term marketable securities due to their highly liquid nature and because they represent the Company&#8217;s investments that are available for current operations.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Convertible note instruments are recorded using the fair value option method of accounting. Accordingly, convertible note instruments are remeasured at fair value on a recurring basis, with any changes in the fair value option recorded in other (expense) income, net.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Public equity securities with readily determinable fair values are recorded at fair value. Subsequent changes in fair value are recorded in other (expense) income, net. Derivative financial instruments to purchase public equity securities are recorded at fair value. The estimated fair value of derivative financial instruments is determined based on the Black-Scholes valuation model. Changes in fair value of derivative instruments are recorded in other (expense) income, net.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Private equity securities without readily determinable fair values and where the Company does not have significant influence are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Adjustments to private equity securities are recorded in other (expense) income, net. </span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Equity investments in common stock or in-substance common stock where the Company has significant influence over the financial and operating policies of the investee are accounted for as equity-method investments. Equity-method investments are initially recorded at cost and subsequently adjusted based on the Company&#8217;s percentage ownership in the investee&#8217;s income and expenses, as well as dividends, if any. The Company records its share of the investee&#8217;s results of operations in other (expense) income, net. The Company records impairment losses on our equity method investments if it deems the impairment to be other-than-temporary. The Company deems an impairment to be other-than-temporary based on various factors, including but not limited to, the length of time the fair value is below the carrying value and ability to retain the investment to allow for a recovery in fair value.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains or losses on sales of investments are determined based on the specific identification method.</span></div>The Company regularly evaluates its investments in debt and equity for impairment. The Company recognizes an allowance on available-for-sale debt securities when a portion of the unrealized loss is attributable to a credit loss and a corresponding credit loss in net income. No allowance for credit losses were recorded for any periods presented.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Property, plant and equipment, other than land and construction in progress, are depreciated using the straight-line method over the estimated useful lives of the respective assets as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful&#160;Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 10 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software, Electronic and Office Equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold Improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of useful life or lease term</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies ASC, Topic 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 842&#8221;) to account for its leases. The Company determines if an arrangement is a lease at inception. The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease component based on the Company&#8217;s policy election to combine lease and non-lease components for its leases. Leases are classified as operating or finance leases in accordance with the recognition criteria in ASC 842-20-25. The Company&#8217;s lease portfolio consists entirely of operating leases as of December&#160;31, 2024. The Company&#8217;s leases do not contain any material residual value guarantees or material restrictive covenants.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the commencement date of a lease, the Company determines the classification of the lease based on the relevant factors present and records a right-of-use (&#8220;ROU&#8221;) asset and lease liability. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and lease liabilities are calculated as the present value of the lease payments not yet paid. Variable lease payments not dependent on an index or rate are excluded from the ROU asset and lease liability calculations and are recognized in expense in the period which the obligation for those payments is incurred. As the rate implicit in the Company&#8217;s leases is not typically readily available, the Company uses an incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. This incremental borrowing rate reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. ROU assets include any lease prepayments and are reduced by lease incentives. Operating lease expense for lease payments is recognized on a straight-line basis over the lease term. Lease terms are based on the non-cancelable term of the lease and may contain options to extend the lease when it is reasonably certain that the Company will exercise that option. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases are included in operating lease right-of-use assets and operating lease liabilities on the consolidated balance sheet. Lease liabilities that become due within one year of the balance sheet date are classified as current liabilities.</span></div>Leases with an initial lease term of 12 months or less are not recorded on the consolidated balance sheet. Lease expense for these leases is recognized on a straight-line basis over the lease term.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_LandUseRightsPolicyPolicyTextBlock', window );">Land Use Right, Net</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Land Use Right, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div>All land in the PRC is owned by the PRC government. The PRC government may sell land use rights for a specified period of time. Land use rights represent operating leases in accordance with ASC 842. The purchase price of land use rights represents lease prepayments to the PRC government and is recorded as an operating lease ROU asset on the balance sheet. The ROU asset is amortized over the remaining lease term.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets acquired through business combinations are recognized as assets separate from goodwill and are measured at fair value upon acquisition. Intangible assets acquired in transactions that are not business combinations are recorded at the allocated portion of total consideration transferred based on their relative fair value in relation to net assets acquired. Intangible assets associated with milestone payments made to third parties subsequent to regulatory approval are recorded at cost. Identifiable intangible assets consist of post-approval milestone payments under license and commercialization agreements, that are amortized over the remainder of the product patent or the term of the commercialization agreements; and trading licenses that are amortized over the initial license term.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite useful lives are tested for impairment when events or circumstances occur that could indicate that the carrying amount of an asset may not be recoverable. When these events occur, the Company evaluates the recoverability of the intangible assets by comparing the carrying amount of the assets to the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected undiscounted cash flows is less than the carrying amount of the assets, the Company recognizes an impairment loss based on the excess of the carrying amount of the assets over their fair value. Fair value is generally determined by discounting the cash flows expected to be generated by the assets, when the market prices are not readily available. For the years ended December&#160;31, 2024, 2023 and 2022, the Company determined that there were no indicators of impairment of its other intangible assets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div>Long-lived assets are reviewed for impairment in accordance with authoritative guidance for impairment or disposal of long-lived assets. Long-lived assets are reviewed for events or changes in circumstances, which indicate that their carrying value may not be recoverable. Long-lived assets are reported at the lower of carrying amount or fair value less cost to sell.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair value of financial instruments</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies ASC topic 820 (&#8220;ASC 820&#8221;), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in measuring fair value. ASC 820 defines fair value, establishes a framework for measuring fair value and requires disclosures to be provided on fair value measurement. ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Include other inputs that are directly or indirectly observable in the marketplace.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Unobservable inputs which are supported by little or no market activity.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 820 describes three main approaches to measuring the fair value of assets and liabilities: (1) market approach; (2) income approach; and (3) cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies ASC, Topic 606,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(&#8220;ASC 606&#8221;) to account for its revenue transactions. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Company recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Revenue</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. and EU, the Company generates product revenues from the sale of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BRUKINSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and TEVIMBRA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In China, the Company generates product revenues from the sale of its internally developed drugs TEVIMBRA, BRUKINSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and PARTRUVIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and the sale of in-licensed products through its agreements with Amgen, BMS, Bio-Thera, EUSA Pharma and Luye Pharmaceutical.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under the commercial profit share arrangement with Amgen, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company is the principal for in-licensed product sales to customers in China during the commercialization period and recognizes 100% of net product revenue on these sales. Amounts due to Amgen for its portion of net product sales are recorded as cost of sales. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the Company distributes its products through specialty pharmacies and specialty distributors. The specialty pharmacies and specialty distributors subsequently resell the product to health care providers and patients. In the EU, the Company distributes its products through distributors or directly to hospitals. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In China, the Company sells its internally developed products to multiple distributors, who in turn sell the product to hospitals or pharmacies within their authorized territories to be sold ultimately to patients. In-licensed products are sold to a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">first tier distributor who subsequently resells the products to second tier distributors who ultimately sell the products to health care providers and patients.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is the principal under the product sales as the Company controls the products with the ability to direct the use of, and obtain substantially all the remaining benefits from the products before they are sold to the customer. For product sales transactions, the Company has a single performance obligation which is to sell the products to its customer. The Company includes variable consideration in the transaction price to the extent it is probable that a significant reversal will not occur and estimates variable consideration from rebates, chargebacks, trade discounts and allowances, sales returns allowances and other incentives using the expected value method. Revenues for product sales are recognized at a point in time when the single performance obligation is satisfied upon delivery to the customer. The Company&#8217;s payment terms are approximately 30-90 days. Actual amounts of consideration ultimately received may differ from the Company&#8217;s estimates.&#160;The Company will reassess estimates for variable consideration periodically. If actual results in the future vary from the Company&#8217;s estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates for variable consideration for which reserves are established at the time of sale include government and commercial rebates, provisions for acceptance of National Reimbursement Drug List (&#8220;NRDL&#8221;) pricing in the PRC, chargebacks, trade discounts and allowances, sales returns allowances and other incentives that are offered within contracts between the Company and its customers, health care providers and other indirect customers. Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as the Company's historical experience, current contractual and statutory requirements, channel inventory levels, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The Company bases its sales returns allowance on estimated distributor inventories, customer demand as reported by third-party sources, and actual returns history, as well as other factors, as appropriate. To date, sales returns have not been significant.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration Revenue</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808,&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;(&#8220;ASC 808&#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities.&#160;For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and therefore within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the five-step model under ASC 606 noted above. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s collaborative arrangements may contain more than one unit of account, or performance obligation, including grants of licenses to intellectual property rights, agreement to provide research and development services and other deliverables. The collaborative arrangements do not include a right of return for any deliverable. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.&#160;In developing the stand-alone selling price for a performance obligation, the Company considers competitor pricing for a similar or identical product, market awareness of and perception of the product, expected product life and current market trends. In general, the consideration allocated to each performance obligation is recognized when the respective obligation is satisfied either by delivering a good or providing a service, limited to the consideration that is not constrained. Non-refundable payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as advances from customers.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Licenses of Intellectual Property:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Upfront non-refundable payments for licensing the Company&#8217;s intellectual property are evaluated to determine if the license is distinct from the other performance obligations identified in the arrangement. For licenses determined to be distinct, the Company recognizes revenues from non-refundable up-front fees allocated to the license at a point in time, when the license is transferred to the licensee and the licensee is able to use and benefit from the license.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Options to License Intellectual Property:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Upfront non-refundable payments for options to license the Company&#8217;s intellectual property are evaluated to determine if the option represents a material right and is distinct from the other performance obligations identified in the arrangement. For options determined to be a material right and distinct, the Company defers the non-refundable up-front fees allocated to the option and recognizes revenues at a point in time, at the earlier of when the option is exercised or the option period expires.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Right to Access Intellectual Property during the Option Period:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The portion of a transaction price allocated to the other parties right to access the Company&#8217;s intellectual property to generate their own data during an option period is deferred and recognized as collaboration revenue over the option period on a straight-line basis as the right to use the intellectual property is provided and the data generated. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Services:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The portion of a transaction price allocated to research and development services performance obligations is deferred and recognized as collaboration revenue over time as delivery or performance of such services occurs.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Payments: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.&#160;If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.&#160;Milestones related to the Company&#8217;s development-based activities may include initiation of various phases of clinical trials. Due to the uncertainty involved in meeting these development-based targets, they are generally fully constrained at contract inception. The Company will assess whether the variable consideration is fully constrained each reporting period based on the facts and circumstances surrounding the clinical trials. Upon changes to constraint associated with the developmental milestones, variable consideration will be included in the transaction price when a significant reversal of revenue recognized is not expected to occur and allocated to the separate performance obligations. Regulatory milestones are fully constrained until the period in which those regulatory approvals are achieved due to the inherent uncertainty with the approval process. Regulatory milestones are included in the transaction price in the period regulatory approval is obtained. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of the costs associated with our research and development activities, conducting preclinical studies and clinical trials, and activities related to regulatory filings, which primarily include (i) payroll and related costs (including share-based compensation) associated with research and development personnel, (ii) costs related to clinical trials and preclinical testing of the Company&#8217;s technologies under development, (iii) costs to develop the product candidates, including raw materials and supplies, product testing, depreciation, and facility related expenses, (iv) expenses for research services provided by universities and contract laboratories, including sponsored research funding, and (v) other research and development expenses. Research and development expenses are charged to expense as incurred when these expenditures relate to the Company&#8217;s research and development services and have no alternative future uses.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial costs are a significant component of the Company&#8217;s research and development expenses. The Company has a history of contracting with third parties that perform various clinical trial activities on behalf of the Company in the ongoing development of the Company&#8217;s product candidates. Expenses related to clinical trials are accrued based on the Company&#8217;s estimates of the actual services performed by the third parties for the respective period. If the contracted amounts are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), the Company will modify the related accruals accordingly on a prospective basis. Revisions in the scope of a contract are charged to expense in the period in which the facts that give rise to the revision become probable. </span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquired In-Process Research and Development Expense</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has acquired rights to develop and commercialize product candidates. Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments (prior to government approval), are immediately expensed as acquired in-process research and development in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#8220;business&#8221; as defined under GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. Milestone payments made to third parties subsequent to regulatory approval are capitalized as intangible assets and amortized over the estimated remaining useful life of the related product. Royalties owed on sales of the products licensed pursuant to the agreements are expensed in the period the related revenues are recognized.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_GovernmentGrantsPolicyPolicyTextBlock', window );">Government Grants</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Grants</span></div>Government financial incentives that involve no conditions or continuing performance obligations of the Company are recognized as other income upon receipt.<div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event government grants or incentives involve continuing performance obligations, the Company will capitalize the payment as a liability and recognize the same financial statement caption as the performance obligation relates over the performance period. The Company received government assistance in the form of cash primarily to support the Guangzhou manufacturing facility build-out and research and development programs.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is defined as the changes in equity of the Company during a period from transactions and other events and circumstances excluding transactions resulting from investments by owners and distributions to owners. Among other disclosures, ASC 220, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, requires that all items that are required to be recognized under current accounting standards as components of comprehensive loss be reported in a financial statement that is displayed with the same prominence as other financial statements. For each of the periods presented, the Company&#8217;s comprehensive loss includes net loss, foreign currency translation adjustments, pension liability adjustments and unrealized holding gains/losses associated with the available-for-sale debt securities, and is presented in the consolidated statements of comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Awards granted to employees</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies ASC 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation&#8212;Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 718&#8221;), to account for its employee share-based payments. In accordance with ASC 718, the Company determines whether an award should be classified and accounted for as a liability award or equity award. All the Company&#8217;s grants of share-based awards to employees were classified as equity awards and are recognized in the financial statements based on their grant date fair values. Specifically, the grant date fair value of share options is calculated using an option pricing model. The fair value of restricted shares and restricted share units are based on the closing market price of our ADSs on the Nasdaq Global Select Market on the date of grant. The Company has elected to recognize compensation expense using the straight-line method for all employee equity awards granted with graded vesting based on service conditions provided that the amount of compensation cost recognized at any date is at least equal to the portion of the grant-date value of the options that are vested at that date. The Company uses the accelerated method for all awards granted with graded vesting based on performance conditions. To the extent the required vesting conditions are not met resulting in the forfeiture of the share-based awards, previously recognized compensation expense relating to those awards are reversed. </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in the subsequent period if actual forfeitures differ from initial estimates. Forfeiture rates are estimated based on historical and future expectations of employee turnover rates and are adjusted to reflect future changes in circumstances and facts, if any. Share-based compensation expense is recorded net of estimated forfeitures such that expense is recorded only for those share-based awards that are expected to vest. To the extent the Company revises these estimates in the future, the share-based payments could be materially impacted in the period of revision, as well as in following periods. The Company, with the assistance of an independent third-party valuation firm, determined the estimated fair value of the stock options granted to employees using the binomial option pricing model.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Awards granted to non-employees</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounted for equity instruments issued to non-employees in accordance with the provisions of ASC 718 and ASC 505, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All transactions in which goods or services are received in exchange for equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The grant date is the measurement date of the fair value of the equity instrument issued. The expense is recognized in the same manner as if the Company had paid cash for the services provided by the non-employees in accordance with ASC 505-50, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity-based payments to non-employees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company estimated the fair value of share options granted to non-employees using the same method as employees.&#160;</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Modification of awards</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in any of the terms or conditions of the awards is accounted for as a modification of the award. Incremental compensation cost is measured as the excess, if any, of the fair value of the modified award over the fair value of the original award immediately before its terms are modified, measured based on the fair value of the awards and other pertinent factors at the modification date. For vested awards, the Company recognizes incremental compensation cost in the period the modification occurs. For unvested awards, the Company recognizes over the remaining requisite service period, the sum of the incremental compensation cost and the remaining unrecognized compensation cost for the original award on the modification date. If the fair value of the modified award is lower than the fair value of the original award immediately before modification, the minimum compensation cost the Company recognizes is the cost of the original award.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using enacted tax rates that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its uncertain tax positions using the provisions of ASC 740, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Company recognizes in the financial statements the benefit of a tax position which is &#8220;more likely than not&#8221; to be sustained under examination based solely on the technical merits of the position assuming a review by tax authorities having all relevant information. Tax positions that meet the recognition threshold are measured using a cumulative probability approach, at the largest amount of tax benefit that has a greater than fifty percent likelihood of being realized upon settlement. It is the Company&#8217;s policy to recognize interest and penalties related to unrecognized tax benefits, if any, as a component of income tax expense.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Share</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Per Share</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share is calculated in accordance with ASC 260, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Basic loss per ordinary share is computed by dividing net loss attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period using the two-class method. Under the two-class method, net income is allocated between ordinary shares and participating securities based on dividends declared (or accumulated) and participating rights in undistributed earnings as if all the earnings for the reporting period had been distributed.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted loss per share, when required, is calculated by dividing net loss attributable to ordinary shareholders as adjusted for the effect of dilutive ordinary equivalent shares, if any, by the weighted average number of ordinary and dilutive ordinary equivalent shares outstanding during the period. Ordinary equivalent shares consist of the ordinary shares issuable upon the conversion of the Company&#8217;s convertible preferred shares, if any, using the if-converted method, and ordinary shares issuable upon the conversion of the share options, and unvested restricted shares units and performance-based restricted shares units (&#8220;PSUs&#8221;), using the treasury stock method. The dilutive effects of PSUs are included in the weighted average common share calculation based on the cumulative achievement against the performance targets only when the performance targets have been achieved as of the end of the reporting period.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ordinary share equivalents are excluded from the computation of diluted loss per share if their effects would be anti-dilutive. Basic and diluted loss per ordinary share is presented in the Company&#8217;s consolidated statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 280, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span>, the Company&#8217;s chief operating decision maker, the Chief Executive Officer, reviews the consolidated results when making decisions about allocating resources and assessing performance of the Company as a whole and hence, the Company has only one reportable segment: pharmaceutical products.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Risks</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risks</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of cash and credit risk</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that are potentially subject to credit risk consist of cash and cash equivalents and accounts receivable.</span></div>The deposits placed with financial institutions are not protected by statutory or commercial insurance. In the event of bankruptcy of one of these financial institutions, the Company may be unable to claim its deposits back in full. Management believes that these financial institutions are of high credit quality and continually monitors the credit worthiness of these financial institutions.The Company monitors economic conditions to identify facts or circumstances that may indicate receivables are at risk of collection.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">New accounting standards which have been adopted</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 280): Improvements to Reportable Segment Disclosures. This update requires disclosure of incremental segment information on an annual and interim basis. This update is effective for annual periods beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024. Early adoption is permitted. This guidance should be applied retrospectively to all prior periods presented in the financial statements. The Company operates in one segment. Its chief operating decision maker is the Chief Executive Officer, who makes operating decisions, assesses performance, and allocates resources on a consolidated basis. The Company adopted ASU 2023-07 effective December 31, 2024. Refer to Footnote 21 for segment related disclosures.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">New accounting standards which have not yet been adopted</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Subtopic 220-40): Disaggregation of Income Statement Expenses. This update requires that at each interim and annual reporting period public entities disclose (1) the amounts of purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions; (2) certain amounts that are already required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirements; (3) a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively; and (4) the total amount of selling expenses and, in annual reporting periods, the definition of selling expenses. In January 2025, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Subtopic 220-40): Clarifying the Effective Date. This update clarifies that ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact on its financial statements of adopting this guidance.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 740): Improvements to Income Tax Disclosures. This update requires that public entities on an annual basis, (1) in the rate reconciliation, disclose specific categories and provide additional information for reconciling items that meet a quantitative threshold; (2) about income taxes paid, disclose the amount of income taxes paid (net of refunds received) disaggregated by federal, state, and foreign taxes and by individual jurisdiction in which income taxes paid (net of refunds received) is equal to or greater than 5 percent of total income taxes paid (net of refunds received); and (3) disclose income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign and income tax expense (or benefit) disaggregated by federal, state, and foreign. This update is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. This guidance should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating the impact on its financial statements of adopting this guidance.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_GovernmentGrantsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for government grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_GovernmentGrantsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_LandUseRightsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for land use rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_LandUseRightsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.M.2.Q4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483530/326-20-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479391/326-20-30-5A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-3C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479366/326-20-35-8A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-3D<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479175/326-30-30-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3D<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 13A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479148/326-30-35-13A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479391/326-20-30-4A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479148/326-30-35-7A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-21<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossFinancialInstrumentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-15<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-11B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914421196432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment Useful Life</a></td>
<td class="text">Property, plant and equipment, other than land and construction in progress, are depreciated using the straight-line method over the estimated useful lives of the respective assets as follows:<div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful&#160;Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 10 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software, Electronic and Office Equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold Improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of useful life or lease term</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net are recorded at cost less accumulated depreciation and consisted of the following:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607,857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software, electronics and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, at cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,510&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832,751&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(399,105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(249,212)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,578,423&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,324,154&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>CIP by fixed asset class are summarized as follows:<div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,897&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,380&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,805&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,687&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,451&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654,018&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740,615&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Component of Lease Expense</a></td>
<td class="text">As of December&#160;31, 2024, the Company held land use rights in the following regions:<div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Terms</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Guangzhou</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beijing</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Suzhou</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shanghai</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 years</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.377%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost </span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,052&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,762&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,071&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other supplemental information related to leases is summarized below:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.377%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used in operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for new operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth assets measured at fair value on a recurring basis as of December&#160;31, 2024 and 2023:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Price<br/>in&#160;Active<br/>Market&#160;for<br/>Identical<br/>Assets<br/>(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">950,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt instrument</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt instrument</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">952,817&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,234&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Price<br/>in&#160;Active<br/>Market&#160;for<br/>Identical<br/>Assets<br/>(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,052,149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt instrument</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Convertible debt instrument</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,057,795&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,883&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914425300624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Licensing Arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research and Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Net Product Sales</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total collaboration revenue recognized for the years ended December&#160;31, 2024, 2023 and 2022:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.429%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue from Collaborators</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development service revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right to access intellectual property revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Material rights revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,695&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268,927&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,309&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes collaboration revenue recognized in connection with the tislelizumab collaboration and license agreement for the years ended December&#160;31, 2024, 2023 and 2022:</span></div><div style="margin-bottom:3pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.429%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development service revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,345&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,148&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Represents revenue recognized on sale of tislelizumab clinical supply to Novartis in conjunction with the collaboration.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes collaboration revenue recognized in connection with the ociperlimab option, collaboration and license agreement for the years ended December&#160;31, 2024, 2023 and 2022:</span></div><div style="margin-bottom:3pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.429%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development service revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right to access intellectual property revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Material rights revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,259&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,469&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,161&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Represents revenue generated under the broad markets marketing and promotion agreement in conjunction with the collaboration.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the Company&#8217;s net product sales for the years ended December&#160;31, 2024, 2023 and 2022.</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue - gross</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,786,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,718,969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,438,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Rebates and sales returns</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,007,198)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(529,117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183,828)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue - net</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,779,546&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,189,852&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254,612&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table disaggregates net product revenue by product for the years ended December&#160;31, 2024, 2023 and 2022.</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BRUKINSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,644,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,290,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tislelizumab</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620,836&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536,620&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422,885&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BLINCYTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,331&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,342&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,107&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">POBEVCY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,509&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,547&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,124&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REVLIMID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,042&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,302&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,702&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenue - net</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,779,546&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,189,852&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254,612&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_CollaborationAgreementsTableTextBlock', window );">Schedule of Collaboration Agreements</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recorded related to the Company&#8217;s portion of the co-development funding on the pipeline assets for the years ended December&#160;31, 2024, 2023 and 2022 were as follows:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.377%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BeiGene&#8217;s portion of the development funding</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,391&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Amortization of research and development cost share liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,165&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,314&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,955&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remaining portion of development funding cap </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335,261&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, the research and development cost share liability recorded in the Company&#8217;s balance sheet was as follows:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.367%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development cost share liability, current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development cost share liability, non-current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,662&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development cost share liability</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,440&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,666&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_ScheduleOfAmountsAndClassificationOfReimbursementExpenseTableTextBlock', window );">Schedule of Amounts and Classification of Reimbursement Expense</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net reimbursement paid under the commercial profit-sharing agreement for in-line product sales is classified in the consolidated statements of operations for the three years ended December&#160;31, 2024 as follows:</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:54.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.437%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.437%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.440%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales - product</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,358&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(83,674)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,917)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,865)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,438)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,216)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48,962)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,871)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,183)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_PaymentsDueToCollaborationPartnersTableTextBlock', window );">Schedule of Payments Due to Collaboration Partners</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront and milestone payments made under these arrangements for the years ended December&#160;31, 2024, 2023 and 2022 are set forth below. All upfront and development milestones were expensed to research and development expense. All regulatory and commercial milestones were capitalized as intangible assets and are being amortized over the remainder of the respective product patent or the term of the commercialization agreements.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments due to collaboration partners</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront payments</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development milestone payments</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Regulatory and commercial milestone payments</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,365&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,027&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,165&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,165&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_CollaborationAgreementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_CollaborationAgreementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_PaymentsDueToCollaborationPartnersTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments Due To Collaboration Partners</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_PaymentsDueToCollaborationPartnersTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_ScheduleOfAmountsAndClassificationOfReimbursementExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Amounts And Classification Of Reimbursement Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_ScheduleOfAmountsAndClassificationOfReimbursementExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914423593808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restricted Cash (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Restrictions on Cash and Cash Equivalents</a></td>
<td class="text">The Company classifies restricted cash as current or non-current based on term of restriction. Restricted cash as of December&#160;31, 2024 and 2023 was as follows:<div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,337&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,184&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914531579904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Schedule of Equity Method Investments</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s investments in equity securities:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.100%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.228%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Leap common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Leap warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities without readily determinable fair values</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pi Health, Inc. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-method investments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,081&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,981&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,317&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,429&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Represents common stock and warrants to purchase additional shares of common stock of Leap. The Company measures the investment in the common stock and warrants at fair value, with changes in fair value recorded to other (expense) income, net.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In the first quarter of 2024, the Company divested the net assets comprising substantially all of its Pi Health business with a carrying value of $38,063. The consideration received for the divestiture consisted of preferred stock in a newly formed entity, Pi Health, Inc., with a fair value of $40,798 and cash consideration of $1,000. The transaction resulted in a pre-tax gain of $3,735 recorded within <span style="-sec-ix-hidden:f-660">other (expense) income, net</span> during year ended December&#160;31, 2024. The Company will account for its investment prospectively as a private equity security without a readily determinable fair value and the divestiture is not treated as a discontinued operation in the Statement of Operations and therefore the historical results of operations of the Pi Health business will remain in the Company&#8217;s continuing operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes unrealized (losses) gains related to investments in equity securities recorded in other (expense) income, net:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair values</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,307)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(425)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,102)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities without readily determinable fair values</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,596)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,448)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity-method investments</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,275)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,856)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,682)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914421339536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s inventories, net consisted of the following:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,772&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">494,986&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416,122&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914413489376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Component of Lease Expense</a></td>
<td class="text">As of December&#160;31, 2024, the Company held land use rights in the following regions:<div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Terms</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Guangzhou</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beijing</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Suzhou</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shanghai</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 years</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.377%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,834&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost </span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,052&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,762&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,071&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other supplemental information related to leases is summarized below:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.377%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows used in operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for new operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of Supplemental Balance Sheet Information</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land use rights, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,309&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, non-current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,853&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,201&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-bottom:4pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities are as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.375%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December&#160;31,&#160;2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December&#160;31,&#160;2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December&#160;31,&#160;2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31, 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31, 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,188&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,534&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,681)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,853&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914531434864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Components of Property and Equipment</a></td>
<td class="text">Property, plant and equipment, other than land and construction in progress, are depreciated using the straight-line method over the estimated useful lives of the respective assets as follows:<div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.806%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful&#160;Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 10 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software, Electronic and Office Equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold Improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lesser of useful life or lease term</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net are recorded at cost less accumulated depreciation and consisted of the following:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607,857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,656&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244,255&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,885&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software, electronics and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, at cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,323,510&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832,751&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(399,105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(249,212)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,578,423&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,324,154&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>CIP by fixed asset class are summarized as follows:<div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:69.324%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.397%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,897&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119,380&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,805&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,687&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,451&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">654,018&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740,615&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914421272016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets Outstanding</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets as of December&#160;31, 2024 and 2023 are summarized as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.581%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intangible<br/>assets, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>carrying<br/>amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intangible<br/>assets, net</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finite-lived intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Developed products</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,889&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,370)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,807)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,467&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,411)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,316)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total finite-lived intangible assets</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,876&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,781)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,095&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,261&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,123)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,138&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>Amortization expense is as follows:<div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.525%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense - Cost of sales - product</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense - Selling, general and administrative</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,824&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,239&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,976&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets Amortization Expense</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense for each of the five succeeding years and thereafter, as of December&#160;31, 2024 is as follows:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.701%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost of Sales - Product</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Selling, General and Administrative Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030 and thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,350&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,519&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,095&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914415342944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income&#160;(Loss) Before Income Taxes</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">loss) before income taxes are as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PRC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(263,159)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(315,852)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(583,610)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(471,358)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(627,430)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,445,171)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(533,001)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(825,836)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,961,037)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Current and Deferred Components of the Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="margin-bottom:4pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current and deferred components of the income tax expense (benefit) from continuing operations are as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current tax expense (benefit)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,222&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PRC</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,547&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,778&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred tax expense (benefit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PRC</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,480&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,007&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,482&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,785&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,872&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,778&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of the Statutory Tax Rate to Effective Income Tax Rate</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation of the statutory tax rate to our effective income tax rate is as follow:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(533,001)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(825,836)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,961,037)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. statutory tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected taxation at U.S. statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111,930)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173,426)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(411,818)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign and preferential tax rate differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,384&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,223&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,988)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,872)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax relief credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(704,928)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research tax credits and incentives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43,602)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64,343)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,844)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deductible research expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,644)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax on unremitted earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign-derived intangible income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,397)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,395)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,272)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxation for the year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,778&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Tax Assets (Liabilities)</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of deferred tax assets (liabilities) are as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.420%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals and reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating losses carryforward</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,137,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">996,588&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax relief credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704,928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">704,928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible asset amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,081,442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D and other capitalized costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,407,710&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,775,085&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,952,357&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,403,505)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,771,470)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,943,775)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,205&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,615&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,582&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,795)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,374)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,480)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax on unremitted earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,735)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,682)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,735)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,098)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total gross deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,212)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,109)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24,578)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets/(liabilities)</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,007)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,494)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,996)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Schedule of Valuation Allowance</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation allowances for the years ended December&#160;31, 2024, 2023 and 2022 were as follows:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance, as of January 1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,771,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,943,775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,758,409&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions/(subtractions) charged to income tax provision</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions/(subtractions) charged to equity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497,823&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,074)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,116)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,184)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance, as of December 31</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,403,505&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,771,470&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,943,775&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Gross Unrecognized Tax Benefits</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross unrecognized tax benefits for the years ended December&#160;31, 2024, 2023 and 2022 were as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance, as of January 1</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,555&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to prior tax years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions based on tax positions related to prior tax years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current tax year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,975&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,709&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,630&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions based on lapse of statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance, as of December 31</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,239&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,264&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,555&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914421339536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets consist of the following:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid research and development costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,859&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,253&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,619&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid manufacturing cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid insurance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,919&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,465&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock', window );">Schedule of Other Non-Current Assets</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-current assets consist of the following:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid supply cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,122&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental deposits and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepayment of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid VAT</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,546&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,362&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_AccruedLiabilitiesAccountsPayableOtherAndOtherLiabilitiesCurrentTableTextBlock', window );">Schedule of Accrued Expenses and Other Payables</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other payables consisted of the following:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Compensation related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales rebates and returns related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External research and development activities related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162,969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued general and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,203&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Individual income tax and other taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,904&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,083&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803,713&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">693,731&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock', window );">Schedule of Other Long-Term Liabilities</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities consist of the following:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred government grant income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset retirement obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,735&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,810&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_AccruedLiabilitiesAccountsPayableOtherAndOtherLiabilitiesCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of accrued liabilities, other accounts payable, and other liabilities, current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_AccruedLiabilitiesAccountsPayableOtherAndOtherLiabilitiesCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other noncurrent liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914531577472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Short-Term and Long-Term Debt Obligations</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s short-term and long-term debt obligations as of December&#160;31, 2024 and 2023: </span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.274%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.186%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.807%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lender</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Borrower</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Line of Credit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr style="height:12pt"><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RMB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RMB</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Construction Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene Guangzhou Biologics Manufacturing Co., Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;RMB580,000 </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9-year </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 11, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Merchants Bank</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene Guangzhou Biologics Manufacturing Co., Ltd.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RMB350,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9-year</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 20, 2029</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62,857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Merchants Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene Guangzhou Biologics Manufacturing Co., Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RMB378,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9-year </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 8, 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China CITIC Bank</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene (Suzhou) Co., Ltd.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RMB480,000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-year </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 28, 2032</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,384&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Merchants Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene, Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$380,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-year </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,773,723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,129,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Minsheng Bank</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene, Ltd.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$150,000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-year </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 16, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.8%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,094,891&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,064,660&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Industrial Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene, Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RMB675,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">364-days</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">March 27, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">675,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Merchants Bank</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene Guangzhou Biologics Manufacturing Co., Ltd.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RMB400,000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-year </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 5, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54,800&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56,356&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HSBC Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene, Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RMB340,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-year</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 5, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47,903&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Industrial Bank</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene (Suzhou) Co., Ltd.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RMB200,000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-year</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 29, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,177&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shanghai Pudong Development Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene, Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RMB700,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-year</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 24, 2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">679,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Merchants Bank</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene (Suzhou) Co., Ltd.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RMB200,000</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1-year</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">May 24, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,037&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="33" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total short-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">851,529&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,215,538&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">688,366&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,885,838&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Construction Bank</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene Guangzhou Biologics Manufacturing Co., Ltd.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;RMB580,000 </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9-year</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">June 11, 2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41,100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59,174&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">420,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Merchants Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene Guangzhou Biologics Manufacturing Co., Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RMB350,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;9-year</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 20, 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,987&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37,638&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">267,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Merchants Bank</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene Guangzhou Biologics Manufacturing Co., Ltd.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;RMB378,000 </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9-year </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">November 8, 2029</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33,020&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">241,025&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,337&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China CITIC Bank</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BeiGene (Suzhou) Co., Ltd.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RMB480,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10-year </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 28, 2032</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">469,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166,484&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,215,211&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197,618&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,402,643&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt">The outstanding borrowings bear floating interest rates benchmarking RMB loan interest rates of financial institutions in the PRC. The loan interest rate was 4.2% as of December&#160;31, 2024. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The Company repaid </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$13,739 (or RMB100,000) during the year ended December&#160;31, 2024. The loan is secured by BeiGene Guangzhou Biologics Manufacturing Co., Ltd.&#8217;s property ownership certificate and fixed assets. </span></div><div style="margin-bottom:9pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt">The outstanding borrowings bear floating interest rates benchmarking RMB loan interest rates of financial institutions in the PRC. The loan interest rate was 3.7% as of December&#160;31, 2024. The Company repaid $8,730 (RMB62,857) during the year ended December&#160;31, 2024. The loan is secured by Guangzhou Factory&#8217;s second land use right and certain fixed assets.</span></div><div style="margin-bottom:9pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt">The outstanding borrowings bear floating interest rates benchmarking RMB loan interest rates of financial institutions in the PRC. The loan interest rate was 3.8% as of December&#160;31, 2024. The Company repaid $5,562 (RMB40,000) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">during the year ended December&#160;31, 2024. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The loan is secured by fixed assets that will be placed into service upon completion of the third phase of the Guangzhou manufacturing facility&#8217;s build out. </span></div><div style="margin-bottom:9pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt">The outstanding borrowings bear a floating interest rate benchmarked against prevailing interest rates of certain PRC financial institutions. The loan interest rate was 3.7% as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">. The Company drew down $9,053 (RMB65,000) </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">during the year ended December&#160;31, 2024. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The loan is secured by BeiGene (Suzhou) Co., Ltd.&#8217;s property ownership certificate of the small molecule manufacturing campus in Suzhou, China. </span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:12pt">The outstanding borrowings bear floating interest rates benchmarking the secured overnight financing rate. The loan interest rate was 6.2% as of December&#160;31, 2024. $80,000 of the borrowing matures on January 27, 2025, and $300,000 matures on December 17, 2025.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt">The outstanding borrowings bear floating interest rates benchmarking RMB loan interest rates of financial institutions in the PRC. The loan interest rate was 2.6% as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt">The outstanding borrowings bear floating interest rates benchmarking Hong Kong interbank market rate for RMB. The loan interest rate was 4.4% as of December&#160;31, 2024.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock', window );">Schedule of Contractual Maturities of Debt Obligations</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate contractual maturities of all borrowings due subsequent to December&#160;31, 2024 are as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.960%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity dates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December&#160;31,&#160;2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851,529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December&#160;31,&#160;2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,207&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,207&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31, 2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,657&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31, 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,756&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,018,013&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Subparagraph (a)<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914413060448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Net Product Sales</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total collaboration revenue recognized for the years ended December&#160;31, 2024, 2023 and 2022:</span></div><div style="margin-bottom:9pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.429%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue from Collaborators</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development service revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right to access intellectual property revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Material rights revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,695&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268,927&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,309&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes collaboration revenue recognized in connection with the tislelizumab collaboration and license agreement for the years ended December&#160;31, 2024, 2023 and 2022:</span></div><div style="margin-bottom:3pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.429%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development service revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,067&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,345&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,148&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Represents revenue recognized on sale of tislelizumab clinical supply to Novartis in conjunction with the collaboration.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes collaboration revenue recognized in connection with the ociperlimab option, collaboration and license agreement for the years ended December&#160;31, 2024, 2023 and 2022:</span></div><div style="margin-bottom:3pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.151%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.429%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development service revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,153&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,167&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right to access intellectual property revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Material rights revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,259&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192,469&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,161&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Represents revenue generated under the broad markets marketing and promotion agreement in conjunction with the collaboration.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the Company&#8217;s net product sales for the years ended December&#160;31, 2024, 2023 and 2022.</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue - gross</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,786,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,718,969&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,438,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Rebates and sales returns</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,007,198)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(529,117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183,828)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue - net</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,779,546&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,189,852&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254,612&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table disaggregates net product revenue by product for the years ended December&#160;31, 2024, 2023 and 2022.</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BRUKINSA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,644,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,290,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tislelizumab</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620,836&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536,620&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">422,885&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XGEVA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BLINCYTO</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,331&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,342&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,107&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KYPROLIS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,171&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">POBEVCY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,509&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,547&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,124&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">REVLIMID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,018&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,049&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,042&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,302&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,702&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenue - net</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,779,546&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,189,852&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,254,612&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_ScheduleOfAccruedSalesRebatesAndReturnsCurrentTableTextBlock', window );">Schedule of Accrued Sales Rebates and Returns</a></td>
<td class="text"><div style="margin-bottom:4pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the roll-forward of accrued sales chargebacks, rebates, returns and other deductions for the years ended December&#160;31, 2024 and 2023.</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rebates, Returns and Other Deductions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contra AR Accruals</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,817&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts charged against product revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,031&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254,086&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176,912)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232,231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(409,143)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,936&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,435&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,371&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts charged against product revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">515,442&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007,198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(396,092)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(495,178)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(891,270)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">235,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,699&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,299&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_ScheduleOfAccruedSalesRebatesAndReturnsCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Accrued Sales Rebates and Returns Current [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_ScheduleOfAccruedSalesRebatesAndReturnsCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914413519680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of the Computations of Basic and Diluted Loss Per Share</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss per share was calculated as follows:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(644,786)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(881,708)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,003,815)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding for computing basic and diluted loss per share</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,368,746,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,357,034,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,340,729,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.47)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.65)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.49)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914536578128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock', window );">Schedule of Shares Issued Under Employee Share Purchase Plan</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarizes the shares issued under the ESPP:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Market Price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchase Price</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">2</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issuance Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Ordinary Shares Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ADS</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ordinary</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ADS</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ordinary</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Proceeds</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035,996&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.69&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.78&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,178&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 29, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,021,397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,063&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">930,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">861,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The market price is the lower of the closing price on Nasdaq on the issuance date or the offering date, in accordance with the terms of the ESPP.</span></div><div style="margin-bottom:9pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> The purchase price is the price which was discounted from the applicable market price, in accordance with the terms of the ESPP.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share Option Activities</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s share option activities under the 2011, 2016 and 2018 Plans:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant<br/>Date&#160;Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic&#160;Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,204,888&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,516,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,898,217)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,258&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,296,634)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,526,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,817,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,974,331)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,051&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,225,334)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,145,113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,180,301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,812,624)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,946&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,530,134)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.87&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,982,656&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.83</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429,581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable as of December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,173,280&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">406,868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,311,250&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">426,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of the Range of Fair Values and the Assumptions Used to Estimate the Fair Values of the Share Options Granted</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the range of fair values and the assumptions used to estimate those fair values of the share options granted in the years presented:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of ordinary share</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.72 ~ $9.19</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7.26 ~ $10.72</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$5.51 ~ $9.04</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8% ~ 4.6%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4% ~ 4.6%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8% ~ 3.9%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected exercise multiple</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57% ~ 58%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58% ~ 60%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51% ~ 60%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contractual life</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 years</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Employee Restricted Shares Activities and Restricted Share Units Activities</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s restricted share unit activities under the 2016 and 2018 Plans:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Numbers<br/>of&#160;Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant&#160;Date&#160;Fair&#160;Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,082,982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,707,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,533,586)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,859,892)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,397,173&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,573,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,862,598)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,707,546)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,401,023&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,693,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,251,477)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,012,471)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,830,667&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest at December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,956,067&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Total Compensation Cost Recognized</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes total share-based compensation cost recognized for the years ended December&#160;31, 2024, 2023 and 2022:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,550&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,814&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441,793&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,588&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303,162&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of employee stock purchase plan activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914421326032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive (Loss) Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive (Loss) Income</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The movement of accumulated other comprehensive (loss) income was as follows:</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign&#160;Currency<br/>Translation<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Gains/Losses&#160;on<br/>Available-for-Sale<br/>Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pension Liability Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62,523)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,011)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,883)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,417)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,464)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,422)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,840)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net-current period other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,464)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,046&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,611)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,029)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87,987)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,494)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,446)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,565)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,753)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,353)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net-current period other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,565)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,942)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,542)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,552)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,436)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148,988)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The amounts reclassified from accumulated other comprehensive (loss) income were included in other (expense) income, net in the consolidated statements of operations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914419100208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock', window );">Schedule of Expected Benefit Payments</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the total expected benefit payments to Swiss Plan participants in the following 10 years and have been estimated based on the same assumptions used to measure the Company&#8217;s benefit obligations as of December&#160;31, 2024:</span></div><div style="margin-bottom:4pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.993%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.223%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December&#160;31,&#160;2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December&#160;31,&#160;2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31, 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31, 2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year ending December 31, 2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,657&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,462&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Subparagraph (f)<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914531579904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Net Product Revenues by Geographic Area</a></td>
<td class="text">Total net revenues by geographic area are presented as follows:<div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. - total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,957,498</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,128,219</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">502,626</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,950,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389,710&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">China- total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,411,307</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,101,951</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">840,032</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,390,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,093,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">840,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Europe- total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">362,626</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">202,014</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63,257</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,228&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rest of world- total revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">78,810</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,595</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,006</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,810&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,387)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,810,241</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,458,779</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,415,921</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914414808288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEC Schedule, Article 12-04, Condensed Financial Information of Registrant (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract', window );"><strong>Condensed Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfCondensedIncomeStatementTableTextBlock', window );">Condensed Statements of Operations</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BeiGene, Ltd.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Information of Parent Company</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Operations</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollars (&#8220;$&#8221;))</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">353,903&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357,103&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228,801&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">711,006&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631,103&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865,953&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(711,006)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(631,103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(865,953)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(297,856)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,173,306)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(644,383)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(879,977)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,999,674)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(644,786)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(881,708)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,003,815)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedStatementOfComprehensiveIncomeTableTextBlock', window );">Condensed Statements of Comprehensive Loss</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BeiGene, Ltd.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Information of Parent Company</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Comprehensive Loss</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollars (&#8220;$&#8221;))</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:58.458%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(644,786)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(881,708)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,003,815)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax of nil:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47,565)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,464)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90,421)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension liability adjustments, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,942)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,611)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized holding gain (loss), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,311)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(694,328)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(903,737)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,099,182)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock', window );">Condensed Balance Sheets</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BeiGene, Ltd.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Information of Parent Company</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Balance Sheets</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollars (&#8220;$&#8221;))</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:71.640%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.792%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As&#160;of&#160;December&#160;31,&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400,135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">723,964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">249,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">785,471&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">649,151&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,509,435&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loans to subsidiaries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,731,266&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,030,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment in wholly owned subsidiaries</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,081,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,207,352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114,728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,576,480&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,816,397&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other payables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">424,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indebtedness to subsidiaries</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">362,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">762,146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">547,215&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,186,257&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,107,421&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171,649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,244,257&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,279,070&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,332,223&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,537,327&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,576,480&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,816,397&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock', window );">Condensed Statements of Cash Flows</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BeiGene, Ltd.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Information of Parent Company</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Cash Flows</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Amounts in thousands of U.S. Dollars (&#8220;$&#8221;))</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:58.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.793%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(644,786)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(881,708)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,003,815)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of research and development cost share liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73,226)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(55,294)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(96,402)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized (gains) losses in subsidiaries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(85,471)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237,351&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">932,071&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other items, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(374,370)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(596,496)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other payables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">627,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(140,126)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">875,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(143,472)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,168,628)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(882,145)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,075)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,485)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale or maturity of short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">552,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,487,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of in-process research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(75,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment in subsidiaries</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(406,624)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(883,328)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,675,908)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(37,120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">188,656&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(441,116)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(159,747)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,186,361)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from short-term loans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">813,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">547,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of short-term loans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(593,898)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(293,002)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(247,460)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from option exercises and employee share purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,965&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264,531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310,552&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95,693&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of foreign exchange rate changes, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,356)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents, and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(324,413)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,017,823)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,972,813)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash, beginning of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">724,548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,742,371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,715,184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash, cash equivalents, and restricted cash, end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400,135&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">724,548&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,742,371&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedStatementOfComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed statement of comprehensive income (loss) including, but not limited to, statements of comprehensive income (loss) of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedStatementOfComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedCashFlowStatementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedIncomeStatementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedIncomeStatementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914535082256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business (Details)<br> employee in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>employee</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 3,810,241<span></span>
</td>
<td class="nump">$ 2,458,779<span></span>
</td>
<td class="nump">$ 1,415,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_RevenueFromContractWithCustomerExcludingAssessedTaxPeriodIncreaseDecrease', window );">Revenue, period increase</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestPeriodIncreaseDecrease', window );">Net loss period decrease</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityNumberOfEmployees', window );">Number of employees | employee</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Income (Loss), Including Portion Attributable To Noncontrolling Interest, Period Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_RevenueFromContractWithCustomerExcludingAssessedTaxPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From Contract With Customer, Excluding Assessed Tax, Period Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_RevenueFromContractWithCustomerExcludingAssessedTaxPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityNumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of persons employed by the Entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityNumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914412219728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Impairment loss</a></td>
<td class="nump">$ 7,635<span></span>
</td>
<td class="nump">$ 7,529<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary decline in value that has been recognized against investment accounted for under equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914413822752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property, Plant and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;lives (in years)</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Manufacturing equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;lives (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Manufacturing equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;lives (in years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bgne_LaboratoryEquipmentMember', window );">Laboratory Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;lives (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bgne_LaboratoryEquipmentMember', window );">Laboratory Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;lives (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software, Electronic and Office Equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;lives (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software, Electronic and Office Equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful&#160;lives (in years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bgne_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bgne_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914418671440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Land Use Right, Net (Details) - Land<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Guangzhou</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Terms</a></td>
<td class="text">50 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Beijing</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Terms</a></td>
<td class="text">36 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Suzhou</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Terms</a></td>
<td class="text">30 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Shanghai</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Terms</a></td>
<td class="text">47 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bgne_GuangzhouMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bgne_GuangzhouMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bgne_BeijingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bgne_BeijingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bgne_SuzhouMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bgne_SuzhouMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bgne_ShanghaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bgne_ShanghaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914419349168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Goodwill and Other Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914415363600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentChargesAbstract', window );"><strong>Impairment of long-lived assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914412344928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level&#160;3) | Convertible debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Other non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Loss on fair value</a></td>
<td class="num">$ (4,842)<span></span>
</td>
<td class="num">$ (1,492)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Quoted&#160;Price in&#160;Active Market&#160;for Identical Assets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Other non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">952,817<span></span>
</td>
<td class="nump">1,057,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Quoted&#160;Price in&#160;Active Market&#160;for Identical Assets (Level&#160;1) | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid expenses and other current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Quoted&#160;Price in&#160;Active Market&#160;for Identical Assets (Level&#160;1) | Convertible debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid expenses and other current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_InvestmentInDebtSecuritiesCurrent', window );">Convertible debt instrument</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Other non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_InvestmentInDebtSecuritiesNonCurrent', window );">Convertible debt instrument</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Quoted&#160;Price in&#160;Active Market&#160;for Identical Assets (Level&#160;1) | Equity securities with readily determinable fair values</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Other non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair values</a></td>
<td class="nump">2,113<span></span>
</td>
<td class="nump">3,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Quoted&#160;Price in&#160;Active Market&#160;for Identical Assets (Level&#160;1) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Assets at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">950,704<span></span>
</td>
<td class="nump">1,052,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Quoted&#160;Price in&#160;Active Market&#160;for Identical Assets (Level&#160;1) | Bank Time Deposits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Assets at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">42,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Other non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">168<span></span>
</td>
<td class="nump">542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Significant Other Observable Inputs (Level&#160;2) | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid expenses and other current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Significant Other Observable Inputs (Level&#160;2) | Convertible debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid expenses and other current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_InvestmentInDebtSecuritiesCurrent', window );">Convertible debt instrument</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Other non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_InvestmentInDebtSecuritiesNonCurrent', window );">Convertible debt instrument</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Significant Other Observable Inputs (Level&#160;2) | Equity securities with readily determinable fair values</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Other non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair values</a></td>
<td class="nump">168<span></span>
</td>
<td class="nump">542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Significant Other Observable Inputs (Level&#160;2) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Assets at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Other non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">5,234<span></span>
</td>
<td class="nump">8,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Significant Unobservable Inputs (Level&#160;3) | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid expenses and other current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Significant Unobservable Inputs (Level&#160;3) | Convertible debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid expenses and other current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_InvestmentInDebtSecuritiesCurrent', window );">Convertible debt instrument</a></td>
<td class="nump">618<span></span>
</td>
<td class="nump">4,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Other non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_InvestmentInDebtSecuritiesNonCurrent', window );">Convertible debt instrument</a></td>
<td class="nump">4,616<span></span>
</td>
<td class="nump">4,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Significant Unobservable Inputs (Level&#160;3) | Equity securities with readily determinable fair values</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Other non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair values</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring Basis | Significant Unobservable Inputs (Level&#160;3) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiabilityAbstract', window );"><strong>Assets at fair value on a recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents:</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_InvestmentInDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment In Debt Securities, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_InvestmentInDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_InvestmentInDebtSecuritiesNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment In Debt Securities, Non Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_InvestmentInDebtSecuritiesNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionChangesInFairValueGainLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914415302768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies -Government Grants (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAmount', window );">Government assistance amount</a></td>
<td class="nump">$ 22,326<span></span>
</td>
<td class="nump">$ 23,989<span></span>
</td>
<td class="nump">$ 32,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">66,735<span></span>
</td>
<td class="nump">50,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceTypeAxis=bgne_GovernmentAssistanceManufacturingFacilityBuildOutMember', window );">Government Assistance, Manufacturing Facility Build-Out</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAmount', window );">Government assistance amount</a></td>
<td class="nump">$ 3,053<span></span>
</td>
<td class="nump">$ 2,938<span></span>
</td>
<td class="nump">$ 3,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration', window );">Government Assistance, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other long-term liabilities<span></span>
</td>
<td class="text">Other long-term liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceLiabilityNoncurrent', window );">Government assistance, liability, noncurrent</a></td>
<td class="nump">$ 30,235<span></span>
</td>
<td class="nump">$ 34,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceTypeAxis=bgne_GovernmentAssistanceManufacturingFacilityBuildOutMember', window );">Government Assistance, Manufacturing Facility Build-Out | Depreciation Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Government Assistance, Income, Increase (Decrease), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Depreciation and amortization expense<span></span>
</td>
<td class="text">Depreciation and amortization expense<span></span>
</td>
<td class="text">Depreciation and amortization expense<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceTypeAxis=bgne_GovernmentAssistanceResearchAndDevelopmentProgramsMember', window );">Government Assistance, Research And Development Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAmount', window );">Government assistance amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceLiabilityNoncurrent', window );">Government assistance, liability, noncurrent</a></td>
<td class="nump">$ 89<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in income from government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability from government assistance, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes liability from government assistance, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes increase (decrease) in income from government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceTypeAxis=bgne_GovernmentAssistanceManufacturingFacilityBuildOutMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceTypeAxis=bgne_GovernmentAssistanceManufacturingFacilityBuildOutMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=bgne_DepreciationExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=bgne_DepreciationExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceTypeAxis=bgne_GovernmentAssistanceResearchAndDevelopmentProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceTypeAxis=bgne_GovernmentAssistanceResearchAndDevelopmentProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914415289792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Segment Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract', window );"><strong>Segment information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914412377536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Concentration of Risks (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,627,410<span></span>
</td>
<td class="nump">$ 3,171,800<span></span>
</td>
<td class="nump">$ 3,869,564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 676,278<span></span>
</td>
<td class="nump">$ 358,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Product Revenue | ASD Specialty Healthcare | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">12.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Product Revenue | McKesson | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">16.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Product Revenue | Shanghai Pharmaceutical | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">11.10%<span></span>
</td>
<td class="nump">14.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Product Revenue | Sinopharm | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Product Revenue | China Resources | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Three Largest Customers | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Four Largest Customers | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bgne_ASDSpecialtyHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bgne_ASDSpecialtyHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bgne_McKessonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bgne_McKessonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bgne_ShanghaiPharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bgne_ShanghaiPharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bgne_SinopharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bgne_SinopharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bgne_ChinaResourcesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bgne_ChinaResourcesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bgne_ThreeLargestCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bgne_ThreeLargestCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=bgne_FourLargestCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=bgne_FourLargestCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914414540656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Licensing Arrangements - Recognized Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 3,810,241<span></span>
</td>
<td class="nump">$ 2,458,779<span></span>
</td>
<td class="nump">$ 1,415,921<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bgne_CollaborationMember', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">30,695<span></span>
</td>
<td class="nump">268,927<span></span>
</td>
<td class="nump">161,309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bgne_CollaborationMember', window );">Collaboration revenue | Novartis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">30,695<span></span>
</td>
<td class="nump">268,927<span></span>
</td>
<td class="nump">161,309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bgne_CollaborationMember', window );">Collaboration revenue | Tislelizumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2,113<span></span>
</td>
<td class="nump">77,345<span></span>
</td>
<td class="nump">49,148<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bgne_CollaborationMember', window );">Collaboration revenue | Ociperlimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">18,259<span></span>
</td>
<td class="nump">192,469<span></span>
</td>
<td class="nump">112,161<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bgne_CollaborationResearchAndDevelopmentServiceMember', window );">Research and development service revenue | Novartis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">79,431<span></span>
</td>
<td class="nump">46,822<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bgne_CollaborationResearchAndDevelopmentServiceMember', window );">Research and development service revenue | Tislelizumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">72,278<span></span>
</td>
<td class="nump">39,655<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bgne_CollaborationResearchAndDevelopmentServiceMember', window );">Research and development service revenue | Ociperlimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,153<span></span>
</td>
<td class="nump">7,167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bgne_RightToAccessIntellectualPropertyRevenueMember', window );">Right to access intellectual property revenue | Novartis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">104,477<span></span>
</td>
<td class="nump">104,994<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bgne_RightToAccessIntellectualPropertyRevenueMember', window );">Right to access intellectual property revenue | Ociperlimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">104,477<span></span>
</td>
<td class="nump">104,994<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bgne_MaterialRightsRevenueMember', window );">Material rights revenue | Novartis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">71,980<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bgne_MaterialRightsRevenueMember', window );">Material rights revenue | Ociperlimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">71,980<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bgne_CollaborationOtherMember', window );">Other | Novartis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">30,695<span></span>
</td>
<td class="nump">13,039<span></span>
</td>
<td class="nump">9,493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bgne_CollaborationOtherMember', window );">Other | Tislelizumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2,113<span></span>
</td>
<td class="nump">5,067<span></span>
</td>
<td class="nump">9,493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bgne_CollaborationOtherMember', window );">Other | Ociperlimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 18,259<span></span>
</td>
<td class="nump">$ 8,859<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bgne_CollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bgne_CollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bgne_NovartisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bgne_NovartisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bgne_TislelizumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bgne_TislelizumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bgne_OciperlimabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bgne_OciperlimabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bgne_CollaborationResearchAndDevelopmentServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bgne_CollaborationResearchAndDevelopmentServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bgne_RightToAccessIntellectualPropertyRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bgne_RightToAccessIntellectualPropertyRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bgne_MaterialRightsRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bgne_MaterialRightsRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bgne_CollaborationOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bgne_CollaborationOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914421532768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaborative and Licensing Arrangements - Novartis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bgne_NovartisMember', window );">Novartis | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Upfront cash payment received</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 650,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bgne_NovartisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bgne_NovartisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914414541232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Licensing Arrangements - Ociperlimab Option, Collaboration and License Agreement and China Broad Market Development Agreement (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>product</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Research and development collaborative arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_NumberOfProductsInitiatedMarketingAndPromotion', window );">Number of products | product</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bgne_NovartisMember', window );">Novartis | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Research and development collaborative arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Upfront cash payment received | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 650,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_NumberOfProductsInitiatedMarketingAndPromotion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Products Initiated Marketing And Promotion</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_NumberOfProductsInitiatedMarketingAndPromotion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bgne_NovartisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bgne_NovartisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914423566352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Licensing Arrangements - Amgen (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 20, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>product</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Ordinary&#160;Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_SharePriceAmericanDepositoryShares', window );">Share price, ADS (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 132.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_ProceedsFromIssuanceOfAssetDepositoryShares', window );">Proceeds from ADS shares</a></td>
<td class="nump">$ 2,109,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=bgne_AmgenIncMember', window );">Amgen, Inc | Beigene Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Minority interest in investment (as a percent)</a></td>
<td class="nump">20.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Product Revenue | Product Concentration Risk | Amgen, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bgne_AmgenIncMember', window );">Amgen, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_CollaborativeArrangementsNumberOfProductsCompanyHasTheRightToRetain', window );">Number of products company has the right to retain | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_CollaborativeArrangementsProductRetentionPeriod', window );">Product retention period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_MaximumCashAndServicesDevelopmentCommitment', window );">Maximum cash and development services commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares) | shares</a></td>
<td class="nump">15,895,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Per share acquisition price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 174.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_FairValueOfLiabilityAcquired', window );">Fair value of cost share liability</a></td>
<td class="nump">$ 601,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Payments to acquire equity interest</a></td>
<td class="nump">2,779,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_FairValueOfEquityInvestmentsIssued', window );">Fair value of equity investments issued</a></td>
<td class="nump">2,162,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_FairValueOfFinancingCommitment', window );">Fair value of financing commitment</a></td>
<td class="nump">$ 616,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bgne_AmgenIncMember', window );">Amgen, Inc | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_CommercializationTerm', window );">Commercialization term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bgne_AmgenIncMember', window );">Amgen, Inc | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_CommercializationTerm', window );">Commercialization term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_RoyaltiesReceivingPeriod', window );">Royalties receiving period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_CollaborativeArrangementsNumberOfProductsCompanyHasTheRightToRetain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangements, Number Of Products Company Has The Right To Retain</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_CollaborativeArrangementsNumberOfProductsCompanyHasTheRightToRetain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_CollaborativeArrangementsProductRetentionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangements, Product Retention Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_CollaborativeArrangementsProductRetentionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_CommercializationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercialization Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_CommercializationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_FairValueOfEquityInvestmentsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value of Equity Investments Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_FairValueOfEquityInvestmentsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_FairValueOfFinancingCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Financing Commitment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_FairValueOfFinancingCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_FairValueOfLiabilityAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Of Liability Acquired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_FairValueOfLiabilityAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_MaximumCashAndServicesDevelopmentCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Cash And Services Development Commitment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_MaximumCashAndServicesDevelopmentCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_ProceedsFromIssuanceOfAssetDepositoryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Asset Depository Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_ProceedsFromIssuanceOfAssetDepositoryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_RoyaltiesReceivingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties Receiving Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_RoyaltiesReceivingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_SharePriceAmericanDepositoryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of each American Depository Share. Each American Depositary Share represents 13 ordinary shares of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_SharePriceAmericanDepositoryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bgne_AmgenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=bgne_AmgenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=bgne_BeigeneLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=bgne_BeigeneLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bgne_AmgenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bgne_AmgenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914419435520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Licensing Arrangements - Funding Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 1,953,295<span></span>
</td>
<td class="nump">$ 1,778,594<span></span>
</td>
<td class="nump">$ 1,640,508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bgne_AmgenIncMember', window );">Amgen, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_FinancingCommitmentExpenses', window );">BeiGene&#8217;s portion of the development funding</a></td>
<td class="nump">148,391<span></span>
</td>
<td class="nump">108,608<span></span>
</td>
<td class="nump">195,357<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_AmortizationOfFinancingCommitment', window );">Less: Amortization of research and development cost share liability</a></td>
<td class="nump">73,226<span></span>
</td>
<td class="nump">55,294<span></span>
</td>
<td class="nump">96,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">75,165<span></span>
</td>
<td class="nump">$ 53,314<span></span>
</td>
<td class="nump">$ 98,955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Remaining portion of development funding cap</a></td>
<td class="nump">$ 335,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_AmortizationOfFinancingCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of Financing Commitment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_AmortizationOfFinancingCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_FinancingCommitmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing Commitment Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_FinancingCommitmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bgne_AmgenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bgne_AmgenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914415170400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaborative and Licensing Arrangements - Financing Liability (Details) - Amgen, Inc - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_FinancingCommitmentCarryingValueCurrent', window );">Research and development cost share liability, current portion</a></td>
<td class="nump">$ 111,154<span></span>
</td>
<td class="nump">$ 68,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_FinancingCommitmentCarryingValueNoncurrent', window );">Research and development cost share liability, non-current portion</a></td>
<td class="nump">54,286<span></span>
</td>
<td class="nump">170,662<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_FinancingCommitmentCarryingValue', window );">Total research and development cost share liability</a></td>
<td class="nump">$ 165,440<span></span>
</td>
<td class="nump">$ 238,666<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_FinancingCommitmentCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing Commitment, Carrying Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_FinancingCommitmentCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_FinancingCommitmentCarryingValueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing Commitment, Carrying Value, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_FinancingCommitmentCarryingValueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_FinancingCommitmentCarryingValueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing Commitment, Carrying Value, Non-current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_FinancingCommitmentCarryingValueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bgne_AmgenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bgne_AmgenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914413823440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Licensing Arrangements - Amounts and Classification of Payments (Income/(Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_ReimbursementExpense', window );">Total</a></td>
<td class="num">$ (48,962)<span></span>
</td>
<td class="num">$ (50,871)<span></span>
</td>
<td class="num">$ (50,183)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">404,997<span></span>
</td>
<td class="nump">315,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bgne_AmgenIncMember', window );">Amgen, Inc | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Collaborative arrangement, inventory purchases</a></td>
<td class="nump">247,655<span></span>
</td>
<td class="nump">108,691<span></span>
</td>
<td class="nump">71,720<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bgne_AmgenIncMember', window );">Amgen, Inc | Collaborative Arrangement | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">116,563<span></span>
</td>
<td class="nump">55,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales - product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_ReimbursementExpense', window );">Total</a></td>
<td class="nump">37,150<span></span>
</td>
<td class="nump">8,358<span></span>
</td>
<td class="nump">5,898<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_ReimbursementExpense', window );">Total</a></td>
<td class="num">(83,674)<span></span>
</td>
<td class="num">(60,917)<span></span>
</td>
<td class="num">(54,865)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_ReimbursementExpense', window );">Total</a></td>
<td class="num">$ (2,438)<span></span>
</td>
<td class="nump">$ 1,688<span></span>
</td>
<td class="num">$ (1,216)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_ReimbursementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursement Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_ReimbursementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bgne_AmgenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bgne_AmgenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914421364752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Licensing Arrangements - Payment Classification (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Research and development collaborative arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_UpfrontAndMilestonePayments', window );">Total</a></td>
<td class="nump">$ 114,027<span></span>
</td>
<td class="nump">$ 71,165<span></span>
</td>
<td class="nump">$ 74,165<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_CollaborativeArrangementCompensationTypeAxis=bgne_UpfrontPaymentsMember', window );">Upfront payments | Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Research and development collaborative arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_UpfrontAndMilestonePayments', window );">Total</a></td>
<td class="nump">60,027<span></span>
</td>
<td class="nump">46,800<span></span>
</td>
<td class="nump">68,665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_CollaborativeArrangementCompensationTypeAxis=bgne_DevelopmentMilestonePaymentsMember', window );">Development milestone payments | Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Research and development collaborative arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_UpfrontAndMilestonePayments', window );">Total</a></td>
<td class="nump">54,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_CollaborativeArrangementCompensationTypeAxis=bgne_RegulatoryAndCommercialMilestonePaymentsMember', window );">Regulatory and commercial milestone payments | Intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Research and development collaborative arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_UpfrontAndMilestonePayments', window );">Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 24,365<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_UpfrontAndMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront And Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_UpfrontAndMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_CollaborativeArrangementCompensationTypeAxis=bgne_UpfrontPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_CollaborativeArrangementCompensationTypeAxis=bgne_UpfrontPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=bgne_ResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=bgne_ResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_CollaborativeArrangementCompensationTypeAxis=bgne_DevelopmentMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_CollaborativeArrangementCompensationTypeAxis=bgne_DevelopmentMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_CollaborativeArrangementCompensationTypeAxis=bgne_RegulatoryAndCommercialMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_CollaborativeArrangementCompensationTypeAxis=bgne_RegulatoryAndCommercialMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis=bgne_IntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis=bgne_IntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914425362544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Restricted Cash and Investments - Restrictions on Cash and Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Short-term restricted cash</a></td>
<td class="nump">$ 9,312<span></span>
</td>
<td class="nump">$ 11,473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Long-term restricted cash</a></td>
<td class="nump">2,025<span></span>
</td>
<td class="nump">2,711<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Total</a></td>
<td class="nump">$ 11,337<span></span>
</td>
<td class="nump">$ 14,184<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914419386272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Restricted Cash - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 11,337<span></span>
</td>
<td class="nump">$ 14,184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bgne_STARMarketMember', window );">STAR Market | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 588,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bgne_STARMarketMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bgne_STARMarketMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914418203296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Investments In Equity Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity-method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,081<span></span>
</td>
<td class="nump">$ 25,981<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124,317<span></span>
</td>
<td class="nump">85,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList', window );">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other (expense) income, net<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Pi Health, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_DisposalGroupNotDiscontinuedOperationNetAssets', window );">Net assets disposed of</a></td>
<td class="nump">$ 38,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from divestiture of businesses</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Pre-tax gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bgne_LeapTherapeuticIncMember', window );">Leap Therapeutic, Inc | Ordinary&#160;Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair values</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,113<span></span>
</td>
<td class="nump">3,046<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bgne_LeapTherapeuticIncMember', window );">Leap Therapeutic, Inc | Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair values</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="nump">542<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bgne_PiHealthIncMember', window );">Pi Health, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity securities without readily determinable fair values</a></td>
<td class="nump">$ 40,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bgne_OtherEquityMethodInvestmentsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity securities without readily determinable fair values</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,157<span></span>
</td>
<td class="nump">$ 55,860<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_DisposalGroupNotDiscontinuedOperationNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net assets attributable to disposal group not classified as discontinued operation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_DisposalGroupNotDiscontinuedOperationNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income that includes gain (loss) recognized on sale or disposal of disposal group. Excludes discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI) and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bgne_PiHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=bgne_PiHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bgne_LeapTherapeuticIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bgne_LeapTherapeuticIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bgne_PiHealthIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bgne_PiHealthIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bgne_OtherEquityMethodInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=bgne_OtherEquityMethodInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914419164064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Equity Method Investments (Details) - Other Operating Income (Expense) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Equity securities with readily determinable fair values</a></td>
<td class="num">$ (1,307)<span></span>
</td>
<td class="num">$ (425)<span></span>
</td>
<td class="num">$ (30,102)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmountNet', window );">Equity securities without readily determinable fair values</a></td>
<td class="num">(7,596)<span></span>
</td>
<td class="num">(6,448)<span></span>
</td>
<td class="nump">5,065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity-method investments</a></td>
<td class="num">$ (10,275)<span></span>
</td>
<td class="num">$ (7,856)<span></span>
</td>
<td class="num">$ (3,682)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmountNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmountNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914414775024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 170,584<span></span>
</td>
<td class="nump">$ 148,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">60,118<span></span>
</td>
<td class="nump">39,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">264,284<span></span>
</td>
<td class="nump">228,252<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories, net</a></td>
<td class="nump">$ 494,986<span></span>
</td>
<td class="nump">$ 416,122<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914413021264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Narratives (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Contract term (years)</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914419113712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 26,575<span></span>
</td>
<td class="nump">$ 25,978<span></span>
</td>
<td class="nump">$ 25,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">4,580<span></span>
</td>
<td class="nump">6,101<span></span>
</td>
<td class="nump">6,834<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">2,897<span></span>
</td>
<td class="nump">1,683<span></span>
</td>
<td class="nump">1,299<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 34,052<span></span>
</td>
<td class="nump">$ 33,762<span></span>
</td>
<td class="nump">$ 34,071<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914531590240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Supplemental Balance Sheet (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Total operating lease right-of-use assets</a></td>
<td class="nump">$ 139,309<span></span>
</td>
<td class="nump">$ 95,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">17,576<span></span>
</td>
<td class="nump">21,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, non-current portion</a></td>
<td class="nump">44,277<span></span>
</td>
<td class="nump">22,251<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">61,853<span></span>
</td>
<td class="nump">44,201<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Total operating lease right-of-use assets</a></td>
<td class="nump">60,639<span></span>
</td>
<td class="nump">43,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land use rights, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Total operating lease right-of-use assets</a></td>
<td class="nump">$ 78,670<span></span>
</td>
<td class="nump">$ 51,717<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914421393232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities of Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Lease Liabilities, Payments Due</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Year ending December&#160;31,&#160;2025</a></td>
<td class="nump">$ 19,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Year ending December&#160;31,&#160;2026</a></td>
<td class="nump">13,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Year ending December&#160;31,&#160;2027</a></td>
<td class="nump">12,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">Year ending December 31, 2028</a></td>
<td class="nump">11,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">Year ending December 31, 2029</a></td>
<td class="nump">7,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">3,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">68,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(6,681)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 61,853<span></span>
</td>
<td class="nump">$ 44,201<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914419196688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Other Supplemental Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows used in operating leases</a></td>
<td class="nump">$ 56,005<span></span>
</td>
<td class="nump">$ 27,985<span></span>
</td>
<td class="nump">$ 28,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">ROU assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 47,066<span></span>
</td>
<td class="nump">$ 11,854<span></span>
</td>
<td class="nump">$ 22,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">5.23%<span></span>
</td>
<td class="nump">7.22%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914414344656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net- Property, Plant and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">$ 1,323,510<span></span>
</td>
<td class="nump">$ 832,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="num">(399,105)<span></span>
</td>
<td class="num">(249,212)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">654,018<span></span>
</td>
<td class="nump">740,615<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">1,578,423<span></span>
</td>
<td class="nump">1,324,154<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">65,485<span></span>
</td>
<td class="nump">65,485<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">607,857<span></span>
</td>
<td class="nump">231,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">528,629<span></span>
</td>
<td class="nump">579,649<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">244,255<span></span>
</td>
<td class="nump">186,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">89,897<span></span>
</td>
<td class="nump">119,380<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bgne_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">240,885<span></span>
</td>
<td class="nump">205,349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">9,805<span></span>
</td>
<td class="nump">16,135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software, electronics and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">100,348<span></span>
</td>
<td class="nump">83,281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">$ 64,680<span></span>
</td>
<td class="nump">$ 60,124<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bgne_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bgne_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914412382608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net - Narratives (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,323,510,000<span></span>
</td>
<td class="nump">$ 832,751,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">654,018,000<span></span>
</td>
<td class="nump">740,615,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">492,663,000<span></span>
</td>
<td class="nump">561,896,000<span></span>
</td>
<td class="nump">$ 325,434,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,938,000<span></span>
</td>
<td class="nump">80,436,000<span></span>
</td>
<td class="nump">$ 62,302,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Accelerated depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,792,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bgne_ShanghaiChinaMember', window );">Shanghai, China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,054,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,485,000<span></span>
</td>
<td class="nump">$ 65,485,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land | Shanghai, China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,431,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="nump">$ 22,538,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress | Shanghai, China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,623,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=bgne_HopewellFacilityMember', window );">Hopewell Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272,670,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=bgne_HopewellFacilityMember', window );">Hopewell Facility | Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAcceleratedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAcceleratedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bgne_ShanghaiChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bgne_ShanghaiChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=bgne_HopewellFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=bgne_HopewellFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914419477008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net - Construction in Progress (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">$ 654,018<span></span>
</td>
<td class="nump">$ 740,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">528,629<span></span>
</td>
<td class="nump">579,649<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">89,897<span></span>
</td>
<td class="nump">119,380<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bgne_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">9,805<span></span>
</td>
<td class="nump">16,135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract', window );"><strong>Property and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">$ 25,687<span></span>
</td>
<td class="nump">$ 25,451<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=bgne_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=bgne_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914424593280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets - Intangible Assets Outstanding (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">$ 71,876<span></span>
</td>
<td class="nump">$ 73,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(20,781)<span></span>
</td>
<td class="num">(16,123)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">51,095<span></span>
</td>
<td class="nump">57,138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">62,889<span></span>
</td>
<td class="nump">64,274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(12,370)<span></span>
</td>
<td class="num">(7,807)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">50,519<span></span>
</td>
<td class="nump">56,467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross carrying amount</a></td>
<td class="nump">8,987<span></span>
</td>
<td class="nump">8,987<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">(8,411)<span></span>
</td>
<td class="num">(8,316)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">$ 576<span></span>
</td>
<td class="nump">$ 671<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914421255232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets - Useful Life (Details) - Weighted Average<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed products</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Other intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">11 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Other intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">11 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914536702048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Amortization Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 4,824<span></span>
</td>
<td class="nump">$ 7,239<span></span>
</td>
<td class="nump">$ 3,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales - Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">4,729<span></span>
</td>
<td class="nump">3,739<span></span>
</td>
<td class="nump">3,225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 95<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="nump">$ 751<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914419187216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets - Expected Amortization Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Year Ending December 31,</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 4,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">4,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">4,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2028</a></td>
<td class="nump">4,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2029</a></td>
<td class="nump">4,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">2030 and thereafter</a></td>
<td class="nump">27,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">51,095<span></span>
</td>
<td class="nump">$ 57,138<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales - Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Year Ending December 31,</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025</a></td>
<td class="nump">4,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">4,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">4,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2028</a></td>
<td class="nump">4,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2029</a></td>
<td class="nump">4,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">2030 and thereafter</a></td>
<td class="nump">27,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">50,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Year Ending December 31,</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025</a></td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2028</a></td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2029</a></td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">2030 and thereafter</a></td>
<td class="nump">241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">$ 576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914414815584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income/(Loss) Before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Components of income / (loss) before income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (533,001)<span></span>
</td>
<td class="num">$ (825,836)<span></span>
</td>
<td class="num">$ (1,961,037)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Components of income / (loss) before income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">201,516<span></span>
</td>
<td class="nump">117,446<span></span>
</td>
<td class="nump">67,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">PRC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Components of income / (loss) before income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">PRC</a></td>
<td class="num">(263,159)<span></span>
</td>
<td class="num">(315,852)<span></span>
</td>
<td class="num">(583,610)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Components of income / (loss) before income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">$ (471,358)<span></span>
</td>
<td class="num">$ (627,430)<span></span>
</td>
<td class="num">$ (1,445,171)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914424116336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Current and Deferred Components Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current tax expense (benefit)</a></td>
<td class="nump">$ 85,778<span></span>
</td>
<td class="nump">$ 55,185<span></span>
</td>
<td class="nump">$ 39,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax expense (benefit)</a></td>
<td class="nump">26,007<span></span>
</td>
<td class="nump">687<span></span>
</td>
<td class="nump">3,482<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">111,785<span></span>
</td>
<td class="nump">55,872<span></span>
</td>
<td class="nump">42,778<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current tax expense (benefit)</a></td>
<td class="nump">57,222<span></span>
</td>
<td class="nump">25,170<span></span>
</td>
<td class="nump">4,844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax expense (benefit)</a></td>
<td class="nump">23,556<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">PRC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current tax expense (benefit)</a></td>
<td class="nump">12,331<span></span>
</td>
<td class="nump">24,956<span></span>
</td>
<td class="nump">27,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax expense (benefit)</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">687<span></span>
</td>
<td class="nump">3,480<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current tax expense (benefit)</a></td>
<td class="nump">16,225<span></span>
</td>
<td class="nump">5,059<span></span>
</td>
<td class="nump">6,547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax expense (benefit)</a></td>
<td class="nump">$ 2,271<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914423540160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of the Statutory Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before tax</a></td>
<td class="num">$ (533,001)<span></span>
</td>
<td class="num">$ (825,836)<span></span>
</td>
<td class="num">$ (1,961,037)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Expected taxation at U.S. statutory tax rate</a></td>
<td class="num">$ (111,930)<span></span>
</td>
<td class="num">$ (173,426)<span></span>
</td>
<td class="num">$ (411,818)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign and preferential tax rate differential</a></td>
<td class="nump">93,741<span></span>
</td>
<td class="nump">144,310<span></span>
</td>
<td class="nump">209,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Non-deductible expenses</a></td>
<td class="nump">1,130<span></span>
</td>
<td class="nump">19,134<span></span>
</td>
<td class="nump">29,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation expenses</a></td>
<td class="nump">53,446<span></span>
</td>
<td class="nump">32,581<span></span>
</td>
<td class="nump">33,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State tax expense (benefit)</a></td>
<td class="num">(7,988)<span></span>
</td>
<td class="num">(5,872)<span></span>
</td>
<td class="nump">1,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">157,286<span></span>
</td>
<td class="nump">845,811<span></span>
</td>
<td class="nump">229,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Tax relief credits</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(704,928)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research tax credits and incentives</a></td>
<td class="num">(43,602)<span></span>
</td>
<td class="num">(64,343)<span></span>
</td>
<td class="num">(42,844)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_EffectiveIncomeTaxRateReconciliationDeductionResearchExpensesAmount', window );">Deductible research expenses</a></td>
<td class="num">(13,644)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion', window );">Tax on unremitted earnings</a></td>
<td class="nump">23,743<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount', window );">Foreign-derived intangible income</a></td>
<td class="num">(40,397)<span></span>
</td>
<td class="num">(37,395)<span></span>
</td>
<td class="num">(6,272)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 111,785<span></span>
</td>
<td class="nump">$ 55,872<span></span>
</td>
<td class="nump">$ 42,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(6.80%)<span></span>
</td>
<td class="num">(2.20%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_EffectiveIncomeTaxRateReconciliationDeductionResearchExpensesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Deduction, Research Expenses, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_EffectiveIncomeTaxRateReconciliationDeductionResearchExpensesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax benefit from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign-derived intangible income (FDII).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deduction for extraterritorial income exclusion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914415164224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Significant Components of Deferred Tax Assets (Liabilities) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred Tax Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and reserves</a></td>
<td class="nump">$ 121,549<span></span>
</td>
<td class="nump">$ 106,708<span></span>
</td>
<td class="nump">$ 97,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating losses carryforward</a></td>
<td class="nump">1,137,890<span></span>
</td>
<td class="nump">996,588<span></span>
</td>
<td class="nump">862,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">38,397<span></span>
</td>
<td class="nump">26,687<span></span>
</td>
<td class="nump">19,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Research tax credits</a></td>
<td class="nump">34,561<span></span>
</td>
<td class="nump">68,117<span></span>
</td>
<td class="nump">86,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign', window );">Tax relief credits</a></td>
<td class="nump">704,928<span></span>
</td>
<td class="nump">704,928<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible asset amortization</a></td>
<td class="nump">1,081,442<span></span>
</td>
<td class="nump">699,974<span></span>
</td>
<td class="nump">813,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_DeferredTaxAssetsPropertyLeaseLiabilityObligation', window );">Lease liability obligation</a></td>
<td class="nump">11,882<span></span>
</td>
<td class="nump">7,893<span></span>
</td>
<td class="nump">10,348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">R&amp;D and other capitalized costs</a></td>
<td class="nump">277,061<span></span>
</td>
<td class="nump">164,190<span></span>
</td>
<td class="nump">63,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">3,407,710<span></span>
</td>
<td class="nump">2,775,085<span></span>
</td>
<td class="nump">1,952,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(3,403,505)<span></span>
</td>
<td class="num">(2,771,470)<span></span>
</td>
<td class="num">(1,943,775)<span></span>
</td>
<td class="num">$ (1,758,409)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">4,205<span></span>
</td>
<td class="nump">3,615<span></span>
</td>
<td class="nump">8,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property, plant and equipment, net</a></td>
<td class="num">(10,795)<span></span>
</td>
<td class="num">(12,374)<span></span>
</td>
<td class="num">(14,480)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings', window );">Tax on unremitted earnings</a></td>
<td class="num">(23,735)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right of use asset</a></td>
<td class="num">(11,682)<span></span>
</td>
<td class="num">(7,735)<span></span>
</td>
<td class="num">(10,098)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total gross deferred tax liabilities</a></td>
<td class="num">(46,212)<span></span>
</td>
<td class="num">(20,109)<span></span>
</td>
<td class="num">(24,578)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax assets/(liabilities)</a></td>
<td class="num">$ (42,007)<span></span>
</td>
<td class="num">$ (16,494)<span></span>
</td>
<td class="num">$ (15,996)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_DeferredTaxAssetsPropertyLeaseLiabilityObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Property, Lease Liability Obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_DeferredTaxAssetsPropertyLeaseLiabilityObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914421215744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Schedule of Valuation Allowances (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_DeferredTaxAssetsActivityRollForward', window );"><strong>Deferred Tax Assets Activity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Beginning balance, as of January 1</a></td>
<td class="nump">$ 2,771,470<span></span>
</td>
<td class="nump">$ 1,943,775<span></span>
</td>
<td class="nump">$ 1,758,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_DeferredTaxAssetValuationAllowanceChangesIncludedInEarnings', window );">Additions/(subtractions) charged to income tax provision</a></td>
<td class="nump">157,286<span></span>
</td>
<td class="nump">845,811<span></span>
</td>
<td class="nump">229,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_DeferredTaxAssetValuationAllowanceGainLossIncludedInOtherComprehensiveIncomeLoss', window );">Additions/(subtractions) charged to equity</a></td>
<td class="nump">497,823<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_DeferredTaxAssetValuationAllowanceCurrencyTranslationAndOther', window );">Currency translation and other</a></td>
<td class="num">(23,074)<span></span>
</td>
<td class="num">(18,116)<span></span>
</td>
<td class="num">(44,184)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Ending balance, as of December 31</a></td>
<td class="nump">$ 3,403,505<span></span>
</td>
<td class="nump">$ 2,771,470<span></span>
</td>
<td class="nump">$ 1,943,775<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_DeferredTaxAssetValuationAllowanceChangesIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset, Valuation Allowance, Changes Included In Earnings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_DeferredTaxAssetValuationAllowanceChangesIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_DeferredTaxAssetValuationAllowanceCurrencyTranslationAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset, Valuation Allowance, Currency Translation And Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_DeferredTaxAssetValuationAllowanceCurrencyTranslationAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_DeferredTaxAssetValuationAllowanceGainLossIncludedInOtherComprehensiveIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset, Valuation Allowance, Gain (Loss) Included In Other Comprehensive Income (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_DeferredTaxAssetValuationAllowanceGainLossIncludedInOtherComprehensiveIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_DeferredTaxAssetsActivityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Activity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_DeferredTaxAssetsActivityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914419466160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Narratives (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 6,720,659<span></span>
</td>
<td class="nump">$ 5,945,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign', window );">Tax relief credits</a></td>
<td class="nump">704,928<span></span>
</td>
<td class="nump">704,928<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">17,239<span></span>
</td>
<td class="nump">14,264<span></span>
</td>
<td class="nump">11,555<span></span>
</td>
<td class="nump">$ 9,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_TaxBenefitFromForeignTaxStatus', window );">Tax benefit from foreign tax status</a></td>
<td class="nump">$ 4,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_TaxBenefitFromForeignTaxStatusPerShare', window );">Tax benefit from foreign tax status (per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings', window );">Tax on unremitted earnings</a></td>
<td class="nump">$ 23,735<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_StateAdministrationOfTaxationChinaMember', window );">State Administration of Taxation, China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">2,185,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_SwissFederalTaxAdministrationFTAMember', window );">Swiss Federal Tax Administration (FTA)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">4,526,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign', window );">Tax relief credits</a></td>
<td class="nump">704,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">BeiGene USA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 43,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_TaxBenefitFromForeignTaxStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Benefit From Foreign Tax Status</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_TaxBenefitFromForeignTaxStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_TaxBenefitFromForeignTaxStatusPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Benefit From Foreign Tax Status, Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_TaxBenefitFromForeignTaxStatusPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_StateAdministrationOfTaxationChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_StateAdministrationOfTaxationChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_SwissFederalTaxAdministrationFTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_SwissFederalTaxAdministrationFTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914531347024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Gross Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Gross unrecognized tax benefits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance, as of January 1</a></td>
<td class="nump">$ 14,264<span></span>
</td>
<td class="nump">$ 11,555<span></span>
</td>
<td class="nump">$ 9,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions based on tax positions related to prior tax years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions based on tax positions related to prior tax years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to the current tax year</a></td>
<td class="nump">2,975<span></span>
</td>
<td class="nump">2,709<span></span>
</td>
<td class="nump">1,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Reductions based on lapse of statute of limitations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance, as of December 31</a></td>
<td class="nump">$ 17,239<span></span>
</td>
<td class="nump">$ 14,264<span></span>
</td>
<td class="nump">$ 11,555<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914415124400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid expenses and other current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_PrepaidResearchAndDevelopmentCosts', window );">Prepaid research and development costs</a></td>
<td class="nump">$ 64,277<span></span>
</td>
<td class="nump">$ 60,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidTaxes', window );">Prepaid taxes</a></td>
<td class="nump">23,792<span></span>
</td>
<td class="nump">37,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">32,828<span></span>
</td>
<td class="nump">37,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_PrepaidGeneralAndAdministrativeExpensesCurrent', window );">Prepaid general and administrative expenses</a></td>
<td class="nump">21,253<span></span>
</td>
<td class="nump">14,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_PrepaidManufacturingCosts', window );">Prepaid manufacturing cost</a></td>
<td class="nump">19,333<span></span>
</td>
<td class="nump">42,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Short-term restricted cash</a></td>
<td class="nump">9,312<span></span>
</td>
<td class="nump">11,473<span></span>
</td>
<td class="nump">$ 196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">6,242<span></span>
</td>
<td class="nump">8,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other current assets</a></td>
<td class="nump">15,882<span></span>
</td>
<td class="nump">44,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 192,919<span></span>
</td>
<td class="nump">$ 257,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_PrepaidGeneralAndAdministrativeExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid General and Administrative Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_PrepaidGeneralAndAdministrativeExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_PrepaidManufacturingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Manufacturing Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_PrepaidManufacturingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_PrepaidResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration paid in advance for research and development that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_PrepaidResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914415172544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information - Schedule of Other Non-current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrentAbstract', window );"><strong>Other non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">$ 128,933<span></span>
</td>
<td class="nump">$ 89,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_PrepaidSupplyCost', window );">Prepaid supply cost</a></td>
<td class="nump">12,249<span></span>
</td>
<td class="nump">18,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_RentalDepositsAndOther', window );">Rental deposits and other</a></td>
<td class="nump">8,481<span></span>
</td>
<td class="nump">8,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_PrepaymentOfLongTermAsset', window );">Prepayment of property and equipment</a></td>
<td class="nump">5,927<span></span>
</td>
<td class="nump">4,144<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivableNoncurrent', window );">Prepaid VAT</a></td>
<td class="nump">2,875<span></span>
</td>
<td class="nump">2,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Long-term restricted cash</a></td>
<td class="nump">2,025<span></span>
</td>
<td class="nump">2,711<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total</a></td>
<td class="nump">$ 160,490<span></span>
</td>
<td class="nump">$ 125,362<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_PrepaidSupplyCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Supply Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_PrepaidSupplyCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_PrepaymentOfLongTermAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of prepayment of long term asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_PrepaymentOfLongTermAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_RentalDepositsAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of rental deposits and other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_RentalDepositsAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValueAddedTaxReceivableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due after one year of the balance sheet date (or one operating cycle), if longer of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValueAddedTaxReceivableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914413536784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information - Schedule of Accrued Expenses and Other Payables (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued expenses and other payables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation related</a></td>
<td class="nump">$ 248,348<span></span>
</td>
<td class="nump">$ 217,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_AccruedSalesRebatesAndReturnsCurrent', window );">Sales rebates and returns related</a></td>
<td class="nump">235,600<span></span>
</td>
<td class="nump">139,936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_AccruedLiabilitiesExternalResearchAndDevelopment', window );">External research and development activities related</a></td>
<td class="nump">154,269<span></span>
</td>
<td class="nump">162,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_AccruedExpensesCommercialActivities', window );">Commercial activities</a></td>
<td class="nump">77,530<span></span>
</td>
<td class="nump">87,572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_AccruedGeneralAndAdministrativeExpensesCurrent', window );">Accrued general and administrative expenses</a></td>
<td class="nump">31,106<span></span>
</td>
<td class="nump">36,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedPayrollTaxesCurrent', window );">Individual income tax and other taxes</a></td>
<td class="nump">34,904<span></span>
</td>
<td class="nump">30,083<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_AccruedProfessionalFeesAndOtherCurrent', window );">Other</a></td>
<td class="nump">21,956<span></span>
</td>
<td class="nump">19,165<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 803,713<span></span>
</td>
<td class="nump">$ 693,731<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_AccruedExpensesCommercialActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Expenses, Commercial Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_AccruedExpensesCommercialActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_AccruedGeneralAndAdministrativeExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued General And Administrative Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_AccruedGeneralAndAdministrativeExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_AccruedLiabilitiesExternalResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date related to external research and development activities related</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_AccruedLiabilitiesExternalResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_AccruedProfessionalFeesAndOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received and amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_AccruedProfessionalFeesAndOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_AccruedSalesRebatesAndReturnsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Sales Rebates and Returns, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_AccruedSalesRebatesAndReturnsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedPayrollTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedPayrollTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914423578864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplemental Balance Sheet Information - Schedule of Other Long-term Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrentAbstract', window );"><strong>Other long-term liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceLiability', window );">Deferred government grant income</a></td>
<td class="nump">$ 30,324<span></span>
</td>
<td class="nump">$ 34,204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent', window );">Pension liability</a></td>
<td class="nump">16,405<span></span>
</td>
<td class="nump">14,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationsNoncurrent', window );">Asset retirement obligation</a></td>
<td class="nump">3,794<span></span>
</td>
<td class="nump">1,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesNoncurrent', window );">Other</a></td>
<td class="nump">16,212<span></span>
</td>
<td class="nump">484<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Total</a></td>
<td class="nump">$ 66,735<span></span>
</td>
<td class="nump">$ 50,810<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligationsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncurrent portion of the carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 410<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481850/410-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligationsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension plan, classified as noncurrent. Excludes other postretirement benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability from government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914417426704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Short-term and Long-term Debt Obligations (Details)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Short-term debt</a></td>
<td class="nump">$ 851,529,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 688,366,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 6,215,538,000<span></span>
</td>
<td class="nump">&#165; 4,885,838,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">166,484,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,618,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,215,211,000<span></span>
</td>
<td class="nump">1,402,643,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of short-term loans | $</a></td>
<td class="nump">704,216,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309,576,000<span></span>
</td>
<td class="nump">$ 417,081,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt | $</a></td>
<td class="nump">28,031,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,690,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from long-term loan | $</a></td>
<td class="nump">$ 9,053,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,502,000<span></span>
</td>
<td class="nump">$ 37,372,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAxis=bgne_ChinaIndustrialBankMember', window );">China Industrial Bank | Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest Rate</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanDatedApril42018Member', window );">Short Term Bank Loan Dated April 4 2018 | China Construction Bank | Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">580,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Short-term debt</a></td>
<td class="nump">$ 16,440,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,089,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanDatedJanuary222020Member', window );">Short Term Bank Loan Dated January 22, 2020 | China Construction Bank | Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="nump">$ 8,730,000<span></span>
</td>
<td class="nump">&#165; 62,857,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanDatedJanuary222020Member', window );">Short Term Bank Loan Dated January 22, 2020 | China Merchants Bank | Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest Rate</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Short-term debt</a></td>
<td class="nump">$ 8,611,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,856,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,857,000<span></span>
</td>
<td class="nump">62,857,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanDatedNovember92020Member', window );">Short Term Bank Loan Dated November 9, 2020 | China Merchants Bank | Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">378,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Short-term debt</a></td>
<td class="nump">$ 8,148,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,636,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 59,475,000<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Fixed annual interest rate (as a percent)</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="nump">$ 5,562,000<span></span>
</td>
<td class="nump">&#165; 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bgne_LongTermBankLoanDatedJuly292022Member', window );">Long Term Bank Loan Dated July 29, 2022 | China Merchants Bank | Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Fixed annual interest rate (as a percent)</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bgne_LongTermBankLoanDatedJuly292022Member', window );">Long Term Bank Loan Dated July 29, 2022 | China CITIC Bank | Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 64,377,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,469,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">469,900,000<span></span>
</td>
<td class="nump">415,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from long-term loan</a></td>
<td class="nump">9,053,000<span></span>
</td>
<td class="nump">&#165; 65,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bgne_LongTermBankLoanDatedJuly292022Member', window );">Long Term Bank Loan Dated July 29, 2022 | China CITIC Bank | Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Short-term debt</a></td>
<td class="nump">1,384,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanDatedJuly282023Member', window );">Short Term Bank Loan Dated July 28, 2023 | China Merchants Bank | Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit | $</a></td>
<td class="nump">$ 380,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest Rate</a></td>
<td class="nump">6.20%<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Short-term debt</a></td>
<td class="nump">$ 380,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,773,723,000<span></span>
</td>
<td class="nump">2,129,321,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanDatedDecember202023Member', window );">Short Term Bank Loan Dated December 20, 2023 | China Minsheng Bank | Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit | $</a></td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest Rate</a></td>
<td class="nump">6.80%<span></span>
</td>
<td class="nump">6.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Short-term debt</a></td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,094,891,000<span></span>
</td>
<td class="nump">1,064,660,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanDatedMarch212024Member', window );">Short Term Bank Loan Dated March 21, 2024 | China Industrial Bank | Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">364 days<span></span>
</td>
<td class="text">364 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Short-term debt</a></td>
<td class="nump">$ 92,475,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">675,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanDatedJune52023Member', window );">Short Term Bank Loan Dated June 5 2023 | China Merchants Bank | Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest Rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Short-term debt</a></td>
<td class="nump">$ 54,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,356,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanDatedMay42023Member', window );">Short Term Bank Loan Dated May 4 2023 | HSBC Bank | Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest Rate</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Short-term debt</a></td>
<td class="nump">$ 46,580,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,903,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340,000,000<span></span>
</td>
<td class="nump">340,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanDatedMay302023Member', window );">Short Term Bank Loan Dated May 30 2023 | China Industrial Bank | Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest Rate</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Short-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,177,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanDatedNovember142023Member', window );">Short Term Bank Loan Dated November 14, 2023 | Shanghai Pudong Development Bank | Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest Rate</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Short-term debt</a></td>
<td class="nump">$ 93,091,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,312,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">679,492,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanDatedMay252023Member', window );">Short Term Bank Loan Dated, May 25, 2023 | China Merchants Bank | Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest Rate</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Short-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,037,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">199,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanDatedMay252023Member', window );">Short Term Bank Loan Dated, May 25, 2023 | Shanghai Pudong Development Bank | Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bgne_LongTermBankLoanApril42018Member', window );">Long-term bank April 4, 2018 | China Construction Bank | Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">580,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest Rate</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 41,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,174,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">420,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="nump">$ 13,739,000<span></span>
</td>
<td class="nump">&#165; 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bgne_LongTermBankLoanDatedJanuary222020Member', window );">Long Term Bank Loan Dated January 22, 2020 | China Merchants Bank | Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 27,987,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,638,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,286,000<span></span>
</td>
<td class="nump">267,143,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bgne_LongTermBankLoanDatedNovember92020Member', window );">Long-term bank November 9, 2020 | China Merchants Bank | Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">378,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">$ 33,020,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,337,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 241,025,000<span></span>
</td>
<td class="nump">&#165; 300,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanMaturingJanuary272025Member', window );">Short Term Bank Loan Maturing January 27, 2025 | China Minsheng Bank | Loans Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Short-term debt | $</a></td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=bgne_ChinaIndustrialBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=bgne_ChinaIndustrialBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanDatedApril42018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanDatedApril42018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=bgne_ChinaConstructionBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=bgne_ChinaConstructionBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanDatedJanuary222020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanDatedJanuary222020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=bgne_ChinaMerchantsBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=bgne_ChinaMerchantsBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanDatedNovember92020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanDatedNovember92020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bgne_LongTermBankLoanDatedJuly292022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bgne_LongTermBankLoanDatedJuly292022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=bgne_ChinaCITICBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=bgne_ChinaCITICBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanDatedJuly282023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanDatedJuly282023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanDatedDecember202023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanDatedDecember202023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=bgne_ChinaMinshengBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=bgne_ChinaMinshengBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanDatedMarch212024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanDatedMarch212024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanDatedJune52023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanDatedJune52023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanDatedMay42023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanDatedMay42023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=bgne_HSBCBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=bgne_HSBCBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanDatedMay302023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanDatedMay302023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanDatedNovember142023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanDatedNovember142023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=bgne_ShanghaiPudongDevelopmentBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=bgne_ShanghaiPudongDevelopmentBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanDatedMay252023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanDatedMay252023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bgne_LongTermBankLoanApril42018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bgne_LongTermBankLoanApril42018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bgne_LongTermBankLoanDatedJanuary222020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bgne_LongTermBankLoanDatedJanuary222020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bgne_LongTermBankLoanDatedNovember92020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bgne_LongTermBankLoanDatedNovember92020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanMaturingJanuary272025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=bgne_ShortTermBankLoanMaturingJanuary272025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914417550560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Contractual maturities of debt obligations (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationFiscalYearMaturityAbstract', window );"><strong>Contractual Maturities of Debt Obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">Year ending December&#160;31,&#160;2025</a></td>
<td class="nump">$ 851,529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">Year ending December&#160;31,&#160;2026</a></td>
<td class="nump">46,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">Year ending December 31, 2027</a></td>
<td class="nump">46,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFourthYear', window );">Year ending December 31, 2028</a></td>
<td class="nump">25,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInFifthYear', window );">Year ending December 31, 2029</a></td>
<td class="nump">19,657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueAfterFifthYear', window );">Thereafter</a></td>
<td class="nump">28,756<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total</a></td>
<td class="nump">$ 1,018,013<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueAfterFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueAfterFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInFifthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInFifthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInFourthYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInFourthYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationFiscalYearMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationFiscalYearMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914421197472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="nump">$ 46,894,000<span></span>
</td>
<td class="nump">$ 20,800,000<span></span>
</td>
<td class="nump">$ 21,699,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Interest capitalized</a></td>
<td class="nump">32,158,000<span></span>
</td>
<td class="nump">16,571,000<span></span>
</td>
<td class="nump">2,594,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">$ 19,723,000<span></span>
</td>
<td class="nump">$ 3,484<span></span>
</td>
<td class="nump">$ 22,489<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914418714768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue - Product Sales (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenue - net</a></td>
<td class="nump">$ 3,810,241<span></span>
</td>
<td class="nump">$ 2,458,779<span></span>
</td>
<td class="nump">$ 1,415,921<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeReductions', window );">Product revenue - gross</a></td>
<td class="nump">4,786,744<span></span>
</td>
<td class="nump">2,718,969<span></span>
</td>
<td class="nump">1,438,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_RevenueRecognitionRevenueReduction', window );">Less: Rebates and sales returns</a></td>
<td class="num">(1,007,198)<span></span>
</td>
<td class="num">(529,117)<span></span>
</td>
<td class="num">(183,828)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenue - net</a></td>
<td class="nump">3,779,546<span></span>
</td>
<td class="nump">2,189,852<span></span>
</td>
<td class="nump">1,254,612<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net | BRUKINSA&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenue - net</a></td>
<td class="nump">2,644,226<span></span>
</td>
<td class="nump">1,290,396<span></span>
</td>
<td class="nump">564,651<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net | Tislelizumab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenue - net</a></td>
<td class="nump">620,836<span></span>
</td>
<td class="nump">536,620<span></span>
</td>
<td class="nump">422,885<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net | XGEVA&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenue - net</a></td>
<td class="nump">224,403<span></span>
</td>
<td class="nump">92,828<span></span>
</td>
<td class="nump">63,398<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net | BLINCYTO&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenue - net</a></td>
<td class="nump">74,331<span></span>
</td>
<td class="nump">54,342<span></span>
</td>
<td class="nump">36,107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net | KYPROLIS&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenue - net</a></td>
<td class="nump">66,171<span></span>
</td>
<td class="nump">39,799<span></span>
</td>
<td class="nump">13,696<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net | POBEVCY&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenue - net</a></td>
<td class="nump">53,509<span></span>
</td>
<td class="nump">56,547<span></span>
</td>
<td class="nump">38,124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net | REVLIMID&#174;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenue - net</a></td>
<td class="nump">36,028<span></span>
</td>
<td class="nump">76,018<span></span>
</td>
<td class="nump">79,049<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product revenue - net</a></td>
<td class="nump">$ 60,042<span></span>
</td>
<td class="nump">$ 43,302<span></span>
</td>
<td class="nump">$ 36,702<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeReductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from Contract with Customer, Excluding Assessed Tax, Before Reductions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeReductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_RevenueRecognitionRevenueReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Revenue Reduction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_RevenueRecognitionRevenueReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_ProductNameAxis=bgne_BRUKINSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_ProductNameAxis=bgne_BRUKINSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_ProductNameAxis=bgne_TislelizumabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_ProductNameAxis=bgne_TislelizumabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_ProductNameAxis=bgne_XGEVAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_ProductNameAxis=bgne_XGEVAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_ProductNameAxis=bgne_BLINCYTOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_ProductNameAxis=bgne_BLINCYTOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_ProductNameAxis=bgne_KYPROLISMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_ProductNameAxis=bgne_KYPROLISMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_ProductNameAxis=bgne_POBEVCYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_ProductNameAxis=bgne_POBEVCYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_ProductNameAxis=bgne_REVLIMIDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_ProductNameAxis=bgne_REVLIMIDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_ProductNameAxis=bgne_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_ProductNameAxis=bgne_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914414826880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue - Accrued Sales Rebates and Returns (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_AccruedSalesRebatesAndReturnsRollForward', window );"><strong>Accrued sales rebates and returns</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions', window );">Beginning balance</a></td>
<td class="nump">$ 286,299<span></span>
</td>
<td class="nump">$ 170,371<span></span>
</td>
<td class="nump">$ 50,397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_RevenueRecognitionRevenueReduction', window );">Amounts charged against product revenue</a></td>
<td class="nump">1,007,198<span></span>
</td>
<td class="nump">529,117<span></span>
</td>
<td class="nump">183,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_RevenueRecognitionRevenueReductionsPaymentsAndCredits', window );">Payments and credits</a></td>
<td class="num">(891,270)<span></span>
</td>
<td class="num">(409,143)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions', window );">Ending balance</a></td>
<td class="nump">286,299<span></span>
</td>
<td class="nump">170,371<span></span>
</td>
<td class="nump">50,397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bgne_RebatesReturnsAndOtherDeductionsMember', window );">Rebates, Returns and Other Deductions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_AccruedSalesRebatesAndReturnsRollForward', window );"><strong>Accrued sales rebates and returns</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions', window );">Beginning balance</a></td>
<td class="nump">139,936<span></span>
</td>
<td class="nump">41,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_RevenueRecognitionRevenueReduction', window );">Amounts charged against product revenue</a></td>
<td class="nump">491,756<span></span>
</td>
<td class="nump">275,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_RevenueRecognitionRevenueReductionsPaymentsAndCredits', window );">Payments and credits</a></td>
<td class="num">(396,092)<span></span>
</td>
<td class="num">(176,912)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions', window );">Ending balance</a></td>
<td class="nump">235,600<span></span>
</td>
<td class="nump">139,936<span></span>
</td>
<td class="nump">41,817<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bgne_ContraARAccrualsMember', window );">Contra AR Accruals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_AccruedSalesRebatesAndReturnsRollForward', window );"><strong>Accrued sales rebates and returns</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_AccountsReceivableAllowanceForChargebacksAndCreditLoss', window );">Beginning balance</a></td>
<td class="nump">30,435<span></span>
</td>
<td class="nump">8,580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_RevenueRecognitionRevenueReduction', window );">Amounts charged against product revenue</a></td>
<td class="nump">515,442<span></span>
</td>
<td class="nump">254,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_RevenueRecognitionRevenueReductionsPaymentsAndCredits', window );">Payments and credits</a></td>
<td class="num">(495,178)<span></span>
</td>
<td class="num">(232,231)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_AccountsReceivableAllowanceForChargebacksAndCreditLoss', window );">Ending balance</a></td>
<td class="nump">$ 50,699<span></span>
</td>
<td class="nump">$ 30,435<span></span>
</td>
<td class="nump">$ 8,580<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_AccountsReceivableAllowanceForChargebacksAndCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Allowance For Chargebacks And Credit Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_AccountsReceivableAllowanceForChargebacksAndCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_AccruedSalesRebatesAndReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Sales Rebates and Returns [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_AccruedSalesRebatesAndReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Allowance For Chargebacks And Credit Loss And Reserves For Sales Returns, Rebates And Other Deductions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition Reserve For Sales Returns, Rebates And Other Deductions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_RevenueRecognitionRevenueReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Revenue Reduction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_RevenueRecognitionRevenueReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_RevenueRecognitionRevenueReductionsPaymentsAndCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition Revenue Reductions Payments And Credits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_RevenueRecognitionRevenueReductionsPaymentsAndCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bgne_RebatesReturnsAndOtherDeductionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bgne_RebatesReturnsAndOtherDeductionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bgne_ContraARAccrualsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bgne_ContraARAccrualsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914424007312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (644,786)<span></span>
</td>
<td class="num">$ (881,708)<span></span>
</td>
<td class="num">$ (2,003,815)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding for computing basic loss per share (in shares)</a></td>
<td class="nump">1,368,746,793<span></span>
</td>
<td class="nump">1,357,034,547<span></span>
</td>
<td class="nump">1,340,729,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding for computing diluted loss per share (in shares)</a></td>
<td class="nump">1,368,746,793<span></span>
</td>
<td class="nump">1,357,034,547<span></span>
</td>
<td class="nump">1,340,729,572<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per share basic (in dollars per share)</a></td>
<td class="num">$ (0.47)<span></span>
</td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (1.49)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Loss per share diluted (in dollars per share)</a></td>
<td class="num">$ (0.47)<span></span>
</td>
<td class="num">$ (0.65)<span></span>
</td>
<td class="num">$ (1.49)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914424088848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - 2016 Share Option and Incentive Plan (Details) - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2018</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bgne_ShareOptionAndIncentivePlan2016Member', window );">2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares reserved and available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,029,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Outstanding number of shares (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in ordinary shares authorized (in shares)</a></td>
<td class="nump">29,603,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,200,000<span></span>
</td>
<td class="nump">38,553,159<span></span>
</td>
<td class="nump">66,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bgne_ShareOptionAndIncentivePlan2016Member', window );">2016 Plan | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,064,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bgne_ShareIncentivePlan2011Member', window );">2011 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriod', window );">Shares cancelled or forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,166,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bgne_ThirdAmendedAndRestated2016PlanMember', window );">Third Amended and Restated 2016 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in ordinary shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,820,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options granted in a plan that were canceled after the initial public offering date, as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bgne_ShareOptionAndIncentivePlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bgne_ShareOptionAndIncentivePlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bgne_ShareIncentivePlan2011Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bgne_ShareIncentivePlan2011Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bgne_ThirdAmendedAndRestated2016PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bgne_ThirdAmendedAndRestated2016PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914535296640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share-Based Compensation - 2018 Inducement Equity Plan (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=bgne_InducementEquityPlan2018Member', window );">Inducement Equity Plan2018</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares reserved and available for issuance (in shares)</a></td>
<td class="nump">12,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bgne_InducementEquityPlan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bgne_InducementEquityPlan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914414816000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - 2018 Employee Share Purchase Plan (Details) - Employee Share Purchase Plan 2018 - shares<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares reserved and available for issuance (in shares)</a></td>
<td class="nump">12,425,315<span></span>
</td>
<td class="nump">7,355,315<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in ordinary shares authorized (in shares)</a></td>
<td class="nump">5,070,000<span></span>
</td>
<td class="nump">3,855,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod', window );">Offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountOnPurchasePriceOfCommonStockPercent', window );">Discount on purchase price of common stock (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_MaximumPercentageOfEligibleEarningsSetSideToPurchaseOrdinaryShares', window );">Maximum percentage of eligible earnings as after-tax withholdings to purchase ordinary shares (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberOfAvailableSharesAvailableForFutureIssuance', window );">Shares available for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,953,682<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_MaximumPercentageOfEligibleEarningsSetSideToPurchaseOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Percentage of Eligible Earnings Set a Side to Purchase Ordinary Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_MaximumPercentageOfEligibleEarningsSetSideToPurchaseOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountOnPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Discount on Purchase Price of Common Stock, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountOnPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Offering Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberOfAvailableSharesAvailableForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number Of Available Shares Available For Future Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberOfAvailableSharesAvailableForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bgne_EmployeeSharePurchasePlan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bgne_EmployeeSharePurchasePlan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914419423376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share-Based Compensation - Shares Issued Under Employee Share Purchase Plan (Details) - Employee Share Purchase Plan 2018 - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Aug. 31, 2023</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Number of Ordinary Shares Issued ( in shares)</a></td>
<td class="nump">1,035,996<span></span>
</td>
<td class="nump">1,021,397<span></span>
</td>
<td class="nump">794,144<span></span>
</td>
<td class="nump">930,582<span></span>
</td>
<td class="nump">861,315<span></span>
</td>
<td class="nump">667,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_SharePriceAmericanDepositoryShares', window );">Market price, ADS (in dollars per share)</a></td>
<td class="nump">$ 165.20<span></span>
</td>
<td class="nump">$ 165.65<span></span>
</td>
<td class="nump">$ 207.55<span></span>
</td>
<td class="nump">$ 171.10<span></span>
</td>
<td class="nump">$ 171.66<span></span>
</td>
<td class="nump">$ 210.52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Market price, Ordinary (in dollars per share)</a></td>
<td class="nump">12.69<span></span>
</td>
<td class="nump">12.74<span></span>
</td>
<td class="nump">15.97<span></span>
</td>
<td class="nump">13.16<span></span>
</td>
<td class="nump">13.20<span></span>
</td>
<td class="nump">16.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice', window );">Purchase price, ADS (in dollars per share)</a></td>
<td class="nump">140.27<span></span>
</td>
<td class="nump">140.80<span></span>
</td>
<td class="nump">176.42<span></span>
</td>
<td class="nump">145.44<span></span>
</td>
<td class="nump">145.91<span></span>
</td>
<td class="nump">178.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice', window );">Purchase Price, Ordinary (in dollars per share)</a></td>
<td class="nump">$ 10.78<span></span>
</td>
<td class="nump">$ 10.83<span></span>
</td>
<td class="nump">$ 13.57<span></span>
</td>
<td class="nump">$ 11.19<span></span>
</td>
<td class="nump">$ 11.22<span></span>
</td>
<td class="nump">$ 13.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds</a></td>
<td class="nump">$ 11,178<span></span>
</td>
<td class="nump">$ 11,063<span></span>
</td>
<td class="nump">$ 10,777<span></span>
</td>
<td class="nump">$ 10,414<span></span>
</td>
<td class="nump">$ 9,667<span></span>
</td>
<td class="nump">$ 9,183<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_SharePriceAmericanDepositoryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of each American Depository Share. Each American Depositary Share represents 13 ordinary shares of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_SharePriceAmericanDepositoryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period American Depository Shares Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bgne_EmployeeSharePurchasePlan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bgne_EmployeeSharePurchasePlan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914424080464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Options and Restricted Shares and Restricted Stock Units Vesting Periods (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Contractual life (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of award (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of award (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of award (in years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Share Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of award (in years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914413639808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Share Option Rollforward (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number&#160;of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning of the year (in shares)</a></td>
<td class="nump">78,145,113<span></span>
</td>
<td class="nump">76,526,853<span></span>
</td>
<td class="nump">72,204,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">9,180,301<span></span>
</td>
<td class="nump">9,817,925<span></span>
</td>
<td class="nump">12,516,816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(6,812,624)<span></span>
</td>
<td class="num">(6,974,331)<span></span>
</td>
<td class="num">(5,898,217)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(2,530,134)<span></span>
</td>
<td class="num">(1,225,334)<span></span>
</td>
<td class="num">(2,296,634)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end of the year (in shares)</a></td>
<td class="nump">77,982,656<span></span>
</td>
<td class="nump">78,145,113<span></span>
</td>
<td class="nump">76,526,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options - Exercisable (in shares)</a></td>
<td class="nump">60,173,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options - Vested and expected to vest (in shares)</a></td>
<td class="nump">75,311,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the beginning of the year (in dollars per share)</a></td>
<td class="nump">$ 9.06<span></span>
</td>
<td class="nump">$ 7.85<span></span>
</td>
<td class="nump">$ 7.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">12.53<span></span>
</td>
<td class="nump">16.37<span></span>
</td>
<td class="nump">12.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">3.87<span></span>
</td>
<td class="nump">4.54<span></span>
</td>
<td class="nump">4.63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">15.87<span></span>
</td>
<td class="nump">17.60<span></span>
</td>
<td class="nump">16.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end of the year (in dollars per share)</a></td>
<td class="nump">9.70<span></span>
</td>
<td class="nump">9.06<span></span>
</td>
<td class="nump">7.85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price - Exercisable (in dollars per share)</a></td>
<td class="nump">8.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price - Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">9.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted Average Grant Date&#160;Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 6.62<span></span>
</td>
<td class="nump">$ 8.14<span></span>
</td>
<td class="nump">$ 6.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">4 years 9 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract', window );"><strong>Aggregate Intrinsic&#160;Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercised</a></td>
<td class="nump">$ 69,946<span></span>
</td>
<td class="nump">$ 92,051<span></span>
</td>
<td class="nump">$ 52,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="nump">429,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at the end of the period</a></td>
<td class="nump">406,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest</a></td>
<td class="nump">426,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total fair value of the employee share option awards vested</a></td>
<td class="nump">$ 68,420<span></span>
</td>
<td class="nump">$ 61,121<span></span>
</td>
<td class="nump">$ 62,548<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract', window );"><strong>Aggregate Intrinsic&#160;Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_ShareBasedPaymentArrangementNonvestedAwardOptionNumberOfShares', window );">Employee service share based compensation nonvested stock options</a></td>
<td class="nump">15,137,970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized share-based compensation costs</a></td>
<td class="nump">$ 82,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period of unrecognized share-based compensation cost over average amortization (in years)</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_ShareBasedPaymentArrangementNonvestedAwardOptionNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee Service Share Based Compensation Nonvested Stock Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_ShareBasedPaymentArrangementNonvestedAwardOptionNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914424417744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Fair Value Assumptions (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Significant unobservable inputs used in the fair value measurement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum', window );">Expected exercise multiple, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Significant unobservable inputs used in the fair value measurement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum (as percent)</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum (as percent)</a></td>
<td class="nump">4.60%<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum', window );">Expected exercise multiple, maximum</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum (as percent)</a></td>
<td class="nump">57.00%<span></span>
</td>
<td class="nump">58.00%<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum (as percent)</a></td>
<td class="nump">58.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (as percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Contractual life (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Significant unobservable inputs used in the fair value measurement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of ordinary share (in dollars per share)</a></td>
<td class="nump">$ 5.72<span></span>
</td>
<td class="nump">$ 7.26<span></span>
</td>
<td class="nump">$ 5.51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Significant unobservable inputs used in the fair value measurement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of ordinary share (in dollars per share)</a></td>
<td class="nump">$ 9.19<span></span>
</td>
<td class="nump">$ 10.72<span></span>
</td>
<td class="nump">$ 9.04<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the expected maximum exercise multiple that is used as an assumption in estimating the fair value of share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914415034032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Restricted Share Units (Details) - Restricted Share Units (RSUs) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Numbers of&#160;Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at the beginning of the year (in shares)</a></td>
<td class="nump">66,401,023<span></span>
</td>
<td class="nump">55,397,173<span></span>
</td>
<td class="nump">36,082,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">49,693,592<span></span>
</td>
<td class="nump">34,573,994<span></span>
</td>
<td class="nump">38,707,669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(21,251,477)<span></span>
</td>
<td class="num">(17,862,598)<span></span>
</td>
<td class="num">(12,533,586)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(9,012,471)<span></span>
</td>
<td class="num">(5,707,546)<span></span>
</td>
<td class="num">(6,859,892)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at the end of the year (in shares)</a></td>
<td class="nump">85,830,667<span></span>
</td>
<td class="nump">66,401,023<span></span>
</td>
<td class="nump">55,397,173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestOutstandingNumber', window );">Number of Shares - Expected to vest (in shares)</a></td>
<td class="nump">72,956,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant&#160;Date&#160;Fair&#160;Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at the beginning of the year (in dollars per share)</a></td>
<td class="nump">$ 15.22<span></span>
</td>
<td class="nump">$ 14.87<span></span>
</td>
<td class="nump">$ 18.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">12.53<span></span>
</td>
<td class="nump">15.57<span></span>
</td>
<td class="nump">12.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">15.53<span></span>
</td>
<td class="nump">14.71<span></span>
</td>
<td class="nump">16.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">14.46<span></span>
</td>
<td class="nump">15.47<span></span>
</td>
<td class="nump">16.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at the end of the year (in dollars per share)</a></td>
<td class="nump">13.67<span></span>
</td>
<td class="nump">$ 15.22<span></span>
</td>
<td class="nump">$ 14.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair value- Expected to vest (in dollars per share)</a></td>
<td class="nump">$ 13.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Additonal disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized share-based compensation costs</a></td>
<td class="nump">$ 801,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period of unrecognized share-based compensation cost over average amortization (in years)</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents, as of the balance sheet date, the number of non-vested equity-based payment instruments, excluding stock (or unit) options that are expected to vest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents, as of the balance sheet date, the weighted average grant date fair value of non-vested equity-based payment instruments, excluding stock (or unit) options that are expected to vest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914413067664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Share-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="nump">$ 441,793<span></span>
</td>
<td class="nump">$ 367,588<span></span>
</td>
<td class="nump">$ 303,162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="nump">186,113<span></span>
</td>
<td class="nump">163,550<span></span>
</td>
<td class="nump">139,348<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>Share-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="nump">$ 255,680<span></span>
</td>
<td class="nump">$ 204,038<span></span>
</td>
<td class="nump">$ 163,814<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914421523072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive (Loss) Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Movement in accumulated other comprehensive loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning of period</a></td>
<td class="nump">$ 3,537,327<span></span>
</td>
<td class="nump">$ 4,383,355<span></span>
</td>
<td class="nump">$ 6,132,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(50,353)<span></span>
</td>
<td class="num">(22,840)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Amounts reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">811<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net-current period other comprehensive (loss) income</a></td>
<td class="num">(49,542)<span></span>
</td>
<td class="num">(22,029)<span></span>
</td>
<td class="num">(95,367)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the ending of period</a></td>
<td class="nump">3,332,222<span></span>
</td>
<td class="nump">3,537,327<span></span>
</td>
<td class="nump">4,383,355<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Income/(Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Movement in accumulated other comprehensive loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning of period</a></td>
<td class="num">(99,446)<span></span>
</td>
<td class="num">(77,417)<span></span>
</td>
<td class="nump">17,950<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net-current period other comprehensive (loss) income</a></td>
<td class="num">(49,542)<span></span>
</td>
<td class="num">(22,029)<span></span>
</td>
<td class="num">(95,367)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the ending of period</a></td>
<td class="num">(148,988)<span></span>
</td>
<td class="num">(99,446)<span></span>
</td>
<td class="num">(77,417)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign&#160;Currency Translation Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Movement in accumulated other comprehensive loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning of period</a></td>
<td class="num">(87,987)<span></span>
</td>
<td class="num">(62,523)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(47,565)<span></span>
</td>
<td class="num">(25,464)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Amounts reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net-current period other comprehensive (loss) income</a></td>
<td class="num">(47,565)<span></span>
</td>
<td class="num">(25,464)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the ending of period</a></td>
<td class="num">(135,552)<span></span>
</td>
<td class="num">(87,987)<span></span>
</td>
<td class="num">(62,523)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized Gains/Losses&#160;on Available-for-Sale Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Movement in accumulated other comprehensive loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning of period</a></td>
<td class="nump">35<span></span>
</td>
<td class="num">(9,011)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(35)<span></span>
</td>
<td class="nump">9,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Amounts reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net-current period other comprehensive (loss) income</a></td>
<td class="num">(35)<span></span>
</td>
<td class="nump">9,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the ending of period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="num">(9,011)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Pension Liability Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Movement in accumulated other comprehensive loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning of period</a></td>
<td class="num">(11,494)<span></span>
</td>
<td class="num">(5,883)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(2,753)<span></span>
</td>
<td class="num">(6,422)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Amounts reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">811<span></span>
</td>
<td class="nump">811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net-current period other comprehensive (loss) income</a></td>
<td class="num">(1,942)<span></span>
</td>
<td class="num">(5,611)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the ending of period</a></td>
<td class="num">$ (13,436)<span></span>
</td>
<td class="num">$ (11,494)<span></span>
</td>
<td class="num">$ (5,883)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914425282400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 15, 2023</div></th>
<th class="th"><div>Aug. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Cancellation of ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 362,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary&#160;Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Cancellation of ordinary shares (in share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,273,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,273,108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue', window );">Cancellation of ordinary shares</a></td>
<td class="nump">$ 362,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914414692496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Restricted Net Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_RestrictedNetAssetsAbstract', window );"><strong>Restricted net assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage', window );">Minimum required statutory reserve of annual after-tax profit (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_RestrictedNetAssetsRequiredStatutoryReserveAsPercentageOfRegisteredCapital', window );">Required statutory reserve as a percentage of registered capital (as a percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_RestrictedNetAssetsAppropriatedToStatutoryReserves', window );">Appropriation to statutory reserves</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">PRC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_RestrictedNetAssetsAbstract', window );"><strong>Restricted net assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_RestrictedNetAssetsAmount', window );">Restricted net assets</a></td>
<td class="nump">$ 1,709,961,000<span></span>
</td>
<td class="nump">$ 2,114,277,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_RestrictedNetAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted Net Assets [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_RestrictedNetAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_RestrictedNetAssetsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted net assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_RestrictedNetAssetsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_RestrictedNetAssetsAppropriatedToStatutoryReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount appropriated to statutory reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_RestrictedNetAssetsAppropriatedToStatutoryReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum required statutory reserve of annual after-tax profit as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_RestrictedNetAssetsRequiredStatutoryReserveAsPercentageOfRegisteredCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Required statutory reserve as a percentage of registered capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_RestrictedNetAssetsRequiredStatutoryReserveAsPercentageOfRegisteredCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R118.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914414819392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Employee defined contribution plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation</a></td>
<td class="nump">$ 80,199<span></span>
</td>
<td class="nump">$ 70,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Defined benefit plan, plan asset</a></td>
<td class="nump">63,794<span></span>
</td>
<td class="nump">55,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Expected employer contributions, 2025</a></td>
<td class="nump">3,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Employee defined contribution plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Employer contribution to retirement plan</a></td>
<td class="nump">$ 20,839<span></span>
</td>
<td class="nump">15,316<span></span>
</td>
<td class="nump">$ 10,298<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Participant's contributions matched (as a percent)</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_CN', window );">PRC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Employee defined contribution plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Employer contribution to retirement plan</a></td>
<td class="nump">$ 101,779<span></span>
</td>
<td class="nump">94,358<span></span>
</td>
<td class="nump">83,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_CH', window );">SWITZERLAND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Employee defined contribution plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Employer contribution to retirement plan</a></td>
<td class="nump">$ 3,825<span></span>
</td>
<td class="nump">$ 2,710<span></span>
</td>
<td class="nump">$ 3,887<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_CH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_CH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R119.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914424423072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Employee Benefit Plans - Total Expected Benefit Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract', window );"><strong>Amounts</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">Year ending December&#160;31,&#160;2025</a></td>
<td class="nump">$ 692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">Year ending December&#160;31,&#160;2026</a></td>
<td class="nump">604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">Year ending December 31, 2027</a></td>
<td class="nump">994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">Year ending December 31, 2028</a></td>
<td class="nump">593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">Year ending December 31, 2029</a></td>
<td class="nump">1,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">Thereafter</a></td>
<td class="nump">8,657<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_DefinedBenefitPlanExpectedFutureBenefitPaymentTotal', window );">Total</a></td>
<td class="nump">$ 13,462<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_DefinedBenefitPlanExpectedFutureBenefitPaymentTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Expected Future Benefit Payment, Total</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_DefinedBenefitPlanExpectedFutureBenefitPaymentTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R120.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914415238384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract', window );"><strong>Purchase and Capital commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount', window );">Purchase commitments</a></td>
<td class="nump">$ 131,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=bgne_InvestmentsFundingCommitmentMember', window );">Investments Funding Commitment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract', window );"><strong>Purchase and Capital commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other commitments</a></td>
<td class="nump">$ 7,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_LongTermFundingCommitmentNumberOfEquityInvestments', window );">Number of equity investments | investment</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_LongTermFundingCommitmentMaximumAmount', window );">Maximum commitment</a></td>
<td class="nump">$ 15,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=bgne_AmgenIncMember', window );">Amgen, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract', window );"><strong>Purchase and Capital commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other commitments</a></td>
<td class="nump">335,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_MaximumCashAndServicesDevelopmentCommitment', window );">Maximum cash and development services commitment</a></td>
<td class="nump">1,250,000<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=bgne_MinimumPurchaseCommitmentsForSupplyPurchasedMember', window );">Minimum Purchase Commitments For Supply Purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract', window );"><strong>Purchase and Capital commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount', window );">Purchase commitments</a></td>
<td class="nump">32,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=us-gaap_InventoriesMember', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract', window );"><strong>Purchase and Capital commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount', window );">Purchase commitments</a></td>
<td class="nump">99,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=us-gaap_CapitalAdditionsMember', window );">Capital Addition Purchase Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract', window );"><strong>Purchase and Capital commitments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other commitments</a></td>
<td class="nump">$ 48,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_LongTermFundingCommitmentMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-term Funding Commitment, Maximum Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_LongTermFundingCommitmentMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_LongTermFundingCommitmentNumberOfEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Funding Commitment, Number of Equity Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_LongTermFundingCommitmentNumberOfEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_MaximumCashAndServicesDevelopmentCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Cash And Services Development Commitment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_MaximumCashAndServicesDevelopmentCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecorded obligation to transfer funds in future for fixed or minimum amount or quantity of product and service at fixed or minimum price. Includes, but is not limited to, lease not yet commenced and take-or-pay and throughput contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=bgne_InvestmentsFundingCommitmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=bgne_InvestmentsFundingCommitmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=bgne_AmgenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=bgne_AmgenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=bgne_MinimumPurchaseCommitmentsForSupplyPurchasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=bgne_MinimumPurchaseCommitmentsForSupplyPurchasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=us-gaap_CapitalAdditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis=us-gaap_CapitalAdditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R121.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914413870144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information - Narratives (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R122.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914409291808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Geographic Information - Schedule of Revenue by Geographic Area (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract', window );"><strong>Net product revenues by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">$ 3,810,241<span></span>
</td>
<td class="nump">$ 2,458,779<span></span>
</td>
<td class="nump">$ 1,415,921<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract', window );"><strong>Net product revenues by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">3,779,546<span></span>
</td>
<td class="nump">2,189,852<span></span>
</td>
<td class="nump">1,254,612<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=bgne_CollaborationMember', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract', window );"><strong>Net product revenues by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">30,695<span></span>
</td>
<td class="nump">268,927<span></span>
</td>
<td class="nump">161,309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. - total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract', window );"><strong>Net product revenues by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">1,957,498<span></span>
</td>
<td class="nump">1,128,219<span></span>
</td>
<td class="nump">502,626<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. - total revenue | Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract', window );"><strong>Net product revenues by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">1,950,530<span></span>
</td>
<td class="nump">945,551<span></span>
</td>
<td class="nump">389,710<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. - total revenue | Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract', window );"><strong>Net product revenues by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">6,968<span></span>
</td>
<td class="nump">182,668<span></span>
</td>
<td class="nump">112,916<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China- total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract', window );"><strong>Net product revenues by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">1,411,307<span></span>
</td>
<td class="nump">1,101,951<span></span>
</td>
<td class="nump">840,032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China- total revenue | Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract', window );"><strong>Net product revenues by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">1,390,699<span></span>
</td>
<td class="nump">1,093,091<span></span>
</td>
<td class="nump">840,032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">China- total revenue | Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract', window );"><strong>Net product revenues by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">20,608<span></span>
</td>
<td class="nump">8,860<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe- total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract', window );"><strong>Net product revenues by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">362,626<span></span>
</td>
<td class="nump">202,014<span></span>
</td>
<td class="nump">63,257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe- total revenue | Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract', window );"><strong>Net product revenues by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">359,507<span></span>
</td>
<td class="nump">122,228<span></span>
</td>
<td class="nump">14,864<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe- total revenue | Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract', window );"><strong>Net product revenues by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">3,119<span></span>
</td>
<td class="nump">79,786<span></span>
</td>
<td class="nump">48,393<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember', window );">Rest of world- total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract', window );"><strong>Net product revenues by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">78,810<span></span>
</td>
<td class="nump">26,595<span></span>
</td>
<td class="nump">10,006<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember', window );">Rest of world- total revenue | Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract', window );"><strong>Net product revenues by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">78,810<span></span>
</td>
<td class="nump">28,982<span></span>
</td>
<td class="nump">10,006<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember', window );">Rest of world- total revenue | Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract', window );"><strong>Net product revenues by geographic area</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from contract with customer</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (2,387)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=bgne_CollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=bgne_CollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R123.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914415373600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule I - Condensed Financial Information of Registrant (Condensed Statements of Operations) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 1,953,295<span></span>
</td>
<td class="nump">$ 1,778,594<span></span>
</td>
<td class="nump">$ 1,640,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">1,831,056<span></span>
</td>
<td class="nump">1,508,001<span></span>
</td>
<td class="nump">1,278,603<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">3,784,351<span></span>
</td>
<td class="nump">3,286,595<span></span>
</td>
<td class="nump">2,919,111<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(568,199)<span></span>
</td>
<td class="num">(1,207,736)<span></span>
</td>
<td class="num">(1,789,665)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income, net</a></td>
<td class="nump">47,836<span></span>
</td>
<td class="nump">74,009<span></span>
</td>
<td class="nump">52,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(12,638)<span></span>
</td>
<td class="nump">307,891<span></span>
</td>
<td class="num">(223,852)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(533,001)<span></span>
</td>
<td class="num">(825,836)<span></span>
</td>
<td class="num">(1,961,037)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">111,785<span></span>
</td>
<td class="nump">55,872<span></span>
</td>
<td class="nump">42,778<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(644,786)<span></span>
</td>
<td class="num">(881,708)<span></span>
</td>
<td class="num">(2,003,815)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">353,903<span></span>
</td>
<td class="nump">326,560<span></span>
</td>
<td class="nump">637,152<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">357,103<span></span>
</td>
<td class="nump">304,543<span></span>
</td>
<td class="nump">228,801<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">711,006<span></span>
</td>
<td class="nump">631,103<span></span>
</td>
<td class="nump">865,953<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(711,006)<span></span>
</td>
<td class="num">(631,103)<span></span>
</td>
<td class="num">(865,953)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income, net</a></td>
<td class="nump">3,101<span></span>
</td>
<td class="nump">48,982<span></span>
</td>
<td class="nump">39,585<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="nump">63,522<span></span>
</td>
<td class="num">(297,856)<span></span>
</td>
<td class="num">(1,173,306)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(644,383)<span></span>
</td>
<td class="num">(879,977)<span></span>
</td>
<td class="num">(1,999,674)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">403<span></span>
</td>
<td class="nump">1,731<span></span>
</td>
<td class="nump">4,141<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (644,786)<span></span>
</td>
<td class="num">$ (881,708)<span></span>
</td>
<td class="num">$ (2,003,815)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R124.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914409178416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule I - Condensed Financial Information of Registrant (Condensed Statements of Comprehensive Loss) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (644,786)<span></span>
</td>
<td class="num">$ (881,708)<span></span>
</td>
<td class="num">$ (2,003,815)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Other comprehensive (loss) income, net of tax of nil:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="num">(47,565)<span></span>
</td>
<td class="num">(25,464)<span></span>
</td>
<td class="num">(90,421)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent', window );">Pension liability adjustments, net</a></td>
<td class="num">(1,942)<span></span>
</td>
<td class="num">(5,611)<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized holding (loss) gain, net</a></td>
<td class="num">(35)<span></span>
</td>
<td class="nump">9,046<span></span>
</td>
<td class="num">(5,311)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to BeiGene, Ltd.</a></td>
<td class="num">(694,328)<span></span>
</td>
<td class="num">(903,737)<span></span>
</td>
<td class="num">(2,099,182)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(644,786)<span></span>
</td>
<td class="num">(881,708)<span></span>
</td>
<td class="num">(2,003,815)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Other comprehensive (loss) income, net of tax of nil:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments</a></td>
<td class="num">(47,565)<span></span>
</td>
<td class="num">(25,464)<span></span>
</td>
<td class="num">(90,421)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent', window );">Pension liability adjustments, net</a></td>
<td class="num">(1,942)<span></span>
</td>
<td class="num">(5,611)<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized holding (loss) gain, net</a></td>
<td class="num">(35)<span></span>
</td>
<td class="nump">9,046<span></span>
</td>
<td class="num">(5,311)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to BeiGene, Ltd.</a></td>
<td class="num">$ (694,328)<span></span>
</td>
<td class="num">$ (903,737)<span></span>
</td>
<td class="num">$ (2,099,182)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (k)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R125.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914408467456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule I - Condensed Financial Information of Registrant (Condensed Balance Sheets) (Details)<br> &#165; in Thousands, $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,627,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,171,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,869,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">192,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">3,991,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,203,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">160,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">5,920,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,805,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other payables</a></td>
<td class="nump">803,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">693,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Short-term debt</a></td>
<td class="nump">851,529<span></span>
</td>
<td class="nump">&#165; 6,215,538<span></span>
</td>
<td class="nump">688,366<span></span>
</td>
<td class="nump">&#165; 4,885,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,214,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,810,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">66,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,588,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,267,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">3,332,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,537,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,383,355<span></span>
</td>
<td class="nump">$ 6,132,563<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">5,920,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,805,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">400,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">723,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">249,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">785,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">649,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,509,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetNoncurrent', window );">Loans to subsidiaries</a></td>
<td class="nump">1,731,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,030,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investment in wholly owned subsidiaries</a></td>
<td class="nump">2,081,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,207,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">114,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">4,576,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,816,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other payables</a></td>
<td class="nump">424,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Research and development cost share liability, current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Short-term debt</a></td>
<td class="nump">762,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">547,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,186,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,107,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">58,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,244,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,279,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">3,332,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,537,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 4,576,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,816,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R126.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914418265952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule I - Condensed Financial Information of Registrant (Condensed Statements of Cash Flows) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (644,786)<span></span>
</td>
<td class="num">$ (881,708)<span></span>
</td>
<td class="num">$ (2,003,815)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">46,800<span></span>
</td>
<td class="nump">68,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_AmortizationOfResearchAndDevelopmentFinancingLiability', window );">Amortization of research and development cost share liability</a></td>
<td class="num">(73,226)<span></span>
</td>
<td class="num">(55,294)<span></span>
</td>
<td class="num">(96,402)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other items, net</a></td>
<td class="nump">11,163<span></span>
</td>
<td class="num">(5,998)<span></span>
</td>
<td class="nump">9,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other payables</a></td>
<td class="nump">111,354<span></span>
</td>
<td class="nump">180,111<span></span>
</td>
<td class="nump">45,627<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(140,631)<span></span>
</td>
<td class="num">(1,157,453)<span></span>
</td>
<td class="num">(1,496,619)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sale or maturity of short-term investments</a></td>
<td class="nump">2,655<span></span>
</td>
<td class="nump">673,240<span></span>
</td>
<td class="nump">1,563,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_PaymentsToPurchaseInProcessResearchAndDevelopment', window );">Purchase of in-process research and development</a></td>
<td class="num">(31,800)<span></span>
</td>
<td class="num">(15,000)<span></span>
</td>
<td class="num">(143,665)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other investing activities</a></td>
<td class="num">(2,862)<span></span>
</td>
<td class="num">(2,075)<span></span>
</td>
<td class="num">(1,485)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(548,350)<span></span>
</td>
<td class="nump">60,004<span></span>
</td>
<td class="nump">1,077,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short-term loans</a></td>
<td class="nump">868,270<span></span>
</td>
<td class="nump">661,530<span></span>
</td>
<td class="nump">313,774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of short-term loans</a></td>
<td class="num">(704,216)<span></span>
</td>
<td class="num">(309,576)<span></span>
</td>
<td class="num">(417,081)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from option exercises and employee share purchase plan</a></td>
<td class="nump">45,373<span></span>
</td>
<td class="nump">55,712<span></span>
</td>
<td class="nump">46,964<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">193,449<span></span>
</td>
<td class="nump">416,478<span></span>
</td>
<td class="num">(18,971)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of foreign exchange rate changes, net</a></td>
<td class="num">(51,705)<span></span>
</td>
<td class="num">(8,082)<span></span>
</td>
<td class="num">(69,383)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(547,237)<span></span>
</td>
<td class="num">(689,053)<span></span>
</td>
<td class="num">(507,850)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, beginning of year</a></td>
<td class="nump">3,185,984<span></span>
</td>
<td class="nump">3,875,037<span></span>
</td>
<td class="nump">4,382,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, end of year</a></td>
<td class="nump">2,638,747<span></span>
</td>
<td class="nump">3,185,984<span></span>
</td>
<td class="nump">3,875,037<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(644,786)<span></span>
</td>
<td class="num">(881,708)<span></span>
</td>
<td class="num">(2,003,815)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_AcquiredInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_AmortizationOfResearchAndDevelopmentFinancingLiability', window );">Amortization of research and development cost share liability</a></td>
<td class="num">(73,226)<span></span>
</td>
<td class="num">(55,294)<span></span>
</td>
<td class="num">(96,402)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_UnrealizedGainLossInSubsidiaries', window );">Unrealized losses on long-term investments</a></td>
<td class="num">(85,471)<span></span>
</td>
<td class="nump">237,351<span></span>
</td>
<td class="nump">932,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other items, net</a></td>
<td class="nump">31,651<span></span>
</td>
<td class="num">(374,370)<span></span>
</td>
<td class="num">(596,496)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,053<span></span>
</td>
<td class="nump">30,519<span></span>
</td>
<td class="nump">6,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other payables</a></td>
<td class="nump">627,307<span></span>
</td>
<td class="num">(140,126)<span></span>
</td>
<td class="nump">875,826<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(143,472)<span></span>
</td>
<td class="num">(1,168,628)<span></span>
</td>
<td class="num">(882,145)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,075)<span></span>
</td>
<td class="num">(1,485)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sale or maturity of short-term investments</a></td>
<td class="nump">2,628<span></span>
</td>
<td class="nump">552,000<span></span>
</td>
<td class="nump">1,487,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bgne_PaymentsToPurchaseInProcessResearchAndDevelopment', window );">Purchase of in-process research and development</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(15,000)<span></span>
</td>
<td class="num">(75,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates', window );">Purchase of long-term investments</a></td>
<td class="num">(406,624)<span></span>
</td>
<td class="num">(883,328)<span></span>
</td>
<td class="num">(2,675,908)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other investing activities</a></td>
<td class="num">(37,120)<span></span>
</td>
<td class="nump">188,656<span></span>
</td>
<td class="nump">79,004<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(441,116)<span></span>
</td>
<td class="num">(159,747)<span></span>
</td>
<td class="num">(1,186,361)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short-term loans</a></td>
<td class="nump">813,058<span></span>
</td>
<td class="nump">547,842<span></span>
</td>
<td class="nump">296,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of short-term loans</a></td>
<td class="num">(593,898)<span></span>
</td>
<td class="num">(293,002)<span></span>
</td>
<td class="num">(247,460)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from option exercises and employee share purchase plan</a></td>
<td class="nump">45,371<span></span>
</td>
<td class="nump">55,712<span></span>
</td>
<td class="nump">46,965<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">264,531<span></span>
</td>
<td class="nump">310,552<span></span>
</td>
<td class="nump">95,693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of foreign exchange rate changes, net</a></td>
<td class="num">(4,356)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(324,413)<span></span>
</td>
<td class="num">(1,017,823)<span></span>
</td>
<td class="num">(1,972,813)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, beginning of year</a></td>
<td class="nump">724,548<span></span>
</td>
<td class="nump">1,742,371<span></span>
</td>
<td class="nump">3,715,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, end of year</a></td>
<td class="nump">$ 400,135<span></span>
</td>
<td class="nump">$ 724,548<span></span>
</td>
<td class="nump">$ 1,742,371<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_AcquiredInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired In Process Research And Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_AcquiredInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_AmortizationOfResearchAndDevelopmentFinancingLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of Research And Development Financing Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_AmortizationOfResearchAndDevelopmentFinancingLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_PaymentsToPurchaseInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of in-process research and development acquired in an exclusive license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_PaymentsToPurchaseInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bgne_UnrealizedGainLossInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrealized Gain (Loss) In Subsidiaries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bgne_UnrealizedGainLossInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bgne_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R127.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45914413452096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule I - Condensed Financial Information (Notes to Condensed Financial Statements) (Details) - Investments Funding Commitment<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other commitments</a></td>
<td class="nump">$ 7,404<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitment', window );">Other commitments</a></td>
<td class="nump">$ 7,350<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 5<br> -Subsection 04<br> -Paragraph c<br> -Subparagraph Schedule I<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 7<br> -Subsection 05<br> -Paragraph c<br> -Subparagraph Schedule II<br> -Publisher SEC<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 9<br> -Subsection 06<br> -Publisher SEC<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=bgne_InvestmentsFundingCommitmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=bgne_InvestmentsFundingCommitmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>148
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M),SFU&M&W[:('T;2=<IX*J/@[F>R3*/\S61W1V@3BE4(AXZ% KSE<NE!P)-
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M8?(&^'Q!J=B?R <<?F,R_ =02P,$%     @ BS%;6APBMT4] @  P@4  !@
M  !X;"]W;W)K<VAE971S+W-H965T,BYX;6R-E&MOVC 4AO^*E4G]5)$0+MMH
MB 2EU9!@0JVV:9KVP20'8C6V,_ND:?_]?(&,21#Q)?'EO*^?X^2<I)'J11<
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M5&?"FZ;>3"2K3%^\9U)U63/,U3T(7 >H_25C\FFB6VUWLR9_ %!+ P04
M" "+,5M:1% *9TL*   E,@  &    'AL+W=O<FMS:&5E=',O<VAE970W+GAM
M;*U;;6_;.!+^*X1O<=@%ZEI\E91+ B16>UN@;ZC;V\^*3,>ZE26O)"?-_OHC
M)<>RR"'C'-P/C2T_'.LAAS//#.7+QZK^LUE+V:*?FZ)LKB;KMMU>S&9-MI:;
MM'E;;66I/EE5]29MU=OZ?M9L:YDNNT&;8D:"0,PV:5Y.KB^[:U_KZ\MJUQ9Y
M*;_6J-EM-FG]="N+ZO%J@B?/%[[E]^M67YA=7V[3>[F0[8_MUUJ]FQVL+/.-
M+)N\*E$M5U>3&WR1\&Y A_A/+A^;H]=(4[FKJC_UFP_+JTF@[T@6,FNUB53]
M>9!S613:DKJ/O_9&)X?OU ./7S];?]^15V3NTD;.J^*/?-FNKR;1!"WE*MT5
M[;?J\7>Y)\2UO:PJFNY_]-ACPW""LEW35IO]8'4'F[SL_Z8_]Q-Q-  +QP"R
M'T#, <PQ@.X'T%,'L/T ULU,3Z6;AR1MT^O+NGI$M48K:_I%-YG=:$4_+_6Z
M+]I:?9JK<>WU_,OGQ9>/'Y*;[^\2M/BN_GQZ]_G[ GUYC^8WB]_1^X]?_EB@
M*?JQ2-"OO_R&?D%YB;ZOJUV3ELOF<M:J>]"69MG^^V[[[R..[\,$?:K*=MV@
M=^52+L<&9NKF#PS(,X-;XK68R.PMHO@-(@%AP W-3Q].@>')Z<.)APT]K ?M
M[%'7>J3-&JW4;FS0JJXV2&WP.FWS\K[?(7F;R^8"FO;>+(/-ZNAQT6S33%Y-
M5'AH9/T@)]?__ <6P;^@*3NGL>1,QD;3R0[3R7S6KS^KR%E4#>BH_<BP&ZG#
MX\/U5# 61N)R]G \&0 NBG 81&-< N!4]*41Y@?@B ,_<.!>E[A9_E?% 15K
MVP:UE0JV655F>2%1N2>GK^K7F?:=72.7>H^>[#C\G(YS3F/)F8R-)ET<)EUX
M'2>1RFB6IWUR*I<HW51UF__=7Y _5=YM)#2=O5EQY 4XQ*$@AE/9L"@4(3=<
MRD8)0<((]J?P0"WT4ENLTUI.=;)<HJS::"8OL@JM&V$,"VQL@;D-HR*T8 D
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M0_D]:ES CZZ*X6O7(KQ^=9WGZ>T]=;W0QR!EMXM9/3E\KI;NGQH[J;X!:4&
MXO4B=0.-HH+K3YK'G)HCE&,@J*0M:8_&V_C65;CG]=)[46I->^&O.CC>4FYL
MFVN% V$0.N*'*$M.2!8*@[>H>;E5PHN.H.2FHX&>,8(K;Q55\:7$&-[I,(L+
M\+E/24/#*1J>CXJ='9.=.!NFI ?T%11];^A9\@I!=82OEO$U%%*I,(92E\S2
M>N:S1W'\W".+5[,'U(:Z$+\WD@P<49@%'%K)Y U60QEJP+1Y;3,K+RGBYEUP
MNQ HC:_F0#$\,3<,6/XPSH/T%<C23RO0"@L%<F^XG% /BI&D=MB,59E[>';[
M>,>Y=FP%-T9#EBW2- 7L>D5'Q/.:7[H8R=FZZ] T8:E;'HY!NW'SG;2G_\;=
MN"[_-A]_.N^%::2V/' UNZ;QMV\B,.,B'P5'?5B>!3E>Q>'8\G"B\0;\O29R
ML^ #G/ZFV[\ 4$L#!!0    ( (LQ6UJ.%LO6OB<  'F&   9    >&PO=V]R
M:W-H965T<R]S:&5E=#$P+GAM;+4]:W/<N)%_A:7D$KMJ).OEQ]I>5\F/Y%QG
M[_HD>W-55_>!0V(T6'/("4%*GOWUUR\ #3Y&\FY2J7@U,P30:#3ZW<V7MTW[
MU:V-Z;)OFZIV/QZLNV[[_-$C5ZS-)G='S=;4\,NJ:3=Y!Q_;ZT=NVYJ\I$&;
MZM'I\?&31YO<U@>O7M)WG]I7+YN^JVQM/K69ZS>;O-V]-E5S^^/!R8'_XM)>
MKSO\XM&KE]O\VER9[LOV4PN?'H592KLQM;--G;5F]>/!Q<GSU^?X/#WPBS6W
M3OV=X4Z63?,5/[PO?SPX1H!,98H.9\CA/S?FC:DJG C ^*?,>1"6Q('Z;S_[
MWVCOL)=E[LR;IOJ'+;OUCP?/#K+2K/*^ZBZ;V_\TLI_'.%_15([^S6[YV?.S
M@ZSH7==L9#! L+$U_S?_)GA0 YX=SPPXE0&G!#<O1%"^S;O\U<NVN<U:?!IF
MPS]HJS0:@+,U'LI5U\*O%L9UKZ[X,+)FE5W9Z]JN;)'77791%$U?=[:^SCXU
ME2VL<2\?=; >CGI4R-RO>>[3F;E/3K./3=VM7?:N+DV93O (  W0GGIH7Y_N
MG?&M*8ZRLY-%=GI\>KYGOK.P^S.:[VQFOHEM9O][L71="]3R?U,[YOG.I^?#
M&_3<;?/"_'@ 5\29]L8<O/K+GTZ>'+_8 ^UY@/9\W^Q_\*S^57-GKW-G'3[X
M";=8=SE?K[J$+VQ=V&UEZ.<W3>U@3,F_?UZ;K C?F#);V3J'I_,J<S"%@8O>
MT; .'GS3;+9YO<O6^8W)EL;4&:!SF[<PS.)-+IJVA,$&+DNWSKX<71UEUZ8V
M;5Y5._S9;'&%/ *_C9 ]^,N?GIV>'K_X^\7%)_KSY,7#HWN"!Y-4?6D(QOO
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M:Y'X[NG96U#LZ3X0$QV-'.KP 5!E&VW1!0%B=PL_WO".D026#8HGP&X)>"A
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M!#IGGAR\AYJ<24RZA%:X"[N4\6(D(%&\,5(1L,WFM!B4FIKG>'_PFDG2B3>
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M-(TIDB5TI(H=8R,F@ 2F(8*)_N8KG$:0,/4)A0]3A4YXBO(/E0_/YAN?O]T
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M^G-M<F"6^ #\OFJ:SG_ !;#PGL![]?]02P,$%     @ BS%;6I=LK'9'%0
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M"AU\!?P&1@/(@H>)RZ!;,D^(OE5O]*\+LK@VL!2@D3<\A0 'LN5)0O. 3X!
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M8;]4>4$_B+',JRK?TL>-@*A7X@-P?Y5#S#9?<('F%U)>_@]02P,$%     @
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M=$_;,9QJD$LB-L-J@:K/G/U$<$"_R[<Z5-^F -L_1/E$Y\>@HK)NT2RY4/#
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MIFD\Z4?&YL+(UFW><VEHCW>G)7TXH;("]'PII=E<6 /;3[&S?P%02P,$%
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M7"J!VW53J]I9T2R$]J]' F:P%V*JD-1J^]0QD<0#:<6BJ9"N]IGXIY+&.U?
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M:,MP4EZ<MN$@:9#A2.B(R.,PB$)JJ- /9$5YTA"7^TE'J(6:3/OF03IA#;,
M07\A?COT@!5+"1R8*E6CHC1WFI(3"XX9?(.(48'PF>*9"'DG=26YC! M. 9"
M.[%!VJ.B6SPB)BLJJ97^I"J4.L"]J!M'%TY80K4U!3N5?<,\N^I//8$A<8[*
MHK&0N$QI81?!*"&+UM$4@##0S=R.Q:N%HS#O1.F["]IFW5C-($AA4BO*F[NA
M&B3#-?! U@_8!7E,^,-"2\:_ PACS=%_G-:V/A'*Q[2![//?,26N&&]7\L&_
M1#@;KRK)UZFK%WO2*NLTIMJMN/0*@-+6[A1LHZO:LV.G _Q14>:R$L2E]M!$
MG+;>&7/_=B2W[5XELD(=Q_W  S_Y@,%_H_Y*T7BM;G5-.8LHK22[T3OK;[)N
M)1JM2/0H(WJ,P561E4"B"6P.H*8AX')DVRD/DG1W(69+:6[):LVPY>24X5.,
M4WW*GV%(3@5ZIU3,XL.VP$\4,P23D;6M.COW&$[@%'HDH_K##2.PN\03F.V(
M+09F%#W^'K7+J^.!OO56LI\D2SGG"#DHQ)1P:YCJGJ,267&.X@UXRS'+$*MS
MX!/,5J"AI$J_]LU)]3 ^)4!P?!^.G;7!+D9C%RKF1C-8+9Z)\Y@F)#0/N1_]
MJ.]CQ.U2B0:?S5+[UD[S\-Q%+G;,L,0T[>T2-TGZW$L-6*;Y)P[%MF%CQC<;
M[3XK4]&:(4-[FF/DLVAG2/O88-2<%@49@R<'<ZP+\9LQEG0J3)7;$+)CB[QS
M6NJ]]XC]MB$!_Z'X[K"%.=Q$$_^X# B%",-:ISL (YU\N:.B.FO027[N@*>;
M"?Y?00(]09RGU$1E62;0=,%??2;O*B!# )<1>@Q+2><S&G%'>N&UU^MQ2N\&
M$YXL_K=,OT90-SA-V7(&%$P*!@0 (IJ9)#PJ9R77:'I@-C_&\F6ET3IUIRBG
MQ/LR*$6 TF3RR G7@S,?;PF65?;* I:K=N[;,&NI;/;ILE!4_"NFM?V >GP0
M? )T'H/=>2<H]7\G QRHCRUY($>F=?T-9Q%GS(XL$)NFK6C6@:T5;Z8.!K5]
MH)@W0!7*.>(_TVO6[+#DJWMM&2=/2\D);7>S'L&GG\L!!TN]+?_W#A,8F@,Z
M&#[$+#Z0]W'EVP.:8)&JMO.:JF7%D#L(P/TC2OS?39F#<\W!><*8QN2OAHP]
MYW$D%L^Q&<V8ZI28@>]X"2LK& 5-;C"4O$7(&"?UX^QB<"*G$+@:N'W?4.A%
M*9>02*W5-;57X"!%W;+XU/N"V^\M"M=<=RD'J3A-;,M!8W=M(,18Z&K_%$RA
M)>1T$*L6>JSQ>I_=;=5,*1B?B/17+1VB8ZY@EE $FOAS4?IFQ#W+O5SI^O#(
M@8I;E R*&[&[1@3]EZS21ZP>EZ>O91A'CQ@2HSV0^+-<>Q&S/8YCC%F I];N
MSOB4';1K=5-__^O-$2_#8;ZX#F&&O&OW_(KIE&+NE%0')MN/OC]:>'6A!]WY
M1S5;UDW5W#Z@<-P1),_%C3)W&ACTEO*">RBOP8\8=_GB%[49$N[6^6+@N6_3
M@Q!0SS6LXGL@CH:@4W9*Q=@KPMU$!UZ*[+7@1LDK,(CP'K3@)*.GK>/YDXL9
M<F,@0'\,=@(C^+#X49^%<H>W>Y//>3@.(QHIA5UR0+2.$)VJV%B\@0^!K(<%
M@@ZTJ1[-NYEQ-^4N=@<+_B/$$3L%@SZV0U\.)S+^M:SE' :4C#-H?@'3!JLP
MV>E:LQY&Z1JUS/$82: *= ,8[$LXJ 7R^('$ PE[[@\_#E",/IPHGAVIXIIN
MQ.U5HQCE@-^/\BY\8<V5))#?%_;89[;+P2?0E<+,1!]ZZ7@!U<U_#>V?]M^2
M7_E/J+OE_D/TSQBY-(2HU *DX;C(SH3Q'W?]C6O6_$%UVCC7K/ARJ21P@1;@
M_:)IW/:&-NB_L%_]!U!+ P04    " "+,5M:*V8\2J$$  "M"@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970Q.2YX;6RM5MN.VS80_17"+?K$Q!))W;:[!KS9
M%%T@01?9-'TH^D!+M$U$(A62WLO?]U"2+PEV%T%3&-"-G)ES9L[0<WYOW6>_
M52J0AZXU_F*V#:$_F\]]O56=]*]MKPQ6UM9U,N#5;>:^=THV@U'7SEF2Y/-.
M:C-;G _?;MSBW.Y"JXVZ<<3ONDZZQTO5VON+63K;?_B@-]L0/\P7Y[W<J%L5
M_NQO'-[F!R^-[I3QVAKBU/IBMDS/+D7</VSXI-6]/WDFD<G*VL_QY;JYF"41
MD&I5':('B=N=>J/:-CH"C"^3S]DA9#0\?=Y[_VW@#BXKZ=4;V_ZEF["]F)4S
MTJBUW+7A@[W_74U\LNBOMJT?KN1^W"NR&:EW/MAN,@:"3IOQ+A^F/)P8E,DS
M!FPR8 /N,=" \DH&N3AW]IZXN!O>XL- =; &.&UB46Z#PZJ&75C<[OJ^5<AR
MD"VYE*TTM2*W@QRNS5AS).]\'A K6LSKR>_EZ)<]XS=EY+TU8>O)6].HYFL'
M<X \(&5[I)?L18]7JGY->$H)2YAXP1\_,.>#/_Z,OZ_)?E"M#*HA5]K7K?4[
MISSY>[GRP4$W_SS%?_0NGO8>>^G,][)6%S,TBU?N3LT6O_R4YLFO+V 7!^SB
M)>\_4+47_3Z-^ON"D1NG>JD;HAYP8'BD3YJ&V+!5#CIV#N9$>J^")[5%3_M
M[)I@F:QMBZ-!F\T96?KX$956W0IV^VK'"R<_X[</$L%)5V^'((VZP^'21X3P
M[1$A%Y05!<D3*HK\8!3D V Q3HN*$5Y0SA+RQP#0(:*^DZL6ZYS1DI5QO<RJ
M@^U&&>7 /\:3#1I11VG$$^5(F*6499RD@N;IT;*39K>&B'8.% =\)*THYYP(
M1I,\1RJM"Z^"<EVD%9RNHQ!KZ;<$^]!(:0H:_.!0&\AS*$).F6"DI&7!)B+?
M9#K-:%DR(@0MRH1\M+&":<5H!7PL*ZC(L\G06//J_RO3.VLV(R-M[L IE@9H
M6$DK\"XKF@MQX..COAZGS#!0JDA:TI0Q-.6@N4;UUNMPJJB2BC+%-:VRT<_C
M4'V@ZAW^L%QX'#:K+SL]ZB*C%2N(H.E)X$_+CP3%+C)<,Y&?H/ZV#B@4B[N*
M--UG,6JK2@ XHSQG9%G7;J>>5#_ C<J:$HI=_R&E;VP7/8^]YJ;3BHF2<E%"
M>5!KPLFMC'&<6F%UA. 4A&?\T8)G-$^ FU>H14[>/H"P :%G.VKXW]1!JZ.3
M-$-_Y2A3#BGA#FR=<K6._7'<710TXPDI<2N."?J>1@+[-,D)A[Y!ZMHT<-GL
M8*1-;3L5&_DDOV-;<T&K1!">T*3DDZC1D%66QW9+(?2Q<$@3RLA)7N'.TVEG
M>RA]J^5*MR.#'^B *[56Z";PM7=(\)#)#;HV[#D *(<!8#/ OIG&G'WT1^26
MBB2+ATD%C2]C2\9B:J=&I:]:O1G%$,\S09 R"'QD UN&<T.48B*=Y^":D2RA
M99J0I_Z YB<C!&JY&0:EF(&=">,T<?AZF,66XPARW#X.<N^EV^",(JU:PS1Y
M76#T<>-P-+X$VP\#R<H&C#?#XQ;SI')Q ];7UH;]2PQPF% 7_P)02P,$%
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MY=K?[/HDK'L "=\>P7#I%"!'&'3YBL>>)K[GQ-.ILR5><>LP'BRV7JIL"?C
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M'%?<<HD#N%16 ._G=6VV&_O ;J3O_PM02P,$%     @ BS%;6D ^8?%9 P
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MV E"@:5U#(P^]WB-0C@BDO%UX@R.2SK@Z?C _L['3K'LF,%K)3[SRC:;8!E
MA37KA?VHAO<XQ3-W?*42QK]A&'VS.("R-U:U$Y@4M%R.7_8PY>$$L'P.D$Z
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M#T"/;7TTK.I\*]TI2XW9#QNZ"5$[!YJOE;('PRUPO%NW_P%02P,$%     @
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MM,O;+^7V1V7L"4C>O,P;_BNV^EG?.Q/SKFG+C1D,#399H7_3.^.'T8#8/C'
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M[ZT8?Q,9VIX,L:;[EG&(Z'4YB(T^KK)&1P%1%TO\6&X50HF!\;);H:B;68X
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M:@VZ<-CGO$AQ/:72<=:2KK42K06LK+2I. I;Q3:92#*6@+;885A9MX-%G<&
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MIB:XKS!O>*4]70R)91 F&9'&1'H8">^:$K#BA=4I!EARYQK *BKX7X?":]&
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M,>X"ZE&1_#G6DJJ/9[H?(N\S_TGW-!@LV.07 001BLEV'R6$U@QT^$</0J9
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MB^QH ]Y3KH\W)&#W0?/L?U!+ P04    " "+,5M:N1*-AF@"  ",!@  &0
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6RM56MOFS 4_2L6JZ966FM>>2@C
M2$W9M$KK%#7K]MF!FV 5;&:;I/WWLPUA246B:.J7X&O?<^Z]Q^00;;EXECF
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M;P'2!ICG>R'T<6(WZ/\_Z1M02P,$%     @ BS%;6CRE,S@1 @  W00  !D
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MRI)L<8%O/EF?1[[Y_UE'WSYZ(+IQ(.WW<^<P5%F<KQ*::FU;6D&!?==8,(^
MRY<OTE7R]H*'Q>1A<8G]GSULF&[=WW]AD'^Y@#,=G--)3JZ<!%/'QK*HTIUR
MP^V;5J?>W0Q7]G?ZT/BWU-1<623@X*')[/42(S,TTQ XW<8+O-?.MT.<-O[]
M 1,2_/Y!:W<,0H'I12M_ 5!+ P04    " "+,5M:6ZS^HBD-  !!/0  &0
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M'PE&RM("W%\:X^,7VB#]:OKU?P!02P,$%     @ BS%;6E1LL);),@  !;D
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M]C^<'.@9SK>IBH;^F]SRM\^>/D@V7=-6>QD,.]CG)?\__22 , .>GTX,6,F
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M/G,QC<B5;0%ZM'^ZI$ F>0FJ0$<@/TE^#GB-L&IH9"!XV-DN!]4-KAI&(NB
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M*5OWWN"[QG^1-\%OBB>D/[!=M!"_M].Y;D'@P3Z(T:'J"8='10C!(%X05?8
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MH'.FT<7KKLDAP:A+8 5:.,:,]R1Y%RO>& 7ST.9T+DD[LM@\Q?N]YT52N]0
MXKN:=5N$;-VS^3S;MS4B5@N<\VV!M([ 0-HCDWG4EOT+\R7AKP?_5^?_&ILV
M2,T+"2*:Z'"&2AYP'I\G9K7_D_D5%C;AH]!H*IK4(" W)OT.]&^*-]/ER'J1
M9H?)UY3 A>?W6IURQZ (]%,">ZDKFB:"$@:QJWF1?. 1;VC$RRXO".M7IZ1+
M-YC?)?X:_'6 W1/$T#/]Z@TG"Z*WY77\R3/YXJK:MK=POD7R&EUC=54"GB$T
M?MUN42).#'N#'C,RB"_WZ,61],PW "XX.QS0'QA]M+5DLR%ZSV%K2(\^FT]I
MIN7'72SW&1A[2@^' B75^=7%(GE?'>#\SY^N%HE\:M)8\/<^E049 <LQ8@7(
MP^F039_S"4TW+ )L9B29P0*:E Q&=V#L?=^3PO(-NAA,%%Y^"Y>% 5?^R2=&
M1/D  XF+.@N8&2[IC;I#.*)4/R:^8 5@ "/7B/KS>QF 2( [M#F#"@$C6+N0
MR9NQ='WQ_?L$49^A!-_*C2U7I\O5LY-1CQKO$YT?0'=Y%>+MR&=KQ^D%84NR
MCY1(^)7;N/T:L%U+/&:6 %6@(FF%F= H5=@M1%NE=,4\P[Q%ED/770HH N*?
M%5CS%<?+T6$-% >@007IW#AE 2R$5VKD"W+%'F"#D>VH4XVE* (F0@8 A[M!
M5JK.?C6R-4D7U8LTSF=5XGGWZP=/.,3K1E)<066 SY05QC8\38KH1DFR9=*5
MI)Q3P("F4\4\\)F))-IX7I/0K$GQ@A+I4>5RWGA[P:\0;74B6Q=1.RTV(JY2
MAK8N[NVSL&F_).+)$<X$FE)VDORFZ>$C7X%, NV2S(V2?:&9^X1(PVE@-26&
ML6?*[]]O?.P*_(Y]'8::(D!@?[(Q(KJF*L62B1:\G@:FVY#.I]O.K<_]G(%"
MNP7-$$T&G\HX04<YG[P]'M#\(L6?34[OP1G)IR/0;#@Y$R@)9")('$IZPY4C
M+#<A,.,4$F^;9VL]4J.DFY +/GK1\?4AKV!03.TJBIYN\T^PQ3J*I-A3<J(S
MS\#NGY#H0_?&B=84G:1X\ 3J">S):M7DO86HNFKDXCD7Q(O]KWP<T)4W.:@0
M.%E$(EI!A'N5);'(16G,XUG68<AZK1^A1"R1X0&\?HVYL$?#K=<N+(X9E"5P
MQ'H:0R,$DCW3$,%$_V82CJ,(F->$PH>QPF8S!?F';DYE\Y5FRE>PW]9)K("_
M!7N[1,.*=BL)\S!2RQ5V:>2^!'%7%"&*0'^N1%OX=2"@>C[IG@2;K#GH?V?Y
M636281PYD!5V=A!M<^W(2D9'+LKLW+BE1QW1F3*O6#-0IZQ-^)]3)D,5U]E\
M$=8;/#I68E'![R+YQ8T;/+.SC,=N1Z:>#32&FH.S^7* 2\"O\II\P^=T?Z,[
M_LPY$O,;Q8H-E8\AWM95=[T#L[OA) 56_%12Q%("%4P>[PN02/Y<5U5&>*P4
M/^' IG(]6IJSCT_F=H;$8GUTWJ>/<F)^NR9EAJSZ#6$U92^+*E0A9XX+LVBQ
MK:-<%,L=8/>4H4'N7>-Q*.77K&-@ *UW@M'3-4TEQB:'57(P@%ND&\_E]IC'
M0Y&1O,XX(X3KU]1?3CZ,8;2]?WBTKV$+XEH@QI8/]F/"S0?X?NEG&]D8*6=
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M)4D2DC!4C=^Z W*N_)'O2*)0H+M^V#R2E#0/;V!I>?_S\?8CWE.IL]%0&!O
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M?=K9VW<7_ZFDZYVP%37RRE2Z!KMRKFFO5Q47,^)*UQ3Q89H<_(,"/T1F<&P
MZ:*/2$F+>7S4$2Z^VS0AU5>"V T%@JJN11PQAV+62@)L>4LMTR5R.TB U X)
MYI3_WDSUU51/H@*IDYH93'3O*$(O+C^)BJ/I7+HB\;U)DP(5);PL+0?@5IWJ
MFKSQT0_M, '@ [C5U)DK]8T?-RG%HKV3:]T=M?&"LK,#->0K>QR%^XA2L<HX
MNJ".'E+>K?:CA^!:=%TY SE?2JU^<+13/L,2\QE R:FZ>J/5X9X;\;(,YV-4
M<,-HXZM%4* '1&$_&6%,? "J.N-@.>"L$:4G<';;<%?MV_.[_0HI$/'Q3X%7
MW+8W=L15TAT715;+10FBT4QY-IZ?/E_8C<'FS^V44<3L]+EUFEJO!J_&.&R'
MLR/?);^30 TI81+L0$U9I"G?EV:>A&ZP%7KU.+K#C4I M339A68BJ9RJ&G94
M1%J,[S)2.VQ2TL39KCT3%XZA\7,^D5^#=<"9&Y@!<R+I%YS,YTT2X ,^=27<
M."O^QI/*8D0_#NDI\4X<%4?=Z<["W;!GH=+T/TJ@JFJ?*HKPIJ1O0-*LJI>>
MSC3_B&K9Q#U1L_H\XSUCP-GMSZ&QSZ")*@T.(,&ZE'.1/.JFI:7*R$^MU6>1
MGX]HGSR:F>8AD0E%5F8_[];.')QEWH56:4),R%3+,9)4;',U3:V+CLTA\I^)
MBRA.7 JW'[O">S[7SD8AJ)@;*\U 51C7*C<1;4=PMLFE>[9_I,P?VWJ;>O(%
M&<"C6J]U@E_7J5QN2(:JR#HG?V_'WB.JI.*L4>2J"@(N8B6Q/=UMQ;MZ@U@7
M'=MT:YHYL11.^ QBJ06@2R4W "E1E"'B9Z7,<F0]/G$F-*L57W33[U%N+U,\
MNG2(8<=KD=.A/WS$6(F4L"'N<JRK.JX^VU9=TO!<U@\>"+;3GD+UV=PZ4P&#
M^*RA019U4V_1&^(5RCCS.XKKBU:^\&%EK"(KA0>3,H&5M =;5.*'>(M/57LJ
M$R.%.8ZWLB9#1Y=\IL5(".+>SNXX,=S;B*80;\HV=#EA[MJC&4E$"F@D;)X"
M%?#O!.$7IC)U*OPGQ0Q<>)@BLSM)?JG*)3!G8!E<EZY9E=XF%,<'.DM\(:$H
MIK[ZB=7581R0'"7^4'U':)K=L-9/5IW1N=\H;X %+RUOT"K+%\F' PPJ6TJ1
M']L^I>G3-(J\P[X<8TR'C"])1\QB2LLE\UX2,_/&1U."6<H,9S)X,Z VPQ-8
M_GFV. @\Z6*3*7]QK*$'F.ZP9(!ML<XKPF![J*%KPZ3?F9/;I.1X"N<#$OX7
M&!\BWY'64X5G"T*9$W^,Q06^A$'0X*^@@"F(\ FU?R,N^ 8FD@""#KU00$>"
M@\S0_Q14T;,-,&5T#^/HDSF.A.[<9R*,G+P74 E/HHS@D89YT[K(.<':8Y;,
MAO%<J3C)--5:_B0.%^#DF/!VP@4.I.:Q(CZ*(S8FQ'B5O*5Y7O##-R%JDX[X
M08=GYAL3^\/7"*:\@_OC%8S12*%$"-"N)J-9-IR6O7.3ABKT%L$\\UV6!\^T
M^)3R>*K)^B3Q+$2UC_B+\4.P4YAS#'U3,CR"S]U"EZI1TEX9)>U*E+3/OX>[
M];Y)BOIB$*+C#;MKJ*NVK^F*#>AW0.YO?!/%URJ\%9[T0LMGO17OW[VQ<5(6
MUNJ_MZ<<EC],9=(;\SZ,DC+187=#W,;:<5]^S!S,>M[[-N0"^/:HOMQK/(P0
M'.Y[#'@6^4=T-<LDZG2_W-XSP,":A08:R&7K(PT, E/"$J#DT]/OW*^YKJCU
MZ1A9FQN1EX&,CT$Z7I+UP,4<>L_:7>2P2T6YV0#YD7;;(K<&E'GENX^%IX2X
MR0[Z2"2SUFDR?>-&MM*B'U;P@F582,T'PU.ZO(O^-YZR,N+9'SJ-)N-*S<@R
MA.+AH09A15&"XI8\N:241X4I#:CH%59+:'"_#[,/]-B:=%(2)RRMVP[*FHA)
M!8C9>B)ZHVGT0'3^>Z$\R;.)X)CQ"MCZ9GE6Q%1"A.#90 #YZK8)'H<<UQ=@
M]8A^>">=;YFJ0J;TI;[H]!DIYI*8TV;'SR^%7GDP%GT\^*J90=L0H-7R+?@?
M"LNYC=X-YC@&,U9SAM6V%/$E*50=TX+SFG\<S4M4:B4OK5!1K8.L]V*D^"Q"
M8?*8^]2.15\39A%DG&]LI+J,WEB@6*O;QRT]_3:$)=VE_/O*<6KC"#O!?$AC
M>#);DXY S#L!))0&Z;^:,&;]OAJ,<55U9!'2-H^ALVY 7?^K8 =BVB%I4<23
M_.]G7[)<A9[JJ_ENYY-*QVMIF36:=?P7YXQ5G='NOZ:DD<WS9J3N$CMC3:HX
M0<A0MT;T9+ 'QGF>V+2 J>+\ZC%*']10066$G*&A;8YNG<:4><C;($HEB%&
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MY3!!EG-&EMP!N\E#YXFEZ,_3S&3ZTHZJ71-/700AX0LP!H=,LIS-;'K=0Q4
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MPH[>GPFY&"3N#X #OF[:-RE<A"BW]=4.:JHXJ=I46,'?"\?5:-1)$K4]H*E
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M[W@<]T"Y:<AMC%PU$\A<&IIGFF5.MJ.R!'2_D-)L-E9!-Y+._@502P,$%
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M*Z=]+>B.C](8T/>%$'H], $V_S7,_@502P,$%     @ BS%;6@;/D],0!
M8@D  !D   !X;"]W;W)K<VAE971S+W-H965T-#(N>&ULG5;O;]LV$/U7#MHP
M)  72=0/RYEM($DSK$"R!DV[?1CV@99.EE!)5$DJ;O[['2E;<3 ['88@EBC>
M/=Y[3T=JL97JBZX0#7QKFTXOO<J8_M+W=5YA*_2%[+&CF5*J5A@:JHVO>X6B
M<$EMX_,@2/U6U)VW6KAG#VJUD(-IZ@X?%.BA;85ZOL9&;I=>Z.T??*PWE;$/
M_-6B%QM\1/.Y?U T\B>4HFZQT[7L0&&Y]*["R^O8QKN /VK<ZH-[L$S64GZQ
M@_?%T@ML0=A@;BR"H,L3WF#36" JX^L.TYN6M(F']WOT7QUWXK(6&F]D\V==
MF&KI91X46(JA,1_E]C?<\4DL7BX;[7YA.\;&<P_R01O9[I*I@K;NQJOXMM/A
M("$+3B3P70)W=8\+N2K?"2-6"R6WH&PTH=D;1]5E4W%U9TUY-(IF:\HSJP=%
M_BKSS."A$9T!T15P^W6H>Q+>,/B=7HNS3V+=H#Y?^(86M&E^O@._'L'Y"?"0
MP[WL3*7AMBNP> W@4Z53N7Q?[C5_$_$=YA<0A0QXP.,W\**)?N3PHO]#'_ZZ
M6FNCZ,7Y^QCW$3D^CFR;Z5+W(L>E1]VB43VAM_KIAS -?GFC[GBJ.WX+??5(
MS5D,#8(LX4:VO>RH7FU'>T:OJ1RK_\T5CM?_(E<_R84O;XLT%2HPE>B@L5/V
M/Y<=:3B,/5AWT"NY(3S-0"BD_B'PO!8&"QATW6TH&\&*;KOI9UL4M&@J68!\
M<M@(J$W=[C*P'!IHJ*\==SM+V#VZ5@>A-9(H0D,I&]I]]"5\'C/N7,;U4#>%
M79,'\(Q":;@7W5"2WX.RCR=F$(&1$.ZC[L1:*F&D>CYX5UQ(LHMXE*79$C\&
MMW;[4;*K<Z?&A[*L<SR5=H>TOU2R*>!]2SH]8>M<O2.YB#L1G B7Y+R"QL:#
M0=7"=YSIJ(^MWB2V5-2*( PYHPU!:%(HSX=V:)RFDR-NS]P96&L[M5-X%),$
MNH0K)SLU);9KJG#?F/8G@A_I[\XBI F+LV1_F51/@QG+DAEP2DN3]*3X/(X9
M3Q((LY3BTT/Y#X,"EA$Z#Q(6Q?,#!W!R0#L^<K3@)34, DK)((L8S\(#$^I#
M$]*8I5E 1;.0"+[JL@.=][*&+.(12^B5R2+.9DGH3"3!3BE]%LWG+ R2<SCC
M\9SQD)]38Q]O'5(R9D&8P8Q(IV'R7\P/63++6$RVV-)B%B;Q]]V;K$IXQE(^
MAV0V9RFI>\JJ;,ZR^0S"<,XB$NNH4Q02D)DI"Z,$/K@=@R>D[<Q>8E+JDS2B
M^1?'8YNF?W#NM:@V[G37Y,#0F?$(G)Y.'Q!7X[GY$CY^?=P+M:D[3?U04FIP
M,4L\4..)/@Z,[-TINI:&SF1W6]%'$"H;0/.EE&8_L M,GU6K?P!02P,$%
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M$_+F 8!_$G],GSVOL;SO\$0+AA$;E:07>W^<SIEM(=5N3]LGUTXYTFG+6S&
MH5AG@+%$@M70;:"7*%WV(J\!5>1+#C0-ZY?YZF$T]<&>DF00"%]ZV&HJ_"2@
MWZKR9WAD!P>BIO=H:T@*Z7LD4US@'.0#W'-MJ^R3(PC,::T?YH>^XVA?B3"1
M!%\Q-!DN3Z%XBKQ,F)P=BH%J$24^7:QU><.!I%M=[#H/<?ATF1F2G/))1 DX
M/)%(<1@6AI[#6VV*W*PH0[[FX*X^Q::Q!QY04-2/7($"=9VMG5W]='8BT,.^
MNN4.)T I\;BH1'!7X+/?%1/,#- 9G%7WD@8O3"76\:RO^8 MQ%9V96TVN64
M8&4)PFR80>+ _V9%%UX$IX9);)V%:YS>OOH&GO#3F&M@C)N0K06]P.H//;@
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M'$ZH;C^7M@^VVKI/E(O*VFKC;M=&HT/F"7B_JBK;/[""X9OUZ7\!4$L#!!0
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M/4**)4@$Q"4.Y+Y ''7EUROJ=XIZ8W>OHK:'^I<D9M^]4+#HUG%A#H@X<*P
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MJ2165V^ \0NMW?C@/[#Y5\C!WU!+ P04    " "+,5M:TTWKP=("  #[!0
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M<[BS+Y&A@^?H*#Q(PI-G/ 3+4YC"Y0"1IA["[PP@"NXA!"U2!&GZ/0W!\#2
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MGD1FUP8#Z%I+"K8]/1EEZ<6E;?7II> KUO@QZ[\DU13*)9JVKB9P)?7:"_T
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MW=!;B<8+T/E*:W=<> /CZSO_%U!+ P04    " "+,5M:L#=\QTX(  "R%@
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M3NF.3D%BRH,P)E)%I/N1Z%R3 O0R\3HI0%FWK@'H12*/ 37> C5^)5 OLQ)
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M*, Q\>TO"263 #^TQ1D6P//^V ]+2X4<0>U)O2>P"B@YAQ(LPCAX&F>[]G7
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M_0M/+7U>MBSE0+*LN,073*J6H'B-59<'7!NH[TO&Y':@'=1]H_\?4$L#!!0
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M/=;HC=,X.@#MN*<=[Y=&ORP9O9K&DY[@Q&NU:'=]C%[=GNMRVE.=OG$63P]
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MRN#TXLP#V5ED%VC1.--8"VTLR TK\U=!:1/,>B&$W@5V@^$_E?P%4$L#!!0
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MV?'P\("::)A8Y/FB/7ROA\#=$+@? O5#V-7PCC#>3>B,9:Q;FL,$6^?0H%:
MTT\?1I?!UUW->D^R[)W(7C4R'AH9'V+_GT9VA%>>T!GJ*@T2LMKNSC\SLD,9
MG0ZR]3HWH"IOBQKY-[+[UP^[@_-.O>&\V9]91^X,]"]-9^=W5%5,:,2AM)3!
M^=4%1JJSR"XPLO6F\2B-M2"_K.U7!91+L.>EE&83N N&[U3Z!U!+ P04
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M+Z!^GPHAGP[R$ZS?MS;\'U!+ P04    " "+,5M:*$P0+9\$  #;%@  &0
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MV5.KDA<WJ<6'9*O\;O&12<G2_#4&/ >N!=3_"\;DRX>>H+K/'O\'4$L#!!0
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M;8X_8U1!37IFGN3P'48]=PZOE$S[+QJ"[Z<[C,I>&\G'8,N 4Q'^Y&6LPUE
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M+T19!ZC/'XI"/N_4)]B_Y#3_#U!+ P04    " "+,5M:8SR.3VT"  !3!@
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ML*2NC]HET/I**?L4N,;2_8]D_P!02P,$%     @ BS%;6JG8W:$4 P  "PL
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MN8WEIX%U;7XW$+35C>^2"ME&Z\=27HV *0/Y?D6IV _4 L-E:_8O4$L#!!0
M   ( (LQ6UJ/[GY7K@(  " '   9    >&PO=V]R:W-H965T<R]S:&5E=#8Y
M+GAM;*U5;4_;,!#^*Z<,32 5DN:-BK61H!4:$M,J7K;/;GIM+!P[L]T6_OUL
M)\U26A"3R(?$E[OG[I[';\.-D$^J0-3P7#*N1EZA=77A^RHOL"3J3%3(C6<A
M9$FT,>725Y5$,G>@DOEA$*1^22CWLJ'[-Y794*PTHQRG$M2J+(E\N4(F-B.O
M[VU_W-%EH>T//QM69(GWJ!^KJ326WV:9TQ*YHH*#Q,7(N^Q?C!,;[P)^4=RH
MSA@LDYD03]:XF8^\P#:$#'-M,Q#S6>,8&;.)3!M_FIQ>6]("N^-M]FO'W7"9
M$85CP7[3N2Y&WL"#.2[(BND[L?F.#1_78"Z8<F_8-+&!!_E*:5$V8--!27G]
M)<^-#AU /WX#$#: \*. J %$CFC=F:,U(9ID0RDV(&VTR68'3AN'-FPHM[-X
MKZ7Q4H/3F:'/R$Q(8M4$PN=P2W,[27P)EU(2OD0S9UK!*5Q33GAN';>4S"BC
M^@6.)Z@)9>K$^"_+)?(>W/#<&(_W$S@^.H$CH!P>"K%2)K<:^MKT;"O[>=/?
M5=U?^$9_$\S/(.KW( S"^ !\_'%XM OWC5*M7&$K5^CR16_DNT.%1.:%4VJ"
M:[,+*JM/5ZL>C 77TBQ0T *F*.U> _."G[I >5"$NFI\N*K=R1>J(CF./+-5
M%<HU>MG7+_TT^'9(DD]*MB-0U H4O9=]5Z!Y1Z!<* VJ(!*!;9=/SZQP*:VW
M$M+NZD/2U/7.73U[)JVSOGD2LQC67=+[8>D@"/Y%[;")6S;Q9[+A@I]^@%%=
M,^VTFL3A('U%:#^J?QZD:7B84=(R2MYE]" T82#_A]<A"LG^I*1)' >O..R'
MA=$@3=-7'/S.^67OCA]$+BE7P'!A@,'9N<DCZ_.X-K2HW)$V$]H<D&Y8F"L,
MI0TP_H40>FO84[*]%+._4$L#!!0    ( (LQ6UKW'0=KL@0  ,<9   9
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M#W] 7=#$\*6<2ON+#G6LYZ!T)Q4O:K#.H""L^L>/M1 M@!^? 00U(#@&1&<
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M@KI='X8],-)U1%0279*R$V _?J2D2)8ML_7 ET24>0_O/>0E[Q%G6\:_BQA
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M'=3O*\;D:T,/4-\/S_\#4$L#!!0    ( (LQ6UJ$_"LHZP(  )D(   9
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MT]J])X ^P>WOM+;'P'M\?*&*5U!+ P04    " "+,5M:9]7PA^0"  #>"
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M95FPXZ3]>"/HKAY6/U$A:%Y?;@E>$58%R/?7E(J7FVK^W?[>L?P/4$L#!!0
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M 93&4;2NQ*W%1!;@V@RUG* T!J4%4!I'T;H_MK>V$S7:'3]8FVOX^5J24F_
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M /7]DC%Y6.0WJ(\R9_\!4$L#!!0    ( (LQ6UI4&3]X @4  (H2   9
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M_MJW%0EW6?JR'LN0Y)AEWU; X;ZB*;BV'BF[S-R*,S975%/%JY[:BQ1Y%DJ
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M\(QP+5#?SQF3SS?ZU';W?X#QOU!+ P04    " "+,5M:P-6X*',#  ! "@
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M:)>*[W3_)ZX2\A1?3%->_()]%6L9(-YQ0;,*+$>0D;S\1R^5$$< Z+X!L"N
M?2K J0#.J0"W KBG KP*4*1NEKD7PH5(H-F$T3U@*EJRJ8-"_0(M]2*Y>E$6
M@LF[1.+$[&L>TPR#1_2".?@-?$.,(54Z#BY"+!!)^:6\O%R$X.++)?@"3, W
MB,G;) ?+G A^)2_*X\<-W7&4)WQB"CDL16[&U1#NRB'8;PPAQ/$U<. 5L"W;
M[8'/3X<[/?#P=+C= X].A\,FW)2EJ.MAU_6P"SYGN!Y"U:-/RA+M]J-55[GA
M6Q3CJ2';!L?L&1NS7W^!OO5[G[ ZR4*=9)$FLD8)G+H$SA#[[)MLS[(1JWF0
MKT%*.0>QG!8_95?>(Y;T5:4D# I"U9J?9WY@6[XWGIC/QX)WX[RQZP6>TXP+
M!P=XKI::R!I:NK66[J"6LJ_(Y20E> 5BAA/9+_KD*SG\(UD"RQW;HY9ZIX6%
M;D=DJQD1#8[Y@XIXM2+>H"++G.&8KG/R'T[4- =/.,>K-X3Q.AG#P';:;U5/
ME&O[;DN6GBCH>5Y+&J\CWGAL'X(:*?MUROZ[+T&5)5@QF@$YD^0"GA?I<X'$
MKC=YOS,4UW=@*_?!)Y_;PG2219K(&HH'M>+!9Q4'%[+%E8OY99_ZY0-&Q[/H
MVFJK/SB*<]77219I(FNH/ZK5'[VKOMP#[^1,SX@0<IYCQ'*YF/2^YJ/.:VX[
M@=.:E_-N5*NIA>]&1(.C_J FXUJ3\: F"_G287";R"TLX4*MK5(ANE(;S^+X
M"LPW)$=] @T2G[OET4D6ZB2+-)$UJ@.M@PVP/K7OK.":JJ"5+=3*%NEB:Q;B
MR(]!W;O/BO%X:;?AR/-<O]5$AA]]MNPZV2)=;$W9#[8+#EJ*V6)/I-+W.)'*
MIZHKM7O5Q?WC;>]".4Q\]LS0ZLFTLD6ZV)HE.M@RZ'RN1>ET37.M;*%6MD@7
M6[,0!T\'ATW=1UI4U[NYGNU;MM5N49J\626[3K9(%UM3]H-QA,/.\30O#;L^
MK]=,#S_L;*%ULD6ZV)I"'^PJ'/:K=YC\(<T36"YN>Q76:1/G6ME"K6R1+K9F
M'0XF%@:?:_@Z'>-<*UNHE2W2Q=8LQ,'/PO<-;=ER&HV^ORA='^HZ?A"TVX\F
M,UJIK9,MTL56JFT>?9Q1W][^0FQ-<@Y2O)+TUG4@FQTK/V>5)X)NB^\U3U0(
MFA6'&XSDQE0%R/LK2L7KB?H$5']4G/T/4$L#!!0    ( (LQ6UI@KD4@4P,
M !\+   9    >&PO=V]R:W-H965T<R]S:&5E=#DU+GAM;*U6V6[;,!#\%4(-
MBA1(H\N6X]06$%L]4B! D*-]IJ6U140B59*RDWY]24I6?,AR"N3%XC$[W-FE
MESM:,?XD4@")GO.,BK&52EE<VK:(4\BQ.&<%4+4S9SS'4DWYPA8%!YP8HSRS
M/<<)[!P3:H4CLW;+PQ$K948HW'(DRCS'_&4"&5N-+==:+]R112KU@AV."KR
M>Y"/Q2U7,[MA24@.5!!&$8?YV+IR+Z.AQAO +P(KL3%&6LF,L2<]N4[&EJ,=
M@@QBJ1FP^BQA"EFFB90;?VI.JSE2&VZ.U^S?C':E988%3%GVFR0R'5L7%DI@
MCLM,WK'5#ZCU]#5?S#)A?M&JQCH6BDLA65X;*P]R0JLO?J[CL&'@!@<,O-K
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MP,\4$#H YV><J[>!/@F'#Y_T+U!+ P04    " "+,5M:O;L>#%\#   %"@
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M<1V*[L[1=12OVV-[QQ5> MIFCO<T$#H G^\Y5Y>.O@D,-[_D!U!+ P04
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MG'>1Z%R+YI%H.HK7ML[.N=)5VS9+_:Z", %Z?L&YVG1,Z>Y>ZO0?4$L#!!0
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MY7VK3NPR.B]#>P*V@/J5#K^Q>[-6-:FI&1FMI^43%N&>KO3CT%3WSYCO07?
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MC+P(OFQVN\W#_L?[NKJMFZY!^^]?-YO=X9?.P?=-\_N^V]?_#U!+ P04
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MHB()S"SUX0O@&["B#^_<P/D\E--;BL5O)+:7H=]FZ!]3CVY+"4I5(GA1-5#
M4'*UPM@HZ *XB?Q@,O4=QPGM33>5/A [$\?I >,!H!M,IUW@GIM1ZV9TFIN$
M5%22G/X]_&QJ1[5*T#G?P^YHTG?4![K!:.SV'?6!>+0?T9ZAH#44G&:H(G30
M2=!+TIV.L==WT@=Z_L0_<-$'8>Q/I@<>[$ZA+("O3,,1*&'K4M:UJ%UM>]J5
M*>4'ZW/5Z^K6]%^F;I1WA*]H*5 .2R7I7(Q5OKQN/O5$LLJ4XP63JKB;8:;Z
M-7 -4/M+QN1NH@]H_P%$_P!02P,$%     @ BS%;6@%F36*S!0  /B8  !H
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MJ-24<DF[DD;8E]:K.<&2F< &X81.KW"<^8M_BSE3-&=%2^9"&\;S2#'"7^\
M+<9@"[EQ[ :CG::Q\V TJ9'F*;V6,NHIH[=J%BWR@& ,0W\2B*D="F4Y&=<<
M\TQ?&XE>AL)G=.B);:6%&?0+-PZ<&(UY:PQA&,@6-";^%@(2]@H2&E75";VE
M!1BLH.L'SKB3:NQT6R/1V VWQI!)+^"@6<%=R^\LAL'E;?.IAPO] AI!7EP
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M0M"\O%P1G!"F$LCO%Y2*W8W*H#E_./T?4$L#!!0    ( (LQ6UJIEYXR/0(
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M9;&X_+# ;@;:.>#Z3BE[,ER%]?TQ>0-02P,$%     @ BS%;6KR=I*+H P
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M<DYALW-8%& 7^Z>P^3DL"$)0N(6=:.NUVGI7M?V3\%?X MKS=$T?T--DB>Y
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M [T'XQYU,L9D;@$'?@;(1J[!H6E_<\=@'O<W1QUJG&II'<WGG.#[>Y//"..
M+G[_#?KV'WJ%C'$N>5PSC\H\MWR-YV0\D*F%$[8E@TE):8K1)<GB"Y'5XN=6
M\7.[V"?_; 07<FNFQ1)@ <2*@!E9ID6A!NA"#[P1S,"5W,?E[KXV1;><Q=>S
MJ#2\G?B^:T.]1[;'D6L#/<^) A@T@'$;Z/AVB*(05<":8J]2['4J_L9PH<[R
M!X*\UO1NY$>.%Z&&H#;0<;W B2*W(<@ # ,[\/W(+,BO!/F=@EYD?OI8C]^:
M_09!Y$$W"!J"#$@8A#[RHK"AR(1$GN-XH6^6%%22@DY)LMHM2-I#5=#V(+(A
M<@/8$&4 >C+XGNLW-!F ?BBE1R>V75A)"L\]:*1(SCEB8<NST L=V_>;"]@&
MFL]BW :VSF)-:U1IC3JUEDE9:2O3L2R27U[71)=00<%6;MB/Q$8MUP(4>;[=
M$MOIR;F9^$)DM:!!^]"EV)VU[(?NWTAR<[<E3/:C0*>J<@+9]Y#RZ2M.6?GT
M@K,-,;84]B5KW479XDNQU6-\U G"R]6[A&89ELW%6FYFO5>-6W4_8WBT5Z%G
MH6:=,,%<*VSLY]@$"RWGQ(F$Z" <]2Y[/765A- Y=@597K.B&W&>Y;64F?G<
M$[4"'EI V-DA'1? GLH<L\<M92:<:S6+2VS$^983G%!V:,Y@=W=6KX,]Q;E&
MIYN%;FK$>9;;6C83SK>"$_40'OHPV-V(]:R(/55[!B\=JU4N]K@/#FML@M4.
M:UWSH56#W;W:>XH'M10/5'8'*K&#K<KI)\IESTCX;==-@>AT].RL?B&V>E@/
M[2(,.BOG79*D@A8X TG*YQGEFQ/_!,+.OO/LRGA)MOA2;/48'OI3V-V@/A>,
MS.FR2'_);:>WU\U,WYC,CV],YI0+<V1+]N"X/;6A:[=R:J<79\?L0FSUF!WZ
M7-C=Z#X0EE*=LC:]HP>H//H [\\_SBD3Z:_RLSKD*N^96^(/?$&E*0A!7EX8
M0002_&9:K&DWU=F+<-&V>7ATSY<3MM3WI5R&;E.(\I:K&JWN9._T361C_%[=
MU>K[PP-->='['3/9\G&0D86DM*U 9GM6WIV6+X*N]6WBC I!<_VX(C@A3 'D
M]P6EXOU%35#=8$_^!U!+ P04    " "+,5M:C+5',3<#  !G#0  &@   'AL
M+W=O<FMS:&5E=',O<VAE970Q,30N>&ULK5?;;J,P$/T5BZU6K=26.R'=!*D)
M>WNH5#7;W6<')@$5,&L[2??OUS:$0DI1*_&2^#+G,'/LL<>S Z%/+ '@Z#G/
M"C;7$L[+&UUG40(Y9M>DA$+,; C-,1==NM5920''"I1GNF48GI[CM-""F1J[
MI\&,['B6%G!/$=OE.:;_%I"1PUPSM>/ 0[I-N!S0@UF)M[ "_EC>4]'3&Y8X
MS:%@*2D0A<U<NS5O0M.0 &7Q.X4#:[61#&5-R)/L_(SGFB$]@@PB+BFP^-O#
M$K),,@D__M:D6O--"6RWC^S?5/ BF#5FL"39GS3FR5SS-13#!N\R_D ./Z .
MR)5\$<F8^D6'VM;04+1CG.0U6'B0IT7UCY]K(5H TWL#8-4 ZQ3@O &P:X#]
M7H!3 QRE3!6*TB'$' <S2@Z(2FO!)AM*3(46X:>%7/<5IV(V%3@>K!),X6HA
ME(O1DN1B.S&L%N0*55/KUU-?GV4;T'D('*<9NQ#&CZL0G9]=H#.4%NA70G8,
M%S&;Z5SX*+^D1[4_B\H?ZPU_3 O=D8(G#'TM8HB[!+H(KHG0.D:XL 890XBN
MD6U>(LNPG!Z'EN^'VSWP\/UP:R :NUDO6_'9@^M5+4K46I0^I2LFIY])'B@W
MK,01S#5Q8C"@>]""SY],S_C2I]*89.%(9!T%G49!9X@]Z&QEJ+9RGWH5RT2Q
MR--S'SB..9F*/;!OZ_+:S/8FKN]WS<(>,\,V/:LQZ\3B-K&X@[$\"'4PC1(D
MDDV<=GMQC)?B4.9]\0PR?70WC$D6CD364=!K%/1&RR=O3 7') M'(NLH.&D4
MG(R23Q6+U\H T_=,\S2?>LP\VW6-DWSJ,;.GMN/WYY/?Q.(/QK(2]4=:;"_1
M=RB XDSEU6TL[MV4<8IEB7*\_?I"'"3_Z 89DRP<B:PCZK01=3I:BDW'5'!,
MLG DLHZ"IO%2I1FC)%E-T[YG+-?U_)/T6?;9&8YAGUY;/78B'7W3.<DSO56!
MYD"WJI)G8KEW!:]*M6:T>2W<JAKY9'PA7Q&JLGVAJ9X@=YANTX*A##:"TKB>
MB&N#5E5]U>&D5'7NFG!1-:MF(EY"0*6!F-\0PH\=^8'F;17\!U!+ P04
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MX/6K-^ 5B#/P><-W!<U6Q:4EI%<EMA4U'MS4'J!G/( (?."9V!3@EVS%5GT
M2X;3QH2>8KI!6D3"HK< PY\ LI&C<.CV^.98T9P<WQQIHL'M".$*#S^#]X'O
MF5QHHJ29'HP6KT8KZHU6(@=+-0)U#XZZAS*U7!1;&K&KF<0J6+YGL\6//T#/
M_EG%GDDP8@BLQZS3,NOHT!<W-*%9Q  50'()ENPASK(X>P!\#;8LC_E*Q66-
MZ5>895;=+["+?8S\2VM_2-/8SL$!QJ[;MR-C.P]BY'JXM>L%Y[;!N=K@/BJF
M1]RLXJ1:TTLFRP:3R3M*:%'$ZSBB92I63J"Z+^_ R;EKR[@',2O,$ H<>Q"R
MUO.)@^ZUO'A:7JY3OLM$<1"V7$OKG*>3%Y<W"CJ <$#,$39$Z_=$5OR6%5_+
MRA],S*-=GI=YII[Z2@J:F5//(Q47_G@".*'KH $="C,DTV4X8$1A%KK8\]4K
M(VAC#4Y9]BQ;O;CF@Y$C&&.$T# NA9TJ-Y"QW3 W]"(+V\A"_=Q^H9C75=RJ
M:[HJ3BW\J77")!@Q!-:C%=J=2++/7H.;+@R1:Q2-F$+KTWN@0>$9"G$#VD\/
MH>-X@T6ILO-]!PX7I<(.^J%KJ]<D1%UTZ'_)K4TW+R97E9TJNZKL-.D5=H(5
M:E7;E 3;(/9\@4X0!L$P.(6A8M")RJX_Z/W@.LT(]:)1[C;E7C*K9_]M-:S1
M=_ YIUF15/H)7*_^EONV,EVH\X 6_^0\8!*-F$+K<]M)5NB>/\T:$I<-O2;1
MB"FT/KV=\H5ZZ3LQS8ZUZSSPPV"XWU'9><A%>+@RSZ%S82=TH5[IFMT7097@
M]5W/'9*C4KRNXSE#<K3.3R6G4\90+XW-;X[@6.K:0VY>-"%ZMZ?2TLEJJ-?5
MQBIX>.1L4=@I9\LY5#'J5#'2RL(I=;Y![-=YN>]QAR)&9:C(.D1EU\\Z_> Z
M38KTFO1+EC.:Q/_*^?X;C;/"*C=-K*CI*ZO\GL8)729L+K/%_)XF#-PS.4EB
M$3/E2M#W=VIA,HI&3*'UN>X4,D)GK_M(*\)/IM<D&C&%UJ>WT^/H)#U^9-U'
M8P6-AXE*83,/[=&;+;U_4^/O)#O22W:S);_IK!?SF)BQ46B/-BEZOZ?RTLEM
MI']%;+[:H_$+X&&U?]F$Z-V>2DLGDY%>)INJ]D@AB,<396RDFBCGT,RHT\Q(
MKYFG%/JQX!W-A+')D!ZBL.DGF'Y$G=!%>J%[UWRY?A_399S$XOM+NW8]WLGE
MQ20:,876Y[)3QR@\?_4V^N;9*!HQA=;_^MNI;'R2RCZR>F.5T(9..-A"W*KL
MW" 8;MKU/D[EH!/C6"_&S59PK'@AC/S1QTR5F><,O_D0O>M3J>FT,]:_739?
MQ/'XO?#X@^8Q1D3O^E1J#@Y.Z'6OJ4*.52^GP]%[=Y69ZXU).8<8QIT8QB<=
M>CBFEN/Q$06Y:7?P\$.+TFZ<<XC*KI=SZM"L@U--*<L?JM-AA1P\.=_KPT#M
MT_8$VG5U[FKP_ 9>D/H<60=3'VO[0'.930N0L+6$M-_Z4GGF]4FQ^D;P;75V
M:LF%X&EUN6%TQ?+20/Z^YEP\W90=M.?U%O\!4$L#!!0    ( (LQ6UI:> 15
M#@,  *(-   :    >&PO=V]R:W-H965T<R]S:&5E=#$Q-BYX;6RMEVUOVC 0
MQ[^*E55;*W7D"0+K(%)+,FTOJE5EW5Z;Y"!6$YO9#K3??K83,N@@ BUOP';\
M_]WYCAR^\8;Q9Y$!2/12Y%1,K$S*U8UMBR2# HL>6P%53Q:,%UBJ*5_:8L4!
MIT94Y+;G.(%=8$*M<&S6'G@X9J7,"84'CD19%)B_WD'.-A/+M;8+CV292;U@
MA^,57L(,Y-/J@:N9W5!24@ 5A%'$83&Q;MV;>*3WFPT_"6S$SACID\P9>]:3
M;^G$<K1#D$,B-0&KKS5,(<\U2+GQNV9:C4DMW!UOZ5_,V=59YEC E.6_2"JS
MB36R4 H+7.;RD6V^0GV>@>8E+!?F$VVJO8/ 0DDI)"MJL?*@(+3ZQB]U''8$
M;O^(P*L%WJD"OQ;X;P7'7.K7@OZI%@:UP!S=KLYN A=AB<,Q9QO$]6Y%TP,3
M?:-6\2)4_TYFDJNG1.ED.,LPAXSE*7#Q <6_2R)?T64$$I-<7*&/Z&D6H<N+
M*W2!"$4_,E8*3%,QMJ4RKA%V4AN**D/>$4.NA^X9E9E ,4TAW0?8RNO&=6_K
M^IW72KPMESWD#JZ1YWC^ 8>F)\@=]Z@\:I='D/207\G[!^3QZ7*_)1A^DT??
M\/QC>2SG@J1$O>K7:(9S0&R!9I(ESP=<NZM0_<,H79ENQ HG,+%4Z1' UV"%
M[]^Y@?/Y4)2[A$5=PN*.8'OYZ#?YZ+?1PRFFB:I^V%1#E0O&4T)5=I#0+]RA
M]^>N%7AN5KJ$115L:&#ZCV<=^H'WR1V.[?5NO#NRN1?O01/O06N\O]?QK8"S
MHT%NI9P;Y"YA49>PN"/87BJ")A5!=Z4HZ#(?7<*B+F%Q1["]? R;? S_IQ2A
M2_7';H97AQ+4RCXW014LV"DDGN\-?=<9[9>2J$NK\0E6]P([:@([ZKK&CTZJ
MI--6N^?^D+N$Q?\>P'L31'OG,EH 7YHN0*"$E516E[MFM6DT;LW]^LUZI!J0
MJE_XBZFZEWO,EX0*E,-"(9W>4)4[7G4$U42RE;GRSIE4%V@SS%03!5QO4,\7
MC,GM1!MHVK+P#U!+ P04    " "+,5M:ZTO_^NH"  #7"P  &@   'AL+W=O
M<FMS:&5E=',O<VAE970Q,3<N>&ULK99=;]HP%(;_BI5-4RNMY(- : >16J)I
MN^B$J+I=N^$$K"9Q:I\ _?>SDS3B(PT@Y0;LY+ROSWFPS1EON'B5*P DVR1.
MY<18(69WIBG#%214]G@&J7H3<9%05%.Q-&4F@"X*41*;CF4-S82RU/#'Q;.9
M\,<\QYBE,!-$YDE"Q?L#Q'PS,6SCX\&<+5>H'YC^.*-+> )\SF9"S<S:9<$2
M2"7C*1$038Q[^RX8Z?@BX"^#C=P9$UW)"^>O>O)[,3$LG1#$$*)VH.IK#5.(
M8VVDTGBK/(UZ22W<'7^X_RQJ5[6\4 E3'O]C"UQ-C)%!%A#1/,8YW_R"JIZ!
M]@MY+(M/LJEB+8.$N42>5&*50<+2\IMN*PX[ N73+' J@7.NH%\)^H<"]Q.!
M6PG<@DQ92L$AH$C]L> ;(G2T<M.# F:A5N6S5/_L3RC46Z9TZ,]!HF APH+\
M49OL7DI 2:X"0,IB>4UNR/-30*Z^7H]-5,MID1E6U@^EM?.)=0!AC_3M[\2Q
M'+=!/CU?WF^0!^?+G7VYJ1C5H)P:E%/X]4^#2A4H6H!J@E+:N,TV^A3?R8R&
M,#'4,94@UF#XW[[80^M'$Z(NS8*.S/;P]6M\_39W_Y&E+,D3=5.\Y4PHB!(I
MYLC%.ZD6(SPB-$US&A,:(8@;I%N2"1XQ)%=4$DHR$"&DV+@5R]5MJUA>WW5K
MW^K98W.]2[,UQ4MI=F2V1].M:;JM-.>?4]PEI>YM357 DDE%5,6'-&.H")\&
MZC8!'1P ;<WR4J =F>T!'=1 !ZU [S.UTS+!:/%GA/P8;.-9+TV]748'A$Y&
M!&T1>[4,ZUJ&K;7,YM.F7%M%E]Y+79H%'9GMP?)J6%XWU[K7);XNS8*.S/;P
MC6I\HQ,7T9GX1D>[W/:LV]NA;5F'1^8XU+%MU_&\H]"@-;E+2S=WNBC=\CY2
ML62I)#%$RM[J>>JDBK*-+"?(LZ*Q>N&HVK1BN%*=-P@=H-Y'G./'1/=J=2_O
M_P=02P,$%     @ BS%;6EU<+9LC!   710  !H   !X;"]W;W)K<VAE971S
M+W-H965T,3$X+GAM;+58;6_;-A#^*X16; G06F_66V8;B*,,"[ 61MRLP+[1
M$FUSE42-I./TWX^D9-F2%35IF2_6V]VC>Q[R3N>;[ G]RK8(<?"49P6;&EO.
MRRO39,D6Y9"-2(D*\61-: ZYN*0;DY44P50YY9GI6)9OYA 7QFRB[BWH;$)V
M/,,%6E# =GD.Z;<YRLA^:MC&X<8]WFRYO&'.)B7<H"7B#^6"BBNS04EQC@J&
M20$H6D^-:_LJMGWIH"S^QFC/3LZ!I+(BY*N\N$NGAB4C0AE*N(2 XO"(;E"6
M2201QW\UJ-&\4SJ>GA_0_U#D!9D59.B&9%]PRK=3(S1 BM9PE_%[LO\3U80\
MB9>0C*E?L*]M+0,D.\9)7CN+"')<5$?X5 MQXB"(]CLXM8/3=1@_X^#6#NY+
M'<:UPU@I4U%1.L20P]F$DCV@TEJ@R1,EIO(6]'$AUWW)J7B*A1^?W>9E1KXA
M!.:H0&O,P2*#!0,?P'6:8KDR, -W1;6_Y#I=Q(A#G+%+8?*PC,'%NTOP#N "
M?-Z2'8-%RB8F%W%)=#.I8YA7,3C/Q& [X",I^):!VR)%:1O %(0:5LZ!U=P9
M1(Q1,@*N_1XXEC/N">CFY>YNCWO\<G=G@(W;K)&K\-SOK9'8S^)1"A*A%L6K
MG5J14BQ8G^85YK@?4Y:3*U;"!$T-42\8HH_(F/WZB^U;O_?II1,LU@36TG+<
M:#D>0I\M*/E7E!PAXJK>\&25X8W:W'TJ5FB!0I,U]'$66G843<S'4WG.K0++
MMZRV53P8V0_R]AK>WB#ON-XZ!]9RU[Q7OP RAG@?]PK1/V'ENT$T[G _M_(\
MW_(ZW >C^T'N?L/='^1^^U162XZJ1**M!&(J3[T^ ?PS:FXD,[K%?_#=KTT-
M36 MF8)&IF!0IH?1<M2GPJ#7:PN)3K!8$UA+K;!1*WR#HASJU%(G6*P)K*5E
MU&@9#2=H7UX"3D1CR3%%HLWDSRH:G95>QPK=;H&.SC+9]ES;[Q2I<RS;<J*P
ML6J1LZUCBV4-?W,@Y3C!)2SX;ZQ=>T0KQT4KGX(+R  $):*)('O9VT-5+Y&'
M)CQK9'4XW S'\MI=H0NMK=Q)<VH/*W=_TRO%H-=KTT@K6JP+K:V8<U3,>8.R
M5(/J$E0G6JP+K2WHL?>V!]O1GZI--72[H-A!T*U.M=UI>8K&KA=VRE./6>B&
MOO5,?3JVQ/9P3[S\<O?YG]O[OZX_Q;TL-/6M-5>=:+$NM+9RQZ;:]MXBVS0U
MP[6@.M%B76AM08^=NOV=5OUGLLT_RS8W=+QNKIU;.8'=_:O6BQ4&G4PS3^8N
M.:(;-;^27_A=P:MA17.WF9%=J\E0Y_Y<SL[4/.<(4PW>/D*ZP:)/R-!:0%JC
M0*P/K699U04GI9KNK CG)%>G6P131*6!>+XFA!\NY N:B>+L?U!+ P04
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M]J0=GI39MMZE]9"52I3ZX5I&2YE7!>K]QRPKGY]4!SCN#)S_#U!+ P04
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M-]=)4?VBYQJ+1VB^+8Q.ZV";01IGNW_Y4A?B(( $/0&T#J#= *\G@-4![-0
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M 3C*18 9K"YHU 6#ZKYJ8R7IDZ9^X*3 N/"8WTEU!N"H"/SNP$8NCH8D)(3
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M3JO#M9(+E9< >W^IM=F?E ]H]M2G_P-02P,$%     @ BS%;6JY/>#&1!
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M]<))C^&D/NOS?ZO9MZ@:,%'W+:.NI9YB'^933FDD^/7LX308@$X(%(6BKTL
MG9K!B4#L*.SYP(X^,&]*O%O^3\TE^Q':5FK"SBHUO-6P+P_.Z4_UZTSGSDZ/
M:35&STX<-F;BC&DL&<E8+^C\&'3N39QWV===7G>AG&[K*I,JS/I7TCI;!VKJ
M4^O3@UIXM[I;H*CNK?.39."A^F>EEJNB7-BJ!+ E.!_(JNCH8.1W<%/5;?[W
M<7$8<B[(JJ8-FG5:RZ#(T[N\R-LGR./(N<II1#"V1Q,@8PS'U/(9D,6<AAAV
M6AR=%EZG_VC7L@YRM=XU5WK(0'X(YY<10IQ8;KBJ*8MC>TIP57%((]B'^.A#
M[%\AUFEY+QMKC#>-5-.#[KOG3AH:[_&8XWU,8\E(QGI11:&!J?"%$9_5.S7@
MY;>M!J-],*LN8;;I4WI72!AW0BA?"+,2>@'I1*BD5LH .LHX'D@:=,**Z,65
M\,4% G00N:F.:,@)LCV$A(A%E!';1]!DS#F*!]S$QDU\$3_EY8-LSED&#W9'
M&A>C6DO&LM:/J4%2Y$6T^:U>_^3R$-$F5>A1U6HCT^YJM1;HQ:-9J\5DVLKZ
M.> =K8!A)D[78\Z8G4JNBJO%A-HK(Z!#C!..Q$ >&6Y$?G"\W:FU4.U)M7??
MB0"'7^AE.4'.\KZ =(@YL)" .DH&20 9P$1>E'I>%H&A OK%W.O @F/;+4@6
M1LSV"I A*H9\,OR&_ !WG.]>'2:\UX'JQ(=<;3J#NZ?SG77A:\JH(,SI19CX
M;*X!9"B,(H3)@,.&YU!TT<RWVA\#G#'S>4'QXIEO3&O)6-;Z,36XB/R\:,U\
M9I8KJK2$\\5%/L$%CIQT<75J^6/$&?2NCB 2170@70Q%(B].S3])134=X/?G
M[V'/8@#P0XJ13?B0D(0QB[CM&R"D>F.-8.>P83GL9[E^OU7;;I,CO\DZRY_)
M3FZV1?4DY6%KLWV>[[=%6D+N8XC+2&3O"P 98VIX6ZY#UKC:X PX;B@/GTEY
MIW.=F0&A.0%TU@4T%!-*8]M;5T<1IY&]#P)T4R3B:*BC#>YA+_K,?UVM9-:E
M\*JJ97ZO>SGK-DB!@EL9[%\/;_8.YOO3NTI!&T@@G0B%TZV C,=$#$SNV" 8
M]B.8[M>ES&JI4U3!N^[CJWU/RZ^[_$$QF0*NJRZSU438UGG6JC[7 M!MEYO4
MJA9A$ME^ T(NXM!!>M!B&(F3=;+ONB$Q[">QQ?FN7@5W\CXO2YW@*B6>%*J!
MWKL@I;B,Q<+>LT%"$;'0#E,"""D16(B!;1LV:(;]:':1]U+O6#U^NZB%N7*(
M.KWN"L$ )9#0"E#?;X-OV(]OMVI25FO3HMILTQ(\;_(;N!1;1K66C&6M'SR#
M@O@R%#S[+!B/BH*C6DO&LM:/J4%![$=!7R4! Z>!8"D!$H*U!$CH+29@ W[8
M?W[XD\L)>-3SQ5&M)6-9ZU?V#)62ETX8?ZRF0%QHM+<5@ 0Z2O!:ZGMGT)/X
MT7/T@@(!H!&J*$ ZJ*0 Z3PU!6(@E/@A]$NIN*S(_U8]J\>/VF"H"!15>7_6
MB1B!T%+!F'V\"N@4KQ%F'R #NIC@<(BUR4EEVL^@YQ1/B(N!!''[&A> ;$HB
M2NQM<@()F>JTF ]X8["2T)]:1B%>:KVXX#ZFM60L:_W0&F8E?F:]K>4VS<%*
M2K:K.Z[;!QJ,JXN4R-EN+  5"1F*[?1Q99P/C@0#I^2EXO!WE8H(<$2((Q+:
M^ WH=,4%V3-? @@5?0L\-#@,0!)_<?B[BT4$J-LB2M36TO81$B(N.+91"%(*
M@1$=("%BD(Z(GU,K(EY4O'CLCVDM&<M:/Z:&+HG_6/&Y;M)<5A8B[E&@@S;
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M7 6?05[=OEL4QN%$D478OO17A.IDDHRD2JEJTH3^,C3H<9J!'<4F4SAK600
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M.6Q.6F-Y&!(F&G.'X':0+F94Y$VMV]%<<UE,?U%,I)\!LWY>, ^'@RDFTL^
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M5[T[0.^N>G> WEWU[@"]N[O9&Z!W5[T[0.^A>@^ WD/U'@"]A^H] 'H/U7L
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M              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @
MBS%;6A<RM*_O    *P(  !$              ( !KP   &1O8U!R;W!S+V-O
M<F4N>&UL4$L! A0#%     @ BS%;6IE<G",0!@  G"<  !,
M ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "+,5M:=)_D
MFE,(  !O,@  &               @($."   >&PO=V]R:W-H965T<R]S:&5E
M=#$N>&UL4$L! A0#%     @ BS%;6APBMT4] @  P@4  !@
M ("!EQ   'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( (LQ
M6UJ)K6*\F@8  $T?   8              " @0H3  !X;"]W;W)K<VAE971S
M+W-H965T,RYX;6Q02P$"% ,4    " "+,5M:4[;U*(X#  !X"P  &
M        @(':&0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%
M  @ BS%;6A$+V:D?!P  ;!X  !@              ("!GAT  'AL+W=O<FMS
M:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( (LQ6UK3F28BB0(  &4'   8
M              " @?,D  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"
M% ,4    " "+,5M:1% *9TL*   E,@  &               @(&R)P  >&PO
M=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ BS%;6FXT!]\J"
M\CP  !@              ("!,S(  'AL+W=O<FMS:&5E=',O<VAE970X+GAM
M;%!+ 0(4 Q0    ( (LQ6UI*;8TT30,  %D'   8              " @9,Z
M  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " "+,5M:CA;+
MUKXG  !YA@  &0              @($6/@  >&PO=V]R:W-H965T<R]S:&5E
M=#$P+GAM;%!+ 0(4 Q0    ( (LQ6UJ7;*QV1Q4  "U%   9
M  " @0MF  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @
MBS%;6L<%Z$6A P  ) @  !D              ("!B7L  'AL+W=O<FMS:&5E
M=',O<VAE970Q,BYX;6Q02P$"% ,4    " "+,5M:W T-KV8$  "'"@  &0
M            @(%A?P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4
M Q0    ( (LQ6UI!&"MYC@(  )@%   9              " @?Z#  !X;"]W
M;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ BS%;6JWRY\]R!0
ME@T  !D              ("!PX8  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX
M;6Q02P$"% ,4    " "+,5M:T16G+@ &  !!#@  &0              @(%L
MC   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( (LQ6UK8
M^':.B 0  &H+   9              " @:.2  !X;"]W;W)K<VAE971S+W-H
M965T,3<N>&UL4$L! A0#%     @ BS%;6G?FF+?!"P  ;1\  !D
M     ("!8I<  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (LQ6UK;'24X_0\  ,\O   9              "
M@4JZ  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ BS%;
M6DX.HXF% P  OP@  !D              ("!?LH  'AL+W=O<FMS:&5E=',O
M<VAE970R-"YX;6Q02P$"% ,4    " "+,5M:BCBFOHL%   Y#0  &0
M        @($ZS@  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0
M   ( (LQ6UH"YP<.=04  *T-   9              " @?S3  !X;"]W;W)K
M<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ BS%;6CJ^5"K)!@  \A$
M !D              ("!J-D  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q0
M2P$"% ,4    " "+,5M:>#M!/+@%  #Z#0  &0              @(&HX
M>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( (LQ6UJ"JTJ4
M@ 4  +8,   9              " @9?F  !X;"]W;W)K<VAE971S+W-H965T
M,CDN>&UL4$L! A0#%     @ BS%;6N_"#'#>"@  W!P  !D
M ("!3NP  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " "+
M,5M:N1*-AF@"  ",!@  &0              @(%C]P  >&PO=V]R:W-H965T
M<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( (LQ6UH& NK+1 (  (L&   9
M          " @0+Z  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#
M%     @ BS%;6CRE,S@1 @  W00  !D              ("!??P  'AL+W=O
M<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " "+,5M:6ZS^HBD-  !!
M/0  &0              @('%_@  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM
M;%!+ 0(4 Q0    ( (LQ6UI4;+"6R3(   6Y   9              " @24,
M 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ BS%;6O@;
MK"79!@  L1$  !D              ("!)3\! 'AL+W=O<FMS:&5E=',O<VAE
M970S-BYX;6Q02P$"% ,4    " "+,5M:%"BR5T8(  "<&   &0
M    @($U1@$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    (
M (LQ6UJ;_^.DGP(  /@%   9              " @;). 0!X;"]W;W)K<VAE
M971S+W-H965T,S@N>&UL4$L! A0#%     @ BS%;6N)V>FEY!   G@H  !D
M             ("!B%$! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"
M% ,4    " "+,5M:R4H:2YX"  "5!0  &0              @($X5@$ >&PO
M=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( (LQ6UJ#WM74S@0
M $$,   9              " @0U9 0!X;"]W;W)K<VAE971S+W-H965T-#$N
M>&UL4$L! A0#%     @ BS%;6@;/D],0!   8@D  !D              ("!
M$EX! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " "+,5M:
MDG4X8>$#  "*"0  &0              @(%98@$ >&PO=V]R:W-H965T<R]S
M:&5E=#0S+GAM;%!+ 0(4 Q0    ( (LQ6UJ!7R:Y+0@  +\6   9
M      " @7%F 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%
M  @ BS%;6A5"L"4&!0  M@P  !D              ("!U6X! 'AL+W=O<FMS
M:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " "+,5M:(*YKPX4'  "&&
M&0              @($2= $ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+
M 0(4 Q0    ( (LQ6UHI&0),/P8  !81   9              " @<Y[ 0!X
M;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ BS%;6M--Z\'2
M @  ^P4  !D              ("!1((! 'AL+W=O<FMS:&5E=',O<VAE970T
M."YX;6Q02P$"% ,4    " "+,5M:L%20"MT'   N%   &0
M@(%-A0$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( (LQ
M6UI0 ?VCE0,  *8(   9              " @6&- 0!X;"]W;W)K<VAE971S
M+W-H965T-3 N>&UL4$L! A0#%     @ BS%;6FXU<4_G @  EP8  !D
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M=#4U+GAM;%!+ 0(4 Q0    ( (LQ6UJQ8AU8/0,  ,D0   9
M  " @5RF 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @
MBS%;6O/%=UR= @  .0H  !D              ("!T*D! 'AL+W=O<FMS:&5E
M=',O<VAE970U-RYX;6Q02P$"% ,4    " "+,5M:U.LW-GT"  "S!@  &0
M            @(&DK $ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4
M Q0    ( (LQ6UJ%U4E_:@(  +,&   9              " @5BO 0!X;"]W
M;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ BS%;6D7?,WQ1"
M>TT  !D              ("!^;$! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX
M;6Q02P$"% ,4    " "+,5M:*$P0+9\$  #;%@  &0              @(&!
MN@$ >&PO=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( (LQ6UI#
M[*\X+0(  ,$$   9              " @5>_ 0!X;"]W;W)K<VAE971S+W-H
M965T-C(N>&UL4$L! A0#%     @ BS%;6@9C![T%!0  02(  !D
M     ("!N\$! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( (LQ6UJ=(4C[HP,  '@-   9              "
M@4#: 0!X;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ BS%;
M6H_N?E>N @  ( <  !D              ("!&MX! 'AL+W=O<FMS:&5E=',O
M<VAE970V.2YX;6Q02P$"% ,4    " "+,5M:]QT':[($  #'&0  &0
M        @('_X $ >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0
M   ( (LQ6UK\W0SRG@,  #P1   9              " @>CE 0!X;"]W;W)K
M<VAE971S+W-H965T-S$N>&UL4$L! A0#%     @ BS%;6FG*HR=T @  ?@8
M !D              ("!O>D! 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q0
M2P$"% ,4    " "+,5M:B8\)F6H"  "E!P  &0              @(%H[ $
M>&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    ( (LQ6UJU<449
M0@4  "L>   9              " @0GO 0!X;"]W;W)K<VAE971S+W-H965T
M-S0N>&UL4$L! A0#%     @ BS%;6H3\*RCK @  F0@  !D
M ("!@O0! 'AL+W=O<FMS:&5E=',O<VAE970W-2YX;6Q02P$"% ,4    " "+
M,5M:4A-&%Y "  #>!@  &0              @(&D]P$ >&PO=V]R:W-H965T
M<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    ( (LQ6UK4-S->^@$  *T$   9
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M970X,2YX;6Q02P$"% ,4    " "+,5M:"9@96YD$  #[&   &0
M    @('."0( >&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4 Q0    (
M (LQ6UJ5R.(Y_@4  '0V   9              " @9X. @!X;"]W;W)K<VAE
M971S+W-H965T.#,N>&UL4$L! A0#%     @ BS%;6HN+#)0Z P  6 \  !D
M             ("!TQ0" 'AL+W=O<FMS:&5E=',O<VAE970X-"YX;6Q02P$"
M% ,4    " "+,5M:YCCFU44#   "#@  &0              @(%$& ( >&PO
M=V]R:W-H965T<R]S:&5E=#@U+GAM;%!+ 0(4 Q0    ( (LQ6UI%.47?,0(
M (X&   9              " @< ; @!X;"]W;W)K<VAE971S+W-H965T.#8N
M>&UL4$L! A0#%     @ BS%;6L#$J,$R P  =PT  !D              ("!
M*!X" 'AL+W=O<FMS:&5E=',O<VAE970X-RYX;6Q02P$"% ,4    " "+,5M:
MWOJ^ZC $   &&   &0              @(&1(0( >&PO=V]R:W-H965T<R]S
M:&5E=#@X+GAM;%!+ 0(4 Q0    ( (LQ6UHE"]RBA ,  +,0   9
M      " @?@E @!X;"]W;W)K<VAE971S+W-H965T.#DN>&UL4$L! A0#%
M  @ BS%;6EL;I>\3!   UA0  !D              ("!LRD" 'AL+W=O<FMS
M:&5E=',O<VAE970Y,"YX;6Q02P$"% ,4    " "+,5M:5!D_> (%  "*$@
M&0              @(']+0( >&PO=V]R:W-H965T<R]S:&5E=#DQ+GAM;%!+
M 0(4 Q0    ( (LQ6UK  '$1>@4  !,8   9              " @38S @!X
M;"]W;W)K<VAE971S+W-H965T.3(N>&UL4$L! A0#%     @ BS%;6L#5N"AS
M P  0 H  !D              ("!YS@" 'AL+W=O<FMS:&5E=',O<VAE970Y
M,RYX;6Q02P$"% ,4    " "+,5M:?R_T+Y0$  !@'   &0
M@(&1/ ( >&PO=V]R:W-H965T<R]S:&5E=#DT+GAM;%!+ 0(4 Q0    ( (LQ
M6UI@KD4@4P,  !\+   9              " @5Q! @!X;"]W;W)K<VAE971S
M+W-H965T.34N>&UL4$L! A0#%     @ BS%;6K$-OP.K P  W T  !D
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M=#$P,"YX;6Q02P$"% ,4    " "+,5M:@ASM=)("  !?!P  &@
M    @(%R90( >&PO=V]R:W-H965T<R]S:&5E=#$P,2YX;6Q02P$"% ,4
M" "+,5M:H[2#C[<"   -"   &@              @($\: ( >&PO=V]R:W-H
M965T<R]S:&5E=#$P,BYX;6Q02P$"% ,4    " "+,5M: 69-8K,%   ^)@
M&@              @($K:P( >&PO=V]R:W-H965T<R]S:&5E=#$P,RYX;6Q0
M2P$"% ,4    " "+,5M:B1:F08H$   N%P  &@              @($6<0(
M>&PO=V]R:W-H965T<R]S:&5E=#$P-"YX;6Q02P$"% ,4    " "+,5M:6P>S
MY$L#  "F"P  &@              @('8=0( >&PO=V]R:W-H965T<R]S:&5E
M=#$P-2YX;6Q02P$"% ,4    " "+,5M:0I9KF"(%  "+*   &@
M    @(%;>0( >&PO=V]R:W-H965T<R]S:&5E=#$P-BYX;6Q02P$"% ,4
M" "+,5M:J9>>,CT"   K!0  &@              @(&U?@( >&PO=V]R:W-H
M965T<R]S:&5E=#$P-RYX;6Q02P$"% ,4    " "+,5M:O)VDHN@#  "]#P
M&@              @($J@0( >&PO=V]R:W-H965T<R]S:&5E=#$P."YX;6Q0
M2P$"% ,4    " "+,5M:_P8!2/\#  #-#P  &@              @(%*A0(
M>&PO=V]R:W-H965T<R]S:&5E=#$P.2YX;6Q02P$"% ,4    " "+,5M:8&WA
M&\$#   N&   &@              @(&!B0( >&PO=V]R:W-H965T<R]S:&5E
M=#$Q,"YX;6Q02P$"% ,4    " "+,5M:/W$I<S4'  "+*0  &@
M    @(%ZC0( >&PO=V]R:W-H965T<R]S:&5E=#$Q,2YX;6Q02P$"% ,4
M" "+,5M:8O],]H,$  "8%P  &@              @('GE ( >&PO=V]R:W-H
M965T<R]S:&5E=#$Q,BYX;6Q02P$"% ,4    " "+,5M:*Z^W52@%  #-%@
M&@              @(&BF0( >&PO=V]R:W-H965T<R]S:&5E=#$Q,RYX;6Q0
M2P$"% ,4    " "+,5M:C+5',3<#  !G#0  &@              @($"GP(
M>&PO=V]R:W-H965T<R]S:&5E=#$Q-"YX;6Q02P$"% ,4    " "+,5M:5*N0
M+#\&  "[)P  &@              @(%QH@( >&PO=V]R:W-H965T<R]S:&5E
M=#$Q-2YX;6Q02P$"% ,4    " "+,5M:6G@$50X#  "B#0  &@
M    @('HJ ( >&PO=V]R:W-H965T<R]S:&5E=#$Q-BYX;6Q02P$"% ,4
M" "+,5M:ZTO_^NH"  #7"P  &@              @($NK ( >&PO=V]R:W-H
M965T<R]S:&5E=#$Q-RYX;6Q02P$"% ,4    " "+,5M:75PMFR,$  !=%
M&@              @(%0KP( >&PO=V]R:W-H965T<R]S:&5E=#$Q."YX;6Q0
M2P$"% ,4    " "+,5M:,AW->8T"   V!P  &@              @(&KLP(
M>&PO=V]R:W-H965T<R]S:&5E=#$Q.2YX;6Q02P$"% ,4    " "+,5M:?E/<
M=/$#  "1%0  &@              @(%PM@( >&PO=V]R:W-H965T<R]S:&5E
M=#$R,"YX;6Q02P$"% ,4    " "+,5M:A N)8S$"  "X!   &@
M    @(&9N@( >&PO=V]R:W-H965T<R]S:&5E=#$R,2YX;6Q02P$"% ,4
M" "+,5M:(-D2QLH&   E.   &@              @($"O0( >&PO=V]R:W-H
M965T<R]S:&5E=#$R,BYX;6Q02P$"% ,4    " "+,5M:!^?-5%H%  !?%P
M&@              @($$Q ( >&PO=V]R:W-H965T<R]S:&5E=#$R,RYX;6Q0
M2P$"% ,4    " "+,5M:KD]X,9$$   -%   &@              @(&6R0(
M>&PO=V]R:W-H965T<R]S:&5E=#$R-"YX;6Q02P$"% ,4    " "+,5M:S"^'
MYE8(  "61P  &@              @(%?S@( >&PO=V]R:W-H965T<R]S:&5E
M=#$R-2YX;6Q02P$"% ,4    " "+,5M:&]X.6=L)  "E-P  &@
M    @('MU@( >&PO=V]R:W-H965T<R]S:&5E=#$R-BYX;6Q02P$"% ,4
M" "+,5M:@$_.*&L"  !O!@  &@              @($ X0( >&PO=V]R:W-H
M965T<R]S:&5E=#$R-RYX;6Q02P$"% ,4    " "+,5M:)/Z16UL#  #(%0
M#0              @ &CXP( >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( (LQ
M6UJ7BKL<P    !,"   +              "  2GG @!?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( (LQ6UIB#^!:T0@  "%3   /              "  1+H @!X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " "+,5M:A>>NP'8#  !^2@  &@
M            @ $0\0( >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    " "+,5M:A:-_>*X"  !11P  $P              @ &^] ( 6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     AP"' $0E  "=]P(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>447</ContextCount>
  <ElementCount>522</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>139</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952151 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952152 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952153 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952154 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952155 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952156 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF SHAREHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Collaborative and Licensing Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/CollaborativeandLicensingArrangements</Role>
      <ShortName>Collaborative and Licensing Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Restricted Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/RestrictedCash</Role>
      <ShortName>Restricted Cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Inventories, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/InventoriesNet</Role>
      <ShortName>Inventories, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Property, Plant and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/PropertyPlantandEquipmentNet</Role>
      <ShortName>Property, Plant and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Supplemental Balance Sheet Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/SupplementalBalanceSheetInformation</Role>
      <ShortName>Supplemental Balance Sheet Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Product Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/ProductRevenue</Role>
      <ShortName>Product Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/LossPerShare</Role>
      <ShortName>Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9952172 - Disclosure - Accumulated Other Comprehensive (Loss) Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncome</Role>
      <ShortName>Accumulated Other Comprehensive (Loss) Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9952173 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9952174 - Disclosure - Restricted Net Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/RestrictedNetAssets</Role>
      <ShortName>Restricted Net Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9952175 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9952176 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9952177 - Disclosure - Segment and Geographic Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/SegmentandGeographicInformation</Role>
      <ShortName>Segment and Geographic Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9952178 - Disclosure - Schedule I - Condensed Financial Information of Registrant</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrant</Role>
      <ShortName>Schedule I - Condensed Financial Information of Registrant</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.beigene.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.beigene.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Collaborative and Licensing Arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/CollaborativeandLicensingArrangementsTables</Role>
      <ShortName>Collaborative and Licensing Arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.beigene.com/role/CollaborativeandLicensingArrangements</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Restricted Cash (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/RestrictedCashTables</Role>
      <ShortName>Restricted Cash (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.beigene.com/role/RestrictedCash</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.beigene.com/role/Investments</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Inventories, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/InventoriesNetTables</Role>
      <ShortName>Inventories, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.beigene.com/role/InventoriesNet</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.beigene.com/role/Leases</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Property, Plant and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/PropertyPlantandEquipmentNetTables</Role>
      <ShortName>Property, Plant and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.beigene.com/role/PropertyPlantandEquipmentNet</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.beigene.com/role/IntangibleAssets</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.beigene.com/role/IncomeTaxes</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Supplemental Balance Sheet Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/SupplementalBalanceSheetInformationTables</Role>
      <ShortName>Supplemental Balance Sheet Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.beigene.com/role/SupplementalBalanceSheetInformation</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.beigene.com/role/Debt</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Product Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/ProductRevenueTables</Role>
      <ShortName>Product Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.beigene.com/role/ProductRevenue</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/LossPerShareTables</Role>
      <ShortName>Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.beigene.com/role/LossPerShare</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.beigene.com/role/ShareBasedCompensation</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncomeTables</Role>
      <ShortName>Accumulated Other Comprehensive (Loss) Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncome</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Employee Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/EmployeeBenefitPlansTables</Role>
      <ShortName>Employee Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.beigene.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Segment and Geographic Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/SegmentandGeographicInformationTables</Role>
      <ShortName>Segment and Geographic Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.beigene.com/role/SegmentandGeographicInformation</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - SEC Schedule, Article 12-04, Condensed Financial Information of Registrant (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/SECScheduleArticle1204CondensedFinancialInformationofRegistrantTables</Role>
      <ShortName>SEC Schedule, Article 12-04, Condensed Financial Information of Registrant (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/DescriptionofBusinessDetails</Role>
      <ShortName>Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.beigene.com/role/DescriptionofBusiness</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Summary of Significant Accounting Policies - Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Summary of Significant Accounting Policies - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Summary of Significant Accounting Policies - Land Use Right, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesLandUseRightNetDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Land Use Right, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Summary of Significant Accounting Policies - Goodwill and Other Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesGoodwillandOtherIntangibleAssetsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Goodwill and Other Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Summary of Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Summary of Significant Accounting Policies -Government Grants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesGovernmentGrantsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies -Government Grants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Summary of Significant Accounting Policies - Concentration of Risks (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesConcentrationofRisksDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Concentration of Risks (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Collaborative and Licensing Arrangements - Recognized Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/CollaborativeandLicensingArrangementsRecognizedRevenueDetails</Role>
      <ShortName>Collaborative and Licensing Arrangements - Recognized Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Collaborative and Licensing Arrangements - Novartis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/CollaborativeandLicensingArrangementsNovartisDetails</Role>
      <ShortName>Collaborative and Licensing Arrangements - Novartis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Collaborative and Licensing Arrangements - Ociperlimab Option, Collaboration and License Agreement and China Broad Market Development Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/CollaborativeandLicensingArrangementsOciperlimabOptionCollaborationandLicenseAgreementandChinaBroadMarketDevelopmentAgreementDetails</Role>
      <ShortName>Collaborative and Licensing Arrangements - Ociperlimab Option, Collaboration and License Agreement and China Broad Market Development Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Collaborative and Licensing Arrangements - Amgen (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails</Role>
      <ShortName>Collaborative and Licensing Arrangements - Amgen (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.beigene.com/role/CollaborativeandLicensingArrangementsTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - Collaborative and Licensing Arrangements - Funding Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/CollaborativeandLicensingArrangementsFundingExpensesDetails</Role>
      <ShortName>Collaborative and Licensing Arrangements - Funding Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Collaborative and Licensing Arrangements - Financing Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/CollaborativeandLicensingArrangementsFinancingLiabilityDetails</Role>
      <ShortName>Collaborative and Licensing Arrangements - Financing Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Collaborative and Licensing Arrangements - Amounts and Classification of Payments (Income/(Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmountsandClassificationofPaymentsIncomeExpenseDetails</Role>
      <ShortName>Collaborative and Licensing Arrangements - Amounts and Classification of Payments (Income/(Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Collaborative and Licensing Arrangements - Payment Classification (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/CollaborativeandLicensingArrangementsPaymentClassificationDetails</Role>
      <ShortName>Collaborative and Licensing Arrangements - Payment Classification (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - Restricted Cash and Investments - Restrictions on Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/RestrictedCashandInvestmentsRestrictionsonCashandCashEquivalentsDetails</Role>
      <ShortName>Restricted Cash and Investments - Restrictions on Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - Restricted Cash - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/RestrictedCashNarrativeDetails</Role>
      <ShortName>Restricted Cash - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - Investments - Investments In Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails</Role>
      <ShortName>Investments - Investments In Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - Investments - Equity Method Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/InvestmentsEquityMethodInvestmentsDetails</Role>
      <ShortName>Investments - Equity Method Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - Inventories, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/InventoriesNetDetails</Role>
      <ShortName>Inventories, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.beigene.com/role/InventoriesNetTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9955553 - Disclosure - Leases - Narratives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/LeasesNarrativesDetails</Role>
      <ShortName>Leases - Narratives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9955554 - Disclosure - Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/LeasesComponentsofLeaseExpenseDetails</Role>
      <ShortName>Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9955555 - Disclosure - Leases - Supplemental Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/LeasesSupplementalBalanceSheetDetails</Role>
      <ShortName>Leases - Supplemental Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9955556 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturities of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9955557 - Disclosure - Leases - Other Supplemental Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/LeasesOtherSupplementalInformationDetails</Role>
      <ShortName>Leases - Other Supplemental Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9955558 - Disclosure - Property, Plant and Equipment, Net- Property, Plant and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/PropertyPlantandEquipmentNetPropertyPlantandEquipmentNetDetails</Role>
      <ShortName>Property, Plant and Equipment, Net- Property, Plant and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9955559 - Disclosure - Property, Plant and Equipment, Net - Narratives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/PropertyPlantandEquipmentNetNarrativesDetails</Role>
      <ShortName>Property, Plant and Equipment, Net - Narratives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9955560 - Disclosure - Property, Plant and Equipment, Net - Construction in Progress (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/PropertyPlantandEquipmentNetConstructioninProgressDetails</Role>
      <ShortName>Property, Plant and Equipment, Net - Construction in Progress (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9955561 - Disclosure - Intangible Assets - Intangible Assets Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/IntangibleAssetsIntangibleAssetsOutstandingDetails</Role>
      <ShortName>Intangible Assets - Intangible Assets Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9955562 - Disclosure - Intangible Assets - Useful Life (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/IntangibleAssetsUsefulLifeDetails</Role>
      <ShortName>Intangible Assets - Useful Life (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9955563 - Disclosure - Intangible Assets - Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/IntangibleAssetsAmortizationExpenseDetails</Role>
      <ShortName>Intangible Assets - Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>9955564 - Disclosure - Intangible Assets - Expected Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/IntangibleAssetsExpectedAmortizationExpenseDetails</Role>
      <ShortName>Intangible Assets - Expected Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>9955565 - Disclosure - Income Taxes - Income/(Loss) Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Income/(Loss) Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>9955566 - Disclosure - Income Taxes - Current and Deferred Components Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/IncomeTaxesCurrentandDeferredComponentsIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Current and Deferred Components Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>9955567 - Disclosure - Income Taxes - Reconciliation of the Statutory Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/IncomeTaxesReconciliationoftheStatutoryRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of the Statutory Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>9955568 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets (Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Significant Components of Deferred Tax Assets (Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>9955569 - Disclosure - Income taxes - Schedule of Valuation Allowances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/IncometaxesScheduleofValuationAllowancesDetails</Role>
      <ShortName>Income taxes - Schedule of Valuation Allowances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>9955570 - Disclosure - Income Taxes - Narratives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/IncomeTaxesNarrativesDetails</Role>
      <ShortName>Income Taxes - Narratives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>9955571 - Disclosure - Income Taxes - Gross Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Gross Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>9955572 - Disclosure - Supplemental Balance Sheet Information - Schedule of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails</Role>
      <ShortName>Supplemental Balance Sheet Information - Schedule of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>9955573 - Disclosure - Supplemental Balance Sheet Information - Schedule of Other Non-current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails</Role>
      <ShortName>Supplemental Balance Sheet Information - Schedule of Other Non-current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>9955574 - Disclosure - Supplemental Balance Sheet Information - Schedule of Accrued Expenses and Other Payables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofAccruedExpensesandOtherPayablesDetails</Role>
      <ShortName>Supplemental Balance Sheet Information - Schedule of Accrued Expenses and Other Payables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>9955575 - Disclosure - Supplemental Balance Sheet Information - Schedule of Other Long-term Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherLongtermLiabilitiesDetails</Role>
      <ShortName>Supplemental Balance Sheet Information - Schedule of Other Long-term Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>9955576 - Disclosure - Debt - Short-term and Long-term Debt Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails</Role>
      <ShortName>Debt - Short-term and Long-term Debt Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>9955577 - Disclosure - Debt - Contractual maturities of debt obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/DebtContractualmaturitiesofdebtobligationsDetails</Role>
      <ShortName>Debt - Contractual maturities of debt obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>9955578 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>9955579 - Disclosure - Product Revenue - Product Sales (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/ProductRevenueProductSalesDetails</Role>
      <ShortName>Product Revenue - Product Sales (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>9955580 - Disclosure - Product Revenue - Accrued Sales Rebates and Returns (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/ProductRevenueAccruedSalesRebatesandReturnsDetails</Role>
      <ShortName>Product Revenue - Accrued Sales Rebates and Returns (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>9955581 - Disclosure - Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/LossPerShareDetails</Role>
      <ShortName>Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.beigene.com/role/LossPerShareTables</ParentRole>
      <Position>105</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>9955582 - Disclosure - Share-Based Compensation - 2016 Share Option and Incentive Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/ShareBasedCompensation2016ShareOptionandIncentivePlanDetails</Role>
      <ShortName>Share-Based Compensation - 2016 Share Option and Incentive Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>9955583 - Disclosure - Share-Based Compensation - 2018 Inducement Equity Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/ShareBasedCompensation2018InducementEquityPlanDetails</Role>
      <ShortName>Share-Based Compensation - 2018 Inducement Equity Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>9955584 - Disclosure - Share-Based Compensation - 2018 Employee Share Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/ShareBasedCompensation2018EmployeeSharePurchasePlanDetails</Role>
      <ShortName>Share-Based Compensation - 2018 Employee Share Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>9955585 - Disclosure - Share-Based Compensation - Shares Issued Under Employee Share Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/ShareBasedCompensationSharesIssuedUnderEmployeeSharePurchasePlanDetails</Role>
      <ShortName>Share-Based Compensation - Shares Issued Under Employee Share Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>9955586 - Disclosure - Share-Based Compensation - Options and Restricted Shares and Restricted Stock Units Vesting Periods (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/ShareBasedCompensationOptionsandRestrictedSharesandRestrictedStockUnitsVestingPeriodsDetails</Role>
      <ShortName>Share-Based Compensation - Options and Restricted Shares and Restricted Stock Units Vesting Periods (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>9955587 - Disclosure - Share-Based Compensation - Share Option Rollforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails</Role>
      <ShortName>Share-Based Compensation - Share Option Rollforward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>111</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>9955588 - Disclosure - Share-Based Compensation - Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/ShareBasedCompensationFairValueAssumptionsDetails</Role>
      <ShortName>Share-Based Compensation - Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>112</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>9955589 - Disclosure - Share-Based Compensation - Restricted Share Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/ShareBasedCompensationRestrictedShareUnitsDetails</Role>
      <ShortName>Share-Based Compensation - Restricted Share Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>113</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>9955590 - Disclosure - Share-Based Compensation - Share-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/ShareBasedCompensationSharebasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation - Share-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>114</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>9955591 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncomeDetails</Role>
      <ShortName>Accumulated Other Comprehensive (Loss) Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncomeTables</ParentRole>
      <Position>115</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>9955592 - Disclosure - Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/ShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.beigene.com/role/ShareholdersEquity</ParentRole>
      <Position>116</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>9955593 - Disclosure - Restricted Net Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/RestrictedNetAssetsDetails</Role>
      <ShortName>Restricted Net Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.beigene.com/role/RestrictedNetAssets</ParentRole>
      <Position>117</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R118.htm</HtmlFileName>
      <LongName>9955594 - Disclosure - Employee Benefit Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/EmployeeBenefitPlansAdditionalInformationDetails</Role>
      <ShortName>Employee Benefit Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>118</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R119.htm</HtmlFileName>
      <LongName>9955595 - Disclosure - Employee Benefit Plans - Total Expected Benefit Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/EmployeeBenefitPlansTotalExpectedBenefitPaymentsDetails</Role>
      <ShortName>Employee Benefit Plans - Total Expected Benefit Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>119</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R120.htm</HtmlFileName>
      <LongName>9955596 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.beigene.com/role/CommitmentsandContingencies</ParentRole>
      <Position>120</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R121.htm</HtmlFileName>
      <LongName>9955597 - Disclosure - Segment and Geographic Information - Narratives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/SegmentandGeographicInformationNarrativesDetails</Role>
      <ShortName>Segment and Geographic Information - Narratives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>121</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R122.htm</HtmlFileName>
      <LongName>9955598 - Disclosure - Segment and Geographic Information - Schedule of Revenue by Geographic Area (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/SegmentandGeographicInformationScheduleofRevenuebyGeographicAreaDetails</Role>
      <ShortName>Segment and Geographic Information - Schedule of Revenue by Geographic Area (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>122</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R123.htm</HtmlFileName>
      <LongName>9955599 - Disclosure - Schedule I - Condensed Financial Information of Registrant (Condensed Statements of Operations) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails</Role>
      <ShortName>Schedule I - Condensed Financial Information of Registrant (Condensed Statements of Operations) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrant</ParentRole>
      <Position>123</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R124.htm</HtmlFileName>
      <LongName>9955600 - Disclosure - Schedule I - Condensed Financial Information of Registrant (Condensed Statements of Comprehensive Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveLossDetails</Role>
      <ShortName>Schedule I - Condensed Financial Information of Registrant (Condensed Statements of Comprehensive Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrant</ParentRole>
      <Position>124</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R125.htm</HtmlFileName>
      <LongName>9955601 - Disclosure - Schedule I - Condensed Financial Information of Registrant (Condensed Balance Sheets) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails</Role>
      <ShortName>Schedule I - Condensed Financial Information of Registrant (Condensed Balance Sheets) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrant</ParentRole>
      <Position>125</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R126.htm</HtmlFileName>
      <LongName>9955602 - Disclosure - Schedule I - Condensed Financial Information of Registrant (Condensed Statements of Cash Flows) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails</Role>
      <ShortName>Schedule I - Condensed Financial Information of Registrant (Condensed Statements of Cash Flows) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrant</ParentRole>
      <Position>126</Position>
    </Report>
    <Report instance="bgne-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R127.htm</HtmlFileName>
      <LongName>9955603 - Disclosure - Schedule I - Condensed Financial Information (Notes to Condensed Financial Statements) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.beigene.com/role/ScheduleICondensedFinancialInformationNotestoCondensedFinancialStatementsDetails</Role>
      <ShortName>Schedule I - Condensed Financial Information (Notes to Condensed Financial Statements) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrant</ParentRole>
      <Position>127</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="bgne-20241231.htm">bgne-20241231.htm</File>
    <File>bgne-20241231.xsd</File>
    <File>bgne-20241231_cal.xml</File>
    <File>bgne-20241231_def.xml</File>
    <File>bgne-20241231_lab.xml</File>
    <File>bgne-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>bgne-20241231_g1.jpg</File>
    <File>bgne-20241231_g2.jpg</File>
    <File>bgne-20241231_g3.jpg</File>
    <File>bgne-20241231_g4.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="5">http://fasb.org/srt/2024</BaseTaxonomy>
    <BaseTaxonomy items="1448">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>155
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "bgne-20241231.htm": {
   "nsprefix": "bgne",
   "nsuri": "http://www.beigene.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "bgne-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "bgne-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "bgne-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bgne-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "bgne-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bgne-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 434,
   "keyCustom": 88,
   "axisStandard": 38,
   "axisCustom": 2,
   "memberStandard": 56,
   "memberCustom": 76,
   "hidden": {
    "total": 12,
    "http://xbrl.sec.gov/dei/2024": 4,
    "http://fasb.org/us-gaap/2024": 7,
    "http://www.beigene.com/20241231": 1
   },
   "contextCount": 447,
   "entityCount": 1,
   "segmentCount": 139,
   "elementCount": 976,
   "unitCount": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 1448,
    "http://xbrl.sec.gov/dei/2024": 40,
    "http://xbrl.sec.gov/cyd/2024": 15,
    "http://fasb.org/srt/2024": 5,
    "http://xbrl.sec.gov/ecd/2024": 5
   },
   "report": {
    "R1": {
     "role": "http://www.beigene.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.beigene.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "longName": "9952151 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GrossProfit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "longName": "9952152 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R5": {
     "role": "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS",
     "longName": "9952153 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:AssetsNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "longName": "9952154 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "9952155 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
     "longName": "9952156 - Statement - CONSOLIDATED STATEMENTS OF SHAREHOLDERS\u2019 EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF SHAREHOLDERS\u2019 EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-16",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-16",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.beigene.com/role/DescriptionofBusiness",
     "longName": "9952157 - Disclosure - Description of Business",
     "shortName": "Description of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.beigene.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952158 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.beigene.com/role/CollaborativeandLicensingArrangements",
     "longName": "9952159 - Disclosure - Collaborative and Licensing Arrangements",
     "shortName": "Collaborative and Licensing Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.beigene.com/role/RestrictedCash",
     "longName": "9952160 - Disclosure - Restricted Cash",
     "shortName": "Restricted Cash",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.beigene.com/role/Investments",
     "longName": "9952161 - Disclosure - Investments",
     "shortName": "Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.beigene.com/role/InventoriesNet",
     "longName": "9952162 - Disclosure - Inventories, Net",
     "shortName": "Inventories, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.beigene.com/role/Leases",
     "longName": "9952163 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.beigene.com/role/PropertyPlantandEquipmentNet",
     "longName": "9952164 - Disclosure - Property, Plant and Equipment, Net",
     "shortName": "Property, Plant and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.beigene.com/role/IntangibleAssets",
     "longName": "9952165 - Disclosure - Intangible Assets",
     "shortName": "Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.beigene.com/role/IncomeTaxes",
     "longName": "9952166 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.beigene.com/role/SupplementalBalanceSheetInformation",
     "longName": "9952167 - Disclosure - Supplemental Balance Sheet Information",
     "shortName": "Supplemental Balance Sheet Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.beigene.com/role/Debt",
     "longName": "9952168 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.beigene.com/role/ProductRevenue",
     "longName": "9952169 - Disclosure - Product Revenue",
     "shortName": "Product Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.beigene.com/role/LossPerShare",
     "longName": "9952170 - Disclosure - Loss Per Share",
     "shortName": "Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.beigene.com/role/ShareBasedCompensation",
     "longName": "9952171 - Disclosure - Share-Based Compensation",
     "shortName": "Share-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncome",
     "longName": "9952172 - Disclosure - Accumulated Other Comprehensive (Loss) Income",
     "shortName": "Accumulated Other Comprehensive (Loss) Income",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.beigene.com/role/ShareholdersEquity",
     "longName": "9952173 - Disclosure - Shareholders' Equity",
     "shortName": "Shareholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.beigene.com/role/RestrictedNetAssets",
     "longName": "9952174 - Disclosure - Restricted Net Assets",
     "shortName": "Restricted Net Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestrictedAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestrictedAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.beigene.com/role/EmployeeBenefitPlans",
     "longName": "9952175 - Disclosure - Employee Benefit Plans",
     "shortName": "Employee Benefit Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.beigene.com/role/CommitmentsandContingencies",
     "longName": "9952176 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.beigene.com/role/SegmentandGeographicInformation",
     "longName": "9952177 - Disclosure - Segment and Geographic Information",
     "shortName": "Segment and Geographic Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrant",
     "longName": "9952178 - Disclosure - Schedule I - Condensed Financial Information of Registrant",
     "shortName": "Schedule I - Condensed Financial Information of Registrant",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R32": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrTrmntdFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrTrmntdFlag",
       "ecd:Rule10b51ArrTrmntdFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "a",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "a",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.beigene.com/role/CollaborativeandLicensingArrangementsTables",
     "longName": "9955513 - Disclosure - Collaborative and Licensing Arrangements (Tables)",
     "shortName": "Collaborative and Licensing Arrangements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "bgne:CollaborationAgreementsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.beigene.com/role/RestrictedCashTables",
     "longName": "9955514 - Disclosure - Restricted Cash (Tables)",
     "shortName": "Restricted Cash (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.beigene.com/role/InvestmentsTables",
     "longName": "9955515 - Disclosure - Investments (Tables)",
     "shortName": "Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.beigene.com/role/InventoriesNetTables",
     "longName": "9955516 - Disclosure - Inventories, Net (Tables)",
     "shortName": "Inventories, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.beigene.com/role/LeasesTables",
     "longName": "9955517 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "bgne:AssetsAndLiabilitiesLesseeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.beigene.com/role/PropertyPlantandEquipmentNetTables",
     "longName": "9955518 - Disclosure - Property, Plant and Equipment, Net (Tables)",
     "shortName": "Property, Plant and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R43": {
     "role": "http://www.beigene.com/role/IntangibleAssetsTables",
     "longName": "9955519 - Disclosure - Intangible Assets (Tables)",
     "shortName": "Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.beigene.com/role/IncomeTaxesTables",
     "longName": "9955520 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.beigene.com/role/SupplementalBalanceSheetInformationTables",
     "longName": "9955521 - Disclosure - Supplemental Balance Sheet Information (Tables)",
     "shortName": "Supplemental Balance Sheet Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "bgne:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "bgne:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.beigene.com/role/DebtTables",
     "longName": "9955522 - Disclosure - Debt (Tables)",
     "shortName": "Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.beigene.com/role/ProductRevenueTables",
     "longName": "9955523 - Disclosure - Product Revenue (Tables)",
     "shortName": "Product Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "bgne:ScheduleOfAccruedSalesRebatesAndReturnsCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.beigene.com/role/LossPerShareTables",
     "longName": "9955524 - Disclosure - Loss Per Share (Tables)",
     "shortName": "Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.beigene.com/role/ShareBasedCompensationTables",
     "longName": "9955525 - Disclosure - Share-Based Compensation (Tables)",
     "shortName": "Share-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncomeTables",
     "longName": "9955526 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Tables)",
     "shortName": "Accumulated Other Comprehensive (Loss) Income (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.beigene.com/role/EmployeeBenefitPlansTables",
     "longName": "9955527 - Disclosure - Employee Benefit Plans (Tables)",
     "shortName": "Employee Benefit Plans (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.beigene.com/role/SegmentandGeographicInformationTables",
     "longName": "9955528 - Disclosure - Segment and Geographic Information (Tables)",
     "shortName": "Segment and Geographic Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.beigene.com/role/SECScheduleArticle1204CondensedFinancialInformationofRegistrantTables",
     "longName": "9955529 - Disclosure - SEC Schedule, Article 12-04, Condensed Financial Information of Registrant (Tables)",
     "shortName": "SEC Schedule, Article 12-04, Condensed Financial Information of Registrant (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "srt:ScheduleOfCondensedIncomeStatementTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "srt:ScheduleOfCondensedIncomeStatementTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.beigene.com/role/DescriptionofBusinessDetails",
     "longName": "9955530 - Disclosure - Description of Business (Details)",
     "shortName": "Description of Business (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "bgne:RevenueFromContractWithCustomerExcludingAssessedTaxPeriodIncreaseDecrease",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails",
     "longName": "9955531 - Disclosure - Summary of Significant Accounting Policies - Investments (Details)",
     "shortName": "Summary of Significant Accounting Policies - Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails",
     "longName": "9955532 - Disclosure - Summary of Significant Accounting Policies - Property, Plant and Equipment (Details)",
     "shortName": "Summary of Significant Accounting Policies - Property, Plant and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-44",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-44",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesLandUseRightNetDetails",
     "longName": "9955533 - Disclosure - Summary of Significant Accounting Policies - Land Use Right, Net (Details)",
     "shortName": "Summary of Significant Accounting Policies - Land Use Right, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-51",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-51",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesGoodwillandOtherIntangibleAssetsDetails",
     "longName": "9955534 - Disclosure - Summary of Significant Accounting Policies - Goodwill and Other Intangible Assets (Details)",
     "shortName": "Summary of Significant Accounting Policies - Goodwill and Other Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails",
     "longName": "9955535 - Disclosure - Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Details)",
     "shortName": "Summary of Significant Accounting Policies - Impairment of Long-Lived Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "longName": "9955536 - Disclosure - Summary of Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "shortName": "Summary of Significant Accounting Policies - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-82",
      "name": "us-gaap:FairValueOptionChangesInFairValueGainLoss1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-82",
      "name": "us-gaap:FairValueOptionChangesInFairValueGainLoss1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesGovernmentGrantsDetails",
     "longName": "9955537 - Disclosure - Summary of Significant Accounting Policies -Government Grants (Details)",
     "shortName": "Summary of Significant Accounting Policies -Government Grants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GovernmentAssistanceAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GovernmentAssistanceAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails",
     "longName": "9955538 - Disclosure - Summary of Significant Accounting Policies - Segment Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesConcentrationofRisksDetails",
     "longName": "9955539 - Disclosure - Summary of Significant Accounting Policies - Concentration of Risks (Details)",
     "shortName": "Summary of Significant Accounting Policies - Concentration of Risks (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-100",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.beigene.com/role/CollaborativeandLicensingArrangementsRecognizedRevenueDetails",
     "longName": "9955540 - Disclosure - Collaborative and Licensing Arrangements - Recognized Revenue (Details)",
     "shortName": "Collaborative and Licensing Arrangements - Recognized Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-121",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.beigene.com/role/CollaborativeandLicensingArrangementsNovartisDetails",
     "longName": "9955541 - Disclosure - Collaborative and Licensing Arrangements - Novartis (Details)",
     "shortName": "Collaborative and Licensing Arrangements - Novartis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-135",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R66": {
     "role": "http://www.beigene.com/role/CollaborativeandLicensingArrangementsOciperlimabOptionCollaborationandLicenseAgreementandChinaBroadMarketDevelopmentAgreementDetails",
     "longName": "9955542 - Disclosure - Collaborative and Licensing Arrangements - Ociperlimab Option, Collaboration and License Agreement and China Broad Market Development Agreement (Details)",
     "shortName": "Collaborative and Licensing Arrangements - Ociperlimab Option, Collaboration and License Agreement and China Broad Market Development Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-134",
      "name": "bgne:NumberOfProductsInitiatedMarketingAndPromotion",
      "unitRef": "product",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-134",
      "name": "bgne:NumberOfProductsInitiatedMarketingAndPromotion",
      "unitRef": "product",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails",
     "longName": "9955543 - Disclosure - Collaborative and Licensing Arrangements - Amgen (Details)",
     "shortName": "Collaborative and Licensing Arrangements - Amgen (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-159",
      "name": "bgne:SharePriceAmericanDepositoryShares",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-159",
      "name": "bgne:SharePriceAmericanDepositoryShares",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.beigene.com/role/CollaborativeandLicensingArrangementsFundingExpensesDetails",
     "longName": "9955544 - Disclosure - Collaborative and Licensing Arrangements - Funding Expenses (Details)",
     "shortName": "Collaborative and Licensing Arrangements - Funding Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-161",
      "name": "bgne:FinancingCommitmentExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bgne:CollaborationAgreementsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.beigene.com/role/CollaborativeandLicensingArrangementsFinancingLiabilityDetails",
     "longName": "9955545 - Disclosure - Collaborative and Licensing Arrangements - Financing Liability (Details)",
     "shortName": "Collaborative and Licensing Arrangements - Financing Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-164",
      "name": "bgne:FinancingCommitmentCarryingValueCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bgne:CollaborationAgreementsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-164",
      "name": "bgne:FinancingCommitmentCarryingValueCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bgne:CollaborationAgreementsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmountsandClassificationofPaymentsIncomeExpenseDetails",
     "longName": "9955546 - Disclosure - Collaborative and Licensing Arrangements - Amounts and Classification of Payments (Income/(Expense) (Details)",
     "shortName": "Collaborative and Licensing Arrangements - Amounts and Classification of Payments (Income/(Expense) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "bgne:ReimbursementExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bgne:ScheduleOfAmountsAndClassificationOfReimbursementExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "bgne:ReimbursementExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bgne:ScheduleOfAmountsAndClassificationOfReimbursementExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.beigene.com/role/CollaborativeandLicensingArrangementsPaymentClassificationDetails",
     "longName": "9955547 - Disclosure - Collaborative and Licensing Arrangements - Payment Classification (Details)",
     "shortName": "Collaborative and Licensing Arrangements - Payment Classification (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "bgne:UpfrontAndMilestonePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "bgne:UpfrontAndMilestonePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.beigene.com/role/RestrictedCashandInvestmentsRestrictionsonCashandCashEquivalentsDetails",
     "longName": "9955548 - Disclosure - Restricted Cash and Investments - Restrictions on Cash and Cash Equivalents (Details)",
     "shortName": "Restricted Cash and Investments - Restrictions on Cash and Cash Equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:RestrictedCashCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:RestrictedCashCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.beigene.com/role/RestrictedCashNarrativeDetails",
     "longName": "9955549 - Disclosure - Restricted Cash - Narrative (Details)",
     "shortName": "Restricted Cash - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:RestrictedCash",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-189",
      "name": "us-gaap:RestrictedCash",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails",
     "longName": "9955550 - Disclosure - Investments - Investments In Equity Securities (Details)",
     "shortName": "Investments - Investments In Equity Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:EquityMethodInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:EquityMethodInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.beigene.com/role/InvestmentsEquityMethodInvestmentsDetails",
     "longName": "9955551 - Disclosure - Investments - Equity Method Investments (Details)",
     "shortName": "Investments - Equity Method Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-201",
      "name": "us-gaap:EquitySecuritiesFvNiGainLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-201",
      "name": "us-gaap:EquitySecuritiesFvNiGainLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.beigene.com/role/InventoriesNetDetails",
     "longName": "9955552 - Disclosure - Inventories, Net (Details)",
     "shortName": "Inventories, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.beigene.com/role/LeasesNarrativesDetails",
     "longName": "9955553 - Disclosure - Leases - Narratives (Details)",
     "shortName": "Leases - Narratives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-44",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-44",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.beigene.com/role/LeasesComponentsofLeaseExpenseDetails",
     "longName": "9955554 - Disclosure - Leases - Components of Lease Expense (Details)",
     "shortName": "Leases - Components of Lease Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.beigene.com/role/LeasesSupplementalBalanceSheetDetails",
     "longName": "9955555 - Disclosure - Leases - Supplemental Balance Sheet (Details)",
     "shortName": "Leases - Supplemental Balance Sheet (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bgne:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-44",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bgne:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.beigene.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails",
     "longName": "9955556 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)",
     "shortName": "Leases - Maturities of Operating Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.beigene.com/role/LeasesOtherSupplementalInformationDetails",
     "longName": "9955557 - Disclosure - Leases - Other Supplemental Information (Details)",
     "shortName": "Leases - Other Supplemental Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.beigene.com/role/PropertyPlantandEquipmentNetPropertyPlantandEquipmentNetDetails",
     "longName": "9955558 - Disclosure - Property, Plant and Equipment, Net- Property, Plant and Equipment, Net (Details)",
     "shortName": "Property, Plant and Equipment, Net- Property, Plant and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.beigene.com/role/PropertyPlantandEquipmentNetNarrativesDetails",
     "longName": "9955559 - Disclosure - Property, Plant and Equipment, Net - Narratives (Details)",
     "shortName": "Property, Plant and Equipment, Net - Narratives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.beigene.com/role/PropertyPlantandEquipmentNetConstructioninProgressDetails",
     "longName": "9955560 - Disclosure - Property, Plant and Equipment, Net - Construction in Progress (Details)",
     "shortName": "Property, Plant and Equipment, Net - Construction in Progress (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:ConstructionInProgressGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-221",
      "name": "us-gaap:ConstructionInProgressGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.beigene.com/role/IntangibleAssetsIntangibleAssetsOutstandingDetails",
     "longName": "9955561 - Disclosure - Intangible Assets - Intangible Assets Outstanding (Details)",
     "shortName": "Intangible Assets - Intangible Assets Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.beigene.com/role/IntangibleAssetsUsefulLifeDetails",
     "longName": "9955562 - Disclosure - Intangible Assets - Useful Life (Details)",
     "shortName": "Intangible Assets - Useful Life (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-227",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-227",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.beigene.com/role/IntangibleAssetsAmortizationExpenseDetails",
     "longName": "9955563 - Disclosure - Intangible Assets - Amortization Expense (Details)",
     "shortName": "Intangible Assets - Amortization Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.beigene.com/role/IntangibleAssetsExpectedAmortizationExpenseDetails",
     "longName": "9955564 - Disclosure - Intangible Assets - Expected Amortization Expense (Details)",
     "shortName": "Intangible Assets - Expected Amortization Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.beigene.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails",
     "longName": "9955565 - Disclosure - Income Taxes - Income/(Loss) Before Income Taxes (Details)",
     "shortName": "Income Taxes - Income/(Loss) Before Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-231",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.beigene.com/role/IncomeTaxesCurrentandDeferredComponentsIncomeTaxesDetails",
     "longName": "9955566 - Disclosure - Income Taxes - Current and Deferred Components Income Taxes (Details)",
     "shortName": "Income Taxes - Current and Deferred Components Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.beigene.com/role/IncomeTaxesReconciliationoftheStatutoryRateDetails",
     "longName": "9955567 - Disclosure - Income Taxes - Reconciliation of the Statutory Rate (Details)",
     "shortName": "Income Taxes - Reconciliation of the Statutory Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails",
     "longName": "9955568 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets (Liabilities) (Details)",
     "shortName": "Income Taxes - Significant Components of Deferred Tax Assets (Liabilities) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R93": {
     "role": "http://www.beigene.com/role/IncometaxesScheduleofValuationAllowancesDetails",
     "longName": "9955569 - Disclosure - Income taxes - Schedule of Valuation Allowances (Details)",
     "shortName": "Income taxes - Schedule of Valuation Allowances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "bgne:DeferredTaxAssetValuationAllowanceChangesIncludedInEarnings",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "unique": true
     }
    },
    "R94": {
     "role": "http://www.beigene.com/role/IncomeTaxesNarrativesDetails",
     "longName": "9955570 - Disclosure - Income Taxes - Narratives (Details)",
     "shortName": "Income Taxes - Narratives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R95": {
     "role": "http://www.beigene.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails",
     "longName": "9955571 - Disclosure - Income Taxes - Gross Unrecognized Tax Benefits (Details)",
     "shortName": "Income Taxes - Gross Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "unique": true
     }
    },
    "R96": {
     "role": "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails",
     "longName": "9955572 - Disclosure - Supplemental Balance Sheet Information - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "shortName": "Supplemental Balance Sheet Information - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "bgne:PrepaidResearchAndDevelopmentCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bgne:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "bgne:PrepaidResearchAndDevelopmentCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bgne:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R97": {
     "role": "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails",
     "longName": "9955573 - Disclosure - Supplemental Balance Sheet Information - Schedule of Other Non-current Assets (Details)",
     "shortName": "Supplemental Balance Sheet Information - Schedule of Other Non-current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:LongTermInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:LongTermInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R98": {
     "role": "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofAccruedExpensesandOtherPayablesDetails",
     "longName": "9955574 - Disclosure - Supplemental Balance Sheet Information - Schedule of Accrued Expenses and Other Payables (Details)",
     "shortName": "Supplemental Balance Sheet Information - Schedule of Accrued Expenses and Other Payables (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bgne:AccruedLiabilitiesAccountsPayableOtherAndOtherLiabilitiesCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bgne:AccruedLiabilitiesAccountsPayableOtherAndOtherLiabilitiesCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R99": {
     "role": "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherLongtermLiabilitiesDetails",
     "longName": "9955575 - Disclosure - Supplemental Balance Sheet Information - Schedule of Other Long-term Liabilities (Details)",
     "shortName": "Supplemental Balance Sheet Information - Schedule of Other Long-term Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:GovernmentAssistanceLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:GovernmentAssistanceLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R100": {
     "role": "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails",
     "longName": "9955576 - Disclosure - Debt - Short-term and Long-term Debt Obligations (Details)",
     "shortName": "Debt - Short-term and Long-term Debt Obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:LongTermDebtCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:LongTermDebtNoncurrent",
      "unitRef": "cny",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "unique": true
     }
    },
    "R101": {
     "role": "http://www.beigene.com/role/DebtContractualmaturitiesofdebtobligationsDetails",
     "longName": "9955577 - Disclosure - Debt - Contractual maturities of debt obligations (Details)",
     "shortName": "Debt - Contractual maturities of debt obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:ContractualObligationDueInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:ContractualObligationDueInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R102": {
     "role": "http://www.beigene.com/role/DebtNarrativeDetails",
     "longName": "9955578 - Disclosure - Debt - Narrative (Details)",
     "shortName": "Debt - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InterestExpenseDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InterestExpenseDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R103": {
     "role": "http://www.beigene.com/role/ProductRevenueProductSalesDetails",
     "longName": "9955579 - Disclosure - Product Revenue - Product Sales (Details)",
     "shortName": "Product Revenue - Product Sales (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "103",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "bgne:RevenueFromContractWithCustomerExcludingAssessedTaxBeforeReductions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "unique": true
     }
    },
    "R104": {
     "role": "http://www.beigene.com/role/ProductRevenueAccruedSalesRebatesandReturnsDetails",
     "longName": "9955580 - Disclosure - Product Revenue - Accrued Sales Rebates and Returns (Details)",
     "shortName": "Product Revenue - Accrued Sales Rebates and Returns (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "104",
     "firstAnchor": {
      "contextRef": "c-331",
      "name": "bgne:RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bgne:ScheduleOfAccruedSalesRebatesAndReturnsCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "bgne:RevenueRecognitionRevenueReductionsPaymentsAndCredits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "bgne:ScheduleOfAccruedSalesRebatesAndReturnsCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "unique": true
     }
    },
    "R105": {
     "role": "http://www.beigene.com/role/LossPerShareDetails",
     "longName": "9955581 - Disclosure - Loss Per Share (Details)",
     "shortName": "Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "105",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R106": {
     "role": "http://www.beigene.com/role/ShareBasedCompensation2016ShareOptionandIncentivePlanDetails",
     "longName": "9955582 - Disclosure - Share-Based Compensation - 2016 Share Option and Incentive Plan (Details)",
     "shortName": "Share-Based Compensation - 2016 Share Option and Incentive Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "106",
     "firstAnchor": {
      "contextRef": "c-332",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-332",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R107": {
     "role": "http://www.beigene.com/role/ShareBasedCompensation2018InducementEquityPlanDetails",
     "longName": "9955583 - Disclosure - Share-Based Compensation - 2018 Inducement Equity Plan (Details)",
     "shortName": "Share-Based Compensation - 2018 Inducement Equity Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "107",
     "firstAnchor": {
      "contextRef": "c-341",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-341",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R108": {
     "role": "http://www.beigene.com/role/ShareBasedCompensation2018EmployeeSharePurchasePlanDetails",
     "longName": "9955584 - Disclosure - Share-Based Compensation - 2018 Employee Share Purchase Plan (Details)",
     "shortName": "Share-Based Compensation - 2018 Employee Share Purchase Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "108",
     "firstAnchor": {
      "contextRef": "c-346",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-346",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R109": {
     "role": "http://www.beigene.com/role/ShareBasedCompensationSharesIssuedUnderEmployeeSharePurchasePlanDetails",
     "longName": "9955585 - Disclosure - Share-Based Compensation - Shares Issued Under Employee Share Purchase Plan (Details)",
     "shortName": "Share-Based Compensation - Shares Issued Under Employee Share Purchase Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "109",
     "firstAnchor": {
      "contextRef": "c-348",
      "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-348",
      "name": "us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R110": {
     "role": "http://www.beigene.com/role/ShareBasedCompensationOptionsandRestrictedSharesandRestrictedStockUnitsVestingPeriodsDetails",
     "longName": "9955586 - Disclosure - Share-Based Compensation - Options and Restricted Shares and Restricted Stock Units Vesting Periods (Details)",
     "shortName": "Share-Based Compensation - Options and Restricted Shares and Restricted Stock Units Vesting Periods (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "110",
     "firstAnchor": {
      "contextRef": "c-361",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-363",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "unique": true
     }
    },
    "R111": {
     "role": "http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails",
     "longName": "9955587 - Disclosure - Share-Based Compensation - Share Option Rollforward (Details)",
     "shortName": "Share-Based Compensation - Share Option Rollforward (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "111",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "unique": true
     }
    },
    "R112": {
     "role": "http://www.beigene.com/role/ShareBasedCompensationFairValueAssumptionsDetails",
     "longName": "9955588 - Disclosure - Share-Based Compensation - Fair Value Assumptions (Details)",
     "shortName": "Share-Based Compensation - Fair Value Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "112",
     "firstAnchor": {
      "contextRef": "c-10",
      "name": "bgne:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "1",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-10",
      "name": "bgne:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "1",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R113": {
     "role": "http://www.beigene.com/role/ShareBasedCompensationRestrictedShareUnitsDetails",
     "longName": "9955589 - Disclosure - Share-Based Compensation - Restricted Share Units (Details)",
     "shortName": "Share-Based Compensation - Restricted Share Units (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "113",
     "firstAnchor": {
      "contextRef": "c-379",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-375",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "unique": true
     }
    },
    "R114": {
     "role": "http://www.beigene.com/role/ShareBasedCompensationSharebasedCompensationExpenseDetails",
     "longName": "9955590 - Disclosure - Share-Based Compensation - Share-based Compensation Expense (Details)",
     "shortName": "Share-Based Compensation - Share-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "114",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R115": {
     "role": "http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncomeDetails",
     "longName": "9955591 - Disclosure - Accumulated Other Comprehensive (Loss) Income (Details)",
     "shortName": "Accumulated Other Comprehensive (Loss) Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "115",
     "firstAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "unique": true
     }
    },
    "R116": {
     "role": "http://www.beigene.com/role/ShareholdersEquityDetails",
     "longName": "9955592 - Disclosure - Shareholders' Equity (Details)",
     "shortName": "Shareholders' Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "116",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockRepurchasedAndRetiredDuringPeriodValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-396",
      "name": "us-gaap:StockRepurchasedAndRetiredDuringPeriodShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "unique": true
     }
    },
    "R117": {
     "role": "http://www.beigene.com/role/RestrictedNetAssetsDetails",
     "longName": "9955593 - Disclosure - Restricted Net Assets (Details)",
     "shortName": "Restricted Net Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "117",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "bgne:RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "bgne:RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R118": {
     "role": "http://www.beigene.com/role/EmployeeBenefitPlansAdditionalInformationDetails",
     "longName": "9955594 - Disclosure - Employee Benefit Plans - Additional Information (Details)",
     "shortName": "Employee Benefit Plans - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "118",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:DefinedBenefitPlanBenefitObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:DefinedBenefitPlanBenefitObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R119": {
     "role": "http://www.beigene.com/role/EmployeeBenefitPlansTotalExpectedBenefitPaymentsDetails",
     "longName": "9955595 - Disclosure - Employee Benefit Plans - Total Expected Benefit Payments (Details)",
     "shortName": "Employee Benefit Plans - Total Expected Benefit Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "119",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R120": {
     "role": "http://www.beigene.com/role/CommitmentsandContingenciesDetails",
     "longName": "9955596 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "120",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R121": {
     "role": "http://www.beigene.com/role/SegmentandGeographicInformationNarrativesDetails",
     "longName": "9955597 - Disclosure - Segment and Geographic Information - Narratives (Details)",
     "shortName": "Segment and Geographic Information - Narratives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "121",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R122": {
     "role": "http://www.beigene.com/role/SegmentandGeographicInformationScheduleofRevenuebyGeographicAreaDetails",
     "longName": "9955598 - Disclosure - Segment and Geographic Information - Schedule of Revenue by Geographic Area (Details)",
     "shortName": "Segment and Geographic Information - Schedule of Revenue by Geographic Area (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "122",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-231",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "unique": true
     }
    },
    "R123": {
     "role": "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails",
     "longName": "9955599 - Disclosure - Schedule I - Condensed Financial Information of Registrant (Condensed Statements of Operations) (Details)",
     "shortName": "Schedule I - Condensed Financial Information of Registrant (Condensed Statements of Operations) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "123",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-440",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfCondensedIncomeStatementTableTextBlock",
       "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "unique": true
     }
    },
    "R124": {
     "role": "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveLossDetails",
     "longName": "9955600 - Disclosure - Schedule I - Condensed Financial Information of Registrant (Condensed Statements of Comprehensive Loss) (Details)",
     "shortName": "Schedule I - Condensed Financial Information of Registrant (Condensed Statements of Comprehensive Loss) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "124",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-440",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "srt:CondensedStatementOfComprehensiveIncomeTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "unique": true
     }
    },
    "R125": {
     "role": "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
     "longName": "9955601 - Disclosure - Schedule I - Condensed Financial Information of Registrant (Condensed Balance Sheets) (Details)",
     "shortName": "Schedule I - Condensed Financial Information of Registrant (Condensed Balance Sheets) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "125",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-443",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "unique": true
     }
    },
    "R126": {
     "role": "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails",
     "longName": "9955602 - Disclosure - Schedule I - Condensed Financial Information of Registrant (Condensed Statements of Cash Flows) (Details)",
     "shortName": "Schedule I - Condensed Financial Information of Registrant (Condensed Statements of Cash Flows) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "126",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-440",
      "name": "bgne:AcquiredInProcessResearchAndDevelopment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "srt:ScheduleOfCondensedCashFlowStatementTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "unique": true
     }
    },
    "R127": {
     "role": "http://www.beigene.com/role/ScheduleICondensedFinancialInformationNotestoCondensedFinancialStatementsDetails",
     "longName": "9955603 - Disclosure - Schedule I - Condensed Financial Information (Notes to Condensed Financial Statements) (Details)",
     "shortName": "Schedule I - Condensed Financial Information (Notes to Condensed Financial Statements) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "127",
     "firstAnchor": {
      "contextRef": "c-412",
      "name": "us-gaap:OtherCommitment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-447",
      "name": "us-gaap:OtherCommitment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bgne-20241231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "presentation": [
      "http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Movement in accumulated other comprehensive loss",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "bgne_ASDSpecialtyHealthcareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ASDSpecialtyHealthcareMember",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesConcentrationofRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASD Specialty Healthcare",
        "label": "ASD Specialty Healthcare [Member]",
        "documentation": "ASD Specialty Healthcare"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Accounts and Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofAccruedExpensesandOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other payables",
        "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmountsandClassificationofPaymentsIncomeExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r1132"
     ]
    },
    "bgne_AccountsReceivableAllowanceForChargebacksAndCreditLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "AccountsReceivableAllowanceForChargebacksAndCreditLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/ProductRevenueAccruedSalesRebatesandReturnsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Accounts Receivable, Allowance For Chargebacks And Credit Loss",
        "documentation": "Accounts Receivable, Allowance For Chargebacks And Credit Loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesConcentrationofRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesConcentrationofRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1344"
     ]
    },
    "bgne_AccruedExpensesCommercialActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "AccruedExpensesCommercialActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofAccruedExpensesandOtherPayablesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofAccruedExpensesandOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial activities",
        "label": "Accrued Expenses, Commercial Activities",
        "documentation": "Accrued Expenses, Commercial Activities"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_AccruedGeneralAndAdministrativeExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "AccruedGeneralAndAdministrativeExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofAccruedExpensesandOtherPayablesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofAccruedExpensesandOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued general and administrative expenses",
        "label": "Accrued General And Administrative Expenses, Current",
        "documentation": "Accrued General And Administrative Expenses, Current"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_AccruedLiabilitiesAccountsPayableOtherAndOtherLiabilitiesCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "AccruedLiabilitiesAccountsPayableOtherAndOtherLiabilitiesCurrentTableTextBlock",
     "presentation": [
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Accrued Expenses and Other Payables",
        "label": "Accrued Liabilities, Accounts Payable, Other, and Other Liabilities, Current [Table Text Block]",
        "documentation": "Tabular disclosure of accrued liabilities, other accounts payable, and other liabilities, current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofAccruedExpensesandOtherPayablesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofAccruedExpensesandOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other payables",
        "totalLabel": "Total",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "bgne_AccruedLiabilitiesExternalResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "AccruedLiabilitiesExternalResearchAndDevelopment",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofAccruedExpensesandOtherPayablesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofAccruedExpensesandOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "External research and development activities related",
        "label": "Accrued Liabilities, External Research And Development",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date related to external research and development activities related"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedPayrollTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedPayrollTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofAccruedExpensesandOtherPayablesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofAccruedExpensesandOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual income tax and other taxes",
        "label": "Accrued Payroll Taxes, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "bgne_AccruedProfessionalFeesAndOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "AccruedProfessionalFeesAndOtherCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofAccruedExpensesandOtherPayablesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofAccruedExpensesandOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Accrued Professional Fees and Other, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received and amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "bgne_AccruedSalesRebatesAndReturnsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "AccruedSalesRebatesAndReturnsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofAccruedExpensesandOtherPayablesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofAccruedExpensesandOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales rebates and returns related",
        "label": "Accrued Sales Rebates and Returns, Current",
        "documentation": "Accrued Sales Rebates and Returns, Current"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_AccruedSalesRebatesAndReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "AccruedSalesRebatesAndReturnsRollForward",
     "presentation": [
      "http://www.beigene.com/role/ProductRevenueAccruedSalesRebatesandReturnsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued sales rebates and returns",
        "label": "Accrued Sales Rebates and Returns [Roll Forward]",
        "documentation": "Accrued Sales Rebates and Returns [Roll Forward]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "presentation": [
      "http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Liability Adjustments",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r5",
      "r12",
      "r23",
      "r96",
      "r1317",
      "r1318",
      "r1319"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetPropertyPlantandEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetPropertyPlantandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r225",
      "r853"
     ]
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "presentation": [
      "http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Gains/Losses\u00a0on Available-for-Sale Securities",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]",
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r243",
      "r251",
      "r252",
      "r1317"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r733",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r97",
      "r235",
      "r848",
      "r882",
      "r883"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r733",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncomeDetails",
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income/(Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r12",
      "r23",
      "r704",
      "r707",
      "r762",
      "r878",
      "r879",
      "r1317",
      "r1318",
      "r1319",
      "r1332",
      "r1333",
      "r1334",
      "r1335"
     ]
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedTranslationAdjustmentMember",
     "presentation": [
      "http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign\u00a0Currency Translation Adjustments",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r12",
      "r23",
      "r94",
      "r95",
      "r251",
      "r252",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r1317"
     ]
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.beigene.com/role/IntangibleAssetsExpectedAmortizationExpenseDetails",
      "http://www.beigene.com/role/IntangibleAssetsUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired Finite-Lived Intangible Assets",
        "label": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r417",
      "r418",
      "r419",
      "r1058"
     ]
    },
    "bgne_AcquiredInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "AcquiredInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired in-process research and development",
        "label": "Acquired In Process Research And Development",
        "documentation": "Acquired In Process Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_AcquiredInProcessResearchAndDevelopmentButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "AcquiredInProcessResearchAndDevelopmentButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of in-process research and development included in accounts payable",
        "label": "Acquired In Process Research And Development But Not Yet Paid",
        "documentation": "Acquired In Process Research And Development But Not Yet Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1213"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r1132",
      "r1503"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r897",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1438",
      "r1504"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1226"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1226"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1226"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1226"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_AdjustmentsToAdditionalPaidInCapitalDeconsolidationOfSubsidiary": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalDeconsolidationOfSubsidiary",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deconsolidation of a subsidiary",
        "label": "Adjustments to Additional Paid in Capital, Deconsolidation Of Subsidiary",
        "documentation": "Adjustments to Additional Paid in Capital, Deconsolidation Of Subsidiary"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62",
      "r599"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cost from issuance of ordinary shares",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r132"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1271"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1184",
      "r1195",
      "r1205",
      "r1238"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1187",
      "r1198",
      "r1208",
      "r1241"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1272"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r1226"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r1233"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r1188",
      "r1199",
      "r1209",
      "r1233",
      "r1242",
      "r1246",
      "r1254"
     ]
    },
    "bgne_AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember",
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesCurrentandDeferredComponentsIncomeTaxesDetails",
      "http://www.beigene.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails",
      "http://www.beigene.com/role/SegmentandGeographicInformationScheduleofRevenuebyGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "verboseLabel": "Rest of world- total revenue",
        "label": "All Other Countries Except China And United States Of America [Member]",
        "documentation": "All Other Countries Except China and The United States of America [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r1252"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r631",
      "r640"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "bgne_AmgenIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "AmgenIncMember",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmountsandClassificationofPaymentsIncomeExpenseDetails",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsFinancingLiabilityDetails",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsFundingExpensesDetails",
      "http://www.beigene.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amgen, Inc",
        "label": "Amgen, Inc [Member]",
        "documentation": "Amgen, Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_AmortizationOfFinancingCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "AmortizationOfFinancingCommitment",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsFundingExpensesDetails": {
       "parentTag": "bgne_FinancingCommitmentExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsFundingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: Amortization of research and development cost share liability",
        "label": "Amortization of Financing Commitment",
        "documentation": "Amortization of Financing Commitment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/IntangibleAssetsAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r415",
      "r421",
      "r1094"
     ]
    },
    "bgne_AmortizationOfResearchAndDevelopmentFinancingLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "AmortizationOfResearchAndDevelopmentFinancingLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of research and development cost share liability",
        "label": "Amortization of Research And Development Financing Liability",
        "documentation": "Amortization of Research And Development Financing Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmountsandClassificationofPaymentsIncomeExpenseDetails",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsNovartisDetails",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsOciperlimabOptionCollaborationandLicenseAgreementandChinaBroadMarketDevelopmentAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_AssetImpairmentChargesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetImpairmentChargesAbstract",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long-lived assets",
        "label": "Asset Impairment Charges [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetRetirementObligationsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetRetirementObligationsNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherLongtermLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherLongtermLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset retirement obligation",
        "label": "Asset Retirement Obligations, Noncurrent",
        "documentation": "Noncurrent portion of the carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees."
       }
      }
     },
     "auth_ref": [
      "r1376"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r157",
      "r228",
      "r266",
      "r302",
      "r310",
      "r328",
      "r331",
      "r382",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r699",
      "r701",
      "r730",
      "r842",
      "r934",
      "r1084",
      "r1085",
      "r1132",
      "r1162",
      "r1385",
      "r1386",
      "r1459"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "presentation": [
      "http://www.beigene.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Supplemental Balance Sheet Information",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r238",
      "r266",
      "r382",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r699",
      "r701",
      "r730",
      "r1132",
      "r1385",
      "r1386",
      "r1459"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r715",
      "r716",
      "r1119"
     ]
    },
    "us-gaap_AssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "label": "Assets, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r382",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r699",
      "r701",
      "r730",
      "r1385",
      "r1386",
      "r1459"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets:",
        "label": "Assets, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.beigene.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r1167",
      "r1168",
      "r1191"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.beigene.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r1167",
      "r1168",
      "r1191"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.beigene.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r1167",
      "r1168",
      "r1191"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Treasury securities",
        "label": "Debt Securities, Available-for-Sale, Current",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r402"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1249"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r1250"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1245"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1245"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1245"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1245"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1245"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1245"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensation2016ShareOptionandIncentivePlanDetails",
      "http://www.beigene.com/role/ShareBasedCompensationFairValueAssumptionsDetails",
      "http://www.beigene.com/role/ShareBasedCompensationOptionsandRestrictedSharesandRestrictedStockUnitsVestingPeriodsDetails",
      "http://www.beigene.com/role/ShareBasedCompensationRestrictedShareUnitsDetails",
      "http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r602",
      "r603",
      "r604",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r1248"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1247"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1246"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1246"
     ]
    },
    "bgne_BLINCYTOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "BLINCYTOMember",
     "presentation": [
      "http://www.beigene.com/role/ProductRevenueProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BLINCYTO\u00ae",
        "label": "BLINCYTO [Member]",
        "documentation": "BLINCYTO"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_BRUKINSAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "BRUKINSAMember",
     "presentation": [
      "http://www.beigene.com/role/ProductRevenueProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BRUKINSA\u00ae",
        "label": "BRUKINSA [Member]",
        "documentation": "Brukinsa [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BankTimeDepositsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BankTimeDepositsMember",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bank Time Deposits [Member]",
        "label": "Bank Time Deposits [Member]",
        "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "bgne_BeigeneLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "BeigeneLtdMember",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Beigene Ltd",
        "label": "Beigene Ltd [Member]",
        "documentation": "Beigene Ltd [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_BeijingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "BeijingMember",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesLandUseRightNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Beijing",
        "label": "Beijing [Member]",
        "documentation": "Beijing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BuildingMember",
     "presentation": [
      "http://www.beigene.com/role/LeasesNarrativesDetails",
      "http://www.beigene.com/role/LeasesSupplementalBalanceSheetDetails",
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetConstructioninProgressDetails",
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetPropertyPlantandEquipmentNetDetails",
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Building",
        "verboseLabel": "Operating lease right-of-use assets",
        "netLabel": "Building",
        "label": "Building [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.beigene.com/role/DescriptionofBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Description of Business",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r115",
      "r116"
     ]
    },
    "country_CH": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "CH",
     "presentation": [
      "http://www.beigene.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SWITZERLAND",
        "label": "SWITZERLAND"
       }
      }
     },
     "auth_ref": []
    },
    "country_CN": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "CN",
     "presentation": [
      "http://www.beigene.com/role/EmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.beigene.com/role/IncomeTaxesCurrentandDeferredComponentsIncomeTaxesDetails",
      "http://www.beigene.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails",
      "http://www.beigene.com/role/RestrictedNetAssetsDetails",
      "http://www.beigene.com/role/SegmentandGeographicInformationScheduleofRevenuebyGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PRC",
        "verboseLabel": "China- total revenue",
        "label": "CHINA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalAdditionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalAdditionsMember",
     "presentation": [
      "http://www.beigene.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital Addition Purchase Commitments",
        "label": "Capital Addition Purchase Commitments [Member]",
        "documentation": "Contractual obligation to increase property, plant and equipment either through construction or future purchases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accruals for capital expenditures",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Abstract]",
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesConcentrationofRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r222",
      "r1062"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Axis]",
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "presentation": [
      "http://www.beigene.com/role/RestrictedCash"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash",
        "label": "Cash and Cash Equivalents Disclosure [Text Block]",
        "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r846"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents:",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1440",
      "r1441"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r141"
     ]
    },
    "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents, and restricted cash, beginning of year",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash, end of year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r112",
      "r262"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net decrease in cash, cash equivalents, and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r112"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1224"
     ]
    },
    "bgne_ChinaCITICBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ChinaCITICBankMember",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "China CITIC Bank",
        "label": "China CITIC Bank [Member]",
        "documentation": "China CITIC Bank"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_ChinaConstructionBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ChinaConstructionBankMember",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "China Construction Bank",
        "label": "China Construction Bank [Member]",
        "documentation": "China Construction Bank [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_ChinaIndustrialBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ChinaIndustrialBankMember",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "China Industrial Bank",
        "label": "China Industrial Bank [Member]",
        "documentation": "China Industrial Bank [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_ChinaMerchantsBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ChinaMerchantsBankMember",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "China Merchants Bank",
        "label": "China Merchants Bank [Member]",
        "documentation": "China Merchants Bank"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_ChinaMinshengBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ChinaMinshengBankMember",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "China Minsheng Bank",
        "label": "China Minsheng Bank [Member]",
        "documentation": "China Minsheng Bank"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_ChinaResourcesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ChinaResourcesMember",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesConcentrationofRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "China Resources",
        "label": "China Resources [Member]",
        "documentation": "China Resources"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1221"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1219"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails",
      "http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r232",
      "r233",
      "r234",
      "r266",
      "r291",
      "r292",
      "r294",
      "r296",
      "r304",
      "r305",
      "r382",
      "r449",
      "r451",
      "r452",
      "r453",
      "r456",
      "r457",
      "r487",
      "r488",
      "r491",
      "r494",
      "r501",
      "r730",
      "r891",
      "r892",
      "r893",
      "r894",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r922",
      "r943",
      "r961",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1276",
      "r1326",
      "r1336"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1225"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1225"
     ]
    },
    "bgne_CollaborationAgreementsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "CollaborationAgreementsTableTextBlock",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Collaboration Agreements",
        "label": "Collaboration Agreements [Table Text Block]",
        "documentation": "Collaboration Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_CollaborationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "CollaborationMember",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsRecognizedRevenueDetails",
      "http://www.beigene.com/role/SegmentandGeographicInformationScheduleofRevenuebyGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration revenue",
        "label": "Collaboration [Member]",
        "documentation": "Collaboration [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_CollaborationOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "CollaborationOtherMember",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsRecognizedRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Collaboration Other [Member]",
        "documentation": "Collaboration Other [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_CollaborationResearchAndDevelopmentServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "CollaborationResearchAndDevelopmentServiceMember",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsRecognizedRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development service revenue",
        "label": "Collaboration Research And Development Service [Member]",
        "documentation": "Collaboration, Research and Development Service [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_CollaborativeArrangementCompensationTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "CollaborativeArrangementCompensationTypeAxis",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsPaymentClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement Compensation Type [Axis]",
        "label": "Collaborative Arrangement Compensation Type [Axis]",
        "documentation": "Collaborative Arrangement Compensation Type"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_CollaborativeArrangementCompensationTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "CollaborativeArrangementCompensationTypeDomain",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsPaymentClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement Compensation Type [Domain]",
        "label": "Collaborative Arrangement Compensation Type [Domain]",
        "documentation": "Collaborative Arrangement Compensation Type [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative and Licensing Arrangements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r166",
      "r177"
     ]
    },
    "us-gaap_CollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementMember",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmountsandClassificationofPaymentsIncomeExpenseDetails",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsNovartisDetails",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsOciperlimabOptionCollaborationandLicenseAgreementandChinaBroadMarketDevelopmentAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement",
        "label": "Collaborative Arrangement [Member]",
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsOciperlimabOptionCollaborationandLicenseAgreementandChinaBroadMarketDevelopmentAgreementDetails",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsPaymentClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development collaborative arrangements",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "bgne_CollaborativeArrangementsNumberOfProductsCompanyHasTheRightToRetain": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "CollaborativeArrangementsNumberOfProductsCompanyHasTheRightToRetain",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of products company has the right to retain",
        "label": "Collaborative Arrangements, Number Of Products Company Has The Right To Retain",
        "documentation": "Collaborative Arrangements, Number Of Products Company Has The Right To Retain"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_CollaborativeArrangementsProductRetentionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "CollaborativeArrangementsProductRetentionPeriod",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product retention period",
        "label": "Collaborative Arrangements, Product Retention Period",
        "documentation": "Collaborative Arrangements, Product Retention Period"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_CommercializationTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "CommercializationTerm",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercialization term (years)",
        "label": "Commercialization Term",
        "documentation": "Commercialization Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r147",
      "r845",
      "r921"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.beigene.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r438",
      "r440",
      "r1044",
      "r1372",
      "r1378"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails",
      "http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails",
      "http://www.beigene.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary\u00a0Shares",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r1150",
      "r1151",
      "r1152",
      "r1154",
      "r1155",
      "r1156",
      "r1157",
      "r1332",
      "r1333",
      "r1335",
      "r1438",
      "r1502",
      "r1504"
     ]
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares",
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r922"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, shares outstanding (in shares)",
        "periodStartLabel": "Balance at the beginning of period (in shares)",
        "periodEndLabel": "Balance at the ending of period (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r84",
      "r922",
      "r940",
      "r1504",
      "r1505"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, 0.0001 par value per share; 9,500,000,000 shares authorized; 1,387,367,704 and 1,359,513,224 shares issued and outstanding as of December\u00a031,\u00a02024 and 2023, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r847",
      "r1132"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1230"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1229"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1231"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1228"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Benefits [Abstract]",
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss attributable to BeiGene, Ltd.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r246",
      "r248",
      "r254",
      "r837",
      "r860",
      "r861"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive (loss) income, net of tax of nil:",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "presentation": [
      "http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r253",
      "r836",
      "r858"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Loss",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails",
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesConcentrationofRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r64",
      "r65",
      "r339",
      "r1043"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails",
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesConcentrationofRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r64",
      "r65",
      "r339",
      "r885",
      "r1043"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails",
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesConcentrationofRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r64",
      "r65",
      "r339",
      "r1043",
      "r1284"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Risks",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r168"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesConcentrationofRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk",
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails",
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesConcentrationofRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk, percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r64",
      "r65",
      "r339"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesConcentrationofRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Table]",
        "label": "Concentration Risk [Table]",
        "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r39",
      "r40",
      "r64",
      "r140",
      "r1043"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails",
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesConcentrationofRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r64",
      "r65",
      "r339",
      "r1043"
     ]
    },
    "srt_CondensedCashFlowStatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CondensedCashFlowStatementTable",
     "presentation": [
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Condensed Cash Flow Statement [Table]",
        "label": "Condensed Cash Flow Statement [Table]",
        "documentation": "Disclosure of information about condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r273",
      "r1280"
     ]
    },
    "srt_CondensedCashFlowStatementsCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CondensedCashFlowStatementsCaptionsLineItems",
     "presentation": [
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Condensed Cash Flow Statements, Captions [Line Items]",
        "label": "Condensed Cash Flow Statements, Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r273",
      "r1280"
     ]
    },
    "srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Information Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
     "presentation": [
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrant"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule I - Condensed Financial Information of Registrant",
        "label": "Condensed Financial Information of Parent Company Only Disclosure [Text Block]",
        "documentation": "The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r1280"
     ]
    },
    "srt_CondensedFinancialStatementsCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CondensedFinancialStatementsCaptionsLineItems",
     "presentation": [
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationNotestoCondensedFinancialStatementsDetails",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Condensed Financial Statements, Captions [Line Items]",
        "label": "Condensed Financial Statements, Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r210",
      "r211",
      "r212",
      "r273",
      "r1280"
     ]
    },
    "srt_CondensedStatementOfComprehensiveIncomeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CondensedStatementOfComprehensiveIncomeTable",
     "presentation": [
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveLossDetails",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Condensed Statement of Comprehensive Income [Table]",
        "label": "Condensed Statement of Comprehensive Income [Table]",
        "documentation": "Disclosure of information about condensed statement of comprehensive income (loss) including, but not limited to, statements of comprehensive income (loss) of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r273",
      "r1280"
     ]
    },
    "srt_CondensedStatementOfComprehensiveIncomeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CondensedStatementOfComprehensiveIncomeTableTextBlock",
     "presentation": [
      "http://www.beigene.com/role/SECScheduleArticle1204CondensedFinancialInformationofRegistrantTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Condensed Statements of Comprehensive Loss",
        "label": "Condensed Statement of Comprehensive Income [Table Text Block]",
        "documentation": "Tabular disclosure of condensed statement of comprehensive income (loss) including, but not limited to, statements of comprehensive income (loss) of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r1292",
      "r1331"
     ]
    },
    "srt_CondensedStatementOfIncomeCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CondensedStatementOfIncomeCaptionsLineItems",
     "presentation": [
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveLossDetails",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Condensed Statement of Income Captions [Line Items]",
        "label": "Condensed Statement of Income Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r273",
      "r1280"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationNotestoCondensedFinancialStatementsDetails",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveLossDetails",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Axis]",
        "label": "Consolidated Entities [Axis]",
        "documentation": "Information by consolidated entity or group of entities."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r200",
      "r273",
      "r699",
      "r700",
      "r701",
      "r702",
      "r767",
      "r1049",
      "r1306",
      "r1307",
      "r1308",
      "r1384",
      "r1387",
      "r1388"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationNotestoCondensedFinancialStatementsDetails",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveLossDetails",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Domain]",
        "label": "Consolidated Entities [Domain]",
        "documentation": "Entity or group of entities consolidated into reporting entity."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r200",
      "r273",
      "r699",
      "r700",
      "r701",
      "r702",
      "r767",
      "r1049",
      "r1306",
      "r1307",
      "r1308",
      "r1384",
      "r1387",
      "r1388"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r1073"
     ]
    },
    "us-gaap_ConstructionInProgressGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionInProgressGross",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetPropertyPlantandEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetConstructioninProgressDetails",
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetNarrativesDetails",
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetPropertyPlantandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress, Gross",
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in Progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "bgne_ContraARAccrualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ContraARAccrualsMember",
     "presentation": [
      "http://www.beigene.com/role/ProductRevenueAccruedSalesRebatesandReturnsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contra AR Accruals",
        "label": "Contra AR Accruals [Member]",
        "documentation": "Contra AR Accruals"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsNovartisDetails",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsOciperlimabOptionCollaborationandLicenseAgreementandChinaBroadMarketDevelopmentAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront cash payment received",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r504",
      "r523"
     ]
    },
    "us-gaap_ContractualObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractualObligation",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/DebtContractualmaturitiesofdebtobligationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.beigene.com/role/DebtContractualmaturitiesofdebtobligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Contractual Obligation",
        "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments."
       }
      }
     },
     "auth_ref": [
      "r1330"
     ]
    },
    "us-gaap_ContractualObligationDueAfterFifthYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractualObligationDueAfterFifthYear",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/DebtContractualmaturitiesofdebtobligationsDetails": {
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/DebtContractualmaturitiesofdebtobligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Contractual Obligation, to be Paid, after Year Five",
        "documentation": "Amount of contractual obligation to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligationDueInFifthYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractualObligationDueInFifthYear",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/DebtContractualmaturitiesofdebtobligationsDetails": {
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/DebtContractualmaturitiesofdebtobligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year ending December 31, 2029",
        "label": "Contractual Obligation, to be Paid, Year Five",
        "documentation": "Amount of contractual obligation to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligationDueInFourthYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractualObligationDueInFourthYear",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/DebtContractualmaturitiesofdebtobligationsDetails": {
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/DebtContractualmaturitiesofdebtobligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year ending December 31, 2028",
        "label": "Contractual Obligation, to be Paid, Year Four",
        "documentation": "Amount of contractual obligation to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligationDueInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractualObligationDueInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/DebtContractualmaturitiesofdebtobligationsDetails": {
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/DebtContractualmaturitiesofdebtobligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year ending December\u00a031,\u00a02025",
        "label": "Contractual Obligation, to be Paid, Year One",
        "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligationDueInSecondYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractualObligationDueInSecondYear",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/DebtContractualmaturitiesofdebtobligationsDetails": {
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/DebtContractualmaturitiesofdebtobligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year ending December\u00a031,\u00a02026",
        "label": "Contractual Obligation, to be Paid, Year Two",
        "documentation": "Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligationDueInThirdYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractualObligationDueInThirdYear",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/DebtContractualmaturitiesofdebtobligationsDetails": {
       "parentTag": "us-gaap_ContractualObligation",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/DebtContractualmaturitiesofdebtobligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year ending December 31, 2027",
        "label": "Contractual Obligation, to be Paid, Year Three",
        "documentation": "Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligationFiscalYearMaturityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractualObligationFiscalYearMaturityAbstract",
     "presentation": [
      "http://www.beigene.com/role/DebtContractualmaturitiesofdebtobligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual Maturities of Debt Obligations",
        "label": "Contractual Obligation, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock",
     "presentation": [
      "http://www.beigene.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Contractual Maturities of Debt Obligations",
        "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r1293",
      "r1331"
     ]
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible debt instrument",
        "label": "Convertible Debt [Member]",
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r459",
      "r460",
      "r470",
      "r471",
      "r472",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cost of sales - product",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r803"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmountsandClassificationofPaymentsIncomeExpenseDetails",
      "http://www.beigene.com/role/IntangibleAssetsAmortizationExpenseDetails",
      "http://www.beigene.com/role/IntangibleAssetsExpectedAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales - product",
        "verboseLabel": "Cost of Sales - Product",
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses",
        "label": "Costs and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmountsandClassificationofPaymentsIncomeExpenseDetails",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsFinancingLiabilityDetails",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsFundingExpensesDetails",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsNovartisDetails",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsOciperlimabOptionCollaborationandLicenseAgreementandChinaBroadMarketDevelopmentAgreementDetails",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsRecognizedRevenueDetails",
      "http://www.beigene.com/role/CommitmentsandContingenciesDetails",
      "http://www.beigene.com/role/RestrictedCashNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]",
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r209",
      "r271",
      "r272",
      "r462",
      "r489",
      "r766",
      "r784",
      "r841",
      "r1070",
      "r1072"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditLossFinancialInstrumentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditLossFinancialInstrumentPolicyTextBlock",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable and Allowance for Credit Losses",
        "label": "Credit Loss, Financial Instrument [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status."
       }
      }
     },
     "auth_ref": [
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405",
      "r407"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/IncomeTaxesCurrentandDeferredComponentsIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesCurrentandDeferredComponentsIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current tax expense (benefit)",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r681",
      "r1329"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesConcentrationofRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r339"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1176",
      "r1265"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1176",
      "r1265"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1178",
      "r1267"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1178",
      "r1267"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1180",
      "r1269"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1178",
      "r1267"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1171",
      "r1260"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1172",
      "r1261"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1172",
      "r1261"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r1170",
      "r1259"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1170",
      "r1259"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r1170",
      "r1259"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1173",
      "r1262"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1175",
      "r1264"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1175",
      "r1264"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1176",
      "r1265"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1179",
      "r1268"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1177",
      "r1266"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1174",
      "r1263"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.beigene.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r264",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r447",
      "r448",
      "r458",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r474",
      "r481",
      "r482",
      "r484",
      "r742"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r72",
      "r73",
      "r143",
      "r146",
      "r273",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r465",
      "r470",
      "r471",
      "r472",
      "r473",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1130",
      "r1327",
      "r1373",
      "r1374",
      "r1375",
      "r1452",
      "r1453"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Rate",
        "label": "Debt Instrument, Interest Rate During Period",
        "documentation": "The average effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r477",
      "r1452"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed annual interest rate (as a percent)",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r460"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r465",
      "r470",
      "r471",
      "r472",
      "r473",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r483",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1130",
      "r1327",
      "r1452",
      "r1453"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r273",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r465",
      "r470",
      "r471",
      "r472",
      "r473",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1130",
      "r1327",
      "r1373",
      "r1374",
      "r1375",
      "r1452",
      "r1453"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r53",
      "r54",
      "r67",
      "r130",
      "r131",
      "r273",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r465",
      "r470",
      "r471",
      "r472",
      "r473",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r483",
      "r1095",
      "r1096",
      "r1097",
      "r1098",
      "r1099",
      "r1130",
      "r1327",
      "r1452",
      "r1453"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term",
        "label": "Debt Instrument, Term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/IncomeTaxesCurrentandDeferredComponentsIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesCurrentandDeferredComponentsIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax expense (benefit)",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r174",
      "r1329"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total gross deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r81",
      "r144",
      "r672"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities",
        "label": "Deferred Income Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r649",
      "r650",
      "r843"
     ]
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred income tax expense",
        "label": "Deferred Income Taxes and Tax Credits",
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "bgne_DeferredTaxAssetValuationAllowanceChangesIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "DeferredTaxAssetValuationAllowanceChangesIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/IncometaxesScheduleofValuationAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions/(subtractions) charged to income tax provision",
        "label": "Deferred Tax Asset, Valuation Allowance, Changes Included In Earnings",
        "documentation": "Deferred Tax Asset, Valuation Allowance, Changes Included In Earnings"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_DeferredTaxAssetValuationAllowanceCurrencyTranslationAndOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "DeferredTaxAssetValuationAllowanceCurrencyTranslationAndOther",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/IncometaxesScheduleofValuationAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation and other",
        "label": "Deferred Tax Asset, Valuation Allowance, Currency Translation And Other",
        "documentation": "Deferred Tax Asset, Valuation Allowance, Currency Translation And Other"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_DeferredTaxAssetValuationAllowanceGainLossIncludedInOtherComprehensiveIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "DeferredTaxAssetValuationAllowanceGainLossIncludedInOtherComprehensiveIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/IncometaxesScheduleofValuationAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Additions/(subtractions) charged to equity",
        "label": "Deferred Tax Asset, Valuation Allowance, Gain (Loss) Included In Other Comprehensive Income (Loss)",
        "documentation": "Deferred Tax Asset, Valuation Allowance, Gain (Loss) Included In Other Comprehensive Income (Loss)"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_DeferredTaxAssetsActivityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "DeferredTaxAssetsActivityRollForward",
     "presentation": [
      "http://www.beigene.com/role/IncometaxesScheduleofValuationAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Tax Assets Activity [Roll Forward]",
        "label": "Deferred Tax Assets Activity [Roll Forward]",
        "documentation": "Deferred Tax Assets Activity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset amortization",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r1431"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total gross deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "R&amp;D and other capitalized costs",
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1431"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1428"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Tax Assets, Net [Abstract]",
        "label": "Deferred Tax Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net operating losses carryforward",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r1431"
     ]
    },
    "bgne_DeferredTaxAssetsPropertyLeaseLiabilityObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "DeferredTaxAssetsPropertyLeaseLiabilityObligation",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability obligation",
        "label": "Deferred Tax Assets, Property, Lease Liability Obligation",
        "documentation": "Deferred Tax Assets, Property, Lease Liability Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research tax credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1431"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsForeign",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesNarrativesDetails",
      "http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax relief credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Foreign",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1431"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1431"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accruals and reserves",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r1431"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails",
      "http://www.beigene.com/role/IncometaxesScheduleofValuationAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less valuation allowance",
        "periodStartLabel": "Beginning balance, as of January 1",
        "periodEndLabel": "Ending balance, as of December 31",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net deferred tax assets/(liabilities)",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1428"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Right of use asset",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r1431"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Property, plant and equipment, net",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r1431"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesNarrativesDetails",
      "http://www.beigene.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax on unremitted earnings",
        "terseLabel": "Tax on unremitted earnings",
        "label": "Deferred Tax Liabilities, Undistributed Foreign Earnings",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences."
       }
      }
     },
     "auth_ref": [
      "r1431"
     ]
    },
    "us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPensionPlanLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherLongtermLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherLongtermLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension liability",
        "label": "Liability, Defined Benefit Pension Plan, Noncurrent",
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension plan, classified as noncurrent. Excludes other postretirement benefit plan."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r56",
      "r78",
      "r133"
     ]
    },
    "us-gaap_DefinedBenefitPlanBenefitObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanBenefitObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Projected benefit obligation",
        "label": "Defined Benefit Plan, Benefit Obligation",
        "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "us-gaap_DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanEstimatedFutureBenefitPaymentsAbstract",
     "presentation": [
      "http://www.beigene.com/role/EmployeeBenefitPlansTotalExpectedBenefitPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_DefinedBenefitPlanExpectedFutureBenefitPaymentTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentTotal",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/EmployeeBenefitPlansTotalExpectedBenefitPaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.beigene.com/role/EmployeeBenefitPlansTotalExpectedBenefitPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Total",
        "documentation": "Defined Benefit Plan, Expected Future Benefit Payment, Total"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/EmployeeBenefitPlansTotalExpectedBenefitPaymentsDetails": {
       "parentTag": "bgne_DefinedBenefitPlanExpectedFutureBenefitPaymentTotal",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/EmployeeBenefitPlansTotalExpectedBenefitPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years",
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/EmployeeBenefitPlansTotalExpectedBenefitPaymentsDetails": {
       "parentTag": "bgne_DefinedBenefitPlanExpectedFutureBenefitPaymentTotal",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/EmployeeBenefitPlansTotalExpectedBenefitPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year ending December\u00a031,\u00a02025",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One",
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/EmployeeBenefitPlansTotalExpectedBenefitPaymentsDetails": {
       "parentTag": "bgne_DefinedBenefitPlanExpectedFutureBenefitPaymentTotal",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/EmployeeBenefitPlansTotalExpectedBenefitPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year ending December 31, 2029",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five",
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/EmployeeBenefitPlansTotalExpectedBenefitPaymentsDetails": {
       "parentTag": "bgne_DefinedBenefitPlanExpectedFutureBenefitPaymentTotal",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/EmployeeBenefitPlansTotalExpectedBenefitPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year ending December 31, 2028",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four",
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/EmployeeBenefitPlansTotalExpectedBenefitPaymentsDetails": {
       "parentTag": "bgne_DefinedBenefitPlanExpectedFutureBenefitPaymentTotal",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/EmployeeBenefitPlansTotalExpectedBenefitPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year ending December 31, 2027",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three",
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/EmployeeBenefitPlansTotalExpectedBenefitPaymentsDetails": {
       "parentTag": "bgne_DefinedBenefitPlanExpectedFutureBenefitPaymentTotal",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/EmployeeBenefitPlansTotalExpectedBenefitPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year ending December\u00a031,\u00a02026",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two",
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected employer contributions, 2025",
        "label": "Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year",
        "documentation": "Amount of contribution expected to be received by defined benefit plan from employer in next fiscal year following current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r1111"
     ]
    },
    "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanFairValueOfPlanAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined benefit plan, plan asset",
        "label": "Defined Benefit Plan, Plan Assets, Amount",
        "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r548",
      "r550",
      "r551",
      "r1108",
      "r1109",
      "r1110"
     ]
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employer contribution to retirement plan",
        "label": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "presentation": [
      "http://www.beigene.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee defined contribution plan",
        "label": "Defined Contribution Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://www.beigene.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Participant's contributions matched (as a percent)",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanTable",
     "presentation": [
      "http://www.beigene.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Contribution Plan [Table]",
        "label": "Defined Contribution Plan [Table]",
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans."
       }
      }
     },
     "auth_ref": [
      "r595"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r50"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization expense",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r302",
      "r313",
      "r331",
      "r1084",
      "r1085"
     ]
    },
    "bgne_DepreciationExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "DepreciationExpenseMember",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesGovernmentGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation Expense",
        "label": "Depreciation Expense [Member]",
        "documentation": "Depreciation Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DevelopedTechnologyRightsMember",
     "presentation": [
      "http://www.beigene.com/role/IntangibleAssetsIntangibleAssetsOutstandingDetails",
      "http://www.beigene.com/role/IntangibleAssetsUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Developed products",
        "label": "Developed Technology Rights [Member]",
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r1359",
      "r1360",
      "r1361",
      "r1362",
      "r1364",
      "r1366",
      "r1369",
      "r1370"
     ]
    },
    "bgne_DevelopmentMilestonePaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "DevelopmentMilestonePaymentsMember",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsPaymentClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development milestone payments",
        "label": "Development Milestone Payments [Member]",
        "documentation": "Development Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsRecognizedRevenueDetails",
      "http://www.beigene.com/role/ProductRevenueAccruedSalesRebatesandReturnsDetails",
      "http://www.beigene.com/role/ProductRevenueProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsRecognizedRevenueDetails",
      "http://www.beigene.com/role/ProductRevenueAccruedSalesRebatesandReturnsDetails",
      "http://www.beigene.com/role/ProductRevenueProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsTables",
      "http://www.beigene.com/role/ProductRevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Net Product Sales",
        "terseLabel": "Schedule of Net Product Sales",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1390"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r597",
      "r601",
      "r632",
      "r633",
      "r635",
      "r1115"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Axis]",
        "label": "Disposal Group Classification [Axis]",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Domain]",
        "label": "Disposal Group Classification [Domain]",
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "presentation": [
      "http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r17"
     ]
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-tax gain",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal",
        "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r429",
      "r1324",
      "r1371"
     ]
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList",
     "presentation": [
      "http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income that includes gain (loss) recognized on sale or disposal of disposal group. Excludes discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "bgne_DisposalGroupNotDiscontinuedOperationNetAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "DisposalGroupNotDiscontinuedOperationNetAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net assets disposed of",
        "label": "Disposal Group, Not Discontinued Operation, Net Assets",
        "documentation": "Net assets attributable to disposal group not classified as discontinued operation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "presentation": [
      "http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Domain]",
        "label": "Disposal Group Name [Domain]",
        "documentation": "Name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r1112",
      "r1113"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r1167",
      "r1168",
      "r1191"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r1167",
      "r1168",
      "r1191",
      "r1234"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1212"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r1165"
     ]
    },
    "us-gaap_DomesticPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticPlanMember",
     "presentation": [
      "http://www.beigene.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic Plan [Member]",
        "label": "Domestic Plan [Member]",
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r1393",
      "r1394",
      "r1395"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1223"
     ]
    },
    "bgne_EarningsPerAmericanDepositoryShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "EarningsPerAmericanDepositoryShareBasic",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per American Depositary Share (ADS), basic (in dollars per share)",
        "label": "Earnings Per American Depository Share, Basic",
        "documentation": "Earnings per American Depository Share, basic and diluted."
       }
      }
     },
     "auth_ref": []
    },
    "bgne_EarningsPerAmericanDepositoryShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "EarningsPerAmericanDepositoryShareDiluted",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per American Depositary Share (ADS), diluted (in dollars per share)",
        "label": "Earnings Per American Depository Share, Diluted",
        "documentation": "Earnings Per American Depository Share, Diluted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.beigene.com/role/LossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss per share, basic (in dollars per share)",
        "terseLabel": "Loss per share basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r289",
      "r291",
      "r294",
      "r295",
      "r296",
      "r301",
      "r694",
      "r697",
      "r712",
      "r713",
      "r838",
      "r862",
      "r1076"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.beigene.com/role/LossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net loss per share, diluted (in dollars per share)",
        "terseLabel": "Loss per share diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r291",
      "r294",
      "r295",
      "r296",
      "r301",
      "r694",
      "r697",
      "r712",
      "r713",
      "r838",
      "r862",
      "r1076"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r298"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.beigene.com/role/LossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r297",
      "r299",
      "r300"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of foreign exchange rate changes, net",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesReconciliationoftheStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r653",
      "r1118"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesReconciliationoftheStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "U.S. statutory tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r653",
      "r684",
      "r1118"
     ]
    },
    "bgne_EffectiveIncomeTaxRateReconciliationDeductionResearchExpensesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationDeductionResearchExpensesAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/IncomeTaxesReconciliationoftheStatutoryRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesReconciliationoftheStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deductible research expenses",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Research Expenses, Amount",
        "documentation": "Effective Income Tax Rate Reconciliation, Deduction, Research Expenses, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationFdiiAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/IncomeTaxesReconciliationoftheStatutoryRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesReconciliationoftheStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Foreign-derived intangible income",
        "label": "Effective Income Tax Rate Reconciliation, FDII, Amount",
        "documentation": "Amount of reported income tax benefit from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign-derived intangible income (FDII)."
       }
      }
     },
     "auth_ref": [
      "r1118",
      "r1424",
      "r1426"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofAccruedExpensesandOtherPayablesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofAccruedExpensesandOtherPayablesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation related",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Share-Based Payment Arrangement, Additional Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationRestrictedShareUnitsDetails",
      "http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period of unrecognized share-based compensation cost over average amortization (in years)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationRestrictedShareUnitsDetails",
      "http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized share-based compensation costs",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1422"
     ]
    },
    "bgne_EmployeeSharePurchasePlan2018Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "EmployeeSharePurchasePlan2018Member",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensation2018EmployeeSharePurchasePlanDetails",
      "http://www.beigene.com/role/ShareBasedCompensationSharesIssuedUnderEmployeeSharePurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Share Purchase Plan 2018",
        "label": "Employee Share Purchase Plan2018 [Member]",
        "documentation": "The 2018 Employee Share Purchase Plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensation2016ShareOptionandIncentivePlanDetails",
      "http://www.beigene.com/role/ShareBasedCompensationFairValueAssumptionsDetails",
      "http://www.beigene.com/role/ShareBasedCompensationOptionsandRestrictedSharesandRestrictedStockUnitsVestingPeriodsDetails",
      "http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Street Address",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Street Address Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1164"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1164"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1164"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1274"
     ]
    },
    "dei_EntityNumberOfEmployees": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityNumberOfEmployees",
     "presentation": [
      "http://www.beigene.com/role/DescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of employees",
        "label": "Entity Number of Employees",
        "documentation": "Number of persons employed by the Entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1164"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1164"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1164"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1164"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1275"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1217"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1270"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r1270"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1270"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncomeDetails",
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.beigene.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r216",
      "r250",
      "r251",
      "r252",
      "r274",
      "r275",
      "r276",
      "r278",
      "r283",
      "r285",
      "r287",
      "r303",
      "r383",
      "r384",
      "r428",
      "r502",
      "r682",
      "r683",
      "r691",
      "r692",
      "r693",
      "r695",
      "r696",
      "r697",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r711",
      "r733",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r743",
      "r745",
      "r762",
      "r858",
      "r878",
      "r879",
      "r880",
      "r897",
      "r961"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Domain]",
        "label": "Investment, Name [Domain]",
        "documentation": "Name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r380",
      "r381",
      "r690",
      "r1277",
      "r1278",
      "r1279",
      "r1433",
      "r1434",
      "r1435",
      "r1436"
     ]
    },
    "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss",
        "label": "Equity Method Investment, Other-than-Temporary Impairment",
        "documentation": "Amount of other-than-temporary decline in value that has been recognized against investment accounted for under equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r1353"
     ]
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails": {
       "parentTag": "us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity-method investments",
        "label": "Equity Method Investments",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r316",
      "r331",
      "r377",
      "r1312",
      "r1354"
     ]
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentsTextBlock",
     "presentation": [
      "http://www.beigene.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Equity Method Investments",
        "label": "Equity Method Investments [Table Text Block]",
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information."
       }
      }
     },
     "auth_ref": [
      "r378"
     ]
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNi",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails": {
       "parentTag": "us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails",
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities with readily determinable fair values",
        "label": "Equity Securities, FV-NI, Current",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r729",
      "r1064"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Equity Securities, FV-NI and without Readily Determinable Fair Value",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI) and investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r729"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/InvestmentsEquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities with readily determinable fair values",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r864",
      "r1352"
     ]
    },
    "us-gaap_EquitySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesMember",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities with readily determinable fair values",
        "label": "Equity Securities [Member]",
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r1133",
      "r1158",
      "r1159",
      "r1160",
      "r1507"
     ]
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails": {
       "parentTag": "us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities without readily determinable fair values",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "documentation": "Amount of investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "bgne_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmountNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmountNet",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/InvestmentsEquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Equity securities without readily determinable fair values",
        "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount, Net",
        "documentation": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount, Net"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1227"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1184",
      "r1195",
      "r1205",
      "r1238"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r1181",
      "r1192",
      "r1202",
      "r1235"
     ]
    },
    "srt_EuropeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EuropeMember",
     "presentation": [
      "http://www.beigene.com/role/SegmentandGeographicInformationScheduleofRevenuebyGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Europe- total revenue",
        "label": "Europe [Member]",
        "documentation": "Continent of Europe."
       }
      }
     },
     "auth_ref": [
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1506",
      "r1508",
      "r1509",
      "r1510"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1233"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r715",
      "r716",
      "r723",
      "r1119"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r715",
      "r716",
      "r723",
      "r1119"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r1119",
      "r1440",
      "r1441",
      "r1446"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r714",
      "r716",
      "r717",
      "r718",
      "r719",
      "r722",
      "r723",
      "r725",
      "r771",
      "r772",
      "r773",
      "r1096",
      "r1097",
      "r1108",
      "r1109",
      "r1110",
      "r1119",
      "r1123"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r715",
      "r716",
      "r717",
      "r719",
      "r1119",
      "r1443",
      "r1447"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quoted\u00a0Price in\u00a0Active Market\u00a0for Identical Assets (Level\u00a01)",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r550",
      "r555",
      "r716",
      "r723",
      "r771",
      "r1108",
      "r1109",
      "r1110",
      "r1119"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Other Observable Inputs (Level\u00a02)",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r550",
      "r555",
      "r716",
      "r717",
      "r723",
      "r772",
      "r1096",
      "r1097",
      "r1108",
      "r1109",
      "r1110",
      "r1119"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Unobservable Inputs (Level\u00a03)",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r716",
      "r717",
      "r718",
      "r719",
      "r723",
      "r773",
      "r1096",
      "r1097",
      "r1108",
      "r1109",
      "r1110",
      "r1119",
      "r1123"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r715",
      "r716",
      "r717",
      "r719",
      "r1119",
      "r1443",
      "r1447"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r714",
      "r716",
      "r717",
      "r718",
      "r719",
      "r722",
      "r723",
      "r725",
      "r771",
      "r772",
      "r773",
      "r1096",
      "r1097",
      "r1108",
      "r1109",
      "r1110",
      "r1119",
      "r1123"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recurring Basis",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r1119",
      "r1440",
      "r1441",
      "r1442",
      "r1443",
      "r1444",
      "r1447"
     ]
    },
    "us-gaap_FairValueNetAssetLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueNetAssetLiabilityAbstract",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets at fair value on a recurring basis",
        "label": "Fair Value, Net Asset (Liability) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_FairValueOfEquityInvestmentsIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "FairValueOfEquityInvestmentsIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair value of equity investments issued",
        "label": "Fair Value of Equity Investments Issued",
        "documentation": "Fair Value of Equity Investments Issued"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_FairValueOfFinancingCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "FairValueOfFinancingCommitment",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair value of financing commitment",
        "label": "Fair Value Of Financing Commitment",
        "documentation": "Fair Value Of Financing Commitment"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_FairValueOfLiabilityAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "FairValueOfLiabilityAcquired",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of cost share liability",
        "label": "Fair Value Of Liability Acquired",
        "documentation": "Fair Value Of Liability Acquired"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOptionChangesInFairValueGainLoss1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOptionChangesInFairValueGainLoss1",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on fair value",
        "label": "Fair Value, Option, Changes in Fair Value, Gain (Loss)",
        "documentation": "For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r389",
      "r390",
      "r391",
      "r392",
      "r397",
      "r406",
      "r407",
      "r408",
      "r483",
      "r499",
      "r709",
      "r726",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r859",
      "r1091",
      "r1119",
      "r1121",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1133",
      "r1285",
      "r1286",
      "r1287",
      "r1288",
      "r1289",
      "r1290",
      "r1291",
      "r1348",
      "r1349",
      "r1350",
      "r1351",
      "r1439",
      "r1442",
      "r1443",
      "r1444",
      "r1445",
      "r1447"
     ]
    },
    "bgne_FinancingCommitmentCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "FinancingCommitmentCarryingValue",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsFinancingLiabilityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsFinancingLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total research and development cost share liability",
        "label": "Financing Commitment, Carrying Value",
        "documentation": "Financing Commitment, Carrying Value"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_FinancingCommitmentCarryingValueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "FinancingCommitmentCarryingValueCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsFinancingLiabilityDetails": {
       "parentTag": "bgne_FinancingCommitmentCarryingValue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsFinancingLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development cost share liability, current portion",
        "label": "Financing Commitment, Carrying Value, Current",
        "documentation": "Financing Commitment, Carrying Value, Current"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_FinancingCommitmentCarryingValueNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "FinancingCommitmentCarryingValueNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsFinancingLiabilityDetails": {
       "parentTag": "bgne_FinancingCommitmentCarryingValue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsFinancingLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development cost share liability, non-current portion",
        "label": "Financing Commitment, Carrying Value, Non-current",
        "documentation": "Financing Commitment, Carrying Value, Non-current"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_FinancingCommitmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "FinancingCommitmentExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsFundingExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsFundingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "BeiGene\u2019s portion of the development funding",
        "label": "Financing Commitment Expenses",
        "documentation": "Financing Commitment Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.beigene.com/role/IntangibleAssetsUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful life",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/IntangibleAssetsIntangibleAssetsOutstandingDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IntangibleAssetsIntangibleAssetsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accumulated amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r412",
      "r420",
      "r1094"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/IntangibleAssetsExpectedAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IntangibleAssetsExpectedAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030 and thereafter",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1367",
      "r1519"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/IntangibleAssetsExpectedAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IntangibleAssetsExpectedAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r1058",
      "r1094"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.beigene.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets Amortization Expense",
        "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/IntangibleAssetsExpectedAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IntangibleAssetsExpectedAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r1058",
      "r1094"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/IntangibleAssetsExpectedAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IntangibleAssetsExpectedAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r1058",
      "r1094"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/IntangibleAssetsExpectedAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IntangibleAssetsExpectedAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r1058",
      "r1094"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/IntangibleAssetsExpectedAmortizationExpenseDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IntangibleAssetsExpectedAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r1058",
      "r1094"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.beigene.com/role/IntangibleAssetsIntangibleAssetsOutstandingDetails",
      "http://www.beigene.com/role/IntangibleAssetsUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r423",
      "r424",
      "r804",
      "r805",
      "r1058"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "presentation": [
      "http://www.beigene.com/role/IntangibleAssetsExpectedAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year Ending December 31,",
        "label": "Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/IntangibleAssetsIntangibleAssetsOutstandingDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IntangibleAssetsIntangibleAssetsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross carrying amount",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r420",
      "r805",
      "r1094"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.beigene.com/role/IntangibleAssetsAmortizationExpenseDetails",
      "http://www.beigene.com/role/IntangibleAssetsIntangibleAssetsOutstandingDetails",
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesLandUseRightNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r420",
      "r423",
      "r424",
      "r426",
      "r804",
      "r1058",
      "r1094"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.beigene.com/role/IntangibleAssetsIntangibleAssetsOutstandingDetails",
      "http://www.beigene.com/role/IntangibleAssetsUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r423",
      "r424",
      "r1058"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.beigene.com/role/IntangibleAssetsIntangibleAssetsOutstandingDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.beigene.com/role/IntangibleAssetsExpectedAmortizationExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.beigene.com/role/IntangibleAssetsExpectedAmortizationExpenseDetails",
      "http://www.beigene.com/role/IntangibleAssetsIntangibleAssetsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible assets, net",
        "totalLabel": "Intangible assets, net",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r804",
      "r1366"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "presentation": [
      "http://www.beigene.com/role/IntangibleAssetsIntangibleAssetsOutstandingDetails",
      "http://www.beigene.com/role/IntangibleAssetsUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "verboseLabel": "Other intangible assets",
        "label": "Finite-Lived Intangible Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Functional Currency and Foreign Currency Translation",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r731"
     ]
    },
    "us-gaap_ForeignPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignPlanMember",
     "presentation": [
      "http://www.beigene.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Plan [Member]",
        "label": "Foreign Plan [Member]",
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r1393",
      "r1394",
      "r1395"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r1188",
      "r1199",
      "r1209",
      "r1242"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r1188",
      "r1199",
      "r1209",
      "r1242"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r1188",
      "r1199",
      "r1209",
      "r1242"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1188",
      "r1199",
      "r1209",
      "r1242"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1188",
      "r1199",
      "r1209",
      "r1242"
     ]
    },
    "bgne_FourLargestCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "FourLargestCustomersMember",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesConcentrationofRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Four Largest Customers",
        "label": "Four Largest Customers [Member]",
        "documentation": "Four Largest Customers"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1222"
     ]
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossRelatedToLitigationSettlement",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gain on BMS termination settlement",
        "label": "Gain (Loss) from Litigation Settlement",
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process."
       }
      }
     },
     "auth_ref": [
      "r1084",
      "r1379"
     ]
    },
    "us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeographicAreasRevenuesFromExternalCustomersAbstract",
     "presentation": [
      "http://www.beigene.com/role/SegmentandGeographicInformationScheduleofRevenuebyGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net product revenues by geographic area",
        "label": "Geographic Areas, Revenues from External Customers [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.beigene.com/role/IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1357",
      "r1358"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined."
       }
      }
     },
     "auth_ref": [
      "r413",
      "r425",
      "r427"
     ]
    },
    "us-gaap_GovernmentAssistanceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentAssistanceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesGovernmentGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government assistance amount",
        "label": "Government Assistance, Income, Increase (Decrease)",
        "documentation": "Amount of increase (decrease) in income from government assistance."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_GovernmentAssistanceLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentAssistanceLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherLongtermLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherLongtermLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred government grant income",
        "label": "Government Assistance, Liability",
        "documentation": "Amount of liability from government assistance."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_GovernmentAssistanceLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentAssistanceLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesGovernmentGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government assistance, liability, noncurrent",
        "label": "Government Assistance, Liability, Noncurrent",
        "documentation": "Amount of liability from government assistance, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_GovernmentAssistanceLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentAssistanceLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesGovernmentGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government Assistance, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "label": "Government Assistance, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes liability from government assistance, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "bgne_GovernmentAssistanceManufacturingFacilityBuildOutMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "GovernmentAssistanceManufacturingFacilityBuildOutMember",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesGovernmentGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government Assistance, Manufacturing Facility Build-Out",
        "label": "Government Assistance, Manufacturing Facility Build-Out [Member]",
        "documentation": "Government Assistance, Manufacturing Facility Build-Out"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_GovernmentAssistanceResearchAndDevelopmentProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "GovernmentAssistanceResearchAndDevelopmentProgramsMember",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesGovernmentGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government Assistance, Research And Development Programs",
        "label": "Government Assistance, Research And Development Programs [Member]",
        "documentation": "Government Assistance, Research And Development Programs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesGovernmentGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government Assistance, Income, Increase (Decrease), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Government Assistance, Income, Increase (Decrease), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes increase (decrease) in income from government assistance."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_GovernmentAssistanceTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentAssistanceTypeAxis",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesGovernmentGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government Assistance, Type [Axis]",
        "label": "Government Assistance, Type [Axis]",
        "documentation": "Information by type of government assistance."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_GovernmentAssistanceTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GovernmentAssistanceTypeDomain",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesGovernmentGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government Assistance, Type [Domain]",
        "label": "Government Assistance, Type [Domain]",
        "documentation": "Type of government assistance."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "bgne_GovernmentGrantsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "GovernmentGrantsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government Grants",
        "label": "Government Grants, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for government grants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r103",
      "r156",
      "r266",
      "r382",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r730",
      "r1078",
      "r1084",
      "r1338",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1385"
     ]
    },
    "bgne_GuangzhouMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "GuangzhouMember",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesLandUseRightNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guangzhou",
        "label": "Guangzhou [Member]",
        "documentation": "Guangzhou"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_HSBCBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "HSBCBankMember",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "HSBC Bank",
        "label": "HSBC Bank [Member]",
        "documentation": "HSBC Bank"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_HopewellFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "HopewellFacilityMember",
     "presentation": [
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hopewell Facility",
        "label": "Hopewell Facility [Member]",
        "documentation": "Hopewell Facility"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IPOMember",
     "presentation": [
      "http://www.beigene.com/role/RestrictedCashNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPO",
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r1167",
      "r1168",
      "r1191"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesGoodwillandOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset impairment",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r415",
      "r425"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesImpairmentofLongLivedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long-lived assets",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r49",
      "r124",
      "r1120"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r125"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PRC",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r652"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.beigene.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.beigene.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r150",
      "r156",
      "r839",
      "r856",
      "r1078",
      "r1084",
      "r1338",
      "r1340",
      "r1341",
      "r1342",
      "r1343"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r652"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesReconciliationoftheStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Loss before tax",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r865",
      "r1078",
      "r1338",
      "r1340",
      "r1341",
      "r1342",
      "r1343"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract",
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of income / (loss) before income taxes",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/InvestmentsEquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity-method investments",
        "label": "Income (Loss) from Equity Method Investments",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r100",
      "r149",
      "r302",
      "r314",
      "r331",
      "r377",
      "r855"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "presentation": [
      "http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Axis]",
        "label": "Disposal Group Name [Axis]",
        "documentation": "Information by name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r1112",
      "r1113"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmountsandClassificationofPaymentsIncomeExpenseDetails",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsPaymentClassificationDetails",
      "http://www.beigene.com/role/IntangibleAssetsAmortizationExpenseDetails",
      "http://www.beigene.com/role/IntangibleAssetsExpectedAmortizationExpenseDetails",
      "http://www.beigene.com/role/InvestmentsEquityMethodInvestmentsDetails",
      "http://www.beigene.com/role/ShareBasedCompensationSharebasedCompensationExpenseDetails",
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesGovernmentGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r436",
      "r437",
      "r720",
      "r721",
      "r724",
      "r875",
      "r877",
      "r946",
      "r1058",
      "r1122",
      "r1473"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmountsandClassificationofPaymentsIncomeExpenseDetails",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsPaymentClassificationDetails",
      "http://www.beigene.com/role/IntangibleAssetsAmortizationExpenseDetails",
      "http://www.beigene.com/role/IntangibleAssetsExpectedAmortizationExpenseDetails",
      "http://www.beigene.com/role/InvestmentsEquityMethodInvestmentsDetails",
      "http://www.beigene.com/role/ShareBasedCompensationSharebasedCompensationExpenseDetails",
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesGovernmentGrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r437",
      "r720",
      "r721",
      "r724",
      "r875",
      "r877",
      "r946",
      "r1058",
      "r1122",
      "r1473"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority, Name [Axis]",
        "label": "Income Tax Authority, Name [Axis]",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r665",
      "r1430"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority, Name [Domain]",
        "label": "Income Tax Authority, Name [Domain]",
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": [
      "r665",
      "r1430"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r645",
      "r653",
      "r662",
      "r663",
      "r664",
      "r670",
      "r676",
      "r685",
      "r687",
      "r688",
      "r689",
      "r896",
      "r1118"
     ]
    },
    "us-gaap_IncomeTaxExaminationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationLineItems",
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesCurrentandDeferredComponentsIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Examination [Line Items]",
        "label": "Income Tax Examination [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "us-gaap_IncomeTaxExaminationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationTable",
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesCurrentandDeferredComponentsIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax, Examination [Table]",
        "label": "Income Tax, Examination [Table]",
        "documentation": "Disclosure of information about income tax examination currently in progress or completed during current period by tax authority. Includes, but is not limited to, description of examination, jurisdiction conducting examination, tax year under examination, likelihood of unfavorable settlement, range of possible loss, liability recorded, increase (decrease) of liability from prior period, and penalty and interest incurred or accrued."
       }
      }
     },
     "auth_ref": [
      "r1427"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.beigene.com/role/IncomeTaxesCurrentandDeferredComponentsIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.beigene.com/role/IncomeTaxesReconciliationoftheStatutoryRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.beigene.com/role/IncomeTaxesCurrentandDeferredComponentsIncomeTaxesDetails",
      "http://www.beigene.com/role/IncomeTaxesReconciliationoftheStatutoryRateDetails",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income tax expense",
        "totalLabel": "Income tax expense (benefit)",
        "terseLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r175",
      "r286",
      "r287",
      "r302",
      "r315",
      "r331",
      "r651",
      "r653",
      "r686",
      "r866",
      "r1118"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r647",
      "r648",
      "r670",
      "r671",
      "r675",
      "r680",
      "r890"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/IncomeTaxesReconciliationoftheStatutoryRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesReconciliationoftheStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r1118",
      "r1424"
     ]
    },
    "us-gaap_IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/IncomeTaxesReconciliationoftheStatutoryRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesReconciliationoftheStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax on unremitted earnings",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Extraterritorial Income Exclusion, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deduction for extraterritorial income exclusion."
       }
      }
     },
     "auth_ref": [
      "r1424",
      "r1425"
     ]
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/IncomeTaxesReconciliationoftheStatutoryRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesReconciliationoftheStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign and preferential tax rate differential",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r654",
      "r657",
      "r1118",
      "r1424"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/IncomeTaxesReconciliationoftheStatutoryRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesReconciliationoftheStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected taxation at U.S. statutory tax rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r653",
      "r1118"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/IncomeTaxesReconciliationoftheStatutoryRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesReconciliationoftheStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-deductible expenses",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r660",
      "r661",
      "r1424"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/IncomeTaxesReconciliationoftheStatutoryRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesReconciliationoftheStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation expenses",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1118",
      "r1424",
      "r1426"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/IncomeTaxesReconciliationoftheStatutoryRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesReconciliationoftheStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State tax expense (benefit)",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r656",
      "r1118",
      "r1424"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationTaxCredits",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/IncomeTaxesReconciliationoftheStatutoryRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesReconciliationoftheStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax relief credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r658",
      "r661",
      "r1424"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/IncomeTaxesReconciliationoftheStatutoryRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesReconciliationoftheStatutoryRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research tax credits and incentives",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r1118",
      "r1424",
      "r1426"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes paid",
        "label": "Income Taxes Paid, Net",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r261",
      "r677",
      "r678"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r801",
      "r1323"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventories",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other payables",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets",
        "label": "Increase (Decrease) in Other Operating Assets",
        "documentation": "Amount of increase (decrease) in operating assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1188",
      "r1199",
      "r1209",
      "r1233",
      "r1242",
      "r1246",
      "r1254"
     ]
    },
    "bgne_InducementEquityPlan2018Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "InducementEquityPlan2018Member",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensation2018InducementEquityPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inducement Equity Plan2018",
        "label": "Inducement Equity Plan2018 [Member]",
        "documentation": "The 2018 Inducement Equity Plan."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1252"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1169",
      "r1258"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1169",
      "r1258"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1169",
      "r1258"
     ]
    },
    "bgne_IntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "IntangibleAssetsMember",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsPaymentClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset",
        "label": "Intangible Assets [Member]",
        "documentation": "Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestCostsCapitalized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestCostsCapitalized",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest capitalized",
        "label": "Interest Costs Capitalized",
        "documentation": "Amount of interest capitalized during the period."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r478",
      "r485",
      "r1098",
      "r1099"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income, net",
        "label": "Interest Income (Expense), Nonoperating",
        "documentation": "Amount of interest income (expense) classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r1084",
      "r1320",
      "r1340"
     ]
    },
    "bgne_InterestPaidIncludingCapitalizedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "InterestPaidIncludingCapitalizedInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest paid",
        "label": "Interest Paid, Including Capitalized Interest",
        "documentation": "Interest Paid, Including Capitalized Interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r259",
      "r260"
     ]
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InternalRevenueServiceIRSMember",
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BeiGene USA",
        "label": "Internal Revenue Service (IRS) [Member]",
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoriesMember",
     "presentation": [
      "http://www.beigene.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventories [Member]",
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory Disclosure [Abstract]",
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.beigene.com/role/InventoriesNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories, Net",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r409"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/InventoriesNetDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/InventoriesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r1067"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.beigene.com/role/InventoriesNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.beigene.com/role/InventoriesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories, net",
        "totalLabel": "Total inventories, net",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r1063",
      "r1132"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r221",
      "r236",
      "r409",
      "r410",
      "r411",
      "r802",
      "r1074"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/InventoriesNetDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/InventoriesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r1069"
     ]
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/InventoriesNetDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/InventoriesNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work in process",
        "label": "Inventory, Work in Process, Net of Reserves",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r1068"
     ]
    },
    "bgne_InvestmentInDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "InvestmentInDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible debt instrument",
        "label": "Investment In Debt Securities, Current",
        "documentation": "Investment In Debt Securities, Current"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_InvestmentInDebtSecuritiesNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "InvestmentInDebtSecuritiesNonCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible debt instrument",
        "label": "Investment In Debt Securities, Non Current",
        "documentation": "Investment In Debt Securities, Non Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r863",
      "r886",
      "r887",
      "r888",
      "r889",
      "r987",
      "r989"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]",
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_InvestmentsFundingCommitmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "InvestmentsFundingCommitmentMember",
     "presentation": [
      "http://www.beigene.com/role/CommitmentsandContingenciesDetails",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationNotestoCondensedFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments Funding Commitment",
        "label": "Investments Funding Commitment [Member]",
        "documentation": "Investments Funding Commitment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in wholly owned subsidiaries",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate."
       }
      }
     },
     "auth_ref": [
      "r1314"
     ]
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.beigene.com/role/Investments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r179",
      "r341",
      "r344",
      "r727",
      "r728",
      "r1468"
     ]
    },
    "bgne_KYPROLISMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "KYPROLISMember",
     "presentation": [
      "http://www.beigene.com/role/ProductRevenueProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "KYPROLIS\u00ae",
        "label": "KYPROLIS [Member]",
        "documentation": "KYPROLIS"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetConstructioninProgressDetails",
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetPropertyPlantandEquipmentNetDetails",
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory Equipment",
        "verboseLabel": "Laboratory equipment",
        "netLabel": "Laboratory equipment",
        "label": "Laboratory Equipment [Member]",
        "documentation": "Represents information pertaining to laboratory equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LandMember",
     "presentation": [
      "http://www.beigene.com/role/LeasesSupplementalBalanceSheetDetails",
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetNarrativesDetails",
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetPropertyPlantandEquipmentNetDetails",
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesLandUseRightNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land",
        "verboseLabel": "Land use rights, net",
        "label": "Land [Member]",
        "documentation": "Part of earth's surface not covered by water."
       }
      }
     },
     "auth_ref": [
      "r1391"
     ]
    },
    "bgne_LandUseRightsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "LandUseRightsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land Use Right, Net",
        "label": "Land Use Rights, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for land use rights"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_LeapTherapeuticIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "LeapTherapeuticIncMember",
     "presentation": [
      "http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leap Therapeutic, Inc",
        "label": "Leap Therapeutic, Inc [Member]",
        "documentation": "Leap Therapeutic, Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.beigene.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r751",
      "r1131"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.beigene.com/role/LeasesTables",
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Component of Lease Expense",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1456"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetPropertyPlantandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r760"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.beigene.com/role/LeasesNarrativesDetails",
      "http://www.beigene.com/role/LeasesSupplementalBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r750",
      "r761"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.beigene.com/role/LeasesNarrativesDetails",
      "http://www.beigene.com/role/LeasesSupplementalBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r750",
      "r761"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r749"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.beigene.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities of Operating Lease Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1457"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.beigene.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.beigene.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year ending December\u00a031,\u00a02025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year ending December 31, 2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year ending December 31, 2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year ending December\u00a031,\u00a02027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year ending December\u00a031,\u00a02026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.beigene.com/role/LeasesNarrativesDetails",
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesLandUseRightNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Terms",
        "terseLabel": "Contract term (years)",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1454"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.beigene.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r72",
      "r73",
      "r74",
      "r77",
      "r78",
      "r79",
      "r82",
      "r266",
      "r382",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r700",
      "r701",
      "r702",
      "r730",
      "r920",
      "r1077",
      "r1162",
      "r1385",
      "r1459",
      "r1460"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and shareholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r148",
      "r850",
      "r1132",
      "r1328",
      "r1355",
      "r1448"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities and shareholders\u2019 equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r220",
      "r266",
      "r382",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r700",
      "r701",
      "r702",
      "r730",
      "r1132",
      "r1385",
      "r1459",
      "r1460"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r77",
      "r78",
      "r79",
      "r82",
      "r266",
      "r382",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r700",
      "r701",
      "r702",
      "r730",
      "r1385",
      "r1459",
      "r1460"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liabilities:",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityAxis",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lender Name [Axis]",
        "label": "Lender Name [Axis]",
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r76",
      "r1327",
      "r1382",
      "r1383"
     ]
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityLenderDomain",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility, Lender [Domain]",
        "label": "Line of Credit Facility, Lender [Domain]",
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r76",
      "r1327",
      "r1382"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r76"
     ]
    },
    "us-gaap_LoansPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LoansPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development cost share liability, current portion",
        "label": "Loans Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "us-gaap_LoansPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LoansPayableMember",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loans Payable",
        "label": "Loans Payable [Member]",
        "documentation": "Borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "bgne_LongTermBankLoanApril42018Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "LongTermBankLoanApril42018Member",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term bank April 4, 2018",
        "label": "Long Term Bank Loan April42018 [Member]",
        "documentation": "Long Term Bank Loan dated April 4, 2018."
       }
      }
     },
     "auth_ref": []
    },
    "bgne_LongTermBankLoanDatedJanuary222020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "LongTermBankLoanDatedJanuary222020Member",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long Term Bank Loan Dated January 22, 2020",
        "label": "Long Term Bank Loan Dated January 22 2020 [Member]",
        "documentation": "Long Term Bank Loan Dated January 22 2020"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_LongTermBankLoanDatedJuly292022Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "LongTermBankLoanDatedJuly292022Member",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long Term Bank Loan Dated July 29, 2022",
        "label": "Long Term Bank Loan Dated July 29, 2022 [Member]",
        "documentation": "Long Term Bank Loan Dated July 29, 2022"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_LongTermBankLoanDatedNovember92020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "LongTermBankLoanDatedNovember92020Member",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term bank November 9, 2020",
        "label": "Long Term Bank Loan Dated November 9 2020 [Member]",
        "documentation": "Long Term Bank Loan Dated November 9 2020"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term debt",
        "label": "Long-Term Debt, Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r230"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "bgne_LongTermFundingCommitmentMaximumAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "LongTermFundingCommitmentMaximumAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum commitment",
        "label": "Long-term Funding Commitment, Maximum Amount",
        "documentation": "Long-term Funding Commitment, Maximum Amount"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_LongTermFundingCommitmentNumberOfEquityInvestments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "LongTermFundingCommitmentNumberOfEquityInvestments",
     "presentation": [
      "http://www.beigene.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of equity investments",
        "label": "Long-Term Funding Commitment, Number of Equity Investments",
        "documentation": "Long-Term Funding Commitment, Number of Equity Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term investments",
        "label": "Long-Term Investments",
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r1373",
      "r1374",
      "r1375"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r52",
      "r1373",
      "r1374",
      "r1375"
     ]
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetConstructioninProgressDetails",
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetPropertyPlantandEquipmentNetDetails",
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Manufacturing equipment",
        "verboseLabel": "Manufacturing equipment",
        "netLabel": "Manufacturing equipment",
        "label": "Machinery and Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesConcentrationofRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]",
        "documentation": "Information by name or description of a single external customer or a group of external customers."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r1103",
      "r1143",
      "r1147",
      "r1390",
      "r1472",
      "r1474",
      "r1475",
      "r1477",
      "r1478",
      "r1479",
      "r1480",
      "r1481",
      "r1482",
      "r1483",
      "r1484",
      "r1485",
      "r1486",
      "r1487",
      "r1488",
      "r1489",
      "r1490",
      "r1491",
      "r1492",
      "r1493",
      "r1494",
      "r1495",
      "r1496",
      "r1497",
      "r1498",
      "r1499",
      "r1500",
      "r1501"
     ]
    },
    "bgne_MaterialRightsRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "MaterialRightsRevenueMember",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsRecognizedRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material rights revenue",
        "label": "Material Rights Revenue [Member]",
        "documentation": "Material Rights Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_MaximumCashAndServicesDevelopmentCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "MaximumCashAndServicesDevelopmentCommitment",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails",
      "http://www.beigene.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum cash and development services commitment",
        "label": "Maximum Cash And Services Development Commitment",
        "documentation": "Maximum Cash And Services Development Commitment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails",
      "http://www.beigene.com/role/ShareBasedCompensationFairValueAssumptionsDetails",
      "http://www.beigene.com/role/ShareBasedCompensationOptionsandRestrictedSharesandRestrictedStockUnitsVestingPeriodsDetails",
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r183",
      "r185",
      "r186",
      "r188",
      "r214",
      "r215",
      "r443",
      "r444",
      "r445",
      "r446",
      "r596",
      "r641",
      "r719",
      "r800",
      "r874",
      "r876",
      "r884",
      "r912",
      "r913",
      "r970",
      "r991",
      "r996",
      "r997",
      "r1026",
      "r1056",
      "r1057",
      "r1090",
      "r1100",
      "r1114",
      "r1123",
      "r1124",
      "r1128",
      "r1129",
      "r1144",
      "r1389",
      "r1461",
      "r1462",
      "r1463",
      "r1464",
      "r1465",
      "r1466"
     ]
    },
    "bgne_MaximumPercentageOfEligibleEarningsSetSideToPurchaseOrdinaryShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "MaximumPercentageOfEligibleEarningsSetSideToPurchaseOrdinaryShares",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensation2018EmployeeSharePurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum percentage of eligible earnings as after-tax withholdings to purchase ordinary shares (as a percent)",
        "label": "Maximum Percentage of Eligible Earnings Set a Side to Purchase Ordinary Shares",
        "documentation": "Maximum Percentage of Eligible Earnings Set a Side to Purchase Ordinary Shares"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_McKessonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "McKessonMember",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesConcentrationofRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "McKesson",
        "label": "McKesson [Member]",
        "documentation": "McKesson"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1225"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1225"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails",
      "http://www.beigene.com/role/ShareBasedCompensationFairValueAssumptionsDetails",
      "http://www.beigene.com/role/ShareBasedCompensationOptionsandRestrictedSharesandRestrictedStockUnitsVestingPeriodsDetails",
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r183",
      "r185",
      "r186",
      "r188",
      "r214",
      "r215",
      "r443",
      "r444",
      "r445",
      "r446",
      "r596",
      "r641",
      "r719",
      "r800",
      "r874",
      "r876",
      "r884",
      "r912",
      "r913",
      "r970",
      "r991",
      "r996",
      "r997",
      "r1026",
      "r1056",
      "r1057",
      "r1090",
      "r1100",
      "r1114",
      "r1123",
      "r1124",
      "r1128",
      "r1144",
      "r1389",
      "r1461",
      "r1462",
      "r1463",
      "r1464",
      "r1465",
      "r1466"
     ]
    },
    "bgne_MinimumPurchaseCommitmentsForSupplyPurchasedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "MinimumPurchaseCommitmentsForSupplyPurchasedMember",
     "presentation": [
      "http://www.beigene.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum Purchase Commitments For Supply Purchased",
        "label": "Minimum Purchase Commitments For Supply Purchased [Member]",
        "documentation": "Minimum Purchase Commitments For Supply Purchased [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minority interest in investment (as a percent)",
        "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner",
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1245"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1392"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1253"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesConcentrationofRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]",
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r1103",
      "r1143",
      "r1147",
      "r1390",
      "r1472",
      "r1474",
      "r1475",
      "r1477",
      "r1478",
      "r1479",
      "r1480",
      "r1481",
      "r1482",
      "r1483",
      "r1484",
      "r1485",
      "r1486",
      "r1487",
      "r1488",
      "r1489",
      "r1490",
      "r1491",
      "r1492",
      "r1493",
      "r1494",
      "r1495",
      "r1496",
      "r1497",
      "r1498",
      "r1499",
      "r1500",
      "r1501"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1226"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r114"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      },
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.beigene.com/role/LossPerShareDetails",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveLossDetails",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "terseLabel": "Net Income (Loss)",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r114",
      "r151",
      "r218",
      "r244",
      "r247",
      "r252",
      "r266",
      "r277",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r286",
      "r287",
      "r293",
      "r382",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r694",
      "r697",
      "r713",
      "r730",
      "r857",
      "r942",
      "r959",
      "r960",
      "r1161",
      "r1385"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
        "label": "Net Income (Loss) Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "presentation": [
      "http://www.beigene.com/role/LossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestPeriodIncreaseDecrease",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/DescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net loss period decrease",
        "label": "Net Income (Loss), Including Portion Attributable To Noncontrolling Interest, Period Increase (Decrease)",
        "documentation": "Net Income (Loss), Including Portion Attributable To Noncontrolling Interest, Period Increase (Decrease)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1225"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r1188",
      "r1199",
      "r1209",
      "r1233",
      "r1242"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1216"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1215"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1233"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1253"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1253"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental non-cash activities:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesAndLoansReceivableNetNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesAndLoansReceivableNetNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loans to subsidiaries",
        "label": "Financing Receivable, after Allowance for Credit Loss, Noncurrent",
        "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": []
    },
    "bgne_NovartisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "NovartisMember",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsNovartisDetails",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsOciperlimabOptionCollaborationandLicenseAgreementandChinaBroadMarketDevelopmentAgreementDetails",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsRecognizedRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Novartis",
        "label": "Novartis [Member]",
        "documentation": "Novartis"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.beigene.com/role/SegmentandGeographicInformationNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r1085",
      "r1339"
     ]
    },
    "bgne_NumberOfProductsInitiatedMarketingAndPromotion": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "NumberOfProductsInitiatedMarketingAndPromotion",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsOciperlimabOptionCollaborationandLicenseAgreementandChinaBroadMarketDevelopmentAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of products",
        "label": "Number Of Products Initiated Marketing And Promotion",
        "documentation": "Number Of Products Initiated Marketing And Promotion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r1079",
      "r1089",
      "r1339"
     ]
    },
    "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncomeDetails": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss) before reclassifications",
        "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r23"
     ]
    },
    "bgne_OciperlimabMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "OciperlimabMember",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsRecognizedRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ociperlimab",
        "label": "Ociperlimab [Member]",
        "documentation": "Ociperlimab"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r1078",
      "r1338",
      "r1340",
      "r1341",
      "r1342",
      "r1343"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r752",
      "r1131"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.beigene.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease Liabilities, Payments Due",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.beigene.com/role/LeasesSupplementalBalanceSheetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.beigene.com/role/LeasesMaturitiesofOperatingLeaseLiabilitiesDetails",
      "http://www.beigene.com/role/LeasesSupplementalBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.beigene.com/role/LeasesSupplementalBalanceSheetDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.beigene.com/role/LeasesSupplementalBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, current portion",
        "verboseLabel": "Current portion of operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.beigene.com/role/LeasesSupplementalBalanceSheetDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.beigene.com/role/LeasesSupplementalBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities, non-current portion",
        "verboseLabel": "Operating lease liabilities, non-current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/LeasesOtherSupplementalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows used in operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r748",
      "r755"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.beigene.com/role/LeasesSupplementalBalanceSheetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Total operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.beigene.com/role/LeasesOtherSupplementalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r758",
      "r1131"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.beigene.com/role/LeasesOtherSupplementalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term (years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r757",
      "r1131"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforward",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails",
      "http://www.beigene.com/role/IncomeTaxesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income taxes",
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails",
      "http://www.beigene.com/role/IncomeTaxesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "totalLabel": "Total",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r227"
     ]
    },
    "us-gaap_OtherAssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrentAbstract",
     "presentation": [
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current assets",
        "label": "Other Assets, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitment",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsFundingExpensesDetails",
      "http://www.beigene.com/role/CommitmentsandContingenciesDetails",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationNotestoCondensedFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Remaining portion of development funding cap",
        "terseLabel": "Other commitments",
        "label": "Other Commitment",
        "documentation": "Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsAxis",
     "presentation": [
      "http://www.beigene.com/role/CommitmentsandContingenciesDetails",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationNotestoCondensedFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Axis]",
        "label": "Other Commitments [Axis]",
        "documentation": "Information by type of other commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCommitmentsDomain",
     "presentation": [
      "http://www.beigene.com/role/CommitmentsandContingenciesDetails",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationNotestoCondensedFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Domain]",
        "label": "Other Commitments [Domain]",
        "documentation": "Other future obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Pension liability adjustments, net",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent",
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r5",
      "r12",
      "r96",
      "r97",
      "r139"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustments",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r12",
      "r139"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized holding (loss) gain, net",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r240",
      "r242",
      "r858"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncomeDetails",
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss",
        "totalLabel": "Net-current period other comprehensive (loss) income",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r19",
      "r245",
      "r248",
      "r253",
      "r283",
      "r733",
      "r734",
      "r739",
      "r836",
      "r858",
      "r1317",
      "r1318"
     ]
    },
    "bgne_OtherEquityMethodInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "OtherEquityMethodInvestmentsMember",
     "presentation": [
      "http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Equity Method Investments [Member]",
        "documentation": "Other Equity Method Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherIntangibleAssetsMember",
     "presentation": [
      "http://www.beigene.com/role/IntangibleAssetsIntangibleAssetsOutstandingDetails",
      "http://www.beigene.com/role/IntangibleAssetsUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Intangible Assets [Member]",
        "documentation": "Intangible assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r1094",
      "r1359",
      "r1360",
      "r1361",
      "r1362",
      "r1363",
      "r1364",
      "r1366",
      "r1368",
      "r1369",
      "r1370"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherLongtermLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesGovernmentGrantsDetails",
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherLongtermLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "totalLabel": "Total",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherLongtermLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "label": "Other Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_OtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "OtherMember",
     "presentation": [
      "http://www.beigene.com/role/ProductRevenueProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other [Member]",
        "documentation": "Other"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Long-Term Liabilities",
        "label": "Other Noncurrent Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of other noncurrent liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other (expense) income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other items, net",
        "label": "Other Operating Activities, Cash Flow Statement",
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherOperatingIncomeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherOperatingIncomeExpenseMember",
     "presentation": [
      "http://www.beigene.com/role/InvestmentsEquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Operating Income (Expense)",
        "label": "Other Operating Income (Expense) [Member]",
        "documentation": "Primary financial statement caption encompassing other operating income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1225"
     ]
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1315",
      "r1356"
     ]
    },
    "us-gaap_OtherSundryLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherSundryLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherLongtermLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherLongtermLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Sundry Liabilities, Noncurrent",
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r145"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1186",
      "r1197",
      "r1207",
      "r1240"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1189",
      "r1200",
      "r1210",
      "r1243"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1189",
      "r1200",
      "r1210",
      "r1243"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Axis]",
        "label": "Ownership [Axis]",
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Domain]",
        "label": "Ownership [Domain]",
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "bgne_POBEVCYMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "POBEVCYMember",
     "presentation": [
      "http://www.beigene.com/role/ProductRevenueProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "POBEVCY\u00ae",
        "label": "POBEVCY [Member]",
        "documentation": "POBEVCY"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ParentCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ParentCompanyMember",
     "presentation": [
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationNotestoCondensedFinancialStatementsDetails",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveLossDetails",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Parent Company",
        "label": "Parent Company [Member]",
        "documentation": "Registrant with controlling financial interest in one or more subsidiaries. Controlling interest in subsidiary includes, but is not limited to, primary beneficiary of variable interest entity (VIE). Controlling interest in subsidiary excludes broker-dealer with controlling financial interest in subsidiary but control is likely to be temporary."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r273"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1214"
     ]
    },
    "bgne_PaymentsDueToCollaborationPartnersTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "PaymentsDueToCollaborationPartnersTableTextBlock",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Payments Due to Collaboration Partners",
        "label": "Payments Due To Collaboration Partners [Table Text Block]",
        "documentation": "Payments Due To Collaboration Partners"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other investing activities",
        "negatedTerseLabel": "Other investing activities",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r1281",
      "r1321"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of intangible assets",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_PaymentsToAcquireInterestInSubsidiariesAndAffiliates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireInterestInSubsidiariesAndAffiliates",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of long-term investments",
        "label": "Payments to Acquire Interest in Subsidiaries and Affiliates",
        "documentation": "The cash outflow associated with the acquisition of or advances to an entity that is related to it but not strictly controlled (for example, an unconsolidated subsidiary, affiliate, and joint venture or equity method investment) or the acquisition of an additional interest in a subsidiary (controlled entity)."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_PaymentsToAcquireLongtermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireLongtermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of long-term investments",
        "label": "Payments to Acquire Long-Term Investments",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, beyond the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the long-term."
       }
      }
     },
     "auth_ref": [
      "r1321"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "terseLabel": "Purchases of property, plant and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireShortTermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of short-term investments",
        "label": "Payments to Acquire Short-Term Investments",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r109"
     ]
    },
    "bgne_PaymentsToPurchaseInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "PaymentsToPurchaseInProcessResearchAndDevelopment",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      },
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of in-process research and development",
        "label": "Payments to Purchase In-process Research and Development",
        "documentation": "The cash outflows from the purchase of in-process research and development acquired in an exclusive license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1224"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1224"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.beigene.com/role/EmployeeBenefitPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefit Plans",
        "label": "Retirement Benefits [Text Block]",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r547",
      "r549",
      "r555",
      "r573",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r593",
      "r594",
      "r595",
      "r1110"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1216"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1233"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1226"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1215"
     ]
    },
    "bgne_PiHealthIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "PiHealthIncMember",
     "presentation": [
      "http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pi Health, Inc",
        "label": "Pi Health, Inc [Member]",
        "documentation": "Pi Health, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensation2016ShareOptionandIncentivePlanDetails",
      "http://www.beigene.com/role/ShareBasedCompensation2018EmployeeSharePurchasePlanDetails",
      "http://www.beigene.com/role/ShareBasedCompensation2018InducementEquityPlanDetails",
      "http://www.beigene.com/role/ShareBasedCompensationSharesIssuedUnderEmployeeSharePurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1396",
      "r1397",
      "r1398",
      "r1399",
      "r1400",
      "r1401",
      "r1402",
      "r1403",
      "r1404",
      "r1405",
      "r1406",
      "r1407",
      "r1408",
      "r1409",
      "r1410",
      "r1411",
      "r1412",
      "r1413",
      "r1414",
      "r1415",
      "r1416",
      "r1417",
      "r1418",
      "r1419",
      "r1420",
      "r1421"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensation2016ShareOptionandIncentivePlanDetails",
      "http://www.beigene.com/role/ShareBasedCompensation2018EmployeeSharePurchasePlanDetails",
      "http://www.beigene.com/role/ShareBasedCompensation2018InducementEquityPlanDetails",
      "http://www.beigene.com/role/ShareBasedCompensationSharesIssuedUnderEmployeeSharePurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1396",
      "r1397",
      "r1398",
      "r1399",
      "r1400",
      "r1401",
      "r1402",
      "r1403",
      "r1404",
      "r1405",
      "r1406",
      "r1407",
      "r1408",
      "r1409",
      "r1410",
      "r1411",
      "r1412",
      "r1413",
      "r1414",
      "r1415",
      "r1416",
      "r1417",
      "r1418",
      "r1419",
      "r1420",
      "r1421"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1217"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1273"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1216"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1316"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets:",
        "label": "Prepaid Expense and Other Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_PrepaidGeneralAndAdministrativeExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "PrepaidGeneralAndAdministrativeExpensesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid general and administrative expenses",
        "label": "Prepaid General and Administrative Expenses, Current",
        "documentation": "Prepaid General and Administrative Expenses, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid insurance",
        "label": "Prepaid Insurance",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1065",
      "r1092",
      "r1356"
     ]
    },
    "bgne_PrepaidManufacturingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "PrepaidManufacturingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid manufacturing cost",
        "label": "Prepaid Manufacturing Costs",
        "documentation": "Prepaid Manufacturing Costs"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_PrepaidResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "PrepaidResearchAndDevelopmentCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid research and development costs",
        "label": "Prepaid Research and Development Costs",
        "documentation": "Amount of consideration paid in advance for research and development that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "bgne_PrepaidSupplyCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "PrepaidSupplyCost",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid supply cost",
        "label": "Prepaid Supply Cost",
        "documentation": "Prepaid Supply Cost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid taxes",
        "label": "Prepaid Taxes",
        "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1066",
      "r1093",
      "r1356"
     ]
    },
    "bgne_PrepaymentOfLongTermAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "PrepaymentOfLongTermAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment of property and equipment",
        "label": "Prepayment of Long Term Asset",
        "documentation": "Amount of prepayment of long term asset."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from divestiture of businesses",
        "label": "Proceeds from Divestiture of Businesses",
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "bgne_ProceedsFromIssuanceOfAssetDepositoryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ProceedsFromIssuanceOfAssetDepositoryShares",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from ADS shares",
        "label": "Proceeds From Issuance Of Asset Depository Shares",
        "documentation": "Proceeds From Issuance Of Asset Depository Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Payments to acquire equity interest",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationSharesIssuedUnderEmployeeSharePurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r16"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from option exercises and employee share purchase plan",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r16"
     ]
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from long-term loan",
        "label": "Proceeds from Long-Term Lines of Credit",
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other financing activities",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r1282",
      "r1322"
     ]
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale or maturity of short-term investments",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r256",
      "r342",
      "r375"
     ]
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromShortTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from short-term loans",
        "label": "Proceeds from Short-Term Debt",
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductConcentrationRiskMember",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product Concentration Risk",
        "label": "Product Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductMember",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.beigene.com/role/ProductRevenueAccruedSalesRebatesandReturnsDetails",
      "http://www.beigene.com/role/ProductRevenueProductSalesDetails",
      "http://www.beigene.com/role/SegmentandGeographicInformationScheduleofRevenuebyGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product revenue, net",
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r1101"
     ]
    },
    "bgne_ProductNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ProductNameAxis",
     "presentation": [
      "http://www.beigene.com/role/ProductRevenueProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product Name [Axis]",
        "label": "Product Name [Axis]",
        "documentation": "Product Name [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_ProductNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ProductNameDomain",
     "presentation": [
      "http://www.beigene.com/role/ProductRevenueProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product Name [Domain]",
        "label": "Product Name [Domain]",
        "documentation": "Product Name"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsRecognizedRevenueDetails",
      "http://www.beigene.com/role/ProductRevenueAccruedSalesRebatesandReturnsDetails",
      "http://www.beigene.com/role/ProductRevenueProductSalesDetails",
      "http://www.beigene.com/role/SegmentandGeographicInformationScheduleofRevenuebyGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r213",
      "r335",
      "r803",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r1060",
      "r1101",
      "r1142",
      "r1144",
      "r1145",
      "r1148",
      "r1149",
      "r1309",
      "r1380",
      "r1381",
      "r1390",
      "r1472",
      "r1474",
      "r1475",
      "r1476",
      "r1477",
      "r1478",
      "r1479",
      "r1480",
      "r1481",
      "r1482",
      "r1483",
      "r1484",
      "r1485",
      "r1486",
      "r1487",
      "r1488",
      "r1489",
      "r1490",
      "r1491",
      "r1492",
      "r1493",
      "r1494",
      "r1495",
      "r1496",
      "r1497",
      "r1498",
      "r1499",
      "r1500",
      "r1501"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsRecognizedRevenueDetails",
      "http://www.beigene.com/role/ProductRevenueAccruedSalesRebatesandReturnsDetails",
      "http://www.beigene.com/role/ProductRevenueProductSalesDetails",
      "http://www.beigene.com/role/SegmentandGeographicInformationScheduleofRevenuebyGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r213",
      "r335",
      "r803",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r1060",
      "r1101",
      "r1142",
      "r1144",
      "r1145",
      "r1148",
      "r1149",
      "r1309",
      "r1380",
      "r1381",
      "r1390",
      "r1472",
      "r1474",
      "r1475",
      "r1476",
      "r1477",
      "r1478",
      "r1479",
      "r1480",
      "r1481",
      "r1482",
      "r1483",
      "r1484",
      "r1485",
      "r1486",
      "r1487",
      "r1488",
      "r1489",
      "r1490",
      "r1491",
      "r1492",
      "r1493",
      "r1494",
      "r1495",
      "r1496",
      "r1497",
      "r1498",
      "r1499",
      "r1500",
      "r1501"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Abstract]",
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.beigene.com/role/LeasesNarrativesDetails",
      "http://www.beigene.com/role/LeasesSupplementalBalanceSheetDetails",
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetConstructioninProgressDetails",
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetNarrativesDetails",
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetPropertyPlantandEquipmentNetDetails",
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesLandUseRightNetDetails",
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r760"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.beigene.com/role/PropertyPlantandEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Net",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r169",
      "r172",
      "r173"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetPropertyPlantandEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetNarrativesDetails",
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetPropertyPlantandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, at cost",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r224",
      "r854"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGrossAbstract",
     "presentation": [
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetConstructioninProgressDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Property, Plant and Equipment, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetConstructioninProgressDetails",
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetNarrativesDetails",
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetPropertyPlantandEquipmentNetDetails",
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesGovernmentGrantsDetails",
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetPropertyPlantandEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetPropertyPlantandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in wholly owned subsidiaries",
        "totalLabel": "Property, plant and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r760",
      "r840",
      "r854",
      "r1132"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "presentation": [
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetPropertyPlantandEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Property, Plant and Equipment, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNetByTypeAbstract",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Property, Plant and Equipment, Net, by Type [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentOtherTypesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentOtherTypesMember",
     "presentation": [
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetConstructioninProgressDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Property, Plant and Equipment, Other Types [Member]",
        "documentation": "Long-lived, physical assets used to produce goods and services and not intended for resale, classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r169",
      "r172",
      "r852"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetTables",
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Property and Equipment Useful Life",
        "terseLabel": "Schedule of Components of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.beigene.com/role/LeasesNarrativesDetails",
      "http://www.beigene.com/role/LeasesSupplementalBalanceSheetDetails",
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetConstructioninProgressDetails",
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetNarrativesDetails",
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetPropertyPlantandEquipmentNetDetails",
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesLandUseRightNetDetails",
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r760"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful\u00a0lives (in years)",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r1214"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1214"
     ]
    },
    "bgne_REVLIMIDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "REVLIMIDMember",
     "presentation": [
      "http://www.beigene.com/role/ProductRevenueProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REVLIMID\u00ae",
        "label": "REVLIMID [Member]",
        "documentation": "Revlimid [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails",
      "http://www.beigene.com/role/IntangibleAssetsUsefulLifeDetails",
      "http://www.beigene.com/role/ShareBasedCompensationFairValueAssumptionsDetails",
      "http://www.beigene.com/role/ShareBasedCompensationOptionsandRestrictedSharesandRestrictedStockUnitsVestingPeriodsDetails",
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [Axis]",
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r183",
      "r185",
      "r186",
      "r188",
      "r214",
      "r215",
      "r443",
      "r444",
      "r445",
      "r446",
      "r547",
      "r596",
      "r627",
      "r628",
      "r629",
      "r641",
      "r719",
      "r774",
      "r783",
      "r800",
      "r874",
      "r876",
      "r884",
      "r912",
      "r913",
      "r970",
      "r991",
      "r996",
      "r997",
      "r1026",
      "r1056",
      "r1057",
      "r1090",
      "r1100",
      "r1114",
      "r1123",
      "r1124",
      "r1128",
      "r1129",
      "r1144",
      "r1152",
      "r1377",
      "r1389",
      "r1443",
      "r1462",
      "r1463",
      "r1464",
      "r1465",
      "r1466"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails",
      "http://www.beigene.com/role/IntangibleAssetsUsefulLifeDetails",
      "http://www.beigene.com/role/ShareBasedCompensationFairValueAssumptionsDetails",
      "http://www.beigene.com/role/ShareBasedCompensationOptionsandRestrictedSharesandRestrictedStockUnitsVestingPeriodsDetails",
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [Domain]",
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r183",
      "r185",
      "r186",
      "r188",
      "r214",
      "r215",
      "r443",
      "r444",
      "r445",
      "r446",
      "r547",
      "r596",
      "r627",
      "r628",
      "r629",
      "r641",
      "r719",
      "r774",
      "r783",
      "r800",
      "r874",
      "r876",
      "r884",
      "r912",
      "r913",
      "r970",
      "r991",
      "r996",
      "r997",
      "r1026",
      "r1056",
      "r1057",
      "r1090",
      "r1100",
      "r1114",
      "r1123",
      "r1124",
      "r1128",
      "r1129",
      "r1144",
      "r1152",
      "r1377",
      "r1389",
      "r1443",
      "r1462",
      "r1463",
      "r1464",
      "r1465",
      "r1466"
     ]
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "presentation": [
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name of Property [Axis]",
        "label": "Name of Property [Axis]",
        "documentation": "Information by name of property."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r201",
      "r1045",
      "r1050",
      "r1298",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1511",
      "r1512",
      "r1513",
      "r1514",
      "r1515",
      "r1516",
      "r1517",
      "r1518"
     ]
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "presentation": [
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name of Property [Domain]",
        "label": "Name of Property [Domain]",
        "documentation": "Name of the property, for example, but not limited to, ABC Shopping Center."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r201",
      "r1045",
      "r1050",
      "r1298",
      "r1299",
      "r1300",
      "r1301",
      "r1302",
      "r1303",
      "r1304",
      "r1305",
      "r1511",
      "r1512",
      "r1513",
      "r1514",
      "r1515",
      "r1516",
      "r1517",
      "r1518"
     ]
    },
    "bgne_RebatesReturnsAndOtherDeductionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "RebatesReturnsAndOtherDeductionsMember",
     "presentation": [
      "http://www.beigene.com/role/ProductRevenueAccruedSalesRebatesandReturnsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rebates, Returns and Other Deductions",
        "label": "Rebates, Returns and Other Deductions [Member]",
        "documentation": "Rebates, Returns and Other Deductions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncomeDetails": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amounts reclassified from accumulated other comprehensive loss",
        "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r23"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1181",
      "r1192",
      "r1202",
      "r1235"
     ]
    },
    "bgne_RegulatoryAndCommercialMilestonePaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "RegulatoryAndCommercialMilestonePaymentsMember",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsPaymentClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory and commercial milestone payments",
        "label": "Regulatory And Commercial Milestone Payments [Member]",
        "documentation": "Regulatory And Commercial Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_ReimbursementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ReimbursementExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmountsandClassificationofPaymentsIncomeExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Total",
        "label": "Reimbursement Expense",
        "documentation": "Reimbursement Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmountsandClassificationofPaymentsIncomeExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r574",
      "r763",
      "r764",
      "r844",
      "r851",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r939",
      "r941",
      "r966"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmountsandClassificationofPaymentsIncomeExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r270",
      "r763",
      "r764",
      "r765",
      "r766",
      "r844",
      "r851",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r939",
      "r941",
      "r966"
     ]
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmountsandClassificationofPaymentsIncomeExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangement, inventory purchases",
        "label": "Related Party Transaction, Purchases from Related Party",
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmountsandClassificationofPaymentsIncomeExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r574",
      "r763",
      "r764",
      "r844",
      "r851",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r939",
      "r941",
      "r966",
      "r1458"
     ]
    },
    "bgne_RentalDepositsAndOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "RentalDepositsAndOther",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rental deposits and other",
        "label": "Rental Deposits and Other",
        "documentation": "Amount of rental deposits and other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayment of long-term loan",
        "terseLabel": "Repayments of long-term debt",
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r894"
     ]
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfShortTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayment of short-term loans",
        "terseLabel": "Repayment of short-term loans",
        "label": "Repayments of Short-Term Debt",
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmountsandClassificationofPaymentsIncomeExpenseDetails",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsFinancingLiabilityDetails",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsFundingExpensesDetails",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsNovartisDetails",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsOciperlimabOptionCollaborationandLicenseAgreementandChinaBroadMarketDevelopmentAgreementDetails",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsRecognizedRevenueDetails",
      "http://www.beigene.com/role/CommitmentsandContingenciesDetails",
      "http://www.beigene.com/role/RestrictedCashNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]",
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r209",
      "r271",
      "r272",
      "r462",
      "r489",
      "r766",
      "r784",
      "r841",
      "r1071",
      "r1072"
     ]
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development [Abstract]",
        "label": "Research and Development [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmountsandClassificationofPaymentsIncomeExpenseDetails",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsFinancingLiabilityDetails",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsFundingExpensesDetails",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsNovartisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r644",
      "r1423"
     ]
    },
    "bgne_ResearchAndDevelopmentCostShareLiabilityCurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ResearchAndDevelopmentCostShareLiabilityCurrentPortion",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development cost share liability, current portion",
        "label": "Research And Development Cost Share Liability, Current Portion",
        "documentation": "Research And Development Cost Share Liability, Current Portion"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development cost share liability, non-current portion",
        "label": "Research And Development Cost Share Liability, Non-current Portion",
        "documentation": "Research And Development Cost Share Liability, Non-current Portion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsFundingExpensesDetails": {
       "parentTag": "bgne_FinancingCommitmentExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsFundingExpensesDetails",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development",
        "terseLabel": "Research and development expense",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r643",
      "r1058",
      "r1084",
      "r1467"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmountsandClassificationofPaymentsIncomeExpenseDetails",
      "http://www.beigene.com/role/ShareBasedCompensationSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "bgne_ResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ResearchAndDevelopmentMember",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsPaymentClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expense",
        "label": "Research And Development [Member]",
        "documentation": "Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1182",
      "r1193",
      "r1203",
      "r1236"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r1183",
      "r1194",
      "r1204",
      "r1237"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1190",
      "r1201",
      "r1211",
      "r1244"
     ]
    },
    "us-gaap_RestrictedAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.beigene.com/role/RestrictedNetAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Net Assets",
        "label": "Restricted Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for assets that are restricted in their use, generally by contractual agreements or regulatory requirements. This would include, but not limited to, a description of the restricted assets and the terms of the restriction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/RestrictedCashandInvestmentsRestrictionsonCashandCashEquivalentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.beigene.com/role/RestrictedCashNarrativeDetails",
      "http://www.beigene.com/role/RestrictedCashandInvestmentsRestrictionsonCashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r1311",
      "r1325",
      "r1469",
      "r1471"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Short-term restricted cash",
        "terseLabel": "Short-term restricted cash",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r222",
      "r262"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Domain]",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Long-term restricted cash",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r162",
      "r262"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/RestrictedCashandInvestmentsRestrictionsonCashandCashEquivalentsDetails": {
       "parentTag": "us-gaap_RestrictedCash",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/RestrictedCashandInvestmentsRestrictionsonCashandCashEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term restricted cash",
        "label": "Restricted Cash, Current",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r1311",
      "r1325"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/RestrictedCashandInvestmentsRestrictionsonCashandCashEquivalentsDetails": {
       "parentTag": "us-gaap_RestrictedCash",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/RestrictedCashandInvestmentsRestrictionsonCashandCashEquivalentsDetails",
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term restricted cash",
        "verboseLabel": "Long-term restricted cash",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r1313",
      "r1325"
     ]
    },
    "bgne_RestrictedNetAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "RestrictedNetAssetsAbstract",
     "presentation": [
      "http://www.beigene.com/role/RestrictedNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted net assets",
        "label": "Restricted Net Assets [Abstract]",
        "documentation": "Restricted Net Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_RestrictedNetAssetsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "RestrictedNetAssetsAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/RestrictedNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted net assets",
        "label": "Restricted Net Assets, Amount",
        "documentation": "Restricted net assets."
       }
      }
     },
     "auth_ref": []
    },
    "bgne_RestrictedNetAssetsAppropriatedToStatutoryReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "RestrictedNetAssetsAppropriatedToStatutoryReserves",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/RestrictedNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Appropriation to statutory reserves",
        "label": "Restricted Net, Assets Appropriated to Statutory Reserves",
        "documentation": "Amount appropriated to statutory reserves."
       }
      }
     },
     "auth_ref": []
    },
    "bgne_RestrictedNetAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "RestrictedNetAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Net Assets Disclosure [Abstract]",
        "label": "Restricted Net Assets Disclosure [Abstract]",
        "documentation": "Restricted Net Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage",
     "presentation": [
      "http://www.beigene.com/role/RestrictedNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum required statutory reserve of annual after-tax profit (as a percent)",
        "label": "Restricted Net Assets, Minimum Required Statutory Reserve of Annual After-tax Profit, Percentage",
        "documentation": "Minimum required statutory reserve of annual after-tax profit as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "bgne_RestrictedNetAssetsRequiredStatutoryReserveAsPercentageOfRegisteredCapital": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "RestrictedNetAssetsRequiredStatutoryReserveAsPercentageOfRegisteredCapital",
     "presentation": [
      "http://www.beigene.com/role/RestrictedNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Required statutory reserve as a percentage of registered capital (as a percent)",
        "label": "Restricted Net Assets, Required Statutory Reserve as Percentage of Registered Capital",
        "documentation": "Required statutory reserve as a percentage of registered capital."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationOptionsandRestrictedSharesandRestrictedStockUnitsVestingPeriodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Shares",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationOptionsandRestrictedSharesandRestrictedStockUnitsVestingPeriodsDetails",
      "http://www.beigene.com/role/ShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Share Units (RSUs)",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringReserveAcceleratedDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringReserveAcceleratedDepreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accelerated depreciation expense",
        "label": "Restructuring and Related Cost, Accelerated Depreciation",
        "documentation": "Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r132",
      "r849",
      "r881",
      "r883",
      "r895",
      "r923",
      "r1132"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r274",
      "r275",
      "r276",
      "r278",
      "r283",
      "r285",
      "r287",
      "r383",
      "r384",
      "r428",
      "r682",
      "r683",
      "r691",
      "r692",
      "r693",
      "r695",
      "r696",
      "r697",
      "r703",
      "r705",
      "r706",
      "r708",
      "r711",
      "r743",
      "r745",
      "r878",
      "r880",
      "r897",
      "r1504"
     ]
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanSponsorLocationAxis",
     "presentation": [
      "http://www.beigene.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Sponsor Location [Axis]",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r574",
      "r577",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r1393",
      "r1394",
      "r1395"
     ]
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetirementPlanSponsorLocationDomain",
     "presentation": [
      "http://www.beigene.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Sponsor Location [Domain]",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r574",
      "r577",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r1393",
      "r1394",
      "r1395"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer [Abstract]",
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.beigene.com/role/ProductRevenueProductSalesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsRecognizedRevenueDetails",
      "http://www.beigene.com/role/DescriptionofBusinessDetails",
      "http://www.beigene.com/role/ProductRevenueProductSalesDetails",
      "http://www.beigene.com/role/SegmentandGeographicInformationScheduleofRevenuebyGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenues",
        "totalLabel": "Product revenue - net",
        "verboseLabel": "Revenue from contract with customer",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r302",
      "r311",
      "r312",
      "r327",
      "r331",
      "r335",
      "r337",
      "r339",
      "r521",
      "r522",
      "r803"
     ]
    },
    "bgne_RevenueFromContractWithCustomerExcludingAssessedTaxBeforeReductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTaxBeforeReductions",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/ProductRevenueProductSalesDetails": {
       "parentTag": "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/ProductRevenueProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product revenue - gross",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax, Before Reductions",
        "documentation": "Revenue from Contract with Customer, Excluding Assessed Tax, Before Reductions"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_RevenueFromContractWithCustomerExcludingAssessedTaxPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTaxPeriodIncreaseDecrease",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/DescriptionofBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, period increase",
        "label": "Revenue From Contract With Customer, Excluding Assessed Tax, Period Increase (Decrease)",
        "documentation": "Revenue From Contract With Customer, Excluding Assessed Tax, Period Increase (Decrease)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r1059"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.beigene.com/role/ProductRevenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product Revenue",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r524"
     ]
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "presentation": [
      "http://www.beigene.com/role/SegmentandGeographicInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Product Revenues by Geographic Area",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "bgne_RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/ProductRevenueAccruedSalesRebatesandReturnsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Revenue Recognition, Allowance For Chargebacks And Credit Loss And Reserves For Sales Returns, Rebates And Other Deductions",
        "documentation": "Revenue Recognition, Allowance For Chargebacks And Credit Loss And Reserves For Sales Returns, Rebates And Other Deductions"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/ProductRevenueAccruedSalesRebatesandReturnsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Revenue Recognition Reserve For Sales Returns, Rebates And Other Deductions",
        "documentation": "Revenue Recognition Reserve For Sales Returns, Rebates And Other Deductions"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_RevenueRecognitionRevenueReduction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "RevenueRecognitionRevenueReduction",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/ProductRevenueProductSalesDetails": {
       "parentTag": "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/ProductRevenueAccruedSalesRebatesandReturnsDetails",
      "http://www.beigene.com/role/ProductRevenueProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Rebates and sales returns",
        "terseLabel": "Amounts charged against product revenue",
        "label": "Revenue Recognition, Revenue Reduction",
        "documentation": "Revenue Recognition, Revenue Reduction"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_RevenueRecognitionRevenueReductionsPaymentsAndCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "RevenueRecognitionRevenueReductionsPaymentsAndCredits",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/ProductRevenueAccruedSalesRebatesandReturnsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments and credits",
        "label": "Revenue Recognition Revenue Reductions Payments And Credits",
        "documentation": "Revenue Recognition Revenue Reductions Payments And Credits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsRecognizedRevenueDetails",
      "http://www.beigene.com/role/ProductRevenueProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://www.beigene.com/role/SegmentandGeographicInformationScheduleofRevenuebyGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/LeasesOtherSupplementalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ROU assets obtained in exchange for new operating lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r1131"
     ]
    },
    "bgne_RightToAccessIntellectualPropertyRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "RightToAccessIntellectualPropertyRevenueMember",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsRecognizedRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right to access intellectual property revenue",
        "label": "Right To Access Intellectual Property Revenue [Member]",
        "documentation": "Right To Access Intellectual Property Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_RoyaltiesReceivingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "RoyaltiesReceivingPeriod",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties receiving period",
        "label": "Royalties Receiving Period",
        "documentation": "Royalties Receiving Period"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1253"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1253"
     ]
    },
    "bgne_STARMarketMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "STARMarketMember",
     "presentation": [
      "http://www.beigene.com/role/RestrictedCashNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STAR Market",
        "label": "STAR Market [Member]",
        "documentation": "STAR Market"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.beigene.com/role/RestrictedCashNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Per share acquisition price (in dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails",
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesConcentrationofRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product Revenue",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r1283"
     ]
    },
    "bgne_ScheduleOfAccruedSalesRebatesAndReturnsCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ScheduleOfAccruedSalesRebatesAndReturnsCurrentTableTextBlock",
     "presentation": [
      "http://www.beigene.com/role/ProductRevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Sales Rebates and Returns",
        "label": "Schedule of Accrued Sales Rebates and Returns Current [Table Text Block]",
        "documentation": "Schedule of Accrued Sales Rebates and Returns Current [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "presentation": [
      "http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncomeTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accumulated Other Comprehensive (Loss) Income",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r1449",
      "r1450"
     ]
    },
    "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable",
     "presentation": [
      "http://www.beigene.com/role/IntangibleAssetsExpectedAmortizationExpenseDetails",
      "http://www.beigene.com/role/IntangibleAssetsUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]",
        "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]",
        "documentation": "Disclosure of information about acquired finite-lived intangible asset by major class."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r417",
      "r418",
      "r419",
      "r1058"
     ]
    },
    "bgne_ScheduleOfAmountsAndClassificationOfReimbursementExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ScheduleOfAmountsAndClassificationOfReimbursementExpenseTableTextBlock",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Amounts and Classification of Reimbursement Expense",
        "label": "Schedule Of Amounts And Classification Of Reimbursement Expense [Table Text Block]",
        "documentation": "Schedule Of Amounts And Classification Of Reimbursement Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsOciperlimabOptionCollaborationandLicenseAgreementandChinaBroadMarketDevelopmentAgreementDetails",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsPaymentClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Current and Deferred Components of the Income Tax Expense (Benefit)",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1432"
     ]
    },
    "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock",
     "presentation": [
      "http://www.beigene.com/role/SECScheduleArticle1204CondensedFinancialInformationofRegistrantTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Condensed Balance Sheets",
        "label": "Condensed Balance Sheet [Table Text Block]",
        "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r1292",
      "r1331"
     ]
    },
    "srt_ScheduleOfCondensedCashFlowStatementTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfCondensedCashFlowStatementTableTextBlock",
     "presentation": [
      "http://www.beigene.com/role/SECScheduleArticle1204CondensedFinancialInformationofRegistrantTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Condensed Statements of Cash Flows",
        "label": "Condensed Cash Flow Statement [Table Text Block]",
        "documentation": "Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r1292",
      "r1331"
     ]
    },
    "srt_ScheduleOfCondensedFinancialStatementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfCondensedFinancialStatementsTable",
     "presentation": [
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationNotestoCondensedFinancialStatementsDetails",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Condensed Financial Statements [Table]",
        "label": "Condensed Financial Statements [Table]",
        "documentation": "Disclosure of information about condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r212",
      "r273",
      "r1280"
     ]
    },
    "srt_ScheduleOfCondensedIncomeStatementTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfCondensedIncomeStatementTableTextBlock",
     "presentation": [
      "http://www.beigene.com/role/SECScheduleArticle1204CondensedFinancialInformationofRegistrantTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Condensed Statements of Operations",
        "label": "Condensed Income Statement [Table Text Block]",
        "documentation": "Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r1292",
      "r1331"
     ]
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://www.beigene.com/role/DebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Short-Term and Long-Term Debt Obligations",
        "label": "Schedule of Debt [Table Text Block]",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Deferred Tax Assets (Liabilities)",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1428"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.beigene.com/role/LossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of the Computations of Basic and Diluted Loss Per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1337"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of the Statutory Tax Rate to Effective Income Tax Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r655",
      "r1118",
      "r1424"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Total Compensation Cost Recognized",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Axis]",
        "label": "Investment, Name [Axis]",
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r380",
      "r381",
      "r690",
      "r1277",
      "r1278",
      "r1279",
      "r1433",
      "r1434",
      "r1435",
      "r1436"
     ]
    },
    "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock",
     "presentation": [
      "http://www.beigene.com/role/EmployeeBenefitPlansTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Expected Benefit Payments",
        "label": "Schedule of Expected Benefit Payments [Table Text Block]",
        "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.beigene.com/role/IntangibleAssetsAmortizationExpenseDetails",
      "http://www.beigene.com/role/IntangibleAssetsIntangibleAssetsOutstandingDetails",
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesLandUseRightNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Asset, Finite-Lived [Table]",
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r420",
      "r423",
      "r424",
      "r426",
      "r804",
      "r1058",
      "r1094"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.beigene.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets Outstanding",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r1094",
      "r1365"
     ]
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income\u00a0(Loss) Before Income Taxes",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r1329"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.beigene.com/role/InventoriesNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r90",
      "r91",
      "r92"
     ]
    },
    "us-gaap_ScheduleOfInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInvestmentsLineItems",
     "presentation": [
      "http://www.beigene.com/role/InvestmentsEquityMethodInvestmentsDetails",
      "http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails",
      "http://www.beigene.com/role/RestrictedCashNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investments",
        "label": "Schedule of Investments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r988",
      "r990",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035"
     ]
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInvestmentsTable",
     "presentation": [
      "http://www.beigene.com/role/InvestmentsEquityMethodInvestmentsDetails",
      "http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails",
      "http://www.beigene.com/role/RestrictedCashNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investments [Table]",
        "label": "Schedule of Investments [Table]",
        "documentation": "Disclosure of information about investments owned by investment company."
       }
      }
     },
     "auth_ref": [
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r988",
      "r990",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035"
     ]
    },
    "us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherAssetsNoncurrentTextBlock",
     "presentation": [
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Non-Current Assets",
        "label": "Schedule of Other Assets, Noncurrent [Table Text Block]",
        "documentation": "Tabular disclosure of noncurrent assets."
       }
      }
     },
     "auth_ref": [
      "r1313"
     ]
    },
    "bgne_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets",
        "label": "Schedule of Prepaid Expenses and Other Current Assets [Table Text Block]",
        "documentation": "Tabular disclosure of prepaid expenses and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetConstructioninProgressDetails",
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetNarrativesDetails",
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetPropertyPlantandEquipmentNetDetails",
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesGovernmentGrantsDetails",
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r760"
     ]
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmountsandClassificationofPaymentsIncomeExpenseDetails",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsFinancingLiabilityDetails",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsFundingExpensesDetails",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsNovartisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development, Contract to Perform for Others [Table]",
        "label": "Research and Development, Contract to Perform for Others [Table]",
        "documentation": "Disclosure of information about research and development arrangement accounted for as contract to perform research and development for others. Includes, but is not limited to, royalty arrangement, purchase provision, license agreement, and commitment to provide additional funding."
       }
      }
     },
     "auth_ref": [
      "r644",
      "r1423"
     ]
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "presentation": [
      "http://www.beigene.com/role/RestrictedCashTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restrictions on Cash and Cash Equivalents",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r141",
      "r1471"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://www.beigene.com/role/SegmentandGeographicInformationScheduleofRevenuebyGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r98"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.beigene.com/role/RestrictedNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r46"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensation2016ShareOptionandIncentivePlanDetails",
      "http://www.beigene.com/role/ShareBasedCompensation2018EmployeeSharePurchasePlanDetails",
      "http://www.beigene.com/role/ShareBasedCompensation2018InducementEquityPlanDetails",
      "http://www.beigene.com/role/ShareBasedCompensationFairValueAssumptionsDetails",
      "http://www.beigene.com/role/ShareBasedCompensationOptionsandRestrictedSharesandRestrictedStockUnitsVestingPeriodsDetails",
      "http://www.beigene.com/role/ShareBasedCompensationRestrictedShareUnitsDetails",
      "http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails",
      "http://www.beigene.com/role/ShareBasedCompensationSharesIssuedUnderEmployeeSharePurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r598",
      "r600",
      "r602",
      "r603",
      "r604",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Shares Issued Under Employee Share Purchase Plan",
        "label": "Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of employee stock purchase plan activity."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share Option Activities",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r135"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of the Range of Fair Values and the Assumptions Used to Estimate the Fair Values of the Share Options Granted",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r137"
     ]
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Employee Restricted Shares Activities and Restricted Share Units Activities",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Gross Unrecognized Tax Benefits",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r1117"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of each class",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1163"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name of each exchange on which registered",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1166"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesCurrentandDeferredComponentsIncomeTaxesDetails",
      "http://www.beigene.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails",
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetNarrativesDetails",
      "http://www.beigene.com/role/RestrictedNetAssetsDetails",
      "http://www.beigene.com/role/SegmentandGeographicInformationScheduleofRevenuebyGeographicAreaDetails",
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesLandUseRightNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r184",
      "r187",
      "r189",
      "r196",
      "r197",
      "r198",
      "r199",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r337",
      "r338",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r909",
      "r910",
      "r911",
      "r976",
      "r992",
      "r1013",
      "r1032",
      "r1042",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1061",
      "r1102",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1146",
      "r1152",
      "r1390",
      "r1472",
      "r1474",
      "r1475",
      "r1477",
      "r1478",
      "r1479",
      "r1480",
      "r1481",
      "r1482",
      "r1483",
      "r1484",
      "r1485",
      "r1486",
      "r1487",
      "r1488",
      "r1489",
      "r1490",
      "r1491",
      "r1492",
      "r1493",
      "r1494",
      "r1495",
      "r1496",
      "r1497",
      "r1498",
      "r1499",
      "r1500",
      "r1501"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting [Abstract]",
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureOfEntitysReportableSegmentsAbstract",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment information",
        "label": "Segment Reporting, Disclosure of Entity's Reportable Segments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.beigene.com/role/SegmentandGeographicInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment and Geographic Information",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r302",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r317",
      "r318",
      "r319",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r335",
      "r336",
      "r339",
      "r1079",
      "r1082",
      "r1083",
      "r1084",
      "r1086",
      "r1088",
      "r1089"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.beigene.com/role/RestrictedNetAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r334",
      "r337",
      "r1080",
      "r1081",
      "r1087"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Selling, general and administrative",
        "terseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmountsandClassificationofPaymentsIncomeExpenseDetails",
      "http://www.beigene.com/role/IntangibleAssetsAmortizationExpenseDetails",
      "http://www.beigene.com/role/IntangibleAssetsExpectedAmortizationExpenseDetails",
      "http://www.beigene.com/role/ShareBasedCompensationSharebasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, General and Administrative Expense",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "bgne_ShanghaiChinaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ShanghaiChinaMember",
     "presentation": [
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shanghai, China",
        "label": "Shanghai, China [Member]",
        "documentation": "Shanghai, China"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_ShanghaiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ShanghaiMember",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesLandUseRightNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shanghai",
        "label": "Shanghai [Member]",
        "documentation": "Shanghai"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_ShanghaiPharmaceuticalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ShanghaiPharmaceuticalMember",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesConcentrationofRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shanghai Pharmaceutical",
        "label": "Shanghai Pharmaceutical [Member]",
        "documentation": "Shanghai Pharmaceutical"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_ShanghaiPudongDevelopmentBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ShanghaiPudongDevelopmentBankMember",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shanghai Pudong Development Bank",
        "label": "Shanghai Pudong Development Bank [Member]",
        "documentation": "Shanghai Pudong Development Bank"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensation2016ShareOptionandIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationOptionsandRestrictedSharesandRestrictedStockUnitsVestingPeriodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period of award (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r1115"
     ]
    },
    "bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountOnPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountOnPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensation2018EmployeeSharePurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount on purchase price of common stock (as a percent)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Discount on Purchase Price of Common Stock, Percent",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Discount on Purchase Price of Common Stock, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additonal disclosures",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Shares - Expected to vest (in shares)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expected To Vest Outstanding Number",
        "documentation": "Represents, as of the balance sheet date, the number of non-vested equity-based payment instruments, excluding stock (or unit) options that are expected to vest."
       }
      }
     },
     "auth_ref": []
    },
    "bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair value- Expected to vest (in dollars per share)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expected To Vest Weighted Average Grant Date Fair Value",
        "documentation": "Represents, as of the balance sheet date, the weighted average grant date fair value of non-vested equity-based payment instruments, excluding stock (or unit) options that are expected to vest."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r619"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r617"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at the beginning of the year (in shares)",
        "periodEndLabel": "Outstanding at the end of the year (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r614",
      "r615"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numbers of\u00a0Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at the beginning of the year (in dollars per share)",
        "periodEndLabel": "Outstanding at the end of the year (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r614",
      "r615"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Grant\u00a0Date\u00a0Fair\u00a0Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationRestrictedShareUnitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r618"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant unobservable inputs used in the fair value measurement",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield (as percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected exercise multiple, maximum",
        "label": "Share-based Compensation Arrangement by Share Based Payment Award, Fair Value Assumptions Expected, Exercise Multiple, Maximum",
        "documentation": "Represents the expected maximum exercise multiple that is used as an assumption in estimating the fair value of share-based compensation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, maximum (as percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, minimum (as percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, maximum (as percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, minimum (as percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensation2016ShareOptionandIncentivePlanDetails",
      "http://www.beigene.com/role/ShareBasedCompensation2018EmployeeSharePurchasePlanDetails",
      "http://www.beigene.com/role/ShareBasedCompensation2018InducementEquityPlanDetails",
      "http://www.beigene.com/role/ShareBasedCompensationFairValueAssumptionsDetails",
      "http://www.beigene.com/role/ShareBasedCompensationOptionsandRestrictedSharesandRestrictedStockUnitsVestingPeriodsDetails",
      "http://www.beigene.com/role/ShareBasedCompensationRestrictedShareUnitsDetails",
      "http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails",
      "http://www.beigene.com/role/ShareBasedCompensationSharesIssuedUnderEmployeeSharePurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r598",
      "r600",
      "r602",
      "r603",
      "r604",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensation2016ShareOptionandIncentivePlanDetails",
      "http://www.beigene.com/role/ShareBasedCompensation2018EmployeeSharePurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in ordinary shares authorized (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensation2016ShareOptionandIncentivePlanDetails",
      "http://www.beigene.com/role/ShareBasedCompensation2018EmployeeSharePurchasePlanDetails",
      "http://www.beigene.com/role/ShareBasedCompensation2018InducementEquityPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares reserved and available for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1116"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensation2016ShareOptionandIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensation2018EmployeeSharePurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering period",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Offering Period",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Offering Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Remaining Contractual Term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriod",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensation2016ShareOptionandIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares cancelled or forfeited (in shares)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Cancelled or Forfeited in Period",
        "documentation": "The number of shares under options granted in a plan that were canceled after the initial public offering date, as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options - Exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price - Exercisable (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at the beginning of the year (in shares)",
        "periodEndLabel": "Outstanding at the end of the year (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r606",
      "r607"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number\u00a0of Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at the beginning of the year (in dollars per share)",
        "periodEndLabel": "Outstanding at the end of the year (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r606",
      "r607"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic\u00a0Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price - Vested and expected to vest (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options - Vested and expected to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensation2016ShareOptionandIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding number of shares (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensation2016ShareOptionandIncentivePlanDetails",
      "http://www.beigene.com/role/ShareBasedCompensationFairValueAssumptionsDetails",
      "http://www.beigene.com/role/ShareBasedCompensationOptionsandRestrictedSharesandRestrictedStockUnitsVestingPeriodsDetails",
      "http://www.beigene.com/role/ShareBasedCompensationRestrictedShareUnitsDetails",
      "http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Award [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r602",
      "r603",
      "r604",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r612"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r610"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r597",
      "r605",
      "r624",
      "r625",
      "r626",
      "r627",
      "r630",
      "r636",
      "r637",
      "r638",
      "r639"
     ]
    },
    "bgne_ShareBasedPaymentArrangementNonvestedAwardOptionNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ShareBasedPaymentArrangementNonvestedAwardOptionNumberOfShares",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee service share based compensation nonvested stock options",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Number of Shares",
        "documentation": "Employee Service Share Based Compensation Nonvested Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_ShareIncentivePlan2011Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ShareIncentivePlan2011Member",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensation2016ShareOptionandIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2011 Plan",
        "label": "Share Incentive Plan2011 [Member]",
        "documentation": "2011 Share Incentive Plan."
       }
      }
     },
     "auth_ref": []
    },
    "bgne_ShareOptionAndIncentivePlan2016Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ShareOptionAndIncentivePlan2016Member",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensation2016ShareOptionandIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2016 Plan",
        "label": "Share Option And Incentive Plan2016 [Member]",
        "documentation": "The 2016 Share Option and Incentive Plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationFairValueAssumptionsDetails",
      "http://www.beigene.com/role/ShareBasedCompensationSharesIssuedUnderEmployeeSharePurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Market price, Ordinary (in dollars per share)",
        "terseLabel": "Fair value of ordinary share (in dollars per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "bgne_SharePriceAmericanDepositoryShares": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "SharePriceAmericanDepositoryShares",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails",
      "http://www.beigene.com/role/ShareBasedCompensationSharesIssuedUnderEmployeeSharePurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share price, ADS (in dollars per share)",
        "terseLabel": "Market price, ADS (in dollars per share)",
        "label": "Share Price, American Depository Shares",
        "documentation": "Price of each American Depository Share. Each American Depositary Share represents 13 ordinary shares of the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationFairValueAssumptionsDetails",
      "http://www.beigene.com/role/ShareBasedCompensationOptionsandRestrictedSharesandRestrictedStockUnitsVestingPeriodsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual life (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable at the end of the period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date\u00a0Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total fair value of the employee share option awards vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock."
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberOfAvailableSharesAvailableForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardNumberOfAvailableSharesAvailableForFutureIssuance",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensation2018EmployeeSharePurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for future issuance (in shares)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number Of Available Shares Available For Future Issuance",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number Of Available Shares Available For Future Issuance"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationSharesIssuedUnderEmployeeSharePurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price, ADS (in dollars per share)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued In Period American Depository Shares Exercise Price",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period American Depository Shares Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensationSharesIssuedUnderEmployeeSharePurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase Price, Ordinary (in dollars per share)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued In Period Exercise Price",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_ShortTermBankLoanDatedApril42018Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ShortTermBankLoanDatedApril42018Member",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short Term Bank Loan Dated April 4 2018",
        "label": "Short Term Bank Loan Dated April 4 2018 [Member]",
        "documentation": "Short Term Bank Loan Dated April 4 2018"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_ShortTermBankLoanDatedDecember202023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ShortTermBankLoanDatedDecember202023Member",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short Term Bank Loan Dated December 20, 2023",
        "label": "Short Term Bank Loan Dated December 20, 2023 [Member]",
        "documentation": "Short Term Bank Loan Dated December 20, 2023"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_ShortTermBankLoanDatedJanuary222020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ShortTermBankLoanDatedJanuary222020Member",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short Term Bank Loan Dated January 22, 2020",
        "label": "Short Term Bank Loan Dated January 22, 2020 [Member]",
        "documentation": "Short Term Bank Loan Dated January 22, 2020"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_ShortTermBankLoanDatedJuly282023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ShortTermBankLoanDatedJuly282023Member",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short Term Bank Loan Dated July 28, 2023",
        "label": "Short Term Bank Loan Dated July 28, 2023 [Member]",
        "documentation": "Short Term Bank Loan Dated July 28, 2023"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_ShortTermBankLoanDatedJune52023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ShortTermBankLoanDatedJune52023Member",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short Term Bank Loan Dated June 5 2023",
        "label": "Short Term Bank Loan Dated June 5 2023 [Member]",
        "documentation": "Short Term Bank Loan Dated June 5 2023"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_ShortTermBankLoanDatedMarch212024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ShortTermBankLoanDatedMarch212024Member",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short Term Bank Loan Dated March 21, 2024",
        "label": "Short Term Bank Loan Dated March 21, 2024 [Member]",
        "documentation": "Short Term Bank Loan Dated March 21, 2024"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_ShortTermBankLoanDatedMay252023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ShortTermBankLoanDatedMay252023Member",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short Term Bank Loan Dated, May 25, 2023",
        "label": "Short Term Bank Loan Dated, May 25, 2023 [Member]",
        "documentation": "Short Term Bank Loan Dated, May 25, 2023"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_ShortTermBankLoanDatedMay302023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ShortTermBankLoanDatedMay302023Member",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short Term Bank Loan Dated May 30 2023",
        "label": "Short Term Bank Loan Dated May 30 2023 [Member]",
        "documentation": "Short Term Bank Loan Dated May 30 2023"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_ShortTermBankLoanDatedMay42023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ShortTermBankLoanDatedMay42023Member",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short Term Bank Loan Dated May 4 2023",
        "label": "Short Term Bank Loan Dated May 4 2023 [Member]",
        "documentation": "Short Term Bank Loan Dated May 4 2023"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_ShortTermBankLoanDatedNovember142023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ShortTermBankLoanDatedNovember142023Member",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short Term Bank Loan Dated November 14, 2023",
        "label": "Short Term Bank Loan Dated November 14, 2023 [Member]",
        "documentation": "Short Term Bank Loan Dated November 14, 2023"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_ShortTermBankLoanDatedNovember92020Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ShortTermBankLoanDatedNovember92020Member",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short Term Bank Loan Dated November 9, 2020",
        "label": "Short Term Bank Loan Dated November 9, 2020 [Member]",
        "documentation": "Short Term Bank Loan Dated November 9, 2020"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_ShortTermBankLoanMaturingJanuary272025Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ShortTermBankLoanMaturingJanuary272025Member",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short Term Bank Loan Maturing January 27, 2025",
        "label": "Short Term Bank Loan Maturing January 27, 2025 [Member]",
        "documentation": "Short Term Bank Loan Maturing January 27, 2025"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term Debt, Type [Axis]",
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r1373",
      "r1374",
      "r1375"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://www.beigene.com/role/DebtShorttermandLongtermDebtObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term Debt, Type [Domain]",
        "label": "Short-Term Debt, Type [Domain]",
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r1373",
      "r1374",
      "r1375"
     ]
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term lease cost",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r753",
      "r1131"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r263"
     ]
    },
    "bgne_SinopharmMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "SinopharmMember",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesConcentrationofRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sinopharm",
        "label": "Sinopharm [Member]",
        "documentation": "Sinopharm"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "presentation": [
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetPropertyPlantandEquipmentNetDetails",
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software, Electronic and Office Equipment",
        "verboseLabel": "Software, electronics and office equipment",
        "label": "Software and Software Development Costs [Member]",
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAdministrationOfTaxationChinaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAdministrationOfTaxationChinaMember",
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State Administration of Taxation, China",
        "label": "State Administration of Taxation, China [Member]",
        "documentation": "Designated tax department of the government of China."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails",
      "http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r232",
      "r233",
      "r234",
      "r266",
      "r291",
      "r292",
      "r294",
      "r296",
      "r304",
      "r305",
      "r382",
      "r449",
      "r451",
      "r452",
      "r453",
      "r456",
      "r457",
      "r487",
      "r488",
      "r491",
      "r494",
      "r501",
      "r730",
      "r891",
      "r892",
      "r893",
      "r894",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r922",
      "r943",
      "r961",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1276",
      "r1326",
      "r1336"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncomeDetails",
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.beigene.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r84",
      "r87",
      "r88",
      "r216",
      "r250",
      "r251",
      "r252",
      "r274",
      "r275",
      "r276",
      "r278",
      "r283",
      "r285",
      "r287",
      "r303",
      "r383",
      "r384",
      "r428",
      "r502",
      "r682",
      "r683",
      "r691",
      "r692",
      "r693",
      "r695",
      "r696",
      "r697",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r711",
      "r733",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r743",
      "r745",
      "r762",
      "r858",
      "r878",
      "r879",
      "r880",
      "r897",
      "r961"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesCurrentandDeferredComponentsIncomeTaxesDetails",
      "http://www.beigene.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails",
      "http://www.beigene.com/role/PropertyPlantandEquipmentNetNarrativesDetails",
      "http://www.beigene.com/role/RestrictedNetAssetsDetails",
      "http://www.beigene.com/role/SegmentandGeographicInformationScheduleofRevenuebyGeographicAreaDetails",
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesLandUseRightNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r182",
      "r184",
      "r187",
      "r189",
      "r196",
      "r197",
      "r198",
      "r199",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r337",
      "r338",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r909",
      "r910",
      "r911",
      "r976",
      "r992",
      "r1013",
      "r1032",
      "r1042",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1061",
      "r1102",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1146",
      "r1152",
      "r1390",
      "r1472",
      "r1474",
      "r1475",
      "r1477",
      "r1478",
      "r1479",
      "r1480",
      "r1481",
      "r1482",
      "r1483",
      "r1484",
      "r1485",
      "r1486",
      "r1487",
      "r1488",
      "r1489",
      "r1490",
      "r1491",
      "r1492",
      "r1493",
      "r1494",
      "r1495",
      "r1496",
      "r1497",
      "r1498",
      "r1499",
      "r1500",
      "r1501"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275",
      "r276",
      "r303",
      "r745",
      "r803",
      "r886",
      "r908",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r922",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r941",
      "r944",
      "r945",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r961",
      "r1153"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionLocationActivityAccrualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionLocationActivityAccrualAxis",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsPaymentClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position Location, Activity, Accrual [Axis]",
        "label": "Statement of Financial Position Location, Activity, Accrual [Axis]",
        "documentation": "Information by location in statement of financial position in which disaggregated accrual activity has been included."
       }
      }
     },
     "auth_ref": [
      "r1437",
      "r1451"
     ]
    },
    "us-gaap_StatementOfFinancialPositionLocationActivityAccrualDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionLocationActivityAccrualDomain",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsPaymentClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position Location, Activity, Accrual [Domain]",
        "label": "Statement of Financial Position Location, Activity, Accrual [Domain]",
        "documentation": "Location in statement of financial position in which disaggregated accrual activity has been included."
       }
      }
     },
     "auth_ref": [
      "r1437",
      "r1451"
     ]
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275",
      "r276",
      "r303",
      "r340",
      "r745",
      "r803",
      "r886",
      "r908",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r922",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r941",
      "r944",
      "r945",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r961",
      "r1153"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1185",
      "r1196",
      "r1206",
      "r1239"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.beigene.com/role/ShareBasedCompensationSharesIssuedUnderEmployeeSharePurchasePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise of options, ESPP and release of RSUs (in shares)",
        "terseLabel": "Number of Ordinary Shares Issued ( in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r83",
      "r84",
      "r132"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmgenDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares issued (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r83",
      "r84",
      "r132",
      "r891",
      "r961",
      "r1037"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.beigene.com/role/ShareBasedCompensationShareOptionRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares reserved for share option exercises (in shares)",
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r83",
      "r84",
      "r132",
      "r611"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of options, ESPP and release of RSUs",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r83",
      "r84",
      "r132"
     ]
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.beigene.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cancellation of ordinary shares (in share)",
        "terseLabel": "Cancellation of ordinary shares (in share)",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "documentation": "Number of shares that have been repurchased and retired during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r83",
      "r84",
      "r132"
     ]
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedAndRetiredDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.beigene.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cancellation of ordinary shares",
        "terseLabel": "Cancellation of ordinary shares",
        "label": "Stock Repurchased and Retired During Period, Value",
        "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r83",
      "r84",
      "r132"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/AccumulatedOtherComprehensiveLossIncomeDetails",
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFSHAREHOLDERSEQUITY",
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total shareholders\u2019 equity",
        "periodStartLabel": "Balance at the beginning of period",
        "periodEndLabel": "Balance at the ending of period",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r87",
      "r88",
      "r120",
      "r924",
      "r940",
      "r962",
      "r963",
      "r1132",
      "r1162",
      "r1328",
      "r1355",
      "r1448",
      "r1504"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.beigene.com/role/ShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shareholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r265",
      "r486",
      "r488",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r500",
      "r502",
      "r710",
      "r964",
      "r965",
      "r1041"
     ]
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "presentation": [
      "http://www.beigene.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock, Type [Table]",
        "documentation": "Disclosure of information about sale of stock made by subsidiary or equity method investee to investor outside consolidated group by type of sale. Includes, but is not limited to, stock issued in business combination in exchange for share of acquired entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.beigene.com/role/RestrictedCashNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://www.beigene.com/role/ShareholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsidiary, Sale of Stock",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Valuation Allowance",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance."
       }
      }
     },
     "auth_ref": [
      "r1429"
     ]
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.beigene.com/role/SupplementalBalanceSheetInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental Balance Sheet Information",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r1310"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental cash flow disclosures:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_SuzhouMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "SuzhouMember",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesLandUseRightNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Suzhou",
        "label": "Suzhou [Member]",
        "documentation": "Suzhou"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SwissFederalTaxAdministrationFTAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SwissFederalTaxAdministrationFTAMember",
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Swiss Federal Tax Administration (FTA)",
        "label": "Swiss Federal Tax Administration (FTA) [Member]",
        "documentation": "Designated tax department of the government of Switzerland."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1232"
     ]
    },
    "bgne_TaxBenefitFromForeignTaxStatus": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "TaxBenefitFromForeignTaxStatus",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax benefit from foreign tax status",
        "label": "Tax Benefit From Foreign Tax Status",
        "documentation": "Tax Benefit From Foreign Tax Status"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_TaxBenefitFromForeignTaxStatusPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "TaxBenefitFromForeignTaxStatusPerShare",
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax benefit from foreign tax status (per share)",
        "label": "Tax Benefit From Foreign Tax Status, Per Share",
        "documentation": "Tax Benefit From Foreign Tax Status, Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforwards",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r679"
     ]
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax payable",
        "label": "Taxes Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73"
     ]
    },
    "bgne_ThirdAmendedAndRestated2016PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ThirdAmendedAndRestated2016PlanMember",
     "presentation": [
      "http://www.beigene.com/role/ShareBasedCompensation2016ShareOptionandIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Third Amended and Restated 2016 Plan",
        "label": "Third Amended And Restated 2016 Plan [Member]",
        "documentation": "Third Amended And Restated 2016 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_ThreeLargestCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "ThreeLargestCustomersMember",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesConcentrationofRisksDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Three Largest Customers",
        "label": "Three Largest Customers [Member]",
        "documentation": "Three Largest Customers"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_TislelizumabMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "TislelizumabMember",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsRecognizedRevenueDetails",
      "http://www.beigene.com/role/ProductRevenueProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tislelizumab",
        "label": "Tislelizumab [Member]",
        "documentation": "Tislelizumab [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1224"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1231"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable and Allowance for Credit Losses",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r1345",
      "r1346",
      "r1347"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1252"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r1254"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.beigene.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol(s)",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r483",
      "r499",
      "r709",
      "r726",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r859",
      "r1119",
      "r1121",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1133",
      "r1285",
      "r1286",
      "r1287",
      "r1288",
      "r1289",
      "r1290",
      "r1291",
      "r1348",
      "r1349",
      "r1350",
      "r1351",
      "r1439",
      "r1442",
      "r1443",
      "r1444",
      "r1445",
      "r1447"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1255"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1256"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1256"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1254"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r1254"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r1257"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1255"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsAmountsandClassificationofPaymentsIncomeExpenseDetails",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsNovartisDetails",
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsOciperlimabOptionCollaborationandLicenseAgreementandChinaBroadMarketDevelopmentAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r698"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://www.beigene.com/role/EmployeeBenefitPlansAdditionalInformationDetails",
      "http://www.beigene.com/role/IncomeTaxesCurrentandDeferredComponentsIncomeTaxesDetails",
      "http://www.beigene.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails",
      "http://www.beigene.com/role/SegmentandGeographicInformationScheduleofRevenuebyGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S.",
        "verboseLabel": "U.S. - total revenue",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Treasury securities",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r1075",
      "r1108",
      "r1110",
      "r1119",
      "r1470"
     ]
    },
    "us-gaap_UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnconditionalPurchaseObligationCategoryOfGoodsOrServicesAcquiredDomain",
     "presentation": [
      "http://www.beigene.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain]",
        "label": "Unconditional Purchase Obligation, Category of Goods or Services Acquired [Domain]",
        "documentation": "General description of the goods or services to be purchased from the counterparty to the unconditional purchase arrangement."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r439",
      "r441",
      "r442"
     ]
    },
    "us-gaap_UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnconditionalPurchaseObligationsExcludingCapitalStockRedemptionsAbstract",
     "presentation": [
      "http://www.beigene.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase and Capital commitments",
        "label": "Unconditional Purchase Obligations (Excluding Capital Stock Redemptions) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r1251"
     ]
    },
    "bgne_UnrealizedGainLossInSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "UnrealizedGainLossInSubsidiaries",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/ScheduleICondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized losses on long-term investments",
        "label": "Unrealized Gain (Loss) In Subsidiaries",
        "documentation": "Unrealized Gain (Loss) In Subsidiaries"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrealizedGainLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized losses on long-term investments",
        "label": "Unrealized Gain (Loss) on Investments",
        "documentation": "Amount of unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails",
      "http://www.beigene.com/role/IncomeTaxesNarrativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "periodStartLabel": "Beginning balance, as of January 1",
        "periodEndLabel": "Ending balance, as of December 31",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r646",
      "r666",
      "r1117"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Reductions based on tax positions related to prior tax years",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r667",
      "r1117"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additions based on tax positions related to the current tax year",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r668",
      "r1117"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions based on tax positions related to prior tax years",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r667",
      "r1117"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "crdr": "debit",
     "presentation": [
      "http://www.beigene.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Reductions based on lapse of statute of limitations",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations."
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase commitments",
        "label": "Unrecorded Unconditional Purchase Obligation",
        "documentation": "Amount of unrecorded obligation to transfer funds in future for fixed or minimum amount or quantity of product and service at fixed or minimum price. Includes, but is not limited to, lease not yet commenced and take-or-pay and throughput contracts."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r1455"
     ]
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis",
     "presentation": [
      "http://www.beigene.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]",
        "label": "Unrecorded Unconditional Purchase Obligation by Category of Item Purchased [Axis]",
        "documentation": "Information by category of product and service for unrecorded unconditional purchase arrangement to acquire product or service or both."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r439",
      "r441"
     ]
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecordedUnconditionalPurchaseObligationLineItems",
     "presentation": [
      "http://www.beigene.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecorded Unconditional Purchase Obligation [Line Items]",
        "label": "Unrecorded Unconditional Purchase Obligation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r439",
      "r441"
     ]
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecordedUnconditionalPurchaseObligationTable",
     "presentation": [
      "http://www.beigene.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecorded Unconditional Purchase Obligation [Table]",
        "label": "Unrecorded Unconditional Purchase Obligation [Table]",
        "documentation": "Disclosure of information about unrecorded unconditional purchase obligation arrangement to purchase product and service. Includes, but is not limited to, information about asset pledged to secure payment and payment due in each of next five years and thereafter."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r439",
      "r441"
     ]
    },
    "bgne_UpfrontAndMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "UpfrontAndMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsPaymentClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Upfront And Milestone Payments",
        "documentation": "Upfront And Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_UpfrontPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "UpfrontPaymentsMember",
     "presentation": [
      "http://www.beigene.com/role/CollaborativeandLicensingArrangementsPaymentClassificationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payments",
        "label": "Upfront Payments [Member]",
        "documentation": "Upfront Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.beigene.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r42",
      "r43",
      "r165",
      "r167",
      "r170",
      "r171"
     ]
    },
    "us-gaap_ValueAddedTaxReceivableNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValueAddedTaxReceivableNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/SupplementalBalanceSheetInformationScheduleofOtherNoncurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid VAT",
        "label": "Value Added Tax Receivable, Noncurrent",
        "documentation": "Carrying amount due after one year of the balance sheet date (or one operating cycle), if longer of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities."
       }
      }
     },
     "auth_ref": [
      "r1313"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.beigene.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.beigene.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease cost",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r754",
      "r1131"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1220"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.beigene.com/role/InvestmentsInvestmentsInEquitySecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r1150",
      "r1151",
      "r1154",
      "r1155",
      "r1156",
      "r1157"
     ]
    },
    "srt_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://www.beigene.com/role/IntangibleAssetsUsefulLifeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average",
        "label": "Weighted Average [Member]",
        "documentation": "Average of a range of values, calculated with consideration of proportional relevance."
       }
      }
     },
     "auth_ref": [
      "r719",
      "r783",
      "r1056",
      "r1057",
      "r1123",
      "r1461",
      "r1463",
      "r1466"
     ]
    },
    "bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average ADSs outstanding, basic (in shares)",
        "label": "Weighted Average Number Of American Depository Shares Outstanding, Basic",
        "documentation": "Weighted Average Number of American Depository Shares Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average ADSs outstanding, diluted (in shares)",
        "label": "Weighted Average Number Of American Depository Shares Outstanding, Diluted",
        "documentation": "Weighted Average Number Of American Depository Shares Outstanding, Diluted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.beigene.com/role/LossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average shares outstanding\u2014 diluted (in shares)",
        "terseLabel": "Weighted average shares outstanding for computing diluted loss per share (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r296"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.beigene.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.beigene.com/role/LossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average shares outstanding\u2014basic (in shares)",
        "terseLabel": "Weighted average shares outstanding for computing basic loss per share (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r296"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://www.beigene.com/role/LossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "bgne_XGEVAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.beigene.com/20241231",
     "localname": "XGEVAMember",
     "presentation": [
      "http://www.beigene.com/role/ProductRevenueProductSalesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "XGEVA\u00ae",
        "label": "XGEVA [Member]",
        "documentation": "XGEVA"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1218"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(j)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(k)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/220/tableOfContent"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479024/942-230-45-1"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/942-320/tableOfContent"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "b",
   "Publisher": "SEC"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column C",
   "Footnote": "5",
   "Publisher": "SEC"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column C",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column C",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column F",
   "Footnote": "7",
   "Publisher": "SEC"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Footnote": "5",
   "Publisher": "SEC"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "m",
   "Subparagraph": "(1)(iii)",
   "Publisher": "SEC"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "m",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "5",
   "Subsection": "04",
   "Paragraph": "c",
   "Subparagraph": "Schedule I",
   "Publisher": "SEC"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "7",
   "Subsection": "05",
   "Paragraph": "c",
   "Subparagraph": "Schedule II",
   "Publisher": "SEC"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "9",
   "Subsection": "06",
   "Publisher": "SEC"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-10"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479391/326-20-30-4A"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479391/326-20-30-5A"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479366/326-20-35-8A"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-5"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-17"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-21"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3C"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3D"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.M.2.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483530/326-20-S99-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479175/326-30-30-1B"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "13A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479148/326-30-35-13A"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479148/326-30-35-7A"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3A"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3C"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3D"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-5"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-6"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-3"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-4"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-8"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-12"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-11"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Subparagraph": "(a)",
   "Publisher": "SEC"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Subparagraph": "(ii)",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "1",
   "Publisher": "SEC"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r1300": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r1301": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r1302": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r1303": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r1304": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r1305": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r1306": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r1307": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r1308": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r1309": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r1310": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/210/tableOfContent"
  },
  "r1311": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1312": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1313": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1314": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1315": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1316": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1317": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1318": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1319": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1320": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1321": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r1322": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1323": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1324": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1325": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r1326": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1327": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1328": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1329": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1330": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1331": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1332": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1333": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1334": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1335": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1336": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1337": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1338": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1339": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1340": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1341": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1342": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1343": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1344": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1345": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1346": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1347": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r1348": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1349": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1350": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1351": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1352": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4"
  },
  "r1353": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r1354": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1355": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1356": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r1357": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r1358": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1359": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1360": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1361": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1362": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1363": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1364": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1365": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1366": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1367": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1368": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1369": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1370": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1371": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5"
  },
  "r1372": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1373": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1374": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1375": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1376": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481850/410-20-50-1"
  },
  "r1377": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1378": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1379": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r1380": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1381": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1382": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1383": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1384": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1385": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1386": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1387": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1388": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r1389": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1390": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1391": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1392": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1393": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480606/715-80-35-1"
  },
  "r1394": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r1395": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-9"
  },
  "r1396": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1397": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1398": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1399": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1400": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1401": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1402": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1403": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1404": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1405": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1406": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1407": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1408": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1409": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1410": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1411": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1412": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1413": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1414": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1415": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1416": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1417": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1418": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1419": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1420": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1421": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1422": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1423": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1424": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1425": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1426": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1427": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1428": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1429": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1430": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1431": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1432": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1433": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1434": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1435": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1436": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1437": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1438": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1439": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1440": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1441": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1442": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1443": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1444": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1445": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1446": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1447": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1448": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1449": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r1450": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r1451": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3"
  },
  "r1452": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1453": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1454": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1455": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1456": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1457": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1458": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1459": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1460": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1461": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1462": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1463": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1464": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1465": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1466": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1467": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1468": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/940-320/tableOfContent"
  },
  "r1469": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1470": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1471": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1472": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1473": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1474": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1475": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1476": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1477": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1478": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1479": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1480": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1481": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1482": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1483": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1484": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1485": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1486": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1487": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1488": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1489": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1490": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1491": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1492": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1493": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1494": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1495": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1496": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1497": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1498": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1499": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1500": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1501": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1502": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1503": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1504": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1505": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1506": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1507": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1508": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1509": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1510": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1511": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1512": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1513": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1514": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1515": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1516": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1517": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1518": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1519": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>156
<FILENAME>0001651308-25-000031-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001651308-25-000031-xbrl.zip
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M,( YP[Q=_Y0]![_L#8-@?/K^_=/3T_YSCSO['A^\9Z[#7(IS?A]PXOHX)1(
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M1$^$V^*?7ZF/(Y)6PHSF9#::H'WO&[.$?Y^UUYSV*:@EB_ISW QT0D]]X;_
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M1RGKY$71(_:M1BGK)'S10_7M12GY5&$VBAZ_YQ.EY,2LHL?\^4<I.3&NZ%C
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MM A_+;I>6F[:'DB!&W 1N7>8_VW> 4#1L&8NWN HSJAK#4>$?YLZ)) XU.^
MJ+HAO:6[&:&:->U0JA<E],;Z0GW?<TN9W&69U [Y>E$FHP/3[H>$CXA%PP!/
M5"LE=)<E5#M@[T4)?1AR2J\)'U _B']_JP+:LBPOE,4?E#V2GK.;Z2>SIAUR
M^;(69:XW1@WZ5N5RNXHSKX!(.RRV-.VEA&8D5#M8N@S92PG-2*AV"/V+$MH>
M,I=TJ.^%W'IUGW4IF8663.WR#B]*YB6(9!D5Y105Y26BVJ554$3;2'O*QT"#
MR2T9I5,IM]XC?,M^6##Q-??<LT,KN.-=RA^9E7Y-VW,<TO.4I,Q-U:B;=C-:
M-K7,U)1RD;>^,+7,CY1RD7.%A6EJF:/(7RXZ;# ,'CQP)ZCO7\%@'(=:04@<
MN <('$R4#[RC5D3+O$ I%3G;$"V1^%(J<K8@6D+A^4O%#5"4,^((Z?!WVUQH
MB36_31'(RS9H">:^31'(RQ!HB9KF+P*9$/,N&%*^HU:@A"3UX'].)J!>0H]Z
M\#\G_5\O(<;7^;^;JK]>HHBYLSXOK5]"A;FS/B^%_U;QP*C8 "LA[OHMSHD[
M$&U>IKN>QB+P2%-7K5\:4ENH41#6M(7:K!<-VGM@OD,=]E<X(KVWDCC,R^07
M#?-[B[*1ET]0-##P+<I&7DY#T5#"O&1CAY'">M&0PEV6@9QL1*-H:.$NRT!.
MMJ!1-,0P+QG833/0*!IJN*/LS\L"% TYW%'VYZ7\-XX>KDH($V>W'"',=1*B
M:"C;6X!1ZVN$41M%@\KN+ 83=-@;0D/R<H&*AI2]0='(RSTJ&E#V!D4C+]>I
M:/C9]D1#D[T8.9F39M% M3<G&#D9DV;1D+8W)Q@YF9)FT3"X[0G&&]K U2P:
M%+?;4I"7D2A:/=]N2T%>%J%H<&1.<><.UV<T2\!2&Q'(RQ:4P*0V(I"7(2@!
M2!W2LWG9@!)CU('[.:G_@Q)(U('[.6G^@Z*AA:W1@+I7KK4.UG>POD ^6W3=
M92X;A:^=YO"#C#9/EF8T7+I&1A<-_=LDH\GS#C.Z: #?DHS^#G8D13[3%/ZA
M(I^#HH%GFZ.P%@*O'8IE4W9Z30?$N1#CV8!26ZEGN_)P-&C9_B9.6CLH&J2V
M'?6 'FZS6J\MY^%F+OTQ=A0-WMJ&/9RF\(_90RW1H[LGEW)_R,8ITIY1!K2E
MUX']H[KOAU6\1NS3#OZ)S44 JQ[O:3O$]^_ZW<"SIBQ*VQN-/%?\4!B"'VJ'
MN.A"<!WLQ>&.(B(%]:8.=Q2W*"A:?%BB"SK!MX<E%#''6#?7"/8<:H<NZ$#A
MQCHIK%V\'/DZ0$5O1&.GZ-JS!,0Q[1#Y 7A*B&SLJ 76+H#6E#]YF63MPF]-
M^9.7C=8VOEZ*/UWJ.,P=?*(NY<1IN7;+'C&7^8'<I7WQ/(;'[JKN.](V5"\0
M[W+2BT?:!?(%Y%U..O-(NZA_)=[-WZBL6+:CFE([8* P',M+/VJ''12&8WEI
MQ1W%(I86#&W:!VFA<;7#34IIR%&;:X?2E-*0HZ70%A/J4 =F9=^C1#P %WQB
MH6WWSR;I7Z9-??++.LJ!WZ)4;B@]<J0MN%4*6NZ"MLXLT7$QD3C9=V9NJ/*C
MG)_>HI3A:]L;82 D1I)4!(M;OH[['&A[3R9XX8X"M\?%!/_>O+CDY#T?%Q-O
M?//BDI-[?5Q,L%-#<4D/@3G4#SR7[KAE*B;L6LJ.#F9*.P"XE)W"V"SMX.+O
MY5V'#D*(TST^ 5G"_0B46XPXJ_)Q:=F.I?JN?\E<XN++[CV?X=!B0;=@_+@1
MR+)X2)S4:*]<"'H'K.?0EN_3G;5JVL'/I73MD-W3#LXNI6N'+*.V&'8W[/G,
M9H1/L#YV[GZ\J_N[#2/5W8=6YX;P;YO8K[^AK,2)=F QTK@+;[1#Y./%GR'#
M#$,P].PK]Q&6OJA=F?F6TBE>7%,R?AA23L8T#)BUQOQ!WEL_-R4)VN' I20L
M+PGK3""=: ?Q[H(D_$;0[2F09= .N2VE( ==H!T&NR8IN&>?*7&"X>9WV-8:
M:V.&=J!FP9BQUI6A'4JX)F:([MWS[]Y 6+LIZZ4=RE9T[JQU[6B'4D7V^9SY
M8\\GSB?NA6-AQN&!\S959"Z4'ZA]US\3^,.M%\!7.&GFAO U$$<\8FU@U502
MZ8PXQ+5H=TAI(/:_V0*V(@Z.PO'\D%/_;)(9L@^/<$*;N8/Y(RVZJ=06J2HE
M;,L2]OU)GXPX_@AP6J]I![.5XE@X<5P;CE^O:8?UK;2A4?A BG/N0-ZRRUN&
MX6DEOPJ4A:W7M,/."L*O?/*:]9IV*%>J(_D8S]N]!WN'E@XC/U&+-:]]^5G(
M'#1P18D#ZS7M *WOHOLU<5]KDZP-,E*O:8=;Z4GSM<JY=FC4=]'\AEA#YE)1
MD1-?6!S!UQ9TTIP):UT)VN(R2S%!)A!E)9O')\5;!*:V0(2^]%^G_)O:1MXK
M*:&NUP^>"*=P7?1G:I\ -JHL3*JH;FH;7!>*)6M=)=K&SZOYJ)3X=.@Y]M5H
MS+U'6J@4:MW<C:!X^TQ8ZTK0+D(6IT12XESX""(A^&Y9X2@4[4#.Z9A3BPE(
MZ9SZ%F=C<1YX/^)8RHI_AF^>J.-<$HLY[-4N(AJM"^T"Z)Q8LJ'U6B0PQ=0N
ML!=E)A&\^XEZ T[&0V9E-JMTA\0=# EK0R!)-I\Q:>20<#6U"_;7S9@BK3XM
M)$([Y*$8$M'V0$'R4+0$NW+AU@&G_A;VYN8A(_5BHR-YL^Q@>98=K(UENP&H
M++Q8Y&+Q^N($CO7= %3R9LDZP\BZMH#*)7-90*_9([6G]U"?36[('QX716E3
MM6@2V*+V [6&KN=X@TF'#88% E?JVH(K!6+(6E>(=D#+#S%$Z*C--R78U.K0
M#F(I&#/6NC*TPSAR455+A7,=;&PBWX<??Z/X9&JW'BDG@PT4SVUJ_6F'GFQ]
M_;TI=FL'C>AS+N*&2-[0%FG0^\BU3;%#.Q3A%7#0PBY$?'+ZM;M)0">/O0X-
M[="#_%F1TS:&AG:H0?ZLR&F'0D,[O&!)5K1O=TY!:8<4Y,^*O!24=CA!_JS(
M2T%IAQ(LDUYM.8X(#D531\ZH?_%LT7$@LJW@U7[%8-,6#_'O^JT1$,3:0L%$
M+EI-NY"_H/S+2Q5J%\,7E'\YZ<^FYH#  WENA<'0XRS=]C;3^2Z- 6"%(=PB
M_MI0F=F&H("F=E# 2HQX8KY_26V$9?#*#$LN'UK%88-V,, J;+C"%M$N<3KT
MD;HA[5+^R"QZU>D6A_[:Q?YQB2)SZ5V_S:G-@JA2.652A+9)5T"=$?>UWKM+
MO_N<]H(K\6@<=*9.S^/! ^4C?-NU1URT!'9KS)G3K-?,XW4-('X/CF1.^2:\
MV;\G$])SBI-^:&J';92BEK>HZ1 2-;4#>DJYS%LN-U1CT=0.R%I%U&XHMX8P
M=S]'.?L?XH:$3^IUX$QMUT1MK=96.Z"N%+6\14T+:ZL= %G*9=YRN2EKJQU6
M6C11N\6-]/"HDUT4M75:VP-M8=U2U-ZRM3W0%N4NY5(#%;A.:WN@+9*_%(QR
M]7#5WHJ877ON8-:G"YU)'46LOFLBME8K6^QDQ:Z)&+XF>,O&M=@)C5T31UTT
MWEJ-:J%S$SKX;T+.CI$MNR9G:[6L96*BE#/M[&N9PBB%<AM&MM@I"9C[D+J#
M',7LG%KB40B1[)ZHK=7.%CLE48K:CIK:PV+G+TJY+(ZU/2QT2N+*M4,0"D:<
M'(7MAH!K63=1!^R:I*W3V!X6.B-12MJNVMI"9S%*L2R0J2UT@D(/ ,6E![OH
MT:W5SI9)BE+,=#.R94*CE,DM6-BBIB@^=\^VD_Q?Y,!-FKLH6VLUJT5-2Y2R
MM6.VM*A)BU(0M3>@1X5./&@"ADP:.YEU6*<Q/2JS#J6<Z698C\H$12F4VS"R
M1<TX1,<BWH>VYPY2YYQKL"',W$G?;JTVMZCIAU+LWHX)+FKNHI310EOD,CWQ
MXXY??2?3$VNUP$5-3^BHW79+XK0POD7-<)1:<'=ELJC)CE(FB^0 'A<Z[['U
MIK/3+036WVXVSV86&_+^C@N=\RAE;.=LZW&A\QVE0!;"L!8UUY&#_S:_,<\F
MVLMJ(FAKM:Y%S6Z4@K;+)K:H^8Q2*@MF9\L,QH\)VD8:RVHB:&NULT7-892"
MMLMVMDQ=E%*Y%3M;Z'S$SC69U43"UFE@3XJ=BB@E3'L==E(F(M:P'WOGCGW2
MP8\[*71*0@,_;F<5X%I-;+&3$KFV5[PA0<B9.XCTWQ'PYF G]-^FA*W0B8G-
M["HK[9QV>0'!\GONV>!9W9(130G"6>?KEZO;;NM'N>_S('K#'>]2_LBL*<:K
M7W>4Y]I!]&^(YXWE>=Y8)\^U0\O?$,_KR_.\ODZ>:X=%O\#S!^8[U&%_A2/2
MVQ6^YZ7?M8.&WQC?\]'QC9IV@.T;XWL^>KY1TPY&?8'O__YT\>O.&/9\%'RC
MIATX^588GI=FUPXG?"L,STNE:X?5O12N75_=MG]_N-L5GN>EU0L%Q>T8S_-2
M[(6"XG:,YWGI]B)!<5]^O^_<75]U=X7G>>GV(D%QN\;SO'1[D6"X7>-Y3KK=
M+!($=W]W=O%K^_==87E.JMTL$OJV8RS/2;.;1<+?=HSE>2GV(B%PG8M?KZ]N
MKLYWA>=Y:?8B@7"[QO.\5'N10+A=XWE>NKU((-Q=,*1\5QB>EV(O$@*W4PS/
M2ZL7"7[;*8;GI=*UP]X6,T2:<MJ#R?H=&H3<]5NN+:3@G-IR?Z&_?C:E=IG4
MU[?+I%'7#@%[A?)M&#\GK4[+LGA(G )16CO@*4>ELRD::X?T:*='=+#O=>W0
MF=R5CA9LT0Y T6[U;*:S0J.N'8R1^X+8%*6U P_TL,)KI;%V\;IV>D0'6*6N
M792=N]+1@BUE++R"WEICQX5&HXR%MT7I,A;>/(VUBX5C2CK$G0)1NT/"Z=T8
M]04HD"O7PK<\4KRR#D/8)-'-0]3SZR*Z=I'M:T2?IK6YFU:UH5ULJ]-JT()#
MVL7 NG+(/%Z:0].7_AB'M(N=->:065^:0VM<0]I%WKIRJ%ZKU@Z7U'+BTD9M
M/1S2+NB..-1Z(MR>[:EV,1H[WH32;N!9WR2W?C39K9-,;,KYUBZ(UXGHWU]R
M4&NL2U4VM0OV7^#0PY!QNP57VM0&%G4H4"F@-G('K]Z\0[BLJFRN454VM0,)
M7N 0]KNT*#[GXL\0QJH6SVM'_/U8Y'J<I?8/::QFD>""V"BAYKH/L7NR3XM'
M\B*!!5LFN0[>=+-(F$&>2V)]?E.S2"! CDLB-YM<) @@MR4Q3?(?6Q)%BNGS
MM1+++HEI*_YC2T+;B%XO_N"B.$[9B5=4UO':K'B10O%<5=;QNJSX09%BZYR7
M1+U:/UER2:0O_:$E<5"DR#K7)9$F^8\MB3*\7KKV>5DKT5BCE3@H8_'ERD37
M:"7*\'KI)0%ZZ'C))9&^],>61!F++[DDTB3_L251AM=+)XV6M1+U=5J),A9?
M;DO?&JU$&5XOO226M1+U=5J),KQ><DFLS4H<EN'UMNLY#K6-F-=6MK,&+"./
MLM%#;0/K[154X>:%#G$'ZDWX\8:Y;!2.=I3GV@;K^?*</.\PS[5%"Q;P'(NT
M.+,":@NN?W59X'>Z7W>4.]IB!<MQ9T>YHBV<D*?7LBD745ML8#<=D4VQ45N\
M83=]BTVQ45M88N=7XSI;B1QI"W7L_&I<*QMW'S[1=36NL[W>48FUY+4:U\K&
MW8=/?C1@RZD#WU'10([M<R:G#L5'!0<X-@<_I924N4XE533L(A^\+Z_E4#2P
M(X_EL%:;7318(I_ED)?=+AK:D,=R6&= >5PT7" /@J\33SO6-H+O8BL$O$=N
MO&][H['GPD<_RX"6986CT,&V"0^<N#[\A?TN[#]"/\"["V,)CK4-PE?GQ"T-
MOKJ<$H?]1>TK]Y%*7GPBS+WV_.*<[7"L;42].D_.:9^YU#ZC+OP18*667\15
MHFTDK:V^TL&1.M8VS"Z <M."@=J&[=IK0BW8IVU<KZW:W%2$HVW 7P!-N"F>
M:!OF:Z_<-L21$VUQ &WUE0Z%B2<[A";DZ^;EQ< = B'R=//R8M\.X17;=_/6
MB:N>[!!.D:>;MU:>[! (D9^;MU:.%!U5@.]'GKN-K2:B0\NRP$'FTA^S*$4'
M#K;,(?-@:0XEE_X8A[0#%+!V,N;.)^H-.!D/F44<R1G+"]V 3T[;MT704-I!
M WE3=XUA?K.F;9C?H0'C@L1H6[N@6GR/7WN6]$<W2&D-PHAF3=LP7@^VY /B
M-VO:!N=ZL"6?FLEF3=N@>P6V?.WNG!+3-@+7@RUY*3%M@W ]V)*7$M,V$E_%
MMGS>.26F;?BM!UOR4F+:Q=QZL24O):9=L!ZQ!?%SR^,VM;^Z,&B;(3N($_7-
MN^LY;"!8=#9IP_0''I_<]:\@QH^NL%.M]]3VXN@G1+B8P'W]2X]WP_'8F<2W
M%04*;IK:0@'KXEWT/,R@N(''&2U,ZJ1I:HL(K)L[;3)F 7%:MGQ2@5BD+3IP
M%PPI3VFIS/&*43;1OPR!>>X@N:XXE-<. %@2(WXAC%GJ%??<LT,KN.-=RA^9
M-;4U2OVZDY4635,[=.$-\3PGK]_4#KIX0SS/*:0PM<-%<N6Y,-IMSW%(S^-D
M9[M/-TWM<)>WQ?:\-+QVN,[;8GM>2EX[W.C'BSP*8]ASTO!U[?"F-\3SG-1[
M73L4ZPWQ/"?=7M<.%LN5YV_%@:\7%9/;$;;GI>&+"LOM"-OS4O)%0^;PYXN0
M>V.ZH^JW:+#9UAB2EV(L&J"U-8;DI;**!C4MS9#"1"1YZ<:BH4V[Q_F<E'"C
M:)C3[G$^)VW?*!KRM W.OQ4LHE$T"&HGF9^7SB\:$+63S,]+[1<-CA*,:3F.
M*ME$;(I1_^+9HN.@/60N:;DV]CC'=N?P$/^NWQH!02RR*_Y!7B:B: #6FQ>4
MO,Q)T8"U-R\H>9F>H@%^&@K*FPE0BH9%EK*2GP$J&GI9RDIN-JBI)=[9QCW1
M#K-A6O8%#@O$(0E][PF'1V$W.>).=E/=-[4$(_5A2TZ:M:DE3*@/6_)28EH"
M>+FR94/[:)M:HF6Z4'J=?1>;6L)-NE!ZC>>5-9M:XC6Z4'J-!TLWF]H!'IOM
M?U H1G^GF7C/GD\Y];V06]27'X>4V&(\-GO\^#/\(_C/K)-FSZZ;!W52-YNU
M9IV8YC$]-H^/37) 3'KPO^CS)O?XP<0!.1@QMSJD;# ,3AN-_:.#<?#AB=G!
M\-2LU?ZQ)R[]^+,/U(ENL#S'XZ=_ SFI]?L?^C#.:I^,F#,Y_=<#4-XW;NF3
MT?%&Q/U7Q2>N7_5A9NI"G_U%X<'P#O'Q2;ZW6:M]<)A+HW&8]=H_/N#LJS;V
M-1'1X2F(!N5X%8R):#,68\AI_Y>]O[U.?%B:#Z3G4,/K&VUD+LC[S^\)< 2)
M&S%FACWBU<1A _?4@ELHWUO(#1CY]U"@/D6!HSD4V/OX]?;JX>+<Z#ZT'BZZ
MV3%K.-KN1?MKY^KAZJ)KM&[/C8M_MS^W;C]=&.V[FYNK;O?J[G;A%$:$#V!)
M]+P@\$:G)KQNXY,Z66I.OQ%_",HQ\-R*<;[?WC?JM8/FR6OS"+SQZ<&"201"
M'M7U/6P@Q*L60C)CGYY&?WRPF3]VR 04EAB3N.E#EDKX@D?* T2<U$O$^^3/
M2I_43_;KC1-4*0'HKL".7JRTS3[,\?WL]R?'^R>U^3_5]DWQ_7OQ/![]&"FS
M<; G[H&)((E^V6OL3<T5:0,,-H1Y,"(&CHF-1NBT9L!O\?/?BWEK+/*7=YV;
M?_[-/*Q]^!E,A.NYMZ' \ QE23JHIZRJN6>X!.V_3=GIN6>%:,KP3.\]843Z
M<,%'LU;](@Q-\I2/1BEHWR]HB3+Y/EG;-@5/3O:/:D<K4W#_L-9XD8#+/NGX
M>-\\.5J&%XL('Q&V/GXVYNKP&2)XXW4OW*/7UJUPL-[=$/[-N'/I3_$*"^SO
MF)9#^S.<E4S=]+QF7"8Q+Z6+TG/*E6<MSHAC?'69Y=G4N.G^T.165[$MUPV)
MTZ%CCP=[1M_C(Q* S_X<G/;9,[6K 0]C%5Q'ZIT<-0\_3&OA]8M(;G+?NKW]
MVKHV.A?W=YT'X_YKI_NU=?M@/-P9X+P]@(<F!<AL&'<=PSQX9_\DO[B[-!X^
M7Q@I#R_V[EKM!^/N4MUWTFBN(GR1Z@1BTR7TRP]>OKDQY.>GO,IVZ:9XW B&
MU.@S'X30F%#"#0KAE&VLOJ;N1<A\(9'M[*+":+\Z@D<,\;:J3295?%65NM$B
M:ZZRBMLA1YC@4@SZ=WC0LB]-WM?8^WA.+8E0( J07=@5 Q&"A<M=4V;>=8KC
M%98^C=;V41QU*=K-+K:1?>+XL9$\4$:RN<M&\J'3NNU>H37,V5 >%M"SCDQ-
M$(N6(4%6H\^]D9R]GO\&G@ZC2/\[*R$+'8VL;FYL T [7LI:B;2"CXD!\#[
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M-%9[TJ)!F8?[1_75X*3-#PHHU:S5?P286JH>LQ#NX0,+9(DW)=;0L!SB^RO
M1:]$A3M$)DZ$QNQ.1CW/>>>O4OOV9H@4 >="E.BS-23N +YPC:<A@V\2U;T*
MJ+9>\HR8;3M4]U!!V;N)6>^)]1F[*T=['U6C ]<XIV//9P'A$Z,[)!Q]1T%X
M3L?P =$@D%=,LG,@4?JJ,>'&(W%":OR]M@\S-C'+;/CXZP\@QUN5\F*P42D-
MJ3-B'A[O?;R[;9>4WL2"N5!*1V8K9U(H\.M48'T"JAW\PUOBV^1/XY/C]2 J
MZX++; 4&UCG38$,) ?VHO8J>^#_K$]="T:AV"$'%&YT[KI-NX%G?C(O8M/>-
MSQY8F2_X3XQ6?W_A33Y1\_^1 ;',[(.2<64L:3RQ8"BB1ZZBZBB+)2+*A6;8
M>(>Q=[WVH77>]<6?YH>?DH=]Q;1-*J!%0#4F:%+QLV\@O;UH3?KRT?"/X7J!
MX: C9:."PV(QX9G"V,7C15<D0[9%,GIA(.Z9<SU,94F.QA/Z_.7B.9K05JJ$
MYO-K?WE@)A^!6AVN&,S"%8([G9NS-.NGQ4%=SI-"%1">$-X%KP!=#=P+A%3C
M?G6/^Y&,W%-O[- 8(>K0<=ASP,#B1E]LKB5D4HD,_HDB W]Z\N[N0ZNC;",^
ML$/=$7-[;'_>@%>15<P&R^]1SL2+HT?T0W? $(&)5]$T)=1+T@]0Q92X"K,^
M\<OW2U>@(MX/XW0]@S["C?!JQX$O)^DI]J@A@"$@-_P)J@/5M: X?/,=PYP=
M!?R*24$#'NP3[07_RK4Q 4V-WL2PAA04RPCWBK$Y8FH0XXDZ#@IA[>3#-]=[
M@L%2XGLNT@^EF%>P[,JF?>9*U=P)46AQF31K!Y'LI]8:K)K]58%AF0OY#4;R
M!8?052.X$@.(MS?5]C[^3F=R+ME"TRU7K2N\5&VZVH N7FX$AB3"K:<),9H?
M=FF-H.[C],^0<:G3114P%]L-_!?L20/51O:KI,I>K9O8XB>K!D1<.R[F)]*K
MZI!?/2=TT0W$:FONQ[K#W/MXZVFO.@JV6IZ&5-2799?,J?'.5%(^!-.!JP5\
M"##;T9))KZ4>51? D^<LG]D5D[(TZ<6#A@BWI!@V_*J\"W V+"H\';,NGR$V
MV4%H $]&1\@/K2'X!!X6$$=[/((A":9UP!/Q9Q6 N%E-Z2?IJ+RKI^;=HQ38
M%/;^0! #;A+7PYTX'O4PT;Q(NF0X7.('QDE-/L$F$_\[S:C:="CW0R'P!8Y=
MF*R$>FE%2RN:AUXP<%7 @E#QD$#WN.<BKN),T+T'!_T*X19BB5J,<Q(0XU+:
MVHS"2)Z1-KXS?FF'#D)'H@5=Y> ^8!!M'AY],.J-^G[LOX*-!TTRQFT$6]$?
M<@*Q1J#^3]^YU%/D0FJIE1\O]4:YU,NEGLM2%Y&E R.'T-RR8*ES(M '=,K0
M5L[]%AQM5RW4N3_[(] 4\"X>6398(*+_G@C0X:%@4)%6 V/ O:=@&/V,0!\5
M(Q1AK-C2*5 ;!:@M&J<"V:++7KU@\?BB"]%)4!<O&&MT92;0-NL]19>Z,2]P
M,%ZMJDD52>E89],T#U:MLZDW]T_J)VLI::GO-]:TUZIQN'_0?'FS_M+S.UGC
M_ Y.#C:T 4RW]D'?LRF7MV%-#[QY=<"R1Z=8[9:Z*$E;UIM['Z_GZX[-]Q98
ME<AK[=,P';9N,@6GFX2U9GF=-V_7VW\KZXZL?\-=GK.[]=SJG,6ZZPQ\*VNS
MN\@#RY_%.?7)D59.T.4L].%!OO]JBYSZDCUREE0+J^Y9?"O">C$_ GCCHAI1
MY9,@BFJP_KK('JX@LKI7PESU7PAF<6O2DJDKQ-L$R@:&#G-8@6>$O@R$@06R
M>]Z<)D<02^.[G F^7*3Z,=_NPM0\U*R/S!>&$[?+HIR .<7-<G@Q=J:W";=]
M SLD,'M^N85A-MZ1G^8'LCL)AJ2R(,HR86V!J*P( @I$$U0! F$_$]P9.Q"9
M@;@RA/@^J&W\*B(:[?>I0/U<M9<-[V08O;O $5QCW',,W-2<8E1B%$4?^I@=
MS5KS72_F1Y?P'H''5N^>'3H1J95WYH&HEVKO&T?U0]S5\Q-./)FE*JP1U2LI
M<>@S/I)XZ!C>3? BD"!5&X,C)J'- C6N_943?E=6G[?P"1YO)72\=,C@U4:I
M1Z]W2M55\OJ&GZI:X_25VB9#[,(RDHJFA?HC+;R)T/C1Z8!SRYQ2%7OR-I7=
MZHO*7?S*\CBG<>,)5&N<8[[+0YEX9%[H.Y-().:]=?\[^GM>,K<;C((+?%,[
M?O\BP<C:D>/7[8BNDO$R6U&'"PYZ8 (D$Q+>1)*4XK98MW'2 A67Y8D4#>@G
M9^(S7S42083DD59[!*T"V@WJ^E*A8?8$?A*IW?CM:?F)%=ST_EONI],P'&S8
M(XI;/ 1EJ=+B+M,Z]69MWZR=5TV0^1TU)@)9]X?4<2*/P'BWJ$#K%=SXI^F*
M$T6P.#FR\F[V+HYK:9_MI+!:N"6D_W]"5Q&Z?BP;\58$C1U,Y/=4M&78Y"71
M'WF^$&Q81J (A=]%T5\#)>^Y=M3N^,]0-#F3CR># 3P(!68DRS_E[@#UCJE:
MQ_1.]DA+ UOP:JQU7+!9:>8AP%>QCE,9FCYJ>UDR.F,8,.%)QN $/C.0  HS
M^[L2I4N1K@3M$+I,"E+HVWM3DE7? WFVX%;'_V6O>CPK9_?"U[AT/!) 4 04
M@E]/XH[)M;V/Q_M'D4Q%;_QH])CC,#P&12JK<*P*0"W'\W'B8XXUGHMY)8I#
MU3TO;%7!2V9%8W'5J)*L9EV>HB3JV/&T(-![!)7BS+E*269&K():<@OI^9X3
M!K.WR%7R\><>?S_=.B+U[Y G$>8 =#JGY%N5]$'R3HGS1"8^QMWE&5"ZGP&U
M;94HDG=2)5[2'@==-5'VIRED_Z!B+%S]4L%,*X!&6@%<W5[.*7+R1B/LU^=9
MW^1^C[LP$.$G+.2LY7'#4=7V! _P@;&^J,7Z H^NJ32.CRJ-PZ/*4:TYJSEF
M].$+F[(JQA/%30+)>"I(&;GY]OBH5CDY;E0.C^HS5>GB-J%HIQ3UX6'EY.2X
M J99Z6P,'8'JE=K!0:5^6)-W)@7Q*Q2HI[/!AWETT)C?LN3\KOWUYN+VH6M<
MW;;O.O=WG1:>(G;VN]&YN+SH7-RV+[)S7#E&\).^C]0^F\"E0$/P9A_@OC,'
MI"J6#C!&%$1F# \0,:2._LC#=%R&Z(X?E2K*Q4CBZH='+&WRGB=)F)4MI(KK
MIJ)5W!(P$,-@,E6>&(,1((WJ3^FNR$M21S1$!QC('QJFLHC&/>(1JA9#%$.]
M,$(,4%B*9^B-\(AK<JO'/3A)\A575U=Q99<\0<7HQ,#+)2PK-;.:<F:^3"V9
M:7=42VN]_ &.1WMKL/#1C$L+G[^%CV:X^8;6TQ28KZ_/*/M$71KUH0[LQ29(
MER$OI1:6/>VQM@W3N>3$'EIGUQ?&W:71OKM]0!NZRB1T+ X[/FBL6AQVM%\[
M6:UV:N'Q*X?[-?/EXJFEB\/V#XY?[IRTWCJ+S>Q2?[6'^Z)3W,HY;;F?P*NG
M6XA9W8,?L,&>H?'4\O 4:AIY"B^/97E/ 9N0WK<Z#\K1C81RQE58+)[?VYEF
M>^MQ*6JN^:C(4GBW(;R'>Q^O(*!3?M;^2G);,B]_YD4U9-MBW)RH0;057JQQ
M2HZNQM'& E9NY&32' ]%+5]=OKI\=?GJ\M7EJ_-Z=>G!YNOO'-4RX4>KC#_R
M'\MJW.LP_YMQ22SLHU?&(+O"U8/O#$+*%9ES_%C+*M2S4J'F/Y85V??5Y=3W
MG$?9 ;3?%\UO%Z2?2_6JR5A6Y+%9.RD5;#&YUY *UC#;:0[FD6V9+I$J];K6
M4M.>]"A76\4FI2[?&;Z6NKRPW,LD/^NEKYS_6%;DWCWWQDAG6CK'N\-4TS1+
MA5I,[IVD%6JC5*CYCV5%[EW3 7$,4*L6%8UV2[VZ.[PM]6I1N6?6TWJU6>K5
M_,>R(O=NX!ZC2_HTF!CGS,<-[B$OO=8=XC#\LXIV+>OW]>'>0:: _VI=BU*L
ML+(^7Q.!**IP'J=-_T%I^O,?RXK<4SUHL(MC9[:%C6R;85S\&;)@4H$K'"+/
M?O2L;T//P;: -]B4D,L34>4!?,9]R*TA\66K'WEOZARFTJO8&>$QS;(2IYC<
MPP/N$L5]6"KN_,>R(O<Z% ;PB"=WE^IT1UAJFH>E.BTF]YII=7I4JM/\Q[(B
M]VYF^V@C$A;Z/E/-MUNI1K:7<>OAMN?:LA\Z7@-*.71D[^.[,95C*AW>W9$2
MTSPJ-70QN7>4T=#E7AX-QK(B^_X?=AQD@6B;)[0M?.%$GU-I"Z/5\\*XNRYN
M 2HU\,X(@5D_?O,:.-%CQV65=6&D]^A@[V/B-W:3HQ-0E77#\=@1G['#+Q[.
M7.JLG>&ZV:B]>9U53.XU&FEM>U(ZC?F/947NM<7Q)7C:E="SX":2 :=*\_Z&
MIY6UY E41)Q9Y$8?\8 'O"'1V(F'6:KFG1$/\Z@,Z O*O<SVF),RH-=@+"NR
M#SN7<^"-4+2BJMLNRPYWBL.E>BTL]S*;94[*5AT:C&5%]MV)\P"O7'FZ$3RJ
M5*P[PUOSJ(1!B\F]YH%JT7'2+G5J_F-9D7,)"(#ELH2+@S(O/0[OPE,<.?-M
MIH[(%2?BWG/ZB,=17;G^6)V=6VKAG9&&%;5PN:M&'^X=9W?5E-MJ2DNCCW0>
M9*JSS5KI*.0_EA79=\XX%6UG*\9%?%S]771</0)>[>AL2N,3'E./:88RL[ [
M F >E8VW"LJ]3#&W61X[I,%85F1?HG+;WFA,7;_$OW:+P:5V+2SW,H789MG7
M4(.QK,@^M9=[8MP]N>#-#ME8G$,-I"?,-<ZH2\'-Q9(9^;OP=I/]-6JCS,*=
MY*66WAE!*;5T4;EWF#VIH6R6J,%85F1?I(^%JL7$ ^AI/Z-\'S@,D\BL1$65
M1TK4PKB"MX+?;-,2E-@EF2@5<F&YEZE$-\LNBQJ,947VW7/F6FP,?G%2<FY<
M4JIV %'^R*RR^G&'&+ZBMBW3P_IP[S"3'OZUS Z7MD0?X<R4YIIEUT4-QK(B
M^RZ>AZS'U-[?.9N"C:XUI';HE.[ #C'=/"ZW 1>3>T>9#O=FV2Y1@[&LR+Y+
MC\?E5-CAJW;RX8O1#4<CPLOC[G:'S>;Q2BT4-QMR;=%Q+^7GA^6G?GBP][%[
M]>FV]?"U<]%]>R'?^X#T'!K--J6OU-W-^O[1 ;QA[/FBX^$I%YF%1_KAB=G!
M4#T]?6//"P)O=%I+;B$]WW/"8/8628J//_?X^VFRI_[%9S/[E[UESA3:BVX:
M\H1- UKM<4J^54D_H/R4.$]DXN^]SXQZQ-SJU)3GCW:+0E[7:,&]/);E%]S1
MWL<'E#A1/  O7'"*^+0T@L4> (>4;)W :-4W@3?&CQM?54=S""(<C"?";>5;
M7'O>-]P:--7F2?6DD_V=TK.<]@X8IM[@T<=;F,\,@\TZS.=AR'RCY;HAQ*4=
M.O9X@-U1T(TR4A[4NV!(#?Q4KWW(7"R^,S_\!-K2Q32DCT<,I CD* +Y"8'$
MABGF/N+I\H8?]GP$R#$LYLS_)ND7NI;,:N)! OO&/.O7(]:W ?= (*N*5'WQ
M?Q^V1SCJTVBVU3GS))P:/>)3&PDZFNT[:X6<(P9 GW'+F,S=BMF/N?>'VD1F
M$-'CL!\&N!5-[#&3UP1PJZUH.2(3@_3[<(N!;.J%/@S6]RM&/T8<K*A]K<S_
M>K)I+8R7RTZV^Z\X&!NEI-%RG#3A/+&A&:;F9K[M&R"J@<?1OAI]8L%W2NB
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MKMEX?:83,L(^Q-I#7):L:JQY*/F_Y;@!<029-D,;+XN-Q8X$(K%\ ?3"G^-
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M7++3_1Q;F1&5Y<A*0V*R[@E="J Z0Z.+7?^%!HQM,/X4-</R21]?(W(DZ%A
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MY6AGO&L]$NQEAYV0?08O(/RGJ6W'I4E<RB3^>O'ILK2)I4TL Y>UIJ&95WW
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M5[X.7J&_:H[6K^&"[$=Z6IW%+N,LF&E#/ L9\_UZ6YMU_L,:2Y?5';,.1(
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M'.*>16N@/K4&YJ,8F^DBLN0"]$.(S$"NT8=#SS02O$BFE,82JP5\><5;X-
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MG=,@@9_H\A?02^;S R%;40(3.ZB^4D,.\UG 1,>SHV?(+K $HOU:>E>:B>3
MIA'5S:<=:N!7$*7:Y[ ?;)ZYGRM_J>'U"GXUQDHH.\8E8D(28E789HM: ;+/
M:90 -PD9HW@_Z-U#$YKY&Z*0/AN&%=U&)=>X6JY1Q97T0JJ P3>0*J]'V-AX
M0Y 6@XR0CSA&+K[**LA1J905/EO>B?J8C/TAVO%DE@G3R+#478/'($][SAP+
M3G,J%\XI*M:Z)KT?28JB^.C?LUH\</R1:@,IU)0C?)7RR^DS77GO]P46R&#8
MDFLS+6V2TXJG0CF%NL1OB$#1=,@9'$RLIB-))7*KFH+,JL!@J\8>)\D^*N"9
M?:A<P8.(IM.EV4'T8+6<=<G;[25OI?%7=#QAFN.9(;,#!@;7!B%JR+.LS_L-
M ]K>6K)C:;66YU@V$1+((F?W89TN_+BI<VVWZZVY-15N M_F_$"%$BVD(?>)
MZ.\YX;@^Z=M.^FA&8V )L-35D':^1"77]H9VQM,X0D$(%.DJT6I.3_FUPXLF
MYLV\*F.-COIMU1BSI!A3[1X]'W$:1L-=K,WS8\_K6YO9'>ANF';+^=S/!^6D
MC-QX0/=*$&DM]83PFC ?C#"=T2S4;M=,ZJ#YRM6>[^5Y0M,=X.]*O-\QXK),
MF-Q9\4XJPV8M !X)S]X_Y'"9\GA:>HQF<PV 2].L!1X("3ICJJRZ4F$LSN\J
MWUJN!^8*(C-;G%U <)>:VL #:',Y>X[-U CP>VYT:J:;V:7>@EDT]M^*J;"W
MH7M0W+P#SVR!PN.W[&*^-MZZE;1L3ZV:P):$P!91BGAL,R+,R<EYJ;/OFWEO
MF\I4]]:ZY]U7JB8O8)>*SCVK"A%,%/D&^H8S)@R3[M ]+>*WE4]RPW;SX5+?
M8?R:2HTT1?/N!&EW-(N%E*%Z3,J ;V68"D[M[2.X/59%?A:P8V8J%6FC&L:U
M:Z)8;J*X$QO6(XAU3&P:I:Q3D8<0>V9$.3F:':4'\P\"D=[$79U6HS46+0L6
MS=*1/\B1#SIR3]NM?I@Q\Z(LKYF:[E1_S!O&T<_V9=1(L3Q(\=YV/5UTV.J4
M,VR.NW0*4>XT-'WF0. '5)%G8N8-FB GD+=N0,1>D@8RU?&1UCA7,ET?:SE^
MLEV.G] !)F-LVC9YT]()1]L;A*WF4P^,-=OK>]_G:&D]@:=E?[$.>)?4S-]V
MN,VXG M6HKO[ZX@T=EAP;]6]H1;P]3VXU^"Q77Y<+0%P4F/R;"<^U8C)G6/@
M4HC;[_5.KH@Z3[&4I]BJ\Q278RT_.D^QUDL>VN3YZ)HT9)?/ZI=S 4??EW'8
M:WC',L;<'/C;<T>:EM099Y#\J6/*K\T?J_ @ND.-+(^FQ-HH@*H/L&/<'TEU
MK3AVRYJF;4Y8(\PR<Y=;SOB+<MBS&D4:E=6EU&#BJIL%7A(4J7*Q.-T'M/KH
M\)X23U(]LP I;+<P6&\L$Q'\45!W2YHFH_ZVFRJ-.I[[^AMXF_'C;-R&JQNO
M[C_ROL;7!\!7_^.QE89&^IE.<%B+J/S%=.Q8OGK#P3OAD=;^[6?_'<F;==+@
M'9,&3:5:2&5ZP$B*5"<,UGF"3^M.37K4?)(2.AN+MTM&BW><L8P!JR1581L4
M$:%/<[YX-!GF[+P_?K48G4>4%XS5AEK1G>FJ5^D%=7[9,N#4 GR^>WR,:'(!
M_S,[Y'*W1)'';OE3YV_5B/\PB/_KR0M%^/:3(GRMU3]]KLM)]T;=/HEE2;>_
MT:33[JH%++J%6W#4.OQ==7C=<0]A#;;1<)&*GUJ1?S+9\U@-RV:KY*9U6J.N
M%5HA)+EGS[V9B0AWTVEJ1OU8C-J,V[6E\Q1<PDK\X*9QNJ=@PNNJW9IQ_S@/
M3""_"9Q$*+)$33Z\A6KG^%YH@M48!#&-R,#,B9M]+L;;8A(_;&_E66.IF;[+
M8T>KK""Z+4PT-UMN);OUM3=:>ZJO/.:8TJA[@3TO3".TW#2L ]",B]0?8GBE
MW#?!EL3KPX_=-AM9J<D.N\8\C/3(0"?^7"51,9(JF0<;-!0I-TM3*3*(*>I6
M:MBE5\*!G8&(U:#EZ=NW_KFK?Z0N:[GM;48)-]S>=AQ&B>JWWVIQ(Q\/9WE*
M;.W8SU7W&(06WZI?T< >-33F;#3FH=#P$MT8@MJ(D#>?!IG31($<VV>F:J,*
M%*2QF"9#@T+0&!QL>4A0(:!2*Q6"#4)ZL.Z=83],/QP;[N=NC,4@MB@PS>!R
M/=]&<%T']SH)?>_/0E#S3C!?L,\9C;^35R(JA-O>!3]0I+%],[Z'Y"Q.,< ?
MX1')#1ZQTTN8);%N04+M6NB:ZLB ?3;,0+KS8S.0CGN,**A09S_< 9\&]F53
M261"-<@TZ*7@!)^[5D2)O3ZH;]!)0OV3L+%1;)JKD'IXC;Y\#_O6Q>I4N)7<
M")^8/@0\O6N1(CN XZ:;U$?P3:65PZU9'D81@#&)KI0RTN"F<[H]([!,/!2W
M%Q*U/G7>:?L@862;^:A=S+5JJP>7KQE_L%N(:6FJ/WW[T(7E8TNYZK<T8L2V
MC6IF#LO J!KV::2V5#=V@D02D-'8:5[8A[?J;H.S6OS0L6;.*XB$<MV9AS-@
M"%&Y'8L5<VJR8B8C;,<TH9/HZ"<-G1JB%S@^ 2/%7EQ0#%"W? R2C/?G+!K9
MT:P'^%XG-4<UU%KWOG#[TH;JJ&NV(PG#L/=DN9'/K)F-GNFVR2^Q35)O!CDU
MN36M)9]1)N\"#LA6>]4\[C0#YW$Z^=^:1$S?KN80:U14TH(<-T:U;&)#O?;F
M_EL2;$Y+TED>O>[Q\6L,X=S%JZ<DT[K^_,+NP^_X&.D3#^%,G-9(5XD"GLH%
M_XPIX->3'X/\]_O.@GA_>PK?6WP+XI7ND4;-%.TD2358H<Z2+V7)M\O@J&98
M+S:R8=,.;/B.U/KM5IU:OZ2I]<LV= /'5)R%8Y(9WIGJM[]B;>PO2_T%N>PH
M*T:P6'A)Q@JTWJ(@E5M7!O&<B?;N@FT$[5&%HX&7I3YPK &L!AVFK?9FZ_\&
MF^M_C <_8?'ZOW[ZSQ;^_G_FTQFHXY*O5_GDSOC;# 6](MH)VGQ94?;N]M[X
M&[*!>1RXM?V2./#FH]0IU<QT]9CIBG FZLR<B[S(= -6V((:VJ>\?#XH:V&
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M#'W^29&!=? EUD+\1( =);TNVCK'>F#\K\/$ZZ3H#C"S17%\S04.!Z([+U,
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MKE22<+*BIY1_-^U5@R(?8I8SV=;2S==:9#]N [4Z/_;'Z> =@QLE9<ID!M"
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M"A.*M/4);JA@@IST)E*DJ&I@0CC5&@A,&.>5F"7.& )JUM' 4@/5;8?EXB*
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MT]]"?W^K%[1;VVW1;FUM;+5%J[4G]UI[>RVQ+5IR^_]V?_KW)8IAU'6Z\$'
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ML!=&83YI>+TBITP4S.1/>G!60B< C8'=2?23-[Q ]J5R@,@8;$N?DV4J.2^
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MUL_;0%7N*(5 \NPJT_;[Z@.UHXD7J LH+,R&NG2.N:2H8C%8",CRM(E#>59
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M<]E#RV$0?!-'0>S+F'0:TSXO-QZ;V$&-QO]JH^E"0] X=VW3@MEF7(HA7GS
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M6+$2;\3L&'R^Y]:\RJ"2"4(Y:2IYD%F+04&5B#X[_:L"L[&6N-R:VB[-+1M
MJ):2/1@/M)O:0IDR%#,Z8[4AIX!7;U'E?9O&2SIFI-,[.X;RL#]@;T'@(^_0
M$'<33>>5JYD53Y6KE:1A9<_:R3N@CA!5KR#[A6;(R>?!HHU@UKVS_/]G[UV;
MVT:R;-&_PI@[,V%'0!J_JJJ[*^Z-D&57E:;MLH[EZCKG?@-)4$(9!#@ *)G]
MZT^N_<J= "C),_TP7?K2719)()'(W+D?:Z\5QA%6:45[A_?,LD29A9C:/1Z(
M+?L*R07,?5RW_B1<^>Y\^,..03&<@F$IE[GD 'H)^TNNRNO!4;:)X:;WP?3*
M9L&/9Z_#:8";T>D^]974W4F7&)0AUIS X* ^;BSW*,NFZ-PH&>]ICY!@^F:O
M, +S+"@3.E5MHOU.41IU751;4!R-)YGH]X/;(. SO(ZB999K.C-O"O<5.FOR
M-<.R!O8EG#_;0E(8%6CM@RL"9P:ONZ<*B[RN2R)$T0P'ANG>\&!>4(;H.W)K
MY!Q8:RO3GKNPOSN7!A@K+R\+9N]>$.EK;'>35+0G?B#$E&;98ZX(96U1I"#H
MLN&[>4VKJ\;#VW<[I8,K:^"1$V)R7HXP6.9E0X+C$O476K&_W?(3MX8':V%H
M'OO;)H\7!#?M64J:,D(</]C2E3V'3!#V_ QE54J#H?=HQ)G!M2:K_Z3+^6QU
MZZ+I>&')KG+W#4,M2C&Z I],WV3F!40068CUO6,I\(TSLN[+-K\9/4U,6A$@
MD6"8VQKFG6.4JR)OOXJ**[T9/80YF49UULA2:S3%O;?VLLA=C86RMQSSH!?,
M-J6'>G#]O=/*2BR"=I+>XZB*SMF;\$,Z2/BBRN^U:+85J5V$I:\ 7B,>%IF$
MU+=PO2'IR<-' ZUWZS9#3V'NQA5NF[<UU:.HXEXL\BT/&$ULO(U\L2LIR&=V
MDY2.6>)Z7[796\IV, :A(LE'/FO*7Q6Q<-GP&-1*&4/+V^LB&'5R<U0EB<)K
M+E[)04!7MFHN2Q5(6MM':.2?3Q_AK%<S>X\2W&MK#:8QO"TU^3N[(*V+RYT%
ML1@)?UPH!,FO #5AZ\(*Z:!9)(TAE<B@E;&M]7/T\O"<%%5A$'WQ^2C:H7!&
M6QETC3%>*0(5UR'T:)91?@.[A3Z712Y>(AY7FF84=]547R5+K&,^IF0E8,?\
MSW.M6SA*U$.8@%L?]U1LA15E#&VRWH2W#N=SE5(+@8"(%FT-;Y);B8TZ61-'
MYI4A9&0UG0FR<.&S5WN5L*NK:DCLBICOW&47TN(OQSLB$$&]Q/)2V C60+5P
M+S)N^E\&9,L.W!]<F?92TR6H)U[67)#F._/?PQ2%U[I+1BX5]*K(E_+=S/.H
M-^(]#$>#X>?]@ VL=!U6&)N4./6VD%>A"]*-M<RI,=O4/7X=D=U/38PH8IGF
MS$ ):JC/0X6N@]@*_U-;$$:%?[PJ\\LZ'()@C_Z:C$'PGR;R9*:LY"%?3O@I
MC/.!TF)$:;&T-4)FI3;;$DFT*0JUH-X 9FWPFX)'KA@ULKC^:JXI=&%+TG\A
M=W$O86PL"J+D(_LUPK?@7FGT,*DA%*J2M+.S/3>"%2D%U%Q2.:;E8$CP.O'*
MW14=&"[HM*<LF/JB ' KKPL6NW-\%DHVNNW,PXXNZL3HS8TT'"DGG?5F%LEI
M@#;Y9!1-YTO.73;L\$:<99(SBUXO)\W=1^'EA4>P$6GBM=MUX7E=PW<F?E^E
M,^HD3>"C5T(+0A-LVB-6,%-'?<\ \4NG1'GL[)A_XIB';3M-#VF.?UOG==UL
M:W38I-2%*;>&,&I$?D++M5C[8\UD6X.HYE'WV/(\@BBQ:7,9VY70'/IT)E:>
M\R<>L!()5N(/#UB)+V,L#UB)VY!]P?S!K)]+X'Y@1&4^=1 .LJK9*?Q-Q9TI
M6J8N"GE6R>M%H5GFRH@1@FJQ^K3*"JAKB$M^-#X&.CUHZVK+,9^)N_0;(6 @
M<2:]A?N0"UV+15$5K,X8$YT_3-X/08FU92.AP_8Y_XR'$H<$X+S.(;)OZ6%,
M$)-<R"OY6 R'T[KH[02M">#W\HX9X?Y1U]SRN:_E;_$$L0'-D;%8*Z@Z.UT"
MYRC7Y+LPU@,8CB@JK5+=X+7;_[;715X;@Y>=L9<-,P"@GD? 2"EKUL/"JU0V
MN_(3,FO]5<<BS.QH^7T0]C&52/>/A!IUT_GDO((B4SWDW3^W.'^:S6O3-*&$
M*@K\S-3)*37G":2$HFKLQ=V_!_4+LSTGSOW;F9)J6%B7I0)KIS:WD*?<:P&G
MJS:&+Y%;AE95^.IJ6R4^N7:&T4J-8%NW5,]B-Y+D*NUQX()[X>!<>Z.9'J[;
MMN&T("GH>DEL-+R&2")8N'QVI/-7"=X92ZV/.\T&U_(%XQ9,KB?5LO"$R*PN
MJ6.[5'Q.V6(]M=QUNF[:>;D4",0:?2CD[AM)T]NW1M)TKY$F#QQ^'8EJAL^0
M8=<RXQ$ABA?!5Y<8$,,C $B;\__+)LBKPN++8O"*J3;";\L@'15. 6R9*?@Y
M:G83/)TQV!.4$G?[#?!#Y6738ND-@BSGY^_C;G25095!2BH3$^C]\*"KLN4^
MMWM.+A7\-)CAPO12T283^EDAUK7V^9A#D54$FQ5>\I93>FA86J7I>*D;E3YA
M3XRF2:Z -\HP*.7O2^Y4P#'%NHLL(Q,%@E%UR65$(4*"Y4"2:>_6=1AC-WN/
M,O*:E.7"3Y\]>?;,Z=Z]>^\DYEPNM6YNT'D702/R(#1.1V2>:=<3PD=^9W-I
M@[TA_'Z);$"3Y$J,8S$V9B,415MCHZV2/?.R%$DC']<^==72>57L\X32BC2G
MN.EQXV->Y9TUG2VC'*8V*HB'2[B2$"8S0L<JMA3$3IEI)JH"BF.XSLK5H+8N
M^QC+6\2_" ZT"ON8;@9#(#@-L3">C=.LX6 ]'-AQJ,B7^&*5=(VS!QXWQ8_:
MQ7IA6E*M<D9GI! 8O6S=D  Y( A%P9(+OJ5G15RH=.=8A+>+^!4Z9(IOT[(T
MT"8P'&$UA>,8OFTBR[XO)!@X7MGDZA+IR;M\Y67#G$J$[>!3I4=+;;L\0/*N
MSV76IF:N8%>#IV+HJ4-XSMN[$\S(Q^=[KVV5KX-I#@O'+/R3YQF!49(^\RJ!
M.@ +G_-!%SZ'<=&CVD$/A.\"L\C_$LG1\&!,KQM68,^EPGR)6K.Q[BG-)!4)
M$9 0=$#Q[BX6&&$&I@@\&,^8EVO*(R\=Y&=CDV'M?<9X7';>#<&A1B#Z<#@O
MM8V?NG@CMN\@ML,]E\E+8(?.K_*P 1;DVN-HQF2>7I75L@TV]P1M%WD2C SC
MD#B]Q2=&]Y%#RMGB$ 5T/JRDH%Q"6_=UL9J<U08G)_S<8 P[8;WT7Y4QZ,F>
M%%*OFRJXR/E8F\>-DFGB)HCA6)OEB&%>LYL6;DV=="8RZH*O<!#KX'/-(GQ/
MZVEZ[_SS0WC8VP/J>I<2;/'ZO-'N3%]$$S99%\TD)+A6//8<ZA:^3#<O ,38
M+H\^%L5F6,G)8EV(C:20'!F%AV/9\IU0(4C7:$EEQ6;;S9)<@2FQP*0O2C=T
M!R]3T59)R)(.D4'UI=:F%-H1?(]%WS;!UY0G%%(F<C*V;3$N60TNA)&'L:R;
MF+/$\_=E-YRFF(?B@*C:.6'O"&9S/\\&5Y8WHL 5CYOV( F. -N",:1F6OB<
M/(YP(;%#? \-_/0DLAC9PP<%^3*T._)BF6[:SC:[ CV;PP>F)3T[1,/R+'BI
MWM+^8&:Y+9S<K!-2,*IFSNB$'8CEV37;=J'(L?JRX9P$VJ+IU)S2T!GD@ 1!
MK)T%DZT<+@=ED$0*#9.=*8!G)H,PG7.A$AV\XL%=A_# "*-C)BER>(8OS"&:
M(QX:?D;'W87#'C@%0NZ1LGDH9":%S#\^%#*_C+'\G@J9MR[)MREBPHP*==PQ
MLI$X#0VM,A9]25-_$[!DH::7-C)*G &=RUYYV4;EWW5*LJG42GK\=E2>HT86
M!?8.'!?VJ\/Q[+$>'N?A-6;V7WD*H4&'2YR?*K]1=9]QT]UFPSEP!)RDTF3'
MW.1),,P&QY:\3+]"YSNFK*P$NPRL\^)C?DF?1(>@Z\-B5T+&JW+CXTM+A[T=
MGZE1?5EYH)<"\?&B<>0L1)!M4?2#KD Y7 TC.V[,0W!!'"CJD\WS/OP+R?FF
MC\E1%HD%15<Q3%RN]RQ9DDV86+&4= 1O-\B;K_"ZF:EO3\NV3 @==-Z[T/%2
MGDK7/OXQB56JFU[SE*)C3.6,HET5)97SX+<A\.[ JUF+L]1S58^<@GRY194B
M[_U.BA2#SG.+O1G;>B6]RLFF_)K0G;X\:YGG&++'K&#P1AH4@2W9W(F27L$,
M1^)*)24'>+])_:Y<C0S!OM4MU/.J$R&I%**4",='V$;-8K%M72X_MOB$[2!(
M1G6[D_88)+^WC.'3J]][5-QJ GX+\L5=2NJ:YN&W+4K7" &UZ*).X@KMR"@3
MA(.@XJ>1OAOIU0H?LC!5,Z),=Q%74?X5A8+X%V##Z]C1M=IV3"'!I15N0EHS
MQS[5'(1M7Y=]YG^CW2U \8YR>I3!V,AKIM^E+SJF JDEQQEF&.3?PN%AUUF4
MUR5C6EO".E2X(S0]4/W]E3NDC.=4N-[]@1<_2SJ[PCX_B WYN7D5SFA]""\4
M"=F^<3+O[^,Z?1VS7 =6GW%LG0F7"-.YD812V.G4[L'9O6XRE>@(H34#J&$J
ML0-HWI)*E^<M,+5 O19]+'+OFVK)>S_]XQ]>9)'%=,#5BFO_A-/WZ-?\$SC0
M3Y2V9?A7V9S4Z,9W;-W-:. 0#MZP?'O8D+LB;SOI6 &G8B0>\P];-4!'F"\T
M9-ZA)^3 TADWBC'%+7(\;OZZ?G +.((]SZM2@L"*DK,E [>GFA>[AI@S^J9G
MEM2G+^19C%AV"-&V4!U.$T_?OK%(L:STL7^#Q957JUA2FQ?]32%0^UA[M\JO
M:-(89Z51D+AO^&[<3;7MIB]^UV\CC"(1ILU[;V>!3.?'T,=VQ !"DC,("# !
MR4:@)[6%[^YJB*WQM\:$K.8[\A<W990[ZNVE\ OZY>+\P[MLQMVE.!PC+BSF
M."-EB^F/=9,# W)\>@_3"6?OWW005MN>J%90XE4\4:8M_TR_SC'$*KU )US&
M=B?*TCN3H]9&UC&'5\'KH&8S-R74 95)^PN=@+7.&E/\,57$/CK=Z'-SC_[8
MYV8PG?[>R*KBVOH^^ ZR<WMJ4!!L22W@CIPY=@273SY)G%:E7=&B"$[8NUNW
MOK!#A/@DDJ)03(INDXX^FAN*1Y9%E>^&>S?)P?(FU=/)^T.:43X]\9@W6.LC
M6#@U3N'7=5,?R2I;#@<I0!4-)W2[K<JVLYW/.=)+&<"0<#H2CY&4+&/5>B+P
M><5' :_$8;4LQ340S0;S2KFV1,S3?(Y_4-B$VRFNY^3G5P;KX=[&;YY\\VC^
M^-&SQ_2]:$=(^TY05,(+RKN<_T9(.38K$=,2"8+B'!BY"*!4X0)7.9+/86M=
M0@&1^!NHH91Z01>%)@P$YI-'!S(E;K 3CQWU%-FJ' "1\HK"C16, Y]C#)F4
M.G0GJJX.X&$&)FQI9 ($.8<U4=8KO!_RI]UJHI5I2XH5D?A>X6*C!<13B2G/
M!F\@\=?EZ+#J*;X0AIX(O254I>@B[XUR+,1\"?;/VOL9H5NTGHD>-V;^MRAA
M&%\C=YJ2TI7@X;I.Q)Z21'M>N5J&OI !NDEA!A.0 HY7A-^JD_UBCX]%)L5A
MFF#>LGY>%Z3=&%4+'8P'KEF(>H-=;1:\,>R@NV4^A1U"UG!XPJMR7L8&//*'
M(ML3MA<GSI@P5A:8;N<FK'>*FP1@@50;PERS/GSH3SZ9T6CMLWZ)D6$5Y9_O
MP>7TA9T'+C+R3^^-K9T#RK0P"4;@X[G=8!^0<7*?'3NL3()?"'M+3M/,'0^)
MRD(*EQ_MZ:KRRO$CJ PGN&*Q2?<*KX=U4TH%-XN+*/M[8R/(G;'G78J_D:#;
MIN:7=$G%\XA$U1 48.W0>E:C&2#.E00"$G8$CWGZY4A/"O$HH<^T:F[$$Y S
M3'[WBCK5Y3![*+"Y/?3\R4.![<L8R^^IP/:9Z;&79=A7X4ZY5"\^(P_V)3SM
MG=GY\Y\N3O2$ZH8N>>0FS/LKP.%7#@[N:?5]!X),5_A7QOC$L&D9[$ +!]Y,
MIG@VR?$OG6,]OOSQ++X$!]\3CSO18.:8U*FSN"XA)7(!6,0G5L8W='RT.BI+
MAG "C0X*U6MD1M-(Q;H(?]/F"YX7DV8U-FES<46.Q?U[.2'8VQI1W9F?3G:7
MTXE(*&CG-G'J_HX?21]V;Q<4=PY96U)4%FCD-X+0!O>##5QINB5S.7G;S*MP
M=5;O*.#9K\$)N1&<C\#DK1%A_'[L(XVIPC*#PIV$5$AXH5MBCI>.7J2261^2
M6V)E-EO3\2%-!*?@1_DA_@]TT- /<0<#L>E9S4!2(9/T'2_CX1Z:VWLR->7.
MPWKZ+ :3B<]I0E\EY[\X!<';?]N.>X)\X5#K1K8DQ,&B:YC0RL#,1-/$71.R
M$'>"BZH&G6*R?'E8RYP8VZSD-.',:I:#39$NNBOB^R",9=?'\?)5]XT0@(!.
M@)\8"!Q39DI_5#ZFE<LQEY4B^7*.M,\&FH6?A-\\_8.ZL_PCWX'I?&!);H0A
M5<@@%O3KB9_STB6GTM6G+>9VK!G7#9.R$^!B6_9V;8TL=<W8;S0'6JZ&R1';
MKHXS-ES^47G]>/;BV7B$D[^-4$<_*O3E"E+09<A>/#NBB\J[_1IK?3XD.3#+
MXZ*P3K(\*ZK;>Y!0%[>];[5G_:0<_:C%=&\\GYPBW1HCPV=/GF3AL; B.H3!
M/KS7YBK]U9JYZ-VO$$"'4'4KFK+V2Z(2,)2WWY#6FZNG;!Y'MVBZ7DCMI&N&
MM8=B 6Y/XXEK.)$3''#HZT+R9UU>%:.F%3_<$TNLDF>@/0<^9^%;MZRP(U4%
M%:*VA$4$A8\(UT6LCM-[CH]^H@O('H^IEC&*Y"_NJ56RNN:S:7]$;R.:YX,\
ME8S,J /VW8KSM67J$#MWM-N2<6F_1N/RJNP65:.GN8G+?B /]FMJ9;O@]=E-
MJ;4Q_]91Y*:,IWR$#4:5+D,[9?MAEX+:Q-P6$<F0!@A)_P3;E; (-]MY>'5P
M<XT' ?GTFYMC_;E$%9?-];%_1>S*CO0=LPDM7[#%YA/J=IGT,K$T .<3G=YF
MYLJ2.2$^]\B!BH(>BB5(H=(3>8$<=DXNK7/O>&:OQQ#P3?C1I3Z/3:6X-4Z)
MM&S'Q5/R+V)2\GB6+O/Q1:((KEA;2H032VE?5I;'5TL[JC%(]P 'A,NQ*W-L
ML!(\(V&9Z&&FW[=O)-$RGQ=_4_%;><NLVHKXQITKVJO\-1JMM,$P3"W(D^ *
M \'#33N$@RK7\VW;4;'K$&;A+D!4XHN$):$%U+!&6TI#F%>0W]F;-L%UKIAL
M#5!P-3Y=&<1 G:^T@2662)@_5EP>4V!TZR=?(\G(!+O)=V1/HGF]Q*]KQB1%
MECZ"(N>@UUU0 Q67$5K".I;7R'.(1&M)$6D"5F[:R[P6*#?(CK15US<%$:QF
M8F1LR^41F&*_3:R7J_3Q"!8L9MT9.#F8CI(H,#9-6-5WSI!49.)KH\)D)[U_
MXQ&*@N>*NOL_Z\*P<)Q6&Q#9TUNBJU.6"/]Q$-;C]N3'2"-"F\-H9H1%F=DH
M30Z*YH"6OG),V0RG;"":0RB@PMH7"83-;B(2Y'+L^)<3,W4,GXJWS6/GGTNO
MC)8I\4\ XQ@'Z&4((JA=";JD S L+<V"$$H"_K-6/)V@!+RB<:^)3 %Z 19;
M9"GC.7@\>QL69$/@"9E'BPC D-')D7;'M%I-O*3F  $I19FEB5E4P%(\<4],
ME,G-6_I+1YSA6*?0BT'_M>T20/B&\*$5#EDP$ZU8;$/$S<+1]=?")IEI:L*?
M^VU;JVBL:W",1.K^T#[\W3:Q1&$78W*6&T22]!)/*\O?YNL(:(A,?=2>(\EZ
MF-BC$7>#?C>FI=&<4[1@R:5CQJKLXAV7[51+,\$'FY:088TH$=UE7-U9RPN5
M=Y3G,"8CD L D=9<P6ZMLMTB;\"=LQMV;9H0[-?-6L@%A/[>!I;F^3]OIKQK
M,#4Q<H;YH$;F8<)EZ(3S:O32E0I&>G_=UI;H.AD;=0?P,U2[HTA#Q>K6,@BV
MS6-NN(PSQ+J5Z6TE:9%!.I7XL)7%R%" 83V04,:L8<%JNN:RR22Y"XYKPFWM
MAG8CM0/A 9J;5#^[*R AU;LLE]9[P!GV@"WPV(*G#]B"+V,LOR=LP5UA%Z&_
MX6>'_>&C+;$QK!^\X<A3_!ARN!4^;\= 5%83M['*;P"EVTFR5"76DNXRCHLT
M 67WN89]# NZ4+^=![;C4X7^D_GY$]JWU[]$Y%FSB;Q,);6:KN<("?I<9"$3
MM:F6.+WTI.7^K'& R8:T5F%['YL1VES;7=7]2T_3O-9#L6^;*OH&W2WWO=JB
M?X9%4]U)Y2]+U6J>M=BZJ)!^SOW86QUH9 UI(T=$D9SCIU/*#L\IFEGG+.NQ
M%.DO\<S<0)!D@>R$0S;?OYVDOII[;Q^.E(8-HPDC7$>OZJ ]9&?R90/58%4:
MH!)Y6\A7:_EO>1^=$\\.)Y<+_'6>R+6HN%MWSPA2YI,/=[<EV++&'ZZH5H2'
MC&-J!V_;*1@P4"'-%=GBH7B!CVLJ@8K*YG ]VLII:0?PGE2W3UM"AF\435,E
M6DK8H\GB7:M\6Q/"06HU84.*J[1J:"S\>&'C;:G[VO*KEO?QM+JT-[2=9:Q+
MU]P4_Y, ?L,<)D=5L?K"\G\_Q8P+TXQ^!7&3O&*?!D,(0_N]0JJ\RGE!4(^#
MIZDAFR-@\"3UBU7!R0&LH,NVN>%^HWB/X+27FL":Q0R6S\NE^VW<XCO>,LGQ
MQ21G\ZXO>V.OH"7LLQ,$4 O[:TD'Z8 T(&RF"VK#6/*)E3Y!M 1T>F!*F8R:
M:ZX\5,152,*QF#.HPWE:Q)V?,A3=Q.EYLEJ!9@F&XA1SA:[-1_A ^U].8_N+
M=7^XEB..#NF ,?S5R)@FN3K_(B)G;%O,Z8R.K0#V$J@X_)9"J7+I^$I=O]PJ
M?JX7"NO$_I;F6UD[< T63PK\4(>!118"#ZEK\8_#]\^1(7TET=6BS$T=,*_K
M+3+,1>&$R@:F601VBDXR1HS,8<Q>Q:-<%4N22? KU@H=LXMXID_07X6WPWMG
M5V@4RLZ7VTM4AJMBP<Y=A7ZJT!8E0]'6_@RN+Y5AR/')!'1:++9,ZJQ@'1SE
M"#^Y^)1)V3D<"1 =0KN>M.%AH;%.H\/YM,6F8%AA^"]3HSV!'!W+%(?IPQD;
M3J0Y=-G0O'MH>!$*\M7<R=01X5:<?G.YF4LK&(4BE?\+CQ[G9G83?(:BSA?D
M78^V],N2/+,PYMG+[?(RK RC,WWZAUDN(L%ZK?G.PPQIF8'__:A9'5&Q1'?'
M3&G;PPE,.W*PTE-ZE9NK1OS#$L"JV<2&(@__FR?_AA7Q7?@_2N]4C0W#4E27
M^0:_7^-(L(NP2<%6'G"HT0SP8Y^*TQT?_ZD!-F^;I&]FE32[7UZB,$E)3Z'6
MZ:*Q:8MH;&/ZEZOQW-/^[-\ V)FMPA2&&2+P'#>2,9\YDK!X,N%B5W#NLR?/
MGRKWJNNC27:CBE2@)IU_+.H!]<?)&H=1>+8/^:<PQC"&]T55%BMZ2+;4R^FG
M,-$698=SY:EHMZ^:;@//!G]<$YE0U*3$:X2_VT:*?/U0VWG4Z!-P)7@#6^XB
M]VZN(XBF@SX>CA3%<48,_S/]"J1F@9["A%N @U&;GO?A7-Z&%5GEM6-U?SH3
M;9(^&2/."CM2:/WQ61,>=Y.A(((D&#(Q'![A&[';7]:RWR7LAC#TF-+(X49$
M(2BS5(>H#NJ]AMZ43Z7):1XL2DUNP7^&BR)T?IIA]"]4"Q0@0T^L1/,Z)':Q
MY>56N-^LL?3H2H*KK?"FZ(?$(I3K,K805S+#$L'>&6&D55WWRZG"KBR,%:'
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M9-&":<'_S81YW;R"PD(RJJ5VP1,IB&B0'"6RVV/20DJ)'+MK?VBWZ\V,!9W
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M%=$'#$<B<65_%<9VO Q5:47$$/EAHU<MU8>]KXNE4O^'V]+6+M50A'7/EM3
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M#D(QI#^T!/N-G$OP](&#4_<P03U2-QF<C7UJL1M]S6Y\!^&*?V[C<#@>WB<
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MJQN42Y.!S/]J.5!A^"6-I^#PU(J1U:\+(0NPN(N6=,(JHZRX-3W^NT2 /']
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MJ-=:$75J+FW:D$B3;!XZ0VM6BD%!F!T"[;PP+&[ZD(;,]P\6"\^65C@ZXQ<
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MV$H4_=3I*-/BV.;&['CRI*WCE_]4K-8/)_^( WD^^6%;$(?D^>2GGUY.^RA
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M,%CKIFE>2Q/YU+4%:$_$H37@G> [(_R/-,5*W)"JQ#E9QE041/OZP,)YOA-
MLJ]?XXA*Y^, .>_D60;68="(G((GK-W.MD-&]8"_$<_#M&>\Z7[;>EF40I^]
MT=IOSC*!^<XI*]VR8(: 9QN&ZVC(J3RWC7%L=JP1?]6PJ86\GFH ^4SH,=@^
MW)(WL=WXK4^9,JCV])T?D,W@1$3Q0T)(;)^VV9Y?6+6]$%3_<#<X$,K4I6T-
MDJSN([MILR2DZ0)T:8%+N0ZV%2FC"A6,J]()N$!*)XPZA<[_&GI;OUVV;SI9
M<Z1/F3WQB?0ZR%B><-GUE,NN<:W1#3]B"O#VF:5W!/(_I68*(O] !S]V)<W'
M"^_0>M'4&R0";YDI_H5K%,5$I5Z-8Z".4?*: N4$%GA<[$A&\5E'-10=CS06
M<??$ER3Z_Q2MZ?:6/AGV:^0?5)@O%V71#G:W+&]\\.-T<A;O]&L,U+E]=3$Y
MH8Q5G,+"\:08A:9,V=*F3*[L2_]D.8/F[/01-0RU-MA2-,G<U<''U/LLHP4W
M<D]-\%4DS;AE:BBP_JNQAVR>:T^(IN$,U0<O[$[(BGO3'D $"<JB5"=P\L?[
M]XZ_G<Q$Q2;^B*(6ZH/6NAB<V/(-':8=*IZY$X+"A/XFGF M\ ?Q>5Z('>$.
MWRFHQO_XX/B^W4MLX?UOC_]LGR4B"1V8EHLWH^.K:)>DL):M"C"$/XAWO7_\
MU>"N[J:TABF,VT@$-9PT@.WPIE?=#G/8+V-_>3PY(1GHLNG+OH(TGA9^=&SC
MX!'B[U+P3?TI&QL4,N_C#P*)6'&%^M*F<^, EM4<'V_\N0<+)\2CZH_1$)CD
M$?A-N@O)-,3_H&/W35%Q)YZU4A9OXF%EPA^29\[3+"7+QY B;%\SS[_9E!5-
MZ<)_?'#_Z_0@6I13HG&.Q-<].6#ONZ4"5Q_ D9H5>>N?O3HYI?C@-=&:O!KY
M03;V@W0 )F__,,7OQ>69-H6YHK, BI:BYE)";^;SJ=$4/N&B2(G%&'OHECE-
M*U4^ @DSL*WM_7)DY8.)^@TW1"H)*]#(#)$I:).WBR/JT]L]).>1H584FL8%
M/F9]4)J(JZU$7;;.&(;:WN->L^>N6+QN:AG@90#9A6@Z\5@6;QTE!,W&@Z3I
M570=\:QL-(A*].WT3SWTXB7R(PC#_KBHBT4Q077="%B#"%.FU&1-S OU>6 @
MS9)29P$*V,IEQ&LNL0,5?"!@(?&=]S^E[+5\2%'T8<R.+G$2].4J-"X;IQ@T
M<ZH-%.=6S8?L91XMQ".,X,?OC-)PI,% F:T=%F$PAL>3E^_ODOY4QEVUT,=Z
M+,?%:>BBSS6W5OW<-I;=? M@Q=V/BB47S['3#%T:L 0M% 49XXA<(R]_93-#
M76\G-C77 +LT;B78"<Y&-@(81@^C,^Q;M3;!I%?[E%B,>,A/(V0M5>S$-U%:
M*5.H^"@0)MS&)BC-)-1>:-4EZY&,68Q>@SP8[8#H'#D(3.J5) D9G#84;PH^
M7&J1&^&VC+>M.*C3;28A]\YVEX?N*,5)>BAL-^6VE@U%"R^.HW_OX8R!L(@/
M LG947V[WL+.D8_*49=/A@/CQD^5%[S=M"1&,M>HA"S'MEU7%)6KVO%(I79J
M?$M;)X=L=Q%"4WXP7D5[7HY>C)KA+3]#9HX4K7H+LPW+"MR'X]?1!)F2@"$A
MKJ(:Z?GMY(5_KY5>2'ZDA>TK*Y)K1/C<>R(F'H-:6B-8!,F#M"B\(W?0T&H1
M&AX,PW ]K(N2FWN);PWK#$2,ZBW3[MG0+IM:\_XY4$]KHBE:'"KA627\FT,E
M_'8\RR=OI;TMY_$OTD50DSN,G%XA,G[8^#VW5T!*O62ADG; JJ9<)M18+D/O
MG,E@/"CG<3:9K,>VZY$\II])DA!W)&<LR,FC_QUGAS.9PN_1DG=*Y35*3$H[
M).EEV04]D:/T&5 2//?:Z1.?21:"-YPF7*Y+#OG8%8;'+!B!17$4DH]#GS>G
M)GDI=#;. ^WQO?4?,GE#S)TY<=H(;BXI)O)\FYXUU?.)YKR6 W;1&Q"HPFT9
M]U L-W\3@E6?CKWSCO O;IUF"S,Y*+V(N-9R 7;FGC6+S8C8E=S"&>F\#JX^
M$KK2I6)(..5PD.05TV,,<C9 NFFF(!4Y<AJ//&?,CG<=J 9:,--(OB\\4*;K
M;XNQS4\)@D;U6]A.A=E&MW^\^[9E.:AZ_^[$M_AW'&$2K<@EN4871;7LFRHN
M(5'1>XSA!5?IVX<RJP_U6(I;)@ ?FVM8">6.I4K?6!:97H<J4R"AUTF\(MW,
M@;X-=*<B.W2=,8K^Z?B@W81O>0\UL9+B_H:4RYDE+*B/IF)E ]!%<Z+2:3ST
M>YP#*626BR'%,A[S?5F5"X/( J8N)#>))WEZ#;,R3@9<B:F4.Z529J;B/I4R
MA8U *7@FYB2 F5,6T\(J4@!#J:D-KIN"O9L,)"JDQD\]03L7AXD8N<%H66BX
M=VHA/NYOD8)N'C.4%./WETLC+Z7E,&MJVBOQ*[W5X 8*EL-"2@ZS<L)K>231
M7F9FA5RZDA;FHBTNB\IMP#B3:VOJLOFKL:PZJM,B&TU%85HM(\G!W=6IP2[X
MYY!K;IKXY/&??[Q__(TF9*\]$&_9\?=BS+1P1+\)KLA&^1MG5F)DN058_O3Y
M(T7GJ Y'&P)7Y4AJJA0\6Z.GBDET8<!399S.!Y<@H"4ZU"6CU<X@R!LZ?4GU
M@:KH\MS[W$'7^<M/KYDF^NW(&[#0H/&B:Z^B:,_T,NM]&L"7S%**BD";(Z &
M4B.F.3H"GEQ1G^J(Z<[35B.'BF!7,)SIWJD5;D14#5BJGM;;0(:DE.0K>!,'
M<8;X!6(2M?E_$)J,W'S$^6!@;7H#S4^_<S20^P"O2W',C?B8S36C+[1C1  V
MJ7U!T+DY%N6\)5P.+NX50\B&SN/YQYF3SO=#4/XN[C^B.RXJ?>N4Y\P>?&J
M%*C^\*''@&BFN7,_'>RW1>IN(QC)UKIB_39,\(^^5Z.Y-&<7G;W];(21XZNC
M>U]B.]DRG)P=_?US:/6$..(/OOKOU,#ANNK<93E,V7;6=>\Y-_D0.RJJI@[C
MK7CQZH-*&&-3OJ+#^(SD$NA)[]_]N$9-Q9-TD#^K 0]Z%=V!GR2332Y!#WO%
MV*T!'6UQQ)410$7I,D[ASTGM))AJVET:)Q7Y3MQI.5["*8TH7/VG/N*@FM6?
M\OL@1J\)OE!5?1[1D6 =Z=$)3C6B>;GWWZ9H52@X/X?T-^TX3Q3*G@I780P"
M[2NZQ2:ZB9N= ]3QNUB=!)G9^#IQ;TKQ31\0SU6T+9E[JW;@H:X:! ;_DBPL
MU[_,;K0[<U]YMNZ:6_+2E>(I"'8C,PN;2\(V/!^V5_?Z[45X:0@W3CUD O:D
MR<L.X65R+-VR,I46IWLP/I^XH*RU:-4TGY1#&](.@6-+LPS ?YES"4L1J(UO
MLRYI!*AJL @K +_I'D*DXUZ=WT<6#.]S@!XNLK.%@@G3^G*!")D.C]^7,F O
M _3@WOUOQ?,S$G[I%*PMK*2Q4*QH(;IR@W6,'23V>\-A43%XSFE/0R-&T=6N
M*Y6U.N- M2 'GH>4EP1AB\)+Z1->7!_/F)QE3(2,:LZ:#W8C[MN!4TL;,+Y.
M*]"8,_D!F:0I#7J,G>(+$U8G'G+,^$?+&9+1 LTT8;QXLH?@^=3TXD% I%*Y
M[H^,0B*I/$59$\U)Y"Z/X,[D^)M\9HOE\\GCYC@>A^2]A,35IU_\X<?$=)4^
M<\G-11/8\:>UOW\5,ID4VKJ2&,\SWL&G$D]\9_3-X(Y-O!6I8H8@HU\MX^UQ
MQ2X<[+]#/2RKAWU[J(?=CF?Y3ZJ'O2,\^B4=*$#?$%I<<H=F2<C@G;A&,SI?
M7^3H:3(B(\(>=U^4[Y<P&O#Y_+2:__'RVHM]_ LL(0E7@,MS^W+4FCV#)R%^
M#Z-Y/1G;GDPV CE3"*9#%KGA:$6#4*]K<QQR+5T^ZWLZ#2V*,(8'R<^4[;YF
M47/YK&;2[S2S']ICI=8M%D02,E,ZQY($P<GS4V&2S^CC[2KR1]:-E0_[7.^:
MT!&W$S_(5./= 4MR7/J 7,_E+I>W! 9!I$?)UW(%AOMU4\5#"NH)93>_(#G1
M/:-.5VIGM+X#I,_2]^$++=HX@?3YNEQ3(7M#>AK@W[(I6+L]G%#*<?^4EA/W
M@L5[IE9S$GL778;[FSI8&,]WR+:)NR"Y9*&*;P=70_?,GK;<4M@^_O;L2><\
M%+"OCJ 7I=6RA[WT\"@7Y$B[ UWZICM+$R(#M&Q9DZV,[FC\2PEA,,9VX>&3
MRD;J-<ML2 \79FT:J2<Y[4;J%Q0@+3HQU\5\3#V8ASJ3;#HQQ:9ICF+(-S@-
MTCDRPHPX1+Z,M7#2&F.5!<5(I,39'L*0=@RWYC+!Y\(=%9R2K72HWT@R]TKU
M;8M"?%NZJ>K&K3"^ Z:.M 6N<)CLFJW!,(?V5+=P?%O;VE9_6S:9$,^>(P1%
MW,_*S^T&<=0H];GA*( )1'.)9+?;IT*;"(MCCT#H%GFR9 V0%Q7LB^XC?5:L
MCL_*^!2]]/:T5S!M>Y/331PMWV482+Q*R^ [/_:P-%UKBAMOA,9\0*>9TDV:
M<3H1?"0>.OK12C$Z]%R)%7Q!N!E40JP+ UCOHFOD.X&8YYAYH< MXM_C&8-X
MN=2,,K,Z^*[4:+G;[5H!J%=M^$6Q(I-.7XF69KL1/"O'_;P!:0RV;3W8B)(9
ME]ZGFVY(AV7(=N0=2V ]0Y:H%D"ZP6^T>2?K/LW9-?I92"PR[J32IE-M&DG%
M3P (M#2C3MIT8&J\V NE>:?2A'2#$U1QSWWO;0JCT-^H;D_Y,[]W5/!.'OGI
M>9,:Y<::^K53_MIC!J8 7ST1KLQXS_+SD:,R?D\DM^",=%OE&X ;ZE^",MDU
MN\*F-("2MY,M/$/&UG$>7"=.=Q4_ &?DKKN"DJG_YA0!0FRV2!R#&+0UH8M\
ME7?6H"(5E[CTRB18(A_F-^8<B&%:CSWPV'J!I6OX^W0PIG*2_(UF9O#A3?4S
MQ1%1@_Q;R+"-:P-F@/K47G8MDP20G]<)Y GS8]/NY9_M\;A=:NW1;\/QZ;E6
MU0^]<_J$96=L15>@T&^G$;]Q>/%NGK=WO+W?#7N)7A5Q.J8Z=,PR6Y6>@<")
M]Y4CAXVMD.W8QO/RC_G9DIGH:YSQILU8FOK1-T8EKYT-:1J=J\T97B9$[C)_
M);G>.[ ;-@("O)'_/:IOEK$>V$B\+W58'V9YS2:F%E_JC#PG^6?74L*2W%YP
M'-UVY%2R$Y4=$.,!1?*+43K;C;^4^*CB]GL"X3S*P4,(BA ]>%++N70Y=;G7
M\.%SO5-S"-#!XLY3H"C4S<;ZFWJ.,T$&*5%Y8Z*D/?7*:78BVR*4EJA2AS"W
M>V+F4],,.]?3GB.NSX('XS0*:$<SGSHNJ)WL1=NT7)E0+V+O%OZL^]R@,<2_
MY.)R3PID/]2C9L_N*_PZ4!7O/=]U-#9)%MUT.*W58#Q1-@IYZ4%K>@W._D=[
MKHJ19./B(/YQ"124"=.-S?!*9)XT%4B^7H+Q%+Z?=#Z:*[@N1!EM:=L?M\3Y
MQ$YAOUH5[3=]SI=WH7P9.3)OJ [XS1UB.GY,6//G1:U:"B^5/I8&XV7:YW<^
M54^._+*%,,]<\&.&5MW/\R%+/4-K9S5N=<+TA*J!IY)E-N"X&-Y(M@I'2&7&
M &\2$FJB>XHC]&SP65SVDBL*JS2?0CW(/:I-72*LS=H7QM^ >W[E 8#L)RNP
M,X2,\8?P]Z>CK\R:2;!^K6HF90#E<:Z0P4@1OT&>I.T)?W,%8*!R-2OJU^SP
MIW+)H?SLR\]_/I2?;\>S?/#R\RTQPSD(5(&0>5&RJ19&4[&(,0DE0SD%$NT,
MLKGZ3S5K82>A@1AL!82G=@.SRVA#8';73,(*]"7[S#-*070)2H0SH8<TNL3-
M?T&2$>WFB Z(P1T_4U"FQR"7G&.LX1(B)%72/GX+,<?&5_@Y9XB:^IQOXBAY
M>G>A%T\,5.NJ4/J&Z B#S.%S[7SW-#5X^7QFP&G'<+\^@+O;KBG0<-2+E3%Z
M,*7N32BVC*J&*B-,MX7G)UFL[B_O[VZLZ;GB0%5AN?G+%U_W')"C3[CTD=_Z
MVOCS/OXCY&-S_\OCKV@LX %*K.87A4Z_@Y[I=MW#9C54WM%4\@A;D6]!RM;)
M\01/I)TP^>JDIR Z3.'IQ1;,10CZYH0]J[I1ICC4E_>L?8'<#;FB1MYL].8<
M_NC5]M%-]2[EI?&Z/=IX7^(M*,W-S)(W__ZTUYG%UNMF\WS-&%S&#?O'^_<2
MNQ?]Z8\/_OR5?M!3O#ILZENWJ8EV$?:^#S[]JX%/:59)AD7_TF=I'/2[[K$.
MH[: ^V;T*+C")KRR-%G"O]:I15&;J.Q=<:9CQP]?>?+OO\W51NJOO(7&[B%S
M<H4!&SS!>UNSO^ZQ9I3(\]]SSS?^@W<V=N:/O+-1^?RVF<,XE](LLV=*Q Q^
M^:!G!K^YM\<,?N@G]LOM!H]>E]5-JT.?*$?UPY;H: =$<7>LI"44O"IGBKDI
M-L"@E2)+R(QM$,MX.P]K]JZI\1#Y>K0%AV;-B7%*VTB_Z61>D3JG=+_^93*G
M9BA4  '(6F[C-0K2F5@P@0F9.C2;HGB\"HMRCOQSO.I%J-:L\[*.EY!42Z.D
M</&>%56J 1C:0./S5<.5N5"S(*]VKS5K*AMLZX0)#JMUU>P"WX>:,QGEPCQS
MDH4FOO0X2$!\4I@1+\$03V-1?Q/XOV-HQBDD[LF@R/ B%-5&<EJAJE2C%U2E
M;#?CA8R[%+EI4@Y>N I>IZC3K7]>O/9E?*N[5D7]Q4L;2K=&M,SH,^[1^)%7
M33:^X (CX\IJ84[F/#\-ZA'WQ\B/;8B.)S]0508K '4 $$V7J,4S/]O2_QRG
MS/V'$^H6E1H!]]MT*>\?E_W%KB,4KG %$7JS.@HDP(&@4Z9;KR40+LUF4NEH
M6VV8#;G KJ/%R)E?^@M*[W JN.NUBGOHG#K4*3Z.3T'9PPHX(83XQ.(0>!MJ
M_W$\##O^Y_'D1)O,J?OH,J@*4+:,DGN!R>;CKV[>(+LXG2RK\+;4_0ET1XV>
MLZN7M8&MB6>^:=-LM=QL)U5TWKF*K@T[C--=6\XOMNU>0\#[6VQ!VN5LST+@
MM9\EY]WB=3EI@"_0<Q9GGSTN)J&P2ZKF?2)O%3QPH@^AFA)(.>CG @$H+HGC
M@[H6O[QW_[/7GR,Y,^"BI?>AIZ _=GMH6M72S97_HZRU)VM@##L(S0)"N0Q*
M?:050_N=JJ3H"NS6HO2LG"!3[B1&[BTN[2FOX!T1QKP)O1_C8.JDG[O+<?R#
MH88):IMB(6HW?K#<*E>@QS9]1WX0OV"@;8@&<_?>0KO[&ZKJTNNRQ BFC+?%
MZ["3+5R':O!@>]=6?LIE&WQXYM$Q!RR!(.JHCS'4Y_20_VQFA" NSVNABXK/
M DIXFD=7P('5:,4MR.X 5LPNA-?,@[DJI "NVT,$-??O$@+\-S' J@/:N.OY
M!:4?,>^JRZ6JD6LZD^^BO;"S>[()H"P'NJ 4MX(/AC@N HG D Z\M#@R<2 +
M3%MAAP<7H6L]6D3PDTUL6A-TFA3=Z\F_MK0XL7O!Z0_8=FBU\F?1;A#OC3QU
MJB%Q]-LKZM&KN*DCC@L4NU==J-[026/-SN1C5E5Z'I_R+FNKS6VH>Q5-MM0/
MNA'O2-\[\(O&H*%JXA%) 0RQ"@V&0X6:'>FT$[LI56*0.,VIZT5$6IC>)M])
MAD#1E<^UQ(2P2=T0IG>:D^M^7S7Q_)X\;A9:*$&7EHK1$O@ *N#QQYO44A#G
MZ.'DAZ*-&Y.U +\CFUXFN6_NF:7&.9YNE,MW#Z/U@/\R>25H _V<OG]"TD"/
MFU9QW_RWN[:93C:I0D"T])<)Y"9!R2QZ'+633]&506, 4</N+Y-'5-MY5I^'
M>HL"S./H=Q6S1@@"SM9E6]*HMR7TT9_$*(@,YES.F!6I:=CZ(5?KI48I3\NV
MVPC1RCG/O4CXX7E6C#"*SB,?4(@P]%3AY@?9+AP2%+S'R'L"_;]0MZD'V&GD
M!<N"NG1J\PI\HC*\L!)?FQT_L(5Y.U. TI  ?6;9=[H/6GQ+^J<6:2$&Q1Z@
MH@ZD74$CU$97_YS+ZK0F2 G\+3BB:6&B%1Q#'C_%#>E!M:D@[O'D;X.3AV&&
MR5F8)CFV^,LXT=-XW,8=4]3*'9 !%OG1L,_$TF9=(ZRTP>_)RA*$L)B#=J'_
M<C0\W%W'YI.4U\5V6/!"CETT2\JL;A0UR3:01Z5-ZW$F+\I923!)W>D6?E>.
ME;.8//CR?[Z9A!C@SJDLN8':$UMX-=]:3E.AEAHL W53[U:066'0 Z@NHX4!
M"*\7?I !?-- D H!3*B(-F0!%ZX5)2O)WUR%X_U/A"]\=>\ 7[@=S_*?U#U_
M ^#ZTS!KMS$*_--_W?_ZWL/[7R*E^Y48)I%SNG]_&A\%X-TC!%8C":>X^R$X
M..G*MT)[S\&"$LVUS=N2,)71"[P__29>+EVD'UJR4>64ABM&VG>4!QM.6@Q2
MXJY93+1DX2GW^6_R$?A4Y$2%MQE/R(XT Y,?X!'G/U/*9^#N<4\@\;7P40O/
M''X!^>H4KK796<+I&LYGS^(R4/#^>1L"^VV</Z4*A'556*,XT-L)EL$$V4^V
MA)HH:FXC-\#>H[;XM:SXN*9QH73MZVBN*_)SVYV$W^G?U(Z'V27?M-.>1TUO
M23.?(L9MA++4Z(SZ_J_2#;BE2-+3>$;1>]+>-OG /Q6K]</)60PBJ4.=78F[
MYO@ZES(3EULV\ZV<^9P/X*!*,WIY8OWJG#KW%MUX!*U:>_H(?SZS6JW*23.'
M:SR@M86(,P&NA3S^O_,=%K:DB/_"B1A]2.6C9#HTN7L5A,[68CRZS_PB_I[]
M9TUTD*..7ZY)Y#D^%?EAM?IBH% @CY:VRL[7 6CW/A16+/TST<G&_ZI20 Q=
M/SP.MK4:*Y?$Y7P0)? 6WBNWO*U4PZ0%HN;@$>Q6XIQQZ&:FBWER*6DKH6Q6
MG< >EI&GBAM\[26_V"KZ5*QO2P*<Y0#4SQ8$G[+R^_PB#C4B&;)1LC)DGFWB
MD*Y/ZP]M%8!.T1JDS%9![137PJAN/[XB\4%^;"Z<&X M[C'8X@3X!1IYR3K\
M@.3KI\.$_.%_)T<:8;I5(GLLJPQZ*P42 ^TM2@5"Y%#;:RS8C=,9MW>I/;@#
M2^U)RKQ03O"Q6;S;L=BRM.ER/$NH)Z1FHRG?PE^20Y:\27!R:!:2#'W7+].A
MS-5&B_T[6'E?W(&5]TRFC=J9S1W8W8)E5ZXD[E!OQ4Y<6C&)DX;)7MZ4;5,G
M5;L:%"Z61Y(PAV@%[OZJ^O(.K*H7AJY+SN\M6%3*5@4WDBH#YRURH(!=061S
M+@+/Y*:6:R0&$1IC/0D6@>K.VHI*3NC<V-ZE5XJ@$DJH?L>BHE^8B0#=%' Q
MX'&FU*OXP.1_DSLJ?FLYISY,:Y:5*J-0VL@O29%D0]QFVLTF_^!8HUN7YI%;
M<@*T"@\]W7CJ[=?J?;HKN2WNDI1=/]\65$<.0C'4-BN0/"MH9I>T(4E:^)<@
M7=%"+-.<M\+8!";>DWBSREI-6!]%.5SX=Y8U7L*):NI>>'899M2U?.=2 $^M
M:?=9;?+FOX_.47NS,KU9RBTIB4B,RH@U1=)^%*0EPO+X-2% !M'>,K2()8WU
MX5TD=%\6[89O\NS94;KCMT=I!L[29@#])C7M,#]##*F_*S:%D1<_S9C8\O<;
M8Z:COJ+W%O_=\^3?'*4>9,,@?V>JOU)'%=YI2K#:\SY6L(?49JU#//&/ZHN.
M/Y]NS4SXH-@N@!$8U3+@B@R36)#,F&&"%H[#$.G7_LWNW(Y^;#;I][2C7?'U
M;5B!8ET;$K+]&A?5B_FF(5CV@V\IAW__GJ;5'Q<[ B4_ZPAF+?FF2HB\3:6<
M55*LH1 ,[9E\U?C%9BS<3H"%+OFFP,GO^JG[WD\A2H7V/,XDNWLQAU+_A?F(
M5?XR]_6&<G9ASQ/&MV#AJX4*)?/7L?&>$V@D7HR)HE!O.&.1NF[R&5_H<R4]
MGT[^_.7DK"&H7=PJX"(GG3;"NDP>D;[.]RU: _CV/_[C_M']^_>^G?:>AU]"
M3DV"<;6":+V\O#R>Q9D/=3B.+^P+ZFZBA=(FV3VN./@4B"/QU=L(_\60E8@>
MF$@ANPLP7]#-K # 2\S?27C2BHWZ!'Q;D)?AIM/LKD4'#>)Q6W;WM5.$2)\R
MMU0^=^L1%+V$3^NFZ;\S:EX,_+8>_0TGHT4J4:Z2$P?5Q<J8SP3HHN=&.B%T
MP53-><,8!H8[,'\P7<(_W<A=4]^,\<+1.T0?41!98P>44,MI7^]HDY#I,L7-
M%%BV+H&("1W2B7*,<J*X)W1/;X^PB#X]A\FHS4FK"?4=E,2?Q)O^@P1J7U-D
M>(-P<@!PH*5\] 5^#6:\>5$)2(&@HEPRC][&-U]^PFZ]&&#2B,>5]>6W#V+$
MLEO-F@KTUALE/A3'L//V@S4VB/A7#?D.;'AS8A6R,*77N$8*%9V*];".$YDG
MY<+;5A48E5D9F#W8'*4SU8O2XW?,5+5I<B,* BW:'&"ZAHKG&AQ"@W6N_(=7
M++X-T($$KT]5THMR+213U$-2+YJV8Q D]<U3QB!^0-^)-P2']=2AD.S>!]A,
M!INY?X#-W(YG^>2PF4\45IP80/D=PHK;YZI 7#"!K=EM5%]Q Y4=9A+V(;+W
MYE362M-"3$L5K9PQ]['XL?Y=><:)&U3J^C%VW[9UR90DT#QX\GA4EI+^9A2D
M)_.-LM-I/PNXY#RS/3#73^/L3.[?._J1W=!_;:/S&1?O;NP[_S?EN5) D7_K
M6[K0=6_)S*?IS0A\ZU3)SF0L[W_Q6?$Y?>W^5Y\M/E??)G]%Q>WD,S6%5"J:
M:5E%03)P,BU39;US3V-#&(?72OYOPWS+9RVB'\(4,T,MD6S16Y*4<J;9/?H>
M7SL2VOSQ3XQC1?K*1E:<6TY(*B?2228][-*S__#CD[>&!3NC^UP498^=5L"J
MKP/[@3Y8V;?2_2/T!I:H/1OZ:9?(TW?*L\_=J""NC:\6"-'5-C5K>/$2[P=F
MY@CHFB<]VF::UKV^Y32]YMF3XVO9ZVZ9:7F*G"!A FEOQ/]O%)6BJFN&I=MG
M6<9<W%DQ?WV.NOV1O,D2__?P8[T7&:\\(O^4GCA;M+]//J/U!9OVNJ;@,Z[5
M5Y=4Q6X_-ZW=^.2W<D3?TB#^C\2KC#[Y]$/Z4UF_#HMG]:T?O0H/6M881$F(
MZ6!./VF02,/XM)B'6=.\OO7#N)0'':[%Y! \B]%K0=V<_FU*_?!VK6((@)3=
MO"*G)*G;^).0J34\Y3*]I/P(0)=912 $Y*7X='?:RT^_.[Z=,YF.%4K[6/_?
M@CM,T<E_H]-G%ECY1$ZM-<%!1P<2N Q2K2E-PI0E+9.T=AS4&/&7K-0YVT$M
M_E.N#A>QV!,3;J10Q6UF,1K-Y>9>)A\_-#A=SW#BLY&](Y]+U3JK55 Z6B )
M*@M*SSDI-%\\?:>$\7]D7N3!_KS(S>F?O[GWAT,RY9!,^7C)%-9I.3F>G!+"
M_"F++M^%2M [X<<$AV$@=SUY)'W1.;5)D9W69(E2X* VRK3SE&(6XGG/@9-!
M_N,Q\X]4Q2.R#=59D%H>D@2L+8C"DU=OB \T;\L9V+DJH3JB1D]_]F6'QE@A
M,>]HWPM%X&2%AR-(B4'Q%A.!6DP^*,IBJN6R&2LQHI]7J'B8L%;['$;9]Q'6
M._9]*"\U<TXD,7,_$ON<Y1&: BHXI,:1X;"K]@ 1\[ZGO "?J4+D83(#X OA
M'K*:'X9S#\)"?+W8@% )V/O*H\9!HX6?BLBT:.&'@B>AM>+O#N!6XP'VJ:*]
MBY)\ FFRLV"7I3^UB'3IZ15)>VE2KI)D R?2(%I1E.T^\;KCR4N&!Z&4I5G)
M\)8H;4Q"@C[*&[N9XIA0 >89QF5$/#!'58PML.73NB>0(/7;7*#[BMH1[P-=
MU2Q_^QKX__X_L_9__O?@*7E/Z8O?Q%/ZXN I'3REC^@IG6VC->..PM_05^+]
M^,]M1SU_M]=]>H03D5AXXL%EX\"'UICGQ*6&VATR_OQ6Z3U3O!-YO)ZD3OH6
M<O&Y#EZ\?=+(,T"81KW]2XG>-\D<00*6@UZGU,FDU'R,X*X&+T@/,.<&3OK+
MJS"_J.-LG.\FSU)+TJ.&F,=4/GR\1$(W.PUUM$&S,K7BVE%NS;CD*FSY$("F
M4EQR._)KT#[*,V"QNH+6A XI^996\BOF(3OE%\EORW[ EXY+)?F5:#WER=4[
MRS@#)C&\$:MPI4-6@,N ,UVH7N'0):;IVS3G(E2&K!C^TWN]>S!..NGX_J!P
M!8*"LU39HJ_;;#RFIC,>")V,LR=.UEK\T;B>F6?5KVAR4KLAU'E<'TH<U&Z?
M/-2!S?P#L9F#_LSZ5%FJK:S0]H7>\R"M(,*P@_;Q<"Z52'')*16WWC!+XDZX
MCDK(3FA/*Q)DT=TD%WM'6FI-V[EM8HP:>!)$#LHI6@=*\]%*8=B=2D8KV>IA
MK7R\M:(T)@K&=IJ!:-")(=&%\BTGM16.IECN"J$/@DHY0^)TB +Y(BW#<=WP
M)5-0&:UQN@-L)W1>O+(+@]HVL)&TG)7!Q&Q?23R8<4$*#;LN9N!*Z:CP.\.J
MQ (9U(=2EGIP?Q-S6LE:8F#$XV=J [#7AX7Z41<J"TZZ23'ZSJ3T3O/)B0FC
M@^V,'"->=.K:^E6]4\Q/^2NSH>*:\;^2"94CL9&N?C%3?)A'/Z"FA;1H#JOA
MXZV&5REY-*211?J/U:+S8W"6[)RAJ(RBX?*B@74BDM#R''T,N%C+!I*.4- :
MEI3](=+1E%*4:W>K: U_!YW0MW3.^0 1WL3<U,/Z6U\L,W I4V:X]B#H'4JC
M3A+L!R7.D)I>$ LE-3:0+6%.R5"N9EL'MNY)+F[K9?$F/@YS I7SGL[B5+F'
M>ZY0SMOH>'#F&E;T4_3O(%Y^6('ON (?QZ_!EW59=.8S S?2A,BJ-Q=,9$2.
M5 V*))$A%1*Z.F69J3F-R"N-M%+3Z:%HJS)0CF^[L!YL2CETWE]9MP$<YP!4
MJL'#U_1:AY7P 6W17!>#S(R4+T#6-8\SAM;8SD*O15BA)06.9;$,PO@,KJ]B
MOM/$/Q&/=\O"8")[Q+"IDM/TD!_LHA*-:U>* #M6@?FY93TGT'+*B<R!C\B5
MPL?4P>$HD3R$<"?.QB7'.9!,.T,8K<V]*CSVI3=.AZ7Z88]-@),0.2U*6G);
M5DT/=1L/2@A^JQ^D//CY\I[F'V;33#:(EZ6=2EA%C$I/"_1P5'V\6:=FRU2*
MY"JL)3Y#%T\8(LMSTS@ETN\M69YMJP'XZ.9=4WTX1F);M QJ8,Q.U$4HWI3H
M=H#5TORTV!_$;]GR4RNSHSMJ@\;0N@AF4#K^G-.D_/1<MB:?S;TTKS:RL($I
MC7P%]K#R/F1H-B+!OO\L<\R[4ZY*3(5?UB7= 3=F]WG/96C]B0,FLL>49]^N
M<'[125=)%K^L*3^/FOVV%B>*+JPIJN%A*.Z\.P'3 FUFTI*4'DI?7F/1WE$W
MS:$ RI7C$AOQ!K3)#O;Q8^7(F=9TITXTSV \OOK.G)LK#>R:^KQQP1PDJAV8
M6=5*B UZX;_$^.#QM!7)W #J46^\N\8A1? F-7^6^.="#.N2:U/L>WHCFCT"
M^'A6B@UR"S^N[_C,\W)=B)9#7.TK1\&<#]W!E_O(V?J+DLJXTOH%MY[H!ORR
MJ<.&@%!=2!DJ=O_='\3P\J(_3-H'G#1$[8'3CG)@N'TMZ#K&_K%R;$9Z+,?6
M2/U$K@7'R*XR=<9A&*8-HK0]<2L873@1EG%8'];)APW41B<X2T623:XAR[(1
M4*\Z&E=:95L6TJ>#A&AXRT3>YHEEESE4-#ZJE6C)LP3T9E#&U,@L&#%-+U\,
M/\.B<YIYHEROH'OWPKN;%J*SATEFA0LA^5W'7(<\0,P",57X4R$+TDH4%OL-
M(5=)3*GD*$ KJ<P<B5_I1P41JPCR@#8 (*^;G:796T8*'_A)<G3IEP=^DMOQ
M+)\ *'JPL^_I0F/'2B/@A/$J*>UE*GO4P=%"L"ZO]GH0BL^GNQ]"1=8NZRZ"
M;'IB^(T^/!0?>_YXECFC1'_<NE5\=Q8F4DW2N'RXK<)=_^"A?5@/38_&)%%7
M2Y*1BBZ+&)I!FA0]2Q<%R>4.';3IL)-*T$Z'NNZG]+R!+1;?.X/Y*$(MSM3_
M]%!#87*R.@^U=8@U]9QQTIH:GSI*\[#(-B_](3<W1D"GB>QX@\/,?^C3P*5.
M.*-"]#N"9^2)8V<XR;KI=X2G_/J*RK174LF C9FU]PGH7K4$JL:*P.0NN\/B
M^) Y8LD(*QQG$4CKO=-JDNIZ@>\!9P&Q]QO15:?,%\6&E/ V4_T6J_/&KQ :
M0!K[PL+IJQ_F] /.J1V[Z"RQ[#EGR)CQ*Q"FASEF6=+]B$JH9"%8#Y$!.Q8
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M!KHA%\6FF.;>3D',R2DL2">,2&NT)5.ZM(2<NP2NEO2F\.8M$E*\3A9].FA
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MM=3S?T7;,'UG[]/*I^IM9N[E1$@16=A]H(:X;(A^VDXD--M*XN(*E<(!=Q\
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M*6=;Z3'U^.<$VW2?*DB27(/$GOU"SCQUY[#***28!SU"PQ@_^X'QZF-V0??
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M![9#C(MFJ(IHP+U*)ER>8B)NZF_>I8A=5I?&6\IIFG(3VB\@@C"KG4Y.["A
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MW:"7+P087B3E2L+@^3Z#4MRW:XXB+41GA4A5]NR"3$XR.5Q/878;-8S[]/F
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M<=_(-B6W+E; U<F7.K3C%6(&P,HX3I&!6B"8(E(/N^">^2/G'<.]X]D5=11
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M]D:X_-@.]]45[L6_(_K@#P_OT0>W8RR?''UP6ZQ^YM'F)WHZQ<4K6TZ<Y*S
M.CS'S3Y;/!8 468WY&0]=-Q'5X*]Y=T&%F[>[K9R@'-94 996#>H!&.,F9YF
M@5J3B4Z""T>7]3(X)NQ@T2O>#,G]Z!*O@.OBOHAB=E*OZ8E.V4=_2N=6,?NA
MG/V9HZMB]HRL"\U PWDJSJUR?GD)<0D.*'L%;M!\TNDC2%DKKE<B09'"\\N:
M#Z?VLLD\9KIW39,R^QM30.[U_B?DY9>S9W1J9$-(\MA_>VI2OA2NT)$%>61/
MVX5O/*\XR6WHU<!Q(WESPS:_I$>[4#HK_O<)PA&>7QD0+\K_;;OLI_%][6^S
M$Y %'KKWB;(^X59X&15K,"^LT_#;:@EB"?H^GP0T.".=>J;Z8CQLFXMOG[]\
MYKK&/"8*N5AHEWG#>HN&NP>S$^M[X$<<]<L-UJJLOJ2KL'1A,O56Y)4F/EZH
MH"TE_+)[,C[#.B%TZ]EJI05#3^%>OQ:U/>V84J9PI,AVM.1"\2=!'UJ+9K:Q
M]]+R67'\A-XF;ECF6>/>L?A$EL.L>Q:B'J!#L9]TUD.4"D<H?=2O/ 9 E[8=
M,5Q5T>8:_048=-.V3Z-VC[_M!DG4]$KZ?;^EW3O*44(E.U64 P5_:'\<EN29
MGJ<*L-/.6A,3?';+!K3J!ECS!*D(N!!6^<'HR&$;8#E*9PE6ERP/[+PY#UF.
M^=[R2_1!9(B3XY72&X8'R8"Z$:(KF %#Z H075<5>BA2RD1Q46C)M''"([5&
MD]A18\CFFR%'O!DFS9B3,K1=>'_L!"W.JGZ<SM3FW4Y/K!AGQ'2U=AA(&L,/
MI+Q*EB/,\QZ=U"Q\M=26MD=_EG'A<1ZQ>>4TE92*N(#3[*AU2B6F82"?@"(Q
MWQD,"R**&%+.0HL%'YOQO0O_K+2QXX(T"=:X:$8+V6VRNFN0(<7M:$[+KN'5
MO 83@I?,1!6HR-(%G&O*S@1+.RI9+EW136+.>)G5IGJ/"NU)!WN+@S+:I_[D
M/B'&MCY]:?.B$!(OLWHWV=RN==BC98G#S!0C0UK.+LAKJ025E>?9M4UG\-;[
MPO%9*)[7YZ7UHDWS;6:UR &,;#1 813?+4^KK=-A^=%AG&&*^AO"RDKX5J=@
M\\P38FJ*#JS%F*.T:?&A]^OVDB\KMA4G>]^'E!LN]F,KG2/"BTD;&5TK2SU;
MK:<V)T^;3."!,S+C61@.=G(-QM7K6F1H#J+UM;V6A8PSU!]J-J9DV/_CT8.'
M\D%K]Y6K2[4HC&33-N 4%4>%5AV]W.?V GK+,F'\^6O0HR21<_;;T,D> )\?
ML]^LM,N3Y[C6M-F,ZSDVZ@L&,76\ISM?SZ5^ZVW[NY@D';;!3W63)JAYM4R?
M.I!1[2K+.8FS2JMGMPD4,;SDS4+;RR=S!X0*+SER0*>O7%S1[LI-Z8]34[J=
MS-F8^3./'CWXBDEJY$-7\O!ME#='/ NIU<+%E=5^(#0P< +G#;C@CCQEU"A6
MY$1<R^OR4A.5#:"MK?!=>3NUH=#M.#QY=_R60U1H"(K=.F%0PUE94W#%P< +
M0SE\P7^TN)"_]EJOY4'19M<#EVG*F-I2@&[?.F><YZ9HAA3LA+R/4Y$:XJF)
MXN>R L\N54NS&PO1UGIMX#=_7"$*3N"-_:'O&^D#3292O2USB'/G([C]*0 )
M&=;,=QVM&N^&S]\N'IB//NXLW91_AW=ZOA-G^E#Z0LA.<(G> KX@MWA@N5CK
MNR+5Y*F8*G^'&"U#Y"9^Y0&^.<NHPYPU!FTY>.><NF5=OV?[SCMR7=8;Q03H
MP\PY0P^XW'J* OB.&;_KR3=9"?F@$9J@:$K-Z#AXWG4@R,_:$VBM'["6 R:G
M,I0&,NH!'$CQBAU>,8>MP]*>^"SP 5'%I<.8X_+H]%S26,XTQK%UDJ\.=ZR0
M@)/^3O="42QLLJ]D/H\<_.906EHC>CCC)%P1?*%0E32%SGSI:OOVC":M&86?
MZCWL[E[]]]M$P(5H601B>B#"/"@57AY0>YEK),6J%-1PN69)5C'C5I**IJ3(
MV*_B_YWNR4]BNK,#<_A+1:AE$'P2H5'CKL%-WJF>5B_INU6[,!UPC5Z<@DE?
MQ[9\;VUY?$C?]+UM6+6FRR)D)D9LR 0PSR7=O]K4?9_@X&MXXD?&J8PP\<GL
M;$=/'+H'[1Q]D@T$V1H+HU1)E+R$NK$+A&XA<!"NT]>53UXLBRTA\;#A(B"'
MPFN'+P&7AP- \ZP3SX.O.F!9F<S1M(59N9@]>4R"3]/: "&!\[-4+B%]4+->
M"-;5B>10D-<061N:I??5WFY,0=LY!U9)5XR)^F4+F%S4VLO_2@O ;H]BZ/KS
M.H?GW[";WO8@C77S8/;"*BQAW>1[V')2D8LKIM+&3RZQ-1[$W&\GQPCU],@>
M5JA78W_Q?5P(:741(+U8:<5,I7'$_JKW$#Q>!4V(<&Z7H]6OR<<E*Y/V@OXI
M&A+#8AD*C"7=0Y*C1(I#:OX+0.EUFM4<3FTB]6(E;3]@":5MU)UF*U+> 7OL
M&F, 23FD\[&(T^XA2>2!6"N\"+M!D!'*R1BY\XK\/ZX9+"-#8S3K@]'),A#?
MT>^6?R:9D"!?).]+H"":6DX9E7[1T?'+5*B&/P[A,3NIN\:<CZH!G'N(99/G
M2FM.,'2ZBE3K5@,D//%Y:$Z4=1"LK*PJ% >19U[8L5,W]G.C&V0P.VHI[B$*
M$:+PZ#!$X2-D/K[^W3VNX=\2UW";I%I>QE;H-]H*??<;2J>(;@QI#.R#20"5
M6^6@L1+^F!1Y@H/-\P&<T+',;?6!CN(^T"IFE[EK7OUKG)12UA3B;CR3ME#
M7QVUVEL'(?\:Z6.>^=KQ$'WP5@(=^Y16L2"]JRWK+&8-VW.3*T8-QMZC.>IR
MEAI?]U5M_M%STD4@?X!3;+W>\8'B<YCGRIC7&C*84?9%E0R9^I4< *G&Z#TR
M#<>0!"A2CUC0,-9.M:KK."5A) !TM.XMOXD23<_<TML^Z"M"-BTNQ[NV^IS
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M7#88\*,B-5=IF_GQ[I1%+K[2/R%53V.B02U:TYRG9SYMZ7KD2W-.%YT@YR7
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MXRD[I>E04QEB-_?"-42<"O7R;)<&FKWG1/S2<MFI\W!0.]]R%LTKM&A*D:Y
MQ<M76_<Q@VN:92'M].1:@1]W'-\V+LN8] \,=9Q^D5^$TRI";A\#\3@3Z,M8
M2N\PEYR"=X&S1SUN8-XL$\5PZV:WF6LGJ[;FIYP5DEWFX22G-O%/0YF35C7
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M]-9O6_( !4V >E?RDL-%0V6YB*6U/!NG&4ODK,F<M%*?P+?D\) BL)A8^T-
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M)!N>)Q@.)H*<O31##@NOP3#:BPAA^&OB44K;CASIPJ0N"1X>4!7$T[0TJM5
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M+$@,((ZM+0H27(P6VAVV;#HX7C$W'<IVHV5*1W[+T598E"'AEJK0+M!OJD9
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MM8NWT>RN-T+^E5].I\[0T=F$_2FRO#S7D>1UW] "7 6:ESX; YG>GC<'2VY
MC_S+0IOTS6??O6&$#LI&N@-3FXV%_CUGZ2!@?.0Q1\*?GUKLXHA-$<.4J4'F
M8,ATA?[:UMP#JP=3*/O)P>L,__U3)'$(8O;&_%H2LF#6KKB"N33RZ&?!NJB)
M<_)9YO.NXK'P_K1>[?1;/2Y!TWX7]BC\8T$88C$O?''-:QE=/H(XVKS0YD.M
MH9O?5$R90A-6D,'&=#G2J+*JF$(L%S[G=(3GI&GD%IKBA5ADPT1[5[:^E001
M<0TZ$VSH G(C'2#\B-6VYM*W_*K7TI'"M=JA4Q=WUDB\Q?;O8L$^Y[!AM,5?
MDZ( EQRNSIXRU9S.IZ(P)GB7CU;CW>)\BLA9YVS^U1V5FPM/'#K042<PRIR[
M<Z"L'00=5WL$;R4:>2?.9.':G:_,XSV)%P.#[,?\)HBW@OZ?:N1.$_EEOA*@
MHPMJ:-]<4&T^KL)?JS:\;TG,D5:^9"$SVU0+TQU?#!^@=R98$#M0VTMK/GV-
M$[ 4R),_%@:.;/:LG%UWQ*&PB;%0O8T-K]]78+Z_JA(SVUS%3'1OD+,H9KR+
M6-/!&'2L2&B0, BW?&SDQ7,\V;2X63U,&/IW_]IQC?X85N56.:,YTM@XG$/I
MW9SV$UH&-^$P#J$=V!9<IC&2/8L*-$LG<V_TU,3* 7=GL[^VUQ5:5C'' C6^
M;@X1  ERA:3ZZTI( A/-8,T.<7!7'":) E5P@2]?"BI2D=D_U^E)10^>2&':
MH!J8M.* "+M6*2>_DPARW8T8XC>L>=HL]B-7O CK&H[OWUJZ9VSUV9S6M3?P
M*?SE'4W3,P1'#&K-!<C49"-LQE&;1N@O)/62!\YGZ&O!I3U265MA8",5<7IM
M4*Y0=9<7;KE.!&QZ=%#* QVN?.I95\6['][V3P@#Q2>K**$$VN\\[3K["$QR
MT)0;.2X\<';*.&8@PV=9<(.5H6BUT6!$Q2CGJ['T4M+ 'H8\J#1(75///J;[
M8%)5IY#C+^3!X>)9U*APKY3[<\YZV25G%W6WV*^E*O+C_)(_#FF1P0H'MPFU
MU M*Y/#HFNY/;]:95;8+]T UTDGON)-TPF#E^*TDF*M+8(WT.)R#5@I1F7AD
M.%M2HN63]/E$BHW]49U*;'E+>ZX()JS,:!9^!%/$2X PSQK+[SU=.A]3&UJ.
MD:@]ERG__^-(WAK4XU]KVGAF""@X<!:!X D)BX.\LG^UW>^B2UZZ-ALF+Q2=
M[@V@&O_IG?E"R#;(^ZB,@K#NI%\F_X:LXE,*:))M/G#]BV[TC9MURXPM6K&_
MM@TLX1=R#4?7F+S6_89YT)^%F3^@0*TG]Q*W^:\OGC\SOKF,U:"._<Z7U8Y/
M$8=[@76#')!K%!9ZOZPUVMIKS  LU)K_"/\6CZ3DD:'+:]VM-4?02PP;K1PL
M$!NM<#OVSY^]^I;IZ*Y;9A5<[&%F<4?W>7CA9B/W><P^T238T ]S5"IWM)"F
MJ5C%A-.,4& L9"A.6;(!DSM;]%6KT&!HC-8-/ K_\0B3K="'4YP6T%]Y:L9(
MD><BX7($2@X%2Q8BC. %M8TZ?_SH;UB#5?#8PY]IZC.FA?FN6E3K>7BA1##.
MK6DZ20#M$V_-]QUQ8/]'N=X^G?U/&./%[*_[<O8CO?J''WZ*BQ8N*&I"PE?A
MKA?+;N4JN1^]9,HZ(AYY*2C(.G[$V07(V=GL/H?O<_B?W>?P;\=8[G/X>MVK
MPTM!2*H"90H>,YL8?H4@%('7ZF:7N&5M=Q&NGW^JBER46T>E%1,CAEKE?@&2
M-J*G&I%3$E^I7$,Y:2];:4J"(:V:1A4(%GP3U5K5YH(*:88*#WH.Y6'<&N';
M-M@ZP1+_L>S[<G&Y)UK1OA"751:$MFA;89].N-N4-15ZUZSGB#O-XB-"1M2D
M:&//?ZWI3.'-P8OD'>XJZ"?N@B<2 FC9X@TZA12*M YTK!A(0G('CEI8E?C:
M===QRNSCYQF=A$U0Q&A^LAR?\[:KVT[#ZN$Z?X1[;%F52[:H65+DZOA+?07L
M7!@?;R7-Q39R]H"VZ2$,"7"<+I59++QD0RV#&MV=DJ'>,M:3!AID+S@ZM()%
M2B%"ZW2IO6*X\=ANRI)EB^+O9;\L?TMNQ3MF>/XREC'WI-L\MSYXX WUHW1.
M@F_UJ&QKH'EIRFN.6Z@Q!TZAK#<D04CYI.X<D9*GB"JE1Q[%>)<1>6Y%NTAC
MC292TYJ_''OHS;7"7F1Y[Q@+488H"-Y$D$U% X2%@&NBT!C#&INO&+YDC(UR
M2!&>PL]6ITJG'$_5\&6DAU7J&XCEM0+ZU9=B;PSN&A/NN7KOC-*_'//FY(EY
M96Q<!3F6BRIW]-*<+;W\]8_?SM[@GZ<>DUOC.L?X91JM[-!8SD 2P[Q"1F"O
MV17FJ1\57^%]&)5LPRPLPJ*(GQ)4]^*M2DJXGZE93G"6$4T+;M@GT4WL65BP
M[H*.8:<!M;SH+*G#L772-"=]6]?>5\$PH^G87W)PUY$=RQ3.D;J?-,4F"''
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MU66,QIA#KBMF/EF50)@HE(5F>M'BNB./J.UP(&)WT<HU#-?^-66L7F+4Q("
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M\PJ/DT$M#DQ!@\]V%/H]N&INGHNURV2F[&"C[1?"1J8#Q+A<BE5T0AC4L44
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M*4K$:!8'-LA==R8NP\^"(*PI=$AEE&SQLM5:INW;I3;1OD/"=-5R4U&!4^F
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M1CXF.5Y:3V/[_:2;U6H]1GY&N8T <,_6^EBK_,OEKWOC$K(CPLZ4E ZQAY>
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M6ZH!L#7R=4FG;?7=8\>W.</2K[4"NB&K#'WT<(>,C!%4[*S]&U3@QO2[-^.
M*EDUP(X.3P=XH;D^@@^"5DU0IF/P928O7P FV@I^#MJ,]/,&9?!N!;G' NUY
M5J#3NT#(*?N@@L8Y@J[%K3 OJ=K<-_N0@ O;@Z6Q4HQ1#$03 F9 '>GI7# :
M%2G#,1'K=%5%EAQMKQ;EP>K4=:Q2Y(X=$UFXV)>8535+>D:K,4M5.'9/)>0(
ME*M>"1R\;QWVEQB3D$/*D^]Q-?T I'?UH=WK#Y2Z9SEP&K*-<ML3;>=J\VM[
M8!V\%WH=" @O3)0198B+S_@#E.RMN0QIF:BEZ;X;] G/R]ABPR^T/ Q?;(F@
M0)DWFW+0Y(+9I=712OH7^>05GVN?LZ2_T@.AD,--&'ZWL\A_C+WGS >X.[GE
M3NS?QS87M_RF"H648\3:"=[]"]/!_JQ\JZ  PF*/J3*%>N=713>1<DLM5%VZ
M+S@3M@=BXT_N/DXW,R+&Z@^AV3!8GY$HK"3=\SL->A$4U#\K#CG3YP*&Z<&X
MXBP'YOH154-I%VI>V2X9S4W\*STJ:HB0JP(#)Z?#](FHL='[P!$B,KGC?E/O
MP)>>?DZ1]*T%Q'D6U+\Y!5=Z Y#K[) RDZ9&\K6L\9#.*H4#>@PY//,B+EKA
MU[G?;RDPT+?) KN2E368.GHG ]R,ALF9+CGQJ/<23BR#8VS[.04-BC$O!T>W
MSG-,V=^PE?+R#][+8N#346G=NT6UU:7+&B H?6>\F^'+1?B!$>#]%FPFJ6V]
M ,3'-TJ9:S%A2FN"S,G1DV*=6-2(R'M.\IDCJE"@>UT/S#33[5C:+-B6N8X@
M]O&]['+)%!VOGF*L$:61QE.Y]\R_OJ?0Q#U#JWH53'#:P$%<*O&F$U;O1=;;
M0WNP'=(!, T?V'RN*JZO]>;5\'U&M_DI7._DB&S#,5T'X=ASSQ+KS*6UTQ0Z
MN@R_@<5_P93$VL4.S+^.$3'5/M:PU#)Y$I2P>)?(L( 1!0RHP9LUN2)V3R^[
M/?6O")8F]?G^!.[C9T'\J%-)%K#S_=(B155L1W7JEOE]2)BPG*$<]T[VD]4]
MG"!R:=?49<[:X<BF%<FA*_)N-=MR\;:\P'\&&:1W2F21VR\)'I&:[-K^"GJ2
MU C4L*4?3%FMNG)=7;?=VSA%.K?9.D0+DLI=<<PO2+7[MM,26E&AO :%,ZT3
MW!MU,0BB2,@5U] .P2]I*5EY:Y?8F<N.+E'G]V?+,B'H-ADF= [#5,=[)_1J
MY/+&#3-F0PT 8:$.0@O/4 *.WRZI82^=O=C#N)2YJXT6)\/>$$ZSB^Y&U:DY
M^:7W1CG9GS6#1O *C3%C>^^6,2RTN7 ^]PMB1UWMF]-6CGLKCVN(3"<@(V-*
M(RXN K*(!<"-E!B^A?;<)F,?#)S)W*B($,D HRS[(0[?>0\S\)HNC.P>9W [
MQO*'XPQNR^VKRG6 ]Q+2*M%Y8#?@[!049[4)]PX2(MRV@N$%<D-.7,LYSZ/7
M[8/7\S78')S2)2JC<"[JX&D=?- YF.(=#(4U$\6DY-CL"9B2DV MXE_;RT-/
M81'R:+A7 ?W@LNTES15#(&2]<VAR4RTL8V6P930/U5L=[#::4B6*Z60U>FL_
MQ[>-&OL(Q\T4ZQC<2,1I@+*3)HYY!-29YZ,]-^E9G.5B32V/,;>-K1*Q*K<4
M0)<(4[SP^)XBA&@OT4'/$I$;:BYW&<VTUZC2@ =_;<Q)C)0#\I?ZOW%9F[=.
MX"7N#LKWHJN$D)B*S%7PWXG\(=Y!52?"T[!7RD(J3%>2S52*^E9Z[O4#8J.$
MLLLZ,"(0LZ;B4.5\0,!^$RQ!G FZ@OO9 V6/)L:1AV<_<X/M1=<^,MN4+0#V
MRMA$Z$%J#_.@OJ+_3#"X<S%B4/Q'[6YQ#Z_:WCK>\AC$=N5Z>;B<6 30K3L+
MTJU)UJ1TK!G=1]ATOF<SHIV^Q7AF/HV8"?7R__[;S<KYFZ"=;Y/;>1S118W-
MPX&P8AS*L+[2S/P;B8!12K[0-@ORZ:?A8!/,AOL"U(MJ"IK@%N _V\ZM 9B<
M26&TI.":*I7>J+,\ZUW3HH=Q6.I#N[_[GO)@$3]V#1GITA""GHEWEQ5N7-6)
M4D!.4:=*8&FEA$370F'$FU""G//02HA:U+;+W_UY1MDLBK59LVBGE"+NIQ.R
M9 3S;!3A7SN*C!$<27-VP36I8%O4BWCA4>"5U.NVW=H]")T>7KDG,+4#%0 X
MHLY9YF=+DU3I8/%T.'@R*LHM[G2G@<.Z;/AGTN'6@[P+\S077)%''U[6V_"'
M7]MP.<_H8MA+M9-";4BOUI(D2DP$[O).Q(0T/,G%Z27'Y<?S0[+&%X(.RKD,
M\+0@;+#5=E3[T.<:OM]3Z1ZM'/NQL'FR8$;4]T\1]=8Q10R'W"AQYCR4]/ZF
MI^]!IT83B_6?IB]V501I9<,>_;XW%"5'$-XAQH\/XT;OM1UXU$]Q!F*;9: )
MZ$;D(M\M&U*NSA)O5CS9T0">Q 5T*D6<E(=/C-^Q0= NNG(M*TZUBDU3<96R
M<";2IRO:P]0*(KXNC?LXAEHMCLH%'DWIN0]>)GLS)0.8CL0)]($W)XR)["A<
M_5[YN*R\M"=WMP0L^!C4XFH*9RV.M0"VJ$?DZXQ,]G6G_9#%6'7LY6](7H.@
MZ\RHC]%3/T[MLXWV*X+N*T:/A F&\*,&!T1B[T^]U!=ZOMJT1R#523% .!>_
MR4Q[OG'E'"#EJ:_/7*\220YLU+M GX"=1 55N^%\4<F[:7XJE=]<EEPI7[%!
MR]2Z<&0H/G? TZE3#L*NRH^(1,7H'#@9%IT,Z\3&)?XL6>N*$A ]UQ76W9)S
M;VD/:1?B)2.;CB.W(V=56/#\N1B)[6H_788_R.O:+B$PQ>*$H:IV2V!5I*'6
M.-OS@Q<TM:;=[TDUE%+*CF L,R"T':]91Z(5-S'V"!HYAER$Q,-]:HJ-%6\G
MG*Y[5Q'G"5H3\89*TSP/3\/5: $NJP=#&GQ!P&,K ?[P*9 MI?"!$K;O("BP
MMX_VVYCA=?7N,:>D 54"P5+70=[]$2MGEA@X3^4<DDX-JI(]_5AS)7]<>;5_
MPE/YYBU$J8^FW&.23_&ACE'HJ>K 65"SA#U>.$7A4$,)2W.N<73)"]\EHHOJ
M2K*0_-!4,AUG;M"J04:#>467)6#O5'>VEWN(GO]HT,W$KFRFD$CL)[NALC&B
M?PS]\_M_T!<OFG8.)]KYH5=UU^(%=]\P3U!S")J@E)SWHG"7H%!EIY<EW/8Z
M".GB<A,&?'&(=QU^RZ""/1KIX2(C)14L<NC<L "4Z15_@!X5KO!]^""1GW@)
MMJL=F89TFO<;-5BD_#"8#)R# RLMHR:B\O57MY5^VTC/9M]V;6E"S2Z_Z$[E
MQB%+8T-]5E&'I'&&_,Y_7Z>FD!Q4([052->S$30Z^$\D71TIHNA6P\S5:1 =
M8"=R _P&>B?V7GW0)IG^ )!6RG)W/E?-=[JXC QT^( ]<QMV]\_[J[&2BLXL
M3*D]^^O?OG^7&)>NE((5Q*)=6LG0XR_/OWPLI3-%[#61/O;O9;\L?_.JUC_S
ML)ZWC3[OU=^?V],4.N:NM.%PW_S\[/7L1]Y4!QXZ-N8OO_[ZR6=?R&NTE[7F
M%8_WM.;)@?XH7<?!9*T/&BUGM%6#Y/--Q,F9CHII+A#$M="\F^[D5(?MBC3"
MDM8^J0E4U3!:9&SB(V!H\FQ*M%^BF% '[A=6OX2'T-<$!'_9596=6RAJ.XLV
MH$L**A?VSUP!/'#MV.4K<A6@F Q]I</Q?1B?P)_WL3=%X8"I86I4LI\\-XX)
MSJ^$<79EW<@/N9L?&U8."]=N'B:L;_'^6)>_XO)1.@#Q,=XW5.BW>HWZ3R67
M0(:&^)')44,7[&LMXXG%A_'U9[,7(W97HN,@N4ONG)JV/PNNP[ZIF7*<(DZ7
MY%.G2OFF#J/N3K270F"&!5SY+8B[GWY"SRJI_Q=K[E9[UNG>C=P<8\9E<CND
MUB5OTF5-4A*,V:''?OIFE0?=*@WE7=F0,XL#9G7TIBY:V4A*<=P##5*@P?D]
MT.!VC.4/!QK<&J/UES%*+7>>@VWI^9(DMH00&E=7+45Y<CHT:6.T@X??;NZ^
M:?D\-@@WG\W[>T,[W%WRN4DNH4Y6M1&7[QGX/*J-0@-+9:MT.X.&1!([3K8I
M>J:<-O(A*$XC12PC$-C*[@^^G>ZB$DN .!T/6[PV/CY%\IW-WHR)BN7S]T.D
ML\\$"B4/WYI=M=WO-+%/OKB$<"!6:6C,D(8F8E)QSZ@2#3Q+@)SO-Q#OQBL]
M5B<6,L33J*9BL&^$V:?X"-:IVZ\J7C!XT\)U[Y7C5)N-2?T2LXL-HJ$]A8<-
MGR4'B<JD@JEV]W7+S[DI>WK>F!4OLE25]7842SY&507)'7NDC)BNTR_15!(%
M;K="7\EDHKW* H^C701- ,>I-_R5_KCM^UIK-?)?D_;!;PLN!6%/ =PE]8X;
M?9&53!H-5"E2(]=36Q4Q@-.TD0,:@]P5==,PZ'>H@*T7L6R4VJIPHGM+J9PC
M8:@_7EK.GQ N'WOZHIIW^[![__'OYU\^?GK^.;4B?O)%,3LO/OOZJ^*S+[\J
MOGK\^7"/P\T@1&[_Y_%9&.<Y;:L>-I"6NLA^$=-)7W_UN/CFZ\^*+[]Z,O!Y
M\+/+JK$Z-7(.Z*=??EE\\\W7Q5>??RZR594HR* >TH+C.O]L.$;:J//S+XK'
M7WQ1//GR,3__4PI3_0+N2/3R2>J# #CCJOP-D7^L9V\>?>9*M[Y_3G^85]P"
M+U9F)UT2PC=^#.?I&PC$9UH,P9BT)[0;GX7___*+X;+'<,*3)T^*KS\+&_#D
MZ\%F9UM\_E5Q_OEY<?[%E^Q_*P5T3VVLA5J4SFG>57&&"DTN.-NY%N92FJ<!
M\' J@8?8]YR+Y=49<"*<S9ZM+Q!&Z%O45@@:!36.O@"+RQ*WKB$!>,OY4E%L
MJ-6G#Z@]%0++*\H!>E0-^E([Z-:5$G4K9RJECIR24NV#!]9]OQ?B1%1*T#\S
M-<;1/B2Z6.$AR;CI!6_09(Q$^ZT$M*SIJ!)O6B4GPA*"V4"X:*P6=,9MQ>S=
M6C:;K1B]7\D=4_"&FS**K\+N%\8^3XY$3 ?JM7"PAIO\[3&[820:=?3NO.GJ
MO/LZ)4EU);)3*)B$Y>JF%&N1!*\L&RQBA^3B?)=X(8[T"R1N$X\=6(,Y:KN,
M=#X)0DL+M:K".Q@Q!ARK@Q.J\83HS)40T3((Q'7:+UG6S5[Y5!/,4*+$HN_[
MP1;L1PO@K7$.& 5).6P+7KO(;#'*=95%'$?CK18A9Y6E++1''YR==034JW+)
MV/"18C%';2>;.HY^OF-*X97/5@%6X!(X12K8PX9_7)A062-!:>)H%QU!N=*^
MCBG<Q'_1 ;G2L6B:9C(9EG[5Y6R4*?RC) [GO,KDS+(@J5=!&20"PH;+*<T+
MZ<4]*KY8QVJCP?)RH]4Z>GN))[Q2+OT$KS&68\B6DZ4]RZOYYHL#]_+48R,%
M"&14$0- -COACM>LW" /T&Z,CP'+9($F84 *MSV(C+8 V:;F#A0C[6G^4 [R
M\$9H!^B8 U5XE'+-PYH@(8HT.RQ."9%"#@O2'H*&?JY75IWC&8"$BXKM+-YP
M7# \\O%%.7G\,2#53J?UT]6."<SL:>'RLTN?"KQ4KWF5-"\7;ZDC]&;Y2+33
M"O_W5/[UY/S)%T^^^1?J*CZ"$4.<"=:HG[^F!C1T_),.CWP>]4\Q>=O+7<_E
MZJ?? Q)R8 TEMA38*CSJTN->D02_DK!DAO9V]70L\OWHZ#6?IW5+]09ETNRG
MP6R_T*S]:#65(VNT=P,U7RW1<'UR5!G5V&AKW-'D@+BTYJT2X=S.X7W%&8Q=
M6,8:$SOE,ZWW[[ZII"G@V)1:BOP''+[1W0Z"PI *M>J)>6R][X$#/,R .@?4
M;$NH]3J!;I_J$ZT0A ^/I\N.7N ;>-Q]<^@7[GR]$6H<Q$[6X80C,0!.MZ8I
M#*IF9?;$!BLD,27 ]KUQQ.XR-D7Z4M"BUT&RLRK,K+O>U,Y3\&-1]I>GB !N
M=B6B(FEP_3M4)I!'RCO G2H.B"=SR2-S%5%=K/$W8'@S;J]PG^9/T_Q/[M/\
MMV,L?WB:_[;H/K &MU1TW*X<*OXR*_!VY*S<7,IZ/[:Q!B8>?V(')OQ6+<IN
M^ (V]GL-=3"]WC*]Y22:-R2<U2ASIG2XA2I(QA J7%;HE83LZQKX>Q[R)>EJ
M=G-C8Z*1:ANFF U*=]6TUU+#(>BPA+*+.8BZ;;.7(<M0,>%8'^2&YUD-E*HE
M9ZDNIKK$%%RO*9AIA];D2DA7E!'-/85T4U8+T6_A,)T?)C8HW$M*MZ?<#Y,6
MP/O>']B<IG[+V7;L$1G%N)L0H787RD<;+W(;"E@THX=][U';0!"(EZ!3QV!%
MHVR(:$ *YB-/1M=P[(#W7L/_'[+G!'9'75")I+[\_3:#9.0@K\ T&FH2C(?R
MIGSXLS\!B_QE JSQ]6Q:$Z;VFE)PP6+;<X<U*R"C?)!\%A:.4MI"(;'?1(**
M6&XV4D V</6UK?/[['.&,WZ_5,<MN[A^OAP-E1U=$K\>'5%G]5JOH_ZD*_E;
M:ID?JPH)- QJ FUC>==BQ7>T\'^IO) 0/XKDP^012)$-'RR_,;42_-[?]L(W
MPE]=H/CLHI+,V4C\R!Y&!*3X.A76AT=?;R[(D>[?2X:B&&/E_AA!YA"871\L
MO+._"KB9(UG70HEV7?)2$.2,,=]626TKPV3 >VV7[J9U9![8LN%ZNTV=+5!+
M&;=H946@H&+H0)*3:@NAWMG0%O&=WLEL^*A"-1/1X3Q!%$8;P>)#0H]+7PC7
M1#'(1J51PR[7#.^[)S%AY:W&C^E==6MN !>3@4CEN0WCM<W#Q;$%X*JZKI*_
M&0\RD?AR:CO&=3FM'M,E31EL3R51(N97*?S$?VN* 7%' T.I8NNH2%%IONIN
MIMV1/X$45J3DKMY5ZVW"P4P!1&5!CO2Y%)'HMJWU]"'Y3O?R# P_]BW*9Y1U
M)[T24%_+%CO"0,$>6@HX@Y843UU701>$3_:,4 7:5K%VTEV2#-@'I75V73&0
MQ!XW@+ \%-XU@QG_$':='B"_>*B:/IU*K&8B%@J" 9/@C'V3\T BD)H_R)/9
MK&66^P4HGHV!BQ:VCI#/Z-VQ#&<G!?(J]6 EH90KX)"M(2W3BKGC,-?#0,NK
M-<^_[I=,C4^&>+44JQ09HS1>GJ;#Z!:E83AN3<VF463;U^P.UPCN<,G$VQ+6
M(TEHEX<,>4U3Q*&>?K.CJ9#\<WBH3JIA5I NS&WGWA!%TEX09O==U>""NVN6
M6Y)(P,)FJYV?Z!'="DU)_IP4ZHO\3LH=$OR<4HB+V5%D2$*X4G.O79*%B6_1
M;D6^*075&UI*AL$*PT=-KB1'*1#RC""B<+BI:V8NCQU(VD3WZ-A$3\C@H_[Q
MP^#&=GJTD*MB5AM 9</[URDY;/Y[Z;]%KSH"KDW6/RX1)V]0]P7EMJFJI=#Y
M6:=IBCX$][LB<B92($QP[R_$TOJ94!X)+,%DG;3O8G*4,Y@)5G ,*T0_0L=!
M(AZ2Z/K4E2U9+.OO8]05$)>P,;@%PG:"Z ]5+0LM=2B/GW&<[U58B@ZAFZ#F
MLTC_P%285W9I\;+6"8V]7.;Y34YVOZ6SJ3:"?T[5"F%E.@$4,@Q;04_!L6=1
M(,F@]69883DZZ+3#4((H78TOK/8IO&E9_?Z/+O%[+O G8-6\D0Y.(WT(ACPF
M7<7]!F/?P;08-+EFR@3&YKC;1="X7S>JS-L%DTS<^-Q$GDEI2,,D4QO,S@F(
MOY!UYDID+HR4NNNN/(ATA/QK)[WD$.C=$PEH4J:/L$P<EORW4G<3GL2_53FS
M-0!8FSD>*ZZ4A&OIR^F3:[Y/UL4Q[*3HPM'^7!^XNTJDWPJ"=P=$^$<\2VR1
M&[<?7[8=UHYK?EMC]I[TOF!>N#<K*'69EX^#NS%"XBH"PS;3RV2*FCM([= N
M(6$/NPSA2>2']T&W9\20BRJ$F7-U=]=AH_5Z%.!$D.U@EEUP_E99:/>V5F+'
MZ;_&=E77/PU!LS'+L?I%>[&I??%<-MSP6!U#+Q=N=%Y&V(5DI\J&>K1>)("+
M\?5 4#LVNY,1_9.3,7$AJ&W-MB)LL"T)ZH>L'R>]@RU5XKBBOWMCW)K&=A68
M_PR[%+3DIZ"VAU0)%#*ZJD9N>>B8U+HZ'''4+<13"DPP9XR,9ZBPKD8RA)&L
M6VM<G\/*BSP84?:#Z][9/*Z?CP4G7&Q+; GYY!X&D,( /KN' =R.L?SA,(!;
M$^;\[Y9I99(XT+/OWLS\]:O^B6#VR,DU;;.L<!)]E=3/\6/U^NB;B"'SQ4-6
MRIZ49]: &#Y<N(JOVMU8]80X^MQF/!NHHG09,RW.D:12\+C,'M3OKRN0@*)+
M']6S,KTFSS>AC;F!AOV3B[3^-6U-CG5%LEA+R'C&5XD C8$XC^PA/X*9'#?,
M3<#=_M(&LH2[YBZZ1Z3N']N6F0SJ+6YC&1C9;]U>KD]$%+QT&T<:G.:>DXF[
M2_U\\)K"?SPNW&1;4DHLD6-^G[$4>#$>HOE'E@!N4)R(<GC!+AV/-DO&+?C=
MZ_V:3@'9Y-)0T'I+K-@P"&:WFM.;#8%+-+PFAX,LV"?GLT79A,F5P=PE-FYU
M"=_W%<2$6-JL1]YT_GGZ)FIN1<6<8]_E)Q. W^]JA$UPQ^=^CRX29)[**&'4
M'%$'B+R@UX9%2V@KEAWBL"2T^;X120>Q5MGW%V6_BV>D&AP-M)Q4EO0U\59T
M,X&FR" R-S*3/)3'DO-V83UGQ453AZ:O0#,Y/ ;A;WZYP&/>$>WK?I>>ZN17
M"!51;J(YR(%!BAM"C_@AX>=;=J<<FW=,/KK!D[OU;N?&%SN$YA?0\+4<]\R_
MEV_Z#IPK3.PM#!Y\WB7+4FW0L#F6F1+I/G8*CBU/7/WDBXK+@_5 &UW+Q^IY
MMDM_W?>[>G6X+:H_*7,^+G;8?9&[+NO04F;-F$W&F 4]%4A:V<+4J2ADE[4_
M\-K3F:>#U7;V7:5C6?&1H@H)^FH6IQH3%7=6LEL-XF@;+JJ.&]<UY>(M'.8]
M<<'4X[QOXW><ANKIH3'I1:JR(MK#NY;0^8?%R ;W9'(O#F3H]S,"IPS &XP]
M!)E(4%0BQ%#$F"8T9CJ'(HP"*3PMVB=!Y_R'Z"H8+<N!YL,U0+HKWD1ZYW!.
MF9D.<LT5Z09T7-5RH%25PH0G<PUTTM3J!MFGV6[\@RF;,_'8G4:R?#BYW:H7
M+NC@4B\R:1K5"IEG>J\5'"DXY:M),_LA$U.]WI;,Q)3DM>Z\[?USHM9 O#6V
MC35CU( O]OI-$4;O(\YZ!4HEH_6_/$VSP;">5PPEXH:[\]Y::-9&U+FLPBSJ
M.6D_#I3Q=7)C#I+.JI\A,DJK9L\L:$E,^6R6>2YC#, TRZ3O^/@*?P(XIF?4
MC8_"A@1D\9Z4\, %"]JSP2[;X/&:04E+$KX$'!OHNHV$@6(!U+1#.SH<4O<8
M'O1D)2WIC6Y'C"('(V[R1I7R,E7K>K^^^Z?YU4?BAIC')7&#7?]S7FJ./7/6
M6'NQ),UT%(*:XA$5(;ANPX$[:)_=/?J=<-0XX@>99:O:7)3<E)>KB1^U*VO_
MAQ81I;JH/\-M=8-VK'JIW1;T4%=?:5!G$'W>W"@P12(Q,Q'UBL /#B<LQ+=S
M)]>LQEQ;$M9D?56]%2_0$"$\1?9&.'_$K#ZDGL(64'L--_^[+[4OT ZDI!Y?
MQ50USR7;L%8PC H<3OD8PFVAZF((7R$M#A*:L%=A*3LE&_+T"K@-: J*96]G
MJ_H=AX7::P6JQ?@E!TN&)%96H<A?+82GIH\\4$7JBQ8QSAD&1LBD6GHW,C.$
MMG:J(B6V)D&:)C*E27(\&,8ELT&5@CCG$>LYUU+ID0OK;/93OCQ\DG:7^QX@
M(>:+"H-:O&W$PN2Q+\J&P&W2[ IMU*2/%>YWWV+;]$.GSOR:6[VM?+XVO9NS
M ,5TU9?(QS\%=VZ4.\@1IW,;08H?Y]:VP"21/UI42K;2%;Y["9E=WF B9(^>
M5S=1@9_@O=WZ$V],Y&E&VRKMELSGQ&0G()NMM,O7KKRX  .:RPW0MT I"YZ_
M+"=*P1:$?*L&ET#' D=6OD;?(SUE.B#AA(/W@A=PQJ$)-Q/76;,*D!. DR(,
M@[A*R'U9L-.OA'ER945ZA9)2U!>LW*6M&1\4I+JE::*W=^9&T*89@#%,[7T^
M-,V'?GZ?#[T=8[G/A_Y>MGIP<,/!(J"CQ?8%B".F4CB<@K)Y%TP34*8'#W>_
MYD2)*"1BV>X][J/DSH3&UP+[WS#"#*V<P B?[I8YU*EV)'=]M V 'X=K/<EP
M"42 E^GJ(F+1(G.@D//='*:Y9=?CQXI&# A2R":&#\D#EW*&:P(:LM_!T,-&
M0,["%-8$_;=AN"QVH<B07F,H+^VN<DSNZ#X=0G%A*:K,S>8=0<MV*>7L7JQ>
MA7$&DZ!CPXL,A!K5^J2[%Y<"'+-BDN6>/-5KEEJ\7X3&9&8H,OQ&6ITH:ZFP
M'QU+V05'E/A!'=\K_<!<5 /+)54W$XC"?KIXQVBN/T)<.$AZ;#J^-,DL#XKA
M:/W2LEWL.JI&H+HAF#;@O]^":-4@?Q[KJO5E_4,N<?@8<5<'$+_Z_85>(>#,
MM(#Z#H]WQ$R";)QX ,!0?,4> Y/I-E1^FZZZMNG1'1%QBLOG6A\\X\C&^3>?
M?59X67E WY.V7.G7I3W70]7UIBM81H-X\Y&DZGS"#C*K@'3 BAA_CO?H3,P:
M%:-Y2!17&SG$KM7R&DN1@_(,&R6IC2RD\U0'NBR"2W4=O,JN&(%>2U@9?&DN
M7YB]][H$-89&IX2"#5=+ OK/ =D0SKVV]74=S#AI@>VY^\[9()J&7"3N\P3)
M$#MAQ-M<T/:B-W"O9[<Y]BP\:E63;HN7_L??\KY%H0LG0QW1]NT)"3R[^W'V
MW],ZX$2V*Y/QB/?]QJ'AA^438A0*<V$EW&;U>HYT];ZW^YZY#&/R#YR8R['B
M*NS5R&O_-QMPHO758,\:S$DLF<@7Y.QIN^0N,>/?>]^HX3 .%7:OD/N,VY?[
M:"<!9$C+:BR%T4D>H5.& Q6LAX-9__1<%R]S3([Q!9IAAK1,B@K43*'WN12L
MP%"E/X 1LT_EB<*]\#A83\5B U\O$-$@]BQ8<Y1]TFC_QZB2VR*F%,Q:E%+T
M#V/ &F,W1*'<I$;ZAA<];-^C_K)>L;&B$DS!N^K*3!OMH F69Z#GJ/R&53UU
MHX<P@^V$.O5*CI?HCI0(N<@&9-<(ES3'T0D6", XC:O)H,XH<- 3%?1F%X/>
M=IN8/'I7H1:$W<*XB.9LU6B]1&*Y"W%5#!F"[EZ+*V$(.F*S@?FNC,1YE_=8
M(H1\L<PG"X)S6))>'R0<G/1+,8%EB+2KBO*@9,;8OD6.?APTS\CF^/JE65:6
M08BF;'IQ.^AALATWX)H]^PF3L V9R>Z^=?4RPX.RIH/N[B.L3%S:Q"V&*K,*
MZU@;;3JLA]LL!''OKW0EU ,\&M'NDJB(0L]UH#+S1FF1"N\Q&2M8%3!;J!AG
MP2M>5M)E7 TU;1/,@+MU7HO]0)0*@21U<@_Y2$E<JF8N$QAZ2"G3H/W5EV>1
M.+ ET!YV]?C&0XL@=(+U'D\1L<;!$8ZJB3VX>K6*\2T=(-^MFA08YIR]/^66
MXM@3,>.DE=&04 .$LADLT6L29])GZ?R\?#;ADX_M%=$=KXO><Y+H3YH [BX1
MS?$")R$+RMN4.Z8^T+]] C 8APGR63V' <+"B^-(=@?E\E?6'DV 3G?-Y/7=
M'C =CMUOF T8]VC;OLW+*L*E2R@J\^<3."!ZS8.1B@XT_UQ<%ER>07K)L>>>
MH,M:@CRYH8C\?=HWF!['5_V@A(B+=E< DG,K !Z9[5'G^BW)AW&OKZE\@#/3
MF&MW;.+<'X#FQYV)DJFMZ%YNN_PGQ"SZ5AH8A0NT[O4^6!*I19"S&#K:'#R'
M*(X9\3RQ-S$:C!QB:P7[C'@.Y[9AUB=-#$: L89I7M"*-TZJ)3(3ZQN.%*B$
MO0F^?7"7R# C0($5T?!C&R/K'#R9T03''\^-,SK2O+ILV6)?@D.H12-4$\"P
M'.K)RM]LOZTWE!WG0<E->$K3+M[RM2IE'PH@V-U0*,)O1@^?\L#NBT%-I%%*
MOH)WWUKR]_7EB&;-P/4?)7!\? %/;<DJ;L-]"_EGLV!7OA,32E%8U#?]0C[#
M;_E@1AH:9E6YK.?USLDF@XZZ)4.2$8$4+ T=-.86Z"3H3L<0;, ^UDBBLJ4?
M\?%32B&:77H"\@E:T$RDG#P&BW'>8P92S, 7]YB!VS&6>\R #]A,E812;W1*
MV$AM".NF"-0G]X^^?Q6NO):Z6C)Y2A++DYI,Y559G9(ZO_57R+]XS?1Y'FF(
M9X.*1DVJH2XN1JV8(N5S!PHL;<H1<6+\><+^/O@Q1N*ST-P_<^1QJ\ZZ:][T
M4,]7O;M4J*DU<1X5(_*\=QINU($)G%2RRFZ3@/ZCC?N./R,NFY\[:CDC8;?9
M \EL?O?S<TUG:K:VBG $WE![0_BR.*?U5M8#[B\S\QFQ2KA:ZP74R+S:5"L.
M.[;74B8X43:^J)9[9<'>$G4^$.#RR/S%Z*NDL'2I0T([V;OO_GY'!/(H?-L,
MS _7OU9J0D9Z]J%,C6EFK!UK]#;B#_I=N=X"W.'8CWQH.6TC,?9#8]QG4TJL
M]Z48VPZV+=MXDE]^ZQ7BRZ&/G&Z%-+Q%T0$7=,V>/#[_&J'BA$MU-@^^#AIK
M#_<NX4_S6 2W$= V^F,]QHP'&12]P^B=:. 8M?'NLNVK!+,F36(5/"-:JDN;
M*<O#)D86J6Y=:S@&* P,[#@LH1.[27);8EZB\!L%[LF7'O2Q]8+H.?;GU>Z:
MJ.2XJ::-D9<$_LL5-LE1\:&1 RO=?.36(4301^D2:+G\U!+=_5,12XSC'-]@
MH[XC3?$*RQ6T2^%!,I1V92V.AE7HN-W%[M0)L2%:(X;;-%PH&Z[)YF:)><R
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M!KG*X\N:S3OAY\\S*=PUT*4<8@MR2WC*I!.ZM<'6*0 ;^$(U%B"W(Y1=:\*
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MGH#,TLT>,17@A*UMG3%W#@#\"R@;P+-C<['*&(M_&-EQI!.9YCN[%CB*;J3
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M5']YO)@(EHBTE/PUNHW!ZGI,%)51-28BGR*!?;8I'F\;!$$!^()1X">I'$
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MS6XO9@]PE0YEDIGZ;#L9J?=*Z"VS&&MIJ>"6\"J[PZ@. B I?!DC(]/5S@-
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MCR/Q<7F]W"!J&G)?&J_4'(,E=)Z()W>JJB!BL: &HQCOGY#](6OF<"/ZI)0
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ML'U?&]3< 37?O!^U8>&T8EECE_*CG7@K''9TFN"LI,2JTTEO;#^R=K:\IUN
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M0>*34HK@U\R8XFB:3?(NM[I%JXT-O9(((!389F];_!5._A(\7)H;R^6@66L
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MFG9%M$#>#?2_P!VAGRZB$+V3] @>@R%1?V_47E$)Z:^F&V);+YU7_"M_W2_
M5RB?4YB84Q1Q).K"G^! (D.M0T7PI9LOR)%)9"9PDP+R!')X4L;Z8^0G,B\R
MC]K#?H7AVB][$04=0C7"4,\4S$.M^9N-2TSB2#HPV%Z=2A]6RSI-5>A_$N#4
MD'ETI2E2;D!1H,RYT*1<<(]+*-N2T93]6%[*0I;%%>4#K"' 1[YC>OYDW@#Z
MGVG4IISW:L;-2AV&)8$NDTG9:T-#Y=!,=;> DX EEQ2'7_)H6SW_TL.G<)9-
M(D&O$3Z6TYBN>UK'K!5A%,19/D=7 M-TCUZ'4Y+:\'P6 *'GQU.C<L(HE _R
M",M-8)E[C-:F?\J]7#\J$T<NP190-L*)LB7^S &#ZB6L!C=7433%]>$'Q1WE
M>577;>054=HFT.]VNJT8V3;BN!P<&R"X[\.KB^L%2812B.ZN'#2V[8I86P!B
MF]-<2ZCOBG0#S+:2DF<2>#Y#B4<IIYR4IAWF.ED(G6 7L9!#+^F-1*:4'Y9>
MH4J4^^0YCXR#:NIA6*A,3/G3?_QTLZ7BN,Y/]4D8Q11U%B#]%L9Z17PI[N#O
MJ8B$_HQJM59;&O='T?W1W^[^V(?,NS\]N-.DK(9L/Z+L5.!F#5I&7H1V\K[S
MDTF6)"I-Y#CT@I5,I_B@??XGRC"7Y1\H7.DG7W1621TNZ]9LL'(2_2/*E&T(
MI#1=BW%.BX#S#,#QA,V-><9JVK,"GC$U.8TN>$RFGEV-L@N;CY(:FR]&F<[Y
M&.585N* "BO(1 ))2.IUD C6+DG>;A3BF+D\*-3@%V B86:!65)D\Z/;3HI&
M%FD@\, 5Z&92D =1]%W.RE9;Y>R2\#(*P$@'J?L=M,^B]4@+X\C$)0&D96'Q
M5#[YF4!&8YS]V8RFB7)V=;!22DM$TP?5Z'AE-K#N>_WFO%QA1*S(7:G!TN0C
MD1 H#ILV_ X3(I*)ER4R4S)4P^39 DZ$W#CF5"1R_")-RM[ 4TP(*KJ2\&RY
M4X#-#J/4BZ^W6>W%GSC'\J,S@#AG1N4%6FS &RM]*,#IHX33>9'>/O$DT7=>
MZAFI!?=9Z55==O Y"H]^/3[^:O#%3Z"A97$]JHSV/.WO0OL,](W0YU[(<^<)
M\3RW>$9>1B8K(UH(BG:(]S)(U"1?S%^:8")_;N#_%OI<4^A)S^;Q0B!'TJE[
M"/L\017T[07EH%!-)&K6&&5&8UYB:7.WYJ4ZGOZ9)?@^*<'@H_<_L$13\B+]
MO4R8??DQ2L#J(F;SI3CM7H&'57C]_ORMP@-+& [$F8.\!V!6] ;)'R-+[ODB
M4S4FB=A<2SJM4YJMC$\I%"E>7N3?F+Q#YIL^HS'*M27/J'> OS1W@14*N%.[
MZ'VS:5LT6AC+5!,V])6GX(AK?\QZ5\Q4S$M]F-,O@$?(#("6KCUE %*2&YZ#
M%D?33R7  J,%9AM*24#&'P^]QEUJ.M) ,P$,Y_:CJ<R<NT(O$N>@++P+(#M$
M!_I!02FF]+HP-1/U^%E*C<3PR)0D@G*JDS?5R([6;U_BG&^9S(M)>"(I3P^]
MXA1F/*NTIB78Z4#74#-MH^#X3LN)QN8#&\9P4=N@@B0#[W"WR$4\I[Q!^*O*
M.*9[C:B8RKS%:VCKFXF)$L8AHR]\4+T-(FV2PDS8N"S/3T:I*R,/%)1& @L
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MVO5.4MN\LQPV:1#Z> C-S9,M!C#>23\,HTO*E"A:T^K> IZ=?[%Y7#</C>Q
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MN*=*VB)5_=4-QN6.;<ZO]^(X&[\K\=.POO8X_HOA&HL>E+HO_D ]^WW!9+#
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MC0+;C'#\*TUA9I "%HI07:,@#T3P)0@J0:-@Y=P]9,5^N/OXE!VO&'"V%^X
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M0.FY4EX==+\LL@41R2SV%N(JBK_K]=Z^_WIN??5)\'Z[BHH*IB*@7-< (J2
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MC<Z6@1<2M)#]3U)8WTN+L-*QP$WOT'7AP"M@D,">B;*R!!O&H-@RA8G9,Y\
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M"1:]A\IP-TPHWKHJ5KF*XN]<AT45&C:6%21@>(U76&L!!\O@Q[HDF$O-"H7
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M _R*_ UB%Q/N^)3$ PPDI:HA+0PVUN_[<J31Q&&*L3[RJ(_QFDNKYI@T-G(
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M,B.L9=Q)HW(TY$=IMB+^K9!NI!AX48]R= H3='+2K\^&L+,([Q:/22.?E-E
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MC<P+65+2%)!/"ZX&Y3,(UDCV-O!2/Z%N"(,Q=CQX$[R!DLG]B'\\H5YM^)R
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M2-:[D1]0"P?>YZ"HEK*D'@6=\];!NQ1XX[Z?\%[6U+F1^B=1PX$%J6LS-/Z
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M,4BS45YV3^F R[,*#-RT.+ZR3F?193B06+DH<%I/N"NS;M2_6&[KW$YG:N!
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M&+5.GF*58Y=B0\E+%(Z?7S O0+8:YGS/>XX8'I,\G!S^Y>+Y5FGW&;[R22A
MRMYT8LCDN4N02MMJ0LKEN"[=GI^L-^8Z0::>9P=)BY9X6E-D9 DZ.1#B_%4D
M+B84D]WP(P?8' IP0^+],]B8$ARI'R:7@P$<',.<:%D'P#Y]RI441C-Y.6CJ
MJ$P"R0:UI8@5)[@.9U]0"+.2N[RY:JAL#T\YG,[Z6_R;]G?_Y\<@#&[!BHSX
M$'C4P+]A@*9W9C:TP'N%%?69_Y$4_S"ZA1\TJ&AF<.98C>XUP"\1!A-<VT_:
MOX !/6M?O][__;>)9]?N>&3&.OHID??$Q1X'?BR@ 6'"#$Y=KG"^1_%&U\;
MUY!']E,<V(WNYQ 83Z"#M1C'7N\%E( $@W7UAH#,L>7XEHFV*K ^$5BW5&"]
M&FLY>&#]U"OEZJD&'*S>;B)CP3AO5Z$";[KB@VI4<C5YWV1523F[MHQS^^ *
MCBS)FR#K0>MLZ.76IT-4VXC2PKN'NW2U!25RBZH1T96 .>RR1JJX*"[U_Y9Z
MP#-K+ZDNX= X/7SYV9+RU(E*QA,J1RVY-$VBM528=<Z=E7!6TETYI"3;4:7<
M0:__8X'5G3E5>7*/*'D#C1;W+CGP1)QM'3[+@S943<P]9OGRG:61N_D/3J-H
M?I84GA; _S'K*)9Z[!IZ22E%@*OO:+8R4!4&[J(P\- "N* PL*IU@9O<>/1@
M9WK;7+7M&(AYEZ.?X$;\;#GGXX$2HE*:);3B*>J"6<KX()8@RMRX]"A_,.\[
M,4[V$YA +HI9$&#<+'%B4AM.(QZXFIDRRAC+(WD>0BZ:2*'Q-!</=1V&^1:H
MT0C&W?.CWO@53PECTO/K!&698+S3.L'*J!]7#&#!NWO@07_%S(N,?9Z2;7VA
M]3:6J52(*'-\^!W@HE#6G!8RP<E:7=#2?2]K'#!/RR'%/^(E;2+=IC!1C^P'
MF8\Q&D>C,&:%A>$KMT71MCHASKEB4>L\ ONI)R7R=&4TEDS"C2?I(?0%XO0L
MH%53ZB3N@?\YV96Y\^TS^. PRUP9<M.*-[W!]CM#TD->)E+1TQ)IZ<[/<AJ
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M@FXOG(YFQQH&3KW9)F=XY[!;HICT_7@T]-YQ]6P^2D_QK]3!;7=P\M?R(CO
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M FNO[R:.QQN</I88Z;;;UFTP*=H%S9YF3Q]5W)T#:L/MV'O ^C9(H'&^M@.
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MB?O/\X=S[2H<#KTHUCZ@Q609GWZA?\U/O^H:^]EC((5!J]! FWAB$7Y(ED*
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M&EG/,QS.A-;F&S9VH&[KEMT^_$ ;!=$#:6 5QV@39)M;W))+8;3N&#T2/NH
M'S7:NEM&)W_E!5L!99>KZU&Z]L2>_2# T&$XT-Z9%]79+U9'GK 62[ 7AV'V
M:UBU,)7)=!V]XVZ=@ZAR3BJ)MV:5\(9EXKK;=G2C0"57>#L&O#E5PAM&GG7;
MM737K0K>2O(1545_F3]08V7]A<$/M]%<*N(4.CI_\EK7WJK2M>_@[,J6[>KM
MYM;77J6<'!E2JZ2 FT:)"KA"ZI$AM4JJNVF6J+JK;*F2]*R'\6@T9%@HX VY
MNH53S+2^'_>&83R.CF=LF0T0Z(?CIR&;08A:70FK.[GN&#3S#^V1:2NESC;(
MT8O$%<P,D'I3LNXBN?2BZ!T.YG^\X9BM+?HL,B>LMMXT5:/,X\35"D9!^;BR
M2?EOF[J[?3&QPE4E<;6""E\^KJA W6UU=.<X.TO40;UXR#JPEI'XIJ*SE= O
M9NSKDF^N@]/Y[.V;$ZG86"71M43+V#6Z6HVN:>K-[1NQ*7A5$EY+E(VUX36+
M("HOGVVE6^M(:GUTBJ_I,#Z52U^?6[FE2G$;!KUQ%,&7:_-[%_T6AC5;N*AL
MRV, UI;:Q!; HOAZVYPMF%? .@9@;:E'; XL"VNM=:M=5H!1>2W6A,E-T M?
MF99X/^&A(\_O*V=%A>_IXFO*:?F(I+P'2MZR]:^C276WS>W'@RF#L9( 6M(2
MJ@0$8;OMEFX8RN5PG C:/0^R0=?LZ$YEVNV>G-?A!F>\@<JWN3Z@/ V'U >>
MG@/V41(1;V%:&7KIC?P$=OD?[*3&?[_V]6Q2=R2SK9P,QXFI.2K";D'EH)M9
M;Q>4Q"M0'0.H#L*I6J!(.+K9*JLS;D6<"U51'E9(4(8S/Z-LRZS%=:W3D]7G
M3SV)^*+7B\; Q9 7:3W.I#3V<\2"OI]@^KW2ERLLAI;EYA$YKW/4O.&.[?[G
M<7(;)O]B)*36%D1MG&RLVV95<O,4K/;J5=L9KMQ&MX.YQ I7QXFK0_&K#N#*
MT>WFUGD_U5*<ZZ-EW,NQO.% \X.S$8X)BF-, F(>_(:JF/KLC0W#$6K:\#=H
M-M%@&5"U>W 4"4;SWKVG(:NLOJV\Z0L=>!>]O\9^A.;O/2?_-T']BZ!_E=%^
MJYMN&XUNRU"C[8X67XN<>7L!&!:1EU+NI !628#MEH,M&G%GVU8E1]S]EJ#4
MA7_[_EOW[_ ?^5IZCA_T8<L?K3; J63ZMI91UT+J3IU,X2+YOG L,HO*7J5I
MR&72$S^2E[>WPL(?7QCI-J^P&DQ9UX(P@?=Y$?PX ,4G8<^1-P2M)Z)A,LD+
M@ W12DTF/$R<%A/WX(_B!'Y TQ;/YYZ$>'G3XEW91V'L([0^1FSHX;CH3S_\
M?O(B[TSN@QP/'XWL(]X3+&*<S/_('D]]X1F;V.DC?Q[Y_^)Z\>KYO4[SJ6^9
MCN599M-H6IYINLPU7=?T',]DSO^:..=:?.HEDIL8><_L["EBWO<S;P![_.@-
M?WCO,5Z<W%&\@KX[=?33IS;W; :#G9T-YP+ ZL*(9H)_'./L</PK6)-7F;5H
M+Q$RYK\MIU$;;A0R*KPKE\C3J1&"URVB?YX\7O0,%!(8MR>%V9ZP.Q-X(.Q^
MOK[Y_?KV6M>^/E[-O]757?_EW>W#W=>;JXO'ZROMX1'^^>/Z]O%!N_NB/?SC
MXMOU/^Z^7EU_>R")U_ZD7?_?/V\>_Z75<*,?+EZY@0K&:O(2CN%9_1AA^.?Y
MP[EV%0Z'7A1K'W"CEO'I%_K7_/2KCG/!&$AE]+R#YOG$(OQ0_ (2(":+> 0_
MH6\UX/?>K\N.!ANE."2&26)G[)O:J/1P':.8?91??.K[\6CHO7_T ]H3?>C3
MY#$CMYK2#NC4^:\%(^MTSMNF@[Q,N#3$BP6;.X<S^FWVYW;KW'2=PE\9YV;A
MS^<]JG/>,8I_,^])\W_NF,U2UN2<M]9\TN[7U%G[Q'>_)M, F=BNV*+<"A+/
M/6^VEQ*OP!24MQRL"7:8OUKB[3S\ G>PV2FEV[(Y7RY\Q$*;O#/S9P5&-Q=_
M^[&ZW96R)NXB6*L7O7/K[(%DV@J.VV7^V2C\,>VJJ-6Q7,!:4</UAG]_BG[K
MHH/@[":@KT7P0QT2IB2,7\=#-''I9.[ ](WX&8&Q'+$7%L1@K])/>'KV;Q^^
MAG$\,\A#G5WWB@W\GK_*G-EC/YG'<+7;55418EJ;BI"<6WA>N])%*7G5(^7*
MXF3Y?D_CP+B!6@(3..2?'5!%+0TMY9S$D:#RE_( J4Y$G8@Z$74BU=?JZEDL
M,4V(XD#[9V_H!3VF>8EVQ7H,/=K<_K=-G7]A&98YEUK;3#RO5&+":J<U-RV!
M1P!F,A-:^<R$F]LO,]F3X>MK&#PD8>\[5Y#OQDF<> $>RVII+D:6BF WNJ9N
MVTU,QM4M=^L^.6O1KP9Y,"<!Q*+\F-;B%%Z"WTLXA,.)L:%.\EZ4Z-+$R'Q9
M#144INJ.J?;ZF%HS:\^AOJ%FQ]0-HZPQ>@IW=<>=NW/<8;_:MMXIF#JM,'<T
MF%MOH'IGQ8'J):"OC;WHC'9+=ZQ9IK?ZV'.%O>IBK\S!MB4@SFUT6[II6[K3
MJJMZ5T-/P:(:=+O:+H/+,$ZT012^:GX<C\E[$ ZT4&0/B&2XC3P&%:RI7.U(
M1 F JGA5U%'4V:4J9BTI<[_H_WL<)U15\1AFF3N\K8](UR&9>0.LB_5O! -#
MEA87"<<.& /.[&"4U14QA2)UQQ5U%'6J3)WUC.$E#2%*YL!-H](<N(:61U7[
M4JR&U9N<R2'*;K C1?2&M96AK+T)1X1C]I-%/3_>T!JI8/GT3J*4EKDD2IF[
MKE?C",[B'I85]GG$DGYY1^<=7XOS7K%$/XM=-DV*7;8=O665%;>LF8>K?C#;
M3*@KZBCJ*.HHZBCJ*.H<#75J: ;4.  AU4P*.W#-4]>N'^[OJ0(_8D,FVM9]
M>_CSQ (1>U7]KU]'P_"=,?HCV2[P?@BK7UO_MZCW?J=EZ%;;K4C'1^4W*C&0
M;2UQ&\T!&LT$)K1]!FSUL9B4!3%UG"ER%N'8'H6>(T3/DK#/)NA9+TVBV6QT
MFRW@4 I?-<&7BCDHZBCJ["%%;0>2?4W>[ C>7.T>]#4T$A?%BBIN)!*TSIX0
M6UHO!Z[3"@55T%>B/%F*.K6@SM[STI!C/4T+PV_LK[$?^PE[8-&;WV-<>GYC
MO? YH*>0(%U;9+8:7=NP=7-[>T;!43$+11U%G2I39^\);OMDY>UZL/(:FC\U
MCI%1 T8R?-+FB]HPC$\L'*:\3(HZBCJ*.L='G?6JIJP5"]A):DQT[.7->K%5
M[RU+[@:/WL^U]1.73W)L;5//KF"E+KVBSI:%.ON\])VJ7_H:FB,UCL8 CC8W
M/VKK=E!.(44=11U%'44=19W*ZHF6O:*>"#(\4PS750@=H]&U=,.P===TMF]L
MIB!4)0BM;&IL!R&S!A"JH5E1;&95V9HH:%JNV::N689E;1/@.(DN@W,J@9I[
M;%7N6%3N[[1TLVGHIKMUJ]6UZ%<#U]1) +%(%VF6T*K<P4;X]JR$4)@Z34SM
MO(6JTZ16Y0[PLDZ[HW!WO+A;S[":F;NPL[;1CM/HMMMZTRS!W:Z 5WO@S0QG
MV!WP6@ \W7 -W6Z6T*1-8:^"V%O+$["! K<FXMJ-;E.W71OLA[KJ>#5T$JBN
M@1L/++#AG/KA^&G(CHX#S/$EN =O*.BXC:[;U*V"(1I;CS181,\:^**/"IE;
MQ:$4315-%4T5315-%4T536M(TQK:40MR6JN>PZG:+E;#0"JO[:+3:72MENZT
M3+UCE>5,J9FG[HC 5N0*7F5>ZK9M%UN&:KMXG.B9&7RZ[]9>+;/1=6S=,%H*
M7_7 EZH@4]11U-E#I.W@+7%;EN#-U6[874,CL<:%?I<89AL."5!EC04^PB3Z
M;>S";VPDC+[^1=#_QA(_*C(3US4&6]@\W=:MMJV;!5>Z(OGUJD1CPYR@50S!
MI<@2#:IF14&SR )4D*DW9%:Q_E:%S)JJA=/H@GZA=ZI;Z*-0I8I!%744=?9:
M9WDXAMR2#'F;#'-5>7DTP<!2V^O7UF&CW&F*.HHZAP]$5:TG<PM[,K?:>LNL
MMF]4P5$Q"T4=19T*Q:TJQ\K=>K#R&IH_-0YSE=I>O[;."^5:4M11U%'4.3[J
MK.66M6=4FCUVVFYA#K>E&]9LXYF*.&85K-2EKP5UUHO%'/+2MXVJ7_H:FB,U
MCL9LU5Z_MFX'Y112U%'44=11U%'4J:R>:.^E-WK;;'1=U]3;6V5N*P!5$$ K
M&QK; <BJ/(!J:%(4FUA5MB06M-:W2^J'=[P-,8NK>FQKCZWUVS9OK=_1'=/6
M+:M9?O^[ W5F+;]=S_$"L4@/F9D!NT%K_7:SE-;Z"E-'@BE[U]U^VPYOK=]Q
M]9:[=0*&PEUU<;>>43739GIG'<[;K4:WT]&;S=D.)&N[VA7P:@^\F6$BNP->
M&UOK=UJ6;CBS Y(4]HX!>VOY 78O;#'547?LMF[OHF_V7F!70R?!HKAC]5OK
M_QGOHZN^.*.CZK6Z;G<0NS7C1U@D?';:7[^-64>ZY;BZV3)+G?MRJ&[ )3FC
MCPJA6X6A%$T5315-%4T5315-%4UK2-,:FE(UKBC;?7?]VN9E;V\G':2[OFLT
MNK:AFZ:EMYJS1I(J J@7V(J\P3,3?G?07=\U 48*/4>(GIDQO?ONX.Q:C6[3
MT9V"^(+"5R7QI0K(%'44=?80;#LX:[8%:ZZVZ*^AC;@HW%9Q&_&* 4HIA)KV
MU_>T>/P4^WW?B]Y5]9\J<5#44=39CYGR]!RPE;IU37&MN\%#RK'6EHHX9T W
M'#5MKB9 4VQ 44=1YV#VRD%XM%,''EU#PZ7&P:U2N\77U@&AW$.*.HHZAP^L
M5*W%L-MJ=)M-LXP6PPJ.BEDHZBCJ5)DZ)<9A*L?)V_7@Y#6T?FH<MBFU67QM
MW1G*V:2HHZBCJ'-\U%FO@\#,(.X]]HUV7=!/.KK3W&98MX*5NO2*.ML-[MWG
MG>]4_<[7T!JI<2QFJU[QM74Z*)>0HHZBCJ*.HHZB3F751'MFS/4N6GUWC$:W
MU6SJ;;>$EH8*0%4"T%YF#73,RN.GAA9%L85594-B0:OX9@E-WOC69GI=G$3[
MQ^+&!DUCCXWD.Q8UDG?;.DZ_;AM;-Y(OD;HU<&@I$!?)I^:2X>\K-:'OX(@#
MNZQI[ J/IXS'5>I\M^JIV\&)"99N !_M%(S649A5F%U7R6_.3/+860_R#HY?
M:+IZIV#VPJ9-7A5J3Q.U,^W+=X?:5J/KZBVCI;OV-B:JPNUQXG8MC\H&8Y/6
M1&L;N^[;MJ5;5EDU<]6";$6\,;\E'AP!_-OWW[I_A__(OW[UHF<_X.=A3&*W
MQP ,4=DPI;<LQ*G%/?MYVN]H!?3$CY@H[?=66-/C"].\'N:R>L$[0$4+P@3>
MAXW^87D^G-9SY VUD1<EV)XD>6$QT[+:4IP,X =>T//AC^($?D#)V^<IP*=I
M(U[>M,[;. AA%,:4G?TQ8D,O\=_8IQ]^/WF1%SOW08%](_N(]P2+&"?S/U(5
MNI-QFS^/_']QO<@Y_%ZG^=2W3,?R++-I-"W/-%WFFJYK>HYG,N=_392#XE,O
MD=S$R'MF9T\1\[Z?>0/8XT=O^,-[C_&6Y*\$W(>49]KG>/3S3DW<GHS7S#^U
MP6 WIP9KXI<6N&P847[_1V"*+,*_@N5XE5F+]A*A7/G;<NJ!5'A$?H6WZ!)%
M$ER3O__F=>?>E!DZS.5CW;\_1;_-?]#^KT&[\!I\OK[Y_?KV6M>^/E[-9Q!5
M6>WMW>/U@_9XISW^XUJ[O+M]N/MZ<W7Q>'VE?;FYO;B]O+GXJCT\P@_^N+Y]
M?*C\=K[<?:.=_.OZXMN#=GU[!1NYNKZ\_N/S];?4R\_'PFH7MU?XA57Y37VX
M> 5E*8E!3H%D"L?PK'Z,%^S/\X=S[2H<#KU(^X !=<OX] O]:W[ZE1HP?V,!
M\,0G/_WUMS\^RS_0*[]Q]K/'0)W#H3R@D&*@)AO9@[L;,3FM!V2T]VN1]%EA
M5_/XRJKBJM-8RM8ZB\3+3H_0/->$W7 [?H5']&9#KY.6P>=Q# ^)XRL6]R*?
M.GI?!/W/7NS'=X-[')04)"0>'N$AGX=@1F0F@<O-$#\8L_Y%(GZ&KX!G>2,D
M031FV \N?3025+Y1&A%BH5,4@=^)9_,F<ND[X?F+3_Y33E'N2/GB@VP+X)#<
M/5"F6%WZS/S?6<! 3B3]<^T#J)R:N*.77$T5]U27/Q8?F/ZQG\S^)$Z9@ \W
M11LR#^TC[7D8/H$"&P:XQ^=W3>C#&M@=O1"L(_P;O%=]]L:&X0B_]8,@?".5
M54M ^^)%B\"%O(24Y]<P(L4:R.>CU,=/>P.XL'U2 I)0ZV&P-0+-.O'IHS_"
M:-@'I8R=:S>!8,>X=[%I[1FV&)'&G82@W<LU1[ D@!7U#AR-HO GF*4)&[YK
MOVR>:.!.8_\;?\F7*'Q%W06?^$\_>;D<QP E%EW_[ W'>) 7<0P;9GU*:Q:6
M<2>[!L 0[/-9SZ/VY ^'\(4.A]J#LXSQ?.6^GMYWL"_JH[/!IGA5Z0U?);MB
M_-_9K0*PD</,QECE5K4!O)7(.X(G1MH[\R)=^_'B S8BUA_W"&* BG"$1,?O
M,,>WZ&-EG]"4&X^.:B*_!+[B!W,?1L0%DR3RG\9DC3^&MWB)X#1!^,*?W* X
M87&R^L$!TS+.9[U\\N#F*XYU86\//B99^*2UH!0GGHT7WC0F+_R+%VM/#$\=
M.-5@/ 3*"GL<F8!D6=&S%_C_X:S_!\"7<Q[@0X$V%P9,S$18U3G69_[':Q Q
MR?LM:1MW SE58=TA"DW#H@'0<,2S));+RO/"*=5E2MBMHX]8^.KU87,@]<1:
M5SUY@&OK#WR0*LE%KX=J,=W0H=_S63RCDC0->T8E@9_-JB0/XU<XCW<4+[DW
M:-DK-/F.3;04\<J"A5CKZ2Z[H])<?UHQW=;4*;GV.$6P=_[? J(U"\ZJ.4LT
M>BR2+*^63M.'5)+UEGN9[RDW=Y%.P2*=V47>@U;5\T=#%@N72/;HQ5"J(<^?
M"W\D'OE@E[I4A?<U)QU \WQB+ !5@(U Y>RC%$%7+JB8*&%(&) AS#5'E!^H
MD([P#5YV?T<9':0M_/O%Q;U4E,]GF:XV=SO.ZMOQ28M@M*=5]HMH1:&9ML<&
MEG.N70R'I+!(OH0",I+:.ZAT0<R%"S>+GWB&(XK5Y <>7=$+?KR ZO)^%OX(
M8.GYMY%>SX;^*ZP6MS4>P<XGVBP6G-4,%US]MOT9,Q"T<4)J79S=K];T3:HE
MHQ1SAM/]U?Z./Y)6CE<Q;>:>K'@3\(]0C0(%BU];O(!@!_PU]M&C TOSGNF/
MT6Y\];X##.6Q<<,RCL>O?,:8L$ ' ]9+Z/VP(E#3\<H+7QD:BF#.)/RC0]\#
MS=H'&S36N8D+)B^8&N.(\V4.YF=\=_&G,%T8WX,;E'LNW"9^;MZ"A+''_XC]
MQ*X^\$V?1C%P<X?L![CO:#? %65H8F?',L8_A[OZ;]@U6N3_'O>?Z1>"R^@:
MV"=T?X,PT? *<SM:EP<IWP,/ DT;_N*-;W\8!L]G^%U?;'_B$V_ %\B<1R*#
MMBHH[R-/#L&(2[38&XI=]= ;^20B"*EUZT7 H_@FX-$^8M@?4!PNYDAB>5:-
M"GQVD)0)[,$*X4M&UA;R\AY1@7F]%SPT4LY1&H1/0_\Y75Z.[U&Y4?M3/&=)
M'AF_\GA\^(@?T<D6'\Z;-Q0B@4^Y2]LOI0[*@JZA*<4G#G>,[I'$P]5Z/S49
M]9MX!SS3#V#521B]SY 2!%[X@_:.;E(P./L^+Y3%]_09R E@Y/C'?09XA24]
M@9@<P-_@6O#I(Q 6N7.#3[T"^.!BR/U3\/PL')P!:B9N!XWVF[@C@F0#.#U:
M/Q$INR9^$ ,KYZ%3[8\,UWA6,7TRN_"PLA<_ABUCQ)Z.#H03;%/7O@<@M- ;
MA5YP?"7B,QS#1ZAAT2R7B%"#&/KLC2X#?*WA]0H#Q+0N+FL\'O([^N/%!TPA
MH.@W3Z1CXM$"0\)CE'<.7OT4CCE3Z &8WOE-&8[9 MX#-[N7C,F=Q5\(F!\B
M,P)&%J5>CSAW#@6685YC7$O2?@&3&92(RW$$9P<Z;4YON CZ].V08V"NTML^
M"J'\!2X=;[FFR<,@2HD#RGZ8.Y.-!?<!=ETLN7.[[N5W/1"[3G_X#-Q(0)?X
MR%'H+%+_'4M60S9#OSAXIL%]S_W^5[C.I#1SH8XW71[6N9:_1BAT9G1I% ]1
MGQLNQ!T+Z" T"F +(R';L_DX1(EX#%QI0M.'0PVECNZGU,.7<CY(OK%Y[WO&
M5T0XMQ48H@0 ^]E[09FH(>_/1,"'5Y"]"2VDD*G]*D>]<H?=%'@R'MP;PN?!
M@N'KY8O\(&3BKZC"A*_ CN%5\J F=,I4Q>*39H42 AP5B2OE7"HOB_8,?)P+
MY5 \/@+U"#0;_/N<H^>!](VH#XCID[U%SY0(N7BX3&,KKFWH6K7RG&8XV!]>
M IN,=[S*A6LZ1[Z*@>M8*K@Q6A#HL6']65\PJJX4GB6< #SQ%S,\"K107\2E
M<EH%HOF%]9^YXWGF0ZEVM;E[O3K<?'IS20FRJBH,&P$SP4=_$'IF;[7DL0B:
M*:8^B:R4[7MOP#H (!FS0^MC0 B5^$P5V<D_$B:@<*^ GL^ 5Y%!"+"3Q\]=
M/5D\2VIZ)&E335@BD3XYO6ZN@OIQ?@/_SP+APXDNM$A&GI]IN0/6U?AUS#ET
M.*>O)UA!]%/@]IS+DB$CDH2%_:0Q2A9>HI46QR^F4B-/*"^R,S\O4F4X5F,M
M*L-193BJ#$>5X5B_#,?Y(6>K,.1LU]1I<^G%+[J&_]6P8NG-&Z;^]F\,+ "_
MA\H-_GZ+8!1^_"+HXS^YE_P91.D;BO^".\PR/YE;,S]9L>9"ATU>??R"9=NM
MO8$Q=V<\QA&3_DN_0S\T!9\HL!I\!\N35-!8ZNEX.<<Y@*"O"+1Z#'#U(^\'
M*/OX4; _N*M"&B0REA*C!U][@;4-W[6A#ROID[=?S(?@@3+TT$<^G",\[=5+
MQA&&T+)05,0P$S-(7F)T7 U9/!.N&HTCL&2XN^>)S>SZG-^K_#GPS<G3&$4^
M$!+H@ ]#?] [K"/Z#O8/V&1];F^0AZ:/;\[\_V6ZKXMOWK<U;V:G@"EV9M,V
M:GE?<WRP-\,':WA+I_:30Z' )>H(O-P0I/Y9WB-*?R^OJC8:HE.(+.$^PT0*
M^ANZSB+N&..UI>!E@DDD))'I]\/0D_Y,1JXTX@P49INZT-*]B9;ZY+KQT62R
M)W@_ ?%G\ML)AR3Z,'.>8'K$;"[H]!VJ(5WGZBQX$;LW@>:)F3C2/3)]H&F&
MB_<4OK%)3X\?RY2"/N8,XZ_NOUUJ,>LAVT3R#+T?^& ,9_(<X[#'6/__9^_-
MF]M6DGW!KX+0])VQ(R U=Y'V"T7(LGQ:MVW+(\E]7\\_+T"R*.*8!-A8)/-\
M^LFEJE#8N$B4N @O[NMC22102U96+K_\I8$Z!G?@!C9BQ(AXC.G3VRDZ,G$3
MV!%]&T:":54*,,%&2V!!$N['E^MGP;LHPA_39Q\%J'Z\+BBZE?MF-G6M!VI
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M"744N=X0E39%.7PXJP$C!9@UQ3BRU$]CDB&04NE9)FD9$/<BW 6A"SO@!&;
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M!7C85N/HK->NV:>U5@[R6FS8/47>:ZONU!JJJQ*LE02K\R*"M1!CW6JB4T#
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M%%Y*V"-G,,#MPHW#G::=S([@Q#J'3P6H["9SN_@S='0#D:B1E.J 5SKP5X3
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M/J=<)GXMK_/<QN\_8M  _LMB(_>'_F(("J/?2&+2$Q@[#U2>#6(+,FLX_0>
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MWDHW<[_$>KG77*KNGRR1F-%TP@2MEXT3R#BF'@$A(+,*- _WJ@!@:0!8IP*
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M,/8-K,#01^]&/WG$5J.M^54Y<U2Z;VI\:)TL.Q?D45'5#0.-^/<$A/0(MY1
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M_]>8!+S&GQ.J/OEZLBJ6?$@6A;2;)VY-D_D:A+%,1>W^9!<SHB>\WUQJBUC
M<$D)<S%!<!'VS>CDL1#7AKHBP;4AO5>"FB-KKUB3)4U$U0M)AG%^!&@88/M
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M#W]X%\TX=J<BUN+SH(-D8VP[QLP1,2W]R5(?[A(6S:3/NS#V@RD5W\<5=(&
MC\>""EH?IV?B[XG\,QLG&;LKBKJ9NXT #P:Q"*9,"UUN,"$[@"S:.@\&'2_R
MOF!E10&FX*JW;)EYH*AHT]ORO=Z>"J-6:IHF*B8KVWL>*V+ ^N; $Q(:***B
MLU)#>PF>[V+-1$$N+F]25*1]SJQ%>$ JBY9>5.4:ZZVUBHTH<=06L@ID1JT1
M^Q+Y^1..C-HUZ>.+_29RM\"82?G!03K[Z#T]E=R4S-U3R5<SJ%E))4\&B8T/
M-H=E*-G])>6.6VK5L'46$[XW/]2.*9-;PIL9/W82J7=)7Z1+3S"]K)3BR\NW
MI+SVQ,/GG944Q.!093'^19$4G;=P/]IF9*/;\=UYQ\JNL#$A+;ADYXV,7LF#
MC[UJ,OM]5J4FVZ*EL-+6_1*"KKNIGW',IMQ<_792/YS)SIN?6>MH8HFHF+GS
M2GBDK6"M,_FB=QI:-PP(R:IW,I("*:+.#*O4I:YVT\ZY%E_C3D+;OOJ3(+.R
M87*(+)KY^;'Y(E>(LME\:3L-97-?LZ]L2J5FBK+%N>A+/+H=DH X@X@$?!5C
M7K'J.$][:Q=2+(FV4A0K&%_)LB5&C)-Y/.8"=KDGT 5I8&:ETRHUPQ+U_)SL
M!R^^*6BUH_<UJZ;.N&KBC ONRWB"U&$N'N>0#<3M? U,D^&GTE3P=]@-A#T\
MUR3]YH\>?#0^Y<RLCYC8)!K6:H;(9[[^%0^0[Z!4F'C]ZHPF!#,O=L\1Y-E:
MK*Z5!65KR<:9Y!CND*VU2OZYD$F43)2&*^;8#UW\P#4EM00O?Y[<\Z_ES*MD
MF-+\*TX7!@7+V=JOK"0P'"D92]:MY;2JQ9_#6>'EV'DF5UW8G?YU13>HU\[H
MS7D/4>2+>5BN-X>Z6D4AKAO_<E*5NBD9;3 XF#+&R *]\ .*A6M ,@GP4_ X
M#C//(@P#- <_N3U;Z_8565<<1=8D37%DV2*6;%FRHSLRT?]CPCZ'9KJ!?;]%
M2T(W.4YMQ]0Y-2VU)IF9VJ_=X)?U%RH?T"O)-Q30-\V[;\U64Q3N.XTJ\T_;
M>NPTVT+G4>C\UA1N'UOMQ_N[1KW3; A?[UKUUNU=_5YH=^"%AV:KTV9^.%\?
MG^A(_FS6G]I"L]6 @32:M\V'F^;3-&JLT9^J4&\UA*4^]*P.ZE.2Q <[$R$:
M^A.X5I^FKOY>;5>%!N:.!L*G?_]D*8KTY6?ZK_SELX"L2$_$ YO8=6=O/SW<
M3#\@,C]P LX]K,'@2@C@0F#@'P8=#IT 4W-A=.![Q'\*?2=R/J>M(Q_6VEDS
M'NE*J:Q[5U-,<'1.,K7Y,1JB3!:YLC>S8[LA?/H%!@,WZ0M=,O+?SC_-6=>J
MLI&-U_KT*+*+>BC5THI[*)/S=N.89/TTL\FGA[%@*CAQ]]FEC7/B[GS$W5Q<
M6\2E<$-QGI3>G.><"X47(ZU2T/2<<"@,L'84^8GQ:/%CN2FG_MJ[)^3RT</T
M7#[SR8-9J>F&*$DZ(XEF/(VQ4 QM::Q8$(BPS[@IVA8'T5F"J!Q+9 .(+%$R
M>.5B>3!X>OP]8:\6_&[DP/MTE28_>D/'>R9Q[!EN531YY^GF^12X@G]@$GY,
M)N#.:R;B_^H'!248*%*EIIF@7+F)/3FU'(M V[+,EXFTN$K(TG.;<8XT%I'&
MD$U38GI#DZEZM.7DIUU/#[73.3TTI:IJ%]1@5ZF:EL7:Z2$\U);Q74SHEC?8
M/?TY/,>3%'Y.=[@&NV<1@_X_^@?I7SGP5 YL9 /R H[(? ,+D_0B?'HG3A"N
M5#MD$<I>(&'6!5S#H:ELCOA,A5V/9?TT%35]LP."EI=<.WC&WG5_$J#PY\X<
M<I^OYHH?J" BS\2>V=QNB>85,K=:I:9NG-M+"+6MF*1I%9< XB8\BA8C,DYT
MW5R&HV6";",1\Q-(^3L)>I1(/]E,7BESD.J5FEY5<A?@%+&7/,Z<_(M7?!X4
MP^KA,6Q4:F:5#58#%C"\IAIMN?HLO1X-);J]W$?!N/JV4(^=EBA^C'H"JRID
MXTK_'N"Y3_3^?>1X4=WK-_^>N&,\W$,\COQP$J20I"MFC'R0)^ W2E[#BR]3
MIT\O+@KT\K2B878#$<8<K749-I0V)+=*>8 -!0\ROOOQ._CJQC*(U7EEI0QB
M+MKQ3+1D+EJ/1)3:/<!:-TQF=B(8?!C!UB@,!:?7F[Q,XD*)/AG#A]Q86'@5
MD%'HAOB6/Q"B(4FXX=%*[%@VD:H-)Q'X-&PPK04%/IDMFS!XX/,L I_QOVMH
M47D@]%RR2_/&0HL(AYZBT#)%1+D*L#R;/.N<9YTCAQ6XISR9?&W>AB+IFQ,W
MUN[UO@5^F#F94[$J-4,7-9X1?*9H,DI%D\T8FB[AO.)FXH[P8?G)Q%HUT+0R
MM4"50 LD4[1TWA_Z'-&D2.7"28:=D"J+ALY*3O@EN*D/CC<9@)0G >:BS(*R
MW'/=H!9FJ6J!6<78.5=GQ=G@KFNQ<+)*A9-:J<F6 8MV;BO+?=<,P8 NLCCZ
MP7M.$WLIGH==JDYH:&(ET<J_G^..+(MPVE:.5C"<= SIZZ*J\>Z+Y0&B[0^B
M-R<@HD!&I!<%ON?V8EI*?S!P>X3[MCMIRI9RNH(UQ0!G1)) 4UAI*\5]VV+A
MM(6NOF XF96:I8I*2@<)[MH>S+7%]-"A/^ICPY; ?R6;&REQ;T193KP]N%+@
MR9<F&I;$B#/"?=MBT51ND!9/OB115EAA4[@$UW8ZA1_S9I,TV3S^+&^D4XK:
M:-@77%055=3EW';XX-WF2G:"+Q>#I3H"FHS>L2*:>E'N,?/]#IFVZMA3[UJH
MKZENN# 'NM!NA0LR;2R(%'X?$?P%5*G^XL/@_Z&OKU6SS!JF5&JJ;8MR"GEI
MZ2T,N9M=+.:VV.JC84[%LPM;5.35*DO>-O, J+GUO3 *)C%B7$\8!_YS *:<
M1Y7WMM>+(KU#U: "W<_)P9[.NB9*,H\HGR64MICA(J&D5VJP<1,-F97$FTOP
MBK>7"N?QC#>VH<6![5QQ<XZZM6](I$6RNRUX\B?JIB5JA5&<%#>Y)^!O<R0?
M(K"R#Y+-.+2GB7)A%,/'1?).+"4%LE"L%4,)T*+T%)TA$6[]%WBD=V'HA,*+
MTR>"(X0@%G< (H)ER/5>21@A1-#G=Z,06>A'[\A#CQ3U+TM9U+33Z[^=E_&7
MAA"78N*7?H//OI'12*2/_3\D",E[5;CS*&W%^[R3WQ0L)2L9E<1*?;ZP6-#-
MU*2)1Q74S]G.Z)9J'0\=YZ7-3Q31,%=/&IB<2:1N27H^O)& H./7HVT?(E^
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MTV'V35&66/&X.=08]@L^0&T530:@26.%#HI#B5WO()_1,JG14G56:.HN(4S
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M?UH/ ;.25$??$(\,W&A-_0/&A'>M?UA-?V>J_F$2!/ 8E'JD3P8$_NI_*(K
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MV#OBOXM?_;7ONGO%!6Q)JM0T253M/%SQ?+/&)*ZV.  '!A963)D +)T#Z]R
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MN!<S[U"MHA#7C7_9/5$WN1^#P<'\U]@)ZB/- <7"-7A[ #GX%#R.P\RS",,
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ML+K//BJI5\HIMQT<S5BS1G.Y\,Z#O$;^ HI)>8W\^<WI.=;"\AIY7B-_X2K
M:^1YC3R,N$$&!)SXOO#LPV-YM&SH.7#@9YRZPP^7]S["^#:3:#U$W]_Q>F2Z
M57K/'@ V:'Z%JK#22HX?*Y=YDE PF$R:]J7D3_OB!\J[MRH@'J8$S,("[SP%
M<F_;"LL67+]_0SSX)4HD^WWD> NQJ!QLF;J%!RZB)G%V[;-$UQ9C>VATV8 N
M3;3S]^'BJ9*[EPDA@R[RDK@!B;MQ=>&A:.B9^[C[I^F@5)]F0GV<R32/?AB8
M2BR:-BO."?=T2\V9.0BD9#"YHIR_OQOW=TM(3K\0+V27=@5M$$OP7HS?82C4
MJU5D5LJ3N5=;IF'=CJ<4R*B5FF:Q4AQV"7[J89O#2)>>L+N+S2W(VF+&KB&:
M:E%%&Z>1=EY&LYB+1_$NEKX@%.N5FBZ)EEQ*LZ.#HWA-VOERFOG'1'1,RD)Y
M;,_J5;#MZ;94KM4$MB.E#<I*5<B6^-<@W:CAAKV1'TZ"M#P_PXBQ"L(D_7HT
M?1&OM)S^AU=:S?A?3(7+]&#MWI#T)R/R., +K\M"-,RTIS-7GVYM<F(\E+01
MGFC.8F<Q&5%($@HG+_"P<)&0YBHBC;KCO6,ZK&Q^"85PZ =1G.&(R:7S?,<^
MB'XAK!8*#LV^7<FFHLG%]+N84G(MG'T*)"B:9AL%Y2VJEE9,WJ)>5<QLESK\
M0UE5V\J6*WKX9]*JLJ$R]DPR7$IB[:'TJFRQAG*C:FO9\GPO]9D,;7,2\S&>
MR9(V&X,D(#!]<[:RQ4O#\HXE\-\^[CY.*C?MGF"9V::LO0TC7)?!=^I"N?$#
M& (7RT>LP"NTLC @?3?BPEF.L(&ORD6R))(')YH$;O0N-)QH?<KG9<KF#A^(
MA)'P5+!L%/EC!G6R%5D.>YQ6!G5]:<N'I:1I*=7;%VS[HVRV=Q)F6S!Y2TXV
M1U3/45R9BDWVE%MQM0[\/OP^IZ=FNU0!Y1;IF<CJZ>&FA)JITY()Q\_^^#GI
M;(;=ZBIOAZ[G(+]-& 63^%SSQO'^V@4T>QTLGY?T;HB+O.C"MXGC/?\S]"?"
MC0MW?G9[H?#@>).!T\-MF_<,$JZ*PGW4KS(JV6,JXZ:*7U3)=>?N/>_]X[F[
MHBT=O-^UOGX\A\3 R^,@#KM\=7JTS.?!^>&^3%[B4!4(Z-89PSM;J[9F1XY6
MI:9;DBBEM&L4&)WOC9I4)H'.;F#8>-:L:%K:,?@=M6F8H8SQI*6YA*?H7?<G
MP3MQ@H5YM"LU^^.1]Q5^YL,!*&-SR9[N_L\$C*(<GR.;C&H >U*3#R:I$ZMI
MR&03=LK'^K NK"9DW?O>,YH)-!S[,H":4ER3J!65B75B&8%G!*'MKL6!((15
M,$JZ*\$Q=%H82C5#>@D84FCQJF2QTDF40ZA0,U0&A+#7L<22&3KI<KPLH9@'
M$O2&#G*D[AV'V:48Z[Q$5U8<YO"296]7DCD"8Y07@4FQ7%JEINKIEHO1*3^O
M4(Q92"C&U->%8G)$8BY1>_\'K)\3O NPI\!@C%V"#IR4?)2#">3$RIT/L=DQ
M2O!4L:&W:,A%]5SA!?-,[77*0)!9J1F*:.FYF4<XA%@T0E8)$++0"%GY^TER
M!+%HA,I D,V8$;J8U)<"XBT\[X7GO1PQWF*7G_%B(?^?:1479>$)+YFB++I4
M2)3%DGG"2S'3U?)?XW(:*T>8Y1(%I_*<E\-M?>S#.ZZ6@EL?6;,8.2?D""IT
MZU,&@M1*3;=%S2R*A8U#B"4CI,LE0$@#"(F&FCO^PA'$H!$J!4%ZI::=4+[+
M"<4*D@JCN\[=[:XAEOP'C:P)81HP^=2>8+CD<Z:XR#F>NV:-<NC*$:(<!E(K
M[YU+<F 4GUS,8L5P[Q>S,#$U,6?0XAPUZG\FHW=!H?$'=9>LAG.4P2[\'3MZ
M6V?D5*6ZY5MHM@MQJK!'EZAF):<_C/=]>=.^?1D]T+1C\RQ)E+/ZTGS>#ZCN
M6LYY'[@_2/_J'Q+X:5-N2UBO;2FR\H7/.3.Z?N YEX\TYSPU@:4C)=9$E^RT
M>=)!)JG]G&TUT8]9XF$KE9JZ_[:<.24YN8V\4<A&WE8IX\$1D@_L,U->G9^A
M'\YQ+J':UM;6&S1^@'5:&$IUQ,O D%ZI*:)IJJ*)M*P<12>-HE1+9): (@,L
M$5-U_QQ#A5JB,C!DHB62%5M4E=Q5>?PT/3TRX'KAD'C/%W^@?M%GZ!DW[=91
M-^UX%K0_+P,_2U^>2[N8+;B=?PM^CHHU:XXA&S2=?Y<-]CG*8:U] 84'\:R:
MF*5TX2WY'M.N+=BTI4&+Q;[#0_K]F?6X4F9(A<>IU(SJ:I+YO_B!_U[F_R"N
MGRS)ZXT\/P8\EL]?QL0CY: HV9IHV1E]?C[UA]-Y0RIAZE6N\\SI?"D3KU&=
M-S31,$J>^HO) +CS^A/PEUQGQ%, > H 6QGYAEQZ1KXLZ; -,'5^]'^DN(.A
M[!EWZ#OO"[.(IPR&MA)X@ ^%G'<@TW0].$%O*"CFSF$*+C84F\$S)@ZWZ3A\
MN:8LF96:K?":\3. T';7XD 0LM:[$AQ#IX6A5#.D'C+[79;L/;/?.7R8@T^J
M"3HL?.1]"V9XBL2ABB?.-D>B8);&<SSHS!S[T,J/?<@R4I3P#(J"(AEZ$1D4
MLJSP#(JU#4!UGCR1(7G"T ^5/"&KE9I:7;4:/'EBY\U$WE+:'3:D,I*8::+%
MSU$9V@64,>_Z^G6=3_RQ%/[PC4=DV0"%-T0U:]L(/N\'5/@RYMT\DL)?0-K$
M;^V;G5D&F3L-YJD2)^+:9PX7F$<(%UC@]*^A-&5THL\KP& 5$V!86Z+!,R4R
M9DJ\9PA(<)FAS$R>)G&X'<;A2W%E10)/TQ!UBQ]QGSJ$MKL5!X*0O-Z-X!@Z
M+0REFJ'#=_B0%07,D"G:$B<F.74(I9JA,B"DLF:&SBU?(GNIR?DF3/ N#7L&
M.DRI_$"'HE5J"L^+*"AL8<J%A"T4/7?8XASU"8,0BDVC$+E;%9RH"+*F19CR
MH=(B% ,,!^>4R+%Y,/.6&6].DE5,SBK/G+=_Z#FW^)RSI^>'[QHB*S988TN4
M39//.S.Z7L*\J])Z]YUG0^2;[/;0\9Z'CBM\G_1AJH0&>24C?XR>$D^2X$D2
MC,4.U/)C!ZI<J9G[QPZ84XZ3BS9HA40;U+55&#Q)(M-LM?S7F/A2T7BJQ&'#
M&MJAPAJJBF$->Z^P!C\"VW.#E+=:>!='6:O4;%64LA(L\E-4YB"TW?TY$(0H
M?98M:K;",73B&$HU0X=O-".KV!3=%E690^C4(91JALJ D%FIJ?M0QO)DCAV3
M.3CY!<_ER!V/,<J+QR0V0EJP$1;/ZB@PSF(6$V?)7XQRCII%LSHTGM61)?QA
M'2K\H4E(=K'JG/*LCIUW$7EKH#>?\&O'ZAO/YWS7Q;[X.5?XG+.GYR7D[6LJ
MS>J05)[5P8ZNES'OV!S$MEG)ZCBO?(2.'SDC(1SZ070%GM$+S&8W.N;I3M</
M^B2XBOSQ-<Y9Z(_<OH!B.*=H68H)E4O(C]+T2LW295%75H_T]@N6[39;)Q"*
MO0C8I5CP4F!G5&J&J,BZJ*NK*?(<>.</O#1[5\(9I68"\"Q+5(V,M&@<=F<!
MNS1[5P;LK$I-$RU+%ZT3L'>)ESM]@JED$58%11WYQT[@8PL 4P%%?7_2'9%E
MA/$;Y;_1N9T.W_HTM!X;WHL_(.;=$;9)*E[]LIX?6T?@ M#L2DVWTD^-A>)F
M;W7%']#_74S>OE4,2X N56HV/T].;9X@R_1 >1<*OG.4@<R/:W<\QK$R%&2W
M?*^WYP9)Q_8SLBASEGIF]L6E3;U2J:F\0P%C:I\A")QG[E7PJ&Q1-C4^]<RH
M?4E3KX'%5WAE/D-IVLP5')_-OIU7L>Z3(VZ56+.?8J#T]74DC$[YB44!$C._
M.1903 V_;N2.!7 =IM$#L(%.\"[ RHT!!)M136!/< HOD#_<;B7#$6X>E]6$
M:31%V\J8;LJ+4YE#T79WXW HHK5GFJA81:6@<!@Q98PRU#CG@9$-[JDI&H7E
MDW 4,66,RD&1@?R(ABG*&BO=,\XM'8(7R_-<B$/G0I182S\S'-BYR;0.G0MQ
M/L&.+6&.8DKH#65=F$.XZ)R'&?.@M7/4XAS%H/*TAUV=^ P5RWG<+VP\I8J2
MPH^^V?&\2YIZ;"RDR2*E0>5SSXC:6^7,O8YGWZ+*Z]894ON2IMZ(LYUTGO9P
MJ/J#N\[=+4]Y*(G+CA_N[9798!]AQV["HK.F>H'1B3ZK+;Z^A8=LURV^5:G)
M4LX]/M?:N!)B]"XH-"2@'NYX_MRDM@L)(3_UV7/_D8$\*8\3:E=JAB:J6;NA
M\;-#YE"TW;LX&(I,"8R!88LV,T3;'$9%&B.[G/H?4\:J6A&0Q%%TXBA*,T9E
MH4C! D*=>=;_DSS CRD!1S!3F1@!=]6,F"PC'N *7\9%T!+E9/_+HS<J;"<-
M0]2LC"5X1<Q:Z3%L#K6\C']YH(:LK93T3Y&S=AGC8#M)L.5D^<L#-ATI@DW1
MD+/FQW*HG234<C+[Y8&:@79-DQ31R)Q%>R2P4=_TE\B!6\VBQ?#<*#[7FSC)
MF<!RB'DQX)Y,B:;#G(W]T,4O7 =D!-]\)5_>W'XTG,[7PK>284KSKSA=&-0D
M6O^5@T?V96D;[!1*&(-\H4O!]86?PV"NKL_DJAL0YZ\K9P!/>^V,WISW$$6^
M,*@7UYN#6JVB$->-_\4)GN'3<X"L'_]@<)CQPS/%R (5\ .*C6O8+9$ /P6/
MXS#S+,(P0,7_R>W96K</CH;B*+(F:8HCRQ:Q9,N2'=V1B?X?$_8T"'[!'R!?
M7030"G_]Q:DMS_&F>5B-T2<S4_NU&_RR_D+E ]I,!?1-\^Y;L]44A?M.H\K\
MT[8>.\VVT'D4.K\UA=O'5OOQ_JY1[S0;PM>[5KUU>U>_%]H=>.&AV>JTF1_.
MU\<G.I(_F_6GMM!L-6 @C>9M\^&F^22H,357W/%)%>JM!OZB,#^H3_47?X)U
M#JXG1$-_ M?JAZA@OU?;5:'ACT9.('S"/BV*].5G^J_\Y;, GQ*>B <VL>O.
MWGYZN)E^0&1^X.1'C\ :#%Z#$/>CPD&'0R> 6^#HQO *_5/H.Y'S.6T=^;#V
M3ET+R3"NE,J&M\TK>=-Z8</S)Z^@$Z'A:AU[#E<88KJ6K:DA<\&(>M'U%;Y2
MNF,7K[ S*U3ZS3\(14$1=(:P.$RB,((9Q,J4[C3K(A2Z>-0^&/DP%_"&F[0/
M$V Y(OBFUQN"S/_"]P#& GS.^_@AP,? ]1ROYSHC>"^,W&B"$YOH#A&^/]U6
M!7R$U6\+;TXH9&V(AHR*AVF(9F)625I#-,&AXVR0'LV\C]W@J6VK"FF3O9;X
MLB0(HL!O_1=XHG<A(&,'O.VC8;)2^SG;R;&\>:_S!.-YQ]D-'P>+^Y[LNQW,
M/U%%4UT]KA$^@0G,G I5VH-C>\DU/'.?A7Y<@(;*1U-I"!C$_EKTSE4S%$("
M&T?X;/==V*/0C?8M,[^$PCCP8:&(W@7_S2-!.'3'0@^W;P/8P('6XT)"NZ"!
M7H4D"JO"CK[J*:T!"E\##K<&:.:AU@"+-L5<S279M@:DV-ML1L\NRW: D:I9
M8/-2:AT_935XY3TTN(Z&(EKZZLP49._F=NXK7-@/WF?6##[D@\4:H=F:A$2@
M\2AJQ-"H.0#Q)6-VAK9,Y;;L@+;,WM.6M2/XT0=;ACM&YYFDVS.LRJNNGAL<
MW)[I6W(EBC,-6J6FB[JQZK=GMV?E/3163:WSWUC<3V2SL4?<:JPQ[XLF&D;A
M1,*;.QJ!21#&(Z<';X$B^_"%X-7M$6$R!J3T /XC0D$#BH(CCX9NT!?&0R<D
MTY?FR\;+DE,\2 H=9JM(=^*.^FBVRO5VCXT;[;26#F?-XC%?.Q!%SPXN#+#-
M(:\.S/+J2@/@F/H&L%RL65 *745LY:"KB+'9*V;18J7;IB-:IN5%M1_ 1?NP
M0<ZZKFXY"/X>^#U"^N'7P'^9+E%8@15.2["RKU5FI6:+DKYZ'KS' EO^TUNP
M<TC/I>0K[2%6VO4EF+O&AY*E-809'0DO_@BN/2(?UM>>\S*>4)\\OHTHT(K9
M?1=7F]'MEZR H/4CK:%P\X-MO^@$)Z#Q7TG@T4UULE#"^_B50A=(W3A8R @K
MD/8X-L@8'\J0 +1O:T];JM36]01+E'(VV:"/H(KHZWC"C$C9I&/311H=R;BN
MF26,3U[?GF5Q/-,9$^1D0'L&=5BU*M1\&Z?EF9]64,?6#F5MP-&O*=55NEWN
MBF=QQ<]0G\TSU.??P.@+_^M//]5UO+\$N@E/5',0'](6JKJ&=3#553$>LEJ;
MLL51^)!DLY+;F@6]BU@]!%1W3$%=W @/8? >YN7ZX,_/K31Z$""DJ_DK/? 3
M/<H^BVE#\ ^6;@E^=^0^.[$Q?W.CH?#JP 3 I1 L<=*2#Q8^$$:XD0K"JM#V
M7Z9[C) L7-7U>J-)G\!E!\YD1$]X?@%\]0(_#*^F+\+6Y=4-Z=UH%+'G3T9]
M(2!_3]R "$ZO1T8D3N;$6P33>#'^@?B<+3CD-7DUN7 5L/X&+P8B?3L1SFS'
M1(?JXLX)<!G A CAT ^BN(0-+NE1YZ4JU$&@2P_Q1I^O"X^&#DX4)W2]P 0-
M,209P8OO@@OWZD6I]W6Z-(HI1#Z,)9X*LBIW=P#"6AF2X/? OP>!US>@>VFX
M.$(W";RZ]%9T1G$;N##Y [ K 8X&L >PH$_C/ >$T,#\:9GVN;[0*UZ[D3-R
M>SMH$&;ZHOV8@ 0></+=R"6)G$$>C_/969;')EJ76:O:,(BN%VXPO]A7%\W:
MGV"_DWN^MWM#TH?M.4U![L"U;D9^[Z\%FP>.$($OC3'),9B0#"E^C-DKYQDP
M]HRK2F]!]B]+LD>D+BQT_0EL<B?=$*P#J@8H4;H2")A0"69PX(]&_EMXO2.$
MM15Y@7AH(<2'FHP>)JR.0W(]_>5+WPW'(^?]VO7H8.F7OBQ?'5/Y/Q1=T-F(
MWYYG^5>E.-,_*0].[IR\786W?EE]W5*KL"%/?4NJRAE?5RTMTS?6/92L5FTC
M_:WII4Z1T'TET9=.UU1_,8^7S&W$N7((IPLAR?)>&OTV;L&M=4P["F@;O]*N
M]5)L2_CG3+)EFH!PIXJ>2NW/)&:/VY<5:Q__HE">7$X\E4&J1;(-I'HVC0FY
M\UIPD<X;&;V2!^HA9P\PZI6:I<NBKK!" ',**U:AFF7D7<O89 EF2D_:-"/R
M3\KEF%5##"3:$A6I9+KH2UUZIB5X)E]P&%2D#B:4[:='YGYZQ!>:?'ID\>7E
MX%KQU9\$T7 _M<"&E+IHI-0)\.7E@&IQN-[)?'G)H4CN8%\]P@)#.[L>\>5E
M^]QWAB0@E%*%KR4'5H$Z2GEO+5 D["AJB::>L;LQ(ZM)C .5=75 0LYC+A_G
M0#C&BLYE5S$9"<<DV8+_%]6VES$FLC6\8]N*?4HKY-G[#'J:_"(T?XR)%Y+]
M3]X9.>:=#0A4@^8:)2D;H4 +(/^>. %\8/0.>A.Y(YJY !\?DQY2Q24?QJ/<
MP62$&1HDBD:D7Q5FER6QG.!+/?_9@P?KTPRF::I_N#'7/^%0PH06Y% 2''IX
M!1^/_&RIMEMJMJ=/FTSJ/N6-\'PT.F'9J\E.8L:'W5*16<C3JK#,2Z*5EA6<
M.9%9+D.\V&]1%@U[]91!7$#DZ%U$E,!V[6WH]H99);\X#FG=,&[], IOG3$U
M&@#H[&/1*S55$65]M48Y%U0.^,3(D6F(NKE*_)L7+@=\:!,@(^HI"DF3)'OS
M2R\C:,%Z41NXM[T2!8_0[# GH59;NF4QQFRM^+[#H[?('HIFT6VPJ:RZ)H<!
M9Z8'E18>%/;K:BKQ^<$@N>^CRKBI4N!9MQFOG1)?\:K;.3(5%:Q,=K_D2"1\
MLEH5=DO4F_,2O!)O0K!J<NJ6_Y\;#6\G(0R,!*MY>0I.<B)-TJ]'TQ?QTLOI
M>M\#OS_I14)RBQ6/]F-V81JY7W+AM/LIIYL0^#%7=IQ(*H@EM9RN"UL. #78
M3YBBN/C-B2E;79IY#"KE.2/Z.8"^/X9/)I<+A9NGW__WKM6N4TWN-/^X>[AY
MJD_SB)&0,JE]%!>2G0/RC+F?7X3_[UOSC[HHW-S?M6[_[#S2C_SOG]^?'N_O
MVGB-N,\HY9T5' '\?NJ@TJ>LOSP3[XOPU/SC_N[AKG&0Z@*#,@9OKR]8X65&
M/%S%?,,?]V-.2&(Z7UB/3.W+09Y[1YA0<?]QUZC__W4NOCW$MQF@-P_M+U3"
MWQ]OFG_<_LE%7+R(7?\*X]5.EBJ4"V14-S^(AS.J<T9USJC.&=4YHSIG5#\4
MH_IT^Y3^MJZH5^KI;J[B,J8N[(7>D&<K1!N<6J&(4:7IS@OW5.'^(:I=2P=/
MM^[*4*JJOKG$:>=J*:FJVWI!)5RZ>MX/94CG5U>6?L*<?F([&Y.LGV:E&,U]
M:RZ9$ER*LU0WG<\D[E"EEG*<SO8$+Q*2Y!WPOJ5]IR@TE0LMN] 4;C?.939_
MSIO#R85RD4*YA(*![Q\.Q*Z$9^3260L.GNJOI><.=9\]LNV,M_D#V8M -O4P
M)/!?O^/\N"&P%R9/!&<!CP,SYS_(F,<EFI8AFEK6GNJ'J@3@Q25%(DYG#7&8
MBR>:LB7:!BLU]!QQ12+.8 UQ&FUYK5JBIJTF@#)9[;0V%_R4O(-[F,%KX8ET
M*>TCQF#C\&U HDG@[><EI(CA1#3H4\%NPE.<8HZ7FKV2J$AV#=%IC89DBK*]
MFJ7[>6?E2 ?IP<SQA]ME-L<7 J8=/(!"P614:KIBB[*<TLJ-0^FDH;3#TEXH
ME$RP2Y8J6@H#5NDR-_0>B?)LYS=6ZDF;BO4^AG].1)T*6.5WS/E.\Y6S:]C_
M8^]=GQ-'LCS0?T7!]&Y41<BTGB!5=1!!V:X>[U;9M;9[]O;]LB$@,9H6$J.'
M79X/]V^_YV1*0B )$ @0D!&[TV5 CSSY.^^3YQAXK*#;-45=JW@&^@![?@*^
M' =X=<OCH  W,=P@&Z9HZ/D)+AS@'.!["'4<$N"*A+Z;HFMB1SX/@!><LC_1
M&C?6[IM.PZ+%8R,[2)N,+Q:V)0;7X#W]B%>YK:IRZVA*\PK*:FM4WM"7JJG*
MK5 5G5'A6,J=VU2!7$RZ?->"K(LL+.+56/NNQMHN-GB.E.-%/IPHIU#Y1*W<
M8WB*R;G]8QU+EFHZEAP?1>+56ODIGPV(8"DR1K ZFB8J2ETAVA.+09T]S)H0
M1U)H',F41-7D,#M/F*V9P'T0F*FMGM[1Q(Z>;Z[6R%*L4TK?/MN! QK^W]'4
M&FR0M3U[O!L-P+O6ZG6P]Z1ZX!;3O-OX*F28#4"&#I)0[8B #HZ,IB!#E=:T
MHST(,G"$EJ*(AJ&?9%OZYGONM&D>=]O/EHG7M&@^"!-C/UY%$S6IKJ[WW)MJ
M%LC6C$\X",B,5L]4"NMC.<;. 6-J S!F@@>CBFK!R9"S<MB/ET:(6_>>O3UR
M]MS:@()N56KUNIJHJA7#:]RIW"<P&I!&4N563P=@:!6+1#DP]@F,!B1^5*75
M4SNB?.X#NX^FWY-N_&>OWR_73&] 8DU5P4P'-BX86L1=P7/ 6 .26:H&JL(4
MNP5CR3C&S@%C#4B+X2 G614[C2E".;=PPY%GJ?!H0TW,NFYPYD&8%7M]J*(N
M550(W*G<)S :D/U2NUCF)>K:@9U*#HQ5P&A QDK%AA.&*"L5NTWR:,.&B#CV
M-#\>;=@[&S<@*:B:-&@H\<3SF6*L :DL#5-9@#&98^P\,=: K)@F \9,4=*:
M$M%:8Z<DC3?@14DY)$_E5V=T].(!IS+S,Q>JW(",IJ:T>AT)F)JGNAL$C ;D
MR#2UU=-4494X,!H$C 8DMC2-NC/=0P/C$GK*/GNAY>0:G>VWLVQY@[ISMZJ;
MX+?I!^XIN^%NGX#+QT'=U#ZR6N? ?60YJ,\<U$UPE+H'[AV[1U 7=(W]=6EP
M>K(]]Q$0T!XN[8>\,,W@:3@AH\@A#^/^<.A'9/2$LVOB839]=_3(AMA<1[Y/
MW/ 9'_L,]_KB>,._,@0&VY8 W6=PVQ#NLFI<>[X=:Y-;V2Z,;/?ARRO WIOE
MCP1O+%B,9/&\G^$$5D40,($(]A^EH)A, :)=:ST,G@ W)".>*O2^3;K>JKSK
M[1DTF&WD2_'9[E76U+SNA(^)R'G,B!P:KP69DHB<^MHZGA1MF&DA]!\%JN;
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M&L,:/UG.F_4>X$9E*]YL=\XW:AM)7T:UQ?(U=545X7B\-\YF> 2N\GR*H$_
M!<3'7\'K6(UY%V'BHVSYV_K= R'P3&L*O;%PC6+)#8/??K5Z&Q8IJD7ISWAG
M>K\-_%_+;W1X-B@NS?UR>_?[[?VM*'Q[OFDW_FWO'YYOGX3G!^'Y[[?"]</]
MT\.WNYO^\^V-\/7NOG]_?=?_)CP]PP??;^^?GQJ_G*\/CW0E?][V'Y^$V_L;
M6,C-[?7M]R^WC\)2 6W__F9QHEQ3%_6A/P7M& :"[0KAQ(O@7B-Z*N./]E-;
MN,$J75_X\)]_,Q1%^OP+_:_\^2.-:C\2%V3BP$Z_?OS^)?F!V/B%DY]# IH;
M2Z-=>@X.%\U.[M'5S> 3=GYD9(76QR+MTXCB_I6+E#OMU:<N<A7Z:*WY9 )6
M&E@2=^[0FY)[+R0%A?8=@QF'8*"043],/L1;+M;?]X?#:!JQ@SKTJ):P\!#A
MPS<O"#X*[&%Y.ZB&PP:9-Z O4+!(? >J7(I6:N:.%"P99QFBP'N<[(F#J?=*
M3]XA*UB97?/HK@T7=\VANV93ZM'#5/!_[,A"L.FQ@25JZ$<X-@#&25MB!ER5
M<P.:TE:5:A7T9;>2E;9FKBZ(KU*D7_P0_E)[?"E=6OWP"ZQ>/:FRPZ^>#W^Z
M;''7D>\3=_A.'8)G'^[J4!%/_^Z/_AD%X90Y'G75;YX4K?YPP4]V\%09)<CO
MENT&OZ+R) &C7T*I5\MV4"A?@85U]60YA'[\1(:1;X<VN53Z_4#U"0;#-]L:
MV(X=O@L<4_F\V@5*S'.MXN:E[8PHE57GMJ0Y,;IPL&P&EDLHL%AN2*5<V#&(
M\H:WA>U(<KFX %8 _\H%0K!]R,1S@#L"UCRG<@*N*[5Z./BT8(P1;U!^ZCC*
MG:?9(XYDUN1XEP;''$;-A%'N^,P>841G<!H&ET;G!B.E<T 4J:U>MRMJ<@.F
M;ES"V9B'@C1"G#^(LPD# EM(NXTY5A#88YMU?PJ$"SLS4U'RY@Z8E?#,P]#^
M0BG\N$S@>Q(^C)^MG_TP].U!1-,IS]X/RP??J#I?:7B:1M0Z^>)T/L:@<5BK
M!C5]=?W?H1"F4S.R,<,(.,IJEFB;6@&'PEL'W%]1*YB$R@7::4,M7Z-_9*1A
MBU%%-+3\0=2#0^W0(4=:+'(,Q"0U<'.[$YMF^MYT;14,FJVI<5KKJW=HA?':
MNMI\]3?&OZ]8??(RH:V L/)?>:F<[3+"JSL:U8OR8%D,? 6X]+VAS>H'0M:D
M=G/1,+9_DM'5OXGO%4H% S.)AB(KGQO2RX&'/0YJ5Q\6;29'VWFC;5/SN@;8
MY>%E2*V>49 !X- Z?6AM;$[O!UERDY!U"2%=V*&K(=NR=-##NF+Q&J9,K:EZ
M.1'&VE>4=\41AX2C*ONEAE)?3'?CTJ6F!T?."HWUQH'W@D&UWJ@OQV$3<;BO
M2/%>$*EA'4)GIW(6#L:S >/&L>2]8%&GD6-),9L,QDLL8RT? +'+G.[S9R>C
M>[A:( .GY'5%TZBA%NCXHKS>5DCG@;UJT#-6V[=%B"L %;8MTO<]H)VCZG0D
M6JZ]\1XEFM'JR;*HF;MX[!Q[9X.]3<-'=4#/!$?=%+4"3[U!T+N$^&Q1R2VM
M62BKM*TI.+MF1/M9,IC9L%(B>)^>UA7U3MX"V<4A7+.UIQ6AN$B<;GIN<%N<
M%D!1+C2$.0R+%W,!&-STS.&A9"6FM\2NOLN!LFK;>M( O02,[EM*5D6HVNKI
MDJCN%Z*G&.+E9<.\;+@Q@<.\$W#$0DY3XX6<YXVV->WX#XLVG:/MO-&VJ=&^
ME^).L].DXDX.K5K+AH\*K&Z3@'4)4>D-JX;12MY+L? EN*\5PM'[J$8RC;T$
MG^L?Q=.4ZKC+P.3&096-,%D .[/V0//Y0NX"\+9QF'D/,E"7I%9/%DVMAJX1
MQR_ X/*OCOJ?H\)1!I5LBOI>\7B* >0FU AK?*[P_K3 X3I3ZI(",E_515W?
MA<L:,:3R.*5YEP/B:AA>TXYD'717AFYU2:T[=,NAFV;]+]G^SAT3W:/DU5#R
MBII:7]'I3AMZZK@]1Y%;";W:X?JBZY(.X-4,T2R8V7YB9D/!;.LC#LK<H!Y"
MV;T>XL!8I@,;!9S8:&U=@K(TOY'XM!>S$XW@][8;7_*!L('MR>]$P24A&Q5+
MD%LH<N@C@A#^0X=8X?!(;T;8G.=@:4IQ?JKY\KS/*L.\NZT&(&S34:S=JJ-8
M\V(%)['>V,$0MB[R"R:5ZE(G/Y,5/LS/9'W"R;;QO:GAU_TLL&>L'<!:-/>4
M/>,DYY[>1#Y(.PKH=V+Y@4!<9('$/V?6[])T9YP/C.-I1'H9QFDL]YWRET.0
M&?!3-@H5;TTH78409PDRD;[M@-2]HI?>\9,=@I ;;H#G+]^?A"<2A@[E^JW7
MTQ08/+A"/WJ)@E"(SVPO[BT=$44E8^@)5F;A% O/Q)_:+N.(_HM/V#<?\ ;Q
M:.S,!>D/TF':;W8X$8">5]?$>2$NH?<<@M*Q4!"/!1N$JC4>VXX-,A9E/:HH
MQ*Q'WS',/!U^C1_-+!]G+":<[;DO'EZ K(M6160Y\5T BQ-[%K#%@G9XM;TH
M<-ZO1DS*H.Z(K[7\@1TRH0X_],#2&,6WA#=U\9_]+X_]_Z=_?WNLNL;M]3@P
M>5?[?%1EG@5+?T[J=)XZW:!O]A"U,<7'4S2;.>]9N,57?WOJ+U[5GS*1QF:V
M4T4]$OX',$"G3Q;"]7\RM\#+\"NJ,N"Q@V#HV[-56,^^P +C#-ZSZ$0[0I'D
M;BQ.9:,M_(C\(++@?C&TB]A&7+B'A1^/\/?3"'$-) 'L3NT@8&O/H!8?L\QE
M2ZPUOQN5UF,P@4H]!C8K/N_R+C2DN;O_6JC6'\DL\H<30."H[XX>26@#D9@J
M8D4L3_'=-_$CI(P!@.VC55'IJJ(LY5T) 0Q_$!7^>S+I/I87B9CSP+:'[Y&*
MZ?LEVR3B/X@UG A#^%@(HL$_R9#N%"6DBQ8GW-X">< D6B*; B;//'=DLV$>
M\4.+-K<MW+G4L+1'L06)%* _C]]X0%#6^"2,?)>,%J7T?/M&OC>CFPMFL0UO
M,-L 6&WA:^2CV3OU?%*&LD38$L:03WVZN/_I@YP4EF/ZH$,R5,J\:"R7092C
M", O$Z-- )'D4''K.$#35W@M#W8+*/9X^X]O=]_O;NCS_G%WT_]_^X#%T';0
M?0,Q'86P>\)7,O CW%]XO"X*;Q-[."$@]P0;#!O+=VSBMZGC4$0 E.NO0/B
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MNGY1&DPLS'$N%#Z-"$@@4&U6:BU1@WC,M!P[>ARTERJ<3Y6%^R#>8@,V7FU
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M(Z)P+; )MJ6GHV(</$>-1]B3$.QBW 4G[(#)'J<NX@01=O8?TQJ'[,Z*R<
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M"L@H54P9#?8P9OHK5E\/KO,^/_;Q#'?]XGC#OS+1#Y.UKK7=B(SZ8?(A/I6
M]SO#C?8CTMJ<W?4&.4,9+7TEI'0KU_V/M+[4M]QP]8&Z@J45;>Y&VQKXX:?D
M/1_&Z4O>N=BB);4XGE'(Y_>O(TF;;Y3:H)WY0NS?B0MJZULXVE2O-.G]-S0?
M3W!E<S;)F+NPL =64;?Y(; F+>I#?XJQY;@5H!?!O49T531^>(/CP<!V_Q#W
M__@E:6V9/U>[\KQZ[S?:)7JN5&E+ZB'>?1:03\D_/H_L8.98[Y]LE[XIO>CS
M(O%0BBYUI*:T9%_/%4Q;8DHF'LD2/SG^N@U?_9K_7#?:NF86?B6UY8J?ZVKQ
M0\JN*'LI66YW9/Y2&[Z4HJZ\U9HI/8T8QF.LL^Y6M(I?L:;"00:ROLG:F80Z
MSNJ+1P[\2:PXA'"+807VSUQLH8!&' "EDS#*Y@1(^5$!S08'1I0VF4ZUR8(O
MB6@J)UIUHBE<O%S8IO_"2<-)4PMI+F'"],/\O-E/++7/I)?K'B_-KZ]^?4UC
M2]F@,J6MZ V'XR,)"&TG@KG&$8ZN\&88R3GF---&CWRK85:PMG:*(MN3OCNZ
MF>_(+1,75:>[=22<0*JKHBFINXX&7H'U!D\>/'LXK1TA6"N<%("3TA'UCL3A
M=)9P4@X*)[75ZZA=4=:5AL"I)B/T9"R )T([4XC)^ MJ"5BCJ>W2#"=6 ^S-
M0EW%;@5D/4MV6V,,Q-OS.]L<8+K^PM9LS7<:6@7 =[M;!2OPOP\QSG%5BU6P
M+USI@"M)$W6-X^H\<;7&/-@7KCJMGJ(8HB'E)U0?!U>U1@K,AAL)SQZVM_+J
MB5W5.U%^?2ST+-EPC=EP[05A -P7\UM0G>&ZK5Y7ED5)ZM1DF%>)73?=";QL
M[*TQ+7;'GH%.H5R'<<JQ=V;86V-^[(X]L]4S.KIHZB>!O4M(F7WS@H#U6_3R
MI:4\)+$)"3_L:%Q@"WCXUS*WI<E,5H2.&U69X? T19FA\9$[BR>.I)RIL$\D
MR>5F T?2J2,II_CWB22EW @X.)(NK23A;MX8&S=0%%S"RQ&.&$I(]H/Q4VQ8
MWWMN&@VZ)V%U#E-;/14D]<[1/)Y$;B2FUH0(]H,IK=73#-$TFI)*YJ ZJ.^_
M'U!A0LL4=4-O"*@NK3Z!#;YEMH#P(4X\?-S>*KA<@[M6JX!N2Y:Y%KBN.IMU
MT'<3=65GV<W]MV;Z;QM' FH&5K?54\RN:.@\O'1^H-HX*% SJ(Q63Q;EKBJJ
M38A:UA0A:+090),  SH$-3$&0NLGKT X@2S!/!#WU?>FUQYM(@2DF3<*^4+W
ME?WN&7?U]F?H6W3DEN6_8]_. )@W,T<M,?6K<ZX)=H:FB:JQ2V2/9Y7/#<N;
M6B=-PK(BM7I&UQ3-;I=CF6.YLE'4*"S+:%&9IBEVNEK#T7P)-1=WJ8F5U'KR
M8,LQ4S Q!\8."QM %18RDM+J:?Q0QYGB9&U:I00G5:6QBM*XJS:EUI[#Z,")
ME)I@A DY4=:: J-+B)/<DU!PP*1K0%QDWMY3&'D1]KO$Y9?;9J?(=WL*F< N
M[E"^I.@LR-$U=@E.UKB9I^,S<LQN'1K9$;.=5L\PP.B0#(Y9CMD#A4!VQ"SF
M%D5)4D5#SI>'G QJJ5GT*VTNG4X;6!QRF/N[8)3$!<V1D,OG2#1R( 1.#DB[
MM:?-VG&&P'3FDPE\#%N5&/W%XP,4(S<^ !X=#X1@/>WGDR+PR46S(A0^=. P
M[W]Y0P<6H"Q\RSI I[.XVH8/5%]JR:"":C<Z[% #TVQKLK[%3 ---VKJU*\:
MU>ZTJE._J=4V/D _\Y?J\)D&?*9!/-. MQN_L,;1?)H!GV9P,*+Q:0:7MNF_
M<*)PHFQ!E$LH"MHIMWBYN?EFY@C-.G*$O+ZCF1@Z3,Y.E>K(V7$,-1-#A\FA
MJ7(].31>(E3Q1/7_W]ZW,"=N+>O^%95SZM3DE  ]$9K)<15C>V8\<6QOXV0G
M]]:M70(MC!(A$3T\X_SZV[TD'C9@D!&@1^^J[,$@A-9:W?WUNP?//.;O$-=_
M7&RYP@?=6]_Q'\]QW^\MGXB^G_W[N?8 4 M.KI_\ /[TA$$<!,P;/ DX=SUT
MDYB69?\9AQ$/ Y%66@2ME N7%8'E]!3/TD.\QS-,?KCKV??S$^W.#A1PY69X
M;WV_]0/^010%3C_FX:)[/PED9D<;S(XW1+U= *@A$CUFAX'BDJ@*"I$N:NU=
MRJ"(1(M)HIGZ%1271+634U,2-64YL;^L"GLY5*%;I 4@,M>Q^H[K1$^+^@\U
M2CR\$K0=UYZS(?RRG9;1W+KPP'MF4)U7TVK+S90R)Z66+"6Z^C2XH02P.#38
M/CG5Q;:\"T80#9:C?#"C%K,[+:X@-^/D5%UAUE6@26/1M9)?O8#!8_S#;&'D
MN_C\PH/E>*E/D3HU%MXW@X[[[J/EN,AD8&+T@+EZ;! '3N2P%:RYDO\Z.%#R
M^/8 $==!.P[D1U)9U0L3;%!1TG:>3D9T5TRAMJN2L7<*!+$+"JZZDX);+"=(
MH;6,YQ4^U.*@J'R[K3*R@F7?SHHX^<?41%6AXG&BX$/%D7*E8 5=ZJIHJ/GU
M<B0*KBL%;ZL[Y4K!*D_D,DU17C& I30TO$&5FA:OPMK8>I*OUE6T):NW9+EE
MQF(_!&J:\;QIAO*\N+P433-Z@Q&S8Y=AJXRT[\!'R[6\ >N-&(O6-<O0M"S-
M,I35S3)4:I9!S3+R:I:14JW R99:8V1::AE;8W2:[8Z6M36&(3?;VNJ/WM#P
M(>.=7FGX8&3LLG&8AS*5TG>A, ]8*VR6LPE%-TR6[P_7])]8L3MT]-4O_J4N
M%'ETH2!.*?.AO]P9ZAWPQDTI=>^ [1;<#4.VQQ*MLF[6CL+D&)MU0.?XFW>K
MU/'P[5:=E(!$@L49JQ#EN278M1TX:_^;54G.*NKT\2VYS I'@N7!6O$%^SMV
M'BV7BHVS;F.VZ*7Z>LHAGDG7L_&?B_F!=*,S*PB>8%]^L]PX^TA?3<>Y69(H
MKTABI8S""E"5=A2J:I^<&HHJFBNJ>4L] ZDL OPV8!,+K,1TB&'(A;F?-$!Y
MID%1X>31!'IZ1NFP,6!"GM*;6(RIFIN=\7 TAV:*DKQS@C@5H161IC:(\[W0
M5 >$>4<7-6/G@7;%*C,KL@"_]R/+S4-6YZ0FE6:V]!$$^8[LQ3M2FJ*LYS4O
MLA SS8GN]B[L=Z,[7<)F";IDBEINME^QYH^76X6_\N&[0N0+8=P/'=NQ H>1
MNGX\*7_M1RP$C8J?RQT;,#"6^RXFCE_[WN"M3"BG$Z=%I4T:>R7):H,0WP]9
M*;PH095$, 8+0E8U<Z%?>H\LJ;3%W,UO(]]UGP3_F\?LW04ZN3[S$.CS$PHO
MO>YPZ+B.!;S86S@=T+#\ 7\7./2K[WC1;W!Y'+#L#9_UI$ZH(XLJN=JK26\;
M)/V!Z4U#S4*1#%'5E^O2R E_ .I)&H[#MC?(YUX0F;_@#MU%O<(^@[(F&BOJ
M[DEGKP 5;9#D.5%1&[LWB&J;W.H'=JL7V)U>>=;:RI>>G9>,DU--U(VVJ'6D
M?3LSRZ9WUY?8MG*@9R>V#A);1VZ+JKG<MJ1HQ%:II.#56?97:5]P)TUT"4=6
MP+ G)PM"+(F5C0\\B3%Z.F8*[,(1O^SK<>Q).UD>K09:PC3)W)W3U=LRS7,N
M2RC,]VMFR'<'@R!F*[/I)M83NNO)IC^BRIB<S@((O#DD;@*P*YHHKVAN279]
M!2AIDSZ8&R6U,;G"-$2E0^&W(X7?;-:/F.VQ,)\D"HJ!Y"&K>93[-L',E;PU
M=+XSN_$/"_R5;"5C=18H],J'@H0TB'P.*: WDL\VHEG!B1F*:,IYV>X%L=#+
M(II[(S^(&A$+Q@+*:-*<CRB-O8=[.(=S.(8WLY-Z<FH .\F[CR0@G;F(-+11
M).= 0]K)J:Z!MKQB%'JIM>4BB^'G%28+KJY"QL7J$*W8)*US,$OY@$2YTQ85
M?>^1BRI%RNI ?IL$?0[DU^;D)QDK9^@6D/QJIIDG"6LN('JBGN\*"J1AY9:S
MML!].Z0<M0U0M#HBK+T@>A91TL'SUG*BI Z(<D,6VU6K+RFR?$Y4=E+5C\]H
MVZOJV3G+Y(G[FD8Z.M'=VW7TS'1G\'IPQ3!%R=A["F6!E//B"_PCI+-M/X:L
MGGRX0?[W(G_P5WIB%_RDLK.C?'*JBJJJB IV#\]%Q2H$#!#Y[1T&\B _C)**
MNFJ(JK*S%G((\JNC^K^/9.=\M;35<PQQEVK-O]N;#UW/SH.;U;V5Q^1PPN4Q
M.HB<=[1*<B)G;6\%.$<B9QJL.:7/K0=KSD?JE'JP)G9>_N3ZWWJ1%3%L#K%N
MNJ:A9YFNJ:Z>KJG1=,W#/'\=IFO.2)9/I.0S Y"2:<YFIJ769LZFWFE*<M;1
ME;6=LUG(AS)5&OZ9882;K&^S]N(-+/R#6>FDSPN0]?::$: TTG"[JMH23.^C
MX9_[W#25-BW[IBDD7FIVZ#6;F$J;DM.F5"KRLWK!W+8>HFTM# -_+/@3%E@1
M/+R /L_'XG0H*=1>EG#*[#%'-M-V%61V:+F+"*Y9)+A^2!4#F7;M7;:(F_0R
MXA;" N#5TG0!%EUZ W_,KN!$LL?9L$.IIHE&9[FV]\=#YW<3">5+0O)A2,@X
M.>UT9-&0EELE$PF5G(24PY!0AT].D%2QLZ(^_.!$5"ES8TV_._O/.)U4@+V3
M @8'/W!<)G@IMN.[^)J/!X\Q%NAXQ35*Z/MU;=OX=^P$G#@;D\ ?8"NP@(7,
M"@;)='N;/3+7GR"AD[:ZO_2P)64U08?^@\?>3\_HTKM-3N@N/:"N9Y_/CR=+
MDS##S*U)&.D=1:2G)<UU5WK:0@GI8'643I735:6I)55VOS*JDU\CPV*IM:71
M#<8^/,L_L[2\=7H![$48)346L\J+HQ96E(\1<W9M)2RY<'PWP]7\F*9@>@_3
M_//LB>8=Y>344$5%V<7_19U&"TEGF_Q?!Z4S]>14UT7%U(C.JD9GFYQD!Z4S
M[>34;(N:M#P1\N!T5C-GQ*]>P. I_F&V\.[!<KSP1^Y)8SSEG$:\'TNY6.#!
M^0E]AO-!5_6EMSB<-3NWZ2>G'5W4C.5>=Q3Z*!HA[4%YR)^@VB>G"I;DZS2?
MI))DM96ND#]9&: 5J(HHK1!4Y(PX )$D?3>=B(U#$>-JY%\X>##B68O$FVDD
MLSL+9"Z5Z6;GLL[)J2J+[=UE-QEZA=0MMTVHV2.)F4!BAB:J*QJXD1^AY.2U
M;;+-_LC+E$Y.=70?F 5PA]:@^]_9R/(>$@?!0FX-GUG,PQ0[CR?=1BNG[V?_
M?LW4U]N 32QGY7C4Z7B1A&I)KSV@7KL&'BZ] 9B/(3MGR;\8U.;'=\Z&# [+
MODA.L>O9'$G>."/=E+&;K*3OW+J2M)$B4MNVNNZAJ V[54JB+N_<C)[(K8CD
MMJWN>RAR4T].VV)[=W=9L73ALN@;-(Z]6)K&)AY,6&TPX!VVTNFMP('+T[:S
M,Z(&C*@8HBKEU:.8 B+%\GJ\7='8(]7A%#U-$N6=TL*(X(HHW-;D 1^%S-HG
MIQU#%SLKR*S\83E%;QH%US.NMZEP*T"3]>6.+B5DT_T5P*/C^S;P'QV;V1^?
M?@TQD7^%?SP[?QH( ZJH&3EDTVUWE"4P16M,DQDJZO=&DQT^8;7=$=O*+@7W
M1)65H<H,1?I[HTH3FT HHJSM4K^_=YJL5$AQNT9BCO?(PEQJ]HL:BRO[]^L6
M2XR#P<A"IYX_%,*1'T3)*.J$4'E+"HHB'LVW!_8M/X)[/ZV)[>$)W<,!7<[/
M)T,=+ BIW.I@*7)32/5C3;'^#A2U6>$P))FW##)R4#>(GHI%3QL<='NB)P7-
M*JU3 'JJ6:R/=UQ@=JJNAG P@A\(<'9QX$1/.2L)Y"//14E(C^P3G%C/PF%7
MW4?+<=$Q_LD/\)T>&^#Q@:UQSOJ9\U -247IOLK!03&_"I#7)HUA[^2E83&^
M0KU^JDI@FU2(O1.8GF@3AB@51H;5U,V "L2^N@/65J//KR1_KLU/#RR_'ER&
MU";?0\DH*Q_?0QZDM8V8-]:V#"0O1,DIZ[5V@0>@K,[)J5$0RJJ9/V+N1:*^
M/<?OV[/6ZW>)<V'@H)YWQL"\O.'0<1TKRA[%-B3SY%23VF);V:5+&YF$A22P
MK&&*?1"8+&&:A"JJ.Z7N$($5DL"RQBWV0F \+-8&U<$LPCB6FOD<TBX_*S)N
MR+UP?-7ADQ\L.O[X85U.S^KMN6^&C*6IAB@K!=#5B;2.4@2]=Q)33T[E3D=L
MZSL7BA"A%9'0MDWAW3NA:2>GABE*TK(!5/["YS(6).6F3.2DQ=<XS7['@J1<
MV%,_.054$F4YA[K4XY=^$$T>N2 I%YIL8Q#$% UMN4*?:+*&-+EC.5(N-&GP
M(KE.6U3;.;1F+U!!4I%'C6Y7D#2<#KDHRA#1S:=[K/&>E7BR#21N.^'$M9Z0
M0=GZ!ZG6536+J+[(\)YG<[L^W)2BJL7(XYY64;PIX5'NG)QV9%64]**D.Q(E
M'2UE>S=*,D].=<T0.]IRSPVBI I04I;<[)TH29%.3A6S#69 4612S<*A=VR2
MN*M?%'&]'?9K&TW(-R(Z.YCP9K@CC\DX,$ 5.V8.O6@H)E4L*MJ ^3E2D8*2
M&K3'(DRM)"HZ:%I4CE2$1:.@.6KM B1BU-K$]R><+MAW%@R<:?MF-IZX_A-C
MZ:CUR;0^:^):'OD "N$#N S#V/(&##D1SBC\U;,QK6  W.D\8L]3_O9'.#7[
MS!]C:VX^SO@63C"$R]P8-[(7^8._;C@%9'?<*]K)J::+:F'F%!(Q'LN-4 !B
MU/G,=D,F3T0EB3&#)Z( Q-@&R=@6S?9RAYKR.S/*E)DU2>/50O]I92R3VD47
M4,M9DVOP:7I^.^0:* :8'6U-U-6\AL4</PF&R'&_>LX^R9$/(99$7=]9:R%R
MK HY;M!T]DF.YLFIJ8MM,Z\Q@07*Q5JM2!59B;D8#MF AV/@&.$#]-$,^ Q:
M(; B)B2O=QA13]F3A\HR3X[R9GB1'N =G-^-AVR,_UW\'3N/P(M>A!TIHL 9
M1&"9P =@JCQ_8^'*S,RM2F"3B.J*HJ0"I5@2Z19#Y]D[P;[>"TJ5<^L%121;
M%9+=H!<=FV25\I!L#;U!=CHA#LOTT#,D)OXA-C]LD0>^@ADM\ LH\:4 VM-.
M/'P+*_'MY4&!J9MW45HD$B2[8J6"$:]HHB8OFTV4$%%R&MVV9J_H-*IAC94D
M&V)'(2JM')5N6\57="KEG9A-0Q$[19"E-? QG6VO"HE"GSTXGH<!-'\H/#$K
MH$R@_5D[VNO6SH%]1^V34P-4'%TK2G8^45NNU*87BMIX0;BA*91:5E5Z:Q>*
MWC **QJR+LJ=G5LI%2MAIQBZQ_I> UOK'@S>W$7KR#<JG6S;>Q4.UO;COLN$
MZ6ZM==K5P4.K%HJK>7]H2935G9/P<C_\$MC,1.FET<XU*3?MG"B=*+W EH$F
MYV@9%(+6N9[7BG":&?QK.X^G?%EX"HX7\[STT^E"K^,Q'/C@]">X;+JL]&0U
M#,%-_-#!+[P/F&MAJON';XX=C:;'OO"M=+'2_"M6']851^N_LK D3*1G0=[$
M*TN;J%?!9^(J>GK"R78M_/\HF#[.Q'I@C7[ K+\:UA">]KWE?K.>0MSRA46-
M':^QN(,O%Y\L\?2G?H!'M?RK+TYJ2J>Z:3:TY]LWMH('^+$YE>U]^Y:4;KY]
MUWZTD/7.%['\E$CJ*$M2XFZ@Y?!>[DSEFN/90 'O&_C.L:B@.5W#X7_]Q;9(
M31VWH3<8,3L&L7$IC*Q0Z#/FS:L/)G& )2F1$/E"-&)@WO"A KR2%LV:._AB
M*,A*0]+>63]R"TC'UX,?^:?L(783 NLU?A?>X1TPU4"1/O O\M?RAQ]%X=O(
M&8RF=T=1#@>%O6G3T@?+%1PO$;EX,WC,]'GFGT\%@CA-+\2 ^?+'4R,M=I,%
M^!,6\)ORORQA8@782F+@C^%XGO"7X&W\I1#00[!Q7 *_!3S,_.T)#S"$_,UD
M)59L.]P&A!NCV+6B9XL)(W@CV<21]<BFF\Y"%% VW /^3+9[9DUZ+(*G"5GR
MV,_NNS@]"%,M&;RGZ/A4@[0MQK/+%^XT7UYJIN++L1]&\,OX7?>)[X3+DL='
M7..6;+/\C*@4CA'O1YLI?X%#&9*J+<0AQC5FI&@-!J J\%;.$SCQ 9($? =.
M6_!C/FLJ2G[F=;)L"I^ EH'[@6]82B1.N.GQ1.$C<SXSCXG"560WGS'\;<)8
M9PEC33F?)QX9'\+%D=N\(37\\VWDNT" _C</?@]Y;FS]Z2?3NOE;S\@>B[V!
M9E'C@3W!NKF$K$&@P!?&+!KYG, 7]@=^!O\*;"RY$[XYT4CH]LX$55$K0-YJ
MX<C[##1)B_<:7Q#D7)+ZD0?@+M@@7UP_C$'H"1Y>@J?O\"AMTJ5\I?R<,<**
MX_RUV6L*G[O=VP4I.R=A('!_[$3( L A\&O^MV>TPR&J*0!;AFSU4Z8P*0S2
MI87Q!&0E/M<+MDWT6N33!+:>HPZ^<S8%',\6.</&@Y&(G\!O+ZPV'/FQ:\-*
MX)867S.LY\_82PPBOFB\&S[I#",W,WOYR5TK'+EW^=&> XR.^RQ(+#Q5%@5%
M4C1^L,)SB0@D"G0(QSH&2D)2&5@3!^D( !BH=-K@ZK^R&<'&ZT8PG^AP-ON!
M[&:M<G)JB*J^W I%X-P]E;]SZ9[J1PXJ*A/&-1L@4Z#GB07&*>_K$<'1<-K%
M?_W'E!L7;I&H6YPSES<QA!U!'N?:'A<A#[$5@ J+6A'>:-HM#&4/W(FO&"5&
MRHA^'TS%.6^F@";T@+?^88&+W_H\[G]9)6[PZ]AZ;,;4#Z[?YYR&92\/S@ V
M!4GR ;4JU[7 /K?F?-L=/X!XNO0&3>':%ZPQPM2B>HCH]N !5=J).$EVCL/R
M;(5K]\3S!9^/C8+3A=WC9,51D'FH(HB"ZP,!\[YISS8@F-\;;P*[YJ+@>9J*
MP71\1!1FEC++SH)Z.P?T]<X!?%[D.&=@:GU;D77%4F1-TA1+ECNL(W<ZLJ5;
M,M/_(QO D#FX%)0D-3JK5V&MVP#!XSF6',F+< G$F,ABN<UUW.E?$FJBDOGA
M9Z$7C^%1GS9AXMJ5/</$(T+B-7(KZ"/. 'UTZS'^Q9G7A-W:>;";TMXKNTTO
MA54.&K!SB*WOPX0\UV_<<+@_38>?GXUF%I?9[[FRC%?!XU@K'Y=]'SE])_IP
M] <41@$J13]L/E4#3'%D&43Q,]2G +Q^:EF;)-ZJ4_KP7%CP-1R>!U:+PHOD
M9!+Y=PG[]'T;,X#KMC]QM_]<#O P U=I)B%[/WWQ8=J0WO'XK_,OO=@1)/L7
M(0:^/\G'<XYH2@E7I(DEZ2^G'S?AH];R^T934=65GTA->>7[Z^ZD-I6.GL^=
MU&9'6_V5K+>2Y:;<6?U1YEMUFJJFY7*K3F[K,YNZT7[U3IM2C9[%QY1-$;!E
MQCQ,[+.S5<Y1RJU@&C2W22/:<NF;!G-4<0?/63@('-X?*\>=+,46?')<9K<2
MB?\I#CPG'#&;:_-?6,#0"JW;CH"Y[0<3U!:8G>Q+_RGY]XX-84_ MI_MC^,E
MGZ"3(MW#F?W@IQZ>:3"M;OL(E(4^JW/8Q[HMO7=Q)B!CM3BAW+&'9D(*US$Z
M_I[MQG: A6I6ICU9E1\+-SF\;24ED0=Y>Q)X?:W;P5..^S7S<1S0KI**;E>]
M_H"I736*HDGXOM7Z]NU;$YZS^> _MKK!8.0\LK#%[ <K:-E69+7DMBZK4J<%
MSYN^5%1\^([>LA0)7K>E#KIDOQO1R!HS^!G;\IJC")B[QQZ!^=%1RM_F#ES,
MT.(>QU_8&)[-L^,Q?[^+A^LFD<MN&/H#)_&TIHY9X%('O;)>Q(,M@S@(DFBW
MXPF,EP"N,/B*2<RK!>+QV+_3^)D+PG=3?0ODP5(!9(77WV[)>@LIN49K!EYN
MJ$9[P:FV!=J5!M"TK0"M-,O9WVH(/0^)GI)F:&T3-$U9DF43T%-1#%51_F'?
M&]I_Y 0RSQGWS0O=AX#Q*)R0Q.<^L7X06T%JZN@8E9;;V&H8L=,:^VE&41I!
M3,+5Z;W@6_RJD>_"(F:ASB[/\(6C7[CLC@T8&-JKG*>;*6\#7)9(.BXAHK8=
M(I9HB4I+EEM(0]5:UDZX]G8"+AA>*(075< + (RV#G@!+SJRUK+D=J,CFYW_
MR.R[9J=XP4TKCA/7?NK&D#'+9 E'Q!1(NI/ <=,+Y01&Q&4<632WSIS(Z5O>
M7Z)PW>PV"4H(2EYHVP0EU862;8QB@I+R0(G::;=E#B6RK!DIEA@)EERQ"#AP
M&3*2FI.OL?NTA!LL^L;2RI<Y9'"(>(X:-4<!66K\ZR4,&!6#@4Y+E@@&*@H#
M&L% A6# D%19[[0!!HQ&IR,;"0J8"0I@B!SE_4LT(&&_@[ W*R;L]538&]5:
M5M7#(ED<0U7!KH64G^%KG@KAW6+EXK-<6[#9LUGM6^[=GBZK#KUFL3[W0:^D
MG1PA/J9+DBFK"H^/M55=3N)C:II2,L':1M!"L#C9&<*)18QW<;@)X'B1G9-!
MK#7707H-^:4*HE9,!9&5EHDJB%ZM9:FJVE D0]/-BNH@>S,E*36#H&?WU(RV
M86!BHZ)*JF(^2\V8VKP\+?$.'RA<YRN]]A\7F@B@IW1CG(U_,"^;]X.05_[S
M]S"3O>: 5H,XFBRW9(,\J-6T0BDGHQI D7A0@4E5N:UHK6BL2*JA*+JM_(=]
MEZ7&JK0,@6=D; 4?T^XS0M)W1GH>8EMH.<3_OIQ"!8'#<W"0I>JA@])2,$M=
MJM:R"!PHRZ(RX+!8'M7NM-(ER9+:L*9XX/D*".Q5(*%L#1*_6$^"RO%!?3,^
MO-H;Z/7&075"EN58'D!+U3QI>DO;MOZI1*NJ>BPOB]^38B-%@I;T>30=KIIU
MMO"'B#)I#=#LW>7RUUG_W1X;Q($382O=Y%.&/55O%]I_PQ7\'K(RO<W"=Z8S
M-(7N@+>IE$U5>Y,940)1\/OQ0[<;Y,ZT\9+G YFLO6NUKEJY)8I<9%F\9KK8
M8FM04;AR!MBN.$F,\L=C%O"^FC,U+JPD(*')38A44D3:*9=04PU>G60TY+9I
M*)A,*$O3^B0>C1=Z<7\.:4OV#&:6"TE)JS&+D4SMFC/F/KQLYWMU=3:S<>;(
M2$ZPRCO!C%:;L@[+!PS*#S\0--0(&I*7LHD/;YAS/YC\>IW1UQCDO*QQ(# W
M%*6NZ_(NS@#C+&T3-YU:L09(1-Z3G05CQ\-4LK2<=;E=$=A+;AS"JE_H=XM=
MX9>+;>.'.(R$9(H BJU:(]1*9UK5(*K3ZB!$F=5:5>4A:F\1F.-DI64"7$+2
M@B.IP@E&D>9(:C9"-*PF,7S?6K2T;OD[@$Y+6'0SB'S,+$C!R%RRM%;DH\TG
MG!!T+5M752OJ4BG#H+(9!I1^5FD\ /DT!X2U*6B;(&*6?=8FB,@'(F2),*($
MJR*,H"RT*F*$;&@MC,;(C2#U8TT3T:8E+:EW:T4JVB:PZ+%)E*"%HLV2E0DN
M*%PS7Z/94K1ZH46+C\PZ/<[,ODW#'FGL73$D_Y''WM%L.)H-1[/A"C'9C&;#
MT6PXF@U'L^$*MH\T&RZ'V7"5<P]1#] JN8=XD:+:GH<0-&VQ2E&-_%5A!'4;
MS]!7R\-1-8(JS8H4R2^T4QA!:VH5<PTI+<6@HL.200!2(N5)$:@5%M0XP3R+
MB\N))XNGZ": MB%E=VV:5+8\Y!>@)A"JK0AW5"W>0<'QZEH_V6I8""J*#A6(
M%;)JMBR,C@^=((QFUD_D<\Q(QR'@1POQ<;!_-A5]X(0U04F,'R4?_"#XJ$OE
MB+)CIF;15D7HP5.K"#TJA1Y++;YD7*GOS?*K4F.CQ]_,!!_32<^"TG[A/B,$
M(02A1E[5\ZE1)Z\:(LBRJTII].&W090_Q*GM\1EP &0\8U3#MS<?E%(Q#*B]
M#ZJ,'<0N_HZ=*.'D&YSWP#NY,B],5,1;T.DJVS2LC0T-%>T#86"-,' ^Z<LP
M)2F9]"4GXU9D:3IO!0!.%FXF,Q80<;B*M=";99A.*O63:ZQ9@[UD9@I_TIIC
MWM(<L I:/;($M$63P$HH^XWLLK_PRVK*>UX4(=41K#4-'U['P6"2HK4E':'G
M.[ZV'L;?>85E@EGW(R>PDV _[<GB+)R7[=1PS%6:2)A"/'X,5BH(86RRAH!?
M<^RN0X5HNZ6CM;IC5EG15D4Q+YXQ04!84:%O+@2^],8DC*UO5F"G]E>:-I':
M9I]=OV^YPBT+$!XLD.^IU/_5 XG6Q>_-0V!\D//%>.+Z3PQV@S\W=VDFL$I
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M;1R7CBW#TGLL/M#T]XY/Z%GX@3JQ4B=6ZL1*G5BI$RMU8N7,3IU8J1/KGK:
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M75>8^-\ BN"#,.Z'D1/%LR%L 5MZ:^$;D2]@#!-OY,=)),Q'UQYO4X:^0C_
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M1K9+:_1<J085!4UH#$F,J<A03SLFNB2&M$CWB'S!D%. ]L_TQU70&(6HR^9
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M])8'*=-SS&NFQTT0CF(08 6)C$Q5"YP3<,+I8E!9.-4^];<>3)]"N,9,:".
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M9G9^JQDTLO.W]?:-%S"X55P357*A/:Q"LA0+UFK)'(3EA>?,6K_>]@"4MC[
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MKK4*7(KU!8)LI,G"J.85ZX_A:="U?OUG_SR=S&:#HH((T3C("@NHPFMK"ND
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M9SA]^WL:G>?: W8V0_I_O34X*-9J5U_"SC$B**T"."P!F,O,6X%>N=9W>W:
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M46]#!!WH,I3:+ZG.B;.!C$<?7;':6M_ZTNH6.$^-(+MH8:0=1%Y <YAC5L9
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M!1F/W%D<("UL7&KT-T(&9T8?L0_ B(N$QAL(UQ,_DDK%U4X8*D90PN=:8%2
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MZI*!?25R::.K@Z)HH9@,*,XC!"X+9#*^'7F!2:?2EQD;GO.$6;&OU#<P8N>
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M<$(GZK-\2O)=+,^]K'4FZ 58'H)%IVFMME:32IG ,6%!"H;1"'*99/,JLSX
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M(A+'93'9-.]6=M^[ _31?X_N 'U$?>CN %MN@5Y?'>^D:2L,K/;=<Y;6D[(
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M]>^,JW#%N'J#R]M^MD>T?=]'[A^';[KH1A'ZK5;N-T(:[J5DG(-AEL@C,X=
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M_0"2;9W.N)_$GS&M2:MGTR696:0<718@HF<UX6K 9V.!JVSI@/)>WPZ)]0+
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M%0O%JFXI_ <6>'%*W5.&K0NVUC1]F.7S^G@QG%U'6PF:UD9(7)(W:0LQ[-&
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M9">C<,)Y-7JP[XF\O&V%(\/+@^\,1BF)=A]F^3RMF?WEO\^GJQ]#U4+O7&C
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M[Q#Q\K;K?G(>)@LKN)5H"H>@F %%'A1XX3-H$YBPTLB8=CUB/=XL;".AW\W
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M9HX9QH^4:KP<%/?1>^O7.MN71A?$7W,MWL\7G\^_?3O[<2FO;3J'/$GE=?+
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M7FDCD,,GX?;ASD9&[T/:'L7N]6KE^D?=@/LMG%4)?W/^U[!8?)_.?OUG.+O
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MJ&A(#(#5R>"9()WU;3X84%J(@ASLWW\[T%3PG>% XNJ)9&\JZOCTFFC-U7E
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MH$8FT05NKTPT3YB:>S;RR-JU65MZS5\@_?'F!\)G2'\66[H*22N,B\Y]VVX
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MS#PZ(*<M@K6ML_D$]^U.2]_)8<-=@\S3+\R]%7S>=N0533H$K56W0&QD*7*
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MFQI>T^N,:VMFSTX_,W D)"73/Z)!E87/ 2P\J(K[8LQH\JA(_'+WV%5F6/E
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M*DXSW9[0]9V3><_O%3;$>V.,#OL,N\P_#9&97@NF*US</!/IBA\])DZ!86-
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M7Z.L5C?N;6+A(ECX"-/'R&K*7.M'H9:8[63R/Q,VD$QO>QN5J[U^6#MW" H
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M"]*VYIL>_C_\>^;_/'9GQ:(.(<<12Y=#KT4*_SN7_->!$0[\#U!+ P04
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M\#Z7!?B#[G_W1@RAO5AMO-)$'8Z).^]9S_V-UWTS@=>T79O'KEK % &($0
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MJ\@]Y0Y#9R#\Z*(G 13"POBL7EURH0LE&^/CO:,U20=-JCVE'G\>,1WH$]\
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M52@J#460<I__@ 217$:?@&74@  -:)BG3CJ-P?&6:7NJL#CX+GW72,DL@GX
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M_R3^*VNB%+AF)C5F3F]NOK*,=(V8=KZ><?_MT>1J_KL DZ8!XAD]@S "*V@
M%\R3!@@=JUF:MR7(9O@(?RZ__U=732?A_NGX12-);9(R=0XC2 -N#DZ/V.$Q
M\;="76&Q.?QN<_UAQY+C\)=,;QOGJOGQGULRU,*+5O).DY)PN]TT@!/!A><M
M682*WDPH\<F1\D^_/WQN^4&BAGA3U0+3Y@5 %O'G!H4]Z,V6A/?N09[.48*O
M-3:,+%Z';F_Y';Y\9N.)7#I=U9_OK8V0(PN'+$K0@(>MFC]AO%<*+@XA]$I+
M?A.QE9D>UEG-Z*@J%J# =+?7/IT+(P1;J,$<"ANX;HF*-X0,D6$E_B<$\SI:
M=M9;LBO?93P__>4;3$<L#8GJ@.&=(2D%PN/","$?20D"Z]OZK?)KU9D]"[R\
M0F,/[=,N^M?N:I,%X$1'_$1[0'2K".':M%4S59=@\.!NR5R9OL)(.W=_JV+$
M9'+/"RVKMJ@EV8*V2+F-,R1MT)OX&'0J!WU=1I1>C14,P]=3[")H0.25\,H]
M.\5[#?+!VO+8N#/B7]F<UHM)ER/DB UXQ#XZ+L]=SZE2(:\@YFX_,<DTH/%;
M(*&.=T(B\ SG&>99Q5]0XI]::"0Y@)*+\;%2[\X;?XZ=!TV/UWRH&BL:V1&5
MS;E4H#84'2?%>]S<]?7"D?TDXA2E7@,RN=71>"OK1@I.16C-\/)(Z(/'?S79
MBRT]P9\K4BH"U'KO):O:0$I>H_OZ4>")Y0U7',\!^&$?#+M&4QI;=Q/U.%]$
MB'W!J$KP!)>.?3V[[&7N;5VG$53E(%DPWXKREFRB':-O4M2-A1\IJ?I0Y^H\
M[>I^QN:ZM4K@K-CKO3K^*9O><!8;]AE!I^7ZC3&ZS;&#Q209LE=2IR[J 4+[
M;42(S0@.,Q* SEP<" S.+,Y./_DC0RS:<$VN/*H%7XH3BN].BT.*$'(>.ZV[
M;.:SDF^6%ZI\-NJ&-&9>)+TIXJU()$^#>_3?-20LQ]"MU,\:*]>)X8B(A)MK
M6D;QCR_:_/I<[6'8%:8G"[!F3^FB>$(Q]?5D0>->Z'M8]P"D?5\D7A]6/C,'
M(GD<?9^=\>8]'IGT\,E%V6C6+D[3X#OZ7]E_L@KMN1+LJ5R:[T[FELR0U?!6
M.6]>=Y>Z?O/5?54EN'%#J/.O<@U;8[&R==-OK9X-7T:BC;C#4-=1H%*RASQ!
MMM&Z)PIJ@1_(:I>M7&L4#]E3;52$Y<HJ#7_XQC:FT+O4UB,FQ?R;F$C.^/.D
MC/4UX<'T[ Q9$\^6Q1ZWD/\IE=3UT:"KFC?P<V7_D2[KW7#8Q,@J9%*,RBG*
MOA$0]A;T['+11,<C DI=*;6>51DIY3NM"^^&XH]EI+\_\++.^ #$I@CJ;>NA
M0KJ$'"T0HV09BF"2PM;NA.F5)707Y+^<Z>.W[+]?4K<IM6XDF(,0YPZT *B1
M*RC\1>OI>-PUD<:):"3/C<;"^%MP=2NOHE7=Q-Y[GRPT@M\NIT=P!JJ/:##M
M8TV0=Y&]4+S#%4(G3NL9?A>G$N>GKX)3-AEHR2EY]5&J-F^Y!L+]Q.?Q0G1X
MG2O7O;Q=V R)^)+N[JX5QN1I)Y%/OUQI[-[9;.'-Q-^\;ZWL&1F98,F37'K[
MLNW$X>/1AH]?8!3?H19J=!\4<BRF@T?[[<'",)2&ZHUQ9/ EUQD%Z53O8T^^
MW[X>5&6.Y3@6,?OQ3\G9_7&$417!JQEV",&%7?FM*I^Z$7JX0CE VB/YT_$\
MDZNZ&](AR=>\I9AW]A._X+<>:FP)@ZCS$QI)K[=JGIT;5^RW?-WZ_6O?O:'>
M*CO(HHL&TYXVX1>5\QXA"8O>T,1A@!7A.5$_B.7$A7QFMY5M_3F;0(PZAY%R
MS(30_D?X(&0CD@;(C1&XJ#WC-&"H#/X5FM+L^9*LCT?6XU+N+J^[G$SS5J;\
MZ!GNED[A^L!YVC,ZD%T6+\_LGTA^/@%;*"\\;*@8\6G+#)3 9TK8C6L&9WR;
M=+]9OR$9>/Q:?>BE>!FI+:"PV=<5:TT6^M7=*@$FB,12#1 &]?AF:[7NH#NE
M+N[.WVZTQT,TWZUOKA5<&'[)G?XN0@KJA?Q& \019B1=ZL ^#4A%*.2H^3IJ
M"V?\U?A 64GOVC.96Z^]Y.)TEIJKJ1QE)(^(->+[K^0[X8L^H8]+ADXJX6JI
MG^HBSC@[VLW4ZWEOGM0-+YO'.SQ9;*3$-SMIJ"E5?@Q_U6@AQN9H'\['PC?*
MY\%.]_2G:4"&$VZ>@ES![)_$1<.L?Z)%*.]@-ZUYJ!\+N>:[&W>:&Y^-=>$&
MK8;]OG,<^]%N-Q-^Z+84IZ4A+YN.;#3*X#<&5)#;,":H<<WZML'8:F:M.^M4
MGKQZ_S5,PL2S[8=LWFF'D#Y]5AW1E3R $O@"8P#S3 ,5*D$L0>P"&$D0Z=0J
M$"$(OUB:Z[<;N9;N,A RS1YWON9\H)'>C')LVT!DX0:%9.=+ ]Y;MP^(=5/%
MAT-GK^[O>L1;1&B>D<NI:FGI*HGKL6\Z);^6+& $/6\+SQZ'X5TDSEH_(/0A
M^+S>D*T;,7F':]9@IY64-[(/]:IG?M[64]>9?!GX(+/9_WLKE :T^QI*70+?
MST$?&K+B?^\??F1VNY';2;@^'6WJ)6!UM$KB=OJ''C7U=*9]BHEW1'C7D? D
M!.R5;Y[):/CTA1)?H1\EH_!@GVM&/Q<GW[ 3T /PZ30J%T?0 D;RIJ0@:(S=
M4/2PTKU=6P@?1WPL:LBV<'*->!&J5)0JJQ*WS)7,S[0;OJ%.$'$ S?#LO07J
M7\=G=Z($SN41Q_R_-IN:B/O;G)$A"&T[D04BB3_!-)(3XB_"]83%2QHZ[WZW
MG BXK.N>WT&]\L1^25GFVN6"L5_S*;"%5P7*8 S>&B?2.9B,9+?FNIE' ^*7
MT\Q&:TB*23X_'KU6R#165[]",B^/-O\4'<Z&:J?'].\U"&-ZLH.$44Z< R@)
M+UH-*!\P"\_WM=>3[GABGVD;&\H3NBFO6UR=O4Y-3[5]_I1Y;H&_^XD87P6O
M8&9_]NRVWP19\!>QXJN&&$ID#48/5'#VSZ\7;?([79X*IXF>_I;+<]JVX113
M@N((<SF ;'1:EHM#+11!!?292<%6>#BN^0B+AWC61;^3\[95-9%W@D[Q>)[V
ME#DYP7/H2JI^YV!_XKXV49E2BSA-NAIA9MOX?F2^<TYN:$KDXI!7[A>^LLWM
M'XE692UBOKS1;UCX/N6 KE2N*_@A#?C#0@A2VMGT2J[C^_SSC7FPW-V<3;2
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MJ\/Z.%88MVMPC+U' ,[,!*UABT>D_I [AQNW3HK BAH^3)*#3TQ_A,=)OPX
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M"\]!Y::H&N"+IGN?$(/7VTPJ9JN3[]A8TON>=WPLQ\?4_^5DU$>QL&J:.8A
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MA!R#7L%?[A:&OUPN8E\/7O1M;+K567'__04)^ETCSD'Y8,?!S].,+^%=9X\
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M+@Y:'Z K'K&>0M5@?"R!#>^?:HR;'A7MU=%"ZB5C#^$R3N@0=5JWC=0<F\S
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M@4 U!\L55=0N9(=BGSL8'6Y%OIWD[_XU/Q9=^>--#JK/IA?^,*2OUZ ^Y;:
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M6Z0=:[\4/#^L(7-T:X"L8 2= NZC.3.;\3Q,_AEI_AI0N^!G>?UGF;Y5/A8
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M<U%-?S3ZGFB]6(# _V#OO:.:BKI]T8V@=) N18+2>U% I4141$3$AB@MTIN
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MXFH_+<_(#*(K8VT[9N\,;7SR""K2^=*68"K*H:&1R2*1$&;QY2-W!.4I/2K
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M9ANC'5?\H#]+#B*;X3%>%58Q>Q#'3=(?(JUV:[4S+TA[3918U#9;*;0V/'<
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M&J\O 2;!OM:.)9<^/DL]=NWT\:D(A5A)8_Z,"=)ZTU3(Q3^+$!V$)2$^Y@#
MID.K8AN0@D3^5&\/_@O)R;V,(BN"&NK'V-\U-]\9K%.CPSBUY@ZH)0K[ <6[
M#7L-*5=M)>;97%8>C<SOS%X1[+H8%(@559LO<V+#[G)Q(NU1S=:-LJY9/ >
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M/;5@3XPP$Q H]33]LM*I')3IR"L%WK?=7'93T12?E?KUS>:;:OLS0!_0%-5
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MP&%YK<ZJ(KT?1E'LGH=X414ILL$V, LO7*3D\,4KVI;/9]RW&3N>>U;!M3D
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M2(K?$!G(:9FK(,6K60>?U5E?O_WAR-H4M@! #-/.TU\82M%X>[_5D+IC_ J
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M+<.6^95D\E[T0L8J9(52OZJ^(58Y%)>WJMO/7A^&T)?:0E<S0'W**E_CPY@
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MZ6I+YEL)SO1JY8,HB$"Z%83&\L'4J-K(/N18 JSX>8S>'B*CZ+4VN/K]H+M
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M A.HWX]TTY7SAX5W2AW8>7@.DV8W[/8UAFX"P->S67^]KK_K$(@ #ML8R5T
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MW!8J>>Y66^6&M0G R>1+Z,64QQ/$[E+X'%&1L66"I-A:EER9TR1PI7N<G'X
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MZ7Z)![0#K?3>5ER'1X(NF;$I2NGG>/18_>%QX[%0"Q, H82LMX1<3J=8UFI
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MO!J?]LA$$N+>W- \=RA^LB87@38C!>D.73K9#PYQ7SKMHI?2K[X2#"Z!\T)
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MFJM5&=;_NIWGPI\QF%FHGA[:*[NSJ*C#*2>'6'5^J?NE?(K0?<=;3P   "N
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MQF/.P8:KR.7T(4,$[70=(@:%K0AN0N#GU_+>G/@V]-& >UJN]_LDZ]Y>ZVH
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MCIN+ L$J333X?1V^)X<?&EY0YPS@5^L559X6'_>_C * O%!_K#;C8+O!;<>
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MF/P0Y 6Q$":J@XG3<ZW^D8UC>Q8>N*>*_SZ(/+CZ*WI*>&/RW.=8HQ-B:Q\
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M4,,BXQV/+K=H.3>B*-W5V#BR1RK.NY0:6/I@CONZ_E.%L<0\EZMOC(M.%0@
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M3(MI9%XAC/MG7 >A%7^YP#[YMEIGNZQ[^Y([G<QG!\#>7&4.*:0?;$V)HZ3
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M8L)ZC[^?AJ@YV\J:]>]R1:'X;RJLY=49'YY]4BA8V;98Z]EH)%T/ !-,B6[
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MFT3CF*"H VY.]J\A&J]IMJ!-EFXFPDDR(MX/HA?K\<\+KQ4RO+PV*IMB+I#
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M<O4QB\!O;;1\"K!UZ.6-^@!.\CD%PBEB#4D?]B,>>PPX;;5J^J?'H+9J/K!
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ME47(5)2/FX3WVYYRQ5B2-ZP3P:"("-50Q1<'N-[#643YV%Y>,:X=W_/A<Y7
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MRK4"C\L_4S&6$A5Z54[Q@1KNW@A,-F?5%207)1_E2OL95*5_9*D<V=[?RZL
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MZ+Q8JMP!YY(Q'1[+&3&19@LBS"FW78560 <:747J7SC4;ITT' JU@PW#@<>
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M(>A'?\?OA&ZUW_F41+B''"-L<KUPRMF/'R:,OY_!/W/MILV*%9NFI5S&N1B
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M/LAS#*A'4Z<LQB'_$D$$"#8[V>=9F=RD.4U&FK:,\";^PB9&0G#%(,P%:F<
M#\F0]LZJ A<<FKP=!TC2FST?Z[:%EV[C(:^(_N;4!1SU8^&AG=ZLV]-O.W7N
MT\WT;D.GO;+JD:T>1*E\,@+8>0PX.DF"S>4;)XWA#JA_ =F/ 5/RL\< '5E
MP.1F!<D:WB%"5AIILCK)["%?0L^H5CK#[:DC)/ZT!D&'7>5#$T>*N=)B\,9*
MW'E$!7"3QG$XDA919]=I+Y#FB]LO4-X5R"9.T\"G9?;W;\5@4M,' F7#GBG?
M&@<ARD:2,SS"X!MNM&_I;Q5+4YEIPE,"@@52XKAH,R1OS/2'PHM+ZT83KZ8F
MX2R6J!6X]G4,9>+SY8Q@C^='Y>/) L/I22V4"/$0!L3"IB5("+18B>!L$25^
MW=7!681[:%R0S?B0.\Y'>?%BV=,3FK:S['S.>]<-L!07>CX$I+V^#)FM(QP
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M)B;:P>^"O?8=0*!$8>NM6X=G)JEL*<\FN]PU..9T'-^1IIKTD9<5VJ;<-(=
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M?N0KN2RGW\9Q/53'3"ZG^E(:V;BJL5M0U2/H#!>'4LJD(^^\W$&Q+++,*@^
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MLN^#*M\B5]1W%L"5X(TI9AH0HQA33U5*,XZ177:CMSQJ20RT0FFS8RKH]X.
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M%UU@?6V&L:LO1 OR5K:$<WR?WCO"*U5Q,_#NC>)?%@@L8A@L:@PF02A&]H)
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M-G?52)#..9G/@,5!'["A?>1=2<3[#S1S#)6]4:B.S6G4W7S@6;G_'Q&J##4
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MH'X92"]>IE>O$X.1.Z87]X(QF]2->+?LVDUL)3@*Z;X5BY<[QH2.958=#"$
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M)-MM$<G(BOGG"]4SYXH;;B\F"W206)($A"8%'[)NXRB:P&_2+B4(B$$2\=*
M)%1ZMMNO<D5+-;H@JZ#J]WTS2QI(>$<"ZKT#QB$IDX +U1%VLHU793YA(K+)
M[=[39//RGB$_'_AIF'0.S[<GXJQ9(@L29]OI+YO/PNPI$ !'E!$B;D6Y22KG
MHZ<FMKTE8?4I-HT1.)YA88\NVSQV"0F.K/O-S?1B+.$#DK6)8U[M!J"7 S/H
MEE7/GH</8@#?SH0:\>-QR9^KSQJ9<5T^J_+YF$PA[6@>4327B)ZJ=B8Q<H..
M_P "G).EY.4'4WS5;8[%!W/R].^##E4TKRU5 "K(3DTQN#>@&K1@+P(S:C?E
MC;LRZFJBS<_K5?% 9JS)^Y-GX'/I.O??PM*H>D3MC@8(/DMU0K2!F9#.)\XI
MN/_N8 ZL;D!3>:+#\(EJNL<3Q7?\@CE*KSG9W.<C+R-UFD\A6^49^C3#YQ5P
M5>5WY$-M0LWZ(RI4C5^L[[LDK"4H5@%7$5-H85-3QO=]4&UZ]#PR.EL_SBS%
MT1=ZH3;3Y2MCL+[J.7PTXOKWZ>&/E]3S4*\3WU;4P(\S_2H5T/@$\YC;@HP8
MV^2NN5[+3-"7TFTP5R&K/XEB21_Z?#Y\Z I'*].Q!VG"B@L&ZU\6'CZ5$X=X
MSRF09M_WU(T9&Q!-MH*\<^8[-#6W% (EVH2J*UT7UNP!]:!V'#A:CMU4%NXT
M]&T6-WE9(_NG:?)M5TNER/.,GJ=7P&NU< ZJ-?SR%WHUUCOD.H2$BO33V(3;
M!/BX??2ZR#K35Z44P9,)F\-IOXB0=H_HI=<#[Z@FR+9[5$D(_%AJ\O:V)M?Y
M B=;FD:0[Z'G_(-0PQ/3H:9Z@ K5'NF.;%6@.;Z8@(W3C-@G7MWSG4P):?^$
MJ]H'-8C\2-H'.=OG5@S:"S &&]/"J9J %9&6[3D9B!=P_44]LG?(2E+<V7\L
MVZ@3O-,;LI98#;RL\$+R[:"CR%\^HHI7QQO?=U9>DW9VZC:^J+6I<E:V*#N5
M:D0U0_25%#(#YFE4^V29&-6M#2&'&6LKZA5+(SB[5*$<^WOV02^'.%XSIO&U
M'#1E".D2.LJQ<G8O X.R2$U8<=A[5_9D(N'/[XTQ>^K..I)DC7^%)%6 'S@A
M!6;:EU9=3V/3K]]O_RGZ"_Y6F'I/UGP?Y.)#'K08IUTGO^B>Q[?%/3<=X2TO
MTVM.X  K36RWE9IF#ML3??Y>)&F^4C>5@ZF9D9K3,G5G1=MX#:?\4;-,,K2,
MYSK!2D(S.+?V0:H\)'OZJQU[NF)CQ0@24)T(I>D$4!7@%\GJ<S(_'I"E]2EJ
MHI\I6E(U$(Q3N>C]+RW3UH0_2HX_K6A">,8U"0*:RKF*_FL5""D'DZ[P<^)A
M.(H!4%"P,K[MPHS@'AK$=H'C[^YFG,6! HWN^YU@)1P,>&G?!W$#OZ\#-<W'
M27-)Q..U4;:G>>^TJ>6*_OPR6_W].L;(\<S:RQ5(R0M\.Y(3EFGS^<<.BOMA
M8_F[PB(G(Z,-4XG<NBNY9@D2UF;"+"W2/([$*)J0)@5+LE\O)-K+\$N7Y\J^
M)W([V2NOMN$'595X-;_UO7[<YM8S.+M;@4$2/D P;C0U0&S>!PFJ'97<ZG!1
MA]SR_I[M=&ME2U+K34"2#N=-1RI6QUV@ ;1WGL'U@#S88M@=!YZWARN3/*,T
MFMN?5JX9=B7DX?)W#>Y]KGML[/6%:Q*/24.F?WB/]T.VGMD'W;^%]>"/6NY
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MKLJO7"\4-(T4'([/067%XWQQ\8'$4--NX"7S$D[1WU8T\ZU">'4KHA#R7X;
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M*MUR5<_*<KT8^NDV:0NWPFSCH.LEZ>_.Y9VL(_;4G[VW!AG>01P,SWN,7$0
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MNY=VIUS1UR=,-X;.F70(DK%IL=C?&L;M//P6>M2VXS? =N4H#L WVT#V;?1
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M@%^K2RS5BA/J%.NYFW"I?TU7Y=WRA'[6XTS[1Q@OR<*2JJ!) 94/AI=RFPT
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MU'35BWIU#&^CRB&(G7]I574,L\[Y"29K^J6+GG=G"J.D3_9)5DDWD#I:C1^
M]4I0 %5\%X[;P?[!G4<32C!;P4XG#D%?'F$.07G,J$FD*L5UIBP2RSI(@\QP
M:U%E6G.<ZR?L@K;Z%F*>%\!SK5TO!+K\D*I;=H*1X&11B@P0Y+*DE$B=$>@:
MVB4? >^NH(.24/A7WJ=OQP66\AG[;[+$M(,Y?U,FR1=(1N'O6_!BF84$SP13
MVYL/NM3&*CKR5]K '3@Q(+Z]/@15"T?C'D*2[+&U<PJAEW;T;E]+O_%\AV*8
M=DGYC4#\VK,(&]XOVHM_)"1L-M]CBIH+ELFCUN5_K6L&%%6,TY[FA0D\V$(P
MEB"@;? Q<0*X'<U[UQ,K2_$JZBO^I6.BUY[4TQ.>W?<[4&BK0S1NOIPI/=U
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M=F.EYQ#$KQ/.\/K''\P4?+(RD.@B,B=2]CZ 4SS4LN-/]X9@755=TKL<418
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M<#IR5?,%Q-!NM"R];SG'^*\E<F3AY:HF0::D1-11"ZCW>BK(J],7$4P-DOX
M8S[@(J7 BI&V?G3]3;)IH%Z[&,6CET="\^8?[;]H>I>S0Y!.X$G5[NSR["YF
MH8/%&"M1O$;L3<K@L(+AU1]F;J\.K=V)=>;L+5ZB=VL9:P5"SP1!O.U+1<C)
M%!'?-$SW)I%*MEB!OKOU0W SA0JMK^96TPI%67!C></+L4'3(I,B(*9G79)1
M)TOW=&<!47P[AB,9G7W6-V[G&-1A7I!!L/![U1!A0JJULNNKI^/2F]T)>!ZD
MD?"I;CO"2FVHF1,0-\?;1;@*C-P>PJ9O[?AB'+B%K3Y?#3$:/+<+#D)6V[6A
MIJTM1_>0("<?E3Q*IK/,EG6V4=:LE&W(*:8HFN4X.E! (/M/TFT@A9I^FR\U
MX&5CO/H@+/;>M6SS5KU5/@)1N=^N;WYE4'\#+_N&;+4X!MD9*@(6,QOUXX6<
MD#73=/D^KHUIS=AC4-Q!#DN%?:DL ";>(RF0<RMG,@;"*5>J)GA&K]173N)F
M9[9$3N%ZV%M$+O!R*:/3OQ$U$:.H\U3LHJI^LK1;[)ZG7:1_LK3[MD9U^EK>
MCO"C&'JKYDJ:C<?0 ?\#+!9GT(X\NP>.F Z/?BT GF@\!FU^0?3*SL@RR37*
M.=?,-(+PWV=;9.]EW;&%\U,Q80R<$9C#;!@QV2.NI+8_;43*#$\\J0S0\E@.
M8N5OOK7\@6ZN+A[$ SIZ$27Y&QD-PSTL#4*=(6EY?G2DR%&&QUULKC^=^I-:
M;N7'I'QU6&*GG38!ZJUU^H($[5J4))HE!HR#0FC:T4[/</X_-KKF-49EQH<G
M=% C6T)//"#C*E_.//T@$:?8*YYT?<"-"$&,S\OCNC>Q&*-(2.5XHA_:M&JB
MN=.%T5Z)HT1Z7OFVC:960JBDGA+8R!%$%(JB6C-%H)6H> P:7/B"1"=M'X-B
M)RQP!91S_#CM)6@'LW@KXB)>=.4@0D$GT<5E9;CD&?0*;\^4CV;NBHY:UBB-
M-2&5W-#,B_B!D!PFJ2_I*?2Z[?/*UK2]:I!_KX:ZGIPT+'/^ 3[^+F&!QO='
M.T8IN%$5TW_EA:6LU8A+E<&=6LWRLW:1MH9H-EH7]\3D 7]2Y/^H7!*(DR5'
M"Q^#[A:45JJ!B2](8N3WU#D$AYA:*>$E:L9EU"Y^ZN5(MJ:=G>/J?RL<(,0D
MM-_J4=?:Y:X)?O[0B@;'25@';A)UG?IS $C'*H6-.>SV<)6J3U66+2CU.CU7
M0E!>Q"T]O@2Z #+H$K0?Q0-!?UR@1= !84N:$XU/O)C]IW[ZJ""BG0_<7%L\
MRN5BHUIPCZO1_L&/*:Q4]*5'.46RF2C>,U3J+/ZTP2E5-C.],=YOMZKZRB3A
MM_K4DL-?^H),@_0CHP]A2B1J-T)>P]F 13RC/L[HM9JN'Q(C_:B?*-U8;]EQ
ME?)4]L;*W*D8$5<_]3)-L-[#IP<=L@+V"XRDB\6^%1U*+ Z?[ G]/GYJ[O(Q
MB:7&[%KB?^C\XEL@,S<68=CK)>O^D""%ADSC8]#]:DZ?ZP,% ZX<<JTT9^Z
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M*=K$[FT\<7$1C!N?9F?@NY9S^PX?Z*LRR/]<^G^X7VEVLQ)B+IL>:9?-"V8
MECHX_5VKI7,;=BZ/N(K#I'<KMVX+ T;<I1Z#"GU&%^W-7<L*>FR_CU+_HR;Q
M;:']\H-U/;68$&5Y&L0_? P_,$U/J 8<B-?Z/W;BZ9_4#F>;FZ7W:%DK_,*S
M:A[NC&*[WV7Z_V[(?H.Z"(?@DUM4=&,:I;U$MX*_=@V;/]5GO/WKZV:X1,NU
MPY3ZN%&:L8=W/"#L%"E?"W1\T#Z$"^A[;"FL.=+VON2<?(S9NZM"GT)^_NP
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M</:ZB#GBC4MA[Y7J9$^_4O5:FNB_!!^TQ,%B@G3'CT&XQ]N1\\( C"BZ[B/
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M.<<7ADYF:P8)@&JV$[=O8 IK6P.?B82G\';M5CO^MNPN(DI Y)X/]Y_UGFV
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MPG]<9^%P6;8TA:9 B-9<+_;$CP(Q"^!X!S%%]\E)\TOHP$#X=I5_#9 V\N0
MA,CQ1AOY8H85IOV7[D.J&%R;+6#WU-GZ<3E2,$?(N8;XN'N%8M%OX^,.0,?O
MS85JF?^?'I?\9Z.IA%SQCW)NSZ%R;N4!Z--5R^+)?ZTM!U$9KB%<!M4S&E!
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M8/IXNL#EM5"8@W#S"_N0!'T!W/NLXMNG)N-[)$WJ[_6FK.5,;AZ "*RD7!.
MG:C?">7>NNN5,R)WAVA;Z2G(JW:<)7!#7%]WT-$'^@KZK^5M._/T$YZY4!BD
M/#I6]Y7AQ6H1W['A+L4[ACXG\2'I&HE??H5"%)LY$?+_M A6!Q9+?@3$=HYT
M<[Z!>HSYQM;A8"'JJD_T.;_6/3*SBL*%%IX]G9+=B*K6WU!EP+@I_B:MI2V.
M@+4ER]%/]93+D\_KP,;U%75=RY8/4NF6)Z8<I\X;G'%QG<,N1",OC!"VZ')
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MNFU)K:=\S1(A< ?\/"#-1$F?H*/A1M_18]XNV,\]LD=<;@9(ZR)\GX0AWJO
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MN2;)M#FRL!-!DZ?'N#B$'U[3K75_85A4^A[:=B2W,MDQ_D=%?>&W[.#'KSW
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M&XG0X!>PHX)Y"8/A&23!HX)YQX*U<JBOM33@B:2WU#3?$F&@7%W@3VK!=$&
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M/0LC43D/7$9M*1,9MUZNA"!/K=5GA!4Y:CU)?LF7DR]SATE:MMWT=?? \ZI
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ME8DYC05N?II#;Z=U?";9/.+U(]+OOF4V,V'!LEQG9=@?XSV0)]+U,81L3KE
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M<-?&^QT[:B[%@XRB?='(K"$X7MH(E5F#S^C(DKCS0[@?B*>^26N?>:VN[[#
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MXB73C=&=J;/G:!8G%B!DH4HZL'5,?G<O' 9@<-D6.CGD(*1F INK6;WGF?Q
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MJU5E+A!];SW.<'59X,J.$VA(.F>384TR[$+Q>-VL?"6D5!TP]7GCUC>?)\#
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M""0BNZ&W84%U1((VU?HNU2+Y1X0CTYTF]C3N#Y9X0&O/I@;5%4CA9:3W-72
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MBD.> 0(VR4A;:DT;-Q(R_FT$Z4%B,QD)='^JTHR\8U(1%R$D0HAV?)KV@>7
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M3M&*,7YOD_U=WL_)*IXIPV\/.K:LH50P_[:KKZK5;*.\3B-\"4>]EK1MC@N
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M[]*)^99U]A$0"PXC_D1[1E\X/\-9-K3KVK=/9HBH6!I[^S?:*:4*M3^(FIO
MG>9LXW1C!=F9"#[(4Q8D3T[>$)9U_[[V9KITJJ3@'1#G8J(O_=RQIQ&X[YP$
M=JR2^8 #OILZ(H45B>*(VS#,<"3YT.IQ]DOZ<L6C2=&D]1Z?T2GF;-!=_SEX
M&:81SK@##Z_E:\90" Q+6%GV-!>HP+;3X7H_OJ3<?81TH;2_KE[>2S9TEUP
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M-#T.";WE78$AS/_/-Q[_DW9I_])?^D^@33]Z&_LQ L*\X;GBY:KU#($2=M!
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M!BG 6Q&O55@\NB*_66N8T^IK&$J6-S!Y)/X]MLOBV/CWAF//]WGN<8^/;&]
M>B 'X53;!/>657@PG/B^XYW'6*M*[))+*Z5Q2MQ/#C)6N/A=:&W?&?/@]$8T
M0\6]'3*2<Q$NZ8U%1>DX64:V3"C3KJ98^@?+?4YNL4R[?(;??>2SOA$0=I]F
MP1'R)#EI6E*P4 ;OY<%78H6H8B>-%_!E_N=GOQO%F*W-P?49J1RAP[3!&ZD<
MY1'4TXH]X43[N=YO+?[]G=J\@R7R?%CD( -$H.U/&(I$!P\EVKEY].X W6;#
MC,A.>P=?+G!GS[GG1ED3V-=4]&(?-;VQ]/UOJ(CAX=RRQX:_=4)1.N0\U\-?
M. <?PR3]<,2/J(J&F6ZU]@&Z@S]:\51?UW(Q0VZMW?X3%X"<8>>C?N>AIGFM
MN,"4%WNUM%?]8</,MV\3/[%ZCT15?=O/$_W[?]7^@XQ1.<@^W-H5V$IX+HB&
MNE#JFM]($"?6G7-1!\<Y@R',_[,SJY# O, %>LYS@6\[T[G UWY4<P_.D[!U
M&+UITLL%-F5QJ(*WD$8H(T2/8L %S+6YP"%9.!=0O/0?Q>&\?PP#4*3?A(IE
MMD0WZZTGBI5@P3*2HV>!;NHU%W@AHL4%DC]M;,7^%?"O@'\%_$\2<#.<D4NS
M:N$"LH9!A8S.-GLTO3M&5TN-$H1SCX5H=\8<L$E1OKKG[,][.2<ZIE+A)O^E
MI/\O/[Q_!?PKX/^% O+X< %B(;IB3%L1U^+ZY9IA^\$G>9%^Q:/W4(I.UY]P
M@1U(]CN=1R[>==V[O&/SE;76'K^KZ8*D]*!]^3%C=9]N^+WUT-R?."G%[/GV
M[L5JMFGQE1;X3A8OF?^\_48X2Z^HY9Z@E[YY0Q.M+\IL'J4/L+H8_F"K]?V*
MR0=HR\U6#M'=$_74Z873MG/"^&H4 0_W8H%Y:T0X8C=C0[<H+6J249$02(RT
MEFX1HJOEN?1(E![].M%3)SN+54+ACZ#<T=$]YVSQ"22'P<L[9I\M9??G?XE>
MBEI-Q$+8;\&^)2)AU+W2LIAF:V>M:%G7FS5]*N85_2YP\QWU-27:/S\IA(L
MR*X>^%-8>3I+PHS,MY@YN9.:'_<.1X-%W<U=T:P_.7DPQ6!4^-YU&4?IZ$18
M("FUYVK6+Z8<TYC3F[V-G5<OF[V?:EQ<'1UN/I-EK%A?^CRI1L=.V89/^%C1
MDXHW%_D*>OX+K*[_I;_T;R*>;@:S/8.O&<(WCSU,.Y._*^GMW#W=UE_3^*;W
MB8T!=U2 0QVW38"4'4@IY "TLCV)"_A!8J\;2U$'T$C#HW2"B@FUZ)6&QO<W
MX8:DX$=G.V:G$RP!]HS?*1 G/B '-U![.?\?>^\9U52[[8\&01 0HO0B1 4$
MJ4I508(B[44$4>D8%!$! 9$6!1**]"8@H*!$1'KO54)O"BA50DNA2$\H<4$*
M-YZ][_C?,\8]8YPSSKA[WP_OA_DE(UDKZYES_N9O/FL^<TJCPEM/-KR@BN&^
M#I_SK$H^!&$R7DL)1VAOZQO%@U:GI]^7:>,87_>F=PK JDU#'4C.,?+)GM&8
M\0J-<SJB%%G6!9O>7T#OV\Y"40/.--#R(>@A$I Z!(73V3!6\&K\U2_YL8&!
M U6Y[_ND*D9L"X[E1SNQE40&&_2Q:FC,_?_@Y>__ER+.3KF#Z$9S'X)<M\ M
MVF<K[#6Z*GKK>KOJ3A:TU$MHWDNDUB9>=?2XK/D7ZBU"%5[=?@@2AF(SH1!W
MCX\-[E?H9P<=BW1*#ORJW9(:A4YYW&F##PES'VO'C-/8+=_2?\"JY\.A+JB(
M*Y%A6I;N3>SH .<@D43M#BQS%3SZE_XS WV60NQWMHN4,_2)^\*T4FWASO(5
M*7FUM0L5:S:BVH^JWB?D--_X*05I8#FE7"&^!AN.#&^Y1N*ELU=2+$WX9^1_
MV]BUZNT5)==A)C(6Q/J03:O,<KX&MY-2G<KGYB,1VC\0Y^&"NB3_2(^)WS<F
MW"5::M_ZRG1J6ODY7;:X_S$4?#;XBNR_NQ#U;_E;_AVR'_EGEJ >='V-HN;F
MCW'"U9 L6I"5-7YQ.$*R3F#_FX1K":?71:O7]\KSBTF6?_;(GIL*TG^(&(1@
M,_U0.+&+-Y-8AQ0W0P<6#D'39SP/#KX?300D3=?1@HQL-<82Q>=+,=74(;XJ
M:GINV&BTIZPA%[ OJTM1Z0H0H7TJ/TF+;>7H)H+)+D2#<*ZF]L)8J=:Q/CN5
M^Z:4?G_Q1>-C[=!.D83QC;%_=YC[EX12(HK*GT)^$(M?;C\'A'VVWB+!0@DN
M"T\FEQI&C;[]"@I$[^5\EW^[6,Q86FP<LB9,'O.[/>CAPAN'@Z&P)?%7CAL7
MP 73,LPC=^;0=S=+'[369F"6)+/F'CU9B-$[7O;9H9"MX#2!GPJLFLW2.R'U
M85''DS" ;E?L6=]9Q7?GCS/]#K"N>+G=6PI"7O>Y<R9#,\HQ3=KZ;)*N1&&?
M@_XUMA'4OSU8_2U_R[]<D-H'5 DR(U\.3;2WF4'F6:VA3M 'IEO=)XS@$M17
M[ >6NR?_=&XQM1"7IZ%;F)_K'X)J7%^&_S;=Q-A]S9I[PT2A_;O/R_VK!!:+
M)-HHL71GTW^TBI#X3KYP*_MU,CH3@G@BE<1^"$*['Z/*D9/1LE!L8UI?=:!@
M PN[M>_;ODT=]1M^&PUT'Z;?Z>MN^&52[WHA,=\R[<[5KBSQFE 7JX66)/TS
M?MJ+.9*4R:K)KTCB3<W\%EH$0JCO$/3"<4QB;<I7-!?RD7]/ZM_>V^=O^5O^
MU<+_WYT4Z?-_8U%@^2'HJ"HI#8U5FF+NOC(<X3MHW-G4I>''*9#]>;;?[5E(
M68X%I^2C"RP\W.#3DPO+[6@>^L1\#5]&#1+<\H(DT56>>RQC]QI^+8J:=([V
M;D=1\/+V?-Y+,[9=03W$:60'(],/#3X$?3?&1](%&#?K]SU 4?A^(4]H:5"4
M 8U;0.ZY0HT$',63'+MFF;>]OD3VBPWLGO??C(/O)["R"76# L+_5\AMB;=
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MP@=-7&)PH %^PQ9)?AR>/UPP$]5CGQ.CO""S:6@'?BY'XK6CE4!=RJ<C\<V
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M'P7>D7B0/'!+6^(N[XK "E]&V0>UJKZ.AX;FJ\I>/RU79_F8]M48<3H1<":
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M7&#(G_N8\5H]1)Y>1"1)J_RKN7P(J]8O-F@HXKQB-,(-2+CR=7PWSZ6,_10
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M]=B%9"=YP_,9=LS%KZMTW6+Z@K1H8TC9_Z!Z9*]_;8-]6JP$=4)F>KHTZ<?
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MO1EXS^(&<&?W]<[Z?QLW<^K>Z4BNIPNDT ]^VFQ$;'_\/+<8S=5W"N@\\MS
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MH+E1[P/'+TXQY("NVZ.JOEN385K64Q\^J!1Q>SP8$--*+0<-O+OWP%"_G,+
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MW$@-^)$XFFN9C(5KP6J#V//1-UUF528C'Y_D-DHMA^L\5B);X+?Z4F:G_G:
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M*<DD)A@CN<-Y@0S#F)Z'\TYR6:_>?#_]8O,#ARIWEBW7^_=#CEZ_0$OQM'J
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M5#'M0.F07XP%SMU:U++E]]R;XJXVZ\*,2/ D<GW\!;LM]5!IH7P'P^#RIX*
MC,7).C>R&KZGPB$FKI(H-&(S>C7A^/SEE^K#Q]6Y[EE=R93UM6I<NA.NG]&'
M)<$P,R.4Y*_W:1:N^)  ./&535OM).WT<O>@0*FDW';53\F.2+?"$:@#[16]
M$7V/.W]ZBF";430+/*TC0FSK$42=/V^W566FJ0X7!/BUU :"$UGS(D4^[.!'
MB!>HSJBA?1Z#(_6C-.-C^24EV3[%ZPSQ]."Z:YJQ/Q87/K)L)_48ZO'8>M 4
M\F=3*+^!3*]*(/_RI)L7GT_O)P+WN1*O25M\36R'\6&CNT'=%=WI#T+/L^P_
MI9Y!6O\=#M>A'W  .@Y$!S=/%I&62SP>!9X<_#*Y3/ANUM=\MKNBK_DX/ =*
M,OM\\A5E:'3VUF)PBADV)*%4SG&@U^XK[N-BE<8^'K\0N>_7#ITYO=@N9C,<
MZ/4&\-YF?;A>.Z)D+#.H^CVW>2G8YY/VC^1O@#%5'@ 3P,F,,_8I43D1J_-Z
MHY7NDP&]9SF&,""V[G=)GP*5F^%+]XGW#UF"4!34%/?=OPHL/:.EL<,E-.G'
M;PQ<V'RIRJ\X1LB^<RE(NY\P&E_@!U/B34P%= WV[ /M &2)]:[M6VSV6[?'
M2F&]4V:[*+&D<IKR5 M+J1?"__2E,->W@/NV>//R11'9YD&<+U?W":N@Y!E!
MRA;M."M%99*)<#$<Z\Y*Y+HFAY"1[C(!BY(CQV;#<O@[)&.D7*MX!CA!TCPK
M#T!2?E3TW]?FYQ>BT()J>BPX;,R\!!F6L%$8KW+)D7PXO.F6;"#/1V,1EMR(
MIMR>C]RN7AW%JRA19CB-I1F2]N;^=M4N')J^W9%1/.]XJT_Y.B],6M?+B>-&
M4E$DCTOB<LLY!M=)J@S-F@0E:I33;I!B8C2@_ #:MC7A5L2>><V3WJI/AD5C
M(1/\!3J^/"9C(CPKTJTW+M-+#T ([)SX53A+"*S]#%(G>5O=KQSX/.OD*%?M
MPLEEH2A]UHA:*G4-9:W>"$+V,S=5/I3\RIGO (11,3T F<MAO/^9PVW^YG 7
MQQ2ZE%+4/Y0-Q,DK$0>@^U@>^/H\-_E82HD1HE0VNV'6AF3X;O9SH>HO=GG0
MHR^(*2RN&GT4"5_$Q.4?6R$M1 5B>3N.I#U([R_R&K]=<=^=[8A"";MD$BCL
M#I5)* :T6Y@YYJ[;%",A!ZL!_>^^,;WVEWN O9OL:,?WNIHT-E^&>I3WX<5?
M0&"-#0&-]CP/\3SW?'D>:O>&8D;4 #E8)TP"T*74C^]*HCM0)[_^WAU3L_JQ
MYF!#(1]1:!3_ >K_/0P*^\/,#F8W_:;M"/:G.6\4\YK]0M<234QQL!7X&>;J
M'D4O"9(S&,U>T/VC/\/N_&T'(U'*"1@FZU?-?NN5G=-;XD_/79JYY=BR8]Y@
M7><^&\LM<3K]@38H[]M.,(TO$G\ BM=C+T8ZP/D!/SO2NI-ET8LCE7=4RK*]
M?VS.+"O\2!I\'?!YMP \QL3FX@QN3FC/,(1 27C?$8QQH&DF7(O9$!8+2._S
M.#Q/V='KO13U(O>%2K]3\V,QZB*%C;P7:R"/^@P]IF=,>/6I[NA#PEB(1W/C
MW;$O'W]8\OANA+I[+EZ\]5=FM !<X/DOA32E;0R#._< =![&6$13[\#?9_[K
M:(4"\'OLWT+=7?0_"W4E%DW[[]O^0O3;Z/XXVMD#4&,^(U=U?>W]?ZC2_=O^
M;?^KFQ*)_1]-'O(S_VSR0#1C%M9H+/_<'A3D/[='SN8OUKW]_P^JZ.#7:)\1
M+IH_>2\\@/E5J'D\H&^R.&O0:4+M'I^YC^=HVB?9"Z?!0Q77Q6 OKQ [-*JH
MXJB!?;N-#%(TF&O6Z>@-^^87"PBQ NNWA*72VR?T8D=M3J?<[3N<]*3N/YSZ
M^T_-+I4QL4[V]7L6G(H4U%0'Y@G+(OP(XHOH'W'V]RZ=G)8T.IIUM/V^HJP=
MYKHA1)G1":D*I3]'*E7"@9B;*=U07IKYZ>'R-:N:%K/WMRJNUX0/[YP[=P%4
MY6LZH+3F_7]S]^EH7!&VQC0!ZI4?3GGL$3'C&S@,ON%DJW_:_#("^591YI[M
M70$SMI=.W>"6<Y\QT5CW_#F91?D-8YPF$$R /<TI+BF:_F'AS]=<_VG<5V;'
M4?9\M+"]0-4?1[]+B6F)J.%10TA\?JUP(M03#2@*5>&3Q"T!M3 \7<8L5.YI
MWOPM OC$S>"L[<#+H/MX._;(+E[U_5?44S3V U T F#%^X',GT@5/2DQE6UH
M2"VSR2+8.]AK1G[Y"O>49XMB"P_!./\WA[/]Z0UZ2N2^OGF6<3TEDL.6Y3C$
M(<=1)=BJ-=58KJ[0Q&0I=:D4>K;JLI>!FU(#VV3?A@]5:15>#>L4T5/R"M"P
M=-]T#:OP?GHE(2']S8/P;1ECJ_?Z"1)"&IL3_Z?2@#KYXKSC2#1*)8(C+_3G
MF.J8]J+UT,:=!R#6,ODZ%!3=<1K%'[+2L5!7GU^ZSF#F]YB2#VF/H[>LQTH:
M8M6-V^=_'8$5(RC_G<T ("B#])>H"XS)?"'E%E$I;'$( F>)F?'S:+P:5DQP
MX4B[PE.;'"-W*=0?_YPV5$?1"D<>+:2=(UV+P4/!<V$9QJ,5BU6USW*[3>(%
MA/2G%V7W9',6_I/#[/\R[,=NK>A?CX0KL*YA_D.GU=^IIO^:RO[3D_+_MG_;
M_]+V'S/4^M[^?VS) M$9;_\'6AP8!7HQU O"C1I$<V^VN!$RE%>7N1TE#>:D
M HF#AVQE1UBCW)5#6,R7<! [S# 44)F*WGVR%8T]&MCL>2_#>+Q.MU'-25A)
M(L-4]%E# 7VB4/^LX:8":_?N"* <TSLB')+8@5LX# 1USO1OGV=RP-O>PE?/
MT:[)6G6#-]_N?4C PVA"&;V/H;'254 A+HEY*Y8[FC#_-[)9V5F+>E7Q=H&I
M*9L_#=KJL+@7\ ;V3K]P%,M$"WBQ<:Y++'>Y>"^.H+ QZ^G+ER;H^C)55*#L
M1F2#N_C[G7P,2A?UF<F)#D"X@NS'\HF_MT1-Y7J>'?51+<.+O[)/FKAO\_;:
ME4]#3^">VC)/6.= $&L TCNKUIW"OBJE0/I)>YP74^XH]ZWHN\M3V?MGM?4B
M='@-3T2 I1L0B^!XS@_,4*6!=K5X1/IAUYLE=J3TZ A-%E=C[/-(Z1XF_89(
MGEG?M63$.^8*A3%FQ%*(3W'0XVMBE.R27_N,F-*BEJPF]P.0PER_B&?^BKMN
M@G+7!P.C+4/(S5$X$\DW:-$$IKH7:M3ZA$G"SUITWZQ?GUF=W!,>7VOS3U.5
M^XX7'@P41Q8>?_3E]M0$N@I+Y#D U1Z VB6Y^X)MZ^O%*KLS9M>$;-T2K6 "
M%8U.W:\%IFGYBP5@G[=8'34LKLA9;^H Y,,.J.-&N(%@JU$L7DZ,?\W.XL'X
MLZ1.IZM!GP6>S9SCX;ECZK"O1>FAU^O)4"& ^X"/[:SED^[] M?B7T+5L?,W
MK5DME)]!3I^YIN62'@+"QX+V3\?3$AO^*DXSOHH5O6L[-<X >PE+<3VK2M_4
MU[+*Y+/9>564,2C"=NA*(*U\ SI=SN ZBH?/KA/%!'+NYPF1OV5^^I1_)?VZ
MLA;?$:XQQ_X.%\[;Y2"3+0(H![3?&;^3,LNZ.,7DL.X+T3KY231'O82269]X
M<<<'/'L9]4&7^--97",>XT#=.%;XBW%TAQOC3,BK[O0#4*<<J:]KS,LL^)5P
M]/;^JJM4=9^TVC6&LWXIZRH$4&@@XO]*, KWYO&.Z4'>A?A9UT^>_^.[XO-P
MEF!G9Z\9'JVX"'*=$-M_1?$!,LMH=P$PSD\<<<;!T;MI.5N0.*2IT'](]]C%
M(^XN!A6P5M0IQCRZKCZ-ZO2=ID\^G)>I^;3"*R>P)ZN\:(!QMTLK1^3\0Q=?
M$_;$<",VOG9YBCA%\ "4 07,F>R9CMTN  >^Q5XX 'DM $I%*5TC4LXA2GB[
M*!SY0XG; Q_Y;Q@Y=+5&NT^E )_ICN7((/9AA.F B$N^UA@:AX$+&TBMYR"A
MP@9@1Z_9L,$E>OK8UM5&=0^>T<I![8?Z9UEZSYY+9=GO,/9'LZ/40CP6&[HJ
M(;WS?"V('\=O)-:Z&\\H7WU7WB>]1 QT,9*:88O@I!'A@%)#7 !D5I7I\_.*
MI -0S'GL8:^V$TWC?H&>BY^>O"#>>?GULX"9$?($3DWV=P%XPEMI6XV@11.J
MZ:T.B?!JX291C>M(3=]#K48(+'I[QTO7,P32WOD:L?N--.@[5H8E43D9\V)P
M8M2[M4GAG"LA?KTY9V6G'B-OA*9^O]CGF<./NG^DW>W"K'VH;BGKVMK?X/='
MBS+/=+2G(4\H%Y/[C.O'#D!X!?*70O99ES':UBEQ3\[3-5<!^<.9X<:B/I4#
MB<=W,U$"S.MWTM,J_W4 JM?$E,&[I%=GZU^Z&N0JJ7T>?:=T/,K@K=F"3.EW
M?6-0():TAYV5<4*L$]6ZG$6H;)#S$5.FGUZJ3!5\9X3V3>SI-]E]A5=C:(+[
MXP2[Q( 13N0-TFY*M.^NHNWLG//8/715Z-"#,F5K(<^)UT>ITX=,#$6]-]&N
M<$ ANSWA !3E#";Y%KYW0&I.G6_5F>]TE+P"J;'7BXW'R :SJD>YBV-#!A;4
MOX2>1UYAWN4-FB2PM5@))QS))N3:F==-%0E'S'6E>-]GS629E_G9L.#R)11Z
M3FLLW&#S;1LOO07JXQ>[4'6M%9>K=(G$2"! P6NSU_G6= :^^(HM'^%6<)6(
M+_D9XEABI[$+VV B?VCR FN+\.)$O&ZH1JN.;D+L2=D^P?:!:PGIU[YE.IF$
MMB^'ZXO%TU+)#32AA-[':MT^05VF)+_HK18UK_>6AXN&L)[4RY0X19N'EYN#
MJT$A(OV8"; 0[>H84HV4;0=$KBCORR4GJ-971W:G5AQQ,:4.'#&H99F:6A:.
M0N.*\X5V,7/6"_BHOHC:6M(&0T&'VRL!<6;"![>3:.*>VJ8E'2F#?/H ;+0#
M-J>'_Q6GC(/4[74//S*=;%'!TR%=308Y?JI^ 3_SAW=RC,T*Q9=<M,#J30&)
M4Z\!+0;7G44P+V-&<^&8'$GK&;Z^D>P8XK,;6_"*B/5PS'JFN7-*RT=T-9%2
M /Z*28 (Z\F3H!U:>6KD^G)Z G[.-/D"QF!8H[<WK?/$#/^YUS4L[5O#CPY
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MV:4$KCN*Z\,=)E7=\HYJ2)ZX6*[G<B+(7>+$6M]KNM(:&I#5HKVLS_VK<W$
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M")8O^6^[SCP+]0H?MS@U.1V>RLY6]5E2)"7^KU[%>]183E;D 8@S*(,$NV;
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M"V*8R3B_"IJ(U%]DY0YYT16(GZ/V)$I;*D8YSV]Y)RJY?4T]HF5B!N)5(BP
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M[556VI2>H [*XI@^I;2#H.22OI11=1BC"\)(X7=#^SY)WX8H[MH,I_V ;=-
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M;@,2-Z_0@0=33G0,0\9EO(*5P9CO?Z&_OG'[PTF_'[31R(.!9(.:Y-;YL <
M.J9?5#6UH8#[#M2MF]_)S >3]R13W[?-GSRC^Y7G7%+^M3UCYN1U&5H';4"?
MLY:41@9(TMUASSW&=Q98#X#[=]2I&/&1^H<FS5R!ET$IH!K_ODIZ/78 8)<Z
MU,<Z)+5[G&UG+;+II;PZR_VA3]R=9\5>A,2E%6(-!R-DR=:T[RZ7J!7Z/"LN
M1R</ ,]6ZKGR7+$\<ZO(<=W&6R:G?'^7?7_TN>/\ISWW!UNJT8=-3BG\)L0/
MK9*J^.WQ]VH#I2LA-=%(WYI06WYTJZO:W(E+F5U=M^I_@1PCQQ;P]H-LUB1_
M_3S\O067,<K=8)GPX#>.?=],W$1;ZK)2<FW2OS&_5'QZ\O42!S!+5V7Z5G6;
M%Y+LL/"XACG%VV/O%]MJ)I1P$\I+L9Q?,F5*69Z>3[@WI%>'[C@^2K=@BO%A
M*RI33$K8MWFOEJ8>LR2S@8"U_(<6D9B<1R^,3438-/?KZ%HT2=CMVTR"< 8C
M1"EWI^Y/5&F:)>2@1N]X-T[Y$Q_;_B7'?#+ST;6A(C-/JI4TL$2["U,^ /[(
M]2X@WJ*;[7C,"-NZ:C\B7E^TE?H*%HRQ6#,["0/SQ*N>6+"(FQ,2BWBA8^QV
M6:WTI.)9EF@FQ.?#1G-Z2XT'0$-VA8!O@XJN,C1#]1W_K!KUMMV:7-_FGA1-
M_P"H@=/]S)BW(F'Z[S]?+N29W5?$T*6<G5Y/PR%F((9XF[0HY2K?3<K575\5
M1+B?G-/CIT9;QO$_5/H>_JA[VG[\D4X!2<YSW:::-HD\ZK^#$$"C9TEI)A,+
MYBVYGSF,'G4X7LMX]AG=<]&:J<].6J03V,]OP^$*UG865=$ZW6ZH>=V1MY-K
M.#?9^I4^G2338WVD4L@KBQNI\2RG$K?#*'^[8A$YV"%+\B%?\8'P27W(Q75U
M*&3KO&N0MWRY7MVH,,#U+&)*J73B-2MW5$;54QYO4A=]X<U:XM>%X5RZ$1+=
MCT:77>3CW9@F>.J[C\DUG9/?W29-FQ#*^^CO*;?;QUX?V]:!KZYSDS(/+3:]
MD&<Q(:4;_8D]];;'I^/Z'K^.V@<2_5$0DG*BMS['AQI"#JKUS:T>H>P!@9S]
M^V]K>D-6U"321UY^[ASB?&0JF468[C\<2*Q!?^RGM-'LEM04C#9MJC5:6<YT
MI'[+$[IH$@)1-Q#@;S&Y_R+6DN<"\U.P,;TL$;5!K!O^[1P5O]EK?F;P;<MX
M<2U!*8"Z+!WMSO?=,!\#&^FA*P37=#(-A6Q@HYP"X6\B4[)K79Z$(6+:%M86
M7K* B-%[(=\D"$$_FW"0MP7':<S?2/[$NZ,TWI6-G,9 DI>7X[-TQ,!9*%?0
MI9AO=1=%=@0I>&@ZS!2/N$U H,B5SY6U%B3 =O4N0@Z^]UT_#N_>.2'/,J&Q
M,%.&_8LH.Q6IL6?]9*I#,?[&G5]>M5N);3%-VB>Z"_#\)&H0SA\=3O?#Q\B%
M]IS=P;.MG]IX5*8&I)R0>6E%#8FRX)UQB=Z(" QX!@I'-6-(!E-/'S3E\S\1
M%;)*K_A2]MMSVA?%0UZRP_BE16!5!>Q_TYAK,IR2?%*<!NO';R_J+6$O!*5M
M\B8@WP"'Q\U=$I$GZ/;*1]98@';\!-&KQKY+>4.IQNSU36=.1AT C05>=]>P
M2%V:T 'PQ5QCF'PVXP!8[EK=M<!8H,C@6# 717EQ#LPZ;C"NO+T=< XYD'PV
M:*-'2']I&N/9O;!G6O;J /!0AU OZ &1!? N>_#29QCD ("TA-*R>EWH">,1
MNEZFVV$7J)'+R'T5; >"OM_/81<G(^5I_7#>>M_C0\Z&=JF<X23EN]9CUTY]
M3/1F?K?4E)WA>MRT4W#/B@S0YASA:WX=&K53;:I/L(K*4/2 2&WSM9+H:["1
M*USZKMT0J^@WQZ$ ]1?B$P])07B])HAPJV<0#\;T]C2U*+>C9U>U12.=&\Q&
M%I5+[CYQ-^D+W%T"CO,*[4-H'%9DY]6"8W!/52[0L=XS>944@ZCB-*MYW4']
MV<\I/[Z94!JD;"Q1&S\2NCA\_A(F*I,V\7\1 TGI<JFZGA@)LS[1P5RF8D-?
M)5/NDGB=7ZX'0-AE->':'VERWI8\4VDD.?B:C2]9D7*1-C5=A<W#&B,Y.LJU
MN8DGFSWJ4N)= ^ZDBO1;"YI'WH-W65*L(K!ILZ%]C;OW3=>W2VO&?4_]MCWM
M*Q!KAW"034<N!N_SX.5H'+T8<.J"L*[FHB(/T^HEY_F/ ;ZXMN;66%S",\_/
M+)F[X6'3 TB\W>9,L0M^H1='2#+]D+N*<MP6PJ^$6I[UKW'I2>)XI:9_%3JF
M7#52^^&"C#O+R&,P22&T1Y7KM]8EE1RR^IS]LJW6LH^O)]>TF;B55.QMEK5V
M +#[ J][2O#+) = S_>A/9]J(MB]'>.3<$'ELS,W3W]H:'G=+W.:J+HQ=M'A
M"> K/CT+Y@(OUBWPY&"J\^D.>9-7+L5W_5EHX++6J*EOL$*U[J>Y4NNH81FU
MO4?&3B+Z/F19V@RH'KGN0+[ML+P/27"O)4%S*Q^$E>6WF&>B[I:Q<R;9-I/!
M+\WD>2O]YDWGTJ,OL]&#Z.$5K2BH,*WO[@%04C<)(4DCNN!'%F"<D[#@<$P[
MV(IP!_V=*&W='G4_XZ1TJE2%T"+LPXWDF]^%<!<[>Q$DY7+*"U7F ^#;5_!V
M=MC* ;"8@MSRVBT@GC^<.E\9!F"1?S>8U(YR0HQV8_;F ?"!'HUI<0VQ]+PF
MF>3S'CI-]!X+KI(:<IK$3]7G-'WF$/):=SDK[1V@HZCQ9/M(YE-NV"K=(IJH
MS>\[)&>@X8M^Q9C*RMDW_CU<2L$^X;%\W76Q1]T-SJ/.7F1[,<>J?EEO@<9Q
M UG'6H#C%K,G?9F7FM*]W^(X:__;1>SCK.K,U=K:3XM95X_.]?UTO7F!S;M:
ML9/N%F\KW\-UM83&=YRD?761)H#BZE>O;5=JQ6TYC$BI9J?7]M['=%BJ:[MO
MZ:W^H!L,)&X'>9R&GE>8U%P]6S*NZ5[;.EZ2J2@Q6.MDQ*^@MAR?,H%['1T^
M/1L63Q&LP[3ILXQMJS[+/SH=7"!Z9[;?HP3JK/$C$8VV+K*6DK[G8%=H_\=&
MG_K'3P#)A\8>\T0&WH1X>E5^*O".A(WD=\DDZIO'73PC?QX "YK;%A1A,9HQ
MXEG!SH\*^.^!L+UQ&GL>=R]RG8K?5VS^JNVM];[.V)BC>=R?A:?S9\=AVQH<
M_-,D/I/6UJ!*%?&_##K\0D^Y0Q@*Z4+6^C^#F99Z$8GH R !F_OK]D3C1CXF
M&WMMTBS?0.$MA@U8PLED[N70-\L,W_<*8S%KV#M0@C:Z*_BC_<UVS6RAT5_Y
M1]0OL+2J*5F$W N?7MFE\(?3;N1@_*E/[L"7[^SL^?[SQ-@Q ALUAAZWJ+SR
M+-MY-(Z+V'43$VH4!?+$]WQ_:(6C-S'C:PSI3'.4!]O,BY8#H+-RR8(D!4:U
MB]D3TGH0(BYH5-![KVRBEB,L QCT4^'Z>?\.=4I*P!+U6EB"'8$$>X-B<D @
MN#N8#RKZZ>S$CL0)=B7#QA&_HJU?L:9K(E@;N=&42# -!6[H'5Z[2+#H(<Z?
MQ6\4!Q>OI%>EUI3UO%6<=5@,_8:107.>?7*[6)"\]"N9EZ<#O%AS '#!+KZG
M#1$CM9O'BR7E1H-UPIV<#=2$#(_TQO3\ JF[LP+;TLD>=</TA:7GZTM)%'JP
MK8D&4\]<WQLGKE+;=B#HOS"#?6F+8+85M!W*7'2%L\K3=O*TH5)FG6!3"E'H
M6ARV!UC[:N):#C;ZUT( *@@QC""=5:=]%84G:_BZX12A2?:$7+J[<2N"^OUZ
MB/0X\65 .MJ&5SA4[%74A46),N05'[P3C2,'T^Z/0C8V)3:8AWWQUAAT4*K>
M7I;YTA_T,'OTZI?D2W=QP1=^G<K?9MJ!TP/;XCO'WOZ8QYL\L'/4EVTF6#"W
M]U3ZLJTO]U)=X56(LK1'XB *5NCN]WDI?)I> =X0^RQ-;8<QGS:N2UQ<>4=<
MW(:LK98=BXRUH^TA/@;SD!0]45 86^EO"+LN9_6JOL;'IM2!:_@6[P'!AOI2
M@Y*KQCVUB,LU9^>2/8+2\?T4?BVQ)/@L&;-M%_C2;\S7X7YRLF!@V3PK*&H0
MB!"FZQ$]I4JOQ,A1GSR [*O/=QQ^>^H$4\$C8^#N"\=(F=='U]<;#@"^7LVA
MB@K?.3V4<D_ZGSFZSVR,NH\S?>XSE?MA05+1IJ1 V,&K ]8'P&CV#A'Q+_5U
MFVG/\#^KZ\L+%(&@7G1J&IF%U+&%]DS=M*X?7Y=]Q88W#V3^PE-W.O@ B++[
M.4QW #0+LQX0D8M>T&]?1DS!T2:+/_K[%V9X>EQ8:SF"]4RN1IOQKM>+O8-]
MQ%B'LT*S3+?=+H.8#A6!)O$;W9\<*0O]0IP2>^-VM:FF=GSI!:M/8(#G>?5?
M&S6\;^/$%YM_FX>74X3 ]#).LV!F?KAO5_2Q6\^^2KF_C\\[8^9/KB\_0%_C
M?MYXVBGY+#"Y,9*-&@?W22KX%H0M>+[>=@LS9[QJ,BGM).%F_ORJ76-=YV9-
MMVF]D/56A;'B[N?AD_IYY&#:?!AB_0G^)\X$#XK9\57$E*4$'YVJJWSPHBC;
M="9QMH_,*6,8> \(N2_]X=8+GK=T94HX .@1@%Z&?NL"T3)E(].F?[%1^$"T
M:\@>,/FD-+U&<$>,[@.*>ZM4NNXM[76(P;\]\*<**L,-LB@[-+I7WH(M<"/7
M-+5IB=E/P477*9W4C@:>&<5ND/B.GG]_H\L9NF>8B:W/"=./#6WDA*N<G!)\
M^?%85+I EO/@T/64;J3%ZMX*:?X,28<< 4VS):44FE=^FR&AS1]LWGS#JLEY
MIO5\D>6"HG2/L0"E?"/__&60&^P&7:E>09MP<ET(82^T]MHDXCO4S7ZT>FW!
M4?N6A>\1;A;V,Z>5B%A-V;J?@-92NLLM>G"R;LF">V\*S3X_>44N9D/&BRSD
M-'NJ',^U\ H!I18A%]^Y")(0^"8(GJT+R>XSKT 03M#(J[R8^Q/U);I[M"@X
MW^#/WE<9ZOV%1N3>!#$+^G)T"8*7EMMN_=-5K!S[$58+>IE.NXD=IO7FJ5+%
M B$5E\ H)_]D2(W*\\6\]K=ZH9V-V6;T4)W^_H6)W"3$AR<8,>!/4LJAO.DM
MH"9I0?:UL$AZCNF)W#L%X0:O.8S3(_<E@)).?UT#BD$!IF#=JHH$LCW3"S,L
M^^[PV?\<9^W69')EZYR5GPGN#OQ9I.AWV@*D_E<_XD2/S,>F&+/)AC<:%6#=
M1-TWETZ8-.7L\!64TA\W.A:J8T-]#?8=/K&J+YEMKDCVE#P]7BUU4GK]VG)@
MZCE:\QV>(D'B H4O%.-/D88SMUGADA)"G*%Y-F3=XR;SC0W6A3&;2IDQM,5"
M'GI^'6U.+W,6N"+Y88_&@DWC9RAZY>!D7]?[9(S4N2%@1U;YMEO% WKI$GV1
MHOV1%$N^"FW%WG\O^IL4^9GX_=-%G]4I5XC>\!]-(OV4;5#:P$+]9ERPQ<PT
M,974NMA^QG/\H5^U9]VY_JW-\?(,G7=NN!H+.?!UJM]_]I<M( "$M_:@OJ0'
MMI->Z/X^6X)0#4YS; K=;X"?&YJ)_"*;E6URY,]3*AO:YYD#.W7, UW8Z+*+
M?(0EN<?;]/#]Q'L$4 )%L]S1I-2A7CMC*(H/5I^2K:C-O165WBJ7O@F1AW=9
M4[2K2*'$*8)M!<+!_,RK2MFL^3<RK^PW?#/0\J^LXF_H^I6++_'/=\Q.@!>K
M"K@Q>,F<(I@,7J7U/6GLY[R.LG3W<KF2[=18%D<ZG]B)+^W,/>4AY[*&+K.A
M(/^^$W\+7VQ>V-*$R1Q>1S0[ (R=IH<*\#>^^2D? /Z;\:/.?7=;31L\<M75
M;/KRH"<CV32W(7^7G@#["!J[+[ZUF\9-S81)8\T539H:IRDF M.7RDJ;'N]R
M-9TP_O/.%I^-\+$+;'(B,@5?D8?IE<8P1R1:4L7YS)CB,83RVF9IZARSZFO\
MZ?1.B9FH>^%U_/-(.^1BWL*6.Y(3OOH%=P!<_W6H\/]R5OMET,=YB98,,FK?
MX^M@BT/5O?39R41FBU^0>!#>8C5[!+E8@E9^\V+.5Z6\"BWH$G2RL46ZW-7*
M @-I%-K?0<;21/K?STLTYH:\4#USL>_$A="FW]R1AU<1S\# $3CD[&UHUMOO
M+3??O'N0HP[GJ!]88MHYLTCXS5,*1&)'_[W+.C_HRZ1#\RJ@TD,:L1MI\W=G
M;_0<#7XX%:R']D]3P6[F!._8P"K_%_-L;_^G+@<Q8/#?B7\]IA:"G"2Q_+-]
MK/VS?6C.C;!M[OP'$_@DK^ L9M@6RWOT',UO]8"X=#4C*J[U_FAU.A+G8/\Z
M.[T8?8?<: XA/2&KPF1(%N^JBS&J\2X2HYHR.ADTSB,^+P^ N:RH8,G.*)<B
M(T"P"V9$8L?CL.O4TMT4&%\1J6QK3)J+?R7;5*=?Y*)":=SEX0N[U<1$H \/
MCWFL&D\3KSWL@UN?I\=SM8ZK$1WQ3$K^'E?O[(-45H>7!8]\4@C3:^/X<JQ_
M@NPTS &_B^J0FO(P2MELD-"_6.9A%7LTX3,0H#CVNY C3#_-#4.5ZK\^KGSZ
MP_A#5S,?)Z?'[.+GI&*OVH@?Y0" Q\RE'36-$^]_UK<U)6Y,N9\;./);0L9:
MS>8/_!6)% LC 'JS@LQ!&]YOWY[. ;&WJ===G\U;(T9>]YSAC04]1=CA+5"'
MI9#6J)T)OB"^'LGM?7VV-S_34Z+>*0&HN0T(71"1RW3:MF1QMC7R\.!ZKV83
M=T4R"XO.6;N%!]E/%SBTDBPPWOY+F8,AM&&CE-F+ \9J\7+5=OD[ZX\MV0J@
M.&($R9.@(*&@*D#BOSQ=-'97B\BWX$WXU%@C[B%]Y*[=#Q<V<8[5-FU,E6(7
MFCOU>=$R<=\VW8TW>NK+V#EQR[Y+"N\6F98=Z<)D"?P8U>@.%6_O<NAX=XM)
MHA+N<ZJ>]:#<.?Z)8K4OH.!3TP70<*(,B1L38:UL8D&RPCQK2WHYC^WU8Q9?
M4G/0!JZ(B[N'(/S>/N6[+15K*7BYDZ40H59+S>G@6^Y0LQ!$4R[@YY#/K?$K
MG'_VEQNK'/T<\=.9-$3M>;T__<[JLF"#LOZTW?C&>U77U)4O*V>BH;+.GV4>
M<M1^V#@FP[=Y1_@IV%,U]@#@V)F::@,M2K"@'.L,IG[NWOB0*G+CX17W[\47
M9.W2[KJD& &P*_2"Q( 4I4!BNT9R**4H-I-2L&DBO4'4S "ECK$6G]X:F7Q9
MR^%?\B]=4XI"EVI$;BV##[M@Y-)#BS,U?VV;.\B5<+/J\7Y'E;B?A.NK2;Z[
M7,>/]Z0P2:?,?KC6A2B-((^-,-D$*ZL/.XYO*&ER7E-=\^/MUVSXZB-C7;18
MJ<A\3#^NBFXI_!6T;F0=#1&A/-??#>%Z/_;Z0U,=[YF(]&-6)(YM_W@X&XP3
MGSJX#A/$< MWCUYC'J!FN8GS:%UZDEP<5! B,WV7;B _]*6H?]".0YMZ[')I
M#?B![OW\AB?::!75ZOI/^0[N&VL]CR(&PQKH-O[',KPVK:M=N&=J7NH#R0,3
M;AZ"7O8OFC@]+N50_%J+H/!!A$N,OMR5=$-^$I&SUHY/,R=$0ZNG,?UQZY3K
M.?&6SK9ZE\X%J)AMJF_VA6[(_)IJ-T@$%+_J.I!5*"#"5(5*.98G3I]_,OCL
MR[:F)E%=5F_['15RZ+G]3)<"(R!@_B))#$_&WL\I6>Y0PONE8!6Y9:_;.SW0
M\E9WK+"QECX":U-(!;<HIM -^"R)_0"X&M]U>+B11%%$_R[D4< CUBKPH9WS
MIVNG87KX<=0EK;I[-(^&G>P\\2"#;](*G>[B)\"BVZNK8K[7AWS,!J#5Z_<-
MQ3_<C!HSDC[J8'&$[]O$MB7;LY6"#XBU Z!RP?Q)(#X/I:A1];%CV'.I[)_6
M?0=^A +&]Z-\!1_#V4GA9OBI/ZK:'):U F>-FI]R"EYF<HO*>**)- (>P?GT
M!:#:V)\YOG2;0%V")"HIEY&O:J%+:X?2/]=7XT\&!/1X?I^@ 20?#"0VC-^K
M@P=/*\!4R9;YQ'B4.;T_)W(2&&XP5C= Z'>W.,HS9?1D&A,^)<GX<=2J?7(-
MB]93'*0_YGWXLQ;_)&5="S?\='<+/,%7EK^KPF&9]XKZM>.&<48@;7!X59BS
M -, [#+):7$S<?^Z=_YY?$<Z-N_8MS;+!U.!WY5N&'.>P8=H7?C>K#E(.4]]
M%2E $9^4F: (+W)SHO:+*PSA/EY(+QOIH[;& PKYB[P\8=MH>99!V'FR)D4!
M[YG\EG _%D]&H2V>%V<XW+*M^Y"J$_M$,-OX..NC+QL\[]P<P7PT5HH^J4LS
M>5[[<%\K'MJ,3>XX:;SNKK[BVAHO@OZXS['A5<@%9X<:7L4+QS^LYSGN;=MR
M)LF]5/F]TCT^0XYL)8-WB^XUX)3 _(O47'T!R@T"5\MFDKXD*;3'\>N[FG9B
M<7F_QM<_U0IK1#K%.;9;Y)DOG$Z=.HEY+G2AV#(A48WN4)C;^K$F:TWX3.S&
M!TW_DS"]D> Y.S''?>SHU0V@DUL*\_+X[//>L"P!IE^CM&$D%X84-G\TK3.7
M&7JQQ*'@JK/^N0=;9X]<^YQ\?HFE>8DPU: O 9/%0[KU]%=072["8Q1ECV#Y
M?*A&JT>4[ N@]:7\TB)3[JI7(?-'_P00)TR" #$U/]\7*3RF>^NNF' BM^.0
M3NSSA"[W^>-]_6(YK"VY\BQ?.T1H7Y$<D<<?9#R(Y,2SQF*H5A-%R(9Z2+U"
M>G2EM$>61< QMG8P"EP'Z4:P0K^H"GE!>-KT2DBY%V6S-'UTCN&:[=(=W%T7
M/96J%_?C-)=O6[)Q$T"+_JC-9'[[01R<]?>\0G:OLS+$IL[TJ\*2$&=SX)O*
M@L+J^&X7WE'=HYA99194KDWU\[<S9\U\.$\^L^PN3>+]\X*(D@7.2<"2+1?Z
MB^A%ND4XWZ.^VJ%$"L<L\/FHO^W;1:<6B(^KO^N.[O&DA\?1Q3@=>[<X&7ML
MBH&4?*<-"\"1D0AL+3P'U2YT6R2U=$ZVW<7O7ID.ON/KLYIDQ-_, F@DQ;GJ
M^,D)%H/6R/@A4'S5HCV%O5 N)M?HU;;1.$X((?7B:O)+E/YEG50+"9\1K\+C
M9ICI;LA1BC3=Z>L*8B)4NZ?LK)__BC%KM#_A '!^C$Z]"8A4-QY>UE3"]Z\A
M\/"N2)EZ FL,?A;E:/S1\W3V@F7=>'&JU^MH3D6F%P$6OUS*Z>X213$[=$(X
M&;5^7!JK5X>\VMEK9R;>9SC<M7YT]1'?1R:]D/3<#?E"'AU2.%D'IDZZ5;ZB
MY<*'5XDO[*JX.N*29Z9QXDX/BO6B>/37-Y'6@9^Q.9A?:W_A!S J#5J(Q6%F
M+_V3DV>:?$Q5-5H%HDV>U=8DUR9G*24$KKQM/YX(_%4 H@U!.&D*/I554%3G
M);;GP1ZQOKT;Y7?%QQ(F,BH^Q@5P:DO^;!U4-:L?V6[5T[%H3!WJ'A)H:FJ*
M-2BQ>AM[V_(2  #A-G_*LT23DO#\F/[>6;+9IBA)VI!@_J/$^*3<I%)&:*KZ
M(QLSKJC\P$UGN1B*6!$,C/^1$T_1+)GY'2;[TJ-Q?.TTGR'O?979VP'J7WO(
MF4X:AUN_2O2F;[UVSXE_8^O=GUX07/B]KY<6OYTDH7BC/@YE7G-XVNP[(A/0
MDRC(=SM 0!Y@&N'X2'>."[SZ0B0=;$=&KF<R1;4$6M:MI2H@VO ZE).?+_IS
MFT1*JK8*=Q"<B^[@(+%@-DU33?!1$HL!GO9NQ7(!C59%"U[KLDFO_5+>?(1E
MOEV+OG(0+MH@G*--!"??YE $T\<3,[%>2]FW)]^O2:=B7(P\TF.B7M>VQJR<
MG$KK@4<A>3K4S-VT4RABQ= _G00?-T38#LJI5;ZP5\'TA51'1K?2K1'T']O$
M'<]4^/VT6#"_KJ%**W8XOD."(%2GH.0?\6Z9,'A>(5E>R3B C;E=)1'8XZ1Q
M1! RQA>'US(1WEJU21%VO=<[)#]$ZY_C3]N.2=M($)S62RJO>C)-X9M>%#\
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M%<Q9KYB0+&S;(5GGDY!V^Q7600;2-5<Y]?O?[ '!@,%_5Q!]$)+2;M<>3)6
M0BWP^F+!K@3CU\K5,BRE<XV\2^2>$1SXN_]U:BXB'^[/,S,(]TZ;&8?@=TJ8
M(2>6<62[JWX_-V0?FA3L>\7BM@=BT$]EJ3&16D8$'-$9;]NVRZF%<'N@$7';
M;T!YLIFO3KOH,;OJF!7D\C1FEW("07Q] ,3R$;IQG9$RK]8HVCAVMUK_^A/1
M U;6ML*ND;\?OLPKEV7'*.ZR_N/;R?P7H+"26UJ65.:\HKW+A[9'&^P*"Y]X
M+6/U-ON^VS> '7R=%D'1X=Y<'R1##64(K4[0IIZXG^YW,X_G\7V_32ZM=XKX
M)-FP?WB:_YA:X4;RQU>#8R_)3NF:87\W/6#5VJMZ//+-->*GA[R>E<>PU1U5
M"E\QT2?3;"P8F;P_5VRB4EA5\EO*IG^#A27P M'3)ED2V9I99\FVPOS.B*-0
M(>HIVQ6S_P=^H&; X!\ $PE#-RPW:DH9*1PGTJ%.NCF(Q(A.^[$1Y]HX>V/_
M NU\?VR:)D/,U*6L*"[#26<*UM=]"?VH$ @W+#!2FO2\=':MOJT9OL?M5$B>
MT?,T8@E8Z?07V2-2!['@X\OYJB/!W/R.'V)NC6D>DT2O#/U@Z==XJ/:E<^>(
M*$6/V@QV'1:@?8I4DKR(UYV>C@3(CM\='F17=Z]>S8MT2[43?RHF=F98#L#4
M-+/L6B=2T-3G!\!B)5H[>?VAK@CA[<:" 8%# >6++>\)"?VV&%%<KRZYV>-9
M\+$37**UR^?BU*M[H@1_O0B7H<557>+.:W*$;_ZIS#\Z-OU?C7O"U$KD PM.
MVA<PYP;, G%I;B5H(^;::'' &61S/P>X):DK]'?Q9&+%(MP'09+71BW,^-QL
M&;?&J@J2MJM/X=>346HUXIH3,5*"RUM;OZ0YDS]0,D<U5),+\-8(-+-#:5:#
MA/&=B#*BD?MXO9E>/P>;#F]0 ZO#K%R&_<C1M&@0.R6<KE#"U'+53<W6O=<N
M-S5!?#Y7(LW$[L3:X]A.212:G(#7Y2?V1.Y#+;I;[*)@JJ704(/:M)NC]:WV
M:VOK]T!*5E*Q-I)MQ\LS)Z8+(@?!=:'/#@"/A;B02%Y\O=BG'G1<N7J4?E&
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M? "P9AP A$2&-(8TAC2&-(8TAC2&-(8TAC2&-(8TAC2&-(8TAK3_,]*JW7K
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M"47YUA#;=DYW?><HWL^\SRPQD'A0G7"Z5QYQ>/;<UA;]:QOS9+^/]VA>TO'
M&#?!],WR^@KS5R)*V/.3COK14I_Y.!MQ@FAL"%XQWU NFW?XYU)RM["KDQ>7
M4')S<MCXHF*WGE,=KF7QM4.\8XQ:X&\6N3OL9K9* ,5W"D@="0#(DB *>HT$
M5/H8DH ARXV]O0X0V@C"@??&I2]*L7@V/D8'/;L2,/5+,C^-4O(G*OR]489@
M;Y36Y,3>2\V/*]7OY.GTOR;DVR;KX;QC"((81;+/ZGD):\WO@"#:1<7+IPM=
M$QGJ55F>LM,DP!Z$7L")+!2VSYZ#7L#4O9N'L$[&&II\B]OT^M$;G9JL0!1R
M^*(6=I:6/TBS5,R#PT%4:?N1F44 VFT.&:.N@AN:[5!GKV;]^6E/^-/KU(@Q
M@3%]6\K:,'^A9(#JC<5//NX_:>J7])0FB@1T<D]NTYZVW)^B>D$Q*& U^>+H
MI9HOZL5HE)I0^]57=6!%]XH?)("5+*PN[8\-+_DPX:\WQAP\,I8WH Z>_<ZA
M0PW[!+Z)LUFD:9MEQ9_!E U&X2V<ZQJ?WKR48)D%53S'HMG'>L_;-$+Y%"W_
M8PVVO_!E>9K7T/G#KJ=M-M)>%/=KT0#.B#/IM(/HO;=R3:W3\CK+S^4"Y2V6
M4=,7 NCXR839_T(X:;)SYA+N29#:C[9D2;$N)^V#.[NR'$=;H)LBYFS[*;3M
M)A/XV5RD'M28!%"E#^77IC:K8$[M,B2E\(061-R,7V,0O RR*_P%880ZXZ06
M$$_4Y1 =]N)5'.//5;]X"US*:8S;3Q;A]S;=ISJK <09TW\LRK>\R9*PRJ#M
M'@SO.$J/J2V1!.E6(DQ&I5S.3J%L!$(N^7T'Q'>8GX'1-^VT3(8$FC&SL=U)
M(6+;RO9)I[XY#KIF) Q-K+/K#>K(K9K($87/Q:;UK!+8CZ06$W%"/S\-NZ:W
M$55>S5Y9Y"VOO:_:H,;6Q]5+"%3\_D=LL*A?P"7.2\56J,HOO)4QE#*O!<OY
M]#8B&M<ZHK4FHWG#(F^(M1>VMQO[3J^(YL:,1#;C0&BX!6X#(Z6'#HPSY]JQ
MK1F_79",8N=*-B?/F=,Z^I0ML%J\+"&>R(1G1>\G2D77;#FZ.^U=J:U@U67O
M>TSS;?+E@Q>^B$;.A/R#BH'$B71L'#IQ<VH1=-8S6W0HP/"FP89055V*08Q(
M<#KLMXQ0DG)JXKM-3[*#> U.>7;,@M1!:S!NM($GAWEBX+ARJ?)3!KJ',:TF
MT/*I9RN..KZO3'_9RCN9Y(^8/U^+C',*:CC<1N3@+^#*/$(*/<;4:3'.YS"^
M/BZ\!;-IH2X1;AX#(7.1$!KB3_#'[71TGE;* LUC@31F9J'BS.R7 T,,:DMB
M?=P*-GT2FJE"J1+2/0Q[AYMAQ9[*%ENRZ*T:Q51OU]'Y^K>.(BMU@5V?!3_M
MUJ?L#]XG^!"*.'X@74G B]Q#CVCBN8V%)DSB5<T9B/TQ=G&6/=:D8T1?Y;U]
MZL7MQ':4:&Z+ULM_O&GZ/X>_23.+4%*3[L6SO>L/S1*>\G4CO<%.)"!>!AJ(
M8WWG>9A046;C/5RKRK.RP$_AM[UF<BMP-@:O7?&=[!F#<?EV!CU$MJ0]QB2;
M]9<]A#%S]WSP<W?D3N9BEVXFYZ:7/LH<K+.6&[/+]/VO*YQI]:76P4':R-$
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MSXNOEY9R@KX6P[!0&$L47R_Y@$-V*AX1IN^5>H5<=GG.FGR.IC=2[16%;5F
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M3-\HI!0L5RI>3J\QB7L@7FZ>U?"[7IO-XL,C:GTO+_GE3G,L1G6O=T%I(=Y
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M(;=9\%@GN+K]J.+IXHA@HE%5,FKQ6'/2T?%65CJW7=4UL%%W?1Z73@FT[M:
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MWG\W4P*SO^+L?NY%N\6U?A:'%^R4)Q%\7WA-<$JP=CF\)6H4F?\&N7_5K\E
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M7/I8@BYNB$@M1 +PL765GQU7D "_ULK@Q,O3),"-_4[(V5DK^9WKY>%J3-!
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MR0AKUU.3 T^(NT**-@.NV\\XC%;_/E3]+LW6KO:9QJ<;.HL$,KFTBD](R-I
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M)MY 9[A$13G/RCG5)ITS.,.9LQ,"=F6/4WA/<^$Q-^""37;4DM(_EA311R/
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M\G#O5[X0,54#P>RO90WYU4C&KU:?HE\R1J;X[*RP#ST93XO^^G+9V3'I6F1
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MT#(P^SZ%2%E53D?&F[E,?)EL[-=?J]RR5SA&UIXU(B3E\H.']UWI)V?$NDD
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M3'DLV(O&RUA3\\]V 9I%4CT'I 8MPXB7K,X!F^E5+E(#[)DW)F-+UZ:0>><
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MQX_%'VFT9%Q653$,2\EO55K-!Q.5I>LW&U13-1Q8*M/VI+@: Z4'%Z^ZATA
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MFIYQZ2*[FQR]&CP:M/2I-;RZ $<W:!3@Q?*S.I/A@FLO#1$=VDR4OH?,]%$
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M5C;A#-X8H"ATQ#&%135X]/+EA7UHC)9JN>;PP.(Q8' 40,N]B6:&.8&2\NM
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M%?AJ'!SCLGP. ) T?TPX\6[\3*(P06!]$T_F385HNNXV>PH!?LTN/YOY>P[
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M/P[RP--!2R7G@ ./)C2>NX[*(XGAEN ;L&ZC<\#:C ]B5\;E'% @,)V,$WU
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M$DB#["[/H@!+YUVQL'+42O8T*T9,$S>1C145-S'M8<*7)O77WJD(, N<<[K
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M:S9B*&7C60H[<H41NH%Z0T4FD@)LL('4[#$MF5QPAIG_X@:C1I#]'*Q)?7$
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M.L\7,J_R.)=8XK[=37M1N@-]1>;](7!F/W!%B4T\ _.DQF-J<@5KZ\43H%'
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M.[RL/0J.8T=]&%LJU0F#,0XNY84F^UE/9;Y]7.1UN9V/,.)[D.C<YVNN3Y5
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MT024S:63)GWY^E9\J#,>8QYV89\U^><93LUH"L"E3I) !:9LJ<"M* #=<0I
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M_K#W8@5R;CP/B8_'' V-&<N_D=$WO,^>AE9$8L/0MM ]"=BNN\TDZ4D$:.&
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M87@G(9O.PD?8QDGW*  [T8J)V$0'BT?!)BZH^@:31Y6>Z[YVL<^Z\A-">B-
M]FE)G_%2GCE9G8:\C_Y'I\S_54-^7Y[T9F(WP"?94;>QV>:)W9/F/.\M*U/A
M.Z"$9D0?R@&ZQHD^(#W^0:ZK(5=T#0*I5_C'0\#\29V,?Z%'+_M?7_XKM)3$
MEL1"K+VG2N1]&%L%+(<%YR]_MY^P[#/+XG,:'B'=/P+O+T"^9O^B;A36U>]Q
M>+3S3SE_^ZTZ5Z5(4C&P6[P]KME?PS<=KD26Q'$FHBO5\\4GKF8MY')[W+AD
M]M@HY,7[)-\-E7Y1!@B/L']&T^5Z4!74Z?J?4$X>V\)W:L@;'K\/]=/^>_3F
M'JQ0!9NSZN1_Z^/E;5>K<Z-Q0^ $("Y>?V3X$G*.?G$3<8[*Y+Z\H$4?E[D*
M'>YSJ/+7.=,TL*,)X.C@*)$ZJO_'P1+=_>N=EC><V_>%EYG.3RC.+9R]N'7*
M"GR,7G6P,&\XC;J%=8"Z;5;JR%PTZ# P9!U[:V! ^DLD_)2&6H$%9,YEI>YW
M MW-YOF)Q7-;X,OR.H(VFC/*BO>9K"RD\DU79C8<PM-/K2,[60"7DAS)38C)
MCE*UP+?DLFY^;4K!O[3;,4H"^,M_UDV>1=HD55DZ;(1[&<):@'<WM+T::D[I
M\OZWUI2?=<T3N"BW?;"?ZJW'SJ))4:'@+A3A(9)I(Y*!;$; &1)VTUT+-]7_
M90XD_.SC2U8;,4M_/94^*)T6HG8T%ENY-DG5^F([+YVMRY]J>'E%5.7S.6??
M*? PG/  \SI2D[R^K'3A"4SR#GVNZ5M[#O0#?8:QO<>M@TFEF6$ GQ/@XI&P
M=\O<4?H[^0#[.YL 6I(@)E<*/[ZF.J!;$4B9X5&1ZQ?\.]_#1A+2JSCHM_%A
MVX*<WKM(("R]+U_\=Z0"; V+#IK$3BVED2:F''JZSEST&^XZ+\<T5":(\XI,
M@Z4O*\71I<-5OA%2W@4@\0K7;WF[UE+NI$;NJ]F'$[7S!8,TU0[ >-83P+EC
M@@!5SL&5SN?S"HYM' $].P&\'>VW4-,=(Y-_[-/73@!M9/^$YAMO L+F'R9]
M7(1W@EJ?%&PA:B%OZNP47"U:?ZMN7-5HCFB;\O'U%%ZS^FK2.?]13.-,SC^K
M]D!:P@G 503R&LZVXUT/XH0_AQT]>-5;U3AGWO^QP9W-@%6RYWI,Y)KVP6@$
MW^-'C3HUOBBYIH,4*J\\W5RC#[)WZGDW[:T+*.=/2;&$S$K_,0_?O%=?1G&B
MZA Y>R&SZSV+0H0&!*VL:E&M)FKF9[(815$RZ+C8Q3+&*D2O?&8G>TDL>!FQ
M<["LQ ;+Z:=HV-4D.#?5'Q1E/W-?>79@-%*R^A0F7>4P4]/XH7X=E7H0V$%#
MJ**2'97T^<F^6& 2_7ISZ@F@SA._ WXT65G-EN3\(FUEF55+8C#;,DE6-+KK
ME U R]E&M._M5S83BX'L=[(TMOY)?'S![Z+T[*S8]G[#2.; $K8A4H0^!JJ+
MVVDA\O0&8=@#/C'U. )G'!YX-'_JN:WZSF'$2D7(RC"5H>$FV#Z]^RGXX:G!
M&#D!\.FST*=R]N*IUD]S%E,K-@_Z_;%FT-)S/KXW#'4:,YRY<2/&]W;6HU]Q
MBBGT&IGE_ M6 3?_.@ F8#C_PD_IXN'R,NKB'475L#(OYQ^OWYY])I[W/7[P
MG*CRJ7%Z%P@G6"F]UF<A^R\!6<G#G?_XXMX<QJL]WK$@Z<I[?"](-N5KD& (
MK7L:MSTF14R$BX)<4I+:E6@U:J!X<98H,>Z?EWS\OVX?"3P0I&Y4<06IVHU\
M<+6*4TX=DZC2Z(><A;LKH2=[<LZG$"WNC^MR+;-?=5)-=_?OE\A#9#3WU=X=
ME;6/6:BYZ82)FLI<.JXS46BNZ0KW(?+M):+<QV;#[*=BU=C-C GXA;Y;P-:P
MOA<TT^HX.LLS[*C! _(,8:YSPGW&EA['J^RA\'EV8/-JD6HV.U<\GXW.4'^-
MR;D4Y6]:Z^,G #>?V9*^]JNTTO:+L,0N1U$!?7;"B+9#6^] 6Q2HUI@1I\.>
M9B+6T%]'_;S^>;!ZG31"RPI$) ,)R3!DIVV2MFMRJRH%K_\KZ$H7$T<%B@E:
M4;TZ,'=PT3<O1JCW+INWX@AY!O<.$=]^U3U4@@#?^8(%Q0KOIOO5&E:X-0<.
MN-[D'!K*2MU]VBEH8OKTT;^<0Q!9)C*7OXJB3;U.#*KZ;% "F[',&E63KTCD
MBR7SN$JVJJC_6F(:&X"="T#>)>S64-QA1;837O5B/)UTSIKZ9Z2*[6BVS: V
MYH#D$#L]0M1UBY?:08A&C0Y.7FHD6>.K>[XHU&[LHCN8B!$)?N:=_?@M+O!V
M3XQ6^*O1I+.LEC\SL)_:*8E9F_D(BCY9XR8AN\N'53^N8+/Y!F93'2S@58(V
M/O,CH^-CFODK'V^+$;^0:CBIB_ S!<LY.]F?OI5CGOQ%_U/1PL(3LQ#/M/JZ
MKJL]J5GGBE+V%-EM:!D6O2V0<^K91' W&A*',(O]W7\WQ2)3*N19LDK2?D:.
MX<)^B7D1DN]/Y"]Q@6E=+X)QO_;Y1"AI 6(UONOEI4#M31E)Q5T"^[\ODCJ4
M8EE!?UV;ZSE6(K%/JD)8Z(/MTN08IKB 803_QEZYN5>YB"#ZP#-HJTM940.O
M^ZZI7_KWMU.U_ G.2)4G1IL2$3T^XIM9D2HSNX&N]7WU+/-];PJ'I;ZJ,YJU
MF!W%:\[VJ?COG2J;TSL8P46]1CX3O P2VQ@N@=AO:5B9.1]QW1=GYA+(>CO[
M\F6WT"BL_;_&@Y&TM/!GU6.$9P%P$9@Q./OE1*![JO@U5R<3<9-VEW/5&RO'
ML:Q* (Z2*]*JGW)5ZIL<DIWZQ8%UM.S3P#XO,D5W6)X 7-SHTOQO0XIMX66/
M=Z^Z2=ULRY:18B!;W ,P.L,F.T+!/4BRG!2:O\FY.3;]RM3#>=N!EJ+WAB77
M"NR#K08^1W<RB6W/T9DBA]KUB!I]O>118O/^:*OI^=^3?T7X.<4JY/"W>TT?
M7'0N+_.LF;?3&G(_ =2> %(^GQ)\C /U7@233Y24$6MYQ'=,WI\+J.F0?%<,
M;I?R=PU19]H6:&*/;'R8>?K5/)B% 0'28<&TF2\^7D=C,H=PA42-W:M/1E_L
M6_1LZ $X'VE6(I)!M<A75,Y3'CDU*_6)2NR;1'*6"+O*\6']JXAJTZ^PUOGA
M=[T6'SHN:3((BH)K3B_VK786\A@NKEN)8U.?>1S54,]J_M3!G!-=T#@'3+^\
M.U+]>;_CJ>B!'1#8SDVN[</4%$<RC@<@&\BE[CD.3=\H=RSI^_QO!G3[7N:=
M\PY^BDN:,@I*XON7@:NLTV585MHY7A)!DJ6K&[&)&';WH\4KK1-J8B9;1Q?E
M[;NOF<O$&UX:OESZ#F9U9EUBK0[NM-U4#5K*Q_!>SK*!+<79FF0FWY;];B,1
MRC[2OV4>IM&-B*8K_H(_"TN):T1;I.*8?@6*7)F,G&1]X6[K)'S\>B1\SS'X
MJ6N:O [I!OD,UN)LY"A=BB"=4E=4N+!UE!U/8(WWYDQ5Y>IO46Y1>K&41[SS
M-2<3\\!RVOW7*F@IDZUD22E^BNL'+/FY48A00^,)@,&><^?-MC255PEW0Y:M
MV(,LL0(?N"T<W F/@M=K[(R%(6%FG:$6L8$^G![9^L^W;=]U"4I$M(3_M5!S
M87*SKS#"R5WGE#J$?&?:01%O+*WCE;$8;EC7O(>P RG7]R+Q0M.;Q+F/TE%&
MSRZ^'_B<^7XU(P#_7N[+\%Y+E2GXR+I!RV)6@&XE0D1L5IQR;Y?PX@]@[5HV
M<;AWO0O#H6M 1/0)6(%([SZU)6SE!&9VIB8E3=CG77*5$E+94HZ1?!\*F9TA
MA1&/7L,]4]XN:LX$ +^1P;;"[VM0%)?6_.#<$-%4.EY*L<E0>LTRZ>D2T=&?
M@"&%T(I!+ICX?/D&,K1X0_\R@=Z\%6T]M7N9J]AC]WGJ^Z&T:_%BW\\VK^2+
MG(W%KN 5$TOEB^NNHY[:29;0_\!Y_KJK&A)H!9.'%[[^$G[TP^Q!X_L4B69J
M]47N)E%A74D"I@L,(3P4"^LZ@-D99G<K%W]1!4\NJT,3SSV+O[L#5%:8+!L-
MU=BIH-R@/B++4ZR@[9)$ZRAHJ!&R9$QL[*U"]6>NMIY1WMU%R_=F*<IB-VKS
M.0"ZMXA0$IP\MX1 GTHD['H7C<&4>"\TRD42U9RL^JJ^N6-;3K=&>>,QK].<
M?N9]T]'9W=?20W5;_H@&PSIU>*-KQUP8+.W"9>$[OKW",8\L2P?.OCI5T=-A
M=!:%\BUQ3?(" ;%LWUC[F!S\,&<Q+/8>H_N+)O7E0;V[$IZA(7&_FQ$I$$"D
M#-6$]H7.1E[DY.@-="J:<U>H=K@5YB,:=- ?-#'/:/Q>AY$]M4[=F.%JFQ)I
MD):A"')KDS:<UM4KZRXD3]X*4@=KL WSEIH\3QIBO<16D/E*4TMP_;*D9F_7
MWN=YNS45D-O>K,"R W)G'1O_%W[!79N=%%,\&N92;MM1%B#.JW@N/>(XF%$N
M.(LRNQT-$8.A^M&H9-32)^USMCT'#J:%L''5EI"UU1S&NM1Q_WFE#X]"&1GJ
MP_H3PB4IS\+=" 7D0&S$C>Y\X*]JZZ=3NJ9B/9?M!J9?Z_18-1W7Y$F9YL<!
M4NTP=0([OI7NF.\^L9%"X:J3=CVAF;'UX@4A4NG=GD=LSS^8*:LTEQY_ CPP
M96#(X[%FEIF]"P[FS=R=D'<#UG)V_S@!//T8*-LJ^W48RYK"/%C=4*_07+\U
M+^*OG9F[)Q?%ZW5.\?P%+2WT*>C9>F1K8&K;R[Q48[#?B8P]#V2E5QZR<=P\
M ;S6 ?:UQ8XMTU&<.]' *,=N<6EQ%OJ NGX G'A(4I(?QK2<PF@0ONT@&1I_
M>B1XN @QKA/X1OOW6YR#)$7@X8_?JZT)G'7=^AM)%V6\QG5DCE-CF<?X,DI&
MF1T.%8PF;(R_TB?1(W0@[1-=$F*G8^@K'A-4=OFE=8[*YQ2+-D?94XSM'%^>
M/ &\F/617(/2/-:>W <UU_0QK2"J(L2(3IW]6(%N3CZRLQBRPCV8WVVV3PCG
M\A!1QK<_0^7&]7 W=H'X8#:'CF+&MV> (PV9=UO-+BL-W=H([E?BXZ*SM=V%
M"VMRSBJTCYUZ*RYR7]K9%(EI4@7#V+]P!6H3,NAT3N^:D3L([%,3QNK*FX-;
MD9-"_2OL(3YX68H0U3@%]PC#3V>',G,T^4O\R.F95V@EFG^35_4\ ;0$O-1W
M]M-./6!XW;&-J47@H103^\=N<)YZMP DQ]Q(K6HVF/_RI9^L%SQ1OS7/X3E?
MS_FMY& 6,HH>?G1WTK/RK=G#G-VA<I;2N\0YQB,EMVR#4I:K(!9AIE>F?21K
M;X^J5N>*WP;X-H:>GBM_^F#Z!$#EP6$MHM;@W.'<Y.SS)<4+W>NV\X^WK!X[
M6' -&CYY?E76:/+HZ+/6S_/0'60\Y/M17+@O1<>.>C4YY)JGIX)$H@7JC[C)
MU7CV[YE+RDXM+W&7Y@2W(1(;(*83@!=GE'8((3NJ_L(A)SNZEM7=:S=@\SF+
M*4@:W9%ZWE3G)H#;]VY>HV]F_6RR&;1H'.4$0D.Q1E^(/C9D$-'CAE+\M:7@
MQN8<S8E5J:3S;L6R^P,LZJN^8\-Y#3LIC=LXS"P3Z1;1IQL5+US2RYD@/!**
M?!=X(5^S:L+IY:_CW.#!:\5/!U\]D'.Q]A\<8*TA1&,%>F=H-:U>2RDB6V=:
M97("%RL*_U2JNWK5M)K@YUOE6UTTWGU7WUT)4,LTZ;/R%@-5L22ZRR.LP:L^
M>*&E/7[8"8#.<JE\0Y]I!K0L2C1$=Y+T+/!^Z&.=@*E@VL[-YE6^[-<_7\*N
MHAZ=FE'26QHB4M^48O=?S66[@)L6^EM$]".*2QRDIE@E<@MK<32S!O'],]G=
M8KKM=;:P^0[\_]@.T?'U:7ZIUC;7T[*I&NS#N8FY$=ZCKA^X9Y]Y:6=)'0SN
M1D!/,Q '@H^1&"/$*L/YB&#\&8H,&J:#C<"Y+VHUO3'WAY4Q' N8GB:7S5E)
M2>]?M[DZ];:-I86,K*#W>ZX$3-S;1;UX:^,SBUDNNC1P GCCUPGG\GY%+VS7
M(RCMH98J'*^XT0/O('P=;_;E1R/Z4ZJ>PB!+&'P!P<#,AYFLN*^#XKR]\PQJ
M-ZKM!O9='Z8X2MV\?_\7KW-Z4KKC-$4X<D!?AFR-4W#%@GH^6>F9]87F6?"^
M+%Y;+CBXX.Z<9:7OSBSRL@G@NJ;SC:_((L=^<#YT:&@.^'0<(D?^;[$PG/3Y
M=A%"_>+G2V0[Y+719R\NU?I?C^T.+_[V4/N,EF@-X*^0*'C:>EAF?VYD5@>1
M"ZKCF[)5HO+V=X)S<#&3.1$*GUTIY24K!COGFD"?(M/!H_ &T$X8E'+/75T[
M.3.,(P6GIWB#KVIZ0-^P1VIWWT6.%2"85GFFSRXZ7_]ERC(*W\N1?@*X$.5Q
M!/KS*N*#!PB=$P)7HF#<I/'_/8*O^%(ZG12QK38__%CC\UC4C#(40GC$R>?@
MYBUBD;QN13$P/KK_YYY?A/$GNAH0S[<$9+,]U74&=#&W7V1_TSCCJ?9.A5V$
M6)*93\"^O?F::DT,>O6;RF-17,X_8Y(&+5GA%,/:]"G@WSZ??X=#R_I7QOP]
M.5.]. Q"+/G/Y/H#1GK8\):OD_(92,VG8"@+1=0!H^G7PF],5(8;!A=W>\=9
M-#<EBZ5URS?7,HM?'^CL.(8$,Y6<KWJ44C>^">49.@YTL "=XE6Y6VAPW%^E
M-VC']&?0+YN_\:7]C)_RY-F4E?YIL"0 +'<8@R'UR)U!PM[R^DY@J7D1#&Q6
M\SM TS-?SU'$12"M*4=S1<7\W=X/G9<]R4: CCX?? 1!"0?&,Q..EN_AEW5T
M$/Q_6#?56O3T_RT**M@:)0Y?<,E=8WQ8JV&0#KE#_XW@#+]%O$'R(1K'M*H]
MHWU!.O9Z?+,-&>]M_=)S'Z.;5'Z]O#\=78+(O 6I1L'\%@;_4(].Y;R(G<^?
MATO!<?1IZ3^!.N^,\7<K;V4J*+(8"!U:MHH&#"E]/M5F/)5[X8&$:DZ6#="I
MJH[7O5*&K@0Y$_F^9(YD&[B+)!4_D;1H"V9H&U/(_PQ&]5-X8-%8SAV'9<ZS
MV^Z<L:T1R]N)+</6/S*OQJMF<S=F2O;8,P8X:UF97/+CN/#EUQ[(JZ!DTU%(
M&!CS=Z#R[IUPTT"UUI27;SL.;H]0KV_9\/D45(7@2%Y%$9X6\ELA"+PE'.ME
M0&(@6X4_<RESIU^.MC&S*PV$B8L@%HP#A6]4O)J5*?<+T1H+_==/,B#++^TQ
MA L0^&M+R%#S1J+88B+C=-^WW^ZDM1 <MPE;C\]<5M\\#L &YJ-X4?G(J<3<
M):68 (6K76,][=?JIY:;IT"UBSHR'!*93WY9*+$V33GY2FMU;.A'DRT+(#"?
M9<@;5:^[DNYECS=(6=E<Y\'*0^_+OPU<N7]!-RE99T9W/=1=>CK'2)]XG!I<
M""LA69 +< [&6,Y.+QUL4'3IPB"(]+/JN>N;LM0_IGR=II))/YX_>1),T'9"
MG)JHIP@!*N<,U0NK1>4LVA;G(S84L&4+"-\O")J84T!]J!STJN7*,))_MR4%
MR/-MKO(0%Z8A([E@>PYMA%52-M'': IQ4;'65_3V F]:\6V7U\_#N2\D9>IR
M:PJ.TS+A+B< <3>$<.LM8B+VY:1JRD4/=[G>@DT=%J.)U+:\ AF -0#P\W'-
M"T\:ON2*C ZJB?[&4'4Z=1W3^+>_ZP10K]2IQ/7DC-B_P0N**/GKR<0+Y_Y%
M$N.PT+_B[>=I):JSD4J1&#@+%>@FE2/&S1JV/2GB?*="WM[$ B@[*^J4_R4C
M&-D.S2_I9%R!BOVQ-.3[Z?;_1BWJ2PA_^P7R0YQ-<I:^U#<5,X[(T0CO.46%
MP>V:FLEI$SD8[C5$=1'>J>[EW!)41WZMRM]#31TM9A;EO-WEPD0_YB-]XNNU
M8XKKT?=(;:&W ,&91)O ="N2H*A!DLX34R5#*?R^KMD2<B=S"16M\;;\9CHT
MYU_2U:+2,Y0\0GBQJ/1,ULI!= ()+5.=$%!@I)LQG8K%'8@ZNCM@E>M%U_ZA
M!@/,!MWXC!W'EXD<<:6;8(7+=AB[02_).S=?5G\QM;HEU+G+[EA8KXL;@KNB
M9E'=D%I(7+T>L%L#77]871"@N!IAZU;\<OGLLWN^G_L 6^P/R32*#)F)E&PF
M&_X0&NA5_@29>;[JR\BW^<J0P:0L&QO[M)LNFH-]*OX[CZP/AG-S_J4/53GU
MMY^A#T6>H>79[$-8;1TLRATE$G#64^L\]JU/5R30Y>5-*S&6>6SK#.(E2#<"
M.<Y@*J B*U5AKVJE(;500A-L55PFD;1T=!YI:3HXN/!.*C-U%52+V<$L(V>1
MW>C\E.5<O.V_F0?- G[M5:I6FB]?7_^J^<L)$'B^S39!5DM+Y]M=M.0Z)@53
MH_0:Y38F9 ?+[LE!QE_SJ=J9Z'6:J)9(OIRPV_&>T+20K4><3#B P9<R$<R7
M,QWJ,8(C194^$1YG_F'_ '^W#Q766;OR.0^N)$X7I9.="+7=0*;P*S[+*&9W
MWTW;1]<F/&T4]TTP(0M_LEYHBJ;_ F@"P$\,^7*]MH9UH;C^G6S" 2D^C17)
M\\?>;IN?>*SL\<^^2R15W.]B6F7U&6F1#)RTX&!U\!)J1YK0N 1_*T$\G^U5
M!@U=J%& AE3-5WZ=?V^T<N?.O25"KZE8/+)@HX*4WJCP5SK3D:0+QLWLQ!'V
M2&]_-+83%3*GLVK/7LBVF7CQV/O>TQ5);QMC\=R,U/0H%:C 4N..TG^'CY>8
MJ:O0H4'M&Z7F(-O!K#?LTOLLN;@80M7GD_O:WQ2FN.OX86ZN@MM2A-))UH0\
M5-WM<!?MV#K=!T5G?UEP_D'AYG9. /Y#F",M"BWB1Q$V>*=B&90(%-!5(/*
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M_OG !U@99.$$ZC5/<A$A"JXXCO*'%JYCOD:_L>ABC<G9>#HR6^245-.Q?0/
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M5G<0<3,P$>J5H;I0K(7EM+#9%;6U)_/?^N[XPR]^E/5,M\L&*8\#>=3F3<
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M7,?4/<<YW6]\ZXY>0P\HS!>_CR1<OFOFV!)I[!UFV&,^YXZ!]:*XNJI#)[J
M\]K%UW:>90/1@O<?2S]]V/(XT[8"J3FJWG_K/Y+WB$Q^<OUMIRP'^SDKP)ID
M_;PH\"V+!U],Y65Z?K0(085QO6DKBQPS!C_KYYTE[S8X?[6?ZY9,N&(LRZJY
MEFY>+C5=PF?S1!34PQFI=Y8XZLI>EJRK[EY=?"'.[;V**9=FO_']BL^:0EWG
M5FOU!*E#J'-Z[)[L, PGTYR'P^NS=W9:LS58F3O8I(9V/Z8PGWGZ72^AVL-A
MYJ>-[;<.LA61=T4Y.2N+0%7'#9<V*?Y=&Y8(+8OC31>PFW/6OW[#6S30G@9@
MHP&>HF+ C'["?SNH7#7C?G/V4/2P=$^[U92-O7V^_N]3/2^?\ 7>G6Y[_22\
MX 4-4+?_RHW8B.+-U1]-$2PM)PRF'F/I9O7+7UW4(4QY\6AG6%R- H<PX#G[
MT++)NOH?:8!GH;EW_D [(@B#<62XG)4"[*(1]]<U^ >SP*BTGI?2?($F3?9G
MPS;C0?3""""VK-IDXAEL?D)G5O<4;BL< AN=9#/7ZU2@>V[<>0*N/_(V<PZT
M+\M,MX?M]YB_$C]-G LL=@J=T*?.91LK39O2=Z);N&X"^Y(6XE9(V3VH0/'K
MG2/J8-UC]^K-A9_1 //:3QK:FQ,X&TP9YT[7QBSR5H@+Q;#TJ:/'S',<O+[:
MBX+CH>>(\KT@SCU=WBHB=-X*UY-G<<O'U=\Y25[8^V:Z^\NO+AHQBY%A:S.<
M9=0>.DO4H]BVH>*-.+$<C^:LT8:G&YAJ4?F*+_%#,=;./\H\FT2#$-Z%.7E9
M0UJVKD,-^W,(S&B"GK 'D/,0S/E]_TW0!QLO13U3@YTKM;%LI#'E]S=XK@!J
M %Q7VWNG&W#AG>(7B:[ KN%;1B3#*&Q#Y$#0<OU04PQ/C/1?_NX\/I<0-VQZ
M6/5(@M/X;P'#MZ&H3B3\-/3TH@>8N57:O3Q9VL$$QK$TH-ZY</-/=CY?7;:[
MQ,(KXP$LTVLP*]&6$$DI@ A6&%>!R8 I-5#\B_&6.Z6]>]?S; 'D-U+CG^-^
M S /?XA_4#_)N./%FH=L1@W%BNQ"GM#1/T%4707&MK'@_>+(IL4+OY!ZDLVQ
MN],A<:[O.GB^\?#I?GZ:^:J?B:W@C?")/ :T2UD!OO[K.4Z4U:?V1-CU^G'.
M*RGI+N;^@%6E-6+#*0O!)[:?QBRT4WS:U@WD+DN.+!,B<.?@ C.K@<^T\)T'
M4WIS 32 +@1^Z.*>346LD]HH896H>%@MHA.>2)5P#NDIX*"KR.0O56&B?QUU
M/]U@VSCOK#L$ "CG 9CN'B;(A14WW'OAG"J72G D.OJL[G,2"R8ZKYWX-GSL
M3?.HVYKA11>S5@XQ9?-^T5 Z7BA[@<V;3J2.MIW*6$63S7R8]#1=<LKFE4";
MJ1G4BJ$_-, 4&16RC%#_]<YB6 GS9/;O:"*8;G1>M6DK9>D&T&'ODZS0/PW?
MRA:@6F3XT@"'EC*!-2\WR_B1V/UH*A^QY".[8$\.>T%+:?G"V\72>SY)O@9
ME6LL(N^B1AVV+Q5]V*KN< NE ;J6YW@Q3)V+SQ5=NZ!,M?53$@]QBT[#ZO.=
M744&[B&S2SM1CB@!%'WLG(($.2N$8O6I\\+V:56@"25%<I',(@VP77QO\_'A
MJ)G\SU]EH_)+)[%R#96/B"WM)TRI$!V]J%7%BQ,.8QN Z_EKCV]K_C)X>66W
MZVT88RNR$UQCW@$ZL\/MV6S[2@$ZS\N4O%\MV_K@X?/S4N/:D9PW&;WF/Q>7
M2%6^M]>+E<=S8L!OH K/=DJ(J"Z"-B6=9ZQJ(>S9^R2!Y%XA%K')*"?@*QK
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MTUDZ8K+WB3NK%0CFV7[QF3O(Y%4N'RVP0OV^\)5#[L-=^=G_Z%C_E#-YF?$
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M"_2$=1HH,Q',"2$9!)@>1H8&<-QHI+1<HW3D;::\*[%4LO+XS9U8;YZ/6OD
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M<Y;H< >?241[TJ_;*8_"JXEW\C9FCMXM40".8SNBC3%>Z_X-HJ!PR7 B_Z=
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MJ1TM')&=69B?^S.CUN]N"C8%#/HKF?C+"%']!Z9E3"8Y"AX&PB#^GM+U"S;
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M(1E,+_JX:VBJ=[D?#^DZC5O)<*Q=\7(]U:PWTJKY:E!S@EE94NEA+KMF#/!
MM[51I;.( NAK=('@%*SA&UJ#4//<]38%4@O2Q=)/;S2\176233OWZIFXNFQ'
MGD<]RT1K;@"</2=,$N@*;W\(7YFKJ23PRB(/<U8_[.S8+WZ>;)?K[44 X/9
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M+G7'!HGE^%@ :SRW'Z(\9Q[V\,$C_09]+$9VR\JXVD5&?UKSTL83X@\=LG[
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M+(P_AST%GR=_A[-M2[[O+<,_MZS)?'QP;0O7&3EU]B5#2[+ *SV(YC04!(E
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M_IA#U^C^!>0=^"F_"* F/25VJ,ZY@:RJ;P=&-8':X5%PML,@B=]$/[2,"05
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M;N@G^4>F[GKJ%B8JB1G.D6[)<E_*L*B(A:J:%A0]FJR#A^=@%BY#G6"&8&B
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MPXVHLU DI/RQ3/\'QI^*=^+,:?D^&M7C]+M!%:4M9Z!\%"O9-EP$/<+J96'
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M0(6%9.'!!IO,P_WPWR#B+:MDK&2T%#2U34T4?'Z]:'CN%M+AK9V]A%&D->M
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M IFL+'0\/##]MWQ7/(42>ZS9I<L4[VI;).K[D=.'_J:?155!T=KYLLEUHZ<
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M8 [Q=_MIVNKCH.(CE]19WJ$BP2.DP6-LS'?Y(2T;^$LLOI#PDHC_AH;Z= @
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M.CJ% =N9-GJYICZWF:0N+5]VTHM2:3F>H?(?X.BI(4!RT2:0G&"9WPZ:=L.
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MGE4#N]'AM??WDJ8$1<T!E!H4/.]?+E_<12B)(D/5'WO7+,H&6BUULY \,SY
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M\TH3*^-'L$NF5:3VR@HS7<7$I*@>!U,>%6%= U5M7AFI'IZ=O[+VH?9U&"
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M;_\F[*\Y!7!W!5!>CK4[ZR!R7QC9/Q"I<T 9+Y+\X5^5*G$.2'E==_%)$^S
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MW@0+I5R*+OYH7\6)>JGBQ=57D-&'NTEAUX]X30A_3#M%=;JKMTN'?/*0W.>
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M[*8>$[5U7[+\YU>41NZ&.7(?HB<W3_</A))V))LJ088_2SW0\%@F#%/; FU
MK@AJV#?N\?PYH-N]_"2I>.>XTS/GJ(,\BN1T SE:?SR-C+:OL9A3R7:3G)'F
M$9X4O?EW:LWE7;_GX)WW/8S]>3,K%AESYFN_]:TS..FP8CM@HIY3\=(7):X^
M-(?H87IYC5Q)YY<4M92(>"$[$#\S+;_P0Z_FY5/_[11<VY)H BY%GZ"&,]0>
MDVIS^5U<$O*EUW6*[_# 406%4V_B&-PNZUFC<-:O\'.N="A<#FE3@?#ZXM@Z
M8LX!5Y4^M.9WL/[%UE'(<8WQ$>G/ 5'Z*6<Z.S#HZL9D3M6QF^,#KYG^VG\8
M#R)V\7T%0@P&">C SA)LVT^'(FEGTUN7B/QZ:9.#,_B0!E(U6WE=><Y7I:IC
MCN*[51]3DO4U^#>>Y_8QBB[^\!L6N:-O]OE_=YNU_TS8$5(Z,H ?? Z@\"VY
MT$B;F[03/WPY&LT.9Y>IUWR \;";"H9!U4&@A$:)7U;R)\X>SL4S/=R/WU[^
M"<G*^;*%0@KZT%CZX_?/"@LK<$Q1\>&,,Z^TW3B:Q4.244K&J&M1%*&SC@5O
M^[V\868$W 7$]*:CC]MF+F0I0:+=/#)*[!#+FZZ1T<WBF,!UFSYVS2M,9Y;]
MW5ME9L6<3GH7B;0"SA'=EY4@;2=X,G(Q&R%.B"HF*4Y Y'$4FI,B\5&2SUZ,
M217+8@+1B;).C3V A954COTKT7*7K+4)-9T95.\J Z4\&,"/Y>YFLK19NC#1
M4#M>";_ZJ8^=_5)/J;-*YZN"7R8FCW_"1;#('0UL2J=YGC-*K9V#&G.J9II?
MD[S^=*1N_2?0?3^$26K32$1F-]('3RT4B1WJ D;.2XR+'N[0=0:)%H<XTLS.
M6J#F\RL?W;LT]TY!,%E<]\4$;<*.&?:# 8X*+U+3;GE9^UE G,E.-+<?OY-1
M(BE68YOYB#,/)MQP=7ASS.C"G%0.^\PT/25CY+78U*TP&(P#=9)JM%EVU#K@
M2LK.*RGX#BVVE]AV6E#GMM1$&<*M]:AD9]F_>[AYQ$[UM_+FC 5%44L'3^;T
MU:%G>76@2.A=!2#.43OG0F>0[Y5/[I1,\0PX\IGS<7/)98DO.[)0R"BE#@:T
MX;,(AHL<-MI"EKC5&-NBYS/V542UKSS:66YOOTZ%9%XQ7$G=>5T_>W@J1--"
M5L NM',\J@+> *,\/@D;54MU9OJDY%5+5$6G? B349CL@6'U%E#>!@1;= .0
M-H"M(PWE$>4N^L+\]^/X@M,)RD]R]/,B,^]G'P:]COZI//CJIT%R=!T^G/%
M>EL(Y]BFQ$5@6QRBA;8:VOX,:)6WB-H]7&U@L*([C&+)'LN>8V;0/0X//@?$
M0)R_!="HI1CC^/[8YCJ79TE-Y+XM*WBKKF<:6][2S)YA$!-;IYH]/O!+J \B
M1C2 \.#2?F;X)>&HGM8BDB8>["S7WZHL#1*DFFF$J0P$I6KIR'^K#[[*V!>P
MARG\0&8V[_#$##%LA'+&N\VKCXDF\Z5S^ G(N@933)0W4A"5(=*$W!"\&$W
MD,:$6'FM6<?;NWX NR2V-Y\XVZ(AI9-EEJY^K,=1D@G44S%S8*.*X>V^3QT=
M9ZW*G$O)3-Z)XF\#\(5.H?='&G5?BU6ZZ0P95PCKO9H:3%$U]67[G)1D+7#Q
MQ/Y9C([:06Z#+LQHWFH)D, 72<K823@+]P =WC,/!LT=I SL><&,AJW 2S"4
M(=J_S4W34KX]5';X<$=5[*@:ZG3@D#"=)"T.LQ&R0)\#.A,NDUXZ3[9:"8U4
MG7QC^Q$VN&)N]VK)6^TX; WQR&R_=[+<Q(+C!V,KH6VIL&TA$M4R M%>$F%[
M.M8.%IOVV!T1>"RMVL89206SM7P>RC-BCUV?'#6H<J,O0:"DZ,5/.%7GR.ZD
M)?=Y[RR;U"^O1O)J/2A)7H00')VIG$F$@FW^%BHQKN!Q?0A*F^O)$^&G.0 >
M[UVANMR"&N;_E5OD_[\A2+-%=!/M#>Z;^50B(C+\(P/C?YW=B5)+@A- D:RM
M:V5/U(7VU$%TS@'E'A?#/>)?R.B7F-,Y21*%1\(.E0(<SP%4%_Z'9&DQJB00
M(&9>;^$FWW%*>]9VJYBVM/!&O(8,X*I-H-0)/1%([C-&5E'68+1HX+<&T+CO
M,VURC8_SH!+!XHMA?;%N9^"I4%EHBP0OP18[:H%SB%PR+%&*<^/=&4B=>_<!
M\J A*S^*;97Z>@O[TL_2'OU"%J\Z%YM"/KCMX6DTP8-\/027V9XCAZV)AO#"
MK;1_601 M_>G+%\]"N2.-WS@I,6I^8'31/$2]S> ]@4Y,9_]DH*&3_@!Z4C<
M0:=^=;]F0HKUQMQF7*LGVBM^>R8=6_96FWI=QAU7/,*+XW/Z$;Y]_2%F&&CL
M/ "KC:O 4<61Y/.LPBY5C4FIW_ML]SX[MGDIIW:IQ)T [3 7B_D],!_YVQ1L
M_&YI:'0W^<+$(!*3K#-!5Z"+7X,*VQ.N3 <4=EH)I[<=;/Z-:0A1FA\=^L)=
MNAR8_>5-O)?AE=,R68K!1GML"J9F&X2KT;"^YL*4T9[>AX^Y7EG+8S^6J\J&
MSIG3&+S.8J76_YW]<'*J53=-?"S!F;?8' CWEWXX/=/GZ2FH?$7=+MF,63#O
M?7)[#H"B26\$HI\/WM?@3"^>VC10E99#O?K^0ZV(6D=H(%0$?$ HQFO@JO_X
M%LPY39J0J9%UF3I-4?D9$ZKEB94ZOR_=^)XJRU&,@1%XADB?=3FA4X)T9QQF
MJMEH 3^1WA&MNE-G%<8U8*5)@A0L GJUT0@C1F>J702NKFYP+4'7.,\,^+VD
M*U?FX=M9J[ZS6JZYV]U4)3<'[<SAQ.8JEVRA'.)?V5/F!K*S(3*G'"I]SC1'
MC:NT,ME^>HC =@<\N)+H_GZ()A6>94%M+B@Q=%P#H\M$6&M'%<3Q^$>,]02Z
MCEI9OG(U<?!X%,'XK+#42XWYU\*U*@]&<B>T6A)(1UEY&A_G66R^48/E6ZFI
MCUA66QE:L=M),G[I+JYL4,>5=51//ZYJGB_F=.CF%%I(B.GB9,=^:,XX_B39
M1+]VI;T^;MMO]<FCY(8I1Q8.1;!!Y^F"P9^P_<& TA)1;K,W.51T[)_:!'O;
MPJYQA<FM(M3.&LC4!#%,9\GB"<0,9Z%%\."-91+RN)OO6I%9-L#B8#FJ%M>@
M!I_?L=: W!O^39+'PEK,=;)_J90ZXUEY4TNJBRZ'Q^_SO&?DTV,I8P<TVQUM
M!DW*1^MK*VK?]G?:<LJ+[O_VK]8C7Z&N0-1?",V?R+9Y=E/W1OL0IDR$'J?\
MM:CFI'1"UN*.81>+PFOI42/".%%KZ]B*AW .P%W>Q7W]D6!65VDY9RQC]_ ;
MZ:X4X]9*;0!&$!&2M#^K\N5E,]JDW.]S-GS:]R3K'! =*APPVCDY8KF%$!BO
MDOWNUC78$!*S_?/F.&<S0*B2H$LT@J@0M(J5%7.0_L7.T6V#([X:J.! )H7W
MM2DLH/D7P%?Q0MT/X.6IK%X)W-'E)\*/C#;&\&69!GO>^,+%A8XFMB7'=[\A
M^GEWU0OZ_>]6W+*K_NJ)X#MFN<*Y^&&^(8APFWP]O'1.M&2IA+D<S!>&P@JL
M5U#Z\(0HLYP#?$P6?+$!O4)T5B^7RHD.AK%I\E34!W-[F]D?':[]^!)NQ,*#
MO0HIQG@0!$Q:AF@)U9;T#A-53GGI/2G&HZXC6E)<BXD#]QM^'KWDP@^$ )<2
M;L!8 Z1?_;U*.K7&__@\H;H_1?>8_CZC<-T2U^UHTO;9MU VTH.S!#+U+(%"
M'WL:L-25PQ>-P72U&TQUW$A[+?[KD=<V;GN(.DO6>*Y&*INY56=D]G 5-77&
MA(V,.?0 !H!U<5211]=\M3G)]Z2JQJ@$MT:17!>ELW@1]%:^Q*>A8THT9QF'
M<^)K'93X_37]SS\0L!\\7J\JWJ=]+JX'O%MT5#1]S>G90NX,O301"B1WXR?2
M6*MRBDL6G@7^-*N&^7+TW]+FNB^3]N++5/&#N<&_*UU<=B0QXJO00808P1(-
MHB,,8:2C5W'2\9!G(<(F0FLL>=51M\2_^0&2)8:?J+ _X,[XY9,O&"^R_N+[
MF(?MT9(V,N'EJ)N'S8WR5^TI]VLOA95=<>0X@2<W*O_C# A&Z+E@@Q&'804+
M3ZGP_FJX5%-V4=PT>Y$=WS+#]]C8=YY3)L/)8-R%AB*"O1++G>N99IASWJEY
M-)X#!$EQ9[!S@!/H$HEO^,@7Y]^:+88Q+BE:B$)M&9M>J_HHID[JMN>-8>*!
MY(<OXWV<BPI0M3HZCT%&R ON0=&T(2LC/XI!U-#%(@:=G2,GOSD5S1\L)7;_
MC%>G[UYRY[$ZZ58P*?CC9J#[)F,?. W%4+5Y1 %ISP%5"%:G"4[V4:O%F!V^
MWDXAU9IZ5,/'*&9JT])9F<$G[+CW6\GG@&)H;FF@D$:QZ8@\)P56 C][P=;$
MSDFE.W]WCK+%3*.9<F2./MV/<[_,+A/;);3R;HV*_7(PZQ;2"802:X/^\8CP
MV?%OGS O.?IQM#:5K\WWX'NB4B>D+/DY<ROGQZRE:%(0(?@-9HA6HQBBC_VS
MG=(2].-[2GV1+3!KY*,?QQ*?8MS6ZJ79R2GKFO2..+$EQ^VOV,F.4ZU+C.2*
M G!(<U4C!O6&1WOW-]W8Z^/2'KWH#"U;1OU]Q-HZ?\31%O0.P5]SHH1!?<>7
M31U^7^/=S:+[5'K-#)=:6%I YB/P-+)HZ$@448K<IT0Q+B)B,P91*]HP?IQA
M__UD_YC&3DSX"]=GY?A+/<+YL<D*F1U0>B38XWTH714A'7.FUH;@PDX0OB.P
MIS/M%=-J0@#&?L][S,+%J<DO&,2O#7C_TC'/\/X>0E2!H'$?\(-_$4#R8!"P
MO4EP<F<RASN*26U45 .(X!:_KGD.N&'J-K7Y!! WS2E!]PGI.@.G2(@J+@H(
M4GQPX8"<$ZZQR33BJV<:(0C]4)/5F;63[/(< =7/&0U_W9V($XU#BPM=_YPY
MXH7 V7%R5HS?CVQ+7].I;4!$2$9@GIC>OFYBT[8RU'\'G1X/[D?<)4^E 1E!
M#AYW"014038\P+W5N\@9EZSO?O?^<&6@[-3:-WZNL#J9GO:S< 7%7Q#YLX3.
MAD(G> GA@W'P@ VM%(^ZU<:^;?B-V*?O6GEE%2E\=G2G]SL./,J\+8N!YOK6
M,%1A#,AU0*UY_AXA1JGP>X"$UD@:.$I!VK/P>3KE R_+?#.NI.C%QS2:-)>2
MQFYO(_^< W8"R IG7WPO/'6.<%DT#9*VJ5T:M['XZU6E9WZNBHU?&L/])1['
MG$O-O*H:EO)1VJXALE82V#7\+RRL?2\6P4]P_K%Q.HYHN!"QE9G%,=WW+$SV
M'4RM^^Q3OZQDT:>R.Q9JGJ2C@1VZJ#9\C,4>!^%BT-O,@>&O:^VJAWV%?$S%
MJ.DR)*$"*^[-=4E,_D\?/EE&OH[S.@>T+U1WM9=8O/SG9'-?^1D.S>!B6B)Y
M2,*JV4KA&#4-#+<N7S'P"KX]Y/<[).$_]X/P+H11O/?9MT;HTM",$,;C?=5<
M\,[\W>&(?#P;7?E,U_*)25(7<(_AX<Y'&R4'V4$=[9!TLY<)0N6>D.Z3XS9D
M]5[;PBW(VSJ"&3[$40=W1?I@(\8W^(J0HTC[BUY]2WN'D^CL.OT<JBOOK9)P
MQ4N4<5A^],XY(-:7"-YJ$A]4ST\6>2P9&)6LHM+LK[+9!I+6),43"A>;H!W6
ME8Z=<5IMX>0Y=+:6WB2L9RB#._K(*/O1G$+S.>"YU)%UIW5"6>A?)%;GS.)5
MZI)EZ,AFYY!)S0O:=!I/ID&FBMHVNB*.XH*7!IY@1_!7P?C!M6EK.K*8$_ 6
M@G$*HOQ^941!WA?,BTXQ%J!19I"@=+[F8$3Q1G9656AMP)M,_1[KH3[!V3L!
M9  ;;S9#G4PW<+]I=Z]4?/\"W#6FBB1=+25IG0/";#<00.RLMN=OW1\G93/<
M;L[M_B7<JHI:@@\IZIKWK,5)@+-<!#U$%(LDW0?>1ER;WJQ/S4KN\O[-=DW4
M([NOIALW>]6I%XL4_E X1_G96>5 WJK?*_/OF11!'M?5@N0@R9P.?:BR'^,*
M_^C_4#U"=B<K-CR)+2GG;2 5U17,GU"IT!$E .&2[0V$V$0::A_M/^.<]M.A
M(<LN]K=MWC)]772IJD2.4!?4!A:Y<.5PSKK=2IB@C!FP-B3Z/&7;N:V7_<BN
MX.FZ0CY#]V-TJMG7]VQUM@,0-%:BY3&TFFHG=ZD)W*7?4^2$TM)]F^$3/V\A
M^.)>S?MR$G6=S26VZ(-$BX=%71DF3>GS)A(5NT/?&]DNJ.@A01HSX**HM*GM
MW2;$?55KP*'G[N7VQ<O#&O?TR:, *B^A>24AB,6P$CU$8JS1]Q?O8'Z>:=>=
MDK,T!C->,Y[G3S.S7\;69^VRFWR!.)U%AC)#3+!1(X=#-S>4KHUS)]G5C%<J
M/GY@^5!UQ4<[[(D)]XT 'OJ1VCT4&)T%I(*^!M$'*$V^1$RX^30$F^;5CU%_
MU<Q<_R+6"Z"N:^9X1\'/^+B0KRXX?#FE[I"N!1G#JM9Y#H@,LHX]% +/:(OI
MBW_*':-G\-U?<9IYJV;/GMO)C(O> :^!"/Q(4H9N&'2^Z<*!]6S-0W1_0UOE
MT4T61ONDA3*4MN_*&EOU/==0F=^%;!H=3$P^F0K%2Y$[@=C)Q:O=93@^..]$
M]4L07BG]5LZZ ,O5SJ==B<ILTQI4W%)=_[RJ"XN$W"/ X,KY(JN%Z)BMKW>%
MWL!G>/3[U_*BN).?6^MFE6H O,"K8E/ 17P241WR!#?9#OTT$85QWBE-RJ]"
M4*KSUGUI:.C^^*;UU\^7LGIL2:V3HTAVY&M0!)+)[;#MN_-$**"I,E-\UHD5
MXBG2+B.?[S3IXCYX#<+P4(UK\GFN)EVR"=);<HVW/Z' 1:CXIZN;0UU=JL@.
M6C59P^[UKVA*+88 P*6L"?^/)"4% 70(OPI3C7GR!KX<%=.W2JO0<N>!/Q?
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M4#5VI.8384&TL O7[!ST9ZQU8!=8+\PR\>;?,4++()T^$B1]SIP(N1$J4V'
M<FA7#4KI')")W/4\EB-Z6^D2I4@!9S"$"$2O9@1"A2T%TA*2YU$64[X"$/E"
MU)?4)\8S/**#S)%=%+D*D^E6T%X+D7/ '/#444II4&' ?.+9JI_YD=(>X?V2
M!3""?&U2P;"HPU,)EC_=$ZS@%UTB=%_ YI;$ WZ*V$3%K?<$;^(+@C\FO:7)
M$:,3GK^5[,QJC5*8N?[ZHU7/\C?__;^:>MB JYV>QE 7^,GCH2@8'G"A!X>U
MK:3. 5<ZXOC.OJS&J]"Q;?F[]+9QA279L?:H!$OSSU8O2"7D(NA(K[#'7727
MG,DBV/X1C8*YW6>,K>$Y\RHR3LMZZL:<[1=:.E&Y= 1!>?;QB)]@2-2$6!)
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M1E?=I,GURF^,7 )67,& _753ZZG9];K*61O;;I@'U\S;CE?<3)\87D&O4*>
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M@?UE?EC,B3[@<O+A"O0LUS8Z>R'$9?O1,KM0+Z82G>B_R^E^8Z-1?34[*V3
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M7-M^[RO55)^+_4=Z#Q_SMPK2 )-E1]0H]M 6\FVZZYLI8#JSM#6@ <9T2W!
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MQS+SX3S3I?2'3(]Q&)VDUS5Z:A+ 2/%QF1V*1GJ<PPDJ( =N>+KP83Q0-1(
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MJ31 @93T@9#I^'9MJ,9&#Y&QH;HQ)C=3X*S%_2>:4B+MC+&4J7]>!@154[G
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MPYH*J0RJKM2Q\2XM&<U_^= XJ9#CQ[?U@[*3 QRE#'8J7>?X6)J59=&Y>C\
M)MPD_F$YY$+<;;?UD,SD13+8UE)^^R5GI?A@[LH6QY9L&[;55:P%OMF@_JR[
M90OR+9 ;'U^"AQ,O=Y?:CWO!:.5FI13O5)33U@R^3/H>='+GUD4O^O;ZLC+B
M)>)W,'63Y:D8WJS/ -L<V[G=F'7?QZVTF(QF=MDCO&^KW))%&R]_@S:&M5(*
MBAMEZ6W#\F_5O_3;B9/!2%CBP6@QL_:.S5Q[5@ZQ?IQWDJX8>,KZ=OGI7X$&
M,\N4_;)<B4U<Y#2M4RY%;H[6 _(57U;H_R348?="B<-XK?'NW=F_H&L+SI8?
M\A<JZ.]<WTG_B9-K S/X7SU[1PA8@-%J>/ DT[\NZ"WR<=^K.:Q]U<$B_U!?
MR8BB1Y#]9HO260;!M@!/2;P\@?,R'5IUM%23B11#9\H*XXZ'IMKZL]V?5%QC
M>$8AU*I-/Y@_4SPV6*FL>VKKSX*%1^;\E-'GF>PL:"-:%%QDG-'@=!<>[N94
MIU)1=5::*%X/O#%<74+/[:@_6B+A'OEE;Q%9FV9%&<\^R\5E'3+@!UDB ;X%
MF,WIX^7.WI, %9EY.&D'=;A<9X*:4E7]BX>\"4[\DB\OP+;G=FZI:)69GJ40
MV0E&$^#G@S%0VITJ,:]V".O5[ 9^WX,/-9'7W\E]I'6Z44:W+"0_S_[*M6Y,
M+^99[4T93M GY%D#B,*^H=V^TO]>A5^84Q@&X_PB1 $C]<":;T96!"4-O&*?
M*3R$\7#B?%@SYMZ7O<?;5)G\/.KQ>O)S?AY58%B@IAU(;J3ELC<+C)PELX)M
MHR%[39NN:-FJ4Y;\"XQI?)DF'S1[W:JRA.?IL_B)08$=)V7M=/?G49W8X@U7
M.ZSEUZ;J<0&OAO"U+RGTEX6D&O6W6^XGS7GHFFE3;RRK.^OU'YT(?:G7O1<E
M].G\?^?1].BP/Q,]=^B$\S-G,7[J$-<W\;3AC=P*/4.Y#,8C8A%&->5]U*:(
MC/"XHIN2\_)PF/FTK\ZE?8;KZK8(!];CEC:-9[J*11XS+;UU1.=C2(P@.UB-
M?PK?I^8)9@8Q;R*IE"T]/FW6_.!**+]M$09Z/&IZ;!-S1+E'R;LK$E?VXSG[
M/3TI8SOB<3OZUK,"]>;+M^YIKY>D4Y^YG'U8K:O#,\YK-/#WG24X2W7SY]]E
M)0&XSR-E0)3^C.-$.>_>.>V1+XEBBK+&HS+<R,:::.4/^^)WKT/J#R_&CUL"
MM:I_ND=S2_6";_;V4F$^Q<!I[3X;!0*H3UZFO!M)AM1T[QU%LZ?PN+0O8[WR
M,Y)VC2N0I22 Q+UE[[).8!#H<MTHF5F)[VEQ1$3K12C?MK2LV:\VJGU^B?^T
M< [SUL1F/LC5:LSBJ$/'M*P%B,]$H=C%Q6\.;V?%L;VK;&1[3_%0@3_SMLCF
M#90O<$#"R-^+G,QED@")^HOZIW1EQ#?:*X& %ZM$ZN<XR1WYNCB5^[T[0PN/
M#[I[B'Z0S__8;(P2#3WG?P?G5!;9I%3D_6HCP/)Y%+=9ESDD0?D=9[+-0\WO
M?'S#=4B4U_Q<)S@46!7E[XS7_]*'5FNY*R$J5I*YOIC:=U51F>I^D_,GV:6U
M;ZO.3)GC(P4R ?TRR]%WR#A$2Z8=K;H@=JWGNX/\OO /UDL?FGJG2( :_P"1
MK3+N#2!](/64 ^*JS"8=Y_U,^2G;\6N],DT('\H^^J(6]5=%NTNK=ON+2V53
M2;^WCY>(1E3%(#A;1.WT%\K*U:)%V$O2I[)3^R1O9(MW/7A@^"-U*5$RTW69
M!*A>7NW2CT+R+&>"PXADQL^^D+%(GYHS^-FJ[ZDWWTOIP>6PO8NA//<9DNP&
M+>*$7SULZ7NXLJP[[39,/(_7[X!7YV&4D3PR/SA@#'@^C0Y?+KD+JXV2X28U
M)("WR)U&^6,O0HC\,Q"A+"R0ECB"J/*LQU&V97)-!-)V+\Q1#WK1Y8R-@EA&
M2PR'YWBO%>\RW<T:??*L9:-8Q&ICY6UU?#\)@!?*.SPBR-2VP_!J\*47Q(%R
M8A\) "$!@%"GC!XR4]L-.$/Z+1^@ZQ#18!ZP P*PX4F\AH]%US?Q\52SQUCV
M/;<I]]$-\S*/UC0-_]4.,A6MYWHE,@MWA$6 1'&"F!(LW&)86:+$(5T@<@0T
M46!JOZ?K!*M\F##7GV!4B#%D6XJYD'ZB<_@!?R&7. 2D@1%47I7?+VJCZTH*
MW/Q1_9W+;<(Z8)PG0N5N:9BAY$-#K;3=FF7K-V=DXO#B#'SH@W?RR)=%VJ*Y
M-3JTZ X&<O)J7A*2[SV[4M_JWEX)X[7U4HU: #]A&XSS5\,AT.\^DY/,T! K
M/T=3"\ #(;._&-I,NO.^JXC\@-M*,/M#\=98(-JV/=9MX2BZ9<HVSU(NPED]
MUNW&<44@9E[C:O(3]J;1+M7C8S[F XDM:^SLW@)\:V)!%VA8F=EMG,XN42;F
M;&VW'*5EB; 6 3P.3KYX]:V:K2'.T&EV6</<A( Z2UW!'\%\%DT#J2XI<;",
M==@_PP0]WW6IY4V$C^/8!LL<UOQYYAC!SOIO4JPNX2-QXA,ZJ=IUGHK&60XU
MM;2];#I+K4R:B7^]-KG*=\F@D>O2/Y8<I,'I_4WGQ?31?MX9[1R#$<:X+=U*
M!Y3_^)> $K=&V_=9GG+BKB,N!X7 VM0M))I-^7FVOR7>/&=.'\W4$+/!XBO6
MJ..Z6M /L><XK_6=&L_]#H&6^;DA8;>8<W)'@+4W[4@BS%_N^?P<K;WBI?28
M],!4>^;DAOH^JL6[T4DS\]3X+")UCZL+@JZ)[KQ2M*F,O9D:T/UKQ++@'"W^
M)/UD9+XVKEK_S1R=NZ6;Q4\)@F2I+GW?F81!50I*T]8*Z/#]<]0UN5O[?!]"
M+,A450G+,7(8A=?/]S8S#ZL8?3R^H]ODHMW^*@@C%N?Y532/:R&2Z[6%]'*/
M@0)GCYOZ]SD\H^U3:^RC;P_MGU[*;&!.35I>I/B+RFWT8, WL]G1;)!X58A@
MGT\#W7J,<^R(];Z^JW8<[WRE)W[6"24_R,8%64T-(7B=F@7VG=S&"B#;CYO,
M<TV719WUDEP+NFE-Y:_JOEQ<7KUNTV/0!6#CB3P5".R'7Y79B=DC..&[5\P=
M;:139%G/7=P1T5B.Y%=#\VL.C,6'#]"SPGYD%PCX*%S6L4D8L(+WFHN1 +^
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MRH+?NP:3[):&^^]2,"$O09_O7@#A;R(5(J@7EQ^E. G,D@"YJ^$5)Q.5U5'
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M=ZQ-TYE;].Y[XES>OCUX;K'</N4&D"MW:V_)5C_GS?P*>>Z?W5H+>MV(*-6
MMR$W2$[V[@%:$;[K2),$1=E\[6?OTJRNY+T"/#KZJJ7N6S6NNMYJBD_L:%><
MHC\%1+=R87"O25+C?J60A[9#@"TE5?88PW+KC<P?'E)'L9K*)ZE4&;CM20$*
MP@SN4SRRCHJB7K4Y)S*QW--0=.5#S(7ARDL%T4GS@ X&(6<M\D09I-DY._8I
M?0(20A__@>FK./3EC/*:@\X3 ,VNV(BSN:')MN6W,DG3L<0%5SF,-.EV8Y>[
M-XYQ#EWQUN 6;'G3X.*Q8S.RKP5($I/NEG3H15^"*V'M;G5!"9C%IDR"HWD?
M;Z!9@.%C!&,=-&6.[\]@93^13 *641Z0@O-(15W^/O:D[BZN,.($TWV7;)B1
M],>DTOWOW$ZO&$""-(.;6XGG2&&;O=E,/PX_+2O^TFU%?8W!!JL2;\5 (=PT
ML"S+<XP->H+UGCB5Q[>:7[H,!_60RL[2'OY)(L,B[.J(7]5%: 7VH_L] V9D
MLMM&*ACPSMIXIUPW4%?\,WQNL.*,?HSC*UNPP*L4/5)9R9Q"?$*;>"]44)1)
M/E'-2"91XXFEV.:U45WO"U75'NVT<+GV*9[C30SZ[6_IC,;Z[\W"M?HV4S4/
M-E=:8$\35CAB;L_<?D__^.ZY8GX [9>25'WO>GIHO,ZRBD;BF!IPT13KL#M+
MR.L)X28MG^&X.Y,/L^;/T:Z9%0<)E7EU&PN%5/[78?-T3F'7P(G4*0?N5EZR
M-2REVUJI"QW9^!Y6^7,WP^^BY(W(_0,QO0_#3'><@?"6QB&./]P*QQ781'I2
M4/]546>L!M.#V=WIQHKV$A?^[T_;[C4G999A0)'4*WCV!W YC#M7=Z'G89'!
M)*;^0&8R("T/%/\8>D\Z0\],V6 [F(46&] 7#R0^(8$P;8_Z9%RMN^Y+^KX#
M&D0J)6U>EI&ZGWR=$5ZXEZW'N46]0'!')K;RYI#231-@;@JQMSU7$S;N#=4,
MA4XIF]]UNS-ZD?LW= SDZAG5O-<K':$DP(W_'?7E%T]"CFHG,?&R6)VUJZQJ
MVY)C&5"!IBMUG6M@]$XP;8<]>U2'/0/^#,PJ"B"X/\&:3!<VO,)^<;B&1A\M
M9G;N[Q=-C=M3]09!>#.<#1;XIIS"N89@^'7\,R//TE:CO<RS8&6$3J(W*1>2
M>NU<$;30\LH L#?F[P&Q\J2L_!3@9LS;*7 1KQ?A%S$]0OJ6QO1!U^6;S =+
MS!RN*21 ^*,T@(\%>JB[/XI^6)\YLW/AMWNA>;*V+(/>H\Y+K'1 ;=O-B#,X
M%N^835Z!>7;QL$;]WK!+-BV O+?1_[5EQ<$F;ODDSKQY^LIMQ:-QI.!9)M:M
MNX5'[<:N9G&COP>K/9K<G>\G7-O]^8":N@NL17<@(C.+.O:B7F=M=J,8[7;
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M8L/"X'?V[*.&A_H PX<#'.RAW]Y[PU04\KKE<=\K3>M_.1V^B/D[2U0\*:]
M01(9[;6+%[4+8=WZ%Z1QCB)#&;PW7*+9],VUZ+W]/_N$B:^/+>:M-?:8GJ-.
MIC=+1[5"*EXN&"Y:R<Y;V:M[G1L/ZW^IO#YCEB=JW+DUY&/@ RRJ PL3'F'3
MH]J924 S OA=E>9@H575LBVWR/N3N3P'K+\Z#2D9(!3B"C-=4^I'+7*MI8XT
MAL,-RF!ZN@$6:1JJ&Q.3AG4,-/GB\?L"P<O-3_6&2B9\C'??;PCSLT['B+-W
MAO!X,I <3,;1CZ<4FMR?7;R55[K$_=N#MTRMYK>!.@M@%4 /USF30)=.JA5
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M2ZY*/E:1YB"?5BF]AL/D]L)*T?XT8T%82_Z9>"Z^?4;U /]51@JG,M9CC;)
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MDTZ(%D]*D;"RFL+4W_PEN_'#J.Y3 (_V6B)KP<Z7F W>X6]O@<VK_D25@5/
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MG6NZR2S?]L)G$U(GX$IG^M]TD/\/6$"#D.]MG3,\!PMASP#A6K^X XG?-Z?
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M^;ZEW0B&7]>BI9;1HVYQJ_731UHVSICUR$>)K?D)/>':1?)-F3]44OR;=CZ
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MI;C*KEBLJ/1**'(1;ES_W;EI!7*304C#^AX8PT<WMU)V[T5_=:3?S.!J#LD
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M1+G8-8:U9C]^'*5YX9+]7&M\@LXL:Y-<9V#1N_DWH)3Q9E8?4$?JAK,?*OB
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MJ$9V["Z/8V\^,?'1B)+*RP3JY G#RK@5H8\7*4(]^>[0JOGM!3@%%*W$)D=
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M[JH4;'X;YX,N/WO8HQ0$6JL(Y&M;_63QFD=MN]Y/9@-M^,Z7V'CI"<L?D'H
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M2A0LN=O5JT9JPO$@?_N6]U].Z_HW.&TM==5\039DHK.]+;_S^AW\P_4LGD?
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M-G$M'+4U,2\:M\]"6H^/Y4<.K[3L6_%I4D:I"!;HXD&   :^)2;0X@ED<I\
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MU]V^:>Z;!'SM1IZQI]%Q'G9&)C5?5/EYM6BOD%> NJJ/1"MXQAX+ZW:Q>A?
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M^,_V2[CJ;O)C9+CTKYU6@V EXLPL>OMA_.YRBM+=X?4&\X\?XTXB.LQ2BMO
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MO\I+D<";U9^@RVDJ3_]40(P;G8 >:4Q:^G,:.T^;+H.4#8DTR^".(RQP9[(
MHH!C'OKV>F!723&Y\:9'9NJ&CM<R[T=M?/6P4STAZ@Q BR5_YB/-0%W=1D0:
M$X+-,Z<M:ISIS\7.O_-\G&(HGQ0#;ALV&4O:0JZY219_0<V$#/_S.E90WN3>
MZ[!'0T\;]>3JIE08Y"_0TQD\TM7>!><M405L&=(2:SX)BVH5]B_\<^Q3=^]A
M>XL!V\]O5UO=R_]^V\W]+*2OVIE#8<@BJGN<AK<%XHS #4WC=1OUH;9BO,?"
M"PJI[6%MOV3,#8B] \! I?2"5>Z;O\%UQFAQJHBD>W$&2"M9AA-I0!28.QE
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MEE)!$LCE)D*)&)6 .-*M&>L^R.Z#Q5WCKH'^,))R_(Y_'%<GRX"6"X \[=?
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M:B86WP7')X_7A_'W##@YK4HKDC_K.<>H5GD: -1*7]P3%JQ$X:[M^0Z$H\\
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M5GU*"5$T9@7,<!"&#?D:PA3^5$MW1;-7Z>. _>PN__76I3B);E:N2SL_UL_
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M>K4VFDMUW0Q<OB',<Q2 1]&8=0DV/8@Y$4&"3HIHLI:)]+'(.X%)>Q3/#K[
M8:R7+WR%\NG<_"?WO'BP.;48Z UZ<=R<5AN.\0C>8GM0V#!CY.FJ6HSK\GC?
MEZ/?Q9C#:@"Y(+<YT5D;B^.IA7R>CH',+C;J36^OXC^$I%SV=2-(%44(%Q2R
M8?C2R'OM,F)O.0TW==Q!I9%\7>P)>+ ;R709)J#KX]-?X[WVTS^_^ZI5HN&+
M0[JQ%]K?SR$T3@#^,'X0.)1:T>@??XLENDQ;W+ Q*IA1=KJA_D/N#&M__,2
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MXYI.^6?$50H]09"()!4OO^^XN^QK:CUUP],1:USA_/714#SKM0%V1G3I^ G
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M0V,=_S2I$$QF>O+-$R;^HKHQ]P7=C'O:_8%W&5_FH@<SP-DW@-[L1P9.F2>
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M1B0<X97!-$6XQ'Y3P!4>RY:<81+->O9!"]\%_>DGIH/B01,?CP<QR%=_37G
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MZ.U0C:[+ *UKM1JE5^U=_.8,2088I02P(SD*,I[D_NF>^8+C%-JJ<Y GL7]
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MZEBZ[*"&?,E:P (2_]%9T#SQVY251M+W:?V+[TY]P/B<-W_HQZSCQWM<#TU
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M6\VCN'<-![>*928./NE@N2C[$4N#W8-*?YS]8YNA&(,GQ!Z2#A'7G,*;E-[
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M^)8$@I+4($E<I./<2P3)9D0D_ H^-#>DO(#D>@F/O?Q[7*&@$\ BSLEBL=W
M2+9OH-2#SI%U\=/UML!W1<VWG[O=^'(_GN>3NO)QHZX>8<_6BMIN?,]S8CQ-
MV:X:C]S( S9!1F%&/V!NB;G#\\'BPYM:UD<)#[;:)H.^AJF;^4]Z[![/-1Q2
MTN%GJ#T@A7$9F!&^IGEL]\F@O>4GL4<CYP,=@-X8UL4N@?G+]Q+,0(+TX*0
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M:+X?< MT[(3B]-\8^@$\9BVI13A8ZK]$T#F')>V&G=.=+5*RMLQ'ENGN4$7
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M2\$=MI[CK4.XPV6"2\OQ=D2#(#'V'KZ]0")\3BA5BL\('7$G3*JQ6Z3E(RN
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M+!_Y<I3W]S"2L09T%L&.]?-]3/3@P$6Z7CB?<V#0@>*Z(&26/M[=%V"G5?S
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M3F*@]C7($W3;VHF#\^J6D>QW R-[=.LB>Q*,:ZH@D$^23#I,,=B?#)=]EEF
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M&A[6K)E6Z]-[YOW0JFQ\91'%CCB\T[7S29 7S$):8@RZ'J64'WY#7)8H+YM
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M5G8@(](%Q0,@-1VB0#::)2&QBCV7@[#IL[4ZM1:.S0D<KOXB"8^&^22NDGL
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M$R^-M7R1=+;#7(?QMG"A,(='U#T'DG-'$W/8WL]QBOJ/S2;.M)%Q/G79<=5
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M,73 \C<[!J+,NS8>4AVJ>TE@JD793Z.\JN=BF8-425_6HPL#5>(BCI?C-VW
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MY87=^>#*O \C <'!HFD:;XWSGKI]XBJ7^2VC_B/Q[FAX<7VPX.\A"$N6F=@
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M%6$G-VR^#\WSOI JA+Z$#J$ND1BPGJO?(MIB@_LPIKK>$E,-)#VQ<-@SIBJ
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MS3110HS;I\R+J9< V&B N;Z(EAR[-?&\911$C_C8%"=_L'KO($WE?DV9[DN
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M@LWJHHY?9 ]_6[^M%FU6]]XHZ/<"_NFD% %,C%X(<S7MSC$UU0VZ/\XW^SO
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MUVMPTE6M==?I[H5H;7.<9%[U(FCT ._?^DM;6B1R<RDE6@O=_'<W$4AGGN1
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M\BG CHOFN]4I3/I$I6)Z0AQ4-NS)PO!$L,QT<)@/^AFB2VJST*WT2T31V/=
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M6!LJ8=U0HBGF280&Z4$50<MRP#+<U+(YD[Q4,"+ W2M^RNF(NH!TPO9\%/0
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M N[GX86>C3>--B?&:"5PIHAVPTR_@@CX(;[_^K!21Q>IFU"O>ZH<GWL\IE[
M;AX4R+<CO<9".4(]/T1G\QR?XQY$8>GBWU7V5(^97!=Z[VB4S:NL;-3X6;,C
M+?=@493Z::A2Q(0H> SC:CHM!0;K/!BV=EPY#\29ID5:+[O<O]AAE\N-CUSG
M&]GE6T,QU2NN4/L4$$.,8RKWR!H%[]^=^^MYJD55#G:EQ<]-3H:L7Z^&RXEN
MGC]_H2$MR<(X[UV8UI/&\'6O;P;THPH,D'A6)W2?6,LL0*FPXH"]/W??93)
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M%!['8N*TP8 YW@[."3CVF6CJU3YP4[C?E(TS:$P\;_EB\G&OM$"/5).:7IJ
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M.VEY-95T%0?K2.1*NMH5*W(M/']E_YC,#^/F"W+GDI,:]SX_N(*M@G@+CS!
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MQ;D][])V?6=Q;QV(8+;[2*'2I<NJ H7;/>3)_W1<-],C=W>8,3(X_@5#-&2
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M)"QH2R.<B,CV5DW3-E+L!Y5$+]U?#RM,)Y?RBE]&Z<;$"S2Q?+LPG*]W5*U
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MQZO^]X81>Y'YK+B6*4)MXFT!ID9N3!1GXY5,\Y74-%>K7*X^[9QX4GP..S]
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MEH'V\2W^4%ELCS/DG>*CRQP<49P5B@#Y3^3<F JJBTK=D,X)?X78>]S/DFT
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M;+ZYZZ+;Q[X<'NV"H.D7XG3HW$::3,"7&2N&,:KFX2?RI$YCD\R/_6B<&DT
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MS'*89\U)7MT$MO)&4V[0(!-_M\[PE5=((,#^2QRYFVB+"Z!P;&'Y5,)!M6>
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M\I(@]?KNDO:*NO[_4'&%UCE"C78WC."KEUO A%QB(DF8.(MI*_?&F"C/M[S
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MQ]/5$5@G6-TK.K]ARJ[R2R[[ ^$HI[N1KY;2S29;H:EFNN[F^<5[_0D6EN_
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M5J4\FB]@GM?G#93HT;,V6"=4?BLNL>2&"YY8GL CSMF&0/56MVP$4!$?MI]
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M9%_LY2"HM]<@)YL#$%,9$78)9\R4?;SN!J//]CN-#Z$PL0Z@@PL5%,#G5Q3
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MUM2.2UI\D@1SF':LY+1O0B,F K]$/_GPUC"N^K-L%_7Y*!2? ^@4!>"$!&S
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M.B+KB"20?0,T,555/W/HX(I[9_=5AX&NN)[?=C-2+!4+5J$ ?INBEGLK*]_
M@FMK<J[1<Y='&FTQ)FAS1H0SKM?"8%!46%CXL, OMO%F7L.[$'9>AMA3T%\+
M>+9)J>1K1/HQJ"LH6E&)](8MQ]4^L1@W[8\0B\FY"?+B6>9(*I$?GP3]CJ+<
MZ%)IRZ*Y,/4L"J:'+\3)D3(]YZ.X>+#P5U )C\>2R1W;LZ]S[(HG[PI$F_&V
MB=@Q-,3\Y.1D/@O+_;U)P[D/#7=M/VD)6B#?PS'Y<!?@$1DK0V8U1A+CK,<)
MW'@F7!)FMZ/%!VN^;I[4BGKTGFX>4G,8<[12TC^;W>=Q6(=FQ>G]Q\IB6:BE
M-9.70)VV8S]H]ELRWN=H/ZAO,7O7CZZ'.E]19W#Y43?\_,.AOSR6[A4^9,%,
MJI,\6/; E=6=UTIQ0/[\#LA\SS_%K&A-S/(>YDO30U5!. ]8<]A:,N[$J 5I
M,9G8IKQP7\0US+>>52E^%>O@.>]O978X;CVNG$25;M1J8)C+95,SU@M4_@9C
M'U%4<2N?LJB\)NOP[O'%&>0>9)HHM8A7E,I&VYV94^_E?;<Z\0.T/E1-P\EX
M2OA%HT*KJ370I2*IJN!@S7',*G9L[D5ETJU>Q^6AD+HG]?!W^JJLA^IA4 F"
M!JP+?D$2'LT,M<(#8>7??5!2LV_2!7(TPU]YZRD<ZG&\I!=*Y^"EBJG1FZS%
M:>"3\H@0O8AYCFK)%'#U4;'DCW0Y6_%M@2*RR4[,>;WN,%W-KDYEUT]YQ:2J
M.K_[1ZP[4$V"(:P;='X%/PC!ABY4K[CCTQ*,=WKZPMGO%:2;I+ G'>H67Z+[
MLEX#<VZ_B:J8WRK%\BE+6D$?X4?]+Y#Y3=_?W&H?U+[Z-C?1!B[@IU'(=:>
MJTCOTOJVHP!N:'654=4?F3Q?%?H9/*6WE+1]RG]92:95VSUW0R9%49E_1'+C
M<?B<-&GZ2$++1$3]W=U2XQ9.@!++HBA1&DF\V7\6WNI* 7"'3F>11RF MZ)$
M__5U"L"(T(><61]J7LU$UC@___0!]V)N$8Q$UO)_WD6 KC0+W5&46_3(\^57
M"Q?[^'JD*%8NQ_;LS>(+%<%I:+NO32PSZP>,X7VILS)?8QXBQ"M!2I+TKM,U
M??LZM<F\P=KA&LN^658GC*Y1G_P@>OMB&5$(CELXKLDBQ+OX'XNBEZ%2 _ J
MQHA<BR.3>:=*1%=]^)J9R4JZ2@/[W>X$.;1B.*$B?'A:2L0F1C'9?'W=E6BW
M>T3^7%I. =B!\:8H3/Y!*=X<M:?@%Q=0259JWDV> Q/]R;L[SAOX?>LDU?L%
M'D+/LV712?G[>MN'&'C'_&4RPT;]Q: #Y'::\15'CMI:POU;3_A>VPK7FQAM
M;HJE[EO[$^Z0N\FW\"&$:U Q3&=<5O%\M*+$V>2>)RZ/(@-Q<!'?]LA%1H['
MBV7>[NE"V^$"46:JO/5403[*/.6DA$;;+ J@!>0E&FH\=<N5RU&&/D Y6>0#
M>]*V>\V\9-<JEL'1HX'SQ7@UN8,".'NLLU)P_@.*$DM-"@0AB^KDC;7J_>44
M>[_9\;6H][J&P2V[ULNJ-PSCX_0*/PED[R"B4/:BDQ0 >DZ65*G,X?O]W@!L
M>M&*TY3^.P508X%>]?,15R!OKS!.&-.L&AQ74AVH^:BB2191<:P$RI09!>^
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M@XW8J1E#<P) F'T<I!%_E\#C&[<XAN2&*/..5*7=_HJ]%2VW:Q?XEOOBU5-
M[M-.=BZZ$H$'1JRIA7)"9MSQS"-'"/(9$L:U$T@-._?=G#_*$[%EI;MLD;@G
MH#S,0,B\=3NC]MY6UIK:)7Y%DR3R&+CB8M1Q4<N$&N-%<[.G");%HZ1,RS;7
MU9E.%3-T\F91R>EQRSV_EIF)XX35*HJ?(2!B+.*/7'&)I 07%(0I%,8QNK.
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MO(C<$L.*+J';>T"<Y 'YH5FT2_>ZALP-=T6"[FI(8_FJ*J,FWU-^T*W6=:\
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M7[M'XB.6[3I=F7W'T!U3UBF0@L:;B;5L>Q(?O_"$K43+">@M@V7@+;*/I2F
MZM<)Y^5NV$+K?MY3];3F'4$Y]4?61"UNJ^M@+;T]$-=-DW0C-*.M3_MT,]\R
M/.QQ5D0X_J3"W2"]^C$?I"P2@8:)C3[2>:;@<+5F\ "WSRPJYEV>>.>6KD2(
MKL*.DI"/B):+1&Q 6*UD7+BB"9FNB0+@BVL%X@# G_K"+]!M\_CKZJV[;+XT
M;>:K:TU+WW9^*(E/X6R"]D;42GFUMBYP/+G=PVF#+'X";U&'41%OXXNQVFWR
MH:^@0O!2,PO[UCF'X@NLFHI'' Y=G O!^/'I>3K/GN*+BZ[!581OEZ=PPVJ5
MM>D7"8-?WG)7(-U46.,+9(<00L*J<@U90:348VT!.@/["L?\NHE)-._73<#3
M<#N"'JX1TU79M>_MM+=TWZ[/:5V)YECO,%  ?W_R ,H LM]&II/"L"Q=['"-
M('.-$/D6=>Y:E]4.9-4D+@VJ&+ZUU.W0U5AGR,7F90B-KL5=4=TQ8U>^?CQ$
M-A.;2!HGJ,X"_)RCB3)/ROU0_<O&V=R^.^R9)O8QHX99S+I#S^6I$(V*XS@:
M;&V;*QW1N&* Z+= $%N2VR$VB;:;E/)P6"#KR[KH8\.UW2I.,13=5L[Z(;'8
MC'3/)BI@FJ)6A%U]G'/,VR1%1Z\\?M =T$)MT@*O]=DR6#H+06-]OR^6A$KG
M3;7%%6R,R3*Q#JQOTXG+NA^6#[Z&(Z)NC*XWR35UQ<LY"V0=6(?O 2<A[60Y
M[,569WFFL*FSY#=+O3(DQC7M5<!<06#%PCE=;48.4L[3@? ?FTNQJ]XRNIOK
MRZ7HM;A%INT->+&CUH"%&3YSV&K_9.SET[%R/4S69SA]J+U+)RPL\DJ%,S\%
MJ2:?>:O)&?:\*-OFG'^0T!IX6ATG%XI[.RPL54RW-*^#K7E__C6[B_BUQF"^
M5^*WJ/.IRXU;6IXPT0CM\;]>)U7 :#?>+%[AT<;*X#RINFJCE:2O/!2@T5_M
MK;A=^/(V1TWD 0WKQ%#II<G)K%,OG#<R<..=R.FGGX$GR'SFOJ#V_+S&?;.<
MF?%DJ+:D=\-D4%'$IUN\(KOQ+$&-'D9P%R6MLW8X*>S'#$>K8I?MFW9A71QJ
M'9=W9I,$/XNGGF\!1"\UFY"0\$>EP..RBP!&D27>%#LI#^,:(G3N+.@$Y&MD
M/P93;R%XTMJE 0" #U,%W E!\UU9D91,=/B ]]=-,1K=Y:EAPWDO7(QS'A%Q
M/S#BQ^2YO^)GO;AIM"K0@)2%M_"A5N[C0RF Q_1@$MN/'S[;0DL0$.TOUGFN
M6F&#3=;D7GV(#*=KHD:R[/!FWR8J"F8'O86'$(RA[%6H:@PX5/%NA@KT.U_W
M70C54>2'$'Y?EY?I"<,0$  $T9N2AYQ5Z(R"L\5QN,P76[<X0\YW'4W11J\]
M[F-*;+<KDZK:R#=<?V[,+>ZH6".-6HB;X_CT"9^SK -5F[>M'$SLR&[I/,I5
MIQJ6K75$DNERL!#"T\ZY*W@_.^GO 5S ;8X# _04WZ4HO?J.Q)\Z8"=8'PC@
MB9C,6GSA"VN9-D ]@_1JD;C;DSRVT=UUL@\ 1I:X'[S(4#(;N1?$TGP3-O[
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MC,E$%!GN</4I(?[DD$:!K.^L"J&5B*<+%,!?^@+]I1UDET[@'X#_ /P'X#\
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M<S\@&S 6(I\S6*7Z+7JM]^.<HP$7S!A>67'3IH2Q/X6=@"[VO[B517"%M_[
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M[Z9[MC39>F "V(32%62$Y37T,@/+1H?*W[FBH#T9',?[O?47IMT]EU)U7W2
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MG*ARQ$YD:.QJ(Y1>Q[^)D:=)^MI>\CX$L"MM6(#ZUG]X'ABLR.DZ?]"(/^7
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M>3@HMKC 1D]7\' UD$LM-_LOU\J?@?%>00R\.S>K7"'S#<Y+NQO$B;!#1D\
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M-2<$T9T@9D"X\C&T P%,JU^P:?9N:CQGRYXCN2D0_CPJSGT'>9]LBH7L%5\
MA%>1)R=Y%X!-Y@D4HLT:M,J+09.;ML%]T[4FRW-RXYL)3BX<+184%TE,^#$H
MZH,C<RY3^"EFGU=A^L"J!5J8/#V\K!.F3R<*F#&*!DM_OFRRR*P(?$9*04 8
MQ' 1$]SMT^/)K=S8U_$%=0E<3]-.8_(DF3_2-0"^%*I=?K@8LXM^C6!P@?.2
MTF',T_8WNB=PY4%^HI*W7+[,>-G-QET]%^$M74R,S;2I[P#A13J-H(Y"]0F@
MFRX!NN[NA_%'L8%"<9?^R>JM7(E34"\6&<GZQ%(;,9OGHA!,(KR C]ORDCX?
MBVFUU*988-ES*][*?;:^N]AP31=,_>:R5S:+(<!3Y\QCD$SGA:76L5)WZD30
MV<6V3R3DTA?!AP!)AL+V P6"2E1QEX9;(+C]<<D3R(RQ63WR699%0MOQC)6[
MN(>$#U<HEUHJ@/6HI0( ."3)VLY@C7$?\8U8XZ6$YL72A:G$3O^Z6ZDIEMT[
MK]^U3U42BMDT_EPS"OW!$SP_9E3 V:UHCOZ</0,QWAO\ .904\0V_\+9BF%J
M9ZRWZJ_FV:?ZZU.5GN8F>?O_^+W_D(I9AQ\950/$B]8.HZ(2?BX21!QJ:R&[
MD^+[@G?7-_YJTNP^I'M/WZ@.?\IHX$O1R4^!=-"57_ZVH"&B^5*\3T<=2Z]3
M@*-\L(J;:2!-JM#4NLAUSTHGOM!6!U*(VNU"*!I7,=)=Z,:V>LM7,6#K>A_7
M]1B%;_QQ+ 4=3(^^XHKCE30'SO,5[VE8^6F4XF4)YM!ZW&>\,395?I!^ZUPS
M(FEI)[<^[86.K.!'_:@8#6__4I9?<5X]?S,/07C!0>(G0S[$I"@3B1<,ASG6
M1DA] #$[ZN3I.OR#M/2R/7#JJ@FQ/_V%"J$05@KHT$B-@E:OBD#'?B*UHCXN
M5J]K1O-\AN70TVG=&[A^!( I@H\M81$:XPXBLPC5@>L=])E4_6</E'9R3K;0
M=8@]KU)R_ZDM2ZS^/_':RG*A$1V(D.\A,8^9<V9"XS6Q="68FOS"78J4$  Z
M9YWX3N%YRN(7H"S^1E?PP#1JJF?ZH96OH>S:VVEL(O%F<V=ZIK<-$83W/^]&
MVKGS9-95!EX_<+O9?7\X]\,55S$6Q69OZH>CFWA#,EU&GBN0:?_NF)J +UG-
M(GE^1'/D2R;]NJ?GSNT7=H 0NH]_TVR:J_P)I[O-2^JJ^J3D%HY";2<Z*S ^
MV$/2C@Z06AC7$EXY6G<TWDK9:J%V4,?^3F!-WNR\E;;GN5:L#P*R#H UPGZ_
M853_E5&YE3U:-)R<WHR);[Q;.WORDXE,%[R\P B=9E!<5NQH\'57SH#A]X:A
M4A(K=IU90@,8:J7VC4I4%5P6!L,,MH'#O:$[QJDHWS-VZ=<,E=P'^4D!6E&&
M3T->I@P]5%MAPPP2V7*FA; +(9)4KL(I!@WQ^3U"9J:B3#_$%S)0^3#3%70$
MB.D"8 ^.5"GL)/'U="H )U6\)[<"S"B8Z.7ISAJ5VLU6MR&5]'[AX_6^&ZXL
M^E[%<M-OS\X0BP4@]I:'D, 2?-"20?[Y3:'H;*NY.7%19=4U@])?VYYBFX@I
M)MSH#]+WPE%?_3ENPI4NE6#T]#S-]Z-7C9&>9LDR#T1-,QX:(UMHA+.AZ>]!
MKLA8#6G,S]98C/"B4%W*$O1QFY.77ZN^9C]+I_+AF[F&Y(>.;6KK+;%DVI@R
M=,W:>5-)P[_]#M%CZK^1[RWULJT%S]PA,B9?QNM%*<IPK3 " 9DZB<795XZ<
M,-S:]S<5?^+5\7;W >^S2\L_([N0&&-#;JL_?G^9EJRT%^WNZ?CQFCI=\QNX
M>5:B5F-'&D+SRKAU(=S+968L24TG$BK'RP/[![KU6:C9H" _R+],D@G6*:S&
M/6")7+H4VZSJ^Z]"[DP\9^;5#4$-B^< WLMQ=KSWI8>C^Z3CE%./:;[/E@U<
MP3F2OJN!"$^A*L'FNO7I3\?$>6^/UC1.JEHU7S8I96J-C^AX!?RT>MV\TGQ-
MD<B"-FZJ)7VM+14)4R^?B-R0+5*3[%T470UB,2=?<SMQ;'1[:/PEJ5S91VM7
M)#?FUW\M@@'_OYA8?,KB8,<9[Q<B_5*AO[+XM&:CX#DRN5GTWEQY"#& E !3
M+W!#UGW_4K!MZ9#S[;O\0!%#ZEB3/BT]U9I6]U4H_XT>3K;SKERB-"8@XH2S
MED&X_1U?.H+]28"9Y=O[?1E4/#)% OQ)Q_)G5@061.^)"R5SE2*VU+O@+>:.
M]UH=-E]KVQT"<3,7@)1MBN[>V:&@PG#0.X(QF4X*ZTA82M\ER*>EJJ4U)49+
M3NBQ=LY8*M%5_WEX 7 Q=AI^#&8CSR .@RV1I& 7T+DA!&R :#-K ?D%_]=Q
MJD6Z>6;KO"W&^R>S/JO[&W69$*>QR'+788]D>]^,WX@V);0#D@Z?TL8*T\%Z
MI+BAYJSG=-T+IL%:0J$T*V>VC[D9RG8)(;]5'UV^KXLJ)TO!_Y OX=L6F^?H
MC3#[62ZJG?U.1=.6@CY3O8FI0Y^NA#SHVZ"Z?L/6B"*KA[%^:3\),I,N]PVX
M;9T#3LTFF!.X8+V6OH+O;MQKHVR\A+%?\"%$U6#/!2 *S-6BN\QT#3]#$.LP
M1]%65Y,7FNH.V]MN*>X/Z578O,1.*!^\[&TT#4@MLZP*K6K<!%<Q[8)+R7_@
M=\;\8I'</64])9;T;O&2\[^ZV-=>]0I_MA>L(B["\B(A'6N#>-$%8CJ8_@(P
M60\DIUJ;!>QR8.F[W]7OF>8ZGR_$RI>;C;UNU75'R=_['I[!GT+M)DU-9>]%
MD<+_ZVF5Y2M<6NB6@V\,A8:/C\7:-!C^J8$QA;]Z4<[O/.H^.N,BA$;=!1IN
MI% %BK7P.%TI+(#94/!#&R,50118 E[J_08-TANRSSQ?<PA6Z1/SX;_Q[5*,
MR&^^DU/#=L294 [#!>"'/)(<I8?O)].-7 #N.'4,$FAL$)LU%:X2!)-X80Q?
M'H&)*(EQB@(Y("]OWRK\X"NA1W:NB*LWSWPKTX=O_LSPIT_W%\!GDNX<HC-4
M<P%@VOJW=6X37Y?UFO&)69UGF=%=76'7(H!],G3?  K>I82_NRF8"P"YT>:_
M=E\GQU<=C%H#MJWA-]DP]5&@Q0*F140"WST,,HHH#^&(E%/=(8#JIG0._*0C
M_[P,,3X,W2^B%;[BI5ZZGTF,P1Q$BA/-*0,6_#GB1^]\(+[077^DQA)B1&QT
M^'B9B<J!FG='[T9<8V/:[\SXTI<G7WS(='Y8IHYW<^4#I9B*!3T,:8:C/A0_
M^]A+[C'7E*R(F5K"([N<U!GH*9G.2*&4AYDH@!&Z ,0Z)0RK_M3:/IQV3.CW
M7NVTB[)/7>40Y^!?\5RG#'FQU.PC^I?A]3DY5P\!K)QT_N=5,<O9M"N3G\"_
MS77_.XT3,Y>01)"UV#;#80O6RXOF#'SN&[4:)'-^9-V\[*EJ?YXY<0K_:[(F
M,+^^UFB,>TQJR25]4S.2^@#3S&W[BO_8?LKN;='W%^)?W/_5["RIG3CWDIG[
M^WUX$58QZBU,8&G.V'ITC=EEVKVL/ET&N90@)]ES> U]#^&D"CU&X^\!ZFJ-
MKM_'IUA'R!N%% DT/P=)BFTC\??JNZH7D:'^\ZS5R/[1%E.?U0;C"/8DMD##
MY6ZAT^MC\O>DG//X"K0@J?7_\"E+Z X;!&X87XL5L$G*UV]['5R^%'AM<=5R
MYLI6<@EH*FZB&=$F!I?DE>J<%\)#@A5^^U&11T>&!J357HG_IBZ]VWW^Q.TO
MV@XU0]V.K&;Z<-*OND"WK=)=6VHK/F)K.7A+.#DZ*J_#I\WE&6(&AQ*,7)%
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M5#B# KK?E+V1?9^<)^HCK!BRYYY[C7)S6\=R*V2[J)+B A"YA6.^ *A2#5X
M+KG"<!-..!BV%R>Z$J\KJM*YPI."+=8=-\_!#G0=<ZX;6L"?3N 5L+9'8IO?
M1S3*N!_?N9YGR] G\VD%S.3$0S/BZA,48% S<MQL_:E2O, DY^GGZ]7T"O*
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MU/<Q#X^1KSK*8:21XK^*(D,F1KBU:*\$:2D+/JFB&EO0*,-[MC\G?V8:S0\
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MFD(N77H4XO?C3P"1JA(#W7LC'JG"93H4[0;$0YX9*OW1T'I0. /_Z58&M5K
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M0-]BU_4$-769J:EU5@+CE-4XD9TXF=YV%9HS.9N\N)WNOOPVV=PN6370EV_
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M52\ /ZPO 'WCL([H\PK05L,6 G<=](>C;3!9-5+VM=T3O<9/"0"RXMLMQMW
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M(7B=:Y5U!.OOR])BZHL'B&6=D,-757P"#-=PY2,X[=H&SUF1]<5"_AR'5D8
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M<#2ZJ&3M%#W#\3]NYU-IS 'QOI45L[^WCMJ5'Y5;:"]SGIXY^YS"672[.2'
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MN9Y\[3'8.0Y_^PDB[SJ7BFU*<;M3O6I*?Y6Q^(Y^EL\7>%M)[=^%B $774$
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M7YX?D1@CM.<JHB,*SN F<#GX_V#OO8.:[KIVX:@H10$% 0$ITI&F=*1$1$!
M0%!Z"0I($Q ! 0E$1'J)@("B$*4K0J0$I(;>B_1.2"(B/:&$0-K)_7SSS9SW
M><\\]_O--^^<<V:>/_8?*[-F[_U;6>M:UP6_[.W?V7!7SL/GB^.2XDF>*UK[
M5VVKGK)=XCY%-%<YCK$-63J#6RKZ(E\0AJ;([]R[7^^W6I6PPCBAX4@0(%D_
M_<(E:->]8BQ_>)>\1T_A(#(CWB9>YZHCV14O5SAE?:&H,TO)Z;8%?%O^E,S
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M@S^8]0\EW-\>&:0!YF2,B97+P'FH-3%MV3_NQ71"9/?WB/1ES^P0:\OM[W=
MO^-99Q8Z8I=37SRJ0Z*K(#[ XRO((\]U%/D%\G9IP;R,&#:<4;0E^4@/>[A)
MJHB<1E;W1!_(W9H38@,;U=2D4GS]KJ0OB67=!NG,3AYJN;RYWBAV$8 S#97/
MP'<0VHFNZ'W<;1@;/#CI@SJU[PQ"/B8@0E&*_UY2_,<VB9^,@VW5DPGPL1QI
M T1F3@-_S.*XC@8E#N(.X@*KX=F:\4J8NZ^)TXXVMVO"N.VNV%TVDJVJ^A66
MVOJT9 6PFM5.2='G>OO[]W9_\@.K-%SV9CUNM2M/B-*H(^=S7!)S4*YVJX6O
M9#;89$C'L]P#%<$IF2TC9;WPZ7N;!B"'5)LH/0S>1E_:+1.B]Y>V>SH"Q.J>
M*1J #8+FQK548PQJTLG#RKDZ/G#)IW7SR('[=9H.O!O1:XX9D5,P1'>1=Q )
M%&U>,G0US&*Q)$:%RS/UVB5>M^NO;I!;H1:@_'WKM&]O'SCZ/W)4\57"(F="
M")9X8 =K.(@(Q0M_P5?4"*IOW2V3?2,+_6TJEESX)=W@;/NJ)^/'RE.KO(7$
M19P2X0OQ/19T&BPWA4!MR1G>JTWT&6$'.=H/,&3?TA5[+/=^N*OCC"C#]'KF
MQ:O#6WW.&()WG^A>/>0)=*[W.^-R""\-\-G$F@; 3AYSE@S)=:745)=D*W5_
M6WNE6@E(BQ[/J=3WT)!^\LWQOD,UVI\HB>J <X<J8':Z&D?.A[K:_?RV4WC?
M)^"+U^Y\3P U39HR?^/EPOG0$0:;Z4A)(G 9R.\-FW,6H?/I8(JA"W0KISC#
M/U"U;32D@3,J@RXAG/0Y2U?D'QI<O=K3 ZS;::N#S$X;XPX[H*>JKX8F\M>-
M-<D5/F5,NU%3+,4Y42H'-?<^.,O.YMU'.M_U634[M&$9QSXS_,X7M:4#F5$-
M<[96\U_<W>H.[)99+"W9$KKJ%)WM &..[$6R@>W0\)D2S%)<&1%D/X9HQ'Z-
MR#9M'O\=^QL;">.3S.:7>KS06MJJ(<HEN1F(8W?",VY"\)RM.C*C!T 6YXT7
MF?VM#8BW66/2J@2J8Z/8/>,$SM++6Z+E$>.VSAJXB+A.=D8?';X)<MO#KW-]
M7DJWYIVL)E+ZPZ^MLY=R^56'[#WZ-4,4759(@7B"9F'Z341;Y!E_LL.*XP E
M\ZOA;T./LQIB61^OI&#D]@#.BFKG[RR?@\X(]CA74Q ZXET8HX+&:73EQ'W+
M'W7B^3ZPVH[?7&)L9_UZ3B7N-\L0'E%*J;P1<".<9'>SXD;'M]G7&Z1?N3R7
M6,K$FZBVIZK4&2M.OT!N?B9)]I& CJ%QG3<.X_F[=)3QS*P1$=_C?_K)]\>T
M/);=RG)-W@*]=5D-,].J>N'TOK01+MI- [B/Q.G(TK70UBS>!S2II5#NU<"%
MF]09^.KLM:?OHT/Z\UZKWNY6[<KI6.9>AE&2 U@#[Y$ ]/6//OZ=AH[P>3 J
M:_:>T&P\8)[CXQ.1\SJ5ZI989./]ID?,Y?+T8HT-L!:\,+7F:F8J^__I&IE_
MC__%X;#O,?ZL:RW7<-2"SQNJ91%%WN=5$)/5E1:R3Z[UWQ%.ANK9!^_5;063
M++U1U39D$=ALY'D:X#6<Y+,5Z;&SI"#:MQMP:%'=.*0=<.A=P"/IN2TQ9O,8
M2KZ&;(4?2]:"B%QTY=+C[6,^$[?LF]D^)-31K)'[@KDH3Y]L52A,%6EQH0'B
M"D/KJ GL5/,A&J!;ZI]LF;+9Z1WBN[W[.C0 ;B=V'\:TQGUL'5=L[WGL_J/3
M^ODUV>N2HP\ 5U<6"WD(5?..'0)=3;VNZ;QO%&^DO2H49!*MA(^8$U\8)D'^
MO*$!?I%1Y$?0_V@6K!^$<VV)1$ACH#.&R_Y)"L5-/W!RS9F#Y?4?[C;DC0*9
M"@(ND;D;D+$T0-5?AZ6\KDL(0_LSK#5$[/LV:,Y&+SH:0&:R'H> 6A./3E$%
MTS"H8S'@$5"-SO\+_J-91K":JR9W#9D'[ALDDK?_YM&OZL#O?Z<4FK<T6:'E
M>'KX!(93,*SRTW9C%39/:K/3F$7]]:)_IG8^NY&(UQ2:X5DV@'V3+Q"*$DG7
MU\QBWMDN>JD&SQK+%)UYI5VV*O0O0_#%HEP >5VC;3LRQG9FWNOY4[M9NBSQ
M.LF$J8LZ:<AWXN77@I> 39EA.KT:@IRC*CO*32=KB7M\!5W=XND=\0^,^LG[
MR/WQJ<LG[W#AI\G:HEW(_3N0W4A_ZG7#_V 9W2OC"3Z"SNEN1X3@Z@CV1 ><
MQST^Z&NRJ(_K5X89%>9?Z;^#+[7-[59?'#9[CM6^85-FLQKR+R;4^VQMMK-W
MVO*LZQJ,([(#Q "VPABI#-  I^;+?XWQ/DX=V\8L,=ON95Q\=C4U;/G<ZL?I
M[\3[[3?4HH+.FG)V'+O7IA7.R??ZRHDRQ6OB;J2'B>T:]<&C(.@U03D:(%^/
M!LC8@^ 3@?]D^Z5XT>GF]<"V)Q%;6"&&/\#S-6=3.#L;3(L1A0N0;XBF^!L<
M-ZZ-& B\<TGM;H)T0+[#6G=8-HR^VA&YEWS>_>*X73<=PF-QA5'T\-F=?@-(
M$RMXG 9@OX/WIW (D6$?:(!DBW^R[Y5.)5:1._+8 _>UN5RMK.Y]+3CQP.7$
MFK-O$74(R5H#BA_!S@//.G1@5NMS\ ASG4>_O?28^;TBFN+\KD?E70==IO/R
M,2T'&N!V' T@^9O>OB]"_OF#3)8R_\'(,<8_*5Q'BW^S(<OC9K.V+9'(^%%0
M+@JW#^6F 4:OT !]1TABE] _VS9?9K0+S4?Y9/8:_V6!T&M1D[$FX5A4/S+D
M/^WN/WT0X5SB0D@#WO:$#^_\R_R&EDUL"HY)_E<>R^+@16[TW&W*A7RD)O)O
MTN"O^@R_ \M7_M=):CBY_IS=B_._4O)2_\<$5?? 5'7>;MQOGS3SFA#RM(GS
MMM&)T;=E"I=WF2OXT=!-$NYP>?)@:R=:2^5,3' X7T> F)+Q[]N,P@+;BQ09
M[+_&&]CW,A^%0>U"=KB6+DF6+(,W3_F%CRQ;WM <N= 7(#".4JX^.5:\^.V!
MNK,JW"]@* C$V<)&U,1*?/ H(0[HQ3E55[\;8;AO),+PK"@$G,Q^Z\5T)_!O
MP@5T=3#?X]%B;]$20K,*M>KP?<=1H]P:GD,?Y3DAOCT9K*PP:I4U6C>_;XO\
M_[^8PD/K0XKAUI7*0^A+\JE/X.NXYI(X\/7BGL(_M46#JFF-BI]#Y!<J);,>
MO3BLL,& -K$X+)8-X5\6VM-Q?J,AINGDG'3QC_>J!KSOI)B6@Q]K*PV! _XN
M<S=])(.1I<V%JD!=95/N@8X7*K$9Q0[B>;D/&9[73N$I,_GZ+(G:+P&17(\Q
M2S(#82YY*EF\#PJZL5?[#9A$?X@@M?XNX4'TE(L<DYR&L=,Y'C(&>19LRAZO
M)8.64O9]=#%T;)W__<S60T04ZQ6&\^%0O0F;K]/_LC!,?Y;)@7X+CIUUW;_5
M!.P!5@+;(/'V'QM2ORPGV2JL/-HU+QZ1R]LU,Y+F_)H>GEX/SZ8!_F:'H@8U
MS\F=JXSU!)MV&F!V'%W7]KX0UK9TH7)T^Q>__=YJ'M8_F*-_<%EP^3+?_HN_
M+\B@JWV+5%?"&P<A.[(1);V% VP_*3ZI9;+<J)EK:6EOLF$G7I-C(,J?^]E]
M*0*E4HGK(800 W#>8?): F@9 ;[MV[MS./\<^JI[;H^?LO/RMO6HX$O^15#,
M9Z80#2^2\GCJCT6=KV#-9TJ6X=#@!!53F];G/A&B_NFF.F&;KU]_3.\[FY\>
M_M$C#[&[\R^F,U;V,?0?O+Q\J+- ],&!6FD QLW56IQ_[).@BS#!H*P_=ZNP
MG\(N9;MHGKS#^]?.N*JI^JA8U,%!! WP2<_NGU'H&56#TL+8V>LK@O?8I!03
M$S55']<Y&7A)7.!N?=3X":LNE.EEEGEGR+2,W/<V'^L6P8J3(3PA^N"K">Y$
MCV"L LO<>MVHYP:'\[=TAX732YW2Z1+6+NPWC4Y)III&G,*-+!]&Z["N*:ZU
MG,,=%$?[*#%F]YX;,[[9JB":OI,ZG]!M"KZ"I@&(=&&/=N(>OS-*96XK]LI*
M6)F?LU_L3^ML2<P_=\+^G^M1VK)<AG# ]_8"P:-S9W85C>HV-1ZYA\^.]3V8
M'[AS][R)\MCGV[(._KW+P9+E(2^</_@6>-7F1+R]=5;SCB73(X8W\5^Y;/)"
M 3:K/?\BUA:;5Q'^$W"O4_N2]RJC'U365S4DF_H$\.O)NKWAO72^ WK/-&RU
MPWRVD9Z56\\C/-J6N.M^'FALY0R;Q#]^/W!K,/4^VZ^(/S_W1[CP(_]BG5N?
MK63^ 9]_C_U%_T\[._Z+M_Y%7FD !B)&X9)GWH7:<;+)Y8R[.:_,E:Z%667I
MQ3YK*ONQMM1L_/=]SR_&SO\HKN;5S/%T-ZP*U Z,SY-HQC/&@SG=2WUXBNPQ
M&T,Y2J*G69B9ECT @:GA4W2I.UN'KNO2".JCB^IX1'W0O(6'CWC7(*D@_AG/
ME3:_\%JC WCJWZT;V5^WWS5R:AO"0Y;'U4'!W%KB\#^X=6<!JP3]Y%3TS>1H
M0=X[?JJI!PYH:-O(&3+_.%Q6B_>S[F?[)6/)/'4GU.!3U5<FE=J:0?#XOZ-X
MSMWEY<?0.;W 37]FZA"*M>DL-@S\\'.H/<H,+U:NU'QLJG1=<750W4-FV-SO
M8"WX;XG%O3]6633 N_ [<E#X@?DL!!V)P.X03>%@4=\ # S1 Z'DCP\*C21_
M,9P3\M.UVDJ5F2C[FR_W\\^OA^2.N9LD.(:Q W@6_.#G!P.\7XQ'Q5I7'5,%
MML^ NGNM0S3\RYDF>#OJ>QV]]IE\O+[.$/F6?$H_:IE 0@)"+KJY)!O*)I>D
MD6_F'/TS;_B/9G'IE/$ O8,*KJ($Y7&1*5CD.51HN'.EJ9Y!2[)^@.=@?Y64
M<%2F<.K-/^'6/!WLKY98B$I>$)_EH3,"+&=7[>0M>=T@U]^>+]QY_(=Y#<3Q
M]U2D.<;!X4"H)G;U+^*VXDL#G+Z-=SN\<#ORPA8;.B2BP4\Q ':@<LQO._SQ
M"UF_V]CA]$4;#3RG?7;'TME)^/*CC![NF9E@Z\=,[,L.P)AG4V5\%XNL'?35
M#AD*Z5+U)S;R"M@OJ>,P?6U.^?J2L\'S :WZZP:+$R<.XX^7PZ=SX=TT '="
MW8<_QC3 B)+?!T@6Q'YY+\]<(AW)U>7Q@VQJJ&+1%60TJ[!W!).YSV-?"!_R
MU_L#C8/P+N/U)U[X?;GXW#[YH[Z8VY$ES"QRC= WLN:<"^+J$=47:;AN>/]-
M_U-=@8V-$<;U'7@HR&1"C 9PT&ZH@>VXLAY'@T(ZWC<[@MWUSN](;41NC/P\
MP*F_MS;C7.3GBL,H"(3ZMQW:1]0V8P1D;O^8<-O]]GG"_U%=>,EI@YF.[_+/
M^J_5DSJF*JE*H;L[Z#AZT5\(S>\PN3%)^.#[6[<D]JK'F^]6SB>T;9^>,3<F
M(XB587A0)T@HDIL(PS2=NHN<@F])C->X%"M\=Y ; ^19]$'%,F+%:8#F$:[#
MMU_"36?_]#N6;!P\*\,[M,EA7-%M6 $ ,<9M-S5=15UG2HC48KUU1.@*@VRU
MX=7N$^^3U$.S'XQ6B%5/5@S:!S=/W(Y[W8]VFB"X?, 9"B^GZH-5@0\7M2&N
MF<0Z[OI2&'>2PA:L2D9R]G0M>:M[D=0)4=V:Z>W6'"\Q-7(V6SQIZ34K>O#B
M.UD?"V<EZFR8UTXWZ15Y9O,EYUF]O9&R:;T3M%PZ?^GYZ6$[ QY@Z(OI(=0)
M&L!SR'N5<,5<T-R3*H&7B/$7SYBOB8M8&.T5A08 TKOL%4/%H?5#8"?\HST,
M,KY%ARR'!W:%GGD/*0?-F99XMMT%N=0Z%)[0*L@0-)(\9T(#A.=)MR>]S?%_
M:%R4.7I,T>?J)3M/(B(8T>;)*G(G[ X:M476,;UBX?/#MN\SSI(-A0.6ZJ<J
MN@O(%GC7-D'&9@?@!>) !U6HT7VI]KCXR^F:F(A;C=&)2Z,'S9J=]N"08RM*
M18FKY$)]]7OW!&IR830("JN&OHQD 3M3)W\0&_$*MC@:(,D/[GR;55'WXGKK
M]2R3]_EI)CR/AW_?[P[; +E0^T!5J*3(,^0'S=-@!6PS3R>*Z<"S\.QE'JC8
M(8O-M3Z$Z+5LZZ.0LMW"/*6:8+-DE[R&=]U^3NS5?^ PH.?(O!H]<:JI""]T
MX=A.DQU6IG=R>31HX9R_IBN'#K/E:O[7ZB L V=W*".5A?EA&#9<@85L0H24
MDZ4G$(P/:K*M97_F+DB_Z;MX]^5'P+Q=V*^H#-NO]WW>BQQAPQV/;;J0%\#2
MRT)5,$XBS "WW"A+1U\$@JD<O/5CL7KP82-_MOI:VH819B1^B1/'-Z>6T&11
M$!KLKQ;Q;GWNM6J^[__L!3H':;-'3I#I4U0TQ.W65NS1MX0%G0@%FA.?@P-P
M*"HWTP^2;8W0?!V?QRS3>7]@PWWD<QNX:5-PN:CQNDZ(^/#TKLZ@];E/T6_"
M&*PA\5KZ1:'F1C\F@YO-1@S&MG"/FR?D.9A<!T[SY_9:I-_\=2#2A"3$4HK!
M<B05HNJ U10FAW!,NKXVIU_ KOJ<A5D,UI"4.1"8T@'(2#SB)+RF5/NU7*4.
MZXB/:IGC!CH% =E.L8LU#B1$NH\,):-#]'3F9VANU#N7:\+!O+SQEF\WMSY;
MYB0<<Z%W.+P$Y<>$)X/D+ ?LQU875T!>A\Q:'+Z/RA$_,]6%HZ/;&*PSP:OT
MMGY(;UQ&.'/2-/+83MN64D>5#(6BX6UR]X@A'2^*J^6_^ =XZ!05]8GY%G0_
M<B64N!FT?SF0 LX5]>WL7MD+;QH\'#"]-46IX)[[S1];][;C6NS-;FD 0X%K
MP<.WRWNOM+V[(B&0-L66JZ&O%-C83T%/>EL27YB4#1#PL6XDD8$JX(+0XI-%
M>H_)>K]:%([:A)$<(!WFB\1:=J(^$,U';?,):"09;D5"<MR%]OI4L?V'P]LS
M*\-O\U%N4D.:0GH6(,TADF,8$%$#88"@+P[CV D[!*CY/K"&!BC=12X#(:BY
M>J 0I$U7&19+ US6,L(=6N-\*>UKX8\03>/RD:,!D*=KG(8L#D>N7A*W%-V
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MR"TE]@'4C%VO=\?>*N&AOJCJI&3%&9]5V*PAX0<-$)M7CP\2;8?A4F@ %_X
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M\M\)Z(<YGH*9':PFX42[3%4[N+["R?M**<@!8%&D7&)O /%%Q87B7PTJY33
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M/>2+9TF&U(LCFQL4>"/)AB1ACO ?WE'KK5[\N/=QM3P8AK/:.6($2]  +VB
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MLBHV_6;KL(\KX1NE%@%Z':E510S#[75(8U#\@PEB^*&+U87BW;]B'L;'I1N
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M:QJTE9*,D?S(1P$0<^G//MT%(S#1MSRJ8*&AKE[4G)AH:5ZYRTCF"*<: 5.
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MA?^3<QS_J<._^7-KRY_G[=+#TX>LW>T)OU"Y,+J6%B405=_QK^F"( 2Z@ W
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MC78A.C,-IJZP7SV:I.H]Q%P>Q/"]-W'VBU3WI%:!2 U68<I:[*N9EY^\;'Y
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MDCOW&HEE%YKXAI<J%E?^M<4-C#H>= :R:6SD!&$\3X<%C29P"<LKHU3$%]>
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M5F"^=TR7BER_PKPB#V]NFTU9?M^\OR7X&A "Q4NEWQ"35W,B9Q"F8 GD^\4
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M2B8FP]OFIN:(X3CW&![]Q%>A+_B]!O2:UOC^2F+8,U>01NZ7?+D$UX ?!M>
M*_G2X"<W. G9 P&01!'!(NR]&,WY4RUQF)9YQBPC63Y#ANA6<$'<X6]QSTR<
M7.O4P=E=HY:&L*VTMXSY1ER[R;K@'IG"F_HD/'H-N#6-%3 T4XP1CS]0XVIU
MA.1T(L_'S/'155_PY"O7@#@8]!^7!!&*/,RC)Y,6$4$8Q@\[LHL:@_M6>C>"
MXK^]#/]2?T[[IM(KI)JBU=_?+\C:?%9G@M0?/U:5KGU3/28=_$^K:NDU(#4
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M!B3KU:0S74L_N)X,><?1VPEZF&3S_6G$,/_;X:C(F/NQT,,)C9#E9*62(BE
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MX9U<FM.%2S1H7U8AL4WTD*;AW^*"?3$ #.QMC;2'8%>W0N(NXV _[>X/#L'
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M&R/+PA]?VU$P<BF(0>CJF=/J'YUMRFS_DB_AGZFC4,- .*0P7C>*/[OA1L@
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M[@P?(P,2+086T9N"T=!#95S601V%K9J#.XI#!<##B\N@GXMD0,*CN6IP1E(
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M@ISHM<<HT6P_Q0,) @>09+RH1P94)E)RCL&N=&<K#VF"#*A>C"()X)P-T&1
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MB$^UG2XFRO"V/RK+NMPX=<VY^J%=EM"TP2SA\ANZ9VI3"]"_\:]&OII*]5Y
M<:MG+%:!MP_R0@?) ):+'8$V@\7S@U<:QA4-',X=^[#&[_3.E  8&E36OHI"
M(:T2X#9UK<O^RLLZ4[%:C/[),DH_705<9"(/TRQ\K=^)BR;I"FC=D[_UHXV.
M&^CZ+\L._[)(8GCC*^?*G*><&Z+/O@I!N#AD-T82FL7A46=;.%M*K'_*BHPE
M^S4%[%+U]?JH0[)< 3N\5=W6@*^G=:BI-F9&;#C.)PBIZ?=*6H1^1S;__JCE
MG*20V/W I1MGU$NO]_R\]3>60JX8?BD8:),L<$ R@J>!V'B<;V-4V-*BP"W!
MJ+V<".C32<^KJ"3][@VAV0[6MMFF,5&+$6CET+:>!U[%QM8_SF[<HV;QTOPM
M[.L@<U#5X^Y[ML^N4M]0.FM3@KX.Z!VJ_!LK1192J8YEPQ^>Y0SE@E^ IN]1
MU'2.%\8LAM48V4IT74U"!( "]_C\Q*]SJJ;IT'R)_6QQJ8VA.5QUGX6%0@8T
M2'+!#S$ZD4-=B[R5HR]N=[7:&MKJHCNOWWVYU_=)925F*7O'#9_^-Y9Q1!Z5
M/4RFNZ3L\PT-BSP<HL&![@XKN)M_'ZV>?55;6W?O7>QUNH8CB61O8Z-E&2UC
MZX[3G/BKI3(39=_R586TY2_0(UYD+L/_[3I;F:I32\(U"!3^3'9ZK1M:99^@
MH5.*@YH-@\IK^#4]A&W%EUWY;?3+T]ANOV$ZWSDU/;%F_^_Q_- D%Y21Y]#/
MX1@HP_%W'C#W[J^TT,L;L7O]-T#"]WV;ZQ_9?V3_D?U_07:J$UH;O:V'@L[<
M6.Y*CR$HE^ "N]N9Q7G/0AXVY*K>C;GZ4Y^>,:$^*6CM;5>(S-_X75<Z-4_,
MG?XTPX&#H5D'K.L$T!44?:J4@<2WJ"%LQA19??A.OR2+ZG(FI-WI$\E.6<F%
M=CS\<U3+KV@+8@:!>YD7R&J[43>S6AY:I3!CGJQQFR;^W'CZ'?6W"D6%6D\'
M ^W_!J7X<%+B[6U]RTIY54L?1XMG)%CBA);W./P39VW0^6[*,_R[.87-RNG
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M#0G:(-DXA3,NCU\FNAQKC!RJ-Y!',@N-WEAJ_]_&_@<#>MMF^/:4D57&[IJ
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MUH8GK"X*>,X@\/[8F0!U^[JQ[4K9)Q/):[O*03DB:2H1;__X.DL$,68<PN/
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MQWHL#@+J/+Y\=;^A=<-+,;"A8"G36UD%ZF6?:5C0P+5'(Q<!E3NZQ >_$37
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M+I*F$%=@_"YQCF? F.+5T5+:'+.3ZL.ITRC]BR)ZG"*2*I<O)?B;YT).NEZ
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MGV)D3.M$_W1] *PF@IWT*"&/ <]QI7[:":O7UEE2MO S[=WX:;_2IUFM6JN
MB8V!<!1/&]86MX>E_N3V!B(F"^:85_<0@$,?B_/DS.Q76?+BD94@9_=)Q%(H
MXEP-GVB,J0E].>B-OK&YGV\Y/]T8LJIM#@T7?WZ:%F^9O,K-?4S](B+-PV3G
M,7?Q3J!.$4$;LQZ+(1UV#A1:SD'>C/?L]V<Y+CO.LQA[AG@U*#1WF73 S EV
M6/$4["$E;,62[D/RVE-58'?J,V?T,36?3)Z%[.V\-5[S;7C$!=->&-/TU<:W
MB:NFD6BR"F8(AG@PEG_)/8)Y"\85VY.JS!J_HF;:]57PP5]UX;UH^DN>.P$3
MON>:9$"+&I2>#*!%/*.@ *-%(+ZD<5*MAPQ@^D;:2$6Y$Z!6?G O7W!;:C]W
MY9OE$V'S=+?8=\0X@LD/?"3.'R-6G50TZ>S+Z1;MY!I E_'[">[7YU#;+T)W
MN(C)+4A[)"?Q"^F*$YJ*8F1RDG\1DYFW454U".O875</%$:3I=^W_H87"7EM
MTZ;7*K%&NKS2W?[=CPAA6@J6^? _&RK;N!@R(-$/GT4&O*XN( -R$B;6-G:D
MS^7QYK@XK%9$)9IYH,"R)6]22X71*3%'GP?A).AY7R7 ? NXR_/O(AM6G=3A
M:D(&Z-Q!?@(M)H(.C%3^)>WE@XZ\?883HX5D7LGZY?1'KN01&$\T,1L?CE7=
METX^RZ;UF>C7!"2/R,8*NU<51GV)7M'&R5WH5+>+\DB/!&.>TD]?,QW_.:;&
MYI+B:=/BX.A-QVGQM4*=\U=Q]6)FT6'1O=VPW0^@APBW\;GHV@W?I^84+$E@
M:LJ NY1<M;3=V;V,#VQ205=T:VVQ%C)Z._48?,_Y(E#LB\:8[I^*9MXD \H
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MV]/R$-?=DM?LVME&(48[ESU@]XB9*&[(2$=;!^?&)YE=W7:N;/==FK&H;U&
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M$6T]O[+$1!O[44K(5',@^%JIBPE(<'B[VMKPI[J,6A=]?7W].]SE-YR5Y40
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M&H:S*W^3[L ;],9P36!:,_)+Z2'A&JDS*O$^R6CWP,0"?\VK<%N,1 ?C('O
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M(.))A2HKIQ<<VM>(E2C=8R>D4I25.Y&'U^/YC@%S?@A*B,Z_3D#MARV]VP_
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M9A"^2%UVV0DB5I!N%U-[H577"UYKB(\X-1C,#!'18=Z\!ZXS9GPR1PS:*MC
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MG"%LW= P.A;R00^3G%^=YMV#A?1 ]E/I9S'&(&:*]3!5V?]4>R>_DJU>)==
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M0+*!/*<;W^NO[K0SOP*2A::S9$?=2/PYT2-^FULOUOCMO]I;$4P@\T>K!S^
M7#OIT+A+QPHOKMS2C(S;2+S!R%3\64:].S@K:&:/"4->0Z>U@SGPSD.76UNJ
MESS>K:B--0UR;]99RP/C5-3:IM4(=K8;/:(M\EKZZ%\!)W51:\+LPL,M?]./
MC[)VJAF:ZJZ;EL8R7A$X%ICT/U,FGJF(VM.RZ"[E)EYQ\E<2TWG Y "N@5^$
M.OE@J58VPXGW(<M.>[@,^D7DZ2_Z.FVBE259'M]=L%5OW?/5_;F#M_#4K\F2
MJW<?-F?KO+CXC:]?B([T#0]:J<?[8>H[VK@_A]NZ-KV^:SC@>_7K_8\)GMU5
M8-7,P\/[_HVGQ)O%(6YE4 5PZ#%)ERP+.3Q8C>HX!S!#<CKU5:9P&9X;]PLC
MQ5P^5IK;7U"W?'79Z!&Q%E\5A 5W@8$P#CP"W4+U&#E=L7=KHN99@52ES9UQ
M0+9)?X)0<J3P.:!UE/V,!,Y&8(SA?U2DPD GXZAS@/[3-CB35/ T2/=;3>-Q
MPEX[5M$,;T90@J0]&2L7JIXJ'[+V;YU\&/5N8-5N$O<L Z,CL!*O!54 /5]2
MASNDX.LY&K\A.&*D]A#?Q47F+M41]WJ6"%UPA;W9OA[5F6DDQG28V],,9S\I
M>5/;?^)$5?^S LZT1PWAT2?^&<A<8P5:^>P9A",$4%&:.9O_\ VS?X+@8#LH
M1&VMB/>XN&#Q669PE9Z("*Q7"P/$Q4Z7PU^P8==Q"6AOEI=/#ZW4FW4#EX9Y
MPY1.K]%*F.>*A%D2,F>Z41Q2&N+XF+6##A0KT>*-:]K9%"EO/B"6K1M'[]1T
MCW5 67H]Z547\K01W3;]-_7\[WINH]W6PE&5%#M-L^;F]W=[^QMT$# '^;7_
MW%GE&28EM_,739O#7'[;^8(X:SW!]_%F:PSZ]YZ&>HWJ-C5\I^7'':7><OP[
M:GV\@>5-C4;1".92#18H:!H*+K8"_ST+?2T=(C<[KC?@1?>HY'L%UZ)OYQOW
M,-7<P*H_\@0E/,U*8??!GDU"#)+E)($)7[=]LGYO0HC9L)2*R[$Q792M*L!C
MWTG-);L6Q[2;0KB#KU_Q[M9?"NP@JXY!#3 )3Z/O5;5##HU>Y?M=S3"5I?7W
M3@M&BNFMJ6IK1!&4R:.@NNG$P#70%9UBB*I9T+K-@BK7C<@G:=7ZGI]--%_]
MZ+$(,#3TLU?'V.A-(9VD%MP?XH,H\_]Z18R<@>F3NLF;U=0ZA&XOX?>J8H/,
MYA[K']O>)-I_RM]C2PK&N<C8UGD0.'&QI&JH% &T\S2;VT"2T)TMTQ)GS\!I
M\*/GJ$Y:<"5%,EBL1-'P[GTUES?PE2^IG-F*WS$57<BH,U1'EKZQO[Z>_XMA
MVJ6.SU<3'_;1_F"H3<O6Y9)?!UXDCYX#F!3P;\\!M#III+)F8_+ 4=/!'[76
MQ@.<';[78RUZ%[E2@II%88J(0%R". %.>-[6FQF4K9.T#%/=6UIW07F^*.K\
M?+_L+&U87-EV [Y2!M[^FRMCQD[SCXU%T#G@$C6VXDT+L)"HJJ&$]Z8X/VK;
MT%)KIKV%.-G==U<4$4NBJ&;QF8)EE1D*1VF_AZR!KSXFCR#G"<A:^'='PE/B
M_A$T1GUN5'DD>,;JOZ<%^1C8X7U:<0Y(J76]<@Y@"$X4P8(TMP_F>7"?,?6[
M,RL+=RQLHMT7=G9["UTY8M7F9F\+)<&V)2WNC"A>O6@HOFXTSXH;;L*74"PC
M[2$6U"EU#7+1+H G8,Q[?UJOM )G=#66XVFD1L#EYV]^O)UT= 8OK V< R*_
MX(5)K;\H1$KJ^\3P456U]P(-HEG-P7EHL][ZC(9,=_/,FCR@<9MS[TI*837'
MC=%;\)H;?]1Q08A(=R5MZ?7QO;1;*,5$=S+MP3G@5O(*XK0"?OP]N(K@333$
M CO!8=9?,0>1)P;.=J;+Z)%0??TDW06=V*[>/<.^N BS;6-XK3F%@66? PY=
M_P:U#Z:L'OHBY2A<\3D@V>._1P(?);%-)9,56@<)- -PS..*Z&R!F,[P'VL_
MTC^U\2=M'Y):GG_6Z/N^FW!*<VJC^ KTJR!HR_Z4($*>1F$F3F%WPLG,1GAM
M9*7UHA=YC !&;'S6(1X:-!RV'C77*:,I;_\'>>CA!Y_UHK3@7G1+(9E6_VY4
M%YC#DY<M,X-C=I&Y=O]^W\Y4A*>I=)IJW;?W=8TFQP]1M;W)!!L=C Z9^?$!
MX!S@=0YX>7P.T"08G26(DZE.2:229.PID8U5#^^-[>Q",/E[7T8M2J;5B=L,
MRVSN<7*>,B;*O<I'IBHD.0K>TCP-2;H$64&&&U/<3(TV[E"BA*=&8N#'FZV\
M[Y5K#0()'6F=W)YM^7\M9=J@ZX51=4MU#].]-0-CIM5T=B5_L#-Z(PT=K!!.
MN4%R[/4!ZS:W5!<BZNR@LR0&8FV9NA;:-=(>>%/-@,TCXDRTW38QZ;*E]1A\
M)0?WDZ@[H::X9A1I+X#ASRCN^^!0M%TZ*"A8^21E]66R&TN04V!O:U#:GL]S
M[U!*Y71XK:N8O"I=N;+MSLCNW8;1BD?5E,NF6N> =QFK/'L\+8/MS;QKH?5L
MDZ+]W3:O><?U=JIP3+T)"<MLI"PB?YL ]O'$=P.IN3T)CY_JW9/_B+B)"CR[
MD-3U1FE3B.HHM(+(EKYC:'/'H1MXB6A"\2>7P,!C[VLTKBQ.(/^/:M(]<[S$
M[T"/F4M_=3D$K>:W_0V:I5]/OC:<2H9GD2LHYCM?G2W]ZT\0;@=L!YL&SB(P
MPZ!KYX!Z-<0N:M>U+NB?A4T'$A"X%]1FKXZU^M8AIFC1:%"WE-T!M23ERB4
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MS%BFB)RVJ"X=T_CQ4]/L0RNA%N=('9E*Y_F$MKNP>[G)W8]R:=S5>T>%0Q5
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M/-AKB7LZHN_ZT,]&YWIH/)7G2!!_9%MO3L++W9E G\-=F#ML.+B^%SX'(K.
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M/Z,,[]YR4S!%^=YC:MQ*+(+GG!O_(%Q4%U6).19-3$V0$:8[27#V99HE#M>
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MDC@[<*2R? N<0%U0"GN_NK ZO"OZ1<+E^V.1<>[A.Z%GZ2Z].2SX-]5#<(Q
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MQ975E_OI?*K:'T<1;WC*NK%?F-]U\75,5SBI:QC'M11:.!T]^A8[^O5;["/
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M@0[F+(T@!?NFSD;5ONC%R\+/['6UH*%Y#ONPXK(G,[-92E#V,11-GS!O@+R
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M((]/+B2/W^+*W(0-5-^!.$SS=2+!T<<^"YP/[4S#-87-_G3PDQY0R?%JN'N
MB9TYJ'[@;^3%QK<U+N0U(.[Y_!KS[W>I#VW8QD/Z76,[3&TY2QT+[>0XSS3O
M3.U#J6OPZ:"-;UG$4>V"TV;^X+X'@P]J'/,L:]YP/XJOHQEE<.B]W9<2.E\)
MLF$U)UQ4B?K!N$\Z8V'L[7>1AE-K6P,=?/6_^P<@GVVIA,]"W'7Z6>I^$)>1
MA>8YB47 @!U R(?$G79Z1)R>JZZK79.1O[WZUJZ$3CG6TZ/-56JM(P#E=R0
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ME^38PJ\!(C=LEHE/9CQ<ZIBJJPO7KP^;FV,ZKORJ'OO(^F49RZ.>\M N  !
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M$#<D1\H&]B?[=F-3^UR#TGJ[-ND(RTKTIK-7.G'DK1_!]X+U-^!'C!M4(=>
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MNQJ8 X/1(^CIGJKZR:TM7U2 _.@%\2M;I8CJ4",AM^R)T^=X9P(OS@<#[LZ
M1!(H2O6_*<^HN"2! WG[9_21-'&&FF.U6479J>%7- U0SAE/4BP/U>?^;DWD
M$F!;C>=&;W'Q) WDSLW^KF63?5A@6#;K%A=REY]5HI5U?V$G"/_*"5X);E<#
MMW/E1/C0OPALMK71<:S*8C*QY+!'/_#ZU %>EI@E 5R IYK(]@4\)0Y. N@D
MEY"=J!R1V1_8G7.Q>H8$N(93;"=>1R9VI/Q,MZQ)IQPOX:BN?AJ:?_]^V"^/
M,<D@J/9^5^RZF9G W-"#+J0+<J:-$:WRLX9(/0(30TOEGR19ZP<5V^0I/,GZ
MEG?AL4-<O=M''KH,?.:Q.$[-%0-95$@O?% RM5W+]7[?I=8,[= &-4N[6Q+U
M*6CM23R[GV<^=K2I]GCY/">8$>>W"(R2WVR2_X(#6U<^=)5=T:U)&%C_U!#*
MUG,<K7CQWB4>NEJ.@5<0C Z"!6J6X9AX2%V0YGJY<]>M;"+!E+K@X$$X">"O
M603<V:@OD-"-7\I]8&9\DCCLTHJ-#&F2QU* K8#,./@C+'W&M5Z&(F?>MCRF
M^#X>WB+>;OG3@I+@=A*@*FNR)%".:U @V<\;B$E2.M6[IC3$8S8*I"<**.[<
MPS _K,#U>WRUWCI!QR\D'U,B^AE34Q^]#5':I-X)DF#7D0DS>UX,63:51;YD
M1.=V'UN-VN$LEH T5D*H##:\3IJ[]'R;.)]Y"!-E/U-%%'?(JN/"!_*(6Q$$
M*D>\@P*[A\I_HR,*OMY/HRZ<FI7\,=79^!I_ER>O7D,@D'+HSL^SH;:&]%"0
MDTRD0K"XC4BWV?!1ORR'BV^%RNG3[T[Y^)^LKC_C/O&@UE$[XG"14/Q+7IFV
M6BG1"+=\<IY$KR5;">G8LHE^(O124Q'TH<" 3[E54$^^Y$>)7680S =XJ]XS
MO/.!H:JSHWO"S--D(9.-&L&++0@RP"^_O]L&#QS77N._;0FM&7TXM<K,TZ,U
M1G]&<ZJR[.V,01%I[M9F%$KM=,>^K*;Z&,'RX+:& /PS@Q?Q-^(;?+'8\J@E
M"Z_V.P#Z7=$RH1&0H'I0?3UUNF*3880$N,B:WZ+L*PR3E2#^#+"&LX">S;FW
M*>[_L+"VW@J04-X?Z99S^77WZ+*O_'YMJTQB1N0.-U:PB\A97S%*\+'W$3($
M*Z04BX%E>?&<0C3M^7&<' Y,,U3JNQAAGZ%($.;1 CLT0R=MQFB<[6R?6O#4
M5@G]L/8UR]$E(;>?1XM,Z K08AJ<L8ES.0C4A6Y!%)I#^02KLJ]<U]M,MG=W
MZ^OVE'"DG+HIE;C8%; Z<B,Y[=O*Q'Y!?3OLBE7BC.+Q+PAPFST $GE][,]N
MM<9(YS T.FU*)I5%]]6H?9^QX"* 6HD3$(3 DZ/7D+XK3Q9C.B?3@%DN^M2$
M7+<]-Y'X GM@6M]%S9N</P)_) 9/8""[2?F_D9>1+_6X$R.&V_-=KI;%DSW"
MX;"@MHQ%8@^3_^,MP6=UK0>,'/)G:Q:F*;%Q*S/W/R/\*[%[QULXJB7X](8M
M1BNRZ3;/KQ_.4FIKN_U_TK;<Y4-]=Y0 E(\!?*>B1X%+.[=F80J8<:/<?I8,
M_1\-2I3F'$^NWMN2."@BTI =B3"X%71\&7[.-W'&O<1K24^UQ!=;/!M-7YT6
M2?\K5T@:;S1GOFO8JT0%\"DPJ3=^8T<O--(&TR9[$JIC_;_S?J*514,/&SD7
M8Z[\>3K*G]!;_F8PZ=N:&<5ZBIJ*V49BY)'">2,(JB)EU<&.!K\Y7$^>,^T*
MK%COOZ2U5A/IJSJ=D_T*,&N@1 ._%TQ/G(#0PYVSW$TPZV]X)V8G;PJOM)=8
M7A?JX:'O*8A6L7+SO*PH!=,C 2CO8I 1JJ)8^S94,%]U]>A1?S]5CF%"Y\.'
MJ2E7^_KJVGF4YL9W^%*]W?*74<VSQNAM^R.%F%5UAJV,['I,2JMR0DWG4>;
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MP<6 EG0)JG^_T ["B=:2 ,MBZWD$9)3G4/T^^_\G2"Q>AD1(QQW'V5-:(M_
M$NCLZA&"0!N1^!_@G9T061#M0V=7";?_LA!.O)[XKP#O?"4+[3)/Y1\8N>YD
M?(').;\2@")2MFO]S^B" DD &K.EC?,KP9Q_9[LBR0*H]9\@\HS#T[$,%B?J
M]TF R$I_,/&M&I1<&2WE_<\ 6YI)@' )S 'Q+8B.!%C,7B !HO+^%66""Z@?
M%RF)SQ& MT\WB9( ]_FJ28#05R/_ 2+$EGP[I?Y=PO,^, *. ;N3 !V&_PN@
M?\?N05K0T#OD?Q@MI_^($H& _Z>Q^E] S4C<)PKTJV_T0/[G$9/[CSA1*.2_
M#A?\/R$=T#J%7_V'4O]0ZA]*_4.I?RCU#Z7^H=0_E/J'4O]0ZK^94N(P*AS2
M$;NP%)RR8D6O'B2->NR<ZNK&:S/6G[I\1S!!EQF'^FS"R_Y@#*98I%'T6SFH
M/-V.[9%OS>/26R(ZHC2?+R3KG&4T6_]!#8^X?C748(GXW__J[9_V7VVL:R1
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MASW%(CIE(A1-B: Q>5H;N-9' :[PH\R93!P/,\^GKW0_2R18#XU>RV-3-SI
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M:CPR77NQ 68_]R(L%^*J?9P_CZWPF7Q3X%M^(6 ?Q3?S(2[[E6R@V;I") E
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MW?:S%<(YNKK>F-L"I]!]OK!:P4\I2ZUXXSM0-IJ&D#]Z;/AJ'?QXPZ\Z<63
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MNJ@;C&[_":),,4X'#RNT2VX#P<HVNT)UF[^^?Z7]M%@)]T=QK[A'0/&4P1-
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M '^A%]^D1Q^![0]BB=2A6,:V%@ JF%]G.9'9B<B=L(4>>.IJ2Y0P%#?-?/5
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M>H=AQY<05_>TX\*XK_SI;XS+/2R42"-X7K_TW'%TH2,] XF^;LWXHT2%DR&
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MBT?U+N^8FH"!_@J)N>=&?'9+ST27"'+3<-(UPITIYKCPZYZ2PWZ^>^T:+&1
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M@/_2<XP2^.4P4J2XO2S2!7LR #LOIU/+O!3,[T;01"!A!#+ $X27]L$6D@1
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M%Q506+73F[F7<]P=II&HPU5 (+8W948?S;HA1X.87;P#N +2Q?A%$MDNZAH
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M[_,//-_ W(#K[B0>%1/42(LG;KC'VW]]HV[)W/;FZ9W^:[]*NR+UW.83J8"
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MAPHY\U7& G"6,K6V:S%;LVJ2^*J'-:S@A /=+CYF^K-3(#-4_$EI*;V9^"$
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M:/@-?I@@!=D^$>WRO[P)X6^Q^C'3[79A&S9==_EX@+4>7>\7FA]WZY%I-0^
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M!Z3-6$^YD;@LK9X$VCKPW1W&EIU-)^]QV)6O<)5UQ'WR'")-YJ+U1"16^[O
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MRVZ\-Q+V :)=(H6M1EHQ&+?;WYR1F?>14'^\<OEWP8J)"IOPFY(8.L97@G$
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M]0UEY @'-B\KV0#^*MFU_)_;L?]CPB'\\04#7AVG/64^,QE"-(KNPE"C\P[
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M8$_,ETR0J!D/;%TBK:@\A-X\W\3>(,;[PL)D,J+B(>Z,?NWWFANEC8/>>E7
M[2)B:EMJDHM4!:\Q9@$"%7[(@%P/9G^2 6]87 F&2+7&.DQE')=6MQ@E5^'M
M=?U<G)VU7_5*>-AC0%Q;H931@@-8.(O9>S$4%,!@A*M$V_:06-#$O?J<TK+Y
M"K]&$_KFY\5!#5IW:R^]"P2<P ;A\PQ8$]Q7O#3.46=&41L5+WT^3CK:U;^7
M4F(YP!T2=V;#IR[V08ERK]=_F0%7CC</'6UV#K @T64'X75KJ:E;@Q(^\A,\
MJ5[=J+K-.=CVSD^_XPJ'L6HI.A>;3801GKB /AXOF;,SO>V]]Y-NXJW($V @
MCR#E:ORON/Z?4B_SMMSY;31*?2;/=;'!N/<HX.6+5"NWKVB4I^D&>5),K+%P
M:'JF;+$7$6AXVG2OW8\,B(JX0!]'?:,7A2[U7.J"8+-=@*'KZ' 5M(4S>/[(
M[*QFV(_W<*H@634IK$IW\-8KQY0XS'B;]$]B!6/A/L)0QWA\NG\-1&!\NF#8
MBONZ J=W%D.>("A-+5O?^Y5^<3]Z23/+KP.:9SI/14?UI+4_PID@.9T'W^R+
MP'S*G5)1^)]B5<C=)[]XJRE,LD-G@+6<Z7MB:)*2TD/>B5:MPEK= L0@I8H#
M0-' -CN!R4N-NRR+XQ6!=67)!5M,3!Z'WMI:YI@6&*>(&[.0_C*?_>FUA@A5
M] T]C<67C];6XC9@FI/C.L,,E7+26,>_N?VB\[J=X-JN-[JKMS)+3$R_(L-W
M/P7V7@98J^GYOV7_#/F6]0/5#*,BZ*%A<8K,MJ@E4<OZ]&[_GWCE?#EI3#M+
M*;#UYI/%BD=J>BY'M%K$G';ET#D0?>7)*'#.V9PKJY GTV#Z[7"&A86CWY"+
MWTUPF'I'I\"&V\GI:2]LKE@%<[J[<8'&ZOK9K"JSL\2<3.BIEU_\>-4WNM,4
MQG+",WM24:QSN\;=NK#/('6ICA]7BI9!-NZ9%;]IS!B>FSG>D]BC=)1.+$GD
M4\R\DCR6S!J5UC30L9G@L@*/((EC!'8C\';0KNH)J85A<.>$2]JY77/([XC\
M-U5Q]OPW9,T^:7ZH>=]4RDDC"(KBND<L(@-L9WW=KVWE7&F9\CG;=+K+X,2P
M?6= "$"5=MC10=_Q8%Z#JXS&I968 K*#18?*XR9H>P]BI1N#;,+0VTD+VP_6
MK:VMKUV3?N-!I?]]D^+!&>/5A5]_XXQDVYVLE:@6-IR'#+>A\[Q89YP5IL5\
MPE>7"SQJ$^((:'B/FIR>91E*ZYO^Q9>L^GB <.U1J"SI%YP2CGR&RQO505LG
MYBUN9;PX-0XJ+*PIG/1ZQB O,1R_3PG^(B9'<;K1ND"Z28OGP86O7MW/71VE
MF+]@ RY^?GF#%VC4H)R_1]!L7/U0==/J=V%04B-''/ 6YOK%R:>@F+M]<5:>
MZ MF%KUH41DQ_:WYZJ+)S.T]0$'5YNM(:]:&*C7/E"PDJZ:89SKA<L&XVU\8
M_CK$9RKT-D$)-^3-(>XL+6^<PE7MZLC[FJEYF8?BW&TYLWI29<^2>7<._SS
M$(GHW7-!@7OB%4PQ[C%NK.NUR5.O'S".,VS\7E@*?<M9!N@*6Y[%EV.?$N/V
ME!D)O#.2HURS\\[-HS&M\#TMCK.D9Y>].7^^"GW-4BMF3<E-%4%Q+D,0*^X$
MG0NPB1+Q[B3!*J/2(RWM ;W4I+/@TM _&5*;>^]RF9FUVZV8?*/K@3]^Z-;M
M/C<2.FW87#^!S0##X'<D#Q* 5'7N[$[&_L9WV(JSURV678\,AS+4=?8*$E[8
MQ7%],-F4+L6+@&%[K1D0(%6].\X8M/#IN\^X&TTVUC6VY;3%;W?$R_\U7)O
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M18UQ9$!%2W:<WO=3(XK$\SVP!>D7HK;YGWO[;K[^4_70X-2J/7-OOK 'NDU
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MB7],^GW.')EG4QR0KE57W_H#;_#Y,I)[]L] W\M'#H9_GR;3B('9(2!<+MZ
M-+S,W(3S+0ZX9=#4&*E!/Z@5?S-XNM[Q]3#6Z;6R9;CW'=;EGP);9D\YEH_Y
M'5X6NK+]F20FD.[C:E=R]_2]T5ZKYDTSBH+SA1LQKAM^;Y#)#/<&D :ZZ2G
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MTWF%?K1<3I4Q+W"J7- ZD!-E@>@E3V]H*0%MQ+)A/MT>HWD)N1_)@)T9#L5
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ML]#.3<5CVE?]T-)5-)C-"&^D+XHXP%66N90E-MG &[.:JTX442D(3=P7O&N
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M]W;@^\.-W;.,2+W6C.]>+I/FPB_U9(;*U_^ N=56U\2J#U7=$3003.G:)W0
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M6?;?5)L,M'OQHO9.@.^)V:\G4N\T?09X@%R8.E1GYDD.7 .8-8GY[5@@_LE
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MO\D:"M]=*('/]:%;HHVV6O\!\P^8?\#\ ^8?,/^ ^0?,/V#^ ?,/F'_ _,\
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MD=_7V820K[O,5FZ'2[+)8.X3%!)_C?%&W[>_5Q*+[_H2^O1#+EM/0L+G#[!
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M-DW+<MG[')#68*M=;MK#+V KV>*:,K=I/@%]4'VI.2H3$-I*!=C@P<A'*U0
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M.=D!L8H6[?C_?"2LG@KP3(G1%L0M[YZ@6S&^#XC^T^&E=NXV'OG0U!-N)G8
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M<R?F_-?ZPJ89LPIJ])IK9]*G9(9^J2Y-*]B\J@L]I)C/>5.VJ(")6U42?50
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M,#S[O?M23[]*QB8^\$UX%@K!N-7!,F'UX+?2FTNLIN;6GDKSSDVQ[)-O=2[
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M)F__'O2QJ+;H\FM(KX6G<:PJKX'KP!A_% +YBFC?^-O/\Y%1B)":<T8#FY"
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MKE_441P4A.Q(__)YF24C+??1[CR'V<.'9O9N1 /H$],(\'FH&?KWH%RE;&*
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MNF739^L=/KO^]E?BM9.RXT%BW3H]K]2D7^IH)G_B.P#/+Z.YNZMC7BY U;%
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M1F48YX>N7Q<"*=>5VC7S-BH_M\=7>F%^S$X^ENH$N]V(E>8(5FLN[K7ZF]L
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MZ;\R^Q_LHZS71JMK?].J18?CI__]_ODC\/\O"MQ@]Q!GH:1O<>[/F1+H5(#
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MX\=<BS:E$D&ZE_#.!W5J@V#)'=TQK1\!N\6N6=>4J6UX/J:20V.P7*W.\T0
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M?+<FPRX84%%Y%@=RG*-L741<@[7(SH/HK%20F!G/K"'7PESN)#GU1Q_C?GY
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M(F#9!X;]_D^\HNZ#%EY@G0F!5B<7K B\\+]R^N=9_H63)."OL_PG5O\\RS^
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MEWG?[JTQ9KSP4EKI."UWU)WP<TA*3FZA9K#V]O_0U2$^PSP240)@$IS,L_4
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M*;TIHX]J_=(YETFE4%GH  7 +H!9[*7/-K688)Y H]RK0:B-0S.L3'WG:SV
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MH 2FK1)TIQT+#V* _-M$Z:RNJ1'/X2_8V=8:[[+R5 KT3O-*%NQ[ZNYV)DF
MWM#X]B.O^7R\4E253PUQD3T\%Z/AI3, ]DCK!,=;;,9+CT:"&ON:5]SL"W0E
M=; 5\\-#C[[\N?5']6W[,'1P9C4B=YE7I!^.><X+[D:AB^;J0G3Z3OQ.3!9L
M^S<TW($"7DS=.Y=D=I<K#L#5AU-!0"]8]Q#Y,@4PBJNG"@VJ%^+"FS[&?LO
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MGGG,NM9%Y;]PC.Z7&P<@EX%U7Q-7:XDS.S$%$['HI(-( :S,#A)C*L/=P=9
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MD!J0HO6KCC!LC3C6:7I3,:VKD/HL6?[)^<WW:3PS$S(L<?G86RGZ+_/:7E,
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MYW'NI^A;2-$CHV@GS=H?G=A4W?*?)&$(>Q>NMXV5T&_7\>$)FW-XD'L]]J9
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M?GNB7MWSAS<%A\A3E_%'FQ*B_VRC_8&_V: \N7:<E.RH]JN;MY.G;T_H\B.
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M<!X]BG+E^-V#3H(?466Z(]\_9&G7$&T?[<"KGT#?JZSE=:K.X=%MS_Z:.25
MQ"$O*9&,(*G-P4) U2/;[4QF;0>42P,(R?GA$KY'M3+F4]<T(2+X9OO.DYE:
M(R\N:#X#!SI9OJ@+C)S2'A;DHTF3_"#QD?W[I3X20NT!_&P7U"?4&HTZ@ WO
M%R1C#Q^AT<?ZI<\03KZI26D^3 =P/S:4NX_;['R2/(^I*?^%.^N0SP$%FV B
M*"@@7+>"D(*K7VZ5L?S%[PSEE?HF=)HC+E$HH5?I=S]WR%D5] JD>4JAQ=*L
M]<?)F=F1UBE_V7M]!3VU1I,G\\9J^RZ+,^^,&T<7")WBSK.DOVXA>R$AV"VH
MBY9G6H1:*N <LC5#M'G4V[4)+X+*>%GTBO/CA3'UM#RI^6$A>H(Z6A-OL(&<
MCPVSE<V\DLR5E#0M5'DGD>64RBD&H.F=71;P&5]DM6C[)G ^?-/36[VRB!S>
MXLN%6YEQ,WEU6OYA]X=<D]L6M5(IG6>A3VQ_$ ."7OPYP# +#S=K41>-V&VW
M!=:?=W&H?S9YHE1 XV?$H$;1+:.K@,P(S]$&IP)]J=#:R5:#E-K@V$$0$R&D
MJR-3<$CNA[1[E1,FL<K/=S!V/D:3L6#G"E(,^:+WZPND^]>;-T5B&/S=99V$
MDTSIWV==%OF@"J!3DML[)+&+SAV2KLZ<*6L4>@5**228SO=$FY,Z!XU0K(>8
M5I.#$V(+,Q,36NI7R%7[3"+VK')'0Q+WPK.WPT10LZFM4:]N]$B6YX&][\BL
MT_A:BX$Z&\&]O6+5-RGU .G*&*8DIZ:,D:RL4?P5N&CJF;[[FL4P'3T /$^Y
MY6\\[_YN#L_RSN?^OABGNG5A=*55]^L'7EF+YHXK6N>$+[B$C2+MD*&6X:UU
M) Y7[.;54<GRSQ+[(M4&-5TW)\4I4(5DIA"PZIX2'0?ND,36UH'&&'1N7_!W
M__W1J3X_5GC0ZNW.$:Y7L ND^4J;1%^Y\ Z[R#1@/1@5GVR\KQQQK>SN8X0P
M^2OT+(IXEW0=WG)PW!@@'#_5YGU0]UCFQ&*\9Y7T/JHT8.J59 <04SGKV )C
M0X23GLW%;@3;E(ZN6-&8Z)0!L4:<HU:375+$*FHYXKNW+7XRQ1(#YX.UY>Z[
M'U\WA1"NP2AJELK:)+9[1S\Q!>V3[7Q+$2C-HQ3/<0R4&38NMV= 4N7#LI!9
M9HZTAD%'@K$$?X5FX#$0N1/]%;:CYA/X0-OQD,=K2$T!6]L"80PZ@[LGR(VK
MKHJS*$XI^/[==7?JP6TFX>C7#!< 6   <,*Z=I.5>)T@=/!QZ(D-]/P+N6*3
M<9?2,5>KSVCA(]>/=[OB]8>&1,^ K]8A_[DG( [G_AJT!X(M\CVD A8"NI**
M@D;];N*JRX)JBV M5U7! G@;E;FSB9Z.WRD[:YWFN0R_U4T<3N]M3U+4\W#A
ME//>6-3Y::LU0871+54[3QYF68(=421S6[N-RY,*./DP\.W@#UV*(!..CA*^
M3<IQ!I)BM?]Y[C7>[7(NH.^AO,]7J0 GR?$CJ%(0G^#)0<1FHXP[_\'VJ=(R
M0E;,34ZY:!VL'<#N302!IBU$BV$#.A4TC+]+TQ9KQRY_V4,V<R-'-GQ2Z1IX
MJG+958AR_DK0@JOQG-M3IEU-QVS2K^\;FR ZT$8JT>H_L[;M,RJ Y2SA%!5P
M]Y!B6,U"T<[YY_[OD:LUG40/F57CQHZO-KX]R">P@#:Y<%4$K1GSV+L?9^[Z
M'12Z_FH[Q[>(X0G86L\<Z?E?G.6G5<&W02>H@"PB%7 -$TX%"(UZAMYO^(K\
M7G"MV@&5 IL=#*@E7RR6)%T$40&"I1) VL1.#S05XV]57:;XO]A[(2-96;5,
M1SGILA+[UUZ?P3Q5 7U'):6L@>C4F0DN6,B;356Q61?3D%9.Z5[97[PN*?H*
MND( Z2Z !^#/'_V6V++[7__F\LLU!=^4 EDSXYA:<JA[%KF(I6.;H+O95S[*
M]XC20SSEWG+ZQ:[J+\?,!I>5F0@X0Z,:/J'Y.#945>^Y6U7#",\UC5Z&&-/[
M$W0NA0O\@1?N7#H"_F726"=:6%3M[; MV!BD^4 ((NX?JHC$!AASD$Z(&MO&
M9KQ*L=/3N)R%4!\ML<O\/LUK'LIFPZ"*[8VWL['CR0;UF8-K>G[MAP/OR_;3
MWK?#&GZJ/S(,\;UZ6S0>?$KT]1F6OYYMG4[C2"K,\[IQ9/TE<B$5\-2="3KH
MW5+2!:7PXET;-5@+-<\EJ;QOF76(O53._[KE#0"[ *!#0?\LSIFYU(<A')JD
M"#')R@*9K)>&L'%+4IZ?[EZ>X(*^>=V,/3B6_,OP?M_3:!(/\Y#3:ZC$D!BP
MP5RSM>]>HA@)OMTOR7QZD=VUM1KZ9\'""=U/P4\-A.-= II\_SVV!OXUI$N"
M,[0/+((&MH+9-8,V_R;@=<=11^9'.9/'5R..)OYRL+&.H,4G?8++ [)FOV?^
MQ8B@6>P, +8"I0)ZY+.H@)][@4I4@!CS\T/U#]G_T9AS_@S#6[MN3X]CM_8O
M@T7P-ZRG+54-E?T<D8'\UVYA_Y:+!]X44_[_S!3:E?"=;TNQWBNI?YLB:NE4
M0&*X;"#\W@!$Y=\[_5],>&.95*+T/S*S7!OI,4%NUCT&R@1OLQ7_1K1)@$M?
MS[DL6O/QY.DX=>91'K7WES[>.1VQL_W7@W7.N+>5P"4+,5XR8*,5!KEWPS/$
M4UT',DX;XX:%%JI>V<<"42WOY^')ZB$_X ?>M+A^2;#"HC](J!K,2=@T/D&,
M=R^-=[JVR_MNJ:]OB$1^7^/^>&+9[;8<YC^9^>A.QBLQ6<K<1:<"[UIR7A-C
M'YXXRUF(;0@V5>.U&G_\R19\/L6L-Q'"=Y=QV4WY$!&)_&=X1.3_O9O7'J\;
MFT; /'3C]3?ATC1(_G^6<XA&4! Y>EM=-DB X(/]'&1X-E'RW>;LFVWA"B?3
MY6?U=S]F=4YNHHQ'J_^^H]4Z,U?YS,P[SHZ_D+A5-2M*A$DRA1Y(!<2:Y0:)
MT4QG29!I55YLRIO;9K,A]$E,WD\-P#"(.5[:^^3NZW/ 6+<=UQ&0_)<!KJ!Z
MUQ2]Q24A&]A9FI-W&(Z0_2IOV257C.FJ5C=OT<BA5V'<.T!\I@+L(6.9AP=V
M^+)*A#6A8@:B=]> >"Z$C_-UUB[KH7V#XY:=X/[@?^0B';FGZ48!1YR3?#]0
M!H1Q7"R8,(]#6>*@WT[>#>;:NJFQY>*$_KP$\7GA&1<7UY]Z1 4<Z--* ](!
M^<$/>J,.'_SG<+A]O7]U1,N72XUQZIN=6JN+\]S;-K%_.579HLZ;UU5 EX*B
MIY>6-U5H/,CQ(*U?XM)PF?# _B;(;TPNTK^MZD[3GMN[6*GS@/E+(8I"HB#1
MYR"<CH";C=$Y'RK@?5+.O; '1[Z<,4/2_)ST B&=7>BE_995B,Y_5)A'.DVP
M)0G$#\[I&>,;2&:HX',8?1!7'L&JS1?^=%!VA?3=3M2;#2R^,37^.=Z@L'2]
MQ>/%,F<T[]0KUT79'AVZKA[SD^=Y.CU<EE%_0\_&A]VVQ)N>'ZH.M8!P^L0\
MPBRPW>"]K7QX9P6YO)IG UGY2]?3,[WK>PKW*V</7SONAS\4RW8/ZLB1+[<Q
MSNO:(R75YB2%.94+KHM-+G;2DQ,[&M)AMB8?;G@/?.;'1U(!?P/)^Z7K-CHH
M@RO!O>9;2$=(F*T(00TWV-MJ*X275;_!Z[13XFXTGN6_B9-O;ZYTF_A)!_([
M!90("/Y;V+2H]Q'>FJ/,?<JNJL- ^T&5[F^I@.?;C%WY_DG3]]U=_>1B2IU"
MZZKMT*=#>/3//L1YCKW6[N -)[%!VL&%&Q6$MWE]!6Y4@(WG$V$OFCCWD#D)
MPYKL_S5E<**S3:TR)KZ/+Y"PN'OPA!S:*$I461.;8XA<536<VQ;O3 UM%[LH
MG_7=_:IJ?(G6H[JGGNFNI]]6$B'0WD-(%1401@+E80@A0)::9#^1[G@78\4$
M+]?F$\D<9G^)SLG;=74;VRL@K\E:=1J7# >OS>P9E2!Q-).3 GX(S4)(;.B6
M3%:TQ+XDEW_\=J>3V]R]H=%^"RLENMR<P$K$MV>HH!BQX?\ T2;Q3%:0[YF6
MSX_/[!$M9 _* Y_;=F3O,%5J,3JHNH[7<D_$2 UQX/XLHXJD<TU?_3[2).C?
MZ \==73BTAN^XLBYD) 88Z]2X_V:/I[.5&X+]G?QD:Y6#0H%?2_TTO7U!%8:
MD-@KVVCBFJ3G,H=@6P?BD@@AW>TU4GG(!">7J^J407!<RZ(YEIEY\K7VV-_5
M[.M:)5,+\$G%[YH6,B,4:?^S!C36&&0PRXTPTT\P+X\?<,N4N?3^&['#2V:O
M+TB "F!.&$&NY%G L+21$?:#Y?XF!,U87/4LKY-;DX5K'?N.820VC<7<ONUV
M0DX4:T?3>^MO6]*.W&27==0XZL .E[R!GNU-8V'YL.W#-X> %=NZREAS_!YI
M!MRXJ7\Q(#W^59G!7X; !^5=4QIIBR\0,%Q&"B"QZ0$&[2Q\UH2NYFF1A!;E
MJ5]+6RZ>YP.]E92DM7IZ!J3<]!48$UZ+10]1 =@4J##>H=K1$R\TUW> ?.)V
M?^<)6Y^4<6RB2,J8=@*E]R7IQ]!?=EZH4V]:20P9_@E[CAJ_"HE$,@1=QQVV
M!BPB0DB2V?>%Y9'V3J2I#Q67/ZX/O8P"=SL\-A"2PT![J0" *]*1)=3#WTAE
M8<3==LVEMW<OO(>]9P&@L3#/6N(R3)X\[/ "_5V0I)E8OWJQN6)6%SAY+#!B
M;VKZL*?MC+D]ZRJ$DR1%*W^!:[!S4%4+_\,VJ%)M[9"$'(]#+#A8+9)/B4',
M*GGWED%2QUW7M5-V469Y_Q$^#W"87L_-;+H]*=*@BNZ X/2M(()! :,DSSD6
M=LU7LV3+G;FE8%XQK9C'%5H]60XL;6(<CWWGQ08;J0"C/]<GKIM99H_?Q=\&
M,FI>#O3?>F$+SC(>TQ(^9U6#U0K OD1D_WTFKFLJK^<0WR_F!T!:@"%0/L(9
MK(H[/<'A^IDBI<RYM=FW>CXR %Z+<P#[4,/7@!.W!<2:_IV9[OMIDAN:SA(B
M+;X-TM"'/SB;<CRG8N4/JW!/#HII,?3J!TC?YQ&F;VG-\7-*O:YMCPK*CA"[
M\G\_\/S?]O]+^Y=#4#:+'C >T()Y-16 Z* Y73!AC#FG%;DC_IP*V%]FH;P6
M,ZH@T6C=E<Y8*L#6@_;)R>KKK_^GR[3_![83_YOOS+0U)IK"NJM)#ZB ;V=F
M*)%R:R.0AT.;/BX\&XC2K!^5&8S>5I-:PC&:JAS/A$X#[^K?[)-2B^U$C1T>
M%%>1DWTDV:=L_'W=+T0_%?-/?-)PX96ME5)WC[PW<@\1@#\D<3RU\6ZUS$^;
MI0).J*<4VEIUNPOL3^<+6WGUF/EKOG<34CIUR9[YA]C6-L$(R0):N8M#4<[3
MB \A(GX&>_BZ9$LHD^6TO]?YG,?=P@%Z]15Q_2'L;VWB2W6,ECR'.S3 %C)8
M".$J5W-P<)!3(%[&N"K-8$!B8Z%\B+1X#>W57>O]5>CSR!V^>LXG49LOG/_<
M5D(%/&/R)79(!YGC;*([OU2TAUM65_*DTGW0R.NYME V\G!L4<=M!0P94+9$
M3?1BO!,WT)+7CZIQ" I]87 6P1FMAT>_RT7+B=FS9ECIUYNG8D^\MO^0?.*'
MN?QYT$NS&,H@I-HO$O3"1AN,:XJ=%7+)GYCBBQ2XV6&[<_#*-W'R5Y',3L).
M493]0LT)Q/ V.XF>X#VOV^TN-W/2W]OTQZ>M^*UUW= E[^W+-EV[I4AZ D.;
M^IE:?U6%V3[1MOZ?7OA54RDKL6"-:WV6I?J2J5+#F6 YASU5R($)@<M[%CD.
M >.XVM5XS_,N;[+9KAHKQFF 5>Y_7=27":D#X%Q@%.XA+)S,'LU%(==2 1RV
M*$WO^O@&OTETHF5',,B@=O ET85/T71Z$",2QIV0?>4UA_8W #TIEO"#"K@N
M""'R[R')/.X0!,=OZR!Y7/12-;G2<]:5,QC29T$%5 D/9;G$2GE6DUH;:AD9
M^1<>FPP6;DRX%TK'RL7$1%PK86+IX=L^^G,(;&P*N&-)ODS8Q1W#(I!G24]F
M54SO_1B177U2XV1>]&IL2G!^S)TA8=4J&K?=&HV N<(9GR];[JIN;[(_X<*H
MHK:/TOS<#G^[9)4N&Z=TE(5Y1B.@!0O)&PE$?>2&^QR(R]^L"\H[PHM9>TF\
MQ_DU9&UP3J)'J^N9J>EI[^_!_5K>%L@+/F0(A?X$T<BIH"U5H"\I>?'.XR:_
M7ZXO<GS]4GVMB_@;PP'[-[Z4KQ\7SH/>4>@)40/(B#_G&</,T?;>SJ:L!L(N
MZ;,VGRJBCGF1LZ!3!.]F7XEGLZ6G'N#(.1?ZSB8["M1+"?R\+1W<Y[HY[R<'
M](]U.'"_H^I4)OE.E:5LG:':3'>HH($OO.>TI\SNY@YZ693$AKCKZCVW'!-D
MX-LYMS;TP/Q!O->#9/:S#BC$EA7E6.[XV2M']T(+E)/?:3_36M8JXSO2=&#6
M,!X+@],7[E_:[WOF[]>B+H +U'\I<$IW@*ES0&JH9+YV5W[9;3-")BK=,5_O
M"6_ZMT^!J8I3!6,3M$K']O^ITB&9:&FT'?,0B@)QE)*>>.:"2[LX<D=G[",\
MSZL_/J424?L@P&Q+TQ..RX,*POK#9^$D]@DJ ,\QH),=XJQS*)-NG>J2A4\F
MJ57>IP*R70.I@+<OJ8!YDTU@Q<QF^3.BOC_2M-\U2-3SBSK<[F!>%5VLZ+ET
MQ;59LVOF=W#Q.&Q6AZ1*HRLL;2""*"V.Y\2,VR@ 7-<[M]RZ?I)"[O-:-M&D
M7:<#J=L;=71.U[[$?616^_JI4&ZKZZ&.V0@\?:;6;Z-M#A8.NRA*:,$&NJ14
M-:3E#F\M5-@,KB87M43E,OO* (C'9\69%5':-(018[=<N6!%:&C>#BSN$!R7
M?%G<$:,2!FQ_^NQ(9H:Q3:E9@&ZE]!6ECJA.DL*+X'^,J OZVQ[CX;\"/U2]
M9XR9V93_5=N_5&@:E9UC:-N^([O-"34."B#LS\=.!';]>5_+_W[H4./BD&SP
M=<$E'[;/I,ZD!TPS:T-+F*(OP7K!6?B<%F5$6RSA:NER6/7/>":(WF#)D[H(
MI5/O8#6M.EO\_([\GON(DB 9[-2I%E\M5!M&,.T+ACW!/=]2VQ5(WGE-7U>\
M@H&]EUVM(AMU3AA]2SMI9?73U!Q^FK7._(+';=7#DQ],#1(U+2X].G1=0[W[
ML]=S9N=J$(V&?0M%4"(#B',5JBI8,EVK5)]@:+831MS[PF!^AI/ ]X\QH2$G
MXM76;<L+04X*0O>[$LT)O11Z!!5P=7=VF\CK2@7LQ6_52Q*NAI-2-V/)H>Z@
MO<N0!_YO6X\5(L4'4=:#XCYI]S[J?'/F[%9UQE[@%@LYT78+5;=?L (5'&R4
M>BS^TE4:!:Y@M+8RG\B5"E/3'P'8CQ -IG;8>[>]@1E(G!%J/)PH32!9XJ;R
M)6Y:/$5C0_UCC#2ZO&.U%$VI !>GA7*Y+3C. (5Y1'I.< Z2*[,YFI;$3;I<
M1 @]VY: ;GA[=S\YY#\.%=U&#]>'93@5CZ&>!;LP;::OV"5-STD)>UU?*\E]
M'&MGCF%I@Y\GF!*F5YJX!JHB^\) 5>9.N):K0U%EBP\]/!0/\M=VC1?B1^@D
M\G[%1""58=A<8-4PIO,+DDY52.9W4#ME,AXM/MAS7VJ\3!F[Z7"J:62CF1)I
M)@5LW3ZK6<QDHBJ4=?7K5>+]'S;RK+>2?;=EH%,3E;\WEE6'C>/?U:5^7TA/
MC#L"X]$'4GB#C75<6PL4%+8SN\]:7IU8JZAL,AZ,N_AL^=2BQOB<)K?B8[H5
MT(8G4<<*.@!GF*MKB%<D6>6^JQZ52#[E/;^0H7UH#X [,"H##+ZOI9HDU17T
MV7T=GUCCE"D;=RW+MA#ZZ-,F=O+<\:A9..G$;.RY*;!W%L']_H";L('$TM#&
MTS?C7LR#AG>$+O$'FB:4;@HY28"CE&Q&.\G0A] !R$Z"F#N11U6-EMLOBO>A
M=>LSX="+P]4MI38$1^WZT;NY.8:IK:+?IU^?=K]5MO'5I 7%S;UJJ%-0Z9IX
M;5=H]RV%OAP+V8!'V%[$6QMNAEL,\0Z:GGHKU[ L.ID[$$LXXP<JA[]&S@J2
M0YLD_)/,#U!S$J!'4C7J>Q<LP;PT_62@WH3#<[W= W)I,EIN?2AP,6SMR-;3
M&E1Y_0ZG$TY'MVJ$\7<'?^O_'>F2-V[UG&)UEPQGJI=HZOR]N-,\\38A+HH_
M=6@"NJDQP;Y!7A;:;:"<%Z6)(JYVQ/%^.8VN+B$R&S7Q;*!WR)KE"-(3N4AG
MPQ6*[/"6Y8 P:XJGSZWFI\S*QV8;[N%!++.H<ZK;7P@PW0%!C].E!1;:;O:G
M%)G*M3P3T*.5[DVL_EQ&C9D[NRVV O4-W^/R4E_M?14$"\18I$38QX.%,^N*
M3-"JN:,+1 5[1#G>\=\ <Q58.4.ZR&= (.-U]7 VR)"RET[N5U(-7UW]4GGC
MR+-R_GF4HXHG^D<P Q5 ;S:[3#X'Y:'1(#4D%<!J5@4)@[+@IK\D'VN'RJK=
M.+ZE86/AU-]V(^36[6</M>YT.%XWJHDCZ>KXC61(0._^V1Y"L^U6"6A]],\5
M09K5T$8SI6R2/"XV;%]D6!;.\+S>YCCDS$A2!J/T:W\AKZ^J9&>GX86HG$D1
M00>X70ZMW+#?1OR$1<[LQ"U2 >4H71IU3=H_QELO=K6YGYMV@4PH"'(..(Z0
M1N!$#3UESN^[7'R07V(-'LTMO[7.N/^)CY3?JJ/*R@2Z>?1F)%X&"^_ZH*HP
MO\W@Q$4%, LNCE^N_B92+:%6P?JV5TCL?@I?\B+?Q[>O[R"0Q3+MZCP#))O\
MIHRR57GE4?CE7LP?R-';USX-[,E._P1I+'N4X*(%?4@9@5^D APA[P59WP?)
MX>X=FT5=_1Y-&7=W$'\<INZ7HQ5;/893- B>?$R<:74ULR5_ F$SC[<JR\Y7
M]06:9KYZ&0CN''\<F'@_Z\A XV05074>I'.\VX8\25.PVD8VVO=P7&%[I7>L
M?R;[ICY@[>7C#T8S)/(SGP"8Z<VQ,#QO$J^,&:*AHER:^<*N$9/&N*BFQSE&
MCA8 -@[N;=5396FH>U>.+A">!/L&V8BF\6H,6V^'\F'47&,P6^?]C9+14>_S
M\=CH';9F&/UG A60GSFR3Y,/+3)-]-*W. ,&V6YQ.[O&;0\VI?4'*>023-O'
M:5Y+BG-L[#X(9'@9HM;%XUH$Z&Y>QE05.=IZ)0Y]F]>_;@'_"*E ?4 @GR$F
M+A!<K)*[JY*.(4QKXC,WI!O>,#;U+IU+ TV)CI9 IWFAQ<64":Y197X#^=J7
M&&M.J<[;CM^?/S5O%HU*$D-'D U&H-S^"C;#B\/5DN>?!X3E7&<2F1I-8ZRH
M P!T*^(]  *!])F'S8+<P]5C^PU(IE4NRU]N\5=SY*(,/$H^C[5J-+RQ9N3'
MOXD86F> 9V+&X(X%$JCP(/"?_2A5501W6%XW=M/N 2%%H&&\EW^5UV+"!F"8
M*UR;LE-CU7M-B4_7KP1)$"EH$7C:98J&7G7VK1A?K;00D'S KF6VJ9*KG?0,
M90*1>'0+F_2$)'<(? ]E)-!U8.9<E)=#@D#%:S_O<-5B[&5T/&Y)_\I-]T7I
MCZ"M)CJ<W/DO:'ULXWUW?_YA4<0_]AC[EDR9?U5LL5R\IC+](#[B6IG=0P0O
MH99XA21-F)W+Q7-%5KE$DDU<X_MU.?;Z8R5T.?@,7Z]UI1Y8WL@1Y7K9/ACX
MC_64.O4SL/[*/^GN J?<C"7XB38CCCG=83A7;RJ@ SW BWY/$X LK<)-W\UK
M@X?7-O=.I2Z%=TQ=[*[]^>.4XM1BF3HR4&[>3C'\Q.O"#4_S1!Y?=PC</06M
M+8FP5=TKK/G!PD\%A'L%T=/HE,,A%7 6#2+9 /]M6VIV57! EVVMC/FD^)KZ
MSMZSX[<_2^GWO\Z-7DDMUBJ0M>U3*=A5<M0>[^[TK-3^A?S7[W/^=6_SW@A'
M;74AZ5?,_8-__#_W;P>0_S4',TQQX(_;".K]MTURH-E)^$GDB@5-I+14HZ@
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M." UC'.+)#MV5='0Z>?%J'$+IW1[FYC.]&GOIT^8+CYADCQ<A4.89PI #&1
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M_2$66IBF^X%Y9L(OW2&^+Y3O(1J/NGJA0N9OCVY_X.MMX#V@H[:56I-C*D1
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MQ%[R0T^0EH>JWE+5CG(^;!Q32@:T;4UB?_L#L.>X1"NIW<C.Y%B#[GLO.NC
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M"+[#0?#P9<8%C&$>I-V"ZBR%/!UQ\G=_*G5P :RDM4A/*P3H#Z8'7#%(\*5
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MD@MHO!ASA[XU\P<DR_*^:(9[OI,@\XN&RL/56]C65=U!UK)WZBLK3!_<CTN
M"_"60#B)@:70-ZN##&"MMRJ:]C4>.2TN/^?23=/0O/J48#M?].E')/= RX"%
M2/ ]Z\Z$1H=,IH <NYHS,TV8'U1ULOX9@8LT?B;= D&Q6..3%M<_T]3[0_TC
MOD$,9>7<?S%]ZA6WLZDVL79/M7V/;UA((0,^@[&&.PXMQDKM$\&U8S'F<_-F
M"M,AJ"F6=4W5+UH1C:D'=%U2AG48/4O5O)BS)$V8+VP2S'SK;QG3Z<F'V+S6
MM&?@"NP:JKA7M**@^RWORF[$FX_USN\-*Y'Q-+3V],I1T+(6.#.,"6)B+=B
MU]P?-,<J1HE41^Z2 8NWHV<6'YT&Z[#K\<2Y Z\F?/A'*R!6[GF2_-$1K='
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MU"(@%" U[%9_KW#>R3^MJ%(I,K68IKV\MV+9ZZZ$]@3ZW59GHR*IAT2#W\5
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MYW%'?"'#HVV#B[T6RI*][VH5-O>$J6,U R/?KS5JF604%#5TM4P$AC!_[LW
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MZ08]U?BC*:8@D<H /O6%=%\NF[5/&P3^--A""W@%>MW+RE<4</VO_B.(3]N
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MN&@C'U.$!';2$P72R'-6;Z5_JL_X^9Q7M3:&P;AD\_?JV@T@"%&8\=:1%)V
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MPU(R+I('@D\:]4]A08$4=:1?V@A2C_4:HI9UJR!)G;L#N&S-]V2"Y"3-$W>
M=U;J#0.*O"\E0$=&3$:7TDO+1I"D ](:7JA]O%"\@.NZ5,>"U"K55F!5M'(;
M+HKQ*8ZAJ,\"=*O:VH^UC_:!V[#R_<VQ)N"#SO_$WGM&-?V\^Z)!$%0$I$M'
MJE*E]Z;2!02D-P6I(31I0NC2.P@JO?<B0NB]BG0(+=0D@+1 0@F1>OG]]]W[
MK'W6/?][W]U[USHOYEU6OC/SS/,I,^N9.0X<#:*BIOU(HGWZ0PXO+O4OOJ9G
MS&+]CYB+@2[2&X!=6[4#KO1"Y=1SS^1DZWHB0K!.Y97-R!";-JG$\S'/W(?K
MN&B$[62[?K5OR1P)USE+@SI\+T!:GOT#E\):;J8/CUFP=(AY;FR[5A$N#*O5
MGO@:6NVZT3"UCVA.6#7P#K\!>(LW$_'XRC+[UMKA@FX ;"P1-X!]!M -H""]
MW.7EPM%$Y V 1E;+"UTZX'<U5CT1XQ7+9(B8_CT^#:5U>T!@4??T=WQ_:MPZ
ML\-L0VZ<MSQ5,X87M]K+@ -E'.F0<26R)+49N4>]5O=P4Y 720".7TH@KEQ[
M%.H/8T_E[L;1!J%3M:B^6@L]:8S_CJ]&E>!/!EJL['PZ?<U8&N8B(/C/QMTC
M+[-8NPN!;["99=$F0I&&>VQ_D^RS)+0CIPO.:4$Z[]!="46X9+2 SJ.Q.V8Z
M/B7FT=9QV?F3TN(BX_?U@IA+JS^I1EQS[K*0!MFMX9'PP<S6G.9![[["(@(G
M'.@=[Z==!P=(Y[B'S8+QTSBNTI-X/Q3GY%7O^_QV_TMN/A0AJUZ,\\$ZHHTN
M.2P9+()ZS_0AG84B0@KO]450F0YZVJ2?[JI) C9F.B=^&:Y\RJ[[@6N"-^^+
M@60&:%@H^#F39:^DJD#['\EW,1HU> KZB3;3'=\\B!YC:Y/;_?,N9=&DD>(=
MZ(FACSM^QPW6\QK38@H0_CZ*Y_$TMX"ZILH4)<>[':^ H,ZY57OW2N(1FN%U
M&,MZIX1&3>(?CB_P69>I*M;_E%/K!MQ/>1[(YWL#L)@!OX3? (A\U4&J4:?U
M[%<5&$U5^SL/&\)5]7L&??_J$(G]L7K<KHRQ65\+5][!@&JC0"ZE:D$-"C\+
MFG+&CI/$ ;]^=9.G"-]_/!28B.C?6V>)[R3%K.9WR,K.I3C2?M5H2U_,]%<9
M"]:^[]*U?TWT[:JRD]?7QQSGV\H<60[;^VI$*Z0ELG,4C6R*-CN4*3%0!U7@
M26V5Z*B6ZYHY^"D,!$73CT>6^[KVYM!$P%RI]C;;RVM%-I9>%0KRXD&1DBS[
M.62 XT#>V4Y.,.V/V/[6H>AJL"L<5_0*"B+-9,J:9']N@:%2$!K&W\(BR\DO
MWV6WW\?8=,O+MD<O]6'1PZ56YARV XWH%VWOW(1O +@=)K5AS T D1Z"<(UL
M8GZ,'BRU1VCY6SB@JJM.A@WAP:M5HTL?FP#,S1L7C.)G4'5G3_K(1$B !-(^
M'*30(#^U?DCI6#.7_/B-<[/!6K/XRG+-ZOVA\8"[6HA#>N!7*P8P__H5X?'^
M7-W2<#F0TSI^1)&47/BWQD8<N%E!LBHQ3IZR&?W/V3O)[G,R&7VT>;I/Q51N
M9]U=$Y6@5B/N:WS-"UFSIAB(("U8N5DGTZK3P=DD<K0Q*3M&[J<BT=5OO]6>
MXAI_ _ :QG*O_U:7-QQ&P-']WD/&K9,9JU*U>$**)>J:O[N]8'GK/I+G1M/4
MQUW]M73&.%IL 7JKM((F5EN:/-0_.#P=</0+OQ&O]P!V']6:A:62L*OI0+@R
M7U)#/6-O )2XB/E!>9K.-DV96YM5GS+NSP5&>9&GT/G^D9)K_B4VY90C.G>+
M"@[9#'WDEJ#)&E'5]I3YWR];WQS@NP["NQGQ$WCC<'__.<-OS"STI>R%Q7=V
M5>Q^Q:BS.T[S8984/W]-7O$@E!/)LL?482B-&M L*'8XB8_)=V=/S7AF+5DK
MS63ZWW3CCY'XAX+<(5DGU!+[,@%_C#"U@QD3G[UT\%X6K0:DR.E;AOY&@6]Y
MF(;=X_*W^^EC^=,_"I2R4HC,"9A1GY");]^%/.)@'*%Y_W80;*G[Y.&@*10W
MQ4'/W\SD-E@NI@\A'HF88 *+SGC*X+P\&S%W&^9IO5]SAHH+Y%..6GVI8TC
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MW<-^O#\;\I)YF'3_W"9KCG9PC1RL,M])A0N[L.DYUXEH<'^0&?:I@KC\%X7
M%$OZG8.5.+OZ:X$^DK/]-70C[[R"?<8?3?6L'&\&[X<?3\9(VD3O\Y;XB03.
M6-*&IR "1/H-802)/Q7(M8I;=PY3@U_^<2>X =3#.L0/S6?V11W%@+$+;#/L
MD2@2[W'9+D&ZE;82(1-YF9E]#IQ/K:GY /U.H=9WNGMXU 3V.W%XJ.E.1PSU
M0=Y:76+$P-)HLKH7E4B3U,7S;&S@X[=#DP;BR)9GSYS]YB]%SR(N<YM(R/I1
M>:Y+5YVBZ1>D(O%+QVUTR(,_L+9<"O"KJ4NI=?5+<TLM594$ZF:C.AB*30A
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ME)<B?&\KNIYN-0E GPY1Q!QVG7A$1AZTB26K-K;;*7Z'VCLCD4.).QU^Z,T
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M??RV^FJ07(B.+',X3-)Q_GKYA*3+?IQSFYRYI:[,),]!YI1!MG*D[7&4\)4
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MCN->#G>8P5$=00\O>(Y-F)UHY';E#L>S>>Z&NC3"/O>[YU@SV@<W!Q:I.@&
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M>T3],87%Y^6CY57:8>(O/LK&ZAZ.SKY70ZO>Z"ID 0MBF_"G94@9B3447:+
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MEU=.7G=J]W,ZGQ%''G'@N,6O\#!)#;"?C;C" 0>0 Z?,Y<"A 4@;G'2T+J:
M'4-R31!NNOQRW]SQS<;J/OL.CX[O'K/\!^:OE6JD\[YA(X1-^W;LA-\&D414
M%J35,^<%:#L4A\V.U*3;A=RAQNG>[RS1N;7R5>:H?+. H.8'@S+E]@'0GBG
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M@+I,,6XJOVORF'L@^L+)4L<QV6*HU:$ID;HJR0J&[M-L@#Z]D"A,]V>DLH!
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M,.:V :>N4CR?">_G])TFZ\,IO /U<GX2X(JPYYQ&&9]'L7ME I1)#;"X>NZ
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M_VY0&$0J4?2)5@D-5_$(/?+)4$_4X_XIMW=CDX8G6F_Q2X0+W;CS<..I9^'
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MZ /[< FO&OAI7S"G$8K$FN+D4QL\>[U')AE- 2XO/HUK*3]:]ZG9/>[[6X6
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M\&8P7+:K;IC&5/Y(* /0;,$,E^ PI']]!U7:.16%[/GR36GSPN1!/P,@(L,
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MY_T%HT,7#AJEAQU@23(HLHH4JF(QRVH_3:PS8\=FB &X];!F+B(+;0NE<#(
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MT.]0O@&9>,6DG1C:)R3.,@V36Q&A+F::'WJ&.OS4A(GK4:[T =BN"0.PW5@
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M*HIEWJ$4>]8N2TA^,C@-5@Z/D?=%>7S?Y0['8TN ;1F5?_2P")9U+I6QK C
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MS<R4[ ?SUF7#\KP]L&G[G9L29]4]NM2!2M>8;G7XAE)1\8N81N)/$"DMS"R
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MY!ELZ8]\+_IQ<A\2<BU#\TK .D7FE=6HK-_YY*+0+ /+!.>D8^VR['=?E#(
M\\@V;<YY@[8M[F">=F\%DGZ\WT+GI58VVP?E08D] 'YW-Y?7;/:O60-'_WMY
MK@MB0XNB7PC>(;U/P[&%$WNUY IG9N*TQ7[!V%L+\E+86HK+0W923G:_$CA>
M0ND2Y0J-T@- D$1-D@K1#ZX"Y"37WB7WO<(@8U]"7].%QZ@V;&%^LG8_LI,&
M,TW6WM<L25Q3Z\M29\(568 0I$=F(62W-Q\A4 ;DT[-U']F6'K]V=V-CVW 2
M)[LQ$-;R2Z;I/YB(&$7*H"$8 $RVEN#7%> ,F@"'N7F/O_SWA]J9<@_:I:-
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M>L@Q,)3FM#9_.4++Y./TGTI!9X5^T[B=M6VMOB=^HAD-D5\\[.#?/YYV>SD
M0LI-/>7):!X802V/E(>'Z#]<J1;OM=O]-6.;R[&X['-^HY;T6R-FOO_2XP_O
M0A6@B#;4 W!9L [Z-E6M0*2DY#1F31AQ3<G%E'65VX-]0HQ6^I>R7^YV,816
M_J5@NA>#!H[!@"REM7MINX]'A .^&<$6V:L+^O+@JV)1N[/10Y!:7<^3=9_E
M3D]O8F:/G%XVPXN_7I_0_(Z(7>*=V,IYQ/#LP#SIFBEV_GY4]$+K-2N/)NFK
MP]?B;ROPJ0_&G@?I_#_^%V62['=7?J37Q>.I3G9M21(V'4UYKZU3LM9JV)\)
M^_DKIQ.6%?QJ0?C?7EW#J\N0\RCGA;]<=%.(MCW9":0I5>?O==4W=N84M6K_
M]VJ=Q$C'AON*"@KE]5DVM[LGC;E.0)YN2@-7W#_X]N^'1?+V0IY%J/?Z@F].
M^A>N]H\;?ZU23?:8FA/O;7HA,7%IH4J[8Y .1)\6%U)CJ!U5#AC?!1S+QLD=
MD7V90/+FE /<5*1 LJF"PU'U4V2>:(PJ>Q7B6F-=#8DW\(&I&DH(]>4N\A9^
MPKSB*?)A.8!V:LK:-:&J_GW3!ON7\8XU[;;RD'QSIF!$5/EU'%UZQS-1@4)=
M0!E.MN!:P\M,M1O7(!3[U-3J[K.Y]6P^]BB<^*;L."+\F?/F6KMLS+TG&:$?
M63\1<1L]Q$@H$V!G/*$J#.^)R'WNY]$QA32M6!B0*L5Q;JE;#>X.2 3QC[1D
MF I>EL^@LY%E? ;U0;,";<X3HDT3?T?\+R!B#J*4;U!#IFW7RW[C+!FE9&Y]
M]G1>LIX7,,F$C&C9U[654,&;ED4()+PU"7#KS<^-#19<G6I$\\U)%DU5E1E;
M8Z[\DPT4NSD:CR@*.>O(L/D8% 9A1?&L85B"%^\(:HT<N5I]Q99._W7VLLV4
M:.ML"> :NG3SYEUV=F[QFX;6=S_(OJ+B-KX2TT5&R6LA+)L./-12A\>:\7/E
MB3<-AI)O?-]*V93 %(1N[,V; U#RJ'^?*]>QTII -J5M2AM:/4> !3*5N(KQ
MJZR'YX5=B=G/,GY<*_V:/N7\KP;%%$V11A)8Q'NG+[QT$5 PZ2\EQ(B)WY X
MX]Z<4*GV*VE;,.W"KP6W)! ND#)PJQ6H *>[YZ\U(AKL52[YV>M^GME6^OS9
MSF_S,(-UJY^9W!%^ HI#NXW'ZX(!.Q(Z?F8O=]9%A'JN^.#- $$A4%OI!ZL8
MO_AYM_L,EDRUPPFS+\PJ4%\=+!*"EUEP\4A^4B?[>L1QFK8^)+[J45W:WKB%
M6\*6 NNL90]?!OE1>-G\:\7A^6 HL;Q=^;VW"">>LE10A6B[1]5KU@Q]6M;#
M:O<-I^77/A$D=ZWG>^?@L7OR;D9)H.A=^@;,W&2_L)GEU\9M?@#7UWHTEG$@
MW%3_;DD?'E).://+<&A\J;8NE-+%7T9PUW5@^^9D8P%XLLG:MTXK(-U(I_#O
M^/?/&VV4/\KP+/ONQQM;+^4'$^SG]5@&N95V&!]^?)#RNNL#:@;%.X&\L'2I
M_0O-D/N[KGAZ=QA*Q,Q;8MHWY#(3>_?O%WP% 8A![^\A8C8:Z^E&]=3IT&/&
M5JIQXI^V<7J"?8_JZ":^3;7>%,X5+B^1ZJ\RX>:SM>]$">\B16L?0.;2IBQ\
MSYW"->IV<G ZUYJFU]XEJFK%7AAA^S'WR(!_(.=<8WW"T+Z00<U5E%L+SO0$
MQ-I(C(+V''/44?:JL0B[^Y21!3,WDKG:ZF55?H'O.6W*C;U6 ]#"GY&)X@^;
M966L2GBT>0]-8"@Y*F/\G[9E%D1!MRGIOD0SY6BOT]]?2+.N.#S.2*S0.)&&
M76+:XI"^(OAC^"-?(><1MEV#-((^[V.)L.MS0#^CF;UG$QCHS9V9&?':(^V(
M??J%8]-<-<EC*+1,J(5 -=Y>6"<R=BVJKRSEU3BL'3355H]6^V3!U6<)"VLJ
M.XNF0C!Q#W:N<SL]OJ"S<@;/[GZ0IUD"=B6T^Q./JQHUL"J''6I[.F:WOS8,
MW;2+B%H(9]:^/3R2P?_4SM:(]88L?1)EF2"[5]/Q!<6'./CWR4$ZX;OO^94U
M-"7?X1MAM-S152*A;J#.E+6&ZX6@B:AW]@Y+:I6Q/VF<H-R#85-53,01%F<3
M:C:UQ>&EXV@OX;+ZKC.+/-9PYZ<>&2\^QQA=)VC73E]D=#D>UA68:5<G"T.=
M9MOUL>LB<FJQME3)/S.D8Y/-4K#_>:85$[%4)NB5FRU+O3_2?F^7 ?!R<ZK#
M,HFN< -^U7O2&PX*.=1X^M,^F7N^#?6=7JLVA;K4HJ.XE_$%C5/=E.T]4,"M
MR+X1-_)G5T8D::$5R.9V[I&O"$NPZ//6?FGF66SK.T%]8-;C:4W/-K(B(\+O
ML$OW*F5T-IF<$\5!MF]HNN]7E'8NKU1*-MX;?[>S+=O*:;!%CYX;]+<#;I;L
M-+'=,#<WR3(H@<LL$;UJ9U6:$J,<N^9B2DJ?\[I!E>[>CC]F2/[O9*T*YJQJ
MP3=SS\<_LHC5C]@_^5E%PA[E^M&31^@1;&GGI$_C'XE%*A[EMZ-)6%;7$Y#'
M^H$+YJ?]4OBUD1_05[%:$K;WNJ (=B?_OM$; Z[UV)X]X*6N)!RO/AEL+XJQ
M_X(T="NK"N-1%"OM9Y:7V_QN^D7WC]SG>)A5YU51^LDJ%-N2B:]=+_IBNR59
M"^YXZ&LDZ^LBK"0S<Y]%B7[/489%82?]N?1JXK6GS2IX%4"9,;'="2\[0;.H
M08CWCKJW^HY5O$TVAK?9A&:*96FUA9/WG=]D9W/WKPI^#+Q_?/6H-!C+MGZP
ME%UVBE_QROY@AX$PK!,BE 4F/FGY9;!2)@=!,&5],/1#KVZ0E]\U[X9B0B<,
M"OZV^"O'A6]2%9/06H@M.0%U&_J[$4-P,%[SZRS!HX$J,MQS,1^>*PQH69\V
M_! 73L""> )B0*J?=DAQH^=P9Z'Y4=8L?O6%6U-^RK=WU,*&-S8V!C0\I0GO
M$18K_8DK1X+$K5QX"#K(:R62SJU<<CIAGNHG/P,+?;LHFJ(9TV:\[?KCNYN@
MY5%IN_P)B.E?S%\(V-''1:6=^M*(;##QYSJ)-S?P"F..@8)$TO6<JT:[LN5\
MSPY[+_=W'E6WRS\L^O7/2Y\J06@J(4E1"A"ALB9WBKP^,!5:^E]59II6*B89
M9I;T)ASVA@?0_7+EP/.OH;D:.J1Z; JWEH25[]?.$.'J-I[Y,R'YJK[#<P:#
M]'0Q1@'&#J/4TXV('!> !_QN]>^%\"&NK-AWI$P@4+_GJK?$Y9N5;X0P4$N3
M@A+=K%\PGDTXS_AZ 45P8$O#D&1'END PC#X_)(\)LD![BCG?3;)-WRP5<Q=
MAG2;D#=<(<<K*M3F2G!SI&SW8U,.Y+?CD>9D13#@Z:R[*O[6WH%KTE=BBI1O
M%"21J=WW>I@HOEO:_5I&4!_T[P1T%E W!B*)SNH]K6P5WQI2=16O,-U.%W>3
MR/%Z8C_W*L?SD1F'J43^"M+W4!7A-E"/.' V.+1]U@[C*;A0M <KMKQ8]^C+
MOE:)EJGTZF*;3M-4(Y:@99!V>'.*)EVR#F'_:^YXRSE"4)&5Q7=B;3M=8=6X
MI9#IJ]-KL>VE7C6N9X^4514)/=VUWL=T'1,-J>@^98  +S"7OC.Y^<@1T^!8
MR;^2YY4C^>Q+:=+\M[/7FDSZO>D[<HDU>>I]<'3"N<C:JJX2TZ(JNMF-5<8W
MGG+_Y[Q5'H@8HO[LUEKFAW/Z:(;U6O A5!;LDV4+G"^0)LU@&3R7XNQ"IZJL
MD!LLW>*>? N./N2RUNF01>,NY:4US=L1_HE2M3!YE=$(#^OGWXLN"_?,-Y30
M?>3K=TW9E&J7_832H+H\I>[J ^A JK"NC,MHF9,SHG5J(R<0?&$LD?]9L=J$
MT80$]I(E6U>.01&?&O<(**2ILRX^1F5^4WF#\6[=1#52^30SG\W$2*3!3QNV
MR,/[7DK].S\<[!Y0AP0Y4(]ZDC!=)Z#Z.^E$S$5$D/4TTI+DSUOQC)0%N? -
M$;.Z9**2L?:#Q^(*TY(7.VK#-&"RV2I@SE/Z]82N'/+F-!H^2..O\IY9$J0H
M(^"6^(]-\(0:?U7FAVV-"<[#=]G/<V?'!<KF=,E+,5M;O'U'WX]4/)0#O+I;
MF])\_Z:&KO<(B!1)51<#!JN.065KN7Y.^[6^<7?F;]>]-/4,-MBW$;P'WT)[
M8%G,B:]47H7(^PRO3O4I([H'[)H*)=OK\#G$U0RC?K'">\SN*24EGNJBWW==
M!@Q!7H@7/:W^R>W0]]X1HZ\CGK]X[V@*"X.KA9ISOK>[D=;+<1U[C8+>F"I%
MN/:Z"'X- 7,A"OK6B(C2Y)XFS:/1]@S8I:D1>4@VJ[]R0F>H1'.XT^7KC^LY
MU__<992D8$]S@I+<I7:*-'ZVM4QM>C;G2>!#PLW,M3ZO9-OPL8G3#>AI_JVQ
MZ%^NMWNN':F>7C:MV.CM>,H,/OZ&>.9+LK-(R8-?M"HW9*%\Y^OG?2-&N>@^
M 24KF.?M,#(<RP&W'$?]0PDW4_K&"L05YZ3J\VVR]$9PH20[?M9SS&3M66DB
M9B[HSI=V>Z)PV%WJ>$J[U1*':='$XY"V-GOYS>*<<\_(_@J+(OZ9N3_S"BTR
MD(""(.'=6S#'Q G(_01TP7NT9&V(I,CA!(@;3>?:3B'9 P/]",[5W1I9<E>C
MG=H#!Y&]2:8$U0>="MQZ,Y-HSV767ZWEZ56.+K]C>R-0;6'8H9KZGKV1.3_K
M4LI8MWPUB_&/@5J;T*J+FZ+]I1$=7'3#-(U&JF1-.OH$Q*RS,!OVQ"<LRR$Y
M7?QSTI?/2P;7GG$S,^-J12_RYSV5YNW'T/]1%$946LUN;_WE\U>D*8<03=V:
MLE13',:(B]-<TJ,, ::RO\L[.)) NX-XQE]W%VDJS;P.3]$@QXZF5ZR9)(](
MU[H7T*%=X=>T-I2_G^QK2N=&/1%S_C=! S>C.H]E]8Z(RV]*)K+D^8[EECNW
M!*WV-;%K^2H-6TKF3;#\L/8UQX\:@A"5Q\-X$5S\G5QC*F]".[1ZK76K CL'
MS^$@-(ZVXS8OM29(?#%EZ5UZ2.>B)NZ3,<=?[G \A.*JI^#+RFY4 8FJ+)WL
M&!Y#$KBI/T10YVYQR3C+?B3H0?6K17ZF[%F_SS)[!!GZ'HFC+!4V,T,@UJL:
M4=_G(MI.G>;)@ N4%P7Z*# U>5[CR]$*3E+@NVR3[L<EY"<W.H?M<F8+24^(
M2&B=UCX!"3GH>[U7?%7PR*2:L'@;*CU\2T,ZT"_PDY#=6TL]B#QBG<B#6_$-
MZOD(R/;H:F;)RW93$!%0#H2BXT1)>SLN@>B+?3MM(TX7("P=JT0O\3;<[?E?
MB[ETHO-VE__3)3X*JI2J6_3HA6F Z)N?-\.]LA[%V-&5LJSZ+GWBF7\=Y%)B
M"'JB">D1EM4'GI*6>7M4IPGIB47U,7O,>0(,CN[!Z2-WWZ8D"H:2@OJO.9U+
M/Y0&@HQ\(7<LV!%9/[L$U$I;FPI6DI.30R<W_=@_9SZ,._.#G'9C5<+JSD3E
MV?V #XQ-$WHBMT^;D=USB=:LE66?^>_4?,3W=$VYJ!;+N\;'V*,[7,C.R*/6
MN58 0NRXX0+$OE]F*2"24W67;W^MVN(76!YZ?EGLC.I\QJWAN07'UV[<O[CN
M,B;#H'7^L2K06+P0$.415M4#CO>'-JIT7F0I/?Z*Z]P5N1&VNO%MAR?'O(LL
MTY7@(4K"WD>-Y:B%XB6;"_I1\NU4S_:9\I]]JSM,JC(SWU:79.(N#OC57E*X
M[6)JRIJ^*KNENAY\ES'!!UV'BB4Y*_8% KE]NE)4-1Q)YO%F!97M3T[@DJ,A
M3!WS.*.49V+^G6F]]"B+G]R-+3YZ _*>YY<0"!/MUI=&X3#GZ4[B@^Y,N$/<
MI*-DET=]VI>ABVEG4_FS1 >^RS:_!ETMF?WU%JQ!9?SDSX*H[.,YF/F8JQF=
MWF/GPO7"(F]V \=C!^8T6P6UX3"2>I>B03C^+K[CBT<%P9VLZTN"TR%@'D1)
M7],Q;YH)#5J^/LLS[E^VG3Z\]%Q&/ O&(]>/#=CY:/M8^//]@[]<=-\)Z(U9
M8JHZ<3P6R<N]5T5P?1;R?[1SIO]0]VL<'[E53$R6073,R9J0&I6DC"7+Y B5
M[$V1T,18PG1,,R%[=EEN>[;LQ5@;DPPF)A39F<P0=S$;XG=K3$=_P3G/SA,/
MWH^_WP?7]?E^KM?K^GQS0FB:A3ZDOS42&,L.F7^'7_%/C83>F)<P6>J Q2)$
M5_'R]_$GBJS'F@T3(8?O!ZU RNGR"O2AI7NZAJ8T*5J\/%L9>?20^!L+$_;Q
M8@DT4Y_2"6&V1H7 P$#R%)M8\]6=J>FBJ?+P]]-4=2@YN7J@:Q$*?0\X;A)&
M-Q!2[D"*"P\1A\,PG8E]GXK'2"9J+].'!N.\$^19Q3%JVN^<\TM"IXM?@\1^
M7#@NG V@N5LV@"MWA4('CRRVO1EY:'B0N/)(-_>6KW+2/N%C#@ZJ$4,RD/MK
M*Y@I86,B 3+5NP"3UXTF&=::U?U%A_[T:IW4UDA&G95T716$]\ '5-(='6[^
M;?K<E+QN#GJDU/GS-&#;@_\#B&58TPKL:R_Z55O7TH<R+)JFW<\G/L@:_,H0
M.W.Z0_:0F03RFTLH 833K6BEG/;Q9[$$L)E^=-ET:66V*@:]Z:$N O^B@=!$
MY66D]?[[=V!L_$OC_@@? :PIL<_H% J,#7.*=?U$TMJD85XYV1XEWU=NG>)O
MQ7EE6JK65]>M19^(]D<7-<;&AE213+SEXOC6Y5BSGC"J_3@?=B?0O\._1.^5
M;ZN>\82D=J]E3NJ@0HMK2D%KN)^,T/(GOM3'.V/D8RCJI8T@+'T$K&.JANT)
ML(2^<:U,/8>K],QGS\(/@ +=%M\VR69X%"KD479'4T14R&-ITU@*87KZS'A%
M^(K\$TEJ0,8,3;JQX$/]ZQK-L&EC#ZVIX\40Q8^$>XFV(E@$A0SCIJ3@?!E6
M1+W08QU-Y-;V\*=MN14AA88UCTHR8Q':,8A3((M?H-RMAP)AP,2+.T/IN)I4
MO/)G;W-G'7_[.7^$*&U=:ZMG^&%"FYN/23<[MH:K/;R/8>3"\?G_[RR2O'?G
M"@J+8+9323X)M&Q2^KF;G14^H=LARP6*C]9<R]_G/#CD')HKG04ZRLO__0.T
M\'NR-E;:G:?1AWJJP,ZK5&-G%[M];[P/[X<K]S0YD>SO2K='&8#7:CP-5*"+
M1L( @IFDP=1]^F77K$'XYES,Y03V&D'FVW+/YE:A(BG&:?),Z#EDH#I53^9A
MJJL+0Y@-2GW^8TY&:#VERQW&;*7H'MS5S"C 8II.HP3E7;+LW0H[A;SSN*(/
M13N72@W<C&Y/E8^0OORZ1"J??%@_!N>SDX]7YIMP,3V=*HX IAIGROO!8I?A
M+C'K@GM:UGVR0N'O&WNT66KM^T>^>I@_A;;8%B#U'GB@-_8G@'B<2/P?$R0M
MG@ISLZ'FV]( M4>A,XE>H&*CF%N:8M,2/209[X94K%<\TF=ALI_4L/D*"*Y&
MOY4G07T9[:719.6IP7F.M&E]OY:O_86Y_@"Q]<QX_]O]?>+?GZT)[:K>*@G,
MZ-3O=8F-9UV\5.X"9-O%WR:-WVF,USWI:5=R#1G)"1%R%(H7]MDHAA0(-/G@
MS[5&%VT6$F'BV,K>6XJ?20AT*;("T.C-\'%LT7-%:EDL@F>LEB+2/=K@LA9V
MIHR<B6/!7.&^;40,3M@SG*&#OLX-H6Y^$)S@6D;B/ ,Q01/ZR:K1RV_>D.,Y
MI@TY&<(!T++4QI);6JQ=Y6'J[A,,%9[_Q#=XY"M'82&Z94=Q;J,X1]\7WQQO
M1M)'D59U48<ENV-M=:)>)+N=MOEN!GLIN( SR&9NO6M0 $Z FU^U31#S$@_6
MHPP]TQ:..;\>FETXS_J3O>OBTO%'<?(3')(?=\W/E<&)(UYG9(4/6COPO%,P
MS35Z02TL,8+7S"^0[Q7XH$H1?$E^DYK6%(QKQ!+F,4FK!&]$%%ZNZ/)4/4#H
MN^E27XG>;(.DH95*S@RK<W^Z2G:TC*FU=QUADAM?/#$ZQ;/L_@5*,)(%Y'B0
M>4ZL &;+=/KA;FW7,8*SD:WR%,ESF9L[.ZJ]HEH%'RKT[ ,EI<69WG70\)_H
M2XG G^=Y4:D5(T3;9MWX5;Z^;)H@>]_C\CHOG0 C;\5S$ YKF+M$;MX]QFVW
M9\!?=LLK+/$'^.<,0@)KQ&%4E)0,,VTLOA^OJV47?C>PH[6W'NPNN?? #Z04
MG-"'4<"V]L&(&JN\RA6\* ;<&4VN"@O\O08TV7ZG,N=/5WN,5NN4V844N(FD
MNA,U"V);?U*'26K-$F4BYY]?0<HD''&W>O>'TD&5YB#Z <!R'A4#OX6<YX@
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M?Y _+3<5O,?X<7E#:;%9U]7-FMW*%:_\S"F72QE9\4IJVNM-6<J%<2D\$J!
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M4R_)3'Q6$^)3NZX]*Z#A!0R868">'2#Y,7-IC>#5\VRG LULU?C JXKS!3C
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M/.EZEOC[G4I#'ZR9M>8.V]OAK.UX!^TC:AH/?KG_1BL4Z*4"/_1R_;@ 6]%
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MNN+XS0)ZO?5Z6D#-+(9[+(U7=WLX'*W[%@S,ZA'8 W3H*UPQDF55(+QFW75
MP7R?<$8@I9$O@_DXA&GH^3"D&4L$HS$21B[^;NBIXW9)R+ DSTYJYLD0)F4<
MBDB*CI)80(P]#X813@AE1$1ALGSB)2FFE7M(PDARL)$VH%1M4:L%6'/#&@4#
M)/1LHYUT9C:O$<M]59!CUEW5^-D-/&_IGB.!CBKR'#]A'FTTMT'N'IJ\0]VE
M].Q[TWTU#3EPES\T%R0DS551;=1%*K>KXD7)K#SJTR/.YDR/"C3TH\<?-/NV
MJK+N-J]_X?5750OO236 YH/$[(R$42+2&'J!KPI#>QBF<BV"$0YB^9O$"[A6
MLNEE4C-L/%5U>ZO$(L%= ZIQ?70+@/EFE)GLVLJH+]:8J9>C#,R\_-=.-S4(
MS**D^H+VVFKPAGVWYY_Y6G58N%FS&R;M;JXR4E7OCVVSU4U9RGE?\LC+9'#+
M8>(A!%% /)A&A$*..(L9]VB$M Z*+&A/K-A]9]_[EINFKBW>XP?PCB'S'LBZ
M\([K_L2@&:[2'5X=(T!R O99&39);KF9#CCS/M(3 'A=2VDG0%KUES:$0J?5
MM.Z0LW>=-I3U5 -JTR$L2]H7*_G/HAUZL+U<2;H?I;QG_GPG?ZI4$_MB7>U\
M?)&BV&=1"J-FIY($F33;803#A I"N9=FV.A\WR5S$]OUS[SB$OROC4%G_(FO
MBL=FFWZ/28 '0AB6H7<Y47JQ^TO!;[9"['&Y=T*BIF+X[]OZ*R]!_16OP?Y+
MT^R#3@&?JUKO+EF;MY+[!* >U6F?@H:=>?["[]70G_FCZDB[OF_/A _3"OR8
MA;$OK2V+XPPB&>A"C'D@?PK3*!8H%)%6C2PCJA,;U(X'\'XMBO*A\77,#*8>
M='J6T#D@9B:NQV)+?YXT#2.I'5DF/9JSFAPC& YMB=G+UI5PN/0%V1W^UG:Q
MEC^\EO_.Z]?2WWB6^J-VX:JESS,OS@2&&<MBB"*>PDPD%$K?S.,Q1V&4&ID)
M3;IS>5ZJ-2MMR!NZ5KKXZ=F*"5 QLQ8] \UMS9:%1?-SRP788\-IH1H3N=W5
MI=&B.G<9&A,H3E2=,7K=SFI\ED'*>L/?2>Y?%^OF:OC?\_KKZTU5%P^#?IW2
MA1 H8@B*D*J@#H60)$(&=1'"#&$/L\#H2K<FW<FM1L,%4),'>C[:^QL])\:]
M3DV1U;,G$^!E9D\<065L4 P%=V10=*G.:E ,H3@T**:OVQD451YK<, DG8TT
MSK '(ZH*]W)"8):R%(89HS%.,&,>,;$;^\-/;!Z:1B-75)8ZP$)/T^TE-%-H
M ^&,E?:T#(YT\V#P657PM&"'FG;F*<O@'Z_XK?A2RPCA4YE3WM_A6 :"8Y2R
M &8TXQ#%"8.ID-Z\2&/.62;5+-%J(7Z)T-1*)A>.ICXUP/1?F[QJLM? H^*@
MJ5W-U$9+68''_CG-,M87\=,,^AV@8ACGX[:S7$-3QO@-$I=OF)D']A<D<Q7+
MGR,S;_A^0=BCB/W2\V;*W%1=*)^7OWY9(I^F7LIB&$4BA<CS?$A2DD%"$(ZH
MR )?[U+4;LB)%?37/W_YLY[*#:3,:,0C/XFE25+&B<8IQ"GU(%,Y['&,X\0+
M]3(D[>2TRHQ4D@((FC[$H&S=)6/)Q\V*G31F!N37C^_OWKX!7^YN[MY^N=Y>
M'+,\DJS6/=P:ANX?.YLP&&H6[3]FO=?S$W^Q]'?+0JY,];-:\^N;-5/9,\V9
MWT=>OWJ^DX-N([T I1B)1$ :H0 BAJ72(T%AE!$2^3R3=L',%]8F/?42WC'2
MG+7QG@M#7UD?1TT_>A)T#'WLCH=%4SNZ/8O<\K$ DI.%*O6OF)DD>#;'P)6/
MKD]X7O_=&) CW]Y\!#O#TIQ3MSM_ZKBQRSVB*"388QA*'T+&TUB:#Q+&"10$
M"Y;ZL<A"HTZE)ZE,;"[:$_AUL88=/:O"J:?Q"?TD\#/!H9^B6.)#(YBQ((%I
M*N*(Q6E N;2Q:H&?"Y\M+6U\[M0K+L#0,Y17BVAF$]O9[T\D=A3=6;U1@1P9
MN-,T9K5EHV(>FJWQARVO@:F:<KM2Q0+QQ)>N#!18!39(*F%&_ 1Z4>;[G*K*
MKT8'B_O#3VR36F+6F_T'4.@IGKV 9AJG+YM%J_13(CCK@KXW^,P-SD\)=MR[
M_.13%JGQ@PHM-P^\S"E>O^&/196K&A#-SL.;?+6I.5O&02*RF"10QM0,(M4%
M+_.3",I?(Q]Y7L+U>B:;D9U8_:3S!%:JDI+:Y>LY 1TKN.RZ88$?;MY\^7$!
M6,O35=N#AJB/:_1T6)II^EY%ID,8BQ[&!>@8F00I@^SX21"S2XQWA9Q93KPQ
M */I\/JCS9<);RSA7A*\^=MVGLR[?)W7_(-JXO!>?CGK^YRL>.LM_5PV]2K#
MB"0Q2B F6(853/BJ7B6"<1AFTK/A7AP:U:N\1'!B<]O0 %3ED:A[KS9]ZB]"
MIN<#N03"S%:VE&%#&NQH;R.3AKP[3TE74$>^TT5RLWI3NL(?^E?:[TU<AN?5
M\VM<\WMI=&Z%2NCNGV WW_)JZ2%,J9<2R$DJ((IP!G%"0L@R/XT\GV>(&S7<
M<L/6U*=")B5FR#/H.54GFXK7[7-,!B:2W:G*^(Q/G9Z1FG]"# ]\9IN+Z<H
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M%,!,2/N741)F2:!ZC6/MI#=W?$UL#7NN0-6S!<J6+X K@%7.6\>;LHKEECM
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MUD))]R3*C>R&#D-/%>S(.FX4:"*@LP.?$5(SG^-<%OKX>$;C'9NE6A4K;(X
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M]GKX,L1^X/F9@$&08(B\D$$2!](/EHYPPB3\,=>ZS.V"F8EMPJ T+Y7D#3=
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MD0V^0&Q6>ZLG^*%MU7S+(F92B8S-AM378B5?^5RO;QYJ[:CIY-L3F\(V]W)
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M$L]=^'R6TMSA\R613X3/%U^YH@OZIZ^X?,"4;^J<XE6WDGDI$W'L(^F (>6
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M_>9!K>K+(/1PD$4Q3+,X@@A% 20<^RIQ!,=I$LD(6*M5J '->7)(U&%01]W
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MC_)I4YYJO9%2E">L0#@4*:)Q+%#,,JJ2@H@DMW*:.G,P]\[=\Q3LF-J817/
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M$"610)CD3/]$0].2F(8DBY-(@H+!+A&<^U+*=,UX6#7WUF<3OH#*X!*$EKK
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MZR7RNM[J'?G.9'U^U6.\6=_1LKIA.(JBG"H4YH0CK/(,,5ID*-2_2+# .$U
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MSW2' >++WV%'=%G/!@B()SX,V-OP)+</Z^J37'^0Z^OOMTVQZB:;;O5HO"2
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MM6?@?P'SE,ZC9+?7^9$=MK &- =UFV?H:759.%^92^<)+9O =%'@)WE,E]^
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MKOWBXW;H'J30:K5,.3=1+$;/WK<X&9-T9;!\T%C6#:>>CNCVTH^>W"V&6>Y
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M6\[9K!)IF/"\0C@L$Y06,495)E<(+O,H+*-"_FL\DUJ5+,V=A^>(03ZN79*
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M[;V@Y[A5N;!;_@+%(,Q-=<TTF/FN)@(7ILYZI@*U"(*!K6##UPE86Z^QFPY
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M]_QT<"UD:&L<O>A9BTD0@N=6E8>5Z^=1QQ>]DUC(\X@$ZB;0O)B;'\=B7[9
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M2X'D*9!,!9(K72C--YH L\TWJG;FFQ]T80;=-<B,&G96 T]GX%TC]YZA=]5
M%E7M5!N/]NU\V?+[I6IJJ'(S/RZ8BK@#=?<\,X9G;:U( 'MYGA/VLE?,E9Q
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MX0J]]#C<6+W#+[\IU[Y.%)$L;RV<3X;Y2H:C^/LB)?'@65]2#>1W[#3'J4I
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M^B<LSU56>L+S+(L%+R#+;XR8YW4XD-9;VR:UD*],6@S"@3-;J*[@@*W8:Y
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MX''V;MW(,T77-[5+OGO_^#1?OG"N'[J3G]!WR80J"=/.0L%CP@5&49$4\B#
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M)LUHR4@H$411E@J44B$0KC*!*DKB*!1A$9N%'H*H>M[U>C:"5O$AS4O-2)_
MK5D!+&=C( VTF@]X8$IN0$:S$'S=0:;G(OA=\1'TC$#TGC%0 #7H S [K>@,
M.)@NA (PJAJ-!YM.4T+EVU.<X)?M/%E#BYC[Y2V5"KKAGY:+!Q58^7'QS%OM
M/VMG+&:5*#!'..(E2B,N3PMA62#,PJ@HRB).*BJM/=5]@-V;^[E,:,.,P ,.
MC!? IIZM/,?/)1-=:&F]90/F'S,"U<QMY@PCNPCPGKJRBGKZ@6*@"TG]:( /
MV,T&$=B1]\V(Y*1..0@(A[XZT+L6QM=;%0JIC3JYQ?3&ORHICK.\1 4K,Y06
M"4<DDL:62'E6I&4DJC@WMK-.$/!L4NU1E&;4,U^,1-^906)@,5TI*&PI[\MH
M<?0[)23 VKE26#O#!B@TS'P9D6C44CGUWG1&R0C7>_;'V'.> N+;<U&!?>S?
MT'>A/1/^-_S^KJDIGQ5I0C,>4I3$A6H\CBDB:<Q1PLJ<AEE<B)@[C7IWRKYG
MC3?0FBBZW>W,FEE./^]\P12W29QZ>R%0?1.*OI%I-!I]T^!$BS9A&+J7*9DJ
MUMPM\S]70+F7B0%'C?OAXF=+[_J\U(8Z9WM^)1%7'.<5*D6FKZ0$PISEJ*)I
M))*<"%&!2B)-R[[O*WC="TA5;_OW?XOR\#^[KB4_2X;6R?ETM(>]VBRYW\/<
MY%IMY)(_;CI$]8VA7#LQ7W>6?OH4JI/,_US;FI>)F2X9:I0+"]?..RYXTW!V
MCW_H0D4J8K)C=CY?_H$EYEWX)'VYE\RW\^YW"Z;YFO&"DZ02!$6XX"BE<8FP
M8*I^*,59',KM*S&_;+N*%=_NHIYRL-J2UK<E2T4<X%*Y#F\##]-D*,*V@X$M
M751(,W83;%@+-KP-4=,2Z1WV=/[,ETF1!KBY)D/<SB'F&WF8!\T)6*.^MNLH
M3.>5<X+$GO_.S8A75Z1[_^-)?H!]LM/'QR=5[ZZF?=K--O7/KB2=V>">=X/#
M(FK*R;)A2UF?AXQ9%Z$SQ')\7Y@$1MAV $8P^-TD3_6:(G0P2%Q4H3.D^%IE
MZ&" C-2A PYDYYS12FRG*UO(0Y*0B"G'2812%A*$2SDAO*QX7E15B;,*UIOZ
M@(+W2-ZO_+$/4.PS%-6ZV$UK%.L%T[W]\!/,\7&(52XB3&@6HR(30I7KRU"9
ME2$*<VG#IVD59C&%>)JN0,I"&W<^@6V#0Z 7Z! ,,S?-%2+"-&4GG<L&?1=$
M<.1D.!Q]4B_ &=$.C^GG'K/30$/ZL;2HWFU7:9_@/8MY%D9IFJ%,9"ICD*:J
M.91 946S#!<EC8L"IH]&Z4V@G4XG6\,6WSAFF<"<\"A$<1:JE(,T1A4/<Q27
M<48KP4*6IQ"]Y PQE\GI'%("Q0PW,Q7F# V80ML#8H>PNP(8( $=J;MQ6I,J
M/R.Q#U6AV4L.'(SMK33^GJ7AMWLU$O.<L#C%<GE3::SE884J(BA*DC2,0UX4
M!3;/33.AZ'FQ'_M<VF#@PCXBW0A*"Q?AM0!=ZPF<#)LKG'K78N3*=[?%RI-#
M;DQ0D-_MY$"OYUX;DVO4BS;ZHIVE^+?EDOU1S^=2V7Z4G\3BH29SWA%[5[=T
MOFS7#=]T$R%A@0O",**QD,?96)I")"OE$8U5"4M)5A0$%-4&HNY940Z\:&-@
MR\WPK6_Y,6E7X@!K,\O)&X(P3>H4/+!U906"(VL+1GM2Z\L*ED-KS&X0VR:1
MCX_+Q;?5DOZS"YKXV+9KSF:$<T&C7-4&P_)_(>&J&62&XJA@517G4B=%L&:0
M)^GX=@XUK%ZHCMTZR+6]Z?\,:DU<A\)V_P*,?SV'FID"<8 %3%5T! --\:8/
MCKD).JHN.S6.BN6L(^-I*A-W7AP5];C#XOCC\+HZ[Q<K:9/TO41$418X4@<F
M0J6)4$@[@10T1K'($N7.Q6$I3.OI[ [L>7%VI(!=58Z$'U]RUX@$6V.FTH#*
MXIQBW:H<SMY DY7!.<7^;OF;D[^WV\<^U0O^1;R5EGN]^H"IOESZ%?^H']>/
M;Y9-L_Q#58C#3_(WJY>9"JT5!0ZE.9W'RN& 4452CDC,\CR/">5E"-G<(,0]
M+RK%BKHIHIH9V*X&PM!LJ_.%#&QM#J!T? 0#(S=!STJPX248F'&W+=I X&BO
M!)&>= .U >5P5[4:P[J5.N6J2[+RWWRMVW_>\4;] W[@D=Q^TZ0D+$8%4RJ%
MEO*$7J8Q$CBD65A$>18"3>7SQ#QKCSW202-IWZ@<L9XZN#'Z><Q,#64W2$"M
MY5T0OFH0[BZ#8-/9_*)T[MJ8GR<U=<_RBT*?:%!^^1V[A7WD[I,_=!I%%Y$5
MG<.O_;!L>/VPF.$LBFC.2R37.T5I5.6($"Y0&0J:"9(3&H&<<3#RGA>_\C(W
M?%[SP7H AE( L313 ?X0NOK>XD;_W-L4>]S<!#T_[I2%'0Z.U >0^*0*Q0Z8
M0Q5C.0H\6O;CHJWED_<-NUO.:UKS]JY9TENV?%IQ]F&.'TPC8R\.Y%E;]/15
MN+@.0QNXT.YHQ0IG:^5JZSDRCX&]C-"XYG .#DQ1 '$)?E?L.(II-1;;*G[U
M\NB3Q:H:"[H;EVK^DITM<4OI^G$]5Q6IWJFJD[36!HO\><[[6/O;1Q7+^2_]
M[Y*XJD+Y<B<_GY7\W:9<X@S3 K,LC5#$"B&MC"1!52X2Q$N<1T(H9_RF^I:9
MG>&*-:-ELU^<"^B^X&W['\$.NP';X1=FCSB;#S-+95*,;<LE;F#=9?$FV#"I
MM=0NFS?!P*C\2;%ZHQ^Y7'X9;.&XQL^1[>.,K4FM(M=@'MI+SL>W*7;.\=/]
M=][@)[Y>U?3C@@ZUSD-<%%F2HS3)*I0*SA$N18K2C.196&2,Q.9YJ>>H^/;C
M2K+!#MV;0%*&U&T^!\ZX,G,F,M!!>TI:JW+5Y\2&5*MV(+Y=P)<E#,""U!?$
M&Z]'?>[E"<M17^!_OQKUI8=A>J=M5K/W:Z7,^L^JB@0IF'+VABK9**L*1$28
MHT**529Y$9/,2-4<#NS[ZE630L%JN<)S6/W#(PC&%<HU@L%T2$?%X6HYQ_J8
M82'?V3$JY-^V!L71<),LF7-"#*OD[.\=A1/=KE??ETW]+\YF/,LJ>:K)4<FB
M!*4I3E'%TD0U(XEQ484L),55(45;6J\45H0W##@,+=I!T/36Q DNT$N3XQ"C
M8$O88Y31L72^(HUV*+UNM-&QR!<CCDZ\8E4*6%W#W'[5M<KQO.VW ,$KSC)!
M4)YC:77C,$0X(0DB-$[3(HI36#7@4S3\7WQ*HL'MUV @"RJ4>Q(5 TO[>EFA
MJ_103+O"P"?E!=4&OE9NV_+ QM,,+0T\)M"%ZL G7YVR0/ 8[P<U@D<?M= H
MQX6PMF6R-M6N=DH^=C7>OHA.J\VRM$BJD)=(L$K:WWE2HC*1A@5A64K2JL@)
M-N]C?!TOODWVQZ?Y\H7SH.7-<TUYW]&8Z-)Y=+?$WF)@-6B5_@^67>TP2'OW
MZR;%0/%-!S5,07;U",E^/<(M:SOE!O<K[1X7'YP.;H#>G0YV._V\^<B_]1^Y
M)AR<J".YG0=MY SU(!VI<S<XC:K]*TE,MSVXP6)O&W$TI,5V\U4.W=14#O^9
MK_H$OR'[*PO+4E0D1P+'<B^):(P(H2EB/!9"X%2DPGPO&2'D>:/84@X6?!5@
M31N@C<8@,M#LC@2'J>T=F275(04.FC1X47R IG4$@VW30TLX8%K20,91%3CV
M_G3ZS4"*/>5E\KRC8,211,!9R47(<UZA*%<)>E&9HQ)7!1)5R?(JS J6&Q5-
ML"'N/;1HD\RJM5> =ZX2KXQ)'(/4S+WF"RB8QCL9CSB>$NPQ&-$  E^AB&.D
M7S<0T0"4BV&()F-8MC.0>XHVN+Z(#_4"+VB-YW?+ME9K[)/Z M0M?E_[H#_N
MW_ZHY6E#1&%5% 7*$M7YB_$<84$HXI1G25[DO,R,?'U7\N%9!6VX4@>Z#5_!
MP%@P<':S*<AQ,[B4Y#XK^0/6*;"=#3.5-0'&P&.V/WCAQ?RO \=557Y++J8M
MKW\=5$=U\J\<SC)3M.^.^(Z3U;T<0J\CBI-<JC6&HHC(LU]%56F^L%#7&+FT
MI7@4E3$H(_0$$=\10YLVIHKH3:#(6NFBDP"9*9IKQ89ID6UC4G.)X>F;(R*Y
M2M,\16+:=,P1(8_2+L>>M:UD\-MROI;V3?/RH9[+3W\6IRS"&8Y1@KE :995
MJ(Q$C+(,)VG!XC(-C:R,LQ1\>^N[:@ ;HD%'%5KCX!"6\57H1%C8$H3*:5']
MX(PL5Y1!.!QQXGH(9P0Z+HQP[D'K](2E'*Z]PR]8'2(6K.\X_JGNBG'7O.TZ
M!*PV#J\TI56>RV58AB1!:5C%J,I3AHI*X#C*XDINCY!MT8('SPNUIS_486VW
M;5V"IXY)8!:D#<QFFZMG\& +?V FZ+GI$@=Z,'<8&AJ+K+Q4(;L"$G?I 6 .
MILX$L(7H1-"_]5"V1;5UBL$=;E8O?91)2?.\P#%!"5-=?FF>H*H4'*4)3:*X
MQ#3!H+Z(QR2\W\]T&3B:(K3N\Q$<9JKC.B&A=S$[\CD,Q[TLB[-BSD<$)J[@
M?$[ X[+-9Y^\[@;BXX(N'_D]_M&7@'[#%US4JQE-RIRDN$(B9BJS1N2()"5'
M,>:XBD+."6SQ7:#G>25N?.@K_&,P ()?2$<;&+9["3G8W8(#/"RO$SK*^E;A
M_8#(FTN(6%\@7)#3\9W!.6JO<DUP0?1S-P.77K.(B3C>Q \V>MTH8^@4=KS7
MWZMGMMVH:(F+,BTK)/^01W<61ZA*A-RODU#(TSNK2,S,6EUXX ZR@JP:8WRC
MWSE;SW6YL<$<?K][MN@ZNMR!SA8^IFE<(;TR]."SR/&QX_" <M,A?[,S":>/
M*9KKP*3?F/<Y L2;O-Y<V86H2'KK.6X"MBU3+5<,[F=ROCLSW6D<#_/Y-,SG
M]J2^]SCM!/JKHR 7/\".QL4X)CE=*(T?K/:B;SR1L#.7SZ:U;\MT[^Z+J=S_
M"H)X3$N4\C1")",1RE21WBC*5"U2B.T,(>[9D#XH$;%?(>)&Q:#!C&D0KF:6
MM2^T8#O5*%![)?N=]KN\!@1'-CB(]*0&N0THA]:YU1A6X<LZ4UNUUGQ8Z'MR
MU;FI>>8?ELTW+.W)KWRU;A;R#X)74C7V:O"=-$FICH^?)4G*1)YC)*(XEB=X
M5J"*B@H5-,RHU$]I$68S*4N]9-]6N%D96.A7,P59;X>L&2^]-_RA7NA^F@3/
M53=D4$SPM;"SI,C2+!0(1U+OIPF-4<G*' D:%E421T5*<0_[^\6%HDZO!?K
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M[U9D9LE&E(F1RE[7$1)CSJ(81[FDF>!<2YXZQ\C+\J8X50+XM@- #K$OK-G
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M6&4R)7DD1"R=.F,YR!K]MKB3CJQX9.6C7OEIHP* W^(2<,,Q)# <X'W=%4B
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M137'-I'\D[;D8$OU:/YSSR-M3@7CA>(Y9Y@D(L8T*Q+,BK3$E,A<QYE.>5:
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M[_(WZ2U?MTJ@KTO;T+MJDKB@]Q-#N+E>1P1" WK[L+5_)_=FF^;S&O*>P<'
M8-<*0[(FOD5P,/OXTL#EI3!IRVW6XAO6S.:K#U6M[LQ?K69Q$B>,)QKKDF?&
MW<V?BJS,<*+C2,92%3IVXH\!RAW9\<^DX'9)MQMMT.]6']0H=&72\CEX+R_Z
M1P(-%A]"XG5URO(%ZP-G+)^3]ET3EB] <"E?^=+K?NN&IH#W5LHF57#76&;7
M+W%&22P$R1E.B6*84I+@DJ<%%B3*-"]4)BDH,?FBQ)'#R/U2/;-*HM]NO\"6
M"I>A<ELN! 4 %A+:<NU&=EMZN)7>;UP:;N'@;&J@Q<-E>9,N()S-/UQ$N+\(
M3]G]9;V<V[W'ZI-NDQ]WV3>.Z;OG1QC9=7\QP7!I&;L:Z78R.Y$%ZY[;.X#$
ML">' P'FOD[V!\XU<K/5*RMX8-C),H0OF];/%G9XVF\:?JOX>M>ZRHJ8&4N*
M@D<,9RDCF,8EPT5J(,QRH646$THCIPXTYT6,[*U6!&R&/8&"VY1ZG6TP)[2R
M>JWC;M"@G> I\[PI@>;($P(FG13/&W@X"PX\Z>=E[ZNZ6IO=^#=UE-!W^[18
MKJO_:8[(.]I72TKSWOP*9CG)9:JR'!=Q9K;3I2*8Y8QBD9$L8H5.\\BIAOXZ
M-4;V5O,[*6#>ZHFFFT>/CQ',ZUM]<*/04:KO#;)Z"$MJU%=NT_G;C!DN/EP'
M3* 8XJG$I''F.J .8]&5HWE0=,SG=[6LOE7RA<U7,+*V4^^.'#Z,2-23">#K
M.&7GY>7WM2;"O/_ NL!494.V^+%XG!IP.BZ/ 7/V&#V&GO.;X']^J1JZV>YG
ME'%&:1)EN%2"8BKS%/,TT5C1M%1ER031H&NO_>%']JB-,-BD?(" 3)2*>%;B
M2#)M;^!SS#C1."H9$S&7,B82QG/FCX$79=FNV&ZN;*K?LOKZN,8+C5]6EG<0
M7I!T %!)$QFGL<(BE0I370K,95QBF9NM5Z(H40F;U6H]&CAE"\Y&Q+0_#[>U
MF/\GAT79C9P1NF*<-B'0:NA@\$E7.:<-.UR]G'G*+\AN2<AV15#;ZILR4IJ*
MPKA3F4F;:)#@LI049SQ-><IS7<:@,N<!62.'WQY!7[^.[W*1#A@S-R<,A 3,
M([U! #NH@WF!O'5(TJ2NZV#RH1^[O.)3K;3E#;D58OFBY&<V5ZL'Q=E:6>:0
M![5^6=:K-^W=PP%C3IID>2%2C<LH%F:)D268EY)C1G1FEGE1G++$O0KI"DU&
M#@A]BIU..=1HASKUFBK@3D%(J<DUX _'CDDAA446$)JH4PY"6Q08:$BMSD2
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MVI)[4I78@HR$8QF51%/)292 KN$O2AS]H'<C'UD%4*<!VJC@=4E_&4;7@^"
MX$#/A:_#Q>-<V-'68,?$E^1-?&KL:/[Q(;+KB]YU^TO+H?%6M?][5S=Y/UN&
MC9;-:"89SR/C_IBD:8(I+14N8RIPG,>93.*XR/)TLZ%UBPQN@CVVM+  T2:8
M^7"&."+G%@H"HN%;T]_(13]M-+!5:ZA%9T>W<J'9LT^!/\#L<+7^+D*G+OL'
M '&" 0#RM@<9P/NJ9K4P0^T2 IO>ZN:_-,N762(3'5%%<2:S&-,HC7&9I0)'
M6DBS+2T*;0G!+]]".4F;Y#;*/* ,2(_-W:E4W]1\\=Q,F&)A=A5M0<3\8EL-
M#RB'(T9P@&"!8BNYEY1[@S;"VRU92#  )?8A0?$KH[\*'%B)O*NQ@V7P%P>9
MKM3=U9Z]<G;GE_S61KWDY]O:[.QJ&TN5$:A.M7J?%7E$=$$RG'!EUDBB3,T:
M*5<XDD2P,A.%$* 2=ICXD3=2_13\)L6MKPYLX02$U6T!-1Y8L/@XB-,>7U)0
MVHSK8 BTL (*GW2!Y0?,X4++<Q2/!==;I:M:R9]5;?[0[/TV;,+O7]9&R.8O
MVK.D9L4R2[.4IKQ@9@U&3  J28&9DB4N5:I56D1EFD7.:S /!:98E@'6%CX0
M.JR]1@8&%FXZ95 GM#G,Z1%/MQKM_K;5Z09- 25@Y38RI'Z+N5&@A2WRKL!E
M<-WG,^YT2\$KK-Y;'5XSSA2M!&ZU68<UI.#FA5G&$IG2*,*2EKD)WEKB,N6E
M^5<M"D8S%6E0C>H5NHR\E(RC)&K61O:,0C$K><P> _LPNZTF)P(/O/7VZ#;0
MX-OU'#!O?J^> R<Q^BZ-!_8U^8&[#YR$[+H6!*>']+PY>'IFU;)E@[&MBQL=
M6LG_KN;R_6+YZTK-:*H9CQG%J:;"9L)9#M \PE&21&6IE50IJ&&1D]21 ]A.
M!UN2UZ2^S1NG]+I&<(+1\18A-#C 2X2M^!O4= YO0U47GZP&6"^6V.@0\ 8!
M8G*H"P0GF=/>'T!@.+H^ +WLT5Q0L8:4V-Z,NW83W+TRLC-WDOX/H$-@SYQA
MO[S"$ICG=4*"W=J?4=ROH5]OG.DZ^!TKO]>R[\1?^W(=+L0?E@9'R;<ORZK^
MVE9?-L?/I[."9H(F65P(FQPN"DR)8)@)7F F.=-%+F6<@7KGPE48V:4V!%-V
M=EQL,O/>?;Z_;U;]2]4V[;#5[)]_!<Z6'G"[39WC@@CSYI9+";7:W+371@Y$
M7^U*WT1KK2J[OPW)G>@+3C B1; "$[,J^@)T3+'H/9)_*<NF<OP+^ZL[%%EM
M4@I6#VKU,K?'W);OJR.&;G4R3]\O5E7+P,>21"81T3B):683!PDN*24X(V66
M,5LO'A>PGD)A%(-XJ5<OHELI6TFH9>]8U$U=W/-& ;2IN5XO[($'VA2XVH=>
MS4X,7B03X&NYQ<3IOP L3O;U:PKP-AHVI(=M/M-6QY;E<D-=WY&GV)>VBH8M
MS@D'7, :G@!*35[J$P[(4Q5! 4?WI"S<)&G9BJ0F>\'LD6UJ>$>G(ZE6-&(Q
M3C2),:4YPP6/.>9IH;(B2IE2H .4"_)&7AKN4@FM>+0GWX_$Z!)^;J$N("JP
M&'85('"J0S<S0W$>7I V+?FAF^E'+(B.KUU1-7B_K(2:E9*4$8ES3*C.,<U$
M@DN5&+>/->,E%YJIS+WGX&Y@IY^N;[_!7]CR#[5&SU;0#?JTE%7-EJ_HIZI&
M<C&?LV53<]<F2_I4W;70%+2(8I$13+249L-<<LR866 R)@5-A1 ZU>"21W=P
M_*-=4Z7VK:E2LUOA#3QM[FA@D!RWN5ZF>VQ?42,D<+G=GN(A"^+:@:<O6=LS
MZ&11V?X30<^HVF.&C^K/YJ]6LR+C&9%<XZS,(TQ%%N.B9"8@97&L<N-[A"K8
M%LY-\.A;M.X\I6H4:?RN\;45U-G<8+SJO.D*:(!.:N5W1TRHU:#;%-ULJ>6-
M&NT3 ;=&,+O'/3XZ%/HC'!F= <+QF.C<V]ZT1H $&B/VK_67/]7\F_IE4:\?
M5S,945[&*L4Z%C:@E KSF$K,XKA(8L[R) .QOEZIS\B3?9-BH>JFT\);)9JF
MNO_Z+R2+_BTA-^T?S \S!;,D7?4)W(+1A,#"HI1G#E[S*3[5 9<?@1 *1]!T
ME393$SB%@.X$P5.083URL^^7"_DBUI;SO"/^C'4F59)*'!7";-XB%6.64(;S
MB,6\R*F.W$A93@\_<N#JY'4<[B NU#-P#$>=ZXV$!9'P]@%2FZ^RTR]QN6]O
MH$3DLU8,IAD?OS5=$O%9C?=2A,\_!0L+4E6S=_6Z6K^^>U++KV8)\(_EXL_U
MH[VG8_7K3&B6987(L(P8P93I&/.H3#"+2E6D95)D;@UH+L@9^UZ_D8PVHE$K
M&W7"W3SJ$E+#H2.@_; 8XFFZLY<Y&C:0@&-&:)<.Y@^[%<.E<2=Q2$?C-I[I
M^K@WX45+"/GN+_94U4UH;6\*RBS1)"I*3(K8MJ 1$G-*C<\:-%5!RT@Q$$OK
M64DCN^F.D=0NE;>B_:Y7SL/EMK4( @+,5WWM]V&O&+8M'&'%&3E3<U0,FWN"
MEN+""QZ+;YN@^D4MG]Z_-%OM747FQQ>[X_ZDVVZD?>90H<J2J#+&*HTB3 DM
M,:,9QS(E.BLRGB3<B=3*4_[([M[*M1<,JNV>"V9@]<7589D_+EJPN-"DI%ME
M4*?-'DO##L:N";$+;6L0& &[B7'A]-MNC  K;'/B#\K@[L5CV.FV-_XV[^U_
MKACFZM;P'7D'FV\R:;:L9F)=?;/=S(18OK!YM^<NTX*G>:9P276*::$4+DB:
M8Z&SO$@+&F51ZMDN'J;)R.%\KSOZ5K-MEMJ6H>\&;;2S?VKT\VQDX_]-7*^Z
M)D :>OLU(LC7M*;W RA\NWJ@'M^KA;T?7 -M[3T'].SGHU8KI3ZTS&TKL:R>
M=[LKE>A<2IEBDB84TYP7V"QB*<X)B2-%DYP5$:@?ZGE9(P>T5O(-:F3?H)YT
MOQWI$&IN 2D0%L#5IS\,\+X_EPT,U?UG0-*T/8 NFWS4"<CA%7BQX\=%_0\S
M>E=AUA]XRVCE6 -Y>:2Q=Y:+&O_C]O8>;<H+>SJXETLZ #+LMN&Q@'GN$ R!
M:;Q@IGJ58SH,/UF5IKNI_>)-P%N^-.DM\^=M+=_N>#][M7:6^&O)Q/K+XEXM
M]<+LGQ;+AG%U]:&JU9U93*QF),]Y7,0Y5C+FF,9<V((HBG7.$[-GT9&(0?N5
M$$J-'"\>^HRI/27WRQ0W>MJ"J$Y39/[1<@T#RT&#?"FW1</4^,-B5 CHT>]6
M4=1H&I3Y/1QPP<CA Z@T,7]\.!"/*>8#COT#=$_:Y ']MIB;82P[<]-!HZJ;
M)CLLSFB6RQBSF#),B2*8Q[F)T+9AFQ1*Q/S[]4\:5'WLV_U-5MVWK? ;]-2*
M_E&Z)PU_6L?CJ!_R@P'/K\;KH+3]&>Q,VK10:JWZ05LH.7V)'[&)TK#B_WO;
M*#E]D%$;*;EIX'$'O2L6MI7!9C94U=?:_$=[D/BRFJF29M)2\,K$\O!&D<2<
MEP(G"9%29&F1NM6K.<@:>4ZP]?&\RZYNZN=U*[]A+U@U&@#N1B_ YG"=' X,
M6+SMD0L@*QEUHAL"@<^!<0#<!X?#P^_N]QI<8)>\;I8.7NA>&&*ZRULW6_8N
M:AU?\5M]MY>\-N N:O,3Z"[WLEQE:58RG.:"F"AFFY9SE>*84)$F)"OB-(<L
ME$]*&7M-V^8<;(5ZWI">!LAMN7FUV;!(!;<8O&P;M"C0"NNTC$D70X-F'JY;
MAA_V<\M;^5\O7=;%1Z,R6STV6^TOBP=E3:CFZJ-:MSEVEIS@R^*->>1^N?A6
MF8WLSZ^_KBPE[*X'5'N!6:G5+5\UV_D9RY(XBPC#K/'P+#%_XG&!=1233$8T
M3E(0Y?38"H\<+'KJVP.RY49I5*MUT^K<_E?[9VL9>K%[JJI&BRV!!]LJ[$@F
M.=F'=HM4/]+G@P6]GN8WJ-.]/<>\L=]LJS\R!J N/;CKSV[^VIJ!-G;87?-/
MO[;?]F_]SG=;<]#O&X,"QM2IL \4GD=7=])(/Q7XAY/&9'+AM]@;5CLVIU'\
M[51;)L=+[(L#C1[4-_*14>"G;W_K]6!RO\.^#,?E*^R@2$#CXWD01KC!=K;4
MZP+[\NB3W5\[&]J_OG9_R;<&\?.CFL\W!75E3B.9Y01+DII%7B$)+C*SEY-2
M2)EE>:JU$W_<Z>''WK^U97>-1-\ZPSTTAMWT>AN!FS6(>1ZUA*>LN**$<&^X
MB2L'3YER7#!X\BE?-[(S[_)YL6R.Q)H<T3>+EWJ]--L\:4G)LI1(+;&2MN2?
M) DN(Z)PDJ:*<!X3\U]@?C4H;QI'VU/AICG!4P8UU"F"K"90_QN&T=4A@X'C
MY:%7X>+AN$[67N')P^-/[-I.QA[[NMMKWIU?GY?J4=6KZIMJ5^#WBWDE7MM_
M[I9]2@NN,EGB),M23!.=X"(B%,=:)CJ.:4%R:,]7)\$CAX,]-1IF4G"+5S?\
MW$XFQD %%@?V 6E5N$&M>/1[][]C=70%V1ZNEZN;V*F[N(+ .-&_%?;^),1I
M34,N\\N;9:72,DT$+M/$T@@E&K-2%UA&J<QESLJ8@8A./?48.;B<(DI#";E!
MYD=8C$J/M@7:+>Q, !\L"EU#AV8U^VY\:(?0?!\>M*T6/S+_V2%45_*>'0UW
M9=UN6V<5Y9E.HXA@H<L(TYQI2U9=XKC,&8\*&[1@291[PX\<?W;%GU[U9P=0
MN(42?P-A$<+=-O\JU3'JR X&_S[UI(/58F>>\L@>>WCWVX>[7^[>_M+,?#.2
MB824*<&1EMP>))A)GR<93JB*<Y4E+ *PD^R//;(C;83]Z[^0G/X;( 'J (%A
M%[K2+IC_;.2@WUM)$)[  ZL :5S^UOFE;3VH;_/JJ9*7K80E:9VV8S IZ^"5
MZ9*P3NNZEW1UYA%?WC'C86JU[CKQOE5\/8N(I+%0=MYDS1EBBCGC&8YB7DC.
MF$I3"F,<.Y(Q<@C82$2J%0DE%SO&Q&T^O=)26%#8&ME)L]7;?!V21^RL,<$8
MQ(XE3,P==M;$8]:P\X_"7&^U7,^:,T&U?&;+]:NE^6RZMN9<:Y4D$N=IEMD.
MG 4NDCC&&2T8D2S.4NZ4^'1.P.BG<SN1':OM<-]7-U2&/2^$K= S-Z"9SHYW
MR98AKS/O]CS._-O.V\X..XFK73)JXV<7G_.;W[8%&%U=MEV5O%^J_WY1M7CM
M,F93:MPND@4N*4\PI9G&/)-FYDMBD2>RS"@'-01PD#FR*^ZJJ&Y03PFTU<(S
MX]@%3;>9,C!&,!?VA 0\@P*,##2CNDB<=(8%0' XXT)>]3P^JK[6E:X$J]>W
M0MC@8UN6V#/W2JUVMT%%$M$RHCEF228Q%9S@DB<"QP7+XEQ'A!2@VS0WL6,?
M-[T\/=FN7PN->OJ@G4)HHQ'P',H-4\?SJ>!( <^MAI$)G*3F9W6HHRXWH=,>
M@8& .#H:@[U]W?[YGE7RHUK/*"FHTDF.RUR8-3R5 C.EHX97W_9%+:4"Q8J#
M\:?:-S\;<7Z;Y@T0L VSAWF>FV4KR5Y.B?E+RPK+GJLUFS?-FC</W9S,L ^_
MLSZP.O"N>C/Z=]E1'YAV;C=]^)AO7DQM*2#:G)N':O7'SZ\_FT7"HYG@_FCV
MD-0LY,T>FF&ME,!4J1)S5=J^.)G@69[G'':#?4G@Z#OMGGADY:.M>-"FVQE
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MQCX'ZW/N-S77C727<FHX;HZG7H'0 )YU^0-Q36N!LQ:&[QYP+.I[-0@X:_1
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M%6*GH4,RX23C'$ H,X"2O "49%2#6(BLT-NLG$.WR5Z78';!<?H<8-F][8)
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M\>ZUBO9J&>+Y@6)1KUG4J :T;@XS57S!'U_Z<T'JYAL\T3Q_D!D.5H>Q-3/
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ML :*3$3KZ0-!L&R^@^B9$_SNH#S/^7O<8]I3?E.)=Z,?GEQ !3.99 E()&<
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M?MW&-*\<^^B-9\NSVY@WS+5;?=ZWR'FCXRLIWM.UH>6H.XHN%5,.B4P!E%
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M4N:%RI@O >YT*?-%=_5-#=6;=6D&HS;COWZM3.GT]U^[-W$A\B17J  YRS%
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M5?MP_(ZSU3Z,&C2L?1C_X*FU-$3]D_[I/_^E_XW^C]G4_.>__#]02P,$%
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MHV2+K-+NU0_#QN!SC0U$.PB(O)O2IY$XQM_P=5B&*[9&KBAON-; F=?U08(
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MY5GY'+Z/7+$B%L>@MB(@CRG667XZ T:733"&#HC6Y<J'T'48$/]+W$ U5],
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M"SX1D\*%J(5$Y+QU<GPO,3T/NVN!@WNC$9L(?J"V8D^3UV/2, ^TBSTU\W(
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MP ?;^@G@/EH. ]?/=F/01/(#0-!V4_E[J1K/DU R0,(Z$L<KI(B%![#&*,1
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M^9"A"*.DEK'YT^4CR.S7<G6'LOTIHVXT.(  X '&7ES4-[?_N=+K[E(94YA
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MW6[$_9F *+SA63# +#TH1/)]C:)#0KDL<I(LE=83%0^EK=^4S3-8STZ4--
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MKY6FK\>3RR5NW['*S%D.&2'(^FPM< 7>VP!!"*M$42DW'UI_)*G]'H]-,/1
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M#R2#VC W/B#.OXUK/<FN@[,^GKB=M7)=O$Y!^GBV5ME&ISSI,3@Z.Y-@M=$
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MS/(D0O.IF(,([#9..@0SV^?D>")ZUODAMVQ9E#<+NC_J376BLW*/=Y^P(=-
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M(_SW8OGR<G6Q^%);V=;S.:N 6E9;F-5^V(P4 >^R!48'LXHY*);V<O+3X^\
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M7@<</YW@EI[.XL1M4-5, !V Z1Z+_L1E_2!\0GXFG;%)F6K_UJ1[2;LC\(R
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M *\W"6?)ND07OF"1@2JL !DJ!9BF-42'QLF]NCL.4*4>)&3:R.S$UU8[$76
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M=&#6W,M-(/;5#\(GY&<H@A(J2."!*=H_ADRT[#E(*W)BQ9J21D]WNT//M$D
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M]^R'J9\T/-%0!-/CZ?WB>SB_F-4^ @EGWVY\BV>*1R$L7?JTG#K<MY1:0F7
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MIFQCPM8S9TY6J?,<^J\?<BE.!H"IC[P'O#[7AMT9LQF9<@YT,;8VF2H0Z4X
M6A^2!BQ3TOM5UC_RDBXU_1'%O1B!]X=C:'$1SEM<FXOEQ:;PZ&$_HC2^"+I0
M@&=?VPX8 SZZ!"46BPPUPVTM;.=-^L2K?H*ZFX/QU%8.W5['FSURIK3*BK8)
MI#JR4VDIP=-!#[4GAL5LDC2M^UH^2M!/4%YS"/3:"ZL#Y*T9<V?C>*NR8<D
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MK!5@)Q'QL6G[3<#]<C$G_EVFNJS7=6&?2+:KJWV:?/19(AE)S&3B:+76I9#
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MDP[@]0C;;OU06B0?L#A05M)?G.X$>I(#'4KVDDL79.M Q3YT]>(TGDJY.TQ
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M(H$AR&M;)#!$JAW<TH_9_$$['TW04%#6EOM)DJF%#(A]/*&G5?X=/6^C@V*
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ML7)O)WQT40[[NA1,=1;L-?7U8KI]<9VM?L%<!\A>7UZW_O+$.6%]$H;>(99
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M$=7@DR23&9E2#!W+<KM^[^/X-L/TK)R";[.+H ZT+U_/#BL".\2,1B=-M%9
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M#)&@T*!E.C4V/FX=8-R[I ];=G^)= "G_1GW@^Q9OJ.Q/%L7F$EU7&:LUZ^
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M%A8!7<BU##M"E#Z#*=;QDNG)-+*%X&]^=)P'HIG@]^9?![9I@\RB*V3G2&.
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MDZ1?^/FOG74V".D^66=#V-Z@Z&P3:)+3P1!O$1,Y@48)BDR$K1#FI"#4.K"
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MD7I5J1E^>LSF],SC90ZQC'I^UG;N=SN=Y>V!IOEB9_%+]->+3=#O"5,FGNA
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MN82H6/[Q,VOVJ@EH*2KR G.J9Q#<5W^52Q78OV8OZ%H*@[S G%:G#WR8+Z?
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MNOZ:(7<H$!^N;QN9::A1/C2 C/,'R+:!%[(N]?T1:8L!VG@TVQC'1/QQR7;
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M_;-;H/S7S>RG/QNWP/L__W%Y=@8(?;JI7?V9DO_70/+2G8!4)-*=@'0GX 4
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M&<(\J@]A_M2+_2G\,4B'X2__'U!+ P04    " ",,5M:1[*A-@@)  #L]0
M'@   &5X:&EB:70R,2TR,#(T<31B96EG96YE;'1D+FAT;>V=:V_;.!:&O^^O
MX*:83@/$BNTDX]I. R1N-TV;MD'<[&#[97$LG5B<TJ) 4G&57[^D;G%SZ>X4
MV=W0.@7J2RA*AR_?1Z1NQ_NQ68B#_1@A.OC+_E\['?9:AMD"$\-"A6 P8IGF
MR9S]'J'^RCJ=:JF)3'/%Y[%A_6Y_C_TNU5=^!66YX4;@0;V>_>WR^_YVL9']
MF8SR@_V(7S$>O=K@?1@,AX/A+@R[@]V]W1Z$T,5P+X3?$'N#W=U_]C9L5;MX
M64>;7."KC05/.C&Z[8]V^\%@+S7C)8],/.IUN[]L?+>HP6^F X+/DU$1L"V]
ME+9Y57$HA52C9]WBW]B5="YAP44^^O4S7Z!F'W')SN4"DE^W-"2ZHU'QRW)!
MS:_1;M%NO/BZ+ ,:V/4(GF =8*_O0GKS+>8S;N7J[6^[I>M&W6G:2KRAE0_5
M_RG@:3;3/.*@..KO0RY>#,P$UC'-I(I0=6QH E*-H_K#..(Z%9"/>%)LH*@T
M7H":V_Z;26/D8N3Z[@J5X2&(JMV%!&5QU:W#83#H#ES/&F7_1_6&JTX/BD[?
M-M'=LEU;<S!\L+@;]'ZR;&]GYZ=J_BC8_LN@W]_S)-C>(.CO/%R\NMKMHM?*
MGK/>T"DDKS9V-NH**421W<>,^NDWUK-V6$% X.4=>Y3.^-]C4>Q:/L("GS_K
M_=8=R\ORO0$E;S"I]/A!4[NNH1O_T:(^J/(N4UQ'/#1<)DQ>LI,DE"J5"LH_
M*/9)S2'AU\7W]LITALKMTV'>6(A]6B:H=,S3\B^SG)FX*CW'.==&@1M#5Q3[
M-S!5^V(CTY&5@VDI>,3JICU-L7;O%>L(^3$FR'K=WN,Z9FT4FD!NU\%.M( D
MTH\A4O_/B]1E]TA5S+2>E%;VM:3JMDP_88JBQ=VGW=Y?_LP^PR?3U[N%0S6W
MNU*> )L&Y\%IT(91Y7Y%&B4>=P^PAI 3QT^G80W'%U-V9G)V:J(6(YRYB9[@
MA# A[(]K&X2=>SFPX\7L;<L9)H*)8(\\6Q/\PG[XPP:]R28RV')C<8OGTV<H
M4X'/G[WL]P9CS<XQS6:"A^Z\UB2F:381[I.9:\*/4,QYMF#3\]/VDEV)0  3
MP!YYM@*8VPW.>:AIB*8AF@A?1\(5:"X<V=!BM*T*UUP0P 2P/Y:MCZ(GD$ $
MF^SB=-)>@$L1"& "V!O+U@#;N:- =LH7W#R2A?W4H]"!"":"O7%L0[#=WF+&
MW4TAA\&TQ=/H6@BBF"CVQK0UQ6^F9UN6X-/@(F 7"4]1:9G HQP4^BG,- 7^
M*/=-$\I/JTEKC_+?%"0ALBFH%N-;BD#\$K_>6+;F]QB575?>\GN[*A6(8"+8
M&\\V!&>0S*]CF:U<0OX 278)H<F4>[:;+BC3!64B?_W(?]&@O\E.DD1>E8_C
M?L8P3MR>("?RB7PB?QW)?ROMN/Y>WMS1[:YI88N?L&H$(9Z)9V]<6_/\5J:X
M1"'8A9I!8@>I!)<@+-9MOM'$K>8=*HWYEKM*X')530T8?.1,"(3X4VC2VB-^
MXG)])<4,'43+3[=-E]Q<HW)I38AE8MD;WS8L*W3>I5GWZM%T)0H!34![X]_F
M>/K$@,@WV310@6CQR;)"!B*8"/;&L37![\ V8HL=OV\OO(4$!"_!ZXUC:WC?
M2X7 _A&\;?'0.Y69B4LEB&%BV!O?U@Q_  &Y=D]F1$G CN(V7W.NM2"0"61O
M3-N C-]X*.VA,(N0N<R[[GT2_+W-/!>2$,U$LS>6K6G^B"8NK[1H=M1JB%>4
M()*)9&]\VY#\A5TDHNU7G-QJOB#0E2:BV"O?UA2?H<K8BZD,.480L8E<H HY
MB&*RC3J5B889%]P5UHE*6''W<F]<_A+&9GOA=^(1]42]-X9MJ(]!+2#$K(A,
MT^U?=/L7T>R=;Q^B>?4Y+'KBBIZX(N;7G_D3K0"+9+X!:R_JI0H$- 'MC67O
M!]H>DL=V#(^!TQ!.0S@1OY;$R^*A#9T&[)K)0+:9;TD'WT2Q5Y:]H5B9;.X>
MCBXRAVHM[>A]VNJ?U*@E(9Z)9V],6_-<S[O;B^\$<KL.=J+IWA0GQW"/&/;$
MN;<99KUNCS@FCHECOYS;/ 9-)\'H)!A-MUN"^&N\0B'3!=IH&MQ;?#&+>*<1
M?8UQ_P )S+&B/=&9,)QR@Q/W-,ZO._CGJ!%4&+/GSW9>CN\?]HE^HI_H]][,
M=T[('6J-AK4^3R%E!Z<YO'>F;6"V 4,J%;(S@T'+A^M&C-:33..R/ZYM4"Z2
M?!U>*AN8I3EO^RFW53T(Z%8 O6U@)M"^1_SJ8-^^U#%5%7?[P6#/KCR5FKMD
M^2.75MKP*QPO>63B:L6K%<L6CKHW56"FI<C,W2JE"@?[,Q=(%5GQY]776-TH
M/L?.3"%\[<"E034"L81<?[_Y!4\ZMV)_*-+;??5?[Y7![5[INY#>?(OYC%L#
M]>X3H7@I.NE&8!6AZMCP!*0:1_6'<<1U*B ?\:382%%IO  UMY)4O>+DN.7(
M0H6RN%)J. P&W8$3J]K=5QNN= P*'6_14);MVIJ#X8/%W:#WDV5[.SL_5?-'
MP?9?!OW^GB?!]@9!?^?AXM75KN% _6*:T?.<=(:,!NYU!7RZQ @3=GC47JY+
M"8A>HM<;R][0VV00H5PJE$N%2/;.M\U$^S/P)22;=(VJ%((@)HB]L>P-Q#%P
M-P1MMOV$=BT$84P8>V/:&N//F?J*.?N 49$2Y4S)* N-9I\51%@/T"YEJ6WK
MH_Q*G)]RE3(1X42X-Y:M";]XW_:3V=4/R;^W\49R01 3Q-Y8MX'X.PL3T 0T
M >VE=1N@IX=;["0)6TSQ:Q2P!(5;]=YM:L @)5$@G/WQ\ W.[*T4+FQM!^?3
M"5%-5!/5OGIXA>H/D&27$)I,-4].TZA-?!/?/GO8\OV'P_DD25 M(6='7'8,
MAC'=^DFW?A+I:T7ZI^+GK2,>VC+-CH6<@6!'F79?-9NBNN*A+9BF ?M"&<+I
M,C;Q[9-E[_!--X;2C:%$L6>^/3IF'R>LU_ILA)1-F!#VU+HEPGU"F! FA/VT
MKEU-*"F=/]%+]'IHW6EV_^]4WTEJT.+!F4YM$_#WI2-Z,$704TQ5M#V346[?
M8K,0!_\"4$L#!!0    ( (PQ6UK*FGP/0 8  #(H   5    97AH:6)I=#(S
M,2TR,#(T<30N:'1MY5IM4^,V$/[>7Z'"E#MFXN"7.+&3'#,<A&NF7& "-TP_
M=11;P6H=R95D(/WU74E. B0,<+T[2)H/&=O:7>WNLR^RI6ZF)OE^-R,XW?^I
M^[/CH".>E!/"%$H$P8JDJ)247:'+E,B_D.-45(>\F IZE2GDNWZ(+KGXBUYC
M.ZZHRLG^3$YWS]YW]\PDW1%/I_O=E%XCFG[8HK[GDW#LN7$K3AM^0N)F&) D
M'?E1ZL8Q(7]X6\ *Y)9'JFE./FQ-*',RHN=O-_QZ*RQ4YX:F*FM[KOO+EB'=
M[XXY4S"? 'Y[:<4L"\/B"N2-N%)\ A) F"*WRL$YO6)M8^66E3;C2'C.17O;
M-;^.'G'&>$+S:?O=!9T0B0;D!@WY!+-W-8F9="01=&P))?V'V$G,[8VUH@5R
M<LK(S"K/UW;T;C,ZHN#CH.[=-^)1]9OWM4\  2)>2?W#T\%Y;W"!3H]1?W#4
M.^O!']P.>Y_ZYQ>]8>\(G7WY>-(_1 >'AZ=?!A?]P2=TW!]^1@>#(Z Z.QT"
M[P"='_[:._IRTGO3'FBL]@!GTN3 <S5_)3TO"4JLJDAQI#*"*$NX*+C BG*&
M1E,DR)@(PA(]9"C&/,_YC:X-0W)%I:I(SQ54#9WX<F<[C#HO *W :0KBG)R,
M53N8PTA9"M+:CA>]FGN\^LR,'S_[?;=X;CW4;ECM<O3^F(L).G<B-.!U% 2!
MX[MQPW-W44&$PI1IN"J$?=?ST&EA))SEF-7TDR8ZS[ @L^>8I:C/= K1:U)1
MZ6<#SAQ]=X]:(CY&'PG]1!BIH1.5UFL;@;Z_QNA[#;?9> [Z&XI=L,[8-:,H
M? 2[)_-T0_%LK#&>?A!X\=?B"757(@RB4Y+6-A3<<)W!#<-&\ BX$>I-BIQ/
M":E0/BM%DF%99:H&>T[99VF9V%EZ?Y=433<YFYOK#'C4BIJK #\GL)1.T8'-
M58/ND$AEWJ6?5;EG\?"$H">B:C,CIK7&$=/PFG'K>T3,_Z$W1&L,?+/9#%8V
M_N\,/-H(Y.-U0SZ8(X_\EM=J^KM+T,QKO""Y0;L07!8D4:7<$-3 5V\%MO"%
MJ!G0PA>!MK,=QAORJ>OM?.MZ"C?!']395AQ'*S]U7614?(L5V3$OA<J^V8I,
M"]B,H'D[G\B>E^R-1=!$7N WOFNR5T\4+]KQJT$$]D'P@C4%%TJBU-AT3$:B
MQ&*ZL^TUW8[?JIG=O!JZH1#E@AA[9SFD]P=X3BWCF#+,$HIS).>?^Q]W(1F/
M01!D$R/2D%&])<. &X0JP7/$KXFX(]1JJ1-X229E25[JY#.[$%2B \9*8!D:
ME@I@SW5^6P'IF NCSY1@@6P*'Q%XV1X183T0>,8#BX],7XONBFW'%PAY,]M7
ME5-U"B492<N<K%O87U0+;5V.,YZG1,AY6'[D&+H"1,D1%1"?7*P(X9<LQMZ$
MP9<$91CZ%BY3JC/U*U/WO>8[Y),"L^FN?LO0;JIR!<W2Q'@2+@*[*:33B^ D
MT[2:766"V&23LSU#:,V4IP]R;R[/BC'J4RE+(%F4+,TN"$3B_<J%9D5K41A(
M+LF-)IZ7B'E-J*-3$&A<(V=:/NV<N62SZ[E,@625'"B'GF-+4Q^&D!?:2>ZJ
M8#V[LQWYOMN9,9I;K[-;URL5N9 'U[8%R0*TI".:ZP^"E>(5.N\D@J#!5T85
M:^ #>BV%(W);"%U^]4*D@-41N)*SNX*T$EZKLYB^AD:P=DDU&9^[[3^7QA^=
M$'VK?65SS5@\=[!VB<%XC*G(IS4-'<YS\"@47=N)3!.4M6I3'&)\8A<5DB@=
M\= H360"(P0=,^%$H<S8,("[/TN6& ;35)\5<4_Z6'O4+'.Z"H_ C&ITQ 7,
M[(!G<UQ(TIY==%(JBQQ/VY09_QBFSGV\]!$::,**)CBO6H_I0G:X.EW3".NN
M'^L#-@K:FTIG$U=G;^KF[,V>2I?'XJ@>NX\/NW5O/K9G9%OY8(&$V/RP%6S-
M&*K57MLO;I%WOU?J!>!#(ZS^/S[VC+$[VPU(*/./>H))!8D?1!WT.R]A;7-R
M<C8'>L,,_\BETLGV&4L)':&$9%%R4XU=ZD7+ANZ9E+N3T,]9)CXXX%9P274A
M:9LW$EA-+QUY6]0!D]+N@@6/H.*4:IGEB5-RU;\]L[=GS@K^"U!+ P04
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M=V3C> @\I:T?(*W65Z# _JH+3['(&K?=Y0N_66H_XR^HCL(OM_X%4$L#!!0
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MMW3>K'#J9JCN_[LM;'+RDD3CA/>PG<_Q,)Q7Y9*F,,_@6^'XE2.WN^1-95A
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M7Z4:E;!><"B&0@4N''Q9'B>BE>\POQ7ITX&9,HS9YI=S.-HEAX*U&_K\NN0
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MWDWU#2"H%5"*AE5US3 '[M:3)GE9TW]G9FF0U[2L.JAB*F80)&(M?164-SH
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M4'9MH%,/%$V,#&PW-%(D&SYJQ"J<;.OK%A8R)Y8$K35K?<>A2 BD+Q(V2>Q
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M'338ZBVG"M?+T$:^U5;%-@<8=0FH;"FL';+I4T%/88/S)YB9.\W+;AQ%V^L
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MAL-K2&Q.GI^\^%+O^2'+<]!*8%A^^_V;Y ?.#-1,)(QGX@\__'B1?-<6,WG
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MN'CNU=M\"G$Z(K)R/.<0?6&:NT0>/\=YPF[]53!7A'[MKY2$.F[_'+<2J9A
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MG2>N.E\>Y#KW*AR5L5X#5 1EY20&_^P3 Z'CXJKB'6RXP&*IPLZS*>$BUT6
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MNL6U*_ZG:.G@LC.M:%1<O*HR[%3LR5%\E^EZO#%S9;/EI,7F3ZV8\C++@W&
MMGM.\\Q<H.ZXKLPRQ8LDOV!N3)8S 6RR@LD-LB5.!ZBFVOK0J$-%&K2>8HFF
M>4<27;$5ZFW==DC>!UJH/T+FIU/LD2WA-_C:*VP-SA3BCT4Y;N\*RN<@+Y@[
MHP9J_XDX;#.LU2).2WP(4@1(IZ4"74@JWR<=28V6E*A##8!G3\ JV3@VC>X6
M(Z((XBV;*D\?L5=@Z_:0K0$.T'^VLVQJ@UY2614Q1-R!K1>'ZFA^E6[9Z<S>
MRS(^-^AK!][4'SL2S[=@/4I,U_4SKZP![Q]V\B9H.J5FF;J$$Y_F)%Y9_8Q+
MGPTZQ=VM [8@<ZYK*W);'L%+*SI'!$Z>DE-E*#-6^]4CRCT)(()JPL&I>SJH
MAOD+(AU,9JW"Y:@Y5\!#IT%L)<%A"$:SN,/BCT^@?ST:7DNX#6W='H.N-]U_
M"S?= ][4OP:5\Q/T0/5XZ^RB<F0[9\SUC$F*K&B=K1Z2V+KS^XZ/%#N O7?8
M^]%1&5PG'!\H(:AX'2/\C3#"\Z$2ID2'@G6C9(4'PE8(Q]<*-7DC5\#2WZL)
MXL-=>]!>?9+B6>;ZU@VH]D;.-#NF$2^9_S3?C)-[8R)"$5)9-6V7J BG#-%
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M[2K6@LZ> 8O(O=\4$$Y,+!WT,M?T(<3:@A2PB,+0&C9?H :;AVO6;VRX.*Y
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MBZ'Z;-Q0_?.DG&W@/XMFF7_S_P!02P,$%     @ C#%;6A4):.FX!   R0L
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M%3<5-L:'-6?&,^!GFBYXS/,(CIU6)8>7/W5"NI>_[C?^?^MW]D(%"8;+X$J
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M92TR,#(T,3(S,5]D968N>&UL4$L! A0#%     @ C#%;6E*&T,EO/   83\
M !0              ( !0BP& &)G;F4M,C R-#$R,S%?9S$N:G!G4$L! A0#
M%     @ C#%;6KSI/&T/S00 C,\' !0              ( !XV@& &)G;F4M
M,C R-#$R,S%?9S(N:G!G4$L! A0#%     @ C#%;6B#EYS*\D P +0,0 !0
M             ( !)#8+ &)G;F4M,C R-#$R,S%?9S,N:G!G4$L! A0#%
M  @ C#%;6DYV/Z$S#@$ XDX! !0              ( !$L<7 &)G;F4M,C R
M-#$R,S%?9S0N:G!G4$L! A0#%     @ C#%;6HC]USJTN0$ &AD1 !4
M         ( !=]48 &)G;F4M,C R-#$R,S%?;&%B+GAM;%!+ 0(4 Q0    (
M (PQ6UI##NU<LB$! !F"#0 5              "  5Z/&@!B9VYE+3(P,C0Q
M,C,Q7W!R92YX;6Q02P$"% ,4    " ",,5M:W#.:N6,.  !,AP  '@
M        @ %#L1L 97AH:6)I=#$P,C-B96EG96YE8FUS+7-E='0N:'1M4$L!
M A0#%     @ C#%;6C ;]%R'-P  %,@! !X              ( !XK\; &5X
M:&EB:70Q.3(M8F5I9V5N97-P96-I86QT+FAT;5!+ 0(4 Q0    ( (PQ6UI'
MLJ$V" D  .SU   >              "  :7W&P!E>&AI8FET,C$M,C R-'$T
M8F5I9V5N96QT9"YH=&U02P$"% ,4    " ",,5M:RII\#T &   R*   %0
M            @ 'I !P 97AH:6)I=#(S,2TR,#(T<30N:'1M4$L! A0#%
M  @ C#%;6O7*V&.8!P  R"4  !4              ( !7 << &5X:&EB:70S
M,3$M,C R-'$T+FAT;5!+ 0(4 Q0    ( (PQ6UI24<.B? <  , E   5
M          "  2</' !E>&AI8FET,S$R+3(P,C1Q-"YH=&U02P$"% ,4
M" ",,5M:H5Y,2L8$  #Z%P  %0              @ '6%AP 97AH:6)I=#,R
M,2TR,#(T<30N:'1M4$L! A0#%     @ C#%;6FZ\#UNY<0  T+0" !X
M         ( !SQL< &5X:&EB:70T-2UD97-C<FEP=&EO;F]F<V5C+FAT;5!+
M 0(4 Q0    ( (PQ6UH5"6CIN 0  ,D+   >              "  <2-' !E
M>&AI8FET.3DQ+61I<V-L;W-U<F5F;W)E:2YH=&U02P4&     !, $P :!0
&N)(<

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>bgne-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bgne="http://www.beigene.com/20241231"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="bgne-20241231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
        </entity>
        <period>
            <instant>2025-02-14</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bgne:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bgne:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bgne:GuangzhouMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bgne:BeijingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bgne:SuzhouMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bgne:ShanghaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">bgne:GovernmentAssistanceManufacturingFacilityBuildOutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">bgne:GovernmentAssistanceManufacturingFacilityBuildOutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">bgne:GovernmentAssistanceManufacturingFacilityBuildOutMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bgne:DepreciationExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">bgne:GovernmentAssistanceManufacturingFacilityBuildOutMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bgne:DepreciationExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">bgne:GovernmentAssistanceManufacturingFacilityBuildOutMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bgne:DepreciationExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">bgne:GovernmentAssistanceManufacturingFacilityBuildOutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">bgne:GovernmentAssistanceManufacturingFacilityBuildOutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">bgne:GovernmentAssistanceManufacturingFacilityBuildOutMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">bgne:GovernmentAssistanceResearchAndDevelopmentProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">bgne:GovernmentAssistanceResearchAndDevelopmentProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">bgne:GovernmentAssistanceResearchAndDevelopmentProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">bgne:GovernmentAssistanceResearchAndDevelopmentProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GovernmentAssistanceTypeAxis">bgne:GovernmentAssistanceResearchAndDevelopmentProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bgne:ASDSpecialtyHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bgne:McKessonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bgne:ShanghaiPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bgne:ThreeLargestCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bgne:SinopharmMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bgne:ShanghaiPharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bgne:ASDSpecialtyHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bgne:ChinaResourcesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">bgne:FourLargestCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationResearchAndDevelopmentServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationResearchAndDevelopmentServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationResearchAndDevelopmentServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:RightToAccessIntellectualPropertyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:RightToAccessIntellectualPropertyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:RightToAccessIntellectualPropertyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:MaterialRightsRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:MaterialRightsRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:MaterialRightsRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:TislelizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationResearchAndDevelopmentServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:TislelizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationResearchAndDevelopmentServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:TislelizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationResearchAndDevelopmentServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:TislelizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:TislelizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:TislelizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:TislelizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:TislelizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:TislelizumabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
        </entity>
        <period>
            <startDate>2021-12-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:OciperlimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationResearchAndDevelopmentServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:OciperlimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationResearchAndDevelopmentServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:OciperlimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationResearchAndDevelopmentServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:OciperlimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:RightToAccessIntellectualPropertyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:OciperlimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:RightToAccessIntellectualPropertyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:OciperlimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:RightToAccessIntellectualPropertyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:OciperlimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:MaterialRightsRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:OciperlimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:MaterialRightsRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:OciperlimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:MaterialRightsRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:OciperlimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:OciperlimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:OciperlimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:OciperlimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:OciperlimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:OciperlimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bgne:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-20</startDate>
            <endDate>2022-04-20</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-20</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">bgne:BeigeneLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bgne:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-20</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-20</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-20</startDate>
            <endDate>2022-04-20</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bgne:ResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bgne:CollaborativeArrangementCompensationTypeAxis">bgne:UpfrontPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bgne:ResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bgne:CollaborativeArrangementCompensationTypeAxis">bgne:UpfrontPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bgne:ResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bgne:CollaborativeArrangementCompensationTypeAxis">bgne:UpfrontPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bgne:ResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bgne:CollaborativeArrangementCompensationTypeAxis">bgne:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bgne:ResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bgne:CollaborativeArrangementCompensationTypeAxis">bgne:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">bgne:ResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bgne:CollaborativeArrangementCompensationTypeAxis">bgne:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOfFinancialPositionLocationActivityAccrualAxis">bgne:IntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bgne:CollaborativeArrangementCompensationTypeAxis">bgne:RegulatoryAndCommercialMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOfFinancialPositionLocationActivityAccrualAxis">bgne:IntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bgne:CollaborativeArrangementCompensationTypeAxis">bgne:RegulatoryAndCommercialMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOfFinancialPositionLocationActivityAccrualAxis">bgne:IntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bgne:CollaborativeArrangementCompensationTypeAxis">bgne:RegulatoryAndCommercialMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">bgne:STARMarketMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bgne:LeapTherapeuticIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bgne:LeapTherapeuticIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bgne:LeapTherapeuticIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bgne:LeapTherapeuticIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bgne:PiHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bgne:PiHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bgne:OtherEquityMethodInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">bgne:OtherEquityMethodInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bgne:PiHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bgne:PiHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">bgne:PiHealthIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherOperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bgne:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">bgne:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">bgne:HopewellFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">bgne:HopewellFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bgne:ShanghaiChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bgne:ShanghaiChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bgne:ShanghaiChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-31</endDate>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bgne:AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bgne:AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bgne:AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:StateAdministrationOfTaxationChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:SwissFederalTaxAdministrationFTAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedApril42018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaConstructionBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedApril42018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaConstructionBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedApril42018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaConstructionBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedJanuary222020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedJanuary222020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedJanuary222020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedNovember92020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedNovember92020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedNovember92020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:LongTermBankLoanDatedJuly292022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaCITICBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:LongTermBankLoanDatedJuly292022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaCITICBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:LongTermBankLoanDatedJuly292022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaCITICBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedJuly282023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedJuly282023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedJuly282023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedDecember202023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMinshengBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedDecember202023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMinshengBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedDecember202023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMinshengBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedMarch212024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaIndustrialBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedMarch212024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaIndustrialBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedMarch212024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaIndustrialBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedJune52023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedJune52023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedJune52023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedMay42023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:HSBCBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedMay42023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:HSBCBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedMay42023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:HSBCBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedMay302023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaIndustrialBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedMay302023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaIndustrialBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedMay302023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaIndustrialBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedNovember142023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ShanghaiPudongDevelopmentBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedNovember142023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ShanghaiPudongDevelopmentBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedNovember142023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ShanghaiPudongDevelopmentBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedMay252023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedMay252023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ShanghaiPudongDevelopmentBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedMay252023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedMay252023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:LongTermBankLoanApril42018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaConstructionBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:LongTermBankLoanApril42018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaConstructionBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:LongTermBankLoanApril42018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaConstructionBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:LongTermBankLoanDatedJanuary222020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:LongTermBankLoanDatedJanuary222020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:LongTermBankLoanDatedJanuary222020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:LongTermBankLoanDatedNovember92020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:LongTermBankLoanDatedNovember92020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:LongTermBankLoanDatedNovember92020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:LongTermBankLoanDatedJuly292022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaCITICBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:LongTermBankLoanDatedJuly292022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaCITICBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanDatedJanuary222020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaConstructionBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:LongTermBankLoanDatedJuly292022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMerchantsBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">bgne:ShortTermBankLoanMaturingJanuary272025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaMinshengBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">bgne:ChinaIndustrialBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:BRUKINSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:BRUKINSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:BRUKINSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:TislelizumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:TislelizumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:TislelizumabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:XGEVAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:XGEVAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:XGEVAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:BLINCYTOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:BLINCYTOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:BLINCYTOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:KYPROLISMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:KYPROLISMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:KYPROLISMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:POBEVCYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:POBEVCYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:POBEVCYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:REVLIMIDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:REVLIMIDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:REVLIMIDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="bgne:ProductNameAxis">bgne:OtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:RebatesReturnsAndOtherDeductionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:ContraARAccrualsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:RebatesReturnsAndOtherDeductionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:ContraARAccrualsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:RebatesReturnsAndOtherDeductionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:ContraARAccrualsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:RebatesReturnsAndOtherDeductionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:ContraARAccrualsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:RebatesReturnsAndOtherDeductionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:ContraARAccrualsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:ShareOptionAndIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-31</instant>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:ShareIncentivePlan2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:ShareOptionAndIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:ShareOptionAndIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-01</endDate>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:ShareOptionAndIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:ShareOptionAndIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:ShareOptionAndIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:ShareOptionAndIncentivePlan2016Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:ThirdAmendedAndRestated2016PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:InducementEquityPlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-31</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-31</instant>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-29</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-29</instant>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-31</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-31</instant>
        </period>
    </context>
    <context id="c-354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-28</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="c-355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-28</instant>
        </period>
    </context>
    <context id="c-356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-31</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="c-358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-28</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="c-359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="c-360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bgne:EmployeeSharePurchasePlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="c-397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-15</startDate>
            <endDate>2023-08-15</endDate>
        </period>
    </context>
    <context id="c-398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">bgne:MinimumPurchaseCommitmentsForSupplyPurchasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnrecordedUnconditionalPurchaseObligationByCategoryOfItemPurchasedAxis">us-gaap:CapitalAdditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bgne:InvestmentsFundingCommitmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bgne:AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bgne:AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bgne:AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bgne:AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bgne:AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">bgne:CollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">bgne:AllOtherCountriesExceptChinaAndUnitedStatesOfAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001651308</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">bgne:InvestmentsFundingCommitmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="employee">
        <measure>bgne:employee</measure>
    </unit>
    <unit id="segment">
        <measure>bgne:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="product">
        <measure>bgne:product</measure>
    </unit>
    <unit id="cny">
        <measure>iso4217:CNY</measure>
    </unit>
    <unit id="investment">
        <measure>bgne:investment</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-33">0001651308</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-34">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-35">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-36">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:GovernmentAssistanceLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration contextRef="c-87" id="f-486">http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</us-gaap:GovernmentAssistanceLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:GovernmentAssistanceLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration contextRef="c-88" id="f-487">http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</us-gaap:GovernmentAssistanceLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration>
    <us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-89" id="f-490">http://fasb.org/us-gaap/2024#DepreciationDepletionAndAmortization</us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-90" id="f-491">http://fasb.org/us-gaap/2024#DepreciationDepletionAndAmortization</us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-91" id="f-492">http://fasb.org/us-gaap/2024#DepreciationDepletionAndAmortization</us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <bgne:CommercializationTerm contextRef="c-151" id="f-567">P5Y</bgne:CommercializationTerm>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList contextRef="c-1" id="f-660">http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-362" id="f-1346">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-3">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-37686</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">BEIGENE,&#160;LTD.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">E9</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">98-1209416</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">c/o Mourant Governance Services (Cayman) Limited</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-11">94 Solaris Avenue, Camana Bay</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-12">Grand Cayman</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c-1" id="f-13">KY</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-14">KY1-1108</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-15">345</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-16">949 4123</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-17">American Depositary Shares, each representing 13 Ordinary Shares, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">ONC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-20">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-21">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-22">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-23">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-24">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-25">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-26">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-27">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-28">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-29">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-8" id="f-30" unitRef="usd">8700000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-31" unitRef="shares">1387367704</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-32">&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;The registrant intends to file&#160;a definitive proxy statement pursuant to Regulation&#160;14A within 120&#160;days of the end of the fiscal&#160;year ended December&#160;31, 2024. Portions of such definitive proxy statement are incorporated by reference into Part&#160;III of this Annual Report on Form&#160;10&#x2011;K.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="c-1" id="f-39">&lt;div style="margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the importance of safeguarding the security of our computer systems, software, networks, and other technology assets. Our cybersecurity efforts are aimed at preserving the confidentiality, integrity, and continued availability of information under our ownership or care with the aim to continually improve security features in order to keep pace with the evolving cyber threat landscape.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c-1" id="f-37">&lt;div style="margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the importance of safeguarding the security of our computer systems, software, networks, and other technology assets. Our cybersecurity efforts are aimed at preserving the confidentiality, integrity, and continued availability of information under our ownership or care with the aim to continually improve security features in order to keep pace with the evolving cyber threat landscape.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Overview of Cybersecurity Risk Management and Strategy&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;padding-right:4.5pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cybersecurity risk identification, assessment and management process is a critical part of our overall enterprise risk management (&#x201c;ERM&#x201d;) system. Within our ERM system, we adhere to our Information Security Management Policy (&#x201c;ISM Policy&#x201d;) which is aimed at providing guidelines to monitor, review and continually improve our Information Security Management System (&#x201c;ISMS&#x201d;). Our ISMS is informed by ISO/IEC 27001:2022 standards and is operated based on an action model that identifies information security missions and objectives, including improvement measures to achieve continuous optimization. Our Cybersecurity Incident Response Plan (&#x201c;CIRP&#x201d;) is a critical component of our cybersecurity incident identification and management process, which, along with our incident response team, is designed to guide our response to potential cybersecurity incidents effectively and efficiently. Our ISM Policy, ISMS and CIRP are all internal processes we use to assess, identify and manage material risks from cybersecurity threats.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also utilize external partnerships to help protect the Company from cybersecurity threats. This combination of people, processes and technology assist us to proactively manage and mitigate threats to our information technology environment. We have controls in place to defend against risks associated with cyber-attacks impacting our operations, compliance and financial reporting objectives. We are externally audited and certified under the ISO 27001 and assessed yearly according to National Institute of Standards and Technology (&#x201c;NIST&#x201d;) guidelines. Our external partners also evaluate our cybersecurity maturity and coverage as part of their services and keep us informed of emerging global threats. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;padding-right:4.5pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We conduct a Testing, Training &amp;amp; Exercise program to test, sustain and refine our ability to respond to cybersecurity incidents in accordance with the best practices. We also maintain an information security training program for our employees.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;padding-right:4.5pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Third-Party Security Management Standard provides a framework for managing third-party information security risks and defines controls to minimize risks to the Company. It applies to third parties who have access to or process Company information. This framework includes processes for conducting, as appropriate, due diligence, risk assessment and planning, contract management, access control, ongoing monitoring, and possible service termination of, or changes to the third-party as part of the selection and management process.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;padding-right:4.5pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have implemented a Threat Intelligence function that informs of external cyber threats which allows us to proactively protect the Company and to allow us to improve the speed of our vulnerability management capabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cybersecurity threats have to date not materially affected us, our business strategy, results of operations or financial condition. Similar to other companies, we and our third-party vendors have and will continue to experience threats to our systems and data.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c-1" id="f-38">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="c-1" id="f-40">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="c-1" id="f-41">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c-1" id="f-42">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c-1" id="f-43">The Board of Directors (&#x201c;Board&#x201d;) oversees risk management related to the operation of the business and corporate functions as well as the implementation of business strategy. Our Board has delegated to the Audit Committee oversight of risk management, which includes risks from cybersecurity threats. We routinely review critical elements of our cybersecurity policies and program with the Audit Committee.</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-46">&lt;div style="margin-bottom:9pt;margin-top:9pt;padding-right:4.5pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The management team &#x2013; including our Chief Information Security Officer (&#x201c;CISO&#x201d;) &#x2013; provides periodic reports to the Audit Committee which cover cybersecurity and other information technology risks affecting the Company. Such reports are typically provided at an Audit Committee meeting and enable Audit Committee members to ask questions of management and engage in additional discussions in an open forum. The Audit Committee also periodically evaluates our overall cybersecurity strategy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Management&#x2019;s Role in Assessing and Managing Material Risks from Cybersecurity Threats&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Information Security Steering Committee (&#x201c;ISSC&#x201d;) is responsible for oversight of matters related to information security and currently consists of professionals in legal operations and risk management, information governance, human resources operations, internal audit, computerized systems, global security and technical operations, and research technology, all whose input bring significant value when assessing and managing cybersecurity risk. Our ISSC meets periodically and is presented with an update on cybersecurity matters from our CISO. Our CISO is responsible for facilitating the implementation of the plans and decisions made by the ISSC and directly provides updates to the Audit Committee as detailed above.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-45">&lt;div style="margin-bottom:9pt;margin-top:9pt;padding-right:4.5pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The management team &#x2013; including our Chief Information Security Officer (&#x201c;CISO&#x201d;) &#x2013; provides periodic reports to the Audit Committee which cover cybersecurity and other information technology risks affecting the Company. Such reports are typically provided at an Audit Committee meeting and enable Audit Committee members to ask questions of management and engage in additional discussions in an open forum. The Audit Committee also periodically evaluates our overall cybersecurity strategy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Management&#x2019;s Role in Assessing and Managing Material Risks from Cybersecurity Threats&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Information Security Steering Committee (&#x201c;ISSC&#x201d;) is responsible for oversight of matters related to information security and currently consists of professionals in legal operations and risk management, information governance, human resources operations, internal audit, computerized systems, global security and technical operations, and research technology, all whose input bring significant value when assessing and managing cybersecurity risk. Our ISSC meets periodically and is presented with an update on cybersecurity matters from our CISO. Our CISO is responsible for facilitating the implementation of the plans and decisions made by the ISSC and directly provides updates to the Audit Committee as detailed above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Vice President of Global Technology Solutions head our Global Technology Solutions Team along with our CISO are responsible for leading the individuals tasked with maintaining our enterprise-wide cyber resilience strategy, policy, standards, architecture, and processes. Our CISO has over eighteen years of information technology and cybersecurity experience in multiple industries, including building and leading governance, risk, and compliance functions that cover ISO 27001 certified compliance, NIST Cybersecurity Framework assessments, Sarbanes-Oxley (&#x201c;SOX&#x201d;) information technology compliance, regional compliances, policy management, information technology risk management, vendor risk management, and security awareness. Our Vice President of Global Technology Solutions has over twenty years of experience leading technology organization and managing information security across multiple industries, including SOX 404 compliance, GxP audit and compliance, NIST Cybersecurity Framework assessments, managing incident response and communication with executives and board of directors.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-44">&lt;div style="margin-bottom:9pt;margin-top:9pt;padding-right:4.5pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The management team &#x2013; including our Chief Information Security Officer (&#x201c;CISO&#x201d;) &#x2013; provides periodic reports to the Audit Committee which cover cybersecurity and other information technology risks affecting the Company. Such reports are typically provided at an Audit Committee meeting and enable Audit Committee members to ask questions of management and engage in additional discussions in an open forum. The Audit Committee also periodically evaluates our overall cybersecurity strategy.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c-1" id="f-47">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="c-1" id="f-48">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="c-1" id="f-49">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Information Security Steering Committee (&#x201c;ISSC&#x201d;) is responsible for oversight of matters related to information security and currently consists of professionals in legal operations and risk management, information governance, human resources operations, internal audit, computerized systems, global security and technical operations, and research technology, all whose input bring significant value when assessing and managing cybersecurity risk. Our ISSC meets periodically and is presented with an update on cybersecurity matters from our CISO. Our CISO is responsible for facilitating the implementation of the plans and decisions made by the ISSC and directly provides updates to the Audit Committee as detailed above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Vice President of Global Technology Solutions head our Global Technology Solutions Team along with our CISO are responsible for leading the individuals tasked with maintaining our enterprise-wide cyber resilience strategy, policy, standards, architecture, and processes. Our CISO has over eighteen years of information technology and cybersecurity experience in multiple industries, including building and leading governance, risk, and compliance functions that cover ISO 27001 certified compliance, NIST Cybersecurity Framework assessments, Sarbanes-Oxley (&#x201c;SOX&#x201d;) information technology compliance, regional compliances, policy management, information technology risk management, vendor risk management, and security awareness. Our Vice President of Global Technology Solutions has over twenty years of experience leading technology organization and managing information security across multiple industries, including SOX 404 compliance, GxP audit and compliance, NIST Cybersecurity Framework assessments, managing incident response and communication with executives and board of directors.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-50">Our Vice President of Global Technology Solutions head our Global Technology Solutions Team along with our CISO are responsible for leading the individuals tasked with maintaining our enterprise-wide cyber resilience strategy, policy, standards, architecture, and processes.</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c-1" id="f-51">Our CISO has over eighteen years of information technology and cybersecurity experience in multiple industries, including building and leading governance, risk, and compliance functions that cover ISO 27001 certified compliance, NIST Cybersecurity Framework assessments, Sarbanes-Oxley (&#x201c;SOX&#x201d;) information technology compliance, regional compliances, policy management, information technology risk management, vendor risk management, and security awareness. Our Vice President of Global Technology Solutions has over twenty years of experience leading technology organization and managing information security across multiple industries, including SOX 404 compliance, GxP audit and compliance, NIST Cybersecurity Framework assessments, managing incident response and communication with executives and board of directors</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <dei:AuditorName contextRef="c-1" id="f-52">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-53">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-4" decimals="-3" id="f-54" unitRef="usd">3779546000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-3" id="f-55" unitRef="usd">2189852000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-56" unitRef="usd">1254612000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-3" id="f-57" unitRef="usd">30695000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-3" id="f-58" unitRef="usd">268927000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="-3" id="f-59" unitRef="usd">161309000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-60" unitRef="usd">3810241000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="-3" id="f-61" unitRef="usd">2458779000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="-3" id="f-62" unitRef="usd">1415921000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-4" decimals="-3" id="f-63" unitRef="usd">594089000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-5" decimals="-3" id="f-64" unitRef="usd">379920000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-6" decimals="-3" id="f-65" unitRef="usd">286475000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c-1" decimals="-3" id="f-66" unitRef="usd">3216152000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-10" decimals="-3" id="f-67" unitRef="usd">2078859000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-11" decimals="-3" id="f-68" unitRef="usd">1129446000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-69" unitRef="usd">1953295000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-10" decimals="-3" id="f-70" unitRef="usd">1778594000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-11" decimals="-3" id="f-71" unitRef="usd">1640508000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-72" unitRef="usd">1831056000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-10" decimals="-3" id="f-73" unitRef="usd">1508001000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-11" decimals="-3" id="f-74" unitRef="usd">1278603000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses contextRef="c-1" decimals="-3" id="f-75" unitRef="usd">3784351000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-10" decimals="-3" id="f-76" unitRef="usd">3286595000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-11" decimals="-3" id="f-77" unitRef="usd">2919111000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-78" unitRef="usd">-568199000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-10" decimals="-3" id="f-79" unitRef="usd">-1207736000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-11" decimals="-3" id="f-80" unitRef="usd">-1789665000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-1" decimals="-3" id="f-81" unitRef="usd">47836000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-10" decimals="-3" id="f-82" unitRef="usd">74009000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-11" decimals="-3" id="f-83" unitRef="usd">52480000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-84" unitRef="usd">-12638000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-10" decimals="-3" id="f-85" unitRef="usd">307891000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-11" decimals="-3" id="f-86" unitRef="usd">-223852000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-87" unitRef="usd">-533001000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-10" decimals="-3" id="f-88" unitRef="usd">-825836000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-11" decimals="-3" id="f-89" unitRef="usd">-1961037000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-90" unitRef="usd">111785000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-10" decimals="-3" id="f-91" unitRef="usd">55872000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-11" decimals="-3" id="f-92" unitRef="usd">42778000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-93" unitRef="usd">-644786000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-10" decimals="-3" id="f-94" unitRef="usd">-881708000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-11" decimals="-3" id="f-95" unitRef="usd">-2003815000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-96"
      unitRef="usdPerShare">-0.47</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-97"
      unitRef="usdPerShare">-0.47</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-10"
      decimals="2"
      id="f-98"
      unitRef="usdPerShare">-0.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-10"
      decimals="2"
      id="f-99"
      unitRef="usdPerShare">-0.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-11"
      decimals="2"
      id="f-100"
      unitRef="usdPerShare">-1.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-11"
      decimals="2"
      id="f-101"
      unitRef="usdPerShare">-1.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-102" unitRef="shares">1368746793</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-103" unitRef="shares">1368746793</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-10" decimals="0" id="f-104" unitRef="shares">1357034547</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-10" decimals="0" id="f-105" unitRef="shares">1357034547</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-11" decimals="0" id="f-106" unitRef="shares">1340729572</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-11" decimals="0" id="f-107" unitRef="shares">1340729572</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <bgne:EarningsPerAmericanDepositoryShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-108"
      unitRef="usdPerShare">-6.12</bgne:EarningsPerAmericanDepositoryShareBasic>
    <bgne:EarningsPerAmericanDepositoryShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-109"
      unitRef="usdPerShare">-6.12</bgne:EarningsPerAmericanDepositoryShareDiluted>
    <bgne:EarningsPerAmericanDepositoryShareBasic
      contextRef="c-10"
      decimals="2"
      id="f-110"
      unitRef="usdPerShare">-8.45</bgne:EarningsPerAmericanDepositoryShareBasic>
    <bgne:EarningsPerAmericanDepositoryShareDiluted
      contextRef="c-10"
      decimals="2"
      id="f-111"
      unitRef="usdPerShare">-8.45</bgne:EarningsPerAmericanDepositoryShareDiluted>
    <bgne:EarningsPerAmericanDepositoryShareDiluted
      contextRef="c-11"
      decimals="2"
      id="f-112"
      unitRef="usdPerShare">-19.43</bgne:EarningsPerAmericanDepositoryShareDiluted>
    <bgne:EarningsPerAmericanDepositoryShareBasic
      contextRef="c-11"
      decimals="2"
      id="f-113"
      unitRef="usdPerShare">-19.43</bgne:EarningsPerAmericanDepositoryShareBasic>
    <bgne:WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted contextRef="c-1" decimals="0" id="f-114" unitRef="shares">105288215</bgne:WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted>
    <bgne:WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic contextRef="c-1" decimals="0" id="f-115" unitRef="shares">105288215</bgne:WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic>
    <bgne:WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic contextRef="c-10" decimals="0" id="f-116" unitRef="shares">104387273</bgne:WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic>
    <bgne:WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted contextRef="c-10" decimals="0" id="f-117" unitRef="shares">104387273</bgne:WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted>
    <bgne:WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic contextRef="c-11" decimals="0" id="f-118" unitRef="shares">103133044</bgne:WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic>
    <bgne:WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted contextRef="c-11" decimals="0" id="f-119" unitRef="shares">103133044</bgne:WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-120" unitRef="usd">-644786000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-10" decimals="-3" id="f-121" unitRef="usd">-881708000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-11" decimals="-3" id="f-122" unitRef="usd">-2003815000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-123" unitRef="usd">-47565000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-10" decimals="-3" id="f-124" unitRef="usd">-25464000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-11" decimals="-3" id="f-125" unitRef="usd">-90421000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-126" unitRef="usd">1942000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-10" decimals="-3" id="f-127" unitRef="usd">5611000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-11" decimals="-3" id="f-128" unitRef="usd">-365000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-129" unitRef="usd">-35000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-10" decimals="-3" id="f-130" unitRef="usd">9046000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-11" decimals="-3" id="f-131" unitRef="usd">-5311000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-132" unitRef="usd">-694328000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-10" decimals="-3" id="f-133" unitRef="usd">-903737000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-11" decimals="-3" id="f-134" unitRef="usd">-2099182000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-12" decimals="-3" id="f-135" unitRef="usd">2627410000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-13" decimals="-3" id="f-136" unitRef="usd">3171800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-12" decimals="-3" id="f-137" unitRef="usd">676278000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-13" decimals="-3" id="f-138" unitRef="usd">358027000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-12" decimals="-3" id="f-139" unitRef="usd">494986000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-13" decimals="-3" id="f-140" unitRef="usd">416122000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-12" decimals="-3" id="f-141" unitRef="usd">192919000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-13" decimals="-3" id="f-142" unitRef="usd">257465000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-12" decimals="-3" id="f-143" unitRef="usd">3991593000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-13" decimals="-3" id="f-144" unitRef="usd">4203414000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-12" decimals="-3" id="f-145" unitRef="usd">1578423000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-13" decimals="-3" id="f-146" unitRef="usd">1324154000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-12" decimals="-3" id="f-147" unitRef="usd">139309000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-13" decimals="-3" id="f-148" unitRef="usd">95207000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-12" decimals="-3" id="f-149" unitRef="usd">51095000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-13" decimals="-3" id="f-150" unitRef="usd">57138000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-12" decimals="-3" id="f-151" unitRef="usd">160490000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-13" decimals="-3" id="f-152" unitRef="usd">125362000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c-12" decimals="-3" id="f-153" unitRef="usd">1929317000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c-13" decimals="-3" id="f-154" unitRef="usd">1601861000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="c-12" decimals="-3" id="f-155" unitRef="usd">5920910000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-13" decimals="-3" id="f-156" unitRef="usd">5805275000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-12" decimals="-3" id="f-157" unitRef="usd">404997000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-13" decimals="-3" id="f-158" unitRef="usd">315111000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-12" decimals="-3" id="f-159" unitRef="usd">803713000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-13" decimals="-3" id="f-160" unitRef="usd">693731000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c-12" decimals="-3" id="f-161" unitRef="usd">25930000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c-13" decimals="-3" id="f-162" unitRef="usd">22951000</us-gaap:TaxesPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-12" decimals="-3" id="f-163" unitRef="usd">17576000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-13" decimals="-3" id="f-164" unitRef="usd">21950000</us-gaap:OperatingLeaseLiabilityCurrent>
    <bgne:ResearchAndDevelopmentCostShareLiabilityCurrentPortion contextRef="c-12" decimals="-3" id="f-165" unitRef="usd">111154000</bgne:ResearchAndDevelopmentCostShareLiabilityCurrentPortion>
    <bgne:ResearchAndDevelopmentCostShareLiabilityCurrentPortion contextRef="c-13" decimals="-3" id="f-166" unitRef="usd">68004000</bgne:ResearchAndDevelopmentCostShareLiabilityCurrentPortion>
    <us-gaap:LongTermDebtCurrent contextRef="c-12" decimals="-3" id="f-167" unitRef="usd">851529000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-13" decimals="-3" id="f-168" unitRef="usd">688366000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-12" decimals="-3" id="f-169" unitRef="usd">2214899000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-13" decimals="-3" id="f-170" unitRef="usd">1810113000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-12" decimals="-3" id="f-171" unitRef="usd">166484000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-13" decimals="-3" id="f-172" unitRef="usd">197618000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-12" decimals="-3" id="f-173" unitRef="usd">44277000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-13" decimals="-3" id="f-174" unitRef="usd">22251000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-12" decimals="-3" id="f-175" unitRef="usd">42007000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-13" decimals="-3" id="f-176" unitRef="usd">16494000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <bgne:ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion contextRef="c-12" decimals="-3" id="f-177" unitRef="usd">54286000</bgne:ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion>
    <bgne:ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion contextRef="c-13" decimals="-3" id="f-178" unitRef="usd">170662000</bgne:ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-12" decimals="-3" id="f-179" unitRef="usd">66735000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-13" decimals="-3" id="f-180" unitRef="usd">50810000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c-12" decimals="-3" id="f-181" unitRef="usd">373789000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c-13" decimals="-3" id="f-182" unitRef="usd">457835000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-12" decimals="-3" id="f-183" unitRef="usd">2588688000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-13" decimals="-3" id="f-184" unitRef="usd">2267948000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-12" id="f-185" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-13" id="f-186" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-13"
      decimals="INF"
      id="f-187"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-12"
      decimals="INF"
      id="f-188"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-12"
      decimals="INF"
      id="f-189"
      unitRef="shares">9500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-13"
      decimals="INF"
      id="f-190"
      unitRef="shares">9500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-12"
      decimals="INF"
      id="f-191"
      unitRef="shares">1387367704</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-12"
      decimals="INF"
      id="f-192"
      unitRef="shares">1387367704</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-13"
      decimals="INF"
      id="f-193"
      unitRef="shares">1359513224</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-13"
      decimals="INF"
      id="f-194"
      unitRef="shares">1359513224</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-12" decimals="-3" id="f-195" unitRef="usd">138000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-13" decimals="-3" id="f-196" unitRef="usd">135000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-12" decimals="-3" id="f-197" unitRef="usd">12087908000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-13" decimals="-3" id="f-198" unitRef="usd">11598688000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-12" decimals="-3" id="f-199" unitRef="usd">-148988000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-13" decimals="-3" id="f-200" unitRef="usd">-99446000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-12" decimals="-3" id="f-201" unitRef="usd">-8606836000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-13" decimals="-3" id="f-202" unitRef="usd">-7962050000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="-3" id="f-203" unitRef="usd">3332222000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-13" decimals="-3" id="f-204" unitRef="usd">3537327000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-12" decimals="-3" id="f-205" unitRef="usd">5920910000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-13" decimals="-3" id="f-206" unitRef="usd">5805275000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-207" unitRef="usd">-644786000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-10" decimals="-3" id="f-208" unitRef="usd">-881708000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-11" decimals="-3" id="f-209" unitRef="usd">-2003815000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-210" unitRef="usd">171762000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-10" decimals="-3" id="f-211" unitRef="usd">87675000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-11" decimals="-3" id="f-212" unitRef="usd">66278000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-213" unitRef="usd">441618000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-10" decimals="-3" id="f-214" unitRef="usd">367618000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-11" decimals="-3" id="f-215" unitRef="usd">303162000</us-gaap:ShareBasedCompensation>
    <bgne:AcquiredInProcessResearchAndDevelopment contextRef="c-1" decimals="-3" id="f-216" unitRef="usd">60000000</bgne:AcquiredInProcessResearchAndDevelopment>
    <bgne:AcquiredInProcessResearchAndDevelopment contextRef="c-10" decimals="-3" id="f-217" unitRef="usd">46800000</bgne:AcquiredInProcessResearchAndDevelopment>
    <bgne:AcquiredInProcessResearchAndDevelopment contextRef="c-11" decimals="-3" id="f-218" unitRef="usd">68665000</bgne:AcquiredInProcessResearchAndDevelopment>
    <bgne:AmortizationOfResearchAndDevelopmentFinancingLiability contextRef="c-1" decimals="-3" id="f-219" unitRef="usd">-73226000</bgne:AmortizationOfResearchAndDevelopmentFinancingLiability>
    <bgne:AmortizationOfResearchAndDevelopmentFinancingLiability contextRef="c-10" decimals="-3" id="f-220" unitRef="usd">-55294000</bgne:AmortizationOfResearchAndDevelopmentFinancingLiability>
    <bgne:AmortizationOfResearchAndDevelopmentFinancingLiability contextRef="c-11" decimals="-3" id="f-221" unitRef="usd">-96402000</bgne:AmortizationOfResearchAndDevelopmentFinancingLiability>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-1" decimals="-3" id="f-222" unitRef="usd">-24022000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-10" decimals="-3" id="f-223" unitRef="usd">-16221000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-11" decimals="-3" id="f-224" unitRef="usd">-21996000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-1" decimals="-3" id="f-225" unitRef="usd">25983000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-10" decimals="-3" id="f-226" unitRef="usd">689000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-11" decimals="-3" id="f-227" unitRef="usd">2059000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:GainLossRelatedToLitigationSettlement contextRef="c-1" decimals="-3" id="f-228" unitRef="usd">0</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement contextRef="c-10" decimals="-3" id="f-229" unitRef="usd">362917000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement contextRef="c-11" decimals="-3" id="f-230" unitRef="usd">0</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-1" decimals="-3" id="f-231" unitRef="usd">11163000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-10" decimals="-3" id="f-232" unitRef="usd">-5998000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-11" decimals="-3" id="f-233" unitRef="usd">9047000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-234" unitRef="usd">329443000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-10" decimals="-3" id="f-235" unitRef="usd">188306000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-11" decimals="-3" id="f-236" unitRef="usd">-304112000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-3" id="f-237" unitRef="usd">91496000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-10" decimals="-3" id="f-238" unitRef="usd">140948000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-11" decimals="-3" id="f-239" unitRef="usd">56689000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-1" decimals="-3" id="f-240" unitRef="usd">-45126000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-10" decimals="-3" id="f-241" unitRef="usd">-12120000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c-11" decimals="-3" id="f-242" unitRef="usd">3282000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-243" unitRef="usd">121497000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-10" decimals="-3" id="f-244" unitRef="usd">21484000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-11" decimals="-3" id="f-245" unitRef="usd">-4352000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="-3" id="f-246" unitRef="usd">111354000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c-10" decimals="-3" id="f-247" unitRef="usd">180111000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c-11" decimals="-3" id="f-248" unitRef="usd">45627000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-249" unitRef="usd">633000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-10" decimals="-3" id="f-250" unitRef="usd">-255587000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-11" decimals="-3" id="f-251" unitRef="usd">-151816000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-1" decimals="-3" id="f-252" unitRef="usd">-14838000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-10" decimals="-3" id="f-253" unitRef="usd">587000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-11" decimals="-3" id="f-254" unitRef="usd">-1209000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-255" unitRef="usd">-140631000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-10" decimals="-3" id="f-256" unitRef="usd">-1157453000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-11" decimals="-3" id="f-257" unitRef="usd">-1496619000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-258" unitRef="usd">492663000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-10" decimals="-3" id="f-259" unitRef="usd">561896000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-11" decimals="-3" id="f-260" unitRef="usd">325434000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="-3" id="f-261" unitRef="usd">2655000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-10" decimals="-3" id="f-262" unitRef="usd">673240000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-11" decimals="-3" id="f-263" unitRef="usd">1563618000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <bgne:PaymentsToPurchaseInProcessResearchAndDevelopment contextRef="c-1" decimals="-3" id="f-264" unitRef="usd">31800000</bgne:PaymentsToPurchaseInProcessResearchAndDevelopment>
    <bgne:PaymentsToPurchaseInProcessResearchAndDevelopment contextRef="c-10" decimals="-3" id="f-265" unitRef="usd">15000000</bgne:PaymentsToPurchaseInProcessResearchAndDevelopment>
    <bgne:PaymentsToPurchaseInProcessResearchAndDevelopment contextRef="c-11" decimals="-3" id="f-266" unitRef="usd">143665000</bgne:PaymentsToPurchaseInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-1" decimals="-3" id="f-267" unitRef="usd">4674000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-10" decimals="-3" id="f-268" unitRef="usd">19365000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-11" decimals="-3" id="f-269" unitRef="usd">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireLongtermInvestments contextRef="c-1" decimals="-3" id="f-270" unitRef="usd">19006000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:PaymentsToAcquireLongtermInvestments contextRef="c-10" decimals="-3" id="f-271" unitRef="usd">14900000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:PaymentsToAcquireLongtermInvestments contextRef="c-11" decimals="-3" id="f-272" unitRef="usd">15911000</us-gaap:PaymentsToAcquireLongtermInvestments>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-1" decimals="-3" id="f-273" unitRef="usd">2862000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-10" decimals="-3" id="f-274" unitRef="usd">2075000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-11" decimals="-3" id="f-275" unitRef="usd">1485000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-276" unitRef="usd">-548350000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-10" decimals="-3" id="f-277" unitRef="usd">60004000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-11" decimals="-3" id="f-278" unitRef="usd">1077123000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromLongTermLinesOfCredit contextRef="c-1" decimals="-3" id="f-279" unitRef="usd">9053000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit contextRef="c-10" decimals="-3" id="f-280" unitRef="usd">22502000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit contextRef="c-11" decimals="-3" id="f-281" unitRef="usd">37372000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-1" decimals="-3" id="f-282" unitRef="usd">28031000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-10" decimals="-3" id="f-283" unitRef="usd">13690000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-11" decimals="-3" id="f-284" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromShortTermDebt contextRef="c-1" decimals="-3" id="f-285" unitRef="usd">868270000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt contextRef="c-10" decimals="-3" id="f-286" unitRef="usd">661530000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt contextRef="c-11" decimals="-3" id="f-287" unitRef="usd">313774000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="c-1" decimals="-3" id="f-288" unitRef="usd">704216000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="c-10" decimals="-3" id="f-289" unitRef="usd">309576000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="c-11" decimals="-3" id="f-290" unitRef="usd">417081000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-1" decimals="-3" id="f-291" unitRef="usd">45373000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-10" decimals="-3" id="f-292" unitRef="usd">55712000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-11" decimals="-3" id="f-293" unitRef="usd">46964000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-1" decimals="-3" id="f-294" unitRef="usd">3000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-10" decimals="-3" id="f-295" unitRef="usd">0</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-11" decimals="-3" id="f-296" unitRef="usd">0</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-297" unitRef="usd">193449000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-10" decimals="-3" id="f-298" unitRef="usd">416478000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-11" decimals="-3" id="f-299" unitRef="usd">-18971000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-3" id="f-300" unitRef="usd">-51705000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-10" decimals="-3" id="f-301" unitRef="usd">-8082000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-11" decimals="-3" id="f-302" unitRef="usd">-69383000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-303" unitRef="usd">-547237000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-10" decimals="-3" id="f-304" unitRef="usd">-689053000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-11" decimals="-3" id="f-305" unitRef="usd">-507850000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-13" decimals="-3" id="f-306" unitRef="usd">3185984000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-14" decimals="-3" id="f-307" unitRef="usd">3875037000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-15" decimals="-3" id="f-308" unitRef="usd">4382887000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-12" decimals="-3" id="f-309" unitRef="usd">2638747000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-13" decimals="-3" id="f-310" unitRef="usd">3185984000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-14" decimals="-3" id="f-311" unitRef="usd">3875037000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-12" decimals="-3" id="f-312" unitRef="usd">2627410000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-13" decimals="-3" id="f-313" unitRef="usd">3171800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-14" decimals="-3" id="f-314" unitRef="usd">3869564000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-12" decimals="-3" id="f-315" unitRef="usd">9312000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-13" decimals="-3" id="f-316" unitRef="usd">11473000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-14" decimals="-3" id="f-317" unitRef="usd">196000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-12" decimals="-3" id="f-318" unitRef="usd">2025000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-13" decimals="-3" id="f-319" unitRef="usd">2711000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="c-14" decimals="-3" id="f-320" unitRef="usd">5277000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-3" id="f-321" unitRef="usd">69430000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-10" decimals="-3" id="f-322" unitRef="usd">56003000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-11" decimals="-3" id="f-323" unitRef="usd">29500000</us-gaap:IncomeTaxesPaidNet>
    <bgne:InterestPaidIncludingCapitalizedInterest contextRef="c-1" decimals="-3" id="f-324" unitRef="usd">51175000</bgne:InterestPaidIncludingCapitalizedInterest>
    <bgne:InterestPaidIncludingCapitalizedInterest contextRef="c-10" decimals="-3" id="f-325" unitRef="usd">19753000</bgne:InterestPaidIncludingCapitalizedInterest>
    <bgne:InterestPaidIncludingCapitalizedInterest contextRef="c-11" decimals="-3" id="f-326" unitRef="usd">25169000</bgne:InterestPaidIncludingCapitalizedInterest>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-327" unitRef="usd">70314000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-10" decimals="-3" id="f-328" unitRef="usd">91804000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-11" decimals="-3" id="f-329" unitRef="usd">95346000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <bgne:AcquiredInProcessResearchAndDevelopmentButNotYetPaid contextRef="c-1" decimals="-3" id="f-330" unitRef="usd">60000000</bgne:AcquiredInProcessResearchAndDevelopmentButNotYetPaid>
    <bgne:AcquiredInProcessResearchAndDevelopmentButNotYetPaid contextRef="c-10" decimals="-3" id="f-331" unitRef="usd">31800000</bgne:AcquiredInProcessResearchAndDevelopmentButNotYetPaid>
    <bgne:AcquiredInProcessResearchAndDevelopmentButNotYetPaid contextRef="c-11" decimals="-3" id="f-332" unitRef="usd">0</bgne:AcquiredInProcessResearchAndDevelopmentButNotYetPaid>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-16"
      decimals="INF"
      id="f-333"
      unitRef="shares">1334804281</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-16" decimals="-3" id="f-334" unitRef="usd">133000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-335" unitRef="usd">11191007000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-336" unitRef="usd">17950000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-337" unitRef="usd">-5076527000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-15" decimals="-3" id="f-338" unitRef="usd">6132563000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-20" decimals="-3" id="f-339" unitRef="usd">152000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-11" decimals="-3" id="f-340" unitRef="usd">152000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-21"
      decimals="INF"
      id="f-341"
      unitRef="shares">1375621</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-21"
      decimals="INF"
      id="f-342"
      unitRef="shares">19960278</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-21" decimals="-3" id="f-343" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-20" decimals="-3" id="f-344" unitRef="usd">46962000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-11" decimals="-3" id="f-345" unitRef="usd">46964000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-20" decimals="-3" id="f-346" unitRef="usd">303162000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-11" decimals="-3" id="f-347" unitRef="usd">303162000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-22" decimals="-3" id="f-348" unitRef="usd">-95367000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-11" decimals="-3" id="f-349" unitRef="usd">-95367000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-23" decimals="-3" id="f-350" unitRef="usd">-2003815000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-11" decimals="-3" id="f-351" unitRef="usd">-2003815000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-24"
      decimals="INF"
      id="f-352"
      unitRef="shares">1356140180</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-353" unitRef="usd">135000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-354" unitRef="usd">11540979000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-355" unitRef="usd">-77417000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-356" unitRef="usd">-7080342000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-14" decimals="-3" id="f-357" unitRef="usd">4383355000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-28"
      decimals="INF"
      id="f-358"
      unitRef="shares">84227</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-28"
      decimals="INF"
      id="f-359"
      unitRef="shares">26561925</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-28" decimals="-3" id="f-360" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-29" decimals="-3" id="f-361" unitRef="usd">53006000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-10" decimals="-3" id="f-362" unitRef="usd">53008000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="c-28"
      decimals="INF"
      id="f-363"
      unitRef="shares">23273108</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-28" decimals="-3" id="f-364" unitRef="usd">2000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-29" decimals="-3" id="f-365" unitRef="usd">362915000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-1" decimals="-3" id="f-366" unitRef="usd">362917000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-29" decimals="-3" id="f-367" unitRef="usd">367618000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-10" decimals="-3" id="f-368" unitRef="usd">367618000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-30" decimals="-3" id="f-369" unitRef="usd">-22029000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-10" decimals="-3" id="f-370" unitRef="usd">-22029000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-31" decimals="-3" id="f-371" unitRef="usd">-881708000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-10" decimals="-3" id="f-372" unitRef="usd">-881708000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-32"
      decimals="INF"
      id="f-373"
      unitRef="shares">1359513224</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-374" unitRef="usd">135000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-375" unitRef="usd">11598688000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-376" unitRef="usd">-99446000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-3" id="f-377" unitRef="usd">-7962050000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-13" decimals="-3" id="f-378" unitRef="usd">3537327000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-36"
      decimals="INF"
      id="f-379"
      unitRef="shares">-2258161</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-36"
      decimals="INF"
      id="f-380"
      unitRef="shares">30112641</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-36" decimals="-3" id="f-381" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-37" decimals="-3" id="f-382" unitRef="usd">45550000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-1" decimals="-3" id="f-383" unitRef="usd">45553000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <bgne:AdjustmentsToAdditionalPaidInCapitalDeconsolidationOfSubsidiary contextRef="c-37" decimals="-3" id="f-384" unitRef="usd">2052000</bgne:AdjustmentsToAdditionalPaidInCapitalDeconsolidationOfSubsidiary>
    <bgne:AdjustmentsToAdditionalPaidInCapitalDeconsolidationOfSubsidiary contextRef="c-1" decimals="-3" id="f-385" unitRef="usd">2052000</bgne:AdjustmentsToAdditionalPaidInCapitalDeconsolidationOfSubsidiary>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-37" decimals="-3" id="f-386" unitRef="usd">441618000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-387" unitRef="usd">441618000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-38" decimals="-3" id="f-388" unitRef="usd">-49542000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-3" id="f-389" unitRef="usd">-49542000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-39" decimals="-3" id="f-390" unitRef="usd">-644786000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-391" unitRef="usd">-644786000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-40"
      decimals="INF"
      id="f-392"
      unitRef="shares">1387367704</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="-3" id="f-393" unitRef="usd">138000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-41" decimals="-3" id="f-394" unitRef="usd">12087908000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-42" decimals="-3" id="f-395" unitRef="usd">-148988000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-43" decimals="-3" id="f-396" unitRef="usd">-8606836000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="-3" id="f-397" unitRef="usd">3332222000</us-gaap:StockholdersEquity>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="c-1" id="f-398">Description of Business&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;BeiGene, Ltd. (the &#x201c;Company&#x201d;, &#x201c;BeiGene&#x201d;, &#x201c;it&#x201d;, &#x201c;its&#x201d;) is a leading global oncology company discovering and developing innovative treatments that are more accessible and affordable to cancer patients worldwide. In 2024, the Company generated total global revenue of approximately $3.8 billion, increasing revenue by approximately $1.4 billion from the prior year, while reducing its operating loss from the prior year by approximately $0.6 billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since its inception in 2010, the Company has become a fully integrated global organization with more than 11,000 employees worldwide.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-8" id="f-399" unitRef="usd">3800000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <bgne:RevenueFromContractWithCustomerExcludingAssessedTaxPeriodIncreaseDecrease contextRef="c-1" decimals="-8" id="f-400" unitRef="usd">1400000000</bgne:RevenueFromContractWithCustomerExcludingAssessedTaxPeriodIncreaseDecrease>
    <bgne:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestPeriodIncreaseDecrease contextRef="c-1" decimals="-8" id="f-401" unitRef="usd">-600000000</bgne:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestPeriodIncreaseDecrease>
    <dei:EntityNumberOfEmployees
      contextRef="c-12"
      decimals="-3"
      id="f-402"
      unitRef="employee">11000</dei:EntityNumberOfEmployees>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-403">Summary of Significant Accounting Policies&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). The consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany transactions and balances between the Company and its wholly-owned subsidiaries are eliminated upon consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Areas where management uses subjective judgment include, but are not limited to, estimating the useful lives of long-lived assets, estimating variable consideration in product sales and collaboration revenue arrangements, identifying separate accounting units and the standalone selling price of each performance obligation in the Company&#x2019;s revenue arrangements, assessing the impairment of long-lived assets, valuation and recognition of share-based compensation expenses, estimating uncertain tax positions, valuation of inventory, estimating the allowance for credit losses, determining defined benefit pension plan obligations, measurement of right-of-use assets and lease liabilities and the fair value of financial instruments. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Functional Currency and Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Functional currency and foreign currency gains and losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the U.S. dollar (&#x201c;$&#x201d; or U.S. dollar) as its reporting currency. Transactions in subsidiaries are recorded in the functional currency of the respective subsidiary and such transactions denominated in currencies other than the functional currency give rise to foreign exchange remeasurement (monetary assets and liabilities) and related gains and losses that are classified in other (expense) income, net in the consolidated statement of operations. The determination of functional currency is based on the criteria of Accounting Standard Codification (&#x201c;ASC&#x201d;) 830, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Matters&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. For those periods presented, the Company has not entered into any foreign currency derivative instruments to hedge its foreign currency positions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign currency translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For subsidiaries whose functional currencies are not the U.S. dollar, the Company uses the average exchange rate for the period and the exchange rate at the balance sheet date to translate the operating results and financial position to the U.S. dollar, which is the Company's reporting currency. Translation differences are recorded in accumulated other comprehensive loss, a component of shareholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of cash on hand and bank deposits, which are unrestricted as to withdrawal and use. The Company considers all highly liquid investments with an original maturity date of three months or less at the date of purchase to be cash equivalents. Cash equivalents which consist primarily of money market funds are stated at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash primarily consists of&#160;RMB-denominated cash deposits pledged in designated bank accounts as collateral for bank loans and letters of credit. The Company classifies restricted cash as current or non-current based on the term of the restriction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the restricted cash balances above, the Company is required by the PRC securities law to use the proceeds from the STAR offering in strict compliance with the planned uses as disclosed in the PRC offering prospectus as well as those disclosed in the Company&#x2019;s proceeds management policy approved by its board of directors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable and Allowance for Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade accounts receivable are recorded at their invoiced amounts, net of trade discounts and allowances as well as an allowance for credit losses. The allowance for credit losses reflects the Company&#x2019;s current estimate of credit losses expected to be incurred over the life of the receivables. The Company considers various factors in establishing, monitoring, and adjusting its allowance for credit losses including the aging of receivables and aging trends, customer creditworthiness and specific exposures related to particular customers. The Company also monitors other risk factors and forward-looking information, such as country specific risks and economic factors that may affect a customer&#x2019;s ability to pay in establishing and adjusting its allowance for credit losses. Accounts receivable are written off after all collection efforts have ceased.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Prior to the regulatory approval of product candidates, the Company may incur costs for the manufacture of drug product to support the commercial launch of those products. Until the date at which regulatory approval has been received or is otherwise considered probable, all such costs are recorded as research and development expenses as incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost and net realizable value, with cost determined in a manner that approximates weighted average cost. The Company periodically analyzes its inventory levels, and writes down inventory that has become obsolete, inventory that has a cost basis in excess of its estimated realizable value and inventory in excess of expected sales requirements as cost of product sales. The determination of whether inventory costs will be realizable requires estimates of future prices by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required, which would be recorded in the consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investments consist of available-for-sale debt securities, convertible note instruments, public equity securities with readily determinable fair values, private equity securities without readily determinable fair values, and equity-method investments. The classification of an investment is determined based on the nature of the investment, the Company&#x2019;s ability and intent to hold the investment, and the degree to which the Company may exercise influence over the investee.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Available-for-sale debt securities are stated at fair value, with the unrealized gains and losses, net of tax, reported in other comprehensive loss. The net carrying value of debt securities classified as available-for-sale is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization is computed using the effective interest method and included in interest income. Interest and dividends are included in interest income. Available-for-sale debt securities with original maturities greater than three months at the date of purchase and less than one year from the date of the balance sheet are classified as short-term. Available-for-sale debt securities with maturities beyond one year may be classified as short-term marketable securities due to their highly liquid nature and because they represent the Company&#x2019;s investments that are available for current operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Convertible note instruments are recorded using the fair value option method of accounting. Accordingly, convertible note instruments are remeasured at fair value on a recurring basis, with any changes in the fair value option recorded in other (expense) income, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Public equity securities with readily determinable fair values are recorded at fair value. Subsequent changes in fair value are recorded in other (expense) income, net. Derivative financial instruments to purchase public equity securities are recorded at fair value. The estimated fair value of derivative financial instruments is determined based on the Black-Scholes valuation model. Changes in fair value of derivative instruments are recorded in other (expense) income, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Private equity securities without readily determinable fair values and where the Company does not have significant influence are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Adjustments to private equity securities are recorded in other (expense) income, net. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Equity investments in common stock or in-substance common stock where the Company has significant influence over the financial and operating policies of the investee are accounted for as equity-method investments. Equity-method investments are initially recorded at cost and subsequently adjusted based on the Company&#x2019;s percentage ownership in the investee&#x2019;s income and expenses, as well as dividends, if any. The Company records its share of the investee&#x2019;s results of operations in other (expense) income, net. The Company records impairment losses on our equity method investments if it deems the impairment to be other-than-temporary. The Company deems an impairment to be other-than-temporary based on various factors, including but not limited to, the length of time the fair value is below the carrying value and ability to retain the investment to allow for a recovery in fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains or losses on sales of investments are determined based on the specific identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company regularly evaluates its investments in debt and equity for impairment. The Company recognizes an allowance on available-for-sale debt securities when a portion of the unrealized loss is attributable to a credit loss and a corresponding credit loss in net income. No allowance for credit losses were recorded for any periods presented. The Company recognized an impairment loss of $7,635 and $7,529 related to its investments in equity during the years ended December&#160;31, 2024 and 2023, respectively. No impairment losses on equity investments were recorded for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Property, plant and equipment, other than land and construction in progress, are depreciated using the straight-line method over the estimated useful lives of the respective assets as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.806%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:27.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Useful&#160;Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software, Electronic and Office Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold Improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lesser of useful life or lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically evaluates whether events and circumstances have occurred that indicate the estimated useful lives of its long-lived assets may require reassessment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies ASC, Topic 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 842&#x201d;) to account for its leases. The Company determines if an arrangement is a lease at inception. The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease component based on the Company&#x2019;s policy election to combine lease and non-lease components for its leases. Leases are classified as operating or finance leases in accordance with the recognition criteria in ASC 842-20-25. The Company&#x2019;s lease portfolio consists entirely of operating leases as of December&#160;31, 2024. The Company&#x2019;s leases do not contain any material residual value guarantees or material restrictive covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the commencement date of a lease, the Company determines the classification of the lease based on the relevant factors present and records a right-of-use (&#x201c;ROU&#x201d;) asset and lease liability. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and lease liabilities are calculated as the present value of the lease payments not yet paid. Variable lease payments not dependent on an index or rate are excluded from the ROU asset and lease liability calculations and are recognized in expense in the period which the obligation for those payments is incurred. As the rate implicit in the Company&#x2019;s leases is not typically readily available, the Company uses an incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. This incremental borrowing rate reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. ROU assets include any lease prepayments and are reduced by lease incentives. Operating lease expense for lease payments is recognized on a straight-line basis over the lease term. Lease terms are based on the non-cancelable term of the lease and may contain options to extend the lease when it is reasonably certain that the Company will exercise that option. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases are included in operating lease right-of-use assets and operating lease liabilities on the consolidated balance sheet. Lease liabilities that become due within one year of the balance sheet date are classified as current liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial lease term of 12 months or less are not recorded on the consolidated balance sheet. Lease expense for these leases is recognized on a straight-line basis over the lease term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Land Use Right, Net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All land in the PRC is owned by the PRC government. The PRC government may sell land use rights for a specified period of time. Land use rights represent operating leases in accordance with ASC 842. The purchase price of land use rights represents lease prepayments to the PRC government and is recorded as an operating lease ROU asset on the balance sheet. The ROU asset is amortized over the remaining lease term. As of December&#160;31, 2024, the Company held land use rights in the following regions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.806%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:27.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Terms&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Guangzhou&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beijing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Suzhou&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shanghai&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets acquired through business combinations are recognized as assets separate from goodwill and are measured at fair value upon acquisition. Intangible assets acquired in transactions that are not business combinations are recorded at the allocated portion of total consideration transferred based on their relative fair value in relation to net assets acquired. Intangible assets associated with milestone payments made to third parties subsequent to regulatory approval are recorded at cost. Identifiable intangible assets consist of post-approval milestone payments under license and commercialization agreements, that are amortized over the remainder of the product patent or the term of the commercialization agreements; and trading licenses that are amortized over the initial license term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with finite useful lives are tested for impairment when events or circumstances occur that could indicate that the carrying amount of an asset may not be recoverable. When these events occur, the Company evaluates the recoverability of the intangible assets by comparing the carrying amount of the assets to the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected undiscounted cash flows is less than the carrying amount of the assets, the Company recognizes an impairment loss based on the excess of the carrying amount of the assets over their fair value. Fair value is generally determined by discounting the cash flows expected to be generated by the assets, when the market prices are not readily available. For the years ended December&#160;31, 2024, 2023 and 2022, the Company determined that there were no indicators of impairment of its other intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets are reviewed for impairment in accordance with authoritative guidance for impairment or disposal of long-lived assets. Long-lived assets are reviewed for events or changes in circumstances, which indicate that their carrying value may not be recoverable. Long-lived assets are reported at the lower of carrying amount or fair value less cost to sell. For the years ended December&#160;31, 2024, 2023 and 2022, there was no impairment of the value of the Company&#x2019;s long-lived assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies ASC topic 820 (&#x201c;ASC 820&#x201d;), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in measuring fair value. ASC 820 defines fair value, establishes a framework for measuring fair value and requires disclosures to be provided on fair value measurement. ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Include other inputs that are directly or indirectly observable in the marketplace.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Unobservable inputs which are supported by little or no market activity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 820 describes three main approaches to measuring the fair value of assets and liabilities: (1) market approach; (2) income approach; and (3) cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial instruments measured at fair value on a recurring basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth assets measured at fair value on a recurring basis as of December&#160;31, 2024 and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.186%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Price&lt;br/&gt;in&#160;Active&lt;br/&gt;Market&#160;for&lt;br/&gt;Identical&lt;br/&gt;Assets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities with readily determinable fair values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;952,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.186%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Price&lt;br/&gt;in&#160;Active&lt;br/&gt;Market&#160;for&lt;br/&gt;Identical&lt;br/&gt;Assets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,052,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities with readily determinable fair values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,057,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cash equivalents are highly liquid investments with original maturities of 3 months or less. The Company&#x2019;s investments in U.S. Treasury securities are classified as available-for-sale debt securities. The Company determines the fair value of cash equivalents and available-for-sale debt securities using a market approach based on quoted prices in active markets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s equity securities carried at fair value consist of holdings in common stock and warrants to purchase additional shares of common stock of Leap Therapeutics, Inc. (&#x201c;Leap&#x201d;), a publicly-traded biotechnology company. The common stock investment is measured and carried at fair value and classified as a Level 1 investment. The warrants to purchase additional shares of common stock are measured using the Black-Scholes option-pricing valuation model and classified as a Level 2 investment. Refer to Note 5, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for details of the determination of the carrying amount of private equity investments without readily determinable fair values and equity method investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company holds convertible notes issued by private biotech companies. The Company has elected the fair value option method of accounting for the convertible notes. Accordingly, the convertible notes are remeasured at fair value on a recurring basis using Level 3 inputs, with any changes in the fair value option recorded in other (expense) income, net. The Company recorded losses on fair value adjustments of $4,842 and $1,492 for the years ended December&#160;31, 2024 and 2023, respectively. There was no fair value adjustment during the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers of instruments between levels of valuation categories during the years ended December&#160;31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024 and 2023, the Company held time deposits of nil and $42,852, respectively, that were classified as cash equivalents. As of December&#160;31, 2024 and 2023, the fair values of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and short-term debt approximated their carrying values due to their short-term nature. Long-term debt approximates its fair value due to the fact that the related interest rates approximate the rates currently offered by financial institutions for similar debt instrument of comparable maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies ASC, Topic 606,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(&#x201c;ASC 606&#x201d;) to account for its revenue transactions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Company recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the U.S. and EU, the Company generates product revenues from the sale of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;BRUKINSA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and TEVIMBRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In China, the Company generates product revenues from the sale of its internally developed drugs TEVIMBRA, BRUKINSA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and PARTRUVIX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and the sale of in-licensed products through its agreements with Amgen, BMS, Bio-Thera, EUSA Pharma and Luye Pharmaceutical.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Under the commercial profit share arrangement with Amgen, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company is the principal for in-licensed product sales to customers in China during the commercialization period and recognizes 100% of net product revenue on these sales. Amounts due to Amgen for its portion of net product sales are recorded as cost of sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the U.S., the Company distributes its products through specialty pharmacies and specialty distributors. The specialty pharmacies and specialty distributors subsequently resell the product to health care providers and patients. In the EU, the Company distributes its products through distributors or directly to hospitals. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In China, the Company sells its internally developed products to multiple distributors, who in turn sell the product to hospitals or pharmacies within their authorized territories to be sold ultimately to patients. In-licensed products are sold to a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;first tier distributor who subsequently resells the products to second tier distributors who ultimately sell the products to health care providers and patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is the principal under the product sales as the Company controls the products with the ability to direct the use of, and obtain substantially all the remaining benefits from the products before they are sold to the customer. For product sales transactions, the Company has a single performance obligation which is to sell the products to its customer. The Company includes variable consideration in the transaction price to the extent it is probable that a significant reversal will not occur and estimates variable consideration from rebates, chargebacks, trade discounts and allowances, sales returns allowances and other incentives using the expected value method. Revenues for product sales are recognized at a point in time when the single performance obligation is satisfied upon delivery to the customer. The Company&#x2019;s payment terms are approximately 30-90 days. Actual amounts of consideration ultimately received may differ from the Company&#x2019;s estimates.&#160;The Company will reassess estimates for variable consideration periodically. If actual results in the future vary from the Company&#x2019;s estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimates for variable consideration for which reserves are established at the time of sale include government and commercial rebates, provisions for acceptance of National Reimbursement Drug List (&#x201c;NRDL&#x201d;) pricing in the PRC, chargebacks, trade discounts and allowances, sales returns allowances and other incentives that are offered within contracts between the Company and its customers, health care providers and other indirect customers. Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as the Company's historical experience, current contractual and statutory requirements, channel inventory levels, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The Company bases its sales returns allowance on estimated distributor inventories, customer demand as reported by third-party sources, and actual returns history, as well as other factors, as appropriate. To date, sales returns have not been significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, the Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(&#x201c;ASC 808&#x201d;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities.&#160;For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and therefore within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the five-step model under ASC 606 noted above. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s collaborative arrangements may contain more than one unit of account, or performance obligation, including grants of licenses to intellectual property rights, agreement to provide research and development services and other deliverables. The collaborative arrangements do not include a right of return for any deliverable. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.&#160;In developing the stand-alone selling price for a performance obligation, the Company considers competitor pricing for a similar or identical product, market awareness of and perception of the product, expected product life and current market trends. In general, the consideration allocated to each performance obligation is recognized when the respective obligation is satisfied either by delivering a good or providing a service, limited to the consideration that is not constrained. Non-refundable payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as advances from customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses of Intellectual Property:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Upfront non-refundable payments for licensing the Company&#x2019;s intellectual property are evaluated to determine if the license is distinct from the other performance obligations identified in the arrangement. For licenses determined to be distinct, the Company recognizes revenues from non-refundable up-front fees allocated to the license at a point in time, when the license is transferred to the licensee and the licensee is able to use and benefit from the license.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Options to License Intellectual Property:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Upfront non-refundable payments for options to license the Company&#x2019;s intellectual property are evaluated to determine if the option represents a material right and is distinct from the other performance obligations identified in the arrangement. For options determined to be a material right and distinct, the Company defers the non-refundable up-front fees allocated to the option and recognizes revenues at a point in time, at the earlier of when the option is exercised or the option period expires.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Right to Access Intellectual Property during the Option Period:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The portion of a transaction price allocated to the other parties right to access the Company&#x2019;s intellectual property to generate their own data during an option period is deferred and recognized as collaboration revenue over the option period on a straight-line basis as the right to use the intellectual property is provided and the data generated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Services:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The portion of a transaction price allocated to research and development services performance obligations is deferred and recognized as collaboration revenue over time as delivery or performance of such services occurs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.&#160;If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.&#160;Milestones related to the Company&#x2019;s development-based activities may include initiation of various phases of clinical trials. Due to the uncertainty involved in meeting these development-based targets, they are generally fully constrained at contract inception. The Company will assess whether the variable consideration is fully constrained each reporting period based on the facts and circumstances surrounding the clinical trials. Upon changes to constraint associated with the developmental milestones, variable consideration will be included in the transaction price when a significant reversal of revenue recognized is not expected to occur and allocated to the separate performance obligations. Regulatory milestones are fully constrained until the period in which those regulatory approvals are achieved due to the inherent uncertainty with the approval process. Regulatory milestones are included in the transaction price in the period regulatory approval is obtained. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of the costs associated with our research and development activities, conducting preclinical studies and clinical trials, and activities related to regulatory filings, which primarily include (i) payroll and related costs (including share-based compensation) associated with research and development personnel, (ii) costs related to clinical trials and preclinical testing of the Company&#x2019;s technologies under development, (iii) costs to develop the product candidates, including raw materials and supplies, product testing, depreciation, and facility related expenses, (iv) expenses for research services provided by universities and contract laboratories, including sponsored research funding, and (v) other research and development expenses. Research and development expenses are charged to expense as incurred when these expenditures relate to the Company&#x2019;s research and development services and have no alternative future uses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Clinical trial costs are a significant component of the Company&#x2019;s research and development expenses. The Company has a history of contracting with third parties that perform various clinical trial activities on behalf of the Company in the ongoing development of the Company&#x2019;s product candidates. Expenses related to clinical trials are accrued based on the Company&#x2019;s estimates of the actual services performed by the third parties for the respective period. If the contracted amounts are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), the Company will modify the related accruals accordingly on a prospective basis. Revisions in the scope of a contract are charged to expense in the period in which the facts that give rise to the revision become probable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquired In-Process Research and Development Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has acquired rights to develop and commercialize product candidates. Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments (prior to government approval), are immediately expensed as acquired in-process research and development in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#x201c;business&#x201d; as defined under GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. Milestone payments made to third parties subsequent to regulatory approval are capitalized as intangible assets and amortized over the estimated remaining useful life of the related product. Royalties owed on sales of the products licensed pursuant to the agreements are expensed in the period the related revenues are recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Government Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government financial incentives that involve no conditions or continuing performance obligations of the Company are recognized as other income upon receipt. During the years ended December&#160;31, 2024, 2023 and 2022, the Company recognized other income of $22,326, $23,989, and $32,540, respectively, for government grants received after the related expenses have been incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the event government grants or incentives involve continuing performance obligations, the Company will capitalize the payment as a liability and recognize the same financial statement caption as the performance obligation relates over the performance period. The Company received government assistance in the form of cash primarily to support the Guangzhou manufacturing facility build-out and research and development programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government assistance received to support the Guangzhou manufacturing facility build-out is recognized as other long-term liabilities and amortized over the same useful lives of the related assets as depreciation expense. As of December&#160;31, 2024 and 2023, &lt;span style="-sec-ix-hidden:f-486"&gt;&lt;span style="-sec-ix-hidden:f-487"&gt;other long-term liabilities&lt;/span&gt;&lt;/span&gt; related to the Guangzhou manufacturing facility build-out totaled $30,235 and $34,084, respectively. For the years ended December&#160;31, 2024, 2023 and 2022, &lt;span style="-sec-ix-hidden:f-490"&gt;&lt;span style="-sec-ix-hidden:f-491"&gt;&lt;span style="-sec-ix-hidden:f-492"&gt;depreciation expense&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; is presented net of amortization of government assistance of $3,053, $2,938 and $3,169, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government assistance received to support research and development programs is recorded as other long-term liabilities upon receipt and recognized as other income when the associated research and development programs are completed. As of December&#160;31, 2024 and 2023, other long-term liabilities related to research and development programs totaled $89 and $120, respectively. For the years ended December&#160;31, 2022, the Company recognized other income of $1,664 upon the completion of a designated research and development program. No income was recognized during the years ended December&#160;31, 2024 and 2023 related to grants received for research and development programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is defined as the changes in equity of the Company during a period from transactions and other events and circumstances excluding transactions resulting from investments by owners and distributions to owners. Among other disclosures, ASC 220, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Comprehensive Income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, requires that all items that are required to be recognized under current accounting standards as components of comprehensive loss be reported in a financial statement that is displayed with the same prominence as other financial statements. For each of the periods presented, the Company&#x2019;s comprehensive loss includes net loss, foreign currency translation adjustments, pension liability adjustments and unrealized holding gains/losses associated with the available-for-sale debt securities, and is presented in the consolidated statements of comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Awards granted to employees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies ASC 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation&#x2014;Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 718&#x201d;), to account for its employee share-based payments. In accordance with ASC 718, the Company determines whether an award should be classified and accounted for as a liability award or equity award. All the Company&#x2019;s grants of share-based awards to employees were classified as equity awards and are recognized in the financial statements based on their grant date fair values. Specifically, the grant date fair value of share options is calculated using an option pricing model. The fair value of restricted shares and restricted share units are based on the closing market price of our ADSs on the Nasdaq Global Select Market on the date of grant. The Company has elected to recognize compensation expense using the straight-line method for all employee equity awards granted with graded vesting based on service conditions provided that the amount of compensation cost recognized at any date is at least equal to the portion of the grant-date value of the options that are vested at that date. The Company uses the accelerated method for all awards granted with graded vesting based on performance conditions. To the extent the required vesting conditions are not met resulting in the forfeiture of the share-based awards, previously recognized compensation expense relating to those awards are reversed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in the subsequent period if actual forfeitures differ from initial estimates. Forfeiture rates are estimated based on historical and future expectations of employee turnover rates and are adjusted to reflect future changes in circumstances and facts, if any. Share-based compensation expense is recorded net of estimated forfeitures such that expense is recorded only for those share-based awards that are expected to vest. To the extent the Company revises these estimates in the future, the share-based payments could be materially impacted in the period of revision, as well as in following periods. The Company, with the assistance of an independent third-party valuation firm, determined the estimated fair value of the stock options granted to employees using the binomial option pricing model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Awards granted to non-employees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has accounted for equity instruments issued to non-employees in accordance with the provisions of ASC 718 and ASC 505, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. All transactions in which goods or services are received in exchange for equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The grant date is the measurement date of the fair value of the equity instrument issued. The expense is recognized in the same manner as if the Company had paid cash for the services provided by the non-employees in accordance with ASC 505-50, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity-based payments to non-employees&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company estimated the fair value of share options granted to non-employees using the same method as employees.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Modification of awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A change in any of the terms or conditions of the awards is accounted for as a modification of the award. Incremental compensation cost is measured as the excess, if any, of the fair value of the modified award over the fair value of the original award immediately before its terms are modified, measured based on the fair value of the awards and other pertinent factors at the modification date. For vested awards, the Company recognizes incremental compensation cost in the period the modification occurs. For unvested awards, the Company recognizes over the remaining requisite service period, the sum of the incremental compensation cost and the remaining unrecognized compensation cost for the original award on the modification date. If the fair value of the modified award is lower than the fair value of the original award immediately before modification, the minimum compensation cost the Company recognizes is the cost of the original award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using enacted tax rates that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its uncertain tax positions using the provisions of ASC 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Company recognizes in the financial statements the benefit of a tax position which is &#x201c;more likely than not&#x201d; to be sustained under examination based solely on the technical merits of the position assuming a review by tax authorities having all relevant information. Tax positions that meet the recognition threshold are measured using a cumulative probability approach, at the largest amount of tax benefit that has a greater than fifty percent likelihood of being realized upon settlement. It is the Company&#x2019;s policy to recognize interest and penalties related to unrecognized tax benefits, if any, as a component of income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per share is calculated in accordance with ASC 260, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Basic loss per ordinary share is computed by dividing net loss attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period using the two-class method. Under the two-class method, net income is allocated between ordinary shares and participating securities based on dividends declared (or accumulated) and participating rights in undistributed earnings as if all the earnings for the reporting period had been distributed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted loss per share, when required, is calculated by dividing net loss attributable to ordinary shareholders as adjusted for the effect of dilutive ordinary equivalent shares, if any, by the weighted average number of ordinary and dilutive ordinary equivalent shares outstanding during the period. Ordinary equivalent shares consist of the ordinary shares issuable upon the conversion of the Company&#x2019;s convertible preferred shares, if any, using the if-converted method, and ordinary shares issuable upon the conversion of the share options, and unvested restricted shares units and performance-based restricted shares units (&#x201c;PSUs&#x201d;), using the treasury stock method. The dilutive effects of PSUs are included in the weighted average common share calculation based on the cumulative achievement against the performance targets only when the performance targets have been achieved as of the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ordinary share equivalents are excluded from the computation of diluted loss per share if their effects would be anti-dilutive. Basic and diluted loss per ordinary share is presented in the Company&#x2019;s consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 280, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company&#x2019;s chief operating decision maker, the Chief Executive Officer, reviews the consolidated results when making decisions about allocating resources and assessing performance of the Company as a whole and hence, the Company has only one reportable segment: pharmaceutical products. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Concentration of cash and credit risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that are potentially subject to credit risk consist of cash and cash equivalents and accounts receivable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024 and 2023, $2,627,410 and $3,171,800 were deposited with various major reputable financial institutions located in the U.S., PRC and other international financial institutions. The deposits placed with financial institutions are not protected by statutory or commercial insurance. In the event of bankruptcy of one of these financial institutions, the Company may be unable to claim its deposits back in full. Management believes that these financial institutions are of high credit quality and continually monitors the credit worthiness of these financial institutions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024 and 2023, the Company had accounts receivable, net of $676,278 and $358,027, respectively. Accounts receivable, net represent amounts arising from product sales. The Company monitors economic conditions to identify facts or circumstances that may indicate receivables are at risk of collection.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Customer concentration risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2024, sales to the Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s three largest product distributors, ASD Specialty Healthcare, McKesson and Shanghai Pharmaceutical represented approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18.0%,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.9%&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.1% &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of product revenue, respectively, and collectively, represented approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;51.0%&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of trade accounts receivable as of December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2023, sales to the Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s four largest product distributors, Sinopharm, Shanghai Pharmaceutical, ASD Specialty Healthcare and China Resources represented approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.0%&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14.2%&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12.4%&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11.4%&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of product revenue, respectively, and collectively, represented approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53.2%&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of trade accounts receivable as of December&#160;31, 2023. For the year ended December&#160;31, 2023, the Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s collaboration revenue consisted entirely of revenue recognized under its out-licensing collaboration agreements with Novartis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;New accounting standards which have been adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 280): Improvements to Reportable Segment Disclosures. This update requires disclosure of incremental segment information on an annual and interim basis. This update is effective for annual periods beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024. Early adoption is permitted. This guidance should be applied retrospectively to all prior periods presented in the financial statements. The Company operates in one segment. Its chief operating decision maker is the Chief Executive Officer, who makes operating decisions, assesses performance, and allocates resources on a consolidated basis. The Company adopted ASU 2023-07 effective December 31, 2024. Refer to Footnote 21 for segment related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;New accounting standards which have not yet been adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Subtopic 220-40): Disaggregation of Income Statement Expenses. This update requires that at each interim and annual reporting period public entities disclose (1) the amounts of purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions; (2) certain amounts that are already required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirements; (3) a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively; and (4) the total amount of selling expenses and, in annual reporting periods, the definition of selling expenses. In January 2025, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Subtopic 220-40): Clarifying the Effective Date. This update clarifies that ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact on its financial statements of adopting this guidance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 740): Improvements to Income Tax Disclosures. This update requires that public entities on an annual basis, (1) in the rate reconciliation, disclose specific categories and provide additional information for reconciling items that meet a quantitative threshold; (2) about income taxes paid, disclose the amount of income taxes paid (net of refunds received) disaggregated by federal, state, and foreign taxes and by individual jurisdiction in which income taxes paid (net of refunds received) is equal to or greater than 5 percent of total income taxes paid (net of refunds received); and (3) disclose income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign and income tax expense (or benefit) disaggregated by federal, state, and foreign. This update is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. This guidance should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating the impact on its financial statements of adopting this guidance.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-404">Basis of PresentationThe consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;).</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-405">Principles of ConsolidationThe consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany transactions and balances between the Company and its wholly-owned subsidiaries are eliminated upon consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-406">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Areas where management uses subjective judgment include, but are not limited to, estimating the useful lives of long-lived assets, estimating variable consideration in product sales and collaboration revenue arrangements, identifying separate accounting units and the standalone selling price of each performance obligation in the Company&#x2019;s revenue arrangements, assessing the impairment of long-lived assets, valuation and recognition of share-based compensation expenses, estimating uncertain tax positions, valuation of inventory, estimating the allowance for credit losses, determining defined benefit pension plan obligations, measurement of right-of-use assets and lease liabilities and the fair value of financial instruments. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from these estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-407">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Functional Currency and Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Functional currency and foreign currency gains and losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the U.S. dollar (&#x201c;$&#x201d; or U.S. dollar) as its reporting currency. Transactions in subsidiaries are recorded in the functional currency of the respective subsidiary and such transactions denominated in currencies other than the functional currency give rise to foreign exchange remeasurement (monetary assets and liabilities) and related gains and losses that are classified in other (expense) income, net in the consolidated statement of operations. The determination of functional currency is based on the criteria of Accounting Standard Codification (&#x201c;ASC&#x201d;) 830, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Matters&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. For those periods presented, the Company has not entered into any foreign currency derivative instruments to hedge its foreign currency positions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign currency translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For subsidiaries whose functional currencies are not the U.S. dollar, the Company uses the average exchange rate for the period and the exchange rate at the balance sheet date to translate the operating results and financial position to the U.S. dollar, which is the Company's reporting currency. Translation differences are recorded in accumulated other comprehensive loss, a component of shareholders&#x2019; equity.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy contextRef="c-1" id="f-408">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of cash on hand and bank deposits, which are unrestricted as to withdrawal and use. The Company considers all highly liquid investments with an original maturity date of three months or less at the date of purchase to be cash equivalents. Cash equivalents which consist primarily of money market funds are stated at fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c-1" id="f-409">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash primarily consists of&#160;RMB-denominated cash deposits pledged in designated bank accounts as collateral for bank loans and letters of credit. The Company classifies restricted cash as current or non-current based on the term of the restriction.&lt;/span&gt;&lt;/div&gt;In addition to the restricted cash balances above, the Company is required by the PRC securities law to use the proceeds from the STAR offering in strict compliance with the planned uses as disclosed in the PRC offering prospectus as well as those disclosed in the Company&#x2019;s proceeds management policy approved by its board of directors.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c-1" id="f-411">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable and Allowance for Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade accounts receivable are recorded at their invoiced amounts, net of trade discounts and allowances as well as an allowance for credit losses. The allowance for credit losses reflects the Company&#x2019;s current estimate of credit losses expected to be incurred over the life of the receivables. The Company considers various factors in establishing, monitoring, and adjusting its allowance for credit losses including the aging of receivables and aging trends, customer creditworthiness and specific exposures related to particular customers. The Company also monitors other risk factors and forward-looking information, such as country specific risks and economic factors that may affect a customer&#x2019;s ability to pay in establishing and adjusting its allowance for credit losses. Accounts receivable are written off after all collection efforts have ceased.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:CreditLossFinancialInstrumentPolicyTextBlock contextRef="c-1" id="f-410">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable and Allowance for Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade accounts receivable are recorded at their invoiced amounts, net of trade discounts and allowances as well as an allowance for credit losses. The allowance for credit losses reflects the Company&#x2019;s current estimate of credit losses expected to be incurred over the life of the receivables. The Company considers various factors in establishing, monitoring, and adjusting its allowance for credit losses including the aging of receivables and aging trends, customer creditworthiness and specific exposures related to particular customers. The Company also monitors other risk factors and forward-looking information, such as country specific risks and economic factors that may affect a customer&#x2019;s ability to pay in establishing and adjusting its allowance for credit losses. Accounts receivable are written off after all collection efforts have ceased.&lt;/span&gt;&lt;/div&gt;</us-gaap:CreditLossFinancialInstrumentPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="c-1" id="f-412">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Prior to the regulatory approval of product candidates, the Company may incur costs for the manufacture of drug product to support the commercial launch of those products. Until the date at which regulatory approval has been received or is otherwise considered probable, all such costs are recorded as research and development expenses as incurred. &lt;/span&gt;&lt;/div&gt;Inventories are stated at the lower of cost and net realizable value, with cost determined in a manner that approximates weighted average cost. The Company periodically analyzes its inventory levels, and writes down inventory that has become obsolete, inventory that has a cost basis in excess of its estimated realizable value and inventory in excess of expected sales requirements as cost of product sales. The determination of whether inventory costs will be realizable requires estimates of future prices by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required, which would be recorded in the consolidated statements of operations.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c-1" id="f-413">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investments consist of available-for-sale debt securities, convertible note instruments, public equity securities with readily determinable fair values, private equity securities without readily determinable fair values, and equity-method investments. The classification of an investment is determined based on the nature of the investment, the Company&#x2019;s ability and intent to hold the investment, and the degree to which the Company may exercise influence over the investee.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Available-for-sale debt securities are stated at fair value, with the unrealized gains and losses, net of tax, reported in other comprehensive loss. The net carrying value of debt securities classified as available-for-sale is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization is computed using the effective interest method and included in interest income. Interest and dividends are included in interest income. Available-for-sale debt securities with original maturities greater than three months at the date of purchase and less than one year from the date of the balance sheet are classified as short-term. Available-for-sale debt securities with maturities beyond one year may be classified as short-term marketable securities due to their highly liquid nature and because they represent the Company&#x2019;s investments that are available for current operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Convertible note instruments are recorded using the fair value option method of accounting. Accordingly, convertible note instruments are remeasured at fair value on a recurring basis, with any changes in the fair value option recorded in other (expense) income, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Public equity securities with readily determinable fair values are recorded at fair value. Subsequent changes in fair value are recorded in other (expense) income, net. Derivative financial instruments to purchase public equity securities are recorded at fair value. The estimated fair value of derivative financial instruments is determined based on the Black-Scholes valuation model. Changes in fair value of derivative instruments are recorded in other (expense) income, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Private equity securities without readily determinable fair values and where the Company does not have significant influence are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Adjustments to private equity securities are recorded in other (expense) income, net. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Equity investments in common stock or in-substance common stock where the Company has significant influence over the financial and operating policies of the investee are accounted for as equity-method investments. Equity-method investments are initially recorded at cost and subsequently adjusted based on the Company&#x2019;s percentage ownership in the investee&#x2019;s income and expenses, as well as dividends, if any. The Company records its share of the investee&#x2019;s results of operations in other (expense) income, net. The Company records impairment losses on our equity method investments if it deems the impairment to be other-than-temporary. The Company deems an impairment to be other-than-temporary based on various factors, including but not limited to, the length of time the fair value is below the carrying value and ability to retain the investment to allow for a recovery in fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains or losses on sales of investments are determined based on the specific identification method.&lt;/span&gt;&lt;/div&gt;The Company regularly evaluates its investments in debt and equity for impairment. The Company recognizes an allowance on available-for-sale debt securities when a portion of the unrealized loss is attributable to a credit loss and a corresponding credit loss in net income. No allowance for credit losses were recorded for any periods presented.</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment contextRef="c-1" decimals="-3" id="f-414" unitRef="usd">7635000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment contextRef="c-10" decimals="-3" id="f-415" unitRef="usd">7529000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-416">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are stated at cost, less accumulated depreciation and amortization. Property, plant and equipment, other than land and construction in progress, are depreciated using the straight-line method over the estimated useful lives of the respective assets as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.806%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:27.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Useful&#160;Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software, Electronic and Office Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold Improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lesser of useful life or lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-417">Property, plant and equipment, other than land and construction in progress, are depreciated using the straight-line method over the estimated useful lives of the respective assets as follows:&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.806%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:27.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Useful&#160;Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software, Electronic and Office Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold Improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lesser of useful life or lease term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net are recorded at cost less accumulated depreciation and consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.221%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As&#160;of&#160;December&#160;31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;607,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software, electronics and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;832,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(399,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(249,212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;740,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,578,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,324,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;CIP by fixed asset class are summarized as follows:&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.324%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.397%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;528,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;579,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;740,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-44" id="f-418">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-45" id="f-419">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-46" id="f-420">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-47" id="f-421">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-48" id="f-422">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-49" id="f-423">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-50" id="f-424">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-425">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies ASC, Topic 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 842&#x201d;) to account for its leases. The Company determines if an arrangement is a lease at inception. The Company has lease agreements with lease and non-lease components, which are accounted for as a single lease component based on the Company&#x2019;s policy election to combine lease and non-lease components for its leases. Leases are classified as operating or finance leases in accordance with the recognition criteria in ASC 842-20-25. The Company&#x2019;s lease portfolio consists entirely of operating leases as of December&#160;31, 2024. The Company&#x2019;s leases do not contain any material residual value guarantees or material restrictive covenants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the commencement date of a lease, the Company determines the classification of the lease based on the relevant factors present and records a right-of-use (&#x201c;ROU&#x201d;) asset and lease liability. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and lease liabilities are calculated as the present value of the lease payments not yet paid. Variable lease payments not dependent on an index or rate are excluded from the ROU asset and lease liability calculations and are recognized in expense in the period which the obligation for those payments is incurred. As the rate implicit in the Company&#x2019;s leases is not typically readily available, the Company uses an incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. This incremental borrowing rate reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. ROU assets include any lease prepayments and are reduced by lease incentives. Operating lease expense for lease payments is recognized on a straight-line basis over the lease term. Lease terms are based on the non-cancelable term of the lease and may contain options to extend the lease when it is reasonably certain that the Company will exercise that option. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases are included in operating lease right-of-use assets and operating lease liabilities on the consolidated balance sheet. Lease liabilities that become due within one year of the balance sheet date are classified as current liabilities.&lt;/span&gt;&lt;/div&gt;Leases with an initial lease term of 12 months or less are not recorded on the consolidated balance sheet. Lease expense for these leases is recognized on a straight-line basis over the lease term.</us-gaap:LesseeLeasesPolicyTextBlock>
    <bgne:LandUseRightsPolicyPolicyTextBlock contextRef="c-1" id="f-426">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Land Use Right, Net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;All land in the PRC is owned by the PRC government. The PRC government may sell land use rights for a specified period of time. Land use rights represent operating leases in accordance with ASC 842. The purchase price of land use rights represents lease prepayments to the PRC government and is recorded as an operating lease ROU asset on the balance sheet. The ROU asset is amortized over the remaining lease term.</bgne:LandUseRightsPolicyPolicyTextBlock>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-427">As of December&#160;31, 2024, the Company held land use rights in the following regions:&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.806%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:27.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Terms&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Guangzhou&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beijing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Suzhou&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shanghai&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other supplemental information related to leases is summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows used in operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.391%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As&#160;of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-51" id="f-428">P50Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-52" id="f-429">P36Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-53" id="f-430">P30Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-54" id="f-431">P47Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="c-1" id="f-432">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets acquired through business combinations are recognized as assets separate from goodwill and are measured at fair value upon acquisition. Intangible assets acquired in transactions that are not business combinations are recorded at the allocated portion of total consideration transferred based on their relative fair value in relation to net assets acquired. Intangible assets associated with milestone payments made to third parties subsequent to regulatory approval are recorded at cost. Identifiable intangible assets consist of post-approval milestone payments under license and commercialization agreements, that are amortized over the remainder of the product patent or the term of the commercialization agreements; and trading licenses that are amortized over the initial license term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with finite useful lives are tested for impairment when events or circumstances occur that could indicate that the carrying amount of an asset may not be recoverable. When these events occur, the Company evaluates the recoverability of the intangible assets by comparing the carrying amount of the assets to the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected undiscounted cash flows is less than the carrying amount of the assets, the Company recognizes an impairment loss based on the excess of the carrying amount of the assets over their fair value. Fair value is generally determined by discounting the cash flows expected to be generated by the assets, when the market prices are not readily available. For the years ended December&#160;31, 2024, 2023 and 2022, the Company determined that there were no indicators of impairment of its other intangible assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-11" decimals="INF" id="f-433" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-1" decimals="INF" id="f-434" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-10" decimals="INF" id="f-435" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c-1" id="f-436">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;Long-lived assets are reviewed for impairment in accordance with authoritative guidance for impairment or disposal of long-lived assets. Long-lived assets are reviewed for events or changes in circumstances, which indicate that their carrying value may not be recoverable. Long-lived assets are reported at the lower of carrying amount or fair value less cost to sell.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-10" decimals="INF" id="f-437" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-1" decimals="INF" id="f-438" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-11" decimals="INF" id="f-439" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-440">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies ASC topic 820 (&#x201c;ASC 820&#x201d;), &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in measuring fair value. ASC 820 defines fair value, establishes a framework for measuring fair value and requires disclosures to be provided on fair value measurement. ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Include other inputs that are directly or indirectly observable in the marketplace.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Unobservable inputs which are supported by little or no market activity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 820 describes three main approaches to measuring the fair value of assets and liabilities: (1) market approach; (2) income approach; and (3) cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="c-1" id="f-441">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth assets measured at fair value on a recurring basis as of December&#160;31, 2024 and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.186%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Price&lt;br/&gt;in&#160;Active&lt;br/&gt;Market&#160;for&lt;br/&gt;Identical&lt;br/&gt;Assets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;950,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities with readily determinable fair values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;952,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.186%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Price&lt;br/&gt;in&#160;Active&lt;br/&gt;Market&#160;for&lt;br/&gt;Identical&lt;br/&gt;Assets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,052,149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities with readily determinable fair values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Convertible debt instrument&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,057,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-55" decimals="-3" id="f-442" unitRef="usd">950704000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-56" decimals="-3" id="f-443" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-57" decimals="-3" id="f-444" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <bgne:InvestmentInDebtSecuritiesCurrent contextRef="c-58" decimals="-3" id="f-445" unitRef="usd">0</bgne:InvestmentInDebtSecuritiesCurrent>
    <bgne:InvestmentInDebtSecuritiesCurrent contextRef="c-59" decimals="-3" id="f-446" unitRef="usd">0</bgne:InvestmentInDebtSecuritiesCurrent>
    <bgne:InvestmentInDebtSecuritiesCurrent contextRef="c-60" decimals="-3" id="f-447" unitRef="usd">618000</bgne:InvestmentInDebtSecuritiesCurrent>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-61" decimals="-3" id="f-448" unitRef="usd">2113000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-62" decimals="-3" id="f-449" unitRef="usd">168000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-63" decimals="-3" id="f-450" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <bgne:InvestmentInDebtSecuritiesNonCurrent contextRef="c-58" decimals="-3" id="f-451" unitRef="usd">0</bgne:InvestmentInDebtSecuritiesNonCurrent>
    <bgne:InvestmentInDebtSecuritiesNonCurrent contextRef="c-59" decimals="-3" id="f-452" unitRef="usd">0</bgne:InvestmentInDebtSecuritiesNonCurrent>
    <bgne:InvestmentInDebtSecuritiesNonCurrent contextRef="c-60" decimals="-3" id="f-453" unitRef="usd">4616000</bgne:InvestmentInDebtSecuritiesNonCurrent>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-64" decimals="-3" id="f-454" unitRef="usd">952817000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-65" decimals="-3" id="f-455" unitRef="usd">168000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-66" decimals="-3" id="f-456" unitRef="usd">5234000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-67" decimals="-3" id="f-457" unitRef="usd">1052149000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-68" decimals="-3" id="f-458" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-69" decimals="-3" id="f-459" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-70" decimals="-3" id="f-460" unitRef="usd">2600000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-71" decimals="-3" id="f-461" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-72" decimals="-3" id="f-462" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <bgne:InvestmentInDebtSecuritiesCurrent contextRef="c-73" decimals="-3" id="f-463" unitRef="usd">0</bgne:InvestmentInDebtSecuritiesCurrent>
    <bgne:InvestmentInDebtSecuritiesCurrent contextRef="c-74" decimals="-3" id="f-464" unitRef="usd">0</bgne:InvestmentInDebtSecuritiesCurrent>
    <bgne:InvestmentInDebtSecuritiesCurrent contextRef="c-75" decimals="-3" id="f-465" unitRef="usd">4668000</bgne:InvestmentInDebtSecuritiesCurrent>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-76" decimals="-3" id="f-466" unitRef="usd">3046000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-77" decimals="-3" id="f-467" unitRef="usd">542000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-78" decimals="-3" id="f-468" unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <bgne:InvestmentInDebtSecuritiesNonCurrent contextRef="c-73" decimals="-3" id="f-469" unitRef="usd">0</bgne:InvestmentInDebtSecuritiesNonCurrent>
    <bgne:InvestmentInDebtSecuritiesNonCurrent contextRef="c-74" decimals="-3" id="f-470" unitRef="usd">0</bgne:InvestmentInDebtSecuritiesNonCurrent>
    <bgne:InvestmentInDebtSecuritiesNonCurrent contextRef="c-75" decimals="-3" id="f-471" unitRef="usd">4215000</bgne:InvestmentInDebtSecuritiesNonCurrent>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-79" decimals="-3" id="f-472" unitRef="usd">1057795000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-80" decimals="-3" id="f-473" unitRef="usd">542000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-81" decimals="-3" id="f-474" unitRef="usd">8883000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="c-82" decimals="-3" id="f-475" unitRef="usd">-4842000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="c-83" decimals="-3" id="f-476" unitRef="usd">-1492000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1 contextRef="c-84" decimals="-3" id="f-477" unitRef="usd">0</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-85" decimals="-3" id="f-478" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-86" decimals="-3" id="f-479" unitRef="usd">42852000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-480">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies ASC, Topic 606,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(&#x201c;ASC 606&#x201d;) to account for its revenue transactions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price, including variable consideration, if any; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. The Company recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the U.S. and EU, the Company generates product revenues from the sale of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;BRUKINSA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and TEVIMBRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In China, the Company generates product revenues from the sale of its internally developed drugs TEVIMBRA, BRUKINSA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and PARTRUVIX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and the sale of in-licensed products through its agreements with Amgen, BMS, Bio-Thera, EUSA Pharma and Luye Pharmaceutical.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Under the commercial profit share arrangement with Amgen, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company is the principal for in-licensed product sales to customers in China during the commercialization period and recognizes 100% of net product revenue on these sales. Amounts due to Amgen for its portion of net product sales are recorded as cost of sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the U.S., the Company distributes its products through specialty pharmacies and specialty distributors. The specialty pharmacies and specialty distributors subsequently resell the product to health care providers and patients. In the EU, the Company distributes its products through distributors or directly to hospitals. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In China, the Company sells its internally developed products to multiple distributors, who in turn sell the product to hospitals or pharmacies within their authorized territories to be sold ultimately to patients. In-licensed products are sold to a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;first tier distributor who subsequently resells the products to second tier distributors who ultimately sell the products to health care providers and patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is the principal under the product sales as the Company controls the products with the ability to direct the use of, and obtain substantially all the remaining benefits from the products before they are sold to the customer. For product sales transactions, the Company has a single performance obligation which is to sell the products to its customer. The Company includes variable consideration in the transaction price to the extent it is probable that a significant reversal will not occur and estimates variable consideration from rebates, chargebacks, trade discounts and allowances, sales returns allowances and other incentives using the expected value method. Revenues for product sales are recognized at a point in time when the single performance obligation is satisfied upon delivery to the customer. The Company&#x2019;s payment terms are approximately 30-90 days. Actual amounts of consideration ultimately received may differ from the Company&#x2019;s estimates.&#160;The Company will reassess estimates for variable consideration periodically. If actual results in the future vary from the Company&#x2019;s estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimates for variable consideration for which reserves are established at the time of sale include government and commercial rebates, provisions for acceptance of National Reimbursement Drug List (&#x201c;NRDL&#x201d;) pricing in the PRC, chargebacks, trade discounts and allowances, sales returns allowances and other incentives that are offered within contracts between the Company and its customers, health care providers and other indirect customers. Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted for relevant factors such as the Company's historical experience, current contractual and statutory requirements, channel inventory levels, specific known market events and trends, industry data and forecasted customer buying and payment patterns. The Company bases its sales returns allowance on estimated distributor inventories, customer demand as reported by third-party sources, and actual returns history, as well as other factors, as appropriate. To date, sales returns have not been significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At contract inception, the Company analyzes its collaboration arrangements to assess whether they are within the scope of ASC 808,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;(&#x201c;ASC 808&#x201d;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities.&#160;For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Company first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are more reflective of a vendor-customer relationship and therefore within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the five-step model under ASC 606 noted above. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s collaborative arrangements may contain more than one unit of account, or performance obligation, including grants of licenses to intellectual property rights, agreement to provide research and development services and other deliverables. The collaborative arrangements do not include a right of return for any deliverable. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract.&#160;In developing the stand-alone selling price for a performance obligation, the Company considers competitor pricing for a similar or identical product, market awareness of and perception of the product, expected product life and current market trends. In general, the consideration allocated to each performance obligation is recognized when the respective obligation is satisfied either by delivering a good or providing a service, limited to the consideration that is not constrained. Non-refundable payments received before all of the relevant criteria for revenue recognition are satisfied are recorded as advances from customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Licenses of Intellectual Property:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Upfront non-refundable payments for licensing the Company&#x2019;s intellectual property are evaluated to determine if the license is distinct from the other performance obligations identified in the arrangement. For licenses determined to be distinct, the Company recognizes revenues from non-refundable up-front fees allocated to the license at a point in time, when the license is transferred to the licensee and the licensee is able to use and benefit from the license.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Options to License Intellectual Property:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Upfront non-refundable payments for options to license the Company&#x2019;s intellectual property are evaluated to determine if the option represents a material right and is distinct from the other performance obligations identified in the arrangement. For options determined to be a material right and distinct, the Company defers the non-refundable up-front fees allocated to the option and recognizes revenues at a point in time, at the earlier of when the option is exercised or the option period expires.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Right to Access Intellectual Property during the Option Period:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The portion of a transaction price allocated to the other parties right to access the Company&#x2019;s intellectual property to generate their own data during an option period is deferred and recognized as collaboration revenue over the option period on a straight-line basis as the right to use the intellectual property is provided and the data generated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Services:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The portion of a transaction price allocated to research and development services performance obligations is deferred and recognized as collaboration revenue over time as delivery or performance of such services occurs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Milestone Payments: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of each arrangement that includes development milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.&#160;If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price.&#160;Milestones related to the Company&#x2019;s development-based activities may include initiation of various phases of clinical trials. Due to the uncertainty involved in meeting these development-based targets, they are generally fully constrained at contract inception. The Company will assess whether the variable consideration is fully constrained each reporting period based on the facts and circumstances surrounding the clinical trials. Upon changes to constraint associated with the developmental milestones, variable consideration will be included in the transaction price when a significant reversal of revenue recognized is not expected to occur and allocated to the separate performance obligations. Regulatory milestones are fully constrained until the period in which those regulatory approvals are achieved due to the inherent uncertainty with the approval process. Regulatory milestones are included in the transaction price in the period regulatory approval is obtained. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-481">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of the costs associated with our research and development activities, conducting preclinical studies and clinical trials, and activities related to regulatory filings, which primarily include (i) payroll and related costs (including share-based compensation) associated with research and development personnel, (ii) costs related to clinical trials and preclinical testing of the Company&#x2019;s technologies under development, (iii) costs to develop the product candidates, including raw materials and supplies, product testing, depreciation, and facility related expenses, (iv) expenses for research services provided by universities and contract laboratories, including sponsored research funding, and (v) other research and development expenses. Research and development expenses are charged to expense as incurred when these expenditures relate to the Company&#x2019;s research and development services and have no alternative future uses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Clinical trial costs are a significant component of the Company&#x2019;s research and development expenses. The Company has a history of contracting with third parties that perform various clinical trial activities on behalf of the Company in the ongoing development of the Company&#x2019;s product candidates. Expenses related to clinical trials are accrued based on the Company&#x2019;s estimates of the actual services performed by the third parties for the respective period. If the contracted amounts are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), the Company will modify the related accruals accordingly on a prospective basis. Revisions in the scope of a contract are charged to expense in the period in which the facts that give rise to the revision become probable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquired In-Process Research and Development Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has acquired rights to develop and commercialize product candidates. Upfront payments that relate to the acquisition of a new drug compound, as well as pre-commercial milestone payments (prior to government approval), are immediately expensed as acquired in-process research and development in the period in which they are incurred, provided that the new drug compound did not also include processes or activities that would constitute a &#x201c;business&#x201d; as defined under GAAP, the drug has not achieved regulatory approval for marketing and, absent obtaining such approval, has no established alternative future use. Milestone payments made to third parties subsequent to regulatory approval are capitalized as intangible assets and amortized over the estimated remaining useful life of the related product. Royalties owed on sales of the products licensed pursuant to the agreements are expensed in the period the related revenues are recognized.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <bgne:GovernmentGrantsPolicyPolicyTextBlock contextRef="c-1" id="f-482">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Government Grants&lt;/span&gt;&lt;/div&gt;Government financial incentives that involve no conditions or continuing performance obligations of the Company are recognized as other income upon receipt.&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the event government grants or incentives involve continuing performance obligations, the Company will capitalize the payment as a liability and recognize the same financial statement caption as the performance obligation relates over the performance period. The Company received government assistance in the form of cash primarily to support the Guangzhou manufacturing facility build-out and research and development programs.&lt;/span&gt;&lt;/div&gt;</bgne:GovernmentGrantsPolicyPolicyTextBlock>
    <us-gaap:GovernmentAssistanceAmount contextRef="c-1" decimals="-3" id="f-483" unitRef="usd">22326000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GovernmentAssistanceAmount contextRef="c-10" decimals="-3" id="f-484" unitRef="usd">23989000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GovernmentAssistanceAmount contextRef="c-11" decimals="-3" id="f-485" unitRef="usd">32540000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GovernmentAssistanceLiabilityNoncurrent contextRef="c-87" decimals="-3" id="f-488" unitRef="usd">30235000</us-gaap:GovernmentAssistanceLiabilityNoncurrent>
    <us-gaap:GovernmentAssistanceLiabilityNoncurrent contextRef="c-88" decimals="-3" id="f-489" unitRef="usd">34084000</us-gaap:GovernmentAssistanceLiabilityNoncurrent>
    <us-gaap:GovernmentAssistanceAmount contextRef="c-92" decimals="-3" id="f-493" unitRef="usd">3053000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GovernmentAssistanceAmount contextRef="c-93" decimals="-3" id="f-494" unitRef="usd">2938000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GovernmentAssistanceAmount contextRef="c-94" decimals="-3" id="f-495" unitRef="usd">3169000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GovernmentAssistanceLiabilityNoncurrent contextRef="c-95" decimals="-3" id="f-496" unitRef="usd">89000</us-gaap:GovernmentAssistanceLiabilityNoncurrent>
    <us-gaap:GovernmentAssistanceLiabilityNoncurrent contextRef="c-96" decimals="-3" id="f-497" unitRef="usd">120000</us-gaap:GovernmentAssistanceLiabilityNoncurrent>
    <us-gaap:GovernmentAssistanceAmount contextRef="c-97" decimals="-3" id="f-498" unitRef="usd">1664000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GovernmentAssistanceAmount contextRef="c-98" decimals="-3" id="f-499" unitRef="usd">0</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GovernmentAssistanceAmount contextRef="c-99" decimals="-3" id="f-500" unitRef="usd">0</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-501">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is defined as the changes in equity of the Company during a period from transactions and other events and circumstances excluding transactions resulting from investments by owners and distributions to owners. Among other disclosures, ASC 220, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Comprehensive Income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, requires that all items that are required to be recognized under current accounting standards as components of comprehensive loss be reported in a financial statement that is displayed with the same prominence as other financial statements. For each of the periods presented, the Company&#x2019;s comprehensive loss includes net loss, foreign currency translation adjustments, pension liability adjustments and unrealized holding gains/losses associated with the available-for-sale debt securities, and is presented in the consolidated statements of comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-502">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Awards granted to employees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company applies ASC 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation&#x2014;Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 718&#x201d;), to account for its employee share-based payments. In accordance with ASC 718, the Company determines whether an award should be classified and accounted for as a liability award or equity award. All the Company&#x2019;s grants of share-based awards to employees were classified as equity awards and are recognized in the financial statements based on their grant date fair values. Specifically, the grant date fair value of share options is calculated using an option pricing model. The fair value of restricted shares and restricted share units are based on the closing market price of our ADSs on the Nasdaq Global Select Market on the date of grant. The Company has elected to recognize compensation expense using the straight-line method for all employee equity awards granted with graded vesting based on service conditions provided that the amount of compensation cost recognized at any date is at least equal to the portion of the grant-date value of the options that are vested at that date. The Company uses the accelerated method for all awards granted with graded vesting based on performance conditions. To the extent the required vesting conditions are not met resulting in the forfeiture of the share-based awards, previously recognized compensation expense relating to those awards are reversed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in the subsequent period if actual forfeitures differ from initial estimates. Forfeiture rates are estimated based on historical and future expectations of employee turnover rates and are adjusted to reflect future changes in circumstances and facts, if any. Share-based compensation expense is recorded net of estimated forfeitures such that expense is recorded only for those share-based awards that are expected to vest. To the extent the Company revises these estimates in the future, the share-based payments could be materially impacted in the period of revision, as well as in following periods. The Company, with the assistance of an independent third-party valuation firm, determined the estimated fair value of the stock options granted to employees using the binomial option pricing model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Awards granted to non-employees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has accounted for equity instruments issued to non-employees in accordance with the provisions of ASC 718 and ASC 505, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. All transactions in which goods or services are received in exchange for equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The grant date is the measurement date of the fair value of the equity instrument issued. The expense is recognized in the same manner as if the Company had paid cash for the services provided by the non-employees in accordance with ASC 505-50, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Equity-based payments to non-employees&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company estimated the fair value of share options granted to non-employees using the same method as employees.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Modification of awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A change in any of the terms or conditions of the awards is accounted for as a modification of the award. Incremental compensation cost is measured as the excess, if any, of the fair value of the modified award over the fair value of the original award immediately before its terms are modified, measured based on the fair value of the awards and other pertinent factors at the modification date. For vested awards, the Company recognizes incremental compensation cost in the period the modification occurs. For unvested awards, the Company recognizes over the remaining requisite service period, the sum of the incremental compensation cost and the remaining unrecognized compensation cost for the original award on the modification date. If the fair value of the modified award is lower than the fair value of the original award immediately before modification, the minimum compensation cost the Company recognizes is the cost of the original award.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-503">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using enacted tax rates that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates its uncertain tax positions using the provisions of ASC 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements. The Company recognizes in the financial statements the benefit of a tax position which is &#x201c;more likely than not&#x201d; to be sustained under examination based solely on the technical merits of the position assuming a review by tax authorities having all relevant information. Tax positions that meet the recognition threshold are measured using a cumulative probability approach, at the largest amount of tax benefit that has a greater than fifty percent likelihood of being realized upon settlement. It is the Company&#x2019;s policy to recognize interest and penalties related to unrecognized tax benefits, if any, as a component of income tax expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-504">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic loss per share is calculated in accordance with ASC 260, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Basic loss per ordinary share is computed by dividing net loss attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period using the two-class method. Under the two-class method, net income is allocated between ordinary shares and participating securities based on dividends declared (or accumulated) and participating rights in undistributed earnings as if all the earnings for the reporting period had been distributed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted loss per share, when required, is calculated by dividing net loss attributable to ordinary shareholders as adjusted for the effect of dilutive ordinary equivalent shares, if any, by the weighted average number of ordinary and dilutive ordinary equivalent shares outstanding during the period. Ordinary equivalent shares consist of the ordinary shares issuable upon the conversion of the Company&#x2019;s convertible preferred shares, if any, using the if-converted method, and ordinary shares issuable upon the conversion of the share options, and unvested restricted shares units and performance-based restricted shares units (&#x201c;PSUs&#x201d;), using the treasury stock method. The dilutive effects of PSUs are included in the weighted average common share calculation based on the cumulative achievement against the performance targets only when the performance targets have been achieved as of the end of the reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ordinary share equivalents are excluded from the computation of diluted loss per share if their effects would be anti-dilutive. Basic and diluted loss per ordinary share is presented in the Company&#x2019;s consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-505">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 280, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;, the Company&#x2019;s chief operating decision maker, the Chief Executive Officer, reviews the consolidated results when making decisions about allocating resources and assessing performance of the Company as a whole and hence, the Company has only one reportable segment: pharmaceutical products.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-506"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-507">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Concentration of cash and credit risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that are potentially subject to credit risk consist of cash and cash equivalents and accounts receivable.&lt;/span&gt;&lt;/div&gt;The deposits placed with financial institutions are not protected by statutory or commercial insurance. In the event of bankruptcy of one of these financial institutions, the Company may be unable to claim its deposits back in full. Management believes that these financial institutions are of high credit quality and continually monitors the credit worthiness of these financial institutions.The Company monitors economic conditions to identify facts or circumstances that may indicate receivables are at risk of collection.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-12" decimals="-3" id="f-508" unitRef="usd">2627410000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-13" decimals="-3" id="f-509" unitRef="usd">3171800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-12" decimals="-3" id="f-510" unitRef="usd">676278000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-13" decimals="-3" id="f-511" unitRef="usd">358027000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-100" decimals="3" id="f-512" unitRef="number">0.180</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-101" decimals="3" id="f-513" unitRef="number">0.169</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-102" decimals="3" id="f-514" unitRef="number">0.111</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-103" decimals="3" id="f-515" unitRef="number">0.510</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-104" decimals="3" id="f-516" unitRef="number">0.160</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-105" decimals="3" id="f-517" unitRef="number">0.142</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-106" decimals="3" id="f-518" unitRef="number">0.124</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-107" decimals="3" id="f-519" unitRef="number">0.114</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-108" decimals="3" id="f-520" unitRef="number">0.532</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-521">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;New accounting standards which have been adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 280): Improvements to Reportable Segment Disclosures. This update requires disclosure of incremental segment information on an annual and interim basis. This update is effective for annual periods beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024. Early adoption is permitted. This guidance should be applied retrospectively to all prior periods presented in the financial statements. The Company operates in one segment. Its chief operating decision maker is the Chief Executive Officer, who makes operating decisions, assesses performance, and allocates resources on a consolidated basis. The Company adopted ASU 2023-07 effective December 31, 2024. Refer to Footnote 21 for segment related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;New accounting standards which have not yet been adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Subtopic 220-40): Disaggregation of Income Statement Expenses. This update requires that at each interim and annual reporting period public entities disclose (1) the amounts of purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions; (2) certain amounts that are already required to be disclosed under current GAAP in the same disclosure as the other disaggregation requirements; (3) a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively; and (4) the total amount of selling expenses and, in annual reporting periods, the definition of selling expenses. In January 2025, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Subtopic 220-40): Clarifying the Effective Date. This update clarifies that ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact on its financial statements of adopting this guidance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 740): Improvements to Income Tax Disclosures. This update requires that public entities on an annual basis, (1) in the rate reconciliation, disclose specific categories and provide additional information for reconciling items that meet a quantitative threshold; (2) about income taxes paid, disclose the amount of income taxes paid (net of refunds received) disaggregated by federal, state, and foreign taxes and by individual jurisdiction in which income taxes paid (net of refunds received) is equal to or greater than 5 percent of total income taxes paid (net of refunds received); and (3) disclose income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign and income tax expense (or benefit) disaggregated by federal, state, and foreign. This update is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. This guidance should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating the impact on its financial statements of adopting this guidance.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-522">Collaborative and Licensing Arrangements&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaborative arrangements for the research and development, manufacture and/or commercialization of drug products and drug candidates. To date, these collaborative arrangements have included out-licenses of and options to out-license internally developed products and drug candidates to other parties, in-licenses of products and drug candidates from other parties, and profit- and cost-sharing arrangements. These arrangements may include non-refundable upfront payments, contingent obligations for potential development, regulatory and commercial performance milestone payments, cost-sharing and reimbursement arrangements, royalty payments, and profit sharing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Out-Licensing Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three years ended December&#160;31, 2024, the Company&#x2019;s collaboration revenue related to its out-licensing collaborative agreements has consisted of research and development services revenue and right to access intellectual property revenue from its former collaboration agreements with Novartis for tislelizumab and ociperlimab. Other collaboration revenue consists primarily of revenue under the Novartis broad markets agreement and, beginning in 2024, royalty revenue under the Amgen collaboration agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes total collaboration revenue recognized for the years ended December&#160;31, 2024, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.429%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue from Collaborators&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development service revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right to access intellectual property revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Material rights revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Novartis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Tislelizumab Collaboration and License &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company entered into a collaboration and license agreement with Novartis, granting Novartis rights to develop, manufacture and commercialize tislelizumab in North America, Europe, and Japan (the &#x201c;Novartis Territory&#x201d;). The Company and Novartis agreed to jointly develop tislelizumab in these licensed countries, with Novartis responsible for regulatory submissions after a transition period and for commercialization upon regulatory approvals. In addition, both companies had the ability to conduct clinical trials globally to explore combinations of tislelizumab with other cancer treatments, and the Company has an option to co-detail the product in North America, funded in part by Novartis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the agreement the Company received an upfront cash payment of $650,000 from Novartis. A portion of the transaction price was allocated to the R&amp;amp;D services to be performed under the agreement and deferred and was being recognized as collaboration revenue as the R&amp;amp;D services were performed using a percentage-of-completion method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2023, the Company and Novartis agreed to mutually terminate the collaboration and license agreement, effective immediately. Pursuant to the termination agreement, the Company regained full, global rights to develop, manufacture and commercialize tislelizumab with no royalty payments due to Novartis. Novartis may continue its ongoing clinical trials and has the ability to conduct future combination trials with tislelizumab subject to BeiGene&#x2019;s approval. BeiGene agreed to provide Novartis with ongoing clinical supply of tislelizumab to support its clinical trials. Pursuant to the termination agreement, Novartis agreed to provide transition services to the Company to enable key aspects of the tislelizumab development and commercialization plan to proceed without disruption, including manufacturing, regulatory, safety and clinical support. Upon termination of the agreement in September 2023, there were no further performance obligations, and the remaining deferred revenue balance associated with the tislelizumab R&amp;amp;D services was recognized in full.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes collaboration revenue recognized in connection with the tislelizumab collaboration and license agreement for the years ended December&#160;31, 2024, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.429%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development service revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Represents revenue recognized on sale of tislelizumab clinical supply to Novartis in conjunction with the collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Ociperlimab Option, Collaboration and License Agreement and China Broad Market Development Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021, the Company expanded its collaboration with Novartis by entering into an option, collaboration and license agreement with Novartis to develop, manufacture and commercialize the Company&#x2019;s investigational TIGIT inhibitor ociperlimab in the Novartis Territory. In addition, the Company and Novartis entered into an agreement granting the Company rights to market, promote and detail five approved Novartis oncology products, TAFINLAR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (dabrafenib), MEKINIST&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (trametinib), VOTRIENT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (pazopanib), AFINITOR&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (everolimus), and ZYKADIA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ceritinib), across designated regions of China referred to as &#x201c;broad markets.&#x201d; In the first quarter of 2022, the Company initiated marketing and promotion of these five products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the option, collaboration and license agreement, the Company received an upfront cash payment of $300,000. At inception, a portion of the upfront cash payment was deferred related to performance obligations to be satisfied at a later point in time or over time. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2023, the Company and Novartis mutually agreed to terminate the ociperlimab option, collaboration and license agreement, effective immediately. Pursuant to the termination agreement, the Company regained full, global rights to develop, manufacture and commercialize ociperlimab. Upon termination the Company had no further performance obligations under the collaboration, and all remaining deferred revenue balances were recognized in full. The China broad markets agreement remains in place.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes collaboration revenue recognized in connection with the ociperlimab option, collaboration and license agreement for the years ended December&#160;31, 2024, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.429%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development service revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right to access intellectual property revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Material rights revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Represents revenue generated under the broad markets marketing and promotion agreement in conjunction with the collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In-Licensing Arrangements - Commercial&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amgen&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2019, the Company entered into a global strategic oncology collaboration with Amgen (&#x201c;Amgen Collaboration Agreement&#x201d;) for the commercialization and development in China, excluding Hong Kong, Taiwan and Macau, of Amgen&#x2019;s XGEVA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, KYPROLIS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and BLINCYTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and the joint global development of a portfolio of oncology assets in Amgen&#x2019;s pipeline, with BeiGene responsible for development and commercialization in China. The agreement became effective on January 2, 2020, following approval by the Company&#x2019;s shareholders and satisfaction of other closing conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the agreement, the Company is responsible for the commercialization of XGEVA, KYPROLIS and BLINCYTO in China for &lt;span style="-sec-ix-hidden:f-567"&gt;five&lt;/span&gt; or seven years. Amgen is responsible for manufacturing the products globally and supplying the products to the Company at an agreed upon price. The Company and Amgen share equally in the China commercial profits and losses during the commercialization period. Following the commercialization period, the Company has the right to retain one product and is entitled to receive royalties on sales in China for an additional five years on the products not retained. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amgen and the Company are also jointly developing a portfolio of Amgen oncology pipeline assets under the collaboration. The Company is responsible for conducting clinical development activities in China and co-funding global development costs by contributing cash and development services up to a total cap of $1,250,000. Amgen is responsible for all development, regulatory and commercial activities outside of China. For each pipeline asset that is approved in China, the Company will receive commercial rights for seven years from approval. The Company has the right to retain approximately one out of every three approved pipeline assets, other than LUMAKRAS (sotorasib) (&#x201c;AMG 510&#x201d;), Amgen&#x2019;s KRAS G12C inhibitor, for commercialization in China. The Company and Amgen will share equally in the China commercial profits and losses during the commercialization period. The Company is entitled to receive royalties from sales in China for pipeline assets returned to Amgen for five years after the seven-year commercialization period. The Company is also entitled to receive royalties from global sales of each product outside of China (with the exception of AMG 510).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 20, 2022, the parties entered into the First Amendment to Amgen Collaboration Agreement, which amends certain terms and conditions relating to the financial responsibilities of the parties in connections with the development and commercialization of certain Amgen proprietary products for the treatment of oncology-related diseases and conditions. In connection with the Company&#x2019;s ongoing assessment of the Amgen Collaboration Agreement cost-share contributions, the Company determined that further investment in the development of LUMAKRAS was no longer commercially viable for BeiGene. As a result, in February 2023, the Company and Amgen entered into the Second Amendment to the Amgen Collaboration Agreement to (i) stop sharing costs with Amgen for the further development of LUMAKRAS during the period starting January 1, 2023 and ending August 31, 2023; and (ii) cooperate in good faith to prepare a transition plan with the termination of LUMAKRAS from the Amgen Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amgen Collaboration Agreement is within the scope of ASC 808, as both parties are active participants and are exposed to the risks and rewards dependent on the commercial success of the activities performed under the agreement. The Company is the principal for product sales to customers in China during the commercialization period and will recognize 100% of net product revenue on these sales. Amounts due to Amgen for its portion of net product sales will be recorded as cost of sales. Cost reimbursements due to or from Amgen under the profit share will be recognized as incurred and recorded to cost of sales; selling, general and administrative expense; or research and development expense, based on the underlying nature of the related activity subject to reimbursement. Costs incurred for the Company&#x2019;s portion of the global co-development funding are recorded to research and development expense as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Amgen Collaboration Agreement, a Share Purchase Agreement (&#x201c;SPA&#x201d;) was entered into by the parties on October 31, 2019. On January 2, 2020, the closing date of the transaction, Amgen purchased 15,895,001 of the Company&#x2019;s ADSs for $174.85 per ADS, representing a 20.5% ownership stake in the Company. Per the SPA, the cash proceeds shall be used as necessary to fund the Company&#x2019;s development obligations under the Amgen Collaboration Agreement. Pursuant to the SPA, Amgen also received the right to designate one member of the Company&#x2019;s board of directors, and Anthony Hooper joined the Company&#x2019;s board of directors as the Amgen designee in January 2020. Amgen relinquished its right to appoint a designated director to the Company&#x2019;s board of directors in January 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the fair value of the common stock at closing, the Company considered the closing price of the common stock on the closing date of the transaction and included a lack of marketability discount because the shares are subject to certain restrictions. The fair value of the shares on the closing date was determined to be $132.74 per ADS, or $2,109,902 in the aggregate. The Company determined that the premium paid by Amgen on the share purchase represents a cost share liability due to the Company&#x2019;s co-development obligations. The fair value of the cost share liability on the closing date was determined to be $601,857 based on the Company&#x2019;s discounted estimated future cash flows related to the pipeline assets. The estimation of future cash flows involved management assumptions of revenue growth rates and probability of technical and regulatory success of the pipeline assets. The total cash proceeds of $2,779,241 were allocated based on the relative fair value method, with $2,162,407 recorded to equity and $616,834 recorded as a research and development cost share liability. The cost share liability is being amortized proportionately as the Company contributes cash and development services to its total co-development funding cap.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recorded related to the Company&#x2019;s portion of the co-development funding on the pipeline assets for the years ended December&#160;31, 2024, 2023 and 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.309%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;BeiGene&#x2019;s portion of the development funding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Amortization of research and development cost share liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining portion of development funding cap &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024 and 2023, the research and development cost share liability recorded in the Company&#x2019;s balance sheet was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.367%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development cost share liability, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development cost share liability, non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total research and development cost share liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net reimbursement paid under the commercial profit-sharing agreement for in-line product sales is classified in the consolidated statements of operations for the three years ended December&#160;31, 2024 as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.437%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.437%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.440%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales - product&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83,674)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,917)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54,865)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,438)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,871)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,183)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company purchases commercial inventory from Amgen to distribute in China. Total inventory purchases amounted to $247,655, $108,691 and $71,720, respectively, during the year ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2024, 2023 and 2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Net amounts payable to Amgen as of December&#160;31, 2024 and 2023 were $116,563 and $55,474, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;In-Licensing Arrangements - Development &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has in-licensed the rights to develop, manufacture and, if approved, commercialize multiple development stage drug candidates globally or in specific territories. These arrangements typically include non-refundable upfront payments, contingent obligations for potential development, regulatory and commercial performance milestone payments, cost-sharing arrangements, royalty payments, and profit sharing. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upfront and milestone payments made under these arrangements for the years ended December&#160;31, 2024, 2023 and 2022 are set forth below. All upfront and development milestones were expensed to research and development expense. All regulatory and commercial milestones were capitalized as intangible assets and are being amortized over the remainder of the respective product patent or the term of the commercialization agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Payments due to collaboration partners&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Upfront payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Development milestone payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regulatory and commercial milestone payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into a number of in-licensing collaborative arrangements during the years ended December&#160;31, 2024, 2023 and 2022. A summary of amounts incurred under these arrangements is included above. The Company may be required to pay additional amounts upon the achievement of various development and commercial milestones under these agreements. The Company may also incur significant research and development costs if the related product candidate were to advance to late-stage clinical trials. In addition, if any products related to these collaborations are approved for sale, the Company may be required to pay significant milestones upon approval and milestones and/or royalties on future sales. The payment of these amounts, however, is contingent upon the occurrence of various future events, which have a high degree of uncertainty of occurrence.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-523">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes total collaboration revenue recognized for the years ended December&#160;31, 2024, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.429%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue from Collaborators&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development service revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right to access intellectual property revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Material rights revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;268,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes collaboration revenue recognized in connection with the tislelizumab collaboration and license agreement for the years ended December&#160;31, 2024, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.429%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development service revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Represents revenue recognized on sale of tislelizumab clinical supply to Novartis in conjunction with the collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes collaboration revenue recognized in connection with the ociperlimab option, collaboration and license agreement for the years ended December&#160;31, 2024, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.429%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development service revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right to access intellectual property revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Material rights revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Represents revenue generated under the broad markets marketing and promotion agreement in conjunction with the collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the Company&#x2019;s net product sales for the years ended December&#160;31, 2024, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenue - gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,786,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,718,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,438,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Rebates and sales returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,007,198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(529,117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(183,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenue - net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,779,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,189,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,254,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table disaggregates net product revenue by product for the years ended December&#160;31, 2024, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.642%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;BRUKINSA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,644,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,290,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tislelizumab&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;XGEVA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;BLINCYTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;KYPROLIS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;POBEVCY&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;REVLIMID&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product revenue - net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,779,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,189,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,254,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-109" decimals="-3" id="f-524" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-110" decimals="-3" id="f-525" unitRef="usd">79431000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-111" decimals="-3" id="f-526" unitRef="usd">46822000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-112" decimals="-3" id="f-527" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-113" decimals="-3" id="f-528" unitRef="usd">104477000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-114" decimals="-3" id="f-529" unitRef="usd">104994000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-115" decimals="-3" id="f-530" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-116" decimals="-3" id="f-531" unitRef="usd">71980000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-117" decimals="-3" id="f-532" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-118" decimals="-3" id="f-533" unitRef="usd">30695000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-119" decimals="-3" id="f-534" unitRef="usd">13039000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-120" decimals="-3" id="f-535" unitRef="usd">9493000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-121" decimals="-3" id="f-536" unitRef="usd">30695000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-122" decimals="-3" id="f-537" unitRef="usd">268927000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-123" decimals="-3" id="f-538" unitRef="usd">161309000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability contextRef="c-124" decimals="-3" id="f-539" unitRef="usd">650000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-125" decimals="-3" id="f-540" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-126" decimals="-3" id="f-541" unitRef="usd">72278000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-127" decimals="-3" id="f-542" unitRef="usd">39655000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-128" decimals="-3" id="f-543" unitRef="usd">2113000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-129" decimals="-3" id="f-544" unitRef="usd">5067000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-130" decimals="-3" id="f-545" unitRef="usd">9493000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-131" decimals="-3" id="f-546" unitRef="usd">2113000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-132" decimals="-3" id="f-547" unitRef="usd">77345000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-133" decimals="-3" id="f-548" unitRef="usd">49148000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <bgne:NumberOfProductsInitiatedMarketingAndPromotion
      contextRef="c-134"
      decimals="INF"
      id="f-549"
      unitRef="product">5</bgne:NumberOfProductsInitiatedMarketingAndPromotion>
    <bgne:NumberOfProductsInitiatedMarketingAndPromotion
      contextRef="c-134"
      decimals="INF"
      id="f-550"
      unitRef="product">5</bgne:NumberOfProductsInitiatedMarketingAndPromotion>
    <us-gaap:ContractWithCustomerLiability contextRef="c-135" decimals="-3" id="f-551" unitRef="usd">300000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-136" decimals="-3" id="f-552" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-137" decimals="-3" id="f-553" unitRef="usd">7153000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-138" decimals="-3" id="f-554" unitRef="usd">7167000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-139" decimals="-3" id="f-555" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-140" decimals="-3" id="f-556" unitRef="usd">104477000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-141" decimals="-3" id="f-557" unitRef="usd">104994000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-142" decimals="-3" id="f-558" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-143" decimals="-3" id="f-559" unitRef="usd">71980000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-144" decimals="-3" id="f-560" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-145" decimals="-3" id="f-561" unitRef="usd">18259000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-146" decimals="-3" id="f-562" unitRef="usd">8859000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-147" decimals="-3" id="f-563" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-148" decimals="-3" id="f-564" unitRef="usd">18259000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-149" decimals="-3" id="f-565" unitRef="usd">192469000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-150" decimals="-3" id="f-566" unitRef="usd">112161000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <bgne:CommercializationTerm contextRef="c-152" id="f-568">P7Y</bgne:CommercializationTerm>
    <bgne:CollaborativeArrangementsNumberOfProductsCompanyHasTheRightToRetain
      contextRef="c-153"
      decimals="INF"
      id="f-569"
      unitRef="product">1</bgne:CollaborativeArrangementsNumberOfProductsCompanyHasTheRightToRetain>
    <bgne:CollaborativeArrangementsProductRetentionPeriod contextRef="c-154" id="f-570">P5Y</bgne:CollaborativeArrangementsProductRetentionPeriod>
    <bgne:MaximumCashAndServicesDevelopmentCommitment contextRef="c-153" decimals="-3" id="f-571" unitRef="usd">1250000000</bgne:MaximumCashAndServicesDevelopmentCommitment>
    <bgne:CommercializationTerm contextRef="c-152" id="f-572">P7Y</bgne:CommercializationTerm>
    <bgne:RoyaltiesReceivingPeriod contextRef="c-152" id="f-573">P5Y</bgne:RoyaltiesReceivingPeriod>
    <bgne:CommercializationTerm contextRef="c-152" id="f-574">P7Y</bgne:CommercializationTerm>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-155"
      decimals="INF"
      id="f-575"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-156"
      decimals="INF"
      id="f-576"
      unitRef="shares">15895001</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-157"
      decimals="INF"
      id="f-577"
      unitRef="usdPerShare">174.85</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners contextRef="c-158" decimals="3" id="f-578" unitRef="number">0.205</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <bgne:SharePriceAmericanDepositoryShares
      contextRef="c-159"
      decimals="INF"
      id="f-579"
      unitRef="usdPerShare">132.74</bgne:SharePriceAmericanDepositoryShares>
    <bgne:ProceedsFromIssuanceOfAssetDepositoryShares contextRef="c-160" decimals="-3" id="f-580" unitRef="usd">2109902000</bgne:ProceedsFromIssuanceOfAssetDepositoryShares>
    <bgne:FairValueOfLiabilityAcquired contextRef="c-157" decimals="-3" id="f-581" unitRef="usd">601857000</bgne:FairValueOfLiabilityAcquired>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-156" decimals="-3" id="f-582" unitRef="usd">2779241000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <bgne:FairValueOfEquityInvestmentsIssued contextRef="c-156" decimals="-3" id="f-583" unitRef="usd">2162407000</bgne:FairValueOfEquityInvestmentsIssued>
    <bgne:FairValueOfFinancingCommitment contextRef="c-156" decimals="-3" id="f-584" unitRef="usd">616834000</bgne:FairValueOfFinancingCommitment>
    <bgne:CollaborationAgreementsTableTextBlock contextRef="c-1" id="f-585">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts recorded related to the Company&#x2019;s portion of the co-development funding on the pipeline assets for the years ended December&#160;31, 2024, 2023 and 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.309%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;BeiGene&#x2019;s portion of the development funding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Amortization of research and development cost share liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remaining portion of development funding cap &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024 and 2023, the research and development cost share liability recorded in the Company&#x2019;s balance sheet was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.367%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development cost share liability, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development cost share liability, non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total research and development cost share liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bgne:CollaborationAgreementsTableTextBlock>
    <bgne:FinancingCommitmentExpenses contextRef="c-161" decimals="-3" id="f-586" unitRef="usd">148391000</bgne:FinancingCommitmentExpenses>
    <bgne:FinancingCommitmentExpenses contextRef="c-162" decimals="-3" id="f-587" unitRef="usd">108608000</bgne:FinancingCommitmentExpenses>
    <bgne:FinancingCommitmentExpenses contextRef="c-163" decimals="-3" id="f-588" unitRef="usd">195357000</bgne:FinancingCommitmentExpenses>
    <bgne:AmortizationOfFinancingCommitment contextRef="c-161" decimals="-3" id="f-589" unitRef="usd">73226000</bgne:AmortizationOfFinancingCommitment>
    <bgne:AmortizationOfFinancingCommitment contextRef="c-162" decimals="-3" id="f-590" unitRef="usd">55294000</bgne:AmortizationOfFinancingCommitment>
    <bgne:AmortizationOfFinancingCommitment contextRef="c-163" decimals="-3" id="f-591" unitRef="usd">96402000</bgne:AmortizationOfFinancingCommitment>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-161" decimals="-3" id="f-592" unitRef="usd">75165000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-162" decimals="-3" id="f-593" unitRef="usd">53314000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-163" decimals="-3" id="f-594" unitRef="usd">98955000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherCommitment contextRef="c-164" decimals="-3" id="f-595" unitRef="usd">335261000</us-gaap:OtherCommitment>
    <bgne:FinancingCommitmentCarryingValueCurrent contextRef="c-164" decimals="-3" id="f-596" unitRef="usd">111154000</bgne:FinancingCommitmentCarryingValueCurrent>
    <bgne:FinancingCommitmentCarryingValueCurrent contextRef="c-165" decimals="-3" id="f-597" unitRef="usd">68004000</bgne:FinancingCommitmentCarryingValueCurrent>
    <bgne:FinancingCommitmentCarryingValueNoncurrent contextRef="c-164" decimals="-3" id="f-598" unitRef="usd">54286000</bgne:FinancingCommitmentCarryingValueNoncurrent>
    <bgne:FinancingCommitmentCarryingValueNoncurrent contextRef="c-165" decimals="-3" id="f-599" unitRef="usd">170662000</bgne:FinancingCommitmentCarryingValueNoncurrent>
    <bgne:FinancingCommitmentCarryingValue contextRef="c-164" decimals="-3" id="f-600" unitRef="usd">165440000</bgne:FinancingCommitmentCarryingValue>
    <bgne:FinancingCommitmentCarryingValue contextRef="c-165" decimals="-3" id="f-601" unitRef="usd">238666000</bgne:FinancingCommitmentCarryingValue>
    <bgne:ScheduleOfAmountsAndClassificationOfReimbursementExpenseTableTextBlock contextRef="c-1" id="f-602">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net reimbursement paid under the commercial profit-sharing agreement for in-line product sales is classified in the consolidated statements of operations for the three years ended December&#160;31, 2024 as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.437%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.437%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.440%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales - product&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(83,674)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,917)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54,865)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,438)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,216)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48,962)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,871)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,183)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bgne:ScheduleOfAmountsAndClassificationOfReimbursementExpenseTableTextBlock>
    <bgne:ReimbursementExpense contextRef="c-166" decimals="-3" id="f-603" unitRef="usd">-37150000</bgne:ReimbursementExpense>
    <bgne:ReimbursementExpense contextRef="c-167" decimals="-3" id="f-604" unitRef="usd">-8358000</bgne:ReimbursementExpense>
    <bgne:ReimbursementExpense contextRef="c-168" decimals="-3" id="f-605" unitRef="usd">-5898000</bgne:ReimbursementExpense>
    <bgne:ReimbursementExpense contextRef="c-169" decimals="-3" id="f-606" unitRef="usd">83674000</bgne:ReimbursementExpense>
    <bgne:ReimbursementExpense contextRef="c-170" decimals="-3" id="f-607" unitRef="usd">60917000</bgne:ReimbursementExpense>
    <bgne:ReimbursementExpense contextRef="c-171" decimals="-3" id="f-608" unitRef="usd">54865000</bgne:ReimbursementExpense>
    <bgne:ReimbursementExpense contextRef="c-172" decimals="-3" id="f-609" unitRef="usd">2438000</bgne:ReimbursementExpense>
    <bgne:ReimbursementExpense contextRef="c-173" decimals="-3" id="f-610" unitRef="usd">-1688000</bgne:ReimbursementExpense>
    <bgne:ReimbursementExpense contextRef="c-174" decimals="-3" id="f-611" unitRef="usd">1216000</bgne:ReimbursementExpense>
    <bgne:ReimbursementExpense contextRef="c-1" decimals="-3" id="f-612" unitRef="usd">48962000</bgne:ReimbursementExpense>
    <bgne:ReimbursementExpense contextRef="c-10" decimals="-3" id="f-613" unitRef="usd">50871000</bgne:ReimbursementExpense>
    <bgne:ReimbursementExpense contextRef="c-11" decimals="-3" id="f-614" unitRef="usd">50183000</bgne:ReimbursementExpense>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="c-175" decimals="-3" id="f-615" unitRef="usd">247655000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="c-176" decimals="-3" id="f-616" unitRef="usd">108691000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="c-177" decimals="-3" id="f-617" unitRef="usd">71720000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:AccountsPayableCurrent contextRef="c-178" decimals="-3" id="f-618" unitRef="usd">116563000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-179" decimals="-3" id="f-619" unitRef="usd">55474000</us-gaap:AccountsPayableCurrent>
    <bgne:PaymentsDueToCollaborationPartnersTableTextBlock contextRef="c-1" id="f-620">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upfront and milestone payments made under these arrangements for the years ended December&#160;31, 2024, 2023 and 2022 are set forth below. All upfront and development milestones were expensed to research and development expense. All regulatory and commercial milestones were capitalized as intangible assets and are being amortized over the remainder of the respective product patent or the term of the commercialization agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Payments due to collaboration partners&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Upfront payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Development milestone payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Regulatory and commercial milestone payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bgne:PaymentsDueToCollaborationPartnersTableTextBlock>
    <bgne:UpfrontAndMilestonePayments contextRef="c-180" decimals="-3" id="f-621" unitRef="usd">60027000</bgne:UpfrontAndMilestonePayments>
    <bgne:UpfrontAndMilestonePayments contextRef="c-181" decimals="-3" id="f-622" unitRef="usd">46800000</bgne:UpfrontAndMilestonePayments>
    <bgne:UpfrontAndMilestonePayments contextRef="c-182" decimals="-3" id="f-623" unitRef="usd">68665000</bgne:UpfrontAndMilestonePayments>
    <bgne:UpfrontAndMilestonePayments contextRef="c-183" decimals="-3" id="f-624" unitRef="usd">54000000</bgne:UpfrontAndMilestonePayments>
    <bgne:UpfrontAndMilestonePayments contextRef="c-184" decimals="-3" id="f-625" unitRef="usd">0</bgne:UpfrontAndMilestonePayments>
    <bgne:UpfrontAndMilestonePayments contextRef="c-185" decimals="-3" id="f-626" unitRef="usd">5500000</bgne:UpfrontAndMilestonePayments>
    <bgne:UpfrontAndMilestonePayments contextRef="c-186" decimals="-3" id="f-627" unitRef="usd">0</bgne:UpfrontAndMilestonePayments>
    <bgne:UpfrontAndMilestonePayments contextRef="c-187" decimals="-3" id="f-628" unitRef="usd">24365000</bgne:UpfrontAndMilestonePayments>
    <bgne:UpfrontAndMilestonePayments contextRef="c-188" decimals="-3" id="f-629" unitRef="usd">0</bgne:UpfrontAndMilestonePayments>
    <bgne:UpfrontAndMilestonePayments contextRef="c-1" decimals="-3" id="f-630" unitRef="usd">114027000</bgne:UpfrontAndMilestonePayments>
    <bgne:UpfrontAndMilestonePayments contextRef="c-10" decimals="-3" id="f-631" unitRef="usd">71165000</bgne:UpfrontAndMilestonePayments>
    <bgne:UpfrontAndMilestonePayments contextRef="c-11" decimals="-3" id="f-632" unitRef="usd">74165000</bgne:UpfrontAndMilestonePayments>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock contextRef="c-1" id="f-633">Restricted Cash&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s restricted cash primarily consist of&#160;RMB-denominated cash deposits held in designated bank accounts for collateral for letters of credit. The Company classifies restricted cash as current or non-current based on term of restriction. Restricted cash as of December&#160;31, 2024 and 2023 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.499%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the restricted cash balances above, the Company is required by the PRC securities law to use the proceeds from the STAR Offering in strict compliance with the planned uses as disclosed in the PRC offering prospectus as well as those disclosed in the Company&#x2019;s proceeds management policy approved by the board of directors. As of December&#160;31, 2024, the Company had cash remaining related to the STAR Offering proceeds of $588,235.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="c-1" id="f-634">The Company classifies restricted cash as current or non-current based on term of restriction. Restricted cash as of December&#160;31, 2024 and 2023 was as follows:&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.499%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:RestrictedCashCurrent contextRef="c-12" decimals="-3" id="f-635" unitRef="usd">9312000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-13" decimals="-3" id="f-636" unitRef="usd">11473000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-12" decimals="-3" id="f-637" unitRef="usd">2025000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-13" decimals="-3" id="f-638" unitRef="usd">2711000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCash contextRef="c-12" decimals="-3" id="f-639" unitRef="usd">11337000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-13" decimals="-3" id="f-640" unitRef="usd">14184000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c-189" decimals="-3" id="f-641" unitRef="usd">588235000</us-gaap:RestrictedCash>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="c-1" id="f-642">Investments&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s investments in equity securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.100%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.226%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.228%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities with readily determinable fair values &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Leap common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Leap warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities without readily determinable fair values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pi Health, Inc. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:9pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-method investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Represents common stock and warrants to purchase additional shares of common stock of Leap. The Company measures the investment in the common stock and warrants at fair value, with changes in fair value recorded to other (expense) income, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In the first quarter of 2024, the Company divested the net assets comprising substantially all of its Pi Health business with a carrying value of $38,063. The consideration received for the divestiture consisted of preferred stock in a newly formed entity, Pi Health, Inc., with a fair value of $40,798 and cash consideration of $1,000. The transaction resulted in a pre-tax gain of $3,735 recorded within &lt;span style="-sec-ix-hidden:f-660"&gt;other (expense) income, net&lt;/span&gt; during year ended December&#160;31, 2024. The Company will account for its investment prospectively as a private equity security without a readily determinable fair value and the divestiture is not treated as a discontinued operation in the Statement of Operations and therefore the historical results of operations of the Pi Health business will remain in the Company&#x2019;s continuing operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes unrealized (losses) gains related to investments in equity securities recorded in other (expense) income, net:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities with readily determinable fair values&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,307)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities without readily determinable fair values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,596)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,448)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-method investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,856)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentsTextBlock contextRef="c-1" id="f-643">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s investments in equity securities:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.100%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.226%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.228%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities with readily determinable fair values &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Leap common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Leap warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities without readily determinable fair values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pi Health, Inc. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:9pt;padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-method investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Represents common stock and warrants to purchase additional shares of common stock of Leap. The Company measures the investment in the common stock and warrants at fair value, with changes in fair value recorded to other (expense) income, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In the first quarter of 2024, the Company divested the net assets comprising substantially all of its Pi Health business with a carrying value of $38,063. The consideration received for the divestiture consisted of preferred stock in a newly formed entity, Pi Health, Inc., with a fair value of $40,798 and cash consideration of $1,000. The transaction resulted in a pre-tax gain of $3,735 recorded within &lt;span style="-sec-ix-hidden:f-660"&gt;other (expense) income, net&lt;/span&gt; during year ended December&#160;31, 2024. The Company will account for its investment prospectively as a private equity security without a readily determinable fair value and the divestiture is not treated as a discontinued operation in the Statement of Operations and therefore the historical results of operations of the Pi Health business will remain in the Company&#x2019;s continuing operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes unrealized (losses) gains related to investments in equity securities recorded in other (expense) income, net:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.356%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.500%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities with readily determinable fair values&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,307)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(425)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,102)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities without readily determinable fair values&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,596)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,448)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity-method investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,856)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-190" decimals="-3" id="f-644" unitRef="usd">2113000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-191" decimals="-3" id="f-645" unitRef="usd">3046000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-192" decimals="-3" id="f-646" unitRef="usd">168000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-193" decimals="-3" id="f-647" unitRef="usd">542000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-194" decimals="-3" id="f-648" unitRef="usd">40798000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-195" decimals="-3" id="f-649" unitRef="usd">0</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-196" decimals="-3" id="f-650" unitRef="usd">48157000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-197" decimals="-3" id="f-651" unitRef="usd">55860000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquityMethodInvestments contextRef="c-12" decimals="-3" id="f-652" unitRef="usd">33081000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-13" decimals="-3" id="f-653" unitRef="usd">25981000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue contextRef="c-12" decimals="-3" id="f-654" unitRef="usd">124317000</us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue>
    <us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue contextRef="c-13" decimals="-3" id="f-655" unitRef="usd">85429000</us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue>
    <bgne:DisposalGroupNotDiscontinuedOperationNetAssets contextRef="c-198" decimals="-3" id="f-656" unitRef="usd">38063000</bgne:DisposalGroupNotDiscontinuedOperationNetAssets>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount contextRef="c-194" decimals="-3" id="f-657" unitRef="usd">40798000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:ProceedsFromDivestitureOfBusinesses contextRef="c-199" decimals="-3" id="f-658" unitRef="usd">1000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal contextRef="c-200" decimals="-3" id="f-659" unitRef="usd">3735000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-201" decimals="-3" id="f-661" unitRef="usd">-1307000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-202" decimals="-3" id="f-662" unitRef="usd">-425000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-203" decimals="-3" id="f-663" unitRef="usd">-30102000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <bgne:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmountNet contextRef="c-201" decimals="-3" id="f-664" unitRef="usd">7596000</bgne:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmountNet>
    <bgne:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmountNet contextRef="c-202" decimals="-3" id="f-665" unitRef="usd">6448000</bgne:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmountNet>
    <bgne:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmountNet contextRef="c-203" decimals="-3" id="f-666" unitRef="usd">-5065000</bgne:EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmountNet>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-201" decimals="-3" id="f-667" unitRef="usd">-10275000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-202" decimals="-3" id="f-668" unitRef="usd">-7856000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-203" decimals="-3" id="f-669" unitRef="usd">-3682000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c-1" id="f-670">Inventories, Net&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s inventories, net consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.245%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.499%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As&#160;of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-671">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s inventories, net consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.245%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.499%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As&#160;of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;494,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-12" decimals="-3" id="f-672" unitRef="usd">170584000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-13" decimals="-3" id="f-673" unitRef="usd">148772000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-12" decimals="-3" id="f-674" unitRef="usd">60118000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-13" decimals="-3" id="f-675" unitRef="usd">39098000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-12" decimals="-3" id="f-676" unitRef="usd">264284000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-13" decimals="-3" id="f-677" unitRef="usd">228252000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet contextRef="c-12" decimals="-3" id="f-678" unitRef="usd">494986000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-13" decimals="-3" id="f-679" unitRef="usd">416122000</us-gaap:InventoryNet>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-680">Leases&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating leases for office and manufacturing facilities in the U.S., Switzerland, and China. The leases have remaining lease terms of up to six years, some of which include options to extend the leases that have not been included in the calculation of the Company&#x2019;s lease liabilities and ROU assets. The Company has land use rights, which represent land acquired for the biologics manufacturing facility in Guangzhou, the land acquired for the Company&#x2019;s research, development and office facility in Changping, Beijing, the land acquired for the Company&#x2019;s research, development and manufacturing facility in Suzhou, and the land acquired for the Company&#x2019;s research and development facility in Shanghai. The Company also has certain leases with terms of 12 months or less for certain equipment, office and lab space, which are expensed and not recorded on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.221%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As&#160;of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land use rights, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of operating lease liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.375%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December&#160;31,&#160;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December&#160;31,&#160;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December&#160;31,&#160;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,681)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other supplemental information related to leases is summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.377%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows used in operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:4pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.391%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As&#160;of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-44" id="f-681">P6Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-682" unitRef="usd">26575000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-10" decimals="-3" id="f-683" unitRef="usd">25978000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-11" decimals="-3" id="f-684" unitRef="usd">25938000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-1" decimals="-3" id="f-685" unitRef="usd">4580000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-10" decimals="-3" id="f-686" unitRef="usd">6101000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-11" decimals="-3" id="f-687" unitRef="usd">6834000</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-1" decimals="-3" id="f-688" unitRef="usd">2897000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-10" decimals="-3" id="f-689" unitRef="usd">1683000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-11" decimals="-3" id="f-690" unitRef="usd">1299000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-691" unitRef="usd">34052000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-10" decimals="-3" id="f-692" unitRef="usd">33762000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-11" decimals="-3" id="f-693" unitRef="usd">34071000</us-gaap:LeaseCost>
    <bgne:AssetsAndLiabilitiesLesseeTableTextBlock contextRef="c-1" id="f-694">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.221%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As&#160;of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land use rights, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bgne:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-44" decimals="-3" id="f-695" unitRef="usd">60639000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-204" decimals="-3" id="f-696" unitRef="usd">43490000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-205" decimals="-3" id="f-697" unitRef="usd">78670000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-206" decimals="-3" id="f-698" unitRef="usd">51717000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-12" decimals="-3" id="f-699" unitRef="usd">139309000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-13" decimals="-3" id="f-700" unitRef="usd">95207000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-12" decimals="-3" id="f-701" unitRef="usd">17576000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-13" decimals="-3" id="f-702" unitRef="usd">21950000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-12" decimals="-3" id="f-703" unitRef="usd">44277000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-13" decimals="-3" id="f-704" unitRef="usd">22251000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="c-12" decimals="-3" id="f-705" unitRef="usd">61853000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="c-13" decimals="-3" id="f-706" unitRef="usd">44201000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-707">&lt;div style="margin-bottom:4pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of operating lease liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.375%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December&#160;31,&#160;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December&#160;31,&#160;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December&#160;31,&#160;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,681)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-12" decimals="-3" id="f-708" unitRef="usd">19824000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-12" decimals="-3" id="f-709" unitRef="usd">13279000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-12" decimals="-3" id="f-710" unitRef="usd">12583000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-12" decimals="-3" id="f-711" unitRef="usd">11738000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-12" decimals="-3" id="f-712" unitRef="usd">7188000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-12" decimals="-3" id="f-713" unitRef="usd">3922000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-12" decimals="-3" id="f-714" unitRef="usd">68534000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-12" decimals="-3" id="f-715" unitRef="usd">6681000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-12" decimals="-3" id="f-716" unitRef="usd">61853000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-717" unitRef="usd">56005000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-10" decimals="-3" id="f-718" unitRef="usd">27985000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-11" decimals="-3" id="f-719" unitRef="usd">28064000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-720" unitRef="usd">47066000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-10" decimals="-3" id="f-721" unitRef="usd">11854000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-11" decimals="-3" id="f-722" unitRef="usd">22278000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-12" id="f-723">P4Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-13" id="f-724">P3Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-12" decimals="4" id="f-725" unitRef="number">0.0523</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-13" decimals="4" id="f-726" unitRef="number">0.0722</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-727">Property, Plant and Equipment, Net&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net are recorded at cost less accumulated depreciation and consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.221%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As&#160;of&#160;December&#160;31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;607,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software, electronics and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,323,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;832,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(399,105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(249,212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;740,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,578,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,324,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has made a significant investment in its newly opened manufacturing and R&amp;amp;D center in Hopewell, New Jersey. In the year ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$272,670&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of assets were placed into service. As of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company had construction in progress of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$500,900&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; related to the Hopewell facility, the majority of which will be put into service in 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2024, the Company acquired a land use right and the facility currently being constructed on the land for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$73,054&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company plans to complete the construction of the facility and build a research and development center on the land. Based on the relative fair values of the land use right and construction in progress, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$29,431&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the total purchase price was allocated to the land use right and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$43,623&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was allocated to the construction in progress. In May 2024, the Company acquired additional construction in progress in connection with the properties for &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$22,538&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction in progress (&#x201c;CIP&#x201d;) a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s of December&#160;31, 2024 and 2023 primarily related to the Hopewell facility, the new research and development facility acquired in 2024, a new building for Beijing Innerway Bio-tech Co., Ltd., and additional capacity at the Guangzhou and Suzhou manufacturing facilities. CIP by fixed asset class are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.324%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.394%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.385%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.397%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 3.25pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;528,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;579,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;654,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;740,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense for the years ended December&#160;31, 2024, 2023 and 2022 were $166,938, $80,436 and $62,302, respectively. Included within depreciation expense for the year ended December&#160;31, 2024 is $59,792 of accelerated depreciation expense resulting from the move of production to more efficient, larger scale equipment for tislelizumab.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-205" decimals="-3" id="f-728" unitRef="usd">65485000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-206" decimals="-3" id="f-729" unitRef="usd">65485000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-44" decimals="-3" id="f-730" unitRef="usd">607857000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-204" decimals="-3" id="f-731" unitRef="usd">231656000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-207" decimals="-3" id="f-732" unitRef="usd">244255000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-208" decimals="-3" id="f-733" unitRef="usd">186856000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-209" decimals="-3" id="f-734" unitRef="usd">240885000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-210" decimals="-3" id="f-735" unitRef="usd">205349000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-211" decimals="-3" id="f-736" unitRef="usd">100348000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-212" decimals="-3" id="f-737" unitRef="usd">83281000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-213" decimals="-3" id="f-738" unitRef="usd">64680000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-214" decimals="-3" id="f-739" unitRef="usd">60124000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-12" decimals="-3" id="f-740" unitRef="usd">1323510000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-13" decimals="-3" id="f-741" unitRef="usd">832751000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-12" decimals="-3" id="f-742" unitRef="usd">399105000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-13" decimals="-3" id="f-743" unitRef="usd">249212000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:ConstructionInProgressGross contextRef="c-12" decimals="-3" id="f-744" unitRef="usd">654018000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross contextRef="c-13" decimals="-3" id="f-745" unitRef="usd">740615000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-12" decimals="-3" id="f-746" unitRef="usd">1578423000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-13" decimals="-3" id="f-747" unitRef="usd">1324154000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-215" decimals="3" id="f-748" unitRef="usd">272670000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:ConstructionInProgressGross contextRef="c-216" decimals="-3" id="f-749" unitRef="usd">500900000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-217" decimals="-3" id="f-750" unitRef="usd">73054000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-218" decimals="-3" id="f-751" unitRef="usd">29431000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-219" decimals="-3" id="f-752" unitRef="usd">43623000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-220" decimals="-3" id="f-753" unitRef="usd">22538000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ConstructionInProgressGross contextRef="c-44" decimals="-3" id="f-754" unitRef="usd">528629000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross contextRef="c-204" decimals="-3" id="f-755" unitRef="usd">579649000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross contextRef="c-207" decimals="-3" id="f-756" unitRef="usd">89897000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross contextRef="c-208" decimals="-3" id="f-757" unitRef="usd">119380000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross contextRef="c-209" decimals="-3" id="f-758" unitRef="usd">9805000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross contextRef="c-210" decimals="-3" id="f-759" unitRef="usd">16135000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross contextRef="c-221" decimals="-3" id="f-760" unitRef="usd">25687000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross contextRef="c-222" decimals="-3" id="f-761" unitRef="usd">25451000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross contextRef="c-12" decimals="-3" id="f-762" unitRef="usd">654018000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross contextRef="c-13" decimals="-3" id="f-763" unitRef="usd">740615000</us-gaap:ConstructionInProgressGross>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-764" unitRef="usd">166938000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-10" decimals="-3" id="f-765" unitRef="usd">80436000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-11" decimals="-3" id="f-766" unitRef="usd">62302000</us-gaap:Depreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation contextRef="c-1" decimals="-3" id="f-767" unitRef="usd">59792000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-768">Intangible Assets&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets as of December&#160;31, 2024 and 2023 are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.209%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;carrying&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intangible&lt;br/&gt;assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;carrying&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intangible&lt;br/&gt;assets, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,316)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,781)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:7pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Developed products represent post-approval milestone payments under license and commercialization agreements. The Company is amortizing the developed products over the remainder of the respective product patent or the term of the commercialization agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense for developed products is included in cost of sales-product in the accompanying consolidated statements of operations. Amortization expense for other intangible assets is included in selling, general and administrative expense in the accompanying consolidated statements of operations. The weighted-average life for each finite-lived intangible assets is approximately 11 years. Amortization expense is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.139%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization expense - Cost of sales - product&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization expense - Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated amortization expense for each of the five succeeding years and thereafter, as of December&#160;31, 2024 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.701%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost of Sales - Product&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Selling, General and Administrative Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c-1" id="f-769">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets as of December&#160;31, 2024 and 2023 are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.209%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.581%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;carrying&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intangible&lt;br/&gt;assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;carrying&lt;br/&gt;amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intangible&lt;br/&gt;assets, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finite-lived intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Developed products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,807)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,411)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,316)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total finite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,781)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Amortization expense is as follows:&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.139%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.525%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization expense - Cost of sales - product&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization expense - Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-223" decimals="-3" id="f-770" unitRef="usd">62889000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-223" decimals="-3" id="f-771" unitRef="usd">12370000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-223" decimals="-3" id="f-772" unitRef="usd">50519000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-224" decimals="-3" id="f-773" unitRef="usd">64274000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-224" decimals="-3" id="f-774" unitRef="usd">7807000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-224" decimals="-3" id="f-775" unitRef="usd">56467000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-225" decimals="-3" id="f-776" unitRef="usd">8987000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-225" decimals="-3" id="f-777" unitRef="usd">8411000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-225" decimals="-3" id="f-778" unitRef="usd">576000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-226" decimals="-3" id="f-779" unitRef="usd">8987000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-226" decimals="-3" id="f-780" unitRef="usd">8316000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-226" decimals="-3" id="f-781" unitRef="usd">671000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-12" decimals="-3" id="f-782" unitRef="usd">71876000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-12" decimals="-3" id="f-783" unitRef="usd">20781000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-12" decimals="-3" id="f-784" unitRef="usd">51095000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-13" decimals="-3" id="f-785" unitRef="usd">73261000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-13" decimals="-3" id="f-786" unitRef="usd">16123000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-13" decimals="-3" id="f-787" unitRef="usd">57138000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-227" id="f-788">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-228" id="f-789">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-166" decimals="-3" id="f-790" unitRef="usd">4729000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-167" decimals="-3" id="f-791" unitRef="usd">3739000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-168" decimals="-3" id="f-792" unitRef="usd">3225000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-169" decimals="-3" id="f-793" unitRef="usd">95000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-170" decimals="-3" id="f-794" unitRef="usd">3500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-171" decimals="-3" id="f-795" unitRef="usd">751000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-3" id="f-796" unitRef="usd">4824000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-10" decimals="-3" id="f-797" unitRef="usd">7239000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-11" decimals="-3" id="f-798" unitRef="usd">3976000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="c-1" id="f-799">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated amortization expense for each of the five succeeding years and thereafter, as of December&#160;31, 2024 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.701%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost of Sales - Product&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Selling, General and Administrative Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2030 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-229" decimals="-3" id="f-800" unitRef="usd">4682000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-230" decimals="-3" id="f-801" unitRef="usd">67000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-12" decimals="-3" id="f-802" unitRef="usd">4749000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-229" decimals="-3" id="f-803" unitRef="usd">4682000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-230" decimals="-3" id="f-804" unitRef="usd">67000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-12" decimals="-3" id="f-805" unitRef="usd">4749000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-229" decimals="-3" id="f-806" unitRef="usd">4682000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-230" decimals="-3" id="f-807" unitRef="usd">67000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-12" decimals="-3" id="f-808" unitRef="usd">4749000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-229" decimals="-3" id="f-809" unitRef="usd">4682000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-230" decimals="-3" id="f-810" unitRef="usd">67000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-12" decimals="-3" id="f-811" unitRef="usd">4749000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-229" decimals="-3" id="f-812" unitRef="usd">4682000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-230" decimals="-3" id="f-813" unitRef="usd">67000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-12" decimals="-3" id="f-814" unitRef="usd">4749000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="c-229" decimals="-3" id="f-815" unitRef="usd">27109000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="c-230" decimals="-3" id="f-816" unitRef="usd">241000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="c-12" decimals="-3" id="f-817" unitRef="usd">27350000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-229" decimals="-3" id="f-818" unitRef="usd">50519000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-230" decimals="-3" id="f-819" unitRef="usd">576000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-12" decimals="-3" id="f-820" unitRef="usd">51095000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-821">Income Taxes&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;(&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;loss) before income taxes are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.322%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.606%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PRC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(263,159)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(315,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(583,610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(471,358)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(627,430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,445,171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(533,001)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(825,836)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,961,037)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The current and deferred components of the income tax expense (benefit) from continuing operations are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.322%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.606%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PRC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PRC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of the statutory tax rate to our effective income tax rate is as follow:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(533,001)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(825,836)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,961,037)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected taxation at U.S. statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111,930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(411,818)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign and preferential tax rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,988)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax relief credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(704,928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research tax credits and incentives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,602)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64,343)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,844)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deductible research expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,644)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax on unremitted earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign-derived intangible income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,397)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,395)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,272)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Taxation for the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of deferred tax assets (liabilities) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accruals and reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating losses carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,137,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;862,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax relief credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;704,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;704,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible asset amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,081,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;699,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;813,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D and other capitalized costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,407,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,775,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,952,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,403,505)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,771,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,943,775)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,795)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,480)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax on unremitted earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,735)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,735)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46,212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets/(liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,007)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,494)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,996)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowances have been provided on deferred tax assets where, based on all available evidence, it was considered more likely than not that some portion or all of the recorded deferred tax assets will not be realized in future periods. After&#160;consideration&#160;of&#160;all&#160;positive&#160;and&#160;negative&#160;evidence, the Company&#160;believes&#160;that&#160;as of December&#160;31, 2024, it&#160;is&#160;more&#160;likely&#160;than not&#160;that net deferred tax assets will not be realized. Adjustments may be required in the future if the Company estimates that the amount of deferred tax assets to be realized is more or less than the net amount recorded.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The valuation allowances for the years ended December&#160;31, 2024, 2023 and 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.322%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.606%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance, as of January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,771,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,943,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,758,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions/(subtractions) charged to income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions/(subtractions) charged to equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,184)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance, as of December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,403,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,771,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,943,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024 and 2023, the Company had net operating losses of approximately $6,720,659 and $5,945,753, respectively. As of December&#160;31, 2024, net operating losses were primarily comprised of: $2,185,546 from entities in the PRC which expire in years 2025 through 2034; and $4,526,020 derived from Switzerland which expires in years 2025 through 2031. The Company has approximately $43,677 of U.S. research tax credits which will expire between 2036 and 2044 and approximately $704,928 of Switzerland tax relief credits which will expire in 2028, if not utilized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The gross unrecognized tax benefits for the years ended December&#160;31, 2024, 2023 and 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.322%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.606%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance, as of January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to prior tax years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions based on tax positions related to prior tax years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to the current tax year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions based on lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance, as of December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current and prior year additions include assessment of U.S. federal and state tax credits and incentives. As of December&#160;31, 2024, the Company had $17,239 of unrecognized tax benefits substantially all of which, if recognized, would reduce the effective tax rate. The Company does not anticipate that the amount of existing unrecognized tax benefits will significantly change within the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected to record interest and penalties related to income taxes as a component of income tax expense. For the years ended December&#160;31, 2024, 2023 and 2022, the Company&#x2019;s accrued interest and penalties, where applicable, related to uncertain tax positions were not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company conducts business in a number of tax jurisdictions and, as such, is required to file income tax returns in multiple jurisdictions globally. As of December&#160;31, 2024, Australia tax matters are open to examination for the years 2013 through 2024, China tax matters are open to examination for the years 2014 through 2024, Switzerland tax matters are open to examination for the years 2021 through 2024, and U.S. federal tax matters are open to examination for years 2015 through 2024. Various U.S. states and other non-US tax jurisdictions in which the Company files tax returns remain open to examination for 2014 through 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company qualifies for the Technology Advanced Service Enterprises and High and New Technology Enterprise status for certain subsidiaries in China, which begin to expire at the end of 2025. The income tax benefits attributable to this status for the year ended December&#160;31, 2024 is approximately $4,631, or less than $0.01 per share outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2024, the Company concluded that a portion of earnings from certain subsidiaries, primarily in the U.S. and Canada, are no longer indefinitely reinvested. As a result, the Company recognized a deferred tax liability of $23,735. The Company continues to assert that earnings in other jurisdictions remain permanently reinvested.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c-1" id="f-822">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;(&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;loss) before income taxes are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.322%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.606%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PRC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(263,159)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(315,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(583,610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(471,358)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(627,430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,445,171)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(533,001)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(825,836)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,961,037)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-231" decimals="-3" id="f-823" unitRef="usd">201516000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-232" decimals="-3" id="f-824" unitRef="usd">117446000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-233" decimals="-3" id="f-825" unitRef="usd">67744000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-234" decimals="-3" id="f-826" unitRef="usd">-263159000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-235" decimals="-3" id="f-827" unitRef="usd">-315852000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-236" decimals="-3" id="f-828" unitRef="usd">-583610000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-237" decimals="-3" id="f-829" unitRef="usd">-471358000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-238" decimals="-3" id="f-830" unitRef="usd">-627430000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-239" decimals="-3" id="f-831" unitRef="usd">-1445171000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-832" unitRef="usd">-533001000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-10" decimals="-3" id="f-833" unitRef="usd">-825836000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-11" decimals="-3" id="f-834" unitRef="usd">-1961037000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-835">&lt;div style="margin-bottom:4pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The current and deferred components of the income tax expense (benefit) from continuing operations are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.322%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.606%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PRC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PRC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-231" decimals="-3" id="f-836" unitRef="usd">57222000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-232" decimals="-3" id="f-837" unitRef="usd">25170000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-233" decimals="-3" id="f-838" unitRef="usd">4844000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-234" decimals="-3" id="f-839" unitRef="usd">12331000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-235" decimals="-3" id="f-840" unitRef="usd">24956000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-236" decimals="-3" id="f-841" unitRef="usd">27905000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-237" decimals="-3" id="f-842" unitRef="usd">16225000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-238" decimals="-3" id="f-843" unitRef="usd">5059000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-239" decimals="-3" id="f-844" unitRef="usd">6547000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-845" unitRef="usd">85778000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-10" decimals="-3" id="f-846" unitRef="usd">55185000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-11" decimals="-3" id="f-847" unitRef="usd">39296000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-231" decimals="-3" id="f-848" unitRef="usd">23556000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-232" decimals="-3" id="f-849" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-233" decimals="-3" id="f-850" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-234" decimals="-3" id="f-851" unitRef="usd">180000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-235" decimals="-3" id="f-852" unitRef="usd">687000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-236" decimals="-3" id="f-853" unitRef="usd">3480000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-237" decimals="-3" id="f-854" unitRef="usd">2271000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-238" decimals="-3" id="f-855" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-239" decimals="-3" id="f-856" unitRef="usd">2000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-857" unitRef="usd">26007000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-10" decimals="-3" id="f-858" unitRef="usd">687000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-11" decimals="-3" id="f-859" unitRef="usd">3482000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-860" unitRef="usd">111785000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-10" decimals="-3" id="f-861" unitRef="usd">55872000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-11" decimals="-3" id="f-862" unitRef="usd">42778000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-863">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation of the statutory tax rate to our effective income tax rate is as follow:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(533,001)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(825,836)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,961,037)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected taxation at U.S. statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(111,930)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(173,426)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(411,818)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign and preferential tax rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,988)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax relief credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(704,928)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research tax credits and incentives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43,602)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(64,343)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,844)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deductible research expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,644)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax on unremitted earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign-derived intangible income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,397)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,395)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,272)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Taxation for the year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-3" id="f-864" unitRef="usd">-533001000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c-10" decimals="-3" id="f-865" unitRef="usd">-825836000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c-11" decimals="-3" id="f-866" unitRef="usd">-1961037000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="INF" id="f-867" unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c-10"
      decimals="INF"
      id="f-868"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c-11"
      decimals="INF"
      id="f-869"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="-3" id="f-870" unitRef="usd">-111930000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-10" decimals="-3" id="f-871" unitRef="usd">-173426000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-11" decimals="-3" id="f-872" unitRef="usd">-411818000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-1" decimals="-3" id="f-873" unitRef="usd">93741000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-10" decimals="-3" id="f-874" unitRef="usd">144310000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-11" decimals="-3" id="f-875" unitRef="usd">209384000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="c-1" decimals="-3" id="f-876" unitRef="usd">1130000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="c-10" decimals="-3" id="f-877" unitRef="usd">19134000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="c-11" decimals="-3" id="f-878" unitRef="usd">29223000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="-3" id="f-879" unitRef="usd">53446000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-10" decimals="-3" id="f-880" unitRef="usd">32581000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-11" decimals="-3" id="f-881" unitRef="usd">33872000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="-3" id="f-882" unitRef="usd">-7988000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-10" decimals="-3" id="f-883" unitRef="usd">-5872000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-11" decimals="-3" id="f-884" unitRef="usd">1683000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="-3" id="f-885" unitRef="usd">157286000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-10" decimals="-3" id="f-886" unitRef="usd">845811000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-11" decimals="-3" id="f-887" unitRef="usd">229550000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationTaxCredits contextRef="c-1" decimals="-3" id="f-888" unitRef="usd">0</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits contextRef="c-10" decimals="-3" id="f-889" unitRef="usd">704928000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits contextRef="c-11" decimals="-3" id="f-890" unitRef="usd">0</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c-1" decimals="-3" id="f-891" unitRef="usd">43602000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c-10" decimals="-3" id="f-892" unitRef="usd">64343000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c-11" decimals="-3" id="f-893" unitRef="usd">42844000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <bgne:EffectiveIncomeTaxRateReconciliationDeductionResearchExpensesAmount contextRef="c-1" decimals="-3" id="f-894" unitRef="usd">13644000</bgne:EffectiveIncomeTaxRateReconciliationDeductionResearchExpensesAmount>
    <bgne:EffectiveIncomeTaxRateReconciliationDeductionResearchExpensesAmount contextRef="c-10" decimals="-3" id="f-895" unitRef="usd">0</bgne:EffectiveIncomeTaxRateReconciliationDeductionResearchExpensesAmount>
    <bgne:EffectiveIncomeTaxRateReconciliationDeductionResearchExpensesAmount contextRef="c-11" decimals="-3" id="f-896" unitRef="usd">0</bgne:EffectiveIncomeTaxRateReconciliationDeductionResearchExpensesAmount>
    <us-gaap:IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion contextRef="c-1" decimals="-3" id="f-897" unitRef="usd">-23743000</us-gaap:IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion>
    <us-gaap:IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion contextRef="c-10" decimals="-3" id="f-898" unitRef="usd">0</us-gaap:IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion>
    <us-gaap:IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion contextRef="c-11" decimals="-3" id="f-899" unitRef="usd">0</us-gaap:IncomeTaxReconciliationDeductionsExtraterritorialIncomeExclusion>
    <us-gaap:EffectiveIncomeTaxRateReconciliationFdiiAmount contextRef="c-1" decimals="-3" id="f-900" unitRef="usd">40397000</us-gaap:EffectiveIncomeTaxRateReconciliationFdiiAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationFdiiAmount contextRef="c-10" decimals="-3" id="f-901" unitRef="usd">37395000</us-gaap:EffectiveIncomeTaxRateReconciliationFdiiAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationFdiiAmount contextRef="c-11" decimals="-3" id="f-902" unitRef="usd">6272000</us-gaap:EffectiveIncomeTaxRateReconciliationFdiiAmount>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-903" unitRef="usd">111785000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-10" decimals="-3" id="f-904" unitRef="usd">55872000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-11" decimals="-3" id="f-905" unitRef="usd">42778000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-906" unitRef="number">-0.210</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-10" decimals="3" id="f-907" unitRef="number">-0.068</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-11" decimals="3" id="f-908" unitRef="number">-0.022</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-909">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of deferred tax assets (liabilities) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accruals and reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating losses carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,137,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;996,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;862,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax relief credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;704,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;704,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible asset amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,081,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;699,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;813,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D and other capitalized costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,407,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,775,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,952,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,403,505)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,771,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,943,775)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,795)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,374)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,480)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax on unremitted earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,735)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,682)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,735)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46,212)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24,578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets/(liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,007)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,494)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,996)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="c-12" decimals="-3" id="f-910" unitRef="usd">121549000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="c-13" decimals="-3" id="f-911" unitRef="usd">106708000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="c-14" decimals="-3" id="f-912" unitRef="usd">97896000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c-12" decimals="-3" id="f-913" unitRef="usd">1137890000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c-13" decimals="-3" id="f-914" unitRef="usd">996588000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="c-14" decimals="-3" id="f-915" unitRef="usd">862214000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-12" decimals="-3" id="f-916" unitRef="usd">38397000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-13" decimals="-3" id="f-917" unitRef="usd">26687000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-14" decimals="-3" id="f-918" unitRef="usd">19700000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-12" decimals="-3" id="f-919" unitRef="usd">34561000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-13" decimals="-3" id="f-920" unitRef="usd">68117000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-14" decimals="-3" id="f-921" unitRef="usd">86000000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign contextRef="c-12" decimals="-3" id="f-922" unitRef="usd">704928000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign contextRef="c-13" decimals="-3" id="f-923" unitRef="usd">704928000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign contextRef="c-14" decimals="-3" id="f-924" unitRef="usd">0</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-12" decimals="-3" id="f-925" unitRef="usd">1081442000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-13" decimals="-3" id="f-926" unitRef="usd">699974000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-14" decimals="-3" id="f-927" unitRef="usd">813043000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <bgne:DeferredTaxAssetsPropertyLeaseLiabilityObligation contextRef="c-12" decimals="-3" id="f-928" unitRef="usd">11882000</bgne:DeferredTaxAssetsPropertyLeaseLiabilityObligation>
    <bgne:DeferredTaxAssetsPropertyLeaseLiabilityObligation contextRef="c-13" decimals="-3" id="f-929" unitRef="usd">7893000</bgne:DeferredTaxAssetsPropertyLeaseLiabilityObligation>
    <bgne:DeferredTaxAssetsPropertyLeaseLiabilityObligation contextRef="c-14" decimals="-3" id="f-930" unitRef="usd">10348000</bgne:DeferredTaxAssetsPropertyLeaseLiabilityObligation>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-12" decimals="-3" id="f-931" unitRef="usd">277061000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-13" decimals="-3" id="f-932" unitRef="usd">164190000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-14" decimals="-3" id="f-933" unitRef="usd">63156000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-12" decimals="-3" id="f-934" unitRef="usd">3407710000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-13" decimals="-3" id="f-935" unitRef="usd">2775085000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-14" decimals="-3" id="f-936" unitRef="usd">1952357000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-12" decimals="-3" id="f-937" unitRef="usd">3403505000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-13" decimals="-3" id="f-938" unitRef="usd">2771470000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-14" decimals="-3" id="f-939" unitRef="usd">1943775000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-12" decimals="-3" id="f-940" unitRef="usd">4205000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-13" decimals="-3" id="f-941" unitRef="usd">3615000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-14" decimals="-3" id="f-942" unitRef="usd">8582000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-12" decimals="-3" id="f-943" unitRef="usd">10795000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-13" decimals="-3" id="f-944" unitRef="usd">12374000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-14" decimals="-3" id="f-945" unitRef="usd">14480000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings contextRef="c-12" decimals="-3" id="f-946" unitRef="usd">23735000</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings contextRef="c-13" decimals="-3" id="f-947" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings contextRef="c-14" decimals="-3" id="f-948" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-12" decimals="-3" id="f-949" unitRef="usd">11682000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-13" decimals="-3" id="f-950" unitRef="usd">7735000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-14" decimals="-3" id="f-951" unitRef="usd">10098000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-12" decimals="-3" id="f-952" unitRef="usd">46212000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-13" decimals="-3" id="f-953" unitRef="usd">20109000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-14" decimals="-3" id="f-954" unitRef="usd">24578000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-12" decimals="-3" id="f-955" unitRef="usd">42007000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-13" decimals="-3" id="f-956" unitRef="usd">16494000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-14" decimals="-3" id="f-957" unitRef="usd">15996000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="c-1" id="f-958">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The valuation allowances for the years ended December&#160;31, 2024, 2023 and 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.322%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.606%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance, as of January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,771,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,943,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,758,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions/(subtractions) charged to income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions/(subtractions) charged to equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;497,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(44,184)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance, as of December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,403,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,771,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,943,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-13" decimals="-3" id="f-959" unitRef="usd">2771470000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-14" decimals="-3" id="f-960" unitRef="usd">1943775000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-15" decimals="-3" id="f-961" unitRef="usd">1758409000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <bgne:DeferredTaxAssetValuationAllowanceChangesIncludedInEarnings contextRef="c-1" decimals="-3" id="f-962" unitRef="usd">157286000</bgne:DeferredTaxAssetValuationAllowanceChangesIncludedInEarnings>
    <bgne:DeferredTaxAssetValuationAllowanceChangesIncludedInEarnings contextRef="c-10" decimals="-3" id="f-963" unitRef="usd">845811000</bgne:DeferredTaxAssetValuationAllowanceChangesIncludedInEarnings>
    <bgne:DeferredTaxAssetValuationAllowanceChangesIncludedInEarnings contextRef="c-11" decimals="-3" id="f-964" unitRef="usd">229550000</bgne:DeferredTaxAssetValuationAllowanceChangesIncludedInEarnings>
    <bgne:DeferredTaxAssetValuationAllowanceGainLossIncludedInOtherComprehensiveIncomeLoss contextRef="c-1" decimals="-3" id="f-965" unitRef="usd">-497823000</bgne:DeferredTaxAssetValuationAllowanceGainLossIncludedInOtherComprehensiveIncomeLoss>
    <bgne:DeferredTaxAssetValuationAllowanceGainLossIncludedInOtherComprehensiveIncomeLoss contextRef="c-10" decimals="-3" id="f-966" unitRef="usd">0</bgne:DeferredTaxAssetValuationAllowanceGainLossIncludedInOtherComprehensiveIncomeLoss>
    <bgne:DeferredTaxAssetValuationAllowanceGainLossIncludedInOtherComprehensiveIncomeLoss contextRef="c-11" decimals="-3" id="f-967" unitRef="usd">0</bgne:DeferredTaxAssetValuationAllowanceGainLossIncludedInOtherComprehensiveIncomeLoss>
    <bgne:DeferredTaxAssetValuationAllowanceCurrencyTranslationAndOther contextRef="c-1" decimals="-3" id="f-968" unitRef="usd">-23074000</bgne:DeferredTaxAssetValuationAllowanceCurrencyTranslationAndOther>
    <bgne:DeferredTaxAssetValuationAllowanceCurrencyTranslationAndOther contextRef="c-10" decimals="-3" id="f-969" unitRef="usd">-18116000</bgne:DeferredTaxAssetValuationAllowanceCurrencyTranslationAndOther>
    <bgne:DeferredTaxAssetValuationAllowanceCurrencyTranslationAndOther contextRef="c-11" decimals="-3" id="f-970" unitRef="usd">-44184000</bgne:DeferredTaxAssetValuationAllowanceCurrencyTranslationAndOther>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-12" decimals="-3" id="f-971" unitRef="usd">3403505000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-13" decimals="-3" id="f-972" unitRef="usd">2771470000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-14" decimals="-3" id="f-973" unitRef="usd">1943775000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards contextRef="c-12" decimals="-3" id="f-974" unitRef="usd">6720659000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-13" decimals="-3" id="f-975" unitRef="usd">5945753000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-240" decimals="-3" id="f-976" unitRef="usd">2185546000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-241" decimals="-3" id="f-977" unitRef="usd">4526020000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-242" decimals="-3" id="f-978" unitRef="usd">43677000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign contextRef="c-241" decimals="-3" id="f-979" unitRef="usd">704928000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c-1" id="f-980">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The gross unrecognized tax benefits for the years ended December&#160;31, 2024, 2023 and 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.322%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.606%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance, as of January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to prior tax years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions based on tax positions related to prior tax years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to the current tax year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions based on lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance, as of December 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-13" decimals="-3" id="f-981" unitRef="usd">14264000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-14" decimals="-3" id="f-982" unitRef="usd">11555000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-15" decimals="-3" id="f-983" unitRef="usd">9925000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-984" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-10" decimals="-3" id="f-985" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-11" decimals="-3" id="f-986" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-987" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-10" decimals="-3" id="f-988" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-11" decimals="-3" id="f-989" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-990" unitRef="usd">2975000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-10" decimals="-3" id="f-991" unitRef="usd">2709000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-11" decimals="-3" id="f-992" unitRef="usd">1630000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c-1" decimals="-3" id="f-993" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c-10" decimals="-3" id="f-994" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c-11" decimals="-3" id="f-995" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-12" decimals="-3" id="f-996" unitRef="usd">17239000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-13" decimals="-3" id="f-997" unitRef="usd">14264000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-14" decimals="-3" id="f-998" unitRef="usd">11555000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-12" decimals="-3" id="f-999" unitRef="usd">17239000</us-gaap:UnrecognizedTaxBenefits>
    <bgne:TaxBenefitFromForeignTaxStatus contextRef="c-12" decimals="-3" id="f-1000" unitRef="usd">4631000</bgne:TaxBenefitFromForeignTaxStatus>
    <bgne:TaxBenefitFromForeignTaxStatusPerShare
      contextRef="c-12"
      decimals="2"
      id="f-1001"
      unitRef="usdPerShare">0.01</bgne:TaxBenefitFromForeignTaxStatusPerShare>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings contextRef="c-12" decimals="-3" id="f-1002" unitRef="usd">23735000</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="c-1" id="f-1003">Supplemental Balance Sheet Information&lt;div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As&#160;of&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid manufacturing cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other non-current assets consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As&#160;of&#160;December&#160;31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid supply cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rental deposits and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepayment of property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid VAT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other payables consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As&#160;of&#160;December&#160;31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales rebates and returns related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;External research and development activities related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Individual income tax and other taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;803,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other long-term liabilities consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As&#160;of&#160;December&#160;31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred government grant income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset retirement obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <bgne:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock contextRef="c-1" id="f-1004">&lt;div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid expenses and other current assets consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As&#160;of&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid research and development costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid manufacturing cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bgne:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
    <bgne:PrepaidResearchAndDevelopmentCosts contextRef="c-12" decimals="-3" id="f-1005" unitRef="usd">64277000</bgne:PrepaidResearchAndDevelopmentCosts>
    <bgne:PrepaidResearchAndDevelopmentCosts contextRef="c-13" decimals="-3" id="f-1006" unitRef="usd">60476000</bgne:PrepaidResearchAndDevelopmentCosts>
    <us-gaap:PrepaidTaxes contextRef="c-12" decimals="-3" id="f-1007" unitRef="usd">23792000</us-gaap:PrepaidTaxes>
    <us-gaap:PrepaidTaxes contextRef="c-13" decimals="-3" id="f-1008" unitRef="usd">37320000</us-gaap:PrepaidTaxes>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="c-12" decimals="-3" id="f-1009" unitRef="usd">32828000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="c-13" decimals="-3" id="f-1010" unitRef="usd">37859000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <bgne:PrepaidGeneralAndAdministrativeExpensesCurrent contextRef="c-12" decimals="-3" id="f-1011" unitRef="usd">21253000</bgne:PrepaidGeneralAndAdministrativeExpensesCurrent>
    <bgne:PrepaidGeneralAndAdministrativeExpensesCurrent contextRef="c-13" decimals="-3" id="f-1012" unitRef="usd">14619000</bgne:PrepaidGeneralAndAdministrativeExpensesCurrent>
    <bgne:PrepaidManufacturingCosts contextRef="c-12" decimals="-3" id="f-1013" unitRef="usd">19333000</bgne:PrepaidManufacturingCosts>
    <bgne:PrepaidManufacturingCosts contextRef="c-13" decimals="-3" id="f-1014" unitRef="usd">42066000</bgne:PrepaidManufacturingCosts>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-12" decimals="-3" id="f-1015" unitRef="usd">9312000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-13" decimals="-3" id="f-1016" unitRef="usd">11473000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidInsurance contextRef="c-12" decimals="-3" id="f-1017" unitRef="usd">6242000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="c-13" decimals="-3" id="f-1018" unitRef="usd">8872000</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c-12" decimals="-3" id="f-1019" unitRef="usd">15882000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="c-13" decimals="-3" id="f-1020" unitRef="usd">44780000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-12" decimals="-3" id="f-1021" unitRef="usd">192919000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-13" decimals="-3" id="f-1022" unitRef="usd">257465000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock contextRef="c-1" id="f-1023">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other non-current assets consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As&#160;of&#160;December&#160;31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid supply cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rental deposits and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepayment of property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid VAT&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock>
    <us-gaap:LongTermInvestments contextRef="c-12" decimals="-3" id="f-1024" unitRef="usd">128933000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments contextRef="c-13" decimals="-3" id="f-1025" unitRef="usd">89644000</us-gaap:LongTermInvestments>
    <bgne:PrepaidSupplyCost contextRef="c-12" decimals="-3" id="f-1026" unitRef="usd">12249000</bgne:PrepaidSupplyCost>
    <bgne:PrepaidSupplyCost contextRef="c-13" decimals="-3" id="f-1027" unitRef="usd">18122000</bgne:PrepaidSupplyCost>
    <bgne:RentalDepositsAndOther contextRef="c-12" decimals="-3" id="f-1028" unitRef="usd">8481000</bgne:RentalDepositsAndOther>
    <bgne:RentalDepositsAndOther contextRef="c-13" decimals="-3" id="f-1029" unitRef="usd">8195000</bgne:RentalDepositsAndOther>
    <bgne:PrepaymentOfLongTermAsset contextRef="c-12" decimals="-3" id="f-1030" unitRef="usd">5927000</bgne:PrepaymentOfLongTermAsset>
    <bgne:PrepaymentOfLongTermAsset contextRef="c-13" decimals="-3" id="f-1031" unitRef="usd">4144000</bgne:PrepaymentOfLongTermAsset>
    <us-gaap:ValueAddedTaxReceivableNoncurrent contextRef="c-12" decimals="-3" id="f-1032" unitRef="usd">2875000</us-gaap:ValueAddedTaxReceivableNoncurrent>
    <us-gaap:ValueAddedTaxReceivableNoncurrent contextRef="c-13" decimals="-3" id="f-1033" unitRef="usd">2546000</us-gaap:ValueAddedTaxReceivableNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-12" decimals="-3" id="f-1034" unitRef="usd">2025000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c-13" decimals="-3" id="f-1035" unitRef="usd">2711000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-12" decimals="-3" id="f-1036" unitRef="usd">160490000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-13" decimals="-3" id="f-1037" unitRef="usd">125362000</us-gaap:OtherAssetsNoncurrent>
    <bgne:AccruedLiabilitiesAccountsPayableOtherAndOtherLiabilitiesCurrentTableTextBlock contextRef="c-1" id="f-1038">&lt;div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other payables consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As&#160;of&#160;December&#160;31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Compensation related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217,803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales rebates and returns related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;External research and development activities related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;162,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Individual income tax and other taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;803,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;693,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bgne:AccruedLiabilitiesAccountsPayableOtherAndOtherLiabilitiesCurrentTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-12" decimals="-3" id="f-1039" unitRef="usd">248348000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-13" decimals="-3" id="f-1040" unitRef="usd">217803000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <bgne:AccruedSalesRebatesAndReturnsCurrent contextRef="c-12" decimals="-3" id="f-1041" unitRef="usd">235600000</bgne:AccruedSalesRebatesAndReturnsCurrent>
    <bgne:AccruedSalesRebatesAndReturnsCurrent contextRef="c-13" decimals="-3" id="f-1042" unitRef="usd">139936000</bgne:AccruedSalesRebatesAndReturnsCurrent>
    <bgne:AccruedLiabilitiesExternalResearchAndDevelopment contextRef="c-12" decimals="-3" id="f-1043" unitRef="usd">154269000</bgne:AccruedLiabilitiesExternalResearchAndDevelopment>
    <bgne:AccruedLiabilitiesExternalResearchAndDevelopment contextRef="c-13" decimals="-3" id="f-1044" unitRef="usd">162969000</bgne:AccruedLiabilitiesExternalResearchAndDevelopment>
    <bgne:AccruedExpensesCommercialActivities contextRef="c-12" decimals="-3" id="f-1045" unitRef="usd">77530000</bgne:AccruedExpensesCommercialActivities>
    <bgne:AccruedExpensesCommercialActivities contextRef="c-13" decimals="-3" id="f-1046" unitRef="usd">87572000</bgne:AccruedExpensesCommercialActivities>
    <bgne:AccruedGeneralAndAdministrativeExpensesCurrent contextRef="c-12" decimals="-3" id="f-1047" unitRef="usd">31106000</bgne:AccruedGeneralAndAdministrativeExpensesCurrent>
    <bgne:AccruedGeneralAndAdministrativeExpensesCurrent contextRef="c-13" decimals="-3" id="f-1048" unitRef="usd">36203000</bgne:AccruedGeneralAndAdministrativeExpensesCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent contextRef="c-12" decimals="-3" id="f-1049" unitRef="usd">34904000</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent contextRef="c-13" decimals="-3" id="f-1050" unitRef="usd">30083000</us-gaap:AccruedPayrollTaxesCurrent>
    <bgne:AccruedProfessionalFeesAndOtherCurrent contextRef="c-12" decimals="-3" id="f-1051" unitRef="usd">21956000</bgne:AccruedProfessionalFeesAndOtherCurrent>
    <bgne:AccruedProfessionalFeesAndOtherCurrent contextRef="c-13" decimals="-3" id="f-1052" unitRef="usd">19165000</bgne:AccruedProfessionalFeesAndOtherCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-12" decimals="-3" id="f-1053" unitRef="usd">803713000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-13" decimals="-3" id="f-1054" unitRef="usd">693731000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherNoncurrentLiabilitiesTableTextBlock contextRef="c-1" id="f-1055">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other long-term liabilities consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.598%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As&#160;of&#160;December&#160;31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred government grant income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset retirement obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherNoncurrentLiabilitiesTableTextBlock>
    <us-gaap:GovernmentAssistanceLiability contextRef="c-12" decimals="-3" id="f-1056" unitRef="usd">30324000</us-gaap:GovernmentAssistanceLiability>
    <us-gaap:GovernmentAssistanceLiability contextRef="c-13" decimals="-3" id="f-1057" unitRef="usd">34204000</us-gaap:GovernmentAssistanceLiability>
    <us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent contextRef="c-12" decimals="-3" id="f-1058" unitRef="usd">16405000</us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent contextRef="c-13" decimals="-3" id="f-1059" unitRef="usd">14995000</us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent>
    <us-gaap:AssetRetirementObligationsNoncurrent contextRef="c-12" decimals="-3" id="f-1060" unitRef="usd">3794000</us-gaap:AssetRetirementObligationsNoncurrent>
    <us-gaap:AssetRetirementObligationsNoncurrent contextRef="c-13" decimals="-3" id="f-1061" unitRef="usd">1127000</us-gaap:AssetRetirementObligationsNoncurrent>
    <us-gaap:OtherSundryLiabilitiesNoncurrent contextRef="c-12" decimals="-3" id="f-1062" unitRef="usd">16212000</us-gaap:OtherSundryLiabilitiesNoncurrent>
    <us-gaap:OtherSundryLiabilitiesNoncurrent contextRef="c-13" decimals="-3" id="f-1063" unitRef="usd">484000</us-gaap:OtherSundryLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-12" decimals="-3" id="f-1064" unitRef="usd">66735000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-13" decimals="-3" id="f-1065" unitRef="usd">50810000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-1066">Debt&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s short-term and long-term debt obligations as of December&#160;31, 2024 and 2023: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.274%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.186%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.940%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.940%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.648%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.807%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lender&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Borrower&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Line of Credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;RMB&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;RMB&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;China Construction Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BeiGene Guangzhou Biologics Manufacturing Co., Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;RMB580,000 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9-year &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 11, 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;China Merchants Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BeiGene Guangzhou Biologics Manufacturing Co., Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;RMB350,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9-year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 20, 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;China Merchants Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BeiGene Guangzhou Biologics Manufacturing Co., Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;RMB378,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9-year &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 8, 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;China CITIC Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BeiGene (Suzhou) Co., Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;RMB480,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10-year &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 28, 2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;China Merchants Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BeiGene, Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$380,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1-year &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,773,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;300,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,129,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;China Minsheng Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BeiGene, Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$150,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1-year &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 16, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,094,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,064,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;China Industrial Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BeiGene, Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;RMB675,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;364-days&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 27, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;675,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;China Merchants Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BeiGene Guangzhou Biologics Manufacturing Co., Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;RMB400,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1-year &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 5, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;HSBC Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BeiGene, Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;RMB340,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1-year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 5, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;China Industrial Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BeiGene (Suzhou) Co., Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;RMB200,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1-year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 29, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shanghai Pudong Development Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BeiGene, Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;RMB700,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1-year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 24, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;93,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;679,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;350,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;China Merchants Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BeiGene (Suzhou) Co., Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;RMB200,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1-year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 24, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total short-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;851,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,215,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;688,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,885,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;China Construction Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BeiGene Guangzhou Biologics Manufacturing Co., Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;RMB580,000 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9-year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 11, 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;300,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;420,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;China Merchants Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BeiGene Guangzhou Biologics Manufacturing Co., Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;RMB350,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;9-year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 20, 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;267,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;China Merchants Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BeiGene Guangzhou Biologics Manufacturing Co., Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;RMB378,000 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9-year &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 8, 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;241,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;300,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;China CITIC Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BeiGene (Suzhou) Co., Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;RMB480,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10-year &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 28, 2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;469,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;415,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;166,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,215,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,402,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;The outstanding borrowings bear floating interest rates benchmarking RMB loan interest rates of financial institutions in the PRC. The loan interest rate was 4.2% as of December&#160;31, 2024. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The Company repaid &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$13,739 (or RMB100,000) during the year ended December&#160;31, 2024. The loan is secured by BeiGene Guangzhou Biologics Manufacturing Co., Ltd.&#x2019;s property ownership certificate and fixed assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;The outstanding borrowings bear floating interest rates benchmarking RMB loan interest rates of financial institutions in the PRC. The loan interest rate was 3.7% as of December&#160;31, 2024. The Company repaid $8,730 (RMB62,857) during the year ended December&#160;31, 2024. The loan is secured by Guangzhou Factory&#x2019;s second land use right and certain fixed assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;The outstanding borrowings bear floating interest rates benchmarking RMB loan interest rates of financial institutions in the PRC. The loan interest rate was 3.8% as of December&#160;31, 2024. The Company repaid $5,562 (RMB40,000) &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;during the year ended December&#160;31, 2024. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The loan is secured by fixed assets that will be placed into service upon completion of the third phase of the Guangzhou manufacturing facility&#x2019;s build out. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;The outstanding borrowings bear a floating interest rate benchmarked against prevailing interest rates of certain PRC financial institutions. The loan interest rate was 3.7% as of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;. The Company drew down $9,053 (RMB65,000) &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;during the year ended December&#160;31, 2024. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The loan is secured by BeiGene (Suzhou) Co., Ltd.&#x2019;s property ownership certificate of the small molecule manufacturing campus in Suzhou, China. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;5.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:12pt"&gt;The outstanding borrowings bear floating interest rates benchmarking the secured overnight financing rate. The loan interest rate was 6.2% as of December&#160;31, 2024. $80,000 of the borrowing matures on January 27, 2025, and $300,000 matures on December 17, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;The outstanding borrowings bear floating interest rates benchmarking RMB loan interest rates of financial institutions in the PRC. The loan interest rate was 2.6% as of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;7.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;The outstanding borrowings bear floating interest rates benchmarking Hong Kong interbank market rate for RMB. The loan interest rate was 4.4% as of December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has numerous financial and non-financial covenants on its debt obligations with various banks and other lenders. Some of these covenants include default and/or cross-default provisions that could require acceleration of repayment of loans in the event of default. However, the Company&#x2019;s debt is primarily short-term in nature. Any acceleration would be a matter of months but may impact the Company&#x2019;s ability to refinance debt obligations if an event of default occurs. As of December&#160;31, 2024, the Company is in compliance with all covenants of our material debt agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contractual Maturities of Debt Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate contractual maturities of all borrowings due subsequent to December&#160;31, 2024 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.256%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December&#160;31,&#160;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December&#160;31,&#160;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:4pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Interest Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on bank loans is paid quarterly until the respective loans are fully settled. Interest expense recognized for the years ended December&#160;31, 2024, 2023 and 2022 amounted to $46,894, $20,800 and $21,699, respectively, among which, $32,158, $16,571 and $2,594 was capitalized, respectively. Interest paid for the years ended December&#160;31, 2024, 2023 and 2022, net of amounts capitalized, amounted to $19,723, $3,484 and $22,489, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="c-1" id="f-1067">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s short-term and long-term debt obligations as of December&#160;31, 2024 and 2023: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.274%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:4.163%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.186%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.940%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.940%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.648%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:6.807%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lender&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Borrower&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Line of Credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;RMB&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;RMB&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;China Construction Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BeiGene Guangzhou Biologics Manufacturing Co., Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;RMB580,000 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9-year &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 11, 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;China Merchants Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BeiGene Guangzhou Biologics Manufacturing Co., Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;RMB350,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9-year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 20, 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;China Merchants Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BeiGene Guangzhou Biologics Manufacturing Co., Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;RMB378,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9-year &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 8, 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;China CITIC Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BeiGene (Suzhou) Co., Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;RMB480,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10-year &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 28, 2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;China Merchants Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BeiGene, Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$380,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1-year &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;380,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,773,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;300,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,129,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;China Minsheng Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BeiGene, Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$150,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1-year &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;December 16, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,094,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,064,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;China Industrial Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BeiGene, Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;RMB675,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;364-days&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;March 27, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;675,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;China Merchants Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BeiGene Guangzhou Biologics Manufacturing Co., Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;RMB400,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1-year &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 5, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;HSBC Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BeiGene, Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;RMB340,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1-year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 5, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;China Industrial Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BeiGene (Suzhou) Co., Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;RMB200,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1-year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 29, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shanghai Pudong Development Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BeiGene, Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;RMB700,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1-year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 24, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;93,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;679,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;350,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;China Merchants Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BeiGene (Suzhou) Co., Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;RMB200,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1-year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;May 24, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;199,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total short-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;851,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,215,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;688,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,885,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;China Construction Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BeiGene Guangzhou Biologics Manufacturing Co., Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;RMB580,000 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9-year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;June 11, 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;300,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;420,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;China Merchants Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BeiGene Guangzhou Biologics Manufacturing Co., Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;RMB350,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;9-year&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 20, 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37,638&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;267,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;China Merchants Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BeiGene Guangzhou Biologics Manufacturing Co., Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;RMB378,000 &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9-year &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;November 8, 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;241,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;300,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;China CITIC Bank&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BeiGene (Suzhou) Co., Ltd.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;RMB480,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10-year &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;July 28, 2032&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;469,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;415,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;166,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,215,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,402,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;The outstanding borrowings bear floating interest rates benchmarking RMB loan interest rates of financial institutions in the PRC. The loan interest rate was 4.2% as of December&#160;31, 2024. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The Company repaid &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$13,739 (or RMB100,000) during the year ended December&#160;31, 2024. The loan is secured by BeiGene Guangzhou Biologics Manufacturing Co., Ltd.&#x2019;s property ownership certificate and fixed assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;The outstanding borrowings bear floating interest rates benchmarking RMB loan interest rates of financial institutions in the PRC. The loan interest rate was 3.7% as of December&#160;31, 2024. The Company repaid $8,730 (RMB62,857) during the year ended December&#160;31, 2024. The loan is secured by Guangzhou Factory&#x2019;s second land use right and certain fixed assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;The outstanding borrowings bear floating interest rates benchmarking RMB loan interest rates of financial institutions in the PRC. The loan interest rate was 3.8% as of December&#160;31, 2024. The Company repaid $5,562 (RMB40,000) &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;during the year ended December&#160;31, 2024. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The loan is secured by fixed assets that will be placed into service upon completion of the third phase of the Guangzhou manufacturing facility&#x2019;s build out. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:4pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;The outstanding borrowings bear a floating interest rate benchmarked against prevailing interest rates of certain PRC financial institutions. The loan interest rate was 3.7% as of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;. The Company drew down $9,053 (RMB65,000) &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;during the year ended December&#160;31, 2024. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;The loan is secured by BeiGene (Suzhou) Co., Ltd.&#x2019;s property ownership certificate of the small molecule manufacturing campus in Suzhou, China. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;5.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:12pt"&gt;The outstanding borrowings bear floating interest rates benchmarking the secured overnight financing rate. The loan interest rate was 6.2% as of December&#160;31, 2024. $80,000 of the borrowing matures on January 27, 2025, and $300,000 matures on December 17, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;6.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;The outstanding borrowings bear floating interest rates benchmarking RMB loan interest rates of financial institutions in the PRC. The loan interest rate was 2.6% as of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;7.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;The outstanding borrowings bear floating interest rates benchmarking Hong Kong interbank market rate for RMB. The loan interest rate was 4.4% as of December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-243" decimals="INF" id="f-1068" unitRef="cny">580000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-244" id="f-1069">P9Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LongTermDebtCurrent contextRef="c-243" decimals="-3" id="f-1070" unitRef="usd">16440000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-243" decimals="-3" id="f-1071" unitRef="cny">120000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-245" decimals="-3" id="f-1072" unitRef="usd">14089000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-245" decimals="-3" id="f-1073" unitRef="cny">100000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-246" decimals="INF" id="f-1074" unitRef="cny">350000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-247" id="f-1075">P9Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LongTermDebtCurrent contextRef="c-246" decimals="-3" id="f-1076" unitRef="usd">8611000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-246" decimals="-3" id="f-1077" unitRef="cny">62857000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-248" decimals="-3" id="f-1078" unitRef="usd">8856000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-248" decimals="-3" id="f-1079" unitRef="cny">62857000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-249" decimals="INF" id="f-1080" unitRef="cny">378000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-250" id="f-1081">P9Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LongTermDebtCurrent contextRef="c-249" decimals="-3" id="f-1082" unitRef="usd">8148000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-249" decimals="-3" id="f-1083" unitRef="cny">59475000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-251" decimals="-3" id="f-1084" unitRef="usd">5636000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-251" decimals="-3" id="f-1085" unitRef="cny">40000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-252" decimals="INF" id="f-1086" unitRef="cny">480000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-253" id="f-1087">P10Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LongTermDebtCurrent contextRef="c-252" decimals="-3" id="f-1088" unitRef="usd">1384000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-252" decimals="-3" id="f-1089" unitRef="cny">10100000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-254" decimals="-3" id="f-1090" unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-254" decimals="-3" id="f-1091" unitRef="cny">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-255" decimals="INF" id="f-1092" unitRef="usd">380000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-256" id="f-1093">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LongTermDebtCurrent contextRef="c-255" decimals="-3" id="f-1094" unitRef="usd">380000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-255" decimals="-3" id="f-1095" unitRef="cny">2773723000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-257" decimals="-3" id="f-1096" unitRef="usd">300000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-257" decimals="-3" id="f-1097" unitRef="cny">2129321000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-258" decimals="INF" id="f-1098" unitRef="usd">150000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-259" id="f-1099">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c-259"
      decimals="3"
      id="f-1100"
      unitRef="number">0.068</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:LongTermDebtCurrent contextRef="c-258" decimals="-3" id="f-1101" unitRef="usd">150000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-258" decimals="-3" id="f-1102" unitRef="cny">1094891000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-260" decimals="-3" id="f-1103" unitRef="usd">150000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-260" decimals="-3" id="f-1104" unitRef="cny">1064660000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-261" decimals="INF" id="f-1105" unitRef="cny">675000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-262" id="f-1106">P364D</us-gaap:DebtInstrumentTerm>
    <us-gaap:LongTermDebtCurrent contextRef="c-261" decimals="-3" id="f-1107" unitRef="usd">92475000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-261" decimals="-3" id="f-1108" unitRef="cny">675000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-263" decimals="-3" id="f-1109" unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-263" decimals="-3" id="f-1110" unitRef="cny">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-264" decimals="INF" id="f-1111" unitRef="cny">400000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-265" id="f-1112">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c-265"
      decimals="3"
      id="f-1113"
      unitRef="number">0.030</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:LongTermDebtCurrent contextRef="c-264" decimals="-3" id="f-1114" unitRef="usd">54800000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-264" decimals="-3" id="f-1115" unitRef="cny">400000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-266" decimals="-3" id="f-1116" unitRef="usd">56356000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-266" decimals="-3" id="f-1117" unitRef="cny">400000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-267" decimals="INF" id="f-1118" unitRef="cny">340000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-268" id="f-1119">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LongTermDebtCurrent contextRef="c-267" decimals="-3" id="f-1120" unitRef="usd">46580000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-267" decimals="-3" id="f-1121" unitRef="cny">340000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-269" decimals="-3" id="f-1122" unitRef="usd">47903000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-269" decimals="-3" id="f-1123" unitRef="cny">340000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-270" decimals="INF" id="f-1124" unitRef="cny">200000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-271" id="f-1125">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c-271"
      decimals="3"
      id="f-1126"
      unitRef="number">0.028</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:LongTermDebtCurrent contextRef="c-270" decimals="-3" id="f-1127" unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-270" decimals="-3" id="f-1128" unitRef="cny">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-272" decimals="-3" id="f-1129" unitRef="usd">28177000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-272" decimals="-3" id="f-1130" unitRef="cny">200000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-273" decimals="INF" id="f-1131" unitRef="cny">700000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-274" id="f-1132">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c-274"
      decimals="3"
      id="f-1133"
      unitRef="number">0.029</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:LongTermDebtCurrent contextRef="c-273" decimals="-3" id="f-1134" unitRef="usd">93091000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-273" decimals="-3" id="f-1135" unitRef="cny">679492000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-275" decimals="-3" id="f-1136" unitRef="usd">49312000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-275" decimals="-3" id="f-1137" unitRef="cny">350000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-276" decimals="INF" id="f-1138" unitRef="cny">200000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-277" id="f-1139">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c-278"
      decimals="3"
      id="f-1140"
      unitRef="number">0.032</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:LongTermDebtCurrent contextRef="c-276" decimals="-3" id="f-1141" unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-276" decimals="-3" id="f-1142" unitRef="cny">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-279" decimals="-3" id="f-1143" unitRef="usd">28037000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-279" decimals="-3" id="f-1144" unitRef="cny">199000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-12" decimals="-3" id="f-1145" unitRef="usd">851529000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-12" decimals="-3" id="f-1146" unitRef="cny">6215538000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-13" decimals="-3" id="f-1147" unitRef="usd">688366000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-13" decimals="-3" id="f-1148" unitRef="cny">4885838000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-280" decimals="INF" id="f-1149" unitRef="cny">580000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-281" id="f-1150">P9Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-280" decimals="-3" id="f-1151" unitRef="usd">41100000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-280" decimals="-3" id="f-1152" unitRef="cny">300000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-282" decimals="-3" id="f-1153" unitRef="usd">59174000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-282" decimals="-3" id="f-1154" unitRef="cny">420000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-283" decimals="INF" id="f-1155" unitRef="cny">350000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-284" id="f-1156">P9Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-283" decimals="-3" id="f-1157" unitRef="usd">27987000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-283" decimals="-3" id="f-1158" unitRef="cny">204286000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-285" decimals="-3" id="f-1159" unitRef="usd">37638000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-285" decimals="-3" id="f-1160" unitRef="cny">267143000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-286" decimals="INF" id="f-1161" unitRef="cny">378000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-287" id="f-1162">P9Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-286" decimals="-3" id="f-1163" unitRef="usd">33020000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-286" decimals="-3" id="f-1164" unitRef="cny">241025000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-288" decimals="-3" id="f-1165" unitRef="usd">42337000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-288" decimals="-3" id="f-1166" unitRef="cny">300500000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-289" decimals="INF" id="f-1167" unitRef="cny">480000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-253" id="f-1168">P10Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-289" decimals="-3" id="f-1169" unitRef="usd">64377000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-289" decimals="-3" id="f-1170" unitRef="cny">469900000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-290" decimals="-3" id="f-1171" unitRef="usd">58469000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-290" decimals="-3" id="f-1172" unitRef="cny">415000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-12" decimals="-3" id="f-1173" unitRef="usd">166484000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-12" decimals="-3" id="f-1174" unitRef="cny">1215211000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-13" decimals="-3" id="f-1175" unitRef="usd">197618000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-13" decimals="-3" id="f-1176" unitRef="cny">1402643000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c-281"
      decimals="3"
      id="f-1177"
      unitRef="number">0.042</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-281" decimals="-3" id="f-1178" unitRef="usd">13739000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-281" decimals="-3" id="f-1179" unitRef="cny">100000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c-247"
      decimals="3"
      id="f-1180"
      unitRef="number">0.037</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-291" decimals="-3" id="f-1181" unitRef="usd">8730000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-291" decimals="-3" id="f-1182" unitRef="cny">62857000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-249"
      decimals="3"
      id="f-1183"
      unitRef="number">0.038</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-250" decimals="-3" id="f-1184" unitRef="usd">5562000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-250" decimals="-3" id="f-1185" unitRef="cny">40000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-292"
      decimals="3"
      id="f-1186"
      unitRef="number">0.037</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromLongTermLinesOfCredit contextRef="c-253" decimals="-3" id="f-1187" unitRef="usd">9053000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit contextRef="c-253" decimals="-3" id="f-1188" unitRef="cny">65000000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c-256"
      decimals="3"
      id="f-1189"
      unitRef="number">0.062</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:LongTermDebtCurrent contextRef="c-293" decimals="-3" id="f-1190" unitRef="usd">80000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-257" decimals="-3" id="f-1191" unitRef="usd">300000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c-294"
      decimals="3"
      id="f-1192"
      unitRef="number">0.026</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c-268"
      decimals="3"
      id="f-1193"
      unitRef="number">0.044</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock contextRef="c-1" id="f-1194">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate contractual maturities of all borrowings due subsequent to December&#160;31, 2024 are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.256%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December&#160;31,&#160;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December&#160;31,&#160;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,018,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock>
    <us-gaap:ContractualObligationDueInNextTwelveMonths contextRef="c-12" decimals="-3" id="f-1195" unitRef="usd">851529000</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInSecondYear contextRef="c-12" decimals="-3" id="f-1196" unitRef="usd">46207000</us-gaap:ContractualObligationDueInSecondYear>
    <us-gaap:ContractualObligationDueInThirdYear contextRef="c-12" decimals="-3" id="f-1197" unitRef="usd">46207000</us-gaap:ContractualObligationDueInThirdYear>
    <us-gaap:ContractualObligationDueInFourthYear contextRef="c-12" decimals="-3" id="f-1198" unitRef="usd">25657000</us-gaap:ContractualObligationDueInFourthYear>
    <us-gaap:ContractualObligationDueInFifthYear contextRef="c-12" decimals="-3" id="f-1199" unitRef="usd">19657000</us-gaap:ContractualObligationDueInFifthYear>
    <us-gaap:ContractualObligationDueAfterFifthYear contextRef="c-12" decimals="-3" id="f-1200" unitRef="usd">28756000</us-gaap:ContractualObligationDueAfterFifthYear>
    <us-gaap:ContractualObligation contextRef="c-12" decimals="-3" id="f-1201" unitRef="usd">1018013000</us-gaap:ContractualObligation>
    <us-gaap:InterestExpenseDebt contextRef="c-1" decimals="-3" id="f-1202" unitRef="usd">46894000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-10" decimals="-3" id="f-1203" unitRef="usd">20800000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-11" decimals="-3" id="f-1204" unitRef="usd">21699000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestCostsCapitalized contextRef="c-1" decimals="0" id="f-1205" unitRef="usd">32158000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized contextRef="c-10" decimals="0" id="f-1206" unitRef="usd">16571000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized contextRef="c-11" decimals="0" id="f-1207" unitRef="usd">2594000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="0" id="f-1208" unitRef="usd">19723000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-10" decimals="0" id="f-1209" unitRef="usd">3484</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-11" decimals="0" id="f-1210" unitRef="usd">22489</us-gaap:InterestPaidNet>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-1211">Product Revenue&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s product revenue is primarily derived from the sale of its internally developed products BRUKINSA and TEVIMBRA in the U.S., China, and other regions; XGEVA, BLINCYTO and KYPROLIS in China under a license from Amgen; REVLIMID&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and VIDAZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in China under a license from BMS; and POBEVCY&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in China under a license from Bio-Thera.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the Company&#x2019;s net product sales for the years ended December&#160;31, 2024, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenue - gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,786,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,718,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,438,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Rebates and sales returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,007,198)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(529,117)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(183,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenue - net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,779,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,189,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,254,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table disaggregates net product revenue by product for the years ended December&#160;31, 2024, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.642%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;BRUKINSA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,644,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,290,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tislelizumab&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;620,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;536,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;422,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;XGEVA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;BLINCYTO&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;KYPROLIS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;POBEVCY&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;REVLIMID&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,018&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total product revenue - net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,779,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,189,852&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,254,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the roll-forward of accrued sales chargebacks, rebates, returns and other deductions for the years ended December&#160;31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.642%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rebates, Returns and Other Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contra AR Accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts charged against product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(176,912)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(232,231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(409,143)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts charged against product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;515,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(396,092)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(495,178)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(891,270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <bgne:RevenueFromContractWithCustomerExcludingAssessedTaxBeforeReductions contextRef="c-4" decimals="-3" id="f-1212" unitRef="usd">4786744000</bgne:RevenueFromContractWithCustomerExcludingAssessedTaxBeforeReductions>
    <bgne:RevenueFromContractWithCustomerExcludingAssessedTaxBeforeReductions contextRef="c-5" decimals="-3" id="f-1213" unitRef="usd">2718969000</bgne:RevenueFromContractWithCustomerExcludingAssessedTaxBeforeReductions>
    <bgne:RevenueFromContractWithCustomerExcludingAssessedTaxBeforeReductions contextRef="c-6" decimals="-3" id="f-1214" unitRef="usd">1438440000</bgne:RevenueFromContractWithCustomerExcludingAssessedTaxBeforeReductions>
    <bgne:RevenueRecognitionRevenueReduction contextRef="c-4" decimals="-3" id="f-1215" unitRef="usd">1007198000</bgne:RevenueRecognitionRevenueReduction>
    <bgne:RevenueRecognitionRevenueReduction contextRef="c-5" decimals="-3" id="f-1216" unitRef="usd">529117000</bgne:RevenueRecognitionRevenueReduction>
    <bgne:RevenueRecognitionRevenueReduction contextRef="c-6" decimals="-3" id="f-1217" unitRef="usd">183828000</bgne:RevenueRecognitionRevenueReduction>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-4" decimals="-3" id="f-1218" unitRef="usd">3779546000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-3" id="f-1219" unitRef="usd">2189852000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-1220" unitRef="usd">1254612000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-295" decimals="-3" id="f-1221" unitRef="usd">2644226000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-296" decimals="-3" id="f-1222" unitRef="usd">1290396000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-297" decimals="-3" id="f-1223" unitRef="usd">564651000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-298" decimals="-3" id="f-1224" unitRef="usd">620836000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-299" decimals="-3" id="f-1225" unitRef="usd">536620000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-300" decimals="-3" id="f-1226" unitRef="usd">422885000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-301" decimals="-3" id="f-1227" unitRef="usd">224403000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-302" decimals="-3" id="f-1228" unitRef="usd">92828000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-303" decimals="-3" id="f-1229" unitRef="usd">63398000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-304" decimals="-3" id="f-1230" unitRef="usd">74331000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-305" decimals="-3" id="f-1231" unitRef="usd">54342000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-306" decimals="-3" id="f-1232" unitRef="usd">36107000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-307" decimals="-3" id="f-1233" unitRef="usd">66171000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-308" decimals="-3" id="f-1234" unitRef="usd">39799000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-309" decimals="-3" id="f-1235" unitRef="usd">13696000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-310" decimals="-3" id="f-1236" unitRef="usd">53509000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-311" decimals="-3" id="f-1237" unitRef="usd">56547000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-312" decimals="-3" id="f-1238" unitRef="usd">38124000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-313" decimals="-3" id="f-1239" unitRef="usd">36028000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-314" decimals="-3" id="f-1240" unitRef="usd">76018000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-315" decimals="-3" id="f-1241" unitRef="usd">79049000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-316" decimals="-3" id="f-1242" unitRef="usd">60042000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-317" decimals="-3" id="f-1243" unitRef="usd">43302000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-318" decimals="-3" id="f-1244" unitRef="usd">36702000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-4" decimals="-3" id="f-1245" unitRef="usd">3779546000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-3" id="f-1246" unitRef="usd">2189852000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-1247" unitRef="usd">1254612000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <bgne:ScheduleOfAccruedSalesRebatesAndReturnsCurrentTableTextBlock contextRef="c-1" id="f-1248">&lt;div style="margin-bottom:4pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the roll-forward of accrued sales chargebacks, rebates, returns and other deductions for the years ended December&#160;31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.642%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rebates, Returns and Other Deductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contra AR Accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts charged against product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(176,912)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(232,231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(409,143)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;170,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts charged against product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;515,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(396,092)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(495,178)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(891,270)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;235,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;286,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</bgne:ScheduleOfAccruedSalesRebatesAndReturnsCurrentTableTextBlock>
    <bgne:RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions contextRef="c-319" decimals="-3" id="f-1249" unitRef="usd">41817000</bgne:RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions>
    <bgne:AccountsReceivableAllowanceForChargebacksAndCreditLoss contextRef="c-320" decimals="-3" id="f-1250" unitRef="usd">8580000</bgne:AccountsReceivableAllowanceForChargebacksAndCreditLoss>
    <bgne:RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions contextRef="c-321" decimals="-3" id="f-1251" unitRef="usd">50397000</bgne:RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions>
    <bgne:RevenueRecognitionRevenueReduction contextRef="c-322" decimals="-3" id="f-1252" unitRef="usd">275031000</bgne:RevenueRecognitionRevenueReduction>
    <bgne:RevenueRecognitionRevenueReduction contextRef="c-323" decimals="-3" id="f-1253" unitRef="usd">254086000</bgne:RevenueRecognitionRevenueReduction>
    <bgne:RevenueRecognitionRevenueReduction contextRef="c-5" decimals="-3" id="f-1254" unitRef="usd">529117000</bgne:RevenueRecognitionRevenueReduction>
    <bgne:RevenueRecognitionRevenueReductionsPaymentsAndCredits contextRef="c-322" decimals="-3" id="f-1255" unitRef="usd">176912000</bgne:RevenueRecognitionRevenueReductionsPaymentsAndCredits>
    <bgne:RevenueRecognitionRevenueReductionsPaymentsAndCredits contextRef="c-323" decimals="-3" id="f-1256" unitRef="usd">232231000</bgne:RevenueRecognitionRevenueReductionsPaymentsAndCredits>
    <bgne:RevenueRecognitionRevenueReductionsPaymentsAndCredits contextRef="c-5" decimals="-3" id="f-1257" unitRef="usd">409143000</bgne:RevenueRecognitionRevenueReductionsPaymentsAndCredits>
    <bgne:RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions contextRef="c-324" decimals="-3" id="f-1258" unitRef="usd">139936000</bgne:RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions>
    <bgne:AccountsReceivableAllowanceForChargebacksAndCreditLoss contextRef="c-325" decimals="-3" id="f-1259" unitRef="usd">30435000</bgne:AccountsReceivableAllowanceForChargebacksAndCreditLoss>
    <bgne:RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions contextRef="c-326" decimals="-3" id="f-1260" unitRef="usd">170371000</bgne:RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions>
    <bgne:RevenueRecognitionRevenueReduction contextRef="c-327" decimals="-3" id="f-1261" unitRef="usd">491756000</bgne:RevenueRecognitionRevenueReduction>
    <bgne:RevenueRecognitionRevenueReduction contextRef="c-328" decimals="-3" id="f-1262" unitRef="usd">515442000</bgne:RevenueRecognitionRevenueReduction>
    <bgne:RevenueRecognitionRevenueReduction contextRef="c-4" decimals="-3" id="f-1263" unitRef="usd">1007198000</bgne:RevenueRecognitionRevenueReduction>
    <bgne:RevenueRecognitionRevenueReductionsPaymentsAndCredits contextRef="c-327" decimals="-3" id="f-1264" unitRef="usd">396092000</bgne:RevenueRecognitionRevenueReductionsPaymentsAndCredits>
    <bgne:RevenueRecognitionRevenueReductionsPaymentsAndCredits contextRef="c-328" decimals="-3" id="f-1265" unitRef="usd">495178000</bgne:RevenueRecognitionRevenueReductionsPaymentsAndCredits>
    <bgne:RevenueRecognitionRevenueReductionsPaymentsAndCredits contextRef="c-4" decimals="-3" id="f-1266" unitRef="usd">891270000</bgne:RevenueRecognitionRevenueReductionsPaymentsAndCredits>
    <bgne:RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions contextRef="c-329" decimals="-3" id="f-1267" unitRef="usd">235600000</bgne:RevenueRecognitionReserveForSalesReturnsRebatesAndOtherDeductions>
    <bgne:AccountsReceivableAllowanceForChargebacksAndCreditLoss contextRef="c-330" decimals="-3" id="f-1268" unitRef="usd">50699000</bgne:AccountsReceivableAllowanceForChargebacksAndCreditLoss>
    <bgne:RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions contextRef="c-331" decimals="-3" id="f-1269" unitRef="usd">286299000</bgne:RevenueRecognitionAllowanceForChargebacksAndCreditLossAndReservesForSalesReturnsRebatesAndOtherDeductions>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-1270">Loss Per Share&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss per share was calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(644,786)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(881,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,003,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding for computing basic and diluted loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,368,746,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,357,034,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340,729,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2024, 2023 and 2022, the computation of basic loss per share using the two-class method was not applicable, as the Company was in a net loss position.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effects of all share options and restricted share units were excluded from the calculation of diluted loss per share as their effect would have been anti-dilutive during the years ended December&#160;31, 2024, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-1271">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss per share was calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(644,786)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(881,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,003,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding for computing basic and diluted loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,368,746,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,357,034,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,340,729,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-1272" unitRef="usd">-644786000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-10" decimals="-3" id="f-1273" unitRef="usd">-881708000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-11" decimals="-3" id="f-1274" unitRef="usd">-2003815000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-1275" unitRef="shares">1368746793</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-1276" unitRef="shares">1368746793</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-10" decimals="0" id="f-1277" unitRef="shares">1357034547</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-10" decimals="0" id="f-1278" unitRef="shares">1357034547</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-11" decimals="0" id="f-1279" unitRef="shares">1340729572</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-11" decimals="0" id="f-1280" unitRef="shares">1340729572</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-1281"
      unitRef="usdPerShare">-0.47</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-1282"
      unitRef="usdPerShare">-0.47</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-10"
      decimals="2"
      id="f-1283"
      unitRef="usdPerShare">-0.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-10"
      decimals="2"
      id="f-1284"
      unitRef="usdPerShare">-0.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-11"
      decimals="2"
      id="f-1285"
      unitRef="usdPerShare">-1.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-11"
      decimals="2"
      id="f-1286"
      unitRef="usdPerShare">-1.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-1287">Share-Based Compensation&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2016 Share Option and Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2016, in connection with its U.S. IPO, the board of directors and shareholders of the Company approved the 2016 Share Option and Incentive Plan (the &#x201c;2016 Plan&#x201d;), which became effective in February 2016. The Company initially reserved 65,029,595 ordinary shares for the issuance of awards under the 2016 Plan, plus any shares available under the 2011 Option Plan (the &#x201c;2011 Plan&#x201d;), and not subject to any outstanding options as of the effective date of the 2016 Plan, along with underlying share awards under the 2011 Plan that are cancelled or forfeited without issuance of ordinary shares. As of December&#160;31, 2024, ordinary shares cancelled or forfeited under the 2011 Plan that were carried over to the 2016 Plan totaled 5,166,900. The 2016 Plan provided for an annual increase in the shares available for issuance, to be added on the first day of each fiscal year, beginning on January 1, 2017, equal to the lesser of (i) five percent (5%)% of the outstanding shares of the Company&#x2019;s ordinary shares on the last day of the immediately preceding fiscal year or (ii) such number of shares determined by the Company&#x2019;s board of directors or the compensation committee. On January 1, 2018, 29,603,616 ordinary shares were added to the 2016 Plan under this provision. However, in August 2018, in connection with the Hong Kong IPO, the board of directors of the Company approved an amended and restated 2016 Plan to remove this &#x201c;evergreen&#x201d; provision and implement other changes required by the Hong Kong Stock Exchange (&#x201c;HKEx&#x201d;) rules. In December 2018, the shareholders of the Company approved a second amended and restated 2016 Plan to increase the number of shares authorized for issuance by 38,553,159 ordinary shares, as well as amend the cap on annual compensation to independent directors and make other changes. In June 2020, the shareholders approved an Amendment No. 1 to the 2016 Plan to increase the number of shares authorized for issuance by 57,200,000 ordinary shares and to extend the term of the plan through April 13, 2030. The number of shares available for issuance under the 2016 Plan is subject to adjustment in the event of a share split, share dividend or other change in the Company&#x2019;s capitalization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, share-based awards to acquire 83,064,175 ordinary shares were available for future grant under the 2016 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to continue to provide incentive opportunities under the 2016 Plan, the Board of Directors and shareholders of the Company approved an amendment to the 2016 Plan (the &#x201c;Amendment No. 2&#x201d;), which became effective as of June 22, 2022, to increase the number of authorized shares available for issuance under the 2016 Plan by 66,300,000 ordinary shares, or 5%, of the Company&#x2019;s outstanding shares as of March 31, 2022. In June 2024, the shareholders approved a third amended and restated 2016 Plan to increase the number of shares authorized for issuance by 92,820,000. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2018 Inducement Equity Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, the board of directors of the Company approved the 2018 Inducement Equity Plan (the &#x201c;2018 Plan&#x201d;) and reserved&#160;12,000,000&#160;ordinary shares to be used exclusively for grants of awards to individuals who were not previously employees of the Company or its subsidiaries, as a material inducement to the individual&#x2019;s entry into employment with the Company or its subsidiaries, within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. The 2018 Plan was approved by the board of directors upon recommendation of the compensation committee, without shareholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The terms and conditions of the 2018 Plan, and the forms of award agreements to be used thereunder, are substantially similar to the 2016 Plan and the forms of award agreements thereunder. In August 2018, in connection with the listing of the Company&#x2019;s ordinary shares on the HKEx, the board of directors of the Company approved an amended and restated 2018 Plan to implement changes required by the HKEx rules.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the effectiveness of Amendment No. 2 to the 2016 Plan, on June 22, 2022, the 2018 Plan was terminated to the effect that no new equity awards shall be granted under the plan but the outstanding equity awards under the plan shall continue to vest and/or be exercisable in accordance with their terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2018 Employee Share Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, the shareholders of the Company approved the 2018 Employee Share Purchase Plan (the &#x201c;ESPP&#x201d;).&#160;Initially,&#160;3,500,000&#160;ordinary shares of the Company were reserved for issuance under the ESPP. In August 2018, in connection with the Hong Kong IPO, the board of directors of the Company approved an amended and restated ESPP to remove an &#x201c;evergreen&#x201d; share replenishment provision originally included in the plan and implement other changes required by the HKEx rules. In December 2018, the shareholders of the Company approved a second amended and restated ESPP to increase the number of shares authorized for issuance by 3,855,315 ordinary shares to 7,355,315 ordinary shares. In June 2024, the shareholders of the Company approved a fourth amended and restated ESPP to increase the number of shares authorized for issuance by 5,070,000 ordinary shares to 12,425,315 ordinary shares. The ESPP allows eligible employees to purchase the Company&#x2019;s ordinary shares (including in the form of ADSs) at the end of each offering period, which will generally be six months, at a&#160;15%&#160;discount to the market price of the Company&#x2019;s ADSs at the beginning or the end of each offering period, whichever is lower, using funds deducted from their payroll during the offering period. Eligible employees are able to authorize payroll deductions of up to&#160;10%&#160;of their eligible earnings, subject to applicable limitations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarizes the shares issued under the ESPP:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.607%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Market Price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Purchase Price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Ordinary Shares Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ADS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Ordinary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ADS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Ordinary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Proceeds&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,035,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 29, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,021,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;930,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 28, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;667,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; The market price is the lower of the closing price on Nasdaq on the issuance date or the offering date, in accordance with the terms of the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; The purchase price is the price which was discounted from the applicable market price, in accordance with the terms of the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, 4,953,682 ordinary shares were available for future issuance under the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, share options have a contractual term of 10 years and vest over a &lt;span style="-sec-ix-hidden:f-1346"&gt;three&lt;/span&gt;- to five-year period, with the first tranche vesting one calendar year after the grant date or the service relationship start date and the remainder of the awards vesting on a monthly basis thereafter. Restricted shares and restricted share units generally vest over a four-year period, with the first tranche vesting one calendar year after the grant date or the service relationship start date and the remainder of the awards vesting on a yearly basis thereafter, or sometimes vest upon the achievement of pre-specified performance conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s share option activities under the 2011, 2016 and 2018 Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.604%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date&#160;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,204,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,516,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,898,217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,296,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,526,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,817,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,974,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,225,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,145,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,180,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,812,624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,530,134)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,982,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,173,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,311,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the unrecognized compensation cost related to 15,137,970 unvested share options expected to vest was $82,424. This unrecognized compensation will be recognized over an estimated weighted-average amortization period of 2.4 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total fair value of employee share option awards vested during the years ended December&#160;31, 2024, 2023 and 2022 was $68,420, $61,121 and $62,548, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair value of options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the binomial option-pricing model in determining the estimated fair value of the options granted. The model requires the input of highly subjective assumptions including the estimated expected stock price volatility and, the exercise multiple for which employees are likely to exercise share options. For expected volatilities, the trading history and observation period of the Company&#x2019;s own share price is used in conjunction with historical price volatilities of ordinary shares of several comparable companies in the same industry as the Company. For the exercise multiple, the Company was not able to develop an exercise pattern as reference, thus the exercise multiple is based on management&#x2019;s estimation, which the Company believes is representative of the future exercise pattern of the options. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury Bills yield curve in effect at the time of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the range of fair values and the assumptions used to estimate those fair values of the share options granted in the years presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.508%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of ordinary share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$5.72 ~ $9.19&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$7.26 ~ $10.72&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$5.51 ~ $9.04&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8% ~ 4.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4% ~ 4.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8% ~ 3.9%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected exercise multiple&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57% ~ 58%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58% ~ 60%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51% ~ 60%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contractual life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted share units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s restricted share unit activities under the 2016 and 2018 Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.391%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Numbers&lt;br/&gt;of&#160;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant&#160;Date&#160;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,082,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,707,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,533,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,859,892)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,397,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,573,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,862,598)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,707,546)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,401,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,693,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,251,477)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,012,471)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,830,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected to vest at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,956,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:4pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the unrecognized compensation cost related to unvested restricted share units expected to vest was $801,403. This unrecognized compensation will be recognized over an estimated weighted-average amortization period of 2.7 years.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes total share-based compensation cost recognized for the years ended December&#160;31, 2024, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.322%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.606%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-332"
      decimals="INF"
      id="f-1288"
      unitRef="shares">65029595</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <bgne:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriod
      contextRef="c-333"
      decimals="INF"
      id="f-1289"
      unitRef="shares">5166900</bgne:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="c-334"
      decimals="INF"
      id="f-1290"
      unitRef="number">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-335"
      decimals="INF"
      id="f-1291"
      unitRef="shares">29603616</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-336"
      decimals="INF"
      id="f-1292"
      unitRef="shares">38553159</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-337"
      decimals="INF"
      id="f-1293"
      unitRef="shares">57200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-338"
      decimals="INF"
      id="f-1294"
      unitRef="shares">83064175</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-339"
      decimals="INF"
      id="f-1295"
      unitRef="shares">66300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="c-339"
      decimals="INF"
      id="f-1296"
      unitRef="number">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-340"
      decimals="INF"
      id="f-1297"
      unitRef="shares">92820000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-341"
      decimals="INF"
      id="f-1298"
      unitRef="shares">12000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-342"
      decimals="INF"
      id="f-1299"
      unitRef="shares">3500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-343"
      decimals="INF"
      id="f-1300"
      unitRef="shares">3855315</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-344"
      decimals="INF"
      id="f-1301"
      unitRef="shares">7355315</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-345"
      decimals="INF"
      id="f-1302"
      unitRef="shares">5070000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-346"
      decimals="INF"
      id="f-1303"
      unitRef="shares">12425315</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <bgne:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod contextRef="c-347" id="f-1304">P6M</bgne:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod>
    <bgne:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountOnPurchasePriceOfCommonStockPercent
      contextRef="c-342"
      decimals="INF"
      id="f-1305"
      unitRef="number">0.15</bgne:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountOnPurchasePriceOfCommonStockPercent>
    <bgne:MaximumPercentageOfEligibleEarningsSetSideToPurchaseOrdinaryShares
      contextRef="c-347"
      decimals="INF"
      id="f-1306"
      unitRef="number">0.10</bgne:MaximumPercentageOfEligibleEarningsSetSideToPurchaseOrdinaryShares>
    <us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock contextRef="c-1" id="f-1307">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarizes the shares issued under the ESPP:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.630%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.607%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Market Price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Purchase Price&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issuance Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Ordinary Shares Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ADS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Ordinary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;ADS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Ordinary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Proceeds&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,035,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 29, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,021,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,777&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 28, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;930,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;August 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;861,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;February 28, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;667,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; The market price is the lower of the closing price on Nasdaq on the issuance date or the offering date, in accordance with the terms of the ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; The purchase price is the price which was discounted from the applicable market price, in accordance with the terms of the ESPP.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-348"
      decimals="INF"
      id="f-1308"
      unitRef="shares">1035996</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <bgne:SharePriceAmericanDepositoryShares
      contextRef="c-349"
      decimals="2"
      id="f-1309"
      unitRef="usdPerShare">165.20</bgne:SharePriceAmericanDepositoryShares>
    <us-gaap:SharePrice
      contextRef="c-349"
      decimals="2"
      id="f-1310"
      unitRef="usdPerShare">12.69</us-gaap:SharePrice>
    <bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice
      contextRef="c-349"
      decimals="2"
      id="f-1311"
      unitRef="usdPerShare">140.27</bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice>
    <bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice
      contextRef="c-349"
      decimals="2"
      id="f-1312"
      unitRef="usdPerShare">10.78</bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans contextRef="c-348" decimals="-3" id="f-1313" unitRef="usd">11178000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-350"
      decimals="INF"
      id="f-1314"
      unitRef="shares">1021397</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <bgne:SharePriceAmericanDepositoryShares
      contextRef="c-351"
      decimals="2"
      id="f-1315"
      unitRef="usdPerShare">165.65</bgne:SharePriceAmericanDepositoryShares>
    <us-gaap:SharePrice
      contextRef="c-351"
      decimals="2"
      id="f-1316"
      unitRef="usdPerShare">12.74</us-gaap:SharePrice>
    <bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice
      contextRef="c-351"
      decimals="2"
      id="f-1317"
      unitRef="usdPerShare">140.80</bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice>
    <bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice
      contextRef="c-351"
      decimals="2"
      id="f-1318"
      unitRef="usdPerShare">10.83</bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans contextRef="c-350" decimals="-3" id="f-1319" unitRef="usd">11063000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-352"
      decimals="INF"
      id="f-1320"
      unitRef="shares">794144</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <bgne:SharePriceAmericanDepositoryShares
      contextRef="c-353"
      decimals="2"
      id="f-1321"
      unitRef="usdPerShare">207.55</bgne:SharePriceAmericanDepositoryShares>
    <us-gaap:SharePrice
      contextRef="c-353"
      decimals="2"
      id="f-1322"
      unitRef="usdPerShare">15.97</us-gaap:SharePrice>
    <bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice
      contextRef="c-353"
      decimals="2"
      id="f-1323"
      unitRef="usdPerShare">176.42</bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice>
    <bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice
      contextRef="c-353"
      decimals="2"
      id="f-1324"
      unitRef="usdPerShare">13.57</bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans contextRef="c-352" decimals="-3" id="f-1325" unitRef="usd">10777000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-354"
      decimals="INF"
      id="f-1326"
      unitRef="shares">930582</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <bgne:SharePriceAmericanDepositoryShares
      contextRef="c-355"
      decimals="2"
      id="f-1327"
      unitRef="usdPerShare">171.10</bgne:SharePriceAmericanDepositoryShares>
    <us-gaap:SharePrice
      contextRef="c-355"
      decimals="2"
      id="f-1328"
      unitRef="usdPerShare">13.16</us-gaap:SharePrice>
    <bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice
      contextRef="c-355"
      decimals="2"
      id="f-1329"
      unitRef="usdPerShare">145.44</bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice>
    <bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice
      contextRef="c-355"
      decimals="2"
      id="f-1330"
      unitRef="usdPerShare">11.19</bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans contextRef="c-354" decimals="-3" id="f-1331" unitRef="usd">10414000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-356"
      decimals="INF"
      id="f-1332"
      unitRef="shares">861315</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <bgne:SharePriceAmericanDepositoryShares
      contextRef="c-357"
      decimals="2"
      id="f-1333"
      unitRef="usdPerShare">171.66</bgne:SharePriceAmericanDepositoryShares>
    <us-gaap:SharePrice
      contextRef="c-357"
      decimals="2"
      id="f-1334"
      unitRef="usdPerShare">13.20</us-gaap:SharePrice>
    <bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice
      contextRef="c-357"
      decimals="2"
      id="f-1335"
      unitRef="usdPerShare">145.91</bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice>
    <bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice
      contextRef="c-357"
      decimals="2"
      id="f-1336"
      unitRef="usdPerShare">11.22</bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans contextRef="c-356" decimals="-3" id="f-1337" unitRef="usd">9667000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-358"
      decimals="INF"
      id="f-1338"
      unitRef="shares">667160</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <bgne:SharePriceAmericanDepositoryShares
      contextRef="c-359"
      decimals="2"
      id="f-1339"
      unitRef="usdPerShare">210.52</bgne:SharePriceAmericanDepositoryShares>
    <us-gaap:SharePrice
      contextRef="c-359"
      decimals="2"
      id="f-1340"
      unitRef="usdPerShare">16.19</us-gaap:SharePrice>
    <bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice
      contextRef="c-359"
      decimals="2"
      id="f-1341"
      unitRef="usdPerShare">178.94</bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodAmericanDepositorySharesExercisePrice>
    <bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice
      contextRef="c-359"
      decimals="2"
      id="f-1342"
      unitRef="usdPerShare">13.76</bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardSharesIssuedInPeriodExercisePrice>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans contextRef="c-358" decimals="-3" id="f-1343" unitRef="usd">9183000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberOfAvailableSharesAvailableForFutureIssuance
      contextRef="c-360"
      decimals="INF"
      id="f-1344"
      unitRef="shares">4953682</bgne:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberOfAvailableSharesAvailableForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-361" id="f-1345">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-363" id="f-1347">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-364" id="f-1348">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-365" id="f-1349">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-1350">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s share option activities under the 2011, 2016 and 2018 Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.604%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date&#160;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,204,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,516,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,898,217)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,296,634)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,526,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,817,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,974,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,225,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,145,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,180,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,812,624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,530,134)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,982,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;429,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable as of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,173,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;406,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,311,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;426,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-15"
      decimals="INF"
      id="f-1351"
      unitRef="shares">72204888</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-15"
      decimals="2"
      id="f-1352"
      unitRef="usdPerShare">7.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-11"
      decimals="INF"
      id="f-1353"
      unitRef="shares">12516816</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-11"
      decimals="2"
      id="f-1354"
      unitRef="usdPerShare">12.34</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-11"
      decimals="2"
      id="f-1355"
      unitRef="usdPerShare">6.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-11"
      decimals="INF"
      id="f-1356"
      unitRef="shares">5898217</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-11"
      decimals="2"
      id="f-1357"
      unitRef="usdPerShare">4.63</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-11" decimals="-3" id="f-1358" unitRef="usd">52258000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-11"
      decimals="INF"
      id="f-1359"
      unitRef="shares">2296634</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-11"
      decimals="2"
      id="f-1360"
      unitRef="usdPerShare">16.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-14"
      decimals="INF"
      id="f-1361"
      unitRef="shares">76526853</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-14"
      decimals="2"
      id="f-1362"
      unitRef="usdPerShare">7.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-10"
      decimals="INF"
      id="f-1363"
      unitRef="shares">9817925</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-10"
      decimals="2"
      id="f-1364"
      unitRef="usdPerShare">16.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-10"
      decimals="2"
      id="f-1365"
      unitRef="usdPerShare">8.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-10"
      decimals="INF"
      id="f-1366"
      unitRef="shares">6974331</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-10"
      decimals="2"
      id="f-1367"
      unitRef="usdPerShare">4.54</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-10" decimals="-3" id="f-1368" unitRef="usd">92051000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-10"
      decimals="INF"
      id="f-1369"
      unitRef="shares">1225334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-10"
      decimals="2"
      id="f-1370"
      unitRef="usdPerShare">17.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-13"
      decimals="INF"
      id="f-1371"
      unitRef="shares">78145113</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-13"
      decimals="2"
      id="f-1372"
      unitRef="usdPerShare">9.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-1"
      decimals="INF"
      id="f-1373"
      unitRef="shares">9180301</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-1374"
      unitRef="usdPerShare">12.53</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-1375"
      unitRef="usdPerShare">6.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-1"
      decimals="INF"
      id="f-1376"
      unitRef="shares">6812624</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-1377"
      unitRef="usdPerShare">3.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-3" id="f-1378" unitRef="usd">69946000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-1"
      decimals="INF"
      id="f-1379"
      unitRef="shares">2530134</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-1380"
      unitRef="usdPerShare">15.87</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-12"
      decimals="INF"
      id="f-1381"
      unitRef="shares">77982656</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-12"
      decimals="2"
      id="f-1382"
      unitRef="usdPerShare">9.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-1383">P4Y9M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-12" decimals="-3" id="f-1384" unitRef="usd">429581000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-12"
      decimals="INF"
      id="f-1385"
      unitRef="shares">60173280</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-12"
      decimals="2"
      id="f-1386"
      unitRef="usdPerShare">8.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-1387">P3Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-12" decimals="-3" id="f-1388" unitRef="usd">406868000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c-12"
      decimals="INF"
      id="f-1389"
      unitRef="shares">75311250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="c-12"
      decimals="2"
      id="f-1390"
      unitRef="usdPerShare">9.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-1391">P4Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-12" decimals="-3" id="f-1392" unitRef="usd">426174000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <bgne:ShareBasedPaymentArrangementNonvestedAwardOptionNumberOfShares
      contextRef="c-366"
      decimals="INF"
      id="f-1393"
      unitRef="shares">15137970</bgne:ShareBasedPaymentArrangementNonvestedAwardOptionNumberOfShares>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-366" decimals="-3" id="f-1394" unitRef="usd">82424000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-361" id="f-1395">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-1" decimals="-3" id="f-1396" unitRef="usd">68420000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-10" decimals="-3" id="f-1397" unitRef="usd">61121000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="c-11" decimals="-3" id="f-1398" unitRef="usd">62548000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-1399">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the range of fair values and the assumptions used to estimate those fair values of the share options granted in the years presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.508%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of ordinary share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$5.72 ~ $9.19&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$7.26 ~ $10.72&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$5.51 ~ $9.04&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8% ~ 4.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4% ~ 4.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8% ~ 3.9%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected exercise multiple&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57% ~ 58%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58% ~ 60%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51% ~ 60%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contractual life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharePrice
      contextRef="c-367"
      decimals="INF"
      id="f-1400"
      unitRef="usdPerShare">5.72</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="c-368"
      decimals="INF"
      id="f-1401"
      unitRef="usdPerShare">9.19</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="c-369"
      decimals="INF"
      id="f-1402"
      unitRef="usdPerShare">7.26</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="c-370"
      decimals="INF"
      id="f-1403"
      unitRef="usdPerShare">10.72</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="c-371"
      decimals="INF"
      id="f-1404"
      unitRef="usdPerShare">5.51</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="c-372"
      decimals="INF"
      id="f-1405"
      unitRef="usdPerShare">9.04</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="c-361"
      decimals="3"
      id="f-1406"
      unitRef="number">0.038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="c-361"
      decimals="3"
      id="f-1407"
      unitRef="number">0.046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="c-373"
      decimals="3"
      id="f-1408"
      unitRef="number">0.034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="c-373"
      decimals="3"
      id="f-1409"
      unitRef="number">0.046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="c-374"
      decimals="3"
      id="f-1410"
      unitRef="number">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="c-374"
      decimals="3"
      id="f-1411"
      unitRef="number">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <bgne:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum
      contextRef="c-361"
      decimals="1"
      id="f-1412"
      unitRef="number">2.8</bgne:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum>
    <bgne:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum contextRef="c-10" decimals="1" id="f-1413" unitRef="number">2.8</bgne:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum>
    <bgne:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum contextRef="c-11" decimals="1" id="f-1414" unitRef="number">2.8</bgne:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedExerciseMultipleMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="c-361"
      decimals="2"
      id="f-1415"
      unitRef="number">0.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="c-361"
      decimals="2"
      id="f-1416"
      unitRef="number">0.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="c-373"
      decimals="2"
      id="f-1417"
      unitRef="number">0.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="c-373"
      decimals="2"
      id="f-1418"
      unitRef="number">0.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="c-374"
      decimals="2"
      id="f-1419"
      unitRef="number">0.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="c-374"
      decimals="2"
      id="f-1420"
      unitRef="number">0.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-361"
      decimals="INF"
      id="f-1421"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-373"
      decimals="INF"
      id="f-1422"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-374"
      decimals="INF"
      id="f-1423"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-361" id="f-1424">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-373" id="f-1425">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-374" id="f-1426">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="c-1" id="f-1427">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s restricted share unit activities under the 2016 and 2018 Plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.391%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.791%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Numbers&lt;br/&gt;of&#160;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant&#160;Date&#160;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,082,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,707,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,533,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,859,892)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,397,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,573,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,862,598)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,707,546)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,401,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,693,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,251,477)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,012,471)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,830,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected to vest at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,956,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-375"
      decimals="INF"
      id="f-1428"
      unitRef="shares">36082982</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-375"
      decimals="2"
      id="f-1429"
      unitRef="usdPerShare">18.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-376"
      decimals="INF"
      id="f-1430"
      unitRef="shares">38707669</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-376"
      decimals="2"
      id="f-1431"
      unitRef="usdPerShare">12.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-376"
      decimals="INF"
      id="f-1432"
      unitRef="shares">12533586</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-376"
      decimals="2"
      id="f-1433"
      unitRef="usdPerShare">16.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-376"
      decimals="INF"
      id="f-1434"
      unitRef="shares">6859892</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-376"
      decimals="2"
      id="f-1435"
      unitRef="usdPerShare">16.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-377"
      decimals="INF"
      id="f-1436"
      unitRef="shares">55397173</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-377"
      decimals="2"
      id="f-1437"
      unitRef="usdPerShare">14.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-378"
      decimals="INF"
      id="f-1438"
      unitRef="shares">34573994</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-378"
      decimals="2"
      id="f-1439"
      unitRef="usdPerShare">15.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-378"
      decimals="INF"
      id="f-1440"
      unitRef="shares">17862598</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-378"
      decimals="2"
      id="f-1441"
      unitRef="usdPerShare">14.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-378"
      decimals="INF"
      id="f-1442"
      unitRef="shares">5707546</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-378"
      decimals="2"
      id="f-1443"
      unitRef="usdPerShare">15.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-379"
      decimals="INF"
      id="f-1444"
      unitRef="shares">66401023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-379"
      decimals="2"
      id="f-1445"
      unitRef="usdPerShare">15.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-364"
      decimals="INF"
      id="f-1446"
      unitRef="shares">49693592</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-364"
      decimals="2"
      id="f-1447"
      unitRef="usdPerShare">12.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-364"
      decimals="INF"
      id="f-1448"
      unitRef="shares">21251477</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-364"
      decimals="2"
      id="f-1449"
      unitRef="usdPerShare">15.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-364"
      decimals="INF"
      id="f-1450"
      unitRef="shares">9012471</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-364"
      decimals="2"
      id="f-1451"
      unitRef="usdPerShare">14.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-380"
      decimals="INF"
      id="f-1452"
      unitRef="shares">85830667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-380"
      decimals="2"
      id="f-1453"
      unitRef="usdPerShare">13.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <bgne:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestOutstandingNumber
      contextRef="c-380"
      decimals="INF"
      id="f-1454"
      unitRef="shares">72956067</bgne:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestOutstandingNumber>
    <bgne:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue
      contextRef="c-380"
      decimals="2"
      id="f-1455"
      unitRef="usdPerShare">13.67</bgne:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-380" decimals="-3" id="f-1456" unitRef="usd">801403000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-364" id="f-1457">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-1458">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes total share-based compensation cost recognized for the years ended December&#160;31, 2024, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.322%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.606%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;186,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;441,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-172" decimals="-3" id="f-1459" unitRef="usd">186113000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-173" decimals="-3" id="f-1460" unitRef="usd">163550000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-174" decimals="-3" id="f-1461" unitRef="usd">139348000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-169" decimals="-3" id="f-1462" unitRef="usd">255680000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-170" decimals="-3" id="f-1463" unitRef="usd">204038000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-171" decimals="-3" id="f-1464" unitRef="usd">163814000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-1465" unitRef="usd">441793000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-10" decimals="-3" id="f-1466" unitRef="usd">367588000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-11" decimals="-3" id="f-1467" unitRef="usd">303162000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ComprehensiveIncomeNoteTextBlock contextRef="c-1" id="f-1468">Accumulated Other Comprehensive (Loss) Income&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The movement of accumulated other comprehensive (loss) income was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.321%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign&#160;Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains/Losses&#160;on&lt;br/&gt;Available-for-Sale&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pension Liability Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,523)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,011)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,883)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,417)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,464)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,422)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,840)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive loss &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net-current period other comprehensive (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,464)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,029)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,494)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99,446)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,753)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,353)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive loss &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net-current period other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,942)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49,542)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135,552)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,436)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(148,988)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The amounts reclassified from accumulated other comprehensive (loss) income were included in other (expense) income, net in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="c-1" id="f-1469">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The movement of accumulated other comprehensive (loss) income was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.321%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign&#160;Currency&lt;br/&gt;Translation&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Gains/Losses&#160;on&lt;br/&gt;Available-for-Sale&lt;br/&gt;Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pension Liability Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(62,523)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,011)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,883)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,417)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,464)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,422)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,840)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive loss &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net-current period other comprehensive (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,464)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,029)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87,987)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,494)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99,446)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive loss before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,753)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,353)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive loss &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net-current period other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,942)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49,542)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135,552)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,436)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(148,988)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The amounts reclassified from accumulated other comprehensive (loss) income were included in other (expense) income, net in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity contextRef="c-381" decimals="-3" id="f-1470" unitRef="usd">-62523000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-382" decimals="-3" id="f-1471" unitRef="usd">-9011000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-383" decimals="-3" id="f-1472" unitRef="usd">-5883000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-1473" unitRef="usd">-77417000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-384" decimals="-3" id="f-1474" unitRef="usd">-25464000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-385" decimals="-3" id="f-1475" unitRef="usd">9046000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-386" decimals="-3" id="f-1476" unitRef="usd">-6422000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-10" decimals="-3" id="f-1477" unitRef="usd">-22840000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-384" decimals="-3" id="f-1478" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-385" decimals="-3" id="f-1479" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-386" decimals="-3" id="f-1480" unitRef="usd">-811000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-10" decimals="-3" id="f-1481" unitRef="usd">-811000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-384" decimals="-3" id="f-1482" unitRef="usd">-25464000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-385" decimals="-3" id="f-1483" unitRef="usd">9046000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-386" decimals="-3" id="f-1484" unitRef="usd">-5611000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-30" decimals="-3" id="f-1485" unitRef="usd">-22029000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-387" decimals="-3" id="f-1486" unitRef="usd">-87987000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-388" decimals="-3" id="f-1487" unitRef="usd">35000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-389" decimals="-3" id="f-1488" unitRef="usd">-11494000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-1489" unitRef="usd">-99446000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-390" decimals="-3" id="f-1490" unitRef="usd">-47565000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-391" decimals="-3" id="f-1491" unitRef="usd">-35000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-392" decimals="-3" id="f-1492" unitRef="usd">-2753000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-1" decimals="-3" id="f-1493" unitRef="usd">-50353000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-390" decimals="-3" id="f-1494" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-391" decimals="-3" id="f-1495" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-392" decimals="-3" id="f-1496" unitRef="usd">-811000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-1" decimals="-3" id="f-1497" unitRef="usd">-811000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-390" decimals="-3" id="f-1498" unitRef="usd">-47565000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-391" decimals="-3" id="f-1499" unitRef="usd">-35000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-392" decimals="-3" id="f-1500" unitRef="usd">-1942000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-38" decimals="-3" id="f-1501" unitRef="usd">-49542000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-393" decimals="-3" id="f-1502" unitRef="usd">-135552000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-394" decimals="-3" id="f-1503" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-395" decimals="-3" id="f-1504" unitRef="usd">-13436000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-42" decimals="-3" id="f-1505" unitRef="usd">-148988000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-1506">Shareholders&#x2019; Equity&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2024, 2023 and 2022, the Company completed the following equity transactions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;BMS Settlement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 1, 2023, the Company entered into a Settlement and Termination Agreement (the &#x201c;Settlement Agreement&#x201d;) with BMS-Celgene and certain of its affiliates relating to the termination of the parties&#x2019; ongoing contractual relationships, the previously-disclosed ongoing arbitration proceeding concerning ABRAXANE&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (the &#x201c;Arbitration&#x201d;), the License and Supply Agreement (&#x201c;LSA&#x201d;), the Amended and Restated Quality Agreement (the &#x201c;QA&#x201d;), and the Share Subscription Agreement (the &#x201c;SSA&#x201d;), entered into by the parties in 2017 and 2018. Pursuant to the Settlement Agreement, the parties agreed to mutually dismiss the Arbitration and BMS-Celgene and its affiliates agreed to transfer 23,273,108 ordinary shares of the Company originally purchased in 2017, in each case subject to and in accordance with the terms and conditions of the Settlement Agreement. In consideration for the shares being returned, the Company agreed to drop its claims pursuant to the Settlement Agreement. Furthermore, the parties agreed to terminate the LSA and QA on December 31, 2023, subject to the Company&#x2019;s right to continue selling all inventory of REVLIMID and VIDAZA until sold out or February 2025, whichever is earlier. The Settlement Agreement provides for a settlement and release by each party of claims arising from or relating to the Arbitration, the LSA, the QA and the SSA, as well as other disputes and potential disputes between the parties, in each case subject to and in accordance with the terms and conditions of the Agreement. The receipt of the shares occurred on August 15, 2023. The Company recorded a noncash gain upon receipt of $362,917, which represents the fair value on the day the shares were received. The gain was recorded within other (expense) income, net in the consolidated statements of operations. The shares were constructively retired during the year ended December 31, 2023. The Company recorded the amount of the cancelled shares in excess of par to additional paid-in capital.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="c-396"
      decimals="INF"
      id="f-1507"
      unitRef="shares">23273108</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodValue contextRef="c-397" decimals="-3" id="f-1508" unitRef="usd">362917000</us-gaap:StockRepurchasedAndRetiredDuringPeriodValue>
    <us-gaap:RestrictedAssetsDisclosureTextBlock contextRef="c-1" id="f-1509">Restricted Net Assets&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s ability to pay dividends may depend on the Company receiving distributions of funds from its PRC subsidiaries. Relevant PRC laws and regulations permit payments of dividends by the Company&#x2019;s PRC subsidiaries only out of its retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. The results of operations reflected in the consolidated financial statements prepared in accordance with GAAP differ from those reflected in the statutory financial statements of the Company&#x2019;s PRC subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the company law of the PRC, a domestic enterprise is required to provide statutory reserves of at least 10% of its annual after-tax profit until such reserve has reached 50% of its respective registered capital based on the enterprise&#x2019;s PRC statutory accounts. A domestic enterprise is also required to provide discretionary surplus reserve, at the discretion of the Board of Directors, from the profits determined in accordance with the enterprise&#x2019;s PRC statutory accounts. The aforementioned reserves can only be used for specific purposes and are not distributable as cash dividends. The Company&#x2019;s PRC subsidiaries were established as domestic invested enterprises and therefore were subject to the above-mentioned restrictions on distributable profits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2024, 2023 and 2022, no appropriation to statutory reserves was made, because the PRC subsidiaries had an accumulated deficit as of the end of such periods.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of these PRC laws and regulations, including the requirement to make annual appropriations of at least 10% of after-tax income and set aside as general reserve fund prior to payment of dividends, the Company&#x2019;s PRC subsidiaries are restricted in their ability to transfer a portion of their net assets to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign exchange and other regulations in the PRC may further restrict the Company&#x2019;s PRC subsidiaries from transferring funds to the Company in the form of dividends, loans, and advances. As of December&#160;31, 2024 and 2023, amounts restricted were the net assets of the Company&#x2019;s PRC subsidiaries, which, after intercompany eliminations, amounted to $1,709,961 and $2,114,277, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:RestrictedAssetsDisclosureTextBlock>
    <bgne:RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage
      contextRef="c-12"
      decimals="INF"
      id="f-1510"
      unitRef="number">0.10</bgne:RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage>
    <bgne:RestrictedNetAssetsRequiredStatutoryReserveAsPercentageOfRegisteredCapital
      contextRef="c-12"
      decimals="INF"
      id="f-1511"
      unitRef="number">0.50</bgne:RestrictedNetAssetsRequiredStatutoryReserveAsPercentageOfRegisteredCapital>
    <bgne:RestrictedNetAssetsAppropriatedToStatutoryReserves contextRef="c-12" decimals="INF" id="f-1512" unitRef="usd">0</bgne:RestrictedNetAssetsAppropriatedToStatutoryReserves>
    <bgne:RestrictedNetAssetsAppropriatedToStatutoryReserves contextRef="c-13" decimals="INF" id="f-1513" unitRef="usd">0</bgne:RestrictedNetAssetsAppropriatedToStatutoryReserves>
    <bgne:RestrictedNetAssetsAppropriatedToStatutoryReserves contextRef="c-14" decimals="INF" id="f-1514" unitRef="usd">0</bgne:RestrictedNetAssetsAppropriatedToStatutoryReserves>
    <bgne:RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage
      contextRef="c-12"
      decimals="INF"
      id="f-1515"
      unitRef="number">0.10</bgne:RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage>
    <bgne:RestrictedNetAssetsAmount contextRef="c-398" decimals="-3" id="f-1516" unitRef="usd">1709961000</bgne:RestrictedNetAssetsAmount>
    <bgne:RestrictedNetAssetsAmount contextRef="c-399" decimals="-3" id="f-1517" unitRef="usd">2114277000</bgne:RestrictedNetAssetsAmount>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="c-1" id="f-1518">Employee Benefit Plans&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Defined Contribution Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Full-time employees of the Company in the PRC participate in a government mandated defined contribution plan, pursuant to which certain pension benefits, medical care, employee housing fund and other welfare benefits are provided to employees. Chinese labor regulations require that the Company&#x2019;s PRC subsidiaries make contributions to the government for these benefits based on certain percentages of the employees&#x2019; salaries. The Company has no legal obligation for the benefits beyond the contributions made. The total amounts for such employee benefits, which were expensed as incurred, were $101,779, $94,358 and $83,860 for the years ended December&#160;31, 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a defined contribution 401(k) savings plan (the &#x201c;401(k) Plan&#x201d;) for U.S. employees. The 401(k) Plan covers all U.S. employees, and allows participants to defer a portion of their annual compensation on a pretax or Roth basis. In addition, the Company has a matching contribution to the 401(k) Plan, which, in the 2024 plan year, matched dollar for dollar of eligible contributions up to 6%. Company contributions to the 401(k) Plan totaled $20,839, $15,316 and $10,298 in the years ended December&#160;31, 2024, 2023 and 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a government mandated&#160;program to cover its employees in Switzerland for pension, death, or disability. The program is considered a defined contribution plan.&#160;Employer and employee contributions are made based on various percentages of salaries and wages that vary based on employee age and other factors.&#160;Company contributions into the program amounted to $3,825, $2,710, and $3,887 in the years ended December&#160;31, 2024, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company contributions into defined contribution plans for the remaining subsidiaries were immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Defined Benefit Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a defined benefit pension plan covering its employees in Switzerland (the &#x201c;Swiss Plan&#x201d;). This plan is a government mandated fund that provides benefits to employees upon retirement, death, or disability. Contributions are made based on various percentages of participants&#x2019; salaries and wages determined based on participants&#x2019; age and other factors. As of December&#160;31, 2024 and 2023, the projected benefit obligations under the Swiss Plan were approximately $80,199 and $70,600, respectively, and plan assets were approximately $63,794 and $55,605, respectively. The funded status of the Swiss Plan is included in other long-term liabilities in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s annual contribution to the Swiss Plan is estimated to be approximately $3,922 in 2025 and is expected to evolve thereafter proportionally with changes in staffing and compensation levels, actuarial assumptions and actual investment returns on plan assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reflects the total expected benefit payments to Swiss Plan participants in the following 10 years and have been estimated based on the same assumptions used to measure the Company&#x2019;s benefit obligations as of December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.993%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December&#160;31,&#160;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December&#160;31,&#160;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-400" decimals="-3" id="f-1519" unitRef="usd">101779000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-401" decimals="-3" id="f-1520" unitRef="usd">94358000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-402" decimals="-3" id="f-1521" unitRef="usd">83860000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="c-403"
      decimals="INF"
      id="f-1522"
      unitRef="number">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-403" decimals="-3" id="f-1523" unitRef="usd">20839000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-404" decimals="-3" id="f-1524" unitRef="usd">15316000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-405" decimals="-3" id="f-1525" unitRef="usd">10298000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-406" decimals="-3" id="f-1526" unitRef="usd">3825000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-407" decimals="-3" id="f-1527" unitRef="usd">2710000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-408" decimals="-3" id="f-1528" unitRef="usd">3887000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-12" decimals="-3" id="f-1529" unitRef="usd">80199000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation contextRef="c-13" decimals="-3" id="f-1530" unitRef="usd">70600000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-12" decimals="-3" id="f-1531" unitRef="usd">63794000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets contextRef="c-13" decimals="-3" id="f-1532" unitRef="usd">55605000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear contextRef="c-12" decimals="-3" id="f-1533" unitRef="usd">3922000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock contextRef="c-1" id="f-1534">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reflects the total expected benefit payments to Swiss Plan participants in the following 10 years and have been estimated based on the same assumptions used to measure the Company&#x2019;s benefit obligations as of December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.993%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December&#160;31,&#160;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December&#160;31,&#160;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year ending December 31, 2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths contextRef="c-12" decimals="-3" id="f-1535" unitRef="usd">692000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo contextRef="c-12" decimals="-3" id="f-1536" unitRef="usd">604000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree contextRef="c-12" decimals="-3" id="f-1537" unitRef="usd">994000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour contextRef="c-12" decimals="-3" id="f-1538" unitRef="usd">593000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive contextRef="c-12" decimals="-3" id="f-1539" unitRef="usd">1922000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter contextRef="c-12" decimals="-3" id="f-1540" unitRef="usd">8657000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <bgne:DefinedBenefitPlanExpectedFutureBenefitPaymentTotal contextRef="c-12" decimals="-3" id="f-1541" unitRef="usd">13462000</bgne:DefinedBenefitPlanExpectedFutureBenefitPaymentTotal>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-1542">Commitments and Contingencies&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the Company had purchase commitments amounting to $131,944, of which $32,538 related to minimum purchase requirements for supply purchased from contract manufacturing organizations and $99,406 related to binding purchase order obligations of inventory from Amgen. The Company does not have any minimum purchase requirements for inventory from Amgen.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Capital Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had capital commitments amounting to $48,347 for the acquisition of property, plant and equipment as of December&#160;31, 2024 related to various facilities across the globe.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Co-Development Funding Commitment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Amgen Collaboration Agreement, the Company is responsible for co-funding global clinical development costs for the Amgen oncology pipeline assets up to a total cap of $1,250,000. The Company is funding its portion of the co-development costs by contributing cash and/or development services. As of December&#160;31, 2024, the Company&#x2019;s remaining co-development funding commitment was $335,261.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Funding Commitment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had committed capital related to two equity method investments in the amount of $15,053. As of December&#160;31, 2024, the remaining capital commitment was $7,404 and is expected to be paid from time to time over the investment period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Business Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into agreements in the ordinary course of business with contract research organizations (&#x201c;CROs&#x201d;) to provide research and development services. These contracts are generally cancellable at any time by the Company with prior written notice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also enters into collaboration agreements with institutions and companies to license intellectual property. The Company may be obligated to make future development, regulatory and commercial milestone payments and royalty payments on future sales of specified products associated with its collaboration agreements. Payments under these agreements generally become due and payable upon achievement of such milestones or sales. These commitments are not recorded on the consolidated balance sheet because the achievement and timing of these milestones are not fixed and determinable. When the achievement of these milestones or sales have occurred, the corresponding amounts are recognized in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount contextRef="c-12" decimals="-3" id="f-1543" unitRef="usd">131944000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount contextRef="c-409" decimals="-3" id="f-1544" unitRef="usd">32538000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount contextRef="c-410" decimals="-3" id="f-1545" unitRef="usd">99406000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount>
    <us-gaap:OtherCommitment contextRef="c-411" decimals="-3" id="f-1546" unitRef="usd">48347000</us-gaap:OtherCommitment>
    <bgne:MaximumCashAndServicesDevelopmentCommitment contextRef="c-164" decimals="-3" id="f-1547" unitRef="usd">1250000000</bgne:MaximumCashAndServicesDevelopmentCommitment>
    <us-gaap:OtherCommitment contextRef="c-164" decimals="-3" id="f-1548" unitRef="usd">335261000</us-gaap:OtherCommitment>
    <bgne:LongTermFundingCommitmentNumberOfEquityInvestments
      contextRef="c-412"
      decimals="INF"
      id="f-1549"
      unitRef="investment">2</bgne:LongTermFundingCommitmentNumberOfEquityInvestments>
    <bgne:LongTermFundingCommitmentMaximumAmount contextRef="c-412" decimals="-3" id="f-1550" unitRef="usd">15053000</bgne:LongTermFundingCommitmentMaximumAmount>
    <us-gaap:OtherCommitment contextRef="c-412" decimals="-3" id="f-1551" unitRef="usd">7404000</us-gaap:OtherCommitment>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-1552">Segment and Geographic Information&lt;div style="margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are defined as components of an enterprise for which separate financial information is available and evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company operates in one segment: pharmaceutical products. Its chief operating decision maker is the Chief Executive Officer, who makes operating decisions, assesses performance, and allocates resources on a consolidated basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The primary measure of segment profitability for the Company&#x2019;s operating segment is considered to be consolidated net loss. Significant segment expenses reviewed by the CODM on a regular basis included within net loss include cost of product sales, research and development expenses and selling, general and administrative expenses which are separately presented on the Company&#x2019;s Consolidated Statements of Operations. Other segment items within net loss include interest income, net, other (expense) income, net and income tax expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s long-lived assets are primarily located in the U.S. and China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues by geographic area are based upon the location of the customer, and net collaboration revenue is recorded in the jurisdiction in which the related income is expected to be sourced from. Total net revenues by geographic area are presented as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.332%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. - total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,957,498&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,128,219&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;502,626&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,950,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;China- total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,411,307&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,101,951&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;840,032&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,390,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,093,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Europe- total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;362,626&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;202,014&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;63,257&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Rest of world- total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;78,810&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;26,595&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,006&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,387)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,810,241&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,458,779&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,415,921&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-1553"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="c-1" id="f-1554">Total net revenues by geographic area are presented as follows:&lt;div style="margin-bottom:9pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.332%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. - total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,957,498&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,128,219&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;502,626&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,950,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;182,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;China- total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,411,307&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,101,951&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;840,032&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,390,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,093,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;840,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Europe- total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;362,626&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;202,014&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;63,257&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;359,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Rest of world- total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;78,810&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;26,595&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,006&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,387)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,810,241&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,458,779&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,415,921&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-231" decimals="-3" id="f-1555" unitRef="usd">1957498000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-232" decimals="-3" id="f-1556" unitRef="usd">1128219000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-233" decimals="-3" id="f-1557" unitRef="usd">502626000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-413" decimals="-3" id="f-1558" unitRef="usd">1950530000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-414" decimals="-3" id="f-1559" unitRef="usd">945551000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-415" decimals="-3" id="f-1560" unitRef="usd">389710000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-416" decimals="-3" id="f-1561" unitRef="usd">6968000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-417" decimals="-3" id="f-1562" unitRef="usd">182668000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-418" decimals="-3" id="f-1563" unitRef="usd">112916000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-234" decimals="-3" id="f-1564" unitRef="usd">1411307000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-235" decimals="-3" id="f-1565" unitRef="usd">1101951000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-236" decimals="-3" id="f-1566" unitRef="usd">840032000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-419" decimals="-3" id="f-1567" unitRef="usd">1390699000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-420" decimals="-3" id="f-1568" unitRef="usd">1093091000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-421" decimals="-3" id="f-1569" unitRef="usd">840032000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-422" decimals="-3" id="f-1570" unitRef="usd">20608000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-423" decimals="-3" id="f-1571" unitRef="usd">8860000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-424" decimals="-3" id="f-1572" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-425" decimals="-3" id="f-1573" unitRef="usd">362626000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-426" decimals="-3" id="f-1574" unitRef="usd">202014000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-427" decimals="-3" id="f-1575" unitRef="usd">63257000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-428" decimals="-3" id="f-1576" unitRef="usd">359507000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-429" decimals="-3" id="f-1577" unitRef="usd">122228000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-430" decimals="-3" id="f-1578" unitRef="usd">14864000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-431" decimals="-3" id="f-1579" unitRef="usd">3119000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-432" decimals="-3" id="f-1580" unitRef="usd">79786000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-433" decimals="-3" id="f-1581" unitRef="usd">48393000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-237" decimals="-3" id="f-1582" unitRef="usd">78810000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-238" decimals="-3" id="f-1583" unitRef="usd">26595000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-239" decimals="-3" id="f-1584" unitRef="usd">10006000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-434" decimals="-3" id="f-1585" unitRef="usd">78810000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-435" decimals="-3" id="f-1586" unitRef="usd">28982000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-436" decimals="-3" id="f-1587" unitRef="usd">10006000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-437" decimals="-3" id="f-1588" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-438" decimals="-3" id="f-1589" unitRef="usd">-2387000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-439" decimals="-3" id="f-1590" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-1591" unitRef="usd">3810241000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="-3" id="f-1592" unitRef="usd">2458779000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="-3" id="f-1593" unitRef="usd">1415921000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-1" id="f-1594">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-1" id="f-1595">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-1" id="f-1596">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-1" id="f-1597">false</ecd:NonRule10b51ArrAdoptedFlag>
    <dei:AuditorFirmId contextRef="c-1" id="f-1598">42</dei:AuditorFirmId>
    <us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock contextRef="c-1" id="f-1599">&lt;div style="margin-bottom:9pt;margin-top:5pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Schedule I - Condensed Financial Information of Registrant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;BeiGene, Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Information of Parent Company&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Condensed Statements of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Amounts in thousands of U.S. Dollars (&#x201c;$&#x201d;))&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;637,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;711,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(711,006)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(631,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(865,953)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(297,856)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,173,306)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(644,383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(879,977)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,999,674)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(644,786)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(881,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,003,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;BeiGene, Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Information of Parent Company&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Condensed Statements of Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Amounts in thousands of U.S. Dollars (&#x201c;$&#x201d;))&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.458%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.388%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.694%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.694%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.696%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(644,786)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(881,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,003,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive (loss) income, net of tax of nil:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,464)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90,421)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension liability adjustments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,942)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized holding gain (loss), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,311)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(694,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(903,737)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,099,182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;BeiGene, Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Information of Parent Company&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Condensed Balance Sheets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Amounts in thousands of U.S. Dollars (&#x201c;$&#x201d;))&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.640%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.792%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As&#160;of&#160;December&#160;31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;723,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;249,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;785,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;649,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,509,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loans to subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,731,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,030,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Investment in wholly owned subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,081,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,207,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;114,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,576,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,816,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities and shareholders&#x2019; equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;424,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;197,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Indebtedness to subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;362,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;762,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;547,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,186,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,107,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;171,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,244,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,279,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total shareholders&#x2019; equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,332,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,537,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities and shareholders&#x2019; equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,576,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,816,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;BeiGene, Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Information of Parent Company&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Condensed Statements of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Amounts in thousands of U.S. Dollars (&#x201c;$&#x201d;))&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash flows from operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(644,786)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(881,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,003,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Adjustments to reconcile net loss to net cash used in operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired in-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of research and development cost share liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(73,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(55,294)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(96,402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized (gains) losses in subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(85,471)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;932,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other items, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(374,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(596,496)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Changes in operating assets and liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;627,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(140,126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;875,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net cash used in operating activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(143,472)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,168,628)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(882,145)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash flows from investing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchases of short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,485)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Proceeds from sale or maturity of short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;552,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,487,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchase of in-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(75,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Investment in subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(406,624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(883,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,675,908)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other investing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(37,120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;188,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net cash used in investing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(441,116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(159,747)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,186,361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash flows from financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Proceeds from short-term loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;813,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;547,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;296,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Repayment of short-term loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(593,898)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(293,002)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(247,460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Proceeds from option exercises and employee share purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net cash provided by financing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;264,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;310,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange rate changes, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,356)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net decrease in cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(324,413)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,017,823)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,972,813)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;724,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,742,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,715,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash, cash equivalents, and restricted cash, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;724,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,742,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Schedule I has been provided pursuant to the requirements of Rules 12-04(a) and 5-04(c) of Regulation S-X (the &#x201c;Rules&#x201d;), which require condensed financial information as to the financial position, changes in financial position and results of operations of a parent company as of the same dates and for the same periods for which audited consolidated financial statements have been presented when the restricted net assets of consolidated subsidiaries exceed 25 percent of consolidated net assets as of the end of the most recently completed fiscal year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;The condensed financial information has been prepared using the same accounting policies as set out in the consolidated financial statements. For purposes of this condensed financial information, BeiGene, Ltd. (the &#x201c;Parent Company&#x201d;)&#x2019;s investments in its wholly owned and majority owned subsidiaries are recorded under the equity method of accounting in accordance with ASC 323.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted as allowed under the Rules. These footnote disclosures provide certain supplemental information relating to the operations of the Company and, as such, these statements should be read in conjunction with the notes to the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;As of December&#160;31, 2024, the Parent Company had a remaining capital commitment of $7,350 on an equity investment which is expected to be paid from time to time over the investment period. The Parent Company has unconditionally guaranteed the payment and performance of the obligations of BeiGene Switzerland GmbH in accordance with the terms of the global strategic oncology collaboration with Amgen Inc. No amounts have been recognized related to this guarantee. The Parent Company has no other material contingencies, long-term obligations or guarantees not already disclosed in its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock>
    <srt:ScheduleOfCondensedIncomeStatementTableTextBlock contextRef="c-1" id="f-1600">&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;BeiGene, Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Information of Parent Company&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Condensed Statements of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Amounts in thousands of U.S. Dollars (&#x201c;$&#x201d;))&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;353,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;637,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;711,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(711,006)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(631,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(865,953)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(297,856)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,173,306)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(644,383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(879,977)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,999,674)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(644,786)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(881,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,003,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</srt:ScheduleOfCondensedIncomeStatementTableTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-440" decimals="-3" id="f-1601" unitRef="usd">353903000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-441" decimals="-3" id="f-1602" unitRef="usd">326560000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-442" decimals="-3" id="f-1603" unitRef="usd">637152000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-440" decimals="-3" id="f-1604" unitRef="usd">357103000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-441" decimals="-3" id="f-1605" unitRef="usd">304543000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-442" decimals="-3" id="f-1606" unitRef="usd">228801000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses contextRef="c-440" decimals="-3" id="f-1607" unitRef="usd">711006000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-441" decimals="-3" id="f-1608" unitRef="usd">631103000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-442" decimals="-3" id="f-1609" unitRef="usd">865953000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-440" decimals="-3" id="f-1610" unitRef="usd">-711006000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-441" decimals="-3" id="f-1611" unitRef="usd">-631103000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-442" decimals="-3" id="f-1612" unitRef="usd">-865953000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-440" decimals="-3" id="f-1613" unitRef="usd">3101000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-441" decimals="-3" id="f-1614" unitRef="usd">48982000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-442" decimals="-3" id="f-1615" unitRef="usd">39585000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-440" decimals="-3" id="f-1616" unitRef="usd">63522000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-441" decimals="-3" id="f-1617" unitRef="usd">-297856000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-442" decimals="-3" id="f-1618" unitRef="usd">-1173306000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-440" decimals="-3" id="f-1619" unitRef="usd">-644383000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-441" decimals="-3" id="f-1620" unitRef="usd">-879977000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-442" decimals="-3" id="f-1621" unitRef="usd">-1999674000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-440" decimals="-3" id="f-1622" unitRef="usd">403000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-441" decimals="-3" id="f-1623" unitRef="usd">1731000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-442" decimals="-3" id="f-1624" unitRef="usd">4141000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-440" decimals="-3" id="f-1625" unitRef="usd">-644786000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-441" decimals="-3" id="f-1626" unitRef="usd">-881708000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-442" decimals="-3" id="f-1627" unitRef="usd">-2003815000</us-gaap:NetIncomeLoss>
    <srt:CondensedStatementOfComprehensiveIncomeTableTextBlock contextRef="c-1" id="f-1628">&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;BeiGene, Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Information of Parent Company&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Condensed Statements of Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Amounts in thousands of U.S. Dollars (&#x201c;$&#x201d;))&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.458%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.388%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.694%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.694%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.696%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(644,786)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(881,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,003,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive (loss) income, net of tax of nil:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,464)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(90,421)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension liability adjustments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,942)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrealized holding gain (loss), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,311)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(694,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(903,737)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,099,182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</srt:CondensedStatementOfComprehensiveIncomeTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-440" decimals="-3" id="f-1629" unitRef="usd">-644786000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-441" decimals="-3" id="f-1630" unitRef="usd">-881708000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-442" decimals="-3" id="f-1631" unitRef="usd">-2003815000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-440" decimals="-3" id="f-1632" unitRef="usd">-47565000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-441" decimals="-3" id="f-1633" unitRef="usd">-25464000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-442" decimals="-3" id="f-1634" unitRef="usd">-90421000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-440" decimals="-3" id="f-1635" unitRef="usd">1942000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-441" decimals="-3" id="f-1636" unitRef="usd">5611000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-442" decimals="-3" id="f-1637" unitRef="usd">-365000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-440" decimals="-3" id="f-1638" unitRef="usd">-35000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-441" decimals="-3" id="f-1639" unitRef="usd">9046000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-442" decimals="-3" id="f-1640" unitRef="usd">-5311000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-440" decimals="-3" id="f-1641" unitRef="usd">-694328000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-441" decimals="-3" id="f-1642" unitRef="usd">-903737000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-442" decimals="-3" id="f-1643" unitRef="usd">-2099182000</us-gaap:ComprehensiveIncomeNetOfTax>
    <srt:ScheduleOfCondensedBalanceSheetTableTextBlock contextRef="c-1" id="f-1644">&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;BeiGene, Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Information of Parent Company&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Condensed Balance Sheets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Amounts in thousands of U.S. Dollars (&#x201c;$&#x201d;))&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.640%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.792%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As&#160;of&#160;December&#160;31,&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;723,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;249,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;785,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;649,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,509,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loans to subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,731,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,030,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Investment in wholly owned subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,081,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,207,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;114,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,576,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,816,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities and shareholders&#x2019; equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;424,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;197,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Indebtedness to subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;362,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;762,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;547,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,186,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,107,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;171,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,244,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,279,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total shareholders&#x2019; equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,332,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,537,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities and shareholders&#x2019; equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,576,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,816,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</srt:ScheduleOfCondensedBalanceSheetTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-443" decimals="-3" id="f-1645" unitRef="usd">400135000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-444" decimals="-3" id="f-1646" unitRef="usd">723964000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-443" decimals="-3" id="f-1647" unitRef="usd">249016000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-444" decimals="-3" id="f-1648" unitRef="usd">785471000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-443" decimals="-3" id="f-1649" unitRef="usd">649151000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-444" decimals="-3" id="f-1650" unitRef="usd">1509435000</us-gaap:AssetsCurrent>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent contextRef="c-443" decimals="-3" id="f-1651" unitRef="usd">1731266000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent contextRef="c-444" decimals="-3" id="f-1652" unitRef="usd">2030249000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c-443" decimals="-3" id="f-1653" unitRef="usd">2081335000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures contextRef="c-444" decimals="-3" id="f-1654" unitRef="usd">1207352000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-443" decimals="-3" id="f-1655" unitRef="usd">114728000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-444" decimals="-3" id="f-1656" unitRef="usd">69361000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-443" decimals="-3" id="f-1657" unitRef="usd">4576480000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-444" decimals="-3" id="f-1658" unitRef="usd">4816397000</us-gaap:Assets>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-443" decimals="-3" id="f-1659" unitRef="usd">424111000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-444" decimals="-3" id="f-1660" unitRef="usd">197289000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LoansPayableCurrent contextRef="c-443" decimals="-3" id="f-1661" unitRef="usd">0</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent contextRef="c-444" decimals="-3" id="f-1662" unitRef="usd">362917000</us-gaap:LoansPayableCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-443" decimals="-3" id="f-1663" unitRef="usd">762146000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-444" decimals="-3" id="f-1664" unitRef="usd">547215000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-443" decimals="-3" id="f-1665" unitRef="usd">1186257000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-444" decimals="-3" id="f-1666" unitRef="usd">1107421000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-443" decimals="-3" id="f-1667" unitRef="usd">58000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-444" decimals="-3" id="f-1668" unitRef="usd">171649000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-443" decimals="-3" id="f-1669" unitRef="usd">1244257000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-444" decimals="-3" id="f-1670" unitRef="usd">1279070000</us-gaap:Liabilities>
    <us-gaap:StockholdersEquity contextRef="c-443" decimals="-3" id="f-1671" unitRef="usd">3332223000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-444" decimals="-3" id="f-1672" unitRef="usd">3537327000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-443" decimals="-3" id="f-1673" unitRef="usd">4576480000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-444" decimals="-3" id="f-1674" unitRef="usd">4816397000</us-gaap:LiabilitiesAndStockholdersEquity>
    <srt:ScheduleOfCondensedCashFlowStatementTableTextBlock contextRef="c-1" id="f-1675">&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;BeiGene, Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Information of Parent Company&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Condensed Statements of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Amounts in thousands of U.S. Dollars (&#x201c;$&#x201d;))&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.540%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.793%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash flows from operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(644,786)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(881,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,003,815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Adjustments to reconcile net loss to net cash used in operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired in-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of research and development cost share liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(73,226)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(55,294)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(96,402)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized (gains) losses in subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(85,471)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;932,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other items, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(374,370)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(596,496)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Changes in operating assets and liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued expenses and other payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;627,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(140,126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;875,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net cash used in operating activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(143,472)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,168,628)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(882,145)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash flows from investing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchases of short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,485)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Proceeds from sale or maturity of short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;552,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,487,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchase of in-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(75,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Investment in subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(406,624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(883,328)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,675,908)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other investing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(37,120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;188,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net cash used in investing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(441,116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(159,747)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,186,361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash flows from financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Proceeds from short-term loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;813,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;547,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;296,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Repayment of short-term loans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(593,898)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(293,002)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(247,460)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Proceeds from option exercises and employee share purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net cash provided by financing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;264,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;310,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of foreign exchange rate changes, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,356)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net decrease in cash, cash equivalents, and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(324,413)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,017,823)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,972,813)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash, beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;724,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,742,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,715,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cash, cash equivalents, and restricted cash, end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;400,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;724,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,742,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</srt:ScheduleOfCondensedCashFlowStatementTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-440" decimals="-3" id="f-1676" unitRef="usd">-644786000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-441" decimals="-3" id="f-1677" unitRef="usd">-881708000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-442" decimals="-3" id="f-1678" unitRef="usd">-2003815000</us-gaap:NetIncomeLoss>
    <bgne:AcquiredInProcessResearchAndDevelopment contextRef="c-440" decimals="-3" id="f-1679" unitRef="usd">0</bgne:AcquiredInProcessResearchAndDevelopment>
    <bgne:AcquiredInProcessResearchAndDevelopment contextRef="c-441" decimals="-3" id="f-1680" unitRef="usd">15000000</bgne:AcquiredInProcessResearchAndDevelopment>
    <bgne:AcquiredInProcessResearchAndDevelopment contextRef="c-442" decimals="-3" id="f-1681" unitRef="usd">0</bgne:AcquiredInProcessResearchAndDevelopment>
    <bgne:AmortizationOfResearchAndDevelopmentFinancingLiability contextRef="c-440" decimals="-3" id="f-1682" unitRef="usd">-73226000</bgne:AmortizationOfResearchAndDevelopmentFinancingLiability>
    <bgne:AmortizationOfResearchAndDevelopmentFinancingLiability contextRef="c-441" decimals="-3" id="f-1683" unitRef="usd">-55294000</bgne:AmortizationOfResearchAndDevelopmentFinancingLiability>
    <bgne:AmortizationOfResearchAndDevelopmentFinancingLiability contextRef="c-442" decimals="-3" id="f-1684" unitRef="usd">-96402000</bgne:AmortizationOfResearchAndDevelopmentFinancingLiability>
    <bgne:UnrealizedGainLossInSubsidiaries contextRef="c-440" decimals="-3" id="f-1685" unitRef="usd">85471000</bgne:UnrealizedGainLossInSubsidiaries>
    <bgne:UnrealizedGainLossInSubsidiaries contextRef="c-441" decimals="-3" id="f-1686" unitRef="usd">-237351000</bgne:UnrealizedGainLossInSubsidiaries>
    <bgne:UnrealizedGainLossInSubsidiaries contextRef="c-442" decimals="-3" id="f-1687" unitRef="usd">-932071000</bgne:UnrealizedGainLossInSubsidiaries>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-440" decimals="-3" id="f-1688" unitRef="usd">31651000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-441" decimals="-3" id="f-1689" unitRef="usd">-374370000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-442" decimals="-3" id="f-1690" unitRef="usd">-596496000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-440" decimals="-3" id="f-1691" unitRef="usd">-1053000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-441" decimals="-3" id="f-1692" unitRef="usd">-30519000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-442" decimals="-3" id="f-1693" unitRef="usd">-6671000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c-440" decimals="-3" id="f-1694" unitRef="usd">627307000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c-441" decimals="-3" id="f-1695" unitRef="usd">-140126000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="c-442" decimals="-3" id="f-1696" unitRef="usd">875826000</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-440" decimals="-3" id="f-1697" unitRef="usd">-143472000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-441" decimals="-3" id="f-1698" unitRef="usd">-1168628000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-442" decimals="-3" id="f-1699" unitRef="usd">-882145000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="c-440" decimals="-3" id="f-1700" unitRef="usd">0</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="c-441" decimals="-3" id="f-1701" unitRef="usd">2075000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="c-442" decimals="-3" id="f-1702" unitRef="usd">1485000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-440" decimals="-3" id="f-1703" unitRef="usd">2628000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-441" decimals="-3" id="f-1704" unitRef="usd">552000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-442" decimals="-3" id="f-1705" unitRef="usd">1487028000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <bgne:PaymentsToPurchaseInProcessResearchAndDevelopment contextRef="c-440" decimals="-3" id="f-1706" unitRef="usd">0</bgne:PaymentsToPurchaseInProcessResearchAndDevelopment>
    <bgne:PaymentsToPurchaseInProcessResearchAndDevelopment contextRef="c-441" decimals="-3" id="f-1707" unitRef="usd">15000000</bgne:PaymentsToPurchaseInProcessResearchAndDevelopment>
    <bgne:PaymentsToPurchaseInProcessResearchAndDevelopment contextRef="c-442" decimals="-3" id="f-1708" unitRef="usd">75000000</bgne:PaymentsToPurchaseInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates contextRef="c-440" decimals="-3" id="f-1709" unitRef="usd">406624000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates contextRef="c-441" decimals="-3" id="f-1710" unitRef="usd">883328000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates contextRef="c-442" decimals="-3" id="f-1711" unitRef="usd">2675908000</us-gaap:PaymentsToAcquireInterestInSubsidiariesAndAffiliates>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-440" decimals="-3" id="f-1712" unitRef="usd">37120000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-441" decimals="-3" id="f-1713" unitRef="usd">-188656000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-442" decimals="-3" id="f-1714" unitRef="usd">-79004000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-440" decimals="-3" id="f-1715" unitRef="usd">-441116000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-441" decimals="-3" id="f-1716" unitRef="usd">-159747000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-442" decimals="-3" id="f-1717" unitRef="usd">-1186361000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromShortTermDebt contextRef="c-440" decimals="-3" id="f-1718" unitRef="usd">813058000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt contextRef="c-441" decimals="-3" id="f-1719" unitRef="usd">547842000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt contextRef="c-442" decimals="-3" id="f-1720" unitRef="usd">296188000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="c-440" decimals="-3" id="f-1721" unitRef="usd">593898000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="c-441" decimals="-3" id="f-1722" unitRef="usd">293002000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="c-442" decimals="-3" id="f-1723" unitRef="usd">247460000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-440" decimals="-3" id="f-1724" unitRef="usd">45371000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-441" decimals="-3" id="f-1725" unitRef="usd">55712000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-442" decimals="-3" id="f-1726" unitRef="usd">46965000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-440" decimals="-3" id="f-1727" unitRef="usd">264531000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-441" decimals="-3" id="f-1728" unitRef="usd">310552000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-442" decimals="-3" id="f-1729" unitRef="usd">95693000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-440" decimals="-3" id="f-1730" unitRef="usd">-4356000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-441" decimals="-3" id="f-1731" unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-442" decimals="-3" id="f-1732" unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-440" decimals="-3" id="f-1733" unitRef="usd">-324413000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-441" decimals="-3" id="f-1734" unitRef="usd">-1017823000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-442" decimals="-3" id="f-1735" unitRef="usd">-1972813000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-444" decimals="-3" id="f-1736" unitRef="usd">724548000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-445" decimals="-3" id="f-1737" unitRef="usd">1742371000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-446" decimals="-3" id="f-1738" unitRef="usd">3715184000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-443" decimals="-3" id="f-1739" unitRef="usd">400135000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-444" decimals="-3" id="f-1740" unitRef="usd">724548000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-445" decimals="-3" id="f-1741" unitRef="usd">1742371000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OtherCommitment contextRef="c-447" decimals="-3" id="f-1742" unitRef="usd">7350000</us-gaap:OtherCommitment>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c-1" id="f-1743">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
